{"meta":{"query_hash":"fe77064d49b2","filters":{"topic":"Pharmaceutical Economics and Policy"},"cohort_total":1682,"direct_labels_cover":5,"predictions_cover":1682,"exported":1682,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/fe77064d49b2","api":"https://metacan.xera.ac/api/v1/cohort?topic=Pharmaceutical+Economics+and+Policy"},"results":[{"id":"W102432712","doi":"","title":"Pharmacy Education in India","year":2008,"lang":"en","type":"article","venue":"American Journal of Pharmaceutical Education","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Government (linguistics); Health care; Pharmaceutical care; Bureaucracy; Developing country; Medicine; Population; Nursing; Family medicine; Economic growth; Political science; Politics; Environmental health","score_opus":0.05753423844105215,"score_gpt":0.3736813859025616,"score_spread":0.31614714746150946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W102432712","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042900426,0.016342282,0.00008333375,0.6002764,0.3792208,0.000013085701,0.00005526714,0.000063333646,0.0035165148],"genre_scores_gemma":[0.0068975203,0.014213851,0.00012695964,0.6202006,0.34869358,0.000028234124,0.00005369343,0.0000366995,0.00974891],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965701,0.0005133323,0.00049443886,0.000542673,0.0011375516,0.00074188574],"domain_scores_gemma":[0.9871018,0.0043401583,0.0012777413,0.00040723538,0.0033478562,0.0035251956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028319198,0.0011118826,0.0009335975,0.0014915911,0.0033166066,0.006608562,0.0027807017,0.01760382,0.0128772445],"category_scores_gemma":[0.014747572,0.00072341284,0.0010596268,0.0012462527,0.0025012933,0.003711343,0.0032484762,0.021818388,0.0040053045],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020338288,0.000025834346,0.00025444923,0.00028462277,0.000011063284,0.00062715175,0.00010726835,0.00002669041,0.000063601816,0.0009959306,0.98025805,0.01732511],"study_design_scores_gemma":[0.000025428506,0.00003439886,0.0014092636,0.0005124636,0.000016170481,0.0011207835,0.00017030808,0.00005993361,0.000091661044,0.0006276073,0.9959122,0.000019824964],"about_ca_topic_score_codex":0.0041817394,"about_ca_topic_score_gemma":0.0076303356,"teacher_disagreement_score":0.01760382,"about_ca_system_score_codex":0.0043926844,"about_ca_system_score_gemma":0.008341918,"threshold_uncertainty_score":0.04307872},"labels":[],"label_agreement":null},{"id":"W103850937","doi":"","title":"Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Warfarin; Medicine; Brand names; Family medicine; Likert scale; Generic drug; Pediatrics; Internal medicine; Advertising; Drug; Psychiatry; Psychology","score_opus":0.11369663477764512,"score_gpt":0.2406447882081845,"score_spread":0.1269481534305394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W103850937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678975,0.00028018965,0.000032475316,0.00087189174,0.0000063805933,0.000031843054,0.0004194614,0.0000025965626,0.0015654096],"genre_scores_gemma":[0.9983027,0.00035467488,0.000060390885,0.00059149694,0.000010406182,0.000018991908,0.00018579663,0.000001495015,0.0004739658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884784,0.00018246008,0.00010101842,0.00009676769,0.0004778583,0.000294082],"domain_scores_gemma":[0.99626833,0.00048559907,0.0016471639,0.000069578055,0.0006894136,0.0008399014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081461266,0.00014495593,0.00019231072,0.00045096703,0.0012254297,0.0006519855,0.00033232154,0.0005423943,0.0024295002],"category_scores_gemma":[0.003915984,0.0003245197,0.00019667992,0.0013276063,0.0006720469,0.00051409565,0.0005089561,0.0004293132,0.00036080924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007675933,0.000058759368,0.9864596,0.00004734389,0.000010298914,0.0002088944,0.0077256267,0.000018755547,0.0003492433,0.000030337269,0.0013300581,0.0036843705],"study_design_scores_gemma":[0.0000127056655,0.00010075562,0.9914402,0.000023271037,0.000006266948,0.00013827736,0.006486938,0.00006820887,0.00002566096,0.000007253595,0.0016848493,0.0000055255955],"about_ca_topic_score_codex":0.64772254,"about_ca_topic_score_gemma":0.7465874,"teacher_disagreement_score":0.35227746,"about_ca_system_score_codex":0.004995188,"about_ca_system_score_gemma":0.0046987515,"threshold_uncertainty_score":0.7087042},"labels":[],"label_agreement":null},{"id":"W109161873","doi":"10.1533/9781908818089.201","title":"Implications of empirical data: are pharmaceutical linkage regulations a success? * *This chapter is based upon material in R.A. Bouchard, ‘I’m Still Your Baby: Canada’s Continuing Support of U.S. Linkage Regulations for Pharmaceuticals,’ Marquette Intellectual Property Law Review 15(1): 79–146 (2011).","year":2012,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competitor analysis; Linkage (software); Legitimacy; Legislation; Enforcement; Political science; Law and economics; Politics; Law; Business; Public administration; Economics; Marketing","score_opus":0.13605083076033583,"score_gpt":0.34532430427076116,"score_spread":0.20927347351042533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W109161873","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018852077,0.047964305,0.01878716,0.7632233,0.004463945,0.00029578758,0.007258445,0.00023710896,0.13891791],"genre_scores_gemma":[0.7105883,0.03765538,0.018031592,0.19463688,0.0128698945,0.0009180609,0.0054073804,0.0005559804,0.019336645],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.8655834,0.08791191,0.007758021,0.010471821,0.02568507,0.0025897212],"domain_scores_gemma":[0.24882929,0.6600978,0.042235974,0.023089264,0.023798807,0.0019490022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10940873,0.0009980362,0.0023433967,0.0055833766,0.0031438384,0.014160066,0.005016233,0.007319867,0.036902115],"category_scores_gemma":[0.5575378,0.0009911861,0.0015508515,0.012208483,0.017350582,0.017950889,0.003658645,0.0090828445,0.006647731],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027677673,0.00023182177,0.04978697,0.001737069,0.00064757426,0.0009799639,0.0017580027,0.001559277,0.0001339568,0.521667,0.33377498,0.08744654],"study_design_scores_gemma":[0.00030681517,0.00013407771,0.026821598,0.004994783,0.0005370845,0.000399749,0.005856676,0.005644538,0.0010234826,0.70781064,0.246321,0.00014942337],"about_ca_topic_score_codex":0.021895543,"about_ca_topic_score_gemma":0.016383665,"teacher_disagreement_score":0.9781045,"about_ca_system_score_codex":0.0066626067,"about_ca_system_score_gemma":0.009158984,"threshold_uncertainty_score":0.57861555},"labels":[],"label_agreement":null},{"id":"W111982779","doi":"10.4000/interventionseconomiques.1441","title":"Procès de production d’une recherche orientée entre chercheurs, malades et entrepreneurs : Le cas d’une « biotech à but non lucratif »","year":2011,"lang":"fr","type":"article","venue":"Interventions économiques","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.3378487349127251,"score_gpt":0.3770503880068065,"score_spread":0.03920165309408141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W111982779","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30559814,0.011085833,0.17945391,0.12589432,0.0005689602,0.0010541029,0.00028855933,0.00039711827,0.37565905],"genre_scores_gemma":[0.9296627,0.0033324785,0.033427846,0.0023309009,0.00016107492,0.0006058456,0.000095573174,0.0001077237,0.030275956],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9635494,0.026613347,0.00084207044,0.0028062577,0.0037852756,0.0024036982],"domain_scores_gemma":[0.9274354,0.04908554,0.007175794,0.0058410387,0.0050119394,0.005450223],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.03525874,0.00095317524,0.00080947275,0.0042530783,0.008021318,0.01905696,0.0020673512,0.0045206742,0.010774551],"category_scores_gemma":[0.04805586,0.0010117139,0.0010225314,0.0036112266,0.024315773,0.0150601035,0.014804361,0.004789736,0.0020231823],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023412165,0.00021607598,0.009596854,0.00037203307,0.00006505399,0.0005875672,0.042968422,0.0014332802,0.0012155949,0.8843302,0.0021107977,0.056869924],"study_design_scores_gemma":[0.00017295723,0.0004849415,0.017733268,0.0010114493,0.00010559312,0.00054696394,0.0589711,0.003718149,0.0028716342,0.70874035,0.20553121,0.00011232785],"about_ca_topic_score_codex":0.00772245,"about_ca_topic_score_gemma":0.006305302,"teacher_disagreement_score":0.9919787,"about_ca_system_score_codex":0.016518956,"about_ca_system_score_gemma":0.027732994,"threshold_uncertainty_score":0.18646824},"labels":[],"label_agreement":null},{"id":"W112126374","doi":"10.1016/j.jacc.2013.08.1665","title":"Polypills","year":2014,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Wellcome Trust","keywords":"Polypill; Medicine; Essential medicines; Secondary prevention; Formulary; Psychological intervention; Intensive care medicine; Alternative medicine; Pharmacy; Family medicine; Traditional medicine; Environmental health; Public health; Internal medicine; Nursing","score_opus":0.027303465693074826,"score_gpt":0.26753332908341915,"score_spread":0.24022986339034433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W112126374","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019345138,0.0023401135,0.00067713455,0.009390043,0.0048405114,0.00018418464,0.008385269,0.0014115267,0.97083676],"genre_scores_gemma":[0.0082310205,0.0016280388,0.0006787685,0.0066369744,0.0017785704,0.000066942295,0.0038595553,0.00057974627,0.97654027],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993218,0.000079874466,0.000034194858,0.00009224875,0.00035631112,0.00011558675],"domain_scores_gemma":[0.9982387,0.00019636218,0.00009816428,0.00015954164,0.0004006927,0.00090661534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040836417,0.0005568033,0.00046759672,0.0015202594,0.00091802917,0.0021674342,0.0008537145,0.0013876574,0.78690964],"category_scores_gemma":[0.0031518196,0.0002788284,0.00060544926,0.00088817603,0.0003117346,0.0012379203,0.0016413485,0.0019482075,0.49363586],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014589136,0.00007959294,0.00029022375,0.000092386144,0.0000066375883,0.00013371732,0.0000107856295,0.000023670606,0.00017000873,0.0021899103,0.892382,0.10447524],"study_design_scores_gemma":[0.000050258026,0.000037806763,0.00065514457,0.000055136563,0.0000047360218,0.00019557566,0.000013871109,0.000036131034,0.000083352155,0.0008224523,0.99804026,0.000005188339],"about_ca_topic_score_codex":0.004074686,"about_ca_topic_score_gemma":0.013661236,"teacher_disagreement_score":0.78690964,"about_ca_system_score_codex":0.0008472379,"about_ca_system_score_gemma":0.0023034469,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W1135736076","doi":"10.71781/4972","title":"Développement d'une technique optique ayant pour but l'analyse de procédés en ligne de comprimés pharmaceutiques","year":2008,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Université de Montréal","keywords":"Humanities; Physics; Art","score_opus":0.01954608343942198,"score_gpt":0.24460302182764937,"score_spread":0.22505693838822738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1135736076","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041531892,0.00011169834,0.9935615,0.00014771879,0.000077012,0.000077612094,0.00006833813,0.00027647003,0.0015263867],"genre_scores_gemma":[0.053456426,0.00021506491,0.93968546,0.00007683991,0.000055173223,0.0002425884,0.00010369476,0.0002360477,0.005928655],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970024,0.0010352447,0.00018058544,0.0005140894,0.0010937575,0.0001738471],"domain_scores_gemma":[0.9904137,0.0063682236,0.00042014787,0.00122436,0.0014744113,0.00009910219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044629914,0.00094157434,0.0013356793,0.0016389895,0.0008276038,0.0029392515,0.0014642321,0.0019693316,0.010882226],"category_scores_gemma":[0.018460484,0.00070545904,0.0022178856,0.002021932,0.0012351496,0.002348748,0.0017207201,0.002123542,0.0018336418],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007841752,0.00036036415,0.0029304205,0.0009323632,0.0003170585,0.00027692693,0.0009539516,0.054888483,0.060398024,0.11804925,0.0048590163,0.75525],"study_design_scores_gemma":[0.00022056924,0.00073151354,0.007605906,0.00023146805,0.00026553133,0.0007543817,0.00046034282,0.7888204,0.059850376,0.09139604,0.049485095,0.000178289],"about_ca_topic_score_codex":0.0056418763,"about_ca_topic_score_gemma":0.005530922,"teacher_disagreement_score":0.010882226,"about_ca_system_score_codex":0.0010433731,"about_ca_system_score_gemma":0.0030726823,"threshold_uncertainty_score":0.03640467},"labels":[],"label_agreement":null},{"id":"W113649872","doi":"10.1155/2002/525819","title":"Funding the New Biologics – Public Policy Issues in Drug Formulary Decision Making","year":2002,"lang":"en","type":"article","venue":"Canadian Journal of Gastroenterology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Formulary; Actuarial science; Public economics; Medicine; Health care; Intervention (counseling); Business; Health economics; Public health; Cost–benefit analysis; Quality (philosophy); Economic evaluation; Family medicine; Economics; Economic growth; Nursing","score_opus":0.07883856683017838,"score_gpt":0.29135276207516325,"score_spread":0.21251419524498488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W113649872","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014523983,0.0089080725,0.0030753782,0.96777916,0.0014139415,0.000041783813,0.000078692334,0.000032907275,0.017217707],"genre_scores_gemma":[0.2957251,0.025695696,0.01741951,0.63353723,0.014506284,0.0005011612,0.00029642117,0.00015641928,0.01216223],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.92839,0.042997178,0.0023016832,0.0036831966,0.016334932,0.006293061],"domain_scores_gemma":[0.7393387,0.20521423,0.009152566,0.0070872,0.022893876,0.016313428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09447705,0.00068355905,0.0016682675,0.0021914649,0.004446442,0.019096298,0.0050728237,0.027533367,0.015717756],"category_scores_gemma":[0.18940103,0.0008189298,0.0015941763,0.0032524695,0.014829043,0.017670186,0.0064531355,0.022662392,0.0016837849],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014406825,0.0001253139,0.0009842842,0.00036443796,0.000081212245,0.00017819923,0.00060202385,0.0029517703,0.00014844854,0.7293565,0.1838894,0.08117429],"study_design_scores_gemma":[0.00025033412,0.0000916796,0.0014234128,0.0021407506,0.00006467615,0.0002625732,0.0008132711,0.003992778,0.00021550021,0.59124887,0.3993871,0.0001091297],"about_ca_topic_score_codex":0.04020276,"about_ca_topic_score_gemma":0.030102057,"teacher_disagreement_score":0.9739425,"about_ca_system_score_codex":0.026057461,"about_ca_system_score_gemma":0.07146883,"threshold_uncertainty_score":0.4996484},"labels":[],"label_agreement":null},{"id":"W1156621861","doi":"","title":"Les conflits d'intérêts des groupes de défense de patients financés par l'industrie pharmaceutique : le cas du remboursement public des médicaments","year":2013,"lang":"fr","type":"article","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Political science; Humanities; Philosophy","score_opus":0.032601946078762316,"score_gpt":0.2190637746046361,"score_spread":0.18646182852587379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1156621861","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32385796,0.01898402,0.0016736912,0.5882103,0.000966604,0.00008955826,0.0007890765,0.000020261188,0.06540858],"genre_scores_gemma":[0.9723508,0.0057678474,0.00043639197,0.01320196,0.0010118848,0.00008418846,0.000186931,0.000023215835,0.0069368007],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.96273714,0.018907448,0.0019188528,0.0020729343,0.007981754,0.0063818907],"domain_scores_gemma":[0.6418357,0.25267717,0.06252036,0.006477795,0.01819229,0.018296648],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.048309434,0.000312359,0.00067282683,0.0043361606,0.00504304,0.011271164,0.0025665653,0.009601841,0.020580037],"category_scores_gemma":[0.25320047,0.00042395873,0.0005904197,0.0077835894,0.007934589,0.0077429092,0.004682989,0.0068015507,0.0011919576],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079338177,0.00019083194,0.36353344,0.0003696101,0.00021107592,0.0014650994,0.017186152,0.00058410777,0.000111802045,0.449855,0.089042686,0.0766568],"study_design_scores_gemma":[0.0005589055,0.00043637873,0.452011,0.0032934553,0.0004117477,0.004310807,0.11769954,0.0061074076,0.0010168597,0.26420248,0.14974336,0.00020800077],"about_ca_topic_score_codex":0.046406303,"about_ca_topic_score_gemma":0.03868855,"teacher_disagreement_score":0.994957,"about_ca_system_score_codex":0.007910573,"about_ca_system_score_gemma":0.011491829,"threshold_uncertainty_score":0.25548774},"labels":[],"label_agreement":null},{"id":"W1165099382","doi":"","title":"La gestion de l’Avastin par le bioéthicien : transfert d’une responsabilité politique?","year":2012,"lang":"fr","type":"article","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Political science; Humanities; Philosophy","score_opus":0.01953958751887841,"score_gpt":0.20186407410113155,"score_spread":0.18232448658225314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1165099382","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048047663,0.008754498,0.012331495,0.8993714,0.0014396473,0.000048740087,0.000030480294,0.000050743674,0.07316832],"genre_scores_gemma":[0.68597883,0.012585252,0.01580698,0.23011918,0.006060448,0.00045962792,0.00007371713,0.00027058684,0.048645332],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9454406,0.03713029,0.0016093308,0.0038776866,0.0076844674,0.004257575],"domain_scores_gemma":[0.9225321,0.05033359,0.005684015,0.008101073,0.00621663,0.0071326643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06907606,0.00063656387,0.0011894181,0.0010339209,0.009638467,0.022069888,0.0023916685,0.022361763,0.009344411],"category_scores_gemma":[0.10216381,0.0007293236,0.0006918593,0.0014606293,0.04798968,0.026255608,0.01109556,0.023635805,0.001723746],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003046121,0.00004252505,0.00037924765,0.00008202775,0.00001722254,0.00011400575,0.0038117669,0.00015853616,0.00022644787,0.95750123,0.021340394,0.016295994],"study_design_scores_gemma":[0.000067627996,0.000057774938,0.00080302614,0.00091926014,0.000016183174,0.0001862046,0.0028121716,0.0004280107,0.00031361807,0.7287033,0.2656406,0.0000521472],"about_ca_topic_score_codex":0.017693782,"about_ca_topic_score_gemma":0.009223891,"teacher_disagreement_score":0.06907606,"about_ca_system_score_codex":0.013348804,"about_ca_system_score_gemma":0.044559356,"threshold_uncertainty_score":0.36531347},"labels":[],"label_agreement":null},{"id":"W128384471","doi":"","title":"Canadian court dismisses Pfizer attempt to prevent approval of generic fluconazole.","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Appeal; Federal court; Fluconazole; Law; Political science; Business; Medicine; Supreme court; Antifungal","score_opus":0.06609035721949574,"score_gpt":0.24512501679093854,"score_spread":0.1790346595714428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W128384471","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010376581,0.004855637,0.00089711696,0.6068146,0.0068326592,0.00023274425,0.0042263274,0.00026446974,0.36549982],"genre_scores_gemma":[0.0897255,0.003356413,0.001504361,0.40048996,0.002313371,0.00014410629,0.001480657,0.00012166589,0.500864],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876387,0.0002877718,0.0002584657,0.0006059229,0.008397562,0.0028116012],"domain_scores_gemma":[0.9910686,0.0015965475,0.0001907116,0.00023265256,0.0058052703,0.0011062764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038007824,0.000982262,0.00088302017,0.0021642582,0.023161178,0.007522516,0.0025750764,0.02745122,0.017721351],"category_scores_gemma":[0.022289189,0.00096938014,0.0019599202,0.0022711852,0.003014485,0.0021630174,0.001552614,0.017146388,0.003703401],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008011528,0.000022638233,0.0011765305,0.00004185458,0.000033476543,0.0004226272,0.00023808672,0.00011897726,0.00033679808,0.062159337,0.92821103,0.0071584713],"study_design_scores_gemma":[0.00010488285,0.00003640101,0.005734454,0.00009844003,0.00008608861,0.00012677677,0.00026925807,0.0004019273,0.0005841547,0.0033897017,0.9890878,0.000080001955],"about_ca_topic_score_codex":0.9790293,"about_ca_topic_score_gemma":0.99106956,"teacher_disagreement_score":0.07850953,"about_ca_system_score_codex":0.07850953,"about_ca_system_score_gemma":0.15295151,"threshold_uncertainty_score":0.5696292},"labels":[],"label_agreement":null},{"id":"W138698383","doi":"","title":"The Case for Mutual Recognition of Drug Approvals","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Jurisdiction; Harm; Agency (philosophy); Business; Medicine; Population; Drug approval; Quality (philosophy); Food and drug administration; Work (physics); Public economics; Pharmaceutical industry; Drug; Pharmacology; Risk analysis (engineering); Political science; Environmental health; Economics; Law; Engineering","score_opus":0.041189549932308396,"score_gpt":0.2703527557907076,"score_spread":0.22916320585839922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W138698383","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00538019,0.0065159993,0.013385483,0.87108445,0.007128654,0.0001912038,0.000095990305,0.00036527572,0.09585271],"genre_scores_gemma":[0.18623659,0.0029868335,0.011508007,0.7626282,0.012272274,0.00064645184,0.00015236155,0.0005319366,0.02303737],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.7222658,0.11071707,0.014835979,0.044504795,0.08443431,0.023242071],"domain_scores_gemma":[0.625908,0.22374836,0.030742142,0.03949896,0.052980457,0.027122142],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.20303231,0.0015809663,0.0033188125,0.004550991,0.011185645,0.025908949,0.008465016,0.065721884,0.03131944],"category_scores_gemma":[0.3831582,0.0024415953,0.0038033524,0.0037943781,0.038177826,0.046607763,0.024946624,0.07417069,0.0075696683],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020040979,0.0001575892,0.0026922205,0.0003442073,0.00017027678,0.0017804608,0.0036076845,0.00047926212,0.00045440844,0.70169425,0.23255007,0.05586924],"study_design_scores_gemma":[0.00023140125,0.00014788474,0.001426023,0.0009363041,0.000091830036,0.0013515898,0.0014201892,0.00095317117,0.00042822122,0.36454266,0.6282855,0.00018512568],"about_ca_topic_score_codex":0.00446704,"about_ca_topic_score_gemma":0.003124137,"teacher_disagreement_score":0.20303231,"about_ca_system_score_codex":0.016874118,"about_ca_system_score_gemma":0.036079016,"threshold_uncertainty_score":0.98280305},"labels":[],"label_agreement":null},{"id":"W140674789","doi":"","title":"New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Food and drug administration; Family medicine; Environmental health","score_opus":0.028610665608134037,"score_gpt":0.22185855994449738,"score_spread":0.19324789433636336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W140674789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808239,0.0046141716,0.00012163145,0.0009185511,0.000026499709,0.00004093238,0.004943992,0.000014980577,0.008495436],"genre_scores_gemma":[0.99221426,0.0021625217,0.00024244847,0.00026277933,0.000019171106,0.000027415497,0.0026687104,0.0000057170496,0.002396911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818027,0.00017892876,0.00013666293,0.00016350514,0.0009947851,0.00034581937],"domain_scores_gemma":[0.99012417,0.0014863997,0.0042412877,0.00008940615,0.0028819225,0.0011769681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011920467,0.00015969084,0.0001798566,0.0020679869,0.0007422033,0.0011340783,0.00031866904,0.00039300908,0.0015371946],"category_scores_gemma":[0.007401529,0.00016545877,0.00032267513,0.004027127,0.00036121882,0.00062753516,0.00040235824,0.0007386415,0.00021088205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001041229,0.00014834986,0.92741895,0.00037732863,0.0002321194,0.0007536421,0.0025455358,0.0012364063,0.0009294557,0.0011887692,0.011445226,0.052682944],"study_design_scores_gemma":[0.00001495114,0.000050642957,0.99163765,0.000024420931,0.000033307304,0.00019665924,0.00065263984,0.00032136193,0.00020294095,0.000053247055,0.0067990394,0.000013157116],"about_ca_topic_score_codex":0.801788,"about_ca_topic_score_gemma":0.83762014,"teacher_disagreement_score":0.98877126,"about_ca_system_score_codex":0.011228752,"about_ca_system_score_gemma":0.008303908,"threshold_uncertainty_score":0.39875865},"labels":[],"label_agreement":null},{"id":"W1416739048","doi":"10.12927/whp.2008.19597","title":"Medicinal Products Liability of the Pharmacists: An Overview of Some Emerging Legal Issues in Nigeria","year":2008,"lang":"en","type":"article","venue":"World health & population","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Liability; Engineering ethics; Risk analysis (engineering); Engineering; Accounting","score_opus":0.17839019245958845,"score_gpt":0.4098828398031117,"score_spread":0.23149264734352323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1416739048","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14054507,0.69163436,0.002363257,0.10566167,0.0008561485,0.00006608437,0.000088654924,0.000015535916,0.058769222],"genre_scores_gemma":[0.43797693,0.54897577,0.0015063725,0.0058680368,0.001289548,0.000025400393,0.000042612,0.0000050112885,0.00431034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989219,0.00037264876,0.00014035452,0.000088381814,0.0003106071,0.00016614379],"domain_scores_gemma":[0.99501085,0.0030932953,0.0011535195,0.000038590337,0.0004468873,0.0002568329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015112141,0.00021958249,0.00023832415,0.002981981,0.0022292635,0.0034876594,0.00043272448,0.002934148,0.002345318],"category_scores_gemma":[0.00260527,0.0002512395,0.0002745837,0.0027354052,0.0018565312,0.0034788887,0.0011031396,0.002069751,0.0001421384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018937323,0.0005166944,0.08306441,0.00628659,0.00004447696,0.030405024,0.016648054,0.0018597938,0.0016666903,0.30463278,0.027023567,0.5276625],"study_design_scores_gemma":[0.000036877867,0.0005694854,0.1521431,0.013162353,0.00010032382,0.05058838,0.065778136,0.00379563,0.0012193996,0.07528267,0.637178,0.00014567631],"about_ca_topic_score_codex":0.00531648,"about_ca_topic_score_gemma":0.0106037995,"teacher_disagreement_score":0.00531648,"about_ca_system_score_codex":0.002831237,"about_ca_system_score_gemma":0.0042818217,"threshold_uncertainty_score":0.020542145},"labels":[],"label_agreement":null},{"id":"W142923118","doi":"10.25071/1929-8404.37158","title":"Catastrophic Drug Coverage in Canada","year":2013,"lang":"en","type":"article","venue":"Healthy Dialogue","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Government (linguistics); Drug; Commission; Medicine; Prescription drug; Environmental health; Business; Pharmacology; Finance","score_opus":0.03444523553367898,"score_gpt":0.2421871737346611,"score_spread":0.2077419382009821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W142923118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49130923,0.023248235,0.002267841,0.16645037,0.00059225084,0.00029130778,0.016728759,0.00014682671,0.29896522],"genre_scores_gemma":[0.9768151,0.006077822,0.00046760007,0.0037070338,0.00009814464,0.000022448985,0.0015592861,0.000013078428,0.011239464],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979126,0.00013357263,0.000040363626,0.00009416165,0.00083748996,0.0009818076],"domain_scores_gemma":[0.99516886,0.0006162274,0.0004935544,0.00007319099,0.0020352297,0.0016129175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093608384,0.00021980326,0.00037760695,0.0018171534,0.002897376,0.002756187,0.0006239301,0.0008208202,0.0073725046],"category_scores_gemma":[0.0054684607,0.0001828932,0.000438709,0.0030569418,0.0012993743,0.00066251616,0.0013025723,0.0013709501,0.00017817291],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020377866,0.00017563571,0.2880997,0.0005590321,0.00024347352,0.0020589654,0.002613494,0.012164694,0.00046027414,0.341046,0.24405527,0.108319744],"study_design_scores_gemma":[0.00011002113,0.00007494135,0.7074685,0.0008677471,0.0001406612,0.0005653788,0.003940425,0.01450924,0.0003643821,0.024255674,0.24756213,0.00014095461],"about_ca_topic_score_codex":0.99600345,"about_ca_topic_score_gemma":0.99574584,"teacher_disagreement_score":0.9098796,"about_ca_system_score_codex":0.09012035,"about_ca_system_score_gemma":0.1365157,"threshold_uncertainty_score":0.653872},"labels":[],"label_agreement":null},{"id":"W1479833118","doi":"10.3386/w19247","title":"Physician Agency and Competition: Evidence from a Major Change to Medicare Chemotherapy Reimbursement Policy","year":2013,"lang":"en","type":"article","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; Robert Wood Johnson Foundation","keywords":"Reimbursement; Agency (philosophy); Competition (biology); Profit margin; Chemotherapy; Business; Health care; Medicine; Family medicine; Finance; Economics; Internal medicine; Economic growth","score_opus":0.42314513704236006,"score_gpt":0.4974304854129782,"score_spread":0.07428534837061812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1479833118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8965559,0.016471684,0.00067562115,0.053510014,0.00028072478,0.00009800439,0.0016840211,0.000017309134,0.03070675],"genre_scores_gemma":[0.9917264,0.001625044,0.00011436927,0.0051935865,0.00024294315,0.000020787471,0.00038378552,0.000006046442,0.0006869457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9842807,0.008483362,0.00068688794,0.00122746,0.0028387888,0.0024828147],"domain_scores_gemma":[0.83521384,0.08728882,0.05731041,0.0034113494,0.0066816458,0.010093912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010700923,0.00021340273,0.0006139699,0.0012815875,0.0014087055,0.0026992885,0.0016557738,0.0028525016,0.009566119],"category_scores_gemma":[0.056794435,0.00031164096,0.0014025023,0.0021968056,0.0027494086,0.0015898916,0.002277659,0.0030131768,0.00046819102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006446019,0.002185877,0.9058809,0.0005933734,0.00186314,0.0005709117,0.0011841274,0.0027805432,0.00024816528,0.021042211,0.016249511,0.040955257],"study_design_scores_gemma":[0.0017480858,0.0014008933,0.963108,0.00054948626,0.0011971603,0.00025780394,0.0025754985,0.0021856148,0.00040134948,0.007564428,0.01894617,0.000065484855],"about_ca_topic_score_codex":0.056539394,"about_ca_topic_score_gemma":0.05311559,"teacher_disagreement_score":0.056539394,"about_ca_system_score_codex":0.005358407,"about_ca_system_score_gemma":0.0069773975,"threshold_uncertainty_score":0.11242056},"labels":[],"label_agreement":null},{"id":"W1484626618","doi":"10.1002/hec.3075","title":"Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals","year":2014,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; European Commission","keywords":"Economics; Monetary economics; Econometrics","score_opus":0.06528709711794856,"score_gpt":0.31855257200655196,"score_spread":0.2532654748886034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1484626618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630663,0.0031639896,0.007919005,0.00499535,0.00008078428,0.000038379683,0.0006085145,0.00012252625,0.020005183],"genre_scores_gemma":[0.9985468,0.00042452317,0.00021840006,0.00010008957,0.000029461775,0.0000028059037,0.000055977715,0.0000061915102,0.0006157023],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986928,0.0002928733,0.000050742634,0.00016211339,0.00036594362,0.00043549936],"domain_scores_gemma":[0.9822447,0.010580355,0.005202901,0.000513454,0.00096843054,0.0004901485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029482266,0.00033092036,0.00069556216,0.0008294347,0.0010124664,0.003968246,0.00096646877,0.0022341625,0.0024260737],"category_scores_gemma":[0.021513697,0.00045226305,0.00070602936,0.0009778799,0.0020769995,0.0016831501,0.00062270125,0.002844612,0.00023767924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016067371,0.00076782645,0.20526183,0.00037686285,0.00052582094,0.0010591958,0.0008952213,0.53825074,0.009223236,0.17723492,0.010793342,0.054004293],"study_design_scores_gemma":[0.0002431919,0.00049115595,0.3432083,0.000083268154,0.0005174241,0.00019603032,0.0008939166,0.5610154,0.0056472025,0.0741506,0.013245419,0.00030806358],"about_ca_topic_score_codex":0.26977286,"about_ca_topic_score_gemma":0.18678765,"teacher_disagreement_score":0.26977286,"about_ca_system_score_codex":0.009225757,"about_ca_system_score_gemma":0.004288986,"threshold_uncertainty_score":0.5364052},"labels":[],"label_agreement":null},{"id":"W1486715292","doi":"","title":"Loophole closure outrages generic drug companies","year":2000,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Champion; Closure (psychology); Medicine; Computer science; Operations research; Medical emergency; History; Law; Engineering; Political science; Archaeology","score_opus":0.03978401165739506,"score_gpt":0.23134642111648057,"score_spread":0.1915624094590855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1486715292","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008169114,0.0039497623,0.007034655,0.66600245,0.015655525,0.00024472518,0.00048007714,0.0018713828,0.29659227],"genre_scores_gemma":[0.20883828,0.0026555003,0.003402663,0.597036,0.015894087,0.00027769012,0.00045029516,0.00060155994,0.17084391],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.984704,0.0028051066,0.0005354229,0.0017118509,0.0074184528,0.002825202],"domain_scores_gemma":[0.9705682,0.014688315,0.0023344092,0.0038494251,0.0044803494,0.004079362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013555798,0.00077925314,0.0007427032,0.0016944509,0.004026396,0.009627817,0.002401883,0.021820372,0.09238607],"category_scores_gemma":[0.07383679,0.0005535579,0.0016666576,0.0010769248,0.004204092,0.008490749,0.0062545165,0.012368397,0.013773215],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014473245,0.000076794655,0.0007441429,0.00009273085,0.000022938162,0.00033342093,0.00032569893,0.00014150976,0.00035409862,0.13025108,0.8107398,0.056772947],"study_design_scores_gemma":[0.00011395871,0.00011206031,0.0010007014,0.00019697043,0.0000199318,0.000373083,0.00026878077,0.0005400576,0.00024128557,0.021695253,0.9754038,0.000034103276],"about_ca_topic_score_codex":0.009375728,"about_ca_topic_score_gemma":0.0058309813,"teacher_disagreement_score":0.09238607,"about_ca_system_score_codex":0.0036565112,"about_ca_system_score_gemma":0.010360542,"threshold_uncertainty_score":0.30906218},"labels":[],"label_agreement":null},{"id":"W1490652015","doi":"10.1111/j.1365-2966.2007.00417.x","title":"Market structure and communicable diseases","year":2007,"lang":"en","type":"article","venue":"Canadian Journal of Economics/Revue canadienne d économique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Monopoly; Externality; Competition (biology); Planner; Social planner; Economics; Communicable disease; Public economics; Microeconomics; Welfare; Market structure; Public health; Industrial organization; Medicine; Computer science; Market economy; Biology","score_opus":0.13311413747276057,"score_gpt":0.21288657263101296,"score_spread":0.07977243515825239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1490652015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63330656,0.008189915,0.12888767,0.03924231,0.000595752,0.0001768986,0.002235096,0.0002646625,0.18710113],"genre_scores_gemma":[0.99249494,0.0010245162,0.0018693706,0.00028212913,0.000055092496,0.000026612373,0.00008495024,0.000010203263,0.004152165],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9996283,0.00016942655,0.00001004967,0.000048022637,0.0000592386,0.000084990636],"domain_scores_gemma":[0.99718034,0.0016487252,0.0006916226,0.00008149776,0.00018200302,0.00021580131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009966984,0.00031687436,0.0005573311,0.0006277475,0.00061847497,0.0024986786,0.00057468895,0.0021690002,0.015774889],"category_scores_gemma":[0.007176151,0.00024935685,0.00047472236,0.00061451737,0.001504662,0.0031864597,0.00080674986,0.0012476993,0.0005418884],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007279582,0.00007541933,0.0042940686,0.00011667491,0.00006397942,0.00023718567,0.00009099886,0.33347577,0.0006779718,0.64749163,0.005804611,0.0075989617],"study_design_scores_gemma":[0.00012858943,0.00008372024,0.003532691,0.000064384454,0.00002230053,0.000105793646,0.00016236387,0.4019451,0.0001817498,0.58688676,0.0068548373,0.000031671574],"about_ca_topic_score_codex":0.008185699,"about_ca_topic_score_gemma":0.0052993535,"teacher_disagreement_score":0.015774889,"about_ca_system_score_codex":0.002427026,"about_ca_system_score_gemma":0.0011121188,"threshold_uncertainty_score":0.052772224},"labels":[],"label_agreement":null},{"id":"W1492226602","doi":"10.1016/s0277-9536(02)00462-8","title":"Public and private sector responses to essential drugs policies:","year":2003,"lang":"en","type":"article","venue":"Social Science & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Private sector; Public sector; Business; Medical prescription; Public economics; Essential drugs; Medicine; Economics; Economic growth; Pharmacology; Environmental health; Health services; Population","score_opus":0.08369354771743316,"score_gpt":0.34139876110673884,"score_spread":0.2577052133893057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1492226602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5746781,0.0040182974,0.0014454026,0.34240028,0.0011317485,0.00012860452,0.0022793328,0.00008956056,0.073828675],"genre_scores_gemma":[0.9817332,0.0007954741,0.00013037417,0.0100389775,0.00031657986,0.000025484222,0.000142113,0.000010080113,0.0068077734],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9932233,0.0021797004,0.00022500253,0.00031937918,0.0011390921,0.002913496],"domain_scores_gemma":[0.9649837,0.022353048,0.0053712497,0.0006274123,0.003431468,0.0032330947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008464388,0.0002809375,0.0007643747,0.0012149266,0.0009143401,0.0056696716,0.00061370403,0.00719087,0.013207326],"category_scores_gemma":[0.03996808,0.0003448841,0.00080935436,0.0014169457,0.0013818555,0.0023046362,0.0023509692,0.0035234336,0.00058789],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010552302,0.0018685719,0.18417726,0.0010204813,0.000997259,0.002099746,0.004362204,0.030752255,0.0051512145,0.4984874,0.14480948,0.11572185],"study_design_scores_gemma":[0.001348228,0.0010244396,0.46109864,0.00044679505,0.00068144524,0.000506459,0.01978356,0.028538805,0.006321513,0.31428257,0.1658005,0.00016707314],"about_ca_topic_score_codex":0.014787561,"about_ca_topic_score_gemma":0.018746534,"teacher_disagreement_score":0.014787561,"about_ca_system_score_codex":0.007000248,"about_ca_system_score_gemma":0.006976555,"threshold_uncertainty_score":0.050790608},"labels":[],"label_agreement":null},{"id":"W1493856646","doi":"10.1002/dta.1326","title":"Regulatory aspects of workplace drug testing in Europe","year":2012,"lang":"en","type":"article","venue":"Drug Testing and Analysis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Legislation; Drug; European union; Occupational safety and health; Business; Political science; Risk analysis (engineering); Medicine; Law; Pharmacology; Economic policy","score_opus":0.060245089088305115,"score_gpt":0.2702190533312976,"score_spread":0.20997396424299247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1493856646","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0445266,0.1968223,0.016495336,0.20542753,0.006270339,0.0002790925,0.0006355358,0.00040745529,0.5291359],"genre_scores_gemma":[0.6020866,0.1002801,0.021516273,0.19599739,0.009523908,0.00035843925,0.00085464015,0.0001634705,0.06921922],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876409,0.0047233487,0.0014123003,0.0011953952,0.0034826293,0.0015454664],"domain_scores_gemma":[0.98597395,0.008204801,0.0016206758,0.00093174726,0.002537321,0.00073157606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016207516,0.00040685263,0.0005754742,0.0017976202,0.0018458493,0.006974805,0.001734497,0.012324474,0.00338911],"category_scores_gemma":[0.017436748,0.00043542113,0.001159492,0.0019781422,0.0041414425,0.0032552923,0.002177477,0.0054877596,0.0006463822],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015032961,0.0003362899,0.0038932764,0.00073610677,0.000038764043,0.0015863843,0.0011573478,0.003782093,0.0036576735,0.7434961,0.049161587,0.19200401],"study_design_scores_gemma":[0.00005209937,0.00039920784,0.01423072,0.0016863374,0.000037816844,0.0011954366,0.0005460868,0.000798169,0.002312155,0.08464562,0.89400595,0.000090383866],"about_ca_topic_score_codex":0.0067268307,"about_ca_topic_score_gemma":0.003970972,"teacher_disagreement_score":0.016207516,"about_ca_system_score_codex":0.0034019626,"about_ca_system_score_gemma":0.0055213603,"threshold_uncertainty_score":0.08571458},"labels":[],"label_agreement":null},{"id":"W1494421313","doi":"10.1111/j.1758-5899.2011.00110.x","title":"Promising Trends in Access to Medicines","year":2012,"lang":"en","type":"article","venue":"Global Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Developing country; Business; Context (archaeology); Language change; Access to medicines; Intellectual property; Principal (computer security); Market access; Economic growth; Economics; Political science; Computer security","score_opus":0.11607057374730569,"score_gpt":0.3984328689915157,"score_spread":0.28236229524421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1494421313","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.110646755,0.20567164,0.005461498,0.39154246,0.0025373725,0.00007523247,0.004306375,0.00026613966,0.27949253],"genre_scores_gemma":[0.774659,0.14460379,0.0041858414,0.035624716,0.00682347,0.00006687396,0.0020741713,0.000079698315,0.031882502],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983431,0.0002672828,0.00014651883,0.00034347654,0.00052396354,0.00037558246],"domain_scores_gemma":[0.99355584,0.0028233766,0.0012539274,0.00024233425,0.0011696229,0.0009548733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022885262,0.00023830005,0.00040695115,0.0024505288,0.00047151968,0.0036504709,0.00085344684,0.0024294574,0.03406476],"category_scores_gemma":[0.009253436,0.00015314127,0.0005333641,0.0035492072,0.0015813652,0.0062940675,0.001667352,0.0030656338,0.002092941],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006970104,0.00027587137,0.03962897,0.002247839,0.00012052801,0.0005369021,0.0013081926,0.0011223658,0.0023700804,0.3633681,0.07283192,0.51549226],"study_design_scores_gemma":[0.000099927216,0.0006529927,0.15531528,0.0011196906,0.0000801923,0.0016838405,0.0020410179,0.0017260475,0.001453003,0.070335165,0.7654238,0.00006917737],"about_ca_topic_score_codex":0.004196555,"about_ca_topic_score_gemma":0.004604204,"teacher_disagreement_score":0.03406476,"about_ca_system_score_codex":0.0033683456,"about_ca_system_score_gemma":0.0018441747,"threshold_uncertainty_score":0.113958},"labels":[],"label_agreement":null},{"id":"W1497115428","doi":"10.1016/j.aogh.2015.02.004","title":"Assessing 15 Proposals for Promoting Innovation and Access to Medicines Globally","year":2015,"lang":"en","type":"review","venue":"Annals of Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Panacea (medicine); General partnership; Transferability; Business; Product (mathematics); Politics; Access to medicines; Intellectual property; Public relations; Essential medicines; Public economics; Political science; Developing country; Economic growth; Economics; Medicine; Finance; Health care; Alternative medicine","score_opus":0.464331985099038,"score_gpt":0.5653241806127831,"score_spread":0.10099219551374511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1497115428","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044614412,0.011671134,0.011891488,0.4309727,0.0088333655,0.005197899,0.002158601,0.0007679455,0.4838924],"genre_scores_gemma":[0.5264273,0.015902873,0.072170116,0.22358502,0.0024961177,0.00946934,0.0034876491,0.00062962086,0.14583187],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.86207324,0.06094983,0.009072603,0.0055140588,0.047427885,0.01496243],"domain_scores_gemma":[0.8785231,0.04608814,0.0077318135,0.008675181,0.02940271,0.02957903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13026087,0.001736712,0.0011082967,0.007190649,0.0072904783,0.029752906,0.005550688,0.02269341,0.06411406],"category_scores_gemma":[0.18553235,0.0011000177,0.0050777816,0.0060035703,0.01029927,0.02446828,0.028233603,0.009491445,0.0067532337],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007262627,0.0007808636,0.015456984,0.004841848,0.00045956267,0.00037260985,0.004101182,0.0022335951,0.0010040586,0.5611297,0.20779417,0.20109911],"study_design_scores_gemma":[0.000618779,0.001075348,0.019025793,0.005223473,0.00046399684,0.00020205826,0.010637619,0.001181175,0.0015046265,0.0981716,0.8616937,0.00020183023],"about_ca_topic_score_codex":0.0054073846,"about_ca_topic_score_gemma":0.0072770007,"teacher_disagreement_score":0.13026087,"about_ca_system_score_codex":0.02273558,"about_ca_system_score_gemma":0.08576034,"threshold_uncertainty_score":0.68889356},"labels":[],"label_agreement":null},{"id":"W1498710310","doi":"10.1186/1472-6963-5-21","title":"International variation in prescribing antihypertensive drugs: Its extent and possible explanations","year":2005,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Health informatics; Nursing research; Health administration; Variation (astronomy); Public health; Quality of Life Research; Nursing","score_opus":0.14787201953803972,"score_gpt":0.4117310898434494,"score_spread":0.26385907030540967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1498710310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809487,0.0050751236,0.0019468245,0.002298651,0.000106791325,0.000060512113,0.00064062665,0.000027397706,0.008895353],"genre_scores_gemma":[0.9989122,0.00041961938,0.0002636176,0.00008005217,0.000024960633,0.000008654328,0.00018222127,0.0000071276195,0.00010140322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924736,0.0036842206,0.0007921563,0.0014835943,0.0009861205,0.00058033934],"domain_scores_gemma":[0.9803853,0.010475573,0.004894778,0.0018751349,0.0014604193,0.0009087402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069746296,0.00021640887,0.0005127723,0.0017064575,0.00068346655,0.0010490862,0.00086925435,0.00052937574,0.0025326263],"category_scores_gemma":[0.013143699,0.00029866863,0.0006901089,0.0052913665,0.0018902132,0.0009148425,0.0014435133,0.00060656545,0.00018050842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058051588,0.000025054476,0.9842239,0.00011939857,0.00016140104,0.00019270164,0.0046035745,0.00014655384,0.0001450481,0.0010290823,0.0005169051,0.008778237],"study_design_scores_gemma":[0.0000029216815,0.000020300382,0.99574405,0.000057161946,0.000028117225,0.00021719093,0.002506129,0.00019530572,0.000050737865,0.00031510214,0.0008537599,0.0000092709615],"about_ca_topic_score_codex":0.015779909,"about_ca_topic_score_gemma":0.01582211,"teacher_disagreement_score":0.015779909,"about_ca_system_score_codex":0.0008911603,"about_ca_system_score_gemma":0.0007013759,"threshold_uncertainty_score":0.036885798},"labels":[],"label_agreement":null},{"id":"W1500858166","doi":"10.71781/1833","title":"Encadrement normatif visant l'utilisation de la marijuana à des fins médicales en Occident","year":2006,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.06149798826525806,"score_gpt":0.34680005933611036,"score_spread":0.2853020710708523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1500858166","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23472673,0.020483328,0.012411537,0.101371504,0.0023775562,0.000294084,0.001460787,0.00015099146,0.6267236],"genre_scores_gemma":[0.87289727,0.0139863,0.010581943,0.017741239,0.0006648873,0.00037979783,0.0005973093,0.0001082463,0.08304307],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9853918,0.004055603,0.00083266804,0.0021179693,0.006369986,0.0012320632],"domain_scores_gemma":[0.97885877,0.0076427474,0.0031771613,0.0013226985,0.008105409,0.0008931417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008702967,0.00032245033,0.00040922285,0.0011728085,0.0061445213,0.008384041,0.0010836904,0.0019891947,0.0046414756],"category_scores_gemma":[0.01925693,0.00027233735,0.0002876579,0.0017579257,0.011894353,0.002658637,0.0022381213,0.0037560256,0.0008941086],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027597873,0.00020429083,0.086947426,0.0028176757,0.00011800274,0.001980148,0.18784523,0.00039274647,0.008954751,0.48492894,0.048344433,0.17719042],"study_design_scores_gemma":[0.000020865244,0.00021948291,0.11177283,0.0036951958,0.00013316094,0.0014996129,0.08793763,0.00023819781,0.006018927,0.031169573,0.7571367,0.0001577987],"about_ca_topic_score_codex":0.11362844,"about_ca_topic_score_gemma":0.1601731,"teacher_disagreement_score":0.11362844,"about_ca_system_score_codex":0.007015183,"about_ca_system_score_gemma":0.019711304,"threshold_uncertainty_score":0.22593409},"labels":[],"label_agreement":null},{"id":"W1504134900","doi":"10.2202/1935-1682.2665","title":"Pecuniary and Non-Pecuniary Incentives in Prescription Pharmaceuticals: The Case of Statins","year":2011,"lang":"en","type":"article","venue":"The B E Journal of Economic Analysis & Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Indemnity; Incentive; Actuarial science; Business; Medical prescription; Order (exchange); Affect (linguistics); Managed care; Value (mathematics); Prescription drug; Health care; Health insurance; Differential (mechanical device); Public economics; Economics; Microeconomics; Finance; Medicine; Pharmacology","score_opus":0.07780076434958608,"score_gpt":0.3308751229542903,"score_spread":0.2530743586047042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1504134900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95496726,0.0016234912,0.0072049135,0.009640706,0.00006775529,0.00010109893,0.0003548255,0.000023154502,0.026016852],"genre_scores_gemma":[0.99746525,0.00027502573,0.0006159629,0.000192013,0.000050294406,0.000016952885,0.000021829326,0.0000030024473,0.0013595746],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99488693,0.0029964247,0.00018698887,0.00032699478,0.0004429512,0.001159662],"domain_scores_gemma":[0.89226246,0.0929565,0.00841518,0.002238152,0.0015575918,0.0025701786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008203899,0.00042541104,0.0019452753,0.0011046055,0.0019076084,0.0040675737,0.0016787138,0.004012353,0.012503663],"category_scores_gemma":[0.032733243,0.0006272565,0.0017812558,0.0011265165,0.0035944341,0.002974447,0.0027570508,0.0038754314,0.00031696862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030809715,0.0026936089,0.13041699,0.0006153657,0.00077594124,0.003743545,0.0012730272,0.2014067,0.003178166,0.6150358,0.0057739,0.032006007],"study_design_scores_gemma":[0.002380359,0.0015946901,0.11757315,0.00030324317,0.00090285996,0.0008750815,0.0041279825,0.47539154,0.00278203,0.3836525,0.010049541,0.00036705515],"about_ca_topic_score_codex":0.02196706,"about_ca_topic_score_gemma":0.015485215,"teacher_disagreement_score":0.02196706,"about_ca_system_score_codex":0.0030605465,"about_ca_system_score_gemma":0.001958009,"threshold_uncertainty_score":0.043678403},"labels":[],"label_agreement":null},{"id":"W1517734398","doi":"10.31235/osf.io/5w8xs_v1","title":"Pharmaceutical Lemons: Innovation and Regulation in the Drug Industry","year":2016,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pharmaceutical industry; Business; Drug; Drug industry; Industrial organization; Pharmacology; Medicine; Engineering; Biochemical engineering","score_opus":0.10152226655298108,"score_gpt":0.32529602586044093,"score_spread":0.22377375930745985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1517734398","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05001887,0.07571229,0.08808834,0.43826464,0.0017429583,0.00018796469,0.00019397915,0.00015579596,0.3456352],"genre_scores_gemma":[0.8935972,0.02203327,0.007888479,0.047163796,0.0038699377,0.0002239764,0.000047921432,0.00003401913,0.025141349],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9888116,0.0059146723,0.00027012458,0.0010330266,0.0024841286,0.0014864493],"domain_scores_gemma":[0.9807689,0.014576493,0.0023520554,0.00074398157,0.001054725,0.0005038447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010449789,0.00046693973,0.0009509039,0.001889804,0.002896854,0.00814123,0.001206646,0.015869115,0.0063601583],"category_scores_gemma":[0.021178208,0.00041264703,0.0017049464,0.001512527,0.015911192,0.010799442,0.0035314604,0.009566544,0.00064372574],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018159788,0.000016634205,0.00027244035,0.000038961258,0.000008096697,0.000053625048,0.00007428831,0.0012400971,0.00006483807,0.99313813,0.002112743,0.002961872],"study_design_scores_gemma":[0.000041090523,0.000056943252,0.00085094414,0.00020652954,0.000022414859,0.0000701343,0.00012698193,0.00406617,0.00025979523,0.96704537,0.027217006,0.00003666403],"about_ca_topic_score_codex":0.007228578,"about_ca_topic_score_gemma":0.0043837954,"teacher_disagreement_score":0.015869115,"about_ca_system_score_codex":0.009706019,"about_ca_system_score_gemma":0.0066112108,"threshold_uncertainty_score":0.07042241},"labels":[],"label_agreement":null},{"id":"W1529002352","doi":"10.18433/j3001b","title":"Generic Drug Product Development Bioequivalence Issues","year":2008,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Drug development; Drug; New product development; Generic drug; Product (mathematics); Pharmacology; Computer science; Risk analysis (engineering); Medicine; Business; Pharmacokinetics; Mathematics; Marketing","score_opus":0.2384531563392742,"score_gpt":0.3924089915411238,"score_spread":0.1539558352018496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1529002352","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0769651,0.13583195,0.106174916,0.40335938,0.0031267842,0.00032812916,0.0026831382,0.00032228656,0.27120826],"genre_scores_gemma":[0.9044456,0.018832242,0.018273067,0.030607056,0.0077583417,0.00014389772,0.00078169757,0.00012520235,0.019032799],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9850381,0.009317551,0.0009458425,0.00097092113,0.0032517507,0.00047581337],"domain_scores_gemma":[0.93907565,0.048424326,0.0039955056,0.0026055037,0.0052027516,0.00069632096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015813338,0.0005215197,0.001175696,0.0021194536,0.000732017,0.004573189,0.0015764822,0.0060445303,0.017525658],"category_scores_gemma":[0.07180186,0.00038034673,0.002174841,0.0015877729,0.0017808448,0.003342094,0.0010698218,0.0049434965,0.0010014041],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010643256,0.00035109016,0.006183481,0.0011960601,0.00058105995,0.000713337,0.00037644213,0.0071191117,0.0021657252,0.47884956,0.041502643,0.45989725],"study_design_scores_gemma":[0.00044824183,0.001360903,0.020954916,0.00183227,0.0010848958,0.005441681,0.00046298464,0.024993006,0.006150329,0.641174,0.29598418,0.000112589194],"about_ca_topic_score_codex":0.0015870089,"about_ca_topic_score_gemma":0.001142368,"teacher_disagreement_score":0.017525658,"about_ca_system_score_codex":0.0026614368,"about_ca_system_score_gemma":0.0021559084,"threshold_uncertainty_score":0.083629906},"labels":[],"label_agreement":null},{"id":"W1531634388","doi":"10.1017/cbo9781107238985.012","title":"India's Pharmaceutical Industry: Policy Space That Fosters Technological Capability","year":2014,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Space (punctuation); Business; Pharmaceutical industry; Industrial organization; Content (measure theory); Marketing; Knowledge management; Computer science; Mathematics; Biotechnology","score_opus":0.07733723758424157,"score_gpt":0.256644806748543,"score_spread":0.17930756916430143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1531634388","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02080222,0.008389963,0.0033620202,0.10682242,0.00057465956,0.00005374724,0.00020374381,0.00029461386,0.85949653],"genre_scores_gemma":[0.8554999,0.013697476,0.00327324,0.01799818,0.0008958121,0.00011164866,0.00018349913,0.00008277976,0.10825747],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819034,0.00048068253,0.000055773766,0.00013410217,0.00055058807,0.0005885131],"domain_scores_gemma":[0.9970427,0.0016988975,0.00022973535,0.00032212623,0.00024470015,0.00046175823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021996903,0.00026759377,0.0002210618,0.0013163207,0.0018277378,0.009130463,0.0008882441,0.0029127584,0.012613114],"category_scores_gemma":[0.004806278,0.00027839144,0.00046413913,0.0024054055,0.0052131303,0.0043944474,0.003845197,0.0035532555,0.0018415126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022089023,0.000021766049,0.00034366333,0.00011065187,0.000006052254,0.00007695003,0.00053275994,0.0005524627,0.00044034864,0.9588871,0.02224543,0.016760735],"study_design_scores_gemma":[0.00003811532,0.00006623996,0.0050895847,0.0005734059,0.000028006227,0.00022474756,0.0017003509,0.0013625767,0.0018949963,0.3215494,0.66743076,0.00004193997],"about_ca_topic_score_codex":0.009362026,"about_ca_topic_score_gemma":0.015180997,"teacher_disagreement_score":0.012613114,"about_ca_system_score_codex":0.008553994,"about_ca_system_score_gemma":0.020220662,"threshold_uncertainty_score":0.062063873},"labels":[],"label_agreement":null},{"id":"W1535329335","doi":"","title":"International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada","year":2001,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical policy; Scrutiny; Government (linguistics); Pharmaceutical industry; Business; Health care; Investment (military); Public economics; Access to medicines; Health policy; Economic growth; Economic policy; Political science; Developing country; Economics; Medicine","score_opus":0.16579989514939428,"score_gpt":0.4106165206196218,"score_spread":0.2448166254702275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1535329335","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.080407925,0.035584595,0.00097377365,0.5257208,0.0014649614,0.00010010392,0.0004659511,0.00006979175,0.3552122],"genre_scores_gemma":[0.79282504,0.067248136,0.0022980336,0.067996435,0.0007666184,0.00006796813,0.0005932884,0.00013175965,0.06807284],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98294836,0.0022079032,0.0004453958,0.00072973914,0.00598547,0.0076831398],"domain_scores_gemma":[0.9800253,0.004401622,0.0010956711,0.00058235123,0.006582967,0.007312242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010712475,0.0005300668,0.00069166475,0.003061367,0.027427258,0.025612999,0.002688695,0.0052156234,0.006524214],"category_scores_gemma":[0.016639905,0.00039445248,0.0007034276,0.01520647,0.017043775,0.0047651487,0.005280224,0.009283061,0.00036612593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014287715,0.00027332825,0.019469483,0.0005437624,0.000074479256,0.0024127509,0.06267391,0.0020057217,0.0006503576,0.58537555,0.20181279,0.12456507],"study_design_scores_gemma":[0.00002697362,0.000044069926,0.018968724,0.0005450594,0.000030737727,0.00031008496,0.06408829,0.00055726425,0.00032781158,0.011923575,0.9030412,0.0001362245],"about_ca_topic_score_codex":0.9853189,"about_ca_topic_score_gemma":0.9899116,"teacher_disagreement_score":0.23487304,"about_ca_system_score_codex":0.23487304,"about_ca_system_score_gemma":0.33099017,"threshold_uncertainty_score":0.88743883},"labels":[],"label_agreement":null},{"id":"W1541980932","doi":"","title":"Drug price index sees first increase in 5 years","year":2000,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Index (typography); Price index; Producer price index; Consumer price index (South Africa); Agricultural economics; Medicine; Economics; Computer science; Monetary economics; Price level; Econometrics; Mid price; World Wide Web","score_opus":0.023213357532807847,"score_gpt":0.22149733307872724,"score_spread":0.1982839755459194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1541980932","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27314708,0.114721976,0.011779358,0.054778222,0.012326304,0.00045429857,0.21233174,0.003671941,0.31678912],"genre_scores_gemma":[0.73768705,0.040084258,0.0071883276,0.010181978,0.0070347968,0.00024214826,0.11478721,0.0004656854,0.08232852],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976266,0.00013479078,0.00024716088,0.0003372507,0.0014487408,0.00020550904],"domain_scores_gemma":[0.99486697,0.00040306326,0.0016539735,0.0002085387,0.0023558482,0.00051169127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001088553,0.00054587127,0.0005398521,0.0029933853,0.00036362925,0.0026058361,0.00048285158,0.0011368829,0.011776083],"category_scores_gemma":[0.0064108483,0.00021709687,0.00063047354,0.004777895,0.00031685774,0.001501717,0.0007476862,0.0021482706,0.008153865],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012488804,0.00022460165,0.17801358,0.001387166,0.0004779175,0.00083104084,0.00022895135,0.0009344106,0.004461669,0.01572144,0.4062036,0.3902668],"study_design_scores_gemma":[0.00004907184,0.00044197316,0.42243868,0.00020451359,0.000119773016,0.0019188307,0.0001249437,0.00080938084,0.0031436454,0.0014877688,0.56919134,0.00007011354],"about_ca_topic_score_codex":0.008475845,"about_ca_topic_score_gemma":0.0070190537,"teacher_disagreement_score":0.011776083,"about_ca_system_score_codex":0.0020840494,"about_ca_system_score_gemma":0.001264033,"threshold_uncertainty_score":0.039394915},"labels":[],"label_agreement":null},{"id":"W1545748427","doi":"","title":"The impact of reference pricing system on brand name’s prices : the case of Tunisia","year":2010,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Quarter (Canadian coin); Order (exchange); Brand names; Reference price; Business; Economics; Marketing; Advertising; Microeconomics; Finance","score_opus":0.09301644793570664,"score_gpt":0.37873120150350936,"score_spread":0.28571475356780274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1545748427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99080044,0.0011126144,0.00027037665,0.0019423502,0.000025330944,0.000015173099,0.00080210785,0.000027293636,0.0050043827],"genre_scores_gemma":[0.9979259,0.00023792872,0.00013035827,0.00011678132,0.000032644686,0.0000061753863,0.00047947004,0.000008108233,0.0010626718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777764,0.00078257953,0.000100077355,0.00026061654,0.00030273563,0.0007763888],"domain_scores_gemma":[0.9906075,0.004253556,0.0029018947,0.00046940584,0.0010957127,0.00067178614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029989732,0.0003322088,0.00082973985,0.0016457873,0.0011917272,0.0041049537,0.0016890069,0.0018928447,0.006686641],"category_scores_gemma":[0.010766239,0.00030860247,0.0013475913,0.0025754366,0.0010755259,0.0021665732,0.0012615727,0.0025285063,0.00044450918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00363906,0.0021167097,0.81374234,0.00039151814,0.0012042805,0.011131897,0.0015396307,0.08122303,0.0038765143,0.033992026,0.016907295,0.030235616],"study_design_scores_gemma":[0.0006281691,0.00075335446,0.8108762,0.000121844445,0.0009663775,0.0012071232,0.005123228,0.15533361,0.004055175,0.0044714063,0.01626958,0.00019400328],"about_ca_topic_score_codex":0.23844714,"about_ca_topic_score_gemma":0.10085205,"teacher_disagreement_score":0.23844714,"about_ca_system_score_codex":0.0060306713,"about_ca_system_score_gemma":0.0016067168,"threshold_uncertainty_score":0.4741184},"labels":[],"label_agreement":null},{"id":"W1550526788","doi":"10.5912/jcb711","title":"The Globetrotting Regulator","year":2015,"lang":"en","type":"article","venue":"Journal of Commercial Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fraternity; Government (linguistics); Battle; China; Health care; Politics; Political science; Economic growth; Public administration; Law; Economics; History; Ancient history","score_opus":0.08344887446268374,"score_gpt":0.2980808370679797,"score_spread":0.214631962605296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1550526788","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016117139,0.0071082283,0.0022160592,0.46763334,0.029934872,0.000058920174,0.000566229,0.00049328106,0.4903773],"genre_scores_gemma":[0.022892071,0.005286667,0.0014239867,0.23603944,0.0043065227,0.000090825604,0.00043827816,0.0003244006,0.72919774],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947996,0.00065758213,0.00013401102,0.0010658298,0.0024260373,0.00091700867],"domain_scores_gemma":[0.9950958,0.0008284666,0.00023411335,0.0005999852,0.0021940072,0.0010476445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004995343,0.00074675836,0.0004960721,0.0008987598,0.0048301523,0.013598963,0.0014335008,0.014803013,0.0652124],"category_scores_gemma":[0.015253498,0.00038086815,0.0008872506,0.001308893,0.0036526916,0.008482436,0.0034890482,0.014243359,0.024966022],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015517135,0.000013571692,0.00017146402,0.000020661939,0.0000030494207,0.000053648466,0.00010155255,0.000055575463,0.0001497914,0.1620152,0.8269815,0.010418503],"study_design_scores_gemma":[0.000004670376,0.0000067225706,0.00015060186,0.00004426973,0.0000019674674,0.000022029431,0.00009451651,0.0000650035,0.00008791544,0.0071450206,0.9923694,0.000007937246],"about_ca_topic_score_codex":0.017325666,"about_ca_topic_score_gemma":0.015990933,"teacher_disagreement_score":0.0652124,"about_ca_system_score_codex":0.004569665,"about_ca_system_score_gemma":0.0162848,"threshold_uncertainty_score":0.21815723},"labels":[],"label_agreement":null},{"id":"W155288181","doi":"","title":"Abstract 6230: Willingness-to-Pay to Avoid Restenosis Following Percutaneous Coronary Intervention in Canadian Patients; A Contingent Valuation","year":2008,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Contingent valuation; Willingness to pay; Restenosis; Percutaneous coronary intervention; Cardiology; Coronary restenosis; Internal medicine; Stent; Myocardial infarction","score_opus":0.06584740804379367,"score_gpt":0.2832931928196446,"score_spread":0.21744578477585091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W155288181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9034321,0.0063569285,0.012781128,0.026012722,0.0004125688,0.0006918274,0.0186966,0.00013387432,0.031482246],"genre_scores_gemma":[0.9939174,0.00066142797,0.00096294953,0.00019280509,0.00010540664,0.00004589176,0.0010649872,0.000009880968,0.0030392047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983576,0.0005825342,0.00007121919,0.00014880022,0.00041330874,0.00042651477],"domain_scores_gemma":[0.9922848,0.004432252,0.00077602384,0.0003227822,0.0013380673,0.000846088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051109255,0.0010134045,0.0009782261,0.0015546106,0.0013967474,0.0024962707,0.002088964,0.0022195503,0.008990988],"category_scores_gemma":[0.028961634,0.00042476453,0.0013723668,0.0019093279,0.0019059897,0.0014973774,0.00060578086,0.0024322383,0.00024812692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007956523,0.0014393477,0.4258027,0.0010201633,0.0015848097,0.0013323984,0.0021482657,0.19693708,0.0020117231,0.17413689,0.060994603,0.1246356],"study_design_scores_gemma":[0.001196071,0.0008973886,0.5420638,0.00046043168,0.0010682127,0.0010869516,0.0017652338,0.38514012,0.0006201324,0.051898625,0.0134596145,0.00034337983],"about_ca_topic_score_codex":0.8529837,"about_ca_topic_score_gemma":0.80890316,"teacher_disagreement_score":0.14701629,"about_ca_system_score_codex":0.027546132,"about_ca_system_score_gemma":0.021102091,"threshold_uncertainty_score":0.29576415},"labels":[],"label_agreement":null},{"id":"W1555399285","doi":"10.1211/jphsr.01.01.0009","title":"Canada's Access to Medicines Regime: a present failure or a future success?","year":2010,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"National Institutes of Health","keywords":"Legislation; TRIPS architecture; Legislature; Government (linguistics); Key (lock); Intellectual property; Access to medicines; Medicine; Public administration; Economic growth; Business; Law; Political science; Economics; Computer science; Computer security","score_opus":0.12930781882747566,"score_gpt":0.47886333216621346,"score_spread":0.3495555133387378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1555399285","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24285962,0.024535596,0.000892818,0.5755192,0.0012765666,0.00013891117,0.00085303193,0.00008125615,0.15384305],"genre_scores_gemma":[0.9451545,0.00976353,0.0011167508,0.024123533,0.00016049092,0.00003192825,0.00022492897,0.000028197013,0.01939623],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.986537,0.001643209,0.00021729294,0.0008211592,0.005169288,0.005611937],"domain_scores_gemma":[0.98787284,0.00187891,0.0009085681,0.00024981966,0.0046153306,0.0044745905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068231504,0.00030921798,0.0005471321,0.0011599018,0.017269883,0.011113479,0.0022367684,0.0029161966,0.0067524887],"category_scores_gemma":[0.011664467,0.00026474142,0.00040641578,0.0032173418,0.012453722,0.004522561,0.0028801837,0.004527729,0.00035260126],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002053413,0.0001771431,0.10182419,0.0023743657,0.0001499638,0.0042920834,0.1680765,0.00084590726,0.0026271695,0.3443226,0.17757075,0.19753405],"study_design_scores_gemma":[0.00002947386,0.0001118492,0.10699799,0.0013533477,0.00006424564,0.0005791346,0.27329427,0.0004992188,0.00075343606,0.0051934267,0.6109032,0.00022042391],"about_ca_topic_score_codex":0.9870734,"about_ca_topic_score_gemma":0.9927897,"teacher_disagreement_score":0.881996,"about_ca_system_score_codex":0.11800402,"about_ca_system_score_gemma":0.3081473,"threshold_uncertainty_score":0.85618305},"labels":[],"label_agreement":null},{"id":"W1559347722","doi":"","title":"Empirical Analysis of Drug Approval-Drug Patenting Linkage for High Value Pharmaceuticals","year":2010,"lang":"en","type":"article","venue":"Northwestern journal of technology and intellectual property","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale","keywords":"Drug; Business; Intellectual property; New drug application; Approved drug; Linkage (software); Value (mathematics); Drug approval; Law and economics; Law; Pharmacology; Economics; Political science; Medicine; Computer science; Chemistry","score_opus":0.06102010696471208,"score_gpt":0.30913543230919827,"score_spread":0.2481153253444862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559347722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992021,0.0009280863,0.0010021583,0.0014850824,0.000022406044,0.000061177794,0.00068881304,0.00004905832,0.003742318],"genre_scores_gemma":[0.995992,0.00021249708,0.00027953478,0.00010142151,0.00007339082,0.000020768282,0.0008700021,0.000010184939,0.0024401695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939224,0.0034019265,0.00038088908,0.0005962706,0.0007047793,0.000993719],"domain_scores_gemma":[0.7721975,0.17801939,0.035769045,0.0037261378,0.0048888526,0.0053991256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011720158,0.00047621506,0.0014376102,0.0035095036,0.0015887113,0.0042643817,0.003094532,0.0028274339,0.01920873],"category_scores_gemma":[0.06065105,0.00069300586,0.0014785476,0.004123103,0.0012311707,0.0033994692,0.0027452882,0.0042536054,0.0018009252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037969816,0.0037202565,0.91080356,0.00033711974,0.0013276874,0.0015013523,0.0010145297,0.02300579,0.001380134,0.016407287,0.005020785,0.031684544],"study_design_scores_gemma":[0.0010805088,0.002472082,0.8768573,0.0001474786,0.0023236063,0.0008931931,0.0063594696,0.08432359,0.0032685627,0.013446828,0.008699488,0.00012790748],"about_ca_topic_score_codex":0.014828493,"about_ca_topic_score_gemma":0.009989723,"teacher_disagreement_score":0.01920873,"about_ca_system_score_codex":0.002357751,"about_ca_system_score_gemma":0.002569241,"threshold_uncertainty_score":0.06425959},"labels":[],"label_agreement":null},{"id":"W1559802115","doi":"10.3386/w17226","title":"Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets","year":2011,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Real world evidence; Business; Family medicine; Medicine; Actuarial science; Internal medicine","score_opus":0.7529492878495362,"score_gpt":0.5967567802891278,"score_spread":0.15619250756040837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559802115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74079347,0.0756998,0.0019219822,0.019884322,0.0004929082,0.0001658815,0.005607411,0.000061627245,0.15537263],"genre_scores_gemma":[0.9763674,0.013716345,0.000266647,0.0037077193,0.0003674889,0.0000322873,0.0024051983,0.000026896872,0.0031099648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948832,0.0014030841,0.00039303396,0.0010304028,0.0015271773,0.0007630837],"domain_scores_gemma":[0.9151895,0.04482778,0.02861215,0.0030099219,0.0049733883,0.003387218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007325108,0.0003665083,0.0009689111,0.0026357672,0.0009697625,0.003652523,0.0013125438,0.0019887157,0.027008863],"category_scores_gemma":[0.03821261,0.00030663778,0.0021562693,0.0035170156,0.0020795106,0.0030597185,0.003419883,0.0019445765,0.0017655098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022432462,0.00097350444,0.86728555,0.0028182075,0.003429956,0.0010420037,0.0014609463,0.0025099567,0.0004906181,0.031285517,0.012797489,0.073662974],"study_design_scores_gemma":[0.00026634344,0.0004493652,0.9658888,0.0010158453,0.0012595124,0.0003471912,0.0022098923,0.0011953419,0.00057901005,0.003364934,0.023377288,0.000046535257],"about_ca_topic_score_codex":0.02142545,"about_ca_topic_score_gemma":0.02263564,"teacher_disagreement_score":0.027008863,"about_ca_system_score_codex":0.0015532256,"about_ca_system_score_gemma":0.0015651718,"threshold_uncertainty_score":0.09035367},"labels":[],"label_agreement":null},{"id":"W1561889056","doi":"10.3386/w20799","title":"Intellectual Property Rights and Access to Innovation: Evidence from TRIPS","year":2014,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"TRIPS architecture; Intellectual property; Business; Competition (biology); TRIPS Agreement; Price premium; Product (mathematics); International economics; International trade; Drug prices; Industrial organization; Economics; Public economics; Microeconomics","score_opus":0.6725693421532669,"score_gpt":0.5429627906360296,"score_spread":0.12960655151723732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1561889056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736703,0.0050440338,0.0006890242,0.0017717314,0.000033369644,0.00003171555,0.0026078778,0.000020339596,0.016131721],"genre_scores_gemma":[0.9948388,0.002117127,0.00012071024,0.00014962594,0.000059594277,0.0000137375655,0.0013362712,0.0000067161623,0.0013574373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977354,0.0008865502,0.00017635485,0.00027210376,0.00052396127,0.00040568906],"domain_scores_gemma":[0.8849327,0.05676719,0.046581667,0.005236803,0.0026958203,0.0037858114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038544498,0.0002807798,0.000433352,0.0022205843,0.0005786168,0.0016712658,0.0010744153,0.0011179151,0.012842383],"category_scores_gemma":[0.030385232,0.00022621233,0.0014718496,0.0035405937,0.001962985,0.0022931548,0.002899294,0.0017600819,0.0011816449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034963568,0.0016069249,0.88966936,0.0011575096,0.0024327436,0.001512434,0.0017775296,0.013591703,0.00040931572,0.014692203,0.008388324,0.061265655],"study_design_scores_gemma":[0.00051632576,0.001401168,0.9632545,0.0003486993,0.0010622372,0.00068257714,0.0021513586,0.0051939297,0.0008162845,0.00992193,0.014583618,0.000067316694],"about_ca_topic_score_codex":0.010280643,"about_ca_topic_score_gemma":0.0064913067,"teacher_disagreement_score":0.012842383,"about_ca_system_score_codex":0.0006316229,"about_ca_system_score_gemma":0.00053742464,"threshold_uncertainty_score":0.042962074},"labels":[],"label_agreement":null},{"id":"W1565226743","doi":"","title":"Ententes entre gouvernements et compagnies pharmaceutiques","year":2012,"lang":"fr","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Publics; Art; Law","score_opus":0.11776891826027439,"score_gpt":0.38860896667140243,"score_spread":0.2708400484111281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1565226743","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38269788,0.019509554,0.016060377,0.07247078,0.0006061511,0.0007344782,0.0013841988,0.0002422611,0.50629437],"genre_scores_gemma":[0.88740337,0.0034346033,0.006972356,0.004764963,0.00013879422,0.00017044325,0.00031523226,0.00004743173,0.0967529],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9640046,0.012612103,0.0009111412,0.002322938,0.015990967,0.004158118],"domain_scores_gemma":[0.9235027,0.034922574,0.009891012,0.0027706132,0.021967348,0.0069456734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016672816,0.00039581396,0.0004553756,0.003062549,0.0081863105,0.0101794405,0.0019053075,0.0025803787,0.018883547],"category_scores_gemma":[0.034459513,0.00036482667,0.00043076643,0.004568754,0.006924862,0.0033158942,0.003894743,0.0027908764,0.0009960458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050398597,0.00037748896,0.1802006,0.0012535218,0.0001717935,0.0025159223,0.07454998,0.0019502068,0.0029825307,0.42940664,0.04045509,0.26563233],"study_design_scores_gemma":[0.00007623443,0.00024537998,0.34331596,0.0014412991,0.00008616154,0.0007332166,0.06376499,0.0014992957,0.0022718583,0.015362611,0.57105345,0.00014964017],"about_ca_topic_score_codex":0.8047016,"about_ca_topic_score_gemma":0.8832983,"teacher_disagreement_score":0.8047016,"about_ca_system_score_codex":0.064182095,"about_ca_system_score_gemma":0.1004647,"threshold_uncertainty_score":0.4656759},"labels":[],"label_agreement":null},{"id":"W1566282614","doi":"10.3386/w20927","title":"Patient Responses to Incentives in Consumer-directed Health Plans: Evidence from Pharmaceuticals","year":2015,"lang":"en","type":"article","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Common Fund; Vanderbilt University; McGill University; California Health Care Foundation; University of Minnesota; University of Southern California; National Institute on Aging; Emory University","keywords":"Incentive; Business; Marketing; Public economics; Health plan; Health care; Economics; Microeconomics; Economic growth","score_opus":0.661288991782228,"score_gpt":0.5713846724613029,"score_spread":0.08990431932092513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1566282614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95256007,0.011893329,0.000757131,0.011366919,0.00022277323,0.0004326897,0.0015859292,0.0000253152,0.021155803],"genre_scores_gemma":[0.994317,0.0019337208,0.00030284646,0.0024367562,0.00015553916,0.00009208661,0.00026696024,0.0000042655442,0.0004908656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.978143,0.016391467,0.0010117162,0.0010477625,0.00230375,0.0011022235],"domain_scores_gemma":[0.8196801,0.12611571,0.043533336,0.004337147,0.0022828407,0.004050853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013801587,0.0003408707,0.0006762368,0.0008315092,0.0010178341,0.0017296927,0.0013582504,0.0033514793,0.010793819],"category_scores_gemma":[0.09866125,0.00047015928,0.0017103871,0.0013046024,0.0015052409,0.0012295734,0.0016668021,0.002339321,0.0005150887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037257675,0.0148500325,0.7027191,0.0026539832,0.004470314,0.00045405122,0.0022991805,0.0039524627,0.00039436275,0.007682668,0.0101281805,0.21313807],"study_design_scores_gemma":[0.013982095,0.011660827,0.9308783,0.001774465,0.00248367,0.0003797209,0.0028333678,0.0039322595,0.0008424255,0.0077816877,0.023314994,0.00013609142],"about_ca_topic_score_codex":0.008741825,"about_ca_topic_score_gemma":0.0069290083,"teacher_disagreement_score":0.013801587,"about_ca_system_score_codex":0.0020394118,"about_ca_system_score_gemma":0.0020018409,"threshold_uncertainty_score":0.072990656},"labels":[],"label_agreement":null},{"id":"W1568860282","doi":"","title":"Should Americans be able to buy cheaper drugs from Canada","year":2015,"lang":"en","type":"article","venue":"Drug Topics E-News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug industry; Medicine; Internet privacy; Actuarial science; Computer science; Engineering","score_opus":0.11547643919255628,"score_gpt":0.29921680350307106,"score_spread":0.18374036431051477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1568860282","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015290894,0.0033590582,0.00018125692,0.6639371,0.003924074,0.000048036964,0.0014256928,0.00007256133,0.31176138],"genre_scores_gemma":[0.1845768,0.0069280453,0.00071469875,0.5988056,0.0024732645,0.00003994813,0.00091823493,0.00007708101,0.20546633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973347,0.0001595135,0.00005436695,0.00013778884,0.0013291606,0.0009844117],"domain_scores_gemma":[0.9926641,0.0008933481,0.00037247446,0.00016517512,0.0038590136,0.002045821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015504454,0.00023526498,0.0002605541,0.0006579263,0.0077922293,0.0053226594,0.0006196514,0.009031355,0.024964673],"category_scores_gemma":[0.015973153,0.0002732935,0.0003711446,0.0009841748,0.0023557115,0.0024090458,0.00088841125,0.0054434016,0.0045234906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008275225,0.00005111709,0.0053037335,0.00007249547,0.000023514745,0.00022626003,0.00040798684,0.000095482355,0.00036605168,0.04019477,0.93536514,0.01781073],"study_design_scores_gemma":[0.000060426082,0.000022453485,0.008558779,0.00013319927,0.000030556053,0.00007899378,0.00088833383,0.00014384717,0.00053735595,0.0045483257,0.98493296,0.000064673164],"about_ca_topic_score_codex":0.9014071,"about_ca_topic_score_gemma":0.935493,"teacher_disagreement_score":0.09859288,"about_ca_system_score_codex":0.014397897,"about_ca_system_score_gemma":0.049902808,"threshold_uncertainty_score":0.19834697},"labels":[],"label_agreement":null},{"id":"W1573407744","doi":"","title":"Investigating Generic and Brand Name Pharmaceutical’s Market Shares and Prices in Tunisia","year":2008,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Market share; Competition (biology); Product (mathematics); Generic drug; Brand names; Quarter (Canadian coin); Business; Advertising; Marketing; Economics; Monetary economics; Drug; Medicine; Mathematics; Pharmacology; Geography","score_opus":0.11948443549014058,"score_gpt":0.35720654513371236,"score_spread":0.23772210964357177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1573407744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962404,0.0005036713,0.00010104542,0.0002962566,0.00000568145,0.0000057336274,0.0008942546,0.0000048292395,0.001947993],"genre_scores_gemma":[0.9981725,0.00016076126,0.000069638416,0.000032222488,0.000016132391,0.000004729973,0.00066581287,0.0000024310343,0.0008756128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994764,0.00009424268,0.000043758922,0.00010805431,0.00011401429,0.00016354643],"domain_scores_gemma":[0.9974832,0.00055446435,0.001580454,0.00005631932,0.00019431082,0.00013129022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076099543,0.00020522006,0.00028679773,0.001582605,0.00035068957,0.0015268474,0.00041473735,0.00051173207,0.0041339938],"category_scores_gemma":[0.0023893316,0.00013965445,0.00057346496,0.0023843334,0.00035741503,0.0010004434,0.0005404714,0.00047203433,0.00040453757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021349048,0.00011277464,0.9838689,0.000055000455,0.00018883099,0.0005501213,0.00063182315,0.0013154844,0.0007692756,0.0014030695,0.0008185289,0.010072654],"study_design_scores_gemma":[0.000010252843,0.00006725746,0.99215794,0.000015814276,0.00004658072,0.00011999489,0.0012686811,0.003321101,0.00043948475,0.00016898898,0.0023734318,0.000010479289],"about_ca_topic_score_codex":0.09023418,"about_ca_topic_score_gemma":0.049953196,"teacher_disagreement_score":0.09023418,"about_ca_system_score_codex":0.0020541286,"about_ca_system_score_gemma":0.0006597548,"threshold_uncertainty_score":0.17941791},"labels":[],"label_agreement":null},{"id":"W1573991396","doi":"10.3386/w13862","title":"Is Medicine an Ivory Tower? Induced Innovation, Technological Opportunity, and For-Profit vs. Non-Profit Innovation","year":2008,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Institute on Aging","keywords":"Ivory tower; Profit (economics); Business; For profit; Industrial organization; Economics; Microeconomics; Political science; Finance; Law","score_opus":0.7419069268046703,"score_gpt":0.567247715320468,"score_spread":0.17465921148420227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1573991396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7784597,0.0098917,0.013879369,0.069267154,0.00032942803,0.00009190787,0.0005211503,0.000076566444,0.12748297],"genre_scores_gemma":[0.99285406,0.0015365037,0.0012461202,0.0017131409,0.00033500226,0.000017740082,0.0000736747,0.000011117383,0.0022127014],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9973935,0.0010269731,0.00012198334,0.0003419473,0.00071184937,0.00040377327],"domain_scores_gemma":[0.9647464,0.022477813,0.007640495,0.0015261665,0.0011969095,0.002412213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053358027,0.00017312796,0.0006598951,0.002474042,0.001117046,0.0039675846,0.00040201162,0.0011877511,0.00862937],"category_scores_gemma":[0.027080882,0.00016252908,0.00044835533,0.0021823996,0.004204054,0.004823103,0.0016449812,0.0011050375,0.0005017369],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011904212,0.00034721318,0.24682865,0.000649085,0.0003900682,0.00051098375,0.0029321203,0.0035234771,0.0015714263,0.53925323,0.008714408,0.19408889],"study_design_scores_gemma":[0.00019808034,0.0005813383,0.44384933,0.00057958567,0.00020758841,0.00048323206,0.004021001,0.0063460255,0.0010560281,0.48927534,0.053333465,0.0000689938],"about_ca_topic_score_codex":0.0019726548,"about_ca_topic_score_gemma":0.0024480063,"teacher_disagreement_score":0.00862937,"about_ca_system_score_codex":0.002021202,"about_ca_system_score_gemma":0.0017536951,"threshold_uncertainty_score":0.028868139},"labels":[],"label_agreement":null},{"id":"W1583275573","doi":"10.2139/ssrn.2567637","title":"Structure-Function Analysis of Global Pharmaceutical Linkage Regulations","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Calgary; University of Manitoba","funders":"","keywords":"Linkage (software); Function (biology); Computational biology; Business; Genetics; Biology; Gene","score_opus":0.046827087808560125,"score_gpt":0.31188395082265036,"score_spread":0.26505686301409026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1583275573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7797788,0.001180674,0.16583905,0.00460591,0.00009295891,0.00013799824,0.0009001268,0.000551728,0.046912838],"genre_scores_gemma":[0.9749268,0.0004978301,0.004640519,0.00019676168,0.00007153138,0.00007688731,0.00032937434,0.00008008622,0.019180167],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9990081,0.0004059858,0.000026877064,0.0001477562,0.00014289249,0.0002682998],"domain_scores_gemma":[0.9938164,0.0041010757,0.0009387424,0.0003989621,0.00044406913,0.00030078125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003220875,0.00073507597,0.0024508121,0.0018770152,0.0010583355,0.0028645466,0.0015904087,0.003326357,0.01211845],"category_scores_gemma":[0.01138355,0.0008438689,0.0023274524,0.0018062914,0.0020700484,0.0026501769,0.0016354332,0.0029647183,0.0006632506],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001216157,0.00017877397,0.004397288,0.000102849954,0.00016116472,0.0002489077,0.00022454877,0.4973865,0.00089409883,0.4815585,0.004536631,0.010189152],"study_design_scores_gemma":[0.00010682873,0.000116823176,0.0067374464,0.000042755724,0.00012360787,0.000055219738,0.00022127554,0.7688278,0.00039479035,0.22105551,0.0022683349,0.00004964133],"about_ca_topic_score_codex":0.016206983,"about_ca_topic_score_gemma":0.011492939,"teacher_disagreement_score":0.016206983,"about_ca_system_score_codex":0.0031556366,"about_ca_system_score_gemma":0.0024626837,"threshold_uncertainty_score":0.040540278},"labels":[],"label_agreement":null},{"id":"W158415122","doi":"10.1177/009885880803400209","title":"Ending Drug Registration Apartheid: Taming Data Exclusivity and Patent/Registration Linkage","year":2008,"lang":"en","type":"article","venue":"American Journal of Law & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Monopoly; Competitor analysis; China; Latin Americans; Government (linguistics); Business; Quarter (Canadian coin); Pharmaceutical industry; International trade; Gold rush; Economics; Market economy; Marketing; Law; Political science","score_opus":0.17800802551524444,"score_gpt":0.3249422304955516,"score_spread":0.14693420498030715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W158415122","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2498173,0.0028357464,0.31494913,0.14276968,0.0008790414,0.00079526036,0.00055502186,0.0027934227,0.2846054],"genre_scores_gemma":[0.95812285,0.0007264592,0.024894377,0.008134009,0.00040156153,0.00031783918,0.00009955092,0.0003830583,0.0069203107],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9489852,0.033616714,0.001961737,0.0047057625,0.007540394,0.0031901568],"domain_scores_gemma":[0.6140407,0.29185,0.024998534,0.05744032,0.007296173,0.004374336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05906504,0.000996106,0.0017125371,0.003499635,0.00575309,0.010556544,0.0045904503,0.006442902,0.02010118],"category_scores_gemma":[0.24606892,0.0010579353,0.0017820727,0.0043570916,0.020830423,0.026665526,0.017069327,0.010044305,0.0036614777],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048752007,0.0003414012,0.008657321,0.00027862226,0.00008191698,0.0005011118,0.0048388764,0.0049292706,0.0012503715,0.86517304,0.009928341,0.103532165],"study_design_scores_gemma":[0.00043756826,0.00048988586,0.00406682,0.00049664156,0.00021209054,0.0008517963,0.0031323659,0.022909172,0.005450035,0.8858181,0.07598314,0.00015240745],"about_ca_topic_score_codex":0.00288051,"about_ca_topic_score_gemma":0.0015750509,"teacher_disagreement_score":0.05906504,"about_ca_system_score_codex":0.004257877,"about_ca_system_score_gemma":0.0117019955,"threshold_uncertainty_score":0.31236953},"labels":[],"label_agreement":null},{"id":"W1584507582","doi":"","title":"How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009.","year":2014,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Interquartile range; Family medicine; Internal medicine","score_opus":0.024051972051048937,"score_gpt":0.1936623092082921,"score_spread":0.16961033715724316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1584507582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88297206,0.035428632,0.0005964911,0.007882311,0.00019067884,0.000292153,0.044618342,0.000082578306,0.027936734],"genre_scores_gemma":[0.98413754,0.0049463785,0.00047341236,0.0011939915,0.00006224719,0.000040858693,0.0062897573,0.000017492144,0.0028383187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99498993,0.00025726878,0.00048040488,0.00048275726,0.0032041827,0.0005854145],"domain_scores_gemma":[0.98582596,0.0014594725,0.0073039318,0.00018516662,0.0039014474,0.0013239984],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026240917,0.00026385998,0.00041971492,0.0021477104,0.0011195132,0.0016061745,0.00087562745,0.0005527404,0.0025952575],"category_scores_gemma":[0.0105502205,0.00018985206,0.00066967716,0.004832392,0.0008666855,0.0007718097,0.00068252435,0.0013468812,0.0003412119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013933058,0.000072388306,0.9156895,0.0010281537,0.00019585948,0.00067777274,0.0012313314,0.00047731283,0.0007479232,0.0005845787,0.013301125,0.0646008],"study_design_scores_gemma":[0.000020560794,0.000050883893,0.990033,0.00011432314,0.00004234978,0.0002860046,0.0004500153,0.0002622654,0.00024164753,0.000049982915,0.008432547,0.000016452403],"about_ca_topic_score_codex":0.9416668,"about_ca_topic_score_gemma":0.9527931,"teacher_disagreement_score":0.9973759,"about_ca_system_score_codex":0.031371627,"about_ca_system_score_gemma":0.025883833,"threshold_uncertainty_score":0.2276181},"labels":[],"label_agreement":null},{"id":"W158531728","doi":"","title":"Hospital Procurement with Concentrated Sellers: A Case Study of Hip Prostheses","year":2013,"lang":"en","type":"preprint","venue":"UEA Digital Repository (University of East Anglia)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Procurement; Diversity (politics); Oligopoly; Business; Competition (biology); Industrial organization; Operations management; Marketing; Economics; Welfare; Market economy; Political science","score_opus":0.04457979910193236,"score_gpt":0.21533992488041975,"score_spread":0.1707601257784874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W158531728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565303,0.00022519853,0.0010723885,0.0006606107,0.0000050983863,0.000048458296,0.00007239468,0.000003227192,0.002259507],"genre_scores_gemma":[0.995317,0.0004967589,0.001962929,0.00018681475,0.000020464518,0.00004948687,0.00007798783,0.0000086548,0.0018800724],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99486214,0.0036023576,0.00019401901,0.00026616777,0.0003989734,0.00067633094],"domain_scores_gemma":[0.9838923,0.011930327,0.001971951,0.0005955251,0.00047006892,0.0011397348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004872446,0.0004694202,0.00073290203,0.0015815616,0.004665098,0.0026052748,0.0016835621,0.0032632342,0.0059615886],"category_scores_gemma":[0.011009417,0.000662168,0.000879127,0.0029249291,0.0023322173,0.0018060233,0.0026022953,0.0018087124,0.00063733093],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013440776,0.0051908707,0.58139217,0.0006620014,0.00038608344,0.20203099,0.11974045,0.012218677,0.001990594,0.031520464,0.004246422,0.039277244],"study_design_scores_gemma":[0.00047815236,0.003527314,0.26247838,0.0004974602,0.00025632136,0.08529603,0.57215923,0.030809928,0.0025201943,0.015383104,0.02629249,0.0003014117],"about_ca_topic_score_codex":0.0169054,"about_ca_topic_score_gemma":0.030662686,"teacher_disagreement_score":0.0169054,"about_ca_system_score_codex":0.0030780316,"about_ca_system_score_gemma":0.0015245003,"threshold_uncertainty_score":0.03361398},"labels":[],"label_agreement":null},{"id":"W1585529854","doi":"10.18433/j3659z","title":"Assessing Bioequivalence of Antiepileptic Drugs: Are the Current Requirements too Permissive?","year":2014,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Cmax; Confidence interval; Medicine; Pharmacokinetics; Pharmacology; Mathematics; Statistics","score_opus":0.2325925722123949,"score_gpt":0.44261156354970543,"score_spread":0.21001899133731053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1585529854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77882385,0.08773675,0.09697135,0.010643111,0.00035407525,0.00064016075,0.001847143,0.00026859387,0.022714956],"genre_scores_gemma":[0.97880334,0.0025516178,0.016539002,0.0010376011,0.00013486051,0.00021485514,0.0005485506,0.000036917016,0.00013329774],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.7647403,0.13849278,0.034868706,0.010253879,0.050504606,0.0011397883],"domain_scores_gemma":[0.48925388,0.32704446,0.12128956,0.035170354,0.026124487,0.0011172052],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.1933143,0.0004970718,0.0017051023,0.0013778075,0.0003739505,0.0035480775,0.0019378823,0.001560459,0.00075786794],"category_scores_gemma":[0.2880483,0.00047688803,0.0014700419,0.0022589369,0.0023064339,0.0035803637,0.0013861788,0.0016045055,0.00026440845],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047334544,0.00051776494,0.45806554,0.010276683,0.0046513425,0.0003997926,0.0056750174,0.008709892,0.025354665,0.013733153,0.0023006697,0.46558207],"study_design_scores_gemma":[0.0004827022,0.009473806,0.8636842,0.006958864,0.0026143217,0.0041317525,0.0022809403,0.0136662815,0.03014361,0.026328733,0.039979637,0.00025509045],"about_ca_topic_score_codex":0.0010124496,"about_ca_topic_score_gemma":0.00090946193,"teacher_disagreement_score":0.1933143,"about_ca_system_score_codex":0.001407266,"about_ca_system_score_gemma":0.0023803895,"threshold_uncertainty_score":0.9947871},"labels":[],"label_agreement":null},{"id":"W1585859626","doi":"10.1007/s10754-015-9172-2","title":"The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011","year":2015,"lang":"en","type":"article","venue":"International Journal of Health Economics and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mortality rate; Demography; Cumulative incidence; Incidence (geometry); Cancer; Cancer incidence; Toxicology; Internal medicine; Biology; Cohort","score_opus":0.13403582872422404,"score_gpt":0.40428684232802925,"score_spread":0.2702510136038052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1585859626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86077124,0.021386521,0.00087228534,0.018013379,0.00031457722,0.00015170874,0.07944713,0.00013221978,0.018910998],"genre_scores_gemma":[0.97354376,0.0069921683,0.00048833573,0.00087092165,0.000096485615,0.00004009312,0.013029764,0.000015048247,0.004923465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971324,0.00017874672,0.00017769431,0.00021074129,0.0013747675,0.00092558214],"domain_scores_gemma":[0.99004805,0.0007264545,0.002510465,0.00017620483,0.0046920828,0.0018467103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014908804,0.0003985414,0.00065174856,0.0026933353,0.0015248582,0.0015077831,0.0010846985,0.00068121817,0.0024943764],"category_scores_gemma":[0.010000712,0.0002768779,0.0019215744,0.0052328934,0.0006439289,0.0005028608,0.0012357638,0.0020126337,0.00022472127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046243236,0.000057580917,0.94954187,0.0003377776,0.0006586249,0.00018732343,0.0003930111,0.0026643637,0.000154446,0.0014830726,0.014013878,0.030045586],"study_design_scores_gemma":[0.00002350627,0.0000473746,0.992568,0.00007843011,0.00018381356,0.000053471435,0.00025770746,0.0014730042,0.00012994518,0.00013555697,0.0050280173,0.000021210379],"about_ca_topic_score_codex":0.99408346,"about_ca_topic_score_gemma":0.99536407,"teacher_disagreement_score":0.059088178,"about_ca_system_score_codex":0.059088178,"about_ca_system_score_gemma":0.086336285,"threshold_uncertainty_score":0.42871672},"labels":[],"label_agreement":null},{"id":"W1592662300","doi":"","title":"Flexible Drug Patent Terms: A Proposed Mechanism to Stimulate Global Innovation and Health","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Incentive; Balance (ability); Business; Public economics; Component (thermodynamics); Law and economics; Access to medicines; Industrial organization; Mechanism (biology); Drug development; Drug; Developing country; International trade; Economic growth; Economics; Market economy; Pharmacology; Medicine","score_opus":0.06278375253874424,"score_gpt":0.30034832197545624,"score_spread":0.237564569436712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592662300","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08659477,0.0026734169,0.35306898,0.14934203,0.0010480959,0.0009586894,0.00043318875,0.0006521792,0.40522859],"genre_scores_gemma":[0.90977466,0.0011281138,0.04999868,0.005791646,0.0011585727,0.0007187426,0.00005737679,0.00006848593,0.031303637],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9937211,0.0031317582,0.00021031093,0.0009390563,0.0011159005,0.0008818698],"domain_scores_gemma":[0.99166405,0.004222483,0.0012807451,0.0013828196,0.0007728361,0.0006769945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010525654,0.0008217773,0.00089755445,0.0024872313,0.0021139989,0.0066219764,0.0026626585,0.009690165,0.018086048],"category_scores_gemma":[0.01922194,0.00061399397,0.0015054984,0.001846003,0.01039487,0.011730928,0.0049619745,0.004250294,0.0013399784],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015568696,0.000018685358,0.00009320483,0.000021972197,0.0000056451827,0.000030492463,0.000072570554,0.0016973418,0.00021307248,0.99320567,0.00095715746,0.003668619],"study_design_scores_gemma":[0.00016715535,0.00008117203,0.00030770007,0.00005054642,0.00001665001,0.00006931097,0.0000721473,0.0051696384,0.000289719,0.97297454,0.020776417,0.000024856992],"about_ca_topic_score_codex":0.0011913492,"about_ca_topic_score_gemma":0.00095473626,"teacher_disagreement_score":0.018086048,"about_ca_system_score_codex":0.004574446,"about_ca_system_score_gemma":0.0053784447,"threshold_uncertainty_score":0.06050384},"labels":[],"label_agreement":null},{"id":"W1592821973","doi":"10.4212/cjhp.v53i4.754","title":"Drugs of Choice: a Formulary for General Practice","year":2000,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Formulary; Family medicine; Medicine","score_opus":0.039194251329043965,"score_gpt":0.30857888820507473,"score_spread":0.26938463687603076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592821973","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059694517,0.030313727,0.23957792,0.24512571,0.009384846,0.0026866451,0.026320348,0.010101052,0.3767952],"genre_scores_gemma":[0.35512587,0.026258692,0.4130421,0.01651216,0.0077015143,0.0014439706,0.012506475,0.0013186234,0.16609061],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980198,0.0006418513,0.00025905084,0.00014907765,0.0008025109,0.00012782846],"domain_scores_gemma":[0.9931677,0.0025228828,0.00081464474,0.0008241197,0.0016577975,0.0010128279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023289798,0.0005981483,0.0008669961,0.003415594,0.0012943976,0.0044985423,0.0010247949,0.003023826,0.026681297],"category_scores_gemma":[0.022140574,0.0004272692,0.0008140928,0.0041020387,0.0010062299,0.004393177,0.001936668,0.0021550797,0.006248645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031296554,0.00019322416,0.006499802,0.0003351066,0.000027551685,0.00037625717,0.00019900102,0.0036185146,0.0005670142,0.1583745,0.3878596,0.44163644],"study_design_scores_gemma":[0.0002468273,0.00032339123,0.0068442603,0.0006300849,0.00010704906,0.0010578551,0.00024403006,0.023639267,0.0008647151,0.11326729,0.8527001,0.0000750789],"about_ca_topic_score_codex":0.015116629,"about_ca_topic_score_gemma":0.018198112,"teacher_disagreement_score":0.026681297,"about_ca_system_score_codex":0.0042673163,"about_ca_system_score_gemma":0.009017121,"threshold_uncertainty_score":0.08925784},"labels":[],"label_agreement":null},{"id":"W1595600554","doi":"","title":"The link between publicly funded health care and compulsory licensing.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Government (linguistics); Order (exchange); Business; Government regulation; Health care; Law; Finance; Political science","score_opus":0.12873320509855748,"score_gpt":0.26773405691954083,"score_spread":0.13900085182098335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1595600554","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018520103,0.0032929385,0.000054355976,0.98049176,0.012932774,0.000006216762,0.00021247177,0.000011289591,0.0028129728],"genre_scores_gemma":[0.0031034935,0.0023732986,0.00008652476,0.9715281,0.019151345,0.000024519602,0.000063029736,0.000012517883,0.003657102],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901454,0.002373205,0.00067828054,0.0015006013,0.0040691164,0.001233389],"domain_scores_gemma":[0.87614334,0.10441104,0.0032425616,0.0012628891,0.011186,0.0037541732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009621185,0.0008120156,0.0016969611,0.0018065271,0.0036477868,0.004801438,0.007434686,0.08485745,0.019410923],"category_scores_gemma":[0.09885932,0.00091044244,0.001884693,0.002654617,0.0065259114,0.008325261,0.00273122,0.047759764,0.0048547355],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047632562,0.000007988559,0.00010508442,0.0001786953,0.000018179857,0.00020836006,0.00010168836,0.000041363568,0.000041433213,0.02538282,0.9703756,0.0034912017],"study_design_scores_gemma":[0.00020758239,0.00003964425,0.0014087992,0.0020845518,0.00008863557,0.0005258224,0.0004899162,0.00024502957,0.00028264688,0.027363848,0.96717715,0.000086385044],"about_ca_topic_score_codex":0.07002097,"about_ca_topic_score_gemma":0.07956288,"teacher_disagreement_score":0.08485745,"about_ca_system_score_codex":0.0090259975,"about_ca_system_score_gemma":0.020238994,"threshold_uncertainty_score":0.1392268},"labels":[],"label_agreement":null},{"id":"W1597065337","doi":"","title":"Why Canada’s Access to Medicines Regime Can Never Succeed","year":2010,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Pledge; Scrutiny; Law; Wonder; Business; China; House of Commons; Political science; Legislation; Parliament","score_opus":0.024292638566285295,"score_gpt":0.2733392153780239,"score_spread":0.2490465768117386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1597065337","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011153237,0.00982708,0.00079529086,0.7584628,0.0027807897,0.00006365643,0.0010529503,0.00019279437,0.21567143],"genre_scores_gemma":[0.2923461,0.00864616,0.0018460513,0.53580743,0.0012418707,0.00009550113,0.00062095345,0.00030715863,0.15908872],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9849599,0.0011406054,0.0002256981,0.0013173288,0.0071981247,0.00515835],"domain_scores_gemma":[0.98755985,0.0019495521,0.00038686433,0.00037010945,0.0061302404,0.0036034267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004476392,0.0005985065,0.0006053578,0.0014424785,0.026761223,0.014164447,0.0025399849,0.013549519,0.021376282],"category_scores_gemma":[0.0172585,0.0008014762,0.0009301171,0.0018084809,0.012763495,0.005658159,0.0034327558,0.012354217,0.0025151873],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070431546,0.000040502106,0.0032384011,0.00012740573,0.000044519904,0.0004933672,0.0018230675,0.0003160543,0.00035668546,0.31212234,0.65842557,0.022941563],"study_design_scores_gemma":[0.00006346147,0.000028968841,0.0049102027,0.00019030717,0.000030610474,0.00011333823,0.0018027986,0.00030252425,0.00033053668,0.017637141,0.9744537,0.00013645944],"about_ca_topic_score_codex":0.98898494,"about_ca_topic_score_gemma":0.98932797,"teacher_disagreement_score":0.8954636,"about_ca_system_score_codex":0.1045364,"about_ca_system_score_gemma":0.2019874,"threshold_uncertainty_score":0.7584682},"labels":[],"label_agreement":null},{"id":"W1601475699","doi":"10.1002/cncr.29246","title":"Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration","year":2015,"lang":"en","type":"article","venue":"Cancer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Formulary; Interquartile range; Drug; Food and drug administration; Timeline; New drug application; Family medicine; Internal medicine; Pharmacology","score_opus":0.13941762883649994,"score_gpt":0.3770549472656633,"score_spread":0.23763731842916336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1601475699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8287002,0.039540734,0.004436496,0.007830595,0.00041640576,0.00038651293,0.039616402,0.00032264777,0.078750044],"genre_scores_gemma":[0.9831033,0.004423588,0.0015619323,0.000848485,0.00007374556,0.00008896787,0.007289649,0.00006400835,0.0025463314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990431,0.0009039911,0.00065631827,0.0009303088,0.005659757,0.0014186638],"domain_scores_gemma":[0.96068066,0.0045464104,0.009622604,0.0004893579,0.022149382,0.0025116012],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042228303,0.00030701543,0.0004453235,0.0049814614,0.001561347,0.0022012042,0.00090421154,0.00036824003,0.003647352],"category_scores_gemma":[0.02175945,0.00022516912,0.00085307006,0.007775425,0.00068809243,0.0006760097,0.0008865872,0.0010671146,0.00040818844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001217775,0.00007840176,0.8804985,0.0006983843,0.0007442058,0.0003385781,0.0015486911,0.0019561714,0.00062384456,0.0026760562,0.024408238,0.08521118],"study_design_scores_gemma":[0.000037695376,0.00009738296,0.971018,0.00016490072,0.00014859655,0.00021391209,0.0010359356,0.00091639004,0.0004902693,0.00013013992,0.025706604,0.000040234234],"about_ca_topic_score_codex":0.962187,"about_ca_topic_score_gemma":0.9694184,"teacher_disagreement_score":0.9957772,"about_ca_system_score_codex":0.0401773,"about_ca_system_score_gemma":0.058582455,"threshold_uncertainty_score":0.29150808},"labels":[],"label_agreement":null},{"id":"W1603625064","doi":"10.1007/s10198-006-0345-2","title":"Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers","year":2006,"lang":"en","type":"article","venue":"The European Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Documentation; Harmonization; Business; Quality (philosophy); Process (computing); Pharmaceutical industry; Public relations; Political science; Medicine; Computer science; Pharmacology","score_opus":0.22480921121266492,"score_gpt":0.40771578315318063,"score_spread":0.1829065719405157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1603625064","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30263108,0.03472986,0.02091516,0.5089432,0.0032381243,0.0014147755,0.0027767695,0.0002922217,0.12505886],"genre_scores_gemma":[0.9530706,0.007824708,0.0061851675,0.01759462,0.002768749,0.001040146,0.0011876955,0.000068711466,0.010259649],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.7329446,0.21309651,0.012225077,0.0058205253,0.0224106,0.013502715],"domain_scores_gemma":[0.20777,0.5914383,0.061583314,0.02265267,0.042500116,0.07405554],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.204681,0.0004887564,0.0016611291,0.008230001,0.0039103837,0.014031933,0.0023769813,0.0062789824,0.019715644],"category_scores_gemma":[0.2905189,0.0005443603,0.0013325664,0.00875786,0.0029974794,0.0069191293,0.01455579,0.005316525,0.0013556534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007557499,0.00315291,0.3130866,0.0030724313,0.00205455,0.0011605325,0.014989394,0.0036178636,0.001596612,0.15288,0.095456086,0.40137544],"study_design_scores_gemma":[0.0053841136,0.0038892222,0.25503466,0.0066880155,0.0015193325,0.0020604192,0.061467744,0.008917831,0.0054090745,0.35764933,0.2915505,0.0004298599],"about_ca_topic_score_codex":0.0019939693,"about_ca_topic_score_gemma":0.0025047127,"teacher_disagreement_score":0.204681,"about_ca_system_score_codex":0.009334528,"about_ca_system_score_gemma":0.061200295,"threshold_uncertainty_score":0.98076993},"labels":[],"label_agreement":null},{"id":"W1606568036","doi":"10.1136/bmj.321.7264.833/b","title":"Effect of drug patents in developing countries","year":2000,"lang":"en","type":"letter","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Per capita; Developing country; Gross domestic product; Human immunodeficiency virus (HIV); Business; Developed country; Drug; Development economics; Economic growth; Medicine; International trade; Environmental health; Economics; Virology; Pharmacology; Population","score_opus":0.04751275463281795,"score_gpt":0.3042359931747397,"score_spread":0.25672323854192175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606568036","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032154573,0.0019101904,0.000039146405,0.9689885,0.0258345,0.0000122467,0.00015936929,0.000016679624,0.0027178605],"genre_scores_gemma":[0.0032462904,0.0016560762,0.00010095682,0.92428845,0.06554272,0.000024200814,0.00003294533,0.000011641538,0.0050966437],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976762,0.00061852805,0.00035529616,0.0003007843,0.00077488663,0.0002743864],"domain_scores_gemma":[0.9872657,0.007837939,0.0012366201,0.00029110312,0.0020687026,0.0013000319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004821123,0.0010161835,0.0014284056,0.00096483383,0.0023993202,0.003345601,0.0019132793,0.034016564,0.00682001],"category_scores_gemma":[0.029437251,0.00067955395,0.0012011783,0.0011362345,0.0018249039,0.0035130472,0.0009194508,0.033583842,0.0050218836],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006951556,0.000017002232,0.00035136956,0.00007903226,0.000015799897,0.00042516936,0.00003995443,0.00003766237,0.00006671782,0.0010714394,0.991301,0.0065253223],"study_design_scores_gemma":[0.00028384093,0.00009174595,0.0036075716,0.00053822953,0.00008151303,0.0009551531,0.0002641549,0.0003735471,0.0003400408,0.004267411,0.98913294,0.00006394475],"about_ca_topic_score_codex":0.005297425,"about_ca_topic_score_gemma":0.007828556,"teacher_disagreement_score":0.034016564,"about_ca_system_score_codex":0.0023786929,"about_ca_system_score_gemma":0.0032705024,"threshold_uncertainty_score":0.02549684},"labels":[],"label_agreement":null},{"id":"W1607471832","doi":"10.2139/ssrn.258289","title":"Should the U.S. Allow Prescription Drug Reimports from Canada?","year":2001,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Prescription drug; Medicine; Pharmacology","score_opus":0.033626949842100136,"score_gpt":0.24569918266906204,"score_spread":0.21207223282696192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1607471832","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035577435,0.0061535337,0.00035047217,0.8549523,0.0029411495,0.00012126707,0.0043553514,0.00017351848,0.09537492],"genre_scores_gemma":[0.38660395,0.008228386,0.0018911503,0.5063627,0.0019887614,0.00009501119,0.001658442,0.00011966328,0.09305196],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939037,0.0003546575,0.00019954491,0.0003086974,0.0022718557,0.002961465],"domain_scores_gemma":[0.9859428,0.0015077916,0.0007570024,0.00026078266,0.007270069,0.004261592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035378525,0.00037854278,0.00059105316,0.0012447692,0.0057495786,0.005276366,0.0018945923,0.010795836,0.017589955],"category_scores_gemma":[0.019632583,0.00037864893,0.0009342159,0.0018199978,0.0016275576,0.0022681581,0.0013919497,0.0056595216,0.0014047379],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040573764,0.00015432424,0.04023127,0.00026448676,0.00015985228,0.0006854719,0.000752998,0.001704787,0.0010291623,0.083675265,0.81316584,0.057770878],"study_design_scores_gemma":[0.00040176397,0.00014588589,0.10993025,0.00077800127,0.00029575283,0.00032936898,0.0027803355,0.0030785664,0.0020420905,0.011058403,0.8688877,0.00027183507],"about_ca_topic_score_codex":0.98588514,"about_ca_topic_score_gemma":0.9932273,"teacher_disagreement_score":0.04274898,"about_ca_system_score_codex":0.04274898,"about_ca_system_score_gemma":0.22277011,"threshold_uncertainty_score":0.310167},"labels":[],"label_agreement":null},{"id":"W1608419","doi":"","title":"�IN CIPRO WE TRUST�: BUT HOW DO WE FEEL ABOUT OUR DRUG PATENT LAWS?","year":2002,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislature; Political science; Incentive; Law; Law and economics; Public administration; Sociology; Economics","score_opus":0.14061384842621152,"score_gpt":0.2672517558786675,"score_spread":0.12663790745245598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1608419","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016177697,0.034348022,0.0018849073,0.79483074,0.001112353,0.000024918008,0.00022387892,0.00006665359,0.1513309],"genre_scores_gemma":[0.60298693,0.05702143,0.002239256,0.27834564,0.0014219005,0.00004711834,0.0003743875,0.00016684413,0.05739645],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9825258,0.0024148105,0.0003479421,0.0017177741,0.008087718,0.004905917],"domain_scores_gemma":[0.98259455,0.0058016987,0.0018129115,0.00070010114,0.00637761,0.0027131066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008723164,0.00034661527,0.0006420684,0.002475059,0.021064822,0.029421516,0.0021053997,0.008787678,0.008326757],"category_scores_gemma":[0.028964981,0.00047307016,0.00053477264,0.004252182,0.039420053,0.014996233,0.0030594436,0.013215121,0.0020291323],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053060085,0.000055956792,0.004915935,0.00037484424,0.000042030184,0.00030781978,0.03416009,0.00020782759,0.00090163306,0.61432385,0.24617471,0.09848235],"study_design_scores_gemma":[0.000013929304,0.00004079571,0.010766931,0.0007735194,0.00003860991,0.00021277028,0.04140742,0.00014346157,0.00052278105,0.048795924,0.8971563,0.00012766564],"about_ca_topic_score_codex":0.7307534,"about_ca_topic_score_gemma":0.72297,"teacher_disagreement_score":0.7307534,"about_ca_system_score_codex":0.051542126,"about_ca_system_score_gemma":0.08175071,"threshold_uncertainty_score":0.5416644},"labels":[],"label_agreement":null},{"id":"W1618254171","doi":"","title":"Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Formulary; CLARITY; Listing (finance); Reimbursement; Medicine; Work (physics); Process (computing); Public relations; Business; Marketing; Family medicine; Finance; Health care; Economic growth; Political science; Computer science","score_opus":0.09467310414187498,"score_gpt":0.300856754266625,"score_spread":0.20618365012475004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1618254171","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67778414,0.006997839,0.014084981,0.22028458,0.0007374222,0.0062300516,0.0036539899,0.00055842684,0.06966846],"genre_scores_gemma":[0.9665867,0.0009644194,0.021222472,0.0066830213,0.0001469201,0.0003203935,0.00082093274,0.00004148199,0.0032135104],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.92907786,0.022837639,0.006081537,0.0025622929,0.03000115,0.009439493],"domain_scores_gemma":[0.6934785,0.12547772,0.047480017,0.0069218273,0.10811961,0.01852241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0956146,0.00042982263,0.00060810667,0.0044717793,0.008761607,0.007850989,0.003102778,0.0030057472,0.004298004],"category_scores_gemma":[0.2527955,0.00085081614,0.0009501437,0.0062901196,0.0033645988,0.0035626867,0.003123466,0.0032269107,0.00045530245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018072701,0.00087606616,0.526197,0.0029428436,0.00023314124,0.0018996693,0.021897174,0.01354695,0.003445936,0.031365268,0.08875656,0.30703205],"study_design_scores_gemma":[0.00042649676,0.0004438368,0.8906577,0.0015532188,0.00017475587,0.0005880512,0.017270261,0.014143676,0.0020848496,0.005605903,0.06658469,0.00046656438],"about_ca_topic_score_codex":0.94448745,"about_ca_topic_score_gemma":0.9481983,"teacher_disagreement_score":0.8797785,"about_ca_system_score_codex":0.120221496,"about_ca_system_score_gemma":0.3062331,"threshold_uncertainty_score":0.8722721},"labels":[],"label_agreement":null},{"id":"W1637876992","doi":"","title":"Price, Property and Trade Across a Regulatory Border: Pharmaceuticals (Re)importation from Canada and Beyond","year":2006,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"International trade; Intellectual property; Business; Property (philosophy); International economics; Economics; Economic geography; Political science; Law","score_opus":0.016352294784881295,"score_gpt":0.26776685351961865,"score_spread":0.25141455873473734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1637876992","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04872557,0.076373816,0.0017426659,0.37387443,0.0022297797,0.00004103974,0.0007321733,0.00004307791,0.4962373],"genre_scores_gemma":[0.6783657,0.08510118,0.0020179388,0.13323833,0.001709437,0.000032967546,0.0004320683,0.0001223583,0.09897997],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960349,0.0003214672,0.00008321213,0.00042616497,0.0018839081,0.0012503439],"domain_scores_gemma":[0.99631786,0.0008693991,0.00026043883,0.0001439659,0.0017402208,0.0006681243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019070866,0.00034471185,0.00045589547,0.001988302,0.014933577,0.015310186,0.0012376503,0.0056480994,0.008150422],"category_scores_gemma":[0.0053914697,0.0002818451,0.0006192385,0.0042573167,0.015505963,0.006212728,0.0021510494,0.0063855913,0.00042048865],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035259083,0.000019737288,0.0041888356,0.00009326068,0.000020781148,0.00040748637,0.0052482653,0.00043380936,0.00026704156,0.85896444,0.103077985,0.0272432],"study_design_scores_gemma":[0.000019898414,0.000024725274,0.01827544,0.00087433663,0.000054633638,0.0002608887,0.012791524,0.00054542563,0.00044942016,0.0712759,0.8952841,0.00014365852],"about_ca_topic_score_codex":0.98438466,"about_ca_topic_score_gemma":0.99070376,"teacher_disagreement_score":0.11103448,"about_ca_system_score_codex":0.11103448,"about_ca_system_score_gemma":0.12954167,"threshold_uncertainty_score":0.8056153},"labels":[],"label_agreement":null},{"id":"W1648976812","doi":"10.4212/cjhp.v61i4.61","title":"Bilan comparatif des médicaments : Par qui et comment?","year":2008,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Gynecology; Medicine","score_opus":0.10740282034183495,"score_gpt":0.3154597458317358,"score_spread":0.20805692548990085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1648976812","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021855712,0.023042735,0.00043967078,0.9463507,0.022090746,0.000038148562,0.0009691441,0.00003505463,0.0048481477],"genre_scores_gemma":[0.047311094,0.009575148,0.0023404355,0.8779364,0.055129323,0.00021918757,0.00088391197,0.00012833043,0.006476121],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.88967407,0.049449623,0.016196055,0.009728733,0.03020606,0.0047453917],"domain_scores_gemma":[0.65992284,0.22918753,0.015998814,0.010492528,0.07830443,0.006093839],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08901467,0.0015880603,0.0044731637,0.0039213873,0.002806641,0.010432221,0.007868055,0.026455032,0.015975896],"category_scores_gemma":[0.3677175,0.00086385885,0.0056921835,0.007121014,0.0066188127,0.0175079,0.0032746645,0.022451548,0.004647324],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00640903,0.00036522912,0.009348083,0.0044488376,0.004099845,0.000650816,0.0010275608,0.00081149105,0.00044487987,0.060343944,0.83733696,0.07471342],"study_design_scores_gemma":[0.004495112,0.0011819552,0.023377832,0.0099012265,0.004343934,0.0013293363,0.005113982,0.0020615195,0.0017347737,0.113518916,0.8323589,0.00058255595],"about_ca_topic_score_codex":0.06373862,"about_ca_topic_score_gemma":0.07408634,"teacher_disagreement_score":0.9857827,"about_ca_system_score_codex":0.014217292,"about_ca_system_score_gemma":0.016996428,"threshold_uncertainty_score":0.47076023},"labels":[],"label_agreement":null},{"id":"W165696036","doi":"","title":"Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Arbitrage; Incentive; Economic rent; Business; TRIPS architecture; Public economics; Medical prescription; Economics; Industrial organization; Microeconomics; Financial economics","score_opus":0.0723133381837423,"score_gpt":0.3070397556881053,"score_spread":0.23472641750436302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W165696036","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.249033,0.05951725,0.18761903,0.13275933,0.0014511489,0.00047186282,0.0010613673,0.0004990052,0.36758795],"genre_scores_gemma":[0.9789025,0.0042606513,0.003404652,0.0013494521,0.00082029734,0.00011502289,0.00006490494,0.000026211665,0.011056267],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99655825,0.0014921644,0.0001570149,0.00037434365,0.00071672234,0.00070144504],"domain_scores_gemma":[0.9816726,0.012991734,0.00270962,0.00046520034,0.00097170554,0.00118921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075062206,0.0005654667,0.0013502866,0.0017756162,0.0020258152,0.0073172413,0.0011447889,0.0060320524,0.02091749],"category_scores_gemma":[0.037252832,0.00045814255,0.0012160086,0.0015748559,0.005636916,0.01149276,0.0044079493,0.0035938893,0.0007631596],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017359725,0.00005164911,0.0025906402,0.00018677485,0.00006911685,0.00027419766,0.00018302645,0.009950942,0.00034226401,0.9528308,0.0070782304,0.026268722],"study_design_scores_gemma":[0.00016845048,0.00007713585,0.0023640122,0.00009052873,0.000081613,0.00012246725,0.00021475907,0.019879878,0.000335341,0.9658034,0.010828042,0.000034403354],"about_ca_topic_score_codex":0.0037589762,"about_ca_topic_score_gemma":0.0031261751,"teacher_disagreement_score":0.02091749,"about_ca_system_score_codex":0.0032341874,"about_ca_system_score_gemma":0.0038209753,"threshold_uncertainty_score":0.06997603},"labels":[],"label_agreement":null},{"id":"W1664544119","doi":"10.1063/1.3137923","title":"Toward a Better Representation of Women in Physics in Burkina Faso","year":2009,"lang":"en","type":"article","venue":"AIP conference proceedings","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Preference; Quarter (Canadian coin); Population; Representation (politics); Mathematics education; Physics; Social science; Demography; Sociology; Geography; Political science; Mathematics; Statistics","score_opus":0.1079414189788852,"score_gpt":0.3114034167226903,"score_spread":0.20346199774380508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1664544119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735396,0.0028094973,0.0005831196,0.008736085,0.00013134882,0.00006132311,0.00019193516,0.000010573502,0.013936607],"genre_scores_gemma":[0.98921996,0.002259701,0.00035249186,0.0015688912,0.000039932656,0.000031588126,0.00007466552,0.0000066146927,0.006446059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995623,0.00013001598,0.000017780883,0.000046754536,0.000052782943,0.00019032646],"domain_scores_gemma":[0.99937385,0.00012996704,0.00016383154,0.000015408077,0.00010170767,0.00021520263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010519155,0.00020558554,0.00022922613,0.0015119907,0.0040457286,0.0016681722,0.0003029448,0.00048221686,0.009690215],"category_scores_gemma":[0.0014800902,0.00017633458,0.00008198012,0.0016305549,0.00069853815,0.001430579,0.0011088412,0.0005480933,0.00060296035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031780254,0.00027791437,0.65438265,0.00042239815,0.000035594483,0.0031841244,0.17577554,0.00014785335,0.012266049,0.012402275,0.010716323,0.13007158],"study_design_scores_gemma":[0.000057872126,0.00025202142,0.62275314,0.0005218849,0.000035151807,0.0018662576,0.20451702,0.0004097019,0.0016902387,0.0023958469,0.16542849,0.00007237943],"about_ca_topic_score_codex":0.050643098,"about_ca_topic_score_gemma":0.10513732,"teacher_disagreement_score":0.050643098,"about_ca_system_score_codex":0.0011408031,"about_ca_system_score_gemma":0.001409465,"threshold_uncertainty_score":0.10069662},"labels":[],"label_agreement":null},{"id":"W1671872086","doi":"10.5539/gjhs.v7n5p311","title":"Assessing the Factors Associated With Iran’s Intra-Industry Trade in Pharmaceuticals","year":2015,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Iran University of Medical Sciences","keywords":"Business; Order (exchange); Pharmaceutical industry; Tariff; Intra-industry trade; Product (mathematics); International trade; Trade barrier; International economics; Economics; Biotechnology","score_opus":0.3115110540027074,"score_gpt":0.43956482908499883,"score_spread":0.12805377508229143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1671872086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953851,0.00050737354,0.00012600976,0.00041995666,0.000011963856,0.000013717479,0.00031974053,0.0000030920587,0.003212949],"genre_scores_gemma":[0.9988875,0.00030080992,0.00021102466,0.000035209534,0.000020262993,0.0000039557317,0.00028138512,0.0000014802591,0.00025840243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994199,0.00010431503,0.00007294234,0.00007715857,0.00022631799,0.00009929139],"domain_scores_gemma":[0.9949143,0.0009436917,0.0031571437,0.00012300955,0.000511833,0.00034998154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000934062,0.00019930149,0.00013756567,0.0015806697,0.00034999687,0.00091128814,0.0002055228,0.0002576755,0.0028044158],"category_scores_gemma":[0.003881754,0.00008109731,0.0004896676,0.002237275,0.00032259518,0.00052865216,0.00037285016,0.0005515172,0.00023977143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002856444,0.00003241523,0.99302024,0.000020858904,0.000027763788,0.00006973082,0.00019218004,0.00011807236,0.00007767308,0.00014548044,0.00021917759,0.006047793],"study_design_scores_gemma":[0.000001012604,0.000024124643,0.99813914,0.000013307313,0.000013141095,0.00009307316,0.0006933709,0.00022116546,0.00007308421,0.00007282372,0.0006529489,0.0000028336092],"about_ca_topic_score_codex":0.008361581,"about_ca_topic_score_gemma":0.008793964,"teacher_disagreement_score":0.008361581,"about_ca_system_score_codex":0.0006828012,"about_ca_system_score_gemma":0.0010424401,"threshold_uncertainty_score":0.016625822},"labels":[],"label_agreement":null},{"id":"W168617775","doi":"","title":"Les risques liés à la création de PHARMA-QUEBEC","year":2014,"lang":"fr","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Geography; Economy; Economics; Art","score_opus":0.08679357500565897,"score_gpt":0.3933359261391098,"score_spread":0.3065423511334508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W168617775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62170434,0.03590892,0.0014532773,0.10461433,0.0007350712,0.00017861651,0.025496487,0.00023739366,0.20967162],"genre_scores_gemma":[0.9247075,0.011069535,0.00043367964,0.002770418,0.00025677105,0.00003540608,0.004090488,0.000032698958,0.056603476],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99742633,0.00038102843,0.000086617394,0.0001880854,0.0013185578,0.00059946097],"domain_scores_gemma":[0.9824247,0.0022577583,0.0039436547,0.00043124438,0.0056180274,0.00532451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016607462,0.0002457633,0.00036622718,0.0019814256,0.001824176,0.0045813844,0.0009117007,0.0012043569,0.019212674],"category_scores_gemma":[0.0114375865,0.00021126766,0.0004707611,0.0025603448,0.00072861055,0.0012895734,0.0012764594,0.0019084077,0.000974983],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066143734,0.00017176746,0.7478361,0.0002887081,0.00060676766,0.00082505716,0.0011312148,0.0013112876,0.00087031286,0.0307505,0.12021645,0.09533036],"study_design_scores_gemma":[0.00006117959,0.00008678672,0.85592276,0.00044722334,0.00026481523,0.00036416,0.0017663905,0.0027166763,0.000745785,0.0015310224,0.13604087,0.00005235763],"about_ca_topic_score_codex":0.9322994,"about_ca_topic_score_gemma":0.9435872,"teacher_disagreement_score":0.978749,"about_ca_system_score_codex":0.021251032,"about_ca_system_score_gemma":0.026084987,"threshold_uncertainty_score":0.15418774},"labels":[],"label_agreement":null},{"id":"W1718518342","doi":"10.1111/j.1360-0443.2006.01315.x","title":"The dangerousness of drugs","year":2006,"lang":"en","type":"review","venue":"Addiction","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psychology; MEDLINE; Medicine; Psychiatry; Criminology; Political science; Law","score_opus":0.07672741082469664,"score_gpt":0.3225229041115093,"score_spread":0.24579549328681266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1718518342","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015298969,0.112673275,0.015005083,0.12766711,0.0071787965,0.00022808301,0.0006118569,0.00022638685,0.7211105],"genre_scores_gemma":[0.54398304,0.097862825,0.015546086,0.17685197,0.009493241,0.00071165565,0.00082731934,0.0003803635,0.15434349],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9777819,0.006343057,0.0017863163,0.002254177,0.01070145,0.0011331692],"domain_scores_gemma":[0.98567593,0.006543428,0.0020853041,0.002122622,0.002627861,0.00094491546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008229233,0.00091499946,0.0011203341,0.0020211951,0.0037967528,0.008490062,0.0016645937,0.00665263,0.010188943],"category_scores_gemma":[0.018432088,0.00046889673,0.0009628554,0.0011808538,0.02186111,0.0071793147,0.0070079085,0.008662766,0.0035839055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009506994,0.000058114038,0.0013883782,0.0008561438,0.00005490605,0.00044193905,0.0027123708,0.00022933226,0.0014173529,0.88841134,0.038840376,0.065494694],"study_design_scores_gemma":[0.000025339372,0.00015183366,0.0011663722,0.0015430069,0.000035278168,0.0013000033,0.0008494534,0.0001269592,0.0012211661,0.16675119,0.8267842,0.00004517989],"about_ca_topic_score_codex":0.0032677832,"about_ca_topic_score_gemma":0.0029013888,"teacher_disagreement_score":0.010188943,"about_ca_system_score_codex":0.003356213,"about_ca_system_score_gemma":0.0045731543,"threshold_uncertainty_score":0.043520927},"labels":[],"label_agreement":null},{"id":"W174126088","doi":"10.1017/s0317167100051957","title":"Generic Substitution for Brand Name Antiepileptic Drugs: A Survey","year":2000,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Substitution (logic); Medicine; Brand names; Lamotrigine; Generic drug; Tolerability; Epilepsy; Drug; Family medicine; Psychiatry; Alternative medicine; Advertising; Business; Computer science","score_opus":0.09312740072709752,"score_gpt":0.2876731702053891,"score_spread":0.19454576947829155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W174126088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404055,0.0014414937,0.000103658014,0.0009806864,0.0000046277255,0.000039677765,0.0012264878,0.000005263249,0.0021574518],"genre_scores_gemma":[0.99360377,0.004387707,0.00017173532,0.00060776324,0.00001307945,0.00001878599,0.0006589153,0.0000029519174,0.00053539535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863464,0.00020397686,0.00018783633,0.0000953933,0.00066078897,0.00021730583],"domain_scores_gemma":[0.9953435,0.00084472925,0.0019997896,0.000081789796,0.0011857406,0.0005444635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012864316,0.00009802047,0.00018925796,0.001231444,0.00038323444,0.0005682963,0.0002911268,0.00037533804,0.0017696149],"category_scores_gemma":[0.0041295653,0.00016481774,0.00016033133,0.0029367036,0.00040671922,0.00055608805,0.0003150471,0.0003650415,0.00031099987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004857503,0.00006347934,0.9737961,0.00022765735,0.000019701472,0.00023577159,0.0026666797,0.00006903166,0.00034607874,0.00014835705,0.0025160916,0.019862495],"study_design_scores_gemma":[0.0000039205584,0.00007946844,0.99213624,0.000054977394,0.0000074340974,0.00031204673,0.003366361,0.00012026137,0.00006440069,0.000014341533,0.0038347298,0.0000057454686],"about_ca_topic_score_codex":0.22593348,"about_ca_topic_score_gemma":0.20857878,"teacher_disagreement_score":0.22593348,"about_ca_system_score_codex":0.002393315,"about_ca_system_score_gemma":0.0029305194,"threshold_uncertainty_score":0.4492368},"labels":[],"label_agreement":null},{"id":"W1743375347","doi":"10.1111/j.1755-5949.2010.00210.x","title":"Switching from Brand‐Name to Generic Psychotropic Medications: A Literature Review","year":2010,"lang":"en","type":"review","venue":"CNS Neuroscience & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lamotrigine; Venlafaxine; Tolerability; Medicine; Psychiatry; Topiramate; Quetiapine; Clonazepam; Cobicistat; Pharmacology; Psychology; Adverse effect; Anxiety; Epilepsy; Schizophrenia (object-oriented programming); Antidepressant","score_opus":0.16065040076187992,"score_gpt":0.3863121722456307,"score_spread":0.22566177148375077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1743375347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047174894,0.99870646,0.000058128044,0.00019877659,0.00007150793,0.00003993372,0.0000688653,0.000004560071,0.00038009477],"genre_scores_gemma":[0.0023860154,0.99690706,0.00024910897,0.00019803845,0.000053595693,0.00004974578,0.00007478631,0.0000013138216,0.00008030833],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977149,0.00048054272,0.000947055,0.00024307589,0.00051152386,0.00010291892],"domain_scores_gemma":[0.9925096,0.0045188214,0.0016452821,0.00009361969,0.001108461,0.0001240987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029670591,0.0013613007,0.003505207,0.018043587,0.0006876424,0.0018461313,0.0020204093,0.0018476448,0.0052959733],"category_scores_gemma":[0.0074384976,0.0007421956,0.0021502555,0.021688746,0.000777212,0.0035551162,0.00092620787,0.0006691735,0.00088204764],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020511002,0.0000802171,0.0014737679,0.60902005,0.0013793865,0.0012915658,0.00041126274,0.00020662382,0.00048657446,0.0007765159,0.012121018,0.37254786],"study_design_scores_gemma":[0.00017595799,0.00044452908,0.012615142,0.7865713,0.015426232,0.0072668074,0.0013246649,0.00026284883,0.00065794325,0.0011192007,0.17404197,0.00009335634],"about_ca_topic_score_codex":0.0041669486,"about_ca_topic_score_gemma":0.010453083,"teacher_disagreement_score":0.018043587,"about_ca_system_score_codex":0.0023925367,"about_ca_system_score_gemma":0.006359833,"threshold_uncertainty_score":0.017716765},"labels":[],"label_agreement":null},{"id":"W1748239555","doi":"10.1111/dewb.12046","title":"Access to Medicines and Distributive Justice: Breaching <scp>D</scp>oha's Ethical Threshold","year":2014,"lang":"en","type":"article","venue":"Developing World Bioethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"McGill University","keywords":"Distributive justice; Mirroring; Economic Justice; Public health; Right to health; Essential medicines; Global health; TRIPS architecture; Global justice; Political science; Access to medicines; Human rights; Law and economics; Medicine; Sociology; Law; Nursing","score_opus":0.14679517657460406,"score_gpt":0.38401018005297527,"score_spread":0.2372150034783712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1748239555","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036497454,0.0063176733,0.008762768,0.9212408,0.0022760343,0.000043297256,0.000063636595,0.000028578275,0.05761745],"genre_scores_gemma":[0.39359012,0.0066626677,0.012706992,0.56196916,0.008715925,0.00031669042,0.000060444076,0.00012015674,0.015857778],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9610897,0.0211914,0.0019237781,0.0032712696,0.009407215,0.003116647],"domain_scores_gemma":[0.9111338,0.06960804,0.0036878346,0.0059045968,0.0062258304,0.0034398206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.052493896,0.0005052769,0.0014561801,0.0011185079,0.007046682,0.018166889,0.0027106043,0.028088715,0.0062249782],"category_scores_gemma":[0.07694309,0.0004984829,0.0014767298,0.0011535167,0.057063524,0.018366203,0.010613699,0.028086632,0.001013447],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025695788,0.00002496771,0.000328916,0.00006119415,0.000015839309,0.00008582443,0.0009974387,0.0002483632,0.0000865966,0.94868535,0.037767936,0.011671865],"study_design_scores_gemma":[0.000024657866,0.000020073485,0.00028801875,0.00026469614,0.00000819524,0.00009070772,0.00048292585,0.00046914778,0.00012994892,0.90411943,0.094073854,0.00002841632],"about_ca_topic_score_codex":0.009662813,"about_ca_topic_score_gemma":0.006702568,"teacher_disagreement_score":0.052493896,"about_ca_system_score_codex":0.007854383,"about_ca_system_score_gemma":0.02142944,"threshold_uncertainty_score":0.27761757},"labels":[],"label_agreement":null},{"id":"W1757527718","doi":"10.1111/j.1475-6773.2005.00420.x","title":"The Impact of Reference Pricing of Nonsteroidal Anti‐Inflammatory Agents on the Use and Costs of Analgesic Drugs","year":2005,"lang":"en","type":"article","venue":"Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St Joseph's Health Centre; University of British Columbia; McMaster University; St. Joseph's Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Health Canada; Michael Smith Health Research BC; Canadian Health Services Research Foundation","keywords":"Reimbursement; Medicine; Subsidy; Beneficiary; Analgesic; Actuarial science; Business; Pharmacology; Finance; Health care; Economics","score_opus":0.21737116999918057,"score_gpt":0.4334958081180873,"score_spread":0.21612463811890673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1757527718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906453,0.0018952539,0.0012030646,0.00068474235,0.000033172837,0.00019657039,0.002171902,0.00003463356,0.003135308],"genre_scores_gemma":[0.9976144,0.00029224277,0.0006362211,0.00014551416,0.000030840256,0.000056069952,0.0008322356,0.0000067857873,0.0003857575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9776119,0.013691431,0.0009083221,0.0017342651,0.004283868,0.0017702287],"domain_scores_gemma":[0.9131691,0.052993298,0.024896244,0.0025705285,0.0049007703,0.001470025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013382835,0.0008492307,0.0007418267,0.0011078644,0.00030219596,0.001790455,0.0014422636,0.0012599198,0.0026416378],"category_scores_gemma":[0.06293681,0.0005431745,0.0020137948,0.0019307727,0.00077226956,0.0015103071,0.0009993445,0.0018760059,0.00034163572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083365645,0.0019634564,0.86637676,0.00045015122,0.002769003,0.00027237178,0.00013719112,0.06810325,0.0006445709,0.0018838837,0.0022477328,0.046815157],"study_design_scores_gemma":[0.00038110407,0.0032522553,0.9479179,0.000062387255,0.0012230129,0.00017593651,0.00011544648,0.043305833,0.0013643755,0.0005622891,0.0015820122,0.000057333356],"about_ca_topic_score_codex":0.06509194,"about_ca_topic_score_gemma":0.03703714,"teacher_disagreement_score":0.06509194,"about_ca_system_score_codex":0.006966985,"about_ca_system_score_gemma":0.0030760553,"threshold_uncertainty_score":0.12942612},"labels":[],"label_agreement":null},{"id":"W176030775","doi":"","title":"How Countries of the Southern African Development Community (SADC) can use the World Trade Organisation and the European Community flexibilities for better access to affordable HIV/AIDS Medicines","year":2008,"lang":"en","type":"book-chapter","venue":"WestminsterResearch (University of Westminster)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"TRIPS architecture; Declaration; Interim; Intellectual property; TRIPS Agreement; International trade; Business; Developing country; Economic growth; Political science; Economics; Law; Engineering","score_opus":0.1502989219528176,"score_gpt":0.26912785873179174,"score_spread":0.11882893677897413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W176030775","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054665253,0.012542218,0.0118539985,0.32436854,0.0022520446,0.00026845126,0.00021645466,0.0002707005,0.59356236],"genre_scores_gemma":[0.8332443,0.015310843,0.020560829,0.06732408,0.0007295285,0.00031728114,0.00023271011,0.00016326783,0.062117156],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934097,0.0033027502,0.00014240849,0.00035940087,0.0007377948,0.002047912],"domain_scores_gemma":[0.9970078,0.0010532839,0.0003785517,0.00030734605,0.0005005761,0.00075239607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009230845,0.0005514867,0.0003246639,0.0013921062,0.0044388976,0.010608103,0.0007837516,0.004658377,0.014467094],"category_scores_gemma":[0.015061442,0.00038692722,0.00080019113,0.0012699795,0.005675492,0.011182923,0.009509151,0.003602783,0.0021217612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007675289,0.00019135968,0.012918204,0.00074206904,0.00013527014,0.0013226408,0.026011446,0.0021626418,0.0019261212,0.54808277,0.141501,0.26492965],"study_design_scores_gemma":[0.000052379102,0.00007909318,0.0058895405,0.0009406657,0.00005434051,0.00044438374,0.02378184,0.0005373194,0.0006965137,0.09117247,0.8762654,0.00008605813],"about_ca_topic_score_codex":0.01923913,"about_ca_topic_score_gemma":0.031998795,"teacher_disagreement_score":0.01923913,"about_ca_system_score_codex":0.0034360802,"about_ca_system_score_gemma":0.012706146,"threshold_uncertainty_score":0.048817933},"labels":[],"label_agreement":null},{"id":"W176444246","doi":"","title":"Views on pharmaceutical access and governance in Australia, Canada and the United Kingdom (UK)","year":2011,"lang":"en","type":"article","venue":"Queensland's institutional digital repository (The University of Queensland)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Kingdom; Corporate governance; Political science; Public administration; Business; Finance","score_opus":0.10989707020272044,"score_gpt":0.27125805862034813,"score_spread":0.1613609884176277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W176444246","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19537376,0.07291084,0.00035910957,0.53795856,0.0022617276,0.0000597533,0.0018694057,0.000052225918,0.18915465],"genre_scores_gemma":[0.7892476,0.030559216,0.00043014486,0.031113243,0.00084211567,0.00003423037,0.00028405903,0.000042513122,0.14744686],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.994831,0.00058282784,0.00020199278,0.00026543043,0.0021680822,0.0019506506],"domain_scores_gemma":[0.9830804,0.0034987177,0.001537865,0.00039105365,0.0031940637,0.0082978485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036582819,0.00017385751,0.0005231009,0.0016499019,0.0055596363,0.013253936,0.00093221135,0.0054966416,0.014926843],"category_scores_gemma":[0.011309531,0.00035709876,0.00039083537,0.005259435,0.0057842433,0.0032200941,0.003487477,0.0042686253,0.00042751734],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049374445,0.00014740627,0.022440534,0.001000747,0.00012675523,0.0019957274,0.051453087,0.0023908278,0.0015506007,0.39290258,0.4067663,0.11873168],"study_design_scores_gemma":[0.000048290938,0.000052256844,0.16081947,0.0006209378,0.00004376691,0.00022519064,0.020333104,0.0005743774,0.00031728996,0.00973755,0.80711395,0.00011384951],"about_ca_topic_score_codex":0.88624245,"about_ca_topic_score_gemma":0.91073775,"teacher_disagreement_score":0.11375755,"about_ca_system_score_codex":0.048959255,"about_ca_system_score_gemma":0.07159625,"threshold_uncertainty_score":0.35522592},"labels":[],"label_agreement":null},{"id":"W1766634659","doi":"10.1111/jlme.12066","title":"Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health","year":2013,"lang":"en","type":"article","venue":"The Journal of Law Medicine & Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"Canadian Institutes of Health Research","keywords":"Incentive; Business; Language change; Value (mathematics); Financial market; Public economics; Public health; Finance; Economics; Microeconomics; Medicine","score_opus":0.37081870959387464,"score_gpt":0.42308298481208667,"score_spread":0.05226427521821203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1766634659","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18544903,0.0090226885,0.16609722,0.49496493,0.0011278667,0.00025351444,0.00010542254,0.00016628436,0.14281316],"genre_scores_gemma":[0.9775384,0.0015740673,0.007861786,0.009837181,0.00057141756,0.00008559365,0.000012013809,0.000025142108,0.002494367],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97201794,0.018090546,0.0007704444,0.0013402567,0.0042627994,0.0035181313],"domain_scores_gemma":[0.95308226,0.02347319,0.012331212,0.0042825793,0.004324602,0.0025061183],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022890331,0.0005047094,0.0010095802,0.0019349571,0.003666956,0.008523395,0.0012602534,0.006444194,0.002718687],"category_scores_gemma":[0.06310975,0.0006176826,0.0008163513,0.0013429801,0.020363588,0.0119882785,0.00735255,0.008390199,0.00029551276],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043986747,0.000054826614,0.0043771975,0.000071629904,0.000037362734,0.00012971477,0.0009663345,0.004435287,0.00025404865,0.97317696,0.0022547045,0.014198035],"study_design_scores_gemma":[0.00009050282,0.00010229956,0.004726067,0.00030794015,0.000039407656,0.00015127273,0.0008683976,0.009673749,0.0008521041,0.959306,0.023820296,0.00006193555],"about_ca_topic_score_codex":0.004087427,"about_ca_topic_score_gemma":0.0031905216,"teacher_disagreement_score":0.9771097,"about_ca_system_score_codex":0.01015731,"about_ca_system_score_gemma":0.015399328,"threshold_uncertainty_score":0.12105709},"labels":[],"label_agreement":null},{"id":"W1772410503","doi":"","title":"U.S. prosecutors investigating Valeant Pharmaceuticals","year":2015,"lang":"en","type":"article","venue":"Drug Topics E-News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Business; Criminology; Law; Sociology","score_opus":0.15823392659555977,"score_gpt":0.3316713487022646,"score_spread":0.17343742210670485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1772410503","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04911471,0.011018514,0.0012290457,0.41780534,0.009374918,0.00024293171,0.0016478187,0.00045800555,0.5091087],"genre_scores_gemma":[0.25803134,0.007793447,0.0015426053,0.38226303,0.00252562,0.00011241334,0.000958892,0.00016778574,0.34660476],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99452066,0.00052540534,0.0003013253,0.0005030911,0.002525262,0.0016242396],"domain_scores_gemma":[0.98865694,0.0053259903,0.0009402137,0.0002960735,0.0037381412,0.0010425475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032332775,0.00075012847,0.00055499515,0.0023845206,0.010486963,0.005508446,0.0013818364,0.017382804,0.013366903],"category_scores_gemma":[0.022325557,0.00057664467,0.00083915604,0.0023479024,0.0022984901,0.0018083731,0.0022249562,0.011088556,0.0038827667],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103791346,0.000060458853,0.0044988203,0.00007804566,0.000018018987,0.001930876,0.0017296496,0.00011382291,0.00059853157,0.04037868,0.9240053,0.026483957],"study_design_scores_gemma":[0.000056987246,0.00008487028,0.00879427,0.0004717455,0.00008749473,0.0009293536,0.0019943765,0.0006484169,0.0022420418,0.0052563064,0.9793696,0.000064607535],"about_ca_topic_score_codex":0.17047542,"about_ca_topic_score_gemma":0.25920948,"teacher_disagreement_score":0.17047542,"about_ca_system_score_codex":0.006687071,"about_ca_system_score_gemma":0.015387426,"threshold_uncertainty_score":0.3389663},"labels":[],"label_agreement":null},{"id":"W1777587551","doi":"10.1016/s0140-6736(15)00469-9","title":"Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":394,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Université Laval; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Canadian Institutes of Health Research; International Development Research Centre; Heart and Stroke Foundation of Canada","keywords":"Pharmacy; Medicine; Environmental health; Disease; Middle income; Rural area; Socioeconomics; Business; Economics; Demographic economics; Family medicine","score_opus":0.08904064535655133,"score_gpt":0.29706354220641584,"score_spread":0.20802289684986452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1777587551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98221564,0.0048824255,0.0005718551,0.00063162163,0.000042129093,0.00003485062,0.010766437,0.000026210164,0.0008287926],"genre_scores_gemma":[0.99014074,0.0011615234,0.00028456078,0.00015551063,0.000044500015,0.000034336936,0.0076987385,0.00001551417,0.00046463215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99044484,0.0064293444,0.000985851,0.0008242107,0.0004999856,0.00081575976],"domain_scores_gemma":[0.9456962,0.034651093,0.012544805,0.0040098354,0.0014975932,0.0016004673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009039382,0.0007194226,0.0025205621,0.002486435,0.00051866105,0.0022002,0.0019483356,0.0015006006,0.0060738362],"category_scores_gemma":[0.02280677,0.0011068782,0.0078386925,0.0061887363,0.001581463,0.0018071515,0.0029021588,0.0020433278,0.0006660961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028915226,0.00017028619,0.9730017,0.00043691363,0.011744505,0.0006207338,0.00031032084,0.0039211498,0.00018721123,0.0011403754,0.0021354703,0.003439748],"study_design_scores_gemma":[0.00038739003,0.0006051971,0.9837172,0.000127296,0.0042957263,0.00042859418,0.0015407248,0.005570081,0.000299032,0.0009341386,0.0020173276,0.00007737307],"about_ca_topic_score_codex":0.052968774,"about_ca_topic_score_gemma":0.03708931,"teacher_disagreement_score":0.052968774,"about_ca_system_score_codex":0.00070197,"about_ca_system_score_gemma":0.0009926495,"threshold_uncertainty_score":0.10532093},"labels":[],"label_agreement":null},{"id":"W1802737629","doi":"","title":"The Globalization of Clinical Trials for New Medicines: Where are the Trials Going and Why?","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Quest University Canada","funders":"","keywords":"Globalization; Latin Americans; Clinical trial; Market size; Intellectual property; Business; International trade; Development economics; Economics; Medicine; Political science; Commerce; Market economy","score_opus":0.22067453449043675,"score_gpt":0.44408514317785824,"score_spread":0.2234106086874215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1802737629","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36800623,0.050125286,0.09420516,0.36819464,0.00068395614,0.0008634739,0.0015328454,0.00019700876,0.11619145],"genre_scores_gemma":[0.9517661,0.020904623,0.015495481,0.008903706,0.0006225529,0.00026706225,0.00026666422,0.000050911232,0.0017230056],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9925343,0.005286727,0.0004399929,0.0005207296,0.00064741104,0.0005707245],"domain_scores_gemma":[0.9469032,0.03123471,0.015957687,0.0011704724,0.0021337306,0.002600162],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0113823535,0.00044313734,0.00091260107,0.00238927,0.001491974,0.009150856,0.00087120547,0.0025524865,0.004958526],"category_scores_gemma":[0.03856559,0.00039499506,0.0006762819,0.0065469556,0.005654107,0.0098036025,0.0028414489,0.0032748515,0.00052059814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043298872,0.0002834212,0.22624294,0.0017971548,0.0001705571,0.0014460637,0.008748995,0.022648286,0.0014884607,0.55726945,0.014421381,0.16505031],"study_design_scores_gemma":[0.00025241755,0.00052183453,0.2516319,0.0024853323,0.00019188928,0.0012802498,0.020895679,0.024561994,0.001295797,0.5816167,0.1150869,0.00017928229],"about_ca_topic_score_codex":0.009344693,"about_ca_topic_score_gemma":0.009119529,"teacher_disagreement_score":0.98861766,"about_ca_system_score_codex":0.0057727755,"about_ca_system_score_gemma":0.0066169566,"threshold_uncertainty_score":0.0601964},"labels":[],"label_agreement":null},{"id":"W1822053319","doi":"10.1515/9783828260160-009","title":"Wettbewerbspotenziale im deutschen Apothekenmarkt","year":2011,"lang":"de","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mitel (Canada)","funders":"","keywords":"Pharmacy; Competition (biology); Business; Industrial organization; Actuarial science; Marketing; Medicine; Family medicine","score_opus":0.10010311090639015,"score_gpt":0.2540085539864817,"score_spread":0.15390544308009155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1822053319","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09985405,0.34523126,0.03965151,0.038755603,0.0034593402,0.00029584934,0.02268658,0.0002710631,0.4497948],"genre_scores_gemma":[0.5548511,0.23306784,0.031310488,0.0039011664,0.002326631,0.0005168844,0.0124228215,0.00019377713,0.16140924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988745,0.00035792153,0.000108577224,0.0001838026,0.00039512047,0.00008006098],"domain_scores_gemma":[0.9954177,0.0035045114,0.00051997055,0.00015790737,0.00031520048,0.00008469199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022421768,0.0004848421,0.00048408893,0.0025260216,0.00030595038,0.003489584,0.0004409632,0.00082562683,0.01763293],"category_scores_gemma":[0.006982977,0.00025353656,0.00071662664,0.0044308193,0.00065261556,0.0027158584,0.00083208864,0.0013875174,0.0022957646],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003561224,0.00015663027,0.02259083,0.0019635556,0.0002492314,0.00023489549,0.00063950237,0.0074754674,0.00066282967,0.28970551,0.12469948,0.5512659],"study_design_scores_gemma":[0.000070316855,0.0003030557,0.05633039,0.0021721018,0.00029624868,0.0018627176,0.0009434942,0.007999553,0.0018305747,0.17562665,0.7524449,0.00011989441],"about_ca_topic_score_codex":0.003069799,"about_ca_topic_score_gemma":0.003793452,"teacher_disagreement_score":0.01763293,"about_ca_system_score_codex":0.002073353,"about_ca_system_score_gemma":0.0013467047,"threshold_uncertainty_score":0.058988035},"labels":[],"label_agreement":null},{"id":"W1826192669","doi":"10.1177/1355819615593302","title":"Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries","year":2015,"lang":"en","type":"article","venue":"Journal of Health Services Research & Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Douglas Pharmaceuticals","keywords":"Pharmacy; Government (linguistics); Medical prescription; Business; Flexibility (engineering); Qualitative research; Marketing; Medicine; Family medicine; Nursing; Economics","score_opus":0.37846617348477435,"score_gpt":0.5591695413858547,"score_spread":0.18070336790108038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1826192669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885399,0.0015004573,0.000560138,0.0022045968,0.000053410164,0.00014923657,0.00023647664,0.000009546772,0.0067462493],"genre_scores_gemma":[0.99809724,0.00065629283,0.0002494247,0.00041700565,0.0000037372583,0.00012494337,0.00005814868,0.0000070634246,0.0003862548],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9860491,0.010354465,0.0007128066,0.00048321928,0.0004469602,0.001953516],"domain_scores_gemma":[0.98126316,0.014557985,0.001593572,0.0005179502,0.0010579443,0.0010093724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013928546,0.0003802253,0.00076483114,0.0024149937,0.005830614,0.0047813198,0.0011325345,0.0014792123,0.0041748905],"category_scores_gemma":[0.02020744,0.00084465084,0.00069807866,0.0037135403,0.007438653,0.0060299854,0.0070701297,0.0018187282,0.00019081608],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079962985,0.000023128887,0.009446762,0.00045490483,0.00001812297,0.0007881293,0.98337317,0.00005080154,0.00029945065,0.0021146648,0.00033365304,0.0030172635],"study_design_scores_gemma":[0.000004821075,0.000019520643,0.0034037759,0.00020406785,0.0000062180734,0.00008304803,0.99365544,0.000024334318,0.000068365,0.00013905407,0.0023843518,0.000007151268],"about_ca_topic_score_codex":0.023683103,"about_ca_topic_score_gemma":0.01935488,"teacher_disagreement_score":0.023683103,"about_ca_system_score_codex":0.00845058,"about_ca_system_score_gemma":0.005810226,"threshold_uncertainty_score":0.0736621},"labels":[],"label_agreement":null},{"id":"W1828580554","doi":"10.2139/ssrn.2171392","title":"Innovation Incentives Under Transferable Fast-Track Regulatory Review","year":2012,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Track (disk drive); Business; Industrial organization; Computer science; Economics; Microeconomics","score_opus":0.042028063192406595,"score_gpt":0.28862421108840336,"score_spread":0.24659614789599676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1828580554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58139926,0.0032232518,0.039307456,0.025648987,0.000748325,0.00086379086,0.0013019078,0.0011314829,0.34637564],"genre_scores_gemma":[0.980684,0.00040840788,0.0015131275,0.0013156878,0.00043878367,0.00013453998,0.000065689346,0.000030273155,0.015409596],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9753754,0.011115497,0.0012088483,0.0029033406,0.0044545853,0.0049422304],"domain_scores_gemma":[0.7217981,0.19880942,0.044312578,0.011529175,0.015493572,0.008057093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.038753174,0.0006092083,0.0025791642,0.0025745914,0.0018560005,0.010675768,0.0025968107,0.01275179,0.028622268],"category_scores_gemma":[0.17686631,0.0008435626,0.001324473,0.001912369,0.0027129478,0.007980826,0.0034399275,0.0051029646,0.0026270545],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025403611,0.0010426039,0.009871077,0.0006246538,0.0002875743,0.0008166484,0.00063248497,0.036845986,0.0028772329,0.85435903,0.025348272,0.06475409],"study_design_scores_gemma":[0.0017662654,0.0020752084,0.02643336,0.00018429705,0.0005507191,0.00055046915,0.00073014497,0.08046818,0.0028209107,0.85367495,0.030495005,0.0002504901],"about_ca_topic_score_codex":0.0038061298,"about_ca_topic_score_gemma":0.0034911812,"teacher_disagreement_score":0.038753174,"about_ca_system_score_codex":0.004517952,"about_ca_system_score_gemma":0.008573297,"threshold_uncertainty_score":0.20494878},"labels":[],"label_agreement":null},{"id":"W1834765452","doi":"10.1185/03007990903044374","title":"Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries","year":2009,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Topiramate; Medicine; Demography; Cohort; Pharmacoepidemiology; Pediatrics; Medical prescription; Epilepsy; Psychiatry; Internal medicine","score_opus":0.32516430329213475,"score_gpt":0.5214437338699924,"score_spread":0.19627943057785768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1834765452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792148,0.0028010083,0.0016606032,0.0014037895,0.000033775104,0.00006610014,0.008005535,0.000043838772,0.00677052],"genre_scores_gemma":[0.99489814,0.0006901592,0.0006652453,0.00017408626,0.000016071728,0.000023418215,0.0031118714,0.0000043987175,0.00041656912],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986266,0.00067033386,0.00009928755,0.00011617326,0.0002060962,0.00028154487],"domain_scores_gemma":[0.9955937,0.0015321834,0.0014887198,0.0001006922,0.0008309401,0.00045367074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002295543,0.0004606384,0.00028643568,0.00065801106,0.00019115006,0.0014459037,0.0004493604,0.000632371,0.0023024487],"category_scores_gemma":[0.010497712,0.00016263557,0.0011800184,0.0009992531,0.0003257857,0.0006064594,0.0006568459,0.00042296082,0.00022931992],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027367033,0.00016643788,0.83863217,0.00027044097,0.00094372476,0.0013772103,0.000080862934,0.109459855,0.0006216302,0.0035976497,0.004275088,0.03783818],"study_design_scores_gemma":[0.00026391292,0.00077392015,0.9227606,0.00021001839,0.00078201597,0.0013525884,0.00048072843,0.0654472,0.0012551192,0.001228233,0.0053960932,0.00004961738],"about_ca_topic_score_codex":0.067145824,"about_ca_topic_score_gemma":0.03173764,"teacher_disagreement_score":0.067145824,"about_ca_system_score_codex":0.0031521283,"about_ca_system_score_gemma":0.0017438775,"threshold_uncertainty_score":0.13351},"labels":[],"label_agreement":null},{"id":"W1838448105","doi":"","title":"NABP pushes for cross-border pharmacy regulation","year":2004,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medicine; Community practice; Community pharmacy; Clinical pharmacy; Pharmaconomist; Family medicine; Multistate Pharmacy Jurisprudence Examination","score_opus":0.08503043637552603,"score_gpt":0.4146419413176108,"score_spread":0.32961150494208474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1838448105","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022833515,0.004732401,0.012563765,0.6910774,0.0029678566,0.00017857578,0.0006760716,0.00038303196,0.26458737],"genre_scores_gemma":[0.32414353,0.003297314,0.018012011,0.5884207,0.0018418718,0.00023386821,0.00061402837,0.00011870053,0.063317955],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98273313,0.0035939422,0.0004601301,0.0016241738,0.00790131,0.0036872737],"domain_scores_gemma":[0.97572553,0.00643588,0.0017019314,0.001387464,0.009273882,0.005475386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02030939,0.0004815331,0.0008448771,0.0015639435,0.004414267,0.012663393,0.0021455735,0.017292105,0.015926527],"category_scores_gemma":[0.03548878,0.0004913665,0.0016057724,0.001356573,0.0040179724,0.004875138,0.007265962,0.014959138,0.0025470222],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104689774,0.00014030364,0.0045841075,0.00016135104,0.0000547697,0.0004883342,0.00062200526,0.0018990806,0.00095979765,0.78770286,0.17707339,0.026209388],"study_design_scores_gemma":[0.00013734015,0.00011757983,0.008854548,0.00048742574,0.000033542223,0.00030481053,0.0010924725,0.0039770682,0.00065559195,0.10832002,0.8759503,0.000069275906],"about_ca_topic_score_codex":0.19756244,"about_ca_topic_score_gemma":0.20313025,"teacher_disagreement_score":0.19756244,"about_ca_system_score_codex":0.016793022,"about_ca_system_score_gemma":0.050908577,"threshold_uncertainty_score":0.392825},"labels":[],"label_agreement":null},{"id":"W1844756772","doi":"","title":"US states ponder buying drugs from Canada.","year":2003,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Governor; Medical prescription; State (computer science); Drug industry; Medicine; Business; Pharmacology; Computer science; Engineering; Engineering ethics","score_opus":0.030629865585705834,"score_gpt":0.21895842542021451,"score_spread":0.1883285598345087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1844756772","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009504997,0.014153581,0.0007632008,0.2241893,0.009968032,0.00014876749,0.02316182,0.001023972,0.71708643],"genre_scores_gemma":[0.053832613,0.008297335,0.0014224623,0.12356191,0.0008852491,0.00006648803,0.0076633925,0.00018400842,0.80408657],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717593,0.00007613059,0.00005270948,0.00013054883,0.002024852,0.0005398622],"domain_scores_gemma":[0.9956572,0.00039650928,0.0001759449,0.00010047234,0.002980445,0.0006894219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089365593,0.0006428398,0.00043501824,0.0016890833,0.006302372,0.0047151325,0.00074660865,0.0050407676,0.0864475],"category_scores_gemma":[0.0057650874,0.0006188057,0.0007465635,0.0028059313,0.0011156099,0.0014960776,0.0013972365,0.0038087543,0.013755951],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003100889,0.000015985788,0.0017515947,0.000041270476,0.000010497492,0.00007601959,0.000058834317,0.00005984872,0.00009624138,0.009584638,0.97642195,0.011852279],"study_design_scores_gemma":[0.000018313582,0.0000102410595,0.004800173,0.000068744834,0.000021869273,0.00004383967,0.00022033516,0.00009233644,0.00023459096,0.0011334469,0.99333316,0.000023036191],"about_ca_topic_score_codex":0.9305105,"about_ca_topic_score_gemma":0.96854657,"teacher_disagreement_score":0.0864475,"about_ca_system_score_codex":0.0150461625,"about_ca_system_score_gemma":0.05400314,"threshold_uncertainty_score":0.28919572},"labels":[],"label_agreement":null},{"id":"W1852804143","doi":"10.4212/cjhp.v60i5.198","title":"Nouvelles normes de gestion des médicaments pour l’agrément de 2008 : de meilleures pratiques pour plus de sécurité","year":2007,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Political science; Gynecology; Medicine","score_opus":0.051439282843818886,"score_gpt":0.29703963736234135,"score_spread":0.24560035451852247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1852804143","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14374106,0.025778659,0.018623488,0.7084962,0.0065546115,0.00007471109,0.0039584804,0.00042532437,0.09234748],"genre_scores_gemma":[0.8847466,0.0073262453,0.023590015,0.04928199,0.0041677817,0.00027100104,0.0017736776,0.00026183916,0.028580809],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.96275616,0.009025464,0.0041481727,0.0040210052,0.01709965,0.002949564],"domain_scores_gemma":[0.87909883,0.063773975,0.014773623,0.005746645,0.03249252,0.0041143512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.040359158,0.00058162387,0.0012692611,0.0019829292,0.0027527607,0.015225003,0.0028829281,0.007799137,0.005979384],"category_scores_gemma":[0.12963752,0.0006736655,0.0011570856,0.0024042206,0.0069448478,0.0094652865,0.0025674235,0.014600323,0.0011290723],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018889199,0.00029758312,0.06301589,0.0006784996,0.00031697445,0.0004102893,0.008517001,0.003967088,0.0028423704,0.61516297,0.16324759,0.13965483],"study_design_scores_gemma":[0.0004667316,0.00063710805,0.27198252,0.0025968498,0.00028572226,0.0007010752,0.009792228,0.010761259,0.006924794,0.13535193,0.559894,0.00060573936],"about_ca_topic_score_codex":0.18774107,"about_ca_topic_score_gemma":0.15188225,"teacher_disagreement_score":0.18774107,"about_ca_system_score_codex":0.019493798,"about_ca_system_score_gemma":0.019165691,"threshold_uncertainty_score":0.37329662},"labels":[],"label_agreement":null},{"id":"W1853635131","doi":"10.1111/jphs.12029","title":"Societal monetary benefits of pharmaceutical innovation: the case of ramipril in Canada","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"Pfizer Canada","keywords":"Ramipril; Medicine; Productivity; Population; Health care; Developing country; Economic growth; Economics; Environmental health","score_opus":0.1717247181537969,"score_gpt":0.43546610408512715,"score_spread":0.26374138593133023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1853635131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851612,0.0014970562,0.0010373167,0.0027360392,0.00001893803,0.00007761889,0.004491263,0.000021131777,0.004959494],"genre_scores_gemma":[0.9954442,0.0005741303,0.0005381699,0.000113730006,0.00000873077,0.000017450195,0.0014185826,0.0000056302124,0.001879323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880934,0.00017360615,0.000041676758,0.0001247175,0.0002181685,0.00063259865],"domain_scores_gemma":[0.9965932,0.0011860664,0.0004982295,0.00011209046,0.0010359134,0.0005743875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014544299,0.00036734677,0.000592254,0.0017830009,0.0014845238,0.0022267946,0.0012422398,0.0009765276,0.0031131567],"category_scores_gemma":[0.0068423813,0.00024055479,0.0010652615,0.0032191852,0.0007829656,0.0008161363,0.0013123432,0.0018701578,0.00015852024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009941738,0.00044212898,0.6893305,0.0002913501,0.0006823213,0.0020460435,0.0013399804,0.22121185,0.00058467267,0.040229134,0.011464084,0.031383645],"study_design_scores_gemma":[0.00020132754,0.0001384904,0.49244747,0.00014419055,0.0003944259,0.0003946558,0.0037779007,0.486314,0.00039770524,0.0068434067,0.008809822,0.00013659774],"about_ca_topic_score_codex":0.99079084,"about_ca_topic_score_gemma":0.9845829,"teacher_disagreement_score":0.046410143,"about_ca_system_score_codex":0.046410143,"about_ca_system_score_gemma":0.02268406,"threshold_uncertainty_score":0.33673072},"labels":[],"label_agreement":null},{"id":"W1866068151","doi":"","title":"Prescription Drug Importation Beyond Canada","year":2005,"lang":"en","type":"article","venue":"California Western international law journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; TRIPS architecture; Business; Medicare Part D; Health insurance; Drug; Health care; Public health; Public economics; Actuarial science; Medicine; Economic growth; Pharmacology; Economics; Computer science","score_opus":0.02157989954778157,"score_gpt":0.2526976405134175,"score_spread":0.23111774096563592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1866068151","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027883716,0.0068368865,0.0016062034,0.10710325,0.0008448948,0.00014117414,0.0035574483,0.00018623848,0.8518403],"genre_scores_gemma":[0.49232608,0.012865514,0.0025337455,0.10840017,0.0011093812,0.00012194101,0.0026756478,0.00020472854,0.37976286],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99370897,0.00029203048,0.00021945074,0.00070950855,0.0032974984,0.0017723739],"domain_scores_gemma":[0.98650384,0.002654317,0.00068270223,0.0008400801,0.006604318,0.0027148447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019915684,0.0003930711,0.000619538,0.0021495647,0.0073774727,0.006359092,0.0012296805,0.0041819043,0.025402244],"category_scores_gemma":[0.012122316,0.00044638387,0.0010897705,0.0025521345,0.0025807791,0.002298641,0.0023350127,0.0052863536,0.0016036624],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012156461,0.00010832069,0.01736848,0.0003926143,0.000073261785,0.001471599,0.0011409003,0.0013351464,0.00086217135,0.56948274,0.3354998,0.07214342],"study_design_scores_gemma":[0.00006115637,0.00004253873,0.03206454,0.0003737387,0.00006263035,0.00032693634,0.00036549664,0.0012883157,0.00060322107,0.013325791,0.95140105,0.00008444907],"about_ca_topic_score_codex":0.97275823,"about_ca_topic_score_gemma":0.9709622,"teacher_disagreement_score":0.06291533,"about_ca_system_score_codex":0.06291533,"about_ca_system_score_gemma":0.1565658,"threshold_uncertainty_score":0.45648485},"labels":[],"label_agreement":null},{"id":"W188107344","doi":"","title":"Minnesota: Leading the Way on Canadian Prescription Medicine Importation","year":2005,"lang":"en","type":"article","venue":"William Mitchell law review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Business; Law; Medicine; Political science; Pharmacology","score_opus":0.07033288168608894,"score_gpt":0.3005335662890904,"score_spread":0.23020068460300147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W188107344","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024770027,0.008499405,0.0017956212,0.5218064,0.007156462,0.00027599212,0.0022037136,0.0008119982,0.43268037],"genre_scores_gemma":[0.09497564,0.010905376,0.009381621,0.2072093,0.00085765717,0.00012141912,0.0020024644,0.00052241865,0.67402416],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99643815,0.00020986598,0.000085578045,0.0003480983,0.0017991364,0.0011193305],"domain_scores_gemma":[0.9938531,0.00028051535,0.00011931342,0.00012022364,0.0022739812,0.0033528802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020754267,0.00081549026,0.00035465232,0.0015846835,0.020179138,0.007059716,0.0018022071,0.0052411333,0.052522864],"category_scores_gemma":[0.0033240896,0.0007391477,0.00076355966,0.0018873949,0.0031436216,0.0026781312,0.00404401,0.0049163857,0.005839701],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000415469,0.00007308159,0.0045816433,0.00012262008,0.000011502387,0.00070840237,0.0012901728,0.00010915544,0.00082466385,0.013927868,0.9337746,0.04453479],"study_design_scores_gemma":[0.000009070371,0.00001599904,0.0046536685,0.00006625608,0.000008066001,0.000103820246,0.0016188201,0.0000983832,0.00017857863,0.00040496336,0.99280787,0.000034476743],"about_ca_topic_score_codex":0.9803977,"about_ca_topic_score_gemma":0.9941379,"teacher_disagreement_score":0.06842803,"about_ca_system_score_codex":0.06842803,"about_ca_system_score_gemma":0.2155814,"threshold_uncertainty_score":0.49648243},"labels":[],"label_agreement":null},{"id":"W1887794268","doi":"10.15406/mojbb.2015.01.00009","title":"Governments Need to Act on Cancer Drug Shortages Affecting Public Health","year":2015,"lang":"en","type":"article","venue":"MOJ Bioequivalence & Bioavailability","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Works and Government Services Canada","funders":"","keywords":"Economic shortage; Drug; Cancer drugs; Public health; Business; Environmental health; Medicine; Government (linguistics); Pharmacology; Nursing","score_opus":0.21432905966513396,"score_gpt":0.36100572859547686,"score_spread":0.1466766689303429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1887794268","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003802039,0.0019037129,0.0002792879,0.9904862,0.003930589,0.000009472068,0.000036400535,0.000042731735,0.0029313762],"genre_scores_gemma":[0.01765035,0.004516492,0.0016517782,0.96594507,0.0065040435,0.00004067096,0.00006399587,0.00004691442,0.0035807483],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9868255,0.004681449,0.00063582725,0.00076594355,0.003956507,0.0031347475],"domain_scores_gemma":[0.9098036,0.049005616,0.0065159397,0.0038958855,0.015844489,0.014934328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021938443,0.0012687112,0.0016651279,0.0022020766,0.008975231,0.019356884,0.0024996367,0.05410347,0.015623394],"category_scores_gemma":[0.08324564,0.0007144538,0.0018645561,0.0031853954,0.012216116,0.020856952,0.009628267,0.043740727,0.0045551755],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006344182,0.000153368,0.0015835864,0.00027495256,0.00006613396,0.00032208487,0.000855224,0.0004970166,0.00020752035,0.08752336,0.87039393,0.038059346],"study_design_scores_gemma":[0.000118313794,0.0001625889,0.0036758883,0.001191848,0.00006646982,0.0002456122,0.004316898,0.00060622755,0.00023501922,0.13302356,0.8562329,0.00012462068],"about_ca_topic_score_codex":0.01614544,"about_ca_topic_score_gemma":0.017321777,"teacher_disagreement_score":0.05410347,"about_ca_system_score_codex":0.008679572,"about_ca_system_score_gemma":0.02611452,"threshold_uncertainty_score":0.116022944},"labels":[],"label_agreement":null},{"id":"W1903125184","doi":"","title":"Drug prices stable but total spending rises by 15","year":2002,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug prices; Drug industry; Medicine; Business; Agricultural economics; Economics; Monetary economics; Biotechnology; Biology","score_opus":0.04841724448494258,"score_gpt":0.23150444944660753,"score_spread":0.18308720496166495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1903125184","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25587034,0.044012994,0.0034970834,0.106632255,0.004530641,0.00016036426,0.12014708,0.0025773768,0.46257183],"genre_scores_gemma":[0.7347113,0.013437303,0.0025572102,0.023753865,0.001394689,0.0001027246,0.06427019,0.00030170937,0.15947098],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99845827,0.0000759237,0.00009613696,0.000341051,0.0006045063,0.0004240348],"domain_scores_gemma":[0.99808574,0.00015617785,0.0003996494,0.00015428693,0.00084498705,0.0003591414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008871754,0.00040097616,0.00042606366,0.0009073349,0.000518016,0.0037459778,0.0005952002,0.0010865683,0.027351039],"category_scores_gemma":[0.0037532414,0.00025920916,0.00067551,0.001998575,0.0005838731,0.0013442272,0.00095612404,0.0014707064,0.009312305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017690153,0.0001432806,0.060620088,0.0006779053,0.00042125446,0.0003470896,0.000319306,0.0010533221,0.005601072,0.05959789,0.50473446,0.36471537],"study_design_scores_gemma":[0.00006645788,0.00018306662,0.17012532,0.00014407348,0.00009815339,0.00041595832,0.00017509286,0.00042257158,0.0022553147,0.0027518258,0.82333267,0.000029465598],"about_ca_topic_score_codex":0.050856594,"about_ca_topic_score_gemma":0.036623213,"teacher_disagreement_score":0.050856594,"about_ca_system_score_codex":0.004642,"about_ca_system_score_gemma":0.0045535173,"threshold_uncertainty_score":0.10112113},"labels":[],"label_agreement":null},{"id":"W1903355409","doi":"10.1016/j.jval.2015.09.2429","title":"The Budget Impact of Orphan Drugs In The Us and Canada: A 2007-2013 Midas Sales Data Analysis","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Orphan drug; Incentive; Medicine; Economics; Bioinformatics","score_opus":0.12856453629218972,"score_gpt":0.3496087187334243,"score_spread":0.22104418244123458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1903355409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7343244,0.0063302256,0.00038294014,0.006790606,0.00009218249,0.00018045117,0.23597187,0.000104417,0.015822947],"genre_scores_gemma":[0.8963521,0.0051751733,0.00089177623,0.00078210555,0.000062005645,0.000085365245,0.0879688,0.00006166232,0.008621013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997445,0.00015352761,0.00014181281,0.00015541083,0.0013995721,0.0007045976],"domain_scores_gemma":[0.9900851,0.0007828195,0.0015487238,0.00015989685,0.006371307,0.0010520078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015478447,0.00048360284,0.00074702676,0.005564236,0.0013722889,0.0026880722,0.0012254051,0.0005685336,0.0022722678],"category_scores_gemma":[0.008347323,0.0004437408,0.0010671254,0.013224839,0.0007104185,0.0009113495,0.0011232434,0.0012895119,0.00031659775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010302981,0.0002302201,0.8081326,0.0005514094,0.0009850366,0.00051554246,0.0009091885,0.018813504,0.00029595304,0.00855296,0.12406171,0.035921462],"study_design_scores_gemma":[0.00007706492,0.00005805815,0.91933435,0.00028319863,0.0003538869,0.000113983224,0.0025544248,0.01309481,0.0006885163,0.00055344525,0.06280647,0.00008175401],"about_ca_topic_score_codex":0.9969553,"about_ca_topic_score_gemma":0.99749774,"teacher_disagreement_score":0.068165,"about_ca_system_score_codex":0.068165,"about_ca_system_score_gemma":0.09242882,"threshold_uncertainty_score":0.494574},"labels":[],"label_agreement":null},{"id":"W1905212215","doi":"10.1186/s12992-015-0118-8","title":"Does Pharmaceutical Pricing Transparency Matter? Examining Brazil’s Public Procurement System","year":2015,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Toronto; Canadian Institutes of Health Research; University of Ottawa","keywords":"Transparency (behavior); Procurement; Purchasing; Economics; Unit (ring theory); Business; Econometrics; Accounting; Computer science; Operations management; Marketing; Mathematics","score_opus":0.2224954896083243,"score_gpt":0.37173131422169103,"score_spread":0.14923582461336674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1905212215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8885218,0.029726664,0.007789703,0.027652921,0.0001285046,0.00018728344,0.0024457637,0.00011152947,0.043435775],"genre_scores_gemma":[0.99502146,0.002966668,0.0010743613,0.00038917185,0.000034966826,0.00002179519,0.00020563867,0.000017918352,0.00026804715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.988383,0.00522692,0.0010319403,0.00090194633,0.0034383927,0.0010179244],"domain_scores_gemma":[0.92046136,0.037996486,0.028103841,0.003214771,0.008887322,0.0013362439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016187176,0.00020386424,0.0004517398,0.0024514406,0.0007720492,0.003026573,0.00087387045,0.0005241745,0.0028355103],"category_scores_gemma":[0.0654696,0.00030893538,0.0007597245,0.005544117,0.0019213166,0.0019796367,0.001557373,0.00083452783,0.00014902322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019726431,0.00015931242,0.72448695,0.0040691257,0.0006497581,0.00085840456,0.018076953,0.007211109,0.0018716577,0.07799824,0.0072326493,0.15718856],"study_design_scores_gemma":[0.000039939572,0.00019862133,0.9093592,0.0040301047,0.00036647203,0.00072044117,0.008689276,0.009176238,0.0012027392,0.008771039,0.057339977,0.00010596138],"about_ca_topic_score_codex":0.102670535,"about_ca_topic_score_gemma":0.08183216,"teacher_disagreement_score":0.102670535,"about_ca_system_score_codex":0.008954844,"about_ca_system_score_gemma":0.013379341,"threshold_uncertainty_score":0.20414591},"labels":[],"label_agreement":null},{"id":"W1911828822","doi":"","title":"Just the berries: Nephrotoxic drugs.","year":2004,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cape Breton Regional Hospital","funders":"","keywords":"Nephrotoxicity; Computer science; Data science; Medicine; World Wide Web; Kidney; Internal medicine","score_opus":0.07821927676451151,"score_gpt":0.2533487448095745,"score_spread":0.17512946804506296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1911828822","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046003885,0.27055246,0.0011609206,0.5796727,0.016734058,0.000025238574,0.0028550054,0.00010853096,0.12429068],"genre_scores_gemma":[0.22207046,0.39970365,0.0023064537,0.16334881,0.04563901,0.00010266505,0.0022601914,0.00010038078,0.16446835],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986155,0.0005355428,0.00010745463,0.00012906082,0.0004659086,0.00014648572],"domain_scores_gemma":[0.9934481,0.002802798,0.0011931497,0.000246317,0.0015028975,0.0008068456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013437791,0.00027204384,0.0005465903,0.0010704879,0.0007740094,0.0029386363,0.00056664366,0.0038165364,0.03072205],"category_scores_gemma":[0.014711587,0.00014697628,0.00023545776,0.002000562,0.0013270841,0.0044809934,0.00094275654,0.0029989262,0.0037461356],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033260422,0.00003996181,0.0013462265,0.00090057,0.00003980909,0.00015492586,0.00006995987,0.00025044577,0.00021121216,0.15695418,0.7236247,0.11607537],"study_design_scores_gemma":[0.00007113497,0.000059834172,0.0054019494,0.0012564671,0.000065795495,0.000364324,0.0001740242,0.00028113482,0.0003663659,0.047912702,0.94402444,0.000021832717],"about_ca_topic_score_codex":0.010828741,"about_ca_topic_score_gemma":0.02011095,"teacher_disagreement_score":0.03072205,"about_ca_system_score_codex":0.0024115122,"about_ca_system_score_gemma":0.003314459,"threshold_uncertainty_score":0.102775514},"labels":[],"label_agreement":null},{"id":"W1916719231","doi":"10.3917/rac.012.0071","title":"Le passage des frontières de médecines pas très douces : prévenir l’innocuité ou préserver l’authenticité ?","year":2011,"lang":"fr","type":"article","venue":"Revue d anthropologie des connaissances","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.24803775046646437,"score_gpt":0.33815055367739405,"score_spread":0.09011280321092968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1916719231","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25593156,0.06121914,0.016304597,0.39872092,0.006132181,0.00027620245,0.0003045186,0.0002834306,0.26082748],"genre_scores_gemma":[0.8327965,0.019714663,0.010405697,0.03215517,0.0010421741,0.00014861854,0.00015497996,0.0001649942,0.103417136],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.99496895,0.002489279,0.0001758434,0.0006252984,0.00091002515,0.0008306654],"domain_scores_gemma":[0.9924528,0.0024048362,0.0009173392,0.0008715096,0.001239083,0.0021144245],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00820646,0.00040137523,0.00055872166,0.00060209754,0.00817955,0.009647219,0.0011989161,0.0034299903,0.016037572],"category_scores_gemma":[0.011224206,0.0002863928,0.0003448481,0.0006091195,0.01192317,0.006379192,0.008611675,0.0051141856,0.0034561078],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004548968,0.00027638013,0.015462857,0.0017406002,0.00006070907,0.0029256514,0.2603602,0.00024039795,0.013279031,0.19510426,0.063272335,0.44682264],"study_design_scores_gemma":[0.000025016077,0.0003603121,0.006430092,0.0012606886,0.000024460061,0.0012429304,0.09834973,0.000090476904,0.0023636268,0.01923781,0.8705646,0.000050303308],"about_ca_topic_score_codex":0.013065551,"about_ca_topic_score_gemma":0.02269277,"teacher_disagreement_score":0.99182045,"about_ca_system_score_codex":0.0051131276,"about_ca_system_score_gemma":0.01688507,"threshold_uncertainty_score":0.053651035},"labels":[],"label_agreement":null},{"id":"W191744706","doi":"10.1533/9781908818089.47","title":"Empirical analysis of drug approval * *This chapter is based upon material in M. Sawicka and R.A. Bouchard, ‘Empirical Analysis of Canadian Drug Approval Data 2001-2008: Are Canadian Pharmaceutical Players “Doing More With Less”?’ McGill Journal of Law &amp; Health 3: 87-151 (2009).","year":2012,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Drug development; Business; Actuarial science; Medicine; Pharmacology; Risk analysis (engineering); Computer science","score_opus":0.13997755886015173,"score_gpt":0.3333490565088204,"score_spread":0.19337149764866868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W191744706","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0951842,0.24732317,0.053418733,0.05447808,0.0009168784,0.00026655852,0.025630035,0.00041849664,0.5223639],"genre_scores_gemma":[0.7521474,0.13457282,0.013793148,0.003955487,0.0012323366,0.00018544873,0.015674755,0.00023666154,0.07820194],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99566466,0.001156527,0.00021985495,0.0004450499,0.002146315,0.00036767512],"domain_scores_gemma":[0.96031433,0.030955777,0.003977096,0.0010885309,0.0032987513,0.00036561288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044663907,0.0005752953,0.0008782521,0.004666772,0.0011187189,0.0034835052,0.001034113,0.0009718483,0.017112043],"category_scores_gemma":[0.033930734,0.0005040118,0.00065590226,0.012864704,0.0025438354,0.0026686392,0.0008741162,0.002380385,0.0022254167],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004487203,0.00013419866,0.06143611,0.0011166837,0.00018129603,0.00033062682,0.0008707791,0.009641166,0.00015513311,0.6010902,0.12848745,0.19651148],"study_design_scores_gemma":[0.0000232139,0.00007984236,0.23366773,0.002406487,0.00018559817,0.00048933807,0.0027901083,0.030518916,0.0011638458,0.2695023,0.45903566,0.00013687552],"about_ca_topic_score_codex":0.24572468,"about_ca_topic_score_gemma":0.27828798,"teacher_disagreement_score":0.9890733,"about_ca_system_score_codex":0.010926723,"about_ca_system_score_gemma":0.008113246,"threshold_uncertainty_score":0.4885888},"labels":[],"label_agreement":null},{"id":"W1919945669","doi":"10.7202/1019196ar","title":"Facteurs associés à l’exposition élevée aux médicaments psychotropes identifiés lors d’une étude épidémiologique montréalaise","year":2013,"lang":"fr","type":"article","venue":"Santé mentale au Québec","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"","keywords":"Art; Humanities","score_opus":0.035378647755679095,"score_gpt":0.3006221221372502,"score_spread":0.2652434743815711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1919945669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958723,0.0013909099,0.00020754333,0.0004238008,0.000016919357,0.000017871358,0.001010646,0.000010947236,0.0010490426],"genre_scores_gemma":[0.9979861,0.0006998026,0.00014872782,0.00007329221,0.000029285353,0.000010990493,0.00033089798,0.000003056578,0.0007178447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991284,0.00018061567,0.00006965626,0.00014791611,0.0002575772,0.0002158049],"domain_scores_gemma":[0.99691534,0.00062616094,0.0013726782,0.00013618966,0.0004972218,0.00045242018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084747694,0.00023274828,0.00029406225,0.0020949994,0.000781769,0.0010364901,0.00040123117,0.00048212166,0.0029943958],"category_scores_gemma":[0.0037619954,0.00029230633,0.00042444395,0.0023503317,0.0005370319,0.0003905225,0.00042302717,0.0006947853,0.00013808058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003438928,0.000012505782,0.9975032,0.000010824277,0.00005546992,0.00007679827,0.00016401497,0.000034345983,0.00017018711,0.00003850436,0.00013735643,0.0017624077],"study_design_scores_gemma":[0.0000014886757,0.000015965303,0.99935263,0.0000047115054,0.000010912173,0.000053666896,0.00009306606,0.00005638625,0.000029597988,0.000007670427,0.00037056583,0.0000031943093],"about_ca_topic_score_codex":0.61177325,"about_ca_topic_score_gemma":0.60274005,"teacher_disagreement_score":0.38822675,"about_ca_system_score_codex":0.0030727116,"about_ca_system_score_gemma":0.0021719972,"threshold_uncertainty_score":0.7810262},"labels":[],"label_agreement":null},{"id":"W1931429111","doi":"","title":"Perspective face aux causes des ruptures d’approvisionnement de médicaments","year":2012,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.10714835934722142,"score_gpt":0.3507433770448012,"score_spread":0.24359501769757977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1931429111","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16799821,0.069015376,0.07144461,0.21485475,0.0032556376,0.0010645587,0.0013038216,0.00062399154,0.47043902],"genre_scores_gemma":[0.81904876,0.045299083,0.034363676,0.011228068,0.0006676199,0.00036089902,0.000513353,0.00013856005,0.08838002],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899921,0.0021727253,0.00050558074,0.0008238819,0.0049663913,0.001539305],"domain_scores_gemma":[0.98495805,0.0040543354,0.0023363251,0.00057529967,0.006813384,0.001262593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076922365,0.0008290017,0.0005234243,0.003678107,0.005721131,0.011024078,0.0024771271,0.003979778,0.016489992],"category_scores_gemma":[0.0141305365,0.0007356696,0.0015653908,0.0034621942,0.007915102,0.004218213,0.0032100528,0.0041547758,0.0012433669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036243076,0.00020303698,0.054076716,0.0035708037,0.00020092017,0.0057206764,0.046235733,0.0058276593,0.0050728954,0.55597454,0.05572809,0.26702654],"study_design_scores_gemma":[0.000057749014,0.000261066,0.03623459,0.0042797145,0.00032190362,0.003458383,0.055903103,0.0034211017,0.0053372066,0.06922472,0.8213241,0.00017631991],"about_ca_topic_score_codex":0.38666186,"about_ca_topic_score_gemma":0.4872648,"teacher_disagreement_score":0.38666186,"about_ca_system_score_codex":0.048238598,"about_ca_system_score_gemma":0.08165888,"threshold_uncertainty_score":0.7688225},"labels":[],"label_agreement":null},{"id":"W1937413232","doi":"","title":"Drug sales up 12.6% annually since 1988","year":2003,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug industry; Brand names; Advertising; Medicine; Engineering","score_opus":0.04091809963677959,"score_gpt":0.23944891243817537,"score_spread":0.19853081280139578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1937413232","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07130304,0.080884084,0.002407544,0.053642876,0.009793982,0.0003973624,0.09345972,0.003411494,0.6846999],"genre_scores_gemma":[0.12729892,0.03669309,0.0027365207,0.01480364,0.0029152525,0.00017514633,0.051576477,0.0001784673,0.7636226],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9990681,0.00005032692,0.000042233136,0.00011849185,0.00058357895,0.0001372465],"domain_scores_gemma":[0.998955,0.000075069554,0.00015809175,0.000051452396,0.0006162384,0.00014403302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039339685,0.00039176212,0.00033872633,0.0017923709,0.0007901268,0.0012853243,0.00046492997,0.0007695811,0.064478844],"category_scores_gemma":[0.0020526825,0.00024536785,0.0003641503,0.002252292,0.00022934396,0.0008161211,0.0012373963,0.0013264833,0.052715585],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017854222,0.00008481357,0.00988514,0.00032185632,0.00003092699,0.0001845479,0.00009060747,0.00008451958,0.0014693536,0.0025511144,0.62558675,0.3595318],"study_design_scores_gemma":[0.000012989073,0.000027765891,0.0139224185,0.00007923121,0.000015032998,0.00023504108,0.00004309896,0.000037355785,0.00030713103,0.00013329406,0.985182,0.0000046698497],"about_ca_topic_score_codex":0.021210603,"about_ca_topic_score_gemma":0.030841522,"teacher_disagreement_score":0.064478844,"about_ca_system_score_codex":0.001340685,"about_ca_system_score_gemma":0.0020779872,"threshold_uncertainty_score":0.21570325},"labels":[],"label_agreement":null},{"id":"W1946372495","doi":"10.1111/j.1525-139x.2011.00970.x","title":"Conditionally Funded Field Evaluations—A Solution to the Economic Barriers Limiting Evidence Generation in Dialysis?","year":2011,"lang":"en","type":"article","venue":"Seminars in Dialysis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Humber River Regional Hospital","funders":"","keywords":"Medicine; Limiting; Nephrology; Intensive care medicine; Patient care; Dialysis; Internal medicine; Nursing","score_opus":0.14000141090134874,"score_gpt":0.33257184363255893,"score_spread":0.1925704327312102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1946372495","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012860346,0.008511689,0.09222141,0.86562526,0.0021648286,0.0011159381,0.00074250106,0.00025439126,0.01650373],"genre_scores_gemma":[0.5897723,0.005337488,0.11696747,0.26851588,0.007208963,0.0061543826,0.0004663967,0.00026668215,0.0053105396],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.6146287,0.3108129,0.018218,0.014972511,0.034544926,0.0068230317],"domain_scores_gemma":[0.12077816,0.7915487,0.03083943,0.026939126,0.021615295,0.008279283],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.5497923,0.0014669172,0.0039998395,0.004943332,0.0033502835,0.015721407,0.005822449,0.020030571,0.011701906],"category_scores_gemma":[0.70273864,0.0018281317,0.002252832,0.0047141365,0.017113328,0.025451116,0.012762197,0.021166813,0.0012303771],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002063025,0.00030828468,0.009586783,0.0021766264,0.0009190764,0.00052953843,0.0018373036,0.0061632507,0.0006608669,0.720698,0.08489684,0.17016044],"study_design_scores_gemma":[0.0018589846,0.00050289877,0.0056992387,0.0038806414,0.0002498265,0.0004656303,0.000584562,0.0076350514,0.00059195346,0.92176056,0.056546703,0.00022388154],"about_ca_topic_score_codex":0.0052128956,"about_ca_topic_score_gemma":0.0047436776,"teacher_disagreement_score":0.5497923,"about_ca_system_score_codex":0.012714115,"about_ca_system_score_gemma":0.04772882,"threshold_uncertainty_score":0.5551863},"labels":[],"label_agreement":null},{"id":"W1948163795","doi":"","title":"2006-5 Price Control, Different Demands between Countries, and Parallel Trade in Pharmaceuticals","year":2006,"lang":"en","type":"preprint","venue":"Scholarship@Western (Western University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Government (linguistics); Welfare; Economics; Social Welfare; Control (management); International economics; International trade; European union; Supply and demand; Public economics; Market economy; Microeconomics; Political science","score_opus":0.1531073960490598,"score_gpt":0.336889435040506,"score_spread":0.1837820389914462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1948163795","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64619076,0.0051128464,0.057321914,0.034814183,0.0005084787,0.00019392718,0.0019692052,0.00029805556,0.25359064],"genre_scores_gemma":[0.97890216,0.0011027014,0.0019351029,0.0005541477,0.00017694886,0.000027090786,0.0002196084,0.00002387386,0.017058397],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920636,0.00025506914,0.000038155013,0.00014800626,0.00012069819,0.00023176828],"domain_scores_gemma":[0.99709046,0.0015315181,0.0008602086,0.0001240984,0.00016515482,0.00022854857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091670576,0.00039544454,0.00095526443,0.00055872835,0.0010323942,0.00608917,0.0006757643,0.0036092096,0.027311468],"category_scores_gemma":[0.003828117,0.00048696366,0.001448545,0.001209774,0.0019238456,0.0042568906,0.0017081065,0.0023282354,0.0011002462],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065559265,0.00053660525,0.030938914,0.00030046093,0.00025983813,0.0030543548,0.00046799483,0.19083652,0.0013723176,0.72753525,0.016841428,0.027200777],"study_design_scores_gemma":[0.00045718648,0.00035378698,0.018423645,0.00011184631,0.00021886169,0.0011740641,0.0007837697,0.27503327,0.001096883,0.6776271,0.024615256,0.00010431031],"about_ca_topic_score_codex":0.0107776765,"about_ca_topic_score_gemma":0.009085904,"teacher_disagreement_score":0.027311468,"about_ca_system_score_codex":0.0031242885,"about_ca_system_score_gemma":0.0013380406,"threshold_uncertainty_score":0.09136599},"labels":[],"label_agreement":null},{"id":"W1950143140","doi":"","title":"Encouraging the use of generic medicines: implications for transition economies.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Business; Payment; Generic drug; Promotion (chess); Public economics; Marketing; Market share; Demand side; Quality (philosophy); Industrial organization; Economics; Finance; Drug; Microeconomics; Medicine","score_opus":0.24958483105771556,"score_gpt":0.26881950643647756,"score_spread":0.019234675378762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1950143140","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0450138,0.32401296,0.0045196875,0.5879076,0.0015845712,0.0001605005,0.00064513367,0.000057279376,0.03609852],"genre_scores_gemma":[0.5839239,0.3644056,0.003936108,0.0373997,0.001991784,0.00013900755,0.00032296038,0.0000096991325,0.007871308],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994541,0.000237176,0.00003654015,0.0000352755,0.00008412056,0.00015274569],"domain_scores_gemma":[0.9948153,0.0033291467,0.0008044684,0.000047061163,0.0004250744,0.00057895266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018002687,0.00039677822,0.00036484926,0.0014944316,0.00091983716,0.0028698416,0.00043087755,0.0026873145,0.009035466],"category_scores_gemma":[0.006852862,0.00010297538,0.00054912054,0.0023984646,0.0014860443,0.0047437386,0.001498677,0.001558418,0.00037575027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005736372,0.00028061983,0.020924179,0.004736517,0.00013796438,0.0031789886,0.0014128536,0.012721753,0.00045550943,0.5482635,0.073867545,0.3334469],"study_design_scores_gemma":[0.0002333907,0.0007320197,0.0816052,0.0078814,0.0004064355,0.0036557436,0.021524835,0.007086293,0.0010018623,0.5033652,0.37233117,0.00017642668],"about_ca_topic_score_codex":0.0136947455,"about_ca_topic_score_gemma":0.016692365,"teacher_disagreement_score":0.0136947455,"about_ca_system_score_codex":0.0041468404,"about_ca_system_score_gemma":0.0043796264,"threshold_uncertainty_score":0.030226648},"labels":[],"label_agreement":null},{"id":"W1965203992","doi":"10.1353/cpp.2011.0038","title":"Socioeconomic Status and the Use of Medicines in the Ontario Public Drug Program","year":2011,"lang":"en","type":"article","venue":"Canadian Public Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Publishing; Indigenous; Politics; Socioeconomic status; The Renaissance; Public culture; Slavic languages; Social science; Sociology; Media studies; Library science; Political science; History; Classics; Art history; Law; Demography","score_opus":0.1678272396124274,"score_gpt":0.27541479054964996,"score_spread":0.10758755093722255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965203992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.937136,0.0027918043,0.00007340463,0.0070671733,0.000058080197,0.00007808616,0.02083413,0.000024965739,0.03193638],"genre_scores_gemma":[0.9865404,0.0019470346,0.00009382102,0.00027490797,0.000026376836,0.000027205768,0.003057128,0.000010199645,0.008023036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993363,0.00005070642,0.000047572263,0.000033901102,0.0003445185,0.00018697229],"domain_scores_gemma":[0.9964981,0.0002504006,0.001091854,0.000069778194,0.0007537547,0.0013361508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038561062,0.000112725334,0.00019850969,0.0012172798,0.0018299705,0.0010591192,0.0006275615,0.00038954627,0.01197981],"category_scores_gemma":[0.0035600504,0.00024739534,0.00051044644,0.00403882,0.000493469,0.0005374388,0.0007311385,0.0005505353,0.000591372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066829256,0.00007716305,0.97896546,0.000063883956,0.000049593807,0.0001131272,0.0010054639,0.00012461343,0.0000705795,0.0006009215,0.010959626,0.007902758],"study_design_scores_gemma":[0.000006091584,0.000010022886,0.9965383,0.00003631439,0.000012399876,0.000024680165,0.0005758545,0.000102174956,0.000014219239,0.000035852867,0.0026388764,0.0000053943336],"about_ca_topic_score_codex":0.9905041,"about_ca_topic_score_gemma":0.99536824,"teacher_disagreement_score":0.01852995,"about_ca_system_score_codex":0.01852995,"about_ca_system_score_gemma":0.021794297,"threshold_uncertainty_score":0.13444483},"labels":[],"label_agreement":null},{"id":"W1965399548","doi":"10.1093/eurheartj/eht308.991","title":"Programming strategies to reduce non-essential therapies and mortality - a systematic review","year":2013,"lang":"en","type":"review","venue":"European Heart Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Confidence interval; MEDLINE; Internal medicine; Meta-analysis","score_opus":0.20067122972659585,"score_gpt":0.40480216938165536,"score_spread":0.20413093965505952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965399548","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013694112,0.9976272,0.00016322486,0.00014548177,0.00008236489,0.0002721386,0.0001453733,0.000009768279,0.00018508678],"genre_scores_gemma":[0.025561288,0.9722395,0.00094996387,0.00035723273,0.00009871016,0.00053247245,0.00016519999,0.000007513209,0.0000881027],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99422765,0.0024876497,0.0019038589,0.00037098068,0.0008445342,0.00016533211],"domain_scores_gemma":[0.9840672,0.012026941,0.0025731144,0.0002084148,0.00095948833,0.00016490807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077775223,0.0017386401,0.008746972,0.005623118,0.00042513356,0.0024466536,0.0015066515,0.0015008843,0.0038548508],"category_scores_gemma":[0.02599093,0.00095171423,0.012687806,0.005344607,0.0005752309,0.0015481212,0.0010015578,0.0012752838,0.00025793313],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006668336,0.00004564013,0.0008368479,0.9148669,0.04463262,0.00006480463,0.0000839689,0.00022265158,0.00016591678,0.00017709279,0.00078247365,0.03745427],"study_design_scores_gemma":[0.0014375243,0.00071877765,0.00496762,0.5543185,0.42610362,0.00029242426,0.00016807894,0.00029350133,0.00036959228,0.00042511866,0.010855369,0.00004982012],"about_ca_topic_score_codex":0.004257907,"about_ca_topic_score_gemma":0.010893251,"teacher_disagreement_score":0.008746972,"about_ca_system_score_codex":0.0020710593,"about_ca_system_score_gemma":0.0055220695,"threshold_uncertainty_score":0.041131973},"labels":[],"label_agreement":null},{"id":"W1965514038","doi":"10.1377/hlthaff.2013.0388","title":"Despite Increased Use And Sales Of Statins In India, Per Capita Prescription Rates Remain Far Below High-Income Countries","year":2014,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"","keywords":"Per capita; Medical prescription; Per capita income; Business; Economics; Environmental health; Demographic economics; Medicine; Population","score_opus":0.02993697283097848,"score_gpt":0.2774550255136146,"score_spread":0.24751805268263613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965514038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9427936,0.0052864994,0.0016081465,0.01608701,0.00008927448,0.000029049843,0.007993033,0.00012467384,0.02598866],"genre_scores_gemma":[0.9908326,0.0040081656,0.00055950996,0.0006171587,0.00013133508,0.000009640195,0.0015829026,0.000007338036,0.0022513003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941254,0.00015232505,0.00005083124,0.00005318677,0.00019402921,0.0001369558],"domain_scores_gemma":[0.99758065,0.00071428914,0.0011251522,0.00012336591,0.0003346874,0.000121918885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050164695,0.00010859889,0.00021047448,0.0010400321,0.0004146512,0.0013750604,0.00025179173,0.0002104498,0.0038161597],"category_scores_gemma":[0.002241636,0.0001185049,0.00032136668,0.0030603209,0.0004337483,0.00040789496,0.0004739286,0.0006048722,0.000739314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001053913,0.0000757236,0.9330789,0.00025048712,0.000100983816,0.0004609398,0.0004949958,0.0026451857,0.00060949486,0.0097654965,0.009331815,0.04308066],"study_design_scores_gemma":[0.0000053408367,0.000031344007,0.9827366,0.000052874482,0.0000346517,0.0004700739,0.00080744387,0.0013084769,0.0003047479,0.0012919871,0.012944698,0.00001168129],"about_ca_topic_score_codex":0.05283414,"about_ca_topic_score_gemma":0.054170102,"teacher_disagreement_score":0.05283414,"about_ca_system_score_codex":0.0014136927,"about_ca_system_score_gemma":0.0017090654,"threshold_uncertainty_score":0.105053246},"labels":[],"label_agreement":null},{"id":"W1965564826","doi":"10.12927/hcpol.2011.22392","title":"Purchasing Prescription Drugs in Canada: Hang Together or Hang Separately","year":2011,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Purchasing; Medical prescription; Hang; Population; Business; Prescription drug; Medicine; Marketing; Environmental health; Pharmacology; Computer science","score_opus":0.17135874554552846,"score_gpt":0.32830337483653627,"score_spread":0.1569446292910078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965564826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38689014,0.030470867,0.0013954473,0.32481748,0.0011481177,0.00020296378,0.009326972,0.00016057189,0.24558742],"genre_scores_gemma":[0.93717086,0.012868309,0.0013087501,0.022548316,0.00030368238,0.000029390945,0.001371066,0.000059436778,0.024340186],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966827,0.00016130567,0.00008923491,0.00015620198,0.0011758129,0.0017347508],"domain_scores_gemma":[0.99581134,0.00035164616,0.00047931448,0.000092959155,0.0011701803,0.002094554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00110416,0.0002679803,0.0005601368,0.0018632882,0.0056821504,0.005378284,0.0010088581,0.0018060431,0.012253664],"category_scores_gemma":[0.005456963,0.00037084837,0.0005435453,0.006862374,0.002424574,0.0022273595,0.0022261166,0.0025496194,0.00058695587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066915806,0.00028351476,0.2618579,0.0005789523,0.00032537477,0.0015448272,0.0062678736,0.0035947592,0.0008254627,0.12806836,0.37724403,0.21873978],"study_design_scores_gemma":[0.00028587657,0.00012276335,0.59919226,0.001260131,0.00057787274,0.000441864,0.028498553,0.006192222,0.0009155853,0.033387206,0.32883567,0.0002900134],"about_ca_topic_score_codex":0.9958598,"about_ca_topic_score_gemma":0.99847883,"teacher_disagreement_score":0.09156895,"about_ca_system_score_codex":0.09156895,"about_ca_system_score_gemma":0.15240394,"threshold_uncertainty_score":0.66438234},"labels":[],"label_agreement":null},{"id":"W1967997471","doi":"10.1371/journal.pone.0023030","title":"The Short-Term Impact of Ontario's Generic Pricing Reforms","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Generic drug; Medical prescription; Purchasing; Reimbursement; Public economics; Economics; Audit; Capital expenditure; Agricultural economics; Business; Demographic economics; Finance; Economic growth; Accounting; Operations management; Drug; Medicine; Health care","score_opus":0.20478650214225946,"score_gpt":0.27752195977273875,"score_spread":0.07273545763047928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967997471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8330723,0.0046388325,0.0012072969,0.05550508,0.0001729834,0.00012800496,0.0137346,0.000103567014,0.09143738],"genre_scores_gemma":[0.9901008,0.0014744825,0.00042506668,0.0014937005,0.00005219932,0.000014271996,0.0012863192,0.000010986617,0.005142135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820006,0.00017286818,0.000043397118,0.00007906863,0.00078958273,0.0007149706],"domain_scores_gemma":[0.99699116,0.00030281537,0.0006193336,0.00006844871,0.0014221767,0.0005960494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001020183,0.00022462146,0.00018233496,0.00050484,0.0014621635,0.0017682879,0.0006157183,0.0006592372,0.0041011153],"category_scores_gemma":[0.0052054925,0.00015557358,0.0004443524,0.0012008528,0.0008945006,0.0006810166,0.00068127725,0.00064986385,0.00023519927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008693125,0.00031128322,0.72291267,0.0013790713,0.00052817963,0.001344816,0.003303655,0.022373104,0.004055787,0.043207742,0.09533323,0.10438119],"study_design_scores_gemma":[0.000053891054,0.00010342519,0.92743367,0.00018997314,0.00010864408,0.00009413173,0.0018635719,0.0048362575,0.000482113,0.0010991327,0.06369977,0.000035406916],"about_ca_topic_score_codex":0.986909,"about_ca_topic_score_gemma":0.99202347,"teacher_disagreement_score":0.9294795,"about_ca_system_score_codex":0.07052052,"about_ca_system_score_gemma":0.07908611,"threshold_uncertainty_score":0.51166457},"labels":[],"label_agreement":null},{"id":"W1968616336","doi":"10.1016/j.jhealeco.2012.02.004","title":"Pricing of drugs with heterogeneous health insurance coverage","year":2012,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University; York University","funders":"","keywords":"Market segmentation; Competition (biology); Business; Brand loyalty; Health insurance; Brand names; Price discrimination; First-mover advantage; Product differentiation; Segmentation; Economics; Microeconomics; Marketing; Health care; Computer science","score_opus":0.059672437391580846,"score_gpt":0.3060569529771553,"score_spread":0.24638451558557445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968616336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.881001,0.00457557,0.083788745,0.010281209,0.00031520936,0.00033740743,0.0013169049,0.00019304514,0.01819091],"genre_scores_gemma":[0.99378526,0.0004440497,0.0026181303,0.00022740483,0.0002781563,0.000032592307,0.00022327562,0.000017297365,0.0023739068],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9938599,0.0032831233,0.0002930276,0.00063379644,0.0008959528,0.0010342399],"domain_scores_gemma":[0.9584273,0.03407995,0.0034113158,0.0014043719,0.00077699294,0.0019000988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008339828,0.001236872,0.00398956,0.001964355,0.00070836634,0.007937352,0.0037949514,0.004770307,0.009263618],"category_scores_gemma":[0.04506504,0.0013738535,0.0025641066,0.0020442808,0.0026432676,0.005012158,0.0017175972,0.0029798085,0.0004899853],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004259354,0.00096165965,0.026968263,0.00039332482,0.0017786735,0.0032402095,0.00028043895,0.58414876,0.0021343043,0.3232106,0.008410794,0.044213634],"study_design_scores_gemma":[0.000962676,0.00057397864,0.012608814,0.00007402851,0.0006212203,0.0008756509,0.00027179276,0.81884694,0.0007288717,0.16257593,0.0017475404,0.00011247113],"about_ca_topic_score_codex":0.0031225216,"about_ca_topic_score_gemma":0.0020646644,"teacher_disagreement_score":0.009263618,"about_ca_system_score_codex":0.0031444093,"about_ca_system_score_gemma":0.0011244173,"threshold_uncertainty_score":0.04410571},"labels":[],"label_agreement":null},{"id":"W1968691101","doi":"10.1016/s0140-6736(07)61094-0","title":"The African private sector steps in to fill the drug gap","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pill; Legislation; Government (linguistics); Business; Index (typography); Law; Artificial intelligence; Political science; Computer science; Medicine; Pharmacology; World Wide Web; Philosophy","score_opus":0.09596589198122327,"score_gpt":0.30302982838767734,"score_spread":0.20706393640645407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968691101","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003251683,0.018015984,0.0008458973,0.9692955,0.00269724,0.0000145019085,0.0001903977,0.000027831675,0.005660918],"genre_scores_gemma":[0.3217712,0.06074807,0.009877417,0.5737492,0.015964774,0.00016776675,0.00027059813,0.0001572283,0.01729376],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953815,0.0024086963,0.00020404546,0.00020215042,0.0007216868,0.0010819345],"domain_scores_gemma":[0.97783613,0.013429419,0.0020622886,0.0009676496,0.002379695,0.0033247785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016163303,0.000678323,0.0012601148,0.0020391033,0.0023268922,0.0067609814,0.0010965269,0.015253484,0.02012655],"category_scores_gemma":[0.039018173,0.00039188654,0.0007792625,0.0027519932,0.006154106,0.013802458,0.0059040147,0.01050498,0.002179266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080711825,0.00024498432,0.004443342,0.0014105324,0.00012388638,0.00058480975,0.0009772658,0.0014471522,0.0008337871,0.56341296,0.29302597,0.13268815],"study_design_scores_gemma":[0.00030428803,0.0001477938,0.005084824,0.0015668186,0.000055818862,0.00032548132,0.0017729906,0.001203413,0.00044179842,0.36497682,0.62407374,0.00004610732],"about_ca_topic_score_codex":0.0064457254,"about_ca_topic_score_gemma":0.005290661,"teacher_disagreement_score":0.02012655,"about_ca_system_score_codex":0.0040416652,"about_ca_system_score_gemma":0.018969756,"threshold_uncertainty_score":0.08548075},"labels":[],"label_agreement":null},{"id":"W1968800010","doi":"10.1016/s1098-3015(10)72458-x","title":"PHP78 UNDERSTANDING DRUG REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE COMMON DRUG REVIEW (CDR)","year":2010,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Drug; Business; Medicine; Pharmacology; Political science; Law; Health care","score_opus":0.1478424321879946,"score_gpt":0.33522112337367155,"score_spread":0.18737869118567696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968800010","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06891198,0.02216326,0.0071945065,0.46544975,0.0019320375,0.00047349394,0.03773636,0.000634915,0.3955037],"genre_scores_gemma":[0.74105674,0.015873339,0.018005729,0.039595645,0.0021057243,0.00019324399,0.009062046,0.00032338616,0.1737841],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.993401,0.0012515057,0.0002772816,0.0005031761,0.0031758612,0.0013911681],"domain_scores_gemma":[0.9702931,0.0099546015,0.001390914,0.0006797599,0.015759267,0.001922353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007182391,0.00050609244,0.0006755048,0.0035817048,0.002810792,0.009502744,0.0010079248,0.0040586167,0.015018021],"category_scores_gemma":[0.03851971,0.00048030497,0.0009800867,0.004583799,0.0016080567,0.00230954,0.0009407869,0.0024841453,0.0014590722],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011183317,0.00005475738,0.013066591,0.00024088746,0.00011069093,0.00026162105,0.00056075514,0.010958043,0.00018612866,0.15124133,0.7734324,0.049774956],"study_design_scores_gemma":[0.00012445894,0.00006107927,0.055923857,0.00074626104,0.00022412057,0.00011959652,0.0015380059,0.030828599,0.0007084411,0.07720746,0.8323133,0.00020480106],"about_ca_topic_score_codex":0.9761752,"about_ca_topic_score_gemma":0.98481905,"teacher_disagreement_score":0.92571187,"about_ca_system_score_codex":0.07428811,"about_ca_system_score_gemma":0.13542427,"threshold_uncertainty_score":0.5390005},"labels":[],"label_agreement":null},{"id":"W1969013485","doi":"10.2165/00019053-200826080-00001","title":"Waiting for Reimbursement of New Medicines in Canada","year":2008,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Reimbursement; Public health; Health economics; Public health insurance; Certification; Medicine; Family medicine; Quality of Life Research; Environmental health; Health insurance; Health administration; Business; Health care; Economic growth; Nursing; Political science","score_opus":0.11448916653243718,"score_gpt":0.31835818760973206,"score_spread":0.20386902107729488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969013485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5617758,0.01816912,0.0007291953,0.36679327,0.0015627339,0.00026739851,0.008142131,0.00017223696,0.042388074],"genre_scores_gemma":[0.94863796,0.004973413,0.0007565187,0.028882397,0.00056229666,0.00003515484,0.0013857115,0.00005056367,0.014716083],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927429,0.0003921935,0.00032561025,0.000383002,0.0022102667,0.003946068],"domain_scores_gemma":[0.9710769,0.004927282,0.0035529167,0.00026345675,0.008129393,0.012050104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037063002,0.00033992878,0.0010617833,0.001844963,0.006708034,0.0072580143,0.0025115088,0.005880982,0.007782336],"category_scores_gemma":[0.021054018,0.00076395704,0.0011482632,0.0044893394,0.0018717938,0.0014672364,0.0012675867,0.007000954,0.0002870675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002032512,0.0007471046,0.4113028,0.0010649286,0.0006519249,0.0031996248,0.0036808443,0.01458921,0.0016451975,0.12531409,0.33151448,0.10425724],"study_design_scores_gemma":[0.0010308349,0.0003801289,0.7031431,0.0012471902,0.0009896463,0.0011074273,0.011313072,0.03660305,0.0017030234,0.016235806,0.22571194,0.0005347121],"about_ca_topic_score_codex":0.9972812,"about_ca_topic_score_gemma":0.99869305,"teacher_disagreement_score":0.7909701,"about_ca_system_score_codex":0.20902994,"about_ca_system_score_gemma":0.3169524,"threshold_uncertainty_score":0.9174132},"labels":[],"label_agreement":null},{"id":"W1969347689","doi":"10.1071/ah090295","title":"Medicines policy and drug company investments: the Irish experience","year":2009,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multinational corporation; Jurisdiction; Business; Globalization; Pharmaceutical industry; European union; Irish; Harmonization; International trade; Economic growth; Economic policy; Economics; Finance; Political science; Biotechnology; Market economy; Law","score_opus":0.18058848397700697,"score_gpt":0.42472291646651983,"score_spread":0.24413443248951286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969347689","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0290195,0.10317318,0.00031811482,0.23037234,0.001955079,0.00007736185,0.00055763946,0.000071723116,0.634455],"genre_scores_gemma":[0.39461753,0.16202188,0.00096522924,0.06619809,0.0018869321,0.00012223623,0.00067832414,0.00014783957,0.37336195],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.991267,0.0027452926,0.00036573646,0.00040086624,0.002998228,0.0022228165],"domain_scores_gemma":[0.9941315,0.0023860063,0.00058692164,0.00025538917,0.0009383172,0.0017017844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009865355,0.00036038778,0.0006656541,0.0010558506,0.0020089669,0.011828928,0.0012431814,0.0035638856,0.0127906995],"category_scores_gemma":[0.010024572,0.00042956046,0.00045138554,0.0040098284,0.0033681537,0.0043013645,0.003304457,0.0049552433,0.001833496],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032967326,0.00027822366,0.002864889,0.0011553208,0.00005428143,0.0008573611,0.006805435,0.0012980729,0.0004482966,0.40912452,0.41928574,0.15749818],"study_design_scores_gemma":[0.000030132838,0.00005385537,0.0023424951,0.00031854332,0.0000067354563,0.00012454293,0.0017774493,0.000086509266,0.00013474227,0.002525794,0.99258137,0.000017791757],"about_ca_topic_score_codex":0.09834194,"about_ca_topic_score_gemma":0.08381374,"teacher_disagreement_score":0.09834194,"about_ca_system_score_codex":0.032713637,"about_ca_system_score_gemma":0.02953709,"threshold_uncertainty_score":0.23735517},"labels":[],"label_agreement":null},{"id":"W1969868159","doi":"10.2190/4m3e-l0yf-w1td-ekg0","title":"Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence","year":2004,"lang":"en","type":"review","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Cost sharing; Medical prescription; Prescription drug; Subsidy; Drug; Health care; Prescription costs; Business; Medicine; Public economics; Environmental health; Actuarial science; Economic growth; Economics; Pharmacology; Nursing","score_opus":0.11319537075335327,"score_gpt":0.40640472417967133,"score_spread":0.29320935342631804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969868159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008479605,0.9985483,0.00004679748,0.00012664238,0.000026580896,0.000030418149,0.00018795699,0.0000021087574,0.00018306567],"genre_scores_gemma":[0.010337837,0.9891962,0.00017404876,0.00010337373,0.000024890911,0.000035064004,0.00008037766,0.0000011825211,0.00004702372],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99547464,0.0018015566,0.001079904,0.00032774976,0.0012133272,0.000102842576],"domain_scores_gemma":[0.96846795,0.024145018,0.0048223957,0.00029675185,0.0020123243,0.00025561516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066846674,0.0007589589,0.005050266,0.00611821,0.0002498061,0.001382266,0.00085459807,0.001034113,0.002916335],"category_scores_gemma":[0.032786656,0.0006049639,0.004241692,0.009149154,0.00050717324,0.0010285773,0.00082613557,0.0006388391,0.00021042452],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006820363,0.000044071192,0.005978027,0.71554756,0.02323007,0.00022309025,0.00013959152,0.0003816362,0.00015105351,0.0004854774,0.0045880275,0.24854939],"study_design_scores_gemma":[0.00082153146,0.00070302223,0.066105895,0.6428054,0.2118737,0.0018183175,0.00044208654,0.00041802952,0.0005719366,0.001515628,0.07283013,0.0000943304],"about_ca_topic_score_codex":0.008730368,"about_ca_topic_score_gemma":0.025568996,"teacher_disagreement_score":0.008730368,"about_ca_system_score_codex":0.0018892554,"about_ca_system_score_gemma":0.0047585974,"threshold_uncertainty_score":0.03535229},"labels":[],"label_agreement":null},{"id":"W1969906875","doi":"10.1377/hlthaff.2011.0209","title":"Longer Exclusivity Does Not Guarantee Better Drugs","year":2011,"lang":"en","type":"letter","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Download; Library science; Political science; Medicine; Computer science; World Wide Web","score_opus":0.06695582585118953,"score_gpt":0.2903711058576489,"score_spread":0.22341528000645938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969906875","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001480294,0.0014144651,0.0003965384,0.9781797,0.0058647157,0.000021751805,0.000115638766,0.000060104667,0.012466806],"genre_scores_gemma":[0.0061565656,0.00028781066,0.0002317536,0.9762838,0.009030473,0.000029587693,0.000022695885,0.000027047714,0.007930422],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97615844,0.0051915785,0.0029381302,0.003681698,0.0076410994,0.004388952],"domain_scores_gemma":[0.91060835,0.06630819,0.0049396427,0.004526251,0.0070935353,0.0065240543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026553588,0.0012189494,0.0033400976,0.0012679851,0.0073776045,0.01559357,0.004703613,0.20977806,0.01920003],"category_scores_gemma":[0.089817435,0.0018860939,0.0030798656,0.0016859648,0.011597237,0.012702252,0.0063644876,0.10818376,0.00887547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003763981,0.00016172818,0.0015094203,0.0001462022,0.00014927087,0.0014549999,0.00035723665,0.0002831019,0.0008452715,0.11165388,0.86945564,0.013606772],"study_design_scores_gemma":[0.0005474406,0.00021479315,0.0039584106,0.0005248572,0.00014770868,0.0010916,0.0005094079,0.0014163471,0.0011859053,0.13439225,0.8557567,0.00025450753],"about_ca_topic_score_codex":0.010782869,"about_ca_topic_score_gemma":0.0240144,"teacher_disagreement_score":0.20977806,"about_ca_system_score_codex":0.010306379,"about_ca_system_score_gemma":0.012802633,"threshold_uncertainty_score":0.14043045},"labels":[],"label_agreement":null},{"id":"W1970577443","doi":"10.1016/j.healthpol.2010.12.002","title":"The cost of drug development: A systematic review","year":2011,"lang":"en","type":"review","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":497,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Audit; Citation; Actuarial science; Medicine; Cash; Transparency (behavior); Confidentiality; Accounting; Business; Computer science; Finance; Library science","score_opus":0.2564027925749183,"score_gpt":0.43412845224029106,"score_spread":0.17772565966537274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970577443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004061197,0.9979462,0.00014153014,0.000643978,0.00013295957,0.000038335544,0.00038246516,0.0000039722413,0.00030447321],"genre_scores_gemma":[0.010168626,0.9885952,0.0003804742,0.0004005536,0.00017215607,0.000057351077,0.0001258295,0.0000038327603,0.000095933116],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9908303,0.003474539,0.0020700411,0.00050437025,0.0028794215,0.00024139951],"domain_scores_gemma":[0.9586938,0.030433318,0.007353634,0.0004799692,0.002649416,0.0003898666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007894718,0.0011536408,0.005582831,0.0077483775,0.00024412223,0.0021554201,0.001328803,0.0019414176,0.0062479884],"category_scores_gemma":[0.051530752,0.00090562506,0.00467618,0.010605205,0.000799925,0.0021428505,0.0012476714,0.0016995101,0.0003385746],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009666959,0.0000543108,0.0031458335,0.68653727,0.02883813,0.00029745832,0.000057920166,0.001263348,0.00016692505,0.0028506855,0.0206358,0.25518566],"study_design_scores_gemma":[0.0018621264,0.0004976277,0.020971538,0.61525327,0.19250661,0.002165462,0.00027634806,0.0010764023,0.0005236758,0.00686019,0.15789045,0.00011637534],"about_ca_topic_score_codex":0.0084829405,"about_ca_topic_score_gemma":0.025355875,"teacher_disagreement_score":0.0084829405,"about_ca_system_score_codex":0.0051199603,"about_ca_system_score_gemma":0.009970062,"threshold_uncertainty_score":0.041751802},"labels":[],"label_agreement":null},{"id":"W1970738061","doi":"10.1038/sj.clpt.6100359","title":"The Morally Uncomfortable Global Drug Gap","year":2007,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Essential medicines; Population; Human rights; Consumption (sociology); Quality (philosophy); Economic growth; Medicine; Business; Development economics; Public relations; Law and economics; Political science; Law; Health care; Economics; Sociology; Environmental health; Social science","score_opus":0.17917928466033714,"score_gpt":0.4357705111054546,"score_spread":0.25659122644511745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970738061","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044249357,0.022993809,0.00278443,0.84740776,0.0027469876,0.000018511228,0.000116397154,0.00004192564,0.1194653],"genre_scores_gemma":[0.37781912,0.045546453,0.006615878,0.50819784,0.009864457,0.0001562813,0.00023355402,0.00025512686,0.05131129],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99458486,0.0031677452,0.00012961046,0.00043382056,0.001198274,0.00048563452],"domain_scores_gemma":[0.99245536,0.0048636226,0.00052630715,0.00047853406,0.00073066226,0.0009453948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077100615,0.00057477766,0.000734562,0.000859077,0.003240881,0.0066224877,0.0010421884,0.009361791,0.018695956],"category_scores_gemma":[0.013638349,0.00019392412,0.00042013422,0.0010570161,0.013186127,0.011214351,0.0063775033,0.011600205,0.0024789716],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001904331,0.000026682897,0.00021281019,0.00009049239,0.0000063855387,0.00013326456,0.0005085209,0.00024775282,0.000051152925,0.8920388,0.085610114,0.02105503],"study_design_scores_gemma":[0.000012106472,0.000016867183,0.0002580736,0.00034156442,0.0000031180036,0.00030117924,0.0007713991,0.00028660774,0.00007880969,0.6345965,0.36332345,0.000010355996],"about_ca_topic_score_codex":0.0017570199,"about_ca_topic_score_gemma":0.0016862497,"teacher_disagreement_score":0.018695956,"about_ca_system_score_codex":0.0044640764,"about_ca_system_score_gemma":0.0056141266,"threshold_uncertainty_score":0.06254417},"labels":[],"label_agreement":null},{"id":"W1970783892","doi":"10.1371/journal.pmed.1000208","title":"Are Patents Impeding Medical Care and Innovation?","year":2010,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; McGill University","funders":"","keywords":"Incentive; Health care; Intellectual property; Business; Medical care; Medical research; Medical device; Public relations; Medicine; Economic growth; Economics; Law; Political science; Family medicine","score_opus":0.10565661841791527,"score_gpt":0.3219407716179689,"score_spread":0.21628415320005365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970783892","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066818595,0.09016971,0.0018635897,0.86339337,0.0010795385,0.00001632187,0.0001923433,0.000015952279,0.03658733],"genre_scores_gemma":[0.5492609,0.211205,0.0014302823,0.19078258,0.039394494,0.00013807861,0.00020313746,0.000045753448,0.007539757],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9882537,0.005479323,0.000591671,0.0015136697,0.0026608887,0.001500822],"domain_scores_gemma":[0.79022664,0.18970579,0.011426774,0.0017817322,0.0048559937,0.002003049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019374639,0.0006168458,0.0014035178,0.0036565547,0.0029586426,0.010088291,0.0018694069,0.017766163,0.01818568],"category_scores_gemma":[0.08088176,0.00046710556,0.0010389442,0.0054588397,0.022781678,0.013270291,0.0035710519,0.01380728,0.0016439869],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062191604,0.000031608164,0.0009806522,0.0004923154,0.000026867898,0.00016689015,0.00030078783,0.00055784354,0.000041309115,0.96063995,0.019210098,0.017489472],"study_design_scores_gemma":[0.000111371664,0.0000496895,0.0037671952,0.002005525,0.000061826846,0.00030587177,0.0008940439,0.00096870755,0.0001400789,0.8708398,0.12081207,0.00004380661],"about_ca_topic_score_codex":0.006970113,"about_ca_topic_score_gemma":0.0027812412,"teacher_disagreement_score":0.019374639,"about_ca_system_score_codex":0.0076667634,"about_ca_system_score_gemma":0.005860477,"threshold_uncertainty_score":0.10246408},"labels":[],"label_agreement":null},{"id":"W1972080304","doi":"10.1503/cmaj.130814","title":"Delays in the submission of new drugs in Canada","year":2014,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Organisation de Coopération et de Développement Économiques; Government of Canada; Mylan; Teva Pharmaceutical Industries","keywords":"Process (computing); Drug approval; Computer science; Medicine; Data science; Pharmacology; Drug","score_opus":0.04566880837996752,"score_gpt":0.29182912028722147,"score_spread":0.24616031190725396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972080304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045680007,0.9839431,0.00009592003,0.010546044,0.0008956596,0.000018058196,0.0001774729,0.000017651862,0.003849288],"genre_scores_gemma":[0.01134482,0.97901595,0.00032059086,0.006667441,0.0008186929,0.000021308948,0.00020652878,0.0000143384395,0.0015902888],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881585,0.0018269246,0.0010821811,0.0007705872,0.007070574,0.0010912155],"domain_scores_gemma":[0.9512196,0.018840976,0.007904585,0.00057502784,0.018988915,0.0024709476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014232243,0.000708557,0.0015080014,0.0042526196,0.0018311528,0.0038993666,0.002514191,0.0027241379,0.0065249684],"category_scores_gemma":[0.041315526,0.0006344634,0.001102105,0.00864504,0.0023822677,0.0024280814,0.0017049602,0.005213541,0.0009824567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004852961,0.0000675889,0.002282415,0.034793805,0.00036432713,0.00038028092,0.00046663056,0.00092083705,0.00047700762,0.018880038,0.3193353,0.62154645],"study_design_scores_gemma":[0.00014234011,0.000082386425,0.0074239024,0.024558028,0.00040845055,0.00064290996,0.00033736692,0.00020288998,0.000524616,0.0020515718,0.96355337,0.00007218703],"about_ca_topic_score_codex":0.623382,"about_ca_topic_score_gemma":0.7173093,"teacher_disagreement_score":0.96426123,"about_ca_system_score_codex":0.03573876,"about_ca_system_score_gemma":0.111295626,"threshold_uncertainty_score":0.757672},"labels":[],"label_agreement":null},{"id":"W1972149089","doi":"10.1586/14760584.2013.850035","title":"Vaccine development costs: a review","year":2013,"lang":"en","type":"review","venue":"Expert Review of Vaccines","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates - Health Solutions","keywords":"Drug development; Pharmaceutical industry; Business; Public economics; Risk analysis (engineering); Medicine; Actuarial science; Drug; Economics; Pharmacology","score_opus":0.11465758690193695,"score_gpt":0.39211783474024897,"score_spread":0.277460247838312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972149089","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008714283,0.9988166,0.000057230547,0.00033895063,0.00008770761,0.0000064198894,0.000045171695,0.00000210166,0.00055874477],"genre_scores_gemma":[0.0005931026,0.9990466,0.00008170442,0.00008899356,0.00006462365,0.00000546367,0.000027781462,5.993109e-7,0.00009116273],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991653,0.00017910653,0.0001556765,0.00009201387,0.00036705998,0.000040878364],"domain_scores_gemma":[0.99668235,0.0023144332,0.0004742263,0.0000354189,0.0004318215,0.00006179458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015561108,0.0010248364,0.0018405109,0.0050728265,0.00029707007,0.0015581308,0.0011366068,0.0013800957,0.008289058],"category_scores_gemma":[0.005139979,0.0005163584,0.001367299,0.0064968294,0.00041156786,0.0015720198,0.00057674805,0.0012938417,0.001192977],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009434448,0.00006505552,0.000373018,0.0889064,0.00044503916,0.0001283485,0.000047844114,0.0007834938,0.0002652404,0.0054997257,0.041123945,0.86226755],"study_design_scores_gemma":[0.000050686565,0.0001332552,0.0031364367,0.07766128,0.0010888597,0.0011337457,0.00011044305,0.0003020467,0.00034474162,0.0037012,0.9122984,0.000038880236],"about_ca_topic_score_codex":0.0038484363,"about_ca_topic_score_gemma":0.005362065,"teacher_disagreement_score":0.008289058,"about_ca_system_score_codex":0.0017201541,"about_ca_system_score_gemma":0.0038118185,"threshold_uncertainty_score":0.02772969},"labels":[],"label_agreement":null},{"id":"W1972281338","doi":"10.1503/cmaj.109-3904","title":"Drug shortage registry under discussion","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Negotiation; Drug; Medicine; Family medicine; Pharmacology; Political science; Government (linguistics)","score_opus":0.040721444869526245,"score_gpt":0.25408855231782657,"score_spread":0.2133671074483003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972281338","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004394865,0.0045264475,0.0038270582,0.38173863,0.02860513,0.0023413375,0.05542666,0.0027295044,0.51641035],"genre_scores_gemma":[0.035327286,0.008040454,0.005487126,0.33339962,0.019757528,0.0028830725,0.07488189,0.0013597906,0.5188633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9847438,0.0023893537,0.0022785482,0.0017953758,0.0059777526,0.0028151989],"domain_scores_gemma":[0.93963265,0.009986557,0.0046857838,0.0043846914,0.029992511,0.011317747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0147704035,0.0004669945,0.0010925449,0.004107964,0.0042963293,0.0065677674,0.0036541477,0.009138033,0.1228265],"category_scores_gemma":[0.044574156,0.00057744054,0.0010832275,0.004459171,0.0011870837,0.004872619,0.004383412,0.005430435,0.051973987],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038985865,0.000021236732,0.0014555504,0.00010338431,0.000004747417,0.00022736078,0.00006466398,0.00002191389,0.000048390506,0.005622432,0.98054034,0.011851012],"study_design_scores_gemma":[0.000040638184,0.000014662472,0.00272895,0.0002908944,0.000009177395,0.00019338606,0.00013813088,0.00005629208,0.00011438943,0.00078931794,0.99561065,0.000013434756],"about_ca_topic_score_codex":0.056416795,"about_ca_topic_score_gemma":0.04767918,"teacher_disagreement_score":0.99333674,"about_ca_system_score_codex":0.006663283,"about_ca_system_score_gemma":0.057621587,"threshold_uncertainty_score":0.4108956},"labels":[],"label_agreement":null},{"id":"W1972305079","doi":"10.3821/1913-701x(2008)141[215:bgtnnc]2.0.co;2","title":"BC government to negotiate new compensation framework and lower payments for generic drugs","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Negotiation; Payment; Government (linguistics); Compensation (psychology); Business; Law and economics; Finance; Economics; Political science; Law; Psychology; Social psychology","score_opus":0.07628393862383165,"score_gpt":0.26896363727336203,"score_spread":0.19267969864953038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972305079","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045230307,0.0031845428,0.005692317,0.26125926,0.00526554,0.0010327867,0.0024843677,0.00044033345,0.6754105],"genre_scores_gemma":[0.32638296,0.0013490936,0.00820473,0.08659968,0.0016957336,0.00031167312,0.00096199405,0.00017484129,0.5743193],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9845888,0.0012494645,0.0003833416,0.00088614033,0.008993819,0.003898343],"domain_scores_gemma":[0.98482555,0.0022766804,0.000551842,0.0007680295,0.007830659,0.0037472753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00732508,0.00044501538,0.00066945225,0.0027307486,0.005719428,0.0089689735,0.0024250573,0.0148163,0.022654817],"category_scores_gemma":[0.02303456,0.0008405873,0.001180304,0.0020760193,0.002098179,0.0019134525,0.002283305,0.011108606,0.0023372632],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002614784,0.0002894869,0.006394992,0.00014511684,0.00010908604,0.00040197314,0.00046201746,0.0030650434,0.0018951179,0.35323,0.5779467,0.055798963],"study_design_scores_gemma":[0.00032888382,0.00010080342,0.02037102,0.0001734437,0.000049674636,0.00023214755,0.00027579485,0.005137968,0.0011759175,0.018233588,0.9538273,0.00009335016],"about_ca_topic_score_codex":0.7168351,"about_ca_topic_score_gemma":0.8329577,"teacher_disagreement_score":0.28316492,"about_ca_system_score_codex":0.06120927,"about_ca_system_score_gemma":0.14200975,"threshold_uncertainty_score":0.5696651},"labels":[],"label_agreement":null},{"id":"W1972313906","doi":"10.1017/s0266462312000499","title":"BENEFITS OF PHARMACEUTICAL INNOVATION: THE CASE OF SIMVASTATIN IN CANADA","year":2012,"lang":"en","type":"review","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"","keywords":"Overtime; Simvastatin; Revenue; Business; Population; Health care; Private sector; Productivity; Medicine; Public economics; Economics; Labour economics; Finance; Economic growth; Environmental health; Pharmacology","score_opus":0.13917123586863284,"score_gpt":0.4498081869635117,"score_spread":0.3106369510948789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972313906","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91079277,0.0047199507,0.0029535103,0.02112343,0.000054321892,0.00020475136,0.0025080238,0.000031473868,0.0576118],"genre_scores_gemma":[0.99262977,0.0012017195,0.0012585538,0.0003822848,0.000022963572,0.000023246846,0.00025549045,0.000006014666,0.004219887],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980642,0.00028438,0.000052194642,0.00012164829,0.00053618697,0.0009412555],"domain_scores_gemma":[0.9953898,0.0017801597,0.0005849828,0.000138361,0.0013200442,0.0007865785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018440263,0.00028889,0.00046399827,0.002070681,0.0037720737,0.0027158028,0.0011314438,0.0016086402,0.0031885025],"category_scores_gemma":[0.008042963,0.00018858373,0.0010300359,0.00429998,0.0016673378,0.0009449976,0.0015220259,0.0016379335,0.00012495839],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005808681,0.000324261,0.6000315,0.00035314634,0.00033384596,0.0075498316,0.0054630064,0.081075214,0.00080464163,0.2097404,0.0153170535,0.07842629],"study_design_scores_gemma":[0.00025509417,0.00019868393,0.67350817,0.00050375424,0.00054644205,0.0022039707,0.02039324,0.18359391,0.00064445956,0.06090171,0.056986634,0.0002639628],"about_ca_topic_score_codex":0.98850703,"about_ca_topic_score_gemma":0.99059767,"teacher_disagreement_score":0.06390323,"about_ca_system_score_codex":0.06390323,"about_ca_system_score_gemma":0.051275063,"threshold_uncertainty_score":0.46365255},"labels":[],"label_agreement":null},{"id":"W1972382554","doi":"10.3821/1913-701x-143.2.62","title":"A Step Forward for Medication Safety: Stakeholders Agree to a Common Standard for Barcoding Pharmaceuticals","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"DNA barcoding; Medicine; Psychology; Business; Biology; Ecology","score_opus":0.12424883608485915,"score_gpt":0.32362095805091196,"score_spread":0.1993721219660528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972382554","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002554891,0.00064486713,0.0077173947,0.98018414,0.0017274006,0.00016195493,0.00010346685,0.00013219636,0.006773762],"genre_scores_gemma":[0.13444945,0.0010990709,0.06290463,0.7924398,0.0037224889,0.000582331,0.00038111233,0.00023224778,0.0041888044],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.6741875,0.11120224,0.036082882,0.019270772,0.12550154,0.03375516],"domain_scores_gemma":[0.37133127,0.24471647,0.041798197,0.04478169,0.22213528,0.075237095],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.31604862,0.0026368732,0.0054608877,0.007797204,0.028577536,0.050896946,0.01703872,0.13989316,0.011602764],"category_scores_gemma":[0.45462266,0.0036719944,0.009132966,0.0048621194,0.04422025,0.050787184,0.03661382,0.11187453,0.0031313866],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036158005,0.00075671874,0.007342285,0.0012208989,0.0007912667,0.001208062,0.012535296,0.004554159,0.0024795767,0.46890867,0.43188414,0.067957334],"study_design_scores_gemma":[0.000682095,0.00061492703,0.017899191,0.0061123683,0.00043820968,0.0006419972,0.017161742,0.0057556517,0.0021795775,0.6015965,0.34523344,0.0016843305],"about_ca_topic_score_codex":0.14109634,"about_ca_topic_score_gemma":0.13355885,"teacher_disagreement_score":0.85890365,"about_ca_system_score_codex":0.05186047,"about_ca_system_score_gemma":0.3014464,"threshold_uncertainty_score":0.84343386},"labels":[],"label_agreement":null},{"id":"W1972463951","doi":"10.1007/s11151-005-5469-5","title":"How do Brands’ “Own Generics” Affect Pharmaceutical Prices?","year":2005,"lang":"en","type":"article","venue":"Review of Industrial Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Health Economics","funders":"Health Canada; Mylan; Teva Pharmaceutical Industries","keywords":"Competition (biology); Drug prices; Affect (linguistics); Brand names; Business; Point (geometry); Market share; Economics; Advertising; Generic drug; Marketing; Industrial organization; Microeconomics; Monetary economics; Drug; Mathematics","score_opus":0.09828502141127128,"score_gpt":0.31119688039122434,"score_spread":0.21291185897995307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972463951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6032822,0.04678137,0.0078099403,0.12343443,0.0017333364,0.00009703992,0.0017941751,0.0001829446,0.21488449],"genre_scores_gemma":[0.98086286,0.006679115,0.0006009581,0.0063217115,0.0010697386,0.000007829883,0.00021088785,0.000030582756,0.0042163376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968575,0.0012132203,0.00015418616,0.00039122935,0.00096582936,0.00041797507],"domain_scores_gemma":[0.9811106,0.009170897,0.0058451234,0.00066627597,0.002334116,0.0008731375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003816239,0.00030620425,0.000744914,0.0013015976,0.0008119727,0.007067295,0.00062352855,0.003455615,0.008076919],"category_scores_gemma":[0.021036414,0.0004999824,0.0009930383,0.0019343753,0.0024698947,0.0042778207,0.000808109,0.0023071198,0.0015330022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015617579,0.0012447378,0.4080852,0.0013420674,0.0029433537,0.000990081,0.0022263487,0.007889487,0.004638822,0.22573476,0.057254963,0.2860885],"study_design_scores_gemma":[0.0003558928,0.0004843928,0.727344,0.00036008828,0.0015303453,0.00063664065,0.002827434,0.0069982377,0.0042156195,0.11753496,0.13750419,0.00020824239],"about_ca_topic_score_codex":0.0064228694,"about_ca_topic_score_gemma":0.0066202325,"teacher_disagreement_score":0.008076919,"about_ca_system_score_codex":0.002705317,"about_ca_system_score_gemma":0.001191554,"threshold_uncertainty_score":0.027019918},"labels":[],"label_agreement":null},{"id":"W1972682547","doi":"10.1017/s104161020999086x","title":"International price comparisons of Alzheimer's drugs: a way to close the affordability gap","year":2009,"lang":"en","type":"article","venue":"International Psychogeriatrics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Douglas Mental Health University Institute","funders":"","keywords":"Donepezil; Purchasing power parity; Memantine; Rivastigmine; High income countries; Galantamine; Purchasing power; Developing country; Development economics; Business; Economic growth; Economics; Medicine; Dementia; Disease; Finance","score_opus":0.06440307358875255,"score_gpt":0.34824507148014056,"score_spread":0.283841997891388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972682547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7337804,0.017456282,0.055781767,0.00569038,0.0021376535,0.00063778355,0.019445857,0.00023230966,0.1648376],"genre_scores_gemma":[0.96933717,0.0016859579,0.018489243,0.0002671455,0.00043708674,0.00033329573,0.008156599,0.000086035885,0.0012074442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912894,0.0049896184,0.0008354265,0.00044692814,0.0021722717,0.0002663896],"domain_scores_gemma":[0.98249036,0.0070189065,0.0045283143,0.001845974,0.0036267648,0.0004896872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008320951,0.0005815116,0.0006396701,0.0070482367,0.00032252935,0.0019027991,0.0006422915,0.0003666182,0.0072986586],"category_scores_gemma":[0.037178043,0.00017548152,0.00092506665,0.013720998,0.00054729613,0.004370394,0.002099851,0.00090319803,0.00047425446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002557887,0.0005356821,0.5287777,0.001791535,0.0017762934,0.0003821145,0.0039895847,0.0037145745,0.001751121,0.07610758,0.023518447,0.35509747],"study_design_scores_gemma":[0.00034255278,0.0018347626,0.84746873,0.00092436525,0.0006548433,0.0005973178,0.006399512,0.005996823,0.001980698,0.041874103,0.09179187,0.00013454584],"about_ca_topic_score_codex":0.0016728736,"about_ca_topic_score_gemma":0.0016581994,"teacher_disagreement_score":0.008320951,"about_ca_system_score_codex":0.0007257627,"about_ca_system_score_gemma":0.0004533806,"threshold_uncertainty_score":0.04400593},"labels":[],"label_agreement":null},{"id":"W1973148128","doi":"10.1208/s12248-009-9142-z","title":"Bioequivalence; Its History, Practice, and Future","year":2009,"lang":"en","type":"review","venue":"The AAPS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Bioequivalence; Pharmaceutical industry; Business; Quality (philosophy); Management science; Risk analysis (engineering); Engineering ethics; Medicine; Pharmacology; Engineering","score_opus":0.17332650120090864,"score_gpt":0.3625870007169042,"score_spread":0.18926049951599555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973148128","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007972706,0.9968119,0.0001224524,0.002314495,0.0000968307,0.00000125872,0.000006548267,0.0000021566457,0.00056452147],"genre_scores_gemma":[0.0024853628,0.9958158,0.00023061644,0.0008070804,0.00040424528,0.0000040557597,0.000007939361,0.0000018687574,0.00024315037],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979505,0.00078352244,0.00022093058,0.00028709805,0.0006791739,0.00007882805],"domain_scores_gemma":[0.9888758,0.007977662,0.0010807081,0.00023442795,0.001485854,0.00034547158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059135943,0.00070526876,0.002390415,0.0028159502,0.0005327726,0.0037744415,0.0013362087,0.0041464386,0.0041129654],"category_scores_gemma":[0.010672339,0.0004972069,0.00058699027,0.0065343007,0.0035268692,0.004089299,0.0009218889,0.004678144,0.0012224994],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015207882,0.00011543404,0.00047429578,0.007939331,0.000088565794,0.00011451137,0.00012393882,0.0006055832,0.00030732868,0.029885143,0.022061491,0.9381323],"study_design_scores_gemma":[0.00006619037,0.00018958155,0.0026655407,0.013173274,0.00017127347,0.0019745855,0.00031568657,0.00058414723,0.00046374075,0.039446488,0.94088787,0.00006152347],"about_ca_topic_score_codex":0.0051165633,"about_ca_topic_score_gemma":0.007986861,"teacher_disagreement_score":0.0059135943,"about_ca_system_score_codex":0.0035907899,"about_ca_system_score_gemma":0.005655775,"threshold_uncertainty_score":0.031274498},"labels":[],"label_agreement":null},{"id":"W197381804","doi":"10.1001/virtualmentor.2006.8.12.ccas1-0612","title":"Pragmatic Principles of Pharmaceutical Donation","year":2006,"lang":"en","type":"article","venue":"The AMA Journal of Ethic","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine; University of British Columbia","funders":"","keywords":"Donation; Business; Political science; Law","score_opus":0.10079377026139226,"score_gpt":0.32729092442757823,"score_spread":0.226497154166186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W197381804","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003300419,0.0038090816,0.08308298,0.15086119,0.0019057516,0.00041864451,0.00020176441,0.0001050423,0.7563152],"genre_scores_gemma":[0.6146469,0.0048076767,0.09728673,0.122912556,0.0059382403,0.0035694176,0.000177094,0.00026334613,0.150398],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.970042,0.013762831,0.0015622257,0.0033787775,0.009157165,0.0020969505],"domain_scores_gemma":[0.9878654,0.006508682,0.0009542662,0.0017988218,0.0021445297,0.0007283113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025963265,0.0008842554,0.0011640614,0.0017742274,0.0091189565,0.011657317,0.0022695896,0.017071806,0.010995589],"category_scores_gemma":[0.047364566,0.0009710644,0.0013532978,0.0011579655,0.027551377,0.009604153,0.008848053,0.01482951,0.0031126312],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000032425712,0.0000056038466,0.000021188931,0.000016881226,0.000003451531,0.000016748163,0.00014517078,0.00008840939,0.000015025145,0.9942204,0.004351798,0.0011121053],"study_design_scores_gemma":[0.000020654727,0.000008155857,0.000045113593,0.00005991532,0.0000047539315,0.000052018313,0.00007044067,0.00021521671,0.000039924085,0.9433775,0.056096796,0.000009340397],"about_ca_topic_score_codex":0.0038068083,"about_ca_topic_score_gemma":0.0036908167,"teacher_disagreement_score":0.025963265,"about_ca_system_score_codex":0.00581692,"about_ca_system_score_gemma":0.009434557,"threshold_uncertainty_score":0.13730848},"labels":[],"label_agreement":null},{"id":"W1974464736","doi":"10.1016/j.cjca.2011.07.110","title":"153 Non-adherence to statin therapy: Discontinuation after a single dispensation","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Saskatoon Medical Imaging","funders":"","keywords":"Medicine; Discontinuation; Statin; Intensive care medicine; Internal medicine","score_opus":0.11609255210633694,"score_gpt":0.26794075840639947,"score_spread":0.15184820630006252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974464736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888691,0.001582077,0.00046075616,0.0037461654,0.00010216863,0.00009092207,0.0014668958,0.000017864337,0.0036641962],"genre_scores_gemma":[0.99696904,0.00034480996,0.00011553775,0.0004565183,0.00011139219,0.000026873926,0.0006137214,0.000004174998,0.0013579855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976387,0.0006122955,0.0003013093,0.0002831368,0.0004016938,0.0007628322],"domain_scores_gemma":[0.9892596,0.004103224,0.0040815887,0.00070243626,0.0005380693,0.0013150222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025198727,0.00018004345,0.0010699868,0.00094120967,0.0010161144,0.0013487417,0.00071245007,0.0021956165,0.009974968],"category_scores_gemma":[0.013901822,0.00035811355,0.0025370545,0.001376958,0.00044005035,0.0005777596,0.0007198012,0.0025507328,0.00084906316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041571846,0.000992024,0.9529828,0.0001140511,0.000608399,0.0034256976,0.00029821362,0.00043833125,0.00030651607,0.0008390579,0.002309166,0.033528596],"study_design_scores_gemma":[0.00018996993,0.0007146664,0.9910148,0.000100691366,0.00045345028,0.0016427776,0.0004718787,0.0027583647,0.00015034451,0.0012863033,0.0011856684,0.000031235293],"about_ca_topic_score_codex":0.025011148,"about_ca_topic_score_gemma":0.02454587,"teacher_disagreement_score":0.025011148,"about_ca_system_score_codex":0.0014612685,"about_ca_system_score_gemma":0.0020039645,"threshold_uncertainty_score":0.049731135},"labels":[],"label_agreement":null},{"id":"W1975879435","doi":"10.1097/01.mlr.0000129494.36245.4b","title":"Drug Spending in Canada","year":2004,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration","keywords":"Per capita; Medical prescription; Inflation (cosmology); Drug prices; Public economics; Drug; Investment (military); Economics; Prescription drug; Demographic economics; Medicine; Environmental health; Pharmacology","score_opus":0.03267895508712495,"score_gpt":0.26378780988782446,"score_spread":0.2311088548006995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975879435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5266482,0.025921348,0.00064658135,0.04460977,0.0005275698,0.0002532747,0.20229806,0.00040470902,0.1986905],"genre_scores_gemma":[0.92580354,0.015118738,0.0007174815,0.002064071,0.00014337468,0.00007305911,0.03354111,0.000044131713,0.022494562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868315,0.00006392356,0.000047399833,0.00008593059,0.00067593897,0.00044358382],"domain_scores_gemma":[0.99681693,0.00015965983,0.00036213602,0.00004091544,0.0018794152,0.0007409048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004692106,0.00030364457,0.00023473756,0.0037025625,0.002148569,0.002138076,0.0006509455,0.00042120475,0.008880357],"category_scores_gemma":[0.003001876,0.00016387813,0.00043918221,0.0075412714,0.0004842729,0.00038865808,0.00065503025,0.000717177,0.0005166863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028344704,0.00010391181,0.59469634,0.0010893224,0.00031711458,0.0005849816,0.0011236708,0.0041846856,0.0005518838,0.017587036,0.26427478,0.11520287],"study_design_scores_gemma":[0.000026787213,0.0000276824,0.88044333,0.00021122344,0.00008336719,0.00017606319,0.0005634417,0.0014761335,0.00020824125,0.00044799066,0.11630729,0.00002838615],"about_ca_topic_score_codex":0.99586606,"about_ca_topic_score_gemma":0.9962184,"teacher_disagreement_score":0.073702425,"about_ca_system_score_codex":0.073702425,"about_ca_system_score_gemma":0.10429795,"threshold_uncertainty_score":0.53475106},"labels":[],"label_agreement":null},{"id":"W1975925894","doi":"10.1016/s0140-6736(04)16243-0","title":"Canada draws near to approving Africa drugs deal","year":2004,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislature; Government (linguistics); Honour; Malaria; Human immunodeficiency virus (HIV); Business; Political science; Law; International trade; Medicine; Virology","score_opus":0.05802132812413667,"score_gpt":0.25756473030568133,"score_spread":0.19954340218154465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975925894","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008375742,0.010267777,0.0014115387,0.6729858,0.025392056,0.00040807528,0.0027198407,0.00047944512,0.2779597],"genre_scores_gemma":[0.05543039,0.0038804393,0.001879221,0.26567668,0.0033813675,0.000107518725,0.0005115365,0.00023447748,0.6688985],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935502,0.00045723395,0.00013708125,0.000388139,0.0035540934,0.0019133644],"domain_scores_gemma":[0.9892797,0.0015161302,0.00028490092,0.00022590584,0.0058859,0.0028073834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033126792,0.00064401753,0.0008493173,0.0024868834,0.008998533,0.008862253,0.0013088706,0.017657321,0.045614295],"category_scores_gemma":[0.01717703,0.0006344495,0.0011436641,0.0017197824,0.002593392,0.0025085635,0.0015844866,0.012184201,0.005631718],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105509724,0.000028858483,0.0015939139,0.00007929188,0.000041504965,0.00027953763,0.00012086384,0.00020543911,0.00032139747,0.06514652,0.9173501,0.014727116],"study_design_scores_gemma":[0.00004747429,0.00003171134,0.0021500033,0.00007967526,0.00003150074,0.00006726563,0.00016406308,0.00023656647,0.00045420954,0.0042515015,0.9924527,0.00003326865],"about_ca_topic_score_codex":0.8646611,"about_ca_topic_score_gemma":0.9277535,"teacher_disagreement_score":0.1353389,"about_ca_system_score_codex":0.03480681,"about_ca_system_score_gemma":0.12991966,"threshold_uncertainty_score":0.2722718},"labels":[],"label_agreement":null},{"id":"W1976743353","doi":"10.1136/bmj.f6159","title":"Maine allows importation of mail order prescription drugs","year":2013,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mail order; Medical prescription; Order (exchange); Computer science; World Wide Web; Data science; Medicine; Business; Pharmacology; Advertising; Finance","score_opus":0.04107958634110478,"score_gpt":0.2869182180752086,"score_spread":0.24583863173410384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976743353","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063183956,0.0023919654,0.0032422587,0.025047451,0.0010895395,0.0004693167,0.012418754,0.0025232285,0.8896334],"genre_scores_gemma":[0.21816497,0.0008730278,0.0025096496,0.021411065,0.001043127,0.000581,0.0055434518,0.00036834076,0.74950534],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960531,0.00074943976,0.00019745616,0.0005012514,0.0016680739,0.00083067646],"domain_scores_gemma":[0.99025446,0.0042861556,0.0008819456,0.0019127694,0.0020760344,0.00058871304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039054148,0.0003150531,0.0003636679,0.0017328993,0.0018452333,0.003356143,0.0009864663,0.0038425091,0.099965736],"category_scores_gemma":[0.016341308,0.00058055104,0.000727903,0.0013190064,0.000996556,0.0018582101,0.0027361964,0.0020486931,0.027495813],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073373446,0.00034621844,0.022343596,0.00032262015,0.0000733301,0.0011829868,0.0011249752,0.0003348885,0.0037242584,0.15057091,0.74740064,0.071841896],"study_design_scores_gemma":[0.00021970106,0.00020313253,0.036150374,0.00016877273,0.000032656113,0.0003228411,0.00011529547,0.0005499039,0.0019387738,0.004411282,0.95584965,0.0000376682],"about_ca_topic_score_codex":0.032650415,"about_ca_topic_score_gemma":0.05382675,"teacher_disagreement_score":0.099965736,"about_ca_system_score_codex":0.004873764,"about_ca_system_score_gemma":0.0039051997,"threshold_uncertainty_score":0.3344187},"labels":[],"label_agreement":null},{"id":"W1976796263","doi":"10.4212/cjhp.v65i3.1138","title":"Drug Shortages: What Can Hospital Pharmacists Do?","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Economic shortage; Pharmacy; Business; Government (linguistics); Hospital pharmacy; Medicine; Quality (philosophy); Medical emergency; Nursing","score_opus":0.04301117159928134,"score_gpt":0.28383707247736617,"score_spread":0.24082590087808484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976796263","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036214339,0.12362358,0.00023828498,0.86087555,0.0055543743,0.000071632894,0.00024466775,0.000059295715,0.0057112253],"genre_scores_gemma":[0.12649286,0.41417688,0.002433341,0.4230528,0.027532361,0.0004073604,0.00082945934,0.000077528566,0.004997426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931966,0.0030023186,0.0008849984,0.00049450324,0.0013117616,0.0011097922],"domain_scores_gemma":[0.9432731,0.017975155,0.007189304,0.0010741437,0.012964093,0.017524166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011289038,0.001148993,0.0020146298,0.002985685,0.0037610158,0.009865415,0.0033015371,0.012763681,0.010403011],"category_scores_gemma":[0.071264856,0.0007282916,0.0012263866,0.0030651663,0.0034249916,0.02027444,0.0066822493,0.009616962,0.0035561891],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001999246,0.00059887074,0.025283275,0.0106356265,0.0001892913,0.0010009013,0.0038295353,0.00017397046,0.00007775971,0.004539813,0.51028085,0.4431901],"study_design_scores_gemma":[0.00065960124,0.0010463374,0.06962334,0.05837535,0.00054490665,0.0028694635,0.078230895,0.0008265083,0.0003682216,0.04429608,0.7426887,0.00047058542],"about_ca_topic_score_codex":0.016668182,"about_ca_topic_score_gemma":0.0343831,"teacher_disagreement_score":0.016668182,"about_ca_system_score_codex":0.0057939007,"about_ca_system_score_gemma":0.021313302,"threshold_uncertainty_score":0.059702873},"labels":[],"label_agreement":null},{"id":"W1977501151","doi":"10.1503/cmaj.109-4199","title":"Africa struggles to improve drug safety","year":2012,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacovigilance; Nothing; Drug; Medicine; Computer science; Medical emergency; Risk analysis (engineering); Data science; Pharmacology","score_opus":0.021389976256235517,"score_gpt":0.24593028549524906,"score_spread":0.22454030923901355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977501151","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0381992,0.019111035,0.0020848555,0.90334284,0.0017891038,0.000060717575,0.00043540908,0.000060969407,0.03491594],"genre_scores_gemma":[0.7167974,0.019953664,0.005354209,0.24639112,0.0033016524,0.00009667792,0.0002179504,0.000062171275,0.007825179],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9866742,0.0073860814,0.0005729641,0.00061560713,0.002205131,0.0025460422],"domain_scores_gemma":[0.9640795,0.019361222,0.0056563797,0.0016299837,0.005595007,0.0036778837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02392184,0.0006011471,0.0004928492,0.0023434467,0.0021381848,0.0052788774,0.00092996156,0.003236643,0.010951672],"category_scores_gemma":[0.062589854,0.00036299543,0.0007099555,0.0022304326,0.0048493636,0.008061523,0.0057257065,0.0070749954,0.00092907815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089008803,0.0001775742,0.047329307,0.0024662851,0.00055103854,0.0014595089,0.00892538,0.0019716811,0.0024271852,0.35436505,0.22145104,0.35798582],"study_design_scores_gemma":[0.00037030294,0.00050076476,0.05264966,0.0030198942,0.00026060775,0.000929976,0.007283135,0.0010149411,0.0028934088,0.091601685,0.8393654,0.00011011205],"about_ca_topic_score_codex":0.012710495,"about_ca_topic_score_gemma":0.010805816,"teacher_disagreement_score":0.02392184,"about_ca_system_score_codex":0.005750969,"about_ca_system_score_gemma":0.012971967,"threshold_uncertainty_score":0.12651223},"labels":[],"label_agreement":null},{"id":"W1977946142","doi":"10.1212/wnl.0b013e3181ae7b04","title":"Selegiline shortage","year":2009,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Research Resources; National Institutes of Health","keywords":"Selegiline; Medicine; Internal medicine; Parkinson's disease","score_opus":0.05087514791795878,"score_gpt":0.28112146551710226,"score_spread":0.2302463175991435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977946142","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89345455,0.024678243,0.0022778015,0.011984268,0.00028964074,0.00018900455,0.01143139,0.00020872727,0.055486415],"genre_scores_gemma":[0.9684559,0.009296541,0.0009786178,0.0045487615,0.00039088386,0.00007915062,0.00708336,0.000029967132,0.009136745],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994686,0.00009691098,0.000079426,0.00011314126,0.00014923982,0.00009256583],"domain_scores_gemma":[0.99793977,0.00045177923,0.00080747704,0.000093870665,0.00037125082,0.0003356975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092828186,0.00024322774,0.00032623543,0.0006288895,0.00032038623,0.0006928223,0.00038700138,0.00031022844,0.010894941],"category_scores_gemma":[0.0028809113,0.00014251881,0.000315393,0.0011652713,0.0003082355,0.00066148594,0.0006844671,0.0005395056,0.0015583906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009553098,0.00018507526,0.7007083,0.001133421,0.00023039141,0.0034019637,0.0005471099,0.0022557701,0.0031262028,0.0041344883,0.05089971,0.23242219],"study_design_scores_gemma":[0.0001689307,0.0009953228,0.7127081,0.0006263638,0.00021217449,0.013513746,0.0008728655,0.002848351,0.0032596171,0.0023621912,0.26239425,0.000038057155],"about_ca_topic_score_codex":0.013504348,"about_ca_topic_score_gemma":0.014014362,"teacher_disagreement_score":0.013504348,"about_ca_system_score_codex":0.002355139,"about_ca_system_score_gemma":0.0021912083,"threshold_uncertainty_score":0.036447227},"labels":[],"label_agreement":null},{"id":"W1978024090","doi":"10.1016/s0828-282x(07)70816-4","title":"Would a national pharmaceuticals strategy be bad for the cardiovascular health of Canadians?","year":2007,"lang":"en","type":"editorial","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Disease; Intensive care medicine; Coronary artery disease; Clopidogrel; Clinical trial; Cardiovascular health; Pharmacotherapy; Angiotensin Receptor Blockers; Aspirin; Internal medicine; Blood pressure","score_opus":0.1101832410553085,"score_gpt":0.351082428882589,"score_spread":0.2408991878272805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978024090","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059099744,0.01019114,0.000057656864,0.27058753,0.71688384,0.000022052118,0.0001631149,0.00003196138,0.0020036374],"genre_scores_gemma":[0.0013725783,0.012674056,0.00016804613,0.1242605,0.85222745,0.000036116664,0.00006883733,0.000029871346,0.009162477],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99295807,0.0009089016,0.00072934193,0.00052503275,0.0040863147,0.000792271],"domain_scores_gemma":[0.9306887,0.02753653,0.0021433942,0.0010707905,0.031155366,0.0074051875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012364595,0.0033536907,0.004783471,0.0036166816,0.0051814723,0.009082789,0.004592266,0.049048472,0.009543592],"category_scores_gemma":[0.0608804,0.0011918037,0.0029448126,0.0033104792,0.0050650737,0.0037150243,0.0010640728,0.041871563,0.003857615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016369788,0.000005545182,0.000021852702,0.00007775486,0.000013949363,0.000043082444,0.0000074026034,0.00001790799,0.0000061961705,0.000351513,0.9981116,0.0013268127],"study_design_scores_gemma":[0.00018608719,0.00002767715,0.000866537,0.0007752243,0.00020110578,0.00015287753,0.0001436594,0.00029708387,0.00007233065,0.0021539666,0.99507046,0.000053004558],"about_ca_topic_score_codex":0.11803302,"about_ca_topic_score_gemma":0.25828263,"teacher_disagreement_score":0.88196695,"about_ca_system_score_codex":0.016378678,"about_ca_system_score_gemma":0.033837907,"threshold_uncertainty_score":0.23469198},"labels":[],"label_agreement":null},{"id":"W1978784436","doi":"10.1057/palgrave.jgm.4940034","title":"Editorial: Canada First to Pass Legislation on Delivering Generic Medicines to Developing Countries","year":2004,"lang":"en","type":"editorial","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Innovative Medicines Canada","funders":"","keywords":"Legislation; Business; Developing country; Medicine; International trade; Political science; Law; Economic growth; Economics","score_opus":0.052324298369772655,"score_gpt":0.2877537100870722,"score_spread":0.23542941171729953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978784436","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045733348,0.003249288,0.00006521267,0.07524093,0.91913855,0.00004086598,0.00011613967,0.00004402972,0.0020592534],"genre_scores_gemma":[0.001068949,0.004583724,0.00019614678,0.076862395,0.8913583,0.000057645102,0.00009427349,0.00007782954,0.025700644],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99100024,0.0008848622,0.00087109883,0.0008229402,0.0054212185,0.0009996031],"domain_scores_gemma":[0.9565405,0.011506926,0.0021208634,0.0009799841,0.023592763,0.005259008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009905716,0.0051435116,0.006460817,0.0071483403,0.008347272,0.011117452,0.0061816717,0.035559736,0.012556438],"category_scores_gemma":[0.04340519,0.0017528889,0.004221659,0.0042112023,0.0046923463,0.003732229,0.0014494212,0.035765704,0.007345322],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017962577,0.000007911124,0.000014608654,0.000058023186,0.000012312365,0.000058643633,0.0000067020824,0.000015056249,0.000015246895,0.00008393482,0.9988367,0.0008729726],"study_design_scores_gemma":[0.00010519274,0.000029277511,0.00062802585,0.00051004096,0.00015464661,0.00014820836,0.000088522895,0.00020534176,0.00014228193,0.00061699946,0.9973346,0.000036937006],"about_ca_topic_score_codex":0.07592956,"about_ca_topic_score_gemma":0.19511457,"teacher_disagreement_score":0.9240704,"about_ca_system_score_codex":0.017561525,"about_ca_system_score_gemma":0.021313217,"threshold_uncertainty_score":0.15097517},"labels":[],"label_agreement":null},{"id":"W1978872749","doi":"10.1016/j.jval.2013.08.1356","title":"Statins in Canada: The Case for Disinvestment","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Disinvestment; Reimbursement; Atorvastatin; Statin; Unit (ring theory); Medicine; Unit cost; Generic drug; Public health; Business; Operations management; Health care; Economics; Drug; Internal medicine; Pharmacology; Mathematics","score_opus":0.13835606983133678,"score_gpt":0.3103241599661802,"score_spread":0.1719680901348434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978872749","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21798594,0.029137956,0.0012186639,0.65732807,0.00089162233,0.00011644079,0.0065427497,0.00008638188,0.086692184],"genre_scores_gemma":[0.94802547,0.009029029,0.0011385052,0.028207289,0.00048491976,0.000026059086,0.0007101983,0.000052145246,0.012326423],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937972,0.0006386083,0.00025297463,0.00041017085,0.0019220673,0.00297911],"domain_scores_gemma":[0.9805714,0.0034361987,0.0024372991,0.0005033689,0.007180385,0.0058712335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003961111,0.000325618,0.0010872912,0.0017216909,0.0040112534,0.006767334,0.0020088733,0.0057680756,0.006893587],"category_scores_gemma":[0.020228324,0.00035579153,0.0011831102,0.0033975358,0.0026101896,0.0018554351,0.0014833128,0.0068625333,0.00025373534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017029155,0.0002908251,0.24706206,0.0006967352,0.0006323808,0.0021122,0.0022066468,0.005363584,0.0007547387,0.3640409,0.24248813,0.13264884],"study_design_scores_gemma":[0.00077909144,0.0002035619,0.47103724,0.0024743814,0.0012499372,0.0016128161,0.00928617,0.015286512,0.0015653045,0.0989935,0.39707896,0.00043240818],"about_ca_topic_score_codex":0.9941513,"about_ca_topic_score_gemma":0.9966673,"teacher_disagreement_score":0.10166614,"about_ca_system_score_codex":0.10166614,"about_ca_system_score_gemma":0.2402317,"threshold_uncertainty_score":0.7376429},"labels":[],"label_agreement":null},{"id":"W1979553117","doi":"10.1177/1715163513494593","title":"Distribution of diluted chemo drugs leads to new oversight in Ontario","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Distribution (mathematics); Business; Mathematics","score_opus":0.043675568637932274,"score_gpt":0.2417652534534388,"score_spread":0.19808968481550654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979553117","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8304806,0.0021029306,0.0012924564,0.07068703,0.00021862473,0.00034696126,0.0011256505,0.00013756887,0.09360817],"genre_scores_gemma":[0.97259086,0.0003749405,0.00034006403,0.0039187446,0.000093156035,0.000017949627,0.00011098799,0.00001732005,0.022536026],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903486,0.0012341628,0.00037431752,0.0006829938,0.004650567,0.0027093384],"domain_scores_gemma":[0.95259655,0.015016953,0.0071588196,0.0014727707,0.01586617,0.007888761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054510217,0.00014902595,0.000349061,0.0010436758,0.0044676927,0.0055906833,0.0015075684,0.002566935,0.007241672],"category_scores_gemma":[0.024801306,0.0005265102,0.0006365178,0.0013840313,0.0032868753,0.001112715,0.0017181108,0.0021196927,0.00023899453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024182284,0.00070137274,0.58571196,0.0006594357,0.00046227846,0.005355178,0.013080258,0.011915371,0.0045969742,0.15018825,0.1310957,0.09381505],"study_design_scores_gemma":[0.0007112684,0.0004510821,0.74973947,0.0002552949,0.00032417834,0.0006485381,0.007415752,0.016844114,0.0034829695,0.010728378,0.20921528,0.00018364102],"about_ca_topic_score_codex":0.96202946,"about_ca_topic_score_gemma":0.98274475,"teacher_disagreement_score":0.10540803,"about_ca_system_score_codex":0.10540803,"about_ca_system_score_gemma":0.123730004,"threshold_uncertainty_score":0.7647923},"labels":[],"label_agreement":null},{"id":"W1979792032","doi":"10.1016/s1098-3015(10)67721-2","title":"PHP20 GENERIC DRUG PRICES REMAIN HIGHER IN CANADA THAN IN THE UNITED STATES","year":2005,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Economics; Medicine; Pharmacology","score_opus":0.09635049559894734,"score_gpt":0.29200393933434815,"score_spread":0.1956534437354008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979792032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73222417,0.01663859,0.00092548947,0.11771684,0.00059612707,0.000036370224,0.024009591,0.0001785748,0.10767427],"genre_scores_gemma":[0.97509277,0.0033680534,0.00031244173,0.0039465595,0.000109371525,0.000004777448,0.002962276,0.000033286517,0.014170442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884665,0.000061258776,0.000027364085,0.00008180556,0.00046630276,0.00051663886],"domain_scores_gemma":[0.99606174,0.00035162424,0.0006307009,0.0000619093,0.00199801,0.0008959076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007565377,0.0001657667,0.00033800842,0.0009781357,0.0017278057,0.0041546337,0.00054558075,0.0010667666,0.009434311],"category_scores_gemma":[0.004762472,0.00014234727,0.00056196353,0.003103998,0.00071212935,0.001163751,0.0004776237,0.0014238402,0.00052404834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024174198,0.0001749991,0.61505634,0.0003272975,0.0003439794,0.0006848739,0.0008400575,0.002942324,0.0015583913,0.036673293,0.18071038,0.1582706],"study_design_scores_gemma":[0.00008473857,0.000056426205,0.9254865,0.00008466038,0.00010084628,0.00020676058,0.001749163,0.0017725382,0.0010944218,0.0017566874,0.06756978,0.00003752027],"about_ca_topic_score_codex":0.9867126,"about_ca_topic_score_gemma":0.99091107,"teacher_disagreement_score":0.03619202,"about_ca_system_score_codex":0.03619202,"about_ca_system_score_gemma":0.036050323,"threshold_uncertainty_score":0.26259267},"labels":[],"label_agreement":null},{"id":"W1981868458","doi":"10.1016/j.jval.2011.08.801","title":"PCV81 Cost-Effectiveness of Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndrome: Results from the Plato Study: A Canadian Analysis","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Ticagrelor; Medicine; Clopidogrel; Acute coronary syndrome; Myocardial infarction; Stroke (engine); Internal medicine; Cardiology; Emergency medicine; Intensive care medicine","score_opus":0.13223122112659944,"score_gpt":0.30803283665559306,"score_spread":0.17580161552899362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981868458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674616,0.008596689,0.00028818264,0.0017030422,0.00005039652,0.00027387796,0.014397273,0.000023677976,0.007205227],"genre_scores_gemma":[0.9883767,0.0028630174,0.0003884466,0.00037495745,0.000052165204,0.00006799747,0.006759479,0.000026860542,0.0010902891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773055,0.0006035694,0.0001238467,0.00025514213,0.0007010494,0.0005858984],"domain_scores_gemma":[0.99482614,0.0019119666,0.001146569,0.00032615138,0.0008346954,0.00095447426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027422716,0.001025844,0.0020313312,0.0012077154,0.0009942629,0.002056428,0.0018162074,0.0011492798,0.0026051311],"category_scores_gemma":[0.008700791,0.0005703893,0.0058790953,0.00442781,0.000929682,0.0008334125,0.0010953487,0.0024849703,0.0001920289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14958946,0.0020171655,0.6812923,0.0025959339,0.020353185,0.0006073302,0.0012273269,0.02407801,0.0010260995,0.0074514686,0.0250808,0.084680915],"study_design_scores_gemma":[0.016406719,0.0021283557,0.94754446,0.0003967029,0.011921477,0.00016588134,0.0010577947,0.013820593,0.00028382783,0.0013121851,0.004716457,0.0002455398],"about_ca_topic_score_codex":0.9484789,"about_ca_topic_score_gemma":0.95649046,"teacher_disagreement_score":0.051521122,"about_ca_system_score_codex":0.026344918,"about_ca_system_score_gemma":0.0298983,"threshold_uncertainty_score":0.19114667},"labels":[],"label_agreement":null},{"id":"W1983081217","doi":"10.3821/1913-701x-142.3.116","title":"Drug Expenditures on the Rise","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.05999633044758467,"score_gpt":0.2690579111071113,"score_spread":0.20906158065952662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983081217","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12587456,0.051240794,0.00081431854,0.3489687,0.0033477815,0.0000806668,0.0352248,0.00032059572,0.43412772],"genre_scores_gemma":[0.8060809,0.02896192,0.00045794365,0.028628932,0.002276806,0.000039007704,0.010137291,0.00009114886,0.12332609],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979455,0.00018064337,0.000064619875,0.00016879149,0.00088130496,0.00075923116],"domain_scores_gemma":[0.9963888,0.00036762372,0.0005491409,0.000107803324,0.0016479319,0.0009387197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007842331,0.0002423629,0.00054702675,0.001715258,0.0010384006,0.004298549,0.00039882396,0.0018524976,0.01676685],"category_scores_gemma":[0.005835652,0.00023121946,0.0004404282,0.003336804,0.00060712505,0.0011170907,0.0007346069,0.0031770319,0.0015831678],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005486537,0.00012839568,0.061500162,0.00039569935,0.00015827741,0.00042284394,0.0004133126,0.0020150125,0.0004937203,0.22394289,0.587025,0.122956015],"study_design_scores_gemma":[0.00005858929,0.000057220826,0.25577283,0.0003879916,0.00009011616,0.00024714833,0.00062176416,0.0017290764,0.0004270027,0.011320285,0.72925156,0.000036476187],"about_ca_topic_score_codex":0.6126661,"about_ca_topic_score_gemma":0.71609163,"teacher_disagreement_score":0.6126661,"about_ca_system_score_codex":0.015432345,"about_ca_system_score_gemma":0.02454256,"threshold_uncertainty_score":0.77923},"labels":[],"label_agreement":null},{"id":"W1983088377","doi":"10.1016/j.cjca.2012.05.010","title":"Clinical Equivalence of Proprietary and Generic Atorvastatin in Lipid Clinic Patients","year":2012,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"Health Canada","keywords":"Atorvastatin; Medicine; Rosuvastatin; Statin; Creatine; Retrospective cohort study; Creatine kinase; Adverse effect; Cohort; Cholesterol; Internal medicine; Pharmacology","score_opus":0.11814041679586458,"score_gpt":0.3213305382368629,"score_spread":0.20319012144099835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983088377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98496604,0.0034873115,0.00049368205,0.0030713344,0.000120579076,0.00007259878,0.0008230216,0.000012148056,0.006953364],"genre_scores_gemma":[0.9987134,0.0002343086,0.00008324197,0.0003799481,0.000097041135,0.000009240229,0.00033876483,0.0000030758335,0.00014101101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99215734,0.0049695154,0.00072936143,0.0006478806,0.0008658805,0.0006299408],"domain_scores_gemma":[0.9690391,0.020993168,0.0047246106,0.0018129263,0.0016654079,0.0017647829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0079569835,0.00018270113,0.0011003058,0.00064440194,0.00036965325,0.0016448387,0.0006918553,0.001467184,0.0058823014],"category_scores_gemma":[0.06124642,0.00023541332,0.0014718608,0.0010214716,0.0011510109,0.0014356703,0.0009615073,0.001682189,0.0005072796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2394057,0.0033760536,0.5422438,0.0007842197,0.003945857,0.0014472557,0.001269444,0.004760046,0.0035579628,0.018659558,0.0078052417,0.1727449],"study_design_scores_gemma":[0.012581151,0.01961249,0.94063234,0.00019351036,0.0018267536,0.0009153584,0.0010282244,0.006610664,0.0008341443,0.012074548,0.003605105,0.00008564798],"about_ca_topic_score_codex":0.00283201,"about_ca_topic_score_gemma":0.0020393897,"teacher_disagreement_score":0.0079569835,"about_ca_system_score_codex":0.0017256719,"about_ca_system_score_gemma":0.0012207469,"threshold_uncertainty_score":0.042081058},"labels":[],"label_agreement":null},{"id":"W1983266155","doi":"10.1016/j.jval.2012.03.095","title":"PHP18 The Impact of Patent Expiries on Future Drug Spending in Canada","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Institute for Health Information","funders":"","keywords":"Generic drug; Prescription drug; Market share; Competition (biology); Business; Audit; Medical prescription; Drug; Drug prices; Product (mathematics); Brand names; Public economics; Marketing; Medicine; Economics; Pharmacology; Accounting","score_opus":0.1685645391951565,"score_gpt":0.3302935532945758,"score_spread":0.16172901409941934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983266155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5129524,0.014536566,0.00055444986,0.24211863,0.001401061,0.00015210874,0.07459132,0.0002210291,0.15347253],"genre_scores_gemma":[0.93377125,0.004699052,0.000245825,0.005351739,0.00054412056,0.00003039028,0.0059085614,0.000076929995,0.049372237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941637,0.0003236773,0.00021152564,0.00030658802,0.002543069,0.002451397],"domain_scores_gemma":[0.9699074,0.005798218,0.0030205578,0.00041488468,0.013799795,0.007059126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030349207,0.00030287696,0.00090808247,0.0029787915,0.0031755522,0.008458123,0.0013780522,0.003218128,0.01437024],"category_scores_gemma":[0.023082167,0.00044674697,0.0016055997,0.0037988906,0.0015282604,0.0012422191,0.0012580989,0.004420021,0.0007056335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014779504,0.0002963585,0.43298593,0.0005976649,0.00081967283,0.001187152,0.0012302436,0.019789424,0.0006053932,0.1127728,0.37037808,0.05785933],"study_design_scores_gemma":[0.00032251823,0.0001378595,0.7881999,0.00035066847,0.00049230433,0.000274557,0.002260137,0.014264438,0.000980842,0.007084002,0.18542638,0.00020643046],"about_ca_topic_score_codex":0.99623966,"about_ca_topic_score_gemma":0.9973314,"teacher_disagreement_score":0.14049959,"about_ca_system_score_codex":0.14049959,"about_ca_system_score_gemma":0.177694,"threshold_uncertainty_score":0.99689865},"labels":[],"label_agreement":null},{"id":"W1983949690","doi":"10.5367/000000007781698356","title":"Surveying the Need for Technology Management for Global Health Training Programmes","year":2007,"lang":"en","type":"article","venue":"Industry and Higher Education","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Profitability index; Training (meteorology); Public relations; Public health; Marketing; Knowledge management; Political science; Medicine; Computer science","score_opus":0.15211797836511234,"score_gpt":0.4071693464668992,"score_spread":0.25505136810178686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983949690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731161,0.00035880177,0.0006596936,0.011655134,0.0000406273,0.00036586332,0.000692627,0.000048639162,0.013062594],"genre_scores_gemma":[0.99416214,0.00039525708,0.0012418217,0.0011534223,0.000037912825,0.00025351296,0.00035088137,0.0000119771785,0.0023930233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938001,0.002062693,0.0006319511,0.00026093255,0.0018484517,0.0013958941],"domain_scores_gemma":[0.94021,0.019667966,0.014065163,0.0015411044,0.010631802,0.013883963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010868279,0.00011863549,0.00021178921,0.0019615213,0.0016443352,0.0026992422,0.00080413424,0.001257047,0.007909963],"category_scores_gemma":[0.044591166,0.00032270406,0.0002389585,0.0019064087,0.00068992714,0.0023959638,0.0016546203,0.002026175,0.0013182134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118370706,0.0009381086,0.8788842,0.00042334505,0.000024610847,0.00019430433,0.009815513,0.0003976242,0.0018837149,0.0019249519,0.011305584,0.09408967],"study_design_scores_gemma":[0.000023962208,0.00040630123,0.94406146,0.0001959462,0.000014493757,0.00012407333,0.02452516,0.0010832432,0.00046292477,0.00039434675,0.028678644,0.00002944199],"about_ca_topic_score_codex":0.011748996,"about_ca_topic_score_gemma":0.021246554,"teacher_disagreement_score":0.011748996,"about_ca_system_score_codex":0.0032290432,"about_ca_system_score_gemma":0.010257782,"threshold_uncertainty_score":0.057477653},"labels":[],"label_agreement":null},{"id":"W1985999538","doi":"10.1002/ddr.10404","title":"Patenting the sun: Enclosing the scientific commons and transforming the university—ethical concerns","year":2004,"lang":"en","type":"article","venue":"Drug Development Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"License; Commons; Legislation; Quarter (Canadian coin); Political science; Engineering ethics; Environmental ethics; Public relations; Sociology; Engineering; Law; History","score_opus":0.205140735119185,"score_gpt":0.35160149033589466,"score_spread":0.14646075521670965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985999538","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020843234,0.011381373,0.011806894,0.87496275,0.0015448383,0.000027472066,0.00002441662,0.00003817172,0.07937092],"genre_scores_gemma":[0.8896528,0.0062793475,0.0053420486,0.08247886,0.003337943,0.000090272195,0.0000146997,0.00003509269,0.01276902],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9740974,0.018310035,0.00079761364,0.0013833825,0.0040731994,0.0013384202],"domain_scores_gemma":[0.86713403,0.10882104,0.007011564,0.0071597416,0.005072028,0.0048015798],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.049114306,0.00024211346,0.00063913694,0.0009867366,0.0061164265,0.0152344145,0.0012505179,0.016572695,0.0045768223],"category_scores_gemma":[0.08634202,0.0002232988,0.00043054213,0.0011720669,0.03357287,0.010439598,0.005431004,0.010411871,0.00056707836],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025557129,0.000025841993,0.0005270917,0.000034121877,0.0000059772638,0.00011603136,0.0010227108,0.00030195544,0.00015552943,0.9641483,0.015080729,0.018556127],"study_design_scores_gemma":[0.000019450346,0.00002635796,0.0005197523,0.0001537343,0.000006404966,0.00012695526,0.0009710915,0.000604092,0.00036463403,0.9403436,0.056847196,0.000016698996],"about_ca_topic_score_codex":0.0014897571,"about_ca_topic_score_gemma":0.0018551729,"teacher_disagreement_score":0.99388355,"about_ca_system_score_codex":0.0048674727,"about_ca_system_score_gemma":0.00941407,"threshold_uncertainty_score":0.25974435},"labels":[],"label_agreement":null},{"id":"W1986191029","doi":"10.3821/1913-701x(2008)141[89:bvocbf]2.0.co;2","title":"BC vision of competitive bidding for Pharmacare meets with opposition from pharmacists and drug industry","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Opposition (politics); Bidding; Drug; Business; Advertising; Marketing; Medicine; Political science; Pharmacology; Law; Politics","score_opus":0.05816575695350652,"score_gpt":0.27104782155833795,"score_spread":0.21288206460483144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986191029","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008955177,0.0010125596,0.0065867244,0.5888984,0.0036374202,0.00012630221,0.00022141436,0.0001858499,0.3903761],"genre_scores_gemma":[0.42641053,0.0011141035,0.007263302,0.24564254,0.0033382028,0.00019944244,0.00023220442,0.00018093475,0.31561872],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98673326,0.0021849633,0.00023029631,0.0010317522,0.0058507044,0.003969084],"domain_scores_gemma":[0.9700997,0.0026982762,0.00084898144,0.00067085,0.007640698,0.018041616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010117189,0.00077141775,0.00071970135,0.0017984966,0.01580956,0.025486493,0.0026536894,0.027946204,0.027826758],"category_scores_gemma":[0.022506977,0.0006852239,0.0009884984,0.0016648481,0.012742999,0.00841651,0.005062505,0.024634985,0.0041483333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060857423,0.0001228647,0.0007625671,0.00004799041,0.000017041415,0.00022294969,0.00066796585,0.00062592374,0.0004395085,0.7066807,0.275353,0.01499857],"study_design_scores_gemma":[0.00008981651,0.00008719032,0.0028343752,0.00012902053,0.000012159493,0.0002424884,0.0017075287,0.0031060025,0.0002173482,0.19492424,0.7965549,0.000094963536],"about_ca_topic_score_codex":0.40103903,"about_ca_topic_score_gemma":0.48348066,"teacher_disagreement_score":0.9577013,"about_ca_system_score_codex":0.042298682,"about_ca_system_score_gemma":0.10199141,"threshold_uncertainty_score":0.7974095},"labels":[],"label_agreement":null},{"id":"W1986635261","doi":"10.1016/j.clinthera.2007.02.005","title":"Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lamotrigine; Medicine; Epilepsy; Adverse effect; Adverse drug reaction; Audit; Drug; Psychiatry; Pharmacology","score_opus":0.17360845331881697,"score_gpt":0.37379915629465627,"score_spread":0.2001907029758393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986635261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534374,0.0013580538,0.00035882858,0.00051911385,0.000013081891,0.00003500001,0.00039812847,0.0000061721557,0.00196783],"genre_scores_gemma":[0.99916935,0.00037236323,0.00013144231,0.0000718045,0.000023994744,0.0000062837216,0.00015175765,7.1241897e-7,0.000072353105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980938,0.0010265599,0.0003386856,0.0001174104,0.00028010277,0.00014347157],"domain_scores_gemma":[0.9821054,0.009504458,0.0070030172,0.00040078867,0.0004964521,0.00048997917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002701275,0.00018385082,0.00042963112,0.00083580194,0.00026267546,0.00056131097,0.00023234298,0.000686825,0.001633089],"category_scores_gemma":[0.016434003,0.00016014463,0.0011523623,0.00081615575,0.00027163772,0.00058419124,0.0003573867,0.0008499038,0.00012869615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027914445,0.00014219213,0.97985476,0.00009279245,0.00027424362,0.0009960455,0.00008357889,0.00074428896,0.00027036777,0.00014837102,0.00030319803,0.014298725],"study_design_scores_gemma":[0.000101805395,0.0011531273,0.98989224,0.000048127316,0.00034703323,0.0031326213,0.00034223346,0.0035087191,0.00047363303,0.0005085367,0.0004726665,0.000019302115],"about_ca_topic_score_codex":0.0014564146,"about_ca_topic_score_gemma":0.001957086,"teacher_disagreement_score":0.002701275,"about_ca_system_score_codex":0.0005510871,"about_ca_system_score_gemma":0.00049051945,"threshold_uncertainty_score":0.014285862},"labels":[],"label_agreement":null},{"id":"W1986874544","doi":"10.1016/j.jval.2014.03.108","title":"Impact Of Drug Reimbursement Modalities On Treatment Adherence In Patients Covered By Private Drug Insurance","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Reimbursement; Medicine; Cohort; Retrospective cohort study; Drug; Internal medicine; Private insurance; Drug class; Emergency medicine; Family medicine; Medicaid; Pharmacology; Health care","score_opus":0.06202613729766446,"score_gpt":0.31449148139421884,"score_spread":0.2524653440965544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986874544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924436,0.0016454004,0.00009262949,0.0035466123,0.000054242857,0.000016339915,0.00045785424,0.0000036268814,0.0017396925],"genre_scores_gemma":[0.99899143,0.00022562608,0.000063361644,0.00023304544,0.000060594073,0.0000051091038,0.00017356116,0.0000014625855,0.00024585833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958134,0.002195423,0.00036583838,0.00026867425,0.0004074634,0.00094915973],"domain_scores_gemma":[0.97161365,0.016725445,0.0073674256,0.0006997085,0.0006325569,0.0029613243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028823772,0.0001855188,0.0009146633,0.00055650773,0.0006892061,0.002004429,0.00056396367,0.001843175,0.0061549805],"category_scores_gemma":[0.031605374,0.00031563276,0.0028704936,0.0010947274,0.00056710135,0.0011029236,0.0011031196,0.0031159474,0.00019964002],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006583206,0.0018321875,0.9611094,0.00009367139,0.001291882,0.0002159145,0.00023384318,0.001865142,0.00015992194,0.0017606487,0.0010533602,0.02380077],"study_design_scores_gemma":[0.00030091245,0.001278542,0.9893777,0.00008374793,0.0007088211,0.0001833217,0.00066670123,0.004941781,0.00008979274,0.0018140179,0.0005302556,0.000024348712],"about_ca_topic_score_codex":0.01787744,"about_ca_topic_score_gemma":0.018995129,"teacher_disagreement_score":0.01787744,"about_ca_system_score_codex":0.0017796898,"about_ca_system_score_gemma":0.0018608076,"threshold_uncertainty_score":0.03554672},"labels":[],"label_agreement":null},{"id":"W1987743296","doi":"10.1016/s0140-6736(13)60756-4","title":"Evaluation of the Affordable Medicines Facility—malaria","year":2013,"lang":"en","type":"letter","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Artemisinin; Malaria; Psychological intervention; Scopus; Medicine; Intervention (counseling); Developing country; Quarter (Canadian coin); Access to medicines; Family medicine; Traditional medicine; Economic growth; Political science; MEDLINE; Economics; Nursing; Geography; Law; Plasmodium falciparum","score_opus":0.1813568597527854,"score_gpt":0.32017461101852934,"score_spread":0.13881775126574394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987743296","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000988742,0.0014206626,0.0001496007,0.985405,0.006384995,0.00005675068,0.0002891963,0.000018170222,0.005286828],"genre_scores_gemma":[0.012365126,0.0008281266,0.00037208808,0.96750313,0.0117270015,0.00014626073,0.00010381177,0.000026799667,0.006927702],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9783192,0.010311147,0.001575807,0.0010452738,0.004117249,0.0046312716],"domain_scores_gemma":[0.9531819,0.027783478,0.0022257783,0.0010732452,0.0061296322,0.0096058985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021618158,0.0011498289,0.0018184262,0.0010208718,0.004378317,0.007149505,0.0046196254,0.09456079,0.01280373],"category_scores_gemma":[0.07882604,0.0013404059,0.00327598,0.0008566477,0.0045810733,0.0069463938,0.0045833266,0.043078355,0.0024018325],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085652375,0.00015591481,0.0017402482,0.00019679822,0.00010472468,0.0008201619,0.00012354465,0.00044873988,0.00034022273,0.023194253,0.9581116,0.013907315],"study_design_scores_gemma":[0.002901628,0.000940244,0.013364206,0.0019326669,0.0004944613,0.0008854028,0.00096778694,0.004551289,0.0019966261,0.053048864,0.91852,0.0003968102],"about_ca_topic_score_codex":0.06943681,"about_ca_topic_score_gemma":0.12185049,"teacher_disagreement_score":0.09456079,"about_ca_system_score_codex":0.01886038,"about_ca_system_score_gemma":0.029448181,"threshold_uncertainty_score":0.13806528},"labels":[],"label_agreement":null},{"id":"W1987752370","doi":"10.1016/j.vaccine.2009.09.117","title":"Joint reviews and inspections: Strategic forms of collaboration for strengthening the regulatory oversight of vaccine clinical trials in Africa","year":2009,"lang":"en","type":"review","venue":"Vaccine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European and Developing Countries Clinical Trials Partnership","keywords":"Clinical trial; Regulatory affairs; Quality (philosophy); Process (computing); Business; Joint (building); Regulatory authority; Medicine; Public relations; Political science; Public administration; Engineering; Computer science; Pathology","score_opus":0.43720334627745616,"score_gpt":0.4470390179293779,"score_spread":0.009835671651921729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987752370","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033309177,0.9901252,0.0022320324,0.004951862,0.00058818253,0.00013878699,0.00003747375,0.000028260436,0.0015651283],"genre_scores_gemma":[0.01624169,0.9713085,0.007011789,0.0028093867,0.0009136191,0.00027260507,0.00010199728,0.000016701362,0.0013238036],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96539223,0.021563053,0.002738454,0.0011852141,0.007970932,0.0011500901],"domain_scores_gemma":[0.86879325,0.085016906,0.025988461,0.0027533157,0.014784258,0.002663825],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.059685793,0.0012505793,0.0028673508,0.0060949125,0.0007202791,0.0037989537,0.0025053904,0.004480825,0.0032472874],"category_scores_gemma":[0.09530146,0.00094712974,0.0015713576,0.007690671,0.0020802063,0.0035895684,0.0024223216,0.0030881471,0.0006710262],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025544188,0.00007214564,0.0006100258,0.024574528,0.00064983394,0.00011032384,0.00015927714,0.00079684006,0.00044768595,0.010872837,0.037980128,0.923471],"study_design_scores_gemma":[0.0009685251,0.0004529457,0.009829374,0.06774911,0.0024516028,0.0014230662,0.00031547016,0.00144402,0.00192342,0.024550673,0.8887582,0.0001336313],"about_ca_topic_score_codex":0.0046827137,"about_ca_topic_score_gemma":0.011779914,"teacher_disagreement_score":0.94031423,"about_ca_system_score_codex":0.004103137,"about_ca_system_score_gemma":0.024214221,"threshold_uncertainty_score":0.31565243},"labels":[],"label_agreement":null},{"id":"W1988578472","doi":"10.1002/hec.1332","title":"Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression","year":2008,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Formulary; Markov chain; Disease; Markov process; Economics; Drug; Drug prices; Externality; Actuarial science; Microeconomics; Computer science; Medicine; Pharmacology; Public economics; Mathematics; Statistics; Machine learning","score_opus":0.13874511098233144,"score_gpt":0.33214207833061843,"score_spread":0.19339696734828699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988578472","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42025563,0.005848703,0.52395105,0.017148573,0.0003814241,0.0006730657,0.0031177038,0.00050942926,0.028114494],"genre_scores_gemma":[0.9659733,0.0023670227,0.018494103,0.0006273466,0.00027159628,0.00036469803,0.0008061957,0.00007492891,0.011020729],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99626356,0.0021663809,0.00012013999,0.00038757888,0.0002463759,0.00081585406],"domain_scores_gemma":[0.97270435,0.022695588,0.0023562564,0.00050528406,0.00056772114,0.0011708254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009085956,0.0018067447,0.0036511107,0.0018416606,0.0011125145,0.0031925014,0.001952665,0.0035264536,0.010124379],"category_scores_gemma":[0.031909194,0.0016600206,0.0022366703,0.001120595,0.0034687498,0.005266315,0.0022860765,0.0042003905,0.00078149413],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006263918,0.00017084568,0.0046963776,0.00012370397,0.00013574917,0.00029858598,0.00015372058,0.7187837,0.0002781153,0.26532093,0.0024347135,0.006977221],"study_design_scores_gemma":[0.00016471361,0.000075630625,0.0014388557,0.000053392032,0.00006868453,0.00007525168,0.000057582303,0.79587144,0.00008747516,0.20132482,0.0007381403,0.000044084547],"about_ca_topic_score_codex":0.022427484,"about_ca_topic_score_gemma":0.016656829,"teacher_disagreement_score":0.022427484,"about_ca_system_score_codex":0.006076027,"about_ca_system_score_gemma":0.0037838197,"threshold_uncertainty_score":0.048051715},"labels":[],"label_agreement":null},{"id":"W1988649996","doi":"10.1038/clpt.2010.90","title":"Refilling and Switching of Antiepileptic Drugs and Seizure-Related Events","year":2010,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Medicine; Medical prescription; Odds ratio; Confidence interval; Epilepsy; Antiepileptic drug; Odds; Pediatrics; Emergency medicine; Anesthesia; Internal medicine; Psychiatry; Pharmacology","score_opus":0.07577093616275075,"score_gpt":0.3784942365549937,"score_spread":0.30272330039224293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988649996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976568,0.0007620669,0.00015554868,0.00013957862,0.000006025959,0.00002790742,0.0008505752,0.0000037049801,0.00039774022],"genre_scores_gemma":[0.99846894,0.00026498715,0.00017664279,0.000065285385,0.000013717095,0.000011893185,0.00080134586,0.0000018359868,0.00019528868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955629,0.001869553,0.00040893382,0.0007683027,0.00077797484,0.00061227684],"domain_scores_gemma":[0.9784734,0.0076344255,0.010812966,0.001061747,0.00092180696,0.0010956588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039437674,0.00029359473,0.00074516254,0.0018368564,0.00045785637,0.0012693494,0.0010631254,0.001084353,0.0018212005],"category_scores_gemma":[0.023264354,0.00044150138,0.0010460025,0.0023783194,0.0005715341,0.00079654664,0.0006064897,0.0013374755,0.00016101463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034142975,0.00008809405,0.9977836,0.000017658273,0.0001892774,0.000106936124,0.00004691866,0.00012140076,0.000034911372,0.00006805135,0.00006343065,0.0011384947],"study_design_scores_gemma":[0.000029354502,0.00010061701,0.99852496,0.000015520054,0.00007248111,0.00015954189,0.000078708574,0.00078329525,0.00003504022,0.000057269513,0.00013694787,0.000006329175],"about_ca_topic_score_codex":0.1746429,"about_ca_topic_score_gemma":0.13355953,"teacher_disagreement_score":0.1746429,"about_ca_system_score_codex":0.0024433148,"about_ca_system_score_gemma":0.0015843885,"threshold_uncertainty_score":0.3472528},"labels":[],"label_agreement":null},{"id":"W1988914230","doi":"10.1007/s00228-012-1396-1","title":"Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO","year":2012,"lang":"en","type":"article","venue":"European Journal of Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Bioequivalence; Medicine; Bioavailability; Confidence interval; Statistics; Pharmacology; Mathematics; Internal medicine","score_opus":0.7357467910902785,"score_gpt":0.5167654140692793,"score_spread":0.21898137702099918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988914230","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2434208,0.015747331,0.72896606,0.0018556864,0.0005465519,0.0020596518,0.0010208675,0.00047803903,0.0059050354],"genre_scores_gemma":[0.6575979,0.004563906,0.3331553,0.0008002766,0.0002721977,0.0016519792,0.00053644774,0.00027066734,0.001151347],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.70656765,0.2747506,0.0041735023,0.0040289,0.009974953,0.00050438516],"domain_scores_gemma":[0.3982543,0.5676594,0.013728169,0.0112516815,0.008388536,0.00071789825],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.16036393,0.00112569,0.0026462085,0.0027125257,0.0003975389,0.0022136897,0.002092226,0.0016142419,0.0034528705],"category_scores_gemma":[0.32193786,0.0005329682,0.0053119785,0.0023364038,0.0017669584,0.0022150455,0.0018042197,0.0027714004,0.0004629459],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03032078,0.0013197984,0.058706958,0.005887173,0.03675182,0.00019813038,0.0036245428,0.02335086,0.0049224766,0.035373352,0.0034161755,0.7961279],"study_design_scores_gemma":[0.013361319,0.079247825,0.25496453,0.0037142932,0.04729391,0.001983533,0.002986587,0.417452,0.01638857,0.13616249,0.025276206,0.0011687374],"about_ca_topic_score_codex":0.0009945486,"about_ca_topic_score_gemma":0.0010762699,"teacher_disagreement_score":0.8396361,"about_ca_system_score_codex":0.0012692556,"about_ca_system_score_gemma":0.0019808195,"threshold_uncertainty_score":0.84809566},"labels":[],"label_agreement":null},{"id":"W1989028508","doi":"10.1503/cmaj.1041606","title":"Rofecoxib (Vioxx) voluntarily withdrawn from market","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sepsis; SOFA score; Internal medicine; Pediatrics; Emergency medicine","score_opus":0.01529079297004724,"score_gpt":0.22892535020679736,"score_spread":0.21363455723675012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989028508","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83433694,0.029562239,0.0018553792,0.007086782,0.0018858303,0.002329174,0.03320653,0.0003934659,0.0893437],"genre_scores_gemma":[0.9385016,0.0042905854,0.0009819276,0.003602124,0.0011133783,0.00075851585,0.0100464225,0.000054428867,0.040650893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946433,0.00013854736,0.00008791703,0.00006987906,0.00014883028,0.00009045031],"domain_scores_gemma":[0.9983228,0.00028127324,0.0007553402,0.00014188916,0.0002560104,0.00024265404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008424171,0.00020522242,0.0004385229,0.0003248128,0.00044781266,0.0008142712,0.0002614078,0.0004776307,0.021109622],"category_scores_gemma":[0.0021213517,0.00013622144,0.0004734405,0.00056626764,0.00024759592,0.00036099833,0.00025610896,0.00058618124,0.00364128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031749394,0.00211751,0.30573037,0.0036262514,0.0009790715,0.0036754825,0.00041013313,0.00031502338,0.017618163,0.002064975,0.121435516,0.5102781],"study_design_scores_gemma":[0.005869466,0.010433777,0.5643082,0.0009591477,0.0005725344,0.004694856,0.00053582253,0.001138435,0.0101662055,0.0005419569,0.4007114,0.00006813577],"about_ca_topic_score_codex":0.0021814767,"about_ca_topic_score_gemma":0.0030952091,"teacher_disagreement_score":0.021109622,"about_ca_system_score_codex":0.00061988534,"about_ca_system_score_gemma":0.0012803533,"threshold_uncertainty_score":0.07061869},"labels":[],"label_agreement":null},{"id":"W1989247444","doi":"10.1001/jama.2008.758","title":"Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease","year":2008,"lang":"en","type":"review","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":430,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging; Agency for Healthcare Research and Quality","keywords":"Medicine; Randomized controlled trial; Jadad scale; Medical prescription; Bioequivalence; Generic drug; Brand names; Clinical trial; MEDLINE; Context (archaeology); Drug; Internal medicine; Pharmacology; Advertising","score_opus":0.17981195311984713,"score_gpt":0.3666103435232169,"score_spread":0.1867983904033698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989247444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008632023,0.9735475,0.0010299654,0.006687734,0.0057219155,0.0008107287,0.0007955013,0.000025043402,0.0027495986],"genre_scores_gemma":[0.29637432,0.6464737,0.013375024,0.0160153,0.022422547,0.0028783143,0.0016703455,0.00007314329,0.00071720884],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.7768177,0.09730595,0.084971905,0.0077938735,0.032124568,0.0009859579],"domain_scores_gemma":[0.29192722,0.5383238,0.129632,0.008226328,0.030044558,0.0018461455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.12543134,0.0013447322,0.007954586,0.016549623,0.0011333072,0.007359863,0.002619462,0.0046801763,0.003860711],"category_scores_gemma":[0.49936524,0.0011070915,0.006227613,0.013852057,0.0034612636,0.0062643373,0.0019011961,0.0025459428,0.00047719883],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006008819,0.00015575206,0.018657818,0.7898102,0.039410237,0.00045830823,0.0010817741,0.0003172372,0.0013037976,0.0026434415,0.0124700265,0.12768264],"study_design_scores_gemma":[0.011217531,0.0032356593,0.0706276,0.67868304,0.1519384,0.0023415477,0.0016742713,0.0007975145,0.00281697,0.011350549,0.06504813,0.0002688542],"about_ca_topic_score_codex":0.0011435557,"about_ca_topic_score_gemma":0.0019903574,"teacher_disagreement_score":0.12543134,"about_ca_system_score_codex":0.0037748164,"about_ca_system_score_gemma":0.008450656,"threshold_uncertainty_score":0.66335225},"labels":[],"label_agreement":null},{"id":"W1990037294","doi":"10.1093/jiplp/jpq218","title":"Methods of medical treatment still unpatentable in Canada","year":2011,"lang":"en","type":"article","venue":"Journal of Intellectual Property Law & Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Windsor","funders":"","keywords":"Notice; Patentability; Allegation; Respondent; Law; Business; Estoppel; Patent infringement; Formulary; Political science; Law and economics; Patent law; Medicine; Intellectual property; Family medicine; Economics","score_opus":0.21113481399395895,"score_gpt":0.3562154891790996,"score_spread":0.14508067518514067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990037294","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05134399,0.07853496,0.013484644,0.15778168,0.0031830438,0.0006643837,0.0019270672,0.00029626014,0.692784],"genre_scores_gemma":[0.57175314,0.04665074,0.023873016,0.04255289,0.0016202619,0.00048370633,0.00083798997,0.00022096303,0.3120074],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910547,0.0010401759,0.0003505564,0.0011259593,0.0048303893,0.001598287],"domain_scores_gemma":[0.99326384,0.0020362847,0.00042498295,0.00063730247,0.0022453014,0.0013923006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005181711,0.0004811083,0.0007119454,0.0025224558,0.008721685,0.008980245,0.002214621,0.0048760837,0.02040232],"category_scores_gemma":[0.012578794,0.00069977617,0.0011977536,0.0033641674,0.0074630734,0.0024482263,0.0032806466,0.005457864,0.001013684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023656599,0.00015224882,0.0043191793,0.00057973986,0.000074292904,0.0007692708,0.00237179,0.0010568767,0.00081294315,0.7818921,0.06041468,0.14732029],"study_design_scores_gemma":[0.0002110678,0.00012894135,0.014516913,0.0006094625,0.000100364006,0.00064761506,0.00085479766,0.0016614328,0.0009238302,0.03460229,0.9456351,0.000108089276],"about_ca_topic_score_codex":0.967556,"about_ca_topic_score_gemma":0.980409,"teacher_disagreement_score":0.11076116,"about_ca_system_score_codex":0.11076116,"about_ca_system_score_gemma":0.20292597,"threshold_uncertainty_score":0.8036322},"labels":[],"label_agreement":null},{"id":"W1990831008","doi":"10.1002/art.21709","title":"Approval process and access to prescription drugs in Canada","year":2006,"lang":"en","type":"article","venue":"Arthritis Care & Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Arthritis Research Centre of Canada; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medical prescription; Process (computing); Medicine; MEDLINE; Business; Family medicine; Pharmacology; Computer science; Political science","score_opus":0.06717020037170766,"score_gpt":0.3467901967328571,"score_spread":0.2796199963611494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990831008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90402,0.009136719,0.00054983114,0.03303987,0.00018210919,0.00021612475,0.012678577,0.000096544754,0.04008017],"genre_scores_gemma":[0.9837595,0.0022200833,0.00023914462,0.0014712921,0.000064342625,0.00001953265,0.0014847383,0.000026929387,0.010714274],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99397606,0.00042015463,0.00033726872,0.00037199326,0.0022284738,0.002666137],"domain_scores_gemma":[0.96398574,0.008563398,0.0068050325,0.0004640284,0.011896608,0.008285227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026411328,0.00028367856,0.00082679914,0.0036087243,0.004549829,0.0069429246,0.0021273082,0.002747472,0.013541179],"category_scores_gemma":[0.025565255,0.0006672,0.0015343707,0.0070840586,0.0019300983,0.0014715308,0.0016168532,0.0037363057,0.00045384624],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014317589,0.0005883025,0.85516375,0.00039891244,0.0004719141,0.0012238541,0.0027624033,0.010154375,0.0004928354,0.05004982,0.042351805,0.034910344],"study_design_scores_gemma":[0.0004189604,0.0001434715,0.94541556,0.0003307125,0.00034673713,0.00027488777,0.0037678184,0.012106765,0.00045119636,0.0048205103,0.031740725,0.0001826522],"about_ca_topic_score_codex":0.99843246,"about_ca_topic_score_gemma":0.9989901,"teacher_disagreement_score":0.8479893,"about_ca_system_score_codex":0.15201071,"about_ca_system_score_gemma":0.17244354,"threshold_uncertainty_score":0.9835474},"labels":[],"label_agreement":null},{"id":"W1990933841","doi":"10.1057/jgm.2008.1","title":"Climate of Change Continues in Canada","year":2008,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liberian dollar; Market share; Business; Brand names; Generic drug; Reimbursement; Value (mathematics); Marketing; Industrial organization; Economics; Finance; Health care; Economic growth; Drug","score_opus":0.19256701491646183,"score_gpt":0.2973795869913426,"score_spread":0.10481257207488076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990933841","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12884632,0.019642584,0.001308788,0.44190627,0.0051256153,0.00011475889,0.007349986,0.00041232572,0.3952933],"genre_scores_gemma":[0.88232934,0.01732635,0.0010813194,0.04693059,0.0010757329,0.00005829226,0.0019007778,0.00018998607,0.04910766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618405,0.00017577293,0.00007142105,0.00024063009,0.0015766699,0.0017514954],"domain_scores_gemma":[0.9964101,0.00017383945,0.00030645312,0.00008219806,0.0017352467,0.0012921307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013513685,0.0003224577,0.00056992634,0.001632918,0.013353164,0.009813722,0.0012753225,0.0025389497,0.01513151],"category_scores_gemma":[0.0038965289,0.00021631728,0.0006574393,0.005056116,0.0056825783,0.0025295888,0.003460068,0.0032438969,0.0007411329],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020535664,0.000101281505,0.06433814,0.00089183386,0.00013522586,0.0025798955,0.020618832,0.0037518737,0.001425069,0.26072735,0.5504513,0.09477388],"study_design_scores_gemma":[0.000012114286,0.000015796617,0.066741996,0.00019459389,0.000017574837,0.00014240228,0.014886512,0.000516855,0.00013146391,0.008766937,0.90849286,0.000080883816],"about_ca_topic_score_codex":0.9830702,"about_ca_topic_score_gemma":0.9885167,"teacher_disagreement_score":0.10890534,"about_ca_system_score_codex":0.10890534,"about_ca_system_score_gemma":0.17640282,"threshold_uncertainty_score":0.7901672},"labels":[],"label_agreement":null},{"id":"W1994686939","doi":"10.1186/1744-8603-10-3","title":"“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”","year":2014,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; Public Health Ontario; University of Toronto","funders":"","keywords":"Supreme court; Medicine; Patentability; Lawsuit; Appeal; Bosutinib; Law; Generic drug; Political science; Intellectual property; Imatinib; Nilotinib; Drug; Myeloid leukemia; Patent law; Pharmacology","score_opus":0.15754371096470804,"score_gpt":0.36710358044380226,"score_spread":0.20955986947909422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994686939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4887409,0.047688123,0.00095730094,0.15516181,0.0011245102,0.00041040868,0.004981214,0.000053949367,0.3008818],"genre_scores_gemma":[0.9191165,0.030847946,0.00089518353,0.036209933,0.0010173803,0.00021729781,0.001753415,0.000026602704,0.009915841],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.9912471,0.0024352218,0.0009447654,0.0008472122,0.0029743195,0.0015514141],"domain_scores_gemma":[0.95603234,0.03358846,0.0062623904,0.0006565489,0.002741519,0.0007187563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058292183,0.00024618965,0.00040444813,0.00899503,0.0055654766,0.008938136,0.0013358244,0.0031970642,0.0036265652],"category_scores_gemma":[0.028267015,0.00030678223,0.0004596804,0.01733342,0.0055113826,0.004443707,0.0027162007,0.0026912587,0.00078596396],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005455201,0.0002881125,0.08917713,0.008624307,0.00022646009,0.03629868,0.16546261,0.0006515679,0.0021422866,0.2757895,0.31493032,0.10586356],"study_design_scores_gemma":[0.00003712222,0.00015041642,0.13513997,0.005719884,0.00048941275,0.008333958,0.28991172,0.000794667,0.0039414912,0.017559655,0.53767276,0.00024892812],"about_ca_topic_score_codex":0.030110627,"about_ca_topic_score_gemma":0.04582283,"teacher_disagreement_score":0.030110627,"about_ca_system_score_codex":0.0062215575,"about_ca_system_score_gemma":0.007898786,"threshold_uncertainty_score":0.05987072},"labels":[],"label_agreement":null},{"id":"W1994958655","doi":"10.2139/ssrn.1523385","title":"Monopoly Pricing Under a Medicaid-Style Most-Favored-Customer Clause and its Welfare Implication","year":2009,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Monopoly; Medicaid; Style (visual arts); Welfare; Business; Price discrimination; Economics; Microeconomics; Marketing; Market economy; Art","score_opus":0.021935355371576374,"score_gpt":0.2735931863704176,"score_spread":0.2516578309988412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994958655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5856424,0.0009100615,0.050893787,0.06488751,0.0005604855,0.00027318046,0.0015665584,0.00045926817,0.29480672],"genre_scores_gemma":[0.9864928,0.00018450261,0.0015000501,0.0031860806,0.0006632318,0.000065613494,0.00007359697,0.0000337828,0.007800325],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9959544,0.0011312583,0.00011804824,0.0004732046,0.0008655554,0.0014575865],"domain_scores_gemma":[0.9773856,0.016442103,0.0021207223,0.0011911949,0.0015494295,0.0013109675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060834903,0.00059278286,0.002456246,0.0014781661,0.0025569738,0.005830973,0.0029035097,0.007094625,0.017613323],"category_scores_gemma":[0.027685883,0.00090321567,0.0015571254,0.0015674431,0.0047393823,0.0061813914,0.0021364226,0.008637822,0.0008435707],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027362828,0.00026289263,0.002800321,0.00006438886,0.00006215302,0.00046748927,0.00018172411,0.004417575,0.0009238856,0.97005266,0.012390648,0.008102623],"study_design_scores_gemma":[0.00029284507,0.00008784004,0.0030571553,0.000042891013,0.00009965263,0.0002453219,0.0003322456,0.033454567,0.00050918636,0.95940727,0.0024274667,0.000043513177],"about_ca_topic_score_codex":0.008112459,"about_ca_topic_score_gemma":0.007446688,"teacher_disagreement_score":0.017613323,"about_ca_system_score_codex":0.0031794158,"about_ca_system_score_gemma":0.004060583,"threshold_uncertainty_score":0.05892241},"labels":[],"label_agreement":null},{"id":"W1994964073","doi":"10.1371/journal.pmed.0030510","title":"Intellectual Property and Access to ART: Authors' Reply","year":2006,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"U.S. National Library of Medicine; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Intellectual property; Argument (complex analysis); Law and economics; Poverty; Access to medicines; Property (philosophy); Political science; Law; Business; Medicine; Sociology","score_opus":0.11607268975520503,"score_gpt":0.30765335830689255,"score_spread":0.19158066855168754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994964073","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008880579,0.00094847486,0.000042048818,0.9908298,0.007785931,0.0000021544508,0.000041445182,0.0000081215285,0.0002531929],"genre_scores_gemma":[0.002435033,0.0011701563,0.000107709224,0.9794,0.015741868,0.000014736594,0.000021207565,0.000013443016,0.0010958515],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960312,0.0011239608,0.0007063581,0.00080806686,0.000981008,0.00034936328],"domain_scores_gemma":[0.95466965,0.03442269,0.0018593853,0.001156688,0.006204468,0.0016871565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008005732,0.0008945913,0.001870424,0.0011816589,0.0028440226,0.0036098785,0.0045877798,0.06198621,0.01094783],"category_scores_gemma":[0.053618103,0.00092900556,0.0015932082,0.0017279405,0.0060578263,0.008313301,0.0029438047,0.053915642,0.003926367],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003656867,0.000013029527,0.0002690919,0.000093272705,0.000016089087,0.00027036233,0.00020189062,0.00006031903,0.000041581552,0.006060559,0.9889177,0.0040194783],"study_design_scores_gemma":[0.00012130486,0.000049470724,0.0017575455,0.0007429414,0.000058968533,0.0014524455,0.0013021065,0.0003618917,0.00035997375,0.024926264,0.9687063,0.00016077765],"about_ca_topic_score_codex":0.0061157774,"about_ca_topic_score_gemma":0.005787979,"teacher_disagreement_score":0.06198621,"about_ca_system_score_codex":0.00405636,"about_ca_system_score_gemma":0.005099516,"threshold_uncertainty_score":0.042338908},"labels":[],"label_agreement":null},{"id":"W1995123216","doi":"10.20430/ete.v76i302.486","title":"¿A quién beneficia el comercio paralelo de medicamentos en la Unión Europea?","year":2017,"lang":"es","type":"article","venue":"El Trimestre Económico","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Emergency Physicians","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.04689818322439119,"score_gpt":0.3357949456912912,"score_spread":0.2888967624669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995123216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.707497,0.041507978,0.0057085734,0.031768307,0.00026500874,0.00007789579,0.00067001645,0.000068933834,0.21243635],"genre_scores_gemma":[0.9609491,0.010763211,0.0019021246,0.0035418593,0.00017630045,0.000038026767,0.00021845987,0.000023244187,0.022387657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663526,0.0012260808,0.00014233452,0.00041413665,0.0010399783,0.00054230646],"domain_scores_gemma":[0.9935126,0.0021328237,0.0015651645,0.00043606578,0.0017592751,0.00059413095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046256986,0.0002147458,0.0004433271,0.0012799577,0.0014344204,0.004454115,0.0005488401,0.0019168705,0.008612677],"category_scores_gemma":[0.007905982,0.00016918009,0.0005011425,0.001432094,0.001993367,0.0022937395,0.0012590536,0.0009550375,0.0009804893],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001822089,0.00053987175,0.28537428,0.0014812674,0.0003882003,0.0016486795,0.01324966,0.0015355274,0.0070173293,0.20817733,0.023409527,0.45535618],"study_design_scores_gemma":[0.00015210826,0.0013057489,0.46386015,0.0029871564,0.00038337745,0.0020748258,0.02195703,0.0008116646,0.0039539407,0.028431058,0.47399804,0.00008491481],"about_ca_topic_score_codex":0.01662932,"about_ca_topic_score_gemma":0.014299479,"teacher_disagreement_score":0.01662932,"about_ca_system_score_codex":0.0023466116,"about_ca_system_score_gemma":0.0033301564,"threshold_uncertainty_score":0.03306502},"labels":[],"label_agreement":null},{"id":"W1995683175","doi":"","title":"Patents and Pharmaceutical R&D: Consolidating Private-Public Partnership Approach to Global Public Health Crises","year":2010,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Intellectual property; Incentive; General partnership; Credibility; Business; Law and economics; Public economics; Public relations; Public administration; Economics; Political science; Market economy; Law; Finance","score_opus":0.15744305108989082,"score_gpt":0.35183458807669227,"score_spread":0.19439153698680145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995683175","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07495741,0.009302756,0.06487226,0.44101733,0.00060516904,0.000144572,0.00013198073,0.0002334045,0.40873513],"genre_scores_gemma":[0.9752983,0.0030232463,0.0026120364,0.008794412,0.0007349243,0.0000980704,0.000018848183,0.000026581412,0.009393611],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9948807,0.0029565808,0.00009977918,0.000454076,0.00090288214,0.0007060019],"domain_scores_gemma":[0.99371946,0.0040031387,0.00063021405,0.0006504059,0.0004724823,0.0005242966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064234086,0.00035385377,0.0005930069,0.0019205038,0.0024342476,0.009934904,0.0010710306,0.011292231,0.0087058805],"category_scores_gemma":[0.014625232,0.0003017411,0.00070030254,0.0010348684,0.015185711,0.012384204,0.0073798676,0.0060723945,0.00044705474],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000086471,0.00001579262,0.00012508663,0.00001594967,0.0000034663574,0.00004969025,0.00013881196,0.00091263675,0.00003390249,0.9940579,0.0013696642,0.0032684398],"study_design_scores_gemma":[0.000035035264,0.000012686149,0.00030462065,0.000041236024,0.0000055826217,0.000037052218,0.000294124,0.0022554037,0.00007429936,0.9837568,0.01317595,0.0000072838334],"about_ca_topic_score_codex":0.0023435538,"about_ca_topic_score_gemma":0.0018831734,"teacher_disagreement_score":0.011292231,"about_ca_system_score_codex":0.006614744,"about_ca_system_score_gemma":0.007259784,"threshold_uncertainty_score":0.04799354},"labels":[],"label_agreement":null},{"id":"W1996591595","doi":"10.3821/145.3.cpj105","title":"New Generic Pricing Rules Come to Newfoundland and Labrador and New Brunswick","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Geography; Oceanography; Geology","score_opus":0.07199614444530232,"score_gpt":0.2699920714320161,"score_spread":0.19799592698671376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996591595","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02079333,0.016352395,0.0019604475,0.39268133,0.009160191,0.00014350485,0.0032165719,0.00055795646,0.55513424],"genre_scores_gemma":[0.18726489,0.011308704,0.0055710706,0.20322715,0.0016315219,0.00009304011,0.0034885455,0.00034634757,0.5870688],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99472165,0.00029076883,0.00024734202,0.00057224475,0.0021122324,0.0020557446],"domain_scores_gemma":[0.9930825,0.00080644415,0.00047750009,0.0005424525,0.0032392712,0.0018518564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025067744,0.0006712442,0.0007632959,0.0019543606,0.0064568482,0.012177855,0.0016855532,0.0048637027,0.035528015],"category_scores_gemma":[0.009384027,0.00070497044,0.0011113363,0.0026601308,0.0039758505,0.0035974188,0.0021377841,0.007436235,0.0040178215],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023643982,0.000094682,0.008518583,0.00015445385,0.000047044214,0.0008041174,0.00059465173,0.00053228193,0.0008714521,0.15942341,0.7604259,0.068296924],"study_design_scores_gemma":[0.00008268208,0.000031003947,0.017754966,0.0002232361,0.000022144004,0.00018710615,0.000623096,0.0002002301,0.0003348618,0.003763506,0.97669286,0.000084207335],"about_ca_topic_score_codex":0.9612636,"about_ca_topic_score_gemma":0.9759814,"teacher_disagreement_score":0.07247909,"about_ca_system_score_codex":0.07247909,"about_ca_system_score_gemma":0.07020356,"threshold_uncertainty_score":0.5258751},"labels":[],"label_agreement":null},{"id":"W1996784805","doi":"10.1179/cih.2009.2.4.341","title":"Drug pricing and reimbursement in Europe: Strategy and tactics","year":2009,"lang":"en","type":"article","venue":"Journal of Communications In Healthcare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Pricing strategies; Business; Product (mathematics); Marketing; Investment (military); Control (management); New product development; Investment strategy; Finance; Health care; Economics","score_opus":0.14868549785318158,"score_gpt":0.39255738209891966,"score_spread":0.24387188424573808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996784805","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04926599,0.12612198,0.016713351,0.56035924,0.006182018,0.00026487873,0.00019085224,0.0002353546,0.24066631],"genre_scores_gemma":[0.6190311,0.04527687,0.026107011,0.23934896,0.007842498,0.00038062848,0.00023910114,0.00013978577,0.06163404],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98905635,0.004818469,0.00080959516,0.0010067784,0.0030382485,0.0012704717],"domain_scores_gemma":[0.9911123,0.0040126652,0.00088677945,0.0004150508,0.0021795726,0.0013935509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0272699,0.0009821451,0.001013543,0.0040963464,0.0020701666,0.015178738,0.0020317885,0.021930665,0.0035348013],"category_scores_gemma":[0.023051037,0.0005315471,0.0011113447,0.002809882,0.0066418773,0.0077772858,0.004733884,0.006443311,0.0006638552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011603138,0.00020433572,0.0026288007,0.000165805,0.000056467376,0.00045269166,0.0003917604,0.0027649824,0.00049581734,0.84778905,0.03342032,0.11151395],"study_design_scores_gemma":[0.00026333178,0.00055933994,0.016513202,0.0026215774,0.00007871902,0.0011885803,0.0010889805,0.0078083156,0.0013775484,0.38696086,0.58127755,0.00026212385],"about_ca_topic_score_codex":0.010926918,"about_ca_topic_score_gemma":0.0062727137,"teacher_disagreement_score":0.0272699,"about_ca_system_score_codex":0.011918054,"about_ca_system_score_gemma":0.013890514,"threshold_uncertainty_score":0.14421874},"labels":[],"label_agreement":null},{"id":"W1998357119","doi":"10.1503/cmaj.109-3828","title":"Comparison shopping for drugs","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Suite; Medical prescription; Computer science; Drug industry; Drug; Web application; Prescription drug; World Wide Web; Internet privacy; Medicine; Pharmacology; Political science; Engineering; Law","score_opus":0.09065336197807232,"score_gpt":0.30246702599453584,"score_spread":0.2118136640164635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998357119","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01031303,0.004671285,0.00738148,0.012961178,0.001904713,0.0004342219,0.013125083,0.0071699047,0.942039],"genre_scores_gemma":[0.18127643,0.0071057878,0.04501585,0.03451871,0.0034525811,0.0006978088,0.031884834,0.005684023,0.69036394],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9960247,0.0009980141,0.00026064517,0.0004139726,0.002038381,0.00026432084],"domain_scores_gemma":[0.9867335,0.005440408,0.00085511553,0.0017624486,0.0028855063,0.0023230268],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002969458,0.0005656079,0.00080491,0.0055550328,0.00265811,0.006635852,0.0009139699,0.00248961,0.38621548],"category_scores_gemma":[0.020465286,0.0005293046,0.000945193,0.004348594,0.00088410545,0.007206216,0.0029457032,0.0018113229,0.119641595],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028064006,0.00015307633,0.0014858181,0.0003838951,0.00003942867,0.00015558556,0.000210884,0.000097557764,0.0006596395,0.023695951,0.80083483,0.17200264],"study_design_scores_gemma":[0.000077954915,0.000101972626,0.00299125,0.00013919687,0.000017785249,0.0003575862,0.00026689516,0.00027961997,0.0005146185,0.0074122245,0.9877884,0.000052431675],"about_ca_topic_score_codex":0.0034423003,"about_ca_topic_score_gemma":0.007705747,"teacher_disagreement_score":0.38621548,"about_ca_system_score_codex":0.0021504303,"about_ca_system_score_gemma":0.0024669243,"threshold_uncertainty_score":0.8754891},"labels":[],"label_agreement":null},{"id":"W1998634611","doi":"10.4212/cjhp.v66i2.1249","title":"Drug Shortages: The Survey Says . . .","year":2013,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Pharmacy; Harm; Medicine; Family medicine; Work (physics); Public relations; Medical education; Psychology; Political science; Government (linguistics); Engineering; Social psychology","score_opus":0.05687214641304922,"score_gpt":0.2709435487748774,"score_spread":0.2140714023618282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998634611","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13289827,0.005436525,0.0010380389,0.59735304,0.006893848,0.0004981282,0.12558487,0.0007632573,0.12953404],"genre_scores_gemma":[0.2862589,0.016188933,0.002661651,0.50268465,0.004562335,0.0012527554,0.08210084,0.0002924986,0.10399745],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982426,0.00023438159,0.00019810622,0.00015330611,0.00081789424,0.0003537221],"domain_scores_gemma":[0.9927321,0.0008556134,0.0009112735,0.00015730753,0.0036354605,0.0017082257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014082615,0.000328141,0.00024129881,0.0009577095,0.0013730014,0.0012007585,0.00044251975,0.0019011978,0.016031524],"category_scores_gemma":[0.0080423085,0.0003477159,0.0003743589,0.0022518418,0.00034284033,0.0024539605,0.00141214,0.0025899888,0.0055534896],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023528572,0.0000650097,0.057858,0.00022976202,0.000016635637,0.00006991452,0.00053797476,0.000021879876,0.00015846905,0.00023284135,0.9122523,0.02853355],"study_design_scores_gemma":[0.000036684567,0.00012228037,0.39430815,0.0005234063,0.00003885167,0.00035774658,0.008480562,0.00017607433,0.0003756231,0.00016969841,0.59536254,0.000048431437],"about_ca_topic_score_codex":0.13542683,"about_ca_topic_score_gemma":0.14067388,"teacher_disagreement_score":0.99853355,"about_ca_system_score_codex":0.001466425,"about_ca_system_score_gemma":0.0055447742,"threshold_uncertainty_score":0.2692771},"labels":[],"label_agreement":null},{"id":"W1999287793","doi":"10.1016/j.jval.2013.08.849","title":"Investigating the Economic Impacts of New Public Pharmaceutical Policies in Greece","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cost sharing; Reimbursement; Medicine; Quarter (Canadian coin); Population; Average cost; Business; Public economics; Environmental health; Economics; Health care; Economic growth; Geography","score_opus":0.22237617927370337,"score_gpt":0.36778010867386485,"score_spread":0.14540392940016147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999287793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826104,0.0012109387,0.00029147282,0.0041812737,0.000038497405,0.000021931668,0.0003446807,0.00001012601,0.011290683],"genre_scores_gemma":[0.9984932,0.00047486706,0.000053526124,0.00011329707,0.00002085195,0.0000045421248,0.000096324606,0.0000023281216,0.0007411263],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9986644,0.00049964414,0.00008451258,0.00013675606,0.00022704847,0.00038769306],"domain_scores_gemma":[0.9967739,0.0017767854,0.00080335484,0.00012525449,0.00022525368,0.0002953898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014581915,0.00021833155,0.00064553635,0.001022772,0.0003722867,0.003706818,0.00056188,0.0016346547,0.0021037553],"category_scores_gemma":[0.0061775018,0.0002509644,0.0007594654,0.0014953185,0.0013383172,0.0014019929,0.0016932801,0.0015331783,0.00011237996],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034706558,0.001826743,0.25642177,0.0011423314,0.0019499934,0.009156677,0.0018295745,0.32527694,0.005717611,0.3149267,0.009275199,0.06900583],"study_design_scores_gemma":[0.0005689943,0.0011817736,0.7387147,0.0003999765,0.0009109653,0.0009779534,0.013772972,0.09408116,0.0041998765,0.10632988,0.038700167,0.00016160725],"about_ca_topic_score_codex":0.03101241,"about_ca_topic_score_gemma":0.021210035,"teacher_disagreement_score":0.03101241,"about_ca_system_score_codex":0.006739095,"about_ca_system_score_gemma":0.0040010745,"threshold_uncertainty_score":0.061663806},"labels":[],"label_agreement":null},{"id":"W1999320018","doi":"10.1503/cmaj.109-4474","title":"Drug patents: the high price of watchdog litigation","year":2013,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug industry; Ask price; Drug; Business; Generic drug; Drug prices; Brand names; Pharmaceutical industry; Internet privacy; Computer science; Medicine; Advertising; Pharmacology; Finance; Economics; Biotechnology","score_opus":0.01719887629675221,"score_gpt":0.21945551415941666,"score_spread":0.20225663786266446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999320018","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008494039,0.016718585,0.0029971157,0.77858883,0.0047947494,0.00002856872,0.00027829292,0.00024917,0.18785058],"genre_scores_gemma":[0.31188074,0.0143429795,0.0022537056,0.55471975,0.020615673,0.00008708027,0.00033421922,0.00029476127,0.095471084],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915047,0.0010695858,0.000219822,0.0009021817,0.0054977,0.000805998],"domain_scores_gemma":[0.9749487,0.017435262,0.0013860534,0.0012726712,0.0032210944,0.0017360996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007641776,0.00032867104,0.0006192078,0.0017061554,0.0036545263,0.011664022,0.0013239388,0.02117521,0.019917862],"category_scores_gemma":[0.050800085,0.00032397933,0.00070088205,0.0011373797,0.0064956257,0.0104963295,0.0018766517,0.013476603,0.0040328247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006214107,0.000024839519,0.0007754933,0.00007049152,0.000024224253,0.00023980044,0.00028987895,0.00012001411,0.00035236587,0.51888794,0.4340762,0.04507647],"study_design_scores_gemma":[0.00013640054,0.00009078266,0.0035849656,0.0006244282,0.0000643198,0.0008293361,0.0005284349,0.0010678562,0.00081382366,0.26079085,0.73139304,0.00007579477],"about_ca_topic_score_codex":0.012626738,"about_ca_topic_score_gemma":0.013127739,"teacher_disagreement_score":0.02117521,"about_ca_system_score_codex":0.0052547073,"about_ca_system_score_gemma":0.00573692,"threshold_uncertainty_score":0.06663191},"labels":[],"label_agreement":null},{"id":"W1999613105","doi":"10.3821/1913-701x(2007)140[218b:ttcdsr]2.0.co;2","title":"Threat to Canada's drug supply recedes – CPhA","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Economics; Natural resource economics","score_opus":0.04375517619715809,"score_gpt":0.26144733454338864,"score_spread":0.21769215834623057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999613105","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059878286,0.0041360185,0.00061798916,0.8273593,0.0039206943,0.00014987384,0.0059953337,0.00023236635,0.097710036],"genre_scores_gemma":[0.48902833,0.004593546,0.0013650407,0.396614,0.004906719,0.00009003462,0.0017268161,0.00014227754,0.10153333],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9887629,0.00046365234,0.00031043874,0.0004738156,0.006860275,0.0031288639],"domain_scores_gemma":[0.98173136,0.0022252656,0.0013270674,0.0003681167,0.008019131,0.006329098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004368399,0.00039188765,0.0007046527,0.0019035691,0.005575572,0.008534727,0.0020576497,0.016106123,0.009983213],"category_scores_gemma":[0.019557618,0.00055720226,0.0013057702,0.0020145243,0.0026124774,0.0014284096,0.001651662,0.011028554,0.0009447964],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043373476,0.0001644368,0.036059994,0.00022460568,0.00019653296,0.0015293898,0.000778905,0.0027459809,0.0011817612,0.11299597,0.80200976,0.04167893],"study_design_scores_gemma":[0.0002551829,0.00013067368,0.08894219,0.00028914408,0.00007860174,0.00053379603,0.00095584546,0.0028315997,0.0005036466,0.007711664,0.89763975,0.00012783485],"about_ca_topic_score_codex":0.97631717,"about_ca_topic_score_gemma":0.980437,"teacher_disagreement_score":0.936206,"about_ca_system_score_codex":0.06379402,"about_ca_system_score_gemma":0.22596586,"threshold_uncertainty_score":0.46286017},"labels":[],"label_agreement":null},{"id":"W2000554966","doi":"10.1503/cmaj.071831","title":"US considers establishing behind-the-counter drugs","year":2007,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Food and drug administration; Agency (philosophy); Over-the-counter; Drug labeling; Medicine; Perspective (graphical); Administration (probate law); Advertising; Medical prescription; Political science; Drug; Law; Pharmacology; Business; Computer science; Sociology","score_opus":0.020246180386641686,"score_gpt":0.25299542395434654,"score_spread":0.23274924356770485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000554966","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011576049,0.013558649,0.0021915277,0.6049941,0.016693726,0.000116520714,0.00074120075,0.00023725595,0.34989092],"genre_scores_gemma":[0.1528302,0.009614904,0.002997303,0.7345428,0.008067935,0.000120399,0.00038804382,0.00011735921,0.09132108],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9871111,0.0037135854,0.00066955073,0.0010854489,0.0050029308,0.0024173532],"domain_scores_gemma":[0.98062724,0.008047205,0.0011576742,0.00095399754,0.006070304,0.003143672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013519927,0.00070162857,0.0006558585,0.0012982028,0.004584671,0.011518053,0.0017776316,0.037025824,0.01927322],"category_scores_gemma":[0.0316029,0.00052234577,0.0012786418,0.0013086755,0.0036599124,0.0087214615,0.0039030786,0.011572965,0.0031751164],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017222714,0.00021297138,0.0027442195,0.00013111511,0.00003711401,0.0007263948,0.00044005478,0.0004845875,0.00073052314,0.47227386,0.47228962,0.04975735],"study_design_scores_gemma":[0.000063520194,0.00013710317,0.0015581094,0.00025084108,0.000035451347,0.00015137186,0.00032719574,0.0004082451,0.0005569788,0.025153778,0.97131944,0.000037997383],"about_ca_topic_score_codex":0.065695204,"about_ca_topic_score_gemma":0.0618295,"teacher_disagreement_score":0.065695204,"about_ca_system_score_codex":0.006301172,"about_ca_system_score_gemma":0.023905028,"threshold_uncertainty_score":0.1306256},"labels":[],"label_agreement":null},{"id":"W2001741737","doi":"10.1080/0003684042000222106","title":"The price premium of generic to brand-names and pharmaceutical price index","year":2004,"lang":"en","type":"article","venue":"Applied Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carbon Engineering (Canada)","funders":"","keywords":"Economics; Generic drug; Brand names; Order (exchange); Market share; Competition (biology); Index (typography); Product (mathematics); Incentive; Marketing; Advertising; Microeconomics; Business; Mathematics; Computer science; Drug","score_opus":0.03745401551847522,"score_gpt":0.26619502292078334,"score_spread":0.22874100740230813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001741737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98679477,0.0010822496,0.0030800418,0.000768895,0.00006064374,0.000024251287,0.0006052553,0.000077334895,0.0075065214],"genre_scores_gemma":[0.9985759,0.00013261354,0.0001823765,0.000037856684,0.00007157423,0.0000023746986,0.0002939218,0.000008527479,0.00069488067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991328,0.00014664857,0.00004935416,0.00015624554,0.000340521,0.00017448762],"domain_scores_gemma":[0.9810482,0.011273642,0.0048231236,0.0007416622,0.0008839239,0.0012293728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023323493,0.0002874128,0.00060197164,0.0014123734,0.0002572109,0.0018397062,0.00071578816,0.0010390363,0.007275744],"category_scores_gemma":[0.01755691,0.00016055562,0.0010437816,0.0013155758,0.000776995,0.0018516417,0.00078298576,0.0015116343,0.0006797104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002683949,0.0007785912,0.84122837,0.00030759434,0.0006279888,0.0016007727,0.00092742586,0.015955063,0.010360925,0.054562055,0.00543864,0.065528646],"study_design_scores_gemma":[0.00007463848,0.00037305648,0.93035305,0.000021255802,0.00026147717,0.0007680163,0.0004635925,0.043721117,0.0020682456,0.019471886,0.0023576468,0.00006606167],"about_ca_topic_score_codex":0.00477843,"about_ca_topic_score_gemma":0.00296777,"teacher_disagreement_score":0.007275744,"about_ca_system_score_codex":0.0012774513,"about_ca_system_score_gemma":0.00042216264,"threshold_uncertainty_score":0.024339736},"labels":[],"label_agreement":null},{"id":"W2001840509","doi":"10.7202/1002468ar","title":"Jongler avec le chaos. Effets de l’hégémonie des pratiques biomédicales en psychiatrie du point de vue des usagers","year":2011,"lang":"fr","type":"article","venue":"Cahiers de recherche sociologique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.16325844159232467,"score_gpt":0.34780185898936067,"score_spread":0.184543417397036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001840509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48134333,0.01867127,0.006176757,0.27153534,0.00053386524,0.0000642669,0.00028716493,0.00006708638,0.22132091],"genre_scores_gemma":[0.98255724,0.0032951708,0.0005757651,0.003336138,0.00013316634,0.000026993972,0.000029110299,0.00002073738,0.010025738],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9960271,0.0024173053,0.000071253875,0.00037154814,0.0005602847,0.00055248116],"domain_scores_gemma":[0.99580956,0.0019108658,0.00084923394,0.00035644675,0.0005269193,0.0005469868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029450213,0.00025279433,0.00027624585,0.0014320074,0.0064637805,0.0057788817,0.0005250711,0.0014021177,0.0062607317],"category_scores_gemma":[0.006718676,0.0002517339,0.00026266044,0.0017056178,0.021872977,0.004218856,0.0038654765,0.0021020363,0.0005786176],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014923608,0.000059073205,0.023788845,0.00026784715,0.00006749325,0.0006095867,0.1444158,0.0005393662,0.00065673335,0.7705878,0.010764741,0.048093505],"study_design_scores_gemma":[0.00008103712,0.00017501814,0.08982355,0.00072111934,0.00008722341,0.00059959065,0.19409175,0.00067507784,0.0007250399,0.28335384,0.42957962,0.00008713479],"about_ca_topic_score_codex":0.061032936,"about_ca_topic_score_gemma":0.07030606,"teacher_disagreement_score":0.061032936,"about_ca_system_score_codex":0.008894923,"about_ca_system_score_gemma":0.009824061,"threshold_uncertainty_score":0.121355414},"labels":[],"label_agreement":null},{"id":"W2002586717","doi":"10.1176/pn.45.22.psychnews_45_22_018","title":"Patients Abandon Antidepressants, Deterred by High Costs","year":2010,"lang":"en","type":"article","venue":"Psychiatric News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Abandonment (legal); Pharmacy; Medicine; Payment; Quarter (Canadian coin); Depression (economics); Family medicine; Psychiatry; Business; Geography; Finance; Political science; Pharmacology; Economics","score_opus":0.014448483322413164,"score_gpt":0.24540265883315804,"score_spread":0.23095417551074487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002586717","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.050008416,0.030220073,0.0012124814,0.32931674,0.014591305,0.00027951988,0.012622364,0.0013684634,0.5603807],"genre_scores_gemma":[0.29457396,0.08430691,0.0030462192,0.15575945,0.03186366,0.00041058127,0.0116063515,0.0009045529,0.41752836],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9991912,0.00013479685,0.00008338337,0.00005618901,0.00038350385,0.00015089047],"domain_scores_gemma":[0.9957729,0.0008818486,0.0010477216,0.00020188208,0.001109344,0.0009863181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051532337,0.00029959492,0.00040363218,0.00084349513,0.00093579415,0.0026525233,0.00040173353,0.0015639651,0.10399307],"category_scores_gemma":[0.013831793,0.0002927877,0.00038575364,0.00091324345,0.00024702176,0.0013504865,0.00092379085,0.0018387003,0.03628337],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007950621,0.000041995438,0.0063297697,0.00015239774,0.000013718713,0.00018778755,0.00008820685,0.000021174388,0.00010873224,0.0005729079,0.8772851,0.11511878],"study_design_scores_gemma":[0.000108954395,0.0001440757,0.04144734,0.0010325054,0.000051901592,0.001498251,0.000587385,0.00012632087,0.0006150727,0.0015507111,0.95280385,0.00003369525],"about_ca_topic_score_codex":0.00424053,"about_ca_topic_score_gemma":0.009579565,"teacher_disagreement_score":0.10399307,"about_ca_system_score_codex":0.0009525765,"about_ca_system_score_gemma":0.0015284925,"threshold_uncertainty_score":0.3478915},"labels":[],"label_agreement":null},{"id":"W2002852368","doi":"10.1377/hlthaff.2010.0317","title":"The Level Of Income Appears To Have No Consistent Bearing On Pharmaceutical Prices Across Countries","year":2011,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"High income countries; Middle income; Developing country; Economics; Low and middle income countries; Developed country; Demographic economics; International economics; Business; Development economics; Economic growth; Population","score_opus":0.27357667007689496,"score_gpt":0.3832275978072387,"score_spread":0.10965092773034374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002852368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569183,0.002500888,0.0012709069,0.0014332297,0.0000732724,0.00002168255,0.0012500739,0.000022134547,0.036509454],"genre_scores_gemma":[0.9980447,0.00051378924,0.00019889318,0.00010574447,0.00002426317,0.000005832153,0.00028262116,0.000008373962,0.0008157233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989604,0.00026906826,0.000095781994,0.00014818375,0.00023401635,0.0002925849],"domain_scores_gemma":[0.99234456,0.0025957455,0.0030145566,0.00036590328,0.0010683633,0.0006108821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014765617,0.00017661341,0.00046824128,0.0013754332,0.0005751939,0.001870433,0.00030935125,0.0002934467,0.005403962],"category_scores_gemma":[0.008271688,0.00014415686,0.00049640605,0.0021078705,0.0010550477,0.0012941844,0.0011520304,0.00060271134,0.00067738304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047616515,0.00010035928,0.9333761,0.00027098402,0.00056707725,0.0004062336,0.0007184797,0.0015553194,0.0008170165,0.016153164,0.0018896511,0.043669492],"study_design_scores_gemma":[0.000018382561,0.00011309673,0.98996836,0.000107415864,0.000109886634,0.00021778293,0.0009577867,0.0004457107,0.0005668689,0.0027165862,0.004758466,0.000019649668],"about_ca_topic_score_codex":0.0032116217,"about_ca_topic_score_gemma":0.004085624,"teacher_disagreement_score":0.005403962,"about_ca_system_score_codex":0.00065936666,"about_ca_system_score_gemma":0.0003960087,"threshold_uncertainty_score":0.018078089},"labels":[],"label_agreement":null},{"id":"W2003146599","doi":"10.1097/01.mlr.0000178217.84354.f1","title":"Booming Prescription Drug Expenditure","year":2005,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Health Canada","keywords":"Per capita; Medical prescription; Cohort; Prescription drug; Population; Medicine; Population ageing; Demography; Gerontology; Environmental health","score_opus":0.03361706033256837,"score_gpt":0.28354789835629796,"score_spread":0.2499308380237296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003146599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88890517,0.010792242,0.0007674688,0.020200593,0.00009540934,0.000059917256,0.018237341,0.00010023416,0.060841642],"genre_scores_gemma":[0.9832313,0.006089545,0.0005059204,0.0011781503,0.00006737693,0.000012439955,0.0039013468,0.00000906951,0.005004902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993199,0.00004956039,0.000029538089,0.000057763315,0.000281979,0.00026131305],"domain_scores_gemma":[0.99865025,0.000120360746,0.00030071384,0.00003604877,0.00064757926,0.0002450332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003624361,0.00019541012,0.00016737482,0.0018141615,0.0005811664,0.001722564,0.00027423393,0.00045538752,0.0050529144],"category_scores_gemma":[0.0022583168,0.00012640211,0.00019604166,0.0038881958,0.0004192003,0.00061294035,0.0005800527,0.0006795553,0.00042325124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013906001,0.000060361293,0.8389702,0.0003544401,0.0001100198,0.00051693135,0.0012572573,0.0020768698,0.00096876215,0.009885869,0.039164867,0.10649535],"study_design_scores_gemma":[0.000004771333,0.000014138017,0.9594271,0.00011526823,0.000026450727,0.00015779508,0.00059421046,0.00066047284,0.00018408535,0.00035395962,0.038453914,0.000007875396],"about_ca_topic_score_codex":0.7681538,"about_ca_topic_score_gemma":0.84422755,"teacher_disagreement_score":0.7681538,"about_ca_system_score_codex":0.011057816,"about_ca_system_score_gemma":0.0077149193,"threshold_uncertainty_score":0.46642315},"labels":[],"label_agreement":null},{"id":"W2003270914","doi":"10.1016/j.cjca.2012.08.012","title":"Statins: Is It Safe and Effective to Use Generic “Equivalents”?","year":2012,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Health Sciences Centre; University Health Network","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Equivalent; Intensive care medicine; Internal medicine","score_opus":0.09915420524323709,"score_gpt":0.28593933402837424,"score_spread":0.18678512878513714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003270914","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003776332,0.0009269054,0.000038923634,0.9953055,0.0018464585,0.000002824342,0.000027803939,0.0000042340935,0.0014697227],"genre_scores_gemma":[0.00790671,0.0019496543,0.00021391352,0.95615524,0.03137566,0.000013715967,0.00003497168,0.000012041089,0.0023380818],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948743,0.0012642605,0.00091662066,0.00061176467,0.0015084362,0.000824585],"domain_scores_gemma":[0.975529,0.013522362,0.002461889,0.00045741285,0.0027998965,0.0052295034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069005727,0.00057491736,0.0023757503,0.001099098,0.0033771296,0.0048921327,0.0014814353,0.06691532,0.008696556],"category_scores_gemma":[0.056702092,0.0006379535,0.0012971405,0.0010182031,0.0049212333,0.0048123254,0.0015682941,0.042051777,0.0045959423],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004319949,0.00011551641,0.0040723695,0.00023988255,0.00008432595,0.0029336668,0.0002473488,0.00017462995,0.00041195442,0.01572133,0.92862475,0.04694236],"study_design_scores_gemma":[0.0007162442,0.0002636949,0.007694978,0.0017880595,0.00019144716,0.0054283133,0.00092207646,0.0011300098,0.00046051788,0.06256557,0.91863155,0.00020747868],"about_ca_topic_score_codex":0.019226443,"about_ca_topic_score_gemma":0.041741677,"teacher_disagreement_score":0.06691532,"about_ca_system_score_codex":0.008388057,"about_ca_system_score_gemma":0.010094393,"threshold_uncertainty_score":0.06085992},"labels":[],"label_agreement":null},{"id":"W2004660332","doi":"10.3821/1913-701x-145.4.160b","title":"PEI Moves to Lower Generic Drug Prices","year":2012,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Business; Computer science; Medicine; Pharmacology","score_opus":0.06312541263013982,"score_gpt":0.2716118327538594,"score_spread":0.2084864201237196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004660332","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02815529,0.004839876,0.007837762,0.33769608,0.0037378608,0.00014266963,0.00090004,0.000580787,0.6161096],"genre_scores_gemma":[0.433739,0.0044864845,0.0074671055,0.32440546,0.0039167115,0.00021342192,0.00054100406,0.00022816984,0.22500266],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99244314,0.0011384841,0.00024329317,0.0005268071,0.003899823,0.0017484729],"domain_scores_gemma":[0.99133545,0.0026909818,0.0007440164,0.00058442535,0.0025362575,0.0021088568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005947203,0.0005302691,0.0007181677,0.001747029,0.0012164518,0.0046067247,0.0014244126,0.008067138,0.045087844],"category_scores_gemma":[0.024227532,0.00043736424,0.0013494485,0.0014288797,0.0017894735,0.0024859512,0.0031218182,0.007224879,0.004134111],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024212038,0.00030164255,0.0037026564,0.0005886792,0.00013451658,0.00046495735,0.0004993448,0.0032089953,0.00092086365,0.63164985,0.2602859,0.098000504],"study_design_scores_gemma":[0.00046555075,0.00033695536,0.022824092,0.0004589043,0.000094625684,0.00057898276,0.0005586146,0.002939634,0.0019327964,0.10149621,0.86823493,0.000078732555],"about_ca_topic_score_codex":0.044065982,"about_ca_topic_score_gemma":0.044492178,"teacher_disagreement_score":0.95593405,"about_ca_system_score_codex":0.007011782,"about_ca_system_score_gemma":0.021067506,"threshold_uncertainty_score":0.15083385},"labels":[],"label_agreement":null},{"id":"W2005311616","doi":"10.3821/1913-701x(2007)140[354a:baapsi]2.0.co;2","title":"BC and Alberta pharmacists seek input into joint buying strategy","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Joint (building); Business; Marketing; Engineering","score_opus":0.06874095744618008,"score_gpt":0.2767010859288065,"score_spread":0.2079601284826264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005311616","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13286565,0.0022921686,0.0022845226,0.11145973,0.00055071566,0.00022451302,0.00036656146,0.00017170954,0.7497845],"genre_scores_gemma":[0.78847843,0.00095379364,0.00237115,0.015172232,0.00023312855,0.000043319575,0.00024329656,0.000057435762,0.19244726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.990875,0.0013934723,0.00018189623,0.00039798487,0.0040168776,0.0031347508],"domain_scores_gemma":[0.9728969,0.007049718,0.0009831181,0.00077177526,0.00752274,0.0107757235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051849517,0.00036551247,0.00041975293,0.001683102,0.008648702,0.010701589,0.00089347124,0.004381176,0.04885755],"category_scores_gemma":[0.019479088,0.0005096527,0.00036018857,0.0023915488,0.0018508224,0.0021905568,0.0027989128,0.003361968,0.0028035308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065196306,0.0006771221,0.10043008,0.00029250502,0.00011501347,0.0018933966,0.007054583,0.0024702107,0.0028985352,0.147345,0.43714482,0.29902676],"study_design_scores_gemma":[0.00031760847,0.00025224604,0.18062836,0.00029905094,0.000110805566,0.00088936626,0.024734963,0.005017823,0.0017937035,0.027233327,0.7585743,0.00014848435],"about_ca_topic_score_codex":0.6504244,"about_ca_topic_score_gemma":0.86575484,"teacher_disagreement_score":0.97038156,"about_ca_system_score_codex":0.029618414,"about_ca_system_score_gemma":0.079214424,"threshold_uncertainty_score":0.7032686},"labels":[],"label_agreement":null},{"id":"W2005821732","doi":"10.4212/cjhp.v65i1.1102","title":"Gestion des ruptures d’approvisionnement de médicaments : perspectives en France, aux États-Unis et au Canada","year":2012,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.0387480593997115,"score_gpt":0.29158616115629316,"score_spread":0.25283810175658167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005821732","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17141457,0.14127952,0.001528113,0.5022537,0.0025072705,0.00007792035,0.00039247866,0.000089272246,0.18045713],"genre_scores_gemma":[0.7970806,0.06782158,0.0018006418,0.07140583,0.0010574153,0.00005720779,0.00017931164,0.0000663133,0.06053124],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9881257,0.0036602546,0.00033950445,0.0007865835,0.003327693,0.003760356],"domain_scores_gemma":[0.97567517,0.006601112,0.0023469185,0.00034385987,0.008957717,0.006075331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010321248,0.0003588625,0.0004364251,0.0021689185,0.018027052,0.015211568,0.001806705,0.005585209,0.009550193],"category_scores_gemma":[0.0129190255,0.00034746653,0.0007895349,0.0027271698,0.013395792,0.0040623383,0.0037895867,0.006143313,0.0006492312],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041450534,0.00041685454,0.050675955,0.0014622257,0.00013293176,0.0041165887,0.29930124,0.0006643124,0.0026758574,0.16063702,0.14978935,0.32971323],"study_design_scores_gemma":[0.000027779457,0.000155137,0.05036139,0.0018286764,0.000058103684,0.0008035122,0.20113888,0.00016400912,0.0006144811,0.004967045,0.73976344,0.000117576565],"about_ca_topic_score_codex":0.9234992,"about_ca_topic_score_gemma":0.96350366,"teacher_disagreement_score":0.106016286,"about_ca_system_score_codex":0.106016286,"about_ca_system_score_gemma":0.1737013,"threshold_uncertainty_score":0.7692056},"labels":[],"label_agreement":null},{"id":"W2006055263","doi":"10.1016/j.urology.2013.05.014","title":"The Relative Value of Some New Drugs Used to Treat Prostate Cancer","year":2013,"lang":"en","type":"letter","venue":"Urology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Value (mathematics); Prostate; Relative value; Cancer; Oncology; Gynecology; Internal medicine; Statistics","score_opus":0.048831931774595626,"score_gpt":0.28660222319086026,"score_spread":0.23777029141626463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006055263","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004992653,0.0055099577,0.0001912379,0.9676367,0.0027011465,0.0000072132652,0.00021088957,0.000010554368,0.018739745],"genre_scores_gemma":[0.21027681,0.00693773,0.00043776876,0.7386652,0.03141493,0.000028881333,0.00015117259,0.0000436044,0.012043878],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924475,0.0037430595,0.00060417055,0.00043059117,0.001954242,0.0008204394],"domain_scores_gemma":[0.9415876,0.04867035,0.0027319982,0.0007469195,0.0036024153,0.0026606813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009138439,0.0002433094,0.0010545754,0.00129477,0.001682547,0.0046715415,0.0011019822,0.022425557,0.005270408],"category_scores_gemma":[0.06428851,0.00033921236,0.0010692828,0.0015925248,0.0028931445,0.0025146455,0.0011303831,0.016048787,0.0010036574],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026746646,0.00018882263,0.013283041,0.00050951634,0.0004108523,0.0031283405,0.00032627833,0.0019333648,0.0012161897,0.15862131,0.7149063,0.102801286],"study_design_scores_gemma":[0.00094642397,0.000753036,0.03040371,0.0012047525,0.0005345216,0.006610095,0.0013400898,0.0066935513,0.0025302295,0.1358316,0.81291926,0.00023277411],"about_ca_topic_score_codex":0.009427625,"about_ca_topic_score_gemma":0.021850754,"teacher_disagreement_score":0.022425557,"about_ca_system_score_codex":0.008681934,"about_ca_system_score_gemma":0.0041664364,"threshold_uncertainty_score":0.062992156},"labels":[],"label_agreement":null},{"id":"W2006204153","doi":"10.1177/2168479012474281","title":"A Review of Regulatory Mechanisms Used by the WHO, EU, and US to Facilitate Access to Quality Medicinal Products in Developing Countries With Constrained Regulatory Capacities","year":2013,"lang":"en","type":"review","venue":"Therapeutic Innovation & Regulatory Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Business; Regulatory agency; Agency (philosophy); Regulatory authority; Quality (philosophy); Regulatory science; European union; Developing country; Pharmacy; Market access; Product (mathematics); Regulatory affairs; Risk analysis (engineering); Public economics; Public administration; Economic growth; Medicine; International trade; Political science; Economics","score_opus":0.26289231732796264,"score_gpt":0.3732875543130458,"score_spread":0.11039523698508313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006204153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010555452,0.99822253,0.000142543,0.00041699377,0.000077666344,0.000009428378,0.00005580626,0.0000036049496,0.0009658315],"genre_scores_gemma":[0.0008271576,0.9984775,0.0002336123,0.00023014253,0.00004655673,0.000007382041,0.000028620634,9.53129e-7,0.00014798506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990792,0.00024803847,0.00018155728,0.000107595704,0.00031160732,0.00007201389],"domain_scores_gemma":[0.9973459,0.0016978623,0.0004617273,0.000049209968,0.00038817464,0.000057023244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003108621,0.0010628236,0.0017864363,0.004854007,0.00038935416,0.0016753307,0.0013510328,0.0013346493,0.0034186305],"category_scores_gemma":[0.004326668,0.00045568906,0.0010205475,0.006819074,0.00071536604,0.0016737425,0.0007238025,0.0013087671,0.00061267987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009563596,0.000066600594,0.0003779036,0.0896868,0.00036218076,0.00015849539,0.00010323873,0.00095220923,0.00084993785,0.01826823,0.03880078,0.850278],"study_design_scores_gemma":[0.000039831433,0.00009339901,0.0021608206,0.04229856,0.000596188,0.00046582436,0.000116708245,0.00016769452,0.00061348005,0.003980315,0.94943076,0.00003645106],"about_ca_topic_score_codex":0.005043062,"about_ca_topic_score_gemma":0.011107297,"teacher_disagreement_score":0.005043062,"about_ca_system_score_codex":0.001941693,"about_ca_system_score_gemma":0.0061026155,"threshold_uncertainty_score":0.016440153},"labels":[],"label_agreement":null},{"id":"W2006585203","doi":"10.1016/s0140-6736(07)61138-6","title":"Is G8 putting profits before the world's poorest children?","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Economic growth; Coronavirus disease 2019 (COVID-19); Political science; Medicine; Business; Economics; Geography; Disease; Infectious disease (medical specialty)","score_opus":0.07303109596224984,"score_gpt":0.31311419465028273,"score_spread":0.2400830986880329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006585203","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070375344,0.0076775504,0.00013409572,0.96122605,0.0039531332,0.000012596208,0.00053058146,0.000028703349,0.01939977],"genre_scores_gemma":[0.18540698,0.023095911,0.0007100425,0.7556915,0.010803456,0.00008389883,0.00049563684,0.00010890707,0.023603696],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964742,0.0008035446,0.00009890363,0.00025762504,0.00059780286,0.0017679533],"domain_scores_gemma":[0.9919235,0.002003019,0.0010470691,0.00027929415,0.0012102727,0.003536862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043517374,0.0006129097,0.00090334215,0.0009767397,0.0020568753,0.0059895236,0.0011950111,0.011456564,0.021469014],"category_scores_gemma":[0.01932689,0.0002957295,0.00047985633,0.0014336796,0.0060712323,0.0059695854,0.0041694683,0.0107261315,0.0045761573],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041090223,0.00007066492,0.011029964,0.0004197284,0.000110690584,0.0005703153,0.000857038,0.00024747546,0.0004500957,0.22299235,0.68902886,0.07381191],"study_design_scores_gemma":[0.00032185414,0.00019686768,0.026542297,0.0015641693,0.0001209022,0.00054218987,0.0037387274,0.00017554298,0.0006943535,0.14735979,0.8186531,0.00009020448],"about_ca_topic_score_codex":0.030099029,"about_ca_topic_score_gemma":0.022432296,"teacher_disagreement_score":0.030099029,"about_ca_system_score_codex":0.0040854863,"about_ca_system_score_gemma":0.014806282,"threshold_uncertainty_score":0.071821034},"labels":[],"label_agreement":null},{"id":"W2008667512","doi":"10.1177/1715163512473933","title":"BC government reveals plans to lower generic drug prices to 20% of brand-name price by April 2014","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Brand names; Government (linguistics); Business; Advertising; Drug prices; Economics; Monetary economics; Linguistics; Philosophy","score_opus":0.028064279524157503,"score_gpt":0.2382762028005628,"score_spread":0.2102119232764053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008667512","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030815689,0.0019696169,0.001156172,0.34668615,0.010082595,0.00036666813,0.008778607,0.0011719228,0.59897256],"genre_scores_gemma":[0.06550881,0.00061266805,0.001070571,0.09439785,0.0011416276,0.00008401934,0.0018224863,0.00014866325,0.83521324],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995955,0.00015390411,0.000071131806,0.00018324055,0.0026561064,0.0009806436],"domain_scores_gemma":[0.9962769,0.00056621584,0.00013936109,0.00011288799,0.0021990004,0.00070567784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014107756,0.0003562742,0.0005547519,0.0009172885,0.0043132543,0.00431628,0.0012254367,0.009045924,0.052074455],"category_scores_gemma":[0.007486549,0.0004921366,0.0008470713,0.0007829365,0.0009686315,0.00072564406,0.00071928,0.005750489,0.008028398],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014275091,0.00006684668,0.0016752682,0.00003698034,0.000015352642,0.0001134346,0.00005584765,0.0001623652,0.00059505325,0.0065929936,0.97690386,0.013639306],"study_design_scores_gemma":[0.000076534205,0.00006923111,0.017714024,0.000046868736,0.000018922636,0.000103223436,0.00015292244,0.00076903106,0.0010604883,0.0014578794,0.97849655,0.000034267243],"about_ca_topic_score_codex":0.687578,"about_ca_topic_score_gemma":0.8181087,"teacher_disagreement_score":0.9773929,"about_ca_system_score_codex":0.022607107,"about_ca_system_score_gemma":0.028689548,"threshold_uncertainty_score":0.62852377},"labels":[],"label_agreement":null},{"id":"W2008814643","doi":"10.1111/anae.12059","title":"Ensuring a sustainable supply of drugs for anaesthesia and peri‐operative care","year":2012,"lang":"en","type":"editorial","venue":"Anaesthesia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Economic shortage; Government (linguistics); Medical emergency; Intensive care medicine","score_opus":0.018883530357095547,"score_gpt":0.2777896521429329,"score_spread":0.25890612178583733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008814643","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031738795,0.06780347,0.07555381,0.5524641,0.009031268,0.0014434017,0.002746397,0.0032990016,0.2559197],"genre_scores_gemma":[0.3780146,0.14257261,0.1521103,0.19286883,0.009956784,0.0016284924,0.005919961,0.0018266345,0.11510182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99211496,0.0014630269,0.000580555,0.00048776163,0.0044197263,0.0009339239],"domain_scores_gemma":[0.98213285,0.0019953826,0.0038483432,0.0009699228,0.006130145,0.004923247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009742515,0.00051160867,0.0007489998,0.0014873714,0.0016255403,0.0064597367,0.0014831468,0.0037760502,0.028426576],"category_scores_gemma":[0.017571261,0.00036737832,0.0007851667,0.0013805071,0.001789339,0.0053460747,0.0075367833,0.0034117575,0.021684373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001543504,0.00036844768,0.00955456,0.0024948912,0.00013008769,0.0007352223,0.0008247931,0.0011331835,0.011234589,0.048339274,0.40067837,0.52435225],"study_design_scores_gemma":[0.00004971034,0.00035844854,0.0078091207,0.0018572547,0.00003022348,0.00091227854,0.0006853651,0.0005724723,0.002582202,0.011523354,0.9735822,0.00003740058],"about_ca_topic_score_codex":0.0030669386,"about_ca_topic_score_gemma":0.0038186202,"teacher_disagreement_score":0.028426576,"about_ca_system_score_codex":0.0034791632,"about_ca_system_score_gemma":0.02803426,"threshold_uncertainty_score":0.09509641},"labels":[],"label_agreement":null},{"id":"W2009112625","doi":"10.1057/jos.2011.26","title":"A multi-agent simulation of the pharmaceutical supply chain","year":2012,"lang":"en","type":"article","venue":"Journal of Simulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profitability index; Supply chain; Computer science; Tracing; Discrete event simulation; Pharmaceutical industry; Industrial organization; Product (mathematics); Work (physics); Quarter (Canadian coin); Business; Operations research; Marketing; Simulation; Finance","score_opus":0.1422285680625195,"score_gpt":0.3678816463697102,"score_spread":0.22565307830719072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009112625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.757959,0.0003264643,0.21762094,0.0012899126,0.000103731596,0.00024372706,0.0016028691,0.00048714902,0.020366188],"genre_scores_gemma":[0.9691831,0.00013514377,0.026764747,0.000064558786,0.000012669499,0.00018200606,0.00043755394,0.000024134533,0.003196072],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99955183,0.00022437598,0.000022896913,0.00006809242,0.00006596031,0.000066765715],"domain_scores_gemma":[0.997526,0.001666421,0.00025285908,0.00012735488,0.00022752186,0.00019999997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008413747,0.00055969495,0.00075372733,0.00063711323,0.0006624114,0.0011722132,0.0010380247,0.001966436,0.003766315],"category_scores_gemma":[0.0039758543,0.00047011784,0.00064640935,0.0007056809,0.000851119,0.00096453656,0.00095146673,0.001036734,0.00028329287],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022268816,0.000015194212,0.00060609315,0.0000055343253,0.0000066636235,0.000022093307,0.000012604063,0.9973628,0.00009152462,0.0013523579,0.00006681846,0.00043603368],"study_design_scores_gemma":[0.000014968196,0.000009766901,0.000098405246,0.0000019719346,0.0000022416234,0.000002829967,0.000007227111,0.99924326,0.000051031475,0.0004316837,0.00013415761,0.0000023927607],"about_ca_topic_score_codex":0.032492295,"about_ca_topic_score_gemma":0.011019556,"teacher_disagreement_score":0.032492295,"about_ca_system_score_codex":0.0013613086,"about_ca_system_score_gemma":0.0019581807,"threshold_uncertainty_score":0.06460631},"labels":[],"label_agreement":null},{"id":"W2009416878","doi":"10.1016/j.jval.2013.08.814","title":"A 10-Year Review of the Canadian Common Drug Review: Pharmaceutical Manufacturers’ Success Rate","year":2013,"lang":"en","type":"review","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Formulary; Medicine; Reimbursement; Listing (finance); Family medicine; Business; Health care; Political science","score_opus":0.18501130182309475,"score_gpt":0.3940084444685437,"score_spread":0.20899714264544897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009416878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034132178,0.99329364,0.00005087578,0.003759136,0.0005796142,0.00003052362,0.0005033131,0.0000098874325,0.0014317585],"genre_scores_gemma":[0.0071869823,0.9882201,0.00027512902,0.0025660968,0.0005456233,0.000023004262,0.0004362198,0.000010892933,0.0007359525],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98829275,0.0014501609,0.0013452222,0.00057098764,0.007691335,0.00064955634],"domain_scores_gemma":[0.93534845,0.014336838,0.0068953987,0.0007863637,0.04007787,0.0025550683],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018599318,0.001084794,0.0032653846,0.014548644,0.00096341694,0.0039754217,0.0021461055,0.0020287645,0.004863663],"category_scores_gemma":[0.048609678,0.0006101871,0.002093431,0.019554427,0.0016218463,0.0020172563,0.0013389374,0.0020941163,0.0007990139],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050763227,0.000051664294,0.0030773336,0.074300885,0.0018790063,0.000098513025,0.00017356087,0.00040382348,0.00041258737,0.0040704235,0.29007715,0.62494737],"study_design_scores_gemma":[0.00013540075,0.0001355544,0.027866699,0.05963354,0.0036158026,0.00030343363,0.00017512188,0.00023193596,0.00038526687,0.00068166654,0.90673745,0.00009822773],"about_ca_topic_score_codex":0.34905598,"about_ca_topic_score_gemma":0.638542,"teacher_disagreement_score":0.98140067,"about_ca_system_score_codex":0.028540542,"about_ca_system_score_gemma":0.06691273,"threshold_uncertainty_score":0.6940485},"labels":[],"label_agreement":null},{"id":"W2009842811","doi":"10.1503/cmaj.1040937","title":"Stockholders protest Pfizer's drug prices","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Shareholder; Drug; Drug industry; Drug prices; Economic Justice; Drug Company; Faith; Business; Drug pricing; Finance; Computer science; Medicine; Monetary economics; Economics; Pharmacology; Actuarial science; Management; Microeconomics; Biology; Corporate governance; Biotechnology","score_opus":0.022230739515691357,"score_gpt":0.24482837157388138,"score_spread":0.22259763205819003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009842811","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019430626,0.0041266754,0.0012668978,0.8260412,0.0062118056,0.000053626583,0.00030232058,0.00018233011,0.1423844],"genre_scores_gemma":[0.22696926,0.0020601605,0.0008633072,0.6794127,0.007996647,0.000078701996,0.00014064538,0.00010436637,0.08237417],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99269944,0.0011799724,0.00023724193,0.00059272686,0.003806398,0.0014841796],"domain_scores_gemma":[0.9914221,0.0047686226,0.0009781317,0.00033615326,0.0011309369,0.0013640004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007016857,0.00077364914,0.0005096331,0.0008936538,0.006249581,0.007379019,0.001235495,0.026644282,0.010957531],"category_scores_gemma":[0.02465607,0.0005589044,0.0008203146,0.0009570982,0.0033889138,0.003288286,0.0026805012,0.019557681,0.0024616602],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002751289,0.00009489069,0.0029553021,0.000046620033,0.00008892504,0.00075664493,0.00081223313,0.00022219762,0.00081208476,0.12302505,0.83553135,0.035379514],"study_design_scores_gemma":[0.00029960735,0.00025026136,0.0056735915,0.00020841394,0.000120342454,0.0005399339,0.00083565695,0.0014256778,0.0036250264,0.024724392,0.962201,0.000096153664],"about_ca_topic_score_codex":0.015499193,"about_ca_topic_score_gemma":0.020207493,"teacher_disagreement_score":0.026644282,"about_ca_system_score_codex":0.0048798774,"about_ca_system_score_gemma":0.0042062723,"threshold_uncertainty_score":0.037109077},"labels":[],"label_agreement":null},{"id":"W2010859221","doi":"10.1186/s12889-015-1475-1","title":"Perceptions of the population regarding generic drugs in Brazil: a nationwide survey","year":2015,"lang":"en","type":"article","venue":"BMC Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Universidade de São Paulo","keywords":"Medicine; Biostatistics; Population; Socioeconomic status; Public health; Gerontology; Perception; Environmental health; Family medicine; Nursing; Psychology","score_opus":0.2085078237389088,"score_gpt":0.3697604662547268,"score_spread":0.161252642515818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010859221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969023,0.00031242284,0.0000815034,0.00040720135,0.0000053039143,0.000045530294,0.0006716321,0.0000034405568,0.0015706545],"genre_scores_gemma":[0.9986474,0.00048034094,0.00017036297,0.0002026882,0.0000044769704,0.000026922758,0.0002779117,0.0000015399718,0.00018836754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995566,0.000110689674,0.00006779494,0.000053037056,0.00013390755,0.00007790086],"domain_scores_gemma":[0.9988587,0.00015589269,0.0005819024,0.000046812696,0.00016527755,0.00019137148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009175128,0.00014930755,0.000266917,0.0007065769,0.00041022158,0.00049883465,0.00023470934,0.0003484134,0.0012780178],"category_scores_gemma":[0.0023576017,0.00026465135,0.00040592847,0.000738087,0.00035952544,0.0004691095,0.0005828847,0.00038677786,0.0001721121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020590338,0.00007772825,0.9864738,0.0001434684,0.000029359817,0.00016378792,0.005024811,0.000017426646,0.00065897655,0.000100133766,0.00042445125,0.006865561],"study_design_scores_gemma":[0.0000044833696,0.0001098364,0.98984236,0.000097922115,0.00001918944,0.00028168465,0.007568286,0.00008902367,0.00007161212,0.000035676276,0.0018712234,0.000008663054],"about_ca_topic_score_codex":0.034322392,"about_ca_topic_score_gemma":0.03820948,"teacher_disagreement_score":0.034322392,"about_ca_system_score_codex":0.0006336768,"about_ca_system_score_gemma":0.00072351145,"threshold_uncertainty_score":0.06824523},"labels":[],"label_agreement":null},{"id":"W2011832705","doi":"10.1377/hlthaff.20.6.306","title":"Rationalizing The Drug Patent System","year":2001,"lang":"en","type":"letter","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Health care; Foundation (evidence); Download; Library science; Medicine; Political science; World Wide Web; Computer science; Law","score_opus":0.13248523850078142,"score_gpt":0.28998387008263093,"score_spread":0.1574986315818495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011832705","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075209537,0.001324807,0.005099178,0.8633309,0.0017214266,0.00009633897,0.00014505662,0.00007849112,0.120682776],"genre_scores_gemma":[0.32060766,0.0013151595,0.004805691,0.61145586,0.011985068,0.0002520994,0.000068530484,0.00009381239,0.049416136],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9863174,0.0067062597,0.0005017787,0.0017307576,0.0026362387,0.0021074729],"domain_scores_gemma":[0.9695691,0.023535062,0.0012332236,0.0018815465,0.0024976293,0.0012833969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02312048,0.0005543856,0.0011814659,0.0013843997,0.0041010743,0.013102051,0.002891134,0.066364475,0.010994946],"category_scores_gemma":[0.058659043,0.0008275191,0.0011193143,0.00075642386,0.013512183,0.009350433,0.00362635,0.025406932,0.0021052763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009462749,0.00005085029,0.00044025472,0.000026408921,0.000027988508,0.00016304447,0.00015354065,0.0011839187,0.00019939132,0.9077157,0.08489197,0.005052313],"study_design_scores_gemma":[0.00026286195,0.00003576506,0.0005808161,0.000059347487,0.000028924069,0.000050536877,0.00012636166,0.004969467,0.00046103584,0.8913985,0.101990335,0.00003601437],"about_ca_topic_score_codex":0.01489231,"about_ca_topic_score_gemma":0.018432982,"teacher_disagreement_score":0.066364475,"about_ca_system_score_codex":0.012282904,"about_ca_system_score_gemma":0.011788087,"threshold_uncertainty_score":0.12227422},"labels":[],"label_agreement":null},{"id":"W2012264231","doi":"10.1136/bmj.331.7522.958","title":"Foreign free riders and the high price of US medicines","year":2005,"lang":"en","type":"review","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Computer science; Data science; World Wide Web; Medicine; Business","score_opus":0.11168298525667418,"score_gpt":0.35494946050225307,"score_spread":0.24326647524557887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012264231","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007953745,0.998024,0.000014804408,0.0013051663,0.000120669705,0.0000012330107,0.0000067957185,0.000001371516,0.00044649583],"genre_scores_gemma":[0.00195408,0.9966859,0.000036580554,0.0008380574,0.0002353666,0.0000036048832,0.000009462867,9.314288e-7,0.00023612945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862885,0.00053569634,0.0001471275,0.000076286386,0.00054565753,0.0000663353],"domain_scores_gemma":[0.9954768,0.0031076472,0.00075851165,0.00007054289,0.0004999591,0.0000865182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030652187,0.0005764518,0.0021590188,0.002745953,0.00041608795,0.0019229695,0.0007861572,0.002991904,0.0069428915],"category_scores_gemma":[0.00802877,0.00041133372,0.001193518,0.003957183,0.0014056138,0.002224029,0.0009989785,0.002272053,0.0011405114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031646612,0.000040963423,0.0004240649,0.042278472,0.0011245878,0.0002591515,0.00013694733,0.0004067355,0.0002478538,0.017163223,0.10962654,0.8279751],"study_design_scores_gemma":[0.0003171066,0.00018123449,0.0046090167,0.06637978,0.0013059846,0.0015008813,0.0003867916,0.00016145947,0.00040963368,0.013912093,0.91078484,0.000051282914],"about_ca_topic_score_codex":0.0062615005,"about_ca_topic_score_gemma":0.011431458,"teacher_disagreement_score":0.0069428915,"about_ca_system_score_codex":0.0022713728,"about_ca_system_score_gemma":0.0025323166,"threshold_uncertainty_score":0.02322632},"labels":[],"label_agreement":null},{"id":"W2013299482","doi":"10.17159/1727-3781/2012/v15i2a2498","title":"Comparative analysis of access to patented HIV/AIDS pharmaceutical medicines through the Canadian and EU TRIPS flexibilities measures: are they efficacious or overly burdensome and ineffective measures?","year":2012,"lang":"en","type":"article","venue":"Potchefstroom Electronic Law Journal/Potchefstroomse Elektroniese Regsblad","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"African Union","keywords":"TRIPS architecture; Access to medicines; Human immunodeficiency virus (HIV); TRIPS Agreement; Medicine; Business; Actuarial science; Traditional medicine; Intellectual property; Virology; Computer science; Political science; Law","score_opus":0.11063137299792307,"score_gpt":0.3449586732713687,"score_spread":0.23432730027344562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013299482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85247856,0.0114020705,0.00071883673,0.0038317288,0.000049746155,0.00019074198,0.009591993,0.00006672763,0.12166964],"genre_scores_gemma":[0.98843014,0.0026721125,0.00024108269,0.00022532235,0.00001672303,0.000016712269,0.001044884,0.0000061031765,0.0073467684],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99763834,0.00025867042,0.00008190944,0.00017540781,0.0010106551,0.00083496416],"domain_scores_gemma":[0.9956255,0.0014835,0.0009767113,0.00016518826,0.0012393139,0.0005098019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001233765,0.00019122788,0.00032580088,0.002548441,0.00091127993,0.0030285476,0.000776788,0.00051407726,0.012164955],"category_scores_gemma":[0.008410447,0.000089553374,0.00057173264,0.004264282,0.0010672346,0.001057284,0.0010379391,0.0008116687,0.0003695262],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003320619,0.0005491262,0.46448004,0.0025351476,0.0015083052,0.0010345917,0.0048771226,0.008254539,0.0044767074,0.1303474,0.02564816,0.3529683],"study_design_scores_gemma":[0.000095149,0.00039925773,0.93692005,0.00024749796,0.00055415,0.00022726922,0.0038628804,0.001679386,0.0015654406,0.0018600855,0.05252088,0.00006796381],"about_ca_topic_score_codex":0.8631804,"about_ca_topic_score_gemma":0.9016341,"teacher_disagreement_score":0.98453254,"about_ca_system_score_codex":0.015467453,"about_ca_system_score_gemma":0.017303597,"threshold_uncertainty_score":0.27525067},"labels":[],"label_agreement":null},{"id":"W2014140411","doi":"10.12927/hcq.2005.17684","title":"Opinions: Another Face of Healthcare Innovation: Commercialization","year":2005,"lang":"en","type":"article","venue":"Healthcare Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Commercialization; Face (sociological concept); Health care; Business; Best practice; Public relations; Marketing; Economic growth; Political science; Management; Economics; Sociology","score_opus":0.10540149285423325,"score_gpt":0.35652408991742957,"score_spread":0.2511225970631963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014140411","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031903925,0.00063199026,0.00009645867,0.9918218,0.0038807413,0.000003495673,0.000037075486,0.0000047626004,0.0032046454],"genre_scores_gemma":[0.009266388,0.0010859151,0.00021182367,0.97818726,0.006483807,0.000011092914,0.00003367027,0.000015328395,0.004704731],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.985637,0.0024252804,0.0009041435,0.0019081001,0.007145819,0.0019796027],"domain_scores_gemma":[0.9325015,0.028185016,0.003075509,0.001752974,0.02697927,0.0075058253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014987656,0.0006700462,0.0009420041,0.001176284,0.004925132,0.0104118455,0.0034025623,0.051828384,0.020384071],"category_scores_gemma":[0.072557665,0.0003744731,0.0012293584,0.0015833005,0.011096318,0.011684526,0.003595638,0.04081161,0.0044811633],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044852415,0.000019916088,0.00065715605,0.000110042325,0.00002348117,0.00027335246,0.00067894754,0.00007722586,0.0002407234,0.0565644,0.93077505,0.010534928],"study_design_scores_gemma":[0.00006808212,0.000028940722,0.0010905706,0.00047716935,0.000037934406,0.00033734174,0.0032698808,0.00023064172,0.00043435558,0.033511203,0.96042055,0.00009330417],"about_ca_topic_score_codex":0.015361648,"about_ca_topic_score_gemma":0.013498296,"teacher_disagreement_score":0.051828384,"about_ca_system_score_codex":0.006351747,"about_ca_system_score_gemma":0.013388849,"threshold_uncertainty_score":0.07926327},"labels":[],"label_agreement":null},{"id":"W2014505378","doi":"10.1186/1472-6963-11-64","title":"Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?","year":2011,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; York University","funders":"Industry Canada; Department of Industry and Science, Australian Government","keywords":"Notice; Compliance (psychology); Business; Tipping point (physics); Law; Political science; Engineering; Psychology; Social psychology","score_opus":0.4058565063433296,"score_gpt":0.4238891179555788,"score_spread":0.018032611612249227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014505378","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016909301,0.012098103,0.0025345134,0.6807378,0.0033587213,0.00029092777,0.000985713,0.00032759653,0.2827573],"genre_scores_gemma":[0.31292224,0.009602101,0.005889689,0.5614531,0.001923148,0.00021464989,0.0006953861,0.00017274731,0.10712699],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9422942,0.004135594,0.0018076815,0.0032919936,0.037063684,0.011406767],"domain_scores_gemma":[0.9471087,0.017070152,0.0034004496,0.0015644134,0.025253488,0.0056027374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022499394,0.0006270046,0.0007223719,0.0029111926,0.017240627,0.018531675,0.005278822,0.02448188,0.010428072],"category_scores_gemma":[0.05415991,0.00089667056,0.0011494746,0.0033886898,0.014698026,0.005582312,0.003449448,0.01586085,0.0012923103],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083142244,0.00010216805,0.0059615984,0.0005562,0.00004791672,0.0010976645,0.004298918,0.00038306846,0.0010750636,0.45246425,0.48052278,0.053407278],"study_design_scores_gemma":[0.00008095715,0.00007784823,0.017220467,0.0011383548,0.00011083506,0.00038502243,0.0031997259,0.0005703046,0.0013396012,0.021535728,0.95408875,0.00025239165],"about_ca_topic_score_codex":0.96251035,"about_ca_topic_score_gemma":0.9723235,"teacher_disagreement_score":0.96251035,"about_ca_system_score_codex":0.12038055,"about_ca_system_score_gemma":0.35100508,"threshold_uncertainty_score":0.8734261},"labels":[],"label_agreement":null},{"id":"W2015182177","doi":"10.1126/scitranslmed.3003490","title":"Recalibrating Intellectual Property Rights to Enhance Translational Research Collaborations","year":2012,"lang":"en","type":"review","venue":"Science Translational Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Provincial Laboratory of Public Health","funders":"National Center for Research Resources","keywords":"Intellectual property; Construct (python library); Translational research; Business; Property rights; Knowledge management; Computer science; Law and economics; Political science; Medicine; Economics; Law","score_opus":0.4425351314643522,"score_gpt":0.4822118095595027,"score_spread":0.03967667809515052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015182177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013579397,0.9369656,0.011920311,0.03076926,0.0009975672,0.00009199792,0.00004689554,0.00006837833,0.017782034],"genre_scores_gemma":[0.04313651,0.9342231,0.011300839,0.006647112,0.0015620103,0.00020504832,0.000075763186,0.000027957547,0.002821713],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98674333,0.0089642815,0.0007277651,0.00064992707,0.0024608427,0.00045392325],"domain_scores_gemma":[0.97098935,0.022858335,0.0030538617,0.001295161,0.0014446016,0.00035873824],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020564498,0.00058622204,0.0011400768,0.003125817,0.0004781986,0.0039485283,0.0020635142,0.0032594055,0.003933985],"category_scores_gemma":[0.028337091,0.0002612491,0.0010487145,0.0033878814,0.0041232733,0.0065297126,0.0032889566,0.002890683,0.001143345],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036035522,0.000052879805,0.00037859907,0.0124149285,0.00014752374,0.00015493373,0.0004113069,0.0012983427,0.0006096545,0.29046255,0.014515698,0.67951757],"study_design_scores_gemma":[0.00007274906,0.00008678604,0.0011996872,0.01893657,0.0001561815,0.0006013314,0.0003546399,0.0006145873,0.00083007634,0.13956289,0.8375476,0.000036803845],"about_ca_topic_score_codex":0.0012059234,"about_ca_topic_score_gemma":0.0022715167,"teacher_disagreement_score":0.9794355,"about_ca_system_score_codex":0.0024915766,"about_ca_system_score_gemma":0.0072350516,"threshold_uncertainty_score":0.10875678},"labels":[],"label_agreement":null},{"id":"W2015351537","doi":"10.1016/j.seizure.2005.12.010","title":"Are there potential problems with generic substitution of antiepileptic drugs?","year":2006,"lang":"en","type":"review","venue":"Seizure","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Dosing; Intensive care medicine; Adverse effect; Bioequivalence; Drug; Epilepsy; Risk analysis (engineering); Psychiatry; Pharmacology; Pharmacokinetics","score_opus":0.07921406813877387,"score_gpt":0.2875214318073167,"score_spread":0.20830736366854286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015351537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002086697,0.967339,0.001513013,0.022099538,0.00036977074,0.000010279052,0.00011893456,0.000014365624,0.006448406],"genre_scores_gemma":[0.022442348,0.9670544,0.0019050129,0.0060282936,0.0013504456,0.0000166801,0.00009538336,0.000010473051,0.0010968851],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988624,0.0004588872,0.00013751499,0.0001190143,0.00033373863,0.000088398294],"domain_scores_gemma":[0.9923815,0.0052562593,0.001380503,0.00017445892,0.0007034001,0.00010392947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004815055,0.0004235794,0.0017947528,0.0014753697,0.00021337527,0.0015928259,0.0012406902,0.00223879,0.008310817],"category_scores_gemma":[0.007862648,0.00025768412,0.0009815169,0.0034082509,0.0014256835,0.0028640698,0.0006540982,0.0019249144,0.0012431814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002613599,0.00008507541,0.0022049309,0.010042989,0.00032526453,0.00036829294,0.00007720775,0.0017469348,0.00048236854,0.03586384,0.023815833,0.92472595],"study_design_scores_gemma":[0.0003887937,0.00039077015,0.014738632,0.015302802,0.00081434095,0.0060376637,0.0005896079,0.001837729,0.0008737195,0.079197414,0.87976354,0.00006492923],"about_ca_topic_score_codex":0.0020994511,"about_ca_topic_score_gemma":0.005403206,"teacher_disagreement_score":0.008310817,"about_ca_system_score_codex":0.0012607408,"about_ca_system_score_gemma":0.0021640214,"threshold_uncertainty_score":0.027802467},"labels":[],"label_agreement":null},{"id":"W2015750704","doi":"10.1177/009286150804200604","title":"Publishing a Drug Information Bulletin: Experiences From a Developing Country","year":2008,"lang":"en","type":"article","venue":"Drug Information Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Publishing; Pharmacy; Library science; Bulletin board; Medicine; Publication; Quarter (Canadian coin); Developing country; Information center; Political science; Family medicine; Advertising; Business; Sociology; Geography; Computer science; Social science","score_opus":0.035906299612316867,"score_gpt":0.23543577925372022,"score_spread":0.19952947964140336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015750704","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8870934,0.0054423125,0.00063773873,0.04818853,0.0004149744,0.00009855825,0.00040819132,0.00009394374,0.05762232],"genre_scores_gemma":[0.9431922,0.008052676,0.0009980898,0.008893948,0.00032021065,0.00002876551,0.0002635965,0.00014153493,0.038109038],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978126,0.0011255534,0.000121938276,0.00011020556,0.00043298665,0.0003967107],"domain_scores_gemma":[0.9739164,0.009911083,0.0033284372,0.00058158056,0.0021782198,0.0100842165],"candidate_categories":["scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.0041513955,0.00026506674,0.000319022,0.001240809,0.00914854,0.008299785,0.00089387735,0.0022130674,0.013718454],"category_scores_gemma":[0.014747239,0.0003673051,0.00024033082,0.0030205145,0.0029024084,0.0034558317,0.003926432,0.0036690908,0.001598464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000793365,0.001613623,0.15394424,0.0012017037,0.000118355085,0.03247895,0.53221214,0.0006229347,0.0057676225,0.011581413,0.10352903,0.15613665],"study_design_scores_gemma":[0.0000836789,0.0006464098,0.06833504,0.00036644563,0.00008523277,0.0066543007,0.51863605,0.00034566186,0.0015253746,0.0008259201,0.4024067,0.00008914837],"about_ca_topic_score_codex":0.018535674,"about_ca_topic_score_gemma":0.035700057,"teacher_disagreement_score":0.99170023,"about_ca_system_score_codex":0.003413499,"about_ca_system_score_gemma":0.006482988,"threshold_uncertainty_score":0.045892835},"labels":[],"label_agreement":null},{"id":"W2016116452","doi":"10.12927/hcq.2013.23040","title":"Ethical Framework for Resource Allocation during a Drug Supply Shortage","year":2012,"lang":"en","type":"article","venue":"Healthcare Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Economic shortage; Scarcity; Business; Health care; Context (archaeology); Scope (computer science); Redistribution (election); Medicine; Economic growth; Economics; Political science; Government (linguistics)","score_opus":0.06107863323110095,"score_gpt":0.3420003014944191,"score_spread":0.28092166826331816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016116452","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034338452,0.0018625751,0.32050937,0.28433043,0.0012353833,0.00082226575,0.00025035487,0.00007858714,0.35657257],"genre_scores_gemma":[0.8979935,0.00092189916,0.05828076,0.020785442,0.0014730685,0.0012748333,0.000072820745,0.000057671255,0.019139934],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9515665,0.034553353,0.0016206948,0.0026922608,0.0058765304,0.0036907233],"domain_scores_gemma":[0.9473696,0.035210032,0.0052960017,0.002985659,0.006285314,0.0028534632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.049910307,0.0007648544,0.0008337978,0.0015563774,0.006375618,0.009203741,0.002114886,0.012931783,0.0056087994],"category_scores_gemma":[0.0693258,0.00063904765,0.0011051644,0.0011447639,0.025076203,0.008480406,0.0071852487,0.01042633,0.0006256665],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004977873,0.000015356063,0.00013143993,0.0000120520435,0.000003898081,0.00009148758,0.00048881094,0.0013554309,0.00003118475,0.9953479,0.0015815982,0.0009359571],"study_design_scores_gemma":[0.000041016232,0.000016796675,0.00016870064,0.000068555695,0.0000044521867,0.000073205934,0.0006300156,0.004198554,0.000045079792,0.9817717,0.012962821,0.000019128423],"about_ca_topic_score_codex":0.005950068,"about_ca_topic_score_gemma":0.003994943,"teacher_disagreement_score":0.049910307,"about_ca_system_score_codex":0.011523364,"about_ca_system_score_gemma":0.021504043,"threshold_uncertainty_score":0.2639541},"labels":[],"label_agreement":null},{"id":"W2016339789","doi":"10.2307/3527681","title":"Pushing the Borders: The Moral Dilemma of International Internet Pharmacies","year":2004,"lang":"en","type":"article","venue":"The Hastings Center Report","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Dilemma; The Internet; Moral dilemma; Pharmacy; Business; Ethical dilemma; Internet privacy; Public relations; Political science; Psychology; Law; Social psychology; Computer science; World Wide Web","score_opus":0.09138039927924876,"score_gpt":0.31007249083598376,"score_spread":0.218692091556735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016339789","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004008142,0.004327088,0.003313084,0.88242227,0.002160986,0.000031659158,0.000033136304,0.00006378662,0.103639856],"genre_scores_gemma":[0.23621224,0.005659937,0.0034052727,0.7190316,0.008537541,0.0001837558,0.000051539148,0.00025593382,0.026662154],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9728485,0.014850175,0.0007567592,0.0019822128,0.006481593,0.0030807785],"domain_scores_gemma":[0.94949156,0.031876475,0.0026731545,0.003647864,0.004864445,0.0074464553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035153303,0.0006281338,0.0009847671,0.0016560087,0.015739273,0.029129043,0.003031842,0.037385978,0.0139577845],"category_scores_gemma":[0.065038934,0.00078477623,0.0009956146,0.0013886185,0.038298644,0.034477398,0.013060677,0.041687004,0.0032147556],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031768042,0.00006421276,0.00041767684,0.000050090188,0.00001405793,0.00043839982,0.0032626232,0.00012994549,0.000072826595,0.84288335,0.13766326,0.01497182],"study_design_scores_gemma":[0.00008968778,0.000064682725,0.00043998097,0.0005580117,0.000022196467,0.0010673153,0.008160486,0.00069278356,0.00025302175,0.4742444,0.5143235,0.000083943734],"about_ca_topic_score_codex":0.0039286898,"about_ca_topic_score_gemma":0.0040352023,"teacher_disagreement_score":0.037385978,"about_ca_system_score_codex":0.005639063,"about_ca_system_score_gemma":0.01182276,"threshold_uncertainty_score":0.18591064},"labels":[],"label_agreement":null},{"id":"W2016350863","doi":"10.2217/dmt.10.5","title":"Improving access to insulin: what can be done?","year":2011,"lang":"en","type":"article","venue":"Diabetes Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Medicine; Insulin; Insulin degludec; Internal medicine; Intensive care medicine; Endocrinology; Hypoglycemia; Insulin glargine","score_opus":0.09691919552221963,"score_gpt":0.27278003648240057,"score_spread":0.17586084096018095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016350863","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012567361,0.23165761,0.00070835423,0.7586683,0.003611127,0.000020355075,0.0002782106,0.000025662512,0.003773669],"genre_scores_gemma":[0.10822689,0.7014824,0.0027838754,0.15470447,0.029304747,0.00023629778,0.0004709913,0.00005376697,0.002736551],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99442226,0.0033180611,0.0004782038,0.00033039905,0.0009990013,0.00045215056],"domain_scores_gemma":[0.93794733,0.04407503,0.004915549,0.00083313865,0.00790895,0.004319942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012581921,0.00094353966,0.002574632,0.0020538121,0.0008094519,0.006850477,0.002066352,0.006053074,0.02566217],"category_scores_gemma":[0.05865496,0.00031874957,0.0013186635,0.0026747456,0.0028714847,0.0072817868,0.0023218687,0.006582166,0.002294329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013569607,0.0005243298,0.0060225483,0.014158376,0.0006768779,0.0003581294,0.00030465142,0.0034602364,0.00009368585,0.0686787,0.32955182,0.5748138],"study_design_scores_gemma":[0.0010697108,0.00064959045,0.017815098,0.10444283,0.0011147558,0.00066844246,0.0040957495,0.006106561,0.00037604533,0.3947593,0.46863967,0.00026220133],"about_ca_topic_score_codex":0.010098263,"about_ca_topic_score_gemma":0.0067529776,"teacher_disagreement_score":0.02566217,"about_ca_system_score_codex":0.0038975114,"about_ca_system_score_gemma":0.008695484,"threshold_uncertainty_score":0.08584857},"labels":[],"label_agreement":null},{"id":"W2018123025","doi":"10.1016/j.jval.2014.03.156","title":"Dissecting The Delays: The Impact Of New Policies And Practices On Total Time To Reimbursement In Ontario","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Reimbursement; Receipt; Notice; Business; Medicine; Actuarial science; Operations management; Accounting; Family medicine; Health care; Economics; Political science","score_opus":0.15040004591590553,"score_gpt":0.37749601616266476,"score_spread":0.22709597024675923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018123025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96769834,0.0011554979,0.0003709757,0.020587565,0.00005451609,0.000039531435,0.0018479122,0.000014978335,0.008230653],"genre_scores_gemma":[0.9965833,0.00040726893,0.00016410941,0.00037800116,0.000023862722,0.000010481273,0.00021587026,0.000009850491,0.0022073484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941016,0.0009300062,0.00033385778,0.00033065592,0.0018083759,0.0024955517],"domain_scores_gemma":[0.9714848,0.008767552,0.0074442457,0.0005021791,0.0056693708,0.006131785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033584852,0.00018202698,0.00041623373,0.0010739419,0.002508443,0.0026446558,0.0013917311,0.0012166469,0.004466688],"category_scores_gemma":[0.032260146,0.00037184224,0.000673695,0.0031373221,0.0017007509,0.0016235776,0.0018915217,0.0020618103,0.00016661003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011077038,0.00030134025,0.86918193,0.00034003204,0.00027543228,0.00069874665,0.01794333,0.013737628,0.00055266026,0.026805552,0.021776907,0.047278706],"study_design_scores_gemma":[0.00009723075,0.00015065254,0.9513054,0.00013136139,0.00012160836,0.00011821901,0.017167414,0.0073493295,0.00025055668,0.00359378,0.019652762,0.000061687264],"about_ca_topic_score_codex":0.9866638,"about_ca_topic_score_gemma":0.99327916,"teacher_disagreement_score":0.89539766,"about_ca_system_score_codex":0.10460237,"about_ca_system_score_gemma":0.117660865,"threshold_uncertainty_score":0.75894684},"labels":[],"label_agreement":null},{"id":"W2018336017","doi":"10.1111/1475-6773.01058","title":"Quantifying Components of Drug Expenditure Inflation: The British Columbia Seniors' Drug Benefit Plan","year":2002,"lang":"en","type":"article","venue":"Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Per capita; Medical prescription; Incentive; Drug; Prescription drug; Public economics; Product (mathematics); Population; Medicine; Business; Actuarial science; Environmental health; Pharmacology; Economics","score_opus":0.170694112784534,"score_gpt":0.3744954558472355,"score_spread":0.20380134306270148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018336017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97248757,0.0007617989,0.0011559597,0.0008290182,0.000010391356,0.00018310656,0.009960171,0.000031455646,0.01458042],"genre_scores_gemma":[0.99419963,0.00019472295,0.00071133825,0.0000542991,0.000008544904,0.000027862956,0.003856682,0.000004353485,0.0009425877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733824,0.0005570833,0.00017301849,0.00017427973,0.001337281,0.0004200516],"domain_scores_gemma":[0.9950401,0.001165958,0.0012456429,0.00020248698,0.0019700092,0.00037578764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019090581,0.00030940818,0.00029443312,0.003360968,0.00052849296,0.0013637845,0.00051968166,0.00032460882,0.0015993523],"category_scores_gemma":[0.013567152,0.00022283601,0.0003691076,0.006386163,0.000441218,0.00037264838,0.00092513324,0.0004828495,0.00014029056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017304014,0.00003643482,0.97246677,0.000060833354,0.0001500096,0.00007890512,0.00017931128,0.007502928,0.00008933868,0.0012446444,0.0019795108,0.016038332],"study_design_scores_gemma":[0.000005795217,0.000017736458,0.9912134,0.000019951338,0.00004017717,0.000033996384,0.00020377398,0.006489386,0.000059034537,0.00025429102,0.0016520787,0.000010336729],"about_ca_topic_score_codex":0.86239,"about_ca_topic_score_gemma":0.8637251,"teacher_disagreement_score":0.13761002,"about_ca_system_score_codex":0.016608132,"about_ca_system_score_gemma":0.009229589,"threshold_uncertainty_score":0.2768408},"labels":[],"label_agreement":null},{"id":"W2019670979","doi":"10.1126/science.311.5758.161c","title":"Canada Targets Chemicals","year":2006,"lang":"en","type":"article","venue":"Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computational biology; Chemistry; Biology","score_opus":0.027073133688221212,"score_gpt":0.2486312245197851,"score_spread":0.2215580908315639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019670979","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025594942,0.0035318832,0.0019667575,0.02464399,0.0014482433,0.0005393003,0.0142734945,0.0009533748,0.9500834],"genre_scores_gemma":[0.019624,0.005765528,0.00519249,0.019605938,0.00015266727,0.0002005161,0.009289238,0.00032904948,0.93984056],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993636,0.00017121021,0.000084256426,0.00038817676,0.005007224,0.0007131844],"domain_scores_gemma":[0.9901244,0.0003197468,0.00019041856,0.00025348194,0.007857119,0.0012548572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017365408,0.0010831145,0.00057268166,0.0033030203,0.0066270665,0.0043325075,0.0028820701,0.0034609707,0.14809535],"category_scores_gemma":[0.005710059,0.0007905373,0.00075330475,0.0031242233,0.0013448712,0.0012196028,0.0014683973,0.0028894532,0.032362897],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044991004,0.000067741654,0.0011950571,0.00025364163,0.000012472526,0.0001809408,0.000086789114,0.00025416582,0.002024129,0.043409586,0.9159646,0.036505822],"study_design_scores_gemma":[0.00000767348,0.000012096948,0.0005871424,0.000045727484,0.0000051293364,0.00003839511,0.000056946123,0.00006543442,0.0006068474,0.00068165374,0.9978853,0.0000076068036],"about_ca_topic_score_codex":0.91250926,"about_ca_topic_score_gemma":0.95275116,"teacher_disagreement_score":0.14809535,"about_ca_system_score_codex":0.03673023,"about_ca_system_score_gemma":0.13612969,"threshold_uncertainty_score":0.49542832},"labels":[],"label_agreement":null},{"id":"W2020026521","doi":"10.1038/clpt.2009.243","title":"The (Possible) Impact of Comparative Effectiveness Research on Pharmaceutical Industry Decision Making","year":2010,"lang":"en","type":"review","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nickel Institute","funders":"National Institutes of Health","keywords":"Pharmaceutical industry; Comparative effectiveness research; Management science; Business; Medicine; Pharmacology; Economics; Alternative medicine","score_opus":0.637574940144511,"score_gpt":0.6468215544832479,"score_spread":0.009246614338736858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020026521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009296112,0.96121687,0.0043163067,0.02346667,0.0025867415,0.00013431752,0.00018858317,0.000012394903,0.007148577],"genre_scores_gemma":[0.09188009,0.8509076,0.01372088,0.031688366,0.009500556,0.00087948894,0.00020779895,0.000053673735,0.0011615988],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.7018358,0.25712958,0.011175777,0.0076389876,0.020903716,0.0013162508],"domain_scores_gemma":[0.18689038,0.78893346,0.009382357,0.008219663,0.0060160886,0.00055809465],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.27511358,0.0023458346,0.009338273,0.006839582,0.0008663161,0.008741517,0.0045487667,0.009329279,0.016536519],"category_scores_gemma":[0.51801693,0.0010559597,0.0065860143,0.010625192,0.009227937,0.013853007,0.0044481833,0.007955929,0.0012610435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032296611,0.00020276333,0.0019028722,0.10237677,0.014537714,0.00026431077,0.00046964342,0.0030626394,0.00030057362,0.31021866,0.013229855,0.5502045],"study_design_scores_gemma":[0.0028355566,0.0016961863,0.0076064784,0.17656156,0.017646855,0.0010505838,0.0008311539,0.0031395555,0.0010916434,0.60801136,0.17930622,0.00022285372],"about_ca_topic_score_codex":0.0039934367,"about_ca_topic_score_gemma":0.0039265705,"teacher_disagreement_score":0.27511358,"about_ca_system_score_codex":0.008935868,"about_ca_system_score_gemma":0.009895293,"threshold_uncertainty_score":0.893914},"labels":[],"label_agreement":null},{"id":"W2020503419","doi":"10.1503/cmaj.061513","title":"Supreme Court rules against drug patent \"evergreening\"","year":2006,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Supreme court; Law; Supreme Court Decisions; Drug industry; Generic drug; Head (geology); Law and economics; Operations research; Political science; Medicine; Drug; Economics; Engineering; Pharmacology; Engineering ethics","score_opus":0.02847752819179248,"score_gpt":0.2285559366361893,"score_spread":0.20007840844439684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020503419","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014135923,0.003966611,0.0071792006,0.21904893,0.004163537,0.00014570825,0.00082602387,0.0003560922,0.7501779],"genre_scores_gemma":[0.4253257,0.0024504159,0.0060250885,0.4263112,0.005949808,0.0004176959,0.0005352892,0.00020103288,0.13278374],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9795202,0.0022832304,0.00085040554,0.0022155505,0.01135336,0.003777211],"domain_scores_gemma":[0.98006105,0.010803524,0.0008345729,0.0017851163,0.0054714833,0.0010442822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016000226,0.00077082333,0.0013571817,0.0016589123,0.010702014,0.01160558,0.004057911,0.028816383,0.007144091],"category_scores_gemma":[0.045641907,0.00091382145,0.0015580204,0.0015060417,0.00865805,0.004464958,0.0039993855,0.024065522,0.0024799695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003087111,0.000026699216,0.00038584598,0.00002479104,0.000027294887,0.00023163379,0.00049856876,0.00021633887,0.000234785,0.82743907,0.16582856,0.005055605],"study_design_scores_gemma":[0.00016558624,0.000071897586,0.0014098434,0.00039623043,0.00021196625,0.00024922146,0.0004235032,0.0020370234,0.0016485302,0.42061526,0.5726565,0.00011451288],"about_ca_topic_score_codex":0.061889574,"about_ca_topic_score_gemma":0.07809357,"teacher_disagreement_score":0.9381104,"about_ca_system_score_codex":0.00725059,"about_ca_system_score_gemma":0.01944263,"threshold_uncertainty_score":0.12305868},"labels":[],"label_agreement":null},{"id":"W2021009463","doi":"10.3821/1913-701x(2008)141[21a:pntic]2.0.co;2","title":"Pharmacist named to immunization coalition","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunization; Pharmacist; Medicine; Family medicine; Pharmacy; Immunology; Antibody","score_opus":0.10187058854414159,"score_gpt":0.273123690131257,"score_spread":0.17125310158711538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021009463","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010550488,0.0024964556,0.00090303126,0.4628414,0.02043636,0.0008591303,0.005236564,0.0006622391,0.49601433],"genre_scores_gemma":[0.02258606,0.0007687546,0.0003466767,0.12605722,0.003665542,0.00017960137,0.0013308577,0.00012791331,0.8449373],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948881,0.00033746473,0.00010453675,0.00048696357,0.0021167828,0.0020662562],"domain_scores_gemma":[0.9911199,0.00065681234,0.00019392862,0.0003840109,0.0022106816,0.0054346756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00277306,0.00048521964,0.0007858793,0.0014277262,0.007129505,0.004620972,0.0017885768,0.00956157,0.12701857],"category_scores_gemma":[0.009095548,0.0006545182,0.0010066048,0.00090051396,0.00075269194,0.001335383,0.0030111193,0.008376563,0.027413461],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062144085,0.000096284704,0.0013128794,0.00002261349,0.000013820727,0.0002536931,0.00006067622,0.00004072731,0.00016896446,0.004684847,0.9810085,0.0122748725],"study_design_scores_gemma":[0.000060059214,0.00003140595,0.0045349104,0.000024243724,0.000011662524,0.00009762844,0.00010148819,0.000085090534,0.00018838236,0.0005624844,0.9942934,0.000009311361],"about_ca_topic_score_codex":0.20404488,"about_ca_topic_score_gemma":0.33607385,"teacher_disagreement_score":0.20404488,"about_ca_system_score_codex":0.010740218,"about_ca_system_score_gemma":0.057707284,"threshold_uncertainty_score":0.42491943},"labels":[],"label_agreement":null},{"id":"W2021329838","doi":"10.3821/1913-701x(2008)141[13:pccbct]2.0.co;2","title":"Pharmacists counter Competition Bureau claim that generic drug rebates don't benefit consumers","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Competition (biology); Over-the-counter; Business; Drug; Advertising; Medicine; Pharmacology; Medical prescription","score_opus":0.0923088144656868,"score_gpt":0.2633609550079636,"score_spread":0.1710521405422768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021329838","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042558797,0.005064208,0.0023900643,0.403047,0.004559137,0.00039813216,0.0024294998,0.0007603752,0.53879285],"genre_scores_gemma":[0.4810603,0.0029191056,0.0017903589,0.3272667,0.008332266,0.00015945292,0.0008705776,0.00022779753,0.17737345],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97727406,0.0017834825,0.0007134852,0.0013113267,0.016381748,0.0025359206],"domain_scores_gemma":[0.9303339,0.036362607,0.007846466,0.0031294911,0.017855758,0.0044717174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011222439,0.000759768,0.0016321493,0.0029063884,0.004682796,0.007008135,0.0026129447,0.03063334,0.03348643],"category_scores_gemma":[0.094974354,0.0008932885,0.0017964552,0.001798791,0.003005616,0.002489661,0.0021518725,0.011980352,0.007765932],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004818989,0.00028759695,0.014578597,0.00022757062,0.00036964365,0.00060045824,0.00043600652,0.00066681486,0.0011369664,0.07755091,0.8561306,0.047533028],"study_design_scores_gemma":[0.0018155444,0.0005059599,0.06384291,0.00066862546,0.0011089483,0.0012494331,0.0007014268,0.0067108045,0.003605356,0.039924063,0.87960404,0.00026287333],"about_ca_topic_score_codex":0.17717208,"about_ca_topic_score_gemma":0.16911957,"teacher_disagreement_score":0.9893113,"about_ca_system_score_codex":0.010688735,"about_ca_system_score_gemma":0.029333727,"threshold_uncertainty_score":0.35228163},"labels":[],"label_agreement":null},{"id":"W2021619142","doi":"10.2190/y8ur-ywvr-budp-cdr0","title":"Intellectual Property Rights and the Canadian Pharmaceutical Marketplace: Where Do We Go from Here?","year":2005,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Intellectual property; Order (exchange); Access to medicines; Argument (complex analysis); Pharmaceutical industry; Investment (military); International trade; Patent Act; Law and economics; TRIPS architecture; Business; Economics; Political science; Law; Patent law; Medicine; Finance; Pharmacology","score_opus":0.03862274916873651,"score_gpt":0.31634609149799225,"score_spread":0.2777233423292558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021619142","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046285847,0.10258876,0.00095492066,0.7905613,0.0012630246,0.000023643554,0.00034884588,0.00004575465,0.09958514],"genre_scores_gemma":[0.39826062,0.37695834,0.0057469807,0.15466087,0.004076506,0.00006123711,0.0005561154,0.0001160404,0.05956331],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99495196,0.0007211511,0.000105182204,0.00030244337,0.002449538,0.0014697949],"domain_scores_gemma":[0.9911323,0.0024109674,0.00070498715,0.00021128167,0.0042827483,0.0012576581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003205424,0.00067837856,0.0009355351,0.0042665307,0.013009281,0.019386414,0.0021881058,0.006625494,0.016757041],"category_scores_gemma":[0.014431682,0.0003403666,0.0006971197,0.009207721,0.020319212,0.014456532,0.0027754994,0.0060937833,0.0011204783],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003462621,0.0000286256,0.0022469906,0.0003564313,0.00001997501,0.0001942724,0.0017867011,0.00037167233,0.0000856542,0.7892982,0.1307411,0.074835755],"study_design_scores_gemma":[0.000041051317,0.000022086595,0.010365942,0.001609195,0.00006281172,0.00014839266,0.009137448,0.0009159072,0.0002223342,0.24757275,0.7297234,0.00017874087],"about_ca_topic_score_codex":0.9781081,"about_ca_topic_score_gemma":0.9838124,"teacher_disagreement_score":0.11600935,"about_ca_system_score_codex":0.11600935,"about_ca_system_score_gemma":0.16048734,"threshold_uncertainty_score":0.8417107},"labels":[],"label_agreement":null},{"id":"W2021817527","doi":"10.1001/jama.300.12.1453","title":"Risks and Benefits of Importing Prescription Medications From Lower-Income Countries","year":2008,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Family medicine; Otorhinolaryngology; Psychiatry","score_opus":0.082842806099664,"score_gpt":0.29137975669927507,"score_spread":0.20853695059961108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021817527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6885258,0.06808521,0.0011269368,0.07471417,0.0004653454,0.00011580026,0.009565219,0.000094093244,0.15730739],"genre_scores_gemma":[0.96443266,0.026530067,0.00047917207,0.0030353307,0.00039364022,0.000025219355,0.001066845,0.00001821968,0.004018894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976197,0.0012326719,0.0002553701,0.00011479595,0.0005177045,0.0002597763],"domain_scores_gemma":[0.9760517,0.012323207,0.008264129,0.000784484,0.0016310742,0.00094551686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026490993,0.00014664898,0.00021572717,0.001765452,0.0005203025,0.0022685695,0.0002218534,0.0010091868,0.012887323],"category_scores_gemma":[0.025963537,0.00019032492,0.00095578557,0.0025990175,0.0008499171,0.0012312217,0.00117248,0.0010900269,0.0006758245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020559004,0.00033768557,0.7850082,0.0010113562,0.0008876472,0.00095120416,0.0005583243,0.0016571822,0.0003054665,0.017890964,0.026371751,0.16296431],"study_design_scores_gemma":[0.00021183545,0.00047065405,0.9423264,0.0019789755,0.00086535537,0.002306917,0.0024343205,0.0014415748,0.0008593018,0.006056519,0.040972076,0.00007607561],"about_ca_topic_score_codex":0.010851351,"about_ca_topic_score_gemma":0.012492099,"teacher_disagreement_score":0.012887323,"about_ca_system_score_codex":0.0012829016,"about_ca_system_score_gemma":0.0010586894,"threshold_uncertainty_score":0.043112397},"labels":[],"label_agreement":null},{"id":"W2022022436","doi":"10.1007/s11673-013-9494-z","title":"Drugs, Money, and Power: The Canadian Drug Shortage","year":2013,"lang":"en","type":"article","venue":"Journal of Bioethical Inquiry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"Sandoz Canada; Australian Government","keywords":"Economic shortage; Scarcity; Medical law; Business; Obligation; Health care; Order (exchange); Public relations; Medicine; Law; Government (linguistics); Economics; Political science; Finance; Market economy","score_opus":0.07767136248439625,"score_gpt":0.3065182377083792,"score_spread":0.22884687522398295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022022436","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044687264,0.029323773,0.00021571082,0.87036705,0.0011697266,0.000020956846,0.0005850993,0.000017687938,0.053612765],"genre_scores_gemma":[0.8240495,0.04228249,0.00062433904,0.09494258,0.0016241869,0.00002959191,0.0002846319,0.000042644548,0.036119983],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99686795,0.00035043695,0.000078458,0.0001572746,0.0012865112,0.001259417],"domain_scores_gemma":[0.989475,0.0023130476,0.0006172772,0.0001654554,0.0036201423,0.0038090106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038885102,0.0003356639,0.00062529184,0.0028707557,0.017459605,0.007198874,0.0018186226,0.0066563864,0.01397763],"category_scores_gemma":[0.016852679,0.00038768802,0.0004006208,0.0072083953,0.009191614,0.0033772544,0.002959398,0.0061759097,0.00048882136],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00026979187,0.000113230824,0.021807598,0.00050223456,0.000043728585,0.001235372,0.0075761857,0.0018760388,0.00029680188,0.31582665,0.5283778,0.12207453],"study_design_scores_gemma":[0.00013845004,0.000042818865,0.06671706,0.0008039744,0.00007473308,0.0004853256,0.03041338,0.0021001298,0.00023992665,0.061862405,0.83691823,0.00020349283],"about_ca_topic_score_codex":0.9937896,"about_ca_topic_score_gemma":0.99764246,"teacher_disagreement_score":0.8302889,"about_ca_system_score_codex":0.1697111,"about_ca_system_score_gemma":0.27817556,"threshold_uncertainty_score":0.96301746},"labels":[],"label_agreement":null},{"id":"W2022778498","doi":"10.3386/w16431","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation","year":2010,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Competition (biology); Legislation; Loyalty; Business; Brand loyalty; Industrial organization; Advertising; Marketing; Commerce; Economics","score_opus":0.3011440009757697,"score_gpt":0.4848980425436471,"score_spread":0.1837540415678774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022778498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661361,0.009103157,0.00025233065,0.005997181,0.0000820271,0.000015304402,0.00044067515,0.000005716983,0.017967552],"genre_scores_gemma":[0.98884165,0.0046452093,0.0001578697,0.0020788729,0.00040940085,0.0000133844915,0.00042535807,0.0000069653247,0.0034211942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924386,0.00010421095,0.000049865765,0.00009664537,0.0002810022,0.00022442281],"domain_scores_gemma":[0.99637467,0.0006383967,0.0018472647,0.000063114305,0.00038084874,0.0006957636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013882357,0.000089077526,0.0002810412,0.0012562171,0.0011394705,0.003235728,0.0003742549,0.001361523,0.0027040013],"category_scores_gemma":[0.0049502025,0.0001407233,0.0003239441,0.002386309,0.0014189497,0.0024704882,0.0012171014,0.0020220887,0.00028157706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074091495,0.00096554257,0.76081705,0.00027648805,0.00012788568,0.0007312104,0.014563244,0.0011643047,0.0010288911,0.07445206,0.011263726,0.13386871],"study_design_scores_gemma":[0.000007936212,0.00019545566,0.9741813,0.00015301719,0.000027391488,0.00028194752,0.0033293758,0.0007223675,0.00020875949,0.0033818686,0.01747948,0.000031003954],"about_ca_topic_score_codex":0.035936613,"about_ca_topic_score_gemma":0.052818898,"teacher_disagreement_score":0.035936613,"about_ca_system_score_codex":0.0030618764,"about_ca_system_score_gemma":0.0017929896,"threshold_uncertainty_score":0.07145488},"labels":[],"label_agreement":null},{"id":"W2022953054","doi":"10.1177/1078155212442562","title":"Using expired supply in times of drug shortage","year":2012,"lang":"en","type":"letter","venue":"Journal of Oncology Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Economic shortage; Drug; Intensive care medicine; Pharmacology; Emergency medicine","score_opus":0.18364378929511835,"score_gpt":0.4199983429826919,"score_spread":0.23635455368757355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022953054","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038984545,0.0020495502,0.004563506,0.9317858,0.003232935,0.00002611238,0.00040948243,0.0000962415,0.01885175],"genre_scores_gemma":[0.7256305,0.003333818,0.0043769125,0.22965008,0.01673655,0.000057233017,0.00022990764,0.00011163122,0.01987326],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976865,0.0013371753,0.0002532058,0.00016365947,0.00034824465,0.00021118642],"domain_scores_gemma":[0.9499095,0.041158672,0.0024843942,0.0013051505,0.0029945148,0.002147812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058822036,0.00021850337,0.0004530071,0.0007902853,0.0010589497,0.002543238,0.0009833964,0.008190811,0.008141291],"category_scores_gemma":[0.07387376,0.00031959458,0.0004671405,0.00077083585,0.0010247935,0.0052360916,0.0013593736,0.0085213445,0.0009513226],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012325463,0.0004532237,0.11112235,0.00042523755,0.00017146095,0.013361659,0.002927494,0.005763272,0.00097118045,0.060256798,0.6068021,0.1965127],"study_design_scores_gemma":[0.0005020916,0.00090270117,0.0731899,0.001676994,0.0001549231,0.010369713,0.0084899645,0.05716483,0.0030861911,0.2184698,0.6257133,0.00027963842],"about_ca_topic_score_codex":0.0037145973,"about_ca_topic_score_gemma":0.0060648704,"teacher_disagreement_score":0.008190811,"about_ca_system_score_codex":0.0013944681,"about_ca_system_score_gemma":0.0015990927,"threshold_uncertainty_score":0.031108439},"labels":[],"label_agreement":null},{"id":"W2023356500","doi":"10.1007/s40258-013-0052-y","title":"Private Expenditures on Brand Name Prescription Drugs after Generic Entry","year":2013,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of British Columbia; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Generic drug; Brand names; Medical prescription; Drug; Business; Prescription drug; Medicine; Pharmacology; Marketing","score_opus":0.055373062857518564,"score_gpt":0.32074227162697666,"score_spread":0.2653692087694581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023356500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94773424,0.0019219363,0.0009450409,0.0052666226,0.00011615137,0.000043825807,0.027659906,0.00012857054,0.016183717],"genre_scores_gemma":[0.97768027,0.0011176564,0.00017993679,0.00027456897,0.0001620093,0.000013129107,0.008033722,0.000014353084,0.012524405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871254,0.00016183467,0.00010009512,0.00015553889,0.00022974206,0.000640206],"domain_scores_gemma":[0.9947314,0.0018727944,0.0021722277,0.0002220406,0.00036456526,0.00063708925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081634166,0.00030606356,0.00068040553,0.0011067521,0.00038902153,0.0017746608,0.00040705415,0.0013381094,0.010167355],"category_scores_gemma":[0.0053645503,0.0005049885,0.0012521191,0.001679666,0.0005226979,0.0015076661,0.00073108554,0.0017119151,0.00088474585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012579117,0.0011146471,0.78930247,0.0008286049,0.0011236755,0.0019461069,0.0005746205,0.031140335,0.004095921,0.045831613,0.033365004,0.07809792],"study_design_scores_gemma":[0.0003650728,0.0006673291,0.95828044,0.00009005575,0.0005110718,0.0009839543,0.00057765876,0.010721887,0.0028652146,0.009200978,0.015688272,0.000048098034],"about_ca_topic_score_codex":0.047071833,"about_ca_topic_score_gemma":0.049203847,"teacher_disagreement_score":0.047071833,"about_ca_system_score_codex":0.00381072,"about_ca_system_score_gemma":0.0026211978,"threshold_uncertainty_score":0.09359568},"labels":[],"label_agreement":null},{"id":"W2023573506","doi":"10.1016/j.jval.2011.08.1043","title":"PRM12 An Application of a Proposed Framework for Formulary Listing in Low-income Countries: Case of Côte d'Ivoire","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Formulary; Reimbursement; Listing (finance); Actuarial science; Medicine; Prior authorization; Family medicine; Business; Health care; Finance; Economics; Pharmacology; Economic growth","score_opus":0.12049046560661278,"score_gpt":0.3506844670838989,"score_spread":0.2301940014772861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023573506","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.098038,0.0020861805,0.4645171,0.028848736,0.0006619613,0.0008759595,0.0037026051,0.0008575755,0.40041193],"genre_scores_gemma":[0.82067984,0.00079690723,0.11137511,0.0009951115,0.0004016609,0.000404271,0.0007848831,0.00009859752,0.06446356],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99621767,0.002102938,0.0001471716,0.0005112543,0.00046970934,0.00055134244],"domain_scores_gemma":[0.99560565,0.0022096152,0.00049841503,0.00058636256,0.00089868676,0.00020133064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040508946,0.00054103014,0.00095740665,0.0018277116,0.00210558,0.0054639573,0.0029520388,0.004515853,0.037149325],"category_scores_gemma":[0.011428156,0.00050491485,0.0019920403,0.0028543577,0.0016769456,0.003915798,0.0020001945,0.0025682587,0.0014106869],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024376222,0.000057642672,0.001250166,0.00007508692,0.00002954884,0.00042879436,0.00020400932,0.01679408,0.000091535294,0.9591135,0.009422835,0.012508433],"study_design_scores_gemma":[0.00016126283,0.0001767417,0.0042287568,0.0001779586,0.00010421527,0.0005469151,0.0009747311,0.22512303,0.00040031105,0.7143028,0.053708978,0.000094380885],"about_ca_topic_score_codex":0.04010486,"about_ca_topic_score_gemma":0.040661886,"teacher_disagreement_score":0.04010486,"about_ca_system_score_codex":0.0029999958,"about_ca_system_score_gemma":0.0040379837,"threshold_uncertainty_score":0.124276936},"labels":[],"label_agreement":null},{"id":"W2023657343","doi":"10.1186/1472-698x-10-1","title":"Framing access to medicines in developing countries: an analysis of media coverage of Canada's Access to Medicines Regime","year":2010,"lang":"en","type":"article","venue":"BMC International Health and Human Rights","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Framing (construction); Newspaper; Legislation; Stakeholder; Civil society; Public relations; Government (linguistics); Intellectual property; Developing country; Political science; News media; Public administration; Business; Economic growth; Law; Economics; Engineering; Politics","score_opus":0.0704420946088392,"score_gpt":0.381917748642545,"score_spread":0.3114756540337058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023657343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9066183,0.0050978987,0.0005901145,0.009693091,0.00020995639,0.00025882648,0.004220072,0.000035766643,0.073276006],"genre_scores_gemma":[0.9875865,0.0048861727,0.00072031823,0.0012477685,0.000096464726,0.00013717372,0.001281282,0.000043962344,0.0040003257],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9949044,0.001161234,0.00025138297,0.00033364756,0.0023540445,0.0009952749],"domain_scores_gemma":[0.95420986,0.02754794,0.004894708,0.00056778546,0.010974593,0.0018051793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056702895,0.0005670516,0.0005420976,0.015393284,0.011853232,0.007803183,0.0014083185,0.0011862213,0.004031095],"category_scores_gemma":[0.028125485,0.00044509408,0.00036169557,0.027433695,0.0064034844,0.0024291766,0.003197052,0.0017243507,0.00019421648],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010212373,0.00004311767,0.05255848,0.0012435993,0.00005399304,0.0019248766,0.9003782,0.00013783228,0.001020845,0.004557508,0.008070433,0.029908963],"study_design_scores_gemma":[0.000010969023,0.000031455755,0.13035902,0.0014192481,0.00008217836,0.0002258301,0.7712982,0.00030121033,0.00051781273,0.0003563716,0.09533296,0.000064650085],"about_ca_topic_score_codex":0.9400449,"about_ca_topic_score_gemma":0.94748384,"teacher_disagreement_score":0.9300227,"about_ca_system_score_codex":0.06997731,"about_ca_system_score_gemma":0.06589507,"threshold_uncertainty_score":0.50772333},"labels":[],"label_agreement":null},{"id":"W2024103874","doi":"10.1111/j.1541-1338.2008.00378.x","title":"The Power of Pills: Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing – By Jillian Clare Cohen, Patricia Illingworth, and Udo Schuklenk","year":2009,"lang":"en","type":"article","venue":"Review of Policy Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pill; Drug pricing; Politics; Political science; Power (physics); Ethical issues; Medicine; Business; Law; Pharmacology; Engineering; Engineering ethics","score_opus":0.07567575780615235,"score_gpt":0.41578370577721196,"score_spread":0.3401079479710596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024103874","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028711895,0.72984385,0.0009024645,0.22788323,0.01652769,0.00004106111,0.000051695853,0.00005772245,0.024405112],"genre_scores_gemma":[0.015215633,0.73668194,0.0027400733,0.07073485,0.03818385,0.00014252486,0.0001286716,0.00022109423,0.13595141],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943105,0.0020114211,0.00034508633,0.00067355606,0.00235128,0.00030812534],"domain_scores_gemma":[0.9932247,0.004296888,0.0006317734,0.0002647755,0.0009984473,0.0005833609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006414285,0.0021896763,0.0012696553,0.0017497452,0.0018477399,0.008465957,0.0019800663,0.0066759125,0.012314333],"category_scores_gemma":[0.008128936,0.0012276769,0.00071053964,0.0023800987,0.009868718,0.015504411,0.0034092665,0.013935377,0.0073665613],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003143336,0.000027071781,0.00007590949,0.0005288553,0.00001741611,0.000053702366,0.000828866,0.00011632202,0.0001963173,0.027056815,0.8950725,0.07599477],"study_design_scores_gemma":[0.000009816168,0.00002439299,0.00022699944,0.0009834806,0.0000042369343,0.00017503076,0.000423548,0.00012932744,0.0000788323,0.017513778,0.9804125,0.000018107321],"about_ca_topic_score_codex":0.004579695,"about_ca_topic_score_gemma":0.005750786,"teacher_disagreement_score":0.012314333,"about_ca_system_score_codex":0.0037219066,"about_ca_system_score_gemma":0.005014167,"threshold_uncertainty_score":0.04119551},"labels":[],"label_agreement":null},{"id":"W2024556879","doi":"10.1086/467458","title":"Does Regulation Drive Out Competition in Pharmaceutical Markets?","year":2000,"lang":"en","type":"article","venue":"The Journal of Law and Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":242,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competitor analysis; Competition (biology); Drug prices; Industrial organization; Business; Economics; Pharmacy; Public economics; Marketing","score_opus":0.0416971653487621,"score_gpt":0.2816545989510505,"score_spread":0.23995743360228838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024556879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7745916,0.010750129,0.010401224,0.038225275,0.00026114902,0.00024610833,0.0009119866,0.00014190913,0.16447057],"genre_scores_gemma":[0.991148,0.00096387585,0.0005018399,0.005806721,0.00020218875,0.000041875086,0.0001462104,0.000012299012,0.001176966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9842404,0.0056496584,0.00080113346,0.0021439975,0.003967213,0.0031976039],"domain_scores_gemma":[0.9361556,0.034332003,0.022558529,0.0021578053,0.0032966265,0.001499428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010021794,0.00032977428,0.0015816996,0.0020755462,0.0022567026,0.0070410892,0.0010247701,0.004190782,0.008773684],"category_scores_gemma":[0.037472907,0.00047878787,0.0018767911,0.0029110252,0.0076784166,0.005701705,0.0027598906,0.0029817938,0.00084285793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000544963,0.00068701414,0.45861682,0.0008179529,0.0009426138,0.001214098,0.0027354418,0.010365945,0.0016071518,0.44499412,0.012778836,0.06469497],"study_design_scores_gemma":[0.00058454997,0.0009886277,0.63487387,0.0010322344,0.0007158157,0.0008898735,0.0042346236,0.014828316,0.0022768902,0.24835178,0.090978116,0.00024531258],"about_ca_topic_score_codex":0.016454179,"about_ca_topic_score_gemma":0.0126444185,"teacher_disagreement_score":0.016454179,"about_ca_system_score_codex":0.0046735685,"about_ca_system_score_gemma":0.0042190664,"threshold_uncertainty_score":0.053000927},"labels":[],"label_agreement":null},{"id":"W2025080629","doi":"10.1503/cmaj.045021","title":"Drug withdrawals from the Canadian market for safety reasons, 1963-2004","year":2005,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Postmarketing surveillance; Drug; Business; Risk analysis (engineering); Medicine; Pharmacology; Adverse effect","score_opus":0.015897718768807714,"score_gpt":0.2403460625558178,"score_spread":0.2244483437870101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025080629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.522379,0.044453274,0.0014081,0.05831433,0.0013670427,0.0013196978,0.23997039,0.0003240247,0.13046418],"genre_scores_gemma":[0.83307254,0.017802957,0.0012531334,0.008813275,0.00047133878,0.00022085727,0.04218641,0.00008705506,0.09609243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930045,0.00016336562,0.00031704246,0.00030214112,0.0047926414,0.0014203031],"domain_scores_gemma":[0.9867474,0.000879666,0.002802818,0.0002742541,0.0073806294,0.0019151218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027776938,0.0004763549,0.0007402358,0.0048800744,0.004400612,0.0034749315,0.0016801546,0.0018598231,0.0054890322],"category_scores_gemma":[0.019648995,0.00057508977,0.0011277657,0.008435398,0.0010917359,0.00086228974,0.0012582104,0.003043461,0.00083132385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003950017,0.00039005408,0.4177148,0.0018096778,0.0007513937,0.0023376187,0.0034494135,0.0030160495,0.0016447797,0.013692375,0.35984626,0.19139752],"study_design_scores_gemma":[0.00020190846,0.00009542821,0.83019537,0.00019390938,0.000210415,0.00034141968,0.0007100396,0.00086011545,0.00090004405,0.000401132,0.1658049,0.000085259904],"about_ca_topic_score_codex":0.9960716,"about_ca_topic_score_gemma":0.9980862,"teacher_disagreement_score":0.14133565,"about_ca_system_score_codex":0.14133565,"about_ca_system_score_gemma":0.13929282,"threshold_uncertainty_score":0.99592894},"labels":[],"label_agreement":null},{"id":"W2025798541","doi":"10.1016/j.healthpol.2013.05.022","title":"Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers","year":2013,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Reimbursement; Confidentiality; Business; Drug; Law and economics; Internet privacy; Law; Economics; Political science; Medicine; Pharmacology; Health care; Computer science","score_opus":0.07997151151293332,"score_gpt":0.3627774933127338,"score_spread":0.2828059817998005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025798541","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35480142,0.008008025,0.0018245004,0.46049508,0.00046292445,0.00014672343,0.0004968307,0.00003388697,0.17373063],"genre_scores_gemma":[0.9693999,0.0028513607,0.00067924336,0.01976174,0.000073690186,0.000033208024,0.00006803726,0.00001693173,0.0071158065],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.96021044,0.01329899,0.0012398091,0.0016437549,0.0126445815,0.01096238],"domain_scores_gemma":[0.9302242,0.041111827,0.004872898,0.0009404853,0.015458866,0.007391745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034788433,0.00052279735,0.0006422346,0.0026424357,0.048375994,0.020158257,0.0028919645,0.009071114,0.0043398365],"category_scores_gemma":[0.05985873,0.0008426323,0.00086069846,0.0057583107,0.022668043,0.004098446,0.004241422,0.009494382,0.0002464339],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00017800745,0.00005640255,0.017938811,0.00043922057,0.000051691197,0.00273548,0.6646074,0.0020145848,0.0015507995,0.23639779,0.05032254,0.023707328],"study_design_scores_gemma":[0.000055759672,0.000044977758,0.023720961,0.0008178912,0.000068065594,0.0003030082,0.64680946,0.0011710735,0.0006492861,0.016593419,0.30936834,0.0003977881],"about_ca_topic_score_codex":0.98638934,"about_ca_topic_score_gemma":0.9839941,"teacher_disagreement_score":0.71957487,"about_ca_system_score_codex":0.28042513,"about_ca_system_score_gemma":0.25966886,"threshold_uncertainty_score":0.83460486},"labels":[],"label_agreement":null},{"id":"W2026426103","doi":"10.3821/145.6.cpj251","title":"New Pharmacy — Where Healthcare Interfaces Innovation","year":2012,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Health care; Curriculum; Capstone; Equity (law); Competition (biology); Capstone course; Strategic management; Entrepreneurship; Business; Management; Medical education; Public relations; Marketing; Medicine; Nursing; Sociology; Political science; Computer science; Pedagogy; Economics; Finance","score_opus":0.10685401501462963,"score_gpt":0.31550996603366466,"score_spread":0.20865595101903503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026426103","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025054472,0.002039356,0.0041293255,0.116126634,0.008490592,0.00067830196,0.0004996417,0.00080213975,0.84217966],"genre_scores_gemma":[0.17762253,0.002142047,0.005066532,0.028838886,0.0020928087,0.00023664304,0.0006483649,0.00016855053,0.7831836],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947208,0.00049395685,0.000085172105,0.00038004073,0.0028398056,0.001480317],"domain_scores_gemma":[0.9965077,0.00011473714,0.00012877391,0.0001245284,0.00040462473,0.0027196507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021295191,0.00033784928,0.00026880583,0.0006333837,0.005501176,0.010240175,0.0011992862,0.0036191207,0.07151552],"category_scores_gemma":[0.0033543874,0.0003786655,0.00057312776,0.00050072424,0.0018345435,0.003945866,0.0063050184,0.0043904292,0.014845604],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011141627,0.00047878636,0.0053158575,0.00016203026,0.000013268975,0.001511005,0.0023451764,0.00020447573,0.0018625958,0.068901666,0.81058705,0.10850667],"study_design_scores_gemma":[0.000017126518,0.000092220085,0.0030619863,0.00005686491,0.0000020554692,0.000279153,0.000994455,0.00012840332,0.00047408714,0.0016365953,0.9932458,0.000011303734],"about_ca_topic_score_codex":0.02064462,"about_ca_topic_score_gemma":0.09085055,"teacher_disagreement_score":0.9793554,"about_ca_system_score_codex":0.011773165,"about_ca_system_score_gemma":0.020393385,"threshold_uncertainty_score":0.23924327},"labels":[],"label_agreement":null},{"id":"W202721108","doi":"10.3833/pdr.v2011i8.1518","title":"Bayer Licenses Regional Rights to Trius Therapeutics’ Phase III Antibiotic for Serious Gram-Positive Infections","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"China; Latin Americans; Medicine; International trade; Political science; Business; Law","score_opus":0.20075728967151268,"score_gpt":0.38651749375098643,"score_spread":0.18576020407947375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W202721108","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012193459,0.09399467,0.006678995,0.0379365,0.0030474435,0.00066434557,0.008750983,0.002432851,0.83430076],"genre_scores_gemma":[0.14741948,0.049211062,0.006931272,0.012736825,0.0025224327,0.00047062212,0.012275678,0.0004918466,0.76794076],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989219,0.0002744734,0.00008405196,0.00013307929,0.00043412973,0.00015241675],"domain_scores_gemma":[0.99666625,0.00079827284,0.00075061916,0.0003941259,0.00077066565,0.00062006956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026629053,0.00038895945,0.0004597503,0.0010639639,0.00035000953,0.001457281,0.0008252811,0.0017031911,0.1439676],"category_scores_gemma":[0.0050503165,0.00017789128,0.00057000294,0.0011719135,0.00058259035,0.0013096724,0.0008994285,0.0017235497,0.04015435],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077727303,0.00022318123,0.0007613942,0.0009033764,0.00005372454,0.00025061873,0.0000822887,0.00020352069,0.0065175667,0.03715644,0.54988366,0.40318713],"study_design_scores_gemma":[0.0002739336,0.00025311217,0.0016673692,0.00021875743,0.000020965981,0.00044107085,0.0000191541,0.00019729417,0.0013602339,0.0014831898,0.9940578,0.0000071031486],"about_ca_topic_score_codex":0.0025760576,"about_ca_topic_score_gemma":0.002662391,"teacher_disagreement_score":0.1439676,"about_ca_system_score_codex":0.0007978524,"about_ca_system_score_gemma":0.0031827951,"threshold_uncertainty_score":0.4816196},"labels":[],"label_agreement":null},{"id":"W2027403669","doi":"10.1017/s0266462312000438","title":"HEALTH TECHNOLOGY REASSESSMENT OF NON-DRUG TECHNOLOGIES: CURRENT PRACTICES","year":2012,"lang":"en","type":"review","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Current (fluid); Drug; Health technology; Medicine; Intensive care medicine; Political science; Pharmacology; Engineering; Health care","score_opus":0.15253103293523793,"score_gpt":0.5156082285207999,"score_spread":0.36307719558556195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027403669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003647361,0.9756118,0.0017315664,0.01287859,0.00038120535,0.00027888862,0.00018207297,0.000062440566,0.0052260584],"genre_scores_gemma":[0.07144618,0.90929013,0.012714849,0.004762856,0.0004772975,0.00042619737,0.00027637932,0.00004002969,0.0005660723],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.877543,0.062097058,0.028263936,0.006145813,0.024483945,0.001466166],"domain_scores_gemma":[0.48290426,0.37902346,0.08351534,0.016353903,0.03591759,0.002285534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.12262352,0.00095422013,0.0029819186,0.012563269,0.0012737936,0.010735021,0.0042760745,0.0033739805,0.0035149325],"category_scores_gemma":[0.33598512,0.00096299394,0.0042882566,0.019561265,0.0052114883,0.013589269,0.004374957,0.00389711,0.000875245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031652057,0.00009281261,0.0055803624,0.20779152,0.0012148102,0.00016699293,0.004820201,0.00055986753,0.0003721668,0.01047604,0.010258573,0.7583502],"study_design_scores_gemma":[0.0003709508,0.0006561357,0.01766442,0.7242492,0.005132897,0.0012838251,0.009197003,0.0008191503,0.0024950327,0.013618295,0.22431275,0.00020041411],"about_ca_topic_score_codex":0.006096678,"about_ca_topic_score_gemma":0.007016824,"teacher_disagreement_score":0.12262352,"about_ca_system_score_codex":0.010249178,"about_ca_system_score_gemma":0.030559158,"threshold_uncertainty_score":0.6485029},"labels":[],"label_agreement":null},{"id":"W2029406121","doi":"10.1136/bmj.328.7442.728-d","title":"Canada's plan to sell generic drugs to developing countries is threatened","year":2004,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Parliament; Prime minister; Action plan; Human immunodeficiency virus (HIV); Malaria; Action (physics); Developing country; Business; Advertising; Political science; Medicine; Law; Economic growth; Family medicine; Economics; Politics; Management","score_opus":0.06543473972507491,"score_gpt":0.28533471291931906,"score_spread":0.21989997319424415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029406121","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031711129,0.0052834237,0.0006317815,0.8969402,0.0025763132,0.000040015213,0.001752807,0.00017072496,0.08943366],"genre_scores_gemma":[0.0951113,0.015527897,0.0040876064,0.6398311,0.002159118,0.00008068776,0.001909668,0.000177557,0.24111508],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937878,0.00034893097,0.00011894081,0.00026757448,0.004021259,0.0014554203],"domain_scores_gemma":[0.99176335,0.00071766967,0.00028998262,0.00019499393,0.0030552025,0.0039787013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034454176,0.0006082408,0.0006045498,0.0009837468,0.009343823,0.008440613,0.0017887087,0.011759907,0.01861413],"category_scores_gemma":[0.010613364,0.00043326686,0.0010844629,0.0020348616,0.0036888884,0.0029468953,0.0019177229,0.0068811635,0.0027104795],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007395081,0.000022890854,0.0016516534,0.00014196138,0.00003497939,0.0001600375,0.00016456097,0.00026332357,0.0002246527,0.06969019,0.90672576,0.020846099],"study_design_scores_gemma":[0.000055624238,0.000024824134,0.0035036248,0.00012302375,0.00002389646,0.000083900755,0.00025910969,0.0003484701,0.00011326045,0.008898703,0.9865329,0.000032648764],"about_ca_topic_score_codex":0.9664276,"about_ca_topic_score_gemma":0.97486115,"teacher_disagreement_score":0.95473087,"about_ca_system_score_codex":0.04526914,"about_ca_system_score_gemma":0.22367308,"threshold_uncertainty_score":0.3284521},"labels":[],"label_agreement":null},{"id":"W2030886922","doi":"10.1517/14656566.3.9.1235","title":"The pharmacoeconomic impact of generics: an evolutionary tale","year":2002,"lang":"en","type":"editorial","venue":"Expert Opinion on Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pride; Human immunodeficiency virus (HIV); Medicine; Position (finance); Law and economics; Economics; Law; Political science; Virology; Finance","score_opus":0.06265118156813454,"score_gpt":0.38548996348098574,"score_spread":0.3228387819128512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030886922","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032573368,0.09720034,0.0009566954,0.46167776,0.43433154,0.000012830111,0.00005555274,0.000038484184,0.005401135],"genre_scores_gemma":[0.0102268085,0.09163238,0.0006436691,0.09409799,0.79102594,0.000019940388,0.000024419078,0.000045338144,0.012283416],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771476,0.0007109678,0.00019066111,0.00027247542,0.001017171,0.000094003124],"domain_scores_gemma":[0.97762614,0.017623963,0.0007018181,0.00033100456,0.0031605815,0.00055641035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055393344,0.0013245833,0.0016160305,0.0014547062,0.0012000827,0.0049694055,0.0016418323,0.012312483,0.003969782],"category_scores_gemma":[0.023432348,0.00037807322,0.0009437528,0.0011541222,0.0034942082,0.0048240386,0.0007096343,0.013350971,0.0011390483],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052026597,0.000013981193,0.00006337699,0.000634712,0.00004572585,0.00032603604,0.0001095499,0.0003806963,0.00011382548,0.018226912,0.94974345,0.030289566],"study_design_scores_gemma":[0.00005698907,0.000043373067,0.0004678229,0.0011698653,0.000074420605,0.00043839225,0.00015140594,0.0009314569,0.0001576882,0.03455121,0.96192515,0.00003224043],"about_ca_topic_score_codex":0.0012482282,"about_ca_topic_score_gemma":0.002256066,"teacher_disagreement_score":0.012312483,"about_ca_system_score_codex":0.0021038214,"about_ca_system_score_gemma":0.001891881,"threshold_uncertainty_score":0.029295087},"labels":[],"label_agreement":null},{"id":"W2030895155","doi":"10.1016/j.jval.2011.02.177","title":"PHP108 THE CASE OF RARE DISEASE DRUGS BEFORE AND AFTER THE INTRODUCTION OF PRICING BODIES: LESSONS LEARNED FROM BRAZIL AND CANADA, IMPLICATIONS FOR THE UNITED STATES","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Drug prices; Purchasing; Natalizumab; Drug pricing; Disease; Economics; Business; Public economics; Actuarial science; Medicine; Marketing; Pathology","score_opus":0.10565085449068398,"score_gpt":0.323450803452887,"score_spread":0.21779994896220303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030895155","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16379085,0.007887543,0.0032194972,0.38617158,0.0010018509,0.00013876437,0.0011663716,0.00006240111,0.4365612],"genre_scores_gemma":[0.8263518,0.004984121,0.002452305,0.0699761,0.0007329974,0.000058946003,0.0002914792,0.000101871716,0.09505039],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99320304,0.0008691547,0.00018110982,0.0006742047,0.0024150624,0.0026573746],"domain_scores_gemma":[0.9843203,0.006703386,0.0011169466,0.0007946944,0.005237975,0.0018267593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004793697,0.00026902786,0.00055055623,0.0012739102,0.009876782,0.0069950954,0.0015827474,0.013765355,0.013947381],"category_scores_gemma":[0.022954324,0.0003434966,0.0009937561,0.002090549,0.007310397,0.0040212674,0.002393667,0.01149956,0.0005719888],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018564834,0.00014300416,0.029628502,0.0001591309,0.00008912578,0.011067411,0.007179467,0.0010291607,0.00084640057,0.79557693,0.104452804,0.049642473],"study_design_scores_gemma":[0.00019248866,0.00016170123,0.08535969,0.0010630066,0.00036639153,0.0073258877,0.024107153,0.0046061384,0.0027101007,0.141429,0.7323228,0.00035554482],"about_ca_topic_score_codex":0.91795474,"about_ca_topic_score_gemma":0.9350842,"teacher_disagreement_score":0.08204526,"about_ca_system_score_codex":0.03637205,"about_ca_system_score_gemma":0.055040296,"threshold_uncertainty_score":0.2638989},"labels":[],"label_agreement":null},{"id":"W2031324922","doi":"10.4088/jcp.v67n0706","title":"Evaluation of an Interchangeability Switch in Patients Treated With Clozapine","year":2006,"lang":"en","type":"article","venue":"The Journal of Clinical Psychiatry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Clozapine; Discontinuation; Medicine; Adverse effect; Population; Schizophrenia (object-oriented programming); Medical record; Retrospective cohort study; Brand names; Pediatrics; Psychiatry; Internal medicine","score_opus":0.15434824418344043,"score_gpt":0.40465260828503863,"score_spread":0.2503043641015982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031324922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840575,0.00019824275,0.000045559274,0.00011873615,0.0000048668776,0.000042210813,0.0002201182,0.0000037851767,0.000960667],"genre_scores_gemma":[0.99918383,0.00013602471,0.00010896007,0.000082959355,0.000009143234,0.000008634337,0.00036368027,0.0000016044204,0.000105148654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982761,0.00021493918,0.000117452575,0.00017009674,0.0009312732,0.0002900253],"domain_scores_gemma":[0.99576545,0.0006774998,0.0022587795,0.0001376526,0.0007297708,0.00043074018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011306803,0.00023446356,0.00049965887,0.0010316471,0.0013977961,0.0010610906,0.00066040404,0.000612801,0.0018943481],"category_scores_gemma":[0.010467318,0.00019430817,0.00045692944,0.0016882786,0.00057205756,0.00033070397,0.0004516532,0.0008841947,0.00012407063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000991219,0.0001684391,0.98866177,0.000025972664,0.000054653723,0.0007022625,0.00039011106,0.000069917514,0.00052466,0.00004326943,0.00018579954,0.008181958],"study_design_scores_gemma":[0.000025299496,0.00025119414,0.99767417,0.0000069628377,0.000040126946,0.0007679715,0.00032968973,0.0002558482,0.00018540239,0.000016928645,0.0004392607,0.0000072247685],"about_ca_topic_score_codex":0.38173512,"about_ca_topic_score_gemma":0.3344673,"teacher_disagreement_score":0.38173512,"about_ca_system_score_codex":0.0060645454,"about_ca_system_score_gemma":0.0046953093,"threshold_uncertainty_score":0.75902635},"labels":[],"label_agreement":null},{"id":"W2031631370","doi":"10.1136/bmj.327.7409.246-a","title":"US agrees to cheap drug imports—as Florida officials break fake drugs ring","year":2003,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Ring (chemistry); Internet privacy; Medicine; Pharmacology; Chemistry; Computer science","score_opus":0.042227142237231056,"score_gpt":0.304939372926408,"score_spread":0.26271223068917693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031631370","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013029892,0.0024231886,0.00067423965,0.77889276,0.0024796298,0.000022269853,0.0007484353,0.0001576323,0.20157197],"genre_scores_gemma":[0.21197616,0.0038050343,0.0015735665,0.40492645,0.0032686002,0.000062893756,0.0006358626,0.00021022435,0.37354124],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987269,0.00029881002,0.000035529556,0.00012643667,0.0004918137,0.0003205125],"domain_scores_gemma":[0.9966614,0.0014692149,0.0003801227,0.00021045841,0.0007511773,0.00052770914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002469514,0.00041817676,0.0002467447,0.00113586,0.0066204024,0.008115465,0.00039460647,0.007926935,0.06655384],"category_scores_gemma":[0.011423545,0.0002978386,0.00039397628,0.0010589326,0.002425228,0.007479954,0.0017486421,0.005538055,0.0069234786],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006363251,0.000026444293,0.0013120841,0.000027783268,0.0000097928,0.00009334304,0.000537136,0.000074753094,0.00021907008,0.109146304,0.8660727,0.022416836],"study_design_scores_gemma":[0.000027752678,0.000027617734,0.0037441028,0.000087549786,0.000014652079,0.000054957694,0.0011380382,0.00016285617,0.00030440922,0.0098643545,0.9845451,0.000028638586],"about_ca_topic_score_codex":0.08163024,"about_ca_topic_score_gemma":0.104469806,"teacher_disagreement_score":0.08163024,"about_ca_system_score_codex":0.0044755274,"about_ca_system_score_gemma":0.0050141984,"threshold_uncertainty_score":0.22264475},"labels":[],"label_agreement":null},{"id":"W2031692846","doi":"10.1211/ijpp.17.02.0002","title":"Consumers' views on generic medicines: A review of the literature","year":2009,"lang":"en","type":"review","venue":"International Journal of Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; MEDLINE; Reimbursement; Grey literature; Scopus; Health care; Seriousness; Family medicine; Public relations; Political science","score_opus":0.18519468087731014,"score_gpt":0.4623296083132797,"score_spread":0.27713492743596957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031692846","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005530463,0.99259734,0.000048983566,0.0009331539,0.000091084614,0.00002228666,0.00011086556,0.0000018539274,0.00066393224],"genre_scores_gemma":[0.024605049,0.97392535,0.00025090147,0.0008233077,0.00013416028,0.000047556165,0.00010152826,0.000001322178,0.00011072008],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9968681,0.0010774288,0.0009537746,0.00021040993,0.0007928348,0.00009739128],"domain_scores_gemma":[0.9843018,0.010970154,0.0028804638,0.00008526865,0.0015925831,0.00016971982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052632857,0.0005481006,0.0015882251,0.008890255,0.00041481206,0.001759668,0.0007328738,0.0016815092,0.002921427],"category_scores_gemma":[0.014112837,0.00048273584,0.0010974365,0.009500128,0.000822569,0.002978123,0.0007086567,0.00067576556,0.00033656467],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004391465,0.000114849405,0.013191507,0.52895695,0.0012534136,0.0015719153,0.006663038,0.0001114766,0.0009069922,0.0009414396,0.010775594,0.43507364],"study_design_scores_gemma":[0.000143683,0.0008687895,0.10387392,0.71143997,0.0063709137,0.0096729845,0.019342177,0.00018299039,0.00060489745,0.0010226264,0.14635432,0.00012275332],"about_ca_topic_score_codex":0.003493946,"about_ca_topic_score_gemma":0.009028314,"teacher_disagreement_score":0.008890255,"about_ca_system_score_codex":0.0015629675,"about_ca_system_score_gemma":0.0030551695,"threshold_uncertainty_score":0.02783525},"labels":[],"label_agreement":null},{"id":"W2031771150","doi":"10.1016/j.jval.2012.08.2176","title":"PCN136 Expenditures on Orphan Drugs in Canada, Europe (EU5 + Belgium, Sweden and the Netherlands) and Australia in 2009","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Orphan drug; Per capita; Authorization; Agency (philosophy); Eu countries; European union; Medicine; Demography; Business; Environmental health; International trade; Population; Biology","score_opus":0.09226563942851991,"score_gpt":0.3095126234444604,"score_spread":0.2172469840159405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031771150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86521536,0.0054708086,0.0002214315,0.0035685264,0.00011306121,0.00004992342,0.10449136,0.00007267245,0.020796886],"genre_scores_gemma":[0.9208145,0.0070356894,0.00044841057,0.00078311516,0.000070388436,0.00004124763,0.04694962,0.000030242147,0.023826981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989489,0.00010031167,0.00009156314,0.00011222253,0.00041273437,0.00033433174],"domain_scores_gemma":[0.9984158,0.00009904664,0.00065330643,0.000029724393,0.0004577477,0.0003443038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004118697,0.0002816227,0.000456045,0.0015294891,0.00054500124,0.001148267,0.0005122892,0.0006564075,0.002674392],"category_scores_gemma":[0.002129056,0.00032480105,0.0010085726,0.003873674,0.00031307575,0.00051932345,0.0008831918,0.0013050485,0.0003852737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024691797,0.00024995126,0.83076185,0.0008435301,0.00090875156,0.0013389146,0.000869448,0.004652921,0.0012082249,0.011471144,0.083582506,0.061643574],"study_design_scores_gemma":[0.00002478841,0.000054166212,0.9634061,0.00009081737,0.00012939735,0.00033752498,0.0003209409,0.0011079834,0.0004001353,0.00014476925,0.0339669,0.000016412288],"about_ca_topic_score_codex":0.89362246,"about_ca_topic_score_gemma":0.91127497,"teacher_disagreement_score":0.10637754,"about_ca_system_score_codex":0.015854748,"about_ca_system_score_gemma":0.013453894,"threshold_uncertainty_score":0.21400797},"labels":[],"label_agreement":null},{"id":"W2031814675","doi":"10.1002/pds.3230","title":"The U.S. Food and Drug Administration's Mini‐Sentinel Program","year":2012,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hamilton Health Sciences Foundation; U.S. Department of Health and Human Services","keywords":"Medicine; Food and drug administration; Administration (probate law); Drug; Pharmacoepidemiology; Drug administration; Environmental health; Pharmacology","score_opus":0.06481087761012193,"score_gpt":0.34486078034882545,"score_spread":0.2800499027387035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031814675","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022534056,0.0037844307,0.0048279637,0.2433753,0.01373462,0.0024781427,0.14896624,0.0025300547,0.5577692],"genre_scores_gemma":[0.17874368,0.009309843,0.017459886,0.08672018,0.0052179624,0.0024354795,0.11714018,0.00070499256,0.58226776],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826604,0.00048451262,0.00009475623,0.00015258377,0.00068239943,0.0003198209],"domain_scores_gemma":[0.99046516,0.0020465567,0.000731023,0.00037389866,0.0037774257,0.0026060622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004074398,0.0004964224,0.0005019993,0.0011677225,0.00067148096,0.0011965813,0.0008784391,0.0015650556,0.11482198],"category_scores_gemma":[0.0075979806,0.00030394318,0.0003969311,0.0012980922,0.00024552722,0.00091611815,0.00083605724,0.0013658063,0.025952285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033768546,0.00020465003,0.0030036813,0.000071219794,0.000011144476,0.000030115432,0.000012286698,0.000090015834,0.00020762654,0.0016441685,0.95585537,0.03853209],"study_design_scores_gemma":[0.00046117796,0.00035069315,0.01913202,0.00017684803,0.000035237288,0.00009022983,0.00011184993,0.0012871854,0.00068658584,0.0015501977,0.97609097,0.000027008968],"about_ca_topic_score_codex":0.023953643,"about_ca_topic_score_gemma":0.035767436,"teacher_disagreement_score":0.11482198,"about_ca_system_score_codex":0.0015958848,"about_ca_system_score_gemma":0.014882618,"threshold_uncertainty_score":0.38411778},"labels":[],"label_agreement":null},{"id":"W2031834292","doi":"","title":"A Review of the Pharmaceutical Industry of Canada","year":2008,"lang":"en","type":"review","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical industry; Intellectual property; Business; Divergence (linguistics); Drug industry; International trade; Industrial organization; Commerce; Engineering; Law; Political science; Medicine; Pharmacology","score_opus":0.16890998709085156,"score_gpt":0.4079537679486644,"score_spread":0.23904378085781283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031834292","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011019833,0.9961689,0.000023052831,0.00055702607,0.00014942774,0.000005602928,0.00010953342,0.0000039886245,0.0028723113],"genre_scores_gemma":[0.0009173357,0.9978557,0.00005704564,0.0002512597,0.00007049149,0.0000035910073,0.00006860829,0.0000011171263,0.0007748122],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991003,0.00007054368,0.00008483766,0.00008361673,0.0005672603,0.00009342241],"domain_scores_gemma":[0.9974226,0.0005130206,0.000255344,0.000034502358,0.0015654132,0.00020910907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010337235,0.00091276376,0.0011876187,0.010649898,0.0011436588,0.0026993528,0.0010121424,0.0011282676,0.009305075],"category_scores_gemma":[0.0025850835,0.00044117513,0.0005943813,0.024699973,0.0007259574,0.0015830187,0.000672949,0.0011668795,0.0021024314],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008516666,0.0000512651,0.0006927069,0.051839277,0.00014167985,0.00038283117,0.00023520274,0.0004311131,0.0007810679,0.007077004,0.21626574,0.72201693],"study_design_scores_gemma":[0.000010485304,0.000020903928,0.003715804,0.008925574,0.000104082574,0.00031274825,0.00009189689,0.000036524783,0.00011962649,0.00043259206,0.9862089,0.000020853908],"about_ca_topic_score_codex":0.37722102,"about_ca_topic_score_gemma":0.54390234,"teacher_disagreement_score":0.9881879,"about_ca_system_score_codex":0.011812108,"about_ca_system_score_gemma":0.033528388,"threshold_uncertainty_score":0.75005066},"labels":[],"label_agreement":null},{"id":"W2031885918","doi":"10.3109/17453671003685467","title":"The Canadian Joint Replacement Registry—what have we learned?","year":2010,"lang":"en","type":"article","venue":"Acta Orthopaedica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Armed Forces; Dalhousie University; Canadian Mennonite University; University of Manitoba","funders":"","keywords":"Medicine; Joint replacement; Arthroplasty; Physical therapy; Surgery","score_opus":0.05969153513577381,"score_gpt":0.2770479774793396,"score_spread":0.21735644234356583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031885918","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045176144,0.22414647,0.0022764602,0.74960566,0.0056205057,0.0001690898,0.007291821,0.00034331504,0.0060290718],"genre_scores_gemma":[0.1384603,0.66425097,0.027097698,0.13367693,0.011965835,0.00046404655,0.019383915,0.00039468016,0.0043057417],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9759015,0.0068028714,0.0023092844,0.0021882,0.010171545,0.002626624],"domain_scores_gemma":[0.7360238,0.07843493,0.012160801,0.012004868,0.12828541,0.033090238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.077745005,0.002052168,0.0029995136,0.0116249155,0.0040279264,0.013049703,0.010298843,0.0067793895,0.009106745],"category_scores_gemma":[0.16609535,0.0014311873,0.0019845427,0.017679384,0.008669594,0.014113488,0.0047356947,0.0106119225,0.002070692],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040846062,0.00014506155,0.0399542,0.006635087,0.00039584885,0.00035748802,0.0010030613,0.001472693,0.00011681585,0.03663356,0.4398571,0.4730206],"study_design_scores_gemma":[0.00026440108,0.00021314101,0.10035739,0.033175286,0.0006085956,0.00063713273,0.0046543577,0.0045830747,0.00029807253,0.023200087,0.83149755,0.00051086437],"about_ca_topic_score_codex":0.9152674,"about_ca_topic_score_gemma":0.89235204,"teacher_disagreement_score":0.9370944,"about_ca_system_score_codex":0.06290559,"about_ca_system_score_gemma":0.19109735,"threshold_uncertainty_score":0.4564141},"labels":[],"label_agreement":null},{"id":"W2031939437","doi":"10.1586/14737167.4.2.179","title":"Evaluating the true cost of hypertension management: evidence from actual practice","year":2004,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GLS Industries (Canada)","funders":"","keywords":"Observational study; Medicine; Intensive care medicine; Cost effectiveness; Pharmacotherapy; Argument (complex analysis); Internal medicine; Risk analysis (engineering)","score_opus":0.3416650622691229,"score_gpt":0.586591635498591,"score_spread":0.24492657322946804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031939437","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08699948,0.8162163,0.008928934,0.05474844,0.0013999239,0.00083166594,0.004922308,0.000039670354,0.025913324],"genre_scores_gemma":[0.5711346,0.41092905,0.0061036306,0.008178659,0.0013083969,0.00046083494,0.0013047885,0.00003537375,0.0005447598],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.92486286,0.054175317,0.006590105,0.002518634,0.011162934,0.00069018477],"domain_scores_gemma":[0.34732857,0.59699345,0.03452495,0.008023041,0.012207866,0.0009221813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06308051,0.0010985872,0.0034039677,0.0036432461,0.00048940955,0.0042226296,0.0026861262,0.0029280207,0.008959887],"category_scores_gemma":[0.37861568,0.0010184404,0.0033930666,0.006393017,0.0030272147,0.0039462014,0.0024904665,0.0031078483,0.0007694979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011514837,0.0007643454,0.12769619,0.09778508,0.03292987,0.00032843094,0.0009403277,0.013988059,0.00018091069,0.04875063,0.016670533,0.64845073],"study_design_scores_gemma":[0.010430499,0.0065435064,0.2710246,0.32388774,0.06578933,0.00157349,0.0027866862,0.025839921,0.0021907887,0.14525127,0.14422922,0.00045298212],"about_ca_topic_score_codex":0.015446844,"about_ca_topic_score_gemma":0.009298831,"teacher_disagreement_score":0.06308051,"about_ca_system_score_codex":0.0071738926,"about_ca_system_score_gemma":0.008041038,"threshold_uncertainty_score":0.3336056},"labels":[],"label_agreement":null},{"id":"W2032458713","doi":"10.1016/j.sapharm.2006.07.003","title":"Canadian Internet pharmacies: Price, policy, and perspective","year":2007,"lang":"en","type":"article","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Pfizer; University of Minnesota; American Heart Association","keywords":"Medical prescription; Discontinuation; Misinformation; Medicine; Direct-to-consumer advertising; Scopus; Testosterone replacement; Family medicine; Advertising; MEDLINE; Psychiatry; Business; Internal medicine; Political science; Pharmacology","score_opus":0.3862383656046429,"score_gpt":0.517372483249521,"score_spread":0.1311341176448781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032458713","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048036262,0.07349071,0.0010463814,0.63768727,0.001081618,0.000052741634,0.003457608,0.000066723005,0.23508058],"genre_scores_gemma":[0.8300276,0.085067086,0.0018025036,0.04156882,0.0023749454,0.00004277132,0.0009734062,0.00005916762,0.038083754],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9934134,0.0008428082,0.00013188014,0.00035291622,0.0033426762,0.0019163521],"domain_scores_gemma":[0.9857905,0.0034600997,0.00078434084,0.0001828226,0.007724662,0.0020576026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035143225,0.00068398943,0.00068546686,0.0043678596,0.005959187,0.013268718,0.0020967876,0.006192057,0.014972451],"category_scores_gemma":[0.015218736,0.0004932158,0.00065379404,0.010710494,0.005379988,0.0034478796,0.0010093137,0.0044162855,0.0005480353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026173473,0.00017699492,0.012261524,0.00068653125,0.00009616808,0.00041418357,0.0010828489,0.004685558,0.000473174,0.69116706,0.22370619,0.06498807],"study_design_scores_gemma":[0.00025115308,0.00013938651,0.12827328,0.0017488272,0.00025339678,0.0003865487,0.01076831,0.008875989,0.0010310512,0.10758733,0.740258,0.00042666512],"about_ca_topic_score_codex":0.98980695,"about_ca_topic_score_gemma":0.994251,"teacher_disagreement_score":0.20069036,"about_ca_system_score_codex":0.20069036,"about_ca_system_score_gemma":0.20469466,"threshold_uncertainty_score":0.9270859},"labels":[],"label_agreement":null},{"id":"W2032555144","doi":"10.1016/j.econlet.2008.04.011","title":"Can health insurance coverage explain the generic competition paradox?","year":2008,"lang":"en","type":"article","venue":"Economics Letters","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Competition (biology); Health insurance; Economics; Actuarial science; Business; Health care; Biology","score_opus":0.0610946542756907,"score_gpt":0.2430156554677373,"score_spread":0.1819210011920466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032555144","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25545236,0.012467984,0.03063866,0.50116163,0.001749712,0.00007337885,0.0018395651,0.00023278598,0.19638397],"genre_scores_gemma":[0.97782075,0.0018959875,0.0009534879,0.011721868,0.0018198529,0.000014420433,0.0001685065,0.000035766625,0.0055693556],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99901307,0.00029646134,0.000041539857,0.00015285048,0.00019188649,0.0003041886],"domain_scores_gemma":[0.9863955,0.009129593,0.0021827118,0.0008135302,0.0007720727,0.0007066018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035944032,0.0004092646,0.0013847669,0.0017343228,0.0010089317,0.0037420327,0.001588532,0.006508616,0.0282918],"category_scores_gemma":[0.020961026,0.0003023507,0.0010452634,0.001345797,0.0034712052,0.0067460313,0.0015845409,0.003488079,0.0016169263],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027159308,0.00011520392,0.008406902,0.00019644413,0.00010776751,0.00043523638,0.00026297136,0.0053797057,0.00029680796,0.9362559,0.025672192,0.022599388],"study_design_scores_gemma":[0.00011390934,0.000029229963,0.0042875027,0.0000557127,0.000044820663,0.00014719147,0.00026995747,0.00975319,0.000090620306,0.97377586,0.011409971,0.000021986341],"about_ca_topic_score_codex":0.008122826,"about_ca_topic_score_gemma":0.00668299,"teacher_disagreement_score":0.0282918,"about_ca_system_score_codex":0.0020829053,"about_ca_system_score_gemma":0.0017296218,"threshold_uncertainty_score":0.0946455},"labels":[],"label_agreement":null},{"id":"W2032655361","doi":"10.1016/j.joca.2012.02.499","title":"Compliance with thromboprophylaxis using an oral factor Xa inhibitor rivaroxaban after total hip and knee arthroplasty. Is oral therapy better? An examination of the non-adherence rate of rivaroxaban","year":2012,"lang":"en","type":"article","venue":"Osteoarthritis and Cartilage","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Rivaroxaban; Arthroplasty; Perioperative; Medical prescription; Knee replacement; Hip replacement; Surgery; Anesthesia; Internal medicine; Warfarin; Atrial fibrillation","score_opus":0.057411922642819184,"score_gpt":0.2694667141147721,"score_spread":0.21205479147195289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032655361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945543,0.0007413032,0.00016809683,0.0021463837,0.000025237292,0.000016356214,0.00046163678,0.000004507127,0.0018821968],"genre_scores_gemma":[0.9988906,0.00022614269,0.00005587701,0.00019040637,0.0000414892,0.000007614896,0.0002587179,0.0000023287241,0.000326848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938313,0.0027648907,0.0010402852,0.00041746552,0.0013416642,0.000604348],"domain_scores_gemma":[0.93273413,0.025155332,0.033731636,0.002842045,0.0036081292,0.0019286678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074915034,0.00009379221,0.00041701077,0.00087344093,0.0004073047,0.0009735461,0.00066510553,0.0009896777,0.0028135357],"category_scores_gemma":[0.050557528,0.00025880686,0.0014851304,0.002012925,0.00050850684,0.0009331075,0.00057350815,0.0017505201,0.0002939975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033759026,0.0001703809,0.98990613,0.000026619135,0.00018594258,0.000056285568,0.0002592944,0.000166378,0.000041960408,0.00025959377,0.00033880377,0.008251089],"study_design_scores_gemma":[0.000008342324,0.0001030025,0.998909,0.00001169824,0.00003306102,0.000052086547,0.0001598279,0.0004127431,0.000020800857,0.0000946614,0.00019073482,0.0000040522373],"about_ca_topic_score_codex":0.013797474,"about_ca_topic_score_gemma":0.0114413565,"teacher_disagreement_score":0.013797474,"about_ca_system_score_codex":0.0009027644,"about_ca_system_score_gemma":0.0010917432,"threshold_uncertainty_score":0.039619327},"labels":[],"label_agreement":null},{"id":"W2034097717","doi":"10.4212/cjhp.v63i3.920","title":"Doit-on s’inspirer de la tarification à l’activité pour le financement des médicaments onéreux en établissements de santé ?","year":2010,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.033628147013296444,"score_gpt":0.30574105495618803,"score_spread":0.27211290794289156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034097717","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012885757,0.023228468,0.00104494,0.9259763,0.0029667441,0.000032498,0.00024025231,0.000077770106,0.033547204],"genre_scores_gemma":[0.4501159,0.07713027,0.0062233796,0.38845366,0.0066662906,0.00017769536,0.00064383424,0.00027804382,0.070310906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98878187,0.004409835,0.00024619963,0.0008619419,0.0030685163,0.0026315923],"domain_scores_gemma":[0.96361727,0.009427417,0.0030239662,0.0013494387,0.013097832,0.009484117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014299209,0.0006635946,0.00083997485,0.0017421343,0.0036360163,0.015574344,0.0021308528,0.00672155,0.024624307],"category_scores_gemma":[0.03935886,0.0003635327,0.0010467885,0.0022702732,0.008321372,0.009136552,0.0034581036,0.009074205,0.004882773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006095443,0.00050911825,0.03382937,0.001753371,0.00026780923,0.0004038353,0.0056668376,0.000684212,0.0012926988,0.20240086,0.36841714,0.3841651],"study_design_scores_gemma":[0.000115557064,0.000253228,0.029010871,0.003907016,0.00010513455,0.00025967282,0.00883382,0.0004957798,0.00062497327,0.032662135,0.9236336,0.00009838104],"about_ca_topic_score_codex":0.17423765,"about_ca_topic_score_gemma":0.2072757,"teacher_disagreement_score":0.17423765,"about_ca_system_score_codex":0.016137792,"about_ca_system_score_gemma":0.050554574,"threshold_uncertainty_score":0.346447},"labels":[],"label_agreement":null},{"id":"W2034460365","doi":"10.1016/j.cjca.2014.07.196","title":"A HYBRID STRATEGY OF BARE METAL COMBINED WITH DRUG-ELUTING STENTING OR DRUG-ELUTING STENTING ONLY FOR MULTIVESSEL PERCUTANEOUS CORONARY INTERVENTION: Results OF LONG-TERM FOLLOW-UP","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Conventional PCI; Percutaneous coronary intervention; TIMI; Mace; Internal medicine; Cardiology; Coronary artery disease; Drug-eluting stent; Fractional flow reserve; Angioplasty; Revascularization; Stent; Surgery; Myocardial infarction; Coronary angiography","score_opus":0.043170417720170634,"score_gpt":0.26773635511140964,"score_spread":0.224565937391239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034460365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692094,0.001315189,0.0006288397,0.0000870625,0.000064171014,0.000038501927,0.00027934866,0.000029067382,0.0006368554],"genre_scores_gemma":[0.9968732,0.00071602466,0.0005903957,0.00016989333,0.0001487999,0.00005355494,0.0006986936,0.000017777631,0.0007316215],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9990658,0.0002870951,0.00008280871,0.0002663664,0.000093905095,0.00020406376],"domain_scores_gemma":[0.9985121,0.00060772395,0.00020690337,0.00025023855,0.00013284897,0.00029024578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015313538,0.0014661059,0.0028809167,0.00090497255,0.00041048936,0.0012938498,0.000776492,0.0017175677,0.003842752],"category_scores_gemma":[0.002440772,0.00035305702,0.002569769,0.00069772976,0.0005802756,0.0012550075,0.00072651147,0.0011193671,0.001051017],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5291033,0.038419124,0.10210704,0.00091561046,0.0068681296,0.0019338927,0.00060092396,0.013597205,0.014254494,0.000679823,0.0020418325,0.2894786],"study_design_scores_gemma":[0.05694206,0.35760465,0.49001208,0.00055572065,0.017678224,0.0037947271,0.0021218867,0.04904873,0.013484179,0.0040508024,0.0041712094,0.000535658],"about_ca_topic_score_codex":0.0019158737,"about_ca_topic_score_gemma":0.0019211246,"teacher_disagreement_score":0.003842752,"about_ca_system_score_codex":0.000612592,"about_ca_system_score_gemma":0.0006093302,"threshold_uncertainty_score":0.012855232},"labels":[],"label_agreement":null},{"id":"W2036463549","doi":"10.1016/j.sapharm.2011.12.004","title":"Generic medications for you, but brand-name medications for me","year":2012,"lang":"en","type":"article","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine; Medicaid; Brand names; Generic drug; Pharmacist; Medical prescription; Pharmacy; Health care; Quarter (Canadian coin); Alternative medicine; Advertising; Nursing; Drug; Psychiatry","score_opus":0.5563216677394746,"score_gpt":0.536764510440715,"score_spread":0.01955715729875951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036463549","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030489549,0.06638413,0.0059409696,0.80410844,0.003939823,0.000042596654,0.0026764416,0.00012743745,0.08629068],"genre_scores_gemma":[0.63852066,0.08244822,0.0076786065,0.18643501,0.014491729,0.00010235867,0.001816742,0.0001481674,0.06835851],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9961216,0.0014080324,0.00037464435,0.0005098697,0.0012097157,0.00037620234],"domain_scores_gemma":[0.9760969,0.010649984,0.0057442435,0.0016031015,0.0036597382,0.0022460546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004050864,0.00044956588,0.0012171001,0.0020322043,0.0015345124,0.0051670424,0.0006317914,0.0038310674,0.0332727],"category_scores_gemma":[0.03028442,0.00040249655,0.00084470474,0.0029733316,0.0027909917,0.0071264706,0.0011891956,0.00316504,0.005830569],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044291056,0.000466446,0.09884276,0.002081255,0.00068838464,0.00042097853,0.0009350284,0.0006405372,0.0017693238,0.2515659,0.39027372,0.25187278],"study_design_scores_gemma":[0.00019112234,0.00036487382,0.09527789,0.003569209,0.00050860154,0.0023764498,0.0042196307,0.0013408181,0.0024230955,0.3873996,0.5021964,0.00013231854],"about_ca_topic_score_codex":0.0038054306,"about_ca_topic_score_gemma":0.005687897,"teacher_disagreement_score":0.0332727,"about_ca_system_score_codex":0.0016747469,"about_ca_system_score_gemma":0.001958942,"threshold_uncertainty_score":0.111308336},"labels":[],"label_agreement":null},{"id":"W2036483116","doi":"10.1001/jamainternmed.2013.1529","title":"When Choosing Statin Therapy","year":2013,"lang":"en","type":"review","venue":"JAMA Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Statin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intensive care medicine; Reduction (mathematics); Physical therapy; Internal medicine","score_opus":0.20453207105522306,"score_gpt":0.38694937927341116,"score_spread":0.1824173082181881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036483116","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052087815,0.9505998,0.001609947,0.030686302,0.0011726243,0.000059702976,0.00021803209,0.000020949643,0.010423839],"genre_scores_gemma":[0.05361592,0.91259205,0.0044297758,0.02480099,0.0021806355,0.000112521346,0.00033838287,0.000015440739,0.0019143291],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99551314,0.0020140884,0.0009700718,0.0002205226,0.0011148218,0.00016739892],"domain_scores_gemma":[0.9954797,0.0032810937,0.00057662,0.000055488843,0.00042920333,0.0001778358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004393406,0.0003091304,0.0016603258,0.001151296,0.00040158918,0.0022610894,0.000625431,0.0021796415,0.0052594002],"category_scores_gemma":[0.017401705,0.00035991948,0.00092649873,0.00132555,0.00059966504,0.0023628394,0.00071241276,0.0028077275,0.0020031454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004964263,0.000114854825,0.006191087,0.011443951,0.00046177948,0.00054307777,0.0004729099,0.00031212307,0.00047034392,0.006416929,0.056499142,0.9165773],"study_design_scores_gemma":[0.00078519207,0.00027959052,0.01703957,0.06880869,0.0017247846,0.00436789,0.0023384155,0.0005453326,0.0012127972,0.033714652,0.8690486,0.00013445485],"about_ca_topic_score_codex":0.002312908,"about_ca_topic_score_gemma":0.00504714,"teacher_disagreement_score":0.0052594002,"about_ca_system_score_codex":0.00087935606,"about_ca_system_score_gemma":0.0022393856,"threshold_uncertainty_score":0.023234844},"labels":[],"label_agreement":null},{"id":"W2036492388","doi":"10.1503/cmaj.050444","title":"Canadian prescription drug costs surpass $18 billion","year":2005,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medical prescription; Prescription drug; Drug; Medicine; Prescription costs; Family medicine; Pharmacology","score_opus":0.023348975075944734,"score_gpt":0.24799636833172806,"score_spread":0.2246473932557833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036492388","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028369011,0.04375733,0.0013863647,0.18242206,0.007724436,0.00014200868,0.116368674,0.001410612,0.6184195],"genre_scores_gemma":[0.3443384,0.060324296,0.005058062,0.03844605,0.002436153,0.0001340834,0.067915775,0.0003994919,0.48094776],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99734616,0.000053722535,0.000059274676,0.00011932252,0.0020419578,0.00037947713],"domain_scores_gemma":[0.99694675,0.000113170056,0.00010719172,0.000065103544,0.0022118692,0.0005559916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065605855,0.0007016212,0.00045101732,0.001619406,0.002250441,0.0027139476,0.00085029344,0.0017981636,0.046760097],"category_scores_gemma":[0.0044493256,0.00027406687,0.0008823814,0.00314036,0.00040620507,0.0009433298,0.00091162033,0.0014418771,0.004954072],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070785754,0.000011305002,0.0032575487,0.00020868261,0.000035201727,0.000047714588,0.000049823524,0.00020385839,0.00019002399,0.007888796,0.94171226,0.046323903],"study_design_scores_gemma":[0.00003541205,0.000012084245,0.024486456,0.00009921747,0.0000428487,0.000064708685,0.000117998745,0.00033231883,0.00029867367,0.00092567457,0.9735665,0.000018097799],"about_ca_topic_score_codex":0.9773158,"about_ca_topic_score_gemma":0.98471004,"teacher_disagreement_score":0.046760097,"about_ca_system_score_codex":0.042183634,"about_ca_system_score_gemma":0.06638161,"threshold_uncertainty_score":0.30606514},"labels":[],"label_agreement":null},{"id":"W2037874618","doi":"10.1212/wnl.0b013e3181aa5300","title":"The risks and costs of multiple-generic substitution of topiramate","year":2009,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Streptokinase; Myocardial infarction; Artery; Internal medicine; Cardiology; Angiography; Surgery","score_opus":0.09161091702826282,"score_gpt":0.29802624314812626,"score_spread":0.20641532611986343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037874618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741334,0.0014107439,0.000095768555,0.00025265073,0.000005438645,0.000012569531,0.0003221968,0.0000023527975,0.00048502116],"genre_scores_gemma":[0.9992926,0.00033028284,0.000076626304,0.00003295681,0.000013406466,0.000004455917,0.00019073386,8.376301e-7,0.000057965914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987929,0.00045155786,0.00010769779,0.000112705195,0.00034031214,0.00019477666],"domain_scores_gemma":[0.99321544,0.0020147413,0.0037003567,0.00017672591,0.00043300822,0.00045970504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013679758,0.00024370317,0.0002982276,0.0005155786,0.00023064896,0.0006809014,0.00033222622,0.0004092859,0.0014741718],"category_scores_gemma":[0.011690904,0.00014059174,0.0010299055,0.0006058192,0.0002683193,0.0004658936,0.0003820092,0.0006136313,0.000081533704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025143286,0.00019858626,0.9751823,0.00010831601,0.00063777284,0.00041055997,0.00003967981,0.0015864826,0.00032477564,0.00016984346,0.00025449542,0.01857291],"study_design_scores_gemma":[0.00004574445,0.00045200522,0.99636674,0.000024420528,0.00017210384,0.000599821,0.000072523784,0.0019182542,0.00011145896,0.0000874095,0.00014258387,0.0000068383497],"about_ca_topic_score_codex":0.011287584,"about_ca_topic_score_gemma":0.01439601,"teacher_disagreement_score":0.011287584,"about_ca_system_score_codex":0.0018136934,"about_ca_system_score_gemma":0.00079301774,"threshold_uncertainty_score":0.022443712},"labels":[],"label_agreement":null},{"id":"W2039581669","doi":"10.1136/bmj.d7706","title":"Developing countries are not making the most of TRIPS flexibilities because of political pressure","year":2011,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"TRIPS architecture; Politics; Computer science; Developing country; Data science; Medicine; Political science; Economic growth; Economics; Law","score_opus":0.22487005983131028,"score_gpt":0.34714454430073993,"score_spread":0.12227448446942965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039581669","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035119437,0.013205396,0.014113893,0.69546425,0.002338586,0.000054724223,0.0012722185,0.00027824,0.23815323],"genre_scores_gemma":[0.7860923,0.034823135,0.010003629,0.10471927,0.0037098879,0.0001602084,0.0011828949,0.00014159201,0.05916715],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760604,0.00084577623,0.00007625115,0.00015483082,0.0009409531,0.00037617882],"domain_scores_gemma":[0.99447435,0.003066509,0.0007773176,0.00043316465,0.00073061034,0.0005180064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047475398,0.00035474548,0.00036468724,0.00079392694,0.0019631193,0.005424537,0.00053069263,0.002565097,0.013966903],"category_scores_gemma":[0.011639711,0.00028314785,0.00047360075,0.0015989023,0.0050055655,0.006159688,0.0023451797,0.0054812967,0.0025690908],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020347626,0.00007461405,0.006406131,0.00036208038,0.00010221666,0.00029922783,0.0011371676,0.0034017467,0.00063413475,0.6939352,0.19580387,0.09764016],"study_design_scores_gemma":[0.00008264382,0.00007838788,0.009320157,0.00042683465,0.000042006253,0.00039234295,0.0020157637,0.0017195245,0.00061931583,0.19571035,0.78950804,0.00008460205],"about_ca_topic_score_codex":0.013357877,"about_ca_topic_score_gemma":0.0070210015,"teacher_disagreement_score":0.013966903,"about_ca_system_score_codex":0.0029037085,"about_ca_system_score_gemma":0.0033901136,"threshold_uncertainty_score":0.046723902},"labels":[],"label_agreement":null},{"id":"W2040835663","doi":"10.3821/145.6.cpj245","title":"Private Insurers Implementing Policies Making Generic Substitution Mandatory","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Substitution (logic); Business; Actuarial science; Medicine; Computer science","score_opus":0.0986726546523255,"score_gpt":0.29789719547724236,"score_spread":0.19922454082491686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040835663","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060969558,0.004767666,0.009384284,0.56794286,0.0094041955,0.0007062839,0.0026908456,0.00225376,0.34188065],"genre_scores_gemma":[0.2412976,0.003594042,0.015481881,0.64935035,0.0041904496,0.00028447947,0.0019706774,0.000435871,0.083394535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9617255,0.0042556003,0.0019868615,0.0023828186,0.02145489,0.008194502],"domain_scores_gemma":[0.90496683,0.039305728,0.005956506,0.0121953,0.028197225,0.009378388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035803363,0.00051156234,0.00047571302,0.001677019,0.0054641827,0.007852024,0.003234816,0.016990988,0.013357668],"category_scores_gemma":[0.08713183,0.0015044286,0.0017169032,0.0012928909,0.004351411,0.0060524307,0.0065700947,0.010224041,0.0025730857],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011409503,0.00022265046,0.00884775,0.0001968293,0.00006822899,0.0003625754,0.0019752008,0.0007524733,0.002134726,0.112377636,0.8115232,0.061424725],"study_design_scores_gemma":[0.00024201212,0.000090544556,0.019578533,0.0005794393,0.00009064702,0.0002007392,0.00084036234,0.0013061796,0.0015033605,0.010028555,0.96540403,0.00013552674],"about_ca_topic_score_codex":0.40600416,"about_ca_topic_score_gemma":0.44914088,"teacher_disagreement_score":0.40600416,"about_ca_system_score_codex":0.017213486,"about_ca_system_score_gemma":0.06413978,"threshold_uncertainty_score":0.8072819},"labels":[],"label_agreement":null},{"id":"W2040946909","doi":"10.1071/ah090176","title":"PBS reform &amp;mdash; a missed opportunity?","year":2009,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Library of Parliament","funders":"","keywords":"Formulary; Pharmaceutical Benefits Scheme; Health economics; Government (linguistics); Population health; Pharmaceutical policy; Business; Public economics; Economics; Medicine; Health care; Health policy; Pharmacology; Economic growth","score_opus":0.3741985915968059,"score_gpt":0.42552529880083695,"score_spread":0.05132670720403104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040946909","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018058256,0.010986814,0.00049290527,0.9647365,0.0034700283,0.000020516107,0.000077025885,0.000056663048,0.018353678],"genre_scores_gemma":[0.18978441,0.03464087,0.003627609,0.6722628,0.009326031,0.00014864632,0.00023936672,0.00010776496,0.08986255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932607,0.003261514,0.00018757409,0.0002960818,0.0014334653,0.0015607795],"domain_scores_gemma":[0.99007285,0.0026700993,0.0009449606,0.00052641967,0.002064328,0.0037214346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0131141795,0.0003345116,0.00052774197,0.0008248354,0.0019397866,0.006219577,0.0011722026,0.008425151,0.039280068],"category_scores_gemma":[0.02693386,0.00033254307,0.0006356954,0.000969086,0.0043042838,0.0101315975,0.0055249506,0.007878987,0.0054653496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006711074,0.00010861416,0.0011971133,0.0004301316,0.000014639926,0.00018662935,0.00046778523,0.00015954017,0.00015368819,0.2773573,0.5789575,0.14089991],"study_design_scores_gemma":[0.000052462165,0.000084004125,0.002846438,0.0005878799,0.000010057789,0.00016130753,0.0010255238,0.00020201244,0.00015773276,0.03564022,0.9592092,0.000023081513],"about_ca_topic_score_codex":0.012243397,"about_ca_topic_score_gemma":0.01526191,"teacher_disagreement_score":0.039280068,"about_ca_system_score_codex":0.004895279,"about_ca_system_score_gemma":0.020283435,"threshold_uncertainty_score":0.13140488},"labels":[],"label_agreement":null},{"id":"W2040971445","doi":"10.1002/hec.976","title":"Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget","year":2005,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University","funders":"","keywords":"Business; Actuarial science; Economics","score_opus":0.09140007972480259,"score_gpt":0.3384640381809,"score_spread":0.2470639584560974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040971445","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3713961,0.0012698435,0.49445757,0.00996035,0.00016793967,0.0005516927,0.0012503649,0.00030666578,0.12063946],"genre_scores_gemma":[0.9564304,0.0007280031,0.021222156,0.0003092062,0.00011643934,0.00033516352,0.00019845513,0.000092715956,0.020567479],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9947767,0.0023642506,0.00018333437,0.0006219094,0.00074906286,0.001304611],"domain_scores_gemma":[0.9898397,0.00677595,0.0014985043,0.00050315727,0.0005028819,0.0008798489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008421267,0.0013640845,0.0028871023,0.0016484909,0.0013265881,0.0059448183,0.002789641,0.0045430595,0.014963228],"category_scores_gemma":[0.021579633,0.0018400485,0.0023811066,0.00149554,0.003741149,0.0082479,0.0032978223,0.0045154886,0.00093019684],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016050175,0.00012737606,0.00068507035,0.000082725346,0.00006262101,0.0002764347,0.00014233356,0.40824044,0.0005332785,0.58330035,0.0015696087,0.0048193666],"study_design_scores_gemma":[0.00015824097,0.0001351559,0.0008150101,0.00006983541,0.00007167624,0.0001279462,0.00022364513,0.6621287,0.00033495526,0.3337228,0.0021348207,0.000077213146],"about_ca_topic_score_codex":0.007813349,"about_ca_topic_score_gemma":0.0028910611,"teacher_disagreement_score":0.014963228,"about_ca_system_score_codex":0.007210037,"about_ca_system_score_gemma":0.00468935,"threshold_uncertainty_score":0.052312672},"labels":[],"label_agreement":null},{"id":"W2041840751","doi":"10.2174/1874613601004020025","title":"Achieving a Dream: Meeting Policy Goals Related to Improving Drug Access","year":2010,"lang":"en","type":"article","venue":"The Open AIDS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Canadian Society for International Health; AIDS Vancouver; Health Canada","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Face (sociological concept); Economic growth; Access to medicines; Public relations; Developing country; Development economics; Political science; Social science; Family medicine; Sociology; Economics","score_opus":0.05368159080485699,"score_gpt":0.35792932113244624,"score_spread":0.3042477303275892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041840751","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007253849,0.01038273,0.007989732,0.93629724,0.0011838325,0.000055553865,0.00025152133,0.0001324642,0.036453113],"genre_scores_gemma":[0.5525599,0.039986033,0.03172775,0.34365216,0.00784613,0.0005485609,0.00055516465,0.00017045054,0.022953885],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.990604,0.005015692,0.000365091,0.0005898733,0.0016217574,0.0018036021],"domain_scores_gemma":[0.98148245,0.008161445,0.0020970572,0.00090738473,0.0022468313,0.005104884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017220022,0.0007871977,0.0012147896,0.0017670963,0.002512018,0.01086611,0.0024736112,0.01702715,0.013894923],"category_scores_gemma":[0.03464194,0.00035662795,0.0008806998,0.0021832285,0.0074435696,0.023294365,0.0075142253,0.010503235,0.0030332406],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001146206,0.00024237359,0.001580145,0.00055129756,0.000044436892,0.00020884386,0.00070144027,0.0028698815,0.0003962344,0.84172404,0.10967377,0.041893084],"study_design_scores_gemma":[0.00008672033,0.00012313154,0.002067987,0.00075120036,0.000020797223,0.00020487983,0.0021724913,0.0029960484,0.00035644142,0.8232565,0.16791022,0.000053577256],"about_ca_topic_score_codex":0.0069922213,"about_ca_topic_score_gemma":0.0031814037,"teacher_disagreement_score":0.017220022,"about_ca_system_score_codex":0.005720144,"about_ca_system_score_gemma":0.020653425,"threshold_uncertainty_score":0.09106928},"labels":[],"label_agreement":null},{"id":"W2041879862","doi":"10.1503/cmaj.090861","title":"Rational use of medications: If Canada can't do it ...","year":2009,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Data science; Computer science; World Wide Web; Family medicine; Pharmacology","score_opus":0.07216155283132238,"score_gpt":0.3056133835646304,"score_spread":0.23345183073330805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041879862","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048643214,0.7729698,0.0002843009,0.21334974,0.0014630826,0.000024744073,0.00066931156,0.000023401048,0.010729226],"genre_scores_gemma":[0.019315103,0.93083316,0.001082548,0.043612167,0.0016044165,0.000024412815,0.0003553604,0.000016573103,0.003156305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968442,0.0006210154,0.0001792489,0.00016402328,0.001906365,0.00028529475],"domain_scores_gemma":[0.9887356,0.003694034,0.0010745716,0.00031833965,0.005309672,0.00086774165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047318777,0.00043819635,0.0012262084,0.0015063989,0.0011029893,0.0025641639,0.001356668,0.0031725967,0.0074850963],"category_scores_gemma":[0.021768698,0.0002592613,0.00071820326,0.0044490364,0.0020089755,0.0020828776,0.0007005889,0.0036563566,0.0014040767],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103414866,0.000039379527,0.0023959698,0.0053915908,0.00023182032,0.000111045134,0.00016549906,0.00036342544,0.0000789382,0.023332762,0.44294327,0.5248429],"study_design_scores_gemma":[0.00020078005,0.000059190952,0.009491109,0.017059535,0.0004435754,0.0003066679,0.0005412597,0.00040157136,0.00014734392,0.016350567,0.9549335,0.00006473614],"about_ca_topic_score_codex":0.7571449,"about_ca_topic_score_gemma":0.8290557,"teacher_disagreement_score":0.9851582,"about_ca_system_score_codex":0.01484181,"about_ca_system_score_gemma":0.06813419,"threshold_uncertainty_score":0.48857057},"labels":[],"label_agreement":null},{"id":"W2041905260","doi":"10.1002/cmdc.200700008","title":"Pharmaceutical Strategy and Innovation: An Academics Perspective","year":2007,"lang":"en","type":"review","venue":"ChemMedChem","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); TransCanada (Canada)","funders":"","keywords":"Pharmaceutical industry; Business; Outsourcing; Context (archaeology); SAFER; Marketing; Productivity; Profit (economics); Perspective (graphical); Industrial organization; Economics; Computer science","score_opus":0.4698464303725707,"score_gpt":0.4730202975959993,"score_spread":0.003173867223428606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041905260","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044529067,0.9052853,0.0014415947,0.052521206,0.0008520315,0.0000068144377,0.000019442523,0.0000147632445,0.039413583],"genre_scores_gemma":[0.015216937,0.96968174,0.00069154275,0.0063245203,0.003036531,0.000013789361,0.000016477063,0.0000046106184,0.0050139097],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848574,0.0005777598,0.000092511065,0.00010742283,0.0006240404,0.00011254725],"domain_scores_gemma":[0.9956781,0.002942438,0.00039775265,0.00011606733,0.00065160554,0.0002140119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028588453,0.0007016149,0.0012660337,0.004754812,0.0009082197,0.005936267,0.00093548425,0.005091669,0.0040408554],"category_scores_gemma":[0.0038174991,0.00028454373,0.00038839105,0.008525838,0.005084857,0.00601313,0.0013221187,0.0037200435,0.0022692604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013777183,0.00009060376,0.00033921583,0.0023001062,0.00003063445,0.0002370944,0.00048891985,0.0015549766,0.00018108787,0.74772257,0.058540147,0.18850094],"study_design_scores_gemma":[0.000013766738,0.000043042415,0.0008789102,0.0021864416,0.0000139008025,0.00037129148,0.0007866274,0.0006361524,0.00015017149,0.27950177,0.71540105,0.000016854432],"about_ca_topic_score_codex":0.0028836436,"about_ca_topic_score_gemma":0.0038967268,"teacher_disagreement_score":0.005936267,"about_ca_system_score_codex":0.0043524047,"about_ca_system_score_gemma":0.006061347,"threshold_uncertainty_score":0.031579077},"labels":[],"label_agreement":null},{"id":"W2042215339","doi":"10.1016/s1098-3015(11)70806-3","title":"PMDH6: AN ECONOMIC EVALUATION OF PHARMACEUTICAL COST CONTAINMENT POLICIES IN ALBERTA, CANADA","year":2000,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Containment (computer programming); Business; Computer science","score_opus":0.13911449783376312,"score_gpt":0.3716451540720326,"score_spread":0.23253065623826946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042215339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416243,0.0028479758,0.0013621066,0.004738655,0.0001668705,0.0010623664,0.014167045,0.00013713726,0.03389345],"genre_scores_gemma":[0.9820287,0.0013366819,0.0019840444,0.00043246482,0.000043138374,0.00014716176,0.0048016054,0.000021807282,0.009204429],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9950877,0.0016064555,0.00018770328,0.00023399248,0.0018045716,0.0010796017],"domain_scores_gemma":[0.9924279,0.0024257805,0.00048739696,0.00021352315,0.0033060913,0.001139273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006176275,0.0012095049,0.0011486165,0.0029262868,0.0026112713,0.0039866585,0.0026241927,0.0017865917,0.0036952363],"category_scores_gemma":[0.0157094,0.0006628102,0.0009940392,0.004975039,0.0018236188,0.0011371629,0.001766167,0.0019690674,0.00022015396],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01586318,0.003526873,0.11245649,0.0016190407,0.0010054483,0.0009716611,0.0006405131,0.68198633,0.0012902813,0.03680406,0.05621208,0.08762395],"study_design_scores_gemma":[0.009576433,0.0045378455,0.30338836,0.00059661083,0.0014882826,0.0002717743,0.0073110242,0.60794854,0.0035723092,0.009584076,0.051177073,0.0005476401],"about_ca_topic_score_codex":0.99285865,"about_ca_topic_score_gemma":0.9929437,"teacher_disagreement_score":0.867141,"about_ca_system_score_codex":0.132859,"about_ca_system_score_gemma":0.1280626,"threshold_uncertainty_score":0.9639641},"labels":[],"label_agreement":null},{"id":"W2042746249","doi":"10.1016/s1098-3015(10)64509-3","title":"PMH8 COST-EFFECTIVENESS OF VENLAFAXINE: A CANADIAN PERSPECTIVE","year":2006,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venlafaxine; Perspective (graphical); Medicine; Psychiatry; Computer science; Artificial intelligence; Anxiety","score_opus":0.09630133463843947,"score_gpt":0.3330484847993053,"score_spread":0.23674715016086584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042746249","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.071240775,0.2059407,0.002440047,0.48057783,0.0014383947,0.00013969048,0.00859846,0.000073722644,0.22955039],"genre_scores_gemma":[0.83636993,0.11866204,0.0038537455,0.02188751,0.0025674575,0.00007670336,0.001782508,0.000056759596,0.014743431],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99517125,0.0013103297,0.00020124338,0.00028643614,0.00199911,0.0010317038],"domain_scores_gemma":[0.9901125,0.0030277695,0.00065949,0.000109735265,0.004888961,0.0012015973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004822995,0.0010111531,0.0016166045,0.0030869085,0.0018710473,0.0046358174,0.0024988863,0.0033973034,0.011229886],"category_scores_gemma":[0.016545191,0.000425422,0.0018678743,0.0038843674,0.0021004495,0.0011663551,0.00067929726,0.0035620485,0.0003010058],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007753699,0.00039984196,0.0306377,0.004343155,0.002785802,0.0016359309,0.0007261362,0.07364493,0.0025410256,0.33949697,0.17979836,0.35623634],"study_design_scores_gemma":[0.0046229432,0.0018056057,0.21473429,0.009386318,0.008127819,0.0022226162,0.004159695,0.05079952,0.0028281796,0.13826798,0.562088,0.0009570236],"about_ca_topic_score_codex":0.9742697,"about_ca_topic_score_gemma":0.9762532,"teacher_disagreement_score":0.109897144,"about_ca_system_score_codex":0.109897144,"about_ca_system_score_gemma":0.104151495,"threshold_uncertainty_score":0.79736334},"labels":[],"label_agreement":null},{"id":"W2042978277","doi":"10.1007/s00228-007-0277-5","title":"Characterizing early prescribers of newly marketed drugs in Canada: a population-based study","year":2007,"lang":"en","type":"article","venue":"European Journal of Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Manitoba Health","funders":"Pfizer","keywords":"Medical prescription; Medicine; Celecoxib; Early adopter; Family medicine; Logistic regression; Pharmacovigilance; Specialty; Population; Drug; Pharmacology; Internal medicine; Environmental health; Business","score_opus":0.08873143451036468,"score_gpt":0.36007470077563947,"score_spread":0.2713432662652748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042978277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693596,0.00038513652,0.00007293633,0.00032123097,0.0000085503825,0.000044209737,0.0015452142,0.000006325024,0.000680332],"genre_scores_gemma":[0.9976344,0.00039819715,0.00013671408,0.00022539095,0.000014542628,0.000015365424,0.0009479264,0.0000062231657,0.0006212381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968285,0.0002732741,0.00027346134,0.0004775574,0.0012008104,0.000946404],"domain_scores_gemma":[0.9877532,0.0012743798,0.004044439,0.00037536904,0.0033355667,0.0032169465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013277131,0.00054040446,0.0010097928,0.0024812403,0.0035655333,0.0026561802,0.0026024994,0.0022929397,0.0025903548],"category_scores_gemma":[0.0070016435,0.0009350503,0.0013577454,0.0066688526,0.0012187556,0.001165329,0.001164209,0.0031025007,0.00035948653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008814761,0.00012743616,0.99748033,0.000014468302,0.00006197235,0.000090539506,0.00041593277,0.00007328387,0.00009306275,0.0000536958,0.00037399618,0.001127122],"study_design_scores_gemma":[0.000010976743,0.000045910358,0.9982919,0.0000119483,0.00003571505,0.00008202207,0.00086937845,0.00028160113,0.000030385436,0.000016172,0.00030933524,0.000014724044],"about_ca_topic_score_codex":0.9770653,"about_ca_topic_score_gemma":0.9859226,"teacher_disagreement_score":0.024362175,"about_ca_system_score_codex":0.024362175,"about_ca_system_score_gemma":0.03004191,"threshold_uncertainty_score":0.1767608},"labels":[],"label_agreement":null},{"id":"W2042983142","doi":"10.1503/cmaj.110226","title":"Is this pill safe? Substandard medicines, mistaken solutions","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pill; Wonder; Vendor; Medical prescription; Medicine; Developing country; Internet privacy; Medical emergency; Business; Computer science; Marketing; Pharmacology; Economic growth","score_opus":0.0755745522056978,"score_gpt":0.2609466279303425,"score_spread":0.1853720757246447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042983142","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0109133255,0.08133128,0.004500249,0.8409177,0.00700067,0.000039124985,0.0003456654,0.000100063815,0.05485195],"genre_scores_gemma":[0.3200659,0.11536325,0.009968853,0.5097095,0.012660831,0.00007204155,0.00028402222,0.00021266275,0.031663015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933942,0.0023919207,0.000609958,0.00042841854,0.0028148307,0.0003605893],"domain_scores_gemma":[0.9872859,0.0066402303,0.0024432305,0.0009122175,0.00198254,0.0007358958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006870064,0.00041860648,0.0008776393,0.00089561095,0.0013675811,0.003991571,0.00079008535,0.0063122227,0.014321149],"category_scores_gemma":[0.050451797,0.0002939339,0.0007363647,0.0008659398,0.0068743494,0.007303106,0.0015326054,0.0057405797,0.0047298167],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008147981,0.00017051252,0.008218668,0.0018217843,0.00020792944,0.002490154,0.0027828927,0.0002921645,0.001770988,0.16054574,0.32085276,0.5000316],"study_design_scores_gemma":[0.00021006116,0.00030828352,0.0048271925,0.0035958001,0.00017745931,0.006741245,0.004068852,0.0005510183,0.0018810761,0.22763786,0.74987966,0.000121542296],"about_ca_topic_score_codex":0.0027257046,"about_ca_topic_score_gemma":0.0031799616,"teacher_disagreement_score":0.014321149,"about_ca_system_score_codex":0.0019655956,"about_ca_system_score_gemma":0.002855081,"threshold_uncertainty_score":0.04790902},"labels":[],"label_agreement":null},{"id":"W2043088524","doi":"10.3821/1913-701x(2008)141[160a:ssgicp]2.0.co;2","title":"2007 saw slowest growth in Canadian prescription drug sales in a decade","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Business; Drug; Medicine; Pharmacology","score_opus":0.0558902058270993,"score_gpt":0.2571253401250214,"score_spread":0.2012351342979221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043088524","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37430975,0.031752154,0.0022401717,0.3948364,0.0050804783,0.00017401426,0.09249817,0.0015710177,0.09753785],"genre_scores_gemma":[0.8705246,0.016868373,0.0023152775,0.025499927,0.0017930621,0.00004854805,0.017507384,0.00023722867,0.06520574],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811304,0.000027486427,0.00009707774,0.00013678294,0.0011142142,0.00051145913],"domain_scores_gemma":[0.98820335,0.0003508697,0.0009713107,0.00012647486,0.008774437,0.0015736335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001789919,0.00070944085,0.00072177564,0.0029164157,0.0022676273,0.0056224437,0.001044377,0.0029420545,0.009239004],"category_scores_gemma":[0.008442425,0.0003560932,0.0008164715,0.0050930846,0.00090907025,0.001530764,0.0010828602,0.0036158946,0.001415893],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000923745,0.00013761481,0.2493363,0.0011604804,0.00023441731,0.0012725313,0.0017415915,0.0034730993,0.0036872795,0.031205585,0.5499465,0.15688092],"study_design_scores_gemma":[0.00005170693,0.000050430346,0.6249319,0.00023553199,0.00008676004,0.0002814644,0.0015748735,0.0016784016,0.0015186241,0.00108226,0.36843765,0.00007031404],"about_ca_topic_score_codex":0.98059994,"about_ca_topic_score_gemma":0.9859228,"teacher_disagreement_score":0.049790557,"about_ca_system_score_codex":0.049790557,"about_ca_system_score_gemma":0.100133896,"threshold_uncertainty_score":0.3612575},"labels":[],"label_agreement":null},{"id":"W2043186204","doi":"10.3138/cras.2013.003","title":"The Maple Peril: From Presidential Policy to Pharmaceutical Importation, 1992–Present","year":2013,"lang":"en","type":"article","venue":"Canadian Review of American Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Presidential system; Legislature; Politics; Executive branch; Public administration; Balance (ability); Public policy; Political science; Presidential campaign; Political economy; Law; Economics; Medicine","score_opus":0.06143048892045852,"score_gpt":0.3578666847622647,"score_spread":0.29643619584180614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043186204","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1042936,0.18423706,0.000672328,0.29994264,0.002271425,0.00005558377,0.0009699914,0.00006074751,0.40749663],"genre_scores_gemma":[0.8869267,0.046504606,0.00035378707,0.0259031,0.0014618756,0.000038676953,0.00027783925,0.00003886471,0.0384945],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99577725,0.00079254975,0.000088421424,0.00036902286,0.001510305,0.0014624103],"domain_scores_gemma":[0.99396944,0.00266396,0.0008608566,0.00014883357,0.0018106324,0.00054631307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045046406,0.00020755174,0.00026423155,0.0017358226,0.0062696915,0.009775947,0.0009971187,0.0037367656,0.009325608],"category_scores_gemma":[0.01450193,0.00037350424,0.0002125462,0.0049866117,0.006234977,0.0034538747,0.001774942,0.005048625,0.00069035986],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028550538,0.000113723894,0.007853009,0.0009388617,0.000038482627,0.00042969405,0.008501527,0.0005044085,0.00025248463,0.7258533,0.18292794,0.072301015],"study_design_scores_gemma":[0.000051520947,0.000040586307,0.07459544,0.0009048134,0.000042577427,0.00013049769,0.0072353953,0.00034976174,0.000567351,0.017978653,0.89805406,0.000049291204],"about_ca_topic_score_codex":0.6348791,"about_ca_topic_score_gemma":0.6663509,"teacher_disagreement_score":0.3651209,"about_ca_system_score_codex":0.055807736,"about_ca_system_score_gemma":0.046671316,"threshold_uncertainty_score":0.7345423},"labels":[],"label_agreement":null},{"id":"W20432676","doi":"10.15173/m.v1i6.647","title":"Big Pharma: In Whose Best Interest?","year":2012,"lang":"en","type":"article","venue":"The Meducator","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Peer review; Medicine; Political science; Law","score_opus":0.19788396286989712,"score_gpt":0.3421402852854408,"score_spread":0.1442563224155437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W20432676","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039000827,0.011221884,0.00022752646,0.9745495,0.007801269,0.000003599694,0.000079175006,0.000025905147,0.00570125],"genre_scores_gemma":[0.057906598,0.023328664,0.0014351484,0.83671695,0.047154237,0.000053814296,0.00017164253,0.0001616511,0.033071257],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98996454,0.0048677153,0.00044395818,0.0007932175,0.0023075717,0.0016230042],"domain_scores_gemma":[0.9284309,0.026410209,0.0057977117,0.002855232,0.0114392135,0.025066795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019008871,0.00088368764,0.0021168252,0.002062659,0.0037190893,0.02402876,0.0019012457,0.02352969,0.025090098],"category_scores_gemma":[0.076750554,0.0005360157,0.00065395294,0.0033788162,0.009800035,0.029072674,0.004507907,0.020352285,0.0103354715],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001931556,0.00007854876,0.0016999387,0.0002764848,0.000044298442,0.0001654304,0.00027547416,0.00009786951,0.00015440573,0.10963077,0.8384119,0.04897173],"study_design_scores_gemma":[0.00012749791,0.00006584075,0.0014704501,0.0014786908,0.00006312345,0.00026751574,0.0017318578,0.00047504113,0.00033601257,0.18328933,0.8105955,0.00009924047],"about_ca_topic_score_codex":0.0043127625,"about_ca_topic_score_gemma":0.0072971275,"teacher_disagreement_score":0.025090098,"about_ca_system_score_codex":0.007770243,"about_ca_system_score_gemma":0.01711903,"threshold_uncertainty_score":0.10052973},"labels":[],"label_agreement":null},{"id":"W2043816730","doi":"10.1016/j.jval.2012.09.004","title":"What Is Wrong with Orphan Drug Policies?","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Orphan drug; Business; Bioinformatics; Biology","score_opus":0.1068436613679914,"score_gpt":0.32903839067299734,"score_spread":0.22219472930500594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043816730","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013820301,0.028485779,0.0037862079,0.91409236,0.004990003,0.000014519368,0.0003049657,0.000047578396,0.03445827],"genre_scores_gemma":[0.6801578,0.035739176,0.003748533,0.25452694,0.018472318,0.00008699647,0.00022111209,0.00012218051,0.0069250152],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97142845,0.017732585,0.0012199504,0.0017221639,0.0058579287,0.0020389224],"domain_scores_gemma":[0.8909903,0.08146923,0.009200776,0.004517791,0.00872993,0.0050918832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028555082,0.00057745044,0.0021579918,0.002092417,0.0021808613,0.01025903,0.0020494247,0.010918253,0.00901278],"category_scores_gemma":[0.14359193,0.0004038273,0.0011300585,0.0024979666,0.016958334,0.018898014,0.003115146,0.011726749,0.00073949195],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028556658,0.00011475339,0.0050105476,0.00045261148,0.00030136897,0.0002927236,0.00046677122,0.0013585495,0.000085030195,0.8653489,0.058654755,0.06762845],"study_design_scores_gemma":[0.0000731992,0.00003902282,0.0013301187,0.00085120363,0.00006870032,0.0001626227,0.00046424597,0.00090127025,0.0001366037,0.9447521,0.051195636,0.00002525081],"about_ca_topic_score_codex":0.006935987,"about_ca_topic_score_gemma":0.0062008104,"teacher_disagreement_score":0.028555082,"about_ca_system_score_codex":0.0061878213,"about_ca_system_score_gemma":0.008356446,"threshold_uncertainty_score":0.15101552},"labels":[],"label_agreement":null},{"id":"W2043981535","doi":"10.1111/j.1365-3156.2008.02186.x","title":"Pharmacy customers’ knowledge of side effects of purchased medicines in Mexico","year":2008,"lang":"en","type":"article","venue":"Tropical Medicine & International Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Simon Fraser University; Rijksuniversiteit Groningen","keywords":"Medical prescription; Pharmacy; Medicine; Family medicine; Multinomial logistic regression; Odds ratio; Logistic regression; Community pharmacy; Environmental health; Traditional medicine; Nursing; Internal medicine","score_opus":0.08161809352521997,"score_gpt":0.3808070559063829,"score_spread":0.29918896238116294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043981535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992077,0.00013684142,0.000010831094,0.00012493916,0.0000010995496,0.0000025075335,0.000062835294,8.2409736e-7,0.00045252952],"genre_scores_gemma":[0.9995547,0.00019421788,0.000022894008,0.00004389887,0.000004625504,0.0000029425505,0.000052617488,4.05499e-7,0.00012364138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999701,0.00007684192,0.00002299064,0.000033996694,0.00010182958,0.00006333443],"domain_scores_gemma":[0.99839205,0.00047112076,0.0008485707,0.000025720616,0.00013532572,0.0001271572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050582335,0.000089439105,0.00019130959,0.00038117563,0.00029718282,0.0005680702,0.00018560479,0.00042368984,0.003187581],"category_scores_gemma":[0.0022390885,0.00014665151,0.00015536041,0.00042920007,0.00018034947,0.00039727008,0.0002669417,0.00034447334,0.00013145179],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012885763,0.000102904196,0.9892191,0.000049325918,0.000025528352,0.00016127247,0.0017394986,0.000040525436,0.00029809304,0.000030646002,0.00031253768,0.007891669],"study_design_scores_gemma":[0.000006480588,0.00011480491,0.99686724,0.000024814432,0.000013862286,0.00019108468,0.0022124478,0.00012184017,0.00004763255,0.000008059855,0.0003886768,0.0000030145638],"about_ca_topic_score_codex":0.017033242,"about_ca_topic_score_gemma":0.011973203,"teacher_disagreement_score":0.017033242,"about_ca_system_score_codex":0.0003733243,"about_ca_system_score_gemma":0.00029508257,"threshold_uncertainty_score":0.033868194},"labels":[],"label_agreement":null},{"id":"W2044157541","doi":"10.1503/cmaj.110808","title":"The backlash against bioequivalence and the interchangeability of brand-name and generic drugs","year":2011,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Agency for Healthcare Research and Quality","keywords":"Interchangeability; Bioequivalence; Brand names; Medicine; Computer science; Pharmacology; Advertising; Business","score_opus":0.03577305740974529,"score_gpt":0.23814005675801553,"score_spread":0.20236699934827024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044157541","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021277725,0.0015647626,0.00020709145,0.9907414,0.0046284012,0.0000055332825,0.0000370244,0.00001617666,0.0025868122],"genre_scores_gemma":[0.0032860285,0.0009342696,0.00036508832,0.98042333,0.012280304,0.000015697904,0.000021842987,0.000021585543,0.0026518586],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97520316,0.007899115,0.0024060446,0.0032904143,0.009706676,0.0014945057],"domain_scores_gemma":[0.91566426,0.06882072,0.0031824487,0.0019485706,0.007038681,0.003345362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025053004,0.00092379743,0.0018672459,0.00121448,0.004924884,0.0054415017,0.0038742903,0.106348455,0.012397193],"category_scores_gemma":[0.08797747,0.0010753153,0.002330986,0.0013575184,0.0116979815,0.010794792,0.0032167288,0.08499252,0.00976092],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002305874,0.000045151788,0.00050479936,0.00014099099,0.000027308875,0.0009893837,0.00027465782,0.00010898161,0.00036115007,0.030953487,0.9386153,0.027748],"study_design_scores_gemma":[0.00028123157,0.00017944624,0.0015082505,0.00089649146,0.000053478496,0.0030703822,0.0004468722,0.0010109241,0.000588206,0.052053247,0.9397871,0.00012439127],"about_ca_topic_score_codex":0.010231581,"about_ca_topic_score_gemma":0.015148146,"teacher_disagreement_score":0.106348455,"about_ca_system_score_codex":0.009735047,"about_ca_system_score_gemma":0.007886547,"threshold_uncertainty_score":0.13249457},"labels":[],"label_agreement":null},{"id":"W2044978514","doi":"10.1515/fhep-2012-0036","title":"Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&amp;D for Neglected Diseases","year":2013,"lang":"en","type":"article","venue":"Forum for Health Economics & Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Altruism (biology); Economics; Perspective (graphical); Affect (linguistics); Public economics; Developing country; Microeconomics; Economic growth; Sociology; Psychology; Social psychology; Computer science","score_opus":0.09748944440223069,"score_gpt":0.3743577228096235,"score_spread":0.2768682784073928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044978514","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2459117,0.016577056,0.1340898,0.3306715,0.00062328804,0.00019977386,0.00069684954,0.00026199047,0.2709681],"genre_scores_gemma":[0.97547024,0.0035693888,0.0046018814,0.00809653,0.00021359404,0.00005328802,0.000044440025,0.000014588154,0.007936054],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9983724,0.0009648726,0.00003246573,0.00013123528,0.00017396269,0.00032506022],"domain_scores_gemma":[0.9960536,0.0020303489,0.0010551674,0.00023732247,0.0002576568,0.00036592974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036963127,0.00033146786,0.00044984513,0.0008651142,0.00087391795,0.0027617312,0.00047419954,0.0019519858,0.006272265],"category_scores_gemma":[0.009661845,0.00018754188,0.0005122201,0.00067882804,0.003242366,0.0030388504,0.0020126845,0.0013784136,0.0004101991],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082781036,0.00005863749,0.009184478,0.0002452616,0.0000804094,0.00026315288,0.00041258024,0.021941284,0.0006908503,0.92343307,0.009878959,0.033728547],"study_design_scores_gemma":[0.000074404175,0.00011590958,0.012863499,0.00038231403,0.00007256197,0.00037166735,0.00068405276,0.016354727,0.00087303313,0.89752865,0.07064048,0.00003875811],"about_ca_topic_score_codex":0.0029714874,"about_ca_topic_score_gemma":0.003138735,"teacher_disagreement_score":0.006272265,"about_ca_system_score_codex":0.0023280038,"about_ca_system_score_gemma":0.0021779735,"threshold_uncertainty_score":0.020982802},"labels":[],"label_agreement":null},{"id":"W2045148891","doi":"10.1038/clpt.2011.10","title":"The Value and Benefits of the International Conference on Harmonisation to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health","year":2011,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Harmonization; Public health; Drug approval; Drug; Value (mathematics); Business; Pharmacology; Medicine; Environmental health; Public administration; Political science; Computer science","score_opus":0.35828282244946014,"score_gpt":0.40471093666152846,"score_spread":0.04642811421206833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045148891","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014913885,0.023601146,0.032499395,0.84078646,0.01974906,0.0006532304,0.00043271077,0.0003741433,0.08041254],"genre_scores_gemma":[0.16415417,0.062121954,0.16302794,0.50801533,0.06308124,0.0028117273,0.0018932503,0.0011309966,0.03376344],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.5936784,0.244969,0.026204092,0.010327342,0.11826684,0.006554352],"domain_scores_gemma":[0.40195382,0.31152064,0.038481813,0.066446416,0.15953499,0.022062387],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.34531003,0.0014843435,0.00376384,0.006715829,0.0060607926,0.029031813,0.00491821,0.020875579,0.01362197],"category_scores_gemma":[0.52033615,0.0013293587,0.002838443,0.0076422854,0.01980145,0.025553754,0.0159758,0.025427764,0.005974638],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027022665,0.0001420896,0.0012183612,0.0012110868,0.00018301092,0.00020332656,0.00090932264,0.0012734358,0.0003199363,0.48634428,0.36679572,0.14112926],"study_design_scores_gemma":[0.00019360236,0.00030636715,0.0043063844,0.0027403943,0.00013916571,0.00034978817,0.00064641057,0.0013964626,0.00057823857,0.22719271,0.7619518,0.00019856889],"about_ca_topic_score_codex":0.004767754,"about_ca_topic_score_gemma":0.0036960247,"teacher_disagreement_score":0.34531003,"about_ca_system_score_codex":0.0122982375,"about_ca_system_score_gemma":0.059545785,"threshold_uncertainty_score":0.8073493},"labels":[],"label_agreement":null},{"id":"W2045226478","doi":"10.2165/00019053-200523120-00002","title":"Comment on ???The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development???","year":2005,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Health Economics","funders":"","keywords":"Drug development; Drug; Pharmaceutical industry; Competition (biology); Drug class; Medicine; Marketing; Pharmacology; Business; Actuarial science","score_opus":0.17386903855911948,"score_gpt":0.36626858022991754,"score_spread":0.19239954167079806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045226478","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003523272,0.0005126563,0.0000670012,0.98435366,0.011631911,0.000016246364,0.0002893733,0.000022747387,0.0027540138],"genre_scores_gemma":[0.0017201825,0.00027652443,0.00007874183,0.97818416,0.012997053,0.000027061571,0.000038429982,0.000013439368,0.0066645434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946044,0.0011300063,0.0008327512,0.00083446765,0.0013706676,0.0012276529],"domain_scores_gemma":[0.9796907,0.012654208,0.0018645218,0.00050764176,0.002939349,0.0023436546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008057238,0.0010540024,0.0024326942,0.0012711805,0.004376702,0.006700984,0.0035773234,0.105521895,0.010311934],"category_scores_gemma":[0.040201202,0.0012734218,0.002039575,0.0016142926,0.0033609888,0.0049821655,0.0020354532,0.05021001,0.00817336],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000819176,0.00002902419,0.0006951816,0.000042896358,0.000019635136,0.0003695296,0.00010109071,0.00007081425,0.00006267766,0.0028745707,0.99300283,0.0026498726],"study_design_scores_gemma":[0.00027758002,0.00013759239,0.0069192005,0.00063268776,0.00012330904,0.000632227,0.00102612,0.0011116625,0.0004476534,0.015169331,0.9733334,0.00018915761],"about_ca_topic_score_codex":0.051275145,"about_ca_topic_score_gemma":0.074519366,"teacher_disagreement_score":0.105521895,"about_ca_system_score_codex":0.010257457,"about_ca_system_score_gemma":0.009346694,"threshold_uncertainty_score":0.10195339},"labels":[],"label_agreement":null},{"id":"W2045394072","doi":"10.1056/nejmsa003087","title":"Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ministry of Health","funders":"Ministry of Health, British Columbia; Pfizer; Bristol-Myers Squibb; Deutsche Forschungsgemeinschaft; Agency for Healthcare Research and Quality; U.S. Department of Health and Human Services","keywords":"Medicine; Medical prescription; Cost sharing; Angiotensin-converting enzyme; Confidence interval; Christian ministry; Hazard ratio; Emergency medicine; Internal medicine; Pharmacology; Blood pressure","score_opus":0.10480406409050488,"score_gpt":0.29846945812680237,"score_spread":0.19366539403629748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045394072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943403,0.002039736,0.00019624668,0.0005864227,0.00004480551,0.000026154172,0.0012230295,0.000011073592,0.0015321913],"genre_scores_gemma":[0.99880004,0.00013554457,0.000057011537,0.00006459157,0.000024165654,0.0000058837013,0.0007899737,0.0000021607514,0.00012056561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923264,0.0033430986,0.00059545593,0.00072037324,0.001862211,0.0011524778],"domain_scores_gemma":[0.93991524,0.020586116,0.028704444,0.0029240877,0.004929048,0.002941134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007891279,0.00029540062,0.00067880936,0.00093280576,0.00063639524,0.001880311,0.00085598463,0.0010134696,0.0021323347],"category_scores_gemma":[0.05380757,0.00021679299,0.0015614876,0.0019229302,0.00069186155,0.000932286,0.0010051357,0.0022405323,0.00017174947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018283646,0.00020655357,0.98682797,0.000051894018,0.00044423837,0.00020625339,0.00007066908,0.0008831272,0.000049602742,0.00028616912,0.0010128444,0.0081322435],"study_design_scores_gemma":[0.0000719283,0.00043630897,0.9959816,0.00003746603,0.00020826324,0.0003259008,0.00010143224,0.001862336,0.000090847265,0.0003165403,0.00054978114,0.000017610086],"about_ca_topic_score_codex":0.04297468,"about_ca_topic_score_gemma":0.01867466,"teacher_disagreement_score":0.04297468,"about_ca_system_score_codex":0.00295727,"about_ca_system_score_gemma":0.0019443773,"threshold_uncertainty_score":0.0854491},"labels":[],"label_agreement":null},{"id":"W2045581095","doi":"10.1016/j.actpha.2014.11.024","title":"Les grossistes-répartiteurs : comparaison Québec/France","year":2015,"lang":"fr","type":"article","venue":"Actualités Pharmaceutiques","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.3103670087201568,"score_gpt":0.4105464221074696,"score_spread":0.10017941338731279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045581095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88445675,0.02045039,0.0016084005,0.00598099,0.00021976668,0.00013799143,0.022949023,0.0002675281,0.0639292],"genre_scores_gemma":[0.94626063,0.0044520563,0.0008872427,0.00058425346,0.00010225408,0.00006122827,0.008019478,0.000089570065,0.03954338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965773,0.000827003,0.00015882091,0.00037839112,0.0010775706,0.0009809652],"domain_scores_gemma":[0.99493706,0.0012602736,0.0007776711,0.00019927061,0.0019453426,0.0008802707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002477727,0.0007669791,0.0010452608,0.0055362564,0.0022924598,0.0058462983,0.0010084597,0.0014602843,0.01378027],"category_scores_gemma":[0.0054233,0.00036444984,0.0013262844,0.007333296,0.001255476,0.0014140476,0.001201628,0.0014527065,0.0011257457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039584143,0.0007365217,0.6792784,0.00084424706,0.0026158732,0.001778389,0.004377658,0.01934534,0.0017472964,0.062502675,0.064380966,0.15843429],"study_design_scores_gemma":[0.00015395212,0.000117593896,0.94584495,0.00016980241,0.00017694551,0.00017858979,0.0028923494,0.002609618,0.0003718253,0.0005882354,0.046842117,0.00005413554],"about_ca_topic_score_codex":0.9688977,"about_ca_topic_score_gemma":0.97769517,"teacher_disagreement_score":0.957065,"about_ca_system_score_codex":0.042935003,"about_ca_system_score_gemma":0.024822837,"threshold_uncertainty_score":0.3115167},"labels":[],"label_agreement":null},{"id":"W2046217307","doi":"10.4212/cjhp.v66i3.1251","title":"Leçons tirées des tragédies liées aux préparations magistrales de médicaments","year":2013,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Art; Gynecology; Political science; Medicine","score_opus":0.08379221427125566,"score_gpt":0.3147730043262652,"score_spread":0.23098079005500954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046217307","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62292916,0.020301474,0.0047246623,0.19348498,0.0076736393,0.00017194077,0.0028911072,0.0006500907,0.14717297],"genre_scores_gemma":[0.7501511,0.011230951,0.001748691,0.009757602,0.0030829338,0.000056048742,0.0008164144,0.0001313139,0.22302502],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957979,0.0010637038,0.00016471311,0.00029761906,0.0017452436,0.0009308036],"domain_scores_gemma":[0.9882677,0.004905515,0.002334264,0.00031356647,0.0024263794,0.0017525065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028138408,0.00091059424,0.00037687854,0.0028868208,0.007947966,0.005410288,0.00091822154,0.0055863345,0.030261356],"category_scores_gemma":[0.023681026,0.0005926099,0.0008677718,0.0014212176,0.0020523984,0.0021077362,0.0018031191,0.006699499,0.0035955033],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049909377,0.001368605,0.122427754,0.00084637635,0.0004588933,0.03765628,0.023028102,0.007010035,0.0054796124,0.0823377,0.4358246,0.2785712],"study_design_scores_gemma":[0.00019506394,0.00084497815,0.13631696,0.0010597472,0.00018518725,0.011659577,0.03102471,0.006418543,0.0039131325,0.010604569,0.7974656,0.0003118311],"about_ca_topic_score_codex":0.21200393,"about_ca_topic_score_gemma":0.24757046,"teacher_disagreement_score":0.21200393,"about_ca_system_score_codex":0.009010634,"about_ca_system_score_gemma":0.0063625067,"threshold_uncertainty_score":0.4215399},"labels":[],"label_agreement":null},{"id":"W2046246470","doi":"10.5433/2176-6665.2006v11n2p113","title":"O medicamento, um objeto de futuro na antropologia da saúde","year":2006,"lang":"pt","type":"article","venue":"Mediações Revista de Ciências Sociais","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint Paul University","funders":"","keywords":"Humanities; Philosophy; Medicine","score_opus":0.03538798236954625,"score_gpt":0.29161400727968695,"score_spread":0.2562260249101407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046246470","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08822459,0.449133,0.018939016,0.13932833,0.0048729233,0.00023193429,0.00053916953,0.0002407137,0.2984903],"genre_scores_gemma":[0.5373108,0.31822023,0.027926594,0.01547823,0.0043434887,0.00031850045,0.00028597136,0.00018034346,0.09593598],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99545246,0.0025617594,0.00019939152,0.00059303496,0.0009700655,0.00022326618],"domain_scores_gemma":[0.9942212,0.0031403343,0.0007155327,0.0007604888,0.0006858614,0.0004765707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004386706,0.0005774133,0.0011186182,0.0027066218,0.0044528632,0.010993167,0.0012997468,0.0033840982,0.0112618245],"category_scores_gemma":[0.00399704,0.00047641934,0.0007953502,0.0035619878,0.01135105,0.004213891,0.0044831187,0.0033506816,0.0025440329],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002782993,0.00046695478,0.015403078,0.006191124,0.00014354505,0.00090337126,0.041952472,0.00067739986,0.009186042,0.54558647,0.029579423,0.34963176],"study_design_scores_gemma":[0.000026782069,0.00041273935,0.0104095545,0.0018408778,0.0000893038,0.0012107899,0.017657844,0.00024352041,0.002942771,0.09376098,0.8713466,0.000058242418],"about_ca_topic_score_codex":0.0036523703,"about_ca_topic_score_gemma":0.011105364,"teacher_disagreement_score":0.0112618245,"about_ca_system_score_codex":0.003179922,"about_ca_system_score_gemma":0.007222841,"threshold_uncertainty_score":0.037674546},"labels":[],"label_agreement":null},{"id":"W2046439479","doi":"10.1503/cmaj.1070167","title":"France's health care system","year":2008,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"LOPES; Healthcare system; Health care; Medicine; Political science; Law","score_opus":0.022216905179399008,"score_gpt":0.24609099521230207,"score_spread":0.22387409003290307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046439479","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013049226,0.0057987743,0.00009061898,0.9352124,0.005131737,0.000008289673,0.00021013015,0.00007883241,0.0521643],"genre_scores_gemma":[0.034654174,0.0034094057,0.00032587256,0.83781016,0.009035918,0.0000387356,0.00023909587,0.000054094107,0.1144325],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99385214,0.0013358705,0.00022612103,0.00072799285,0.0022085493,0.0016493078],"domain_scores_gemma":[0.99583215,0.0017231721,0.00027612897,0.00018967371,0.0009923825,0.000986503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033180807,0.00075666246,0.0007316306,0.0008255257,0.007114042,0.007760121,0.0011095422,0.025093298,0.029770015],"category_scores_gemma":[0.013346079,0.00042286346,0.00090430066,0.0005290247,0.0020236995,0.0025649348,0.0023661836,0.013542751,0.0055198255],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002447179,0.000011381916,0.000586316,0.000040912408,0.000014124892,0.00029888982,0.00014633729,0.00006493987,0.00009488961,0.03489868,0.9523023,0.0115167815],"study_design_scores_gemma":[0.000025858497,0.000020027743,0.0017429785,0.00015273395,0.00000800654,0.0001726701,0.00012376014,0.00011612539,0.000052473762,0.0031303586,0.9944372,0.000017845501],"about_ca_topic_score_codex":0.17115222,"about_ca_topic_score_gemma":0.2382515,"teacher_disagreement_score":0.17115222,"about_ca_system_score_codex":0.018187704,"about_ca_system_score_gemma":0.022717826,"threshold_uncertainty_score":0.34031206},"labels":[],"label_agreement":null},{"id":"W2046647352","doi":"10.1097/mlr.0b013e31818af850","title":"Is There a Relationship Between Patient Beliefs or Communication About Generic Drugs and Medication Utilization?","year":2009,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging; Canadian Institutes of Health Research","keywords":"Pharmacy; Scale (ratio); Medical prescription; Medicine; Generic drug; Family medicine; Health communication; Drug; Actuarial science; Psychology; Nursing; Business; Pharmacology","score_opus":0.13411466758024482,"score_gpt":0.3455821168426299,"score_spread":0.2114674492623851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046647352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527895,0.0010868992,0.00031609266,0.0019028898,0.00001321455,0.000011954392,0.00017434085,0.0000059265285,0.0012096963],"genre_scores_gemma":[0.99931765,0.0002297342,0.0001392764,0.00017212665,0.000025558078,0.000007097865,0.000059068632,0.0000010219779,0.000048367267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705577,0.001764605,0.00022634036,0.00025651883,0.00043048838,0.0002662636],"domain_scores_gemma":[0.9535502,0.031723794,0.011430074,0.0006921697,0.0011287126,0.0014750314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004597127,0.00025030103,0.0002834104,0.0007701897,0.00022523996,0.001035471,0.00040956863,0.0013147866,0.0069728764],"category_scores_gemma":[0.03950105,0.00025152182,0.0006637252,0.0009797459,0.0010804583,0.0010038099,0.0005680496,0.001098574,0.00038590518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009980278,0.00006298488,0.9961349,0.000031068263,0.00007483943,0.000025712907,0.00013722989,0.000043551114,0.000027911816,0.00003323904,0.000074126765,0.0032546858],"study_design_scores_gemma":[0.000012272084,0.00018496104,0.99836034,0.00004018596,0.00006866656,0.00015693098,0.00031164987,0.0005812029,0.000037643433,0.0001244151,0.00011601641,0.000005650461],"about_ca_topic_score_codex":0.0021332654,"about_ca_topic_score_gemma":0.0019133459,"teacher_disagreement_score":0.0069728764,"about_ca_system_score_codex":0.00048206173,"about_ca_system_score_gemma":0.0006887364,"threshold_uncertainty_score":0.024312198},"labels":[],"label_agreement":null},{"id":"W2047820600","doi":"10.1136/bmj.327.7419.832-e","title":"Canada decides to lead the way in exempting AIDS drugs from patent laws","year":2003,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Law; Computer science; Data science; Political science","score_opus":0.09205129873463155,"score_gpt":0.2849247797897849,"score_spread":0.19287348105515337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047820600","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013472808,0.0052501783,0.0010532399,0.86006045,0.0033220537,0.000117619886,0.0036890383,0.00022541243,0.11280912],"genre_scores_gemma":[0.23614806,0.008136054,0.0052615763,0.36735168,0.0012712782,0.000081936225,0.0018558037,0.000113951646,0.37977967],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99447894,0.0002624594,0.00011368768,0.00016894033,0.0032946279,0.0016812603],"domain_scores_gemma":[0.9932888,0.0011296169,0.00019135133,0.00014507638,0.0033325304,0.0019126284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037539438,0.00029762913,0.00049010396,0.0011395367,0.0074613458,0.0072776964,0.0008198079,0.0075590583,0.012395676],"category_scores_gemma":[0.011344512,0.0004160076,0.0007719175,0.0017939952,0.0024889081,0.0020080311,0.0009797656,0.006402799,0.0016861534],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010274549,0.00003349349,0.0030640604,0.000085735395,0.000025617213,0.00020981679,0.0002887615,0.00040367083,0.0004016201,0.116335995,0.8612155,0.01783304],"study_design_scores_gemma":[0.0001071532,0.0000343819,0.008119061,0.00009506592,0.000033562075,0.00006010865,0.00039514728,0.00057217875,0.0005155587,0.009131458,0.98087597,0.000060313698],"about_ca_topic_score_codex":0.9765088,"about_ca_topic_score_gemma":0.9834726,"teacher_disagreement_score":0.9486906,"about_ca_system_score_codex":0.05130943,"about_ca_system_score_gemma":0.1905563,"threshold_uncertainty_score":0.37227768},"labels":[],"label_agreement":null},{"id":"W2048129967","doi":"10.1503/cmaj.109-3919","title":"Company profits from side effects of glaucoma treatment","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bimatoprost; Glaucoma; Medicine; Open angle glaucoma; Side effect (computer science); Optometry; Ophthalmology; Computer science; Ocular hypertension","score_opus":0.03451371428176609,"score_gpt":0.24105030886724152,"score_spread":0.20653659458547544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048129967","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.080377616,0.019445509,0.002439594,0.026325759,0.0017925104,0.00016853967,0.0036556746,0.0003826495,0.8654122],"genre_scores_gemma":[0.78597677,0.011362664,0.0010380112,0.0048746513,0.0029707332,0.000099788165,0.0033030047,0.00010625738,0.1902682],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99596584,0.0005594744,0.00018638257,0.00021777698,0.0025323129,0.00053811],"domain_scores_gemma":[0.9918256,0.0019992783,0.0018897537,0.00051905774,0.0022802043,0.0014861068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015247901,0.00042378454,0.00030172642,0.0017326865,0.0008585537,0.0028144552,0.0004415081,0.0014854146,0.026122821],"category_scores_gemma":[0.009825002,0.00021258512,0.000651774,0.0010977325,0.00053401064,0.0007371732,0.0011108234,0.0015148058,0.007334288],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006765812,0.000391318,0.08470995,0.00041923838,0.00042124843,0.002806706,0.00035628412,0.0018345733,0.0033832,0.04358271,0.3291625,0.5322557],"study_design_scores_gemma":[0.00020134017,0.00056626333,0.12831557,0.00061210385,0.00034997286,0.007540057,0.0005503345,0.0033352887,0.003326742,0.013245333,0.8418834,0.00007354579],"about_ca_topic_score_codex":0.0032972503,"about_ca_topic_score_gemma":0.0041421484,"teacher_disagreement_score":0.026122821,"about_ca_system_score_codex":0.0021809463,"about_ca_system_score_gemma":0.0019502474,"threshold_uncertainty_score":0.08738953},"labels":[],"label_agreement":null},{"id":"W2048384137","doi":"10.1159/000103270","title":"Availability and Costs of Antiepileptic Drugs and Quality of Phenobarbital in Vientiane Municipality, Lao PDR","year":2007,"lang":"en","type":"article","venue":"Neuroepidemiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Francophone University Association","funders":"","keywords":"Phenobarbital; Medicine; Carbamazepine; Clonazepam; Pharmacy; Diazepam; Phenytoin; Pharmacology; Epilepsy; Family medicine; Psychiatry","score_opus":0.1166024646436997,"score_gpt":0.3604408273471674,"score_spread":0.24383836270346773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048384137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995214,0.00008490417,0.0000144546675,0.00002897283,7.1542104e-7,0.000004606711,0.00019263058,0.0000016439118,0.00015075416],"genre_scores_gemma":[0.9993037,0.00009210476,0.00008895019,0.000020199666,0.0000033840547,0.0000075234498,0.00029517064,7.37783e-7,0.00018839574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996245,0.000091207985,0.000038079786,0.000066866916,0.00009145291,0.00008785752],"domain_scores_gemma":[0.99862754,0.00013074784,0.00089496234,0.000037252506,0.00016819798,0.00014133814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003278483,0.00016395391,0.0001536308,0.0008613269,0.00037192166,0.0005319714,0.00030785723,0.00024985088,0.00073657],"category_scores_gemma":[0.0010123671,0.00019982895,0.00017299019,0.0010339214,0.00023592763,0.00036026962,0.00033373028,0.00023154487,0.00011273608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003155819,0.00003810022,0.99726164,0.000018676474,0.000015028765,0.00013637007,0.00020989944,0.000029091405,0.00032856365,0.000008293509,0.00008779593,0.0018348455],"study_design_scores_gemma":[0.000002293846,0.000040864878,0.99903,0.000003679916,0.000005246881,0.00017398731,0.00038580512,0.00006438077,0.000045414403,0.000002652668,0.00024386679,0.0000017348212],"about_ca_topic_score_codex":0.073962264,"about_ca_topic_score_gemma":0.12874722,"teacher_disagreement_score":0.073962264,"about_ca_system_score_codex":0.0010942421,"about_ca_system_score_gemma":0.00067030225,"threshold_uncertainty_score":0.14706355},"labels":[],"label_agreement":null},{"id":"W2048635853","doi":"10.1016/s0828-282x(07)70815-2","title":"Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand","year":2007,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); Hôtel-Dieu de Montréal","funders":"GlaxoSmithKline; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Formulary; Medicine; Health care; Environmental health; Economic growth; Family medicine","score_opus":0.1997814222660779,"score_gpt":0.3553022238896094,"score_spread":0.15552080162353152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048635853","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036456387,0.011101225,0.00045644338,0.91673607,0.0012019719,0.00019465724,0.00076431315,0.00005689125,0.033032026],"genre_scores_gemma":[0.6704975,0.028384827,0.012302822,0.25333878,0.0008625205,0.00030446966,0.0015192018,0.000092294125,0.032697562],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98900115,0.0012257239,0.0007291034,0.00069565204,0.004461975,0.0038864017],"domain_scores_gemma":[0.96835953,0.0027215076,0.0012295058,0.00048295135,0.0110281315,0.016178366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010968135,0.00060099416,0.00080188987,0.002058149,0.007126761,0.010313424,0.0029465326,0.006093168,0.0061661475],"category_scores_gemma":[0.024987921,0.00049417885,0.0011580515,0.0030461198,0.0050107953,0.0045915353,0.0036326677,0.006834686,0.00035787205],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00053829217,0.0004380642,0.054121602,0.0015528303,0.00031704255,0.0042527453,0.010324472,0.0037732827,0.0015666924,0.25732905,0.47907516,0.18671075],"study_design_scores_gemma":[0.0006649429,0.00052457966,0.20897345,0.0039053948,0.00033940203,0.0010816284,0.021769842,0.005555104,0.00085090776,0.04431748,0.7115639,0.00045344912],"about_ca_topic_score_codex":0.99145764,"about_ca_topic_score_gemma":0.99162227,"teacher_disagreement_score":0.84707737,"about_ca_system_score_codex":0.15292266,"about_ca_system_score_gemma":0.48084256,"threshold_uncertainty_score":0.98248965},"labels":[],"label_agreement":null},{"id":"W2049305235","doi":"10.2217/cer.12.71","title":"Use of relative effectiveness information in reimbursement and pricing decisions in Europe","year":2012,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Reimbursement; Process (computing); Medicine; Comparative effectiveness research; Actuarial science; Public economics; Economics; Health care; Computer science; Alternative medicine; Economic growth","score_opus":0.34571217471328664,"score_gpt":0.45467960943436125,"score_spread":0.10896743472107462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049305235","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16741742,0.29419318,0.23720983,0.06103348,0.0028978158,0.00067880296,0.0076194014,0.00035748028,0.22859268],"genre_scores_gemma":[0.91866845,0.02454032,0.04647811,0.0051519084,0.0015962174,0.00025538236,0.0017644117,0.00011449389,0.0014308202],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.7353851,0.21312815,0.014696729,0.006072956,0.028943496,0.0017736001],"domain_scores_gemma":[0.68446636,0.27179077,0.020672122,0.010368056,0.011644291,0.0010584587],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.21830185,0.00068920257,0.003686697,0.017008461,0.0007781008,0.010125923,0.0028218883,0.0044436287,0.0049023856],"category_scores_gemma":[0.380977,0.0007273303,0.003377715,0.014423708,0.0057776463,0.014891862,0.0044755447,0.0036069793,0.00048433544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018385086,0.00019439949,0.016693043,0.0030952503,0.001880457,0.00022344047,0.0011113933,0.030348118,0.00015955418,0.69405645,0.01273679,0.23766252],"study_design_scores_gemma":[0.0009327449,0.0015627258,0.047506273,0.010495893,0.0026159177,0.0013184354,0.0012217852,0.040302325,0.0025285766,0.7887217,0.102182396,0.0006112425],"about_ca_topic_score_codex":0.0048607956,"about_ca_topic_score_gemma":0.0016665657,"teacher_disagreement_score":0.21830185,"about_ca_system_score_codex":0.0070412722,"about_ca_system_score_gemma":0.0042997557,"threshold_uncertainty_score":0.963973},"labels":[],"label_agreement":null},{"id":"W2049843830","doi":"10.1111/j.1365-2710.2006.00776.x","title":"Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Pharmacy and Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Global Positioning System; Generic drug; Family medicine; Quarter (Canadian coin); Health care; Population; Quality (philosophy); Sample (material); Actuarial science; Drug; Business; Environmental health; Pharmacology; Geography; Computer science","score_opus":0.2811160729881908,"score_gpt":0.4623177939581965,"score_spread":0.1812017209700057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049843830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966397,0.0009903498,0.000026597121,0.00024864325,0.000019801168,0.000013839628,0.00009923308,0.0000017567917,0.0019600214],"genre_scores_gemma":[0.99867404,0.0007362467,0.000041833413,0.000182857,0.000011789668,0.000011491985,0.00010541702,0.0000015140924,0.00023491262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983323,0.0007191227,0.00019902016,0.00014423895,0.00033327026,0.00027207212],"domain_scores_gemma":[0.9971059,0.00073088385,0.0010995115,0.00010322716,0.00048769545,0.00047276547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023364695,0.00020042487,0.0003545883,0.0020653512,0.00048809807,0.0011639174,0.00020547678,0.0004589737,0.0020396234],"category_scores_gemma":[0.004842741,0.00017729675,0.0004660204,0.0023058513,0.00082229,0.00051821454,0.00075983745,0.00038748462,0.0002652103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021326693,0.00014347643,0.96469325,0.0002930704,0.000077052115,0.00036632977,0.01718416,0.000050375824,0.00023920689,0.000103422746,0.00063913787,0.015997188],"study_design_scores_gemma":[0.000013407352,0.00014374411,0.9838087,0.00010957649,0.000029181032,0.00027096967,0.014228042,0.00003361164,0.00002667281,0.000013317701,0.0013170514,0.0000056443423],"about_ca_topic_score_codex":0.013059004,"about_ca_topic_score_gemma":0.013108946,"teacher_disagreement_score":0.013059004,"about_ca_system_score_codex":0.0011961994,"about_ca_system_score_gemma":0.00070035964,"threshold_uncertainty_score":0.025965929},"labels":[],"label_agreement":null},{"id":"W2050192040","doi":"10.1016/s1098-3015(10)70023-1","title":"CASE 2 DRUG ELUTING STENTS—AN EXAMPLE OFTHETRANSITION FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO COMPREHENSIVE APPROACHTOTHE DIFFUSION OF HEALTHTECHNOLOGIES","year":2008,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Diffusion; Drug-eluting stent; Medicine; Internal medicine; Pharmacology; Stent; Physics; Thermodynamics; Restenosis","score_opus":0.3444027444756034,"score_gpt":0.32492176232762154,"score_spread":0.01948098214798183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050192040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45280918,0.001485264,0.012137644,0.21299924,0.00047339805,0.0007383148,0.00133341,0.000088119275,0.31793538],"genre_scores_gemma":[0.94337136,0.0008039467,0.0042771865,0.015054484,0.00013669393,0.00013120715,0.00018416945,0.00003853185,0.03600241],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.993046,0.001260638,0.00022993091,0.0003328824,0.0018809821,0.0032496427],"domain_scores_gemma":[0.9912287,0.0037008221,0.0010385088,0.00048626092,0.0016549072,0.0018907286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040806294,0.00038485907,0.00046190253,0.0013799585,0.008443487,0.003733398,0.0013785281,0.0077977423,0.010832021],"category_scores_gemma":[0.016632158,0.000392716,0.00084653025,0.0020034297,0.004816488,0.0021916346,0.0036637606,0.004980213,0.0003407854],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005687532,0.0007685865,0.07629662,0.0004069073,0.00011348679,0.071781866,0.034394566,0.007109114,0.0049709002,0.6511328,0.09234784,0.06010851],"study_design_scores_gemma":[0.0005807073,0.00044087978,0.1218463,0.0008425575,0.00022853723,0.02417551,0.052861046,0.013151803,0.0062206252,0.1371229,0.64208996,0.00043915465],"about_ca_topic_score_codex":0.8007306,"about_ca_topic_score_gemma":0.8983698,"teacher_disagreement_score":0.96926737,"about_ca_system_score_codex":0.030732624,"about_ca_system_score_gemma":0.04941642,"threshold_uncertainty_score":0.40088588},"labels":[],"label_agreement":null},{"id":"W2051453363","doi":"10.1016/j.vaccine.2013.06.055","title":"Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines","year":2013,"lang":"en","type":"article","venue":"Vaccine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Dalhousie University; University of Toronto","funders":"","keywords":"Seasonal influenza; Virology; Medicine; Coronavirus disease 2019 (COVID-19); Infectious disease (medical specialty); Disease; Internal medicine","score_opus":0.21976071450235382,"score_gpt":0.3590766264748642,"score_spread":0.1393159119725104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051453363","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06394975,0.005928557,0.58394194,0.23295169,0.001148089,0.00065873004,0.0005196716,0.00040082232,0.110500745],"genre_scores_gemma":[0.7647461,0.00411818,0.20329782,0.014184901,0.0018447875,0.00046198594,0.00021247077,0.00018871644,0.010944946],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.95427936,0.029830555,0.0020459816,0.0026172674,0.0075261686,0.0037007085],"domain_scores_gemma":[0.8309035,0.12682123,0.013441099,0.014296612,0.0112210205,0.0033165384],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.05954898,0.0015762405,0.0025572402,0.002495474,0.0026221878,0.015842007,0.003735997,0.018677965,0.009112397],"category_scores_gemma":[0.17044531,0.0019142284,0.0022273795,0.002207396,0.006770688,0.02205277,0.0057120654,0.018357253,0.0007364517],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013083956,0.00020785237,0.0013979597,0.00019898433,0.0001352645,0.00021715123,0.00029559984,0.03643345,0.0007448173,0.93047285,0.0061325314,0.023632746],"study_design_scores_gemma":[0.00011499915,0.0000482607,0.0014272034,0.00023247708,0.00007262401,0.00013865488,0.00023978305,0.032142773,0.00085107895,0.9517233,0.01293508,0.000073757124],"about_ca_topic_score_codex":0.009544565,"about_ca_topic_score_gemma":0.010535392,"teacher_disagreement_score":0.940451,"about_ca_system_score_codex":0.009477687,"about_ca_system_score_gemma":0.018000107,"threshold_uncertainty_score":0.3149289},"labels":[],"label_agreement":null},{"id":"W2052186938","doi":"10.1212/wnl.0b013e3181df091b","title":"Generic antiepileptic drugs and associated medical resource utilization in the United States","year":2010,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Antiepileptic drug; Resource (disambiguation); MEDLINE; Medicine; Epilepsy; Intensive care medicine; Business; Psychiatry; Computer science; Political science","score_opus":0.05237934913727455,"score_gpt":0.28304846131644285,"score_spread":0.2306691121791683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052186938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731183,0.0010997864,0.000056018,0.00015717455,0.0000054257002,0.0000068677145,0.0010287298,0.00000484846,0.00032933278],"genre_scores_gemma":[0.9987882,0.00028428604,0.00007136988,0.00007601277,0.0000140018565,0.000005241711,0.000732141,9.875283e-7,0.00002779969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928087,0.00024531447,0.00011780019,0.00011418175,0.00015711253,0.00008469114],"domain_scores_gemma":[0.9959617,0.00061007653,0.002881939,0.000091265225,0.00019247395,0.0002625899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080281385,0.00016011715,0.0002404995,0.00081543514,0.0001289353,0.00045668337,0.00023052518,0.00034106133,0.0009320909],"category_scores_gemma":[0.003291698,0.00014268822,0.0004999073,0.0013722465,0.00017864072,0.00026054416,0.00033858605,0.0003431485,0.00007715214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056653647,0.000021524062,0.9985923,0.000010054557,0.00007157869,0.000027490632,0.000008383409,0.00006146101,0.000029139946,0.000012427886,0.00010860682,0.0010004776],"study_design_scores_gemma":[0.000005496652,0.000032754797,0.9994592,0.000006241819,0.000025552046,0.00010618416,0.000022635268,0.0002630483,0.00001241733,0.000009959219,0.000055120043,0.000001341587],"about_ca_topic_score_codex":0.010088373,"about_ca_topic_score_gemma":0.009910197,"teacher_disagreement_score":0.010088373,"about_ca_system_score_codex":0.00049076125,"about_ca_system_score_gemma":0.0003551314,"threshold_uncertainty_score":0.020059347},"labels":[],"label_agreement":null},{"id":"W2052701745","doi":"10.5539/ibr.v6n1p211","title":"Pharmacokinetic Tests: A Public Policy Tool of Science, Technology, and Innovation in Pharmaceutical Drugs for Brazil","year":2012,"lang":"en","type":"article","venue":"International Business Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Incentive; Pharmaceutical industry; Bioavailability; Government (linguistics); Business; Public economics; Public policy; Scope (computer science); Pharmacology; Accounting; Economics; Medicine; Economic growth; Computer science","score_opus":0.16683643636581413,"score_gpt":0.4613731958151695,"score_spread":0.29453675944935537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052701745","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07969878,0.026531009,0.12279277,0.35493842,0.0014041213,0.0008520435,0.0030221124,0.00054905174,0.41021162],"genre_scores_gemma":[0.95778483,0.007189502,0.02057728,0.004995858,0.0006961741,0.00040905658,0.0002721271,0.0000682901,0.008006995],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9902104,0.004536752,0.0005567232,0.000776597,0.0032802487,0.0006393006],"domain_scores_gemma":[0.9563691,0.029069787,0.006727882,0.0020273584,0.0048279446,0.0009779708],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.016216971,0.000639426,0.00066658447,0.0047003236,0.0018075678,0.0071050585,0.00086931605,0.0032144345,0.005389539],"category_scores_gemma":[0.048218034,0.000376602,0.0007353184,0.0041581388,0.0054570977,0.00686072,0.00327367,0.0035651524,0.00032480477],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023566761,0.000052063726,0.004718671,0.00028195622,0.00001997228,0.000119166194,0.00066952634,0.0025400918,0.0003637833,0.94247204,0.006523234,0.042215955],"study_design_scores_gemma":[0.00006402862,0.00016256869,0.019069357,0.0012575646,0.00012275156,0.00027749923,0.0019290438,0.021591391,0.0018969518,0.6993521,0.25417504,0.0001017128],"about_ca_topic_score_codex":0.029704066,"about_ca_topic_score_gemma":0.022446727,"teacher_disagreement_score":0.9981924,"about_ca_system_score_codex":0.019320378,"about_ca_system_score_gemma":0.03195735,"threshold_uncertainty_score":0.14017981},"labels":[],"label_agreement":null},{"id":"W2052791582","doi":"10.1016/j.jhealeco.2009.11.007","title":"Monopoly pricing of an antibiotic subject to bacterial resistance","year":2009,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Monopoly; Economics; Externality; Microeconomics; Antibiotic resistance; Antibiotics; Population; Quality (philosophy); Industrial organization; Biology; Medicine; Microbiology","score_opus":0.061884719706315594,"score_gpt":0.32484066913720366,"score_spread":0.26295594943088807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052791582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70583844,0.0032158336,0.13629144,0.027175926,0.00087950926,0.00037371743,0.0010727477,0.00076177745,0.12439055],"genre_scores_gemma":[0.980944,0.0004240319,0.002220328,0.0003550032,0.00043456137,0.00004086009,0.0000584873,0.00003866549,0.015484127],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9971771,0.0011316404,0.000115458744,0.00029237414,0.0005305635,0.0007528867],"domain_scores_gemma":[0.98135597,0.013411842,0.0017247961,0.0009093606,0.001105795,0.0014922098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058433088,0.0010987201,0.00293893,0.0016977361,0.0011425143,0.006531949,0.0033863187,0.0092814425,0.015466066],"category_scores_gemma":[0.024047665,0.0012867245,0.0014398454,0.0012786868,0.0029548036,0.0040771333,0.0017219417,0.00473868,0.0011601709],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029036629,0.0007723519,0.0032772422,0.00044769456,0.00025724265,0.0026903283,0.00025933134,0.24588944,0.010535739,0.68717974,0.0158738,0.029913427],"study_design_scores_gemma":[0.00045117806,0.00080598536,0.003216557,0.0000630126,0.00021987768,0.0006697371,0.00013399182,0.7539522,0.0014440691,0.23525934,0.003651663,0.0001323785],"about_ca_topic_score_codex":0.0039795567,"about_ca_topic_score_gemma":0.002414416,"teacher_disagreement_score":0.015466066,"about_ca_system_score_codex":0.0034476076,"about_ca_system_score_gemma":0.002660447,"threshold_uncertainty_score":0.051739156},"labels":[],"label_agreement":null},{"id":"W2052972684","doi":"10.1016/j.mib.2003.08.003","title":"Why is big Pharma getting out of antibacterial drug discovery?","year":2003,"lang":"en","type":"review","venue":"Current Opinion in Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":501,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Drug discovery; Bureaucracy; Clinical trial; Drug development; Drug; Biology; Investment (military); Business; Process (computing); Intensive care medicine; Biotechnology; Pharmacology; Bioinformatics; Medicine; Political science; Law; Computer science","score_opus":0.184830175105148,"score_gpt":0.39166833003440066,"score_spread":0.20683815492925267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052972684","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009857572,0.6173709,0.0013063601,0.36678773,0.0059492895,0.000016632861,0.000065330845,0.00006166905,0.0074563827],"genre_scores_gemma":[0.021405704,0.7502159,0.0022939278,0.20453501,0.016218642,0.00003895737,0.00006713785,0.000054474785,0.0051702205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99522334,0.0014090035,0.00028199347,0.00039672523,0.0022476618,0.0004413297],"domain_scores_gemma":[0.96449673,0.02422144,0.0028645892,0.0007055913,0.0056952536,0.0020164696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012618548,0.00067198195,0.0026529648,0.0015847484,0.0010423844,0.0052622748,0.0014406911,0.009258661,0.0059251795],"category_scores_gemma":[0.022102835,0.0004862999,0.0009591568,0.0033181296,0.0040332917,0.009935349,0.001524549,0.009553388,0.002527882],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019238352,0.00010418812,0.0015148553,0.0050035417,0.00023427804,0.0004464276,0.00021337708,0.00047984527,0.000942593,0.055957615,0.29352504,0.64138585],"study_design_scores_gemma":[0.00012315565,0.00017232164,0.00451396,0.00472321,0.00017656364,0.001038388,0.00060172635,0.00043329588,0.0005177788,0.095612876,0.89201814,0.000068516776],"about_ca_topic_score_codex":0.003220812,"about_ca_topic_score_gemma":0.007922242,"teacher_disagreement_score":0.012618548,"about_ca_system_score_codex":0.0036905627,"about_ca_system_score_gemma":0.007044787,"threshold_uncertainty_score":0.066734016},"labels":[],"label_agreement":null},{"id":"W2053086896","doi":"10.1177/097226290000400209","title":"Privatisation: The Berlin-Chemie Way","year":2000,"lang":"en","type":"article","venue":"Vision The Journal of Business Perspective","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); German; Public sector; Quarter (Canadian coin); Communism; Business; Management; Economic history; Political science; Economy; Economics; History; Law; Politics","score_opus":0.0362725886722212,"score_gpt":0.2878927191570368,"score_spread":0.2516201304848156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053086896","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009835886,0.04139952,0.0068159974,0.63680315,0.009877005,0.00005511223,0.00015854918,0.00016678202,0.29488802],"genre_scores_gemma":[0.4376055,0.03981094,0.0066383793,0.26260212,0.0074007297,0.0002502626,0.00017687595,0.0002664903,0.24524866],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948494,0.00156432,0.0001565004,0.00073497416,0.0015708933,0.0011238531],"domain_scores_gemma":[0.99608684,0.00190559,0.00036385836,0.0003423083,0.00036279857,0.0009386339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007830624,0.0006482935,0.000577514,0.0012138971,0.004271655,0.014983532,0.00071406306,0.012082239,0.018988818],"category_scores_gemma":[0.012325309,0.00047413624,0.00045231025,0.0012548101,0.0122736795,0.0147095,0.006042551,0.011215852,0.0032904544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023927902,0.00002880179,0.00009355465,0.000040163362,0.000006334672,0.00011702342,0.00038363624,0.00021249741,0.000106166306,0.9338958,0.051849734,0.013242364],"study_design_scores_gemma":[0.000046434423,0.000040193503,0.00035203804,0.00017964018,0.0000040849454,0.000103176775,0.00034162423,0.00020660294,0.00015881215,0.23703882,0.7614996,0.000028996079],"about_ca_topic_score_codex":0.0064646443,"about_ca_topic_score_gemma":0.005280525,"teacher_disagreement_score":0.018988818,"about_ca_system_score_codex":0.007940386,"about_ca_system_score_gemma":0.008497151,"threshold_uncertainty_score":0.06352395},"labels":[],"label_agreement":null},{"id":"W2054254219","doi":"10.1016/j.drudis.2014.11.012","title":"Drug hunters incorporated! Is there a formula?","year":2014,"lang":"en","type":"editorial","venue":"Drug Discovery Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vertex Pharmaceuticals (Canada)","funders":"","keywords":"Drug; Drug discovery; Pharmaceutical sciences; Computational biology; Pharmacology; Computer science; Chemistry; Medicine; Biology; Biochemistry","score_opus":0.01916430772263744,"score_gpt":0.25769857305484684,"score_spread":0.2385342653322094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054254219","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001700139,0.0082252445,0.0001309818,0.10532847,0.88460386,0.0000121693865,0.00004295733,0.0000421255,0.0015972318],"genre_scores_gemma":[0.00034378178,0.005577423,0.00016633635,0.04974844,0.9295747,0.00002439814,0.000022157948,0.00004658485,0.014496111],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9870827,0.0027655272,0.0016289954,0.0010330059,0.006779715,0.00070998137],"domain_scores_gemma":[0.94645053,0.028222825,0.003671164,0.0017113806,0.014794169,0.0051500103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019219045,0.004247436,0.0054438272,0.00629023,0.00408766,0.0145485075,0.0052612866,0.03135328,0.019041466],"category_scores_gemma":[0.071914874,0.002033159,0.0034076953,0.003667416,0.0048165545,0.0096699605,0.002983297,0.037658837,0.012682802],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014238026,0.000009721395,0.000012031703,0.00008370227,0.000013340125,0.000029033912,0.0000063956036,0.0000195844,0.000011953599,0.0005020901,0.996514,0.0027839083],"study_design_scores_gemma":[0.00008429856,0.000020358333,0.00018708785,0.00048396614,0.0000700598,0.0000725526,0.000039153976,0.00017630728,0.000060054615,0.003225286,0.9955532,0.000027707534],"about_ca_topic_score_codex":0.0052979332,"about_ca_topic_score_gemma":0.017821083,"teacher_disagreement_score":0.03135328,"about_ca_system_score_codex":0.007083518,"about_ca_system_score_gemma":0.008459207,"threshold_uncertainty_score":0.10164124},"labels":[],"label_agreement":null},{"id":"W2054408060","doi":"10.1177/1715163513482704","title":"Provincial/territorial governments join forces to make further cuts to generic drug prices","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Join (topology); Business; Operations management; Economics; Mathematics","score_opus":0.03739916178167512,"score_gpt":0.24956288412597552,"score_spread":0.2121637223443004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054408060","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.114417486,0.003967399,0.0077307164,0.35217172,0.0049342457,0.00074713223,0.0050286027,0.0012099842,0.5097928],"genre_scores_gemma":[0.5990789,0.00238167,0.009564932,0.14778912,0.0017660247,0.00035120707,0.0027550438,0.00037722342,0.23593588],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98896664,0.00080083904,0.00024720142,0.0003645691,0.005491993,0.0041286848],"domain_scores_gemma":[0.98337674,0.002365891,0.0010551492,0.0007354987,0.0071131904,0.0053535565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005907632,0.0005567332,0.00076963025,0.0029030046,0.0053942115,0.0076889605,0.0016817484,0.007844606,0.020599587],"category_scores_gemma":[0.02060793,0.0007529473,0.0019098496,0.003056077,0.002215131,0.0012434224,0.003638311,0.0062800446,0.002080729],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003314376,0.00024552643,0.024222538,0.00035796626,0.00042864244,0.00053529383,0.0016784751,0.0028222604,0.0031223518,0.27764425,0.6245798,0.064031534],"study_design_scores_gemma":[0.0002744611,0.00009790451,0.08148829,0.00018051497,0.00015904782,0.00017134994,0.0017696089,0.002304488,0.00091571495,0.011953453,0.9006168,0.000068265115],"about_ca_topic_score_codex":0.80103296,"about_ca_topic_score_gemma":0.87727934,"teacher_disagreement_score":0.19896704,"about_ca_system_score_codex":0.034181748,"about_ca_system_score_gemma":0.11722194,"threshold_uncertainty_score":0.40027755},"labels":[],"label_agreement":null},{"id":"W2054930055","doi":"10.1016/j.healthpol.2005.12.015","title":"A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences","year":2006,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Drug; Value (mathematics); Family medicine; Pharmacology","score_opus":0.07921757057824212,"score_gpt":0.35509443292711473,"score_spread":0.2758768623488726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054930055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9415871,0.010228859,0.00043997887,0.026138175,0.000103673585,0.000043612818,0.005741968,0.000027001006,0.015689665],"genre_scores_gemma":[0.99472624,0.0017102138,0.00020199269,0.00080353615,0.000040725485,0.000005847405,0.00077551656,0.000006893581,0.0017291023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807477,0.00023561974,0.00006733605,0.00013239829,0.0005833483,0.0009064648],"domain_scores_gemma":[0.99160576,0.0027186219,0.0011887006,0.000101660014,0.0025373267,0.0018479312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015778294,0.00015607281,0.00051156845,0.002415382,0.0016846604,0.003002023,0.0011344979,0.0011633248,0.004613142],"category_scores_gemma":[0.008533035,0.0002230677,0.0008976896,0.0060877996,0.0011939654,0.0011809916,0.00079035613,0.0014933491,0.00010872218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042378497,0.00059628027,0.78795946,0.00046424824,0.0008183223,0.0012545903,0.002387572,0.020218318,0.0011022268,0.07925757,0.035226237,0.06647732],"study_design_scores_gemma":[0.00015183003,0.00011259552,0.9728769,0.000090984744,0.00027442726,0.00015259342,0.0036470583,0.00564121,0.00042573863,0.0029200905,0.013649289,0.000057215053],"about_ca_topic_score_codex":0.98755324,"about_ca_topic_score_gemma":0.9932318,"teacher_disagreement_score":0.9524851,"about_ca_system_score_codex":0.04751492,"about_ca_system_score_gemma":0.039757125,"threshold_uncertainty_score":0.34474647},"labels":[],"label_agreement":null},{"id":"W2055400723","doi":"10.1177/0046958015584641","title":"The Opportunity Cost of Capital","year":2015,"lang":"en","type":"article","venue":"INQUIRY The Journal of Health Care Organization Provision and Financing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Sanofi (Canada); University of Toronto","funders":"","keywords":"Cost of capital; Implicit cost; Capital (architecture); Economics; Capital cost; Value (mathematics); Relevant cost; Opportunity cost; Weighted average cost of capital; Field (mathematics); Total cost; Microeconomics; Business; Neoclassical economics; Economic capital; Individual capital; Computer science; Mathematics; Macroeconomics; Incentive","score_opus":0.10587017775234542,"score_gpt":0.3294780776599226,"score_spread":0.22360789990757718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055400723","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06398155,0.023830626,0.22274916,0.045375865,0.0024794254,0.00033361957,0.0022612982,0.00027300743,0.63871545],"genre_scores_gemma":[0.90150696,0.01531035,0.01637519,0.002736048,0.0017193372,0.000360125,0.00049322756,0.00013370962,0.06136495],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9964322,0.00087751896,0.00016877937,0.00039925298,0.0014649193,0.0006572639],"domain_scores_gemma":[0.9928848,0.0041746804,0.00077924714,0.0006432631,0.0011058422,0.00041210363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023426898,0.0007239294,0.00063728995,0.0018139161,0.0011406586,0.006362738,0.0013365523,0.0032266101,0.013088617],"category_scores_gemma":[0.015611057,0.00041737285,0.0007595167,0.0014495337,0.00414974,0.006997481,0.0019477097,0.0030305681,0.0012644381],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018754892,0.0000132492805,0.0004893271,0.000083185405,0.000021735152,0.00011872191,0.00005563429,0.0043973764,0.00013680103,0.97897834,0.004020319,0.011666504],"study_design_scores_gemma":[0.000016529197,0.00006084131,0.0015052332,0.0003264491,0.00003789862,0.0006512052,0.00016481464,0.0070469584,0.00051767024,0.90696025,0.08266606,0.000046038567],"about_ca_topic_score_codex":0.0025067911,"about_ca_topic_score_gemma":0.001522855,"teacher_disagreement_score":0.013088617,"about_ca_system_score_codex":0.0045466386,"about_ca_system_score_gemma":0.002697341,"threshold_uncertainty_score":0.04378575},"labels":[],"label_agreement":null},{"id":"W2057067950","doi":"10.1002/hec.1392","title":"Competition between brand‐name and generics – analysis on pricing of brand‐name pharmaceutical","year":2008,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Brand names; Competition (biology); Business; Brand management; Advertising; Marketing; Biology","score_opus":0.12970522711036553,"score_gpt":0.33977328384453725,"score_spread":0.21006805673417173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057067950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66887134,0.0026339537,0.22882028,0.00580855,0.000184589,0.00035622524,0.00075440516,0.00014971627,0.092420876],"genre_scores_gemma":[0.98744804,0.00040541575,0.0037062645,0.00018254864,0.000054079712,0.000055072658,0.00007202543,0.000015708405,0.008060944],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9986853,0.0005383699,0.000035116336,0.00014680518,0.00021096242,0.0003833934],"domain_scores_gemma":[0.9954241,0.003266781,0.00045998447,0.00017087732,0.00029990333,0.00037849272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021099658,0.00073556864,0.0016514527,0.000865505,0.0007766104,0.0025178266,0.0022573865,0.002810153,0.012567883],"category_scores_gemma":[0.0070251618,0.00056346663,0.0021484187,0.0007477988,0.00202598,0.0039950474,0.0014616213,0.002004243,0.0006413648],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031158436,0.00020045275,0.003279021,0.00021623816,0.00009627188,0.0006741136,0.0003197294,0.2719313,0.0030950059,0.71011096,0.003192459,0.006572953],"study_design_scores_gemma":[0.00010899096,0.00016632186,0.0022784485,0.000021758375,0.00005847529,0.00015883987,0.0001869982,0.82069546,0.00031304357,0.17402191,0.001935113,0.000054683125],"about_ca_topic_score_codex":0.00998317,"about_ca_topic_score_gemma":0.005466549,"teacher_disagreement_score":0.012567883,"about_ca_system_score_codex":0.0029382482,"about_ca_system_score_gemma":0.0018203312,"threshold_uncertainty_score":0.042043746},"labels":[],"label_agreement":null},{"id":"W2057160780","doi":"10.1097/00043764-200107000-00002","title":"Workers??? Compensation Claims From Latex Glove Use","year":2001,"lang":"en","type":"letter","venue":"Journal of Occupational and Environmental Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Officer; Workers' compensation; Occupational medicine; Public health; Occupational safety and health; West virginia; Occupational exposure; Environmental health; Unit (ring theory); Medicine; Medical examiner; Family medicine; Compensation (psychology); Gerontology; Political science; Poison control; Human factors and ergonomics; Psychology; Geography; Nursing","score_opus":0.10458523623908458,"score_gpt":0.2848355416102437,"score_spread":0.18025030537115913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057160780","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033554606,0.0018669228,0.00021491564,0.8830044,0.009871799,0.00007471773,0.0025367388,0.00010850547,0.06876737],"genre_scores_gemma":[0.23458353,0.002660573,0.00018821908,0.59677535,0.026046894,0.000109822184,0.0013762794,0.00004184563,0.13821755],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9984823,0.00027450258,0.00023450806,0.00015005267,0.00036434593,0.0004943818],"domain_scores_gemma":[0.99508023,0.0020172328,0.0007932453,0.00019050835,0.0010894263,0.0008293911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001705678,0.00030520285,0.00066237827,0.00070064573,0.0024322453,0.0015031183,0.00062216824,0.015777992,0.0108207045],"category_scores_gemma":[0.012352662,0.00040336233,0.00051391654,0.00056868105,0.00044646472,0.0009119453,0.0006793669,0.0037643546,0.004806747],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021804053,0.00009360712,0.02411165,0.00009325918,0.000020858348,0.0037252386,0.00035816542,0.00009206172,0.00040002604,0.0019040508,0.95268404,0.016298866],"study_design_scores_gemma":[0.0005714468,0.00034882544,0.26359457,0.0008629018,0.0001364442,0.009506745,0.0023167913,0.0021037948,0.0012900949,0.0064562806,0.7126678,0.00014427151],"about_ca_topic_score_codex":0.0130306175,"about_ca_topic_score_gemma":0.031218702,"teacher_disagreement_score":0.015777992,"about_ca_system_score_codex":0.0022131293,"about_ca_system_score_gemma":0.001475312,"threshold_uncertainty_score":0.036198914},"labels":[],"label_agreement":null},{"id":"W2058625864","doi":"10.1071/ah090241","title":"PBS copayments and safety nets - A commentary on Sweeny and Doran and Robertson","year":2009,"lang":"en","type":"letter","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical Benefits Scheme; Access to medicines; Subsidy; Health economics; Pharmaceutical policy; Wonder; Government (linguistics); Business; Health care; Population health; Public administration; Public economics; Health policy; Political science; Economic growth; Economics; Medicine; Law; Developing country; Nursing","score_opus":0.11510145559668244,"score_gpt":0.35933535845088277,"score_spread":0.24423390285420032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058625864","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000097973076,0.0049969316,0.000044781526,0.98656136,0.0066155954,0.000006314054,0.00004837883,0.0000086699765,0.001619904],"genre_scores_gemma":[0.0011195479,0.0018055486,0.000092339185,0.98785025,0.0052896184,0.000019859046,0.000010295194,0.000011440212,0.0038011246],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98480415,0.006402604,0.0012843186,0.0020471427,0.0041841078,0.0012777436],"domain_scores_gemma":[0.95672643,0.032613225,0.002048669,0.0007346347,0.005770995,0.0021060647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020618765,0.0012680116,0.002637,0.0011123128,0.0056528095,0.0077796495,0.0059297425,0.08038024,0.009661854],"category_scores_gemma":[0.076086745,0.001486834,0.0028016022,0.0019647186,0.007848375,0.0126081975,0.0026792996,0.057548847,0.005289943],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028171926,0.000011705498,0.00007756199,0.000088411725,0.000008712095,0.00009966454,0.0001416177,0.000046593883,0.000021926324,0.011291136,0.98453844,0.0036459826],"study_design_scores_gemma":[0.00010394342,0.000036531266,0.0007363941,0.0006778285,0.00002610147,0.00014445918,0.00040350005,0.00017899454,0.00009521588,0.012060191,0.985471,0.00006586134],"about_ca_topic_score_codex":0.07470324,"about_ca_topic_score_gemma":0.10944584,"teacher_disagreement_score":0.08038024,"about_ca_system_score_codex":0.013708652,"about_ca_system_score_gemma":0.026917214,"threshold_uncertainty_score":0.14853686},"labels":[],"label_agreement":null},{"id":"W2058801790","doi":"10.1586/14737167.3.3.303","title":"Fixed and flexible formularies as cost-control mechanisms","year":2003,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Centre for Addiction and Mental Health","funders":"Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Health and Long-Term Care","keywords":"Formulary; Control (management); Cost control; Fixed cost; Operations management; Computer science; Medicine; Intensive care medicine; Operations research; Risk analysis (engineering); Business; Economics; Pharmacology; Mathematics; Accounting","score_opus":0.08692920275430051,"score_gpt":0.49891468068463857,"score_spread":0.4119854779303381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058801790","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008321092,0.96021044,0.011676016,0.0014242217,0.00045260484,0.00019047607,0.0000651939,0.000045950546,0.017613936],"genre_scores_gemma":[0.13232456,0.8431028,0.015773017,0.0012447345,0.0005345565,0.00036109396,0.0001058952,0.000025005009,0.0065282276],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972115,0.000883803,0.00026262947,0.00027883804,0.0011559925,0.00020731289],"domain_scores_gemma":[0.9957801,0.0028203973,0.0008031181,0.00017455095,0.00035441568,0.0000673122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003094338,0.00064649805,0.0012570207,0.0013776853,0.00032959357,0.0024866704,0.0021318945,0.0014579181,0.003968706],"category_scores_gemma":[0.0072202976,0.00031917408,0.0011323905,0.0017998496,0.0016813242,0.0031034653,0.0008800988,0.001455178,0.00041087638],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033548003,0.00014754542,0.00090933655,0.02964007,0.00041315032,0.00036680774,0.000279491,0.0067032184,0.002436977,0.31783015,0.007105737,0.6338321],"study_design_scores_gemma":[0.00031951276,0.0018104841,0.0049120844,0.019073639,0.0014784733,0.0016343404,0.0002913514,0.0070234016,0.009389879,0.11411273,0.83981675,0.00013737041],"about_ca_topic_score_codex":0.0012310394,"about_ca_topic_score_gemma":0.0010368234,"teacher_disagreement_score":0.003968706,"about_ca_system_score_codex":0.0013603696,"about_ca_system_score_gemma":0.0019876598,"threshold_uncertainty_score":0.016364634},"labels":[],"label_agreement":null},{"id":"W2059053469","doi":"10.1016/s0140-6736(13)60845-4","title":"A modest but meaningful decision for Indian drug patents","year":2014,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Supreme court; Victory; Imatinib mesylate; Political science; Medicine; High Court; Law; Imatinib; Internal medicine","score_opus":0.10131092052055442,"score_gpt":0.2985495018781089,"score_spread":0.1972385813575545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059053469","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018647403,0.0048977314,0.0035247542,0.69319916,0.010351267,0.00012389905,0.0009976317,0.000357794,0.26790044],"genre_scores_gemma":[0.44537413,0.0023079459,0.0035605477,0.45883235,0.011797963,0.00020744657,0.0003337258,0.000280224,0.07730575],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97865933,0.00596333,0.0013472827,0.002224514,0.0076236264,0.0041820006],"domain_scores_gemma":[0.96339923,0.020783933,0.0012416124,0.003286314,0.0059469533,0.0053419215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01525541,0.00082864356,0.0015175641,0.0024482056,0.0057677506,0.018927757,0.0032859975,0.029887483,0.0249245],"category_scores_gemma":[0.069524236,0.00067278644,0.0020334232,0.002306243,0.009030288,0.008042643,0.00478835,0.024641996,0.0063983197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004150524,0.00012739172,0.0008395458,0.00019202876,0.000102846374,0.00052628777,0.00033826823,0.0006521482,0.0013952988,0.728122,0.23122145,0.036067743],"study_design_scores_gemma":[0.0003263806,0.00021617356,0.004352499,0.00049576757,0.00025848037,0.00067493616,0.0006902779,0.0014406727,0.002066199,0.47831112,0.51092905,0.00023844301],"about_ca_topic_score_codex":0.012931047,"about_ca_topic_score_gemma":0.018382905,"teacher_disagreement_score":0.029887483,"about_ca_system_score_codex":0.008616557,"about_ca_system_score_gemma":0.01975395,"threshold_uncertainty_score":0.0833807},"labels":[],"label_agreement":null},{"id":"W2059657285","doi":"10.1377/hlthaff.25.5.1353","title":"Prices And Availability Of Biopharmaceuticals: An International Comparison","year":2006,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Per capita; European union; Product (mathematics); International trade; Agricultural economics; Economics; Member states; International economics; Business; Environmental health; Medicine; Mathematics","score_opus":0.09391597464132455,"score_gpt":0.3715708587017222,"score_spread":0.2776548840603976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059657285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94105166,0.015853113,0.00142172,0.0013530654,0.00008384186,0.00002178581,0.004122136,0.000027284073,0.036065467],"genre_scores_gemma":[0.99386567,0.0024456051,0.00031527496,0.0001086951,0.00007679733,0.0000069238195,0.002348072,0.000014073685,0.00081879663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890673,0.00023596508,0.000118680226,0.00022311597,0.00038809457,0.00012733818],"domain_scores_gemma":[0.98581034,0.0052008773,0.006588686,0.0005016135,0.0014033151,0.00049527944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012403746,0.00019593346,0.00034843513,0.0028817467,0.00027215175,0.0014240971,0.00031187574,0.00031546128,0.0051222006],"category_scores_gemma":[0.008545099,0.00015943963,0.0006795598,0.003845847,0.00061096606,0.001880141,0.0009271831,0.0006977348,0.00031311397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014927135,0.00021748056,0.89386827,0.00059899426,0.0011601723,0.00071316364,0.0011422765,0.0027920236,0.0013001984,0.01414406,0.005237619,0.07733304],"study_design_scores_gemma":[0.000052146224,0.00023944225,0.981316,0.00016434213,0.00025515928,0.0005871482,0.0008756195,0.0008883281,0.0007455247,0.0014915927,0.013356017,0.000028670454],"about_ca_topic_score_codex":0.005559781,"about_ca_topic_score_gemma":0.0050321775,"teacher_disagreement_score":0.005559781,"about_ca_system_score_codex":0.0007578438,"about_ca_system_score_gemma":0.00019498837,"threshold_uncertainty_score":0.0171355},"labels":[],"label_agreement":null},{"id":"W2060894663","doi":"10.1038/clpt.2014.145","title":"Accelerated Access to Innovative Medicines for Patients in Need","year":2014,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Institut National d'Excellence en Santé et en Services Sociaux","funders":"Innovative Medicines Initiative; National Comprehensive Cancer Network; European Federation of Pharmaceutical Industries and Associations; Bill and Melinda Gates Foundation","keywords":"Clinical pharmacology; Variety (cybernetics); Access to medicines; Business; Health care; Medicine; Pharmacology; Economic growth; Computer science; Economics; Nursing; Public health","score_opus":0.27197532223787846,"score_gpt":0.47316314814981514,"score_spread":0.20118782591193668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060894663","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47277677,0.01969823,0.018043071,0.31200314,0.00096247834,0.0003653375,0.0020535642,0.00035143748,0.17374595],"genre_scores_gemma":[0.9516977,0.01059974,0.00838686,0.013460939,0.002243263,0.00012473587,0.00070347014,0.00005183021,0.01273149],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805707,0.0009850346,0.000103047634,0.00012418757,0.0003616855,0.00036890528],"domain_scores_gemma":[0.9899635,0.004360581,0.0026412772,0.00038899566,0.0008119366,0.0018337925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030598321,0.00014917209,0.00028081995,0.00100638,0.0006397286,0.002706076,0.00044755344,0.0016515708,0.028864289],"category_scores_gemma":[0.014499436,0.00014247424,0.0007998412,0.0009020886,0.0006559041,0.0022023302,0.003046395,0.002319706,0.0015136539],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000877032,0.0009705999,0.17590785,0.001042168,0.00021619929,0.0012223913,0.0016929128,0.003076801,0.0025294148,0.19246192,0.0725409,0.5474618],"study_design_scores_gemma":[0.0009870735,0.0016881465,0.33574745,0.0017044726,0.00036036313,0.0049678776,0.0051530977,0.0061154356,0.002528184,0.14068873,0.49993485,0.00012427679],"about_ca_topic_score_codex":0.0020426745,"about_ca_topic_score_gemma":0.0029867399,"teacher_disagreement_score":0.028864289,"about_ca_system_score_codex":0.0017792138,"about_ca_system_score_gemma":0.004256395,"threshold_uncertainty_score":0.09656066},"labels":[],"label_agreement":null},{"id":"W2061118140","doi":"10.1503/cmaj.050663","title":"Nonpatentable drugs and the cost of our ignorance","year":2006,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Pharmaceutical industry; Ignorance; Drug industry; Randomized controlled trial; Clinical trial; Medicine; Computer science; Data science; Operations research; Pharmacology; Surgery; Engineering; Political science; Law; Engineering ethics; Pathology","score_opus":0.015219609763506317,"score_gpt":0.23308183254714138,"score_spread":0.21786222278363507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061118140","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016229844,0.099148646,0.009566287,0.778354,0.0018477811,0.000056061283,0.0010820465,0.0000668844,0.09364841],"genre_scores_gemma":[0.7316853,0.123607546,0.005820932,0.11653565,0.010653604,0.00011949097,0.0005174912,0.00010800722,0.010952014],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889339,0.005895824,0.00045871403,0.000695286,0.0035037934,0.00051247573],"domain_scores_gemma":[0.9321433,0.052095033,0.0060689445,0.0028894355,0.003983939,0.0028193756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012539524,0.0004607396,0.0012654093,0.0018438656,0.0011899689,0.0062027737,0.0013548357,0.0051572714,0.018100008],"category_scores_gemma":[0.08035201,0.00038907237,0.00075633585,0.001741273,0.009005569,0.009136328,0.0029213852,0.007986385,0.0013865683],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012375548,0.0002370934,0.013847537,0.0013845668,0.0006240628,0.0012185816,0.00092382834,0.005545344,0.00031967906,0.5832142,0.14803104,0.24341662],"study_design_scores_gemma":[0.0001718659,0.00023714984,0.0071914867,0.0028253463,0.0002551974,0.0021946437,0.0011653764,0.003129256,0.00028356482,0.74999225,0.2324552,0.00009863274],"about_ca_topic_score_codex":0.008627416,"about_ca_topic_score_gemma":0.0057852957,"teacher_disagreement_score":0.018100008,"about_ca_system_score_codex":0.006752821,"about_ca_system_score_gemma":0.004326666,"threshold_uncertainty_score":0.06631613},"labels":[],"label_agreement":null},{"id":"W2061120801","doi":"10.1038/nbt1106-1324","title":"Democracy unleashed—unpacking the tooth fairy in drug industry R&amp;D","year":2006,"lang":"en","type":"letter","venue":"Nature Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institutes of Health","keywords":"Unpacking; Democracy; Drug; Drug industry; Political science; Biology; Biotechnology; Pharmacology; Philosophy; Law","score_opus":0.02973020496102218,"score_gpt":0.2746882769496241,"score_spread":0.24495807198860192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061120801","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001405707,0.0012664569,0.00048488495,0.97183144,0.007232427,0.000025932446,0.00004644284,0.00003136779,0.017675256],"genre_scores_gemma":[0.011879199,0.00028183687,0.00026160854,0.95720524,0.004166429,0.000037366477,0.000010458905,0.000023073218,0.026134875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98173136,0.004626009,0.0010392441,0.0021587687,0.0053100265,0.005134557],"domain_scores_gemma":[0.9793323,0.012259206,0.0011473857,0.0010413196,0.0022043097,0.004015463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018793015,0.0010330776,0.0018862223,0.00104005,0.018055387,0.018694915,0.00310733,0.15058315,0.010616769],"category_scores_gemma":[0.04426492,0.0013197623,0.0021461402,0.0009581219,0.016451886,0.014593827,0.010067475,0.0767246,0.0041409764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013474461,0.0000821133,0.0006157872,0.00006539174,0.00003769351,0.0007341832,0.0006491418,0.00017353604,0.00039794194,0.1437251,0.84180677,0.011577613],"study_design_scores_gemma":[0.00020481671,0.00009041734,0.0016055633,0.00021483327,0.000036848433,0.00026656027,0.0010495614,0.00078076194,0.0007225955,0.16356826,0.831325,0.000134783],"about_ca_topic_score_codex":0.030377073,"about_ca_topic_score_gemma":0.08642658,"teacher_disagreement_score":0.15058315,"about_ca_system_score_codex":0.012133422,"about_ca_system_score_gemma":0.018472292,"threshold_uncertainty_score":0.09938818},"labels":[],"label_agreement":null},{"id":"W2061188413","doi":"10.1056/nejmp048284","title":"Merck's Recall of Rofecoxib — A Strategic Perspective","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rofecoxib; Medicine; Quarter (Canadian coin); Recall; Stock (firearms); Anesthesia; Psychology","score_opus":0.0945081546443999,"score_gpt":0.31959761944108106,"score_spread":0.22508946479668115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061188413","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019145731,0.03290094,0.00018897203,0.93573385,0.002351027,0.0000037319353,0.00007186228,0.000010312519,0.02682477],"genre_scores_gemma":[0.24250396,0.10747915,0.0005777336,0.6117855,0.01850298,0.000026943224,0.000114537695,0.00005901757,0.018950222],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935628,0.0027082309,0.00032261317,0.0006654776,0.0016934111,0.0010474715],"domain_scores_gemma":[0.9850301,0.008717266,0.0017972856,0.00039131148,0.002090995,0.0019730811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008156491,0.0007004561,0.00084315997,0.0020459392,0.005706716,0.016234461,0.0012904911,0.023001477,0.0067117903],"category_scores_gemma":[0.02035458,0.0005099567,0.000593094,0.0027375603,0.010836053,0.0099976435,0.0025759696,0.019422371,0.001551451],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010627518,0.00004916728,0.0011242401,0.00019033758,0.000041012332,0.00072353316,0.0022025309,0.00034303856,0.00018302702,0.34777373,0.612052,0.03521113],"study_design_scores_gemma":[0.0000630341,0.0001242836,0.002125529,0.00092616765,0.000037108668,0.0005399465,0.005183235,0.00033088843,0.00024796452,0.093279734,0.8970222,0.000119924385],"about_ca_topic_score_codex":0.03277889,"about_ca_topic_score_gemma":0.03547866,"teacher_disagreement_score":0.03277889,"about_ca_system_score_codex":0.010318156,"about_ca_system_score_gemma":0.00868022,"threshold_uncertainty_score":0.07486385},"labels":[],"label_agreement":null},{"id":"W2061307501","doi":"10.3821/1913-701x(2007)140[227b:pdssft]2.0.co;2","title":"Prescription drug spending slowing for the first time in more than 20 years","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medical prescription; Economics; Medicine; Pharmacology","score_opus":0.05143248377977991,"score_gpt":0.27388826716450476,"score_spread":0.22245578338472485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061307501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7630978,0.025492128,0.0015523317,0.108824104,0.0022096857,0.0000893168,0.02172344,0.0004365036,0.0765746],"genre_scores_gemma":[0.96191865,0.007180892,0.00090693205,0.007683061,0.0010028803,0.000023663237,0.005975112,0.00007143315,0.015237414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988154,0.00010706223,0.00006494166,0.00013201649,0.00044401715,0.00043666875],"domain_scores_gemma":[0.9921261,0.00056589476,0.002386431,0.00040066536,0.0030168493,0.0015039394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015073525,0.000313357,0.0005267426,0.0012663032,0.0012368608,0.0024220736,0.00047455268,0.0015556721,0.006850403],"category_scores_gemma":[0.008303079,0.00021253608,0.0006907686,0.0034187848,0.0005034313,0.0011624652,0.00085062895,0.0021938642,0.0008395643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006971673,0.00034087847,0.6664442,0.00055132725,0.0005941537,0.00066651613,0.0010489732,0.0013216593,0.0017956697,0.008027722,0.13674343,0.18176831],"study_design_scores_gemma":[0.000026336007,0.000114389564,0.8986363,0.00014960887,0.00013742322,0.00034336004,0.00065140764,0.000527001,0.0005359243,0.00063182914,0.09821867,0.00002771125],"about_ca_topic_score_codex":0.40395388,"about_ca_topic_score_gemma":0.5253995,"teacher_disagreement_score":0.5960461,"about_ca_system_score_codex":0.005022012,"about_ca_system_score_gemma":0.011155543,"threshold_uncertainty_score":0.8032052},"labels":[],"label_agreement":null},{"id":"W2061389534","doi":"10.1016/j.jval.2012.03.075","title":"UT3 Firm- and Drug-Specific Patterns of Generic Drug Prices Experienced by United States Medicaid Programs: 1991-2008","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicaid; Generic drug; Reimbursement; Unit price; Drug prices; Quarter (Canadian coin); Drug; Business; Relative price; Economics; Actuarial science; Demographic economics; Monetary economics; Medicine; Health care; Pharmacology; Microeconomics; Economic growth","score_opus":0.09323204748075149,"score_gpt":0.30785787904224043,"score_spread":0.21462583156148896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061389534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9528926,0.00034699275,0.00012720672,0.0008492924,0.000015404723,0.000021719417,0.042430155,0.000038764345,0.003277704],"genre_scores_gemma":[0.9734071,0.00020840908,0.00015417294,0.00018785593,0.000021351672,0.000018390167,0.022357283,0.000011260525,0.0036342004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99951255,0.00003776463,0.00005680101,0.000090717906,0.000099686964,0.00020238648],"domain_scores_gemma":[0.99570066,0.0007567651,0.0026046867,0.00007952608,0.00044272223,0.0004155864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005220228,0.00013131648,0.00020239326,0.0011493979,0.00031891372,0.00091087585,0.00056573865,0.0005972261,0.0063204947],"category_scores_gemma":[0.002989703,0.0001968557,0.00053046807,0.0023287092,0.0002465535,0.0005700543,0.0007478659,0.00071846996,0.00056055206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002735347,0.00007214344,0.98216945,0.00005095077,0.000114545466,0.000076084725,0.0001780702,0.0005280594,0.00036290826,0.00042542024,0.010626337,0.0051225317],"study_design_scores_gemma":[0.0000053670237,0.000022296374,0.9974377,0.000009440509,0.000020533977,0.00003987363,0.0002625866,0.000432088,0.00019916045,0.000028411843,0.0015385759,0.0000038595927],"about_ca_topic_score_codex":0.14749208,"about_ca_topic_score_gemma":0.20539378,"teacher_disagreement_score":0.14749208,"about_ca_system_score_codex":0.0013345032,"about_ca_system_score_gemma":0.0011600201,"threshold_uncertainty_score":0.2932672},"labels":[],"label_agreement":null},{"id":"W2062153244","doi":"10.1345/aph.1k249","title":"Drug Importation and Safety of Drugs Obtained from Canada","year":2007,"lang":"en","type":"review","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; Drug prices; Opposition (politics); Competition (biology); Pharmacology; Public economics; Law","score_opus":0.14255423938027267,"score_gpt":0.39979936934093113,"score_spread":0.25724512996065846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062153244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004281455,0.9962979,0.000030634048,0.0003673969,0.000048420137,0.000004524395,0.000069745416,0.0000024783483,0.0027508477],"genre_scores_gemma":[0.0034401172,0.99564666,0.00004481101,0.00013255228,0.000029994622,0.0000025275099,0.000057169655,7.422416e-7,0.0006454488],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99918574,0.000080320046,0.00006488333,0.00007068427,0.00052971113,0.000068646754],"domain_scores_gemma":[0.9979857,0.00062438636,0.0003583958,0.000029631168,0.00093091524,0.000070829075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011921347,0.00041479606,0.0012834992,0.0028473458,0.0006164211,0.0012283203,0.00065521593,0.0008619378,0.0038913537],"category_scores_gemma":[0.003195056,0.00020711744,0.00068684504,0.0054768817,0.00069741474,0.000520422,0.00041658623,0.00088050554,0.00080177636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012310024,0.000034708213,0.0017469963,0.01999636,0.00023456044,0.00035456405,0.00009607119,0.00034304356,0.0005855375,0.0028531135,0.037493348,0.9361385],"study_design_scores_gemma":[0.00006184192,0.0001261254,0.01500215,0.015238219,0.00046353784,0.0020337251,0.00018562797,0.00014629519,0.001726,0.0011919268,0.9637862,0.000038251008],"about_ca_topic_score_codex":0.28040305,"about_ca_topic_score_gemma":0.36669624,"teacher_disagreement_score":0.719597,"about_ca_system_score_codex":0.0051040202,"about_ca_system_score_gemma":0.011711059,"threshold_uncertainty_score":0.55754185},"labels":[],"label_agreement":null},{"id":"W2062442241","doi":"10.1089/dis.2007.104649","title":"The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of Lamotrigine","year":2007,"lang":"en","type":"article","venue":"Disease Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis; Montreal Neurological Institute and Hospital","funders":"","keywords":"Lamotrigine; Medicine; Pharmacy; Pill; Medical prescription; Drug; Generic drug; Pharmacology; Family medicine; Epilepsy; Psychiatry","score_opus":0.05154753667624997,"score_gpt":0.2957712121430586,"score_spread":0.24422367546680865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062442241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98796403,0.0014358676,0.00042485638,0.0053568715,0.00003370269,0.000045320063,0.00042663413,0.000009448885,0.0043032384],"genre_scores_gemma":[0.99889165,0.00030747373,0.00018192892,0.00026973773,0.000033797263,0.000008438976,0.000109214045,0.0000019530785,0.00019576098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697924,0.0013347934,0.00010345963,0.00015066228,0.00046162293,0.0009701733],"domain_scores_gemma":[0.9909304,0.004462285,0.0024881791,0.00039392637,0.00076098606,0.00096434494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003115225,0.00030631752,0.0006118264,0.00057235395,0.0008848314,0.0027685687,0.0008654927,0.0015455914,0.003137989],"category_scores_gemma":[0.013693193,0.00028520642,0.001182882,0.0011804552,0.0010323672,0.00096020923,0.00095785095,0.00168622,0.00013975396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003600492,0.0011690963,0.86884975,0.00024788498,0.0010559508,0.008408692,0.0004448045,0.038952,0.0011400969,0.013085763,0.007032875,0.05601251],"study_design_scores_gemma":[0.0006301381,0.0010644046,0.8848812,0.00017708214,0.0008480834,0.0044607525,0.0046135206,0.09002887,0.0009004937,0.005777073,0.0064887316,0.0001296249],"about_ca_topic_score_codex":0.11860501,"about_ca_topic_score_gemma":0.14578092,"teacher_disagreement_score":0.11860501,"about_ca_system_score_codex":0.009616425,"about_ca_system_score_gemma":0.004659113,"threshold_uncertainty_score":0.2358293},"labels":[],"label_agreement":null},{"id":"W2062511238","doi":"10.1177/1715163513494586","title":"Report says extending use of pharmacists and generic drugs can save health care system up to $11 billion over 3 years","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Health care; Medicine; Business; Economic growth; Economics","score_opus":0.06725005893130952,"score_gpt":0.2769036334247863,"score_spread":0.20965357449347677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062511238","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009098669,0.003261024,0.0009475425,0.8413742,0.02198569,0.00019324354,0.033859707,0.0007860435,0.088493936],"genre_scores_gemma":[0.06934237,0.0062310044,0.0021927992,0.43765414,0.009585158,0.00038525288,0.014722877,0.00022547143,0.45966095],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99588495,0.00025109376,0.00017372165,0.00020341174,0.0026166213,0.00087013305],"domain_scores_gemma":[0.98991346,0.0020427322,0.0005270334,0.00023790033,0.005551973,0.0017268287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002721415,0.0008539273,0.00061432173,0.0013864897,0.0018327483,0.0030372648,0.0010752354,0.011133647,0.015043336],"category_scores_gemma":[0.01027313,0.00049780577,0.00222934,0.0010793101,0.00063506985,0.0016878977,0.001128129,0.006657138,0.003759178],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078541496,0.000053719075,0.0021866355,0.00003908694,0.000053138057,0.00006805872,0.000032225835,0.00012143639,0.0001458588,0.00230556,0.9859781,0.008937624],"study_design_scores_gemma":[0.00024893723,0.00013485356,0.036479633,0.0002549982,0.00034445277,0.00011975448,0.0003585775,0.000847658,0.0009661656,0.001732204,0.9584089,0.00010397377],"about_ca_topic_score_codex":0.73448884,"about_ca_topic_score_gemma":0.7466392,"teacher_disagreement_score":0.9917374,"about_ca_system_score_codex":0.008262587,"about_ca_system_score_gemma":0.0551406,"threshold_uncertainty_score":0.5341496},"labels":[],"label_agreement":null},{"id":"W2062605727","doi":"10.1038/nbt1206-1515","title":"Moving goalposts—regulatory oversight of antibacterial drugs","year":2006,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Antimicrobial; Business; Drug approval; Infectious disease (medical specialty); Investment (military); Drug; Pharmacology; Biotechnology; Disease; Biology; Medicine; Microbiology; Political science; Law; Internal medicine","score_opus":0.008325642742799032,"score_gpt":0.22911719331785813,"score_spread":0.2207915505750591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062605727","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.056075376,0.011622401,0.046963178,0.6875275,0.006651471,0.0002625433,0.000639817,0.00073987915,0.18951792],"genre_scores_gemma":[0.80608886,0.0041853506,0.018527955,0.1360673,0.004158237,0.00016210043,0.00026853767,0.00017355432,0.030368099],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98074293,0.008199635,0.0006881031,0.0016931653,0.0059639392,0.002712305],"domain_scores_gemma":[0.95505553,0.021861322,0.0054941326,0.0029583499,0.009774531,0.004856181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029152246,0.0005642333,0.00082994025,0.0017219991,0.0021853496,0.012600436,0.002378678,0.015140132,0.010219892],"category_scores_gemma":[0.06570628,0.00051086186,0.00092798646,0.0011931452,0.003558314,0.0073542697,0.003114921,0.010761395,0.0014857781],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043926755,0.00023312554,0.0023865395,0.0002250133,0.00012245876,0.00019000044,0.00028540537,0.0060409205,0.0020044881,0.7434092,0.14520417,0.09945934],"study_design_scores_gemma":[0.00024292892,0.00041792015,0.0093971575,0.00046609112,0.0000909167,0.00009915299,0.00051043753,0.010565835,0.0038484512,0.66295385,0.3112809,0.00012638782],"about_ca_topic_score_codex":0.010163727,"about_ca_topic_score_gemma":0.012341609,"teacher_disagreement_score":0.029152246,"about_ca_system_score_codex":0.0068261526,"about_ca_system_score_gemma":0.020268539,"threshold_uncertainty_score":0.15417367},"labels":[],"label_agreement":null},{"id":"W2063171295","doi":"10.1186/2047-2994-2-s1-p325","title":"P325: Evaluation of rational prescribing of essential generic drugs in a rural community in Mali","year":2013,"lang":"en","type":"article","venue":"Antimicrobial Resistance and Infection Control","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medical prescription; Medicine; Euros; Brand names; Alternative medicine; Family medicine; Traditional medicine; Pharmacology; Advertising","score_opus":0.038771741700659584,"score_gpt":0.2789625073523325,"score_spread":0.24019076565167294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063171295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997192,0.000018095037,0.00001733653,0.000054811175,3.483784e-7,0.000012288822,0.000044906727,7.7639754e-7,0.00013224725],"genre_scores_gemma":[0.99982506,0.000017878188,0.000052557993,0.000014281042,0.0000014560314,0.000007452787,0.000038167604,4.0078191e-7,0.00004281321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983158,0.0009203412,0.00009360633,0.000112628906,0.00038251726,0.00017511162],"domain_scores_gemma":[0.9909956,0.0025531724,0.00398017,0.00019089553,0.0011718128,0.0011084052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022962366,0.00022637156,0.00028951562,0.0009856246,0.0006993858,0.0007594455,0.00051013124,0.0004971656,0.0017871319],"category_scores_gemma":[0.012098789,0.00029264734,0.00028281222,0.0014989818,0.00061023864,0.0006167138,0.00074971607,0.00038735647,0.00017641732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000163978,0.00031867248,0.9954454,0.000031809846,0.000025233036,0.00016220508,0.0010158606,0.00020129651,0.000110481305,0.000036710913,0.00007814903,0.0024100645],"study_design_scores_gemma":[0.000017516973,0.00060940173,0.99531794,0.000007892176,0.000008101755,0.00010233744,0.0026306727,0.0011434235,0.00005132377,0.000022721611,0.00008422047,0.000004559063],"about_ca_topic_score_codex":0.037733078,"about_ca_topic_score_gemma":0.036378395,"teacher_disagreement_score":0.037733078,"about_ca_system_score_codex":0.0021339597,"about_ca_system_score_gemma":0.0017194656,"threshold_uncertainty_score":0.07502687},"labels":[],"label_agreement":null},{"id":"W2063448633","doi":"10.1503/cmaj.100375","title":"New approaches to rewarding pharmaceutical innovation","year":2010,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; University of Toronto","funders":"","keywords":"Pharmaceutical industry; Pharmaceutical sciences; Computer science; Data science; Drug industry; Knowledge management; Management science; Engineering ethics; Medicine; Pharmacology; Engineering","score_opus":0.1239400253679965,"score_gpt":0.29322301626275654,"score_spread":0.16928299089476004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063448633","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0136306705,0.036859486,0.35302827,0.119312316,0.0038246245,0.00025111638,0.00026147324,0.00050167413,0.47233042],"genre_scores_gemma":[0.79932725,0.026201744,0.08404411,0.009120823,0.009712835,0.0006874405,0.00008430685,0.00016762294,0.070653856],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955974,0.0019189842,0.00012826927,0.0006510719,0.0014523624,0.00025192584],"domain_scores_gemma":[0.9921813,0.0048745503,0.00071915425,0.00072584883,0.00089469086,0.00060449855],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005870632,0.0011743781,0.0010511631,0.0021032628,0.0017515462,0.0051455954,0.0028416272,0.0052769072,0.020887055],"category_scores_gemma":[0.015337504,0.00043683505,0.000644871,0.0018211997,0.008148584,0.008285499,0.0035532368,0.0065483167,0.0018462227],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018674007,0.000026478872,0.00008194472,0.000078729005,0.000008200089,0.000019163248,0.00006551534,0.0019055128,0.000085092914,0.97969943,0.003366469,0.014644774],"study_design_scores_gemma":[0.000039755723,0.000029878573,0.00009724861,0.000073075884,0.0000062314384,0.000019182782,0.00003807166,0.004701349,0.00009227021,0.96305305,0.03183913,0.000010772373],"about_ca_topic_score_codex":0.0013313954,"about_ca_topic_score_gemma":0.0024784128,"teacher_disagreement_score":0.99491596,"about_ca_system_score_codex":0.0050840173,"about_ca_system_score_gemma":0.003313512,"threshold_uncertainty_score":0.06987411},"labels":[],"label_agreement":null},{"id":"W2063658953","doi":"10.1016/s0140-6736(04)17630-7","title":"The black market in prescription drugs","year":2004,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"British Columbia Centre of Excellence for Women's Health; University of British Columbia","funders":"","keywords":"Black market; Biosimilar; Business; Multinational corporation; Profit (economics); Market access; Medical prescription; Developing country; Government (linguistics); International trade; Market economy; Economic growth; Finance; Economics; Medicine","score_opus":0.059949966516962175,"score_gpt":0.2803978101395967,"score_spread":0.22044784362263453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063658953","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03245116,0.054789193,0.0028097313,0.8583073,0.003337434,0.000026458389,0.00063019793,0.000040130944,0.047608454],"genre_scores_gemma":[0.7256053,0.04469673,0.0012311776,0.16903071,0.027695866,0.00008482286,0.0002230239,0.00010646568,0.031325884],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99545467,0.0026046806,0.000100667385,0.00033364366,0.0008847977,0.0006215405],"domain_scores_gemma":[0.97760856,0.015039589,0.003170626,0.00061039894,0.0015198531,0.0020510457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008751426,0.00035222783,0.0013137865,0.0011631221,0.0019246615,0.0045964266,0.00070981745,0.008060802,0.012943901],"category_scores_gemma":[0.02654234,0.0003912773,0.00048719373,0.0014462844,0.005572461,0.0059775864,0.0016988752,0.008089478,0.0009675196],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067843497,0.00009429045,0.0051945313,0.00024918056,0.0001504741,0.00027904386,0.0005315959,0.0009877112,0.00027536415,0.79244703,0.15354252,0.045569807],"study_design_scores_gemma":[0.00037769342,0.000076780685,0.008543262,0.0005234305,0.00009286841,0.00014857322,0.0005395575,0.0023326585,0.00029904165,0.87006426,0.116963625,0.00003831783],"about_ca_topic_score_codex":0.0107079735,"about_ca_topic_score_gemma":0.0110599445,"teacher_disagreement_score":0.012943901,"about_ca_system_score_codex":0.0036253836,"about_ca_system_score_gemma":0.0035137315,"threshold_uncertainty_score":0.04628247},"labels":[],"label_agreement":null},{"id":"W2063959707","doi":"10.1211/ijpp.14.2.0003","title":"A review of pharmaceutical scheduling processes in six countries and the effect on consumer access to medicines","year":2006,"lang":"en","type":"review","venue":"International Journal of Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Pharmacy; Family medicine; Developed country; Alternative medicine; Traditional medicine; Environmental health; Pharmacology","score_opus":0.13992365188237044,"score_gpt":0.49070401458939733,"score_spread":0.3507803627070269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063959707","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42839622,0.55565006,0.0009725134,0.0014937726,0.00027011338,0.00033833797,0.0023910129,0.000043804168,0.010444091],"genre_scores_gemma":[0.65433514,0.33923593,0.0036780802,0.00058078807,0.00016040975,0.00017666642,0.0012081971,0.000026206731,0.0005985874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9869239,0.006760985,0.0030708269,0.0007203578,0.0021646577,0.00035939817],"domain_scores_gemma":[0.90148205,0.057900615,0.025440736,0.0010960571,0.013299896,0.00078062824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01291108,0.00030577133,0.0008473158,0.008924803,0.0004205017,0.0016090262,0.00058268587,0.0003949,0.0011123524],"category_scores_gemma":[0.037147935,0.00042039366,0.0020219723,0.020327404,0.00045288814,0.0010793549,0.0004837734,0.0004317284,0.000107441534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041106935,0.0002715803,0.30917755,0.0577231,0.0028998845,0.00081826554,0.0033876533,0.0030530298,0.0018301109,0.0014489663,0.0051432033,0.61013603],"study_design_scores_gemma":[0.00024188035,0.0023757403,0.9035359,0.015440907,0.0046168207,0.00093559024,0.0049994537,0.0009366643,0.0027812524,0.00020964285,0.063801415,0.00012467818],"about_ca_topic_score_codex":0.024376296,"about_ca_topic_score_gemma":0.026881073,"teacher_disagreement_score":0.024376296,"about_ca_system_score_codex":0.004330404,"about_ca_system_score_gemma":0.0056547397,"threshold_uncertainty_score":0.068281114},"labels":[],"label_agreement":null},{"id":"W2064173156","doi":"10.1177/1715163512473930","title":"Don’t sacrifice generic drug industry for sake of Canada-European trade deal","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Intellectual property; European union; Commission; Business; CITES; International trade; Brand names; Generic drug; Political science; Law; Finance; Drug; Marketing; Medicine","score_opus":0.057729886446134374,"score_gpt":0.2433459687130251,"score_spread":0.18561608226689075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064173156","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027671803,0.007342248,0.0014630784,0.54745626,0.010758913,0.00007389654,0.00076669216,0.00060522096,0.42876643],"genre_scores_gemma":[0.038477466,0.0036229205,0.0017066242,0.6278467,0.0019300457,0.000055796158,0.00063529745,0.0004288364,0.32529628],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9831821,0.0007981497,0.00028517,0.0013666332,0.010890644,0.0034773701],"domain_scores_gemma":[0.9809326,0.0016167058,0.00051075616,0.001337975,0.011296931,0.0043049254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005111338,0.00092023995,0.00082175847,0.0025881885,0.014009632,0.021978907,0.0021828474,0.016577281,0.044700213],"category_scores_gemma":[0.02469987,0.0005938052,0.0011433385,0.0024432938,0.01024689,0.010545398,0.0045135724,0.013334078,0.017548177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004452996,0.000041479812,0.0010317622,0.00007862221,0.000020706673,0.00015481873,0.00036448738,0.000056306068,0.00032093294,0.1458782,0.82520175,0.026806418],"study_design_scores_gemma":[0.000011685309,0.000008241817,0.00059592177,0.00006126992,0.000008303219,0.00006839158,0.00020338352,0.00003975235,0.00013315059,0.0035795427,0.99526924,0.000021056136],"about_ca_topic_score_codex":0.687604,"about_ca_topic_score_gemma":0.78881234,"teacher_disagreement_score":0.960615,"about_ca_system_score_codex":0.039385013,"about_ca_system_score_gemma":0.07245419,"threshold_uncertainty_score":0.6284715},"labels":[],"label_agreement":null},{"id":"W2064908274","doi":"10.1057/jors.2013.106","title":"Health-based pharmaceutical pay-for-performance risk-sharing agreements","year":2013,"lang":"en","type":"article","venue":"Journal of the Operational Research Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Actuarial science; Markov chain; Clinical trial; Risk analysis (engineering); Population; Health care; Business; Marketing; Computer science; Medicine; Economics; Environmental health","score_opus":0.22293858660637894,"score_gpt":0.4309106411635537,"score_spread":0.20797205455717477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064908274","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27801692,0.0016808793,0.62828666,0.012117862,0.00034097262,0.0014834544,0.0021160622,0.0006509671,0.0753062],"genre_scores_gemma":[0.9768246,0.0003253663,0.01467752,0.00028471637,0.00008738478,0.0002747193,0.00020208814,0.00003184228,0.0072917845],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.98347557,0.008212913,0.0007615761,0.0021817037,0.0025356812,0.0028325184],"domain_scores_gemma":[0.95360637,0.03269397,0.0068666195,0.002554806,0.002264929,0.0020132656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024577191,0.0019206164,0.0025096163,0.0012571244,0.0019277637,0.006571956,0.0038889684,0.007366673,0.01447199],"category_scores_gemma":[0.06886635,0.001327131,0.002135834,0.0014731537,0.0040823678,0.007885737,0.0035759758,0.0069027464,0.0016451088],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005106027,0.00027403136,0.0033602829,0.000107370775,0.00008602705,0.00054277154,0.00044904894,0.52815473,0.0008293573,0.44576445,0.0032750159,0.016646322],"study_design_scores_gemma":[0.0003421318,0.00046515634,0.0022902633,0.00008818252,0.00007445582,0.00033362833,0.0003235444,0.6598347,0.0007371871,0.33029383,0.005079376,0.00013762104],"about_ca_topic_score_codex":0.006906147,"about_ca_topic_score_gemma":0.0025652046,"teacher_disagreement_score":0.024577191,"about_ca_system_score_codex":0.0072543314,"about_ca_system_score_gemma":0.005008689,"threshold_uncertainty_score":0.12997812},"labels":[],"label_agreement":null},{"id":"W2065142793","doi":"10.1136/bmj.327.7417.700-d","title":"Illinois is to estimate savings from letting its employees import cheap drugs","year":2003,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Economics; Actuarial science","score_opus":0.06270099590364692,"score_gpt":0.3378026839206845,"score_spread":0.2751016880170376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065142793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55476594,0.015156132,0.0200559,0.047938958,0.0011979236,0.00021891063,0.0640222,0.0015694608,0.29507455],"genre_scores_gemma":[0.8182199,0.0058821044,0.0077154734,0.0018523767,0.0004005134,0.0002167497,0.033476923,0.00019585944,0.13204019],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99957913,0.00012076165,0.000019750905,0.00006663701,0.00015501313,0.00005862306],"domain_scores_gemma":[0.9980107,0.000869279,0.0002546602,0.00013052211,0.0005870214,0.00014786355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081838423,0.00046381165,0.0002906936,0.0022888952,0.00044855435,0.0020449064,0.0002950308,0.0009686397,0.022258004],"category_scores_gemma":[0.006377065,0.0002960491,0.0004650233,0.0026954252,0.0003514423,0.0013698648,0.00055619463,0.0011275171,0.005172207],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008985064,0.0004187786,0.23671353,0.00038231854,0.00042237516,0.0004113111,0.00056187884,0.11229005,0.0003824155,0.074749015,0.41742995,0.15533993],"study_design_scores_gemma":[0.00036002113,0.00074743456,0.31830025,0.00070583326,0.00033914004,0.00050720683,0.002949252,0.1820283,0.0019016152,0.09473717,0.39711347,0.00031039698],"about_ca_topic_score_codex":0.10690486,"about_ca_topic_score_gemma":0.08052803,"teacher_disagreement_score":0.10690486,"about_ca_system_score_codex":0.003052488,"about_ca_system_score_gemma":0.0017128583,"threshold_uncertainty_score":0.21256524},"labels":[],"label_agreement":null},{"id":"W2066125418","doi":"10.1300/j371v12n01_02","title":"Canadian Public Policies and Practices Related to Drug Prices, Utilization and Expenditures","year":2004,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Finance Economics & Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public economics; Business; Public policy; Drug; Economics; Economic growth; Medicine; Pharmacology","score_opus":0.09016908950677895,"score_gpt":0.36679151783508546,"score_spread":0.2766224283283065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066125418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7803599,0.01431837,0.0007575486,0.06536578,0.00023807859,0.00020488181,0.034933217,0.00016466297,0.10365755],"genre_scores_gemma":[0.97604,0.005266515,0.0006406525,0.0019219788,0.000101544654,0.000029462031,0.004446323,0.000023997574,0.011529596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99549085,0.00033335303,0.00019909804,0.00020328199,0.0024277973,0.0013455835],"domain_scores_gemma":[0.9790469,0.003666663,0.00387364,0.0003288268,0.010049939,0.0030340215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026178355,0.00028997278,0.00031417757,0.004179877,0.0034853034,0.003252683,0.0009307257,0.0010953002,0.0072991936],"category_scores_gemma":[0.02252109,0.0004263379,0.00078959356,0.011156443,0.0012071312,0.0006454561,0.00080303417,0.0013993172,0.00030312364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000621901,0.00031839646,0.73860234,0.00065149256,0.00035355208,0.0003411211,0.0044132397,0.008070887,0.0005211043,0.05132425,0.112930514,0.081851184],"study_design_scores_gemma":[0.000038932583,0.000029846038,0.96055585,0.00011596119,0.00008428266,0.00006243532,0.0020827905,0.001534016,0.00021789783,0.0010975577,0.034133382,0.00004710861],"about_ca_topic_score_codex":0.99805355,"about_ca_topic_score_gemma":0.9987332,"teacher_disagreement_score":0.8631793,"about_ca_system_score_codex":0.13682067,"about_ca_system_score_gemma":0.18760972,"threshold_uncertainty_score":0.9927081},"labels":[],"label_agreement":null},{"id":"W2067181723","doi":"10.1016/j.healthpol.2012.02.005","title":"International comparison of assessments of pharmaceutical innovation","year":2012,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Business; Medicine","score_opus":0.31662892213048066,"score_gpt":0.5343481796147236,"score_spread":0.21771925748424292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067181723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49912202,0.013966718,0.015524966,0.011105962,0.00053819,0.00015271513,0.010388287,0.0002242035,0.44897702],"genre_scores_gemma":[0.9883831,0.0017397564,0.0020028332,0.00034424302,0.00015177976,0.00006435395,0.002750632,0.00005009483,0.0045131505],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.98837835,0.004639958,0.00067879393,0.00084608013,0.004731146,0.000725796],"domain_scores_gemma":[0.9616882,0.019010548,0.0038658043,0.0017839517,0.012851344,0.00080008025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015305464,0.0006147674,0.00067312253,0.008483502,0.00067039777,0.004622738,0.0008917604,0.0015012452,0.0051409085],"category_scores_gemma":[0.042338107,0.0001739026,0.0009506004,0.010186039,0.0014950694,0.004024282,0.002290051,0.002200918,0.00055443525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025946966,0.00042486397,0.17041507,0.0012995258,0.0011742387,0.00027898094,0.005004157,0.028721517,0.0017546746,0.56255853,0.029298272,0.19647552],"study_design_scores_gemma":[0.00021304353,0.0010223198,0.7281887,0.0014671643,0.00089086633,0.0004475648,0.0067218198,0.017026989,0.008508995,0.114474244,0.120824166,0.0002140755],"about_ca_topic_score_codex":0.005008402,"about_ca_topic_score_gemma":0.0049445545,"teacher_disagreement_score":0.015305464,"about_ca_system_score_codex":0.005049468,"about_ca_system_score_gemma":0.0021473896,"threshold_uncertainty_score":0.080944},"labels":[],"label_agreement":null},{"id":"W2067457166","doi":"10.7326/0003-4819-144-3-200602070-00027","title":"Savings from Canadian Internet Pharmacies Are Limited","year":2006,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pharmacy; Family medicine","score_opus":0.10869930703517935,"score_gpt":0.3256653015680864,"score_spread":0.21696599453290702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067457166","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007233907,0.005582539,0.0002491294,0.032141667,0.0032831985,0.00021187564,0.010923296,0.0012907807,0.9455942],"genre_scores_gemma":[0.0051886123,0.006230903,0.00060789095,0.008504757,0.0004811137,0.00007398219,0.0050667753,0.00027129523,0.97357464],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9942638,0.00023191383,0.0001814271,0.0003076857,0.004292332,0.0007228122],"domain_scores_gemma":[0.9858074,0.0009632315,0.0004931166,0.00076425454,0.008670058,0.003301929],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014250645,0.0012368108,0.00096047367,0.0035272895,0.0046821046,0.0062056044,0.0013700442,0.004103231,0.652647],"category_scores_gemma":[0.013697193,0.0005833577,0.001011713,0.005852737,0.0008231465,0.0023776882,0.001995063,0.002220094,0.42439634],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018594159,0.000010988092,0.00013324196,0.000061315885,0.0000027297087,0.000021328293,0.00001541332,0.0000149867765,0.00003979853,0.000641344,0.9687139,0.03032643],"study_design_scores_gemma":[0.000007373715,0.0000045950087,0.0006507762,0.00006903687,0.0000030820229,0.00002497247,0.00003639216,0.00002012123,0.00003259774,0.0000980628,0.9990458,0.000007068054],"about_ca_topic_score_codex":0.5855353,"about_ca_topic_score_gemma":0.7430357,"teacher_disagreement_score":0.652647,"about_ca_system_score_codex":0.01602508,"about_ca_system_score_gemma":0.044057846,"threshold_uncertainty_score":0.83381116},"labels":[],"label_agreement":null},{"id":"W2067675266","doi":"10.1016/j.jhealeco.2010.06.007","title":"Is newer always better? Re-evaluating the benefits of newer pharmaceuticals","year":2010,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Department of Veterans Affairs","keywords":"Observational study; Replicate; Actuarial science; Medicine; Test (biology); Economics; Econometrics; Statistics; Internal medicine","score_opus":0.243692680031206,"score_gpt":0.41715412907153016,"score_spread":0.17346144904032415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067675266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41935524,0.24845159,0.0069565815,0.25343975,0.0067987805,0.00031239173,0.0055274097,0.00012277832,0.05903543],"genre_scores_gemma":[0.9690596,0.017088741,0.0022074513,0.006708642,0.0031640898,0.000029964342,0.00035178722,0.000037110924,0.001352685],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9829419,0.010289517,0.001457279,0.00078758196,0.0038666043,0.00065711024],"domain_scores_gemma":[0.8337677,0.121592484,0.01881226,0.0059625567,0.016938051,0.0029269014],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.026859745,0.0008207822,0.002470703,0.0023883837,0.00063265284,0.0062100436,0.0014130345,0.0024793183,0.009492391],"category_scores_gemma":[0.1611529,0.0003506209,0.0017840941,0.0020252957,0.001755317,0.008987145,0.0014381121,0.0035214103,0.00072116964],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029491143,0.0009818653,0.08390126,0.005529433,0.008804914,0.0012112681,0.000987713,0.019567972,0.002263045,0.070939966,0.07487547,0.701446],"study_design_scores_gemma":[0.005821648,0.010780091,0.25764927,0.012316045,0.033619948,0.0027501364,0.007828539,0.057267793,0.013179651,0.2866206,0.311353,0.000813401],"about_ca_topic_score_codex":0.0072086724,"about_ca_topic_score_gemma":0.00904707,"teacher_disagreement_score":0.97314024,"about_ca_system_score_codex":0.004399311,"about_ca_system_score_gemma":0.004006796,"threshold_uncertainty_score":0.14204961},"labels":[],"label_agreement":null},{"id":"W2068029045","doi":"10.4212/cjhp.v65i5.1182","title":"Additional Thoughts on Drug Shortages","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Economic shortage; Drug; Medicine; Pharmacology; Philosophy","score_opus":0.048423556585147236,"score_gpt":0.2774468638294957,"score_spread":0.22902330724434844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068029045","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00080190477,0.011153415,0.00031768513,0.81505644,0.05790989,0.0001025093,0.0030073596,0.00036072813,0.11129005],"genre_scores_gemma":[0.013370027,0.017107138,0.0014958077,0.55866814,0.050208203,0.000173233,0.0020768766,0.00037467174,0.35652593],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879694,0.00019165094,0.00006792027,0.00012252635,0.00051920593,0.00030179493],"domain_scores_gemma":[0.9927483,0.0020881235,0.00037433495,0.00022517133,0.002750596,0.0018135522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016246793,0.00086120015,0.0005342417,0.0024474836,0.0045712143,0.0045861816,0.0015877564,0.009858011,0.17141683],"category_scores_gemma":[0.009898643,0.00037115804,0.0009692129,0.0025848043,0.0014096302,0.0060837353,0.0020305987,0.0074036308,0.025442028],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004263324,0.00000581851,0.000109007065,0.000028363687,7.746577e-7,0.000052790903,0.000069273185,0.000008184923,0.000009712869,0.0011916519,0.9952924,0.0032277822],"study_design_scores_gemma":[0.00000833858,0.0000046414466,0.0007834795,0.0001116323,0.0000020931095,0.000074256,0.0004952588,0.00001980731,0.00001831143,0.00072246685,0.9977469,0.000012800287],"about_ca_topic_score_codex":0.16495796,"about_ca_topic_score_gemma":0.29441637,"teacher_disagreement_score":0.83504206,"about_ca_system_score_codex":0.006122192,"about_ca_system_score_gemma":0.008007182,"threshold_uncertainty_score":0.5734464},"labels":[],"label_agreement":null},{"id":"W2068054498","doi":"10.1136/bmj.g6153","title":"Canada bans imports of drugs from three Indian facilities","year":2014,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Quality (philosophy); Environmental health; Medicine","score_opus":0.03501038781365816,"score_gpt":0.2477762149291287,"score_spread":0.21276582711547054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068054498","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24109961,0.003537076,0.004335421,0.103578426,0.0018749963,0.0007768254,0.010453262,0.0014364235,0.632908],"genre_scores_gemma":[0.6450626,0.002807242,0.0065071913,0.085818276,0.00033151358,0.00021634238,0.005000824,0.00021855297,0.25403747],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99424344,0.00031494757,0.00019414019,0.00023504253,0.0032310046,0.0017814005],"domain_scores_gemma":[0.9840337,0.0026282105,0.00091766147,0.0010012112,0.007812775,0.003606336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002239376,0.00035095948,0.00048172707,0.0014558709,0.005557022,0.0026736686,0.0018272088,0.0026408075,0.010521618],"category_scores_gemma":[0.007643595,0.0005738772,0.0010342037,0.0021796601,0.0019935188,0.000529234,0.0016277551,0.0050377217,0.0012086959],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010080364,0.0005632546,0.08082908,0.0010122323,0.00028593148,0.0019419953,0.0023886985,0.0012882493,0.01166007,0.11296597,0.64495146,0.14110504],"study_design_scores_gemma":[0.00025783142,0.00030948242,0.19386601,0.00045453064,0.00018673908,0.00054310984,0.0013057903,0.0010288206,0.0047885533,0.001753911,0.79533994,0.00016526868],"about_ca_topic_score_codex":0.96986973,"about_ca_topic_score_gemma":0.97557145,"teacher_disagreement_score":0.030130267,"about_ca_system_score_codex":0.02484777,"about_ca_system_score_gemma":0.08211867,"threshold_uncertainty_score":0.18028402},"labels":[],"label_agreement":null},{"id":"W2068434752","doi":"10.1080/11926422.2009.9673491","title":"Canada's menu of choices to improve global drug access","year":2009,"lang":"en","type":"article","venue":"Canadian Foreign Policy Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Internet privacy; Political science; Business; Drug; Advertising; Public relations; Marketing; Computer science; Medicine; Pharmacology","score_opus":0.030255649483672684,"score_gpt":0.2923043864660658,"score_spread":0.2620487369823931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068434752","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07474015,0.0046424908,0.00699636,0.13859981,0.0010481558,0.0005259572,0.007932756,0.00078496203,0.7647294],"genre_scores_gemma":[0.80356425,0.002849598,0.019127239,0.03905241,0.00031386485,0.00021605154,0.0011176462,0.00027235862,0.13348657],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99447566,0.00071249116,0.00014383406,0.00031073226,0.0029589788,0.0013983079],"domain_scores_gemma":[0.9937975,0.0013551799,0.00015432212,0.0002646724,0.0024168408,0.002011531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036266618,0.000498983,0.00053974916,0.0026402373,0.004643649,0.0061829174,0.0012115603,0.0035059466,0.027128102],"category_scores_gemma":[0.011009011,0.00051719847,0.0010769366,0.0028096829,0.0018144646,0.0016485488,0.0018390425,0.0032161248,0.0011963772],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041309386,0.000264205,0.015062766,0.00036023796,0.00013782941,0.00035156318,0.0008364804,0.0076933666,0.0014717052,0.35497755,0.49794415,0.12048702],"study_design_scores_gemma":[0.0003984835,0.00014100083,0.050490044,0.00048566714,0.00022704387,0.00023469845,0.0010730892,0.009468258,0.0019020034,0.042292103,0.893002,0.00028567662],"about_ca_topic_score_codex":0.9564715,"about_ca_topic_score_gemma":0.9820354,"teacher_disagreement_score":0.96024,"about_ca_system_score_codex":0.03976001,"about_ca_system_score_gemma":0.115022056,"threshold_uncertainty_score":0.2884804},"labels":[],"label_agreement":null},{"id":"W2068750827","doi":"10.1007/s40271-013-0042-z","title":"Patient Perceptions of Generic Medicines: A Mixed-Methods Study","year":2014,"lang":"en","type":"article","venue":"Patient","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Likert scale; Quality (philosophy); Pharmacy; Family medicine; Medicine; Irish; Preference; Generic drug; Quarter (Canadian coin); Qualitative property; Medical prescription; Legislation; Alternative medicine; Medical education; Psychology; Nursing; Computer science; Drug; Political science; Pharmacology; Statistics","score_opus":0.0486403129079753,"score_gpt":0.3380780943796304,"score_spread":0.2894377814716551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068750827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99788505,0.00027437686,0.00057998544,0.00010559584,0.00001543038,0.00040444586,0.00030186065,0.0000035195928,0.00042962006],"genre_scores_gemma":[0.99603796,0.00025837717,0.001385986,0.0005259942,0.000058572692,0.0009221873,0.00037574122,0.00000649461,0.00042880865],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9801123,0.01529401,0.001547511,0.0009345105,0.0013629205,0.00074874144],"domain_scores_gemma":[0.94906145,0.0385118,0.0066667744,0.0026014114,0.0020277635,0.0011308015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015704902,0.0010572387,0.0017931978,0.0013423202,0.0014822446,0.0024902427,0.0011517704,0.0021164112,0.0073497533],"category_scores_gemma":[0.041707918,0.0014392512,0.002449721,0.0015276747,0.0014709311,0.003357156,0.0017649066,0.0019796593,0.0011099254],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038557827,0.043644495,0.84435725,0.0021370673,0.0052873045,0.0006946055,0.019237664,0.0010466513,0.001280618,0.0017137381,0.0019486833,0.040094186],"study_design_scores_gemma":[0.013833417,0.09952828,0.81004226,0.001087687,0.005127576,0.0027362672,0.046692546,0.010363171,0.0018587505,0.0032326237,0.0048068394,0.0006905427],"about_ca_topic_score_codex":0.0021412086,"about_ca_topic_score_gemma":0.002303802,"teacher_disagreement_score":0.015704902,"about_ca_system_score_codex":0.0013739386,"about_ca_system_score_gemma":0.0012971276,"threshold_uncertainty_score":0.08305645},"labels":[],"label_agreement":null},{"id":"W2069359870","doi":"10.1016/s1098-3015(10)64771-7","title":"PHP22 PRESCRIPTION DRUG PRICE COMPARISONS BETWEEN CANADIAN AND US ON-LINE PHARMACIES OVER A SIX-MONTH PERIOD","year":2006,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Pharmacy; Period (music); Prescription drug; Medicine; Drug; Family medicine; Pharmacology","score_opus":0.11288744499185155,"score_gpt":0.3256395606394327,"score_spread":0.21275211564758117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069359870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80010957,0.0008761505,0.00030531277,0.002052764,0.00014291977,0.00014914734,0.17465459,0.00015954988,0.021550046],"genre_scores_gemma":[0.9447732,0.00026896654,0.00027733276,0.0003665797,0.00007895531,0.000036351645,0.04538846,0.000021498709,0.008788668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982351,0.00010788388,0.00007885317,0.00015430884,0.0010346507,0.00038910992],"domain_scores_gemma":[0.9907419,0.0010894933,0.0012793979,0.00016299712,0.0057709212,0.000955305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009993303,0.00030411998,0.00046550672,0.00217742,0.0010681384,0.0015877775,0.0008790352,0.00065009063,0.0056408574],"category_scores_gemma":[0.0085498905,0.00021254904,0.0006262186,0.004805956,0.00030054242,0.00050051545,0.0005307576,0.0007872558,0.00058007485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070181154,0.00042050806,0.844636,0.0003413453,0.00060650276,0.00043209037,0.00037198336,0.005181678,0.0008879325,0.0012706413,0.09410107,0.044732146],"study_design_scores_gemma":[0.000043580418,0.00008448365,0.9938075,0.000007176584,0.000031520496,0.000041049636,0.0001722505,0.00091729884,0.00027939669,0.00003323632,0.004567274,0.0000152227485],"about_ca_topic_score_codex":0.96995753,"about_ca_topic_score_gemma":0.97350717,"teacher_disagreement_score":0.03004247,"about_ca_system_score_codex":0.018447157,"about_ca_system_score_gemma":0.014481494,"threshold_uncertainty_score":0.13384414},"labels":[],"label_agreement":null},{"id":"W2069391653","doi":"10.1592/phco.31.4.386","title":"Brand Name versus Generic Warfarin: A Systematic Review of the Literature","year":2011,"lang":"en","type":"review","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Warfarin; Observational study; Medicine; Randomized controlled trial; Clinical trial; Clinical study design; MEDLINE; Anticoagulant; Crossover study; Intensive care medicine; Internal medicine; Alternative medicine; Placebo; Atrial fibrillation","score_opus":0.11062478987365605,"score_gpt":0.371436240655243,"score_spread":0.26081145078158696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069391653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010676658,0.9978393,0.00007664295,0.00021385023,0.000090596615,0.00022572573,0.00030720193,0.0000055284004,0.00017350554],"genre_scores_gemma":[0.010413242,0.9876889,0.00046257637,0.0005775564,0.00009140073,0.0004372555,0.00022409215,0.0000046590967,0.00010028073],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99246454,0.0021245012,0.0032573852,0.00061190914,0.0013106072,0.00023101205],"domain_scores_gemma":[0.97436315,0.01671545,0.005629581,0.000312476,0.002603793,0.0003754937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075190137,0.0016494038,0.009484674,0.01735194,0.0007224363,0.0025572327,0.0018916316,0.002036236,0.0051184376],"category_scores_gemma":[0.027065787,0.0011250399,0.006616471,0.018239623,0.0009953191,0.0029193454,0.0016831917,0.0010672498,0.00043028407],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017507945,0.000012404146,0.00064309774,0.9718711,0.00501942,0.00013884019,0.00015752683,0.00005543302,0.00013464014,0.00010288495,0.0011898597,0.020499812],"study_design_scores_gemma":[0.00035158178,0.00028850604,0.0056873094,0.9026071,0.072998494,0.0007970159,0.0005156874,0.00009162448,0.00018311403,0.0002744019,0.01615629,0.000048888345],"about_ca_topic_score_codex":0.0083816815,"about_ca_topic_score_gemma":0.025873115,"teacher_disagreement_score":0.01735194,"about_ca_system_score_codex":0.004482655,"about_ca_system_score_gemma":0.011500107,"threshold_uncertainty_score":0.039764762},"labels":[],"label_agreement":null},{"id":"W2069756197","doi":"10.1503/cmaj.109-3070","title":"China's counterfeit medicine trade booming","year":2009,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Department of Justice","keywords":"Counterfeit; China; Government (linguistics); Counterfeit Drugs; Traditional medicine; Business; Computer security; Medicine; Computer science; Advertising; Political science; Law; Philosophy","score_opus":0.02268013354975217,"score_gpt":0.26129972802682777,"score_spread":0.2386195944770756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069756197","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17123726,0.021029096,0.0017863709,0.3156709,0.0072560916,0.00011952992,0.0023567686,0.00087217503,0.47967187],"genre_scores_gemma":[0.506421,0.012563976,0.0013888617,0.056175675,0.0023273057,0.000044025306,0.0015970966,0.00008991626,0.41939205],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9991704,0.00006460597,0.000021221202,0.000075479176,0.00042227216,0.0002461126],"domain_scores_gemma":[0.9985733,0.00018216047,0.0001680686,0.000116977055,0.0004671467,0.0004923568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001019532,0.0005579968,0.00032162108,0.0021756908,0.003806052,0.0051858444,0.00040099237,0.00278026,0.029472383],"category_scores_gemma":[0.0018822146,0.00023818013,0.0004250412,0.0027240939,0.0021914158,0.0021994966,0.0013816922,0.0022625776,0.002634553],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021143556,0.00007523022,0.021449443,0.00029727496,0.000057695866,0.0016446622,0.0020105639,0.0003965729,0.0025315091,0.13352409,0.69357973,0.14422177],"study_design_scores_gemma":[0.00002378138,0.00006191648,0.028735224,0.00009700262,0.00002180775,0.00029911386,0.0008006129,0.0007763289,0.0008208474,0.004476094,0.96385086,0.000036348763],"about_ca_topic_score_codex":0.069955766,"about_ca_topic_score_gemma":0.10086818,"teacher_disagreement_score":0.069955766,"about_ca_system_score_codex":0.0058511808,"about_ca_system_score_gemma":0.012485054,"threshold_uncertainty_score":0.13909715},"labels":[],"label_agreement":null},{"id":"W2069951160","doi":"10.12927/hcpap..16909","title":"Let Evidence be the Arbiter","year":2002,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"C17 Council","funders":"","keywords":"Arbiter; Negotiation; Formulary; Courage; Value (mathematics); Business; Law and economics; Public relations; Internet privacy; Political science; Economics; Computer science; Medicine; Law; Pharmacology","score_opus":0.2378774069783038,"score_gpt":0.34068040933946403,"score_spread":0.10280300236116022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069951160","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009460012,0.0020061377,0.00028874626,0.99047196,0.0045754486,0.000014987566,0.000026914378,0.000010852314,0.0025102876],"genre_scores_gemma":[0.0028601468,0.001523842,0.0008993151,0.98159194,0.01032537,0.000040315383,0.000017808203,0.000015197761,0.002726034],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.94529325,0.021738648,0.006774157,0.006845676,0.016748395,0.0025998435],"domain_scores_gemma":[0.7968129,0.16109376,0.005203975,0.008598211,0.022022843,0.0062682964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06521845,0.0014489458,0.0042226817,0.002476995,0.0064778454,0.0150772575,0.005907147,0.11655571,0.010901777],"category_scores_gemma":[0.23147406,0.001627793,0.003070434,0.001974741,0.03214535,0.029017486,0.005918664,0.11903979,0.009343568],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017111933,0.00007176466,0.0006702961,0.00046391942,0.00013715315,0.0012050627,0.00039860685,0.00021115631,0.000262546,0.14165401,0.83116794,0.02358643],"study_design_scores_gemma":[0.00037275118,0.00009615657,0.00083192304,0.002030398,0.00009427399,0.0009857933,0.00070889684,0.00050830655,0.00023956422,0.28951126,0.70446414,0.00015663507],"about_ca_topic_score_codex":0.014267092,"about_ca_topic_score_gemma":0.017408088,"teacher_disagreement_score":0.11655571,"about_ca_system_score_codex":0.0120257195,"about_ca_system_score_gemma":0.019589342,"threshold_uncertainty_score":0.34491223},"labels":[],"label_agreement":null},{"id":"W2070185921","doi":"10.1503/cmaj.109-4513","title":"PEI government announces catastrophic drug plan","year":2013,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Formulary; Surprise; Government (linguistics); Plan (archaeology); Medical prescription; Ceiling (cloud); Medicine; Family medicine; History; Geography; Pharmacology","score_opus":0.017372502552922664,"score_gpt":0.21553988146523992,"score_spread":0.19816737891231725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070185921","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024433361,0.002161673,0.0010488818,0.26663685,0.012994509,0.00032474348,0.0053312047,0.0013523477,0.68571645],"genre_scores_gemma":[0.12687407,0.0015472398,0.0020167006,0.16398369,0.0038524992,0.00024173246,0.0047164103,0.0001460054,0.69662166],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984547,0.00009327766,0.000030004438,0.00009185465,0.0008788625,0.00045133953],"domain_scores_gemma":[0.99764866,0.00045006388,0.00007835518,0.00010829991,0.0010202581,0.0006943675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013660294,0.00028930893,0.0002072498,0.0005515687,0.0025423418,0.0032029278,0.0005263203,0.004909325,0.022291398],"category_scores_gemma":[0.005495294,0.00027521534,0.00039425978,0.00038910387,0.0007052886,0.0007638427,0.0012392198,0.0056888303,0.0035921037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000643962,0.000033604858,0.0017905822,0.00003167173,0.000007871172,0.00043807333,0.00008131938,0.000113540635,0.0001939768,0.017422179,0.97016406,0.0096588135],"study_design_scores_gemma":[0.000039820537,0.00004211161,0.0071470863,0.000026538595,0.000006088499,0.00011309303,0.00010117958,0.00020085285,0.00026294467,0.0012638152,0.9907794,0.000017063701],"about_ca_topic_score_codex":0.12839113,"about_ca_topic_score_gemma":0.17421173,"teacher_disagreement_score":0.9951172,"about_ca_system_score_codex":0.004882819,"about_ca_system_score_gemma":0.020674884,"threshold_uncertainty_score":0.25528765},"labels":[],"label_agreement":null},{"id":"W2071408769","doi":"10.1016/j.socscimed.2011.06.059","title":"Product development public–private partnerships for public health: A systematic review using qualitative data","year":2011,"lang":"en","type":"review","venue":"Social Science & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Public Health Ontario","funders":"","keywords":"Transparency (behavior); Business; Public relations; Public health; Population; General partnership; Citizen journalism; Public–private partnership; Stakeholder; Medicine; Political science; Environmental health; Nursing; Finance","score_opus":0.8603555550577737,"score_gpt":0.5468427409509209,"score_spread":0.31351281410685283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071408769","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008355288,0.97893804,0.001520565,0.0022975388,0.00016914772,0.002806886,0.0042683952,0.000022849232,0.0016213723],"genre_scores_gemma":[0.16025116,0.8211118,0.0074527543,0.0022346699,0.00008247319,0.0070322882,0.0013788346,0.00001853071,0.0004375027],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.94604975,0.029732449,0.012556193,0.0017495377,0.008626416,0.0012856125],"domain_scores_gemma":[0.821761,0.13925192,0.025006248,0.0026974503,0.00968452,0.001598887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05293196,0.0013060898,0.0058330633,0.012914483,0.00091385754,0.0032804594,0.001961316,0.0018346198,0.008603842],"category_scores_gemma":[0.17188355,0.0015604479,0.0061996407,0.0166605,0.0018237081,0.0043366174,0.004971693,0.002013427,0.00036550392],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007956818,0.00007718071,0.005763265,0.8481391,0.010007477,0.000118351025,0.0013318638,0.00023256533,0.000099652905,0.0012177785,0.004818229,0.12739894],"study_design_scores_gemma":[0.0016096024,0.00043408334,0.013874713,0.89119923,0.045516226,0.0003377338,0.0036681364,0.00024621066,0.0004616371,0.0025021413,0.04007264,0.00007757802],"about_ca_topic_score_codex":0.012776756,"about_ca_topic_score_gemma":0.04057213,"teacher_disagreement_score":0.05293196,"about_ca_system_score_codex":0.011387995,"about_ca_system_score_gemma":0.036466774,"threshold_uncertainty_score":0.27993435},"labels":[],"label_agreement":null},{"id":"W2071714847","doi":"10.3821/1913-701x-145.1.6","title":"Call for Political Action to Address Continuing Drug Shortages","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); House of Commons; Politics; Public administration; Medicine; Medical prescription; Economic shortage; Political science; Health care; Call to action; Public relations; Law; Business; Nursing","score_opus":0.10549187281686004,"score_gpt":0.32419602098714306,"score_spread":0.21870414817028302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071714847","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045175315,0.0016465705,0.0003538128,0.9523225,0.031835128,0.000065518034,0.00007521429,0.00016539074,0.013084147],"genre_scores_gemma":[0.0039175292,0.000562612,0.0008277428,0.9621571,0.004908491,0.00009867253,0.00007998468,0.00008927396,0.027358662],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95191854,0.015277959,0.0017838472,0.003025942,0.014577586,0.013416126],"domain_scores_gemma":[0.89758444,0.028145885,0.003505231,0.0040327287,0.01668379,0.050047874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.037691563,0.001920576,0.001540482,0.002274183,0.014086417,0.0188234,0.0051286025,0.07868043,0.064469874],"category_scores_gemma":[0.06671704,0.0016020127,0.0033844635,0.0015252504,0.011086919,0.012992015,0.017714564,0.060603034,0.022203734],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028735563,0.00011512832,0.00014596785,0.000068633,0.000009698932,0.00019069978,0.00023982083,0.00004396652,0.00018234935,0.00862799,0.98369366,0.006653351],"study_design_scores_gemma":[0.00007597637,0.000048661386,0.0005338366,0.00018700644,0.000009351294,0.00008719785,0.00081648456,0.000101596874,0.00015298986,0.0042485236,0.99369264,0.000045652843],"about_ca_topic_score_codex":0.016654635,"about_ca_topic_score_gemma":0.025691116,"teacher_disagreement_score":0.07868043,"about_ca_system_score_codex":0.012380011,"about_ca_system_score_gemma":0.06156608,"threshold_uncertainty_score":0.21567321},"labels":[],"label_agreement":null},{"id":"W2071885854","doi":"10.1136/bmj.38582.703866.ae","title":"“Breakthrough” drugs and growth in expenditure on prescription drugs in Canada","year":2005,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"","keywords":"Medical prescription; Medicine; Drug industry; Computer science; Data science; Pharmacology; Biology; Biotechnology","score_opus":0.030169819471617676,"score_gpt":0.2681968652973627,"score_spread":0.23802704582574502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071885854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8184055,0.01453283,0.0006203054,0.04623874,0.0003453873,0.000109701316,0.07898232,0.00015937902,0.04060592],"genre_scores_gemma":[0.9718536,0.007558336,0.00040042188,0.001096474,0.0001008263,0.000023896535,0.012932663,0.00003332009,0.0060005714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979961,0.00011821773,0.00010400591,0.00013751672,0.0007608592,0.00088337174],"domain_scores_gemma":[0.98877233,0.00091099343,0.0021306628,0.00017077512,0.0055337655,0.0024814324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009341487,0.00038821355,0.00055173266,0.0039720964,0.0025368421,0.002537711,0.0011781803,0.0011036115,0.007371022],"category_scores_gemma":[0.009823175,0.00033959936,0.0007747635,0.01297253,0.0010645756,0.0010652001,0.0014976406,0.0019838694,0.00040921874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038868116,0.00013905196,0.86021936,0.00032840748,0.00024221923,0.00067733886,0.0011385772,0.005606617,0.00018285602,0.015519826,0.08516999,0.030386984],"study_design_scores_gemma":[0.00006017709,0.0000265599,0.967165,0.0002978549,0.00012885431,0.00016614539,0.0018926681,0.0069093495,0.00023670885,0.0014149564,0.021644436,0.000057233803],"about_ca_topic_score_codex":0.9984114,"about_ca_topic_score_gemma":0.9982829,"teacher_disagreement_score":0.8807251,"about_ca_system_score_codex":0.11927494,"about_ca_system_score_gemma":0.100308925,"threshold_uncertainty_score":0.8654043},"labels":[],"label_agreement":null},{"id":"W2072560809","doi":"10.1016/s0160-2527(03)00084-0","title":"Manufacturing uncertainty: Adverse effects of drug development for women","year":2003,"lang":"en","type":"article","venue":"International Journal of Law and Psychiatry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Drug; Drug development; Adverse effect; Medicine; Medical emergency; Risk analysis (engineering); Pharmacology","score_opus":0.018478166774410033,"score_gpt":0.2727999053773897,"score_spread":0.25432173860297963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072560809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6896328,0.03033523,0.00378834,0.19128871,0.00057177106,0.00007729237,0.0031425797,0.0000957397,0.08106754],"genre_scores_gemma":[0.9920344,0.0031614094,0.00010117083,0.0021032232,0.00038042813,0.000005348773,0.00008697832,0.0000046495725,0.002122388],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9982602,0.0008092545,0.00007884651,0.00012955173,0.00034975779,0.00037241596],"domain_scores_gemma":[0.9609446,0.027538145,0.007839859,0.0007924663,0.001577657,0.0013073573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002814518,0.00020717451,0.0004310378,0.00089731545,0.0007582935,0.0019390953,0.00034866575,0.00232746,0.011988025],"category_scores_gemma":[0.028410316,0.00018134253,0.0005877384,0.00088453264,0.00086753163,0.001226303,0.0011727012,0.0018333207,0.0004036214],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052843676,0.0006355217,0.475475,0.0006606212,0.0009934374,0.006198678,0.0024216229,0.044236366,0.001529784,0.21235171,0.06958637,0.18062651],"study_design_scores_gemma":[0.0004609721,0.0020556413,0.44215006,0.0007970606,0.0017799378,0.0037174856,0.008937832,0.0357197,0.004005845,0.42155904,0.07853758,0.0002789274],"about_ca_topic_score_codex":0.010183212,"about_ca_topic_score_gemma":0.010793143,"teacher_disagreement_score":0.011988025,"about_ca_system_score_codex":0.0017074505,"about_ca_system_score_gemma":0.0010662697,"threshold_uncertainty_score":0.040103912},"labels":[],"label_agreement":null},{"id":"W2073143549","doi":"10.1186/1475-9276-8-43","title":"Towards equitable access to medicines for the rural poor: analyses of insurance claims reveal rural pharmacy initiative triggers price competition in Kyrgyzstan","year":2009,"lang":"en","type":"article","venue":"International Journal for Equity in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"United States Agency for International Development","keywords":"Pharmacy; Quarter (Canadian coin); Competition (biology); Access to medicines; Market share; Drug prices; Competitor analysis; Medicine; Business; Public health; Family medicine; Finance; Marketing; Economics; Public economics; Geography","score_opus":0.32962598135848,"score_gpt":0.5338731273743518,"score_spread":0.2042471460158718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073143549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9998161,0.000013322795,0.000010115161,0.00003472843,1.9774004e-7,0.0000024192025,0.000041755273,4.0554707e-7,0.00008093552],"genre_scores_gemma":[0.9998834,0.000013149679,0.000020429805,0.000011336792,9.3036226e-7,0.0000017626825,0.000043720884,2.6560116e-7,0.000024998344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937576,0.00018448521,0.00004381306,0.0000768762,0.00011469945,0.00020430487],"domain_scores_gemma":[0.99750644,0.00036775612,0.0017255945,0.00008851417,0.00014035359,0.00017129244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095683476,0.00012125769,0.00019516898,0.0006373376,0.0004481498,0.00063044473,0.00026715122,0.00025532828,0.0013290979],"category_scores_gemma":[0.002832201,0.0001195206,0.00029277013,0.0010436717,0.0004168951,0.00041563917,0.00078098045,0.00040348253,0.000069924026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006641095,0.000053377407,0.99704367,0.000008788248,0.000020829326,0.00006798947,0.0004447867,0.00007227323,0.0003288874,0.000059209247,0.00006900755,0.00176472],"study_design_scores_gemma":[0.0000017486494,0.00002130669,0.9992749,0.0000015713287,0.0000037716115,0.000022174012,0.00041179438,0.00015350549,0.000030688334,0.000009839677,0.000067854606,7.6033785e-7],"about_ca_topic_score_codex":0.037276864,"about_ca_topic_score_gemma":0.04229561,"teacher_disagreement_score":0.037276864,"about_ca_system_score_codex":0.0010171022,"about_ca_system_score_gemma":0.0012371641,"threshold_uncertainty_score":0.07411981},"labels":[],"label_agreement":null},{"id":"W2074251263","doi":"10.1504/ijbt.2006.008961","title":"Enabling knowledge societies in developing countries: the example of genomics","year":2006,"lang":"en","type":"article","venue":"International Journal of Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Naval Medical Research Center; New Partnership for Africa's Development; Office of Naval Research; Bill and Melinda Gates Foundation","keywords":"Transformative learning; Futures studies; Expansive; Intellectual property; Developing country; Corporate governance; Business; Knowledge management; Global public good; Equity (law); Action plan; Public good; Public relations; Political science; Economic growth; Sociology; Economics; Computer science; Management","score_opus":0.05318838713030455,"score_gpt":0.2953390947559154,"score_spread":0.24215070762561086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074251263","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15173781,0.011810483,0.06996864,0.1888437,0.00070071104,0.00034466383,0.00024241136,0.00016754218,0.57618403],"genre_scores_gemma":[0.96011335,0.004843577,0.025712866,0.0029847927,0.00010939309,0.00020545468,0.000040932646,0.00002658701,0.0059629995],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9919016,0.0065633217,0.000101490274,0.00019512865,0.00045728308,0.00078129506],"domain_scores_gemma":[0.9937215,0.0044428636,0.00041879163,0.00042580857,0.0004961504,0.00049505266],"candidate_categories":["open_science"],"consensus_categories":[],"category_scores_codex":[0.007933628,0.00052108173,0.0004115069,0.0017132099,0.007575904,0.007292981,0.00090430584,0.0045423196,0.003730212],"category_scores_gemma":[0.009535195,0.0002801586,0.0007748204,0.0021849223,0.01422161,0.010708195,0.009661804,0.0036378682,0.00043495191],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003602294,0.000045845947,0.00064225,0.0001240438,0.000011929534,0.00079192524,0.0067498777,0.0026016869,0.00032093274,0.97639465,0.0029557857,0.009325043],"study_design_scores_gemma":[0.00009691959,0.00006411396,0.0011112691,0.00027568606,0.000027035274,0.0003444592,0.015703185,0.004417582,0.0010353555,0.7645549,0.2123188,0.000050752187],"about_ca_topic_score_codex":0.0065703094,"about_ca_topic_score_gemma":0.004451933,"teacher_disagreement_score":0.9990957,"about_ca_system_score_codex":0.0057380814,"about_ca_system_score_gemma":0.0057381415,"threshold_uncertainty_score":0.041957557},"labels":[],"label_agreement":null},{"id":"W2075267475","doi":"10.1503/cmaj.1070071","title":"Reforming Canada's Access to Medicines Regime","year":2007,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug industry; Access to medicines; Developing country; Drug approval; Business; Medicine; Law and economics; Political science; Drug; Law; Intellectual property; Engineering ethics; Pharmacology; Economics; Economic growth; Engineering","score_opus":0.038196808491926255,"score_gpt":0.2840582139326335,"score_spread":0.24586140544070723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075267475","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062703723,0.0030876128,0.0006851609,0.8996087,0.005000743,0.00006601012,0.00052120915,0.000121006495,0.084639214],"genre_scores_gemma":[0.05413883,0.001131938,0.00074468367,0.8830028,0.0036294973,0.000053052434,0.00012323208,0.000064564774,0.057111368],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98053014,0.0016135538,0.0004956755,0.0014109522,0.010603984,0.005345584],"domain_scores_gemma":[0.98344153,0.0058206185,0.0005621512,0.00054832466,0.0056377263,0.003989592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008317938,0.0007728338,0.0012040576,0.0018745011,0.017530734,0.01010047,0.0050620707,0.059130777,0.011567975],"category_scores_gemma":[0.027249778,0.0009867455,0.001524758,0.0022441274,0.009648085,0.004515688,0.0049262163,0.034877475,0.0014404496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011949609,0.000060839175,0.002160513,0.00013290271,0.00006059851,0.00096284924,0.001578039,0.0005655397,0.00083015696,0.31082207,0.66528827,0.017418718],"study_design_scores_gemma":[0.00023637997,0.000078431854,0.0052193343,0.00030830232,0.00006722324,0.00023525525,0.00065176754,0.001330488,0.0005699708,0.02873562,0.9623889,0.0001784373],"about_ca_topic_score_codex":0.9583804,"about_ca_topic_score_gemma":0.98309845,"teacher_disagreement_score":0.9078471,"about_ca_system_score_codex":0.092152916,"about_ca_system_score_gemma":0.20486747,"threshold_uncertainty_score":0.66861933},"labels":[],"label_agreement":null},{"id":"W2076220047","doi":"10.1182/blood-2010-09-308858","title":"Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Clinical trial; Stakeholder; Process (computing); Diversification (marketing strategy); Data monitoring committee; Public relations; Business; Institutional review board; Stakeholder engagement; Process management; Accounting; Medicine; Political science; Computer science; Marketing","score_opus":0.3393740713216744,"score_gpt":0.40507151576369416,"score_spread":0.06569744444201975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076220047","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019108959,0.003196101,0.67275155,0.15777075,0.0013025958,0.0025087297,0.00026580316,0.0012161855,0.1418793],"genre_scores_gemma":[0.65902656,0.00298636,0.27642787,0.028719196,0.0037849615,0.0034983014,0.00027435587,0.00041455988,0.024867848],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.69090664,0.2349933,0.0069111413,0.02026295,0.03473322,0.012192696],"domain_scores_gemma":[0.6550018,0.21053557,0.04140306,0.029652633,0.0456782,0.017728774],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2008957,0.0019560931,0.0018356302,0.0058448603,0.004434384,0.015140843,0.0069245277,0.013219973,0.011748641],"category_scores_gemma":[0.2623256,0.0019880182,0.0019594063,0.0055132387,0.019562608,0.015263473,0.009537307,0.008862589,0.006327773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039871168,0.000471329,0.004951003,0.0004277919,0.000119451404,0.00027463253,0.0009510095,0.012704051,0.00043134615,0.8909665,0.018430674,0.06987345],"study_design_scores_gemma":[0.0016332607,0.0014191355,0.004499645,0.00056760735,0.00012689308,0.00071909296,0.0008011978,0.06822224,0.0008103414,0.8163042,0.10460818,0.0002882893],"about_ca_topic_score_codex":0.0075427955,"about_ca_topic_score_gemma":0.0076364838,"teacher_disagreement_score":0.79910433,"about_ca_system_score_codex":0.011596581,"about_ca_system_score_gemma":0.036221586,"threshold_uncertainty_score":0.98543787},"labels":[],"label_agreement":null},{"id":"W2076826991","doi":"10.4088/jcp.09m05315","title":"Comparison of Pharmacokinetic Profiles of Brand-Name and Generic Formulations of Citalopram and Venlafaxine","year":2009,"lang":"en","type":"article","venue":"The Journal of Clinical Psychiatry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Citalopram; Venlafaxine; Bioequivalence; Crossover study; Pharmacokinetics; Confidence interval; Pharmacology; Placebo; Psychology; Medicine; Anesthesia; Internal medicine; Serotonin; Antidepressant","score_opus":0.1563976754259859,"score_gpt":0.44028342190431324,"score_spread":0.2838857464783273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076826991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981067,0.0010991441,0.00035804807,0.000021396927,0.000013472125,0.00006884443,0.0000896164,0.000010556165,0.00023219931],"genre_scores_gemma":[0.998103,0.00047546896,0.00085461617,0.000046271653,0.000034407694,0.000054658674,0.00017126596,0.0000065288564,0.0002537903],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9993333,0.00030758738,0.00005318575,0.00011583427,0.00013927712,0.00005082372],"domain_scores_gemma":[0.9991111,0.0003328322,0.00030371375,0.00007908503,0.000059472175,0.00011382902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010590007,0.00024639678,0.00054375594,0.00019717656,0.00007427181,0.0003844733,0.00035174095,0.0004879462,0.0021248378],"category_scores_gemma":[0.0026338089,0.00022722247,0.0003760665,0.00018484253,0.0003227265,0.0006432299,0.00014058691,0.00043555087,0.00019207067],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39654905,0.008216659,0.037592087,0.0011685523,0.0020240927,0.00046855162,0.0007008469,0.0021105092,0.37776956,0.0005080747,0.0008464493,0.17204556],"study_design_scores_gemma":[0.044744596,0.5338091,0.31150877,0.000071164926,0.001967157,0.0029106792,0.0004054672,0.008488686,0.08995581,0.00037758664,0.0056490167,0.00011192122],"about_ca_topic_score_codex":0.0003053169,"about_ca_topic_score_gemma":0.00035410267,"teacher_disagreement_score":0.0021248378,"about_ca_system_score_codex":0.00029715392,"about_ca_system_score_gemma":0.00019346332,"threshold_uncertainty_score":0.0071083307},"labels":[],"label_agreement":null},{"id":"W2076928451","doi":"10.1016/s0167-6296(02)00035-8","title":"Should the US allow prescription drug reimports from Canada?","year":2002,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Outrage; Legislation; Economics; Drug prices; Bargaining problem; Unit price; Business; Public economics; Microeconomics; Law","score_opus":0.11640730136987056,"score_gpt":0.28394609539247034,"score_spread":0.1675387940225998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076928451","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045917057,0.009244756,0.0004748144,0.8458641,0.0032245512,0.0001498054,0.0047129192,0.00019605353,0.09021598],"genre_scores_gemma":[0.37664223,0.007398652,0.0015510983,0.5497685,0.0027088204,0.00011032893,0.0011596755,0.00013868563,0.060521957],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901664,0.00079252856,0.0003414295,0.0005602216,0.0032306297,0.0049087],"domain_scores_gemma":[0.97206986,0.0044701714,0.0018185478,0.0007400785,0.012669374,0.008232047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006027531,0.00059189193,0.0010976436,0.0015477526,0.007483956,0.007907969,0.0028264702,0.016099392,0.015581124],"category_scores_gemma":[0.03592709,0.00063639437,0.0016303934,0.0023194135,0.0026756388,0.0035306532,0.0024387978,0.01001705,0.001077636],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007319642,0.0001964685,0.04613551,0.00036450886,0.00043478012,0.0012347915,0.0011949204,0.003052404,0.00071121345,0.13100085,0.77018136,0.04476125],"study_design_scores_gemma":[0.0008199782,0.00016721278,0.07883693,0.0010342804,0.000803129,0.00046607692,0.0030460802,0.0032581086,0.001981902,0.020261617,0.88889265,0.00043204296],"about_ca_topic_score_codex":0.9883796,"about_ca_topic_score_gemma":0.9939632,"teacher_disagreement_score":0.053770144,"about_ca_system_score_codex":0.053770144,"about_ca_system_score_gemma":0.25772756,"threshold_uncertainty_score":0.39013147},"labels":[],"label_agreement":null},{"id":"W2077018378","doi":"10.1038/nm0712-991b","title":"Accord could make Canadian generics industry a 'rust bucket'","year":2012,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rust (programming language); Business; Operations management; Computer science; Engineering","score_opus":0.06759830387206095,"score_gpt":0.3187807513350691,"score_spread":0.25118244746300816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077018378","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016614242,0.0019829157,0.0028785102,0.55662346,0.015849942,0.00030048314,0.0045643374,0.0012151976,0.39997095],"genre_scores_gemma":[0.17417522,0.0009500201,0.0037252868,0.41253975,0.0047372524,0.00020461193,0.00094666204,0.00020285802,0.40251842],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99033874,0.0008065856,0.00020626692,0.0007340747,0.0054444945,0.0024699166],"domain_scores_gemma":[0.9877527,0.0022464662,0.00042961695,0.000647948,0.006344418,0.0025788478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00697499,0.0011155503,0.0007232977,0.0024578015,0.0057952194,0.008346503,0.0022056315,0.030084427,0.029215915],"category_scores_gemma":[0.027800508,0.00067411305,0.002434748,0.0016407367,0.003003482,0.0027553313,0.0018345873,0.0098174345,0.0038560175],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002643907,0.00007823356,0.0016211756,0.00007134145,0.00006417152,0.0001461272,0.0001691788,0.0011065736,0.00053844706,0.22580819,0.7545566,0.015575466],"study_design_scores_gemma":[0.00038166172,0.00012358694,0.013060133,0.00013336557,0.0001298865,0.00008062551,0.0002400665,0.0018068287,0.0006586168,0.027213315,0.9559775,0.00019445052],"about_ca_topic_score_codex":0.8709641,"about_ca_topic_score_gemma":0.89241225,"teacher_disagreement_score":0.96538556,"about_ca_system_score_codex":0.034614433,"about_ca_system_score_gemma":0.09222859,"threshold_uncertainty_score":0.25959158},"labels":[],"label_agreement":null},{"id":"W2077165819","doi":"10.1177/0091270011402500","title":"Optimizing Drug Development and Use in Patients With Kidney Disease","year":2011,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Kidney disease; Intensive care medicine; Population; Public health; Disease; Dosing; Drug development; Health care; Clearance; Drug; Internal medicine; Environmental health; Pharmacology; Pathology; Economic growth","score_opus":0.15558054303457677,"score_gpt":0.35719692523095314,"score_spread":0.20161638219637637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077165819","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20863369,0.48315609,0.02865899,0.14491269,0.0030911278,0.0013178219,0.0022591657,0.0010814944,0.12688899],"genre_scores_gemma":[0.64000994,0.24893121,0.051737204,0.035670307,0.005207942,0.0007951211,0.0018382814,0.00026957062,0.015540401],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9965366,0.0017272921,0.00048473492,0.00021343036,0.00084763253,0.00019040493],"domain_scores_gemma":[0.99544024,0.0012813369,0.0014908039,0.00016691642,0.00088347716,0.0007372076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041805366,0.00029007014,0.00071749353,0.00057056715,0.0005379774,0.001653765,0.0007021165,0.000937542,0.006072642],"category_scores_gemma":[0.01616843,0.00013252471,0.0006017456,0.00082165434,0.00033270608,0.0018204829,0.001199241,0.0014814333,0.0019270803],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010031144,0.0011679278,0.034507662,0.0015976687,0.0002324247,0.00033582468,0.00029058772,0.00076451903,0.0015099557,0.0031716218,0.061713964,0.8937048],"study_design_scores_gemma":[0.0011528626,0.0075188377,0.093913265,0.005346976,0.0012289392,0.0041093784,0.0009841443,0.0055878456,0.008538749,0.014894549,0.85660046,0.00012392772],"about_ca_topic_score_codex":0.0011632163,"about_ca_topic_score_gemma":0.0033638745,"teacher_disagreement_score":0.006072642,"about_ca_system_score_codex":0.0009840211,"about_ca_system_score_gemma":0.002898937,"threshold_uncertainty_score":0.022109032},"labels":[],"label_agreement":null},{"id":"W2077420003","doi":"10.1136/bmj.e4348","title":"Pharmaceutical research and development: what do we get for all that money?","year":2012,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Incentive; Mythology; Business; Economics; Market economy; Art; Literature","score_opus":0.4040375696304965,"score_gpt":0.44863132398909544,"score_spread":0.04459375435859897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077420003","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024217453,0.024149835,0.00042672196,0.96423787,0.006502872,0.000007891489,0.00006586619,0.000059877733,0.004306851],"genre_scores_gemma":[0.041270234,0.09930683,0.0036369076,0.8019368,0.036305446,0.00011640323,0.0002739067,0.00029705223,0.016856503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97076863,0.012014532,0.0014334343,0.0016564865,0.01012829,0.003998534],"domain_scores_gemma":[0.8929502,0.040403187,0.008089612,0.0055704596,0.02180834,0.031178204],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.033113465,0.0019848505,0.0036821652,0.005154525,0.0072073545,0.033018604,0.003346649,0.023706635,0.043883696],"category_scores_gemma":[0.13840404,0.0008256559,0.0017818918,0.005452532,0.018675618,0.04553854,0.011449838,0.021486538,0.022261715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022717805,0.00018428397,0.0017177573,0.0014784471,0.00027278633,0.0001886894,0.0004612206,0.00038352315,0.00020525685,0.079986356,0.77376354,0.14113091],"study_design_scores_gemma":[0.00014928935,0.0001478411,0.0024598367,0.003669103,0.00013806194,0.00031005734,0.002329712,0.00038358566,0.0002061396,0.19661053,0.7934479,0.00014800248],"about_ca_topic_score_codex":0.009742506,"about_ca_topic_score_gemma":0.006772169,"teacher_disagreement_score":0.9668865,"about_ca_system_score_codex":0.009912677,"about_ca_system_score_gemma":0.030278148,"threshold_uncertainty_score":0.17512286},"labels":[],"label_agreement":null},{"id":"W2079994436","doi":"10.1176/pn.40.2.00400004","title":"Govt. Cites Few Benefits From Legal Drug Imports","year":2005,"lang":"en","type":"article","venue":"Psychiatric News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CITES; Government (linguistics); Legislation; Business; Prescription drug; Incentive; Scope (computer science); Medical prescription; Law; Medicine; Political science; Pharmacology; Economics","score_opus":0.02926849896999632,"score_gpt":0.25710285615216455,"score_spread":0.22783435718216824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079994436","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00063941034,0.0020910937,0.00021023452,0.012253408,0.0039216722,0.00010080517,0.011624745,0.0013263125,0.96783227],"genre_scores_gemma":[0.0028827812,0.0013831016,0.00021113778,0.00927394,0.00077047374,0.00005705509,0.007381394,0.00031985706,0.97772026],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999124,0.000055313205,0.000034719782,0.00006253234,0.0006105999,0.000112795904],"domain_scores_gemma":[0.99852717,0.00029476022,0.00011751618,0.00013301261,0.000716086,0.00021149262],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004377438,0.00051812344,0.00049118244,0.0018342581,0.0019290817,0.0026879841,0.0008795299,0.0039599543,0.5841424],"category_scores_gemma":[0.0024876308,0.0004258468,0.0005595618,0.0023239672,0.00042863464,0.001504006,0.001181839,0.002190171,0.43744373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018766928,0.0000268861,0.00008726005,0.00007441565,0.0000019285649,0.00006396868,0.000011242468,0.000016329901,0.0001191237,0.0011704185,0.9754023,0.023007415],"study_design_scores_gemma":[0.00000739807,0.000007235445,0.0004449722,0.00003828397,0.0000013517894,0.000032059685,0.000013725316,0.000012332015,0.000046494402,0.00017630053,0.9992161,0.0000036738227],"about_ca_topic_score_codex":0.024009371,"about_ca_topic_score_gemma":0.05480011,"teacher_disagreement_score":0.5841424,"about_ca_system_score_codex":0.0022092252,"about_ca_system_score_gemma":0.0031005458,"threshold_uncertainty_score":0.5931704},"labels":[],"label_agreement":null},{"id":"W2080608213","doi":"10.1161/hc4301.101126","title":"Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001","year":2001,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Biostatistics; Food and drug administration; Advisory committee; Steering committee; Library science; Internal medicine; Management; Epidemiology; Pharmacology","score_opus":0.05232949601813492,"score_gpt":0.2585653543213317,"score_spread":0.2062358583031968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080608213","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063077854,0.017830633,0.0029843613,0.46811333,0.3058375,0.0019309314,0.04147129,0.0007967072,0.15472743],"genre_scores_gemma":[0.01366483,0.012455354,0.0016459902,0.07262294,0.06741781,0.0010144713,0.010845245,0.00024097784,0.82009244],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662054,0.0003730107,0.00016064363,0.00027378363,0.0020061536,0.0005659004],"domain_scores_gemma":[0.98427236,0.003415344,0.001253938,0.00042614294,0.008503093,0.0021291089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064259553,0.0017858826,0.0016637541,0.0026797238,0.0026863061,0.0069882325,0.0018553557,0.014082331,0.091680236],"category_scores_gemma":[0.012969636,0.0008429784,0.0011093223,0.0025452273,0.0005327295,0.0022555776,0.0014544382,0.007148235,0.04209384],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014818735,0.00005776536,0.00027716585,0.00005540241,0.000008102264,0.000022976288,0.0000074765794,0.000043328047,0.00008141235,0.000109246386,0.9950216,0.004167267],"study_design_scores_gemma":[0.00036070615,0.00014214488,0.012233386,0.00028816878,0.00010691723,0.000044687156,0.00015535904,0.00059529766,0.00063514075,0.00075295253,0.9846335,0.00005159687],"about_ca_topic_score_codex":0.014604878,"about_ca_topic_score_gemma":0.0436278,"teacher_disagreement_score":0.091680236,"about_ca_system_score_codex":0.003232549,"about_ca_system_score_gemma":0.008031064,"threshold_uncertainty_score":0.30670094},"labels":[],"label_agreement":null},{"id":"W2081257393","doi":"10.7326/0003-4819-150-8-200904210-02006","title":"Review: Brand-name drugs are not more effective than generic versions for treating cardiovascular disease","year":2009,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Brand names; Disease; Intensive care medicine; Internal medicine; Advertising","score_opus":0.08459671899370333,"score_gpt":0.3395196093529283,"score_spread":0.254922890359225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081257393","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004083596,0.20090458,0.000586915,0.67623293,0.10499178,0.00018552464,0.0017515348,0.00023878721,0.014699628],"genre_scores_gemma":[0.006974495,0.15399426,0.0012662138,0.714927,0.1089639,0.00030692588,0.00058676495,0.00019119849,0.012789299],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9771584,0.007397125,0.004943706,0.0015918784,0.008326441,0.00058242487],"domain_scores_gemma":[0.89513946,0.06157403,0.012109023,0.0022956652,0.026400356,0.0024815113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02514272,0.0011392827,0.006987313,0.0040229787,0.0021273638,0.005111607,0.003831084,0.019784752,0.011381716],"category_scores_gemma":[0.09745019,0.0012797017,0.0033476811,0.0059797494,0.0030016664,0.0037138597,0.0018192191,0.013384434,0.010209743],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014455835,0.000006476969,0.00013920722,0.0044310535,0.00018858441,0.00012303365,0.00003107012,0.000026828655,0.000088851884,0.0009329304,0.970296,0.023591306],"study_design_scores_gemma":[0.0006601409,0.00013872808,0.0026224905,0.024553409,0.0011691755,0.00069750537,0.000109953406,0.0002648284,0.0003210949,0.005783166,0.963601,0.00007862175],"about_ca_topic_score_codex":0.007406494,"about_ca_topic_score_gemma":0.02537521,"teacher_disagreement_score":0.02514272,"about_ca_system_score_codex":0.008603675,"about_ca_system_score_gemma":0.010307745,"threshold_uncertainty_score":0.13296896},"labels":[],"label_agreement":null},{"id":"W2081303573","doi":"10.1016/j.jval.2011.08.712","title":"PHP162 Impact of AMNOG on Pharmaceutical Pricing Trends in Germany","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Inflation (cosmology); Deflation; German; Biosimilar; Price setting; Health care; Business; Product (mathematics); Economics; Reference price; Monetary economics; Monetary policy; Geography; Medicine; Economic growth; Microeconomics","score_opus":0.26620551699215866,"score_gpt":0.40005730019361646,"score_spread":0.1338517832014578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081303573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710373,0.0011097013,0.00035837933,0.0055251573,0.00013483662,0.00000899105,0.0080736615,0.000103359554,0.013648506],"genre_scores_gemma":[0.99418783,0.00045538004,0.00010003992,0.0002222609,0.00006116524,0.000004045697,0.0016977933,0.000016561798,0.0032548874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995003,0.00007315205,0.000033672106,0.000066283035,0.000114529335,0.00021207679],"domain_scores_gemma":[0.99820936,0.0004739737,0.00060236524,0.00009084907,0.0002809788,0.00034247123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009226702,0.00013258007,0.00019402843,0.0012353584,0.00019016929,0.001969236,0.00024229658,0.0006337793,0.004321909],"category_scores_gemma":[0.0035660672,0.00011989923,0.00027529564,0.0013172859,0.00025462403,0.0006252424,0.00057959405,0.00059470575,0.00082595256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038653943,0.00050272973,0.63157946,0.00041029608,0.0004379366,0.0014605462,0.0006390117,0.02558987,0.0033424713,0.05498682,0.07318722,0.20399827],"study_design_scores_gemma":[0.00006631532,0.00025227806,0.9421965,0.00007326923,0.0001371353,0.00025604517,0.0004392521,0.010439956,0.003030348,0.00208331,0.040991172,0.00003442891],"about_ca_topic_score_codex":0.024994034,"about_ca_topic_score_gemma":0.012946642,"teacher_disagreement_score":0.024994034,"about_ca_system_score_codex":0.0017714176,"about_ca_system_score_gemma":0.0016190538,"threshold_uncertainty_score":0.0496971},"labels":[],"label_agreement":null},{"id":"W2081870126","doi":"10.1001/2013.jamainternmed.332","title":"Drug Shortages and Clinicians","year":2012,"lang":"en","type":"letter","venue":"Archives of Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital","funders":"Canadian Institutes of Health Research","keywords":"Economic shortage; Drug; Medical prescription; Medicine; Business; Pharmacology","score_opus":0.057614419204155,"score_gpt":0.31515617728646855,"score_spread":0.25754175808231355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081870126","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023960204,0.00087166287,0.000017916642,0.9946116,0.0019619467,0.0000021482006,0.0000059096797,0.000004426002,0.0022847566],"genre_scores_gemma":[0.004225662,0.00084776914,0.00004976459,0.9826918,0.008138888,0.000011506279,0.000005995395,0.00000817787,0.004020424],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923159,0.0023859474,0.0005888088,0.0010645116,0.0019978331,0.0016469185],"domain_scores_gemma":[0.97415245,0.011319456,0.0021594393,0.0008861527,0.0027588347,0.008723684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008435103,0.0006594964,0.00097123085,0.00078278995,0.01066402,0.0077008125,0.0018906181,0.07395449,0.014950702],"category_scores_gemma":[0.042801246,0.0009964524,0.00094067,0.0009463536,0.008330222,0.008855743,0.005021736,0.050645962,0.006125239],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026677862,0.00003619532,0.0007414777,0.000046151516,0.000005919191,0.0009273847,0.00030612832,0.0000474655,0.00008437651,0.01016687,0.97881657,0.008794754],"study_design_scores_gemma":[0.00012156065,0.00006016496,0.0019698031,0.00057618786,0.000011413269,0.0018580414,0.0014824205,0.00033746118,0.00011932969,0.02144285,0.97197646,0.00004436163],"about_ca_topic_score_codex":0.016488971,"about_ca_topic_score_gemma":0.038348842,"teacher_disagreement_score":0.07395449,"about_ca_system_score_codex":0.011043273,"about_ca_system_score_gemma":0.014074381,"threshold_uncertainty_score":0.080124855},"labels":[],"label_agreement":null},{"id":"W2081991539","doi":"10.1177/1715163513488327","title":"BC pharmacists propose new clinical services to save millions in health care budget","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Health care; Business; Medicine; Economic growth; Economics","score_opus":0.06418847774852117,"score_gpt":0.32281917203691335,"score_spread":0.2586306942883922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081991539","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005375626,0.002693868,0.0022287534,0.86990905,0.006673596,0.00025831145,0.0007742507,0.00025271106,0.11183377],"genre_scores_gemma":[0.21200435,0.0072909533,0.016679375,0.38748437,0.01035834,0.0003657653,0.001191529,0.00027456385,0.3643508],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9872995,0.0028609636,0.00042462567,0.00060154754,0.0060371915,0.0027762034],"domain_scores_gemma":[0.9611502,0.0059710564,0.0016513445,0.0011562374,0.0136001995,0.016470931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006984481,0.0006673498,0.0006052635,0.001810916,0.005251986,0.0124572,0.0015908448,0.014212142,0.059981976],"category_scores_gemma":[0.039388396,0.00057812786,0.0010040388,0.0021926498,0.0031986025,0.0031610108,0.0023178558,0.00859433,0.0062395176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007970701,0.00015501006,0.0030740432,0.000085711785,0.00004234653,0.00009953262,0.00012506376,0.0009934452,0.00018407866,0.053542994,0.90778434,0.03383379],"study_design_scores_gemma":[0.00035083186,0.00012329278,0.008439384,0.00025665466,0.00005645131,0.00014846722,0.000745894,0.0028650083,0.00030672605,0.023455067,0.9631915,0.000060792914],"about_ca_topic_score_codex":0.5199275,"about_ca_topic_score_gemma":0.6981658,"teacher_disagreement_score":0.966606,"about_ca_system_score_codex":0.033393957,"about_ca_system_score_gemma":0.17065702,"threshold_uncertainty_score":0.9657995},"labels":[],"label_agreement":null},{"id":"W2082327598","doi":"10.3917/seve.042.0047","title":"Xavier Bertrand 2011 : électrochoc dans le monde du médicament","year":2014,"lang":"fr","type":"article","venue":"Les Tribunes de la santé","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.014492646420290854,"score_gpt":0.265330714982783,"score_spread":0.25083806856249213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082327598","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041899527,0.14902855,0.0029113316,0.69277096,0.02327288,0.000047660007,0.00030487528,0.00021637087,0.12725753],"genre_scores_gemma":[0.102094516,0.06200838,0.0038174533,0.1664051,0.01794643,0.00009660386,0.00019215635,0.0003235531,0.6471158],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950132,0.0016389157,0.00022949763,0.0005439891,0.0020741008,0.000500298],"domain_scores_gemma":[0.99528366,0.0021304486,0.0005138839,0.0002459057,0.0013940838,0.00043196752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044141854,0.0007817176,0.00051029515,0.0009657058,0.0040915716,0.0077220113,0.0013338133,0.014724476,0.016816571],"category_scores_gemma":[0.015990289,0.0004753155,0.00052153686,0.0011915325,0.003163333,0.006281402,0.001933905,0.008570092,0.0055426084],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013628462,0.000022652905,0.0004834968,0.00014412876,0.000014668601,0.00023571057,0.0010714628,0.00016773865,0.00034243593,0.17171466,0.7916979,0.033968743],"study_design_scores_gemma":[0.000015901152,0.000017595854,0.000899661,0.00024210445,0.000008078672,0.00014043019,0.0002638292,0.0001013011,0.0003704694,0.011129506,0.98678166,0.0000294438],"about_ca_topic_score_codex":0.036654055,"about_ca_topic_score_gemma":0.058162242,"teacher_disagreement_score":0.036654055,"about_ca_system_score_codex":0.0054680686,"about_ca_system_score_gemma":0.006767443,"threshold_uncertainty_score":0.0728814},"labels":[],"label_agreement":null},{"id":"W2082354773","doi":"10.1377/hlthaff.2012.1268","title":"International Best Practices For Negotiating ‘Reimbursement Contracts’ With Price Rebates From Pharmaceutical Companies","year":2013,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"Canadian Institutes of Health Research","keywords":"Reimbursement; Transparency (behavior); Negotiation; Business; Confidentiality; Best practice; Globe; Work (physics); Public economics; Actuarial science; Finance; Economics; Health care; Economic growth; Medicine","score_opus":0.14597376048653304,"score_gpt":0.375892090641841,"score_spread":0.22991833015530794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082354773","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03903927,0.006909292,0.5497574,0.14424765,0.0016038081,0.0047486327,0.000377184,0.0015049867,0.2518118],"genre_scores_gemma":[0.28170907,0.0035866273,0.6934173,0.009989437,0.00023123583,0.002387504,0.0003056849,0.00039034395,0.007982846],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.6374888,0.27706283,0.032981113,0.009812162,0.033324495,0.009330642],"domain_scores_gemma":[0.69752675,0.1582916,0.033196785,0.059021678,0.04482969,0.007133496],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.25015107,0.0013679159,0.0010892105,0.008166756,0.0092521375,0.026254015,0.008106848,0.010466197,0.0063188416],"category_scores_gemma":[0.26076853,0.0022239857,0.0020296702,0.00900508,0.016436918,0.019229325,0.008189277,0.011494422,0.002627402],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001082833,0.0005509239,0.009836574,0.0014027375,0.00016863753,0.0009910093,0.06678391,0.0067699044,0.0018240017,0.62452465,0.053546105,0.23349318],"study_design_scores_gemma":[0.0001962731,0.00028492496,0.012607962,0.00809145,0.00017765396,0.0014018655,0.05374674,0.010652643,0.004602962,0.38603288,0.5215676,0.0006370891],"about_ca_topic_score_codex":0.012276323,"about_ca_topic_score_gemma":0.017817043,"teacher_disagreement_score":0.25015107,"about_ca_system_score_codex":0.015619369,"about_ca_system_score_gemma":0.042482335,"threshold_uncertainty_score":0.9246972},"labels":[],"label_agreement":null},{"id":"W2082501248","doi":"10.1111/j.1528-1167.2007.01007.x","title":"Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes","year":2007,"lang":"en","type":"article","venue":"Epilepsia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis; McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Lamotrigine; Clobazam; Pharmacy; Epilepsy; Adverse effect; Drug; Anticonvulsant; Generic drug; Brand names; Pharmacology; Family medicine; Psychiatry; Advertising","score_opus":0.03838946776967719,"score_gpt":0.28095209294857937,"score_spread":0.24256262517890217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082501248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985782,0.0004986889,0.0000866232,0.0000905563,0.0000023203622,0.000012583226,0.0003558559,0.000005637009,0.00036961364],"genre_scores_gemma":[0.9991211,0.0001922804,0.000103419814,0.000060968712,0.0000067463207,0.0000045122706,0.0004385103,0.0000016352586,0.00007070518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982151,0.00028637232,0.00026871572,0.00029605423,0.00075552164,0.00017835233],"domain_scores_gemma":[0.9942204,0.00094276643,0.0039696153,0.00024249172,0.0003713461,0.0002535027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012052441,0.00019462376,0.0003075061,0.00096278574,0.00029141977,0.0006661885,0.000501336,0.00037136243,0.0013554243],"category_scores_gemma":[0.0043999897,0.00016610466,0.00054152415,0.0019916708,0.00035583548,0.00036331356,0.00037433248,0.00045658002,0.00011038643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018006537,0.000023819333,0.9939435,0.000021910631,0.00007325238,0.0000679453,0.00007765852,0.000057338148,0.0002130135,0.000015501753,0.00009142927,0.0052345674],"study_design_scores_gemma":[0.000010218308,0.000039045164,0.99919325,0.0000053547838,0.000030504663,0.00023391534,0.00005387426,0.00021587407,0.000107051164,0.00000800551,0.00010077398,0.0000020856792],"about_ca_topic_score_codex":0.07534926,"about_ca_topic_score_gemma":0.09429579,"teacher_disagreement_score":0.07534926,"about_ca_system_score_codex":0.002478895,"about_ca_system_score_gemma":0.0010048744,"threshold_uncertainty_score":0.1498214},"labels":[],"label_agreement":null},{"id":"W2082560103","doi":"10.1002/hec.698","title":"The importance of being first: evidence from Canadian generic pharmaceuticals","year":2002,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Health Canada","keywords":"Competitor analysis; Market share; Generic drug; Business; Drug industry; Drug approval; Industrial organization; Economics; Marketing; Public economics; Drug; Medicine; Pharmacology; Engineering","score_opus":0.18842965258691116,"score_gpt":0.334590399991603,"score_spread":0.14616074740469184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082560103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89210445,0.028182931,0.00036842196,0.0098547265,0.000102180915,0.00011915859,0.007863609,0.000024800876,0.061379746],"genre_scores_gemma":[0.98596734,0.009013784,0.000116611336,0.0007953112,0.00005722689,0.000009868076,0.0019022994,0.000010668611,0.002126957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99404055,0.00064514176,0.00026600022,0.000545239,0.0032075243,0.0012955443],"domain_scores_gemma":[0.95777255,0.014564415,0.015435141,0.0014516145,0.007876648,0.0028996747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039883456,0.00048262815,0.00084195327,0.0030319602,0.0026893038,0.0030642964,0.0014245713,0.0014521318,0.009664281],"category_scores_gemma":[0.043680336,0.00042058644,0.00083820627,0.007197613,0.0022635886,0.0011620179,0.0016490176,0.0017395655,0.00040932998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001980758,0.00018744115,0.9177313,0.0009900094,0.0007519731,0.00074444804,0.0034813334,0.00092733616,0.00020373614,0.0047791777,0.012513858,0.055708762],"study_design_scores_gemma":[0.000064907166,0.0000780466,0.9877757,0.00019009535,0.00034468863,0.00013597037,0.0016119056,0.00017761366,0.00016957683,0.00029423623,0.009121489,0.00003571343],"about_ca_topic_score_codex":0.96901333,"about_ca_topic_score_gemma":0.9727949,"teacher_disagreement_score":0.030986667,"about_ca_system_score_codex":0.017702114,"about_ca_system_score_gemma":0.02170926,"threshold_uncertainty_score":0.12843847},"labels":[],"label_agreement":null},{"id":"W2082675534","doi":"10.1177/0269881107081126","title":"Generic medications: another variable in the treatment of illnesses","year":2007,"lang":"en","type":"editorial","venue":"Journal of Psychopharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Bioequivalence; Audit; Medicine; Enforcement; Pharmacovigilance; European union; Government (linguistics); Agency (philosophy); Generic drug; Postmarketing surveillance; Family medicine; Actuarial science; Public economics; Accounting; Business; Drug; Pharmacology; Adverse effect; Political science; Pharmacokinetics; Economics","score_opus":0.0472767077174043,"score_gpt":0.36010374439530696,"score_spread":0.3128270366779027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082675534","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2165087,0.27244902,0.022965157,0.21301316,0.015315643,0.0007539101,0.014470398,0.0002863992,0.2442377],"genre_scores_gemma":[0.83792704,0.043140557,0.013435904,0.06556914,0.014626964,0.00073028705,0.0029028528,0.0002049438,0.021462245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98226017,0.006423148,0.0031582015,0.0013609104,0.0061409376,0.0006567384],"domain_scores_gemma":[0.95728475,0.024886461,0.008911112,0.0020966916,0.004968738,0.0018521722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009629327,0.00028359282,0.00073944684,0.0014139849,0.0010967922,0.0025971194,0.0007100215,0.0017441198,0.017091293],"category_scores_gemma":[0.042815886,0.00012731759,0.0009807597,0.0045740097,0.0019767624,0.0024848036,0.0015918374,0.0030549646,0.0025024859],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002512611,0.00061567925,0.19858637,0.006510557,0.00075867114,0.0008855987,0.0054055005,0.0006140412,0.0018254592,0.044339433,0.0925875,0.64535844],"study_design_scores_gemma":[0.0002364058,0.0009229346,0.35189608,0.0046610306,0.0005563426,0.00455903,0.002608427,0.00041599068,0.0009985776,0.010701967,0.62228894,0.0001542511],"about_ca_topic_score_codex":0.008245077,"about_ca_topic_score_gemma":0.0058035036,"teacher_disagreement_score":0.017091293,"about_ca_system_score_codex":0.0031168316,"about_ca_system_score_gemma":0.0021244101,"threshold_uncertainty_score":0.057176113},"labels":[],"label_agreement":null},{"id":"W2083690385","doi":"10.1016/s1359-6446(05)03456-2","title":"Canadian drug reimportation debate goes on","year":2005,"lang":"en","type":"article","venue":"Drug Discovery Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Drug discovery; Pharmaceutical sciences; Pharmacology; Computational biology; Chemistry; Medicine; Biology; Biochemistry","score_opus":0.022656620041822086,"score_gpt":0.25049837565374244,"score_spread":0.22784175561192035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083690385","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003117228,0.011618502,0.00047394692,0.83953774,0.007186519,0.000026373295,0.00059737347,0.000098688106,0.13734365],"genre_scores_gemma":[0.1586261,0.012997945,0.0014904761,0.6199809,0.007923431,0.000048758357,0.00043684142,0.00020574385,0.19828974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98310465,0.0016353962,0.000418458,0.0016393373,0.009771108,0.0034309283],"domain_scores_gemma":[0.9767925,0.0065807686,0.0009096751,0.0010248574,0.011258455,0.0034336904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010005373,0.0010882511,0.0016207496,0.0041673603,0.012784909,0.018874794,0.0035663093,0.027315408,0.026593035],"category_scores_gemma":[0.03516107,0.00072562095,0.0016319925,0.004486401,0.010166888,0.0050001442,0.0025004868,0.016080316,0.002154085],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012159639,0.000023757326,0.00065121526,0.00009928915,0.000036234753,0.00010684463,0.00029426385,0.0002767856,0.00017518012,0.33850092,0.6423552,0.017358655],"study_design_scores_gemma":[0.000060010396,0.00001653979,0.0020292567,0.00016604915,0.000049581176,0.000057533278,0.00034927978,0.00027913885,0.00022260364,0.019590417,0.9771261,0.000053473144],"about_ca_topic_score_codex":0.9288165,"about_ca_topic_score_gemma":0.9550057,"teacher_disagreement_score":0.8856204,"about_ca_system_score_codex":0.114379585,"about_ca_system_score_gemma":0.159246,"threshold_uncertainty_score":0.82988584},"labels":[],"label_agreement":null},{"id":"W2084635253","doi":"10.1016/j.jval.2012.08.2038","title":"PRS39 Preference and Willingness to Pay for a Treatment of Pulmonary Arterial Hypertension","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McMaster University; PharmIdeas (Canada)","funders":"","keywords":"Treprostinil; Medicine; Willingness to pay; Preference; Population; Confidence interval; Descriptive statistics; Pulmonary hypertension; Demography; Physical therapy; Internal medicine; Environmental health; Economics; Statistics","score_opus":0.26733216273145527,"score_gpt":0.33045040279658777,"score_spread":0.0631182400651325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084635253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976429,0.0004891791,0.00151591,0.004320904,0.000053390315,0.000026083095,0.00048630568,0.000011669945,0.016667578],"genre_scores_gemma":[0.9984775,0.000064272186,0.00017687104,0.0001217926,0.000043249223,0.0000036400693,0.00011116375,0.0000025535774,0.0009989659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886644,0.0006544783,0.00009600224,0.00007330728,0.00014538325,0.00016449449],"domain_scores_gemma":[0.9857531,0.009434974,0.0023572806,0.00057777367,0.00046721872,0.0014096497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002346404,0.00014086267,0.0002740141,0.00047813726,0.00023493661,0.0012111542,0.00025397423,0.0014523447,0.02056832],"category_scores_gemma":[0.0173084,0.00013148513,0.0007142077,0.00043382726,0.00039123738,0.00054612913,0.00032018102,0.0016020729,0.0012536801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012751486,0.003176726,0.78234255,0.0003050602,0.0013163245,0.0020132628,0.00057183625,0.015507378,0.005817311,0.046001904,0.006541227,0.12365489],"study_design_scores_gemma":[0.0007349529,0.0027484961,0.8773093,0.00012990172,0.00032798192,0.0053423196,0.0013510257,0.037358847,0.0011416789,0.06561608,0.007847439,0.00009202603],"about_ca_topic_score_codex":0.0016131764,"about_ca_topic_score_gemma":0.0010505675,"teacher_disagreement_score":0.02056832,"about_ca_system_score_codex":0.00048433704,"about_ca_system_score_gemma":0.00039646143,"threshold_uncertainty_score":0.06880784},"labels":[],"label_agreement":null},{"id":"W2084964497","doi":"10.3366/ajicl.2013.0062","title":"Rwanda's New Intellectual Property Law and Compulsory Licensing for Export Under the WTO: Not Quite a Panacea","year":2013,"lang":"en","type":"article","venue":"African Journal of International and Comparative Law","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Panacea (medicine); TRIPS architecture; International trade; Order (exchange); Business; TRIPS Agreement; International trade law; Access to medicines; Law; Political science; Law and economics; Economics; Engineering; Finance; Medicine","score_opus":0.1383288975416506,"score_gpt":0.30431759133223574,"score_spread":0.16598869379058515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084964497","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07892362,0.014954645,0.013478486,0.20507501,0.0039056072,0.0001797676,0.00039827314,0.00028384334,0.68280077],"genre_scores_gemma":[0.73253673,0.007612753,0.010768233,0.08572848,0.0018019566,0.00025406666,0.0002292055,0.00017051845,0.16089801],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99283916,0.0019434867,0.00038989724,0.00082462025,0.002404087,0.0015988896],"domain_scores_gemma":[0.99374384,0.003344539,0.0009353051,0.0006784933,0.0009806312,0.00031723164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007071984,0.000452207,0.00039620828,0.0009281098,0.0035570762,0.007217478,0.0010393783,0.0065957527,0.0039505786],"category_scores_gemma":[0.016101416,0.00051820837,0.00053183956,0.00092902867,0.00814242,0.0055385437,0.002134819,0.010593465,0.000978392],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042282743,0.000028672319,0.001373212,0.00011350487,0.000015182917,0.0008827343,0.0024822406,0.00019565276,0.00092310976,0.93888754,0.03565333,0.019402625],"study_design_scores_gemma":[0.000060408132,0.00010509926,0.0045181317,0.0008876922,0.000050054987,0.002019549,0.0011329058,0.00054884626,0.0015668095,0.06632377,0.92267036,0.000116442396],"about_ca_topic_score_codex":0.06542294,"about_ca_topic_score_gemma":0.08698859,"teacher_disagreement_score":0.06542294,"about_ca_system_score_codex":0.006423137,"about_ca_system_score_gemma":0.011144303,"threshold_uncertainty_score":0.13008428},"labels":[],"label_agreement":null},{"id":"W2085083234","doi":"10.1038/bjp.2008.248","title":"The failure of torcetrapib: what have we learned?","year":2008,"lang":"en","type":"letter","venue":"British Journal of Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Adverse effect; Cholesterylester transfer protein; Blood pressure; Heart failure; Internal medicine; Aldosterone; Pharmacology; Cardiology; Cholesterol","score_opus":0.0595520396669502,"score_gpt":0.2968323390963135,"score_spread":0.23728029942936332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085083234","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001896377,0.0030219674,0.000055169403,0.9910164,0.005195806,0.000002890518,0.000019095842,0.000010935784,0.00048805075],"genre_scores_gemma":[0.0028857372,0.006608382,0.00025124304,0.93812156,0.050219443,0.00001742275,0.000027079906,0.00001936292,0.0018498339],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99522495,0.0014843195,0.0007112032,0.00068861246,0.0014399304,0.00045086248],"domain_scores_gemma":[0.96747947,0.022453362,0.0013488313,0.001049412,0.0042348653,0.003434043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009528883,0.00096917327,0.0031201344,0.0009617735,0.0028275764,0.0048182597,0.0023629486,0.051174957,0.0071311793],"category_scores_gemma":[0.051701315,0.00060680456,0.0016696992,0.0011295204,0.005205327,0.009525045,0.001462575,0.05113354,0.0068307645],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020097698,0.00008385513,0.0011865154,0.00025694416,0.000047733985,0.0029882363,0.00020941692,0.00013434932,0.00023839217,0.0070298105,0.92522675,0.062397018],"study_design_scores_gemma":[0.0002689908,0.00024554032,0.0035451232,0.0011180142,0.00006652462,0.005056095,0.00074277836,0.0007233002,0.00032056365,0.03793955,0.9498229,0.00015067591],"about_ca_topic_score_codex":0.0050129616,"about_ca_topic_score_gemma":0.007486028,"teacher_disagreement_score":0.051174957,"about_ca_system_score_codex":0.006029597,"about_ca_system_score_gemma":0.0046014446,"threshold_uncertainty_score":0.050394177},"labels":[],"label_agreement":null},{"id":"W2085556622","doi":"10.1016/j.socscimed.2009.11.034","title":"Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandinos","year":2010,"lang":"en","type":"letter","venue":"Social Science & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Medicine; Sociology; Gerontology","score_opus":0.0954362643238633,"score_gpt":0.35672899975091255,"score_spread":0.2612927354270492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085556622","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005981276,0.0010585018,0.000019866364,0.98807573,0.010045624,0.0000038894245,0.000018817313,0.000004432003,0.0007132387],"genre_scores_gemma":[0.00072861556,0.00038284846,0.000033367873,0.98477215,0.012107024,0.000015438043,0.0000059876893,0.000008650771,0.0019458797],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9791387,0.005370704,0.002248362,0.00311983,0.006025231,0.004097327],"domain_scores_gemma":[0.90970796,0.06876249,0.0041030897,0.0014320717,0.007797999,0.008196429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021692209,0.0021091339,0.0046568536,0.0019644839,0.014697267,0.0162929,0.008058949,0.24989907,0.01051463],"category_scores_gemma":[0.10806971,0.002255393,0.0034258366,0.0025883964,0.013531111,0.015159548,0.007157036,0.16203463,0.007114503],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034951077,0.000009790131,0.000054373104,0.00006488998,0.000013948516,0.00023352298,0.00024657743,0.000024558414,0.000037814523,0.0053092106,0.9922409,0.0017293873],"study_design_scores_gemma":[0.00022719362,0.000044381224,0.0007879103,0.0013875186,0.00012105487,0.00041972342,0.0016166803,0.00036117845,0.0002570557,0.02903028,0.9655813,0.00016570526],"about_ca_topic_score_codex":0.03972388,"about_ca_topic_score_gemma":0.075319216,"teacher_disagreement_score":0.24989907,"about_ca_system_score_codex":0.01979217,"about_ca_system_score_gemma":0.027557785,"threshold_uncertainty_score":0.14360291},"labels":[],"label_agreement":null},{"id":"W2086522963","doi":"10.3821/145.3.cpj106","title":"Quebec Pharmacists and Physicians Call for Legislative Changes to Combat Drug Shortages in Canada","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Legislature; Economic shortage; Pharmacy; Notice; Mandate; Business; Political science; Medicine; Family medicine; Law; Government (linguistics)","score_opus":0.05665391661493917,"score_gpt":0.27021478609281496,"score_spread":0.21356086947787578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086522963","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057740407,0.0073725325,0.0005100997,0.9308878,0.0069784224,0.00019206811,0.00077237317,0.0003003902,0.047212247],"genre_scores_gemma":[0.05722507,0.009329143,0.0034220398,0.81362444,0.002144738,0.0001624415,0.0011892699,0.00015196066,0.11275081],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9883692,0.0009136531,0.0004182353,0.0007317951,0.004804881,0.004762119],"domain_scores_gemma":[0.9579106,0.0025631092,0.0013979867,0.0005719974,0.015812526,0.021743873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007761179,0.0007619634,0.00083265605,0.0020653973,0.020989789,0.007347489,0.003689712,0.011958934,0.029784184],"category_scores_gemma":[0.014453095,0.0011029742,0.0012149815,0.003140639,0.0045689344,0.0027231886,0.0043171654,0.01091503,0.0027418595],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025410805,0.000062198174,0.0031224692,0.00013017449,0.000018320388,0.00025603917,0.00048131304,0.0001385333,0.00018269155,0.0032087825,0.9728668,0.019507255],"study_design_scores_gemma":[0.00010754744,0.000045495737,0.02096869,0.00036964164,0.000025820025,0.00011976555,0.0018256842,0.00028173922,0.00014075567,0.00076491054,0.9752764,0.0000735321],"about_ca_topic_score_codex":0.99072367,"about_ca_topic_score_gemma":0.9966697,"teacher_disagreement_score":0.88408697,"about_ca_system_score_codex":0.11591301,"about_ca_system_score_gemma":0.4587515,"threshold_uncertainty_score":0.8410117},"labels":[],"label_agreement":null},{"id":"W2086566703","doi":"10.12927/hcpap..16912","title":"Drugs, Health and the Economy: Investment, Innovation, Outcomes, Growth","year":2002,"lang":"en","type":"review","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Investment (military); Business; Innovation economics; Economics; Economic system; Political science","score_opus":0.1729561571059661,"score_gpt":0.3656938275191458,"score_spread":0.1927376704131797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086566703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010708934,0.9960658,0.000076432494,0.0018344595,0.0000775358,0.00000289932,0.0000083313935,0.0000024123403,0.0018251158],"genre_scores_gemma":[0.0032997916,0.99553055,0.00012257115,0.00031323257,0.00013028158,0.00000472368,0.000008517371,6.984985e-7,0.00058970205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988986,0.00042693052,0.000062692445,0.00007222693,0.00048043244,0.000059038684],"domain_scores_gemma":[0.99787664,0.0013972772,0.00025776654,0.000046770598,0.00034582466,0.00007574044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002218259,0.0006648438,0.0013704266,0.0034095417,0.00043533708,0.0025449598,0.0006172371,0.0020641368,0.0037468104],"category_scores_gemma":[0.004141822,0.00027512616,0.00040963912,0.00828421,0.0018371608,0.002348328,0.0006381944,0.0012183592,0.00064915663],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065681124,0.000073615156,0.0010115316,0.014064527,0.00016019352,0.00011904015,0.00013498642,0.0014844805,0.0001531307,0.055174895,0.041420046,0.88613784],"study_design_scores_gemma":[0.000050058254,0.00009960876,0.008646804,0.01584637,0.00019722027,0.0005918287,0.0005163757,0.0007094335,0.00029260395,0.052330587,0.9206755,0.00004355379],"about_ca_topic_score_codex":0.04187206,"about_ca_topic_score_gemma":0.057716973,"teacher_disagreement_score":0.04187206,"about_ca_system_score_codex":0.0062570926,"about_ca_system_score_gemma":0.008835271,"threshold_uncertainty_score":0.08325666},"labels":[],"label_agreement":null},{"id":"W2086814699","doi":"10.3821/145.5.cpj202","title":"Provinces and territories agree to work together to purchase generic drugs and to expand use of bulk purchasing for brand-name drugs","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Purchasing; Procurement; Business; Bidding; Medical prescription; Brand names; Health care; Work (physics); Marketing; Economics; Economic growth; Medicine; Engineering","score_opus":0.07661303361822375,"score_gpt":0.2787111270980182,"score_spread":0.20209809347979446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086814699","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015047044,0.004822955,0.0034082609,0.24583095,0.0077889897,0.0005411505,0.0054184175,0.0009073388,0.7162349],"genre_scores_gemma":[0.07093631,0.0028407108,0.005297077,0.1695109,0.0004650828,0.00022694918,0.0038960206,0.00025414972,0.74657285],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917862,0.00032516432,0.00022536538,0.00047365847,0.0038812645,0.003308333],"domain_scores_gemma":[0.9910273,0.0005532167,0.0002867342,0.00046067292,0.004835838,0.002836328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002838635,0.0006897611,0.0006749504,0.0007632239,0.011221264,0.00637338,0.0018425812,0.007476192,0.052613582],"category_scores_gemma":[0.0067261327,0.0009728359,0.0012517578,0.0019041843,0.0030344129,0.0022675088,0.003504872,0.005222756,0.010440828],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077561635,0.00006136514,0.005092407,0.00016134752,0.00003430713,0.000321542,0.0007868578,0.00014529374,0.0007379406,0.028764715,0.91834927,0.045467354],"study_design_scores_gemma":[0.00003502984,0.000016798589,0.007118465,0.000049697683,0.0000127152125,0.00007614025,0.0007897089,0.000058205467,0.00021761528,0.0006181701,0.99097013,0.00003733522],"about_ca_topic_score_codex":0.9483318,"about_ca_topic_score_gemma":0.9690953,"teacher_disagreement_score":0.979249,"about_ca_system_score_codex":0.020751014,"about_ca_system_score_gemma":0.12464221,"threshold_uncertainty_score":0.17600995},"labels":[],"label_agreement":null},{"id":"W2086929860","doi":"10.12927/hcpol.2013.21638","title":"Canada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort?","year":2010,"lang":"fr","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ontario Drug Policy Research Network","funders":"","keywords":"Intellectual property; Business; Access to medicines; Production (economics); International trade; Law and economics; Law; Political science; Economics","score_opus":0.07243743497400673,"score_gpt":0.3606102366693208,"score_spread":0.28817280169531406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086929860","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026947392,0.008607365,0.0019522477,0.8320719,0.00063806406,0.0000756273,0.001563037,0.00007942274,0.12806487],"genre_scores_gemma":[0.8687369,0.011604834,0.0026317888,0.079342924,0.0011102976,0.00008236935,0.00050630816,0.000069038826,0.03591553],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98790306,0.00163312,0.00021671865,0.00069028686,0.005254429,0.0043024416],"domain_scores_gemma":[0.9824107,0.005044873,0.0013143204,0.0006379655,0.006036736,0.0045553423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011000106,0.00043496373,0.00093345746,0.0017942555,0.0066029923,0.010465812,0.0022490849,0.0064439187,0.012033563],"category_scores_gemma":[0.03142562,0.00024964634,0.0005963629,0.002794265,0.009645685,0.0055258176,0.0032435453,0.0060876375,0.0004946259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012526868,0.00005215226,0.00661252,0.00029685866,0.000108287524,0.00031852885,0.0012973817,0.0023544794,0.00021689614,0.83745265,0.11559809,0.035566926],"study_design_scores_gemma":[0.00021618526,0.00015175396,0.0311697,0.0013964967,0.00015493798,0.00032174928,0.007227553,0.0069256416,0.0007015406,0.28317377,0.6682664,0.00029429526],"about_ca_topic_score_codex":0.9432783,"about_ca_topic_score_gemma":0.93762875,"teacher_disagreement_score":0.91300786,"about_ca_system_score_codex":0.08699213,"about_ca_system_score_gemma":0.20111997,"threshold_uncertainty_score":0.63117504},"labels":[],"label_agreement":null},{"id":"W2087882132","doi":"10.7326/0003-4819-144-3-200602070-00026","title":"Savings from Canadian Internet Pharmacies Are Limited","year":2006,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medicine; The Internet; Drug prices; Purchasing; Advertising; Family medicine; Business; Marketing","score_opus":0.12809494610255967,"score_gpt":0.3250109907026511,"score_spread":0.19691604460009143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087882132","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001353861,0.008233098,0.00032742583,0.07986649,0.006571132,0.00017272873,0.007992642,0.0012095976,0.894273],"genre_scores_gemma":[0.0124769695,0.011718648,0.0007731394,0.024679398,0.0014778848,0.00006465519,0.004507827,0.00028076262,0.9440206],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99591917,0.00015798843,0.00010761409,0.00022409073,0.003079497,0.0005117097],"domain_scores_gemma":[0.9902716,0.0006343136,0.00036644764,0.00044714022,0.0060701757,0.002210271],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010180795,0.0009396847,0.0006962105,0.0024253041,0.0043321108,0.005198482,0.0012931568,0.0036154361,0.57212716],"category_scores_gemma":[0.010221541,0.0004540395,0.0007392217,0.003582816,0.0008988021,0.002047397,0.0016783088,0.002250697,0.25745663],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020424965,0.0000113914075,0.0001982653,0.000053749733,0.0000029492599,0.000034679942,0.000016593189,0.0000122210795,0.000050812312,0.0008004441,0.96348363,0.03531491],"study_design_scores_gemma":[0.000008728134,0.000005333392,0.00079342816,0.00006950945,0.0000032131159,0.000047049496,0.000040319628,0.000024524057,0.00004041171,0.00013808269,0.9988213,0.000007964172],"about_ca_topic_score_codex":0.57688624,"about_ca_topic_score_gemma":0.74793935,"teacher_disagreement_score":0.57212716,"about_ca_system_score_codex":0.01597263,"about_ca_system_score_gemma":0.032355033,"threshold_uncertainty_score":0.85121113},"labels":[],"label_agreement":null},{"id":"W2088456832","doi":"10.1002/mde.1348","title":"A primer on the economics of re‐importation of prescription drugs","year":2007,"lang":"en","type":"article","venue":"Managerial and Decision Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profitability index; Revenue; Politics; Economics; Market size; Outcome (game theory); Medical prescription; International economics; Economy; Microeconomics; Political science; Finance; Law","score_opus":0.050657124121851534,"score_gpt":0.27538065293150327,"score_spread":0.22472352880965174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088456832","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037317711,0.17512676,0.08021363,0.3368427,0.0095082335,0.00026468502,0.0009839195,0.00014272009,0.3931856],"genre_scores_gemma":[0.17543338,0.3157268,0.054775327,0.16285929,0.031878773,0.0008954254,0.0005894832,0.00026928217,0.25757226],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99852246,0.0007265065,0.000069251284,0.000141619,0.00045372054,0.00008634784],"domain_scores_gemma":[0.9950846,0.0040930393,0.000179148,0.00017087233,0.00036620186,0.000106196545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026743324,0.00070678,0.00063257595,0.0027691675,0.0012133955,0.0051554665,0.0011470818,0.0058792485,0.016312743],"category_scores_gemma":[0.0052644024,0.00070037064,0.00093944784,0.0024960393,0.0062846555,0.008812266,0.0020439199,0.007654102,0.0028914104],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000066967186,0.000024071602,0.00011872212,0.00007860744,0.000006728869,0.00009492362,0.00015305883,0.00095251575,0.00010770513,0.94142556,0.041799773,0.015231725],"study_design_scores_gemma":[0.0000065634927,0.000025641273,0.0004525682,0.00070122385,0.0000042710317,0.00016658218,0.00016112182,0.0010421564,0.00015424135,0.5578853,0.43937898,0.000021267866],"about_ca_topic_score_codex":0.0031893086,"about_ca_topic_score_gemma":0.0023975463,"teacher_disagreement_score":0.016312743,"about_ca_system_score_codex":0.0034891828,"about_ca_system_score_gemma":0.0019593728,"threshold_uncertainty_score":0.05457157},"labels":[],"label_agreement":null},{"id":"W2088519281","doi":"10.1163/15691497-12341254","title":"Ethical Ramifications for a Proposed FTA between India and the EU","year":2013,"lang":"en","type":"article","venue":"Perspectives on Global Development and Technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Disadvantaged; Negotiation; Position (finance); Compensation (psychology); International trade; Development economics; Economic growth; Economics; Political science; Business; Law","score_opus":0.032097307783126354,"score_gpt":0.2847090548554232,"score_spread":0.25261174707229683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088519281","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05368174,0.0012857796,0.020040335,0.67110854,0.0056502027,0.0002430654,0.00009260563,0.00011572028,0.24778205],"genre_scores_gemma":[0.7846214,0.00033386098,0.012421167,0.16726424,0.0016355057,0.00034863394,0.000033592594,0.000052508607,0.033289067],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9645573,0.020667465,0.0013023769,0.0030481901,0.005129975,0.0052946396],"domain_scores_gemma":[0.96851337,0.020241901,0.0012999694,0.0035977645,0.002979226,0.0033678743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.045143742,0.00044968628,0.00064406235,0.00086697086,0.00891984,0.0158112,0.003052662,0.030114163,0.0070176153],"category_scores_gemma":[0.051609002,0.0003391244,0.0013968665,0.0007479788,0.015477294,0.006775265,0.009483038,0.021192007,0.0010721888],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003010045,0.000031426003,0.00022479307,0.000012407074,0.000008829418,0.00027744425,0.0008438371,0.00043610428,0.00014046009,0.9872186,0.0077778334,0.002997987],"study_design_scores_gemma":[0.00012128446,0.00013027246,0.0008474828,0.0002839638,0.000052539945,0.00068248156,0.0049007917,0.0044108066,0.0008738166,0.83852506,0.14904825,0.00012317092],"about_ca_topic_score_codex":0.0045984886,"about_ca_topic_score_gemma":0.0045605213,"teacher_disagreement_score":0.045143742,"about_ca_system_score_codex":0.0062153284,"about_ca_system_score_gemma":0.015145671,"threshold_uncertainty_score":0.23874575},"labels":[],"label_agreement":null},{"id":"W2088820584","doi":"10.1377/hlthaff.w4.396","title":"Doughnut Holes And Price Controls","year":2004,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicare Part D; Drug prices; Prescription drug; Business; Pharmaceutical industry; Cost sharing; Drug industry; Public economics; Drug pricing; Medical prescription; Actuarial science; Economics; Medicine; Pharmacology","score_opus":0.05110420427915781,"score_gpt":0.3001486910607471,"score_spread":0.2490444867815893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088820584","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20849958,0.02431246,0.0855164,0.06433665,0.003005816,0.0004553091,0.0022689272,0.0012692256,0.6103356],"genre_scores_gemma":[0.9479688,0.0024178687,0.0029733442,0.0059324345,0.0010819706,0.00017019197,0.00021313028,0.00012398437,0.039118376],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99560505,0.00079099135,0.00017642562,0.0013606566,0.0008964154,0.0011704523],"domain_scores_gemma":[0.9923987,0.0035297412,0.0023071154,0.0007746573,0.0004994037,0.0004904043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046600993,0.0009882142,0.0018380388,0.0017160207,0.003253238,0.0068344465,0.002175314,0.0052570784,0.027970403],"category_scores_gemma":[0.01760434,0.00085256743,0.0012266552,0.0015817599,0.011315414,0.0084864665,0.0036906798,0.006695663,0.0010908013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008142405,0.000026076614,0.0008084297,0.00004060785,0.000022258015,0.000121516714,0.00011682627,0.0010712016,0.00008504108,0.9858328,0.0059041497,0.005889652],"study_design_scores_gemma":[0.00017642602,0.0000648289,0.0018070434,0.00009449034,0.000031154854,0.000078651516,0.00012799584,0.0027872224,0.00023238939,0.960705,0.033847906,0.000046956142],"about_ca_topic_score_codex":0.018145781,"about_ca_topic_score_gemma":0.014305657,"teacher_disagreement_score":0.027970403,"about_ca_system_score_codex":0.004008429,"about_ca_system_score_gemma":0.002846137,"threshold_uncertainty_score":0.09357029},"labels":[],"label_agreement":null},{"id":"W2089278217","doi":"10.2165/00148365-200806010-00002","title":"Differences in Generic Drug Prices between the US and Canada","year":2008,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; St. Michael's Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medical prescription; Pharmacy; Medicine; Generic drug; Drug prices; Prescription drug; Pharmacoepidemiology; Drug; Brand names; Family medicine; Business; Advertising; Pharmacology; Public economics; Economics","score_opus":0.12126561824674134,"score_gpt":0.3206131181645682,"score_spread":0.19934749991782688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089278217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9013328,0.012114249,0.000835644,0.023159409,0.00018649116,0.00005401107,0.016632354,0.00008305175,0.045601953],"genre_scores_gemma":[0.99018466,0.0019446079,0.0003301622,0.0009144553,0.000036817175,0.0000052855207,0.0021906195,0.000020618027,0.0043728086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974541,0.00018273415,0.00013027253,0.00021842192,0.0011526257,0.0008617155],"domain_scores_gemma":[0.99436283,0.0010299635,0.00084109453,0.00009222602,0.002684106,0.0009896938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010851837,0.00018385626,0.00051264523,0.0022163654,0.0014248869,0.0032295943,0.00079625595,0.0008800811,0.0050542406],"category_scores_gemma":[0.009996831,0.00025937677,0.0009942368,0.006243158,0.0010228388,0.00087469304,0.0006417108,0.001441706,0.00019599267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025765374,0.00020540408,0.73393553,0.000580029,0.0012228092,0.00078241585,0.0020486603,0.014685118,0.0015041557,0.089179836,0.052317,0.10096251],"study_design_scores_gemma":[0.00010127861,0.00004572901,0.9732878,0.0000678392,0.00020769311,0.0001527384,0.001568022,0.0037690317,0.0005486736,0.0021878015,0.018006654,0.000056687233],"about_ca_topic_score_codex":0.99261063,"about_ca_topic_score_gemma":0.99614006,"teacher_disagreement_score":0.06314387,"about_ca_system_score_codex":0.06314387,"about_ca_system_score_gemma":0.047789004,"threshold_uncertainty_score":0.458143},"labels":[],"label_agreement":null},{"id":"W2089453005","doi":"10.1038/clpt.2009.179","title":"Expediting Patients’ Access to Medicines by Improving the Predictability of Drug Development and the Regulatory Approval Process","year":2009,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Expediting; Drug development; Clinical pharmacology; Regulatory science; Risk analysis (engineering); Drug approval; Business; Access to medicines; Process (computing); Medicine; Drug; Process management; Pharmacology; Computer science; Engineering","score_opus":0.08671489304942995,"score_gpt":0.38417699705932334,"score_spread":0.29746210400989337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089453005","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20758381,0.00905348,0.54096496,0.12889197,0.00066991925,0.003217235,0.00052981026,0.002144544,0.106944196],"genre_scores_gemma":[0.8680929,0.0035345047,0.12142145,0.0029300267,0.00096903025,0.00061647024,0.00020640877,0.00017482738,0.0020543954],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8796181,0.08563541,0.008135385,0.0042534512,0.018912144,0.0034456586],"domain_scores_gemma":[0.53138524,0.35414782,0.06437185,0.022121916,0.023399977,0.0045731748],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.14627741,0.0007935559,0.0012401491,0.0033939069,0.0020757844,0.014617929,0.0020316842,0.0021041606,0.008409804],"category_scores_gemma":[0.2653387,0.0010675524,0.0014812018,0.0033933823,0.0025671916,0.0110442145,0.006165958,0.006372957,0.0018123671],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011971071,0.0008452276,0.053935185,0.0012691171,0.00036943523,0.00052714,0.0036667653,0.06574216,0.0041104225,0.18512028,0.02329747,0.6599197],"study_design_scores_gemma":[0.0015660165,0.003644966,0.12360187,0.0020700318,0.000611577,0.0020851474,0.004117315,0.15774865,0.023640709,0.43546537,0.24457851,0.00086987216],"about_ca_topic_score_codex":0.0027752526,"about_ca_topic_score_gemma":0.003952153,"teacher_disagreement_score":0.8537226,"about_ca_system_score_codex":0.0069327955,"about_ca_system_score_gemma":0.029843424,"threshold_uncertainty_score":0.77359813},"labels":[],"label_agreement":null},{"id":"W2089540131","doi":"10.1071/hp070411","title":"Reshaping Australian drug policy: the dilemmas of generic medicines policy","year":2007,"lang":"en","type":"article","venue":"Australia and New Zealand Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical Benefits Scheme; Health economics; Population health; Public health; Health policy; Public policy; Public relations; Pharmaceutical policy; Pharmaceutical industry; Economics; Public administration; Political science; Health care; Medicine; Economic growth; Medical prescription","score_opus":0.17439772928819594,"score_gpt":0.40428571970651417,"score_spread":0.22988799041831823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089540131","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024591489,0.018430253,0.003248026,0.8651885,0.00089328125,0.000052527743,0.000087410124,0.000039363043,0.08746905],"genre_scores_gemma":[0.7307272,0.02856416,0.009726377,0.17574963,0.0026129351,0.00015766884,0.0000828998,0.00006525548,0.052313842],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9873863,0.0064280597,0.00038425685,0.0004802272,0.003599455,0.001721692],"domain_scores_gemma":[0.98809063,0.0065779067,0.00085283205,0.00047570918,0.0025232544,0.0014796394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014827991,0.00043688648,0.00073938974,0.0027109603,0.0055727065,0.009710783,0.0016955102,0.011503099,0.0062128725],"category_scores_gemma":[0.029397065,0.00046843122,0.00064656185,0.003381036,0.009085484,0.007504832,0.0039948635,0.007675762,0.0005362909],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060928596,0.00007520622,0.0013226855,0.00048326512,0.00002765996,0.00045320735,0.0045755277,0.0014028086,0.00038092944,0.8557393,0.0688253,0.066653185],"study_design_scores_gemma":[0.000055987515,0.00013880903,0.012271539,0.00087974075,0.000044943667,0.00045573778,0.0060170987,0.005664062,0.00033534478,0.44212508,0.5319048,0.00010690038],"about_ca_topic_score_codex":0.06796511,"about_ca_topic_score_gemma":0.064240076,"teacher_disagreement_score":0.06796511,"about_ca_system_score_codex":0.017041435,"about_ca_system_score_gemma":0.017408855,"threshold_uncertainty_score":0.13513905},"labels":[],"label_agreement":null},{"id":"W2090189145","doi":"10.1517/14656560903140525","title":"The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Food and drug administration; Bioequivalence; Generic drug; MEDLINE; Drug; Substitution (logic); Drug approval; Antiepileptic drug; Alternative medicine; Epilepsy; Family medicine; Psychiatry; Pharmacology","score_opus":0.2535574849152221,"score_gpt":0.45538050080739784,"score_spread":0.20182301589217572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090189145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016554337,0.9992494,0.000026782653,0.00028047682,0.000040842875,0.000005066844,0.00002188187,6.8498224e-7,0.00020929516],"genre_scores_gemma":[0.0017438818,0.99800605,0.00006253037,0.00009522084,0.000046919184,0.000006491222,0.000012525506,3.712611e-7,0.000026027563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998247,0.0005294502,0.0004077874,0.00016958691,0.0005703317,0.0000757242],"domain_scores_gemma":[0.9816627,0.015014603,0.002199535,0.00009587019,0.0009215312,0.000105720734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041407463,0.0008694056,0.0031967408,0.00636269,0.00023092337,0.0019257959,0.0011302739,0.0018572578,0.0046501593],"category_scores_gemma":[0.017043399,0.00061255076,0.0021856981,0.010351207,0.0005934083,0.0015744308,0.0005366694,0.0009477788,0.0003914883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048285417,0.00007827051,0.0013706575,0.42177033,0.0033646205,0.0003816563,0.0000764767,0.0010540754,0.00020053527,0.004006936,0.011234561,0.55597895],"study_design_scores_gemma":[0.0004915568,0.00059615925,0.018733893,0.6177686,0.021204224,0.003121912,0.0005632339,0.0012616493,0.00061375496,0.0066616633,0.32888943,0.00009387756],"about_ca_topic_score_codex":0.0052607176,"about_ca_topic_score_gemma":0.007942998,"teacher_disagreement_score":0.00636269,"about_ca_system_score_codex":0.0032416093,"about_ca_system_score_gemma":0.0048460076,"threshold_uncertainty_score":0.023519635},"labels":[],"label_agreement":null},{"id":"W2090343559","doi":"10.3917/riges.274.0017","title":"L'évolution du commerce électronique et la performance de la chaîne d'approvisionnement du secteur de la santé : changement de paradigme","year":2002,"lang":"fr","type":"article","venue":"Gestion","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"HEC Montréal; Bell (Canada)","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.02758046922631156,"score_gpt":0.28057207084959995,"score_spread":0.2529916016232884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090343559","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23973404,0.041385997,0.11374552,0.10930062,0.0008459105,0.00024665127,0.00020400241,0.0000949247,0.49444222],"genre_scores_gemma":[0.93135405,0.016152572,0.01925276,0.0023612494,0.00028793406,0.00012425936,0.000054737997,0.00003255986,0.030379834],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99505734,0.0026189138,0.00018687523,0.00047271207,0.0012397565,0.00042454858],"domain_scores_gemma":[0.98913145,0.005828486,0.0014235552,0.00082971994,0.0022416073,0.0005451061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006872159,0.00037422936,0.00036336033,0.0019837485,0.0021704156,0.010885844,0.0010793513,0.0035305577,0.008108187],"category_scores_gemma":[0.008044112,0.00029917705,0.0005815213,0.0029555932,0.009139095,0.008301925,0.0029043409,0.002400599,0.00060246035],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045782817,0.000041722164,0.0030428544,0.00018092162,0.000019741656,0.0001160732,0.0018269361,0.0021459644,0.0005356693,0.9622212,0.0010512184,0.028771942],"study_design_scores_gemma":[0.00004703644,0.00041056442,0.023994043,0.0017474741,0.000063455096,0.0005795538,0.0102880085,0.008597298,0.0025165908,0.6976881,0.2539732,0.00009476527],"about_ca_topic_score_codex":0.0098959515,"about_ca_topic_score_gemma":0.008426653,"teacher_disagreement_score":0.012968499,"about_ca_system_score_codex":0.012968499,"about_ca_system_score_gemma":0.009379719,"threshold_uncertainty_score":0.09409344},"labels":[],"label_agreement":null},{"id":"W2090997748","doi":"10.1017/s1744133108004477","title":"Addressing legal and political barriers to global pharmaceutical access: Options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards","year":2008,"lang":"en","type":"article","venue":"Health Economics Policy and Law","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institutes of Health Research; University of Toronto","funders":"","keywords":"TRIPS architecture; Intellectual property; TRIPS Agreement; Legitimacy; Politics; International trade; Business; Developing country; Human rights; Political science; Public economics; Economics; Economic growth; Law; Engineering","score_opus":0.13388102143293948,"score_gpt":0.40779007139012363,"score_spread":0.2739090499571841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090997748","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11560448,0.014532762,0.09675543,0.48155445,0.00070693204,0.00023269022,0.00018703185,0.00012271944,0.29030353],"genre_scores_gemma":[0.9531754,0.0076239845,0.014560769,0.015391899,0.00082913745,0.00023449218,0.000060075316,0.000025808962,0.008098313],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.988863,0.006279058,0.00046246336,0.0010103704,0.0021134715,0.0012716244],"domain_scores_gemma":[0.96393394,0.027627671,0.004610723,0.0014352651,0.0015682183,0.00082419865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018546391,0.0005080752,0.000877238,0.0018430242,0.0027845507,0.012594682,0.0015986376,0.008464719,0.009130769],"category_scores_gemma":[0.038022567,0.0004137829,0.0010609096,0.0016329942,0.015658084,0.01273811,0.008864469,0.0074783964,0.00045353253],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000133811,0.000021746842,0.00049652735,0.00007838885,0.000008096744,0.000085761596,0.00026097242,0.0017041122,0.00012713589,0.989238,0.0009916247,0.0069742445],"study_design_scores_gemma":[0.00003726027,0.00004167678,0.00089411257,0.00033477106,0.0000221761,0.00007504053,0.0008322235,0.002106377,0.00034487486,0.97078854,0.024500677,0.000022282524],"about_ca_topic_score_codex":0.0037616573,"about_ca_topic_score_gemma":0.0039229207,"teacher_disagreement_score":0.018546391,"about_ca_system_score_codex":0.0039543724,"about_ca_system_score_gemma":0.0120704,"threshold_uncertainty_score":0.09808385},"labels":[],"label_agreement":null},{"id":"W2091189859","doi":"10.1007/s10198-014-0626-0","title":"Using price–volume agreements to manage pharmaceutical leakage and off-label promotion","year":2014,"lang":"en","type":"article","venue":"The European Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Lakehead University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Profit (economics); Leakage (economics); Volume (thermodynamics); Decision maker; Business; Promotion (chess); Marketing; Operations research; Microeconomics; Economics; Mathematics","score_opus":0.2031576688548169,"score_gpt":0.35376807473931415,"score_spread":0.15061040588449726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091189859","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30415034,0.0040172883,0.4935383,0.018476076,0.0016653064,0.0014052886,0.00061625656,0.0037782867,0.17235288],"genre_scores_gemma":[0.9830482,0.00017895697,0.010401273,0.000498769,0.00027028497,0.000112647474,0.000058500125,0.00008456851,0.0053468402],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9764396,0.0107581485,0.001467093,0.0024810685,0.0059774565,0.0028766615],"domain_scores_gemma":[0.92367893,0.04865939,0.013500523,0.0055753426,0.005616167,0.0029696478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03364264,0.0010535271,0.0017559673,0.0030043544,0.002150684,0.01162927,0.0036785735,0.006587805,0.01020941],"category_scores_gemma":[0.10183288,0.0013194211,0.0017847387,0.0021036542,0.003648007,0.013498498,0.006202459,0.006944844,0.0012945696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013477454,0.0019411986,0.0118443705,0.0004650491,0.00038270737,0.00048097203,0.00108884,0.18547715,0.003698855,0.6010601,0.014964435,0.17724861],"study_design_scores_gemma":[0.0005469263,0.00082895835,0.005681924,0.0002279651,0.00024519788,0.00018249245,0.00065556244,0.2777794,0.0032833796,0.6892612,0.021075986,0.00023097428],"about_ca_topic_score_codex":0.0029093262,"about_ca_topic_score_gemma":0.0019797394,"teacher_disagreement_score":0.03364264,"about_ca_system_score_codex":0.00513996,"about_ca_system_score_gemma":0.007564247,"threshold_uncertainty_score":0.17792141},"labels":[],"label_agreement":null},{"id":"W2091361563","doi":"10.3821/1913-701x(2008)141[15a:gpdmlp]2.0.co;2","title":"Government policies don't mean lower prescription drug costs","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Medical prescription; Drug; Prescription drug; Business; Medicine; Pharmacology; Philosophy","score_opus":0.052727717648247845,"score_gpt":0.2477164549479737,"score_spread":0.19498873729972585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091361563","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08470554,0.007712433,0.003264342,0.6979681,0.003728822,0.000037702204,0.0025437393,0.0004683302,0.19957091],"genre_scores_gemma":[0.7667601,0.0047186436,0.0022561639,0.18910061,0.003029633,0.000052348758,0.00068871846,0.00018441917,0.03320937],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99378455,0.0011823004,0.00021367866,0.00060707785,0.0024889999,0.0017233583],"domain_scores_gemma":[0.97745717,0.009834506,0.0044685993,0.0016663949,0.003708977,0.0028643266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037961756,0.00046967284,0.0011229331,0.0012569752,0.0014687323,0.006279601,0.00075232156,0.0072630937,0.02457017],"category_scores_gemma":[0.0348002,0.00043778634,0.0010519755,0.002154396,0.0032534683,0.0031078958,0.0010513093,0.0056123035,0.0021172785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010361914,0.00059837266,0.048290733,0.0009122045,0.0014535327,0.00042374706,0.0007118233,0.010304088,0.0014550458,0.50912327,0.32949933,0.09619163],"study_design_scores_gemma":[0.0011578827,0.00037392453,0.14897783,0.0010344272,0.0012475038,0.00037964495,0.0019067806,0.004049131,0.0026819487,0.3723932,0.4656648,0.00013290525],"about_ca_topic_score_codex":0.1070286,"about_ca_topic_score_gemma":0.173442,"teacher_disagreement_score":0.8929714,"about_ca_system_score_codex":0.010640547,"about_ca_system_score_gemma":0.015820343,"threshold_uncertainty_score":0.21281123},"labels":[],"label_agreement":null},{"id":"W2092680813","doi":"10.1080/15265161.2011.634952","title":"Are We Asking the Right Ethics Questions on Drug Shortages? Suggestions for a Global and Anticipatory Ethics Framework","year":2012,"lang":"en","type":"letter","venue":"The American Journal of Bioethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Salary; Sociology; Economic shortage; Corporate governance; Research ethics; Ethics committee; Political science; Engineering ethics; Law; Management; Public administration; Philosophy; Government (linguistics); Engineering","score_opus":0.2229923078224549,"score_gpt":0.41785784958102357,"score_spread":0.19486554175856866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092680813","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008670933,0.00016513916,0.00013878634,0.9974419,0.0008897081,0.000003733583,0.0000071585564,0.0000043549594,0.0012624577],"genre_scores_gemma":[0.0036086394,0.00023997594,0.0005076494,0.99014646,0.0030144614,0.000027451351,0.000007100602,0.000010460935,0.002437671],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97867787,0.010972038,0.0018843155,0.001718316,0.0034816384,0.0032658684],"domain_scores_gemma":[0.9053368,0.07169429,0.003902593,0.0014445462,0.010027607,0.00759423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034209598,0.00086513936,0.0013870338,0.0010179412,0.010827734,0.012390126,0.0033615353,0.09805748,0.012416556],"category_scores_gemma":[0.10338605,0.0009774044,0.0017590324,0.001114658,0.01843606,0.02065678,0.0061288546,0.0952483,0.004502321],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051954303,0.0000810318,0.00041355015,0.00010391668,0.000012456137,0.00061787793,0.0016292172,0.00019482094,0.00019414989,0.12248803,0.8658974,0.008315715],"study_design_scores_gemma":[0.00021732174,0.00005585235,0.0010594745,0.00072812586,0.000031346433,0.00076730264,0.007431446,0.0010379029,0.00037207763,0.31999615,0.6681013,0.00020166734],"about_ca_topic_score_codex":0.015097963,"about_ca_topic_score_gemma":0.02773586,"teacher_disagreement_score":0.09805748,"about_ca_system_score_codex":0.011352463,"about_ca_system_score_gemma":0.02795212,"threshold_uncertainty_score":0.18091977},"labels":[],"label_agreement":null},{"id":"W2093516009","doi":"10.1038/430141b","title":"Saving vital time in the war on drug resistance","year":2004,"lang":"en","type":"letter","venue":"Nature","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Drug; Drug resistance; Pharmacology; Business; Medicine; Biology; Microbiology","score_opus":0.01875605575970608,"score_gpt":0.25510164080641295,"score_spread":0.23634558504670689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093516009","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066901,0.0010148813,0.00013236768,0.98458374,0.007007027,0.000009633008,0.000048946724,0.000014982233,0.006519388],"genre_scores_gemma":[0.0055390564,0.00045429877,0.00013873477,0.9697468,0.008247632,0.000021073389,0.000011989942,0.000016945156,0.015823346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99446183,0.002015982,0.0003854167,0.00056312693,0.0011907273,0.0013829445],"domain_scores_gemma":[0.98571646,0.009255843,0.0008828479,0.00044283012,0.0011689845,0.0025329995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0086426865,0.0009454325,0.001761158,0.00076846173,0.00590645,0.0084851105,0.002152449,0.122244895,0.009236568],"category_scores_gemma":[0.03616417,0.0008799537,0.0013706444,0.0006851449,0.0056387126,0.0065559056,0.0028706286,0.0535859,0.0043456326],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016230463,0.00004261516,0.0005286477,0.00004613236,0.000033530272,0.0007522066,0.00024964692,0.00017853237,0.0002845567,0.023841748,0.9650612,0.008818908],"study_design_scores_gemma":[0.000154808,0.00009131051,0.0017016374,0.00027192335,0.00004482255,0.0004928659,0.00070226495,0.00056022796,0.0005271572,0.041571986,0.9538056,0.000075313474],"about_ca_topic_score_codex":0.014438845,"about_ca_topic_score_gemma":0.0333561,"teacher_disagreement_score":0.122244895,"about_ca_system_score_codex":0.00900722,"about_ca_system_score_gemma":0.0112601,"threshold_uncertainty_score":0.0653522},"labels":[],"label_agreement":null},{"id":"W2093520537","doi":"10.1377/hlthaff.20.5.301","title":"Drug Cost Containment In Canada","year":2001,"lang":"en","type":"letter","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Liberian dollar; Statement (logic); Health care; Medicine; Business; Political science; Law; Finance","score_opus":0.050987000387542926,"score_gpt":0.2757853900753864,"score_spread":0.22479838968784346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093520537","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066628554,0.0057130028,0.00021092258,0.93303233,0.00603681,0.000100414305,0.00052249513,0.000060745646,0.047660373],"genre_scores_gemma":[0.047170132,0.0034664578,0.00052195723,0.84460294,0.0060491883,0.000077888115,0.00020403038,0.00006617059,0.097841375],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98760146,0.0010164247,0.0006299859,0.00089933485,0.0054642777,0.00438847],"domain_scores_gemma":[0.97979546,0.005343535,0.0009232083,0.00034870385,0.0072801444,0.0063088695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006833,0.00076441,0.0016786908,0.0024171958,0.014905293,0.010893486,0.0032970402,0.05284343,0.012438549],"category_scores_gemma":[0.026532557,0.0012198392,0.0018299355,0.0027542883,0.004180221,0.0021412403,0.0022786765,0.022566114,0.0012127144],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001492052,0.00005588828,0.0031802347,0.00016080827,0.00007598595,0.00079166185,0.0003616278,0.0007140837,0.00030867485,0.042717334,0.93439287,0.017091589],"study_design_scores_gemma":[0.00043020427,0.00007993394,0.01792451,0.00046928175,0.00017735657,0.00030564933,0.0007152472,0.0026075388,0.0005037792,0.012125516,0.96450573,0.00015525329],"about_ca_topic_score_codex":0.97353417,"about_ca_topic_score_gemma":0.9902958,"teacher_disagreement_score":0.12208473,"about_ca_system_score_codex":0.12208473,"about_ca_system_score_gemma":0.23940846,"threshold_uncertainty_score":0.8857908},"labels":[],"label_agreement":null},{"id":"W2094376331","doi":"10.1503/cmaj.070779","title":"US Senate passes FDA Revitalization Act","year":2007,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Legislation; Elixir (programming language); Food and drug administration; Medical prescription; Administration (probate law); Political science; Medicine; Public administration; Law; Pharmacology; Computer science","score_opus":0.024163765709815016,"score_gpt":0.26878868739818307,"score_spread":0.24462492168836805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094376331","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033535552,0.0025493982,0.00076250645,0.22801675,0.008918205,0.00019517825,0.005996442,0.0008858347,0.74932206],"genre_scores_gemma":[0.023586411,0.0017669293,0.0010864267,0.3157905,0.0019303544,0.00043523905,0.0030134977,0.0003588437,0.6520318],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98834294,0.0015002963,0.0004990169,0.000824634,0.006820072,0.0020131096],"domain_scores_gemma":[0.9860496,0.0035450822,0.0005193269,0.0008593118,0.008291741,0.0007349964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008205148,0.0011590696,0.0011218608,0.002456233,0.00815567,0.010597093,0.0018113176,0.019446949,0.05867231],"category_scores_gemma":[0.026424477,0.0010970216,0.0018515597,0.0026651009,0.0029257024,0.0042299726,0.0036609697,0.0131358085,0.053644992],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003378468,0.000030990566,0.00042180583,0.000028321054,0.000010846846,0.000114407485,0.000096170756,0.000030790827,0.00011571812,0.028100792,0.96586686,0.0051495526],"study_design_scores_gemma":[0.000028647499,0.000021921647,0.001517088,0.00006858035,0.000026071111,0.000051568055,0.000100568934,0.000052480536,0.0002499815,0.0026009437,0.9952592,0.00002284627],"about_ca_topic_score_codex":0.10939693,"about_ca_topic_score_gemma":0.14033537,"teacher_disagreement_score":0.10939693,"about_ca_system_score_codex":0.0076331235,"about_ca_system_score_gemma":0.024242235,"threshold_uncertainty_score":0.21752036},"labels":[],"label_agreement":null},{"id":"W2094681946","doi":"10.1310/3ere-blaq-69dk-r6vb","title":"The Two Towers: Quest for Drugs from Discovery to Approval","year":2004,"lang":"en","type":"article","venue":"Topics in Spinal Cord Injury Rehabilitation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute","funders":"","keywords":"Viewpoints; Process (computing); Medicine; Pharmaceutical industry; Marketing; Engineering ethics; Public relations; Business; Computer science; Pharmacology; Engineering; Political science","score_opus":0.046141533259630906,"score_gpt":0.35824610851286365,"score_spread":0.31210457525323276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094681946","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009717426,0.071817026,0.038534928,0.7710823,0.008648749,0.00013713879,0.00022331905,0.0003010426,0.09953811],"genre_scores_gemma":[0.4443937,0.121701054,0.057048064,0.25304896,0.02410663,0.0006306447,0.00036194382,0.00066283764,0.098046176],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98703116,0.0049551893,0.0005435457,0.0014296041,0.0050383033,0.001002164],"domain_scores_gemma":[0.9819012,0.010151842,0.0014777555,0.0014925834,0.0021302118,0.0028463847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015621365,0.0008793213,0.0017485848,0.002838122,0.0054936213,0.01786579,0.0017028408,0.012144532,0.019193077],"category_scores_gemma":[0.04129901,0.000935021,0.001004645,0.00215827,0.021038314,0.036318693,0.008079364,0.020368544,0.006020613],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020747555,0.00007900776,0.0004148318,0.0003020134,0.00003240586,0.00024353284,0.0011390878,0.00046420033,0.00040773384,0.8434286,0.10256344,0.05071763],"study_design_scores_gemma":[0.0000932353,0.00013127663,0.00029644676,0.00042719446,0.000015469617,0.00025727286,0.0009486214,0.00085136393,0.0002906192,0.77194756,0.22469325,0.000047702746],"about_ca_topic_score_codex":0.0021720952,"about_ca_topic_score_gemma":0.0024123702,"teacher_disagreement_score":0.019193077,"about_ca_system_score_codex":0.0066010123,"about_ca_system_score_gemma":0.012777797,"threshold_uncertainty_score":0.08261466},"labels":[],"label_agreement":null},{"id":"W2096039402","doi":"10.12927/hcpol.2015.24046","title":"The Drivers of Overspending on Prescription Drugs in Quebec","year":2014,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Per capita; Context (archaeology); Health spending; Rest (music); Demographic economics; Public economics; Business; Economics; Geography; Medicine; Health services; Environmental health; Pharmacology; Internal medicine","score_opus":0.05142054456718465,"score_gpt":0.3235295969694712,"score_spread":0.27210905240228656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096039402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95638174,0.0022075993,0.00028762032,0.0170007,0.000037729555,0.00006315113,0.004435681,0.000030088802,0.019555617],"genre_scores_gemma":[0.99389315,0.0007655843,0.00010075093,0.00075554696,0.000020836109,0.000010286192,0.000685136,0.000007619137,0.003761059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984061,0.0002144927,0.000054310036,0.0001165106,0.00044042367,0.00076831767],"domain_scores_gemma":[0.9943551,0.00087022345,0.0014960105,0.00010778735,0.0018105198,0.0013603949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009834437,0.00015766612,0.00032647094,0.0015538571,0.002575891,0.002917651,0.0011697582,0.0007235921,0.0074876193],"category_scores_gemma":[0.004787666,0.00019573758,0.00039327497,0.004047061,0.001020671,0.0006525904,0.00090668275,0.0014445529,0.00029970662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014161086,0.00010167312,0.9479944,0.000077495395,0.00011142311,0.00082270213,0.00272897,0.0018143752,0.00057519734,0.010810577,0.014662792,0.020158812],"study_design_scores_gemma":[0.00001239535,0.00001688865,0.9827443,0.0000880198,0.00002316936,0.00010410101,0.0040895687,0.0025238234,0.00009983057,0.00039082416,0.0098834215,0.000023617144],"about_ca_topic_score_codex":0.9951557,"about_ca_topic_score_gemma":0.99601537,"teacher_disagreement_score":0.0696227,"about_ca_system_score_codex":0.0696227,"about_ca_system_score_gemma":0.03592587,"threshold_uncertainty_score":0.50515044},"labels":[],"label_agreement":null},{"id":"W2096719808","doi":"10.1016/j.hcmf.2012.11.003","title":"From Framework to the Frontline: Designing a Structure and Process for Drug Supply Shortage Planning","year":2013,"lang":"en","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Economic shortage; Process (computing); Business; Process management; Drug; Operations management; Knowledge management; Medicine; Computer science; Pharmacology; Engineering","score_opus":0.045671777907375165,"score_gpt":0.3230099725547227,"score_spread":0.27733819464734755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096719808","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015325349,0.0002919646,0.94487053,0.012032664,0.00013480127,0.0025023324,0.00018805673,0.0006837455,0.023970477],"genre_scores_gemma":[0.10389287,0.0002327083,0.89221585,0.00044126133,0.00005168527,0.0010955519,0.00024853263,0.000112666545,0.0017088949],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9842643,0.011538841,0.0006787938,0.0010822545,0.0013413908,0.0010944406],"domain_scores_gemma":[0.98043734,0.011126148,0.0019159715,0.0014976417,0.0030021942,0.0020207262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029799165,0.0009741473,0.00080974784,0.004383273,0.006141575,0.012218303,0.0029719141,0.0037947565,0.0115705775],"category_scores_gemma":[0.036397256,0.0016504814,0.0012515462,0.004110355,0.007022072,0.014562316,0.0068515283,0.0047827084,0.0023010154],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010780212,0.00049247907,0.0033921693,0.00033852836,0.000044253215,0.00064424134,0.010187412,0.08629207,0.0014487581,0.76514065,0.013075949,0.11883571],"study_design_scores_gemma":[0.00026912187,0.0003263557,0.0015450001,0.0009373469,0.000035967027,0.00016110436,0.010379943,0.17389016,0.0013441256,0.73904645,0.07189298,0.00017144367],"about_ca_topic_score_codex":0.015669966,"about_ca_topic_score_gemma":0.025547726,"teacher_disagreement_score":0.029799165,"about_ca_system_score_codex":0.011469094,"about_ca_system_score_gemma":0.035209857,"threshold_uncertainty_score":0.15759492},"labels":[],"label_agreement":null},{"id":"W2096918198","doi":"10.1212/01.wnl.0000349653.30398.e8","title":"CLINICAL CONSEQUENCES OF GENERIC SUBSTITUTION OF LAMOTRIGINE FOR PATIENTS WITH EPILEPSY","year":2009,"lang":"en","type":"letter","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lamotrigine; Epilepsy; Substitution (logic); Medicine; Clinical neurology; Psychiatry; Psychology; Neuroscience; Computer science","score_opus":0.07985443588549204,"score_gpt":0.3069363065674907,"score_spread":0.22708187068199867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096918198","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1298932,0.00321386,0.00037317513,0.832522,0.0016269801,0.00006212567,0.00036020807,0.000034616216,0.03191387],"genre_scores_gemma":[0.65566415,0.002449485,0.00043056757,0.32646754,0.008516824,0.00002592159,0.00017715426,0.000014697007,0.006253605],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99919266,0.00028533404,0.00009209821,0.00007510588,0.00017126615,0.00018350466],"domain_scores_gemma":[0.9926046,0.0044589425,0.0011419753,0.00018840311,0.0008363762,0.00076965324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001105652,0.00016324602,0.00030349233,0.000396098,0.0012331388,0.0009175739,0.00045236436,0.0064881123,0.0039965087],"category_scores_gemma":[0.013269043,0.00013370873,0.00037217527,0.00068840105,0.0008772605,0.00057902833,0.00032293456,0.0033858742,0.00077020214],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016533773,0.0005446813,0.29897776,0.00018596389,0.0001223833,0.17739952,0.0010460808,0.0015897917,0.0018282221,0.009856209,0.41904378,0.08775224],"study_design_scores_gemma":[0.001194885,0.0015960443,0.48778635,0.0008919649,0.00023986815,0.20706283,0.00449201,0.014773686,0.0015622108,0.02763019,0.25253698,0.00023302849],"about_ca_topic_score_codex":0.025427952,"about_ca_topic_score_gemma":0.064424776,"teacher_disagreement_score":0.025427952,"about_ca_system_score_codex":0.005509167,"about_ca_system_score_gemma":0.0022587024,"threshold_uncertainty_score":0.05055988},"labels":[],"label_agreement":null},{"id":"W2097263300","doi":"","title":"Are drug too expensive in Canada? No.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Data science; Computer science; Medicine; World Wide Web","score_opus":0.04188622934438089,"score_gpt":0.2062551664396284,"score_spread":0.16436893709524752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097263300","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020187283,0.04392897,0.00014550604,0.90669596,0.011167956,0.000026931575,0.0065286364,0.00004572267,0.029441595],"genre_scores_gemma":[0.05125054,0.13573499,0.001167498,0.68172956,0.018709384,0.000055743905,0.0034291316,0.00015045604,0.10777273],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99710196,0.00018955622,0.00021162382,0.00025778194,0.0016919761,0.0005470265],"domain_scores_gemma":[0.9775679,0.0032652365,0.0013292187,0.00037162844,0.014412135,0.0030539366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002243266,0.00038065398,0.0009626944,0.0018863452,0.0038461136,0.0046946877,0.0017909656,0.0058038337,0.038240254],"category_scores_gemma":[0.022292202,0.0003149528,0.0007617456,0.0045211297,0.0027249982,0.0037741994,0.0008502237,0.0053978506,0.0042724274],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009160203,0.000012137548,0.002615875,0.0005267134,0.000047772424,0.00010261073,0.00007090861,0.00006098811,0.000050934974,0.009537634,0.9613279,0.025554886],"study_design_scores_gemma":[0.000050119736,0.00002317817,0.007779187,0.0018949279,0.00014361991,0.00016935234,0.0008071173,0.00014396272,0.0001949016,0.006312404,0.9824095,0.00007163147],"about_ca_topic_score_codex":0.93116546,"about_ca_topic_score_gemma":0.9674348,"teacher_disagreement_score":0.06883454,"about_ca_system_score_codex":0.032436397,"about_ca_system_score_gemma":0.13786127,"threshold_uncertainty_score":0.23534364},"labels":[],"label_agreement":null},{"id":"W2098786187","doi":"10.1016/j.healthpol.2008.01.003","title":"Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia","year":2008,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research; University of British Columbia; Vancouver Coastal Health; University of Toronto; Providence Health Care","funders":"","keywords":"Pharmaceutical policy; Pharmaceutical industry; Reimbursement; Health policy; Incentive; Government (linguistics); Business; Industrial policy; Audit; Public economics; Economics; Accounting; Health care; Economic growth; Medicine; Market economy; International trade","score_opus":0.3553180744422676,"score_gpt":0.4494373061556191,"score_spread":0.09411923171335151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098786187","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30899742,0.022216365,0.016767656,0.40346867,0.00050967495,0.00018635712,0.0001596498,0.000051232426,0.24764305],"genre_scores_gemma":[0.96898514,0.0052130567,0.0027621535,0.011545201,0.00033492126,0.00004462751,0.000024820363,0.000016004522,0.0110741425],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99388134,0.0028694922,0.0001717312,0.00029683582,0.0009329044,0.001847711],"domain_scores_gemma":[0.98795646,0.0070404503,0.00075637386,0.0002688288,0.0025409332,0.0014368888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011387393,0.00041395155,0.00095548516,0.0010749609,0.0026914096,0.009352373,0.0009217322,0.0073382193,0.003402784],"category_scores_gemma":[0.022328356,0.00036970136,0.000517181,0.0013510804,0.0058843205,0.0050840704,0.004244883,0.005985349,0.0002720065],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002955259,0.00023478163,0.012290514,0.0004122702,0.00013886162,0.00065462355,0.0037760162,0.022250403,0.0008987165,0.8894098,0.011201447,0.058437087],"study_design_scores_gemma":[0.00021792405,0.00022791029,0.038911227,0.0009521541,0.0001522843,0.00015867455,0.007454801,0.025103204,0.0011657127,0.8581316,0.06743016,0.000094403826],"about_ca_topic_score_codex":0.19126524,"about_ca_topic_score_gemma":0.21600375,"teacher_disagreement_score":0.19126524,"about_ca_system_score_codex":0.022175046,"about_ca_system_score_gemma":0.029495955,"threshold_uncertainty_score":0.38030386},"labels":[],"label_agreement":null},{"id":"W2099171964","doi":"10.1002/pds.1283","title":"Epidemiology in the pharmaceutical Industry: a Canadian perspective","year":2006,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); Memorial University of Newfoundland; University of Toronto; University of Waterloo","funders":"","keywords":"Library science; Pharmacy; Medicine; Management; Family medicine","score_opus":0.09028622778025515,"score_gpt":0.3635956619330042,"score_spread":0.27330943415274905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099171964","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044783927,0.18420377,0.003181655,0.7696718,0.0024940514,0.00003886652,0.0014142604,0.00004534714,0.034471907],"genre_scores_gemma":[0.2561781,0.5909252,0.0056359316,0.117455095,0.014958706,0.00006803854,0.00078198867,0.000061646875,0.013935225],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9942932,0.0015568422,0.00040641596,0.0005665854,0.0019862948,0.0011906946],"domain_scores_gemma":[0.9744762,0.006811791,0.0017601573,0.0003503448,0.012418445,0.0041829958],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0068949875,0.0013559659,0.0018131515,0.013269616,0.0037096594,0.008861671,0.0026234165,0.00718265,0.0076880115],"category_scores_gemma":[0.024256023,0.00079241034,0.0016549204,0.013927687,0.0072843484,0.004476682,0.0023054949,0.0055580707,0.0004522331],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00021754602,0.00023144585,0.02647765,0.0023462784,0.00051304523,0.0013435646,0.0014393671,0.019445864,0.00071100227,0.6512058,0.1736072,0.12246136],"study_design_scores_gemma":[0.0001891359,0.00011730686,0.0969747,0.006204542,0.0005673387,0.0009188823,0.0038970108,0.008805174,0.00030108282,0.25807938,0.62348527,0.00046017018],"about_ca_topic_score_codex":0.98365295,"about_ca_topic_score_gemma":0.98178434,"teacher_disagreement_score":0.993105,"about_ca_system_score_codex":0.14287208,"about_ca_system_score_gemma":0.16948465,"threshold_uncertainty_score":0.9941469},"labels":[],"label_agreement":null},{"id":"W2099473096","doi":"10.1002/agr.20156","title":"Firm, market, and regulatory factors influencing innovation and commercialization in Canada's functional food and nutraceutical sector","year":2008,"lang":"en","type":"article","venue":"Agribusiness","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Guelph","funders":"","keywords":"Commercialization; EconLit; Business; New product development; Product (mathematics); Harmonization; Marketing; Scale (ratio); Nutraceutical; Industrial organization; Economics","score_opus":0.06595811088790704,"score_gpt":0.22734285664943646,"score_spread":0.16138474576152942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099473096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789301,0.001020424,0.00032627978,0.0029590656,0.000012710183,0.00007285828,0.0021985914,0.000017330629,0.014462613],"genre_scores_gemma":[0.99698585,0.00035600847,0.000107237225,0.000090299094,0.000007670162,0.00000871581,0.0006949851,0.0000022226914,0.0017469298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979346,0.0002121881,0.000080215344,0.00019690722,0.00087071315,0.0007054647],"domain_scores_gemma":[0.9838102,0.004644367,0.004496657,0.00026336886,0.0036146576,0.0031708644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019560421,0.00015551751,0.00027859112,0.0023406313,0.0018475279,0.0028039613,0.0007293782,0.0005045583,0.0054105166],"category_scores_gemma":[0.0101467585,0.00017031825,0.0004380483,0.0033987404,0.0013376252,0.00061653246,0.0010282148,0.00086161215,0.00020838538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015393079,0.00013393509,0.9689103,0.00007212011,0.00006735168,0.00019689531,0.0008282348,0.0035800647,0.00033466233,0.0061272318,0.0048165736,0.014778652],"study_design_scores_gemma":[0.000018057328,0.00003731043,0.98700935,0.000054763026,0.000034030192,0.000027065904,0.0018839467,0.004826722,0.000192469,0.0005387702,0.0053585074,0.000019078689],"about_ca_topic_score_codex":0.98054594,"about_ca_topic_score_gemma":0.9808322,"teacher_disagreement_score":0.96189976,"about_ca_system_score_codex":0.03810024,"about_ca_system_score_gemma":0.044809937,"threshold_uncertainty_score":0.27643788},"labels":[],"label_agreement":null},{"id":"W2099541887","doi":"10.1108/14468951111123346","title":"Encouraging pharmaceutical innovation to meet the needs of both developed and developing countries","year":2011,"lang":"en","type":"article","venue":"International Journal of Development Issues","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Developing country; Government (linguistics); Variety (cybernetics); Business; Pharmaceutical industry; Originality; Product (mathematics); Value (mathematics); Limiting; Donation; Public economics; Marketing; Economics; Medicine; Economic growth; Engineering; Political science","score_opus":0.13290009156767474,"score_gpt":0.35000216518785787,"score_spread":0.21710207362018313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099541887","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042640325,0.13627978,0.06744755,0.298435,0.003066845,0.00095451664,0.00028898465,0.0003882181,0.45049882],"genre_scores_gemma":[0.6861489,0.12957302,0.08759103,0.06346364,0.0027701694,0.0006605431,0.00015615771,0.0000924262,0.029544143],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907811,0.0048381765,0.00036348388,0.0005421708,0.0027053247,0.00076972804],"domain_scores_gemma":[0.9858204,0.009125376,0.0017855196,0.0009247143,0.001615683,0.0007283415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01674932,0.00036888983,0.00035053934,0.0020466568,0.0016735945,0.010976972,0.0009546853,0.0032820737,0.0045171627],"category_scores_gemma":[0.016510978,0.00019882811,0.00056394347,0.0018520666,0.0050040153,0.0055377637,0.0046957596,0.0027470838,0.00082772225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004182846,0.00009284937,0.002127073,0.001908536,0.000028452103,0.00021013917,0.0012325202,0.0012207142,0.0013630887,0.82187074,0.016676659,0.1532274],"study_design_scores_gemma":[0.000059610167,0.00049594126,0.004506066,0.0030371204,0.000069015594,0.00094004837,0.0041722194,0.0019474895,0.0036838606,0.22012147,0.7609113,0.00005587326],"about_ca_topic_score_codex":0.0012529125,"about_ca_topic_score_gemma":0.0020348527,"teacher_disagreement_score":0.01674932,"about_ca_system_score_codex":0.004397016,"about_ca_system_score_gemma":0.012783242,"threshold_uncertainty_score":0.08857995},"labels":[],"label_agreement":null},{"id":"W2099722439","doi":"10.1503/cmaj.110493","title":"Canada’s laws on pharmaceutical intellectual property: the case for fundamental reform: Figure 1:","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Intellectual property; Government (linguistics); Value (mathematics); Law; Property (philosophy); Computer science; Law and economics; Political science; Sociology; Epistemology; Philosophy","score_opus":0.08612977742327967,"score_gpt":0.2756571802187956,"score_spread":0.18952740279551594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099722439","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010689298,0.0046573887,0.0027244715,0.69921964,0.0010525498,0.00009678748,0.001006698,0.00009480508,0.2804584],"genre_scores_gemma":[0.5278828,0.006093098,0.0063789566,0.33665237,0.0017645252,0.00017679234,0.0006680815,0.000123784,0.120259576],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98320836,0.0015027713,0.00027542136,0.0012951721,0.009268116,0.004450132],"domain_scores_gemma":[0.98377323,0.0055743493,0.0007988966,0.0010297123,0.006444448,0.0023793576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008002468,0.0005292151,0.00076661893,0.0014948829,0.0136949,0.012803927,0.0035030257,0.024406785,0.009903289],"category_scores_gemma":[0.025179075,0.00065830146,0.0009779255,0.0023602075,0.018796133,0.0061602537,0.0031451061,0.016910266,0.00095130893],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015108653,0.000013172927,0.000405464,0.000041144227,0.000005487466,0.00010109887,0.00067762204,0.00023739676,0.00007747817,0.89433795,0.10008418,0.0040038726],"study_design_scores_gemma":[0.00011806431,0.000029709867,0.0045479448,0.00046705938,0.00004151512,0.00014460218,0.00091861497,0.0017172383,0.0004443187,0.28986174,0.70159113,0.00011802806],"about_ca_topic_score_codex":0.9617162,"about_ca_topic_score_gemma":0.96650076,"teacher_disagreement_score":0.90254384,"about_ca_system_score_codex":0.09745615,"about_ca_system_score_gemma":0.26121235,"threshold_uncertainty_score":0.7070972},"labels":[],"label_agreement":null},{"id":"W2099981452","doi":"10.1002/hpm.819","title":"Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs?","year":2005,"lang":"en","type":"article","venue":"The International Journal of Health Planning and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Incentive; Government (linguistics); Business; Competition (biology); Public economics; Health care; Medical prescription; Industrial organization; Pharmaceutical industry; Market share; Economics; Marketing; Market economy; Economic growth; Medicine; Pharmacology","score_opus":0.07771333742491245,"score_gpt":0.3658252932535264,"score_spread":0.288111955828614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099981452","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.062581114,0.055186126,0.17396486,0.3564888,0.0020428111,0.00051086204,0.00062365766,0.00031902565,0.34828275],"genre_scores_gemma":[0.87918156,0.018628377,0.029128099,0.02704651,0.0030009921,0.00047807078,0.00028168867,0.00026983762,0.041984778],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.98747057,0.0055861133,0.0005688898,0.0013751053,0.0030884123,0.0019109171],"domain_scores_gemma":[0.9821723,0.009039393,0.0041094967,0.0014599075,0.002534909,0.0006839696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012422352,0.00069584,0.0011931465,0.0012977794,0.0011213009,0.01015005,0.0025171787,0.0050890683,0.012119701],"category_scores_gemma":[0.034315754,0.00043782726,0.00097004947,0.0020004648,0.0047574798,0.015496496,0.002474919,0.0033212532,0.0012865363],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043064367,0.00009437553,0.0014345756,0.00033743746,0.00007081389,0.00011528007,0.0002895704,0.0072863908,0.0006405032,0.92568344,0.012298025,0.05170651],"study_design_scores_gemma":[0.00020415313,0.00015576466,0.004628645,0.00065563427,0.00009915509,0.00021940566,0.00072923605,0.015891997,0.0016257169,0.75760686,0.21808492,0.00009852448],"about_ca_topic_score_codex":0.015211505,"about_ca_topic_score_gemma":0.008516169,"teacher_disagreement_score":0.015211505,"about_ca_system_score_codex":0.0072147963,"about_ca_system_score_gemma":0.009041074,"threshold_uncertainty_score":0.06569648},"labels":[],"label_agreement":null},{"id":"W2102168783","doi":"10.1111/j.1475-6773.2005.00495.x","title":"Prescription Drug Expenditures and Population Demographics","year":2006,"lang":"en","type":"article","venue":"Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Centre for Disease Control; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Prescription drug; Medical prescription; Population; Per capita; Medicine; Pharmacy; Medical Expenditure Panel Survey; Drug; Demography; Environmental health; Health care; Health insurance; Economic growth; Economics; Family medicine","score_opus":0.08342037843931394,"score_gpt":0.39128446189343646,"score_spread":0.30786408345412253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102168783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96644294,0.00041233236,0.00032715983,0.00040014373,0.000004233726,0.000054480584,0.024300812,0.00001637255,0.008041456],"genre_scores_gemma":[0.988942,0.0004878384,0.00031841092,0.00005137143,0.000011813332,0.000050509003,0.009187682,0.000002458357,0.00094781094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996736,0.00007128656,0.00003140181,0.000047527632,0.000106794505,0.000069414615],"domain_scores_gemma":[0.9983146,0.00023820942,0.00081252574,0.0000570814,0.00044678582,0.00013090685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037265974,0.00009885063,0.00012048995,0.0014468156,0.00018723082,0.00038820688,0.00011912282,0.00012388562,0.00311379],"category_scores_gemma":[0.0029786457,0.000093056355,0.00008714659,0.0021479414,0.000122023,0.0003043886,0.00022491482,0.00019456456,0.00036193582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023521452,0.000013176106,0.99048305,0.000026458392,0.000024178104,0.000039126244,0.00010756748,0.0004818149,0.00007286318,0.00026517262,0.0012373547,0.0072257146],"study_design_scores_gemma":[6.038538e-7,0.0000038676853,0.998906,0.000004880403,0.0000022494958,0.000025224086,0.000048662034,0.00011204394,0.000017984978,0.0000228869,0.0008544477,0.0000011085132],"about_ca_topic_score_codex":0.11830517,"about_ca_topic_score_gemma":0.16999882,"teacher_disagreement_score":0.11830517,"about_ca_system_score_codex":0.001057959,"about_ca_system_score_gemma":0.00090375805,"threshold_uncertainty_score":0.23523313},"labels":[],"label_agreement":null},{"id":"W2104086837","doi":"10.1002/hec.1103","title":"A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British Columbia","year":2006,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Toronto; Canadian Institutes of Health Research","funders":"","keywords":"Reimbursement; Counterfactual thinking; Context (archaeology); Drug pricing; Drug; Actuarial science; Plan (archaeology); Drug prices; Medicine; Public economics; Business; Economics; Pharmacology; Health care; Economic growth; Geography; Psychology","score_opus":0.0656231207171754,"score_gpt":0.2997996327226722,"score_spread":0.23417651200549677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104086837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766781,0.0012229723,0.00033802935,0.003950586,0.000034658133,0.000044697834,0.004833134,0.00004931188,0.012848422],"genre_scores_gemma":[0.9893773,0.0006157767,0.00021590723,0.00042167853,0.00001585044,0.000016517035,0.0024478424,0.000017770777,0.006871373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961538,0.0008319544,0.00019917228,0.0003224633,0.001518102,0.0009744921],"domain_scores_gemma":[0.98093915,0.00847442,0.0017899561,0.0010042089,0.0068042465,0.0009880242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029470383,0.0003584587,0.0009430651,0.0019224894,0.0016195418,0.002389494,0.001907978,0.00074522034,0.00548515],"category_scores_gemma":[0.020458432,0.00039096747,0.0008706768,0.0054708594,0.000682498,0.0006152097,0.0009492171,0.001587653,0.00034764712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012664507,0.00031752724,0.8809321,0.000292268,0.00071818463,0.0015047723,0.0012847523,0.021518895,0.0009887478,0.008330365,0.02064454,0.062201437],"study_design_scores_gemma":[0.000047053054,0.000065004024,0.9816413,0.00005202569,0.00018694818,0.00006954461,0.0011390207,0.009760676,0.0005177485,0.00026123153,0.006225105,0.0000343618],"about_ca_topic_score_codex":0.9920474,"about_ca_topic_score_gemma":0.99216014,"teacher_disagreement_score":0.039280087,"about_ca_system_score_codex":0.039280087,"about_ca_system_score_gemma":0.025702642,"threshold_uncertainty_score":0.2849983},"labels":[],"label_agreement":null},{"id":"W2104400639","doi":"10.1503/cmaj.141564","title":"Estimated cost of universal public coverage of prescription drugs in Canada","year":2015,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research; Health Canada; Michael Smith Health Research BC","keywords":"Medical prescription; Government (linguistics); Prescription drug; Business; Public health; Public economics; Medicine; Economics; Pharmacology","score_opus":0.04436535506075406,"score_gpt":0.2471488685197388,"score_spread":0.20278351345898474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104400639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65568686,0.013154569,0.012425877,0.0058126315,0.00020312527,0.0006624601,0.22090998,0.00072664855,0.090417825],"genre_scores_gemma":[0.9595306,0.004254558,0.005618352,0.00028006322,0.000034473393,0.00013845372,0.024218092,0.00005175913,0.005873838],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998063,0.00022503105,0.00010298764,0.0001254801,0.0011137611,0.00036964833],"domain_scores_gemma":[0.99566275,0.00047192778,0.00046388243,0.00008991082,0.0031203516,0.00019124043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093695073,0.00092400645,0.0005059393,0.0033477878,0.00093711994,0.0018308695,0.0012368372,0.00048955187,0.0036893913],"category_scores_gemma":[0.0060466826,0.00039666443,0.0016173036,0.0054648337,0.0004536793,0.0006447088,0.0008039943,0.000875897,0.00031250765],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004221926,0.00011087416,0.39340466,0.001365453,0.0016072736,0.0008791378,0.0002985117,0.46130815,0.000750317,0.019604925,0.03315112,0.087097436],"study_design_scores_gemma":[0.00023320972,0.00016710737,0.5473206,0.00094979437,0.0012754689,0.0010484589,0.0009940705,0.3572152,0.002705841,0.005820965,0.082052015,0.00021725472],"about_ca_topic_score_codex":0.9852004,"about_ca_topic_score_gemma":0.97807854,"teacher_disagreement_score":0.089445435,"about_ca_system_score_codex":0.089445435,"about_ca_system_score_gemma":0.049244285,"threshold_uncertainty_score":0.6489751},"labels":[],"label_agreement":null},{"id":"W2105192804","doi":"10.1038/nchembio.1113","title":"A public-private partnership to unlock the untargeted kinome","year":2012,"lang":"en","type":"article","venue":"Nature Chemical Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium","funders":"Engineering and Physical Sciences Research Council; Cancer Research UK; Wellcome Trust","keywords":"Kinome; General partnership; Drug discovery; Business; Redundancy (engineering); Access to medicines; Kinase; Intellectual property; Computational biology; Computer science; Data science; Chemistry; Biology; Bioinformatics; Biochemistry; Finance","score_opus":0.10390653320461236,"score_gpt":0.31861269691085775,"score_spread":0.2147061637062454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105192804","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052751854,0.005313957,0.26362965,0.4947099,0.0035641142,0.00030637666,0.00059966854,0.0011199694,0.17800458],"genre_scores_gemma":[0.909573,0.0022538924,0.030007472,0.026025048,0.001325898,0.0003036134,0.00023064716,0.0002534258,0.030027116],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931166,0.0032658386,0.00015073078,0.00077954726,0.0016091646,0.0010781153],"domain_scores_gemma":[0.95088416,0.02376028,0.0021304784,0.009019925,0.0045437464,0.009661397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018579867,0.00046199962,0.00083327043,0.0011171178,0.0025000598,0.007677222,0.0017278452,0.00816555,0.027316233],"category_scores_gemma":[0.03964998,0.00047572324,0.000579746,0.0013320664,0.0056025637,0.015955385,0.011881677,0.008318669,0.0037090867],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002164421,0.00032257376,0.0014515121,0.00012162359,0.000066918015,0.00023683831,0.00063830335,0.0042810016,0.0019030111,0.8720394,0.042414498,0.07630795],"study_design_scores_gemma":[0.00008571637,0.000063850865,0.0007437689,0.00009087708,0.000014867711,0.00010279296,0.00042116904,0.0085606,0.0006811259,0.8931831,0.09601596,0.000036162888],"about_ca_topic_score_codex":0.0015325187,"about_ca_topic_score_gemma":0.0017150595,"teacher_disagreement_score":0.027316233,"about_ca_system_score_codex":0.0034509904,"about_ca_system_score_gemma":0.014714338,"threshold_uncertainty_score":0.09826094},"labels":[],"label_agreement":null},{"id":"W2106708480","doi":"","title":"Getting ready for inspection of investigational site at short notice.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Notice; Quality (philosophy); Clinical trial; Business; Audit; Process (computing); Public relations; Accounting; Operations management; Medicine; Process management; Political science; Computer science; Engineering; Law","score_opus":0.11332516057880392,"score_gpt":0.2772018098902221,"score_spread":0.16387664931141815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106708480","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015241748,0.037797492,0.06666892,0.24260926,0.09581361,0.029678686,0.06796679,0.05824155,0.38598198],"genre_scores_gemma":[0.053604618,0.020039782,0.1520616,0.07734483,0.015595468,0.015635632,0.045750383,0.010593939,0.60937387],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9740791,0.0071079466,0.0040698657,0.0012851926,0.012488743,0.0009692275],"domain_scores_gemma":[0.83303374,0.038246967,0.018840786,0.03174459,0.07020589,0.007928039],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.027302144,0.0007132802,0.0012589091,0.0051346007,0.0019316357,0.004751737,0.0023843572,0.004635336,0.14570135],"category_scores_gemma":[0.11568959,0.0011481936,0.0010870991,0.0031888236,0.0015192595,0.005044507,0.002450853,0.0039672037,0.13723195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018526752,0.00004523204,0.0005743637,0.0013744922,0.000013457274,0.0002683993,0.00022705339,0.000013169691,0.0016092354,0.0013250933,0.8885827,0.10578165],"study_design_scores_gemma":[0.00007943928,0.00014194685,0.002889529,0.0005370115,0.000016306887,0.0004504269,0.0002499264,0.0000518839,0.0012782455,0.00073916727,0.9935407,0.000025437947],"about_ca_topic_score_codex":0.002784858,"about_ca_topic_score_gemma":0.0053341202,"teacher_disagreement_score":0.97269785,"about_ca_system_score_codex":0.002071223,"about_ca_system_score_gemma":0.008807,"threshold_uncertainty_score":0.48741955},"labels":[],"label_agreement":null},{"id":"W2107091005","doi":"10.12927/hcpap..16872","title":"To Build a Wooden Horse … Integrating Drugs into the Public Health System","year":2004,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Mental Health Commission of Canada","funders":"","keywords":"Horse; Public health; Business; Engineering; Medicine; Biology; Nursing","score_opus":0.08394013748423351,"score_gpt":0.31707520575465736,"score_spread":0.23313506827042385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107091005","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034437145,0.0009887837,0.00013298048,0.9896041,0.0013369581,0.000007523338,0.00001451145,0.000012656206,0.007558217],"genre_scores_gemma":[0.010398854,0.0006400154,0.00031048793,0.97239447,0.0022392578,0.000016299851,0.0000100179805,0.000014530247,0.013976042],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9875502,0.0031922937,0.0003255248,0.0009964062,0.0047529144,0.0031826757],"domain_scores_gemma":[0.986953,0.0057239244,0.00055126083,0.00070110994,0.0026006675,0.0034700888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009027891,0.00077149173,0.0009038028,0.0013005876,0.017510952,0.01657233,0.0029124264,0.0739531,0.010324493],"category_scores_gemma":[0.035362687,0.0008815439,0.0012006857,0.0013218278,0.02874518,0.014365758,0.0048483326,0.045731597,0.0027752751],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031438416,0.000031269832,0.00047072663,0.000043164717,0.000011462812,0.0002473585,0.00079292146,0.00017750743,0.00013193862,0.1256636,0.86280686,0.009591693],"study_design_scores_gemma":[0.000107971005,0.00003342279,0.0014096686,0.00022754393,0.000013705991,0.00013533483,0.0017807294,0.00045776635,0.00012555544,0.0535301,0.94210476,0.000073429066],"about_ca_topic_score_codex":0.64117837,"about_ca_topic_score_gemma":0.7075114,"teacher_disagreement_score":0.64117837,"about_ca_system_score_codex":0.05839999,"about_ca_system_score_gemma":0.07154295,"threshold_uncertainty_score":0.7218696},"labels":[],"label_agreement":null},{"id":"W2107227483","doi":"10.1287/mksc.1120.0743","title":"Offering Pharmaceutical Samples: The Role of Physician Learning and Patient Payment Ability","year":2012,"lang":"en","type":"article","venue":"Marketing Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"Social Sciences and Humanities Research Council of Canada","keywords":"Subsidy; Payment; Sample (material); Prescription drug; Business; Sampling (signal processing); Investment (military); Product (mathematics); Marketing; Actuarial science; Medical prescription; Medicare Part D; Reimbursement; Microeconomics; Industrial organization; Economics; Medicine; Health care; Computer science; Finance; Pharmacology","score_opus":0.0378308833169652,"score_gpt":0.28986280227076816,"score_spread":0.25203191895380295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107227483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95706767,0.0019655295,0.009131697,0.013570746,0.00003213273,0.00008987996,0.00017895932,0.000058127516,0.01790522],"genre_scores_gemma":[0.99837625,0.00017001941,0.0005672499,0.00021181547,0.000029051738,0.00000568444,0.000013351843,0.0000031441205,0.00062346814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931049,0.0049066604,0.00019236127,0.00043683377,0.00043582366,0.0009235075],"domain_scores_gemma":[0.7846769,0.18388431,0.020485707,0.0027910422,0.0013438654,0.0068181246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072523993,0.0003597099,0.00070218544,0.0006420017,0.0007935465,0.003701757,0.0009719862,0.0023782696,0.0121291885],"category_scores_gemma":[0.06596157,0.00031879457,0.00061982597,0.00062354037,0.0026719193,0.0025894616,0.0017793662,0.002028526,0.0005182262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020611838,0.0022508472,0.77390265,0.00019611942,0.0004216917,0.00092404097,0.0015117843,0.033767376,0.0013656544,0.051597007,0.0021584034,0.12984315],"study_design_scores_gemma":[0.00065953913,0.0019864042,0.72063285,0.00026145464,0.0006037427,0.0012192868,0.0034474907,0.107732944,0.0024186193,0.15420574,0.0066599627,0.0001719497],"about_ca_topic_score_codex":0.004735481,"about_ca_topic_score_gemma":0.0045029707,"teacher_disagreement_score":0.0121291885,"about_ca_system_score_codex":0.0021021962,"about_ca_system_score_gemma":0.0020396924,"threshold_uncertainty_score":0.04057616},"labels":[],"label_agreement":null},{"id":"W2107229542","doi":"10.1093/jlb/lsv013","title":"Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; University of Toronto","funders":"University of Toronto; Government of Canada; Genome Canada; Ontario Genomics; University of Saskatchewan; Ontario Genomics Institute","keywords":"Pharmacogenomics; Orphan drug; Incentive; Context (archaeology); Legislation; Medicine; Biotechnology; Business; Political science; Pharmacology; Bioinformatics; Biology; Economics; Law","score_opus":0.058914420877443766,"score_gpt":0.30186397327622577,"score_spread":0.24294955239878202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107229542","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10717631,0.010796228,0.0016305177,0.7770632,0.00090219534,0.00018820401,0.00083050434,0.00007907217,0.10133373],"genre_scores_gemma":[0.7619926,0.012240041,0.0033486304,0.19460052,0.0006186949,0.00011709367,0.0003209289,0.000062693354,0.026698867],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97310567,0.0040101116,0.00088716875,0.0013282635,0.011467582,0.009201162],"domain_scores_gemma":[0.94290274,0.026554637,0.0030633907,0.00090024015,0.017476512,0.009102489],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017712224,0.00037250074,0.0009008049,0.0027060607,0.014355398,0.014973914,0.0034698974,0.012349754,0.0052250656],"category_scores_gemma":[0.06039501,0.00065021357,0.0010910217,0.0047203694,0.009290958,0.0040769377,0.004384721,0.009194984,0.00019171645],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00021766374,0.0001202629,0.016111217,0.00031721167,0.00008703657,0.0010548353,0.0050779725,0.004661316,0.00076512713,0.8501106,0.0870083,0.03446844],"study_design_scores_gemma":[0.00044790286,0.00019096349,0.08714776,0.0015473374,0.00031050574,0.00044715768,0.020894652,0.013760107,0.0017614464,0.11684191,0.756054,0.00059636205],"about_ca_topic_score_codex":0.9895886,"about_ca_topic_score_gemma":0.99214137,"teacher_disagreement_score":0.98228776,"about_ca_system_score_codex":0.2637472,"about_ca_system_score_gemma":0.42388448,"threshold_uncertainty_score":0.8539489},"labels":[],"label_agreement":null},{"id":"W2107260549","doi":"10.1503/cmaj.051687","title":"Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices","year":2006,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Competition (biology); Brand names; Drug industry; Drug prices; Business; Market competition; Marketing; Pharmaceutical industry; Industrial organization; Commerce; Advertising; Computer science; Medicine; Economics; Pharmacology; Public economics; Biotechnology; Market economy","score_opus":0.01142841339657643,"score_gpt":0.2441961481669817,"score_spread":0.23276773477040527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107260549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7038234,0.014847933,0.016648084,0.022489242,0.00021369939,0.0003874485,0.0018019645,0.00021743843,0.23957081],"genre_scores_gemma":[0.9873602,0.0020200321,0.0010194383,0.0012218755,0.00035858108,0.000039186918,0.00044852763,0.00003177148,0.0075003575],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9965707,0.00065710425,0.0001175706,0.00034731688,0.0014096239,0.00089772645],"domain_scores_gemma":[0.9706763,0.019147806,0.0057983445,0.00067097927,0.002297276,0.0014093518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030607386,0.00043774612,0.0010128311,0.0018979594,0.0015520552,0.0066913017,0.0016950794,0.002672448,0.020412814],"category_scores_gemma":[0.021819707,0.00071180565,0.0013182516,0.0029678433,0.0021633643,0.0059527704,0.0015588403,0.0034809937,0.0016125806],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016495709,0.0012749931,0.17943084,0.0008200768,0.00035889237,0.0021842087,0.0033254598,0.014424586,0.0020042288,0.6367793,0.05342745,0.10432035],"study_design_scores_gemma":[0.0007780388,0.00172829,0.51350963,0.0005567901,0.0008811177,0.0015217804,0.008359254,0.091139294,0.0025289583,0.2900906,0.08857265,0.0003337233],"about_ca_topic_score_codex":0.014247437,"about_ca_topic_score_gemma":0.011442133,"teacher_disagreement_score":0.020412814,"about_ca_system_score_codex":0.0051297997,"about_ca_system_score_gemma":0.0023948958,"threshold_uncertainty_score":0.06828761},"labels":[],"label_agreement":null},{"id":"W2110275302","doi":"10.1017/s0963180107070107","title":"Montréal Statement on the Human Right to Essential Medicines","year":2006,"lang":"en","type":"article","venue":"Cambridge Quarterly of Healthcare Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Statement (logic); Medicine; Business; Political science; Law","score_opus":0.06832354498650149,"score_gpt":0.34676617438847385,"score_spread":0.27844262940197234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110275302","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014650289,0.0150617,0.0034195124,0.74932164,0.0133022275,0.00023562655,0.005063181,0.00014969452,0.21198133],"genre_scores_gemma":[0.065317236,0.01055001,0.011499602,0.6236266,0.009097402,0.000598865,0.0021769141,0.00022479615,0.2769087],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9827617,0.0038212885,0.0009970271,0.0011539571,0.008997143,0.0022689505],"domain_scores_gemma":[0.9880415,0.004087625,0.00092826615,0.000712854,0.004654145,0.0015756027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015359954,0.0011678087,0.0008675519,0.0014079141,0.005244518,0.005715649,0.0033566838,0.017442878,0.016267048],"category_scores_gemma":[0.031226913,0.00079233554,0.0011065744,0.001653125,0.0055230856,0.0030093458,0.0030337912,0.015322712,0.0041826074],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000307323,0.000011486625,0.00017495622,0.00006298249,0.000008571457,0.000093631774,0.00022739347,0.00016795621,0.00022076226,0.19130717,0.8029477,0.0047466345],"study_design_scores_gemma":[0.000019187648,0.00001075045,0.0011003156,0.0001709622,0.000007747721,0.000037479273,0.00006833856,0.00010811147,0.00018146196,0.011884688,0.9863689,0.00004209602],"about_ca_topic_score_codex":0.47535378,"about_ca_topic_score_gemma":0.44512987,"teacher_disagreement_score":0.47535378,"about_ca_system_score_codex":0.017084636,"about_ca_system_score_gemma":0.05025188,"threshold_uncertainty_score":0.9451738},"labels":[],"label_agreement":null},{"id":"W2110388478","doi":"10.3386/w9598","title":"Intellectual Property &amp; External Consumption Effects: Generalizations from Pharmaceutical Markets","year":2003,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Toronto","funders":"","keywords":"Consumption (sociology); Intellectual property; Property (philosophy); Business; Industrial organization; Microeconomics; Economics; Commerce; Monetary economics; Computer science","score_opus":0.5935807885117556,"score_gpt":0.537475263079884,"score_spread":0.05610552543187153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110388478","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07592086,0.015597551,0.2503668,0.02050039,0.00074091525,0.00038429195,0.0010790498,0.0003693892,0.63504076],"genre_scores_gemma":[0.8944852,0.012411361,0.025126224,0.0045537865,0.0019331401,0.00045849607,0.00036186693,0.00025544863,0.060414504],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9983157,0.0005711553,0.000076734264,0.0003062739,0.00047383775,0.00025629488],"domain_scores_gemma":[0.9937179,0.003798276,0.0009927435,0.0007197074,0.0005039565,0.00026745818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032751362,0.0011361712,0.0012853171,0.0022705388,0.0014596817,0.0040235347,0.0018107815,0.0033464548,0.024816731],"category_scores_gemma":[0.009118302,0.0005515545,0.0032488483,0.0021449937,0.005620492,0.006369667,0.004546906,0.004222259,0.0014117783],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003398777,0.000088069326,0.00049313036,0.00016287065,0.000030229005,0.00027866394,0.00013184988,0.010927322,0.0003790462,0.97281986,0.0032546634,0.011400422],"study_design_scores_gemma":[0.00003674063,0.000035198354,0.0004728894,0.00007697198,0.000020067891,0.00012345673,0.000049331407,0.012928583,0.00027454665,0.97353137,0.012431554,0.00001930886],"about_ca_topic_score_codex":0.0029378473,"about_ca_topic_score_gemma":0.0018470602,"teacher_disagreement_score":0.024816731,"about_ca_system_score_codex":0.0029680931,"about_ca_system_score_gemma":0.0014347825,"threshold_uncertainty_score":0.08302021},"labels":[],"label_agreement":null},{"id":"W2110607907","doi":"10.18553/jmcp.2005.11.9.746","title":"Product-Line Extensions and Pricing Strategies of Brand-Name Drugs Facing Patent Expiration","year":2005,"lang":"en","type":"article","venue":"Journal of Managed Care Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Generic drug; Prescription drug; Medicine; Marketing; Medical prescription; Brand extension; Brand loyalty; Product (mathematics); Advertising; Market share; Brand names; Panel data; Expiration date; Drug; Business; Brand management; Economics; Pharmacology","score_opus":0.09298290153023488,"score_gpt":0.3140020313484577,"score_spread":0.22101912981822286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110607907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99889094,0.00017067352,0.0002500576,0.000054681168,0.0000010330422,0.000009675816,0.000014256899,0.0000024211279,0.000606211],"genre_scores_gemma":[0.9994629,0.00006986916,0.00019739845,0.000015135345,0.0000061924525,0.0000025587851,0.000024905155,8.429276e-7,0.00022019059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995901,0.00014073521,0.000033620483,0.00006270755,0.00008883773,0.00008398371],"domain_scores_gemma":[0.99540114,0.0015479678,0.002275856,0.00019423987,0.0002484143,0.00033246737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012842952,0.00018508134,0.0002262216,0.0006467695,0.0002276653,0.0010796578,0.0004043936,0.00046446334,0.0030080702],"category_scores_gemma":[0.0073085595,0.00015603397,0.00032758334,0.00042246497,0.00048128,0.0013698041,0.00053653406,0.0005733225,0.000250552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009472402,0.00089539285,0.9352583,0.00008346886,0.00009119981,0.0011153343,0.0012583503,0.0012881323,0.007017578,0.0022882384,0.00017851155,0.049578182],"study_design_scores_gemma":[0.000051176776,0.00086937856,0.9856553,0.00002247107,0.000056582412,0.0013920187,0.0006981963,0.0073139896,0.0015326241,0.0014524347,0.0009359402,0.000019940033],"about_ca_topic_score_codex":0.0009496767,"about_ca_topic_score_gemma":0.0007416925,"teacher_disagreement_score":0.0030080702,"about_ca_system_score_codex":0.0004199991,"about_ca_system_score_gemma":0.00032159255,"threshold_uncertainty_score":0.010062993},"labels":[],"label_agreement":null},{"id":"W2111161004","doi":"10.1177/1745790413516971","title":"Use of generic medicines: Perspectives of consumers living in urban and suburban areas of Klang Valley in Malaysia","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Marketing Device Diagnostic and Pharmaceutical Marketing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Perception; Medicine; Guideline; Medical prescription; Willingness to pay; Quarter (Canadian coin); Health care; Business; Marketing; Family medicine; Nursing; Economic growth; Geography; Psychology; Economics","score_opus":0.04710268892922692,"score_gpt":0.2984243311579019,"score_spread":0.251321642228675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111161004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994313,0.0000799882,0.000009674515,0.0001741271,0.000002059969,0.000003914775,0.000031400275,4.5471052e-7,0.00026705],"genre_scores_gemma":[0.99933845,0.00017706642,0.000024705345,0.00015420267,0.0000030533586,0.000005392318,0.000025226609,4.77209e-7,0.00027141912],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99958354,0.0001605612,0.000027120788,0.000033339104,0.000060782713,0.00013465162],"domain_scores_gemma":[0.9992111,0.00015555703,0.00029614082,0.000012982888,0.000082027305,0.00024220151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000552908,0.00021033004,0.0002592556,0.00041297683,0.001245575,0.0011256139,0.00024149191,0.00045942742,0.0035103788],"category_scores_gemma":[0.0008358549,0.00025685504,0.00036557764,0.00045701393,0.00064174563,0.0008684492,0.00086810754,0.0006474692,0.00026396866],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010981433,0.000294692,0.902504,0.00014888203,0.000042693635,0.0011544636,0.08386898,0.00004827043,0.00071180495,0.000110326386,0.0007037776,0.010302216],"study_design_scores_gemma":[0.000008107371,0.00036789448,0.692659,0.000086126536,0.000023741537,0.0008920449,0.3039943,0.00015521179,0.00013111942,0.000052299292,0.0016060806,0.000024020248],"about_ca_topic_score_codex":0.025586883,"about_ca_topic_score_gemma":0.0381609,"teacher_disagreement_score":0.025586883,"about_ca_system_score_codex":0.00077923015,"about_ca_system_score_gemma":0.0006838943,"threshold_uncertainty_score":0.050875902},"labels":[],"label_agreement":null},{"id":"W2111436115","doi":"10.1111/j.1468-2354.2010.00615.x","title":"A DYNAMIC OLIGOPOLY STRUCTURAL MODEL FOR THE PRESCRIPTION DRUG MARKET AFTER PATENT EXPIRATION*","year":2010,"lang":"en","type":"article","venue":"International Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Oligopoly; Expiration date; Welfare; Nested logit; Microeconomics; Expiration; Economics; Prescription drug; Consumer welfare; Medical prescription; Market structure; Business; Industrial organization; Econometrics; Medicine; Market economy; Pharmacology","score_opus":0.06074069930950473,"score_gpt":0.3125100873626672,"score_spread":0.2517693880531625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111436115","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11278182,0.002458135,0.7597147,0.01085752,0.00049717765,0.00073549245,0.0055351015,0.00072101713,0.106699124],"genre_scores_gemma":[0.84149677,0.003048696,0.050541453,0.0009463629,0.00034125237,0.0008658236,0.0014047392,0.00013252444,0.101222254],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99832875,0.0006023765,0.00005633471,0.00038994383,0.00020086596,0.00042175732],"domain_scores_gemma":[0.99705625,0.0016237826,0.0005636868,0.00013643823,0.0002517014,0.00036808194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022090161,0.0014256204,0.0032020053,0.0012382906,0.0015191371,0.0041054934,0.0034483578,0.0047374843,0.02637274],"category_scores_gemma":[0.004255108,0.0012868065,0.0019000833,0.0021287207,0.0027632534,0.0039476934,0.0019156638,0.0038657684,0.0032471332],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018416831,0.00018027886,0.0010008222,0.00014998275,0.00008249676,0.00046169572,0.00014374634,0.5263786,0.00086730986,0.4586501,0.0051273084,0.00677351],"study_design_scores_gemma":[0.0003192518,0.00016437915,0.00066492206,0.00003674124,0.00006369961,0.00012828919,0.00009927157,0.8249313,0.00011926433,0.16630557,0.0070952354,0.00007209045],"about_ca_topic_score_codex":0.024556024,"about_ca_topic_score_gemma":0.023179812,"teacher_disagreement_score":0.02637274,"about_ca_system_score_codex":0.0049842154,"about_ca_system_score_gemma":0.003927098,"threshold_uncertainty_score":0.0882256},"labels":[],"label_agreement":null},{"id":"W2111850269","doi":"10.1377/hlthaff.25.4.1185-a","title":"Drugs Down Under: The Authors Respond","year":2006,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Download; Public health; Foundation (evidence); Political science; Library science; Internet privacy; Medicine; Computer science; World Wide Web; Law; Nursing","score_opus":0.044547687794190514,"score_gpt":0.30449440926837334,"score_spread":0.25994672147418285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111850269","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005677894,0.002461549,0.0001879018,0.87462753,0.10577803,0.000052517367,0.00022913194,0.00008028144,0.01601523],"genre_scores_gemma":[0.003462246,0.0025354102,0.00020670642,0.83158684,0.089214385,0.00007373129,0.00010832352,0.000070431954,0.072741985],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994947,0.00087818276,0.0007057972,0.00056845765,0.0017872566,0.0011131946],"domain_scores_gemma":[0.9808771,0.0079047335,0.00196501,0.0008208177,0.004532848,0.0038994772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00513301,0.0012661748,0.0027092579,0.0013920267,0.0035766608,0.0089146225,0.0022611464,0.07176774,0.059756216],"category_scores_gemma":[0.032515187,0.0011741264,0.0023212899,0.0012297895,0.002523285,0.0046575717,0.0035362341,0.03503332,0.03114097],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050382885,0.000029572086,0.00042927617,0.000052914733,0.000015737372,0.0003307865,0.00004118921,0.000039059436,0.00010598132,0.0018388538,0.9915509,0.005515365],"study_design_scores_gemma":[0.000056016244,0.00004170355,0.00087451964,0.000119274286,0.000035140223,0.0002577947,0.00029129395,0.00013650212,0.00016302799,0.0025547256,0.9954201,0.00004988963],"about_ca_topic_score_codex":0.0028003466,"about_ca_topic_score_gemma":0.005413559,"teacher_disagreement_score":0.07176774,"about_ca_system_score_codex":0.0023566901,"about_ca_system_score_gemma":0.0058620977,"threshold_uncertainty_score":0.19990444},"labels":[],"label_agreement":null},{"id":"W2112595571","doi":"10.3821/145.5.cpj197a","title":"Canada falls short on safeguarding its drug supply","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Pharmacists Association","funders":"","keywords":"Government (linguistics); Safeguarding; Legislature; Medicine; Legislation; Business; Parliament; Intensive care medicine; Political science; Law; Nursing","score_opus":0.06841401077393293,"score_gpt":0.2652409268873919,"score_spread":0.19682691611345898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112595571","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005901342,0.022690097,0.0024400353,0.8266753,0.01662146,0.0001890058,0.0049325596,0.001648262,0.1189019],"genre_scores_gemma":[0.09163244,0.03714049,0.015981572,0.5572423,0.0049368823,0.0001454988,0.00533299,0.00087939185,0.28670856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.990759,0.00047866104,0.00028176597,0.0005675828,0.0060571725,0.0018557827],"domain_scores_gemma":[0.9575088,0.0021506492,0.0008892706,0.0012002584,0.018225336,0.020025628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004825937,0.0010853616,0.0012377299,0.0020173045,0.014747176,0.0122568,0.003748117,0.00916304,0.046424307],"category_scores_gemma":[0.0167671,0.0006986088,0.0012224552,0.0035205518,0.0051541068,0.004599663,0.0037980352,0.008746992,0.008189935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007627963,0.000050053088,0.0020589917,0.00031700934,0.000033479937,0.0001994335,0.00022198778,0.0002287173,0.00038844763,0.015932018,0.9248924,0.05560106],"study_design_scores_gemma":[0.000037028243,0.00003590095,0.0040151486,0.00036077175,0.000015851463,0.000061412225,0.00028388033,0.00024690098,0.00015013396,0.0025549256,0.9921983,0.000039899816],"about_ca_topic_score_codex":0.9749699,"about_ca_topic_score_gemma":0.9834057,"teacher_disagreement_score":0.92691696,"about_ca_system_score_codex":0.07308305,"about_ca_system_score_gemma":0.47390497,"threshold_uncertainty_score":0.5302571},"labels":[],"label_agreement":null},{"id":"W2113321591","doi":"10.1177/171516350513800105","title":"Drug Shortages — Risk or Reality?","year":2005,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Pharmacy; Medicine; Drug; Business; Environmental health; Family medicine; Pharmacology","score_opus":0.07657052916478492,"score_gpt":0.2888910542361798,"score_spread":0.21232052507139487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113321591","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14085154,0.030167606,0.0008570949,0.8023597,0.0006645511,0.000027121103,0.0007124287,0.000042237367,0.02431763],"genre_scores_gemma":[0.9521468,0.025130766,0.00034926596,0.01964774,0.0012284868,0.000009346806,0.00021369859,0.000007101153,0.0012667098],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826175,0.00040310764,0.00011201515,0.00018538034,0.00055282103,0.00048504316],"domain_scores_gemma":[0.9829578,0.0044124685,0.006194076,0.0002259073,0.0029658345,0.0032438221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002988035,0.00018922602,0.00038457644,0.0014468156,0.0018970411,0.0030162625,0.0005582729,0.0017807235,0.00562379],"category_scores_gemma":[0.023579214,0.00020532265,0.00014550403,0.002695557,0.004417571,0.004109248,0.0016014826,0.0018464056,0.00028641245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002766975,0.00023954899,0.5814761,0.0019428254,0.00012012918,0.0036682938,0.011427072,0.0012467594,0.00024804164,0.060927715,0.1547909,0.18363585],"study_design_scores_gemma":[0.00007987584,0.0002802319,0.5402898,0.0059817717,0.00014319713,0.007649,0.12740907,0.0029120983,0.00027974808,0.10297794,0.21177566,0.00022163583],"about_ca_topic_score_codex":0.26092598,"about_ca_topic_score_gemma":0.27839667,"teacher_disagreement_score":0.739074,"about_ca_system_score_codex":0.009563224,"about_ca_system_score_gemma":0.012817467,"threshold_uncertainty_score":0.51881444},"labels":[],"label_agreement":null},{"id":"W2113782760","doi":"10.1016/j.jval.2014.03.852","title":"Impact Of The Pan-Canadian Pricing Alliance (Pcpa) On Access To Drug Treatment Options For Canadian Patients","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Université de Montréal","funders":"","keywords":"Medicine; Formulary; Listing (finance); Drug; Pharmacotherapy; Medical prescription; Emergency medicine; Internal medicine; Intensive care medicine; Family medicine; Pharmacology; Business; Finance","score_opus":0.13799005764256228,"score_gpt":0.3637228376764445,"score_spread":0.2257327800338822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113782760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3924489,0.016201463,0.0012734863,0.35617396,0.0025300577,0.00026217918,0.017474534,0.00024185162,0.21339352],"genre_scores_gemma":[0.9676898,0.0024474657,0.0011435406,0.01784921,0.0005834357,0.000039060065,0.0017911438,0.00005024647,0.008406038],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9916127,0.0011614803,0.00024171479,0.00036500735,0.003935373,0.0026836589],"domain_scores_gemma":[0.9559993,0.0088677285,0.0029988699,0.00065046205,0.012653057,0.01883062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072168224,0.00041669465,0.0006075945,0.0019830556,0.0039085713,0.006363251,0.0021541896,0.0035099739,0.013201238],"category_scores_gemma":[0.04870072,0.00045055366,0.0017515495,0.0027440481,0.0021974014,0.0018245277,0.002832601,0.0044340324,0.000379104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003430633,0.00084971316,0.20000583,0.000683552,0.00062284555,0.00067299017,0.0011643358,0.016925884,0.0005740429,0.26038274,0.39965752,0.11502999],"study_design_scores_gemma":[0.0013682994,0.0005437339,0.6776944,0.0012473237,0.0008149978,0.00080862886,0.0035722915,0.023562968,0.0008433555,0.020006616,0.2690975,0.00044000172],"about_ca_topic_score_codex":0.9833445,"about_ca_topic_score_gemma":0.98893446,"teacher_disagreement_score":0.89619106,"about_ca_system_score_codex":0.10380894,"about_ca_system_score_gemma":0.1672974,"threshold_uncertainty_score":0.7531901},"labels":[],"label_agreement":null},{"id":"W2115652323","doi":"10.1503/cmaj.070680","title":"Drug spending tops $25 billion","year":2007,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Health spending; Drug industry; Drug; Prescription drug; Environmental health; Business; Health services; Pharmacology; Biotechnology; Biology","score_opus":0.029667406675378975,"score_gpt":0.27027860883123067,"score_spread":0.2406112021558517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115652323","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046747662,0.04281607,0.0012625285,0.12137587,0.0067498484,0.00013238328,0.072135784,0.002710655,0.70606923],"genre_scores_gemma":[0.40119907,0.061856087,0.002644553,0.025750915,0.002904407,0.00007896894,0.06440682,0.00034871267,0.4408104],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891496,0.00002565303,0.000017924898,0.000046488152,0.00071920763,0.00027564142],"domain_scores_gemma":[0.9991516,0.000023929328,0.000033077882,0.000015329146,0.0004743145,0.00030172017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035483716,0.0005169417,0.00029867148,0.0017991199,0.0011912107,0.0023839388,0.0004451223,0.000816267,0.027553827],"category_scores_gemma":[0.001469618,0.000146925,0.00038202084,0.0023359659,0.0004286105,0.0007601861,0.00094965263,0.0008936291,0.010786766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094791925,0.00002293,0.006505883,0.00019350316,0.00003785222,0.00008830921,0.00004713059,0.00019460836,0.00075852673,0.006737555,0.85536253,0.12995629],"study_design_scores_gemma":[0.000014068759,0.000021643924,0.023153568,0.00013922044,0.000027132626,0.000060851715,0.00013046696,0.00021947613,0.0005275982,0.0007101698,0.97498465,0.000010989338],"about_ca_topic_score_codex":0.7085072,"about_ca_topic_score_gemma":0.76008207,"teacher_disagreement_score":0.29149282,"about_ca_system_score_codex":0.010795011,"about_ca_system_score_gemma":0.017988902,"threshold_uncertainty_score":0.5864189},"labels":[],"label_agreement":null},{"id":"W2115689023","doi":"10.4212/cjhp.v64i6.1084","title":"Perspective sur les ruptures d’approvisionnement de médicaments en établissement de santé de 2006 à 2010","year":2011,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Stock (firearms); Pharmacy; Medicine; Descriptive statistics; Business; Geography; Family medicine; Statistics; Mathematics","score_opus":0.05291684109774701,"score_gpt":0.29069162013084665,"score_spread":0.23777477903309963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115689023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8218794,0.041215003,0.0017234582,0.06919536,0.00055405917,0.0003579966,0.012154264,0.00008582382,0.052834623],"genre_scores_gemma":[0.96129256,0.015431258,0.0013338322,0.0070550805,0.00023923039,0.00023900416,0.0027526785,0.0000256709,0.011630674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913769,0.0013745466,0.0008138957,0.0007240672,0.0038344925,0.0018760199],"domain_scores_gemma":[0.9483476,0.008264569,0.020912236,0.0009828308,0.015995866,0.0054968903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00797093,0.00025267724,0.00030155847,0.0023474435,0.0022649362,0.0031794521,0.0016556303,0.0012112309,0.0067745466],"category_scores_gemma":[0.036572482,0.00042104177,0.000587978,0.0041727503,0.0014578584,0.0016203267,0.0017476245,0.002646971,0.00056616456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008411659,0.00023371524,0.6888387,0.0020913281,0.000280735,0.00072941737,0.034828577,0.0013607725,0.0017036924,0.009149161,0.03898454,0.2209581],"study_design_scores_gemma":[0.000020055897,0.0001657437,0.91256434,0.00094446243,0.00006215709,0.00017202253,0.010143437,0.00024924873,0.00048674614,0.00020528582,0.07495043,0.00003613785],"about_ca_topic_score_codex":0.8044579,"about_ca_topic_score_gemma":0.8429583,"teacher_disagreement_score":0.9499065,"about_ca_system_score_codex":0.050093498,"about_ca_system_score_gemma":0.059088767,"threshold_uncertainty_score":0.39338732},"labels":[],"label_agreement":null},{"id":"W2115986688","doi":"10.5539/ijef.v4n11p24","title":"Private Health Care and Drug Quality in Germany – A Game-Theoretical Approach","year":2012,"lang":"en","type":"article","venue":"International Journal of Economics and Finance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Statutory law; Business; Casualty insurance; Group insurance; Actuarial science; Health insurance; General insurance; Self-insurance; Quality (philosophy); German; Insurance policy; Public economics; Health care; Key person insurance; Insurance law; Economics; Income protection insurance; Economic growth; Law; Political science","score_opus":0.044308962508070815,"score_gpt":0.324868741184755,"score_spread":0.2805597786766842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115986688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48051456,0.0075351424,0.27418527,0.030260341,0.0002794866,0.00039980313,0.0015490331,0.00021092288,0.20506549],"genre_scores_gemma":[0.9878741,0.0010271181,0.004323092,0.00034857925,0.0000555793,0.00007741668,0.000054794913,0.0000073717556,0.0062318984],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9985152,0.00071231293,0.000037579535,0.00015666685,0.00015503047,0.00042321678],"domain_scores_gemma":[0.9976451,0.0016081008,0.00029413748,0.00007089071,0.00012780484,0.00025394058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018735656,0.0006913399,0.0011627227,0.0011756211,0.00089860475,0.004011059,0.0010228704,0.003253869,0.006896983],"category_scores_gemma":[0.0037371614,0.0004858241,0.0009862789,0.000906529,0.0024582434,0.0033767025,0.0016549707,0.0014704367,0.00029164908],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012221995,0.000103274266,0.0017880119,0.0001170082,0.00007593247,0.00028276967,0.00014760406,0.17655706,0.00039764564,0.8115156,0.0025678084,0.0063249883],"study_design_scores_gemma":[0.0002356241,0.00016516901,0.003446304,0.00012553706,0.000121106044,0.00016948351,0.0003564972,0.51252353,0.0002669986,0.47514617,0.007363876,0.00007965935],"about_ca_topic_score_codex":0.022608554,"about_ca_topic_score_gemma":0.012190521,"teacher_disagreement_score":0.022608554,"about_ca_system_score_codex":0.009650326,"about_ca_system_score_gemma":0.0026136045,"threshold_uncertainty_score":0.07001829},"labels":[],"label_agreement":null},{"id":"W2116893689","doi":"10.4212/cjhp.v54i2.630","title":"Sept stratégies pour consolider notre système d’utilisation des médicaments","year":2001,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Gynecology; Medicine","score_opus":0.06667956537304386,"score_gpt":0.29474832488228175,"score_spread":0.22806875950923788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116893689","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10204495,0.010154093,0.13716798,0.60392016,0.0023234051,0.0007698461,0.00054516905,0.0009793278,0.14209509],"genre_scores_gemma":[0.70266044,0.008535642,0.19004926,0.016087621,0.0031990807,0.00067289843,0.0005621371,0.00022489524,0.078007974],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97314215,0.014618431,0.0020912425,0.0011516623,0.0069130757,0.002083316],"domain_scores_gemma":[0.9464825,0.023871547,0.0034745382,0.0037002815,0.017825281,0.0046459027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029206954,0.00079243374,0.0007330411,0.0025529794,0.0027363095,0.019296207,0.002181814,0.007043133,0.01307407],"category_scores_gemma":[0.06898064,0.0008153695,0.001367622,0.0026812484,0.0026817864,0.009688344,0.004184089,0.0069933273,0.0020764463],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067234295,0.0008379066,0.018719546,0.00044662514,0.00018011981,0.00065367285,0.0024167984,0.017642962,0.0024832617,0.5577544,0.05601141,0.342181],"study_design_scores_gemma":[0.00066104165,0.00091470586,0.024555452,0.0012600755,0.00017466284,0.0009766544,0.003895683,0.083690524,0.006670957,0.2080005,0.66892415,0.00027554238],"about_ca_topic_score_codex":0.047119852,"about_ca_topic_score_gemma":0.065069474,"teacher_disagreement_score":0.9836564,"about_ca_system_score_codex":0.016343623,"about_ca_system_score_gemma":0.03120335,"threshold_uncertainty_score":0.15446293},"labels":[],"label_agreement":null},{"id":"W2117061783","doi":"10.12927/hcpap..16876","title":"Recognize the Role of Employers","year":2004,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Health care; Public health; Equity (law); Population health; Public policy; Health policy; Health equity; Library science; Sociology; Political science; Management; Medicine; Nursing","score_opus":0.08843719614225959,"score_gpt":0.3039964429660322,"score_spread":0.2155592468237726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117061783","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021064513,0.0011097462,0.000033285443,0.9934633,0.0029452692,0.000003472421,0.000005691851,0.0000040209666,0.0022245282],"genre_scores_gemma":[0.003073379,0.00040134887,0.000080414124,0.9883471,0.0031164351,0.000011296532,0.0000029276016,0.000005284539,0.0049618734],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99055535,0.0028207852,0.0005896053,0.0015579504,0.0027117694,0.0017646105],"domain_scores_gemma":[0.98324615,0.010185587,0.0009466472,0.0006232514,0.0023918413,0.0026065556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009029137,0.00077318965,0.0014095985,0.00078617485,0.010072228,0.009150014,0.0031106656,0.09508397,0.0068980246],"category_scores_gemma":[0.03419164,0.0008394699,0.0009714475,0.00088689144,0.010530671,0.011321288,0.004099384,0.06727678,0.0033543601],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020727695,0.000027846289,0.00035298482,0.00004866911,0.0000069509515,0.0008071632,0.00066618464,0.000051044255,0.00013556084,0.023344161,0.96733356,0.0072051524],"study_design_scores_gemma":[0.000052417043,0.000037904476,0.0010518299,0.00039641978,0.000011410494,0.0008591444,0.002519042,0.00022351989,0.00012731737,0.022360118,0.97230285,0.000058055797],"about_ca_topic_score_codex":0.031360675,"about_ca_topic_score_gemma":0.05349055,"teacher_disagreement_score":0.09508397,"about_ca_system_score_codex":0.010120987,"about_ca_system_score_gemma":0.018008474,"threshold_uncertainty_score":0.07343328},"labels":[],"label_agreement":null},{"id":"W2117161914","doi":"","title":"International drug price comparisons: quality assessment.","year":2011,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Drug prices; Public economics; Business; Drug; Health care; Quality (philosophy); Order (exchange); Socioeconomic status; Balance (ability); Drug pricing; Actuarial science; Environmental health; Economics; Economic growth; Medicine; Finance; Pharmacology","score_opus":0.2676717146812108,"score_gpt":0.33966954075130457,"score_spread":0.07199782607009375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117161914","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009486245,0.9213635,0.020356078,0.006945996,0.002614952,0.013213922,0.020356927,0.00027024208,0.005392151],"genre_scores_gemma":[0.3535366,0.4023878,0.13611482,0.007546683,0.0032798422,0.066967994,0.028145453,0.00054224906,0.0014785833],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.44030824,0.23128983,0.22450268,0.01363432,0.08890951,0.0013554979],"domain_scores_gemma":[0.22419138,0.45961696,0.20722634,0.03204305,0.07454785,0.0023744411],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.39587677,0.0023768083,0.010893292,0.039398406,0.0015994916,0.011103893,0.0053848666,0.0026202668,0.008460538],"category_scores_gemma":[0.68222016,0.0018458668,0.012579026,0.04868878,0.004221391,0.008907893,0.0059855534,0.0029070033,0.00073426665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023408458,0.00015778949,0.025352119,0.66047126,0.039477877,0.00010230514,0.0016908705,0.00069432013,0.00029133004,0.004277523,0.014219973,0.2509237],"study_design_scores_gemma":[0.003916591,0.001741416,0.098015584,0.6549968,0.092680566,0.00096463383,0.002485198,0.0021318805,0.0018170683,0.012997092,0.12784235,0.00041078217],"about_ca_topic_score_codex":0.00573646,"about_ca_topic_score_gemma":0.005500897,"teacher_disagreement_score":0.39587677,"about_ca_system_score_codex":0.011602004,"about_ca_system_score_gemma":0.02085107,"threshold_uncertainty_score":0.74499154},"labels":[],"label_agreement":null},{"id":"W2117404492","doi":"10.4212/cjhp.v65i2.1123","title":"Drug Shortages in Health Care Institutions: Perspectives in Early 2012","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"AstraZeneca","keywords":"Economic shortage; Health care; Business; Medicine; Political science; Law; Government (linguistics)","score_opus":0.07052146778960224,"score_gpt":0.32873195397487165,"score_spread":0.2582104861852694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117404492","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048207533,0.059519414,0.00024879427,0.86011034,0.0021778385,0.000024460267,0.0011772283,0.000017363032,0.028517082],"genre_scores_gemma":[0.5689212,0.112554446,0.0005370605,0.2907419,0.012337758,0.00008721165,0.00095363625,0.000044499742,0.01382241],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99581426,0.0013112493,0.00026731836,0.00017102649,0.0006138942,0.0018223055],"domain_scores_gemma":[0.98430854,0.0042021032,0.0024212715,0.00014096312,0.003846884,0.0050802967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062217787,0.00035938338,0.0005322532,0.002024683,0.005057193,0.010550792,0.0009178804,0.009339557,0.009632274],"category_scores_gemma":[0.013243245,0.0003963016,0.000550178,0.0038922466,0.0028264136,0.009271158,0.0041290377,0.00934085,0.0005818232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011580668,0.0012472585,0.07506859,0.0035597908,0.00007834284,0.0048556877,0.028491365,0.00095471524,0.00051294087,0.1936757,0.50677264,0.18362495],"study_design_scores_gemma":[0.00010100917,0.0004375241,0.18757032,0.0061491695,0.00004280907,0.0016313874,0.08506696,0.000733632,0.00042414642,0.013525055,0.70413774,0.00018027761],"about_ca_topic_score_codex":0.1722322,"about_ca_topic_score_gemma":0.3045853,"teacher_disagreement_score":0.97716147,"about_ca_system_score_codex":0.022838524,"about_ca_system_score_gemma":0.015174241,"threshold_uncertainty_score":0.34245944},"labels":[],"label_agreement":null},{"id":"W2117505050","doi":"","title":"Perspective canadienne du contrôle des prix des médicaments","year":2000,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.04585698487684167,"score_gpt":0.26889104693639404,"score_spread":0.22303406205955237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117505050","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027781352,0.19347303,0.005801415,0.33171645,0.0040549445,0.00026197097,0.0008209798,0.00016618051,0.43592358],"genre_scores_gemma":[0.5199526,0.15854906,0.0074879588,0.0895901,0.0030067614,0.00031642395,0.0005454078,0.000072842326,0.2204788],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99011993,0.0017218693,0.0002165555,0.0010710848,0.0052228267,0.0016477149],"domain_scores_gemma":[0.9887179,0.0024606895,0.0010197184,0.0003110505,0.0064247358,0.0010657642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006150788,0.0009174503,0.0006146433,0.0029771463,0.0024041964,0.008701774,0.001673111,0.0051697344,0.01814098],"category_scores_gemma":[0.007410039,0.0003881344,0.00072709116,0.0024455448,0.00432059,0.0023280769,0.0020954919,0.004350591,0.0014906703],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009747075,0.0007706418,0.014254271,0.0040738443,0.00027990458,0.0017419993,0.0045350576,0.0039444705,0.016082445,0.45142424,0.15069176,0.35122663],"study_design_scores_gemma":[0.00006112504,0.00048037778,0.012136318,0.0012511689,0.00011393619,0.0003289143,0.0017660798,0.00044194548,0.00371312,0.013825898,0.965813,0.0000682579],"about_ca_topic_score_codex":0.44570127,"about_ca_topic_score_gemma":0.45560616,"teacher_disagreement_score":0.9680778,"about_ca_system_score_codex":0.031922232,"about_ca_system_score_gemma":0.059147846,"threshold_uncertainty_score":0.886214},"labels":[],"label_agreement":null},{"id":"W2118900911","doi":"10.3821/1913-701x-142.3.126","title":"The Future of Canadian Pharmacy","year":2009,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medicine; Family medicine","score_opus":0.051226179959604545,"score_gpt":0.2707043559813752,"score_spread":0.21947817602177067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118900911","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034199157,0.053965226,0.00040077235,0.80438316,0.0044684685,0.000021810903,0.0006770061,0.000078131685,0.13258551],"genre_scores_gemma":[0.3825276,0.16816501,0.0040771565,0.2094132,0.008294681,0.00007979655,0.0010405626,0.00016651233,0.22623542],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99012965,0.0013005123,0.00020361893,0.000703105,0.0046795905,0.002983479],"domain_scores_gemma":[0.9744323,0.0017151085,0.00065549737,0.00054559443,0.01097322,0.0116783185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064453445,0.0006713233,0.0008018123,0.003400684,0.011660873,0.01794298,0.0021075385,0.009084591,0.0433938],"category_scores_gemma":[0.01829585,0.000453539,0.00080663495,0.0054488485,0.008154744,0.00521158,0.0036350938,0.0068002045,0.002776335],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006688191,0.00003943392,0.0020688793,0.00028817786,0.000031979085,0.00015707173,0.0006643606,0.00049296656,0.000096227595,0.37190124,0.5554884,0.068704434],"study_design_scores_gemma":[0.000020794869,0.000010599821,0.0053760507,0.00037917795,0.00001301955,0.000051989973,0.0008117618,0.00031802495,0.000032519445,0.021046888,0.97190213,0.0000370363],"about_ca_topic_score_codex":0.9740006,"about_ca_topic_score_gemma":0.98075783,"teacher_disagreement_score":0.8239459,"about_ca_system_score_codex":0.17605413,"about_ca_system_score_gemma":0.34778398,"threshold_uncertainty_score":0.9556604},"labels":[],"label_agreement":null},{"id":"W2119190560","doi":"10.1177/0306312714536270","title":"The shipwreck of the singular","year":2014,"lang":"en","type":"letter","venue":"Social Studies of Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Reactionary; Epistemology; Sociology; Law and economics; Philosophy; Law; Political science; Politics","score_opus":0.15997032251670426,"score_gpt":0.3446144239884833,"score_spread":0.18464410147177904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119190560","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013848832,0.005545196,0.000839747,0.93167067,0.009056019,0.000011892411,0.000022885104,0.00004035597,0.051428445],"genre_scores_gemma":[0.04178789,0.0045913975,0.00074036507,0.8732487,0.015476915,0.000042819654,0.00002727918,0.000104889004,0.06397969],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952852,0.0013975296,0.0001961954,0.0009795495,0.0016197456,0.00052166515],"domain_scores_gemma":[0.9920473,0.005007984,0.0003920821,0.0007958899,0.0008262232,0.000930585],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.005444568,0.00045215053,0.00087638997,0.00053351687,0.010656708,0.007008271,0.0014041882,0.02236487,0.009285771],"category_scores_gemma":[0.024773672,0.00044963337,0.0007243317,0.00043941592,0.021450559,0.009332875,0.0046486678,0.045021478,0.0045849564],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004266167,0.000022210077,0.00031613113,0.000050556766,0.000012501404,0.0015553472,0.0020641724,0.000054384418,0.00020371174,0.36041236,0.6159996,0.01926641],"study_design_scores_gemma":[0.0000137100105,0.000014996451,0.00018736799,0.0001358901,0.000003610135,0.00084690575,0.0010867529,0.00009738385,0.00009156457,0.072962694,0.9245469,0.000012318252],"about_ca_topic_score_codex":0.006935662,"about_ca_topic_score_gemma":0.011727472,"teacher_disagreement_score":0.9893433,"about_ca_system_score_codex":0.0056342417,"about_ca_system_score_gemma":0.0054320856,"threshold_uncertainty_score":0.040879548},"labels":[{"model":"gemma","categories":["sts"],"domain":null,"study_design":"theoretical_or_conceptual","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2119369919","doi":"10.1371/journal.pmed.1001054","title":"Global Pharmacovigilance for Antiretroviral Drugs: Overcoming Contrasting Priorities","year":2011,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Ministério da Saúde; Centers for Disease Control and Prevention; U.S. President’s Emergency Plan for AIDS Relief; amfAR, The Foundation for AIDS Research; Kaiser Permanente; European Commission; World Health Organization; National Institutes of Health; United States Agency for International Development; Global Fund to Fight AIDS, Tuberculosis and Malaria; University of Washington; York University; Bristol-Myers Squibb; Pfizer; Bill and Melinda Gates Foundation; Gilead Sciences; Incyte; U.S. Department of State","keywords":"Pharmacovigilance; Global health; Stakeholder; ANTIRETROVIRAL AGENTS; Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Drug; Public health; Pharmacology; Political science; Family medicine; Public relations","score_opus":0.134963732930019,"score_gpt":0.31449395320421347,"score_spread":0.17953022027419446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119369919","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0092215175,0.00636345,0.009311728,0.96753925,0.0019037715,0.000060282582,0.000049797138,0.000035679415,0.0055145496],"genre_scores_gemma":[0.441544,0.01131448,0.036161188,0.50109,0.007242268,0.00027051798,0.00016478845,0.00013842451,0.0020743737],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9103532,0.059413463,0.004676756,0.0040011723,0.012822269,0.008733124],"domain_scores_gemma":[0.76816577,0.17651434,0.008050015,0.0050226804,0.02345609,0.018791093],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.19145726,0.0011593534,0.0020935894,0.0052330224,0.0051426375,0.020118544,0.0037512772,0.022623016,0.003249347],"category_scores_gemma":[0.14404564,0.000979339,0.0022816467,0.003967918,0.013304457,0.014263176,0.023550393,0.02588227,0.00035297882],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046412728,0.0002486444,0.0077804457,0.0033590375,0.0010327277,0.002640886,0.018414743,0.005881968,0.0021908416,0.6274761,0.14694484,0.18356563],"study_design_scores_gemma":[0.000398119,0.00038843215,0.011419477,0.003804329,0.000576904,0.0010738957,0.033739552,0.0038429892,0.00187796,0.62130666,0.3212192,0.0003525607],"about_ca_topic_score_codex":0.006624057,"about_ca_topic_score_gemma":0.009896938,"teacher_disagreement_score":0.19145726,"about_ca_system_score_codex":0.011798585,"about_ca_system_score_gemma":0.030690534,"threshold_uncertainty_score":0.99707717},"labels":[],"label_agreement":null},{"id":"W2119432905","doi":"10.2139/ssrn.1003132","title":"The Determinants of Pricing in Pharmaceuticals: Are U.S. Prices Really Higher than Those of Canada?","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministerio de Ciencia y Tecnología; Merck Company Foundation","keywords":"Nationality; Economics; Product (mathematics); Market power; Quality (philosophy); Power (physics); Monetary economics; Business; Microeconomics; Immigration; Geography","score_opus":0.03920626024854755,"score_gpt":0.3084373042249196,"score_spread":0.26923104397637204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119432905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8563627,0.014321987,0.00061053404,0.089207575,0.00037840017,0.0000305761,0.0044498234,0.000044116165,0.034594342],"genre_scores_gemma":[0.99571747,0.001830088,0.00009012077,0.0011665742,0.000099724915,0.0000022205709,0.0003875399,0.000010285447,0.00069609884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984692,0.00020530244,0.00007406827,0.00014447144,0.00053116685,0.0005757528],"domain_scores_gemma":[0.98796743,0.002892941,0.0036247221,0.0002363505,0.0035044875,0.0017739853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001115647,0.00020046443,0.0005099295,0.0011911858,0.0012568472,0.003363376,0.0005017125,0.0012047011,0.005483423],"category_scores_gemma":[0.011838537,0.00024432363,0.00058243965,0.004765798,0.0013975225,0.0011753086,0.00064151484,0.0022870905,0.00041161044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028454486,0.000094545154,0.9293525,0.00010752542,0.00029973095,0.00019649825,0.0006463028,0.001320721,0.00026751938,0.0150931515,0.024396967,0.02793998],"study_design_scores_gemma":[0.000027984668,0.00002816013,0.98436743,0.00011621966,0.00014897021,0.00007255223,0.0015288665,0.0015421424,0.00026620837,0.0039817537,0.007886359,0.000033345314],"about_ca_topic_score_codex":0.8766058,"about_ca_topic_score_gemma":0.90292954,"teacher_disagreement_score":0.12339419,"about_ca_system_score_codex":0.009506784,"about_ca_system_score_gemma":0.013764255,"threshold_uncertainty_score":0.24824172},"labels":[],"label_agreement":null},{"id":"W2120237434","doi":"10.1503/cmaj.104001","title":"Internet pharmacy: prices on the up-and-up","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"The Internet; Pharmacy; Advertising; Business; Medical prescription; Marketing; GRASP; Prescription drug; Internet privacy; Commerce; World Wide Web; Engineering; Computer science; Medicine; Family medicine; Pharmacology","score_opus":0.05119907451602446,"score_gpt":0.27570261363029475,"score_spread":0.2245035391142703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120237434","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019580168,0.0042892327,0.0013602778,0.027951797,0.0096935965,0.00009943613,0.010181673,0.0053163683,0.9391497],"genre_scores_gemma":[0.025230154,0.005366787,0.0021671015,0.0146396095,0.0045762635,0.000109630644,0.01026656,0.0018921237,0.9357519],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9985663,0.000064480635,0.000052228323,0.000083802785,0.0010915286,0.00014156719],"domain_scores_gemma":[0.99820864,0.00019155377,0.00010316999,0.00014050934,0.00089916587,0.00045705476],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005292176,0.0009404988,0.00071035005,0.0023129035,0.0026358324,0.0071437736,0.00087488483,0.0034997782,0.32468295],"category_scores_gemma":[0.0059903725,0.000642315,0.0005182938,0.0028679506,0.000770088,0.00464315,0.0014846128,0.0030954517,0.29067123],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003488569,0.000017910323,0.00020857765,0.000020310274,0.000002305668,0.000032897984,0.000016557582,0.000043675907,0.00015731735,0.0035791434,0.96159947,0.034286972],"study_design_scores_gemma":[0.000017797318,0.000017732531,0.0018288707,0.0000352851,0.0000038733165,0.000103953746,0.00004790784,0.00015398057,0.00022705065,0.0013515283,0.9961922,0.000019967436],"about_ca_topic_score_codex":0.020348692,"about_ca_topic_score_gemma":0.024007153,"teacher_disagreement_score":0.32468295,"about_ca_system_score_codex":0.0027302722,"about_ca_system_score_gemma":0.0024011186,"threshold_uncertainty_score":0.9632578},"labels":[],"label_agreement":null},{"id":"W2121002488","doi":"10.12927/hcpap..16910","title":"More of the Same Is Not Enough","year":2002,"lang":"en","type":"review","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Health care; Public health; Population health; Equity (law); Health policy; Public policy; Health equity; Library science; Political science; Sociology; Medicine; Nursing","score_opus":0.23949401677181467,"score_gpt":0.3790834923111838,"score_spread":0.13958947553936915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121002488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043329896,0.9245564,0.00034982263,0.0654744,0.0026964776,0.0000068067548,0.00007307378,0.000021145477,0.006388531],"genre_scores_gemma":[0.010989447,0.94388765,0.000684918,0.035466395,0.0032024437,0.000011651669,0.000115834715,0.000018796298,0.005622817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973279,0.0006191672,0.00015357518,0.00044883258,0.0012488939,0.00020146363],"domain_scores_gemma":[0.9947621,0.0022685651,0.00059519877,0.00041851218,0.0016484447,0.00030713264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002995303,0.000895809,0.0022985514,0.0026497762,0.0013032331,0.0043665883,0.0011800651,0.0029428897,0.010822042],"category_scores_gemma":[0.006828093,0.00037416784,0.0011920915,0.004174853,0.004485017,0.006882558,0.0016537949,0.004510328,0.00408332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017994431,0.00007828439,0.0011341184,0.013625287,0.0006344783,0.00023438476,0.0003794765,0.00050715107,0.0009876317,0.047506686,0.23304117,0.7016914],"study_design_scores_gemma":[0.000026846948,0.000038294165,0.0024073035,0.006782511,0.0001427449,0.000452295,0.0005637573,0.00007434386,0.00009973957,0.018742599,0.9706354,0.000034126875],"about_ca_topic_score_codex":0.036008712,"about_ca_topic_score_gemma":0.05856828,"teacher_disagreement_score":0.036008712,"about_ca_system_score_codex":0.004704785,"about_ca_system_score_gemma":0.007721,"threshold_uncertainty_score":0.07159823},"labels":[],"label_agreement":null},{"id":"W2121098095","doi":"10.1016/j.healthpol.2003.07.007","title":"The effect of generic competition on the price of brand-name drugs","year":2003,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York University; University Health Network","funders":"","keywords":"Competition (biology); Formulary; Competitor analysis; Brand names; Business; Generic drug; Product (mathematics); Market share; Government (linguistics); Marketing; Economics; Advertising; Medicine","score_opus":0.04911101962320849,"score_gpt":0.33301550369442395,"score_spread":0.2839044840712155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121098095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8311237,0.012119626,0.0045475024,0.0748941,0.0006367042,0.000077181336,0.0032554949,0.00016556316,0.07318016],"genre_scores_gemma":[0.991981,0.0016154348,0.0002817215,0.0021541226,0.00053253176,0.0000076055017,0.00018522747,0.000013215478,0.0032291107],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99517536,0.0021752624,0.00021724604,0.00039676361,0.0005927726,0.0014425003],"domain_scores_gemma":[0.9566133,0.033043228,0.0059260484,0.0006992683,0.0016511455,0.0020670255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059081754,0.0005056985,0.0014404757,0.0016294096,0.001036645,0.0064516775,0.0010660762,0.00732266,0.014819572],"category_scores_gemma":[0.036571003,0.00083150005,0.0018567911,0.0019771557,0.002859169,0.003978597,0.0011984783,0.004946805,0.00085438957],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015494818,0.0020877298,0.171739,0.0013567088,0.0018053869,0.0029446017,0.00076457433,0.11128804,0.008739907,0.56884414,0.046059873,0.068875246],"study_design_scores_gemma":[0.0038731394,0.0042426805,0.4725018,0.00032625665,0.0031196806,0.001441598,0.0018112833,0.13528751,0.0071525965,0.3256195,0.04410357,0.00052049966],"about_ca_topic_score_codex":0.03128559,"about_ca_topic_score_gemma":0.026548639,"teacher_disagreement_score":0.03128559,"about_ca_system_score_codex":0.008061275,"about_ca_system_score_gemma":0.0035702374,"threshold_uncertainty_score":0.062206984},"labels":[],"label_agreement":null},{"id":"W2121918894","doi":"10.1071/ah11153","title":"The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high?","year":2012,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"Hunter Medical Research Institute","keywords":"Medical prescription; Medicine; Pharmaceutical Benefits Scheme; Health economics; Family medicine; Environmental health; Population health; Public health; Population; Nursing","score_opus":0.1618427688143668,"score_gpt":0.3890418043736473,"score_spread":0.22719903555928053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121918894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895699,0.003605553,0.00048698275,0.003930364,0.0000243222,0.000039030463,0.000482252,0.0000065734453,0.0018549612],"genre_scores_gemma":[0.998847,0.00049733924,0.0002438226,0.0001830623,0.000022220898,0.000016333242,0.00008801436,0.0000011626818,0.0001010088],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944993,0.002325235,0.0007644811,0.0003820508,0.0014834565,0.00054552115],"domain_scores_gemma":[0.97464615,0.00481118,0.016262747,0.00028809754,0.0020368642,0.0019549115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004579182,0.0002100767,0.00056842336,0.0009942685,0.000377327,0.0009256623,0.0008785383,0.0007126185,0.0012464396],"category_scores_gemma":[0.029001914,0.00039818024,0.00037094188,0.00223127,0.0007216753,0.0014553332,0.0014044283,0.0007693461,0.00013303128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013208618,0.000067204295,0.97720826,0.00039102416,0.0001261241,0.00015636752,0.001475728,0.00030863812,0.00019304559,0.0003972323,0.0008221716,0.018722037],"study_design_scores_gemma":[0.000005478832,0.00008321671,0.99803525,0.00008324275,0.000019472815,0.00008245494,0.00039673244,0.00049686775,0.00003322641,0.00020582628,0.0005525944,0.000005590874],"about_ca_topic_score_codex":0.06511929,"about_ca_topic_score_gemma":0.065860026,"teacher_disagreement_score":0.06511929,"about_ca_system_score_codex":0.00217125,"about_ca_system_score_gemma":0.001992465,"threshold_uncertainty_score":0.12948054},"labels":[],"label_agreement":null},{"id":"W2121948404","doi":"10.1345/aph.1d110","title":"Canadian and US Drug Approval Times and Safety Considerations","year":2003,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug approval; Drug; Family medicine; Pharmacology","score_opus":0.08089578326775908,"score_gpt":0.3286247004778745,"score_spread":0.24772891721011542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121948404","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22303581,0.22261162,0.0055504334,0.10807314,0.0034767366,0.00053443015,0.036161833,0.00043675193,0.40011922],"genre_scores_gemma":[0.9019838,0.046883624,0.005056732,0.0146854585,0.0010833077,0.00027401556,0.00829117,0.000257152,0.021484708],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98131657,0.0027097974,0.001837516,0.0014820397,0.010552243,0.0021018109],"domain_scores_gemma":[0.93197966,0.014888033,0.010826029,0.0009739775,0.037228435,0.004103896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010821189,0.00041497702,0.0004255159,0.0062250583,0.0020332974,0.003402648,0.00092575967,0.0011003562,0.008574007],"category_scores_gemma":[0.05727381,0.0002609561,0.00100941,0.009143302,0.000972948,0.0011617988,0.0007131841,0.0015900249,0.00066464586],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031944478,0.00014841379,0.21746662,0.0054885414,0.00057492685,0.0012894936,0.004552776,0.0025328947,0.002679938,0.038745265,0.30473232,0.41859448],"study_design_scores_gemma":[0.00012629501,0.00022858303,0.4311538,0.0015188386,0.0005597729,0.001471967,0.0026786246,0.00094755064,0.0018212768,0.0020418898,0.5573422,0.000109221706],"about_ca_topic_score_codex":0.8822249,"about_ca_topic_score_gemma":0.9179155,"teacher_disagreement_score":0.9577776,"about_ca_system_score_codex":0.04222237,"about_ca_system_score_gemma":0.062356904,"threshold_uncertainty_score":0.30634612},"labels":[],"label_agreement":null},{"id":"W2122150879","doi":"10.1002/jps.22300","title":"Increasing Access to Essential Medicines: Diversifying Canada's Approach","year":2010,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Access to medicines; Intellectual property; Essential medicines; Legislation; Business; Developing country; International trade; TRIPS Agreement; Medicine; Political science; Economic growth; Law; Health care; Economics","score_opus":0.10628549659776387,"score_gpt":0.3686975397853304,"score_spread":0.2624120431875665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122150879","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.084398486,0.010793867,0.005834571,0.73447204,0.0017391855,0.0005923639,0.0013784718,0.00026622164,0.16052476],"genre_scores_gemma":[0.725478,0.0069914525,0.007823494,0.23084383,0.0017267218,0.0001675995,0.0003616567,0.00009075897,0.026516385],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98511064,0.0025683197,0.00047863313,0.0010363668,0.0061761537,0.004629947],"domain_scores_gemma":[0.96678716,0.0069700233,0.0015606977,0.0011611555,0.011328088,0.012192898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010310742,0.00067194866,0.0009845387,0.0038636667,0.00515632,0.007483566,0.003138532,0.009028745,0.011142668],"category_scores_gemma":[0.031002082,0.0004406922,0.0013511034,0.003590469,0.004893505,0.0031571516,0.0049301703,0.006411642,0.0002923487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084633735,0.0005457227,0.030790236,0.00090794195,0.00052425667,0.0008607719,0.0033439137,0.014323541,0.0023725822,0.46408165,0.24767223,0.23373075],"study_design_scores_gemma":[0.0010008566,0.00039931136,0.073711924,0.0017188843,0.00058435486,0.00049379154,0.0032601869,0.013588245,0.001723362,0.13405997,0.7690895,0.00036965328],"about_ca_topic_score_codex":0.95566756,"about_ca_topic_score_gemma":0.9722652,"teacher_disagreement_score":0.91479546,"about_ca_system_score_codex":0.08520452,"about_ca_system_score_gemma":0.2577689,"threshold_uncertainty_score":0.61820495},"labels":[],"label_agreement":null},{"id":"W2122650459","doi":"10.1503/cmaj.081913","title":"Long-term trends in use of and expenditures for cardiovascular medications in Canada","year":2009,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université Laval; Health Sciences Centre; University of British Columbia; McGill University Health Centre; Sunnybrook Health Science Centre; Statistics Canada; University of Ottawa; University of Toronto; Dalhousie University","funders":"Department of Family and Community Medicine, University of Toronto; Health Canada; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; University of Toronto; Dalhousie University; Western University of Health Sciences; Toronto Rehabilitation Institute; Department of Medicine, University of Toronto; University of Ottawa; McGill University Health Centre; Institute for Clinical Evaluative Sciences; McGill University; Jewish General Hospital; University of Alberta; Université Laval","keywords":"Medicine; Medical prescription; Population; Health care; Prescription drug; Drug class; Demographics; Environmental health; Demography; Drug; Economic growth; Pharmacology; Economics","score_opus":0.03664679675875496,"score_gpt":0.26689873036555134,"score_spread":0.23025193360679638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122650459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9365893,0.0041158823,0.00029796548,0.0027075824,0.00003091148,0.000053836848,0.049413465,0.00007381545,0.0067172316],"genre_scores_gemma":[0.98547506,0.002099276,0.00039829867,0.00026203823,0.000015870257,0.000022354328,0.009961628,0.000011551167,0.0017539563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883336,0.00004243466,0.0000989533,0.000118867916,0.0005847576,0.00032160117],"domain_scores_gemma":[0.9948488,0.00018540598,0.0009798168,0.000077287754,0.0032048465,0.00070390594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051069853,0.0002657991,0.00038423677,0.0023451864,0.0015429365,0.0012931955,0.0011116364,0.00039755233,0.0020097692],"category_scores_gemma":[0.0025749137,0.000247985,0.00066682085,0.0069753393,0.0004513801,0.0004992533,0.00072651485,0.0008601656,0.00022645123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009007719,0.00003951604,0.9810798,0.000111398746,0.00015063642,0.00009555384,0.0003250236,0.0005840923,0.00018875633,0.0002876116,0.0054677348,0.011579816],"study_design_scores_gemma":[0.0000039801275,0.000010690838,0.9974529,0.00003442485,0.000034785495,0.00004148001,0.00026610208,0.0004960172,0.00006242948,0.000021021007,0.0015666289,0.000009559646],"about_ca_topic_score_codex":0.9968262,"about_ca_topic_score_gemma":0.99758387,"teacher_disagreement_score":0.05069816,"about_ca_system_score_codex":0.05069816,"about_ca_system_score_gemma":0.043727078,"threshold_uncertainty_score":0.3678426},"labels":[],"label_agreement":null},{"id":"W2124890015","doi":"10.1016/s0149-2918(03)80080-2","title":"Timeliness of review and approval of new drugs in Canada from 1999 through 2001: Is progress being made?","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada","keywords":"Medicine; European union; Agency (philosophy); Drug approval; Family medicine; International trade; Drug; Business; Pharmacology","score_opus":0.1803435469890641,"score_gpt":0.38183239178521533,"score_spread":0.20148884479615123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124890015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5714971,0.07991688,0.0016824333,0.23319325,0.002932537,0.00035896615,0.07265167,0.0005756248,0.037191495],"genre_scores_gemma":[0.9450665,0.015205736,0.00082883687,0.011552415,0.0011188214,0.000082019804,0.011200001,0.00007564865,0.014870065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97826993,0.0014545064,0.0020475849,0.0011637217,0.013395881,0.003668314],"domain_scores_gemma":[0.78872865,0.032485858,0.06886582,0.001787419,0.0890193,0.01911299],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011373547,0.0004696245,0.0008735916,0.007492454,0.0021125788,0.006290376,0.0025447686,0.003409106,0.0039039352],"category_scores_gemma":[0.08875661,0.00065584696,0.0010231594,0.011074312,0.001311062,0.0025042824,0.0012400611,0.003818337,0.00050525856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031031617,0.0003705336,0.5772528,0.0025206571,0.0012258865,0.0010344144,0.0028130072,0.009821487,0.0015869524,0.010971352,0.23463598,0.15466376],"study_design_scores_gemma":[0.00012173713,0.00014149323,0.9351884,0.00026996847,0.00024219188,0.00020201394,0.0008410114,0.0023615255,0.0010633885,0.00040882648,0.059068963,0.000090426045],"about_ca_topic_score_codex":0.97378135,"about_ca_topic_score_gemma":0.9824294,"teacher_disagreement_score":0.9886265,"about_ca_system_score_codex":0.0815799,"about_ca_system_score_gemma":0.16812246,"threshold_uncertainty_score":0.59190637},"labels":[],"label_agreement":null},{"id":"W2127520342","doi":"10.1016/s0140-6736(02)11527-3","title":"The pharmaceutical industry as a medicines provider","year":2002,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":167,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Business; Intellectual property; Developing country; Drug prices; Essential drugs; Production (economics); Pharmaceutical industry; Essential medicines; International trade; Developed country; Access to medicines; Marginal cost; Industrial organization; Public economics; Commerce; Health care; Economic growth; Economics; Environmental health; Medicine; Health services; Pharmacology","score_opus":0.2876269035881042,"score_gpt":0.41387446557552665,"score_spread":0.12624756198742243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127520342","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036375364,0.9913496,0.00007795562,0.0063028517,0.0006290008,0.0000025697195,0.000012375268,0.0000030386477,0.0015862513],"genre_scores_gemma":[0.0009038686,0.9951768,0.00013658711,0.0020538962,0.0010273899,0.000004568453,0.000009518741,0.0000013567793,0.00068603817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998382,0.0006128447,0.0001102041,0.00014421738,0.00065346627,0.00009717856],"domain_scores_gemma":[0.99246734,0.0051352805,0.0010015727,0.0001111785,0.0009884136,0.00029619483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036735681,0.0010480672,0.0017515728,0.0030326664,0.0005582234,0.0032654216,0.0009892201,0.00574459,0.006288591],"category_scores_gemma":[0.008263137,0.00044532286,0.0005199827,0.0071034883,0.0019520723,0.003463532,0.0008757806,0.004124474,0.0021637206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015988716,0.00007633572,0.0003704789,0.018489482,0.00017337869,0.00018838827,0.000059327693,0.0008793216,0.00026663355,0.042559788,0.22671263,0.7100644],"study_design_scores_gemma":[0.00008145844,0.000044973574,0.0014225593,0.010097259,0.0001723584,0.0004359811,0.00009587721,0.00019320521,0.00013867031,0.019284831,0.9680159,0.000016828137],"about_ca_topic_score_codex":0.006457775,"about_ca_topic_score_gemma":0.01679318,"teacher_disagreement_score":0.006457775,"about_ca_system_score_codex":0.004269252,"about_ca_system_score_gemma":0.008596033,"threshold_uncertainty_score":0.030975759},"labels":[],"label_agreement":null},{"id":"W2128772904","doi":"10.1371/journal.pone.0039737","title":"Potential Savings of Harmonising Hospital and Community Formularies for Chronic Disease Medications Initiated in Hospital","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"Institute of Nutrition, Metabolism and Diabetes; Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Formulary; Medicine; Medical prescription; Emergency medicine; Pharmacology","score_opus":0.10075004349833491,"score_gpt":0.2830804431393995,"score_spread":0.1823303996410646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128772904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688598,0.0011812337,0.002207115,0.0100259,0.00005494727,0.0004130004,0.0025354193,0.000116271134,0.014606376],"genre_scores_gemma":[0.99741286,0.00016777788,0.0009249463,0.00023495407,0.000022131806,0.00003575841,0.00043539607,0.0000035811665,0.00076260965],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9965125,0.0014523088,0.00015066715,0.00016182118,0.00083552964,0.0008872817],"domain_scores_gemma":[0.9926494,0.0019257226,0.0020180973,0.0005044142,0.0015554093,0.0013470802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002701626,0.00032490975,0.00029050795,0.0009719237,0.00056491536,0.0016408976,0.00089608727,0.00091304904,0.0023624215],"category_scores_gemma":[0.016050385,0.00021087019,0.00045671387,0.0016585302,0.0005874078,0.00087945536,0.001349478,0.0005413254,0.00014493188],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025161793,0.0021404664,0.6315859,0.0004835093,0.00062196207,0.0004925036,0.0007649243,0.06863902,0.0019817764,0.015498717,0.018269127,0.25700587],"study_design_scores_gemma":[0.00075267017,0.0014868445,0.91762424,0.00026219024,0.00043534752,0.00032399152,0.0017644158,0.050393093,0.0015427185,0.0044329287,0.02089346,0.00008806326],"about_ca_topic_score_codex":0.4250723,"about_ca_topic_score_gemma":0.45851135,"teacher_disagreement_score":0.4250723,"about_ca_system_score_codex":0.02498943,"about_ca_system_score_gemma":0.024022248,"threshold_uncertainty_score":0.84519625},"labels":[],"label_agreement":null},{"id":"W2129720637","doi":"10.1126/scitranslmed.3002678","title":"Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines","year":2011,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; University of Toronto","funders":"","keywords":"Crowdsourcing; Data science; Drug discovery; Medicine; Computer science; Computational biology; Bioinformatics; Biology; World Wide Web","score_opus":0.27718716008632155,"score_gpt":0.32208033763943295,"score_spread":0.044893177553111396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129720637","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12966143,0.009533534,0.6997693,0.039377093,0.0020490896,0.0018704833,0.012978885,0.0027966725,0.10196345],"genre_scores_gemma":[0.79737353,0.00377059,0.18022315,0.0031494757,0.0012047157,0.0011089522,0.0046549295,0.00025822435,0.008256384],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9845269,0.00893613,0.0004934826,0.0014771859,0.004075612,0.00049072446],"domain_scores_gemma":[0.9204566,0.06409044,0.003482737,0.007468208,0.0034189583,0.0010830113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019276572,0.0011117989,0.0017397004,0.0061887065,0.0020028776,0.004287253,0.0022880342,0.0030495003,0.0061553223],"category_scores_gemma":[0.06081649,0.0006296587,0.0015381435,0.0074633663,0.0020627475,0.00377068,0.0064397617,0.0025155689,0.0019186796],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013472236,0.0006709168,0.02091354,0.002302757,0.0013045709,0.0011543196,0.0023129696,0.2705026,0.006246352,0.13006733,0.065760516,0.49741697],"study_design_scores_gemma":[0.00031383795,0.00015671604,0.006553692,0.00035768806,0.00014440827,0.00012330721,0.0010381087,0.55410415,0.0032508383,0.36104724,0.072717495,0.00019260266],"about_ca_topic_score_codex":0.011845935,"about_ca_topic_score_gemma":0.012429607,"teacher_disagreement_score":0.019276572,"about_ca_system_score_codex":0.0025906935,"about_ca_system_score_gemma":0.0037358035,"threshold_uncertainty_score":0.10194546},"labels":[],"label_agreement":null},{"id":"W2130342117","doi":"10.1345/aph.1h117","title":"Relationship Between Pharmaceutical Company User Fees and Drug Approvals in Canada and Australia: A Hypothesis-Generating Study","year":2006,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Revenue; Government (linguistics); Workload; Pharmaceutical industry; Medicine; Public economics; Business; Accounting; Economics; Pharmacology; Management","score_opus":0.27145347124165425,"score_gpt":0.3802026077202118,"score_spread":0.10874913647855755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130342117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99814165,0.0001608635,0.00012626141,0.0002195638,0.000009074363,0.00012876335,0.00038033893,0.000003851157,0.0008295498],"genre_scores_gemma":[0.9985195,0.00009823714,0.00029445396,0.0001238469,0.000008970695,0.00013558315,0.00033645242,0.0000034664856,0.00047956608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99060297,0.003325393,0.00064170954,0.0010954454,0.0025678691,0.0017666807],"domain_scores_gemma":[0.9326659,0.028532984,0.019311816,0.0013808556,0.011326389,0.0067820954],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008047255,0.00042525984,0.00075785967,0.0025644312,0.0014865672,0.0015826426,0.0014010238,0.0009854574,0.0034565576],"category_scores_gemma":[0.037147127,0.0003686413,0.0012783421,0.0040628863,0.0021995772,0.00093444076,0.0015808104,0.0018417676,0.00021454562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022375843,0.0001269009,0.99684167,0.000040316427,0.00010077217,0.000062342864,0.0009769076,0.000062644125,0.000035347486,0.00010828292,0.00024079905,0.0011802869],"study_design_scores_gemma":[0.000029724766,0.00019704712,0.9961429,0.000025177811,0.00008400338,0.00004821977,0.0021895973,0.000935231,0.000026254665,0.000052543117,0.00025788276,0.000011367061],"about_ca_topic_score_codex":0.7397098,"about_ca_topic_score_gemma":0.6521859,"teacher_disagreement_score":0.9919527,"about_ca_system_score_codex":0.011824978,"about_ca_system_score_gemma":0.018783212,"threshold_uncertainty_score":0.5236462},"labels":[],"label_agreement":null},{"id":"W2130482828","doi":"10.1186/1744-8603-10-53","title":"Innovation in regulation of rapidly changing health markets","year":2014,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Economic and Social Research Council","keywords":"Context (archaeology); Goods and services; Business; Public economics; Health services research; Health care; Accountability; Health policy; Quality (philosophy); Social policy; Industrial organization; Economics; Economic growth; Market economy; Political science","score_opus":0.06476299931814562,"score_gpt":0.3320488705674759,"score_spread":0.2672858712493303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130482828","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07983731,0.01154805,0.2961538,0.18208918,0.0020086726,0.0009609178,0.0001708652,0.0005756697,0.42665556],"genre_scores_gemma":[0.9060284,0.0047037285,0.045113824,0.01886974,0.0012127206,0.00087729923,0.00007374497,0.00010349259,0.023017088],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97021824,0.016671943,0.00117225,0.0035255041,0.005869537,0.002542483],"domain_scores_gemma":[0.96178454,0.024116352,0.003989435,0.0049030823,0.0040832586,0.0011231843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034083955,0.00045234646,0.00060725183,0.0019117875,0.0029148434,0.010377002,0.003183334,0.0066774464,0.005263056],"category_scores_gemma":[0.03521927,0.00052367034,0.0012165902,0.0013248275,0.02735187,0.00797872,0.007858725,0.0060249865,0.0007215057],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014340077,0.000041181294,0.0008695818,0.00014386493,0.000015817017,0.00013474566,0.0019034313,0.0019724434,0.0005542696,0.977454,0.0020052446,0.014891185],"study_design_scores_gemma":[0.00006308796,0.0001340021,0.0014768724,0.00060281536,0.000019477107,0.0001369485,0.0015745398,0.0056010657,0.0014633482,0.8574508,0.13140498,0.00007212268],"about_ca_topic_score_codex":0.004186711,"about_ca_topic_score_gemma":0.0028748056,"teacher_disagreement_score":0.034083955,"about_ca_system_score_codex":0.01101302,"about_ca_system_score_gemma":0.014470405,"threshold_uncertainty_score":0.1802553},"labels":[],"label_agreement":null},{"id":"W2130616861","doi":"10.2471/blt.12.109827","title":"Assessing implementation mechanisms for an international agreement on research and development for health products","year":2012,"lang":"en","type":"article","venue":"Bulletin of the World Health Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Unanimity; Delegation; Voting; Business; Compliance (psychology); Public relations; Politics; Law and economics; Public economics; Political science; Economics; Law","score_opus":0.2516505935752133,"score_gpt":0.4590684949775408,"score_spread":0.20741790140232752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130616861","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19046281,0.0066817007,0.2092821,0.03596612,0.002059918,0.050821204,0.0039485847,0.000720343,0.5000573],"genre_scores_gemma":[0.65690696,0.0024226618,0.29260257,0.006374308,0.00022440248,0.026201647,0.0024560925,0.00027063914,0.012540695],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.53217334,0.27157494,0.054239757,0.014956844,0.105120346,0.021934733],"domain_scores_gemma":[0.3227906,0.43149033,0.07305657,0.047578637,0.11466893,0.010414934],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5668079,0.002012197,0.0021282993,0.016242025,0.007334764,0.03440753,0.0072832345,0.010632839,0.019045154],"category_scores_gemma":[0.5571529,0.0022814297,0.0055402485,0.013123514,0.011717458,0.032931704,0.019728642,0.009287385,0.002519052],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007284728,0.00082645717,0.04258672,0.0043048034,0.000805694,0.00021011791,0.009017375,0.0073087425,0.0007539284,0.82413274,0.011623945,0.097701035],"study_design_scores_gemma":[0.0024534308,0.006917432,0.11547892,0.024533473,0.0031544613,0.0005661401,0.055165183,0.028524695,0.009328674,0.44211528,0.3107029,0.0010594152],"about_ca_topic_score_codex":0.009466298,"about_ca_topic_score_gemma":0.008309705,"teacher_disagreement_score":0.43319207,"about_ca_system_score_codex":0.03846307,"about_ca_system_score_gemma":0.08502027,"threshold_uncertainty_score":0.534203},"labels":[],"label_agreement":null},{"id":"W2132811452","doi":"10.1002/chir.20520","title":"A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States","year":2008,"lang":"en","type":"review","venue":"Chirality","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Chemistry; Patentability; Enantiomer; Pharmaceutical industry; Nanotechnology; Pharmacology; Stereochemistry; Law; Patent law; Intellectual property","score_opus":0.30351961201780536,"score_gpt":0.40379211505860124,"score_spread":0.10027250304079588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132811452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030051902,0.9945363,0.00010675189,0.0010721693,0.00013729336,0.0000021186177,0.0000090139665,0.0000014854212,0.003834388],"genre_scores_gemma":[0.003940738,0.994599,0.00016345497,0.0005492003,0.00016200473,0.0000032776982,0.00001195687,7.950448e-7,0.00056954165],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998716,0.00035213417,0.00013149122,0.00014652798,0.00058954395,0.000064385706],"domain_scores_gemma":[0.9963031,0.002375793,0.00061295973,0.00006913862,0.0005523863,0.00008663751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028108188,0.00034704196,0.0011477349,0.003342794,0.0005201262,0.0019906217,0.00064844184,0.0019602065,0.0032501689],"category_scores_gemma":[0.0046931305,0.000304656,0.0008124804,0.005992389,0.0008632603,0.0023046625,0.0006093503,0.0017474813,0.0006733544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065798784,0.00004552067,0.0006784562,0.012992267,0.0001159999,0.0005894443,0.00013685698,0.00048774134,0.0010220085,0.042120088,0.020247858,0.921498],"study_design_scores_gemma":[0.000024263152,0.00022406226,0.006344134,0.014472537,0.00027851513,0.0027963736,0.00027801702,0.00025532942,0.0009307334,0.015925825,0.95843834,0.00003188747],"about_ca_topic_score_codex":0.004478586,"about_ca_topic_score_gemma":0.0077723716,"teacher_disagreement_score":0.004478586,"about_ca_system_score_codex":0.0014344293,"about_ca_system_score_gemma":0.0037718639,"threshold_uncertainty_score":0.01486522},"labels":[],"label_agreement":null},{"id":"W2133193005","doi":"10.1111/fcp.12155","title":"Generic medicines: issues and relevance for global health","year":2015,"lang":"en","type":"review","venue":"Fundamental and Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Product (mathematics); Quality (philosophy); Biosimilar; European union; Sustainability; Cornerstone; Generic drug; International trade; Marketing; Medicine; Pharmacology; Drug","score_opus":0.31138506214660017,"score_gpt":0.5373507876161616,"score_spread":0.22596572546956145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133193005","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008991973,0.99255776,0.00010467892,0.004377419,0.0002718712,0.0000038380585,0.000024461988,0.000004666222,0.0025654105],"genre_scores_gemma":[0.0015951751,0.9958007,0.00013090075,0.0014517726,0.0004620573,0.0000042344786,0.00002465724,0.0000021378771,0.00052825647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990195,0.00025902307,0.000106662046,0.000121553916,0.0003949047,0.00009835215],"domain_scores_gemma":[0.99728656,0.0017209154,0.0003791101,0.00007871913,0.0003932655,0.00014143456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021477593,0.00076467736,0.0016628061,0.0031825185,0.00057573523,0.0035940022,0.0009895675,0.0033579138,0.011704791],"category_scores_gemma":[0.0037441077,0.0003820422,0.0010896465,0.00673193,0.002179792,0.004735535,0.0017467204,0.0032149022,0.0022434474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004951486,0.000046924633,0.00031844058,0.030312011,0.00013361224,0.00028574083,0.00025148192,0.0005007271,0.00037701748,0.07281472,0.067110084,0.82779974],"study_design_scores_gemma":[0.000011529993,0.000029123528,0.00072326395,0.01006935,0.000062909705,0.0006283808,0.00019781462,0.000074273354,0.00008298927,0.0156453,0.97245985,0.000015273534],"about_ca_topic_score_codex":0.0030111393,"about_ca_topic_score_gemma":0.0034734048,"teacher_disagreement_score":0.011704791,"about_ca_system_score_codex":0.0024991017,"about_ca_system_score_gemma":0.004797632,"threshold_uncertainty_score":0.039156437},"labels":[],"label_agreement":null},{"id":"W2134418108","doi":"10.1503/cmaj.081429","title":"Policy alternatives for treatments for rare diseases","year":2010,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bench to bedside; Medicine; Intensive care medicine; Drug industry; Risk analysis (engineering); Computer science; Drug approval; Business; Pharmacology; Engineering ethics; Medical physics; Drug; Engineering","score_opus":0.028035951907171727,"score_gpt":0.3042755118506796,"score_spread":0.27623955994350785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134418108","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016589256,0.008196321,0.027939996,0.6008628,0.003321141,0.00019009903,0.00094592816,0.00031835327,0.34163618],"genre_scores_gemma":[0.6862377,0.009077084,0.016699895,0.18940867,0.00701585,0.0006227939,0.0008671204,0.00014508044,0.08992581],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99173015,0.004219077,0.00026305494,0.0006217666,0.0019132,0.0012526925],"domain_scores_gemma":[0.98577034,0.008388292,0.0015428792,0.0009257006,0.00183018,0.0015426761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0079291295,0.0005387227,0.0005398286,0.0015329724,0.0016243189,0.004516322,0.0013631684,0.00925877,0.03871186],"category_scores_gemma":[0.026825564,0.00030200384,0.00086117507,0.0013332525,0.0023386714,0.005076409,0.0025363788,0.0063456916,0.0024290623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006491137,0.0000638212,0.000366712,0.00008037905,0.00001920186,0.00012118301,0.000097032505,0.002116658,0.00011403561,0.94470006,0.037709437,0.014546517],"study_design_scores_gemma":[0.00022354067,0.00006873121,0.0016171674,0.00033883707,0.000026024853,0.00020638279,0.00032626765,0.0047779377,0.00021236503,0.705143,0.28702357,0.00003617648],"about_ca_topic_score_codex":0.0075480086,"about_ca_topic_score_gemma":0.0063539175,"teacher_disagreement_score":0.99245197,"about_ca_system_score_codex":0.0051810057,"about_ca_system_score_gemma":0.0077367383,"threshold_uncertainty_score":0.12950414},"labels":[],"label_agreement":null},{"id":"W2134825292","doi":"10.4000/quaderni.262","title":"Orphan Drugs, Patient Activism and Contemporary Healthcare","year":2009,"lang":"en","type":"article","venue":"Quaderni","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"Humanities; Political science; Orphan drug; Philosophy","score_opus":0.07357785694484663,"score_gpt":0.29333490683515,"score_spread":0.21975704989030337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134825292","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12076877,0.026968729,0.002643827,0.48219296,0.00069590897,0.000055155768,0.00008576569,0.000015286347,0.36657354],"genre_scores_gemma":[0.9534726,0.011415141,0.00035313083,0.022966467,0.0011127541,0.00004630574,0.000027357799,0.0000094189645,0.010596731],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99441564,0.003233531,0.0001659305,0.0003001526,0.0006365324,0.0012481039],"domain_scores_gemma":[0.9916283,0.005196317,0.001728374,0.0001919275,0.0002723683,0.0009827234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047689695,0.00017548201,0.00023399478,0.0010653137,0.0024612902,0.0061574955,0.00050064217,0.0041503,0.012272171],"category_scores_gemma":[0.009137821,0.0001625562,0.00020779512,0.0012009867,0.012043687,0.0037661095,0.004181571,0.0043130945,0.000398985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051409013,0.00009103887,0.0046242285,0.00011740434,0.000013117546,0.00023381664,0.0061766403,0.0002964256,0.00009621272,0.9560249,0.007797572,0.024477115],"study_design_scores_gemma":[0.00009045598,0.00016243875,0.014890129,0.0011305936,0.00001612868,0.0008691085,0.02630098,0.0008440061,0.00027694422,0.56383294,0.39153785,0.000048450573],"about_ca_topic_score_codex":0.0026638617,"about_ca_topic_score_gemma":0.0034583798,"teacher_disagreement_score":0.012272171,"about_ca_system_score_codex":0.004902432,"about_ca_system_score_gemma":0.0040411027,"threshold_uncertainty_score":0.041054547},"labels":[],"label_agreement":null},{"id":"W2134917281","doi":"","title":"Multimarket Contact in Pharmaceutical Markets","year":2007,"lang":"en","type":"preprint","venue":"RECERCAT (Consorci de Serveis Universitaris de Catalunya)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universidad Carlos III de Madrid; Ministerio de Ciencia y Tecnología; Merck Company Foundation","keywords":"Market power; Economics; Industrial organization; Contrast (vision); Microeconomics; Business; International economics","score_opus":0.06695236867343733,"score_gpt":0.3045806709896152,"score_spread":0.23762830231617788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134917281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869081,0.0006662661,0.007749776,0.00087836146,0.000018686107,0.000055698696,0.0007073054,0.00013836427,0.002877494],"genre_scores_gemma":[0.9983339,0.00010753277,0.00048125512,0.000057701203,0.000029259762,0.000021442736,0.00024589483,0.000005965095,0.000716988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948236,0.0019008913,0.00034235022,0.001336519,0.00092441525,0.00067224394],"domain_scores_gemma":[0.85077953,0.09409146,0.044329032,0.0067127584,0.001495408,0.0025918172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007675696,0.0003101261,0.0014833714,0.0015402429,0.0007702374,0.0032671527,0.0013072342,0.0019778127,0.01380406],"category_scores_gemma":[0.04497007,0.00041917415,0.001164758,0.0020432188,0.0012600146,0.0049000527,0.0020352558,0.002581373,0.001022153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002838048,0.0022491075,0.8139629,0.0003109728,0.0010664708,0.0021413784,0.0012626556,0.06102403,0.0021526122,0.0356172,0.005216331,0.07215832],"study_design_scores_gemma":[0.0006115166,0.0018801319,0.6126821,0.00007394712,0.00048473026,0.0019369768,0.0014056874,0.28351584,0.004844459,0.086941205,0.0054504033,0.00017296501],"about_ca_topic_score_codex":0.0032088174,"about_ca_topic_score_gemma":0.0025145856,"teacher_disagreement_score":0.01380406,"about_ca_system_score_codex":0.0011777686,"about_ca_system_score_gemma":0.00061090203,"threshold_uncertainty_score":0.046179116},"labels":[],"label_agreement":null},{"id":"W2135561239","doi":"10.1136/bmjopen-2014-006235","title":"How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001–2012","year":2014,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Formulary; Medicine; Observational study; Family medicine; Quarter (Canadian coin); Drug; Pharmacology; Internal medicine","score_opus":0.15231994535985727,"score_gpt":0.37573199912965044,"score_spread":0.22341205376979317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135561239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886234,0.0044168406,0.0001939518,0.00020478536,0.000025301764,0.00009273051,0.005044022,0.000010002228,0.0013888773],"genre_scores_gemma":[0.9914077,0.0035014441,0.00023492287,0.000404211,0.000049852428,0.0001182434,0.0036586565,0.000010822983,0.00061406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948606,0.0007179408,0.0015886448,0.0009347471,0.001445081,0.00045295164],"domain_scores_gemma":[0.9768076,0.0024551912,0.017391419,0.0006669476,0.0015587521,0.0011200868],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020615817,0.00042424272,0.0009723943,0.0022651064,0.0005322577,0.0015981139,0.0007694305,0.0009803071,0.0023328576],"category_scores_gemma":[0.009324445,0.0007540686,0.00093629974,0.004587856,0.0007462334,0.0016234306,0.0013337922,0.0009676726,0.000758541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003092491,0.000049231472,0.9941315,0.0002382851,0.000091427195,0.00028570907,0.0003668395,0.000052052477,0.00019506087,0.000035608256,0.00067075493,0.0035742612],"study_design_scores_gemma":[0.000016976113,0.00018749379,0.99658066,0.00012350534,0.000059637165,0.00093146425,0.00048351294,0.00008035985,0.00008888793,0.000010499954,0.0014234607,0.0000135373775],"about_ca_topic_score_codex":0.0254498,"about_ca_topic_score_gemma":0.025791291,"teacher_disagreement_score":0.9979384,"about_ca_system_score_codex":0.0017748281,"about_ca_system_score_gemma":0.0014344766,"threshold_uncertainty_score":0.05060333},"labels":[],"label_agreement":null},{"id":"W2135643683","doi":"10.1093/heapol/czh021","title":"Interactions between patent medicine vendors and customers in urban and rural Nigeria","year":2004,"lang":"en","type":"article","venue":"Health Policy and Planning","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":179,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Rockefeller Foundation; United States Agency for International Development","keywords":"Medical prescription; Quarter (Canadian coin); Business; Payment; Medicine; Position (finance); Marketing; Family medicine; Advertising; Nursing; History","score_opus":0.15448731554912754,"score_gpt":0.3877181498090497,"score_spread":0.23323083425992214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135643683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99960107,0.00005259831,0.000014783494,0.000055430995,0.0000014287043,0.0000062568365,0.000010487997,5.927801e-7,0.0002573648],"genre_scores_gemma":[0.99910116,0.00019440045,0.000083441555,0.000093996765,0.000005246109,0.0000113585365,0.000018248295,0.0000011898009,0.00049098505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992213,0.00036819337,0.00004754874,0.000063343294,0.0001221032,0.00017745694],"domain_scores_gemma":[0.9984458,0.0005649873,0.0005559373,0.000034627657,0.00013470091,0.00026386618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006470038,0.00022772237,0.0004110987,0.00058287726,0.0030658483,0.001364223,0.00044381543,0.0009644791,0.0027735243],"category_scores_gemma":[0.0018799943,0.0005747021,0.00020103004,0.0006278172,0.00079725625,0.0010480798,0.001248475,0.00093910954,0.00037877075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003075724,0.00061064673,0.7787715,0.00013651267,0.000025616628,0.0039807702,0.19832477,0.00007621915,0.0018317534,0.00024911723,0.00086448167,0.014821088],"study_design_scores_gemma":[0.000011306437,0.0006889418,0.47594872,0.00007343538,0.000021972242,0.0021258951,0.5180211,0.0003414937,0.00036414794,0.00009413252,0.0022711502,0.000037737213],"about_ca_topic_score_codex":0.0069835493,"about_ca_topic_score_gemma":0.013924741,"teacher_disagreement_score":0.0069835493,"about_ca_system_score_codex":0.0007617003,"about_ca_system_score_gemma":0.0007088285,"threshold_uncertainty_score":0.013885796},"labels":[],"label_agreement":null},{"id":"W2136610976","doi":"10.1177/097206340801000303","title":"A Status Report on the Health Care Sector in France","year":2008,"lang":"en","type":"article","venue":"Journal of Health Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Order (exchange); Pharmaceutical industry; TRIPS architecture; Gross domestic product; Product (mathematics); Business; Health care; Medical prescription; Economic growth; Economics; Finance; Medicine","score_opus":0.11200114911072016,"score_gpt":0.34457385578135447,"score_spread":0.2325727066706343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136610976","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24509962,0.1572156,0.0019765845,0.044121906,0.0052455305,0.000879233,0.15289001,0.0016257514,0.39094582],"genre_scores_gemma":[0.4238471,0.08518375,0.003596236,0.006885585,0.00423934,0.00084312673,0.13492668,0.00021840559,0.34025985],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663264,0.0005805403,0.00032652367,0.00022970831,0.0015397617,0.00069088227],"domain_scores_gemma":[0.99436015,0.00096021674,0.0010415005,0.00012679631,0.0026985926,0.00081272115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034322958,0.000836757,0.00031465208,0.008715413,0.0008519735,0.003664424,0.00065210456,0.0014341986,0.016659977],"category_scores_gemma":[0.0034746164,0.00024538187,0.0007312567,0.0062668785,0.00026191448,0.0017243237,0.001290866,0.00063089037,0.004620417],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000632944,0.00041654875,0.18939021,0.002689314,0.00025435156,0.0014271566,0.0023934988,0.001987699,0.002601029,0.012981446,0.52753264,0.25769308],"study_design_scores_gemma":[0.000023410263,0.0003123096,0.35531145,0.00039239135,0.00003686624,0.00030008378,0.0015111028,0.00029009106,0.00047060792,0.00025576726,0.64106256,0.000033394797],"about_ca_topic_score_codex":0.091496706,"about_ca_topic_score_gemma":0.05769159,"teacher_disagreement_score":0.091496706,"about_ca_system_score_codex":0.0063948617,"about_ca_system_score_gemma":0.005600439,"threshold_uncertainty_score":0.18192828},"labels":[],"label_agreement":null},{"id":"W2136777787","doi":"10.12927/hcpol.2008.19525","title":"The Effect of Evidence-Based Drug Coverage Policies on Pharmaceutical R&amp;D: A Case Study from British Columbia - Abridged Version -","year":2008,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Political science; Operations research; Medicine; Pharmacology; Engineering","score_opus":0.18334742511102717,"score_gpt":0.38648175497601084,"score_spread":0.20313432986498367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136777787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9420435,0.0011864237,0.00015488018,0.0048608356,0.000016569387,0.00014665454,0.0008429464,0.000023786646,0.05072438],"genre_scores_gemma":[0.98554486,0.0005868773,0.00024040691,0.00076107215,0.000005301023,0.000050843955,0.00027808442,0.000008059734,0.012524521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968395,0.00063961867,0.00012549708,0.00013030902,0.00078504824,0.001480003],"domain_scores_gemma":[0.98836166,0.005949602,0.000692586,0.000354114,0.0027609412,0.001881113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020239805,0.00035818474,0.00049710023,0.0015252125,0.005148943,0.0042365575,0.0017623334,0.0026923376,0.0068256357],"category_scores_gemma":[0.010619244,0.00039222138,0.00044909917,0.0033933131,0.0019306698,0.00083499,0.002347842,0.0027870927,0.0003829718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029445656,0.0035932753,0.6341212,0.0012300175,0.0005547905,0.038377244,0.020725913,0.0411511,0.006644499,0.06386926,0.058935966,0.12785216],"study_design_scores_gemma":[0.0009400413,0.0011323896,0.8116395,0.0008143677,0.0007900432,0.003477392,0.093971,0.016434338,0.0033757742,0.0054127974,0.06166646,0.0003459144],"about_ca_topic_score_codex":0.97682834,"about_ca_topic_score_gemma":0.98697585,"teacher_disagreement_score":0.047672074,"about_ca_system_score_codex":0.047672074,"about_ca_system_score_gemma":0.05046867,"threshold_uncertainty_score":0.34588677},"labels":[],"label_agreement":null},{"id":"W2137840922","doi":"10.1111/jlme.12012","title":"Pharmaceutical Knowledge Governance: A Human Rights Perspective","year":2013,"lang":"en","type":"article","venue":"The Journal of Law Medicine & Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transparency (behavior); Misrepresentation; Human rights; Corporate governance; Obligation; Business; Political science; Pharmaceutical industry; Drug control; Public relations; Law and economics; Public economics; Public administration; Economics; Law; Medicine; Pharmacology","score_opus":0.20270876457574855,"score_gpt":0.4249189313450158,"score_spread":0.22221016676926725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137840922","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02039566,0.0064877835,0.12797524,0.33465394,0.000620252,0.00016181891,0.00015073517,0.000062186686,0.5094924],"genre_scores_gemma":[0.93402576,0.0037602212,0.017389735,0.02446771,0.00203486,0.00026567088,0.00006926382,0.00005222119,0.017934533],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97253823,0.016625619,0.0008825148,0.0026011071,0.004338165,0.0030143445],"domain_scores_gemma":[0.9578208,0.030057285,0.0035565046,0.0037507864,0.0032227375,0.001591848],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.032254387,0.0004786797,0.00069946813,0.0023348117,0.0057316325,0.013397438,0.0022485477,0.011073622,0.0052197813],"category_scores_gemma":[0.027954593,0.0005045124,0.0011099725,0.0017839082,0.058208898,0.015118852,0.0057681687,0.0078514,0.00069034897],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000018050771,0.000004622681,0.00006831493,0.000007805451,0.000002396921,0.000019176126,0.00025725193,0.00016204867,0.000015074039,0.99832934,0.00034182306,0.0007903382],"study_design_scores_gemma":[0.000009768413,0.000012611933,0.00013691514,0.00008421273,0.000005710867,0.000041755644,0.00040715953,0.00043709032,0.00009204399,0.98077756,0.017986627,0.000008595777],"about_ca_topic_score_codex":0.0067141494,"about_ca_topic_score_gemma":0.003085679,"teacher_disagreement_score":0.99426836,"about_ca_system_score_codex":0.009466262,"about_ca_system_score_gemma":0.015402111,"threshold_uncertainty_score":0.1705795},"labels":[],"label_agreement":null},{"id":"W2138122752","doi":"10.3329/jce.v27i2.17801","title":"Pharmaceutical Waste Water Treatment &amp; Related Economic Aspects for Reuse in the Context of Bangladesh","year":2014,"lang":"en","type":"article","venue":"Journal of Chemical Engineering","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Reuse; Context (archaeology); Waste management; Water treatment; Wastewater; Environmental science; Business; Engineering; Geography","score_opus":0.03840331859545675,"score_gpt":0.2712852651911948,"score_spread":0.23288194659573802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138122752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9110062,0.0024713236,0.00433461,0.0057787355,0.00002952956,0.00020039084,0.0012813027,0.000013140856,0.074884705],"genre_scores_gemma":[0.99461925,0.0017861805,0.0006550059,0.000053330605,0.0000074903387,0.000034683893,0.00012922839,0.0000038127314,0.0027110106],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991598,0.0003411896,0.000040518462,0.00007410876,0.00023436706,0.0001499543],"domain_scores_gemma":[0.9989083,0.000501927,0.0002257881,0.00004512563,0.00023372624,0.0000851517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077055854,0.0003162653,0.0003765126,0.00092063245,0.00083969673,0.0025139984,0.00036488805,0.0008430519,0.007970542],"category_scores_gemma":[0.0020633512,0.00017789536,0.0004931185,0.0023973386,0.000745012,0.0016571181,0.0008272699,0.0005302277,0.00035438093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001911558,0.0011443001,0.28249368,0.002658698,0.00039484,0.018061565,0.0017417768,0.22560751,0.036740776,0.26777914,0.011909197,0.14955696],"study_design_scores_gemma":[0.00028937624,0.002355841,0.4121198,0.0011683648,0.0005958882,0.004087906,0.06225524,0.17136495,0.039695688,0.17556588,0.12992787,0.00057325873],"about_ca_topic_score_codex":0.033640776,"about_ca_topic_score_gemma":0.03679956,"teacher_disagreement_score":0.033640776,"about_ca_system_score_codex":0.006551581,"about_ca_system_score_gemma":0.0024268932,"threshold_uncertainty_score":0.06688994},"labels":[],"label_agreement":null},{"id":"W2138250448","doi":"10.12927/hcpol.2013.23477","title":"Product Listing Agreements (PLAs): A New Tool for Reaching Quebec's Pharmaceutical Policy Objectives?","year":2013,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Listing (finance); Product (mathematics); Drug pricing; Confidentiality; Business; Pharmaceutical industry; Actuarial science; Public economics; Risk analysis (engineering); Economics; Finance; Law; Medicine; Political science; Pharmacology","score_opus":0.11662815094573493,"score_gpt":0.38250331873034626,"score_spread":0.26587516778461134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138250448","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0306077,0.00864153,0.09404418,0.32698187,0.001413058,0.0007220189,0.0049024667,0.0025660314,0.530121],"genre_scores_gemma":[0.7072555,0.004709881,0.12296918,0.036815006,0.0008128958,0.0005550255,0.001265648,0.00028283766,0.12533398],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929376,0.002709339,0.0002772017,0.00060768286,0.0026052378,0.0008628448],"domain_scores_gemma":[0.98135984,0.00961225,0.0017295848,0.0015226777,0.004481416,0.0012942044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010959086,0.00051716843,0.00051219517,0.003109524,0.004202629,0.010175712,0.0020451096,0.0057335184,0.018712409],"category_scores_gemma":[0.03505482,0.0004642035,0.00053771364,0.0038435971,0.0037100455,0.005533084,0.0017258642,0.0032711504,0.0011248763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006039788,0.000051853694,0.004722783,0.0001754402,0.000023434897,0.0002174727,0.0009555075,0.0066846525,0.00028432006,0.71477425,0.15764268,0.114407174],"study_design_scores_gemma":[0.00017302923,0.0000816279,0.012498566,0.00081293425,0.00006624982,0.00019301646,0.0013468361,0.03236236,0.00079210696,0.12134195,0.8300641,0.00026723006],"about_ca_topic_score_codex":0.9025054,"about_ca_topic_score_gemma":0.90869373,"teacher_disagreement_score":0.9558227,"about_ca_system_score_codex":0.044177283,"about_ca_system_score_gemma":0.074571244,"threshold_uncertainty_score":0.32053012},"labels":[],"label_agreement":null},{"id":"W2138404206","doi":"10.1016/j.jhealeco.2005.07.001","title":"Extraordinary claims require extraordinary evidence","year":2005,"lang":"en","type":"letter","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Michael Smith Health Research BC; University of Victoria","funders":"","keywords":"Intellectual property; Developing country; Exploit; Negative binomial distribution; Profit (economics); Empirical evidence; Economics; Business; Public economics; Computer science; Economic growth; Microeconomics","score_opus":0.2200125721140884,"score_gpt":0.35990576374524014,"score_spread":0.13989319163115174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138404206","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011328143,0.0010553912,0.00057686405,0.97056615,0.0066916607,0.000021209818,0.000092214934,0.00003586669,0.01982789],"genre_scores_gemma":[0.02184171,0.00061113614,0.0006615088,0.9273988,0.040206958,0.000040139763,0.00003403526,0.000030929343,0.009174747],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9880432,0.002691229,0.001437649,0.0021714796,0.003932739,0.0017237348],"domain_scores_gemma":[0.92137295,0.06159328,0.0028874432,0.004290404,0.0053031836,0.004552669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0219255,0.0010129706,0.0036524762,0.0017783806,0.0062240083,0.012415579,0.003392995,0.13360512,0.008714383],"category_scores_gemma":[0.118191175,0.0013807465,0.0021554295,0.0009822681,0.016054384,0.009803742,0.004165083,0.096507564,0.0046635335],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014911644,0.00006469708,0.0010193278,0.00006759181,0.00009554379,0.0041606263,0.00031106942,0.00020634999,0.00025270553,0.18081751,0.8056184,0.007237017],"study_design_scores_gemma":[0.00036947694,0.00006758516,0.0025723234,0.0004646992,0.00014573384,0.0028842632,0.0006384431,0.0026163186,0.0005138125,0.59536356,0.39417857,0.0001852502],"about_ca_topic_score_codex":0.0057936483,"about_ca_topic_score_gemma":0.012723409,"teacher_disagreement_score":0.13360512,"about_ca_system_score_codex":0.0062285964,"about_ca_system_score_gemma":0.0052905604,"threshold_uncertainty_score":0.11595446},"labels":[],"label_agreement":null},{"id":"W2140068746","doi":"10.1017/s0266462309990249","title":"Scanning the horizon of obsolete technologies: Possible sources for their identification","year":2009,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Identification (biology); Agency (philosophy); Nice; Ranking (information retrieval); Health technology; Medicine; Food and drug administration; Emerging technologies; Family medicine; Business; Operations management; Environmental health; Computer science; Health care; Political science; Engineering","score_opus":0.04611526574616532,"score_gpt":0.3792387491165271,"score_spread":0.3331234833703618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140068746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6973687,0.07572047,0.061159488,0.012548888,0.00072471786,0.0013192316,0.013263938,0.0005812688,0.1373133],"genre_scores_gemma":[0.91715604,0.02098583,0.04225942,0.0010320342,0.0004042984,0.00044909603,0.006809646,0.00030377606,0.010599728],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9805322,0.0047471425,0.0024888671,0.0012911833,0.009908724,0.0010318104],"domain_scores_gemma":[0.8526949,0.09515627,0.024823587,0.0066230814,0.019022483,0.001679685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019022316,0.0009289569,0.0010156013,0.031335197,0.0015590428,0.007923464,0.0019360651,0.0020855742,0.012301499],"category_scores_gemma":[0.08277565,0.00062276627,0.0010658066,0.022182861,0.0014911912,0.009885907,0.004811022,0.0016101857,0.0032685674],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010149316,0.00019676905,0.28827906,0.010775064,0.00044544783,0.004241637,0.032374687,0.0009495422,0.0041355477,0.033247016,0.019119011,0.6052213],"study_design_scores_gemma":[0.00013232791,0.00063666585,0.34938464,0.024563668,0.0018129045,0.0110404845,0.109242864,0.006389008,0.013518821,0.045828573,0.43692088,0.00052927877],"about_ca_topic_score_codex":0.0023159746,"about_ca_topic_score_gemma":0.0020691473,"teacher_disagreement_score":0.031335197,"about_ca_system_score_codex":0.0024070549,"about_ca_system_score_gemma":0.0036842423,"threshold_uncertainty_score":0.10060084},"labels":[],"label_agreement":null},{"id":"W2140732319","doi":"10.1377/hlthaff.w4.561","title":"Re-Naming And Re-Gaming: Medicare's Doomed Attempt To Reform Reimbursement For Injectable Drugs","year":2004,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Reimbursement; Modernization theory; Government (linguistics); Medical prescription; Drug; Prescription drug; Public economics; Medicine; Actuarial science; Business; Public administration; Law; Pharmacology; Economics; Political science; Health care","score_opus":0.05815838577290411,"score_gpt":0.3272348721042413,"score_spread":0.2690764863313372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140732319","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051727083,0.0192613,0.010243451,0.8444473,0.0031406211,0.000053321633,0.00019714514,0.00021935192,0.070710495],"genre_scores_gemma":[0.70648795,0.007368431,0.0071427836,0.25178713,0.0049898704,0.00005414356,0.000116218944,0.00010321863,0.021950254],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99297214,0.003420662,0.00019778551,0.00050637656,0.002126339,0.00077664945],"domain_scores_gemma":[0.9888021,0.0062178443,0.0014154946,0.0010022161,0.0012246149,0.001337718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011712362,0.00028243606,0.0003320223,0.0010344549,0.0029587469,0.0068977736,0.0010623074,0.008779208,0.0030526652],"category_scores_gemma":[0.040557843,0.00023755597,0.0005124743,0.0011168274,0.006098114,0.005578026,0.0022158816,0.007492383,0.0004900759],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013943911,0.00006408509,0.004002709,0.0000781013,0.000035332672,0.00013087393,0.0013056906,0.0010119781,0.0004887255,0.7302874,0.19719595,0.06525973],"study_design_scores_gemma":[0.0001455261,0.00016254438,0.019805653,0.00046978524,0.00007747783,0.00033318702,0.001492988,0.004354462,0.0010070454,0.26047418,0.71156687,0.00011023347],"about_ca_topic_score_codex":0.026268356,"about_ca_topic_score_gemma":0.032391146,"teacher_disagreement_score":0.026268356,"about_ca_system_score_codex":0.007161117,"about_ca_system_score_gemma":0.008372599,"threshold_uncertainty_score":0.061941624},"labels":[],"label_agreement":null},{"id":"W2141595217","doi":"10.5430/bmr.v1n4p20","title":"Pharmaceutical Wholesalers Service in Macau: An Investigation from the Perspective of Stakeholders","year":2012,"lang":"en","type":"article","venue":"Business and Management Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Pharmacy; Perspective (graphical); Circulation (fluid dynamics); Service (business); Marketing; Medicine; Nursing; Computer science","score_opus":0.4101102207270177,"score_gpt":0.4059066512492269,"score_spread":0.0042035694777907695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141595217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99032646,0.00010664393,0.00023520821,0.0027162903,0.0000050330486,0.000025044434,0.000015652957,0.0000030590018,0.0065664966],"genre_scores_gemma":[0.99845254,0.00009027674,0.00007139681,0.00021364543,0.0000029300925,0.000010318097,0.0000067245073,0.0000010913885,0.001151033],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.998293,0.0007234699,0.000039090428,0.00009327092,0.0002784027,0.00057289616],"domain_scores_gemma":[0.9976277,0.0009810555,0.0003322293,0.000031759777,0.0003895918,0.0006376099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00163581,0.00012262008,0.00013671201,0.00072209624,0.0038020264,0.002538916,0.000630488,0.0011711981,0.004604982],"category_scores_gemma":[0.0037997083,0.0001931546,0.000120084704,0.0010568575,0.0016009697,0.002154075,0.0018487613,0.00086839264,0.00021372242],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019909658,0.00041689616,0.2923983,0.00037259996,0.000018974166,0.015721379,0.598416,0.00041238748,0.0067674736,0.044159614,0.003031018,0.03808617],"study_design_scores_gemma":[0.00001041051,0.00017481366,0.13565375,0.00013489011,0.000011113279,0.0009366708,0.83342063,0.0014763435,0.0006595273,0.0014604446,0.026043087,0.000018269551],"about_ca_topic_score_codex":0.04626229,"about_ca_topic_score_gemma":0.06472032,"teacher_disagreement_score":0.04626229,"about_ca_system_score_codex":0.0075015016,"about_ca_system_score_gemma":0.007731557,"threshold_uncertainty_score":0.09198606},"labels":[],"label_agreement":null},{"id":"W2141749161","doi":"10.1177/1745790413497388","title":"Product lifecycle management through patents and regulatory strategies","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Marketing Device Diagnostic and Pharmaceutical Marketing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product lifecycle; Business; Product management; New product development; Product (mathematics); Application lifecycle management; Commercialization; European union; Outsourcing; Service product management; Product life-cycle management; Service (business); Process management; Marketing; Service provider; Computer science","score_opus":0.04338497239815697,"score_gpt":0.30866686158725953,"score_spread":0.26528188918910256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141749161","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015196891,0.023908796,0.19440286,0.023397908,0.0011575825,0.0027075114,0.0007455896,0.0025287205,0.73595417],"genre_scores_gemma":[0.47547665,0.042920247,0.23420554,0.013646363,0.0017622767,0.0033135435,0.0027470174,0.0013425151,0.22458592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9813153,0.004223517,0.0014316823,0.0018712811,0.009799834,0.0013584194],"domain_scores_gemma":[0.9765137,0.006156339,0.0036237666,0.0034241732,0.009414632,0.0008674633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024728628,0.0012368202,0.00062430574,0.0054747113,0.0018668434,0.013413627,0.0031750982,0.0030190398,0.014990268],"category_scores_gemma":[0.034611523,0.0005964917,0.0012113554,0.00326262,0.0034413761,0.01277749,0.003969999,0.0037658538,0.010512016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007211454,0.00020093139,0.0012775601,0.0008784826,0.00003003648,0.0004274453,0.0012060874,0.00255978,0.003075413,0.3933762,0.040879466,0.55601645],"study_design_scores_gemma":[0.00004158355,0.0002568612,0.0010643058,0.0013190471,0.000048336446,0.0006495581,0.0006685574,0.002834001,0.005254889,0.07072954,0.91704786,0.00008537657],"about_ca_topic_score_codex":0.003230331,"about_ca_topic_score_gemma":0.0023400187,"teacher_disagreement_score":0.024728628,"about_ca_system_score_codex":0.0059756036,"about_ca_system_score_gemma":0.015298724,"threshold_uncertainty_score":0.13077903},"labels":[],"label_agreement":null},{"id":"W2142000732","doi":"10.1504/ijipm.2006.011024","title":"Pledges and pitfalls: Canada's legislation on compulsory licensing of pharmaceuticals for export","year":2006,"lang":"en","type":"article","venue":"International Journal of Intellectual Property Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; TRIPS architecture; Business; International trade; World trade; TRIPS Agreement; Intellectual property; Law; Political science; Engineering","score_opus":0.06511728233811544,"score_gpt":0.28739083885113015,"score_spread":0.22227355651301473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142000732","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037053593,0.012658661,0.0076166242,0.4527804,0.0028534327,0.00035682842,0.0017333273,0.00045960344,0.48448765],"genre_scores_gemma":[0.44699836,0.00778708,0.008053715,0.35701972,0.0011977974,0.00020640744,0.0008288193,0.0002286252,0.17767946],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9775285,0.0016061978,0.0007532981,0.0016023233,0.014605218,0.0039044588],"domain_scores_gemma":[0.9799501,0.010501604,0.0011987587,0.00093143055,0.0056055468,0.001812451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011551511,0.0007336938,0.00064563606,0.002512178,0.014831251,0.012724079,0.0038366416,0.017933493,0.0071794037],"category_scores_gemma":[0.030963428,0.00093583285,0.0011929895,0.0040899767,0.011028612,0.0052883327,0.0030927556,0.013937769,0.0008707838],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010660175,0.00007711096,0.00389373,0.00022578138,0.00004331684,0.00094825996,0.003985596,0.0012031602,0.00090963003,0.6568597,0.2987819,0.032965206],"study_design_scores_gemma":[0.0001637353,0.00009196717,0.018116096,0.0008686613,0.00012571369,0.0004528173,0.0022408634,0.0019006494,0.0014888769,0.047488183,0.92681164,0.00025081562],"about_ca_topic_score_codex":0.94791836,"about_ca_topic_score_gemma":0.9677081,"teacher_disagreement_score":0.061241228,"about_ca_system_score_codex":0.061241228,"about_ca_system_score_gemma":0.13371515,"threshold_uncertainty_score":0.44433826},"labels":[],"label_agreement":null},{"id":"W2142139579","doi":"10.1126/scitranslmed.aaa2360","title":"Financing translation: Analysis of the NCATS rare-diseases portfolio","year":2015,"lang":"en","type":"review","venue":"Science Translational Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada); Alpha Technologies (Canada)","funders":"National Center for Advancing Translational Sciences; National Institutes of Health","keywords":"Portfolio; Medicine; Translation (biology); Business; Finance; Genetics; Biology","score_opus":0.2232317094537266,"score_gpt":0.3972406493256112,"score_spread":0.1740089398718846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142139579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15487571,0.6354828,0.06459545,0.019486556,0.0005464305,0.0016963326,0.0036118852,0.0001622508,0.119542554],"genre_scores_gemma":[0.72081256,0.24899828,0.020211428,0.00096811727,0.00029758606,0.00089055573,0.0016253917,0.000032388707,0.0061637573],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981634,0.0011818619,0.00007933628,0.00007287273,0.00041584624,0.00008662042],"domain_scores_gemma":[0.9949083,0.0039796913,0.00048817636,0.000091801325,0.00048642384,0.000045725825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053223814,0.00045991444,0.0006160875,0.0011398504,0.00015167047,0.0010963624,0.00070401974,0.0007416197,0.005152308],"category_scores_gemma":[0.015276393,0.000183759,0.00074719015,0.0022099633,0.00028618373,0.0012622284,0.00044086087,0.00060230534,0.00041489318],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041348397,0.00014962762,0.009904456,0.008535203,0.0007433915,0.00042049878,0.00017364361,0.15888926,0.0005583261,0.1722388,0.020047441,0.62792593],"study_design_scores_gemma":[0.0008679913,0.0012446451,0.041016888,0.014632305,0.0027770714,0.0023313432,0.0007671182,0.2752067,0.004333509,0.20991355,0.44677413,0.0001348027],"about_ca_topic_score_codex":0.0042429348,"about_ca_topic_score_gemma":0.003203007,"teacher_disagreement_score":0.0053223814,"about_ca_system_score_codex":0.0027207187,"about_ca_system_score_gemma":0.0037034245,"threshold_uncertainty_score":0.028147757},"labels":[],"label_agreement":null},{"id":"W2144684304","doi":"10.2190/x4xq-y1a8-7lwe-lwma","title":"Globalization and International Trade in the Twenty-First Century: Opportunities for and Threats to the Health Sector in the South","year":2000,"lang":"en","type":"review","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"International Development Research Centre; World Bank Group","keywords":"Globalization; International trade; Developing country; Business; Goods and services; Liberalization; International health; Health care; Free trade; Trade barrier; Global health; Economic growth; Health policy; International economics; Economics; Economy; Market economy","score_opus":0.2126795629489433,"score_gpt":0.40347154867325546,"score_spread":0.19079198572431216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144684304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046615538,0.9931352,0.00003387118,0.0031532838,0.00014950639,0.0000011596383,0.0000031944373,0.0000013867859,0.003056234],"genre_scores_gemma":[0.0032510608,0.99524325,0.000040009556,0.0006624209,0.00016526411,0.0000014713494,0.000004230676,5.8784104e-7,0.0006317411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99960786,0.0001203402,0.000029995437,0.00003877151,0.00016164612,0.00004127013],"domain_scores_gemma":[0.9991561,0.00040618327,0.00016290073,0.000023747021,0.00015777803,0.00009313654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010815035,0.00034474191,0.0007679167,0.0020395294,0.0005808375,0.0028624511,0.0002735203,0.0014689427,0.003036729],"category_scores_gemma":[0.0011802753,0.00019410893,0.0003828545,0.0048372857,0.0019212654,0.0024297787,0.00092964835,0.0010467407,0.000555526],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008666247,0.000091613976,0.0031591966,0.012153989,0.0001244322,0.0004930839,0.0016189561,0.0011123861,0.0007727557,0.07461446,0.04326856,0.86250395],"study_design_scores_gemma":[0.0000161787,0.0000706282,0.0075287838,0.007246263,0.00005124442,0.0008259947,0.0016605973,0.00007796512,0.00018928379,0.020364447,0.96194804,0.000020588759],"about_ca_topic_score_codex":0.004446737,"about_ca_topic_score_gemma":0.008041429,"teacher_disagreement_score":0.004446737,"about_ca_system_score_codex":0.0018401064,"about_ca_system_score_gemma":0.0051864227,"threshold_uncertainty_score":0.013350904},"labels":[],"label_agreement":null},{"id":"W2145692217","doi":"10.2139/ssrn.4362460","title":"AIDS Policy and Pharmaceutical Patents: Brazil’s Strategy to Safeguard Public Health","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Safeguard; Public health; Business; Public policy; Public administration; Political science; International trade; Law; Medicine","score_opus":0.10121770095333617,"score_gpt":0.36222705573137776,"score_spread":0.2610093547780416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145692217","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028698478,0.017008075,0.004582846,0.815431,0.0018417501,0.00018413173,0.0009183436,0.00023719248,0.13109814],"genre_scores_gemma":[0.77183735,0.0112225,0.005766632,0.1592248,0.0034374841,0.0002532816,0.00028466698,0.00013027717,0.047842894],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9916083,0.0025827931,0.00037734056,0.0007417805,0.002630451,0.002059253],"domain_scores_gemma":[0.97097236,0.014280195,0.0027666783,0.0024198296,0.006141906,0.0034191278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016211608,0.00082099263,0.00085567153,0.0033541038,0.0027779858,0.011391168,0.002264474,0.020187832,0.012951707],"category_scores_gemma":[0.054526802,0.000514644,0.0014223509,0.0024714344,0.0065412507,0.006760101,0.0057477634,0.009118319,0.0012592418],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007443898,0.00008437786,0.003141367,0.00041923375,0.00007437775,0.00029383547,0.0007703917,0.0010608445,0.0008630566,0.90158254,0.049136873,0.042498693],"study_design_scores_gemma":[0.00029576683,0.00020392278,0.010390713,0.0019816663,0.00024715497,0.0005041273,0.0011321299,0.0035774552,0.0021140245,0.29432163,0.68513054,0.00010085691],"about_ca_topic_score_codex":0.09610056,"about_ca_topic_score_gemma":0.08415539,"teacher_disagreement_score":0.09610056,"about_ca_system_score_codex":0.017328823,"about_ca_system_score_gemma":0.06251908,"threshold_uncertainty_score":0.19108242},"labels":[],"label_agreement":null},{"id":"W2145803845","doi":"","title":"Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Computer science; Data science; Medicine; World Wide Web","score_opus":0.17617993243603366,"score_gpt":0.290734989946972,"score_spread":0.11455505751093834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145803845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8999897,0.0107483715,0.0019181739,0.034272086,0.00033874996,0.00027166368,0.0040723644,0.0001052092,0.04828359],"genre_scores_gemma":[0.9912949,0.0013300908,0.00087542756,0.0015531818,0.000037856196,0.00004323812,0.0007723219,0.00003404873,0.0040589515],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99290496,0.003045008,0.00035361556,0.00035464496,0.0022910628,0.001050694],"domain_scores_gemma":[0.95848864,0.019162435,0.0018726989,0.0012775959,0.016322888,0.002875789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009834879,0.00041785795,0.0009601837,0.0016402182,0.0028585326,0.0046209786,0.0029371043,0.0020818748,0.005037841],"category_scores_gemma":[0.087549634,0.0004352769,0.0003764767,0.0044694217,0.001881139,0.002043033,0.0013995949,0.003253504,0.0003703317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011659949,0.0018143577,0.41052696,0.00096502854,0.0009781478,0.0016143618,0.004927323,0.046456262,0.0009976288,0.061286863,0.16911371,0.28965938],"study_design_scores_gemma":[0.0021445227,0.0013978498,0.71717536,0.0018585504,0.0019030321,0.00051718426,0.019362634,0.14520055,0.0027105806,0.029303845,0.0776474,0.0007784807],"about_ca_topic_score_codex":0.9791372,"about_ca_topic_score_gemma":0.98540175,"teacher_disagreement_score":0.056987394,"about_ca_system_score_codex":0.056987394,"about_ca_system_score_gemma":0.040649567,"threshold_uncertainty_score":0.41347438},"labels":[],"label_agreement":null},{"id":"W2146907829","doi":"10.1038/sj.clpt.6100074","title":"Tackling Corruption in the Pharmaceutical Systems Worldwide with Courage and Conviction","year":2007,"lang":"en","type":"review","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"World Bank Group","keywords":"Language change; Poverty; Counterfeit; Conviction; Business; Pharmaceutical industry; Economics; Economic growth; Law; Medicine; Political science; Pharmacology","score_opus":0.33285393291899273,"score_gpt":0.4837387517086571,"score_spread":0.15088481878966437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146907829","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039859442,0.98524183,0.0003372273,0.010342383,0.00023443278,0.0000026093599,0.00000302086,0.0000051979596,0.0034346867],"genre_scores_gemma":[0.004776922,0.9916442,0.00035978234,0.0015980621,0.00054105715,0.000003727675,0.0000048212196,0.0000019634383,0.0010693452],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889886,0.00039812093,0.000061646206,0.00008111174,0.00046994738,0.00009020631],"domain_scores_gemma":[0.99763,0.0013927949,0.00034163918,0.00009609953,0.00043798072,0.00010138583],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018358136,0.0005366067,0.00092850206,0.0017858334,0.0007018931,0.00291899,0.0006175525,0.0023573213,0.0018755712],"category_scores_gemma":[0.0028131185,0.00027147512,0.00040153923,0.0035665773,0.002369831,0.003567767,0.000990944,0.0027275456,0.00080301694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029017872,0.0000685304,0.00061967317,0.0065661096,0.0001006453,0.00026401342,0.0005031821,0.0013011589,0.00054919324,0.093392864,0.049835138,0.84677047],"study_design_scores_gemma":[0.000014132631,0.000058135793,0.0022676003,0.007386167,0.00005648973,0.0006689587,0.0005446701,0.0003531137,0.0004290982,0.04394134,0.94425666,0.000023632789],"about_ca_topic_score_codex":0.003140754,"about_ca_topic_score_gemma":0.0038330606,"teacher_disagreement_score":0.9981642,"about_ca_system_score_codex":0.001596974,"about_ca_system_score_gemma":0.00437803,"threshold_uncertainty_score":0.0115869045},"labels":[],"label_agreement":null},{"id":"W2147450289","doi":"10.1345/aph.1p389","title":"Physician Perceptions About Generic Drugs","year":2011,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Family medicine; Descriptive statistics; Likert scale; Generic drug; Logistic regression; Perception; Population; Quarter (Canadian coin); Health care; Environmental health; Drug; Internal medicine; Pharmacology; Psychology","score_opus":0.21927570371910032,"score_gpt":0.36698745182271336,"score_spread":0.14771174810361304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147450289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796371,0.0028719562,0.000523284,0.0040190914,0.00006152961,0.00003879514,0.00022686493,0.000012369624,0.012608945],"genre_scores_gemma":[0.99777645,0.00090947904,0.00017894951,0.00070903054,0.000049906535,0.000005957036,0.000055015586,0.0000016282307,0.00031358522],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9972767,0.0011321238,0.00022938989,0.00014874518,0.0010186657,0.0001942995],"domain_scores_gemma":[0.9844855,0.006370285,0.0057207956,0.00024869537,0.0014950916,0.0016797043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032881128,0.00012622145,0.0002217263,0.00042084412,0.0003800189,0.0009039862,0.00018653,0.0005392984,0.0060619935],"category_scores_gemma":[0.016296469,0.00010658964,0.00038836384,0.00029732424,0.0005379874,0.00046287992,0.00047253544,0.0006528604,0.00039354857],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059466524,0.00025810042,0.9155671,0.00070306653,0.00019832849,0.00077444414,0.014317971,0.0004099961,0.0033710473,0.0006327384,0.004324098,0.0588485],"study_design_scores_gemma":[0.00006569737,0.0012893663,0.9680127,0.00033811003,0.00011397775,0.0025433456,0.014313449,0.0004020037,0.00058600906,0.00043083238,0.01186618,0.000038365513],"about_ca_topic_score_codex":0.002968435,"about_ca_topic_score_gemma":0.0022046336,"teacher_disagreement_score":0.0060619935,"about_ca_system_score_codex":0.0005731521,"about_ca_system_score_gemma":0.0005921583,"threshold_uncertainty_score":0.020279408},"labels":[],"label_agreement":null},{"id":"W2147598538","doi":"10.1016/j.jval.2014.08.1028","title":"The Trend of the Prices Of New Marketed Drugs in Turkey","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Christian ministry; Factory (object-oriented programming); Government (linguistics); Business; Quarter (Canadian coin); Health care; Descriptive statistics; Consumption (sociology); Agricultural economics; Agricultural science; Geography; Economics; Economic growth; Mathematics; Political science; Statistics; Computer science; Environmental science","score_opus":0.07080932889010885,"score_gpt":0.30057025108409685,"score_spread":0.229760922193988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147598538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870402,0.0019386229,0.00033555692,0.003283186,0.00013969737,0.000005047631,0.0025135109,0.000031634885,0.0047124466],"genre_scores_gemma":[0.9969031,0.0008272568,0.00017716837,0.00014462875,0.00007528923,0.0000025137608,0.000857744,0.00000929584,0.0010029578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994783,0.00006381743,0.00007590905,0.00012134282,0.00012766184,0.00013304145],"domain_scores_gemma":[0.9976592,0.00031763734,0.00089880207,0.00005491582,0.000908524,0.00016102297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005817497,0.00024335485,0.00030235128,0.0011582738,0.00024339384,0.0018229532,0.00053120253,0.0011181292,0.0017990231],"category_scores_gemma":[0.0024307233,0.00021847755,0.00044946154,0.0019274013,0.00041201833,0.0010424068,0.00043482217,0.0011195847,0.00043766244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035371457,0.0002873213,0.80049515,0.0010204364,0.00057045463,0.0044507906,0.0022070897,0.021604659,0.008375933,0.031248778,0.042898633,0.08330359],"study_design_scores_gemma":[0.00004213799,0.00016885974,0.9679976,0.00005812924,0.00008607183,0.0010151281,0.001288495,0.008458614,0.0013187935,0.0011060018,0.018403137,0.00005704767],"about_ca_topic_score_codex":0.020819966,"about_ca_topic_score_gemma":0.0135752205,"teacher_disagreement_score":0.020819966,"about_ca_system_score_codex":0.0031923812,"about_ca_system_score_gemma":0.0012739773,"threshold_uncertainty_score":0.04139757},"labels":[],"label_agreement":null},{"id":"W2147650534","doi":"10.5539/gjhs.v7n4p70","title":"R&amp;D Implementation in a Department of Laboratory Medicine and Pathology: A Systematic Review Based on Pharmaceutical Companies","year":2015,"lang":"en","type":"review","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"","keywords":"Productivity; Profitability index; Commercialization; Health care; Business; Cash flow; Marketing; Pharmaceutical industry; Systematic review; Investment (military); MEDLINE; Accounting; Economics; Medicine; Finance","score_opus":0.24407936914804043,"score_gpt":0.5052441182236047,"score_spread":0.2611647490755643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147650534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004232692,0.9909614,0.0005011338,0.0009097305,0.00017939128,0.001108885,0.0012725801,0.000017353612,0.00081684394],"genre_scores_gemma":[0.036777418,0.9568017,0.002197461,0.0011677002,0.00009884361,0.002059716,0.0006509105,0.000012600768,0.00023363825],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.968229,0.0102837775,0.013346358,0.0016197131,0.0057315654,0.0007895564],"domain_scores_gemma":[0.8810785,0.08444789,0.020149639,0.0021457647,0.011254729,0.00092350005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023324447,0.0013924894,0.00620442,0.020326769,0.00093417894,0.0033980592,0.0020012273,0.0018376792,0.0038347032],"category_scores_gemma":[0.10115962,0.00120289,0.0074113435,0.025339788,0.0011590994,0.0042203786,0.0021362281,0.0012668214,0.00046058372],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013614481,0.000019395202,0.0022044429,0.956324,0.00502392,0.00013875881,0.0004739122,0.00008401351,0.00020062475,0.00033955066,0.0015352867,0.033520006],"study_design_scores_gemma":[0.00013435425,0.00014949829,0.006279529,0.942768,0.033372242,0.00027207323,0.0006938426,0.0000780749,0.00028073735,0.0002611131,0.015679365,0.000031194017],"about_ca_topic_score_codex":0.009624494,"about_ca_topic_score_gemma":0.0360356,"teacher_disagreement_score":0.023324447,"about_ca_system_score_codex":0.007060361,"about_ca_system_score_gemma":0.030697903,"threshold_uncertainty_score":0.123352945},"labels":[],"label_agreement":null},{"id":"W2148406648","doi":"10.1345/aph.1a044","title":"Influence of Socioeconomic Status on Drug Selection for the Elderly in Canada","year":2002,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Medicine; Socioeconomic status; Drug; Population; Defined daily dose; Demography; Statin; Internal medicine; Environmental health; Pharmacology","score_opus":0.08166526870339184,"score_gpt":0.3332222127991411,"score_spread":0.25155694409574925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148406648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724615,0.0004892658,0.000041431922,0.000391669,0.000006847467,0.000008630736,0.00080237986,0.0000029837524,0.0010105565],"genre_scores_gemma":[0.9994289,0.00014758123,0.000026985772,0.000040750412,0.000004447948,0.000002174552,0.00026282642,9.378606e-7,0.000085287465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992299,0.00012293852,0.000052717405,0.00008017773,0.00024621506,0.00026803784],"domain_scores_gemma":[0.99731535,0.00022569328,0.001001052,0.00005595925,0.0006879952,0.000713933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004727825,0.00016458484,0.00025168926,0.0008544119,0.0012243039,0.0007746347,0.00044764043,0.0002727284,0.0012489383],"category_scores_gemma":[0.003955695,0.00013571941,0.00039236032,0.0016916639,0.00049829145,0.00021517456,0.0006746411,0.00036689985,0.00008898134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029216852,0.000006413777,0.9985701,0.000004500252,0.000021381498,0.000041067804,0.00006797204,0.000038305257,0.000021523707,0.000016974203,0.00017110069,0.0010115175],"study_design_scores_gemma":[0.0000018236792,0.000006976358,0.9995542,0.0000069347275,0.0000064419683,0.000037779133,0.00013378292,0.000109976216,0.00000928711,0.000008682748,0.00012197034,0.000002029893],"about_ca_topic_score_codex":0.8964907,"about_ca_topic_score_gemma":0.9299645,"teacher_disagreement_score":0.10350931,"about_ca_system_score_codex":0.005294509,"about_ca_system_score_gemma":0.0057937284,"threshold_uncertainty_score":0.20823777},"labels":[],"label_agreement":null},{"id":"W2149939436","doi":"10.1503/cmaj.109-3171","title":"Canada lags behind United States in drug return, reuse and recycling programs","year":2010,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reuse; Toilet; Computer science; Food and drug administration; Work (physics); Flushing; Drug; Business; Risk analysis (engineering); Medicine; Ecology; Biology; Pharmacology; Engineering; Pathology","score_opus":0.016534088556982546,"score_gpt":0.23664467077426815,"score_spread":0.2201105822172856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149939436","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15391944,0.012713795,0.0056084204,0.3360373,0.0015750946,0.00033633807,0.0058319094,0.001108201,0.4828695],"genre_scores_gemma":[0.80131704,0.005951424,0.007400369,0.06623278,0.00021727072,0.00008772321,0.0013976888,0.00014724172,0.117248364],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9940965,0.00039364505,0.00013815331,0.0003911774,0.002554144,0.0024262979],"domain_scores_gemma":[0.9908047,0.0008345698,0.00042400134,0.00021710408,0.0047619725,0.0029576968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025466308,0.00027057252,0.00040931476,0.0022203277,0.0055763335,0.005796855,0.0011741124,0.0019904105,0.01690681],"category_scores_gemma":[0.008432073,0.00036557135,0.000718271,0.00314056,0.0017220785,0.0017684848,0.0019802784,0.0026037944,0.0010456005],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046981045,0.00029642344,0.0609174,0.00037610723,0.00016764576,0.00047379424,0.0012435905,0.0032832122,0.0017786315,0.4269219,0.32817456,0.17589694],"study_design_scores_gemma":[0.00018569762,0.00017438289,0.07614082,0.00044436567,0.00017035013,0.00021299963,0.0026623928,0.0029783307,0.0023823057,0.010544574,0.9039571,0.00014667073],"about_ca_topic_score_codex":0.9866729,"about_ca_topic_score_gemma":0.9934982,"teacher_disagreement_score":0.077443935,"about_ca_system_score_codex":0.077443935,"about_ca_system_score_gemma":0.22698872,"threshold_uncertainty_score":0.5618977},"labels":[],"label_agreement":null},{"id":"W2151809988","doi":"10.1136/bmjopen-2013-004289","title":"Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study","year":2014,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cohort; Patient safety; Pharmacology; Family medicine; Health care; Internal medicine","score_opus":0.09530373278615463,"score_gpt":0.34116526251797635,"score_spread":0.24586152973182174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151809988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405175,0.0005993203,0.00017193091,0.000600671,0.000026101738,0.000090312664,0.003149187,0.0000063368575,0.0013044772],"genre_scores_gemma":[0.99686,0.00042586378,0.000118999524,0.0002772588,0.000022034586,0.00003248067,0.0014644014,0.000005289178,0.00079364644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739766,0.00021532139,0.0001466752,0.000622588,0.0009201992,0.00069752225],"domain_scores_gemma":[0.99236745,0.0005310207,0.003926905,0.0005614524,0.0014714228,0.00114169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002090781,0.0004282374,0.000599429,0.0011792965,0.0023234831,0.0014603289,0.001320955,0.0009818143,0.004141],"category_scores_gemma":[0.0065041985,0.0005445391,0.0012381297,0.0027584422,0.00090959796,0.001022264,0.0010051912,0.0018078329,0.0003205757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024300735,0.000055639604,0.99683446,0.000017507362,0.000111247646,0.000046548474,0.00021762523,0.00003347419,0.000042660406,0.000080460086,0.0006914068,0.0016261253],"study_design_scores_gemma":[0.00006436902,0.00015231434,0.99728954,0.000049789553,0.00012326654,0.00013367625,0.00061868416,0.00037335843,0.000044180353,0.00007505046,0.001055587,0.00002018094],"about_ca_topic_score_codex":0.89580345,"about_ca_topic_score_gemma":0.87451065,"teacher_disagreement_score":0.10419655,"about_ca_system_score_codex":0.007359351,"about_ca_system_score_gemma":0.015339147,"threshold_uncertainty_score":0.2096203},"labels":[],"label_agreement":null},{"id":"W2153297078","doi":"10.1186/2052-3211-7-8","title":"The future of medicines use and access research: using the Journal of Pharmaceutical Policy and Practice as a platform for change","year":2014,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University","funders":"","keywords":"Globe; Pharmacy; Publication; Pharmaceutical policy; Medicine; Access to medicines; Alternative medicine; Public relations; Dissemination; Health policy; Political science; Public health; Family medicine; Nursing","score_opus":0.5367016781329578,"score_gpt":0.5493782482278896,"score_spread":0.012676570094931838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153297078","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014973254,0.03912267,0.0016289477,0.9383787,0.009529567,0.00002929794,0.00005516948,0.00005039134,0.009708005],"genre_scores_gemma":[0.2623192,0.18730457,0.03654429,0.41500217,0.08798698,0.00046788738,0.00020904814,0.0002320168,0.00993375],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9043223,0.064509384,0.0053757946,0.0042809877,0.016964056,0.004547378],"domain_scores_gemma":[0.61939377,0.2661999,0.024130408,0.016982704,0.02897493,0.044318363],"candidate_categories":["scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.11216492,0.0006882203,0.001742924,0.008280525,0.008967053,0.063860275,0.0043427283,0.035966657,0.009695964],"category_scores_gemma":[0.15861715,0.0010355484,0.0010876702,0.008760514,0.04512912,0.06427856,0.014975891,0.018180404,0.002520646],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011207435,0.00024240979,0.002763029,0.002475933,0.00006764078,0.0004809726,0.008462056,0.00029306635,0.0005717896,0.70580685,0.16170458,0.117019646],"study_design_scores_gemma":[0.000042335756,0.00011707451,0.0030312743,0.003965754,0.000030916955,0.0005027908,0.01068302,0.0006328168,0.00032407106,0.33381364,0.64672583,0.00013060369],"about_ca_topic_score_codex":0.0020430526,"about_ca_topic_score_gemma":0.0022249203,"teacher_disagreement_score":0.9361397,"about_ca_system_score_codex":0.010871186,"about_ca_system_score_gemma":0.04129657,"threshold_uncertainty_score":0.59319186},"labels":[],"label_agreement":null},{"id":"W2153458009","doi":"","title":"Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Food and drug administration; Family medicine; Drug approval; Environmental health; Drug; Pharmacology","score_opus":0.1003660951352786,"score_gpt":0.27103814390293113,"score_spread":0.17067204876765252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153458009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562814,0.015344674,0.00025237582,0.0007760234,0.00006159007,0.00010319444,0.013431736,0.000054521046,0.013694452],"genre_scores_gemma":[0.9837818,0.0044704727,0.0006049082,0.00023867295,0.000019895604,0.000037766386,0.007379425,0.000013429701,0.0034535518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778914,0.00016969448,0.00021250281,0.00018061526,0.0012387541,0.00040923702],"domain_scores_gemma":[0.9937808,0.00080700155,0.002496467,0.00006152702,0.0022669802,0.0005872593],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010703212,0.00026313044,0.00026359645,0.0018696791,0.00090317056,0.0011265611,0.00033449568,0.00032494473,0.001662785],"category_scores_gemma":[0.0055293753,0.00017404326,0.00031843188,0.0029835934,0.00039070813,0.0003888217,0.0004743139,0.00038461422,0.00027596313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016067707,0.00007473321,0.90152526,0.0005653061,0.0001995786,0.00088956376,0.0016190854,0.0010369174,0.00090245105,0.0006975078,0.012100928,0.078781925],"study_design_scores_gemma":[0.000024011595,0.000071105074,0.98521936,0.00005916303,0.00006273858,0.00036020295,0.0007308799,0.00042915557,0.00043247567,0.000046071913,0.012546915,0.000017877917],"about_ca_topic_score_codex":0.88468164,"about_ca_topic_score_gemma":0.9008739,"teacher_disagreement_score":0.9989297,"about_ca_system_score_codex":0.0134140365,"about_ca_system_score_gemma":0.009281114,"threshold_uncertainty_score":0.23199493},"labels":[],"label_agreement":null},{"id":"W2153769961","doi":"10.1185/030079904125003250","title":"Generic replacement of clozapine: a simple decision model from a Canadian perspective","year":2004,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Royal Ottawa Mental Health Centre","funders":"","keywords":"Clozapine; Medicine; Schizophrenia (object-oriented programming); Incidence (geometry); Psychiatry","score_opus":0.22165207092856176,"score_gpt":0.4459791323805348,"score_spread":0.22432706145197306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153769961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68577516,0.00612622,0.1568399,0.020998154,0.0007894134,0.003165011,0.018969472,0.00054159143,0.10679508],"genre_scores_gemma":[0.9484731,0.0026105253,0.024395695,0.0007569905,0.00018129367,0.00090269884,0.002346572,0.00003837088,0.020294767],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99792933,0.00084349967,0.000055072,0.00032285607,0.0002317044,0.0006174625],"domain_scores_gemma":[0.99510914,0.0033246307,0.00031675238,0.0000596182,0.0007283661,0.00046144633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031642623,0.0022079432,0.002497134,0.0018374511,0.0015835885,0.0042137285,0.0028365958,0.0033112406,0.01329746],"category_scores_gemma":[0.007702073,0.0012882517,0.00238936,0.0020900618,0.0015602346,0.0013020991,0.0013467086,0.0026649258,0.0006738089],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005598183,0.000081512575,0.0022223284,0.00010323305,0.00011292588,0.000197587,0.00004517287,0.98184925,0.000089796216,0.008184737,0.0018727306,0.0046809204],"study_design_scores_gemma":[0.00035708823,0.00011316536,0.001056016,0.00003626664,0.00017598362,0.000046899764,0.0000673812,0.9927954,0.000038732607,0.004063781,0.0012161251,0.0000331988],"about_ca_topic_score_codex":0.69039255,"about_ca_topic_score_gemma":0.4864464,"teacher_disagreement_score":0.97594863,"about_ca_system_score_codex":0.024051392,"about_ca_system_score_gemma":0.024605224,"threshold_uncertainty_score":0.62286156},"labels":[],"label_agreement":null},{"id":"W2154163772","doi":"10.1177/009286150904300612","title":"A Matrix to Determine Health Economic Viability Throughout Product Development: A Pharmaceutical Industry Perspective","year":2009,"lang":"en","type":"article","venue":"Drug Information Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Market penetration; Reimbursement; New product development; Drug development; Business; Risk analysis (engineering); Product (mathematics); Pharmaceutical industry; Industrial organization; Marketing; Process management; Public economics; Environmental economics; Operations management; Operations research; Management science; Economics; Drug; Health care; Economic growth; Medicine; Pharmacology; Engineering; Mathematics","score_opus":0.05471813702570248,"score_gpt":0.362655317404229,"score_spread":0.3079371803785265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154163772","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39731997,0.0020210603,0.44612738,0.01369196,0.00039038906,0.000885596,0.013780542,0.0006791551,0.12510397],"genre_scores_gemma":[0.8832541,0.0008775831,0.103733964,0.00021050578,0.000157139,0.0002441593,0.0020239037,0.00006424363,0.009434426],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9989588,0.00032578048,0.000078630364,0.000110138295,0.00043513207,0.00009150835],"domain_scores_gemma":[0.9883051,0.008057211,0.0010295408,0.0003189816,0.0019435376,0.00034569166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021311287,0.00044685497,0.0005915756,0.003771554,0.0006603553,0.0034821979,0.0005517385,0.0008852923,0.013202045],"category_scores_gemma":[0.016458154,0.00033827292,0.0006643843,0.0026267187,0.00065433077,0.0032401572,0.0009039665,0.0012768619,0.0010622168],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006268745,0.0003297201,0.041982975,0.00038258833,0.00025896926,0.00079426746,0.00051475305,0.138119,0.0051857936,0.63970274,0.01834127,0.15376103],"study_design_scores_gemma":[0.000098927834,0.00068943424,0.030220756,0.00022160306,0.00016123141,0.00066391646,0.0016214094,0.4811038,0.0048032324,0.43799222,0.04231175,0.000111678644],"about_ca_topic_score_codex":0.00850539,"about_ca_topic_score_gemma":0.008511637,"teacher_disagreement_score":0.013202045,"about_ca_system_score_codex":0.0016526576,"about_ca_system_score_gemma":0.0017492399,"threshold_uncertainty_score":0.044165254},"labels":[],"label_agreement":null},{"id":"W2154209739","doi":"10.7202/019618ar","title":"Quelques réflexions sur des pratiques d’utilisation des médicaments hors cadre médical","year":2009,"lang":"fr","type":"article","venue":"Drogues santé et société","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.0792959884621629,"score_gpt":0.3667453148892661,"score_spread":0.2874493264271032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154209739","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08188822,0.23019055,0.013543538,0.48453662,0.0059658242,0.0001669219,0.00054294476,0.00009906532,0.1830663],"genre_scores_gemma":[0.67955124,0.18399608,0.007654832,0.08836679,0.0053936085,0.0002769409,0.00032535655,0.00011373711,0.034321442],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98102045,0.010191764,0.0011752865,0.0024982197,0.0040819417,0.0010323176],"domain_scores_gemma":[0.94496435,0.038477942,0.0061757504,0.0021424007,0.0063705263,0.001869095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014282606,0.00056014536,0.00078769895,0.0030979365,0.004693897,0.008796541,0.0013748877,0.004973691,0.009449638],"category_scores_gemma":[0.03999824,0.0004609828,0.00075872213,0.0036441116,0.01848615,0.011500948,0.0038104719,0.008456655,0.0015554359],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023052758,0.00022301053,0.024121158,0.0050136377,0.00020431494,0.00083103665,0.26525483,0.00025336765,0.0017819833,0.4212309,0.04194776,0.23890756],"study_design_scores_gemma":[0.000033896005,0.00023877845,0.0369133,0.009492844,0.00010222303,0.0019077872,0.11837508,0.00024825457,0.0009569327,0.07413647,0.75744796,0.00014649284],"about_ca_topic_score_codex":0.023587687,"about_ca_topic_score_gemma":0.028561153,"teacher_disagreement_score":0.023587687,"about_ca_system_score_codex":0.0067038,"about_ca_system_score_gemma":0.013559133,"threshold_uncertainty_score":0.07553452},"labels":[],"label_agreement":null},{"id":"W2154416265","doi":"10.3821/1913-701x-142.1.3.b","title":"Quelques Perspectives Pharmaceutiques Internationales","year":2009,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.06381744080790648,"score_gpt":0.3037903348477171,"score_spread":0.23997289403981065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154416265","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019153984,0.23592713,0.0010465587,0.66734576,0.011515545,0.000015577032,0.00048711014,0.00007722866,0.08166971],"genre_scores_gemma":[0.12251952,0.48460913,0.0039994395,0.1910646,0.042308792,0.000085552485,0.0008643009,0.00018224359,0.15436652],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98779035,0.002220313,0.00038919775,0.0010892018,0.0060474207,0.0024636453],"domain_scores_gemma":[0.9771238,0.0054054344,0.00095160917,0.00084671134,0.012977095,0.0026953593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01131281,0.0015719801,0.0016797323,0.005180637,0.004437846,0.01930367,0.002818453,0.010382277,0.03151015],"category_scores_gemma":[0.018823352,0.0006443064,0.0012839217,0.008275381,0.008834398,0.008224647,0.001809248,0.012241829,0.0029266067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021898093,0.00012772252,0.000830347,0.00069091795,0.000075916476,0.00021736747,0.0006457936,0.0010241215,0.00042529576,0.5057683,0.40511808,0.08485722],"study_design_scores_gemma":[0.00006259258,0.000018141696,0.0024184294,0.0004994851,0.000026477574,0.0000866511,0.0006108571,0.00040630862,0.00015161214,0.029245958,0.96644187,0.000031674488],"about_ca_topic_score_codex":0.7564285,"about_ca_topic_score_gemma":0.7162648,"teacher_disagreement_score":0.7564285,"about_ca_system_score_codex":0.06847093,"about_ca_system_score_gemma":0.087048955,"threshold_uncertainty_score":0.4967937},"labels":[],"label_agreement":null},{"id":"W2155067918","doi":"10.1016/j.jval.2014.03.118","title":"A Comparison Of The Medicare Average Sales Price And The Average Wholesaler Price","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicaid; Medicine; Business; Actuarial science; Health care; Economics","score_opus":0.07900655963932553,"score_gpt":0.32525023505912637,"score_spread":0.24624367541980086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155067918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96088713,0.002891339,0.003938363,0.0029092361,0.00021397442,0.00002084479,0.0017636887,0.0000619343,0.027313538],"genre_scores_gemma":[0.9973441,0.00025173827,0.0008670782,0.00010665849,0.00008925684,0.000004245833,0.000492639,0.000012681522,0.0008315901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986802,0.00054918707,0.000044072207,0.00012407599,0.00050776347,0.000094785515],"domain_scores_gemma":[0.98807716,0.009222547,0.0008297399,0.00046895936,0.0010543248,0.00034737014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023480565,0.00013064753,0.00037058262,0.0010061441,0.00030385103,0.0014411261,0.0006473295,0.0006500958,0.0039390745],"category_scores_gemma":[0.019019682,0.00010091184,0.0005646163,0.0018397578,0.00040265714,0.0013366529,0.00041795295,0.0005988691,0.0002562306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009921055,0.00048069176,0.333097,0.0006988597,0.0010363864,0.0008479283,0.0011638395,0.07572706,0.005366405,0.32730252,0.038352042,0.20600614],"study_design_scores_gemma":[0.0005135913,0.0021010726,0.79896206,0.00010347365,0.00046431023,0.0009304879,0.0018474762,0.13170291,0.003090035,0.037586614,0.0225968,0.00010125999],"about_ca_topic_score_codex":0.011901905,"about_ca_topic_score_gemma":0.009236176,"teacher_disagreement_score":0.011901905,"about_ca_system_score_codex":0.0020980302,"about_ca_system_score_gemma":0.00076529954,"threshold_uncertainty_score":0.02366525},"labels":[],"label_agreement":null},{"id":"W2155126456","doi":"10.1586/erp.09.34","title":"How should we support pharmaceutical innovation?","year":2009,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Incentive; Subsidy; Business; Productivity; Pharmaceutical industry; Risk analysis (engineering); Industrial organization; Marketing; Economics; Medicine; Pharmacology; Economic growth","score_opus":0.21842768923524403,"score_gpt":0.557909442245123,"score_spread":0.33948175300987893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155126456","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051634545,0.015425442,0.00660711,0.92445743,0.0018552573,0.000034069388,0.00010961567,0.00010822409,0.046239465],"genre_scores_gemma":[0.67674136,0.04649731,0.010471602,0.23184447,0.013606952,0.0002553123,0.00010475647,0.00009939685,0.020378841],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9897198,0.004933428,0.00034292194,0.00080999616,0.0026942973,0.0014994523],"domain_scores_gemma":[0.9612858,0.024490284,0.004900958,0.0016943251,0.0044713784,0.0031572082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012886019,0.0005166811,0.0010397047,0.0020475597,0.002342585,0.010548921,0.0011020693,0.01206916,0.012591356],"category_scores_gemma":[0.067815654,0.00033610966,0.000624826,0.0021126834,0.009640697,0.01729806,0.0031890175,0.0073965974,0.003010658],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042906293,0.00009742521,0.0014222712,0.0002952141,0.000052740827,0.00008947942,0.00022457376,0.0017468602,0.00013369675,0.9016223,0.054991126,0.03928139],"study_design_scores_gemma":[0.000071217924,0.000035467005,0.0010345636,0.0002972495,0.000016768292,0.00005224685,0.00027463882,0.0010026001,0.00013089764,0.84127253,0.15578905,0.000022753584],"about_ca_topic_score_codex":0.0052756276,"about_ca_topic_score_gemma":0.002284686,"teacher_disagreement_score":0.012886019,"about_ca_system_score_codex":0.005462043,"about_ca_system_score_gemma":0.012130719,"threshold_uncertainty_score":0.06814861},"labels":[],"label_agreement":null},{"id":"W2155298214","doi":"10.1016/j.healthpol.2008.12.002","title":"Pricing of multiple dosage prescription medications: An analysis of the Ontario Drug Benefit Formulary","year":2009,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Formulary; Generic drug; Listing (finance); Business; Actuarial science; Medical prescription; Drug; Drug pricing; Medicine; Pharmacology; Finance","score_opus":0.06052141823828256,"score_gpt":0.34002259709760074,"score_spread":0.2795011788593182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155298214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92820364,0.0028778887,0.005112849,0.009701077,0.0000621878,0.00030708913,0.0032284246,0.00009383713,0.050412975],"genre_scores_gemma":[0.9742967,0.0013643219,0.002355576,0.00028593486,0.00007047762,0.000054118547,0.0010418072,0.000030655407,0.020500448],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99788743,0.0004174161,0.00006338216,0.00013962727,0.0007456118,0.00074650574],"domain_scores_gemma":[0.99405646,0.0032319992,0.00074037554,0.00023838031,0.0011868902,0.00054588594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002496577,0.0005269362,0.0011650731,0.0014653864,0.0023184658,0.0037585045,0.0020500137,0.0020255512,0.009412456],"category_scores_gemma":[0.013009275,0.0008266195,0.0016152282,0.002642569,0.0014892699,0.0019214838,0.0009305169,0.0017504425,0.00032934418],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017922904,0.0010073752,0.123325765,0.0005209561,0.0006474083,0.0015735151,0.0019223398,0.34314865,0.0023086509,0.3937337,0.057184715,0.072834626],"study_design_scores_gemma":[0.0005683404,0.0004166236,0.21258497,0.00013073174,0.0006915366,0.0002790238,0.002071664,0.70602566,0.0008490247,0.04466078,0.031530686,0.00019092218],"about_ca_topic_score_codex":0.9260979,"about_ca_topic_score_gemma":0.9444244,"teacher_disagreement_score":0.07390207,"about_ca_system_score_codex":0.0484297,"about_ca_system_score_gemma":0.030962693,"threshold_uncertainty_score":0.3513837},"labels":[],"label_agreement":null},{"id":"W2156182284","doi":"10.1016/j.healthpol.2010.04.001","title":"Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector","year":2010,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Decree; Private sector; Government (linguistics); Enforcement; Business; Essential medicines; Pharmacy; Public sector; Distribution (mathematics); Public economics; Economic growth; Economics; Medicine; Economy; Health care; Law; Family medicine","score_opus":0.062318028672044556,"score_gpt":0.40377774122570437,"score_spread":0.3414597125536598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156182284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97073215,0.0011142523,0.0008086899,0.008572242,0.00006625653,0.00009957862,0.0013021122,0.000029860026,0.017274698],"genre_scores_gemma":[0.9971419,0.0003439855,0.00018733514,0.0004347559,0.000042173906,0.000034534616,0.00019998112,0.0000039521487,0.001611413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955474,0.0021148177,0.00017109141,0.00020097914,0.0006573501,0.001308322],"domain_scores_gemma":[0.98307,0.011261647,0.0032748892,0.00029145848,0.0015032227,0.00059880834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00460688,0.00037817145,0.0005553915,0.00081088865,0.00055397913,0.0033753817,0.0009594096,0.0018018965,0.0039429977],"category_scores_gemma":[0.015356853,0.0003667757,0.0011198934,0.0012763421,0.0012290773,0.0011912368,0.0013684174,0.002149706,0.00026032762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009160925,0.0021061115,0.45807728,0.0016993026,0.0019229755,0.003771499,0.0016719014,0.2083647,0.011057223,0.2260304,0.013667927,0.06246977],"study_design_scores_gemma":[0.00089901016,0.0033136716,0.831936,0.0002986529,0.0011027725,0.00033863555,0.0036873757,0.1120607,0.009141687,0.020111874,0.016961038,0.00014854045],"about_ca_topic_score_codex":0.062477387,"about_ca_topic_score_gemma":0.052621726,"teacher_disagreement_score":0.062477387,"about_ca_system_score_codex":0.013775301,"about_ca_system_score_gemma":0.007021294,"threshold_uncertainty_score":0.124227464},"labels":[],"label_agreement":null},{"id":"W2157246911","doi":"10.1007/s12630-013-9920-z","title":"Drug shortages in Canadian anesthesia: a national survey","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Anesthesia/Journal canadien d anesthésie","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Ottawa Hospital; Capital District Health Authority; University of Ottawa; Dalhousie University","funders":"","keywords":"Economic shortage; Anesthesia; Medicine","score_opus":0.03657152801939509,"score_gpt":0.24802814337633716,"score_spread":0.21145661535694207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157246911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94397837,0.0032368433,0.00013935933,0.0053142165,0.00005788838,0.00014079662,0.038353454,0.000032430442,0.008746752],"genre_scores_gemma":[0.9829584,0.003556445,0.00027305516,0.0013986717,0.00004175927,0.00006345032,0.009387498,0.000008935705,0.0023118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979874,0.00008201581,0.0001931406,0.00013084857,0.0010324076,0.00057421],"domain_scores_gemma":[0.9920968,0.00033910613,0.0022387037,0.00011386707,0.0031962355,0.0020152512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011492759,0.00032269422,0.000407985,0.0029580432,0.0018798332,0.0011675485,0.001457882,0.001047959,0.0036683867],"category_scores_gemma":[0.0055180616,0.0005173203,0.0007534264,0.00840966,0.00056707894,0.00082334527,0.0010968774,0.0011319509,0.00042714132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059694998,0.0001074221,0.9817492,0.000117787065,0.000077216515,0.00007822678,0.0008284448,0.00014069464,0.000082654995,0.00017373949,0.011069378,0.0055155177],"study_design_scores_gemma":[0.0000037413984,0.000008529961,0.9972646,0.000020023353,0.000008904581,0.000028033583,0.00057203043,0.0000917086,0.0000118564985,0.0000075657435,0.0019747426,0.000008215529],"about_ca_topic_score_codex":0.99291116,"about_ca_topic_score_gemma":0.99555826,"teacher_disagreement_score":0.9673988,"about_ca_system_score_codex":0.032601204,"about_ca_system_score_gemma":0.04367931,"threshold_uncertainty_score":0.23653942},"labels":[],"label_agreement":null},{"id":"W2157428390","doi":"10.2139/ssrn.946395","title":"Informational Spillovers and Strategic Launch Delay of Pharmaceutical Drugs","year":2006,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Health Economics Association","funders":"","keywords":"Business; Industrial organization; Marketing; Process management","score_opus":0.024375922371507697,"score_gpt":0.2646331026692938,"score_spread":0.2402571802977861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157428390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94762963,0.002213309,0.00896805,0.006244074,0.00010284694,0.000064260734,0.0005159722,0.00015452087,0.034107506],"genre_scores_gemma":[0.9975013,0.00033895683,0.00026488895,0.000106905776,0.00005643761,0.0000060099155,0.000037728663,0.000005080247,0.0016825747],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99886864,0.00031781322,0.00008493252,0.00015310207,0.00019288686,0.00038256927],"domain_scores_gemma":[0.9345028,0.046551935,0.013518366,0.0016683484,0.0016287751,0.0021298653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043534567,0.0004687166,0.0010963916,0.0013972337,0.00073125144,0.0037604317,0.00073471817,0.0029750806,0.017873548],"category_scores_gemma":[0.03939348,0.00058836705,0.0006494921,0.001030617,0.0012296998,0.0039625936,0.0015052975,0.0026528374,0.0011893671],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011520995,0.002998703,0.12448569,0.0011854842,0.00071542984,0.004345031,0.0024573973,0.19980289,0.016553918,0.4607133,0.019821092,0.15540007],"study_design_scores_gemma":[0.0015509435,0.0032354074,0.14726,0.00020607388,0.0012740386,0.0014157619,0.004315557,0.22776112,0.011000705,0.5899445,0.011625328,0.00041061395],"about_ca_topic_score_codex":0.0027351766,"about_ca_topic_score_gemma":0.002844086,"teacher_disagreement_score":0.017873548,"about_ca_system_score_codex":0.0019515649,"about_ca_system_score_gemma":0.0015092561,"threshold_uncertainty_score":0.059792995},"labels":[],"label_agreement":null},{"id":"W2157607103","doi":"10.1504/ijtip.2004.004925","title":"A wealth of failures: sensemaking in a pharmaceutical R&amp;D pipeline","year":2004,"lang":"en","type":"article","venue":"International Journal of Technology Intelligence and Planning","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Illinois at Urbana-Champaign; Canada Research Chairs","keywords":"Shadow (psychology); Sensemaking; Investment (military); Pipeline (software); Business; Proposition; Economics; Marketing; Industrial organization; Computer science; Knowledge management; Political science; Psychology","score_opus":0.09550204824972933,"score_gpt":0.37904234430300304,"score_spread":0.2835402960532737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157607103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631204,0.00041183224,0.011967294,0.0034839732,0.00002149647,0.000030399591,0.000044022418,0.000035870034,0.020884784],"genre_scores_gemma":[0.9981179,0.00008871163,0.0011627887,0.00006938251,0.0000067799156,0.000007636513,0.000012918247,0.0000054616416,0.0005284206],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9920351,0.0045981337,0.0002738736,0.00076310843,0.0015257271,0.0008040607],"domain_scores_gemma":[0.9776544,0.012250002,0.0050479244,0.0013807932,0.0010687846,0.0025980917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010163281,0.00031149213,0.00038818637,0.002415489,0.0031125173,0.007695105,0.0008089353,0.0017198339,0.0032195265],"category_scores_gemma":[0.03801592,0.00061209034,0.00043957445,0.0012724724,0.011287361,0.010133095,0.011600057,0.002190755,0.00034505644],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001407317,0.0005693975,0.16397743,0.00034382436,0.00013973983,0.006490157,0.44771305,0.008065246,0.009731707,0.1351266,0.0047055287,0.22173],"study_design_scores_gemma":[0.00009611729,0.0010406965,0.13693249,0.00037697228,0.0000798421,0.0036185507,0.5273881,0.017062273,0.0023803792,0.269316,0.041344788,0.00036382847],"about_ca_topic_score_codex":0.0017546245,"about_ca_topic_score_gemma":0.0015505899,"teacher_disagreement_score":0.010163281,"about_ca_system_score_codex":0.0017885768,"about_ca_system_score_gemma":0.0017102072,"threshold_uncertainty_score":0.053749204},"labels":[],"label_agreement":null},{"id":"W2158310952","doi":"10.1016/s0140-6736(02)09096-7","title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","year":2002,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":882,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Private sector; Public health; Pharmaceutical industry; Drug development; Developing country; Business; Market failure; Medicine; Disease; Neglected tropical diseases; Agency (philosophy); Economic growth; Public economics; Drug; Economics; Pharmacology","score_opus":0.15799736751510596,"score_gpt":0.3480298722680117,"score_spread":0.19003250475290573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158310952","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028091116,0.91691595,0.0006162519,0.07892991,0.0011224954,0.0000063535886,0.000054352196,0.000016624484,0.0020572215],"genre_scores_gemma":[0.0068354625,0.97366107,0.0007286242,0.01544341,0.0026515732,0.000014919162,0.000036426587,0.000008483173,0.00061997934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580956,0.001744111,0.0003264903,0.00024497058,0.0015670763,0.00030788616],"domain_scores_gemma":[0.9745744,0.018735409,0.0026306792,0.00050118245,0.002655505,0.00090291724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012477672,0.0012767179,0.0037395537,0.003954051,0.0007661975,0.0054136687,0.0017997493,0.008459034,0.0054708933],"category_scores_gemma":[0.02044174,0.0006572918,0.0007124402,0.006391279,0.0052734814,0.007795529,0.0022741172,0.0057393443,0.0013954644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021547548,0.00015254777,0.0006985575,0.015227401,0.00033208748,0.00034255863,0.00013762983,0.0017405793,0.00040464042,0.13220342,0.15650073,0.69204444],"study_design_scores_gemma":[0.00026027614,0.00016793283,0.0025466692,0.017926486,0.0002816925,0.0011644927,0.000482014,0.0010349451,0.0003864848,0.19914049,0.77654886,0.000059572147],"about_ca_topic_score_codex":0.0052437717,"about_ca_topic_score_gemma":0.00886031,"teacher_disagreement_score":0.012477672,"about_ca_system_score_codex":0.0065482706,"about_ca_system_score_gemma":0.01610908,"threshold_uncertainty_score":0.06598902},"labels":[],"label_agreement":null},{"id":"W2158413176","doi":"10.12927/hcpap..16873","title":"Taking Our Medicine: Who Should Pay for What?","year":2004,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Liberian dollar; Point (geometry); Risk analysis (engineering); Actuarial science; Law and economics; Business; Engineering ethics; Economics; Engineering; Finance; Mathematics","score_opus":0.21902921022448749,"score_gpt":0.3804007118734278,"score_spread":0.1613715016489403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158413176","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007598232,0.07748308,0.00033827295,0.9095006,0.010969278,0.000004448688,0.000034882523,0.000009229841,0.0015842173],"genre_scores_gemma":[0.009276128,0.1728218,0.0012201144,0.73698413,0.074342296,0.00008510557,0.00006813239,0.000037797865,0.0051644985],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98941433,0.0063789156,0.00087764766,0.000557821,0.0024469267,0.00032438795],"domain_scores_gemma":[0.9038596,0.07740646,0.0035892406,0.0026804018,0.010401539,0.0020628031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019346546,0.00085630285,0.0024613591,0.0019437354,0.001917073,0.006503148,0.0027479513,0.016608832,0.005256614],"category_scores_gemma":[0.07878362,0.0007323711,0.0012794805,0.0020760165,0.006570244,0.010633793,0.0016192404,0.021882946,0.002826911],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031551193,0.000016013388,0.00012938878,0.00029490414,0.000027649872,0.000105564264,0.00010167014,0.0001806766,0.000010255216,0.025476377,0.9384427,0.035183184],"study_design_scores_gemma":[0.00008495724,0.00003253576,0.0005787059,0.0034000534,0.00005408215,0.0004546202,0.0003438305,0.00074350263,0.000039425307,0.106591694,0.88763654,0.000040063656],"about_ca_topic_score_codex":0.012031823,"about_ca_topic_score_gemma":0.019186126,"teacher_disagreement_score":0.019346546,"about_ca_system_score_codex":0.010399541,"about_ca_system_score_gemma":0.012373297,"threshold_uncertainty_score":0.102315545},"labels":[],"label_agreement":null},{"id":"W2158467616","doi":"10.18553/jmcp.2009.15.1.71","title":"Prior Authorization and Clopidogrel Use - The Truth Lies in the Details","year":2009,"lang":"en","type":"editorial","venue":"Journal of Managed Care Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prior authorization; Clopidogrel; Authorization; Internal medicine; Aspirin; Pharmacology; Computer security","score_opus":0.05385844944678472,"score_gpt":0.3197232124911843,"score_spread":0.26586476304439954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158467616","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001164633,0.011884646,0.0001237827,0.102546476,0.8841662,0.000014608013,0.0000740086,0.000036638066,0.0010371885],"genre_scores_gemma":[0.0009046652,0.0058205808,0.000085583066,0.0288247,0.9619539,0.000015844354,0.000018483095,0.000019902367,0.0023564138],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99431866,0.0013987846,0.0011459109,0.0007659286,0.0020469846,0.0003237129],"domain_scores_gemma":[0.958324,0.028852036,0.0016224919,0.0010423335,0.00812429,0.0020349007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0097483825,0.0034374748,0.003765487,0.002323388,0.0028554408,0.0055397786,0.0040326845,0.023762472,0.0070366138],"category_scores_gemma":[0.04871322,0.0014451466,0.0022364394,0.0017875886,0.0036354961,0.00616953,0.0012184683,0.032016397,0.0038120504],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059674654,0.00002234541,0.00009780171,0.00022432877,0.000024457004,0.00013241445,0.00002483144,0.000032931093,0.000023909013,0.0006250964,0.9928402,0.005892048],"study_design_scores_gemma":[0.00033729832,0.00010203597,0.0018490808,0.002053922,0.00018791841,0.000671258,0.00016787581,0.0006574964,0.00021905701,0.004291931,0.98939973,0.000062471205],"about_ca_topic_score_codex":0.00462009,"about_ca_topic_score_gemma":0.0075159892,"teacher_disagreement_score":0.023762472,"about_ca_system_score_codex":0.003494127,"about_ca_system_score_gemma":0.0037114643,"threshold_uncertainty_score":0.051554978},"labels":[],"label_agreement":null},{"id":"W2158818165","doi":"10.2139/ssrn.1818243","title":"Access Delayed, Access Denied: Waiting for New Medicines in Canada: 2010 Report","year":2010,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Access to medicines; Business; Internet privacy; Medicine; Computer security; Computer science; Nursing; Public health","score_opus":0.0512746259876294,"score_gpt":0.3188238063129418,"score_spread":0.26754918032531244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158818165","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66722554,0.011057913,0.00042244248,0.10748087,0.0008189784,0.00045106083,0.18005145,0.00015635786,0.032335445],"genre_scores_gemma":[0.9062911,0.011507438,0.0005681244,0.014643355,0.0005523438,0.00010751351,0.03230003,0.000075873795,0.03395429],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971507,0.00006652483,0.00017703214,0.00014988572,0.001234337,0.0012215113],"domain_scores_gemma":[0.9865339,0.0005122904,0.0027232587,0.000113452996,0.005721483,0.0043957564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001068746,0.0003963586,0.00055831496,0.0016192171,0.002742659,0.003060622,0.0019269373,0.0028071683,0.004467343],"category_scores_gemma":[0.0052807177,0.00049287017,0.00078391255,0.005319136,0.00083361263,0.0011093293,0.001319815,0.004499762,0.00045186118],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049228984,0.00031899774,0.73071885,0.00048681512,0.00021925023,0.0011347254,0.0012914389,0.0009081102,0.00025788942,0.0015337453,0.23888724,0.023750583],"study_design_scores_gemma":[0.00010371401,0.000082874256,0.9490588,0.00030854455,0.00032187757,0.0004871069,0.006585621,0.001676899,0.0003786981,0.0002834479,0.04061409,0.00009836006],"about_ca_topic_score_codex":0.99702966,"about_ca_topic_score_gemma":0.9989322,"teacher_disagreement_score":0.94338024,"about_ca_system_score_codex":0.056619756,"about_ca_system_score_gemma":0.1692968,"threshold_uncertainty_score":0.410807},"labels":[],"label_agreement":null},{"id":"W2158936341","doi":"10.4212/cjhp.v66i6.1297","title":"Drug Shortages through the Decades: A Big-Picture Perspective","year":2013,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacy; Negotiation; Economic shortage; Pooling; Purchasing; Business; Health care; Perspective (graphical); Pharmacist; Product (mathematics); Pharmaceutical industry; Marketing; Medicine; Nursing; Political science; Economic growth; Economics; Pharmacology","score_opus":0.04306039342203261,"score_gpt":0.28697491198936326,"score_spread":0.24391451856733065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158936341","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10525918,0.064380184,0.002279359,0.7156512,0.0018915851,0.00006889171,0.0025870048,0.00006889231,0.10781369],"genre_scores_gemma":[0.86996275,0.07008786,0.0010895246,0.04540844,0.0033925327,0.000059699236,0.0009055878,0.0000513487,0.009042264],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936384,0.0001408474,0.000035168254,0.00006462581,0.00017246242,0.00022306186],"domain_scores_gemma":[0.9947508,0.0016558999,0.0011691548,0.000113376474,0.0008038526,0.001506978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023655533,0.00047385137,0.0005254328,0.0037200365,0.0021252371,0.0061771357,0.00081041356,0.002410597,0.011690955],"category_scores_gemma":[0.0057422617,0.00033693918,0.00044432338,0.0048772823,0.002521309,0.010223047,0.0027018944,0.003891731,0.0005540269],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045013562,0.00055337383,0.10942018,0.0011818915,0.00022507846,0.0015880461,0.0062520993,0.0044804076,0.00037841708,0.45880315,0.2143632,0.20230402],"study_design_scores_gemma":[0.00013826607,0.00042869183,0.20666714,0.003587331,0.0001718001,0.0011228878,0.034673035,0.0051592607,0.00048283336,0.32579944,0.42161664,0.00015261315],"about_ca_topic_score_codex":0.030713446,"about_ca_topic_score_gemma":0.059403878,"teacher_disagreement_score":0.96928656,"about_ca_system_score_codex":0.007085585,"about_ca_system_score_gemma":0.0047453125,"threshold_uncertainty_score":0.06106931},"labels":[],"label_agreement":null},{"id":"W2159056885","doi":"","title":"Effects of 'Authorized-Generics' on Canadian Drug Prices","year":2007,"lang":"en","type":"article","venue":"Social and Economic Dimensions of an Aging Population Research Papers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Business; Earnings; Competitor analysis; Competition (biology); Brand names; Incentive; Market share; Prescription drug; Monetary economics; Product (mathematics); Advertising; Economics; Medical prescription; Marketing; Microeconomics; Finance; Pharmacology","score_opus":0.0706960881479631,"score_gpt":0.3656404973994411,"score_spread":0.294944409251478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159056885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69517726,0.004199009,0.0012974713,0.027024705,0.00036836186,0.0002024095,0.01839406,0.00018951918,0.25314716],"genre_scores_gemma":[0.9793444,0.0010818391,0.0004090476,0.0015112507,0.00006413455,0.000019185538,0.0020201064,0.000051211373,0.015498884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932875,0.0005781311,0.0001807225,0.00055410236,0.0039233267,0.001476173],"domain_scores_gemma":[0.98489815,0.0033604978,0.0026252512,0.0005065862,0.006619179,0.0019903125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002256201,0.00040708116,0.0004826836,0.0017855153,0.003710886,0.005087668,0.0014552613,0.0010306608,0.015170856],"category_scores_gemma":[0.021050835,0.0003775679,0.0012294169,0.0032792652,0.0016003129,0.0012476079,0.0013581475,0.002218032,0.00062334107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096279546,0.00032063446,0.76507086,0.00043377865,0.0005371842,0.00095491804,0.003898736,0.008719689,0.0019488977,0.06185866,0.07699251,0.0783013],"study_design_scores_gemma":[0.00007704771,0.00012380976,0.9063821,0.00010089891,0.00020347668,0.00017152078,0.0027993752,0.00486549,0.0012032371,0.0016118765,0.0822863,0.00017482952],"about_ca_topic_score_codex":0.99229395,"about_ca_topic_score_gemma":0.9929502,"teacher_disagreement_score":0.09192766,"about_ca_system_score_codex":0.09192766,"about_ca_system_score_gemma":0.058443937,"threshold_uncertainty_score":0.66698503},"labels":[],"label_agreement":null},{"id":"W2159099688","doi":"10.1586/14737167.2014.868313","title":"Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor","year":2013,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Economics; Ticagrelor; Set (abstract data type); Frontier; Efficient frontier; Microeconomics; Actuarial science; Public economics; Econometrics; Financial economics; Medicine; Computer science; Internal medicine","score_opus":0.1267396604495972,"score_gpt":0.5269130122506183,"score_spread":0.4001733518010211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159099688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57655877,0.016708257,0.33235812,0.0073183137,0.00042057913,0.0007749575,0.0028314642,0.00021442048,0.06281519],"genre_scores_gemma":[0.94166714,0.0020775523,0.052730158,0.00038628856,0.000063359104,0.00023163116,0.000931264,0.000044924567,0.0018677966],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99028945,0.006573017,0.0002935938,0.0005523074,0.0018160075,0.00047565447],"domain_scores_gemma":[0.9842308,0.013714254,0.0006947086,0.00059027266,0.0006863293,0.000083566425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014947428,0.0006545453,0.0010077356,0.0025124957,0.00052613317,0.0032377802,0.0010093258,0.0018732705,0.0020228117],"category_scores_gemma":[0.035383753,0.0002825772,0.0011626508,0.0029505235,0.0014546134,0.0031133962,0.0017592921,0.0016597006,0.00018370942],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010606975,0.00015207031,0.008811821,0.0008006007,0.00027033512,0.0004288148,0.00045107055,0.30495235,0.00065274176,0.503693,0.008011506,0.17071499],"study_design_scores_gemma":[0.0005134972,0.0009581938,0.04764071,0.0007668482,0.0004089736,0.0004077986,0.0016788208,0.6762391,0.0032892057,0.23965655,0.028202198,0.00023814666],"about_ca_topic_score_codex":0.0170618,"about_ca_topic_score_gemma":0.007402863,"teacher_disagreement_score":0.0170618,"about_ca_system_score_codex":0.00724663,"about_ca_system_score_gemma":0.002558801,"threshold_uncertainty_score":0.07905048},"labels":[],"label_agreement":null},{"id":"W2159386167","doi":"10.1503/cmaj.109-4716","title":"Putting patients first in the age of pharma","year":2014,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Alliance; Drug industry; Health professionals; Medicine; Global health; Alternative medicine; Drug approval; Business; Family medicine; Political science; Public relations; Engineering ethics; Nursing; Health care; Drug; Public health; Pathology; Engineering; Pharmacology; Law","score_opus":0.024014485658968254,"score_gpt":0.24669898776605353,"score_spread":0.2226845021070853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159386167","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014187874,0.002796249,0.0012961973,0.9649375,0.012213065,0.000014919201,0.000038919825,0.00008550599,0.01719889],"genre_scores_gemma":[0.054377586,0.0030663575,0.0026124872,0.89392966,0.012857107,0.00005794293,0.00007222945,0.00023926534,0.03278749],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9674919,0.014837951,0.001506157,0.002489727,0.008136127,0.0055381376],"domain_scores_gemma":[0.92982614,0.016399622,0.0044071535,0.0037891536,0.009897502,0.03568049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019644063,0.0010017372,0.0014425734,0.0010696184,0.014722311,0.02691771,0.0019731412,0.031145643,0.041366667],"category_scores_gemma":[0.08257686,0.0010830159,0.0013964862,0.0007511617,0.01582815,0.033522137,0.017201455,0.059465867,0.014584935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001381742,0.00012169168,0.0013934759,0.00013640303,0.00004099493,0.000754211,0.0035375936,0.0000713853,0.00041547744,0.10142686,0.86700743,0.024956483],"study_design_scores_gemma":[0.00007409641,0.00015022384,0.00068336434,0.00054505444,0.00002131123,0.0009454075,0.006662537,0.00011682288,0.00038911574,0.07662804,0.91369826,0.00008587468],"about_ca_topic_score_codex":0.0026301937,"about_ca_topic_score_gemma":0.006325184,"teacher_disagreement_score":0.041366667,"about_ca_system_score_codex":0.0050792852,"about_ca_system_score_gemma":0.021303501,"threshold_uncertainty_score":0.1383853},"labels":[],"label_agreement":null},{"id":"W2159480705","doi":"10.7939/r39g5gf7c","title":"Challenges for Intellectual Property Management of HIV Vaccine-Related Research and Development: Part 2, The Canadian Context","year":2014,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"HIV vaccine; Context (archaeology); Government (linguistics); Economic growth; Political science; Public health; Global health; Public relations; Health care; Medicine; Public administration; Human immunodeficiency virus (HIV); Immunology; Economics; Vaccine trial","score_opus":0.2698144403549777,"score_gpt":0.2967032603739566,"score_spread":0.02688882001897891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159480705","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004137889,0.032765005,0.004012303,0.8361314,0.0024652786,0.00036723257,0.00032196418,0.00015026568,0.11964861],"genre_scores_gemma":[0.31232527,0.113569215,0.021993833,0.41684148,0.008338452,0.0008371932,0.00082599366,0.00040860297,0.12485996],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.90731627,0.016256774,0.0041761044,0.00686956,0.04841788,0.016963504],"domain_scores_gemma":[0.6925616,0.10969624,0.013475002,0.013953754,0.11735641,0.052956965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10093569,0.0014406211,0.0022370673,0.010224326,0.036945604,0.06145303,0.0112004215,0.032806177,0.016343271],"category_scores_gemma":[0.14979476,0.0017105116,0.002049295,0.0119705405,0.0504102,0.021304784,0.014093161,0.026860476,0.0019613255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006923525,0.00012088529,0.0017797786,0.0005684867,0.000076804645,0.0010399178,0.0041662077,0.0008547142,0.00036625477,0.7376827,0.17974287,0.07353221],"study_design_scores_gemma":[0.0000968684,0.00007954738,0.0032300819,0.0018391871,0.000074964184,0.00058414944,0.0053436565,0.0015674689,0.00044648323,0.16316801,0.823305,0.00026457824],"about_ca_topic_score_codex":0.923504,"about_ca_topic_score_gemma":0.9113962,"teacher_disagreement_score":0.8223231,"about_ca_system_score_codex":0.17767689,"about_ca_system_score_gemma":0.53412825,"threshold_uncertainty_score":0.95377827},"labels":[],"label_agreement":null},{"id":"W2159809648","doi":"10.1503/cmaj.120527","title":"Canadian drug shortage: recent history of a mystery","year":2012,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Economic shortage; Prochlorperazine; Street drugs; Medicine; Pharmacist; Drug; Computer science; World Wide Web; Pharmacy; Family medicine; Pharmacology; Surgery","score_opus":0.032619379993617734,"score_gpt":0.23999918819182958,"score_spread":0.20737980819821183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159809648","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023143983,0.0631582,0.00024915763,0.88102996,0.007123327,0.000024086565,0.0009401205,0.000080677535,0.045080017],"genre_scores_gemma":[0.13997771,0.20145391,0.0012933001,0.5826074,0.011079608,0.00008408929,0.0018867675,0.00022161318,0.06139553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99472356,0.0003406304,0.00020500759,0.0004538002,0.0027314879,0.0015454912],"domain_scores_gemma":[0.97671336,0.0021228269,0.0010476508,0.00040727344,0.009848376,0.009860536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049460516,0.0006450394,0.00083928596,0.0036239438,0.013365149,0.008656016,0.003007338,0.007062244,0.041553292],"category_scores_gemma":[0.019160323,0.00063740596,0.00053137774,0.008358798,0.0082872035,0.0043299147,0.0045275097,0.010439789,0.00250635],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004126023,0.000036254747,0.002123688,0.0004882666,0.0000221315,0.00023771015,0.00065992004,0.00010759264,0.000045914556,0.031644695,0.90825653,0.05633609],"study_design_scores_gemma":[0.000022350347,0.0000093015005,0.007899667,0.00063693075,0.000013505779,0.00014163759,0.0013720546,0.00008571751,0.000028899152,0.003777179,0.9859716,0.000041237643],"about_ca_topic_score_codex":0.9467074,"about_ca_topic_score_gemma":0.9760251,"teacher_disagreement_score":0.8876171,"about_ca_system_score_codex":0.11238292,"about_ca_system_score_gemma":0.19425759,"threshold_uncertainty_score":0.81539893},"labels":[],"label_agreement":null},{"id":"W2159987332","doi":"10.3238/arztebl.2009.0783","title":"The Effect of Introducing Rebate Contracts to Promote Generic Drug Substitution, on Doctors’ Prescribing Practices","year":2009,"lang":"de","type":"article","venue":"Deutsches Ärzteblatt international","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Statutory law; Health insurance; Prescription drug; Substitution (logic); Quarter (Canadian coin); Family medicine; Drug; Health economics; Population; Actuarial science; Environmental health; Health care; Public health; Law; Business; Pharmacology; Nursing","score_opus":0.043471832872591765,"score_gpt":0.3126113739242415,"score_spread":0.2691395410516497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159987332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99911064,0.00015848383,0.000026647047,0.00022866203,0.0000068840664,0.000014227271,0.000052377283,0.000002378745,0.00039965138],"genre_scores_gemma":[0.9994881,0.00006830914,0.000103472215,0.00011364751,0.000018679082,0.000016280846,0.0000462354,9.541992e-7,0.0001442654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99580574,0.002567788,0.00025440016,0.00042061703,0.00047577612,0.00047565298],"domain_scores_gemma":[0.9462003,0.029873926,0.016931495,0.0011271581,0.0012427352,0.0046243276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058704703,0.00017157939,0.00016917121,0.00035619253,0.00030889153,0.0006228882,0.00057008414,0.00113367,0.0018392727],"category_scores_gemma":[0.02818894,0.00018045335,0.0004400216,0.00038441428,0.00071209675,0.00053205836,0.0006210817,0.0007842832,0.0001869691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008119583,0.0021487146,0.9628752,0.0001061865,0.00017885842,0.00014432412,0.00065808755,0.00087993464,0.00091757555,0.00012223507,0.0006267122,0.023222644],"study_design_scores_gemma":[0.00008171301,0.0013982923,0.99762446,0.000014651916,0.000031419193,0.000036847137,0.00015653112,0.00027741664,0.00010874105,0.00001237055,0.00025296683,0.000004587605],"about_ca_topic_score_codex":0.008164523,"about_ca_topic_score_gemma":0.012848177,"teacher_disagreement_score":0.008164523,"about_ca_system_score_codex":0.0019604268,"about_ca_system_score_gemma":0.0019124909,"threshold_uncertainty_score":0.03104639},"labels":[],"label_agreement":null},{"id":"W2160118117","doi":"10.18433/j31k51","title":"Determination of Bioequivalence for Drugs with Narrow Therapeutic Index: Reduction of the Regulatory Burden","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bioequivalence; Replicate; Food and drug administration; Statistics; Econometrics; Pharmacology; Mathematics; Medicine; Toxicology; Computer science; Pharmacokinetics; Biology","score_opus":0.08461377102741516,"score_gpt":0.35033936272757626,"score_spread":0.2657255917001611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160118117","genre_codex":"methods","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11965512,0.099135056,0.6992479,0.04010533,0.0017069633,0.0019510109,0.0010910421,0.0009247878,0.036182754],"genre_scores_gemma":[0.6192932,0.031238616,0.33014357,0.008481893,0.0021838422,0.0019157564,0.0010154988,0.00044339302,0.0052842186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8180456,0.11800807,0.0043222117,0.0061087995,0.052769274,0.0007459791],"domain_scores_gemma":[0.8111548,0.13561882,0.016836235,0.01554897,0.01994202,0.00089918164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11612616,0.0012832797,0.0042293537,0.0025147386,0.0008959622,0.002891336,0.002307899,0.0036742873,0.0031437518],"category_scores_gemma":[0.15670192,0.00073187053,0.001423054,0.0029298465,0.0038041414,0.0038682737,0.0028789914,0.004827293,0.001269957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020290425,0.000788071,0.010387841,0.0031673543,0.0005069291,0.0004510121,0.0013632744,0.0048546623,0.034183897,0.047536306,0.010645693,0.88408595],"study_design_scores_gemma":[0.0016755068,0.015637768,0.13957295,0.006806005,0.0029956517,0.009372305,0.002556411,0.11358147,0.11981699,0.1662643,0.4208153,0.00090539164],"about_ca_topic_score_codex":0.0014251263,"about_ca_topic_score_gemma":0.0009819486,"teacher_disagreement_score":0.11612616,"about_ca_system_score_codex":0.002273307,"about_ca_system_score_gemma":0.004795078,"threshold_uncertainty_score":0.61414117},"labels":[],"label_agreement":null},{"id":"W2160490347","doi":"10.1002/jps.23474","title":"Review of the Quality of Pediatric Medications in Developing Countries","year":2013,"lang":"en","type":"review","venue":"Journal of Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Developing country; MEDLINE; Quality (philosophy); Adverse effect; Family medicine; Alternative medicine; Traditional medicine; Intensive care medicine; Environmental health; Pediatrics; Pharmacology; Pathology","score_opus":0.38852537713787966,"score_gpt":0.49931259627354735,"score_spread":0.11078721913566769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160490347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011800338,0.99935335,0.000034332363,0.0002227738,0.00004652204,0.0000030181188,0.0000528714,0.0000010384347,0.00016809723],"genre_scores_gemma":[0.0013131421,0.9983631,0.00009297409,0.0001007108,0.00006498181,0.000002359966,0.000030104376,4.7192296e-7,0.000032198743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983047,0.0003698981,0.0004970963,0.00015055343,0.0006013666,0.00007642799],"domain_scores_gemma":[0.9921629,0.0042645964,0.0020100647,0.00010564387,0.0013115976,0.00014524454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003831047,0.00077149976,0.0022624838,0.0051600123,0.00021956135,0.0017317663,0.0011417717,0.00086878653,0.002688356],"category_scores_gemma":[0.008564244,0.0004579044,0.0015112594,0.007938674,0.0004961941,0.0013738712,0.00065769535,0.0009883407,0.00026042544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021060056,0.00006377671,0.0024036297,0.16252123,0.0018594849,0.00016895463,0.000090009504,0.0009202582,0.00044680104,0.0036511868,0.025063323,0.8026008],"study_design_scores_gemma":[0.0001391092,0.00042174564,0.028429506,0.15222698,0.0069388472,0.0014678764,0.00029218599,0.00052211067,0.0010074828,0.0026248705,0.80583835,0.000090949274],"about_ca_topic_score_codex":0.007351183,"about_ca_topic_score_gemma":0.014016399,"teacher_disagreement_score":0.007351183,"about_ca_system_score_codex":0.0020732838,"about_ca_system_score_gemma":0.0060184933,"threshold_uncertainty_score":0.020260751},"labels":[],"label_agreement":null},{"id":"W2160754141","doi":"10.2174/1875692110806020108","title":"Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health","year":2008,"lang":"en","type":"article","venue":"Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research; Mayo Clinic","keywords":"Bioethics; Personalized medicine; Pharmacogenomics; Pharmaceutical industry; Biobank; Sustainability; Business; Health care; Prosperity; Public relations; Medicine; Economic growth; Political science; Pharmacology; Economics","score_opus":0.2833368804131214,"score_gpt":0.44206263021824593,"score_spread":0.15872574980512455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160754141","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042408207,0.008897088,0.0057690805,0.9605027,0.0016003246,0.000019324136,0.000012334925,0.000026072126,0.018932221],"genre_scores_gemma":[0.5507375,0.018558228,0.0147205135,0.39763087,0.0057627573,0.00020367542,0.00004071139,0.00014092463,0.01220486],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9604664,0.02831092,0.00084219413,0.0022780362,0.0048440667,0.0032582527],"domain_scores_gemma":[0.9714704,0.019216074,0.0015141206,0.0017815691,0.0023419824,0.0036758918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05481492,0.00083935837,0.00096642785,0.0022329947,0.014572934,0.029044477,0.0024837411,0.022098105,0.0033074329],"category_scores_gemma":[0.029198932,0.00061610865,0.0012102206,0.0016931607,0.11497243,0.03260291,0.014739814,0.02536472,0.00082340883],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013002874,0.000029644045,0.00042785917,0.00006939904,0.000012863132,0.000099637226,0.013336248,0.0002829517,0.00014013992,0.9565422,0.015167059,0.013878948],"study_design_scores_gemma":[0.000014760761,0.000024346642,0.0004113879,0.00033688152,0.000010301998,0.00009776726,0.014267135,0.00029721714,0.00015452123,0.85399956,0.13035312,0.000032995835],"about_ca_topic_score_codex":0.007076385,"about_ca_topic_score_gemma":0.008872827,"teacher_disagreement_score":0.05481492,"about_ca_system_score_codex":0.01510326,"about_ca_system_score_gemma":0.03253623,"threshold_uncertainty_score":0.2898925},"labels":[],"label_agreement":null},{"id":"W2160956735","doi":"","title":"The Misguided War against Medicines 2011","year":2011,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Health care; Public economics; Medical prescription; Business; Government (linguistics); Population; Goods and services; Monopoly; Revenue; Prescription drug; Subsidy; Consumption (sociology); Government spending; Government revenue; Tax revenue; Economics; Economic growth; Welfare; Finance; Medicine; Environmental health; Market economy","score_opus":0.04930729963309457,"score_gpt":0.2615680378649145,"score_spread":0.21226073823181993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160956735","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031684313,0.0382717,0.0007701175,0.7885613,0.025944643,0.00003949932,0.0013548873,0.00019960561,0.14168988],"genre_scores_gemma":[0.08885487,0.021048203,0.0015562,0.57736814,0.0118288845,0.00007838781,0.0009021466,0.0002484308,0.29811472],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99343914,0.0012231617,0.00027576924,0.0009308918,0.0027788563,0.0013521119],"domain_scores_gemma":[0.99557567,0.0010815188,0.00026386278,0.0005241371,0.0015291411,0.0010257869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005682401,0.000847319,0.00072435517,0.0011853256,0.005280898,0.008569788,0.001410517,0.0106748715,0.020600058],"category_scores_gemma":[0.017192412,0.00051435124,0.00082946394,0.00096494704,0.0084951855,0.0048531415,0.0048889746,0.016074078,0.008376761],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011677159,0.000025960837,0.0005607629,0.00013031409,0.000032599437,0.00015864706,0.00048977055,0.000100397534,0.00037475038,0.16194214,0.7935847,0.042483184],"study_design_scores_gemma":[0.000015109265,0.000016014823,0.00054791354,0.00008428831,0.000007119097,0.00006121138,0.00008681086,0.000035771016,0.00017260089,0.006456357,0.992504,0.000012758673],"about_ca_topic_score_codex":0.125002,"about_ca_topic_score_gemma":0.14575239,"teacher_disagreement_score":0.125002,"about_ca_system_score_codex":0.017753927,"about_ca_system_score_gemma":0.020727612,"threshold_uncertainty_score":0.2485488},"labels":[],"label_agreement":null},{"id":"W2161016869","doi":"10.1377/hlthaff.2014.0658","title":"Compulsory Licensing Often Did Not Produce Lower Prices For Antiretrovirals Compared To International Procurement","year":2015,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"Canadian Institutes of Health Research","keywords":"Procurement; License; Business; Developing country; Quality (philosophy); Work (physics); Public economics; International economics; Economics; Economic growth; Marketing; Political science; Law","score_opus":0.1985946618427264,"score_gpt":0.36835580051017586,"score_spread":0.16976113866744946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161016869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98042667,0.0008490615,0.0031447532,0.00048013165,0.000024835299,0.00013571173,0.0014103547,0.000018832141,0.013509746],"genre_scores_gemma":[0.99787414,0.00020014077,0.00057678786,0.00007179031,0.000012044022,0.00002828965,0.0005709824,0.000007073904,0.00065875606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931339,0.002789192,0.00087702065,0.000894317,0.0015476843,0.00075782527],"domain_scores_gemma":[0.9275522,0.04708402,0.016523179,0.004881572,0.0033959844,0.00056297384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007201475,0.0002259711,0.00046285655,0.0023836214,0.00078102254,0.002790181,0.00060993736,0.0004949711,0.0065926192],"category_scores_gemma":[0.041017946,0.0002167932,0.00079519325,0.004747741,0.0012738815,0.0018181923,0.0014826447,0.0008897277,0.0003268107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004692634,0.00016920685,0.91738784,0.00051233644,0.00035639742,0.0013137513,0.0011743412,0.0037528365,0.00068892253,0.01928988,0.00161537,0.05326994],"study_design_scores_gemma":[0.00013199546,0.0007649561,0.9203098,0.00047721795,0.0005978152,0.0060589,0.008689592,0.00912105,0.007953124,0.01464415,0.031161988,0.00008942142],"about_ca_topic_score_codex":0.007606664,"about_ca_topic_score_gemma":0.007802005,"teacher_disagreement_score":0.007606664,"about_ca_system_score_codex":0.0020824466,"about_ca_system_score_gemma":0.0011557114,"threshold_uncertainty_score":0.03808552},"labels":[],"label_agreement":null},{"id":"W2161560309","doi":"10.1071/ah090258","title":"Policy challenges of nanomedicine for Australia's PBS","year":2009,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; National Institutes of Health; Anhui University of Science and Technology","keywords":"Government (linguistics); Pharmaceutical Benefits Scheme; Health economics; Risk analysis (engineering); Population health; Business; Pharmaceutical industry; Precautionary principle; Public economics; Medicine; Public health; Economics; Population; Pharmacology; Environmental health; Biotechnology","score_opus":0.32554781708392805,"score_gpt":0.45355650347110005,"score_spread":0.128008686387172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161560309","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03201011,0.017820569,0.00408364,0.8995155,0.00080885383,0.00006673846,0.00013672351,0.00004433305,0.045513496],"genre_scores_gemma":[0.67617804,0.025321765,0.010458361,0.22946338,0.0023154512,0.00029807264,0.00013402349,0.000038484126,0.05579253],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952786,0.002193138,0.00018732813,0.00042746973,0.0012249111,0.0006885626],"domain_scores_gemma":[0.9910315,0.005049387,0.00093964,0.00028288073,0.0018230316,0.0008734989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074214144,0.0003458747,0.00073386787,0.0009948034,0.0035742312,0.006133666,0.0010709765,0.010423103,0.0073219156],"category_scores_gemma":[0.022003155,0.0004886141,0.00082295673,0.00082992646,0.0040945043,0.006104768,0.0036448769,0.007698094,0.00068789674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044389108,0.000058430345,0.00082225184,0.0002665608,0.000021539914,0.00036958535,0.00062220887,0.0028269019,0.00045645144,0.94162303,0.033220463,0.019668022],"study_design_scores_gemma":[0.00011588229,0.00017800121,0.0076444396,0.000765158,0.000043332948,0.0005014398,0.0012812763,0.0122815985,0.000511049,0.5389054,0.43768927,0.00008308037],"about_ca_topic_score_codex":0.060805768,"about_ca_topic_score_gemma":0.042285524,"teacher_disagreement_score":0.060805768,"about_ca_system_score_codex":0.013834318,"about_ca_system_score_gemma":0.03050767,"threshold_uncertainty_score":0.12090367},"labels":[],"label_agreement":null},{"id":"W2162449291","doi":"10.1111/jphs.12007","title":"Changes in use of antidiabetic medications following price regulations in China (1999–2009)","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Foundation","keywords":"Medicine; Per capita; Population; China; Quarter (Canadian coin); Environmental health","score_opus":0.17448598034800167,"score_gpt":0.45411405832387014,"score_spread":0.27962807797586847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162449291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815995,0.0001393809,0.000070814756,0.00008387267,0.000008805205,0.000009541612,0.0012287109,0.000006275255,0.0002926894],"genre_scores_gemma":[0.99760675,0.000095947486,0.00008659978,0.00007155743,0.000015570271,0.000013452451,0.0018658417,0.000002148932,0.00024202511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990833,0.00010664842,0.00016274415,0.0002341983,0.00024251628,0.00017066438],"domain_scores_gemma":[0.99587125,0.00023942893,0.002508927,0.00020579017,0.0007573215,0.00041720207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011142079,0.00037324725,0.00034243395,0.0012638597,0.0003355692,0.0006416347,0.000615191,0.00047915176,0.0012512393],"category_scores_gemma":[0.0025629022,0.00029330628,0.0007701735,0.0022908724,0.00032500672,0.00050098443,0.0005025527,0.00060837617,0.00017891586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067947236,0.000036207573,0.99749386,0.000017527147,0.000084206964,0.00006575167,0.000068256704,0.00016564937,0.0001695618,0.000020804417,0.00022300064,0.0015872355],"study_design_scores_gemma":[0.0000026578384,0.000021904867,0.9995844,0.0000017450571,0.000013039167,0.000017769207,0.000025069163,0.00020316841,0.00003621542,0.0000038243243,0.00008762131,0.0000027116166],"about_ca_topic_score_codex":0.06913535,"about_ca_topic_score_gemma":0.052664574,"teacher_disagreement_score":0.06913535,"about_ca_system_score_codex":0.0019105478,"about_ca_system_score_gemma":0.0019332404,"threshold_uncertainty_score":0.1374659},"labels":[],"label_agreement":null},{"id":"W2163707071","doi":"10.1377/hlthaff.w3.521","title":"Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries","year":2003,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liberian dollar; Pound (networking); Economics; Agricultural economics; International economics; Demographic economics; Business; Finance","score_opus":0.11861515730467714,"score_gpt":0.35180144592992774,"score_spread":0.2331862886252506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163707071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655694,0.017028794,0.00027844735,0.0010360285,0.00003729274,0.000015754278,0.004414086,0.0000084475405,0.011611809],"genre_scores_gemma":[0.99174786,0.0057310928,0.00013130205,0.000142632,0.000028633349,0.000005852039,0.0020066982,0.000004126221,0.00020183068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984459,0.0004100852,0.00022243764,0.00026015693,0.00044912897,0.00021230713],"domain_scores_gemma":[0.9845354,0.004858007,0.0076704645,0.00045663674,0.0017889666,0.0006904705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012568269,0.00016154842,0.0003685185,0.0025099611,0.00052356377,0.0019625635,0.0003746574,0.00046945037,0.0021257882],"category_scores_gemma":[0.008999592,0.00030903847,0.00053199875,0.006025532,0.0008622894,0.0009773746,0.0011473797,0.0005694635,0.00022303496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004735987,0.000054094635,0.9744013,0.0005210132,0.00065801974,0.0004809384,0.0005520211,0.0009618952,0.00018430111,0.0017502052,0.0020414013,0.017921232],"study_design_scores_gemma":[0.00005074008,0.00010261211,0.99067163,0.00022095816,0.00020224812,0.00041151178,0.001093461,0.00022365955,0.00033280204,0.000260778,0.0064069307,0.000022704164],"about_ca_topic_score_codex":0.034271885,"about_ca_topic_score_gemma":0.03370957,"teacher_disagreement_score":0.034271885,"about_ca_system_score_codex":0.000985996,"about_ca_system_score_gemma":0.0006265691,"threshold_uncertainty_score":0.0681448},"labels":[],"label_agreement":null},{"id":"W2164632177","doi":"10.1016/s1474-4422(04)00883-x","title":"Comparison studies of cholinesterase inhibitors for Alzheimer's disease","year":2004,"lang":"en","type":"review","venue":"The Lancet Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; McMaster University; Toronto Rehabilitation Institute; University of Toronto; University of Calgary","funders":"Pfizer","keywords":"Checklist; Cholinesterase; Medicine; Disease; Alzheimer's disease; Clinical trial; Consolidated Standards of Reporting Trials; Psychology; Pharmacology; Internal medicine","score_opus":0.43499645769402145,"score_gpt":0.4622165648417724,"score_spread":0.02722010714775097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164632177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010690897,0.99815255,0.000093305214,0.00017619217,0.00006133261,0.000026096408,0.00009665313,0.0000020658088,0.00032275802],"genre_scores_gemma":[0.026968373,0.9717001,0.0005296861,0.00027127351,0.00013226515,0.000057055502,0.00013910678,0.0000031247516,0.00019903335],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9945056,0.0032482608,0.0009673565,0.00035145847,0.0007828473,0.00014442614],"domain_scores_gemma":[0.9820133,0.014756455,0.0020383142,0.0002002873,0.0008107568,0.00018087633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010236681,0.0011346996,0.0063082343,0.0029048314,0.0001655574,0.0013447566,0.0013179227,0.0014287335,0.005371134],"category_scores_gemma":[0.02687105,0.00041774605,0.004082552,0.0046457336,0.00043727813,0.0010106422,0.0007465482,0.0010897643,0.0002969735],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020624047,0.00020901773,0.0023201457,0.28178543,0.07230731,0.00027120503,0.00011124014,0.001219973,0.00085109466,0.0028539954,0.0066636857,0.6107829],"study_design_scores_gemma":[0.030614356,0.009860425,0.044837862,0.17640647,0.45421767,0.0027326813,0.00055922143,0.0009514814,0.003197657,0.013002977,0.2634619,0.00015727436],"about_ca_topic_score_codex":0.003254463,"about_ca_topic_score_gemma":0.00603565,"teacher_disagreement_score":0.010236681,"about_ca_system_score_codex":0.0017217762,"about_ca_system_score_gemma":0.0020896292,"threshold_uncertainty_score":0.05413741},"labels":[],"label_agreement":null},{"id":"W2165570102","doi":"10.1016/j.vaccine.2009.08.113","title":"Regulatory oversight of clinical trials in Africa: Progress over the past 5 years","year":2009,"lang":"en","type":"article","venue":"Vaccine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Clinical trial; Medicine; Clinical research; Developed country; Developing country; Alternative medicine; Intensive care medicine; Economic growth; Environmental health; Pathology","score_opus":0.17828205870286468,"score_gpt":0.39057357714760393,"score_spread":0.21229151844473926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165570102","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04648965,0.39816964,0.041075416,0.4573965,0.006534903,0.0013253537,0.000716936,0.00044170642,0.047849987],"genre_scores_gemma":[0.6587264,0.19474012,0.032982603,0.08873655,0.013896957,0.00095496804,0.0008440674,0.00029529384,0.008823025],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.88389874,0.07580545,0.008915731,0.005503212,0.019746378,0.0061305882],"domain_scores_gemma":[0.37262213,0.45124686,0.08427154,0.010132146,0.066595525,0.015131734],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.21834579,0.0012046489,0.0020256764,0.005624675,0.0021041569,0.013171287,0.0038754386,0.009194611,0.0049815485],"category_scores_gemma":[0.38617325,0.0009672509,0.0012014272,0.0078017395,0.008883161,0.0060887225,0.0037252323,0.010688941,0.00050353014],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001541175,0.0005145428,0.02449788,0.010985563,0.00055660604,0.00086561014,0.0027203406,0.012455038,0.0038202966,0.1834411,0.059832145,0.6987696],"study_design_scores_gemma":[0.0014327174,0.0014002542,0.06971976,0.020526357,0.0005581514,0.0018189094,0.0019035483,0.010047506,0.0061487244,0.109115236,0.7770898,0.00023908484],"about_ca_topic_score_codex":0.009982482,"about_ca_topic_score_gemma":0.009849549,"teacher_disagreement_score":0.21834579,"about_ca_system_score_codex":0.015741032,"about_ca_system_score_gemma":0.07527184,"threshold_uncertainty_score":0.9639188},"labels":[],"label_agreement":null},{"id":"W2167152117","doi":"10.1111/j.1468-0009.2007.00496.x","title":"Public/Private Partnerships for Prescription Drug Coverage: Policy Formulation and Outcomes in Quebec's Universal Drug Insurance Program, with Comparisons to the Medicare Prescription Drug Program in the United States","year":2007,"lang":"en","type":"article","venue":"Milbank Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Université de Montréal; Pierre Elliott Trudeau Foundation","funders":"","keywords":"Prescription drug; Medical prescription; Government (linguistics); Principal (computer security); Public administration; Modernization theory; Private sector; Parallels; Business; Private insurance; Drug; Health insurance; Political science; Medicine; Economics; Law; Pharmacology; Health care","score_opus":0.06209852393718964,"score_gpt":0.3045910277155536,"score_spread":0.24249250377836393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167152117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6385942,0.015438989,0.0011330324,0.18182382,0.00016804892,0.00060443516,0.0029259704,0.000089410954,0.15922219],"genre_scores_gemma":[0.98654944,0.0016482867,0.00047506596,0.002919075,0.000041954776,0.00010843859,0.0003073738,0.0000072894236,0.0079430835],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99449664,0.00205565,0.00006173049,0.00016238402,0.0008212793,0.0024022101],"domain_scores_gemma":[0.99199414,0.0021046225,0.0007333821,0.00015354942,0.0017991449,0.003215195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057111494,0.00030958877,0.00031510115,0.0012017419,0.004635356,0.006041901,0.0011150844,0.0020911233,0.008019145],"category_scores_gemma":[0.009687914,0.00017382718,0.00033063875,0.002528415,0.002436772,0.0024186405,0.0023793073,0.0018664818,0.00024264661],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015704017,0.0033121854,0.24369328,0.000660852,0.000282998,0.000936779,0.0055169356,0.016034156,0.0008956297,0.38512018,0.14495064,0.197026],"study_design_scores_gemma":[0.0012438212,0.0009272961,0.7058761,0.0014871209,0.00045596928,0.0002064579,0.046337787,0.035366956,0.0014426742,0.038654562,0.16784988,0.00015135658],"about_ca_topic_score_codex":0.95259506,"about_ca_topic_score_gemma":0.98109657,"teacher_disagreement_score":0.085024044,"about_ca_system_score_codex":0.085024044,"about_ca_system_score_gemma":0.09775596,"threshold_uncertainty_score":0.6168955},"labels":[],"label_agreement":null},{"id":"W2167341868","doi":"10.1016/j.diagmicrobio.2012.11.020","title":"Perspectives and concerns regarding antimicrobial agent shortages among infectious disease specialists","year":2013,"lang":"en","type":"article","venue":"Diagnostic Microbiology and Infectious Disease","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Public Health Service; National Institute of Allergy and Infectious Diseases; Centers for Disease Control and Prevention; U.S. Food and Drug Administration; Association des pharmaciens du Canada","keywords":"Medicine; Economic shortage; Antimicrobial; Pharmacy; Infectious disease (medical specialty); Antimicrobial stewardship; Intensive care medicine; Disease; Family medicine; Antibiotics; Internal medicine; Antibiotic resistance; Microbiology; Biology","score_opus":0.018614195525129513,"score_gpt":0.251248768188824,"score_spread":0.2326345726636945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167341868","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021078054,0.0027327526,0.00033963827,0.9695795,0.00045647286,0.0000031682775,0.00007398052,0.0000046418127,0.005731732],"genre_scores_gemma":[0.6691627,0.008126586,0.0008134145,0.3086246,0.009674075,0.00003259938,0.00010919879,0.000013313401,0.0034435422],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.9948744,0.0029409158,0.0002040232,0.0003024628,0.0006581298,0.0010201049],"domain_scores_gemma":[0.92639256,0.0449548,0.011199497,0.00057899964,0.005487751,0.011386414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012202941,0.00017813282,0.0003751615,0.0010120663,0.0018772252,0.0050862827,0.00094779197,0.008640889,0.01617047],"category_scores_gemma":[0.049476966,0.0002686137,0.00047500545,0.0014555182,0.00337986,0.004164306,0.0023519034,0.0065131215,0.000688739],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010169431,0.00092618814,0.14529109,0.0011867249,0.0001413011,0.003969187,0.008834525,0.005597563,0.001605265,0.3456469,0.35093898,0.1348453],"study_design_scores_gemma":[0.00051533146,0.0005744729,0.13981257,0.0035540143,0.00013487296,0.0039669718,0.07403691,0.0075104563,0.0008257379,0.44751674,0.32137355,0.00017836201],"about_ca_topic_score_codex":0.0054269223,"about_ca_topic_score_gemma":0.009624457,"teacher_disagreement_score":0.01617047,"about_ca_system_score_codex":0.0045052352,"about_ca_system_score_gemma":0.0057465453,"threshold_uncertainty_score":0.064536035},"labels":[],"label_agreement":null},{"id":"W2167393130","doi":"10.1506/ap.7.2.6","title":"Transition Therapeutics inc.*","year":2008,"lang":"en","type":"article","venue":"Accounting Perspectives","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"HEC Montréal","funders":"","keywords":"Business; Accounting; Equity (law); Shareholder; Pro forma; Finance; Actuarial science; Political science; Corporate governance","score_opus":0.07396176409851335,"score_gpt":0.2826814762400178,"score_spread":0.20871971214150448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167393130","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040246337,0.0118316505,0.0026938496,0.019637171,0.0046652183,0.0003748247,0.0038168419,0.0033595178,0.9495963],"genre_scores_gemma":[0.027265655,0.004778068,0.002184779,0.0057126936,0.00054351403,0.00013509441,0.003028639,0.00031524818,0.9560363],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898773,0.00007533148,0.00005356545,0.00021968056,0.00050513685,0.00015852238],"domain_scores_gemma":[0.99825317,0.00015640364,0.00011886969,0.000105891595,0.0006509607,0.00071472157],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069254165,0.00065959606,0.00047108612,0.0013842309,0.0012324385,0.002560614,0.00085383246,0.0015715971,0.50273037],"category_scores_gemma":[0.0019909467,0.0003433237,0.00060962414,0.0008703102,0.00057002035,0.0011134386,0.0010253999,0.002096239,0.20753516],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037685048,0.00018163942,0.0007043747,0.0004130246,0.000010497831,0.00041741182,0.000116670606,0.000080707534,0.002539395,0.009543101,0.6946632,0.2909531],"study_design_scores_gemma":[0.000062315914,0.000089979054,0.0004502191,0.000082060964,0.0000093304325,0.00047784555,0.000047787467,0.00008078865,0.00083475426,0.00069976755,0.9971589,0.0000063868047],"about_ca_topic_score_codex":0.005443171,"about_ca_topic_score_gemma":0.010773046,"teacher_disagreement_score":0.50273037,"about_ca_system_score_codex":0.001517653,"about_ca_system_score_gemma":0.0042113485,"threshold_uncertainty_score":0.7092948},"labels":[],"label_agreement":null},{"id":"W2168785648","doi":"10.3109/j058v16n03_08","title":"Internet Pharmacy: Undoing Canada's Goals for Life Science Innovation?","year":2004,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Marketing & Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Undoing; Attractiveness; Pharmacy; Business; The Internet; Legislation; Investment (military); Marketing; Public economics; Economics; Political science","score_opus":0.08319619769619306,"score_gpt":0.336420053319961,"score_spread":0.2532238556237679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168785648","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033192711,0.0065909997,0.0005754005,0.94880724,0.0015029621,0.000023520393,0.0002534204,0.00009245257,0.03883481],"genre_scores_gemma":[0.2430289,0.03538822,0.0047916034,0.6186839,0.0033854162,0.000088410976,0.00050150894,0.0002128242,0.09391925],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99128294,0.0008492102,0.00017191455,0.00048030092,0.0046688016,0.0025468546],"domain_scores_gemma":[0.9694194,0.0036469202,0.00083636097,0.00063584343,0.010038864,0.015422553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074986513,0.00054404343,0.0006104224,0.0024608453,0.013668467,0.01701402,0.0022496628,0.013936255,0.020985587],"category_scores_gemma":[0.023305563,0.00028089707,0.00079222466,0.0033346987,0.011113541,0.0084772,0.0047784504,0.010935167,0.0022265564],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010995482,0.000079793754,0.00232116,0.00028927028,0.000029304692,0.0002689179,0.001097262,0.0003000959,0.00035437825,0.26612142,0.64912224,0.079906255],"study_design_scores_gemma":[0.00010220295,0.000056668297,0.0066339653,0.00054171286,0.000044006432,0.00014028401,0.0022590742,0.0005818638,0.00041314148,0.039648034,0.94949996,0.0000790378],"about_ca_topic_score_codex":0.9375457,"about_ca_topic_score_gemma":0.962412,"teacher_disagreement_score":0.9234284,"about_ca_system_score_codex":0.076571584,"about_ca_system_score_gemma":0.32787,"threshold_uncertainty_score":0.55556834},"labels":[],"label_agreement":null},{"id":"W2168880717","doi":"10.4212/cjhp.v65i5.1181","title":"Drug Shortages: What Does France Do Better than Canada?","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Drug; Geography; Medicine; Pharmacology","score_opus":0.023056351909771525,"score_gpt":0.24944907714120787,"score_spread":0.22639272523143633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168880717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66134673,0.041410286,0.0004345524,0.1060029,0.00094952004,0.00014305698,0.045467235,0.00023358168,0.14401215],"genre_scores_gemma":[0.97063744,0.0067302594,0.00026236766,0.0043455893,0.0001738476,0.000028098335,0.0061291927,0.000040153194,0.011653175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964688,0.0002679953,0.00015093379,0.00017731746,0.0013293396,0.0016055661],"domain_scores_gemma":[0.9915242,0.00062003476,0.0010804995,0.000088611596,0.004312039,0.002374677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013935235,0.00032467226,0.0007704147,0.0042028204,0.0031734111,0.0033653455,0.00087278115,0.00095681293,0.011351536],"category_scores_gemma":[0.0069427663,0.00021996848,0.00079264597,0.008820922,0.0010280571,0.0013848474,0.0011797509,0.0010778301,0.00050882535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014520583,0.00015842439,0.6313202,0.0014165626,0.00060700864,0.00076499925,0.002186653,0.0032788615,0.0006476065,0.02253606,0.20011221,0.13551942],"study_design_scores_gemma":[0.00010098963,0.00011786812,0.9159468,0.00047604792,0.00015543036,0.00014767797,0.0068280105,0.00060064,0.00022358228,0.0006775133,0.07467847,0.00004699227],"about_ca_topic_score_codex":0.98277205,"about_ca_topic_score_gemma":0.99219257,"teacher_disagreement_score":0.04823691,"about_ca_system_score_codex":0.04823691,"about_ca_system_score_gemma":0.06708693,"threshold_uncertainty_score":0.34998488},"labels":[],"label_agreement":null},{"id":"W2168932305","doi":"10.1080/13880200590963736","title":"Linking Medicinal/Nutraceutical Products Research with Commercialization","year":2005,"lang":"en","type":"article","venue":"Pharmaceutical Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Fredericton; Natural Resources Canada; Canadian Forest Service","funders":"","keywords":"Commercialization; Nutraceutical; Biotechnology; Business; Marketing; Product (mathematics); Biology","score_opus":0.3249006839457479,"score_gpt":0.44568582610875074,"score_spread":0.12078514216300285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168932305","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07552237,0.08838772,0.11992089,0.10089148,0.0010960639,0.00085379044,0.00063734956,0.00026251026,0.61242783],"genre_scores_gemma":[0.8168175,0.09281432,0.048775814,0.006750132,0.002588712,0.0003879662,0.00030750156,0.000104916835,0.031453125],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9964296,0.0018489345,0.00023770274,0.0003711772,0.0008738564,0.000238677],"domain_scores_gemma":[0.98345554,0.012050559,0.0023649074,0.0004749626,0.0013343936,0.00031972345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073977564,0.00054672104,0.0005738247,0.0043374267,0.0008112132,0.006626969,0.00056455715,0.00170572,0.013623861],"category_scores_gemma":[0.013177549,0.000371123,0.0004944434,0.004590638,0.0035354127,0.0063210935,0.0025523142,0.002149568,0.0014389211],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008549164,0.00023981846,0.009571552,0.0011567554,0.00005171128,0.0003227843,0.00027044196,0.011637568,0.001643004,0.80267495,0.007794399,0.16455159],"study_design_scores_gemma":[0.000035458932,0.00024652304,0.016627163,0.0012708054,0.00008557946,0.0002838827,0.0020283016,0.025416909,0.005438042,0.7896864,0.15880093,0.0000799568],"about_ca_topic_score_codex":0.0029434187,"about_ca_topic_score_gemma":0.0017773516,"teacher_disagreement_score":0.013623861,"about_ca_system_score_codex":0.005477235,"about_ca_system_score_gemma":0.0032882532,"threshold_uncertainty_score":0.045576334},"labels":[],"label_agreement":null},{"id":"W2169253622","doi":"10.1186/1744-8603-3-12","title":"Canada's implementation of the Paragraph 6 Decision: is it sustainable public policy?","year":2007,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Connaught Fund; University of Toronto","keywords":"Legislation; Population; Developing country; Incentive; Business; Government (linguistics); Economics; Public administration; Economic growth; Law; Political science; Medicine; Environmental health; Market economy","score_opus":0.0641052028159014,"score_gpt":0.3724271668373059,"score_spread":0.30832196402140455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169253622","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0143050775,0.0038576259,0.0010052873,0.7815077,0.0033470723,0.00024519718,0.0009718527,0.00010288546,0.19465739],"genre_scores_gemma":[0.33128345,0.004390918,0.0045849574,0.5282254,0.0009981272,0.00037612228,0.00076400215,0.00017122646,0.1292058],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9516235,0.0054551843,0.0012892032,0.0030114884,0.024127442,0.0144931665],"domain_scores_gemma":[0.93293303,0.02157858,0.0020800275,0.0017847139,0.028407682,0.013216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023405058,0.0005181457,0.00089001225,0.0017849165,0.03024606,0.023924014,0.0053072944,0.024058009,0.01585164],"category_scores_gemma":[0.07973232,0.0007882892,0.0012527406,0.0036230467,0.017128581,0.0056396914,0.005917357,0.018315526,0.0017440966],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00007265634,0.00006708741,0.005065081,0.00048528117,0.000065282635,0.0010505501,0.010993473,0.0008327958,0.0004835216,0.38731888,0.5694206,0.024144791],"study_design_scores_gemma":[0.000043557837,0.000026878488,0.005268943,0.00061224535,0.000032289212,0.00007739318,0.006303968,0.00033855182,0.00037032986,0.011019802,0.9757746,0.00013153991],"about_ca_topic_score_codex":0.9775573,"about_ca_topic_score_gemma":0.9769009,"teacher_disagreement_score":0.81149864,"about_ca_system_score_codex":0.18850133,"about_ca_system_score_gemma":0.5945108,"threshold_uncertainty_score":0.94122344},"labels":[],"label_agreement":null},{"id":"W2169369869","doi":"10.1185/030079907x199655","title":"Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease","year":2007,"lang":"en","type":"letter","venue":"Current Medical Research and Opinion","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; PharmIdeas (Canada)","funders":"Amgen","keywords":"Medicine; Darbepoetin alfa; Epoetin alfa; Dosing; Kidney disease; Internal medicine; Erythropoietin","score_opus":0.23062913471945348,"score_gpt":0.4338414552437033,"score_spread":0.20321232052424984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169369869","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003077382,0.00054736156,0.00007282405,0.9807319,0.016157987,0.000014682811,0.00015280009,0.000018317229,0.0019964196],"genre_scores_gemma":[0.0017159543,0.0003135161,0.00009614791,0.97044635,0.024078477,0.000024284232,0.000032012387,0.000015568981,0.0032776494],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933215,0.0016417914,0.0011359729,0.0009818869,0.0016790351,0.0012398831],"domain_scores_gemma":[0.97903377,0.0141286105,0.001538181,0.0003809337,0.0030108467,0.0019075661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007566753,0.0010635154,0.0027263684,0.0011224508,0.004413789,0.0048742127,0.0038178149,0.1220867,0.009089932],"category_scores_gemma":[0.045277018,0.0012267564,0.0026840025,0.0017416644,0.0038498715,0.0031426016,0.002139452,0.06386197,0.007584947],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011600708,0.000018033972,0.00050804595,0.000056919936,0.000029618404,0.00088057696,0.00012079578,0.00008629765,0.000086403146,0.0027025614,0.99254817,0.0028465928],"study_design_scores_gemma":[0.0005624031,0.00013385013,0.004175563,0.0009567479,0.00024499986,0.0016584535,0.00075881963,0.0011261635,0.0005548123,0.013890039,0.9757783,0.00015977041],"about_ca_topic_score_codex":0.027137961,"about_ca_topic_score_gemma":0.034693033,"teacher_disagreement_score":0.1220867,"about_ca_system_score_codex":0.011005072,"about_ca_system_score_gemma":0.010531879,"threshold_uncertainty_score":0.07984775},"labels":[],"label_agreement":null},{"id":"W2169845877","doi":"10.1038/clpt.2014.144","title":"Adjusted Indirect Treatment Comparison of the Bioavailability of WHO-Prequalified First-Line Generic Antituberculosis Medicines","year":2014,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"World Health Organization","keywords":"Bioequivalence; Interchangeability; Medicine; Confidence interval; Pharmacology; Bioavailability; Innovator; Clinical pharmacology; Isoniazid; Ethambutol; Pyrazinamide; Internal medicine; Tuberculosis; Computer science","score_opus":0.2971360709396938,"score_gpt":0.4304960972344246,"score_spread":0.13336002629473082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169845877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9507337,0.005169685,0.02865348,0.00025911682,0.000220559,0.0007560182,0.0060690646,0.00009793931,0.008040388],"genre_scores_gemma":[0.9909285,0.00024077133,0.005201671,0.0001238293,0.00004255342,0.00039705078,0.0020084889,0.000020990909,0.0010362585],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96057177,0.032286264,0.001531406,0.0018624611,0.003058756,0.0006892306],"domain_scores_gemma":[0.9421457,0.04430264,0.0050350344,0.0060333377,0.002196645,0.00028667206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02357314,0.00071156427,0.0016930818,0.0008559908,0.00018325122,0.0010778254,0.00082645845,0.0008494589,0.0054451646],"category_scores_gemma":[0.04708773,0.00024411362,0.003139345,0.00087056524,0.00061288016,0.0007233977,0.0010237249,0.0017266694,0.00042490082],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25538564,0.0025889813,0.33890006,0.0046116384,0.073090896,0.0006250755,0.0012849156,0.02714913,0.014357088,0.019018298,0.005500869,0.25748745],"study_design_scores_gemma":[0.01162614,0.06144656,0.76807034,0.0004396124,0.039030477,0.0011276869,0.0007700854,0.04118259,0.040190984,0.013464737,0.022232065,0.00041868936],"about_ca_topic_score_codex":0.0007552573,"about_ca_topic_score_gemma":0.000553199,"teacher_disagreement_score":0.02357314,"about_ca_system_score_codex":0.0010168871,"about_ca_system_score_gemma":0.0005713633,"threshold_uncertainty_score":0.12466818},"labels":[],"label_agreement":null},{"id":"W2170271804","doi":"10.2308/accr-10199","title":"Gray Markets and Multinational Transfer Pricing","year":2011,"lang":"en","type":"article","venue":"The Accounting Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transfer pricing; Multinational corporation; Grey market; Business; Monetary economics; Gray (unit); Subsidiary; Variable pricing; Revenue; Economics; Microeconomics; Market economy; Finance","score_opus":0.08662903373861464,"score_gpt":0.28044761961464937,"score_spread":0.19381858587603473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170271804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4836037,0.005233891,0.119827665,0.008749668,0.00019307356,0.00014035983,0.00014659643,0.00020207863,0.38190284],"genre_scores_gemma":[0.9907059,0.0005966737,0.0017999205,0.0002240535,0.000048633152,0.000021245765,0.000009166913,0.00000705799,0.0065873154],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9991393,0.00033210436,0.000026911064,0.000113092545,0.00019582409,0.00019270026],"domain_scores_gemma":[0.99768937,0.0010835242,0.0005899503,0.00026083094,0.00020755707,0.00016883026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018851669,0.00031342663,0.00048756518,0.00067035056,0.00074273895,0.0020707953,0.00061715004,0.0013276177,0.011190656],"category_scores_gemma":[0.004761975,0.00017332386,0.00056599866,0.0006633002,0.003172494,0.0024590539,0.0014043294,0.0013889353,0.00028006086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017651875,0.00003035476,0.0006905438,0.000028175864,0.000014148607,0.00009565364,0.00006952151,0.0103182765,0.00023465102,0.9769927,0.0013956408,0.010112601],"study_design_scores_gemma":[0.000030387582,0.000039775325,0.0015959116,0.00005727352,0.000017889854,0.00008735934,0.00015215135,0.03321787,0.0004872803,0.9533566,0.010942155,0.000015258503],"about_ca_topic_score_codex":0.003869924,"about_ca_topic_score_gemma":0.003151917,"teacher_disagreement_score":0.011190656,"about_ca_system_score_codex":0.0022165321,"about_ca_system_score_gemma":0.0010805078,"threshold_uncertainty_score":0.037436485},"labels":[],"label_agreement":null},{"id":"W2171407238","doi":"10.1016/j.drudis.2008.09.015","title":"Value networks identify innovation in 21st century pharmaceutical research","year":2008,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Pharmaceutical industry; Identification (biology); Value (mathematics); Productivity; CLARION; Pharmaceutical sciences; Business; Knowledge management; Marketing; Computer science; Medicine; Pharmacology; Economics","score_opus":0.18888439426689835,"score_gpt":0.4271825262802506,"score_spread":0.23829813201335226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171407238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031180207,0.9825293,0.0053206584,0.0020903128,0.00024134728,0.000019678824,0.000065669876,0.00001776454,0.006597351],"genre_scores_gemma":[0.037818577,0.95660436,0.00336143,0.00026313405,0.00048567352,0.000019599558,0.00008239887,0.0000044174626,0.001360453],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99932647,0.00020963274,0.000038157195,0.00010920471,0.00026813077,0.000048463313],"domain_scores_gemma":[0.9927602,0.0056014718,0.00079832727,0.00012317873,0.0006384998,0.00007830306],"candidate_categories":["bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.0020972576,0.00063314836,0.0010398879,0.0037850065,0.00026270654,0.0019173687,0.0008437181,0.0013577802,0.0024957957],"category_scores_gemma":[0.0074481573,0.0003110835,0.00042152888,0.006068591,0.0009036125,0.0036396042,0.0007993924,0.0010126787,0.00059086754],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045194338,0.000044764613,0.0032220688,0.005150096,0.00019891655,0.00007256249,0.000073711795,0.0032655245,0.00036296996,0.058693293,0.006695244,0.9221757],"study_design_scores_gemma":[0.00006520595,0.00014478898,0.022229346,0.016559456,0.00074363884,0.0009905974,0.0005103026,0.011401457,0.0028209414,0.39586988,0.5485706,0.00009381368],"about_ca_topic_score_codex":0.0022302894,"about_ca_topic_score_gemma":0.003987334,"teacher_disagreement_score":0.996215,"about_ca_system_score_codex":0.0018904347,"about_ca_system_score_gemma":0.0016148153,"threshold_uncertainty_score":0.013716161},"labels":[],"label_agreement":null},{"id":"W2171639414","doi":"10.1001/jama.286.15.1886","title":"Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?","year":2001,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Intellectual property; Market access; Scarcity; Developing country; Access to medicines; De facto; Antiretroviral treatment; Business; Universal design; Human immunodeficiency virus (HIV); Economic growth; Development economics; International trade; Medicine; Political science; Antiretroviral therapy; Geography; Economics; Virology; Law","score_opus":0.1285627916980011,"score_gpt":0.33598889894447,"score_spread":0.20742610724646887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171639414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92571855,0.01999577,0.0012354882,0.035145175,0.000062657185,0.000031607615,0.00084252615,0.000012746636,0.0169555],"genre_scores_gemma":[0.9944998,0.0043436615,0.00011272736,0.00046257128,0.00009781863,0.0000066743382,0.00007761712,0.0000016956919,0.00039738047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981274,0.00102295,0.00008531721,0.00010821701,0.00018339191,0.00047273558],"domain_scores_gemma":[0.9650298,0.024619035,0.008736998,0.00027585047,0.0007089195,0.0006295025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029025117,0.00019516377,0.0005521665,0.0017985335,0.00049853756,0.0021202979,0.00035074545,0.0011349666,0.006959527],"category_scores_gemma":[0.028969187,0.00022417642,0.00033233548,0.0033881408,0.0014425417,0.0027087205,0.00095648115,0.00090441096,0.00023441482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029059348,0.00012379844,0.8445713,0.00045005168,0.0002902041,0.0012167979,0.0009598662,0.011932539,0.0002300411,0.07614863,0.0064586373,0.05732744],"study_design_scores_gemma":[0.00010557326,0.00013097633,0.90103847,0.00043429568,0.00022818509,0.00068422663,0.0054155258,0.020464761,0.00023190095,0.054331224,0.016907852,0.000027016638],"about_ca_topic_score_codex":0.024245147,"about_ca_topic_score_gemma":0.019516438,"teacher_disagreement_score":0.024245147,"about_ca_system_score_codex":0.0017753172,"about_ca_system_score_gemma":0.0013819153,"threshold_uncertainty_score":0.048208058},"labels":[],"label_agreement":null},{"id":"W2172637990","doi":"10.12927/hcpol.2015.24359","title":"Canada’s New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem","year":2015,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Drug pricing; Economics; Business; Public economics; Operations research; Computer science; Actuarial science; Engineering","score_opus":0.1629821833149132,"score_gpt":0.32281812955915223,"score_spread":0.15983594624423902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172637990","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03441103,0.0076290825,0.31316474,0.4552103,0.0018159299,0.0004964023,0.0039664176,0.00036535106,0.18294087],"genre_scores_gemma":[0.81313634,0.006688252,0.10491446,0.024313657,0.002952715,0.00039897405,0.000790717,0.00015717797,0.04664775],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99385494,0.0020756563,0.00018767719,0.0008965959,0.0020115583,0.0009734657],"domain_scores_gemma":[0.9883801,0.00818706,0.0007210672,0.00040174465,0.0017282382,0.0005818256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008760261,0.001008248,0.0025202793,0.0027207446,0.004158196,0.010421185,0.0035238103,0.011507916,0.006957148],"category_scores_gemma":[0.021863721,0.0012937986,0.0018157173,0.0031384395,0.007708421,0.0073731365,0.0018203261,0.0107158,0.00034090498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014385987,0.000021480979,0.00026955202,0.00003668752,0.0000221228,0.00012846068,0.000101255966,0.012062909,0.00004418444,0.9755967,0.009272217,0.0024298788],"study_design_scores_gemma":[0.000049999453,0.000013736298,0.00045746,0.00006663324,0.00002387861,0.00005605187,0.0001990578,0.034679204,0.00010061308,0.93746316,0.026830425,0.00005970943],"about_ca_topic_score_codex":0.51337737,"about_ca_topic_score_gemma":0.48231614,"teacher_disagreement_score":0.9506199,"about_ca_system_score_codex":0.0493801,"about_ca_system_score_gemma":0.0738021,"threshold_uncertainty_score":0.9789769},"labels":[],"label_agreement":null},{"id":"W2173121992","doi":"10.1200/jco.2015.61.8736","title":"Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; National Institutes of Health; World Health Organization","keywords":"Medicine; Cancer; Intensive care medicine; Internal medicine","score_opus":0.6455804736146742,"score_gpt":0.6181926204129479,"score_spread":0.02738785320172632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173121992","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042684663,0.09083783,0.44976464,0.24631274,0.003413101,0.028942173,0.004066234,0.0008953217,0.13308324],"genre_scores_gemma":[0.20999388,0.0505233,0.7061423,0.013247321,0.001345668,0.010975186,0.002090863,0.00017789427,0.0055036275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8851935,0.07727363,0.008080149,0.004858432,0.022624956,0.0019693298],"domain_scores_gemma":[0.8192464,0.10564882,0.026875852,0.0100182025,0.034588844,0.0036218632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.15879102,0.0020099643,0.0013434483,0.009337554,0.0036825566,0.0134841055,0.003267777,0.0029229994,0.0049117315],"category_scores_gemma":[0.15858601,0.0008331903,0.0023219725,0.011390175,0.008091583,0.0119528165,0.008884374,0.005182476,0.0012239645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028514763,0.0010322199,0.017797567,0.029492881,0.0005435014,0.00030235873,0.01101003,0.0067593805,0.0016952185,0.29139844,0.0384493,0.60123396],"study_design_scores_gemma":[0.00041420234,0.0012901066,0.015101813,0.034806423,0.0010567625,0.00041809442,0.01817064,0.014761203,0.010154627,0.45039147,0.45309108,0.00034361955],"about_ca_topic_score_codex":0.0066694273,"about_ca_topic_score_gemma":0.011354277,"teacher_disagreement_score":0.15879102,"about_ca_system_score_codex":0.019151418,"about_ca_system_score_gemma":0.060869884,"threshold_uncertainty_score":0.83977723},"labels":[],"label_agreement":null},{"id":"W2183209710","doi":"10.22270/ijdra.v2i2.130","title":"A PRAGMATIC WAY TO SUSTAIN IN GENERIC PHARMA ENVIRONMENT: PLCM THROUGH REGULATORY STRATEGIES","year":2018,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Scope (computer science); Profitability index; Business; Quality (philosophy); Product (mathematics); Sustainability; Preference; Marketing; Work (physics); Competitive advantage; Process management; Risk analysis (engineering); Economics; Computer science; Engineering; Finance","score_opus":0.025933142335729867,"score_gpt":0.28150899596129453,"score_spread":0.2555758536255647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2183209710","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029876713,0.007480481,0.09999194,0.40020975,0.0012603842,0.0006889541,0.00014622336,0.00052056386,0.459825],"genre_scores_gemma":[0.8590114,0.0046331915,0.046343744,0.057097208,0.00065903424,0.00047555883,0.000082856626,0.00022643936,0.03147049],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9840209,0.008901089,0.00050266477,0.0011725881,0.003685119,0.0017176878],"domain_scores_gemma":[0.98874694,0.0043778927,0.0016300488,0.0013248527,0.0024002066,0.0015200451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01643499,0.0007544459,0.0005729115,0.0017633598,0.0048706452,0.019454014,0.0017247482,0.009294316,0.00906374],"category_scores_gemma":[0.021689238,0.00040773867,0.00088062265,0.0012318733,0.017636672,0.015790384,0.007862046,0.00842435,0.0024376335],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002775842,0.000101308295,0.0007126872,0.00023829544,0.00001980204,0.00034424607,0.0028219048,0.0006815666,0.000933915,0.9465803,0.01482695,0.032711167],"study_design_scores_gemma":[0.00003742417,0.00020421617,0.0010949596,0.0008626889,0.000022773671,0.00034892865,0.0069375345,0.0013347629,0.0016925612,0.6072969,0.3800803,0.000086903274],"about_ca_topic_score_codex":0.002728245,"about_ca_topic_score_gemma":0.0032759258,"teacher_disagreement_score":0.019454014,"about_ca_system_score_codex":0.0075046406,"about_ca_system_score_gemma":0.018641483,"threshold_uncertainty_score":0.08691752},"labels":[],"label_agreement":null},{"id":"W2185030980","doi":"","title":"THE SIGNIFICANCE OF BRANDING IN THE PHARMACEUTICAL INDUSTRY","year":2005,"lang":"en","type":"dissertation","venue":"Summit (Simon Fraser University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Simon Fraser University","keywords":"Pharmaceutical industry; Business; Advertising; Biotechnology; Biology","score_opus":0.04684109745479109,"score_gpt":0.2808766986261215,"score_spread":0.23403560117133043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185030980","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29920706,0.07346466,0.014944799,0.12070537,0.0013517918,0.00015829742,0.00012326724,0.00005199491,0.4899928],"genre_scores_gemma":[0.9566112,0.02799748,0.002534663,0.0036939585,0.0010686489,0.0000210056,0.000032282525,0.000015437872,0.008025242],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99562114,0.0024611228,0.00016626164,0.0002539538,0.0011556682,0.00034188275],"domain_scores_gemma":[0.97797054,0.01593263,0.0027220706,0.0006007478,0.0017312668,0.0010426695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067947605,0.00019628556,0.0003254504,0.0016892971,0.0018245277,0.007543174,0.00034129506,0.0016277729,0.0053386027],"category_scores_gemma":[0.018794365,0.00025512633,0.0003570862,0.002367537,0.0057731373,0.005517523,0.0017184223,0.0024542534,0.0004094119],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075564916,0.00016005913,0.048046764,0.00045620135,0.00003685445,0.00041040604,0.0072787395,0.0016373635,0.0004731729,0.74360067,0.008815077,0.18900912],"study_design_scores_gemma":[0.000032358632,0.00030660725,0.13318375,0.0014230611,0.00012268344,0.0007946541,0.015261502,0.004229484,0.0010478955,0.71337545,0.13008589,0.00013679985],"about_ca_topic_score_codex":0.0036661027,"about_ca_topic_score_gemma":0.0029610307,"teacher_disagreement_score":0.007543174,"about_ca_system_score_codex":0.0036090913,"about_ca_system_score_gemma":0.0022326452,"threshold_uncertainty_score":0.035934567},"labels":[],"label_agreement":null},{"id":"W2186044971","doi":"10.1016/j.jval.2015.09.2007","title":"Comparative Analysis of The Reimbursement Landscape of Orphan Drugs on An International Level","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Orphan drug; Reimbursement; Listing (finance); Medicine; Family medicine; Business; Public economics; Health care; Economic growth; Economics; Finance; Bioinformatics","score_opus":0.3080938908832449,"score_gpt":0.39867403604382745,"score_spread":0.09058014516058255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2186044971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8409202,0.013880098,0.0050787367,0.009602505,0.00011691353,0.00004974557,0.0016462208,0.000039664217,0.1286659],"genre_scores_gemma":[0.99460465,0.0015335198,0.0006732546,0.00021930654,0.00005510808,0.000011829498,0.0005021557,0.000021813728,0.002378368],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99818146,0.00077096367,0.00006693526,0.00015412216,0.00045443195,0.00037208482],"domain_scores_gemma":[0.99546105,0.0020664781,0.0010477906,0.00020079044,0.00079315616,0.00043066515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002325229,0.00021220036,0.00059637765,0.0020944523,0.000425272,0.0034064031,0.00049344834,0.00081252726,0.008130632],"category_scores_gemma":[0.009401161,0.00013771608,0.0008818477,0.0036187682,0.0008361967,0.0015832908,0.0011754591,0.0012362159,0.00029197126],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027463299,0.0005101294,0.10912614,0.00058497675,0.0008560587,0.0008898181,0.0011762688,0.033636186,0.004219439,0.68623143,0.015834192,0.14418912],"study_design_scores_gemma":[0.00028183332,0.0013067153,0.73386586,0.00060426653,0.0010653653,0.0013402775,0.007163344,0.035323635,0.003572768,0.12313673,0.092221655,0.00011752567],"about_ca_topic_score_codex":0.0053199055,"about_ca_topic_score_gemma":0.00865271,"teacher_disagreement_score":0.008130632,"about_ca_system_score_codex":0.0029166623,"about_ca_system_score_gemma":0.0012927977,"threshold_uncertainty_score":0.027199686},"labels":[],"label_agreement":null},{"id":"W2189839493","doi":"10.1007/s40258-015-0208-z","title":"A Review of “The New Drug Reimbursement Game: A Regulator’s Guide to Playing and Winning”","year":2015,"lang":"en","type":"review","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Reimbursement; Health economics; Regulator; Health administration; Quality of Life Research; Public health; Drug; Public finance; Medicine; Business; Pharmacology; Nursing; Political science; Health care; Law","score_opus":0.17407458428908373,"score_gpt":0.44635993039105404,"score_spread":0.2722853461019703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2189839493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004049864,0.9881088,0.0006996169,0.0066653145,0.0013614101,0.000025381616,0.00010710168,0.000016988488,0.0029748937],"genre_scores_gemma":[0.0009537784,0.98590195,0.0014168905,0.007905023,0.0014455646,0.00006389508,0.00012467412,0.000015874226,0.0021723302],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973242,0.00088401634,0.0004185677,0.00020292817,0.00102699,0.00014324],"domain_scores_gemma":[0.99395627,0.003931171,0.00052633055,0.00009889788,0.0013049056,0.00018241488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004688106,0.0013385568,0.002131429,0.0053230557,0.00065922434,0.003326645,0.0019991943,0.0040060575,0.0092926165],"category_scores_gemma":[0.0135195395,0.0006530393,0.0013996683,0.006319132,0.0015962793,0.00447019,0.0015635852,0.0041731824,0.004104657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005328687,0.00006813415,0.00010680965,0.01757808,0.00010703133,0.000076495344,0.000077108685,0.00043729166,0.00023031006,0.032194212,0.4360744,0.51299673],"study_design_scores_gemma":[0.000018853081,0.000025798194,0.00028156734,0.011067043,0.00005985597,0.00012279375,0.000032834138,0.000097381235,0.00007281619,0.008008292,0.98019224,0.000020414242],"about_ca_topic_score_codex":0.005774659,"about_ca_topic_score_gemma":0.014117695,"teacher_disagreement_score":0.0092926165,"about_ca_system_score_codex":0.0036856914,"about_ca_system_score_gemma":0.008722101,"threshold_uncertainty_score":0.031086862},"labels":[],"label_agreement":null},{"id":"W2199056744","doi":"10.4000/ethiquepublique.1858","title":"L’impact psychosocial du rationnement de l’accès aux traitements antirétroviraux dans les pays à ressources limitées","year":2006,"lang":"fr","type":"article","venue":"Éthique Publique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Human immunodeficiency virus (HIV); Philosophy; Medicine; Virology","score_opus":0.04091444852943463,"score_gpt":0.2973324199794017,"score_spread":0.25641797144996703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199056744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8325806,0.020845935,0.0017252875,0.08352549,0.00035368308,0.00007895172,0.00047466834,0.000020766727,0.060394544],"genre_scores_gemma":[0.9873476,0.006547413,0.0004554448,0.0025064507,0.0001337079,0.000028865197,0.00005276681,0.0000068228005,0.0029208476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950523,0.00340676,0.0001374123,0.00021326881,0.0006014167,0.0005889282],"domain_scores_gemma":[0.9909025,0.004287274,0.0023875802,0.00026757424,0.0009831962,0.0011719791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004791537,0.00019010057,0.000272083,0.0005917913,0.00096492626,0.0024192582,0.00040906042,0.00078355044,0.0073134573],"category_scores_gemma":[0.0125388615,0.00017468604,0.00042278128,0.0005712305,0.0019900135,0.00091654155,0.0012238683,0.0009770842,0.000328171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001185087,0.0010722515,0.5023235,0.0021163838,0.0009881892,0.0012418884,0.022033134,0.0019992997,0.0031109822,0.07671368,0.012900841,0.3743148],"study_design_scores_gemma":[0.0002145776,0.0022929513,0.8264993,0.0028950716,0.0004458607,0.0011900277,0.034967586,0.0013071698,0.0012389551,0.023271853,0.10558587,0.00009073518],"about_ca_topic_score_codex":0.025041725,"about_ca_topic_score_gemma":0.023787385,"teacher_disagreement_score":0.025041725,"about_ca_system_score_codex":0.003622384,"about_ca_system_score_gemma":0.006164065,"threshold_uncertainty_score":0.049791932},"labels":[],"label_agreement":null},{"id":"W2199975518","doi":"10.1161/circoutcomes.7.suppl_1.22","title":"Abstract 22: Impact Of Drug Policy On Regional Trends In Ezetimibe Use","year":2014,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Ezetimibe; Formulary; Population; Medicine; Restrictiveness; Demography; Proxy (statistics); Geography; Environmental health; Statistics; Family medicine; Internal medicine; Mathematics","score_opus":0.148349463738525,"score_gpt":0.36434580763360935,"score_spread":0.21599634389508435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199975518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91721267,0.006750928,0.0013634538,0.019270582,0.00014057389,0.0001629134,0.035104595,0.00012487086,0.019869264],"genre_scores_gemma":[0.99334794,0.0009988227,0.00053280045,0.0009862357,0.000045792258,0.000036475114,0.0026182213,0.000026441052,0.001407138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99638784,0.0010896237,0.00027954965,0.0005693447,0.00066433096,0.0010092857],"domain_scores_gemma":[0.9841664,0.002633734,0.006705967,0.00072577107,0.0041768146,0.0015913658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030634825,0.00019649172,0.00039866526,0.0010422559,0.00058806094,0.002206595,0.0011208374,0.00057840697,0.0039386214],"category_scores_gemma":[0.018226124,0.00021469913,0.0010746015,0.0027513823,0.0006375776,0.0006482367,0.0010229124,0.0009329466,0.00048006905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052176975,0.00006461428,0.97257274,0.00019503266,0.00046502985,0.0001601719,0.00020950845,0.0034983708,0.00024762432,0.0017163472,0.008413379,0.011935372],"study_design_scores_gemma":[0.000035060242,0.000046502766,0.9925844,0.000062817635,0.00015381628,0.00005720014,0.00030858914,0.0013463421,0.00022817607,0.00012909196,0.005033416,0.0000144230125],"about_ca_topic_score_codex":0.8838012,"about_ca_topic_score_gemma":0.8375533,"teacher_disagreement_score":0.8838012,"about_ca_system_score_codex":0.014539378,"about_ca_system_score_gemma":0.018679358,"threshold_uncertainty_score":0.23376614},"labels":[],"label_agreement":null},{"id":"W2209930065","doi":"10.2139/ssrn.2649260","title":"Funding Translational Medicine via Public Markets: The Business Development Company","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Translational medicine; Business; Industrial organization; Medicine","score_opus":0.1077964548714761,"score_gpt":0.28855949494863287,"score_spread":0.18076304007715677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2209930065","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006275008,0.045130264,0.003929328,0.832874,0.0255132,0.00030123597,0.0014973083,0.0006155328,0.083864026],"genre_scores_gemma":[0.27758127,0.07084555,0.011021485,0.18920743,0.0489346,0.00095891516,0.003445553,0.0006621738,0.397343],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948079,0.0015645456,0.00020982575,0.0005465122,0.001811227,0.0010600241],"domain_scores_gemma":[0.97259945,0.0077735214,0.0025166739,0.0011510685,0.00353843,0.012420885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01184766,0.00081720395,0.0007432653,0.0011682699,0.0010803003,0.007916297,0.0006627006,0.010629766,0.04077935],"category_scores_gemma":[0.027516104,0.0004719351,0.00070106913,0.0009187537,0.0020386046,0.005347566,0.0029712997,0.009156734,0.010048659],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054083514,0.0001806757,0.0015720442,0.00029109,0.000053161326,0.00016418549,0.00006106834,0.00033604619,0.001075694,0.07821673,0.7517097,0.16579875],"study_design_scores_gemma":[0.0012613613,0.0005139247,0.005536106,0.0012686795,0.000109451365,0.0005223874,0.00015277465,0.00257867,0.002319764,0.052326795,0.93333375,0.00007641308],"about_ca_topic_score_codex":0.0011231374,"about_ca_topic_score_gemma":0.0017225934,"teacher_disagreement_score":0.04077935,"about_ca_system_score_codex":0.00443018,"about_ca_system_score_gemma":0.021433996,"threshold_uncertainty_score":0.13642055},"labels":[],"label_agreement":null},{"id":"W2216816010","doi":"","title":"Federal Delays in Approving New Medicines 2013","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Notice; Harmonization; Government (linguistics); Order (exchange); Business; Population; Medicine; Political science; Environmental health; Law; Finance","score_opus":0.026471493947228805,"score_gpt":0.25366425673031895,"score_spread":0.22719276278309014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216816010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49130842,0.009370576,0.006181305,0.07805318,0.001515997,0.0008066201,0.034590505,0.00079705846,0.37737635],"genre_scores_gemma":[0.96350455,0.0012778713,0.0014864124,0.0054737,0.00025379634,0.00013187541,0.0034037058,0.000036423335,0.024431594],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9823446,0.0020327694,0.0010230822,0.0010969652,0.0095594125,0.0039432114],"domain_scores_gemma":[0.9440612,0.021001084,0.01228727,0.0020480757,0.017803412,0.0027988988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008644415,0.00021873244,0.00040105087,0.0019289219,0.002695275,0.003149829,0.0010079906,0.0015443027,0.016408665],"category_scores_gemma":[0.04754421,0.00039962414,0.00076009345,0.002019727,0.0007859494,0.0014571692,0.0010256041,0.0023811166,0.0013971553],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002592867,0.0007317142,0.26956224,0.0014587019,0.0005017706,0.0007550658,0.0039330847,0.008741241,0.0023849576,0.16750652,0.31861395,0.22321789],"study_design_scores_gemma":[0.00025045723,0.00061980664,0.46751827,0.00036690646,0.00030161106,0.00046244208,0.0023619705,0.0051267794,0.0066200253,0.0076223635,0.5085719,0.00017747498],"about_ca_topic_score_codex":0.67183965,"about_ca_topic_score_gemma":0.67203075,"teacher_disagreement_score":0.67183965,"about_ca_system_score_codex":0.041143615,"about_ca_system_score_gemma":0.042197723,"threshold_uncertainty_score":0.6601859},"labels":[],"label_agreement":null},{"id":"W2221479424","doi":"10.1016/j.ejpb.2007.01.003","title":"Drug delivery: A Canadian perspective","year":2007,"lang":"en","type":"editorial","venue":"European Journal of Pharmaceutics and Biopharmaceutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Drug; Drug delivery; Pharmacology; Medicine; Chemistry; Computer science","score_opus":0.05037846334896324,"score_gpt":0.31348842040875363,"score_spread":0.2631099570597904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2221479424","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009398355,0.20816937,0.000193629,0.36246303,0.412988,0.00002241414,0.00018729511,0.000053583113,0.01582877],"genre_scores_gemma":[0.007858941,0.29419982,0.0006315969,0.2025465,0.44288796,0.000036299556,0.00009660524,0.00008469799,0.051657483],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877038,0.001210734,0.0009316172,0.0010027374,0.0077907587,0.0013604349],"domain_scores_gemma":[0.96093863,0.005682133,0.0010781088,0.0005221085,0.026731052,0.005048105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01066723,0.0042722365,0.004186017,0.009923677,0.0063593597,0.017997868,0.0067048096,0.04179622,0.0125819035],"category_scores_gemma":[0.033455554,0.0011998381,0.00293466,0.009110602,0.010283412,0.00632777,0.0021894274,0.031198854,0.0036482376],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027757504,0.000011636795,0.000019552243,0.00033384154,0.000024515894,0.00009284596,0.000038213846,0.000108689215,0.000037937294,0.006872519,0.98535603,0.0070765438],"study_design_scores_gemma":[0.000033313627,0.000008873519,0.00015668309,0.0005241764,0.00005574297,0.000062005034,0.00007533217,0.00009150808,0.000038380993,0.0023275432,0.99659985,0.000026516456],"about_ca_topic_score_codex":0.7373847,"about_ca_topic_score_gemma":0.848828,"teacher_disagreement_score":0.9113346,"about_ca_system_score_codex":0.08866542,"about_ca_system_score_gemma":0.118338086,"threshold_uncertainty_score":0.6433157},"labels":[],"label_agreement":null},{"id":"W2226623001","doi":"","title":"Employers favor legalizing Rx purchases from Canada","year":2005,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Medical prescription; Government (linguistics); Community practice; Pharmacy; Family medicine; Nursing","score_opus":0.07846345986425894,"score_gpt":0.2732057644464797,"score_spread":0.19474230458222075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226623001","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09647639,0.0030266829,0.00047310867,0.38266888,0.0011246349,0.00010678066,0.0019345523,0.00018956742,0.51399934],"genre_scores_gemma":[0.5570646,0.0039394004,0.0006312058,0.23902193,0.0014410691,0.000042775857,0.0012259282,0.00007555707,0.19655761],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99388003,0.0002747623,0.00011873559,0.00036392146,0.0036003394,0.0017622318],"domain_scores_gemma":[0.98988974,0.003721172,0.000800997,0.00030847627,0.0029566358,0.0023229397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019891048,0.00025996153,0.0003066036,0.0010445118,0.007710518,0.004844432,0.0010630651,0.006473437,0.02817229],"category_scores_gemma":[0.01322892,0.00037287455,0.0005783863,0.0011974102,0.00211333,0.00086924405,0.001517065,0.0050508506,0.0024840706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034317523,0.00023460413,0.09303873,0.00020553637,0.00010227089,0.0011420932,0.0016609522,0.00043942218,0.0035272893,0.059015304,0.7697068,0.07058369],"study_design_scores_gemma":[0.0003208619,0.00021041422,0.16407615,0.0004813204,0.00022915084,0.0006668167,0.0038858815,0.0009555075,0.0038004383,0.00357849,0.8216698,0.00012501753],"about_ca_topic_score_codex":0.8725701,"about_ca_topic_score_gemma":0.9355408,"teacher_disagreement_score":0.1274299,"about_ca_system_score_codex":0.013603025,"about_ca_system_score_gemma":0.051568463,"threshold_uncertainty_score":0.2563607},"labels":[],"label_agreement":null},{"id":"W2227034299","doi":"","title":"The politics of the EU pharmaceutical industry","year":2004,"lang":"en","type":"book-chapter","venue":"London School of Economics and Political Science Research Online (London School of Economics and Political Science)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Politics; Pharmaceutical industry; Business; Political science; Law; Medicine; Pharmacology","score_opus":0.11704074008761553,"score_gpt":0.38505406423716715,"score_spread":0.2680133241495516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227034299","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051566567,0.05165188,0.0012900368,0.1359604,0.00223524,0.00001677907,0.00007510326,0.00006497724,0.8035489],"genre_scores_gemma":[0.3299994,0.03800671,0.0033035593,0.24205117,0.0034009474,0.00015791829,0.00021021711,0.00013984668,0.38273022],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926721,0.0027926688,0.00020295146,0.00079779595,0.0023945193,0.0011400337],"domain_scores_gemma":[0.9985783,0.0006759447,0.0001497603,0.00013352108,0.00024662822,0.00021579677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048003765,0.00038706654,0.0005224227,0.0012454565,0.0048131705,0.014706265,0.00087766355,0.007613363,0.008900588],"category_scores_gemma":[0.006393186,0.00036359963,0.0006456077,0.0017168059,0.006068154,0.0060768453,0.0053339656,0.006413607,0.002119141],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000106110265,0.000006938682,0.00007680065,0.000032931184,0.0000049631294,0.000053446773,0.00042855783,0.00008694757,0.00007359515,0.9378548,0.051043343,0.010327013],"study_design_scores_gemma":[0.000007884525,0.000014647807,0.00048252236,0.00021792376,0.000004033898,0.000064950815,0.00072137197,0.00015341483,0.000115215684,0.064065814,0.93414384,0.00000834919],"about_ca_topic_score_codex":0.0045001907,"about_ca_topic_score_gemma":0.0030716776,"teacher_disagreement_score":0.014706265,"about_ca_system_score_codex":0.00486268,"about_ca_system_score_gemma":0.0052316305,"threshold_uncertainty_score":0.03528136},"labels":[],"label_agreement":null},{"id":"W2245971688","doi":"","title":"How should we support pharmaceutical innovation","year":2009,"lang":"en","type":"article","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Business; Subsidy; Health care; Pharmaceutical industry; Risk analysis (engineering); Industrial organization; Marketing; Pharmacology; Medicine; Economics; Economic growth","score_opus":0.18106743541340944,"score_gpt":0.3992432614849622,"score_spread":0.21817582607155275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245971688","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005120134,0.0067361393,0.0043842862,0.91866094,0.003710713,0.000037988983,0.00012406481,0.00018017407,0.06104556],"genre_scores_gemma":[0.4294643,0.018651795,0.0091582965,0.48064628,0.016813312,0.0003037841,0.0001688984,0.0002084094,0.044584982],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98586804,0.0057201358,0.00049644464,0.0014756173,0.0035810631,0.0028587505],"domain_scores_gemma":[0.955868,0.018514913,0.0054288222,0.0040919036,0.009241099,0.006855264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015858231,0.00063952233,0.0009908174,0.0020118284,0.003298294,0.013346487,0.0015234903,0.016345156,0.023173809],"category_scores_gemma":[0.077938154,0.00039422917,0.00096485636,0.0016818374,0.011100552,0.02247928,0.005311875,0.010166625,0.008760439],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007591778,0.00017392094,0.0014855136,0.00034879806,0.00008884622,0.0001261,0.0005042194,0.0011127861,0.00028983378,0.8225574,0.1348725,0.03836417],"study_design_scores_gemma":[0.00013374501,0.00006835764,0.0012534203,0.00036990002,0.000033286782,0.000078008015,0.00046859856,0.0006481363,0.00036183067,0.56339085,0.43315852,0.00003531538],"about_ca_topic_score_codex":0.004467714,"about_ca_topic_score_gemma":0.0020502917,"teacher_disagreement_score":0.023173809,"about_ca_system_score_codex":0.0057002236,"about_ca_system_score_gemma":0.0144862505,"threshold_uncertainty_score":0.08386737},"labels":[],"label_agreement":null},{"id":"W2248814847","doi":"10.1016/j.hcmf.2012.07.017","title":"Drug Shortages: Canadian Strategies for a Complex Global Problem","year":2012,"lang":"en","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Purchasing; Procurement; Economic shortage; Competition (biology); Supply chain; Marketing; Service (business); Industrial organization","score_opus":0.09820773978414382,"score_gpt":0.33362530713366084,"score_spread":0.23541756734951702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248814847","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010868514,0.013037876,0.0012420497,0.88717616,0.0018412533,0.00009265075,0.00041976685,0.00013694682,0.08518482],"genre_scores_gemma":[0.37114292,0.06328218,0.0119738225,0.40568238,0.002483792,0.00021233306,0.001119777,0.00028261426,0.14382008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953467,0.00051595096,0.00015846212,0.0003479832,0.0019204122,0.0017104624],"domain_scores_gemma":[0.9883327,0.0012394352,0.00060323754,0.00026509503,0.0046892855,0.004870237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053327666,0.000850385,0.0005231256,0.0040212213,0.014571283,0.008044245,0.002023425,0.006378621,0.020074837],"category_scores_gemma":[0.011817246,0.0004094279,0.0010407194,0.005584761,0.005833337,0.0035573246,0.0063828416,0.0064035687,0.0010623751],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068688554,0.00012919331,0.009610841,0.000517435,0.000054261414,0.0012636501,0.0035064488,0.0012843272,0.00042632027,0.21530923,0.6305394,0.13729033],"study_design_scores_gemma":[0.00007906775,0.00005730973,0.011214967,0.00072016555,0.00005284587,0.00038707303,0.006979165,0.0012246002,0.00019382198,0.027332122,0.95166594,0.00009291205],"about_ca_topic_score_codex":0.9583186,"about_ca_topic_score_gemma":0.97574776,"teacher_disagreement_score":0.91398555,"about_ca_system_score_codex":0.08601444,"about_ca_system_score_gemma":0.30123535,"threshold_uncertainty_score":0.6240814},"labels":[],"label_agreement":null},{"id":"W2253608104","doi":"","title":"Рынок ОНЛС РФ по итогам i квартала 2011 г.","year":2011,"lang":"ru","type":"article","venue":"Ремедиум. Журнал о российском рынке лекарств и медицинской технике","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Agricultural economics; Commerce; Business; Economics; Geography","score_opus":0.16935549050366325,"score_gpt":0.2793907760325379,"score_spread":0.11003528552887468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2253608104","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03525,0.016829863,0.0137499245,0.016928721,0.0052932207,0.00045946453,0.0074913446,0.0009543178,0.90304303],"genre_scores_gemma":[0.2535234,0.014986322,0.015349019,0.0025786157,0.0010577269,0.00052983756,0.0040899296,0.00026996032,0.7076153],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9990662,0.000116149386,0.00006146726,0.00011628216,0.0004989483,0.00014102612],"domain_scores_gemma":[0.99926716,0.00012114272,0.000109581924,0.00006489153,0.00034659167,0.00009058257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009309931,0.00029528802,0.00019265374,0.0010084391,0.0013042234,0.0022660377,0.00028826215,0.0010469656,0.03871479],"category_scores_gemma":[0.0018324291,0.00030618877,0.00026428446,0.0013083084,0.0005745627,0.00085764856,0.0006341678,0.0017146546,0.029442638],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003945579,0.000097225944,0.0067640664,0.00056101516,0.000041166877,0.0006913515,0.0010275098,0.0007785942,0.009323504,0.3605305,0.3099212,0.30986938],"study_design_scores_gemma":[0.000011573162,0.000045412376,0.0069068396,0.000044808294,0.000012338567,0.0002477719,0.0001331916,0.00015495281,0.0022017483,0.0041823303,0.9860314,0.00002753108],"about_ca_topic_score_codex":0.017361732,"about_ca_topic_score_gemma":0.02112711,"teacher_disagreement_score":0.03871479,"about_ca_system_score_codex":0.0023453347,"about_ca_system_score_gemma":0.003993797,"threshold_uncertainty_score":0.12951392},"labels":[],"label_agreement":null},{"id":"W2254545690","doi":"","title":"Denaturalizing Transparency in Drug Regulation","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Transparency (behavior); Business; Drug; Law and economics; Accounting; Political science; Law; Pharmacology; Economics; Medicine","score_opus":0.05359186535836978,"score_gpt":0.27909450932715746,"score_spread":0.22550264396878766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254545690","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041039396,0.014175107,0.13533218,0.3800678,0.0019142076,0.00026292846,0.00017473345,0.00034722913,0.42668638],"genre_scores_gemma":[0.9426347,0.004519667,0.014474834,0.02544037,0.0014700732,0.000149682,0.000042407148,0.000083607774,0.011184608],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.91354173,0.04216475,0.0026866628,0.0055880197,0.028104424,0.00791444],"domain_scores_gemma":[0.88946337,0.07416593,0.010674983,0.011102292,0.012392224,0.0022011644],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.058899473,0.0005382385,0.00093083206,0.0033565308,0.0067687063,0.016811425,0.0020440754,0.009373895,0.0028795227],"category_scores_gemma":[0.11706077,0.0006687973,0.0010604358,0.002536998,0.060720403,0.01459788,0.009720894,0.015482128,0.00056373555],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000069148837,0.000005759914,0.00025861542,0.000026591164,0.000004807772,0.00003247446,0.00086769514,0.0004259582,0.000065723194,0.9930621,0.001350011,0.0038933393],"study_design_scores_gemma":[0.000023462639,0.000021496244,0.0007228625,0.00022408232,0.00001331122,0.00006431311,0.00048411544,0.0013379743,0.0004271707,0.938683,0.057961807,0.000036383997],"about_ca_topic_score_codex":0.058825627,"about_ca_topic_score_gemma":0.029974364,"teacher_disagreement_score":0.9932313,"about_ca_system_score_codex":0.026569944,"about_ca_system_score_gemma":0.036991157,"threshold_uncertainty_score":0.31149393},"labels":[],"label_agreement":null},{"id":"W2255400834","doi":"","title":"Access Delayed, Access Denied 2012: Waiting for New Medicines in Canada","year":2011,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Government (linguistics); Medicine; Business; Environmental health; Public administration; Political science","score_opus":0.09396964474850476,"score_gpt":0.3085533339003749,"score_spread":0.21458368915187015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255400834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7904451,0.007596946,0.00047219906,0.1443083,0.0004795327,0.00022367305,0.009523857,0.000061926694,0.046888493],"genre_scores_gemma":[0.98029125,0.0030798153,0.0002803749,0.008371291,0.00014502968,0.000030687548,0.0015643135,0.000024894372,0.006212389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99401987,0.00035058433,0.00020138374,0.00039653262,0.0017949481,0.0032367753],"domain_scores_gemma":[0.9797442,0.0024960858,0.0034458125,0.00028513497,0.0050022826,0.009026462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021017252,0.00025702824,0.0006998809,0.0017219211,0.009547953,0.005763464,0.002176431,0.0029683572,0.008065646],"category_scores_gemma":[0.012061868,0.00044884838,0.0008981323,0.007480071,0.0020845474,0.0018426059,0.0022672433,0.0069956523,0.00031292834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010955882,0.00082394015,0.7103165,0.00040956144,0.0003541587,0.00440034,0.006943852,0.0032306928,0.00039266076,0.04052146,0.15998997,0.071521275],"study_design_scores_gemma":[0.0005143874,0.00028374884,0.8559486,0.0008121624,0.0005851522,0.0017833314,0.03222345,0.013843335,0.00046004634,0.008183914,0.08492723,0.00043455488],"about_ca_topic_score_codex":0.9972355,"about_ca_topic_score_gemma":0.9983877,"teacher_disagreement_score":0.1328293,"about_ca_system_score_codex":0.1328293,"about_ca_system_score_gemma":0.21849412,"threshold_uncertainty_score":0.9637485},"labels":[],"label_agreement":null},{"id":"W2255665729","doi":"10.1177/0020731418789610","title":"Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario","year":2018,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); York University; McMaster University; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Formulary; Listing (finance); Business; Intellectual property; Generic drug; Drug; Medicine; Finance; Pharmacology; Law; Political science","score_opus":0.09767670350483715,"score_gpt":0.3186185929819469,"score_spread":0.22094188947710974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255665729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8925386,0.015209975,0.00040412802,0.011585714,0.00007660629,0.00017909863,0.02592945,0.000037744336,0.054038584],"genre_scores_gemma":[0.98525304,0.0050381217,0.00016380972,0.000878881,0.00005178171,0.000032137952,0.0042997217,0.000013408059,0.004269128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960013,0.00029477768,0.00024401039,0.0003431123,0.0022496234,0.0008671785],"domain_scores_gemma":[0.9587244,0.0067191594,0.021543782,0.0012074664,0.007967949,0.0038371943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018117377,0.00021334698,0.00044412503,0.0024525623,0.0024590571,0.0019844736,0.0013387353,0.00063694234,0.007003981],"category_scores_gemma":[0.020400891,0.0003908562,0.000796711,0.007873521,0.0013215622,0.00087124616,0.0011300516,0.0009159484,0.0002475775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045363532,0.00007467856,0.96520233,0.00043875963,0.00025986202,0.0002343095,0.0015133267,0.00037677708,0.000112598354,0.0020786664,0.010597225,0.018657863],"study_design_scores_gemma":[0.000055520137,0.000031880707,0.98691285,0.00018822441,0.00015226168,0.000049106795,0.0006697211,0.00030664247,0.00009380606,0.000091168884,0.0114366785,0.000012194318],"about_ca_topic_score_codex":0.9933407,"about_ca_topic_score_gemma":0.99543864,"teacher_disagreement_score":0.051493466,"about_ca_system_score_codex":0.051493466,"about_ca_system_score_gemma":0.062127374,"threshold_uncertainty_score":0.373613},"labels":[],"label_agreement":null},{"id":"W2260302947","doi":"","title":"U.S. Senate Testimony on the Dept. of Commerce OECD Drug Pricing Report","year":2005,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Prescription drug; Business; Government (linguistics); Drug prices; Cash; Medical prescription; International trade; International economics; Health care; Economics; Development economics; Economic growth; Public economics; Finance; Medicine","score_opus":0.03214763514563925,"score_gpt":0.2723394979906702,"score_spread":0.24019186284503094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260302947","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027994611,0.0086169625,0.0003225283,0.33312416,0.014827788,0.0002840475,0.007994119,0.00025084012,0.6317802],"genre_scores_gemma":[0.021559926,0.007022291,0.0005249448,0.31782943,0.0041320575,0.00045959282,0.0017050363,0.00014700407,0.64661974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716884,0.0002708399,0.00018792514,0.00026408295,0.0014937351,0.0006145192],"domain_scores_gemma":[0.9968495,0.0011820731,0.00018012073,0.0001275155,0.0014294529,0.00023127187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001976629,0.0007942114,0.00062798505,0.0020727364,0.00529523,0.004620053,0.0012798315,0.014025548,0.05219976],"category_scores_gemma":[0.008922269,0.0005137846,0.0008478743,0.0026439528,0.0010072888,0.0014665297,0.0012374913,0.007793855,0.027935566],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017660146,0.000013673175,0.0003977945,0.000025872407,0.0000053628023,0.00019647442,0.000032669217,0.000030235566,0.000047777125,0.004890919,0.99039394,0.003947593],"study_design_scores_gemma":[0.000018066288,0.000011669313,0.0021523065,0.00013993116,0.000019101888,0.00009080668,0.000095942334,0.00008815077,0.00020341697,0.0010493738,0.99611014,0.000021122942],"about_ca_topic_score_codex":0.10605315,"about_ca_topic_score_gemma":0.15018506,"teacher_disagreement_score":0.10605315,"about_ca_system_score_codex":0.0061737006,"about_ca_system_score_gemma":0.009525243,"threshold_uncertainty_score":0.2108717},"labels":[],"label_agreement":null},{"id":"W2262056843","doi":"","title":"Twelve years after Canada's access to medicines regime : should South Africa follow the path?","year":2015,"lang":"en","type":"article","venue":"South African Law Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Legislation; Exportation; Order (exchange); Business; Mechanism (biology); Drug industry; International trade; Developing country; Economic growth; Law; Political science; Economics; Finance; Engineering","score_opus":0.09757953290351798,"score_gpt":0.28458232801573463,"score_spread":0.18700279511221665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262056843","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036080368,0.041138668,0.0007122269,0.79050195,0.0017962867,0.0000820967,0.00059902354,0.000028413833,0.12906101],"genre_scores_gemma":[0.5629314,0.053651024,0.0025485745,0.2778723,0.0007086956,0.00007702721,0.00043640012,0.000086997636,0.10168756],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955187,0.00041304808,0.00012011658,0.00026633427,0.0013629886,0.0023187725],"domain_scores_gemma":[0.99479586,0.0013072047,0.0004121053,0.00012663032,0.0019266217,0.0014316357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032394764,0.00030487712,0.00043362012,0.0010567653,0.009292196,0.009452951,0.0012589085,0.008167702,0.0082339635],"category_scores_gemma":[0.012405358,0.00026614754,0.0007481759,0.0024103285,0.005254949,0.0052088317,0.0022214255,0.008157514,0.00056975585],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018141852,0.00007000414,0.0075659836,0.0009582024,0.00008288072,0.0031942117,0.012065706,0.00059431774,0.0014231798,0.73772335,0.1616004,0.07454028],"study_design_scores_gemma":[0.000050699815,0.00006094268,0.0135096405,0.0010890095,0.000065480046,0.0004512654,0.008665858,0.00020392041,0.0007697058,0.018820658,0.95621365,0.0000991778],"about_ca_topic_score_codex":0.94963175,"about_ca_topic_score_gemma":0.96337646,"teacher_disagreement_score":0.93379873,"about_ca_system_score_codex":0.06620128,"about_ca_system_score_gemma":0.1806558,"threshold_uncertainty_score":0.48032612},"labels":[],"label_agreement":null},{"id":"W2271290295","doi":"","title":"Formulary Pricing with Optional Participation: Reconciling Static and Dynamic Efficiency","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Formulary; Dynamic efficiency; Incentive; Economic surplus; Public economics; Listing (finance); Variety (cybernetics); Externality; Business; Negotiation; Economics; Welfare; Industrial organization; Microeconomics; Finance; Market economy","score_opus":0.024026847104903656,"score_gpt":0.2851835727259557,"score_spread":0.261156725621052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271290295","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25440437,0.0010248617,0.6464638,0.0047209635,0.000119065815,0.00037647976,0.00020924599,0.00028889856,0.09239233],"genre_scores_gemma":[0.9622335,0.00034106002,0.030082708,0.0002389385,0.00010275128,0.00011305261,0.00005471556,0.00007066775,0.006762533],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9927487,0.0031771406,0.00030390473,0.00079755095,0.001731905,0.0012408426],"domain_scores_gemma":[0.9860766,0.0075084125,0.0018289282,0.0028644537,0.0011066489,0.0006149028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073042857,0.0013386396,0.0025243533,0.0012767743,0.0011838542,0.0075503993,0.004422596,0.0045036334,0.008613394],"category_scores_gemma":[0.024893234,0.0010388523,0.0023392318,0.0018402509,0.0043530846,0.01160558,0.005703816,0.0037926065,0.0005254601],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009722308,0.00016821854,0.0013294935,0.00011057142,0.000046349964,0.0003362865,0.00021821016,0.12804599,0.0009630341,0.8481405,0.0008549514,0.019689191],"study_design_scores_gemma":[0.00011367313,0.00017468329,0.0011392541,0.000062773215,0.000067361434,0.00020659674,0.00015035235,0.46673393,0.0007053204,0.526231,0.004363864,0.00005113096],"about_ca_topic_score_codex":0.0040708203,"about_ca_topic_score_gemma":0.00255267,"teacher_disagreement_score":0.008613394,"about_ca_system_score_codex":0.0040794765,"about_ca_system_score_gemma":0.00377967,"threshold_uncertainty_score":0.038629174},"labels":[],"label_agreement":null},{"id":"W2277482329","doi":"10.2139/ssrn.920063","title":"Economic Prizes: Filling the Gaps in Pharmaceutical Innovations","year":2005,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Business; Economics","score_opus":0.03866585999831631,"score_gpt":0.30853067608029533,"score_spread":0.26986481608197904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277482329","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15085325,0.04069219,0.043976244,0.55794823,0.013673516,0.00015737716,0.0014544082,0.00092327234,0.1903216],"genre_scores_gemma":[0.96086586,0.0073411576,0.003967964,0.0058533363,0.004392349,0.00008848921,0.0002544042,0.000107582295,0.017128915],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9919329,0.0038824019,0.00036643265,0.000550238,0.0019067534,0.0013612263],"domain_scores_gemma":[0.9480423,0.032715183,0.0051665865,0.0020282737,0.004233705,0.007813997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018356487,0.00058451114,0.0016163874,0.0026310582,0.002612819,0.008070454,0.0015712634,0.0045654094,0.03313388],"category_scores_gemma":[0.098142155,0.00031931346,0.0005229538,0.003253702,0.0045583416,0.0175608,0.0070511047,0.005690071,0.002125924],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008794202,0.00033030033,0.004569193,0.0005520915,0.00004987422,0.00014164267,0.000691369,0.004349659,0.00013669975,0.6379188,0.10520096,0.24518001],"study_design_scores_gemma":[0.0003399005,0.0002462164,0.0069080503,0.00046149647,0.000057205627,0.000112888534,0.0014428801,0.008579153,0.00029438332,0.8686244,0.112872265,0.00006121953],"about_ca_topic_score_codex":0.0017467728,"about_ca_topic_score_gemma":0.0024418728,"teacher_disagreement_score":0.03313388,"about_ca_system_score_codex":0.0025639664,"about_ca_system_score_gemma":0.0078091803,"threshold_uncertainty_score":0.1108439},"labels":[],"label_agreement":null},{"id":"W2279506649","doi":"10.1371/journal.pone.0148939","title":"Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products?","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bruyère; University of Ottawa","funders":"Canadian Institutes of Health Research; Canadian Foundation for Healthcare Improvement","keywords":"Medicine; Food and drug administration; Intellectual property; Product (mathematics); Pulmonary disease; Active ingredient; Business; Pharmacology; Law; Internal medicine","score_opus":0.3945351596196885,"score_gpt":0.325407430884167,"score_spread":0.06912772873552148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279506649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7228906,0.10359676,0.0076629366,0.06749,0.0006916402,0.0001430896,0.002458048,0.00016698042,0.09489981],"genre_scores_gemma":[0.97438884,0.01731661,0.001189347,0.0048185852,0.001154466,0.000036534835,0.00044818883,0.000023869996,0.00062348356],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.989195,0.0026496386,0.0015149006,0.0015520769,0.0039751497,0.0011132088],"domain_scores_gemma":[0.8619417,0.08880747,0.036368623,0.0054288483,0.0052071805,0.00224613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017934965,0.0002276781,0.0007705263,0.0044294903,0.0008621941,0.0045307647,0.0011933418,0.0016026625,0.010878202],"category_scores_gemma":[0.06796449,0.00021054994,0.0010273551,0.007042253,0.003819413,0.0074996734,0.0013334685,0.0013013459,0.00082268653],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009888448,0.00033364908,0.44312847,0.0023932685,0.00052582385,0.0019091755,0.0016764335,0.00083395414,0.004001606,0.056657534,0.016150052,0.47140124],"study_design_scores_gemma":[0.00021755107,0.0010852407,0.73566806,0.0032080342,0.0011755973,0.011515999,0.0046495134,0.00182833,0.0040542623,0.06953699,0.16693129,0.00012915205],"about_ca_topic_score_codex":0.0017648973,"about_ca_topic_score_gemma":0.00184269,"teacher_disagreement_score":0.017934965,"about_ca_system_score_codex":0.0018463333,"about_ca_system_score_gemma":0.0023137531,"threshold_uncertainty_score":0.0948503},"labels":[],"label_agreement":null},{"id":"W2280050709","doi":"10.1186/s12889-015-2589-1","title":"Essential psychiatric medicines: wrong selection, high consumption and social problems","year":2015,"lang":"en","type":"article","venue":"BMC Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Public health; Essential medicines; Biostatistics; Environmental health; Government (linguistics); Essential drugs; Product (mathematics); Family medicine; Psychiatry; Population; Nursing; Health services","score_opus":0.14454133153575027,"score_gpt":0.34378474755607297,"score_spread":0.1992434160203227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280050709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98522264,0.003069853,0.00096946384,0.0037993437,0.00003655032,0.000055506145,0.0003904075,0.000015626541,0.006440561],"genre_scores_gemma":[0.9980673,0.0008086167,0.00044849503,0.00035904537,0.000033162705,0.000009827655,0.00009271018,0.0000043575446,0.0001764943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99333405,0.0029144199,0.0010130822,0.00045308677,0.001913385,0.00037197073],"domain_scores_gemma":[0.97522324,0.010273655,0.011185376,0.0011206287,0.0016810017,0.0005159855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046811407,0.00023145415,0.00033473494,0.001790328,0.0010775668,0.00086400704,0.00046239485,0.0005657837,0.003258964],"category_scores_gemma":[0.024343684,0.00018462079,0.00040941755,0.0030846333,0.0014534545,0.0011045355,0.0011707636,0.00054801936,0.0002614594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114453585,0.000081373415,0.9566861,0.00035682615,0.0000727095,0.0010007087,0.0035875724,0.00007021286,0.00023939066,0.00085436006,0.0012205851,0.03571572],"study_design_scores_gemma":[0.000014850763,0.000068276255,0.97843415,0.00043323048,0.00009481354,0.005173362,0.0075898264,0.00080364017,0.00041084067,0.0019294677,0.0050246795,0.000022839255],"about_ca_topic_score_codex":0.010668408,"about_ca_topic_score_gemma":0.009040032,"teacher_disagreement_score":0.010668408,"about_ca_system_score_codex":0.001574771,"about_ca_system_score_gemma":0.0013780318,"threshold_uncertainty_score":0.02475655},"labels":[],"label_agreement":null},{"id":"W2281013566","doi":"","title":"Should the U.S. Permit Reimport of Prescripton Drugs from Canada","year":2002,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.13511193497949156,"score_gpt":0.2888259963581512,"score_spread":0.15371406137865964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281013566","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030852666,0.00368567,0.0013983949,0.44344294,0.010993521,0.000634395,0.0081705265,0.0006721231,0.5001498],"genre_scores_gemma":[0.16397409,0.0021450203,0.0022392536,0.28322104,0.0019239202,0.00011255224,0.0018265654,0.00020113471,0.54435647],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99298686,0.00025875497,0.00021985435,0.00036227258,0.0035634497,0.0026087284],"domain_scores_gemma":[0.9875172,0.0014758777,0.00040819036,0.00045445256,0.0076517346,0.0024925303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029726163,0.0004428576,0.00066367077,0.0013697526,0.00673273,0.0043936335,0.0020488063,0.015161426,0.03292916],"category_scores_gemma":[0.021702986,0.0006335788,0.0012912952,0.001255476,0.0012668197,0.0015574746,0.0013751489,0.0056616315,0.0057042493],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003242263,0.00011214341,0.010195887,0.00015294617,0.00007553254,0.00054348924,0.00036803426,0.00087262836,0.0014963726,0.053186473,0.90560615,0.027066171],"study_design_scores_gemma":[0.00014619375,0.00006453056,0.015663987,0.0001718809,0.000077266785,0.00021002728,0.00040886644,0.0011331479,0.0018088234,0.0044215983,0.97577375,0.00012001577],"about_ca_topic_score_codex":0.9582183,"about_ca_topic_score_gemma":0.9793697,"teacher_disagreement_score":0.041781723,"about_ca_system_score_codex":0.031026388,"about_ca_system_score_gemma":0.120760866,"threshold_uncertainty_score":0.22511321},"labels":[],"label_agreement":null},{"id":"W2283867889","doi":"10.1093/annonc/mdu438.33","title":"Cross-Comparison of Cancer Drug Approvals Among International Regulatory Bodies","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Drug; Cancer drugs; Drug approval; Cancer; Oncology; Pharmacology; Internal medicine","score_opus":0.15396424428328415,"score_gpt":0.44321385571232835,"score_spread":0.2892496114290442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283867889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735435,0.0038198403,0.0012514899,0.0015343515,0.00010066563,0.000068429035,0.001742431,0.000051071667,0.01788837],"genre_scores_gemma":[0.9954497,0.00030784798,0.00015933672,0.00020604389,0.00006190532,0.00001959588,0.0016315441,0.000015669126,0.0021481777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98723036,0.0063878936,0.0009283899,0.0011634794,0.0024123779,0.0018774436],"domain_scores_gemma":[0.8438447,0.1047047,0.02932002,0.005839329,0.012526743,0.0037645297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016557556,0.00025595323,0.00081266125,0.003376571,0.0006391917,0.003761736,0.0009153652,0.0016786021,0.012853761],"category_scores_gemma":[0.07445942,0.0003445686,0.0017221163,0.0032239992,0.000967549,0.002374015,0.001957371,0.0020537865,0.0012915406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013569208,0.0016313356,0.85361964,0.00057811686,0.0047911257,0.00050073443,0.001536148,0.016820805,0.0022821669,0.025182888,0.014421071,0.065066844],"study_design_scores_gemma":[0.0003463134,0.0013612247,0.9801324,0.0000891234,0.0010317719,0.00021349601,0.0016076543,0.004122843,0.0014432824,0.00252157,0.0070718853,0.00005845151],"about_ca_topic_score_codex":0.005132745,"about_ca_topic_score_gemma":0.004714544,"teacher_disagreement_score":0.016557556,"about_ca_system_score_codex":0.0015459572,"about_ca_system_score_gemma":0.0009603963,"threshold_uncertainty_score":0.08756578},"labels":[],"label_agreement":null},{"id":"W2285334580","doi":"","title":"Orphan drug pricing and payer management in the United States: are we approaching the tipping point?","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Orphan drug; Scrutiny; Tipping point (physics); Business; Public economics; Medicine; Economics; Bioinformatics; Political science; Engineering","score_opus":0.06686367527375277,"score_gpt":0.2490064903042446,"score_spread":0.18214281503049184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285334580","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23965937,0.056408126,0.0017522563,0.6758138,0.00085134886,0.00003602566,0.0008876035,0.000046609955,0.024544721],"genre_scores_gemma":[0.9429355,0.023395736,0.00100421,0.028995918,0.0015125402,0.00003643284,0.00042527434,0.000011389422,0.0016830084],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958668,0.0024568834,0.00020754928,0.00021109697,0.0006994289,0.0005582082],"domain_scores_gemma":[0.98421335,0.0075423177,0.0045397347,0.00031400588,0.0015257391,0.0018648651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057449304,0.00020970867,0.0004536391,0.0014559819,0.0009799275,0.004036492,0.0006231302,0.0031798526,0.0047379294],"category_scores_gemma":[0.024685584,0.0002355388,0.0005076155,0.0033472804,0.001520691,0.0042116744,0.0013707385,0.0029864118,0.0002437917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003714909,0.0005242105,0.43448538,0.00027511144,0.00017695826,0.000556374,0.0022317956,0.0043602986,0.00012416183,0.14698927,0.20140697,0.20849802],"study_design_scores_gemma":[0.00016713845,0.00027333005,0.6695969,0.0015262044,0.00015206293,0.0006502857,0.010548362,0.018784318,0.00022955342,0.19515936,0.102732465,0.0001799994],"about_ca_topic_score_codex":0.040383924,"about_ca_topic_score_gemma":0.037641603,"teacher_disagreement_score":0.040383924,"about_ca_system_score_codex":0.0037248745,"about_ca_system_score_gemma":0.0042485874,"threshold_uncertainty_score":0.08029777},"labels":[],"label_agreement":null},{"id":"W2285593923","doi":"10.1016/j.ahj.2016.02.004","title":"The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action","year":2016,"lang":"en","type":"review","venue":"American Heart Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Economic shortage; Scope (computer science); Stakeholder; Call to action; Action (physics); Disease; Public health; Drug; Health care; Intensive care medicine; Risk analysis (engineering); Public relations; Business; Economic growth; Nursing; Marketing; Pharmacology; Economics","score_opus":0.07750357332300327,"score_gpt":0.3612219542229399,"score_spread":0.2837183808999366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285593923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013545708,0.9925264,0.000036391295,0.0067336806,0.00024488725,0.0000018605554,0.0000330305,0.0000021291821,0.0002860124],"genre_scores_gemma":[0.0022333453,0.9956695,0.000060400533,0.0013016855,0.00063872355,0.0000030173233,0.000021300631,8.665221e-7,0.00007126437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984931,0.00048485535,0.00020620076,0.00013117983,0.00055508845,0.00012972277],"domain_scores_gemma":[0.98644537,0.009230395,0.002318801,0.000114846946,0.0013164058,0.00057412573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058905995,0.00078046566,0.0021532173,0.0026859115,0.00044417923,0.0022694762,0.0011969735,0.0033111083,0.0041647446],"category_scores_gemma":[0.012967377,0.0003899262,0.0014201818,0.0039204094,0.0012620571,0.0026447803,0.0014391087,0.0036672314,0.00051964377],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023860762,0.00012542779,0.0037545464,0.033940695,0.0010050547,0.00017767547,0.00011409683,0.0013607717,0.00015130287,0.01666197,0.07105774,0.87141204],"study_design_scores_gemma":[0.00025091186,0.0002577491,0.025616195,0.09750145,0.001800784,0.0012433511,0.000913208,0.001125694,0.00023018663,0.037141874,0.8337899,0.00012867714],"about_ca_topic_score_codex":0.007932611,"about_ca_topic_score_gemma":0.017638322,"teacher_disagreement_score":0.007932611,"about_ca_system_score_codex":0.002384322,"about_ca_system_score_gemma":0.009326797,"threshold_uncertainty_score":0.031152785},"labels":[],"label_agreement":null},{"id":"W2288154790","doi":"10.21450/rahis.v12i1.2574","title":"Health insurance in Canada and Brazil, access to drugs, co-payment cards, loyalty programs, brand name drugs","year":2015,"lang":"en","type":"article","venue":"RAHIS - Revista de Administração Hospitalar e Inovação em Saúde","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"École Nationale d'Administration Publique","funders":"","keywords":"Business; Brand names; Payment; Generic drug; Loyalty; Pharmaceutical industry; Brand loyalty; Marketing; Typology; Actuarial science; Drug; Public economics; Finance; Economics; Pharmacology; Medicine","score_opus":0.04674130838534073,"score_gpt":0.3254032239373113,"score_spread":0.27866191555197056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288154790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5225035,0.071227446,0.0064662513,0.079491846,0.00043796052,0.0003605239,0.02698297,0.00020015375,0.29232934],"genre_scores_gemma":[0.95535934,0.019230844,0.0025653208,0.0015693123,0.000118430915,0.00007505861,0.0034876086,0.000021404458,0.017572796],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99889284,0.00011718982,0.000038575727,0.00009958166,0.00040914328,0.00044269432],"domain_scores_gemma":[0.997656,0.00062969176,0.0006102786,0.000055142777,0.0005773419,0.00047163712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077516644,0.0003089837,0.00048449772,0.0036257072,0.0026758309,0.0029479014,0.0005843427,0.0007291471,0.007844495],"category_scores_gemma":[0.0039955596,0.00016006462,0.0005686962,0.0076814047,0.0015451662,0.0011067811,0.0010399028,0.001206257,0.00018411713],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074387484,0.00012244064,0.21200752,0.0006899051,0.00019302119,0.000883626,0.0025247957,0.0029609199,0.0003404965,0.64526623,0.0387187,0.09621796],"study_design_scores_gemma":[0.000089133595,0.00008278094,0.5999513,0.0017541975,0.00038786014,0.000873481,0.008668282,0.007000932,0.00066722557,0.055952158,0.32442728,0.00014527705],"about_ca_topic_score_codex":0.9823778,"about_ca_topic_score_gemma":0.98557043,"teacher_disagreement_score":0.032534376,"about_ca_system_score_codex":0.032534376,"about_ca_system_score_gemma":0.03764245,"threshold_uncertainty_score":0.23605454},"labels":[],"label_agreement":null},{"id":"W2290251572","doi":"10.1016/j.mayocp.2015.12.012","title":"Lowering the High Cost of Cancer Drugs—III","year":2016,"lang":"en","type":"letter","venue":"Mayo Clinic Proceedings","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Pharmacy; Scopus; The Internet; Cancer drugs; Family medicine; Cancer; Advertising; MEDLINE; Law; Business; Political science; World Wide Web; Internal medicine","score_opus":0.07221531348669695,"score_gpt":0.3235453162530976,"score_spread":0.25133000276640066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290251572","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007381479,0.0019851734,0.00010143641,0.9842889,0.0064162537,0.0000146635575,0.000060720988,0.000018502475,0.0063760686],"genre_scores_gemma":[0.010216952,0.0014189014,0.00025264986,0.9399485,0.032175306,0.000042008152,0.000050588842,0.00003040373,0.01586473],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99409795,0.0015983081,0.00046272957,0.0005264763,0.0018185264,0.0014960559],"domain_scores_gemma":[0.98932076,0.0043467986,0.0009183512,0.00048280167,0.0016723197,0.003258933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075645116,0.0007232802,0.0012251256,0.0007681568,0.0026748283,0.0074360897,0.0022239168,0.049700204,0.008987289],"category_scores_gemma":[0.028233176,0.000758253,0.0016013972,0.00069283514,0.0029653104,0.003470069,0.002365711,0.038220074,0.0035969317],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013069896,0.00006430325,0.0012958939,0.00006795981,0.00006580826,0.0005255395,0.00005779165,0.00019948417,0.00039073947,0.015294343,0.96568555,0.016221972],"study_design_scores_gemma":[0.00026430885,0.00011328938,0.005171033,0.00046344043,0.00008640403,0.00054949376,0.00015868022,0.0013609204,0.0005348532,0.017016534,0.97420925,0.000071865186],"about_ca_topic_score_codex":0.022829527,"about_ca_topic_score_gemma":0.06401026,"teacher_disagreement_score":0.049700204,"about_ca_system_score_codex":0.00783225,"about_ca_system_score_gemma":0.010247712,"threshold_uncertainty_score":0.056827188},"labels":[],"label_agreement":null},{"id":"W2293256549","doi":"10.5430/jha.v5n3p48","title":"Regulatory uncertainties in the pharmaceutical sector: Perceptions among Nigerian pharmacists and policy implications for decision making","year":2016,"lang":"en","type":"article","venue":"Journal of Hospital Administration","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Enforcement; Context (archaeology); Pharmacy; Pharmaceutical policy; Government (linguistics); Business; Pharmaceutical care; Pharmacist; Medicine; Public relations; Family medicine; Political science; Nursing; Health policy","score_opus":0.050833635302058554,"score_gpt":0.3530211771930406,"score_spread":0.30218754189098207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2293256549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99172723,0.000729039,0.0002935413,0.0034632934,0.000016669925,0.000021865111,0.000018965242,0.0000019450765,0.0037274328],"genre_scores_gemma":[0.99867636,0.00068176707,0.00013245585,0.00028556192,0.000009721108,0.000005165614,0.0000065470763,6.265172e-7,0.0002016935],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9968015,0.0013185042,0.0002353223,0.00017492606,0.0010619708,0.000407767],"domain_scores_gemma":[0.98992026,0.005280538,0.0029558246,0.00012889005,0.0007405474,0.0009740064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042081582,0.00012593388,0.00021384045,0.00067937915,0.0022377688,0.00295826,0.00031372887,0.0012734958,0.0016989398],"category_scores_gemma":[0.011874357,0.00028673402,0.00023269837,0.00066702865,0.0017391011,0.0018373705,0.0016152936,0.0016967731,0.00010571115],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000228204,0.0005033559,0.6901725,0.00082953443,0.00009247742,0.0054146163,0.21452565,0.0013301169,0.0037278584,0.0047083176,0.0032377574,0.075229615],"study_design_scores_gemma":[0.000026004162,0.0006081172,0.36064288,0.00091171835,0.000056993103,0.004511429,0.6038463,0.0018388787,0.0013908981,0.0033735307,0.022653123,0.00014018758],"about_ca_topic_score_codex":0.00509402,"about_ca_topic_score_gemma":0.005998883,"teacher_disagreement_score":0.00509402,"about_ca_system_score_codex":0.0012708385,"about_ca_system_score_gemma":0.0032868753,"threshold_uncertainty_score":0.022255182},"labels":[],"label_agreement":null},{"id":"W2294169926","doi":"10.1053/j.ackd.2016.01.013","title":"Drug Disposition Issues in CKD: Implications for Drug Discovery and Regulatory Approval","year":2016,"lang":"en","type":"review","venue":"Advances in Chronic Kidney Disease","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Lawson Health Research Institute","funders":"","keywords":"Medicine; Kidney disease; Drug; Intensive care medicine; Pharmacokinetics; Adverse effect; Hemodialysis; Population; Pharmacology; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.03579520739453439,"score_gpt":0.35924449413193615,"score_spread":0.32344928673740175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294169926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024382137,0.9926259,0.00052877597,0.00540913,0.0001868732,0.0000034833522,0.00003305259,0.000002913574,0.0009660678],"genre_scores_gemma":[0.0055211997,0.99154836,0.0005647096,0.0013528974,0.0007107707,0.000007779467,0.000023348943,0.0000020449997,0.00026885327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845755,0.0007283768,0.00017966029,0.00015080353,0.00039623372,0.00008740366],"domain_scores_gemma":[0.98716754,0.01070871,0.0010924409,0.00013425013,0.00074723846,0.00014979513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006189197,0.00054182543,0.0025732669,0.0020991166,0.00028594755,0.0025239969,0.0011713766,0.0028598786,0.0044496176],"category_scores_gemma":[0.011981542,0.00032105463,0.0011231776,0.0036221258,0.0015718454,0.003087334,0.0010691737,0.003481394,0.00047852803],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002313107,0.00015203196,0.0015555287,0.022910515,0.00055960566,0.00031577042,0.00007747066,0.00457544,0.00028910473,0.11051489,0.030505797,0.8283126],"study_design_scores_gemma":[0.00016250803,0.00018597304,0.0068524973,0.03417766,0.00099159,0.0015953499,0.00030901207,0.002877151,0.00045734856,0.18156727,0.7707278,0.00009582188],"about_ca_topic_score_codex":0.0038650685,"about_ca_topic_score_gemma":0.008088017,"teacher_disagreement_score":0.006189197,"about_ca_system_score_codex":0.0026546104,"about_ca_system_score_gemma":0.0056309537,"threshold_uncertainty_score":0.03273201},"labels":[],"label_agreement":null},{"id":"W2302160661","doi":"10.1377/hlthaff.2015.0453","title":"Compulsory Licenses: The Authors Reply","year":2015,"lang":"en","type":"letter","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Library science; Alternative medicine; Human immunodeficiency virus (HIV); Medicine; Variety (cybernetics); Political science; Family medicine; Computer science","score_opus":0.1330706287951086,"score_gpt":0.32944839848747554,"score_spread":0.19637776969236695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2302160661","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023854298,0.0005112845,0.000051044728,0.98833317,0.009370704,0.000007739362,0.000051749565,0.000012194922,0.001423549],"genre_scores_gemma":[0.0015123631,0.00016227855,0.000040975734,0.9884035,0.007155898,0.000013934567,0.000009093609,0.000007677615,0.0026942575],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99165523,0.0019947055,0.0010614861,0.0012640948,0.0021239049,0.0019006124],"domain_scores_gemma":[0.9773974,0.0143068805,0.0015658516,0.00068213965,0.0031434658,0.0029043346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009757261,0.00090560265,0.0024408824,0.0011196593,0.007219054,0.0101331,0.0039117937,0.16617966,0.0077272337],"category_scores_gemma":[0.059444472,0.0020337629,0.0028063916,0.0010689038,0.006597765,0.0065760696,0.004167639,0.09826079,0.0049344064],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006174096,0.0000320505,0.00076994044,0.000041022504,0.00003620016,0.0007552497,0.00025244363,0.00007485112,0.00012159621,0.007073032,0.98816794,0.002613888],"study_design_scores_gemma":[0.00022173137,0.00008101795,0.0030288552,0.0005480397,0.00011090001,0.0007704739,0.0011419393,0.00057460443,0.00045334428,0.02287126,0.96997815,0.00021969387],"about_ca_topic_score_codex":0.021088675,"about_ca_topic_score_gemma":0.027895357,"teacher_disagreement_score":0.16617966,"about_ca_system_score_codex":0.008516833,"about_ca_system_score_gemma":0.012232555,"threshold_uncertainty_score":0.06179422},"labels":[],"label_agreement":null},{"id":"W2304031919","doi":"10.1056/nejmp1512206","title":"Uber’s Message for Health Care","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Health care; Medical care; Public relations; Nursing; Economic growth; Political science; Economics","score_opus":0.06441006312412344,"score_gpt":0.33722741803269984,"score_spread":0.2728173549085764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304031919","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010921351,0.002406582,0.00014546858,0.9658414,0.0227911,0.0000054050765,0.00013668768,0.000071140494,0.008492929],"genre_scores_gemma":[0.0030227269,0.002182009,0.00036391514,0.9378321,0.023183512,0.00002660791,0.000112753296,0.00006124405,0.0332152],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950848,0.0011676345,0.0002097219,0.0006006951,0.002152273,0.0007847815],"domain_scores_gemma":[0.98924786,0.0045388625,0.0005468073,0.0006992231,0.0024520205,0.0025152091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075068884,0.0010716205,0.0011083342,0.0010162896,0.004124004,0.008925048,0.0019933574,0.039489646,0.06583014],"category_scores_gemma":[0.036517195,0.00041297937,0.0011804827,0.0009370472,0.004484575,0.01065427,0.0044593043,0.03566313,0.025150662],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029063629,0.000011863945,0.000058109053,0.000026870519,0.0000033844626,0.000033087632,0.000047205216,0.000013219141,0.000039217626,0.013951674,0.9794788,0.0063075344],"study_design_scores_gemma":[0.000023607367,0.000015680967,0.00026223733,0.00013874147,0.0000056696917,0.00004584357,0.000117299234,0.00004570188,0.000059544902,0.0060543315,0.9932139,0.00001736808],"about_ca_topic_score_codex":0.010059636,"about_ca_topic_score_gemma":0.011456581,"teacher_disagreement_score":0.06583014,"about_ca_system_score_codex":0.0036121928,"about_ca_system_score_gemma":0.0075120633,"threshold_uncertainty_score":0.22022378},"labels":[],"label_agreement":null},{"id":"W2304820100","doi":"10.9745/ghsp-d-15-00173","title":"Results-Based Financing in Mozambique’s Central Medical Store: A Review After 1 Year","year":2016,"lang":"en","type":"review","venue":"Global Health Science and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute on Governance","funders":"World Bank Group; United States Agency for International Development","keywords":"Incentive; Accountability; Interdependence; Payment; Business; Teamwork; Finance; Process management; Computer science; Economics; Political science","score_opus":0.13055569122884803,"score_gpt":0.4700580465584649,"score_spread":0.33950235532961687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304820100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012443488,0.9958585,0.00008865392,0.0017028811,0.00023834624,0.0000932171,0.00015644028,0.0000086159735,0.0006090632],"genre_scores_gemma":[0.008961796,0.98918855,0.00040502395,0.00079466164,0.00017403613,0.00014212805,0.00015755907,0.000006182881,0.00017010613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995497,0.0012833929,0.0012521297,0.000311713,0.0012268554,0.0004290039],"domain_scores_gemma":[0.95778507,0.022040421,0.00991531,0.00062529795,0.008414493,0.001219362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013087053,0.00080758246,0.0018853894,0.018676763,0.0010700602,0.0038984574,0.0016558778,0.001749718,0.0032106114],"category_scores_gemma":[0.03463274,0.0011384988,0.0014689064,0.019700292,0.0018668044,0.003544381,0.001764694,0.0017530234,0.00030376329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017829186,0.0001240788,0.0035639298,0.27563602,0.0005765781,0.00041141352,0.0019778863,0.000222697,0.00077703095,0.0033683921,0.025085349,0.6880783],"study_design_scores_gemma":[0.000089147936,0.0002855133,0.027916584,0.49691328,0.0019360553,0.001010865,0.0022935667,0.00017336152,0.00057421037,0.00046839495,0.46826103,0.000078038574],"about_ca_topic_score_codex":0.05036344,"about_ca_topic_score_gemma":0.08102917,"teacher_disagreement_score":0.05036344,"about_ca_system_score_codex":0.011759713,"about_ca_system_score_gemma":0.03813168,"threshold_uncertainty_score":0.10014063},"labels":[],"label_agreement":null},{"id":"W2305745693","doi":"","title":"Potential effects of rational prescribing on national health care spending: More than half a billion dollars in annual savings.","year":2016,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bruyère; College of Family Physicians of Canada","funders":"","keywords":"Medical prescription; Medicine; Health care; Drug class; Public health; Drug; Business; Environmental health; Pharmacology; Economics; Economic growth","score_opus":0.04209483166030748,"score_gpt":0.2714040410703456,"score_spread":0.22930920941003813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305745693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71012914,0.05304011,0.016654002,0.06704518,0.0013183901,0.0008167925,0.029513853,0.0003388427,0.1211437],"genre_scores_gemma":[0.98028713,0.0072423522,0.004844447,0.0026819846,0.00012136461,0.00012365733,0.0024777052,0.000021847327,0.002199381],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9963008,0.0018178892,0.00014732768,0.00018443186,0.0011845933,0.00036495033],"domain_scores_gemma":[0.99499017,0.002048064,0.0012384144,0.00028367667,0.0011017327,0.00033783022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037549802,0.0008787798,0.00046860115,0.0009417771,0.0003956759,0.0013716135,0.00040765005,0.00074587116,0.0026250402],"category_scores_gemma":[0.0128344195,0.00022867144,0.001195134,0.002008402,0.00077969104,0.0011355738,0.0008272676,0.0010657132,0.0003221354],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031280112,0.0006203618,0.33789492,0.0020840378,0.003152937,0.00047997452,0.0004084792,0.08128744,0.0011634364,0.040667582,0.06220205,0.46691078],"study_design_scores_gemma":[0.00046961193,0.0017870491,0.7253001,0.0042083003,0.0037550083,0.0009996999,0.002150923,0.08811958,0.0039680824,0.0485378,0.12051668,0.00018723714],"about_ca_topic_score_codex":0.15561028,"about_ca_topic_score_gemma":0.2078086,"teacher_disagreement_score":0.15561028,"about_ca_system_score_codex":0.011632681,"about_ca_system_score_gemma":0.011972684,"threshold_uncertainty_score":0.30940902},"labels":[],"label_agreement":null},{"id":"W2306501823","doi":"10.71781/4465","title":"L’assurance médicaments et son impact sur l’adhésion des patients à leurs médicaments","year":2014,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Université de Montréal; Purdue Pharma; AstraZeneca Canada; Pfizer Canada; Sanofi; Purdue University; AstraZeneca; Amgen Canada; Pfizer; Amgen","keywords":"Medicine; Pharmacology; Gynecology","score_opus":0.1289340829678552,"score_gpt":0.3741011480051643,"score_spread":0.24516706503730912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306501823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88229525,0.081946306,0.0037688054,0.0068163723,0.0004905149,0.00038232192,0.003727865,0.000055051725,0.020517519],"genre_scores_gemma":[0.9714534,0.019352753,0.0019144953,0.0014955492,0.0003750889,0.0003811258,0.0009562522,0.00002511384,0.004046327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9876232,0.005186014,0.0017626663,0.0011014957,0.0034900145,0.00083655206],"domain_scores_gemma":[0.947647,0.022886595,0.021475416,0.0020967326,0.0044817273,0.001412647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008668493,0.0003588368,0.0009925379,0.0011575927,0.00094029406,0.002527453,0.00061029504,0.0010969532,0.0068373927],"category_scores_gemma":[0.04605032,0.0003594264,0.0016158612,0.0021850355,0.00085397775,0.00132363,0.0011010309,0.0016705523,0.00071846746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043106712,0.00044494396,0.80767393,0.0049028974,0.0023579446,0.0006195066,0.004398837,0.0005817007,0.0015897609,0.0025561375,0.006290263,0.16427338],"study_design_scores_gemma":[0.000211221,0.0021238823,0.95683926,0.0031145015,0.0017439175,0.0010840324,0.0019058812,0.0005612709,0.0011761641,0.0010351073,0.03011848,0.00008628416],"about_ca_topic_score_codex":0.01030846,"about_ca_topic_score_gemma":0.009842093,"teacher_disagreement_score":0.98969156,"about_ca_system_score_codex":0.0013415962,"about_ca_system_score_gemma":0.0026106876,"threshold_uncertainty_score":0.04584396},"labels":[],"label_agreement":null},{"id":"W2306625559","doi":"10.14288/1.0102579","title":"The impact of international trade agreements on health : patent system harmonization and medicines in Mexico","year":2012,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"International trade; Harmonization; Business; International economics; Economics","score_opus":0.04337602820954703,"score_gpt":0.24062634641321407,"score_spread":0.19725031820366704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306625559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67955315,0.014067395,0.0020832461,0.056719653,0.00011598035,0.00019046653,0.000630968,0.0000231115,0.246616],"genre_scores_gemma":[0.98959863,0.0045175697,0.00060815853,0.0010247112,0.00004092704,0.00007626442,0.000107942185,0.000004330512,0.004021504],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9965321,0.0016358091,0.00011200826,0.00026636905,0.00056278956,0.0008909113],"domain_scores_gemma":[0.99429095,0.0032645923,0.0016658852,0.00017608776,0.0003729869,0.0002293844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058902893,0.00018595961,0.00035371905,0.001613797,0.0029529526,0.0063258554,0.00088476687,0.0016215313,0.008270495],"category_scores_gemma":[0.009370375,0.0001726183,0.00051164033,0.0025652593,0.004231401,0.0043744273,0.0046100034,0.001794365,0.00009509564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031418618,0.00027626535,0.049924,0.00092543964,0.00013732037,0.0012634197,0.0221134,0.0031446707,0.000864888,0.85836834,0.0052632773,0.057404816],"study_design_scores_gemma":[0.00025873186,0.0009036609,0.3497496,0.00449793,0.0006518895,0.00064560544,0.11320241,0.0041536717,0.0024163115,0.13834749,0.38503343,0.00013932615],"about_ca_topic_score_codex":0.044860683,"about_ca_topic_score_gemma":0.036536466,"teacher_disagreement_score":0.044860683,"about_ca_system_score_codex":0.014283586,"about_ca_system_score_gemma":0.008366964,"threshold_uncertainty_score":0.10363513},"labels":[],"label_agreement":null},{"id":"W2308781355","doi":"10.1684/sss.2016.0102","title":"Le « spirituel », le biomédical et le politique","year":2016,"lang":"fr","type":"article","venue":"Sciences sociales et santé","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.14438223242937698,"score_gpt":0.3764713710166625,"score_spread":0.23208913858728553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308781355","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011068586,0.06513191,0.026205052,0.68587583,0.0073578176,0.000045604153,0.00029749074,0.00012499631,0.20389268],"genre_scores_gemma":[0.70302993,0.049216505,0.016970946,0.09088608,0.027935961,0.00029653247,0.00031929094,0.00021082356,0.11113397],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9910415,0.005342722,0.00031013266,0.0008141156,0.0019008513,0.0005906682],"domain_scores_gemma":[0.9904018,0.0061999448,0.00097543467,0.00091706734,0.00069383567,0.00081191206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010567776,0.00072013773,0.000981784,0.0019082378,0.0025376242,0.013312634,0.0010736969,0.009750016,0.010725009],"category_scores_gemma":[0.01815439,0.00041002568,0.00047078583,0.0024506513,0.017848946,0.011307813,0.002972834,0.01055032,0.0013285468],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012786399,0.000011866279,0.00021643554,0.000040194587,0.000008083938,0.00001713318,0.00015080515,0.00014369549,0.000063365296,0.98627675,0.006069411,0.006989461],"study_design_scores_gemma":[0.00002326924,0.00003080076,0.00089705695,0.00015678296,0.0000075648627,0.00009100212,0.0003620952,0.00052041304,0.00010576029,0.8253583,0.17243052,0.000016454227],"about_ca_topic_score_codex":0.006793714,"about_ca_topic_score_gemma":0.00552738,"teacher_disagreement_score":0.013312634,"about_ca_system_score_codex":0.0072998707,"about_ca_system_score_gemma":0.00836743,"threshold_uncertainty_score":0.055888355},"labels":[],"label_agreement":null},{"id":"W2308882864","doi":"","title":"Towards an International Treaty on Antimicrobial Resistance","year":2016,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York University","funders":"","keywords":"Treaty; Resistance (ecology); Antibiotic resistance; Political science; International trade; Law and economics; Business; Law; Economics; Microbiology; Biology; Antibiotics","score_opus":0.030230274506121337,"score_gpt":0.28244317801179725,"score_spread":0.25221290350567593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308882864","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015814194,0.024520556,0.008986657,0.82713413,0.040393762,0.000046019293,0.0001665789,0.00015418524,0.09701671],"genre_scores_gemma":[0.09263765,0.045783956,0.015731221,0.66579705,0.07031117,0.00037754746,0.00041499818,0.00035202273,0.10859438],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9899935,0.003173488,0.0008671263,0.0008943976,0.0037845313,0.0012868473],"domain_scores_gemma":[0.9870688,0.005068602,0.0017556766,0.0015146754,0.002956206,0.0016360054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013104635,0.0015663257,0.0012939662,0.0028803167,0.0020611824,0.008990822,0.0016967811,0.027805883,0.016949218],"category_scores_gemma":[0.030841747,0.00046943763,0.0016963038,0.001746994,0.007849046,0.008560414,0.007945759,0.03149688,0.0047612716],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008684786,0.00013881663,0.00023956673,0.00026301827,0.000045451652,0.00017035443,0.00023225308,0.00074615463,0.00063716836,0.65549403,0.27651188,0.065434456],"study_design_scores_gemma":[0.000061891486,0.00010873592,0.00074860005,0.0011069981,0.000054748903,0.00016305209,0.0002615648,0.000403569,0.00043431012,0.20132418,0.79530156,0.0000307878],"about_ca_topic_score_codex":0.0019870913,"about_ca_topic_score_gemma":0.002692412,"teacher_disagreement_score":0.027805883,"about_ca_system_score_codex":0.0031697555,"about_ca_system_score_gemma":0.010648717,"threshold_uncertainty_score":0.069304764},"labels":[],"label_agreement":null},{"id":"W2309323648","doi":"","title":"Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Rosuvastatin; Medicine; Pravastatin; Atorvastatin; Dyslipidemia; Statin; Rosuvastatin Calcium; Cost effectiveness; Simvastatin; Willingness to pay; Pharmacology; Internal medicine; Cholesterol; Risk analysis (engineering)","score_opus":0.08803016733899666,"score_gpt":0.2806454956538217,"score_spread":0.19261532831482503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309323648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72545236,0.13872747,0.003512899,0.004691776,0.00025030045,0.0019356826,0.09983137,0.0001179645,0.025480103],"genre_scores_gemma":[0.9699185,0.014029192,0.0022313718,0.00037656806,0.000050063478,0.0001706904,0.011898885,0.000037350168,0.0012874125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965532,0.000943042,0.0002535891,0.00030410732,0.0014778235,0.00046815668],"domain_scores_gemma":[0.9941871,0.0020083885,0.0011834021,0.00021026834,0.0017516239,0.000659206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004720927,0.0012395551,0.0019458418,0.0055252495,0.0009949835,0.0022449135,0.001767973,0.0009562852,0.0040359246],"category_scores_gemma":[0.014221015,0.0006894548,0.008221754,0.010570259,0.0006457037,0.0007291829,0.0009635579,0.0017044538,0.00020354397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041624546,0.0009853741,0.48672456,0.022268001,0.053383645,0.001388708,0.00073869806,0.1535902,0.0015081911,0.020830423,0.05700168,0.15995613],"study_design_scores_gemma":[0.008341615,0.0021462936,0.7647991,0.0028432156,0.041775867,0.001708342,0.0012736771,0.13948973,0.00071088894,0.004391507,0.031940874,0.00057889085],"about_ca_topic_score_codex":0.9693932,"about_ca_topic_score_gemma":0.9589213,"teacher_disagreement_score":0.06453081,"about_ca_system_score_codex":0.06453081,"about_ca_system_score_gemma":0.046008058,"threshold_uncertainty_score":0.468206},"labels":[],"label_agreement":null},{"id":"W2311899267","doi":"","title":"New drug approval times and safety warnings in the United States and Canada, 1992-2011.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto East General Hospital","funders":"","keywords":"Medicine; Drug approval; Drug; Pharmacology","score_opus":0.02232840750964075,"score_gpt":0.19828945190299652,"score_spread":0.17596104439335578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311899267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7056768,0.12873457,0.0005796844,0.012484054,0.0003678622,0.0003095562,0.11579093,0.00020124264,0.035855364],"genre_scores_gemma":[0.95562327,0.020238329,0.0007303266,0.0018573167,0.00010208552,0.00006887941,0.015448803,0.000035019955,0.0058959527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966106,0.00013086472,0.00034557746,0.0003391412,0.0020951582,0.0004785961],"domain_scores_gemma":[0.98239017,0.0010730986,0.0059762555,0.00012907435,0.008125656,0.00230572],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019021734,0.00036752262,0.00041628507,0.003873541,0.0015330511,0.002254642,0.00076664845,0.0006952497,0.0024199225],"category_scores_gemma":[0.0101869805,0.0003199998,0.0008196185,0.007933655,0.0007680144,0.00075622165,0.00062724965,0.0012060985,0.00030620425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002529224,0.00017528188,0.80662787,0.0027357044,0.00059014565,0.0007230664,0.0017629294,0.002430892,0.00073147105,0.0020329193,0.05751085,0.12214964],"study_design_scores_gemma":[0.00008944278,0.000097935656,0.9675925,0.00029342322,0.0002030937,0.00037321885,0.00075246114,0.0007271178,0.00038791526,0.0001025047,0.029329432,0.000051034698],"about_ca_topic_score_codex":0.9887983,"about_ca_topic_score_gemma":0.99016154,"teacher_disagreement_score":0.99809784,"about_ca_system_score_codex":0.06751138,"about_ca_system_score_gemma":0.077596106,"threshold_uncertainty_score":0.48983163},"labels":[],"label_agreement":null},{"id":"W2312616658","doi":"10.1177/171516350714000212","title":"What You Should Know about NAPRA's National Drug Schedules and Natural Health Products","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Natural (archaeology); Medicine; Pharmacology; Geography","score_opus":0.06939565309677763,"score_gpt":0.3102690773532508,"score_spread":0.24087342425647318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312616658","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004303501,0.07572493,0.00057827093,0.82457274,0.012285018,0.000017511651,0.0020706074,0.00007195521,0.08037542],"genre_scores_gemma":[0.18037434,0.19900219,0.0038372253,0.40479854,0.02407184,0.000066821754,0.0031867446,0.00018225584,0.18448007],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979856,0.0004184616,0.00009871415,0.00011729797,0.0011109753,0.00026899672],"domain_scores_gemma":[0.98343104,0.0043141064,0.0015037496,0.0005332646,0.00801374,0.0022039784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002980853,0.00027162477,0.0005295219,0.0016977248,0.0019039062,0.0047203847,0.0008608576,0.003617044,0.03071733],"category_scores_gemma":[0.023514422,0.00017519646,0.00044831386,0.0030467757,0.0023735373,0.006354414,0.0005477847,0.0040721735,0.0047415374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000832914,0.000047555375,0.006355628,0.0005544053,0.000032832257,0.00020623373,0.00045150385,0.00031122685,0.00010342636,0.026771247,0.83997536,0.12510721],"study_design_scores_gemma":[0.000011708119,0.000018491532,0.010900369,0.00072894496,0.000019405126,0.00013782775,0.0010753057,0.00013652763,0.00009922144,0.0074488865,0.97939324,0.000030123743],"about_ca_topic_score_codex":0.52786535,"about_ca_topic_score_gemma":0.62193257,"teacher_disagreement_score":0.47213465,"about_ca_system_score_codex":0.011299931,"about_ca_system_score_gemma":0.02103772,"threshold_uncertainty_score":0.9498303},"labels":[],"label_agreement":null},{"id":"W2314281061","doi":"10.3821/1913-701x-143.5.226","title":"The Effect of US Pharmaceutical Drug Importation on the Canadian Pharmaceutical Supply","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Business; Supply chain; Pharmaceutical industry; Distribution (mathematics); Brand names; Supply and demand; Medicine; Marketing; Pharmacology; Economics","score_opus":0.03291657335430672,"score_gpt":0.2767341657348822,"score_spread":0.24381759238057546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314281061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8616668,0.0055570337,0.010112242,0.011181752,0.00023366838,0.00042149815,0.022068467,0.00033131745,0.08842721],"genre_scores_gemma":[0.9857304,0.0021596577,0.0020554268,0.00041373863,0.000020452198,0.000043253764,0.0026770802,0.000028810855,0.006871207],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.997924,0.00034607004,0.00007296372,0.00021172072,0.0007710258,0.00067425316],"domain_scores_gemma":[0.9957391,0.0015049584,0.0006967317,0.00009459599,0.0016132094,0.00035138702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017019592,0.0007841684,0.00058323814,0.001256332,0.0014721355,0.0028995313,0.0011645167,0.0009141938,0.0063491897],"category_scores_gemma":[0.0072174375,0.00048800194,0.0019585197,0.0017114141,0.0011751356,0.001095919,0.001230537,0.0016448982,0.00038785808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000791358,0.00016854465,0.25773644,0.0005774838,0.0006926395,0.0006073874,0.00043298127,0.6655758,0.0009554279,0.028686607,0.01745479,0.026320567],"study_design_scores_gemma":[0.00035451067,0.00070645893,0.26324758,0.00041828133,0.0014056389,0.0005543172,0.0022171717,0.66047496,0.002665974,0.008712471,0.05893885,0.00030380304],"about_ca_topic_score_codex":0.9761066,"about_ca_topic_score_gemma":0.9545826,"teacher_disagreement_score":0.94614106,"about_ca_system_score_codex":0.05385893,"about_ca_system_score_gemma":0.04478518,"threshold_uncertainty_score":0.39077568},"labels":[],"label_agreement":null},{"id":"W2315382297","doi":"10.1177/1715163513494594","title":"Pace of growth in drug expenditures slows to lowest level in 16 years","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pace; Medical prescription; Demographic economics; Prescription drug; Health care; Business; Economics; Public economics; Medicine; Economic growth; Geography; Pharmacology","score_opus":0.058945350216289744,"score_gpt":0.26234717651228245,"score_spread":0.2034018262959927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315382297","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26926357,0.049309723,0.003530053,0.40139022,0.009352064,0.00016399332,0.043249093,0.0024319983,0.22130932],"genre_scores_gemma":[0.6722348,0.072285846,0.0068713715,0.08754964,0.0034097258,0.00014096967,0.03650337,0.00095636887,0.12004795],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99605054,0.00015788215,0.00023023301,0.00045651855,0.0017106747,0.0013941698],"domain_scores_gemma":[0.9910336,0.00030886516,0.0009849598,0.0003684106,0.0048999633,0.0024041405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022651409,0.0005901536,0.0007120737,0.0022969316,0.0021839226,0.008069419,0.000961065,0.0018734462,0.011112902],"category_scores_gemma":[0.009291629,0.0004480281,0.00084079086,0.004694309,0.0013384102,0.0031288958,0.0026786956,0.0042581963,0.0057128584],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005587931,0.00013408456,0.14030214,0.0006763457,0.00025021704,0.00089424796,0.0013146017,0.0010899403,0.002139576,0.035388134,0.55642253,0.26082945],"study_design_scores_gemma":[0.00004591532,0.00012569867,0.16681662,0.0006697931,0.000052885563,0.0005557903,0.0011347012,0.0004495715,0.0010602655,0.0027787965,0.82623005,0.000079960366],"about_ca_topic_score_codex":0.3745921,"about_ca_topic_score_gemma":0.3157758,"teacher_disagreement_score":0.62540793,"about_ca_system_score_codex":0.013022672,"about_ca_system_score_gemma":0.02122874,"threshold_uncertainty_score":0.74482346},"labels":[],"label_agreement":null},{"id":"W2316837318","doi":"10.1097/00005650-200301000-00015","title":"Lowering Generic Drug Prices","year":2003,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Health Evaluation and Outcome Sciences; Providence Health Care","funders":"","keywords":"Formulary; Procurement; Generic drug; Drug prices; Business; Government (linguistics); Economics; Demographic economics; Agricultural economics; Monetary economics; Drug; Medicine; Marketing; Pharmacology","score_opus":0.04207700297570712,"score_gpt":0.27704116711700943,"score_spread":0.2349641641413023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316837318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51630986,0.025385367,0.019766005,0.04722012,0.0012335981,0.001193065,0.009855035,0.0010036493,0.37803322],"genre_scores_gemma":[0.96354985,0.0065706503,0.004652919,0.0053490964,0.00092913694,0.00013370597,0.0021372891,0.0000726646,0.016604787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99598193,0.00048783954,0.00018571221,0.00036071573,0.0023179995,0.0006658207],"domain_scores_gemma":[0.99056786,0.0017567076,0.003347778,0.0004871685,0.0026302785,0.0012101837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002810363,0.00044773516,0.00038496562,0.0013929205,0.0007568207,0.002608806,0.0010230732,0.00084138074,0.01216672],"category_scores_gemma":[0.018172286,0.00020377913,0.0005293473,0.0026847494,0.00097035593,0.0012307826,0.0010877672,0.0011757453,0.001770668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005431986,0.0003615375,0.3248682,0.0016490951,0.00022607962,0.00060062733,0.0009683761,0.0025233526,0.005649482,0.026473273,0.09707507,0.5390617],"study_design_scores_gemma":[0.00013662255,0.000410865,0.76712614,0.00030070395,0.000099043114,0.0007850663,0.0003938675,0.0019725556,0.002111848,0.0027573588,0.22386475,0.000041149106],"about_ca_topic_score_codex":0.20412666,"about_ca_topic_score_gemma":0.19351196,"teacher_disagreement_score":0.20412666,"about_ca_system_score_codex":0.013908715,"about_ca_system_score_gemma":0.012554593,"threshold_uncertainty_score":0.405877},"labels":[],"label_agreement":null},{"id":"W2316918956","doi":"10.1016/j.cjca.2014.07.593","title":"A PHARMACODYNAMIC COMPARISON OF PERSONALIZED STRATEGY TO ANTIPLATLET THERAPY AGAINST TICAGRELOR IN ACHIEVING A THERAPEUTIC WINDOW","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ticagrelor; Prasugrel; Medicine; Clopidogrel; P2Y12; CYP2C19; Internal medicine; Conventional PCI; Percutaneous coronary intervention; Aspirin; Acute coronary syndrome; Pharmacodynamics; Cardiology; Myocardial infarction; Pharmacokinetics","score_opus":0.07940936019054527,"score_gpt":0.3170155043213086,"score_spread":0.2376061441307633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316918956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838876,0.005274279,0.0025770892,0.001442975,0.00022798077,0.00018595699,0.00046031777,0.000069628484,0.0058741244],"genre_scores_gemma":[0.9977119,0.00069142465,0.0005403842,0.00033111227,0.00015785678,0.000032905056,0.00014466094,0.0000058893206,0.0003837762],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99891305,0.00062962837,0.000058868394,0.00014839481,0.00010938493,0.00014068536],"domain_scores_gemma":[0.9973936,0.0017682341,0.0003025865,0.00016781033,0.00007624793,0.00029151732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017753983,0.00046853392,0.001298426,0.00038038302,0.00011112519,0.0010533766,0.000454078,0.0008640354,0.006514471],"category_scores_gemma":[0.0053006276,0.0001878728,0.0013382356,0.00029365014,0.00035792528,0.0010340061,0.00034611946,0.0014656563,0.00043433954],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.804452,0.005805849,0.0053435536,0.00052974455,0.0031777692,0.000208114,0.00007606453,0.016439412,0.009239615,0.0046682353,0.0018759506,0.14818372],"study_design_scores_gemma":[0.17694056,0.56352603,0.10814268,0.00034154044,0.020645143,0.0011799851,0.00034519454,0.086291656,0.015273491,0.013682986,0.013404018,0.00022672226],"about_ca_topic_score_codex":0.0004288404,"about_ca_topic_score_gemma":0.00041794064,"teacher_disagreement_score":0.006514471,"about_ca_system_score_codex":0.0005607589,"about_ca_system_score_gemma":0.0005297036,"threshold_uncertainty_score":0.021793067},"labels":[],"label_agreement":null},{"id":"W2317727536","doi":"10.1016/j.jval.2014.08.404","title":"Assesing the Impact of Patent Loss on Overall Revenues and Stocks Price of Pharmaceutical Companies","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Revenue; Total revenue; Business; Quarter (Canadian coin); Stock price; Stock (firearms); Agricultural economics; Commerce; Finance; Economics; Engineering","score_opus":0.2048130438536943,"score_gpt":0.3792123093480543,"score_spread":0.17439926549435997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317727536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99130005,0.00056834024,0.00081723765,0.0011958819,0.000028710798,0.000011836951,0.00060950144,0.000032965,0.0054355725],"genre_scores_gemma":[0.998192,0.00010916732,0.00004872134,0.00003843307,0.000026738115,0.0000017523139,0.00020395004,0.0000031568043,0.001376033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989882,0.00025787012,0.00006859183,0.00014602186,0.00019617238,0.00034311326],"domain_scores_gemma":[0.9791651,0.014270215,0.0037313036,0.0005722773,0.0011524928,0.001108685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002554069,0.00026342136,0.00042720503,0.00085126626,0.00035265152,0.0025585736,0.00074088323,0.0012503637,0.006503558],"category_scores_gemma":[0.015302358,0.00025218888,0.001087806,0.000791478,0.0007106237,0.00168382,0.00068927085,0.0019671014,0.0006969496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036149065,0.001068475,0.8352723,0.0001610625,0.0009193284,0.002124506,0.00026749287,0.10791031,0.0039799726,0.013542802,0.003926566,0.02721234],"study_design_scores_gemma":[0.00012761402,0.0010773793,0.7569757,0.00003368882,0.0008183721,0.00047393795,0.0008213394,0.22076921,0.004846781,0.0118002985,0.0021659748,0.000089602836],"about_ca_topic_score_codex":0.012035554,"about_ca_topic_score_gemma":0.009071817,"teacher_disagreement_score":0.012035554,"about_ca_system_score_codex":0.0015820498,"about_ca_system_score_gemma":0.0010898251,"threshold_uncertainty_score":0.023930967},"labels":[],"label_agreement":null},{"id":"W2318896726","doi":"10.3821/1913-701x-144.5.205","title":"Tackling Drug Shortages Remains a Daunting Task but CPhA Reports Some Progress","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Task (project management); Drug; Political science; Environmental planning; Environmental science; Medicine; Economics; Pharmacology; Management; Philosophy","score_opus":0.06686427663010097,"score_gpt":0.2589190675039927,"score_spread":0.1920547908738917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318896726","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064089405,0.027899534,0.0073014232,0.9136648,0.008511201,0.0001510821,0.0021199097,0.00043722062,0.03350597],"genre_scores_gemma":[0.28948355,0.144606,0.05692273,0.38005227,0.025072152,0.00048507954,0.0068917503,0.0005429033,0.095943555],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954727,0.0010347265,0.00019116125,0.00029002313,0.0016556167,0.0013557076],"domain_scores_gemma":[0.96485525,0.011634585,0.0023661584,0.00062446244,0.010897093,0.009622416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010911222,0.001275571,0.0019803604,0.0024251947,0.0037502812,0.008232091,0.0022453216,0.007516772,0.033768192],"category_scores_gemma":[0.026765097,0.00039762794,0.0015063006,0.003754923,0.0022856656,0.0038950283,0.004395111,0.007851891,0.0046809805],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029257982,0.00064497,0.009561169,0.0028106272,0.00022078778,0.00024126147,0.0003431122,0.0068533556,0.0006068943,0.09601428,0.59556854,0.2868424],"study_design_scores_gemma":[0.00024669332,0.0002780706,0.023324152,0.003771605,0.00012922064,0.00021422829,0.0024301757,0.0074044107,0.0005727669,0.055272892,0.9062326,0.00012317556],"about_ca_topic_score_codex":0.36332586,"about_ca_topic_score_gemma":0.42060068,"teacher_disagreement_score":0.36332586,"about_ca_system_score_codex":0.013993741,"about_ca_system_score_gemma":0.10560811,"threshold_uncertainty_score":0.7224221},"labels":[],"label_agreement":null},{"id":"W2319489330","doi":"10.1177/171516350613900310","title":"Book Review: Two Views of the Pharmaceutical Industry","year":2006,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmaceutical industry; Engineering ethics; Epistemology; Engineering; Philosophy; Medicine; Pharmacology","score_opus":0.065601345845865,"score_gpt":0.299229866300763,"score_spread":0.233628520454898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319489330","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004029001,0.16192923,0.00023106376,0.6623474,0.08895074,0.00003533583,0.00023125469,0.000068058616,0.08580403],"genre_scores_gemma":[0.010754963,0.11058627,0.00034846948,0.18518175,0.10634272,0.00006610244,0.00025510232,0.00015149928,0.5863131],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99628395,0.00045823544,0.0001009461,0.00024914826,0.002495543,0.00041219938],"domain_scores_gemma":[0.9867792,0.0032406796,0.0005033146,0.0003180414,0.007038143,0.0021205642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030508095,0.0008881197,0.0011701917,0.0027357007,0.0028497023,0.0107220905,0.0016767165,0.011400225,0.035912015],"category_scores_gemma":[0.01353565,0.00052643043,0.00061098294,0.004037924,0.002271304,0.004670912,0.0016080681,0.007443277,0.015261407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035801713,0.0000029318426,0.000017321387,0.000030074221,0.0000014367448,0.000013022516,0.000018507546,0.000013915511,0.000011894772,0.0013332298,0.99422246,0.004331605],"study_design_scores_gemma":[0.0000050446065,0.0000035685687,0.00017537418,0.000105938845,0.0000043085606,0.00002884946,0.000053800264,0.000027743512,0.000019825768,0.0006968051,0.99887294,0.0000057022244],"about_ca_topic_score_codex":0.056277625,"about_ca_topic_score_gemma":0.14756823,"teacher_disagreement_score":0.056277625,"about_ca_system_score_codex":0.013042225,"about_ca_system_score_gemma":0.013451611,"threshold_uncertainty_score":0.12013763},"labels":[],"label_agreement":null},{"id":"W2320624260","doi":"10.2174/1389557043403765","title":"Predicting Synthetic Accessibility: Application in Drug Discovery and Development","year":2004,"lang":"en","type":"review","venue":"Mini-Reviews in Medicinal Chemistry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Drug discovery; Prioritization; Computer science; Process (computing); Retrosynthetic analysis; Synthetic data; Data science; Risk analysis (engineering); Artificial intelligence; Management science; Engineering; Bioinformatics; Medicine; Biology; Chemistry","score_opus":0.08561049642649078,"score_gpt":0.3521774650157009,"score_spread":0.26656696858921014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320624260","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005976922,0.9189378,0.06500162,0.0019596359,0.00033489225,0.00009569976,0.00036467664,0.0002080641,0.0071206624],"genre_scores_gemma":[0.047547363,0.92605203,0.024203131,0.00023185334,0.000354681,0.00010897996,0.00037198616,0.000019080238,0.0011109698],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984737,0.00069213804,0.000097549826,0.00015419199,0.0005412217,0.000041087624],"domain_scores_gemma":[0.9938059,0.0048325015,0.00072303356,0.00013554841,0.00044221047,0.000060819104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035380542,0.0012613876,0.001914458,0.0030836936,0.00024226864,0.0016212057,0.0012999672,0.0012295949,0.0033297436],"category_scores_gemma":[0.011577991,0.0004082472,0.0007911797,0.0038147836,0.00092076097,0.002078716,0.0007285209,0.0011202195,0.0015577734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060338534,0.00006843853,0.0029489417,0.0074376203,0.0002501492,0.00009654225,0.0000562952,0.026670566,0.0012857012,0.01865147,0.006118588,0.93635535],"study_design_scores_gemma":[0.00016525111,0.0015954647,0.026630236,0.011089479,0.0011529585,0.0030470458,0.0005532071,0.13134855,0.014979195,0.26386163,0.5451738,0.00040313014],"about_ca_topic_score_codex":0.0021423877,"about_ca_topic_score_gemma":0.0023936308,"teacher_disagreement_score":0.0035380542,"about_ca_system_score_codex":0.000998761,"about_ca_system_score_gemma":0.0012542863,"threshold_uncertainty_score":0.018711269},"labels":[],"label_agreement":null},{"id":"W2322087671","doi":"10.1177/1741134314545250","title":"Selection of the comparator product in the World Health Organisation Prequalification of Medicines Programme","year":2013,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Bioequivalence; Medicine; Product (mathematics); Innovator; Quality (philosophy); Pharmacology; Business","score_opus":0.14693579883615218,"score_gpt":0.33541004693518345,"score_spread":0.18847424809903127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322087671","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16708659,0.05274569,0.11407721,0.019041335,0.017324192,0.16969855,0.024157995,0.0022901783,0.43357828],"genre_scores_gemma":[0.44969448,0.020148009,0.30163562,0.025119955,0.0023193904,0.08006495,0.022874039,0.0011489604,0.09699468],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.987817,0.004870384,0.002016018,0.0009902504,0.0038503448,0.00045610176],"domain_scores_gemma":[0.9947648,0.0013109942,0.0009421562,0.00061853614,0.0019285,0.0004349601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014530962,0.0006606879,0.0012717091,0.0014911509,0.0007711352,0.0020874368,0.0013409569,0.0031568978,0.02854115],"category_scores_gemma":[0.024487894,0.00038185445,0.0013729543,0.0009096152,0.0009656064,0.0011859224,0.0010742996,0.0016565275,0.011535677],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023664856,0.0035010073,0.006390546,0.01054147,0.00022725058,0.0010853477,0.0008761775,0.00049237796,0.06907533,0.012982693,0.0812214,0.7899415],"study_design_scores_gemma":[0.0040437095,0.01628359,0.014439691,0.005071798,0.00055651536,0.0016365822,0.000382982,0.0008680821,0.05895494,0.0032194161,0.8943242,0.00021842332],"about_ca_topic_score_codex":0.0005324366,"about_ca_topic_score_gemma":0.00065892754,"teacher_disagreement_score":0.02854115,"about_ca_system_score_codex":0.0009212128,"about_ca_system_score_gemma":0.0024225796,"threshold_uncertainty_score":0.09547967},"labels":[],"label_agreement":null},{"id":"W2325832068","doi":"10.1016/j.jval.2012.03.110","title":"PHP34 Eliciting Preferences for Reimbursed Drugs Selection Criteria in Cote d'Ivoire","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Formulary; Listing (finance); Transparency (behavior); Health care; Medicine; Population; Actuarial science; Family medicine; Business; Environmental health; Computer science; Economics; Finance; Economic growth","score_opus":0.18082155817440582,"score_gpt":0.37261353063410063,"score_spread":0.19179197245969482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325832068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98178124,0.00024043443,0.0077073593,0.0015942636,0.000027611104,0.0003351895,0.0007819021,0.000066106986,0.007465774],"genre_scores_gemma":[0.9859222,0.00008959782,0.010142883,0.00014802814,0.000010453007,0.00015446253,0.00033431477,0.00001820568,0.003179833],"study_design_codex":"simulation_or_modeling","study_design_gemma":"qualitative","domain_scores_codex":[0.99714965,0.0020248992,0.00008205622,0.00016966937,0.00019930983,0.00037448117],"domain_scores_gemma":[0.9854961,0.012672924,0.00026311338,0.00024367726,0.0006422975,0.00068185007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068472526,0.0005034236,0.0009481077,0.00069881283,0.00077850505,0.0018098052,0.00060066144,0.0015408751,0.00991977],"category_scores_gemma":[0.017908636,0.00047651978,0.0005709964,0.0008859514,0.00047704144,0.0006723756,0.00082011067,0.0014163211,0.0004769383],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01948171,0.006863462,0.11702757,0.0013764782,0.00063094235,0.0028920083,0.0022833063,0.4863657,0.017221281,0.03839031,0.038308155,0.26915908],"study_design_scores_gemma":[0.0024773376,0.0035445618,0.1648042,0.00025076288,0.0001721495,0.00034508022,0.0030079323,0.781078,0.006903442,0.020822324,0.016431326,0.00016292214],"about_ca_topic_score_codex":0.10593925,"about_ca_topic_score_gemma":0.09927302,"teacher_disagreement_score":0.10593925,"about_ca_system_score_codex":0.0047979485,"about_ca_system_score_gemma":0.0040907925,"threshold_uncertainty_score":0.2106452},"labels":[],"label_agreement":null},{"id":"W2327664688","doi":"10.1093/jlb/lsv060","title":"Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Pharmacogenomics; Incentive; Context (archaeology); Orphan drug; Drug response; Medicine; Drug; Political science; Biology; Pharmacology; Economics; Bioinformatics","score_opus":0.04346633919352118,"score_gpt":0.2945346442872339,"score_spread":0.25106830509371275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327664688","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34223798,0.008515677,0.00072558114,0.5803972,0.0006294376,0.00020642864,0.0019698106,0.000062195344,0.06525575],"genre_scores_gemma":[0.90327245,0.0056282985,0.0008710555,0.07598498,0.00037604035,0.000057245925,0.0003367098,0.00003356971,0.013439806],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9827806,0.002328092,0.0004863984,0.00080397417,0.005220421,0.008380548],"domain_scores_gemma":[0.95481235,0.01674785,0.0034112623,0.00052634027,0.012698459,0.011803661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009845504,0.00031644083,0.0009780932,0.0020438605,0.008335574,0.011077048,0.0031251085,0.010811496,0.007201714],"category_scores_gemma":[0.039850302,0.00056092726,0.0011465613,0.003708854,0.0048255916,0.002513892,0.0033112436,0.008118816,0.00016889544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015580247,0.00077882106,0.124715135,0.0007160276,0.0004339433,0.0019508285,0.00871743,0.009995413,0.0021868516,0.59439385,0.18388999,0.07066373],"study_design_scores_gemma":[0.0016648457,0.00049127097,0.4058167,0.001592333,0.0010124684,0.00057619077,0.028656453,0.01950237,0.0028318889,0.075303294,0.4618629,0.0006893257],"about_ca_topic_score_codex":0.99079216,"about_ca_topic_score_gemma":0.9955415,"teacher_disagreement_score":0.17721973,"about_ca_system_score_codex":0.17721973,"about_ca_system_score_gemma":0.35812175,"threshold_uncertainty_score":0.9543085},"labels":[],"label_agreement":null},{"id":"W2327826446","doi":"10.1097/00126450-200307000-00013","title":"Consumers Devise Drug Cost-Cutting Measures","year":2003,"lang":"en","type":"article","venue":"The Health Care Manager","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Pill; Per capita; Health care; Business; Prescription costs; Drug; Drug prices; Health care cost; Health insurance; Medicine; Environmental health; Actuarial science; Public economics; Pharmacology; Economic growth; Economics","score_opus":0.07284092232313097,"score_gpt":0.3160500224500772,"score_spread":0.24320910012694621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327826446","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042577486,0.032613963,0.045259908,0.6975425,0.0027176696,0.00090300763,0.00038782615,0.0006776346,0.1773201],"genre_scores_gemma":[0.6204912,0.026218444,0.053233054,0.26923296,0.006303045,0.0004966886,0.0002546686,0.00011412958,0.023655744],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9896797,0.0028282013,0.00048820119,0.00049948815,0.005931526,0.000572991],"domain_scores_gemma":[0.97997403,0.009317003,0.0040367832,0.0012887209,0.0038790945,0.0015043829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013658205,0.00090485404,0.0009722775,0.0027681354,0.0015155264,0.0069360174,0.0021358014,0.0058618276,0.0052351328],"category_scores_gemma":[0.03481654,0.00043687233,0.00054289756,0.0018936069,0.004132855,0.0057866704,0.003312547,0.0043990123,0.0012767671],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016424264,0.0007817657,0.019250844,0.0009789051,0.0003533928,0.00026477163,0.0013980722,0.0050609047,0.0014777862,0.48187432,0.21393149,0.27446353],"study_design_scores_gemma":[0.00027787496,0.00051573414,0.030043582,0.0021722526,0.00026486887,0.00027467852,0.0030218065,0.010203106,0.0025991062,0.43093464,0.51952296,0.0001694729],"about_ca_topic_score_codex":0.0069210487,"about_ca_topic_score_gemma":0.0063721878,"teacher_disagreement_score":0.013658205,"about_ca_system_score_codex":0.0035978258,"about_ca_system_score_gemma":0.0075989617,"threshold_uncertainty_score":0.072232366},"labels":[],"label_agreement":null},{"id":"W2327987781","doi":"10.1358/dot.2014.50.1.2118308","title":"A report from the 16th IGPA conference (December 9-11, 2013 -Brussels, Belgium)","year":2014,"lang":"en","type":"article","venue":"Drugs of today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alliance; Medicine; Negotiation; Member states; Economic growth; International trade; Political science; Business; Law","score_opus":0.042667258274655735,"score_gpt":0.26738202488049334,"score_spread":0.2247147666058376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327987781","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012471349,0.05798961,0.005672843,0.18375808,0.3257062,0.0017384668,0.036542904,0.0015708511,0.37454966],"genre_scores_gemma":[0.02618415,0.02039072,0.0045057205,0.018444337,0.027860904,0.001006993,0.020431021,0.0010188713,0.88015723],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970061,0.00041494003,0.00008555311,0.0002620818,0.0014545603,0.00077682047],"domain_scores_gemma":[0.99438757,0.00053191214,0.000247714,0.00016337364,0.0028304493,0.0018389178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004975792,0.0013831945,0.0007300896,0.0019804894,0.0021571089,0.008237376,0.0015228848,0.0042072153,0.12361184],"category_scores_gemma":[0.007170246,0.00045743646,0.0010805653,0.0020754691,0.00062179036,0.002464819,0.0025662577,0.0039679348,0.052068625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006188677,0.00003864754,0.00024413771,0.00011334979,0.000005325104,0.000065263426,0.00004374248,0.00007377493,0.00011260517,0.0003815558,0.9885566,0.010303023],"study_design_scores_gemma":[0.000013482052,0.000030930198,0.0025180704,0.00019077046,0.000007524609,0.000038111397,0.00025798322,0.00006810419,0.00018396691,0.000209489,0.99646735,0.000014171902],"about_ca_topic_score_codex":0.027056774,"about_ca_topic_score_gemma":0.036341798,"teacher_disagreement_score":0.12361184,"about_ca_system_score_codex":0.004101135,"about_ca_system_score_gemma":0.009297179,"threshold_uncertainty_score":0.41352278},"labels":[],"label_agreement":null},{"id":"W2328948358","doi":"10.1177/1715163513482702","title":"Patient care and health compromised by drug shortages in Canada","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Drug; Health care; Medicine; Intensive care medicine; Medical emergency; Business; Political science; Pharmacology","score_opus":0.03543608171186143,"score_gpt":0.24453119183930333,"score_spread":0.2090951101274419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328948358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.846962,0.008201129,0.00018904105,0.12020837,0.00042678762,0.00010715324,0.0064281705,0.00002864512,0.017448721],"genre_scores_gemma":[0.9914724,0.0019147778,0.0000754127,0.003893639,0.00010900662,0.00001271432,0.0005951841,0.000006006564,0.0019209187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623233,0.00034721184,0.00013488099,0.00013602471,0.000694187,0.002455351],"domain_scores_gemma":[0.9826423,0.001153329,0.0029548814,0.00011052083,0.0031344022,0.010004513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014847522,0.00019903656,0.0006283284,0.001488038,0.0041946387,0.0031670218,0.0016149653,0.0022813038,0.007052029],"category_scores_gemma":[0.007594756,0.00047111083,0.00079871016,0.004695782,0.0019107452,0.00089716155,0.0022773426,0.0037174856,0.00022929432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056071085,0.0006576771,0.88990724,0.00032596366,0.00032810163,0.0011669635,0.0027744947,0.0035705098,0.00020812431,0.012851346,0.06340254,0.024246423],"study_design_scores_gemma":[0.00017096975,0.000091150134,0.9696982,0.00028791436,0.00010413605,0.00021262358,0.007972834,0.002212628,0.00008593875,0.0016212731,0.017473351,0.000069107155],"about_ca_topic_score_codex":0.9957539,"about_ca_topic_score_gemma":0.9978967,"teacher_disagreement_score":0.1143851,"about_ca_system_score_codex":0.1143851,"about_ca_system_score_gemma":0.15111764,"threshold_uncertainty_score":0.8299259},"labels":[],"label_agreement":null},{"id":"W2329406519","doi":"","title":"Processus d’appels d’offres relatif à l’approvisionnement en médicaments au sein des centres hospitaliers du Québec","year":2016,"lang":"fr","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bidding; Interim; Business; Audit; Government (linguistics); Economic shortage; Political science; Welfare economics; Accounting; Marketing; Economics; Law","score_opus":0.05013385462371856,"score_gpt":0.32071749755239615,"score_spread":0.2705836429286776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329406519","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26624075,0.007045994,0.09040281,0.09673573,0.003901081,0.010550639,0.0011936652,0.0016529971,0.52227634],"genre_scores_gemma":[0.60382724,0.0019903418,0.042096913,0.010209913,0.0008512201,0.0012713522,0.00065376353,0.0003946086,0.33870468],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.92779344,0.02633149,0.0028028863,0.0049558077,0.027433366,0.010682981],"domain_scores_gemma":[0.90250546,0.03744,0.007472755,0.007616661,0.032353632,0.0126113435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06683775,0.0009877896,0.00064440904,0.003506588,0.016111966,0.015533712,0.003840223,0.0067737214,0.028323324],"category_scores_gemma":[0.08523133,0.0012205307,0.0015029975,0.0022604559,0.005813838,0.0033687586,0.006861695,0.0067960513,0.0062225633],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013544585,0.0014096448,0.057201825,0.0011015388,0.00024765826,0.012471719,0.060912833,0.008451105,0.016042745,0.18505335,0.23418705,0.42156613],"study_design_scores_gemma":[0.00015421714,0.00054978556,0.037458275,0.0008133398,0.000069335656,0.001308379,0.021280771,0.0055361693,0.0058933427,0.011332529,0.91530246,0.0003014401],"about_ca_topic_score_codex":0.45613518,"about_ca_topic_score_gemma":0.4265535,"teacher_disagreement_score":0.9644576,"about_ca_system_score_codex":0.035542455,"about_ca_system_score_gemma":0.075320475,"threshold_uncertainty_score":0.90696037},"labels":[],"label_agreement":null},{"id":"W2330503964","doi":"10.1139/cjm-2013-0089","title":"Is the GAIN Act a turning point in new antibiotic discovery?","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Incentive; Antibiotics; Drug discovery; Legislation; Business; Turning point; Action (physics); Public economics; Biology; Economics; Political science; Bioinformatics; Law; Market economy; Microbiology","score_opus":0.035644665123110555,"score_gpt":0.24377122034081886,"score_spread":0.2081265552177083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330503964","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006172889,0.011729439,0.0035344018,0.93567216,0.005007241,0.000026761882,0.00013029776,0.00009026753,0.037636574],"genre_scores_gemma":[0.37359184,0.021142513,0.007238306,0.5451467,0.016664352,0.00019422967,0.00018842917,0.00020457497,0.03562911],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9810946,0.0067254305,0.0005341532,0.0012229129,0.00792556,0.0024972567],"domain_scores_gemma":[0.9537049,0.030559903,0.0034291109,0.0019230184,0.0044953777,0.0058876867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026980055,0.00045823838,0.0014773717,0.0016982477,0.0036019206,0.013934067,0.0017811642,0.015545444,0.016794188],"category_scores_gemma":[0.07492812,0.00039172196,0.0009835964,0.0014210247,0.014679088,0.022004362,0.004603929,0.01810378,0.0029588325],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011927097,0.000095239404,0.001039737,0.000092917384,0.000016941567,0.00011158287,0.00024660994,0.0005123931,0.00010640582,0.85742587,0.11091844,0.029314466],"study_design_scores_gemma":[0.00010586302,0.00017732863,0.00260519,0.00051999337,0.00002158513,0.00015008678,0.0006384092,0.0014663808,0.0002650917,0.6286754,0.36528215,0.00009249824],"about_ca_topic_score_codex":0.009693396,"about_ca_topic_score_gemma":0.008204147,"teacher_disagreement_score":0.026980055,"about_ca_system_score_codex":0.009015694,"about_ca_system_score_gemma":0.015144874,"threshold_uncertainty_score":0.14268589},"labels":[],"label_agreement":null},{"id":"W2331265150","doi":"10.3821/1913-701x(2008)141[191:cipsea]2.0.co;2","title":"Canadian Internet pharmacies: Some ethical and economic issues","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; The Internet; Business; Internet privacy; Medicine; Family medicine; Computer science; World Wide Web","score_opus":0.07160511364793833,"score_gpt":0.2826959703774997,"score_spread":0.2110908567295614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331265150","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005435843,0.0065744105,0.0009022834,0.9571265,0.00093507714,0.00007054164,0.00009212058,0.000022492683,0.028840747],"genre_scores_gemma":[0.31476194,0.015691742,0.01331132,0.6137285,0.003948669,0.00032248924,0.00015719929,0.000085773645,0.037992436],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9550033,0.008570592,0.0017278021,0.0019831585,0.027716378,0.004998596],"domain_scores_gemma":[0.9180218,0.049579944,0.0031455979,0.0017961715,0.020175753,0.007280643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034066927,0.0007602217,0.00093193294,0.0035409117,0.022625947,0.016952682,0.0059718327,0.033132076,0.004467994],"category_scores_gemma":[0.08964875,0.00071538956,0.0013345788,0.006343816,0.021894773,0.0049659642,0.0040618503,0.019553531,0.00044724252],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006540981,0.000104595085,0.0034201718,0.00027258898,0.000038243405,0.002044123,0.005883145,0.00097570865,0.00029076004,0.67218244,0.26252142,0.05220145],"study_design_scores_gemma":[0.00012883278,0.000071080256,0.014044099,0.0015814552,0.00009086328,0.0020637999,0.01435381,0.004085644,0.00051180104,0.26447833,0.69815564,0.0004346336],"about_ca_topic_score_codex":0.87108994,"about_ca_topic_score_gemma":0.9091769,"teacher_disagreement_score":0.12891006,"about_ca_system_score_codex":0.091507964,"about_ca_system_score_gemma":0.16935153,"threshold_uncertainty_score":0.66393983},"labels":[],"label_agreement":null},{"id":"W2332270253","doi":"10.1177/171516350413700607","title":"BCE Emergis Acquires Pharmacy Management Systems","year":2004,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacy; Computer science; Business; Medicine; Family medicine","score_opus":0.06814307923856633,"score_gpt":0.272002194774843,"score_spread":0.20385911553627667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332270253","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20578362,0.0019182961,0.0028939424,0.047296584,0.0006679927,0.00053535926,0.004831932,0.0005296881,0.73554265],"genre_scores_gemma":[0.4407463,0.00094609446,0.0018027853,0.0043921573,0.0004992509,0.00006886768,0.0020656327,0.000055184802,0.54942364],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959176,0.0002559178,0.0001287038,0.00029024686,0.0023186156,0.0010888374],"domain_scores_gemma":[0.99055415,0.0013141738,0.00087882293,0.00052016723,0.0039774086,0.002755361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002060856,0.0003218149,0.0003669625,0.0024608267,0.0031048628,0.006021127,0.0007085682,0.0017203056,0.06260323],"category_scores_gemma":[0.0090883225,0.00033959158,0.00040945993,0.0016784966,0.0007174043,0.0023623654,0.0017759402,0.002072406,0.0061837463],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005335567,0.0010643824,0.17992024,0.0002720354,0.00010474765,0.0013346068,0.00084477465,0.0025133297,0.0026973095,0.12111406,0.35474512,0.3348559],"study_design_scores_gemma":[0.00013776052,0.00027519817,0.19581778,0.00014832086,0.000049996434,0.00073605776,0.0012385831,0.0050986717,0.0027607735,0.004152083,0.78953665,0.000048131755],"about_ca_topic_score_codex":0.31302923,"about_ca_topic_score_gemma":0.42952088,"teacher_disagreement_score":0.31302923,"about_ca_system_score_codex":0.01683855,"about_ca_system_score_gemma":0.024712108,"threshold_uncertainty_score":0.62241435},"labels":[],"label_agreement":null},{"id":"W2333326120","doi":"10.1097/fbp.0b013e328363d163","title":"Principles of assessment of abuse liability","year":2013,"lang":"en","type":"review","venue":"Behavioural Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bureau of Justice Statistics","keywords":"Abuse liability; Business; Liability; Jurisdiction; Substance abuse; Enforcement; Medicine; Risk analysis (engineering); Drug; Pharmacology; Political science; Law; Psychiatry; Accounting","score_opus":0.31778926003576896,"score_gpt":0.43888259735216006,"score_spread":0.1210933373163911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333326120","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033639856,0.012045045,0.41082665,0.03302615,0.0023764088,0.002426851,0.0011368538,0.00051432714,0.53428376],"genre_scores_gemma":[0.23226205,0.023710804,0.58847183,0.036125742,0.005847783,0.009768549,0.0015751512,0.00049285975,0.10174529],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.8996812,0.03477278,0.010722183,0.007160184,0.04445637,0.0032073122],"domain_scores_gemma":[0.92561346,0.04275823,0.00472101,0.0071539087,0.018609293,0.0011441478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05582854,0.0032260534,0.002919927,0.0097042825,0.0066863745,0.017474359,0.010229828,0.017050168,0.014516617],"category_scores_gemma":[0.07526613,0.002030473,0.0042203907,0.004369085,0.03665931,0.016012385,0.01073451,0.01597505,0.0077986573],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014975872,0.00004809375,0.00038321913,0.0002272075,0.000033023596,0.000262203,0.0007466391,0.00071601657,0.00015508043,0.9671463,0.010747176,0.019520072],"study_design_scores_gemma":[0.00003344069,0.00007969252,0.0005248803,0.0012657442,0.000052330866,0.0008206055,0.0006254055,0.0017431226,0.000457242,0.78484416,0.20946743,0.000085960346],"about_ca_topic_score_codex":0.008704165,"about_ca_topic_score_gemma":0.0066709784,"teacher_disagreement_score":0.05582854,"about_ca_system_score_codex":0.0077994955,"about_ca_system_score_gemma":0.021310428,"threshold_uncertainty_score":0.2952531},"labels":[],"label_agreement":null},{"id":"W2333798253","doi":"10.1097/00005650-200308000-00004","title":"Physician and Practice Characteristics Associated with the Early Utilization of New Prescription Drugs","year":2003,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medical prescription; Medicine; MEDLINE; Intensive care medicine; Family medicine; Pharmacology; Political science","score_opus":0.05608320431829633,"score_gpt":0.2916851483422187,"score_spread":0.23560194402392237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333798253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987717,0.00032056842,0.00006550166,0.00009842064,0.000002621541,0.000013628348,0.00036905176,0.0000038279704,0.00035458285],"genre_scores_gemma":[0.99941194,0.00010489649,0.00008196738,0.000019169334,0.000006485381,0.0000057600596,0.00026991297,7.3337037e-7,0.00009911483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994141,0.000111853704,0.000054846154,0.000091928625,0.00018474,0.00014252082],"domain_scores_gemma":[0.9925356,0.0010578888,0.0045441324,0.000111188376,0.00075168203,0.0009994913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057993195,0.00016568326,0.00015597165,0.00093339523,0.00033578777,0.0004358152,0.00028227293,0.0004618158,0.0020379955],"category_scores_gemma":[0.0039490024,0.00015385596,0.00023085158,0.0010746532,0.00029087462,0.00020405892,0.00023364632,0.00038525695,0.00014118433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014306048,0.000008917338,0.9994985,0.0000025712225,0.000006712071,0.000023133676,0.000014942592,0.000020865798,0.000041149564,0.0000022445365,0.0000346235,0.0003319625],"study_design_scores_gemma":[0.0000010136689,0.0000110482615,0.9998142,0.0000020351804,0.000002025812,0.00006390418,0.000017658946,0.00004969819,0.00000818643,0.0000012134367,0.000028513208,5.933296e-7],"about_ca_topic_score_codex":0.16111256,"about_ca_topic_score_gemma":0.25234964,"teacher_disagreement_score":0.16111256,"about_ca_system_score_codex":0.0011842682,"about_ca_system_score_gemma":0.0014720586,"threshold_uncertainty_score":0.3203495},"labels":[],"label_agreement":null},{"id":"W2333810059","doi":"10.3324/haematol.2015.139931","title":"Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed","year":2016,"lang":"en","type":"editorial","venue":"Haematologica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children; Novo Nordisk; Bayer HealthCare; CSL Behring; Baxalta; Sick Kids Foundation; Biogen; Pfizer","keywords":"Reimbursement; Haemophilia; Business; Medicine; Cost–benefit analysis; Health care; Intensive care medicine; Medical emergency; Political science; Surgery","score_opus":0.031195118780093522,"score_gpt":0.2879831488459305,"score_spread":0.256788030065837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333810059","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033436972,0.010305504,0.00022276556,0.18355577,0.8048394,0.000017278338,0.000039057202,0.000054206947,0.0009326362],"genre_scores_gemma":[0.00042329045,0.011495578,0.0003849477,0.053982314,0.92962915,0.000021384749,0.000031013722,0.00005033664,0.003982021],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98436177,0.003956368,0.0030450337,0.0011854098,0.0067147412,0.00073677866],"domain_scores_gemma":[0.8850331,0.070869625,0.00490727,0.0028270173,0.028441347,0.00792162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027164733,0.0031991669,0.005527726,0.0026778104,0.003043607,0.012946911,0.0043024714,0.029849727,0.012363046],"category_scores_gemma":[0.09043769,0.0012735019,0.003932924,0.0021220047,0.0044977902,0.013539325,0.0021462892,0.049823765,0.008099585],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017859895,0.000016116463,0.00002628983,0.00021540241,0.00002617445,0.00004954383,0.00002106852,0.0000415984,0.000020404852,0.0010816782,0.9899422,0.0085415365],"study_design_scores_gemma":[0.000074393094,0.000027449585,0.0003466014,0.0012008613,0.00007092218,0.00013756886,0.00008479219,0.00028886026,0.000060739945,0.0072154207,0.9904463,0.00004601019],"about_ca_topic_score_codex":0.0023680248,"about_ca_topic_score_gemma":0.0054117665,"teacher_disagreement_score":0.029849727,"about_ca_system_score_codex":0.004524414,"about_ca_system_score_gemma":0.008682078,"threshold_uncertainty_score":0.14366251},"labels":[],"label_agreement":null},{"id":"W2334865396","doi":"10.5539/ibr.v9n6p53","title":"A Quantitative Analysis of the Causes of Drug Shortages in Jordan: A Supply Chain Perspective","year":2016,"lang":"en","type":"article","venue":"International Business Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Supply chain; Legislature; Business; Distribution (mathematics); Perspective (graphical); Drug; Marketing; Medicine; Pharmacology; Geography; Computer science","score_opus":0.1381664222172123,"score_gpt":0.4199900470063689,"score_spread":0.28182362478915657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334865396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96397704,0.0025123204,0.004997189,0.0024680807,0.00002277003,0.00022207599,0.0016463995,0.00002964282,0.024124596],"genre_scores_gemma":[0.9955011,0.0010770538,0.001290409,0.00010301788,0.000025230815,0.00006274026,0.00060756097,0.0000050934145,0.001327884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800843,0.0007181243,0.00024080239,0.00016840016,0.0006673326,0.00019697401],"domain_scores_gemma":[0.98395514,0.0064382735,0.00464633,0.00018036948,0.004305084,0.0004747591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033752795,0.000245835,0.000279196,0.0073518655,0.0009832751,0.0020452372,0.0004027583,0.00042162734,0.005584351],"category_scores_gemma":[0.008899511,0.0002386129,0.00036906183,0.011225338,0.0008070401,0.0020580022,0.0012669493,0.0004377035,0.0002932456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001526804,0.0002701463,0.8892879,0.0013433545,0.00013658384,0.00129524,0.011401695,0.006032955,0.0008928646,0.019580338,0.0030010098,0.066605315],"study_design_scores_gemma":[0.000025985079,0.00033606368,0.8606453,0.00068042096,0.000099728386,0.0006416559,0.08399052,0.018742377,0.0014214744,0.007871425,0.02548129,0.0000637728],"about_ca_topic_score_codex":0.0070852824,"about_ca_topic_score_gemma":0.0074708797,"teacher_disagreement_score":0.0073518655,"about_ca_system_score_codex":0.003656301,"about_ca_system_score_gemma":0.0043592225,"threshold_uncertainty_score":0.026528418},"labels":[],"label_agreement":null},{"id":"W2335916510","doi":"10.1097/tp.0000000000000782","title":"What Is the Future of Generics in Transplantation?","year":2015,"lang":"en","type":"review","venue":"Transplantation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Generic drug; Innovator; Medicine; Drug; Bioequivalence; Scope (computer science); Substitution (logic); Risk analysis (engineering); Transplantation; Intensive care medicine; Business; Pharmacology; Computer science; Surgery","score_opus":0.11311823276975891,"score_gpt":0.3510769102565545,"score_spread":0.2379586774867956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335916510","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005032682,0.18799905,0.00064441026,0.77194226,0.026825925,0.000010067355,0.000039882412,0.000057718997,0.011977466],"genre_scores_gemma":[0.017036498,0.34838185,0.0032018148,0.5329498,0.08017816,0.000042549087,0.000090547626,0.00010396793,0.01801481],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939161,0.0023603744,0.00045852654,0.0004857803,0.002002036,0.00077718584],"domain_scores_gemma":[0.970312,0.017703602,0.0024713532,0.0010270867,0.004244893,0.0042410367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011343197,0.0007660949,0.0013636793,0.0016207664,0.0019936962,0.011039612,0.0015989976,0.01662766,0.017809426],"category_scores_gemma":[0.020369925,0.00036764285,0.0015312203,0.002262766,0.0066543473,0.019016212,0.0023128926,0.012007339,0.003307991],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010546482,0.00008276505,0.0009933317,0.0017752879,0.000037492915,0.00068093726,0.0006269733,0.00021033094,0.00023815077,0.119266674,0.55050355,0.3254791],"study_design_scores_gemma":[0.000014971428,0.00008491783,0.00057774247,0.0015060222,0.00001602783,0.00080938835,0.0005258522,0.0000835498,0.00005581856,0.016888103,0.97940916,0.00002843439],"about_ca_topic_score_codex":0.0029095956,"about_ca_topic_score_gemma":0.005394035,"teacher_disagreement_score":0.017809426,"about_ca_system_score_codex":0.004753476,"about_ca_system_score_gemma":0.0064834883,"threshold_uncertainty_score":0.059989274},"labels":[],"label_agreement":null},{"id":"W2336377795","doi":"","title":"How cheap are Canada's drugs really?","year":2004,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Drug prices; Government (linguistics); Business; Economics; Schedule; Differential (mechanical device); Agricultural economics; Public economics; Engineering","score_opus":0.04372754451490109,"score_gpt":0.21087734989349172,"score_spread":0.16714980537859064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336377795","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08399959,0.16315088,0.002648973,0.46990055,0.0036437623,0.00011711475,0.0113946395,0.00021348959,0.264931],"genre_scores_gemma":[0.8465544,0.0842619,0.0028838508,0.042093247,0.0021157016,0.000042458196,0.0021261224,0.00014426598,0.019778188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951605,0.0006607475,0.00015142463,0.00026798263,0.0030436197,0.00071575836],"domain_scores_gemma":[0.98377836,0.0045843334,0.0023608087,0.00036365568,0.007035313,0.0018775718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019049349,0.00036301013,0.0007463046,0.0024670053,0.0023171636,0.007163945,0.00080707466,0.0016086554,0.012858468],"category_scores_gemma":[0.027928561,0.00018549581,0.00050346775,0.005238742,0.0036689532,0.0030311688,0.0007067234,0.0021993397,0.0011852342],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008025129,0.00014735745,0.08557656,0.003594186,0.00083266094,0.0005059737,0.0009173427,0.003283233,0.0009589789,0.16560456,0.4007615,0.33701506],"study_design_scores_gemma":[0.00021538814,0.00019981602,0.20397095,0.0036540735,0.0010665816,0.0011208144,0.005613697,0.0026334268,0.0016580747,0.061228514,0.7183732,0.000265441],"about_ca_topic_score_codex":0.87986165,"about_ca_topic_score_gemma":0.885738,"teacher_disagreement_score":0.12013835,"about_ca_system_score_codex":0.041023944,"about_ca_system_score_gemma":0.05124604,"threshold_uncertainty_score":0.29765093},"labels":[],"label_agreement":null},{"id":"W2338102190","doi":"","title":"Congress, Illinois Think Canada Is Answer to Prescription Drug Woes","year":2003,"lang":"en","type":"article","venue":"Public interest law reporter","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Political science; Medicine; Pharmacology","score_opus":0.06726258631704106,"score_gpt":0.2623693629867958,"score_spread":0.19510677666975473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338102190","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015798146,0.0021327964,0.00017105261,0.93113303,0.005889146,0.00002602867,0.00028528197,0.000051388408,0.058731526],"genre_scores_gemma":[0.033582043,0.0020527558,0.00045978028,0.74902385,0.004269608,0.0000672115,0.00020114868,0.000098662684,0.21024497],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9887788,0.0011597123,0.00035616456,0.001180215,0.005532715,0.0029923455],"domain_scores_gemma":[0.9729898,0.0091227,0.0008884905,0.0007638773,0.011534164,0.0047009466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076326826,0.00070854963,0.0009614525,0.002712664,0.021362297,0.023428999,0.0019291496,0.041257974,0.040766995],"category_scores_gemma":[0.052805483,0.0009069407,0.0011506359,0.0023367417,0.008928587,0.0066021136,0.0029647832,0.025745427,0.0058811773],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032829117,0.000023922852,0.00096535,0.000031845935,0.0000147055325,0.00006879181,0.00034651978,0.00006708268,0.00008143079,0.07002429,0.92259556,0.0057476233],"study_design_scores_gemma":[0.00005870416,0.000015708812,0.002241893,0.00016620437,0.00004177965,0.000033217075,0.0010932529,0.00021298346,0.00024605778,0.017029408,0.9787972,0.000063575804],"about_ca_topic_score_codex":0.8032143,"about_ca_topic_score_gemma":0.8644577,"teacher_disagreement_score":0.95994484,"about_ca_system_score_codex":0.040055133,"about_ca_system_score_gemma":0.12504302,"threshold_uncertainty_score":0.39588916},"labels":[],"label_agreement":null},{"id":"W2339312117","doi":"10.1186/s40545-016-0064-8","title":"Upstream solutions for price-gouging on critical generic medicines","year":2016,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Divestment; Upstream (networking); Pharmacy; Drug prices; Business; Psychological intervention; Law and economics; Public relations; Economics; Medicine; Political science; Law; Public economics; Computer science; Finance; Telecommunications","score_opus":0.21312437811457274,"score_gpt":0.4391385945673652,"score_spread":0.22601421645279246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339312117","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17322132,0.006822505,0.12673,0.2381715,0.0016763685,0.0009626193,0.0004701671,0.0010740412,0.45087153],"genre_scores_gemma":[0.9485598,0.0017282233,0.0091968775,0.015975963,0.0009849825,0.00022644702,0.00006154115,0.000086172186,0.023179963],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9914709,0.002726001,0.00032997184,0.0010378817,0.002787981,0.0016473272],"domain_scores_gemma":[0.98575115,0.008674676,0.002339509,0.0010417886,0.001409317,0.00078362843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009557716,0.000571882,0.0007176217,0.0018498446,0.003752778,0.0080767125,0.0019776893,0.010909868,0.025680633],"category_scores_gemma":[0.029871944,0.0007447096,0.0010208689,0.0007106771,0.00608249,0.010875139,0.007422581,0.010281039,0.0015880987],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008284352,0.00012848187,0.0014451848,0.00016810592,0.000027719587,0.0006507454,0.00052272755,0.0028816818,0.0015271989,0.95623523,0.015523981,0.020806072],"study_design_scores_gemma":[0.00013833104,0.00021277589,0.00357011,0.0006191745,0.000066145054,0.00031951343,0.0012904876,0.010027151,0.0045037908,0.89056313,0.088559344,0.00012996462],"about_ca_topic_score_codex":0.0031397077,"about_ca_topic_score_gemma":0.0032087548,"teacher_disagreement_score":0.025680633,"about_ca_system_score_codex":0.0074690976,"about_ca_system_score_gemma":0.011004662,"threshold_uncertainty_score":0.08591026},"labels":[],"label_agreement":null},{"id":"W2339383866","doi":"10.1503/cmaj.109-5245","title":"US seeking more transparency from pharma","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Transparency (behavior); Government (linguistics); Administration (probate law); Fiscal year; Business; Public administration; Medicine; Accounting; Computer science; Finance; Political science; Computer security; Law","score_opus":0.031265472286556795,"score_gpt":0.26117523024299577,"score_spread":0.22990975795643898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339383866","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019541981,0.006785825,0.0012060048,0.91653395,0.009289459,0.000019269373,0.00031914495,0.00013795958,0.06375418],"genre_scores_gemma":[0.06363585,0.008488689,0.0042440225,0.86774635,0.008250592,0.0000547218,0.00046357384,0.000194048,0.0469222],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98676956,0.0035381222,0.00056130614,0.0011370997,0.0061947335,0.0017991172],"domain_scores_gemma":[0.97552174,0.008187962,0.0018716219,0.0016706086,0.006520652,0.006227407],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013608893,0.0007375607,0.0005885852,0.0013324838,0.004561019,0.012928532,0.00074296404,0.013452863,0.024932306],"category_scores_gemma":[0.0421184,0.00045703395,0.0007477269,0.0016371991,0.0035473157,0.008302671,0.005279854,0.016053585,0.0057830587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007618261,0.00003886432,0.0006206386,0.00010704474,0.000016815953,0.00013243029,0.00030658467,0.00010275266,0.0004668756,0.16705339,0.79902005,0.03205831],"study_design_scores_gemma":[0.000032546548,0.000027971599,0.0009340327,0.0003529251,0.000012556682,0.00009075504,0.00021751763,0.00014515524,0.00048708793,0.027769037,0.96990716,0.000023314646],"about_ca_topic_score_codex":0.014744274,"about_ca_topic_score_gemma":0.019162271,"teacher_disagreement_score":0.9863911,"about_ca_system_score_codex":0.008716105,"about_ca_system_score_gemma":0.026530514,"threshold_uncertainty_score":0.083406866},"labels":[],"label_agreement":null},{"id":"W2341632540","doi":"10.1177/0840470415588677","title":"Triage in times of drug shortage","year":2015,"lang":"en","type":"review","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. John’s Health Sciences Centre; Newfoundland and Labrador Centre for Applied Health Research; Memorial University of Newfoundland","funders":"","keywords":"Economic shortage; Triage; Process (computing); Drug; Risk analysis (engineering); Business; Process management; Computer science; Medical emergency; Medicine; Pharmacology","score_opus":0.15777052451575213,"score_gpt":0.3883288184811249,"score_spread":0.23055829396537275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341632540","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005898319,0.99246913,0.0006701881,0.0037209373,0.0003793141,0.000033334658,0.000011285958,0.000009122266,0.0021169188],"genre_scores_gemma":[0.010780658,0.98490727,0.0009742883,0.0021747898,0.0006008035,0.000052283383,0.000031181866,0.0000039939896,0.00047477274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761176,0.0013302946,0.0002850837,0.00014019584,0.000487808,0.00014486453],"domain_scores_gemma":[0.9945879,0.0032498965,0.0012580282,0.00007303437,0.0006232058,0.0002078925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040626703,0.000514312,0.0013293726,0.0024962125,0.0006540991,0.0015495465,0.0012817767,0.0025040503,0.0038679098],"category_scores_gemma":[0.016482562,0.0002815717,0.00089138537,0.0018364438,0.00088760484,0.0021587866,0.0016450721,0.0030369544,0.0011352911],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000202021,0.000119651246,0.000774464,0.021285415,0.00016745893,0.0005359283,0.00038626214,0.0006199157,0.000207433,0.007581468,0.027699994,0.94042],"study_design_scores_gemma":[0.00040386443,0.0005391984,0.006749906,0.07719375,0.0005581784,0.008215681,0.0023037577,0.00095213123,0.00089930533,0.018544456,0.88355124,0.00008857546],"about_ca_topic_score_codex":0.002417978,"about_ca_topic_score_gemma":0.004312478,"teacher_disagreement_score":0.0040626703,"about_ca_system_score_codex":0.0013150639,"about_ca_system_score_gemma":0.004906572,"threshold_uncertainty_score":0.021485686},"labels":[],"label_agreement":null},{"id":"W2341662826","doi":"10.1071/hc15093","title":"Guest Editorial: A drug by any other name... generic and brand-name drugs are clinically equivalent","year":2015,"lang":"en","type":"editorial","venue":"Journal of Primary Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Brand names; Drug; Medicine; Generic drug; MEDLINE; Family medicine; Pharmacology; Business; Advertising; Political science; Law","score_opus":0.03695820340460198,"score_gpt":0.3339786750175078,"score_spread":0.2970204716129058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341662826","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035934918,0.0014573552,0.000081997845,0.02247429,0.97331333,0.000020772657,0.00006190319,0.00007732905,0.0024771707],"genre_scores_gemma":[0.00055041234,0.0018649613,0.00008906239,0.016229153,0.9614261,0.000020865114,0.000055986708,0.00004588988,0.019717548],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956175,0.00063732266,0.0005630385,0.00052604254,0.0023511758,0.00030493006],"domain_scores_gemma":[0.9820764,0.005905427,0.0014826016,0.0005192394,0.007134465,0.0028817668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050727087,0.0031396167,0.003430745,0.0028761674,0.0025095267,0.007195879,0.002884502,0.0113678435,0.04054162],"category_scores_gemma":[0.02649615,0.0011020651,0.0025355155,0.0012521276,0.00196661,0.0037693726,0.0011962127,0.015221994,0.029781176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028970522,0.000011474153,0.00001723135,0.00009401159,0.000012253094,0.00009322218,0.0000036010806,0.000017472687,0.000032034553,0.00015944976,0.9972101,0.0023202016],"study_design_scores_gemma":[0.00013737485,0.000050139988,0.00036788385,0.00040012784,0.000053714994,0.00033795403,0.0000302726,0.00023828646,0.000153766,0.0010692129,0.99713767,0.000023582195],"about_ca_topic_score_codex":0.0011346207,"about_ca_topic_score_gemma":0.0035779492,"teacher_disagreement_score":0.04054162,"about_ca_system_score_codex":0.0021561084,"about_ca_system_score_gemma":0.0026931162,"threshold_uncertainty_score":0.13562524},"labels":[],"label_agreement":null},{"id":"W2343104801","doi":"","title":"La relation entre le CMFC et l’industrie pharmaceutique et des soins de santé","year":2014,"lang":"fr","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Medicine; Philosophy","score_opus":0.06206803256118652,"score_gpt":0.29350222606836923,"score_spread":0.2314341935071827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343104801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32111746,0.19057225,0.0059113754,0.3193094,0.002703181,0.000099904064,0.015225426,0.00030572191,0.14475523],"genre_scores_gemma":[0.9314102,0.034891225,0.0029251056,0.0065165684,0.0018065026,0.00007024365,0.002945531,0.00006156503,0.019373054],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801254,0.00062593963,0.00008745141,0.00026274472,0.0007006091,0.00031068444],"domain_scores_gemma":[0.9841462,0.007862581,0.003987388,0.00031813065,0.0024738065,0.0012120139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018484057,0.00035988158,0.0003020292,0.002141936,0.0005579014,0.0025707837,0.0005540718,0.0017903262,0.03972597],"category_scores_gemma":[0.016212413,0.00020832835,0.0008883063,0.003544561,0.0007969733,0.0011578116,0.0009457614,0.0022377113,0.0023078145],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071761676,0.00023635813,0.6054212,0.0017076336,0.0011932874,0.0005187469,0.0010840243,0.0028148736,0.0011568374,0.05887358,0.10287097,0.2234049],"study_design_scores_gemma":[0.00006899676,0.00019041405,0.83525914,0.0020498312,0.00045544506,0.0008319395,0.0013530286,0.0014217647,0.00073340314,0.01194317,0.14561513,0.000077669],"about_ca_topic_score_codex":0.07392712,"about_ca_topic_score_gemma":0.040654607,"teacher_disagreement_score":0.07392712,"about_ca_system_score_codex":0.0032368803,"about_ca_system_score_gemma":0.004910028,"threshold_uncertainty_score":0.14699358},"labels":[],"label_agreement":null},{"id":"W2343292785","doi":"10.1016/j.jval.2015.03.587","title":"Evaluation Of A Pharmaceutical Risk-Sharing Agreement When Patients Are Screened For The Probability Of Success","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Alberta","funders":"","keywords":"Formulary; Subsidy; Stackelberg competition; Outcome (game theory); Listing (finance); Actuarial science; Business; Microeconomics; Welfare; Population; Distribution (mathematics); Prescription drug; Social Welfare; Economics; Medical prescription; Finance; Medicine; Pharmacology","score_opus":0.43066247223099796,"score_gpt":0.40867515345984246,"score_spread":0.021987318771155506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343292785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8608448,0.00081336504,0.066570975,0.014869771,0.00047344604,0.0046221744,0.001440351,0.0004931431,0.049871925],"genre_scores_gemma":[0.9894174,0.000082332626,0.0064842007,0.00037466487,0.00009247526,0.00053376553,0.00015522935,0.0000194458,0.0028405583],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.94968903,0.038028207,0.0011630583,0.0026782681,0.00408347,0.004358049],"domain_scores_gemma":[0.75052124,0.2192618,0.008317203,0.0062180166,0.0058901804,0.009791573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07030081,0.0021397432,0.004507154,0.0014476314,0.0017536508,0.006177613,0.00561283,0.009980507,0.018774467],"category_scores_gemma":[0.1515404,0.0012383832,0.0025609415,0.00103637,0.0038009807,0.0066831075,0.005368167,0.0071881814,0.0009132557],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0405228,0.0071383202,0.011049043,0.00095032796,0.0009896514,0.00060019887,0.0007699199,0.74811786,0.0018576272,0.13564539,0.006158648,0.046200283],"study_design_scores_gemma":[0.009447554,0.012750817,0.0055761966,0.0001954728,0.0007834262,0.00019818897,0.0010218945,0.88855654,0.0015486719,0.0773427,0.0023987226,0.00017981148],"about_ca_topic_score_codex":0.008055462,"about_ca_topic_score_gemma":0.0030140209,"teacher_disagreement_score":0.07030081,"about_ca_system_score_codex":0.0085159885,"about_ca_system_score_gemma":0.017397871,"threshold_uncertainty_score":0.37179065},"labels":[],"label_agreement":null},{"id":"W2343433672","doi":"10.1016/j.jval.2015.03.430","title":"Analysis of the Drug price reviews performed by the Canadian Patented Medicine Prices review Board (1998-2014)","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Notice; Drug prices; Business; Database transaction; Descriptive statistics; Medicine; Economics; Monetary economics; Law","score_opus":0.1724730036183695,"score_gpt":0.34448059725966984,"score_spread":0.17200759364130033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343433672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5953536,0.08483803,0.0018383749,0.007852946,0.00047165758,0.0010298786,0.25923708,0.000361699,0.04901673],"genre_scores_gemma":[0.86083484,0.020544916,0.0026828528,0.002028926,0.0005161684,0.00045739714,0.08840363,0.00011986205,0.024411451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9800116,0.0011213208,0.0012091165,0.00091723085,0.015028467,0.0017123263],"domain_scores_gemma":[0.9088285,0.021161214,0.025350342,0.0009408755,0.042044804,0.0016743242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068554166,0.00072719576,0.0010113717,0.027292702,0.0012623834,0.0031320208,0.0012043552,0.0010651448,0.003175581],"category_scores_gemma":[0.048969515,0.00058621727,0.0013466931,0.034897592,0.0005075006,0.0007897956,0.00076991966,0.0009656666,0.0006658146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021304737,0.0002068508,0.5467731,0.0072045852,0.003269829,0.0009217322,0.0012534936,0.006410797,0.00234478,0.0062016407,0.24214946,0.1811333],"study_design_scores_gemma":[0.000058261336,0.00007056766,0.9471534,0.0003457525,0.00054570124,0.00015899692,0.0002955204,0.002247141,0.0010513086,0.000108142296,0.047913708,0.00005160728],"about_ca_topic_score_codex":0.8414444,"about_ca_topic_score_gemma":0.89829814,"teacher_disagreement_score":0.97306246,"about_ca_system_score_codex":0.026937556,"about_ca_system_score_gemma":0.03654797,"threshold_uncertainty_score":0.31897873},"labels":[],"label_agreement":null},{"id":"W2343931953","doi":"10.7202/1035190ar","title":"Cooperation and Drug Policies in the Americas. Trends in the Twenty-First Century, Roberto Zepeda et Jonathan d. Rosen (dir.), 2015, Lanham, The Rowman and Littlefield Publishing Group, 249 p.","year":2015,"lang":"en","type":"article","venue":"Études internationales","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Publishing; Political science; Humanities; Art; Law","score_opus":0.0639309121217175,"score_gpt":0.31402827574382247,"score_spread":0.250097363622105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343931953","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007340627,0.9574405,0.000072842384,0.035898484,0.0019136182,0.000002323408,0.00012558734,0.0000116696065,0.004461586],"genre_scores_gemma":[0.0058096997,0.9654168,0.0003545733,0.0074024484,0.0049411017,0.000017745699,0.00020208026,0.000033279917,0.015822258],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717283,0.0010425067,0.00025899813,0.00037861508,0.00087594136,0.00027106816],"domain_scores_gemma":[0.99694747,0.0011876087,0.00071490236,0.00009861372,0.0006830776,0.00036839716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035438957,0.0019770542,0.0012552764,0.004094386,0.0018641221,0.0071202926,0.0010813124,0.004279635,0.017230112],"category_scores_gemma":[0.004347151,0.0009577209,0.00068669644,0.008123675,0.0042221844,0.007815719,0.002398589,0.0053969217,0.006956202],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002808756,0.000023880264,0.0004214036,0.0006802079,0.00002446952,0.000030228617,0.0006692699,0.00011348741,0.000049465718,0.032840032,0.8915345,0.07358493],"study_design_scores_gemma":[0.000011198309,0.000013543341,0.0022891015,0.0012706846,0.000014229242,0.00008758514,0.0006266225,0.000056058976,0.00005583361,0.016241714,0.9793164,0.0000169615],"about_ca_topic_score_codex":0.045865513,"about_ca_topic_score_gemma":0.06833842,"teacher_disagreement_score":0.045865513,"about_ca_system_score_codex":0.009156232,"about_ca_system_score_gemma":0.0085571045,"threshold_uncertainty_score":0.09119707},"labels":[],"label_agreement":null},{"id":"W2344145331","doi":"10.1016/j.jval.2015.03.1231","title":"The Disconnect Between Funding Decisions of Cancer Drugs And Companion Diagnostic Tests in Canada","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Companion diagnostic; Diagnostic test; Medicine; Test (biology); Cancer; Cancer drugs; Family medicine; Intensive care medicine; Medical physics; Pediatrics; Internal medicine","score_opus":0.21203949751455525,"score_gpt":0.36278646560157163,"score_spread":0.15074696808701638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344145331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56886935,0.020068245,0.0010845345,0.33596775,0.0005217804,0.00010570916,0.008694287,0.000073231604,0.06461506],"genre_scores_gemma":[0.9833191,0.0026974252,0.0003265608,0.006159344,0.0001293483,0.000013378908,0.0006261828,0.00002471836,0.006704022],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.991542,0.0009523704,0.00035169403,0.00051763287,0.0028234036,0.0038129764],"domain_scores_gemma":[0.96473396,0.010701503,0.0039277407,0.00044752329,0.010314658,0.009874451],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0055343434,0.000244518,0.0008372375,0.0027156104,0.0041032736,0.008261747,0.0020829232,0.0038776542,0.00548566],"category_scores_gemma":[0.031699695,0.0006553546,0.00087124616,0.005217178,0.002584609,0.001619073,0.001729719,0.004542035,0.00019275463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001542783,0.00029877963,0.3366776,0.0006220093,0.000747798,0.0014011649,0.0034240999,0.028376969,0.0009334657,0.39354292,0.14433798,0.0880944],"study_design_scores_gemma":[0.0007087367,0.00015645362,0.74361306,0.0011322087,0.00068267796,0.00048050677,0.007995504,0.029692149,0.0013132059,0.05013039,0.16364197,0.00045323017],"about_ca_topic_score_codex":0.99657875,"about_ca_topic_score_gemma":0.9981192,"teacher_disagreement_score":0.99446565,"about_ca_system_score_codex":0.21406749,"about_ca_system_score_gemma":0.2258175,"threshold_uncertainty_score":0.9115703},"labels":[],"label_agreement":null},{"id":"W2345038106","doi":"10.1016/j.jval.2015.03.492","title":"Impact of Clinical and Health Economic Publications on Commercial success of Pharmaceutical products in the U.S","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicine; Casual; Asthma; Confounding; Internal medicine; Geography","score_opus":0.5591690276145322,"score_gpt":0.5192826927033346,"score_spread":0.03988633491119764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345038106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5654709,0.06314366,0.0003832492,0.17918397,0.0024788266,0.000063963766,0.018770583,0.00017174201,0.1703331],"genre_scores_gemma":[0.964056,0.016471997,0.0001562221,0.0036763668,0.0023886282,0.000019240117,0.0026461864,0.000053309876,0.010532063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9908565,0.0033899294,0.0008397152,0.00046665524,0.0037068173,0.000740353],"domain_scores_gemma":[0.7323962,0.14961624,0.066593096,0.0032204736,0.03441999,0.013754092],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009761952,0.00024768186,0.0003700991,0.0064217555,0.0007756948,0.008919477,0.0006059172,0.0016064377,0.01166858],"category_scores_gemma":[0.10420369,0.00021100754,0.0004039114,0.010053123,0.0017522466,0.0031773036,0.0017850482,0.0025051094,0.0016227143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013932098,0.00055883656,0.58106244,0.0010667063,0.000590928,0.0011315987,0.0013456534,0.0023652804,0.0005039754,0.042526744,0.20795788,0.1594968],"study_design_scores_gemma":[0.00020859875,0.00036143724,0.8535068,0.0016369895,0.0003262907,0.001006794,0.0052330284,0.002537705,0.0018472217,0.00807669,0.12512751,0.00013097294],"about_ca_topic_score_codex":0.014332948,"about_ca_topic_score_gemma":0.014129288,"teacher_disagreement_score":0.9902381,"about_ca_system_score_codex":0.0038263407,"about_ca_system_score_gemma":0.0047807572,"threshold_uncertainty_score":0.051626742},"labels":[],"label_agreement":null},{"id":"W2346987006","doi":"","title":"Soundings: Geese of a different feather","year":2003,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Revenue; Medicine; Business; Drug Company; Economic policy; Economics; Law; Political science; Finance","score_opus":0.06449739226768803,"score_gpt":0.2775112193344337,"score_spread":0.21301382706674565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346987006","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069558215,0.010215946,0.0041629192,0.2425643,0.070224755,0.0001504104,0.0010778691,0.002503363,0.6621446],"genre_scores_gemma":[0.015715413,0.0019764833,0.0014837605,0.041878536,0.003300843,0.00003573771,0.00026758868,0.0011180412,0.93422365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846977,0.00037809747,0.00004049199,0.00022244423,0.00052935025,0.0003598742],"domain_scores_gemma":[0.9973411,0.00044576733,0.000095987176,0.00025659244,0.0008176249,0.0010429276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013468587,0.0012450276,0.0007487365,0.0012571531,0.007352798,0.008032903,0.0010753876,0.0037430052,0.24485463],"category_scores_gemma":[0.007323191,0.0005530305,0.0008173823,0.0007760818,0.0032309287,0.008070202,0.0052524144,0.0069707334,0.101978965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003068135,0.000024714618,0.00023113834,0.00003780264,0.0000054528673,0.0001974975,0.0011435654,0.000028546143,0.00019492276,0.0050321417,0.97106576,0.022007685],"study_design_scores_gemma":[0.000003946146,0.00001024959,0.00020521382,0.000063320316,0.0000019877277,0.00014621839,0.0020893137,0.000029653165,0.000039613056,0.0010130266,0.99638724,0.000010236509],"about_ca_topic_score_codex":0.0180077,"about_ca_topic_score_gemma":0.03936225,"teacher_disagreement_score":0.24485463,"about_ca_system_score_codex":0.0016070649,"about_ca_system_score_gemma":0.0015729511,"threshold_uncertainty_score":0.81912035},"labels":[],"label_agreement":null},{"id":"W2348645494","doi":"","title":"Drug Expenditure and Drug Price Regulation in Canada","year":2009,"lang":"en","type":"article","venue":"Zhongguo yaofang","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Per capita; Drug; Drug prices; Drug pricing; Public economics; Economics; Business; Medicine; Pharmacology; Actuarial science; Environmental health","score_opus":0.01998588614738545,"score_gpt":0.23459213732313516,"score_spread":0.21460625117574972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2348645494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80176675,0.038794715,0.0011028771,0.021417974,0.00014138727,0.000105896994,0.017061934,0.00014991206,0.11945864],"genre_scores_gemma":[0.98686403,0.006024328,0.00035530637,0.00052832207,0.000025922296,0.0000123789005,0.002109174,0.0000095676705,0.0040709614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975642,0.00018386125,0.00011323064,0.00015506963,0.0013209711,0.0006627801],"domain_scores_gemma":[0.99316347,0.0007536995,0.0015630292,0.00010290534,0.0040024845,0.00041450036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010011237,0.00018881528,0.00027103908,0.0041165296,0.0013927931,0.0018583277,0.0005904155,0.00037446865,0.0027637463],"category_scores_gemma":[0.006374981,0.00016211877,0.0004073832,0.011298611,0.0008621891,0.0004641414,0.0005449745,0.00066342036,0.00011743948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046885404,0.00012162916,0.6856057,0.0016891225,0.0004325737,0.0019795499,0.0034883746,0.011159776,0.0012889815,0.08770637,0.06679819,0.139261],"study_design_scores_gemma":[0.000018543042,0.000024218496,0.95411783,0.00023663741,0.00009420634,0.00014407517,0.0009845032,0.0028613063,0.00047456357,0.0007814446,0.04021214,0.000050504383],"about_ca_topic_score_codex":0.9911094,"about_ca_topic_score_gemma":0.9894785,"teacher_disagreement_score":0.92886,"about_ca_system_score_codex":0.07114,"about_ca_system_score_gemma":0.066198036,"threshold_uncertainty_score":0.51615924},"labels":[],"label_agreement":null},{"id":"W2349864794","doi":"","title":"Summary and Analysis of the 2nd Quarter 2010 Results of the Global Top Ten Pharmaceutical Companies","year":2010,"lang":"en","type":"article","venue":"Chinese Journal of Pharmaceuticals","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemistry; Quarter (Canadian coin); History","score_opus":0.03978681178303938,"score_gpt":0.3396183372690985,"score_spread":0.2998315254860591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2349864794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70660233,0.013981432,0.0015924742,0.0049236217,0.0003853929,0.00013839363,0.20478988,0.0006798824,0.066906646],"genre_scores_gemma":[0.83396226,0.004567877,0.0010643974,0.0009719234,0.00029415716,0.00009891812,0.12739907,0.00014450954,0.031496905],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982054,0.0002542398,0.00013322629,0.00019452033,0.00079217023,0.00042038434],"domain_scores_gemma":[0.99407613,0.0011347404,0.0012400172,0.00030865468,0.0028362009,0.00040413297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025376363,0.0007585338,0.0010933315,0.0051962975,0.00038031462,0.002048705,0.000417385,0.0006269556,0.0055922684],"category_scores_gemma":[0.0040724734,0.00025373875,0.0013382776,0.007847308,0.0002068072,0.0008886945,0.00083485123,0.00053978025,0.0028890357],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040650307,0.0006275747,0.49251938,0.0019324562,0.0015669774,0.0008132992,0.00047408615,0.026025483,0.0025130643,0.0030333772,0.33542424,0.13100494],"study_design_scores_gemma":[0.000066818175,0.00043054967,0.94475746,0.00011164494,0.0006018352,0.00023585068,0.0006756636,0.0039695753,0.002201873,0.0003468017,0.046551004,0.000050967337],"about_ca_topic_score_codex":0.049621936,"about_ca_topic_score_gemma":0.06303877,"teacher_disagreement_score":0.049621936,"about_ca_system_score_codex":0.0024617105,"about_ca_system_score_gemma":0.002121499,"threshold_uncertainty_score":0.09866619},"labels":[],"label_agreement":null},{"id":"W2356090071","doi":"","title":"Evaluation and Analysis of The Component Ratio of The Drug Income in Outpatient","year":2012,"lang":"en","type":"article","venue":"Zhongguo yiyuan yongyao pingjia yu fenxi","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Beijing; Drug; Quarter (Canadian coin); Medicine; Outpatient clinic; Pharmacology; Internal medicine; Geography","score_opus":0.064307456535151,"score_gpt":0.29497056160434987,"score_spread":0.23066310506919885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356090071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887784,0.0003505279,0.0076580117,0.00021631675,0.00002071736,0.00012652735,0.0006160346,0.000050698738,0.0021827891],"genre_scores_gemma":[0.9969777,0.000064777436,0.0020459108,0.000009019856,0.000013086057,0.00003974634,0.00053450436,0.0000062766994,0.00030896338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968418,0.0014732848,0.00018937704,0.00034760984,0.00087235315,0.0002756108],"domain_scores_gemma":[0.99317354,0.0029618333,0.0013704125,0.00032141918,0.0018224978,0.00035033326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003960063,0.0004738554,0.00048003517,0.0030216805,0.00024715558,0.0009315308,0.0005938881,0.00031227028,0.0015513838],"category_scores_gemma":[0.015292368,0.00012209831,0.0007903859,0.0024287978,0.0003880021,0.00094466505,0.0005621688,0.00038990093,0.0001659163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005027825,0.00021026806,0.94745797,0.00010803233,0.00025098491,0.00016577386,0.00017723374,0.0053834626,0.00056709227,0.0019658096,0.0010816649,0.042128958],"study_design_scores_gemma":[0.000020179757,0.00024890827,0.955411,0.000016259519,0.00013667134,0.000073565,0.00043116751,0.041759424,0.0006966244,0.00054348446,0.0006463779,0.000016319793],"about_ca_topic_score_codex":0.00981736,"about_ca_topic_score_gemma":0.0039678104,"teacher_disagreement_score":0.00981736,"about_ca_system_score_codex":0.0017596161,"about_ca_system_score_gemma":0.0016281898,"threshold_uncertainty_score":0.020943046},"labels":[],"label_agreement":null},{"id":"W2356112331","doi":"10.1002/hec.3348","title":"Inducing optimal substitution between antibiotics under open access to the resource of antibiotic susceptibility","year":2016,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université Laval","funders":"Fonds de Recherche du Québec-Société et Culture","keywords":"Antibiotics; Subsidy; Resource (disambiguation); Quality (philosophy); Economics; Environmental economics; Business; Biology; Computer science; Microbiology","score_opus":0.2565137280104969,"score_gpt":0.4085173708935644,"score_spread":0.1520036428830675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356112331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7190853,0.00075717043,0.24042809,0.004329095,0.000109791996,0.00032995635,0.00047711984,0.00019585628,0.034287594],"genre_scores_gemma":[0.98635894,0.00025430266,0.008554192,0.00012421103,0.000018836228,0.0000894475,0.000029696264,0.000009987306,0.004560357],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988973,0.0005154404,0.000039604078,0.00016342112,0.00011907807,0.00026507027],"domain_scores_gemma":[0.9971002,0.0016122839,0.00069655845,0.00016382211,0.0001035478,0.0003236614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014243475,0.00075568317,0.0012536502,0.0006095605,0.0004582041,0.001639649,0.0009904938,0.002458385,0.0046135318],"category_scores_gemma":[0.005667761,0.00064277434,0.0008944456,0.00040267134,0.0019393528,0.0019608813,0.0015494949,0.0014743817,0.00033941842],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008945054,0.0006313825,0.0034528677,0.00025984828,0.0001288285,0.0007893618,0.000170827,0.6292724,0.009271023,0.33762538,0.0015644187,0.015939314],"study_design_scores_gemma":[0.00053566374,0.00054326653,0.0022071225,0.000058756938,0.00011256544,0.00020052785,0.00018406524,0.77034104,0.0018149237,0.22028933,0.0036565273,0.000056161625],"about_ca_topic_score_codex":0.0032617906,"about_ca_topic_score_gemma":0.0022287131,"teacher_disagreement_score":0.0046135318,"about_ca_system_score_codex":0.0028744913,"about_ca_system_score_gemma":0.0022517026,"threshold_uncertainty_score":0.020856023},"labels":[],"label_agreement":null},{"id":"W2356701730","doi":"","title":"Investigation of Connotation and Way of Payment of Pharmaceutical Service Fee in Medical Institutions in China","year":2011,"lang":"en","type":"article","venue":"Zhongguo yaofang","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Payment; China; Fee-for-service; Service (business); Connotation; Medical prescription; Marketing; Medicine; Finance; Pharmacology; Health care; Economic growth; Economics; Law; Political science","score_opus":0.14742560366257068,"score_gpt":0.3188041699350903,"score_spread":0.17137856627251963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356701730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497614,0.0117866285,0.003057322,0.0048175044,0.00038216801,0.00016587526,0.0009540992,0.000048154187,0.029026851],"genre_scores_gemma":[0.99451184,0.0022083374,0.0015270469,0.00019521758,0.00009296941,0.00003567168,0.00027927326,0.000009457726,0.0011402322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904889,0.0034453196,0.001800691,0.0005780316,0.0030721168,0.00061506004],"domain_scores_gemma":[0.9751628,0.010102535,0.0067373323,0.00075659284,0.00640506,0.0008356474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006215184,0.0003225226,0.0005800478,0.014001244,0.0020584243,0.0035015661,0.0009937178,0.00062820927,0.0040453756],"category_scores_gemma":[0.03152894,0.00021051662,0.0006329287,0.019699123,0.002387877,0.004616252,0.0016874254,0.000637539,0.00021562906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038927112,0.00012241391,0.6686264,0.0033327555,0.00022752305,0.0026762618,0.028337445,0.0011130751,0.0013524082,0.08457377,0.01067311,0.19857553],"study_design_scores_gemma":[0.000045106535,0.00013696232,0.9210198,0.0014374439,0.00019420934,0.0012508873,0.025013799,0.0043788813,0.0010032698,0.009391466,0.035989225,0.00013898998],"about_ca_topic_score_codex":0.021097446,"about_ca_topic_score_gemma":0.02236974,"teacher_disagreement_score":0.021097446,"about_ca_system_score_codex":0.009802793,"about_ca_system_score_gemma":0.0061233616,"threshold_uncertainty_score":0.07112455},"labels":[],"label_agreement":null},{"id":"W2395091928","doi":"","title":"Promotion of drugs and devices at international conferences held in Canada.","year":2009,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Medicine; Business; Political science; Law","score_opus":0.05734305370875159,"score_gpt":0.23976745933885776,"score_spread":0.18242440563010617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395091928","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011333106,0.097408794,0.0013165094,0.21025717,0.088601254,0.0006600447,0.025562612,0.0007192639,0.56414133],"genre_scores_gemma":[0.06606179,0.060292218,0.0012723828,0.010999548,0.017196748,0.00010043921,0.00672094,0.00018355201,0.83717245],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.997809,0.00013667869,0.000059796374,0.00011155485,0.0012416587,0.00064129423],"domain_scores_gemma":[0.9860371,0.0008599378,0.00047013964,0.00016817852,0.00549185,0.0069727977],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023518575,0.0007280494,0.0006246051,0.0033227406,0.002166633,0.003975395,0.0010915841,0.0022960117,0.21050139],"category_scores_gemma":[0.0065971958,0.00022321942,0.00041876675,0.0027091869,0.00078351266,0.0016033959,0.0014532746,0.0022785086,0.022888092],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010247696,0.00003439528,0.0005542127,0.0003888057,0.000007902838,0.000077214,0.000059959264,0.00003271174,0.00034183334,0.0032131737,0.9558576,0.039329685],"study_design_scores_gemma":[0.000027798022,0.000033384615,0.006023575,0.0002090572,0.0000122339125,0.00006662226,0.00021498487,0.00008919364,0.00033440374,0.00043435654,0.99254507,0.000009194814],"about_ca_topic_score_codex":0.32413945,"about_ca_topic_score_gemma":0.5924187,"teacher_disagreement_score":0.9976481,"about_ca_system_score_codex":0.010972635,"about_ca_system_score_gemma":0.049613524,"threshold_uncertainty_score":0.7041973},"labels":[],"label_agreement":null},{"id":"W2395780527","doi":"10.5539/gjhs.v9n1p163","title":"Requirements and Incentives for Implementation of Pharmaceutical Strategic Purchasing in Iranian Health System: A Qualitative Study","year":2016,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Snowball sampling; Purchasing; Incentive; Reimbursement; Business; Payment; Qualitative research; Marketing; Pharmaceutical industry; Profit margin; Service provider; Health care; Service (business); Economics; Medicine; Finance","score_opus":0.2514656708275062,"score_gpt":0.5104479060088445,"score_spread":0.2589822351813383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395780527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901688,0.00016782807,0.0024943394,0.0019893874,0.00001955165,0.0002820951,0.00008019815,0.000009970284,0.0047877817],"genre_scores_gemma":[0.99682707,0.0001897289,0.0016013219,0.00035149176,0.000006141164,0.00017872061,0.000030419164,0.0000039181773,0.0008109909],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9901973,0.0065316935,0.00035903815,0.00036082257,0.0009784747,0.0015726197],"domain_scores_gemma":[0.9850971,0.01068276,0.0015416439,0.0003462066,0.0012508591,0.0010813943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012922802,0.00020346383,0.0003047533,0.0009621933,0.003794416,0.0019478174,0.00093586225,0.00096096797,0.0028464657],"category_scores_gemma":[0.016166594,0.00038913006,0.00024431993,0.0010482955,0.003629659,0.002250982,0.0019578675,0.0011516074,0.00015987855],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007614154,0.00020317757,0.01857637,0.0004558409,0.000008923517,0.0013612394,0.9495492,0.00022311903,0.0020305447,0.0079543935,0.0010990506,0.01846199],"study_design_scores_gemma":[0.000011285015,0.00011510308,0.007460743,0.00018427183,0.0000054513234,0.00035818634,0.98120433,0.0004411006,0.00068249577,0.0008564081,0.008661116,0.000019523615],"about_ca_topic_score_codex":0.0045364415,"about_ca_topic_score_gemma":0.006184702,"teacher_disagreement_score":0.012922802,"about_ca_system_score_codex":0.006296579,"about_ca_system_score_gemma":0.008449849,"threshold_uncertainty_score":0.06834316},"labels":[],"label_agreement":null},{"id":"W2395935292","doi":"10.1016/j.jval.2016.03.154","title":"A Comparison of Cardiovascular Drugs Approved by the Us Food and Drug Administration and Health Canada (1980-2014)","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Food and drug administration; Drug; Medicine; Administration (probate law); Drug administration; Pharmacology; Business; Political science; Law","score_opus":0.07895263609743292,"score_gpt":0.3073892872669409,"score_spread":0.228436651169508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395935292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8523255,0.04871291,0.0005305461,0.012737478,0.0003197746,0.00013776911,0.039651047,0.00005423939,0.045530774],"genre_scores_gemma":[0.97547024,0.0054662717,0.0002612351,0.00093478005,0.000103380175,0.000020029047,0.010734742,0.000015699194,0.0069937115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715304,0.00025824766,0.00013593973,0.00020778229,0.001420896,0.0008240967],"domain_scores_gemma":[0.99140644,0.0016985745,0.0016343835,0.00013486133,0.004027162,0.0010986364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022173359,0.00028083174,0.0007299947,0.0042120763,0.0009241646,0.0026287807,0.0010105598,0.00096178864,0.003851366],"category_scores_gemma":[0.010826106,0.00026365378,0.0013405967,0.0068518072,0.00070725736,0.0010875252,0.0012613499,0.0013626037,0.00026598418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004118602,0.000476858,0.774009,0.0013142192,0.002279759,0.0010473748,0.0008900236,0.0130767,0.0008636154,0.02509451,0.0711711,0.10565829],"study_design_scores_gemma":[0.00011648242,0.00011891743,0.97240025,0.00014923826,0.0005298611,0.00016629926,0.0008622574,0.0013923104,0.00036002212,0.000712382,0.023160001,0.000032067328],"about_ca_topic_score_codex":0.9452269,"about_ca_topic_score_gemma":0.972462,"teacher_disagreement_score":0.054773092,"about_ca_system_score_codex":0.033855427,"about_ca_system_score_gemma":0.030500175,"threshold_uncertainty_score":0.24563944},"labels":[],"label_agreement":null},{"id":"W2396616515","doi":"","title":"Combination Pharmacotherapy to Prevent Cardiovascular Disease: Present Status and Challenges","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Pill; Medicine; Tolerability; Polypill; Intensive care medicine; Combination therapy; Pharmacotherapy; Aspirin; Disease; Statin; Pharmacology; Internal medicine; Adverse effect","score_opus":0.0384150897321311,"score_gpt":0.2703013156562675,"score_spread":0.23188622592413644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396616515","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045252923,0.92341375,0.0009939605,0.07068235,0.001201468,0.000013371489,0.00003929792,0.00004067736,0.0031626872],"genre_scores_gemma":[0.009644828,0.95401716,0.0034958532,0.020904426,0.010482775,0.00009552242,0.000087645596,0.000036663416,0.0012350726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99420196,0.0024198177,0.0007558985,0.00067034713,0.0016996514,0.0002523277],"domain_scores_gemma":[0.9593075,0.027765157,0.001985576,0.0013359013,0.0075213173,0.0020844773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025920395,0.001148774,0.0032535922,0.0019894626,0.001296271,0.005910128,0.0030690401,0.0070347246,0.010626801],"category_scores_gemma":[0.017323075,0.00073362846,0.0015328774,0.002206431,0.006673557,0.01374386,0.003795779,0.011923535,0.0036431733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028287846,0.00024072028,0.0009834439,0.0063841683,0.00013800946,0.00016929522,0.0003432072,0.0005251238,0.00044564746,0.03656884,0.06323201,0.89068663],"study_design_scores_gemma":[0.00019279956,0.0008889763,0.0028467774,0.01748992,0.00020785461,0.0016730753,0.0012500128,0.0016411963,0.00037886633,0.075465426,0.89782417,0.00014105046],"about_ca_topic_score_codex":0.0016552646,"about_ca_topic_score_gemma":0.0036677818,"teacher_disagreement_score":0.025920395,"about_ca_system_score_codex":0.0027741548,"about_ca_system_score_gemma":0.0046835938,"threshold_uncertainty_score":0.13708174},"labels":[],"label_agreement":null},{"id":"W2396658021","doi":"10.1097/mlr.0000000000000577","title":"The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms","year":2016,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; Memorial University of Newfoundland; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Formulary; Competitor analysis; Business; Generic drug; Market share; Product (mathematics); Medical prescription; Poisson regression; Finance; Marketing; Medicine; Drug; Environmental health","score_opus":0.06535781078046521,"score_gpt":0.34338033349475494,"score_spread":0.27802252271428973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396658021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247074,0.00050288363,0.0003221805,0.00072773435,0.000015670059,0.00006238658,0.00051250844,0.000012021836,0.005373958],"genre_scores_gemma":[0.99856585,0.00015269773,0.00005848806,0.00016306601,0.000011552778,0.0000071069944,0.00032613156,0.0000031096254,0.000712091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99588203,0.00093567424,0.00021619617,0.00042630846,0.0010126858,0.001527096],"domain_scores_gemma":[0.97289026,0.007373093,0.01422643,0.00064606447,0.0023803825,0.0024837411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046883263,0.0002230762,0.00033754762,0.0006917541,0.00070099736,0.0015227209,0.0007407385,0.0007211414,0.0035859],"category_scores_gemma":[0.026123391,0.00018151863,0.00079826923,0.0006291344,0.0010002446,0.0009105808,0.0013489088,0.00094998436,0.00023934408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006040017,0.00015629959,0.98377085,0.000047804893,0.00006650288,0.00022153382,0.0005968376,0.000975603,0.00023749843,0.00060831616,0.0013137235,0.011401079],"study_design_scores_gemma":[0.000015307185,0.00013685171,0.9969183,0.000033677527,0.000021090622,0.000050155162,0.0006990465,0.00086024136,0.000114640665,0.000088645415,0.0010541882,0.000007831734],"about_ca_topic_score_codex":0.24024428,"about_ca_topic_score_gemma":0.26430944,"teacher_disagreement_score":0.24024428,"about_ca_system_score_codex":0.005619136,"about_ca_system_score_gemma":0.0038201422,"threshold_uncertainty_score":0.47769177},"labels":[],"label_agreement":null},{"id":"W2396728641","doi":"10.1213/ane.0000000000000798","title":"Survey of the National Drug Shortage Effect on Anesthesia and Patient Safety","year":2015,"lang":"en","type":"article","venue":"Anesthesia & Analgesia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital","funders":"","keywords":"Medicine; Economic shortage; Confidence interval; Neostigmine; Family medicine; Anesthesia; Internal medicine","score_opus":0.05259130024727278,"score_gpt":0.27238286665967737,"score_spread":0.2197915664124046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396728641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716777,0.00008158328,0.00005937484,0.0005070481,0.000005629638,0.000021079548,0.0006938628,0.0000036069562,0.0014601551],"genre_scores_gemma":[0.99896395,0.00008953782,0.000091980946,0.0002377609,0.000008419457,0.000028478176,0.00030586336,6.9790474e-7,0.00027326314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880624,0.0006267825,0.00011411837,0.00006592129,0.0002557419,0.0001311907],"domain_scores_gemma":[0.9922231,0.0026410331,0.0030708553,0.00018582404,0.0008597966,0.0010194196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018996187,0.00007874343,0.00010123501,0.00039517038,0.00026302732,0.00023181658,0.00015489344,0.00028915206,0.0027080227],"category_scores_gemma":[0.0069812313,0.000119917866,0.00017802008,0.00068076386,0.0002365119,0.00026562862,0.00038160587,0.00047287022,0.00033958108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010323412,0.00008839485,0.99217683,0.000036277066,0.000014173798,0.000033774402,0.00036370358,0.000056524,0.00015960692,0.000030185774,0.00136325,0.0055740364],"study_design_scores_gemma":[0.000008942193,0.00016359599,0.9979341,0.000012789447,0.0000038960184,0.00006407366,0.00053452444,0.00012862061,0.000054525262,0.000006992377,0.0010849223,0.000003065603],"about_ca_topic_score_codex":0.01891789,"about_ca_topic_score_gemma":0.022858331,"teacher_disagreement_score":0.01891789,"about_ca_system_score_codex":0.0010531492,"about_ca_system_score_gemma":0.000786379,"threshold_uncertainty_score":0.037615538},"labels":[],"label_agreement":null},{"id":"W2396932950","doi":"","title":"[Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali].","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Restructuring; Private sector; Government (linguistics); Public sector; Context (archaeology); Pharmaceutical industry; Business; Distribution (mathematics); Public policy; Public economics; Economics; Finance; Economic growth; Medicine","score_opus":0.04394840788607885,"score_gpt":0.27383884559906213,"score_spread":0.2298904377129833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396932950","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35576394,0.019820193,0.02624673,0.22086501,0.0016930153,0.0005268939,0.0016139037,0.00048008922,0.37299025],"genre_scores_gemma":[0.95643735,0.0029927567,0.0024254709,0.012229962,0.00044832888,0.00016959065,0.00011580751,0.000022611786,0.025158111],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99858826,0.0003431961,0.00005276466,0.00017951304,0.0002835985,0.000552723],"domain_scores_gemma":[0.99652857,0.0016059948,0.001025073,0.00017734706,0.000476739,0.00018631882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020284585,0.00030377778,0.0003094657,0.0014459002,0.0026685745,0.004075416,0.0021300276,0.005023397,0.0147794485],"category_scores_gemma":[0.006986813,0.0004442152,0.0008920205,0.0009522212,0.0047589764,0.002219488,0.0020369086,0.0017137937,0.00093719584],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001555471,0.000055228575,0.0061060796,0.00020944468,0.00007468991,0.0008469378,0.0008543977,0.0013227757,0.0013812543,0.9504416,0.028675903,0.009876258],"study_design_scores_gemma":[0.0004989573,0.00020203608,0.09850717,0.0005961623,0.00025618036,0.00160384,0.0018900105,0.02121313,0.0063800816,0.73456436,0.13404764,0.00024037361],"about_ca_topic_score_codex":0.025066972,"about_ca_topic_score_gemma":0.015550055,"teacher_disagreement_score":0.025066972,"about_ca_system_score_codex":0.0062119067,"about_ca_system_score_gemma":0.003984158,"threshold_uncertainty_score":0.04984212},"labels":[],"label_agreement":null},{"id":"W2397649954","doi":"10.1016/j.jval.2016.03.655","title":"Evaluating The Cost Effectiveness of Personalised Medicine Co-Dependent Technologies: A Conceptual Framework","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Test (biology); Point (geometry); Personalized medicine; Medicine; Health care; Marginal cost; Actuarial science; Computer science; Mathematics; Economics","score_opus":0.2810152615169229,"score_gpt":0.43742987770943853,"score_spread":0.15641461619251562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397649954","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19478619,0.0327535,0.6177134,0.04839201,0.0006955344,0.0012609615,0.0013550305,0.00014777288,0.10289555],"genre_scores_gemma":[0.9547236,0.0069861216,0.03290019,0.00065783,0.00043920585,0.0005158337,0.0001824536,0.000030273484,0.003564553],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9811844,0.0140334405,0.00061891513,0.0010749458,0.0020091748,0.0010791797],"domain_scores_gemma":[0.9451022,0.049534958,0.0024675136,0.0009466238,0.0011629139,0.0007857796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019163791,0.0023612787,0.0032931045,0.0049281004,0.00088580145,0.011378771,0.0049174726,0.010000683,0.0073027327],"category_scores_gemma":[0.045344982,0.0013455118,0.0027947263,0.0040965057,0.007994432,0.010751897,0.0039828885,0.005321334,0.00029801243],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001814559,0.00027543103,0.0012283032,0.00040913094,0.00032678636,0.00013429024,0.000118356096,0.24197732,0.0002746115,0.7394334,0.00078959693,0.014851379],"study_design_scores_gemma":[0.0002226853,0.0008248189,0.0018947051,0.00077342085,0.00052627083,0.00023737957,0.00047265034,0.24817413,0.00065937644,0.7404974,0.005614265,0.00010283767],"about_ca_topic_score_codex":0.0038183413,"about_ca_topic_score_gemma":0.0023476477,"teacher_disagreement_score":0.019163791,"about_ca_system_score_codex":0.010467816,"about_ca_system_score_gemma":0.0059798453,"threshold_uncertainty_score":0.101348996},"labels":[],"label_agreement":null},{"id":"W2398268096","doi":"","title":"Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Drug pricing; Market access; Business; Economics; Actuarial science; Geography; Economic growth; Health care","score_opus":0.12864864562859257,"score_gpt":0.3261058709861791,"score_spread":0.19745722535758653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398268096","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054877503,0.20298491,0.006077683,0.13746215,0.028998619,0.00022245407,0.027959026,0.0012783571,0.58952904],"genre_scores_gemma":[0.022873037,0.060196258,0.0023226412,0.0035443518,0.0059854165,0.0001850312,0.011998194,0.00039329028,0.89250183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902344,0.00011602374,0.000061194645,0.00009738922,0.0005281248,0.00017371477],"domain_scores_gemma":[0.998386,0.00044471942,0.00021231992,0.0000734957,0.00056745566,0.0003159834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021431257,0.0014113756,0.0007919921,0.0013593606,0.00088139577,0.0049304185,0.0010078609,0.0042775525,0.14852038],"category_scores_gemma":[0.0040768697,0.000564129,0.0003324521,0.0027042688,0.0006117451,0.0048561706,0.0012697097,0.0027269751,0.05162408],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049991086,0.000012764251,0.00012506694,0.00007622453,0.0000030709612,0.00004160853,0.000023164466,0.00015315284,0.000081357626,0.0018310873,0.9644622,0.03314031],"study_design_scores_gemma":[0.00001800313,0.00002409209,0.0031723245,0.00031204778,0.0000072603384,0.000072259354,0.00009182748,0.0003566026,0.00021779354,0.0012972303,0.99441385,0.00001669807],"about_ca_topic_score_codex":0.01793856,"about_ca_topic_score_gemma":0.047832366,"teacher_disagreement_score":0.14852038,"about_ca_system_score_codex":0.0038786007,"about_ca_system_score_gemma":0.002964097,"threshold_uncertainty_score":0.4968502},"labels":[],"label_agreement":null},{"id":"W2398445710","doi":"","title":"We may lose dementia drugs that work.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alzheimer Society of Canada","funders":"","keywords":"Dementia; Work (physics); Psychology; Medicine; Engineering; Internal medicine; Disease","score_opus":0.08378079117423873,"score_gpt":0.2527808837611113,"score_spread":0.16900009258687257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398445710","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003108592,0.045998424,0.0021448026,0.8560023,0.025370054,0.00005925752,0.0011595313,0.0004304374,0.06572663],"genre_scores_gemma":[0.06313475,0.053450424,0.0039905207,0.71419275,0.03541337,0.00017488269,0.0011785207,0.00036993463,0.12809494],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99441093,0.0021148254,0.00046356616,0.00040503006,0.0016697162,0.0009358624],"domain_scores_gemma":[0.97463894,0.009636781,0.0026371835,0.0024730142,0.0054975897,0.005116489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009139302,0.0010517441,0.001915054,0.0026348198,0.0030647276,0.008082583,0.0017495272,0.011826382,0.07907726],"category_scores_gemma":[0.07081799,0.0004518065,0.00172831,0.0018858128,0.0045072245,0.011914792,0.0042227223,0.008095403,0.031204576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057010696,0.00028349314,0.0023534796,0.0005453876,0.00015841688,0.00030965684,0.00016768885,0.00023897254,0.00026387727,0.05431333,0.77020407,0.1705915],"study_design_scores_gemma":[0.00021289718,0.00018417442,0.001877903,0.001243573,0.000100784804,0.00063807244,0.0003573968,0.00022811475,0.00031803103,0.054914646,0.9398767,0.00004766743],"about_ca_topic_score_codex":0.0071502733,"about_ca_topic_score_gemma":0.007357173,"teacher_disagreement_score":0.07907726,"about_ca_system_score_codex":0.0031260548,"about_ca_system_score_gemma":0.008146684,"threshold_uncertainty_score":0.26453978},"labels":[],"label_agreement":null},{"id":"W2399061482","doi":"","title":"British Columbia poised to reduce drug coverage.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Medical prescription; Columbia university; Public administration; Political science; Prescription drug; Plan (archaeology); Medicine; History; Sociology; Media studies; Pharmacology","score_opus":0.05428801188230593,"score_gpt":0.22727636791817726,"score_spread":0.17298835603587134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399061482","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013478305,0.019725762,0.0008925288,0.3218448,0.012883247,0.00044703681,0.018290361,0.00075494364,0.61168295],"genre_scores_gemma":[0.038993668,0.0038210403,0.0016130303,0.0896319,0.000487927,0.00020024848,0.0036464722,0.000087108536,0.86151856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889225,0.00007992012,0.000034159497,0.000075437005,0.0005945978,0.000323637],"domain_scores_gemma":[0.99803334,0.00014009842,0.000067043315,0.000056043562,0.0009640267,0.00073937763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007485318,0.0005382741,0.00031701816,0.0011646077,0.002410715,0.002646236,0.00069526955,0.004486578,0.037414294],"category_scores_gemma":[0.0034588317,0.00024280792,0.00047933197,0.0010248652,0.00056247367,0.0005705712,0.0009506901,0.0035425236,0.0065539367],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058862086,0.000033064167,0.0013327523,0.000092719165,0.000012260116,0.00012502719,0.000057241123,0.00011282593,0.0002629112,0.008818995,0.9540776,0.03501583],"study_design_scores_gemma":[0.00005386249,0.000030422734,0.009877966,0.00010516097,0.000017172491,0.000073840834,0.00010341663,0.00018139438,0.00022727315,0.0007099215,0.98860675,0.000012892415],"about_ca_topic_score_codex":0.88631797,"about_ca_topic_score_gemma":0.9241782,"teacher_disagreement_score":0.9856241,"about_ca_system_score_codex":0.014375942,"about_ca_system_score_gemma":0.04719927,"threshold_uncertainty_score":0.22870302},"labels":[],"label_agreement":null},{"id":"W2399173259","doi":"10.1016/j.jval.2016.03.1274","title":"ANALYSIS OF TRENDS IN UTILIZATION AND COST OF INSULIN IN THE UNITED STATES AND CANADA","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Insulin; Unit (ring theory); Quarter (Canadian coin); Business; Medicine; Agricultural economics; Agricultural science; Geography; Economics; Internal medicine; Environmental science","score_opus":0.1408378403607111,"score_gpt":0.3340619785729026,"score_spread":0.1932241382121915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399173259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776139,0.0020198831,0.00017720879,0.0015055465,0.000019014728,0.000021013448,0.015776118,0.000028487022,0.0028387927],"genre_scores_gemma":[0.9891334,0.0013266667,0.00018077483,0.0001753823,0.000011087591,0.000007155888,0.007474064,0.000009872008,0.0016816129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989699,0.00006628591,0.00007863979,0.00011120287,0.00042351434,0.00035049833],"domain_scores_gemma":[0.9947672,0.0005874005,0.00079878775,0.000093577946,0.0030330408,0.00072000886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076189666,0.00023786513,0.00048893533,0.002785826,0.0011203346,0.0019815294,0.0014184031,0.0006781381,0.0015944282],"category_scores_gemma":[0.0051326524,0.00031028138,0.0009866478,0.010102921,0.0006100787,0.0005756513,0.0005863612,0.0010974057,0.00015769333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031933637,0.00006467844,0.98049027,0.000058606616,0.00022829059,0.00012508397,0.0002882648,0.004129693,0.00014495099,0.0011856545,0.004625142,0.008340034],"study_design_scores_gemma":[0.000010527533,0.000020708929,0.99261636,0.000020747932,0.00006191808,0.000057320976,0.0007923255,0.0043148273,0.00012849744,0.00008559187,0.0018772944,0.000013882278],"about_ca_topic_score_codex":0.9955456,"about_ca_topic_score_gemma":0.9962047,"teacher_disagreement_score":0.041084304,"about_ca_system_score_codex":0.041084304,"about_ca_system_score_gemma":0.034343008,"threshold_uncertainty_score":0.2980889},"labels":[],"label_agreement":null},{"id":"W2399640665","doi":"10.1016/j.jval.2016.03.754","title":"Prescription Factors Associated With A Do Not Substitute Prescription In Canada","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medical prescription; Medicine; Specialty; Generic drug; Family medicine; Pharmacist; Brand names; Pharmacy; Drug; Pharmacology; Business; Advertising","score_opus":0.126930399827186,"score_gpt":0.2746551098800359,"score_spread":0.14772471005284987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399640665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9364207,0.007058136,0.0002979215,0.02258265,0.00024927955,0.00009557005,0.019040229,0.000052292162,0.014203237],"genre_scores_gemma":[0.9916815,0.0016050291,0.00014003365,0.0009105762,0.000056514105,0.000010043431,0.0020281645,0.000015864463,0.003552157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968894,0.0002339119,0.0002499465,0.0003235452,0.0010246614,0.0012786567],"domain_scores_gemma":[0.976641,0.0030706525,0.0065805926,0.000556057,0.0064502233,0.0067014806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013681373,0.00027560815,0.00078292825,0.001776121,0.0029314402,0.0033754364,0.0016354121,0.001659233,0.0067535504],"category_scores_gemma":[0.013418663,0.00045852503,0.0014835374,0.005703343,0.0012705663,0.00075091625,0.0011905177,0.0038524088,0.00023209589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045684396,0.0001390285,0.96849334,0.00011242777,0.0003359059,0.00032478024,0.0005361049,0.0011509754,0.0001278939,0.005334895,0.013595162,0.009392689],"study_design_scores_gemma":[0.00006741462,0.00005013184,0.9848194,0.00015949774,0.00018844809,0.00020485735,0.0016886217,0.0019655693,0.0001418026,0.0007868784,0.009880437,0.00004690446],"about_ca_topic_score_codex":0.9968754,"about_ca_topic_score_gemma":0.9976793,"teacher_disagreement_score":0.057425503,"about_ca_system_score_codex":0.057425503,"about_ca_system_score_gemma":0.10869298,"threshold_uncertainty_score":0.4166531},"labels":[],"label_agreement":null},{"id":"W2401695302","doi":"10.1016/j.jval.2016.03.1507","title":"Oncology Drugs Lag Between Europe and other Countries: Comparaison between EMA and others Agencies (FDA, Health Canada, TGA, and Swissmedic)","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Food and drug administration; Drug approval; Agency (philosophy); Regulatory affairs; Drug; Regulatory agency; Family medicine; Internal medicine; Oncology; Pharmacology; Operations management; Political science","score_opus":0.1278358697310247,"score_gpt":0.3378959370583687,"score_spread":0.21006006732734397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401695302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79240984,0.09323433,0.002188002,0.03476204,0.00077994633,0.00005630704,0.011085057,0.0001001098,0.06538439],"genre_scores_gemma":[0.98587567,0.0067902743,0.0003168448,0.0028173574,0.00015138087,0.000009108449,0.002489614,0.000030622396,0.0015190851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973802,0.00066241145,0.0002590557,0.00031569423,0.00053434673,0.00084828044],"domain_scores_gemma":[0.9806716,0.0061419522,0.007842016,0.0007225151,0.0030412541,0.0015806764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046459697,0.00024232431,0.0006073548,0.0034953856,0.00059916714,0.007905103,0.00041553893,0.0012973777,0.0060472297],"category_scores_gemma":[0.014194214,0.00023896717,0.0009864127,0.008954104,0.0011532486,0.0034998963,0.0020233875,0.0015825944,0.00064324803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025558402,0.00030150116,0.8184276,0.00055654923,0.0010230988,0.00057523383,0.0014116158,0.0031697582,0.0003157349,0.066422045,0.027991556,0.07724948],"study_design_scores_gemma":[0.00013992636,0.00022022118,0.91953796,0.00071282417,0.00040281235,0.00033949246,0.004359113,0.0007769533,0.00063094305,0.0056112795,0.0672319,0.000036547743],"about_ca_topic_score_codex":0.030948225,"about_ca_topic_score_gemma":0.0301321,"teacher_disagreement_score":0.9690518,"about_ca_system_score_codex":0.0031226852,"about_ca_system_score_gemma":0.0034805043,"threshold_uncertainty_score":0.061536193},"labels":[],"label_agreement":null},{"id":"W2402029394","doi":"10.12927/hcpol.2016.24626","title":"Some Numbers behind Canada’s Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997–2012","year":2016,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"Dalhousie University; Canada Research Chairs; Genome Canada","keywords":"Orphan drug; Medicine; Access to medicines; Drug; Drug approval; Family medicine; Pharmacology; Bioinformatics; Public health; Biology","score_opus":0.03465915678921029,"score_gpt":0.2997397643554006,"score_spread":0.26508060756619034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402029394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90597117,0.008897156,0.0005355993,0.030446004,0.00012074148,0.00009318512,0.017609201,0.000039685372,0.03628732],"genre_scores_gemma":[0.98960894,0.002407664,0.00029170944,0.0015568322,0.000043619737,0.000015128627,0.0023097189,0.000014128408,0.0037523198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954124,0.00023952367,0.00024232882,0.00035836123,0.0018489469,0.0018983576],"domain_scores_gemma":[0.9836997,0.0021855936,0.00441673,0.0002680184,0.006545494,0.0028846187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027438041,0.00018915458,0.000486515,0.0026015467,0.0026398543,0.0046004485,0.0010468843,0.0012362347,0.0041698464],"category_scores_gemma":[0.01170461,0.0003476645,0.0007522775,0.006274503,0.001885043,0.0011900896,0.0010543765,0.0021872877,0.0001708951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014224994,0.00014200406,0.8737254,0.0005029678,0.0005383499,0.0007943248,0.005541694,0.005005663,0.001282394,0.02461602,0.031699833,0.054728854],"study_design_scores_gemma":[0.00004666619,0.00005236693,0.95902336,0.00018530506,0.00011532635,0.00009532503,0.004285793,0.0012121148,0.00057207514,0.000510583,0.033825476,0.000075494005],"about_ca_topic_score_codex":0.99654645,"about_ca_topic_score_gemma":0.9976629,"teacher_disagreement_score":0.90096056,"about_ca_system_score_codex":0.09903943,"about_ca_system_score_gemma":0.10435314,"threshold_uncertainty_score":0.7185847},"labels":[],"label_agreement":null},{"id":"W2402061885","doi":"10.1503/cmaj.109-5281","title":"Consensus mounts for national drug formulary","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Parliament; Multitude; Medicine; Public administration; Political science; Family medicine; Law; Politics","score_opus":0.0324228663964499,"score_gpt":0.27053441441059506,"score_spread":0.23811154801414516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402061885","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010230417,0.0040686917,0.0018861297,0.97079706,0.010688088,0.000038253052,0.00008224821,0.000066232526,0.011350302],"genre_scores_gemma":[0.035697706,0.0044875774,0.0134115815,0.9245811,0.0064385505,0.00024045102,0.00042941276,0.00012619192,0.014587438],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9171012,0.020308759,0.0072785565,0.01030056,0.034806192,0.01020473],"domain_scores_gemma":[0.8830226,0.038143616,0.005219376,0.007116814,0.043213382,0.023284221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1146351,0.0009998397,0.002047131,0.002691261,0.012476585,0.019012246,0.008012558,0.043028846,0.021852914],"category_scores_gemma":[0.13911298,0.0012928126,0.003858337,0.0019503847,0.013793244,0.021308642,0.016778376,0.059029687,0.0037078501],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005655972,0.00016404381,0.00057809986,0.0004208352,0.000054860353,0.00020426839,0.001222669,0.0003331556,0.0004015685,0.24647889,0.71089166,0.039193314],"study_design_scores_gemma":[0.00009562685,0.000065885215,0.0014907856,0.0015234136,0.00004217619,0.00010617522,0.002334432,0.0004739544,0.00030108108,0.08384273,0.90962815,0.00009562384],"about_ca_topic_score_codex":0.035323136,"about_ca_topic_score_gemma":0.059163466,"teacher_disagreement_score":0.97315264,"about_ca_system_score_codex":0.026847335,"about_ca_system_score_gemma":0.100241356,"threshold_uncertainty_score":0.60625565},"labels":[],"label_agreement":null},{"id":"W2402672329","doi":"","title":"Prescription drug prices in Canada.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Prescription drug; Business; Drug prices; Medicine; Pharmacology; Economics; Public economics","score_opus":0.04747730526664789,"score_gpt":0.2104754989316394,"score_spread":0.1629981936649915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402672329","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22599208,0.08114701,0.0011049479,0.14331317,0.0030476104,0.0002455314,0.36651567,0.00036003534,0.17827396],"genre_scores_gemma":[0.8327438,0.04588173,0.0011871057,0.0066661467,0.0007263752,0.000073252166,0.032034084,0.000079814876,0.08060765],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9985537,0.00007005696,0.0000927865,0.00007931668,0.00086725515,0.00033691298],"domain_scores_gemma":[0.9938123,0.0006587344,0.00053751643,0.000057140845,0.0040137162,0.0009205791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057664997,0.00021778331,0.00037686844,0.0024581568,0.0016805937,0.0026165945,0.00079258217,0.0009489273,0.012070792],"category_scores_gemma":[0.00792298,0.00023948312,0.0004241079,0.007655888,0.00047153674,0.0006457859,0.0003978357,0.0013170269,0.00081659335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007442327,0.00011211912,0.121644184,0.0012882166,0.0002313997,0.00049242075,0.0004013035,0.0033692436,0.00029181753,0.035393927,0.7384732,0.097557984],"study_design_scores_gemma":[0.0002557621,0.00009126405,0.60836095,0.0006623496,0.0002905336,0.00036144216,0.0011626515,0.005832967,0.0008917576,0.0026979647,0.37929624,0.000096108386],"about_ca_topic_score_codex":0.99685585,"about_ca_topic_score_gemma":0.9975655,"teacher_disagreement_score":0.07332504,"about_ca_system_score_codex":0.07332504,"about_ca_system_score_gemma":0.12635021,"threshold_uncertainty_score":0.5320129},"labels":[],"label_agreement":null},{"id":"W2403383281","doi":"10.1016/s0197-2510(11)70300-x","title":"10.1016/s0197-2510(11)70300-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Philosophy; Linguistics; Government (linguistics)","score_opus":0.02642989772515737,"score_gpt":0.2121917994619067,"score_spread":0.18576190173674934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403383281","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003666338,0.0004832945,0.00073919026,0.0005611072,0.00028602907,0.00008166051,0.0012201444,0.0009513294,0.9953105],"genre_scores_gemma":[0.0006888543,0.0002251566,0.00035242524,0.00021106347,0.0000631976,0.000049804068,0.0004740069,0.00015729711,0.99777824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993569,0.00005338856,0.000057557758,0.00020497316,0.00019111614,0.00013606658],"domain_scores_gemma":[0.9979528,0.0006161141,0.00019706938,0.00027203228,0.0003108004,0.0006510343],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010995043,0.0024850776,0.0018024482,0.002843614,0.0017655828,0.004058559,0.0030283171,0.0065837284,0.9884588],"category_scores_gemma":[0.002296089,0.0010269221,0.0011993907,0.0030039274,0.0017440186,0.0059672114,0.0030360667,0.0028315575,0.9920266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002852996,0.00019542155,0.0008716142,0.0005630646,0.00003106279,0.00018815244,0.000086109445,0.00052314985,0.0013252028,0.008383435,0.39230126,0.5952462],"study_design_scores_gemma":[0.000050246395,0.00007620125,0.0006726677,0.00031687543,0.000012523084,0.00022166599,0.00009299876,0.00028449262,0.00033264078,0.0010576762,0.99686,0.00002189497],"about_ca_topic_score_codex":0.0047339196,"about_ca_topic_score_gemma":0.0033079407,"teacher_disagreement_score":0.011541188,"about_ca_system_score_codex":0.0013023088,"about_ca_system_score_gemma":0.001405642,"threshold_uncertainty_score":0.016462088},"labels":[],"label_agreement":null},{"id":"W2404563259","doi":"10.1016/j.jval.2016.03.1271","title":"A COMPARISON OF ANTI-TYPE 2 DIABETES MELLITUS DRUGS IN CANADA, UNITED STATES, AND UNITED KINGDOM BETWEEN 1958–2015","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Regulatory agency; Type 2 Diabetes Mellitus; Food and drug administration; Drug; Pharmacology; Diabetes mellitus; Family medicine","score_opus":0.12513342820040843,"score_gpt":0.3400936963470292,"score_spread":0.21496026814662075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404563259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537458,0.013880657,0.00019268946,0.00415713,0.0001504582,0.000036017587,0.020921428,0.000019356901,0.0068965703],"genre_scores_gemma":[0.9868507,0.0026809573,0.00010630622,0.00042623587,0.00003482834,0.000007668017,0.007702869,0.0000053652207,0.002185042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875104,0.0000762571,0.00013620588,0.00013652867,0.00041238038,0.00048753558],"domain_scores_gemma":[0.9959079,0.00039071057,0.0012320422,0.000063201674,0.0017702889,0.00063580513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086458353,0.00021072246,0.00047913415,0.002071349,0.0009193592,0.0021028186,0.0008231982,0.00094020355,0.0019412033],"category_scores_gemma":[0.004726213,0.000284214,0.00087456306,0.0058176424,0.00065529806,0.00092809525,0.0011969028,0.0012720496,0.0001174163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009953907,0.00011338966,0.9596524,0.00034246693,0.00056983344,0.00044705608,0.0010838704,0.0021604886,0.00019908688,0.0039325426,0.012237759,0.018265702],"study_design_scores_gemma":[0.000014328515,0.000025783851,0.98918086,0.00009321126,0.00008681659,0.000091935384,0.00088291045,0.00042889055,0.00011046595,0.00009664137,0.008972416,0.000015772208],"about_ca_topic_score_codex":0.9655525,"about_ca_topic_score_gemma":0.9806855,"teacher_disagreement_score":0.03444749,"about_ca_system_score_codex":0.024827005,"about_ca_system_score_gemma":0.016543321,"threshold_uncertainty_score":0.18013334},"labels":[],"label_agreement":null},{"id":"W2406062760","doi":"","title":"Why are drug prices lower in Canada?","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug prices; Drug; Managed care; Intensive care medicine; Family medicine; Pharmacology; Health care; Public economics; Economic growth","score_opus":0.0354474246477301,"score_gpt":0.2065476486445004,"score_spread":0.1711002239967703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406062760","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12309335,0.060849283,0.00061806996,0.6767685,0.003336768,0.00008868557,0.019756142,0.00021825172,0.115271],"genre_scores_gemma":[0.79904455,0.036373608,0.0015961834,0.12496119,0.0023833695,0.00006145856,0.005755079,0.00017777045,0.029646838],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9945639,0.00034055117,0.00028606647,0.0004226688,0.0023665533,0.0020202184],"domain_scores_gemma":[0.96801704,0.0035589046,0.0036704582,0.00041021203,0.018318828,0.0060245963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002478328,0.0002945991,0.00078399736,0.0026927127,0.0035769,0.006513795,0.0018631713,0.0029516222,0.019721197],"category_scores_gemma":[0.023849733,0.00032816196,0.0009794212,0.008205141,0.0025829636,0.0019564964,0.00079276116,0.004283959,0.0010858875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015369686,0.00020610951,0.18440673,0.002089926,0.0006274277,0.0007831441,0.0011059616,0.0015790063,0.001026411,0.06689385,0.55158883,0.18815559],"study_design_scores_gemma":[0.0005998922,0.00017520456,0.5342669,0.0016348634,0.00073710777,0.00057639106,0.0035117136,0.0014421648,0.0017625836,0.0132476,0.44183487,0.00021077236],"about_ca_topic_score_codex":0.9929905,"about_ca_topic_score_gemma":0.99512947,"teacher_disagreement_score":0.08963133,"about_ca_system_score_codex":0.08963133,"about_ca_system_score_gemma":0.14786284,"threshold_uncertainty_score":0.65032387},"labels":[],"label_agreement":null},{"id":"W2406399824","doi":"10.1016/j.jval.2016.03.219","title":"Impact Of New Entrants To The Market For Multiple-Sclerosis Disease-Modifying Drugs In Canada","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fingolimod; Medical prescription; Glatiramer acetate; Medicine; Teriflunomide; Dimethyl fumarate; Multiple sclerosis; Pediatrics; Family medicine; Pharmacology; Psychiatry","score_opus":0.16186943729508668,"score_gpt":0.32432642627937486,"score_spread":0.16245698898428818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406399824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9387122,0.0032293994,0.00015042778,0.029025901,0.00026209513,0.00009186876,0.0036514895,0.000032707056,0.024843948],"genre_scores_gemma":[0.98545223,0.0013381547,0.000065278924,0.0016251124,0.00010526169,0.000010598659,0.000777871,0.000011115799,0.010614441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971577,0.0002003424,0.00009304782,0.00014919224,0.00078595144,0.001613723],"domain_scores_gemma":[0.9825829,0.0018036503,0.002340722,0.00013668246,0.0044317353,0.00870435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014220184,0.00023375417,0.00064688484,0.0016063964,0.0028151711,0.0059158173,0.0012961728,0.0022940342,0.009058389],"category_scores_gemma":[0.009006246,0.00034979192,0.0010226737,0.0018463974,0.0015563872,0.0010343997,0.0017886355,0.0031665282,0.00029796385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002882033,0.0010334805,0.8540657,0.00030887677,0.00036710332,0.0030684583,0.0018798225,0.008583804,0.0011972268,0.038688287,0.051637832,0.0362873],"study_design_scores_gemma":[0.00038582552,0.0001977464,0.9450249,0.00017663436,0.00018029672,0.00043286092,0.005198722,0.007912655,0.00074073445,0.0013770178,0.038264744,0.00010791224],"about_ca_topic_score_codex":0.9873032,"about_ca_topic_score_gemma":0.9926165,"teacher_disagreement_score":0.07898171,"about_ca_system_score_codex":0.07898171,"about_ca_system_score_gemma":0.083781175,"threshold_uncertainty_score":0.57305515},"labels":[],"label_agreement":null},{"id":"W2407503563","doi":"","title":"Health Canada authorizes access to experimental HIV drugs, but only after a long struggle.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Business; Political science; Medicine; Virology","score_opus":0.04126160815445923,"score_gpt":0.2708850276264387,"score_spread":0.22962341947197945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407503563","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07952235,0.017174033,0.0051435856,0.15256573,0.006235686,0.001565253,0.026818516,0.0016369908,0.70933783],"genre_scores_gemma":[0.38861725,0.009223561,0.0060533565,0.034359787,0.001449234,0.00034947126,0.006533262,0.00026674956,0.55314726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956358,0.00043555893,0.00012914251,0.00019993137,0.0020593358,0.0015401841],"domain_scores_gemma":[0.98195374,0.0033953893,0.0008859185,0.0012190817,0.007285852,0.005260116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026726667,0.00043919016,0.0004761869,0.0013605782,0.0045539388,0.0026072904,0.0014229253,0.0030913432,0.04764484],"category_scores_gemma":[0.011971747,0.00039885571,0.00068606157,0.0021896116,0.0016062213,0.00096736755,0.0013578882,0.0023001782,0.0036572323],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089773536,0.0004563304,0.047191564,0.00060901116,0.00015820799,0.00097409874,0.00040077497,0.0007422679,0.0027542051,0.07234506,0.72216535,0.15130544],"study_design_scores_gemma":[0.00024501435,0.00017756068,0.021780476,0.00013235987,0.000070033355,0.00040890262,0.00025693377,0.0008565574,0.0019264834,0.0016806284,0.9724061,0.00005891902],"about_ca_topic_score_codex":0.91618466,"about_ca_topic_score_gemma":0.9623014,"teacher_disagreement_score":0.9754947,"about_ca_system_score_codex":0.02450531,"about_ca_system_score_gemma":0.12562823,"threshold_uncertainty_score":0.17779928},"labels":[],"label_agreement":null},{"id":"W2409644905","doi":"","title":"XVI International AIDS Conference. New drug classes from Toronto. Plus some older ones.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Human immunodeficiency virus (HIV); Media studies; Library science; Medicine; Gerontology; Sociology; Family medicine; Pharmacology; Computer science","score_opus":0.07160809336894638,"score_gpt":0.273456847412095,"score_spread":0.20184875404314864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409644905","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001145245,0.545003,0.0006798945,0.0979305,0.07508949,0.00016084871,0.025765993,0.0006237736,0.25360125],"genre_scores_gemma":[0.005394068,0.17501433,0.0008350051,0.011281076,0.019662343,0.00009508415,0.010592271,0.00019483041,0.7769311],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995952,0.000033430646,0.000031805303,0.00003852724,0.00023715773,0.00006385711],"domain_scores_gemma":[0.9983719,0.00017272936,0.00016306763,0.000057162415,0.00070890214,0.00052627304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005831715,0.0015184336,0.0008115291,0.0029879967,0.0009220695,0.0023419766,0.001063331,0.0020650711,0.19611889],"category_scores_gemma":[0.0015883769,0.00048357772,0.000541107,0.0040799766,0.0006100583,0.0012622296,0.0006999839,0.002989568,0.07290665],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024216964,0.0000058588735,0.00007223158,0.00018988302,0.0000035680803,0.000031531607,0.000007855847,0.000035244346,0.000052179104,0.00017496197,0.97553635,0.02386604],"study_design_scores_gemma":[0.000010037514,0.00001137395,0.0019645714,0.00023761875,0.000007969139,0.000052685984,0.00002557914,0.000024224357,0.000038420043,0.00016064954,0.9974617,0.0000051055827],"about_ca_topic_score_codex":0.17096111,"about_ca_topic_score_gemma":0.54545414,"teacher_disagreement_score":0.19611889,"about_ca_system_score_codex":0.0044083362,"about_ca_system_score_gemma":0.005630009,"threshold_uncertainty_score":0.65608305},"labels":[],"label_agreement":null},{"id":"W2409840291","doi":"","title":"Delivery past due: global precedent set under Canada's Access to Medicines Regime.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Parliament; Access to medicines; Developing country; Key (lock); Public health; Political science; Public administration; Business; International trade; Law and economics; Economics; Law; Economic growth; Medicine; Computer science; Computer security; Politics","score_opus":0.1105232199363151,"score_gpt":0.278808130186546,"score_spread":0.1682849102502309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409840291","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017006746,0.019843142,0.003113803,0.36064237,0.0066261417,0.00031250477,0.010704218,0.00041235256,0.58133876],"genre_scores_gemma":[0.30648136,0.010670639,0.005682186,0.21015123,0.0021929315,0.00027849234,0.0036549796,0.0002428488,0.46064535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98924375,0.0006583272,0.00035408928,0.0007196591,0.0057774256,0.0032466517],"domain_scores_gemma":[0.98641634,0.0023044497,0.000798919,0.00062594557,0.0063214405,0.0035329957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051260996,0.00037842736,0.00045494759,0.0013256422,0.007043083,0.00740871,0.0017733949,0.0068926173,0.024049534],"category_scores_gemma":[0.01910217,0.00047938817,0.00080397906,0.0016470529,0.0027962667,0.0026797312,0.002438697,0.007543524,0.0023984164],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110572146,0.00006430896,0.0063999314,0.00028033333,0.000031232954,0.0004903155,0.0016766557,0.00035800223,0.0008559119,0.41194686,0.5224345,0.055351324],"study_design_scores_gemma":[0.000030250167,0.000032647553,0.013414454,0.00022531066,0.000019403064,0.0001478565,0.0003590433,0.00024712848,0.0002877678,0.0065935883,0.9785851,0.00005741064],"about_ca_topic_score_codex":0.94708997,"about_ca_topic_score_gemma":0.9717439,"teacher_disagreement_score":0.9496107,"about_ca_system_score_codex":0.050389264,"about_ca_system_score_gemma":0.17739345,"threshold_uncertainty_score":0.36560136},"labels":[],"label_agreement":null},{"id":"W2412189619","doi":"","title":"International pharmaceutical expenditure differentials: why?","year":2004,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product (mathematics); Harm; Balance (ability); Business; Intellectual property; State (computer science); Prescription drug; Medical prescription; Public economics; Economics; Political science; Law; Medicine","score_opus":0.0967582142415576,"score_gpt":0.29470744710448005,"score_spread":0.19794923286292243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412189619","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15417746,0.025665732,0.010259559,0.28767788,0.0023665214,0.00016126857,0.013590994,0.00047586756,0.5056248],"genre_scores_gemma":[0.8995812,0.014148441,0.0039336192,0.02798249,0.0024078111,0.00019424187,0.0051129768,0.0001985897,0.0464406],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99729294,0.00048623476,0.0002103519,0.00045419746,0.00080434594,0.00075196195],"domain_scores_gemma":[0.9950777,0.0016080949,0.0014371589,0.00044917385,0.00087436935,0.00055344065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025680843,0.0004425997,0.0007218823,0.0032429842,0.00061793637,0.00424199,0.000661933,0.0014378635,0.027304653],"category_scores_gemma":[0.012682611,0.00023392562,0.00074402615,0.0061795954,0.0012982448,0.0040294034,0.0016886194,0.0021032288,0.0022692366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020130373,0.00009624858,0.03828548,0.0004011436,0.00024625118,0.00031598308,0.0008860917,0.0016363108,0.0002714152,0.69601506,0.09180819,0.16983666],"study_design_scores_gemma":[0.00014547241,0.000103102284,0.22542676,0.0013255992,0.00023797335,0.001366521,0.0030797923,0.0016827624,0.0013342127,0.18858176,0.57661504,0.00010090841],"about_ca_topic_score_codex":0.01288312,"about_ca_topic_score_gemma":0.009476256,"teacher_disagreement_score":0.027304653,"about_ca_system_score_codex":0.0038486135,"about_ca_system_score_gemma":0.0014723768,"threshold_uncertainty_score":0.091343164},"labels":[],"label_agreement":null},{"id":"W2413309707","doi":"","title":"Removing barriers? An overview of the Canadian Access to Medicines Regime.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislature; Access to medicines; Order (exchange); Business; Public health; Intersection (aeronautics); Human immunodeficiency virus (HIV); International trade; Developing country; Economic growth; Public administration; Political science; Medicine; Economics; Law; Engineering; Finance; Transport engineering; Virology","score_opus":0.24707737555519318,"score_gpt":0.3208551707366549,"score_spread":0.07377779518146174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413309707","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008819333,0.27701193,0.004200811,0.0878991,0.0013263398,0.0001688632,0.0040028417,0.00011603031,0.61645466],"genre_scores_gemma":[0.30464187,0.5839509,0.008790157,0.0137894815,0.0016156622,0.00020098028,0.0019451285,0.00011872378,0.08494716],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99666804,0.00031658093,0.00006970535,0.00015232833,0.002059893,0.00073352474],"domain_scores_gemma":[0.9974733,0.00063644996,0.00016370941,0.00007231961,0.0013267046,0.00032748518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018987517,0.0007218004,0.0005592294,0.0076803686,0.0037754832,0.0060495916,0.0013312573,0.0024858862,0.012819778],"category_scores_gemma":[0.0050984663,0.00032826676,0.00073239725,0.016480722,0.0030529187,0.0024769115,0.0010328748,0.002319571,0.0006749427],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021664704,0.000032972093,0.0019298743,0.00049242005,0.00002163749,0.000116228366,0.00031433988,0.0027605603,0.00008901524,0.8548284,0.07260077,0.06679203],"study_design_scores_gemma":[0.000019756166,0.000020104748,0.013142015,0.00082479994,0.000044052947,0.00017859899,0.0005390572,0.0034099042,0.00015859584,0.06379801,0.91778356,0.00008143806],"about_ca_topic_score_codex":0.9675667,"about_ca_topic_score_gemma":0.9682532,"teacher_disagreement_score":0.095627956,"about_ca_system_score_codex":0.095627956,"about_ca_system_score_gemma":0.11120335,"threshold_uncertainty_score":0.69383264},"labels":[],"label_agreement":null},{"id":"W2414866897","doi":"","title":"Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Cancer drugs; Family medicine; Advisory committee; Drug; Fiscal year; Cancer; Public administration; Finance; Pharmacology; Business; Internal medicine; Political science","score_opus":0.07186099767569792,"score_gpt":0.269627058369929,"score_spread":0.19776606069423108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414866897","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046540167,0.015117459,0.006343077,0.18695101,0.0028830585,0.0036445656,0.060280863,0.0011203757,0.6771194],"genre_scores_gemma":[0.4291893,0.013198985,0.01440949,0.026045628,0.0016167224,0.0021145593,0.02011487,0.00023410747,0.49307632],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9941941,0.00064711814,0.0001280279,0.00024355606,0.0037346878,0.0010525549],"domain_scores_gemma":[0.985713,0.0017082229,0.0011742511,0.00052684575,0.005879175,0.004998514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038603717,0.00035499703,0.00030024315,0.0016416393,0.0031943393,0.002748235,0.0011164874,0.001293267,0.015259058],"category_scores_gemma":[0.012834209,0.00042776883,0.00048504715,0.002999615,0.0012557523,0.00081204,0.0014914399,0.0011980748,0.0016826054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003154085,0.00010124602,0.018745812,0.00048038957,0.000054917877,0.00012762193,0.00036237837,0.0009147605,0.00052879605,0.046918396,0.8442603,0.08718993],"study_design_scores_gemma":[0.00022964785,0.00007779321,0.04719123,0.00011608114,0.00003724214,0.00008243176,0.000101473284,0.0009795622,0.00021433723,0.0010174311,0.94992745,0.000025275443],"about_ca_topic_score_codex":0.9397403,"about_ca_topic_score_gemma":0.9678717,"teacher_disagreement_score":0.9428999,"about_ca_system_score_codex":0.05710014,"about_ca_system_score_gemma":0.21694174,"threshold_uncertainty_score":0.41429245},"labels":[],"label_agreement":null},{"id":"W2416250252","doi":"","title":"Blame Canada. New Hampshire will defy the FDA and buy drugs on the Net.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blame; Drug approval; Business; Advertising; Political science; Internet privacy; Psychology; Medicine; Computer science; Drug; Pharmacology; Psychiatry","score_opus":0.04453381333965289,"score_gpt":0.20241723532458364,"score_spread":0.15788342198493074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416250252","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021557482,0.03139135,0.0006821459,0.33101416,0.009711248,0.00009305986,0.015500399,0.0010581708,0.6083938],"genre_scores_gemma":[0.019069474,0.012528655,0.00062282017,0.04621452,0.0012704519,0.0000315717,0.0030947388,0.0002320284,0.9169357],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987412,0.000047629026,0.000028799119,0.00006242783,0.00085981487,0.00026006982],"domain_scores_gemma":[0.9954963,0.00044577228,0.00017420024,0.000106785454,0.0028174308,0.0009595461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008029232,0.0005550494,0.0004843241,0.001252233,0.0034284093,0.0045323004,0.00092187535,0.0057301405,0.19107358],"category_scores_gemma":[0.0068632616,0.00037409292,0.0004558533,0.0017386301,0.0010490263,0.0021979786,0.00085288554,0.003983846,0.037479308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002294414,0.0000044100248,0.00019751236,0.00003901951,0.000003485803,0.000029908966,0.00001960769,0.000018080978,0.000049464386,0.005633267,0.98433924,0.009643038],"study_design_scores_gemma":[0.000016312915,0.000007603536,0.002006751,0.00011025577,0.000010504483,0.00003751318,0.00009610079,0.00006830931,0.00012533105,0.001394473,0.9961152,0.000011786564],"about_ca_topic_score_codex":0.85644287,"about_ca_topic_score_gemma":0.9270344,"teacher_disagreement_score":0.19107358,"about_ca_system_score_codex":0.016928224,"about_ca_system_score_gemma":0.04644164,"threshold_uncertainty_score":0.6392048},"labels":[],"label_agreement":null},{"id":"W2417865952","doi":"","title":"A comparison of United States and Canadian laws as they affect generic pharmaceutical market entry.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Affect (linguistics); Business; Public economics; Law and economics; Industrial organization; International trade; Economics; Sociology","score_opus":0.07446477824861633,"score_gpt":0.30066187766914365,"score_spread":0.22619709942052732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417865952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5798398,0.013699029,0.0008001807,0.048243754,0.0005595383,0.00027615318,0.01535087,0.000101614714,0.341129],"genre_scores_gemma":[0.9720863,0.003326285,0.0003103783,0.0037546877,0.00011498387,0.000033792076,0.0023144868,0.000023854867,0.018035306],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99457645,0.00033150392,0.00013744026,0.0001944517,0.002901864,0.0018583178],"domain_scores_gemma":[0.9794169,0.006602431,0.0028862238,0.0003172345,0.008867718,0.0019095158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027224233,0.00020230355,0.00041551123,0.003692697,0.0033921166,0.004470198,0.0009588521,0.0014641212,0.011212987],"category_scores_gemma":[0.027236506,0.0001603801,0.00064450974,0.0068267058,0.0015962814,0.0014240566,0.00090203405,0.001832682,0.000415034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020878143,0.00058970693,0.35420012,0.0006170932,0.00032805122,0.0007633168,0.005518607,0.0034207106,0.0010173311,0.25725478,0.23285712,0.14134541],"study_design_scores_gemma":[0.000163281,0.00015316595,0.8914399,0.00022853525,0.0004003499,0.00010370777,0.008390745,0.0017348307,0.0008802265,0.003622333,0.09279056,0.000092431656],"about_ca_topic_score_codex":0.9826768,"about_ca_topic_score_gemma":0.9918733,"teacher_disagreement_score":0.040926374,"about_ca_system_score_codex":0.040926374,"about_ca_system_score_gemma":0.06760561,"threshold_uncertainty_score":0.296943},"labels":[],"label_agreement":null},{"id":"W2420469801","doi":"10.1161/circoutcomes.6.suppl_1.a153","title":"Abstract 153: Impact Of The Enhance Trial On The Use Of Ezetimibe In The Us And Canada","year":2013,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Ezetimibe; Medicine; Medical prescription; Population; Clinical trial; Demography; Environmental health; Internal medicine; Statin; Pharmacology","score_opus":0.16331413585285623,"score_gpt":0.32360883537020124,"score_spread":0.160294699517345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2420469801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9249,0.014692425,0.0005328881,0.008701537,0.00018657796,0.00080893724,0.03275292,0.00006813939,0.017356649],"genre_scores_gemma":[0.9878006,0.0023177962,0.0007431512,0.002268254,0.00014097031,0.00028843968,0.0047667683,0.000019035693,0.0016550844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936498,0.0020319214,0.0005802591,0.00047074194,0.0024594457,0.000807848],"domain_scores_gemma":[0.9784894,0.0067147273,0.006818479,0.001077187,0.0051663467,0.0017339406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074223876,0.00021166101,0.0008726466,0.0005847413,0.00076007174,0.0013090128,0.00058596703,0.00052814855,0.0022038575],"category_scores_gemma":[0.03436803,0.00017366001,0.00089831714,0.0016654792,0.0008102703,0.0003765763,0.0006736395,0.0008928941,0.00014807322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051432878,0.00043753668,0.7969626,0.0020332672,0.004450937,0.00023302154,0.00043690705,0.0027022893,0.00095480896,0.0025114873,0.04381124,0.09403295],"study_design_scores_gemma":[0.003394942,0.001164701,0.97779053,0.0004995682,0.001958864,0.00007558481,0.00025822787,0.0010926035,0.00077449414,0.00023649905,0.012695357,0.000058649268],"about_ca_topic_score_codex":0.8048655,"about_ca_topic_score_gemma":0.88937205,"teacher_disagreement_score":0.19513452,"about_ca_system_score_codex":0.010528127,"about_ca_system_score_gemma":0.03295542,"threshold_uncertainty_score":0.3925674},"labels":[],"label_agreement":null},{"id":"W2425036397","doi":"10.1093/ajhp/60.19.1943","title":"Use of a personal digital assistant in a pharmacy-directed warfarin dosing program","year":2003,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pharmacy; Clinical pharmacy; Pharmacist; Medicine; Library science; Family medicine","score_opus":0.12163080215461872,"score_gpt":0.35693002085541636,"score_spread":0.23529921870079765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2425036397","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066502085,0.0095046265,0.004148292,0.026178299,0.0050092046,0.0011926276,0.015072145,0.009062314,0.92318225],"genre_scores_gemma":[0.040441934,0.03280109,0.0126270875,0.020097185,0.0076580113,0.0014261365,0.009823646,0.0021490955,0.8729758],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9966079,0.00068384333,0.0003993657,0.00031540828,0.0016844771,0.00030885026],"domain_scores_gemma":[0.97921205,0.0043872655,0.0025438445,0.0014438225,0.0050313133,0.007381709],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020295754,0.00047041706,0.0010451603,0.0034730348,0.0014900997,0.0029254758,0.0013552841,0.0014382243,0.55566067],"category_scores_gemma":[0.024673412,0.00045289315,0.00088875927,0.004028449,0.0005202732,0.004878479,0.0031094253,0.0013548016,0.34585574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006180237,0.00012407271,0.0014188786,0.0006088848,0.000013621452,0.00016088515,0.00013008874,0.00002935541,0.0001939722,0.00020234284,0.778479,0.2185771],"study_design_scores_gemma":[0.00008443247,0.00015990456,0.0056706644,0.000979816,0.000036295085,0.0007766269,0.0003156075,0.00011260213,0.00030913966,0.0003609906,0.99115413,0.000039772734],"about_ca_topic_score_codex":0.0045200884,"about_ca_topic_score_gemma":0.0125152785,"teacher_disagreement_score":0.55566067,"about_ca_system_score_codex":0.001442513,"about_ca_system_score_gemma":0.006802823,"threshold_uncertainty_score":0.6337961},"labels":[],"label_agreement":null},{"id":"W2429636260","doi":"","title":"Legislative and regulatory modernization for therapeutic products.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Legislature; Modernization theory; Legislation; Business; Presentation (obstetrics); Work (physics); Action plan; Order (exchange); Health professionals; Action (physics); Consumer protection; Health care; Medicine; Political science; Engineering; Management; Finance; Economics; Commerce","score_opus":0.07737842813077492,"score_gpt":0.2514797362142745,"score_spread":0.17410130808349958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2429636260","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064343023,0.0425174,0.005931026,0.26951587,0.0037937972,0.00034293902,0.0017498579,0.0002737148,0.6694411],"genre_scores_gemma":[0.321173,0.05686705,0.019013472,0.26700628,0.005969643,0.00062513165,0.0024411532,0.00021527892,0.32668895],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97304845,0.0031742791,0.00087489444,0.0014693075,0.019131234,0.0023018545],"domain_scores_gemma":[0.9736763,0.006263352,0.0022013949,0.0018348913,0.014658286,0.0013657631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014695747,0.0005845638,0.00039377974,0.0022889997,0.005567026,0.0076472233,0.0019218223,0.0067467312,0.009491826],"category_scores_gemma":[0.028060881,0.0006220879,0.00089496427,0.002445311,0.009567738,0.002672232,0.0017869744,0.007142762,0.0011840939],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029627232,0.000034865723,0.0011027531,0.00019406447,0.000013904925,0.00011441868,0.00076953275,0.0007106742,0.0004664586,0.8002421,0.16782974,0.028491877],"study_design_scores_gemma":[0.000015126445,0.000026308406,0.0053700455,0.00044672942,0.000024546674,0.00013828438,0.0002742641,0.00046794032,0.00044124367,0.019966187,0.97279185,0.000037462418],"about_ca_topic_score_codex":0.7527528,"about_ca_topic_score_gemma":0.7673074,"teacher_disagreement_score":0.7527528,"about_ca_system_score_codex":0.058123134,"about_ca_system_score_gemma":0.12960918,"threshold_uncertainty_score":0.4974066},"labels":[],"label_agreement":null},{"id":"W2430198404","doi":"","title":"Canada: Federal Court dismisses prohibition application for quetiapine tablets (SEROQUEL XR).","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quetiapine; Quetiapine Fumarate; Federal court; Law; Medicine; Business; Political science; Psychiatry; Supreme court; Atypical antipsychotic; Schizophrenia (object-oriented programming); Antipsychotic","score_opus":0.03909270774846913,"score_gpt":0.22474106216165451,"score_spread":0.1856483544131854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2430198404","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021946276,0.009648078,0.0011125288,0.5402387,0.008482462,0.00071164034,0.016461017,0.00057972217,0.40081957],"genre_scores_gemma":[0.11857743,0.007843247,0.0016065533,0.41336814,0.0022996909,0.00029357264,0.0034039305,0.0002178854,0.4523895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9897798,0.00034118848,0.00043255588,0.0006088944,0.006601212,0.002236359],"domain_scores_gemma":[0.987695,0.0036899277,0.00034056106,0.00029484983,0.0068497877,0.0011299725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033048356,0.0007323439,0.0009660269,0.0022492113,0.012127959,0.0058056964,0.0042467075,0.02808069,0.015752606],"category_scores_gemma":[0.016916666,0.0012268189,0.0016471439,0.0026513315,0.0025824476,0.0012680969,0.0015230604,0.015024844,0.0031325342],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011923407,0.000059088503,0.001977221,0.00012525164,0.00004988584,0.0008340204,0.00025133567,0.00015614627,0.00061269326,0.024246497,0.96357065,0.007998014],"study_design_scores_gemma":[0.00023886391,0.000055249162,0.015694372,0.00038211717,0.00023516692,0.0003331204,0.00045992018,0.0007154196,0.0016646407,0.0039052973,0.9761815,0.00013438056],"about_ca_topic_score_codex":0.9720495,"about_ca_topic_score_gemma":0.98714256,"teacher_disagreement_score":0.06263097,"about_ca_system_score_codex":0.06263097,"about_ca_system_score_gemma":0.17604189,"threshold_uncertainty_score":0.45442158},"labels":[],"label_agreement":null},{"id":"W2432561189","doi":"","title":"Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmaceutical industry; Business; Management; Economics; Medicine; Pharmacology; History","score_opus":0.1054695009722585,"score_gpt":0.2813184614801285,"score_spread":0.17584896050787002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2432561189","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41876456,0.064939,0.0019748784,0.04758803,0.0016347859,0.00017064746,0.088744715,0.00054824,0.37563515],"genre_scores_gemma":[0.8100648,0.021988457,0.0011977347,0.0062958132,0.0020510494,0.00016969298,0.04199491,0.0001783954,0.11605917],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914193,0.00010341664,0.000060708488,0.00012261393,0.00041857667,0.00015277168],"domain_scores_gemma":[0.995611,0.0010754485,0.002159415,0.00007756724,0.00064564054,0.00043098192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086092734,0.0002237933,0.00022460667,0.0021507137,0.0006241526,0.0041726213,0.00030966994,0.0009733471,0.010734033],"category_scores_gemma":[0.00444653,0.00020493458,0.00020006497,0.006360406,0.00040332772,0.0024998875,0.00093993894,0.0009756851,0.0026733836],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005371025,0.00010636425,0.09034937,0.00065480825,0.00008251959,0.0011569809,0.0018761922,0.000725042,0.0012722991,0.033218678,0.7131472,0.15687348],"study_design_scores_gemma":[0.000028230541,0.000074041694,0.28663117,0.00018753845,0.000025674237,0.0007629258,0.0017246833,0.0005836919,0.0006627374,0.0019747568,0.7073145,0.000030079298],"about_ca_topic_score_codex":0.00505024,"about_ca_topic_score_gemma":0.008726183,"teacher_disagreement_score":0.010734033,"about_ca_system_score_codex":0.0017995635,"about_ca_system_score_gemma":0.0007811163,"threshold_uncertainty_score":0.035908878},"labels":[],"label_agreement":null},{"id":"W24331064","doi":"","title":"Tifacogin (Chiron Corp/Pharmacia Corp).","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Recombinant DNA; Tissue factor pathway inhibitor; Sepsis; Pharmacology; Medicine; Chemistry; Biochemistry; Gene; Internal medicine; Coagulation; Tissue factor","score_opus":0.14513373516470696,"score_gpt":0.24507400132998802,"score_spread":0.09994026616528107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W24331064","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12148958,0.1018293,0.029630039,0.011440994,0.0046310555,0.0035863102,0.03442707,0.014342327,0.6786234],"genre_scores_gemma":[0.33864614,0.044165116,0.035159245,0.008606233,0.0010677072,0.002341132,0.06015286,0.00075541605,0.50910616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995503,0.000035082154,0.000019602956,0.00009354633,0.00024038703,0.00006107052],"domain_scores_gemma":[0.9997814,0.00002467374,0.000037220045,0.000017874681,0.000041754938,0.00009716307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036244493,0.0010167428,0.0003847822,0.0016839211,0.0004317107,0.0005572232,0.0006217438,0.0007251578,0.07456283],"category_scores_gemma":[0.0005841258,0.0002377001,0.00044447696,0.00074450095,0.00032624477,0.0006338699,0.0007353689,0.0017819911,0.03529887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021826355,0.0006897047,0.0014764584,0.0012583771,0.000056433615,0.0011297395,0.00011757379,0.0005219966,0.17872852,0.004203661,0.19203123,0.61760366],"study_design_scores_gemma":[0.0011862959,0.0027241425,0.0042851074,0.00027995557,0.000073849085,0.0063284654,0.000043446606,0.0008583903,0.061404604,0.0011286923,0.9216386,0.000048514157],"about_ca_topic_score_codex":0.0013398591,"about_ca_topic_score_gemma":0.0025701139,"teacher_disagreement_score":0.07456283,"about_ca_system_score_codex":0.00074331387,"about_ca_system_score_gemma":0.0011706287,"threshold_uncertainty_score":0.24943751},"labels":[],"label_agreement":null},{"id":"W2442133109","doi":"10.1071/hc15094","title":"The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand","year":2015,"lang":"en","type":"article","venue":"Journal of Primary Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"University of Auckland","keywords":"Olanzapine; Medicine; Medical prescription; Subsidy; Actuarial science; Psychiatry; Business; Schizophrenia (object-oriented programming); Economics; Nursing","score_opus":0.2377371799552184,"score_gpt":0.4149426726992649,"score_spread":0.17720549274404648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2442133109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984586,0.0003169574,0.00004869844,0.00023041137,0.000007105926,0.00003640863,0.00037446423,0.0000013916078,0.00052598584],"genre_scores_gemma":[0.9993474,0.00016516756,0.000075256765,0.000029502271,0.000009201814,0.00001706513,0.00027176578,7.6863466e-7,0.00008385912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716055,0.00090242986,0.00040571662,0.00033791875,0.0008266911,0.00036668841],"domain_scores_gemma":[0.98703206,0.0013743767,0.009540475,0.00035171394,0.0010949828,0.0006063719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032751644,0.00027146348,0.00043880413,0.0006926176,0.0002988552,0.000785255,0.0005822281,0.0004181259,0.0012292525],"category_scores_gemma":[0.010343419,0.00013728341,0.0014190382,0.001137412,0.0007292659,0.00046846265,0.000766452,0.0011846833,0.00010251058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019852873,0.00018701422,0.9856265,0.00015978259,0.00022727212,0.00037991835,0.00050556817,0.00024657857,0.00041231603,0.000039561637,0.00018127509,0.010048869],"study_design_scores_gemma":[0.000026044228,0.0005252617,0.9986185,0.000018427432,0.00006515906,0.00012587255,0.00022609101,0.0001538816,0.0000960067,0.000012729687,0.00012521274,0.00000678439],"about_ca_topic_score_codex":0.1082442,"about_ca_topic_score_gemma":0.07113017,"teacher_disagreement_score":0.1082442,"about_ca_system_score_codex":0.0038108246,"about_ca_system_score_gemma":0.002239052,"threshold_uncertainty_score":0.21522832},"labels":[],"label_agreement":null},{"id":"W2443926831","doi":"10.1503/cmaj.160134","title":"The case for an essential medicines list for Canada","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ontario Drug Policy Research Network; Queen's University","funders":"McMaster University","keywords":"Essential medicines; MEDLINE; Developing country; Medicine; Computer science; World Wide Web; Data science; Economic growth; Political science; Public health; Nursing; Law","score_opus":0.026999029158899308,"score_gpt":0.27718927255860354,"score_spread":0.25019024339970425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2443926831","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002071744,0.0025020693,0.00066139887,0.9524087,0.0023618017,0.00002199048,0.00036903398,0.0000402291,0.039563183],"genre_scores_gemma":[0.09344758,0.005094645,0.0046358523,0.85976785,0.0035021096,0.000052311716,0.0004789197,0.00013995777,0.032880697],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98468614,0.0020254962,0.000498263,0.0014120539,0.0075388593,0.0038391554],"domain_scores_gemma":[0.9559026,0.011328862,0.0017480043,0.0012925252,0.015631331,0.014096739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009158335,0.00042828088,0.0007064318,0.001399893,0.011569558,0.00952698,0.0030131596,0.022027627,0.023949247],"category_scores_gemma":[0.04240466,0.00059343065,0.0012335894,0.0022197298,0.0071588154,0.008136576,0.004188976,0.024098221,0.00190719],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009706476,0.000035637167,0.0022016743,0.00014922596,0.000030852723,0.00070855225,0.00047666975,0.0003119791,0.00025914639,0.29686132,0.67717695,0.021690995],"study_design_scores_gemma":[0.00012515232,0.000035700672,0.0033773684,0.0008437311,0.000057723144,0.00047143202,0.0009201351,0.0011445463,0.00024743372,0.0488403,0.943808,0.00012842777],"about_ca_topic_score_codex":0.9187054,"about_ca_topic_score_gemma":0.95123696,"teacher_disagreement_score":0.081294596,"about_ca_system_score_codex":0.054444198,"about_ca_system_score_gemma":0.19887953,"threshold_uncertainty_score":0.3950221},"labels":[],"label_agreement":null},{"id":"W2460956080","doi":"10.12927/whp.2016.24670","title":"Negotiating Pharmaceutical Prices: A Change in Chinese Health Policy","year":2016,"lang":"en","type":"article","venue":"World health & population","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Negotiation; China; Pharmaceutical policy; Competition (biology); Drug prices; Business; Public economics; Health policy; Price policy; Economics; International economics; International trade; Health care; Economic growth; Political science; Law; Geography","score_opus":0.13519071952009268,"score_gpt":0.421726045225969,"score_spread":0.28653532570587636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460956080","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14176342,0.013075645,0.006314376,0.77691054,0.0028166384,0.00017615367,0.00034010253,0.00013557235,0.058467463],"genre_scores_gemma":[0.7980531,0.009846625,0.0072066663,0.15080787,0.0037896037,0.00017911536,0.000253977,0.0000675499,0.029795505],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9952376,0.0012847574,0.00033179106,0.0005884192,0.0014497855,0.0011076146],"domain_scores_gemma":[0.99537647,0.001636888,0.0004551221,0.00022149573,0.00089686183,0.0014131177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009756634,0.00049545564,0.0008483721,0.0017053158,0.004130295,0.007395974,0.0021186552,0.008352899,0.005164976],"category_scores_gemma":[0.009639195,0.00054763875,0.0011237261,0.0027552291,0.006753601,0.0050525884,0.0026011162,0.0067744944,0.00033499833],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021866031,0.0002500737,0.00992884,0.0006331268,0.00014647743,0.0015088872,0.009886836,0.004955398,0.0024715003,0.84098566,0.05304922,0.0759653],"study_design_scores_gemma":[0.0006081987,0.00046897412,0.08230529,0.0007440501,0.00018207738,0.00062184973,0.008466989,0.01770684,0.0024248776,0.29015025,0.59586465,0.0004558618],"about_ca_topic_score_codex":0.09309474,"about_ca_topic_score_gemma":0.061066214,"teacher_disagreement_score":0.09309474,"about_ca_system_score_codex":0.032139767,"about_ca_system_score_gemma":0.041751534,"threshold_uncertainty_score":0.23319137},"labels":[],"label_agreement":null},{"id":"W2462041422","doi":"10.1016/j.jval.2015.09.2521","title":"How Good Are Physicians And Chart Reviews At Capturing Health Resources And Drug Utilisation By Patients? Results Of The Pgrx-3 Prospective Real World Dataset Validation Study","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Family medicine; Pharmacy; Depression (economics); Medical record; Alternative medicine; Informed consent; Internal medicine","score_opus":0.12260972437845959,"score_gpt":0.31762735581036905,"score_spread":0.19501763143190948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462041422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8986331,0.0018526035,0.0063027847,0.00530815,0.00028113456,0.00041099745,0.0819733,0.000338783,0.0048991577],"genre_scores_gemma":[0.8815764,0.000400586,0.0057518706,0.0011891891,0.00013683854,0.00025221563,0.1088928,0.00014785069,0.001652288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.96669436,0.024783175,0.001482268,0.003228971,0.0029031583,0.0009080242],"domain_scores_gemma":[0.8712795,0.07879664,0.015987182,0.019220695,0.012440988,0.002275031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.046855528,0.0010151288,0.0009948997,0.0017546304,0.00085031975,0.0034841376,0.0027122367,0.0033038713,0.0019322904],"category_scores_gemma":[0.12976906,0.0007550951,0.002129533,0.0022771985,0.0013660177,0.0039897533,0.0024967515,0.0020819264,0.0015688676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027907752,0.00077438075,0.9353849,0.0002713948,0.0021078708,0.00007084139,0.0007213071,0.0060807066,0.00027690097,0.00074888964,0.032439146,0.018332765],"study_design_scores_gemma":[0.0010948261,0.0005376072,0.94687855,0.0004104498,0.0009665097,0.00024337323,0.0015573148,0.026365705,0.0010773026,0.0019153528,0.01881823,0.00013477956],"about_ca_topic_score_codex":0.04178191,"about_ca_topic_score_gemma":0.040601537,"teacher_disagreement_score":0.046855528,"about_ca_system_score_codex":0.0014021838,"about_ca_system_score_gemma":0.0027228387,"threshold_uncertainty_score":0.24779868},"labels":[],"label_agreement":null},{"id":"W2462357409","doi":"10.1213/ane.0000000000000823","title":"Drug Shortages in Perioperative Medicine","year":2015,"lang":"en","type":"letter","venue":"Anesthesia & Analgesia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Economic shortage; Perioperative; Harm; Anesthesiology; Drug; Intensive care medicine; Pharmacology; Psychiatry; Surgery; Law; Government (linguistics)","score_opus":0.06384122520091927,"score_gpt":0.290348845079617,"score_spread":0.22650761987869772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462357409","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023174407,0.031377725,0.00032285898,0.86890036,0.097397,0.00001266566,0.000043339256,0.0000345957,0.0016797077],"genre_scores_gemma":[0.008923968,0.052299526,0.0006981448,0.7700499,0.16501957,0.000041412317,0.00004566677,0.000067820554,0.0028538876],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98145366,0.0060463175,0.0034002461,0.0016695699,0.0065297736,0.0009005121],"domain_scores_gemma":[0.85718685,0.070477545,0.013586931,0.0029518926,0.049778417,0.0060183294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015748696,0.0007704976,0.0012134064,0.0024361762,0.0031899756,0.00685109,0.002854207,0.018179901,0.006450131],"category_scores_gemma":[0.12604453,0.00073862384,0.001550779,0.0020142684,0.007866916,0.012128428,0.0032373308,0.021954231,0.0033610207],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002058582,0.000012655274,0.000617176,0.00088781095,0.000026420772,0.0003169708,0.00047275962,0.000057459823,0.00005306751,0.0058237393,0.9692285,0.022482745],"study_design_scores_gemma":[0.000028316032,0.000041722375,0.0012416893,0.0036218953,0.000043187665,0.0011997072,0.0010377617,0.00015640126,0.00018206613,0.014280353,0.978097,0.00006991083],"about_ca_topic_score_codex":0.004933702,"about_ca_topic_score_gemma":0.008459006,"teacher_disagreement_score":0.018179901,"about_ca_system_score_codex":0.0060605803,"about_ca_system_score_gemma":0.0156798,"threshold_uncertainty_score":0.08328807},"labels":[],"label_agreement":null},{"id":"W2462866164","doi":"","title":"American Association of Pharmaceutical Scientists 2002 Annual Meeting and Exposition, Drug development in a global marketplace: challenges and opportunities. 10-14 November 2002, Toronto, Canada.","year":2003,"lang":"en","type":"other","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Exposition (narrative); Association (psychology); Library science; Political science; Psychology; Computer science","score_opus":0.04180395314149797,"score_gpt":0.2504522796526228,"score_spread":0.2086483265111248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462866164","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013180776,0.2886093,0.0017286702,0.08028586,0.045686595,0.00030458096,0.033601336,0.0010245441,0.547441],"genre_scores_gemma":[0.004370313,0.19606426,0.00093343307,0.0054103625,0.0045889462,0.0001330477,0.008918577,0.00018439809,0.77939665],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993268,0.000039322145,0.00004633807,0.00007279768,0.00041956382,0.000095155825],"domain_scores_gemma":[0.9969313,0.00023505528,0.00018749412,0.00008412424,0.002050931,0.0005110834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012154602,0.0014918318,0.0011231258,0.002829427,0.0017331551,0.0032563522,0.0008863579,0.0024653783,0.13371512],"category_scores_gemma":[0.0023168635,0.0007393573,0.00042899698,0.0071268217,0.00069853954,0.0015681237,0.000802324,0.0026270233,0.06641175],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017581884,0.000008840692,0.00008693854,0.00012081277,0.000002752917,0.000012050743,0.000008268433,0.000030408397,0.000056040655,0.00030516513,0.9823163,0.017034896],"study_design_scores_gemma":[0.000015347308,0.000009581312,0.0028226867,0.00020348943,0.000010317591,0.000026868789,0.000032259497,0.000047259204,0.00010407427,0.00026845906,0.9964516,0.000007986758],"about_ca_topic_score_codex":0.14842808,"about_ca_topic_score_gemma":0.4036358,"teacher_disagreement_score":0.14842808,"about_ca_system_score_codex":0.004561805,"about_ca_system_score_gemma":0.013955644,"threshold_uncertainty_score":0.44732165},"labels":[],"label_agreement":null},{"id":"W2463885522","doi":"10.1007/s10611-016-9627-5","title":"It came from the north: assessing the claim of Canada’s rising role as a global supplier of synthetic drugs","year":2016,"lang":"en","type":"article","venue":"Crime Law and Social Change","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; Université de Montréal; International Centre for Comparative Criminology","funders":"","keywords":"Scope (computer science); Production (economics); Exportation; Business; Quality (philosophy); Economics; International trade; Macroeconomics","score_opus":0.06373805513632705,"score_gpt":0.2928897934372456,"score_spread":0.22915173830091853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463885522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8845953,0.001533901,0.00017960614,0.047313467,0.00008248322,0.00006130158,0.0013651309,0.0000067454152,0.06486218],"genre_scores_gemma":[0.9936086,0.00057605293,0.00007318071,0.0022411179,0.000031920506,0.0000054465368,0.00019642833,0.000004812074,0.0032625382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959915,0.00029841793,0.00009484512,0.00017756685,0.0018814928,0.0015561364],"domain_scores_gemma":[0.9809607,0.003380746,0.0029204034,0.00029304234,0.0093981335,0.0030469503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024275722,0.00023078227,0.0003893525,0.0018258231,0.0056953826,0.0061130077,0.0012281968,0.0021287359,0.003932326],"category_scores_gemma":[0.015041682,0.00022786594,0.00040129354,0.0041476595,0.0046287887,0.0016217452,0.0021828297,0.003606619,0.00019581821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012290197,0.00030284497,0.71102715,0.0005034395,0.00037759764,0.0016222659,0.015240985,0.0056418725,0.0010267816,0.16864365,0.04757864,0.0468057],"study_design_scores_gemma":[0.000112723625,0.00021329074,0.8156968,0.00059163914,0.0005477396,0.00024197373,0.078488566,0.0069411984,0.0020615938,0.009037735,0.08592943,0.00013726308],"about_ca_topic_score_codex":0.9938012,"about_ca_topic_score_gemma":0.9960311,"teacher_disagreement_score":0.1045364,"about_ca_system_score_codex":0.1045364,"about_ca_system_score_gemma":0.12575457,"threshold_uncertainty_score":0.7584682},"labels":[],"label_agreement":null},{"id":"W2464934251","doi":"10.2147/dddt.s106802","title":"Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod","year":2016,"lang":"en","type":"review","venue":"Drug Design Development and Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Novartis Pharma; World Health Organization","keywords":"Fingolimod; Medicine; Food and drug administration; Marketing authorization; Quality (philosophy); Authorization; Good manufacturing practice; Documentation; Agency (philosophy); Bioequivalence; Pharmacy; Risk analysis (engineering); Intensive care medicine; Business; Family medicine; Multiple sclerosis; Pharmacology; Marketing; Computer security; Bioinformatics; Computer science","score_opus":0.3702865754020696,"score_gpt":0.3829632242045164,"score_spread":0.012676648802446788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464934251","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005338408,0.6629687,0.0030957123,0.28831285,0.0050987075,0.000071152666,0.00006907379,0.00010825199,0.03493715],"genre_scores_gemma":[0.08976526,0.7104835,0.009071064,0.13457239,0.03393085,0.00013444509,0.00012567553,0.00009272487,0.021824202],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740833,0.0010449094,0.00025346183,0.00020512576,0.0009501777,0.00013803036],"domain_scores_gemma":[0.99344337,0.004037977,0.0007457101,0.00013765457,0.0012146473,0.00042063167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00396189,0.0005133413,0.0007477322,0.0006668984,0.00083101646,0.0023315516,0.0006617892,0.004427964,0.008755215],"category_scores_gemma":[0.008746761,0.00019184005,0.0009473347,0.00055589917,0.0018451957,0.002948636,0.0015793421,0.0051086303,0.0019340392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043259395,0.00025053002,0.0036567762,0.0054267566,0.00008110623,0.013170184,0.001141109,0.0004108639,0.006739408,0.030376747,0.17763796,0.760676],"study_design_scores_gemma":[0.000117060714,0.00076109177,0.0044245142,0.00636327,0.0001353212,0.04015516,0.001258538,0.00035227445,0.0018495977,0.017277436,0.92724085,0.00006483265],"about_ca_topic_score_codex":0.00083681085,"about_ca_topic_score_gemma":0.0024715778,"teacher_disagreement_score":0.008755215,"about_ca_system_score_codex":0.0014796702,"about_ca_system_score_gemma":0.0021289457,"threshold_uncertainty_score":0.029289067},"labels":[],"label_agreement":null},{"id":"W2467894892","doi":"10.1017/s1092852900024706","title":"Generic Substitution for Psychotropic Drugs","year":2009,"lang":"en","type":"article","venue":"CNS Spectrums","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mental Health Research Canada","funders":"","keywords":"Bioequivalence; Drug; Generic drug; Medicine; Brand names; Food and drug administration; Pharmacology; Pharmacokinetics; Marketing; Business","score_opus":0.05915964262169584,"score_gpt":0.29233050901001884,"score_spread":0.233170866388323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467894892","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038951278,0.02026818,0.009836,0.20428327,0.016055906,0.002257798,0.00301209,0.0025217491,0.7028136],"genre_scores_gemma":[0.20581257,0.014297442,0.030337084,0.19419283,0.005656414,0.0012014265,0.0019500612,0.001206956,0.54534525],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997062,0.0011195502,0.00026274842,0.00028114798,0.00092146994,0.00035290132],"domain_scores_gemma":[0.9970884,0.0016350396,0.00024200205,0.00023563349,0.00055601867,0.00024299185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027656595,0.00046559126,0.0007146653,0.0004001075,0.00183323,0.001213485,0.0006892959,0.0029220434,0.17340423],"category_scores_gemma":[0.008431247,0.00019508248,0.00044917347,0.0003826414,0.00069966214,0.0024936658,0.0020628083,0.001846684,0.056857202],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023577474,0.00011513097,0.00069993484,0.0009025507,0.000005030604,0.0005012132,0.0025253515,0.00005819483,0.0027726807,0.0063275527,0.7789923,0.2068643],"study_design_scores_gemma":[0.00002370722,0.000070079455,0.0008726425,0.00020923256,0.0000029681896,0.0004032598,0.0010117354,0.00005267026,0.00024369465,0.00045816586,0.99663913,0.000012589802],"about_ca_topic_score_codex":0.002240656,"about_ca_topic_score_gemma":0.0035116384,"teacher_disagreement_score":0.17340423,"about_ca_system_score_codex":0.0015923392,"about_ca_system_score_gemma":0.0012164129,"threshold_uncertainty_score":0.58009493},"labels":[],"label_agreement":null},{"id":"W2471028722","doi":"","title":"Improving safety, quality and efficacy of medicines in the Americas.","year":2016,"lang":"en","type":"editorial","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Quality (philosophy); Business; Medicine; Traditional medicine; Physics","score_opus":0.06576026971609744,"score_gpt":0.32312730538353,"score_spread":0.2573670356674326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471028722","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034602443,0.06341852,0.00018415666,0.107857004,0.82588303,0.00004306253,0.0003810211,0.00005653201,0.002141974],"genre_scores_gemma":[0.0006202536,0.061015308,0.00027429804,0.026138619,0.9068038,0.000049940332,0.00012261063,0.00003519724,0.0049399133],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98811555,0.002381124,0.0026181305,0.00076089514,0.005658649,0.00046557677],"domain_scores_gemma":[0.90371853,0.062842414,0.004660314,0.0014266374,0.023560362,0.0037917288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020804573,0.004089295,0.00641897,0.0054173823,0.0018467184,0.008439479,0.0054827733,0.021422092,0.014714089],"category_scores_gemma":[0.10236096,0.001618935,0.0034076774,0.003969818,0.0025885813,0.0077611534,0.001885566,0.026267689,0.008095008],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029702162,0.0000104724995,0.000016282382,0.0006966532,0.000048883845,0.000029265666,0.0000069462417,0.000032136773,0.00001472321,0.00080312445,0.99103206,0.007279596],"study_design_scores_gemma":[0.00022123945,0.00004967812,0.0005350659,0.003889353,0.00030487226,0.00011083932,0.000050246264,0.0002719852,0.00012228366,0.0070006154,0.9874034,0.000040303687],"about_ca_topic_score_codex":0.008067431,"about_ca_topic_score_gemma":0.015909191,"teacher_disagreement_score":0.021422092,"about_ca_system_score_codex":0.00743828,"about_ca_system_score_gemma":0.013906936,"threshold_uncertainty_score":0.11002642},"labels":[],"label_agreement":null},{"id":"W2473960571","doi":"","title":"Pulse: Drug prices stable but total spending rises by 15%","year":2002,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Demographics; Population; Medicine; Drug prices; Price index; Agricultural economics; Index (typography); Demography; Economics; Demographic economics; Monetary economics; Environmental health","score_opus":0.02647678158875794,"score_gpt":0.2398846699334881,"score_spread":0.21340788834473015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473960571","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014944083,0.027230747,0.0008456631,0.3192666,0.012378678,0.00015858306,0.015756954,0.0030225038,0.60639614],"genre_scores_gemma":[0.12992644,0.03267459,0.0015684349,0.09112096,0.008327795,0.00010711646,0.014162996,0.00045672146,0.721655],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99836916,0.000052289117,0.00005996172,0.0001426934,0.001099152,0.00027677647],"domain_scores_gemma":[0.99616134,0.00020146742,0.00020757978,0.00014052706,0.002178402,0.0011107338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007724565,0.00035062822,0.0003947863,0.0011617645,0.0012718581,0.004035476,0.0006742139,0.002154643,0.06701173],"category_scores_gemma":[0.0035624397,0.00022195136,0.00026551948,0.0025212024,0.0008287742,0.0011566932,0.00070730486,0.0017325693,0.027919624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006705131,0.000023594195,0.0026746525,0.000105028776,0.0000079548245,0.00008146129,0.000031414565,0.00002478425,0.00051829126,0.0012685404,0.88885516,0.1063421],"study_design_scores_gemma":[0.00003071172,0.00003199217,0.02406178,0.00006938195,0.000009541015,0.00018033212,0.000060506434,0.00007412492,0.00035175536,0.00028806273,0.9748325,0.000009365599],"about_ca_topic_score_codex":0.18325162,"about_ca_topic_score_gemma":0.2370325,"teacher_disagreement_score":0.8167484,"about_ca_system_score_codex":0.006853076,"about_ca_system_score_gemma":0.015257495,"threshold_uncertainty_score":0.36436993},"labels":[],"label_agreement":null},{"id":"W2481684576","doi":"10.1111/ijpp.12288","title":"Emerging trends on drug use globally","year":2016,"lang":"en","type":"editorial","venue":"International Journal of Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; Environmental health; Pharmacology","score_opus":0.05787431601986959,"score_gpt":0.4060232547565728,"score_spread":0.3481489387367032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2481684576","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048288867,0.22362505,0.0029493328,0.28064466,0.011405649,0.00012648989,0.015307666,0.00080204936,0.41685027],"genre_scores_gemma":[0.34437966,0.4068989,0.0048652478,0.113471836,0.022203347,0.00024930353,0.015379867,0.0006223614,0.0919295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776435,0.00026029165,0.0002570519,0.0005072492,0.000883015,0.00032803338],"domain_scores_gemma":[0.9927019,0.001174416,0.0018184205,0.00028139167,0.002194681,0.0018291596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016616305,0.000663341,0.0006850855,0.0047906297,0.0008593288,0.004260965,0.0008466976,0.0022494285,0.062918745],"category_scores_gemma":[0.0052641924,0.00023264115,0.0007225981,0.010435337,0.0016009322,0.007277583,0.0024476782,0.0042192363,0.011897711],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014160878,0.00018371262,0.055615257,0.002168937,0.00010334268,0.00061408064,0.0018323109,0.0003658664,0.00081912486,0.080655545,0.4069838,0.45051643],"study_design_scores_gemma":[0.000010137227,0.00007111792,0.060444493,0.0013644228,0.000026559093,0.0011168033,0.0018998666,0.00025023127,0.00017356998,0.0048188744,0.92979616,0.000027779937],"about_ca_topic_score_codex":0.010756051,"about_ca_topic_score_gemma":0.00911629,"teacher_disagreement_score":0.062918745,"about_ca_system_score_codex":0.0035098153,"about_ca_system_score_gemma":0.0030110748,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2482824289","doi":"10.1057/9780230244399_14","title":"The Partnership Prescription: Access to HIV/AIDS-related Medicines and Public—Private Partnerships","year":2009,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Economic growth; General partnership; Public health; Civil society; Political science; Poverty; Population; Public–private partnership; Business; Politics; Public administration; Medicine; Environmental health; Economics; Finance","score_opus":0.11233988468592798,"score_gpt":0.2933265379832078,"score_spread":0.1809866532972798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2482824289","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028072381,0.02484341,0.0066748825,0.41958165,0.0030296308,0.00011696,0.0004212309,0.0000941043,0.54243106],"genre_scores_gemma":[0.2677123,0.061603405,0.009627401,0.074254215,0.0024323536,0.00046894077,0.00066829217,0.00016265277,0.58307034],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672973,0.0016516319,0.00011336252,0.00034837917,0.0007053276,0.00045160812],"domain_scores_gemma":[0.9937419,0.0031709988,0.00051539455,0.00036415263,0.0006672516,0.0015402063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004161323,0.00037925402,0.00038547794,0.0007595652,0.0028925363,0.010624571,0.0007165072,0.010174829,0.057763617],"category_scores_gemma":[0.011228471,0.0003455652,0.0003672456,0.0025935858,0.0040811524,0.01203468,0.007588724,0.006512529,0.006133823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014922502,0.000022986402,0.00042818216,0.00008113637,0.000004975929,0.000062835665,0.0003702033,0.00015114014,0.00003076152,0.77963316,0.18463509,0.034564637],"study_design_scores_gemma":[0.000021646663,0.000024191564,0.000598544,0.0004266837,0.0000059579725,0.00014111251,0.00069216324,0.00038525,0.00006350015,0.13368843,0.86393905,0.000013331747],"about_ca_topic_score_codex":0.008021273,"about_ca_topic_score_gemma":0.011223004,"teacher_disagreement_score":0.057763617,"about_ca_system_score_codex":0.005055487,"about_ca_system_score_gemma":0.013558495,"threshold_uncertainty_score":0.19323856},"labels":[],"label_agreement":null},{"id":"W2483043008","doi":"","title":"Pénuries de médicaments : 10 ans de recul au Canada","year":2016,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Economic shortage; Art; Philosophy","score_opus":0.03736077141760889,"score_gpt":0.2653573792023123,"score_spread":0.22799660778470338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483043008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7803812,0.042604115,0.0015763853,0.03132373,0.0016284395,0.0006713401,0.053050667,0.00029247312,0.088471614],"genre_scores_gemma":[0.86293817,0.030731393,0.0017146243,0.009369551,0.00042157492,0.00024098216,0.014068805,0.0001280898,0.080386914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673164,0.00012488014,0.00013588175,0.0002935273,0.0018507343,0.0008633197],"domain_scores_gemma":[0.99210864,0.00035324215,0.0011147291,0.00009608475,0.004670895,0.0016564134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013542398,0.00043196653,0.0004692059,0.0027375384,0.0038514119,0.0028806934,0.0013042707,0.0010052812,0.012943334],"category_scores_gemma":[0.004689931,0.0004355826,0.0006875061,0.005486443,0.0010366397,0.0009305776,0.0014069692,0.0023383175,0.0013416404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051431183,0.0002589544,0.7135538,0.0012343072,0.00018106226,0.0020348052,0.015111764,0.00049344724,0.0011759744,0.003780205,0.09545339,0.16620804],"study_design_scores_gemma":[0.000018470411,0.00010024147,0.8551783,0.0011020581,0.00007668128,0.00043857482,0.010296718,0.00030693863,0.00034894375,0.00019497008,0.13188164,0.00005657203],"about_ca_topic_score_codex":0.99192786,"about_ca_topic_score_gemma":0.9947832,"teacher_disagreement_score":0.94225997,"about_ca_system_score_codex":0.05774004,"about_ca_system_score_gemma":0.09471894,"threshold_uncertainty_score":0.4189353},"labels":[],"label_agreement":null},{"id":"W2492890185","doi":"10.1093/acprof:oso/9780195342109.003.00011","title":"Expanding Patent Rights in Pharmaceuticals","year":2008,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Law and economics; Economics","score_opus":0.21078797504574198,"score_gpt":0.31692684699665596,"score_spread":0.10613887195091398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492890185","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024786238,0.018306596,0.012211161,0.0075183087,0.00043103375,0.000044134948,0.000066864784,0.000063486346,0.95887977],"genre_scores_gemma":[0.3999969,0.0618984,0.025621232,0.010348185,0.0037125535,0.00037671716,0.0002491598,0.00015914763,0.49763775],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9980301,0.0007153263,0.00008331809,0.00027395342,0.0007408723,0.00015647207],"domain_scores_gemma":[0.99722075,0.0018503054,0.00012965365,0.0003869466,0.0003201891,0.0000921886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025221715,0.00053744565,0.0004552274,0.0020782086,0.0015607465,0.00513302,0.0008523981,0.00255898,0.014466059],"category_scores_gemma":[0.0033454592,0.00034151052,0.00055534864,0.0016429354,0.008163994,0.006098371,0.0029288128,0.00390666,0.0033310952],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023405728,0.0000049360888,0.000018525054,0.00002415579,8.818697e-7,0.000020448695,0.00015688408,0.00018806261,0.00007872026,0.9835897,0.0049769366,0.010938402],"study_design_scores_gemma":[0.0000072730622,0.000013259316,0.00013361315,0.0001992021,0.000003553492,0.00009303466,0.000056912293,0.00039365113,0.00020706287,0.5662148,0.4326704,0.000007361413],"about_ca_topic_score_codex":0.0019550119,"about_ca_topic_score_gemma":0.0016927418,"teacher_disagreement_score":0.014466059,"about_ca_system_score_codex":0.0036115511,"about_ca_system_score_gemma":0.0023096718,"threshold_uncertainty_score":0.048393726},"labels":[],"label_agreement":null},{"id":"W2493092156","doi":"10.5639/gabij.2016.0502.014","title":"Adjusted indirect comparisons between generics – bioequivalence and interchangeability","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interchangeability; Bioequivalence; Medicine; Pharmacology; Computer science; Pharmacokinetics","score_opus":0.2569267108682741,"score_gpt":0.31465631857701165,"score_spread":0.05772960770873753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493092156","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.348903,0.04800359,0.4134516,0.006984215,0.0071936995,0.0070624766,0.07141212,0.00090606586,0.09608321],"genre_scores_gemma":[0.9158445,0.0020231835,0.0590383,0.0020156908,0.0009879383,0.0034680208,0.01060363,0.00030269896,0.0057160985],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.840991,0.12681325,0.009834121,0.007495538,0.013261871,0.0016042106],"domain_scores_gemma":[0.65871096,0.270904,0.023365568,0.033964198,0.011805334,0.001249809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07638894,0.0015881449,0.0026662848,0.0027389366,0.00074550876,0.0040226597,0.002192369,0.0016038379,0.029017001],"category_scores_gemma":[0.3064476,0.00052533066,0.0064453385,0.004711513,0.0020049708,0.005167329,0.003763452,0.0048111863,0.0020764957],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038155023,0.0010268808,0.16221039,0.018923232,0.11457642,0.0011102032,0.002769428,0.016018646,0.0031464892,0.19422203,0.040501464,0.4073398],"study_design_scores_gemma":[0.0071795327,0.011257097,0.34423518,0.0029705383,0.053128317,0.0030738548,0.0013517379,0.030468145,0.014340525,0.40165445,0.12932979,0.0010107841],"about_ca_topic_score_codex":0.0018776691,"about_ca_topic_score_gemma":0.00177485,"teacher_disagreement_score":0.07638894,"about_ca_system_score_codex":0.0018531987,"about_ca_system_score_gemma":0.0014877964,"threshold_uncertainty_score":0.40398818},"labels":[],"label_agreement":null},{"id":"W2493427157","doi":"10.1136/ebm.14.3.81","title":"Review: brand-name drugs are not more effective than generic versions for treating cardiovascular disease","year":2009,"lang":"en","type":"letter","venue":"Evidence-Based Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Brand names; Disease; Medicine; Citation; Equivalence (formal languages); Computer science; Internal medicine; Advertising; World Wide Web; Linguistics; Business; Philosophy","score_opus":0.09080153094382207,"score_gpt":0.3133321435995569,"score_spread":0.22253061265573484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493427157","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024579957,0.11549253,0.0004161893,0.79166526,0.08158084,0.00011212752,0.0013511856,0.00017992294,0.008956166],"genre_scores_gemma":[0.0043788324,0.10030577,0.001007106,0.78649753,0.0969232,0.00021651783,0.0004539261,0.00014999697,0.010067196],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9809579,0.0054896544,0.0041168504,0.0014258656,0.0074883485,0.00052132143],"domain_scores_gemma":[0.8977457,0.063662745,0.008595129,0.0019619921,0.025808077,0.0022261848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021581128,0.0012141821,0.006689666,0.0038507641,0.002409307,0.0047017112,0.0046355645,0.024002617,0.010483619],"category_scores_gemma":[0.0912235,0.0012749485,0.0033830649,0.005994082,0.0034276226,0.004247831,0.0017899086,0.019005865,0.012101491],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088048255,0.0000049239366,0.00008680968,0.002201066,0.00008737297,0.00011012772,0.000021609361,0.000025550396,0.000057221034,0.0009047532,0.979192,0.017220488],"study_design_scores_gemma":[0.00048408238,0.00010231536,0.0018514951,0.016482465,0.00062106544,0.0007956979,0.000107312626,0.0002870389,0.0003058312,0.0074504227,0.9714317,0.000080639635],"about_ca_topic_score_codex":0.009465019,"about_ca_topic_score_gemma":0.026372679,"teacher_disagreement_score":0.024002617,"about_ca_system_score_codex":0.009701657,"about_ca_system_score_gemma":0.011215118,"threshold_uncertainty_score":0.1141333},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2501073323","doi":"10.1057/9780230244399_13","title":"Patents, Policies and Pricing: Access to Medicines for Vulnerable Populations in a Global Economy*","year":2009,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Business; Public economics; Premise; Essential medicines; Population; Economic growth; Health care; Development economics; Medicine; Economics; Environmental health","score_opus":0.12751267530729277,"score_gpt":0.33560621736212953,"score_spread":0.20809354205483677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501073323","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037578184,0.14455476,0.0051710503,0.11276033,0.0026446339,0.000048179103,0.00030946702,0.000092674774,0.7306611],"genre_scores_gemma":[0.17556015,0.25039002,0.005713271,0.023632638,0.0060664294,0.0002045158,0.0002900506,0.00013261766,0.5380103],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.999485,0.00015333042,0.000020587271,0.00006168132,0.00021804517,0.00006126304],"domain_scores_gemma":[0.9993005,0.0005171041,0.000046595236,0.000036680252,0.00006469071,0.000034484478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008472315,0.0005137373,0.0003418146,0.00093660044,0.0008404544,0.0040984517,0.00044048828,0.0031884825,0.013982481],"category_scores_gemma":[0.0024572029,0.0002331214,0.00027834126,0.0022657649,0.0031748354,0.0063335896,0.001169503,0.0024376926,0.0020315514],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008859384,0.000018042456,0.00019599596,0.00014325156,0.000004434145,0.00007054441,0.00037610272,0.00090238993,0.00005680698,0.80563575,0.13917926,0.053408552],"study_design_scores_gemma":[0.0000058006895,0.000012327794,0.0007213518,0.00040915547,0.000003795488,0.00017216495,0.00026692665,0.0006401061,0.00005218804,0.39883745,0.5988687,0.0000101592295],"about_ca_topic_score_codex":0.004446283,"about_ca_topic_score_gemma":0.0053580585,"teacher_disagreement_score":0.013982481,"about_ca_system_score_codex":0.0031449534,"about_ca_system_score_gemma":0.0029245813,"threshold_uncertainty_score":0.046776056},"labels":[],"label_agreement":null},{"id":"W2501244108","doi":"10.4103/2468-5577.187082","title":"Seven alternative opportunities to overcome the \"Valley of Death\" for CNS drug candidates developed by academic researchers","year":2016,"lang":"en","type":"article","venue":"Asia Pacific Clinical and Translational Nervous System Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Drug; Medicine; Intensive care medicine; Pharmacology","score_opus":0.24415136270456247,"score_gpt":0.3825053458334726,"score_spread":0.13835398312891015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501244108","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10996076,0.0855761,0.18323323,0.27646542,0.0029800076,0.00085991225,0.001158549,0.00079348235,0.3389725],"genre_scores_gemma":[0.761695,0.04594627,0.1253373,0.016159266,0.0027192424,0.0014815938,0.00067066593,0.00013224027,0.04585843],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953852,0.0027265958,0.00020330113,0.00025422362,0.0007874726,0.0006432996],"domain_scores_gemma":[0.99103606,0.005758246,0.0010354309,0.00036454643,0.00072236493,0.0010834213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076972893,0.00084567367,0.00088773854,0.0023131776,0.0020646635,0.0059818095,0.0013306056,0.0049836785,0.025352133],"category_scores_gemma":[0.010612818,0.000419118,0.001481858,0.001308782,0.002955308,0.0073149037,0.0052028536,0.004432822,0.0017021876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003160532,0.00020753403,0.0022276845,0.00066710566,0.000054039756,0.00042381644,0.00024660514,0.0029547648,0.00046679043,0.8573069,0.025796605,0.10933208],"study_design_scores_gemma":[0.0005073538,0.00054862374,0.0038725163,0.0013013557,0.000060018956,0.00062180194,0.0011074162,0.010444259,0.00084366737,0.8217182,0.15881504,0.00015968356],"about_ca_topic_score_codex":0.00062503654,"about_ca_topic_score_gemma":0.0015162482,"teacher_disagreement_score":0.025352133,"about_ca_system_score_codex":0.0018763408,"about_ca_system_score_gemma":0.0035820603,"threshold_uncertainty_score":0.08481127},"labels":[],"label_agreement":null},{"id":"W2507917158","doi":"10.1186/s12967-016-0997-3","title":"Could patents interfere with the development of a cardiovascular polypill?","year":2016,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Population Health Research Institute; Institute of Population and Public Health; Hamilton Health Sciences; University of Ottawa","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Polypill; Assertion; Medicine; Intellectual property; Pill; Alternative medicine; Brand names; Generic drug; Business; Drug; Family medicine; Pharmacology; Computer science; Political science; Marketing; Law","score_opus":0.0873083713006572,"score_gpt":0.2743798914096524,"score_spread":0.1870715201089952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507917158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34152353,0.112611756,0.021041399,0.19895002,0.0044305953,0.0009581309,0.024278296,0.0005453586,0.29566088],"genre_scores_gemma":[0.9281859,0.025665354,0.0077928114,0.022622515,0.00198343,0.00024683966,0.004517888,0.00017414405,0.0088110855],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9726988,0.0071253045,0.0035974514,0.0033138066,0.0112582315,0.0020063003],"domain_scores_gemma":[0.80074877,0.12935282,0.04531393,0.008628639,0.012621698,0.0033341702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030394044,0.00028871157,0.00059463124,0.004463845,0.0020887454,0.004700201,0.0017904857,0.0028621897,0.018068844],"category_scores_gemma":[0.1532304,0.00026821677,0.0008675548,0.009660636,0.0030366222,0.0066823475,0.0021144103,0.002163521,0.0020383475],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017336212,0.00025986112,0.21637622,0.008231588,0.00043555663,0.004745219,0.004988612,0.0009584682,0.0024399753,0.12857568,0.12199586,0.5092594],"study_design_scores_gemma":[0.00022157555,0.0006281348,0.19606428,0.00688682,0.0012996688,0.005656193,0.00337681,0.0019274948,0.008132204,0.026797611,0.74882996,0.0001792475],"about_ca_topic_score_codex":0.025112325,"about_ca_topic_score_gemma":0.024268918,"teacher_disagreement_score":0.030394044,"about_ca_system_score_codex":0.0059877727,"about_ca_system_score_gemma":0.011401655,"threshold_uncertainty_score":0.16074103},"labels":[],"label_agreement":null},{"id":"W2508484044","doi":"10.1177/0020731416662612","title":"The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia","year":2016,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Transparency (behavior); Formulary; General partnership; Pharmaceutical policy; Technical barriers to trade; Listing (finance); Intellectual property; Business; International trade; Access to medicines; Political science; Public administration; Public economics; Economics; Economic growth; Finance; Health policy; Law; Medicine; Trade barrier; Health care","score_opus":0.08727949480308496,"score_gpt":0.35360049134526406,"score_spread":0.2663209965421791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508484044","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037130143,0.016232958,0.004223786,0.0693389,0.00074857933,0.00023569915,0.00035381856,0.00006300803,0.871673],"genre_scores_gemma":[0.6721953,0.020162923,0.007749417,0.03057186,0.00038064117,0.0004155515,0.00036453104,0.000085841035,0.268074],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98512983,0.0025400165,0.00037584413,0.0009889746,0.0071287937,0.0038366623],"domain_scores_gemma":[0.9901635,0.0027170365,0.0007644529,0.0004640687,0.0037560328,0.0021349164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051785754,0.00035427895,0.0003729975,0.0015904133,0.011606024,0.010780081,0.0011654678,0.0054162573,0.008520515],"category_scores_gemma":[0.01731463,0.000640317,0.0005775481,0.0038396774,0.010798886,0.0038344413,0.0050700284,0.0068353983,0.0005031533],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021349628,0.000030207284,0.0020335242,0.000087790206,0.000016064416,0.00029453624,0.0023652788,0.000801584,0.0001352417,0.95191294,0.027948603,0.014352798],"study_design_scores_gemma":[0.000043298693,0.000055276505,0.023746215,0.0007137444,0.000041041632,0.00022817231,0.0045688814,0.0028355143,0.00043277125,0.10883983,0.85839176,0.00010359157],"about_ca_topic_score_codex":0.9502378,"about_ca_topic_score_gemma":0.9400906,"teacher_disagreement_score":0.06755924,"about_ca_system_score_codex":0.06755924,"about_ca_system_score_gemma":0.25678435,"threshold_uncertainty_score":0.49017888},"labels":[],"label_agreement":null},{"id":"W2508878195","doi":"10.4269/ajtmh.16-0099","title":"The Tropical Disease Priority Review Voucher: A Game-Changer for Tropical Disease Products","year":2016,"lang":"en","type":"review","venue":"American Journal of Tropical Medicine and Hygiene","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute of Mining, Metallurgy and Petroleum","funders":"","keywords":"Tropical disease; Voucher; Bedaquiline; Neglected tropical diseases; Product (mathematics); Medicine; Disease; Malaria; Business; Environmental health; Tuberculosis; Immunology; Pathology; Mycobacterium tuberculosis","score_opus":0.09606949253072214,"score_gpt":0.3663003961777781,"score_spread":0.27023090364705593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508878195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033540052,0.9882996,0.00064999214,0.0022862153,0.0004333477,0.00008082589,0.000091127025,0.000027066159,0.007796459],"genre_scores_gemma":[0.006287378,0.9860524,0.0018426089,0.0015114227,0.00037390663,0.000083888124,0.00009949144,0.000011938488,0.003736842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993554,0.00021176979,0.000068293884,0.00005402357,0.00026877114,0.00004185429],"domain_scores_gemma":[0.99805874,0.0013226736,0.0002201223,0.00004493521,0.00025538652,0.00009807651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019487982,0.0004664188,0.0010026094,0.0024791828,0.00033453235,0.0015106314,0.0009513688,0.0015443352,0.008856826],"category_scores_gemma":[0.0040166765,0.00022861085,0.00085374626,0.002300663,0.0005297127,0.0015728171,0.0005914081,0.0011372952,0.0016013035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008285808,0.00007121116,0.00014263987,0.02611352,0.00018406585,0.0001178163,0.000061357074,0.0005069732,0.00048897107,0.02340165,0.073549494,0.8752794],"study_design_scores_gemma":[0.000057969086,0.000090186666,0.0006030485,0.009777104,0.00018092507,0.00036625465,0.000041100553,0.00019855217,0.00022338878,0.004820164,0.983624,0.000017280552],"about_ca_topic_score_codex":0.0016788545,"about_ca_topic_score_gemma":0.004454637,"teacher_disagreement_score":0.008856826,"about_ca_system_score_codex":0.0012241312,"about_ca_system_score_gemma":0.0022148,"threshold_uncertainty_score":0.029629052},"labels":[],"label_agreement":null},{"id":"W2513318489","doi":"10.1038/nbt.3664","title":"Which patent and where? Why international patent transparency by companies is needed for medicines","year":2016,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Business; Transparency (behavior); Patent law; International trade; Intellectual property; Political science; Law","score_opus":0.0531491252106876,"score_gpt":0.2750210722662557,"score_spread":0.22187194705556812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513318489","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014832469,0.017277507,0.008525099,0.91158724,0.0022621944,0.000026455225,0.00020984893,0.00011885822,0.04516032],"genre_scores_gemma":[0.8516806,0.010117322,0.0051640333,0.12105024,0.006628578,0.00006494127,0.00014312794,0.00025878294,0.004892415],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9654075,0.015605876,0.0024372195,0.002785498,0.009515792,0.004248121],"domain_scores_gemma":[0.7436679,0.1878506,0.025918672,0.0128732845,0.021448461,0.008241117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03821154,0.00040314897,0.0011752935,0.0023068506,0.0025720813,0.016839348,0.0014516043,0.013087472,0.012849405],"category_scores_gemma":[0.19117829,0.0005942247,0.0011323144,0.0021631317,0.013639857,0.02824651,0.0039377706,0.01833678,0.0016994624],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028996373,0.00007609652,0.0026394664,0.00053335796,0.000115346425,0.00023679876,0.0008003354,0.0013389335,0.00059499417,0.86124134,0.069444776,0.06268858],"study_design_scores_gemma":[0.00009741421,0.00004150984,0.0033211482,0.0008206452,0.000084865445,0.0002998984,0.00092869956,0.0019315155,0.0009471123,0.9137834,0.077662855,0.000081038896],"about_ca_topic_score_codex":0.004870111,"about_ca_topic_score_gemma":0.0026512218,"teacher_disagreement_score":0.03821154,"about_ca_system_score_codex":0.0063843327,"about_ca_system_score_gemma":0.0112279635,"threshold_uncertainty_score":0.20208436},"labels":[],"label_agreement":null},{"id":"W2516386876","doi":"","title":"South African Association of Pharmacists in Industry Report to the PSSA AGM","year":2016,"lang":"en","type":"article","venue":"South African Pharmaceutical Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Quarter (Canadian coin); Political science; General assembly; Public administration; Business; History; Law; Advertising; Archaeology","score_opus":0.07546944848336117,"score_gpt":0.32609067100979766,"score_spread":0.2506212225264365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516386876","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015054887,0.010905656,0.0006112428,0.7964841,0.03294483,0.00043146484,0.0041751727,0.0002951753,0.13909751],"genre_scores_gemma":[0.09249806,0.01528691,0.0012980419,0.16667323,0.012288707,0.0004839792,0.002780156,0.0002018426,0.70848906],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970692,0.00033820115,0.00018622265,0.00019783167,0.0014756249,0.0007329003],"domain_scores_gemma":[0.98877114,0.0013505858,0.00083822996,0.00030591912,0.004410122,0.0043240716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036050621,0.0003846432,0.0002868716,0.0010306872,0.00281349,0.0037800074,0.00066379854,0.0059297904,0.058224708],"category_scores_gemma":[0.010821838,0.0003607078,0.00038705376,0.0010364086,0.00055639556,0.0015787557,0.0023854203,0.0045450456,0.015814703],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003528493,0.000048189333,0.0024863104,0.000097507815,0.000006295953,0.0003363694,0.00013601716,0.000028113789,0.00017984462,0.0019408703,0.97740686,0.017298425],"study_design_scores_gemma":[0.0000150454325,0.000027186217,0.007707005,0.00012044803,0.0000059288855,0.00018729032,0.000422026,0.000059759197,0.00022327346,0.00027619596,0.9909469,0.000008865519],"about_ca_topic_score_codex":0.012142553,"about_ca_topic_score_gemma":0.015007994,"teacher_disagreement_score":0.058224708,"about_ca_system_score_codex":0.0022198344,"about_ca_system_score_gemma":0.018861698,"threshold_uncertainty_score":0.19478106},"labels":[],"label_agreement":null},{"id":"W2519124869","doi":"10.1186/s12992-016-0190-8","title":"ReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&amp;D) landscape","year":2016,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Engineers Without Borders Canada","funders":"World Health Organization; Open Society Foundations","keywords":"Redress; Health services research; Value (mathematics); Field (mathematics); Phase (matter); Health policy; Management science; Public relations; Computer science; Political science; Health care; Economics; Law","score_opus":0.4426786952154276,"score_gpt":0.4129090026843963,"score_spread":0.02976969253103129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519124869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9007021,0.001615395,0.007743162,0.009215016,0.00005412756,0.00020770259,0.00058221084,0.00019248958,0.079687774],"genre_scores_gemma":[0.9876966,0.00068653637,0.0058424757,0.00068775564,0.0000190721,0.00008518446,0.0002021028,0.0000659295,0.004714461],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9951774,0.0025226825,0.0001927127,0.0004629575,0.001146834,0.0004974695],"domain_scores_gemma":[0.9816767,0.010162431,0.0028343906,0.00241012,0.0019754635,0.0009409039],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.006944035,0.00023462545,0.00031157324,0.004008484,0.003412148,0.0051681087,0.00096688926,0.0012027073,0.0032003634],"category_scores_gemma":[0.022449434,0.00034803757,0.00051571673,0.0065310393,0.0036471526,0.0040332247,0.0040381104,0.0016641993,0.0005458151],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092520483,0.0010966697,0.20152374,0.0009836593,0.00012706943,0.0039899917,0.18602748,0.012180031,0.0065117525,0.2534575,0.016340515,0.31683633],"study_design_scores_gemma":[0.00017146161,0.0011114443,0.3399724,0.00075395533,0.000066892455,0.002387634,0.17495777,0.010551819,0.0059467247,0.090300515,0.37351897,0.0002604385],"about_ca_topic_score_codex":0.00809705,"about_ca_topic_score_gemma":0.010489824,"teacher_disagreement_score":0.9965879,"about_ca_system_score_codex":0.0031376607,"about_ca_system_score_gemma":0.0033466695,"threshold_uncertainty_score":0.03672397},"labels":[],"label_agreement":null},{"id":"W2520578273","doi":"10.1016/j.cjca.2016.08.010","title":"Drug Shortages: Patients and Health Care Providers Are All Drawing the Short Straw","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Workload; Economic shortage; Health care; Public health; Drug; Medical emergency; Intensive care medicine; Nursing; Psychiatry; Government (linguistics); Economic growth","score_opus":0.10218671265414604,"score_gpt":0.33189549667966345,"score_spread":0.22970878402551742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520578273","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002496826,0.91270345,0.00041803918,0.08183357,0.002636935,0.0000076085776,0.00004024722,0.000008273057,0.0021021743],"genre_scores_gemma":[0.007787014,0.9488513,0.0005915154,0.03396237,0.0074593076,0.000016747226,0.00005434802,0.000010323985,0.0012670951],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658513,0.0013002796,0.0003154504,0.00024629277,0.0012969421,0.00025595308],"domain_scores_gemma":[0.9772735,0.01602852,0.0020962518,0.00033855348,0.0029057853,0.0013573733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009266336,0.0007847841,0.0028243714,0.0025030584,0.0013934392,0.005270191,0.0016181545,0.0062560225,0.009691931],"category_scores_gemma":[0.018645858,0.00049887603,0.0008291822,0.004464172,0.004837497,0.008402407,0.003206105,0.008407919,0.0016353171],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015875287,0.0001147044,0.0012850445,0.011643056,0.00033822187,0.0001477527,0.00028965276,0.00045386702,0.000117866366,0.06220962,0.20991074,0.7133308],"study_design_scores_gemma":[0.00009688195,0.00007730963,0.0028426622,0.024435725,0.00022345528,0.0004449227,0.0009850026,0.00026290602,0.000069757436,0.057983354,0.9125267,0.000051281128],"about_ca_topic_score_codex":0.013269566,"about_ca_topic_score_gemma":0.034546435,"teacher_disagreement_score":0.013269566,"about_ca_system_score_codex":0.0045076353,"about_ca_system_score_gemma":0.015069861,"threshold_uncertainty_score":0.049005628},"labels":[],"label_agreement":null},{"id":"W2521193918","doi":"10.11604/pamj.2016.25.18.10658","title":"An appeal for large scale production of antiretroviral drugs in Africa","year":2016,"lang":"en","type":"article","venue":"Pan African Medical Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Civil Aviation Organization","funders":"","keywords":"Medicine; Economic growth; Government (linguistics); Pandemic; Sustainability; Antiretroviral treatment; Politics; Millennium Development Goals; Scale (ratio); Development economics; Public health; Developing country; Distribution (mathematics); Human immunodeficiency virus (HIV); Scarcity; Antiretroviral therapy; Coronavirus disease 2019 (COVID-19); Economics; Political science; Disease; Immunology; Nursing; Viral load; Market economy","score_opus":0.03428552310859228,"score_gpt":0.28879873179133153,"score_spread":0.25451320868273924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521193918","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04385964,0.04560209,0.03493011,0.4799903,0.0050438587,0.0002080796,0.0006478191,0.00039148677,0.3893267],"genre_scores_gemma":[0.83011967,0.025260575,0.016503468,0.042536728,0.009772056,0.00023967924,0.0002502991,0.00020810154,0.07510939],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840564,0.0006764707,0.000047520527,0.0002160333,0.00050782185,0.00014656252],"domain_scores_gemma":[0.99307877,0.0044508306,0.0006395873,0.00070799567,0.0006899553,0.00043279634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029793936,0.0003922463,0.00028459472,0.0009462031,0.0015044264,0.005117379,0.0004916792,0.0029833594,0.015680721],"category_scores_gemma":[0.013862671,0.00021733501,0.0005655707,0.0007650068,0.0024587216,0.0048090885,0.0020251733,0.0028081601,0.0017526537],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017724022,0.000073160416,0.001959065,0.000298115,0.0000358052,0.00076512736,0.00026411988,0.0019028686,0.0023698653,0.85655165,0.0646506,0.070952415],"study_design_scores_gemma":[0.00010019001,0.00015827277,0.004491192,0.00044145997,0.000037691945,0.00092182413,0.00040386262,0.0030517902,0.0017051763,0.2887031,0.6999396,0.000045762317],"about_ca_topic_score_codex":0.0018333558,"about_ca_topic_score_gemma":0.0013329326,"teacher_disagreement_score":0.015680721,"about_ca_system_score_codex":0.0024871991,"about_ca_system_score_gemma":0.0022130683,"threshold_uncertainty_score":0.052457273},"labels":[],"label_agreement":null},{"id":"W2521668303","doi":"10.21518/1561-5936-2013-7-8-88-91","title":"Top list of pharmaceutical companies by production volume in the 1st quarter of 2013","year":2013,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Volume (thermodynamics); Production (economics); Business; Commerce; Agricultural economics; Economics; Geography; Physics; Archaeology","score_opus":0.024673093949437102,"score_gpt":0.27993897671834045,"score_spread":0.25526588276890333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521668303","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06857934,0.09180511,0.0015757685,0.0102926465,0.008904683,0.00041158724,0.5252595,0.0059548584,0.2872166],"genre_scores_gemma":[0.18395494,0.08085246,0.0022997372,0.004300187,0.009203297,0.00028392414,0.32956433,0.0007747018,0.3887664],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99868864,0.000056444194,0.000112837966,0.00019351109,0.0006977194,0.00025075558],"domain_scores_gemma":[0.9962226,0.0003952695,0.0011164724,0.000091896385,0.0013121868,0.00086158735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004429298,0.0010219738,0.0010952662,0.010139922,0.00063974265,0.002768126,0.0007360858,0.0009063537,0.060194623],"category_scores_gemma":[0.0021860756,0.0003928145,0.00088780286,0.009953057,0.00023848303,0.0012572267,0.0007674895,0.0010593851,0.043317843],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037088577,0.0001228117,0.017303534,0.0016779864,0.00010767739,0.00021370854,0.000061246035,0.000274756,0.0017417673,0.0017674785,0.8859829,0.09037533],"study_design_scores_gemma":[0.0001527306,0.0002107198,0.15207164,0.00062462705,0.00010291545,0.00075341284,0.00021268342,0.0006921061,0.0025559117,0.0004308283,0.8421534,0.000038995007],"about_ca_topic_score_codex":0.003845248,"about_ca_topic_score_gemma":0.0035254932,"teacher_disagreement_score":0.060194623,"about_ca_system_score_codex":0.0007192978,"about_ca_system_score_gemma":0.001666127,"threshold_uncertainty_score":0.20137107},"labels":[],"label_agreement":null},{"id":"W2523601083","doi":"10.3851/imp3089","title":"Interchangeability between First-Line Generic Antiretroviral Products Prequalified by WHO using Adjusted Indirect Comparisons","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Universiteit Utrecht; World Health Organization","keywords":"Interchangeability; Medicine; Statistics; Antiretroviral therapy; Human immunodeficiency virus (HIV); Mathematics; Computer science; Viral load; Virology","score_opus":0.2677889492011937,"score_gpt":0.3342942277627913,"score_spread":0.06650527856159755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523601083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65757215,0.02901292,0.28225207,0.00052787934,0.00072867505,0.004676288,0.011784756,0.00032559628,0.013119589],"genre_scores_gemma":[0.9483538,0.0009615987,0.045861892,0.000119018965,0.000086828026,0.0016160811,0.0024580283,0.000073375115,0.0004693373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8207535,0.13206187,0.01672787,0.010881229,0.01810717,0.0014684533],"domain_scores_gemma":[0.7392174,0.20976144,0.027059667,0.016435986,0.007170687,0.0003548028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07952707,0.0017342352,0.0022109088,0.0034694162,0.00038685385,0.0024470552,0.0017355534,0.00086825155,0.0036757032],"category_scores_gemma":[0.15700822,0.00038339413,0.008379459,0.0048069092,0.0011927828,0.0019859362,0.0024263402,0.0018670976,0.00029992755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023782002,0.0005253757,0.4982992,0.011645077,0.11547731,0.0007924332,0.0037021548,0.019544307,0.005386583,0.017230943,0.0028062304,0.30080846],"study_design_scores_gemma":[0.00212704,0.020922327,0.729333,0.0022208402,0.063970976,0.0024762836,0.0018613397,0.07404183,0.03106179,0.038962603,0.032227676,0.0007942451],"about_ca_topic_score_codex":0.0015303456,"about_ca_topic_score_gemma":0.0011998924,"teacher_disagreement_score":0.07952707,"about_ca_system_score_codex":0.0014399292,"about_ca_system_score_gemma":0.0012192758,"threshold_uncertainty_score":0.42058438},"labels":[],"label_agreement":null},{"id":"W2523823607","doi":"10.1002/cpt.512","title":"Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision‐Making","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Real world evidence; Clinical decision making; Computer science; Data science; MEDLINE; Medical decision making; Management science; Medicine; Intensive care medicine; Engineering; Internal medicine; Political science; Medical emergency","score_opus":0.5963858748892129,"score_gpt":0.5456894304575541,"score_spread":0.05069644443165877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523823607","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003571938,0.0025058454,0.9746859,0.011019806,0.00019446746,0.0010317423,0.00072710816,0.00020803153,0.0060550994],"genre_scores_gemma":[0.16338474,0.0021221484,0.82598984,0.0020888115,0.00048240036,0.0041151894,0.00076355506,0.000082496306,0.00097080134],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8207498,0.15262567,0.0073418245,0.0074639088,0.010333055,0.0014857712],"domain_scores_gemma":[0.5767976,0.3862652,0.0125720715,0.012368539,0.009533102,0.0024635443],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.17343794,0.0036255969,0.0050655347,0.014270338,0.002250046,0.01599853,0.009920814,0.008959006,0.008470189],"category_scores_gemma":[0.30557352,0.002528903,0.005355897,0.013533403,0.015163199,0.016465371,0.010963294,0.0088625215,0.0011969164],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027601726,0.000207971,0.003718654,0.0013923877,0.00078782596,0.00061227265,0.0014635937,0.09870836,0.00020952417,0.82008934,0.0031093536,0.069424726],"study_design_scores_gemma":[0.00012028662,0.00011207777,0.00036277992,0.0005523035,0.00012567792,0.000119221986,0.00022842828,0.091491245,0.00018492143,0.89949137,0.007135887,0.00007574865],"about_ca_topic_score_codex":0.0071482826,"about_ca_topic_score_gemma":0.0043652887,"teacher_disagreement_score":0.82656205,"about_ca_system_score_codex":0.008820308,"about_ca_system_score_gemma":0.010667255,"threshold_uncertainty_score":0.9172385},"labels":[],"label_agreement":null},{"id":"W2525448133","doi":"10.1177/1741134316669967","title":"A comparison of mechanisms for setting generic drug prices in Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of Calgary","funders":"","keywords":"Reimbursement; Procurement; Benchmarking; Competition (biology); Business; Incentive; Discretion; Generic drug; Pharmacy; Public economics; Actuarial science; Drug; Industrial organization; Economics; Marketing; Microeconomics; Pharmacology; Medicine; Health care","score_opus":0.09433249734598782,"score_gpt":0.31471393864421765,"score_spread":0.22038144129822984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525448133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7022483,0.017749427,0.008212854,0.016352113,0.00025049664,0.001214909,0.008117628,0.0004452405,0.24540912],"genre_scores_gemma":[0.98394245,0.0037537557,0.0037108546,0.0007273199,0.000026058799,0.00008061703,0.0010847705,0.000033446948,0.006640822],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9912854,0.0010260908,0.00038682844,0.0004166191,0.0044231266,0.002461951],"domain_scores_gemma":[0.98898005,0.0028398728,0.0009695415,0.0003708961,0.0055725854,0.0012669951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004443487,0.00046877653,0.0006799741,0.0037552677,0.0039835996,0.005381864,0.0024508168,0.0011617551,0.004944932],"category_scores_gemma":[0.019774033,0.00047178715,0.0010401222,0.005991971,0.0015836615,0.0012774421,0.0015817101,0.0011722572,0.00024263965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026750218,0.0006044111,0.17302352,0.0026158714,0.00091032044,0.0011706959,0.0047417004,0.06047511,0.0038039712,0.4306134,0.06545798,0.25390807],"study_design_scores_gemma":[0.0011704717,0.0006930431,0.735766,0.0010016134,0.0013110472,0.00056690583,0.009684451,0.063518524,0.0050917547,0.015997909,0.16455646,0.0006417803],"about_ca_topic_score_codex":0.99286544,"about_ca_topic_score_gemma":0.99417454,"teacher_disagreement_score":0.16450296,"about_ca_system_score_codex":0.16450296,"about_ca_system_score_gemma":0.12783115,"threshold_uncertainty_score":0.96905816},"labels":[],"label_agreement":null},{"id":"W2526266002","doi":"10.1080/01436597.2016.1233491","title":"PATH: pioneering innovation for global health at the public–private interface","year":2016,"lang":"en","type":"article","venue":"Third World Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Balsillie School of International Affairs","funders":"GlaxoSmithKline; Bill and Melinda Gates Foundation","keywords":"Economic growth; Global health; Public health; Public relations; Multidisciplinary approach; Developing country; Business; Health care; Political science; Sociology; Economics; Medicine; Social science","score_opus":0.06120375483350839,"score_gpt":0.31810406611858594,"score_spread":0.25690031128507756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526266002","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010198882,0.024587434,0.0529296,0.45127648,0.00540292,0.00023267882,0.00026708742,0.0007534126,0.45435148],"genre_scores_gemma":[0.64521873,0.051851783,0.076942205,0.0659107,0.010245401,0.001075506,0.0003762506,0.0006697312,0.14770971],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99067956,0.005407789,0.00016403427,0.0008433525,0.0018307604,0.0010745075],"domain_scores_gemma":[0.9714604,0.019592153,0.0010002765,0.0028849274,0.0015629517,0.0034993386],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.02006942,0.00066220085,0.0005204652,0.001928608,0.0027262361,0.011910004,0.0012466266,0.008630218,0.026496127],"category_scores_gemma":[0.02199977,0.0003438216,0.0008504749,0.0019687037,0.013379097,0.016160209,0.009315089,0.010084182,0.004758313],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026194015,0.000041946027,0.00025977223,0.0001333117,0.000009011675,0.00009158745,0.00057038735,0.00036849777,0.00013340899,0.92392635,0.0391143,0.03532514],"study_design_scores_gemma":[0.00005201487,0.000082270795,0.0003236841,0.00047043557,0.000007750041,0.0001253718,0.0006586757,0.001099273,0.00028757355,0.49342483,0.50344646,0.000021687842],"about_ca_topic_score_codex":0.0014066296,"about_ca_topic_score_gemma":0.0014556167,"teacher_disagreement_score":0.99727374,"about_ca_system_score_codex":0.0060476027,"about_ca_system_score_gemma":0.014287849,"threshold_uncertainty_score":0.10613853},"labels":[],"label_agreement":null},{"id":"W2527343785","doi":"10.1016/j.cjca.2016.07.438","title":"ADVERSE EVENTS FOLLOWING GENERIC ANTIHYPERTENSIVE DRUGS COMMERCIALIZATION IN QUÉBEC","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Commercialization; Adverse effect; Drug; Brand names; Bioavailability; Pharmacology; Marketing; Business","score_opus":0.04502260531042499,"score_gpt":0.251639745957123,"score_spread":0.20661714064669803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527343785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691683,0.004563078,0.00024185514,0.005757979,0.000093983916,0.00008643758,0.009889554,0.000021451968,0.010177458],"genre_scores_gemma":[0.9939215,0.0011016179,0.000073893374,0.00057027105,0.000052952495,0.0000144454725,0.0014802451,0.0000049700757,0.002780129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867505,0.00029405023,0.00012393628,0.0001237381,0.00037153924,0.00041160075],"domain_scores_gemma":[0.9909276,0.0014308717,0.0033030615,0.00013377615,0.0027168037,0.0014878511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011627931,0.00017215543,0.00035396326,0.0010699277,0.0010627573,0.0017741236,0.0008607489,0.001016999,0.0048245057],"category_scores_gemma":[0.0065129865,0.00019277135,0.0008331351,0.0023547593,0.00049564603,0.0004889763,0.00055516604,0.0016948082,0.00021797068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049294013,0.000108108754,0.9833958,0.0000708033,0.00024998747,0.00042174265,0.00034193048,0.0007672682,0.00012376776,0.0005702522,0.004763218,0.008694255],"study_design_scores_gemma":[0.00003282229,0.000040564108,0.99693215,0.000028188815,0.0000437723,0.000054228105,0.00033785228,0.0009319105,0.000036324833,0.00003331393,0.0015175332,0.000011333521],"about_ca_topic_score_codex":0.98824906,"about_ca_topic_score_gemma":0.9885411,"teacher_disagreement_score":0.035563726,"about_ca_system_score_codex":0.035563726,"about_ca_system_score_gemma":0.01849792,"threshold_uncertainty_score":0.25803405},"labels":[],"label_agreement":null},{"id":"W2527450042","doi":"10.51847/9kqlr7e4f6","title":"10.51847/9kQlR7E4f6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Drug; Environmental regulation; Public economics; Pharmacology; Economics; Medicine","score_opus":0.029545278218479097,"score_gpt":0.22240923156837925,"score_spread":0.19286395334990014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527450042","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010680764,0.00045413268,0.0023991026,0.0011294978,0.0005680921,0.00013062652,0.0024638604,0.002830138,0.9889564],"genre_scores_gemma":[0.0031187362,0.00022935549,0.001183425,0.0003100727,0.00009984973,0.000047048237,0.0016221862,0.00050465134,0.9928846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993228,0.0000583042,0.00004590739,0.00017377907,0.00027064566,0.00012861204],"domain_scores_gemma":[0.9982481,0.00029215132,0.000114131195,0.00033280894,0.0006231979,0.00038964825],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010477159,0.0013992657,0.0009970104,0.0023175273,0.0011529428,0.003356497,0.0017086278,0.003915229,0.9733838],"category_scores_gemma":[0.0022021164,0.00044707756,0.0006563994,0.002070824,0.0008350557,0.0023652236,0.0027323854,0.001228429,0.9797234],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023471212,0.0001545061,0.00086679455,0.0003161154,0.000016180145,0.00024508184,0.00005886293,0.00041400912,0.004122645,0.0063849064,0.37291786,0.6142683],"study_design_scores_gemma":[0.000034206936,0.000037279486,0.00078016997,0.00011497004,0.0000069855687,0.00018517615,0.00003713029,0.00032567247,0.0008492301,0.0011281089,0.99648523,0.00001571852],"about_ca_topic_score_codex":0.0029170034,"about_ca_topic_score_gemma":0.002776558,"teacher_disagreement_score":0.026616216,"about_ca_system_score_codex":0.001198404,"about_ca_system_score_gemma":0.0007303892,"threshold_uncertainty_score":0.0379647},"labels":[],"label_agreement":null},{"id":"W2528798488","doi":"","title":"Regulatory requirements for generic drugs (ANDS) in Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Developing Drugs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Computational biology; Medicine; Pharmacology; Biology","score_opus":0.11564544587469897,"score_gpt":0.297484809420133,"score_spread":0.18183936354543404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528798488","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33612573,0.017001066,0.005892232,0.09325018,0.0013460078,0.0015208111,0.034158867,0.0008040898,0.5099011],"genre_scores_gemma":[0.9135116,0.0045703743,0.00530737,0.02442777,0.000415859,0.00021876184,0.0042012427,0.00015421276,0.047192764],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.976858,0.0019092989,0.0014636939,0.0012154712,0.012599163,0.0059543983],"domain_scores_gemma":[0.93768096,0.017549705,0.0052341074,0.0011614539,0.033066172,0.005307685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012515714,0.00041891786,0.0008364305,0.003903579,0.0032880765,0.0062746606,0.0035585535,0.003978342,0.006285075],"category_scores_gemma":[0.03672053,0.0008218678,0.0016714361,0.0035562736,0.0019854845,0.0008969683,0.0010299477,0.0030907907,0.00042329464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013164175,0.0003901865,0.08558482,0.0022343951,0.00044264863,0.0022727288,0.0029199172,0.035525665,0.010202704,0.43379083,0.30875945,0.11656022],"study_design_scores_gemma":[0.00048160256,0.00028167802,0.34669155,0.0015083114,0.00042395116,0.0008262658,0.0012062154,0.0161891,0.004677946,0.018173143,0.6090897,0.0004506008],"about_ca_topic_score_codex":0.9795027,"about_ca_topic_score_gemma":0.98299843,"teacher_disagreement_score":0.09785675,"about_ca_system_score_codex":0.09785675,"about_ca_system_score_gemma":0.1914747,"threshold_uncertainty_score":0.71000373},"labels":[],"label_agreement":null},{"id":"W2529647339","doi":"10.3138/9781442677609-007","title":"6. The Pharmaceutical Industry: Ending Canada's Compulsory Licensing Regime","year":2000,"lang":"en","type":"book-chapter","venue":"University of Toronto Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical industry; Business; Law and economics; Law; Political science; Economics; Medicine; Pharmacology","score_opus":0.0609606851332827,"score_gpt":0.24089337182394574,"score_spread":0.17993268669066304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529647339","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069537135,0.021041198,0.0010742296,0.11512846,0.0020007812,0.00010562714,0.0012212127,0.0001473708,0.8523274],"genre_scores_gemma":[0.08289191,0.006166687,0.0009805828,0.062630095,0.00055318006,0.0000711076,0.00026394796,0.00008459922,0.84635794],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9968251,0.0001548785,0.00005396825,0.0001809353,0.0014795222,0.0013056333],"domain_scores_gemma":[0.99808806,0.00035515957,0.00007027415,0.00006689409,0.0009895376,0.00043001858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012226461,0.0005945199,0.0003723382,0.0015229058,0.010019348,0.009356284,0.0014038861,0.01688105,0.025116615],"category_scores_gemma":[0.003611321,0.0005368776,0.0005774056,0.0019456152,0.003456201,0.0025652545,0.00142722,0.0060511637,0.0030006848],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021253389,0.000030285702,0.0006130171,0.00008528974,0.0000058153814,0.00016127233,0.0009947442,0.00022277197,0.00018692677,0.45183015,0.5273013,0.018547188],"study_design_scores_gemma":[0.000017490833,0.0000084814465,0.0027454507,0.00012994731,0.000010553972,0.000043737782,0.00032521438,0.00016448216,0.00021331926,0.013923117,0.98239094,0.000027243761],"about_ca_topic_score_codex":0.9694611,"about_ca_topic_score_gemma":0.99084187,"teacher_disagreement_score":0.94496095,"about_ca_system_score_codex":0.055039033,"about_ca_system_score_gemma":0.11561449,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2529976752","doi":"","title":"Le marketing pharmaceutique : les enjeux du développement et de la commercialisation des médicaments orphelins au Canada","year":2016,"lang":"fr","type":"article","venue":"Archipelago (Université du Québec à Montréal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.027468840949278508,"score_gpt":0.2509334307204122,"score_spread":0.22346458977113368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529976752","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0929066,0.24665897,0.012692257,0.0874008,0.002192943,0.00061709725,0.0057637193,0.00057629024,0.5511912],"genre_scores_gemma":[0.5406879,0.21156083,0.016678859,0.016288012,0.00090824877,0.0002675675,0.002937393,0.00032999428,0.21034126],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923808,0.00076940336,0.0001990889,0.0006888076,0.0049141957,0.0010476067],"domain_scores_gemma":[0.99108136,0.0016324916,0.0009111492,0.00025779972,0.0048995446,0.0012176464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042216755,0.000502392,0.00048683397,0.0032278558,0.004192502,0.0112110255,0.0011238492,0.0016982089,0.018364394],"category_scores_gemma":[0.008622947,0.00043217168,0.0006112759,0.0061660865,0.0032944384,0.0034294704,0.0017451838,0.0027757594,0.0018037295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059202133,0.00016911543,0.023416668,0.0030998318,0.00014368664,0.0009484553,0.0054719592,0.0014625598,0.0077065057,0.2537831,0.09428011,0.608926],"study_design_scores_gemma":[0.000033828117,0.00008142107,0.042478975,0.0013606646,0.00007289036,0.00033959665,0.0017089538,0.00069039484,0.0026122404,0.0040083867,0.9465336,0.0000788653],"about_ca_topic_score_codex":0.91314894,"about_ca_topic_score_gemma":0.9285646,"teacher_disagreement_score":0.08685106,"about_ca_system_score_codex":0.06936891,"about_ca_system_score_gemma":0.13646927,"threshold_uncertainty_score":0.503309},"labels":[],"label_agreement":null},{"id":"W253643620","doi":"10.1093/oxfordhb/9780199742998.013.0015","title":"Empirical Evidence on the Value of Pharmaceuticals","year":2012,"lang":"en","type":"book-chapter","venue":"Oxford University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Health benefits; Public economics; Value (mathematics); Medical prescription; Cost–benefit analysis; Empirical evidence; Health economics; Economics; Business; Actuarial science; Medicine; Health care; Pharmacology; Economic growth; Political science; Traditional medicine","score_opus":0.27135607638238374,"score_gpt":0.31447842886326915,"score_spread":0.04312235248088542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W253643620","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15170786,0.32491937,0.002329658,0.09635327,0.0009381276,0.00006546036,0.0087490035,0.00004723407,0.41489002],"genre_scores_gemma":[0.88421893,0.099806406,0.00043405278,0.0053882143,0.0012353716,0.000026726582,0.0025384356,0.00002374918,0.0063280948],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9932995,0.0026317027,0.00046515724,0.00052531174,0.0026226505,0.00045571593],"domain_scores_gemma":[0.7972602,0.1618888,0.024356743,0.0027404195,0.011531922,0.0022217561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061274725,0.00041639007,0.0008179242,0.005380238,0.00057920965,0.0058654915,0.0012720113,0.0017506726,0.02485365],"category_scores_gemma":[0.066137046,0.00030711028,0.00064294215,0.007027254,0.0029124706,0.0033472502,0.0013630833,0.0022791396,0.0017751743],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014143039,0.00051672535,0.26222625,0.009840471,0.0029094215,0.0019024216,0.00083591393,0.014053355,0.0003428141,0.39402938,0.08217395,0.22975492],"study_design_scores_gemma":[0.00051562604,0.0005066181,0.46713382,0.019934008,0.002309163,0.001517205,0.006020814,0.008400167,0.0017284213,0.17385696,0.3179196,0.00015758202],"about_ca_topic_score_codex":0.008647734,"about_ca_topic_score_gemma":0.006065738,"teacher_disagreement_score":0.02485365,"about_ca_system_score_codex":0.0032581121,"about_ca_system_score_gemma":0.0023126516,"threshold_uncertainty_score":0.08314371},"labels":[],"label_agreement":null},{"id":"W2547352560","doi":"10.4103/0253-7613.193309","title":"Assessment of knowledge and perceptions toward generic medicines among basic science undergraduate medical students at Aruba","year":2016,"lang":"en","type":"article","venue":"Indian Journal of Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Respondent; Test (biology); Likert scale; Family medicine; Nationality; Medical education; Psychology; Perception; Health care; Medicine; Demography; Geography","score_opus":0.04689818290394433,"score_gpt":0.3807402770403581,"score_spread":0.3338420941364138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547352560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993662,0.000069821435,0.0000140606635,0.00007455284,0.0000031031852,0.000011767097,0.000022432992,8.7585465e-7,0.0004372113],"genre_scores_gemma":[0.9993513,0.000121164136,0.000037219506,0.00006196129,0.000004557201,0.000010693936,0.000027989952,3.2670994e-7,0.00038483637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992576,0.00016660478,0.00006330815,0.000043716234,0.00024178583,0.00022695077],"domain_scores_gemma":[0.9977831,0.00039301542,0.0005621164,0.00004155639,0.0003379073,0.00088231696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011696696,0.00021658701,0.0003212022,0.000777778,0.000692095,0.000935049,0.00026466092,0.00059127767,0.0040894873],"category_scores_gemma":[0.003289008,0.00020558886,0.00034795597,0.0005151125,0.00042068548,0.00038246159,0.0006991329,0.0007172765,0.0005180444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012978379,0.0012958138,0.9723612,0.0001366024,0.000024407496,0.00031886625,0.007745222,0.000084176994,0.0015038457,0.00006969885,0.000345151,0.015985236],"study_design_scores_gemma":[0.000021901455,0.002269631,0.9756589,0.00008723907,0.000025627112,0.00039558782,0.019535575,0.00022747416,0.0005156005,0.000057505316,0.0011831885,0.000021657568],"about_ca_topic_score_codex":0.0040145237,"about_ca_topic_score_gemma":0.0039113425,"teacher_disagreement_score":0.0040894873,"about_ca_system_score_codex":0.0004922293,"about_ca_system_score_gemma":0.0012316088,"threshold_uncertainty_score":0.013680637},"labels":[],"label_agreement":null},{"id":"W2547467223","doi":"10.1080/14737167.2017.1256775","title":"Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa","year":2016,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Alternative medicine; Family medicine; Political science; Traditional medicine","score_opus":0.18886071628508216,"score_gpt":0.4957692279024389,"score_spread":0.3069085116173567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547467223","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.090942875,0.013707222,0.006307312,0.6557345,0.14494073,0.005230104,0.010231218,0.0002509703,0.07265509],"genre_scores_gemma":[0.40155932,0.018437719,0.017267324,0.1893282,0.0535852,0.010592534,0.011748917,0.00051574997,0.296965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965592,0.0013961354,0.00009888452,0.00020049883,0.00080608315,0.0009392556],"domain_scores_gemma":[0.9863651,0.0022302894,0.000670611,0.00022303798,0.0037169594,0.0067940047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02205124,0.0010220021,0.00055562344,0.00078455155,0.0021066542,0.0038419613,0.0008555517,0.005247656,0.012733397],"category_scores_gemma":[0.017688546,0.0003297155,0.0011077578,0.0005069857,0.00049844297,0.0013250792,0.003876634,0.005744881,0.0029341215],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017442802,0.0010731851,0.0053240047,0.0017028784,0.00013147817,0.0016187358,0.004686219,0.0004844865,0.0037524847,0.0033423766,0.92201453,0.054125417],"study_design_scores_gemma":[0.0005883032,0.00092584506,0.03609019,0.0011825669,0.0001183488,0.00022785715,0.007436633,0.0003588236,0.003059822,0.0020135026,0.9479136,0.00008441085],"about_ca_topic_score_codex":0.005364258,"about_ca_topic_score_gemma":0.010005675,"teacher_disagreement_score":0.02205124,"about_ca_system_score_codex":0.0034811012,"about_ca_system_score_gemma":0.011328773,"threshold_uncertainty_score":0.11661953},"labels":[],"label_agreement":null},{"id":"W2560037486","doi":"10.1503/cmaj.109-5363","title":"Brand-name drug costs expected to rise under CETA","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Brand names; European union; Computer science; Business; Agricultural economics; International trade; Marketing; Economics","score_opus":0.021766611679500985,"score_gpt":0.2551134863785143,"score_spread":0.2333468746990133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560037486","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.083776966,0.03894277,0.014712736,0.44653198,0.022025395,0.0003764903,0.02962198,0.0015305311,0.3624811],"genre_scores_gemma":[0.6328965,0.03436988,0.013156424,0.15060581,0.016550045,0.00032909546,0.023004508,0.00032901263,0.12875876],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954639,0.00059506117,0.00018381461,0.00023526665,0.0026105535,0.0009113792],"domain_scores_gemma":[0.99091035,0.0013752027,0.0015217259,0.00016588435,0.0032991257,0.0027276839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027231537,0.00070036727,0.00059456663,0.0015649832,0.001039831,0.0042880997,0.000971361,0.0060556047,0.029051442],"category_scores_gemma":[0.015376427,0.00028035796,0.0013924099,0.0015381002,0.0007589213,0.0025271538,0.0013224536,0.0050184466,0.010888987],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012670897,0.00037702976,0.018508129,0.0005488427,0.00016381456,0.0011447142,0.00012479111,0.004443704,0.002380286,0.1100512,0.6678512,0.1931392],"study_design_scores_gemma":[0.0003020912,0.00079874316,0.056865003,0.0013068143,0.00037195787,0.0034359845,0.00066716975,0.011017911,0.003976606,0.04689264,0.8741655,0.00019967218],"about_ca_topic_score_codex":0.02147718,"about_ca_topic_score_gemma":0.019230997,"teacher_disagreement_score":0.97852284,"about_ca_system_score_codex":0.007671082,"about_ca_system_score_gemma":0.0089277765,"threshold_uncertainty_score":0.097186804},"labels":[],"label_agreement":null},{"id":"W2561784549","doi":"","title":"Blame Canada (and the Rest of the World): The Twenty-Year War on Imported Prescription Drugs","year":2005,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blame; Rest (music); Medical prescription; Political science; Medicine; Psychiatry; Nursing; Internal medicine","score_opus":0.021297038549947096,"score_gpt":0.23265071818830552,"score_spread":0.2113536796383584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561784549","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1692841,0.024490887,0.002891595,0.42247853,0.0009565671,0.000044742697,0.0010782302,0.00014149697,0.3786338],"genre_scores_gemma":[0.8587608,0.015407982,0.0016476492,0.043953083,0.00038083238,0.000012279112,0.00034573648,0.00006279406,0.07942885],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9988858,0.000103032246,0.000014027124,0.00006353059,0.00046518218,0.00046834486],"domain_scores_gemma":[0.9982514,0.0003305232,0.00021790797,0.00006511312,0.0008527058,0.0002823604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010213461,0.00024579983,0.00025734137,0.0011340631,0.009106819,0.0069424603,0.0006501188,0.0026987393,0.006627829],"category_scores_gemma":[0.004102389,0.00015566884,0.00030327542,0.0017681413,0.0054006036,0.001893432,0.0012849977,0.003364754,0.00041502606],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100744895,0.00004945857,0.025094299,0.0001523251,0.0000559616,0.0010674385,0.0048435023,0.0024804196,0.0005486908,0.6545115,0.24010183,0.070993766],"study_design_scores_gemma":[0.000044841083,0.000045542496,0.05802251,0.000774513,0.00012503297,0.000496776,0.015080374,0.0042301435,0.0010732522,0.07184768,0.84811425,0.0001451098],"about_ca_topic_score_codex":0.9709966,"about_ca_topic_score_gemma":0.9795554,"teacher_disagreement_score":0.054893002,"about_ca_system_score_codex":0.054893002,"about_ca_system_score_gemma":0.07315263,"threshold_uncertainty_score":0.39827847},"labels":[],"label_agreement":null},{"id":"W2564973924","doi":"10.54648/bula2016013","title":"Parallel Trade in Pharmaceuticals: Re-Aligning National Patent Exhaustion and Life-Saving Drugs","year":2016,"lang":"en","type":"article","venue":"Business Law Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Intellectual property; Position (finance); Order (exchange); Law and economics; Economics; Access to medicines; International trade; Business; Public economics; Law; Political science; Finance","score_opus":0.19268689812017709,"score_gpt":0.33826957938159746,"score_spread":0.14558268126142038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564973924","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047276992,0.0752589,0.013645841,0.5369784,0.0032840578,0.00011286984,0.000071268914,0.00005252275,0.32331917],"genre_scores_gemma":[0.7702485,0.041798178,0.005663472,0.14743443,0.006989081,0.00012381881,0.000046468333,0.000043523887,0.027652517],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.987282,0.004992795,0.0009419218,0.0015755608,0.0037589928,0.0014487489],"domain_scores_gemma":[0.9438852,0.044915378,0.0042009824,0.0024312793,0.0037935392,0.00077368936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015984116,0.00029660852,0.0011088056,0.0024532182,0.0032037576,0.011168722,0.0019354821,0.020638999,0.0045977617],"category_scores_gemma":[0.036239967,0.00032139395,0.0010090821,0.0027091044,0.019324128,0.017119577,0.004204659,0.010658995,0.0005192138],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001848237,0.0000267038,0.00024184179,0.00007288326,0.000005882601,0.00015133826,0.0003018111,0.00026692127,0.0000883182,0.987253,0.004315889,0.0072568352],"study_design_scores_gemma":[0.000032456384,0.00009978943,0.0018943879,0.0008646344,0.000027912074,0.0003395464,0.0013274954,0.0017311625,0.0007377268,0.87093127,0.12197021,0.00004344358],"about_ca_topic_score_codex":0.005412809,"about_ca_topic_score_gemma":0.008260613,"teacher_disagreement_score":0.020638999,"about_ca_system_score_codex":0.0076621464,"about_ca_system_score_gemma":0.0107772695,"threshold_uncertainty_score":0.084533095},"labels":[],"label_agreement":null},{"id":"W2565558088","doi":"10.1097/qad.0000000000001369","title":"To break patent or not to break patent","year":2016,"lang":"de","type":"article","venue":"AIDS","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"U.S. President’s Emergency Plan for AIDS Relief; Université de Montréal; Brown University; Global Fund to Fight AIDS, Tuberculosis and Malaria","keywords":"Intellectual property; Blueprint; TRIPS architecture; Right to health; Government (linguistics); Negotiation; Disappointment; TRIPS Agreement; Exclusive right; Human rights; Political science; Law; International trade; Economic growth; Business; Economics; Engineering","score_opus":0.15245929378222314,"score_gpt":0.30345704587026573,"score_spread":0.15099775208804259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565558088","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023871174,0.023022404,0.0070287758,0.74647677,0.03215264,0.00012225163,0.00020008898,0.00044734086,0.18816265],"genre_scores_gemma":[0.081638776,0.0168037,0.0071524815,0.7866257,0.016347297,0.00026637997,0.0003171445,0.0005445523,0.09030395],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.96717024,0.011940262,0.0021725341,0.0042512952,0.010710499,0.0037551983],"domain_scores_gemma":[0.9471061,0.03181177,0.0031343538,0.006566821,0.0077485647,0.003632313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030096374,0.00083367067,0.0010842888,0.0012225384,0.004619779,0.015256987,0.0029460858,0.02417671,0.03072704],"category_scores_gemma":[0.10777444,0.00048711806,0.0013418818,0.0010674639,0.018419351,0.021805394,0.004475713,0.01835934,0.01473188],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057632373,0.00005085889,0.00033050272,0.0003693831,0.000028661212,0.00017101462,0.0014928933,0.0000973238,0.00051974657,0.4763897,0.4561358,0.06435652],"study_design_scores_gemma":[0.000026451393,0.000049241105,0.00021086689,0.00048505206,0.000015392543,0.00024252743,0.00090279547,0.00008042097,0.00032044473,0.09428333,0.9033468,0.00003680315],"about_ca_topic_score_codex":0.0031425373,"about_ca_topic_score_gemma":0.0029496022,"teacher_disagreement_score":0.03072704,"about_ca_system_score_codex":0.0030761021,"about_ca_system_score_gemma":0.0072921803,"threshold_uncertainty_score":0.1591667},"labels":[],"label_agreement":null},{"id":"W2574777418","doi":"","title":"Brand-name and Generic Drug Pricing in a Regulated Environment: Findings from Canadian Data","year":2012,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product differentiation; Profitability index; Competition (biology); Generic drug; Context (archaeology); Business; Product (mathematics); Market share; Quality (philosophy); Marketing; Brand names; Advertising; Economics; Industrial organization; Microeconomics; Drug; Finance","score_opus":0.09039875302109344,"score_gpt":0.308945340895767,"score_spread":0.21854658787467351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574777418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93699545,0.0025988347,0.00068496,0.00248882,0.000041313535,0.000098021286,0.043405257,0.00007694733,0.013610344],"genre_scores_gemma":[0.97580385,0.001144012,0.00059014873,0.0003815252,0.000016020433,0.000030015086,0.019809257,0.000053346062,0.0021717483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99412704,0.00059269136,0.00041244077,0.00078933407,0.0029747253,0.001103864],"domain_scores_gemma":[0.9601083,0.009711787,0.009270004,0.0029000056,0.01566413,0.0023458446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041499725,0.00048431463,0.0011062999,0.0041439603,0.002805184,0.0030143375,0.0020609607,0.000899347,0.0049192044],"category_scores_gemma":[0.034718867,0.00041803383,0.0011490608,0.020990413,0.0015232495,0.0013301191,0.0017986585,0.0014656989,0.000642941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048739812,0.00017626586,0.9503248,0.0003711703,0.00037746024,0.0003962398,0.0049011726,0.0010173112,0.00024860812,0.0046156826,0.01925468,0.017829254],"study_design_scores_gemma":[0.000035470817,0.000024807201,0.9852754,0.00008651135,0.000110384106,0.00009275943,0.0028322812,0.00124681,0.0001455251,0.00031231815,0.009768915,0.00006889721],"about_ca_topic_score_codex":0.9956126,"about_ca_topic_score_gemma":0.99610174,"teacher_disagreement_score":0.026286846,"about_ca_system_score_codex":0.026286846,"about_ca_system_score_gemma":0.0323285,"threshold_uncertainty_score":0.19072533},"labels":[],"label_agreement":null},{"id":"W2577762934","doi":"10.1016/j.hcmf.2012.09.014","title":"Les ruptures d'approvisionnement en médicaments: Les stratégies canadiennes pour un problème mondial complexe","year":2012,"lang":"fr","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.06934214974738728,"score_gpt":0.310047422528066,"score_spread":0.24070527278067871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577762934","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036133334,0.13024992,0.039755315,0.66334194,0.005265952,0.000914687,0.0002196036,0.00054371357,0.123575516],"genre_scores_gemma":[0.5338236,0.19927959,0.07624349,0.0788996,0.0033671937,0.0011945153,0.00036834733,0.0003409178,0.10648279],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9737065,0.010426955,0.0014008373,0.001985321,0.008981862,0.0034985547],"domain_scores_gemma":[0.95229495,0.015874296,0.0065478636,0.0026888684,0.015791364,0.006802571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027190957,0.0015929927,0.001253187,0.0043033767,0.011175259,0.019142136,0.004694819,0.0087169,0.01515586],"category_scores_gemma":[0.053150147,0.00082262815,0.0018484392,0.0043083727,0.011047944,0.009476667,0.010171578,0.010490522,0.0027167122],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023909843,0.0005138022,0.022431867,0.0050312737,0.00041874673,0.0029994966,0.03150105,0.002721618,0.0017030614,0.15824442,0.07647149,0.69772404],"study_design_scores_gemma":[0.00005634591,0.00051782676,0.011764256,0.008243252,0.00024103768,0.0025398158,0.048561938,0.0013269532,0.0020355647,0.058176897,0.86634165,0.00019447897],"about_ca_topic_score_codex":0.12748258,"about_ca_topic_score_gemma":0.1683839,"teacher_disagreement_score":0.9734534,"about_ca_system_score_codex":0.026546625,"about_ca_system_score_gemma":0.09178742,"threshold_uncertainty_score":0.25348115},"labels":[],"label_agreement":null},{"id":"W2582303529","doi":"10.1371/journal.pmed.1002191","title":"What Is the Purpose of the Orphan Drug Act?","year":2017,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Orphan drug; Drug; Medicine; Pharmacology; Bioinformatics; Biology","score_opus":0.09471316794752938,"score_gpt":0.3094459043501145,"score_spread":0.2147327364025851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582303529","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009022794,0.009775503,0.0006586521,0.9622957,0.008146076,0.0000076278743,0.00009214192,0.00003773561,0.018084336],"genre_scores_gemma":[0.037227415,0.013291566,0.001694584,0.9150284,0.0067684813,0.000053173557,0.000103475875,0.00010862519,0.025724307],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9860166,0.005264437,0.0008294792,0.0013440083,0.004816646,0.0017288425],"domain_scores_gemma":[0.9625508,0.025778975,0.0019672846,0.0015112015,0.0057002325,0.0024915799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020134315,0.00053637096,0.0011341117,0.0011839861,0.0044693477,0.0103292875,0.0022167398,0.019368103,0.0068861283],"category_scores_gemma":[0.060581367,0.00042664405,0.0011239005,0.0013580782,0.013054875,0.012520176,0.0027266897,0.022245094,0.0026966918],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070196314,0.000030620646,0.0009853224,0.00012733902,0.00002594298,0.00014489662,0.0005794975,0.000116633084,0.000114585186,0.5543457,0.42565504,0.01780422],"study_design_scores_gemma":[0.000024702225,0.000038211714,0.0013197754,0.00065908016,0.00003114288,0.00013548379,0.00089732703,0.00023942895,0.0003329902,0.08446585,0.9117857,0.00007035742],"about_ca_topic_score_codex":0.028261889,"about_ca_topic_score_gemma":0.028320784,"teacher_disagreement_score":0.028261889,"about_ca_system_score_codex":0.005593613,"about_ca_system_score_gemma":0.016730852,"threshold_uncertainty_score":0.10648173},"labels":[],"label_agreement":null},{"id":"W2582669396","doi":"10.1257/aer.p20171086","title":"Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs","year":2017,"lang":"en","type":"article","venue":"American Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Common Fund; NIH Office of the Director; National Institute on Aging; National Science Foundation; National Institutes of Health; Pfizer","keywords":"Medical prescription; Quality (philosophy); Health care; Prescription drug; Drug; Medicine; Actuarial science; Business; Political science; Pharmacology; Law; Philosophy; Epistemology","score_opus":0.09844971992391113,"score_gpt":0.3812103827982905,"score_spread":0.2827606628743794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582669396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81068546,0.050806962,0.004356475,0.04883614,0.00020205868,0.000110260335,0.003088863,0.0000334008,0.08188042],"genre_scores_gemma":[0.9812563,0.010307772,0.0006371496,0.0059102247,0.00023392262,0.00003264305,0.00062667904,0.000016402377,0.0009789927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98686767,0.0071868477,0.0008824913,0.0013007416,0.0025942835,0.0011680356],"domain_scores_gemma":[0.8681303,0.07347717,0.035336915,0.0089126285,0.010583048,0.0035598967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01478081,0.00041022451,0.0017385556,0.0042349203,0.0018050022,0.0041841967,0.001351812,0.002078193,0.0080215465],"category_scores_gemma":[0.08033936,0.00053817075,0.001084356,0.008315991,0.00501139,0.0035353268,0.0033041982,0.002301045,0.0006769932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019175856,0.0004819954,0.7596541,0.001749093,0.0023880617,0.00053385546,0.0024804492,0.003168745,0.00027545122,0.12624855,0.01870923,0.08239281],"study_design_scores_gemma":[0.00092185073,0.00055684417,0.875196,0.0027916469,0.0029239974,0.00083478604,0.0078213075,0.0029718908,0.0011703961,0.05235631,0.05232171,0.00013327782],"about_ca_topic_score_codex":0.04458763,"about_ca_topic_score_gemma":0.027947357,"teacher_disagreement_score":0.04458763,"about_ca_system_score_codex":0.0030188118,"about_ca_system_score_gemma":0.002625592,"threshold_uncertainty_score":0.08865625},"labels":[],"label_agreement":null},{"id":"W2582749134","doi":"10.1007/s41669-017-0013-8","title":"Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”","year":2017,"lang":"en","type":"letter","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Economics; Financial economics; Econometrics","score_opus":0.2637735742554665,"score_gpt":0.4504590824979789,"score_spread":0.1866855082425124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582749134","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000086073436,0.001018902,0.000055400524,0.9845405,0.013793971,0.0000073376373,0.00007649932,0.000012682569,0.00040858667],"genre_scores_gemma":[0.00082139065,0.00058549846,0.0000805578,0.98102784,0.016474638,0.000019404471,0.000014119787,0.00001181466,0.00096484105],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99337703,0.00210036,0.0014270365,0.0008188141,0.0017370303,0.0005397425],"domain_scores_gemma":[0.9566413,0.028175,0.0033584177,0.0008930675,0.008830166,0.0021020852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009282969,0.00079361186,0.0020010455,0.0012316046,0.0024519209,0.0037321243,0.002357991,0.049518324,0.0061359163],"category_scores_gemma":[0.07342687,0.00097383367,0.0019286401,0.0015598974,0.0028171088,0.0045147277,0.0017520139,0.04611826,0.007872386],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005994215,0.000009923575,0.0002621756,0.0000791844,0.000016212967,0.00032192716,0.000087112814,0.00002922286,0.00006090068,0.0010992775,0.9945221,0.0034520635],"study_design_scores_gemma":[0.00021864861,0.0000783984,0.0016807761,0.0012192548,0.000081905615,0.0018075933,0.00055028254,0.00045856618,0.00048738782,0.009798539,0.9834471,0.00017148166],"about_ca_topic_score_codex":0.0061531872,"about_ca_topic_score_gemma":0.008082881,"teacher_disagreement_score":0.049518324,"about_ca_system_score_codex":0.0046371534,"about_ca_system_score_gemma":0.0066009657,"threshold_uncertainty_score":0.049093604},"labels":[],"label_agreement":null},{"id":"W2586280892","doi":"10.18192/uojm.v7i1.1438","title":"Is Brand Name Best? Brand name versus generic pharmaceuticals in clinical practice","year":2017,"lang":"en","type":"article","venue":"University of Ottawa Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Brand names; Political science; Humanities; Medicine; Business; Advertising; Art","score_opus":0.17279746123905682,"score_gpt":0.39618807524055144,"score_spread":0.22339061400149463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586280892","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006977241,0.044669963,0.0007975394,0.91157126,0.0014313295,0.000020969414,0.00013096775,0.000013237646,0.03438748],"genre_scores_gemma":[0.6103661,0.0634228,0.0016834425,0.30717838,0.010342365,0.00004832165,0.00011743981,0.00007498521,0.0067661237],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.97034675,0.013154299,0.0016804407,0.0030080155,0.008456268,0.0033542213],"domain_scores_gemma":[0.906794,0.056339793,0.008379825,0.003063608,0.01652977,0.008893095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025829682,0.00022240597,0.001189957,0.0020423916,0.003780864,0.012978294,0.0015721029,0.008456927,0.010999816],"category_scores_gemma":[0.11927263,0.00036424265,0.00061586354,0.0032531004,0.021998994,0.011772139,0.0022454413,0.006803545,0.00089344394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000451215,0.00012264236,0.022438375,0.0020853407,0.00019154063,0.00055505155,0.007243122,0.0006156483,0.00024582556,0.60806835,0.1802012,0.1777817],"study_design_scores_gemma":[0.00040526903,0.00032502186,0.04206751,0.009997994,0.0002723489,0.0010026512,0.016721288,0.001327812,0.00045726495,0.46062112,0.46657625,0.0002254304],"about_ca_topic_score_codex":0.18945378,"about_ca_topic_score_gemma":0.2312455,"teacher_disagreement_score":0.18945378,"about_ca_system_score_codex":0.029650657,"about_ca_system_score_gemma":0.03344648,"threshold_uncertainty_score":0.37670207},"labels":[],"label_agreement":null},{"id":"W2587542073","doi":"10.1093/ndt/gfw135.03","title":"MO031IS THE INCIDENCE OF RENAL REPLACEMENT THERAPY IN WESTERNIZED COUNTRIES DECLINING?","year":2016,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Renal replacement therapy; Incidence (geometry); Intensive care medicine; Internal medicine","score_opus":0.03616128925059323,"score_gpt":0.2869231237212905,"score_spread":0.2507618344706972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587542073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.941499,0.016174251,0.0005125437,0.012396364,0.00016131057,0.00003063492,0.013056728,0.00003479525,0.016134445],"genre_scores_gemma":[0.9884702,0.0055109486,0.00047303113,0.00095208164,0.00018214708,0.000030425173,0.0035951047,0.000009571315,0.0007763642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934727,0.00020625358,0.00012315318,0.00010899421,0.00011752243,0.00009677011],"domain_scores_gemma":[0.9960445,0.0005618673,0.0026259234,0.00011247076,0.00044215788,0.00021315699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012105596,0.00012124104,0.00029200607,0.0015538816,0.00016507473,0.001252567,0.00030687643,0.00031156314,0.0021637916],"category_scores_gemma":[0.0060175722,0.00011380832,0.00033049568,0.005188839,0.00038519767,0.0006014758,0.00035070613,0.00045718363,0.00029103967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056278102,0.000015031751,0.9823299,0.00012255175,0.00008441183,0.00008831525,0.00020739988,0.00014806264,0.000046130393,0.0008330276,0.0027352294,0.013333795],"study_design_scores_gemma":[0.0000048391007,0.000017527738,0.99381775,0.0001264847,0.000032927823,0.00015731968,0.00037444776,0.00019302363,0.00003426029,0.0001670227,0.005070635,0.0000037165848],"about_ca_topic_score_codex":0.032923438,"about_ca_topic_score_gemma":0.024084382,"teacher_disagreement_score":0.032923438,"about_ca_system_score_codex":0.0007242503,"about_ca_system_score_gemma":0.0010885799,"threshold_uncertainty_score":0.0654636},"labels":[],"label_agreement":null},{"id":"W2588195939","doi":"10.1093/eurpub/ckw169.001","title":"Examining the unanticipated effects of public-private partnerships for preventing chronic disease","year":2016,"lang":"en","type":"article","venue":"European Journal of Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada; Impact; University of Waterloo","funders":"","keywords":"Disease; Medicine; Chronic disease; Intensive care medicine; Business; Internal medicine","score_opus":0.3635397401906284,"score_gpt":0.35317790156311907,"score_spread":0.010361838627509334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588195939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88832384,0.007128195,0.0030892293,0.039773047,0.00024866915,0.0008446534,0.00012889385,0.00002401645,0.060439546],"genre_scores_gemma":[0.9972996,0.0009083689,0.00056980725,0.0007783871,0.00001764099,0.00013017263,0.000007452112,0.000003970115,0.00028459256],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.88209224,0.10081352,0.0018824263,0.0015171206,0.0071139284,0.0065807574],"domain_scores_gemma":[0.7289653,0.21984355,0.023558915,0.0061913244,0.013821025,0.00761988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.099772304,0.0003470294,0.00036576344,0.0017458268,0.0063648764,0.00630998,0.0017567505,0.0014921345,0.0036396976],"category_scores_gemma":[0.12363743,0.00043853358,0.0005989967,0.0016620845,0.009725926,0.0061249896,0.009495543,0.0028137767,0.00014008724],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006708052,0.001999845,0.28181577,0.005484748,0.0003981863,0.0015567399,0.31167704,0.0015410013,0.0012912523,0.11867061,0.008133621,0.26676035],"study_design_scores_gemma":[0.00026170193,0.0019265844,0.24254216,0.0063598906,0.0005232978,0.0007528463,0.6419757,0.0020836152,0.002574544,0.0239993,0.076900996,0.00009926466],"about_ca_topic_score_codex":0.01287084,"about_ca_topic_score_gemma":0.035063885,"teacher_disagreement_score":0.099772304,"about_ca_system_score_codex":0.014565458,"about_ca_system_score_gemma":0.026340773,"threshold_uncertainty_score":0.5276527},"labels":[],"label_agreement":null},{"id":"W2589088062","doi":"10.1016/j.healthpol.2017.02.002","title":"Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia","year":2017,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of British Columbia; Commonwealth Fund","keywords":"Confidentiality; Negotiation; Business; Statutory law; Discounting; Public health; Revenue; Public economics; Actuarial science; Marketing; Economics; Law; Finance; Medicine; Political science; Nursing","score_opus":0.15116486108529856,"score_gpt":0.3988349864480218,"score_spread":0.24767012536272323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589088062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972516,0.000184472,0.00007019779,0.0013891106,0.0000070078827,0.0000119192755,0.00003601644,0.0000022300067,0.0010474194],"genre_scores_gemma":[0.99903274,0.00019334881,0.000072051414,0.00045885314,0.000011097641,0.000008014383,0.000023801265,0.0000018108851,0.00019832865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99336493,0.003551532,0.00063792133,0.00029161994,0.001161294,0.0009926407],"domain_scores_gemma":[0.9594565,0.014662046,0.017802294,0.0010190884,0.0023033826,0.0047565848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00807242,0.00013777282,0.00032704134,0.00085195113,0.0016236316,0.002258391,0.00049941486,0.0010374734,0.002406202],"category_scores_gemma":[0.02862065,0.00045263895,0.00039167734,0.0011168997,0.0015844143,0.0020390858,0.0019845304,0.0017387923,0.00018485611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018946556,0.00041207907,0.7490684,0.00013513054,0.00006970068,0.00085936894,0.21634662,0.00016199776,0.00093954784,0.00088932214,0.0025223738,0.028406112],"study_design_scores_gemma":[0.000032229906,0.00050571543,0.69357437,0.00019682411,0.00002615634,0.0011502447,0.2938584,0.0005935842,0.00024502494,0.0003569855,0.009393859,0.00006657494],"about_ca_topic_score_codex":0.021118335,"about_ca_topic_score_gemma":0.018354472,"teacher_disagreement_score":0.021118335,"about_ca_system_score_codex":0.0020271093,"about_ca_system_score_gemma":0.0026552824,"threshold_uncertainty_score":0.04269153},"labels":[],"label_agreement":null},{"id":"W2589546335","doi":"10.1177/1715163517691254","title":"The misrepresentation of high drug costs","year":2017,"lang":"fr","type":"editorial","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Misrepresentation; Drug; Business; Pharmacology; Medicine; Political science; Law","score_opus":0.04023179273685439,"score_gpt":0.28747116861362493,"score_spread":0.24723937587677053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589546335","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000088066765,0.010912323,0.00015298113,0.33075565,0.6552311,0.000008284961,0.00015882356,0.000044944638,0.0026478118],"genre_scores_gemma":[0.0024682994,0.0069127786,0.00013277016,0.11553708,0.870445,0.000017558894,0.00004362544,0.000054070144,0.004388836],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97393024,0.005094825,0.0025857622,0.0020884438,0.01479296,0.0015077656],"domain_scores_gemma":[0.84489846,0.10416571,0.0075724167,0.0042734793,0.03391643,0.005173515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024115857,0.0030094648,0.0040007075,0.00717376,0.004425358,0.012568995,0.0060356217,0.043193135,0.009627253],"category_scores_gemma":[0.16049671,0.0014992374,0.0029140136,0.005919068,0.010325556,0.00679551,0.0027945694,0.03754793,0.0041909055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001635363,0.0000035503733,0.000037720452,0.00012272266,0.000030778963,0.000070103284,0.00003122328,0.000020011985,0.000011472053,0.0012362347,0.9949302,0.0034896962],"study_design_scores_gemma":[0.00008949935,0.000016136213,0.00080818264,0.001552265,0.00014354796,0.00023695831,0.0001694324,0.0002586178,0.00012688607,0.0050324667,0.99151176,0.000054280838],"about_ca_topic_score_codex":0.029232377,"about_ca_topic_score_gemma":0.043078575,"teacher_disagreement_score":0.043193135,"about_ca_system_score_codex":0.013423594,"about_ca_system_score_gemma":0.0121412035,"threshold_uncertainty_score":0.12753838},"labels":[],"label_agreement":null},{"id":"W2590702803","doi":"10.1200/jco.2013.31.31_suppl.192","title":"Managing chemotherapy drug shortages in Ontario.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Economic shortage; Chemotherapy; Drug; Intensive care medicine; Surgery; Pharmacology","score_opus":0.191689334561121,"score_gpt":0.43035365550137833,"score_spread":0.23866432094025733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590702803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5302069,0.02174277,0.0024918178,0.20017347,0.001497483,0.001510055,0.004951322,0.00051554805,0.23691069],"genre_scores_gemma":[0.87807757,0.015893046,0.004946087,0.022717854,0.0005827822,0.00047026345,0.0026312897,0.0001512938,0.07452969],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99895763,0.000083758656,0.000060103182,0.00006449692,0.00034781903,0.00048613083],"domain_scores_gemma":[0.9951815,0.00023641608,0.00081498775,0.000056650806,0.00098832,0.002722054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008245061,0.00021719436,0.00012523787,0.0005997082,0.0044861776,0.0014357605,0.0009813163,0.000892835,0.012046211],"category_scores_gemma":[0.0025781756,0.00033467275,0.0002601939,0.0017564931,0.001057687,0.00070345204,0.002611332,0.0008540262,0.0006466989],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041343548,0.0003266501,0.33969083,0.0021615874,0.00008969464,0.012050928,0.013441397,0.0025558022,0.0034076194,0.005780384,0.3654049,0.25467667],"study_design_scores_gemma":[0.0001168988,0.00031942374,0.40006307,0.0006016379,0.000040467046,0.0025627504,0.010737273,0.0013989441,0.00047594676,0.001134493,0.58249557,0.00005349777],"about_ca_topic_score_codex":0.91761845,"about_ca_topic_score_gemma":0.9692368,"teacher_disagreement_score":0.95598805,"about_ca_system_score_codex":0.04401198,"about_ca_system_score_gemma":0.11535167,"threshold_uncertainty_score":0.31933075},"labels":[],"label_agreement":null},{"id":"W2590797524","doi":"10.1080/13543776.2017.1296950","title":"Patent disclosure requirements for therapeutic antibody patents","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Antibody; Pharmacology; Medicine; Immunology","score_opus":0.6197336892953145,"score_gpt":0.48238085560467564,"score_spread":0.13735283369063883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590797524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021621718,0.8701632,0.0047743022,0.027505986,0.0017771636,0.00025942692,0.0018564487,0.00008168393,0.09141958],"genre_scores_gemma":[0.07153792,0.8857454,0.0056363847,0.014564889,0.0040972363,0.0005147375,0.002645612,0.00003577533,0.015222019],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879881,0.0032691404,0.0015889757,0.0008256047,0.005843628,0.0004845192],"domain_scores_gemma":[0.9597558,0.028991323,0.0061497795,0.00076640095,0.0040173545,0.0003194259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009971257,0.00052729744,0.001106944,0.0032281284,0.00058179215,0.0028353904,0.0018175426,0.005046458,0.022604693],"category_scores_gemma":[0.03964463,0.0002620144,0.0012894707,0.0026743053,0.0016139975,0.0028001494,0.0011237063,0.002870592,0.003494859],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013016447,0.000055894325,0.000698982,0.02218823,0.00013480961,0.00065019645,0.00022790307,0.0009870452,0.001228761,0.1655979,0.11257071,0.6955294],"study_design_scores_gemma":[0.000049122944,0.00008771496,0.0021021608,0.016326735,0.00014606191,0.0015753851,0.000081161226,0.00021153511,0.00087672396,0.023704642,0.9548077,0.00003107881],"about_ca_topic_score_codex":0.0025826576,"about_ca_topic_score_gemma":0.0017954472,"teacher_disagreement_score":0.022604693,"about_ca_system_score_codex":0.0020160722,"about_ca_system_score_gemma":0.0062697716,"threshold_uncertainty_score":0.07562029},"labels":[],"label_agreement":null},{"id":"W2593759362","doi":"10.3821/1913-701x-143.2.96","title":"The Sale of Non-Approved Marketed Health Products — A Regulatory Perspective","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Business; Marketing; Computer science","score_opus":0.0349640961202045,"score_gpt":0.2699871753106098,"score_spread":0.23502307919040527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593759362","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030030644,0.08314394,0.012842877,0.2410886,0.0014366851,0.00022633915,0.0012342653,0.000108456596,0.6298882],"genre_scores_gemma":[0.7576587,0.07801167,0.0051689344,0.07375542,0.009254883,0.00016388446,0.00051356415,0.00011792577,0.075354904],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.988991,0.0026050312,0.0004075071,0.00127712,0.0050210613,0.0016982419],"domain_scores_gemma":[0.9629321,0.021902503,0.0032865661,0.0010603091,0.009278827,0.0015396129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009154679,0.00095629616,0.0016389935,0.0052015404,0.0031609386,0.016310647,0.004080081,0.021214252,0.010961603],"category_scores_gemma":[0.020566648,0.0011171497,0.002457971,0.0030200405,0.014336686,0.00672462,0.0016694043,0.010782065,0.00091016275],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014104224,0.00017592506,0.0021404258,0.00034497707,0.000075191456,0.0009836798,0.00034411586,0.0033199086,0.0013454205,0.9402225,0.027372817,0.023533927],"study_design_scores_gemma":[0.00023239672,0.0005686088,0.03592619,0.0026191701,0.00034410268,0.0017795523,0.0018942695,0.014044759,0.00270643,0.40228936,0.5372969,0.00029820812],"about_ca_topic_score_codex":0.27895445,"about_ca_topic_score_gemma":0.29206142,"teacher_disagreement_score":0.97411126,"about_ca_system_score_codex":0.025888763,"about_ca_system_score_gemma":0.03001568,"threshold_uncertainty_score":0.5546615},"labels":[],"label_agreement":null},{"id":"W2594076047","doi":"10.1503/cmaj.161082","title":"Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Essential medicines; Government (linguistics); Medical prescription; Essential drugs; Medicine; Public health; Generic drug; Business; Environmental health; Drug; Pharmacology; Population; Health services","score_opus":0.03224340550308577,"score_gpt":0.27353159747386263,"score_spread":0.24128819197077686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594076047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8938164,0.0063202037,0.0059707747,0.0050227013,0.00015566815,0.0008687442,0.064917095,0.0003542709,0.022574127],"genre_scores_gemma":[0.98646045,0.00104486,0.0029390247,0.0003598061,0.000020488163,0.00011117799,0.006909713,0.000014686605,0.002139931],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9957457,0.0011076371,0.00022543823,0.00049814227,0.0011974026,0.0012257115],"domain_scores_gemma":[0.9920682,0.0029802455,0.0010387809,0.000273335,0.0031817737,0.0004576867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037421728,0.0009890411,0.0010872927,0.0016472184,0.000680235,0.0015480084,0.0015703322,0.00063512527,0.0035587738],"category_scores_gemma":[0.014479036,0.0005354408,0.0027395475,0.0027498938,0.00067610794,0.0007935041,0.001422403,0.0019973419,0.00020961052],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018661288,0.00027545606,0.42577538,0.0008427874,0.0033143095,0.00045393355,0.00017848182,0.49841473,0.0005308443,0.010881063,0.0114785135,0.045988332],"study_design_scores_gemma":[0.0009906914,0.00084146747,0.6086788,0.0005228327,0.0051884167,0.0002713278,0.0011039951,0.35067034,0.0025256656,0.0042755706,0.02475804,0.00017279685],"about_ca_topic_score_codex":0.9861666,"about_ca_topic_score_gemma":0.9698608,"teacher_disagreement_score":0.919727,"about_ca_system_score_codex":0.08027297,"about_ca_system_score_gemma":0.05018142,"threshold_uncertainty_score":0.5824239},"labels":[],"label_agreement":null},{"id":"W2594128595","doi":"10.1038/543174a","title":"Show drugs work before selling them","year":2017,"lang":"en","type":"article","venue":"Nature","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Work (physics); Business; Chemistry; Engineering","score_opus":0.050694209092408765,"score_gpt":0.29551176398356355,"score_spread":0.24481755489115478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594128595","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0783058,0.019354345,0.010969015,0.25522062,0.008130226,0.00023152633,0.0032232099,0.0006599201,0.6239053],"genre_scores_gemma":[0.7372793,0.008572133,0.0041442346,0.05064755,0.0029012775,0.00013538284,0.000905137,0.00026748143,0.19514748],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959401,0.0015576878,0.00015073178,0.00037048606,0.0015062953,0.00047473572],"domain_scores_gemma":[0.9770553,0.015206592,0.0028284502,0.0013657665,0.0021534485,0.0013904438],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004279464,0.0005029888,0.00087378186,0.00085109466,0.0016959688,0.0058860527,0.00072425406,0.006375497,0.07000924],"category_scores_gemma":[0.026771873,0.00039781828,0.0007121235,0.0013794532,0.002904221,0.007204326,0.0012761232,0.004185027,0.0132762045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011693854,0.00068124157,0.016329817,0.0009523851,0.0003193157,0.00033130104,0.0005091317,0.0031614294,0.0031094563,0.5348665,0.2872158,0.15135424],"study_design_scores_gemma":[0.00030699288,0.00061313587,0.029104343,0.000476995,0.000305864,0.00031969094,0.0014741154,0.0036388645,0.0069490084,0.39333478,0.56336117,0.00011512639],"about_ca_topic_score_codex":0.008946081,"about_ca_topic_score_gemma":0.010380949,"teacher_disagreement_score":0.99572057,"about_ca_system_score_codex":0.0037481617,"about_ca_system_score_gemma":0.0038934408,"threshold_uncertainty_score":0.23420423},"labels":[],"label_agreement":null},{"id":"W2594847000","doi":"10.1208/s12248-017-0068-6","title":"Global Harmonization of Comparator Products for Bioequivalence Studies","year":2017,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"World Health Organization","keywords":"Comparator; Harmonization; Bioequivalence; Product (mathematics); Innovator; Risk analysis (engineering); Medicine; Business; Computer science; Pharmacology; Engineering; Mathematics; Intellectual property; Pharmacokinetics","score_opus":0.3103234213113339,"score_gpt":0.40726290997474685,"score_spread":0.09693948866341295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594847000","genre_codex":"methods","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23585494,0.06425263,0.3703255,0.06895026,0.005586225,0.006473402,0.021096027,0.0023997638,0.22506131],"genre_scores_gemma":[0.80197024,0.007947827,0.14046292,0.024745945,0.0011660777,0.0021293992,0.015260112,0.00074516487,0.0055723074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.94045705,0.04589627,0.00408883,0.0027968166,0.005314248,0.0014467309],"domain_scores_gemma":[0.9496703,0.018554324,0.0053204265,0.015583986,0.009659754,0.00121121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07554149,0.00055859465,0.0016500871,0.0026538635,0.0005356738,0.003377349,0.0023860605,0.002477899,0.007692327],"category_scores_gemma":[0.07092783,0.0005081231,0.002545134,0.003916477,0.0016174305,0.002456884,0.0039501884,0.0036244637,0.0011848278],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008308688,0.0012011332,0.015322433,0.004858294,0.002232409,0.00040316384,0.0012940627,0.016052175,0.015637238,0.13260153,0.07084043,0.7312484],"study_design_scores_gemma":[0.0067922925,0.0076223076,0.19049604,0.007560978,0.004355817,0.0019996269,0.0015318583,0.0131664835,0.02723714,0.13252899,0.6064471,0.00026142615],"about_ca_topic_score_codex":0.0020303503,"about_ca_topic_score_gemma":0.0018173384,"teacher_disagreement_score":0.07554149,"about_ca_system_score_codex":0.0023249171,"about_ca_system_score_gemma":0.0060353125,"threshold_uncertainty_score":0.39950633},"labels":[],"label_agreement":null},{"id":"W2595954084","doi":"10.1056/jw200404060000002","title":"Restricting Access to Nebulizers: Creative and Successful Policy Experiment","year":2004,"lang":"en","type":"article","venue":"Journal watch","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Government (linguistics); Medicine; Public economics; Business; Finance; Economics; Economic growth; Health care","score_opus":0.08424132363743976,"score_gpt":0.3643301369220854,"score_spread":0.28008881328464563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595954084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32218978,0.005628853,0.0579298,0.3182506,0.0069049005,0.019569565,0.005155173,0.00060157414,0.26376972],"genre_scores_gemma":[0.8863366,0.0018556239,0.035827894,0.053128067,0.0012907045,0.010317033,0.00026618928,0.000103558115,0.010874244],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.91757447,0.05439035,0.0016170159,0.0034311272,0.016015252,0.006971802],"domain_scores_gemma":[0.78473973,0.18581294,0.005378933,0.010247074,0.009475932,0.0043453462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.097637944,0.00165139,0.0021881827,0.0015930254,0.007086178,0.009662602,0.0044470537,0.013992004,0.007314769],"category_scores_gemma":[0.14023153,0.0008850444,0.0014295445,0.0026925695,0.013950587,0.0053759506,0.005593202,0.009762722,0.00067117036],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011252896,0.0067675114,0.0066137784,0.0014922066,0.0013036153,0.0007476236,0.0043069553,0.020803966,0.0027805523,0.8204485,0.072382845,0.051099475],"study_design_scores_gemma":[0.076767094,0.005561691,0.007498086,0.0009586037,0.0023872447,0.00015362984,0.007614685,0.045616843,0.009674309,0.6463678,0.19654983,0.00085014],"about_ca_topic_score_codex":0.12952664,"about_ca_topic_score_gemma":0.11841931,"teacher_disagreement_score":0.12952664,"about_ca_system_score_codex":0.02562648,"about_ca_system_score_gemma":0.061043553,"threshold_uncertainty_score":0.51636493},"labels":[],"label_agreement":null},{"id":"W2596575759","doi":"10.1287/msom.2017.0616","title":"Clinical Trials for New Drug Development: Optimal Investment and Application","year":2017,"lang":"en","type":"article","venue":"Manufacturing & Service Operations Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interim; Clinical trial; Revenue; Interim analysis; Drug development; Investment (military); Value (mathematics); Computer science; Net present value; Actuarial science; Medicine; Test (biology); Operations management; Operations research; Drug; Business; Economics; Finance; Microeconomics; Mathematics; Production (economics); Pharmacology","score_opus":0.1940947930245319,"score_gpt":0.39059059635366644,"score_spread":0.19649580332913455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596575759","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03348613,0.023438973,0.7278811,0.061437868,0.00065991987,0.0017785223,0.001880663,0.00073648384,0.14870049],"genre_scores_gemma":[0.7654521,0.022949144,0.18937655,0.0021826657,0.0010008265,0.001664726,0.00076008314,0.0001896869,0.016424218],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99073106,0.0064372434,0.00026725943,0.00082620105,0.0011859832,0.0005521913],"domain_scores_gemma":[0.9644324,0.029448116,0.00290236,0.0010855389,0.0011664156,0.00096521893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01282198,0.0015901627,0.0025870528,0.0021316996,0.0011727967,0.007672643,0.0016952278,0.0048294123,0.017241575],"category_scores_gemma":[0.058303177,0.0019071973,0.0009789454,0.0034145778,0.0036666738,0.0077588176,0.0024852208,0.0047750548,0.0019323078],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001827214,0.0001534274,0.00128175,0.00043384102,0.00007201155,0.00011113837,0.000101182115,0.18024045,0.00024998168,0.72069824,0.015058475,0.0814168],"study_design_scores_gemma":[0.0001349314,0.00012765733,0.0006777557,0.00030713264,0.000044588345,0.00008938772,0.00008362061,0.1979477,0.00021580634,0.78484297,0.01549112,0.00003743667],"about_ca_topic_score_codex":0.0035790387,"about_ca_topic_score_gemma":0.003342613,"teacher_disagreement_score":0.017241575,"about_ca_system_score_codex":0.008657337,"about_ca_system_score_gemma":0.00921475,"threshold_uncertainty_score":0.06780994},"labels":[],"label_agreement":null},{"id":"W2600754488","doi":"10.1093/schbul/sbx024.108","title":"SU112. The Dark Side of Haloperidol Decanoate Shortage in Canada","year":2017,"lang":"en","type":"article","venue":"Schizophrenia Bulletin","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Université Laval","funders":"","keywords":"Medicine; Economic shortage; Population; Pharmacy; Health care; Antipsychotic; Schizophrenia (object-oriented programming); Psychiatry; Family medicine; Environmental health; Political science; Government (linguistics)","score_opus":0.03332338507526344,"score_gpt":0.2442739957015216,"score_spread":0.21095061062625817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600754488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90779316,0.016217722,0.00021940713,0.023792792,0.00031925802,0.00036008237,0.016649999,0.0000641885,0.03458343],"genre_scores_gemma":[0.98082,0.006521424,0.00031035277,0.0045511466,0.000090974885,0.000049398124,0.0030783878,0.000024747927,0.004553595],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867344,0.000046291036,0.000083795385,0.00010308757,0.0005297276,0.00056357466],"domain_scores_gemma":[0.9921433,0.0002896014,0.0019180652,0.00008815816,0.00306184,0.00249912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006335833,0.00020098941,0.00026669164,0.0018640697,0.004948902,0.0014803677,0.0010323451,0.00072724017,0.005996543],"category_scores_gemma":[0.0029027506,0.00030642736,0.0003089993,0.0048248107,0.0009998208,0.0006567426,0.0013189224,0.0013544842,0.0003643816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024354598,0.0002339703,0.91787916,0.00066011824,0.000039906052,0.0034098155,0.0029111719,0.00011715659,0.0006576074,0.0011553527,0.027514039,0.045178168],"study_design_scores_gemma":[0.000020756705,0.000085361775,0.96674836,0.0005110224,0.000027685148,0.001895706,0.007728522,0.00023402325,0.00017538367,0.0001482345,0.022391224,0.000033752465],"about_ca_topic_score_codex":0.9899659,"about_ca_topic_score_gemma":0.99417675,"teacher_disagreement_score":0.9638288,"about_ca_system_score_codex":0.036171224,"about_ca_system_score_gemma":0.12287086,"threshold_uncertainty_score":0.26244187},"labels":[],"label_agreement":null},{"id":"W2600790561","doi":"10.1200/jco.2013.31.15_suppl.6614","title":"International comparison on the factors influencing reimbursement of expensive cancer drugs.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Sunitinib; Erlotinib; Family medicine; Health care; Cancer; Internal medicine; Economic growth","score_opus":0.342264293485292,"score_gpt":0.4938104700091927,"score_spread":0.15154617652390068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600790561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937098,0.0013162034,0.00048220746,0.00019845337,0.000014940248,0.00001737715,0.00087259925,0.000004875376,0.0033835296],"genre_scores_gemma":[0.9988133,0.00019440151,0.00027740258,0.000022294269,0.0000068714585,0.000006068015,0.0004903594,0.0000026876473,0.00018667831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844235,0.00053269573,0.00024299738,0.00021492661,0.00033597086,0.00023094019],"domain_scores_gemma":[0.9927764,0.0020336187,0.0037219275,0.00024886706,0.0007662071,0.00045304967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00261033,0.00018890225,0.00020198473,0.0022175615,0.00022080966,0.00074809755,0.00017992056,0.00027212736,0.002318757],"category_scores_gemma":[0.006752997,0.00008621604,0.0007638922,0.0026898296,0.0003465999,0.00041176015,0.0005440102,0.00019882924,0.00018614817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001635425,0.000016735286,0.98935926,0.00004011915,0.0001723312,0.00008752363,0.00012282678,0.00030076253,0.00015499006,0.00045256584,0.00033143157,0.008797948],"study_design_scores_gemma":[0.0000054036136,0.00005705261,0.9966156,0.00002221795,0.000100467434,0.00025497153,0.00052320724,0.00061330665,0.0001570208,0.00012192751,0.0015228828,0.0000059635863],"about_ca_topic_score_codex":0.003440011,"about_ca_topic_score_gemma":0.003126948,"teacher_disagreement_score":0.003440011,"about_ca_system_score_codex":0.0006764273,"about_ca_system_score_gemma":0.0005014376,"threshold_uncertainty_score":0.013804913},"labels":[],"label_agreement":null},{"id":"W2604225864","doi":"10.1016/s2214-109x(17)30113-4","title":"Can a multistakeholder initiative improve transparency and accountability in the pharmaceutical sector? Evidence from the Medicines Transparency Alliance","year":2017,"lang":"en","type":"article","venue":"The Lancet Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transparency (behavior); Accountability; Stakeholder; Alliance; Stakeholder engagement; Essential medicines; Public sector; Medicine; Business; Government (linguistics); Public health; Public relations; Political science; Nursing","score_opus":0.3617425865175071,"score_gpt":0.43384377090035775,"score_spread":0.07210118438285062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604225864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5071981,0.15755391,0.009543612,0.17345825,0.0013444441,0.0024549507,0.0014534266,0.00012246043,0.14687082],"genre_scores_gemma":[0.9720577,0.01564071,0.002797564,0.008143275,0.00016801272,0.00042161703,0.00012762232,0.000025962787,0.0006175451],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.79306644,0.16601592,0.010351676,0.0048792716,0.019378327,0.0063084327],"domain_scores_gemma":[0.3359198,0.52955425,0.0924849,0.015595495,0.018584682,0.007860974],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.14861585,0.00053182465,0.0008664403,0.003319606,0.0025846274,0.009513836,0.002330628,0.0028963939,0.010893749],"category_scores_gemma":[0.33345088,0.00066764303,0.0021612695,0.005584404,0.007745727,0.014022449,0.011155859,0.004683618,0.0006255112],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003630386,0.0024871808,0.23977813,0.05507406,0.004975114,0.0007400215,0.06840377,0.0016261055,0.00061218557,0.14400841,0.017779421,0.4608853],"study_design_scores_gemma":[0.0024836692,0.0032940914,0.50538343,0.1398371,0.0073849093,0.00066517445,0.06731542,0.0021733271,0.0034065067,0.047909535,0.21979779,0.00034902908],"about_ca_topic_score_codex":0.007927513,"about_ca_topic_score_gemma":0.011748847,"teacher_disagreement_score":0.85138416,"about_ca_system_score_codex":0.00838456,"about_ca_system_score_gemma":0.021454217,"threshold_uncertainty_score":0.78596514},"labels":[],"label_agreement":null},{"id":"W2605970134","doi":"","title":"MAKING DECISIONS UNDER UNCERTAINTY: THE VALUE OF ECONOMIC EVALUATIONS IN THE ASSESSMENT OF NON-DRUG HEALTH TECHNOLOGIES IN CANADA","year":2016,"lang":"en","type":"article","venue":"38th Annual North American Meeting of the Society for Medical Decision Making","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Value (mathematics); Risk analysis (engineering); Actuarial science; Computer science; Public economics; Economics; Medicine; Statistics; Mathematics","score_opus":0.04471865151052981,"score_gpt":0.38444427113596485,"score_spread":0.339725619625435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605970134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5717441,0.035741836,0.029092282,0.18404457,0.0007869743,0.00083566474,0.0034047596,0.0001729411,0.174177],"genre_scores_gemma":[0.9861682,0.004229333,0.005623147,0.0011779311,0.00013024695,0.000048896014,0.00021902182,0.000027592889,0.0023756542],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97637093,0.015130304,0.0008340927,0.00082842493,0.004903759,0.0019325017],"domain_scores_gemma":[0.7913792,0.17140047,0.003939404,0.0018452876,0.026975619,0.004459968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.037199,0.0007813214,0.0016043007,0.0034955766,0.004233802,0.011482899,0.0018949952,0.0029294633,0.0036252767],"category_scores_gemma":[0.20675762,0.00052512315,0.0009515569,0.0043385886,0.005386754,0.0051189456,0.002463409,0.0050079883,0.00013929298],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003525176,0.00048299975,0.084709294,0.0015111027,0.0010387776,0.0010541427,0.0030157887,0.3256756,0.00028177883,0.22823445,0.047310006,0.30316085],"study_design_scores_gemma":[0.000692283,0.00027750738,0.05806033,0.0017944353,0.000773391,0.00016907543,0.0057074693,0.59694844,0.00087475224,0.30294555,0.031269543,0.000487225],"about_ca_topic_score_codex":0.9607108,"about_ca_topic_score_gemma":0.9649536,"teacher_disagreement_score":0.9124808,"about_ca_system_score_codex":0.087519206,"about_ca_system_score_gemma":0.14340477,"threshold_uncertainty_score":0.6349993},"labels":[],"label_agreement":null},{"id":"W2606813978","doi":"10.9778/cmajo.20170001","title":"Publication of confirmatory studies required by Health Canada for drugs approved under a Notice of Compliance with conditions: a cohort study","year":2017,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Notice; Medicine; Confirmatory factor analysis; Health care; Web site; Family medicine; Business; Marketing; World Wide Web; Political science; Computer science; The Internet; Law","score_opus":0.22250544491531704,"score_gpt":0.405297029768289,"score_spread":0.18279158485297198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606813978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8255633,0.083209865,0.006240426,0.0040138313,0.0008562635,0.016144438,0.049801245,0.00016952142,0.014001119],"genre_scores_gemma":[0.9655955,0.007719578,0.0052746646,0.0021651515,0.00041577945,0.006904722,0.009834565,0.00010792055,0.001982183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.90444654,0.02375511,0.041822612,0.0072458186,0.018822577,0.003907186],"domain_scores_gemma":[0.44950503,0.2567023,0.19781592,0.040650543,0.04920861,0.006117545],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.069861606,0.00076777773,0.0016865171,0.009409003,0.0025211724,0.004311375,0.0015460749,0.0020796065,0.011563697],"category_scores_gemma":[0.21396643,0.0011092178,0.0044183154,0.010377755,0.001275859,0.0037946033,0.0026870922,0.0016790351,0.0020207365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007712507,0.00044394395,0.9227883,0.017268667,0.0040388764,0.0018145564,0.00398184,0.00010707347,0.0008846352,0.0010522739,0.010301016,0.029606286],"study_design_scores_gemma":[0.001604535,0.0026472535,0.9115379,0.01863291,0.008518047,0.004721348,0.005379404,0.0005550882,0.0022469638,0.0006905595,0.043116778,0.00034922556],"about_ca_topic_score_codex":0.017651457,"about_ca_topic_score_gemma":0.023937725,"teacher_disagreement_score":0.9957108,"about_ca_system_score_codex":0.004289218,"about_ca_system_score_gemma":0.01110892,"threshold_uncertainty_score":0.3694679},"labels":[],"label_agreement":null},{"id":"W2607317376","doi":"10.71781/25443","title":"De l'ADPIC à Cancún : l'accès aux médicaments comme enjeu de gouvernance internationale","year":2005,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.14270188726073582,"score_gpt":0.3798945332060354,"score_spread":0.23719264594529957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607317376","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043004705,0.34987298,0.0027787487,0.32481003,0.021851758,0.000056437955,0.0045987363,0.0004168308,0.29131404],"genre_scores_gemma":[0.14692804,0.31628954,0.008232387,0.04366895,0.018680505,0.00017348878,0.0038238156,0.0005115357,0.46169183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969195,0.00065307,0.000130233,0.00037931337,0.0013944947,0.00052332063],"domain_scores_gemma":[0.9912778,0.0024365506,0.00077881064,0.00063051604,0.0034571069,0.0014192471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052256873,0.00073453685,0.0007009382,0.0041344003,0.0029375218,0.011583759,0.0014786455,0.0040504197,0.04770679],"category_scores_gemma":[0.014605929,0.00043446213,0.00051221,0.0064488845,0.0027243698,0.0042509744,0.0020365366,0.005921507,0.0054328507],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014385078,0.000042697266,0.0016572502,0.0005168235,0.00002749984,0.00017354694,0.00092513626,0.00029466537,0.00035745074,0.16110808,0.7069165,0.12783642],"study_design_scores_gemma":[0.000011710344,0.000009844148,0.002894852,0.00034233936,0.000007884592,0.000049490918,0.00015356221,0.00006220577,0.00018102647,0.0033574435,0.9929182,0.000011428017],"about_ca_topic_score_codex":0.30325904,"about_ca_topic_score_gemma":0.29380608,"teacher_disagreement_score":0.30325904,"about_ca_system_score_codex":0.018128539,"about_ca_system_score_gemma":0.03179068,"threshold_uncertainty_score":0.60298777},"labels":[],"label_agreement":null},{"id":"W2607334866","doi":"10.1503/cmaj.1095168","title":"Canada wins legal battle to set patent rules","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Battle; Computer science; Set (abstract data type); Data science; Operations research; World Wide Web; History; Engineering; Programming language; Ancient history","score_opus":0.05232028738140876,"score_gpt":0.2634194069348799,"score_spread":0.21109911955347116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607334866","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070581785,0.0052115363,0.002356665,0.7158583,0.0063850456,0.000101001875,0.00095411803,0.00034867102,0.26172647],"genre_scores_gemma":[0.18383695,0.0051510422,0.005314192,0.52512085,0.0032843235,0.00012298918,0.000756012,0.0004425616,0.2759711],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.967967,0.0015372427,0.0006534951,0.0022811962,0.022240661,0.005320508],"domain_scores_gemma":[0.96655965,0.0075171813,0.0007267536,0.0016743429,0.016492559,0.00702951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011723074,0.00069645466,0.0010408801,0.0029889173,0.023073383,0.020348316,0.004636203,0.02445028,0.02022809],"category_scores_gemma":[0.053211167,0.0010570916,0.00093551725,0.0024539104,0.012316693,0.005370571,0.005220772,0.02433388,0.0033616056],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003595757,0.000020146337,0.00075773173,0.000050433016,0.000020575118,0.00020502518,0.00068706775,0.00028536562,0.00022399382,0.28902903,0.69221526,0.016469277],"study_design_scores_gemma":[0.00007204487,0.000019683785,0.0015562576,0.00023030999,0.00003251212,0.00007374612,0.00061358715,0.00061177963,0.000391543,0.037763964,0.9585537,0.00008087356],"about_ca_topic_score_codex":0.9598107,"about_ca_topic_score_gemma":0.9743566,"teacher_disagreement_score":0.8944824,"about_ca_system_score_codex":0.105517626,"about_ca_system_score_gemma":0.2725003,"threshold_uncertainty_score":0.76558757},"labels":[],"label_agreement":null},{"id":"W2607457584","doi":"10.1016/j.sapharm.2017.02.012","title":"Economic evaluation of pharmacy services","year":2017,"lang":"en","type":"article","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Pharmacy; Business; Medicine; Nursing","score_opus":0.6413577111345987,"score_gpt":0.5809909106068237,"score_spread":0.06036680052777499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607457584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5680897,0.049971964,0.022383967,0.047771327,0.002120748,0.001845885,0.010325027,0.0001616199,0.29732984],"genre_scores_gemma":[0.9904958,0.0028952488,0.0011250856,0.0004065833,0.0004319107,0.000116979005,0.0007428151,0.000012773844,0.0037728874],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9457285,0.03884083,0.0014716426,0.0010042653,0.010372317,0.0025825042],"domain_scores_gemma":[0.921797,0.05596271,0.0059356345,0.0021343047,0.011173805,0.0029965132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02218123,0.0007600167,0.0016055462,0.004678628,0.0007950012,0.005519742,0.0012212669,0.002031744,0.008744806],"category_scores_gemma":[0.11148126,0.0003913282,0.0014698593,0.0051140687,0.0016985016,0.0027196645,0.0015379786,0.0025217084,0.00042719243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011249596,0.0030164581,0.10225657,0.0034085216,0.0034993165,0.00045397156,0.00040273077,0.1638575,0.0005210384,0.41228765,0.04313418,0.25591248],"study_design_scores_gemma":[0.0029080713,0.006222894,0.2086956,0.0027264105,0.0036791961,0.0006994413,0.0032249868,0.39964047,0.002642403,0.24546018,0.12380115,0.00029911465],"about_ca_topic_score_codex":0.017496552,"about_ca_topic_score_gemma":0.010993447,"teacher_disagreement_score":0.02218123,"about_ca_system_score_codex":0.013517109,"about_ca_system_score_gemma":0.013287235,"threshold_uncertainty_score":0.11730695},"labels":[],"label_agreement":null},{"id":"W2607667747","doi":"","title":"Prohibiting Gray Market Prescription Drugs: The Ethical Dimensions","year":2017,"lang":"en","type":"article","venue":"Southern law journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Government (linguistics); Politics; China; Prescription drug; Gray (unit); Political science; Business; Law; Medicine","score_opus":0.0559869386348769,"score_gpt":0.29642626165330366,"score_spread":0.24043932301842674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607667747","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014195053,0.026912065,0.014697673,0.6798972,0.003741437,0.00008636147,0.000056790137,0.000058583348,0.26035488],"genre_scores_gemma":[0.61830723,0.01642642,0.008320232,0.32088715,0.0051283226,0.00022724706,0.00003553264,0.00007695946,0.030590901],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.96311796,0.02317053,0.0012977221,0.0018224297,0.008315074,0.0022763237],"domain_scores_gemma":[0.9546893,0.03579867,0.0031291696,0.001673399,0.0030865467,0.0016229011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024447894,0.00046959834,0.00045934576,0.0007755905,0.008741648,0.015562353,0.0014312099,0.013708375,0.004177857],"category_scores_gemma":[0.026143197,0.0003926782,0.00047851843,0.0008794902,0.05304861,0.008251856,0.00687323,0.017304042,0.0006403304],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007504082,0.000020078001,0.00049338065,0.00007770415,0.0000049058663,0.00020260666,0.008425404,0.00015789198,0.00014419014,0.9505317,0.029709268,0.010225431],"study_design_scores_gemma":[0.000011674696,0.00004617339,0.0010260061,0.0013360715,0.000010290274,0.0005504267,0.011011996,0.00063239125,0.000527848,0.45649874,0.5283019,0.000046571764],"about_ca_topic_score_codex":0.0074708834,"about_ca_topic_score_gemma":0.009169077,"teacher_disagreement_score":0.024447894,"about_ca_system_score_codex":0.008628762,"about_ca_system_score_gemma":0.014183837,"threshold_uncertainty_score":0.12929434},"labels":[],"label_agreement":null},{"id":"W2610291029","doi":"10.1016/j.socscimed.2017.05.012","title":"A method for understanding generic procurement of HIV medicines by developing countries with patent protection","year":2017,"lang":"en","type":"article","venue":"Social Science & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Procurement; Business; Intellectual property; Developing country; Enforcement; Essential medicines; Relevance (law); International trade; Industrial organization; Marketing; Health care; Economics; Economic growth; Law; Political science","score_opus":0.29415058940251737,"score_gpt":0.38242238875379686,"score_spread":0.08827179935127949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610291029","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030619856,0.00034799514,0.9348459,0.0017482723,0.000088188564,0.00021067756,0.0016974582,0.00028442923,0.030157218],"genre_scores_gemma":[0.46105215,0.0008088919,0.51020145,0.00039918942,0.00019198873,0.0011141909,0.0011048346,0.0001447635,0.024982542],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9989254,0.00063981436,0.00004535365,0.00015398013,0.00013285693,0.00010248244],"domain_scores_gemma":[0.9932462,0.0054734866,0.00042574859,0.0004538175,0.0002993334,0.000101382946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003196689,0.00067376374,0.00083085307,0.0026049328,0.0007552825,0.0020761883,0.0011722808,0.0014763711,0.020002764],"category_scores_gemma":[0.009943857,0.0003836784,0.001553142,0.002331555,0.0010047776,0.003048477,0.0011741621,0.0013617708,0.0013930657],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000755796,0.00012430466,0.007459322,0.00012809013,0.00012807403,0.00020954788,0.0004435926,0.05971596,0.00076391385,0.870082,0.007567239,0.05330245],"study_design_scores_gemma":[0.000089875015,0.000060309194,0.0033229094,0.0000499915,0.000077394085,0.0001771947,0.00040977215,0.3402445,0.0008443238,0.6322726,0.022403868,0.000047200952],"about_ca_topic_score_codex":0.009302904,"about_ca_topic_score_gemma":0.006730958,"teacher_disagreement_score":0.020002764,"about_ca_system_score_codex":0.0016403275,"about_ca_system_score_gemma":0.0022478686,"threshold_uncertainty_score":0.06691587},"labels":[],"label_agreement":null},{"id":"W2612689878","doi":"10.7202/1039145ar","title":"La croissance technologique et la privatisation passive des systèmes publics de santé : le cas du Québec","year":2017,"lang":"fr","type":"article","venue":"Revue Gouvernance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Medical Association","keywords":"Political science; Humanities; Philosophy","score_opus":0.03117651979444838,"score_gpt":0.28901183403802566,"score_spread":0.2578353142435773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612689878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6610024,0.0074737584,0.0047922,0.052248783,0.00020509897,0.000093256625,0.0016788675,0.0000997058,0.2724059],"genre_scores_gemma":[0.95597476,0.0017101188,0.00057655975,0.00067350524,0.000023827744,0.000023266675,0.00019377298,0.000018393699,0.04080574],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99876237,0.00017779662,0.00002291086,0.00012488362,0.00033491515,0.00057717355],"domain_scores_gemma":[0.99752694,0.00041632645,0.00029668587,0.000112616886,0.0010915291,0.0005558979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009060329,0.00021513968,0.00024285536,0.0011884612,0.0044034687,0.00511796,0.0006896996,0.0008532632,0.011761648],"category_scores_gemma":[0.0029566586,0.00022175928,0.0002967075,0.0025070033,0.0030706555,0.0015767487,0.0010939769,0.001462699,0.00031390064],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026961623,0.00012871671,0.14021155,0.0004413288,0.00012536741,0.0013178535,0.024748063,0.008938495,0.0023300585,0.68891454,0.037820384,0.09475408],"study_design_scores_gemma":[0.00005595583,0.0001202878,0.51651096,0.0006840635,0.00013995128,0.00035483413,0.02884674,0.010964653,0.0010234403,0.018907312,0.42226738,0.00012449603],"about_ca_topic_score_codex":0.99117893,"about_ca_topic_score_gemma":0.9938088,"teacher_disagreement_score":0.08328714,"about_ca_system_score_codex":0.08328714,"about_ca_system_score_gemma":0.06581304,"threshold_uncertainty_score":0.60429335},"labels":[],"label_agreement":null},{"id":"W2614477129","doi":"10.1503/cmaj.170169","title":"The role and impact of cost-sharing mechanisms for prescription drug coverage","year":2017,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"Cost sharing; Medical prescription; Drug; Prescription drug; Medicine; Computer science; Pharmacology; Nursing","score_opus":0.02643571802987166,"score_gpt":0.27297820408646883,"score_spread":0.24654248605659718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614477129","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003799454,0.002276033,0.00028819466,0.9782914,0.00080435246,0.000010334465,0.00008186972,0.000007827289,0.01444061],"genre_scores_gemma":[0.17696503,0.0035185143,0.0006082974,0.79468864,0.019037133,0.00004956901,0.00006816936,0.000038958664,0.005025693],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98064685,0.008971191,0.0008415061,0.0022444776,0.0044850847,0.0028109653],"domain_scores_gemma":[0.7918845,0.186148,0.0059357323,0.00396928,0.006756816,0.0053056865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024939958,0.00048667807,0.0010853491,0.0013837736,0.0029605029,0.0068308776,0.0042760866,0.046137746,0.01549934],"category_scores_gemma":[0.11767646,0.0005762969,0.0016530738,0.0012327355,0.010076822,0.007627325,0.0034151413,0.03649945,0.0023648199],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008745278,0.00019193292,0.011266993,0.00023317026,0.0001392697,0.0025498883,0.0009129041,0.0014192807,0.00056975515,0.49912688,0.40540412,0.07731127],"study_design_scores_gemma":[0.001050784,0.00050688937,0.028364245,0.0023299996,0.0002974206,0.0032519456,0.0026476244,0.0094567565,0.0018447384,0.43815643,0.51168394,0.0004092926],"about_ca_topic_score_codex":0.02368682,"about_ca_topic_score_gemma":0.030207554,"teacher_disagreement_score":0.9763132,"about_ca_system_score_codex":0.015996292,"about_ca_system_score_gemma":0.011067201,"threshold_uncertainty_score":0.13189667},"labels":[],"label_agreement":null},{"id":"W2614999677","doi":"","title":"Advance Market Commitment for Pneumococcal Vaccines: Putting Theory into practice/Engagement Prealable Relatif Au Marche Pour Les Vaccins Contre le Pneumocoque: Mettre la Theorie En pratique/Compromiso De Mercado Avanzado Para Vacunas Neumococicas: Poniendo En Practica la Teoria","year":2011,"lang":"fr","type":"article","venue":"Bulletin of the World Health Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Developing country; Vaccination; Sustainability; Business; Investment (military); Medicine; Marketing; Economic growth; Economics; Immunology; Political science","score_opus":0.03227675536921406,"score_gpt":0.3154956361983563,"score_spread":0.28321888082914226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614999677","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029018419,0.06801124,0.19751379,0.4982715,0.0025883925,0.0007646663,0.0002194825,0.000260548,0.20335205],"genre_scores_gemma":[0.8190319,0.04375232,0.10719222,0.018557036,0.0012145862,0.0010460058,0.00012569659,0.00011692245,0.008963291],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.973396,0.0201273,0.0005413518,0.0016113187,0.0031995396,0.0011245888],"domain_scores_gemma":[0.92304194,0.06430908,0.0034152647,0.0026337176,0.0035652518,0.003034695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.033912614,0.0012422114,0.0008647932,0.0028123856,0.0025387045,0.011165336,0.004636953,0.008182332,0.011374539],"category_scores_gemma":[0.045439843,0.0005728462,0.00096546015,0.0018917135,0.024664747,0.011777416,0.006544394,0.0068159066,0.0013564315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061815015,0.0003160617,0.0023073903,0.0014043523,0.000050195616,0.00018678252,0.005252946,0.0049823853,0.00014695346,0.89657724,0.00839506,0.08031876],"study_design_scores_gemma":[0.00005225691,0.00012735742,0.0009052956,0.004540857,0.000040771454,0.000086137035,0.005114562,0.0066964575,0.0003379352,0.92763346,0.05441829,0.000046512312],"about_ca_topic_score_codex":0.0050770566,"about_ca_topic_score_gemma":0.00504094,"teacher_disagreement_score":0.033912614,"about_ca_system_score_codex":0.01247682,"about_ca_system_score_gemma":0.020560699,"threshold_uncertainty_score":0.17934918},"labels":[],"label_agreement":null},{"id":"W2615558757","doi":"10.1007/s40290-017-0191-9","title":"Myths and Realities About Why Prescription Drug Prices in the United States Are So High","year":2017,"lang":"en","type":"article","venue":"Pharmaceutical Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Medical prescription; Drug; Medicine; Pharmacotherapy; Mythology; Drug prices; Environmental health; Political science; Family medicine; Traditional medicine; Pharmacology; Psychiatry; Public economics; Economics; History","score_opus":0.11022600024979189,"score_gpt":0.3562483066323625,"score_spread":0.2460223063825706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615558757","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06899132,0.008958888,0.0012695576,0.9042188,0.0012539397,0.0000075292182,0.0004162306,0.000026746142,0.014856951],"genre_scores_gemma":[0.91372406,0.006913597,0.00053868233,0.07516855,0.0025254278,0.0000159544,0.00012238175,0.000028457203,0.00096289994],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9962484,0.00135103,0.00021619508,0.00070683396,0.0009385329,0.0005389438],"domain_scores_gemma":[0.9555387,0.027082475,0.010175871,0.0011460903,0.0038208184,0.002236068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076161595,0.0002255376,0.00035393442,0.0012943372,0.0012801376,0.005231169,0.0009034011,0.005110666,0.0038453704],"category_scores_gemma":[0.054177303,0.0003715949,0.00039910464,0.001852563,0.010037067,0.0059610237,0.0013005468,0.0075190878,0.00042850716],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061769906,0.00030809158,0.16795446,0.00084193866,0.0006881356,0.00082384347,0.010726147,0.0043309852,0.0006417256,0.45382497,0.27009797,0.08914399],"study_design_scores_gemma":[0.00018099461,0.00007666461,0.14884315,0.0014342924,0.00017993788,0.0005746735,0.024542471,0.004852338,0.0014527445,0.6838256,0.13381958,0.00021754531],"about_ca_topic_score_codex":0.010175117,"about_ca_topic_score_gemma":0.0092181545,"teacher_disagreement_score":0.010175117,"about_ca_system_score_codex":0.0033485466,"about_ca_system_score_gemma":0.0032329732,"threshold_uncertainty_score":0.040278614},"labels":[],"label_agreement":null},{"id":"W2615756116","doi":"10.3386/w23068","title":"Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs","year":2017,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Common Fund; NIH Office of the Director; National Institute on Aging; National Science Foundation; National Institutes of Health; Pfizer","keywords":"Medical prescription; Health care; Prescription drug; Business; Family medicine; Medicine; Nursing; Political science; Law","score_opus":0.5913179908200392,"score_gpt":0.5767842673581781,"score_spread":0.014533723461861103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615756116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71980995,0.04357009,0.005191946,0.08310505,0.0003457432,0.00016962257,0.0066029467,0.000058037695,0.14114664],"genre_scores_gemma":[0.979481,0.007786209,0.00080237177,0.009118667,0.00037783798,0.000050847757,0.0009468327,0.000025684383,0.0014105511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9853886,0.00832285,0.0009957453,0.001581202,0.002324498,0.0013872151],"domain_scores_gemma":[0.8309308,0.10275786,0.039496176,0.011771911,0.010486483,0.00455673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014873189,0.00045260653,0.001660947,0.0048269536,0.0018201431,0.0049908888,0.0015822125,0.0023046962,0.013899091],"category_scores_gemma":[0.087165706,0.00055152056,0.0012018724,0.008898106,0.005582797,0.0037355481,0.003529355,0.0021390743,0.0008835517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013721577,0.00045330936,0.79058915,0.0014934173,0.002107167,0.0005084785,0.0017611185,0.002617919,0.00017559332,0.1009032,0.019948106,0.07807036],"study_design_scores_gemma":[0.00092625245,0.00036636452,0.87596655,0.0035588893,0.0027667298,0.00074725325,0.006705567,0.0029014274,0.00076382706,0.061060093,0.044123046,0.00011403105],"about_ca_topic_score_codex":0.054112058,"about_ca_topic_score_gemma":0.03492832,"teacher_disagreement_score":0.054112058,"about_ca_system_score_codex":0.003244458,"about_ca_system_score_gemma":0.003905506,"threshold_uncertainty_score":0.10759413},"labels":[],"label_agreement":null},{"id":"W2616641036","doi":"10.71781/26112","title":"Établissement d'un prototype de laboratoire et d'un pilote industriel d'amylose substitué pour la libération contrôlée de médicament à partir de comprimés matriciels","year":2005,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Chemistry","score_opus":0.06360537604681456,"score_gpt":0.34088684656576557,"score_spread":0.277281470518951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616641036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982271,0.0007820006,0.013598467,0.00021466802,0.00010103498,0.0003329017,0.0002256784,0.00047882446,0.0019953789],"genre_scores_gemma":[0.97404385,0.0003466235,0.01956347,0.00007157026,0.00001716792,0.00022327232,0.0002567962,0.000056587374,0.0054205423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925035,0.00015981011,0.000041871608,0.00016330686,0.00025996158,0.00012468264],"domain_scores_gemma":[0.9985216,0.00058377336,0.00014588017,0.0002234941,0.00040095768,0.0001243038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001522586,0.00052644423,0.000680916,0.0004690049,0.00050624757,0.00091399904,0.0008063617,0.0011103653,0.0049710516],"category_scores_gemma":[0.002972157,0.00030606447,0.000707372,0.00031888697,0.00064620975,0.0009231006,0.0005094621,0.00048692836,0.0006202651],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038709957,0.0033181473,0.0036567769,0.0005645271,0.00009956668,0.0004293758,0.00078356237,0.004151256,0.8778807,0.00085427734,0.0010268544,0.103364095],"study_design_scores_gemma":[0.002394296,0.029912978,0.047052495,0.00010873023,0.0005024289,0.00051396684,0.0009492509,0.034268703,0.8577,0.0005726613,0.025879998,0.00014447447],"about_ca_topic_score_codex":0.0058475044,"about_ca_topic_score_gemma":0.0037581532,"teacher_disagreement_score":0.0058475044,"about_ca_system_score_codex":0.0007341796,"about_ca_system_score_gemma":0.00077245466,"threshold_uncertainty_score":0.016629815},"labels":[],"label_agreement":null},{"id":"W2616945700","doi":"10.1503/cmaj.1095429","title":"Fair pricing or pricing for profit?","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profit (economics); sort; Drug pricing; Cash; Actuarial science; Medicine; Business; Computer science; Economics; Finance; Microeconomics; Information retrieval","score_opus":0.05832148119612866,"score_gpt":0.30569873728450303,"score_spread":0.24737725608837435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616945700","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022672894,0.018532827,0.0116788335,0.77788395,0.016550561,0.000036010908,0.00032355465,0.00019976364,0.17252721],"genre_scores_gemma":[0.33906096,0.030521536,0.008212549,0.45360324,0.04353568,0.00011832849,0.0003313311,0.0007840188,0.123832375],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9894091,0.0028495057,0.0003197868,0.0012001016,0.004669756,0.0015518119],"domain_scores_gemma":[0.98099273,0.008000465,0.0012203999,0.0024464242,0.004992217,0.0023477194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01190182,0.0006187385,0.0011773295,0.001582904,0.0031637375,0.012496353,0.00186688,0.0101056155,0.036057234],"category_scores_gemma":[0.08051996,0.00033817638,0.0006350436,0.0022293876,0.018568415,0.022324516,0.0024090216,0.011789914,0.0060579125],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033608907,0.000022162923,0.0003289619,0.0000506868,0.000013750462,0.00003270533,0.00015782517,0.0002504905,0.0000377758,0.7608491,0.2064818,0.03174103],"study_design_scores_gemma":[0.000027235159,0.000015471904,0.0004562008,0.00034562062,0.000013499725,0.00008559644,0.00036751636,0.00073323277,0.000115343304,0.7052377,0.29255673,0.000045923254],"about_ca_topic_score_codex":0.04559023,"about_ca_topic_score_gemma":0.0296057,"teacher_disagreement_score":0.04559023,"about_ca_system_score_codex":0.0077728685,"about_ca_system_score_gemma":0.011521132,"threshold_uncertainty_score":0.12062347},"labels":[],"label_agreement":null},{"id":"W2620986503","doi":"","title":"Pharmaceutical M&A Activity: Effects on Prices, Innovation, and Competition","year":2017,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Upstream (networking); Downstream (manufacturing); Competition (biology); Pharmaceutical industry; Harm; Industrial organization; Business; Market concentration; Marketing; Politics; Product (mathematics); Distribution (mathematics); Market structure; Political science; Biotechnology; Engineering","score_opus":0.08957918890393224,"score_gpt":0.34046398662732147,"score_spread":0.25088479772338923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620986503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92162025,0.0014731204,0.0006073563,0.0057125455,0.00004348172,0.000044350738,0.00026746202,0.000020176534,0.07021116],"genre_scores_gemma":[0.99748105,0.00029937172,0.00008098248,0.0001908216,0.000052915922,0.000010128937,0.00003969241,0.000003850554,0.0018411586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693584,0.0015640048,0.00013419561,0.00024197425,0.00054906396,0.00057492754],"domain_scores_gemma":[0.9624348,0.024336854,0.00718407,0.00059940544,0.0016557417,0.003789131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031339477,0.00019109428,0.0004393231,0.0011514467,0.0013399132,0.0059736953,0.0006009217,0.0021443937,0.015688865],"category_scores_gemma":[0.021363085,0.00020319241,0.0006944802,0.001724684,0.0021832525,0.0028135371,0.002336099,0.0017913865,0.0011081584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040801773,0.0043491083,0.7412695,0.00037192352,0.00039970624,0.0020177683,0.0025581992,0.009351616,0.0045770835,0.14319399,0.0065704905,0.081260405],"study_design_scores_gemma":[0.0004025742,0.0027464817,0.9007644,0.00012211225,0.00035012932,0.00055085856,0.005915164,0.013351256,0.0029212313,0.060705394,0.0120688155,0.00010158286],"about_ca_topic_score_codex":0.0060636485,"about_ca_topic_score_gemma":0.0064808014,"teacher_disagreement_score":0.015688865,"about_ca_system_score_codex":0.0032132568,"about_ca_system_score_gemma":0.0025264013,"threshold_uncertainty_score":0.052484512},"labels":[],"label_agreement":null},{"id":"W2621322531","doi":"10.17480/psk.2017.61.2.100","title":"The Review of Orphan or Anticancer Drugs Funding Programs from Foreign Countries' Experiences","year":2017,"lang":"en","type":"article","venue":"Yakhak Hoeji","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Orphan drug; Medicine; Pharmacology; Political science; Business; Bioinformatics; Biology","score_opus":0.11557511783315258,"score_gpt":0.3500591458298644,"score_spread":0.23448402799671184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621322531","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043740112,0.9057918,0.00082925457,0.010954955,0.00048787126,0.000053259813,0.0004983009,0.000017904365,0.03762658],"genre_scores_gemma":[0.16344164,0.83221066,0.00089813874,0.0017061826,0.0002167408,0.000055313958,0.0003220402,0.000013859014,0.0011352914],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99671304,0.00166816,0.0005341966,0.00015086876,0.00060934544,0.00032445684],"domain_scores_gemma":[0.98785156,0.007850975,0.0020054553,0.00020844834,0.0016575337,0.00042606698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007817505,0.00021298094,0.00050000264,0.0056008585,0.00046527738,0.0024120936,0.0004975506,0.00067304395,0.0038006827],"category_scores_gemma":[0.015577943,0.00018775571,0.0005024579,0.013959438,0.00075431797,0.0017456715,0.0009284269,0.00065832905,0.0002190877],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000349086,0.00014529051,0.017276008,0.0737157,0.0006210272,0.002491675,0.0063565015,0.002267956,0.00069101504,0.083144896,0.044008184,0.7689326],"study_design_scores_gemma":[0.000055707602,0.000155706,0.050843764,0.062944576,0.00069685787,0.0028671878,0.010154338,0.00032068853,0.0008468305,0.0037971535,0.8672546,0.00006258925],"about_ca_topic_score_codex":0.0074785245,"about_ca_topic_score_gemma":0.0076109497,"teacher_disagreement_score":0.007817505,"about_ca_system_score_codex":0.003234349,"about_ca_system_score_gemma":0.009954358,"threshold_uncertainty_score":0.04134345},"labels":[],"label_agreement":null},{"id":"W2624511976","doi":"10.1503/cmaj.161481","title":"Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Commonwealth Fund","keywords":"Per capita; Medical prescription; Medicine; Health care; Per capita income; Environmental health; Demography; Economic growth; Economics; Population; Nursing","score_opus":0.010683231209502337,"score_gpt":0.23533816091115653,"score_spread":0.22465492970165418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624511976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996932,0.000506927,0.00006628507,0.00022418457,0.000004319886,0.000009907572,0.0015868567,0.0000039647134,0.0006655361],"genre_scores_gemma":[0.9988256,0.00016847345,0.00007190237,0.000026022295,0.0000034422508,0.0000073847764,0.00086159003,0.0000013062307,0.00003432284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982502,0.00057232555,0.00023048215,0.00024229326,0.00023545964,0.0004691044],"domain_scores_gemma":[0.9940983,0.0012509048,0.003507777,0.00017543134,0.0004964275,0.00047113502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017854255,0.00036994935,0.00051917444,0.001833868,0.00036604545,0.0014066959,0.0003995127,0.0003796494,0.0015893974],"category_scores_gemma":[0.0057563097,0.0003370182,0.0009653028,0.0041422625,0.00078925205,0.0006940538,0.0018126821,0.00058779446,0.00010915152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054337364,0.000016319998,0.99641377,0.000051669107,0.00014091675,0.00012462026,0.000156628,0.0004611016,0.000050188137,0.0002287263,0.00024202127,0.0020596727],"study_design_scores_gemma":[0.0000054640386,0.000022889615,0.99872166,0.000036528978,0.000035703648,0.00015421912,0.00042666664,0.0002811729,0.000028021577,0.000041598018,0.00024214684,0.0000039291417],"about_ca_topic_score_codex":0.03109168,"about_ca_topic_score_gemma":0.02304216,"teacher_disagreement_score":0.03109168,"about_ca_system_score_codex":0.0013933112,"about_ca_system_score_gemma":0.0009826832,"threshold_uncertainty_score":0.06182146},"labels":[],"label_agreement":null},{"id":"W2625162755","doi":"10.1503/cmaj.170440","title":"Drug prices: How do we get to a better place?","year":2017,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"York University; University Health Network","funders":"","keywords":"Publicity; Drug prices; Medicine; Specialty; Drug; Drug approval; Advertising; Family medicine; Intensive care medicine; Pharmacology; Business; Economics; Marketing; Public economics","score_opus":0.02808735274091519,"score_gpt":0.25359936934868876,"score_spread":0.22551201660777356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625162755","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056750905,0.00075538096,0.0000339458,0.99530506,0.0026049325,0.0000020112902,0.000020228212,0.000011024688,0.0012107915],"genre_scores_gemma":[0.0025249198,0.0027454428,0.00021397104,0.96703124,0.023893554,0.000014401308,0.00005370084,0.0000371977,0.0034855325],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940252,0.0016530737,0.00050944113,0.00052523025,0.0025208094,0.0007663753],"domain_scores_gemma":[0.97781646,0.010176445,0.0016610199,0.0006754877,0.0049884277,0.0046822005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006720487,0.0009260363,0.0017701406,0.0017124637,0.004601076,0.009140314,0.0025946614,0.049198978,0.03346171],"category_scores_gemma":[0.05878372,0.0006215643,0.0013376456,0.0017142768,0.006762176,0.014903242,0.0026820146,0.057109475,0.027667915],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032068474,0.000030148276,0.0003831204,0.000045213834,0.000008721543,0.0002535068,0.000059352427,0.000036476704,0.0000497504,0.005794918,0.97707456,0.016232159],"study_design_scores_gemma":[0.00016745855,0.000071387614,0.0012993641,0.0007084933,0.000019706606,0.0007501856,0.0006247502,0.00047802256,0.00016193054,0.038778648,0.95683295,0.00010705681],"about_ca_topic_score_codex":0.016335668,"about_ca_topic_score_gemma":0.020337254,"teacher_disagreement_score":0.049198978,"about_ca_system_score_codex":0.009884119,"about_ca_system_score_gemma":0.010326179,"threshold_uncertainty_score":0.11194062},"labels":[],"label_agreement":null},{"id":"W2633062079","doi":"10.1503/cmaj.170372","title":"Importation of drugs into the United States from Canada","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Lawson Health Research Institute","funders":"","keywords":"Economic shortage; Medical prescription; Medicine; Supply chain; Vulnerability (computing); Medical emergency; Business; Environmental health; Pharmacology; Computer science; Computer security; Marketing","score_opus":0.018799629971086952,"score_gpt":0.2529994476517882,"score_spread":0.23419981768070128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2633062079","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32491007,0.009347182,0.0013004638,0.032836802,0.00080334325,0.0002065097,0.04388995,0.00032791067,0.58637786],"genre_scores_gemma":[0.8790174,0.013123825,0.0015919154,0.0073292246,0.00015964088,0.00002286666,0.012173323,0.00013922504,0.086442605],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868137,0.000038206017,0.00005328921,0.00009214612,0.00081871933,0.00031622848],"domain_scores_gemma":[0.9960324,0.0002909538,0.00040761832,0.00009985069,0.002757245,0.00041179653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004412912,0.00024973872,0.00027109103,0.0021721697,0.003678603,0.0032753758,0.0004425782,0.0005153561,0.01237346],"category_scores_gemma":[0.004025251,0.00023439314,0.0006273671,0.004983298,0.00078424247,0.00057961175,0.0010215169,0.001391784,0.00081451645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041998635,0.00010497942,0.40004018,0.0012265679,0.00028338915,0.004318923,0.0045754756,0.0032862027,0.002050222,0.053071715,0.34474358,0.18587886],"study_design_scores_gemma":[0.00007511107,0.000062559746,0.5144705,0.0007124622,0.00019852287,0.0008925184,0.004420689,0.002581306,0.0026039553,0.0016709181,0.47219628,0.0001152186],"about_ca_topic_score_codex":0.99475104,"about_ca_topic_score_gemma":0.9953635,"teacher_disagreement_score":0.049340587,"about_ca_system_score_codex":0.049340587,"about_ca_system_score_gemma":0.07273344,"threshold_uncertainty_score":0.3579927},"labels":[],"label_agreement":null},{"id":"W2649444365","doi":"","title":"The Delivery of Pharmaceutical Health Care in Nunavut, Canada: Language, Culture and Policy","year":2016,"lang":"en","type":"dissertation","venue":"TSpace","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Health care delivery; Health care; Political science; Medicine; Business; Economic growth; Economics","score_opus":0.02522676735923643,"score_gpt":0.3582756165664064,"score_spread":0.33304884920716993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2649444365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8921464,0.015193006,0.0010224679,0.041892536,0.00021743143,0.00031570473,0.0017127271,0.00004906638,0.047450807],"genre_scores_gemma":[0.9801722,0.00622325,0.001798617,0.0029302675,0.000016810012,0.000096911026,0.00030715924,0.000020428353,0.008434275],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9972886,0.0005109494,0.00013395917,0.00032229786,0.0006433211,0.0011009575],"domain_scores_gemma":[0.9948436,0.0011219187,0.00045630356,0.00011569896,0.0013986285,0.0020638027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023051284,0.00033226926,0.0003651788,0.0014575294,0.02142558,0.006439621,0.0018647949,0.0009440733,0.00350379],"category_scores_gemma":[0.004972936,0.00048980553,0.0003521961,0.0037505126,0.0049200007,0.0012974859,0.003062517,0.0017645545,0.00027031958],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005276816,0.0004282547,0.5146433,0.0015893171,0.000200284,0.0042946343,0.20067544,0.002411293,0.0038059114,0.08010001,0.033527967,0.15779589],"study_design_scores_gemma":[0.00009745673,0.00016546692,0.49114704,0.0028263193,0.00016807951,0.00097296125,0.35645792,0.0036278786,0.0016740198,0.005384837,0.13712265,0.00035534755],"about_ca_topic_score_codex":0.9986681,"about_ca_topic_score_gemma":0.9993837,"teacher_disagreement_score":0.2122072,"about_ca_system_score_codex":0.2122072,"about_ca_system_score_gemma":0.28433987,"threshold_uncertainty_score":0.913728},"labels":[],"label_agreement":null},{"id":"W2660824563","doi":"10.1016/j.jval.2017.05.004","title":"Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Biosimilar; Competition (biology); Notice; Liberian dollar; Marketing authorization; Business; Generic drug; Product (mathematics); Market share; Authorization; Marketing; Pharmaceutical industry; Interquartile range; Medicine; Advertising; Drug; Finance; Pharmacology; Law","score_opus":0.06924952983056451,"score_gpt":0.32369687843816025,"score_spread":0.25444734860759577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2660824563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894287,0.001277682,0.00007724549,0.000965148,0.00003384826,0.000041345585,0.0063623455,0.000013579191,0.0018001065],"genre_scores_gemma":[0.9934629,0.0006196755,0.00008910066,0.00020348675,0.000019217012,0.000015685888,0.002391971,0.000014416491,0.0031835085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788195,0.00010357999,0.00012057615,0.0004064508,0.00047416287,0.0010132014],"domain_scores_gemma":[0.98823977,0.0007331381,0.00370814,0.0006452667,0.0031243514,0.003549387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017002133,0.0004814452,0.0008996393,0.0021261263,0.0038392523,0.0036750468,0.00278095,0.0021549626,0.0069981036],"category_scores_gemma":[0.0058049066,0.0008232959,0.0018350212,0.0052875676,0.0011366112,0.0014698214,0.00136693,0.0034007877,0.0006183114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024418894,0.000114448834,0.9947378,0.00001752417,0.00014604247,0.000106750915,0.000860051,0.00006719008,0.00010239461,0.00027578342,0.0015182764,0.001809518],"study_design_scores_gemma":[0.000013709279,0.00003480119,0.9973863,0.000025221187,0.00006676659,0.000067216046,0.0010569894,0.00022885829,0.000036350288,0.00005549008,0.0010029178,0.00002540068],"about_ca_topic_score_codex":0.98741376,"about_ca_topic_score_gemma":0.9893768,"teacher_disagreement_score":0.97388244,"about_ca_system_score_codex":0.026117546,"about_ca_system_score_gemma":0.03797723,"threshold_uncertainty_score":0.18949693},"labels":[],"label_agreement":null},{"id":"W2700625500","doi":"10.1186/s12992-017-0262-4","title":"In which developing countries are patents on essential medicines being filed?","year":2017,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Developing country; Index (typography); Medicine; Intellectual property; Essential medicines; Estate; Actuarial science; Public health; Business; Accounting; Economic growth; Finance; Economics; Political science; Law; Computer science","score_opus":0.08860450906852528,"score_gpt":0.3672285794589975,"score_spread":0.2786240703904722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2700625500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94114894,0.010092812,0.0011366596,0.0039925557,0.00007833525,0.000116445226,0.008339763,0.00002440345,0.035070155],"genre_scores_gemma":[0.99199593,0.0053640953,0.00047637688,0.00042975706,0.000077202356,0.000051777555,0.0012441061,0.0000062144704,0.00035448314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774855,0.0005786217,0.00048971095,0.0003568133,0.00046580035,0.0003605208],"domain_scores_gemma":[0.97918093,0.007930237,0.010791645,0.0004449805,0.0010264461,0.000625647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024816568,0.00019452414,0.0003147631,0.0026669265,0.0005426756,0.0015639799,0.00034398667,0.00034916718,0.006368158],"category_scores_gemma":[0.014946467,0.00011250691,0.00036001625,0.005522855,0.0010636603,0.0015737428,0.001149438,0.00046437676,0.00053891225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017325718,0.00004399623,0.9440706,0.0005673589,0.00009500685,0.0007196449,0.0019341522,0.00038418724,0.0003104247,0.0036011888,0.002765684,0.045334473],"study_design_scores_gemma":[0.000029950443,0.00013056688,0.9599996,0.00071852,0.00015922777,0.0026195615,0.008553278,0.00028871966,0.00068113086,0.0023985594,0.024396783,0.000024074143],"about_ca_topic_score_codex":0.0061246296,"about_ca_topic_score_gemma":0.0038679026,"teacher_disagreement_score":0.006368158,"about_ca_system_score_codex":0.0007665082,"about_ca_system_score_gemma":0.0015686682,"threshold_uncertainty_score":0.021303594},"labels":[],"label_agreement":null},{"id":"W2727801247","doi":"10.7196/samj.2017.v107i7.11356","title":"Inefficient procurement processes undermine access to medicines in the Western Cape Province of South Africa","year":2017,"lang":"en","type":"article","venue":"South African Medical Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Belgisch Ontwikkelingsagentschap; European Commission; University of the Western Cape; International Development Research Centre","keywords":"Call for bids; Medicine; Procurement; Essential medicines; Stock (firearms); Public health; Workload; Access to medicines; Public sector; Context (archaeology); Business; Marketing; Nursing","score_opus":0.10588044136775397,"score_gpt":0.335302430371814,"score_spread":0.22942198900406002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727801247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227965,0.00036211903,0.00023098223,0.0023102607,0.000010159138,0.00005550101,0.000019880745,0.0000040606233,0.0047274223],"genre_scores_gemma":[0.998242,0.00038594793,0.00025012597,0.00022694378,0.000003844242,0.000022895036,0.000005980421,0.0000033328843,0.00085894065],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9971576,0.0014119304,0.00014895368,0.00013399855,0.00035180067,0.000795734],"domain_scores_gemma":[0.99195635,0.0047018086,0.0020547705,0.00020466122,0.00041211402,0.00067032466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003174585,0.00036164367,0.0002623291,0.00092622556,0.007102445,0.002536987,0.0011850388,0.00090825424,0.0035837798],"category_scores_gemma":[0.0093495725,0.0004604393,0.00017375889,0.0014824811,0.008313002,0.0020074865,0.0028631182,0.0011909265,0.00013754312],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066730856,0.000050227085,0.019850334,0.00048035494,0.000012731398,0.0068571353,0.95442814,0.00019911517,0.0030478975,0.0045891055,0.0011554599,0.00926283],"study_design_scores_gemma":[0.0000068362565,0.00006854101,0.017115386,0.00032801487,0.000010215235,0.00076455186,0.96546406,0.0001918147,0.0005821229,0.0004970654,0.014953997,0.000017340975],"about_ca_topic_score_codex":0.113668464,"about_ca_topic_score_gemma":0.14281121,"teacher_disagreement_score":0.113668464,"about_ca_system_score_codex":0.011153655,"about_ca_system_score_gemma":0.014804452,"threshold_uncertainty_score":0.22601372},"labels":[],"label_agreement":null},{"id":"W2729536024","doi":"10.20959/wjpr20177-8722","title":"A REVIEW ON GENERIC DRUGS REGISTRATION PROCEDURE IN USA &amp; CANADA","year":2017,"lang":"en","type":"review","venue":"World Journal of Pharmaceutical Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacology; Medicine; Business","score_opus":0.5744497842545812,"score_gpt":0.5380934266051773,"score_spread":0.036356357649403814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2729536024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038802167,0.99542,0.000077258184,0.0012365213,0.00024266276,0.000033766795,0.00047069901,0.000008126157,0.0021229284],"genre_scores_gemma":[0.0028302877,0.99536586,0.00024093835,0.0005891992,0.000094096176,0.000013126835,0.00021048212,0.000003722694,0.0006522183],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721426,0.00032371326,0.0004950421,0.00019644147,0.0015251802,0.0002453821],"domain_scores_gemma":[0.98930967,0.0037550507,0.0016180604,0.00015463152,0.0047169975,0.0004454925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004557219,0.00084467174,0.0020590022,0.010021497,0.001131405,0.0025825312,0.001845815,0.00125286,0.0056712497],"category_scores_gemma":[0.012725535,0.00042245432,0.0016911791,0.014767019,0.0012790096,0.0012117571,0.0007875616,0.0015397165,0.0005746221],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001995549,0.000065973305,0.0018920391,0.07600646,0.00045522317,0.00015732813,0.00020341841,0.00041356153,0.00030664948,0.0047926256,0.111169286,0.804338],"study_design_scores_gemma":[0.00006225135,0.00009281928,0.011551564,0.050132245,0.0016999651,0.00032635144,0.00022894674,0.000122037156,0.0003770606,0.00066354475,0.93468374,0.000059461865],"about_ca_topic_score_codex":0.66166145,"about_ca_topic_score_gemma":0.8216034,"teacher_disagreement_score":0.33833855,"about_ca_system_score_codex":0.020113252,"about_ca_system_score_gemma":0.10377878,"threshold_uncertainty_score":0.68066216},"labels":[],"label_agreement":null},{"id":"W2734611933","doi":"10.2139/ssrn.1329308","title":"Pharmaceutical Pricing and Reimbursement Policies in Canada","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Business; Drug pricing; Actuarial science; Economics; Health care; Economic growth","score_opus":0.02875904113165939,"score_gpt":0.28240739020707656,"score_spread":0.25364834907541717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734611933","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7367209,0.020798746,0.00083706336,0.15293972,0.0007560427,0.00020845635,0.019675808,0.00019320767,0.067870066],"genre_scores_gemma":[0.9609775,0.0050087073,0.0005893915,0.0063544987,0.00018901618,0.000032991727,0.0019410119,0.00005341273,0.024853447],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933563,0.00050053006,0.00032831295,0.0003727228,0.0023398846,0.003102153],"domain_scores_gemma":[0.98229086,0.0033088601,0.0021087779,0.00022460039,0.0072298553,0.0048370077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003070342,0.00034208823,0.0009981475,0.0033263399,0.00523488,0.009146768,0.0021235975,0.00446981,0.009139696],"category_scores_gemma":[0.020017046,0.00079834147,0.0015522483,0.007549767,0.0017777678,0.0012342093,0.0013878471,0.0041878857,0.00041544606],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018910969,0.0007848496,0.43825275,0.0006998087,0.0008408002,0.0014884116,0.002780841,0.032755785,0.00080876856,0.23532727,0.20372997,0.08063959],"study_design_scores_gemma":[0.0007955136,0.00017730852,0.79905665,0.0006583458,0.0005777025,0.00034486977,0.004229751,0.03140635,0.00093515037,0.015672013,0.14576232,0.00038394125],"about_ca_topic_score_codex":0.99864167,"about_ca_topic_score_gemma":0.99918836,"teacher_disagreement_score":0.26515505,"about_ca_system_score_codex":0.26515505,"about_ca_system_score_gemma":0.30636352,"threshold_uncertainty_score":0.852316},"labels":[],"label_agreement":null},{"id":"W2735024050","doi":"10.1177/171516350413701002","title":"Drug Regulatory Bodies Dogged by Credibility Crisis","year":2004,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Credibility; Medicine; Political science; Law","score_opus":0.04321773927358489,"score_gpt":0.25552717853986784,"score_spread":0.21230943926628296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735024050","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012644914,0.004837784,0.002000606,0.8893827,0.0032929087,0.0000350219,0.00014858771,0.00011739301,0.08754011],"genre_scores_gemma":[0.46840048,0.0038165883,0.0013352918,0.4686764,0.0054640705,0.00004192202,0.00008950523,0.0001693361,0.05200637],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97876817,0.004350051,0.00053667696,0.0019413022,0.010654679,0.0037490218],"domain_scores_gemma":[0.9295658,0.028585833,0.0054471833,0.0031952863,0.023515522,0.009690408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020636031,0.0004382448,0.000991172,0.0029288854,0.008598126,0.016550072,0.002017414,0.029042823,0.007938598],"category_scores_gemma":[0.101009056,0.0007692218,0.00091779826,0.0022174255,0.018039241,0.0061809868,0.0031274506,0.0305674,0.0012945579],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014739572,0.00003615972,0.0022633376,0.00006739097,0.00006318431,0.0004386693,0.0013574995,0.0009890223,0.0003436643,0.6851363,0.2910101,0.01814716],"study_design_scores_gemma":[0.00021376983,0.00005015564,0.007431606,0.00041404535,0.00007936671,0.0003078127,0.0017041228,0.0028148615,0.0007810753,0.31792095,0.6681373,0.00014491937],"about_ca_topic_score_codex":0.38460904,"about_ca_topic_score_gemma":0.3506572,"teacher_disagreement_score":0.38460904,"about_ca_system_score_codex":0.040630195,"about_ca_system_score_gemma":0.053768925,"threshold_uncertainty_score":0.7647407},"labels":[],"label_agreement":null},{"id":"W2736010367","doi":"10.1787/244264621247","title":"Pharmaceutical Pricing and Reimbursement Policies in Slovakia","year":2008,"lang":"en","type":"paratext","venue":"OECD health working papers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada; Eötvös Loránd Tudományegyetem","keywords":"Reimbursement; Pharmaceutical policy; Incentive; Public economics; Payment; Limiting; Business; Quarter (Canadian coin); Scope (computer science); Competition (biology); Pharmaceutical industry; Economics; Health care; Health policy; Finance; Economic growth; Market economy","score_opus":0.11642908632103247,"score_gpt":0.35949354517050686,"score_spread":0.2430644588494744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736010367","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7822404,0.062049072,0.0010542875,0.045332357,0.0004929459,0.00008047999,0.00506408,0.000173863,0.1035126],"genre_scores_gemma":[0.96864545,0.01363361,0.00054823194,0.004555124,0.00013027736,0.000040322342,0.001485064,0.000030270627,0.010931729],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770856,0.00051714166,0.00028328167,0.0002606862,0.0004192061,0.0008110171],"domain_scores_gemma":[0.9984439,0.00029349836,0.0006408675,0.000060018905,0.00034971727,0.00021212416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022228083,0.00022744204,0.00063951866,0.002201597,0.0013546861,0.0057922397,0.0005533305,0.00197869,0.0036453633],"category_scores_gemma":[0.0033353216,0.0004467493,0.00095142773,0.0026516204,0.0014267837,0.00083210284,0.0015329658,0.001735341,0.00055253104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018552424,0.00053853664,0.23069087,0.003487919,0.0011850891,0.00575229,0.0038551965,0.028650673,0.010542731,0.50537485,0.07415225,0.13391438],"study_design_scores_gemma":[0.00043503605,0.00022895477,0.7933677,0.0014349414,0.00034416237,0.0013566266,0.0015755811,0.0034743836,0.0017179626,0.007170528,0.18875378,0.00014031287],"about_ca_topic_score_codex":0.20684947,"about_ca_topic_score_gemma":0.14117576,"teacher_disagreement_score":0.20684947,"about_ca_system_score_codex":0.015572072,"about_ca_system_score_gemma":0.023013016,"threshold_uncertainty_score":0.41129094},"labels":[],"label_agreement":null},{"id":"W2738563879","doi":"10.18579/jpcrkc/2017/16/2/116432","title":"Drug Master File Filing in US, Europe, Canada and Australia","year":2017,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.38342138121012354,"score_gpt":0.4595554708074974,"score_spread":0.07613408959737389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738563879","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06202718,0.0054074475,0.005629557,0.02614119,0.0025258574,0.002929216,0.025249286,0.002941486,0.86714864],"genre_scores_gemma":[0.3494495,0.009696012,0.019821083,0.023916531,0.00071843213,0.0015874534,0.034283616,0.0030990038,0.5574283],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96552783,0.002475694,0.0020194754,0.002448114,0.022578655,0.004950229],"domain_scores_gemma":[0.92862195,0.0058489214,0.0035655317,0.0037362673,0.05292184,0.0053053964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012431469,0.00048909127,0.000633257,0.006936943,0.006121449,0.009763529,0.0019257906,0.002218961,0.053274132],"category_scores_gemma":[0.05865678,0.0005008104,0.0009137266,0.0069985446,0.0024286313,0.00537396,0.0029734417,0.0023634026,0.019552032],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005246839,0.00024127093,0.028154215,0.0010508054,0.00005389004,0.0007950935,0.0057604513,0.00058577425,0.002737864,0.09388395,0.65290165,0.21331039],"study_design_scores_gemma":[0.000054383596,0.00010031104,0.06853978,0.0007360777,0.000030649906,0.00058955787,0.003821543,0.00037727458,0.0023863665,0.0014441338,0.92178506,0.00013476792],"about_ca_topic_score_codex":0.5598211,"about_ca_topic_score_gemma":0.49593443,"teacher_disagreement_score":0.44017887,"about_ca_system_score_codex":0.030359335,"about_ca_system_score_gemma":0.07273229,"threshold_uncertainty_score":0.88554233},"labels":[],"label_agreement":null},{"id":"W2738734168","doi":"10.1056/nejmp1704489","title":"The Price of Crossing the Border for Medications","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Competition (biology)","score_opus":0.08233974538477716,"score_gpt":0.37725898449067063,"score_spread":0.29491923910589346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738734168","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032757867,0.0072508054,0.007943477,0.1889096,0.0056575383,0.0000483251,0.0013781876,0.0003179444,0.7557362],"genre_scores_gemma":[0.7828004,0.006482482,0.0070878,0.05995881,0.005545356,0.00007780495,0.0013569639,0.0004207536,0.13626961],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9951704,0.00051460415,0.00015006271,0.00035586028,0.0032707748,0.0005383501],"domain_scores_gemma":[0.9930441,0.0024540937,0.00048620027,0.00059210305,0.0022545063,0.0011689311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022302489,0.00040392124,0.00062144164,0.0011101813,0.0031468347,0.011499013,0.0008800291,0.0069753267,0.023148095],"category_scores_gemma":[0.025866501,0.0004096602,0.0007146945,0.0012863642,0.0030718455,0.005803671,0.0017666322,0.0095017655,0.0036764562],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021504184,0.00005284986,0.0021153667,0.00007282903,0.000039512754,0.00034823574,0.00025757373,0.0012689405,0.0008354148,0.71385205,0.22383997,0.05710226],"study_design_scores_gemma":[0.0001592123,0.00019359983,0.015329224,0.00065404165,0.00007650639,0.00094091496,0.00095284,0.0044085924,0.0011540102,0.17860429,0.79740167,0.00012516469],"about_ca_topic_score_codex":0.054645482,"about_ca_topic_score_gemma":0.045067754,"teacher_disagreement_score":0.054645482,"about_ca_system_score_codex":0.01034258,"about_ca_system_score_gemma":0.0069557643,"threshold_uncertainty_score":0.1086548},"labels":[],"label_agreement":null},{"id":"W2743519407","doi":"10.1177/1715163517714201","title":"Drug costs in Canada","year":2017,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.05891626071313478,"score_gpt":0.27431665280086104,"score_spread":0.21540039208772627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743519407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39115393,0.058564924,0.0010366018,0.19680238,0.0022949511,0.0003869252,0.07952918,0.00022124297,0.27000988],"genre_scores_gemma":[0.9033337,0.021161577,0.00087176205,0.007307553,0.0004846641,0.000076067074,0.0077581685,0.000056870584,0.05894961],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99620074,0.00021911449,0.00017721517,0.0002138718,0.0020950343,0.0010940847],"domain_scores_gemma":[0.993616,0.0004545464,0.0006793422,0.00008049493,0.0034247017,0.001744947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079472363,0.00041477018,0.00055509806,0.0042146794,0.0026957777,0.0050906884,0.0010484513,0.0015578356,0.010869842],"category_scores_gemma":[0.008132348,0.0004900278,0.0010636137,0.00783172,0.00089016446,0.000830407,0.0010520713,0.0022533885,0.00048821815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067894196,0.00032157972,0.2483118,0.0010656217,0.0007912588,0.001411879,0.0010206342,0.013486487,0.0004004329,0.1519714,0.4591576,0.1213823],"study_design_scores_gemma":[0.00027621747,0.00011726252,0.56655705,0.000716439,0.00045340485,0.00066024583,0.002122524,0.008688672,0.0004169638,0.00781874,0.41201884,0.00015361317],"about_ca_topic_score_codex":0.9958403,"about_ca_topic_score_gemma":0.9972396,"teacher_disagreement_score":0.15797585,"about_ca_system_score_codex":0.15797585,"about_ca_system_score_gemma":0.19303279,"threshold_uncertainty_score":0.97662866},"labels":[],"label_agreement":null},{"id":"W2743792024","doi":"10.1177/1715163517711144","title":"Drug costs in Canada","year":2017,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.05891626071313478,"score_gpt":0.27431665280086104,"score_spread":0.21540039208772627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743792024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39115393,0.058564924,0.0010366018,0.19680238,0.0022949511,0.0003869252,0.07952918,0.00022124297,0.27000988],"genre_scores_gemma":[0.9033337,0.021161577,0.00087176205,0.007307553,0.0004846641,0.000076067074,0.0077581685,0.000056870584,0.05894961],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99620074,0.00021911449,0.00017721517,0.0002138718,0.0020950343,0.0010940847],"domain_scores_gemma":[0.993616,0.0004545464,0.0006793422,0.00008049493,0.0034247017,0.001744947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079472363,0.00041477018,0.00055509806,0.0042146794,0.0026957777,0.0050906884,0.0010484513,0.0015578356,0.010869842],"category_scores_gemma":[0.008132348,0.0004900278,0.0010636137,0.00783172,0.00089016446,0.000830407,0.0010520713,0.0022533885,0.00048821815],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00067894196,0.00032157972,0.2483118,0.0010656217,0.0007912588,0.001411879,0.0010206342,0.013486487,0.0004004329,0.1519714,0.4591576,0.1213823],"study_design_scores_gemma":[0.00027621747,0.00011726252,0.56655705,0.000716439,0.00045340485,0.00066024583,0.002122524,0.008688672,0.0004169638,0.00781874,0.41201884,0.00015361317],"about_ca_topic_score_codex":0.9958403,"about_ca_topic_score_gemma":0.9972396,"teacher_disagreement_score":0.84202415,"about_ca_system_score_codex":0.15797585,"about_ca_system_score_gemma":0.19303279,"threshold_uncertainty_score":0.97662866},"labels":[],"label_agreement":null},{"id":"W2747517682","doi":"10.1186/s12992-017-0285-x","title":"Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016","year":2017,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Carleton University","funders":"Canadian Institutes of Health Research; Bloomberg L.P.","keywords":"Mergers and acquisitions; Social policy; Quality of Life Research; Mania; Business; Public finance; Public health; Economics; Political science; Medicine; Finance; Psychiatry; Law; Market economy","score_opus":0.09444721960396195,"score_gpt":0.33800347680941223,"score_spread":0.24355625720545027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747517682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8719419,0.021883283,0.0008418069,0.0075532338,0.00029114468,0.00036429233,0.037374705,0.0002165585,0.059533086],"genre_scores_gemma":[0.9414564,0.011462696,0.00085616106,0.0013847824,0.0005058695,0.00020942808,0.03251458,0.00004862497,0.011561379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964954,0.00046824114,0.00043946787,0.00037303218,0.0016602473,0.00056372234],"domain_scores_gemma":[0.9863674,0.0012328915,0.009489434,0.00021065409,0.0016181158,0.0010815648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029638615,0.00046810042,0.0002588444,0.005558685,0.000892321,0.0028976777,0.00054020644,0.00057708536,0.004368382],"category_scores_gemma":[0.011819552,0.0002854186,0.00040795814,0.0070894775,0.00061798503,0.0022108445,0.0023420502,0.0012453188,0.0013960805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063975324,0.00016300978,0.807148,0.0006224201,0.0001428418,0.0011015997,0.0029041367,0.0005424324,0.0003405774,0.005425328,0.08147768,0.09949236],"study_design_scores_gemma":[0.000028566259,0.00014672271,0.9131881,0.0003371069,0.00006836214,0.0016271,0.0027314532,0.00041968442,0.00047458705,0.00067509274,0.08027326,0.000029941804],"about_ca_topic_score_codex":0.016802324,"about_ca_topic_score_gemma":0.020769699,"teacher_disagreement_score":0.016802324,"about_ca_system_score_codex":0.003197546,"about_ca_system_score_gemma":0.0031128444,"threshold_uncertainty_score":0.033409},"labels":[],"label_agreement":null},{"id":"W2748295223","doi":"10.1371/journal.pone.0182742","title":"The cost of entry: An analysis of pharmaceutical registration fees in low-, middle-, and high-income countries","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of British Columbia","keywords":"Gross domestic product; Business; Authorization; Population; Product (mathematics); Public economics; Medicine; Environmental health; Economics; Economic growth","score_opus":0.12290040756593322,"score_gpt":0.30926712340999885,"score_spread":0.1863667158440656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748295223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903858,0.0012431006,0.0005720092,0.0005090154,0.000013094819,0.000047149737,0.004606922,0.000013616354,0.0026093235],"genre_scores_gemma":[0.99681634,0.00020501204,0.00014122787,0.00005746692,0.000011904192,0.000013871286,0.0025741016,0.000004944384,0.0001751333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964474,0.0013059217,0.0004564642,0.00042707514,0.00058696576,0.0007762156],"domain_scores_gemma":[0.9725389,0.010250982,0.013536252,0.0006350279,0.0016057935,0.0014329872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031717252,0.0003893703,0.0007196424,0.0038293155,0.0005626359,0.0028021047,0.00066236657,0.00079765596,0.0032054498],"category_scores_gemma":[0.01759044,0.00040383998,0.0023313453,0.005904334,0.0010382492,0.0020354805,0.0017978786,0.0012345174,0.0003140593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019893819,0.000047436766,0.99005616,0.000062779705,0.00030740388,0.00020602919,0.000116512114,0.004198779,0.00003586716,0.0015245063,0.0009974273,0.0022482781],"study_design_scores_gemma":[0.000046128105,0.00012295433,0.9884674,0.00006636988,0.00017437576,0.0004433519,0.00066799915,0.0072477334,0.0001263413,0.0006675832,0.0019428782,0.000026981008],"about_ca_topic_score_codex":0.022734644,"about_ca_topic_score_gemma":0.009562465,"teacher_disagreement_score":0.022734644,"about_ca_system_score_codex":0.002262259,"about_ca_system_score_gemma":0.0010961472,"threshold_uncertainty_score":0.04520464},"labels":[],"label_agreement":null},{"id":"W2750285636","doi":"10.1503/cmaj.1095454","title":"Tackling Pharma corruption in Ukraine","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Christian ministry; Guard (computer science); Language change; Procurement; Outsourcing; Business; Political science; Public administration; Medicine; Economic growth; Computer science; Law; Economics; Marketing","score_opus":0.04233519668014477,"score_gpt":0.3006444263596866,"score_spread":0.2583092296795418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750285636","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62012106,0.03430257,0.011273437,0.15941718,0.00084461883,0.0002200846,0.00020742281,0.000198231,0.17341544],"genre_scores_gemma":[0.9813936,0.0041017863,0.0013771775,0.007346131,0.00011018308,0.000028490533,0.000036679055,0.000018335446,0.005587632],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733305,0.0011351322,0.00009295934,0.00012216548,0.00040025797,0.000916367],"domain_scores_gemma":[0.9974245,0.0005272363,0.00085759006,0.00011939177,0.00039394872,0.00067736546],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002835354,0.00021424024,0.00041234816,0.0009187248,0.0034359398,0.00430125,0.00047266766,0.0014015638,0.0024612807],"category_scores_gemma":[0.0035969694,0.00015615781,0.00030417452,0.00084173115,0.0018646005,0.0016305603,0.0051071616,0.0018460433,0.00028330853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028134556,0.00057921844,0.12154182,0.0017678208,0.00033132578,0.007651563,0.01810841,0.012440095,0.004170983,0.526822,0.057512518,0.24879292],"study_design_scores_gemma":[0.00014762724,0.0006460056,0.23936222,0.004644348,0.00021525871,0.0028935664,0.045324873,0.0141418595,0.0057195337,0.11740901,0.5693689,0.00012672963],"about_ca_topic_score_codex":0.017782122,"about_ca_topic_score_gemma":0.028923333,"teacher_disagreement_score":0.99859846,"about_ca_system_score_codex":0.005726067,"about_ca_system_score_gemma":0.01632623,"threshold_uncertainty_score":0.04154575},"labels":[],"label_agreement":null},{"id":"W2751738273","doi":"10.2139/ssrn.3024095","title":"&lt;p&gt;&lt;b&gt;&lt;span&gt;Launch Price and Advertising as Strategic Substitutes: Evidence from Pharmaceutical Markets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;","year":2017,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medical prescription; Power (physics); Business; Economics; Medicine; Pharmacology; Physics","score_opus":0.05740121175034991,"score_gpt":0.31022022908207775,"score_spread":0.25281901733172785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751738273","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19133219,0.058181245,0.0071490332,0.11148391,0.0020777292,0.00018599333,0.017517846,0.0005480643,0.611524],"genre_scores_gemma":[0.8342011,0.038277313,0.0024691042,0.009645312,0.0011273699,0.00009706134,0.004906625,0.00034143866,0.108934626],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99902284,0.0002931931,0.000058486825,0.00013106506,0.00038262064,0.00011183189],"domain_scores_gemma":[0.9820726,0.011341702,0.0039027464,0.00060932076,0.0013222024,0.00075139717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016338293,0.00044250695,0.0006546957,0.0018440709,0.00094489136,0.0043582562,0.00060635415,0.002604649,0.072912],"category_scores_gemma":[0.0115292035,0.00032533068,0.0005551597,0.0039844927,0.0017497286,0.0039946185,0.0008186568,0.0016446046,0.010722116],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019919267,0.00056722655,0.038486656,0.0016614656,0.00039414293,0.00081103056,0.00047119905,0.0034327125,0.00093604444,0.18097137,0.3827576,0.38751855],"study_design_scores_gemma":[0.0011001149,0.00089228613,0.13126472,0.0016686562,0.001205085,0.0004507531,0.0020785425,0.008049199,0.0080423895,0.29202518,0.5529893,0.00023376917],"about_ca_topic_score_codex":0.021481624,"about_ca_topic_score_gemma":0.030475,"teacher_disagreement_score":0.072912,"about_ca_system_score_codex":0.0023032092,"about_ca_system_score_gemma":0.0025940556,"threshold_uncertainty_score":0.24391496},"labels":[],"label_agreement":null},{"id":"W2751849735","doi":"10.1016/s2468-2667(17)30141-x","title":"Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data","year":2017,"lang":"en","type":"article","venue":"The Lancet Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Université Laval; Simon Fraser University; Population Health Research Institute; McMaster University","funders":"Deanship of Scientific Research, King Saud University; Philippine Council for Health Research and Development; Canadian Institutes of Health Research; Servier; Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu; United Arab Emirates University; Universiti Kebangsaan Malaysia; Universiti Teknologi MARA; International Development Research Centre; Svenska Forskningsrådet Formas; Forskningsrådet för Arbetsliv och Socialvetenskap; Indian Council of Medical Research; North-West University; South Africa Netherlands research Programme on Alternatives in Development; Public Health Agency of Canada; AFA Försäkring; Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences; Universidad de La Frontera; Ministerstwo Edukacji i Nauki; GlaxoSmithKline; Vetenskapsrådet; Heart and Stroke Foundation of Canada; Boehringer Ingelheim; Ministry of Higher Education, Malaysia; AstraZeneca Canada; AstraZeneca","keywords":"Developing country; Medicine; Environmental health; Business; Economics; Economic growth","score_opus":0.06005507458694665,"score_gpt":0.325043724570828,"score_spread":0.26498864998388133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751849735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985721,0.00024644096,0.00007232441,0.000015240605,0.0000018548785,0.000011771378,0.0009359898,0.000002040989,0.00014222282],"genre_scores_gemma":[0.99841905,0.00012888244,0.00013345294,0.00001460022,0.000004421371,0.00002985637,0.0012269401,0.000002193483,0.000040620926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99614125,0.002090465,0.00049832737,0.000499692,0.00042653087,0.00034380288],"domain_scores_gemma":[0.9889731,0.0040338854,0.0047209864,0.0010856305,0.00064446614,0.000541993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003448214,0.00053581654,0.0010467811,0.0024467644,0.0005296183,0.0010466026,0.0008433215,0.00043080136,0.0016592868],"category_scores_gemma":[0.00688338,0.0005535608,0.0025010149,0.0046781264,0.000677764,0.0008400024,0.0020824089,0.00061154953,0.00017414885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021858723,0.000037569633,0.997974,0.000058102032,0.00072439044,0.00007397,0.00014351908,0.00011471391,0.000048424732,0.000026034768,0.00007303825,0.00050771417],"study_design_scores_gemma":[0.000013515242,0.00012755275,0.99839383,0.000018112994,0.00019929795,0.00011758714,0.00058711064,0.00038324497,0.000026322852,0.000017477902,0.00010933872,0.0000065738627],"about_ca_topic_score_codex":0.0139578115,"about_ca_topic_score_gemma":0.014700305,"teacher_disagreement_score":0.0139578115,"about_ca_system_score_codex":0.00039183217,"about_ca_system_score_gemma":0.00044570657,"threshold_uncertainty_score":0.027753115},"labels":[],"label_agreement":null},{"id":"W2752438457","doi":"10.1111/poms.12780","title":"Contracts to Promote Optimal Use of Optional Diagnostic Tests in Cancer Treatment","year":2017,"lang":"en","type":"article","venue":"Production and Operations Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Wilfrid Laurier University","funders":"Natural Sciences and Engineering Research Council of Canada; Hong Kong Polytechnic University; University of Hong Kong; Centers for Disease Control and Prevention; National Comprehensive Cancer Network","keywords":"Test (biology); Radiation oncologist; Health care; Moral hazard; Diagnostic test; Payment; Quality (philosophy); Medicine; Actuarial science; Adverse selection; Private information retrieval; Business; Incentive; Economics; Finance; Internal medicine; Computer science; Pediatrics; Microeconomics","score_opus":0.12128450182497498,"score_gpt":0.3441382699279324,"score_spread":0.22285376810295743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752438457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50998515,0.0040041613,0.30231127,0.023970688,0.0005954025,0.002377601,0.0011599791,0.00049407606,0.15510166],"genre_scores_gemma":[0.9810017,0.00045333823,0.011475295,0.0011190762,0.0001711633,0.00037302237,0.00008413772,0.000025903972,0.005296385],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9681506,0.020427905,0.001174446,0.0018087699,0.0036076813,0.0048305695],"domain_scores_gemma":[0.8791039,0.08791891,0.020180646,0.004508873,0.0038241283,0.0044635846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.033069547,0.001551254,0.0022735547,0.0012560938,0.0015018135,0.0044525773,0.0027407934,0.007964319,0.009867278],"category_scores_gemma":[0.10037239,0.0013323171,0.0013201847,0.001273098,0.00426339,0.0061062835,0.0034217297,0.0058039436,0.0007158107],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015240663,0.0014214485,0.01318413,0.000599158,0.00032860957,0.0005655952,0.00076299015,0.18991138,0.0030113396,0.727973,0.005969297,0.05474897],"study_design_scores_gemma":[0.0021103355,0.0020348087,0.017454945,0.0006368278,0.00029366286,0.0006748212,0.0007214653,0.2970734,0.0027197436,0.65261877,0.02347369,0.00018756927],"about_ca_topic_score_codex":0.0031678244,"about_ca_topic_score_gemma":0.0019822847,"teacher_disagreement_score":0.033069547,"about_ca_system_score_codex":0.006712515,"about_ca_system_score_gemma":0.0092088,"threshold_uncertainty_score":0.17489058},"labels":[],"label_agreement":null},{"id":"W2754568616","doi":"","title":"Pharmaceutical practices in France and in Quebec and exchange prospects","year":2002,"lang":"en","type":"article","venue":"Journal de Pharmacie Clinique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.15613457282557777,"score_gpt":0.38498353689260834,"score_spread":0.22884896406703056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754568616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98003024,0.0034073375,0.0001470958,0.0058158967,0.000023612056,0.00002234268,0.0028112065,0.000018323197,0.007723858],"genre_scores_gemma":[0.9916352,0.0008151325,0.00007836597,0.00025748566,0.000017459635,0.000007768196,0.00074434327,0.0000046670184,0.006439457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858296,0.0003046564,0.00007862184,0.00012617312,0.00031251353,0.000595199],"domain_scores_gemma":[0.99407554,0.0010672701,0.0017867513,0.00008908114,0.0013458005,0.0016355173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010526172,0.000227917,0.00037177882,0.0022487778,0.0018991007,0.003627122,0.00091494445,0.001451095,0.006706868],"category_scores_gemma":[0.004376135,0.00020913238,0.00050249306,0.005463406,0.00093437533,0.0012697043,0.0011017134,0.0014785173,0.00031022518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034444034,0.00021829995,0.96029425,0.00005964791,0.00024685555,0.0007147977,0.0031096442,0.0021759358,0.0001925236,0.0075926874,0.0056968266,0.019354222],"study_design_scores_gemma":[0.000012739773,0.000032314652,0.9914063,0.000027620003,0.000018943994,0.00006540957,0.0025498986,0.00073139014,0.00003843155,0.00011953863,0.0049815294,0.000015944108],"about_ca_topic_score_codex":0.9727832,"about_ca_topic_score_gemma":0.9864442,"teacher_disagreement_score":0.035743076,"about_ca_system_score_codex":0.035743076,"about_ca_system_score_gemma":0.012983047,"threshold_uncertainty_score":0.25933534},"labels":[],"label_agreement":null},{"id":"W2755091626","doi":"10.55016/ojs/sppp.v2i1.42316","title":"Generic Drug Pricing and Procurement: A Policy for Alberta","year":2009,"lang":"en","type":"article","venue":"The School of Public Policy Publications","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Drug pricing; Procurement; Business; Drug; Actuarial science; Marketing; Pharmacology; Medicine","score_opus":0.08461818533324403,"score_gpt":0.31983079935070446,"score_spread":0.23521261401746044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755091626","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03120523,0.009008179,0.0024992314,0.61432743,0.0042456146,0.00051797676,0.0023985826,0.0005831594,0.33521453],"genre_scores_gemma":[0.16885485,0.010084198,0.011231416,0.10850963,0.00090880337,0.00013687016,0.0014776002,0.00012855629,0.698668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960957,0.00021778358,0.000092035254,0.0001925597,0.002107137,0.0012948026],"domain_scores_gemma":[0.99481684,0.0005307045,0.0001420194,0.0001503996,0.0020653151,0.0022946536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003063472,0.00049120374,0.00041043657,0.0010915544,0.007327581,0.0070145754,0.0023549618,0.008989727,0.023041649],"category_scores_gemma":[0.0058891894,0.00052019936,0.0006342149,0.0018350764,0.0021084624,0.0022093346,0.0021046996,0.0038818538,0.0021060721],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002758156,0.0003080413,0.0087391725,0.00031638946,0.000033728225,0.0013204182,0.00071572006,0.002479227,0.0020845411,0.2093144,0.6461271,0.12828548],"study_design_scores_gemma":[0.00018948782,0.00012179179,0.016147144,0.0002287055,0.000032857308,0.00022194523,0.0014273124,0.002640358,0.00075217045,0.010313703,0.9678324,0.000092126094],"about_ca_topic_score_codex":0.96143734,"about_ca_topic_score_gemma":0.9758848,"teacher_disagreement_score":0.074114814,"about_ca_system_score_codex":0.074114814,"about_ca_system_score_gemma":0.31264138,"threshold_uncertainty_score":0.5377431},"labels":[],"label_agreement":null},{"id":"W2759020488","doi":"","title":"The role of the economic analysis in the decision making process at the Drug Quality and Therapeutics Committee of Ontario","year":2000,"lang":"en","type":"dissertation","venue":"TSpace (University of Toronto)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality (philosophy); Drug; Process (computing); Medicine; Management science; Political science; Risk analysis (engineering); Pharmacology; Engineering; Computer science","score_opus":0.0325307249676474,"score_gpt":0.3070082247096982,"score_spread":0.27447749974205077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759020488","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019881608,0.026802436,0.010933097,0.67028296,0.0019452729,0.0003258081,0.0009607097,0.0000595743,0.26880845],"genre_scores_gemma":[0.65342367,0.042461865,0.027686186,0.027636657,0.0029068477,0.00023450216,0.000509138,0.0002250377,0.24491614],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9832978,0.005573532,0.00062935485,0.00085725693,0.0070903483,0.0025518122],"domain_scores_gemma":[0.946363,0.025407314,0.002135585,0.0010976833,0.020031711,0.004964707],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02392159,0.00040997585,0.0005471892,0.0019371363,0.010131932,0.010960037,0.0010849413,0.0035741127,0.010057912],"category_scores_gemma":[0.04924885,0.00066985236,0.0004600065,0.002918231,0.0073067923,0.0026042354,0.0014557872,0.0039713606,0.001035328],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012825246,0.00003519534,0.010345354,0.00040132675,0.00009277974,0.00031028633,0.0044713845,0.004396054,0.0006894501,0.53252465,0.37605044,0.07055493],"study_design_scores_gemma":[0.000111058216,0.000034531608,0.037287153,0.0011138082,0.00013682338,0.000073301395,0.0032157195,0.010199673,0.0012298003,0.114777096,0.83160144,0.00021962913],"about_ca_topic_score_codex":0.92180365,"about_ca_topic_score_gemma":0.9612727,"teacher_disagreement_score":0.9760784,"about_ca_system_score_codex":0.11451916,"about_ca_system_score_gemma":0.21304466,"threshold_uncertainty_score":0.8308985},"labels":[],"label_agreement":null},{"id":"W2762117546","doi":"10.1093/pch/pxy014","title":"What does mainstream media say about enzyme replacement therapies?","year":2018,"lang":"en","type":"article","venue":"Paediatrics & Child Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Mainstream; Medicine; Government (linguistics); Thematic analysis; Family medicine; Inclusion (mineral); Clinical trial; Health care; Psychology; Political science; Qualitative research; Pathology","score_opus":0.030421992523179786,"score_gpt":0.2905839722643495,"score_spread":0.2601619797411697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762117546","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09574657,0.24245898,0.0009159731,0.5417486,0.0051884945,0.00012038728,0.004702389,0.00006384313,0.10905481],"genre_scores_gemma":[0.67126423,0.233737,0.0006939151,0.07643615,0.011212067,0.00010997769,0.0014870237,0.00009254076,0.0049670916],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9893505,0.003618125,0.0013217385,0.00063353596,0.0043662693,0.0007098881],"domain_scores_gemma":[0.8201997,0.13642369,0.02499654,0.001660475,0.013984422,0.0027351214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012532162,0.00050255965,0.0008429226,0.009342288,0.001964221,0.012241892,0.00091052917,0.0030473424,0.011096193],"category_scores_gemma":[0.113161966,0.00041437816,0.00059606344,0.009616289,0.005620117,0.011849363,0.0019087538,0.0021610844,0.0013100504],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012841013,0.00022602572,0.08308896,0.044598866,0.0007040778,0.0019127122,0.07262321,0.0004020094,0.0013944975,0.068175435,0.20243548,0.5231547],"study_design_scores_gemma":[0.00015947642,0.00026576247,0.12698445,0.08483073,0.0009159713,0.0020464812,0.096590206,0.0005524406,0.0010269863,0.02376536,0.6626889,0.00017319985],"about_ca_topic_score_codex":0.03346326,"about_ca_topic_score_gemma":0.024022676,"teacher_disagreement_score":0.03346326,"about_ca_system_score_codex":0.008342218,"about_ca_system_score_gemma":0.0071512447,"threshold_uncertainty_score":0.06653696},"labels":[],"label_agreement":null},{"id":"W2762459231","doi":"10.1080/13543776.2018.1388780","title":"Bill C-30: who wins and who loses in Canada’s pharmaceutical patent battles?","year":2017,"lang":"en","type":"editorial","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Business; Patent analysis; Patent troll; Patent law; Law; Political science; Computer science; Intellectual property","score_opus":0.14818294676430427,"score_gpt":0.340395631864411,"score_spread":0.19221268510010675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762459231","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006315545,0.012419913,0.00009010532,0.45138875,0.52971005,0.00004110642,0.00022460026,0.00004392681,0.006018364],"genre_scores_gemma":[0.0014828764,0.009604037,0.00020142457,0.31544816,0.6483722,0.00006777769,0.00010284199,0.00007325434,0.024647491],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9799137,0.0022469657,0.0019228713,0.0017378015,0.011462607,0.0027160414],"domain_scores_gemma":[0.94376683,0.024091402,0.0027347717,0.0011160561,0.02240325,0.005887659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017559888,0.00318886,0.0043357713,0.0056743966,0.010147448,0.016163614,0.007937679,0.08582657,0.014934069],"category_scores_gemma":[0.07173857,0.0017391151,0.0033243771,0.0044033495,0.009088782,0.006452271,0.0026861683,0.055466153,0.007125523],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005040503,0.0000031761326,0.000012487554,0.000035807632,0.000004156102,0.00002879107,0.000014063598,0.0000069128423,0.0000059087247,0.00040768276,0.99843067,0.0010453343],"study_design_scores_gemma":[0.00004951619,0.0000075266107,0.00029037934,0.00065794715,0.00004600809,0.00006429541,0.00014075763,0.0000859173,0.00005103707,0.001919576,0.9966479,0.000039118342],"about_ca_topic_score_codex":0.1993058,"about_ca_topic_score_gemma":0.39482814,"teacher_disagreement_score":0.9681714,"about_ca_system_score_codex":0.03182857,"about_ca_system_score_gemma":0.05841027,"threshold_uncertainty_score":0.39629143},"labels":[],"label_agreement":null},{"id":"W2765265353","doi":"10.1177/1468018117734153","title":"The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries","year":2017,"lang":"en","type":"article","venue":"Global Social Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Intellectual property; General partnership; Negotiation; Developing country; Legislature; Differential treatment; Political science; Criticism; Politics; Differential (mechanical device); Business; International trade; Law and economics; Economics; Economic growth; Law; Engineering","score_opus":0.12673319282987103,"score_gpt":0.35879654926922266,"score_spread":0.23206335643935164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765265353","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10781032,0.011146893,0.004448449,0.044613577,0.00043522828,0.0002213306,0.00061124447,0.000038011985,0.8306748],"genre_scores_gemma":[0.95062953,0.011550148,0.0025480238,0.00932573,0.00020016277,0.0002938293,0.0004622551,0.00006416369,0.024926152],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98371327,0.007376421,0.0005363937,0.00060757954,0.0052809888,0.0024853384],"domain_scores_gemma":[0.9861443,0.007743793,0.0020612031,0.00065100903,0.0021107546,0.0012889022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01600808,0.00036217982,0.0003007686,0.0023991342,0.0043257107,0.012493564,0.000808151,0.0021762012,0.009538636],"category_scores_gemma":[0.027223606,0.00024153196,0.00063747825,0.0052623996,0.008883543,0.009650536,0.011666936,0.005612404,0.00060742686],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010240408,0.000066598186,0.011718169,0.0004388578,0.00003455065,0.00090760516,0.008850101,0.00084238395,0.00020072723,0.9207009,0.0097945435,0.04634314],"study_design_scores_gemma":[0.00011589296,0.00039533482,0.07296488,0.0036924486,0.00011492869,0.001302109,0.056074232,0.0012353489,0.002495997,0.3380985,0.5233609,0.00014940176],"about_ca_topic_score_codex":0.011588281,"about_ca_topic_score_gemma":0.013765897,"teacher_disagreement_score":0.01600808,"about_ca_system_score_codex":0.0062126545,"about_ca_system_score_gemma":0.01510805,"threshold_uncertainty_score":0.084659815},"labels":[],"label_agreement":null},{"id":"W2765388428","doi":"10.1016/j.jval.2017.08.2753","title":"Interrupted Time Series Analysis Evaluating The Impact of A Pro-Generic Policy on Drug Pricing and Utilization In Argentina","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Unit price; Unit (ring theory); Interrupted time series; Interrupted Time Series Analysis; Generic drug; Panel data; Public economics; Economics; Drug; Business; Econometrics; Medicine; Macroeconomics; Statistics; Pharmacology; Mathematics","score_opus":0.25661781000631123,"score_gpt":0.4364669964465159,"score_spread":0.17984918644020464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765388428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392736,0.0007500943,0.0010052491,0.0009984465,0.000056426863,0.0000144949345,0.0016994006,0.000038604896,0.0015098962],"genre_scores_gemma":[0.9949744,0.00058142334,0.000368125,0.000050907463,0.0000650007,0.000020247004,0.0025249522,0.000011949024,0.0014030548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865663,0.0005772927,0.0000884489,0.0001665276,0.00017543472,0.00033557473],"domain_scores_gemma":[0.9934062,0.0034998967,0.0016139748,0.00032621768,0.00076666503,0.0003870194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002465362,0.00042849,0.0009453745,0.00069166016,0.00032304172,0.0015393911,0.00080877426,0.0010856108,0.0022552651],"category_scores_gemma":[0.00794201,0.00027876886,0.00066868606,0.0013625713,0.00054178044,0.0006782935,0.000629093,0.0014710537,0.00025706037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007619788,0.0019174111,0.7239534,0.000390572,0.00144027,0.0028559396,0.0007574137,0.18593924,0.0035092698,0.02698821,0.014525145,0.030103324],"study_design_scores_gemma":[0.00047932324,0.001147227,0.67470413,0.00006885995,0.000657947,0.00036443432,0.0012220964,0.30627704,0.0015410039,0.0046705576,0.008772948,0.00009449327],"about_ca_topic_score_codex":0.10077718,"about_ca_topic_score_gemma":0.038971648,"teacher_disagreement_score":0.10077718,"about_ca_system_score_codex":0.0024612856,"about_ca_system_score_gemma":0.001144927,"threshold_uncertainty_score":0.20038116},"labels":[],"label_agreement":null},{"id":"W2767071034","doi":"10.1684/pnv.2017.0679","title":"High rate of errors in pillbox filling by cognitively healthy elderly people","year":2017,"lang":"en","type":"article","venue":"Gériatrie et Psychologie Neuropsychiatrie du Viellissement","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psychology; Geriatric Depression Scale; Task (project management); Cognition; Stroop effect; Commit; Neuropsychology; Depressive symptoms; Psychiatry; Computer science","score_opus":0.05656790365275587,"score_gpt":0.3261221446164835,"score_spread":0.2695542409637276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767071034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994186,0.00016560331,0.00008001381,0.000015517746,0.0000062987788,0.0000065440995,0.00005922578,0.0000060657953,0.00024204628],"genre_scores_gemma":[0.99926907,0.00012427672,0.00011567007,0.000029620109,0.000012904292,0.000005035209,0.00011463712,0.00000281791,0.00032599634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876946,0.00023167266,0.00022844838,0.00017670843,0.00047823272,0.00011539502],"domain_scores_gemma":[0.9967182,0.0006988016,0.0016831637,0.00027510506,0.0003986393,0.00022599977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073361763,0.00048293077,0.00047697467,0.0010446358,0.00033975916,0.00053350924,0.00025325728,0.00054172165,0.0010519346],"category_scores_gemma":[0.0048555555,0.00019635164,0.00036698257,0.0005263248,0.0002912451,0.0003852287,0.00046698004,0.00036042076,0.00039285605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042391388,0.00016998548,0.9831872,0.00006317096,0.0000764645,0.0011619756,0.0009143163,0.000038050577,0.001571602,0.000021682366,0.00017201972,0.012199619],"study_design_scores_gemma":[0.0000070050146,0.000311489,0.9966647,0.000016464463,0.000028549252,0.0016747785,0.00040750287,0.00011973737,0.00044993634,0.0000499623,0.0002613138,0.000008570699],"about_ca_topic_score_codex":0.0019460595,"about_ca_topic_score_gemma":0.002211778,"teacher_disagreement_score":0.0019460595,"about_ca_system_score_codex":0.000160265,"about_ca_system_score_gemma":0.00022756372,"threshold_uncertainty_score":0.0038797855},"labels":[],"label_agreement":null},{"id":"W2767845149","doi":"10.1161/circ.134.suppl_1.12799","title":"Abstract 12799: Hospitalizations and Emergency Consultations Following Generic Antihypertensive Drugs Commercialization in Quebec","year":2016,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Institut National de Santé Publique du Québec; Université Laval","funders":"","keywords":"Medicine; Commercialization; Emergency department; Family medicine; Medical emergency; Emergency medicine; Intensive care medicine; Nursing","score_opus":0.044759773805366436,"score_gpt":0.2789102906140184,"score_spread":0.23415051680865195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767845149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97975874,0.00068148016,0.0003621232,0.00032156313,0.000014490854,0.000044653192,0.016807072,0.00002244993,0.0019875537],"genre_scores_gemma":[0.99367684,0.00022063748,0.00016754428,0.000064645836,0.000010094532,0.000017516533,0.004682811,0.0000046692912,0.0011551947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994093,0.000091674556,0.000046305973,0.00010773344,0.00019341947,0.00015156077],"domain_scores_gemma":[0.9977202,0.00029638901,0.0010275153,0.00006986337,0.00061607687,0.00026995377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006608533,0.00017782056,0.00024235227,0.0007478099,0.0004413257,0.0005715823,0.0006016114,0.00034431854,0.005086582],"category_scores_gemma":[0.0022477605,0.0001064586,0.00044930924,0.0016570772,0.00022811876,0.00024137957,0.0003631804,0.0005262367,0.00018259471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012448848,0.000037762744,0.9920736,0.000058168236,0.0000770097,0.00006804053,0.000121761244,0.00029752258,0.000157676,0.000045382676,0.0016380323,0.0053005274],"study_design_scores_gemma":[0.0000029433202,0.000017777564,0.999206,0.000007813632,0.000009893789,0.00001601815,0.00006364193,0.00036949752,0.000023345334,0.0000030149354,0.00027781195,0.0000022713023],"about_ca_topic_score_codex":0.9482298,"about_ca_topic_score_gemma":0.93883425,"teacher_disagreement_score":0.05177021,"about_ca_system_score_codex":0.007463783,"about_ca_system_score_gemma":0.0051273303,"threshold_uncertainty_score":0.10415012},"labels":[],"label_agreement":null},{"id":"W2768318977","doi":"10.1089/omi.2017.0141","title":"Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New “Fast-Second Winner” Strategy","year":2017,"lang":"en","type":"article","venue":"OMICS A Journal of Integrative Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Heart, Lung, and Blood Institute; United Arab Emirates University","keywords":"Precision medicine; Genomic medicine; Personalized medicine; Computer science; Business; Biology; Computational biology; Genetics","score_opus":0.1397923509181222,"score_gpt":0.4010220524421782,"score_spread":0.261229701524056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768318977","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01840523,0.028758138,0.052167762,0.7749574,0.0036761179,0.00032941776,0.00022148578,0.00025920305,0.12122527],"genre_scores_gemma":[0.6318775,0.025182974,0.071027994,0.24340157,0.0020120675,0.0009249417,0.00026626737,0.000242947,0.025063735],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98231435,0.0090432875,0.0007370364,0.0017261406,0.0033369104,0.0028422698],"domain_scores_gemma":[0.98120785,0.00981115,0.0017473986,0.0017708432,0.002792796,0.0026699437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04278293,0.0012451024,0.0011159361,0.0024172005,0.004581165,0.02122112,0.0028641392,0.012763566,0.0064404085],"category_scores_gemma":[0.03146354,0.00050386623,0.0012429411,0.0017911778,0.020834342,0.03031268,0.013772113,0.011152183,0.0014644251],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006984539,0.00005407239,0.0014070659,0.00034978878,0.000040902643,0.00026382916,0.0023041465,0.000650158,0.00046712483,0.93183845,0.01960347,0.04295117],"study_design_scores_gemma":[0.00012434369,0.0002462759,0.0017149629,0.0016915547,0.000057869536,0.00042734644,0.008633455,0.0015805572,0.0010156231,0.6843468,0.30005035,0.000110966495],"about_ca_topic_score_codex":0.0033017304,"about_ca_topic_score_gemma":0.0028711872,"teacher_disagreement_score":0.04278293,"about_ca_system_score_codex":0.0073920824,"about_ca_system_score_gemma":0.019496523,"threshold_uncertainty_score":0.22626048},"labels":[],"label_agreement":null},{"id":"W2769848324","doi":"10.2147/ceor.s144695","title":"Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?","year":2017,"lang":"en","type":"article","venue":"ClinicoEconomics and Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute; Institute of Health Services and Policy Research; Oakville-Trafalgar Memorial Hospital; Canadian Institute for Health Information","funders":"","keywords":"Accountability; Transparency (behavior); Health care; Corporate governance; Public administration; Reimbursement; Agency (philosophy); Government (linguistics); Political science; Public relations; Medicine; Business; Law; Sociology; Finance; Social science","score_opus":0.19176607204055293,"score_gpt":0.42345594978000467,"score_spread":0.23168987773945174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769848324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38756332,0.010755784,0.013515243,0.26426023,0.0010229235,0.0031570273,0.0070726494,0.00062041945,0.3120324],"genre_scores_gemma":[0.94842255,0.0029410669,0.008155673,0.023808308,0.00009917755,0.00036890386,0.0016945682,0.0001233181,0.014386566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9125721,0.013642171,0.0051641613,0.005238224,0.044596255,0.018787142],"domain_scores_gemma":[0.7987119,0.03785969,0.029779706,0.012162226,0.10512095,0.01636555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.044421636,0.00040202469,0.0009841317,0.0037963344,0.01567402,0.018677449,0.00414193,0.0033695865,0.006478342],"category_scores_gemma":[0.17403041,0.0009232509,0.0012753882,0.0143853305,0.007290255,0.0060860394,0.00379374,0.0050851246,0.00087926013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033077606,0.000499679,0.34975377,0.0010266582,0.00039934652,0.0006856827,0.049986456,0.005051182,0.00076716155,0.21007326,0.14477754,0.2366484],"study_design_scores_gemma":[0.00025957724,0.00014578528,0.6263693,0.0013833205,0.00022165287,0.00023505013,0.027620532,0.00620614,0.0009956764,0.019699363,0.31633586,0.0005278054],"about_ca_topic_score_codex":0.9935243,"about_ca_topic_score_gemma":0.9949995,"teacher_disagreement_score":0.76253456,"about_ca_system_score_codex":0.23746546,"about_ca_system_score_gemma":0.4296468,"threshold_uncertainty_score":0.88443196},"labels":[],"label_agreement":null},{"id":"W2770180185","doi":"10.1186/s13012-017-0671-z","title":"The impact of a physician detailing and sampling program for generic atorvastatin: an interrupted time series analysis","year":2017,"lang":"en","type":"article","venue":"Implementation Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of Alberta; University of British Columbia","funders":"Institute of Health Services and Policy Research; National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Atorvastatin; Medicine; Statin; Medical prescription; Family medicine; Internal medicine; Pharmacology","score_opus":0.20557690782907959,"score_gpt":0.5039357824066903,"score_spread":0.2983588745776108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770180185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879062,0.0010912538,0.007133531,0.000991479,0.000092557166,0.00019814172,0.0016368487,0.00004830868,0.00090160413],"genre_scores_gemma":[0.9955178,0.0002791295,0.0021609543,0.00014402998,0.000055023807,0.0001670785,0.0012652681,0.000008893783,0.00040167483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9810097,0.012665676,0.0011092133,0.0017439786,0.001950071,0.0015214031],"domain_scores_gemma":[0.9207563,0.049298607,0.021429976,0.003297639,0.0027171737,0.002500397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026964972,0.00057803857,0.0010094013,0.0016354292,0.00051834155,0.0014681057,0.0020315293,0.0011219927,0.0023024147],"category_scores_gemma":[0.056488384,0.00040292344,0.002412811,0.0027382062,0.0008030242,0.00074024743,0.0012551269,0.0020019705,0.00019267065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036080081,0.0009825787,0.9531586,0.0002790401,0.003083525,0.00039531098,0.00068727025,0.019067788,0.00040082843,0.0016249692,0.0014586968,0.015253299],"study_design_scores_gemma":[0.0004663419,0.0024196273,0.7931955,0.00017843049,0.002519318,0.00016742024,0.0010466345,0.19608732,0.0005660406,0.0011204899,0.0021523186,0.00008055972],"about_ca_topic_score_codex":0.094271585,"about_ca_topic_score_gemma":0.03219448,"teacher_disagreement_score":0.094271585,"about_ca_system_score_codex":0.0038637638,"about_ca_system_score_gemma":0.0036243277,"threshold_uncertainty_score":0.18744576},"labels":[],"label_agreement":null},{"id":"W2770561817","doi":"10.21518/1561-5936-2017-10-62-65","title":"Financial results of pharmaceutical industry: I quarter of 2017","year":2017,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Business; Pharmaceutical industry; Finance; Medicine; Geography; Pharmacology","score_opus":0.05145097070951388,"score_gpt":0.3290579000827906,"score_spread":0.27760692937327675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770561817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37763214,0.060643725,0.0009432334,0.14249694,0.03008706,0.00017873265,0.14132242,0.00064609235,0.2460497],"genre_scores_gemma":[0.68483824,0.044183783,0.0004107534,0.0072444193,0.016469559,0.00012103378,0.07062588,0.00031996766,0.17578645],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832946,0.000083898194,0.00010327599,0.00008594489,0.0010237545,0.00037363713],"domain_scores_gemma":[0.995414,0.00043019434,0.0012867389,0.00010822606,0.0021680787,0.0005926516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017796049,0.0005303255,0.00046269223,0.0031842417,0.00086356996,0.006082798,0.0003944124,0.0014907881,0.0061508026],"category_scores_gemma":[0.0068200976,0.00018086334,0.00041002256,0.004084612,0.00060590473,0.0021356796,0.0013986316,0.0021391434,0.0034119226],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009287483,0.00020217117,0.060780425,0.0005979267,0.00011316703,0.0004916786,0.00066799286,0.0008825397,0.0011578804,0.019863907,0.8497577,0.064555936],"study_design_scores_gemma":[0.00006941099,0.00015661144,0.28867602,0.0005312856,0.00007470683,0.00027498198,0.0018007902,0.0012078271,0.0039060928,0.0030021686,0.70023215,0.000067889654],"about_ca_topic_score_codex":0.020890106,"about_ca_topic_score_gemma":0.023806095,"teacher_disagreement_score":0.020890106,"about_ca_system_score_codex":0.003458779,"about_ca_system_score_gemma":0.0042968066,"threshold_uncertainty_score":0.041537046},"labels":[],"label_agreement":null},{"id":"W2770849724","doi":"10.3389/fonc.2017.00273","title":"Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":286,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Repurposing; Drug repositioning; Leverage (statistics); Clinical trial; Medicine; Cancer drugs; Drug development; Drug; Business; Approved drug; Alternative medicine; Government (linguistics); Pharmacology; Computer science; Engineering; Pathology","score_opus":0.10362814686053974,"score_gpt":0.3817537428207261,"score_spread":0.2781255959601864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770849724","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006698062,0.98261964,0.0014049539,0.007959636,0.00031265573,0.000008802026,0.0000127105295,0.000008021187,0.0070037614],"genre_scores_gemma":[0.009546643,0.9849594,0.001255353,0.0020410502,0.0007034747,0.000015479283,0.000014733323,0.000007446418,0.0014564176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987936,0.0005013805,0.00007521643,0.00009235109,0.0004542382,0.00008314488],"domain_scores_gemma":[0.9963716,0.0028479954,0.0002863848,0.00009473285,0.00032726265,0.00007205644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035964223,0.0004985314,0.00088685344,0.0022751,0.0003843212,0.002454493,0.00071674515,0.002163803,0.0040675737],"category_scores_gemma":[0.0052863713,0.0002330254,0.0006044817,0.0029637855,0.0018888275,0.004261558,0.00086901744,0.0030744313,0.0008774056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055729764,0.00008537032,0.00041654805,0.008395214,0.00010035645,0.00029484,0.0002121926,0.0022537496,0.0006086796,0.29628372,0.026204225,0.66508937],"study_design_scores_gemma":[0.000025854724,0.00007898745,0.0013748244,0.009397886,0.000070542315,0.00082830054,0.00035018224,0.0006343165,0.00051350123,0.074889354,0.91179967,0.000036638008],"about_ca_topic_score_codex":0.002157272,"about_ca_topic_score_gemma":0.0032491214,"teacher_disagreement_score":0.0040675737,"about_ca_system_score_codex":0.001866727,"about_ca_system_score_gemma":0.0028271582,"threshold_uncertainty_score":0.019019961},"labels":[],"label_agreement":null},{"id":"W2772200885","doi":"","title":"The EpiPen Problem: Analyzing Unethical Drug Price Increases and the Need for Greater Government Regulation","year":2017,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Government (linguistics); Public economics; Drug; Economics; Pharmacology; Medicine","score_opus":0.047193452853052605,"score_gpt":0.28020897763526786,"score_spread":0.23301552478221527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772200885","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3173749,0.013794642,0.03824654,0.36248338,0.0014768332,0.00087552145,0.0015421747,0.00012684512,0.26407918],"genre_scores_gemma":[0.9074524,0.0056827078,0.012007799,0.05764947,0.0016868311,0.0007152298,0.00039508345,0.00013870922,0.014271803],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.96483904,0.017696366,0.0013460637,0.0031633088,0.009700499,0.0032547712],"domain_scores_gemma":[0.79989,0.14704116,0.030445399,0.0082401885,0.012529918,0.0018532823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02776012,0.0004571381,0.0014924826,0.0058500045,0.006007666,0.010848961,0.0030510111,0.009518318,0.0065303775],"category_scores_gemma":[0.13009694,0.0005128065,0.001826196,0.010880127,0.021002753,0.017762627,0.00505414,0.013505009,0.0003764218],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111580004,0.000268415,0.027097424,0.00033723816,0.000119401506,0.0006974735,0.008029364,0.0020922308,0.000093862334,0.91311944,0.02486737,0.023166187],"study_design_scores_gemma":[0.00015284836,0.00021618318,0.06129841,0.0013987398,0.00020175637,0.00052126707,0.035813168,0.018128702,0.0006043653,0.6954837,0.18598378,0.0001970765],"about_ca_topic_score_codex":0.032511827,"about_ca_topic_score_gemma":0.034199756,"teacher_disagreement_score":0.032511827,"about_ca_system_score_codex":0.01477865,"about_ca_system_score_gemma":0.015340912,"threshold_uncertainty_score":0.1468113},"labels":[],"label_agreement":null},{"id":"W2772655920","doi":"10.1111/epi.13974","title":"A longitudinal cohort study on the impact of the clobazam shortage on patients with epilepsy","year":2017,"lang":"en","type":"article","venue":"Epilepsia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary","funders":"Canadian Institutes of Health Research; Cumming School of Medicine, University of Calgary; University of Calgary","keywords":"Clobazam; Epilepsy; Economic shortage; Medicine; Drug Resistant Epilepsy; Quality of life (healthcare); Family medicine; Cohort; Psychology; Psychiatry; Internal medicine; Nursing","score_opus":0.06361991238232872,"score_gpt":0.3136888269260263,"score_spread":0.25006891454369756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772655920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988066,0.00012510025,0.000056643006,0.00017958363,0.00001231507,0.000060562474,0.0004073564,0.0000013956607,0.00035056606],"genre_scores_gemma":[0.99902964,0.00012510075,0.00008244096,0.00017856121,0.000011425612,0.00009265984,0.00028963757,0.0000011036365,0.00018950745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988354,0.0004714981,0.00012941429,0.00012655923,0.00016771877,0.00026940994],"domain_scores_gemma":[0.99778986,0.0004943109,0.0008448594,0.00014331439,0.00029348602,0.00043419082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025179668,0.00018273354,0.00029326548,0.0006737909,0.0012007362,0.0008605546,0.00033411672,0.0004827232,0.0023287504],"category_scores_gemma":[0.0056855995,0.0002722605,0.0005142919,0.0012272245,0.00027370654,0.0011828094,0.00086122105,0.0009935219,0.00031029733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001306715,0.00023019676,0.99566203,0.00002628299,0.000041471336,0.00015537378,0.0020098332,0.000012199342,0.00010124606,0.000034514946,0.00032370142,0.0012725554],"study_design_scores_gemma":[0.00003151606,0.0006725841,0.9899052,0.000048548733,0.00003720955,0.00021525781,0.008413547,0.000105851446,0.00003229143,0.000039202892,0.0004873982,0.000011362393],"about_ca_topic_score_codex":0.010222255,"about_ca_topic_score_gemma":0.017378295,"teacher_disagreement_score":0.010222255,"about_ca_system_score_codex":0.00060104026,"about_ca_system_score_gemma":0.0011610548,"threshold_uncertainty_score":0.020325541},"labels":[],"label_agreement":null},{"id":"W2776969814","doi":"10.1503/cmaj.171070","title":"We need to mandate drug cost transparency on electronic medical records","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Mandate; Transparency (behavior); Drug; Per capita; Medical prescription; Prescription drug; Medical record; Health care; Medicine; Business; Family medicine; Internet privacy; Computer science; Environmental health; Pharmacology; Computer security; Economic growth; Political science; Economics; Law; Internal medicine","score_opus":0.029832836080908177,"score_gpt":0.2845445318179955,"score_spread":0.2547116957370873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776969814","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015122243,0.0018827079,0.011964853,0.9554701,0.006056546,0.0001684705,0.0008077604,0.00041822737,0.021719154],"genre_scores_gemma":[0.0729934,0.0033219862,0.040565483,0.8567145,0.011860818,0.000477309,0.001785186,0.00040840462,0.011872984],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.84543484,0.0635995,0.01470979,0.007833058,0.060891364,0.0075314515],"domain_scores_gemma":[0.30824578,0.34622192,0.054093864,0.069446236,0.19148189,0.030510334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.121278375,0.0008198184,0.0015797849,0.0044849664,0.0031016055,0.016339997,0.0075148335,0.018867224,0.022605335],"category_scores_gemma":[0.4946763,0.0010266091,0.0018122075,0.0051312693,0.008519637,0.025438417,0.007761598,0.029621243,0.008709824],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017124548,0.0002219982,0.0069064843,0.0005799125,0.00010827689,0.0001484009,0.00066792406,0.00093620404,0.00066891406,0.22909807,0.67215407,0.088338435],"study_design_scores_gemma":[0.00016607736,0.00017077515,0.011259966,0.00549946,0.00011702544,0.00054083794,0.0012117847,0.0031213644,0.0021061427,0.16073516,0.8147504,0.00032112264],"about_ca_topic_score_codex":0.029663956,"about_ca_topic_score_gemma":0.023281967,"teacher_disagreement_score":0.121278375,"about_ca_system_score_codex":0.010987969,"about_ca_system_score_gemma":0.055010445,"threshold_uncertainty_score":0.641389},"labels":[],"label_agreement":null},{"id":"W2781278768","doi":"10.46827/ejefr.v0i0.223","title":"ETHICS AND SUSTAINABILITY: ELICITING MILLENNIAL PERSPECTIVES ON THE ETHICS WITHIN PHARMACEUTICALS","year":2017,"lang":"en","type":"article","venue":"European Journal of Economic and Financial Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sustainability; Chemist; Pharmaceutical industry; Workforce; Business; Law; Political science; Medicine; Pharmacology","score_opus":0.3413175092739393,"score_gpt":0.4590533764949633,"score_spread":0.11773586722102403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781278768","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12360779,0.0077043613,0.008402244,0.6343331,0.0012606191,0.00018275176,0.000082397644,0.00002803717,0.22439864],"genre_scores_gemma":[0.918824,0.004197007,0.0033709218,0.066848636,0.00061149313,0.00012805617,0.000028345836,0.000037625403,0.005953831],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.92979234,0.057359166,0.0018249337,0.001421352,0.0065811523,0.0030210642],"domain_scores_gemma":[0.82294697,0.13562958,0.01838092,0.0046139103,0.00899695,0.009431677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.050167777,0.00044807376,0.0005309704,0.0023256638,0.012964471,0.02555709,0.0010014876,0.00726297,0.007640192],"category_scores_gemma":[0.082501866,0.00047582644,0.0005869052,0.0018971845,0.038110778,0.016173763,0.019348506,0.014290528,0.0008568852],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008640576,0.00017469614,0.023102304,0.00068253186,0.00006070575,0.0014240481,0.31033897,0.00051026506,0.0007854983,0.5488798,0.058937144,0.055017643],"study_design_scores_gemma":[0.00003867125,0.00009518857,0.010398195,0.0016762066,0.000026072415,0.00063431513,0.37667513,0.00059785595,0.00038062935,0.24501565,0.36439618,0.00006590734],"about_ca_topic_score_codex":0.0019944164,"about_ca_topic_score_gemma":0.003134958,"teacher_disagreement_score":0.050167777,"about_ca_system_score_codex":0.013154223,"about_ca_system_score_gemma":0.016136203,"threshold_uncertainty_score":0.26531577},"labels":[],"label_agreement":null},{"id":"W2781608438","doi":"","title":"Does co-payment by consumers affect adherence to, and outcomes of, psychological treatment","year":2017,"lang":"en","type":"article","venue":"Epidemiology Open Access","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Copayment; Consumption (sociology); Public economics; Balance (ability); Payment; Economics; Affect (linguistics); Business; Actuarial science; Economic growth; Medicine; Health care; Finance; Psychology","score_opus":0.4093627957601251,"score_gpt":0.5485284429350138,"score_spread":0.13916564717488872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781608438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94529015,0.006850862,0.0007033963,0.030111156,0.00037143892,0.00010168743,0.0023189331,0.000025220032,0.014227192],"genre_scores_gemma":[0.99556917,0.000980015,0.00021501542,0.0012041033,0.00013482822,0.000029397743,0.00047459037,0.000009936362,0.0013828758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963606,0.0018844513,0.00025871315,0.0003459633,0.00060262845,0.0005476156],"domain_scores_gemma":[0.9677683,0.012667448,0.013026085,0.0016322158,0.0022417097,0.002664208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049488526,0.00018777415,0.000734534,0.0005841386,0.0008177302,0.002649393,0.00059263397,0.002015116,0.014706887],"category_scores_gemma":[0.050481595,0.00028512077,0.0016267954,0.001401182,0.00084618066,0.0022356787,0.0011430215,0.0024038672,0.001084199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002409403,0.0009944078,0.9328138,0.0002453819,0.0013839093,0.00009919991,0.0008982621,0.0004810537,0.00007111783,0.0023805378,0.0047127507,0.05351012],"study_design_scores_gemma":[0.00025022656,0.00057135086,0.98345715,0.00033923067,0.00089030206,0.00016082129,0.0014416554,0.0015645918,0.00012645636,0.0043828557,0.006762602,0.000052827036],"about_ca_topic_score_codex":0.020006182,"about_ca_topic_score_gemma":0.019474363,"teacher_disagreement_score":0.020006182,"about_ca_system_score_codex":0.0021651385,"about_ca_system_score_gemma":0.0015128094,"threshold_uncertainty_score":0.049199402},"labels":[],"label_agreement":null},{"id":"W2781939692","doi":"10.2139/ssrn.3095246","title":"Developing Novel Drugs","year":2017,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Novelty; Drug; Drug development; Shock (circulatory); Business; Value (mathematics); Risk analysis (engineering); Economics; Microeconomics; Pharmacology; Medicine; Computer science; Psychology; Machine learning","score_opus":0.06670909538872312,"score_gpt":0.3087312871797478,"score_spread":0.2420221917910247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781939692","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04053461,0.28638008,0.049008943,0.14896218,0.011148604,0.0009457111,0.0024112852,0.0008240651,0.45978448],"genre_scores_gemma":[0.29326332,0.39946926,0.052408457,0.0333363,0.008937285,0.0006459784,0.0020797416,0.00015015114,0.20970951],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.999443,0.00017212673,0.000039393908,0.0000890214,0.00017812134,0.00007825767],"domain_scores_gemma":[0.998782,0.00035680822,0.00023503842,0.00013064865,0.00026657406,0.00022892843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017831849,0.0005675916,0.00054582657,0.0008896544,0.00035786064,0.0021628332,0.00063358445,0.00131361,0.029017242],"category_scores_gemma":[0.0021404335,0.00023522842,0.00060984446,0.00048766925,0.00087844074,0.0021003785,0.001398236,0.0018460997,0.007120346],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003030395,0.00037940426,0.0013984116,0.0018862135,0.00015805743,0.00051375263,0.00013505181,0.0019313141,0.015056233,0.17104438,0.07994569,0.72724843],"study_design_scores_gemma":[0.00023423668,0.0009148846,0.0013795452,0.0008516349,0.00014714868,0.0008516114,0.000104169245,0.0018032964,0.009027598,0.049804702,0.9348561,0.00002508569],"about_ca_topic_score_codex":0.00043095887,"about_ca_topic_score_gemma":0.00074799627,"teacher_disagreement_score":0.029017242,"about_ca_system_score_codex":0.0013317226,"about_ca_system_score_gemma":0.0024374467,"threshold_uncertainty_score":0.09707236},"labels":[],"label_agreement":null},{"id":"W2784138586","doi":"10.1161/circoutcomes.117.004425","title":"Elephant in the Room","year":2018,"lang":"en","type":"letter","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Institute for Clinical Evaluative Sciences; Western University","funders":"","keywords":"Environmental science","score_opus":0.15397626202656695,"score_gpt":0.327548511722191,"score_spread":0.17357224969562407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784138586","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003623714,0.0010763868,0.00009021402,0.98215693,0.011922206,0.0000042754255,0.00001891261,0.000011664328,0.0043570767],"genre_scores_gemma":[0.007992927,0.0012439316,0.00015070324,0.9306411,0.045103163,0.000025750169,0.000017914048,0.000032398206,0.014792065],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695754,0.00089341577,0.00019428215,0.0005406071,0.0007421165,0.0006720384],"domain_scores_gemma":[0.9913926,0.0045282394,0.00037546727,0.0004164016,0.00065401336,0.0026332655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049902257,0.0005883488,0.0011453818,0.0006483924,0.0044998876,0.0051618484,0.0012469093,0.044828475,0.021891441],"category_scores_gemma":[0.028818205,0.00045457456,0.00091523473,0.00040262743,0.00639176,0.0070341085,0.0039315475,0.057732232,0.0064402344],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006328372,0.000057030655,0.0006716768,0.000037108006,0.000016682654,0.0017810306,0.00020579425,0.00005916867,0.00013139403,0.022359364,0.96280056,0.0118168285],"study_design_scores_gemma":[0.00014820146,0.000052657582,0.0008794797,0.0003836882,0.000021051777,0.0011857016,0.0008744125,0.00032522445,0.00019310194,0.05446549,0.9414234,0.000047439145],"about_ca_topic_score_codex":0.00356644,"about_ca_topic_score_gemma":0.0090261595,"teacher_disagreement_score":0.044828475,"about_ca_system_score_codex":0.0032048603,"about_ca_system_score_gemma":0.0054599326,"threshold_uncertainty_score":0.0732342},"labels":[],"label_agreement":null},{"id":"W2784268328","doi":"10.1503/cmaj.109-5538","title":"Considering transparency and value for fairer drug prices","year":2018,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Transparency (behavior); Government (linguistics); Plan (archaeology); Point (geometry); Drug prices; Value (mathematics); Computer science; Business; Computer security; Public economics; Economics; Mathematics; Geography","score_opus":0.032346630505633966,"score_gpt":0.2659385589055039,"score_spread":0.23359192839986992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784268328","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.064875595,0.0066459044,0.041725926,0.39035767,0.002386729,0.00018536288,0.00026921934,0.00009864698,0.49345496],"genre_scores_gemma":[0.9595498,0.000979084,0.005214621,0.022543618,0.0024290802,0.000083552084,0.000046084588,0.00006348008,0.0090907095],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9617844,0.01767188,0.0011184927,0.0035580352,0.011431921,0.004435354],"domain_scores_gemma":[0.9039417,0.06934613,0.007518191,0.0062073604,0.008950503,0.004036091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.032975417,0.0004920993,0.0009360246,0.0014407529,0.0048644803,0.018919,0.0020966718,0.015680708,0.010606036],"category_scores_gemma":[0.1517204,0.0004811727,0.0011949121,0.0012913223,0.020200046,0.016024869,0.0065798806,0.017299607,0.0006803491],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007233307,0.000028327308,0.0008347886,0.00003458443,0.000023717608,0.00010849909,0.00037341603,0.0010854499,0.00014384667,0.9843211,0.006254487,0.006719422],"study_design_scores_gemma":[0.00006446841,0.000037466278,0.00084446016,0.00009494181,0.000022639328,0.0000640123,0.00022937071,0.0016775671,0.00023748598,0.9824226,0.014275921,0.00002901809],"about_ca_topic_score_codex":0.006628627,"about_ca_topic_score_gemma":0.0078110904,"teacher_disagreement_score":0.99337137,"about_ca_system_score_codex":0.011931054,"about_ca_system_score_gemma":0.013119315,"threshold_uncertainty_score":0.17439276},"labels":[],"label_agreement":null},{"id":"W2786242593","doi":"10.4000/lectures.24217","title":"Mathieu Noury, La nanosanté. La médecine à l’heure des nanotechnologies","year":2017,"lang":"fr","type":"article","venue":"Lectures","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Philosophy; Humanities","score_opus":0.052972131172721905,"score_gpt":0.31109076207612074,"score_spread":0.2581186309033988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786242593","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020883495,0.4207052,0.004305357,0.42273542,0.015518551,0.000018887242,0.00022449669,0.00012978418,0.13427395],"genre_scores_gemma":[0.14530954,0.3104848,0.006352575,0.0854203,0.03372173,0.000113285125,0.00016328302,0.0002895234,0.41814494],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9987324,0.0004272816,0.000042740245,0.00028494163,0.00040711777,0.00010555778],"domain_scores_gemma":[0.99823976,0.0010585746,0.00019031134,0.0000846389,0.00022152805,0.00020514683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015084681,0.0007585797,0.000470544,0.00088382023,0.0017564588,0.0028526483,0.00053338415,0.005190651,0.022475066],"category_scores_gemma":[0.0033069442,0.00032400468,0.0004174779,0.00082440797,0.004745508,0.00529735,0.001276739,0.005734875,0.0061634807],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068364265,0.000049674723,0.00044607336,0.00038820851,0.000019676441,0.00012003784,0.0011867422,0.00035737414,0.0006062595,0.5580177,0.37442887,0.06431108],"study_design_scores_gemma":[0.000011578665,0.00002819591,0.0007155966,0.00020921165,0.000006127214,0.0001698342,0.00023954229,0.00021507828,0.00026553584,0.13224779,0.8658688,0.000022645163],"about_ca_topic_score_codex":0.008689887,"about_ca_topic_score_gemma":0.009926572,"teacher_disagreement_score":0.022475066,"about_ca_system_score_codex":0.004289933,"about_ca_system_score_gemma":0.0023346283,"threshold_uncertainty_score":0.07518655},"labels":[],"label_agreement":null},{"id":"W2789814320","doi":"10.1161/circ.137.suppl_1.p146","title":"Abstract P146: Public Health Surveillance Reveals an Increase in Health Care Utilization for Generic versus Brand-name Warfarin Users","year":2018,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; The Quebec Population Health Research Network; Institut National de Santé Publique du Québec; Université Laval","funders":"","keywords":"Medicine; Warfarin; Commercialization; Health care; Confidence interval; Public health; Emergency medicine; Environmental health; Family medicine; Internal medicine; Marketing; Nursing; Business","score_opus":0.24216637915183645,"score_gpt":0.37194903013301345,"score_spread":0.129782650981177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789814320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93431395,0.0010174552,0.0007432207,0.0007762978,0.000023048911,0.00006146952,0.059985336,0.00007803372,0.0030012697],"genre_scores_gemma":[0.98813397,0.00018454168,0.0003184604,0.00014943443,0.000015067261,0.00002829307,0.010762707,0.0000075722137,0.0003999626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983423,0.0003269862,0.00017577919,0.00033990355,0.0005908387,0.0002241549],"domain_scores_gemma":[0.99274796,0.0011052786,0.0037025763,0.00046210736,0.0015930173,0.0003890985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001610746,0.00017125235,0.00026205386,0.0015416882,0.00029016082,0.00071918644,0.0006814227,0.00037893237,0.002873711],"category_scores_gemma":[0.007598405,0.000112636146,0.00079468725,0.0038361445,0.0002660722,0.00027079784,0.00035722987,0.0003808026,0.00024112815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008635692,0.000012111061,0.9930195,0.00006189929,0.000111159236,0.000027578884,0.0000832133,0.00016672089,0.00010602823,0.000054014967,0.0022790574,0.003992283],"study_design_scores_gemma":[0.0000035040114,0.00001750643,0.9989454,0.000014121974,0.000021555385,0.00003185637,0.000050183146,0.00034955572,0.000060388513,0.0000073221236,0.00049658417,0.0000020769453],"about_ca_topic_score_codex":0.627626,"about_ca_topic_score_gemma":0.5293847,"teacher_disagreement_score":0.627626,"about_ca_system_score_codex":0.003319303,"about_ca_system_score_gemma":0.0035627207,"threshold_uncertainty_score":0.74913394},"labels":[],"label_agreement":null},{"id":"W2790556892","doi":"","title":"Défragmentation de discours de la chaîne d'approvisionnement en médicaments en vue d'une résilience collective aux pénuries de médicaments","year":2017,"lang":"fr","type":"article","venue":"Archipelago (University of Quebec in Montreal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.019912470153945715,"score_gpt":0.28296823473650945,"score_spread":0.26305576458256374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790556892","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39231178,0.013786317,0.03183327,0.14825934,0.0012815949,0.0002758236,0.00029684987,0.00020523547,0.4117497],"genre_scores_gemma":[0.9564739,0.0028245915,0.0033493834,0.0067691193,0.00014632715,0.00013003241,0.00005272818,0.000076570526,0.030177422],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.98816794,0.0066305636,0.00031779538,0.0010587149,0.0025122538,0.0013126169],"domain_scores_gemma":[0.9855817,0.005207904,0.003370242,0.0011472303,0.0027887523,0.001904213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0083941985,0.00070428214,0.00059780636,0.0016969508,0.018754378,0.009331385,0.0015868986,0.0041228756,0.01097938],"category_scores_gemma":[0.013532818,0.00048007636,0.0005425396,0.0014900983,0.046800714,0.006416008,0.008174956,0.007960322,0.0011489234],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009107774,0.000049895112,0.0077100624,0.00053074106,0.000052370375,0.0010064312,0.65713996,0.00024091073,0.0013659446,0.29795936,0.009554779,0.024298409],"study_design_scores_gemma":[0.00003846285,0.00013737238,0.018972678,0.002156258,0.00007230902,0.0011028154,0.3713124,0.0004288597,0.00088648824,0.06568597,0.5390818,0.00012458897],"about_ca_topic_score_codex":0.12592712,"about_ca_topic_score_gemma":0.21258426,"teacher_disagreement_score":0.12592712,"about_ca_system_score_codex":0.021528436,"about_ca_system_score_gemma":0.025421234,"threshold_uncertainty_score":0.25038826},"labels":[],"label_agreement":null},{"id":"W2791189944","doi":"10.1002/ace.20259","title":"Learning in Global Collaborations for Impact and Innovation","year":2017,"lang":"en","type":"article","venue":"New Directions for Adult and Continuing Education","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Face (sociological concept); Adult Learning; Engineering ethics; Sociology; Knowledge management; Political science; Public relations; Adult education; Pedagogy; Engineering; Computer science; Social science","score_opus":0.03790203494020773,"score_gpt":0.3545179815282184,"score_spread":0.3166159465880107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791189944","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060704034,0.007977448,0.03585568,0.10403256,0.0011884741,0.00018688489,0.00011890461,0.00038832062,0.7895476],"genre_scores_gemma":[0.9571858,0.004906973,0.009797483,0.003842086,0.0005711843,0.00017437556,0.00006000841,0.00012209186,0.023339994],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9889958,0.0073086885,0.00022388207,0.0007723464,0.0011879639,0.0015112883],"domain_scores_gemma":[0.98118365,0.01040317,0.0012364013,0.002323066,0.0013473395,0.0035063536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010999142,0.0006325183,0.00075403583,0.0013188061,0.005808978,0.020474205,0.0013908049,0.0037846968,0.035753094],"category_scores_gemma":[0.018672591,0.0002810677,0.0008446577,0.0017864557,0.015067156,0.021553895,0.0208711,0.0053059855,0.0033999064],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004475228,0.000119505225,0.0014812629,0.00029543746,0.000031810323,0.0001908643,0.012713911,0.0011453605,0.00036443147,0.8978435,0.016148938,0.069620304],"study_design_scores_gemma":[0.00003919369,0.000119416014,0.001609019,0.0011459047,0.000031532563,0.0001435706,0.023158364,0.0012026271,0.0006098124,0.695658,0.27624342,0.000039185164],"about_ca_topic_score_codex":0.001187833,"about_ca_topic_score_gemma":0.0016246516,"teacher_disagreement_score":0.035753094,"about_ca_system_score_codex":0.0048579155,"about_ca_system_score_gemma":0.006774145,"threshold_uncertainty_score":0.11960602},"labels":[],"label_agreement":null},{"id":"W2791408908","doi":"10.1136/bmj.k831","title":"Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study","year":2018,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences","keywords":"Orphan drug; Medical prescription; Medicine; Off-label use; Observational study; European union; Generic drug; Prescription drug; Package insert; Business; Drug; Family medicine; Pharmacology; International trade","score_opus":0.26441459102540815,"score_gpt":0.3858876853257406,"score_spread":0.12147309430033243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791408908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618334,0.0006199524,0.000115848474,0.00018019737,0.000014070563,0.000034326815,0.002206392,0.0000033062672,0.00064257137],"genre_scores_gemma":[0.9972863,0.00025293292,0.000086208056,0.00009023091,0.000027125223,0.000026381838,0.0021047252,0.000003054805,0.0001230756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979322,0.00049909286,0.00041137444,0.0004777482,0.0003417922,0.00033787047],"domain_scores_gemma":[0.9835141,0.0021952288,0.011477752,0.000872723,0.0006139802,0.0013262075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026888917,0.00033073805,0.000710964,0.0015918389,0.00076354365,0.0013722138,0.0012191016,0.0012200692,0.0037230437],"category_scores_gemma":[0.009247771,0.000552012,0.0017858096,0.0029162588,0.00066821784,0.0021199428,0.0017861938,0.0022049933,0.0004978896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018589162,0.00008234986,0.99890363,0.000019051537,0.00012646317,0.000044241184,0.000054806533,0.000025832396,0.000019940988,0.000031869375,0.0001842741,0.0003216849],"study_design_scores_gemma":[0.000041164487,0.00021998498,0.99761117,0.00005423751,0.00013921755,0.0003034062,0.0006942176,0.00033538748,0.000034449924,0.000074012525,0.0004774037,0.000015448288],"about_ca_topic_score_codex":0.011827691,"about_ca_topic_score_gemma":0.010121364,"teacher_disagreement_score":0.011827691,"about_ca_system_score_codex":0.0006119845,"about_ca_system_score_gemma":0.0007516812,"threshold_uncertainty_score":0.023517668},"labels":[],"label_agreement":null},{"id":"W2791772618","doi":"","title":"Price Discrimination in the United States: Why Are Pharmaceuticals Cheaper in Canada and Are Americans Seizing the Opportunities across the Border","year":2003,"lang":"en","type":"article","venue":"SMU Scholar (Southern Methodist University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; International trade; Economics; Political science","score_opus":0.14179830239503377,"score_gpt":0.32120628993342765,"score_spread":0.17940798753839388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791772618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44980824,0.02189261,0.00015907835,0.39137986,0.0006280571,0.000055620647,0.0019612005,0.000020408897,0.1340949],"genre_scores_gemma":[0.94971913,0.01171851,0.00012020099,0.02751577,0.0002332178,0.0000123566015,0.00043514842,0.000009443518,0.0102362195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882215,0.0001001359,0.00002273384,0.00007868681,0.00037640258,0.00059985527],"domain_scores_gemma":[0.9974699,0.00029145874,0.00030903338,0.000037800655,0.00092627783,0.0009655632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080397975,0.00017549757,0.00025218335,0.0012347096,0.007257732,0.005261399,0.0005413177,0.0021054707,0.005883255],"category_scores_gemma":[0.0045230375,0.0001273771,0.00024561127,0.0038896664,0.0023442907,0.0015886455,0.0009768876,0.0021958349,0.00020236084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003984425,0.000307336,0.41824156,0.00022460512,0.00011548194,0.0012260481,0.00995579,0.0010782126,0.00040507966,0.119969636,0.31857815,0.12949967],"study_design_scores_gemma":[0.000117409596,0.00005533347,0.7640646,0.00059492467,0.00014639366,0.00022327842,0.03430047,0.0018909768,0.00030438768,0.013615084,0.18454424,0.0001429921],"about_ca_topic_score_codex":0.9924843,"about_ca_topic_score_gemma":0.99573356,"teacher_disagreement_score":0.052698806,"about_ca_system_score_codex":0.052698806,"about_ca_system_score_gemma":0.057064727,"threshold_uncertainty_score":0.38235837},"labels":[],"label_agreement":null},{"id":"W2792366488","doi":"10.9778/cmajo.20170132","title":"Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program","year":2018,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Drug; Medicine; Government (linguistics); Population; Health care; Emergency medicine; Environmental health; Demography; Pharmacology; Economic growth","score_opus":0.09998687371225493,"score_gpt":0.3175620618307343,"score_spread":0.2175751881184794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792366488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87311214,0.0037311425,0.0007426868,0.012537945,0.0000720884,0.00031506503,0.06349206,0.000057241843,0.0459396],"genre_scores_gemma":[0.9688812,0.0035966812,0.0012800315,0.0014271805,0.00011227486,0.0001319153,0.019717168,0.00001930789,0.0048342403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935406,0.000057273683,0.00003892028,0.000041732113,0.00032652318,0.00018141023],"domain_scores_gemma":[0.9970933,0.00020902848,0.0007900744,0.00007872888,0.0012587591,0.00057006604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068937434,0.00021226126,0.0001438338,0.0023272908,0.0011004658,0.0009522906,0.0004917711,0.000247808,0.00239568],"category_scores_gemma":[0.002949435,0.00013668412,0.00039936134,0.0056272335,0.00026882018,0.00041551594,0.0007773082,0.00040727426,0.00026236888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004166948,0.0000546118,0.9523225,0.00011422354,0.000049036407,0.0001188487,0.0012888828,0.0003303047,0.00012467583,0.0004918246,0.024566134,0.020497283],"study_design_scores_gemma":[0.0000048683373,0.000011964231,0.98997366,0.00007122397,0.000014622984,0.00003664516,0.00073206046,0.0004970997,0.00004001743,0.00007082103,0.00853976,0.000007340287],"about_ca_topic_score_codex":0.9770179,"about_ca_topic_score_gemma":0.9914477,"teacher_disagreement_score":0.02298212,"about_ca_system_score_codex":0.017891185,"about_ca_system_score_gemma":0.02377886,"threshold_uncertainty_score":0.12981021},"labels":[],"label_agreement":null},{"id":"W2792379285","doi":"10.1177/0972063417747747","title":"Use of Generic Medicines","year":2018,"lang":"en","type":"article","venue":"Journal of Health Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Business; Quality (philosophy); Health care; Essential medicines; Access to medicines; Pharmaceutical policy; Argument (complex analysis); Health policy; Medicine; Economic growth; Public health; Nursing; Economics","score_opus":0.22408026156110017,"score_gpt":0.3633334338850559,"score_spread":0.13925317232395573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792379285","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0427045,0.0945908,0.0072953906,0.056984566,0.0019669267,0.0004325576,0.022966683,0.0007382408,0.7723204],"genre_scores_gemma":[0.74935997,0.08823081,0.0073961103,0.028450456,0.0039847856,0.00031561474,0.015437186,0.00018729377,0.106637836],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954991,0.0007256066,0.00036742017,0.000500898,0.0024042188,0.0005027973],"domain_scores_gemma":[0.9916298,0.0019030275,0.0031606643,0.00087060663,0.0013325021,0.0011035053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018063851,0.00034615988,0.00048432942,0.0016549369,0.0007562894,0.0028012507,0.0009374691,0.0014346384,0.057112493],"category_scores_gemma":[0.012605788,0.00021191768,0.0013089329,0.0020959696,0.0009389431,0.0019459743,0.0015587073,0.0018010648,0.010523499],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055675354,0.00037766504,0.03639701,0.0048445547,0.00037946372,0.0008234399,0.00047448708,0.00069609523,0.0028871668,0.106370844,0.20718713,0.6390055],"study_design_scores_gemma":[0.000104083614,0.0005657306,0.048525836,0.0023297698,0.00016904413,0.0034440814,0.00030920058,0.00038159004,0.0014408985,0.01077362,0.93191296,0.00004318079],"about_ca_topic_score_codex":0.006205369,"about_ca_topic_score_gemma":0.0032652945,"teacher_disagreement_score":0.057112493,"about_ca_system_score_codex":0.002218199,"about_ca_system_score_gemma":0.0026762153,"threshold_uncertainty_score":0.1910603},"labels":[],"label_agreement":null},{"id":"W2792570196","doi":"10.3389/fphar.2018.00009","title":"The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore","year":2018,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada","keywords":"Agency (philosophy); Medicine; Certificate; Business; Computer science","score_opus":0.044637407938886334,"score_gpt":0.3365412927677193,"score_spread":0.291903884828833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792570196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579575,0.0030541136,0.0014095255,0.0046475017,0.000078167555,0.0015672921,0.0011047603,0.000093439296,0.030087719],"genre_scores_gemma":[0.99314463,0.0012200425,0.0018073004,0.00066189584,0.000017776745,0.00019953193,0.00055762526,0.000034691315,0.002356591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9460685,0.018765135,0.0057271514,0.0026044014,0.02360243,0.0032323215],"domain_scores_gemma":[0.84793204,0.032808248,0.043790687,0.005031586,0.058778264,0.011659182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.040877823,0.00025288644,0.00033110025,0.0032155716,0.00240206,0.0046504834,0.0015085068,0.000703323,0.002883948],"category_scores_gemma":[0.08581359,0.00042875353,0.0007803403,0.00462961,0.001472139,0.0018954473,0.0025414797,0.0010037218,0.0006239003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013784117,0.00054703926,0.84607,0.0014272474,0.00029970103,0.00047552254,0.021529147,0.0008469841,0.001657418,0.004351512,0.007942053,0.11347501],"study_design_scores_gemma":[0.00008753396,0.0005322884,0.96192664,0.00029583735,0.00008428437,0.00037106883,0.011398946,0.0013024687,0.00092593004,0.0001203809,0.022879569,0.000075126816],"about_ca_topic_score_codex":0.57711923,"about_ca_topic_score_gemma":0.548432,"teacher_disagreement_score":0.42288077,"about_ca_system_score_codex":0.023453351,"about_ca_system_score_gemma":0.059298296,"threshold_uncertainty_score":0.8507424},"labels":[],"label_agreement":null},{"id":"W2793416798","doi":"10.1111/jwip.12091","title":"Broadening the conversation on the TRIPS agreement: Access to medicines includes addressing access to medical devices","year":2018,"lang":"en","type":"article","venue":"The Journal of World Intellectual Property","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Community Based Research; University of Ottawa","funders":"","keywords":"Intellectual property; TRIPS architecture; Access to medicines; TRIPS Agreement; Negotiation; Conversation; Business; General partnership; Developing country; International trade; Law and economics; Market access; Health care; Law; Economic growth; Political science; Economics; Finance; Sociology; Engineering","score_opus":0.2729941177595916,"score_gpt":0.38208092637995766,"score_spread":0.10908680862036607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793416798","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013965331,0.0041471105,0.0012103583,0.9638543,0.0016356083,0.000007163298,0.000038169568,0.0000062805702,0.027704453],"genre_scores_gemma":[0.17662033,0.016383735,0.0032460408,0.7582443,0.012493352,0.000097687116,0.00008564928,0.000094880816,0.03273402],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97473043,0.014176501,0.0010975886,0.0016740233,0.0056631425,0.0026584032],"domain_scores_gemma":[0.90713024,0.08204339,0.0026998967,0.001291106,0.0036650356,0.0031704025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.032118443,0.0006748469,0.0013352145,0.0012730337,0.009512727,0.01722786,0.0030323206,0.04960836,0.014305676],"category_scores_gemma":[0.05491354,0.000582582,0.0015127071,0.0019570608,0.018158576,0.03618869,0.008546067,0.034852743,0.002058301],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028014656,0.000024134577,0.00017244348,0.00012067415,0.0000067043084,0.00026317095,0.0035204228,0.00018885518,0.00012206938,0.8728942,0.11613043,0.006528927],"study_design_scores_gemma":[0.000026577483,0.00005533621,0.0009209273,0.00082987663,0.000014262824,0.00020455246,0.0058733756,0.00063046924,0.00028426136,0.27888066,0.71219534,0.00008433614],"about_ca_topic_score_codex":0.009962892,"about_ca_topic_score_gemma":0.008358679,"teacher_disagreement_score":0.04960836,"about_ca_system_score_codex":0.009173111,"about_ca_system_score_gemma":0.016631762,"threshold_uncertainty_score":0.1698606},"labels":[],"label_agreement":null},{"id":"W2793482020","doi":"10.1017/s174413311700041x","title":"Expanding Canadian Medicare to include a national pharmaceutical benefit while controlling expenditures: possible lessons from Israel","year":2018,"lang":"en","type":"article","venue":"Health Economics Policy and Law","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Per capita; Distribution (mathematics); Business; Public economics; Constraint (computer-aided design); Health care; Economics; Economic growth; Medicine; Environmental health; Population","score_opus":0.121241974293171,"score_gpt":0.392363136024876,"score_spread":0.271121161731705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793482020","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12357479,0.015788164,0.0026204658,0.45150176,0.0005700509,0.00013201665,0.00085407443,0.00009191522,0.40486684],"genre_scores_gemma":[0.87720174,0.009560974,0.004293912,0.061674945,0.00058088487,0.00006957272,0.00034293084,0.00006126786,0.04621374],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9965598,0.00058058195,0.00006433462,0.00014673518,0.0010076833,0.0016408106],"domain_scores_gemma":[0.9948078,0.0018776908,0.0001774436,0.00019601807,0.002104228,0.0008368724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045323586,0.0003301729,0.0005842892,0.0010357646,0.003358501,0.004363919,0.0015488156,0.0027711897,0.005132852],"category_scores_gemma":[0.009308108,0.0001644987,0.0006856103,0.0014189543,0.0023525904,0.0021121264,0.0016105904,0.0029554542,0.00025953163],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038748092,0.00017153367,0.014623458,0.0002280306,0.00010348795,0.000727135,0.0012536023,0.009799355,0.0006647398,0.7772735,0.08666589,0.10810189],"study_design_scores_gemma":[0.000771046,0.00025737062,0.06758084,0.0012717261,0.00037424426,0.00041827874,0.007013899,0.020099921,0.0026316512,0.20773572,0.6914352,0.0004101447],"about_ca_topic_score_codex":0.9528073,"about_ca_topic_score_gemma":0.9629414,"teacher_disagreement_score":0.94517124,"about_ca_system_score_codex":0.054828748,"about_ca_system_score_gemma":0.08611635,"threshold_uncertainty_score":0.39781225},"labels":[],"label_agreement":null},{"id":"W2793652288","doi":"10.1186/s40545-018-0132-3","title":"Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University Health Network","funders":"Innovative Medicines Canada","keywords":"Promotion (chess); Context (archaeology); Marketing; Business; Pharmaceutical industry; Pharmacy; Advertising; Medicine; Family medicine; Political science","score_opus":0.2866072893969136,"score_gpt":0.46076754451485086,"score_spread":0.17416025511793726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793652288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90675795,0.00351808,0.00025346852,0.0011910681,0.000050254846,0.00014888897,0.08359648,0.000046767767,0.0044370224],"genre_scores_gemma":[0.9757411,0.0032704803,0.0003758797,0.000205499,0.000026141644,0.00009995078,0.017869616,0.00002971157,0.0023816123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981041,0.000077777426,0.00011988948,0.0002855687,0.0007714761,0.0006411643],"domain_scores_gemma":[0.99607843,0.00013932909,0.0010925,0.0001699636,0.0016490108,0.00087075535],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015153714,0.0005609326,0.00069123483,0.0038927863,0.0024497828,0.0018329568,0.0016261394,0.00045276058,0.0034072192],"category_scores_gemma":[0.0037258782,0.0006233503,0.0016612594,0.012049437,0.0007051317,0.0008190075,0.0014486064,0.0011309319,0.00043110354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021091237,0.000028706452,0.9882316,0.00012325487,0.00024689545,0.000063489504,0.00055212877,0.00017564587,0.00006559464,0.00026392323,0.004943229,0.0050944807],"study_design_scores_gemma":[0.000012730916,0.000025417397,0.99540776,0.00008493443,0.00011898276,0.000062737905,0.0007789144,0.00026614362,0.00004024304,0.000039208593,0.0031452654,0.000017697186],"about_ca_topic_score_codex":0.99378526,"about_ca_topic_score_gemma":0.9944905,"teacher_disagreement_score":0.9984846,"about_ca_system_score_codex":0.038233306,"about_ca_system_score_gemma":0.059761167,"threshold_uncertainty_score":0.27740335},"labels":[],"label_agreement":null},{"id":"W2794220948","doi":"10.20529/ijme.2018.022","title":"Combating corruption in the pharmaceutical arena","year":2018,"lang":"en","type":"article","venue":"Indian Journal of Medical Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Sainte-Anne; Centre for Global Health Research; Carleton University; York University","funders":"","keywords":"Transparency (behavior); Incentive; Legislature; Sanctions; Language change; Intellectual property; Public relations; Business; Payment; Accountability; Health care; Pharmaceutical industry; Conflict of interest; Public economics; Accounting; Economics; Finance; Political science; Medicine; Law; Economic growth","score_opus":0.18990769590023285,"score_gpt":0.41661246137884844,"score_spread":0.2267047654786156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794220948","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10504134,0.01875429,0.06592017,0.54152083,0.002051439,0.00048390392,0.00008642112,0.00019128599,0.26595035],"genre_scores_gemma":[0.9513878,0.005962925,0.0068121315,0.022535264,0.0013871953,0.0002219923,0.000030717216,0.000056704725,0.011605251],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9609428,0.02704922,0.0010038159,0.0011467851,0.00481981,0.0050374623],"domain_scores_gemma":[0.915851,0.05076377,0.015128309,0.004881408,0.0070948997,0.0062805256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034073956,0.0004206482,0.0007844633,0.0019238162,0.005655426,0.013825213,0.0009851312,0.004974076,0.005103865],"category_scores_gemma":[0.06678352,0.0003203517,0.00060296187,0.0016059529,0.0136656705,0.0067243204,0.010549519,0.006879512,0.0011084687],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008099721,0.00017101839,0.011004081,0.00061080954,0.000074547635,0.00083864736,0.011315231,0.0027233178,0.0008053718,0.8141713,0.03256799,0.12563665],"study_design_scores_gemma":[0.000116913776,0.00032836405,0.012061807,0.0026416532,0.00007195228,0.0007521276,0.011365712,0.00600583,0.0019531221,0.69915694,0.26544854,0.000097042015],"about_ca_topic_score_codex":0.0018497496,"about_ca_topic_score_gemma":0.0018537801,"teacher_disagreement_score":0.034073956,"about_ca_system_score_codex":0.005025158,"about_ca_system_score_gemma":0.017772514,"threshold_uncertainty_score":0.18020248},"labels":[],"label_agreement":null},{"id":"W2795608932","doi":"","title":"The OECD publishes an interesting new report on competition in the pharmaceuticals sector","year":2014,"lang":"en","type":"article","venue":"e-Competitions Bulletin","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Political science; Business; Economics; Accounting","score_opus":0.08292024654365691,"score_gpt":0.30912852209738084,"score_spread":0.22620827555372391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795608932","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011384177,0.031523384,0.0027848978,0.39261973,0.11034889,0.00047754296,0.06704781,0.0012662701,0.3825473],"genre_scores_gemma":[0.07550462,0.07637207,0.006224687,0.16823046,0.06555679,0.0007681945,0.06835229,0.0013113933,0.5376795],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99301577,0.0004032209,0.0002983014,0.00021976349,0.0053724446,0.0006904684],"domain_scores_gemma":[0.97632295,0.008319861,0.0019046797,0.00055438926,0.010845657,0.002052441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045037596,0.0008693182,0.00089035695,0.0068639307,0.0017709698,0.0077313003,0.0010212642,0.0043865433,0.009744834],"category_scores_gemma":[0.013035929,0.00027293258,0.001238237,0.010280628,0.0011081975,0.002477061,0.0012821051,0.004116686,0.0044256207],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036805923,0.000038737024,0.001533739,0.0002016707,0.000020945101,0.00013341065,0.000059237158,0.00010257591,0.0001910952,0.005493039,0.97799426,0.014194557],"study_design_scores_gemma":[0.0000119438055,0.00002264788,0.009439341,0.00011117525,0.000025317151,0.00004176299,0.00015399852,0.000089901536,0.00047475842,0.00087689876,0.98872095,0.000031267162],"about_ca_topic_score_codex":0.09070844,"about_ca_topic_score_gemma":0.099119924,"teacher_disagreement_score":0.09070844,"about_ca_system_score_codex":0.0064645465,"about_ca_system_score_gemma":0.015758188,"threshold_uncertainty_score":0.18036091},"labels":[],"label_agreement":null},{"id":"W2796682857","doi":"10.1161/circ.135.suppl_1.p251","title":"Abstract P251: Substitution to Generic Angiotensin II Receptor Blockers: Impact on Risk of Hospitalizations, Emergency Room Consultations and Mortality","year":2017,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; The Quebec Population Health Research Network; Institut National de Santé Publique du Québec; Université Laval","funders":"","keywords":"Medicine; Candesartan; Losartan; Valsartan; Hazard ratio; Proportional hazards model; Internal medicine; Adverse effect; Emergency medicine; Angiotensin II; Confidence interval; Blood pressure","score_opus":0.06244090340085148,"score_gpt":0.3239219950167297,"score_spread":0.2614810916158782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796682857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925922,0.0015478333,0.00018279225,0.00049701217,0.000042900054,0.000025397767,0.0041887,0.000015178142,0.0009080669],"genre_scores_gemma":[0.9977283,0.00021322022,0.000052517942,0.00006890449,0.00003683488,0.0000069049497,0.0013029848,0.0000036446645,0.00058655033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918336,0.00016381827,0.000048751033,0.00024922934,0.00019166386,0.00016320203],"domain_scores_gemma":[0.998302,0.00032678005,0.0005508745,0.00010915145,0.00024272932,0.00046834908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008834772,0.00039368815,0.00041270978,0.00040615685,0.00038761413,0.0007556555,0.00067921245,0.0005764101,0.0056131096],"category_scores_gemma":[0.0026188877,0.00012269833,0.0019381174,0.0007688426,0.00034407573,0.00029452017,0.00043982576,0.00086712046,0.00040899488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004450983,0.00014415286,0.9781221,0.00015298439,0.0011736624,0.0003988633,0.00006133225,0.0007298073,0.000604381,0.0000753886,0.0028957755,0.011190495],"study_design_scores_gemma":[0.00007786899,0.00035676445,0.9973911,0.000022492108,0.0004117676,0.00014567736,0.000066172564,0.00092955126,0.0001347754,0.000048890266,0.00040766902,0.000007082729],"about_ca_topic_score_codex":0.15693119,"about_ca_topic_score_gemma":0.08739379,"teacher_disagreement_score":0.15693119,"about_ca_system_score_codex":0.001806577,"about_ca_system_score_gemma":0.0021049317,"threshold_uncertainty_score":0.3120355},"labels":[],"label_agreement":null},{"id":"W2796860482","doi":"10.5539/gjhs.v10n5p88","title":"Separating Prescription From Dispensation Medicines: Economic Effect Estimation in Japan","year":2018,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Pharmacy; Separation (statistics); Variables; Regression analysis; Family medicine; Actuarial science; Business; Medical emergency; Statistics; Pharmacology; Mathematics","score_opus":0.04803466913417451,"score_gpt":0.37541665151012943,"score_spread":0.32738198237595495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796860482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905269,0.0012625013,0.006933709,0.00020323746,0.000018965424,0.00015805266,0.00022002115,0.00002008251,0.00065642904],"genre_scores_gemma":[0.9944622,0.00064796215,0.0038547493,0.000058758764,0.00003453604,0.00010481227,0.00046465546,0.0000058600926,0.0003664656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99522287,0.0026374348,0.00040046225,0.00068707013,0.00042893382,0.00062336575],"domain_scores_gemma":[0.9790045,0.017320355,0.0021397874,0.00042768166,0.0005847,0.0005228973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007098428,0.0015568081,0.0029443256,0.0027527865,0.00062919105,0.0017398646,0.0010662661,0.0011212303,0.0020933761],"category_scores_gemma":[0.019127507,0.00095851865,0.00392081,0.0024042549,0.0008709398,0.0016055325,0.0015744712,0.0012896672,0.000093553084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049956767,0.0032523398,0.6194427,0.0011545412,0.0044066706,0.0019173942,0.000575884,0.29021862,0.0014369584,0.0045861294,0.00094003184,0.06707311],"study_design_scores_gemma":[0.0005242536,0.0014701695,0.32305577,0.000065502114,0.0037969977,0.00021134967,0.0008892745,0.6666371,0.00075843657,0.0016019044,0.0008769353,0.0001123518],"about_ca_topic_score_codex":0.056353144,"about_ca_topic_score_gemma":0.018445415,"teacher_disagreement_score":0.056353144,"about_ca_system_score_codex":0.0031754677,"about_ca_system_score_gemma":0.0024070034,"threshold_uncertainty_score":0.112050295},"labels":[],"label_agreement":null},{"id":"W2797272908","doi":"10.1503/cmaj.180197","title":"New generic pricing scheme maintains high prices and risks of shortages","year":2018,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Procurement; Economic shortage; Scheme (mathematics); Key (lock); Drug pricing; Computer science; Pharmacy; Business; Generic drug; Pharmaceutical Benefits Scheme; Finance; Risk analysis (engineering); Operations research; Actuarial science; Drug; Computer security; Medicine; Marketing; Pharmacology; Government (linguistics); Medical prescription; Family medicine; Engineering","score_opus":0.05394417246285982,"score_gpt":0.29600402285225097,"score_spread":0.24205985038939115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797272908","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10165686,0.0048095235,0.03739411,0.2279586,0.0041834945,0.0004344833,0.0030425852,0.0017920386,0.6187282],"genre_scores_gemma":[0.817153,0.0024628565,0.014850332,0.037458733,0.0041193077,0.00013655663,0.0025340528,0.0004713673,0.12081383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99496424,0.00058695185,0.00013376222,0.0004295886,0.0032109243,0.0006744728],"domain_scores_gemma":[0.9914551,0.0014068367,0.00072038756,0.0010255335,0.003914163,0.0014780674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005526258,0.00024002783,0.0003855138,0.0010483224,0.0021713285,0.0049254824,0.001621458,0.0024992502,0.031235857],"category_scores_gemma":[0.016882846,0.00026661382,0.0004460438,0.0014876683,0.0016660708,0.0032496992,0.0016807577,0.0033256,0.004898607],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050203985,0.00029597394,0.015551899,0.000285929,0.00005184836,0.0005599052,0.0009190162,0.0022669684,0.004726438,0.27750707,0.41811752,0.27921546],"study_design_scores_gemma":[0.00020379398,0.00031299843,0.024975738,0.0003236648,0.00004880958,0.0017027764,0.00049557775,0.0048518456,0.0016857566,0.02968257,0.9356202,0.00009635483],"about_ca_topic_score_codex":0.042265635,"about_ca_topic_score_gemma":0.049621437,"teacher_disagreement_score":0.99091,"about_ca_system_score_codex":0.009090001,"about_ca_system_score_gemma":0.012226012,"threshold_uncertainty_score":0.10449433},"labels":[],"label_agreement":null},{"id":"W2799437595","doi":"10.1007/s40273-018-0664-z","title":"Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation","year":2018,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Health economics; Wake; Quality of Life Research; Public health; Health administration; Economics; Business; Actuarial science; Public economics; Medicine; Pathology; Engineering","score_opus":0.07024198141245815,"score_gpt":0.310089570329557,"score_spread":0.23984758891709884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799437595","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030604773,0.001379525,0.0002453007,0.988902,0.0061223735,0.000007422169,0.000033841472,0.000024858273,0.0029786674],"genre_scores_gemma":[0.0036179936,0.0006126749,0.00034438987,0.97554296,0.01682272,0.00002016674,0.000018759074,0.000029674842,0.0029906903],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98184985,0.004439569,0.0013937008,0.0023497273,0.007367132,0.0026000764],"domain_scores_gemma":[0.9376842,0.044268228,0.0031786307,0.0020982544,0.0051782695,0.0075925104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016540049,0.0009264551,0.0023921998,0.0010662494,0.0044423696,0.011388237,0.0041030827,0.14296901,0.013626346],"category_scores_gemma":[0.076048605,0.00086423557,0.0026227767,0.0009779525,0.012208558,0.011689957,0.005031149,0.09669547,0.005869096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009953102,0.00007550209,0.00040630947,0.00007832481,0.00002554455,0.00103678,0.000195219,0.00012219592,0.00048348831,0.05144851,0.92963994,0.016388668],"study_design_scores_gemma":[0.00030044292,0.0000854457,0.0011103002,0.0004301937,0.00003383705,0.0007976384,0.0003276715,0.0005825946,0.00048606374,0.0959997,0.8997281,0.00011803028],"about_ca_topic_score_codex":0.004196603,"about_ca_topic_score_gemma":0.008823173,"teacher_disagreement_score":0.14296901,"about_ca_system_score_codex":0.008591811,"about_ca_system_score_gemma":0.011297673,"threshold_uncertainty_score":0.08747321},"labels":[],"label_agreement":null},{"id":"W2800515685","doi":"10.1016/j.yrtph.2018.05.002","title":"Canadian, European and United States new drug approval times now relatively similar","year":2018,"lang":"en","type":"article","venue":"Regulatory Toxicology and Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute; Canadian Institute for Health Information","funders":"","keywords":"Food and drug administration; Medicine; Drug approval; Quartile; Drug; Environmental health; Internal medicine; Pharmacology; Confidence interval","score_opus":0.03401939678412594,"score_gpt":0.27452350339588766,"score_spread":0.24050410661176172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800515685","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19520484,0.034968656,0.0053570378,0.08975445,0.0032441514,0.000088244145,0.01761633,0.0006837059,0.65308255],"genre_scores_gemma":[0.79770756,0.008148065,0.0020055517,0.017587798,0.00079436786,0.0000418519,0.007891461,0.00025953783,0.16556388],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99774617,0.00013432055,0.00007876458,0.00026277956,0.0012663439,0.00051162526],"domain_scores_gemma":[0.993056,0.0015906539,0.0009905195,0.00018157724,0.0030956601,0.0010856431],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019809674,0.0002881234,0.00056648167,0.002133909,0.0020244902,0.0060253837,0.00046641196,0.0019276628,0.02554136],"category_scores_gemma":[0.011651369,0.0002217631,0.0007065493,0.0029932628,0.0009917392,0.0016115598,0.0005834995,0.003015616,0.0018866729],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029962673,0.00015831746,0.036650464,0.0005243952,0.00043914712,0.0004295724,0.0014571514,0.0071509867,0.0033861906,0.30478245,0.4558987,0.18612646],"study_design_scores_gemma":[0.000160035,0.0001525766,0.2793917,0.00016440812,0.0002991259,0.00043532028,0.0023088828,0.0023206654,0.0019702597,0.013620833,0.6990446,0.00013156865],"about_ca_topic_score_codex":0.74119496,"about_ca_topic_score_gemma":0.8672512,"teacher_disagreement_score":0.99801904,"about_ca_system_score_codex":0.027556926,"about_ca_system_score_gemma":0.016657783,"threshold_uncertainty_score":0.5206584},"labels":[],"label_agreement":null},{"id":"W2800955910","doi":"10.1136/bmj.k2133","title":"Trump promises to reduce drug prices but drops campaign promises","year":2018,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Data science; Computer science; Drug; Drug prices; World Wide Web; Medicine; Pharmacology; Economics; Public economics","score_opus":0.07459406788040011,"score_gpt":0.3305366650573484,"score_spread":0.2559425971769483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800955910","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015394272,0.0041829017,0.0009189623,0.9228438,0.014079055,0.000028349576,0.00020865817,0.00014442774,0.056054335],"genre_scores_gemma":[0.075202785,0.005957839,0.0030003083,0.7708525,0.038694687,0.00016690983,0.00042815067,0.0004928515,0.10520402],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9820946,0.0044755046,0.0004684028,0.00111592,0.009994813,0.0018507943],"domain_scores_gemma":[0.9733526,0.012324246,0.0018743305,0.0015972907,0.005548484,0.0053030495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010491626,0.0010278157,0.00092537387,0.0014588076,0.003512493,0.0105145695,0.0012834747,0.011688784,0.057857793],"category_scores_gemma":[0.07829451,0.0005103416,0.00087573595,0.001137313,0.0045095785,0.009763496,0.0039853654,0.0196367,0.014077724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009945433,0.00006905115,0.0004381064,0.00007043951,0.000023619501,0.000054638545,0.00013542824,0.0000730927,0.00014868706,0.06367223,0.9069526,0.028262539],"study_design_scores_gemma":[0.00008706851,0.00013318934,0.0013716049,0.00023237341,0.000017755123,0.000067010966,0.00018243877,0.00037728128,0.000322557,0.030312201,0.96685946,0.000037115336],"about_ca_topic_score_codex":0.009325423,"about_ca_topic_score_gemma":0.009507098,"teacher_disagreement_score":0.057857793,"about_ca_system_score_codex":0.0055987267,"about_ca_system_score_gemma":0.0068491083,"threshold_uncertainty_score":0.19355363},"labels":[],"label_agreement":null},{"id":"W2801602939","doi":"10.1108/ijhg-12-2017-0062","title":"Policy to encourage the development of antimicrobials","year":2018,"lang":"en","type":"article","venue":"International Journal of Health Governance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Business; Intellectual property; Legislature; Antimicrobial stewardship; Public economics; Revenue; Procurement; Pharmaceutical industry; Economics; Antibiotic resistance; Political science; Marketing; Finance; Medicine; Market economy; Pharmacology","score_opus":0.07046330379538379,"score_gpt":0.3692006646353467,"score_spread":0.2987373608399629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801602939","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013695581,0.009048532,0.03306667,0.663487,0.0066675013,0.00077205774,0.0006168877,0.00073105365,0.2719147],"genre_scores_gemma":[0.40354994,0.014519319,0.0533155,0.4320897,0.0066626593,0.0013338345,0.0005014971,0.00030071137,0.08772683],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.96578336,0.01564101,0.0014207192,0.0026550922,0.010840703,0.0036591054],"domain_scores_gemma":[0.8976999,0.061166782,0.014643824,0.0066487174,0.011664935,0.008175754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027282437,0.00082465576,0.00055457663,0.002245701,0.0021984274,0.013755279,0.0020838294,0.014577694,0.01921288],"category_scores_gemma":[0.07248188,0.00063695415,0.0011013299,0.002169094,0.0068216086,0.009829029,0.007282091,0.010480632,0.004859956],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096145304,0.00030164397,0.0022738816,0.0009811965,0.00005904283,0.00021681664,0.000823373,0.0026005034,0.0010232696,0.8413998,0.09516916,0.055055134],"study_design_scores_gemma":[0.00013795638,0.0001546868,0.002089439,0.0014234884,0.00004707685,0.00019823403,0.0006607905,0.0013238768,0.001528076,0.18218496,0.81019765,0.000053711843],"about_ca_topic_score_codex":0.0034393033,"about_ca_topic_score_gemma":0.0029728028,"teacher_disagreement_score":0.027282437,"about_ca_system_score_codex":0.008539089,"about_ca_system_score_gemma":0.036439195,"threshold_uncertainty_score":0.14428502},"labels":[],"label_agreement":null},{"id":"W2801650451","doi":"10.1503/jpn.180051","title":"Drug coverage in Canada: gaps and opportunities","year":2018,"lang":"en","type":"editorial","venue":"Journal of Psychiatry and Neuroscience","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public health; Health insurance; Political science; Economic growth; Public administration; Business; Medicine; Health care; Nursing; Economics; Law","score_opus":0.046545957747827646,"score_gpt":0.2725316829208049,"score_spread":0.22598572517297721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801650451","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001436478,0.11073264,0.00013554115,0.37974852,0.5035075,0.000022762702,0.0009534898,0.00008589144,0.0046699774],"genre_scores_gemma":[0.0047180993,0.12992792,0.00033558396,0.13061821,0.7246102,0.000033906355,0.00059913174,0.00014092258,0.0090160435],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877144,0.0011682214,0.0013127428,0.0010058298,0.0076479805,0.0011508428],"domain_scores_gemma":[0.93036395,0.024219263,0.0026565685,0.0010378454,0.034380198,0.00734225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011361522,0.0018522596,0.003312141,0.0068262885,0.005770852,0.01122139,0.0040913736,0.017171727,0.008383108],"category_scores_gemma":[0.061789434,0.0009345062,0.0016559511,0.0065849293,0.0063982466,0.0051946067,0.0020637135,0.019244265,0.0027577416],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000110830315,0.0000039258393,0.00005637802,0.0002643452,0.000012412039,0.000044952467,0.00003283778,0.0000270761,0.0000072139023,0.00071514933,0.9914621,0.007362455],"study_design_scores_gemma":[0.000023113851,0.00000817634,0.0008088181,0.0022329935,0.000052284202,0.00009875156,0.00013744595,0.000099175326,0.000035965673,0.0015285156,0.9949421,0.000032677704],"about_ca_topic_score_codex":0.56357676,"about_ca_topic_score_gemma":0.7052303,"teacher_disagreement_score":0.43642324,"about_ca_system_score_codex":0.03860417,"about_ca_system_score_gemma":0.11015774,"threshold_uncertainty_score":0.87798685},"labels":[],"label_agreement":null},{"id":"W2802367354","doi":"","title":"Usage des médicaments recommandés à la suite d'un premier infarctus aigu du myocarde au Québec chez les personnes âgées : effet de la défavorisation et du sexe","year":2016,"lang":"fr","type":"article","venue":"Corpus Université Laval (Université Laval)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology","score_opus":0.015857126735127486,"score_gpt":0.2166866123748827,"score_spread":0.20082948563975522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802367354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888926,0.004218558,0.0003024046,0.0006941228,0.000041842162,0.0000938494,0.0031125385,0.000012290854,0.0026317767],"genre_scores_gemma":[0.99544144,0.001523391,0.0002676312,0.00036757867,0.00002380721,0.0000639588,0.0007045917,0.000005062412,0.0016024094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990533,0.00022113317,0.000069666305,0.00018827079,0.00025876152,0.00020880198],"domain_scores_gemma":[0.9961998,0.00062224217,0.0014552737,0.00017293837,0.00107058,0.00047914332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010841794,0.000335917,0.0005325817,0.0006444228,0.00092601596,0.0011939092,0.0005258118,0.0005443998,0.0029079637],"category_scores_gemma":[0.0044580535,0.00023658993,0.0006611018,0.0013038787,0.0005353267,0.0004798767,0.0004171718,0.0008644488,0.00019486906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006859566,0.000055104945,0.9872781,0.00017792029,0.0003358642,0.000096663134,0.00075597304,0.000093134746,0.0004935589,0.00007495408,0.00084298826,0.009109675],"study_design_scores_gemma":[0.000018452625,0.00017346305,0.9980545,0.000081799786,0.00011206069,0.00004377755,0.00036572036,0.00014163273,0.000073502335,0.000013247433,0.00091361627,0.000008184251],"about_ca_topic_score_codex":0.8584497,"about_ca_topic_score_gemma":0.9134703,"teacher_disagreement_score":0.1415503,"about_ca_system_score_codex":0.005300942,"about_ca_system_score_gemma":0.005220284,"threshold_uncertainty_score":0.2847678},"labels":[],"label_agreement":null},{"id":"W2803104889","doi":"10.29315/gm.v4i1.33","title":"Inovação Terapêutica, um Desafio de Farmacovigilância a Longo Prazo","year":2017,"lang":"pt","type":"article","venue":"Gazeta Médica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"","keywords":"Humanities; Philosophy; Medicine","score_opus":0.09756162896222598,"score_gpt":0.3397021914163031,"score_spread":0.2421405624540771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803104889","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09181225,0.5260047,0.047909793,0.22860809,0.0029535575,0.00033135057,0.0023183934,0.0004303128,0.09963166],"genre_scores_gemma":[0.72536093,0.20621635,0.018332746,0.025854327,0.0044624815,0.00049548474,0.0007362585,0.0001050202,0.018436356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912174,0.004623549,0.0007617555,0.0008481197,0.0020856312,0.00046345836],"domain_scores_gemma":[0.9668323,0.017644739,0.0088730045,0.0016798716,0.0036143695,0.0013556433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008491673,0.0004608764,0.0013038048,0.0011354495,0.0011060875,0.005719078,0.0010404057,0.002968154,0.0059997607],"category_scores_gemma":[0.024884805,0.0002908494,0.0010144714,0.0015458136,0.0028844841,0.002185072,0.0021104438,0.0033152811,0.0013649877],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014833948,0.0004995574,0.051433604,0.007358525,0.0012042628,0.0011200433,0.002751171,0.006644793,0.009544286,0.20232876,0.03663054,0.67900103],"study_design_scores_gemma":[0.00030557372,0.0031441823,0.07609095,0.007120386,0.0013851466,0.0041813985,0.0022701414,0.005375173,0.0072953547,0.2409061,0.65171385,0.00021175115],"about_ca_topic_score_codex":0.005795376,"about_ca_topic_score_gemma":0.004363542,"teacher_disagreement_score":0.008491673,"about_ca_system_score_codex":0.0038548766,"about_ca_system_score_gemma":0.008072737,"threshold_uncertainty_score":0.04490882},"labels":[],"label_agreement":null},{"id":"W2804241493","doi":"10.1136/bmj.k1039","title":"Healing an ailing pharmaceutical system: prescription for reform for United States and Canada","year":2018,"lang":"en","type":"review","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"SAFER; Medical prescription; Business; Public administration; Law and economics; Political science; Medicine; Pharmacology; Computer security; Economics; Computer science","score_opus":0.21182328897110753,"score_gpt":0.40429781424051,"score_spread":0.19247452526940245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804241493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003972635,0.9660523,0.00006423516,0.030352773,0.00078021496,0.000024542558,0.00019599614,0.000010356593,0.0021223626],"genre_scores_gemma":[0.009017077,0.978467,0.0005443602,0.009737881,0.00042047648,0.000025907806,0.00014300318,0.000009462733,0.001634843],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99756014,0.00033338333,0.00014872986,0.00010766709,0.0014010753,0.00044899125],"domain_scores_gemma":[0.9870624,0.0036031746,0.0007957945,0.00018996604,0.006868295,0.0014803808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060210326,0.0008630045,0.002056021,0.0051069385,0.002838636,0.004775399,0.0017260776,0.004366381,0.008309981],"category_scores_gemma":[0.017967766,0.00034862437,0.0012905268,0.009194953,0.0026995903,0.0025562565,0.0015332331,0.005020211,0.00044551535],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020767603,0.00011253535,0.0017118689,0.022607021,0.0004890679,0.00012345913,0.0004759649,0.00085495913,0.00020025487,0.04594563,0.41161057,0.515661],"study_design_scores_gemma":[0.00013971416,0.000041817628,0.008784871,0.040612485,0.0006064353,0.000110326495,0.00077488035,0.00040582495,0.00014498369,0.0065647224,0.9417281,0.00008586166],"about_ca_topic_score_codex":0.90793836,"about_ca_topic_score_gemma":0.96082705,"teacher_disagreement_score":0.09206164,"about_ca_system_score_codex":0.05775777,"about_ca_system_score_gemma":0.2743344,"threshold_uncertainty_score":0.41906387},"labels":[],"label_agreement":null},{"id":"W2804591124","doi":"10.1093/oso/9780190623784.003.0007","title":"The Demand for Pharmaceuticals in Major International Markets","year":2018,"lang":"en","type":"book","venue":"Oxford University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Negotiation; China; Distribution (mathematics); Government (linguistics); Business; International market; Health care; Drug prices; Public economics; International trade; International economics; Economics; Economic growth; Political science","score_opus":0.05866647668375386,"score_gpt":0.27596711668569546,"score_spread":0.2173006400019416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804591124","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18104897,0.029775796,0.0023709564,0.005643771,0.00018308466,0.000023900304,0.004542658,0.000079902566,0.776331],"genre_scores_gemma":[0.90140283,0.039992448,0.0021464736,0.0011465701,0.0005228302,0.000047477894,0.00443367,0.00008720686,0.050220497],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996561,0.00005392379,0.000019821018,0.00005776864,0.00013079977,0.00008162191],"domain_scores_gemma":[0.99949443,0.00023683865,0.000096917545,0.000025755351,0.0000943982,0.00005170464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004231536,0.0002855318,0.00027481155,0.0017108854,0.00048265114,0.003283824,0.00023991114,0.00048426597,0.016080074],"category_scores_gemma":[0.0012202285,0.00017393743,0.00039509562,0.003519319,0.00056871545,0.0020269156,0.00078506797,0.00072791585,0.0017726894],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004146324,0.0000783407,0.029564066,0.0008219809,0.00010321229,0.00063161005,0.0027114495,0.0057037957,0.0045783278,0.61415905,0.061443094,0.2797905],"study_design_scores_gemma":[0.000040255873,0.00017453765,0.14898941,0.0010681903,0.00008720929,0.0015877609,0.005721224,0.0036507605,0.0025762655,0.0885354,0.7474904,0.00007855768],"about_ca_topic_score_codex":0.0020992905,"about_ca_topic_score_gemma":0.0024260853,"teacher_disagreement_score":0.016080074,"about_ca_system_score_codex":0.0011973731,"about_ca_system_score_gemma":0.0005186603,"threshold_uncertainty_score":0.05379325},"labels":[],"label_agreement":null},{"id":"W2808961473","doi":"10.1016/j.jcjo.2018.04.017","title":"Randomized crossover trial comparing effectiveness and tolerability of generic and brand-name travoprost","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"Department of Surgery; Centre Hospitalier Universitaire de Québec; Université de Sherbrooke","keywords":"Tolerability; Crossover study; Randomized controlled trial; Crossover; Travoprost; Medicine; Internal medicine; Alternative medicine; Computer science; Artificial intelligence; Surgery; Adverse effect; Placebo","score_opus":0.083037588767876,"score_gpt":0.31237278597445817,"score_spread":0.2293351972065822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808961473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819886,0.0041512074,0.0013153303,0.00084214134,0.002133697,0.005298057,0.0016308933,0.00015169889,0.0024883798],"genre_scores_gemma":[0.9862752,0.0013703465,0.0019858975,0.0009302253,0.0011527265,0.0037813068,0.0012700462,0.000038360144,0.0031958937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99751866,0.0012000849,0.000202787,0.0005975467,0.00017103336,0.0003099966],"domain_scores_gemma":[0.9921349,0.0038580785,0.0013474161,0.0009991302,0.00051735615,0.001143077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038191227,0.002134368,0.0060185846,0.0005288185,0.0007277209,0.0017603725,0.001512103,0.0035433571,0.016878422],"category_scores_gemma":[0.006897153,0.0014333464,0.0036392496,0.0006431242,0.0027214345,0.0023941873,0.0006229808,0.0055733253,0.0019587313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9950165,0.0025551696,0.00012651196,0.000108033644,0.00039330433,0.000011489296,0.000015592203,0.00007556673,0.00032380762,0.00005332047,0.00011475625,0.0012059918],"study_design_scores_gemma":[0.96930987,0.02932867,0.00042419223,0.000013844662,0.00039673172,0.0000090393505,0.000013103351,0.00016769985,0.00010476869,0.00009788181,0.00012294507,0.000011358501],"about_ca_topic_score_codex":0.002200866,"about_ca_topic_score_gemma":0.0018897966,"teacher_disagreement_score":0.016878422,"about_ca_system_score_codex":0.0014640563,"about_ca_system_score_gemma":0.0016987021,"threshold_uncertainty_score":0.056463957},"labels":[],"label_agreement":null},{"id":"W2809722184","doi":"10.1016/j.jval.2018.04.387","title":"Three-Part Pricing to Reward Pharmaceutical Innovation and Increase Access: Case of PCSK9 Inhibitors","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Business; Actuarial science; Accrual; Cash flow; Revenue; Public economics; Economics; Finance; Earnings","score_opus":0.185399073756288,"score_gpt":0.3928800009505027,"score_spread":0.20748092719421468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809722184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6709553,0.0031318495,0.15403666,0.029077087,0.00093081454,0.0004057239,0.0012611503,0.00051958347,0.1396819],"genre_scores_gemma":[0.9829678,0.00021197018,0.006065014,0.00023123513,0.0001639543,0.000033127842,0.000051082134,0.000028147484,0.010247666],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9962606,0.001559605,0.00012219891,0.0003352995,0.0004481323,0.0012741885],"domain_scores_gemma":[0.98612833,0.009255529,0.0009919356,0.0010292619,0.0009415297,0.001653497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005452604,0.0010875567,0.0031387783,0.0012767415,0.0015190663,0.0060620164,0.0032777712,0.008127976,0.017900018],"category_scores_gemma":[0.019470278,0.0006683873,0.002507199,0.0013979545,0.0025535892,0.0041790875,0.0026425086,0.0049716434,0.0008957496],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001426848,0.001184175,0.008579432,0.00025027755,0.0002956733,0.0048396494,0.0003341567,0.21200302,0.0025637697,0.7107213,0.018238727,0.039563008],"study_design_scores_gemma":[0.0006068134,0.0003585943,0.004383286,0.000046999132,0.00020515794,0.0012171254,0.00040781798,0.7232385,0.0010057861,0.26271045,0.0056842878,0.00013517916],"about_ca_topic_score_codex":0.010107395,"about_ca_topic_score_gemma":0.0057922886,"teacher_disagreement_score":0.017900018,"about_ca_system_score_codex":0.002917339,"about_ca_system_score_gemma":0.0021328889,"threshold_uncertainty_score":0.05988151},"labels":[],"label_agreement":null},{"id":"W2809867426","doi":"10.1016/j.jval.2018.04.525","title":"The Cost of New Oral Anti-Diabetic Drugs in Canada and Internationally","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Canagliflozin; Sitagliptin; Metformin; Business; Market share; Public economics; International economics; Economics; Medicine; Diabetes mellitus; Type 2 diabetes; Health care; Finance; Economic growth; Endocrinology","score_opus":0.07862818365720377,"score_gpt":0.3103516778663703,"score_spread":0.23172349420916655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809867426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7122159,0.053957682,0.0011607242,0.09861284,0.0007616025,0.00012810632,0.021104984,0.000105497646,0.11195259],"genre_scores_gemma":[0.97451854,0.01098518,0.00067381514,0.0012823718,0.00014969677,0.000014391099,0.0017601817,0.000022345941,0.010593324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967578,0.00023104405,0.00013922881,0.00015727087,0.0018214282,0.00089319],"domain_scores_gemma":[0.9909889,0.0010173038,0.0012696735,0.000107437525,0.0045729037,0.0020437848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013598884,0.00037886138,0.0006654705,0.0034929947,0.0023583905,0.0058341995,0.0014241087,0.0014846736,0.004150294],"category_scores_gemma":[0.010856869,0.00039820417,0.0009979511,0.0076445392,0.0018372228,0.0012728956,0.0012130608,0.0024721716,0.00015521633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017881222,0.00038922258,0.45203808,0.0010506015,0.0009200488,0.0020747592,0.001660094,0.04594825,0.00078513933,0.18527086,0.101672225,0.2064026],"study_design_scores_gemma":[0.00029985054,0.00020123125,0.7867512,0.0012269216,0.0007916855,0.001360221,0.0062912484,0.026913103,0.0010282813,0.01407006,0.1608097,0.00025649584],"about_ca_topic_score_codex":0.99524504,"about_ca_topic_score_gemma":0.99620193,"teacher_disagreement_score":0.2091009,"about_ca_system_score_codex":0.2091009,"about_ca_system_score_gemma":0.123674825,"threshold_uncertainty_score":0.91733086},"labels":[],"label_agreement":null},{"id":"W2809869737","doi":"","title":"Navigating the Canadian drug establishment licensing system","year":2018,"lang":"en","type":"article","venue":"Journal of Developing Drugs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Computer science; Data science; Medicine; Pharmacology","score_opus":0.04110722154173923,"score_gpt":0.2897979904900463,"score_spread":0.24869076894830705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809869737","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29686773,0.0060011586,0.007439159,0.3104865,0.00065314554,0.0006573078,0.0025616225,0.00020529336,0.37512812],"genre_scores_gemma":[0.95112437,0.0022178134,0.0035846375,0.012126123,0.00018881785,0.00008133852,0.00039270055,0.00004613913,0.03023806],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9850803,0.0022166597,0.00033132522,0.0007821331,0.0052949004,0.00629472],"domain_scores_gemma":[0.9760266,0.0052734083,0.0013062787,0.0005859153,0.010593167,0.0062145893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011234736,0.00038710487,0.000638184,0.004630628,0.012180126,0.012970651,0.0029686887,0.00566915,0.01224319],"category_scores_gemma":[0.036029994,0.0005328356,0.000793888,0.004875619,0.0047127944,0.0036520911,0.0037306673,0.0041289143,0.00047519457],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00017258327,0.0002496254,0.050846074,0.0002817088,0.000120878336,0.0008107872,0.0039653857,0.021049298,0.0010537462,0.7252235,0.1107566,0.085469864],"study_design_scores_gemma":[0.00025464158,0.00018640941,0.16930169,0.00086013204,0.00023781609,0.00023901022,0.016346093,0.038197342,0.0011637403,0.10739761,0.6653268,0.00048867107],"about_ca_topic_score_codex":0.99155384,"about_ca_topic_score_gemma":0.9960834,"teacher_disagreement_score":0.80662227,"about_ca_system_score_codex":0.1933777,"about_ca_system_score_gemma":0.31947443,"threshold_uncertainty_score":0.9355675},"labels":[],"label_agreement":null},{"id":"W2809894823","doi":"10.1016/j.jval.2018.04.726","title":"Potential Impact of Changes to Basket of Comparator Countries from PMPRB7 to Pmprb12 has on Canadian Product List Prices","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sample (material); Product (mathematics); Formulary; Comparator; Economics; Business; Database transaction; Agricultural economics; Actuarial science; Medicine; Computer science; Mathematics; Engineering","score_opus":0.1348878784726197,"score_gpt":0.34733144081204054,"score_spread":0.21244356233942083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809894823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7055648,0.0068514277,0.0018271238,0.04373751,0.0016900285,0.00056883506,0.052290574,0.00031660352,0.18715301],"genre_scores_gemma":[0.9670788,0.001372808,0.0023907777,0.0061134486,0.00018688258,0.00007522772,0.009820161,0.00005984324,0.012902002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942061,0.0015239482,0.00026911127,0.00044340774,0.0022719193,0.0012855057],"domain_scores_gemma":[0.98941004,0.0024489542,0.0012110161,0.00043066338,0.0049924273,0.0015069724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059601,0.00038554813,0.00047680916,0.0015694908,0.0014462286,0.003630139,0.001533133,0.0013974586,0.0134242],"category_scores_gemma":[0.022241708,0.000374935,0.0011085607,0.0024264432,0.0007401119,0.0010751565,0.0009936724,0.001536411,0.00078839285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040481467,0.002371435,0.3348514,0.0023794353,0.00276347,0.001454057,0.0008700658,0.04754297,0.014129998,0.09559161,0.18282674,0.27473736],"study_design_scores_gemma":[0.0026333153,0.003056768,0.7539099,0.0006093365,0.0015785005,0.0004639499,0.0019748085,0.016648864,0.009675022,0.0044011795,0.20473842,0.00031003557],"about_ca_topic_score_codex":0.7939355,"about_ca_topic_score_gemma":0.77915156,"teacher_disagreement_score":0.9820736,"about_ca_system_score_codex":0.017926393,"about_ca_system_score_gemma":0.016418096,"threshold_uncertainty_score":0.41455615},"labels":[],"label_agreement":null},{"id":"W2811394421","doi":"10.1016/j.jval.2018.04.1643","title":"The Cost of Drugs for Age-Related Macular Degeneration in Canada and Internationally","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Aflibercept; Macular degeneration; Ranibizumab; Reimbursement; Drug prices; Generic drug; Drug; Business; Medicine; International economics; Economics; Ophthalmology; Monetary economics; Pharmacology; Internal medicine; Economic growth; Bevacizumab; Health care","score_opus":0.06700896132124044,"score_gpt":0.3012974722135881,"score_spread":0.23428851089234765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811394421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70516455,0.066344574,0.0010473041,0.11208497,0.0008750236,0.00015875296,0.026264017,0.000094718,0.08796606],"genre_scores_gemma":[0.97049576,0.014187871,0.00073347695,0.0016255123,0.00016043673,0.000019563038,0.0022347383,0.000023811112,0.010518825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970139,0.00024453306,0.00014932903,0.00013449133,0.0015492329,0.00090849155],"domain_scores_gemma":[0.9913043,0.0008988111,0.0010693502,0.00009339424,0.0046059494,0.0020282767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001277565,0.00036716403,0.0006151027,0.003676842,0.0021160375,0.0042243865,0.00140631,0.0013678728,0.0033707253],"category_scores_gemma":[0.0106563615,0.00033997252,0.0010361786,0.007213454,0.0015746325,0.000995874,0.0011692935,0.0022422567,0.00014094112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013018693,0.00030559377,0.5342095,0.0010447578,0.0009719699,0.0021543212,0.0017127573,0.02818703,0.0006784939,0.13208443,0.11090942,0.18643999],"study_design_scores_gemma":[0.00021539876,0.00015187054,0.84262943,0.0011146987,0.0006706143,0.001365883,0.004700916,0.01547653,0.00061795994,0.008105149,0.12476482,0.00018671223],"about_ca_topic_score_codex":0.99596906,"about_ca_topic_score_gemma":0.9968514,"teacher_disagreement_score":0.17267743,"about_ca_system_score_codex":0.17267743,"about_ca_system_score_gemma":0.13057387,"threshold_uncertainty_score":0.9595769},"labels":[],"label_agreement":null},{"id":"W2821537775","doi":"10.22270/ijdra.v6i2.236","title":"Regulatory requirements for Drug master file in context to Canada and Australia","year":2018,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada","keywords":"Legislation; Context (archaeology); Terminology; Drug; Business; Quality (philosophy); Product (mathematics); Computer science; Political science; Pharmacology; Medicine; Law; Biology","score_opus":0.05655171049066777,"score_gpt":0.2988763481879289,"score_spread":0.24232463769726115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2821537775","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018629,0.0034788651,0.017806465,0.033221137,0.0034913688,0.009549506,0.032907724,0.007926133,0.8729897],"genre_scores_gemma":[0.109004915,0.004463845,0.044861604,0.041627966,0.0010273568,0.007199219,0.028730322,0.002527746,0.7605571],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96225774,0.004248557,0.0029159987,0.002944087,0.023711225,0.003922336],"domain_scores_gemma":[0.8820846,0.01527812,0.003206321,0.00956036,0.08590235,0.0039681727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020809589,0.00055429287,0.00094364304,0.0053799194,0.006524208,0.008290418,0.004654973,0.005993332,0.05861229],"category_scores_gemma":[0.079114355,0.0012645159,0.0011688159,0.0050987513,0.0030957873,0.0036572637,0.0031145227,0.004000229,0.029780397],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036452996,0.00020240214,0.0030464432,0.00083884713,0.000023339606,0.0008463169,0.0028172801,0.0006285614,0.00493617,0.084514745,0.8118141,0.08996727],"study_design_scores_gemma":[0.000033648037,0.00004398596,0.008210308,0.0003977778,0.000015397176,0.000272277,0.0003256185,0.00030643685,0.0016182079,0.0010434936,0.9876666,0.00006619272],"about_ca_topic_score_codex":0.5827163,"about_ca_topic_score_gemma":0.52650815,"teacher_disagreement_score":0.4172837,"about_ca_system_score_codex":0.024685804,"about_ca_system_score_gemma":0.097382545,"threshold_uncertainty_score":0.83948237},"labels":[],"label_agreement":null},{"id":"W2870026317","doi":"10.4212/cjhp.v71i3.2581","title":"La valeur des études de stabilité des médicaments et de leur publication","year":2018,"lang":"fr","type":"editorial","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Philosophy; Political science","score_opus":0.05643973880521349,"score_gpt":0.3259648270227272,"score_spread":0.26952508821751375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2870026317","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024145852,0.050391927,0.0003667729,0.087092035,0.85935247,0.000010173106,0.0003954095,0.00006255147,0.0020871847],"genre_scores_gemma":[0.005047542,0.02701918,0.00048434065,0.014759712,0.93791974,0.000032623087,0.00017651825,0.00010601175,0.014454273],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9838162,0.0037910466,0.0019898599,0.0017482915,0.007845191,0.0008093422],"domain_scores_gemma":[0.85753447,0.08668892,0.004514546,0.0024847286,0.045278534,0.0034987465],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022994438,0.0037389018,0.004354453,0.010520208,0.0027240901,0.011495263,0.0036073236,0.013665541,0.016071877],"category_scores_gemma":[0.118856564,0.0010629664,0.003868985,0.0073641804,0.0036757712,0.0055134506,0.0011565568,0.013039525,0.0050151004],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020711235,0.000021126647,0.00022568039,0.0007641709,0.00014357791,0.000095246374,0.000038758364,0.00011415937,0.00004369676,0.0035068267,0.982451,0.012388657],"study_design_scores_gemma":[0.00028459937,0.00005276582,0.002172277,0.002290401,0.00043575626,0.0002681937,0.00010880513,0.0011394081,0.00032888653,0.008031299,0.98480886,0.00007877597],"about_ca_topic_score_codex":0.024564298,"about_ca_topic_score_gemma":0.031468686,"teacher_disagreement_score":0.97700554,"about_ca_system_score_codex":0.012114884,"about_ca_system_score_gemma":0.011337723,"threshold_uncertainty_score":0.12160772},"labels":[],"label_agreement":null},{"id":"W2880424339","doi":"10.1002/hec.3796","title":"The effects of state‐level pharmacist regulations on generic substitution of prescription drugs","year":2018,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Aging; U.S. Department of Health and Human Services; Agency for Healthcare Research and Quality; National Institutes of Health; National Heart, Lung, and Blood Institute; McGill University","keywords":"Generic drug; Medical prescription; Purchasing; Business; Prescription drug; Profit (economics); Pharmacist; Brand names; Pharmacy; Actuarial science; Difference in differences; Public economics; Substitution (logic); State (computer science); Work (physics); Law; Drug; Economics; Medicine; Pharmacology; Marketing; Microeconomics; Computer science; Econometrics; Political science","score_opus":0.11314325176040257,"score_gpt":0.33531745664970897,"score_spread":0.2221742048893064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2880424339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584327,0.00059160235,0.006016938,0.0036948363,0.00010925702,0.00013763257,0.00060529204,0.00008063902,0.03033114],"genre_scores_gemma":[0.9975775,0.00017014053,0.0007525819,0.0004199072,0.000023359422,0.000028793862,0.00005643557,0.0000025500544,0.00096883776],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99269307,0.0040051965,0.0003568567,0.00070870685,0.0010198917,0.0012163093],"domain_scores_gemma":[0.9313915,0.05155484,0.012030138,0.0023565167,0.001775003,0.00089196855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076042786,0.00037216817,0.00073045463,0.000622095,0.00095015723,0.0024958362,0.0009585087,0.0020027012,0.0049206167],"category_scores_gemma":[0.026669003,0.00047148304,0.0015247181,0.0006674146,0.0026738083,0.0012814379,0.0011886825,0.0023751594,0.00026050291],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005628329,0.00721032,0.268454,0.00065562513,0.001595449,0.0008320642,0.00088345376,0.22001538,0.010220428,0.40343413,0.010616583,0.070454285],"study_design_scores_gemma":[0.0019789194,0.006936991,0.5533185,0.00025059114,0.0034306685,0.00038603524,0.0018343582,0.28283274,0.01779155,0.11150587,0.019384587,0.0003492184],"about_ca_topic_score_codex":0.0215284,"about_ca_topic_score_gemma":0.026286723,"teacher_disagreement_score":0.0215284,"about_ca_system_score_codex":0.0038948078,"about_ca_system_score_gemma":0.0038444207,"threshold_uncertainty_score":0.04280615},"labels":[],"label_agreement":null},{"id":"W2883084383","doi":"10.1016/j.healthpol.2018.07.005","title":"An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries","year":2018,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Commonwealth Fund","keywords":"Per capita; Medical prescription; Medicine; Primary care; Environmental health; Family medicine; Population; Nursing","score_opus":0.08342797164970099,"score_gpt":0.3844772828350063,"score_spread":0.3010493111853053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883084383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953259,0.00084892835,0.000119978045,0.00059987424,0.00001616531,0.0000097446755,0.0014685558,0.000007294118,0.0016036383],"genre_scores_gemma":[0.99772185,0.00026369042,0.000073893076,0.00007554951,0.00001038737,0.0000065941254,0.0014578141,0.0000025583552,0.00038772184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884653,0.00055128854,0.00006168903,0.00013494505,0.0001361723,0.0002692786],"domain_scores_gemma":[0.99717295,0.001330821,0.00069026835,0.0000924662,0.00034464838,0.0003688614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011506551,0.0003905465,0.0007024133,0.001355552,0.0005810005,0.001783819,0.0005046396,0.0008947401,0.0017680512],"category_scores_gemma":[0.0036531582,0.00034902777,0.0011174844,0.0038015402,0.0006010357,0.0007895371,0.0008312224,0.00085483614,0.00012253394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041053635,0.00068792235,0.9122505,0.00019507627,0.0013080749,0.0008886328,0.00044044288,0.050159734,0.00088961644,0.010169089,0.00770349,0.011201926],"study_design_scores_gemma":[0.000118071155,0.00035771736,0.97805417,0.000036829424,0.00034461988,0.00018319109,0.0019910967,0.015275589,0.00044431354,0.0007903255,0.0023791182,0.000025120755],"about_ca_topic_score_codex":0.13364537,"about_ca_topic_score_gemma":0.13325034,"teacher_disagreement_score":0.13364537,"about_ca_system_score_codex":0.0038025193,"about_ca_system_score_gemma":0.0013493052,"threshold_uncertainty_score":0.2657349},"labels":[],"label_agreement":null},{"id":"W2883095823","doi":"","title":"Abstract 153: Impact Of The Enhance Trial On The Use Of Ezetimibe In The Us And Canada","year":2013,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ezetimibe; Medical prescription; Medicine; Population; Clinical trial; Prescription drug; Family medicine; Demography; Environmental health; Internal medicine; Statin; Pharmacology","score_opus":0.16331413585285623,"score_gpt":0.32360883537020124,"score_spread":0.160294699517345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883095823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9122017,0.015037875,0.0004383934,0.013388383,0.00026066497,0.0006963802,0.039834417,0.00006261313,0.018079437],"genre_scores_gemma":[0.98763764,0.0020712551,0.00051168393,0.0022553983,0.0002144346,0.00023185734,0.0053343363,0.00001519968,0.0017282977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949992,0.0019457802,0.0004694606,0.0003582155,0.001540903,0.0006864386],"domain_scores_gemma":[0.9773915,0.00810895,0.0068170796,0.0014618121,0.004246997,0.0019736767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074285585,0.0002051328,0.0008139931,0.00041678245,0.000599457,0.0012362878,0.00048683767,0.0005838867,0.002698271],"category_scores_gemma":[0.037216887,0.00014984726,0.0009015842,0.0010891306,0.00074861955,0.00040241424,0.00063185615,0.00090588914,0.00017155241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15138404,0.00078054843,0.61749095,0.002351982,0.008980369,0.00028817359,0.00037054362,0.005252643,0.0010263482,0.0052877096,0.09415471,0.11263193],"study_design_scores_gemma":[0.019477416,0.0027944795,0.9416532,0.00092526234,0.0052240896,0.00011847096,0.00030759876,0.002135918,0.001197407,0.0006871843,0.025373876,0.00010518582],"about_ca_topic_score_codex":0.6708837,"about_ca_topic_score_gemma":0.78627074,"teacher_disagreement_score":0.32911628,"about_ca_system_score_codex":0.0075624785,"about_ca_system_score_gemma":0.023836372,"threshold_uncertainty_score":0.662109},"labels":[],"label_agreement":null},{"id":"W2883423601","doi":"10.1128/jcm.01137-18","title":"A List To Cement the Rightful Place of Diagnostics in Health Care","year":2018,"lang":"en","type":"editorial","venue":"Journal of Clinical Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cement; MEDLINE; Medicine; Data science; Computer science; History; Political science; Archaeology; Law","score_opus":0.07406482268287204,"score_gpt":0.41702483786748434,"score_spread":0.3429600151846123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883423601","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000140036445,0.0043286243,0.0001405377,0.050438996,0.9441017,0.000009354505,0.00003196967,0.000030882104,0.000903939],"genre_scores_gemma":[0.00028210663,0.0031274715,0.00019325255,0.021838805,0.97123563,0.0000153096,0.000013645317,0.000035815247,0.0032580097],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98119384,0.004281493,0.0031098893,0.0017306829,0.008384051,0.0012999193],"domain_scores_gemma":[0.8865325,0.067954145,0.004934185,0.003389229,0.027837334,0.009352662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023522833,0.0052775797,0.0048239245,0.0058847805,0.0051352587,0.018390376,0.0052517396,0.03396772,0.020273624],"category_scores_gemma":[0.10194905,0.0016760151,0.003219476,0.0027486307,0.008146891,0.012209392,0.0040198597,0.047476627,0.011054114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023148494,0.000012395542,0.000016426498,0.000275108,0.000021018532,0.000068124275,0.000022947288,0.000030124398,0.000029520395,0.0021194748,0.9923366,0.005045162],"study_design_scores_gemma":[0.00009330804,0.000030309557,0.00019334389,0.0011918822,0.00006466964,0.00014563177,0.00011424993,0.00017994223,0.00010841887,0.00990638,0.98792714,0.000044740187],"about_ca_topic_score_codex":0.0019245864,"about_ca_topic_score_gemma":0.0048768013,"teacher_disagreement_score":0.03396772,"about_ca_system_score_codex":0.005021471,"about_ca_system_score_gemma":0.008565486,"threshold_uncertainty_score":0.124402165},"labels":[],"label_agreement":null},{"id":"W2883710555","doi":"","title":"Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison","year":2000,"lang":"en","type":"article","venue":"Monographs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Business; Industrial organization; Economics; Biology; Ecology","score_opus":0.08258621709521968,"score_gpt":0.35176539017023706,"score_spread":0.2691791730750174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883710555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73175406,0.08007898,0.0014099284,0.00598201,0.00027343724,0.00011189659,0.0011334702,0.000018601242,0.17923759],"genre_scores_gemma":[0.9729926,0.020355808,0.00056329987,0.0017883624,0.0002196029,0.000059109825,0.0009973842,0.00001709699,0.0030067698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949714,0.001331399,0.00040304792,0.00049270625,0.0021940782,0.00060734636],"domain_scores_gemma":[0.98882335,0.00440104,0.003369497,0.00031718236,0.0024574492,0.00063135056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037308764,0.00021792435,0.0005961194,0.004114843,0.0011334901,0.004816248,0.00058542634,0.0012289779,0.004642621],"category_scores_gemma":[0.0091005815,0.00020545503,0.0012279552,0.0077431547,0.002152069,0.0034070618,0.003093835,0.0010534413,0.00031652654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001775579,0.0009576703,0.619559,0.0028390642,0.0025756157,0.0013948547,0.016375108,0.00409092,0.0010680854,0.16560188,0.01430152,0.1694608],"study_design_scores_gemma":[0.000053089738,0.0004067914,0.9535153,0.00053494977,0.0003311224,0.00045949305,0.0072485665,0.00093472784,0.0002964778,0.004731379,0.031436104,0.00005204958],"about_ca_topic_score_codex":0.018566225,"about_ca_topic_score_gemma":0.022237446,"teacher_disagreement_score":0.018566225,"about_ca_system_score_codex":0.0046864953,"about_ca_system_score_gemma":0.0019882766,"threshold_uncertainty_score":0.036916316},"labels":[],"label_agreement":null},{"id":"W2883811532","doi":"10.1257/pol.20180489","title":"Preferred Pharmacy Networks and Drug Costs","year":2021,"lang":"en","type":"article","venue":"American Economic Journal Economic Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Pharmacy; Business; Cost sharing; Subsidy; Medical prescription; Prescription drug; Health care; Medicare Part D; Drug; Marketing; Actuarial science; Family medicine; Medicine; Economics; Pharmacology; Nursing","score_opus":0.03243208827070266,"score_gpt":0.3073212594919792,"score_spread":0.27488917122127654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883811532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81054527,0.0059245694,0.012524073,0.0166867,0.0001800047,0.00018191857,0.005558001,0.000111361136,0.14828803],"genre_scores_gemma":[0.98795927,0.0015755759,0.0006179501,0.0002825384,0.00010247307,0.000034778994,0.00059531635,0.000010600825,0.008821537],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9983368,0.00054554053,0.000086564854,0.00017904182,0.00049836707,0.00035366908],"domain_scores_gemma":[0.9893133,0.004987459,0.004088152,0.00024942184,0.0005922723,0.0007694458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011674144,0.00025622937,0.00034231922,0.001348772,0.00064335467,0.0029067323,0.00047055926,0.0009773797,0.026752453],"category_scores_gemma":[0.014476024,0.00028974036,0.00039473156,0.0026618643,0.0009811312,0.0019447468,0.0012165797,0.0014552292,0.00084620476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006577078,0.0004810526,0.32215145,0.00044161212,0.0002658865,0.00060379936,0.00044527953,0.13399592,0.00045472707,0.39051294,0.035683177,0.114306405],"study_design_scores_gemma":[0.00027552192,0.00040721757,0.50400394,0.0004888326,0.00021032992,0.0010545481,0.0021043837,0.14902002,0.00082892657,0.24429666,0.09718527,0.00012440511],"about_ca_topic_score_codex":0.01634699,"about_ca_topic_score_gemma":0.019193022,"teacher_disagreement_score":0.026752453,"about_ca_system_score_codex":0.006471803,"about_ca_system_score_gemma":0.0014965315,"threshold_uncertainty_score":0.08949584},"labels":[],"label_agreement":null},{"id":"W2883887224","doi":"10.1007/s40258-018-0406-6","title":"The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review","year":2018,"lang":"en","type":"review","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"EconLit; Drug prices; Expiration date; Generic drug; Drug pricing; Business; Drug; Health economics; Medicine; Actuarial science; Economics; MEDLINE; Public economics; Public health; Pharmacology; Political science; Law","score_opus":0.23120070494700198,"score_gpt":0.44387325458408705,"score_spread":0.21267254963708507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883887224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018235862,0.99584526,0.00030617375,0.0006538084,0.0001888672,0.00034320384,0.00043323098,0.000008042951,0.0003978293],"genre_scores_gemma":[0.028772516,0.9675986,0.0012340685,0.0008298893,0.00026724505,0.0006882238,0.0004691274,0.000011696931,0.00012854452],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.94762087,0.020273156,0.017063681,0.0022875804,0.011838235,0.0009164907],"domain_scores_gemma":[0.6550108,0.27776653,0.04584457,0.0033572514,0.016829269,0.001191604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.053281084,0.0015991948,0.0076519833,0.019954113,0.0007573374,0.0049235434,0.0027649624,0.00384721,0.005710018],"category_scores_gemma":[0.21889742,0.001399032,0.010262784,0.018545792,0.0016361449,0.007209928,0.002476751,0.0028554953,0.00044735442],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035139403,0.000038720496,0.0016329767,0.9314095,0.009319264,0.00025775892,0.00022217982,0.0002144685,0.00014365268,0.00075346616,0.0014779958,0.05417858],"study_design_scores_gemma":[0.00034578872,0.00041018572,0.0075948117,0.9191328,0.04938247,0.0009229188,0.00040486487,0.00024792427,0.00031812015,0.0010190131,0.020163035,0.00005807299],"about_ca_topic_score_codex":0.0047114147,"about_ca_topic_score_gemma":0.008211417,"teacher_disagreement_score":0.053281084,"about_ca_system_score_codex":0.0066672633,"about_ca_system_score_gemma":0.021856615,"threshold_uncertainty_score":0.28178066},"labels":[],"label_agreement":null},{"id":"W2883967689","doi":"10.1016/j.drudis.2018.07.006","title":"Patent term restoration for top-selling drugs in the United States","year":2018,"lang":"en","type":"article","venue":"Drug Discovery Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Laura and John Arnold Foundation","keywords":"Term (time); Competition (biology); Business; Patent law; Generic drug; Brand names; Drug approval; Intellectual property; Drug; Medicine; Marketing; Pharmacology; Law; Political science","score_opus":0.07311118270361142,"score_gpt":0.2924885767058551,"score_spread":0.21937739400224368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883967689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81721586,0.022958245,0.0024397345,0.0551142,0.0017981249,0.0001267718,0.0067259846,0.00043609116,0.09318496],"genre_scores_gemma":[0.9804975,0.0021063676,0.00041364023,0.0038986949,0.0005491038,0.00002436395,0.0011274391,0.000028792414,0.011354022],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966419,0.000513975,0.00024516784,0.0003232573,0.0012494245,0.0010262941],"domain_scores_gemma":[0.9883245,0.0046761623,0.0029910759,0.0005283539,0.0016015864,0.001878348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004786596,0.00020023654,0.00079612277,0.0021605736,0.001452087,0.0062550944,0.0009995536,0.0029194648,0.0047184587],"category_scores_gemma":[0.020825643,0.00026167012,0.0012268435,0.0016705913,0.0010658614,0.001840992,0.0009773732,0.0042048367,0.00046791552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038034252,0.001647227,0.20602438,0.0006547247,0.00048454234,0.0017135444,0.0010296073,0.025776269,0.002883711,0.2739463,0.21195097,0.27008528],"study_design_scores_gemma":[0.000650276,0.0011816465,0.667809,0.0005111635,0.0008538534,0.0010055779,0.0022768448,0.03517182,0.00419668,0.06601956,0.220147,0.00017658077],"about_ca_topic_score_codex":0.0874884,"about_ca_topic_score_gemma":0.07703375,"teacher_disagreement_score":0.0874884,"about_ca_system_score_codex":0.0066810055,"about_ca_system_score_gemma":0.008918728,"threshold_uncertainty_score":0.17395836},"labels":[],"label_agreement":null},{"id":"W2885482527","doi":"","title":"Abstract 22: Impact Of Drug Policy On Regional Trends In Ezetimibe Use","year":2014,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ezetimibe; Formulary; Restrictiveness; Proxy (statistics); Medicine; Medical prescription; Demography; Population; Observational study; Treasury; Environmental health; Geography; Statistics; Family medicine; Mathematics; Pharmacology; Internal medicine","score_opus":0.148349463738525,"score_gpt":0.36434580763360935,"score_spread":0.21599634389508435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885482527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574277,0.0028095108,0.001166322,0.0078104436,0.00005303168,0.0000925925,0.021062559,0.00007413428,0.009503637],"genre_scores_gemma":[0.99620783,0.0004476793,0.00035996098,0.00031353178,0.00002537817,0.00002114666,0.0017091128,0.0000123073605,0.0009029616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970278,0.0010138509,0.00021342847,0.0004286441,0.0005001142,0.0008160483],"domain_scores_gemma":[0.9855068,0.002987409,0.0070475526,0.0006431638,0.0027248897,0.0010901703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002782871,0.0001778896,0.0004023124,0.0010893034,0.00043958644,0.0018629982,0.0007899051,0.00045555207,0.003278561],"category_scores_gemma":[0.016614223,0.00015482536,0.0009645696,0.0024399175,0.0006141391,0.00045434947,0.0008753851,0.0007860655,0.0003454552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003641796,0.000048336016,0.9831806,0.00008393251,0.0003808505,0.00011170054,0.000108143446,0.0044374177,0.0001889656,0.0013644745,0.003156984,0.0065743565],"study_design_scores_gemma":[0.000029566108,0.00004839941,0.9941719,0.000031079602,0.00016541686,0.00003886848,0.00020149678,0.0021923005,0.00022536286,0.00014688646,0.0027392535,0.000009447869],"about_ca_topic_score_codex":0.8131422,"about_ca_topic_score_gemma":0.7343532,"teacher_disagreement_score":0.8131422,"about_ca_system_score_codex":0.008488281,"about_ca_system_score_gemma":0.01117577,"threshold_uncertainty_score":0.37591648},"labels":[],"label_agreement":null},{"id":"W2886822650","doi":"","title":"Stratégie biopharmaceutique québécoise poursuivre dans l'excellence en créant la richesse du Québec de demain / [ressource électronique] : [Gouvernement du Québec]","year":2009,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Excellence; Political science; Business; Humanities; Art","score_opus":0.016650226538618543,"score_gpt":0.2566329899479714,"score_spread":0.23998276340935287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886822650","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049665466,0.06657279,0.015569848,0.5512304,0.0037023576,0.0003157792,0.0011660261,0.00034372672,0.3114336],"genre_scores_gemma":[0.5891254,0.033133008,0.029881246,0.0449281,0.00090126705,0.00023838035,0.0007606864,0.00017472959,0.30085722],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932642,0.002225298,0.00022120199,0.00046000848,0.0025372207,0.0012920779],"domain_scores_gemma":[0.9928121,0.0008070414,0.00036711578,0.00027047176,0.003995069,0.0017481374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007988013,0.00077269465,0.00068126107,0.001975697,0.0051320726,0.01042725,0.0010008295,0.0039106794,0.016615087],"category_scores_gemma":[0.0070303325,0.00035279864,0.0005968698,0.0030804102,0.0036650402,0.0028940206,0.0017265436,0.003838162,0.0012307749],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021133696,0.0002814336,0.018013988,0.0006744356,0.0001912164,0.00050292356,0.003366802,0.0038326636,0.0026301334,0.46474946,0.33353412,0.17201144],"study_design_scores_gemma":[0.000101886675,0.00008809622,0.026121091,0.00083578465,0.000080230726,0.00016482604,0.0026833583,0.0028726838,0.0011325557,0.01893292,0.9468957,0.000090823116],"about_ca_topic_score_codex":0.9501718,"about_ca_topic_score_gemma":0.9657133,"teacher_disagreement_score":0.9137126,"about_ca_system_score_codex":0.08628735,"about_ca_system_score_gemma":0.18157169,"threshold_uncertainty_score":0.62606144},"labels":[],"label_agreement":null},{"id":"W2887681591","doi":"10.3389/fphar.2018.00938","title":"Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications","year":2018,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Agency (philosophy); Drug approval; Pharmacology; Medicine; Business; Traditional medicine; Drug","score_opus":0.022556895054590888,"score_gpt":0.2886370621784222,"score_spread":0.2660801671238313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887681591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98937243,0.0041764174,0.0002944346,0.0004953799,0.000022115326,0.000021671241,0.0025293338,0.000007862536,0.0030802765],"genre_scores_gemma":[0.99871325,0.00051096303,0.0001338459,0.00004464498,0.000011276797,0.0000055735463,0.0004974586,0.000003837835,0.00007902271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974969,0.0007273319,0.00063495367,0.00043060677,0.00048398657,0.00022616706],"domain_scores_gemma":[0.9708985,0.0047443835,0.021577325,0.00055581407,0.0010540866,0.0011699431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038152714,0.00022218596,0.00032412919,0.0024377008,0.0002002098,0.0012583685,0.00031192842,0.0002534556,0.0042115604],"category_scores_gemma":[0.011640556,0.00015700047,0.0013348052,0.0033654575,0.00050853466,0.0015889851,0.0009065895,0.0005084663,0.00021092509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006136739,0.000035688212,0.98471075,0.000281161,0.000613069,0.00024332386,0.00015818368,0.00035519613,0.00022509336,0.00042255694,0.00032290927,0.012018279],"study_design_scores_gemma":[0.000027189624,0.00023552291,0.9950098,0.00014594274,0.0001927659,0.0007567826,0.00043658112,0.00042857786,0.00018604957,0.00018612783,0.0023775415,0.000017078446],"about_ca_topic_score_codex":0.0043147514,"about_ca_topic_score_gemma":0.003686583,"teacher_disagreement_score":0.0043147514,"about_ca_system_score_codex":0.00056842394,"about_ca_system_score_gemma":0.00051142287,"threshold_uncertainty_score":0.020177364},"labels":[],"label_agreement":null},{"id":"W2887837505","doi":"","title":"Survol des décisions et des modifications législatives significatives en matières de brevets pharmaceutiques en 2017","year":2018,"lang":"fr","type":"article","venue":"Les Cahiers de propriété intellectuelle","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Philosophy","score_opus":0.09597503590107938,"score_gpt":0.3566629990615595,"score_spread":0.26068796316048015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887837505","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11070362,0.049300913,0.011113467,0.2600268,0.012838997,0.0015127544,0.007697046,0.0012961678,0.5455102],"genre_scores_gemma":[0.3032175,0.020872792,0.010986904,0.11693124,0.0023263698,0.0008584348,0.0033696843,0.00062098436,0.54081625],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.95654106,0.0034783783,0.0020019521,0.0028961785,0.026959173,0.008123161],"domain_scores_gemma":[0.9524306,0.008854883,0.0021640738,0.0017240391,0.031068759,0.0037575637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022398038,0.00066244864,0.00088398583,0.003338763,0.012655406,0.014573741,0.0033236851,0.009585452,0.011117572],"category_scores_gemma":[0.046455145,0.0011132212,0.0015043253,0.003840907,0.0070058284,0.0031623843,0.003773253,0.009448823,0.0024694742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043760947,0.00014890163,0.01272087,0.0010841195,0.0001329003,0.0010379318,0.019984482,0.0014563464,0.0057234005,0.4910719,0.34862715,0.11757445],"study_design_scores_gemma":[0.000025274878,0.00004304156,0.00963176,0.00046730644,0.000057903784,0.00006608186,0.0019463619,0.0001936585,0.0017706893,0.0027815322,0.9829292,0.00008725077],"about_ca_topic_score_codex":0.88506657,"about_ca_topic_score_gemma":0.91085416,"teacher_disagreement_score":0.88506657,"about_ca_system_score_codex":0.09681644,"about_ca_system_score_gemma":0.24407518,"threshold_uncertainty_score":0.70245576},"labels":[],"label_agreement":null},{"id":"W2888116915","doi":"10.1161/circoutcomes.117.003891","title":"Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada","year":2017,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université du Québec à Trois-Rivières; The Quebec Population Health Research Network","funders":"","keywords":"Angiotensin Receptor Blockers; Commercialization; Adverse effect; Receptor; Business; Pharmacology; Medicine; Internal medicine; Angiotensin-converting enzyme; Marketing","score_opus":0.10073162593953226,"score_gpt":0.31658607859373905,"score_spread":0.21585445265420677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888116915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98395777,0.002770201,0.00034349097,0.0012742273,0.000034218196,0.00007183096,0.008100166,0.000029906672,0.0034181376],"genre_scores_gemma":[0.99709094,0.00051173905,0.00018232666,0.00018876344,0.0000093297085,0.000013104404,0.0013512366,0.0000045737006,0.0006479904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976246,0.0005553731,0.00018032249,0.0002494136,0.0008122964,0.0005781309],"domain_scores_gemma":[0.9906606,0.00180204,0.0028075657,0.00025263548,0.0031983715,0.0012786977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021640407,0.00029105466,0.0003232096,0.0007602869,0.0008490575,0.001136622,0.0009381643,0.0004573728,0.002442901],"category_scores_gemma":[0.008232617,0.00017165385,0.0010455551,0.0016088668,0.0004889094,0.00029529422,0.0005931785,0.00064976665,0.00008825325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007517685,0.00008808565,0.97936785,0.000113835624,0.000372421,0.00017279127,0.00018066248,0.0019426317,0.00029476045,0.00024299319,0.00238645,0.0140856765],"study_design_scores_gemma":[0.000026632864,0.00008238765,0.99724174,0.000025932857,0.000080655016,0.000035383968,0.00015022485,0.0016112808,0.00008945697,0.000016254016,0.00062777486,0.000012222985],"about_ca_topic_score_codex":0.99215925,"about_ca_topic_score_gemma":0.99049944,"teacher_disagreement_score":0.03685517,"about_ca_system_score_codex":0.03685517,"about_ca_system_score_gemma":0.027801268,"threshold_uncertainty_score":0.2674042},"labels":[],"label_agreement":null},{"id":"W2888506300","doi":"10.1016/j.healthpol.2018.08.006","title":"Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs","year":2018,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Carleton University; Concordia University","funders":"Canadian Institutes of Health Research","keywords":"Specialty; Niche; Business; Niche market; Medicine; Family medicine; Marketing; Biology; Ecology","score_opus":0.05998470427813103,"score_gpt":0.3322116371568782,"score_spread":0.27222693287874716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888506300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68008316,0.0053305086,0.0015976985,0.22975554,0.00032295377,0.00027552806,0.0009881221,0.000093753326,0.081552744],"genre_scores_gemma":[0.9804346,0.0014724726,0.0006449787,0.009353841,0.0001927037,0.000022979337,0.00017240997,0.000020945585,0.007684979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933611,0.0006385275,0.00010050991,0.00024466068,0.0014426016,0.0042125294],"domain_scores_gemma":[0.98592454,0.0022514174,0.002065095,0.00020665083,0.0024856927,0.007066521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049370998,0.00026750882,0.0003757399,0.0017403092,0.0060064844,0.008486708,0.0017342435,0.004696785,0.010889152],"category_scores_gemma":[0.019140398,0.00021351142,0.000659818,0.0018243002,0.0027192845,0.002218104,0.0027789883,0.0042250063,0.00040980199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095509016,0.00069707097,0.30846044,0.00058667583,0.00030697827,0.002544865,0.029908586,0.0054487865,0.003724669,0.26577157,0.18538061,0.19621465],"study_design_scores_gemma":[0.00018812405,0.00034376924,0.5778645,0.0011868281,0.00026362404,0.0006044675,0.11734529,0.01406076,0.0016234531,0.037014037,0.24927245,0.00023265049],"about_ca_topic_score_codex":0.7471209,"about_ca_topic_score_gemma":0.901276,"teacher_disagreement_score":0.97430164,"about_ca_system_score_codex":0.025698343,"about_ca_system_score_gemma":0.06501538,"threshold_uncertainty_score":0.5087366},"labels":[],"label_agreement":null},{"id":"W2888621937","doi":"10.1186/s12992-018-0402-5","title":"Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence","year":2018,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Brandon University; University of Toronto; York University","funders":"Canadian Institutes of Health Research; Canadian Patient Safety Institute","keywords":"Harmonization; Regulatory state; Globalization; Context (archaeology); Parallels; International trade; Corporate governance; Regulatory competition; Convergence (economics); European union; Economics; Political science; Business; Market economy; Economic growth; Finance; Biology","score_opus":0.10375770848868926,"score_gpt":0.3936725585011876,"score_spread":0.28991485001249834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888621937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82204616,0.0014024881,0.0260481,0.016360065,0.00012373226,0.00020544868,0.00011018438,0.00013356644,0.13357028],"genre_scores_gemma":[0.99681455,0.00013415766,0.0017384451,0.00032095486,0.000012123422,0.000045064477,0.000026731614,0.000019207586,0.0008887776],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9884809,0.0063656536,0.00050061604,0.0014989398,0.0016961418,0.0014578159],"domain_scores_gemma":[0.9800876,0.0108838845,0.0030796675,0.0025713907,0.0019903579,0.0013870794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01788604,0.00021605281,0.00046836023,0.0034750572,0.006975264,0.010362062,0.0013917092,0.0018953732,0.0042237528],"category_scores_gemma":[0.028285775,0.0003584035,0.0005134842,0.0041356273,0.018182099,0.008362118,0.010999422,0.003297012,0.0002560245],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001175988,0.00006802307,0.034027956,0.00019357247,0.000046067376,0.0006234295,0.1588108,0.0009567533,0.0012938275,0.7625115,0.0017637274,0.039586715],"study_design_scores_gemma":[0.00005624527,0.00016388876,0.12555985,0.0006617072,0.000059857302,0.0007773314,0.3029164,0.0053359345,0.0013522502,0.4178511,0.1451345,0.00013090867],"about_ca_topic_score_codex":0.005535535,"about_ca_topic_score_gemma":0.005578547,"teacher_disagreement_score":0.01788604,"about_ca_system_score_codex":0.01004891,"about_ca_system_score_gemma":0.006387349,"threshold_uncertainty_score":0.09459156},"labels":[],"label_agreement":null},{"id":"W2889089805","doi":"10.1016/s2213-8587(18)30233-x","title":"Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study","year":2018,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Simon Fraser University; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; Population Health Research Institute","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Metformin; Pharmacy; Environmental health; Audit; Diabetes mellitus; Glibenclamide; Epidemiology; Family medicine; Business; Internal medicine; Accounting; Endocrinology","score_opus":0.04565561249153537,"score_gpt":0.3240000573649068,"score_spread":0.2783444448733714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889089805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963291,0.0012203029,0.0000870373,0.00016481278,0.000011553974,0.000006651311,0.0017625876,0.0000024081733,0.00041564077],"genre_scores_gemma":[0.99879164,0.00033045397,0.000054183434,0.00003412021,0.0000077653085,0.0000050872795,0.000697631,0.0000016610485,0.000077507226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985039,0.00045938793,0.00027095358,0.00028211498,0.00014389248,0.00033972232],"domain_scores_gemma":[0.9931282,0.0013310596,0.0037977274,0.0005482495,0.00045453038,0.0007403472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016097159,0.00036392282,0.00062673184,0.0015493126,0.0005687125,0.001496406,0.00074425415,0.0010151926,0.002666493],"category_scores_gemma":[0.004528997,0.0007916564,0.0019204939,0.0048608785,0.00081853004,0.0014477018,0.0017553705,0.0016624707,0.00030860864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014504523,0.00005397701,0.99851793,0.00002415208,0.00028859553,0.000057667276,0.000115826326,0.0000848191,0.000035592213,0.00008821776,0.00014400968,0.0004441989],"study_design_scores_gemma":[0.000009962965,0.000054495198,0.99878687,0.000021439582,0.000111210706,0.00009840993,0.00050639897,0.00014122407,0.0000179697,0.000065819004,0.00017801019,0.000008151528],"about_ca_topic_score_codex":0.026655557,"about_ca_topic_score_gemma":0.02051129,"teacher_disagreement_score":0.026655557,"about_ca_system_score_codex":0.0005695644,"about_ca_system_score_gemma":0.0004305126,"threshold_uncertainty_score":0.053000808},"labels":[],"label_agreement":null},{"id":"W2889213083","doi":"10.1093/jlb/lsy019","title":"Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives","year":2018,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"Government of Canada; Ontario Genomics; Ontario Genomics Institute; Genome Canada","keywords":"Orphan drug; Voucher; Incentive; Subsidy; Public economics; Business; Drug; Pharmaceutical industry; Order (exchange); Investment (military); Medicine; Actuarial science; Economics; Finance; Pharmacology; Political science; Accounting; Bioinformatics; Law; Market economy","score_opus":0.1253909957631091,"score_gpt":0.33721907695773534,"score_spread":0.21182808119462623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889213083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.525325,0.0145431375,0.0029280004,0.10595244,0.0006238804,0.0040969425,0.0023930916,0.00008332137,0.34405413],"genre_scores_gemma":[0.9646015,0.00750707,0.0058298144,0.014148985,0.00014185997,0.00071426533,0.00049152016,0.000021427051,0.0065435],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9638129,0.013585756,0.00094806193,0.000630293,0.014667476,0.006355482],"domain_scores_gemma":[0.9267703,0.033035386,0.0043001845,0.0010854292,0.027041622,0.0077670403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029304566,0.00068070804,0.0010266472,0.0023657065,0.008551937,0.006933285,0.002047734,0.0038511157,0.0050577302],"category_scores_gemma":[0.07744033,0.0003065466,0.0015403595,0.0043019094,0.0034944508,0.0025627608,0.003997775,0.002932384,0.00019794662],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00686894,0.0032616958,0.096331246,0.006805382,0.0011696311,0.0012271741,0.012961189,0.018952651,0.0018349587,0.40378436,0.09157226,0.35523054],"study_design_scores_gemma":[0.005873533,0.008026182,0.26276767,0.010684806,0.0050217127,0.00079934264,0.0699376,0.027248941,0.003947763,0.05898905,0.54553425,0.001169172],"about_ca_topic_score_codex":0.8854971,"about_ca_topic_score_gemma":0.9452054,"teacher_disagreement_score":0.11450291,"about_ca_system_score_codex":0.111076966,"about_ca_system_score_gemma":0.23685259,"threshold_uncertainty_score":0.8059236},"labels":[],"label_agreement":null},{"id":"W2889860594","doi":"10.1177/1741134318799385","title":"Establishing healthy pharmaceutical regulations on statutory exclusivity: Lessons from the experience in the European Union, Canada, South Korea, Australia, and the United States","year":2018,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Statutory law; Legislation; European union; Business; International trade; Constructive; Law; Political science; Process (computing)","score_opus":0.1891385280060947,"score_gpt":0.35939947576919407,"score_spread":0.17026094776309936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889860594","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21468237,0.12472892,0.016377583,0.2976601,0.0018812501,0.0006756363,0.00030968597,0.0001499121,0.34353456],"genre_scores_gemma":[0.86509067,0.051502008,0.016166667,0.0504144,0.0003170683,0.00014445047,0.00021145004,0.000117480195,0.016035717],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9576298,0.016735548,0.0034470705,0.0028963105,0.013802556,0.005488728],"domain_scores_gemma":[0.81583005,0.105171904,0.007273004,0.0056845467,0.058972795,0.0070676515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09046639,0.00048729917,0.00065709517,0.0037972522,0.012719834,0.016241727,0.0029223645,0.005387324,0.0022104902],"category_scores_gemma":[0.081582725,0.00061671465,0.00075997,0.0067299884,0.025661286,0.0102600325,0.0054269074,0.008460934,0.00019120383],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008032133,0.00019324894,0.014531406,0.0014833072,0.000052928048,0.0024277798,0.16744924,0.0016110556,0.001202675,0.54903895,0.034576442,0.22735272],"study_design_scores_gemma":[0.000038627833,0.00019122649,0.03125635,0.008863275,0.000081440776,0.00075416616,0.16006133,0.0008280004,0.0023311956,0.039412435,0.75590056,0.00028141626],"about_ca_topic_score_codex":0.80171233,"about_ca_topic_score_gemma":0.8375875,"teacher_disagreement_score":0.19828767,"about_ca_system_score_codex":0.084970236,"about_ca_system_score_gemma":0.266249,"threshold_uncertainty_score":0.6165051},"labels":[],"label_agreement":null},{"id":"W2890036184","doi":"","title":"A Comparative Study on Different Pharmaceutical Industries and Proposing a Model for the Context of Iran.","year":2018,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Pharmaceutical industry; Business; Order (exchange); Liberalization; Developing country; Marketing; Economic growth; Economics; Political science; Finance; Medicine; Geography; Law","score_opus":0.3461900757473962,"score_gpt":0.3612884879677138,"score_spread":0.015098412220317603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890036184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6108237,0.012931342,0.008553111,0.014107425,0.00021738383,0.0011250842,0.0006379336,0.00003609724,0.35156792],"genre_scores_gemma":[0.9887355,0.0029627949,0.005104382,0.0004904346,0.000018277888,0.00024513455,0.00012933288,0.0000047537524,0.0023093217],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9962094,0.002651584,0.00010744955,0.00022012509,0.00049649016,0.0003149074],"domain_scores_gemma":[0.9961903,0.002378071,0.0006226931,0.00010907399,0.000528869,0.00017097511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004481004,0.00036810682,0.00022111807,0.005451836,0.0028282877,0.0034379177,0.0007108638,0.0008173294,0.005827281],"category_scores_gemma":[0.0057032946,0.00015545524,0.00061609544,0.0064350893,0.002484683,0.004485194,0.0018320017,0.00074648275,0.00022182146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019493401,0.0006099804,0.06568686,0.0025811105,0.00012584733,0.0028154831,0.123571485,0.002306328,0.0007894286,0.64725834,0.009943223,0.14411704],"study_design_scores_gemma":[0.00014283575,0.00088076846,0.10643273,0.003503714,0.0003118795,0.0015804515,0.5159167,0.006709514,0.0008053241,0.082808524,0.28082725,0.00008033914],"about_ca_topic_score_codex":0.012852538,"about_ca_topic_score_gemma":0.016212694,"teacher_disagreement_score":0.012852538,"about_ca_system_score_codex":0.008407713,"about_ca_system_score_gemma":0.0068189315,"threshold_uncertainty_score":0.061002493},"labels":[],"label_agreement":null},{"id":"W2890118891","doi":"10.1200/jco.2017.35.15_suppl.6598","title":"Examining the relationship between cost of novel oncology drugs and their clinical benefit over time.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical trial; Drug; Internal medicine; Oncology; Pharmacology","score_opus":0.5846933505889429,"score_gpt":0.5167507478294732,"score_spread":0.06794260275946973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890118891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8450123,0.11668471,0.008754254,0.0031156526,0.00032726035,0.0011138339,0.018482374,0.00007161546,0.006437821],"genre_scores_gemma":[0.98434675,0.006120714,0.0038304348,0.00032627015,0.0001676846,0.00056451844,0.0037633772,0.000022689099,0.0008574969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98114026,0.00821155,0.004247751,0.0017879582,0.0040440666,0.00056841515],"domain_scores_gemma":[0.82775784,0.09461137,0.06753657,0.0030089372,0.005872307,0.0012129407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026904788,0.00057657604,0.001103355,0.0047429665,0.00025970812,0.0014301791,0.0007217502,0.00071867055,0.0039527104],"category_scores_gemma":[0.09868088,0.00041902432,0.005301329,0.00702136,0.00054544973,0.0018896501,0.001236882,0.0015582935,0.0003179453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004830628,0.00019052693,0.9142525,0.004845099,0.016104123,0.00019731831,0.0001515182,0.0040157386,0.0003987897,0.001052722,0.0019256985,0.052035324],"study_design_scores_gemma":[0.00038275085,0.0019612631,0.9654837,0.0009369553,0.011560169,0.0008874633,0.00023593531,0.009326098,0.0006076023,0.0016654567,0.006872005,0.000080688944],"about_ca_topic_score_codex":0.0023229062,"about_ca_topic_score_gemma":0.00416685,"teacher_disagreement_score":0.026904788,"about_ca_system_score_codex":0.0018256718,"about_ca_system_score_gemma":0.0015260086,"threshold_uncertainty_score":0.14228785},"labels":[],"label_agreement":null},{"id":"W2890378724","doi":"10.2139/ssrn.3192558","title":"Assessing Canada's Drug Shortage Problem","year":2018,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Economic shortage; Drug; Political science; Medicine; Pharmacology; Government (linguistics); Philosophy","score_opus":0.027007804250252558,"score_gpt":0.2752467944481282,"score_spread":0.24823899019787565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890378724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6594987,0.007887476,0.0014930431,0.23365565,0.0005602328,0.0002715907,0.020104636,0.00012106932,0.07640774],"genre_scores_gemma":[0.9826005,0.0015907745,0.0010718337,0.0062723686,0.00019115153,0.00003282221,0.002088144,0.000027539618,0.006124922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959442,0.00058316236,0.00014405142,0.00024311934,0.00145238,0.0016331128],"domain_scores_gemma":[0.9800095,0.004866572,0.0018966849,0.00020339077,0.0089821555,0.0040417057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032805938,0.00038833646,0.000750117,0.004129183,0.0047180983,0.0054351883,0.0018159826,0.0027520836,0.006232239],"category_scores_gemma":[0.022873173,0.00036544626,0.0006400052,0.0074746143,0.0013507329,0.0014009973,0.0016695061,0.0022835417,0.00024057107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006439596,0.00054433156,0.4722572,0.00061375776,0.0005255735,0.0016283985,0.0015599757,0.061360773,0.00034741635,0.11163241,0.27103192,0.077854395],"study_design_scores_gemma":[0.0004642798,0.00037327316,0.6382975,0.00091935816,0.00065520045,0.0005417883,0.030576758,0.11669213,0.0009933951,0.03363915,0.17655347,0.0002936368],"about_ca_topic_score_codex":0.9946905,"about_ca_topic_score_gemma":0.996702,"teacher_disagreement_score":0.097341746,"about_ca_system_score_codex":0.097341746,"about_ca_system_score_gemma":0.15997994,"threshold_uncertainty_score":0.7062671},"labels":[],"label_agreement":null},{"id":"W2890449704","doi":"10.1080/13571516.2011.584423","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation","year":2011,"lang":"en","type":"article","venue":"International Journal of the Economics of Business","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fell; Quarter (Canadian coin); Legislation; Medical prescription; Brand loyalty; Market share; Generic drug; Competition (biology); Index (typography); Price index; Economics; Business; Advertising; Marketing; Medicine; Drug; Microeconomics","score_opus":0.04733761495156,"score_gpt":0.26680568921646597,"score_spread":0.21946807426490597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890449704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928998,0.0011037237,0.000046544614,0.0020750384,0.000023220728,0.0000054682228,0.00023629461,0.0000020688296,0.0036078661],"genre_scores_gemma":[0.9978765,0.00042544436,0.000016292834,0.00036226594,0.00009253745,0.0000025648305,0.00021805061,0.000001478565,0.0010048797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994062,0.00007342878,0.000037593563,0.00006195661,0.00020286618,0.00021780458],"domain_scores_gemma":[0.99225426,0.0012202809,0.004644846,0.00010079403,0.0006497585,0.0011299959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001282802,0.00005842282,0.000245304,0.000816998,0.0007625152,0.0022426408,0.00034819837,0.0010552106,0.0036485428],"category_scores_gemma":[0.006341517,0.00010476822,0.00028844524,0.0012476578,0.00077613577,0.0013439148,0.0007818308,0.0017083919,0.00030321238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004214478,0.00053710176,0.96334356,0.000047553116,0.00007389134,0.00028010426,0.0020553402,0.0003284534,0.00036688618,0.0066359504,0.0031725974,0.02273714],"study_design_scores_gemma":[0.0000070925726,0.0001218996,0.9957995,0.000026581796,0.000014832406,0.000089422196,0.0010429271,0.0003338904,0.000120750425,0.00042301213,0.0020105063,0.000009598337],"about_ca_topic_score_codex":0.032723304,"about_ca_topic_score_gemma":0.04185851,"teacher_disagreement_score":0.032723304,"about_ca_system_score_codex":0.0018286685,"about_ca_system_score_gemma":0.0011642167,"threshold_uncertainty_score":0.06506568},"labels":[],"label_agreement":null},{"id":"W2893328979","doi":"10.1186/s13731-018-0092-5","title":"Emerging health technology firms’ strategies and their impact on economic and healthcare system actors: a qualitative study","year":2018,"lang":"en","type":"article","venue":"Journal of Innovation and Entrepreneurship","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Health care; Influencer marketing; Business; Thematic analysis; Public relations; Agency (philosophy); Health technology; Marketing; Qualitative research; Economics; Sociology; Economic growth; Political science","score_opus":0.10662757475939018,"score_gpt":0.39892363612155335,"score_spread":0.2922960613621632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893328979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925411,0.00019735175,0.0012888031,0.0013529105,0.000017438491,0.00010979994,0.00014215538,0.000004590903,0.0043459306],"genre_scores_gemma":[0.996669,0.00027732228,0.00055471045,0.00042880644,0.000007834205,0.00015596375,0.00006830219,0.000008034096,0.0018299274],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9919437,0.0057028136,0.00020681706,0.00038819437,0.00050127,0.001257266],"domain_scores_gemma":[0.9693712,0.025861405,0.0016859318,0.00048374693,0.0012542505,0.0013434795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011913657,0.000292807,0.00040671532,0.0018698927,0.005300939,0.004106453,0.0009494704,0.0015450757,0.0048979255],"category_scores_gemma":[0.01701468,0.00044788673,0.00023256971,0.0017233561,0.00569301,0.0046103643,0.003840199,0.001900314,0.00037412718],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072785166,0.000101032536,0.012662317,0.0001307498,0.0000063542825,0.00076868496,0.974226,0.00008287813,0.0010310744,0.0053147045,0.0005030155,0.005100316],"study_design_scores_gemma":[0.0000059974705,0.000039120918,0.003559428,0.000069228015,0.0000030133776,0.00009886342,0.9893975,0.00017220774,0.00037274248,0.00046854618,0.0058034407,0.000009803369],"about_ca_topic_score_codex":0.0069284933,"about_ca_topic_score_gemma":0.008665301,"teacher_disagreement_score":0.011913657,"about_ca_system_score_codex":0.0050227153,"about_ca_system_score_gemma":0.0032660086,"threshold_uncertainty_score":0.06300622},"labels":[],"label_agreement":null},{"id":"W2893479309","doi":"10.1016/j.cjca.2018.07.151","title":"PUBLIC HEALTH SURVEILLANCE REVEALS AN INCREASE IN HEALTH CARE UTILIZATION FOR GENERIC VS. BRAND-NAME WARFARIN USERS","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Cégep de Lévis","funders":"","keywords":"Medicine; Warfarin; Health care; Public health; Confidence interval; Reimbursement; Emergency medicine; Family medicine; Medical emergency; Pediatrics; Internal medicine; Nursing; Atrial fibrillation","score_opus":0.17958106890652795,"score_gpt":0.331143511998481,"score_spread":0.15156244309195308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893479309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98453635,0.00086304743,0.00026221317,0.0012826569,0.00002561423,0.0000088347515,0.009909832,0.000042629497,0.0030687915],"genre_scores_gemma":[0.99551165,0.0003750967,0.00013118563,0.00023094716,0.000032123815,0.0000041988887,0.0032399702,0.000005064682,0.00046969348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992737,0.0001765087,0.00010009435,0.00015073607,0.00017260597,0.00012641979],"domain_scores_gemma":[0.99404716,0.0015923253,0.002960283,0.00043355336,0.00058352214,0.00038325734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007159239,0.00012046088,0.00025667096,0.0011114706,0.00019967316,0.0006872257,0.00029376245,0.0004483827,0.0032375015],"category_scores_gemma":[0.00437472,0.00015057976,0.00089829613,0.0016877066,0.00015407015,0.00037405212,0.00039649845,0.00050535996,0.00033179193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001305797,0.000022982773,0.9925431,0.000026122392,0.000087868626,0.000033588996,0.000051478844,0.000054681746,0.00026226672,0.00007098311,0.0012059874,0.005510332],"study_design_scores_gemma":[0.000002280377,0.000020053305,0.99935,0.000004770842,0.000024224059,0.000066639775,0.00007315961,0.00010537787,0.000058231937,0.000015958778,0.00027784402,0.0000015146061],"about_ca_topic_score_codex":0.040702645,"about_ca_topic_score_gemma":0.042992353,"teacher_disagreement_score":0.040702645,"about_ca_system_score_codex":0.00047642872,"about_ca_system_score_gemma":0.00055715104,"threshold_uncertainty_score":0.080931425},"labels":[],"label_agreement":null},{"id":"W2894176568","doi":"10.1016/j.tips.2018.09.003","title":"Refining Early Antitumoral Drug Development","year":2018,"lang":"en","type":"review","venue":"Trends in Pharmacological Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"CRIS Cancer Foundation; Junta de Castilla y León","keywords":"Drug development; Drug; Failure rate; Medicine; Pharmacology; Intensive care medicine; Oncology; Internal medicine; Engineering; Reliability engineering","score_opus":0.3877860642907061,"score_gpt":0.44850539055289185,"score_spread":0.060719326262185735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894176568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062210625,0.99334127,0.0011422703,0.0022499952,0.00024097812,0.000015738522,0.000047811347,0.00001292845,0.002326878],"genre_scores_gemma":[0.011412378,0.9841929,0.0015457934,0.001180488,0.0004391978,0.000015993643,0.00006704357,0.0000078765415,0.0011383307],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988568,0.00048300604,0.00012036199,0.00011951032,0.00031261024,0.00010780067],"domain_scores_gemma":[0.99341077,0.0048595904,0.00075296324,0.00016208888,0.0006828233,0.0001317268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004765239,0.00088950136,0.0015903618,0.0021139071,0.00019460559,0.0020185048,0.0012723386,0.0015968644,0.007752235],"category_scores_gemma":[0.00950638,0.0003417481,0.000751369,0.0016724261,0.0011384706,0.0026446523,0.0012254793,0.0025587853,0.0012767817],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016124247,0.000119963224,0.00054955366,0.018225145,0.00013639245,0.00014250103,0.00004690298,0.0021128878,0.000578359,0.04384217,0.012271425,0.9218134],"study_design_scores_gemma":[0.0002076365,0.00028787556,0.0019368014,0.02286277,0.00039717695,0.0007207697,0.00008717368,0.0013271981,0.0020734405,0.039560705,0.9305043,0.00003415633],"about_ca_topic_score_codex":0.0018693402,"about_ca_topic_score_gemma":0.0035337815,"teacher_disagreement_score":0.007752235,"about_ca_system_score_codex":0.0019631053,"about_ca_system_score_gemma":0.004430887,"threshold_uncertainty_score":0.025933802},"labels":[],"label_agreement":null},{"id":"W2894335643","doi":"10.5539/gjhs.v10n10p152","title":"A Comparative Study on Medicine Pricing in Brazil, Russia, India, China and South Africa (BRICS)","year":2018,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Mental Health; Common Fund; Fogarty International Center; National Institutes of Health; National Research Foundation","keywords":"Transparency (behavior); China; Business; Emerging markets; Alliance; Population; Access to medicines; Control (management); Developing country; Economic growth; Economics; Medicine; Political science; Environmental health; Finance","score_opus":0.10372548278398984,"score_gpt":0.3984082257123087,"score_spread":0.29468274292831886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894335643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975914,0.00016785898,0.00002519781,0.00013965227,0.0000029192934,0.000015185409,0.00009099175,9.014625e-7,0.0019659095],"genre_scores_gemma":[0.9994024,0.00020578298,0.00004487743,0.000039603587,0.000002688089,0.000009776705,0.00006810757,0.0000010081486,0.0002257863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990645,0.00038432988,0.00006737783,0.00006344325,0.0001899103,0.00023039337],"domain_scores_gemma":[0.9954945,0.002030826,0.0014427701,0.0001213352,0.00046443744,0.000446107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017146971,0.0001622451,0.00034571084,0.0018943903,0.0008576159,0.0011389034,0.00033515008,0.0003504157,0.0030227266],"category_scores_gemma":[0.0066370377,0.00016816684,0.00033152915,0.0027901425,0.00095567276,0.000775884,0.0009597766,0.0005002977,0.00012561187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024666384,0.00060756714,0.9095458,0.000351648,0.0001371445,0.0013821612,0.05855286,0.00021470108,0.0009835607,0.0053435224,0.0011468505,0.02148751],"study_design_scores_gemma":[0.000015395211,0.00019339769,0.9343501,0.00009834034,0.00004319399,0.00038930838,0.060400803,0.00023304424,0.00017188766,0.00017224965,0.0039183972,0.000014050705],"about_ca_topic_score_codex":0.06742468,"about_ca_topic_score_gemma":0.08370006,"teacher_disagreement_score":0.06742468,"about_ca_system_score_codex":0.0019851972,"about_ca_system_score_gemma":0.002404065,"threshold_uncertainty_score":0.13406444},"labels":[],"label_agreement":null},{"id":"W2894444481","doi":"10.9778/cmajo.20180049","title":"Canadian status of “drugs to avoid” in 2017: a descriptive analysis","year":2018,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Agency for Healthcare Research and Quality; Government of Canada; Gordon and Betty Moore Foundation; National Health and Medical Research Council; St. Michael's Hospital Foundation; Medical Research Council; American Diabetes Association","keywords":"Formulary; Medicine; Listing (finance); Drug; Family medicine; Summary of Product Characteristics; Alternative medicine; Pharmacology; Business","score_opus":0.10058326846073487,"score_gpt":0.3342084100822495,"score_spread":0.23362514162151463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894444481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6113427,0.013841481,0.0005540807,0.0030919896,0.0001657909,0.00077646447,0.30658472,0.00021811026,0.06342458],"genre_scores_gemma":[0.92083067,0.0108292205,0.00090138655,0.0009648343,0.00009057196,0.0003452576,0.061182708,0.0001084601,0.0047469195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934471,0.00019245599,0.00054792315,0.0004386166,0.004286827,0.0010869794],"domain_scores_gemma":[0.97923356,0.0015401427,0.005192064,0.00034452745,0.012033037,0.00165666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020046656,0.0004835897,0.00075032224,0.009861489,0.0021286428,0.0025744077,0.0018369072,0.0005747799,0.006967919],"category_scores_gemma":[0.011542509,0.00035485122,0.0014810573,0.021996237,0.0009253421,0.0009908656,0.0012828136,0.0012634757,0.00069054967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006209772,0.00007451694,0.91174525,0.0018501643,0.00037162867,0.0003402859,0.0016184566,0.00038433427,0.00029664728,0.0015415698,0.049818322,0.031337727],"study_design_scores_gemma":[0.000029200031,0.00006840522,0.94082856,0.0006491802,0.0002573766,0.00045804412,0.004079366,0.0005010046,0.00025307483,0.000111984926,0.052703388,0.000060413066],"about_ca_topic_score_codex":0.97384226,"about_ca_topic_score_gemma":0.9717149,"teacher_disagreement_score":0.040318847,"about_ca_system_score_codex":0.040318847,"about_ca_system_score_gemma":0.078413375,"threshold_uncertainty_score":0.29253507},"labels":[],"label_agreement":null},{"id":"W2894720341","doi":"","title":"The Life Cycle of Pharmaceuticals: A Cross-National Perspective","year":2002,"lang":"en","type":"article","venue":"Monographs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Per capita; Consumption (sociology); Relative price; Investment (military); Economics; Price level; Pharmaceutical industry; Public economics; Agricultural economics; Point (geometry); Business; Monetary economics","score_opus":0.1116558898907889,"score_gpt":0.34786533591565555,"score_spread":0.23620944602486665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894720341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6922343,0.032926105,0.050032973,0.0086595025,0.00025058413,0.00014848693,0.0043137125,0.00006383889,0.21137044],"genre_scores_gemma":[0.97843313,0.009989824,0.006140045,0.0007377121,0.00009177879,0.000046440757,0.0014748586,0.000028861969,0.0030574661],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878365,0.00040107625,0.00008527712,0.00019928107,0.0003011429,0.00022968547],"domain_scores_gemma":[0.99685633,0.0012430857,0.0008469989,0.00018271331,0.0006763937,0.0001943575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017429811,0.00022672235,0.00038466393,0.003003846,0.00059860316,0.0033950165,0.0005059188,0.0005971632,0.0029903445],"category_scores_gemma":[0.0056149703,0.00020982086,0.0007037185,0.0036507866,0.0009046437,0.004384505,0.0012248561,0.00088872196,0.00023306583],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003207658,0.00024561127,0.35228387,0.00049060205,0.000400645,0.0010921644,0.002918544,0.051630113,0.0015138478,0.40051344,0.0059697945,0.18262067],"study_design_scores_gemma":[0.000016668475,0.0004881255,0.6712684,0.00060553243,0.00022897974,0.0014167359,0.0068310318,0.043329474,0.0018694033,0.12178192,0.15201482,0.00014896118],"about_ca_topic_score_codex":0.016023958,"about_ca_topic_score_gemma":0.012561144,"teacher_disagreement_score":0.016023958,"about_ca_system_score_codex":0.0035986258,"about_ca_system_score_gemma":0.0012060812,"threshold_uncertainty_score":0.031861365},"labels":[],"label_agreement":null},{"id":"W2897256035","doi":"10.33423/jabe.v20i6.369","title":"Do Focusing Events and Narratives Drive Pharma Rent-seeking: Evidence from Disease Outbreaks","year":2018,"lang":"en","type":"article","venue":"Journal of Applied Business and Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Outbreak; Narrative; Economic rent; Window of opportunity; Disease; Business; Economics; Medicine; Engineering; Market economy; Virology","score_opus":0.0624418156537383,"score_gpt":0.28767297370063105,"score_spread":0.22523115804689275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897256035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99113315,0.00076639274,0.00012381768,0.0022561438,0.000016056953,0.00002410473,0.00027332202,0.0000023106193,0.00540479],"genre_scores_gemma":[0.9975152,0.00081397995,0.00021417871,0.00048625685,0.000030428697,0.000030831452,0.00034950912,0.000007724604,0.0005519247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973308,0.0013733025,0.00026253544,0.00028580934,0.0003183457,0.00042916156],"domain_scores_gemma":[0.8914837,0.06372504,0.034183208,0.0032837314,0.0028622374,0.00446209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005981725,0.0002893481,0.00040483888,0.0017801472,0.0022193813,0.0049342564,0.001084837,0.0018251297,0.0064963214],"category_scores_gemma":[0.056977347,0.00064573507,0.0004842736,0.0016473118,0.0021411995,0.00692359,0.0038347451,0.00208496,0.0009590746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050231715,0.0005355671,0.92123383,0.00023546678,0.0001754615,0.0004119827,0.06015715,0.00013661708,0.00022850385,0.0023654636,0.001828981,0.012188789],"study_design_scores_gemma":[0.00008980703,0.00018410782,0.86645603,0.00028271825,0.00016096546,0.00032628898,0.12169724,0.0006245706,0.00031578357,0.0029445302,0.006872603,0.000045400746],"about_ca_topic_score_codex":0.014042954,"about_ca_topic_score_gemma":0.015984775,"teacher_disagreement_score":0.014042954,"about_ca_system_score_codex":0.001233724,"about_ca_system_score_gemma":0.00095221755,"threshold_uncertainty_score":0.031634808},"labels":[],"label_agreement":null},{"id":"W2897590646","doi":"10.1108/jes-01-2016-0002.html?utm_source=repec&utm_medium=feed&utm_campaign=repec","title":"The Search for New Drugs: A Theory of R&D in the Pharmaceutical Industry","year":2010,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Product (mathematics); Quality (philosophy); Externality; Microeconomics; Process (computing); Business; Industrial organization; Pharmaceutical industry; Brand names; Network effect; Unit price; Economics; Marketing; Biotechnology; Computer science; Mathematics","score_opus":0.1418124963604259,"score_gpt":0.4056171873832325,"score_spread":0.26380469102280657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897590646","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037386708,0.018823646,0.7265541,0.019574527,0.0004520111,0.00030917156,0.00060335,0.000244609,0.19605193],"genre_scores_gemma":[0.80962294,0.02468052,0.09545939,0.002147809,0.0010437241,0.00083164393,0.0002651028,0.00012282447,0.06582603],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981066,0.00077438605,0.000058995698,0.00038763045,0.00047233325,0.00020004674],"domain_scores_gemma":[0.9969836,0.002067378,0.00039478453,0.00016284536,0.00020129557,0.00019001332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021638132,0.0012042869,0.0017968212,0.0020257274,0.0012389796,0.0050322586,0.0025471542,0.00435908,0.0134617705],"category_scores_gemma":[0.0038340474,0.0007972992,0.002311302,0.002294236,0.0049916185,0.005563574,0.0014856976,0.0023624485,0.001784771],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025589961,0.00004607656,0.00029012896,0.00015199618,0.000025843847,0.00008296447,0.00007874945,0.06600799,0.00021162577,0.92366815,0.0016089081,0.0078021577],"study_design_scores_gemma":[0.0000933885,0.00012654469,0.0003653815,0.00011423292,0.000047439324,0.00013127606,0.00008031014,0.1690933,0.0002003478,0.81547874,0.014230787,0.000038263817],"about_ca_topic_score_codex":0.0047979807,"about_ca_topic_score_gemma":0.0030617411,"teacher_disagreement_score":0.0134617705,"about_ca_system_score_codex":0.0060463757,"about_ca_system_score_gemma":0.0043181987,"threshold_uncertainty_score":0.04503411},"labels":[],"label_agreement":null},{"id":"W2898387476","doi":"10.1093/annonc/mdy297.007","title":"Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Food and drug administration; Marketing authorization; Authorization; Family medicine; Internal medicine; Pharmacology; Bioinformatics","score_opus":0.4063064808284143,"score_gpt":0.4844896776090462,"score_spread":0.0781831967806319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898387476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68245983,0.21908477,0.011852938,0.01326425,0.0018552762,0.014589419,0.015852924,0.00030193114,0.0407386],"genre_scores_gemma":[0.97520864,0.006670152,0.007328188,0.0018921259,0.000646574,0.004390567,0.0032723527,0.00004371508,0.0005476769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.84571445,0.07627943,0.04621535,0.008115598,0.021828244,0.0018469694],"domain_scores_gemma":[0.43029946,0.36007634,0.1636366,0.011473357,0.028802041,0.005712214],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.1882299,0.00071639864,0.0021047324,0.005856215,0.0009314619,0.0036568067,0.00093943,0.0013948685,0.0043864287],"category_scores_gemma":[0.24600999,0.000378815,0.0049917884,0.0044125193,0.0023041526,0.0039927615,0.0030380848,0.0022821755,0.0004685893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06359781,0.00056650897,0.6255468,0.04653223,0.030244617,0.00032143085,0.002245603,0.002690693,0.0041429754,0.0057417275,0.014820216,0.2035493],"study_design_scores_gemma":[0.010322393,0.018769525,0.8405195,0.015249174,0.027666999,0.0016859161,0.0013080137,0.00301063,0.0048200036,0.007934522,0.068303645,0.0004097878],"about_ca_topic_score_codex":0.00040429353,"about_ca_topic_score_gemma":0.0012446666,"teacher_disagreement_score":0.8117701,"about_ca_system_score_codex":0.0021854579,"about_ca_system_score_gemma":0.0035346583,"threshold_uncertainty_score":0.99546677},"labels":[],"label_agreement":null},{"id":"W2898425160","doi":"10.1016/j.gheart.2018.09.025","title":"MS06.5 Equivalence In Active Pharmaceutical Ingredient of Generic Antihypertensive Medicines Available In Three Nigerian States (EQUIMEDS): A Case For Further Surveillance","year":2018,"lang":"en","type":"article","venue":"Global Heart","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Medicine; Excellence; Heart disease; Health care; Medical emergency; Family medicine; Intensive care medicine; Cardiology; Economic growth","score_opus":0.08692875682813082,"score_gpt":0.33987196829942207,"score_spread":0.25294321147129123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898425160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99606496,0.0004533214,0.00027418952,0.00095641235,0.000023618753,0.000033181757,0.00023797473,0.000004067773,0.0019522825],"genre_scores_gemma":[0.9984333,0.00020668884,0.00068332563,0.00025938364,0.000008729388,0.000011764231,0.00012404707,0.0000014146262,0.000271396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924123,0.00027630426,0.00010151336,0.00009607646,0.00017007992,0.000114791685],"domain_scores_gemma":[0.9980069,0.0005416021,0.0005674988,0.00012229699,0.00063149305,0.00013020284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021908474,0.00014291877,0.00018882967,0.0007546354,0.0006494348,0.000769444,0.0003052136,0.00052603864,0.0010832972],"category_scores_gemma":[0.0024295696,0.000110284374,0.00017872865,0.0007268071,0.000573166,0.0005201274,0.00043981988,0.0006635386,0.00010828906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035631945,0.00019952076,0.9627166,0.00010327759,0.000019839512,0.0016290133,0.0025037408,0.00005715793,0.003536735,0.001007657,0.0006859397,0.027184159],"study_design_scores_gemma":[0.000014981089,0.0005778959,0.9715125,0.0001773427,0.00005162744,0.0031856669,0.013169908,0.0007307626,0.0025771167,0.00075673615,0.007229237,0.000016297403],"about_ca_topic_score_codex":0.0074863825,"about_ca_topic_score_gemma":0.013848187,"teacher_disagreement_score":0.0074863825,"about_ca_system_score_codex":0.00052701205,"about_ca_system_score_gemma":0.00054880424,"threshold_uncertainty_score":0.014885604},"labels":[],"label_agreement":null},{"id":"W2898784478","doi":"10.1016/j.yrtph.2018.10.019","title":"Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand","year":2018,"lang":"en","type":"article","venue":"Regulatory Toxicology and Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute; Canadian Institute for Health Information","funders":"","keywords":"Drug approval; Government (linguistics); Medicine; Orphan drug; Regulatory authority; Business; Pharmacology; Drug; Public administration; Political science","score_opus":0.0805506554114334,"score_gpt":0.3408345033275702,"score_spread":0.2602838479161368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898784478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95826405,0.0046415906,0.0010222592,0.007865394,0.000111958696,0.00013416607,0.0056242277,0.00009141742,0.022244964],"genre_scores_gemma":[0.99089664,0.0013432559,0.0005448985,0.00039251905,0.00004100496,0.000020909158,0.0010746636,0.00002936412,0.0056567234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99503255,0.00046735402,0.0004809109,0.0005189112,0.002403154,0.0010971823],"domain_scores_gemma":[0.9637254,0.009849346,0.012694779,0.00058210565,0.008835998,0.0043123076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034297882,0.00022443179,0.00067272363,0.0038016615,0.0010893294,0.0033119393,0.0012198956,0.0009326298,0.004921644],"category_scores_gemma":[0.025334809,0.0006464029,0.0011028737,0.0037410762,0.0014088571,0.001116294,0.0009788587,0.0018214848,0.0002285969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044358033,0.00030059018,0.8148645,0.0008514606,0.00089266006,0.0018516924,0.003232,0.02459183,0.0039453036,0.031578295,0.02430906,0.08914673],"study_design_scores_gemma":[0.000106051215,0.00012297335,0.98322046,0.00006720606,0.00007286159,0.00020216742,0.0010967972,0.0038744651,0.00046630905,0.0005536992,0.010157282,0.000059661317],"about_ca_topic_score_codex":0.95485395,"about_ca_topic_score_gemma":0.96493995,"teacher_disagreement_score":0.9574601,"about_ca_system_score_codex":0.042539902,"about_ca_system_score_gemma":0.030538527,"threshold_uncertainty_score":0.30865002},"labels":[],"label_agreement":null},{"id":"W2899402063","doi":"10.1159/000493119","title":"Prescription Drug Shortages: Impact on Neonatal Intensive Care","year":2018,"lang":"en","type":"article","venue":"Neonatology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Economic shortage; Medicine; Medical prescription; Interquartile range; Drug; Internal medicine; Pharmacology","score_opus":0.038681748679167786,"score_gpt":0.31206471261296853,"score_spread":0.27338296393380074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899402063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9503757,0.026617076,0.00048904883,0.009375877,0.00013259899,0.00006869914,0.004822777,0.000030490699,0.008087792],"genre_scores_gemma":[0.9816768,0.01320399,0.00061653194,0.0016903321,0.00018026204,0.000045783698,0.0020946877,0.000011095834,0.0004805555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805427,0.00043206263,0.00047215895,0.00019516496,0.00058243604,0.0002640544],"domain_scores_gemma":[0.980431,0.0037134823,0.012343257,0.00018314675,0.001977359,0.0013518009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022103745,0.00014880755,0.00025352038,0.0016784471,0.00041761543,0.0008482481,0.000387006,0.0003150348,0.0040783393],"category_scores_gemma":[0.0139821395,0.0001633276,0.00035730208,0.002437391,0.00031079148,0.001227079,0.0014601356,0.00069137843,0.00033115517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008583014,0.00004129147,0.9618849,0.00052204356,0.00005324316,0.00043992896,0.00048414947,0.0002670022,0.00011935294,0.00031495703,0.0038527437,0.031934556],"study_design_scores_gemma":[0.0000043380714,0.000059825634,0.9900383,0.0007559507,0.000027240047,0.00069957995,0.0014032985,0.00047974408,0.0001361562,0.00020460726,0.006182176,0.00000879621],"about_ca_topic_score_codex":0.016422668,"about_ca_topic_score_gemma":0.020635819,"teacher_disagreement_score":0.016422668,"about_ca_system_score_codex":0.0019186813,"about_ca_system_score_gemma":0.0026917232,"threshold_uncertainty_score":0.032654166},"labels":[],"label_agreement":null},{"id":"W2899724228","doi":"10.11575/prism/32040","title":"Universal Prescription Drug Coverage: Rethinking Outpatient Pharmaceutical Provision in Alberta","year":2017,"lang":"en","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Business; Medicine; Pharmacology","score_opus":0.0871792487612392,"score_gpt":0.3523052466169871,"score_spread":0.26512599785574786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899724228","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6668501,0.007281897,0.008425907,0.15191934,0.00041846474,0.00029028117,0.00065098726,0.00014667152,0.16401637],"genre_scores_gemma":[0.9709405,0.0025302465,0.003223086,0.005117855,0.0001344453,0.000028363047,0.0001978379,0.000024553945,0.017803159],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959468,0.00073704135,0.00006575878,0.00018664474,0.0013059948,0.0017577123],"domain_scores_gemma":[0.99514824,0.0022760578,0.00023794398,0.00018154884,0.0009638464,0.0011923353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038049768,0.00019648328,0.0003138695,0.0010644946,0.0034984832,0.0050269444,0.0019970424,0.0020596401,0.003750828],"category_scores_gemma":[0.010649013,0.00029658023,0.00040139913,0.0015605569,0.0032467167,0.0014594203,0.004038133,0.0023454207,0.00011668278],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036943523,0.0003981274,0.084396064,0.0003254709,0.0001139168,0.0016276357,0.008699092,0.034426186,0.0014551742,0.6114958,0.057127815,0.19956526],"study_design_scores_gemma":[0.00034091147,0.00040461696,0.33354995,0.001342904,0.00031847644,0.00037247274,0.022906926,0.06464443,0.0017872732,0.15471515,0.41933852,0.00027843018],"about_ca_topic_score_codex":0.9738714,"about_ca_topic_score_gemma":0.98250294,"teacher_disagreement_score":0.9088043,"about_ca_system_score_codex":0.09119571,"about_ca_system_score_gemma":0.13611287,"threshold_uncertainty_score":0.66167426},"labels":[],"label_agreement":null},{"id":"W2899812694","doi":"10.11575/sppp.v11i0.53048","title":"Making Sure Orphan Drugs Don’t Get Left Behind","year":2018,"lang":"en","type":"article","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Orphan drug; Incentive; Business; Yardstick; Government (linguistics); Competitor analysis; Reimbursement; Pharmaceutical industry; Profit (economics); Public economics; Industrial organization; Actuarial science; Economics; Marketing; Health care; Medicine; Microeconomics; Economic growth","score_opus":0.08603383365744059,"score_gpt":0.36544796682228614,"score_spread":0.27941413316484554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899812694","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059413933,0.008228649,0.009015384,0.8077102,0.024240494,0.00030215512,0.0004845613,0.0012094023,0.1428679],"genre_scores_gemma":[0.08803891,0.008189229,0.018591573,0.7747395,0.011078506,0.00041633632,0.00073703384,0.0010664209,0.097142495],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.95183265,0.015887396,0.003627148,0.0044735083,0.01999163,0.004187766],"domain_scores_gemma":[0.9112946,0.03440385,0.007937676,0.011616062,0.023689318,0.011058456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034305222,0.0011383524,0.0013538651,0.0015699937,0.0055750166,0.01245296,0.0029742634,0.016606169,0.039995898],"category_scores_gemma":[0.19447479,0.0009698074,0.0019084612,0.0010559935,0.0076685417,0.018423103,0.008446341,0.019699361,0.022832396],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023152282,0.00018358104,0.0036951988,0.00058742124,0.00019332285,0.0007028061,0.0013041007,0.00043965195,0.0012145694,0.062131345,0.71033025,0.21898617],"study_design_scores_gemma":[0.00011870622,0.00015401714,0.0015840966,0.0007175151,0.0000958299,0.00049244,0.00058309647,0.00032257233,0.0013031672,0.02810784,0.9664325,0.0000881815],"about_ca_topic_score_codex":0.007017259,"about_ca_topic_score_gemma":0.007117543,"teacher_disagreement_score":0.039995898,"about_ca_system_score_codex":0.004583009,"about_ca_system_score_gemma":0.017091349,"threshold_uncertainty_score":0.18142557},"labels":[],"label_agreement":null},{"id":"W2899914486","doi":"10.1136/heartasia-2018-011034","title":"Single-use medical devices: economic issues","year":2018,"lang":"en","type":"article","venue":"Heart Asia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.10668737320955592,"score_gpt":0.3349997483859336,"score_spread":0.2283123751763777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899914486","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025306163,0.16341309,0.0068221563,0.43683422,0.0058110366,0.00026592726,0.0022993211,0.00011115658,0.35913682],"genre_scores_gemma":[0.6050036,0.17715691,0.006682099,0.13703012,0.018828211,0.0005077116,0.002314358,0.00021456876,0.052262556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99499893,0.0010539482,0.00025207835,0.00029356973,0.0029510234,0.00045057765],"domain_scores_gemma":[0.9798835,0.011102124,0.0025581734,0.00042035876,0.0042628436,0.0017730597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060398453,0.00050466415,0.00052749424,0.0028125914,0.0010774697,0.006292546,0.0015890858,0.0036002041,0.039862502],"category_scores_gemma":[0.02964214,0.00023529236,0.0008123055,0.0026154225,0.0018769582,0.0047617084,0.0017764413,0.004278164,0.0036525251],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027206537,0.00031572176,0.012498967,0.0013284552,0.00011409968,0.00070315186,0.00018136567,0.0014582032,0.00020405535,0.2877647,0.31285456,0.3823046],"study_design_scores_gemma":[0.00009724195,0.00038453593,0.026258552,0.006177339,0.00012552376,0.0035117164,0.0014569743,0.0030638836,0.00045707994,0.10404165,0.8543195,0.00010606452],"about_ca_topic_score_codex":0.005667417,"about_ca_topic_score_gemma":0.0060665607,"teacher_disagreement_score":0.039862502,"about_ca_system_score_codex":0.004907247,"about_ca_system_score_gemma":0.0043403846,"threshold_uncertainty_score":0.13335341},"labels":[],"label_agreement":null},{"id":"W2900339493","doi":"","title":"Data That Heals: A Three Horizon Analysis","year":2018,"lang":"en","type":"other","venue":"OCAD University Open Research Repository (OCAD University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario College of Art and Design","funders":"","keywords":"Business; Futures studies; Big data; Marketing; Emerging markets; Health care; Emerging technologies; Position (finance); Product (mathematics); Industrial organization; Economics; Finance; Economic growth; Computer science","score_opus":0.33377910629579666,"score_gpt":0.36793778656367104,"score_spread":0.034158680267874386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900339493","genre_codex":"methods","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08890375,0.02308197,0.5214534,0.1851742,0.0021384254,0.0026267874,0.009421091,0.00093743467,0.16626294],"genre_scores_gemma":[0.69267446,0.008588793,0.27438477,0.0059842183,0.00051347975,0.0012207205,0.0037416634,0.0002809328,0.012610898],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98198986,0.011330703,0.00066415034,0.0011444378,0.0032295089,0.0016413762],"domain_scores_gemma":[0.96162957,0.025913013,0.002832356,0.0018237289,0.0056051533,0.0021960766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029601673,0.000905447,0.00089455646,0.0055374256,0.0031658676,0.011162836,0.0019461021,0.0023425338,0.014189245],"category_scores_gemma":[0.062110394,0.0006136023,0.0020572795,0.0069454326,0.004670852,0.014424657,0.0060476027,0.0047898996,0.0010687674],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044284452,0.00015460617,0.009866451,0.0011547377,0.00027469124,0.0003504996,0.0038190244,0.016358687,0.00026739802,0.79840946,0.027109327,0.14179227],"study_design_scores_gemma":[0.00006886063,0.00024210481,0.005237302,0.0021168233,0.00020338777,0.00017366857,0.011969603,0.063562535,0.00052825204,0.8049136,0.11086874,0.00011519784],"about_ca_topic_score_codex":0.02786423,"about_ca_topic_score_gemma":0.01835797,"teacher_disagreement_score":0.029601673,"about_ca_system_score_codex":0.012777622,"about_ca_system_score_gemma":0.01612955,"threshold_uncertainty_score":0.15655053},"labels":[],"label_agreement":null},{"id":"W2901198550","doi":"10.1007/s40256-018-0309-9","title":"Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis","year":2018,"lang":"en","type":"article","venue":"American Journal of Cardiovascular Drugs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; The Quebec Population Health Research Network; Université du Québec à Trois-Rivières; Université Laval; Institut National de Santé Publique du Québec","funders":"Fonds de Recherche du Québec - Santé; Abbott Vascular; Institut National de Santé Publique du Québec","keywords":"Medicine; Warfarin; Population; Pharmacotherapy; Brand names; Series (stratigraphy); Advertising; Internal medicine; Atrial fibrillation; Business; Environmental health","score_opus":0.010188573071487614,"score_gpt":0.226260074158103,"score_spread":0.21607150108661538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901198550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.964273,0.0014506143,0.00023724105,0.0007108651,0.000026303842,0.00004475356,0.03166119,0.000053235748,0.0015427482],"genre_scores_gemma":[0.98577034,0.0007055938,0.00018803967,0.00016563233,0.000016169819,0.000023058017,0.011466935,0.000012290585,0.001651837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893934,0.000092455346,0.000121025514,0.00020887813,0.00026419354,0.00037406475],"domain_scores_gemma":[0.99638903,0.000295001,0.000830041,0.00014825846,0.0015948638,0.0007429102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084968633,0.0004932144,0.0006219539,0.0017504651,0.0012030677,0.0015557159,0.0018552975,0.0012391496,0.003494771],"category_scores_gemma":[0.0030230614,0.00040816606,0.0015848903,0.0065476187,0.00060352474,0.00082226534,0.00077790505,0.0013150828,0.00045565804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015078307,0.000050875966,0.9933106,0.0000352694,0.00021731346,0.00008043389,0.00021699328,0.00055435806,0.00009484871,0.00010547528,0.002459054,0.0027239164],"study_design_scores_gemma":[0.000007215862,0.000017059701,0.99813616,0.000013390134,0.00004460753,0.000028947414,0.00029343393,0.00092921936,0.000016738419,0.0000113218175,0.00049195683,0.000009909536],"about_ca_topic_score_codex":0.9943798,"about_ca_topic_score_gemma":0.9935133,"teacher_disagreement_score":0.025281508,"about_ca_system_score_codex":0.025281508,"about_ca_system_score_gemma":0.017375274,"threshold_uncertainty_score":0.18343103},"labels":[],"label_agreement":null},{"id":"W2902080463","doi":"10.12688/wellcomeopenres.14947.1","title":"Ideation and implementation of an open science drug discovery business model – M4K Pharma","year":2018,"lang":"en","type":"preprint","venue":"Wellcome Open Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalton Pharma Services (Canada); Structural Genomics Consortium; University of Toronto","funders":"Structural Genomics Consortium; Brain Tumour Charity; Ontario Institute for Cancer Research; Wellcome Trust; Wellcome","keywords":"Intellectual property; Business; Venture capital; Ideation; Government (linguistics); Business model; Investment (military); Key (lock); Foundation (evidence); Asset (computer security); Finance; Industrial organization; Marketing; Computer science; Political science; Computer security","score_opus":0.32673138679746005,"score_gpt":0.4993886351626393,"score_spread":0.17265724836517926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902080463","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049252193,0.001782042,0.3444693,0.3018476,0.002157858,0.0014056141,0.000523729,0.00066437933,0.29789725],"genre_scores_gemma":[0.7544926,0.0015591467,0.15860851,0.02031701,0.0011677775,0.0014931132,0.00029016266,0.00024367907,0.061827958],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98833114,0.0060992637,0.00034977193,0.0010036158,0.0033945313,0.00082152995],"domain_scores_gemma":[0.9862818,0.007007551,0.00080388447,0.0017081258,0.0022458758,0.0019527791],"candidate_categories":["open_science"],"consensus_categories":[],"category_scores_codex":[0.01661067,0.0006041074,0.00046648798,0.0011330227,0.0014713067,0.011331705,0.002304531,0.0077148173,0.011727849],"category_scores_gemma":[0.023560451,0.00042987222,0.0011975094,0.00072254025,0.0055403747,0.008754943,0.004484845,0.007296897,0.0029028626],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000619248,0.000079672114,0.00037493976,0.000053329644,0.000012959833,0.00008551622,0.00014525242,0.0042667845,0.0003203586,0.9793402,0.006511054,0.008748188],"study_design_scores_gemma":[0.00017804574,0.00019143829,0.0005764865,0.00020852075,0.000022645929,0.00012325025,0.00031067932,0.031545717,0.00087573734,0.8551729,0.110728465,0.00006608584],"about_ca_topic_score_codex":0.0019762388,"about_ca_topic_score_gemma":0.0013106962,"teacher_disagreement_score":0.99769545,"about_ca_system_score_codex":0.006848994,"about_ca_system_score_gemma":0.0106139695,"threshold_uncertainty_score":0.08784664},"labels":[],"label_agreement":null},{"id":"W2902306742","doi":"10.1128/jcm.01637-18","title":"Industry Perspectives on the WHO Essential Diagnostics List","year":2018,"lang":"en","type":"letter","venue":"Journal of Clinical Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Outbreak; Communicable disease; Healthcare system; Medicine; Low and middle income countries; Global health; Intensive care medicine; Health care; Environmental health; Business; Developing country; Public health; Economic growth; Virology; Pathology","score_opus":0.13043208718089475,"score_gpt":0.383639576013895,"score_spread":0.25320748883300026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902306742","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019353215,0.0013780345,0.000114464834,0.97973484,0.008312648,0.000007974508,0.00004484632,0.000018462433,0.010195199],"genre_scores_gemma":[0.0034151594,0.0014751061,0.00023419368,0.9656172,0.019602,0.000027664491,0.00006504918,0.000025311328,0.009538331],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910415,0.0019271944,0.0007306,0.00079005654,0.0036106906,0.001900034],"domain_scores_gemma":[0.97936064,0.010850069,0.0009369391,0.00072707847,0.0043151304,0.0038101203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00882777,0.0007288376,0.00068512204,0.0009954395,0.0034963058,0.0073108785,0.0021642775,0.04980645,0.025123669],"category_scores_gemma":[0.03093473,0.0004793169,0.0011320836,0.0012090869,0.004069289,0.0060276026,0.0038832254,0.036811184,0.012529165],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017068045,0.00002328562,0.00026441342,0.00004708766,0.0000029250848,0.0004647523,0.00010388842,0.00004157608,0.00015511292,0.022040665,0.96450716,0.012331945],"study_design_scores_gemma":[0.000018919773,0.000020563322,0.0003057092,0.00018974043,0.0000034282273,0.00033799093,0.00017072266,0.00008867828,0.00008561918,0.008883835,0.98987997,0.000014731221],"about_ca_topic_score_codex":0.005850737,"about_ca_topic_score_gemma":0.01267885,"teacher_disagreement_score":0.04980645,"about_ca_system_score_codex":0.0063103987,"about_ca_system_score_gemma":0.0102510005,"threshold_uncertainty_score":0.08404702},"labels":[],"label_agreement":null},{"id":"W2902663565","doi":"10.1257/aer.20140202","title":"Identifying Industry Margins with Price Constraints: Structural Estimation on Pharmaceuticals","year":2018,"lang":"en","type":"article","venue":"American Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Center for Interuniversity Research and Analysis on Organizations","funders":"Agence Nationale de la Recherche","keywords":"Counterfactual thinking; Economics; Consumption (sociology); Estimation; Relative price; Price setting; Reference price; Microeconomics; Structural estimation; Limit price; Pharmaceutical industry; Mid price; Econometrics; Price level; Monetary economics","score_opus":0.082991323703105,"score_gpt":0.3758207466615359,"score_spread":0.29282942295843095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902663565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76427907,0.0013284154,0.21347517,0.005882882,0.00011327824,0.00029608465,0.0024009435,0.00040544334,0.011818671],"genre_scores_gemma":[0.9868203,0.00048919226,0.008211619,0.00022711401,0.00009840027,0.0001291252,0.00092253863,0.000027112226,0.0030747035],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972234,0.0016277467,0.00010824445,0.0004144137,0.00021667201,0.00040944753],"domain_scores_gemma":[0.9713239,0.022614827,0.00404138,0.000806523,0.00077226985,0.00044110316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004980041,0.0010958089,0.0023044464,0.0013218266,0.00071061315,0.002270296,0.0017341536,0.0030769696,0.0073337364],"category_scores_gemma":[0.024452271,0.00106417,0.0020482128,0.0013380507,0.0017045446,0.0022022778,0.002078006,0.003237166,0.00073643797],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018357749,0.00023451768,0.022743186,0.000099772435,0.00025231054,0.00027119354,0.00014814574,0.9162238,0.00044757096,0.049201924,0.0019560612,0.008237885],"study_design_scores_gemma":[0.00015968665,0.0001426105,0.0055350126,0.00002724644,0.00009584127,0.0000247736,0.000091080554,0.9619971,0.0002401677,0.030414212,0.0012388445,0.000033438286],"about_ca_topic_score_codex":0.04250588,"about_ca_topic_score_gemma":0.030204283,"teacher_disagreement_score":0.04250588,"about_ca_system_score_codex":0.0026313534,"about_ca_system_score_gemma":0.0025263375,"threshold_uncertainty_score":0.08451694},"labels":[],"label_agreement":null},{"id":"W2903790720","doi":"10.5703/1288284316836","title":"The Pharmaceutical Industry: A Pharmacy Student's Guide","year":2018,"lang":"en","type":"article","venue":"Purdue Journal of Service-Learning and International Engagement","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Nuclear Safety Commission","keywords":"Internship; Pharmacy; Graduation (instrument); Medical education; Pharmaceutical industry; Work (physics); Pharmacy practice; Management; Medicine; Psychology; Engineering; Pharmacology; Family medicine","score_opus":0.09629959071635974,"score_gpt":0.39024732780850807,"score_spread":0.29394773709214833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903790720","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028649482,0.08943702,0.02469746,0.39052635,0.028390327,0.001522286,0.0031769916,0.008008458,0.45137608],"genre_scores_gemma":[0.011860567,0.094661176,0.03641275,0.2148874,0.015079601,0.0015327327,0.00246829,0.0011246796,0.62197286],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985734,0.00034046342,0.00014389263,0.00009465704,0.000697059,0.00015046402],"domain_scores_gemma":[0.99519604,0.00075193826,0.00023601223,0.00018165748,0.0014079482,0.002226458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024038272,0.0011694389,0.0010328011,0.0024959585,0.0019375316,0.004809689,0.0015748723,0.0044463445,0.086652026],"category_scores_gemma":[0.00686447,0.0009434929,0.0006608451,0.0019650625,0.00078912417,0.005887445,0.005329262,0.006590646,0.119090945],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008959957,0.0001244021,0.00021876182,0.00009594264,0.000001805032,0.00015650193,0.00017832646,0.000057122426,0.00009977359,0.00105314,0.9026191,0.09538627],"study_design_scores_gemma":[0.000008986976,0.00004024278,0.0003606476,0.00019900629,0.0000010026562,0.000665024,0.00027276814,0.000051606265,0.000026512465,0.0019217836,0.99644417,0.000008358183],"about_ca_topic_score_codex":0.0018616208,"about_ca_topic_score_gemma":0.0065591177,"teacher_disagreement_score":0.086652026,"about_ca_system_score_codex":0.0009983364,"about_ca_system_score_gemma":0.0056547076,"threshold_uncertainty_score":0.28987992},"labels":[],"label_agreement":null},{"id":"W2905138060","doi":"10.1177/1741134318810061","title":"Tough medicine: Ensuring access to affordable drugs requires fixing trade agreements starting with NAFTA","year":2018,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; International trade; General partnership; Negotiation; Market access; Business; Biosimilar; International trade law; Modernization theory; Subsidy; Balance (ability); International economics; Economics; Law; Economic growth; Political science; Finance; Medicine; Market economy","score_opus":0.14072967902078418,"score_gpt":0.3383205404430396,"score_spread":0.19759086142225543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905138060","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034009743,0.01399695,0.02934477,0.56958854,0.009832356,0.00026968223,0.00036758542,0.00043336485,0.342157],"genre_scores_gemma":[0.6081378,0.008631155,0.05626176,0.24212,0.003680923,0.0005972048,0.00042863446,0.00025435092,0.07988822],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98378307,0.004942527,0.00094106,0.0022541564,0.0056963707,0.0023829285],"domain_scores_gemma":[0.9834246,0.0071464297,0.0020301817,0.0018887746,0.0040307348,0.0014793935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023063859,0.00079249643,0.0008303635,0.0017671216,0.006717279,0.013050569,0.0018331062,0.01573881,0.015730752],"category_scores_gemma":[0.050020054,0.00048526333,0.0014062016,0.0011428179,0.0104145,0.017254466,0.0054773907,0.012798156,0.0027278662],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087996494,0.00005213719,0.00097288314,0.000171462,0.000033627617,0.0002684905,0.001494421,0.0003132925,0.0009474198,0.9226961,0.041311,0.031651124],"study_design_scores_gemma":[0.00005363518,0.0001364133,0.0020867037,0.0009502653,0.000041494066,0.00025571813,0.0013771752,0.00060480786,0.00097427686,0.3517604,0.6416611,0.00009806627],"about_ca_topic_score_codex":0.019471772,"about_ca_topic_score_gemma":0.01291046,"teacher_disagreement_score":0.023063859,"about_ca_system_score_codex":0.007889775,"about_ca_system_score_gemma":0.016572734,"threshold_uncertainty_score":0.121974766},"labels":[],"label_agreement":null},{"id":"W2906206060","doi":"10.3968/10512","title":"Legal and Economic Analysis of Medicine Purchased Oversea","year":2018,"lang":"en","type":"article","venue":"Canadian social science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Principle of legality; Intellectual property; Counterfeit; Business; Purchasing; Balance (ability); Law and economics; Law; Medicine; Marketing; Economics; Political science","score_opus":0.046352609813666824,"score_gpt":0.3064504852286596,"score_spread":0.26009787541499274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906206060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5320813,0.011879669,0.0162339,0.031402975,0.00023057075,0.00025130104,0.0016678256,0.00008208851,0.40617037],"genre_scores_gemma":[0.9787531,0.002565332,0.0009801213,0.0007694546,0.00023194726,0.00006669615,0.00026362037,0.000014308885,0.016355388],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972486,0.000869801,0.00010588596,0.00021478739,0.00095077057,0.0006100376],"domain_scores_gemma":[0.98624504,0.0090016825,0.0024903712,0.00043699853,0.0011726549,0.0006532113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029820944,0.00032887762,0.0007481338,0.0035794554,0.0019597346,0.0046091606,0.0011745308,0.003049264,0.01314363],"category_scores_gemma":[0.013693353,0.0006173771,0.0014482649,0.0020164358,0.003980054,0.0036292523,0.0018367313,0.003938558,0.0004560976],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008891119,0.00016071786,0.0052353456,0.000116042705,0.00007495411,0.00081747136,0.00020694999,0.00895686,0.00041769535,0.97585255,0.003021826,0.0050506815],"study_design_scores_gemma":[0.00025265655,0.00034885327,0.04274776,0.0005970211,0.00034234862,0.0010982066,0.0014318746,0.1582928,0.0017008107,0.7387905,0.054194786,0.0002022681],"about_ca_topic_score_codex":0.036867544,"about_ca_topic_score_gemma":0.025191374,"teacher_disagreement_score":0.036867544,"about_ca_system_score_codex":0.010193027,"about_ca_system_score_gemma":0.0052462993,"threshold_uncertainty_score":0.07395589},"labels":[],"label_agreement":null},{"id":"W2906254779","doi":"10.1016/j.jval.2018.09.1178","title":"PHP284 - TIME TO HTA DECISION FOR INTERNATIONALISED MEDICINES IN AUSTRALIA, CANADA AND EUROPE","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cohort; Internal medicine","score_opus":0.12341032519558928,"score_gpt":0.3578184141197676,"score_spread":0.23440808892417833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906254779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49162486,0.0066279247,0.0035700796,0.09845541,0.0012195043,0.000691624,0.025780894,0.0004038426,0.37162584],"genre_scores_gemma":[0.9286051,0.0006292574,0.001240606,0.009775386,0.00036030807,0.000078927085,0.0024365964,0.00010076912,0.056773063],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9916047,0.0012867376,0.00031360134,0.00058886677,0.002638992,0.0035670572],"domain_scores_gemma":[0.9814913,0.0087562855,0.0009990078,0.00027737362,0.0037306142,0.0047454364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009872921,0.00035400141,0.00129245,0.0017304049,0.0016373543,0.008993513,0.0017421527,0.0067162076,0.020545341],"category_scores_gemma":[0.026531424,0.0007508089,0.001760184,0.0013348706,0.0013089391,0.0021833864,0.0012363573,0.0065463497,0.0011406204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077870926,0.00081377686,0.09029298,0.0008317814,0.0011489156,0.0025517729,0.0012856892,0.09116463,0.002274404,0.40120056,0.31791416,0.082734294],"study_design_scores_gemma":[0.0020549272,0.0014372353,0.34550568,0.00088112353,0.0012823762,0.0009143446,0.00434017,0.14564866,0.0062502567,0.09114327,0.399955,0.0005870886],"about_ca_topic_score_codex":0.74368834,"about_ca_topic_score_gemma":0.7626322,"teacher_disagreement_score":0.9663957,"about_ca_system_score_codex":0.03360434,"about_ca_system_score_gemma":0.0480064,"threshold_uncertainty_score":0.5156422},"labels":[],"label_agreement":null},{"id":"W2907166494","doi":"10.1016/j.mayocp.2018.07.027","title":"Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials","year":2019,"lang":"en","type":"article","venue":"Mayo Clinic Proceedings","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; CRIS Cancer Foundation","keywords":"Medicine; Food and drug administration; Drug; Postmarketing surveillance; Pharmacology; Randomized controlled trial; Drug approval; Intensive care medicine; Clinical trial; Safety profile; Adverse effect; Internal medicine","score_opus":0.0380535121699198,"score_gpt":0.3018423973481216,"score_spread":0.2637888851782018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907166494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63223875,0.15892078,0.017976668,0.01987544,0.008597568,0.013231997,0.092291944,0.00057730835,0.0562896],"genre_scores_gemma":[0.9570802,0.007580624,0.0041741133,0.006287432,0.0021962733,0.001930268,0.015272144,0.00006203002,0.005416922],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.97333634,0.011719622,0.0054373383,0.003884616,0.0043268334,0.0012952561],"domain_scores_gemma":[0.88028026,0.052755542,0.044563334,0.011307182,0.009134027,0.0019596652],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02564489,0.0007018854,0.0017232528,0.0022571052,0.0006019466,0.0021961806,0.0015075031,0.0022864987,0.0074826092],"category_scores_gemma":[0.08927576,0.0005617349,0.0059471917,0.0023177632,0.0013481702,0.0021868348,0.0010096662,0.0024970495,0.00067865796],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4018374,0.0024727306,0.16980548,0.026728477,0.051239632,0.000725345,0.00029927643,0.0028804915,0.0020532596,0.0074989735,0.057021476,0.27743754],"study_design_scores_gemma":[0.07539711,0.019799706,0.6520943,0.008759109,0.07246182,0.0009327843,0.00021029232,0.0048303204,0.010527108,0.008940752,0.14573531,0.00031147286],"about_ca_topic_score_codex":0.003001562,"about_ca_topic_score_gemma":0.006090272,"teacher_disagreement_score":0.9743551,"about_ca_system_score_codex":0.002523526,"about_ca_system_score_gemma":0.0039204503,"threshold_uncertainty_score":0.1356247},"labels":[],"label_agreement":null},{"id":"W2907169668","doi":"10.22215/etd/2009-08900","title":"The review of Bill C-91 : pharmaceutical policy development under a majority Liberal government","year":2009,"lang":"en","type":"dissertation","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Industry Canada; Australian Government; Queen's University; McGill University","keywords":"Political science; Government (linguistics); Public administration; Humanities; Philosophy; Linguistics","score_opus":0.05492035577011735,"score_gpt":0.3368289630221087,"score_spread":0.28190860725199135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907169668","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00711343,0.36001676,0.0013023845,0.37109733,0.01731137,0.00016490505,0.0010039866,0.00009276242,0.2418971],"genre_scores_gemma":[0.20525685,0.31815356,0.0025141407,0.30946746,0.02203028,0.0003601622,0.0010711243,0.00021082295,0.14093561],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98224753,0.0038742484,0.0011831301,0.0013990725,0.00899513,0.0023010152],"domain_scores_gemma":[0.9762347,0.0100010745,0.0021839656,0.0012187609,0.009278026,0.0010835305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017071158,0.0006265996,0.0010208738,0.0030867043,0.002018401,0.008853408,0.0016309749,0.010147808,0.0045551406],"category_scores_gemma":[0.04941912,0.0006437442,0.0009406642,0.0042182948,0.0046761264,0.0044702725,0.0017299389,0.009870582,0.0016405516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009335588,0.00003377355,0.00032003937,0.0008298442,0.0000379593,0.0000827589,0.00024801915,0.0006904535,0.00020675614,0.4758504,0.46015954,0.061447076],"study_design_scores_gemma":[0.00003578875,0.000059251248,0.004727133,0.0017393467,0.000036394176,0.00006704123,0.00020348506,0.00022740157,0.00038586443,0.026887292,0.96559274,0.000038307873],"about_ca_topic_score_codex":0.051323187,"about_ca_topic_score_gemma":0.056581557,"teacher_disagreement_score":0.980791,"about_ca_system_score_codex":0.019209,"about_ca_system_score_gemma":0.035863463,"threshold_uncertainty_score":0.1393717},"labels":[],"label_agreement":null},{"id":"W2907596760","doi":"10.1017/s0266462318001745","title":"OP172 Do Expedited Regulatory Pathways Affect Time To Health Technology Assessment Decision?","year":2018,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Health technology; Drug approval; Regulatory science; Regulatory authority; Pharmacology; Political science; Health care; Public administration; Drug","score_opus":0.03681897121431954,"score_gpt":0.40337846501788205,"score_spread":0.3665594938035625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907596760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8839586,0.014251021,0.008902188,0.030055637,0.0006894281,0.0014877914,0.0150236385,0.00035157698,0.04528013],"genre_scores_gemma":[0.9880476,0.0024213062,0.00429423,0.0013806012,0.0002594513,0.00044207496,0.0013823021,0.00007125263,0.0017012161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9416614,0.032526933,0.008714467,0.005724399,0.008478019,0.0028947245],"domain_scores_gemma":[0.5045041,0.30215782,0.1573212,0.0071289777,0.0189629,0.009925042],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.045445874,0.00026460894,0.0006145255,0.0015341188,0.00078826625,0.005402345,0.0015370145,0.0012438507,0.017860854],"category_scores_gemma":[0.2857683,0.00041164362,0.0016312584,0.0031729918,0.0008843767,0.0031610075,0.0022665984,0.00197744,0.00156331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006217766,0.00046125744,0.8038159,0.0039056172,0.0013623515,0.00064766326,0.0020432652,0.0039461665,0.0006698052,0.0053793658,0.017621154,0.15392973],"study_design_scores_gemma":[0.00088119245,0.0018701076,0.909672,0.0031773204,0.0011225382,0.0012158114,0.0027698167,0.0054586376,0.0019041063,0.007450887,0.064312704,0.00016493045],"about_ca_topic_score_codex":0.009948172,"about_ca_topic_score_gemma":0.00947132,"teacher_disagreement_score":0.95455414,"about_ca_system_score_codex":0.0034327656,"about_ca_system_score_gemma":0.015607675,"threshold_uncertainty_score":0.24034363},"labels":[],"label_agreement":null},{"id":"W2907669356","doi":"10.1161/circ.135.suppl_1.p250","title":"Abstract P250: Emergency Room Consultations and Hospitalizations Following Generic Clopidogrel Commercialization in Quebec, Canada","year":2017,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; The Quebec Population Health Research Network; Institut National de Santé Publique du Québec; Université Laval","funders":"","keywords":"Clopidogrel; Medicine; Commercialization; Adverse effect; Emergency medicine; Internal medicine; Aspirin; Marketing; Business","score_opus":0.051762168949510086,"score_gpt":0.289765514441781,"score_spread":0.23800334549227092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907669356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96326435,0.0016691487,0.00039999784,0.0013186756,0.000039904095,0.00012340091,0.028544195,0.000035340458,0.0046049505],"genre_scores_gemma":[0.9924345,0.00039571465,0.00020448648,0.00022802675,0.000015946705,0.000028717956,0.0052253194,0.000008126485,0.0014590985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988457,0.00010246996,0.000085191205,0.0001847179,0.00039041357,0.00039151087],"domain_scores_gemma":[0.99616146,0.00025977314,0.0010282623,0.00008231748,0.0017650041,0.0007031891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087805546,0.00035307658,0.00032751716,0.0011485092,0.0013488644,0.0009609276,0.001473839,0.00071665266,0.005525611],"category_scores_gemma":[0.0029516993,0.0002353994,0.00071222504,0.002840271,0.0004829441,0.0004608303,0.0007287373,0.0009528669,0.0003078094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016739109,0.000059808946,0.9894488,0.000062585634,0.00007703812,0.00013040508,0.0002865042,0.0002634514,0.00013036655,0.00009886893,0.0036702992,0.005604424],"study_design_scores_gemma":[0.0000103506445,0.000031992942,0.99808925,0.000027784581,0.000022543209,0.00004655434,0.00040546115,0.0005760468,0.000040223047,0.000010470158,0.00072947453,0.00000974636],"about_ca_topic_score_codex":0.9959757,"about_ca_topic_score_gemma":0.9952225,"teacher_disagreement_score":0.032566737,"about_ca_system_score_codex":0.032566737,"about_ca_system_score_gemma":0.029252334,"threshold_uncertainty_score":0.23628932},"labels":[],"label_agreement":null},{"id":"W2907795332","doi":"10.3390/pharmacy7010006","title":"Evaluation of Prescription Adaptation Following Changes to A Provincial Drug Insurance Formulary","year":2019,"lang":"en","type":"article","venue":"Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Formulary; Prescription drug; Medical prescription; Adaptation (eye); Drug; Business; Actuarial science; Medicine; Pharmacology; Psychology","score_opus":0.12990815543427484,"score_gpt":0.3426043152502544,"score_spread":0.21269615981597959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907795332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972926,0.00009632932,0.000082561986,0.00026927947,0.000008454283,0.00014505786,0.00037961875,0.000009657147,0.0017163914],"genre_scores_gemma":[0.9985701,0.00010573083,0.00026973963,0.000094990326,0.0000084266985,0.000042319545,0.00043241828,0.0000029748937,0.00047320375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99438125,0.0016792251,0.0006004468,0.00030231863,0.002398069,0.00063878775],"domain_scores_gemma":[0.9688317,0.0045153163,0.01420283,0.0011386697,0.008431479,0.002879924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00435602,0.00017495773,0.00029620042,0.0015417314,0.0018710071,0.0013540727,0.0009982673,0.000435724,0.0013188971],"category_scores_gemma":[0.034341566,0.00026033557,0.0004375448,0.0026528994,0.0005787905,0.00048740272,0.0011471682,0.000936149,0.00016635445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026451855,0.00025023083,0.983442,0.000030205238,0.00003360645,0.00021071003,0.0022244712,0.0001910403,0.00018723201,0.000046208217,0.00053298176,0.012586837],"study_design_scores_gemma":[0.0000050995786,0.00013931825,0.99676585,0.000015337999,0.000007739116,0.00007635269,0.0017693286,0.00043907846,0.000106898806,0.000009725856,0.0006580652,0.000007239024],"about_ca_topic_score_codex":0.3987082,"about_ca_topic_score_gemma":0.5092332,"teacher_disagreement_score":0.3987082,"about_ca_system_score_codex":0.010418083,"about_ca_system_score_gemma":0.009022381,"threshold_uncertainty_score":0.7927749},"labels":[],"label_agreement":null},{"id":"W2907797723","doi":"10.1002/soej.12325","title":"The Effects of Competition on Prescription Payments in Retail Pharmacy Markets","year":2019,"lang":"en","type":"article","venue":"Southern Economic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Ceteris paribus; Competition (biology); Market power; Payment; Business; Medical prescription; Market concentration; Quarter (Canadian coin); Percentile; Marketing; Economics; Industrial organization; Market structure; Microeconomics; Finance; Medicine; Pharmacology; Monopoly; Family medicine; Statistics","score_opus":0.02485515604065731,"score_gpt":0.25655106368478237,"score_spread":0.23169590764412507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907797723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951816,0.00037596672,0.0001142645,0.0005982685,0.000009599264,0.000010120604,0.0007048708,0.000005182816,0.0030000948],"genre_scores_gemma":[0.99934477,0.000053719417,0.000030605515,0.00003830987,0.000013051554,0.0000025847094,0.0002542088,0.0000013125027,0.00026142766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707544,0.0008830426,0.0001819025,0.00048155303,0.00070748647,0.00067065743],"domain_scores_gemma":[0.9665976,0.01567483,0.012759415,0.00048722845,0.001527097,0.0029538374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018323523,0.00022564492,0.00052594265,0.0015175396,0.00091275235,0.0029004316,0.0007789057,0.00097777,0.0047432007],"category_scores_gemma":[0.015399386,0.00024977466,0.00080675335,0.0023124502,0.00128811,0.0013623079,0.0017505228,0.001446288,0.00036636542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025206833,0.0001478633,0.99051255,0.000032660828,0.00014600593,0.00033262486,0.00025606275,0.0023512891,0.00030608638,0.0011227187,0.0011841316,0.0033559483],"study_design_scores_gemma":[0.000016751072,0.00008119187,0.99576724,0.00001063246,0.000034972683,0.00007430575,0.00052136084,0.0027696479,0.00010785605,0.00021595653,0.00038867118,0.000011462535],"about_ca_topic_score_codex":0.1196141,"about_ca_topic_score_gemma":0.14299804,"teacher_disagreement_score":0.1196141,"about_ca_system_score_codex":0.005720206,"about_ca_system_score_gemma":0.0016714919,"threshold_uncertainty_score":0.2378357},"labels":[],"label_agreement":null},{"id":"W2907973703","doi":"10.18433/jpps30215","title":"A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme","year":2019,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Bioequivalence; European union; Product (mathematics); Jurisdiction; Business; Medicine; Public economics; International trade; Pharmacology; Political science; Economics; Law","score_opus":0.16345039461533242,"score_gpt":0.3704488296778767,"score_spread":0.20699843506254426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907973703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5618702,0.05475307,0.024719693,0.06418252,0.0012063069,0.002338847,0.009213289,0.0010320431,0.28068402],"genre_scores_gemma":[0.93860286,0.016677998,0.01371219,0.015790952,0.00063095475,0.0010168275,0.0043204376,0.0002622386,0.008985554],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.92543864,0.02299205,0.01019887,0.0040619057,0.032191105,0.005117487],"domain_scores_gemma":[0.66638017,0.15867122,0.06188667,0.01244325,0.09030417,0.010314567],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.11253351,0.00039735663,0.0006380502,0.006116131,0.0021878444,0.0075420495,0.0023646455,0.0036172813,0.0049676844],"category_scores_gemma":[0.13886161,0.00058333296,0.0016883204,0.008483258,0.0020918269,0.0032311573,0.0019897637,0.0046113273,0.0010776232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012867725,0.0009941634,0.3412519,0.0049017854,0.00047632295,0.0013248152,0.012987338,0.0023352138,0.008470804,0.08121217,0.08825698,0.45650172],"study_design_scores_gemma":[0.00011314849,0.00081102655,0.6495045,0.0034743554,0.0003045532,0.00199605,0.0068025356,0.0014557444,0.0031995482,0.004065237,0.32805428,0.00021913018],"about_ca_topic_score_codex":0.006001803,"about_ca_topic_score_gemma":0.003763903,"teacher_disagreement_score":0.8874665,"about_ca_system_score_codex":0.0038447147,"about_ca_system_score_gemma":0.012455823,"threshold_uncertainty_score":0.5951412},"labels":[],"label_agreement":null},{"id":"W2909254160","doi":"10.1016/j.pharma.2018.11.007","title":"Drug shortages in Canada: Data for 2016–2017 and perspectives on the problem","year":2019,"lang":"en","type":"article","venue":"Annales Pharmaceutiques Françaises","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"Teva Pharmaceutical Industries; Mylan; Pfizer","keywords":"Economic shortage; Context (archaeology); Medicine; Business; Drug; Pharmacology; Geography; Government (linguistics)","score_opus":0.1433892823090276,"score_gpt":0.32761893555663707,"score_spread":0.18422965324760948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909254160","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27776954,0.062171623,0.0015631272,0.17284858,0.0014732642,0.00022640445,0.44961542,0.00026151066,0.034070417],"genre_scores_gemma":[0.8022085,0.03340121,0.0015033928,0.01585857,0.0009010405,0.00015566437,0.13200803,0.00010566453,0.013857897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99435776,0.00034843554,0.0005138197,0.00039983934,0.002409149,0.0019710122],"domain_scores_gemma":[0.97243416,0.0023963521,0.006222631,0.00039110647,0.014706734,0.0038490396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003486397,0.00046330632,0.0009960439,0.0057517486,0.001807579,0.0035488463,0.00156197,0.0010186029,0.005555394],"category_scores_gemma":[0.016523613,0.00039195077,0.00094289763,0.020061255,0.0010613959,0.0018685671,0.0019128205,0.0022375623,0.0005691859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000375576,0.0001171271,0.58434045,0.0017435635,0.00046231848,0.00026786583,0.0012873486,0.0032324765,0.00011932974,0.009738518,0.35195032,0.046365086],"study_design_scores_gemma":[0.000050648432,0.000038616934,0.80235547,0.0013212445,0.00012994518,0.00017856868,0.0033041998,0.002176874,0.00023142644,0.0013556712,0.18878622,0.00007110928],"about_ca_topic_score_codex":0.993899,"about_ca_topic_score_gemma":0.9962016,"teacher_disagreement_score":0.048657,"about_ca_system_score_codex":0.048657,"about_ca_system_score_gemma":0.14802004,"threshold_uncertainty_score":0.3530329},"labels":[],"label_agreement":null},{"id":"W2910979606","doi":"10.1111/hiv.12701","title":"De‐simplifying single‐tablet antiretroviral treatments: uptake, risks and cost savings","year":2019,"lang":"en","type":"article","venue":"HIV Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"","keywords":"Medicine; Abacavir; Lamivudine; Viral load; Incentive; Human immunodeficiency virus (HIV); Antiretroviral therapy; Generic drug; Family medicine; Drug; Pharmacology; Virology","score_opus":0.12773601658021735,"score_gpt":0.31837524491124336,"score_spread":0.190639228331026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910979606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98243433,0.003523131,0.00049771456,0.0047756773,0.000020292553,0.00013983487,0.00018518433,0.000013602899,0.008410312],"genre_scores_gemma":[0.9977835,0.00089145184,0.00048126924,0.00024338513,0.000047436868,0.00003122039,0.00007817475,0.0000027224326,0.00044095464],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947125,0.0028570907,0.00028273172,0.0001817539,0.0014883974,0.0004775903],"domain_scores_gemma":[0.99077374,0.004131975,0.0036690522,0.00027198854,0.0006790865,0.0004741312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048296875,0.00023272299,0.00026869564,0.00047651588,0.0003142183,0.0016682547,0.0004569492,0.0007931749,0.0038641049],"category_scores_gemma":[0.01762539,0.0001246983,0.0007478024,0.0007487308,0.0004233241,0.00111347,0.0011002435,0.00063801586,0.00030306814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013288154,0.0015544895,0.40051663,0.0005687795,0.00027725453,0.0002785343,0.0014105568,0.0017485232,0.00093304564,0.0021372153,0.0021865424,0.5870596],"study_design_scores_gemma":[0.00041824754,0.005682658,0.9619049,0.0008683859,0.0004016741,0.0017175981,0.004297232,0.010383768,0.0018494092,0.0022688948,0.010130631,0.000076614284],"about_ca_topic_score_codex":0.003636588,"about_ca_topic_score_gemma":0.004359802,"teacher_disagreement_score":0.0048296875,"about_ca_system_score_codex":0.001250032,"about_ca_system_score_gemma":0.0012402831,"threshold_uncertainty_score":0.02554214},"labels":[],"label_agreement":null},{"id":"W2911140943","doi":"10.4155/ppa-2018-0024","title":"Discussions on the New Molecular Formula and New Molecular Entity Definitions of Pharmaceutical Innovation","year":2018,"lang":"en","type":"article","venue":"Pharmaceutical Patent Analyst","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"MEDLINE; Medicine; Library science; Computer science; Political science","score_opus":0.27535559192031356,"score_gpt":0.35251569796290894,"score_spread":0.07716010604259538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911140943","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013540457,0.03618046,0.061632685,0.63399124,0.015924573,0.00011491115,0.00033071745,0.0000731436,0.2382118],"genre_scores_gemma":[0.5696867,0.026783956,0.05624287,0.22667366,0.058076676,0.00089011545,0.00029104698,0.00036281743,0.060992222],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9793411,0.01067943,0.0014369804,0.0019653114,0.0053802426,0.0011968422],"domain_scores_gemma":[0.96783227,0.024592353,0.0023027898,0.0017782645,0.0027987557,0.0006955218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028158376,0.0009959509,0.0015223541,0.0036109863,0.003879255,0.011061817,0.0051560877,0.016485259,0.009310413],"category_scores_gemma":[0.035501596,0.00080093916,0.0020430214,0.003593717,0.027463935,0.031561207,0.004330279,0.026208695,0.0010159009],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034339232,0.000002520471,0.000012027673,0.00001368611,0.0000011198035,0.0000060607176,0.00011775879,0.000036194255,0.000019974874,0.99722207,0.0018003612,0.0007648299],"study_design_scores_gemma":[0.000018342238,0.00001477143,0.00019648994,0.0001608299,0.000009335621,0.00006417616,0.0002636369,0.00054259365,0.00024086854,0.90073675,0.09772687,0.000025247824],"about_ca_topic_score_codex":0.0015776752,"about_ca_topic_score_gemma":0.0017372725,"teacher_disagreement_score":0.028158376,"about_ca_system_score_codex":0.0076432293,"about_ca_system_score_gemma":0.0027332392,"threshold_uncertainty_score":0.14891756},"labels":[],"label_agreement":null},{"id":"W2912496264","doi":"10.1177/0272989x18818165","title":"Prescriber Variation in Relation to Prescribing Trends within the Preferred Drugs Initiative in Ireland (2012–2015): An Interrupted Time-Series Study Using Latent Curve Models","year":2019,"lang":"en","type":"article","venue":"Medical Decision Making","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Medicine; Interrupted Time Series Analysis; Pharmacy; Pharmacoepidemiology; Drug class; Population; Medical prescription; Drug; Pharmaceutical Benefits Scheme; Emergency medicine; Family medicine; Pharmacology; Environmental health","score_opus":0.1263360287822225,"score_gpt":0.35236520173614216,"score_spread":0.22602917295391967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912496264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879027,0.00051098195,0.0036873948,0.00064808,0.00005295173,0.00011509704,0.0058385753,0.000073087605,0.0011710963],"genre_scores_gemma":[0.9922438,0.00017180834,0.00093081634,0.00009907987,0.000032914453,0.00014728434,0.0055060443,0.000022842156,0.0008454622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98952687,0.0049486742,0.0010999434,0.0017603894,0.0013101181,0.001353999],"domain_scores_gemma":[0.9611976,0.014416312,0.016321199,0.0037592642,0.0024943848,0.0018112207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016368134,0.0005271796,0.0010182454,0.0018943993,0.00038182008,0.0017653847,0.0019403924,0.0011818238,0.0029602847],"category_scores_gemma":[0.04461363,0.0005333183,0.0023281998,0.0038420528,0.00089098583,0.0013135931,0.0019399168,0.0022501468,0.0008766062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010156751,0.0003188348,0.9818507,0.00011119873,0.0006663447,0.00014386864,0.0010905716,0.0050726836,0.00011030013,0.0008557268,0.0019732506,0.0067909276],"study_design_scores_gemma":[0.0000747228,0.0006328794,0.95702356,0.000092259244,0.00026118255,0.000118332464,0.0012709582,0.03747643,0.00017674483,0.00052427605,0.0022817103,0.00006698721],"about_ca_topic_score_codex":0.06626957,"about_ca_topic_score_gemma":0.029708376,"teacher_disagreement_score":0.06626957,"about_ca_system_score_codex":0.0032751272,"about_ca_system_score_gemma":0.002232164,"threshold_uncertainty_score":0.13176769},"labels":[],"label_agreement":null},{"id":"W2912844763","doi":"10.1080/13651501.2018.1508724","title":"Switching medication products during the treatment of psychiatric illness","year":2019,"lang":"en","type":"review","venue":"International Journal of Psychiatry in Clinical Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Ottawa Mental Health Centre; Pfizer (Canada); Dalhousie University; University of Ottawa","funders":"Pfizer","keywords":"Tolerability; Medicine; Psychiatry; Drug class; Mood; Generic drug; Drug; Pharmacology; Adverse effect","score_opus":0.1746879947255537,"score_gpt":0.4861467449533723,"score_spread":0.31145875022781855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912844763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00088305696,0.99797684,0.00007691948,0.00024616442,0.000060361726,0.000012630395,0.000036180492,0.0000018237242,0.0007060808],"genre_scores_gemma":[0.012499262,0.9865573,0.00028209118,0.0002732245,0.00017359406,0.000020911612,0.000050912207,0.0000012502652,0.00014144897],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99749315,0.0009723517,0.00047580217,0.0002561819,0.0006967137,0.00010587912],"domain_scores_gemma":[0.9909915,0.005752772,0.0027235788,0.000085729866,0.000344066,0.00010242835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029542851,0.00046298804,0.0016974102,0.0032100603,0.00025046957,0.0013003479,0.00080195325,0.001386557,0.003455073],"category_scores_gemma":[0.010959402,0.00025821067,0.0017329208,0.003937967,0.0005929407,0.0010916777,0.0005887468,0.0010809453,0.00038688575],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005666568,0.00011115048,0.0027679682,0.1328028,0.0015287207,0.00046405493,0.00013661692,0.00058417243,0.0003246523,0.0029108555,0.005620196,0.8521822],"study_design_scores_gemma":[0.0011723791,0.0016700388,0.06622174,0.3581819,0.01128567,0.014070709,0.000971739,0.0014593693,0.0021250867,0.010319519,0.5323511,0.00017073534],"about_ca_topic_score_codex":0.00246634,"about_ca_topic_score_gemma":0.0034328178,"teacher_disagreement_score":0.003455073,"about_ca_system_score_codex":0.0011556327,"about_ca_system_score_gemma":0.0021907496,"threshold_uncertainty_score":0.015623987},"labels":[],"label_agreement":null},{"id":"W2913167212","doi":"10.1177/2325958218822304","title":"Desimplification of Single Tablet Antiretroviral (ART) Regimens—A Practical Cost-Savings Strategy?","year":2019,"lang":"en","type":"article","venue":"Journal of the International Association of Providers of AIDS Care (JIAPAC)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"","keywords":"Antiretroviral therapy; Control (management); Human immunodeficiency virus (HIV); Quality (philosophy); Operations management; Cost control; Medicine; Actuarial science; Business; Economics; Family medicine; Viral load","score_opus":0.040890408243349254,"score_gpt":0.29038804655517686,"score_spread":0.2494976383118276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913167212","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06271393,0.012062356,0.033124093,0.83210146,0.00082162546,0.00031958922,0.00024316508,0.00027472244,0.058339074],"genre_scores_gemma":[0.8817902,0.017818758,0.057695594,0.027102899,0.0026563443,0.00020200455,0.00019431887,0.00004233603,0.012497549],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990458,0.00050749513,0.000024755458,0.00006849832,0.00022649513,0.00012687282],"domain_scores_gemma":[0.99783903,0.0010625946,0.0003123522,0.00010604682,0.00031166247,0.0003682954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027874822,0.0004538919,0.00032051915,0.0011325759,0.00051552337,0.0028892665,0.0007800876,0.001618334,0.010399526],"category_scores_gemma":[0.007725892,0.00012934301,0.00023733593,0.0007766977,0.0013344098,0.002047099,0.001115205,0.0016536737,0.0006553224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026478825,0.00071078946,0.015089144,0.00066882465,0.00012029506,0.00029784886,0.000483857,0.0094570415,0.001384327,0.11287464,0.10816198,0.75048643],"study_design_scores_gemma":[0.00070859265,0.0009869682,0.05074427,0.003384001,0.00025252605,0.0012075738,0.006050023,0.06267642,0.0027797013,0.4916655,0.37935975,0.00018470355],"about_ca_topic_score_codex":0.0074591497,"about_ca_topic_score_gemma":0.017918125,"teacher_disagreement_score":0.010399526,"about_ca_system_score_codex":0.0029366377,"about_ca_system_score_gemma":0.007449335,"threshold_uncertainty_score":0.03478986},"labels":[],"label_agreement":null},{"id":"W2914255516","doi":"10.5539/gjhs.v11n3p23","title":"An Exploratory Study Into the Use and Pricing of Schedule Zero Medicines Post Exemption From the Single Exit Price Policy in South Africa","year":2019,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Schedule; Legislation; Medicine; Business; Economics; Pharmacology","score_opus":0.10820288710548952,"score_gpt":0.34478945341974465,"score_spread":0.23658656631425512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914255516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99954754,0.00003053897,0.000020159729,0.000043397184,5.739999e-7,0.000019767544,0.00007431782,3.2771783e-7,0.00026330122],"genre_scores_gemma":[0.9992142,0.00015179906,0.00011850014,0.000051077313,0.0000024896644,0.000036831312,0.00006515989,9.656289e-7,0.00035890818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993648,0.00025990655,0.000044422133,0.00005857372,0.00008481836,0.00018752173],"domain_scores_gemma":[0.998009,0.0007801474,0.00079824304,0.000051544856,0.000173267,0.00018782017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079768867,0.00014244585,0.00023085291,0.00096277834,0.00095442025,0.0007599779,0.0003184762,0.00037460434,0.0027162693],"category_scores_gemma":[0.0030428332,0.00032753526,0.00023555408,0.0015367043,0.0006498775,0.0010440064,0.0007320616,0.0005248119,0.00024370525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026654682,0.0006883337,0.8757503,0.0003482741,0.000033480243,0.0023914888,0.10085679,0.00008609634,0.002740454,0.00041477545,0.00049512956,0.015928242],"study_design_scores_gemma":[0.000006882641,0.0005310637,0.8985999,0.00006934027,0.000008709423,0.0005398261,0.09837882,0.000116055126,0.00017610246,0.00004959729,0.0015133958,0.0000102339245],"about_ca_topic_score_codex":0.015187322,"about_ca_topic_score_gemma":0.02733527,"teacher_disagreement_score":0.015187322,"about_ca_system_score_codex":0.0012746637,"about_ca_system_score_gemma":0.0012035944,"threshold_uncertainty_score":0.030197859},"labels":[],"label_agreement":null},{"id":"W2915100501","doi":"10.4212/cjhp.v66i1.1211","title":"Drug Shortages in Health Care Institutions: Perspectives in Early 2013","year":2013,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Drug; Health care; Business; Medicine; Family medicine; Political science; Pharmacology; Government (linguistics)","score_opus":0.052564066889183345,"score_gpt":0.30751464066545764,"score_spread":0.2549505737762743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915100501","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06936646,0.02063331,0.00026429497,0.88646024,0.0021860702,0.000029931283,0.0009980849,0.0000112202715,0.02005038],"genre_scores_gemma":[0.714951,0.03429554,0.0004662585,0.22293395,0.0074980394,0.000075956676,0.0007903335,0.00003796992,0.018950958],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99507564,0.0007609333,0.00024028511,0.00014459911,0.0006484655,0.0031300304],"domain_scores_gemma":[0.9833898,0.0026802432,0.0019919632,0.000094831754,0.0042224694,0.007620684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007223918,0.00029460862,0.0005518192,0.001764894,0.0054872367,0.009771996,0.0010509884,0.009314513,0.008497383],"category_scores_gemma":[0.011823596,0.0003949687,0.00072101835,0.003002053,0.00318352,0.0060534296,0.005252038,0.011777066,0.00042826906],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012812006,0.0011910903,0.13271557,0.0021357741,0.00010195643,0.0036351716,0.03138267,0.001455728,0.0008915833,0.27719623,0.43444744,0.11356567],"study_design_scores_gemma":[0.00016734721,0.0003232588,0.293576,0.0030444795,0.00005443482,0.00084184675,0.10558055,0.0010527672,0.00075970026,0.024495957,0.56992614,0.00017750864],"about_ca_topic_score_codex":0.3857885,"about_ca_topic_score_gemma":0.6339316,"teacher_disagreement_score":0.6142115,"about_ca_system_score_codex":0.031829514,"about_ca_system_score_gemma":0.044107657,"threshold_uncertainty_score":0.7670859},"labels":[],"label_agreement":null},{"id":"W2915394608","doi":"10.21518/1561-5936-2016-6-54-58","title":"Pharmaceutical industry in quarter I 2016","year":2016,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmaceutical industry; Business; Commerce; History; Medicine; Pharmacology; Archaeology","score_opus":0.033051913347888075,"score_gpt":0.30152530976617875,"score_spread":0.26847339641829066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915394608","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08700404,0.047345664,0.0016270638,0.12616953,0.067202285,0.00036227144,0.048050392,0.0012721393,0.6209665],"genre_scores_gemma":[0.118971266,0.010791018,0.00041306985,0.007643561,0.00857655,0.00007064899,0.012791367,0.00014070235,0.84060186],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854624,0.0000809374,0.00008932916,0.00018018985,0.00080107554,0.0003022785],"domain_scores_gemma":[0.9982278,0.00017011024,0.00050533784,0.00011099094,0.00062197394,0.00036376447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015169408,0.00059415336,0.0006177827,0.0015900651,0.001057006,0.005811383,0.0005268179,0.0030495597,0.030453991],"category_scores_gemma":[0.0045690755,0.00027608575,0.00054423505,0.0016254577,0.00047799462,0.0017588575,0.0012609354,0.0024827821,0.017673248],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092742726,0.0001802836,0.009151206,0.00040704093,0.00007201348,0.0003342942,0.00017478719,0.000560381,0.0015679512,0.019390533,0.89472795,0.072506085],"study_design_scores_gemma":[0.000047568876,0.00013884288,0.026370507,0.00014058243,0.000022083601,0.000116357136,0.00016799364,0.00047604984,0.001536673,0.0016110349,0.9693508,0.000021486785],"about_ca_topic_score_codex":0.008147428,"about_ca_topic_score_gemma":0.01498128,"teacher_disagreement_score":0.030453991,"about_ca_system_score_codex":0.0030501366,"about_ca_system_score_gemma":0.0025490166,"threshold_uncertainty_score":0.1018787},"labels":[],"label_agreement":null},{"id":"W2915570611","doi":"10.4212/cjhp.v72i1.2863","title":"Drug Shortages in Canada and Selected European Countries: A Cross-Sectional, Institution-Level Comparison","year":2019,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Cross-sectional study; Economic shortage; Cross country; Institution; Political science; Medicine; Demographic economics; Economics; Law","score_opus":0.04561149111757885,"score_gpt":0.2789338870765939,"score_spread":0.23332239595901505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915570611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643743,0.0005479997,0.00007129791,0.000074076685,0.0000072300027,0.00005303057,0.0017938719,0.000004943344,0.0010100908],"genre_scores_gemma":[0.99739933,0.00040099924,0.00010379404,0.00008694203,0.000008453533,0.00003467321,0.0017673615,0.0000025552608,0.00019597958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836415,0.00014182577,0.0001657038,0.0002270404,0.00055474666,0.00054660486],"domain_scores_gemma":[0.99598974,0.00032223717,0.0016768835,0.00008379126,0.0012328004,0.0006945748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014708618,0.00042114052,0.00041239,0.0034126248,0.001510343,0.0012528076,0.00082029426,0.0004874218,0.0019362791],"category_scores_gemma":[0.0031093513,0.00032747939,0.0006443107,0.0067702704,0.0007616665,0.0007692427,0.001490984,0.00053262006,0.00014411578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062075844,0.000028619377,0.99797386,0.00002845071,0.00006599462,0.000041735686,0.00022668557,0.00004144634,0.000023986066,0.000019053183,0.00026261003,0.0012255821],"study_design_scores_gemma":[0.0000038760386,0.000025004412,0.9987594,0.0000138096175,0.000013084213,0.000026789516,0.0008642119,0.00006466432,0.000016712396,0.0000035948146,0.0002052967,0.000003504251],"about_ca_topic_score_codex":0.8344999,"about_ca_topic_score_gemma":0.90494126,"teacher_disagreement_score":0.1655001,"about_ca_system_score_codex":0.011203654,"about_ca_system_score_gemma":0.009096072,"threshold_uncertainty_score":0.33294952},"labels":[],"label_agreement":null},{"id":"W2915644223","doi":"10.4212/cjhp.v67i5.1394","title":"Drug Shortages in Health Care Institutions: Perspectives in Early 2014","year":2014,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Drug; Health care; Medicine; Family medicine; Business; Nursing; Political science; Pharmacology; Government (linguistics)","score_opus":0.04621862564451133,"score_gpt":0.3106650756337845,"score_spread":0.26444644998927314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915644223","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021394333,0.08022742,0.00029605345,0.85519767,0.009390389,0.000040772058,0.0011112486,0.000033676126,0.032308493],"genre_scores_gemma":[0.2841038,0.1580345,0.0010730451,0.51087123,0.02362923,0.00013877107,0.0015397482,0.000113935064,0.02049573],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9935668,0.0016042044,0.00039203378,0.00032657303,0.0011760716,0.0029343807],"domain_scores_gemma":[0.9822955,0.0028325054,0.0017408845,0.00019900237,0.004810194,0.008121868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072229956,0.00065176527,0.00065550854,0.002992742,0.009069486,0.014998008,0.0019784255,0.010937441,0.013725399],"category_scores_gemma":[0.0131093655,0.000544116,0.000812134,0.0054225777,0.005842647,0.012566587,0.008634834,0.012668176,0.001330199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034424913,0.0004299865,0.022415837,0.002910529,0.000065692824,0.004543367,0.027932767,0.00032457238,0.0002599577,0.08488805,0.7129639,0.14292113],"study_design_scores_gemma":[0.000041928273,0.00020104948,0.043823887,0.007341822,0.000028257436,0.0013196004,0.079648755,0.0001663938,0.00018261615,0.0070750564,0.8600467,0.00012394619],"about_ca_topic_score_codex":0.2733476,"about_ca_topic_score_gemma":0.5081307,"teacher_disagreement_score":0.7266524,"about_ca_system_score_codex":0.044086963,"about_ca_system_score_gemma":0.056188405,"threshold_uncertainty_score":0.54351306},"labels":[],"label_agreement":null},{"id":"W2916169982","doi":"10.4212/cjhp.v72i1.2860","title":"Drug Shortages: More than Just Background Noise","year":2019,"lang":"en","type":"editorial","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Economic shortage; Drug; Medicine; Pharmacology","score_opus":0.04607434770409242,"score_gpt":0.3041020493665591,"score_spread":0.2580277016624667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916169982","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019987641,0.010344478,0.000049622933,0.10175374,0.8867667,0.00000853872,0.00007185515,0.000024432891,0.00096072024],"genre_scores_gemma":[0.0004589693,0.0056130714,0.000044342934,0.04484424,0.9451712,0.000013827743,0.000029796483,0.00002690851,0.0037976338],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98443663,0.0028775516,0.002074859,0.0017172225,0.007906609,0.0009871868],"domain_scores_gemma":[0.9000804,0.05120057,0.005764613,0.0021128955,0.03293533,0.007906186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017794028,0.0044158706,0.005457452,0.00892849,0.0050070905,0.018060442,0.0048600435,0.03215198,0.021138523],"category_scores_gemma":[0.07654393,0.001805712,0.0031252063,0.005512162,0.005707804,0.0076938556,0.0034600564,0.030040583,0.008101459],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015443584,0.000006466666,0.000024138406,0.00019259585,0.000019984187,0.000040964944,0.000015482943,0.000013597342,0.000009146662,0.0003148144,0.9968796,0.0024678544],"study_design_scores_gemma":[0.00010870599,0.000022498247,0.0005916009,0.001781479,0.00013698847,0.00014299127,0.00017626243,0.00020413812,0.000059272552,0.0027733874,0.9939615,0.00004109298],"about_ca_topic_score_codex":0.014219806,"about_ca_topic_score_gemma":0.03807792,"teacher_disagreement_score":0.03215198,"about_ca_system_score_codex":0.013474715,"about_ca_system_score_gemma":0.012060589,"threshold_uncertainty_score":0.0977664},"labels":[],"label_agreement":null},{"id":"W2916282897","doi":"10.3138/cpp.2018-021","title":"Can Competition and Patent Policies Avert the Antibiotic Crisis?","year":2019,"lang":"en","type":"article","venue":"Canadian Public Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Subsidy; Business; Competition (biology); Competitor analysis; Incentive; Public economics; Antibiotics; Economics; Industrial organization; Economic policy; Market economy; Marketing","score_opus":0.05972796083446977,"score_gpt":0.24416927528542517,"score_spread":0.1844413144509554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916282897","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09182037,0.016929368,0.020556994,0.51443905,0.0013505269,0.00015831726,0.00091083103,0.00033422466,0.35350034],"genre_scores_gemma":[0.9474787,0.008680016,0.0020003917,0.02304343,0.0013577176,0.000049366223,0.00010647231,0.000044625085,0.017239258],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976432,0.00049917796,0.000051942065,0.00020854703,0.0004030848,0.0011941032],"domain_scores_gemma":[0.99315405,0.0033082564,0.0012718826,0.00023724037,0.00097156456,0.0010570445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037183347,0.00048150326,0.0011420099,0.0015001369,0.0021433146,0.006930911,0.0011859614,0.008772596,0.01587561],"category_scores_gemma":[0.02111603,0.00032086982,0.0008974321,0.0013705825,0.0060896724,0.007871931,0.0020014436,0.004102124,0.0010656655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001078542,0.00006752022,0.0018894078,0.00013676332,0.000039183047,0.00020957731,0.00009429306,0.009407287,0.00027435523,0.94930094,0.021989882,0.016482938],"study_design_scores_gemma":[0.0002488742,0.00008595335,0.003788483,0.00019820758,0.00004708238,0.0000912674,0.0003440661,0.010156095,0.00031847766,0.91596407,0.068709575,0.00004781575],"about_ca_topic_score_codex":0.11189982,"about_ca_topic_score_gemma":0.0731456,"teacher_disagreement_score":0.98744375,"about_ca_system_score_codex":0.01255626,"about_ca_system_score_gemma":0.020895012,"threshold_uncertainty_score":0.22249699},"labels":[],"label_agreement":null},{"id":"W2917947737","doi":"","title":"Access Delayed, Access Denied Waiting for New Medicines in Canada 2011 Report","year":2011,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Internet privacy; Business; Computer security; Computer science","score_opus":0.22677063767406186,"score_gpt":0.34039137682998305,"score_spread":0.11362073915592119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917947737","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26343492,0.010419363,0.00060130766,0.19093959,0.002541142,0.0006310876,0.47021097,0.00042604547,0.060795546],"genre_scores_gemma":[0.6339317,0.013725025,0.001239912,0.025449196,0.0015916534,0.00036555433,0.13313898,0.00018550904,0.1903724],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99441755,0.00011076126,0.00025810915,0.00023861088,0.0028578707,0.002117138],"domain_scores_gemma":[0.98152626,0.0009757164,0.0018974168,0.00025511757,0.010424047,0.004921558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018654773,0.00047617962,0.0007222163,0.0028599452,0.0038141825,0.0052553,0.0020735373,0.0035018092,0.007364947],"category_scores_gemma":[0.009185041,0.00068947877,0.0010715873,0.0056722583,0.0007079678,0.0011064543,0.0012243488,0.005776288,0.000759313],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004038973,0.00023059247,0.14059608,0.00041879926,0.00021158558,0.0007151851,0.0007162676,0.0015535429,0.00021116105,0.0052533457,0.8336126,0.016076932],"study_design_scores_gemma":[0.00022726672,0.000100369834,0.7277195,0.0004230383,0.00035405025,0.0003619268,0.0039649024,0.002973958,0.0007892997,0.0006883364,0.2622085,0.00018897936],"about_ca_topic_score_codex":0.9977101,"about_ca_topic_score_gemma":0.9991622,"teacher_disagreement_score":0.8933575,"about_ca_system_score_codex":0.1066425,"about_ca_system_score_gemma":0.28178883,"threshold_uncertainty_score":0.7737491},"labels":[],"label_agreement":null},{"id":"W2920524859","doi":"10.1007/bf03405283","title":"A Global Call to Action for Science-based Drug Policy","year":2010,"lang":"en","type":"article","venue":"Canadian Journal of Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Call to action; Action (physics); Drug; Computer science; Business; Medicine; Pharmacology; Advertising; Physics","score_opus":0.14827468074706104,"score_gpt":0.37566054054880954,"score_spread":0.2273858598017485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920524859","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000403375,0.003304922,0.0011237875,0.9754632,0.011674296,0.0000307868,0.00013702929,0.00007893078,0.007783588],"genre_scores_gemma":[0.016661597,0.0032410661,0.005162295,0.95508945,0.01068674,0.00012515392,0.00017283914,0.00009737558,0.008763448],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95831394,0.012724996,0.0026639774,0.0036706524,0.017213464,0.005413012],"domain_scores_gemma":[0.8627838,0.059045836,0.009862784,0.0088685565,0.0287428,0.030696271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07023258,0.0026857264,0.0045143696,0.0056539006,0.0066605564,0.023639012,0.0054149525,0.12359561,0.03944693],"category_scores_gemma":[0.10019867,0.0014456732,0.0058762953,0.0040206504,0.02965135,0.02450559,0.01686897,0.06005795,0.008064154],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023711627,0.0002942265,0.00062637846,0.00065751595,0.00019611024,0.00036135837,0.00042172344,0.001012886,0.0009068582,0.31463552,0.6571403,0.023510018],"study_design_scores_gemma":[0.00038426436,0.000120550074,0.0017528897,0.00079986436,0.00010520784,0.00018650127,0.00062141457,0.0008026795,0.00038865104,0.3166524,0.678042,0.00014361746],"about_ca_topic_score_codex":0.0103578875,"about_ca_topic_score_gemma":0.012935496,"teacher_disagreement_score":0.12359561,"about_ca_system_score_codex":0.015063039,"about_ca_system_score_gemma":0.0733206,"threshold_uncertainty_score":0.3714298},"labels":[],"label_agreement":null},{"id":"W2921045172","doi":"","title":"Comité régional sur les services pharmaceutiques de Montréal : règlement concernant la composition, la durée du mandat, les modalités d'élection et de nomination [ressource électronique]","year":2008,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nomination; Political science","score_opus":0.04320070539307163,"score_gpt":0.2958104670835288,"score_spread":0.2526097616904572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921045172","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5957205,0.060251705,0.006214693,0.113393016,0.001244995,0.00040143405,0.054786135,0.0005320633,0.16745543],"genre_scores_gemma":[0.8341388,0.01178471,0.0030216265,0.0028841211,0.00040951846,0.00013918144,0.004251787,0.00007275438,0.14329748],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828315,0.00025031838,0.000047059046,0.00018887257,0.0006113125,0.000619297],"domain_scores_gemma":[0.9946128,0.0013827957,0.00069842493,0.000098453456,0.0019880228,0.0012194543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022340966,0.00037293034,0.00036149696,0.0021671937,0.0020064379,0.0030694064,0.0010373836,0.000836814,0.019977435],"category_scores_gemma":[0.007975954,0.00038490014,0.00036749057,0.0044107204,0.0007649821,0.0009744805,0.0010308296,0.0010103774,0.0006492903],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011576077,0.00020437599,0.24367307,0.0012199263,0.00058463134,0.0007335249,0.0038573972,0.016926546,0.005541556,0.11612291,0.3206932,0.2892852],"study_design_scores_gemma":[0.000054915057,0.00006914876,0.7666827,0.00020692691,0.00012475831,0.00007892255,0.0008424999,0.0028611103,0.0012135608,0.0011061248,0.2266818,0.00007755439],"about_ca_topic_score_codex":0.9817208,"about_ca_topic_score_gemma":0.98879284,"teacher_disagreement_score":0.9817208,"about_ca_system_score_codex":0.044427868,"about_ca_system_score_gemma":0.057735037,"threshold_uncertainty_score":0.3223483},"labels":[],"label_agreement":null},{"id":"W2921733062","doi":"10.1503/cmaj.181041","title":"The impact of pharmaceutical rebates on patients’ drug expenditures","year":2019,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Calgary","funders":"","keywords":"Drug; Business; Private insurance; Pharmaceutical industry; Drug industry; Key (lock); Public economics; Health insurance; Pharmacology; Medicine; Computer science; Economics; Health care; Economic growth; Biotechnology; Computer security","score_opus":0.018282389163884492,"score_gpt":0.2842291619788378,"score_spread":0.2659467728149533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921733062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5321644,0.036490235,0.0012289565,0.20071635,0.0011859061,0.0002079702,0.04920704,0.00025819562,0.17854095],"genre_scores_gemma":[0.98340166,0.0045456435,0.000256489,0.0030622643,0.0005036185,0.000016156755,0.0035574231,0.00002747028,0.004629376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947582,0.0010733688,0.00020008,0.00023676058,0.0020930474,0.0016385481],"domain_scores_gemma":[0.9768124,0.006508785,0.0047760643,0.00038122287,0.007593628,0.0039278287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028272376,0.00036937668,0.0006725829,0.0013791582,0.0013219877,0.003547009,0.0008822612,0.0012692187,0.014142749],"category_scores_gemma":[0.030474221,0.00022847965,0.0013181467,0.002375929,0.0009953765,0.0010930144,0.0013755504,0.004061991,0.0010849604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028252609,0.00067975564,0.566202,0.00063926924,0.0012298739,0.0006492546,0.00053532457,0.016950808,0.00036024078,0.031815834,0.24152562,0.13658683],"study_design_scores_gemma":[0.000245083,0.00035028928,0.92962366,0.0007277122,0.00068206043,0.0004530552,0.0014393897,0.010384283,0.0004890181,0.0068247328,0.048664473,0.000116141004],"about_ca_topic_score_codex":0.7673607,"about_ca_topic_score_gemma":0.83728296,"teacher_disagreement_score":0.7673607,"about_ca_system_score_codex":0.025150532,"about_ca_system_score_gemma":0.038569737,"threshold_uncertainty_score":0.4680187},"labels":[],"label_agreement":null},{"id":"W2925101360","doi":"","title":"Pharmaceutical Prices in the United States, Canada, and Europe : Why Differences Exist and Economic Consequences","year":2019,"lang":"en","type":"dissertation","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economics; International economics; Political science; International trade; Development economics","score_opus":0.06616721102229767,"score_gpt":0.30039701230579324,"score_spread":0.23422980128349558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925101360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7709131,0.06886305,0.0007668431,0.08763609,0.00044199484,0.000028435157,0.0075600687,0.00004218244,0.06374822],"genre_scores_gemma":[0.9802286,0.013553095,0.00030499464,0.0019846503,0.0001761207,0.0000046672876,0.0011846413,0.000020723974,0.0025425446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837226,0.00017773666,0.00007159786,0.0001873019,0.0006193142,0.0005717032],"domain_scores_gemma":[0.9939421,0.0015210066,0.0008471128,0.00011371488,0.0028681655,0.00070783915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016837368,0.0001517341,0.0004855236,0.0020673503,0.0011578889,0.00467073,0.00065543765,0.0010681602,0.0034648557],"category_scores_gemma":[0.010186077,0.0002144665,0.00046577503,0.007272328,0.0017540633,0.001859785,0.0008157515,0.0017407029,0.00019849889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012734698,0.00036755588,0.52212465,0.00059798773,0.00084375474,0.0005755263,0.0036303597,0.007778113,0.0005501248,0.2107561,0.07775312,0.17374936],"study_design_scores_gemma":[0.00007057627,0.000035393445,0.93531746,0.00035627163,0.00021412686,0.0000939287,0.004875948,0.0026489866,0.0004091115,0.020261282,0.035639677,0.000077119425],"about_ca_topic_score_codex":0.90158194,"about_ca_topic_score_gemma":0.9023544,"teacher_disagreement_score":0.09841806,"about_ca_system_score_codex":0.021585684,"about_ca_system_score_gemma":0.016915841,"threshold_uncertainty_score":0.19799525},"labels":[],"label_agreement":null},{"id":"W2925824047","doi":"","title":"FDA Issues Warning to CanaRx","year":2019,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Computer security","score_opus":0.05577438013880978,"score_gpt":0.29738087720839285,"score_spread":0.24160649706958306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925824047","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015611438,0.0071264636,0.0010782201,0.53538424,0.03842831,0.00019762325,0.0026936934,0.0021644104,0.41136587],"genre_scores_gemma":[0.01156377,0.0025409467,0.001147596,0.49579298,0.008486827,0.00012919433,0.0013276574,0.00032756783,0.47868347],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99592376,0.0003896206,0.00016657074,0.0003991292,0.0026008617,0.00052006467],"domain_scores_gemma":[0.99345666,0.002248014,0.000292107,0.00041471922,0.0025198408,0.0010685727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035272276,0.0007867114,0.0010481477,0.0012915233,0.0035107844,0.0043855705,0.0019916678,0.02674636,0.121217474],"category_scores_gemma":[0.014731548,0.0005481437,0.0018395011,0.0010459662,0.0020284506,0.0023511627,0.0014483181,0.014019654,0.057698034],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003435222,0.000019253039,0.00010315512,0.000029904413,0.000004411162,0.00014522365,0.000022400747,0.000014364273,0.00011061717,0.0030937744,0.98991454,0.0065079913],"study_design_scores_gemma":[0.000036048932,0.0000425794,0.0004453338,0.00009798573,0.000009900918,0.00015867095,0.00003704944,0.00005840932,0.00018585418,0.0012158627,0.9977018,0.000010487155],"about_ca_topic_score_codex":0.019850593,"about_ca_topic_score_gemma":0.034151986,"teacher_disagreement_score":0.121217474,"about_ca_system_score_codex":0.0021833356,"about_ca_system_score_gemma":0.008008625,"threshold_uncertainty_score":0.40551287},"labels":[],"label_agreement":null},{"id":"W2935300031","doi":"10.1001/jama.2019.2280","title":"Canada’s Amendment to Patented Drug Price Regulation","year":2019,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Amendment; Drug; Drug prices; Pharmacology; Law; Public economics","score_opus":0.028950503740531524,"score_gpt":0.2393885861356744,"score_spread":0.2104380823951429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935300031","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025943352,0.0039075087,0.004278535,0.12269775,0.011581684,0.0006536632,0.0097419545,0.0014348514,0.8431097],"genre_scores_gemma":[0.056641426,0.0032487006,0.010040805,0.25663906,0.0039733066,0.00091294927,0.002981525,0.0006253879,0.66493684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9740382,0.001698413,0.0012090418,0.0021667366,0.01637235,0.0045151887],"domain_scores_gemma":[0.96366507,0.00984534,0.00091373234,0.0040785503,0.018828243,0.0026690874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010735238,0.0010594821,0.001399651,0.0028933135,0.0065787616,0.009759998,0.0036795924,0.028657295,0.03325114],"category_scores_gemma":[0.051699817,0.0015347565,0.0025520956,0.0033462336,0.004860002,0.0032214383,0.0020937806,0.015137892,0.017009513],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062637046,0.000056396817,0.0005459121,0.00009162797,0.000018656903,0.00015350783,0.00018367909,0.0002436511,0.00025930908,0.104595944,0.87775576,0.016033027],"study_design_scores_gemma":[0.000084136824,0.00002773448,0.0017769733,0.00017489024,0.000026803309,0.00009660725,0.000036426958,0.0002703906,0.00024225016,0.005218279,0.9919966,0.000048875176],"about_ca_topic_score_codex":0.7869494,"about_ca_topic_score_gemma":0.79847854,"teacher_disagreement_score":0.96694815,"about_ca_system_score_codex":0.033051826,"about_ca_system_score_gemma":0.12860674,"threshold_uncertainty_score":0.42861056},"labels":[],"label_agreement":null},{"id":"W2943349812","doi":"10.1377/hlthaff.2018.05207","title":"Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries","year":2019,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reference price; Drug prices; Drug pricing; Medicare Part D; Economics; List price; Differential (mechanical device); Brand names; Business; Actuarial science; Monetary economics; Prescription drug; Finance; Microeconomics; Medicine; Advertising; Medical prescription; Pharmacology","score_opus":0.08785879272333032,"score_gpt":0.33781160926171766,"score_spread":0.24995281653838736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943349812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5852607,0.016748056,0.108012885,0.028863512,0.0019437653,0.0016262953,0.0061572753,0.002030726,0.24935679],"genre_scores_gemma":[0.9666257,0.001408517,0.02107858,0.0059297644,0.000449415,0.0003408286,0.0017507075,0.00016584653,0.002250703],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9883491,0.006537711,0.0009632581,0.0009905056,0.002401033,0.0007583743],"domain_scores_gemma":[0.9741596,0.011224992,0.005873939,0.0027243586,0.0049896445,0.0010275054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016567932,0.00051046634,0.0007479357,0.003995943,0.00075332844,0.0033591571,0.0009571607,0.0007262868,0.005213202],"category_scores_gemma":[0.09038667,0.00029227373,0.001226122,0.005086121,0.00063326396,0.0026702476,0.003677134,0.0012836257,0.00066508685],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010526367,0.00065390614,0.31949633,0.0007070523,0.00088745216,0.00071279315,0.0012372356,0.026071677,0.001158574,0.059853233,0.057506137,0.5306629],"study_design_scores_gemma":[0.00095874286,0.0014227009,0.6337007,0.0018433246,0.0005657282,0.0013330122,0.0015608745,0.06205174,0.004228722,0.045299873,0.24671383,0.00032078466],"about_ca_topic_score_codex":0.023091834,"about_ca_topic_score_gemma":0.0107208565,"teacher_disagreement_score":0.023091834,"about_ca_system_score_codex":0.003792758,"about_ca_system_score_gemma":0.0033394673,"threshold_uncertainty_score":0.087620616},"labels":[],"label_agreement":null},{"id":"W2944534256","doi":"10.1007/s40266-019-00679-4","title":"Did Generic Clopidogrel Commercialization Affect Trends of ER Consultations and Hospitalizations in the Population Treated with Clopidogrel?","year":2019,"lang":"en","type":"article","venue":"Drugs & Aging","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; The Quebec Population Health Research Network; Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval; Institut National de Santé Publique du Québec","funders":"","keywords":"Clopidogrel; Medicine; Population; Confidence interval; Internal medicine; Emergency medicine; Aspirin; Environmental health","score_opus":0.024673320030101645,"score_gpt":0.2744015478837693,"score_spread":0.24972822785366766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944534256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98282975,0.00237332,0.000185924,0.007637827,0.00007816351,0.000008823745,0.0049569663,0.0000089795285,0.0019203143],"genre_scores_gemma":[0.9973469,0.0006047001,0.000049284172,0.00049070106,0.00012293058,0.0000042944725,0.0010496385,0.0000038176563,0.00032767298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999116,0.00021468493,0.00010575697,0.00018856526,0.00009862174,0.00027630996],"domain_scores_gemma":[0.9935548,0.001667849,0.0033366508,0.0002529491,0.00052044285,0.00066740654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012662038,0.00010632591,0.00044134527,0.000658822,0.00022455226,0.0011258723,0.0005005625,0.0015683217,0.003751721],"category_scores_gemma":[0.010586695,0.0002780718,0.0015335456,0.0019222404,0.00027042013,0.0010614526,0.00037741134,0.0020559358,0.0003713796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033111015,0.000056911704,0.99511033,0.000029831815,0.0002171463,0.000052491756,0.00009196158,0.0001676532,0.00006718647,0.0003208186,0.00105916,0.002495334],"study_design_scores_gemma":[0.000011505244,0.00005983812,0.998459,0.000012568988,0.00010421553,0.000050906587,0.00019766524,0.00047314324,0.000029650111,0.00011180022,0.00048530722,0.0000044711423],"about_ca_topic_score_codex":0.046340123,"about_ca_topic_score_gemma":0.04106172,"teacher_disagreement_score":0.046340123,"about_ca_system_score_codex":0.0009234753,"about_ca_system_score_gemma":0.000966303,"threshold_uncertainty_score":0.092140734},"labels":[],"label_agreement":null},{"id":"W2944574521","doi":"10.1001/jamanetworkopen.2019.3392","title":"Pharmaceutical Industry–Initiated Postapproval Studies—Not Requested by the US FDA, Little Value, and Many Questions","year":2019,"lang":"en","type":"letter","venue":"JAMA Network Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"National Health and Medical Research Council; Canadian Institutes of Health Research; Government of Canada; American Diabetes Association; Medical Research Council; Gordon and Betty Moore Foundation","keywords":"Postmarketing surveillance; Pharmaceutical industry; Clinical trial; Medicine; Value (mathematics); Drug industry; Drug approval; Business; Pharmacology; Adverse effect; Engineering; Drug; Computer science; Engineering ethics","score_opus":0.1707176296327443,"score_gpt":0.3700630340247693,"score_spread":0.199345404392025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944574521","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017392883,0.0005358967,0.000078619356,0.9926731,0.0039026227,0.0000073458286,0.0000327037,0.000011720881,0.0025840038],"genre_scores_gemma":[0.0011889616,0.0002922478,0.00019388765,0.9893526,0.006169328,0.000018273084,0.00001262263,0.000013150818,0.0027588482],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9758361,0.009343137,0.003356321,0.0029854667,0.006836794,0.0016422584],"domain_scores_gemma":[0.8664555,0.10326458,0.0045910166,0.0039938088,0.014460216,0.007234853],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.033165626,0.0008968816,0.0016196766,0.0014543842,0.0062769507,0.007409033,0.0035696186,0.1036545,0.011241539],"category_scores_gemma":[0.121729136,0.0012360134,0.0025656656,0.0016475501,0.009156933,0.010538016,0.0029949297,0.0715241,0.0102134645],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074512136,0.000040373154,0.00087850133,0.00007441399,0.000021605496,0.0009885614,0.00016592174,0.000054138,0.00018196748,0.015170743,0.9730049,0.009344445],"study_design_scores_gemma":[0.00022409759,0.000095946816,0.0015735726,0.0008075561,0.00004491168,0.0019412681,0.0005255895,0.00067249505,0.00042934448,0.041009836,0.9525566,0.00011860252],"about_ca_topic_score_codex":0.0114844255,"about_ca_topic_score_gemma":0.01867869,"teacher_disagreement_score":0.96683437,"about_ca_system_score_codex":0.0095771765,"about_ca_system_score_gemma":0.0139845,"threshold_uncertainty_score":0.17539865},"labels":[],"label_agreement":null},{"id":"W2945189225","doi":"10.4324/9780429439186-8","title":"Regional trade agreements, TRIPS-plus provisions and the African access to medicines conundrum","year":2019,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"TRIPS architecture; Access to medicines; International trade; Regional trade; TRIPS Agreement; Business; Political science; Intellectual property; Free trade; Law; Computer science","score_opus":0.12219970398366592,"score_gpt":0.3098346432104223,"score_spread":0.1876349392267564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945189225","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005329999,0.03183623,0.0057517844,0.02826972,0.000897453,0.000050068367,0.00032761804,0.00006986955,0.9274672],"genre_scores_gemma":[0.2872919,0.071791306,0.013573773,0.0087382365,0.0016102775,0.0002460618,0.00048572058,0.00017339889,0.6160893],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99915314,0.00031253693,0.00003188281,0.00008229725,0.00029146209,0.00012859756],"domain_scores_gemma":[0.9991178,0.0005239065,0.00010889884,0.00007674262,0.00011094273,0.00006181262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014571728,0.00038114583,0.00024551363,0.00087486184,0.0013545686,0.0046895235,0.0008181772,0.002208991,0.025168894],"category_scores_gemma":[0.0031217397,0.0002496761,0.00038935416,0.0023537355,0.0030168218,0.0049077566,0.0018450781,0.0034886734,0.0025802364],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000037154214,0.0000026419298,0.000020133379,0.000047855257,0.0000011734667,0.00003509482,0.00019604081,0.0002692522,0.00004051906,0.97855157,0.012613269,0.008218646],"study_design_scores_gemma":[0.0000033179326,0.0000108072645,0.00027957666,0.00035138795,0.0000039458055,0.00015986909,0.0004826109,0.00040949477,0.00013329185,0.17266141,0.8254973,0.000007011133],"about_ca_topic_score_codex":0.0055688764,"about_ca_topic_score_gemma":0.006590774,"teacher_disagreement_score":0.025168894,"about_ca_system_score_codex":0.0044111162,"about_ca_system_score_gemma":0.0042020003,"threshold_uncertainty_score":0.084198356},"labels":[],"label_agreement":null},{"id":"W2946348981","doi":"10.1016/s2214-109x(19)30039-7","title":"The AEIOU of essential diagnostics: align, expand, implement, oversee, and update","year":2019,"lang":"en","type":"article","venue":"The Lancet Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital","funders":"","keywords":"Medical diagnosis; Scopus; Medicine; Diagnostic test; Health care; Family medicine; MEDLINE; Alternative medicine; Medical emergency; Political science; Pediatrics; Pathology","score_opus":0.039620463568611444,"score_gpt":0.35076239487999494,"score_spread":0.3111419313113835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946348981","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013145511,0.1559028,0.016998086,0.70706964,0.03496557,0.00055605563,0.0038248412,0.0037195152,0.07564894],"genre_scores_gemma":[0.0386169,0.41044474,0.15042344,0.28863585,0.038911726,0.0012619018,0.0155455535,0.0033930847,0.05276687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9719614,0.009049541,0.004925782,0.0016377643,0.010249004,0.002176577],"domain_scores_gemma":[0.85022545,0.038531914,0.012780081,0.008805922,0.06637186,0.023284735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030511925,0.001448832,0.0016691025,0.0079454705,0.002037817,0.01174692,0.0042355997,0.006422906,0.025228607],"category_scores_gemma":[0.15246417,0.0011094096,0.0018119083,0.0053289817,0.0028562965,0.017518952,0.011349825,0.011813661,0.025396403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042069987,0.00005620756,0.0017808907,0.0016983559,0.00003985504,0.00013717904,0.0003875593,0.00015490157,0.00018230887,0.008077164,0.66168475,0.32575879],"study_design_scores_gemma":[0.000015624491,0.00002858003,0.0010729027,0.005360208,0.000030624986,0.00021857563,0.00038943195,0.00014341445,0.00018702025,0.004463099,0.9880657,0.000024868868],"about_ca_topic_score_codex":0.014741912,"about_ca_topic_score_gemma":0.020210488,"teacher_disagreement_score":0.030511925,"about_ca_system_score_codex":0.0073750145,"about_ca_system_score_gemma":0.043848705,"threshold_uncertainty_score":0.16136444},"labels":[],"label_agreement":null},{"id":"W2951842580","doi":"10.1093/ajhp/zxz109","title":"National trends in prescription drug expenditures and projections for 2019","year":2019,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; Women's College Hospital","funders":"Eisai","keywords":"Medical prescription; Prescription drug; Specialty; Medicine; Drug; Business; Family medicine; Pharmacology","score_opus":0.05982580759082185,"score_gpt":0.3604819375848714,"score_spread":0.30065612999404956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951842580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.538155,0.012942123,0.006003695,0.02017409,0.00072750065,0.000109805376,0.34416458,0.0009275018,0.07679568],"genre_scores_gemma":[0.8304676,0.009094127,0.0040217075,0.0020200864,0.00036341016,0.0001738323,0.14785999,0.0000696873,0.0059295986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999418,0.000084952415,0.000072881565,0.00008687151,0.00021687255,0.000120455006],"domain_scores_gemma":[0.9980118,0.0001764138,0.00067777466,0.000041200423,0.0009172215,0.00017551634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076727377,0.0004883857,0.0001790056,0.0021882402,0.00032719978,0.0011820282,0.00034670086,0.00042562847,0.0062815235],"category_scores_gemma":[0.0031993296,0.00016021641,0.0008809944,0.0036580856,0.00017042774,0.0013560931,0.0006667856,0.0010185684,0.0020361238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047848857,0.00020416144,0.64414895,0.0012890153,0.00040492433,0.0004499477,0.00044055763,0.01547122,0.0010339213,0.012721003,0.21027909,0.11307872],"study_design_scores_gemma":[0.000043533477,0.0002251965,0.8005323,0.0007524059,0.00024668287,0.0008955486,0.0011717704,0.02177802,0.0012131635,0.0032724238,0.16979533,0.000073592084],"about_ca_topic_score_codex":0.04524808,"about_ca_topic_score_gemma":0.044031445,"teacher_disagreement_score":0.04524808,"about_ca_system_score_codex":0.0026077442,"about_ca_system_score_gemma":0.0018277238,"threshold_uncertainty_score":0.089969456},"labels":[],"label_agreement":null},{"id":"W2952092910","doi":"","title":"Brevet Pharmaceutique: le critère de l’utilité canadien – fluctuations et divergences","year":2019,"lang":"fr","type":"article","venue":"Les Cahiers de propriété intellectuelle","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Philosophy","score_opus":0.032137349166446116,"score_gpt":0.28494104439376855,"score_spread":0.25280369522732243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952092910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59540206,0.015764656,0.16622235,0.032963544,0.00063531473,0.00016673334,0.0013721697,0.0004806332,0.18699262],"genre_scores_gemma":[0.98252535,0.00091675227,0.009328361,0.0004202705,0.00029291635,0.000110629786,0.00016184662,0.000110872505,0.006132973],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889994,0.0040730545,0.0006578945,0.0016810653,0.0039032078,0.0006852888],"domain_scores_gemma":[0.9561113,0.02996446,0.0036236974,0.0036388552,0.00509012,0.0015716136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012000502,0.0009757539,0.0022878805,0.00402997,0.0022301036,0.012962739,0.0016670981,0.0033557552,0.0044445083],"category_scores_gemma":[0.068868704,0.00058797013,0.001072808,0.004709767,0.0072678677,0.009012436,0.0041143503,0.007369553,0.0008079997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042414246,0.00010250816,0.0132044405,0.00022180482,0.00022302383,0.00033927333,0.003070322,0.010887318,0.0018440732,0.91784924,0.0025408121,0.04929297],"study_design_scores_gemma":[0.000089233836,0.0002328289,0.05125994,0.00032477768,0.00008255111,0.0006597922,0.0018973894,0.040207747,0.0016492108,0.8736649,0.029793642,0.00013798077],"about_ca_topic_score_codex":0.010290836,"about_ca_topic_score_gemma":0.0035109445,"teacher_disagreement_score":0.98970914,"about_ca_system_score_codex":0.0055227606,"about_ca_system_score_gemma":0.0025704927,"threshold_uncertainty_score":0.063465476},"labels":[],"label_agreement":null},{"id":"W2952840127","doi":"10.1093/ndt/gfz103.sp677","title":"SP677IMPLEMENTING A PATIENT-REPORTED OUTCOME MEASURE FOR HEMODIALYSIS PATIENTS IN ROUTINE CLINICAL CARE: PERSPECTIVES OF PATIENTS AND CLINICIANS","year":2019,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; London Health Sciences Centre; Ontario Stroke Network","funders":"","keywords":"Medicine; Hemodialysis; Intensive care medicine; Patient-reported outcome; MEDLINE; Measure (data warehouse); Quality of life (healthcare); Surgery; Nursing","score_opus":0.0530823228496729,"score_gpt":0.32524749755570087,"score_spread":0.27216517470602797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952840127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799288,0.0008783064,0.00030799126,0.013425286,0.00007181587,0.00017479114,0.00023500048,0.000018520692,0.004959472],"genre_scores_gemma":[0.99574596,0.0006978869,0.0010879607,0.0017053774,0.000039863215,0.000120865596,0.00012746183,0.0000049264345,0.0004697516],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9888603,0.0068022273,0.0007405889,0.0003399108,0.0022207664,0.0010362082],"domain_scores_gemma":[0.9763737,0.007148613,0.0048844777,0.00059538614,0.0061088735,0.0048890403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012502739,0.00015153241,0.00028723147,0.0002621421,0.0017202097,0.0021168443,0.0006437844,0.00065034407,0.0018026069],"category_scores_gemma":[0.024247745,0.00018991306,0.000370754,0.00051053497,0.0008932086,0.0008554008,0.0014340236,0.001173409,0.00019554133],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003368284,0.00062870217,0.74989635,0.00084175356,0.00008718831,0.00046963795,0.09586431,0.00015906733,0.0014531664,0.00027407915,0.011711214,0.13827772],"study_design_scores_gemma":[0.00013119355,0.0013495735,0.8491507,0.0008811107,0.00007648104,0.00034662313,0.12464873,0.00049540744,0.0006611807,0.00017077381,0.022024125,0.00006417132],"about_ca_topic_score_codex":0.06509891,"about_ca_topic_score_gemma":0.13791592,"teacher_disagreement_score":0.06509891,"about_ca_system_score_codex":0.005681299,"about_ca_system_score_gemma":0.014458618,"threshold_uncertainty_score":0.12944001},"labels":[],"label_agreement":null},{"id":"W2952893943","doi":"10.4324/9781315677972-9","title":"The Price of Exclusivity","year":2017,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economics; Business","score_opus":0.09984760495861708,"score_gpt":0.29264391056409844,"score_spread":0.19279630560548136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952893943","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05710516,0.021354642,0.026499828,0.019803416,0.0006082581,0.00009164961,0.00030508844,0.00015621391,0.8740757],"genre_scores_gemma":[0.8100325,0.010984464,0.007010239,0.0052691796,0.0011754254,0.0002555867,0.00016556648,0.00026793024,0.16483916],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682117,0.0007329451,0.00016271048,0.0006438253,0.0012768182,0.00036259342],"domain_scores_gemma":[0.9914692,0.0049650976,0.0008194041,0.0014897352,0.00096354337,0.00029300628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037471913,0.0005648211,0.0009812602,0.0008142847,0.0021053136,0.010482694,0.001558007,0.0050570634,0.029376011],"category_scores_gemma":[0.013670447,0.00079466903,0.0009113868,0.001041563,0.009880718,0.012861004,0.0028865861,0.006945094,0.0029685574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004570333,0.000016206504,0.00030767437,0.00005240422,0.000012022663,0.00008775294,0.00025707574,0.0010117361,0.00041931513,0.9799405,0.0026832114,0.015166443],"study_design_scores_gemma":[0.00005091232,0.00017666361,0.0030289663,0.0006423926,0.000054016782,0.0004987262,0.00068559166,0.0025498245,0.0017904489,0.71602196,0.27442917,0.00007134364],"about_ca_topic_score_codex":0.006698947,"about_ca_topic_score_gemma":0.004105166,"teacher_disagreement_score":0.029376011,"about_ca_system_score_codex":0.0081954375,"about_ca_system_score_gemma":0.0031437445,"threshold_uncertainty_score":0.0982725},"labels":[],"label_agreement":null},{"id":"W2953069276","doi":"10.1016/j.jhealeco.2019.102228","title":"Medical innovation, education, and labor market outcomes of cancer patients","year":2019,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"W.E. Upjohn Institute for Employment Research","keywords":"Medicine; Cancer; Prostate cancer; Breast cancer; Educational attainment; Cancer registry; Economics; Internal medicine; Economic growth","score_opus":0.033604685302864666,"score_gpt":0.34833318741701724,"score_spread":0.3147285021141526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953069276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939242,0.00061777595,0.00004233844,0.0020438177,0.000023969153,0.000011787935,0.0007627489,0.000003907874,0.0025694948],"genre_scores_gemma":[0.99877614,0.00013077752,0.000009436675,0.00013690213,0.000035492358,0.000004104235,0.00035862924,0.0000011904783,0.0005472862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988187,0.00029258468,0.00010261974,0.00008209101,0.0001144066,0.0005895865],"domain_scores_gemma":[0.98771113,0.0035377294,0.0049671717,0.00027768855,0.0006171581,0.0028891047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016127886,0.0001635698,0.00036458782,0.0011849699,0.0007042791,0.0020122603,0.00059012236,0.0016306071,0.011557561],"category_scores_gemma":[0.0133615965,0.00018572676,0.0008985744,0.0016089281,0.0006007096,0.0013302319,0.0010469536,0.001932487,0.00094431406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043088745,0.00059732154,0.99378407,0.000016912854,0.00008197282,0.00006968278,0.00017357273,0.0004467328,0.000057857545,0.00036076095,0.0005791949,0.0034010995],"study_design_scores_gemma":[0.000056944034,0.00034511238,0.9955883,0.000026116368,0.00006473536,0.00008326117,0.00095051975,0.0011660103,0.0000781075,0.0009452284,0.0006774604,0.000018253979],"about_ca_topic_score_codex":0.013347229,"about_ca_topic_score_gemma":0.014189132,"teacher_disagreement_score":0.013347229,"about_ca_system_score_codex":0.0011379095,"about_ca_system_score_gemma":0.0015916214,"threshold_uncertainty_score":0.038663864},"labels":[],"label_agreement":null},{"id":"W2953974800","doi":"10.1016/j.jval.2019.04.739","title":"PDG60 DID CITIZEN PETITIONS PROLONG THE NUMBER OF APPROVAL DAYS OF GENERIC DRUGS?","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicine; Value (mathematics); Food and drug administration; Pharmacology; Geography; Statistics; Mathematics","score_opus":0.07224846029655808,"score_gpt":0.3052642194823649,"score_spread":0.2330157591858068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953974800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7634386,0.00245104,0.0015523548,0.15293768,0.0015881748,0.000099802346,0.0053776368,0.000107126834,0.0724476],"genre_scores_gemma":[0.98341656,0.00023335888,0.00013021988,0.008965208,0.00047371024,0.000033163426,0.00042083746,0.000019138664,0.006307679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698144,0.0010393662,0.000103926424,0.0003165464,0.0004435617,0.0011151565],"domain_scores_gemma":[0.95600724,0.025731381,0.009860672,0.0011791935,0.0034989817,0.0037225373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005777775,0.00015789585,0.00045162413,0.000459342,0.00078806723,0.0027918718,0.00062040694,0.0047016307,0.012106161],"category_scores_gemma":[0.047079317,0.00027137366,0.00084325037,0.0006070449,0.0011175829,0.0019025964,0.0009294048,0.004944125,0.0011660579],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013337997,0.0015475976,0.52557117,0.00061316986,0.0009321462,0.00084181275,0.0022055241,0.0059413672,0.0018304415,0.1253859,0.17802387,0.14376898],"study_design_scores_gemma":[0.0013681033,0.0020467662,0.6980632,0.0005045292,0.00082407234,0.00044453482,0.0038180053,0.011760805,0.0030528274,0.050303087,0.22765565,0.00015841099],"about_ca_topic_score_codex":0.021307224,"about_ca_topic_score_gemma":0.026217932,"teacher_disagreement_score":0.021307224,"about_ca_system_score_codex":0.003292812,"about_ca_system_score_gemma":0.004350632,"threshold_uncertainty_score":0.042366445},"labels":[],"label_agreement":null},{"id":"W2956015350","doi":"10.1016/j.jval.2019.04.766","title":"PDG87 DRUG UTILIZATION IN PERSISTENT NAMD PATIENTS TREATED WITH LICENSED ANTI-VEGFS IN CANADA: A REAL WORLD STUDY USING THE ONTARIO PUBLIC CLAIMS DATABASE","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Aflibercept; Ranibizumab; Medicine; Cohort; Macular degeneration; Retrospective cohort study; Dosing; Cohort study; Medical prescription; Bevacizumab; Pediatrics; Internal medicine; Pro re nata; Ophthalmology; Pharmacology; Chemotherapy","score_opus":0.20157718155231333,"score_gpt":0.2979772143020565,"score_spread":0.09640003274974315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956015350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970746,0.0019663067,0.0001555723,0.0011173056,0.00002256411,0.00010292649,0.023545455,0.000018776529,0.0023252228],"genre_scores_gemma":[0.99093294,0.0011217677,0.00023910339,0.00036561963,0.00002079534,0.000035400488,0.006450567,0.000010695318,0.0008232171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788386,0.00018234274,0.00021664397,0.0002786519,0.00080734474,0.00063110364],"domain_scores_gemma":[0.9921272,0.0006870602,0.0029468325,0.00025750016,0.0024450445,0.0015363689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009994084,0.0004577442,0.0008367307,0.0019366052,0.0020691592,0.002596322,0.0016162021,0.00096171716,0.0023837457],"category_scores_gemma":[0.005689353,0.0006418723,0.0014443975,0.008908928,0.0010491662,0.00085173437,0.0012409112,0.0015885873,0.00027009752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002770746,0.00009689987,0.99202347,0.00011269003,0.00025511096,0.00012587209,0.00046764835,0.0002789967,0.000075687036,0.00026057838,0.002923802,0.0031022779],"study_design_scores_gemma":[0.000046373694,0.00004310455,0.9958675,0.00008316388,0.00012987814,0.00009736937,0.0009567477,0.0010894582,0.00004424557,0.000044483986,0.0015714568,0.000026337773],"about_ca_topic_score_codex":0.99406993,"about_ca_topic_score_gemma":0.9950481,"teacher_disagreement_score":0.053493198,"about_ca_system_score_codex":0.053493198,"about_ca_system_score_gemma":0.047785662,"threshold_uncertainty_score":0.38812214},"labels":[],"label_agreement":null},{"id":"W2959633209","doi":"10.1016/s1470-2045(19)30459-0","title":"Improving affordability of new Essential Cancer Medicines","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Public Health Ontario","funders":"","keywords":"Essential medicines; Business; Access to medicines; Investment (military); Workforce; Quality (philosophy); Low and middle income countries; Supply chain; Cancer drugs; Medicine; Health care; Cancer; Economic growth; Developing country; Marketing; Nursing; Public health; Political science; Economics","score_opus":0.08620239956862087,"score_gpt":0.3603103379768915,"score_spread":0.27410793840827063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959633209","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46374246,0.075600386,0.12855268,0.14869656,0.002316124,0.000464956,0.013000378,0.0010989152,0.1665276],"genre_scores_gemma":[0.98758405,0.0048977314,0.0037261306,0.0008792939,0.0006998802,0.00004148771,0.00050230714,0.00006094944,0.0016080175],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918853,0.003876333,0.00061097107,0.00050877564,0.0023146167,0.0008040874],"domain_scores_gemma":[0.9594335,0.029821519,0.0056300713,0.0019204831,0.001746803,0.0014476328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01109365,0.00060706603,0.0016818574,0.0022483594,0.00034523263,0.0035369971,0.0012200512,0.0022381297,0.013463804],"category_scores_gemma":[0.06134503,0.00056147255,0.0016279512,0.0022611315,0.0015545904,0.0075159995,0.0026273846,0.0033709912,0.00039919425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024232084,0.0006892977,0.026730403,0.0028661774,0.0014808666,0.00039577845,0.00036483168,0.18077639,0.0018658675,0.52861917,0.023170605,0.23061746],"study_design_scores_gemma":[0.00074875186,0.0008603853,0.017363338,0.00054833613,0.0006705089,0.00026000966,0.00029434913,0.06546369,0.0015830968,0.8561922,0.055933654,0.00008168423],"about_ca_topic_score_codex":0.009848745,"about_ca_topic_score_gemma":0.0054766377,"teacher_disagreement_score":0.013463804,"about_ca_system_score_codex":0.004488423,"about_ca_system_score_gemma":0.005360931,"threshold_uncertainty_score":0.058669508},"labels":[],"label_agreement":null},{"id":"W2959919038","doi":"","title":"Drug Product Registration in US, EUROPE, JAPAN and CANADA for New Drug and Generics","year":2014,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Product (mathematics); Business; Drug approval; Approved drug; Marketing; Drug development; Medicine; Pharmacology","score_opus":0.03460662745522742,"score_gpt":0.23820609364860984,"score_spread":0.20359946619338243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959919038","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01182562,0.0064489073,0.0075361286,0.006692846,0.0008573209,0.0007292782,0.027034853,0.00076844177,0.93810666],"genre_scores_gemma":[0.3225313,0.019531438,0.025531098,0.004785941,0.0009896086,0.00058853434,0.0426509,0.00047872556,0.5829125],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99602664,0.00033906923,0.00027860157,0.00037970243,0.0024967433,0.00047922155],"domain_scores_gemma":[0.99478513,0.000614097,0.0005799229,0.00037662746,0.003291179,0.00035312932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015581301,0.0003930351,0.000493938,0.0049508954,0.0018737752,0.0032060775,0.00070791686,0.0013413522,0.041919798],"category_scores_gemma":[0.0066825245,0.00023235097,0.000650252,0.008632703,0.0014992773,0.001977806,0.00071904354,0.0015593724,0.014717816],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015624586,0.00011630073,0.014684657,0.0007968492,0.00005591581,0.00038032432,0.00063248316,0.0008448524,0.0013963996,0.35683966,0.43553016,0.18856616],"study_design_scores_gemma":[0.000019303307,0.000035218814,0.01996759,0.00015534055,0.000025897696,0.00023864345,0.00027304667,0.00060977763,0.0006210796,0.007368964,0.9706532,0.000031989694],"about_ca_topic_score_codex":0.3180976,"about_ca_topic_score_gemma":0.30148178,"teacher_disagreement_score":0.6819024,"about_ca_system_score_codex":0.011784205,"about_ca_system_score_gemma":0.02354585,"threshold_uncertainty_score":0.6324921},"labels":[],"label_agreement":null},{"id":"W2965709677","doi":"10.1016/j.gheart.2019.07.008","title":"Access to Essential Medicines for Circulatory Diseases: A Call to Action","year":2019,"lang":"en","type":"letter","venue":"Global Heart","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"World Heart Federation; Sanofi","keywords":"Medicine; Checklist; Observational study; Global health; Call to action; Strengthening the reporting of observational studies in epidemiology; Alternative medicine; Download; Family medicine; Systematic review; Medical education; Public health; MEDLINE; Pathology; Political science; Business; Psychology; Computer science; World Wide Web","score_opus":0.08889832200331568,"score_gpt":0.3729764602790041,"score_spread":0.2840781382756884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965709677","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039305163,0.00094121444,0.000095619325,0.98876065,0.008083045,0.000008763413,0.00006511014,0.000033976,0.0019722541],"genre_scores_gemma":[0.000965118,0.0015797983,0.0007842909,0.9752941,0.014741281,0.000046980505,0.00007848943,0.000056197907,0.0064538405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97686255,0.0059553226,0.0032490967,0.002075192,0.009047696,0.0028101082],"domain_scores_gemma":[0.85147905,0.09674199,0.00515699,0.006435286,0.018738514,0.021448119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02554136,0.0011919809,0.0025978968,0.0020292867,0.005953662,0.0127767855,0.004096043,0.110803716,0.050701946],"category_scores_gemma":[0.121105336,0.0013537968,0.0036185603,0.0021121446,0.00972364,0.03013447,0.011465673,0.077951536,0.033302598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002127301,0.000028925331,0.00007026681,0.00009646008,0.0000046450937,0.00018923666,0.00010245996,0.000020281566,0.00006699268,0.005346015,0.98403513,0.010018418],"study_design_scores_gemma":[0.00006529213,0.000032523396,0.0003506315,0.00055585813,0.000011107948,0.00034337846,0.00033297352,0.00013323317,0.000064605774,0.012828719,0.9852297,0.00005198523],"about_ca_topic_score_codex":0.012523485,"about_ca_topic_score_gemma":0.01259801,"teacher_disagreement_score":0.110803716,"about_ca_system_score_codex":0.008352113,"about_ca_system_score_gemma":0.033241715,"threshold_uncertainty_score":0.16961491},"labels":[],"label_agreement":null},{"id":"W2967833784","doi":"10.1371/journal.pone.0220781","title":"Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists","year":2019,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Essential medicines; Medicine; Selection (genetic algorithm); MEDLINE; Traditional medicine; Biology; Public health; Computer science","score_opus":0.06477105250715584,"score_gpt":0.30091967244005324,"score_spread":0.2361486199328974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967833784","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4377215,0.009851386,0.0069085583,0.0016451618,0.00020531984,0.003821588,0.5120871,0.00035660033,0.027402857],"genre_scores_gemma":[0.7393617,0.0046936683,0.036186654,0.0012201683,0.00009780219,0.004810714,0.2110074,0.00012161307,0.0025002323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9893162,0.0032519684,0.0035195744,0.0009171829,0.0025625138,0.0004325451],"domain_scores_gemma":[0.97086203,0.011367132,0.011330026,0.0014430946,0.0043729637,0.000624778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008591044,0.00041024564,0.0009794096,0.0077882335,0.00039100528,0.0011529487,0.0010749097,0.00043960338,0.007885118],"category_scores_gemma":[0.031896822,0.00023814174,0.0011192785,0.0108836675,0.00027392842,0.0011793767,0.0011688715,0.00048768366,0.0017075993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028657068,0.00020830582,0.7570335,0.009278937,0.00083599397,0.00038925448,0.00091114844,0.0019918552,0.0011698992,0.0026135915,0.05392941,0.1687724],"study_design_scores_gemma":[0.0006339857,0.0006182809,0.8721937,0.0046485434,0.0009631886,0.0009167615,0.001524078,0.0035053745,0.0042517106,0.0017056798,0.108922906,0.00011570598],"about_ca_topic_score_codex":0.006979797,"about_ca_topic_score_gemma":0.010569457,"teacher_disagreement_score":0.008591044,"about_ca_system_score_codex":0.0014546515,"about_ca_system_score_gemma":0.0030832728,"threshold_uncertainty_score":0.045434296},"labels":[],"label_agreement":null},{"id":"W2969793212","doi":"10.1016/s2468-2667(19)30165-3","title":"Essential medicines and essential diagnostics: a package deal","year":2019,"lang":"en","type":"letter","venue":"The Lancet Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Essential medicines; Medicine; Family medicine; Public health; Nursing","score_opus":0.10184946357700442,"score_gpt":0.3273830573798961,"score_spread":0.22553359380289167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969793212","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068346807,0.019724391,0.0077849925,0.18133432,0.05046571,0.00050107995,0.0044286265,0.005551459,0.72952586],"genre_scores_gemma":[0.005697634,0.0153645165,0.011348002,0.08767997,0.021004936,0.00044752215,0.0057242834,0.0025953092,0.85013777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948532,0.000754232,0.00028987363,0.0005832818,0.0030492533,0.00047018207],"domain_scores_gemma":[0.9888409,0.002424518,0.00052366965,0.0015726648,0.0038496556,0.0027886864],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0043889782,0.0010599105,0.001009306,0.0022802502,0.0016469675,0.009791441,0.0019574603,0.0063936375,0.4062502],"category_scores_gemma":[0.019224644,0.0008461822,0.0009892145,0.0023915248,0.001788455,0.0132713895,0.006913931,0.0072754957,0.3160295],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017991064,0.000037837643,0.000039265793,0.00011654792,0.0000030710587,0.00003213665,0.00005981993,0.000024324412,0.00017288387,0.014182967,0.9328024,0.052510742],"study_design_scores_gemma":[0.0000030163342,0.000006823563,0.000052794298,0.00006375215,9.986696e-7,0.000034990808,0.000016405538,0.000009118371,0.00002307519,0.0012709686,0.99851483,0.000003067577],"about_ca_topic_score_codex":0.0013022312,"about_ca_topic_score_gemma":0.0013928993,"teacher_disagreement_score":0.4062502,"about_ca_system_score_codex":0.001745737,"about_ca_system_score_gemma":0.0059502036,"threshold_uncertainty_score":0.846912},"labels":[],"label_agreement":null},{"id":"W2970343731","doi":"10.1200/jco.2007.25.18_suppl.6612","title":"The utilization of new oncology drugs: A global perspective","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vintage; Cancer; Cancer drugs; Drug; Demography; Environmental health; Internal medicine; Pharmacology; Geography","score_opus":0.3505697983439747,"score_gpt":0.5386506553253644,"score_spread":0.18808085698138965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970343731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4789547,0.38579217,0.0023481091,0.08199131,0.00089905714,0.000038890896,0.007851758,0.00008845067,0.042035572],"genre_scores_gemma":[0.8191449,0.17072228,0.0009334211,0.0048545916,0.0015015664,0.00002058555,0.0016331167,0.000025277614,0.0011642778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878913,0.00054477213,0.0001401973,0.0001505989,0.00020779994,0.00016765692],"domain_scores_gemma":[0.99592966,0.0013783507,0.0014761217,0.0000827447,0.0006768672,0.00045625857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013072087,0.00040876746,0.00047877303,0.0035232261,0.0002038831,0.0020803914,0.00034172463,0.0009909652,0.0045149913],"category_scores_gemma":[0.0031423965,0.00015342525,0.00073581963,0.006870347,0.00063956494,0.003192257,0.0008683661,0.0010061173,0.0003419769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004718584,0.00022687552,0.6800525,0.0037609679,0.00083780964,0.0010090625,0.001854508,0.0039042088,0.0012842132,0.008748912,0.021282675,0.27656642],"study_design_scores_gemma":[0.000030523395,0.00073905056,0.87015706,0.0019136852,0.0004792817,0.0037998066,0.0066346955,0.0022403344,0.00091300654,0.0026806695,0.11033191,0.000080011305],"about_ca_topic_score_codex":0.0077455365,"about_ca_topic_score_gemma":0.008551868,"teacher_disagreement_score":0.0077455365,"about_ca_system_score_codex":0.0014041589,"about_ca_system_score_gemma":0.00084466254,"threshold_uncertainty_score":0.015400887},"labels":[],"label_agreement":null},{"id":"W2971990713","doi":"10.1186/s40545-019-0187-9","title":"Assessing national governance of medicine promotion: an exploratory study in Ghana to trial a structured set of indicators","year":2019,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; Public Health Ontario; University of Toronto","funders":"","keywords":"Transparency (behavior); Accountability; Corporate governance; Promotion (chess); Business; Good governance; Essential medicines; Medical prescription; Medicine; Desk; Public relations; Public health; Nursing; Political science; Finance","score_opus":0.21834318702432393,"score_gpt":0.4694165047824969,"score_spread":0.251073317758173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971990713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99717355,0.00007238204,0.00061125524,0.00018052431,0.00000408827,0.0010033802,0.00015669258,0.0000033997444,0.0007947991],"genre_scores_gemma":[0.9922213,0.0001480883,0.00464362,0.00016017983,0.0000065240492,0.0022946068,0.00020816391,0.000004453043,0.00031312314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99287957,0.0054952414,0.00033129548,0.0003531802,0.0002828666,0.0006578426],"domain_scores_gemma":[0.9750352,0.014520458,0.005089408,0.0010075836,0.0030677328,0.0012796405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012531489,0.00047517777,0.0005066504,0.0013452267,0.0019717643,0.0013106744,0.00068647956,0.000657622,0.002284524],"category_scores_gemma":[0.021758355,0.0004227097,0.00040909354,0.0022502677,0.0026325965,0.0021995835,0.0016776441,0.0010122788,0.00025127613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011042207,0.006787202,0.735535,0.0013610622,0.00009378441,0.0018614641,0.19527043,0.0013284229,0.0021206124,0.0037837438,0.0016092026,0.04914474],"study_design_scores_gemma":[0.000522857,0.006176186,0.53823185,0.0007992566,0.00009366575,0.00039502542,0.44018015,0.0023260883,0.001263548,0.0013983274,0.008550594,0.00006242472],"about_ca_topic_score_codex":0.020572498,"about_ca_topic_score_gemma":0.0425396,"teacher_disagreement_score":0.020572498,"about_ca_system_score_codex":0.0067517273,"about_ca_system_score_gemma":0.006355293,"threshold_uncertainty_score":0.06627363},"labels":[],"label_agreement":null},{"id":"W2972150441","doi":"10.1080/21556660.2019.1658313","title":"Understanding purchasing patterns and product access of newly launched specialty generics","year":2019,"lang":"en","type":"article","venue":"Journal of Drug Assessment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Product (mathematics); Purchasing; Pharmacy; Launched; Specialty; Marketing; Business; Medicine; Advertising; Family medicine; Engineering","score_opus":0.16158098750113523,"score_gpt":0.3508699535733115,"score_spread":0.1892889660721763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972150441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952678,0.006180619,0.00090628717,0.0073405695,0.00004833262,0.000021474074,0.028272087,0.000020571551,0.0045321016],"genre_scores_gemma":[0.97917557,0.0030591646,0.0014089277,0.00067149586,0.00008171686,0.000022960774,0.013973104,0.000007957857,0.0015991483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996995,0.00007246263,0.000037077065,0.000059596136,0.00008252905,0.000048898055],"domain_scores_gemma":[0.99609536,0.0014178925,0.0016029896,0.00012088311,0.00037684452,0.00038590183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012075641,0.00022448527,0.00023543688,0.0012699692,0.00020756402,0.0009923796,0.0003896503,0.00055407075,0.004541763],"category_scores_gemma":[0.005891973,0.000222992,0.0005829092,0.0026113705,0.0001624403,0.0016119167,0.0007116005,0.00081289315,0.0010033145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016837618,0.00008899164,0.9426602,0.00008078315,0.00016210657,0.00008190996,0.00034124625,0.0006933641,0.00017095514,0.00072679395,0.008447844,0.046377465],"study_design_scores_gemma":[0.000010418764,0.00007484702,0.9900315,0.00007660561,0.000085397565,0.00011855589,0.0005530407,0.0026150427,0.000110996734,0.0011473699,0.0051649376,0.000011349503],"about_ca_topic_score_codex":0.04256643,"about_ca_topic_score_gemma":0.06799283,"teacher_disagreement_score":0.04256643,"about_ca_system_score_codex":0.00071897503,"about_ca_system_score_gemma":0.00072015007,"threshold_uncertainty_score":0.084637284},"labels":[],"label_agreement":null},{"id":"W2973094055","doi":"10.1503/cmaj.190289","title":"Do practice guidelines cause drug shortages? The historical example of β-blockers","year":2019,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Economic shortage; Authorization; Drug; Medicine; Intensive care medicine; Pharmacology; Computer science; Computer security","score_opus":0.06497287707141305,"score_gpt":0.30936009485317956,"score_spread":0.2443872177817665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973094055","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066067483,0.020104961,0.001628814,0.939137,0.0027722681,0.000029376588,0.00034813126,0.000043776625,0.029328994],"genre_scores_gemma":[0.3873432,0.07583229,0.0055787372,0.49896705,0.01722906,0.00017306136,0.0008158745,0.0003198846,0.0137407575],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.979292,0.0072125103,0.0011419535,0.0017756307,0.007254736,0.0033231743],"domain_scores_gemma":[0.8748657,0.04463306,0.017661428,0.004339523,0.04085527,0.017644936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019305179,0.0003063827,0.00051008945,0.0029478988,0.005165072,0.00704832,0.0014554198,0.008413379,0.01011527],"category_scores_gemma":[0.119569995,0.00074682315,0.0004907266,0.0061284187,0.0073760445,0.004950205,0.003011248,0.013075263,0.0013986502],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011480869,0.00014429505,0.021681655,0.0009786317,0.00009434202,0.001129006,0.0055406997,0.00057909306,0.00015472923,0.23483986,0.59868705,0.13605583],"study_design_scores_gemma":[0.00014951147,0.00008789417,0.031954832,0.0039169705,0.000077674864,0.001027517,0.0041063596,0.00067391933,0.00019754513,0.06467861,0.8930302,0.0000989092],"about_ca_topic_score_codex":0.23307824,"about_ca_topic_score_gemma":0.2608452,"teacher_disagreement_score":0.23307824,"about_ca_system_score_codex":0.023103315,"about_ca_system_score_gemma":0.039650224,"threshold_uncertainty_score":0.46344316},"labels":[],"label_agreement":null},{"id":"W2973726810","doi":"10.1016/j.healthpol.2019.09.005","title":"How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?","year":2019,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Context (archaeology); Multinational corporation; Medical prescription; Competition (biology); Business; European union; Market access; International trade; Public economics; Economics; International economics; Finance; Medicine","score_opus":0.1440734088236462,"score_gpt":0.3934999045225454,"score_spread":0.24942649569889921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973726810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45118552,0.013930107,0.0014130385,0.42307803,0.0010032986,0.00013006272,0.015026454,0.00012409322,0.094109416],"genre_scores_gemma":[0.94095856,0.005324341,0.0008156066,0.029552117,0.00056181086,0.000032332337,0.0013872554,0.00003403771,0.021333868],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9931639,0.00053843413,0.00022935198,0.00037498088,0.002301896,0.0033914228],"domain_scores_gemma":[0.9800095,0.004034114,0.0032521952,0.0003665939,0.008405446,0.0039321873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052289064,0.000328014,0.00068790134,0.0023255066,0.0033384613,0.008443826,0.0015953287,0.0050044614,0.009291256],"category_scores_gemma":[0.021463841,0.0005014101,0.0017496081,0.0036710037,0.0028366,0.002566459,0.0013943432,0.0048970655,0.00041551457],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007374228,0.0005134031,0.37278876,0.00060838775,0.0010259693,0.0006963721,0.0021447483,0.017874952,0.0013133752,0.41919574,0.123984285,0.059116602],"study_design_scores_gemma":[0.00042231038,0.00019796632,0.715149,0.00085913873,0.00077926,0.00021275724,0.004232953,0.011717456,0.0016420878,0.033050872,0.23140043,0.00033580564],"about_ca_topic_score_codex":0.9929069,"about_ca_topic_score_gemma":0.9954228,"teacher_disagreement_score":0.11964547,"about_ca_system_score_codex":0.11964547,"about_ca_system_score_gemma":0.1902032,"threshold_uncertainty_score":0.8680927},"labels":[],"label_agreement":null},{"id":"W2973742237","doi":"10.1016/s2352-4642(19)30294-9","title":"NCDs and the WHO Essential Medicines Lists: children need universal health coverage too","year":2019,"lang":"en","type":"review","venue":"The Lancet Child & Adolescent Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; McMaster University Medical Centre; BC Children's Hospital","funders":"World Diabetes Foundation; World Heart Federation; American Academy of Pediatrics","keywords":"Equity (law); Medicine; MEDLINE; Alternative medicine; Family medicine; Medical education; Business; Political science; Pathology","score_opus":0.06956492419658926,"score_gpt":0.3398701215782803,"score_spread":0.270305197381691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973742237","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00061072275,0.9426808,0.0004373572,0.04373508,0.0019050863,0.00002133397,0.001018062,0.00002551789,0.00956602],"genre_scores_gemma":[0.01596582,0.95060146,0.001319255,0.026189998,0.0022952582,0.00007116002,0.00075920747,0.000020878473,0.002776933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987544,0.00030648414,0.00013936128,0.00010106853,0.00056630047,0.00013241517],"domain_scores_gemma":[0.9962708,0.0022594603,0.0007496604,0.000092487884,0.00047493933,0.0001527068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002666437,0.00049973006,0.0013596695,0.0011620241,0.00019106515,0.0016150291,0.00074394676,0.001993756,0.012952219],"category_scores_gemma":[0.006893995,0.00020732984,0.0011214478,0.0026636005,0.000908549,0.0020980053,0.0011247729,0.002678758,0.0011718124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018517244,0.000036954294,0.001049938,0.024396868,0.0005823968,0.000084210114,0.00007009336,0.00046989325,0.00029708663,0.051289517,0.15030181,0.771236],"study_design_scores_gemma":[0.00015727486,0.00006824633,0.008503115,0.046842176,0.0006869886,0.00026525927,0.00018215655,0.00020569238,0.00018481172,0.0213349,0.9215414,0.00002804825],"about_ca_topic_score_codex":0.021228848,"about_ca_topic_score_gemma":0.032742117,"teacher_disagreement_score":0.021228848,"about_ca_system_score_codex":0.002715932,"about_ca_system_score_gemma":0.0062208204,"threshold_uncertainty_score":0.043329477},"labels":[],"label_agreement":null},{"id":"W2974366251","doi":"10.1016/j.jcjd.2019.07.092","title":"83 - Patient and Family Physician Perspectives on Facilitated Relay to Enhance Use of Statins","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Bible College","funders":"","keywords":"Medicine; Psychological intervention; Guideline; Intervention (counseling); Family medicine; Statin; Relay; Intensive care medicine; Nursing; Internal medicine","score_opus":0.030379899083035566,"score_gpt":0.24572857772167644,"score_spread":0.21534867863864088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974366251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86792785,0.0014466344,0.0006636263,0.07780785,0.0006315895,0.00012663101,0.0003595193,0.000041191604,0.050995186],"genre_scores_gemma":[0.99054646,0.0009780771,0.00061567477,0.0056366287,0.00032886065,0.00003419624,0.000049867205,0.0000134580405,0.0017968038],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99431545,0.004306094,0.0002790829,0.00012337005,0.00036447291,0.0006114677],"domain_scores_gemma":[0.97662735,0.014762665,0.002217152,0.00027711227,0.0021595166,0.0039562117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046823937,0.00014258377,0.0002384553,0.00039056776,0.0023734933,0.0017120661,0.00034725195,0.00224109,0.014101046],"category_scores_gemma":[0.03448,0.00016469866,0.00046435202,0.00030872104,0.0005753181,0.0009496735,0.0014408188,0.0017922975,0.0009020581],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069564898,0.0037107524,0.25014102,0.001741573,0.0003671403,0.045133334,0.25833383,0.001457447,0.009327188,0.007356966,0.1265952,0.2888791],"study_design_scores_gemma":[0.0011070936,0.0054823775,0.32465085,0.0020518492,0.0005059828,0.018186335,0.41580352,0.0018805952,0.003923005,0.0032761684,0.22279969,0.0003324425],"about_ca_topic_score_codex":0.005486274,"about_ca_topic_score_gemma":0.010713394,"teacher_disagreement_score":0.014101046,"about_ca_system_score_codex":0.0020497388,"about_ca_system_score_gemma":0.0023998842,"threshold_uncertainty_score":0.047172725},"labels":[],"label_agreement":null},{"id":"W2974532578","doi":"10.1093/acrefore/9780190625979.013.77","title":"The Effect of Government Policy on Pharmaceutical Drug Innovation","year":2019,"lang":"en","type":"reference-entry","venue":"Oxford Research Encyclopedia of Economics and Finance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Underinsured; Business; Public economics; Revenue; Intellectual property; Drug; Public policy; Government (linguistics); Tax revenue; Drug development; Finance; Economics; Pharmacology; Economic growth; Medicine; Health insurance; Political science; Health care; Law","score_opus":0.06208273139301879,"score_gpt":0.3482250298800441,"score_spread":0.2861422984870253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974532578","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0671639,0.14502166,0.0042037917,0.17519319,0.002669463,0.00009658436,0.001431615,0.00016684429,0.6040529],"genre_scores_gemma":[0.8880175,0.06485172,0.0014660513,0.02106573,0.002117433,0.000089248904,0.00040517803,0.000071115675,0.02191623],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9893372,0.0047640884,0.00033778354,0.0005978013,0.0032106775,0.0017524848],"domain_scores_gemma":[0.9757253,0.01568314,0.0033040007,0.0006993422,0.003692629,0.0008954325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007060334,0.00029249504,0.00045448705,0.0021604442,0.0006458545,0.005931961,0.0005667539,0.0024938304,0.009425937],"category_scores_gemma":[0.020067014,0.00018979721,0.0008747148,0.0025530816,0.002524644,0.002274471,0.0015671045,0.0023636771,0.0009247723],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030073672,0.00012235013,0.0049006706,0.0009472396,0.00020631244,0.00023546434,0.00016047875,0.008707556,0.000578313,0.8660137,0.03391442,0.0839127],"study_design_scores_gemma":[0.00027737644,0.0003818554,0.044458434,0.0042362637,0.00035980792,0.0003678617,0.00062986347,0.006172978,0.0035334397,0.32694423,0.6125127,0.00012522956],"about_ca_topic_score_codex":0.012349226,"about_ca_topic_score_gemma":0.0061846282,"teacher_disagreement_score":0.012349226,"about_ca_system_score_codex":0.011944901,"about_ca_system_score_gemma":0.007940894,"threshold_uncertainty_score":0.08666676},"labels":[],"label_agreement":null},{"id":"W2974685686","doi":"10.1186/s12992-019-0497-3","title":"A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications","year":2019,"lang":"en","type":"review","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"","keywords":"Intellectual property; Essential medicines; Formulary; Negotiation; Medicine; Treaty; Health policy; Public economics; Health care; Business; Economic growth; Political science; Economics; Family medicine; Law","score_opus":0.1973249682521508,"score_gpt":0.45781894500895015,"score_spread":0.26049397675679936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974685686","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003470143,0.9923496,0.00025971493,0.0042739683,0.0004757879,0.000015625425,0.00006692005,0.000004514944,0.0022069472],"genre_scores_gemma":[0.00321372,0.9936395,0.0004344005,0.0020820724,0.00026143828,0.000020435602,0.00006213376,0.0000045197307,0.00028161853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99064565,0.0033440266,0.0020493234,0.00071570685,0.002837424,0.00040794138],"domain_scores_gemma":[0.9527789,0.037635416,0.0039023133,0.000584712,0.004571665,0.00052699295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013419583,0.0008179301,0.00148282,0.012507196,0.001057693,0.0043641264,0.0013247877,0.0024195367,0.0029072561],"category_scores_gemma":[0.026342766,0.0006290912,0.0017738763,0.014155168,0.0022071819,0.0056894072,0.0017223245,0.003235588,0.00049502257],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007103308,0.000080471604,0.0015702915,0.11704148,0.00053342734,0.00040925667,0.0023659726,0.00090012857,0.000983782,0.0692323,0.092075035,0.71473694],"study_design_scores_gemma":[0.000010072003,0.000057939702,0.0042592064,0.13073549,0.000524535,0.00036775967,0.001074414,0.0001240596,0.00028382769,0.00737587,0.8551461,0.000040726194],"about_ca_topic_score_codex":0.009745335,"about_ca_topic_score_gemma":0.02332151,"teacher_disagreement_score":0.013419583,"about_ca_system_score_codex":0.0064136614,"about_ca_system_score_gemma":0.024456419,"threshold_uncertainty_score":0.070970416},"labels":[],"label_agreement":null},{"id":"W2978302277","doi":"10.22270/ijdra.v7i3.327","title":"Intellectual Property Right in India- A Review","year":2019,"lang":"en","type":"review","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure","funders":"","keywords":"Business; Intellectual property; Order (exchange); Quality (philosophy); Process (computing); Risk analysis (engineering); Marketing; Computer science; Law; Finance; Political science","score_opus":0.07087529224784708,"score_gpt":0.3310711663333638,"score_spread":0.2601958740855167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978302277","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011279241,0.9969573,0.000034662404,0.0005844157,0.00010066274,0.0000027868668,0.0000121144785,0.000002518238,0.0021927129],"genre_scores_gemma":[0.0019674886,0.99729735,0.000041406634,0.0002539632,0.00012547907,0.0000026705195,0.000012166459,0.0000010509024,0.0002984495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994129,0.000111580935,0.0000843791,0.000067238056,0.0002602889,0.00006362275],"domain_scores_gemma":[0.9973181,0.0018220358,0.00033533465,0.00006696416,0.00035915,0.0000983661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012182251,0.00054981105,0.0010307924,0.005146831,0.00057851314,0.0027413617,0.00093518,0.0012329385,0.005473107],"category_scores_gemma":[0.002486635,0.00032467165,0.00062261405,0.007481154,0.0019847278,0.0019947153,0.00088951836,0.0017038016,0.0010110707],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005211025,0.000092478986,0.00056473294,0.03990253,0.00013139904,0.00047267668,0.00022802709,0.0006244702,0.0004013589,0.040183917,0.064581774,0.85276455],"study_design_scores_gemma":[0.000010692261,0.00005938454,0.003840055,0.024533743,0.00015243425,0.0016116182,0.00021784489,0.00010931003,0.00026361673,0.006207742,0.96296746,0.000026086786],"about_ca_topic_score_codex":0.005944503,"about_ca_topic_score_gemma":0.00999409,"teacher_disagreement_score":0.005944503,"about_ca_system_score_codex":0.002818884,"about_ca_system_score_gemma":0.006908786,"threshold_uncertainty_score":0.0204525},"labels":[],"label_agreement":null},{"id":"W2979994774","doi":"10.1109/icesi.2019.8863026","title":"Comprehensive Literature Review about Drug Shortages in the Canadian Hospital's Pharmacy Supply Chain","year":2019,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"École de Technologie Supérieure","funders":"","keywords":"Supply chain; Pharmacy; Economic shortage; Compromise; Hospital pharmacy; Business; Health care; Drug; Medicine; Medical emergency; Operations management; Marketing; Family medicine; Pharmacology; Engineering; Economics; Government (linguistics)","score_opus":0.029414643803349506,"score_gpt":0.2862807713794999,"score_spread":0.2568661275761504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979994774","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024183507,0.98527664,0.00017858244,0.002944265,0.00019171381,0.000051494073,0.0012388568,0.000014091047,0.00768607],"genre_scores_gemma":[0.018293977,0.9791095,0.00056230207,0.0006145342,0.000112518566,0.00002592195,0.0006783305,0.0000041016206,0.0005988752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99729306,0.00035383683,0.00047103906,0.00019994963,0.001391808,0.00029034686],"domain_scores_gemma":[0.98054034,0.009628334,0.0020616036,0.00018145912,0.00696241,0.0006259214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003106376,0.00081136666,0.0014392657,0.03224912,0.002344495,0.0041700443,0.0014701609,0.0012845619,0.005722146],"category_scores_gemma":[0.012334061,0.0004983361,0.0012574735,0.07577579,0.001400127,0.0023804847,0.0010167859,0.00075739867,0.00045590723],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013172254,0.00008904009,0.013339889,0.30480695,0.00061427674,0.0016363467,0.0040956214,0.0017320127,0.00041793805,0.013424665,0.12486344,0.53484803],"study_design_scores_gemma":[0.000025586343,0.000091049646,0.06408137,0.2799685,0.002310511,0.001273656,0.009128471,0.00074893294,0.00043362423,0.0024587782,0.6393413,0.00013818477],"about_ca_topic_score_codex":0.81076527,"about_ca_topic_score_gemma":0.89516413,"teacher_disagreement_score":0.18923473,"about_ca_system_score_codex":0.03867202,"about_ca_system_score_gemma":0.12471126,"threshold_uncertainty_score":0.38069832},"labels":[],"label_agreement":null},{"id":"W2981787459","doi":"10.4212/cjhp.v72i5.2935","title":"Should Medical Devices Be Regulated as Rigorously as Drugs?","year":2019,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Medicine; Data science","score_opus":0.04366684319506033,"score_gpt":0.301962483706302,"score_spread":0.2582956405112417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981787459","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0117789395,0.013634352,0.007592605,0.8736853,0.008366582,0.000067392604,0.0002646983,0.00012758463,0.084482566],"genre_scores_gemma":[0.33170104,0.00535225,0.0056214184,0.62760913,0.009230619,0.00010143272,0.00017444693,0.00008843365,0.020121213],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.95802796,0.008752086,0.002701435,0.0042817146,0.02016946,0.0060673356],"domain_scores_gemma":[0.9197456,0.028177647,0.0137529895,0.008461182,0.023249377,0.0066131707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02828834,0.0005106226,0.0015506727,0.0017915623,0.0030297297,0.014421775,0.0034021745,0.028084358,0.00685905],"category_scores_gemma":[0.10676349,0.0005770546,0.0015775379,0.0014052745,0.018169219,0.01210514,0.003514974,0.020104926,0.0019108651],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017895113,0.00020420144,0.0054116207,0.00025903963,0.0001519121,0.0001894587,0.0005114488,0.00052199647,0.0008293007,0.8498425,0.1047546,0.037144996],"study_design_scores_gemma":[0.000272107,0.0002411325,0.02527783,0.0019994488,0.00026725553,0.00058767316,0.0015267902,0.0015036301,0.0025760988,0.62356853,0.34192353,0.0002558833],"about_ca_topic_score_codex":0.044426132,"about_ca_topic_score_gemma":0.055146504,"teacher_disagreement_score":0.044426132,"about_ca_system_score_codex":0.008259168,"about_ca_system_score_gemma":0.02650934,"threshold_uncertainty_score":0.1496048},"labels":[],"label_agreement":null},{"id":"W2981884241","doi":"10.3233/jrs-195007","title":"Affordability versus innovation: Is compulsory licensing the solution?","year":2019,"lang":"en","type":"review","venue":"International Journal of Risk & Safety in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Premise; Access to medicines; Intellectual property; Business; Investment (military); Life expectancy; Health technology; Public economics; Developing country; Politics; Health care; Economic growth; Economics; Political science; Medicine; Law; Environmental health","score_opus":0.19841033989054546,"score_gpt":0.4201610780763578,"score_spread":0.2217507381858123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981884241","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4007534,0.054213062,0.041561157,0.2911576,0.0013253724,0.0007361221,0.0005830326,0.00010718815,0.2095631],"genre_scores_gemma":[0.9801324,0.0065674223,0.0030651735,0.0067389267,0.00034254146,0.000116271534,0.00007480755,0.00001830167,0.0029441973],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9807396,0.006462817,0.0013019894,0.0017341813,0.0065480005,0.0032134876],"domain_scores_gemma":[0.94473135,0.037265904,0.010526059,0.0025539922,0.0027917,0.0021309378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017046755,0.00034959952,0.0010128784,0.0031184675,0.002339724,0.010124394,0.0019008766,0.005122025,0.009343704],"category_scores_gemma":[0.06974878,0.0002081068,0.0012015015,0.004147581,0.016241278,0.018001746,0.0069184713,0.0038047347,0.00038952642],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016479398,0.0001461299,0.024940763,0.0011486325,0.00012053768,0.0005715603,0.0035814107,0.001097246,0.000491605,0.85130495,0.0025169072,0.11391558],"study_design_scores_gemma":[0.00018277881,0.0006027589,0.041174967,0.004733524,0.00025382594,0.0016383836,0.019328319,0.0025870944,0.0019481592,0.7350819,0.19229019,0.00017805451],"about_ca_topic_score_codex":0.012714768,"about_ca_topic_score_gemma":0.013220489,"teacher_disagreement_score":0.017046755,"about_ca_system_score_codex":0.007261753,"about_ca_system_score_gemma":0.015036385,"threshold_uncertainty_score":0.09015292},"labels":[],"label_agreement":null},{"id":"W2982160900","doi":"10.1007/s40264-019-00871-w","title":"Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy","year":2019,"lang":"en","type":"article","venue":"Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Health care; Drug; Database; Pharmacology; Economic growth","score_opus":0.03774148058192039,"score_gpt":0.28706842246698766,"score_spread":0.24932694188506727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982160900","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02120364,0.02936006,0.016098537,0.8421106,0.0032043222,0.0005981754,0.007908406,0.00079183374,0.078724414],"genre_scores_gemma":[0.44842982,0.11427648,0.13573213,0.1085834,0.008170926,0.0019371314,0.057977144,0.0014295519,0.1234635],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.976939,0.010659415,0.0014301448,0.0013139175,0.0059502763,0.0037072673],"domain_scores_gemma":[0.8792513,0.037836555,0.005267968,0.007787371,0.041638616,0.028218156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.12528983,0.0008601541,0.0008131019,0.007090054,0.0041624,0.017283874,0.004767261,0.0051241983,0.015826462],"category_scores_gemma":[0.067154825,0.000747334,0.0011061254,0.012603201,0.003846315,0.013638357,0.008351343,0.0052227513,0.0023274447],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051415205,0.0006030203,0.024588628,0.00071113126,0.000071005954,0.0002085248,0.003716722,0.00180739,0.00074132107,0.116243035,0.5717843,0.27901068],"study_design_scores_gemma":[0.000098200755,0.00005700719,0.016475776,0.0013763655,0.000033306587,0.000108987006,0.003560762,0.0017369,0.00038987672,0.006236995,0.969875,0.000050644914],"about_ca_topic_score_codex":0.4249703,"about_ca_topic_score_gemma":0.32017443,"teacher_disagreement_score":0.95744216,"about_ca_system_score_codex":0.042557813,"about_ca_system_score_gemma":0.12043536,"threshold_uncertainty_score":0.8449934},"labels":[],"label_agreement":null},{"id":"W2983518626","doi":"10.1503/cmaj.191447","title":"Co-pay cards in Canada: Improving choice or institutionalizing bribes?","year":2019,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Carleton University","funders":"Health Canada","keywords":"Key (lock); Competition (biology); Computer science; Business; Operations research; Advertising; Computer security; Engineering","score_opus":0.03412926311961462,"score_gpt":0.2606043335636188,"score_spread":0.22647507044400417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983518626","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058316584,0.0024350737,0.00029579023,0.95295465,0.0015543927,0.000028665812,0.00015156089,0.000020306605,0.036727846],"genre_scores_gemma":[0.22866811,0.004444189,0.001017556,0.70646816,0.004494826,0.00006599384,0.00014141944,0.000061894396,0.054637793],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99192965,0.0010544247,0.00022338878,0.0006449818,0.0026126944,0.0035349587],"domain_scores_gemma":[0.9789252,0.008264637,0.0009355397,0.00063690357,0.0057758265,0.0054618777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074183103,0.00039094026,0.0008101588,0.0009188263,0.0118728345,0.0080258455,0.0031411885,0.026457077,0.018640948],"category_scores_gemma":[0.03914561,0.00039437893,0.0006061727,0.0013851204,0.007838118,0.0044093034,0.0029736778,0.021400431,0.0013724876],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018662792,0.00006199689,0.006679778,0.000085463886,0.00003293883,0.0007449151,0.0015350563,0.00029221384,0.0002136258,0.16083796,0.7828396,0.046489816],"study_design_scores_gemma":[0.0005854727,0.00009240675,0.016403217,0.0009238511,0.00011467886,0.00049543777,0.004038327,0.0028943336,0.00064596714,0.094301544,0.8792668,0.00023802926],"about_ca_topic_score_codex":0.9357819,"about_ca_topic_score_gemma":0.97190124,"teacher_disagreement_score":0.92235816,"about_ca_system_score_codex":0.07764183,"about_ca_system_score_gemma":0.17149028,"threshold_uncertainty_score":0.5633335},"labels":[],"label_agreement":null},{"id":"W2984254829","doi":"","title":"Comparaison des processus de mise sur le marché des médicaments et autres produits de santé entre le Canada et l'Europe sur l'année 2017-2018","year":2019,"lang":"fr","type":"article","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; European union; Art; Business","score_opus":0.04205244839686926,"score_gpt":0.26595383028397146,"score_spread":0.2239013818871022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984254829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7530501,0.029647302,0.0067711575,0.028356163,0.00066606293,0.00051234383,0.032296408,0.00029857786,0.14840186],"genre_scores_gemma":[0.88611275,0.0139459735,0.004826664,0.0017011123,0.00016716123,0.00018712512,0.0090856515,0.00012169857,0.08385195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99248743,0.0005289952,0.0002409097,0.00053735403,0.0048820614,0.0013232545],"domain_scores_gemma":[0.97934955,0.0035263707,0.002820943,0.00043581318,0.012082705,0.0017845682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005077909,0.00032705412,0.00052366237,0.004198586,0.0018541013,0.0063263974,0.000827082,0.00088011136,0.009454269],"category_scores_gemma":[0.013824069,0.00030912747,0.0009689849,0.0057378123,0.0011373997,0.0016386714,0.0013181688,0.001954154,0.0009320413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001985869,0.00038545526,0.5122674,0.0016575387,0.0012807451,0.00057171396,0.012579546,0.012092317,0.0032108242,0.07995522,0.053091075,0.32092234],"study_design_scores_gemma":[0.00005279549,0.00024058559,0.79639876,0.00068934256,0.00028366613,0.000092511254,0.00834467,0.0016716489,0.0027216747,0.0021178462,0.18727614,0.0001104518],"about_ca_topic_score_codex":0.9202364,"about_ca_topic_score_gemma":0.9477302,"teacher_disagreement_score":0.95825195,"about_ca_system_score_codex":0.04174806,"about_ca_system_score_gemma":0.057545353,"threshold_uncertainty_score":0.30290478},"labels":[],"label_agreement":null},{"id":"W2988982017","doi":"10.1177/0020731419886526","title":"Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia","year":2019,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; York University","funders":"","keywords":"Orphan drug; Government (linguistics); Food and drug administration; Drug; Business; Medicine; Political science; Environmental health; Pharmacology","score_opus":0.06257735410674499,"score_gpt":0.3923231565615992,"score_spread":0.32974580245485424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988982017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72805166,0.015490897,0.0005278159,0.059734177,0.00023508492,0.00016620252,0.0026334454,0.000039142837,0.19312155],"genre_scores_gemma":[0.9849685,0.0046268976,0.00028072813,0.0043729283,0.000054531043,0.000030973133,0.0004074931,0.000019048428,0.0052389908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99120295,0.0008282469,0.0003510141,0.00031921256,0.003854447,0.0034441964],"domain_scores_gemma":[0.98560554,0.0020852631,0.0018787463,0.0002951608,0.0061222613,0.004013094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002672232,0.00018216137,0.0005883923,0.0032064815,0.0031371925,0.0037822274,0.0009828531,0.0009865279,0.006081818],"category_scores_gemma":[0.01662437,0.00023279889,0.000698974,0.0057366863,0.001874034,0.002085708,0.002153823,0.0017784974,0.00020206565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019362635,0.00057229755,0.52479464,0.0016483538,0.00083568966,0.0025738082,0.017388638,0.0032722037,0.0019125087,0.18942407,0.06078153,0.19485998],"study_design_scores_gemma":[0.00014426751,0.0002401563,0.8888769,0.00084060547,0.00026601087,0.000494108,0.0108353365,0.0011783662,0.00042376708,0.0034279844,0.09316033,0.000112157926],"about_ca_topic_score_codex":0.97096395,"about_ca_topic_score_gemma":0.98131,"teacher_disagreement_score":0.044511925,"about_ca_system_score_codex":0.044511925,"about_ca_system_score_gemma":0.06019286,"threshold_uncertainty_score":0.32295817},"labels":[],"label_agreement":null},{"id":"W2993505955","doi":"10.1371/journal.pone.0225429","title":"Withdrawn medicines included in the essential medicines lists of 136 countries","year":2019,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"NIHR School for Primary Care Research; Canadian Institutes of Health Research; National Institute for Health and Care Research; Wellcome Trust","keywords":"Traditional medicine; Medicine; Pharmacology","score_opus":0.05401948122909569,"score_gpt":0.2696207607289425,"score_spread":0.21560127949984678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993505955","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16856298,0.7191954,0.0024541134,0.0038151362,0.00086437364,0.0054843156,0.083148584,0.00016940053,0.016305646],"genre_scores_gemma":[0.5514665,0.37458208,0.017947294,0.006268616,0.0005085555,0.0064531304,0.040967856,0.00011417456,0.0016916726],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9134217,0.014468488,0.05434222,0.0032104622,0.013378878,0.001178263],"domain_scores_gemma":[0.7645381,0.12001425,0.07574256,0.007292066,0.03126333,0.0011496326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047116384,0.0007202966,0.0024732314,0.03241185,0.0009998322,0.0024658872,0.0017789842,0.001440375,0.0031747841],"category_scores_gemma":[0.1349619,0.0010863806,0.005180101,0.033488005,0.0014589486,0.0033948356,0.002530436,0.00085050124,0.0006080951],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022673467,0.000061491206,0.12767564,0.6323295,0.0068752277,0.002739398,0.0056936303,0.00048402915,0.0021179938,0.0018492701,0.014598397,0.20330808],"study_design_scores_gemma":[0.00083503494,0.00088918506,0.31851873,0.45417088,0.026975246,0.0042325663,0.0053782035,0.00035866673,0.005841401,0.0012083614,0.18128242,0.00030924697],"about_ca_topic_score_codex":0.010351418,"about_ca_topic_score_gemma":0.024243928,"teacher_disagreement_score":0.047116384,"about_ca_system_score_codex":0.00559212,"about_ca_system_score_gemma":0.018875109,"threshold_uncertainty_score":0.24917823},"labels":[],"label_agreement":null},{"id":"W2995633581","doi":"","title":"Pharmacy Associations Offer Perspective on Canada Drug Import Proposal","year":2019,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Perspective (graphical); Drug; Business; Medicine; Pharmacology; Family medicine; Computer science","score_opus":0.03333513892710892,"score_gpt":0.2903337143017926,"score_spread":0.2569985753746837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995633581","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010277249,0.0055391444,0.00064658106,0.7438318,0.005226532,0.000106707805,0.0011874092,0.000073084215,0.23311149],"genre_scores_gemma":[0.1603034,0.0062863906,0.001385787,0.43884242,0.005902015,0.00010187123,0.00040735243,0.00012436326,0.3866463],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912238,0.0006371427,0.00018318465,0.000568823,0.0046819323,0.0027051088],"domain_scores_gemma":[0.9888677,0.0031442798,0.00037895943,0.00020415457,0.005717619,0.0016872478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042514065,0.00070463395,0.0007099731,0.0026149387,0.014091039,0.017130284,0.0017994471,0.032508813,0.023657553],"category_scores_gemma":[0.017801603,0.00065886386,0.0014024008,0.0029634812,0.0049378914,0.0034390076,0.0021596332,0.015597721,0.0020312965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007496915,0.000048470654,0.0017250173,0.00006419738,0.000020056825,0.0005967789,0.0006239064,0.00088137365,0.00026539052,0.32751286,0.6603808,0.0078062788],"study_design_scores_gemma":[0.000081475046,0.000029626455,0.0045408956,0.00014298254,0.000038584356,0.000120553304,0.001635718,0.0009212302,0.00034054392,0.029559374,0.9624383,0.00015077053],"about_ca_topic_score_codex":0.9393925,"about_ca_topic_score_gemma":0.97225213,"teacher_disagreement_score":0.0790617,"about_ca_system_score_codex":0.0790617,"about_ca_system_score_gemma":0.13526012,"threshold_uncertainty_score":0.57363546},"labels":[],"label_agreement":null},{"id":"W2995889671","doi":"10.1016/j.jval.2019.09.2661","title":"PSY33 HTA REVIEW OF DECISIONS FOR PRODUCTS INDICATED IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND LUPUS NEPHRITIS (N) IN UK, GERMANY, FRANCE, ITALY, SPAIN, CANADA AND TURKEY","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Belimumab; Medicine; Lupus nephritis; Rituximab; Systemic lupus erythematosus; European union; Reimbursement; Disease; Dermatology; Immunology; Internal medicine; Lymphoma","score_opus":0.04953274642682193,"score_gpt":0.28781476204506123,"score_spread":0.2382820156182393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995889671","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005423272,0.9668674,0.00046482004,0.008785311,0.0010731557,0.000059003214,0.0023521755,0.00002636189,0.014948458],"genre_scores_gemma":[0.08367438,0.89736426,0.0019086406,0.004915073,0.0012370114,0.00007986011,0.002399716,0.000033242522,0.008387718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981218,0.00073650264,0.00028557377,0.00012969656,0.00058953743,0.00013684075],"domain_scores_gemma":[0.9914315,0.0045724576,0.0013247922,0.00010210412,0.0023153268,0.00025388578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034940506,0.00036467437,0.00077573804,0.0029696007,0.000216975,0.001641597,0.0006181696,0.0009620682,0.009852456],"category_scores_gemma":[0.010752861,0.00024329178,0.0014142353,0.0044396077,0.0002925207,0.0007293456,0.0003454519,0.0009040914,0.0008571882],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013045745,0.000067628076,0.0045199296,0.020589557,0.0008182892,0.0002860121,0.00010692282,0.0030744593,0.00033984444,0.0064931745,0.18735689,0.7750427],"study_design_scores_gemma":[0.0003147723,0.00037324673,0.05572686,0.038545005,0.0017433242,0.0005194402,0.00028632997,0.0010425791,0.0006660871,0.0018843081,0.8988456,0.000052392],"about_ca_topic_score_codex":0.028256245,"about_ca_topic_score_gemma":0.044047624,"teacher_disagreement_score":0.97174376,"about_ca_system_score_codex":0.005412352,"about_ca_system_score_gemma":0.0067329793,"threshold_uncertainty_score":0.056183517},"labels":[],"label_agreement":null},{"id":"W2996570620","doi":"10.1016/j.jval.2019.09.2408","title":"PRO78 THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Orphan drug; Medicine; Drug; Population; Public health; Environmental health; Pharmacology; Bioinformatics","score_opus":0.04297398827064129,"score_gpt":0.306910077215501,"score_spread":0.2639360889448597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996570620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68943304,0.022248043,0.0021148748,0.044391673,0.0004395279,0.0007016035,0.104280785,0.00015381486,0.13623665],"genre_scores_gemma":[0.93634486,0.010066063,0.00230745,0.0019361984,0.00016071677,0.00014535789,0.011776847,0.000060830927,0.037201565],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9963565,0.00036050464,0.00010798567,0.00013542331,0.0016934825,0.0013461936],"domain_scores_gemma":[0.9942946,0.0009881523,0.00049567514,0.00009790548,0.003285289,0.00083835726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00216282,0.0005501413,0.0007058807,0.00405163,0.0021789023,0.003996334,0.0010818976,0.0013088444,0.008821743],"category_scores_gemma":[0.009582551,0.0005702165,0.001464248,0.0071913097,0.00082501024,0.0011095533,0.0008855311,0.0017542636,0.0002863715],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028016542,0.00066761905,0.33341682,0.0013761261,0.0016765344,0.0011342084,0.0012882035,0.13067362,0.00079750555,0.20304619,0.19505763,0.12806387],"study_design_scores_gemma":[0.00090750086,0.00033840374,0.6657506,0.001185422,0.001999794,0.00048972626,0.004324291,0.092312045,0.001456761,0.021152308,0.2097593,0.0003238551],"about_ca_topic_score_codex":0.99593544,"about_ca_topic_score_gemma":0.997482,"teacher_disagreement_score":0.15646146,"about_ca_system_score_codex":0.15646146,"about_ca_system_score_gemma":0.16953582,"threshold_uncertainty_score":0.97838515},"labels":[],"label_agreement":null},{"id":"W2996599204","doi":"10.1093/heapol/czz084","title":"How does performance-based financing affect the availability of essential medicines in Cameroon? A qualitative study","year":2019,"lang":"en","type":"article","venue":"Health Policy and Planning","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research; Alliance for Health Policy and Systems Research","keywords":"Nonprobability sampling; Accountability; Essential medicines; Business; Qualitative research; Autonomy; Health care; Thematic analysis; Pharmacy; Health facility; Psychological intervention; Payment; Nursing; Medicine; Environmental health; Public health; Finance; Economic growth; Population; Health services","score_opus":0.08255505547302189,"score_gpt":0.3981021488320766,"score_spread":0.31554709335905473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996599204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942042,0.0006630262,0.000645472,0.002102852,0.000046493624,0.00013617726,0.00009035891,0.0000045569204,0.0021068195],"genre_scores_gemma":[0.9975594,0.0005909979,0.00037725465,0.00037698777,0.000011397259,0.00013046607,0.000025435344,0.000003288489,0.00092469854],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9957514,0.0029602665,0.00009883131,0.00017725943,0.0001597129,0.00085250183],"domain_scores_gemma":[0.99302423,0.0051281364,0.000676016,0.00010328436,0.00040201272,0.0006663184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006697278,0.0004448328,0.00042760596,0.0012088375,0.0062211305,0.0021048507,0.00084259897,0.0011161689,0.0037891513],"category_scores_gemma":[0.008406452,0.00047802468,0.0002633121,0.0014122301,0.005432848,0.0027097282,0.0021324302,0.0015389827,0.00015523218],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009445934,0.00010330878,0.017062834,0.00048006888,0.000008155343,0.0043143597,0.9632177,0.00015949071,0.001984965,0.0025909783,0.00093591,0.009047771],"study_design_scores_gemma":[0.0000035790829,0.00008190076,0.006675983,0.0002522264,0.0000051900834,0.0004154572,0.9866079,0.00013379708,0.00031006598,0.00017945739,0.0053206948,0.000013772636],"about_ca_topic_score_codex":0.016266027,"about_ca_topic_score_gemma":0.020974431,"teacher_disagreement_score":0.016266027,"about_ca_system_score_codex":0.006386741,"about_ca_system_score_gemma":0.004439222,"threshold_uncertainty_score":0.046339273},"labels":[],"label_agreement":null},{"id":"W2997149761","doi":"10.1016/j.healthpol.2019.12.010","title":"Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature","year":2019,"lang":"en","type":"review","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University; University of British Columbia","funders":"","keywords":"Formulary; Medicine; Concordance; Family medicine; Variety (cybernetics); Transparency (behavior); Medical prescription; Variation (astronomy); Alternative medicine; MEDLINE; Specialty; Inclusion (mineral); Actuarial science; Business; Psychology; Political science; Computer science; Nursing","score_opus":0.13748444372214425,"score_gpt":0.46242274539414563,"score_spread":0.3249383016720014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997149761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001597145,0.9970747,0.00011695555,0.0021298265,0.00020380474,0.00003471419,0.000116264506,0.000003906784,0.00016009332],"genre_scores_gemma":[0.004338615,0.9934331,0.00058106775,0.0011770056,0.00018794493,0.000114529284,0.0001181938,0.000003863502,0.000045692224],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9812533,0.006024859,0.0065647806,0.0021684568,0.0033684773,0.00062009745],"domain_scores_gemma":[0.8602569,0.11053445,0.014681777,0.0016474037,0.01194428,0.00093517447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0302192,0.0016079189,0.0059033604,0.027656687,0.0010627947,0.005983452,0.0034669307,0.0032164874,0.005480002],"category_scores_gemma":[0.10623938,0.0014129793,0.0062421104,0.025111351,0.002054597,0.0070415293,0.0030805317,0.0030393316,0.00055551727],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013300666,0.00005411725,0.0033388273,0.66889465,0.0042621004,0.00017581576,0.000994654,0.00043842496,0.00015437815,0.0059938594,0.014916041,0.30064416],"study_design_scores_gemma":[0.000054385422,0.000062897394,0.007845405,0.88644594,0.009360287,0.00027113213,0.0012195414,0.00016908428,0.00013355643,0.0038028078,0.090576075,0.000058822552],"about_ca_topic_score_codex":0.02511372,"about_ca_topic_score_gemma":0.040197518,"teacher_disagreement_score":0.0302192,"about_ca_system_score_codex":0.010894571,"about_ca_system_score_gemma":0.033452157,"threshold_uncertainty_score":0.15981632},"labels":[],"label_agreement":null},{"id":"W2998196003","doi":"","title":"Les ruptures de médicaments : comparaison transversale entre la France, la Belgique, l'Espagne, la Suisse et le Canada","year":2018,"lang":"fr","type":"article","venue":"ORBi (University of Liège)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.022543386939042596,"score_gpt":0.24743892405230075,"score_spread":0.22489553711325816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998196003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858803,0.007073337,0.00022472351,0.00050317176,0.000018182904,0.000018627417,0.004635089,0.0000093129765,0.0016372919],"genre_scores_gemma":[0.9923286,0.002956648,0.00019622635,0.00010872725,0.000033478358,0.000023747478,0.0026104283,0.000009731735,0.0017323812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669135,0.00090939156,0.0003754828,0.00050187774,0.00065570604,0.0008661579],"domain_scores_gemma":[0.98688203,0.004002217,0.005916722,0.00025174246,0.001827572,0.0011196382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002548556,0.0004250298,0.0009812771,0.0059599276,0.000962648,0.0033112247,0.000845376,0.001587281,0.005267946],"category_scores_gemma":[0.0068588327,0.0005491046,0.0016764108,0.009386576,0.001048295,0.001472641,0.0013751823,0.0016905174,0.00044288544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041095272,0.00016126693,0.9907968,0.00007995224,0.00082584145,0.0001244908,0.001155669,0.000411521,0.000096431155,0.00058093295,0.00053883065,0.0048172493],"study_design_scores_gemma":[0.000013126363,0.00009247496,0.99637955,0.000077121585,0.00013308764,0.000107057094,0.0016744783,0.0001657965,0.000045366636,0.000052314568,0.0012447315,0.000014774646],"about_ca_topic_score_codex":0.5883194,"about_ca_topic_score_gemma":0.59522074,"teacher_disagreement_score":0.41168058,"about_ca_system_score_codex":0.008824337,"about_ca_system_score_gemma":0.0064280964,"threshold_uncertainty_score":0.8282101},"labels":[],"label_agreement":null},{"id":"W2998221831","doi":"10.1016/j.sapharm.2019.12.015","title":"Did citizen petitions prolong the number of approval days of generic drugs?","year":2019,"lang":"en","type":"article","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicine; Value (mathematics); Statistics; Geography; Mathematics","score_opus":0.3508905521151091,"score_gpt":0.48007574395070096,"score_spread":0.12918519183559185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998221831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91511816,0.0021490308,0.0019626128,0.047077976,0.00083501544,0.00005920155,0.0013111173,0.000057383008,0.031429566],"genre_scores_gemma":[0.9941195,0.00022280058,0.000114193834,0.0017877712,0.00023431321,0.000015387583,0.00015392406,0.000010593022,0.0033415435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996811,0.0011309191,0.0001722788,0.00040368896,0.00043043646,0.0010516689],"domain_scores_gemma":[0.92370605,0.0408828,0.02294833,0.002311854,0.004954874,0.005195965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064077117,0.00015689647,0.000504254,0.00046835284,0.0010420156,0.0027702267,0.00064369023,0.003775636,0.015790563],"category_scores_gemma":[0.0630286,0.00035621255,0.00080455455,0.00052610284,0.0011697091,0.0030631342,0.0010123425,0.0047605378,0.0012641792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076838825,0.0020128605,0.7676391,0.0004354424,0.000737843,0.0010027767,0.002794612,0.0046596616,0.001973776,0.07321616,0.04315958,0.09468438],"study_design_scores_gemma":[0.00063442765,0.002133805,0.8496016,0.0003471096,0.00065375585,0.0007991797,0.0059958003,0.010447641,0.0023007684,0.05682664,0.07012732,0.0001318934],"about_ca_topic_score_codex":0.012531613,"about_ca_topic_score_gemma":0.023282798,"teacher_disagreement_score":0.015790563,"about_ca_system_score_codex":0.0021616993,"about_ca_system_score_gemma":0.0032617922,"threshold_uncertainty_score":0.052824676},"labels":[],"label_agreement":null},{"id":"W2999258267","doi":"10.1136/bmj.l4627","title":"Pricing of pharmaceuticals is becoming a major challenge for health systems","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"World Health Organization","keywords":"Drug pricing; Business; Market power; Healthcare system; Industrial organization; Risk analysis (engineering); Economics; Computer science; Health care; Marketing; Microeconomics; Actuarial science; Economic growth","score_opus":0.26048616987151846,"score_gpt":0.4106091592542288,"score_spread":0.15012298938271035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999258267","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025493707,0.0016076326,0.00044598346,0.9895271,0.0031739294,0.000004177366,0.000013608882,0.000018523582,0.0049541127],"genre_scores_gemma":[0.039859835,0.014365639,0.0037664887,0.88293266,0.043385625,0.000041182608,0.000074654185,0.00010622172,0.015467735],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9593154,0.011668381,0.0016447218,0.0019279646,0.022947438,0.002496089],"domain_scores_gemma":[0.8492751,0.08860494,0.008488078,0.006109729,0.031823315,0.015698742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028515248,0.0008770043,0.0013301185,0.0018035595,0.004959477,0.019421762,0.0024076207,0.028671023,0.017660338],"category_scores_gemma":[0.12706779,0.0007308749,0.0016542186,0.0019050882,0.010155349,0.016301148,0.0049083414,0.028118394,0.0065453392],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044914388,0.000089686386,0.0007575662,0.0001958096,0.00008141668,0.00010318844,0.00036833924,0.0006428308,0.00025084417,0.12843038,0.82482064,0.0442144],"study_design_scores_gemma":[0.00008520886,0.00009306165,0.0012914492,0.0005979344,0.00004863396,0.0001988396,0.0011398498,0.0011992609,0.00028099716,0.2511564,0.7438099,0.0000985151],"about_ca_topic_score_codex":0.009444811,"about_ca_topic_score_gemma":0.013468972,"teacher_disagreement_score":0.028671023,"about_ca_system_score_codex":0.010334008,"about_ca_system_score_gemma":0.024668181,"threshold_uncertainty_score":0.15080488},"labels":[],"label_agreement":null},{"id":"W2999388575","doi":"10.15171/ijhpm.2020.03","title":"It’s Time to Finally Kill the Zombies Comment on \"Universal Pharmacare in Canada\"","year":2020,"lang":"en","type":"letter","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Underinsured; Multinational corporation; Cover (algebra); Plan (archaeology); Political science; Public administration; Law; History; Engineering; Health insurance; Health care","score_opus":0.06739283782282568,"score_gpt":0.3337474092298733,"score_spread":0.2663545714070476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999388575","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030727047,0.0009199737,0.000045078366,0.98368627,0.0052461005,0.000010539787,0.00011567983,0.000021809494,0.009647298],"genre_scores_gemma":[0.0031894746,0.0003501214,0.00008094385,0.9720622,0.0021156082,0.00001464035,0.000027647808,0.000026529722,0.022132866],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960522,0.0004775422,0.00018147076,0.00032088193,0.0017479683,0.0012199747],"domain_scores_gemma":[0.99088097,0.0032727085,0.0003450883,0.00014176396,0.0035940362,0.001765556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037803485,0.00057328946,0.00093001965,0.00089641946,0.014849872,0.005820056,0.0028307496,0.04410394,0.014012504],"category_scores_gemma":[0.018441383,0.000679689,0.0010598117,0.0013392696,0.0050051305,0.0033592083,0.0015057614,0.030388275,0.004981785],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010308131,0.000005028963,0.00018181697,0.000012484191,0.000002257692,0.00011533186,0.00016464047,0.000031240812,0.00002709955,0.0031170014,0.9951213,0.0012114313],"study_design_scores_gemma":[0.00003704977,0.0000102850145,0.0022089898,0.00019935958,0.000015099821,0.00010565454,0.0018960619,0.00028607887,0.00012172053,0.004016176,0.99102134,0.00008226956],"about_ca_topic_score_codex":0.8653541,"about_ca_topic_score_gemma":0.9307039,"teacher_disagreement_score":0.9661039,"about_ca_system_score_codex":0.03389608,"about_ca_system_score_gemma":0.07097785,"threshold_uncertainty_score":0.2708776},"labels":[],"label_agreement":null},{"id":"W2999591574","doi":"10.1136/bmj.l4408","title":"New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pooling; Business; Business model; Marketing; Risk analysis (engineering); Finance; Process management; Computer science","score_opus":0.4007367688829906,"score_gpt":0.40736535361088905,"score_spread":0.006628584727898457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999591574","genre_codex":"methods","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041128756,0.0051449593,0.47773898,0.42094257,0.0031340832,0.0004325788,0.00047863432,0.0008945495,0.087120846],"genre_scores_gemma":[0.30299643,0.011872833,0.57644564,0.057379264,0.009099127,0.0014835283,0.0009319988,0.0011565052,0.03863454],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9753905,0.014224107,0.0011525594,0.0016109182,0.006242519,0.0013794177],"domain_scores_gemma":[0.9203773,0.05371054,0.004908702,0.006847788,0.010029218,0.004126479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03412214,0.0018452975,0.0021723837,0.002544541,0.0022496958,0.014941392,0.0037513163,0.009080334,0.028095001],"category_scores_gemma":[0.083580665,0.0013785168,0.0031761578,0.002492505,0.008127265,0.029163897,0.004262321,0.013658198,0.009079999],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002883413,0.00006682662,0.0003589903,0.000111613816,0.00003698508,0.000038526676,0.00009829278,0.0064915726,0.000098306096,0.9537101,0.024808511,0.01415132],"study_design_scores_gemma":[0.000046180467,0.00001916223,0.00024235771,0.000115613846,0.000016070699,0.00005093978,0.00012455936,0.017526345,0.00005242778,0.9289809,0.052778456,0.000047036803],"about_ca_topic_score_codex":0.006059259,"about_ca_topic_score_gemma":0.006561144,"teacher_disagreement_score":0.03412214,"about_ca_system_score_codex":0.012790169,"about_ca_system_score_gemma":0.008607381,"threshold_uncertainty_score":0.1804573},"labels":[],"label_agreement":null},{"id":"W3000339863","doi":"10.1136/bmjinnov-2019-000370","title":"Switching among branded and generic medication products during ongoing treatment of psychiatric illness","year":2020,"lang":"en","type":"article","venue":"BMJ Innovations","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; Pfizer (Canada); University of Toronto; Dalhousie University; Thornhill Medical (Canada)","funders":"Pfizer Canada; Pfizer","keywords":"Tolerability; Pharmacy; Medicine; Generic drug; Drug; Product (mathematics); Intensive care medicine; Psychiatry; Pharmacology; Adverse effect; Family medicine","score_opus":0.07910411897296551,"score_gpt":0.3016740841160494,"score_spread":0.2225699651430839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000339863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8500876,0.017485991,0.012070034,0.041928984,0.00043052222,0.00040561781,0.0027880406,0.00008257225,0.074720815],"genre_scores_gemma":[0.99013525,0.0034555814,0.0012035094,0.0009395546,0.00026269778,0.000050066465,0.0003360052,0.000006289238,0.0036110394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703586,0.0015167432,0.00022680862,0.00023510346,0.00059758284,0.0003879241],"domain_scores_gemma":[0.9835058,0.008729629,0.0057218103,0.00044818455,0.0005487613,0.001045824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040607275,0.0001480944,0.00040111187,0.0009196601,0.00056198123,0.0017433895,0.00052720244,0.001578655,0.0101394905],"category_scores_gemma":[0.02018847,0.00020853683,0.0008353453,0.0010234392,0.00089886517,0.0014551101,0.00067339686,0.001546761,0.0005236184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027717834,0.0014191984,0.42873296,0.001185814,0.00063272397,0.0035375592,0.0011587479,0.024543114,0.0019346928,0.14042561,0.015853515,0.37780428],"study_design_scores_gemma":[0.00076226745,0.0020332842,0.7106335,0.001755052,0.0005196019,0.004227554,0.0027850785,0.062437475,0.0015308923,0.15598182,0.05713739,0.00019604719],"about_ca_topic_score_codex":0.00879445,"about_ca_topic_score_gemma":0.008614851,"teacher_disagreement_score":0.0101394905,"about_ca_system_score_codex":0.0032308025,"about_ca_system_score_gemma":0.0014354802,"threshold_uncertainty_score":0.03391999},"labels":[],"label_agreement":null},{"id":"W3000585251","doi":"10.1200/jgo.19.00300","title":"Access to WHO Essential Medicines for Childhood Cancer Care in Trinidad and Tobago: A Health System Analysis of Barriers and Enablers","year":2020,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Public Health Ontario; University of Toronto; University of British Columbia","funders":"Hospital for Sick Children","keywords":"Essential medicines; Access to medicines; Procurement; Business; Incentive; Context (archaeology); Childhood cancer; Qualitative research; Health care; Medicine; Family medicine; Cancer; Nursing; Public economics; Economic growth; Marketing; Economics; Geography; Sociology","score_opus":0.04562358146426952,"score_gpt":0.3757707441144798,"score_spread":0.33014716265021027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000585251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951036,0.00031586524,0.00026028173,0.0010210646,0.0000053521258,0.00018204867,0.0011333802,0.000009544164,0.0019689712],"genre_scores_gemma":[0.997163,0.00040020212,0.0005017776,0.00015621912,0.0000029330051,0.00030398654,0.00092107605,0.0000052454034,0.0005455054],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9983334,0.00062601815,0.000090825786,0.00013421364,0.00014669132,0.0006688039],"domain_scores_gemma":[0.9954548,0.0018243858,0.0010672313,0.00018820423,0.00094552804,0.0005199187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002691549,0.00032384097,0.00033356357,0.0032686251,0.0012709541,0.001852302,0.0010386746,0.0004222174,0.0031756852],"category_scores_gemma":[0.006578426,0.00030961947,0.0004593357,0.0055793193,0.001049758,0.0012584938,0.0036136017,0.000751063,0.00009910792],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015208435,0.00016733923,0.9144877,0.0010527308,0.000208232,0.0012273527,0.04804895,0.0021970035,0.000637886,0.0025223468,0.0025443528,0.026753906],"study_design_scores_gemma":[0.000021295327,0.00010711809,0.8605327,0.0006551883,0.00009728614,0.00014034918,0.13209936,0.0018083238,0.00014586562,0.00047818053,0.0038842137,0.000030153997],"about_ca_topic_score_codex":0.6627191,"about_ca_topic_score_gemma":0.65029395,"teacher_disagreement_score":0.6627191,"about_ca_system_score_codex":0.022779984,"about_ca_system_score_gemma":0.02483219,"threshold_uncertainty_score":0.6785345},"labels":[],"label_agreement":null},{"id":"W3001328276","doi":"10.1007/s43441-020-00114-6","title":"Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation","year":2020,"lang":"en","type":"review","venue":"Therapeutic Innovation & Regulatory Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Authorization; Competitor analysis; Business; Competition (biology); Product (mathematics); Harmonization; Law and economics; Medicine; Marketing; Computer science; Economics; Computer security; Biology","score_opus":0.14794574260159118,"score_gpt":0.3219237387184541,"score_spread":0.1739779961168629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001328276","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028367637,0.9967975,0.00014379036,0.0013418326,0.000085402506,0.000006870329,0.00007999117,0.0000033581935,0.0012575507],"genre_scores_gemma":[0.0031244634,0.99504423,0.0003671462,0.00094825466,0.00007490142,0.000007073837,0.00007554851,0.0000030999533,0.00035530535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987355,0.00026304237,0.00014557535,0.00015829083,0.0005584711,0.0001391244],"domain_scores_gemma":[0.99524057,0.0030597586,0.00064119784,0.00009640976,0.0008388309,0.00012331514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004025175,0.0006875002,0.00226618,0.0028125835,0.0003372615,0.0034749813,0.0013898343,0.0019599136,0.005660094],"category_scores_gemma":[0.005004269,0.0003456939,0.0013402457,0.005297946,0.0015803891,0.0024820406,0.0010207663,0.0027583935,0.0006492414],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030090392,0.00006744564,0.00043395004,0.04212422,0.0004090652,0.00016358426,0.00015405045,0.0017308585,0.00073962193,0.07023484,0.026628463,0.8570129],"study_design_scores_gemma":[0.00008158191,0.00008600093,0.003554754,0.028001748,0.0005262971,0.0004030577,0.00020680449,0.00039931398,0.0003080593,0.014257852,0.95212805,0.000046371773],"about_ca_topic_score_codex":0.045131464,"about_ca_topic_score_gemma":0.093665875,"teacher_disagreement_score":0.9925703,"about_ca_system_score_codex":0.0074297367,"about_ca_system_score_gemma":0.014782776,"threshold_uncertainty_score":0.089737535},"labels":[],"label_agreement":null},{"id":"W3001960456","doi":"10.26633/rpsp.2020.5","title":"A comparison of national essential medicines lists in the Americas","year":2020,"lang":"en","type":"article","venue":"Revista Panamericana de Salud Pública","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Essential medicines; Geography; Latin Americans; Public health; Business; Political science; Medicine; Library science; Computer science","score_opus":0.1179361448584686,"score_gpt":0.38490938613814274,"score_spread":0.26697324127967414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001960456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66877306,0.026271187,0.0050512305,0.00744176,0.00096970773,0.00082295743,0.19208404,0.00052551745,0.09806053],"genre_scores_gemma":[0.84766716,0.006119764,0.008962613,0.0030113815,0.00032964963,0.0006960411,0.13036898,0.00015227363,0.0026921362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99002224,0.0026863012,0.0023583516,0.0010356011,0.003186015,0.00071141555],"domain_scores_gemma":[0.96300596,0.009534927,0.01033976,0.0012598069,0.014769862,0.0010897402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010110554,0.00034868467,0.00056447,0.010505466,0.0004710549,0.0019055714,0.0006065614,0.00043992617,0.005635652],"category_scores_gemma":[0.0318864,0.0002488348,0.0012646177,0.014101702,0.0004760628,0.0027339398,0.0021875394,0.0007124077,0.0009937258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039921436,0.00025886745,0.59349275,0.009434186,0.003884627,0.00028727922,0.004523148,0.0027139818,0.0020107478,0.011224574,0.113507986,0.25466967],"study_design_scores_gemma":[0.00016623952,0.00041425283,0.8902534,0.002347792,0.00066192995,0.0003241937,0.007845459,0.0013719785,0.0009876225,0.0018368446,0.09369726,0.00009288349],"about_ca_topic_score_codex":0.021279728,"about_ca_topic_score_gemma":0.028286505,"teacher_disagreement_score":0.021279728,"about_ca_system_score_codex":0.0035771364,"about_ca_system_score_gemma":0.003661048,"threshold_uncertainty_score":0.053470373},"labels":[],"label_agreement":null},{"id":"W3004553411","doi":"10.1177/0020731420902600","title":"A Critical Discourse Analysis of Intellectual Property Rights Within NAFTA 1.0: Implications for NAFTA 2.0 and for Democratic (Health) Governance in Canada","year":2020,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Intellectual property; Ratification; Government (linguistics); Competition (biology); International trade; Democracy; Business; Economics; Political science; Law; Politics","score_opus":0.07331061639543,"score_gpt":0.37268528562620973,"score_spread":0.2993746692307797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004553411","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30096346,0.010153458,0.01077696,0.15052351,0.00043629174,0.0005203469,0.00082510646,0.000076504024,0.52572435],"genre_scores_gemma":[0.97831,0.0019930166,0.0033403675,0.0037411305,0.00006477478,0.00012804485,0.00015378077,0.000034785175,0.012234146],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9904046,0.0031415715,0.00028957234,0.00082987134,0.0030236265,0.0023107184],"domain_scores_gemma":[0.98314214,0.010291574,0.0009973635,0.00032556735,0.004301161,0.00094230036],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.01243893,0.0007756471,0.0007902002,0.005082264,0.037103057,0.022673734,0.0023093226,0.005370907,0.0038609034],"category_scores_gemma":[0.01578059,0.00045678508,0.0006383939,0.0072300835,0.056620643,0.007290209,0.004782518,0.007152365,0.00022407279],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000017597677,0.000013752953,0.0010278819,0.00008314366,0.000005488994,0.0004098008,0.35158494,0.00024122812,0.00023509913,0.6365224,0.004306445,0.005552283],"study_design_scores_gemma":[0.000024787949,0.000013694297,0.0047392417,0.0009459529,0.000041590418,0.00016627459,0.60653365,0.0013706378,0.0007010403,0.09751721,0.2878684,0.00007748092],"about_ca_topic_score_codex":0.9690008,"about_ca_topic_score_gemma":0.94617975,"teacher_disagreement_score":0.96289694,"about_ca_system_score_codex":0.27004364,"about_ca_system_score_gemma":0.2432163,"threshold_uncertainty_score":0.8466459},"labels":[],"label_agreement":null},{"id":"W3006990860","doi":"10.3917/vaca.089.0132","title":"Le Conseil constitutionnel contre la transparence du prix des médicaments","year":2020,"lang":"fr","type":"article","venue":"Vacarme","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux des Laurentides","funders":"","keywords":"Political science; Philosophy","score_opus":0.07406654749651886,"score_gpt":0.2618192328633744,"score_spread":0.18775268536685552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006990860","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13122673,0.04308527,0.062912315,0.36107853,0.006901012,0.00026300567,0.00106828,0.0006216312,0.39284316],"genre_scores_gemma":[0.90696746,0.0052045165,0.012170112,0.016394874,0.005227179,0.0003422033,0.00019489382,0.00018329736,0.053315368],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9451886,0.019881455,0.0026638126,0.004203907,0.02412602,0.003936147],"domain_scores_gemma":[0.88928926,0.079850264,0.0081967665,0.0050426195,0.014472784,0.0031481765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030887725,0.000747387,0.0016068965,0.0023002503,0.0032232993,0.020021955,0.0022040568,0.013848134,0.010841732],"category_scores_gemma":[0.10731646,0.0010798852,0.0013819173,0.0015494138,0.005541899,0.008552538,0.0030940527,0.01624274,0.0018026592],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034242176,0.00012957434,0.0017529769,0.00017151002,0.00012514682,0.00015001472,0.00029294248,0.002986116,0.0013926968,0.94585603,0.015135498,0.03166514],"study_design_scores_gemma":[0.000856531,0.0007651941,0.028835913,0.0016942277,0.0002824984,0.0010508148,0.00068047224,0.028071225,0.006183755,0.53581774,0.3954312,0.00033054664],"about_ca_topic_score_codex":0.024745842,"about_ca_topic_score_gemma":0.013533314,"teacher_disagreement_score":0.030887725,"about_ca_system_score_codex":0.015431716,"about_ca_system_score_gemma":0.019250097,"threshold_uncertainty_score":0.16335183},"labels":[],"label_agreement":null},{"id":"W3010104093","doi":"10.1161/circ.141.suppl_1.p373","title":"Abstract P373: Are Generic Drugs Used in Cardiology as Effective and Safe as Their Brand-name Counterparts? A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institut National de Santé Publique du Québec; Université du Québec à Trois-Rivières","funders":"","keywords":"Medicine; Meta-analysis; Confidence interval; MEDLINE; Systematic review; Publication bias; Subgroup analysis; Relative risk; Generic drug; Internal medicine; Brand names; Intensive care medicine; Drug; Pharmacology","score_opus":0.12818646474173778,"score_gpt":0.34098992793424626,"score_spread":0.21280346319250848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010104093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029846127,0.994201,0.0005939343,0.00041506477,0.00021963227,0.00067081075,0.00061004,0.000022967568,0.00028189458],"genre_scores_gemma":[0.16058913,0.8286898,0.0036534274,0.0018346662,0.0006058442,0.003105736,0.0010078432,0.000039552466,0.00047395268],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97844976,0.010630394,0.0064560035,0.0014955144,0.0025064258,0.0004617941],"domain_scores_gemma":[0.95939344,0.029361418,0.0071663177,0.00096769683,0.002751244,0.00035987407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025120277,0.0031645768,0.021425162,0.010056071,0.00071286166,0.004895038,0.002330539,0.0029750043,0.0060209557],"category_scores_gemma":[0.06013719,0.0015177802,0.042091947,0.009893182,0.0012362748,0.0030402015,0.0017353211,0.0022223694,0.0005060184],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013140915,0.000017029786,0.0029305646,0.5286353,0.4573341,0.00012520117,0.00007563169,0.0002732174,0.00015359835,0.00014809493,0.0006876376,0.008305503],"study_design_scores_gemma":[0.0007472084,0.00017453825,0.0029390242,0.058610793,0.93535405,0.000113578106,0.00006742037,0.00019860484,0.00010656018,0.00030693357,0.0013579124,0.000023314906],"about_ca_topic_score_codex":0.005741091,"about_ca_topic_score_gemma":0.010416584,"teacher_disagreement_score":0.025120277,"about_ca_system_score_codex":0.0038393766,"about_ca_system_score_gemma":0.0047305105,"threshold_uncertainty_score":0.13285029},"labels":[],"label_agreement":null},{"id":"W3011217342","doi":"10.20529/ijme.2020.027","title":"On being heckled at a National Health Technology Conference: Patient participation and democratic discourse","year":2020,"lang":"en","type":"article","venue":"Indian Journal of Medical Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Democracy; Political science; Sociology; Politics; Law","score_opus":0.1471069526644052,"score_gpt":0.4049433546229817,"score_spread":0.2578364019585765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011217342","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14755312,0.004536195,0.003808323,0.6984158,0.0026261995,0.00013839515,0.000049014576,0.000078251745,0.14279471],"genre_scores_gemma":[0.9159936,0.0013162051,0.0007366524,0.0710375,0.0006482373,0.0001018741,0.000019093663,0.00006997412,0.010076865],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9039049,0.06945622,0.0016817959,0.00349149,0.01078986,0.0106757805],"domain_scores_gemma":[0.90250105,0.068189114,0.006394333,0.0021292693,0.006691976,0.014094297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05112931,0.000727987,0.0010839201,0.0021080903,0.06719371,0.027135532,0.003417672,0.016249515,0.006441504],"category_scores_gemma":[0.0803451,0.0007427294,0.0008187129,0.0022489126,0.077654585,0.014761019,0.024728235,0.037457794,0.0007720279],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005289303,0.00007238554,0.0026201135,0.000118282565,0.000030048774,0.0012344936,0.8099611,0.00014945545,0.00041409864,0.1480316,0.02516483,0.012150712],"study_design_scores_gemma":[0.000025199632,0.00006570643,0.00094712095,0.00042226524,0.00002411225,0.00051019236,0.6322598,0.00032637274,0.0003511624,0.024476042,0.34049648,0.00009556619],"about_ca_topic_score_codex":0.060627267,"about_ca_topic_score_gemma":0.060016796,"teacher_disagreement_score":0.06719371,"about_ca_system_score_codex":0.03038594,"about_ca_system_score_gemma":0.044671927,"threshold_uncertainty_score":0.27040088},"labels":[],"label_agreement":null},{"id":"W3011937804","doi":"10.1080/16549716.2019.1694745","title":"The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk","year":2020,"lang":"en","type":"review","venue":"Global Health Action","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"World Health Organization","keywords":"Transparency (behavior); Procurement; Accountability; Language change; Business; Corporate governance; Accounting; Public relations; Public economics; Economics; Finance; Marketing; Political science; Law","score_opus":0.27567535385746905,"score_gpt":0.4388084882619515,"score_spread":0.16313313440448246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011937804","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07393509,0.09491808,0.03245781,0.59751827,0.0020194869,0.00045411006,0.00015596507,0.0001435908,0.19839753],"genre_scores_gemma":[0.8984238,0.063351445,0.0092843035,0.01977596,0.000984864,0.00021021291,0.00006687759,0.000059038062,0.007843555],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.95959204,0.028572343,0.0012804397,0.0012022309,0.00545393,0.0038990655],"domain_scores_gemma":[0.92078507,0.04852647,0.016622068,0.002827393,0.008432914,0.0028060803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03142323,0.0005010269,0.00067954784,0.0027653042,0.006654937,0.019890217,0.0017001178,0.0058542965,0.005807816],"category_scores_gemma":[0.054425135,0.0004866535,0.0011535343,0.0034771548,0.01585114,0.015805554,0.006890633,0.005712482,0.00087309856],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013334361,0.00024118574,0.018212298,0.0033395377,0.00019089335,0.0016646578,0.022126053,0.0034489122,0.0005145264,0.78989625,0.028430555,0.13180196],"study_design_scores_gemma":[0.00007065475,0.0003433818,0.02083422,0.022817409,0.0002563084,0.0017249385,0.044726398,0.0036268001,0.0022229548,0.5941336,0.30901328,0.00023001888],"about_ca_topic_score_codex":0.007156572,"about_ca_topic_score_gemma":0.00929292,"teacher_disagreement_score":0.03142323,"about_ca_system_score_codex":0.013265634,"about_ca_system_score_gemma":0.02538042,"threshold_uncertainty_score":0.16618389},"labels":[],"label_agreement":null},{"id":"W3012043672","doi":"10.1016/s0735-1097(20)31820-9","title":"DUAL ANTIPLATELET VS. DUAL PATHWAY STRATEGIES: AN IN VITRO MECHANISTIC STUDY","year":2020,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Dual (grammatical number); In vitro; Pharmacology; Biochemistry","score_opus":0.048542225950742875,"score_gpt":0.2847921519922366,"score_spread":0.23624992604149375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012043672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9536445,0.02625299,0.004654083,0.0018814366,0.00057386514,0.00018898246,0.001983202,0.00007717936,0.0107437195],"genre_scores_gemma":[0.9877764,0.007813614,0.0016102492,0.0004089056,0.00016577641,0.000053990443,0.0006771347,0.000017203227,0.0014767657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907494,0.00036620133,0.00005185371,0.00014181013,0.00013587221,0.00022933214],"domain_scores_gemma":[0.9980416,0.0012281042,0.00022627352,0.00017025866,0.00020910958,0.00012448149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013527212,0.0008484445,0.0021894637,0.00050925673,0.00049295987,0.002675602,0.0011729901,0.0020573325,0.006810808],"category_scores_gemma":[0.0020220908,0.00068895175,0.0017814102,0.00046080176,0.0004961057,0.0025304975,0.0003999149,0.0022478183,0.0013714104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03414413,0.021541707,0.0072361873,0.005374614,0.0024375836,0.004751943,0.00058218604,0.020825401,0.8033797,0.025151493,0.011683276,0.06289187],"study_design_scores_gemma":[0.009840084,0.0789054,0.03679159,0.00070834754,0.008812376,0.010891992,0.0029925383,0.16624443,0.62311417,0.026828706,0.03437759,0.0004927379],"about_ca_topic_score_codex":0.0018090982,"about_ca_topic_score_gemma":0.001398372,"teacher_disagreement_score":0.006810808,"about_ca_system_score_codex":0.00074234087,"about_ca_system_score_gemma":0.0007939958,"threshold_uncertainty_score":0.022784472},"labels":[],"label_agreement":null},{"id":"W3012663038","doi":"10.15586/jptcp.v27i1.658","title":"Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?","year":2020,"lang":"en","type":"article","venue":"Journal of Population Therapeutics and Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Fraser Institute; Canadian Institute for Health Information","funders":"","keywords":"Negotiation; Lead (geology); Business; Public economics; Medicine; Risk analysis (engineering); Economics; Political science; Biology","score_opus":0.13099916809363715,"score_gpt":0.4388243945956525,"score_spread":0.3078252265020153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012663038","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32309332,0.023720998,0.012865876,0.4337673,0.0020426498,0.0039807106,0.009669782,0.0006756987,0.19018373],"genre_scores_gemma":[0.9369772,0.0048382827,0.017511627,0.03151782,0.00047949093,0.0007142595,0.0027858743,0.00020560063,0.0049697785],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.84531564,0.052280214,0.01136979,0.005794662,0.06447665,0.02076308],"domain_scores_gemma":[0.74282,0.064203545,0.033441413,0.010445612,0.11345831,0.035631068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07228091,0.00047180065,0.0012774385,0.004898365,0.006141997,0.013741953,0.0035001955,0.0023785955,0.0075562648],"category_scores_gemma":[0.24026617,0.00084278325,0.0016819398,0.011291614,0.0031366216,0.006412683,0.0065365364,0.005471635,0.0006853313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013441984,0.00063483755,0.39444435,0.002653418,0.0014439013,0.00068622665,0.0149069065,0.004352969,0.0010056066,0.034772728,0.075344354,0.4684105],"study_design_scores_gemma":[0.000640247,0.00064851105,0.76008934,0.00399695,0.00078956573,0.00049119105,0.015415246,0.007041794,0.0011811289,0.010399993,0.19870132,0.0006047818],"about_ca_topic_score_codex":0.92266893,"about_ca_topic_score_gemma":0.9424505,"teacher_disagreement_score":0.8948914,"about_ca_system_score_codex":0.10510859,"about_ca_system_score_gemma":0.31811827,"threshold_uncertainty_score":0.76261973},"labels":[],"label_agreement":null},{"id":"W3013750113","doi":"10.1007/s10728-020-00394-x","title":"When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing","year":2020,"lang":"en","type":"article","venue":"Health Care Analysis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Philosophy of medicine; Business; Health informatics; Actuarial science; Drug pricing; Public health; Medicine; Alternative medicine","score_opus":0.198469277717815,"score_gpt":0.4060448817579801,"score_spread":0.2075756040401651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013750113","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17620127,0.0030469499,0.68904495,0.045477994,0.0006923327,0.00051618717,0.0023010706,0.00064569316,0.08207352],"genre_scores_gemma":[0.9305881,0.0012558445,0.020739269,0.001800465,0.0008261766,0.00021374832,0.00046655635,0.00010353103,0.04400623],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99363685,0.0028513272,0.00027186348,0.0013244945,0.0008471887,0.0010683578],"domain_scores_gemma":[0.9813297,0.013678871,0.0022142448,0.0009256871,0.0008954253,0.0009560858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009924239,0.0019637686,0.005319545,0.0013642847,0.0012478408,0.008729105,0.006674383,0.009813815,0.01670689],"category_scores_gemma":[0.036683027,0.0016567317,0.0031491541,0.0020390123,0.004201278,0.012791169,0.002462528,0.0065191844,0.0018982315],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004966842,0.00023732218,0.0018908075,0.00017480823,0.00019284019,0.0005693608,0.0004192652,0.21535562,0.0007186123,0.7566344,0.0075591304,0.015751215],"study_design_scores_gemma":[0.00020645083,0.000099055294,0.0008988575,0.00004132568,0.00010787189,0.00021140926,0.00014557866,0.57679135,0.00017253438,0.41903436,0.0021969432,0.00009428397],"about_ca_topic_score_codex":0.01032863,"about_ca_topic_score_gemma":0.004553042,"teacher_disagreement_score":0.01670689,"about_ca_system_score_codex":0.004111942,"about_ca_system_score_gemma":0.002627391,"threshold_uncertainty_score":0.055890083},"labels":[],"label_agreement":null},{"id":"W3015964222","doi":"","title":"Quelle transparence pour une utilisation sécuritaire des médicaments en dehors de l’étiquette?","year":2020,"lang":"fr","type":"article","venue":"Lex Electronica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Philosophy; Political science","score_opus":0.06450244904673559,"score_gpt":0.2986999481819888,"score_spread":0.23419749913525323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015964222","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1256609,0.022985704,0.009079072,0.5656788,0.006041705,0.00010648354,0.0012995815,0.00040809542,0.2687397],"genre_scores_gemma":[0.80391014,0.011399564,0.006974294,0.04556953,0.008647257,0.00019502224,0.0006251189,0.0003911551,0.12228795],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96547323,0.011567345,0.0019698532,0.0020024267,0.015512363,0.0034747303],"domain_scores_gemma":[0.8633791,0.07531576,0.017943876,0.005874295,0.028132567,0.009354371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028229473,0.00054987764,0.0007089674,0.002245953,0.002025902,0.014145962,0.0013714711,0.005110472,0.045744687],"category_scores_gemma":[0.12716228,0.0005602671,0.0012201621,0.0021039785,0.0031551337,0.009287118,0.0030423456,0.0070169065,0.0065301424],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013330594,0.00054652954,0.041847218,0.0013913722,0.00029750777,0.0008969855,0.00578164,0.0012635033,0.0046192748,0.38861927,0.12597126,0.42743242],"study_design_scores_gemma":[0.00026594847,0.0008298903,0.117941566,0.0032899373,0.00024383541,0.001972999,0.0056662434,0.0043094237,0.0050115897,0.06055301,0.79973024,0.00018537852],"about_ca_topic_score_codex":0.027134009,"about_ca_topic_score_gemma":0.020698445,"teacher_disagreement_score":0.045744687,"about_ca_system_score_codex":0.009046942,"about_ca_system_score_gemma":0.016015684,"threshold_uncertainty_score":0.15303123},"labels":[],"label_agreement":null},{"id":"W3016167110","doi":"10.1007/s40265-020-01296-x","title":"Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Drugs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; McGill University; Université Laval; Institut National de Santé Publique du Québec","funders":"Université du Québec à Trois-Rivières","keywords":"Medicine; Meta-analysis; Confidence interval; MEDLINE; Brand names; Subgroup analysis; Systematic review; Internal medicine; Relative risk; Randomized controlled trial; Emergency medicine","score_opus":0.10560598533298951,"score_gpt":0.34000375411428563,"score_spread":0.23439776878129612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016167110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011632901,0.9980028,0.0001927487,0.00015123321,0.00011229966,0.000058611946,0.00017499395,0.0000055926707,0.000138439],"genre_scores_gemma":[0.055843156,0.9410198,0.0010491451,0.0011416142,0.00028129903,0.00017329668,0.00024619573,0.000014221193,0.00023125391],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99280894,0.002917305,0.0024546406,0.00077924033,0.0008115872,0.00022836463],"domain_scores_gemma":[0.9799289,0.014200673,0.0043245493,0.00055288017,0.0008007237,0.00019220941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011865531,0.0015417204,0.013870292,0.0042804577,0.00034802116,0.003377808,0.0016254289,0.0025629385,0.005475288],"category_scores_gemma":[0.030778479,0.00114839,0.02006267,0.004862719,0.0009597007,0.0024146491,0.0013727027,0.0022424967,0.00046111442],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021234239,0.000031964857,0.0025441714,0.54640007,0.41167143,0.00010162548,0.0000756846,0.00030950247,0.00021002398,0.00040191473,0.0011233994,0.035006788],"study_design_scores_gemma":[0.0013008185,0.00024129778,0.0042098775,0.060158905,0.9272232,0.00014206204,0.00009245811,0.00012503284,0.0001266804,0.00060157466,0.0057441182,0.000033970904],"about_ca_topic_score_codex":0.004515739,"about_ca_topic_score_gemma":0.0149667775,"teacher_disagreement_score":0.013870292,"about_ca_system_score_codex":0.0022071053,"about_ca_system_score_gemma":0.002937445,"threshold_uncertainty_score":0.06275165},"labels":[],"label_agreement":null},{"id":"W3016416029","doi":"10.1177/1741134320918339","title":"A Novel Development and Portfolio Management Strategy for Generic Small Molecule Drug Products: Watergile ANDA","year":2020,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Portfolio; Business; New product development; Commercialization; Project portfolio management; Drug development; Product (mathematics); Process (computing); Risk analysis (engineering); Process management; Marketing; Industrial organization; Drug; Economics; Computer science; Finance; Project management; Pharmacology; Medicine; Management","score_opus":0.13791547266274154,"score_gpt":0.2835873039882082,"score_spread":0.14567183132546666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016416029","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030657854,0.0020789083,0.8241394,0.03725732,0.00037514715,0.0013366995,0.0003323873,0.0015956052,0.1022266],"genre_scores_gemma":[0.42613244,0.0015350566,0.53181475,0.004807836,0.00046243565,0.0008158793,0.0004603789,0.00018197803,0.033789195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99102306,0.00400846,0.0004262871,0.0011827748,0.0028065701,0.00055290974],"domain_scores_gemma":[0.9933915,0.001953856,0.000916285,0.00092936045,0.0019528193,0.00085624575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014684566,0.0009309727,0.00094498094,0.004228824,0.0015746691,0.00948187,0.0021904567,0.0028938309,0.008659621],"category_scores_gemma":[0.021755215,0.000596594,0.0010292826,0.0022086443,0.0017160525,0.0104564475,0.007282763,0.0020445008,0.0017327443],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001783409,0.00044465586,0.004887461,0.0001946463,0.00013233998,0.0005648199,0.0006114263,0.020667752,0.0021379744,0.41841468,0.03091267,0.52085316],"study_design_scores_gemma":[0.00021539311,0.0006287453,0.003605292,0.00039306024,0.00011507698,0.0007027206,0.00093186804,0.266308,0.004237479,0.50725204,0.21542871,0.00018158808],"about_ca_topic_score_codex":0.0030266636,"about_ca_topic_score_gemma":0.003145399,"teacher_disagreement_score":0.014684566,"about_ca_system_score_codex":0.004035988,"about_ca_system_score_gemma":0.009103154,"threshold_uncertainty_score":0.07766038},"labels":[],"label_agreement":null},{"id":"W3016738206","doi":"10.1097/02024458-200912000-00056","title":"The importance of knowledge brokering and the role of knowledge brokers in the formulation of Swiss Drug Policy","year":2009,"lang":"en","type":"article","venue":"The Canadian Journal of Addiction","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Business; Knowledge management; Computer science; Pharmacology; Medicine","score_opus":0.01975994752557149,"score_gpt":0.2569806246863683,"score_spread":0.2372206771607968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016738206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49981564,0.014884869,0.023486001,0.22584029,0.00048700732,0.00016356296,0.00025424265,0.00016955644,0.23489882],"genre_scores_gemma":[0.995999,0.0010180224,0.0005527554,0.00054358714,0.00014806255,0.000019236157,0.000016716109,0.0000059574477,0.0016967095],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99001443,0.0055535724,0.00038346916,0.00076012174,0.0014704404,0.0018180171],"domain_scores_gemma":[0.94053686,0.046766095,0.0056517054,0.0013416976,0.0027104202,0.0029932484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014120975,0.00031903747,0.0006065854,0.0025779563,0.0042936844,0.013561072,0.00082482514,0.009002034,0.011432617],"category_scores_gemma":[0.04651165,0.00034074724,0.0004880069,0.0024853782,0.006581757,0.010925187,0.003355049,0.003089642,0.0006444259],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048793355,0.00019887155,0.011993135,0.00027163108,0.00010075369,0.0015139157,0.0057820445,0.011448749,0.0010512231,0.9248238,0.008248364,0.03407952],"study_design_scores_gemma":[0.00038614267,0.00018614517,0.01955501,0.0006003833,0.00015647036,0.00047676847,0.008228724,0.044103064,0.0014605345,0.87210065,0.052595556,0.00015045311],"about_ca_topic_score_codex":0.02504027,"about_ca_topic_score_gemma":0.012804579,"teacher_disagreement_score":0.02504027,"about_ca_system_score_codex":0.01018143,"about_ca_system_score_gemma":0.014229915,"threshold_uncertainty_score":0.07467979},"labels":[],"label_agreement":null},{"id":"W3016847231","doi":"10.1097/02024458-200912000-00084","title":"Decade Lecture #6: Trends in Prescription Drug Misuse: Strategies for Addressing a Growing Global Public Health Problem","year":2009,"lang":"en","type":"article","venue":"The Canadian Journal of Addiction","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Public health; Medical prescription; Drug misuse; Drug; Prescription drug; Medicine; Political science; Environmental health; Psychiatry; Pharmacology; Nursing","score_opus":0.09851279950154208,"score_gpt":0.3189647399884825,"score_spread":0.22045194048694045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016847231","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010955838,0.015585901,0.0008051032,0.88583887,0.079942666,0.000028004497,0.00040693083,0.00006923067,0.016227586],"genre_scores_gemma":[0.040526748,0.056563146,0.0023702346,0.34386483,0.3234106,0.000110994966,0.0011875164,0.00028210878,0.23168384],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797887,0.000549417,0.00013026662,0.00029131782,0.00060726015,0.00044287846],"domain_scores_gemma":[0.98657334,0.0025111556,0.0007661704,0.0003124911,0.0032295978,0.0066071297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069053224,0.0008180209,0.00059806654,0.0012062708,0.0015789232,0.007483474,0.0015997285,0.009782698,0.03845266],"category_scores_gemma":[0.01357803,0.00038583935,0.0007974029,0.001243936,0.0012351432,0.004671626,0.0027983922,0.008165635,0.014973726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026143765,0.00004955692,0.0005821995,0.0001105787,0.000008269519,0.000042264677,0.00006584814,0.00005913559,0.00013817659,0.002284991,0.9734789,0.023154005],"study_design_scores_gemma":[0.00007097528,0.00015286979,0.005777615,0.0005034709,0.000045824738,0.00016732668,0.0009920537,0.0004928419,0.00048125902,0.008647842,0.9826317,0.000036118257],"about_ca_topic_score_codex":0.0065463316,"about_ca_topic_score_gemma":0.019015891,"teacher_disagreement_score":0.03845266,"about_ca_system_score_codex":0.0038993834,"about_ca_system_score_gemma":0.010227791,"threshold_uncertainty_score":0.12863696},"labels":[],"label_agreement":null},{"id":"W3017378975","doi":"","title":"Le respect des Bonnes pratiques dans le secteur pharmaceutique français","year":2020,"lang":"fr","type":"article","venue":"Lex Electronica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.04526026856775616,"score_gpt":0.2816317558050605,"score_spread":0.23637148723730433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017378975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4141129,0.024509702,0.0025205817,0.34842655,0.0024976116,0.000050364153,0.0019751585,0.00009468737,0.20581241],"genre_scores_gemma":[0.93200004,0.0035802566,0.00056377234,0.0069150794,0.00091900124,0.000021283362,0.0002900643,0.0000331655,0.05567726],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912985,0.002860979,0.00040658965,0.0007001993,0.002658018,0.0020755806],"domain_scores_gemma":[0.980792,0.0074394513,0.0032301792,0.00072291953,0.0038693768,0.0039461073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065122982,0.00035592553,0.0004481964,0.0014031569,0.002888853,0.0077439607,0.00058930344,0.0047129197,0.013208818],"category_scores_gemma":[0.025045296,0.0003425303,0.000614001,0.0020182012,0.0019170302,0.0018099921,0.0016276079,0.005901307,0.0010046499],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020593125,0.0003560111,0.1068573,0.00041843878,0.00040911575,0.0023511876,0.004535542,0.0072286082,0.0051293722,0.68692684,0.06643252,0.11729568],"study_design_scores_gemma":[0.00036501157,0.00067066954,0.38669583,0.0009601809,0.00012413565,0.0021928346,0.005854712,0.004381311,0.0017510584,0.037222862,0.5596226,0.00015871225],"about_ca_topic_score_codex":0.26037854,"about_ca_topic_score_gemma":0.2690902,"teacher_disagreement_score":0.26037854,"about_ca_system_score_codex":0.019659128,"about_ca_system_score_gemma":0.02302217,"threshold_uncertainty_score":0.51772594},"labels":[],"label_agreement":null},{"id":"W3020645024","doi":"10.1007/s40268-020-00307-2","title":"Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers","year":2020,"lang":"en","type":"article","venue":"Drugs in R&D","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec; Université Laval; Institut National de Santé Publique du Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Institut National de Santé Publique du Québec","keywords":"Angiotensin Receptor Blockers; Pharmacology; Brand names; Business; Chemistry; Medicine; Internal medicine; Renin–angiotensin system; Advertising","score_opus":0.10373590454889006,"score_gpt":0.28739270910938797,"score_spread":0.1836568045604979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020645024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956416,0.00042142373,0.00024343822,0.0003034721,0.000017043296,0.000023709144,0.0017049205,0.000009173394,0.0016350934],"genre_scores_gemma":[0.9987301,0.00011747865,0.00007386306,0.000075894925,0.000015287183,0.000011322075,0.0008620164,0.0000026931448,0.00011132821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976076,0.00060334476,0.00017831997,0.0004753374,0.00048991607,0.00064550363],"domain_scores_gemma":[0.9893868,0.0020160389,0.0061953394,0.0007183605,0.0010848357,0.0005986192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00320405,0.00024017229,0.00030439324,0.001371893,0.00040119656,0.0012209807,0.00046062344,0.00062249065,0.0015737009],"category_scores_gemma":[0.0109317945,0.00018704365,0.0010101402,0.0017562982,0.00048800223,0.0006887807,0.00053819024,0.000826638,0.00025141297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011497937,0.00002731278,0.9981269,0.000008523791,0.00008623893,0.00003962262,0.00006882744,0.000058839687,0.000042484717,0.00004154689,0.00009066465,0.0012941109],"study_design_scores_gemma":[0.000003315706,0.00003324963,0.9996228,0.000004167836,0.000032155425,0.000030998184,0.000054668544,0.00008248118,0.000023545635,0.0000442575,0.00006611312,0.0000021808064],"about_ca_topic_score_codex":0.030737277,"about_ca_topic_score_gemma":0.030257463,"teacher_disagreement_score":0.030737277,"about_ca_system_score_codex":0.0013895114,"about_ca_system_score_gemma":0.0010763285,"threshold_uncertainty_score":0.061116755},"labels":[],"label_agreement":null},{"id":"W3022487952","doi":"10.1016/j.cjca.2020.04.033","title":"Corporate Lobbyists: Open Season on Academic Health Science?","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Abbott Vascular; Servier; Sanofi; Roche; Pfizer","keywords":"Face (sociological concept); Medicine; Institution; Work (physics); Public relations; Academic institution; Affect (linguistics); Health care; Engineering ethics; Medical education; Management; Political science; Social science; Sociology","score_opus":0.2514492318961906,"score_gpt":0.3437562517202675,"score_spread":0.09230701982407691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022487952","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0122726485,0.003669627,0.00040338095,0.8958096,0.012715166,0.00004360816,0.00028359398,0.00007579817,0.074726544],"genre_scores_gemma":[0.31975216,0.003869392,0.00046873104,0.5553305,0.035008315,0.00017065882,0.00031098095,0.0002478692,0.08484146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9850653,0.0032590341,0.0003756751,0.0008684228,0.00292835,0.0075033163],"domain_scores_gemma":[0.8618387,0.031312577,0.008484422,0.0028983783,0.010266984,0.085198894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02561588,0.0005558639,0.0011108832,0.0020461155,0.007990451,0.026788805,0.0025369485,0.037134517,0.10544945],"category_scores_gemma":[0.089318365,0.0005582125,0.0009277238,0.0015968874,0.0073901694,0.014079121,0.009525963,0.018191822,0.0112051545],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031183468,0.0002904686,0.0055117263,0.000071203496,0.000028490216,0.00024752883,0.000755934,0.000063023996,0.0002028641,0.06501944,0.893883,0.033614438],"study_design_scores_gemma":[0.00039632086,0.00021329949,0.035361912,0.0009918502,0.000060810475,0.00029041583,0.0092928335,0.000796999,0.0003877394,0.07338551,0.8786691,0.00015329855],"about_ca_topic_score_codex":0.014582325,"about_ca_topic_score_gemma":0.038059104,"teacher_disagreement_score":0.10544945,"about_ca_system_score_codex":0.0063664266,"about_ca_system_score_gemma":0.025753008,"threshold_uncertainty_score":0.35276353},"labels":[],"label_agreement":null},{"id":"W3022749090","doi":"10.1016/s0140-6736(20)30160-4","title":"Unfortunate distinction or corporate protectionism by design?","year":2020,"lang":"en","type":"letter","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Scopus; Intellectual property; Protectionism; Government (linguistics); Democracy; Medical prescription; Political science; Prescription drug; Corporate governance; Medicine; Business; Law; MEDLINE; International trade; Economics; Politics; Nursing; Management","score_opus":0.245760973841721,"score_gpt":0.2897544372364884,"score_spread":0.043993463394767424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022749090","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016523933,0.0019213998,0.00028658166,0.98571116,0.007303053,0.000005882467,0.000036959016,0.00001206112,0.0045575295],"genre_scores_gemma":[0.0054399674,0.00081649015,0.00035749283,0.96092325,0.024269177,0.000043141736,0.000017747223,0.00002955179,0.008103205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9759571,0.008706356,0.0013688775,0.0032667199,0.007814509,0.002886368],"domain_scores_gemma":[0.93361235,0.05107386,0.0027167022,0.0029758562,0.005297403,0.004323796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.032437492,0.0011909645,0.0026028324,0.0016352985,0.005439298,0.014522491,0.0046491837,0.115067996,0.011858583],"category_scores_gemma":[0.115090795,0.0011858586,0.0016124516,0.0015265042,0.022874476,0.01393427,0.004921485,0.07365657,0.004755062],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008648325,0.000038406037,0.00022237092,0.00009281439,0.00003456505,0.0002431553,0.00024898307,0.0000898141,0.00008408305,0.23798199,0.7507028,0.010174603],"study_design_scores_gemma":[0.00033890596,0.000043499014,0.0005407163,0.00038293176,0.000036653117,0.00021614794,0.00037993182,0.0004569764,0.00016697714,0.4245479,0.5728133,0.00007605814],"about_ca_topic_score_codex":0.015521817,"about_ca_topic_score_gemma":0.021503936,"teacher_disagreement_score":0.115067996,"about_ca_system_score_codex":0.009097989,"about_ca_system_score_gemma":0.0123184165,"threshold_uncertainty_score":0.17154789},"labels":[],"label_agreement":null},{"id":"W3023863232","doi":"10.1017/dem.2018.11","title":"THE IMPACT OF NEW DRUG LAUNCHES ON LIFE-YEARS LOST IN 2015 FROM 19 TYPES OF CANCER IN 36 COUNTRIES","year":2018,"lang":"en","type":"article","venue":"Journal of Demographic Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute on Aging; Incyte","keywords":"Cancer drugs; Medicine; Demography; Drug; Cancer; Population; Cancer incidence; Incidence (geometry); Environmental health; Mathematics; Pharmacology; Internal medicine","score_opus":0.03581662994321924,"score_gpt":0.31419359977584327,"score_spread":0.27837696983262405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023863232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99064857,0.002295925,0.00075931166,0.00021134698,0.000040130846,0.00003495944,0.0054602055,0.000017959695,0.00053154136],"genre_scores_gemma":[0.99711347,0.00030072563,0.00022399795,0.000034500415,0.000010788271,0.0000189031,0.0021128273,0.0000025671743,0.0001821966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958817,0.0019210449,0.0005320724,0.0006898931,0.00041987235,0.0005554401],"domain_scores_gemma":[0.9881543,0.0037029462,0.006505871,0.000440289,0.00058438006,0.00061229535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057661184,0.00052593136,0.0009289746,0.0015474962,0.00023039927,0.0012736206,0.00063947076,0.00051146554,0.0020996241],"category_scores_gemma":[0.009336667,0.0003549324,0.0045038434,0.0020219146,0.00066092855,0.0008451182,0.0016555932,0.0009811382,0.00022696305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010028287,0.00009855305,0.9831229,0.00015675055,0.0029987153,0.00009289962,0.00006248547,0.008386506,0.000097498276,0.00029405425,0.000438755,0.0032480108],"study_design_scores_gemma":[0.000089574874,0.0008240067,0.9906879,0.000068172594,0.0013884169,0.00009369182,0.0002282121,0.0051170425,0.00045394484,0.00020265573,0.0008128866,0.00003353216],"about_ca_topic_score_codex":0.017407682,"about_ca_topic_score_gemma":0.007810008,"teacher_disagreement_score":0.017407682,"about_ca_system_score_codex":0.0016792046,"about_ca_system_score_gemma":0.0009924343,"threshold_uncertainty_score":0.034612715},"labels":[],"label_agreement":null},{"id":"W3025432734","doi":"10.1093/ajhp/zxaa116","title":"National trends in prescription drug expenditures and projections for 2020","year":2020,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; St. Michael's Hospital","funders":"","keywords":"Biosimilar; Medical prescription; Specialty; Prescription drug; Drug; Business; Medicine; Legislation; Family medicine; Pharmacology; Political science","score_opus":0.09670610145906848,"score_gpt":0.3671401722862621,"score_spread":0.2704340708271936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025432734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6814701,0.011090566,0.010507169,0.010440311,0.00053256244,0.00010409783,0.22869742,0.0010389952,0.056118764],"genre_scores_gemma":[0.8585037,0.0070185256,0.0081959935,0.0009847285,0.00022344041,0.00015826826,0.12074016,0.000067797126,0.0041074827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993461,0.00009715393,0.00008065274,0.00010549057,0.00027163612,0.00009903111],"domain_scores_gemma":[0.9977837,0.00020525914,0.00071435113,0.00005213988,0.0010909702,0.00015354298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011073966,0.00051789137,0.0002163513,0.0024554,0.00025495488,0.0012363101,0.0003870868,0.00043346765,0.003148576],"category_scores_gemma":[0.004024936,0.00018959807,0.00086292136,0.003499662,0.00016610308,0.0015015469,0.00062025734,0.00082029856,0.0012378425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047923758,0.00018656594,0.739952,0.00097467215,0.0005296624,0.00031604973,0.0003562652,0.037928924,0.0009593403,0.014412478,0.0904563,0.11344856],"study_design_scores_gemma":[0.000039666753,0.00024439435,0.7896551,0.0006644468,0.00024440463,0.0008817819,0.0010031383,0.05383852,0.0014123946,0.003945431,0.14799191,0.00007887743],"about_ca_topic_score_codex":0.039802067,"about_ca_topic_score_gemma":0.033192445,"teacher_disagreement_score":0.039802067,"about_ca_system_score_codex":0.0025278786,"about_ca_system_score_gemma":0.0015227355,"threshold_uncertainty_score":0.07914078},"labels":[],"label_agreement":null},{"id":"W3026036024","doi":"10.1016/j.jval.2020.04.1082","title":"PNS79 MONOPSONY BUYER: A CRITIQUE OF THE NATIONAL PHARMACEUTICAL PROGRAM PROPOSED FOR CANADA","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Monopsony; Government (linguistics); Agency (philosophy); Prescription drug; Medical prescription; Investment (military); Business; Public economics; Political science; Public administration; Economic growth; Economics; Politics; Medicine; Law; Labour economics; Sociology","score_opus":0.1793486899776441,"score_gpt":0.37779381546604734,"score_spread":0.19844512548840323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026036024","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021340314,0.0035930814,0.003392969,0.6310742,0.0011971827,0.00018339985,0.0010950423,0.000111029265,0.33801275],"genre_scores_gemma":[0.5891744,0.003514058,0.004556487,0.24167931,0.0025702743,0.00030435168,0.00023216827,0.0002690596,0.15769996],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9833889,0.0019361136,0.00036450033,0.0019020784,0.008773964,0.0036344358],"domain_scores_gemma":[0.971412,0.010757565,0.0007542156,0.00083705044,0.013176109,0.0030630825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011308145,0.0007518303,0.0016824924,0.002926718,0.012703711,0.012214068,0.0052067935,0.02309458,0.014451403],"category_scores_gemma":[0.047037166,0.00091726886,0.0015506905,0.0030782234,0.015064552,0.0039630267,0.003124492,0.018700514,0.0011740951],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047126443,0.000017972556,0.0007403488,0.000054720676,0.00002266497,0.00006468877,0.00051392865,0.0005691079,0.00007612124,0.91049546,0.08174886,0.005648848],"study_design_scores_gemma":[0.0004104031,0.00005872446,0.008361423,0.000575511,0.00020485283,0.00013264907,0.002061686,0.0058928286,0.00076945085,0.3684998,0.6127865,0.00024614148],"about_ca_topic_score_codex":0.9765902,"about_ca_topic_score_gemma":0.97280294,"teacher_disagreement_score":0.8847091,"about_ca_system_score_codex":0.11529086,"about_ca_system_score_gemma":0.20391469,"threshold_uncertainty_score":0.83649766},"labels":[],"label_agreement":null},{"id":"W3026957398","doi":"10.1016/j.healthpol.2020.05.001","title":"What happens to drug use and expenditure when cost sharing is completely removed? Evidence from a Canadian provincial public drug plan","year":2020,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Centre for Advancing Health Outcomes; University of British Columbia","funders":"National Health and Medical Research Council; Canada Research Chairs; Michael Smith Health Research BC","keywords":"Cost sharing; Medical prescription; Business; Public economics; Drug; Actuarial science; Demographic economics; Medicine; Economics; Pharmacology; Nursing","score_opus":0.2820006895554179,"score_gpt":0.3537951674710592,"score_spread":0.07179447791564131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026957398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85647935,0.007186932,0.00032299734,0.08028375,0.0002672999,0.00018862076,0.010449931,0.000034374054,0.04478684],"genre_scores_gemma":[0.98810464,0.0013689386,0.00015281704,0.003969276,0.000075202,0.00003402049,0.0015558584,0.000009318583,0.0047300775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9872312,0.0021062174,0.0004547397,0.0006622355,0.003342654,0.006202909],"domain_scores_gemma":[0.96166694,0.015027986,0.007737165,0.0016602434,0.008195825,0.005711914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006762944,0.00032066705,0.0013302807,0.0016155189,0.0037072,0.0044886363,0.0031973864,0.0029321667,0.007754631],"category_scores_gemma":[0.044976253,0.00061100244,0.0018827405,0.0055538057,0.0029715835,0.0017769786,0.0021593662,0.0045084762,0.0004123354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027320993,0.0009768057,0.84854716,0.0007182101,0.0013575554,0.0007446104,0.0060563018,0.0066880793,0.00033772073,0.037027795,0.051423647,0.04339003],"study_design_scores_gemma":[0.00048439027,0.00016049155,0.9635361,0.00031353423,0.00079502066,0.0000717677,0.007813437,0.0023125734,0.00023431133,0.0036384575,0.020549582,0.000090273235],"about_ca_topic_score_codex":0.99525803,"about_ca_topic_score_gemma":0.99674594,"teacher_disagreement_score":0.079634406,"about_ca_system_score_codex":0.079634406,"about_ca_system_score_gemma":0.1389308,"threshold_uncertainty_score":0.57779074},"labels":[],"label_agreement":null},{"id":"W3027314007","doi":"10.1016/j.jval.2020.04.1073","title":"PNS70 US “IMPORT-FROM-CANADA” DRUG LEGISLATION: WILL IT LOWER DRUG COSTS FOR AMERICAN CONSUMERS?","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; European union; Business; Medical prescription; CINAHL; MEDLINE; Public economics; Medicine; International trade; Economics; Political science; Pharmacology; Law","score_opus":0.07922509688112722,"score_gpt":0.30170426512868065,"score_spread":0.22247916824755343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027314007","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04507577,0.0039506485,0.0006707969,0.41831043,0.0037952473,0.00023495291,0.0095055,0.00036062495,0.518096],"genre_scores_gemma":[0.2700585,0.0037685898,0.0024435127,0.3728365,0.0020055356,0.00017191643,0.0036258716,0.00020390071,0.3448857],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99382824,0.0004977839,0.00013117817,0.00029619507,0.0033082028,0.0019383873],"domain_scores_gemma":[0.9878513,0.0023873555,0.0006452878,0.00024572178,0.006132409,0.0027378346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037883986,0.00047367797,0.00049500534,0.0016397062,0.003652131,0.006122433,0.0019397083,0.010044964,0.02698281],"category_scores_gemma":[0.01528061,0.00037947064,0.0011453567,0.0014952844,0.0024258732,0.0014531964,0.0011970327,0.004324885,0.002399705],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000258699,0.00021174447,0.009066945,0.00014680474,0.00006107343,0.00016367635,0.00020178476,0.00055673654,0.0007232815,0.11474522,0.8473436,0.02652037],"study_design_scores_gemma":[0.00019659115,0.00013367183,0.060628023,0.0004053695,0.00017621391,0.000113976974,0.0006205561,0.0014214922,0.0021113683,0.009425272,0.92463666,0.00013089438],"about_ca_topic_score_codex":0.9339193,"about_ca_topic_score_gemma":0.9588794,"teacher_disagreement_score":0.06608069,"about_ca_system_score_codex":0.04228833,"about_ca_system_score_gemma":0.11908426,"threshold_uncertainty_score":0.30682474},"labels":[],"label_agreement":null},{"id":"W3028345760","doi":"10.1016/j.jval.2020.04.136","title":"PCV31 COST-EFFECTIVENESS OF EVOLOCUMAB FOR THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE KINGDOM OF SAUDI ARABIA","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Evolocumab; Medicine; Familial hypercholesterolemia; Ezetimibe; PCSK9; Statin; Internal medicine; Population; Atherosclerotic cardiovascular disease; Cohort; Observational study; Gastroenterology; Cholesterol; Lipoprotein; Disease; LDL receptor","score_opus":0.17483326838493118,"score_gpt":0.3406081854431775,"score_spread":0.16577491705824632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028345760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846485,0.011518949,0.00008630976,0.0019667374,0.000053985674,0.000028197252,0.00052068674,0.00000497563,0.0011717067],"genre_scores_gemma":[0.99843234,0.0010828234,0.000060601644,0.00009504564,0.000023251985,0.0000057818856,0.00018262926,8.8955636e-7,0.000116643634],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99920267,0.00042233287,0.00007908942,0.000053379605,0.00009900812,0.00014353046],"domain_scores_gemma":[0.9976701,0.00101594,0.00053255237,0.000050283536,0.00025334946,0.00047776577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011986317,0.00022742621,0.0006502471,0.00039374258,0.00016002114,0.0009256904,0.00031089495,0.00058355124,0.0022973663],"category_scores_gemma":[0.005461644,0.00014778631,0.0011435318,0.0004777072,0.00030315717,0.00051275594,0.00043909202,0.00083912845,0.00009642223],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13705869,0.001736003,0.46627522,0.0039736517,0.007453429,0.0018918563,0.00066948374,0.051327106,0.0024311745,0.005804543,0.009473372,0.31190556],"study_design_scores_gemma":[0.01915079,0.020895839,0.8779175,0.0021464531,0.008081516,0.0025570644,0.002182486,0.052187376,0.0014363372,0.0019643311,0.011327967,0.00015238125],"about_ca_topic_score_codex":0.027632244,"about_ca_topic_score_gemma":0.023267254,"teacher_disagreement_score":0.027632244,"about_ca_system_score_codex":0.0031667405,"about_ca_system_score_gemma":0.0021458655,"threshold_uncertainty_score":0.054942787},"labels":[],"label_agreement":null},{"id":"W3032207135","doi":"10.1177/1715163520929387","title":"Role of Canadian pharmacists in managing drug shortage concerns amid the COVID-19 pandemic","year":2020,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Economic shortage; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Drug; Virology; Business; Medicine; Pharmacology; Infectious disease (medical specialty); Outbreak; Government (linguistics); Internal medicine","score_opus":0.1395501260332121,"score_gpt":0.3000084131879554,"score_spread":0.1604582871547433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032207135","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023520475,0.0074160886,0.00059261353,0.91060007,0.0015842215,0.00011882942,0.00029981424,0.00005560103,0.05581235],"genre_scores_gemma":[0.7585163,0.016054412,0.002990379,0.19979092,0.0034286794,0.000101046746,0.00030802368,0.00007028306,0.018739872],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.98436606,0.0035530129,0.0004381801,0.00058281404,0.004908805,0.00615114],"domain_scores_gemma":[0.90180653,0.012148239,0.0054101082,0.00063075766,0.028781626,0.051222693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015339587,0.0004156114,0.000499766,0.0029471363,0.010682,0.01080068,0.0021340754,0.00792002,0.010243085],"category_scores_gemma":[0.060139876,0.00048706977,0.0007082087,0.0022618833,0.003744275,0.0025104196,0.004618207,0.007668835,0.00054755574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004371518,0.00046351706,0.10523009,0.0007091199,0.00031602048,0.0029018237,0.006025102,0.004334945,0.0006318623,0.057334922,0.6157018,0.20591368],"study_design_scores_gemma":[0.0004001916,0.0003105868,0.15600704,0.002277362,0.00024509153,0.0012319429,0.022803247,0.0060681975,0.00046826285,0.016815275,0.792996,0.00037678724],"about_ca_topic_score_codex":0.93369114,"about_ca_topic_score_gemma":0.9727083,"teacher_disagreement_score":0.92370063,"about_ca_system_score_codex":0.076299384,"about_ca_system_score_gemma":0.3258949,"threshold_uncertainty_score":0.5535934},"labels":[],"label_agreement":null},{"id":"W3032641233","doi":"10.1377/hlthaff.2019.00673","title":"Estimating The Cost Of Delayed Generic Drug Entry To Medicaid","year":2020,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicaid; Quarter (Canadian coin); Generic drug; Brand names; Market share; Business; Medicine; Actuarial science; Advertising; Marketing; Economics; Health care; Drug; Pharmacology","score_opus":0.08222174286204792,"score_gpt":0.3187130681155804,"score_spread":0.2364913252535325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032641233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925781,0.00042802165,0.0013759903,0.0009639456,0.000013181933,0.00003673046,0.0029477768,0.000019451578,0.0016368417],"genre_scores_gemma":[0.9968144,0.0002607048,0.00057415647,0.000054591124,0.000022321363,0.000019166211,0.00165167,0.0000040006335,0.00059900817],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989876,0.0002941619,0.000090639995,0.00017071445,0.0001641172,0.0002927679],"domain_scores_gemma":[0.98833025,0.006565208,0.0037823117,0.00029225054,0.0005472695,0.00048275618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020479173,0.00031406825,0.0003985184,0.0017854382,0.00036618265,0.0014259905,0.00067372835,0.0008662534,0.003614007],"category_scores_gemma":[0.018892353,0.00052374025,0.0010640175,0.001752611,0.00040004856,0.0015478949,0.0010294253,0.001770856,0.00025193536],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021209512,0.00014996772,0.93968856,0.000050722123,0.00018930451,0.00028130884,0.00007513027,0.043545645,0.0001520382,0.0038466202,0.0010823766,0.010726172],"study_design_scores_gemma":[0.00006995889,0.00040296014,0.7269852,0.00008879193,0.00034121802,0.00071521994,0.00088280614,0.2583847,0.0007562012,0.0067074033,0.004606685,0.000058865633],"about_ca_topic_score_codex":0.060398474,"about_ca_topic_score_gemma":0.046912163,"teacher_disagreement_score":0.060398474,"about_ca_system_score_codex":0.004033424,"about_ca_system_score_gemma":0.0019063144,"threshold_uncertainty_score":0.12009382},"labels":[],"label_agreement":null},{"id":"W3032689621","doi":"10.1542/28.12.15","title":"Manufacturing issue leads to shortage of PedvaxHIB vaccine","year":2007,"lang":"en","type":"article","venue":"AAP News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Quarter (Canadian coin); Conjugate vaccine; Business; Virology; Medicine; Immunization; Immunology; Antigen; Geography","score_opus":0.04836549465739591,"score_gpt":0.3077629444850202,"score_spread":0.25939744982762425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032689621","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23052776,0.010385618,0.002186961,0.4505406,0.015863853,0.00015215781,0.0027168624,0.0014618988,0.28616428],"genre_scores_gemma":[0.6496976,0.010389986,0.0017866265,0.16415684,0.008012329,0.0000657124,0.003978039,0.0005935126,0.16131938],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872786,0.00015642282,0.000079952864,0.0001335314,0.0005715491,0.00033061285],"domain_scores_gemma":[0.99512273,0.0014710093,0.001256218,0.00019798437,0.0012477741,0.00070431735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001939267,0.00031676985,0.00023022426,0.0009577181,0.0020377957,0.0030731673,0.00048766696,0.004314395,0.04359716],"category_scores_gemma":[0.0073134843,0.00037384962,0.000470272,0.0008876011,0.00053628505,0.0012736722,0.0007851491,0.0031395673,0.014599176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044865676,0.00029438222,0.028395293,0.00017133474,0.000025093197,0.012637264,0.00057532516,0.00023731869,0.002479913,0.006169625,0.88716245,0.061403297],"study_design_scores_gemma":[0.00014120074,0.00048751567,0.062174175,0.00038441355,0.00007167219,0.010367063,0.004134059,0.0014626728,0.006145794,0.005522918,0.90904397,0.00006456914],"about_ca_topic_score_codex":0.003912294,"about_ca_topic_score_gemma":0.0044496953,"teacher_disagreement_score":0.04359716,"about_ca_system_score_codex":0.0016419244,"about_ca_system_score_gemma":0.001503691,"threshold_uncertainty_score":0.14584702},"labels":[],"label_agreement":null},{"id":"W3033230077","doi":"10.1177/0972266120929146","title":"Pharmaceutical Market and Drug Price Policy in India","year":2020,"lang":"en","type":"article","venue":"Review of Development and Change","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute on Governance","funders":"","keywords":"Drug prices; Business; Pharmaceutical industry; Drug pricing; Health care; Price policy; Public economics; Drug; Economics; Industrial organization; Economic growth; Actuarial science; Pharmacology; Medicine","score_opus":0.10543514359858008,"score_gpt":0.31927073114878085,"score_spread":0.21383558755020077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033230077","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045566086,0.66710305,0.0015098547,0.12900604,0.0013163073,0.00001954721,0.0006141635,0.00007263154,0.15479235],"genre_scores_gemma":[0.5906571,0.38204914,0.0009635004,0.014676651,0.0019284504,0.000021336127,0.00021827182,0.000026187232,0.009459335],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901533,0.00026129215,0.000060056118,0.00009792739,0.00040888274,0.00015657156],"domain_scores_gemma":[0.9987214,0.0006280677,0.0002134516,0.000045080935,0.0003316133,0.000060331055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094608276,0.0001459942,0.00027374906,0.0018807477,0.00066119095,0.0032057015,0.00055649446,0.0013307255,0.0018080084],"category_scores_gemma":[0.0021353604,0.00015011484,0.00032594227,0.0034923656,0.0022583585,0.001465138,0.00084184296,0.0018609733,0.00024492515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005643597,0.00004520465,0.0023323917,0.0011814452,0.000043767745,0.00030544147,0.000336787,0.0037443824,0.00065603456,0.87020993,0.034301892,0.08678627],"study_design_scores_gemma":[0.00004076816,0.00013521478,0.059481654,0.0020020579,0.00008903667,0.00085154467,0.0013395062,0.0031807525,0.001229852,0.1721665,0.75938743,0.00009559512],"about_ca_topic_score_codex":0.02542774,"about_ca_topic_score_gemma":0.019442588,"teacher_disagreement_score":0.02542774,"about_ca_system_score_codex":0.008054368,"about_ca_system_score_gemma":0.005290937,"threshold_uncertainty_score":0.058438778},"labels":[],"label_agreement":null},{"id":"W3034059041","doi":"10.1186/s12992-020-00579-y","title":"Revisiting the public health implications of the United States–Mexico– Canada agreement","year":2020,"lang":"en","type":"letter","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public health; Agreement; Social policy; Biosimilar; Political science; Free trade agreement; Health services research; Medicine; Law; International trade; Business; Health care; Free trade","score_opus":0.13236834519523386,"score_gpt":0.3292878207365232,"score_spread":0.19691947554128933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034059041","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055790663,0.0010581813,0.000057251425,0.9896965,0.0037146457,0.0000050038575,0.00004960726,0.0000072896432,0.004853714],"genre_scores_gemma":[0.0067510344,0.0005786164,0.00012541543,0.9835339,0.0041704657,0.000011893752,0.000020200663,0.000014305794,0.0047941473],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98651475,0.0019613225,0.0006920851,0.0011733017,0.0054756003,0.004182894],"domain_scores_gemma":[0.9707071,0.017829046,0.0012134353,0.00049491064,0.007140091,0.002615382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013239637,0.0005058947,0.0010922586,0.0013592637,0.016383704,0.011303747,0.0041639498,0.07531478,0.005731665],"category_scores_gemma":[0.039308637,0.0007397643,0.0015217128,0.0014374871,0.010001202,0.0047027427,0.0039044041,0.043209754,0.0011646793],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004393164,0.000019063125,0.0007111335,0.00006640644,0.000017613937,0.0008887203,0.0012606686,0.00016645787,0.00014809475,0.056834925,0.93227077,0.0075722123],"study_design_scores_gemma":[0.000068045985,0.000012855988,0.0018772242,0.00035346957,0.00003501181,0.00022318038,0.0017608026,0.0003531363,0.00023336946,0.0130832335,0.98189235,0.00010724316],"about_ca_topic_score_codex":0.7726074,"about_ca_topic_score_gemma":0.834527,"teacher_disagreement_score":0.22739261,"about_ca_system_score_codex":0.061488923,"about_ca_system_score_gemma":0.10219935,"threshold_uncertainty_score":0.4574635},"labels":[],"label_agreement":null},{"id":"W3034406571","doi":"10.7189/jogh.10.010314","title":"Collective pharmaceutical procurement in China may have unintended consequences in supply and pricing","year":2020,"lang":"en","type":"review","venue":"Journal of Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Procurement; Business; Unintended consequences; China; Drug prices; Drug industry; Industrial organization; Commerce; Monetary economics; Economics; Marketing","score_opus":0.13724960773687855,"score_gpt":0.43478856578825276,"score_spread":0.2975389580513742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034406571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021185137,0.9939944,0.00019238655,0.0011802437,0.0001826428,0.000012514121,0.00007135812,0.000009911823,0.0022379903],"genre_scores_gemma":[0.0155308265,0.9830996,0.00015593188,0.00033751124,0.00014761926,0.000013731569,0.000062300845,0.0000021376545,0.000650374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996923,0.00006968188,0.000040651208,0.00003857878,0.00011671367,0.000042175136],"domain_scores_gemma":[0.9994137,0.00025498585,0.00013528526,0.000026295844,0.00013533869,0.000034297947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015040475,0.00059592654,0.0009984928,0.0013650787,0.0002886304,0.00090472214,0.0006967215,0.00069294806,0.004747202],"category_scores_gemma":[0.0014926192,0.00022345535,0.0010284318,0.0025709402,0.00066822703,0.0009996525,0.00058139605,0.00097383506,0.00045937597],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016387613,0.00007004769,0.0017468121,0.023959992,0.0003658805,0.00020612168,0.00006875648,0.0017518946,0.0008360636,0.015827509,0.016333746,0.9386693],"study_design_scores_gemma":[0.0005001687,0.0012342704,0.047442697,0.019230485,0.0016524328,0.0017528657,0.00028985503,0.002744414,0.002742036,0.012748186,0.90948373,0.00017879414],"about_ca_topic_score_codex":0.011913596,"about_ca_topic_score_gemma":0.025188621,"teacher_disagreement_score":0.011913596,"about_ca_system_score_codex":0.0016646016,"about_ca_system_score_gemma":0.00492844,"threshold_uncertainty_score":0.023688495},"labels":[],"label_agreement":null},{"id":"W3034653469","doi":"10.1016/j.sapharm.2020.06.007","title":"Drug price transparency initiative: The need for a broader view","year":2020,"lang":"en","type":"letter","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Transparency (behavior); Drug; Business; Accounting; Computer science; Medicine; Pharmacology; Computer security","score_opus":0.5817841710345911,"score_gpt":0.5001402218073251,"score_spread":0.08164394922726603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034653469","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021494384,0.0003507151,0.00011241976,0.9924522,0.0033811496,0.0000098758155,0.000030434741,0.0000131063825,0.0034351174],"genre_scores_gemma":[0.0024165625,0.00014944853,0.00027233697,0.98624724,0.0054848646,0.000034479766,0.000014038139,0.000020758125,0.005360274],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9494759,0.013268676,0.0041178833,0.0054523805,0.019703176,0.007982039],"domain_scores_gemma":[0.8373544,0.10533386,0.0072391685,0.0042034127,0.019710531,0.026158614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.039439827,0.0012729192,0.0032531018,0.0022244004,0.01548909,0.027911717,0.0062071984,0.26547784,0.01763026],"category_scores_gemma":[0.123692155,0.0019428125,0.0030786828,0.0019431341,0.015993817,0.022861803,0.010945872,0.14372842,0.006789295],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108856424,0.00012899828,0.0005785582,0.000095974625,0.000033681394,0.00082862703,0.0004735604,0.00013145627,0.00031532478,0.07702289,0.9104218,0.009860325],"study_design_scores_gemma":[0.000379367,0.0001223305,0.0024822722,0.0005874662,0.00006435246,0.00058042264,0.0014360524,0.0018831439,0.0006058944,0.11131483,0.8802083,0.00033548698],"about_ca_topic_score_codex":0.02657288,"about_ca_topic_score_gemma":0.03794301,"teacher_disagreement_score":0.26547784,"about_ca_system_score_codex":0.013855887,"about_ca_system_score_gemma":0.051128823,"threshold_uncertainty_score":0.20858026},"labels":[],"label_agreement":null},{"id":"W3035438457","doi":"10.15586/jptcp.v27i2.673","title":"Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand","year":2020,"lang":"en","type":"article","venue":"Journal of Population Therapeutics and Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Fraser Institute; Canadian Institute for Health Information","funders":"","keywords":"Formulary; Orphan drug; Listing (finance); Negotiation; Business; Reimbursement; Public health; Population; Pharmaceutical industry; Medicine; Family medicine; Health care; Finance; Environmental health; Political science; Economic growth; Pharmacology; Economics","score_opus":0.13788971459259763,"score_gpt":0.35350292540534456,"score_spread":0.21561321081274692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035438457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6987112,0.0055751977,0.0028103772,0.032469332,0.00025083937,0.0009916009,0.018267872,0.00021001142,0.24071348],"genre_scores_gemma":[0.97463316,0.0016346074,0.0018566042,0.0034305134,0.00006474178,0.00012269322,0.0050933873,0.000039072358,0.013125362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98660475,0.0010687367,0.00061325164,0.00074991415,0.007687598,0.0032757747],"domain_scores_gemma":[0.96871525,0.0064615197,0.00787268,0.00078492454,0.012618965,0.0035466563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057858448,0.00017618937,0.00044834038,0.003326841,0.0020920916,0.004032388,0.00089688465,0.00077251426,0.00677504],"category_scores_gemma":[0.028908579,0.00038751788,0.0008213659,0.0039014902,0.0013671922,0.0011024983,0.000967714,0.0017841825,0.00025004748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013550312,0.0003297314,0.62386817,0.0009459093,0.0006473991,0.0014713174,0.004368552,0.009761815,0.0020543225,0.10233852,0.10396025,0.14889899],"study_design_scores_gemma":[0.00018087568,0.00011147105,0.88629234,0.00025880846,0.000146047,0.00024599794,0.002377472,0.004475182,0.0007162424,0.0016650697,0.1034164,0.00011420944],"about_ca_topic_score_codex":0.9806739,"about_ca_topic_score_gemma":0.9806646,"teacher_disagreement_score":0.93701863,"about_ca_system_score_codex":0.0629814,"about_ca_system_score_gemma":0.1152547,"threshold_uncertainty_score":0.45696414},"labels":[],"label_agreement":null},{"id":"W3036463221","doi":"10.71781/4599","title":"L’impact du type d’assurance médicaments (privée/publique) sur le coût des médicaments et les dépenses des Québécois","year":2019,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Université de Montréal","keywords":"Political science; Medicine","score_opus":0.11288569780830918,"score_gpt":0.3546237424207439,"score_spread":0.24173804461243473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036463221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92347974,0.008756985,0.00094985584,0.017882913,0.00030395717,0.00014631166,0.0070409696,0.0000451243,0.041394215],"genre_scores_gemma":[0.97603625,0.0021244986,0.0005864068,0.0018743958,0.000060118768,0.000054818058,0.0010298196,0.000017984548,0.01821574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970335,0.0009121739,0.00010631355,0.0002662521,0.00094257016,0.0007393057],"domain_scores_gemma":[0.9874719,0.0025189305,0.0026858307,0.00030970777,0.0042514475,0.0027622806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024234925,0.00031564868,0.00037753946,0.0010600439,0.0020290338,0.002074471,0.0008950508,0.0007368683,0.012323696],"category_scores_gemma":[0.009874217,0.00023711745,0.0007649809,0.0018779222,0.0010829597,0.00068420626,0.00075966003,0.0013516871,0.0005716384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005312567,0.00013657553,0.9307074,0.00024791277,0.00053505,0.00020115665,0.0020166347,0.0006838109,0.0007064742,0.0021881,0.013548422,0.048497323],"study_design_scores_gemma":[0.000021841504,0.00009793959,0.98793554,0.00017324093,0.00012488531,0.000038650523,0.001311298,0.00036103657,0.00016363032,0.00010442103,0.009651581,0.000016037235],"about_ca_topic_score_codex":0.9810657,"about_ca_topic_score_gemma":0.9922915,"teacher_disagreement_score":0.029437251,"about_ca_system_score_codex":0.029437251,"about_ca_system_score_gemma":0.02799482,"threshold_uncertainty_score":0.21358323},"labels":[],"label_agreement":null},{"id":"W3036756415","doi":"10.1177/0840470420932185","title":"Gross profits of Canadian pharmacies: A changing policy regime","year":2020,"lang":"en","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Alberta","funders":"Association des pharmaciens du Canada","keywords":"Gross profit; Pharmacy; Business; Profit (economics); Finance; Government (linguistics); Agricultural economics; Economics; Public economics","score_opus":0.10983196799634733,"score_gpt":0.3117122706118717,"score_spread":0.20188030261552437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036756415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5019889,0.0075893165,0.0052357167,0.13065545,0.0003637446,0.00018680633,0.0063412385,0.00038748942,0.3472513],"genre_scores_gemma":[0.9791622,0.0021922821,0.0013485344,0.0033085903,0.00009829747,0.00002039137,0.00066731195,0.000030665244,0.013171787],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99175733,0.0005975479,0.00013633125,0.00048762205,0.005412792,0.0016083866],"domain_scores_gemma":[0.9936194,0.0011761406,0.00066609326,0.0002284155,0.003527468,0.00078248803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003536362,0.0003909814,0.00041161673,0.002561553,0.0032050444,0.0076542213,0.0017023238,0.0013530027,0.002172946],"category_scores_gemma":[0.016119957,0.00033549353,0.0006881675,0.003480117,0.0024135963,0.0013804514,0.0010073578,0.0019684255,0.00020257782],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033019876,0.0001997182,0.10930699,0.0002729793,0.00026544064,0.0004892163,0.0016712052,0.069716945,0.0019989663,0.5779598,0.09030065,0.14748788],"study_design_scores_gemma":[0.000119653305,0.00016629716,0.5838377,0.0003076979,0.00020908307,0.00018007317,0.0020684288,0.06551367,0.0027534466,0.037738245,0.3066824,0.00042330622],"about_ca_topic_score_codex":0.98410946,"about_ca_topic_score_gemma":0.97949284,"teacher_disagreement_score":0.8366878,"about_ca_system_score_codex":0.16331217,"about_ca_system_score_gemma":0.11702751,"threshold_uncertainty_score":0.9704393},"labels":[],"label_agreement":null},{"id":"W3038035002","doi":"10.1186/s12916-020-01661-3","title":"Why the COVID-19 pandemic should be a call for action to advance equitable access to medicines","year":2020,"lang":"en","type":"article","venue":"BMC Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Pandemic; 2019-20 coronavirus outbreak; Call to action; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Action (physics); Coronavirus Infections; Betacoronavirus; Infectious disease (medical specialty); Outbreak; Disease; Internal medicine; Marketing","score_opus":0.5341244586341032,"score_gpt":0.46794289125974886,"score_spread":0.06618156737435432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038035002","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013548697,0.002285461,0.0005307239,0.98280394,0.0044399644,0.000009378708,0.00024823294,0.000030488522,0.008297039],"genre_scores_gemma":[0.097326204,0.004873985,0.0026253213,0.8733414,0.011897568,0.0000858329,0.0003540309,0.00018037605,0.009315279],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914631,0.0030212635,0.00038091384,0.00067812693,0.0025194525,0.0019371022],"domain_scores_gemma":[0.9651026,0.015105217,0.002773434,0.0012911592,0.008502652,0.0072249444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015983725,0.00053704873,0.0010382695,0.00096120656,0.0019706385,0.008977004,0.0013817088,0.021641916,0.029255586],"category_scores_gemma":[0.07582133,0.00043642713,0.0012266997,0.000845092,0.006065261,0.014239858,0.003870996,0.022944178,0.005218722],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032319644,0.00014055685,0.0026117284,0.00024317126,0.00012126422,0.00023504578,0.0002743312,0.0011383069,0.0004944274,0.2817419,0.68953156,0.02314457],"study_design_scores_gemma":[0.00024558482,0.00012229568,0.005891982,0.0010558494,0.00007301891,0.00027331675,0.0013447086,0.0021805053,0.00057196594,0.41270578,0.57537746,0.00015748532],"about_ca_topic_score_codex":0.018615324,"about_ca_topic_score_gemma":0.016758699,"teacher_disagreement_score":0.029255586,"about_ca_system_score_codex":0.006719007,"about_ca_system_score_gemma":0.017209744,"threshold_uncertainty_score":0.097869754},"labels":[],"label_agreement":null},{"id":"W3038651714","doi":"10.1002/cpt.1981","title":"Comparing Onset of Biosimilar Versus Generic Competition in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk Fonden","keywords":"Biosimilar; Statutory law; Competition (biology); Medicine; Generic drug; Business; Pharmacology; Drug; Internal medicine; Law; Political science","score_opus":0.40271137957245057,"score_gpt":0.4240386167015656,"score_spread":0.02132723712911505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038651714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837586,0.00276628,0.0004095793,0.0010136012,0.000045411092,0.000047014084,0.0038131054,0.000023721854,0.008122741],"genre_scores_gemma":[0.9956027,0.0005538227,0.0001853871,0.00052785187,0.000041275805,0.00001787978,0.0026859066,0.000009306939,0.00037576456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996851,0.0008113531,0.00033608472,0.0007371767,0.0007298916,0.0005344647],"domain_scores_gemma":[0.98092616,0.0047394643,0.010156903,0.0003911188,0.0019912724,0.0017950282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004711095,0.00016037966,0.00037363247,0.0014298176,0.00039537423,0.0020432782,0.0005315023,0.0007052167,0.003887042],"category_scores_gemma":[0.012755638,0.00019511188,0.0007036401,0.0017952124,0.00065268995,0.0014845832,0.0008696603,0.0011588698,0.00032115597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094529573,0.00022738345,0.9756763,0.00014281578,0.0002246917,0.00016234902,0.00035561612,0.00082641444,0.00038917884,0.0021185386,0.0034066674,0.0155248195],"study_design_scores_gemma":[0.000047733,0.00039661909,0.9908693,0.000111011555,0.000072457864,0.00035027694,0.0005058036,0.0012248127,0.00032980624,0.00030181423,0.005765743,0.0000246588],"about_ca_topic_score_codex":0.01601642,"about_ca_topic_score_gemma":0.018424641,"teacher_disagreement_score":0.01601642,"about_ca_system_score_codex":0.0017888586,"about_ca_system_score_gemma":0.001393832,"threshold_uncertainty_score":0.031846404},"labels":[],"label_agreement":null},{"id":"W3039703740","doi":"10.34172/ijhpm.2020.100","title":"Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study","year":2020,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Medical prescription; Medicine; Cohort; Demography; Pharmacology; Internal medicine","score_opus":0.10679156050896219,"score_gpt":0.33212547263110587,"score_spread":0.22533391212214368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039703740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98897856,0.0011095766,0.00013733382,0.00032937978,0.000020314234,0.00006877711,0.006735232,0.000011023359,0.0026097964],"genre_scores_gemma":[0.9945799,0.0007686216,0.00014906905,0.0001179222,0.000012809193,0.000031677067,0.0028789344,0.000012071859,0.0014491136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983688,0.00006950991,0.00010991296,0.00031380312,0.0006056093,0.00053230557],"domain_scores_gemma":[0.9960556,0.00029839217,0.0013631788,0.0002580161,0.0011568598,0.000868016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011767542,0.00038783182,0.0005663518,0.0017307616,0.0024823216,0.0017331376,0.0013195323,0.0006232053,0.0034605742],"category_scores_gemma":[0.0039057937,0.00046483363,0.001445618,0.005432848,0.00070181116,0.0008213913,0.0010769361,0.0018246328,0.00039361106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002326428,0.000044228353,0.9954135,0.000033629865,0.00010507645,0.00008290983,0.00054399524,0.000057353438,0.000092004855,0.00013294947,0.0008424105,0.0024194666],"study_design_scores_gemma":[0.0000145640915,0.00006304303,0.99687684,0.000034657554,0.00009277452,0.00010239162,0.0009851195,0.00020772057,0.00004382237,0.000038980994,0.0015207492,0.00001926924],"about_ca_topic_score_codex":0.9606008,"about_ca_topic_score_gemma":0.967627,"teacher_disagreement_score":0.039399207,"about_ca_system_score_codex":0.01587026,"about_ca_system_score_gemma":0.023141298,"threshold_uncertainty_score":0.11514729},"labels":[],"label_agreement":null},{"id":"W3041069404","doi":"10.1136/bmj.m2797","title":"US purchases world stocks of remdesivir: why the rest of the world should be glad to be at the back of the queue","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Rest (music); Queue; Coronavirus disease 2019 (COVID-19); Economics; History; Computer science; Medicine; Internal medicine","score_opus":0.20237255918506483,"score_gpt":0.3375962559495461,"score_spread":0.1352236967644813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041069404","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016095287,0.0106315585,0.00006956191,0.96548617,0.0066443733,0.0000033169958,0.00063580583,0.00003622175,0.014883406],"genre_scores_gemma":[0.06815416,0.031236514,0.00046712052,0.8081083,0.022026755,0.000023244833,0.0011432036,0.00021317326,0.06862753],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857473,0.00027460055,0.00010254734,0.00010494915,0.00067278807,0.0002704059],"domain_scores_gemma":[0.99327856,0.002031972,0.0007425939,0.0002164192,0.0020723606,0.0016581485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003069354,0.00039227636,0.00053316535,0.0008209121,0.002218446,0.0072776345,0.0006909855,0.0074061994,0.017825365],"category_scores_gemma":[0.016429372,0.00027691378,0.0004941989,0.001161837,0.0017868469,0.006243936,0.0014386456,0.010349909,0.005850862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010742077,0.000018245679,0.0016591601,0.000033789456,0.000017809665,0.000059986727,0.00009543637,0.00003771363,0.00007941557,0.01020763,0.97091216,0.016771184],"study_design_scores_gemma":[0.00008025549,0.000044958117,0.005258804,0.00039835338,0.000035234527,0.00013844298,0.00082307984,0.00022809592,0.00037035628,0.01013086,0.98242444,0.00006721054],"about_ca_topic_score_codex":0.057844408,"about_ca_topic_score_gemma":0.07087361,"teacher_disagreement_score":0.057844408,"about_ca_system_score_codex":0.0028324085,"about_ca_system_score_gemma":0.004817528,"threshold_uncertainty_score":0.11501539},"labels":[],"label_agreement":null},{"id":"W3041984362","doi":"10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4764","title":"Attitudes and Behaviours of Physicians Towards Use of Industry-Provided Inhaled Medication Samples","year":2020,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Environmental health; Medicine","score_opus":0.18539430333581702,"score_gpt":0.32094811586713934,"score_spread":0.13555381253132232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041984362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99878734,0.0000684133,0.000030140242,0.0002993113,0.0000049023392,0.000006130245,0.00004302224,9.543791e-7,0.0007599093],"genre_scores_gemma":[0.99922705,0.00007628588,0.000049291928,0.00020931943,0.000010877555,0.0000037793122,0.000035465062,8.9397724e-7,0.0003870396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984688,0.0006446712,0.00014866728,0.00013896752,0.00036546364,0.00023340917],"domain_scores_gemma":[0.98568046,0.0060756383,0.0049833176,0.00032792057,0.0010167474,0.001915903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015928821,0.00010939669,0.00017702545,0.0007375171,0.0005379135,0.0010205834,0.00021683538,0.0012436647,0.0035598357],"category_scores_gemma":[0.015478551,0.00027803282,0.00039789642,0.0004834881,0.00052565424,0.00062969764,0.000555283,0.0009620824,0.0004887366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033256185,0.0004268306,0.98937947,0.000019530735,0.00004535596,0.00008197355,0.0040664943,0.00009457511,0.00066057954,0.000070293245,0.00017015211,0.0046522566],"study_design_scores_gemma":[0.000012741648,0.00037524113,0.9926582,0.000023351258,0.000020141468,0.00016169398,0.005739736,0.00036573227,0.00016896908,0.000052796546,0.00040928973,0.0000120028435],"about_ca_topic_score_codex":0.010291186,"about_ca_topic_score_gemma":0.008516685,"teacher_disagreement_score":0.010291186,"about_ca_system_score_codex":0.0004617333,"about_ca_system_score_gemma":0.0005036785,"threshold_uncertainty_score":0.020462573},"labels":[],"label_agreement":null},{"id":"W3043637706","doi":"","title":"School of Pharmacy Intellectual Property Report FY20, Fourth Quarter Report","year":2020,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmacy; Property (philosophy); Pharmacy school; Multistate Pharmacy Jurisprudence Examination; Medicine; Pharmacy practice; Pharmaconomist; Family medicine; History","score_opus":0.12491231922106276,"score_gpt":0.30972583799707804,"score_spread":0.18481351877601526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043637706","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018092114,0.003088953,0.0011422981,0.04378438,0.00783449,0.0016435027,0.45566097,0.0034539117,0.46529937],"genre_scores_gemma":[0.025725923,0.002546835,0.0006747891,0.002952493,0.0021962451,0.0007753638,0.09718276,0.00026464148,0.867681],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99560213,0.00017001282,0.00020399418,0.000318465,0.0029550393,0.00075034425],"domain_scores_gemma":[0.98902994,0.0013061219,0.00087268715,0.0005546677,0.0066094445,0.0016270716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030933793,0.0011734331,0.0010703218,0.0055242693,0.0024585451,0.00590303,0.0017102438,0.0048956973,0.20193116],"category_scores_gemma":[0.012715858,0.00062894553,0.0006678957,0.0048915083,0.00036986827,0.0023585428,0.0013403901,0.0027266794,0.10087251],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013955268,0.00015667362,0.0025075788,0.000052649724,0.000008686198,0.000035352343,0.000013774142,0.000102800324,0.0001216048,0.00078442367,0.98464775,0.011429244],"study_design_scores_gemma":[0.0002107438,0.00019929335,0.0513645,0.000105837134,0.000046988822,0.00007610422,0.00019662711,0.0010791034,0.0020924811,0.00082488445,0.943773,0.000030420224],"about_ca_topic_score_codex":0.10784831,"about_ca_topic_score_gemma":0.10253981,"teacher_disagreement_score":0.20193116,"about_ca_system_score_codex":0.006661074,"about_ca_system_score_gemma":0.020060297,"threshold_uncertainty_score":0.67552704},"labels":[],"label_agreement":null},{"id":"W3043725192","doi":"10.1038/s41416-020-0990-8","title":"Increasing operational and scientific efficiency in clinical trials","year":2020,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Clinical trial; Drug development; Key (lock); Medicine; MEDLINE; Intensive care medicine; Medical physics; Computer science; Drug; Pathology; Pharmacology; Political science","score_opus":0.23072288466261529,"score_gpt":0.42167349427240414,"score_spread":0.19095060960978885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043725192","genre_codex":"methods","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05185205,0.043472495,0.5885885,0.1904778,0.0024508766,0.0043874406,0.0008874507,0.0013676172,0.11651575],"genre_scores_gemma":[0.7570533,0.011961597,0.19811592,0.017463423,0.004963669,0.0036942305,0.0005514793,0.0004850061,0.0057113934],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.4391985,0.47995988,0.024477996,0.010189654,0.03921317,0.006960923],"domain_scores_gemma":[0.15773769,0.6796284,0.051509164,0.06319155,0.038656656,0.009276593],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.4683633,0.0022253564,0.004398843,0.007648903,0.0016279969,0.021552496,0.005696365,0.007073307,0.009864144],"category_scores_gemma":[0.72476196,0.001992193,0.0021539438,0.007485511,0.019098785,0.02540039,0.014829309,0.009455702,0.004089802],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025030863,0.00040405028,0.016727645,0.004353729,0.001408127,0.00032591927,0.0019395829,0.05509431,0.0015133847,0.5843933,0.021948814,0.309388],"study_design_scores_gemma":[0.0012631128,0.0012693729,0.011802651,0.003333861,0.00043584497,0.00048072744,0.00083032117,0.03704709,0.0012894819,0.89394677,0.048125707,0.00017503092],"about_ca_topic_score_codex":0.0019447957,"about_ca_topic_score_gemma":0.0013056527,"teacher_disagreement_score":0.5316367,"about_ca_system_score_codex":0.016106267,"about_ca_system_score_gemma":0.032319725,"threshold_uncertainty_score":0.6556027},"labels":[],"label_agreement":null},{"id":"W3047321073","doi":"10.1377/hlthaff.2019.01554","title":"Compared With Other Countries, Women In The US Are More Likely Than Men To Forgo Medicines Because Of Cost","year":2020,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Business; Family medicine; Environmental health","score_opus":0.07361314984354529,"score_gpt":0.3114713086377136,"score_spread":0.23785815879416833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047321073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95364547,0.0062836236,0.0007509758,0.00602502,0.00017531724,0.000042113996,0.0046302676,0.000030302142,0.028417023],"genre_scores_gemma":[0.9888102,0.0047805132,0.00047422567,0.0018228369,0.0000949502,0.000033973072,0.0012971095,0.000006385939,0.0026797545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997621,0.000081204606,0.000024568939,0.000034376913,0.00005051084,0.00004719272],"domain_scores_gemma":[0.998978,0.00019246455,0.0005882466,0.000033342618,0.00009379669,0.000114022674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032405718,0.00012332576,0.0002496775,0.0007734376,0.00038522098,0.0005644218,0.00008032917,0.0001797186,0.008800625],"category_scores_gemma":[0.0019306357,0.00007608797,0.0002546228,0.0018015389,0.00016290361,0.0003929289,0.00024697278,0.00033540145,0.0004902196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050943356,0.00004999763,0.9557304,0.000074036456,0.000082673934,0.00009662088,0.00040443026,0.000086653934,0.00013393261,0.0008838381,0.0054969033,0.036909673],"study_design_scores_gemma":[0.000013248894,0.00006820242,0.97637546,0.00012870222,0.00007293879,0.0003065679,0.0019320673,0.00015351547,0.00010370114,0.0006732686,0.020162778,0.000009519179],"about_ca_topic_score_codex":0.04866117,"about_ca_topic_score_gemma":0.076353826,"teacher_disagreement_score":0.04866117,"about_ca_system_score_codex":0.00034545784,"about_ca_system_score_gemma":0.0005149534,"threshold_uncertainty_score":0.09675586},"labels":[],"label_agreement":null},{"id":"W3047360337","doi":"10.5639/gabij.2020.0901.005","title":"It is time to change US trade policy to foster access to medicines","year":2020,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Negotiation; Biosimilar; Balance (ability); Business; Access to medicines; Sustainability; International trade; International economics; Economics; Economic growth; Political science; Medicine; Developing country; Law","score_opus":0.24197099643837727,"score_gpt":0.3549841684586827,"score_spread":0.11301317202030542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047360337","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038728872,0.002892733,0.0005946548,0.97838634,0.013505316,0.000009555081,0.00006751157,0.000121534846,0.0040350524],"genre_scores_gemma":[0.0087289605,0.0031600092,0.0034471627,0.97296405,0.0055726143,0.000038590413,0.0001209735,0.000093386625,0.0058743106],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9786645,0.005639034,0.0014457515,0.0013373458,0.008201405,0.004711985],"domain_scores_gemma":[0.92158806,0.01846859,0.0063396827,0.0039563924,0.023303315,0.026343886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022548592,0.0010692766,0.001766738,0.0017110516,0.0053335587,0.018786974,0.0037561664,0.03305809,0.029786376],"category_scores_gemma":[0.08146176,0.00068285747,0.0022871916,0.0020369668,0.0077985395,0.015719527,0.0057043843,0.035610527,0.014901373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015787096,0.00033912095,0.00055673486,0.0002582429,0.000064255255,0.00022246543,0.00032166092,0.00041414922,0.0004597798,0.0602936,0.8907071,0.046205148],"study_design_scores_gemma":[0.00007510334,0.00009724546,0.0009172572,0.00064765546,0.00003100948,0.000108345565,0.001205278,0.00019449434,0.00023486173,0.058536347,0.9378926,0.000059808892],"about_ca_topic_score_codex":0.013085889,"about_ca_topic_score_gemma":0.019813629,"teacher_disagreement_score":0.03305809,"about_ca_system_score_codex":0.0073595806,"about_ca_system_score_gemma":0.036828917,"threshold_uncertainty_score":0.11924976},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3047994869","doi":"10.2139/ssrn.3667006","title":"Pharmaceutical Policies from 1978 Alma Ata to 2018 Ebola: A Critical Interpretive Synthesis","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Ebola virus; Political science; Engineering ethics; Medicine; Virology; Engineering","score_opus":0.04981366501919154,"score_gpt":0.319813220938039,"score_spread":0.26999955591884744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047994869","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22545758,0.46850288,0.0012267114,0.15266031,0.0037890214,0.00017342648,0.007646596,0.000038765826,0.14050467],"genre_scores_gemma":[0.8538514,0.12445039,0.0006034884,0.010333611,0.0022370156,0.00025867863,0.001410289,0.000052203686,0.0068030306],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99817395,0.00054240297,0.00016371615,0.00019838073,0.00037318154,0.0005483525],"domain_scores_gemma":[0.9839256,0.012092465,0.0018516349,0.00024758207,0.0016949736,0.00018774955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004270736,0.00058906,0.0009019558,0.0067671,0.0016688156,0.0054130526,0.001013837,0.002713252,0.008600475],"category_scores_gemma":[0.023957035,0.00033266898,0.0005582567,0.008687181,0.002567603,0.0051590553,0.0020621703,0.004228302,0.0005559179],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030361833,0.00032304044,0.03706651,0.021876184,0.0012452049,0.002959482,0.041627016,0.005823563,0.00071588496,0.5776272,0.104810745,0.20288907],"study_design_scores_gemma":[0.00026292398,0.00018571573,0.19722158,0.040068336,0.0013787161,0.00033356607,0.081393,0.0017607469,0.0023478363,0.08885905,0.5860499,0.00013862508],"about_ca_topic_score_codex":0.08126696,"about_ca_topic_score_gemma":0.08252694,"teacher_disagreement_score":0.08126696,"about_ca_system_score_codex":0.017097237,"about_ca_system_score_gemma":0.008967523,"threshold_uncertainty_score":0.1615879},"labels":[],"label_agreement":null},{"id":"W3049236550","doi":"10.3389/fsoc.2020.00058","title":"Access to Medicines, Access to Markets","year":2020,"lang":"en","type":"review","venue":"Frontiers in Sociology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Access to medicines; Context (archaeology); Market access; Business; Public relations; Universal design; Pharmaceutical industry; Marketing; Economic growth; Developing country; Political science; Economics; Medicine; Engineering","score_opus":0.16917839079106953,"score_gpt":0.4108678165250835,"score_spread":0.24168942573401395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049236550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009835457,0.9902018,0.0001301593,0.0029993134,0.00023983764,0.0000027549202,0.000018505743,0.0000034426882,0.006305932],"genre_scores_gemma":[0.0038246694,0.99290186,0.00014064323,0.0013805323,0.00057692867,0.000007402882,0.000024547671,0.000001992092,0.0011413714],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991492,0.00034337316,0.000073747426,0.00010368413,0.00025190716,0.000078045974],"domain_scores_gemma":[0.9980829,0.0013856067,0.0002212435,0.000052992407,0.00015250675,0.00010485625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012091536,0.00057898724,0.00095670816,0.002862726,0.00053328346,0.0027710698,0.00058682606,0.002616867,0.011735705],"category_scores_gemma":[0.0034595744,0.00020355504,0.0004486989,0.0045961514,0.0024999827,0.0046736435,0.0015928017,0.0024720398,0.0014484291],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005926788,0.000068037334,0.00039802777,0.02774449,0.00010129454,0.00019019499,0.00041471765,0.0005532472,0.00031415533,0.3350228,0.06054771,0.57458603],"study_design_scores_gemma":[0.000008436229,0.000021543467,0.0007686892,0.008085793,0.000027525388,0.00031434995,0.00018012941,0.000039696177,0.000052199248,0.044339065,0.94615346,0.000009070108],"about_ca_topic_score_codex":0.0034256182,"about_ca_topic_score_gemma":0.0035801223,"teacher_disagreement_score":0.011735705,"about_ca_system_score_codex":0.0016907293,"about_ca_system_score_gemma":0.0030279357,"threshold_uncertainty_score":0.03925985},"labels":[],"label_agreement":null},{"id":"W3056551509","doi":"10.3389/fmed.2020.00457","title":"The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage","year":2020,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"World Health Organization","keywords":"Benchmarking; Business; Process management; Knowledge management; Engineering management; Computer science; Engineering; Marketing","score_opus":0.03681927475095572,"score_gpt":0.2817846207367667,"score_spread":0.24496534598581096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3056551509","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07597514,0.0057749585,0.2925036,0.030783335,0.0037343178,0.010498557,0.11068981,0.010888601,0.4591516],"genre_scores_gemma":[0.43753856,0.0036492888,0.44793096,0.0049356,0.0006124574,0.01710805,0.07171778,0.0015708947,0.014936356],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9669658,0.02055588,0.003353985,0.000978957,0.006771696,0.0013736833],"domain_scores_gemma":[0.95642513,0.016843293,0.0074243303,0.0032301995,0.013421744,0.0026553099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035195526,0.0014637586,0.0010642831,0.014484229,0.0011310158,0.00438828,0.001480769,0.0010199881,0.010433176],"category_scores_gemma":[0.07215669,0.0004077068,0.0013439565,0.019778032,0.0010711036,0.005755688,0.005848153,0.0016874889,0.0017132026],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036325227,0.0004719597,0.033932656,0.0028900972,0.00039311824,0.00021585706,0.002016757,0.013891472,0.00074454176,0.09293644,0.44530445,0.4068393],"study_design_scores_gemma":[0.0005380169,0.0009547133,0.11995041,0.005588977,0.0003174076,0.00045299734,0.0058897664,0.020688409,0.0033160078,0.10459793,0.73733115,0.0003742002],"about_ca_topic_score_codex":0.0059159687,"about_ca_topic_score_gemma":0.003492429,"teacher_disagreement_score":0.035195526,"about_ca_system_score_codex":0.0034107699,"about_ca_system_score_gemma":0.011743367,"threshold_uncertainty_score":0.18613398},"labels":[],"label_agreement":null},{"id":"W3080884038","doi":"10.1111/jphs.12379","title":"Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective","year":2020,"lang":"en","type":"review","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Essential medicines; Government (linguistics); Health care; Access to medicines; Economic interventionism; Quality (philosophy); Intervention (counseling); Medicine; Business; Market access; Public economics; Marketing; Public health; Economic growth; Nursing; Economics","score_opus":0.19242216909559795,"score_gpt":0.5392150905523204,"score_spread":0.34679292145672247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080884038","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058722607,0.995141,0.00018367107,0.0023113955,0.00022791928,0.000103866034,0.00008771306,0.0000043545333,0.001352687],"genre_scores_gemma":[0.011542943,0.98608685,0.00044264493,0.0012905502,0.00016877138,0.00022240716,0.00007592504,0.0000035171586,0.00016636349],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9920798,0.0033101775,0.0021681942,0.000553379,0.0014902498,0.00039825105],"domain_scores_gemma":[0.9572556,0.035173226,0.0034374476,0.00043864228,0.0034718297,0.00022329863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009255845,0.0010054077,0.0032342824,0.00863587,0.0007896511,0.00532297,0.0014905396,0.003875378,0.0048139542],"category_scores_gemma":[0.046466604,0.0006738462,0.0045013684,0.009838961,0.0016533958,0.0050046183,0.0016497682,0.0017597215,0.0004081575],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013664337,0.00006919812,0.0010792956,0.79328936,0.0023156584,0.00019271625,0.00078821665,0.00046280495,0.0002147942,0.012416435,0.007495799,0.1815391],"study_design_scores_gemma":[0.0000750061,0.00011776147,0.0030653866,0.89623433,0.007932528,0.0003170083,0.00122603,0.0002522479,0.00031231597,0.0040889187,0.08634284,0.00003555568],"about_ca_topic_score_codex":0.007997106,"about_ca_topic_score_gemma":0.010632684,"teacher_disagreement_score":0.009255845,"about_ca_system_score_codex":0.0053729657,"about_ca_system_score_gemma":0.01847383,"threshold_uncertainty_score":0.048950136},"labels":[],"label_agreement":null},{"id":"W3081616766","doi":"10.3138/cpp.2020-107","title":"COVID-19’s Limited Impact on Drug Shortages in Canada","year":2020,"lang":"en","type":"article","venue":"Canadian Public Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Economic shortage; Coronavirus disease 2019 (COVID-19); Pandemic; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Medicine; Drug; Business; Demography; Environmental health; Disease; Virology; Infectious disease (medical specialty); Internal medicine; Pharmacology; Outbreak; Sociology","score_opus":0.08655622030873825,"score_gpt":0.2946264292240056,"score_spread":0.20807020891526737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081616766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8039208,0.009731082,0.00044089486,0.06642583,0.00032847852,0.0000963493,0.06875426,0.00012649629,0.050175793],"genre_scores_gemma":[0.9806174,0.0028017361,0.00017712911,0.0026064056,0.00008968783,0.000017313643,0.007729116,0.00001890289,0.005942392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981388,0.00011298382,0.00006858857,0.0001176043,0.00068022,0.00088182715],"domain_scores_gemma":[0.98726326,0.0012532971,0.0026027765,0.00014495298,0.00490585,0.0038299426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013604001,0.00019952736,0.00039992252,0.0019452003,0.0018195967,0.0018561346,0.00059002446,0.00047669734,0.007328586],"category_scores_gemma":[0.008756822,0.00025665408,0.00048443172,0.004681296,0.000641094,0.0006336768,0.0013349233,0.0009809308,0.00039103345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037003667,0.0001428421,0.84102064,0.00043376998,0.0001517391,0.0003682058,0.0007573625,0.0034176665,0.00023835196,0.003909639,0.1133996,0.035790134],"study_design_scores_gemma":[0.000037548634,0.000044160308,0.9738317,0.00017584521,0.000032649084,0.000048362046,0.0014691647,0.0017396694,0.00012652003,0.00027163068,0.022201626,0.000021108137],"about_ca_topic_score_codex":0.9954835,"about_ca_topic_score_gemma":0.996861,"teacher_disagreement_score":0.054155864,"about_ca_system_score_codex":0.054155864,"about_ca_system_score_gemma":0.10246644,"threshold_uncertainty_score":0.39293015},"labels":[],"label_agreement":null},{"id":"W3082494315","doi":"10.9778/cmajo.20200036","title":"Factors associated with drug shortages in Canada: a retrospective cohort study","year":2020,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; Ontario Drug Policy Research Network; University of Calgary; University of British Columbia","funders":"Canadian Institutes of Health Research; Teva Pharmaceutical Industries","keywords":"Economic shortage; Medical prescription; Retrospective cohort study; Medicine; Logistic regression; Odds ratio; Business; Workload; Generic drug; Drug; Emergency medicine; Internal medicine; Pharmacology; Economics","score_opus":0.10502986373352755,"score_gpt":0.29231469785483166,"score_spread":0.18728483412130412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082494315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98801595,0.00075633026,0.00022308277,0.0003156369,0.000019501604,0.00011235666,0.009344413,0.000012885018,0.001199867],"genre_scores_gemma":[0.99526274,0.0005852859,0.00021409756,0.00021451365,0.000014422376,0.000052200343,0.0033634221,0.000007686361,0.00028560704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851507,0.00008926922,0.00012313185,0.00033200483,0.00051441113,0.00042610144],"domain_scores_gemma":[0.99648523,0.0001845779,0.0015548712,0.00017244699,0.000996901,0.0006060093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009942893,0.00040059316,0.00054437853,0.0015609262,0.0018096941,0.0010674492,0.0011300155,0.0005179299,0.0018422112],"category_scores_gemma":[0.0027498782,0.0006070478,0.00073653593,0.0054173237,0.00069441035,0.0006260486,0.00095804303,0.0010313493,0.00022102805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027220009,0.0000146185475,0.9988023,0.000015976002,0.000033178963,0.00003934317,0.00008631785,0.000025387933,0.00003363124,0.000020838683,0.00048400887,0.00041714066],"study_design_scores_gemma":[0.0000069723933,0.000029273797,0.99850994,0.00003468905,0.000031771528,0.000100395046,0.00045608266,0.00022830104,0.000023108703,0.000016778591,0.0005543699,0.0000082404795],"about_ca_topic_score_codex":0.921805,"about_ca_topic_score_gemma":0.93341154,"teacher_disagreement_score":0.078194976,"about_ca_system_score_codex":0.00897239,"about_ca_system_score_gemma":0.016481705,"threshold_uncertainty_score":0.1573109},"labels":[],"label_agreement":null},{"id":"W3083281660","doi":"10.34172/ijhpm.2020.166","title":"Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity","year":2020,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Gilead Sciences","keywords":"Equity (law); Pandemic; Public health; Business; Context (archaeology); Transparency (behavior); Economics; Public economics; Public relations; Coronavirus disease 2019 (COVID-19); Political science; Medicine; Disease; Infectious disease (medical specialty)","score_opus":0.3335500280267978,"score_gpt":0.47862457763086746,"score_spread":0.14507454960406968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083281660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84626937,0.0012060814,0.0030042806,0.0548689,0.00010801313,0.00015272193,0.000101294725,0.000023811506,0.09426539],"genre_scores_gemma":[0.99551165,0.000394821,0.0004367047,0.0011619821,0.000041715663,0.000041054198,0.00001419545,0.000008281317,0.0023895737],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9925559,0.004789106,0.00011305653,0.0002774701,0.00044510205,0.0018193923],"domain_scores_gemma":[0.9877017,0.009149471,0.001101576,0.00038224916,0.00048626433,0.0011786473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009055127,0.00032141083,0.00046312952,0.0011069799,0.00961405,0.0072144177,0.0011558215,0.0056826137,0.0048957835],"category_scores_gemma":[0.011817441,0.000219359,0.00081237545,0.001188154,0.008485331,0.0053472314,0.00830877,0.0055356342,0.00032145187],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036725905,0.0013969464,0.047899656,0.00023785973,0.0000616792,0.023935266,0.18609418,0.0052237376,0.0010620892,0.6673332,0.010655331,0.055732794],"study_design_scores_gemma":[0.00020256624,0.00071637094,0.039208125,0.0008645295,0.000118856435,0.00585393,0.6287863,0.012993652,0.0016342271,0.19586559,0.113584094,0.00017177679],"about_ca_topic_score_codex":0.02119033,"about_ca_topic_score_gemma":0.02645787,"teacher_disagreement_score":0.02119033,"about_ca_system_score_codex":0.009496413,"about_ca_system_score_gemma":0.0063025397,"threshold_uncertainty_score":0.06890154},"labels":[],"label_agreement":null},{"id":"W3084095311","doi":"10.1186/s12992-020-00610-2","title":"Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study","year":2020,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Research Foundation of Korea; Ministry of Science and ICT, South Korea; Korea Institute of Science and Technology Information; Korea Institute of Science and Technology; National Research Foundation","keywords":"Business; Population; Global health; Public health; Economic growth; Geography; Economics; Environmental health; Health care; Medicine","score_opus":0.28110521488243534,"score_gpt":0.42250992008401955,"score_spread":0.1414047052015842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084095311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926615,0.0028141956,0.00044293547,0.0002201341,0.000008955532,0.0000211639,0.0016276538,0.00000794552,0.0021954654],"genre_scores_gemma":[0.9985203,0.00046391212,0.00024169778,0.000017645596,0.00001739114,0.000008569984,0.00065799215,0.0000025336494,0.000070032984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986504,0.0005578364,0.00013870346,0.00021125622,0.00026436182,0.000177464],"domain_scores_gemma":[0.98932904,0.0026719,0.0060439273,0.00041419186,0.0009365161,0.0006043532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031279707,0.00032057625,0.0003921911,0.005872146,0.00020260179,0.0012059888,0.00036888107,0.0003661287,0.001541344],"category_scores_gemma":[0.007308844,0.00013842016,0.0011223188,0.0071517047,0.00045881883,0.0012978528,0.001102827,0.00047073868,0.00021690279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008430537,0.000032122785,0.99233574,0.000080290534,0.00030388264,0.00008630692,0.00025407327,0.00045940912,0.00007038545,0.00033817766,0.00024395963,0.0057113245],"study_design_scores_gemma":[0.000005010374,0.00008642718,0.9978399,0.00002699984,0.00009562366,0.00023043402,0.00043889543,0.0004928706,0.000038058235,0.00008307817,0.00065597415,0.00000655197],"about_ca_topic_score_codex":0.004677936,"about_ca_topic_score_gemma":0.0041909134,"teacher_disagreement_score":0.005872146,"about_ca_system_score_codex":0.0007900139,"about_ca_system_score_gemma":0.00061715744,"threshold_uncertainty_score":0.016542494},"labels":[],"label_agreement":null},{"id":"W3085196972","doi":"10.1016/s0140-6736(20)31876-6","title":"An activist history of drug shortages and its silos","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Economic shortage; Drug; Information silo; Medicine; Business; Medical emergency; Silo; Pharmacology; History; Archaeology","score_opus":0.1384564861851789,"score_gpt":0.29575425988813586,"score_spread":0.15729777370295697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085196972","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041534593,0.022156399,0.00080350414,0.91798824,0.0078111403,0.000013225881,0.00012600698,0.000027124705,0.046920825],"genre_scores_gemma":[0.26995477,0.02596672,0.0009544609,0.6041747,0.03921265,0.00011117208,0.00010854399,0.00012058091,0.059396427],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99553996,0.0019128295,0.0001691101,0.0003963348,0.0009759106,0.0010058153],"domain_scores_gemma":[0.9757715,0.016781477,0.0018296419,0.000813327,0.0017719627,0.0030321272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010920379,0.00051676563,0.0006110007,0.0017641867,0.0042891586,0.009783013,0.0009114206,0.013449022,0.010655215],"category_scores_gemma":[0.02705726,0.00044792515,0.0005357767,0.00210795,0.015981529,0.0058155027,0.0044794213,0.020304883,0.0013375762],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015046296,0.00013704997,0.0010608328,0.00023304649,0.000040670606,0.0002675642,0.002108489,0.00033377227,0.00020352338,0.67585903,0.29427016,0.025335371],"study_design_scores_gemma":[0.000090842004,0.000045841964,0.0018167892,0.00056348223,0.000012865461,0.00012219057,0.0013844059,0.0003019263,0.00020205931,0.1626664,0.83276147,0.000031764892],"about_ca_topic_score_codex":0.009211067,"about_ca_topic_score_gemma":0.01227642,"teacher_disagreement_score":0.013449022,"about_ca_system_score_codex":0.01041392,"about_ca_system_score_gemma":0.008185754,"threshold_uncertainty_score":0.0755586},"labels":[],"label_agreement":null},{"id":"W3085644262","doi":"10.1002/hec.4160","title":"Patient income and health innovation","year":2020,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Seventh Framework Programme","keywords":"Harm; Clinical trial; Investment (military); Disease; Medicine; Business; Actuarial science; Psychology; Pathology; Political science","score_opus":0.17481105262612476,"score_gpt":0.3397922161482721,"score_spread":0.16498116352214734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085644262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86025023,0.012071263,0.01942474,0.02313347,0.00029384112,0.00014882255,0.005106943,0.00014744038,0.07942329],"genre_scores_gemma":[0.9951794,0.0010685521,0.0004766528,0.00026984833,0.00015645799,0.000020017684,0.00049590314,0.0000072107177,0.002325922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972633,0.0013837378,0.00015114233,0.0001616925,0.00052881596,0.00051131716],"domain_scores_gemma":[0.96655434,0.019179488,0.009147111,0.00067792565,0.0018522919,0.002588827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033007686,0.000182652,0.00035396547,0.0016238163,0.00037740578,0.00126266,0.00035159913,0.0006328784,0.005941427],"category_scores_gemma":[0.030083578,0.000109380744,0.0003671413,0.0017308805,0.0008334237,0.0012323533,0.0010881351,0.0011017245,0.0005536991],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005183101,0.00030259052,0.79758877,0.0001936266,0.00047029575,0.00047419683,0.000377191,0.015991434,0.00018491368,0.090350844,0.008793588,0.08475426],"study_design_scores_gemma":[0.00012883259,0.0006034414,0.8128999,0.00030417138,0.00023970367,0.0018587551,0.0008745407,0.024041053,0.000557189,0.118885174,0.039509848,0.00009739199],"about_ca_topic_score_codex":0.0014224593,"about_ca_topic_score_gemma":0.0011242421,"teacher_disagreement_score":0.005941427,"about_ca_system_score_codex":0.0013107811,"about_ca_system_score_gemma":0.0007051112,"threshold_uncertainty_score":0.019876003},"labels":[],"label_agreement":null},{"id":"W3086015271","doi":"10.33974/ijrpst.v1i4.196","title":"An overview on comparative study of registration requirements for generics in US, Canada and Europe","year":2020,"lang":"en","type":"article","venue":"International Journal of Research in Pharmaceutical Sciences and Technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; World Health Organization","keywords":"Product (mathematics); Agency (philosophy); Business; Authorization; Marketing authorization; Process (computing); European market; Regulatory agency; New product development; Marketing; Industrial organization; International trade; Computer science; Computer security; Political science; Public administration","score_opus":0.5678317604296913,"score_gpt":0.539922613965676,"score_spread":0.027909146464015322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086015271","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16001049,0.5154059,0.0026615714,0.009317204,0.0008664606,0.0005660434,0.050201785,0.00021820418,0.26075232],"genre_scores_gemma":[0.59098154,0.33840027,0.0063012084,0.0028582725,0.00034704438,0.00022440423,0.030662369,0.00015481684,0.03007011],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99488693,0.00042391114,0.00033448482,0.00046914184,0.0029044936,0.00098109],"domain_scores_gemma":[0.9857992,0.0023394334,0.00091735926,0.00020285023,0.010103168,0.0006380437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034690206,0.00058398856,0.00069018715,0.021972701,0.002087408,0.0038102723,0.0014183864,0.00059003325,0.008338344],"category_scores_gemma":[0.009123598,0.0003317391,0.001558924,0.044972137,0.00087467936,0.0012688108,0.0007964909,0.00092063856,0.00042897693],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084870856,0.0002562129,0.24497107,0.01112355,0.000965052,0.0013278308,0.0035679324,0.0041032843,0.0009679365,0.10880863,0.15725896,0.46580082],"study_design_scores_gemma":[0.000034899356,0.00011086414,0.71001387,0.003719046,0.00057774514,0.00047920374,0.0051109167,0.00097277685,0.00087975134,0.0012004009,0.27678573,0.0001148078],"about_ca_topic_score_codex":0.9800218,"about_ca_topic_score_gemma":0.98283917,"teacher_disagreement_score":0.06676951,"about_ca_system_score_codex":0.06676951,"about_ca_system_score_gemma":0.07133788,"threshold_uncertainty_score":0.48444897},"labels":[],"label_agreement":null},{"id":"W3087510675","doi":"10.1212/wnl.94.15_supplement.2804","title":"A comparative analysis of licensing and reimbursement of anti-epileptic drugs in Canada and Australia (2804)","year":2020,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Political science; Law; Health care","score_opus":0.08843257227484601,"score_gpt":0.298854448855535,"score_spread":0.210421876580689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087510675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919512,0.001092391,0.00010695558,0.0007775755,0.000009442538,0.000054783766,0.0018639985,0.0000048424185,0.0041387896],"genre_scores_gemma":[0.9960353,0.0007286756,0.00014063127,0.0002805886,0.000008228754,0.000019739644,0.0011577687,0.0000041735234,0.0016249827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718946,0.00031088534,0.00020988485,0.00020473408,0.0011658613,0.00091904064],"domain_scores_gemma":[0.9906719,0.0012121191,0.002622449,0.00013115234,0.0031491844,0.0022131852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013098546,0.00016911686,0.00040532585,0.0027371035,0.0013178455,0.0017566511,0.0006959663,0.00059957127,0.0019186912],"category_scores_gemma":[0.008104743,0.00033278,0.0006625604,0.0065115327,0.00071031664,0.0004030381,0.0011795037,0.00088974676,0.00014407291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043760397,0.00012655332,0.9763573,0.00016420019,0.0002573622,0.0005743658,0.001301676,0.0008628491,0.00035433163,0.002429555,0.0027433424,0.014390849],"study_design_scores_gemma":[0.0000105952695,0.00003029856,0.99687505,0.000026608324,0.000034102384,0.0000864053,0.0008822713,0.00039045775,0.000052808984,0.00003955625,0.0015630827,0.000008720253],"about_ca_topic_score_codex":0.9739985,"about_ca_topic_score_gemma":0.98252654,"teacher_disagreement_score":0.034933094,"about_ca_system_score_codex":0.034933094,"about_ca_system_score_gemma":0.03485189,"threshold_uncertainty_score":0.2534585},"labels":[],"label_agreement":null},{"id":"W3089069670","doi":"10.1136/bmjgh-2020-002906","title":"Health system determinants of access to essential medicines for children with cancer in Ghana","year":2020,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Access to medicines; Essential medicines; Medicine; Environmental health; Public health; Cancer; Family medicine; Political science; Economic growth; Nursing; Internal medicine; Economics","score_opus":0.09233797436299467,"score_gpt":0.4295418200016156,"score_spread":0.33720384563862094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089069670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967146,0.00046921548,0.00004462636,0.0009912627,0.0000026931853,0.000019251853,0.00044486325,0.000002608488,0.0013108168],"genre_scores_gemma":[0.99957997,0.00020977332,0.00004814867,0.000028926323,0.0000017796608,0.000007971613,0.00006602183,8.422235e-7,0.000056570752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993944,0.0002595071,0.00004664132,0.000050536924,0.000053151634,0.00019576725],"domain_scores_gemma":[0.99516135,0.0014924493,0.0025335248,0.00006829285,0.00020811615,0.0005363116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007004257,0.00011315083,0.00016973043,0.00048524322,0.0003744344,0.00072253536,0.0002784918,0.00018736227,0.0039970134],"category_scores_gemma":[0.004092098,0.00012510468,0.00014197813,0.001564519,0.00074880075,0.0008186584,0.0008657203,0.0004925693,0.00012836474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006174319,0.000039203598,0.98587185,0.00015057238,0.000019101426,0.0005668408,0.0054559875,0.00023968279,0.00018018612,0.00081955607,0.0005235029,0.0060718656],"study_design_scores_gemma":[0.000009228024,0.000052113708,0.9828829,0.000120062025,0.0000089166915,0.00028483244,0.0146074435,0.00018910956,0.000055673823,0.00023881375,0.0015459252,0.000004947864],"about_ca_topic_score_codex":0.07101435,"about_ca_topic_score_gemma":0.06908193,"teacher_disagreement_score":0.07101435,"about_ca_system_score_codex":0.0027462598,"about_ca_system_score_gemma":0.0021772098,"threshold_uncertainty_score":0.14120197},"labels":[],"label_agreement":null},{"id":"W3090451134","doi":"10.1177/1715163520958023","title":"How do community pharmacies in Ontario manage drug shortage problems? Results of an exploratory qualitative study","year":2020,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Ontario College of Pharmacists","keywords":"Economic shortage; Pharmacy; Government (linguistics); Exploratory research; Qualitative research; Business; Medicine; Nursing; Sociology","score_opus":0.17353538607677,"score_gpt":0.3090060159147469,"score_spread":0.13547062983797692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090451134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756623,0.00034563174,0.0003951059,0.0045122253,0.000025445164,0.0003229657,0.00020519848,0.000010199923,0.0066169747],"genre_scores_gemma":[0.99394673,0.00069018506,0.0005068352,0.0011567567,0.000011112745,0.00022772067,0.00007265151,0.000009733002,0.003378208],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9952205,0.002165847,0.00013945038,0.00025789172,0.00070016715,0.0015162054],"domain_scores_gemma":[0.9900836,0.0054983604,0.001051809,0.00017817457,0.0014976077,0.0016903313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062845605,0.0003232737,0.00040350348,0.0013538174,0.016592633,0.0033153472,0.0016692342,0.001479068,0.0030946205],"category_scores_gemma":[0.012638831,0.00047352404,0.00023539198,0.0026975847,0.007191813,0.0019231031,0.002940884,0.0014917715,0.0001452818],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023778717,0.00004633372,0.0073827147,0.000101190555,0.0000026198866,0.0005655454,0.98647517,0.00003084175,0.00034416502,0.00048911496,0.0010727299,0.0034657884],"study_design_scores_gemma":[0.0000032793444,0.000017910992,0.006299026,0.0000610459,0.0000018352838,0.00004319866,0.98831546,0.000044656,0.000043788772,0.00005152114,0.0051135295,0.000004813282],"about_ca_topic_score_codex":0.7907091,"about_ca_topic_score_gemma":0.8953958,"teacher_disagreement_score":0.20929092,"about_ca_system_score_codex":0.05006538,"about_ca_system_score_gemma":0.054859173,"threshold_uncertainty_score":0.4210469},"labels":[],"label_agreement":null},{"id":"W3092276302","doi":"10.1200/jco.2020.38.29_suppl.60","title":"Better treatment at what cost? A study of myeloma spending.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Multiple myeloma; Cancer drugs; Lenalidomide; Cancer; Pharmacy; Bortezomib; Government (linguistics); Family medicine; Internal medicine","score_opus":0.43226107861873403,"score_gpt":0.4829282545247874,"score_spread":0.05066717590605335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092276302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570042,0.0048315236,0.00010341673,0.007919635,0.000028266277,0.000059470993,0.019119447,0.0000120671575,0.010921968],"genre_scores_gemma":[0.9951314,0.0010622074,0.000059252176,0.00031676306,0.000028051758,0.00002705381,0.0026301194,0.000009462751,0.00073584885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891675,0.00020658551,0.00008820083,0.00009334237,0.00032092887,0.00037421007],"domain_scores_gemma":[0.9891621,0.0015633764,0.0059864707,0.00019073069,0.0014743129,0.0016229929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001175176,0.00020012145,0.00033976225,0.0026672487,0.0011835966,0.001740595,0.00086408405,0.00064165454,0.0048916736],"category_scores_gemma":[0.011366986,0.00026497527,0.0010310246,0.011378202,0.00071575644,0.0017339322,0.0010948073,0.0011025439,0.00036537697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016195307,0.000051256942,0.98996735,0.00008511389,0.00014071759,0.0000627274,0.0008697064,0.00014707878,0.00001885127,0.000652919,0.0034283763,0.004413891],"study_design_scores_gemma":[0.000010201804,0.000021653046,0.9962579,0.000077806995,0.000040385876,0.000043994503,0.0010878433,0.0002327853,0.000006746068,0.00008512671,0.0021299394,0.0000056125627],"about_ca_topic_score_codex":0.7793849,"about_ca_topic_score_gemma":0.7237806,"teacher_disagreement_score":0.7793849,"about_ca_system_score_codex":0.015972456,"about_ca_system_score_gemma":0.011648678,"threshold_uncertainty_score":0.44382864},"labels":[],"label_agreement":null},{"id":"W3092486526","doi":"10.1093/eurpub/ckaa165.1054","title":"Measures to manage, reduce and prevent medicines shortages in European countries in 2020","year":2020,"lang":"en","type":"article","venue":"European Journal of Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Business; Reimbursement; Public health; Quarter (Canadian coin); Sanctions; Medicine; Environmental health; Economic growth; Health care; Political science; Government (linguistics); Economics; Geography; Nursing","score_opus":0.16824046598448542,"score_gpt":0.3316727112019646,"score_spread":0.1634322452174792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092486526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79887205,0.046174537,0.008219725,0.054768283,0.000892315,0.00078462827,0.0026366445,0.00046058834,0.08719119],"genre_scores_gemma":[0.95937467,0.008878257,0.013992123,0.009814364,0.00015662395,0.0003484722,0.001924441,0.000022940449,0.0054881386],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981029,0.00095055834,0.00026814695,0.000095261246,0.00023442121,0.00034868883],"domain_scores_gemma":[0.9974056,0.00037263724,0.0010613808,0.000108510336,0.0005619222,0.00048986304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00516393,0.00038253178,0.0002003534,0.0009465304,0.00041277174,0.00091207953,0.00055440963,0.00078663195,0.0031889477],"category_scores_gemma":[0.003993315,0.00012681246,0.00030830692,0.00079008803,0.00036524946,0.0010220654,0.0019703056,0.00044286452,0.0003989774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005557793,0.0012866196,0.31978038,0.008391406,0.0002940688,0.001613377,0.0056276526,0.004334881,0.006891558,0.016810091,0.06021731,0.57419693],"study_design_scores_gemma":[0.0001430984,0.0011871649,0.6601869,0.0051310793,0.00012091996,0.0011118909,0.013098997,0.0014442864,0.0035899158,0.0027287302,0.31119776,0.0000591901],"about_ca_topic_score_codex":0.0027827795,"about_ca_topic_score_gemma":0.0018635578,"teacher_disagreement_score":0.00516393,"about_ca_system_score_codex":0.0009736847,"about_ca_system_score_gemma":0.004189413,"threshold_uncertainty_score":0.027309775},"labels":[],"label_agreement":null},{"id":"W3095012872","doi":"10.1371/journal.pone.0240966","title":"How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study","year":2020,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Notice; Marketing authorization; Medicine; Authorization; Product (mathematics); Family medicine; Business; Marketing; Computer science; Political science; Bioinformatics","score_opus":0.10152309232902855,"score_gpt":0.24574030204348993,"score_spread":0.1442172097144614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095012872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424356,0.00046765106,0.00009018969,0.00028572654,0.000021304539,0.00008910249,0.0033746166,0.000006294721,0.0014215778],"genre_scores_gemma":[0.99662834,0.00036382518,0.00014340089,0.0002060647,0.000023236838,0.000066525754,0.0016746758,0.0000111719455,0.00088259444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727947,0.00020859868,0.00022812236,0.00064932584,0.00097379554,0.00066066015],"domain_scores_gemma":[0.9911748,0.0010695461,0.0043639857,0.000520871,0.0014879911,0.0013827775],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023913896,0.00032131828,0.0005805403,0.0014786982,0.0025005,0.0022467095,0.0013212331,0.00085962686,0.0049095694],"category_scores_gemma":[0.010394517,0.0004664137,0.0012609378,0.003058346,0.00072745746,0.0014283423,0.00087493734,0.0015021496,0.00080622843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003874453,0.00007568063,0.99525887,0.000037870337,0.00008706685,0.000073125884,0.0007930964,0.00003337395,0.00007314862,0.00006420054,0.00083486224,0.00228116],"study_design_scores_gemma":[0.000032836655,0.00020370347,0.9964862,0.000043621934,0.00007290774,0.00016482164,0.0013849611,0.00015560756,0.00005030847,0.00003535952,0.0013393828,0.00003028241],"about_ca_topic_score_codex":0.6194778,"about_ca_topic_score_gemma":0.6660874,"teacher_disagreement_score":0.9976086,"about_ca_system_score_codex":0.008772804,"about_ca_system_score_gemma":0.011899157,"threshold_uncertainty_score":0.7655263},"labels":[],"label_agreement":null},{"id":"W3095341396","doi":"","title":"Liste canadienne des médicaments essentiels: Potentiel et incertitudes.","year":2017,"lang":"fr","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Library science; Computer science; Data science","score_opus":0.06941845999817141,"score_gpt":0.27293754980809143,"score_spread":0.20351908980992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095341396","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004619132,0.8399609,0.0014991093,0.022134302,0.008451184,0.00027274358,0.047308203,0.00053711236,0.07521733],"genre_scores_gemma":[0.051392738,0.813959,0.0070477272,0.010046528,0.011043358,0.0007188627,0.037576485,0.00027693436,0.067938276],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967188,0.0005547792,0.00093819463,0.0002643739,0.001339831,0.00018398893],"domain_scores_gemma":[0.978108,0.012281801,0.0033564325,0.00051032007,0.0050066896,0.0007368469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022877795,0.0008229931,0.0021436112,0.010933394,0.0008776125,0.0032932989,0.0008829609,0.0017579525,0.0865547],"category_scores_gemma":[0.022731544,0.00037862852,0.0016057449,0.014227842,0.00067645276,0.0020184529,0.0010619117,0.0029116578,0.022775166],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015243267,0.00010646216,0.005581206,0.026078453,0.0008741552,0.0005403548,0.00027125492,0.0003105883,0.0008601764,0.016286867,0.41037965,0.5371865],"study_design_scores_gemma":[0.00023898826,0.0001476581,0.016582936,0.010530993,0.0005082863,0.0013265911,0.00012556883,0.00011161103,0.00059349,0.0026991602,0.9670865,0.000048280934],"about_ca_topic_score_codex":0.013302398,"about_ca_topic_score_gemma":0.0116226915,"teacher_disagreement_score":0.9866976,"about_ca_system_score_codex":0.0026684033,"about_ca_system_score_gemma":0.0056588054,"threshold_uncertainty_score":0.28955436},"labels":[],"label_agreement":null},{"id":"W3095577850","doi":"10.1101/2020.10.27.20220871","title":"Estimating the Financial Impact of Gene Therapy*","year":2020,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Proxy (statistics); Payment; Actuarial science; Medicine; Demography; Finance; Economics; Statistics","score_opus":0.1243739019988602,"score_gpt":0.33659603873633887,"score_spread":0.21222213673747867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095577850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.918402,0.0016810172,0.04779985,0.008611509,0.00012669341,0.00016515396,0.0049268524,0.00014519112,0.018141707],"genre_scores_gemma":[0.9932532,0.0003966345,0.003506997,0.0001791595,0.00003112274,0.00003991303,0.00070835574,0.000010712737,0.0018739441],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986424,0.0008103599,0.00004208117,0.0001469922,0.00016811244,0.00019014586],"domain_scores_gemma":[0.98350483,0.013673897,0.0016290348,0.00029502678,0.00048296122,0.00041419058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039015436,0.00057175016,0.00063744513,0.0011047665,0.00032076336,0.0017744731,0.0007038913,0.0013884564,0.0056662266],"category_scores_gemma":[0.024569493,0.0004691576,0.00062403356,0.0012622621,0.000787227,0.0018010725,0.00084121554,0.0016390855,0.00040877835],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002553686,0.00010112954,0.028336627,0.000048307917,0.000078415826,0.00014690116,0.000026414522,0.93866336,0.00017368713,0.019197745,0.002144063,0.010828042],"study_design_scores_gemma":[0.00007597352,0.00016621494,0.010566652,0.00004431957,0.00005944374,0.00008963674,0.000108275475,0.96548027,0.00037371626,0.021084309,0.0019205232,0.00003058705],"about_ca_topic_score_codex":0.015708191,"about_ca_topic_score_gemma":0.006789678,"teacher_disagreement_score":0.015708191,"about_ca_system_score_codex":0.0034756432,"about_ca_system_score_gemma":0.0016928432,"threshold_uncertainty_score":0.03123349},"labels":[],"label_agreement":null},{"id":"W3095635585","doi":"10.1136/bmjgh-2020-002640","title":"Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries","year":2020,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McMaster University; Population Health Research Institute; Simon Fraser University","funders":"Faculty of Medicine and Health, University of Sydney; McMaster University; Hamilton Health Sciences","keywords":"Low and middle income countries; Income distribution; High income countries; Comprehensive income; Economics; Adjusted gross income; Business; Public economics; Gross income; Economic growth; Developing country; Inequality","score_opus":0.043750542612328275,"score_gpt":0.3226200611086289,"score_spread":0.2788695184963006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095635585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991992,0.00019261093,0.00003802563,0.000028340028,0.0000024457495,0.000008007726,0.00037816013,0.0000010207572,0.00015215289],"genre_scores_gemma":[0.9995479,0.00008277908,0.000045842822,0.00001571582,0.0000044914555,0.000008818735,0.0002536886,5.0838366e-7,0.000040107567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907243,0.00041704183,0.00010538477,0.00013837924,0.000093777744,0.00017304055],"domain_scores_gemma":[0.9981135,0.00029002948,0.0011167252,0.000085478256,0.000105408,0.0002889043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011897162,0.00036059367,0.00039231902,0.0010972416,0.0005659199,0.001029463,0.0003899065,0.0005279014,0.0013253922],"category_scores_gemma":[0.0023773205,0.00039482114,0.0008115213,0.0017167126,0.000545671,0.0005765315,0.0014001036,0.00055161625,0.00014726484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059090617,0.000027659346,0.99934834,0.000014455997,0.00006814546,0.00003407596,0.000062159146,0.00003538531,0.00003219019,0.000011873376,0.00003178608,0.00027477532],"study_design_scores_gemma":[0.000009903315,0.00007436779,0.9992461,0.000010393619,0.000039733877,0.00008577142,0.00030222852,0.00010883589,0.0000196651,0.000014789623,0.00008480522,0.000003447367],"about_ca_topic_score_codex":0.009858482,"about_ca_topic_score_gemma":0.009416463,"teacher_disagreement_score":0.009858482,"about_ca_system_score_codex":0.0003410233,"about_ca_system_score_gemma":0.00037406263,"threshold_uncertainty_score":0.01960224},"labels":[],"label_agreement":null},{"id":"W3097249531","doi":"","title":"Reputation and Authority: The FDA and the Fight over U.S. Prescription Drug Importation","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rulemaking; Notice; Medical prescription; Legislation; Business; Generic drug; Statutory law; Prescription drug; Public economics; Law and economics; Drug; Political science; Law; Pharmacology; Medicine; Economics","score_opus":0.021611360939218508,"score_gpt":0.24769835720536648,"score_spread":0.22608699626614798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097249531","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017142834,0.022497097,0.0010199376,0.7969898,0.0022803019,0.000010902624,0.000051750685,0.000052664185,0.15995474],"genre_scores_gemma":[0.7462501,0.0150543135,0.0010540098,0.21175316,0.005064197,0.000034731358,0.000047299553,0.00006823092,0.020673972],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.98351604,0.0055149593,0.0006602868,0.0021614681,0.005443812,0.0027033896],"domain_scores_gemma":[0.96215963,0.018688073,0.0041055363,0.0024064037,0.0069894227,0.0056509683],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.01935028,0.00035918885,0.0008377718,0.0025876185,0.014453795,0.024814216,0.0014612727,0.02223455,0.00782348],"category_scores_gemma":[0.037498377,0.00044527106,0.0009304282,0.0023294473,0.034032658,0.014203259,0.0060424455,0.016444666,0.0010268644],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004183336,0.00003489027,0.0020766705,0.00003909351,0.000015996782,0.00019610277,0.002270939,0.00009236484,0.00013868857,0.9036413,0.067275375,0.02417673],"study_design_scores_gemma":[0.00013307383,0.00016866605,0.010225808,0.0010229885,0.00010659275,0.00049976865,0.006786416,0.0008450193,0.00057584327,0.39827198,0.58114266,0.00022110599],"about_ca_topic_score_codex":0.035794564,"about_ca_topic_score_gemma":0.049658094,"teacher_disagreement_score":0.98554623,"about_ca_system_score_codex":0.01477618,"about_ca_system_score_gemma":0.017061528,"threshold_uncertainty_score":0.107209146},"labels":[],"label_agreement":null},{"id":"W3097362378","doi":"","title":"La production, le contrôle, l'assurance qualité et la distribution des produits pharmaceutiques au Canada","year":2017,"lang":"fr","type":"article","venue":"Publications Pimido","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.08039366196907588,"score_gpt":0.354669537821509,"score_spread":0.2742758758524331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097362378","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52302337,0.05346459,0.024504552,0.073994756,0.00090587157,0.00036543148,0.013457295,0.0006159606,0.3096681],"genre_scores_gemma":[0.86876744,0.008600612,0.003568615,0.0005528257,0.00014886481,0.00004279798,0.0008455285,0.000047441947,0.117425844],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971902,0.00026835667,0.0000688708,0.00019402953,0.001708091,0.0005705691],"domain_scores_gemma":[0.99560803,0.0014992276,0.00035520334,0.000079989724,0.0020062225,0.00045122986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016570947,0.00038563818,0.000409743,0.0016666808,0.0019441692,0.0051322407,0.0006448003,0.00112928,0.012848764],"category_scores_gemma":[0.0062821996,0.00034697945,0.00048692958,0.0024655142,0.0017037953,0.0010544222,0.0005006524,0.0017019827,0.0005222818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011170544,0.00033433584,0.07708517,0.0010416879,0.00027769324,0.0006610922,0.0019325301,0.07147689,0.0070124255,0.4885207,0.071702756,0.27883765],"study_design_scores_gemma":[0.0003951574,0.0004315592,0.3741076,0.00076573936,0.00023223128,0.0003082759,0.0027883213,0.08608463,0.008264364,0.047002986,0.47936854,0.00025070374],"about_ca_topic_score_codex":0.99171054,"about_ca_topic_score_gemma":0.98679894,"teacher_disagreement_score":0.8968947,"about_ca_system_score_codex":0.10310528,"about_ca_system_score_gemma":0.116707705,"threshold_uncertainty_score":0.74808466},"labels":[],"label_agreement":null},{"id":"W3099001503","doi":"10.1136/bmjgh-2020-003282","title":"Shortages and price variability of essential cytotoxic medicines for treating children with cancers","year":2020,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"Fogarty International Center; World Health Organization","keywords":"Medicine; Purchasing power parity; Essential medicines; Access to medicines; Gross national income; Economic shortage; Developing country; Environmental health; Business; Finance; Public health; Economic growth; Economics","score_opus":0.04170877436286529,"score_gpt":0.3616002697051675,"score_spread":0.3198914953423022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099001503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984561,0.00020326662,0.00008058106,0.000087366876,0.0000022058596,0.0000029819216,0.0005975786,0.0000018911437,0.0005679205],"genre_scores_gemma":[0.99953985,0.000069123795,0.000055024273,0.00001315148,0.000005960711,0.0000026803125,0.00027162375,9.468786e-7,0.000041685693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869823,0.00043599273,0.00020607185,0.00018975559,0.00030011314,0.00016972086],"domain_scores_gemma":[0.9856856,0.004638312,0.0083176335,0.0003423353,0.00066186296,0.0003542579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015639248,0.00010706874,0.00017404926,0.0009169814,0.00017045262,0.0005522707,0.0003372263,0.00023265023,0.0039971103],"category_scores_gemma":[0.010350201,0.0001401697,0.0002494893,0.0019580072,0.00031514053,0.00064343016,0.0005508242,0.00023816967,0.00023377869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006847677,0.000014801347,0.9957273,0.000021768608,0.000028912715,0.000044188368,0.0001745883,0.00019652529,0.00010849049,0.000058892627,0.00018558456,0.003370632],"study_design_scores_gemma":[0.0000020587192,0.00003446097,0.9989423,0.000009573272,0.000006259383,0.00015819185,0.0003520694,0.00019726969,0.00006418239,0.00003239168,0.0001992888,0.000001946242],"about_ca_topic_score_codex":0.0040068096,"about_ca_topic_score_gemma":0.003549305,"teacher_disagreement_score":0.0040068096,"about_ca_system_score_codex":0.00040902023,"about_ca_system_score_gemma":0.0002484354,"threshold_uncertainty_score":0.013371706},"labels":[],"label_agreement":null},{"id":"W3103659536","doi":"10.34172/ijhpm.2020.215","title":"The Impact of Tiered-Pricing Framework on Generic Entry in Canada","year":2020,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of Calgary; Centre for Advancing Health Outcomes; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Listing (finance); Generic drug; Medical prescription; Business; Market share; Market size; Actuarial science; Finance; Medicine; Drug; Pharmacology; Commerce","score_opus":0.07440123481709053,"score_gpt":0.37071387874853184,"score_spread":0.2963126439314413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103659536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97953355,0.0017269474,0.0005529945,0.0030714711,0.000047898666,0.00014139745,0.006500516,0.00006523704,0.008360027],"genre_scores_gemma":[0.9966421,0.00042476796,0.0001927633,0.00023019449,0.000012003964,0.000011750902,0.0015218671,0.000007953347,0.00095654494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996223,0.0003533331,0.00013825856,0.00037096572,0.0013469289,0.0015674548],"domain_scores_gemma":[0.9901866,0.0015138433,0.0028874471,0.00037670974,0.0027739299,0.0022614626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002441975,0.00033529932,0.000448272,0.0014481194,0.0017001946,0.0022823014,0.0016402182,0.0006518684,0.003960069],"category_scores_gemma":[0.009867194,0.00026371586,0.0012301761,0.003050621,0.0010267949,0.00070920866,0.0013900091,0.0014371127,0.00015770325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093395956,0.00020630509,0.9542014,0.00013608029,0.00026276856,0.00040296966,0.0006743621,0.006368471,0.0003687926,0.0034430698,0.007337535,0.025664264],"study_design_scores_gemma":[0.000059904876,0.00016945173,0.98621327,0.000061291335,0.00009639951,0.000108663604,0.00092955015,0.0082750125,0.00016029495,0.00035907462,0.0035221467,0.000044813052],"about_ca_topic_score_codex":0.9901455,"about_ca_topic_score_gemma":0.991167,"teacher_disagreement_score":0.05629035,"about_ca_system_score_codex":0.05629035,"about_ca_system_score_gemma":0.07237948,"threshold_uncertainty_score":0.408417},"labels":[],"label_agreement":null},{"id":"W3106342198","doi":"10.1016/j.arcmed.2020.10.021","title":"Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments","year":2020,"lang":"en","type":"review","venue":"Archives of Medical Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Repurposing; Drug repositioning; Pharmaceutical industry; Drug; Revenue; Business; Government (linguistics); Risk analysis (engineering); Pharmacology; Medicine; Engineering; Finance","score_opus":0.43808934115265624,"score_gpt":0.48985832056164524,"score_spread":0.051768979408989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106342198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018118227,0.98502606,0.0003443837,0.011355228,0.00073076057,0.000013619288,0.000059956197,0.000018979004,0.0022698406],"genre_scores_gemma":[0.0033880998,0.9849178,0.001083567,0.007780365,0.0012383336,0.000027828182,0.00006887922,0.000012557004,0.0014825216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814844,0.0007624166,0.00021443448,0.00016422442,0.0005452314,0.00016533576],"domain_scores_gemma":[0.9927032,0.004340984,0.001125828,0.00014768708,0.0013270306,0.00035514514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006277227,0.00092519226,0.0029908975,0.0018681634,0.0003687798,0.003441224,0.0017536466,0.0040086196,0.013938425],"category_scores_gemma":[0.009593174,0.00034410984,0.0011792936,0.0021698445,0.0013211331,0.0053621694,0.0012079645,0.00565589,0.0038760295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023672055,0.00011471045,0.00017666916,0.013402676,0.00015119501,0.00019060346,0.00005921695,0.0005239384,0.0006268109,0.028313242,0.07386733,0.8823369],"study_design_scores_gemma":[0.00015617606,0.000225165,0.0006960421,0.020802872,0.0002734993,0.0006059676,0.00015096205,0.0003128573,0.00022968659,0.019275885,0.9572353,0.000035578672],"about_ca_topic_score_codex":0.0025748499,"about_ca_topic_score_gemma":0.011908853,"teacher_disagreement_score":0.013938425,"about_ca_system_score_codex":0.002121619,"about_ca_system_score_gemma":0.006548525,"threshold_uncertainty_score":0.046628654},"labels":[],"label_agreement":null},{"id":"W3108815630","doi":"10.3389/fphar.2020.594549","title":"Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study","year":2020,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Health technology; Business; Medicine; Product (mathematics); Accounting; Health care; Economic growth","score_opus":0.09243305490311675,"score_gpt":0.38178799816593745,"score_spread":0.2893549432628207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108815630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98810625,0.0034706683,0.0007053619,0.001539469,0.000016950704,0.0002980372,0.0009956883,0.00003280766,0.0048347046],"genre_scores_gemma":[0.9961111,0.0009923887,0.0014201932,0.00027557142,0.000012378081,0.0001323815,0.0006694409,0.000011976032,0.00037447183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.96396226,0.011082599,0.0048106927,0.0029029832,0.014609373,0.0026320105],"domain_scores_gemma":[0.84434897,0.04390604,0.044320952,0.0042488724,0.052976932,0.010198175],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.038673446,0.0002787141,0.000482064,0.0086428495,0.0013097934,0.004248321,0.0011173572,0.0008441584,0.0007249321],"category_scores_gemma":[0.07388082,0.00034879407,0.00063300563,0.009424254,0.0014421276,0.0018026378,0.0024745844,0.0007086452,0.00012296444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033190206,0.00022569779,0.9143845,0.00047535432,0.00023969861,0.0002112837,0.013200453,0.0005659383,0.00035492046,0.001147373,0.0026480486,0.06621489],"study_design_scores_gemma":[0.000022882301,0.0001925754,0.98448944,0.00025921615,0.00007353772,0.00016156843,0.007785148,0.001093795,0.00026573986,0.00009122837,0.005519728,0.000045267912],"about_ca_topic_score_codex":0.3075616,"about_ca_topic_score_gemma":0.2982808,"teacher_disagreement_score":0.9709179,"about_ca_system_score_codex":0.029082112,"about_ca_system_score_gemma":0.02675096,"threshold_uncertainty_score":0.6115428},"labels":[],"label_agreement":null},{"id":"W3111185175","doi":"10.1016/j.jval.2020.08.743","title":"PDG60 The IMPACT of International Reference Pricing (IRP) in France, Italy, Spain, United Kingdom, and Canada to New and Existing Marketed Medications","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Negotiation; Publication; International economics; Developing country; Confidentiality; Price index; Business; Economics; International trade; Public economics; Political science; Economic growth; Advertising; Macroeconomics; Law","score_opus":0.17518797701970895,"score_gpt":0.3549262249663573,"score_spread":0.17973824794664833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111185175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58447284,0.018789696,0.0014185795,0.08923323,0.0018111769,0.00017284157,0.029637503,0.00048432735,0.27397978],"genre_scores_gemma":[0.97161597,0.002080721,0.0004790835,0.0058132424,0.0004988999,0.000022246351,0.00547363,0.00012412196,0.013891968],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9901703,0.0019358721,0.00038369308,0.0008058064,0.0043070093,0.0023973135],"domain_scores_gemma":[0.9699985,0.009739388,0.0028096635,0.0009324958,0.012544035,0.003975914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009215211,0.0003654872,0.000923291,0.0026547962,0.00085293717,0.011820148,0.0015630599,0.0031247695,0.006493374],"category_scores_gemma":[0.04468928,0.00032022226,0.0014168256,0.0038209227,0.0017765022,0.0017532177,0.0019156083,0.0033007748,0.0006854022],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010274869,0.0010495479,0.2573982,0.0007564774,0.0013777345,0.0016081777,0.00096299953,0.08166114,0.0010358321,0.18601751,0.27929902,0.17855859],"study_design_scores_gemma":[0.0016654405,0.0008707052,0.6731431,0.0006415348,0.00096699677,0.0004942798,0.001994566,0.045516778,0.00251258,0.019731598,0.25205877,0.000403751],"about_ca_topic_score_codex":0.77416444,"about_ca_topic_score_gemma":0.64345556,"teacher_disagreement_score":0.22583556,"about_ca_system_score_codex":0.036412418,"about_ca_system_score_gemma":0.023866229,"threshold_uncertainty_score":0.4543311},"labels":[],"label_agreement":null},{"id":"W3111651503","doi":"10.1016/j.jval.2020.08.567","title":"PCV76 NEWLY Introduced Drugs for Second-LINE Treatment of Stable Angina: Approvals and Reimbursement Decisions in the UK, Canada, Australia and Scotland","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ranolazine; Reimbursement; Trimetazidine; Ivabradine; Medicine; Nicorandil; Angina; Formulary; Health care; Intensive care medicine; Pharmacology; Internal medicine; Political science","score_opus":0.18607472664411934,"score_gpt":0.33849278440518543,"score_spread":0.1524180577610661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111651503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9035056,0.031839307,0.0003149919,0.027755262,0.00037378434,0.00007979524,0.0061920676,0.00003181903,0.02990731],"genre_scores_gemma":[0.98175347,0.007864921,0.0003123429,0.002484889,0.00023857686,0.00001397003,0.0013792735,0.000022106846,0.0059304982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961486,0.000560547,0.0003438884,0.00025996682,0.0016597242,0.0010272027],"domain_scores_gemma":[0.988366,0.002736962,0.0025089618,0.00012086359,0.002947904,0.0033193235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002235061,0.0001498224,0.00059108355,0.001924438,0.00076948834,0.003355301,0.0007539371,0.0012695139,0.003101032],"category_scores_gemma":[0.009595685,0.00027860224,0.00080885325,0.0034451527,0.0012077402,0.00068616786,0.0007793044,0.0019708532,0.00021343367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009842107,0.0003604631,0.5550057,0.0019626694,0.0007773813,0.0067077344,0.0044070845,0.0064036236,0.004725502,0.039968174,0.07569082,0.2941487],"study_design_scores_gemma":[0.00031959044,0.00033707387,0.9593295,0.0003656457,0.00015425142,0.0011046083,0.0013726297,0.0015309599,0.00058122515,0.00039588223,0.03441549,0.000093119816],"about_ca_topic_score_codex":0.7367076,"about_ca_topic_score_gemma":0.8370143,"teacher_disagreement_score":0.26329237,"about_ca_system_score_codex":0.023397954,"about_ca_system_score_gemma":0.018761452,"threshold_uncertainty_score":0.52968585},"labels":[],"label_agreement":null},{"id":"W3118556611","doi":"10.1186/s40545-020-00282-8","title":"Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997","year":2021,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Arnold Ventures","keywords":"Medicine; Repurposing; Status quo; Drug repositioning; Drug; Pharmacy; Cohort; Generic drug; Pharmacology; Actuarial science; Business; Family medicine; Economics; Internal medicine","score_opus":0.15032365945261286,"score_gpt":0.412750019562576,"score_spread":0.2624263601099631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118556611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756444,0.00017935636,0.00012883662,0.00006258519,0.000008322376,0.000019952882,0.0016250364,0.000004001785,0.00040753363],"genre_scores_gemma":[0.99806076,0.00012116229,0.00008090214,0.00005491205,0.000009594844,0.000020237536,0.0012517768,0.000005347807,0.00039530022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796414,0.00036885618,0.00018605983,0.00075519056,0.00033756305,0.0003882286],"domain_scores_gemma":[0.991389,0.0014569304,0.004215589,0.0011831207,0.0007175603,0.0010378499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035594143,0.00030730243,0.0004159481,0.0010866678,0.000582375,0.0012978141,0.0008077441,0.0008011769,0.0028238103],"category_scores_gemma":[0.006962114,0.0003684902,0.00084764446,0.0013831945,0.0003827273,0.0009928514,0.0008842048,0.0012066886,0.0006444234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002714613,0.00006455615,0.9975938,0.0000058800824,0.00010720106,0.000046159126,0.00014025845,0.000050905757,0.000111262656,0.0000341327,0.00024593668,0.0013284711],"study_design_scores_gemma":[0.00001384996,0.00020118113,0.99843436,0.000007426468,0.000055454122,0.00012729313,0.00025848087,0.0003799595,0.000064255495,0.000025959835,0.00042207798,0.000009699297],"about_ca_topic_score_codex":0.019172477,"about_ca_topic_score_gemma":0.013756695,"teacher_disagreement_score":0.019172477,"about_ca_system_score_codex":0.000708149,"about_ca_system_score_gemma":0.000830739,"threshold_uncertainty_score":0.03812176},"labels":[],"label_agreement":null},{"id":"W3119641211","doi":"10.1287/mnsc.2020.3857","title":"Alleviating Drug Shortages: The Role of Mandated Reporting Induced Operational Transparency","year":2021,"lang":"en","type":"article","venue":"Management Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Transparency (behavior); Mandate; Economic shortage; Leverage (statistics); Public economics; Economics; Government (linguistics); Political science","score_opus":0.07525656714082045,"score_gpt":0.3060672752210256,"score_spread":0.23081070808020515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119641211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5969398,0.0074560908,0.042960662,0.21019495,0.0011455073,0.0012440716,0.0016630205,0.00072540663,0.13767044],"genre_scores_gemma":[0.98688555,0.00075065356,0.004772259,0.005850477,0.0002472875,0.00009539258,0.00013820273,0.000025760726,0.0012344565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9506593,0.030265957,0.0022725328,0.0018258757,0.008927746,0.0060486435],"domain_scores_gemma":[0.69696975,0.17573187,0.083690315,0.011355625,0.025770346,0.006482111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.036367305,0.0004585622,0.00068541203,0.0015074722,0.002038824,0.006795594,0.0016495035,0.001980301,0.0044606486],"category_scores_gemma":[0.1442485,0.00040445488,0.0009984233,0.0020806645,0.0031332313,0.0049997075,0.0040309173,0.004034177,0.00033723112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010426695,0.0021679413,0.38838392,0.0022970792,0.0008208195,0.0013892553,0.0072263954,0.05145503,0.00636502,0.24362186,0.06377338,0.23145664],"study_design_scores_gemma":[0.000787011,0.0021201181,0.5725554,0.0038848028,0.00081939355,0.0006895887,0.01652503,0.08725271,0.016861739,0.16061981,0.13713214,0.0007522162],"about_ca_topic_score_codex":0.047537208,"about_ca_topic_score_gemma":0.03957087,"teacher_disagreement_score":0.047537208,"about_ca_system_score_codex":0.010246339,"about_ca_system_score_gemma":0.037200913,"threshold_uncertainty_score":0.19233102},"labels":[],"label_agreement":null},{"id":"W3120260298","doi":"10.1177/1073110520979391","title":"Generic Competition for Drugs Treating Rare Diseases","year":2020,"lang":"en","type":"article","venue":"The Journal of Law Medicine & Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Competition (biology); Internet privacy; Business; Content (measure theory); Computer science; Medicine; Biology","score_opus":0.23318470178039563,"score_gpt":0.37127673689967505,"score_spread":0.13809203511927942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120260298","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0734061,0.031703737,0.007086775,0.12168036,0.00336821,0.00021369084,0.016722178,0.0007611244,0.7450579],"genre_scores_gemma":[0.8844642,0.010553775,0.0029698224,0.03305324,0.006014137,0.00013184824,0.0073838485,0.0002963345,0.05513283],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99525285,0.0017363772,0.00026538348,0.00042599585,0.001535574,0.00078374933],"domain_scores_gemma":[0.98562324,0.0061045894,0.0017653957,0.0009889199,0.0016538894,0.0038639943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040536276,0.00019305904,0.00047824052,0.001361614,0.00085383165,0.0027050779,0.00071943423,0.002055933,0.080513254],"category_scores_gemma":[0.024997776,0.00017201235,0.0010374611,0.0016902166,0.0007919642,0.0012970979,0.0016460489,0.0019378482,0.0054058977],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016530991,0.00021799319,0.010895449,0.0014820405,0.00027775223,0.0009756653,0.00039750693,0.002541213,0.0020273945,0.20906611,0.52289367,0.24757211],"study_design_scores_gemma":[0.001255015,0.00088890997,0.06743627,0.0015915947,0.00033178736,0.003769928,0.00036712817,0.004666238,0.0014227153,0.053141344,0.8650303,0.00009875375],"about_ca_topic_score_codex":0.006167545,"about_ca_topic_score_gemma":0.010374823,"teacher_disagreement_score":0.080513254,"about_ca_system_score_codex":0.0029374198,"about_ca_system_score_gemma":0.0035065378,"threshold_uncertainty_score":0.26934367},"labels":[],"label_agreement":null},{"id":"W3120931056","doi":"10.1111/dom.14316","title":"Essential diabetes medicines and health outcomes in 127 countries","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University; St. Michael's Hospital","funders":"St. Michael's Hospital Foundation; Canadian Institutes of Health Research; Ontario SPOR SUPPORT Unit","keywords":"Medicine; Diabetes mellitus; Per capita; Population; Interquartile range; Gross domestic product; Confidence interval; Environmental health; Internal medicine; Demography; Endocrinology","score_opus":0.026657386207932794,"score_gpt":0.2758455092691804,"score_spread":0.2491881230612476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120931056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785428,0.002202432,0.00013247019,0.00024905836,0.000017373904,0.00004281166,0.017307863,0.000015868438,0.0014892631],"genre_scores_gemma":[0.9893273,0.00084062974,0.00025565585,0.00006284841,0.000017517437,0.00007116266,0.00928679,0.0000040047194,0.00013410779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780434,0.0008390398,0.00040766955,0.0002755425,0.00042938828,0.00024400634],"domain_scores_gemma":[0.99150217,0.0011799198,0.006196926,0.00019611455,0.00049713725,0.0004277645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019161244,0.00037009257,0.00057082885,0.002376242,0.00032489983,0.00077498954,0.00042191282,0.00036249487,0.0017742249],"category_scores_gemma":[0.0047274358,0.00036231018,0.0009783226,0.00582352,0.00040569928,0.00049795455,0.0012129142,0.00066731224,0.00021944624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014831465,0.000036379563,0.99624676,0.00016306974,0.00024268118,0.00004552931,0.000072762086,0.00025790103,0.000035577425,0.0000508219,0.00056373293,0.0021364307],"study_design_scores_gemma":[0.00003254802,0.00008035395,0.998667,0.00008542832,0.00009287405,0.00010454297,0.00014532928,0.00015579812,0.000045032673,0.000033820193,0.0005502493,0.0000070231454],"about_ca_topic_score_codex":0.01556469,"about_ca_topic_score_gemma":0.010025476,"teacher_disagreement_score":0.01556469,"about_ca_system_score_codex":0.0011322481,"about_ca_system_score_gemma":0.0009103869,"threshold_uncertainty_score":0.030948162},"labels":[],"label_agreement":null},{"id":"W3121136854","doi":"10.1111/j.1467-9701.2005.00668.x","title":"AIDS Policy and Pharmaceutical Patents: Brazil's Strategy to Safeguard Public Health","year":2005,"lang":"en","type":"article","venue":"World Economy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Negotiation; Context (archaeology); Developing country; Balance (ability); International trade; Pharmaceutical industry; Business; Access to medicines; Safeguard; Public health; Economics; International economics; Economic growth; Political science; Law; Medicine","score_opus":0.111899194250039,"score_gpt":0.3541797735718175,"score_spread":0.24228057932177852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121136854","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03315589,0.043823987,0.0036500485,0.7093808,0.00074864423,0.00007759982,0.0003350358,0.00007021446,0.20875785],"genre_scores_gemma":[0.8824779,0.029223125,0.0033939602,0.06142631,0.0011522254,0.00009127631,0.00010967352,0.000031069838,0.022094395],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99640477,0.0014132083,0.00011919943,0.00023490918,0.0011262614,0.0007015849],"domain_scores_gemma":[0.99122846,0.0048239045,0.0010583644,0.0003876861,0.0016360658,0.0008654775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007055653,0.00036998463,0.00035659023,0.0018219409,0.0025102466,0.006695641,0.0008210564,0.0056918864,0.005200672],"category_scores_gemma":[0.024498815,0.00017190282,0.0004895418,0.0023341265,0.0052642124,0.0042169853,0.0024294297,0.0034194496,0.0004182535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029312632,0.000024569807,0.0016449823,0.00018218662,0.000014848348,0.00014702669,0.00084957026,0.0006399379,0.0003729286,0.93588495,0.020058155,0.0401516],"study_design_scores_gemma":[0.00012923806,0.000110671244,0.00848282,0.0016519976,0.00008903902,0.0004456063,0.0021038887,0.002029383,0.001041962,0.40026596,0.5835999,0.00004959886],"about_ca_topic_score_codex":0.0665511,"about_ca_topic_score_gemma":0.05703602,"teacher_disagreement_score":0.0665511,"about_ca_system_score_codex":0.009003994,"about_ca_system_score_gemma":0.025863172,"threshold_uncertainty_score":0.13232744},"labels":[],"label_agreement":null},{"id":"W3121226665","doi":"10.1057/jgm.2010.14","title":"Ever-Greening: A Status Check in Selected Countries","year":2010,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Mylan","keywords":"Business; Greening; Product (mathematics); Index (typography); Developing country; Duration (music); Generic drug; International trade; Development economics; International economics; Economics; Economic growth; Medicine; Political science","score_opus":0.06957175371250879,"score_gpt":0.29925292180352275,"score_spread":0.22968116809101397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121226665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9053883,0.024630627,0.00047435303,0.013132904,0.00047811697,0.00012046718,0.007346468,0.00015729484,0.048271485],"genre_scores_gemma":[0.9849029,0.0077904724,0.00041303644,0.0014800383,0.00014513572,0.000031329277,0.0021141828,0.000031258125,0.0030915947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895144,0.0001860172,0.0001890686,0.0001141785,0.0002824657,0.00027682277],"domain_scores_gemma":[0.9873704,0.001771627,0.0053177862,0.000596523,0.0037227778,0.0012209866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003120998,0.00019585817,0.00038257337,0.0043776287,0.0008325033,0.0025888719,0.00044335154,0.0007220773,0.00350136],"category_scores_gemma":[0.006306943,0.00020204755,0.00043032423,0.007928319,0.0008029894,0.002137243,0.0013299077,0.00066972885,0.00048359914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010129575,0.00015150932,0.82402176,0.0012536983,0.00016428561,0.0016567877,0.0036666638,0.0005229881,0.0014800307,0.00433056,0.025658347,0.13608049],"study_design_scores_gemma":[0.00003299221,0.00028489318,0.93847084,0.00042000113,0.00008726943,0.00079763576,0.0060824994,0.00018775564,0.0008074649,0.00035739833,0.052440964,0.000030311845],"about_ca_topic_score_codex":0.013268536,"about_ca_topic_score_gemma":0.016383987,"teacher_disagreement_score":0.013268536,"about_ca_system_score_codex":0.0010673786,"about_ca_system_score_gemma":0.0014864949,"threshold_uncertainty_score":0.026382625},"labels":[],"label_agreement":null},{"id":"W3121236048","doi":"","title":"Monitoring and Forecasting Currency Crises","year":2005,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Voting; Currency; Logit; Medical prescription; Economics; Business; Actuarial science; Public economics; Monetary economics; Political science; Econometrics; Law; Politics","score_opus":0.2116574126150867,"score_gpt":0.3907073941798291,"score_spread":0.1790499815647424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121236048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9034616,0.0028162391,0.08328695,0.0013420729,0.0001612892,0.000073156996,0.0012404856,0.00068634,0.0069318106],"genre_scores_gemma":[0.9881968,0.0005267756,0.010194196,0.000045518445,0.000083610335,0.00001322423,0.00047356234,0.000014889659,0.00045144046],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9995146,0.0002140998,0.000038549268,0.0000896877,0.00010406665,0.00003896902],"domain_scores_gemma":[0.9938433,0.0035693287,0.0011389127,0.0002496092,0.0009244728,0.00027437383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002749338,0.00091809384,0.00079858454,0.0022953528,0.00015962888,0.0011967625,0.00034031773,0.0005817652,0.0012057762],"category_scores_gemma":[0.0125879245,0.00021798004,0.00025740347,0.0012992203,0.00020488106,0.0013620354,0.00064562034,0.0009423336,0.0004388767],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013946396,0.00032928865,0.39822832,0.00036034733,0.000398247,0.00014641807,0.00018423847,0.26807174,0.008128999,0.00412376,0.0050654425,0.31356853],"study_design_scores_gemma":[0.00005464706,0.00015506583,0.052194543,0.000058334423,0.000059567174,0.00006546911,0.0000723461,0.9360248,0.0054870704,0.0047535906,0.0010409193,0.000033681816],"about_ca_topic_score_codex":0.0022272333,"about_ca_topic_score_gemma":0.0014478914,"teacher_disagreement_score":0.002749338,"about_ca_system_score_codex":0.00038197133,"about_ca_system_score_gemma":0.00029177702,"threshold_uncertainty_score":0.014540076},"labels":[],"label_agreement":null},{"id":"W3121390674","doi":"10.1111/joie.12026","title":"Innovation Incentives under Transferable Fast‐Track Regulatory Review","year":2013,"lang":"en","type":"article","venue":"Journal of Industrial Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Voucher; Track (disk drive); Incentive; Competition (biology); Fast track; Empirical evidence; Public economics; Business; Computer science; Economics; Industrial organization; Microeconomics; Accounting","score_opus":0.1277136331172883,"score_gpt":0.28954549005368146,"score_spread":0.16183185693639315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121390674","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34559673,0.004072533,0.06837436,0.022529636,0.000587473,0.0010275017,0.0019943167,0.0008320406,0.5549854],"genre_scores_gemma":[0.9528048,0.00071804516,0.0033944359,0.0022188067,0.000419426,0.00030778564,0.00014901975,0.0000451088,0.0399426],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9838171,0.0062045893,0.0006610927,0.002596826,0.0031800566,0.0035402838],"domain_scores_gemma":[0.9252698,0.04237427,0.01613442,0.0047490913,0.0076126074,0.0038597856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021060357,0.0006335576,0.002018988,0.0017095788,0.0022068059,0.006714626,0.002632897,0.008904459,0.031882755],"category_scores_gemma":[0.07786111,0.0008037002,0.001423403,0.0014331881,0.0037427456,0.0063181,0.0032268402,0.003807987,0.0030826323],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003773828,0.00038562727,0.0046992977,0.00023845039,0.000068827525,0.00048488093,0.00030920902,0.024130203,0.0011989668,0.9270763,0.013737808,0.0272932],"study_design_scores_gemma":[0.0009064157,0.00094919966,0.01253212,0.00024341873,0.00019670321,0.00050631346,0.0004877969,0.06415313,0.0016672212,0.85412997,0.0640121,0.00021559103],"about_ca_topic_score_codex":0.0074275434,"about_ca_topic_score_gemma":0.0059233624,"teacher_disagreement_score":0.031882755,"about_ca_system_score_codex":0.0057433043,"about_ca_system_score_gemma":0.007895237,"threshold_uncertainty_score":0.11137915},"labels":[],"label_agreement":null},{"id":"W3121470554","doi":"","title":"High Drug Prices, Big R&D Spenders and “Free Riders”: Canada in the Topsy Turvy World of Pharmaceuticals","year":2019,"lang":"en","type":"article","venue":"C.D. Howe Institute Commentary","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Subsidy; Government (linguistics); Negotiation; Purchasing; Pharmaceutical industry; Public economics; Incentive; Finance; Economics; Marketing; Market economy; Law; Political science; Biotechnology","score_opus":0.049627100195706694,"score_gpt":0.2595724084930369,"score_spread":0.2099453082973302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121470554","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0067501767,0.03778612,0.0004600221,0.905122,0.0067317486,0.000022684588,0.00012570711,0.000029966684,0.042971645],"genre_scores_gemma":[0.16865495,0.029648373,0.0010113401,0.7651436,0.0044768625,0.00003489917,0.00007161344,0.00009147495,0.03086694],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.992392,0.0012090643,0.00024113386,0.0007412946,0.0034996765,0.0019168964],"domain_scores_gemma":[0.9880265,0.004330956,0.0004839949,0.00020421311,0.0053499397,0.0016044561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039227377,0.0005423191,0.0007004527,0.0013889108,0.023471165,0.011597084,0.0027849386,0.01604452,0.0025392745],"category_scores_gemma":[0.014996184,0.0003676612,0.00094005273,0.0019936422,0.015534164,0.0043441635,0.001851527,0.016474333,0.00032328576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000781645,0.000023870152,0.0018365455,0.00031214734,0.00004801886,0.00081945583,0.011669391,0.0003587614,0.0003560311,0.30641937,0.65566075,0.022417488],"study_design_scores_gemma":[0.000050354236,0.000019864698,0.0031458887,0.00084342516,0.00008952428,0.00020748348,0.009678582,0.00046435016,0.00033749492,0.026872542,0.95813906,0.0001514059],"about_ca_topic_score_codex":0.98047763,"about_ca_topic_score_gemma":0.99104357,"teacher_disagreement_score":0.8878024,"about_ca_system_score_codex":0.11219756,"about_ca_system_score_gemma":0.16175592,"threshold_uncertainty_score":0.81405413},"labels":[],"label_agreement":null},{"id":"W3121502174","doi":"","title":"Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets","year":2011,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Competition (biology); Pharmacy; Business; Public economics; Industrial organization; Monetary economics; Economics; Microeconomics; Political science","score_opus":0.27095662518883845,"score_gpt":0.4402510333360323,"score_spread":0.16929440814719388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121502174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7480177,0.06882461,0.0024849898,0.01898659,0.0005132516,0.0001572846,0.0057882615,0.00007352936,0.15515374],"genre_scores_gemma":[0.9770264,0.012768754,0.000292364,0.003510984,0.0003869668,0.000032123182,0.0025869173,0.00003332684,0.0033622582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994713,0.0013983456,0.00040111612,0.0011471265,0.0015519148,0.0007883398],"domain_scores_gemma":[0.913132,0.04623996,0.0287348,0.0035299947,0.004974954,0.0033882845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006965438,0.00038204945,0.0011010293,0.0025234807,0.0010323894,0.0038019037,0.0013224877,0.0020664386,0.028092872],"category_scores_gemma":[0.039514836,0.00032424973,0.0021607762,0.003707466,0.0022403148,0.0031723722,0.0035941028,0.0020374449,0.0019552025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028270464,0.0011129577,0.8434937,0.0032981683,0.004071102,0.001140291,0.001902301,0.003631701,0.0006706334,0.03972629,0.0143498825,0.08377588],"study_design_scores_gemma":[0.00029784936,0.00049341406,0.96057385,0.001052598,0.0013677643,0.00036518546,0.002365888,0.001358456,0.00071303797,0.004459806,0.026895937,0.000056183224],"about_ca_topic_score_codex":0.021079192,"about_ca_topic_score_gemma":0.01944054,"teacher_disagreement_score":0.028092872,"about_ca_system_score_codex":0.0015570727,"about_ca_system_score_gemma":0.0014528352,"threshold_uncertainty_score":0.093979955},"labels":[],"label_agreement":null},{"id":"W3121538607","doi":"10.17848/wp19-306","title":"Medical Innovation, Education, and Labor Market Outcomes for Cancer Patients","year":2019,"lang":"en","type":"report","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Statistics Canada","funders":"Syddansk Universitet; Institut für Arbeitsmarkt- und Berufsforschung; W.E. Upjohn Institute for Employment Research","keywords":"Cancer; Educational attainment; Medicine; Prostate cancer; Breast cancer; Cancer treatment; Cancer registry; Work (physics); Economics; Internal medicine; Economic growth","score_opus":0.06855752737312243,"score_gpt":0.3701336889775521,"score_spread":0.3015761616044297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121538607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708946,0.0014552906,0.00035395598,0.0065373546,0.00005096069,0.000051781128,0.008288577,0.000015916608,0.012351634],"genre_scores_gemma":[0.9923652,0.0005886842,0.00009590432,0.000359933,0.00011628163,0.000030685325,0.0035395662,0.0000044016506,0.0028993373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994425,0.00012571887,0.00003618815,0.00005102335,0.00011951986,0.00022500388],"domain_scores_gemma":[0.99295676,0.0019391881,0.0034382849,0.00016027119,0.00043734655,0.0010681303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015531804,0.00016878852,0.00026291073,0.0012530866,0.00052637974,0.0011977542,0.0003314372,0.0006337267,0.008761574],"category_scores_gemma":[0.007493745,0.0000870823,0.0006032877,0.0022270107,0.00037695866,0.0006766333,0.00071343256,0.0009542234,0.000928721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008156228,0.0001769474,0.9870243,0.000022225004,0.000047057827,0.000038403377,0.00015371756,0.0009111808,0.000031468637,0.0011022165,0.0032130003,0.007197884],"study_design_scores_gemma":[0.000035144734,0.00010428166,0.99321306,0.00003707771,0.000043627926,0.000040067098,0.0005404933,0.001594478,0.00009106015,0.0009963041,0.0032944216,0.000010020089],"about_ca_topic_score_codex":0.06855772,"about_ca_topic_score_gemma":0.0918118,"teacher_disagreement_score":0.06855772,"about_ca_system_score_codex":0.0016956048,"about_ca_system_score_gemma":0.0021051562,"threshold_uncertainty_score":0.13631731},"labels":[],"label_agreement":null},{"id":"W3121702970","doi":"10.24926/15529541.3494","title":"Structure-Function Analysis of Global Pharmaceutical Linkage Regulations","year":2011,"lang":"en","type":"article","venue":"Minnesota journal of law, science & technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Linkage (software); Tying; Business; Intellectual property; Generic drug; Public economics; Function (biology); International trade; Industrial organization; Law and economics; Economics; Law; Drug; Political science; Medicine; Pharmacology","score_opus":0.06382007411605199,"score_gpt":0.3134450849888588,"score_spread":0.2496250108728068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121702970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41222417,0.002797645,0.34463578,0.0078788875,0.00018958186,0.0003782965,0.0013059347,0.00078332063,0.22980638],"genre_scores_gemma":[0.9620198,0.0010282903,0.009210312,0.0004466766,0.0001543224,0.00018962349,0.00034015797,0.000099825695,0.026510974],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980159,0.00073377456,0.000043649754,0.00029220124,0.00041490185,0.00049958617],"domain_scores_gemma":[0.9936638,0.0035790794,0.0011890596,0.00054436934,0.00074493006,0.0002787293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045132404,0.00077035883,0.001570203,0.0023678648,0.0012337533,0.0031539642,0.0013504584,0.002954742,0.015265657],"category_scores_gemma":[0.01423154,0.0006051291,0.0022427624,0.0019000482,0.0026747063,0.0030178835,0.0021859547,0.0027882645,0.00088239997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043082706,0.00009391704,0.002083131,0.00006216098,0.00007646441,0.00017065089,0.00014058339,0.13223596,0.00038225792,0.85073054,0.004039909,0.009941408],"study_design_scores_gemma":[0.0001062956,0.00015342094,0.006371402,0.00008106403,0.00011655722,0.0000946266,0.00022158143,0.3275311,0.00038444428,0.65165865,0.013221488,0.00005941323],"about_ca_topic_score_codex":0.012134577,"about_ca_topic_score_gemma":0.00578883,"teacher_disagreement_score":0.015265657,"about_ca_system_score_codex":0.0042263507,"about_ca_system_score_gemma":0.0025125938,"threshold_uncertainty_score":0.051068664},"labels":[],"label_agreement":null},{"id":"W3121980999","doi":"10.2139/ssrn.3353887","title":"Medical Innovation, Education, and Labor Market Outcomes of Cancer Patients","year":2019,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"","keywords":"Labour economics; Business; Cancer; Economics; Medicine; Internal medicine","score_opus":0.011114487463749656,"score_gpt":0.2873216248207831,"score_spread":0.27620713735703345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121980999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935621,0.0006305119,0.000036065336,0.0020220107,0.000025937452,0.000011538931,0.00084669207,0.0000041185917,0.0028610816],"genre_scores_gemma":[0.998431,0.00016765198,0.00000993368,0.0001713881,0.000043970966,0.0000047974245,0.00042374205,0.0000013475018,0.00074611005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989219,0.000259857,0.00009607479,0.00008040182,0.0001022782,0.00053951464],"domain_scores_gemma":[0.9899394,0.0026535296,0.0042311503,0.00022188912,0.00049559615,0.0024584334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013946029,0.00016162438,0.0003298966,0.0012211476,0.0006855024,0.0019314804,0.000509644,0.0015762721,0.012219402],"category_scores_gemma":[0.011484252,0.00017724452,0.0008040748,0.0016301335,0.0005332248,0.0012775231,0.0009962437,0.0018284356,0.0010153165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046081233,0.0006234901,0.9930669,0.000019018464,0.00007230573,0.00007016899,0.00017935871,0.0003789563,0.00005703839,0.00034099462,0.00067970215,0.004051221],"study_design_scores_gemma":[0.00005098151,0.0003465891,0.9960967,0.00002776992,0.000054467186,0.00007850975,0.00093212904,0.0008412579,0.000069539004,0.00074315094,0.0007424217,0.000016575726],"about_ca_topic_score_codex":0.0136369765,"about_ca_topic_score_gemma":0.014543101,"teacher_disagreement_score":0.0136369765,"about_ca_system_score_codex":0.0011278732,"about_ca_system_score_gemma":0.001599935,"threshold_uncertainty_score":0.04087794},"labels":[],"label_agreement":null},{"id":"W3122208036","doi":"10.3386/w20469","title":"Poor Quality Drugs and Global Trade: A Pilot Study","year":2014,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health; University of Ottawa","funders":"Social Sciences and Humanities Research Council of Canada","keywords":"Business; Quality (philosophy); Intermediary; Consumption (sociology); Distribution (mathematics); Pharmaceutical industry; Commerce; International trade; Marketing; Medicine; Pharmacology","score_opus":0.5521944559050764,"score_gpt":0.5542266859490793,"score_spread":0.0020322300440028807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122208036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955271,0.00020915065,0.00005078465,0.00030198108,0.000005505295,0.000051311352,0.00046575183,0.0000047205963,0.0033838458],"genre_scores_gemma":[0.99866164,0.00023196622,0.00006187102,0.00009812162,0.000018804385,0.000026391377,0.00036354273,0.000005006372,0.00053278555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874026,0.0006760063,0.000055326564,0.00012753265,0.00013028149,0.00027061097],"domain_scores_gemma":[0.9750947,0.013175991,0.006943895,0.0013162999,0.0011161781,0.0023530074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030139505,0.00054535904,0.00040736567,0.0033647139,0.0011908987,0.0023504437,0.0004770638,0.0010046101,0.01051663],"category_scores_gemma":[0.008806708,0.00028032373,0.0007553696,0.0052550714,0.0026430779,0.0028313368,0.0022185599,0.0014665353,0.0011143087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009649552,0.0021462834,0.9674364,0.00021228186,0.00015125478,0.0015332389,0.010439432,0.00031005082,0.000164758,0.0018035785,0.0017092613,0.013128485],"study_design_scores_gemma":[0.00013042848,0.0013521317,0.9708425,0.00007187012,0.00010631383,0.00045167372,0.023351947,0.00039876415,0.00013016691,0.0005111198,0.0026301525,0.000022943354],"about_ca_topic_score_codex":0.009062061,"about_ca_topic_score_gemma":0.008105222,"teacher_disagreement_score":0.01051663,"about_ca_system_score_codex":0.001124781,"about_ca_system_score_gemma":0.0007394792,"threshold_uncertainty_score":0.0351817},"labels":[],"label_agreement":null},{"id":"W3122229012","doi":"","title":"Foreign Free Riders and the High Price of U.S. Medicines","year":2005,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Argument (complex analysis); Order (exchange); Government (linguistics); Pharmaceutical industry; Business; Economics; Public economics; International economics; Monetary economics; Finance","score_opus":0.015440610335339758,"score_gpt":0.23762914882340563,"score_spread":0.22218853848806588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122229012","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49454093,0.04334411,0.002109577,0.16132767,0.0013461572,0.000041943043,0.0011613966,0.00009227184,0.2960359],"genre_scores_gemma":[0.9855898,0.004113667,0.0001321472,0.0050907754,0.00042131162,0.00000846509,0.000113616064,0.000011541114,0.004518618],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985372,0.00057095406,0.00007590386,0.00013244648,0.00035735665,0.00032611506],"domain_scores_gemma":[0.98532176,0.0068511404,0.0052890363,0.0005883862,0.001179577,0.00077009236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028379639,0.00019396645,0.00056571845,0.0014883208,0.0017430981,0.0052533164,0.00039157787,0.0032457134,0.01557705],"category_scores_gemma":[0.016021553,0.0001958862,0.00041655803,0.0021741665,0.0031862871,0.00220025,0.0013604454,0.0025993797,0.0007072072],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013131141,0.00034793682,0.101972565,0.00044891224,0.0004911206,0.002058328,0.0022784113,0.0058347443,0.00042692377,0.63750935,0.15774694,0.08957168],"study_design_scores_gemma":[0.0010528559,0.00057424995,0.28344506,0.001555644,0.00057837646,0.0017678633,0.008629619,0.012068472,0.0018070774,0.42021388,0.26799166,0.0003152818],"about_ca_topic_score_codex":0.023548136,"about_ca_topic_score_gemma":0.015741993,"teacher_disagreement_score":0.023548136,"about_ca_system_score_codex":0.003898591,"about_ca_system_score_gemma":0.0013569412,"threshold_uncertainty_score":0.052110434},"labels":[],"label_agreement":null},{"id":"W3122706492","doi":"10.2139/ssrn.1139226","title":"Liberalization and Protection: Antidumping Duties in the Indian Pharmaceutical Industry","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; University of British Columbia","funders":"","keywords":"Pharmaceutical industry; International trade; Business; Liberalization; International economics; Economics; Law; Political science; Medicine","score_opus":0.051178187883626124,"score_gpt":0.3022812672424783,"score_spread":0.2511030793588522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122706492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6388562,0.0058658337,0.00383329,0.045254763,0.00024033751,0.000068265916,0.00022406621,0.00008078031,0.30557638],"genre_scores_gemma":[0.99168605,0.00048321552,0.00020498318,0.001908843,0.00012787836,0.000007784429,0.000017690474,0.0000054658894,0.0055579753],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9950041,0.0012825282,0.00023590327,0.0004768771,0.0009922611,0.0020083624],"domain_scores_gemma":[0.98554164,0.007464109,0.0029621674,0.0012156136,0.0012711876,0.0015452805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044671777,0.00026594207,0.0006862656,0.001343305,0.0035251048,0.009324767,0.0014600946,0.006109497,0.0075924667],"category_scores_gemma":[0.015341754,0.00028814125,0.0008516601,0.0018837694,0.007053385,0.0031737655,0.0034315912,0.006595459,0.00040014487],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034004461,0.00021715884,0.01399741,0.00015712157,0.000048814374,0.00085742155,0.00224277,0.0020324085,0.0019615751,0.9379681,0.006708346,0.03346895],"study_design_scores_gemma":[0.00017444523,0.00034394278,0.12326743,0.0004757336,0.00017732116,0.0009513598,0.0073116357,0.007594209,0.004414717,0.76315826,0.09198369,0.00014724911],"about_ca_topic_score_codex":0.016001225,"about_ca_topic_score_gemma":0.017093712,"teacher_disagreement_score":0.016001225,"about_ca_system_score_codex":0.005392099,"about_ca_system_score_gemma":0.008012437,"threshold_uncertainty_score":0.03912264},"labels":[],"label_agreement":null},{"id":"W3123073191","doi":"","title":"Monopoly Pricing of an Antibiotic Subject to Bacterial Resistance","year":2009,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Monopoly; Externality; Economics; Antibiotics; Antibiotic resistance; Microeconomics; Population; Quality (philosophy); Industrial organization; Biology; Microbiology","score_opus":0.06558288736456924,"score_gpt":0.34728194405641616,"score_spread":0.2816990566918469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123073191","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34266296,0.002526602,0.4838952,0.017439328,0.00052382523,0.00031743955,0.001359984,0.0003705568,0.15090412],"genre_scores_gemma":[0.9456844,0.0008783835,0.009504644,0.00040724353,0.00015897167,0.00020591581,0.00013795086,0.00004557574,0.042976893],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9988085,0.00047430498,0.000037249065,0.00020104837,0.0002149726,0.00026390894],"domain_scores_gemma":[0.99724066,0.0013740954,0.00047704985,0.00019577002,0.0002510584,0.00046131678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017036938,0.0010658036,0.001929492,0.0009761359,0.0007789733,0.0034916704,0.002732627,0.0056659766,0.010370025],"category_scores_gemma":[0.0057539092,0.00086308585,0.0013284455,0.00088825804,0.0027275365,0.0029189582,0.0016929078,0.0024154834,0.0013809056],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027063827,0.00019323152,0.0008030387,0.00016063529,0.00008245951,0.0008457539,0.00016125385,0.36935288,0.0041998182,0.6151029,0.0028995029,0.005927951],"study_design_scores_gemma":[0.0001432379,0.00014961054,0.00042763085,0.000026255851,0.00004285253,0.00016383387,0.000051017312,0.84694993,0.00026121247,0.14897577,0.0027624476,0.00004611444],"about_ca_topic_score_codex":0.0059144995,"about_ca_topic_score_gemma":0.0027515092,"teacher_disagreement_score":0.010370025,"about_ca_system_score_codex":0.002868687,"about_ca_system_score_gemma":0.0020993503,"threshold_uncertainty_score":0.034691155},"labels":[],"label_agreement":null},{"id":"W3123155668","doi":"","title":"Clinical Trials for New Drug Development: Optimal Investment and Application","year":2016,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interim; Clinical trial; Revenue; Interim analysis; Drug development; Investment (military); Net present value; Value (mathematics); Actuarial science; Medicine; Test (biology); Computer science; Drug; Operations management; Business; Economics; Finance; Microeconomics; Pharmacology; Production (economics)","score_opus":0.13029262257687854,"score_gpt":0.37911165261758556,"score_spread":0.24881903004070702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123155668","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059392884,0.01993711,0.721911,0.060551684,0.0005221243,0.0019102101,0.0014315054,0.00066718645,0.13367641],"genre_scores_gemma":[0.85501474,0.012481881,0.118528545,0.0017723361,0.0005909128,0.0012046151,0.0003827687,0.00010062733,0.009923575],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99037534,0.006856158,0.0002520017,0.0008154054,0.0010883083,0.0006127909],"domain_scores_gemma":[0.9597116,0.033872012,0.0032353261,0.0011045415,0.0011228673,0.0009536492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013536287,0.0015881555,0.0029733414,0.0019576838,0.0012007459,0.007260602,0.0017791366,0.0051616775,0.011838157],"category_scores_gemma":[0.061618134,0.0019762209,0.0010181265,0.0027749743,0.004138826,0.007800872,0.0023608082,0.004745682,0.0010837147],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002252843,0.00016301783,0.0014166444,0.0003648431,0.00008378764,0.00013267748,0.00011362358,0.23854032,0.0002480932,0.6939858,0.00830045,0.056425497],"study_design_scores_gemma":[0.00018382886,0.00014528904,0.0007134909,0.00023165415,0.000048784972,0.00009277037,0.00008297424,0.22060414,0.00019188876,0.76918155,0.008485751,0.000037858466],"about_ca_topic_score_codex":0.003618665,"about_ca_topic_score_gemma":0.0031019566,"teacher_disagreement_score":0.013536287,"about_ca_system_score_codex":0.009067356,"about_ca_system_score_gemma":0.008572423,"threshold_uncertainty_score":0.07158762},"labels":[],"label_agreement":null},{"id":"W3123210912","doi":"10.2139/ssrn.3262241","title":"Innovation and Antibiotic Use Within Antibiotic Classes: Market Incentives and Economic Instruments","year":2013,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Treasury Board of Canada Secretariat; Université Laval","funders":"","keywords":"Exploit; Incentive; Subsidy; Antibiotics; Industrial organization; Business; Public economics; Economics; Microeconomics; Market economy; Computer science; Computer security","score_opus":0.03355401645458533,"score_gpt":0.2715443589131024,"score_spread":0.23799034245851708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123210912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80152917,0.024117677,0.06628932,0.056793604,0.0006978278,0.00033064792,0.0017123168,0.00019042351,0.04833903],"genre_scores_gemma":[0.98897576,0.0032022952,0.0018333332,0.0008006185,0.0006196644,0.00005016427,0.00012416023,0.000012647012,0.0043813223],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99563897,0.0021292474,0.00029035777,0.00059125153,0.0005800361,0.00077020656],"domain_scores_gemma":[0.87460697,0.094054565,0.02464765,0.0020316734,0.0020411818,0.0026179366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009816947,0.0004887678,0.0015984093,0.0018084215,0.00054669945,0.0042160205,0.00086924236,0.0053857425,0.012512698],"category_scores_gemma":[0.053081345,0.00041677093,0.0011932151,0.0018856783,0.002767779,0.0044347607,0.0019264725,0.0034915097,0.0004843451],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00247262,0.0016010497,0.16033064,0.00096931006,0.0008628107,0.0006365314,0.0005339141,0.05877218,0.002705408,0.6372318,0.007436223,0.12644751],"study_design_scores_gemma":[0.00068411976,0.0008368169,0.108877376,0.0003634523,0.00046123422,0.0003805442,0.00042973552,0.090779155,0.0014762197,0.7833325,0.012202444,0.00017645363],"about_ca_topic_score_codex":0.0021229016,"about_ca_topic_score_gemma":0.0016935397,"teacher_disagreement_score":0.012512698,"about_ca_system_score_codex":0.0023179795,"about_ca_system_score_gemma":0.0017819131,"threshold_uncertainty_score":0.051917613},"labels":[],"label_agreement":null},{"id":"W3123337039","doi":"","title":"A Dynamic Oligopoly Structural Model for the Prescription Drug Market After Patent Expiration","year":2004,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Stylized fact; Oligopoly; Economics; Microeconomics; Expiration date; Nested logit; Dynamic pricing; Discrete choice; Econometrics; Cournot competition","score_opus":0.08745713741393496,"score_gpt":0.33445026735143374,"score_spread":0.24699312993749878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123337039","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18209554,0.0029762136,0.6622605,0.014976717,0.00059478683,0.0010596691,0.011241678,0.0011049842,0.12368999],"genre_scores_gemma":[0.8392445,0.0033532593,0.05190879,0.0011588675,0.00041848083,0.0013269279,0.0024047687,0.00014347203,0.1000409],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987446,0.00043775057,0.000047966183,0.0003201186,0.00015121505,0.00029833242],"domain_scores_gemma":[0.99736446,0.0012698713,0.0006068281,0.00016940257,0.0002322868,0.00035715947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001741041,0.0015826515,0.003101843,0.0012889439,0.0012935657,0.0038313277,0.0037754118,0.005864315,0.029457193],"category_scores_gemma":[0.0039296187,0.0011664685,0.002066707,0.0020887046,0.002581368,0.0033423319,0.0021703877,0.003840878,0.0038067123],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031764107,0.0002447161,0.0013313348,0.0002414933,0.000088428256,0.00057115604,0.0002234169,0.50325173,0.0012648565,0.47875363,0.0059818784,0.0077297017],"study_design_scores_gemma":[0.00045586927,0.0002015046,0.0007496242,0.000037816702,0.00007035392,0.0001214909,0.00009905393,0.8358785,0.00014582675,0.15569083,0.0064719715,0.00007722151],"about_ca_topic_score_codex":0.019428207,"about_ca_topic_score_gemma":0.01677759,"teacher_disagreement_score":0.029457193,"about_ca_system_score_codex":0.003744883,"about_ca_system_score_gemma":0.0026290158,"threshold_uncertainty_score":0.09854406},"labels":[],"label_agreement":null},{"id":"W3123463615","doi":"10.1257/pandp.20211104","title":"Private and Social Returns to R&amp;D: Drug Development and Demographics","year":2021,"lang":"en","type":"article","venue":"AEA Papers and Proceedings","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Productivity; Demographics; Life expectancy; Investment (military); Welfare; Demographic economics; Business; Capital (architecture); Economics; Monetary economics; Labour economics; Public economics; Economic growth; Market economy; Demography; Geography; Environmental health; Medicine; Political science","score_opus":0.043646406593664006,"score_gpt":0.25682264080211864,"score_spread":0.21317623420845463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123463615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88912064,0.01964671,0.0010702286,0.013414549,0.00006374918,0.00007803998,0.013407899,0.000046559908,0.06315168],"genre_scores_gemma":[0.98403823,0.0067992746,0.00016271784,0.0005028482,0.00014469266,0.000022076874,0.0023991594,0.000012231267,0.0059188553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992687,0.00015921688,0.00007265868,0.000100345795,0.00023955117,0.00015954702],"domain_scores_gemma":[0.9904096,0.0016676493,0.004779119,0.00017468774,0.0010142468,0.0019546596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013752562,0.00010904145,0.00024066695,0.0022689775,0.00035932707,0.0021930565,0.0003021899,0.0005641102,0.011228774],"category_scores_gemma":[0.0064362357,0.00012241458,0.0002734118,0.002916231,0.0005543216,0.0019919474,0.00084259774,0.0008684864,0.0030052955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027980102,0.00019535644,0.9161764,0.00013443166,0.00013519484,0.0001363285,0.00035894488,0.0011306627,0.00034996198,0.009068606,0.0110152885,0.061019015],"study_design_scores_gemma":[0.0000080468735,0.000072887415,0.9818277,0.000040049505,0.000016493548,0.000302167,0.00035478108,0.0005645309,0.00013796531,0.001865988,0.0147937285,0.000015779104],"about_ca_topic_score_codex":0.006166908,"about_ca_topic_score_gemma":0.0068507656,"teacher_disagreement_score":0.011228774,"about_ca_system_score_codex":0.0013296354,"about_ca_system_score_gemma":0.00064006867,"threshold_uncertainty_score":0.03756398},"labels":[],"label_agreement":null},{"id":"W3123480629","doi":"10.2139/ssrn.3262741","title":"Open Access to the Resource of Antibiotic Treatment Efficacy Subject to Bacterial Resistance","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Antibiotics; Context (archaeology); Antibiotic resistance; Quality (philosophy); Resource (disambiguation); Intensive care medicine; Economics; Business; Medicine; Computer science; Biology; Microbiology","score_opus":0.062272553518112374,"score_gpt":0.3292029225876436,"score_spread":0.2669303690695312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123480629","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3217041,0.026724556,0.09129492,0.11890515,0.0045430763,0.00040901318,0.038823806,0.0023642357,0.3952311],"genre_scores_gemma":[0.9430412,0.0060557225,0.004557931,0.0018368664,0.0029827484,0.0001364829,0.0031078523,0.00023225514,0.038048923],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99519277,0.002053894,0.00043183786,0.00045889817,0.0014318499,0.00043075692],"domain_scores_gemma":[0.9114418,0.052431654,0.012342082,0.010319441,0.008877502,0.00458744],"candidate_categories":["open_science"],"consensus_categories":[],"category_scores_codex":[0.006080706,0.00038104103,0.0011354348,0.0029326866,0.00046494373,0.0046014646,0.0015378776,0.0021839775,0.06693073],"category_scores_gemma":[0.07349998,0.00045272714,0.0007779055,0.0031046607,0.0019725338,0.0056272945,0.0029636994,0.0024072635,0.0049977726],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023506796,0.000633439,0.019475507,0.0014796926,0.0005549223,0.0012311572,0.0007888853,0.016072232,0.004272023,0.5837555,0.08156112,0.28782487],"study_design_scores_gemma":[0.00033639293,0.0006193958,0.031150125,0.00075196184,0.00025881224,0.0011386508,0.0005675657,0.020825341,0.0027972711,0.73787254,0.20349848,0.0001834552],"about_ca_topic_score_codex":0.001853092,"about_ca_topic_score_gemma":0.0012672342,"teacher_disagreement_score":0.99846214,"about_ca_system_score_codex":0.0022852784,"about_ca_system_score_gemma":0.003414482,"threshold_uncertainty_score":0.22390562},"labels":[],"label_agreement":null},{"id":"W3123587989","doi":"10.1787/346071162287","title":"Pharmaceutical Pricing and Reimbursement Policies in Canada","year":2006,"lang":"en","type":"report","venue":"OECD health working papers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada","keywords":"Reimbursement; Business; Economics; Health care; Economic growth","score_opus":0.1197748693753356,"score_gpt":0.3462153728127145,"score_spread":0.22644050343737887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123587989","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21157585,0.05578263,0.0034125773,0.14875251,0.0015424857,0.0004376555,0.0067530703,0.0006090802,0.5711342],"genre_scores_gemma":[0.87127644,0.0253075,0.0054696244,0.01836067,0.00040154517,0.000098052195,0.002552661,0.00011154703,0.07642198],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877638,0.0006006728,0.000414269,0.00048270015,0.007152979,0.0035855875],"domain_scores_gemma":[0.9829959,0.0020177718,0.001603205,0.00025827304,0.009030705,0.00409416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038613915,0.00037097075,0.00043037345,0.0053721024,0.007003759,0.009144391,0.0019061838,0.002572217,0.0053034243],"category_scores_gemma":[0.013073301,0.00055509066,0.00081366935,0.007894154,0.002769801,0.0013031842,0.0014022712,0.00238345,0.0004006059],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016568012,0.00022564598,0.076153904,0.00055614987,0.00011295407,0.0011772239,0.003500945,0.009674631,0.0012083035,0.55763334,0.16278231,0.186809],"study_design_scores_gemma":[0.00008260912,0.00009295295,0.21092008,0.0007768021,0.00009320762,0.00041926073,0.0026056785,0.0059661414,0.0006978942,0.009721605,0.7683514,0.00027246028],"about_ca_topic_score_codex":0.9947279,"about_ca_topic_score_gemma":0.99481034,"teacher_disagreement_score":0.24321584,"about_ca_system_score_codex":0.24321584,"about_ca_system_score_gemma":0.33458713,"threshold_uncertainty_score":0.8777624},"labels":[],"label_agreement":null},{"id":"W3123636550","doi":"","title":"Consumer Out-of-Pocket Spending for Pharmaceuticals in Kazakhstan: Implications for Sectoral Reform","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Revenue; Restructuring; Government revenue; Business; Rural area; Government (linguistics); Payment; Health care; Psychological intervention; Informal sector; Public economics; Development economics; Economic growth; Economics; Finance","score_opus":0.112846958860362,"score_gpt":0.3836861376218571,"score_spread":0.2708391787614951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123636550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9498439,0.0029952303,0.00044454832,0.03584278,0.00006586444,0.000036143465,0.0009751764,0.000025750167,0.009770596],"genre_scores_gemma":[0.9962224,0.0010385839,0.0001693878,0.0010142596,0.000046316527,0.000013169906,0.00024511752,0.0000032117464,0.0012475987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988701,0.00055426813,0.000047288006,0.00006975936,0.00010484081,0.000353802],"domain_scores_gemma":[0.9972211,0.0013493241,0.00071116525,0.000089820816,0.0003416617,0.0002869454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017140099,0.00013767721,0.0003764397,0.00078788854,0.00062916585,0.0025488154,0.00044215695,0.00068495586,0.005790197],"category_scores_gemma":[0.006316178,0.00014070654,0.00034967254,0.0030521934,0.0008442626,0.0012325506,0.00078937085,0.0009202439,0.00028526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012717926,0.0008025219,0.741011,0.00064247963,0.00018082428,0.00092004414,0.0033331881,0.020175356,0.0011477253,0.12199683,0.020420887,0.0880974],"study_design_scores_gemma":[0.00012348291,0.00026042125,0.9305776,0.00018955916,0.00014199845,0.00013255746,0.011379925,0.02021557,0.0007125686,0.01989074,0.016342629,0.000032961183],"about_ca_topic_score_codex":0.096648745,"about_ca_topic_score_gemma":0.08615825,"teacher_disagreement_score":0.096648745,"about_ca_system_score_codex":0.0074359677,"about_ca_system_score_gemma":0.0055750455,"threshold_uncertainty_score":0.19217241},"labels":[],"label_agreement":null},{"id":"W3123696229","doi":"","title":"Healthcare's Grand Challenge: Stimulating Basic Science on Diseases that Primarily Afflict the Poor","year":2016,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"TRIPS architecture; Intellectual property; TRIPS Agreement; Health care; Political science; Grand Challenges; Public economics; Economics; Business; Economic growth; Law; Engineering","score_opus":0.05374224915885468,"score_gpt":0.30054913214872053,"score_spread":0.24680688298986586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123696229","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.416618,0.016237233,0.011478335,0.43273965,0.0007201103,0.00012584189,0.00054369087,0.00008990684,0.121447295],"genre_scores_gemma":[0.97957236,0.0030035859,0.0012819974,0.013903719,0.00039630436,0.000040180097,0.000037211295,0.0000074251175,0.0017572672],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99331975,0.0039523584,0.0001580488,0.00048963475,0.0010796,0.0010005734],"domain_scores_gemma":[0.95016074,0.03566252,0.00871711,0.001135211,0.0013321758,0.0029922847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009306909,0.00027420174,0.00056667236,0.0013633675,0.0019516569,0.0069761784,0.0005518169,0.0035137564,0.0072451686],"category_scores_gemma":[0.037575234,0.00016732296,0.00041441745,0.0019116102,0.007314083,0.00676396,0.004284089,0.0025913934,0.0004148188],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006192324,0.0003285659,0.052891348,0.0012268616,0.00028121198,0.0013247035,0.0042404053,0.0128744785,0.0019329811,0.8188518,0.035759423,0.06966888],"study_design_scores_gemma":[0.00023343373,0.00065508514,0.09655152,0.001350213,0.00021930429,0.0006576974,0.012862639,0.009671713,0.0033981272,0.7336709,0.14061286,0.00011650207],"about_ca_topic_score_codex":0.003702226,"about_ca_topic_score_gemma":0.0033311064,"teacher_disagreement_score":0.009306909,"about_ca_system_score_codex":0.004127848,"about_ca_system_score_gemma":0.0058832043,"threshold_uncertainty_score":0.049220204},"labels":[],"label_agreement":null},{"id":"W3124106193","doi":"10.3386/w21239","title":"The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011","year":2015,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Demography; Sociology","score_opus":0.5239881777160328,"score_gpt":0.5570451334642875,"score_spread":0.033056955748254735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124106193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.862883,0.013949072,0.0006373543,0.018195089,0.00022401828,0.000074844684,0.09377973,0.00011472207,0.010142191],"genre_scores_gemma":[0.9778901,0.0038949966,0.0002863852,0.00059242005,0.00007534355,0.000022974453,0.012800442,0.00001356376,0.0044238535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786866,0.000110764515,0.00012619414,0.0002039215,0.0008161093,0.00087432173],"domain_scores_gemma":[0.9913122,0.0006669011,0.0022384122,0.00017038599,0.0036594414,0.001952604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012907591,0.00037042613,0.000635481,0.0022708965,0.0015282138,0.0015980455,0.0012108826,0.00086287165,0.0026689959],"category_scores_gemma":[0.009573731,0.00026996492,0.0014992016,0.0048309066,0.00075857237,0.00053589547,0.0012861792,0.0022779384,0.00026142452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046992968,0.000062539984,0.951961,0.00019993108,0.00043265766,0.00015077132,0.00040987958,0.0036584886,0.00014921204,0.002003486,0.017847773,0.022654388],"study_design_scores_gemma":[0.000025418738,0.000042716078,0.9918839,0.000072003444,0.0001812616,0.000052645697,0.00040739213,0.0020947724,0.0001724738,0.00020318717,0.0048390874,0.000025182137],"about_ca_topic_score_codex":0.99496967,"about_ca_topic_score_gemma":0.99598724,"teacher_disagreement_score":0.050905272,"about_ca_system_score_codex":0.050905272,"about_ca_system_score_gemma":0.07029124,"threshold_uncertainty_score":0.3693453},"labels":[],"label_agreement":null},{"id":"W3124219969","doi":"","title":"Intellectual Property Protection And Drug Plan Coverage: Evidence From Ontario","year":2015,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Revenue; Business; Intellectual property; Plan (archaeology); Generic drug; Drug; Finance; Pharmacology; Medicine; Political science; Law; Geography","score_opus":0.18944166173265897,"score_gpt":0.3360256779149801,"score_spread":0.14658401618232114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124219969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8573181,0.014599347,0.0004986469,0.0120927105,0.000067510846,0.00020818297,0.052805766,0.000045790166,0.062363923],"genre_scores_gemma":[0.97642386,0.0058929366,0.00020546558,0.0009179438,0.000050642375,0.000041452164,0.009828275,0.000017313714,0.0066222046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99563605,0.00031744546,0.00027402153,0.0003747284,0.0024351336,0.0009625314],"domain_scores_gemma":[0.96011263,0.0059704264,0.01865077,0.0012405758,0.010566053,0.0034594256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017187194,0.00026666163,0.00051206775,0.002943245,0.0024691536,0.002212979,0.0014258017,0.00067131943,0.007888998],"category_scores_gemma":[0.01942362,0.00041942872,0.00077642134,0.011255095,0.0013836123,0.0009356225,0.0013356424,0.00073648116,0.0004070307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048213013,0.00008920398,0.9503281,0.0005702098,0.0003971162,0.0002873047,0.0024083066,0.0005805741,0.00013984577,0.0029627709,0.021641806,0.020112554],"study_design_scores_gemma":[0.000060243605,0.000031339696,0.97982395,0.00022140554,0.00019952904,0.00004873059,0.0011681364,0.00039967717,0.000115275536,0.00016738502,0.01774631,0.000017987368],"about_ca_topic_score_codex":0.99448156,"about_ca_topic_score_gemma":0.99629754,"teacher_disagreement_score":0.047469493,"about_ca_system_score_codex":0.047469493,"about_ca_system_score_gemma":0.051116645,"threshold_uncertainty_score":0.34441692},"labels":[],"label_agreement":null},{"id":"W3124418915","doi":"10.1177/009885880603200206","title":"Oy Canada! Trade's Non-Solution to “<i>the</i> Problem” of U.S. Drug Prices","year":2006,"lang":"en","type":"article","venue":"American Journal of Law & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"SAFER; Law; Political science; Law and economics; Sociology; Computer security","score_opus":0.01601723944256,"score_gpt":0.2502375098141847,"score_spread":0.23422027037162468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124418915","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034414493,0.006100676,0.002178003,0.5274648,0.0052500414,0.000054234664,0.0010092251,0.00058972824,0.45391193],"genre_scores_gemma":[0.07511892,0.0055038845,0.0026458926,0.20008303,0.0012041272,0.00004068579,0.00061186444,0.00046457653,0.71432704],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9972556,0.00019373995,0.0000437433,0.00021448186,0.0015059379,0.0007865108],"domain_scores_gemma":[0.99573994,0.0003998109,0.00016062848,0.00022328849,0.0022301779,0.0012462611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015412163,0.0005371425,0.00033965634,0.0010219374,0.009030225,0.0088782795,0.0010221817,0.008276206,0.0875283],"category_scores_gemma":[0.009355444,0.00043631857,0.0005375868,0.0013845677,0.0032234937,0.003784814,0.0017747122,0.0068649547,0.009898844],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017527627,0.000011152827,0.00056905026,0.000029879147,0.00000826793,0.000097037395,0.0001331168,0.00008968306,0.00013140608,0.06687444,0.9184681,0.013570368],"study_design_scores_gemma":[0.000009882119,0.0000052999544,0.0009865975,0.000052741365,0.0000038767016,0.000055446435,0.00027742208,0.00014742294,0.00011974923,0.005372096,0.99295217,0.000017232716],"about_ca_topic_score_codex":0.83798945,"about_ca_topic_score_gemma":0.9092906,"teacher_disagreement_score":0.16201055,"about_ca_system_score_codex":0.021777017,"about_ca_system_score_gemma":0.0631292,"threshold_uncertainty_score":0.32592928},"labels":[],"label_agreement":null},{"id":"W3124476680","doi":"10.1093/rfs/hhab024","title":"Missing Novelty in Drug Development","year":2021,"lang":"en","type":"article","venue":"Review of Financial Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Novelty; Shock (circulatory); Drug; Business; Drug development; Value (mathematics); Economics; Microeconomics; Pharmacology; Computer science; Medicine; Psychology; Machine learning","score_opus":0.13248601471570198,"score_gpt":0.35391681117802987,"score_spread":0.22143079646232788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124476680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37207544,0.317912,0.08224926,0.08043621,0.001461946,0.00016662829,0.00081584475,0.00020919162,0.1446735],"genre_scores_gemma":[0.9573751,0.033096835,0.002620733,0.002049852,0.0010128547,0.000026730964,0.000066778586,0.000008464301,0.0037425645],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99776876,0.0010032709,0.00009738822,0.00031726772,0.0006780411,0.00013523879],"domain_scores_gemma":[0.96399033,0.02706879,0.005691867,0.001196058,0.0013158841,0.00073712406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036861172,0.00029450248,0.00077377266,0.0013754095,0.0003897911,0.0022749568,0.00047573706,0.001534788,0.0062210686],"category_scores_gemma":[0.018829782,0.00025303452,0.0006450013,0.0010899252,0.0026226316,0.0034837585,0.0012942466,0.0018852295,0.0004677425],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048452505,0.00024202387,0.029647404,0.003165997,0.00052423135,0.00068580353,0.00025233044,0.02755929,0.0027355372,0.6387317,0.008799453,0.28717163],"study_design_scores_gemma":[0.00017277869,0.00077151565,0.034803536,0.001168733,0.00024937475,0.0012671072,0.000172078,0.01985477,0.002689018,0.87566674,0.06310905,0.00007533349],"about_ca_topic_score_codex":0.0004014812,"about_ca_topic_score_gemma":0.0003282092,"teacher_disagreement_score":0.0062210686,"about_ca_system_score_codex":0.0014417754,"about_ca_system_score_gemma":0.0006499475,"threshold_uncertainty_score":0.020811498},"labels":[],"label_agreement":null},{"id":"W3124578120","doi":"","title":"Funding Antibiotic Innovation with Vouchers: Recommendations on How to Strengthen a Flawed Incentive Policy","year":2016,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Voucher; Liberian dollar; Notice; Public economics; Incentive; Business; Antibiotics; Value (mathematics); Economics; Finance; Accounting; Political science; Market economy; Law","score_opus":0.07285952110814095,"score_gpt":0.2981186263086669,"score_spread":0.22525910520052597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124578120","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004584827,0.00686214,0.021448977,0.9185874,0.006574276,0.00079703884,0.0003134937,0.0008158389,0.04001609],"genre_scores_gemma":[0.14780034,0.011790238,0.10585774,0.6926866,0.006665416,0.0041130185,0.00037587888,0.00039757063,0.030313231],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.94612265,0.028126974,0.004216777,0.0036503207,0.01087068,0.0070126303],"domain_scores_gemma":[0.7774093,0.1621971,0.008302002,0.012068437,0.03058928,0.009433878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08882145,0.0022313804,0.0030240861,0.005447492,0.00499262,0.01985906,0.0072792503,0.06607431,0.022670662],"category_scores_gemma":[0.25600344,0.0014313966,0.0048836186,0.0034371892,0.016389336,0.04035181,0.00909324,0.026869062,0.0048311795],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022390502,0.00070147717,0.0016267695,0.0006244016,0.000119484015,0.00030133853,0.00059982814,0.005881249,0.00040349847,0.7671792,0.17890303,0.04343584],"study_design_scores_gemma":[0.0012178605,0.00032999233,0.0016261501,0.0036635515,0.00019029641,0.00023430733,0.0012565543,0.0064951167,0.001114948,0.6037907,0.3796994,0.00038112365],"about_ca_topic_score_codex":0.022110568,"about_ca_topic_score_gemma":0.013858232,"teacher_disagreement_score":0.08882145,"about_ca_system_score_codex":0.009756151,"about_ca_system_score_gemma":0.055466387,"threshold_uncertainty_score":0.4697383},"labels":[],"label_agreement":null},{"id":"W3124610394","doi":"","title":"Orphan Drug Incentives in the Pharmacogenomic Context: Policy Responses in the US and Canada","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; University of Toronto","funders":"","keywords":"Incentive; Pharmacogenomics; Context (archaeology); Orphan drug; Drug; Business; Public economics; Economics; Pharmacology; Medicine; Geography; Bioinformatics; Biology; Market economy","score_opus":0.03254740105091719,"score_gpt":0.2816638010917783,"score_spread":0.2491164000408611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124610394","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42462802,0.011982763,0.00061218697,0.4966081,0.00055907684,0.00019315846,0.0027967938,0.000055601282,0.06256431],"genre_scores_gemma":[0.94208634,0.005891339,0.0006517502,0.04060477,0.0002979133,0.000040139363,0.00040047732,0.000025139469,0.01000216],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9873186,0.0017729132,0.00038164566,0.0005674972,0.0038447466,0.0061145877],"domain_scores_gemma":[0.96381456,0.011585218,0.003475499,0.0003966662,0.01035243,0.010375617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007760811,0.00027032886,0.00083840155,0.0016902431,0.005263079,0.008731828,0.002210426,0.0064394777,0.007093462],"category_scores_gemma":[0.03392515,0.00041019812,0.0010293189,0.003279337,0.0032812282,0.0020480314,0.002628168,0.0055613504,0.0001526009],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023686315,0.0008428212,0.20663184,0.00091879355,0.0004922865,0.0016283543,0.0075453487,0.013828207,0.002096053,0.49268323,0.16772364,0.103240825],"study_design_scores_gemma":[0.00124005,0.0004396156,0.54502875,0.0014766321,0.00078915193,0.00046523614,0.022923067,0.016555697,0.0023964972,0.04503411,0.36319867,0.0004524559],"about_ca_topic_score_codex":0.98918647,"about_ca_topic_score_gemma":0.99412364,"teacher_disagreement_score":0.8427956,"about_ca_system_score_codex":0.15720442,"about_ca_system_score_gemma":0.31191716,"threshold_uncertainty_score":0.9775234},"labels":[],"label_agreement":null},{"id":"W3124722174","doi":"10.2139/ssrn.2858703","title":"The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia","year":2016,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Download; General partnership; Agreement; Political science; World Wide Web; Computer science; Business; Internet privacy; Law","score_opus":0.055435387865612744,"score_gpt":0.28667293687004936,"score_spread":0.2312375490044366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124722174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5667392,0.013330821,0.0014244443,0.1257143,0.00043305,0.00013674762,0.0006710198,0.000041828112,0.29150864],"genre_scores_gemma":[0.9609645,0.0024082845,0.00039940394,0.005837586,0.00007530369,0.000051930834,0.000082907165,0.000013688224,0.03016652],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891425,0.0017124774,0.00034712095,0.0006029801,0.0035737944,0.0046210987],"domain_scores_gemma":[0.98419976,0.0053867544,0.0018432391,0.00036268108,0.0047096284,0.0034980115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00508016,0.00019675306,0.0006297196,0.0017648654,0.009236337,0.0100789815,0.0011363843,0.0060041593,0.0068924376],"category_scores_gemma":[0.023285383,0.0005553788,0.0006774573,0.004657636,0.0065507772,0.0037907967,0.004848655,0.006636289,0.00023902094],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029115687,0.00018236141,0.041582238,0.00018778574,0.000114010945,0.0008626651,0.0077158716,0.0035448724,0.00031834163,0.8888452,0.029046962,0.027308594],"study_design_scores_gemma":[0.00026198803,0.0002780752,0.4078927,0.0011296257,0.00033523914,0.00048560346,0.036822386,0.011517513,0.0009375672,0.17938042,0.36061102,0.0003478178],"about_ca_topic_score_codex":0.9722445,"about_ca_topic_score_gemma":0.98289454,"teacher_disagreement_score":0.082321756,"about_ca_system_score_codex":0.082321756,"about_ca_system_score_gemma":0.19632843,"threshold_uncertainty_score":0.59728897},"labels":[],"label_agreement":null},{"id":"W3125080756","doi":"","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation","year":2010,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Brand loyalty; Legislation; Competition (biology); Business; Loyalty; Marketing; Advertising; Law; Political science; Biology; Geography","score_opus":0.017079788326487426,"score_gpt":0.26399444263107846,"score_spread":0.24691465430459103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125080756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661361,0.009103157,0.00025233065,0.005997181,0.0000820271,0.000015304402,0.00044067515,0.000005716983,0.017967552],"genre_scores_gemma":[0.98884165,0.0046452093,0.0001578697,0.0020788729,0.00040940085,0.0000133844915,0.00042535807,0.0000069653247,0.0034211942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924386,0.00010421095,0.000049865765,0.00009664537,0.0002810022,0.00022442281],"domain_scores_gemma":[0.99637467,0.0006383967,0.0018472647,0.000063114305,0.00038084874,0.0006957636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013882357,0.000089077526,0.0002810412,0.0012562171,0.0011394705,0.003235728,0.0003742549,0.001361523,0.0027040013],"category_scores_gemma":[0.0049502025,0.0001407233,0.0003239441,0.002386309,0.0014189497,0.0024704882,0.0012171014,0.0020220887,0.00028157706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074091495,0.00096554257,0.76081705,0.00027648805,0.00012788568,0.0007312104,0.014563244,0.0011643047,0.0010288911,0.07445206,0.011263726,0.13386871],"study_design_scores_gemma":[0.000007936212,0.00019545566,0.9741813,0.00015301719,0.000027391488,0.00028194752,0.0033293758,0.0007223675,0.00020875949,0.0033818686,0.01747948,0.000031003954],"about_ca_topic_score_codex":0.035936613,"about_ca_topic_score_gemma":0.052818898,"teacher_disagreement_score":0.035936613,"about_ca_system_score_codex":0.0030618764,"about_ca_system_score_gemma":0.0017929896,"threshold_uncertainty_score":0.07145488},"labels":[],"label_agreement":null},{"id":"W3125183276","doi":"","title":"Externalities and Benefit Design in Health Insurance","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Externality; Prescription drug; Download; Subsidy; Incentive; Business; Public economics; Prescription costs; Medical prescription; Consumption (sociology); Actuarial science; Medicare Part D; Economics; Microeconomics; Pharmacology; Medicine","score_opus":0.08196332851849211,"score_gpt":0.29564165059986897,"score_spread":0.21367832208137685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125183276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6548316,0.0013141359,0.21468712,0.005626828,0.00014797047,0.00075271475,0.00078272267,0.0001572127,0.12169967],"genre_scores_gemma":[0.98140645,0.000403089,0.0073972316,0.00032866895,0.000094389376,0.00018321867,0.0001191764,0.000028096423,0.010039652],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9952348,0.0027941514,0.00018929402,0.0004761816,0.0006404864,0.0006650503],"domain_scores_gemma":[0.9908598,0.0054537393,0.0019262568,0.0006841131,0.00049279426,0.00058324647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007015681,0.00075824256,0.0009529722,0.0010350444,0.000838889,0.003003279,0.00067799207,0.001853302,0.011074322],"category_scores_gemma":[0.012328776,0.00068605575,0.000922591,0.0009016413,0.0031182012,0.0027812093,0.0022981174,0.0017112675,0.00051039],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038783436,0.0005200172,0.052402828,0.0001265161,0.00023721906,0.00034042663,0.00043478404,0.13140877,0.0016643533,0.7808919,0.0016409282,0.029944355],"study_design_scores_gemma":[0.00039572502,0.0010645398,0.043126754,0.00016080364,0.00023785146,0.00044671659,0.00048919226,0.1088535,0.0012221833,0.82221544,0.02169052,0.00009667832],"about_ca_topic_score_codex":0.0017018563,"about_ca_topic_score_gemma":0.0028747332,"teacher_disagreement_score":0.011074322,"about_ca_system_score_codex":0.003790728,"about_ca_system_score_gemma":0.0014236999,"threshold_uncertainty_score":0.037102878},"labels":[],"label_agreement":null},{"id":"W3125347212","doi":"","title":"The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mortality rate; Developing country; Download; Access to medicines; Cancer; Pharmaceutical industry; Developed country; Demography; Economics; Demographic economics; Medicine; Economic growth; Population; Sociology","score_opus":0.07341799769722925,"score_gpt":0.34664858433126133,"score_spread":0.2732305866340321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125347212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88159543,0.020142963,0.0006522188,0.026746774,0.00022269088,0.00010072686,0.052799996,0.000096501186,0.017642574],"genre_scores_gemma":[0.98081243,0.0064018536,0.00025916976,0.0007273179,0.000075282354,0.000019243216,0.0074733375,0.000008709057,0.0042226757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976266,0.00015409924,0.00012399357,0.00013953992,0.0010207522,0.00093502156],"domain_scores_gemma":[0.99203295,0.00077585166,0.0020239793,0.00012197894,0.0034005942,0.001644619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013796083,0.00029227903,0.00056636723,0.002250699,0.0013613332,0.0016645114,0.0009242354,0.0007917129,0.0025022537],"category_scores_gemma":[0.010607231,0.0002150597,0.0015223374,0.004299945,0.0007538986,0.0005242949,0.0011586633,0.0020270776,0.0002088128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006117864,0.00010077994,0.92591995,0.00039493645,0.00061007,0.00032875687,0.0005191676,0.0070849955,0.00019782213,0.004528466,0.017489117,0.04221414],"study_design_scores_gemma":[0.000032642132,0.00006761601,0.9876259,0.000116486226,0.00024038303,0.00008364287,0.0004316243,0.0033637367,0.00018748743,0.0003477472,0.0074721766,0.000030654624],"about_ca_topic_score_codex":0.99359566,"about_ca_topic_score_gemma":0.9947126,"teacher_disagreement_score":0.065824844,"about_ca_system_score_codex":0.065824844,"about_ca_system_score_gemma":0.07450517,"threshold_uncertainty_score":0.4775949},"labels":[],"label_agreement":null},{"id":"W3125490444","doi":"","title":"Assessing Canada’s Drug Shortage Problem","year":2018,"lang":"en","type":"article","venue":"C.D. Howe Institute Commentary","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Innovator; Medical prescription; Harm; Business; Medicine; Health care; Enforcement; Economic growth; Nursing; Economics; Political science; Finance; Government (linguistics); Law","score_opus":0.07127745277737396,"score_gpt":0.2994371149421321,"score_spread":0.22815966216475814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125490444","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16688178,0.041075155,0.00093090837,0.63441443,0.0030466137,0.0003823739,0.03248295,0.00018935344,0.12059645],"genre_scores_gemma":[0.7929996,0.04344101,0.003396927,0.13043141,0.001385728,0.0002019955,0.011087506,0.00013112485,0.016924612],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933327,0.00039592342,0.0003753917,0.0003999749,0.0036069853,0.0018890621],"domain_scores_gemma":[0.9535222,0.003067263,0.0029038808,0.00030265088,0.032001838,0.0082020825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036160406,0.0004889234,0.0005432858,0.007257399,0.011284185,0.004964605,0.0023268224,0.0022809522,0.0075523],"category_scores_gemma":[0.018438553,0.0004251672,0.0008749027,0.013264004,0.0022434613,0.00244977,0.002713736,0.0036210592,0.00044934158],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009374693,0.00010921728,0.28282133,0.0022133943,0.00019800455,0.0017327354,0.009569384,0.00072730746,0.00025433078,0.017304681,0.59365815,0.09131778],"study_design_scores_gemma":[0.000043300413,0.000072940195,0.4973478,0.0035895265,0.00019184897,0.0007650444,0.037763454,0.0020737324,0.00033127895,0.0029699404,0.45463565,0.00021542737],"about_ca_topic_score_codex":0.9969043,"about_ca_topic_score_gemma":0.998319,"teacher_disagreement_score":0.15346572,"about_ca_system_score_codex":0.15346572,"about_ca_system_score_gemma":0.33358556,"threshold_uncertainty_score":0.9818598},"labels":[],"label_agreement":null},{"id":"W3125788429","doi":"","title":"Tough Choices: The Private Sale of Drugs in Public Hospitals","year":2014,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Business; Public economics; Law and economics; Economics","score_opus":0.022420106456979685,"score_gpt":0.25268388802295294,"score_spread":0.23026378156597327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125788429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9415482,0.00087824976,0.0008379539,0.032406926,0.00009452277,0.000062511084,0.0007761977,0.000041555388,0.02335393],"genre_scores_gemma":[0.99492174,0.00021881543,0.00010241803,0.0005764425,0.000100697776,0.000011739726,0.00008453772,0.0000096680415,0.0039739404],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9969561,0.0010510986,0.00010460301,0.00025225378,0.00032173292,0.0013142894],"domain_scores_gemma":[0.9641257,0.023081759,0.0059831385,0.00064340257,0.00083128316,0.0053347093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040056696,0.00033882534,0.0010523284,0.0009485707,0.002580834,0.0077707763,0.001507315,0.008378639,0.01900171],"category_scores_gemma":[0.02472132,0.0009295625,0.00086549885,0.0015198947,0.0042161746,0.0058809575,0.0037368257,0.0073718736,0.0008131802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011840249,0.0056138164,0.28365487,0.0005830966,0.0006933972,0.01091948,0.008409496,0.06918992,0.003366504,0.45397997,0.09017562,0.0615736],"study_design_scores_gemma":[0.0020233046,0.0014837569,0.32697827,0.00035094947,0.0005941676,0.001543337,0.04730382,0.15326075,0.0018885353,0.4412857,0.022780413,0.00050709187],"about_ca_topic_score_codex":0.04961603,"about_ca_topic_score_gemma":0.07375472,"teacher_disagreement_score":0.04961603,"about_ca_system_score_codex":0.006338189,"about_ca_system_score_gemma":0.0041822935,"threshold_uncertainty_score":0.09865451},"labels":[],"label_agreement":null},{"id":"W312868857","doi":"10.1177/009885880603200204","title":"How Parallel Trade Affects Drug Policies and Prices in Canada and the United States","year":2006,"lang":"en","type":"article","venue":"American Journal of Law & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"The King's University; Institute of Health Economics; University of Calgary","funders":"","keywords":"Scrutiny; Drug prices; Economics; International trade; Pharmaceutical industry; International economics; Commercial policy; Business; Public economics; Political science; Law; Biotechnology","score_opus":0.01748899685676759,"score_gpt":0.24304247799975154,"score_spread":0.22555348114298396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W312868857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81905675,0.0073730666,0.00073741004,0.053415023,0.00014187366,0.000043606888,0.0012639094,0.000045528537,0.11792282],"genre_scores_gemma":[0.993479,0.0018105962,0.00016764036,0.0014053112,0.000024732188,0.0000049639652,0.00013789366,0.000009123384,0.002960626],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9965641,0.00034903522,0.00009186802,0.00024082017,0.0010771547,0.0016770444],"domain_scores_gemma":[0.994117,0.001321788,0.0009034327,0.000153899,0.0023851956,0.0011186865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019149318,0.00017133172,0.0004485259,0.0019164005,0.00581983,0.0064920667,0.0008064608,0.0015812545,0.0041653956],"category_scores_gemma":[0.010875227,0.0002743537,0.0006045267,0.0042722407,0.0036990035,0.0016405305,0.0013815567,0.0020309445,0.00017638839],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000930006,0.00038175957,0.32311162,0.00020729283,0.00041141326,0.0011210692,0.0068328725,0.028817998,0.0015627635,0.4925309,0.045129236,0.09896304],"study_design_scores_gemma":[0.00020049541,0.00012918982,0.8085019,0.00029213974,0.00040630475,0.0002386905,0.01474911,0.021496037,0.0017107471,0.062839754,0.08916888,0.00026678207],"about_ca_topic_score_codex":0.9927004,"about_ca_topic_score_gemma":0.9934284,"teacher_disagreement_score":0.8930142,"about_ca_system_score_codex":0.10698581,"about_ca_system_score_gemma":0.08598803,"threshold_uncertainty_score":0.77624},"labels":[],"label_agreement":null},{"id":"W3133577532","doi":"10.3917/ems.bent.2019.01.0360","title":"Supply Chain Management de la santé","year":2019,"lang":"fr","type":"book-chapter","venue":"EMS Editions eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache; Musée de la Civilisation; Ministère de l’Emploi et de la Solidarité Sociale (Québec); Université du Québec à Montréal","funders":"","keywords":"Business","score_opus":0.03140389886087217,"score_gpt":0.28206560490196236,"score_spread":0.25066170604109017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133577532","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002695805,0.13725206,0.04700409,0.0499274,0.010555426,0.00020132097,0.0025729942,0.0008871575,0.7489038],"genre_scores_gemma":[0.027666837,0.07684011,0.02349487,0.0030204074,0.004115848,0.00020832653,0.0018493154,0.00023937154,0.8625649],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864215,0.00030535719,0.00006126551,0.00017241333,0.000712216,0.00010652876],"domain_scores_gemma":[0.9991903,0.00029100408,0.000083051316,0.000100638164,0.00027991165,0.00005514979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019071174,0.0012008705,0.0007740621,0.0013411018,0.0008945121,0.0051520336,0.0007593214,0.0027966578,0.05749222],"category_scores_gemma":[0.0024572671,0.0005729172,0.000568328,0.0026605583,0.0010413543,0.002742886,0.0011145528,0.002775139,0.02443622],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039236966,0.00007033382,0.00024212232,0.00034589058,0.000022549371,0.000054419103,0.00016575608,0.004947309,0.0005944627,0.1977897,0.46837467,0.32735357],"study_design_scores_gemma":[0.000008672398,0.00001881906,0.0003694289,0.000344925,0.0000059814697,0.000055776163,0.000063483814,0.0024630178,0.00022242674,0.039781384,0.95665574,0.000010340081],"about_ca_topic_score_codex":0.017721053,"about_ca_topic_score_gemma":0.015689703,"teacher_disagreement_score":0.05749222,"about_ca_system_score_codex":0.006744364,"about_ca_system_score_gemma":0.007325701,"threshold_uncertainty_score":0.19233066},"labels":[],"label_agreement":null},{"id":"W3133774058","doi":"10.1001/jamanetworkopen.2021.1143","title":"Time to Marketing of Generic Drugs After Patent Expiration in Canada","year":2021,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Expiration; Expiration date; Business; Marketing; Medicine; Advertising; Internal medicine; Chemistry; Food science","score_opus":0.051733867047955406,"score_gpt":0.24136504879544468,"score_spread":0.18963118174748927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133774058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96161115,0.0039882134,0.00037782933,0.0029659686,0.00006823825,0.00011068972,0.019970655,0.0000711007,0.010836106],"genre_scores_gemma":[0.98294353,0.0015025255,0.00021567261,0.00038916894,0.000043261738,0.000028914552,0.008601544,0.000018538663,0.006256802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808574,0.00011853893,0.00013523686,0.0002491895,0.00070431165,0.0007068745],"domain_scores_gemma":[0.9870335,0.0023669964,0.0045687016,0.00021763671,0.0035353072,0.0022778579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015657844,0.00026929218,0.00054168084,0.0027888108,0.0019524114,0.0027864724,0.0012893179,0.001281881,0.00556781],"category_scores_gemma":[0.013908233,0.00042090006,0.0008047616,0.0042930115,0.00064478803,0.0011495946,0.0012107037,0.0025859296,0.00060366536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066267233,0.00023152457,0.97284514,0.000102459344,0.0002088176,0.0002598683,0.0010652447,0.00093550445,0.00027325592,0.0018761066,0.006616459,0.014923054],"study_design_scores_gemma":[0.000029310455,0.00005624294,0.99280727,0.000050777406,0.000051392028,0.00007666596,0.0007541829,0.001036569,0.00016750145,0.00010347117,0.0048389197,0.00002772947],"about_ca_topic_score_codex":0.98739827,"about_ca_topic_score_gemma":0.9855985,"teacher_disagreement_score":0.030022293,"about_ca_system_score_codex":0.030022293,"about_ca_system_score_gemma":0.029863475,"threshold_uncertainty_score":0.21782798},"labels":[],"label_agreement":null},{"id":"W3135068797","doi":"10.1007/s40273-021-01007-8","title":"The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases","year":2021,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Pharmacoeconomics; Medicine; Intensive care medicine; Nursing","score_opus":0.16470911239705432,"score_gpt":0.3657572656773199,"score_spread":0.2010481532802656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135068797","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028869245,0.0009776967,0.00025575023,0.99135417,0.0042760847,0.000012823966,0.00008981103,0.000016439764,0.0027284904],"genre_scores_gemma":[0.0033414662,0.0005485651,0.00091290247,0.9825117,0.010858048,0.000038700924,0.000043093456,0.000022541755,0.0017230734],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9252914,0.03395925,0.008484381,0.00529827,0.02203151,0.004935042],"domain_scores_gemma":[0.45278165,0.4824859,0.013404046,0.008805091,0.027034177,0.015489199],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08813626,0.0009593433,0.004086412,0.002491745,0.0053026397,0.016400725,0.0075257914,0.15008393,0.010511485],"category_scores_gemma":[0.32840583,0.0018007656,0.0036992375,0.0023333346,0.018289577,0.018529054,0.0075670574,0.09351962,0.005153442],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035053742,0.00009403901,0.00092928804,0.00035778846,0.00012417247,0.0009285643,0.0004054367,0.00038226735,0.00042143997,0.07654032,0.8991513,0.020314666],"study_design_scores_gemma":[0.0008477502,0.00013434954,0.0029717186,0.0022428436,0.00014829218,0.00085791544,0.0009810001,0.0019701517,0.0005385438,0.2530323,0.7359699,0.00030523606],"about_ca_topic_score_codex":0.015549077,"about_ca_topic_score_gemma":0.024437131,"teacher_disagreement_score":0.91186374,"about_ca_system_score_codex":0.010314407,"about_ca_system_score_gemma":0.032355923,"threshold_uncertainty_score":0.4661147},"labels":[],"label_agreement":null},{"id":"W3135225309","doi":"10.1038/s41429-021-00414-5","title":"Market concentration of new antibiotic sales","year":2021,"lang":"en","type":"article","venue":"The Journal of Antibiotics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Antibiotics; Revenue; Business; Incentive; Value (mathematics); Economics; Microeconomics; Finance; Chemistry; Mathematics","score_opus":0.05698176783501902,"score_gpt":0.28348680470215804,"score_spread":0.22650503686713902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135225309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9554751,0.0059721717,0.0036089916,0.0074704993,0.00010787608,0.000032519372,0.0014062638,0.00012899544,0.025797516],"genre_scores_gemma":[0.9964354,0.00052228564,0.00014392714,0.00015411338,0.00018243336,0.0000052362598,0.0002273219,0.00001008015,0.0023192726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989374,0.00028159757,0.00006211552,0.00025436652,0.00023045768,0.00023404311],"domain_scores_gemma":[0.97093594,0.01811434,0.0068643205,0.0006457392,0.0022132583,0.0012263311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021804557,0.00023217735,0.0009836237,0.0021876467,0.00043295493,0.0041906107,0.000814433,0.0017044321,0.011600303],"category_scores_gemma":[0.017552724,0.00050110475,0.00061565486,0.0016549393,0.0010031506,0.0031755194,0.0007998381,0.0018272732,0.0010469392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040850486,0.00086298,0.43234643,0.0008097844,0.001462194,0.0021261298,0.0013633677,0.112138994,0.014143698,0.30507252,0.034009207,0.09157964],"study_design_scores_gemma":[0.00039631742,0.0010881443,0.57810074,0.00019052986,0.0005311705,0.00087069767,0.0016321122,0.28767195,0.0068170386,0.102488555,0.020045938,0.00016676383],"about_ca_topic_score_codex":0.009978029,"about_ca_topic_score_gemma":0.007890264,"teacher_disagreement_score":0.011600303,"about_ca_system_score_codex":0.0033442418,"about_ca_system_score_gemma":0.00077521184,"threshold_uncertainty_score":0.038806915},"labels":[],"label_agreement":null},{"id":"W3139400359","doi":"10.1007/s10389-021-01485-2","title":"The challenges of drug shortages in the Canadian hospital pharmacy supply chain — a systematic literature review","year":2021,"lang":"en","type":"article","venue":"Journal of Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"École de Technologie Supérieure","funders":"","keywords":"Pharmacy; Economic shortage; Medicine; Hospital pharmacy; Supply chain; MEDLINE; Business; Systematic review; Environmental health; Family medicine; Medical emergency; Political science; Marketing","score_opus":0.09439757050382781,"score_gpt":0.34034468046644306,"score_spread":0.24594710996261526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139400359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01191795,0.9800168,0.00019969854,0.0041297623,0.00012986628,0.0002271276,0.002040732,0.0000067095675,0.0013312936],"genre_scores_gemma":[0.15257345,0.84139085,0.0012292884,0.0027151555,0.00020025695,0.00025729887,0.0013900084,0.000008133403,0.00023556598],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98404956,0.0036210392,0.0038088697,0.0013071841,0.0057872175,0.0014260756],"domain_scores_gemma":[0.8765012,0.06512605,0.025481578,0.0013786174,0.028056663,0.0034559255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023268268,0.0010408751,0.0033328386,0.023814647,0.0021290185,0.0054409853,0.0027305824,0.0024684044,0.0031860857],"category_scores_gemma":[0.09041325,0.0012493981,0.0043028756,0.03966001,0.002163456,0.0033573566,0.0029542532,0.0020315757,0.00018179645],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045437965,0.00018935653,0.13011782,0.604522,0.015262142,0.00077802007,0.0043017627,0.0024310304,0.00020131578,0.0047016856,0.023159586,0.21388088],"study_design_scores_gemma":[0.00019755415,0.00020406756,0.1933454,0.6669735,0.027439337,0.0008027652,0.012587351,0.001681534,0.00025215457,0.0017105264,0.09451378,0.0002920253],"about_ca_topic_score_codex":0.818388,"about_ca_topic_score_gemma":0.93573356,"teacher_disagreement_score":0.9482953,"about_ca_system_score_codex":0.051704682,"about_ca_system_score_gemma":0.20940219,"threshold_uncertainty_score":0.3751455},"labels":[],"label_agreement":null},{"id":"W3139447851","doi":"10.1186/s12872-021-01955-1","title":"Associations between essential medicines and health outcomes for cardiovascular disease","year":2021,"lang":"en","type":"article","venue":"BMC Cardiovascular Disorders","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Athabasca University; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs; St. Michael's Hospital Foundation","keywords":"Medicine; Reimbursement; Disease; Health care; Angiology; Heart disease; Public health; Family medicine; Emergency medicine; Internal medicine; Nursing","score_opus":0.07080388545600512,"score_gpt":0.3076432253559906,"score_spread":0.23683933989998546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139447851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907919,0.002412317,0.00046610224,0.0014450009,0.000031831383,0.000013199033,0.0022703437,0.000018322527,0.0025510062],"genre_scores_gemma":[0.9987147,0.0002821608,0.00010372071,0.000060242455,0.000025459507,0.0000048766497,0.000580371,0.000001803686,0.00022667175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904615,0.0004048174,0.00011237557,0.0001347562,0.0001612702,0.00014056436],"domain_scores_gemma":[0.9801562,0.010128128,0.007269765,0.0005408836,0.0007283949,0.0011766388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023003116,0.00016343196,0.00018834686,0.00096816506,0.00014567826,0.00055065495,0.00029188555,0.0003774155,0.0060002217],"category_scores_gemma":[0.0115073575,0.00013043419,0.00081638526,0.0011104811,0.00031672756,0.00038376142,0.00055712793,0.0009907439,0.00019028065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001646067,0.00006281305,0.99646604,0.000053109474,0.00026553601,0.000027243887,0.000023768682,0.00031995136,0.00005304276,0.00022692491,0.00031448822,0.0020225067],"study_design_scores_gemma":[0.000008931371,0.000060849965,0.9989208,0.000020237461,0.00008440781,0.000047412832,0.000030944233,0.0004073727,0.000037621274,0.00019729986,0.00018141807,0.0000027286046],"about_ca_topic_score_codex":0.0051702172,"about_ca_topic_score_gemma":0.004747303,"teacher_disagreement_score":0.0060002217,"about_ca_system_score_codex":0.00048744833,"about_ca_system_score_gemma":0.00055918517,"threshold_uncertainty_score":0.020072758},"labels":[],"label_agreement":null},{"id":"W313968408","doi":"","title":"Patents for second medical indications and their potential impact on pharmacare in Canada.","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Formulary; Medicine; Appeal; Notice; Law; Political science; Family medicine","score_opus":0.054384051330907554,"score_gpt":0.2660631059125948,"score_spread":0.21167905458168723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W313968408","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02555334,0.08480925,0.0011606553,0.4866303,0.003876248,0.0001440705,0.003680866,0.00017198353,0.39397323],"genre_scores_gemma":[0.54458666,0.09525436,0.0024139325,0.16399029,0.0034534126,0.00009678852,0.0015208918,0.00011194125,0.18857168],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98786455,0.00048645725,0.0002741682,0.0008478335,0.0069218087,0.0036051294],"domain_scores_gemma":[0.97953266,0.0052387863,0.0017773727,0.0003520425,0.009631478,0.0034677205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00358286,0.0006120052,0.00054459076,0.0046147606,0.011131509,0.014051586,0.0026250766,0.013001281,0.023228621],"category_scores_gemma":[0.01364859,0.0006272694,0.0009682808,0.006337873,0.008352977,0.0036125942,0.0027461606,0.0074615898,0.0009670809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008649515,0.00006643302,0.007486699,0.00045579852,0.00003104654,0.0015900581,0.0017285573,0.0006901515,0.00033982724,0.48426983,0.40180826,0.10144686],"study_design_scores_gemma":[0.000056982917,0.000065886044,0.023837449,0.0010712259,0.00006280124,0.0006912589,0.0019148639,0.0013210652,0.00044487396,0.02509511,0.9452739,0.00016453055],"about_ca_topic_score_codex":0.9828529,"about_ca_topic_score_gemma":0.98386467,"teacher_disagreement_score":0.14249231,"about_ca_system_score_codex":0.14249231,"about_ca_system_score_gemma":0.19083394,"threshold_uncertainty_score":0.99458736},"labels":[],"label_agreement":null},{"id":"W3143498503","doi":"10.1136/bmjgh-2021-005518","title":"Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too","year":2021,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Unitaid","keywords":"Intellectual property; TRIPS architecture; Business; TRIPS Agreement; Essential medicines; Market access; Public health; Pandemic; International trade; Monopolistic competition; Access to medicines; Global health; Economic growth; Public economics; Law and economics; Health care; Coronavirus disease 2019 (COVID-19); Economics; Political science; Monopoly; Medicine; Law; Market economy; Infectious disease (medical specialty)","score_opus":0.048613461184934495,"score_gpt":0.37063407129528136,"score_spread":0.3220206101103469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143498503","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023346466,0.0067735775,0.0023887646,0.9697768,0.0018444161,0.000015239676,0.00008394526,0.00003690678,0.016745694],"genre_scores_gemma":[0.31252304,0.017536977,0.0146137215,0.60885555,0.009688197,0.00014397918,0.00021605921,0.00012100086,0.036301453],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9949432,0.0023725084,0.00018749034,0.0005687035,0.0010121616,0.0009158868],"domain_scores_gemma":[0.9677591,0.018236445,0.0025955897,0.002753348,0.0035961217,0.005059478],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.015428876,0.0005886076,0.0010465797,0.0011223867,0.0038535383,0.0141778765,0.0015388796,0.021182489,0.029962707],"category_scores_gemma":[0.033759676,0.00031857184,0.0012087898,0.000983387,0.013978952,0.024069268,0.0051795137,0.01675452,0.0040578917],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087690874,0.00008677841,0.001063521,0.00015927784,0.000025026098,0.00023447721,0.00042271314,0.00054640835,0.000306371,0.76510745,0.1982158,0.033744503],"study_design_scores_gemma":[0.00007296571,0.00008185038,0.0013946232,0.0008360448,0.000015509731,0.00024689658,0.0012328088,0.0014212864,0.00037437835,0.6441654,0.35005382,0.00010441216],"about_ca_topic_score_codex":0.0066884873,"about_ca_topic_score_gemma":0.0060326154,"teacher_disagreement_score":0.99614644,"about_ca_system_score_codex":0.00385953,"about_ca_system_score_gemma":0.0126804495,"threshold_uncertainty_score":0.10023528},"labels":[],"label_agreement":null},{"id":"W3146414094","doi":"10.1371/journal.pone.0248567","title":"Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Impact; McMaster University; Population Health Research Institute","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Warfarin; Medicine; Confidence interval; Randomized controlled trial; Randomization; Crossover study; Atrial fibrillation; Internal medicine; Placebo","score_opus":0.20442747505756972,"score_gpt":0.3054063070032948,"score_spread":0.10097883194572507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146414094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552921,0.02588826,0.0024476226,0.0022967448,0.0011503701,0.008260026,0.0009179741,0.0000993933,0.0036474827],"genre_scores_gemma":[0.98460174,0.0038370911,0.0031107988,0.0010905392,0.00037875713,0.005617621,0.0003697596,0.000010617006,0.0009830464],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99381894,0.0043293103,0.0005157189,0.0007539438,0.00032319434,0.00025888733],"domain_scores_gemma":[0.9921812,0.0035528776,0.0026828812,0.0005286636,0.00044365652,0.00061070005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006088296,0.0011326789,0.003163366,0.0004409754,0.00046481652,0.0011266163,0.00079814333,0.0021013983,0.007180464],"category_scores_gemma":[0.014739378,0.0005710149,0.0026853944,0.00055252126,0.0013326464,0.0010955778,0.0005529449,0.0014958185,0.00037112122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96706045,0.003028717,0.0016401712,0.0025489202,0.004471688,0.000048100625,0.00013658899,0.00024472072,0.0011550621,0.0005515766,0.0004437215,0.018670322],"study_design_scores_gemma":[0.9568274,0.03391111,0.0036499773,0.00036404692,0.0032561766,0.000042511987,0.000045280147,0.00048766227,0.00022304873,0.00034103455,0.00083144585,0.000020429967],"about_ca_topic_score_codex":0.0016913466,"about_ca_topic_score_gemma":0.0024551805,"teacher_disagreement_score":0.007180464,"about_ca_system_score_codex":0.0012025853,"about_ca_system_score_gemma":0.0024056186,"threshold_uncertainty_score":0.03219843},"labels":[],"label_agreement":null},{"id":"W3148820128","doi":"10.1053/j.seminoncol.2021.03.001","title":"Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China","year":2021,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Natural Science Foundation of China","keywords":"Medicine; Gefitinib; Erlotinib; Reimbursement; Public economics; Cancer; Economic growth; Epidermal growth factor receptor; Economics; Health care; Internal medicine","score_opus":0.054499248969912276,"score_gpt":0.3286563674087065,"score_spread":0.27415711843879426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148820128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.712553,0.0043742647,0.003563966,0.060250547,0.00023622236,0.00030865122,0.00045450008,0.0001101615,0.2181487],"genre_scores_gemma":[0.9839392,0.00081166765,0.00063717546,0.0023926713,0.000048297803,0.000041405016,0.00008418002,0.000010696697,0.012034612],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99869365,0.0005131152,0.000033321812,0.00007587609,0.00021683674,0.00046726313],"domain_scores_gemma":[0.9982514,0.000717815,0.00019768447,0.00009643564,0.0003039071,0.00043277693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024902378,0.0002618311,0.00044573416,0.0007920597,0.0030115359,0.0025490073,0.0009169032,0.0019505649,0.008461006],"category_scores_gemma":[0.0041299947,0.00013396946,0.0006039525,0.0014428166,0.0020870625,0.0013611848,0.0019098888,0.0020052742,0.00029758032],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026474122,0.0013933664,0.09203155,0.0011610324,0.0005130515,0.010497305,0.012282495,0.026367227,0.0063999323,0.59863204,0.058030505,0.1900441],"study_design_scores_gemma":[0.0032761644,0.0021103173,0.22329818,0.0007312701,0.00079893,0.0010114575,0.020307958,0.051304694,0.008005007,0.15007369,0.5387153,0.00036703266],"about_ca_topic_score_codex":0.15658134,"about_ca_topic_score_gemma":0.16645338,"teacher_disagreement_score":0.15658134,"about_ca_system_score_codex":0.008104506,"about_ca_system_score_gemma":0.011768073,"threshold_uncertainty_score":0.31133986},"labels":[],"label_agreement":null},{"id":"W3149592704","doi":"","title":"The determinants of pricing in pharmaceuticals : are U.S. prices really higher than those of Canada?","year":2007,"lang":"en","type":"article","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nationality; Market power; Economics; Monetary economics; Product (mathematics); Quality (philosophy); Power (physics); Phenomenon; International economics; Business; Market economy","score_opus":0.08286905979129951,"score_gpt":0.3714895997745227,"score_spread":0.28862053998322323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149592704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647239,0.0044403174,0.00046477956,0.0072580376,0.000058250982,0.0000243785,0.0033168944,0.000027959632,0.019685531],"genre_scores_gemma":[0.99686533,0.0011074981,0.00012207535,0.00026142498,0.000019117972,0.0000031884383,0.0009793948,0.0000063847783,0.00063549815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986318,0.00016856706,0.00007557985,0.00016046417,0.00059074524,0.00037292016],"domain_scores_gemma":[0.9906598,0.0024264033,0.0041600415,0.00020896636,0.0016390146,0.0009057197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009193544,0.00016080934,0.00041581452,0.0015638362,0.0013073524,0.0027653766,0.0004313993,0.000639632,0.0031668458],"category_scores_gemma":[0.009217049,0.0001848473,0.0004573364,0.006053544,0.0009764425,0.0009816628,0.00070858706,0.0010771834,0.000330165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010775786,0.00006309062,0.96665424,0.000059738977,0.00016384356,0.0002071394,0.00069037545,0.0015049835,0.00019904278,0.0060268333,0.0057855113,0.018537426],"study_design_scores_gemma":[0.00001434283,0.000026726135,0.99110717,0.000035404653,0.00006178798,0.00006204763,0.0011239676,0.0013742363,0.00027002374,0.00090627477,0.0049919137,0.00002608843],"about_ca_topic_score_codex":0.82365555,"about_ca_topic_score_gemma":0.8503393,"teacher_disagreement_score":0.17634445,"about_ca_system_score_codex":0.0069587096,"about_ca_system_score_gemma":0.0070527634,"threshold_uncertainty_score":0.35476595},"labels":[],"label_agreement":null},{"id":"W3150852188","doi":"","title":"INFRINGING ON INVESTMENT: HOW ONE COMPANY IS USING INVESTMENT PROTECTIONS OF NAFTA TO SAVE ITS INTELLECTUAL PROPERTY","year":2015,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tariff; International trade; Intellectual property; Investment (military); Order (exchange); Business; Free trade agreement; Clothing; Prescription drug; Medical prescription; Free trade; International economics; Economics; Finance; Political science; Law","score_opus":0.34872923892520585,"score_gpt":0.3147525149365832,"score_spread":0.03397672398862267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3150852188","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015701398,0.021265836,0.021746205,0.5715118,0.0033666445,0.00012670511,0.000085403204,0.00036868878,0.36582732],"genre_scores_gemma":[0.50430495,0.02158676,0.019237932,0.31206626,0.004056284,0.00038114496,0.00017265385,0.0007103701,0.13748367],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97371733,0.008622338,0.00091258006,0.00272576,0.00959194,0.0044299713],"domain_scores_gemma":[0.97547317,0.013394278,0.0016656338,0.0018357047,0.00589604,0.0017351261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03768828,0.0010987441,0.0008818633,0.003024956,0.016742898,0.028681051,0.00402231,0.026637167,0.014339457],"category_scores_gemma":[0.06256573,0.0006419889,0.0013332792,0.0021884358,0.019119099,0.028193472,0.006598903,0.018098252,0.0025890456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044204568,0.0000733663,0.00196107,0.000114258626,0.00003458183,0.00057328714,0.0045006233,0.00043253374,0.00026332782,0.8037084,0.124500856,0.06379349],"study_design_scores_gemma":[0.00003787441,0.00010494246,0.0010981737,0.0012410716,0.0000669416,0.00043660545,0.003928241,0.00093278545,0.0005725928,0.33414736,0.65731543,0.00011801418],"about_ca_topic_score_codex":0.040560704,"about_ca_topic_score_gemma":0.033059437,"teacher_disagreement_score":0.9594393,"about_ca_system_score_codex":0.013943131,"about_ca_system_score_gemma":0.021826826,"threshold_uncertainty_score":0.1993171},"labels":[],"label_agreement":null},{"id":"W3151177152","doi":"","title":"Rebuttal: Does family medicine have a professional obligation to play a leading role in pharmaceutical industry?sponsored drug research?: YES.","year":2011,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rebuttal; Obligation; Drug industry; Medicine; Alternative medicine; Family medicine; Management; Medical education; Library science; Political science; Law; Engineering ethics; Engineering; Computer science","score_opus":0.18021284942450377,"score_gpt":0.36716376808869194,"score_spread":0.18695091866418817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151177152","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015316752,0.0011904389,0.00007174333,0.95007616,0.045071125,0.0000045773704,0.000070431764,0.000015991058,0.0033463973],"genre_scores_gemma":[0.016820759,0.0047321864,0.00069848466,0.85872704,0.07849863,0.00005699607,0.00016579978,0.000072091156,0.040228073],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98915356,0.0015964265,0.001450122,0.0019895227,0.0046335137,0.0011768166],"domain_scores_gemma":[0.91230667,0.029460894,0.004136338,0.0038564263,0.04269938,0.007540309],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0124078235,0.00081607566,0.0018581942,0.00086312986,0.0054899333,0.008432834,0.0035459509,0.04453616,0.035018224],"category_scores_gemma":[0.10487841,0.00059585524,0.0010644357,0.0010256912,0.0070491745,0.009126068,0.0029193482,0.03042962,0.023198945],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049276146,0.000013745277,0.00021463125,0.000068826805,0.00001473295,0.00018227907,0.00015488794,0.000018507231,0.00009435893,0.011441717,0.9806951,0.007051855],"study_design_scores_gemma":[0.000062168554,0.00003593455,0.0008051012,0.00070530735,0.00004879447,0.0003808565,0.00082754804,0.00015923301,0.00024876033,0.013245473,0.9834156,0.00006520853],"about_ca_topic_score_codex":0.028055726,"about_ca_topic_score_gemma":0.022704693,"teacher_disagreement_score":0.98759216,"about_ca_system_score_codex":0.0070847287,"about_ca_system_score_gemma":0.014879297,"threshold_uncertainty_score":0.117147684},"labels":[],"label_agreement":null},{"id":"W3151383188","doi":"","title":"Pharmaceutical Patent Policy in Developing Countries: Learning from the Canadian Experience","year":2011,"lang":"en","type":"article","venue":"Chapters","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Harmonization; Globalization; Context (archaeology); International trade; Access to medicines; Politics; Developing country; Business; Production (economics); Political science; Economic growth; Economics; Law; Geography","score_opus":0.25889257821766615,"score_gpt":0.30954313838660646,"score_spread":0.05065056016894032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151383188","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030866235,0.15605257,0.0009946978,0.28274828,0.001896904,0.00008648656,0.0009827132,0.00009179032,0.5262803],"genre_scores_gemma":[0.42290968,0.39373526,0.004307415,0.023284066,0.0007545728,0.00008463561,0.00056774274,0.00014795637,0.15420873],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99506617,0.0006316395,0.00017314995,0.00019433587,0.0022645653,0.0016700733],"domain_scores_gemma":[0.98959935,0.0036278574,0.000361859,0.00022620652,0.004237522,0.0019471539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00513868,0.0005563065,0.00068120455,0.0034828514,0.015258806,0.011874138,0.0016983383,0.0033054324,0.010384197],"category_scores_gemma":[0.011678901,0.000385004,0.00052554853,0.014041198,0.007283797,0.0037691935,0.0019685624,0.0036319036,0.0007262937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00011207465,0.00012242871,0.0049674953,0.0010544532,0.000034049266,0.0012169586,0.01831745,0.0023980357,0.00049589534,0.4980094,0.3169439,0.15632778],"study_design_scores_gemma":[0.000019827157,0.000018623174,0.0052270847,0.00045414973,0.000016704042,0.00014628688,0.011572516,0.00027642676,0.00020443658,0.008378223,0.97363836,0.00004734366],"about_ca_topic_score_codex":0.990103,"about_ca_topic_score_gemma":0.99375266,"teacher_disagreement_score":0.82475436,"about_ca_system_score_codex":0.17524567,"about_ca_system_score_gemma":0.25261647,"threshold_uncertainty_score":0.9565981},"labels":[],"label_agreement":null},{"id":"W3154522180","doi":"10.1002/cncr.33568","title":"Forecasting essential childhood cancer drug need: An innovative model‐based approach","year":2021,"lang":"en","type":"article","venue":"Cancer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Medicine; Health care; Procurement; Environmental health; Economic growth; Business; Marketing; Economics","score_opus":0.09705375534285139,"score_gpt":0.31242406542869056,"score_spread":0.21537031008583918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154522180","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27260256,0.0022529073,0.68213624,0.0066331145,0.0003974333,0.0007289669,0.0055577853,0.0021580807,0.027532924],"genre_scores_gemma":[0.86108327,0.0006656534,0.12887247,0.0007183755,0.0002036467,0.00069279404,0.0023823658,0.00010300725,0.005278366],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990946,0.00042531197,0.000047945763,0.00018654543,0.00010475353,0.00014068732],"domain_scores_gemma":[0.9942942,0.0047172694,0.00024993188,0.000073962554,0.000466543,0.00019799183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002072397,0.0015304141,0.0017401726,0.0019460632,0.00071292213,0.0024371915,0.0021031948,0.002511443,0.005820807],"category_scores_gemma":[0.005833644,0.0009042218,0.0016821744,0.0013298133,0.0005464491,0.0011687028,0.0014962045,0.001884259,0.0003432943],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003509076,0.00005668541,0.001583379,0.000029284944,0.000056567627,0.000036074864,0.000014468122,0.99096924,0.00004968513,0.0014530742,0.00063449517,0.0050819283],"study_design_scores_gemma":[0.00001157639,0.00001359597,0.00010836588,0.000004962409,0.000011509625,0.0000041551066,0.000009799938,0.99844486,0.000015872969,0.0012016593,0.00016995684,0.000003698576],"about_ca_topic_score_codex":0.06082308,"about_ca_topic_score_gemma":0.040645692,"teacher_disagreement_score":0.06082308,"about_ca_system_score_codex":0.0023163622,"about_ca_system_score_gemma":0.0040108627,"threshold_uncertainty_score":0.12093812},"labels":[],"label_agreement":null},{"id":"W3154938279","doi":"10.1093/ajhp/zxab160","title":"National trends in prescription drug expenditures and projections for 2021","year":2021,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Biosimilar; Medical prescription; Specialty; Prescription drug; Medicine; Drug; Legislation; Business; Pharmacy; Family medicine; Pharmacology; Political science","score_opus":0.08007821918919704,"score_gpt":0.37293936534222777,"score_spread":0.2928611461530307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154938279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7557648,0.007380205,0.009102483,0.0074088606,0.00038464295,0.000084153224,0.1758558,0.00085949624,0.043159664],"genre_scores_gemma":[0.8897328,0.0043294174,0.006190867,0.000693969,0.0001416382,0.00011462173,0.094685726,0.00005157024,0.004059375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940443,0.0001034223,0.0000662954,0.000098175224,0.00023479384,0.000092921444],"domain_scores_gemma":[0.998027,0.0002184736,0.0006207462,0.00005426679,0.00094316306,0.00013636179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010850385,0.00054573704,0.00021201026,0.0022124082,0.0002461547,0.0012111034,0.00035635656,0.0004826636,0.002601585],"category_scores_gemma":[0.0034429647,0.00019511521,0.00089356187,0.0029480879,0.00015557492,0.0013043985,0.0005189318,0.00084128644,0.0010790018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005342267,0.00020236023,0.7739273,0.0008106932,0.0005788188,0.00032785267,0.0002916623,0.06346686,0.0010284514,0.011107186,0.060094822,0.08762976],"study_design_scores_gemma":[0.00003495163,0.00024249837,0.8279094,0.0004675629,0.00022254321,0.00082533655,0.00095631665,0.07179857,0.0016199701,0.002905556,0.092936054,0.00008125932],"about_ca_topic_score_codex":0.039770223,"about_ca_topic_score_gemma":0.034574915,"teacher_disagreement_score":0.039770223,"about_ca_system_score_codex":0.002478756,"about_ca_system_score_gemma":0.0013390732,"threshold_uncertainty_score":0.07907748},"labels":[],"label_agreement":null},{"id":"W3155589128","doi":"10.1182/blood.v130.suppl_1.3403.3403","title":"Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Pomalidomide; Medicine; Randomized controlled trial; Internal medicine; Meta-analysis; Refractory (planetary science); Oncology; Multiple myeloma; Lenalidomide","score_opus":0.1858870700279212,"score_gpt":0.37302470508607205,"score_spread":0.18713763505815084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155589128","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12553427,0.86445296,0.005238656,0.0010257005,0.000877924,0.00041339357,0.0013745456,0.00013734128,0.00094518],"genre_scores_gemma":[0.90478456,0.087504745,0.004338232,0.0010123417,0.0005764989,0.00041823718,0.00093856355,0.00006706112,0.00035967137],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96817243,0.023463724,0.0037526905,0.0023424577,0.0016237672,0.0006448763],"domain_scores_gemma":[0.94136477,0.04765363,0.006278383,0.0030326003,0.0011551376,0.0005154348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035199445,0.0037334333,0.014017742,0.0027383987,0.00047254623,0.0040771,0.0021835016,0.0031725455,0.0027348357],"category_scores_gemma":[0.05963265,0.0022709277,0.05962416,0.0033952987,0.0012879297,0.0024977732,0.002184671,0.004474234,0.00025970043],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019379416,0.00003199631,0.0048681265,0.00937469,0.96119726,0.000042892792,0.00002061411,0.0010323972,0.000121643505,0.00012838905,0.00013527222,0.003667194],"study_design_scores_gemma":[0.0036513975,0.00052022934,0.0034872682,0.00070292916,0.99019927,0.000047694764,0.000018222736,0.00053180015,0.000115181676,0.00038980698,0.00031815635,0.000017986647],"about_ca_topic_score_codex":0.0031834897,"about_ca_topic_score_gemma":0.0034781399,"teacher_disagreement_score":0.035199445,"about_ca_system_score_codex":0.0020548883,"about_ca_system_score_gemma":0.0014493136,"threshold_uncertainty_score":0.18615472},"labels":[],"label_agreement":null},{"id":"W3158347929","doi":"10.1016/j.ptdy.2021.04.012","title":"Cash-based pharmacies deliver transparency, savings","year":2021,"lang":"en","type":"article","venue":"Pharmacy Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Cash; Pharmacist; Business; Medical prescription; Transparency (behavior); Quarter (Canadian coin); Finance; Family medicine; Medicine; Nursing; Law; Political science","score_opus":0.11352079610011583,"score_gpt":0.3209135052362714,"score_spread":0.20739270913615554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158347929","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26282915,0.024709193,0.06386022,0.25676495,0.003966057,0.00057130586,0.00762899,0.00429188,0.37537834],"genre_scores_gemma":[0.9668966,0.001955713,0.0043787784,0.0064877593,0.0011593306,0.000036485504,0.0005378036,0.00012461434,0.018422976],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9900373,0.0034406679,0.00033272887,0.0004885199,0.004336287,0.0013645199],"domain_scores_gemma":[0.95075315,0.028516905,0.00976487,0.0031095452,0.0058730086,0.0019824835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009896489,0.0005955452,0.0005695883,0.0018791372,0.0010313645,0.007885786,0.0006470266,0.0033342976,0.018751975],"category_scores_gemma":[0.053802606,0.00042990746,0.0008636477,0.0022286451,0.001046827,0.004603614,0.0017802363,0.003533362,0.0024306895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020468212,0.0008740659,0.039060634,0.001037118,0.0005546296,0.00028532583,0.0006913218,0.024629513,0.0036137102,0.41074568,0.2073433,0.3091179],"study_design_scores_gemma":[0.0012799606,0.001627247,0.12431136,0.0012542872,0.0011465222,0.00090542634,0.0018862347,0.050057266,0.01575523,0.44327736,0.35821736,0.0002817853],"about_ca_topic_score_codex":0.0068992497,"about_ca_topic_score_gemma":0.00465644,"teacher_disagreement_score":0.018751975,"about_ca_system_score_codex":0.005767895,"about_ca_system_score_gemma":0.007433729,"threshold_uncertainty_score":0.06273162},"labels":[],"label_agreement":null},{"id":"W3158871097","doi":"10.1503/cmaj.210531","title":"Managing drug shortages during a pandemic: tocilizumab and COVID-19","year":2021,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; Health Sciences Centre; McMaster University; Women's College Hospital; Trillium Health Centre; Hamilton Health Sciences; University of Toronto; University Health Network; Sinai Health System; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Pandemic; Economic shortage; Coronavirus disease 2019 (COVID-19); Tocilizumab; Supply chain; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Drug; Key (lock); Distribution (mathematics); Computer science; Business; Medicine; Virology; Pharmacology; Computer security; Pathology; Marketing; Infectious disease (medical specialty); Disease","score_opus":0.032834146659226134,"score_gpt":0.27987997617109117,"score_spread":0.24704582951186504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158871097","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13104224,0.09485966,0.007538114,0.7085295,0.001866702,0.00011295788,0.0012553809,0.0001186251,0.054676875],"genre_scores_gemma":[0.93951595,0.03954042,0.0014666759,0.011560507,0.0026005625,0.00003395601,0.0003055202,0.00002317238,0.004953278],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992601,0.0003166448,0.000020493972,0.00005212051,0.00014038049,0.00021032088],"domain_scores_gemma":[0.99702877,0.0011367117,0.0006847531,0.000029204906,0.0003547662,0.0007658592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019168523,0.00031927574,0.00048016585,0.0009243292,0.0012320105,0.0027118525,0.0004296866,0.002600306,0.004994421],"category_scores_gemma":[0.009215341,0.00022300179,0.00023841985,0.001382101,0.0012039824,0.0027056101,0.0012697134,0.002668751,0.00025776253],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090251915,0.0005156063,0.05234979,0.000992259,0.00022060475,0.0041178996,0.0011108032,0.0656382,0.0004058916,0.20659947,0.4357779,0.23136903],"study_design_scores_gemma":[0.00050555205,0.0005344748,0.09474777,0.0024566387,0.00019847497,0.0016648341,0.013139946,0.123872645,0.00042137172,0.52299255,0.23920394,0.00026180438],"about_ca_topic_score_codex":0.111633904,"about_ca_topic_score_gemma":0.09482367,"teacher_disagreement_score":0.111633904,"about_ca_system_score_codex":0.008356968,"about_ca_system_score_gemma":0.0076638255,"threshold_uncertainty_score":0.22196823},"labels":[],"label_agreement":null},{"id":"W3158905218","doi":"10.1016/j.rcsop.2021.100020","title":"A systematic review of pharmaceutical price mark-up practice and its implementation","year":2021,"lang":"en","type":"review","venue":"Exploratory Research in Clinical and Social Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Margin (machine learning); Control (management); Value (mathematics); Pharmaceutical industry; Systematic review; Business; Economics; MEDLINE; Medicine; Political science; Management; Computer science","score_opus":0.6866369439326083,"score_gpt":0.6337531141768776,"score_spread":0.052883829755730694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158905218","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001566218,0.9953159,0.0004555586,0.00034680017,0.00016780112,0.0008508314,0.000661951,0.000014314288,0.0006205342],"genre_scores_gemma":[0.015057283,0.98121005,0.0013923233,0.0004422881,0.00006332243,0.0012509942,0.00037416056,0.000007985975,0.00020159209],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98569286,0.005356569,0.0051153162,0.00087953924,0.0026347844,0.00032098364],"domain_scores_gemma":[0.96114373,0.028376447,0.005643389,0.00071694836,0.0038054062,0.00031401642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013056197,0.00155551,0.006611161,0.012663346,0.0008382565,0.0031843234,0.002133978,0.002042785,0.0044783903],"category_scores_gemma":[0.061920363,0.0010067208,0.0054657194,0.015072232,0.0010330953,0.0031194375,0.0017014504,0.0011450775,0.00045181537],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009648709,0.000011364366,0.00036908741,0.96419317,0.0034094858,0.00007088452,0.00021956369,0.00008069528,0.00014581348,0.0004145746,0.0012948584,0.029694032],"study_design_scores_gemma":[0.00013557788,0.00014917995,0.0020950849,0.9461652,0.028478246,0.00022525025,0.00030998536,0.000064800166,0.00021781342,0.00030415092,0.02182769,0.00002690246],"about_ca_topic_score_codex":0.008345631,"about_ca_topic_score_gemma":0.027385365,"teacher_disagreement_score":0.013056197,"about_ca_system_score_codex":0.0051988643,"about_ca_system_score_gemma":0.022686848,"threshold_uncertainty_score":0.06904864},"labels":[],"label_agreement":null},{"id":"W3160997078","doi":"10.5334/gh.927","title":"Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal","year":2021,"lang":"en","type":"review","venue":"Global Heart","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Pharmacy; Descriptive statistics; Health facility; Essential medicines; Private sector; Public health; Environmental health; Public sector; Family medicine; Economic growth; Population; Health services; Nursing","score_opus":0.14902970365781118,"score_gpt":0.3843194712923159,"score_spread":0.23528976763450474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160997078","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9518546,0.023449114,0.0005424778,0.008837256,0.00003758227,0.00011195847,0.0025422939,0.000013083312,0.012611616],"genre_scores_gemma":[0.99499786,0.0040195156,0.00018413042,0.00039049503,0.000011538459,0.00005914154,0.00022011418,0.0000019440445,0.00011524477],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746764,0.0011396657,0.00039602022,0.00024076099,0.000348664,0.00040735284],"domain_scores_gemma":[0.9880696,0.0070392024,0.0031741867,0.00019325213,0.00094612135,0.00057766715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029895997,0.00014862433,0.0003933104,0.001659936,0.00066336564,0.0016250839,0.00084828486,0.0004187568,0.00315995],"category_scores_gemma":[0.014123683,0.00030030584,0.0005171159,0.0021796809,0.0009586461,0.0019487573,0.0021063816,0.0007256579,0.00009812972],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011255263,0.00016024179,0.9130696,0.007714824,0.0008144124,0.0012489728,0.015295871,0.00077676465,0.00031475775,0.0039708954,0.0024527658,0.054068398],"study_design_scores_gemma":[0.00003187227,0.00015560593,0.9614907,0.00664864,0.00037657196,0.00084804196,0.018744957,0.0011093015,0.00018121683,0.002130905,0.008232056,0.000050121802],"about_ca_topic_score_codex":0.04020987,"about_ca_topic_score_gemma":0.043348644,"teacher_disagreement_score":0.04020987,"about_ca_system_score_codex":0.0017633968,"about_ca_system_score_gemma":0.004481825,"threshold_uncertainty_score":0.079951644},"labels":[],"label_agreement":null},{"id":"W3162560322","doi":"10.1111/cts.13046","title":"The timing of 30‐month stay expirations and generic entry: A cohort study of first generics, 2013–2020","year":2021,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk Fonden","keywords":"Generic drug; Paragraph; Medicine; Certification; Brand names; Food and drug administration; Advertising; Business; Drug; Medical emergency; Pharmacology; Law; Political science","score_opus":0.15052911303879832,"score_gpt":0.3585425818910221,"score_spread":0.2080134688522238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162560322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921095,0.0010900497,0.00014243656,0.00021359313,0.000032390533,0.000048185047,0.004493789,0.000009105699,0.0018609848],"genre_scores_gemma":[0.9955656,0.0005160078,0.00007839138,0.00015551082,0.000049264047,0.00003683104,0.0027261355,0.000013516368,0.0008587456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986084,0.00013803785,0.00015082605,0.00033063986,0.00034471916,0.00042733678],"domain_scores_gemma":[0.99388015,0.00053251756,0.0036068764,0.00033681386,0.00071115245,0.00093245896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023152374,0.0003250687,0.00055985927,0.0010799885,0.0010417993,0.0020012162,0.00089015847,0.0010139095,0.004936029],"category_scores_gemma":[0.007753453,0.00051277597,0.0016031463,0.0013516685,0.00041254732,0.00207047,0.0013125413,0.0021225885,0.0015336389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048371463,0.000091193826,0.99581003,0.000026803238,0.000077476645,0.00011373459,0.00022973027,0.00004299917,0.0000901508,0.00009807415,0.0007690525,0.0021670905],"study_design_scores_gemma":[0.000021835349,0.0002795487,0.9969367,0.000042679836,0.0000754874,0.00031675748,0.00056403596,0.00019156456,0.000057227793,0.00006378556,0.0014314476,0.000018985356],"about_ca_topic_score_codex":0.026258098,"about_ca_topic_score_gemma":0.023330068,"teacher_disagreement_score":0.026258098,"about_ca_system_score_codex":0.0009951693,"about_ca_system_score_gemma":0.0013110333,"threshold_uncertainty_score":0.05221057},"labels":[],"label_agreement":null},{"id":"W3164318960","doi":"10.3233/jrs-210013","title":"Companies’ statements about drugs withdrawn from the Canadian market: A descriptive analysis","year":2021,"lang":"en","type":"article","venue":"International Journal of Risk & Safety in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Government (linguistics); Business; Drug Company; Descriptive statistics; Drug; Position (finance); Brand names; Product (mathematics); Drug withdrawal; Medicine; Marketing; Finance; Psychiatry; Management; Economics","score_opus":0.037290061303913415,"score_gpt":0.3274937796348996,"score_spread":0.2902037183309862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164318960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95006496,0.0032122321,0.00046831148,0.0013172248,0.000025308604,0.0012088738,0.035662513,0.00003232562,0.008008352],"genre_scores_gemma":[0.9760843,0.004627688,0.0014861401,0.0006623817,0.000028353701,0.0014050177,0.014171208,0.00002519859,0.0015097082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98928916,0.0011290769,0.0019942047,0.00046248818,0.0062063416,0.00091879227],"domain_scores_gemma":[0.93049866,0.033894233,0.01734997,0.00073006836,0.01626298,0.0012641125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009317589,0.000342762,0.00060033955,0.017455827,0.0017047103,0.0021169249,0.0010199861,0.0006224562,0.0029121826],"category_scores_gemma":[0.050106335,0.00038901356,0.00084882695,0.019694146,0.0016582855,0.001360748,0.0015468207,0.0007873526,0.00035746905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096860377,0.00016322864,0.9040137,0.006283937,0.00026942542,0.0010860792,0.044528116,0.00024568103,0.00094947155,0.0010665072,0.009534136,0.030891255],"study_design_scores_gemma":[0.000043181397,0.00016146047,0.9018147,0.0026468672,0.00022894493,0.0006074366,0.072533846,0.0005206508,0.0006427046,0.00019352339,0.020512579,0.00009410561],"about_ca_topic_score_codex":0.5138751,"about_ca_topic_score_gemma":0.54170334,"teacher_disagreement_score":0.48612487,"about_ca_system_score_codex":0.013976929,"about_ca_system_score_gemma":0.02219741,"threshold_uncertainty_score":0.97797555},"labels":[],"label_agreement":null},{"id":"W3164448554","doi":"10.1002/prp2.794","title":"Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)","year":2021,"lang":"en","type":"review","venue":"Pharmacology Research & Perspectives","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Food and drug administration; Regulatory science; Sacubitril, Valsartan; Valsartan; Agency (philosophy); Medicine; Drug development; Business; Strengths and weaknesses; Pharmacology; Sacubitril; Drug; Psychology","score_opus":0.4617126359250331,"score_gpt":0.4775476366956166,"score_spread":0.01583500077058353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164448554","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010085651,0.97087777,0.00068364217,0.010764981,0.0010910792,0.00020996871,0.00059974566,0.000028916893,0.014735336],"genre_scores_gemma":[0.010183126,0.97726,0.0020281181,0.0056916093,0.0006829863,0.00016696198,0.00042370937,0.000017322425,0.0035462356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936214,0.0023229185,0.0010470643,0.00028494385,0.002503654,0.00021994932],"domain_scores_gemma":[0.97470605,0.014815889,0.0040857,0.0004337245,0.0055759964,0.00038250105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012090232,0.00051400106,0.0010676327,0.007253672,0.00051423605,0.002082942,0.0009074247,0.0018628264,0.0047319927],"category_scores_gemma":[0.028746406,0.00036642377,0.0011881285,0.00718864,0.00059971644,0.0019460688,0.0006935403,0.0015867203,0.0010876522],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017974626,0.00007383754,0.0005671904,0.079102755,0.00079149473,0.00023975894,0.0002900132,0.00036753362,0.0013943192,0.02013441,0.12628534,0.7705736],"study_design_scores_gemma":[0.000071807764,0.00010697876,0.0029804478,0.04270325,0.0008713024,0.00025471955,0.00011459374,0.00013157899,0.0007064007,0.0019176287,0.9501153,0.000025954396],"about_ca_topic_score_codex":0.006326469,"about_ca_topic_score_gemma":0.019513115,"teacher_disagreement_score":0.012090232,"about_ca_system_score_codex":0.002987457,"about_ca_system_score_gemma":0.014607137,"threshold_uncertainty_score":0.06394005},"labels":[],"label_agreement":null},{"id":"W3171961774","doi":"10.3386/w28866","title":"Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market","year":2021,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Pharmacy; Medical prescription; Business; Drug; Prescription drug; Pharmacology; Medicine; Family medicine","score_opus":0.46272300715943177,"score_gpt":0.5027236993859804,"score_spread":0.04000069222654862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171961774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61580735,0.002892826,0.07071503,0.05508276,0.0003750322,0.00034847355,0.0006808997,0.00022537669,0.25387222],"genre_scores_gemma":[0.9751947,0.00046301156,0.0027763399,0.00091588637,0.0001848583,0.0000531038,0.000040725452,0.000013797973,0.020357652],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9981944,0.00056453724,0.000043043674,0.00036710588,0.00026965846,0.00056123885],"domain_scores_gemma":[0.99632204,0.0013577315,0.001026277,0.00024069921,0.00020765427,0.00084561453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024555216,0.00044325396,0.0012087749,0.0006568616,0.0020455234,0.0059316116,0.00110898,0.0044584344,0.02384729],"category_scores_gemma":[0.007230371,0.0005401853,0.00073482806,0.0008021455,0.0033178898,0.009536006,0.002411847,0.0028587298,0.0013919054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021793225,0.00032386003,0.0071489443,0.00007870073,0.000037685222,0.00052626285,0.00042487678,0.018308956,0.0005849074,0.942782,0.010544438,0.01902141],"study_design_scores_gemma":[0.0007518499,0.00037189733,0.010305419,0.00015831349,0.00013852336,0.00047437032,0.0022300107,0.15329362,0.0008843838,0.78209305,0.049173236,0.00012531059],"about_ca_topic_score_codex":0.0070647686,"about_ca_topic_score_gemma":0.008120394,"teacher_disagreement_score":0.02384729,"about_ca_system_score_codex":0.0029972217,"about_ca_system_score_gemma":0.0025125544,"threshold_uncertainty_score":0.07977712},"labels":[],"label_agreement":null},{"id":"W3173458844","doi":"","title":"CANADIAN PHARMACEUTICAL INDUSTRY IN GLOBAL VALUE CHAINS: THE INFLUENCE OF DOMINANT TRADING PARTNER","year":2019,"lang":"en","type":"article","venue":"World Economy and International Relations","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Value (mathematics); Industrial organization; Commerce; International trade; Mathematics; Statistics","score_opus":0.040918460155378894,"score_gpt":0.31083228159211557,"score_spread":0.2699138214367367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173458844","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46791837,0.0071178707,0.00144875,0.03643155,0.00025798933,0.00011827539,0.0010134755,0.000080260725,0.48561338],"genre_scores_gemma":[0.9888256,0.0015239764,0.00018907923,0.00071031,0.000027875492,0.0000050512713,0.00009071878,0.000015536887,0.008611851],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963966,0.0004792158,0.00007133308,0.0003093973,0.0013520042,0.0013915121],"domain_scores_gemma":[0.98939717,0.002056794,0.0008414535,0.00025169182,0.0048286174,0.002624324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002448414,0.00042878868,0.0005367755,0.0030692269,0.009013368,0.012896219,0.0010434551,0.0019136382,0.015968299],"category_scores_gemma":[0.016021237,0.00031136713,0.0003596576,0.0060266345,0.00415761,0.003244583,0.002746039,0.0021468368,0.0006783411],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009791096,0.00023488422,0.17847916,0.00051486626,0.00029234338,0.0015995114,0.017959328,0.009174865,0.0018165418,0.5958547,0.07172518,0.121369585],"study_design_scores_gemma":[0.0003603746,0.00018923066,0.39577565,0.0011874973,0.00090548117,0.00046152083,0.095075235,0.015171204,0.0035517025,0.08688993,0.400056,0.00037609437],"about_ca_topic_score_codex":0.9742543,"about_ca_topic_score_gemma":0.9878015,"teacher_disagreement_score":0.08062184,"about_ca_system_score_codex":0.08062184,"about_ca_system_score_gemma":0.09148602,"threshold_uncertainty_score":0.5849551},"labels":[],"label_agreement":null},{"id":"W3177665412","doi":"10.1038/s41408-021-00522-3","title":"Drug importation: limitations of current proposals and opportunities for improvement","year":2021,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Panacea (medicine); Business; Drug prices; Authorization; Drug; International trade; Law; Public economics; Economic policy; Medicine; Economics; Pharmacology; Political science; Computer security; Alternative medicine","score_opus":0.18921442342185205,"score_gpt":0.34818537186670157,"score_spread":0.15897094844484952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177665412","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004677635,0.019251328,0.0004248443,0.34592745,0.6313385,0.000018977813,0.000056510075,0.00008225979,0.0028534438],"genre_scores_gemma":[0.00091185863,0.019884007,0.0008150197,0.094078474,0.878457,0.00003401565,0.000039824605,0.00005846017,0.005721295],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9768935,0.0054918765,0.0035400782,0.0020876245,0.011124461,0.00086239935],"domain_scores_gemma":[0.7626965,0.14499536,0.0053738803,0.006079157,0.07331059,0.0075446195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047888484,0.0027302357,0.0034468065,0.0045363666,0.0043884595,0.0155279245,0.0053583407,0.025207894,0.0104194],"category_scores_gemma":[0.16725469,0.0011192871,0.002770428,0.0036462622,0.008190725,0.01575353,0.0023704085,0.03521914,0.007866537],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016549368,0.000016440681,0.000027546355,0.00030504173,0.000012031036,0.00005676286,0.00003760045,0.000052675296,0.00002163609,0.0054794885,0.9809522,0.01302194],"study_design_scores_gemma":[0.000033938148,0.000016434973,0.00017121699,0.0010675362,0.000026656708,0.00011749943,0.00012494087,0.00027075675,0.00004851814,0.016386919,0.9817073,0.000028357357],"about_ca_topic_score_codex":0.0035437865,"about_ca_topic_score_gemma":0.0070744185,"teacher_disagreement_score":0.047888484,"about_ca_system_score_codex":0.007831742,"about_ca_system_score_gemma":0.011948239,"threshold_uncertainty_score":0.25326157},"labels":[],"label_agreement":null},{"id":"W3178430533","doi":"10.4212/cjhp.v74i3.3155","title":"Pénuries de médicaments en établissement de santé : une étude qualitative à partir de cas réels pris en charge par les pharmaciens hospitaliers","year":2021,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.0450229921323941,"score_gpt":0.34931794896148616,"score_spread":0.3042949568290921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178430533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95208806,0.008998697,0.005807951,0.0085047,0.00006595259,0.0004484199,0.0012771663,0.000017615283,0.022791475],"genre_scores_gemma":[0.99436533,0.0019060947,0.0011119016,0.00050959265,0.0000110496485,0.00022069161,0.0001045907,0.000006459676,0.001764353],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9725112,0.017491322,0.0015706642,0.001206705,0.0057778037,0.0014423159],"domain_scores_gemma":[0.8741794,0.09810642,0.016760353,0.0009679033,0.0090742195,0.0009117261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026869208,0.00024483434,0.00058643916,0.002311565,0.0016603613,0.0046881814,0.00096447277,0.001303307,0.0077514504],"category_scores_gemma":[0.07710324,0.0005005102,0.00094573345,0.0038984152,0.002969797,0.0044830847,0.0020678146,0.0017657351,0.00024126614],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015291731,0.00092547404,0.44673845,0.005882742,0.00074344187,0.0010717724,0.26015767,0.003645376,0.0017448306,0.12997515,0.0061546885,0.1414312],"study_design_scores_gemma":[0.00023285567,0.0009966952,0.54448533,0.0070159985,0.00067128916,0.0010066462,0.3553909,0.0074661346,0.0026073689,0.014488795,0.065487824,0.00015023457],"about_ca_topic_score_codex":0.07498423,"about_ca_topic_score_gemma":0.07473899,"teacher_disagreement_score":0.07498423,"about_ca_system_score_codex":0.017564727,"about_ca_system_score_gemma":0.011372866,"threshold_uncertainty_score":0.14909554},"labels":[],"label_agreement":null},{"id":"W3178864507","doi":"10.33731/22021.236692","title":"Pharmaceutical nationalism as an instrument to ensure the access to medicines","year":2021,"lang":"en","type":"article","venue":"Theory and Practice of Intellectual Property","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Access to medicines; Nationalism; Medicine; Business; Traditional medicine; Political science; Law; Nursing; Politics; Public health","score_opus":0.14831300892680452,"score_gpt":0.38966866282480667,"score_spread":0.24135565389800215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178864507","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11769947,0.007289329,0.01063992,0.044550948,0.00040427144,0.000104134975,0.00014932104,0.000104380866,0.81905824],"genre_scores_gemma":[0.9689763,0.0014660958,0.0018097257,0.0028909682,0.000181174,0.000046056502,0.000049646882,0.000014843356,0.02456523],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9934568,0.002757647,0.0004746208,0.00065405323,0.0017543848,0.00090242556],"domain_scores_gemma":[0.9935522,0.0026221583,0.0016326155,0.00073160056,0.00090178265,0.00055967603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047668745,0.00015183947,0.0002537489,0.0008096455,0.003566923,0.0064033237,0.0005163483,0.002515855,0.0076847957],"category_scores_gemma":[0.0060325437,0.00016431606,0.000333666,0.0011932645,0.011706644,0.0033284018,0.00499498,0.0028871105,0.0007511302],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003739971,0.000061518316,0.003440642,0.00014202282,0.000013259962,0.00021169957,0.003925866,0.0001903873,0.0006769626,0.95823747,0.0050659166,0.02799686],"study_design_scores_gemma":[0.00003707539,0.00017592846,0.025082305,0.00076263025,0.00005383537,0.001626462,0.00819698,0.0013271163,0.0025888672,0.315418,0.64466995,0.00006085361],"about_ca_topic_score_codex":0.003756645,"about_ca_topic_score_gemma":0.0039824895,"teacher_disagreement_score":0.0076847957,"about_ca_system_score_codex":0.0049321945,"about_ca_system_score_gemma":0.0077084135,"threshold_uncertainty_score":0.035785735},"labels":[],"label_agreement":null},{"id":"W3181614690","doi":"10.1093/cid/ciab612","title":"Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020","year":2021,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Norwegian Institute of Public Health; Basilea Pharmaceutica; Shionogi; Norges Forskningsråd; Novo Holdings; Roivant Sciences; Meiji Seika Pharma; Bill and Melinda Gates Foundation; European Commission; Wellcome Trust","keywords":"Medicine; Food and drug administration; Agency (philosophy); Drug; Administration (probate law); Antibiotics; Family medicine; Environmental health; Pharmacology; Law","score_opus":0.0570680239702596,"score_gpt":0.36910930934883496,"score_spread":0.31204128537857534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181614690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947143,0.00041875095,0.0000851497,0.0001153916,0.0000033064111,0.00002352863,0.003822767,0.0000045262295,0.0008123054],"genre_scores_gemma":[0.99769753,0.00019458384,0.00014715552,0.00007962639,0.0000042081483,0.000041122454,0.0017005312,0.0000016502576,0.00013368668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761665,0.000751841,0.00048718456,0.00043018805,0.0003085237,0.00040561138],"domain_scores_gemma":[0.99026006,0.002045139,0.0063102674,0.00019057073,0.0005662821,0.00062770693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019250326,0.00026206762,0.00034629143,0.0018450903,0.00043253336,0.0009903884,0.00042212947,0.00053397805,0.0033731721],"category_scores_gemma":[0.004846727,0.0002554498,0.00067121413,0.003636251,0.0006938858,0.00079878053,0.0012278453,0.0005044403,0.0004119015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007532977,0.000034605375,0.99783474,0.00003871507,0.000045538603,0.000047435053,0.000093240815,0.00007175257,0.00003325704,0.00004606947,0.0002796071,0.0013996653],"study_design_scores_gemma":[0.000021570067,0.00009985509,0.997547,0.00005741457,0.000040567105,0.00024447415,0.0009367162,0.00031827018,0.00008489905,0.000038838785,0.0006018866,0.00000859468],"about_ca_topic_score_codex":0.0124687385,"about_ca_topic_score_gemma":0.012252136,"teacher_disagreement_score":0.0124687385,"about_ca_system_score_codex":0.0009288865,"about_ca_system_score_gemma":0.0011234418,"threshold_uncertainty_score":0.024792314},"labels":[],"label_agreement":null},{"id":"W3182324768","doi":"10.1136/bmjopen-2020-047557","title":"Time to market for drugs approved in Canada between 2014 and 2018: an observational study","year":2021,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Medicine; Observational study; Trademark; Psychological intervention; Family medicine; Internal medicine; Law; Psychiatry","score_opus":0.3012718976363224,"score_gpt":0.40056220960087513,"score_spread":0.09929031196455274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182324768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95471627,0.005245768,0.00028557924,0.0011820315,0.00006377478,0.00035418663,0.032523032,0.00003773781,0.0055916454],"genre_scores_gemma":[0.9842295,0.0029077495,0.00039863115,0.0005125569,0.000059776394,0.00021200861,0.010444908,0.000024809055,0.0012100323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936028,0.00036420615,0.00090019,0.0008919108,0.0031770503,0.0010637403],"domain_scores_gemma":[0.96902037,0.0030032634,0.017228242,0.00048327658,0.007089571,0.0031752458],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002314134,0.00038231886,0.0010684915,0.0040247715,0.0025338237,0.0023993945,0.0019388333,0.0008251867,0.004361436],"category_scores_gemma":[0.016892195,0.0005255718,0.0011990161,0.011612556,0.0009734872,0.0017791019,0.0014045767,0.0023722618,0.00053181424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039404898,0.00012899413,0.98886275,0.0003307368,0.00022246479,0.00012336852,0.00064786745,0.00010073924,0.00006664295,0.00017439829,0.003889747,0.0050581885],"study_design_scores_gemma":[0.00004319632,0.00012039704,0.99393964,0.00019729932,0.00014445909,0.00022079793,0.0012480353,0.00019836717,0.000084650135,0.00004743636,0.003716022,0.000039811206],"about_ca_topic_score_codex":0.9102343,"about_ca_topic_score_gemma":0.9094555,"teacher_disagreement_score":0.99768585,"about_ca_system_score_codex":0.025160577,"about_ca_system_score_gemma":0.03852622,"threshold_uncertainty_score":0.18255365},"labels":[],"label_agreement":null},{"id":"W3182527377","doi":"10.24926/iip.v12i3.3939","title":"Comparison of Drug Withdrawal Processes in the U.S. and Other Nations","year":2021,"lang":"en","type":"review","venue":"INNOVATIONS in pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Agency (philosophy); Drug withdrawal; Business; Medicine; Pharmacology; Process (computing); Variety (cybernetics); Political science; Computer science; Sociology","score_opus":0.2164653586927439,"score_gpt":0.45154307371031543,"score_spread":0.23507771501757155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182527377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025821696,0.99525946,0.00008179326,0.00040803896,0.000050774437,0.000022285649,0.00014801936,0.0000026496796,0.0014447658],"genre_scores_gemma":[0.019110208,0.9799717,0.00018364622,0.00027654378,0.00004879417,0.000033255634,0.0001656931,0.0000021025705,0.00020799585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975485,0.0010098671,0.00061247963,0.00017524189,0.000530817,0.000123154],"domain_scores_gemma":[0.9941995,0.0032518508,0.0015297078,0.00006415667,0.00082606275,0.00012866165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043239594,0.00043565073,0.0010206214,0.004283601,0.00024571738,0.0011698757,0.0005321453,0.0005373478,0.00220509],"category_scores_gemma":[0.008414553,0.0002576635,0.0016691778,0.006610027,0.00043086812,0.0012158835,0.0006499416,0.0008111499,0.00022688496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010696617,0.00012700808,0.010353867,0.09658086,0.0017954853,0.0003512717,0.00051718135,0.0013966701,0.00051943905,0.008667624,0.013364316,0.86525655],"study_design_scores_gemma":[0.0004662465,0.0021341925,0.16328725,0.14426771,0.0054696314,0.0031911125,0.002350301,0.00093017396,0.0022611043,0.0041885264,0.6713096,0.00014414512],"about_ca_topic_score_codex":0.009866579,"about_ca_topic_score_gemma":0.016755274,"teacher_disagreement_score":0.009866579,"about_ca_system_score_codex":0.0021219319,"about_ca_system_score_gemma":0.003312418,"threshold_uncertainty_score":0.02286756},"labels":[],"label_agreement":null},{"id":"W3183715790","doi":"10.1177/17411343211035168","title":"Brand drug companies impeding generic drug company access to product samples: Estimated prevalence and impact on drug costs","year":2021,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Association canadienne du médicament générique","keywords":"Generic drug; Drug; Business; Market share; Brand names; Product (mathematics); Drug development; Marketing; Competition (biology); Order (exchange); Medicine; Pharmacology; Finance","score_opus":0.13494569130732337,"score_gpt":0.3561349865959504,"score_spread":0.22118929528862702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183715790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797346,0.003928719,0.0012823162,0.0007249627,0.00001221638,0.00022682281,0.009666465,0.000024591967,0.004399288],"genre_scores_gemma":[0.99169743,0.002165059,0.0006850102,0.00008769075,0.000020428832,0.000046721856,0.004332291,0.000007982319,0.0009573263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99457127,0.0011486013,0.00056571944,0.0005659084,0.001977424,0.0011710247],"domain_scores_gemma":[0.95446557,0.015322454,0.023708817,0.0012465878,0.0035969126,0.0016595884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004700759,0.0004167932,0.00058020145,0.0053431955,0.0006131367,0.0024214748,0.0012350249,0.00079421856,0.0037619597],"category_scores_gemma":[0.031942155,0.00062199426,0.0014965186,0.0063065332,0.0012540944,0.0014382469,0.0018896258,0.0014725127,0.00034102233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008962649,0.000051271814,0.99032253,0.00010605576,0.00018212036,0.000105945364,0.00013966783,0.0013405208,0.000038696347,0.0007637114,0.00062524073,0.0062345834],"study_design_scores_gemma":[0.000013180119,0.00005363708,0.99215573,0.00010533959,0.00021375428,0.00026162813,0.00067380123,0.0044319606,0.00018604193,0.00028655113,0.0016029424,0.000015350979],"about_ca_topic_score_codex":0.41493052,"about_ca_topic_score_gemma":0.3823254,"teacher_disagreement_score":0.41493052,"about_ca_system_score_codex":0.008933621,"about_ca_system_score_gemma":0.0044940617,"threshold_uncertainty_score":0.8250307},"labels":[],"label_agreement":null},{"id":"W3184416667","doi":"10.2139/ssrn.3240967","title":"Preferred Pharmacy Networks and Drug Costs","year":2018,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Pharmacy; Drug; Business; Medicine; Pharmacology; Family medicine","score_opus":0.031757733459773424,"score_gpt":0.2865006707293634,"score_spread":0.25474293726958996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184416667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9051666,0.0056270696,0.0027875253,0.0140286805,0.00015800873,0.00011448467,0.006334835,0.000061988445,0.06572087],"genre_scores_gemma":[0.9938951,0.0010257589,0.00028473328,0.00016050221,0.00014834858,0.000012178471,0.00064509537,0.000008009291,0.0038202289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689996,0.0012623441,0.00029889672,0.00022708956,0.00071677525,0.0005950584],"domain_scores_gemma":[0.9360801,0.032243457,0.019945651,0.0014839715,0.0031181232,0.0071287137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020200433,0.000196827,0.000456471,0.002830653,0.00073000265,0.0037560007,0.0008240643,0.0012064271,0.035764083],"category_scores_gemma":[0.035982925,0.00032323488,0.0005905427,0.004009655,0.0007931624,0.0029176723,0.0011906758,0.0019923702,0.0009721289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016421705,0.0011995856,0.8322509,0.00030370348,0.0008020384,0.00071961,0.00039261318,0.016765047,0.00017131484,0.0633648,0.013699837,0.06868847],"study_design_scores_gemma":[0.0005836865,0.00063580956,0.809851,0.00032417843,0.0008105976,0.0027875206,0.0038188105,0.039511256,0.0005124127,0.10637459,0.034682136,0.00010806608],"about_ca_topic_score_codex":0.019095907,"about_ca_topic_score_gemma":0.030437542,"teacher_disagreement_score":0.035764083,"about_ca_system_score_codex":0.0032159474,"about_ca_system_score_gemma":0.0016621234,"threshold_uncertainty_score":0.119642735},"labels":[],"label_agreement":null},{"id":"W3187423611","doi":"10.1136/bmjopen-2020-045262","title":"Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study","year":2021,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; North York General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Department of Family and Community Medicine, University of Toronto; University of Toronto","keywords":"Medicine; High income countries; Essential medicines; Developing country; Gross national income; Developed country; Cross-sectional study; Traditional medicine; Environmental health; Family medicine; Public health; Population; Economic growth; Pathology","score_opus":0.13136520759752374,"score_gpt":0.44430424446326117,"score_spread":0.31293903686573743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187423611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99902034,0.00012135676,0.000077920944,0.00002082084,0.0000033250908,0.00002204686,0.00047144375,0.0000018823008,0.00026084433],"genre_scores_gemma":[0.9990965,0.00006705088,0.00013123883,0.00002749237,0.000004413187,0.000027339833,0.00059429463,0.0000016545918,0.00005005293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755245,0.0009274444,0.00038770112,0.00043443457,0.00041135555,0.00028670125],"domain_scores_gemma":[0.99194944,0.0019368469,0.004256449,0.000461069,0.00090539164,0.000490811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035969317,0.00033525837,0.000488731,0.0016087895,0.00074339815,0.0011109551,0.0005862122,0.00071520486,0.0016157113],"category_scores_gemma":[0.006910505,0.00060852757,0.0007135355,0.0028598432,0.00061870157,0.0013748241,0.0011820806,0.00069301866,0.00040682897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002739987,0.00002860838,0.9993081,0.000011979012,0.000054733224,0.000017118102,0.00013987393,0.000014188415,0.00003271916,0.000008213026,0.00003921767,0.00031785722],"study_design_scores_gemma":[0.000004273077,0.000096614895,0.9989287,0.0000088726765,0.000021096464,0.00007759724,0.0006663666,0.00006417907,0.000026610276,0.0000072793277,0.00009449641,0.0000037553157],"about_ca_topic_score_codex":0.0051534297,"about_ca_topic_score_gemma":0.0048227687,"teacher_disagreement_score":0.0051534297,"about_ca_system_score_codex":0.0005733668,"about_ca_system_score_gemma":0.00043099996,"threshold_uncertainty_score":0.019022644},"labels":[],"label_agreement":null},{"id":"W3189159100","doi":"10.1016/s0140-6736(21)01378-7","title":"What are the obligations of pharmaceutical companies in a global health emergency?","year":2021,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Toronto","funders":"Colton Foundation","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Business; Global health; Medical emergency; 2019-20 coronavirus outbreak; Public relations; Medicine; Political science; Infectious disease (medical specialty); Disease; Public health; Virology; Nursing; Outbreak","score_opus":0.3107279181499173,"score_gpt":0.4581563595230358,"score_spread":0.1474284413731185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189159100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002778024,0.8992285,0.00018910364,0.09570018,0.0010211825,0.0000052978153,0.00007169334,0.0000037319314,0.0035026008],"genre_scores_gemma":[0.011112782,0.96691483,0.00028661167,0.017788846,0.0030003164,0.000021693477,0.000043614273,0.000005289367,0.0008259869],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9957052,0.0022668778,0.00025652093,0.00016885354,0.0011661344,0.00043648708],"domain_scores_gemma":[0.98043627,0.013835493,0.0027140127,0.00027208764,0.0017587641,0.0009833957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010772818,0.0005889,0.0014955436,0.0016893953,0.00087362947,0.005173979,0.0013185391,0.0070690345,0.0068204748],"category_scores_gemma":[0.026581414,0.00036940508,0.0006697707,0.002961833,0.004469273,0.009106608,0.00227324,0.0072985515,0.0011667602],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021823695,0.00009121343,0.0007432106,0.015597198,0.00037932274,0.0002356985,0.0003518327,0.001489284,0.00018412583,0.2809616,0.120213546,0.57953477],"study_design_scores_gemma":[0.00010753539,0.00005740123,0.0037190327,0.038290825,0.00019649079,0.0004157283,0.0011865047,0.0004478159,0.00016029573,0.21875344,0.73660386,0.00006107626],"about_ca_topic_score_codex":0.006888493,"about_ca_topic_score_gemma":0.01133317,"teacher_disagreement_score":0.010772818,"about_ca_system_score_codex":0.0042507867,"about_ca_system_score_gemma":0.014436246,"threshold_uncertainty_score":0.0569728},"labels":[],"label_agreement":null},{"id":"W3190464317","doi":"10.1016/j.jval.2021.04.1277","title":"Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk Fonden","keywords":"Tying; Monopoly; Duration (music); Product (mathematics); Competition (biology); Business; Value (mathematics); New product development; Prescription drug; Generic drug; Pharmaceutical industry; Industrial organization; Medical prescription; Marketing; Economics; Drug; Microeconomics; Computer science; Medicine; Pharmacology","score_opus":0.1694680259873237,"score_gpt":0.36037445588318173,"score_spread":0.19090642989585804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190464317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50828147,0.015449241,0.36409017,0.036597196,0.0015708642,0.00033641982,0.0009914641,0.0008962485,0.071786955],"genre_scores_gemma":[0.98837554,0.00076591375,0.00674876,0.0008950597,0.0003984395,0.00006359602,0.000058313424,0.00007278487,0.0026215492],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99627006,0.001445713,0.0002405038,0.0007308575,0.0006185105,0.0006943477],"domain_scores_gemma":[0.93902427,0.0425865,0.009694651,0.0043135765,0.0021958451,0.0021852723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015707828,0.00068334246,0.0020265402,0.0007063171,0.00088047585,0.0057017314,0.0030761594,0.0047077867,0.008399237],"category_scores_gemma":[0.09424713,0.00088968105,0.001012345,0.0008460331,0.002772269,0.012641104,0.0018344965,0.0077892807,0.0005862011],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002213206,0.0005348919,0.008236981,0.0008160547,0.00033657893,0.0004506388,0.0012476846,0.0938222,0.0068030804,0.62751687,0.011025174,0.24699666],"study_design_scores_gemma":[0.00038599517,0.0009097436,0.010370227,0.0004983705,0.0002386244,0.00029724344,0.0007627847,0.08056444,0.0034674164,0.8807433,0.02163455,0.00012731417],"about_ca_topic_score_codex":0.0018245861,"about_ca_topic_score_gemma":0.0016166045,"teacher_disagreement_score":0.015707828,"about_ca_system_score_codex":0.0021729884,"about_ca_system_score_gemma":0.003343641,"threshold_uncertainty_score":0.08307195},"labels":[],"label_agreement":null},{"id":"W3190681024","doi":"10.21203/rs.3.rs-725738/v1","title":"An International Comparative Analysis Highlighting that Canada is Not Keeping Pace With Patient Access to Drugs for Rare Diseases","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Novartis (Canada); University of Ottawa","funders":"University of Ottawa","keywords":"Pace; Business; Medicine; Regional science; Political science; International trade; Geography","score_opus":0.19871769268058312,"score_gpt":0.43448957018199674,"score_spread":0.23577187750141362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190681024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9013878,0.022305835,0.002226175,0.0053758803,0.00018086258,0.0002043265,0.02109947,0.000040432173,0.047179177],"genre_scores_gemma":[0.9923322,0.0021432952,0.001077367,0.0005801903,0.000032351094,0.000037658818,0.0031687918,0.00001298777,0.00061511056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9910081,0.0027952157,0.0005483442,0.0010361283,0.003025042,0.0015871285],"domain_scores_gemma":[0.97610384,0.007490173,0.004922072,0.0012274513,0.008767462,0.0014890803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008283027,0.0002978741,0.0006483813,0.0046644253,0.0017121026,0.0024172592,0.0008424805,0.00046202762,0.0064726304],"category_scores_gemma":[0.029395305,0.00013703517,0.0012565324,0.012886685,0.0011502535,0.00083767483,0.0012191387,0.00066676206,0.00013355531],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020205185,0.000119375254,0.88533175,0.0013376811,0.0052342876,0.00052540447,0.002288316,0.0022460837,0.0005475253,0.019226195,0.016775353,0.0643475],"study_design_scores_gemma":[0.0002097768,0.00038001544,0.9579732,0.0013622236,0.003694645,0.0004510467,0.006970562,0.0019118484,0.00045348884,0.0012465718,0.025269791,0.00007676489],"about_ca_topic_score_codex":0.8896692,"about_ca_topic_score_gemma":0.9212447,"teacher_disagreement_score":0.9785366,"about_ca_system_score_codex":0.02146337,"about_ca_system_score_gemma":0.025706261,"threshold_uncertainty_score":0.22196114},"labels":[],"label_agreement":null},{"id":"W3191283888","doi":"10.1016/j.chest.2021.08.007","title":"Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic","year":2021,"lang":"en","type":"article","venue":"CHEST Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Agency for Healthcare Research and Quality; National Institutes of Health; Canadian Institutes of Health Research; Soochow University; Health Services Research and Development","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Business; Medicine; Virology; Infectious disease (medical specialty); Outbreak; Internal medicine","score_opus":0.18119868262674801,"score_gpt":0.358086953817939,"score_spread":0.17688827119119097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191283888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96146214,0.0016283235,0.00020178368,0.019860214,0.0002587773,0.000028139519,0.009370362,0.00001919904,0.0071711685],"genre_scores_gemma":[0.9928871,0.0005928468,0.00006839668,0.0014071828,0.00022018413,0.000012201022,0.002951357,0.000007602508,0.0018531464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870014,0.0002515882,0.00015032922,0.00017214994,0.00022909706,0.00049663725],"domain_scores_gemma":[0.9928368,0.0017753661,0.0033666808,0.00014211409,0.0008215044,0.0010575522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001158807,0.00018208132,0.00028986583,0.0007449243,0.00041016508,0.0025430033,0.00044665992,0.0023832368,0.005273054],"category_scores_gemma":[0.009146426,0.00029637894,0.0006302425,0.0013218536,0.00047396973,0.0013140335,0.0009154603,0.003005597,0.0006394827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002363612,0.00046630268,0.95858717,0.0001703724,0.000289548,0.0007668341,0.00078316836,0.004943905,0.00095193397,0.003598152,0.013742889,0.013336143],"study_design_scores_gemma":[0.00002004824,0.00008515786,0.99404716,0.000032125903,0.000020220381,0.00011334771,0.001138111,0.0015314526,0.0001638797,0.00022869022,0.0026055349,0.000014253813],"about_ca_topic_score_codex":0.07377031,"about_ca_topic_score_gemma":0.074860595,"teacher_disagreement_score":0.07377031,"about_ca_system_score_codex":0.003015857,"about_ca_system_score_gemma":0.0014746962,"threshold_uncertainty_score":0.14668185},"labels":[],"label_agreement":null},{"id":"W3193584288","doi":"","title":"Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among Regulators: A National Academies Report","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Agency (philosophy); Jurisdiction; Government (linguistics); Product (mathematics); Pharmaceutical industry; Harm; Public health; Medicine; Political science; Pharmacology; Law","score_opus":0.045676362677783994,"score_gpt":0.273355394810436,"score_spread":0.22767903213265203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193584288","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004105371,0.063761875,0.0008818364,0.82326156,0.010049076,0.00013256927,0.00053434126,0.00017333498,0.09710008],"genre_scores_gemma":[0.073873304,0.089747235,0.0045760744,0.78230506,0.008720891,0.00024811787,0.001034037,0.0001374623,0.0393579],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.96136063,0.008155895,0.002742821,0.0018105718,0.020360248,0.005569839],"domain_scores_gemma":[0.9270569,0.026681012,0.0052023707,0.0019569169,0.03143884,0.007663938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027769221,0.0006565978,0.00056151324,0.004174403,0.0059768613,0.015375684,0.0018219305,0.015186594,0.0078081866],"category_scores_gemma":[0.03349421,0.00062110124,0.0018645079,0.005712585,0.003487152,0.009421152,0.0068650846,0.0122276405,0.0016506708],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039104554,0.0001309242,0.0034397242,0.00084074493,0.0001204605,0.0004956208,0.0010391164,0.00022352539,0.0004785685,0.05767859,0.8623617,0.07315197],"study_design_scores_gemma":[0.00001539066,0.000032969587,0.0063719833,0.0006927255,0.00007120779,0.00016731431,0.0009487262,0.00012849848,0.000411342,0.0034452695,0.98766124,0.00005336183],"about_ca_topic_score_codex":0.04133595,"about_ca_topic_score_gemma":0.059273195,"teacher_disagreement_score":0.04133595,"about_ca_system_score_codex":0.014591646,"about_ca_system_score_gemma":0.054088622,"threshold_uncertainty_score":0.14685947},"labels":[],"label_agreement":null},{"id":"W3194340912","doi":"10.1016/s2214-109x(21)00287-4","title":"Determinants of access to childhood cancer medicines: a comparative, mixed-methods analysis of four Caribbean countries","year":2021,"lang":"en","type":"article","venue":"The Lancet Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Caribbean region; Environmental health; Medicine; Geography; Demography; Political science; Latin Americans; Sociology","score_opus":0.16894696253683233,"score_gpt":0.48251927669594086,"score_spread":0.3135723141591085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194340912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931994,0.00161434,0.0011796175,0.00014962132,0.000007050857,0.0014253303,0.0010536144,0.0000071094523,0.0013638262],"genre_scores_gemma":[0.9877543,0.0014373272,0.004193917,0.00028078796,0.000008684998,0.004891804,0.0010921202,0.000010889065,0.00033020982],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99196833,0.0055411793,0.00071764656,0.0004884567,0.00045847235,0.00082586677],"domain_scores_gemma":[0.9821863,0.0126048345,0.002027224,0.00083960773,0.0019481524,0.00039384604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01354727,0.0007743738,0.0011779509,0.006154027,0.002422954,0.002245531,0.0014444408,0.0009887066,0.0033538998],"category_scores_gemma":[0.023416292,0.00078229513,0.001480719,0.008900883,0.0014296059,0.0016521536,0.0036296386,0.00089996425,0.00025763107],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011605237,0.0017601259,0.7041283,0.008056399,0.0017325905,0.0024990514,0.21628003,0.0013180055,0.001847286,0.0038665037,0.0016182457,0.055732872],"study_design_scores_gemma":[0.0002670802,0.0014007515,0.5017031,0.003895307,0.0014211569,0.000545118,0.47877073,0.003207017,0.00091585086,0.001127445,0.006629314,0.00011711224],"about_ca_topic_score_codex":0.12043658,"about_ca_topic_score_gemma":0.11381193,"teacher_disagreement_score":0.12043658,"about_ca_system_score_codex":0.0064707994,"about_ca_system_score_gemma":0.005471962,"threshold_uncertainty_score":0.23947114},"labels":[],"label_agreement":null},{"id":"W3195112423","doi":"10.1016/j.jaad.2021.06.242","title":"25200 Public versus private drug insurance and psoriasis degree of severity in patients with prescribed biologics in Canada: A retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Psoriasis; Retrospective cohort study; Drug; Cohort; Private insurance; Public health insurance; Health insurance; Family medicine; Cohort study; Internal medicine; Dermatology; Pharmacology; Health care","score_opus":0.03783819804355346,"score_gpt":0.2634106845124622,"score_spread":0.22557248646890873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195112423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018735,0.0007702923,0.000077962985,0.00029054962,0.000025499905,0.00004433098,0.007231063,0.000011505859,0.0013614775],"genre_scores_gemma":[0.99479634,0.0004728802,0.00010927553,0.00023674754,0.000021777956,0.000022234233,0.0030777126,0.000010311105,0.0012528041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828595,0.00011596518,0.00012619128,0.00037540952,0.000499886,0.0005965373],"domain_scores_gemma":[0.9952721,0.00024973287,0.0013661394,0.00030465864,0.0014933984,0.0013140516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007252849,0.00053283,0.0008204069,0.0018788349,0.0027389391,0.0020667256,0.0019208218,0.0014067891,0.0040089223],"category_scores_gemma":[0.002702204,0.0010266658,0.0014785138,0.0062437793,0.0010617378,0.0007674277,0.0009208487,0.0021063616,0.0005781689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110450994,0.000039901657,0.99838054,0.000009930697,0.000096763666,0.00008222303,0.00012310775,0.000032410626,0.00007390978,0.000054533375,0.0004500381,0.0005462316],"study_design_scores_gemma":[0.00001724731,0.000033612763,0.9985555,0.000015905945,0.000058120862,0.00011814386,0.00042472832,0.0001476956,0.000028678254,0.000022593655,0.00056242786,0.000015346233],"about_ca_topic_score_codex":0.97592384,"about_ca_topic_score_gemma":0.9779482,"teacher_disagreement_score":0.024076164,"about_ca_system_score_codex":0.018438974,"about_ca_system_score_gemma":0.022763548,"threshold_uncertainty_score":0.13378471},"labels":[],"label_agreement":null},{"id":"W3195451158","doi":"10.1080/00207543.2021.1950937","title":"Data analytics in pharmaceutical supply chains: state of the art, opportunities, and challenges","year":2021,"lang":"en","type":"article","venue":"International Journal of Production Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Polytechnique Montréal","funders":"","keywords":"Supply chain; Analytics; Scopus; Data science; Computer science; Supply chain management; Economic shortage; Big data; Data analysis; Knowledge management; Business; Data mining; MEDLINE; Marketing; Government (linguistics)","score_opus":0.6582236673124685,"score_gpt":0.46822801534568353,"score_spread":0.18999565196678497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195451158","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015919939,0.8317223,0.054423906,0.08200707,0.0011701009,0.00028487176,0.0027327994,0.0002745839,0.011464386],"genre_scores_gemma":[0.1324016,0.7728339,0.081929706,0.00578175,0.0028062202,0.000408656,0.0029400287,0.00013214839,0.0007659677],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97104126,0.015769694,0.0034068616,0.002316596,0.006763178,0.00070235267],"domain_scores_gemma":[0.7453597,0.22213843,0.008500766,0.005425004,0.017017188,0.0015588708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03522533,0.0009718483,0.0020800242,0.014731922,0.001533087,0.011717799,0.0029319576,0.0026775303,0.0024354174],"category_scores_gemma":[0.07557087,0.0008926538,0.0021057473,0.030896978,0.0041577024,0.023334617,0.0043857517,0.004501962,0.0009914474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001607863,0.00014229995,0.019299177,0.04736897,0.00049503846,0.0003478745,0.003548418,0.008104613,0.0008390071,0.109772116,0.024822388,0.78509927],"study_design_scores_gemma":[0.000051802286,0.00023256062,0.010381632,0.09309997,0.00047443225,0.00091491954,0.025063986,0.026196914,0.002288402,0.31924713,0.52176535,0.00028293979],"about_ca_topic_score_codex":0.005071792,"about_ca_topic_score_gemma":0.004834702,"teacher_disagreement_score":0.03522533,"about_ca_system_score_codex":0.0034596468,"about_ca_system_score_gemma":0.009915173,"threshold_uncertainty_score":0.18629158},"labels":[],"label_agreement":null},{"id":"W3196294283","doi":"10.1177/17411343211029995","title":"Comparison of generic drug registration strategies between health Canada and Gulf Cooperation Council","year":2021,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Innovator; Product (mathematics); Health care; Business; Quality (philosophy); Political science; Finance; Law","score_opus":0.19154054837280224,"score_gpt":0.33928873365898493,"score_spread":0.1477481852861827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196294283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6887088,0.01841532,0.0022001474,0.019272363,0.00026529393,0.0011488186,0.009924563,0.00028665696,0.25977805],"genre_scores_gemma":[0.9668046,0.0051865466,0.0017394674,0.0023543455,0.00005056245,0.00011072064,0.004588134,0.000051027393,0.019114563],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9886363,0.0014165173,0.00046756663,0.000604604,0.0055923024,0.003282736],"domain_scores_gemma":[0.9839536,0.0024373098,0.0015861163,0.00041569822,0.008698087,0.0029092294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065694284,0.00031905176,0.00041982756,0.0051596505,0.0025979832,0.00465376,0.0014341322,0.00094410434,0.0064686574],"category_scores_gemma":[0.01812949,0.00026135598,0.0008524931,0.0077639446,0.0011752319,0.001046025,0.0015867059,0.001039723,0.0007430381],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035901216,0.0007843312,0.33307773,0.002061025,0.0004577193,0.0013425921,0.005597112,0.00816925,0.0026152213,0.102886856,0.13995075,0.3994674],"study_design_scores_gemma":[0.0005147316,0.00085356936,0.7451554,0.000691086,0.00040840034,0.0007819918,0.013031625,0.008541333,0.0027451606,0.0020970479,0.22495489,0.00022471696],"about_ca_topic_score_codex":0.928651,"about_ca_topic_score_gemma":0.9440965,"teacher_disagreement_score":0.9400296,"about_ca_system_score_codex":0.059970386,"about_ca_system_score_gemma":0.11164896,"threshold_uncertainty_score":0.43511766},"labels":[],"label_agreement":null},{"id":"W3197163053","doi":"","title":"Big pharma official to Congress: Force countries to pay more for drugs in new trade deals","year":2019,"lang":"en","type":"article","venue":"FOXBusiness","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug industry; Business; International trade; Political science; Law; Engineering","score_opus":0.05179029078199631,"score_gpt":0.30919942569684133,"score_spread":0.257409134914845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197163053","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012767555,0.004379179,0.0008988894,0.7787558,0.015779864,0.00014004145,0.0007405198,0.00025704634,0.18628113],"genre_scores_gemma":[0.16440874,0.0033843417,0.002987198,0.6620624,0.008375265,0.00029456505,0.00078382535,0.0003052561,0.15739848],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927873,0.0017145767,0.00027071816,0.00045412357,0.0029625755,0.0018107486],"domain_scores_gemma":[0.9816636,0.005753133,0.0014177596,0.0008384381,0.004134284,0.0061927796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014352948,0.00071769283,0.0005478577,0.0013441389,0.005957713,0.015321074,0.0014380326,0.016573107,0.03202476],"category_scores_gemma":[0.034568585,0.00039853228,0.0008037032,0.001808369,0.0029473423,0.006480909,0.0041742465,0.010210663,0.0054458515],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015464818,0.00012321577,0.0024914872,0.00012011355,0.000035895264,0.00017743018,0.0004819328,0.00015299596,0.00068080676,0.09840705,0.87659687,0.020577623],"study_design_scores_gemma":[0.00019536373,0.00008822915,0.008939381,0.0003176087,0.00004198923,0.000058511272,0.0014300635,0.000346625,0.00076665997,0.016832253,0.9709217,0.00006148137],"about_ca_topic_score_codex":0.027002607,"about_ca_topic_score_gemma":0.045934256,"teacher_disagreement_score":0.03202476,"about_ca_system_score_codex":0.0061613163,"about_ca_system_score_gemma":0.0264885,"threshold_uncertainty_score":0.10713351},"labels":[],"label_agreement":null},{"id":"W3197805492","doi":"10.1186/s12992-021-00744-x","title":"The Health Impact Fund: making the case for engagement with pharmaceutical laboratories in Brazil, Russia, India, and China","year":2021,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University","keywords":"BRIC; Business; Essential medicines; General partnership; Economic growth; Global health; Poverty; Pharmaceutical industry; Developing country; Health economics; Health policy; Health care; Economics; Finance; Emerging markets; Medicine","score_opus":0.10041900311789678,"score_gpt":0.421353670059538,"score_spread":0.3209346669416412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197805492","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005774712,0.017276397,0.00036535526,0.9584851,0.005846035,0.000028992845,0.000033727454,0.00002208865,0.012167584],"genre_scores_gemma":[0.2120918,0.013795754,0.00070862443,0.7593378,0.0051730424,0.00013117137,0.000036819245,0.00005500049,0.008670065],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9729759,0.015885493,0.0012679513,0.001790849,0.00383935,0.0042404803],"domain_scores_gemma":[0.95806104,0.030769566,0.0031361012,0.0008628932,0.003442401,0.0037280559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019261343,0.00047126444,0.0007338452,0.00084030465,0.00945736,0.009361655,0.005055389,0.027282957,0.0024022635],"category_scores_gemma":[0.043740917,0.00039434663,0.0015473415,0.0012110763,0.01305181,0.0071552033,0.005993295,0.016193563,0.00025292163],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013127958,0.000043844684,0.0027219306,0.0025492343,0.00010222105,0.010821459,0.07248336,0.0005483882,0.00070983364,0.4383119,0.43313846,0.038437963],"study_design_scores_gemma":[0.00006707173,0.000045342338,0.0027308355,0.0041026156,0.0000855563,0.00087989046,0.021252561,0.00035962506,0.00039055847,0.020772448,0.9492103,0.00010312032],"about_ca_topic_score_codex":0.07359286,"about_ca_topic_score_gemma":0.09463457,"teacher_disagreement_score":0.07359286,"about_ca_system_score_codex":0.0187247,"about_ca_system_score_gemma":0.06505712,"threshold_uncertainty_score":0.14632899},"labels":[],"label_agreement":null},{"id":"W3198450170","doi":"10.18192/uojm.v11is1.5927","title":"A Time for Change: The Argument for National Pharmacare","year":2021,"lang":"en","type":"article","venue":"University of Ottawa Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Milestone; Argument (complex analysis); Plan (archaeology); Health care; Public relations; Medicine; Political science; Medical education; History; Law","score_opus":0.09424989256261795,"score_gpt":0.30427287540805137,"score_spread":0.21002298284543341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198450170","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017457032,0.0015159058,0.00045103885,0.9535541,0.0021019098,0.000013636531,0.000041750827,0.000015609003,0.040560387],"genre_scores_gemma":[0.12700522,0.0016571989,0.0008826605,0.8472371,0.0032719718,0.00009682691,0.000046525984,0.000058304922,0.019744186],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9810002,0.007328512,0.00061587326,0.0022249413,0.005349437,0.0034812207],"domain_scores_gemma":[0.974608,0.012814413,0.0017890643,0.0015712866,0.0030539404,0.0061632195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020283189,0.0004220311,0.00080777565,0.00095402065,0.008190265,0.013265515,0.0024122635,0.03462233,0.02010085],"category_scores_gemma":[0.060867947,0.00042887084,0.00095249974,0.00095138326,0.020754881,0.019862525,0.007735845,0.0352731,0.0023614538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007423504,0.00006768789,0.0007236365,0.000071195194,0.000026203192,0.00016084514,0.0010012632,0.00013802668,0.000050131934,0.7516845,0.23476264,0.011239654],"study_design_scores_gemma":[0.0001641531,0.000053191765,0.0017144602,0.0005656958,0.000030298044,0.0002103029,0.002524121,0.00046484344,0.00014836348,0.24131776,0.7527414,0.00006550466],"about_ca_topic_score_codex":0.023459058,"about_ca_topic_score_gemma":0.023872228,"teacher_disagreement_score":0.9873448,"about_ca_system_score_codex":0.012655216,"about_ca_system_score_gemma":0.021896835,"threshold_uncertainty_score":0.10726905},"labels":[],"label_agreement":null},{"id":"W3200608261","doi":"10.1016/s1470-2045(21)00463-0","title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Queen's University; World Health Organization","keywords":"Medicine; Snowball sampling; Essential medicines; Access to medicines; Cross-sectional study; Family medicine; Developing country; Descriptive statistics; Public health; Alternative medicine; Global health; Cancer; Environmental health; Nursing; Economic growth; Pathology","score_opus":0.23093750127483378,"score_gpt":0.4812587039765077,"score_spread":0.2503212027016739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200608261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962347,0.00018663942,0.00008761339,0.00011182949,0.0000039455717,0.00008190395,0.0021699064,0.000005161803,0.001118402],"genre_scores_gemma":[0.9976737,0.00031758778,0.00021090334,0.00024980915,0.0000062626227,0.000101470076,0.0012568826,0.000003299283,0.00018004166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984738,0.0005421697,0.00027510384,0.00023287316,0.00021035448,0.00026569725],"domain_scores_gemma":[0.99544406,0.0010172882,0.0022062499,0.00024469907,0.00043669445,0.0006510707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002534082,0.00027208612,0.00041666528,0.0013160205,0.00050489965,0.0008301103,0.0003985184,0.00073496957,0.0021535442],"category_scores_gemma":[0.0046078395,0.00056780013,0.00039588526,0.002710518,0.00046844236,0.0011800892,0.0010550302,0.0007596478,0.0005599137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052515417,0.00009878442,0.9962788,0.000049827162,0.000025542886,0.000071202456,0.0011982212,0.000041820178,0.00014492133,0.000017871525,0.00044800315,0.0015724852],"study_design_scores_gemma":[0.000009480385,0.00015349909,0.9957373,0.000034099576,0.000014139238,0.00013906635,0.0032124908,0.000094990166,0.000053633725,0.000006492136,0.0005392433,0.000005516145],"about_ca_topic_score_codex":0.010081232,"about_ca_topic_score_gemma":0.009394783,"teacher_disagreement_score":0.010081232,"about_ca_system_score_codex":0.00048355767,"about_ca_system_score_gemma":0.000551632,"threshold_uncertainty_score":0.020045102},"labels":[],"label_agreement":null},{"id":"W3203471344","doi":"10.2139/ssrn.3926761","title":"Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Procurement; Pooling; Business; Instrumental variable; Developing country; Estimation; Identification (biology); Biopharmaceutical; Industrial organization; Public economics; Economics; Economic growth; Marketing; Biotechnology","score_opus":0.022270858696866028,"score_gpt":0.2632794089533283,"score_spread":0.24100855025646228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203471344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98403096,0.0060691535,0.0002853101,0.0028114326,0.000028600463,0.000011787548,0.0011798857,0.000012273065,0.00557066],"genre_scores_gemma":[0.99743867,0.0013572699,0.00004604653,0.00009143744,0.000021350186,0.0000041883454,0.00037228214,0.0000021530045,0.000666619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990829,0.00022539876,0.00007368488,0.000052692816,0.00007924391,0.00048607914],"domain_scores_gemma":[0.98962784,0.0031524247,0.0050347243,0.0001456784,0.00069420703,0.0013452295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011588769,0.0002465984,0.0005920127,0.0021760634,0.0007596148,0.0033202716,0.00036241108,0.0007670084,0.006835411],"category_scores_gemma":[0.0036897107,0.00033625547,0.0004957762,0.004274136,0.0015365916,0.0014289382,0.0019995207,0.0009917732,0.00034132416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011837835,0.0003086744,0.9353134,0.00041609397,0.00029475443,0.0014248731,0.00097304495,0.008146483,0.0004727425,0.031942084,0.0033528858,0.016171161],"study_design_scores_gemma":[0.00015509967,0.00031088656,0.9707336,0.000413638,0.00017306018,0.00043017307,0.0069239195,0.0031554468,0.0005798717,0.008878534,0.008202476,0.00004326418],"about_ca_topic_score_codex":0.027957017,"about_ca_topic_score_gemma":0.030775137,"teacher_disagreement_score":0.027957017,"about_ca_system_score_codex":0.0024648916,"about_ca_system_score_gemma":0.0023911998,"threshold_uncertainty_score":0.055588603},"labels":[],"label_agreement":null},{"id":"W3206808995","doi":"10.1016/j.lanepe.2021.100219","title":"Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review","year":2021,"lang":"en","type":"review","venue":"The Lancet Regional Health - Europe","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"European union; Authorization; Political science; Accession; Welfare economics; Humanities; Member states; Business; Geography; International trade; Economics","score_opus":0.3258325079105963,"score_gpt":0.46635105421863565,"score_spread":0.14051854630803934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206808995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006980063,0.9968376,0.00011071234,0.0006669872,0.00018605836,0.00006641559,0.00019978744,0.0000046406763,0.0012297767],"genre_scores_gemma":[0.009907821,0.9884785,0.0003244355,0.00069091853,0.00009443655,0.00016037977,0.00019284173,0.000005067473,0.00014570192],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.983853,0.0060125175,0.0055167987,0.0010378419,0.0029480364,0.0006317496],"domain_scores_gemma":[0.92488134,0.062474925,0.006686843,0.00080956344,0.004715648,0.00043164115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019307634,0.0013709337,0.0039466755,0.021893844,0.001061935,0.0068518557,0.0016128254,0.0036137344,0.0057879766],"category_scores_gemma":[0.08671001,0.0008870253,0.0040262225,0.02473145,0.0017031846,0.005517329,0.00337049,0.0017045236,0.0005604198],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019288607,0.000049341994,0.0022793207,0.7208714,0.0030975486,0.00030270955,0.0009824106,0.0005151636,0.00016410669,0.0063389507,0.007209662,0.25799644],"study_design_scores_gemma":[0.00002146261,0.000056612334,0.0032746275,0.938411,0.0041548214,0.00020156846,0.00069784006,0.000071533235,0.00014724789,0.0010211346,0.05192223,0.000019945765],"about_ca_topic_score_codex":0.007978478,"about_ca_topic_score_gemma":0.013395357,"teacher_disagreement_score":0.021893844,"about_ca_system_score_codex":0.004970252,"about_ca_system_score_gemma":0.014842111,"threshold_uncertainty_score":0.10210973},"labels":[],"label_agreement":null},{"id":"W3211053119","doi":"10.2139/ssrn.3940088","title":"Competitive Bidding in Drug Procurement: Evidence from China","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Bidding; Procurement; Business; China; Drug; Industrial organization; Marketing; Pharmacology; Medicine; Political science; Law","score_opus":0.03818976762224978,"score_gpt":0.2786745380140626,"score_spread":0.24048477039181282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211053119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949228,0.0010200295,0.000098332006,0.00050606776,0.0000045922475,0.000015433629,0.00022754727,0.0000047135622,0.0032004074],"genre_scores_gemma":[0.9987929,0.0003568424,0.00003285524,0.000091397225,0.000008715251,0.0000036189415,0.00019923238,0.0000011581568,0.0005132729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853945,0.0004346923,0.00008498967,0.000115372626,0.00036590386,0.0004595616],"domain_scores_gemma":[0.98841536,0.0048820353,0.0035857873,0.0004862084,0.0016499042,0.0009806536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002774201,0.000300378,0.0007080117,0.0016626496,0.0010814499,0.0016468853,0.00072516844,0.0007925459,0.0038142565],"category_scores_gemma":[0.0057036215,0.0002679282,0.00066254206,0.0036953506,0.0014813726,0.00076715933,0.0008846064,0.000672266,0.00029364513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015536218,0.0005539601,0.955478,0.0003652647,0.00046212616,0.0011668522,0.0015202811,0.0036667942,0.0009131796,0.006909838,0.0030727072,0.024337443],"study_design_scores_gemma":[0.00029871202,0.00042140495,0.98676854,0.000051378578,0.00039507565,0.000197786,0.002122589,0.0045019854,0.00076568057,0.0014177647,0.0030215995,0.000037510803],"about_ca_topic_score_codex":0.16128206,"about_ca_topic_score_gemma":0.20134479,"teacher_disagreement_score":0.16128206,"about_ca_system_score_codex":0.0034625875,"about_ca_system_score_gemma":0.005676407,"threshold_uncertainty_score":0.32068658},"labels":[],"label_agreement":null},{"id":"W3216045111","doi":"10.1016/j.therap.2022.05.001","title":"Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic","year":2022,"lang":"en","type":"article","venue":"Therapies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pandemic; Health literacy; Novelty; Quarter (Canadian coin); Public health; Pharmaceutical industry; Drug; Health care; Medicine; Population; Drug development; Coronavirus disease 2019 (COVID-19); Psychology; Family medicine; Public relations; Business; Disease; Environmental health; Pharmacology; Political science; Nursing; Geography; Social psychology","score_opus":0.06547488920242431,"score_gpt":0.2930643236378194,"score_spread":0.22758943443539512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216045111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9287948,0.0026968853,0.0002353927,0.057834662,0.000084658976,0.0000121975845,0.0004208873,0.000011159133,0.009909293],"genre_scores_gemma":[0.997757,0.00035194785,0.000034133565,0.0012351688,0.00012496107,0.0000031414004,0.00007001536,0.0000020634704,0.00042157044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587256,0.0018104422,0.00015078609,0.0002404615,0.00089424546,0.0010315116],"domain_scores_gemma":[0.97859657,0.010782146,0.0062547466,0.0002824531,0.0019852733,0.0020988444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055917436,0.00013722725,0.00032442348,0.0010520568,0.00087429024,0.00425285,0.0003362672,0.0027958215,0.0033936098],"category_scores_gemma":[0.017455025,0.00015656976,0.00048691424,0.0008437813,0.0015448049,0.0013601285,0.00092294626,0.0026019304,0.00017553891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002643933,0.0007624758,0.8898818,0.00018069017,0.00045099476,0.0013631793,0.0074299225,0.009857817,0.0016029598,0.031306818,0.015744591,0.03877484],"study_design_scores_gemma":[0.00007023505,0.00040243787,0.9772866,0.00011302607,0.00003729359,0.00024132057,0.005191849,0.0025146266,0.00019358781,0.0018323937,0.012051194,0.000065423956],"about_ca_topic_score_codex":0.10347998,"about_ca_topic_score_gemma":0.067313075,"teacher_disagreement_score":0.10347998,"about_ca_system_score_codex":0.009847824,"about_ca_system_score_gemma":0.003719517,"threshold_uncertainty_score":0.2057553},"labels":[],"label_agreement":null},{"id":"W3216742648","doi":"10.5639/gabij.2021.1003.016","title":"A critical review of substitution policy for biosimilars in Canada","year":2021,"lang":"en","type":"review","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Competition (biology); Business; Market competition; Public economics; Marketing; Medicine; Economics; Market economy","score_opus":0.21793994318783752,"score_gpt":0.38310764969058575,"score_spread":0.16516770650274823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216742648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011111517,0.9967667,0.000052923784,0.0017758366,0.00027190647,0.000021114924,0.00012575279,0.0000034339728,0.00087122194],"genre_scores_gemma":[0.002283564,0.9962179,0.00019284963,0.0009249277,0.000107222804,0.000019897048,0.000077964534,0.0000032683197,0.00017230015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948265,0.0009660052,0.0010203808,0.00033925887,0.0024996148,0.00034821537],"domain_scores_gemma":[0.9700523,0.013222781,0.0027815609,0.0004240959,0.012849001,0.00067015964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010047473,0.0009305852,0.0030619886,0.008630879,0.0013298494,0.0035581277,0.002489397,0.0024918814,0.004254906],"category_scores_gemma":[0.032574475,0.0007599048,0.0018463202,0.014738117,0.0015344474,0.0018516075,0.0009110369,0.00298817,0.0005976933],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003064885,0.000056479188,0.00080033817,0.203462,0.0009446386,0.0002612787,0.00039687759,0.0012568928,0.00035721075,0.01869692,0.13034853,0.6431123],"study_design_scores_gemma":[0.000060116483,0.00006958016,0.0028543377,0.18560745,0.0013567539,0.0003087146,0.00020111466,0.00017797611,0.0002464355,0.0017739042,0.80728966,0.000053830794],"about_ca_topic_score_codex":0.41025195,"about_ca_topic_score_gemma":0.52501476,"teacher_disagreement_score":0.96679574,"about_ca_system_score_codex":0.033204254,"about_ca_system_score_gemma":0.10257329,"threshold_uncertainty_score":0.815728},"labels":[],"label_agreement":null},{"id":"W3216749353","doi":"10.51731/cjht.2021.209","title":"Canadian Trends and Projections in Prescription Drug Purchases: 2001–2023","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Women's College Hospital; Nova Scotia Health Authority; University of Calgary; Institute for Clinical Evaluative Sciences; Université Laval; Queen Elizabeth II Health Sciences Centre; University of British Columbia; Public Health Ontario; University of Toronto","funders":"","keywords":"Medical prescription; Pace; Audit; Prescription drug; Specialty; Business; Annual growth %; Medicine; Family medicine; Agricultural economics; Accounting; Pharmacology; Economics; Geography","score_opus":0.0745478460040486,"score_gpt":0.30158214108106585,"score_spread":0.22703429507701725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216749353","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14957605,0.009160934,0.0019388591,0.015646022,0.00029652324,0.00014112814,0.7757243,0.00073973084,0.046776358],"genre_scores_gemma":[0.58437765,0.019088777,0.0059992624,0.002534215,0.00016134488,0.00016442516,0.36317918,0.00018941435,0.024305813],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9985857,0.000055543725,0.00009724402,0.00012298085,0.0007714826,0.00036702974],"domain_scores_gemma":[0.99398994,0.00012771532,0.00037153863,0.000063991014,0.005032143,0.00041463904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001222177,0.00089252455,0.00045112547,0.0045521534,0.001642775,0.0028099527,0.0012735042,0.00087845663,0.0075886887],"category_scores_gemma":[0.004100496,0.00047309065,0.0016673307,0.012571268,0.00039973538,0.0012050833,0.0010730348,0.0016166822,0.0024421518],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084158755,0.00019636148,0.3833767,0.0013941567,0.0007168808,0.0006386942,0.0010663626,0.029134631,0.0006021723,0.015057338,0.4783025,0.08867266],"study_design_scores_gemma":[0.000106098974,0.00007152452,0.73843265,0.00058927824,0.00024305133,0.0003660636,0.0018552624,0.031003995,0.00076151657,0.0013609541,0.22502103,0.00018861839],"about_ca_topic_score_codex":0.9963169,"about_ca_topic_score_gemma":0.9956542,"teacher_disagreement_score":0.06245548,"about_ca_system_score_codex":0.06245548,"about_ca_system_score_gemma":0.064372234,"threshold_uncertainty_score":0.4531483},"labels":[],"label_agreement":null},{"id":"W3217537576","doi":"10.1186/s40545-021-00381-0","title":"Pharmacists’ perceptions and attitudes toward drug importation into the State of Florida","year":2021,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Action plan; Pharmacist; Medicine; Family medicine; Descriptive statistics; Management","score_opus":0.09571015455046528,"score_gpt":0.40938947577119245,"score_spread":0.31367932122072717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217537576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031025,0.00011856337,0.00009312369,0.003700591,0.000009086343,0.000015225905,0.000025550493,0.000002476534,0.005725174],"genre_scores_gemma":[0.99869543,0.0003071156,0.000064326196,0.0004919748,0.000010450672,0.0000050476083,0.00001318843,8.64823e-7,0.0004115878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981823,0.0006773603,0.00008296278,0.00010587388,0.0006340059,0.0003176254],"domain_scores_gemma":[0.989829,0.003370155,0.0040594283,0.0001195251,0.0012210689,0.001400832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002444503,0.00011026324,0.00012049925,0.00076507067,0.0019357714,0.0019764344,0.00029726754,0.00091710285,0.0044889026],"category_scores_gemma":[0.012138,0.00017008327,0.00021167718,0.0005798073,0.0012082153,0.0010624713,0.0010597873,0.0010628231,0.00016856338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002558466,0.00065605436,0.85242087,0.00025629153,0.00010533874,0.0023388045,0.07969823,0.000625747,0.0032426526,0.0025308412,0.0054013007,0.052468076],"study_design_scores_gemma":[0.00002154112,0.00052322465,0.8456589,0.00019113455,0.000040543895,0.001230929,0.1362569,0.00086895825,0.00049455214,0.00037644219,0.014285442,0.000051331772],"about_ca_topic_score_codex":0.04661696,"about_ca_topic_score_gemma":0.053582605,"teacher_disagreement_score":0.04661696,"about_ca_system_score_codex":0.0021922959,"about_ca_system_score_gemma":0.0028707448,"threshold_uncertainty_score":0.09269124},"labels":[],"label_agreement":null},{"id":"W376535567","doi":"10.1155/2015/789369","title":"Antimicrobial Shortages: Another Hurdle for Clinicians","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Inland Hospital; University of Calgary; Université de Sherbrooke","funders":"","keywords":"Antimicrobial stewardship; Business; Economic shortage; Discontinuation; Intensive care medicine; Quality (philosophy); Risk analysis (engineering); Medicine; Antibiotic resistance; Antibiotics; Surgery","score_opus":0.042768933100784924,"score_gpt":0.28639386744789086,"score_spread":0.24362493434710594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W376535567","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058103894,0.005361761,0.0003431489,0.98427814,0.004007277,0.0000071247428,0.000048146925,0.000041231644,0.0053321016],"genre_scores_gemma":[0.03818626,0.023129337,0.0027741967,0.8994787,0.027898934,0.0001069726,0.00020141569,0.00017058947,0.008053614],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98574,0.005448561,0.0011370422,0.001208078,0.004167853,0.002298556],"domain_scores_gemma":[0.87276226,0.027974917,0.0069712154,0.0033260866,0.020371692,0.06859379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022855647,0.00073092605,0.0014410362,0.0016060431,0.0068054236,0.0103535475,0.003927089,0.02099469,0.06462685],"category_scores_gemma":[0.07925485,0.000865404,0.0010489383,0.0021229712,0.0063291406,0.014434455,0.008950766,0.024026643,0.020504221],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006098831,0.00010770895,0.0017937835,0.00027384257,0.000027477241,0.0005402299,0.0005756553,0.00015709327,0.00007641481,0.012564957,0.92521054,0.058611363],"study_design_scores_gemma":[0.00016839894,0.0002040447,0.003597134,0.0034003267,0.0000332274,0.0019609092,0.006920626,0.00032034586,0.000097007265,0.089459315,0.89375144,0.00008720115],"about_ca_topic_score_codex":0.008462494,"about_ca_topic_score_gemma":0.01349789,"teacher_disagreement_score":0.06462685,"about_ca_system_score_codex":0.0063325516,"about_ca_system_score_gemma":0.022466192,"threshold_uncertainty_score":0.21619833},"labels":[],"label_agreement":null},{"id":"W3859919","doi":"","title":"The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.","year":2006,"lang":"en","type":"article","venue":"Bulletin of the American Physical Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Incentive; Government (linguistics); Business; Intervention (counseling); Public economics; Drug prices; Economic interventionism; Health care; Drug; Prescription costs; Health economics; Finance; Economics; Economic growth; Medicine; Pharmacology; Political science; Nursing; Market economy","score_opus":0.004944201188767932,"score_gpt":0.19609721507417444,"score_spread":0.1911530138854065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3859919","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1193426,0.090190664,0.0014582596,0.47295094,0.00088405126,0.00009951616,0.0042695333,0.00006313704,0.31074125],"genre_scores_gemma":[0.9290256,0.033696145,0.000434356,0.0130454535,0.0006583619,0.000024726907,0.00038214144,0.000017971477,0.022715176],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99694026,0.00045518574,0.00005000343,0.00011613137,0.0012729231,0.0011654543],"domain_scores_gemma":[0.9924792,0.0026591683,0.0014221602,0.00009511049,0.002044843,0.0012995532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015988079,0.00030151708,0.00045670496,0.0011772537,0.0036156436,0.005364339,0.0007094155,0.0034722083,0.0075252177],"category_scores_gemma":[0.013593813,0.00029265686,0.0004330897,0.0027448535,0.0051106494,0.0017282087,0.0012956318,0.003097112,0.00022841562],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043718092,0.00024089031,0.057361715,0.00040344574,0.00023154487,0.0008105956,0.001051132,0.006668019,0.00028983905,0.7370292,0.14237702,0.053099405],"study_design_scores_gemma":[0.00042720782,0.00014227087,0.2985371,0.0010701178,0.00049547007,0.0005281242,0.0044466266,0.011845967,0.0006269041,0.33493835,0.34668303,0.00025885444],"about_ca_topic_score_codex":0.95356286,"about_ca_topic_score_gemma":0.96231294,"teacher_disagreement_score":0.06563627,"about_ca_system_score_codex":0.06563627,"about_ca_system_score_gemma":0.07465589,"threshold_uncertainty_score":0.4762267},"labels":[],"label_agreement":null},{"id":"W40167909","doi":"","title":"World Trade Organization: Canada First Notice to Manufacture Generic Drug for Export : Introductory Note","year":2007,"lang":"en","type":"article","venue":"International Legal Materials","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Notice; International trade; Business; Drug; World trade; Political science; Law; Medicine; Pharmacology","score_opus":0.020532945780819403,"score_gpt":0.2544194955989843,"score_spread":0.2338865498181649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W40167909","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009220073,0.0131514715,0.0014989852,0.43137753,0.035299122,0.0013850944,0.017870704,0.0008769295,0.48932013],"genre_scores_gemma":[0.030002058,0.0072482075,0.0028685618,0.23494795,0.0070743333,0.00030780447,0.0030141508,0.0003279716,0.7142089],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99406815,0.00019361233,0.00031719383,0.00036661365,0.0034456064,0.0016088842],"domain_scores_gemma":[0.9878451,0.0023828472,0.00042424226,0.00038195262,0.007877463,0.0010882748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004194025,0.0012311501,0.0011429623,0.00407565,0.009963588,0.00677045,0.003920495,0.039784987,0.03356056],"category_scores_gemma":[0.014500806,0.0016977693,0.0015357316,0.00425587,0.0028792282,0.0033860835,0.0013192961,0.014369283,0.013240596],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028775898,0.00007041841,0.000389928,0.00007641375,0.0000096991525,0.00015622038,0.00014129066,0.00010061962,0.00038971548,0.009548824,0.98507535,0.004012753],"study_design_scores_gemma":[0.000049049784,0.00003423117,0.008539982,0.00028212531,0.00003509404,0.00008603548,0.0002856963,0.00014082601,0.0006702291,0.002920331,0.98684597,0.000110519366],"about_ca_topic_score_codex":0.8906966,"about_ca_topic_score_gemma":0.94810015,"teacher_disagreement_score":0.109303415,"about_ca_system_score_codex":0.037350196,"about_ca_system_score_gemma":0.11482472,"threshold_uncertainty_score":0.27099586},"labels":[],"label_agreement":null},{"id":"W414373","doi":"","title":"Drugs Via Canada: The Side Effects Could Hurt","year":2004,"lang":"en","type":"article","venue":"Business week","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.02681023007619758,"score_gpt":0.22902740675137204,"score_spread":0.20221717667517447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W414373","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13381268,0.13054918,0.0010642682,0.15151994,0.003045332,0.00035761873,0.0071662287,0.000322017,0.5721628],"genre_scores_gemma":[0.6220811,0.07062191,0.0020495458,0.061285295,0.0009108523,0.00012396785,0.002051871,0.00009928442,0.2407761],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995003,0.00010107688,0.000027471446,0.00004933833,0.00021674111,0.00010498933],"domain_scores_gemma":[0.998678,0.00018697996,0.00018625899,0.000054643657,0.00053704245,0.00035700406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058867136,0.0002301211,0.0002447685,0.00057835487,0.0016724541,0.0012611407,0.0003577133,0.0017082528,0.03168371],"category_scores_gemma":[0.003098355,0.00012861345,0.00029503924,0.0007813229,0.00079305924,0.000460359,0.0005396293,0.0013473365,0.0038012082],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019718527,0.00026755646,0.049637686,0.0011175553,0.0001353449,0.0032805563,0.0005688362,0.00026580328,0.0042162808,0.018002424,0.31063473,0.60990137],"study_design_scores_gemma":[0.00027950134,0.00047926136,0.04984914,0.0007110322,0.00012148044,0.0030807403,0.00031143776,0.00025134318,0.00182239,0.0016169519,0.9414376,0.0000391503],"about_ca_topic_score_codex":0.3813381,"about_ca_topic_score_gemma":0.71969825,"teacher_disagreement_score":0.6186619,"about_ca_system_score_codex":0.005815511,"about_ca_system_score_gemma":0.009237384,"threshold_uncertainty_score":0.7582369},"labels":[],"label_agreement":null},{"id":"W4200104033","doi":"10.9778/cmajo.20200232","title":"Extent of a valsartan drug shortage and its effect on antihypertensive drug use in the Canadian population: a national cross-sectional study","year":2021,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Health; Women's College Hospital; University of Toronto; Alberta Health Services","funders":"","keywords":"Valsartan; Medicine; Medical prescription; Drug; Antihypertensive drug; Economic shortage; Population; Pharmacology; Internal medicine; Blood pressure; Environmental health","score_opus":0.1207520102464535,"score_gpt":0.3587804840500626,"score_spread":0.2380284738036091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200104033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98983043,0.0004433396,0.00010305098,0.00036683987,0.000014404932,0.00005938225,0.007473313,0.000011887883,0.0016973912],"genre_scores_gemma":[0.99518687,0.0003393816,0.0002776969,0.00022964628,0.000010383748,0.000030312975,0.0033708818,0.000005386751,0.00054944726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990243,0.000061213024,0.00007232991,0.00015213872,0.0004324578,0.00025763435],"domain_scores_gemma":[0.9976483,0.00013262889,0.0005644816,0.000109320754,0.0010764402,0.00046892237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009709737,0.00035102054,0.0003640635,0.0012239937,0.0019605295,0.0009087655,0.0012749345,0.0006398902,0.0021019974],"category_scores_gemma":[0.0022684874,0.00037857998,0.0009925322,0.0037369216,0.0006451925,0.00043475608,0.0006864802,0.0007857592,0.0002414553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030147265,0.00002938477,0.9979487,0.000019413797,0.00006101151,0.000020641297,0.0001913281,0.000038827868,0.00005595758,0.00002968375,0.0005971137,0.0009778782],"study_design_scores_gemma":[0.000002574439,0.000012712357,0.99910957,0.000010179909,0.00001806873,0.000020098902,0.00035223292,0.00013213132,0.000021272002,0.000005360283,0.00031132955,0.0000044453222],"about_ca_topic_score_codex":0.99065334,"about_ca_topic_score_gemma":0.9924079,"teacher_disagreement_score":0.016401595,"about_ca_system_score_codex":0.016401595,"about_ca_system_score_gemma":0.020021398,"threshold_uncertainty_score":0.11900246},"labels":[],"label_agreement":null},{"id":"W4200138363","doi":"10.54194/yqyb2454","title":"Rogue Regulator: PMPRB’s false narrative is driving dangerous drug price controls","year":2021,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Regulator; Narrative; Computer security; Drug; Criminology; Law and economics; Forensic engineering; Psychology; Computer science; Economics; Medicine; Pharmacology; Engineering; Biology; Literature; Art","score_opus":0.0505062294203681,"score_gpt":0.322771688282505,"score_spread":0.27226545886213693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200138363","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001808663,0.0018558173,0.00076898857,0.9711593,0.003851933,0.00000679851,0.0001492142,0.000059019047,0.020340195],"genre_scores_gemma":[0.15670927,0.002332282,0.0008789085,0.8096968,0.008650374,0.000027081742,0.00011577857,0.00016996404,0.021419566],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9772964,0.0043087117,0.0006384719,0.002371095,0.011723172,0.0036621322],"domain_scores_gemma":[0.93059534,0.033410262,0.0048243203,0.0032222783,0.020959854,0.006987839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02197455,0.0006760989,0.0011305995,0.0017888031,0.0065998556,0.01671576,0.0027982993,0.039086852,0.009788589],"category_scores_gemma":[0.12212459,0.0006283179,0.0009507309,0.0015117762,0.013644412,0.009080806,0.003176357,0.0378467,0.0027427254],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101756195,0.000019467107,0.0013920977,0.00007119428,0.000047063502,0.00031546582,0.00083865284,0.00029677668,0.0002749168,0.3007294,0.6852816,0.010631576],"study_design_scores_gemma":[0.000118812895,0.000041384414,0.0030272217,0.00060580706,0.00008690788,0.00026955112,0.0010962172,0.0019016918,0.0008630141,0.19566438,0.79613096,0.00019402805],"about_ca_topic_score_codex":0.22367947,"about_ca_topic_score_gemma":0.18015033,"teacher_disagreement_score":0.9817206,"about_ca_system_score_codex":0.01827935,"about_ca_system_score_gemma":0.033400577,"threshold_uncertainty_score":0.44475502},"labels":[],"label_agreement":null},{"id":"W4200344687","doi":"10.21203/rs.3.rs-1173063/v1","title":"Access to and Barriers to Access for Essential Medicines in Nephrology and Related Non-Communicable Diseases: A Scoping Review Protocol","year":2021,"lang":"en","type":"review","venue":"Research Square","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia","funders":"","keywords":"Protocol (science); Medicine; Business; Alternative medicine","score_opus":0.21578064015120194,"score_gpt":0.5493818243270466,"score_spread":0.3336011841758447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200344687","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015965715,0.04072572,0.0036109488,0.0033174492,0.0011276143,0.91276383,0.0314776,0.00021356127,0.005166734],"genre_scores_gemma":[0.0021168117,0.031392533,0.010744072,0.0009313772,0.00014952665,0.94939035,0.0028371748,0.000028928405,0.00240917],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.971823,0.00826331,0.013134443,0.0017359478,0.0037767414,0.00126656],"domain_scores_gemma":[0.94955206,0.018806782,0.01181377,0.002960213,0.015155501,0.0017116199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06177286,0.0034667843,0.009665965,0.020402377,0.0042781457,0.0075425142,0.0032076582,0.007303632,0.06998813],"category_scores_gemma":[0.0854987,0.0043660947,0.01569539,0.014866496,0.0033304794,0.005517172,0.007650361,0.0053064763,0.010219241],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016052354,0.00018824104,0.0008780484,0.88316894,0.0015585272,0.00027340368,0.0012244863,0.00056655315,0.0008042072,0.004298027,0.03202868,0.0734056],"study_design_scores_gemma":[0.0047955937,0.0005418674,0.0046034027,0.78470886,0.008363875,0.00023032285,0.0015716625,0.00023130217,0.00089237076,0.0038791236,0.18999496,0.00018663003],"about_ca_topic_score_codex":0.010287729,"about_ca_topic_score_gemma":0.035175476,"teacher_disagreement_score":0.06998813,"about_ca_system_score_codex":0.0127169,"about_ca_system_score_gemma":0.085124366,"threshold_uncertainty_score":0.32669008},"labels":[],"label_agreement":null},{"id":"W4200451039","doi":"10.3138/9781487529055-fm","title":"Frontmatter","year":2021,"lang":"en","type":"book-chapter","venue":"University of Toronto Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ECW Press (Canada); Dalhousie University","funders":"","keywords":"Computer science","score_opus":0.05705843300925302,"score_gpt":0.22454872195676284,"score_spread":0.16749028894750984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200451039","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001799013,0.001083216,0.00032988525,0.00083303085,0.0009344605,0.000018795712,0.0004849605,0.0003554229,0.99578035],"genre_scores_gemma":[0.00036545846,0.00022625084,0.00007729333,0.00023641724,0.000060621616,0.0000041377248,0.00013282968,0.00007276051,0.9988242],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997776,0.000014691999,0.0000077155155,0.00005874631,0.00011145764,0.000029717114],"domain_scores_gemma":[0.99969935,0.000057317626,0.000015334099,0.00003968527,0.00011227781,0.00007600416],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016963738,0.0007231951,0.0005112099,0.0011887318,0.0013159849,0.003618261,0.00083770556,0.002063256,0.82806253],"category_scores_gemma":[0.0008482251,0.00037276116,0.0003629039,0.0011296544,0.00040002645,0.0027130444,0.0015679118,0.0018079774,0.72609246],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021794587,0.000021855363,0.00008670996,0.000098536955,0.0000016666013,0.00010033038,0.00008891415,0.000060215476,0.00040893996,0.013873634,0.86537814,0.11985916],"study_design_scores_gemma":[0.0000018230061,0.0000032598425,0.000089338006,0.00003276956,4.6393666e-7,0.000047423662,0.000023456098,0.000023280265,0.000051813415,0.00081391097,0.9989109,0.0000016492246],"about_ca_topic_score_codex":0.0024438738,"about_ca_topic_score_gemma":0.00873565,"teacher_disagreement_score":0.17193747,"about_ca_system_score_codex":0.0010547609,"about_ca_system_score_gemma":0.00051269145,"threshold_uncertainty_score":0.24524784},"labels":[],"label_agreement":null},{"id":"W4200559252","doi":"10.1007/s40278-021-04835-4","title":"Health Canada seizes unauthorised injectable drugs, medical devices","year":2021,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Medicine","score_opus":0.038911877414166234,"score_gpt":0.2953924568948479,"score_spread":0.25648057948068165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200559252","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09314995,0.013137216,0.0025713937,0.29703116,0.0051594507,0.00036381226,0.026023872,0.0009864311,0.56157666],"genre_scores_gemma":[0.50687265,0.008041264,0.0011346252,0.044394463,0.0019917197,0.00006253498,0.0038868662,0.00019796831,0.43341792],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942684,0.0002971758,0.00011372531,0.00014429411,0.004092917,0.0010834285],"domain_scores_gemma":[0.9887481,0.0030970888,0.0015979435,0.00041007518,0.0038080693,0.0023387342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023282066,0.0004139332,0.0004125096,0.0033001818,0.0030205115,0.005754883,0.001049811,0.0055749584,0.02083999],"category_scores_gemma":[0.012884958,0.00047937903,0.0005736377,0.002173791,0.0014259686,0.0009793638,0.0008328942,0.0051152385,0.0022852283],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022930396,0.00014108642,0.016526949,0.00014438962,0.000076134216,0.00050281646,0.00024098,0.0009783322,0.0010571516,0.049136553,0.87968,0.051286284],"study_design_scores_gemma":[0.00010241106,0.00013154016,0.07227968,0.0002508285,0.00009053082,0.0004249523,0.00095825776,0.0039935843,0.0026550451,0.007251056,0.91177034,0.00009196489],"about_ca_topic_score_codex":0.9256671,"about_ca_topic_score_gemma":0.94637495,"teacher_disagreement_score":0.07433289,"about_ca_system_score_codex":0.037958223,"about_ca_system_score_gemma":0.06207092,"threshold_uncertainty_score":0.27540743},"labels":[],"label_agreement":null},{"id":"W4205538827","doi":"10.21065/19257430.168.1","title":"REVIEW OF THE BASIC COMPONENTS OF CLINICAL PHARMACEUTICAL CARE IN PAKISTAN","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Applied Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Health care; Pharmaceutical care; Developing country; Quality (philosophy); Medicine; Business; Nursing; Economic growth; Economics","score_opus":0.2463575681449729,"score_gpt":0.3929560541419099,"score_spread":0.14659848599693703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205538827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005552862,0.994393,0.00012640291,0.0018470471,0.00030211007,0.000026955371,0.00013628678,0.000004285148,0.0026085721],"genre_scores_gemma":[0.002904302,0.9957724,0.0002454408,0.00037503615,0.00027990583,0.000010091732,0.00006552868,8.310559e-7,0.00034642525],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920964,0.00016855543,0.00022686306,0.000055101445,0.0002828539,0.000056879722],"domain_scores_gemma":[0.99750143,0.0010541818,0.00055816525,0.000034227523,0.0007297976,0.00012220893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013736645,0.0004433243,0.00061875,0.004080428,0.0004218879,0.0015837378,0.00047899672,0.00057350757,0.0044324542],"category_scores_gemma":[0.00310433,0.0003386414,0.0005097465,0.0075027547,0.00047296894,0.0013595588,0.00045446295,0.00077981927,0.0005685379],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011375609,0.00007463636,0.0020311228,0.04372317,0.00012492709,0.0003525971,0.00019699239,0.0005503356,0.00035178426,0.0077707632,0.055917855,0.8887921],"study_design_scores_gemma":[0.000034736207,0.00019706503,0.025865523,0.024862902,0.0002656751,0.0015349571,0.0003528437,0.00023298746,0.00034469028,0.0019282929,0.9443435,0.000036854166],"about_ca_topic_score_codex":0.017247053,"about_ca_topic_score_gemma":0.027423143,"teacher_disagreement_score":0.017247053,"about_ca_system_score_codex":0.004040053,"about_ca_system_score_gemma":0.011238074,"threshold_uncertainty_score":0.034293354},"labels":[],"label_agreement":null},{"id":"W4205704930","doi":"10.1038/s41574-021-00621-y","title":"Global accessibility of therapeutics for diabetes mellitus","year":2022,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto","funders":"NIHR Leicester Biomedical Research Centre; Madras Diabetes Research Foundation; Universidade Federal do Rio Grande do Sul; University of Toronto; National Institute for Health and Care Research","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Type 2 Diabetes Mellitus; Health care; Endocrinology; Economic growth","score_opus":0.19314444386505936,"score_gpt":0.4247148174847424,"score_spread":0.23157037361968302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205704930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010875015,0.99664474,0.00016156262,0.0015492256,0.00014482932,0.0000018327304,0.00005610287,0.000004873802,0.0013281588],"genre_scores_gemma":[0.0019842288,0.99694186,0.00009667049,0.00039982842,0.00035250196,0.0000033773704,0.00003463768,0.0000019045362,0.00018508529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907243,0.00033132613,0.00010638923,0.0001021774,0.00030526597,0.00008241171],"domain_scores_gemma":[0.9958127,0.0028248006,0.0007796237,0.00008918118,0.00037791318,0.00011580316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002267854,0.0007585099,0.0017409539,0.0029652582,0.00015648366,0.00163354,0.00054856966,0.0014161026,0.008426306],"category_scores_gemma":[0.0060378844,0.00031027696,0.0008361107,0.004281525,0.00085271255,0.002255745,0.0014231097,0.0019672185,0.0012048113],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012338409,0.000032733245,0.00050041976,0.015048679,0.00034096107,0.00009494821,0.000036226284,0.0012298485,0.00021700146,0.024841098,0.0352282,0.9223065],"study_design_scores_gemma":[0.0000944722,0.00010748949,0.007945697,0.029432038,0.0007961144,0.0009817639,0.00012670443,0.00045604,0.00030929866,0.032525316,0.9271841,0.000041036397],"about_ca_topic_score_codex":0.0034265318,"about_ca_topic_score_gemma":0.0053219777,"teacher_disagreement_score":0.008426306,"about_ca_system_score_codex":0.0018087588,"about_ca_system_score_gemma":0.0025847047,"threshold_uncertainty_score":0.028188825},"labels":[],"label_agreement":null},{"id":"W4206302808","doi":"10.1177/171516350714000307","title":"Canadian Internet Pharmacy Sales to US Cut in Half in 2006","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Business; The Internet; Medicine; Advertising; Family medicine; World Wide Web; Computer science","score_opus":0.05936089931618948,"score_gpt":0.2892019651350632,"score_spread":0.2298410658188737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206302808","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17388126,0.028679496,0.0017121317,0.13645339,0.0077021974,0.00029921462,0.33616933,0.0026403184,0.31246272],"genre_scores_gemma":[0.5582754,0.011149582,0.002113539,0.016217953,0.0005445023,0.00009061771,0.058840558,0.0003472705,0.35242054],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99760854,0.000044696037,0.00006656414,0.0001370991,0.0014838607,0.00065929047],"domain_scores_gemma":[0.99515224,0.00013016266,0.0002175362,0.000054918535,0.0034988269,0.00094628154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083753635,0.0006094801,0.0005530274,0.0031665857,0.002754933,0.0055317273,0.0010677518,0.002138193,0.022344131],"category_scores_gemma":[0.0056589935,0.00044434858,0.0010882936,0.005127087,0.0005251509,0.0009500024,0.00082632026,0.0027205404,0.0029269534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044780527,0.00007534535,0.039296884,0.00034526704,0.00010613376,0.00024042295,0.00032473245,0.0010983975,0.00035860515,0.011471436,0.87544054,0.07079435],"study_design_scores_gemma":[0.00006553606,0.00004574766,0.24980415,0.00018701598,0.00008641542,0.0001579444,0.0008901542,0.0012965645,0.0012880127,0.0005321516,0.74559724,0.00004902034],"about_ca_topic_score_codex":0.99135816,"about_ca_topic_score_gemma":0.9957014,"teacher_disagreement_score":0.07808983,"about_ca_system_score_codex":0.07808983,"about_ca_system_score_gemma":0.105856,"threshold_uncertainty_score":0.56658405},"labels":[],"label_agreement":null},{"id":"W4206578020","doi":"10.7895/ijadr.347","title":"Correlates and comparisons of use of a variety of drugs and associated harms in various high and middle-income countries","year":2021,"lang":"en","type":"article","venue":"The International Journal of Alcohol and Drug Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Variety (cybernetics); Econometrics; Low and middle income countries; Computer science; Economics; Developing country; Artificial intelligence; Economic growth","score_opus":0.126214143375046,"score_gpt":0.35714120791997694,"score_spread":0.23092706454493095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206578020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875073,0.004031936,0.00012699254,0.0005068407,0.000059615864,0.000029265635,0.002909774,0.000004994908,0.004823204],"genre_scores_gemma":[0.996546,0.00190667,0.00011245637,0.0000694016,0.000031405165,0.000020041387,0.0009980752,0.0000032380376,0.0003127735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833554,0.00072715234,0.00028495665,0.00013398321,0.000337096,0.00018139395],"domain_scores_gemma":[0.9920465,0.0016670515,0.004185898,0.00037522687,0.0011183439,0.0006069971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001623695,0.00016279801,0.00027732068,0.0032334111,0.000670392,0.001151252,0.00033003092,0.00032050873,0.0018743845],"category_scores_gemma":[0.0059302147,0.00018852529,0.0005239238,0.0045160027,0.0006998369,0.0006331577,0.001496979,0.0004960279,0.00027937975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054506505,0.000017868168,0.99638426,0.000047419522,0.000100306366,0.00003953655,0.00032372805,0.00003946377,0.000040286857,0.00014163647,0.0004078397,0.0024031366],"study_design_scores_gemma":[0.0000012159119,0.000013681423,0.99886096,0.000027239237,0.000012210196,0.000047902926,0.00056239206,0.000018109562,0.000023271976,0.00002040109,0.00040983822,0.0000028250506],"about_ca_topic_score_codex":0.011575006,"about_ca_topic_score_gemma":0.011742032,"teacher_disagreement_score":0.011575006,"about_ca_system_score_codex":0.00038549263,"about_ca_system_score_gemma":0.0004138022,"threshold_uncertainty_score":0.02301526},"labels":[],"label_agreement":null},{"id":"W4210321301","doi":"","title":"Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe","year":2018,"lang":"en","type":"article","venue":"Archive ouverte UNIGE (University of Geneva)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":216,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Essential medicines; Economic shortage; Scopus; Antibiotic resistance; Business; Medicine; Antibiotics; Political science; Health care; MEDLINE; Biology; Law","score_opus":0.07596587356098482,"score_gpt":0.27042834704100666,"score_spread":0.19446247348002182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210321301","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032816693,0.13937534,0.023101501,0.26624924,0.013020843,0.00694861,0.18533285,0.0028493577,0.33030555],"genre_scores_gemma":[0.24132256,0.21769944,0.21889651,0.09136017,0.008159245,0.005362058,0.15149315,0.0016295268,0.06407732],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964162,0.0007230353,0.001090876,0.00013065954,0.0014017968,0.00023745505],"domain_scores_gemma":[0.9912122,0.002318899,0.001867186,0.00038969514,0.0037748546,0.00043712556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023031652,0.0005535117,0.0007951989,0.0043882555,0.0005244503,0.001997533,0.00094176224,0.0010314526,0.03168879],"category_scores_gemma":[0.030756539,0.00024440634,0.0012751016,0.0041358,0.00033124423,0.0026921956,0.001650007,0.0018069029,0.017567104],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025531623,0.00008635428,0.014899838,0.0052121524,0.00007707026,0.00020056654,0.00035251887,0.00016343573,0.00049432594,0.0033814118,0.60881734,0.36605966],"study_design_scores_gemma":[0.00015251782,0.00018528302,0.038936026,0.017039455,0.00021521182,0.0007791695,0.0011037813,0.0005384964,0.0013421064,0.00569006,0.93393284,0.000085059546],"about_ca_topic_score_codex":0.010863108,"about_ca_topic_score_gemma":0.019108385,"teacher_disagreement_score":0.03168879,"about_ca_system_score_codex":0.0012769197,"about_ca_system_score_gemma":0.006270283,"threshold_uncertainty_score":0.10600954},"labels":[],"label_agreement":null},{"id":"W4210330881","doi":"10.1016/j.ssaho.2022.100255","title":"“Health for all” and the challenges for pharmaceutical policies: A critical interpretive synthesis over 40 years","year":2022,"lang":"en","type":"article","venue":"Social Sciences & Humanities Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"","keywords":"Mainstream; Politics; Declaration; Globe; Pharmaceutical policy; Value (mathematics); Political science; Health care; Public relations; Inclusion (mineral); Health policy; Sociology; Medicine; Social science; Law; Computer science","score_opus":0.26003601200546744,"score_gpt":0.44046451460758534,"score_spread":0.1804285026021179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210330881","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010624096,0.72443867,0.007535082,0.21456608,0.0050457716,0.00013990149,0.00046386974,0.0000393929,0.037147164],"genre_scores_gemma":[0.42588645,0.5101313,0.006668462,0.040359057,0.011125473,0.00067979493,0.00037634003,0.0001381556,0.0046349433],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"systematic_review","domain_scores_codex":[0.98012537,0.015229315,0.0009068874,0.0010943856,0.0018796987,0.0007642437],"domain_scores_gemma":[0.9058077,0.08688849,0.002421151,0.0009498573,0.0035566506,0.0003761035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03156793,0.0017278903,0.0019100469,0.018045755,0.006283101,0.01995678,0.0020023144,0.0054594507,0.0032027543],"category_scores_gemma":[0.049546283,0.00047897614,0.00089033745,0.016786922,0.025024239,0.017910592,0.004174359,0.0056445203,0.00037942798],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006810055,0.000023143366,0.00051608327,0.008792115,0.00010123329,0.0004284113,0.1180023,0.000653952,0.00015359199,0.80204123,0.030834394,0.038385443],"study_design_scores_gemma":[0.000019623676,0.0000406524,0.0017944792,0.04365128,0.0001283806,0.00020849917,0.14892349,0.00073250534,0.00036702628,0.24360277,0.5604626,0.000068693],"about_ca_topic_score_codex":0.012773936,"about_ca_topic_score_gemma":0.013453243,"teacher_disagreement_score":0.03156793,"about_ca_system_score_codex":0.02864573,"about_ca_system_score_gemma":0.013506045,"threshold_uncertainty_score":0.20784032},"labels":[],"label_agreement":null},{"id":"W4210434457","doi":"10.1007/bf03275923","title":"US seniors retaliate against GSK over reduced drug supplies in Canada","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Public health; Drug; Environmental health; Business; Medicine; Pharmacology; Nursing","score_opus":0.02673352025819704,"score_gpt":0.2930338517553045,"score_spread":0.26630033149710747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210434457","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5659233,0.0034500374,0.00024313245,0.34434122,0.001099497,0.000155224,0.0014928806,0.00012116824,0.08317359],"genre_scores_gemma":[0.8809975,0.0018372176,0.0001374748,0.055652577,0.00047230086,0.000020210924,0.00032704143,0.000040323728,0.060515337],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949602,0.0002295272,0.00012959595,0.00018472513,0.0018710762,0.002624869],"domain_scores_gemma":[0.97956103,0.0025283406,0.0032027233,0.0002609503,0.005025324,0.009421665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002430285,0.0002206499,0.00045188062,0.0014327407,0.008298345,0.0046965685,0.001454398,0.0073148375,0.008077267],"category_scores_gemma":[0.015249924,0.00047406415,0.00056982884,0.0016833673,0.0024248876,0.00096492626,0.0017829855,0.0066279355,0.0006633018],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010423581,0.0004658172,0.28493512,0.00017017098,0.00017372286,0.002375937,0.006463757,0.0014048885,0.0007800996,0.015628794,0.6285164,0.058043033],"study_design_scores_gemma":[0.0006545088,0.00034421415,0.6992579,0.0003635702,0.00037142436,0.001091437,0.02908358,0.0057278303,0.0014609207,0.0033985404,0.2580034,0.00024251586],"about_ca_topic_score_codex":0.9865568,"about_ca_topic_score_gemma":0.9961175,"teacher_disagreement_score":0.06550599,"about_ca_system_score_codex":0.06550599,"about_ca_system_score_gemma":0.102610365,"threshold_uncertainty_score":0.47528142},"labels":[],"label_agreement":null},{"id":"W4210693913","doi":"10.3821/1913-701x-143.2.73.a","title":"NAPRA Directive on Sale of NHPs in Pharmacies","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Directive; Pharmacy; Business; Medicine; Family medicine; Computer science","score_opus":0.05010579447535842,"score_gpt":0.2678952313800483,"score_spread":0.21778943690468985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210693913","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018081907,0.0067728627,0.004713062,0.28374788,0.013953346,0.0013118117,0.015478267,0.0020622131,0.6538786],"genre_scores_gemma":[0.058124695,0.0029530835,0.006367028,0.43757415,0.0053322394,0.0011101589,0.0028938567,0.000388281,0.48525652],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97249687,0.003660218,0.0017342482,0.0019717298,0.015467442,0.0046695895],"domain_scores_gemma":[0.9528406,0.020871729,0.0019106417,0.0028359815,0.017547755,0.0039931973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013565091,0.0011606965,0.001678022,0.0031666171,0.004106997,0.008748088,0.0063763973,0.053092416,0.02227827],"category_scores_gemma":[0.043208983,0.0026292733,0.0034375878,0.002633254,0.0032441204,0.0030138274,0.0027851094,0.017522097,0.009987406],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005008125,0.0002732849,0.0023865725,0.00034782258,0.00007919765,0.0009686146,0.00063577143,0.00058815227,0.0038409207,0.06874846,0.904226,0.01740437],"study_design_scores_gemma":[0.00022884033,0.00012347224,0.01657175,0.00052439776,0.00008906926,0.00044148526,0.0001821826,0.0006574621,0.0010769424,0.0030525592,0.9769388,0.000113155795],"about_ca_topic_score_codex":0.40637693,"about_ca_topic_score_gemma":0.49581942,"teacher_disagreement_score":0.98664737,"about_ca_system_score_codex":0.013352622,"about_ca_system_score_gemma":0.047252,"threshold_uncertainty_score":0.8080231},"labels":[],"label_agreement":null},{"id":"W4210700769","doi":"10.1037/e533742006-001","title":"Technical Report for the Price and Purity of Illicit Drugs: 1981 Through the Second Quarter of 2003","year":2004,"lang":"en","type":"dataset","venue":"PsycEXTRA Dataset","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Economics; Business; History; Archaeology","score_opus":0.05099725095179771,"score_gpt":0.3263705390992224,"score_spread":0.27537328814742473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210700769","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018223535,0.000023334333,0.000022667587,0.000028835853,0.00000805251,0.000005711686,0.9994393,0.000055515553,0.00023430992],"genre_scores_gemma":[0.00067842414,0.00004657397,0.00010658243,0.000019276215,0.000008119789,0.000048665148,0.99774086,0.000021038046,0.0013303995],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986486,0.00010799148,0.0002303348,0.00028603364,0.0004956227,0.0002314737],"domain_scores_gemma":[0.9932875,0.0010434202,0.0017299325,0.0011510309,0.0023976264,0.00039043024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013042823,0.0020270573,0.0016822697,0.006309657,0.0007110616,0.0023574291,0.002602382,0.0019132722,0.048027124],"category_scores_gemma":[0.007682026,0.0009597158,0.0012907934,0.012394478,0.00031825734,0.0011951227,0.0011124341,0.0019144716,0.055234708],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009858165,0.000054427368,0.0038924674,0.00032443632,0.000050876853,0.000023384733,0.000018188703,0.0005024278,0.00006653113,0.0002727248,0.9915872,0.0031087347],"study_design_scores_gemma":[0.00055057975,0.00004947896,0.078908384,0.00030441632,0.00010758988,0.00009167699,0.000157599,0.0011704724,0.00095129694,0.0007769319,0.91687506,0.000056547113],"about_ca_topic_score_codex":0.15493359,"about_ca_topic_score_gemma":0.14893724,"teacher_disagreement_score":0.15493359,"about_ca_system_score_codex":0.0029024677,"about_ca_system_score_gemma":0.0048156083,"threshold_uncertainty_score":0.3080635},"labels":[],"label_agreement":null},{"id":"W4210745007","doi":"10.1136/bmj.o316","title":"Can medical product development be better aligned with global needs?","year":2022,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"World Health Organization","keywords":"Computer science; Data science; Product (mathematics); New product development; World Wide Web; Business; Marketing; Mathematics","score_opus":0.03674261430554597,"score_gpt":0.30001883262093315,"score_spread":0.26327621831538717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210745007","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004875632,0.031362664,0.00012834705,0.43884793,0.52501816,0.000024937557,0.00008938015,0.00005408343,0.0044257147],"genre_scores_gemma":[0.0013623041,0.038026575,0.00026467905,0.14972313,0.8010996,0.000039213486,0.00004064167,0.000062052284,0.009381764],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98315316,0.004117199,0.0017106329,0.0010245587,0.009138684,0.00085575297],"domain_scores_gemma":[0.9051162,0.06485676,0.003471278,0.0024957221,0.019277569,0.0047824527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02724247,0.0024035915,0.003247752,0.004472132,0.0026520719,0.0139288,0.0037251862,0.039322723,0.02249005],"category_scores_gemma":[0.12594922,0.0011510695,0.002976753,0.0025231338,0.006060233,0.015781777,0.0021797887,0.03637975,0.011873562],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024487359,0.000013719668,0.000024687231,0.0005104719,0.000023631559,0.00006483794,0.000039653318,0.00002779273,0.000026716538,0.0044009625,0.9858494,0.008993705],"study_design_scores_gemma":[0.000061215054,0.000017879393,0.0001972992,0.0013343925,0.00003729717,0.00006764494,0.000083834486,0.000096705335,0.000040557767,0.007528749,0.9905155,0.00001895074],"about_ca_topic_score_codex":0.0058270823,"about_ca_topic_score_gemma":0.009027081,"teacher_disagreement_score":0.039322723,"about_ca_system_score_codex":0.007908414,"about_ca_system_score_gemma":0.0109821,"threshold_uncertainty_score":0.14407367},"labels":[],"label_agreement":null},{"id":"W4210845468","doi":"10.1177/171516350714000209","title":"Move by US Congress Raises Risk to Canada's Drug Supply, Say Pharmacy Groups","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medicine; Drug; Family medicine; Political science; Pharmacology","score_opus":0.027318698234613158,"score_gpt":0.2602021589784698,"score_spread":0.23288346074385666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210845468","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08079425,0.0019140815,0.00038009248,0.79134125,0.0010254314,0.000045307665,0.0011306023,0.00010001324,0.1232691],"genre_scores_gemma":[0.74492717,0.0020034409,0.00036516087,0.17319281,0.0016325989,0.000034062337,0.00040890847,0.00007030237,0.07736547],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99532217,0.0004839254,0.00008155049,0.00025142662,0.0021943431,0.0016666735],"domain_scores_gemma":[0.9867748,0.0037967402,0.001823573,0.00041302797,0.0036604102,0.0035314732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002744706,0.00028936082,0.0004843583,0.0012564576,0.008768377,0.011510032,0.0008024276,0.011678961,0.017217295],"category_scores_gemma":[0.025487157,0.00027840657,0.00083700503,0.0018880687,0.0025728557,0.0023825285,0.0016088026,0.0059623853,0.0010478392],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029978636,0.00021217874,0.0937102,0.000070074035,0.00017451581,0.0005717288,0.002507572,0.0021314605,0.00038737195,0.15569933,0.7096222,0.034613546],"study_design_scores_gemma":[0.00028789483,0.00016101316,0.107691385,0.00027640274,0.0003823904,0.00023468267,0.009705255,0.0043666544,0.0013008404,0.07103786,0.8043527,0.00020292414],"about_ca_topic_score_codex":0.8639641,"about_ca_topic_score_gemma":0.90673393,"teacher_disagreement_score":0.13603592,"about_ca_system_score_codex":0.03491728,"about_ca_system_score_gemma":0.075679265,"threshold_uncertainty_score":0.27367407},"labels":[],"label_agreement":null},{"id":"W4210984771","doi":"10.1136/bmjopen-2021-053349","title":"Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO","year":2022,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Hamilton Regional Laboratory Medicine Program; McMaster University; Impact","funders":"Foreign, Commonwealth and Development Office; Irish Aid; European Commission; National Institute for Health and Care Research; Ministère de l'Europe et des Affaires Étrangères; World Health Organization","keywords":"Medicine; Alternative medicine; Selection (genetic algorithm); Family medicine; MEDLINE; Traditional medicine; Pathology","score_opus":0.12780785009405132,"score_gpt":0.44134294264697743,"score_spread":0.3135350925529261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210984771","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32259375,0.48195356,0.009722845,0.00652074,0.0010541539,0.002725113,0.1644781,0.00046252817,0.010489175],"genre_scores_gemma":[0.8154181,0.097679034,0.019926853,0.003191171,0.00034532815,0.003390462,0.05929622,0.0002593497,0.0004934305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.93598944,0.017812677,0.027749272,0.0067292643,0.010865367,0.00085389445],"domain_scores_gemma":[0.780577,0.1298289,0.057427887,0.009243499,0.021544496,0.0013782087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.046497438,0.0006800914,0.003060318,0.025170738,0.00055517134,0.0019186528,0.0017408048,0.0008619591,0.0024544273],"category_scores_gemma":[0.17097344,0.0005770257,0.0053145364,0.03205203,0.0012855644,0.0035236194,0.003435984,0.0010551563,0.00034079773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002198574,0.00006253306,0.55999464,0.16084065,0.026075164,0.0001759994,0.0032745132,0.00089710875,0.0008605503,0.0019454486,0.023077272,0.22059746],"study_design_scores_gemma":[0.00063365285,0.0004391789,0.8080423,0.10433091,0.022864558,0.0007453616,0.0034680555,0.0015583911,0.0009940515,0.001893521,0.05481113,0.00021888893],"about_ca_topic_score_codex":0.011705625,"about_ca_topic_score_gemma":0.020714695,"teacher_disagreement_score":0.046497438,"about_ca_system_score_codex":0.0026114364,"about_ca_system_score_gemma":0.0064623808,"threshold_uncertainty_score":0.24590486},"labels":[],"label_agreement":null},{"id":"W4212892338","doi":"10.3390/curroncol29020100","title":"Treatment Access, Health Economics, and the Wave of a Magic Wand","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Drug prices; Medicine; Magic bullet; Inflation (cosmology); Economic shortage; Health economics; Government (linguistics); Public economics; Actuarial science; Economics; Public health; Bioinformatics","score_opus":0.31686726860562864,"score_gpt":0.42542248772631214,"score_spread":0.1085552191206835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212892338","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024417812,0.03826573,0.0061135497,0.84013563,0.0010076795,0.00003301581,0.0002849874,0.000035842084,0.08970582],"genre_scores_gemma":[0.8429115,0.03605563,0.0030446874,0.093156636,0.0059260367,0.000100820565,0.00015604973,0.000056461766,0.0185921],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805826,0.00096124155,0.00005082427,0.0001325611,0.00048462415,0.00031248367],"domain_scores_gemma":[0.9902508,0.0067278533,0.0008946165,0.00026252307,0.00070476066,0.0011594899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004557236,0.00024754964,0.00045718323,0.0015619352,0.0014806908,0.0056144698,0.0004740129,0.0039218324,0.014168989],"category_scores_gemma":[0.015853886,0.00021735037,0.00029189276,0.0013671903,0.00815137,0.0058803884,0.0021315527,0.0058912137,0.00057604077],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007492778,0.00006895947,0.0043252893,0.00008158473,0.000029088047,0.00014538602,0.00026764386,0.0010845584,0.000073857795,0.9143771,0.0396283,0.039843224],"study_design_scores_gemma":[0.000055694072,0.000046457204,0.008042517,0.0003691211,0.000015483009,0.00028162744,0.0008102694,0.0015888552,0.00006956847,0.903924,0.08475871,0.000037685568],"about_ca_topic_score_codex":0.012471428,"about_ca_topic_score_gemma":0.007908036,"teacher_disagreement_score":0.014168989,"about_ca_system_score_codex":0.00639365,"about_ca_system_score_gemma":0.0031700777,"threshold_uncertainty_score":0.047399938},"labels":[],"label_agreement":null},{"id":"W4214578304","doi":"10.1002/9780470041000.cedt101","title":"Pharmaceutical Pricing and Reimbursement in Canada","year":2006,"lang":"en","type":"other","venue":"Wiley Handbook of Current and Emerging Drug Therapies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Currency; Business; European market; Market size; International trade; Health care; Economics; Commerce; Economic growth; Monetary economics","score_opus":0.0360708801900133,"score_gpt":0.28192519576755565,"score_spread":0.24585431557754234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214578304","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036761045,0.18552239,0.0024247223,0.12767684,0.0020169863,0.00016602108,0.0059233694,0.00030515762,0.6392035],"genre_scores_gemma":[0.5703267,0.22440805,0.0074170153,0.019791596,0.0019066674,0.00009089116,0.0045668003,0.0001810787,0.1713112],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960984,0.0002360168,0.00012285846,0.00018251294,0.0027531993,0.00060693984],"domain_scores_gemma":[0.9946549,0.0007338322,0.00026195715,0.00009858964,0.0034515518,0.0007992645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016697819,0.0002842319,0.0003183417,0.0037018217,0.0023859083,0.0059052436,0.0009838097,0.0017641322,0.012512168],"category_scores_gemma":[0.008790718,0.00023325214,0.00041834838,0.009079236,0.0013424967,0.0011231514,0.000960428,0.0016824355,0.0009295661],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058817168,0.00008024165,0.0119349705,0.0006042053,0.000032042877,0.0007476909,0.00095773226,0.0037413293,0.0003780207,0.2462685,0.36812118,0.36707523],"study_design_scores_gemma":[0.000031328997,0.000029675452,0.042848486,0.0010703487,0.000029891087,0.00045101537,0.0008388641,0.003581998,0.00037457942,0.016635977,0.93402946,0.000078389254],"about_ca_topic_score_codex":0.97492,"about_ca_topic_score_gemma":0.9726564,"teacher_disagreement_score":0.082832076,"about_ca_system_score_codex":0.082832076,"about_ca_system_score_gemma":0.13075894,"threshold_uncertainty_score":0.6009916},"labels":[],"label_agreement":null},{"id":"W4214855737","doi":"10.1017/9781108975759.005","title":"The Harrington Discovery Institute and Alzheimer’s Disease Drug Development","year":2022,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Portfolio; Disease; Drug discovery; Medicine; Drug development; Action (physics); Engineering ethics; Political science; Drug; Business; Engineering; Pharmacology; Bioinformatics; Pathology; Finance","score_opus":0.05975326701860171,"score_gpt":0.22219423513874004,"score_spread":0.16244096812013833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214855737","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023957899,0.20046476,0.0019349379,0.026027692,0.0034393056,0.00003267536,0.000231964,0.00014544511,0.7674836],"genre_scores_gemma":[0.012113669,0.15092374,0.0029828867,0.010264275,0.0019690988,0.000109061286,0.00024449022,0.00013714332,0.8212556],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988123,0.00024205499,0.000041054347,0.00017847437,0.00062243914,0.00010355362],"domain_scores_gemma":[0.9990779,0.0004112874,0.00007278746,0.00008569567,0.00022718994,0.00012510989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013089086,0.0009591577,0.0005062729,0.0022271262,0.0014898741,0.006404698,0.0010050304,0.0033117158,0.048359115],"category_scores_gemma":[0.0027897803,0.00050522346,0.000337495,0.0035797413,0.0028846709,0.005203083,0.0018974141,0.0046351864,0.02030894],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016028764,0.000016388576,0.00006594438,0.0001692135,0.0000035987298,0.00004630281,0.000092436785,0.000239268,0.00006132295,0.31906012,0.6143002,0.06592924],"study_design_scores_gemma":[0.0000041590333,0.0000044839985,0.00006391419,0.00012944655,0.0000014753457,0.00005200649,0.000019903706,0.00006693425,0.0000351546,0.026687289,0.97293067,0.000004516328],"about_ca_topic_score_codex":0.008609742,"about_ca_topic_score_gemma":0.012683483,"teacher_disagreement_score":0.048359115,"about_ca_system_score_codex":0.007258412,"about_ca_system_score_gemma":0.0056463513,"threshold_uncertainty_score":0.16177738},"labels":[],"label_agreement":null},{"id":"W4220701728","doi":"10.1016/j.vhri.2022.01.006","title":"Prevalence and Factors Associated With Out-of-Pocket Pharmaceutical Expenditure Among Primary Healthcare Patients: Evidence From the Prover Project","year":2022,"lang":"en","type":"article","venue":"Value in Health Regional Issues","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fundação Oswaldo Cruz; Fundação de Amparo à Pesquisa do Estado de Minas Gerais","keywords":"Medicine; Confidence interval; Odds ratio; Logistic regression; Descriptive statistics; Family medicine; Health care; Environmental health; Population; Internal medicine","score_opus":0.2302382974945727,"score_gpt":0.37134424277588074,"score_spread":0.14110594528130804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220701728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645054,0.0004506946,0.000055038767,0.00029081097,0.0000050991134,0.000013594446,0.001633958,0.0000025440227,0.0010976666],"genre_scores_gemma":[0.99861205,0.00034988995,0.000040296884,0.00006126957,0.000015781736,0.000010525091,0.0006963567,0.0000020194514,0.00021182549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980844,0.0009923497,0.00017813557,0.00014029664,0.0003041694,0.00030077368],"domain_scores_gemma":[0.9852106,0.004792929,0.00742651,0.0005795953,0.00073732185,0.0012530892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019527235,0.00023450334,0.00038339797,0.0013117995,0.0003729085,0.001080955,0.0006127671,0.000667498,0.0034456225],"category_scores_gemma":[0.013644496,0.00035634247,0.00062577776,0.0029939758,0.0005751602,0.00085568905,0.0012616039,0.0008916028,0.00032868359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001854982,0.0001364275,0.99736387,0.00002652907,0.00005885125,0.000026351827,0.00013021342,0.000023836903,0.0000211232,0.000066347624,0.00036738053,0.0015935872],"study_design_scores_gemma":[0.00000828924,0.00005406584,0.9993326,0.000012600397,0.000022277778,0.000040584335,0.00030514607,0.00007264933,0.000009659382,0.000026371988,0.00011390085,0.0000018535969],"about_ca_topic_score_codex":0.018654263,"about_ca_topic_score_gemma":0.014460248,"teacher_disagreement_score":0.018654263,"about_ca_system_score_codex":0.00053692673,"about_ca_system_score_gemma":0.0006663272,"threshold_uncertainty_score":0.037091374},"labels":[],"label_agreement":null},{"id":"W4220736806","doi":"10.1136/bmj.o693","title":"High US drug prices have global implications","year":2022,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Drug; Drug prices; Business; Economics; Medicine; Monetary economics; Pharmacology","score_opus":0.04113243283835117,"score_gpt":0.33308069017508357,"score_spread":0.2919482573367324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220736806","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002615433,0.006275409,0.00007645358,0.06342924,0.9282789,0.000023193848,0.00017514273,0.00004386472,0.0016716102],"genre_scores_gemma":[0.00043785165,0.0048413053,0.000097770564,0.03923937,0.9487761,0.00004028942,0.000059698727,0.000042815034,0.006464872],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9853698,0.003313357,0.0018897674,0.0011329968,0.0074560847,0.0008378805],"domain_scores_gemma":[0.9201551,0.04655153,0.0044013816,0.0021945166,0.020876156,0.0058212955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018123338,0.0060084006,0.007372362,0.00810995,0.0052170516,0.014879374,0.0054423506,0.04158257,0.026821135],"category_scores_gemma":[0.08740985,0.002656606,0.0048961085,0.005811063,0.004236704,0.006107772,0.0023637377,0.033203624,0.01584951],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032304113,0.000008171007,0.000018636358,0.00025653586,0.000035296416,0.000042104868,0.000007801442,0.00001590262,0.00001192522,0.00022151503,0.9974112,0.0019384882],"study_design_scores_gemma":[0.0004024304,0.000050228107,0.0007744878,0.0018965005,0.00041540948,0.00018374674,0.00009525677,0.00039696755,0.00012078825,0.004193821,0.99141544,0.000054940545],"about_ca_topic_score_codex":0.008844704,"about_ca_topic_score_gemma":0.022197384,"teacher_disagreement_score":0.04158257,"about_ca_system_score_codex":0.0074416213,"about_ca_system_score_gemma":0.008303173,"threshold_uncertainty_score":0.095846534},"labels":[],"label_agreement":null},{"id":"W4220994714","doi":"10.4212/cjhp.v75i1.3090","title":"Gestion des approvisionnements en médicaments pendant la pandémie de COVID-19 : expérience québécoise en établissement de santé","year":2022,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Centre intégré de santé et de services sociaux de la Montérégie-Centre; Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache; Université de Montréal; Santé Montérégie; Montreal Heart Institute; Centre hospitalier universitaire de Québec; Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Medicine; Political science; Virology; Infectious disease (medical specialty)","score_opus":0.04156462629408934,"score_gpt":0.3117706846471695,"score_spread":0.27020605835308015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220994714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881281,0.0013350577,0.00023940456,0.0030501108,0.000066719054,0.00018235063,0.00022419267,0.00002073001,0.0067534023],"genre_scores_gemma":[0.97584176,0.0019034004,0.0010007018,0.0017787343,0.00006496837,0.00015103495,0.00033853675,0.000024274152,0.018896623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983107,0.00052560103,0.00007278791,0.000120771845,0.00039819608,0.00057194877],"domain_scores_gemma":[0.99340326,0.0014595779,0.0007508207,0.00015261414,0.0013817543,0.0028520015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024475034,0.00034580578,0.00041665256,0.00039385483,0.0036562055,0.0015949203,0.00064309663,0.0015517657,0.003116269],"category_scores_gemma":[0.007078,0.0003402874,0.0004640332,0.0005736852,0.00093040784,0.00059967506,0.0011066584,0.0020061878,0.00043391454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004794073,0.013623095,0.42675397,0.0005379178,0.000373683,0.009835863,0.0859809,0.0014237242,0.008193523,0.0019594776,0.026488159,0.42003557],"study_design_scores_gemma":[0.0006655056,0.0077144178,0.8844422,0.00032379894,0.0002002088,0.0017542549,0.02448758,0.0015132788,0.0025055725,0.00030458852,0.07595315,0.0001353957],"about_ca_topic_score_codex":0.6651893,"about_ca_topic_score_gemma":0.7796819,"teacher_disagreement_score":0.98851144,"about_ca_system_score_codex":0.01148853,"about_ca_system_score_gemma":0.017794767,"threshold_uncertainty_score":0.6735649},"labels":[],"label_agreement":null},{"id":"W4221078239","doi":"10.3390/diabetology3010014","title":"Availability and Affordability of Medicines for Diabetes and Cardiovascular Disease across Countries: Information Learned from the Prospective Urban Rural Epidemiological Study","year":2022,"lang":"en","type":"article","venue":"Diabetology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Epidemiology; Environmental health; Medicine; Disease; Diabetes mellitus; Developing country; Prospective cohort study; Incidence (geometry); Cohort; Economic growth; Geography; Socioeconomics; Economics; Internal medicine","score_opus":0.05058501668805227,"score_gpt":0.29279513372318944,"score_spread":0.24221011703513717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221078239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82520694,0.041062742,0.0040199463,0.07288964,0.0005006605,0.000086288805,0.042613953,0.000038040158,0.013581882],"genre_scores_gemma":[0.9656258,0.017830929,0.0021162678,0.0036169821,0.00063364155,0.00007670833,0.009339424,0.000023595077,0.00073661807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99577725,0.0026666883,0.0005430631,0.00032481103,0.0004717071,0.00021642879],"domain_scores_gemma":[0.9433231,0.037562996,0.009000255,0.004394243,0.003755641,0.0019637966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008554277,0.00026195793,0.00051934127,0.0019047027,0.00027173638,0.0010453097,0.00045532567,0.0005006371,0.0029172336],"category_scores_gemma":[0.039379537,0.0002875567,0.00091113365,0.004984391,0.0004800441,0.0015534275,0.0014624149,0.0017789064,0.00026757258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034592763,0.00014552857,0.9079803,0.00080440514,0.0014501755,0.00022913687,0.0013263177,0.0014600545,0.00009339658,0.0033961048,0.026378881,0.05638962],"study_design_scores_gemma":[0.000071295166,0.00019942528,0.9714266,0.000731261,0.00059482007,0.00024362617,0.0018881027,0.0013568454,0.00011820201,0.0035389874,0.019778363,0.000052442316],"about_ca_topic_score_codex":0.026889892,"about_ca_topic_score_gemma":0.02087399,"teacher_disagreement_score":0.026889892,"about_ca_system_score_codex":0.00041643973,"about_ca_system_score_gemma":0.00092207425,"threshold_uncertainty_score":0.053466737},"labels":[],"label_agreement":null},{"id":"W4223889261","doi":"10.1016/j.ijindorg.2022.102841","title":"R&amp;D competition and the direction of innovation","year":2022,"lang":"en","type":"article","venue":"International Journal of Industrial Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"Social Sciences and Humanities Research Council of Canada","keywords":"Social planner; Competition (biology); Subsidy; Context (archaeology); Distortion (music); Economics; Industrial organization; Ex-ante; Value (mathematics); Planner; Value creation; Coronavirus disease 2019 (COVID-19); Microeconomics; Business; Market economy","score_opus":0.07693062535061311,"score_gpt":0.28164557783853095,"score_spread":0.20471495248791782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223889261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52272177,0.00709979,0.020602709,0.025922049,0.0004162367,0.00007833784,0.0009735296,0.00013989305,0.42204562],"genre_scores_gemma":[0.99145365,0.0007472661,0.0009649301,0.00033986717,0.000098286204,0.000006895906,0.000057448655,0.000010813478,0.0063208477],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9985404,0.000687687,0.00006708909,0.00015832466,0.00033313475,0.00021326805],"domain_scores_gemma":[0.9876502,0.0077367886,0.0016449724,0.00031969175,0.0015261673,0.0011221027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028800168,0.00018417103,0.00029011382,0.0011832071,0.0005434199,0.00528984,0.0004880511,0.0017000675,0.011793254],"category_scores_gemma":[0.014204601,0.00016537108,0.00030451457,0.0009224355,0.0014294751,0.0019359842,0.0006999796,0.0012015696,0.0012936501],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008408378,0.0002920124,0.05976289,0.00018591528,0.00006948359,0.00035896618,0.0003668648,0.010427401,0.0024944749,0.8575058,0.010003462,0.05769176],"study_design_scores_gemma":[0.0006037899,0.00041681348,0.059026744,0.00014303668,0.00010170561,0.0004945165,0.001194612,0.025177263,0.0032726957,0.85691464,0.052584585,0.00006959593],"about_ca_topic_score_codex":0.0024741478,"about_ca_topic_score_gemma":0.0034883355,"teacher_disagreement_score":0.011793254,"about_ca_system_score_codex":0.0016642902,"about_ca_system_score_gemma":0.002540043,"threshold_uncertainty_score":0.039452374},"labels":[],"label_agreement":null},{"id":"W4223997537","doi":"10.54194/gcap7754","title":"Access to new medicines in Canada 2016-2021 Federal-provincial public drug programs and private sector drug plans","year":2022,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Private sector; Public administration; Drug; Public sector; Public health; Business; Political science; Medicine; Pharmacology; Law; Nursing","score_opus":0.07772323839453224,"score_gpt":0.31431870365319126,"score_spread":0.23659546525865902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223997537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38957375,0.021577405,0.00080046133,0.18914108,0.0018712534,0.00049491297,0.28423038,0.00031120467,0.111999534],"genre_scores_gemma":[0.8541801,0.011141659,0.0014443349,0.011614149,0.00047935147,0.00015467068,0.05628901,0.00008932865,0.064607374],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9928699,0.00015281845,0.00022715052,0.00032497064,0.0035992812,0.0028258276],"domain_scores_gemma":[0.9880183,0.00040568007,0.0011264344,0.00009144875,0.005406945,0.0049512126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018769534,0.000538978,0.0009370882,0.0030299027,0.0037530917,0.005955107,0.0020452985,0.0017131665,0.01089196],"category_scores_gemma":[0.007184279,0.0006227974,0.0017596185,0.0060757627,0.001226923,0.0017652854,0.00268265,0.0038611563,0.00081851636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010517031,0.0005231465,0.37358227,0.0009805704,0.00070262677,0.0005737979,0.0019257438,0.005181529,0.00050307676,0.044398863,0.47802117,0.0925556],"study_design_scores_gemma":[0.0002569191,0.00009415628,0.7738161,0.00076022785,0.00021576979,0.00018712503,0.0033458287,0.0037364631,0.0006783388,0.0024013643,0.21436842,0.0001392283],"about_ca_topic_score_codex":0.99845517,"about_ca_topic_score_gemma":0.9993247,"teacher_disagreement_score":0.7843782,"about_ca_system_score_codex":0.21562184,"about_ca_system_score_gemma":0.25992742,"threshold_uncertainty_score":0.9097675},"labels":[],"label_agreement":null},{"id":"W4224019748","doi":"10.3390/curroncol29040204","title":"Access Denied? The Unintended Consequences of Pending Drug Pricing Rules","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; Essar Steel Algoma (Canada); University of Ottawa; Jewish General Hospital; Ottawa Hospital","funders":"Seagen; Pfizer; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Government (linguistics); Cornerstone; Medicine; Unintended consequences; Drug pricing; Clinical trial; Health care; Duty; Business; Medical emergency; Actuarial science; Law; Political science","score_opus":0.2949148983371442,"score_gpt":0.4304033890130218,"score_spread":0.1354884906758776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224019748","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057200324,0.0056236745,0.004748513,0.70290846,0.0010048184,0.00007327543,0.00097531616,0.000065247266,0.22740032],"genre_scores_gemma":[0.823285,0.0066403095,0.0019654445,0.13998796,0.002519433,0.000071928254,0.00026650424,0.00008001199,0.025183365],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98667544,0.003058636,0.000647886,0.0011174345,0.0057610082,0.002739671],"domain_scores_gemma":[0.93558013,0.040995512,0.0059488197,0.0032955932,0.010456646,0.003723365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017886778,0.00020256218,0.00075745536,0.0012912079,0.0047587985,0.009296503,0.0018556984,0.009844863,0.011967512],"category_scores_gemma":[0.07575668,0.00040864688,0.00068575627,0.0016973991,0.011288053,0.006896587,0.0026660198,0.012098128,0.0009789948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010009814,0.00007631946,0.0091187395,0.00004877668,0.000031282398,0.00079232303,0.0011765953,0.0008970964,0.000116177005,0.8762815,0.08519078,0.026170205],"study_design_scores_gemma":[0.00011367952,0.000047973073,0.014326438,0.00045864738,0.00007720839,0.00085748744,0.002580818,0.00430855,0.00037283325,0.7687191,0.20797572,0.00016152603],"about_ca_topic_score_codex":0.25275838,"about_ca_topic_score_gemma":0.19461583,"teacher_disagreement_score":0.25275838,"about_ca_system_score_codex":0.013240491,"about_ca_system_score_gemma":0.02017222,"threshold_uncertainty_score":0.5025743},"labels":[],"label_agreement":null},{"id":"W4224020286","doi":"10.17749/2070-4909/farmakoekonomika.2022.107","title":"The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies","year":2022,"lang":"en","type":"article","venue":"FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical Practice; Quarter (Canadian coin); Economic evaluation; Russian federation; Quality (philosophy); Actuarial science; Accounting; Family medicine; Business; Pathology","score_opus":0.277111289096794,"score_gpt":0.5229341812689959,"score_spread":0.24582289217220193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224020286","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24815112,0.5306375,0.059647646,0.052271802,0.0029546493,0.01648367,0.02885592,0.00024951712,0.06074826],"genre_scores_gemma":[0.8595347,0.06465374,0.053950515,0.005242052,0.0015789062,0.008382242,0.005445297,0.00006991605,0.0011426503],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.51806647,0.39050987,0.04365116,0.009295548,0.035749055,0.0027279332],"domain_scores_gemma":[0.283052,0.5154487,0.1066383,0.035798747,0.055720717,0.0033416236],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2969014,0.0006612827,0.0021574148,0.008874823,0.0009156003,0.0070618796,0.0024649573,0.0025534579,0.0036591685],"category_scores_gemma":[0.3563907,0.00057974627,0.0021843964,0.011496487,0.0026078904,0.0029964608,0.0022095994,0.0013252092,0.00054664107],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077119917,0.0007621577,0.2506849,0.10690491,0.008854495,0.0008923916,0.0023497322,0.010364287,0.0029683844,0.037892886,0.02210055,0.54851323],"study_design_scores_gemma":[0.0032406321,0.0065112337,0.54492456,0.12513907,0.011743506,0.002846379,0.004002007,0.012023705,0.010932321,0.023785722,0.25440228,0.00044863843],"about_ca_topic_score_codex":0.0037033802,"about_ca_topic_score_gemma":0.0035748242,"teacher_disagreement_score":0.2969014,"about_ca_system_score_codex":0.006356155,"about_ca_system_score_gemma":0.026974337,"threshold_uncertainty_score":0.86704576},"labels":[],"label_agreement":null},{"id":"W4224222628","doi":"10.1016/j.lanepe.2022.100375","title":"European governments should align medicines pricing practices with global transparency norms and legal principles","year":2022,"lang":"en","type":"article","venue":"The Lancet Regional Health - Europe","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Vlaamse Interuniversitaire Raad","keywords":"Transparency (behavior); Business; Accounting; Law and economics; Political science; Economics; Law","score_opus":0.2568805748780021,"score_gpt":0.36279313596244495,"score_spread":0.10591256108444286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224222628","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011002647,0.0063999975,0.01816376,0.8492281,0.0033599488,0.00012842393,0.00023468537,0.0003900723,0.111092426],"genre_scores_gemma":[0.40971875,0.0049811695,0.053193923,0.5126787,0.0029007008,0.0003502096,0.00047166902,0.00037266928,0.015332202],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.94772714,0.022705873,0.0043433695,0.0036003904,0.015590352,0.006032847],"domain_scores_gemma":[0.9235151,0.03795212,0.009203481,0.01057717,0.015629584,0.0031225889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07770711,0.0008172908,0.0014271296,0.0021415895,0.0025129546,0.015859436,0.0033961136,0.02542484,0.0044816253],"category_scores_gemma":[0.12382636,0.00072824577,0.0022743943,0.0029369828,0.010411158,0.018096002,0.008451846,0.01804728,0.0010933226],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059376034,0.00007073075,0.0007937204,0.00014826401,0.00004307123,0.000117090225,0.0009935169,0.0015434833,0.00019847865,0.9311669,0.04599976,0.018865611],"study_design_scores_gemma":[0.0001541644,0.00006571229,0.0028869421,0.0007556769,0.000041668172,0.00017247097,0.0009819234,0.001641783,0.000617321,0.6486156,0.3439568,0.000109884924],"about_ca_topic_score_codex":0.010012427,"about_ca_topic_score_gemma":0.006401828,"teacher_disagreement_score":0.07770711,"about_ca_system_score_codex":0.008952446,"about_ca_system_score_gemma":0.021524273,"threshold_uncertainty_score":0.41095942},"labels":[],"label_agreement":null},{"id":"W4225016550","doi":"10.51731/cjht.2022.321","title":"Harmonization of Public Coverage Policies for Biologic Drugs in the Treatment of Rheumatoid Arthritis","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Department of Veterans Affairs","keywords":"Veterans Affairs; Medicine; Public administration; Political science; Internal medicine","score_opus":0.09433791284355138,"score_gpt":0.2939799318032812,"score_spread":0.19964201895972983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225016550","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05029925,0.008155507,0.063845016,0.40015122,0.008628426,0.01094522,0.009227119,0.0031315815,0.44561672],"genre_scores_gemma":[0.367785,0.0048212544,0.11102344,0.39561275,0.0041669747,0.012824072,0.012733149,0.0010040627,0.09002931],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9215314,0.026802097,0.0062696724,0.004598843,0.028090445,0.012707585],"domain_scores_gemma":[0.8746778,0.035715822,0.010353473,0.0120678125,0.049915724,0.017269403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.108161904,0.00078477326,0.0011879982,0.004605741,0.0027715282,0.01031301,0.0072605703,0.0097473515,0.012221739],"category_scores_gemma":[0.11670044,0.0013475124,0.0027325817,0.0036626938,0.0027737683,0.0054089515,0.007974935,0.008048385,0.0032899946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006831207,0.0011971323,0.016876128,0.0009664528,0.00032179386,0.00043087025,0.0034785038,0.007927751,0.003546504,0.16365093,0.57682365,0.2240972],"study_design_scores_gemma":[0.00067960104,0.0005133074,0.047006156,0.0022823398,0.00016349186,0.00023229855,0.0020299666,0.004303042,0.001676574,0.01987097,0.9210375,0.0002047501],"about_ca_topic_score_codex":0.063116014,"about_ca_topic_score_gemma":0.04940353,"teacher_disagreement_score":0.9763643,"about_ca_system_score_codex":0.023635658,"about_ca_system_score_gemma":0.085619256,"threshold_uncertainty_score":0.57202166},"labels":[],"label_agreement":null},{"id":"W4225408416","doi":"10.1002/14651858.cd011703.pub2","title":"Pharmaceutical policies: effects of regulating drug insurance schemes","year":2022,"lang":"en","type":"review","venue":"Cochrane Database of Systematic Reviews","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; MEDLINE; Payment; Citation; Actuarial science; Alternative medicine; Systematic review; Family medicine; Drug; Health care; Business; Pharmacology; Political science; Computer science; World Wide Web; Pathology","score_opus":0.20117095391088036,"score_gpt":0.4072512196268243,"score_spread":0.20608026571594396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225408416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017743198,0.9549292,0.0010001812,0.008754139,0.0008428352,0.0012035202,0.0012216087,0.000025856572,0.014279533],"genre_scores_gemma":[0.34787962,0.63108766,0.0044213147,0.010308783,0.0012131797,0.0033609567,0.0006055151,0.00003624342,0.0010867211],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.8923506,0.07232125,0.016897975,0.0041785394,0.012332035,0.0019195705],"domain_scores_gemma":[0.6878435,0.25512168,0.047514636,0.0029199584,0.00568461,0.0009155349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.058435503,0.00091946346,0.0027881637,0.0037916051,0.0006527925,0.0063423673,0.0025726685,0.004704428,0.007399539],"category_scores_gemma":[0.18076512,0.00079834677,0.00645642,0.005486183,0.002855752,0.004486957,0.002586238,0.0031408572,0.00032994946],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008574358,0.000248697,0.008893388,0.72345614,0.020088298,0.00031338705,0.0016174708,0.0013734899,0.0004282823,0.026863853,0.0056073773,0.20253517],"study_design_scores_gemma":[0.006232471,0.0020145292,0.033551704,0.79311955,0.06660115,0.00041733697,0.0016244176,0.0008132478,0.0013705136,0.0090816235,0.08503081,0.00014269221],"about_ca_topic_score_codex":0.008107454,"about_ca_topic_score_gemma":0.010547454,"teacher_disagreement_score":0.058435503,"about_ca_system_score_codex":0.007936511,"about_ca_system_score_gemma":0.011089043,"threshold_uncertainty_score":0.30904013},"labels":[],"label_agreement":null},{"id":"W4225654180","doi":"10.2139/ssrn.4086763","title":"Rethinking Business Model for Drug Discovery, Post-COVID","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Telus (Canada)","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Business model; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Business; 2019-20 coronavirus outbreak; Virology; Medicine; Outbreak; Internal medicine; Infectious disease (medical specialty); Marketing","score_opus":0.040726789223837295,"score_gpt":0.27152109873617064,"score_spread":0.23079430951233335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225654180","genre_codex":"methods","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12455536,0.0031139466,0.5116044,0.17465593,0.0017288529,0.00030966147,0.0018963494,0.00087958964,0.18125588],"genre_scores_gemma":[0.90189236,0.0012174593,0.031713802,0.004118301,0.00050162803,0.00011720675,0.00039553753,0.00027040142,0.05977319],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99697614,0.0014150447,0.00010750374,0.00044947705,0.0007182075,0.00033355824],"domain_scores_gemma":[0.9957306,0.0021211973,0.00031087195,0.0004902021,0.0008399777,0.00050719036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053329947,0.0004926017,0.0012664807,0.000897604,0.0013775516,0.007651165,0.0022971272,0.004192446,0.012551644],"category_scores_gemma":[0.01305436,0.0005239035,0.00133801,0.00077849574,0.001953016,0.0071445345,0.002104291,0.006693235,0.002496184],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004818101,0.000066468936,0.0009539199,0.000029824088,0.000020323816,0.00010552251,0.00011496407,0.025623228,0.00025495846,0.950487,0.013021838,0.009273689],"study_design_scores_gemma":[0.000050404287,0.000055852724,0.00087255694,0.00003805252,0.000019465746,0.00009635991,0.00014744549,0.25383404,0.00027015246,0.7244567,0.020121386,0.000037503072],"about_ca_topic_score_codex":0.012090346,"about_ca_topic_score_gemma":0.012710124,"teacher_disagreement_score":0.012551644,"about_ca_system_score_codex":0.005105638,"about_ca_system_score_gemma":0.00537448,"threshold_uncertainty_score":0.041989386},"labels":[],"label_agreement":null},{"id":"W4225984271","doi":"10.2139/ssrn.4037548","title":"Equilibrium Effects of Pharmaceutical Bundling: Evidence from India","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Business; Economics","score_opus":0.04066466494971812,"score_gpt":0.29435463163979986,"score_spread":0.25368996669008176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225984271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807308,0.0005743376,0.0006748023,0.00081593177,0.000021586238,0.000022442286,0.0006144889,0.00008641234,0.016459106],"genre_scores_gemma":[0.9971481,0.0003044767,0.00018755796,0.00007591459,0.000015305415,0.0000050878625,0.00029573412,0.0000100051175,0.001957809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998872,0.00030992378,0.00007205563,0.00012489196,0.00014268905,0.00047853525],"domain_scores_gemma":[0.99084973,0.0051077628,0.0018260081,0.000711073,0.00080083957,0.00070460205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001639582,0.0003145897,0.0008535873,0.001151041,0.0010237327,0.0033688182,0.0009347444,0.0012232477,0.009465264],"category_scores_gemma":[0.006463646,0.0004900409,0.0011779716,0.0020045491,0.001329215,0.0015101905,0.0012581743,0.0015510109,0.0009378573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01839152,0.008814116,0.47902176,0.0011427916,0.0020794312,0.0021237584,0.0022862277,0.12256966,0.017810328,0.23868968,0.015700698,0.09137004],"study_design_scores_gemma":[0.002579108,0.0028277084,0.79426235,0.00013566465,0.0028136973,0.00034785518,0.0061136433,0.08078656,0.014817808,0.07498462,0.020019546,0.00031139475],"about_ca_topic_score_codex":0.07628853,"about_ca_topic_score_gemma":0.06520012,"teacher_disagreement_score":0.07628853,"about_ca_system_score_codex":0.0033526744,"about_ca_system_score_gemma":0.0023285188,"threshold_uncertainty_score":0.15168893},"labels":[],"label_agreement":null},{"id":"W4226081173","doi":"10.1093/ajhp/zxac102","title":"National trends in prescription drug expenditures and projections for 2022","year":2022,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; St. Michael's Hospital","funders":"","keywords":"Medical prescription; Biosimilar; Prescription drug; Specialty; Business; Legislation; Drug; Medicine; Family medicine; Pharmacology; Political science","score_opus":0.0760131426806438,"score_gpt":0.3648791130348588,"score_spread":0.288865970354215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226081173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75507903,0.0070332917,0.008381029,0.006584603,0.00039955194,0.00008698019,0.17697003,0.000872837,0.04459261],"genre_scores_gemma":[0.8837617,0.00401864,0.005435789,0.0008396619,0.00015731226,0.00012732284,0.10073417,0.000058454196,0.0048669926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994624,0.00008997103,0.000056392175,0.00008621475,0.00020990515,0.000095126634],"domain_scores_gemma":[0.998384,0.00015654383,0.00048625914,0.000048827984,0.0007960117,0.0001282958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009021458,0.00063945405,0.00021460415,0.0020495777,0.00024923705,0.0012481599,0.00033894583,0.0004977126,0.0029410603],"category_scores_gemma":[0.0026856305,0.00018524501,0.00092699047,0.0031475932,0.00014902765,0.0012591826,0.00056644954,0.0007669327,0.0011292761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005784625,0.0002475819,0.78001755,0.0007164347,0.0006403634,0.00043099312,0.00026384654,0.058158945,0.0011234174,0.010046747,0.06694606,0.08082961],"study_design_scores_gemma":[0.000042301977,0.00025368048,0.8192708,0.0003854283,0.00022331548,0.0010015471,0.0009908146,0.065640174,0.0017008018,0.002980085,0.10742619,0.00008488354],"about_ca_topic_score_codex":0.043126117,"about_ca_topic_score_gemma":0.036576774,"teacher_disagreement_score":0.043126117,"about_ca_system_score_codex":0.0023051987,"about_ca_system_score_gemma":0.0013729028,"threshold_uncertainty_score":0.08575016},"labels":[],"label_agreement":null},{"id":"W4226174514","doi":"10.2139/ssrn.4076263","title":"Does Entry Remedy Collusion? Evidence from the Generic Prescription Drug Cartel","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Cartel; Collusion; Business; Medical prescription; Drug; Pharmacology; Industrial organization; Medicine","score_opus":0.03313510832817863,"score_gpt":0.2545927019690797,"score_spread":0.22145759364090106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226174514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9224146,0.010346327,0.00089741615,0.01737927,0.00018811905,0.0001405302,0.00095569546,0.000046224264,0.047631755],"genre_scores_gemma":[0.99401665,0.0013902738,0.00012391433,0.0014175484,0.0002001785,0.0000105747185,0.0001581357,0.000006680142,0.0026761526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99556583,0.0020686646,0.00030668156,0.00037582126,0.00080742553,0.0008755578],"domain_scores_gemma":[0.8555106,0.1015829,0.03138791,0.004829851,0.00284065,0.0038481748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075262687,0.00048008485,0.0013567267,0.0011709661,0.0014072198,0.0041827704,0.0013558819,0.0042446917,0.027951783],"category_scores_gemma":[0.04934772,0.00045904354,0.0009936213,0.0012631358,0.0028053469,0.0031448011,0.0027499686,0.0022672077,0.0019074461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042737976,0.005237449,0.5866991,0.003724818,0.0037770674,0.0071731773,0.0068685245,0.0071397726,0.002532598,0.07825655,0.03524078,0.22061217],"study_design_scores_gemma":[0.017361896,0.013028764,0.7231628,0.0026662366,0.0073747574,0.0035012006,0.018841527,0.016343085,0.0052973344,0.11270166,0.07925009,0.00047067142],"about_ca_topic_score_codex":0.007927933,"about_ca_topic_score_gemma":0.008773828,"teacher_disagreement_score":0.027951783,"about_ca_system_score_codex":0.0011910116,"about_ca_system_score_gemma":0.001966461,"threshold_uncertainty_score":0.093508005},"labels":[],"label_agreement":null},{"id":"W4226227114","doi":"10.1201/9781003063858-2","title":"Canadian Public Policies and Practices Related to Drug Prices, Utilization and Expenditures","year":2022,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Public economics; Economics; Medicine; Pharmacology","score_opus":0.11506167346968993,"score_gpt":0.3141541879059953,"score_spread":0.19909251443630538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226227114","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10800326,0.026160711,0.0054083797,0.10778416,0.00050343276,0.0005393103,0.059220005,0.0006512332,0.69172955],"genre_scores_gemma":[0.85300976,0.025179017,0.0064489204,0.010355344,0.00034718768,0.000262954,0.016592298,0.00014702155,0.08765755],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99013746,0.0007829834,0.0003292802,0.0004902662,0.0066258847,0.0016340545],"domain_scores_gemma":[0.9879296,0.002499142,0.002059876,0.00044374287,0.006062199,0.001005422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037772649,0.00035112764,0.00041997686,0.005045072,0.004147697,0.0061040446,0.00085185934,0.001188095,0.0091767125],"category_scores_gemma":[0.018248219,0.0005184848,0.0007232694,0.012025329,0.0015314973,0.00085328677,0.00074958685,0.0013642854,0.000552913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017390674,0.0001476437,0.095529705,0.000858703,0.00019354612,0.00031284813,0.003117838,0.008996582,0.0003990406,0.40055072,0.35525832,0.13446113],"study_design_scores_gemma":[0.00011214335,0.000053651092,0.4116161,0.0007094738,0.00015614141,0.00018932956,0.002091602,0.008197247,0.0007718544,0.022896525,0.5530141,0.0001918822],"about_ca_topic_score_codex":0.99443406,"about_ca_topic_score_gemma":0.99275595,"teacher_disagreement_score":0.119375676,"about_ca_system_score_codex":0.119375676,"about_ca_system_score_gemma":0.1667723,"threshold_uncertainty_score":0.86613524},"labels":[],"label_agreement":null},{"id":"W4229027994","doi":"10.5539/gjhs.v14n5p1","title":"Drug Shortages and Its Effects on Service Delivery among Key Informants (KIs) in Fiji","year":2022,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Economic shortage; Pharmacy; Workload; Family medicine; Emergency medicine; Environmental health; Medical emergency","score_opus":0.036927977399999944,"score_gpt":0.31321879633767535,"score_spread":0.27629081893767543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229027994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987086,0.00021039732,0.000032280834,0.00050217065,0.0000064198807,0.00001343415,0.000091225455,0.0000010931958,0.00043447147],"genre_scores_gemma":[0.9992373,0.0002756957,0.00005955699,0.00019646322,0.00000583901,0.00001899088,0.00004925714,5.40161e-7,0.0001563576],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99894017,0.00042226544,0.00012279955,0.000074988086,0.00013003583,0.00030971272],"domain_scores_gemma":[0.9966264,0.0009525118,0.0015693634,0.00006161111,0.00027999948,0.0005101478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016437396,0.00021434811,0.00019857613,0.0008193202,0.0012729204,0.0006292924,0.00034957755,0.00040655685,0.0034162367],"category_scores_gemma":[0.0041531087,0.0002499736,0.00020582697,0.00092737476,0.00073545333,0.00086000457,0.0012215065,0.0005349299,0.00019935964],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008613267,0.00009308331,0.94307214,0.0003391818,0.00002589338,0.0008104127,0.047475666,0.000031609412,0.0006137801,0.00012227324,0.00068355986,0.0066463347],"study_design_scores_gemma":[0.0000042892502,0.00023764581,0.8843237,0.00017056189,0.00001757238,0.00048092334,0.1129815,0.00009736135,0.00018282048,0.000045984107,0.0014430281,0.000014691237],"about_ca_topic_score_codex":0.019426621,"about_ca_topic_score_gemma":0.025550185,"teacher_disagreement_score":0.019426621,"about_ca_system_score_codex":0.0013671083,"about_ca_system_score_gemma":0.0017548609,"threshold_uncertainty_score":0.038627088},"labels":[],"label_agreement":null},{"id":"W4229374356","doi":"10.1016/j.jsxm.2022.03.427","title":"156 Direct-To-Consumer vs. Traditional Prescriptions of PDE5 Inhibitors: A Contemporary Cost-Analysis","year":2022,"lang":"en","type":"article","venue":"The Journal of Sexual Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Pharmacy; Reimbursement; Family medicine; Medicine; Business; Telehealth; Health care; Telemedicine; Nursing; Political science","score_opus":0.1618433259708692,"score_gpt":0.3099797790188621,"score_spread":0.1481364530479929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229374356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766816,0.012625108,0.002021901,0.0007581356,0.000054557288,0.00029248724,0.004428266,0.000019272775,0.0031185548],"genre_scores_gemma":[0.9939715,0.0018623415,0.0011227261,0.00012825755,0.00007690769,0.00011691846,0.0022755496,0.000012438945,0.00043337152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980697,0.0009441159,0.00017816556,0.00025432595,0.00037888534,0.00017498483],"domain_scores_gemma":[0.9920448,0.006016808,0.00095033913,0.00022726109,0.0005417839,0.00021897796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030474553,0.00051657896,0.0011819499,0.004163242,0.00036068732,0.002487327,0.0010115423,0.00078209536,0.0075521106],"category_scores_gemma":[0.009459133,0.00041760068,0.0069158175,0.005449487,0.00042711486,0.0015250114,0.0010630292,0.001070022,0.00043928163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013261162,0.001107393,0.8068902,0.0024703906,0.021364331,0.0008917888,0.0002818252,0.060640085,0.00049907016,0.0070967735,0.005932996,0.079563975],"study_design_scores_gemma":[0.002220586,0.004545609,0.8037596,0.00089331437,0.01652928,0.002141494,0.0020276525,0.15423468,0.00063222076,0.0047765994,0.008024272,0.00021478396],"about_ca_topic_score_codex":0.016280454,"about_ca_topic_score_gemma":0.008265662,"teacher_disagreement_score":0.016280454,"about_ca_system_score_codex":0.0040965797,"about_ca_system_score_gemma":0.0010696612,"threshold_uncertainty_score":0.032371342},"labels":[],"label_agreement":null},{"id":"W4229757230","doi":"10.1037/e306002005-001","title":"Rx Depot Agrees to Stop Importing Unapproved Drugs from Canada","year":2004,"lang":"en","type":"dataset","venue":"PsycEXTRA Dataset","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Depot; Business; Political science; Law","score_opus":0.04287161131428772,"score_gpt":0.28501746107081166,"score_spread":0.24214584975652395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229757230","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013746462,0.000050419152,0.000015168678,0.00006156669,0.000008720671,0.0000077110335,0.9991567,0.000056875248,0.000505457],"genre_scores_gemma":[0.0011940065,0.00014361873,0.00012726283,0.000066159984,0.000010743398,0.000048970553,0.9959706,0.000036694815,0.0024019869],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779284,0.00013114761,0.00024448332,0.00033876806,0.00091538805,0.0005774001],"domain_scores_gemma":[0.9913694,0.0014809195,0.0016133193,0.0007990105,0.003964333,0.00077300123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011157411,0.0026007018,0.0023359002,0.010246368,0.0014888395,0.003738804,0.0033388485,0.002657555,0.055456452],"category_scores_gemma":[0.010587783,0.001372255,0.0015955961,0.023179017,0.0005828942,0.0009716669,0.001290566,0.0029428715,0.025941763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085112304,0.00002562065,0.002044185,0.00032760637,0.000042065632,0.000019284025,0.000012055569,0.00055902294,0.000022414943,0.0003858875,0.9948532,0.001623528],"study_design_scores_gemma":[0.0007771881,0.000033014665,0.036766313,0.0005256068,0.0001410078,0.00006426359,0.00012041636,0.0022539482,0.000675205,0.0010148035,0.95756143,0.00006672524],"about_ca_topic_score_codex":0.87458587,"about_ca_topic_score_gemma":0.88670003,"teacher_disagreement_score":0.12541413,"about_ca_system_score_codex":0.014514324,"about_ca_system_score_gemma":0.03546471,"threshold_uncertainty_score":0.2523054},"labels":[],"label_agreement":null},{"id":"W4230018298","doi":"10.1111/j.1538-7836.2007.02673.x","title":"TALKING ABOUT…","year":2007,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Medicine","score_opus":0.11837957648128075,"score_gpt":0.3458084260836932,"score_spread":0.22742884960241247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230018298","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041600238,0.011236924,0.002336087,0.6541486,0.029666236,0.000015716729,0.00013099817,0.00006392804,0.2982414],"genre_scores_gemma":[0.20823807,0.014801949,0.0015011007,0.3938511,0.03928269,0.00009491217,0.00025675923,0.00021203655,0.3417614],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953467,0.0023256554,0.00019780411,0.00051482586,0.0010868495,0.0005280766],"domain_scores_gemma":[0.99346113,0.003021073,0.0007382641,0.00053637504,0.001261079,0.0009820657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005233837,0.0004536793,0.00045092104,0.0009959196,0.0038392965,0.007356808,0.00079672306,0.005208859,0.03964354],"category_scores_gemma":[0.024212087,0.00024350757,0.00044239892,0.0009036801,0.006726515,0.0070992215,0.002577554,0.009540095,0.012373053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066662564,0.000032384338,0.00095835625,0.00012544861,0.000028335642,0.00017893415,0.007846822,0.00007394829,0.0001821837,0.36043152,0.5887942,0.041281212],"study_design_scores_gemma":[0.000009742618,0.000021881187,0.0006556598,0.0002462211,0.000014706005,0.00027218298,0.0031513795,0.000066971945,0.00013200853,0.06697833,0.92842954,0.000021243599],"about_ca_topic_score_codex":0.0019628147,"about_ca_topic_score_gemma":0.002269513,"teacher_disagreement_score":0.03964354,"about_ca_system_score_codex":0.001934423,"about_ca_system_score_gemma":0.0021564614,"threshold_uncertainty_score":0.13262093},"labels":[],"label_agreement":null},{"id":"W4230131359","doi":"10.3821/1913-701x-143.5.209","title":"BC Deal Lowers Generic Drug Prices and Increases Reimbursement to Pharmacy","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Reimbursement; Pharmacy; Drug; Drug prices; Medicine; Business; Generic drug; Family medicine; Pharmacology; Monetary economics; Economics; Health care","score_opus":0.04552413883228632,"score_gpt":0.26972190635796794,"score_spread":0.22419776752568163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230131359","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17916493,0.004801695,0.004693542,0.08229352,0.0018387644,0.00035255015,0.0040584295,0.0017306306,0.721066],"genre_scores_gemma":[0.6777431,0.0015319627,0.003324539,0.018297102,0.0016131394,0.00011961579,0.0020295463,0.0003044881,0.2950365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944765,0.0005865513,0.00008496818,0.00024297043,0.0038202696,0.00078874227],"domain_scores_gemma":[0.9896367,0.0036377802,0.0010891361,0.00041164094,0.0028187162,0.0024059685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017576279,0.00041427702,0.00053570216,0.0020408079,0.001734809,0.0044521634,0.0009119796,0.0043631173,0.069005236],"category_scores_gemma":[0.014900832,0.0004854958,0.0008186478,0.0014150046,0.0010356066,0.0014224518,0.001030894,0.0024968465,0.0077410964],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036557727,0.0019203431,0.0389632,0.00040616613,0.00031633835,0.0006694805,0.00032539404,0.004704637,0.0089841215,0.08602673,0.65654635,0.19748145],"study_design_scores_gemma":[0.0018516087,0.0016951535,0.27775365,0.00020099684,0.0005474635,0.0013775601,0.001028755,0.016805835,0.009556678,0.025587287,0.6633739,0.00022107166],"about_ca_topic_score_codex":0.21301648,"about_ca_topic_score_gemma":0.29373184,"teacher_disagreement_score":0.98701894,"about_ca_system_score_codex":0.012981075,"about_ca_system_score_gemma":0.015992165,"threshold_uncertainty_score":0.42355317},"labels":[],"label_agreement":null},{"id":"W4232172019","doi":"10.1002/div.5471","title":"Abbott Laboratories","year":2007,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Product line; Business; Commerce; Manufacturing engineering; Engineering","score_opus":0.049215644571057454,"score_gpt":0.28248594109782005,"score_spread":0.2332702965267626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232172019","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055041434,0.03315046,0.023868985,0.017727591,0.01166547,0.0012236114,0.021115784,0.018704025,0.86703986],"genre_scores_gemma":[0.042649217,0.013045371,0.023764167,0.009558416,0.003073606,0.0009894994,0.020520946,0.0020189483,0.88437974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962747,0.0004586015,0.00031060225,0.001127832,0.001504349,0.00032394077],"domain_scores_gemma":[0.99658453,0.0006009158,0.00036451034,0.00041899428,0.0012081423,0.000822998],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020080435,0.0017166425,0.0021037443,0.0030799927,0.00070059125,0.0035596273,0.0015621054,0.002707201,0.50012785],"category_scores_gemma":[0.005317045,0.0009271275,0.00074644363,0.0016320235,0.0008224287,0.001813987,0.0016018067,0.0044423128,0.2990565],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023520186,0.00037538115,0.0013242464,0.0010846698,0.00009440997,0.0005921978,0.00009306362,0.0003878123,0.0038426055,0.011530945,0.5724688,0.40585378],"study_design_scores_gemma":[0.0007342985,0.0003510016,0.0013871378,0.00029883813,0.00006250895,0.001304908,0.00004108345,0.0007060495,0.0013237065,0.003981677,0.98978513,0.000023653358],"about_ca_topic_score_codex":0.0010810101,"about_ca_topic_score_gemma":0.0013723491,"teacher_disagreement_score":0.50012785,"about_ca_system_score_codex":0.0011543746,"about_ca_system_score_gemma":0.0029910938,"threshold_uncertainty_score":0.713007},"labels":[],"label_agreement":null},{"id":"W4232524019","doi":"10.2165/00128415-201213950-00011","title":"Apotex Inc. is recalling one lot of ramipril [Apo-Ramipril] 5mg capsules from retail outlets across Canada,","year":2012,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ramipril; Business; Medicine; Internal medicine","score_opus":0.10349865834339776,"score_gpt":0.2879434823452813,"score_spread":0.1844448240018835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232524019","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04282097,0.023498353,0.002528747,0.19495805,0.015925765,0.000388813,0.021125326,0.0036304768,0.6951235],"genre_scores_gemma":[0.025515448,0.0049750265,0.0011756048,0.009197254,0.00061282725,0.000012346897,0.0026749906,0.00025356194,0.95558286],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999196,0.00003431416,0.0000303773,0.0000753043,0.000542176,0.00012186931],"domain_scores_gemma":[0.9961345,0.00025963137,0.00019246714,0.000114429546,0.0022970117,0.001001851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088355085,0.00039250398,0.00039787896,0.0010924981,0.0027743052,0.0032668605,0.00061068835,0.0013669638,0.15871799],"category_scores_gemma":[0.0028666107,0.0003240995,0.00031890368,0.0013532025,0.0008156594,0.00083549705,0.0004703292,0.0015613791,0.030157905],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019836426,0.00006554423,0.004191144,0.00011595371,0.000012580483,0.00017518061,0.0001404999,0.000074488475,0.0016229687,0.0013657797,0.91481483,0.07722265],"study_design_scores_gemma":[0.000020713178,0.000041359384,0.008023617,0.00003502318,0.000010951311,0.00011792928,0.00034772255,0.00008329979,0.00064301025,0.00011185709,0.99054646,0.000018069128],"about_ca_topic_score_codex":0.75016385,"about_ca_topic_score_gemma":0.8910238,"teacher_disagreement_score":0.24983615,"about_ca_system_score_codex":0.008967731,"about_ca_system_score_gemma":0.01855063,"threshold_uncertainty_score":0.5309646},"labels":[],"label_agreement":null},{"id":"W4233594955","doi":"10.1201/9780429155826","title":"Economic Evaluation of Cancer Drugs","year":2019,"lang":"en","type":"book","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cancer drugs; Medicine; Internal medicine","score_opus":0.10319243788967612,"score_gpt":0.3505644891733145,"score_spread":0.24737205128363837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233594955","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025555698,0.1671458,0.12304656,0.05232036,0.007898317,0.0028236487,0.003834839,0.00037601913,0.6169988],"genre_scores_gemma":[0.7115511,0.12401078,0.06283506,0.010136714,0.00455698,0.0040001636,0.0029239643,0.00035099362,0.07963435],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9691223,0.024756005,0.00094997574,0.00065887946,0.0036945273,0.00081843213],"domain_scores_gemma":[0.95619684,0.036419783,0.0015656787,0.0013900823,0.003656622,0.00077095366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01982791,0.0016924097,0.0023596091,0.002281139,0.0007798497,0.005570765,0.001520688,0.0036755567,0.020578707],"category_scores_gemma":[0.08301384,0.0005013688,0.0020736915,0.0025394089,0.0016757062,0.0040342477,0.0016856366,0.003944262,0.0015118833],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019986683,0.00031580246,0.0019174393,0.0049590752,0.0011820156,0.0003123989,0.00017267068,0.10269232,0.0002696755,0.44562167,0.094624415,0.34593385],"study_design_scores_gemma":[0.0010596471,0.0015292693,0.0033382713,0.008142813,0.0011553151,0.0007868709,0.00060124736,0.13573976,0.001073016,0.5533157,0.29309154,0.00016657502],"about_ca_topic_score_codex":0.0026020862,"about_ca_topic_score_gemma":0.0015288652,"teacher_disagreement_score":0.020578707,"about_ca_system_score_codex":0.007733273,"about_ca_system_score_gemma":0.005969407,"threshold_uncertainty_score":0.10486132},"labels":[],"label_agreement":null},{"id":"W4234163504","doi":"10.1007/bf03267040","title":"Canada's health system restricts drug access","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Public health; Drug; Health economics; Business; Environmental health; Medicine; Pharmacology; Nursing","score_opus":0.05204346335349221,"score_gpt":0.34481938233646964,"score_spread":0.29277591898297745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234163504","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041066624,0.008312582,0.0015390294,0.5354985,0.0034096197,0.0001769682,0.008334681,0.0004646578,0.40119737],"genre_scores_gemma":[0.4262327,0.007771613,0.0021781898,0.37567163,0.0025117644,0.00012054962,0.0020151967,0.00015819947,0.18334018],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98560065,0.0007297535,0.00032926776,0.0006905053,0.009003436,0.00364635],"domain_scores_gemma":[0.9684341,0.0112588005,0.0016549665,0.0008113297,0.010168128,0.007672726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043313145,0.00052619964,0.0009906306,0.0030842624,0.0060197655,0.010402672,0.0020499562,0.009025042,0.02326279],"category_scores_gemma":[0.028188666,0.0007242109,0.0016804865,0.0035474403,0.0038906028,0.0018606766,0.002301207,0.0070365,0.0013867742],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001911735,0.00008360207,0.015723346,0.0002671791,0.00015208287,0.000316894,0.00047340855,0.0015049184,0.00062010373,0.16769354,0.78382456,0.029149188],"study_design_scores_gemma":[0.00024505644,0.00009003516,0.06679459,0.00036695492,0.00019783957,0.00022661944,0.000848301,0.0022368273,0.0009097132,0.017803164,0.91012424,0.00015664478],"about_ca_topic_score_codex":0.9877893,"about_ca_topic_score_gemma":0.99216,"teacher_disagreement_score":0.9285629,"about_ca_system_score_codex":0.07143713,"about_ca_system_score_gemma":0.19191836,"threshold_uncertainty_score":0.5183151},"labels":[],"label_agreement":null},{"id":"W4234596508","doi":"10.2165/00151234-200504830-00043","title":"Trastuzumab to be provided free in British Columbia","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Public health; Medicine","score_opus":0.04803241967852492,"score_gpt":0.3218295073160283,"score_spread":0.2737970876375034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234596508","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7716814,0.0075481315,0.00025485002,0.07113916,0.00089189626,0.00017248228,0.021408135,0.0001102073,0.12679371],"genre_scores_gemma":[0.8341144,0.003753908,0.00027869988,0.01499185,0.000118419666,0.00008084952,0.0039305664,0.00006218665,0.14266913],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977564,0.00017906952,0.00009956983,0.00016712428,0.0004651051,0.001332753],"domain_scores_gemma":[0.99404955,0.0009625307,0.00041735455,0.00012277634,0.0013397213,0.0031080847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011572929,0.00017603152,0.00048477235,0.0013865689,0.0028219873,0.0030809226,0.0013976584,0.0024169395,0.010780544],"category_scores_gemma":[0.0058278088,0.00046538824,0.00047674507,0.0026354953,0.00063197874,0.0006191986,0.0010450742,0.0036957879,0.0007794162],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004006142,0.00065074174,0.38844222,0.00058580865,0.0003111154,0.0050090603,0.0020273966,0.0043718345,0.0020422046,0.030816998,0.43697596,0.12476054],"study_design_scores_gemma":[0.0004606534,0.00014325517,0.80758923,0.00052258756,0.00022447905,0.000778065,0.00553667,0.003380492,0.0009918951,0.0018435925,0.17837396,0.00015498117],"about_ca_topic_score_codex":0.9864422,"about_ca_topic_score_gemma":0.9960251,"teacher_disagreement_score":0.052462406,"about_ca_system_score_codex":0.052462406,"about_ca_system_score_gemma":0.06776875,"threshold_uncertainty_score":0.3806432},"labels":[],"label_agreement":null},{"id":"W4235067815","doi":"10.1002/div.6224","title":"Abbott Laboratories","year":2007,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.049215644571057454,"score_gpt":0.28248594109782005,"score_spread":0.2332702965267626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235067815","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054654093,0.030723263,0.02288622,0.017247457,0.011290277,0.0012484482,0.022588525,0.019320842,0.8692295],"genre_scores_gemma":[0.04129894,0.012212841,0.023138003,0.009253053,0.00291312,0.00097170373,0.021600423,0.002038965,0.88657296],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961163,0.0004842918,0.0003217511,0.0011761369,0.0015608083,0.000340678],"domain_scores_gemma":[0.9965449,0.00061130006,0.00036850627,0.00043012013,0.0011992577,0.0008459546],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020389722,0.001691651,0.002163595,0.0032475141,0.00073713454,0.0037559685,0.0016181228,0.0028004888,0.5193018],"category_scores_gemma":[0.0051757926,0.00094161474,0.0007746166,0.0017352741,0.00084876065,0.0018247709,0.0016304177,0.0044826805,0.3153941],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024378551,0.00039301842,0.0013674756,0.0011292713,0.000096522126,0.0006156634,0.00009624059,0.00038380324,0.004272842,0.011080994,0.58536327,0.39276302],"study_design_scores_gemma":[0.00073894433,0.00035334093,0.0014268792,0.0002993642,0.00006249001,0.0012670845,0.000043706805,0.00071376114,0.0013857994,0.0039026306,0.9897816,0.000024436458],"about_ca_topic_score_codex":0.0011632539,"about_ca_topic_score_gemma":0.0015067697,"teacher_disagreement_score":0.5193018,"about_ca_system_score_codex":0.0011489048,"about_ca_system_score_gemma":0.0030932997,"threshold_uncertainty_score":0.6856577},"labels":[],"label_agreement":null},{"id":"W4235233362","doi":"10.1111/j.1538-7836.2007.02416.x","title":"TALKING ABOUT…","year":2007,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Chagas disease; Food and drug administration; Medicine; Test (biology); Disease; Virology; Environmental health; Biology; Pathology","score_opus":0.11837957648128075,"score_gpt":0.3458084260836932,"score_spread":0.22742884960241247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235233362","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041600238,0.011236924,0.002336087,0.6541486,0.029666236,0.000015716729,0.00013099817,0.00006392804,0.2982414],"genre_scores_gemma":[0.20823807,0.014801949,0.0015011007,0.3938511,0.03928269,0.00009491217,0.00025675923,0.00021203655,0.3417614],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953467,0.0023256554,0.00019780411,0.00051482586,0.0010868495,0.0005280766],"domain_scores_gemma":[0.99346113,0.003021073,0.0007382641,0.00053637504,0.001261079,0.0009820657],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005233837,0.0004536793,0.00045092104,0.0009959196,0.0038392965,0.007356808,0.00079672306,0.005208859,0.03964354],"category_scores_gemma":[0.024212087,0.00024350757,0.00044239892,0.0009036801,0.006726515,0.0070992215,0.002577554,0.009540095,0.012373053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066662564,0.000032384338,0.00095835625,0.00012544861,0.000028335642,0.00017893415,0.007846822,0.00007394829,0.0001821837,0.36043152,0.5887942,0.041281212],"study_design_scores_gemma":[0.000009742618,0.000021881187,0.0006556598,0.0002462211,0.000014706005,0.00027218298,0.0031513795,0.000066971945,0.00013200853,0.06697833,0.92842954,0.000021243599],"about_ca_topic_score_codex":0.0019628147,"about_ca_topic_score_gemma":0.002269513,"teacher_disagreement_score":0.9603565,"about_ca_system_score_codex":0.001934423,"about_ca_system_score_gemma":0.0021564614,"threshold_uncertainty_score":0.13262093},"labels":[],"label_agreement":null},{"id":"W4235376273","doi":"10.21518/1561-5936-2014-1-2-93-98","title":"Steps to success: changes in the ranking of pharmaceutical producers in the III quarter of 2013","year":2014,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Ranking (information retrieval); Business; Marketing; Operations management; Computer science; Economics; Information retrieval; Geography","score_opus":0.03101080426950721,"score_gpt":0.3016633879560541,"score_spread":0.2706525836865469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235376273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86638427,0.0015420852,0.0007499685,0.064794965,0.00073643704,0.000072324714,0.018973542,0.0002147692,0.046531692],"genre_scores_gemma":[0.98430586,0.0004251935,0.0002458148,0.0015699704,0.00016780561,0.000024469688,0.0032738738,0.000036728343,0.009950311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982919,0.0001782858,0.00010825467,0.00010669552,0.0005309586,0.00078382116],"domain_scores_gemma":[0.99375904,0.00038195218,0.0015639532,0.00009719232,0.002310694,0.0018871975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002604363,0.00017583123,0.0002985132,0.0014100724,0.0009924216,0.003503072,0.000559958,0.0010476161,0.0063261543],"category_scores_gemma":[0.006970196,0.00017145526,0.0003370585,0.0021443346,0.00048234966,0.00132462,0.0012466308,0.0011747635,0.0014732076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014087432,0.00025684433,0.6828668,0.00021622729,0.00010875089,0.00055772846,0.00440709,0.0016266574,0.0012265061,0.012968069,0.2346321,0.05972451],"study_design_scores_gemma":[0.000024553217,0.00008817945,0.96518785,0.00003640064,0.000012650489,0.000056994155,0.0048744227,0.000789908,0.0004222905,0.00053519383,0.0279476,0.000023983],"about_ca_topic_score_codex":0.11784586,"about_ca_topic_score_gemma":0.1569123,"teacher_disagreement_score":0.11784586,"about_ca_system_score_codex":0.0037352445,"about_ca_system_score_gemma":0.006895301,"threshold_uncertainty_score":0.23431987},"labels":[],"label_agreement":null},{"id":"W4235698704","doi":"10.3821/1913-701x-144.6.254","title":"BC Government Re-Opens Talks on Generic Drug Pricing Because Promised Savings Fall Short","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug pricing; Government (linguistics); Drug; Business; Law and economics; Operations research; Economics; Engineering; Actuarial science; Medicine; Philosophy; Pharmacology","score_opus":0.10920721802770139,"score_gpt":0.2542881119863801,"score_spread":0.14508089395867874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235698704","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00926434,0.0033264079,0.0016255468,0.6163791,0.017472759,0.00011825624,0.0012652072,0.0006200328,0.3499284],"genre_scores_gemma":[0.1497564,0.0015247307,0.0016429789,0.205037,0.008943155,0.00009460548,0.0005473442,0.000622926,0.63183093],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9854966,0.0011355197,0.00031540633,0.0006606741,0.009717215,0.0026745494],"domain_scores_gemma":[0.965999,0.013430644,0.0009329523,0.0016259992,0.012790518,0.0052208384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006487215,0.00057397265,0.0009810106,0.0023105775,0.008551787,0.010988897,0.0017644386,0.024287656,0.08295975],"category_scores_gemma":[0.050027058,0.00073818164,0.0012569824,0.00201114,0.0030533196,0.003245007,0.0019417123,0.018432172,0.012301528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013254193,0.000041219646,0.0009601292,0.000041192296,0.00001657445,0.0001585935,0.00021088391,0.00017147783,0.00058207463,0.035063468,0.9432484,0.01937345],"study_design_scores_gemma":[0.000085933774,0.000041883137,0.005966887,0.00010532984,0.000026282632,0.00015164488,0.0003587699,0.0011696683,0.0007530668,0.011060402,0.9802115,0.00006865797],"about_ca_topic_score_codex":0.4129952,"about_ca_topic_score_gemma":0.52647394,"teacher_disagreement_score":0.5870048,"about_ca_system_score_codex":0.031126209,"about_ca_system_score_gemma":0.03708763,"threshold_uncertainty_score":0.8211826},"labels":[],"label_agreement":null},{"id":"W4236816095","doi":"10.1002/div.5059","title":"Abbott Laboratories","year":2006,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Business; Commerce","score_opus":0.0318628504712109,"score_gpt":0.24495603045411096,"score_spread":0.21309317998290006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236816095","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005446499,0.033177156,0.023785105,0.01741445,0.011580291,0.001205115,0.020786652,0.018241316,0.8683634],"genre_scores_gemma":[0.04195738,0.013025906,0.023486406,0.009169455,0.0029441593,0.0009696085,0.020042561,0.0019216271,0.88648295],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962658,0.00045508932,0.00031056514,0.0011370096,0.0015046786,0.00032688043],"domain_scores_gemma":[0.9965958,0.00059471314,0.00036146387,0.00042067023,0.0012055134,0.00082175486],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019880591,0.0017511243,0.0021140198,0.0031111639,0.00071038294,0.0035299268,0.0015753305,0.0027269789,0.4999966],"category_scores_gemma":[0.005271253,0.0009334539,0.00074794743,0.0016493244,0.000819631,0.0018086185,0.0015876506,0.0044347206,0.3000639],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023354548,0.00037854255,0.0013240334,0.0010868552,0.00009345116,0.0005957892,0.000093765935,0.00039006167,0.003922559,0.011621549,0.57137984,0.40677804],"study_design_scores_gemma":[0.0007215818,0.00034755043,0.0013807407,0.00028705513,0.00006136356,0.0013009188,0.000040488885,0.00069334276,0.0013372417,0.0038759208,0.9899305,0.000023382227],"about_ca_topic_score_codex":0.0010829747,"about_ca_topic_score_gemma":0.001379628,"teacher_disagreement_score":0.4999966,"about_ca_system_score_codex":0.0011557196,"about_ca_system_score_gemma":0.002982622,"threshold_uncertainty_score":0.71319413},"labels":[],"label_agreement":null},{"id":"W4236823326","doi":"10.3821/1913-701x(2007)140[354:baapsi]2.0.co;2","title":"BC and Alberta pharmacists seek input into joint buying strategy","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Joint (building); Marketing; Business; Advertising; Engineering","score_opus":0.06874095744618008,"score_gpt":0.2767010859288065,"score_spread":0.2079601284826264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236823326","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13286565,0.0022921686,0.0022845226,0.11145973,0.00055071566,0.00022451302,0.00036656146,0.00017170954,0.7497845],"genre_scores_gemma":[0.78847843,0.00095379364,0.00237115,0.015172232,0.00023312855,0.000043319575,0.00024329656,0.000057435762,0.19244726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.990875,0.0013934723,0.00018189623,0.00039798487,0.0040168776,0.0031347508],"domain_scores_gemma":[0.9728969,0.007049718,0.0009831181,0.00077177526,0.00752274,0.0107757235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051849517,0.00036551247,0.00041975293,0.001683102,0.008648702,0.010701589,0.00089347124,0.004381176,0.04885755],"category_scores_gemma":[0.019479088,0.0005096527,0.00036018857,0.0023915488,0.0018508224,0.0021905568,0.0027989128,0.003361968,0.0028035308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065196306,0.0006771221,0.10043008,0.00029250502,0.00011501347,0.0018933966,0.007054583,0.0024702107,0.0028985352,0.147345,0.43714482,0.29902676],"study_design_scores_gemma":[0.00031760847,0.00025224604,0.18062836,0.00029905094,0.000110805566,0.00088936626,0.024734963,0.005017823,0.0017937035,0.027233327,0.7585743,0.00014848435],"about_ca_topic_score_codex":0.6504244,"about_ca_topic_score_gemma":0.86575484,"teacher_disagreement_score":0.34957558,"about_ca_system_score_codex":0.029618414,"about_ca_system_score_gemma":0.079214424,"threshold_uncertainty_score":0.7032686},"labels":[],"label_agreement":null},{"id":"W4237064351","doi":"10.3821/1913-701x-144.4.156a","title":"Saskatchewan Pharmacists Adjust to New Generic Price Regime with Aid of Additional Compensation","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Compensation (psychology); Business; Computer science; Psychology","score_opus":0.09231855320419673,"score_gpt":0.24615709552159404,"score_spread":0.1538385423173973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237064351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49386302,0.0008414061,0.00866535,0.03170324,0.0015215132,0.0041361623,0.012335866,0.003129854,0.44380367],"genre_scores_gemma":[0.70696616,0.00042295284,0.006424678,0.0072594327,0.00058286387,0.000514803,0.0032478208,0.00017530713,0.27440605],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964056,0.00045197003,0.00024731006,0.00034347427,0.001464066,0.0010875347],"domain_scores_gemma":[0.99446625,0.0010152932,0.0007840633,0.0005296093,0.001960726,0.0012441251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028482324,0.00040563062,0.0005454781,0.0016976148,0.0020169916,0.0035891407,0.0015383229,0.0023523744,0.045519955],"category_scores_gemma":[0.013709709,0.00055851747,0.0009926505,0.0013102862,0.0004641706,0.0007276436,0.0011874585,0.0023875795,0.009832423],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028627152,0.0027645514,0.15290283,0.00020462598,0.000331653,0.0013530107,0.00094853,0.010606395,0.00931526,0.013949598,0.38791507,0.4168457],"study_design_scores_gemma":[0.0016485131,0.0015917419,0.58647996,0.00011569268,0.00020989856,0.0011638661,0.0019441337,0.020968188,0.0046943766,0.0052327346,0.37573946,0.00021140525],"about_ca_topic_score_codex":0.2325457,"about_ca_topic_score_gemma":0.3855805,"teacher_disagreement_score":0.76745427,"about_ca_system_score_codex":0.0074079633,"about_ca_system_score_gemma":0.017358739,"threshold_uncertainty_score":0.46238428},"labels":[],"label_agreement":null},{"id":"W4238184128","doi":"10.3821/1913-701x-144.3.109b","title":"30 Years of Growth in Canadian Pharmaceutical Sales Projected to End in 2011","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Marketing","score_opus":0.09849729603284312,"score_gpt":0.2809651125494973,"score_spread":0.18246781651665417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238184128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50378585,0.029442824,0.0030563525,0.07442053,0.002795458,0.00018586058,0.2980394,0.0009477457,0.087325916],"genre_scores_gemma":[0.85002846,0.017165827,0.0013800736,0.0032244765,0.0003569907,0.00006540393,0.08936811,0.000056674064,0.03835402],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984334,0.000037288377,0.00007591263,0.00009466183,0.0007385278,0.0006201184],"domain_scores_gemma":[0.99651116,0.00008921599,0.00048260397,0.000027453856,0.00223422,0.0006552731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009403197,0.0007949352,0.000393666,0.0023409443,0.0016021659,0.0032030127,0.00073273544,0.0020772053,0.0076592136],"category_scores_gemma":[0.0037795762,0.0002735187,0.0014567302,0.004350574,0.0005129109,0.0015152595,0.0010200323,0.0023930545,0.002201402],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015887743,0.00028046555,0.41608456,0.0016945703,0.0006196782,0.0027206205,0.0014116829,0.018071728,0.0025276805,0.024986783,0.42374957,0.106263936],"study_design_scores_gemma":[0.0000619779,0.00013119758,0.78335243,0.00044003638,0.00018917187,0.0006914026,0.00241474,0.007135072,0.0010631012,0.0018660376,0.2024839,0.00017094247],"about_ca_topic_score_codex":0.95040196,"about_ca_topic_score_gemma":0.96146655,"teacher_disagreement_score":0.04959804,"about_ca_system_score_codex":0.027124237,"about_ca_system_score_gemma":0.048153527,"threshold_uncertainty_score":0.19680107},"labels":[],"label_agreement":null},{"id":"W4238428746","doi":"10.3821/1913-701x-143.6.264","title":"New Momentum for a Pan-Canadian Purchasing Alliance for Prescription Drugs","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alliance; Medical prescription; Purchasing; Momentum (technical analysis); Business; Medicine; Marketing; Pharmacology; History; Finance; Archaeology","score_opus":0.059600275183962804,"score_gpt":0.27952967275080925,"score_spread":0.21992939756684646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238428746","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012008053,0.007226795,0.0014258488,0.8389656,0.007056858,0.00010588205,0.00087076484,0.00021553434,0.1321247],"genre_scores_gemma":[0.29915735,0.010219061,0.011830996,0.38091072,0.0067363535,0.00016681732,0.0015901148,0.00025849347,0.28913003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876304,0.0009145478,0.00029391563,0.0006860735,0.0071872324,0.0032878527],"domain_scores_gemma":[0.9555494,0.004148904,0.0010389105,0.0012532321,0.016013056,0.021996524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010815413,0.000621697,0.00068198337,0.0022969097,0.007882369,0.0155843645,0.0021366288,0.014791778,0.04485787],"category_scores_gemma":[0.023636587,0.0006548742,0.0011749621,0.0026135724,0.0045097903,0.0056712874,0.0037176285,0.011761648,0.0029252393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013760227,0.00010911083,0.0036956756,0.00012162759,0.000031992004,0.000270081,0.00044389418,0.00027310936,0.0005542823,0.17161445,0.7836657,0.03908234],"study_design_scores_gemma":[0.00007262032,0.00003170076,0.0071743815,0.00017910819,0.000020329895,0.000092341215,0.00070168945,0.00047930737,0.00013158385,0.008210399,0.9828689,0.000037730944],"about_ca_topic_score_codex":0.8475363,"about_ca_topic_score_gemma":0.9328021,"teacher_disagreement_score":0.946931,"about_ca_system_score_codex":0.053069003,"about_ca_system_score_gemma":0.22619227,"threshold_uncertainty_score":0.3850444},"labels":[],"label_agreement":null},{"id":"W4238438364","doi":"10.1007/bf03276740","title":"Pharmaceutical sales rise by 14% in Canada, China","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; China; Business; Public health; Political science; Medicine; Law","score_opus":0.03730183461446839,"score_gpt":0.3188371479028117,"score_spread":0.2815353132883433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238438364","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81217283,0.009787101,0.00044343353,0.0648082,0.0010590209,0.0001154809,0.048202306,0.0008431756,0.062568456],"genre_scores_gemma":[0.9113781,0.0037165675,0.00047362424,0.005038241,0.00029254876,0.000018283234,0.010494218,0.000055366076,0.06853308],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99927276,0.000021126685,0.000030133619,0.00005386786,0.00031729904,0.00030479912],"domain_scores_gemma":[0.9986338,0.00005505026,0.00018062943,0.000025778025,0.00068711874,0.00041763112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042858845,0.00040272184,0.000363382,0.0022924521,0.0019625048,0.0028862897,0.00062462746,0.0015232967,0.0066255503],"category_scores_gemma":[0.0015287115,0.0002859372,0.00081536366,0.004443114,0.0007258187,0.0006419714,0.0006134476,0.0012392334,0.0007700983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001053192,0.00020362221,0.6346445,0.00044092958,0.0003520201,0.002640802,0.0012100935,0.0024271063,0.002493665,0.007077455,0.26384076,0.08361579],"study_design_scores_gemma":[0.00005138301,0.00004164974,0.9362207,0.00002772056,0.00006455897,0.00013845881,0.0009231348,0.0011914031,0.0006007941,0.00020288273,0.060508315,0.000029044388],"about_ca_topic_score_codex":0.986568,"about_ca_topic_score_gemma":0.9925613,"teacher_disagreement_score":0.026220756,"about_ca_system_score_codex":0.026220756,"about_ca_system_score_gemma":0.053258818,"threshold_uncertainty_score":0.19024575},"labels":[],"label_agreement":null},{"id":"W4238611738","doi":"10.1007/bf03269365","title":"Formulary listing times drop in 4 Canadian provinces","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Listing (finance); Quality of Life Research; Business; Medicine; Public health; Finance; Family medicine","score_opus":0.048418104041826705,"score_gpt":0.3334772051408186,"score_spread":0.28505910109899185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238611738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.883413,0.0026785792,0.00021649447,0.02398406,0.00038150206,0.00009730126,0.027356528,0.00026045673,0.061611958],"genre_scores_gemma":[0.9559262,0.0011316043,0.00023759562,0.0025368803,0.00008435036,0.00002034985,0.0063698324,0.000069620146,0.033623546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972115,0.0000918951,0.00011314442,0.00016809952,0.0012451229,0.0011702274],"domain_scores_gemma":[0.98861045,0.0009281892,0.0018507747,0.00022402569,0.0059565757,0.0024299861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012916593,0.00026336836,0.0005362199,0.0032972249,0.003968221,0.0042145513,0.0014665045,0.0014124318,0.01062395],"category_scores_gemma":[0.009937728,0.0004213547,0.000646203,0.0070391158,0.00087504566,0.0007972437,0.00095597963,0.0014219654,0.00070710405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019890903,0.00023265935,0.6395209,0.00041047807,0.0002567539,0.0015897373,0.0045671724,0.0044811335,0.001417352,0.01298623,0.2562994,0.0762492],"study_design_scores_gemma":[0.000060681275,0.000036374007,0.9469108,0.00005054545,0.00004679963,0.00013383529,0.0040075756,0.0019529279,0.00041476512,0.00023774973,0.046091706,0.000056117206],"about_ca_topic_score_codex":0.9962857,"about_ca_topic_score_gemma":0.9978212,"teacher_disagreement_score":0.07925177,"about_ca_system_score_codex":0.07925177,"about_ca_system_score_gemma":0.08444967,"threshold_uncertainty_score":0.5750146},"labels":[],"label_agreement":null},{"id":"W4238683263","doi":"10.4324/9781315614601-23","title":"Price Competition in the Chinese Pharmaceutical Market","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Business; Chinese market; Industrial organization; China; Geography; Biology","score_opus":0.05401953543150875,"score_gpt":0.29674821737440127,"score_spread":0.24272868194289252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238683263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55277205,0.027606534,0.0027007929,0.0059725484,0.00021112597,0.000091099144,0.00053318474,0.00008331822,0.41002938],"genre_scores_gemma":[0.9678922,0.0066122287,0.0005332293,0.00047582237,0.00020821723,0.00002825807,0.00019271793,0.000010867777,0.024046347],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9995271,0.000047284913,0.00002315566,0.000078758494,0.00019825088,0.00012551915],"domain_scores_gemma":[0.9997634,0.00007580229,0.00006087917,0.00001865346,0.000045212055,0.000036069545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006057356,0.0002459677,0.00039806828,0.0018475007,0.0014511496,0.0020344327,0.00044119023,0.00067461084,0.008520373],"category_scores_gemma":[0.0008570742,0.00017764635,0.00054604845,0.0027068704,0.00149396,0.0016535117,0.0009129668,0.00053911365,0.00045816766],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021799287,0.00007640617,0.0154337315,0.0005921718,0.00006128727,0.002216361,0.0042070374,0.005398204,0.0021126713,0.8415661,0.022689905,0.105428055],"study_design_scores_gemma":[0.00022588413,0.00041109987,0.25422263,0.00049418997,0.00022656177,0.002345241,0.0030477003,0.045732513,0.0037362594,0.3279838,0.36128715,0.00028693865],"about_ca_topic_score_codex":0.02840357,"about_ca_topic_score_gemma":0.020655097,"teacher_disagreement_score":0.02840357,"about_ca_system_score_codex":0.005459497,"about_ca_system_score_gemma":0.0027064236,"threshold_uncertainty_score":0.056476533},"labels":[],"label_agreement":null},{"id":"W4239993890","doi":"10.4135/9781483349985.n88","title":"Canada: Variation in Prescription Drug Benefits byProvince/Territory","year":2016,"lang":"en","type":"reference-entry","venue":"The SAGE Encyclopedia of Pharmacology and Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Variation (astronomy); Medical prescription; Drug; Prescription drug; Geography; Medicine; Pharmacology","score_opus":0.01899929944331407,"score_gpt":0.2471093315104131,"score_spread":0.228110032067099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239993890","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52384686,0.017063484,0.0014975298,0.025692515,0.0004108277,0.00024542736,0.36994913,0.0005021805,0.060791988],"genre_scores_gemma":[0.92216283,0.0048490306,0.0010357578,0.0013595792,0.00006720864,0.000051491254,0.035073593,0.00018025046,0.035220265],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.996935,0.00019999036,0.0002276746,0.00036376034,0.0013195167,0.00095397874],"domain_scores_gemma":[0.991091,0.0008503366,0.0011524162,0.00019982588,0.0049885344,0.001717863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010925609,0.00039113333,0.0010126358,0.003560541,0.0022393323,0.0036685173,0.0018762613,0.0011674995,0.018816836],"category_scores_gemma":[0.0066179037,0.00054921897,0.0014373262,0.015273767,0.00086995406,0.0010348631,0.0016645074,0.0017212156,0.0013724883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005673266,0.00012524624,0.71105087,0.0005666399,0.0010004331,0.00054168253,0.0020423718,0.003863461,0.0002995783,0.018089138,0.22272703,0.03912612],"study_design_scores_gemma":[0.000068686946,0.000031428855,0.93723273,0.0002777013,0.00024135898,0.00014962156,0.0035331664,0.0026915797,0.0002594345,0.00073998154,0.054677222,0.000097084034],"about_ca_topic_score_codex":0.99888045,"about_ca_topic_score_gemma":0.99926955,"teacher_disagreement_score":0.9412843,"about_ca_system_score_codex":0.058715727,"about_ca_system_score_gemma":0.10862631,"threshold_uncertainty_score":0.42601442},"labels":[],"label_agreement":null},{"id":"W4240245679","doi":"10.2139/ssrn.946400","title":"Informational Spillovers and Strategic Launch Delay of Pharmaceutical Drugs","year":2006,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Health Economics Association","funders":"","keywords":"Business; Industrial organization; Marketing","score_opus":0.024375922371507697,"score_gpt":0.2646331026692938,"score_spread":0.2402571802977861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240245679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94762963,0.002213309,0.00896805,0.006244074,0.00010284694,0.000064260734,0.0005159722,0.00015452087,0.034107506],"genre_scores_gemma":[0.9975013,0.00033895683,0.00026488895,0.000106905776,0.00005643761,0.0000060099155,0.000037728663,0.000005080247,0.0016825747],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99886864,0.00031781322,0.00008493252,0.00015310207,0.00019288686,0.00038256927],"domain_scores_gemma":[0.9345028,0.046551935,0.013518366,0.0016683484,0.0016287751,0.0021298653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043534567,0.0004687166,0.0010963916,0.0013972337,0.00073125144,0.0037604317,0.00073471817,0.0029750806,0.017873548],"category_scores_gemma":[0.03939348,0.00058836705,0.0006494921,0.001030617,0.0012296998,0.0039625936,0.0015052975,0.0026528374,0.0011893671],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011520995,0.002998703,0.12448569,0.0011854842,0.00071542984,0.004345031,0.0024573973,0.19980289,0.016553918,0.4607133,0.019821092,0.15540007],"study_design_scores_gemma":[0.0015509435,0.0032354074,0.14726,0.00020607388,0.0012740386,0.0014157619,0.004315557,0.22776112,0.011000705,0.5899445,0.011625328,0.00041061395],"about_ca_topic_score_codex":0.0027351766,"about_ca_topic_score_gemma":0.002844086,"teacher_disagreement_score":0.017873548,"about_ca_system_score_codex":0.0019515649,"about_ca_system_score_gemma":0.0015092561,"threshold_uncertainty_score":0.059792995},"labels":[],"label_agreement":null},{"id":"W4240252137","doi":"10.3821/1913-701x-142.6.271.a","title":"BC Government Invests in New UBC Facility to Support Education of More Pharmacists","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Medicine; Business; Medical education; Family medicine","score_opus":0.061703458918506524,"score_gpt":0.2953443771967481,"score_spread":0.23364091827824157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240252137","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11667547,0.002234324,0.003698612,0.35611713,0.009439946,0.0011247167,0.008011162,0.0021909184,0.5005077],"genre_scores_gemma":[0.16788119,0.00063669635,0.004101992,0.029484618,0.00065022474,0.000091143025,0.001259856,0.00014323776,0.7957511],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538887,0.0003663229,0.00007425386,0.00025336433,0.002244884,0.0016722047],"domain_scores_gemma":[0.9772813,0.0013995582,0.0005167017,0.00044558934,0.0061909165,0.014166068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018663318,0.00037069974,0.0003384271,0.0014227912,0.0055159116,0.0038369552,0.0014149836,0.006351428,0.084555425],"category_scores_gemma":[0.007190574,0.0005568059,0.00063740654,0.0011015602,0.00096533773,0.0010111738,0.0013725386,0.003611254,0.007945373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031933727,0.0007893294,0.016011229,0.00016599499,0.000044676948,0.0006189452,0.0002599313,0.0010313576,0.0018857069,0.016345344,0.8629977,0.09953044],"study_design_scores_gemma":[0.00018632681,0.00027249582,0.05413122,0.00008855786,0.000027946928,0.00043412068,0.0007744332,0.0025379795,0.0015551858,0.00092606316,0.93903023,0.000035376135],"about_ca_topic_score_codex":0.7288352,"about_ca_topic_score_gemma":0.9001934,"teacher_disagreement_score":0.95620364,"about_ca_system_score_codex":0.043796357,"about_ca_system_score_gemma":0.11920029,"threshold_uncertainty_score":0.5455234},"labels":[],"label_agreement":null},{"id":"W4240390045","doi":"10.3821/1913-701x-142.3.117.a","title":"Retail Prescription Volume up 7.1% in 2008: Generic Prescriptions Now Account for Majority","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Business; Volume (thermodynamics); Medicine; Pharmacology; Physics","score_opus":0.08390761934245095,"score_gpt":0.2736221673259697,"score_spread":0.18971454798351878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240390045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48916128,0.041179713,0.002258231,0.11026572,0.0053875614,0.00013078228,0.20186232,0.0020634048,0.14769101],"genre_scores_gemma":[0.7908413,0.014578901,0.0014900093,0.02349448,0.0023260112,0.00004506515,0.059946183,0.00025925317,0.10701875],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99907565,0.00004497143,0.000051447863,0.00012140387,0.0005184972,0.00018801463],"domain_scores_gemma":[0.9980636,0.00023416597,0.00041300658,0.000058894224,0.00084862416,0.00038166496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042754135,0.0002603877,0.00045275068,0.0011592761,0.0004807154,0.0020994851,0.00059723004,0.0012590399,0.017388899],"category_scores_gemma":[0.002350787,0.00029654658,0.0007818517,0.0023914773,0.00024359513,0.0007688034,0.0006362667,0.002089327,0.004241388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068763527,0.00012967094,0.2385092,0.00061907334,0.00016474703,0.00070013554,0.00036210407,0.00058988953,0.003319897,0.0050658435,0.5095014,0.24035038],"study_design_scores_gemma":[0.00003586053,0.00005342001,0.5796488,0.00017718026,0.00012576202,0.00097408274,0.0005664453,0.0008606355,0.0011205444,0.0004219534,0.41598275,0.00003260695],"about_ca_topic_score_codex":0.27888694,"about_ca_topic_score_gemma":0.37894484,"teacher_disagreement_score":0.7211131,"about_ca_system_score_codex":0.0045715244,"about_ca_system_score_gemma":0.00561713,"threshold_uncertainty_score":0.5545273},"labels":[],"label_agreement":null},{"id":"W4240991983","doi":"10.3109/9781420073553-13","title":"A Primer of Drug/Device Law","year":2008,"lang":"es","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Primer (cosmetics); Law; Drug; Medicine; Political science; Pharmacology; Physics; Thermodynamics","score_opus":0.08261269360930884,"score_gpt":0.2820376533771653,"score_spread":0.19942495976785646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240991983","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004367038,0.071450226,0.011879826,0.11081541,0.008178535,0.00007199111,0.00016335913,0.00020026405,0.7968038],"genre_scores_gemma":[0.03311421,0.07455564,0.012893115,0.11574449,0.012412149,0.00029438463,0.00021540433,0.00032181828,0.7504487],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9971246,0.00074150896,0.0001208854,0.00027292082,0.0015572086,0.00018296616],"domain_scores_gemma":[0.99818975,0.0011691669,0.00007725234,0.0001607346,0.00030749803,0.0000956103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032636344,0.0008137015,0.0005693541,0.0015939418,0.002889761,0.007990175,0.0015051098,0.008411557,0.023451788],"category_scores_gemma":[0.0046512294,0.0005547257,0.0005178277,0.0012879714,0.008666374,0.009401002,0.0026099465,0.013055016,0.010103999],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000036026956,0.000014773657,0.00002196875,0.0000509724,0.0000013520421,0.000043053555,0.0002649903,0.000092400114,0.000056454024,0.82120013,0.15651384,0.021736357],"study_design_scores_gemma":[0.0000024793828,0.0000075398457,0.00003388748,0.00017211928,7.119895e-7,0.000060582835,0.00007314064,0.00009725528,0.000047457645,0.16972157,0.82977927,0.0000039699094],"about_ca_topic_score_codex":0.0024443213,"about_ca_topic_score_gemma":0.0032374293,"teacher_disagreement_score":0.023451788,"about_ca_system_score_codex":0.0029016028,"about_ca_system_score_gemma":0.0038735524,"threshold_uncertainty_score":0.07845402},"labels":[],"label_agreement":null},{"id":"W4240996743","doi":"10.1002/div.6574","title":"Abbott Laboratories","year":2008,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.08134316636998808,"score_gpt":0.2612341988136709,"score_spread":0.17989103244368282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240996743","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055142753,0.030710865,0.023021286,0.017273784,0.011277457,0.0012482322,0.0227789,0.019318134,0.868857],"genre_scores_gemma":[0.041871656,0.0122628575,0.02317386,0.009230111,0.002957676,0.00096909073,0.021576539,0.0020297812,0.8859285],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961099,0.00048597765,0.00032361792,0.0011816844,0.0015594042,0.00033943908],"domain_scores_gemma":[0.99653673,0.000615725,0.00037253994,0.00042926177,0.0012035134,0.00084217876],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0020424158,0.0016793341,0.002164221,0.0032535566,0.00073515414,0.0037596996,0.0016087099,0.0027884848,0.5177795],"category_scores_gemma":[0.0051930966,0.0009421589,0.00077423366,0.0017447735,0.0008458151,0.0018180202,0.001615622,0.004484743,0.31270233],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002460019,0.00039381385,0.0013838848,0.0011329071,0.00009674372,0.00061369356,0.00009604386,0.00038581007,0.0043043713,0.011173501,0.58450675,0.39345247],"study_design_scores_gemma":[0.0007466575,0.00035615262,0.0014466273,0.0003004032,0.00006300505,0.0012682523,0.00004352072,0.0007242987,0.0014006005,0.003907455,0.9897183,0.000024626168],"about_ca_topic_score_codex":0.0011649738,"about_ca_topic_score_gemma":0.0014992066,"teacher_disagreement_score":0.48222047,"about_ca_system_score_codex":0.0011466788,"about_ca_system_score_gemma":0.003101172,"threshold_uncertainty_score":0.68782896},"labels":[],"label_agreement":null},{"id":"W4241240264","doi":"10.3821/1913-701x-142.4.172","title":"Economic Woes Lead More Employers to Implement or Consider Drug Benefit Changes","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lead (geology); Drug; Business; Risk analysis (engineering); Medicine; Pharmacology","score_opus":0.08331422154918329,"score_gpt":0.31656979228697857,"score_spread":0.2332555707377953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241240264","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029826075,0.0040266095,0.0039334833,0.8360997,0.003963549,0.00016737779,0.00031600185,0.00020215141,0.12146518],"genre_scores_gemma":[0.48223948,0.005413952,0.006810352,0.41599065,0.0069180187,0.00017415182,0.00036550555,0.00011087777,0.08197701],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9872945,0.0030022403,0.00040471187,0.00068435346,0.005957299,0.0026567625],"domain_scores_gemma":[0.925176,0.028969085,0.0074059856,0.003013666,0.013448148,0.021987136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013478284,0.00052074157,0.0007009432,0.002420475,0.004012427,0.011940761,0.0012186088,0.01350473,0.049819436],"category_scores_gemma":[0.061301656,0.0004802599,0.0011778846,0.0013986862,0.0034572673,0.005309563,0.0030911888,0.008711944,0.0032727614],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053714233,0.00309939,0.053559758,0.0005696773,0.00025499042,0.00040319192,0.00078754924,0.0058542998,0.0012405402,0.2004053,0.5088701,0.22441804],"study_design_scores_gemma":[0.0007130804,0.00043604115,0.09706052,0.0009891412,0.0001543998,0.00014119814,0.0038454982,0.005855258,0.0011278047,0.11166678,0.7778177,0.00019254694],"about_ca_topic_score_codex":0.08642634,"about_ca_topic_score_gemma":0.18412589,"teacher_disagreement_score":0.08642634,"about_ca_system_score_codex":0.014614256,"about_ca_system_score_gemma":0.0390724,"threshold_uncertainty_score":0.17184657},"labels":[],"label_agreement":null},{"id":"W4241437092","doi":"10.1177/171516350714000601","title":"BC and Alberta Pharmacists Seek Input into Joint Buying Strategy","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Joint (building); Business; Marketing; Advertising; Medicine; Family medicine; Engineering","score_opus":0.06874095744618008,"score_gpt":0.2767010859288065,"score_spread":0.2079601284826264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241437092","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13286565,0.0022921686,0.0022845226,0.11145973,0.00055071566,0.00022451302,0.00036656146,0.00017170954,0.7497845],"genre_scores_gemma":[0.78847843,0.00095379364,0.00237115,0.015172232,0.00023312855,0.000043319575,0.00024329656,0.000057435762,0.19244726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.990875,0.0013934723,0.00018189623,0.00039798487,0.0040168776,0.0031347508],"domain_scores_gemma":[0.9728969,0.007049718,0.0009831181,0.00077177526,0.00752274,0.0107757235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051849517,0.00036551247,0.00041975293,0.001683102,0.008648702,0.010701589,0.00089347124,0.004381176,0.04885755],"category_scores_gemma":[0.019479088,0.0005096527,0.00036018857,0.0023915488,0.0018508224,0.0021905568,0.0027989128,0.003361968,0.0028035308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065196306,0.0006771221,0.10043008,0.00029250502,0.00011501347,0.0018933966,0.007054583,0.0024702107,0.0028985352,0.147345,0.43714482,0.29902676],"study_design_scores_gemma":[0.00031760847,0.00025224604,0.18062836,0.00029905094,0.000110805566,0.00088936626,0.024734963,0.005017823,0.0017937035,0.027233327,0.7585743,0.00014848435],"about_ca_topic_score_codex":0.6504244,"about_ca_topic_score_gemma":0.86575484,"teacher_disagreement_score":0.97038156,"about_ca_system_score_codex":0.029618414,"about_ca_system_score_gemma":0.079214424,"threshold_uncertainty_score":0.7032686},"labels":[],"label_agreement":null},{"id":"W4241638634","doi":"10.1002/div.7606","title":"Abbott Laboratories","year":2008,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.08134316636998808,"score_gpt":0.2612341988136709,"score_spread":0.17989103244368282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241638634","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005700876,0.032504767,0.022665853,0.018736571,0.01176697,0.0012495902,0.023058303,0.0189231,0.86539394],"genre_scores_gemma":[0.04410562,0.012783436,0.023083683,0.0096547315,0.003146855,0.00094758364,0.021013988,0.001945116,0.883319],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962373,0.00047727712,0.00031877882,0.0011195702,0.0015157829,0.00033133596],"domain_scores_gemma":[0.99648297,0.00062200666,0.00038327207,0.00043486655,0.0011998374,0.0008771813],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002052111,0.0016176846,0.0021408736,0.0031019903,0.00069905934,0.0036234616,0.0015474182,0.0027102113,0.5037031],"category_scores_gemma":[0.005265086,0.00090136006,0.0007609751,0.0017241406,0.0008216297,0.0017916561,0.0015175656,0.0044808015,0.2972603],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025000502,0.00037499177,0.0013297454,0.0010616871,0.00009473107,0.0005699073,0.000092548355,0.00036290794,0.0038061873,0.011038363,0.6002525,0.37851647],"study_design_scores_gemma":[0.0007629012,0.00035879176,0.0014733213,0.00029224847,0.00006242229,0.0012312209,0.000041572337,0.0007000438,0.0012916861,0.003933209,0.98982877,0.000023844039],"about_ca_topic_score_codex":0.0011314298,"about_ca_topic_score_gemma":0.001465715,"teacher_disagreement_score":0.5037031,"about_ca_system_score_codex":0.0011067368,"about_ca_system_score_gemma":0.0030059873,"threshold_uncertainty_score":0.70790726},"labels":[],"label_agreement":null},{"id":"W4241790324","doi":"10.3821/1913-701x-143.4.164","title":"Pharmacists in Canada Challenged to Deal with Drug Shortages","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Drug; Business; Medicine; Pharmacology; Philosophy; Government (linguistics)","score_opus":0.038957714271485,"score_gpt":0.248686951541044,"score_spread":0.209729237269559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241790324","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07199803,0.0026307844,0.0004055439,0.8973688,0.000986848,0.000085297266,0.00041244796,0.00005204325,0.026060171],"genre_scores_gemma":[0.7477199,0.0050071655,0.0014593676,0.20587912,0.001728507,0.000059290633,0.0002942132,0.00004519399,0.037807327],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926644,0.00084534154,0.00018524338,0.00024393758,0.0018185953,0.004242488],"domain_scores_gemma":[0.9639542,0.00332084,0.0024293861,0.00018485152,0.0077497633,0.022360971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048153796,0.00026017477,0.00050783786,0.001425129,0.00944457,0.00792811,0.0018655102,0.011031749,0.009122875],"category_scores_gemma":[0.020124637,0.0005009861,0.00068205554,0.0018966232,0.0029791358,0.0019350447,0.002963684,0.0075792675,0.0006199122],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042421854,0.00053904543,0.11491992,0.0005378644,0.00022910457,0.0044513852,0.0042571407,0.008940121,0.0011432845,0.11554447,0.6729737,0.07603975],"study_design_scores_gemma":[0.0006080036,0.00029351548,0.21559168,0.0009989266,0.00018045699,0.0013610545,0.025029244,0.013179191,0.0006103041,0.027243791,0.7146235,0.00028037693],"about_ca_topic_score_codex":0.95451367,"about_ca_topic_score_gemma":0.9783312,"teacher_disagreement_score":0.07085888,"about_ca_system_score_codex":0.07085888,"about_ca_system_score_gemma":0.29426476,"threshold_uncertainty_score":0.51411957},"labels":[],"label_agreement":null},{"id":"W4242395580","doi":"10.3821/145.5.cpj380","title":"Canada falls short on safeguarding its drug supply","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Safeguarding; Drug; Business; Computer security; Criminology; Medicine; Psychology; Psychiatry; Computer science; Nursing","score_opus":0.06841401077393293,"score_gpt":0.2652409268873919,"score_spread":0.19682691611345898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242395580","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055724713,0.010662949,0.0018204276,0.90905845,0.0096255625,0.00007458394,0.0022239117,0.0006678553,0.060293674],"genre_scores_gemma":[0.1501787,0.013508127,0.007089858,0.63777006,0.005093117,0.000100261546,0.0015108861,0.00035717303,0.18439183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9817809,0.00096292363,0.00049996044,0.0007082151,0.012813459,0.0032344926],"domain_scores_gemma":[0.94961107,0.006388554,0.0018049988,0.001529396,0.02462751,0.016038438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008099314,0.0008691102,0.0016392323,0.0032623706,0.0069134957,0.012613654,0.0033839312,0.01891709,0.021481749],"category_scores_gemma":[0.03913985,0.0006652675,0.0020166489,0.0037765885,0.005009174,0.0038017281,0.002689351,0.0134676555,0.0037305115],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001472009,0.000052183444,0.0021845177,0.00022797009,0.000096246404,0.00016455435,0.00022513008,0.0010505457,0.0006123611,0.078644626,0.8782145,0.038380276],"study_design_scores_gemma":[0.00009366182,0.000050953313,0.004936601,0.00026759517,0.000048559148,0.000054178876,0.00026615823,0.00096790417,0.00037308686,0.015574193,0.97730833,0.00005866626],"about_ca_topic_score_codex":0.9607969,"about_ca_topic_score_gemma":0.9610189,"teacher_disagreement_score":0.07569708,"about_ca_system_score_codex":0.07569708,"about_ca_system_score_gemma":0.3941061,"threshold_uncertainty_score":0.5492233},"labels":[],"label_agreement":null},{"id":"W4242669538","doi":"10.1177/171516351114400401","title":"Alberta Also Moving into Pharmacy Technician Regulation","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy technician; Pharmacy; Technician; Business; Medicine; Medical education; Family medicine; Engineering; Electrical engineering","score_opus":0.08393959551566883,"score_gpt":0.2667134031083221,"score_spread":0.18277380759265327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242669538","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059182193,0.008985609,0.006538947,0.3826532,0.010654007,0.0003861632,0.002286433,0.0011728494,0.5281406],"genre_scores_gemma":[0.15649197,0.0027337219,0.0044174283,0.10937594,0.0011492622,0.0000779528,0.0006869984,0.000101478014,0.7249652],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98987633,0.0006256061,0.00021722878,0.00083657,0.005722796,0.0027214899],"domain_scores_gemma":[0.9845526,0.0018452562,0.0005032759,0.0004664524,0.0072378726,0.005394558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045982245,0.0005779336,0.000588989,0.002738541,0.0077204,0.009575779,0.0027052448,0.0139953,0.029440463],"category_scores_gemma":[0.0077533135,0.0008305261,0.0014477673,0.0027344585,0.0031135695,0.0018597204,0.0022938314,0.0077619464,0.0021581776],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031599205,0.00034403775,0.022054778,0.000388675,0.0001269107,0.0015744506,0.0012055136,0.0032943178,0.005268408,0.35141596,0.5096378,0.104373254],"study_design_scores_gemma":[0.00011255438,0.00008476878,0.035474665,0.00015151655,0.00005815359,0.00017872774,0.0006436524,0.0012642621,0.0011388473,0.005095715,0.9557225,0.00007469925],"about_ca_topic_score_codex":0.9540779,"about_ca_topic_score_gemma":0.9731563,"teacher_disagreement_score":0.9266422,"about_ca_system_score_codex":0.073357835,"about_ca_system_score_gemma":0.25745207,"threshold_uncertainty_score":0.5322509},"labels":[],"label_agreement":null},{"id":"W4243601053","doi":"10.13162/hro-ors.v4i2.2681","title":"Reforming the Regulation of Therapeutic Products in Canada: The Protecting of Canadians from Unsafe Drugs Act (Vanessa’s Law)","year":2016,"lang":"fr","type":"article","venue":"Health Reform Observer - Observatoire des Réformes de Santé","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Law; Business; Political science","score_opus":0.0651486595134997,"score_gpt":0.2744713208779029,"score_spread":0.2093226613644032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243601053","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.104112886,0.05074611,0.017983496,0.48464334,0.0028820608,0.00059522357,0.0061272597,0.00030752277,0.33260214],"genre_scores_gemma":[0.84280133,0.02099723,0.01394274,0.047289725,0.0009949527,0.00017026074,0.0011264517,0.000066185414,0.07261116],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9883797,0.0017281205,0.00026944844,0.0006292977,0.006492277,0.0025011727],"domain_scores_gemma":[0.9923774,0.002367846,0.00071498734,0.00017090695,0.0034118306,0.00095702894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006483906,0.00045619239,0.00052040984,0.0017234341,0.0056933365,0.0068909265,0.0016260837,0.0044396245,0.0032038763],"category_scores_gemma":[0.017477686,0.00048214282,0.00082731573,0.0025640787,0.0048086112,0.001450883,0.0017809685,0.0037665982,0.00031651446],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012945429,0.0000849689,0.00934216,0.0003567548,0.00009555762,0.0004093955,0.0014212681,0.011772758,0.0005860065,0.7794666,0.15560316,0.040731963],"study_design_scores_gemma":[0.00035890596,0.00017607126,0.06519172,0.0011030681,0.00026462993,0.00015846422,0.0015629228,0.026185658,0.0014703613,0.12060972,0.78254956,0.00036890936],"about_ca_topic_score_codex":0.99542975,"about_ca_topic_score_gemma":0.9929779,"teacher_disagreement_score":0.8633328,"about_ca_system_score_codex":0.13666719,"about_ca_system_score_gemma":0.31157172,"threshold_uncertainty_score":0.9915945},"labels":[],"label_agreement":null},{"id":"W4243725364","doi":"10.3821/1913-701x-142.4.165","title":"Drug Purchasing Scheme Triggers Hefty Fines and Criminal Charges for Pharmacies, Wholesalers and Generic Drug Companies","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Purchasing; Pharmacy; Business; Drug; Medicine; Pharmacology; Marketing; Family medicine","score_opus":0.07312520284831585,"score_gpt":0.2730096610454079,"score_spread":0.19988445819709205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243725364","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8438679,0.0008070128,0.00053190003,0.027721616,0.00044562502,0.00022295037,0.0035852804,0.00021845306,0.12259922],"genre_scores_gemma":[0.9678059,0.00022376988,0.0001683024,0.004551968,0.00013942357,0.000020328975,0.00084836374,0.000029557532,0.026212422],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99279433,0.0008111953,0.0003173513,0.00036734174,0.0032958086,0.0024140459],"domain_scores_gemma":[0.9621092,0.014057669,0.009310876,0.0015798537,0.00814058,0.00480177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028459502,0.00020240233,0.000661212,0.0026573832,0.0033442338,0.0042219018,0.0011099962,0.0049170945,0.023739591],"category_scores_gemma":[0.031665582,0.00059105316,0.00069212535,0.001991975,0.000827626,0.0013901913,0.0015040617,0.003824985,0.0023797748],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017633362,0.0011613378,0.6556221,0.00014572324,0.00022603865,0.0027312804,0.0012564118,0.0013716306,0.0012721781,0.029316142,0.23080355,0.07433028],"study_design_scores_gemma":[0.00022849409,0.00033169374,0.9309163,0.000104162355,0.00021196091,0.0011870555,0.0033715968,0.004401895,0.001215899,0.007387105,0.050532226,0.00011160132],"about_ca_topic_score_codex":0.26436874,"about_ca_topic_score_gemma":0.36680233,"teacher_disagreement_score":0.7356312,"about_ca_system_score_codex":0.0068983804,"about_ca_system_score_gemma":0.013060848,"threshold_uncertainty_score":0.5256599},"labels":[],"label_agreement":null},{"id":"W4243737142","doi":"10.1038/s41571-018-0120-1","title":"Addendum: Low-value approvals and high prices might incentivize ineffective drug development","year":2018,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Revenue; Hindsight bias; Profit (economics); Actuarial science; Finance; Economics; Business; Microeconomics","score_opus":0.18648345030762592,"score_gpt":0.46972368995637276,"score_spread":0.28324023964874684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243737142","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019653307,0.76358455,0.0057541905,0.15084934,0.027389254,0.00013298809,0.0024030528,0.00018912218,0.047732107],"genre_scores_gemma":[0.050327037,0.77957636,0.0071544936,0.073556624,0.045841917,0.0002743773,0.0019121653,0.00013094273,0.041226074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849904,0.0005781864,0.00014027116,0.000159535,0.0005077377,0.000115239076],"domain_scores_gemma":[0.9827533,0.013353478,0.0016522298,0.0004590282,0.0014424769,0.00033951298],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035125448,0.00079141883,0.0008720505,0.0013151154,0.0003611584,0.0024236734,0.001073745,0.0034237048,0.059874233],"category_scores_gemma":[0.018941823,0.00021494164,0.0010603414,0.0012293772,0.0011226471,0.00236317,0.0016804088,0.0043077245,0.008894961],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034590106,0.000106393476,0.0007898274,0.010939808,0.00037874313,0.0003271562,0.00008484628,0.0006534287,0.00061153003,0.07186394,0.44829038,0.465608],"study_design_scores_gemma":[0.00020231542,0.000103742685,0.0013099193,0.0057393652,0.0005638195,0.0009107421,0.00006733119,0.000475383,0.00071145047,0.047321305,0.9425589,0.00003586698],"about_ca_topic_score_codex":0.00082206476,"about_ca_topic_score_gemma":0.0022552202,"teacher_disagreement_score":0.99648744,"about_ca_system_score_codex":0.0010174685,"about_ca_system_score_gemma":0.0024550639,"threshold_uncertainty_score":0.20029926},"labels":[],"label_agreement":null},{"id":"W4243838391","doi":"10.1345/aph.1l590a","title":"Comment: The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa","year":2010,"lang":"en","type":"letter","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Darbepoetin alfa; Epoetin alfa; Medicine; Medical physics; Intensive care medicine; Internal medicine; Erythropoietin","score_opus":0.4256081945036461,"score_gpt":0.47627577323056536,"score_spread":0.05066757872691924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243838391","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006895576,0.0003351563,0.00010498361,0.9867878,0.010609786,0.000028967572,0.00022148794,0.000017600309,0.0012046547],"genre_scores_gemma":[0.0020617712,0.0001362903,0.00021029386,0.9882904,0.008178857,0.00004670659,0.000029053544,0.000016433909,0.0010302789],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9635649,0.015858855,0.0067850645,0.0039389096,0.006885452,0.002966985],"domain_scores_gemma":[0.8158436,0.15008031,0.009272955,0.0029656596,0.01698999,0.004847566],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.042319894,0.0012571213,0.002433245,0.0013315222,0.0046006087,0.0052797687,0.0063281422,0.087635435,0.008779176],"category_scores_gemma":[0.19514674,0.0014733683,0.0035931638,0.00289528,0.0055706934,0.0050434372,0.0029870719,0.053645935,0.0058402293],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005135758,0.00005983511,0.0018227084,0.00029596794,0.00015856035,0.00091840397,0.00042386496,0.00024537937,0.0002168857,0.0050592977,0.9835693,0.0067163045],"study_design_scores_gemma":[0.0018813303,0.00034116607,0.009065375,0.0025857822,0.00078059884,0.0019730176,0.002191276,0.0022153952,0.0016820173,0.026005004,0.95086175,0.00041716849],"about_ca_topic_score_codex":0.030472364,"about_ca_topic_score_gemma":0.04398352,"teacher_disagreement_score":0.9576801,"about_ca_system_score_codex":0.0123551125,"about_ca_system_score_gemma":0.0131885335,"threshold_uncertainty_score":0.22381169},"labels":[],"label_agreement":null},{"id":"W4243894068","doi":"10.3821/1913-701x-143.2.63","title":"Alberta Compromises on Generic Drug Pricing to Soften Impact of Cost-Reduction Measures on Pharmacies","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Drug pricing; Reduction (mathematics); Drug; Business; Generic drug; Medicine; Actuarial science; Pharmacology; Family medicine; Mathematics","score_opus":0.07341108497266996,"score_gpt":0.29706570197717314,"score_spread":0.22365461700450318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243894068","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11962071,0.0027682646,0.0065088104,0.31913406,0.0028704894,0.0004133178,0.0012981488,0.0011138687,0.5462723],"genre_scores_gemma":[0.78504795,0.00082558475,0.0065121427,0.10611056,0.0013898766,0.0000965547,0.00031317395,0.00015867855,0.09954557],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97614324,0.0034243956,0.00053098705,0.0008772005,0.014183171,0.0048409807],"domain_scores_gemma":[0.9771582,0.008956591,0.0011786072,0.001027101,0.007911917,0.0037676357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012934449,0.0006949466,0.0007664403,0.0026772832,0.005399323,0.010539563,0.0038923041,0.015378037,0.013716211],"category_scores_gemma":[0.052732587,0.0010500597,0.0014691736,0.0022479692,0.0034094334,0.002432163,0.0028280227,0.008373862,0.00082866603],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012106064,0.0004979981,0.017626623,0.0003300248,0.00043443148,0.0015503721,0.0015777746,0.031327233,0.006153557,0.45299384,0.39906192,0.08723559],"study_design_scores_gemma":[0.0012780859,0.00084636145,0.15889694,0.000579395,0.0006595286,0.00070344115,0.002000345,0.040799934,0.0051381807,0.08201116,0.7064656,0.0006210351],"about_ca_topic_score_codex":0.77181005,"about_ca_topic_score_gemma":0.8715739,"teacher_disagreement_score":0.22818995,"about_ca_system_score_codex":0.055843122,"about_ca_system_score_gemma":0.10247953,"threshold_uncertainty_score":0.45906758},"labels":[],"label_agreement":null},{"id":"W4244057138","doi":"10.1503/cmaj.170248","title":"Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada","year":2017,"lang":"en","type":"erratum","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Public health; Medicine; Essential drugs; Data science; Environmental health; Nursing; Health services","score_opus":0.029587557810663533,"score_gpt":0.27049652574935146,"score_spread":0.24090896793868793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244057138","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66002303,0.016043732,0.0035385569,0.032450736,0.0017965656,0.00090886187,0.23777819,0.0007215614,0.046738684],"genre_scores_gemma":[0.93870795,0.004438457,0.0020648274,0.0015545023,0.00021182813,0.00012388603,0.026074683,0.00009113169,0.026732648],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970505,0.0005917164,0.00016812385,0.00030834333,0.0006575369,0.0012237519],"domain_scores_gemma":[0.99202806,0.0024730281,0.0008401766,0.00020813865,0.0034425694,0.0010080945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022547117,0.0009277897,0.001671039,0.0015501117,0.0010228329,0.0025507852,0.0021040828,0.0011458494,0.015772609],"category_scores_gemma":[0.011934056,0.00070661365,0.0031048171,0.0028490573,0.0009938907,0.00082110614,0.0017605384,0.0039005359,0.0010435649],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042551775,0.00068243046,0.43075034,0.0013493078,0.0045018336,0.0010745561,0.0005783455,0.20869765,0.0005421542,0.03088023,0.2614585,0.055229418],"study_design_scores_gemma":[0.0050192135,0.0011224116,0.60119987,0.0015734724,0.013105913,0.00037401446,0.005535925,0.25401345,0.0034887479,0.008366325,0.10567145,0.00052920944],"about_ca_topic_score_codex":0.99574393,"about_ca_topic_score_gemma":0.9939673,"teacher_disagreement_score":0.056137502,"about_ca_system_score_codex":0.056137502,"about_ca_system_score_gemma":0.07637118,"threshold_uncertainty_score":0.40730798},"labels":[],"label_agreement":null},{"id":"W4244145168","doi":"10.1016/j.kint.2016.09.025","title":"The Authors Reply","year":2016,"lang":"en","type":"letter","venue":"Kidney International","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; University Health Network","funders":"","keywords":"Disease; Kidney disease; Medicine; Scopus; Heredity; Counterfeit; Traditional medicine; Family medicine; MEDLINE; Pathology; Genetics; Internal medicine; Political science; Biology","score_opus":0.05207962826794838,"score_gpt":0.28826474626607634,"score_spread":0.23618511799812797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244145168","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021673946,0.00086367794,0.000061959174,0.9743692,0.022337796,0.000018776109,0.00006386278,0.000023347196,0.0020446093],"genre_scores_gemma":[0.0009665167,0.00022787486,0.000037097056,0.9840385,0.0097501455,0.000026878593,0.000010976206,0.000013009233,0.0049290117],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889859,0.0021655136,0.0012042947,0.0018427474,0.0028697476,0.0029317648],"domain_scores_gemma":[0.9794693,0.010856759,0.0018815978,0.00077518047,0.003513501,0.003503607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00928589,0.001254545,0.0036499281,0.0015527338,0.009175382,0.013134671,0.0047164885,0.1810154,0.013420537],"category_scores_gemma":[0.06591695,0.0021117646,0.0032583768,0.0012689318,0.00680073,0.0062736915,0.0055132727,0.107967265,0.010993235],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045411674,0.000015458148,0.0003529148,0.00004858376,0.000029648481,0.0006659544,0.00023527932,0.000044682653,0.00008954023,0.0034694143,0.99282587,0.0021772182],"study_design_scores_gemma":[0.00014548289,0.000043452535,0.0014373874,0.0005285216,0.00008117042,0.00053400657,0.0009020648,0.00027432485,0.00028031893,0.011155922,0.9844505,0.00016677326],"about_ca_topic_score_codex":0.023299672,"about_ca_topic_score_gemma":0.031092742,"teacher_disagreement_score":0.1810154,"about_ca_system_score_codex":0.010176313,"about_ca_system_score_gemma":0.015753567,"threshold_uncertainty_score":0.07383466},"labels":[],"label_agreement":null},{"id":"W4244575943","doi":"10.1038/ki.2010.121","title":"The Authors Reply:","year":2010,"lang":"en","type":"article","venue":"Kidney International","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Scopus; Rosuvastatin; Medicine; Statin; Atorvastatin; Randomized controlled trial; Medical prescription; MEDLINE; Hemodialysis; Family medicine; Internal medicine; Pharmacology; Political science; Law","score_opus":0.03509962690311793,"score_gpt":0.2935718319874536,"score_spread":0.2584722050843357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244575943","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002723518,0.000745109,0.000072284376,0.9621678,0.035975873,0.000009813781,0.00005617489,0.000024874405,0.0006756824],"genre_scores_gemma":[0.0013552901,0.00028333723,0.000057196976,0.98458385,0.011389654,0.000018749792,0.000013473503,0.000013515985,0.002284981],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939027,0.00139006,0.0008097859,0.0012486337,0.0015604179,0.0010884558],"domain_scores_gemma":[0.97560424,0.013057765,0.0021013194,0.0009789794,0.005629126,0.0026286615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007828119,0.0010147281,0.0027471124,0.0013841992,0.005043758,0.0071156626,0.0038733594,0.08022458,0.011888447],"category_scores_gemma":[0.060032476,0.0015518611,0.0023179373,0.0012640998,0.005239726,0.005399735,0.004197332,0.073532894,0.008778739],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051707266,0.000012230567,0.00043069402,0.000059768485,0.00003843272,0.0003250658,0.00018523935,0.000037466136,0.000115200186,0.0018080435,0.9955913,0.0013448558],"study_design_scores_gemma":[0.00013628743,0.000054794633,0.002681979,0.00036423432,0.00012316325,0.0007819252,0.0016830936,0.0002955832,0.00072330056,0.0057818345,0.98716277,0.00021105973],"about_ca_topic_score_codex":0.007791274,"about_ca_topic_score_gemma":0.007774494,"teacher_disagreement_score":0.08022458,"about_ca_system_score_codex":0.004568041,"about_ca_system_score_gemma":0.0059738625,"threshold_uncertainty_score":0.04139954},"labels":[],"label_agreement":null},{"id":"W4244895795","doi":"10.1377/forefront.20130528.031611","title":"Strengthen Medicare: End Drug Company Price Setting","year":2013,"lang":"en","type":"dataset","venue":"Forefront Group","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Operations management; Actuarial science; Economics; Medicine; Pharmacology","score_opus":0.035019468074938824,"score_gpt":0.2571944976735281,"score_spread":0.22217502959858926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244895795","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042121386,0.00013964412,0.0001230996,0.00029533156,0.000024508154,0.0000136040235,0.99668676,0.00031486936,0.0019809376],"genre_scores_gemma":[0.0023368236,0.00020179867,0.00040331413,0.00024558557,0.00003240482,0.00008386307,0.99482805,0.000111068955,0.0017571297],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998456,0.00025086725,0.00021672292,0.00030152107,0.00051988976,0.000254977],"domain_scores_gemma":[0.9951433,0.0008738285,0.0013884846,0.0007982169,0.0013954313,0.00040080503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012026912,0.0012986005,0.00091746385,0.0038927733,0.0005713315,0.0026662026,0.0018697451,0.0015568421,0.057393547],"category_scores_gemma":[0.0105429655,0.0006029161,0.0010907119,0.009796731,0.00026884043,0.0017542344,0.001609771,0.002045754,0.052293114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006858733,0.00002823575,0.0046751807,0.0001843307,0.00003222294,0.000016170217,0.000008561777,0.0002502667,0.000014336255,0.0005503127,0.98897636,0.0051953807],"study_design_scores_gemma":[0.00041388132,0.00003628444,0.02606099,0.00039953904,0.000049086288,0.00010509409,0.000070114795,0.0015516051,0.00026219542,0.0019710406,0.96903324,0.00004674627],"about_ca_topic_score_codex":0.064977795,"about_ca_topic_score_gemma":0.06940036,"teacher_disagreement_score":0.064977795,"about_ca_system_score_codex":0.0023294706,"about_ca_system_score_gemma":0.0028722945,"threshold_uncertainty_score":0.19200057},"labels":[],"label_agreement":null},{"id":"W4245736962","doi":"10.4102/hsag.v21i0.991","title":"Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013","year":2016,"lang":"en","type":"article","venue":"Health SA Gesondheid","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Antipsychotic; Defined daily dose; Medicine; Pharmacoepidemiology; Population; Psychiatry; Schizophrenia (object-oriented programming); Medical prescription; Environmental health; Drug; Pharmacology","score_opus":0.08670254261078536,"score_gpt":0.3180471346277256,"score_spread":0.23134459201694024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245736962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979106,0.002592871,0.0011162619,0.0008670671,0.000034137975,0.00007811876,0.011253179,0.000051867726,0.004900516],"genre_scores_gemma":[0.9912224,0.0015468098,0.0012376892,0.00015997399,0.000039380742,0.00005464702,0.005047829,0.000007363057,0.0006839237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988096,0.00032426082,0.0001624735,0.000115434,0.00038846786,0.0001996894],"domain_scores_gemma":[0.9986854,0.00018623,0.0008328622,0.00004678373,0.00016391414,0.00008477591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009044334,0.0003675414,0.00033717696,0.0009142539,0.00018268319,0.000581303,0.00042497757,0.00034812602,0.0017686851],"category_scores_gemma":[0.0035463737,0.00020386386,0.0015823487,0.001259008,0.00021624014,0.00035684084,0.00065044046,0.0005143912,0.00026170033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042097797,0.00019306749,0.861033,0.0007862364,0.0011264357,0.0006814427,0.00014609261,0.009885178,0.0030578377,0.0013109897,0.004852427,0.112717494],"study_design_scores_gemma":[0.0000877574,0.00039560205,0.9885443,0.0001702356,0.00056092924,0.00096870726,0.00014918501,0.0027883302,0.0012146417,0.00043839865,0.0046626455,0.000019317089],"about_ca_topic_score_codex":0.012899739,"about_ca_topic_score_gemma":0.017291902,"teacher_disagreement_score":0.012899739,"about_ca_system_score_codex":0.0036338505,"about_ca_system_score_gemma":0.0017754355,"threshold_uncertainty_score":0.026365578},"labels":[],"label_agreement":null},{"id":"W4245833257","doi":"10.1377/forefront.20200925.874730","title":"Administration Finalizes Drug Importation Plans, But Legal And Practical Questions Remain","year":2020,"lang":"en","type":"dataset","venue":"Forefront Group","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Yesterday; Administration (probate law); Element (criminal law); Business; Drug administration; Prescription drug; Medical prescription; Public administration; Food and drug administration; Law and economics; Political science; Law; Pharmacology; Economics; Risk analysis (engineering); Medicine","score_opus":0.047043340236014045,"score_gpt":0.31083553922784696,"score_spread":0.2637921989918329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245833257","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017205275,0.000058604193,0.0001520183,0.00040396265,0.00006337688,0.000012247236,0.99556196,0.00023266661,0.0033431049],"genre_scores_gemma":[0.00090807746,0.00010111505,0.0005762497,0.00022501791,0.000017488259,0.00006518748,0.9947948,0.000073080286,0.0032389774],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969382,0.00039981556,0.0003708319,0.00045226878,0.0014277312,0.0004112105],"domain_scores_gemma":[0.99086326,0.0017290182,0.0013357389,0.0022388585,0.0032784478,0.0005546486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034006017,0.0013417643,0.001181646,0.0043239165,0.0009817128,0.004063369,0.0026654939,0.0025443232,0.04929243],"category_scores_gemma":[0.013871487,0.00091795047,0.0010921177,0.0079105245,0.00050350616,0.0021344968,0.0018307475,0.0033392643,0.071263],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033440603,0.000017323873,0.0011626574,0.00011571138,0.00001088059,0.00000905001,0.00000754774,0.00014816475,0.000021569245,0.0014759878,0.99488586,0.0021117644],"study_design_scores_gemma":[0.000068597554,0.000013388642,0.0054641864,0.00014941959,0.000011435728,0.000034048502,0.00004677438,0.0004886937,0.00023500792,0.0014573971,0.99200976,0.000021288259],"about_ca_topic_score_codex":0.09248111,"about_ca_topic_score_gemma":0.13937706,"teacher_disagreement_score":0.09248111,"about_ca_system_score_codex":0.004280474,"about_ca_system_score_gemma":0.0052709584,"threshold_uncertainty_score":0.18388563},"labels":[],"label_agreement":null},{"id":"W4245860914","doi":"10.32388/0zwgt7","title":"Canada DrugBank","year":2020,"lang":"en","type":"reference-entry","venue":"Definitions","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DrugBank; Medicine; Pharmacology","score_opus":0.1670936865811174,"score_gpt":0.27161503631682643,"score_spread":0.10452134973570903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245860914","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038554092,0.002927026,0.0004552278,0.0067673605,0.0014045545,0.00017239062,0.042900987,0.0007658379,0.94422114],"genre_scores_gemma":[0.0017036317,0.0012796805,0.00046334782,0.0015449267,0.00014169129,0.000056560293,0.008949505,0.00025425456,0.9856064],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99584144,0.00021456205,0.00013491578,0.0005333697,0.0026577162,0.000617939],"domain_scores_gemma":[0.9933136,0.00042466333,0.00018935575,0.0003626791,0.004610187,0.0010995991],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017942394,0.0016685391,0.001411664,0.0073732585,0.0049594534,0.010825488,0.0023347184,0.00412112,0.4680866],"category_scores_gemma":[0.0072621964,0.0009214428,0.0008409654,0.007251376,0.0014236605,0.0025910363,0.001878412,0.0045590345,0.2750726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014815127,0.000011869757,0.00006650123,0.000051269013,0.0000019853123,0.000012620647,0.000012613585,0.00004700126,0.00003720766,0.01387204,0.97382677,0.012045297],"study_design_scores_gemma":[0.000007977568,0.000003058253,0.00034407218,0.00004321361,0.0000020352393,0.000008622781,0.0000149816115,0.000055937286,0.00005246124,0.0009991811,0.9984615,0.0000069349326],"about_ca_topic_score_codex":0.7998454,"about_ca_topic_score_gemma":0.8632582,"teacher_disagreement_score":0.4680866,"about_ca_system_score_codex":0.033952728,"about_ca_system_score_gemma":0.07064545,"threshold_uncertainty_score":0.7587099},"labels":[],"label_agreement":null},{"id":"W4246684384","doi":"10.1503/cmaj.050460","title":"Prescription drug expenditures rising -- too fast?","year":2005,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Computer science; Prescription drug; Data science; Medicine; World Wide Web; Pharmacology","score_opus":0.023715853902406086,"score_gpt":0.24948181486364404,"score_spread":0.22576596096123797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246684384","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012322554,0.001950018,0.00007256906,0.98621017,0.0026999628,0.000005651751,0.00025029987,0.000029080447,0.0075500417],"genre_scores_gemma":[0.025770925,0.0052711647,0.0002673869,0.95119256,0.012269566,0.000011508841,0.0002037605,0.00006403384,0.0049490463],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995389,0.0007701211,0.00035780127,0.00043039833,0.0022811233,0.0007715944],"domain_scores_gemma":[0.9805876,0.0069950586,0.0030594533,0.0006367668,0.0053085107,0.0034125755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045383824,0.000429787,0.000782728,0.0015873943,0.0028331345,0.0053480454,0.001207291,0.012787467,0.015238958],"category_scores_gemma":[0.036832187,0.00035217564,0.0007215456,0.0028242467,0.0025477635,0.005486318,0.0013309232,0.015283108,0.0049523073],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052671214,0.000016742286,0.0043981075,0.00007118793,0.000015926511,0.00028361753,0.00016461474,0.00003457097,0.00009305009,0.0077839633,0.95611686,0.030968724],"study_design_scores_gemma":[0.00010139317,0.000073844785,0.0297173,0.0013693015,0.00005727327,0.0011745421,0.0017322176,0.0004963987,0.0003327225,0.018535197,0.9463106,0.00009931179],"about_ca_topic_score_codex":0.14106293,"about_ca_topic_score_gemma":0.1984069,"teacher_disagreement_score":0.8589371,"about_ca_system_score_codex":0.011841075,"about_ca_system_score_gemma":0.0126117775,"threshold_uncertainty_score":0.28048366},"labels":[],"label_agreement":null},{"id":"W4246933292","doi":"10.2139/ssrn.2261740","title":"Pharmaceutical Followers","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Business","score_opus":0.03190136203016355,"score_gpt":0.279585688794307,"score_spread":0.24768432676414345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246933292","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03834318,0.0029060158,0.0020770032,0.02397978,0.003411023,0.00033531556,0.0021741912,0.00047339598,0.9263002],"genre_scores_gemma":[0.061460756,0.0008281269,0.00040506248,0.005864537,0.0012817665,0.00009246395,0.0005144134,0.000062921274,0.92949],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99865806,0.00016675812,0.000061920146,0.00021752698,0.00057497463,0.00032070687],"domain_scores_gemma":[0.99396133,0.0010934497,0.0008287178,0.0008674077,0.0011577337,0.002091341],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014777579,0.00038618656,0.00043671974,0.0014968073,0.0021627522,0.0034803187,0.0007431269,0.0022521794,0.321153],"category_scores_gemma":[0.00748522,0.00027090628,0.00049873715,0.0008213401,0.0004624506,0.0019709922,0.0016787946,0.0024084009,0.11194231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003224695,0.00040297158,0.012435491,0.00025128527,0.00003727708,0.0009791696,0.00075154984,0.0001818786,0.0021754531,0.035305537,0.67166555,0.2754914],"study_design_scores_gemma":[0.000058314912,0.00019839431,0.011171943,0.000093544644,0.000023487904,0.00076133147,0.00051543553,0.0005088753,0.0009002636,0.0036339127,0.9821148,0.000019590021],"about_ca_topic_score_codex":0.0018557655,"about_ca_topic_score_gemma":0.0033361602,"teacher_disagreement_score":0.321153,"about_ca_system_score_codex":0.000873297,"about_ca_system_score_gemma":0.001635472,"threshold_uncertainty_score":0.96829283},"labels":[],"label_agreement":null},{"id":"W4247614496","doi":"10.2174/1874120701004010025","title":"Achieving a Dream: Meeting Policy Goals Related to Improving Drug Access","year":2010,"lang":"en","type":"article","venue":"The Open AIDS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Canadian Society for International Health; University of Toronto; Health Canada","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Face (sociological concept); Access to medicines; Public relations; Economic growth; Developing country; Development economics; Internet privacy; Political science; Social science; Sociology; Family medicine; Economics; Computer science","score_opus":0.05368159080485699,"score_gpt":0.35792932113244624,"score_spread":0.3042477303275892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247614496","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007253849,0.01038273,0.007989732,0.93629724,0.0011838325,0.000055553865,0.00025152133,0.0001324642,0.036453113],"genre_scores_gemma":[0.5525599,0.039986033,0.03172775,0.34365216,0.00784613,0.0005485609,0.00055516465,0.00017045054,0.022953885],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.990604,0.005015692,0.000365091,0.0005898733,0.0016217574,0.0018036021],"domain_scores_gemma":[0.98148245,0.008161445,0.0020970572,0.00090738473,0.0022468313,0.005104884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017220022,0.0007871977,0.0012147896,0.0017670963,0.002512018,0.01086611,0.0024736112,0.01702715,0.013894923],"category_scores_gemma":[0.03464194,0.00035662795,0.0008806998,0.0021832285,0.0074435696,0.023294365,0.0075142253,0.010503235,0.0030332406],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001146206,0.00024237359,0.001580145,0.00055129756,0.000044436892,0.00020884386,0.00070144027,0.0028698815,0.0003962344,0.84172404,0.10967377,0.041893084],"study_design_scores_gemma":[0.00008672033,0.00012313154,0.002067987,0.00075120036,0.000020797223,0.00020487983,0.0021724913,0.0029960484,0.00035644142,0.8232565,0.16791022,0.000053577256],"about_ca_topic_score_codex":0.0069922213,"about_ca_topic_score_gemma":0.0031814037,"teacher_disagreement_score":0.017220022,"about_ca_system_score_codex":0.005720144,"about_ca_system_score_gemma":0.020653425,"threshold_uncertainty_score":0.09106928},"labels":[],"label_agreement":null},{"id":"W4248447100","doi":"10.3821/1913-701x-144.4.161","title":"Alberta also moving into pharmacy technician regulation","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy technician; Pharmacy; Technician; Medical education; Medicine; Nursing; Engineering; Electrical engineering","score_opus":0.08393959551566883,"score_gpt":0.2667134031083221,"score_spread":0.18277380759265327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248447100","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059182193,0.008985609,0.006538947,0.3826532,0.010654007,0.0003861632,0.002286433,0.0011728494,0.5281406],"genre_scores_gemma":[0.15649197,0.0027337219,0.0044174283,0.10937594,0.0011492622,0.0000779528,0.0006869984,0.000101478014,0.7249652],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98987633,0.0006256061,0.00021722878,0.00083657,0.005722796,0.0027214899],"domain_scores_gemma":[0.9845526,0.0018452562,0.0005032759,0.0004664524,0.0072378726,0.005394558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045982245,0.0005779336,0.000588989,0.002738541,0.0077204,0.009575779,0.0027052448,0.0139953,0.029440463],"category_scores_gemma":[0.0077533135,0.0008305261,0.0014477673,0.0027344585,0.0031135695,0.0018597204,0.0022938314,0.0077619464,0.0021581776],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031599205,0.00034403775,0.022054778,0.000388675,0.0001269107,0.0015744506,0.0012055136,0.0032943178,0.005268408,0.35141596,0.5096378,0.104373254],"study_design_scores_gemma":[0.00011255438,0.00008476878,0.035474665,0.00015151655,0.00005815359,0.00017872774,0.0006436524,0.0012642621,0.0011388473,0.005095715,0.9557225,0.00007469925],"about_ca_topic_score_codex":0.9540779,"about_ca_topic_score_gemma":0.9731563,"teacher_disagreement_score":0.9266422,"about_ca_system_score_codex":0.073357835,"about_ca_system_score_gemma":0.25745207,"threshold_uncertainty_score":0.5322509},"labels":[],"label_agreement":null},{"id":"W4248681043","doi":"10.3821/1913-701x-144.1.12b","title":"Quebec Government Reveals Details of Plan to Match Ontario Generic Drug Pricing","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug pricing; Plan (archaeology); Government (linguistics); Business; Computer science; Geography; Actuarial science; Archaeology","score_opus":0.08995293817803823,"score_gpt":0.23718299521928152,"score_spread":0.14723005704124328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248681043","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044756804,0.0019871518,0.0034174165,0.13768506,0.0031956302,0.0017670328,0.093558334,0.0020605188,0.71157193],"genre_scores_gemma":[0.12857772,0.0013504905,0.0041803755,0.028056443,0.00059603056,0.00044967025,0.012643492,0.00037259105,0.8237732],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99615854,0.00023496471,0.00010974014,0.00016525906,0.0023997265,0.0009318203],"domain_scores_gemma":[0.99098575,0.0015274177,0.0002672565,0.00029544425,0.0060872333,0.00083697506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001973314,0.00039483598,0.00041150668,0.0017384338,0.004866854,0.0036614393,0.0011405271,0.0041817036,0.05684319],"category_scores_gemma":[0.010762278,0.000677857,0.0008330274,0.002354758,0.00064504676,0.00089031924,0.00054468936,0.0025228409,0.0065479353],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011474727,0.00005772767,0.005893264,0.00006185195,0.000023919614,0.00014606069,0.00018751863,0.0009948079,0.00034531966,0.0072971624,0.97166944,0.013208174],"study_design_scores_gemma":[0.000117757656,0.00003835616,0.031800557,0.00005499603,0.000033560227,0.00004357229,0.00037213898,0.0024967887,0.0005784046,0.00067187054,0.96372604,0.00006598718],"about_ca_topic_score_codex":0.9849851,"about_ca_topic_score_gemma":0.99323785,"teacher_disagreement_score":0.93795055,"about_ca_system_score_codex":0.062049426,"about_ca_system_score_gemma":0.10283981,"threshold_uncertainty_score":0.45020223},"labels":[],"label_agreement":null},{"id":"W4249018754","doi":"10.21518/1561-5936-2014-4-48-53","title":"Steps to Success: changes in the ranking of pharmaceutical producers in the iv quarter of 2013","year":2014,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Ranking (information retrieval); Business; Computer science; Information retrieval; Geography","score_opus":0.032355899338920684,"score_gpt":0.30273915032552595,"score_spread":0.27038325098660526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249018754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8908203,0.0014891486,0.0005897501,0.050138935,0.0005923424,0.000058031157,0.01785947,0.00018189305,0.038270142],"genre_scores_gemma":[0.98547703,0.00042189864,0.00020021453,0.0011727021,0.00015117195,0.000020205105,0.0034406267,0.000030515199,0.009085576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998428,0.00016491648,0.00010258078,0.000100634104,0.0004848321,0.00071906415],"domain_scores_gemma":[0.99436605,0.0003458451,0.0015628204,0.00008789905,0.0020195895,0.0016177498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022275692,0.00017098704,0.00029787637,0.0015003434,0.000874706,0.0033332459,0.0005526322,0.0010010827,0.005972359],"category_scores_gemma":[0.0065544494,0.00016984795,0.00031772832,0.0021672382,0.00045946092,0.0012831503,0.0012254606,0.0010848059,0.0013652699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013145375,0.00022643192,0.7315433,0.00020163834,0.000106605905,0.0005373787,0.0037953334,0.0016183903,0.0010956172,0.011003412,0.19523741,0.05331988],"study_design_scores_gemma":[0.000021683598,0.00008256686,0.9701341,0.000033510627,0.000012187117,0.00005483311,0.0043127425,0.00076653535,0.00037689137,0.00046140372,0.023722332,0.00002108512],"about_ca_topic_score_codex":0.10856075,"about_ca_topic_score_gemma":0.14316969,"teacher_disagreement_score":0.10856075,"about_ca_system_score_codex":0.003396598,"about_ca_system_score_gemma":0.005990796,"threshold_uncertainty_score":0.21585768},"labels":[],"label_agreement":null},{"id":"W4249522221","doi":"10.1111/j.1538-7836.2006.01863.x","title":"Talking about…","year":2006,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Certification; Audit; Business; German; Management; Accounting; Economics","score_opus":0.08685233289832375,"score_gpt":0.3135475061597368,"score_spread":0.22669517326141306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249522221","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040754476,0.011219297,0.0023296159,0.64511615,0.029565424,0.00001565621,0.0001300527,0.000064002976,0.30748433],"genre_scores_gemma":[0.20422047,0.014445731,0.0014872114,0.38702723,0.03860043,0.000095393756,0.00025027271,0.00021003337,0.35366324],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953778,0.0023079119,0.00019533055,0.0005192274,0.0010758621,0.000523841],"domain_scores_gemma":[0.99364233,0.002910606,0.00072548306,0.0005311418,0.0012349183,0.00095539866],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00516093,0.0004543954,0.00044762893,0.0009924283,0.00391242,0.0074505974,0.0007966734,0.0052220873,0.0397734],"category_scores_gemma":[0.023637071,0.00024264982,0.00043876295,0.0009067217,0.0067353873,0.0071691903,0.0025835275,0.009561833,0.012629437],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064964355,0.000031069423,0.00092968973,0.00012220156,0.000027237253,0.00017438167,0.007979691,0.00007081669,0.00018084313,0.36419696,0.5859892,0.040232886],"study_design_scores_gemma":[0.000009263915,0.000020742498,0.00062958285,0.00023439941,0.000013876431,0.00025654086,0.0031115278,0.00006400141,0.00012624764,0.06483199,0.9306816,0.000020353546],"about_ca_topic_score_codex":0.0019891066,"about_ca_topic_score_gemma":0.0023396316,"teacher_disagreement_score":0.9602266,"about_ca_system_score_codex":0.0019428687,"about_ca_system_score_gemma":0.002115362,"threshold_uncertainty_score":0.13305527},"labels":[],"label_agreement":null},{"id":"W4249635125","doi":"10.1177/171516350714000111","title":"Threat to Canadian Drug Supply Increases","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.04631851956006836,"score_gpt":0.26696087519509504,"score_spread":0.22064235563502668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249635125","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.069363005,0.00715568,0.0006503272,0.6847892,0.0027620313,0.000069513386,0.004026904,0.00026753463,0.23091584],"genre_scores_gemma":[0.70299196,0.008532315,0.0009572252,0.16078074,0.0034209404,0.000052276002,0.0015440163,0.00012330669,0.121597156],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9918544,0.00042291012,0.00017790981,0.00041337314,0.0048767664,0.002254584],"domain_scores_gemma":[0.98179114,0.0025530648,0.0013162729,0.00042158342,0.009863868,0.0040541156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033433344,0.0004901367,0.00063287147,0.003209142,0.00745404,0.008818404,0.0016891782,0.011321833,0.025828047],"category_scores_gemma":[0.023565903,0.00052358425,0.001253609,0.0039817556,0.0029870009,0.002163632,0.0022249562,0.007080648,0.0015512634],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047078586,0.00011802394,0.023729566,0.00031460717,0.00013367718,0.0013528279,0.0012169351,0.00403279,0.0011457085,0.2849055,0.63733184,0.045247734],"study_design_scores_gemma":[0.00015044943,0.000054442527,0.051594615,0.00018109455,0.00005932289,0.0003320892,0.0014845137,0.002745595,0.0005004508,0.016813068,0.92595214,0.00013222288],"about_ca_topic_score_codex":0.97688204,"about_ca_topic_score_gemma":0.9776628,"teacher_disagreement_score":0.10759137,"about_ca_system_score_codex":0.10759137,"about_ca_system_score_gemma":0.14950328,"threshold_uncertainty_score":0.7806337},"labels":[],"label_agreement":null},{"id":"W4249687475","doi":"10.1089/blr.2007.9911","title":"PTO Agrees to Review Patents on Anti-HIV Drug; Canadian Decision May or May Not Have Profound Implications; PTO Strives to Get a Handle on <i>Markush</i> Claim; CAFC Agrees Patent Law Preempts D.C. Price-Control Measure","year":2007,"lang":"en","type":"article","venue":"Biotechnology Law Report","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Patent law; Law; Control (management); Political science; Law and economics; Business; Economics; Medicine; Virology; Intellectual property; Management","score_opus":0.084812807088495,"score_gpt":0.31325044976366906,"score_spread":0.22843764267517405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249687475","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006071235,0.0012825328,0.0017885214,0.3397746,0.0072713704,0.0003504222,0.0033144592,0.00064371544,0.63950306],"genre_scores_gemma":[0.057952,0.00084415043,0.0029329178,0.21586789,0.0021673136,0.00015524044,0.0009741075,0.00023515413,0.7188711],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98776895,0.0004990047,0.00044036587,0.001084619,0.0070964578,0.0031105008],"domain_scores_gemma":[0.9767346,0.004775369,0.00071984925,0.0012986439,0.013441394,0.0030302608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061936444,0.00048493137,0.0014425946,0.0018193983,0.012656962,0.008650252,0.0033101737,0.029360691,0.05251686],"category_scores_gemma":[0.027419131,0.00084792887,0.001923267,0.0022832756,0.00274847,0.003338287,0.0016035364,0.014266463,0.0209371],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011046206,0.00006648377,0.00111905,0.00006232226,0.000028140183,0.00034766106,0.00019433639,0.00008829745,0.00092762714,0.053175174,0.9340856,0.009794846],"study_design_scores_gemma":[0.00006141919,0.0000437905,0.003506765,0.00006997495,0.00006327283,0.0001920552,0.00021871,0.00045362997,0.0018227443,0.0048973444,0.98859113,0.00007916825],"about_ca_topic_score_codex":0.48018494,"about_ca_topic_score_gemma":0.66934043,"teacher_disagreement_score":0.5198151,"about_ca_system_score_codex":0.020346606,"about_ca_system_score_gemma":0.06962698,"threshold_uncertainty_score":0.9547799},"labels":[],"label_agreement":null},{"id":"W4249714071","doi":"10.1177/171516350714000313","title":"BC Program — Extra Compensation for Deciding Not to Fill a Prescription","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Compensation (psychology); Medicine; Business; Psychology; Pharmacology; Social psychology","score_opus":0.11667514674457966,"score_gpt":0.3281795375108488,"score_spread":0.21150439076626912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249714071","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2863153,0.0018713496,0.0025074584,0.18461101,0.0033616966,0.001328865,0.008535405,0.0009695592,0.51049936],"genre_scores_gemma":[0.77424985,0.000559553,0.00195949,0.026440226,0.0016061732,0.00020672962,0.0019106395,0.00010217124,0.19296506],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99334735,0.0010279565,0.00022949521,0.00033242116,0.002959102,0.002103617],"domain_scores_gemma":[0.9727213,0.007778615,0.0014670516,0.00091898546,0.0053084767,0.011805506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030741638,0.0003110998,0.00064246013,0.0019428522,0.0033002805,0.0029083954,0.0018064566,0.00511135,0.04912808],"category_scores_gemma":[0.028357958,0.00049242005,0.00058663817,0.0013207997,0.0010230922,0.00087777845,0.0013137395,0.0039523165,0.0039393175],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018777032,0.0018483684,0.08882457,0.00019996903,0.0001685079,0.0011260316,0.00040943892,0.0025001792,0.00130952,0.020804847,0.6484453,0.23248562],"study_design_scores_gemma":[0.001631433,0.0018907953,0.45746484,0.00043054472,0.00054849393,0.003019899,0.0020787374,0.021251084,0.0024861346,0.01222444,0.49679735,0.00017628419],"about_ca_topic_score_codex":0.45638826,"about_ca_topic_score_gemma":0.64297944,"teacher_disagreement_score":0.54361176,"about_ca_system_score_codex":0.011677326,"about_ca_system_score_gemma":0.045916643,"threshold_uncertainty_score":0.90746355},"labels":[],"label_agreement":null},{"id":"W4249848371","doi":"10.1142/s0219030315000816","title":"INSIDE INDUSTRY","year":2015,"lang":"en","type":"article","venue":"Asia-Pacific Biotech News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Daratumumab; Health care; Disease control; Business; Quarter (Canadian coin); Engineering; Medicine; Management; Medical education; Political science; Environmental health; Internal medicine; Geography; Economics","score_opus":0.12173767522859101,"score_gpt":0.29511956228963204,"score_spread":0.17338188706104102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249848371","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054348115,0.0019264872,0.0014046443,0.0077412794,0.0031823015,0.000118941876,0.0019507265,0.0024745932,0.9806575],"genre_scores_gemma":[0.0022834935,0.0009748105,0.00044630672,0.0021505142,0.0004282361,0.00003293531,0.0013804113,0.00042529352,0.99187803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969386,0.00025761928,0.00013552039,0.00052897056,0.0016909374,0.00044849183],"domain_scores_gemma":[0.9912986,0.0006041098,0.00059411203,0.0013012323,0.0033207727,0.0028811547],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021305305,0.0013593154,0.00064487744,0.002054031,0.0018671384,0.011026126,0.0011329326,0.0034401696,0.76846975],"category_scores_gemma":[0.006988712,0.0006545288,0.0008703202,0.0022051728,0.0009062639,0.005796412,0.0038861595,0.0027696628,0.734709],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024306157,0.00004456977,0.0002572238,0.000096383046,0.0000032003038,0.00005920882,0.00004828756,0.000034686418,0.00030794184,0.0058745923,0.9150778,0.078171715],"study_design_scores_gemma":[0.0000035745227,0.000008966839,0.00019643374,0.000042274893,9.3108724e-7,0.000047826037,0.000032941403,0.000023904524,0.00007700876,0.00046383817,0.9990988,0.0000036194945],"about_ca_topic_score_codex":0.002373071,"about_ca_topic_score_gemma":0.0038256322,"teacher_disagreement_score":0.23153025,"about_ca_system_score_codex":0.0018951849,"about_ca_system_score_gemma":0.004480189,"threshold_uncertainty_score":0.3302498},"labels":[],"label_agreement":null},{"id":"W4250067304","doi":"10.1177/1715163517706056","title":"The cost of drugs","year":2017,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Business; Computer science","score_opus":0.07378903314630209,"score_gpt":0.2963373003694376,"score_spread":0.22254826722313553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250067304","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04481308,0.059421748,0.013441244,0.1392623,0.0051986235,0.00020292586,0.013420152,0.00023122298,0.72400874],"genre_scores_gemma":[0.72550184,0.033699717,0.0038615272,0.009997759,0.0037960028,0.0001225565,0.0035528012,0.00008896699,0.21937881],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99473566,0.0009774786,0.00021624324,0.00040673217,0.003128967,0.0005348222],"domain_scores_gemma":[0.99371207,0.0018834916,0.0010256679,0.00048667748,0.0021276483,0.0007644749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014548649,0.0005730955,0.0008166167,0.0022922407,0.0010124602,0.0064613004,0.0008253016,0.0033338764,0.020752981],"category_scores_gemma":[0.016020412,0.0004714635,0.0007060923,0.0029689525,0.0017859046,0.0029807822,0.00091233285,0.0033573506,0.0020810487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002666812,0.000107094434,0.009270071,0.0004380651,0.000276086,0.0003926863,0.00016361954,0.007861314,0.00042693107,0.71382207,0.16491581,0.1020595],"study_design_scores_gemma":[0.00008304748,0.0001240263,0.028257076,0.00064699905,0.00023453622,0.001208996,0.0003800509,0.009219375,0.00048715688,0.16887651,0.7904024,0.00007967823],"about_ca_topic_score_codex":0.12497724,"about_ca_topic_score_gemma":0.123338,"teacher_disagreement_score":0.87502277,"about_ca_system_score_codex":0.015185512,"about_ca_system_score_gemma":0.011956056,"threshold_uncertainty_score":0.24849957},"labels":[],"label_agreement":null},{"id":"W4250075058","doi":"10.1002/div.6918","title":"Abbott Laboratories","year":2008,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.08134316636998808,"score_gpt":0.2612341988136709,"score_spread":0.17989103244368282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250075058","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055142753,0.030710865,0.023021286,0.017273784,0.011277457,0.0012482322,0.0227789,0.019318134,0.868857],"genre_scores_gemma":[0.041871656,0.0122628575,0.02317386,0.009230111,0.002957676,0.00096909073,0.021576539,0.0020297812,0.8859285],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961099,0.00048597765,0.00032361792,0.0011816844,0.0015594042,0.00033943908],"domain_scores_gemma":[0.99653673,0.000615725,0.00037253994,0.00042926177,0.0012035134,0.00084217876],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020424158,0.0016793341,0.002164221,0.0032535566,0.00073515414,0.0037596996,0.0016087099,0.0027884848,0.5177795],"category_scores_gemma":[0.0051930966,0.0009421589,0.00077423366,0.0017447735,0.0008458151,0.0018180202,0.001615622,0.004484743,0.31270233],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002460019,0.00039381385,0.0013838848,0.0011329071,0.00009674372,0.00061369356,0.00009604386,0.00038581007,0.0043043713,0.011173501,0.58450675,0.39345247],"study_design_scores_gemma":[0.0007466575,0.00035615262,0.0014466273,0.0003004032,0.00006300505,0.0012682523,0.00004352072,0.0007242987,0.0014006005,0.003907455,0.9897183,0.000024626168],"about_ca_topic_score_codex":0.0011649738,"about_ca_topic_score_gemma":0.0014992066,"teacher_disagreement_score":0.5177795,"about_ca_system_score_codex":0.0011466788,"about_ca_system_score_gemma":0.003101172,"threshold_uncertainty_score":0.68782896},"labels":[],"label_agreement":null},{"id":"W4250378947","doi":"10.1016/s2213-8587(17)30115-8","title":"Insulin affordability","year":2017,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Hippocratic Oath; Dilemma; Biography; Oath; Classics; Law; Philosophy; Political science; Psychiatry; History; Epistemology","score_opus":0.10115656115893289,"score_gpt":0.30389343822611214,"score_spread":0.20273687706717924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250378947","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011954549,0.0076228306,0.0004985567,0.917404,0.013577066,0.000012039665,0.00045250906,0.00003625436,0.059201214],"genre_scores_gemma":[0.048588127,0.0048472723,0.00043855645,0.8533963,0.058818873,0.00007321333,0.00037419773,0.00006328911,0.033400167],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961312,0.001003151,0.00027216595,0.0005496677,0.0013725144,0.00067135366],"domain_scores_gemma":[0.98923266,0.006845244,0.00060977315,0.0007053653,0.0011601284,0.001446717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005481998,0.00040061356,0.0010291046,0.00090206496,0.0014916728,0.004210339,0.0010446507,0.017112508,0.0244487],"category_scores_gemma":[0.037475023,0.00034632505,0.0010219684,0.0005879752,0.0035668008,0.002842153,0.0024776738,0.020501515,0.005342103],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022012937,0.000056586054,0.001362124,0.00009656046,0.000037969003,0.0004512587,0.00007380819,0.00017288719,0.00014890877,0.16220063,0.7923737,0.04280544],"study_design_scores_gemma":[0.00021504475,0.00004052646,0.0020545758,0.00042370334,0.000037218128,0.00047967667,0.00011624039,0.0004949651,0.00020632565,0.16258448,0.8333148,0.000032559892],"about_ca_topic_score_codex":0.010176851,"about_ca_topic_score_gemma":0.012717462,"teacher_disagreement_score":0.0244487,"about_ca_system_score_codex":0.00430037,"about_ca_system_score_gemma":0.004270257,"threshold_uncertainty_score":0.08178902},"labels":[],"label_agreement":null},{"id":"W4250458882","doi":"10.1503/cmaj.1041127","title":"Correction","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Information retrieval; World Wide Web; Data science","score_opus":0.021946549106719865,"score_gpt":0.24808749571057748,"score_spread":0.2261409466038576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250458882","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028709904,0.0012158412,0.0012062654,0.14776926,0.8033933,0.00005423871,0.006149206,0.0009287808,0.038995977],"genre_scores_gemma":[0.0141725335,0.00415329,0.0030007118,0.114469476,0.16035312,0.0001978212,0.008459583,0.002076351,0.69311714],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99426174,0.0007756225,0.0006290306,0.00077379064,0.0029736545,0.0005861415],"domain_scores_gemma":[0.9631884,0.006607489,0.001471259,0.0029540772,0.024690373,0.0010883296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035005668,0.0014699859,0.0010048461,0.0032626586,0.0033974696,0.005092698,0.0024231328,0.005226952,0.19772081],"category_scores_gemma":[0.06247328,0.0006456532,0.0012778126,0.0025083155,0.0016022841,0.0029892412,0.0022576367,0.0072528212,0.11993968],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000991647,0.0000015959179,0.000040344778,0.000028075623,0.0000024494825,0.0000507968,0.000023015093,0.000011431597,0.000015610858,0.0013785551,0.9940982,0.0043400936],"study_design_scores_gemma":[0.000008053354,0.000003941448,0.00021801502,0.000083296036,0.0000046540035,0.00009737848,0.000035624675,0.00003472385,0.00006370451,0.0007530385,0.9986884,0.000009175649],"about_ca_topic_score_codex":0.023848645,"about_ca_topic_score_gemma":0.022611605,"teacher_disagreement_score":0.19772081,"about_ca_system_score_codex":0.004919363,"about_ca_system_score_gemma":0.00723364,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4250541937","doi":"10.3917/dec.orang.2014.01.0440","title":"Histoire secrète du patronat de 1945 à nos jours","year":2014,"lang":"fr","type":"book-chapter","venue":"Cahiers libres","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Labour, Employment and Social Solidarity","funders":"","keywords":"Political science; Art","score_opus":0.025476628047227726,"score_gpt":0.22187255731990527,"score_spread":0.19639592927267754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250541937","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057994863,0.094092414,0.0029152983,0.068342306,0.05931219,0.00006796982,0.0018733435,0.00031711502,0.76727986],"genre_scores_gemma":[0.027540976,0.012179941,0.0007091601,0.0050941287,0.0067353244,0.000030542553,0.00027578787,0.00023098601,0.9472031],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986934,0.00029305564,0.00005320373,0.00022346927,0.0005693083,0.00016761529],"domain_scores_gemma":[0.99910164,0.0003059108,0.0000775202,0.000102351354,0.00033457906,0.00007799323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001147494,0.00066940597,0.00037959567,0.0028635592,0.0037828654,0.005633339,0.00062500825,0.002205089,0.049108513],"category_scores_gemma":[0.005037179,0.00036831637,0.000460661,0.0022878752,0.0040635075,0.002700109,0.002091609,0.0031296231,0.01637618],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013710282,0.000019732874,0.00041372256,0.00021434005,0.000016003929,0.00034982024,0.0022139843,0.00015908407,0.0004660853,0.22504845,0.71440256,0.056559082],"study_design_scores_gemma":[0.0000017742576,0.0000027211186,0.00017334547,0.000040404957,0.0000011750816,0.000045341818,0.00006696397,0.0000075682633,0.000084221596,0.0011421195,0.9984315,0.0000028484055],"about_ca_topic_score_codex":0.027785916,"about_ca_topic_score_gemma":0.035728384,"teacher_disagreement_score":0.049108513,"about_ca_system_score_codex":0.0075492486,"about_ca_system_score_gemma":0.003184705,"threshold_uncertainty_score":0.16428429},"labels":[],"label_agreement":null},{"id":"W4250745188","doi":"10.1007/bf03266922","title":"Generics deal for pharmaceutical industry in Quebec?","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Business; Pharmaceutical industry; Public health; Medicine; Pharmacology","score_opus":0.08134391400180845,"score_gpt":0.3750161646133117,"score_spread":0.29367225061150326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250745188","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08575048,0.018325185,0.0004863323,0.65752,0.0032101532,0.00016757117,0.010202794,0.00023356946,0.2241039],"genre_scores_gemma":[0.41432303,0.007812576,0.0007196895,0.15911178,0.0022628817,0.00006607023,0.0023011314,0.000091377035,0.41331136],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983652,0.00013558302,0.00005063889,0.00012867273,0.0005071997,0.0008126561],"domain_scores_gemma":[0.9945716,0.0006449164,0.0006719964,0.00010659911,0.0016910624,0.0023138465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017665774,0.00025490264,0.00033335475,0.0009822531,0.0029027176,0.0051041874,0.0013031283,0.0066141053,0.052592304],"category_scores_gemma":[0.0048319777,0.00032384717,0.0005804448,0.0015294607,0.0010574124,0.0019842242,0.000664796,0.002746125,0.002614991],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004527741,0.00014095573,0.061223052,0.00036639778,0.00010749774,0.0009763444,0.0005183857,0.00068048114,0.001180665,0.041238204,0.8301438,0.06297159],"study_design_scores_gemma":[0.00016685741,0.000074745265,0.16150935,0.0002818829,0.000080978134,0.0003001126,0.001267684,0.0015119485,0.00047690223,0.0015741099,0.832686,0.00006942047],"about_ca_topic_score_codex":0.9614142,"about_ca_topic_score_gemma":0.98688763,"teacher_disagreement_score":0.052592304,"about_ca_system_score_codex":0.04532292,"about_ca_system_score_gemma":0.069559745,"threshold_uncertainty_score":0.3288424},"labels":[],"label_agreement":null},{"id":"W4250881677","doi":"10.2165/00151234-200604990-00023","title":"Canadian generic market grows, but new drug access lags","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Drug; Business; Economics; Public health; Medicine; Pharmacology","score_opus":0.04633601836258157,"score_gpt":0.31835120293496816,"score_spread":0.2720151845723866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250881677","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0776007,0.030358681,0.002356459,0.45657963,0.0039487337,0.00010643791,0.040414575,0.0010486246,0.38758624],"genre_scores_gemma":[0.7100231,0.02893723,0.0024430982,0.045116473,0.0027225763,0.000032248467,0.0114068715,0.00023977723,0.19907863],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786323,0.00006355858,0.000053813117,0.00017631824,0.0013241449,0.00051898585],"domain_scores_gemma":[0.9929092,0.0008088557,0.00060469605,0.00017866482,0.0030932978,0.0024053059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016495561,0.0007245201,0.00066077645,0.0026429147,0.0025391188,0.0064699296,0.00089122227,0.002518302,0.04346445],"category_scores_gemma":[0.0069540422,0.0003064519,0.00085139525,0.003541467,0.0013977402,0.0031157932,0.00093086803,0.002977775,0.003039434],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006102006,0.00008162812,0.034075256,0.0005446545,0.00010027072,0.00044702654,0.00046796812,0.0017201857,0.0017400859,0.105832554,0.69873804,0.15564214],"study_design_scores_gemma":[0.00012422647,0.00007248332,0.14090903,0.00023720988,0.000125159,0.00024562803,0.00126004,0.002619383,0.0011110358,0.010145497,0.8430793,0.000071000206],"about_ca_topic_score_codex":0.96842927,"about_ca_topic_score_gemma":0.978874,"teacher_disagreement_score":0.044177704,"about_ca_system_score_codex":0.044177704,"about_ca_system_score_gemma":0.051725127,"threshold_uncertainty_score":0.32053316},"labels":[],"label_agreement":null},{"id":"W4251029145","doi":"10.1108/ijhcqa.2012.06225daa.003","title":"Canada - Canadian government increases options for natural health products","year":2012,"lang":"en","type":"article","venue":"International Journal of Health Care Quality Assurance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Government (linguistics); Natural (archaeology); Geography","score_opus":0.07275373504630955,"score_gpt":0.37011618051676287,"score_spread":0.2973624454704533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251029145","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21086787,0.004339231,0.0025324393,0.03924242,0.00064477045,0.00046600524,0.0113016395,0.0006752988,0.7299303],"genre_scores_gemma":[0.90711546,0.0012351654,0.0021716272,0.0042819027,0.00017259804,0.000056746932,0.0012615921,0.000058935762,0.083646014],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9934614,0.00046643164,0.00010136739,0.00038909155,0.0038171874,0.0017644586],"domain_scores_gemma":[0.99187356,0.001598598,0.0004103887,0.00024223654,0.0042607533,0.0016144351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025068985,0.00047064404,0.00036129667,0.0024561114,0.0034903022,0.005061367,0.0012069937,0.002932228,0.03083413],"category_scores_gemma":[0.010071528,0.00026198992,0.0011604124,0.0021605128,0.0012484269,0.0012407581,0.0015049021,0.0014775827,0.0014476845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029516334,0.0011715844,0.074011184,0.0009435539,0.00033294866,0.0013651851,0.001296817,0.018441152,0.009470576,0.28074124,0.4221984,0.18707578],"study_design_scores_gemma":[0.00049471855,0.00046832042,0.18209992,0.00030627297,0.00043817682,0.00039098228,0.002693026,0.010228016,0.007640333,0.016549038,0.7785344,0.00015680907],"about_ca_topic_score_codex":0.9582024,"about_ca_topic_score_gemma":0.97752464,"teacher_disagreement_score":0.06680876,"about_ca_system_score_codex":0.06680876,"about_ca_system_score_gemma":0.093973085,"threshold_uncertainty_score":0.48473376},"labels":[],"label_agreement":null},{"id":"W4251307755","doi":"10.1177/171516350714000208","title":"BC Study Itemizing Costs of Pharmacy Services is Potential Template for other Jurisdictions","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacy; Business; Medicine; Family medicine","score_opus":0.062380855740922884,"score_gpt":0.30885133944865395,"score_spread":0.24647048370773106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251307755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46967122,0.0020790908,0.019176347,0.06133425,0.005658992,0.015575385,0.16947314,0.0004928711,0.2565387],"genre_scores_gemma":[0.79242545,0.000571272,0.024400761,0.020120073,0.0013938361,0.018648645,0.05929805,0.00048743724,0.082654476],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9463388,0.029027887,0.0062241703,0.0025687157,0.010319978,0.005520445],"domain_scores_gemma":[0.843775,0.036729507,0.013376048,0.014129795,0.086389974,0.0055998056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027856093,0.0011929396,0.001609518,0.0052531697,0.006610481,0.0044412836,0.005093546,0.0021331161,0.03847833],"category_scores_gemma":[0.10093374,0.00070042006,0.002461214,0.01443799,0.0015715625,0.0032053322,0.0026434525,0.0030857362,0.0052666073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016911771,0.0028380775,0.5293159,0.0010100594,0.0010151739,0.00031045923,0.003186287,0.0017563135,0.00041216845,0.030058356,0.3675354,0.06087071],"study_design_scores_gemma":[0.0012826967,0.0012416067,0.65181774,0.00091843685,0.0011911816,0.00036286743,0.010544758,0.0064798426,0.0039017992,0.012382249,0.3095837,0.00029319111],"about_ca_topic_score_codex":0.6156273,"about_ca_topic_score_gemma":0.67072004,"teacher_disagreement_score":0.3843727,"about_ca_system_score_codex":0.014043265,"about_ca_system_score_gemma":0.034884963,"threshold_uncertainty_score":0.7732727},"labels":[],"label_agreement":null},{"id":"W4251325721","doi":"10.18433/j37g80","title":"Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence","year":2016,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Food and Drug Safety; American Sleep Medicine Foundation","keywords":"Agency (philosophy); European union; Certification; Good manufacturing practice; Christian ministry; Business; Food and drug administration; Medicine; Environmental health; Marketing; Management; Political science; Supply chain","score_opus":0.23924886246479937,"score_gpt":0.38687395133013114,"score_spread":0.14762508886533177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251325721","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787975,0.0010088223,0.0056106574,0.002663469,0.000050635997,0.0002991788,0.00018184312,0.000031288717,0.011356533],"genre_scores_gemma":[0.99546754,0.00030220245,0.0029981593,0.00035409164,0.000015367797,0.00015378963,0.00015271528,0.00001662213,0.00053948315],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.94219416,0.03197447,0.006697644,0.0042840703,0.012071107,0.0027785448],"domain_scores_gemma":[0.829547,0.086348325,0.03569891,0.010665263,0.033243258,0.0044972715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0756073,0.00021486764,0.00039529544,0.005839548,0.0018945778,0.0034567267,0.0014270351,0.000997046,0.001516576],"category_scores_gemma":[0.10424974,0.0003888473,0.00043445468,0.0046484466,0.0037786218,0.0052161235,0.004454087,0.0012174185,0.0002037902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021414975,0.00029936372,0.6388331,0.0005492695,0.000058245558,0.00015556165,0.21498716,0.0003819318,0.002315426,0.013897622,0.0017247455,0.12658343],"study_design_scores_gemma":[0.00001531947,0.0003303477,0.737583,0.0006521414,0.00002000816,0.00027838157,0.23519145,0.0010212563,0.0011913023,0.0023307237,0.021327576,0.00005847121],"about_ca_topic_score_codex":0.008515976,"about_ca_topic_score_gemma":0.0054727225,"teacher_disagreement_score":0.0756073,"about_ca_system_score_codex":0.0047545005,"about_ca_system_score_gemma":0.0071763964,"threshold_uncertainty_score":0.39985442},"labels":[],"label_agreement":null},{"id":"W4251475153","doi":"10.21518/1561-5936-2014-11-78-83","title":"Steps to Success: changes in the ranking of pharmaceutical producers in quarter II 2014","year":2014,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Ranking (information retrieval); Business; Advertising; Agricultural economics; Geography; Computer science; Economics; Information retrieval; Archaeology","score_opus":0.027464634708670492,"score_gpt":0.2984104831746834,"score_spread":0.2709458484660129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251475153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8981805,0.00089112815,0.00061564555,0.05405829,0.00063580106,0.000052896605,0.008207129,0.00015841908,0.03720015],"genre_scores_gemma":[0.9843017,0.0002202666,0.00019522225,0.0012248026,0.0001638166,0.000020297452,0.0023100965,0.000025648353,0.0115381945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797946,0.0002673445,0.00012292621,0.00013155851,0.0005964406,0.00090243143],"domain_scores_gemma":[0.9915582,0.00062723074,0.0021359592,0.00013297901,0.0029268528,0.0026188018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026634498,0.0001868116,0.0003257618,0.0017051615,0.0010241122,0.0042851893,0.00060896244,0.0013157662,0.008357726],"category_scores_gemma":[0.009065865,0.00020175012,0.0003046894,0.0017152326,0.0005055794,0.001585849,0.0015239684,0.00120749,0.0017312634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014269388,0.00032750965,0.70126307,0.00016018593,0.00012556025,0.0004900614,0.0036725614,0.0018683438,0.0011013708,0.015098,0.2073406,0.06712569],"study_design_scores_gemma":[0.000029178464,0.00014779165,0.96675825,0.00003547913,0.000015409101,0.000053947948,0.005811393,0.0009150179,0.00041848733,0.00091012125,0.024879238,0.000025667401],"about_ca_topic_score_codex":0.045389373,"about_ca_topic_score_gemma":0.060512997,"teacher_disagreement_score":0.045389373,"about_ca_system_score_codex":0.0027820757,"about_ca_system_score_gemma":0.0049933973,"threshold_uncertainty_score":0.09025037},"labels":[],"label_agreement":null},{"id":"W4251576488","doi":"10.1377/forefront.20190731.727552","title":"Trump Administration, In Shift, Announces Plan To Permit Drug Importation","year":2019,"lang":"en","type":"dataset","venue":"Forefront Group","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Administration (probate law); Plan (archaeology); Drug administration; Business; Drug; Food and drug administration; Pharmacology; Political science; Medicine; Geography; Risk analysis (engineering); Law","score_opus":0.05084466596624171,"score_gpt":0.29111825311813105,"score_spread":0.24027358715188935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251576488","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015497871,0.000056005734,0.0000555648,0.00020986322,0.00003465999,0.000005470238,0.9981818,0.00014788551,0.0011537921],"genre_scores_gemma":[0.0007212688,0.00007570335,0.0002268755,0.00014387428,0.000014096367,0.000038455397,0.99621767,0.000048799462,0.0025133218],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986765,0.00021060515,0.0001623651,0.00024186632,0.00045288866,0.00025576405],"domain_scores_gemma":[0.9951971,0.0010410147,0.0008624609,0.0007153871,0.0017704914,0.00041348566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015756747,0.001119141,0.00097185385,0.003442755,0.0007106294,0.0030313479,0.0024371557,0.0018950821,0.05981215],"category_scores_gemma":[0.009781298,0.00061408407,0.0009457529,0.0060905553,0.0004017174,0.0013674515,0.0018067196,0.0021727341,0.07378805],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047473313,0.000013856625,0.0012621896,0.00018513085,0.000013426688,0.000014361225,0.00000892528,0.00011252905,0.000026668133,0.0005789159,0.9965161,0.0012204754],"study_design_scores_gemma":[0.00021909615,0.000022046786,0.00862897,0.00023335945,0.00002211457,0.000048250364,0.00008092608,0.00051221927,0.00025720068,0.00094517745,0.9890057,0.00002496699],"about_ca_topic_score_codex":0.090288006,"about_ca_topic_score_gemma":0.1642922,"teacher_disagreement_score":0.090288006,"about_ca_system_score_codex":0.0027679487,"about_ca_system_score_gemma":0.0033694375,"threshold_uncertainty_score":0.2000916},"labels":[],"label_agreement":null},{"id":"W4251772664","doi":"10.1002/div.7263","title":"Abbott Laboratories","year":2008,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.08134316636998808,"score_gpt":0.2612341988136709,"score_spread":0.17989103244368282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251772664","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005482812,0.031023314,0.021965597,0.01868825,0.011727001,0.0011921498,0.022840526,0.019036757,0.86804366],"genre_scores_gemma":[0.042826895,0.012304853,0.021990603,0.009432159,0.0030874065,0.00089695666,0.020613512,0.001964101,0.8868836],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99627644,0.00046059614,0.00031572673,0.0011135621,0.0015021783,0.00033150447],"domain_scores_gemma":[0.9964665,0.00062041637,0.00038358624,0.0004351618,0.0012050121,0.0008893964],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020243293,0.0016309827,0.0021559822,0.0030978832,0.0007151207,0.0037312752,0.0015563967,0.0027551043,0.51354754],"category_scores_gemma":[0.005235761,0.00091239717,0.000766574,0.0017236582,0.0008282508,0.0018366054,0.0015404372,0.004518342,0.30394453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024180335,0.000371103,0.0013132906,0.0010317494,0.000092044014,0.0005614159,0.000091829555,0.00035804123,0.0036612041,0.011022143,0.6083368,0.37074232],"study_design_scores_gemma":[0.00074062566,0.00034777966,0.0014434698,0.00028772315,0.00006100537,0.0012088618,0.00004172729,0.0007035909,0.0012619841,0.0040288493,0.98985064,0.000023721408],"about_ca_topic_score_codex":0.0011472749,"about_ca_topic_score_gemma":0.0014948095,"teacher_disagreement_score":0.51354754,"about_ca_system_score_codex":0.0011185426,"about_ca_system_score_gemma":0.0030225639,"threshold_uncertainty_score":0.6938654},"labels":[],"label_agreement":null},{"id":"W4251774901","doi":"10.3821/1913-701x-143.6.263","title":"Steps Being Taken to Ease Drug Shortages","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Drug; Medicine; Computer science; Pharmacology; Philosophy","score_opus":0.03860060843814241,"score_gpt":0.26016843006468676,"score_spread":0.22156782162654434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251774901","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056581837,0.004777885,0.002490717,0.9606767,0.009583715,0.00020790011,0.00033660486,0.0004756521,0.015792659],"genre_scores_gemma":[0.13748176,0.008898548,0.02339408,0.771574,0.006728988,0.0004043217,0.0005416127,0.00017514217,0.050801646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9826491,0.0035026805,0.000995315,0.00086268294,0.0056597795,0.0063304063],"domain_scores_gemma":[0.9248402,0.006660922,0.003475567,0.0015276322,0.02153937,0.04195626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018972022,0.0011908063,0.001314888,0.0033599746,0.005382336,0.011520111,0.0037457906,0.021864356,0.026841132],"category_scores_gemma":[0.04853389,0.00062622817,0.0024647405,0.0021448724,0.004436437,0.0059407256,0.0063046394,0.01634399,0.0042222026],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023903309,0.00076889625,0.006825514,0.001304517,0.0002606905,0.00090266776,0.0013430868,0.0021614425,0.0018046149,0.045761842,0.8001226,0.13850501],"study_design_scores_gemma":[0.0004141736,0.00031763638,0.034542155,0.0019345019,0.00019179058,0.00046569324,0.004577623,0.0017195236,0.0011059861,0.021095958,0.93344253,0.00019241548],"about_ca_topic_score_codex":0.23290111,"about_ca_topic_score_gemma":0.285576,"teacher_disagreement_score":0.7670989,"about_ca_system_score_codex":0.017167913,"about_ca_system_score_gemma":0.15515873,"threshold_uncertainty_score":0.4630909},"labels":[],"label_agreement":null},{"id":"W4252192041","doi":"10.4414/cvm.2005.01108","title":"Directives 2005 concernant les contrôles de patients porteurs de stimulateurs cardiaques","year":2005,"lang":"fr","type":"article","venue":"Kardiovask Med","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministère de l’Emploi et de la Solidarité Sociale (Québec)","funders":"","keywords":"Philosophy; Political science","score_opus":0.036004933760991883,"score_gpt":0.2773360917101871,"score_spread":0.24133115794919519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252192041","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054973044,0.08276529,0.023580741,0.5684608,0.060292933,0.0021094105,0.008645659,0.0012695559,0.19790258],"genre_scores_gemma":[0.2195686,0.022631127,0.036068548,0.32158977,0.027157191,0.0027893165,0.0040108874,0.00032326856,0.36586133],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.986304,0.003275774,0.0019657568,0.00080088066,0.0058310423,0.0018224614],"domain_scores_gemma":[0.9718186,0.016592834,0.003667269,0.00051559735,0.004108594,0.00329713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01434427,0.0014827452,0.0020216089,0.0019616466,0.0011990875,0.0049467343,0.003556091,0.031498566,0.007538335],"category_scores_gemma":[0.044237074,0.0011388476,0.0021746154,0.0012938251,0.0014161302,0.0014252084,0.0011351012,0.011952704,0.0021070824],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045700986,0.0014481081,0.009863156,0.0017278084,0.00043985998,0.004134457,0.0012871802,0.00507341,0.0099850595,0.10005871,0.7427705,0.11864166],"study_design_scores_gemma":[0.0022590412,0.00089020625,0.02170973,0.0010926509,0.00030059824,0.0019544759,0.00023393631,0.003425993,0.003080393,0.004882405,0.96006924,0.00010125835],"about_ca_topic_score_codex":0.040521517,"about_ca_topic_score_gemma":0.028843192,"teacher_disagreement_score":0.040521517,"about_ca_system_score_codex":0.005523913,"about_ca_system_score_gemma":0.014539178,"threshold_uncertainty_score":0.080571294},"labels":[],"label_agreement":null},{"id":"W4252445278","doi":"10.1057/9781137453648_8","title":"A multi-agent simulation of the pharmaceutical supply chain","year":2014,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profitability index; Supply chain; Business; Industrial organization; Tracing; Pharmaceutical industry; Quarter (Canadian coin); Product (mathematics); Work (physics); Computer science; Marketing; Engineering; Finance; Mathematics","score_opus":0.07615983211597162,"score_gpt":0.2923086054928009,"score_spread":0.2161487733768293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252445278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6341148,0.0005651781,0.31575304,0.001961376,0.00014543101,0.0002966695,0.0020924308,0.00064218225,0.044428777],"genre_scores_gemma":[0.94953895,0.00023791855,0.042127214,0.00010182635,0.000019343035,0.00024528976,0.0006145247,0.000042498086,0.0070723398],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99961627,0.00019171271,0.000018775567,0.00005848117,0.00006238256,0.000052232546],"domain_scores_gemma":[0.9981211,0.0013360855,0.00016823554,0.0000839728,0.00016072723,0.0001298072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006864462,0.00051028177,0.00064945983,0.00051729934,0.0006445134,0.0011974239,0.0010195324,0.0019474577,0.004445631],"category_scores_gemma":[0.0030663307,0.00042698396,0.00063215586,0.0006945917,0.0008228936,0.00089929043,0.0009898923,0.0009692974,0.00036707844],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002122945,0.000013597062,0.00046815278,0.000006854287,0.0000064019687,0.000022707127,0.000015895757,0.99643135,0.00009556976,0.0021507065,0.0001165266,0.0006510281],"study_design_scores_gemma":[0.000012707479,0.000008650967,0.00008302367,0.0000026378073,0.000002063152,0.0000031065024,0.000007920183,0.9988405,0.000053613923,0.00073990395,0.00024340283,0.0000024535302],"about_ca_topic_score_codex":0.02782621,"about_ca_topic_score_gemma":0.0108298445,"teacher_disagreement_score":0.02782621,"about_ca_system_score_codex":0.0013172752,"about_ca_system_score_gemma":0.0017069425,"threshold_uncertainty_score":0.05532849},"labels":[],"label_agreement":null},{"id":"W4252658922","doi":"10.1201/b14674-36","title":"Canadian Health Products and Food Branch (HPFB) and Therapeutic Products Directorate (TPD)","year":2012,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Food products; Business; Environmental health; Environmental science; Food science; Medicine; Chemistry","score_opus":0.09076159160031785,"score_gpt":0.2600745730170859,"score_spread":0.16931298141676807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252658922","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00081908517,0.028896673,0.0017024077,0.019148331,0.0022076159,0.00007965578,0.005493,0.00039480958,0.94125843],"genre_scores_gemma":[0.003794517,0.008921875,0.00091903494,0.0010740494,0.00015934848,0.000019979963,0.0007400258,0.00008396194,0.98428726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851793,0.000051723826,0.000022190858,0.00012533454,0.0010964636,0.00018642993],"domain_scores_gemma":[0.99847764,0.00018290282,0.00004734644,0.000059251444,0.0009994864,0.00023330953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001095211,0.001088164,0.0007385714,0.0036743062,0.0027646376,0.0044076163,0.0009561007,0.0023040674,0.07819112],"category_scores_gemma":[0.002440866,0.00057568203,0.00034307098,0.0055781715,0.001291866,0.0016652722,0.0005653826,0.0019859474,0.019129217],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007841828,0.000011283243,0.00016827151,0.000060450773,0.000001983799,0.000017580322,0.000039264745,0.00020584952,0.00007487197,0.039385818,0.90299416,0.057032607],"study_design_scores_gemma":[0.0000020406465,0.0000024150522,0.00076066115,0.000054403674,0.0000023998396,0.0000136596345,0.000033866745,0.0001780899,0.00011836449,0.003414438,0.9954125,0.0000071975032],"about_ca_topic_score_codex":0.8997521,"about_ca_topic_score_gemma":0.96745,"teacher_disagreement_score":0.9501831,"about_ca_system_score_codex":0.04981689,"about_ca_system_score_gemma":0.06540989,"threshold_uncertainty_score":0.36144853},"labels":[],"label_agreement":null},{"id":"W4253296631","doi":"10.1353/crv.2013.0007","title":"The Maple Peril: From Presidential Policy to Pharmaceutical Importation, 1992-Present","year":2013,"lang":"en","type":"article","venue":"Canadian Review of American Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Philosophy","score_opus":0.06144120684799439,"score_gpt":0.35823525986087323,"score_spread":0.29679405301287887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253296631","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19089733,0.061271705,0.00087001425,0.26838276,0.0023026254,0.000064382104,0.0005099641,0.00011768481,0.47558355],"genre_scores_gemma":[0.8124221,0.014867326,0.000498022,0.026617767,0.0011815474,0.000069774745,0.00018335975,0.000060006638,0.14410008],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692434,0.0006807943,0.00007399417,0.00032586756,0.00079765986,0.0011972557],"domain_scores_gemma":[0.99745256,0.0011564797,0.00051138346,0.0000782454,0.0003987911,0.00040246543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028192527,0.00028545395,0.0002687838,0.000937445,0.009506689,0.010045993,0.0006564748,0.0047721434,0.011700197],"category_scores_gemma":[0.009710366,0.0005147468,0.00017848203,0.0021383385,0.0046314606,0.004016009,0.003256273,0.0050282585,0.0012708107],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039542897,0.000120593504,0.0077931415,0.00067981187,0.000027004453,0.0012476823,0.03973008,0.0003241967,0.0008873993,0.7107945,0.15860277,0.07939736],"study_design_scores_gemma":[0.000032057058,0.00006505061,0.020430326,0.0002025686,0.000013655078,0.0001393215,0.0070925336,0.00009484199,0.0005533778,0.0054805805,0.96587247,0.00002315031],"about_ca_topic_score_codex":0.087898955,"about_ca_topic_score_gemma":0.13889796,"teacher_disagreement_score":0.91210103,"about_ca_system_score_codex":0.02075125,"about_ca_system_score_gemma":0.01591845,"threshold_uncertainty_score":0.1747747},"labels":[],"label_agreement":null},{"id":"W4253716176","doi":"10.1037/e533732006-001","title":"The Price and Purity of Illicit Drugs: 1981 Through the Second Quarter of 2003","year":2004,"lang":"en","type":"dataset","venue":"PsycEXTRA Dataset","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Illicit drug; Pharmacology; Medicine; Geography; Drug","score_opus":0.03715002072952046,"score_gpt":0.29703845382078464,"score_spread":0.2598884330912642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253716176","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001064331,0.000089364396,0.000019302975,0.000053356525,0.00001086929,0.000008674627,0.99836975,0.000041724023,0.0003426101],"genre_scores_gemma":[0.003699295,0.00020954675,0.000084730455,0.000042766802,0.000017123639,0.00006579604,0.9941116,0.000018287985,0.0017508471],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9984869,0.00010523074,0.00028860997,0.00027383346,0.0005717421,0.00027374257],"domain_scores_gemma":[0.992339,0.0010026784,0.0031970206,0.00077478803,0.0022774674,0.00040896033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011194684,0.0016329669,0.0018642545,0.006269781,0.0006279109,0.0022344943,0.0029734063,0.0020361315,0.020850515],"category_scores_gemma":[0.00804612,0.0008763699,0.0012344498,0.016662985,0.0003541604,0.0010056199,0.0011275251,0.00182516,0.019847946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056264095,0.0001325212,0.026227582,0.0013122711,0.00021594093,0.000101147816,0.00006973221,0.0013917903,0.00017081796,0.0005499456,0.96245253,0.0068130777],"study_design_scores_gemma":[0.0009227211,0.00011819021,0.35461354,0.0007250427,0.00027549558,0.00023486846,0.00032657865,0.001752101,0.0012589348,0.00064485654,0.63904035,0.000087332446],"about_ca_topic_score_codex":0.24459487,"about_ca_topic_score_gemma":0.22060023,"teacher_disagreement_score":0.24459487,"about_ca_system_score_codex":0.0038457154,"about_ca_system_score_gemma":0.004810191,"threshold_uncertainty_score":0.48634237},"labels":[],"label_agreement":null},{"id":"W4255275834","doi":"10.1021/cen-09433-notw11","title":"Piramal to acquire API maker Ash Stevens","year":2016,"lang":"en","type":"article","venue":"C&EN Global Enterprise","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical industry; Business; Medicine; Pharmacology","score_opus":0.029874759922232607,"score_gpt":0.28390996173172334,"score_spread":0.25403520180949074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255275834","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009924567,0.013666151,0.0025466506,0.22567992,0.009241671,0.00019880202,0.0018138896,0.0007423579,0.73618597],"genre_scores_gemma":[0.07708017,0.0076957247,0.0013268335,0.055573884,0.0059521147,0.00007293347,0.0011729045,0.00012991781,0.8509956],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999033,0.000070988106,0.0000351004,0.00013369058,0.0005942441,0.00013296088],"domain_scores_gemma":[0.99837434,0.00026239167,0.00016185195,0.00010441281,0.0005850387,0.0005118566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094966573,0.0003508546,0.0003240059,0.00068069866,0.0009726019,0.0026875483,0.00042521686,0.002500934,0.09914827],"category_scores_gemma":[0.0038722553,0.0001822868,0.0003568279,0.0004667593,0.00040713197,0.0016939015,0.00087188394,0.003526435,0.021513436],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001003253,0.00009077736,0.00092056254,0.00008184306,0.000008417968,0.00041557,0.000041367297,0.00014708434,0.0005453497,0.056733634,0.8748577,0.06605734],"study_design_scores_gemma":[0.000036877882,0.000088906185,0.001670094,0.000056563273,0.000004908304,0.00038642372,0.000039957107,0.00024957646,0.00048084807,0.0040974026,0.99287367,0.000014656788],"about_ca_topic_score_codex":0.00455553,"about_ca_topic_score_gemma":0.007670073,"teacher_disagreement_score":0.09914827,"about_ca_system_score_codex":0.0013237649,"about_ca_system_score_gemma":0.003289155,"threshold_uncertainty_score":0.331684},"labels":[],"label_agreement":null},{"id":"W4255714731","doi":"10.1179/175380609790795707","title":"Drug pricing and reimbursement in Europe: Strategy and tactics","year":2009,"lang":"en","type":"article","venue":"Journal of Communications In Healthcare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Business; Product (mathematics); Pricing strategies; Marketing; Investment (military); Control (management); New product development; Return on investment; Health care; Industrial organization; Economics; Production (economics); Microeconomics; Economic growth","score_opus":0.14868549785318158,"score_gpt":0.39255738209891966,"score_spread":0.24387188424573808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255714731","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022798743,0.14293899,0.0251719,0.60156643,0.008843221,0.00033041326,0.00014934274,0.0003036409,0.1978973],"genre_scores_gemma":[0.36653188,0.07624998,0.04823431,0.411451,0.014127291,0.0006938042,0.00024557742,0.0002529263,0.0822132],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9862504,0.0051987697,0.0010370514,0.0016115725,0.0045254277,0.0013768014],"domain_scores_gemma":[0.9919065,0.0033476856,0.0008185882,0.00043988824,0.0020853006,0.0014019653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031013545,0.0015932826,0.0014717851,0.004314327,0.0025950614,0.018562265,0.0026371013,0.030543014,0.003329658],"category_scores_gemma":[0.02728397,0.0007381999,0.0013782976,0.0034641528,0.010115556,0.012699214,0.006673899,0.009284859,0.001112352],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088413406,0.00020486845,0.0016991929,0.00018426198,0.00005456777,0.0003667032,0.00044367707,0.0019105639,0.00045369318,0.8252347,0.046813153,0.1225461],"study_design_scores_gemma":[0.00019658418,0.00040807357,0.007373254,0.0018778752,0.000058302016,0.00092667685,0.00087579055,0.0042787693,0.0008741538,0.40491077,0.5780078,0.00021196203],"about_ca_topic_score_codex":0.009403688,"about_ca_topic_score_gemma":0.0059437873,"teacher_disagreement_score":0.031013545,"about_ca_system_score_codex":0.011969645,"about_ca_system_score_gemma":0.014985299,"threshold_uncertainty_score":0.16401726},"labels":[],"label_agreement":null},{"id":"W4255896083","doi":"10.1037/e407442005-001","title":"The Price and Purity of Illicit Drugs: 1981 Through the Second Quarter of 2003","year":2004,"lang":"en","type":"dataset","venue":"PsycEXTRA Dataset","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Illicit drug; Business; Economics; Medicine; Pharmacology; Drug; Geography","score_opus":0.03715002072952046,"score_gpt":0.29703845382078464,"score_spread":0.2598884330912642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255896083","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001064331,0.000089364396,0.000019302975,0.000053356525,0.00001086929,0.000008674627,0.99836975,0.000041724023,0.0003426101],"genre_scores_gemma":[0.003699295,0.00020954675,0.000084730455,0.000042766802,0.000017123639,0.00006579604,0.9941116,0.000018287985,0.0017508471],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9984869,0.00010523074,0.00028860997,0.00027383346,0.0005717421,0.00027374257],"domain_scores_gemma":[0.992339,0.0010026784,0.0031970206,0.00077478803,0.0022774674,0.00040896033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011194684,0.0016329669,0.0018642545,0.006269781,0.0006279109,0.0022344943,0.0029734063,0.0020361315,0.020850515],"category_scores_gemma":[0.00804612,0.0008763699,0.0012344498,0.016662985,0.0003541604,0.0010056199,0.0011275251,0.00182516,0.019847946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056264095,0.0001325212,0.026227582,0.0013122711,0.00021594093,0.000101147816,0.00006973221,0.0013917903,0.00017081796,0.0005499456,0.96245253,0.0068130777],"study_design_scores_gemma":[0.0009227211,0.00011819021,0.35461354,0.0007250427,0.00027549558,0.00023486846,0.00032657865,0.001752101,0.0012589348,0.00064485654,0.63904035,0.000087332446],"about_ca_topic_score_codex":0.24459487,"about_ca_topic_score_gemma":0.22060023,"teacher_disagreement_score":0.24459487,"about_ca_system_score_codex":0.0038457154,"about_ca_system_score_gemma":0.004810191,"threshold_uncertainty_score":0.48634237},"labels":[],"label_agreement":null},{"id":"W4256019501","doi":"10.1177/171516350714000210","title":"Manitoba Drug Plan Brings in New Option for Patients Facing High Drug Costs","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Plan (archaeology); Medicine; Business; Intensive care medicine; Risk analysis (engineering); Pharmacology; History","score_opus":0.04475039639649905,"score_gpt":0.2526263616058926,"score_spread":0.20787596520939353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256019501","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1491336,0.0097018,0.0018573981,0.5403701,0.0026395123,0.00035050305,0.0042893984,0.00034161768,0.29131618],"genre_scores_gemma":[0.6599434,0.009446443,0.008540073,0.08744046,0.0013699582,0.00014617652,0.0016357612,0.00012226336,0.23135543],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989838,0.00016770785,0.000024588193,0.000050411436,0.00044518284,0.000328331],"domain_scores_gemma":[0.99668354,0.0006113478,0.00016571523,0.000086720785,0.00076983497,0.0016828385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010107745,0.00025315903,0.00031789287,0.00107453,0.003342996,0.005194077,0.00058860035,0.0026241192,0.042517222],"category_scores_gemma":[0.0050427127,0.00037546043,0.00070487504,0.0014440502,0.0008562078,0.0013297461,0.0012012566,0.0024250492,0.0017381179],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007124865,0.00047545694,0.11650076,0.00027172393,0.00025778,0.001771083,0.0006281879,0.003041681,0.00143155,0.08087504,0.65170574,0.14232847],"study_design_scores_gemma":[0.0006600131,0.000354006,0.12728852,0.0004381416,0.00025588254,0.0012537873,0.0028532136,0.00506374,0.00085710606,0.013179959,0.84767944,0.00011612331],"about_ca_topic_score_codex":0.7371001,"about_ca_topic_score_gemma":0.9476368,"teacher_disagreement_score":0.26289988,"about_ca_system_score_codex":0.018733583,"about_ca_system_score_gemma":0.069249876,"threshold_uncertainty_score":0.5288963},"labels":[],"label_agreement":null},{"id":"W4256036976","doi":"10.3821/1913-701x(2008)141[135:cbspfa]2.0.co;2","title":"Competition Bureau shouldn't point finger at pharmacies","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Competition (biology); Pharmacy; Point (geometry); Business; Advertising; Marketing; Medicine; Family medicine; Mathematics; Biology","score_opus":0.10679685866139066,"score_gpt":0.27391626499236205,"score_spread":0.1671194063309714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256036976","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030773014,0.0017306578,0.00097314786,0.7352088,0.04475121,0.00015856672,0.0011565044,0.0016981082,0.21124575],"genre_scores_gemma":[0.015367902,0.0005391585,0.0009334766,0.32499522,0.0049660704,0.00007203775,0.00034341437,0.00029775582,0.6524849],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9880404,0.00044825338,0.0004124824,0.0010572708,0.0071724406,0.0028691457],"domain_scores_gemma":[0.9725467,0.0023417615,0.0010852631,0.0012824326,0.013647961,0.00909596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036235682,0.00079403474,0.0016445944,0.0017688196,0.007211884,0.008679587,0.0025379395,0.031152738,0.13946094],"category_scores_gemma":[0.026209868,0.0012055064,0.0012950104,0.0014155748,0.0018519687,0.0045704963,0.0018094358,0.02004651,0.07982106],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035487414,0.000031692223,0.00044866075,0.000020047082,0.000006899997,0.000040445582,0.00002419983,0.000025866564,0.00014174904,0.0036978454,0.9879631,0.007564164],"study_design_scores_gemma":[0.000049003185,0.000034969435,0.003496235,0.000051174495,0.000012803278,0.00006400302,0.00010239005,0.00015196609,0.00025102159,0.0021838888,0.99355763,0.000045017023],"about_ca_topic_score_codex":0.14231664,"about_ca_topic_score_gemma":0.23664749,"teacher_disagreement_score":0.85768336,"about_ca_system_score_codex":0.008353479,"about_ca_system_score_gemma":0.02817197,"threshold_uncertainty_score":0.46654332},"labels":[],"label_agreement":null},{"id":"W4256136035","doi":"10.1212/01.wnl.0000313154.55518.25","title":"Clinical consequences of generic substitution of lamotrigine for patients with epilepsy","year":2008,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lamotrigine; Medicine; Epilepsy; Gabapentin; Carbamazepine; Pharmacy; Psychiatry; Family medicine; Alternative medicine","score_opus":0.10281787248921477,"score_gpt":0.3094421319751415,"score_spread":0.20662425948592672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256136035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967938,0.0008350262,0.00004295406,0.00059264794,0.000008163054,0.000013063956,0.0004675771,0.0000038597173,0.0012429082],"genre_scores_gemma":[0.99927646,0.00017342335,0.0000412799,0.00017346884,0.000012118643,0.0000028701243,0.0002531794,9.443064e-7,0.00006621639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916565,0.00021542677,0.00011232976,0.00010085975,0.00023336189,0.00017239449],"domain_scores_gemma":[0.9950885,0.0006880826,0.0033259,0.00010107934,0.0003632336,0.0004332925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006043631,0.0001221138,0.0002032738,0.00036278283,0.0004063342,0.00051882816,0.0002631096,0.00037483565,0.0022882211],"category_scores_gemma":[0.0066185086,0.00010523512,0.0003534236,0.00093878445,0.00028566906,0.00028262977,0.0003157408,0.00046364212,0.0001385316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032265874,0.000043333035,0.9928838,0.000021565704,0.00006443895,0.00031472032,0.000045912988,0.00010993846,0.00019091737,0.000022630942,0.00029832547,0.0056818333],"study_design_scores_gemma":[0.000015056215,0.00008304153,0.9987515,0.000010466968,0.000024262068,0.00059489993,0.000112091046,0.00017059616,0.00004137939,0.000015157077,0.0001785786,0.0000029516261],"about_ca_topic_score_codex":0.05666453,"about_ca_topic_score_gemma":0.085191734,"teacher_disagreement_score":0.05666453,"about_ca_system_score_codex":0.0020015,"about_ca_system_score_gemma":0.0011410199,"threshold_uncertainty_score":0.11266941},"labels":[],"label_agreement":null},{"id":"W4256674571","doi":"10.1517/eotp.13.7.979.22985","title":"Epilepsy drug review: patent activity from 1999 to 2002","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Drug; Epilepsy; Pharmacology; Drug development; Medicine; Business; Psychiatry","score_opus":0.17062245208788937,"score_gpt":0.33226603316605974,"score_spread":0.16164358107817037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256674571","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024591503,0.9830961,0.00020796982,0.0032683723,0.0008431852,0.000030735668,0.00094268407,0.000019559244,0.009132229],"genre_scores_gemma":[0.012723585,0.97939694,0.00046270288,0.0015084024,0.0010561966,0.000025351765,0.00071525667,0.000005941732,0.0041057663],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999186,0.00014046514,0.0001373355,0.00009756637,0.00036569335,0.00007297613],"domain_scores_gemma":[0.9959494,0.0014488896,0.0012950422,0.000053901564,0.0011381698,0.00011465885],"candidate_categories":["bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.0015082152,0.00049443473,0.00094191666,0.006702876,0.00023096564,0.0015246563,0.0004223305,0.0009140225,0.005199338],"category_scores_gemma":[0.006555713,0.00017800345,0.00063632766,0.012734602,0.0002510455,0.0013557012,0.00036990742,0.00051411893,0.0014011647],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049525965,0.00006418216,0.00097637094,0.023229051,0.0002886428,0.0004252454,0.00007159204,0.0006355737,0.0009225125,0.0045467373,0.1631273,0.8052175],"study_design_scores_gemma":[0.00007324914,0.00015168964,0.008658006,0.005916786,0.00058138825,0.0008130299,0.000048347407,0.00015675575,0.0005357859,0.0008094668,0.98224163,0.000013715791],"about_ca_topic_score_codex":0.0037984846,"about_ca_topic_score_gemma":0.010158384,"teacher_disagreement_score":0.9932971,"about_ca_system_score_codex":0.0020920418,"about_ca_system_score_gemma":0.0033363856,"threshold_uncertainty_score":0.01739353},"labels":[],"label_agreement":null},{"id":"W4280498760","doi":"10.1016/j.healthpol.2022.05.003","title":"The effect of patented drug price on the share of new medicines across OECD countries","year":2022,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute on Governance; University of Toronto","funders":"Innovative Medicines Canada","keywords":"Drug prices; Government (linguistics); Extant taxon; Drug; Public economics; Economics; Estimation; Business; Actuarial science; Medicine; Pharmacology; Biology","score_opus":0.06423632173922453,"score_gpt":0.37588932529915237,"score_spread":0.31165300355992787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280498760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97234476,0.0030519709,0.0005470046,0.0041340236,0.000050626313,0.000026654287,0.0026486756,0.00006163311,0.01713451],"genre_scores_gemma":[0.99746597,0.00084305013,0.0000847114,0.00018388752,0.000033391614,0.00000869881,0.0005718794,0.000008243749,0.00080010586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969387,0.0009955831,0.0001875377,0.0003323759,0.0005390308,0.0010067386],"domain_scores_gemma":[0.9685752,0.016396936,0.00953525,0.0010182161,0.0027839441,0.0016903778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00378286,0.00030116196,0.0006985668,0.0025042612,0.0007367873,0.0043809535,0.000759015,0.0008619887,0.0042712553],"category_scores_gemma":[0.03046829,0.00024701635,0.0011498136,0.0045996304,0.0017945598,0.001738549,0.001506617,0.0015731197,0.00027010884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009810912,0.00023775439,0.8918258,0.00023581757,0.0010206705,0.0011113158,0.00063888106,0.050765775,0.00071604043,0.020078873,0.006656874,0.025731118],"study_design_scores_gemma":[0.000103277634,0.00022449339,0.9803586,0.000073917254,0.00039953008,0.00012506181,0.0014108863,0.009950521,0.0008809357,0.0019089791,0.0045100423,0.000053869524],"about_ca_topic_score_codex":0.52353173,"about_ca_topic_score_gemma":0.23633978,"teacher_disagreement_score":0.52353173,"about_ca_system_score_codex":0.009021737,"about_ca_system_score_gemma":0.0043864353,"threshold_uncertainty_score":0.95854855},"labels":[],"label_agreement":null},{"id":"W4280526549","doi":"10.3386/w30053","title":"Bargaining and International Reference Pricing in the Pharmaceutical Industry","year":2022,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Agence Nationale de la Recherche; National Institute for Health Care Management Foundation","keywords":"Pharmaceutical industry; Industrial organization; Business; Microeconomics; Economics; Commerce; Biotechnology","score_opus":0.7229083225269128,"score_gpt":0.5841179119715677,"score_spread":0.13879041055534513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280526549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74294555,0.0022984052,0.056672778,0.0048564454,0.00020165443,0.000149561,0.00035435206,0.00018386479,0.19233744],"genre_scores_gemma":[0.992485,0.0006588052,0.0022172,0.0002583747,0.000043591834,0.00004375189,0.000118267846,0.000022099885,0.004152887],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9965305,0.0020278203,0.00010902594,0.0003078095,0.00048120078,0.00054365734],"domain_scores_gemma":[0.99274546,0.004692819,0.0016386712,0.0003802641,0.0002474054,0.0002952956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056142434,0.00064000004,0.0011175579,0.0012754003,0.001389788,0.0044910763,0.0014244004,0.001923255,0.018342126],"category_scores_gemma":[0.01564265,0.00048033433,0.0015141346,0.0029820378,0.003369968,0.00420635,0.0023417482,0.0031344052,0.001115528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034766053,0.0005059639,0.01274906,0.000076197524,0.00011932973,0.00021997174,0.00062120333,0.3725288,0.0006494488,0.59362566,0.0024409532,0.016115798],"study_design_scores_gemma":[0.0007981042,0.0006973581,0.014107836,0.00013667047,0.00016621288,0.00010083014,0.001815558,0.38749593,0.0015251738,0.5811914,0.01182807,0.00013685071],"about_ca_topic_score_codex":0.011067384,"about_ca_topic_score_gemma":0.008236628,"teacher_disagreement_score":0.018342126,"about_ca_system_score_codex":0.0037211217,"about_ca_system_score_gemma":0.0020759997,"threshold_uncertainty_score":0.061360538},"labels":[],"label_agreement":null},{"id":"W4281556573","doi":"10.3389/fddsv.2022.898654","title":"Overcoming Market Failures in Pandemic Drug Discovery Through Open Science: A Canadian Solution","year":2022,"lang":"en","type":"article","venue":"Frontiers in Drug Discovery","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Structural Genomics Consortium; University of Toronto; McGill University","funders":"","keywords":"Pandemic; Business; Private sector; Incentive; Variety (cybernetics); Investment (military); Drug development; Market failure; Coronavirus disease 2019 (COVID-19); Public relations; Public economics; Industrial organization; Economics; Economic growth; Drug; Political science; Market economy; Pharmacology; Infectious disease (medical specialty); Medicine","score_opus":0.031947902120840796,"score_gpt":0.27624080807343865,"score_spread":0.24429290595259784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281556573","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036842772,0.018155685,0.015131683,0.88138145,0.0029273953,0.000096224794,0.00028928858,0.0002186209,0.07811528],"genre_scores_gemma":[0.5107042,0.105607055,0.074969314,0.18533693,0.011445805,0.00044312616,0.00084920577,0.00039814838,0.110246085],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99167365,0.0022545536,0.00020198675,0.00068917096,0.0033741568,0.0018064444],"domain_scores_gemma":[0.9731479,0.0091327485,0.0011174983,0.0018375939,0.009222404,0.0055418024],"candidate_categories":["metaresearch","open_science"],"consensus_categories":[],"category_scores_codex":[0.02087404,0.0012500427,0.0011198897,0.003508101,0.0072546275,0.010905115,0.002412858,0.010674097,0.02029023],"category_scores_gemma":[0.035587545,0.0005814869,0.0013116035,0.0030189063,0.01425959,0.0121107865,0.008575341,0.010969184,0.0019939449],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009089413,0.00008732704,0.000741035,0.00025926786,0.000049813236,0.00027942492,0.000353192,0.003889337,0.00029123423,0.8179557,0.120675355,0.055327415],"study_design_scores_gemma":[0.0001390869,0.00005456261,0.0012133822,0.0006180043,0.000027693395,0.00007851084,0.0007023274,0.005421057,0.0002279243,0.6062291,0.3852146,0.00007380427],"about_ca_topic_score_codex":0.4939139,"about_ca_topic_score_gemma":0.43585,"teacher_disagreement_score":0.99758714,"about_ca_system_score_codex":0.04744702,"about_ca_system_score_gemma":0.15450306,"threshold_uncertainty_score":0.98207796},"labels":[],"label_agreement":null},{"id":"W4281745128","doi":"10.2337/db22-680-p","title":"680-P: Effect of the FreeStyle Libre System on Diabetes Treatment for People with T2D: Results from a Retrospective Cohort Study Using Canadian Private Payer Claims Database","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Concomitant; Diabetes mellitus; Type 2 diabetes; Cohort; Glycemic; Reimbursement; Retrospective cohort study; Internal medicine; Insulin; Endocrinology; Health care","score_opus":0.026113028722674476,"score_gpt":0.24502088775554412,"score_spread":0.21890785903286963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281745128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987912,0.00034154754,0.000054553297,0.00012780749,0.000008785358,0.00007453481,0.010646786,0.000007078345,0.00082682696],"genre_scores_gemma":[0.9941585,0.00017949767,0.00013798704,0.00009604757,0.000012577703,0.000038265545,0.005033793,0.000004792958,0.0003386081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981987,0.00019243495,0.00015584035,0.00035280501,0.0007656049,0.00033462816],"domain_scores_gemma":[0.99465793,0.00035733462,0.0024060025,0.00032547637,0.0014371063,0.0008162192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013956472,0.00034607854,0.00039803714,0.001624247,0.0013584794,0.001155996,0.000987552,0.0004919314,0.0022463752],"category_scores_gemma":[0.004575302,0.00037063102,0.0012744641,0.004196593,0.0003918445,0.00049995113,0.00079873606,0.00072296726,0.0002715222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102929676,0.00002713847,0.9987845,0.000013122982,0.00007286726,0.000014869918,0.000053327352,0.000019596944,0.000021508526,0.000012429543,0.00032272685,0.00055492145],"study_design_scores_gemma":[0.000011424109,0.00002866209,0.9994862,0.000007221227,0.000032524928,0.000028292474,0.000096201795,0.000099091856,0.000011319661,0.0000045508536,0.00019092787,0.000003605777],"about_ca_topic_score_codex":0.86286813,"about_ca_topic_score_gemma":0.854335,"teacher_disagreement_score":0.13713187,"about_ca_system_score_codex":0.006726805,"about_ca_system_score_gemma":0.008348875,"threshold_uncertainty_score":0.2758789},"labels":[],"label_agreement":null},{"id":"W4281978943","doi":"10.1056/nejmp2200601","title":"Perverse Incentives — HIV Prevention and the 340B Drug Pricing Program","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Incentive; Drug pricing; Quarter (Canadian coin); Drug; Business; Medicine; Actuarial science; Economics; Family medicine; Pharmacology; Microeconomics","score_opus":0.03581128909195185,"score_gpt":0.292668399218413,"score_spread":0.2568571101264611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281978943","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33906487,0.009564749,0.019143492,0.24964812,0.0010438574,0.00042043367,0.0018007776,0.0005279234,0.37878573],"genre_scores_gemma":[0.9663137,0.0011524603,0.0017175425,0.0103463195,0.0003275272,0.000095526964,0.00012366447,0.000025902676,0.019897392],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99639565,0.0021495197,0.000055526558,0.00016576599,0.0005514567,0.00068206695],"domain_scores_gemma":[0.9857245,0.008585293,0.0019880217,0.00058498915,0.0009232859,0.0021939385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005823313,0.00026791848,0.00049431855,0.0009053784,0.0012703858,0.0030141927,0.0009374213,0.0038679244,0.018148666],"category_scores_gemma":[0.023386812,0.00030971246,0.00040677722,0.0008040239,0.002302588,0.002142821,0.0025755065,0.0031999315,0.0009433905],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072177016,0.000828654,0.026146851,0.00014120399,0.00010519722,0.00022419654,0.0002623161,0.012705926,0.00045975784,0.8012194,0.055164814,0.10201993],"study_design_scores_gemma":[0.0012907675,0.0009206806,0.063224,0.00051872013,0.00013126072,0.00049475126,0.0006546915,0.05024769,0.000781133,0.7548771,0.12669821,0.00016096701],"about_ca_topic_score_codex":0.011550046,"about_ca_topic_score_gemma":0.009307933,"teacher_disagreement_score":0.018148666,"about_ca_system_score_codex":0.0032130447,"about_ca_system_score_gemma":0.005261938,"threshold_uncertainty_score":0.06071329},"labels":[],"label_agreement":null},{"id":"W4281988284","doi":"10.12927/hcpol.2022.26829","title":"Commentary: University Technology Transfer Has Made a Significant Contribution to Fighting COVID-19 while Ensuring Global Access","year":2022,"lang":"en","type":"letter","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Technology transfer; Pandemic; Bench to bedside; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Personal protective equipment; Health care; Business; Public health; Public sector; Public relations; Political science; Engineering ethics; Medicine; Virology; Engineering; Law; International trade; Nursing","score_opus":0.13231464744672883,"score_gpt":0.3447495712387703,"score_spread":0.21243492379204149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281988284","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016355282,0.0005459943,0.0000436593,0.98755616,0.00924591,0.000009812158,0.000054558877,0.000023224637,0.0023571483],"genre_scores_gemma":[0.0010866618,0.00018932497,0.000071149574,0.9878321,0.0065237214,0.000024157356,0.00000894159,0.000014878417,0.004249086],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9898893,0.002676907,0.0009277632,0.001505955,0.0034474412,0.0015526481],"domain_scores_gemma":[0.97158337,0.0193808,0.0013641862,0.0006040305,0.004550328,0.0025174012],"candidate_categories":["scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.009224886,0.0014240653,0.0020049517,0.0012053871,0.010099893,0.007572348,0.005859575,0.14684176,0.013905531],"category_scores_gemma":[0.049859103,0.001444857,0.0022244786,0.00196167,0.007710186,0.0084564,0.002800052,0.080574565,0.015814539],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000272975,0.000009687301,0.00011271495,0.000050605675,0.000005666834,0.00043597765,0.00024857352,0.000044894132,0.00011052358,0.003493732,0.9935401,0.0019202383],"study_design_scores_gemma":[0.000086425134,0.00004893509,0.0006993083,0.00046139825,0.000025699876,0.0007269246,0.00077950076,0.0003570452,0.0003103764,0.008791767,0.98761916,0.00009337533],"about_ca_topic_score_codex":0.036056064,"about_ca_topic_score_gemma":0.040486086,"teacher_disagreement_score":0.99242765,"about_ca_system_score_codex":0.012286282,"about_ca_system_score_gemma":0.021022262,"threshold_uncertainty_score":0.089143574},"labels":[],"label_agreement":null},{"id":"W4282553966","doi":"10.1503/cmaj.212070","title":"COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022","year":2022,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Calgary","funders":"","keywords":"Economic shortage; Pandemic; Medicine; Medical prescription; Coronavirus disease 2019 (COVID-19); Demography; Government (linguistics); Environmental health; Internal medicine; Infectious disease (medical specialty); Pharmacology","score_opus":0.02103351348107317,"score_gpt":0.2660224292272247,"score_spread":0.2449889157461515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282553966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96064305,0.00093387265,0.00025544784,0.0010676355,0.000038649367,0.00006939195,0.034512375,0.00003043473,0.002449324],"genre_scores_gemma":[0.9860599,0.00045492346,0.00031664057,0.00021152922,0.000019829009,0.000051368275,0.0119106155,0.000010776416,0.000964351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986663,0.00011835477,0.00012437445,0.00020852633,0.00045229014,0.00043021687],"domain_scores_gemma":[0.9941527,0.00046242063,0.00195955,0.00022390415,0.0021135767,0.001087755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015859046,0.00038752414,0.00043906606,0.0018552137,0.0014391032,0.0012792186,0.0015392327,0.0005573945,0.003440487],"category_scores_gemma":[0.0054846015,0.00043461975,0.0009742132,0.0054102116,0.00066220463,0.0005627319,0.0011509735,0.0012030242,0.0003213955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053876152,0.000021897986,0.9967919,0.000024360872,0.0000720454,0.000026958907,0.00014569194,0.00016606993,0.000031665244,0.00005897094,0.0014247729,0.0011819033],"study_design_scores_gemma":[0.0000053751546,0.000018636149,0.99757606,0.00003000269,0.000030943123,0.000024070345,0.0004666016,0.00075811567,0.000031131138,0.00001757531,0.0010331204,0.000008319473],"about_ca_topic_score_codex":0.98657566,"about_ca_topic_score_gemma":0.9837536,"teacher_disagreement_score":0.01941096,"about_ca_system_score_codex":0.01941096,"about_ca_system_score_gemma":0.027719107,"threshold_uncertainty_score":0.14083701},"labels":[],"label_agreement":null},{"id":"W4282828457","doi":"10.1097/01.hjh.0000838088.86579.f9","title":"THE CHRONIC KIDNEY DISEASE IN AFRICA (CKD-AFRICA) COLLABORATION: A NEW PAN-AFRICAN NETWORK","year":2022,"lang":"en","type":"article","venue":"Journal of Hypertension","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Kidney disease; Disease; Internal medicine","score_opus":0.06498537054336183,"score_gpt":0.2553227033943191,"score_spread":0.19033733285095727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282828457","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20144439,0.14429976,0.12749869,0.26764053,0.010148625,0.020864248,0.12622169,0.0020038418,0.09987819],"genre_scores_gemma":[0.40867504,0.05569362,0.38581586,0.016552426,0.0029628987,0.026538374,0.08806149,0.0009445167,0.014755712],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9732501,0.01788843,0.0025792297,0.00171593,0.0028765537,0.0016896895],"domain_scores_gemma":[0.9418934,0.0136085255,0.00982609,0.0051176017,0.013720426,0.01583394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06387314,0.0010823837,0.0012335012,0.0050956057,0.0023378446,0.0047294106,0.0027052704,0.001796735,0.0057858806],"category_scores_gemma":[0.043169633,0.0007037481,0.0008978538,0.007954367,0.0014400128,0.0065041217,0.014618211,0.0024138729,0.0011120939],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024735034,0.0004776711,0.23211116,0.009706416,0.0011357658,0.0010572876,0.008152249,0.0014675078,0.004475196,0.023700122,0.22982123,0.48542184],"study_design_scores_gemma":[0.0008173621,0.00034389738,0.16045575,0.010738798,0.00048677696,0.0011419775,0.004249718,0.0017334905,0.0010843666,0.009019888,0.8097993,0.00012875114],"about_ca_topic_score_codex":0.009536249,"about_ca_topic_score_gemma":0.011510227,"teacher_disagreement_score":0.06387314,"about_ca_system_score_codex":0.003034671,"about_ca_system_score_gemma":0.030530803,"threshold_uncertainty_score":0.33779752},"labels":[],"label_agreement":null},{"id":"W4283695065","doi":"10.1007/s13311-022-01259-y","title":"Quantifying Patient Investment in Novel Neurological Drug Development","year":2022,"lang":"en","type":"article","venue":"Neurotherapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Drug; Drug development; Clinical trial; Neurology; Drug trial; Neurosurgery; Intensive care medicine; Emergency medicine; Internal medicine; Pharmacology; Psychiatry","score_opus":0.1701863428192845,"score_gpt":0.2955142501117551,"score_spread":0.1253279072924706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283695065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72245556,0.014763087,0.10379402,0.07516792,0.0005732438,0.00045486543,0.0063019814,0.00033547622,0.076153874],"genre_scores_gemma":[0.9931028,0.0013417891,0.0023878794,0.00048529348,0.00010443299,0.000033379743,0.00027556787,0.0000124256085,0.0022564766],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99518627,0.0033183217,0.00015705165,0.00028935022,0.0004721754,0.0005768433],"domain_scores_gemma":[0.9634645,0.029759726,0.0034420048,0.0006007883,0.0011871473,0.0015457384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006844533,0.000755694,0.0008573964,0.0014652845,0.0003919536,0.0039879405,0.0007717012,0.0033619662,0.007344238],"category_scores_gemma":[0.042004507,0.00060026656,0.00066088286,0.0015376433,0.0010644494,0.0031023223,0.001301002,0.00278982,0.00043790424],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016683592,0.00083030126,0.06754007,0.00048630103,0.00055642845,0.00059041416,0.00017469795,0.5986237,0.0008754796,0.21981868,0.011986278,0.09684939],"study_design_scores_gemma":[0.0002541667,0.0014223068,0.03480209,0.00038679174,0.00047837372,0.00067720626,0.00088167615,0.63878775,0.002437873,0.29759055,0.02217537,0.00010578292],"about_ca_topic_score_codex":0.004707736,"about_ca_topic_score_gemma":0.0039340095,"teacher_disagreement_score":0.007344238,"about_ca_system_score_codex":0.0058279717,"about_ca_system_score_gemma":0.004149594,"threshold_uncertainty_score":0.042285144},"labels":[],"label_agreement":null},{"id":"W4284664108","doi":"10.4212/cjhp.3257","title":"Drug Optimization, Sustainability, and Evaluation (DOSE) Project in Alberta Health Services","year":2022,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Health; University of Alberta; Alberta Health Services","funders":"","keywords":"Sustainability; Drug; Business; Medicine; Pharmacology","score_opus":0.0350320599945246,"score_gpt":0.3195058206936279,"score_spread":0.2844737606991033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284664108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80937004,0.0038421152,0.009836883,0.07831528,0.00042841394,0.0049156495,0.016233552,0.0009057263,0.07615232],"genre_scores_gemma":[0.93153656,0.0016218891,0.01813619,0.0060525364,0.00018939385,0.0009362393,0.004608209,0.00012581074,0.036793165],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9915255,0.0031636006,0.00014176231,0.00033580107,0.003222679,0.0016107333],"domain_scores_gemma":[0.9788968,0.0049910205,0.0012735327,0.00085618446,0.004719418,0.00926309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0103388075,0.0004378298,0.0004231385,0.00118314,0.0027893318,0.003517502,0.0018731349,0.0012376733,0.004748669],"category_scores_gemma":[0.012445216,0.0004356422,0.00046873136,0.0015587696,0.0020181406,0.00079526065,0.0029227687,0.0014327788,0.00026283582],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008689733,0.007734439,0.23092756,0.0007328722,0.0006728328,0.0009205141,0.001821024,0.05897494,0.0039516715,0.05279329,0.17277372,0.4600075],"study_design_scores_gemma":[0.0052024084,0.0088077625,0.667893,0.00051554164,0.0006823509,0.000541138,0.007703498,0.103974655,0.0066015576,0.015250345,0.18261258,0.00021512544],"about_ca_topic_score_codex":0.8789348,"about_ca_topic_score_gemma":0.9011973,"teacher_disagreement_score":0.1210652,"about_ca_system_score_codex":0.0699195,"about_ca_system_score_gemma":0.3102752,"threshold_uncertainty_score":0.50730383},"labels":[],"label_agreement":null},{"id":"W4285085793","doi":"10.54194/zjih9721","title":"Effect of amended Patented Medicine Regulations on industry decisions to launch new drugs in Canada","year":2022,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Market access; Business; Access to medicines; Political science; Law; Intellectual property; Geography","score_opus":0.08258027770115917,"score_gpt":0.3543446535820593,"score_spread":0.27176437588090013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285085793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49160632,0.007965377,0.0011511703,0.25646994,0.002425578,0.00081378897,0.014762369,0.00032579788,0.22447973],"genre_scores_gemma":[0.89927095,0.0027778149,0.0008148028,0.04788353,0.0005583116,0.00015807744,0.0026826754,0.00007627776,0.045777623],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.95240176,0.003452635,0.0020539344,0.0019164573,0.020823617,0.019351637],"domain_scores_gemma":[0.8610446,0.052205566,0.017183589,0.002482555,0.04791887,0.019164847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01791528,0.00067815103,0.0017497478,0.004569208,0.008362257,0.014658764,0.0041415486,0.012519623,0.010596268],"category_scores_gemma":[0.090060145,0.0017316312,0.0036656794,0.0045125294,0.0038831923,0.0018234244,0.003563286,0.0128806755,0.00065744907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005479537,0.0021503533,0.24483721,0.00084920996,0.0025079302,0.0031626176,0.0033539992,0.053009965,0.0045355745,0.19881974,0.4291732,0.052120674],"study_design_scores_gemma":[0.002849586,0.0007805127,0.7775918,0.00070072943,0.001972936,0.00023115141,0.004599699,0.024109319,0.004769079,0.012284195,0.16913904,0.0009718232],"about_ca_topic_score_codex":0.99463475,"about_ca_topic_score_gemma":0.99615175,"teacher_disagreement_score":0.7743671,"about_ca_system_score_codex":0.22563288,"about_ca_system_score_gemma":0.3369722,"threshold_uncertainty_score":0.8981561},"labels":[],"label_agreement":null},{"id":"W4285530742","doi":"10.2139/ssrn.3841485","title":"Reconsidering Repositioning Incentives: An Empirical Legal Analysis of Market Protection for New Therapeutic Indications","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Incentive; Business; Law and economics; Economics; Public economics; Actuarial science; Microeconomics","score_opus":0.10132708045213218,"score_gpt":0.3286953274778326,"score_spread":0.2273682470257004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285530742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8858461,0.005893498,0.018239267,0.0259124,0.00022625638,0.00039791336,0.0016354201,0.00017018226,0.06167892],"genre_scores_gemma":[0.99351704,0.0005121847,0.0008499913,0.0006430359,0.00018196012,0.000028815155,0.00018709931,0.000031822976,0.0040480397],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99163896,0.0031061794,0.0006724244,0.0012664187,0.0016636602,0.0016524273],"domain_scores_gemma":[0.69691974,0.23625977,0.049582,0.0089071775,0.005027732,0.0033036899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020150619,0.000807544,0.0032515673,0.0026352685,0.0022856959,0.009646107,0.0049253493,0.008729929,0.032459408],"category_scores_gemma":[0.12790488,0.00085915555,0.0028452058,0.002369891,0.008202246,0.009945918,0.0032332558,0.009842757,0.001448941],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022062038,0.0024062512,0.09775867,0.0008677196,0.0009156847,0.002000029,0.0021148128,0.04841879,0.002378104,0.7758709,0.015387363,0.049675465],"study_design_scores_gemma":[0.0014321473,0.0018934134,0.14249478,0.0006896929,0.0021194376,0.00075877516,0.005620508,0.17971313,0.0028458422,0.6348532,0.02722808,0.0003509991],"about_ca_topic_score_codex":0.017210737,"about_ca_topic_score_gemma":0.013090552,"teacher_disagreement_score":0.032459408,"about_ca_system_score_codex":0.004643421,"about_ca_system_score_gemma":0.0061859535,"threshold_uncertainty_score":0.10858756},"labels":[],"label_agreement":null},{"id":"W4286255302","doi":"10.1200/go.22.00060","title":"Cancer Medicines: What Is Essential and Affordable in India?","year":2022,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Research Council; Pfizer; Servier; European Society for Medical Oncology; World Health Organization; Genentech; AstraZeneca","keywords":"Medicine; Family medicine; Essential medicines; Cohort; Snowball sampling; Public health; Population; Environmental health; Internal medicine; Nursing; Pathology","score_opus":0.033042006242484594,"score_gpt":0.3401625093126421,"score_spread":0.3071205030701575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286255302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7527936,0.07100067,0.0005157294,0.116427116,0.00063311786,0.00007824529,0.0076286523,0.00007543328,0.050847508],"genre_scores_gemma":[0.97536373,0.018038902,0.0004721584,0.004470084,0.00025815822,0.000019839292,0.0008671498,0.000010292519,0.0004995733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984627,0.0003028337,0.00018634266,0.00012824303,0.0005002039,0.00041969787],"domain_scores_gemma":[0.99253535,0.0021883491,0.003061362,0.00024194525,0.0008724832,0.0011004676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013024781,0.00020142818,0.00033218533,0.0021864208,0.00065766554,0.0027683051,0.00061998516,0.0005412767,0.0048776227],"category_scores_gemma":[0.0070331753,0.00017239148,0.0003978509,0.0063595073,0.0012313495,0.0017183259,0.0011530838,0.0009850797,0.00038155937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038656054,0.00018776892,0.690521,0.00588123,0.00022832926,0.0012397573,0.0030278803,0.00040439283,0.0008251179,0.009836704,0.025960017,0.26150122],"study_design_scores_gemma":[0.000025211928,0.00015032731,0.9324374,0.0021592935,0.0001913401,0.0019711105,0.009728037,0.00029831362,0.00030949703,0.0025843706,0.050102856,0.00004214455],"about_ca_topic_score_codex":0.024452481,"about_ca_topic_score_gemma":0.035691313,"teacher_disagreement_score":0.024452481,"about_ca_system_score_codex":0.0024261603,"about_ca_system_score_gemma":0.0047538932,"threshold_uncertainty_score":0.048620284},"labels":[],"label_agreement":null},{"id":"W4286293804","doi":"10.1200/jco.2022.40.16_suppl.6598","title":"National trends in post-launch cancer prescription drug prices and the impact of generic entry, 2014-2020.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Cancer Society","keywords":"Medicine; Cancer drugs; Medical prescription; Drug prices; Cancer; Observational study; Competition (biology); Drug; Cohort; Ordinary least squares; Internal medicine; Oncology; Pharmacology; Public economics; Econometrics","score_opus":0.15504623829462838,"score_gpt":0.46430494089556673,"score_spread":0.30925870260093835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537221,0.0022033735,0.00042476563,0.00089205493,0.000030275114,0.000023847027,0.04020855,0.000034592515,0.002460453],"genre_scores_gemma":[0.97614235,0.00078786945,0.000300181,0.00013286018,0.000035676574,0.000020697855,0.021904642,0.000008194765,0.00066750066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992994,0.000098522236,0.00010885976,0.00014584755,0.00024194886,0.00010543677],"domain_scores_gemma":[0.99579996,0.00032838792,0.0031273433,0.000077169905,0.00044723487,0.00021980538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009429061,0.00014521796,0.00020691511,0.00094844465,0.00012995175,0.0008959626,0.00037677577,0.000372667,0.0016812835],"category_scores_gemma":[0.004332594,0.00015823422,0.0007153534,0.0022287958,0.00018060757,0.0007251826,0.00048526615,0.0006064941,0.00034560642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017279189,0.00004312277,0.99184424,0.000072998395,0.00009322169,0.000056359047,0.000043279986,0.00049061206,0.000123173,0.00020671391,0.0015492141,0.0053041894],"study_design_scores_gemma":[0.000004500093,0.000044524208,0.9973242,0.00001363939,0.000025359335,0.00010487412,0.000067184745,0.000880619,0.00008153487,0.000038039183,0.0014113808,0.0000040891373],"about_ca_topic_score_codex":0.026469234,"about_ca_topic_score_gemma":0.028300984,"teacher_disagreement_score":0.026469234,"about_ca_system_score_codex":0.001439526,"about_ca_system_score_gemma":0.0009303937,"threshold_uncertainty_score":0.052630305},"labels":[],"label_agreement":null},{"id":"W4286793490","doi":"","title":"Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications","year":2019,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacogenomics; Psychiatry; Medicine; Pharmacology","score_opus":0.19512289948268033,"score_gpt":0.5016387625671583,"score_spread":0.306515863084478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286793490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9068191,0.010088246,0.0047797007,0.0062297005,0.00013145593,0.00051604694,0.037552185,0.0002932159,0.03359031],"genre_scores_gemma":[0.98597395,0.0019810488,0.0038293134,0.00042741327,0.000037921356,0.000058310645,0.006404413,0.000019202987,0.0012683502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725527,0.0004994957,0.0001537501,0.00026337692,0.0015605704,0.00026762096],"domain_scores_gemma":[0.99535924,0.0011734981,0.0011538964,0.00018833914,0.0016504388,0.000474586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014795349,0.00062858034,0.00043765033,0.0020535148,0.0007731546,0.0014737626,0.0010105193,0.0004685739,0.0031518436],"category_scores_gemma":[0.011497002,0.00034881153,0.0014019562,0.0035268036,0.00034485172,0.00044850563,0.00078935054,0.0007712263,0.00018381892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017777622,0.00015747307,0.7789598,0.00064482057,0.0019570002,0.00029616023,0.00028599796,0.04951564,0.00038354995,0.0059974394,0.023036098,0.13698834],"study_design_scores_gemma":[0.00034272645,0.00043280705,0.91167796,0.00046736316,0.0010888606,0.0005246148,0.0004267153,0.065433815,0.0006634884,0.0015269323,0.017298168,0.000116677],"about_ca_topic_score_codex":0.9428996,"about_ca_topic_score_gemma":0.9510997,"teacher_disagreement_score":0.057100415,"about_ca_system_score_codex":0.037298188,"about_ca_system_score_gemma":0.027319014,"threshold_uncertainty_score":0.27061856},"labels":[],"label_agreement":null},{"id":"W4288006027","doi":"","title":"North American cost analysis of brand name versus generic drugs for the treatment of glaucoma","year":2019,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Brand names; Glaucoma; Optometry; Advertising; Medicine; Business; Ophthalmology","score_opus":0.3032576435521129,"score_gpt":0.5168849147495224,"score_spread":0.21362727119740949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288006027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.750005,0.17106925,0.0019980846,0.017448667,0.000844511,0.00043091408,0.032046374,0.000066411456,0.026090845],"genre_scores_gemma":[0.96728075,0.017350234,0.0010674339,0.0018520157,0.0003156588,0.00024854342,0.01038869,0.000029642806,0.0014669391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99604166,0.0022474038,0.0003434071,0.00019014327,0.00098822,0.00018920591],"domain_scores_gemma":[0.9940095,0.003108376,0.0013663667,0.00020952083,0.0010137407,0.0002925169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033803713,0.00035400412,0.00081789034,0.0019870943,0.00032143685,0.0011817827,0.0006992309,0.0005592622,0.00423447],"category_scores_gemma":[0.013108034,0.00034469692,0.003191791,0.0045726704,0.00022726579,0.00078075053,0.000797412,0.0013091923,0.00025901227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046316564,0.0012666936,0.3981686,0.01021053,0.036656722,0.0006771806,0.0005662709,0.033959895,0.00059318705,0.021515569,0.15751007,0.2925587],"study_design_scores_gemma":[0.0039093974,0.0019164555,0.88603973,0.0033493359,0.013514685,0.001354002,0.0015448583,0.031057376,0.00030604476,0.005359231,0.051437728,0.00021107806],"about_ca_topic_score_codex":0.045235537,"about_ca_topic_score_gemma":0.056708958,"teacher_disagreement_score":0.045235537,"about_ca_system_score_codex":0.0052397684,"about_ca_system_score_gemma":0.0023481906,"threshold_uncertainty_score":0.08994448},"labels":[],"label_agreement":null},{"id":"W4289261040","doi":"10.1093/ajhp/zxac210","title":"US drug shortages compared to the World Health Organization’s Model List of Essential Medicines for Children: A cross-sectional study","year":2022,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University","funders":"","keywords":"Economic shortage; Interquartile range; Medicine; Formulary; Family medicine; Surgery; Government (linguistics)","score_opus":0.05493826230208361,"score_gpt":0.3763516243403229,"score_spread":0.3214133620382393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289261040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995481,0.0008043472,0.000089915324,0.0001861993,0.000016594986,0.000026450238,0.0025951338,0.0000049563914,0.00079532544],"genre_scores_gemma":[0.9971192,0.00046206938,0.00011905715,0.0001625353,0.000023349803,0.00003910573,0.001939839,0.000004083733,0.00013092489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987035,0.00028240774,0.00027453905,0.00025075354,0.00030002484,0.00018883609],"domain_scores_gemma":[0.99271023,0.0009943659,0.0049244706,0.0001861491,0.0006698624,0.0005149078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021488133,0.00020942751,0.000337357,0.0016475854,0.00038321194,0.0006663552,0.00047319123,0.00047669464,0.0023605071],"category_scores_gemma":[0.0060556964,0.00033854088,0.00057817745,0.0024247468,0.0003266998,0.001509333,0.00088519655,0.00078231934,0.00033886457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002453875,0.000025784804,0.9990289,0.000017422995,0.00003555637,0.000014952376,0.000080231504,0.000022592016,0.0000143420475,0.000016237895,0.0002282812,0.0004910765],"study_design_scores_gemma":[0.0000036282138,0.00007035626,0.99865204,0.000036646565,0.000019845482,0.00014068991,0.0005098827,0.00011729461,0.000022947666,0.000012198797,0.00041058665,0.0000039276015],"about_ca_topic_score_codex":0.01190289,"about_ca_topic_score_gemma":0.010554378,"teacher_disagreement_score":0.01190289,"about_ca_system_score_codex":0.0007458946,"about_ca_system_score_gemma":0.0007308686,"threshold_uncertainty_score":0.023667216},"labels":[],"label_agreement":null},{"id":"W4290465140","doi":"10.5281/zenodo.1079864","title":"Generic Drug In Global Market And Regulatory Environment","year":2017,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Pharmacology; Medicine","score_opus":0.05578305027386,"score_gpt":0.2503811975851249,"score_spread":0.1945981473112649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290465140","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015551683,0.059785903,0.013200758,0.0639029,0.0018003514,0.0001730314,0.0036902328,0.0005824925,0.8413125],"genre_scores_gemma":[0.651002,0.08156987,0.015619978,0.03266405,0.0052922824,0.00035028858,0.0033371784,0.00032530047,0.20983899],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971528,0.00071959157,0.00012214363,0.00065873645,0.001090218,0.00025639188],"domain_scores_gemma":[0.9976277,0.0006418942,0.0005408477,0.00026097504,0.0007019792,0.000226597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023972942,0.00036731915,0.00043414376,0.002054244,0.0009245741,0.005771293,0.00043108134,0.0028037305,0.030074956],"category_scores_gemma":[0.005644927,0.00014742333,0.00036982752,0.003189974,0.002836476,0.005194471,0.0014145317,0.0021207107,0.0074045593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003530204,0.00002991817,0.0018194478,0.00029684821,0.000016827993,0.00020704126,0.00017532312,0.00063493074,0.0003334883,0.810082,0.100975014,0.085393794],"study_design_scores_gemma":[0.000013020853,0.000046864137,0.004562875,0.0002563117,0.000013334566,0.0005677255,0.00023557231,0.0003644644,0.00023051153,0.069476835,0.9242142,0.00001834395],"about_ca_topic_score_codex":0.0028456468,"about_ca_topic_score_gemma":0.0014302336,"teacher_disagreement_score":0.030074956,"about_ca_system_score_codex":0.003188546,"about_ca_system_score_gemma":0.0029568805,"threshold_uncertainty_score":0.10061073},"labels":[],"label_agreement":null},{"id":"W4291312838","doi":"10.1016/j.jhealeco.2022.102671","title":"Global drug diffusion and innovation with the medicines patent pool","year":2022,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Institute for Humane Studies, George Mason University; Cornell University","keywords":"License; Business; Drug; Procurement; Industrial organization; Clinical trial; Drug approval; Product (mathematics); International trade; Pharmacology; Public economics; Marketing; Medicine; Economics; Computer science","score_opus":0.07989695667515356,"score_gpt":0.30393930599111557,"score_spread":0.224042349315962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291312838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94392866,0.0053269668,0.009157424,0.0046151136,0.00008675731,0.00012422433,0.021125652,0.00025163073,0.015383501],"genre_scores_gemma":[0.98407334,0.00079791876,0.0021640547,0.00036015266,0.00011881128,0.00007410245,0.01005019,0.00004411178,0.0023171871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659556,0.0014462116,0.00017306088,0.00076879864,0.00047711172,0.0005392273],"domain_scores_gemma":[0.9688807,0.016913362,0.010318127,0.00198139,0.0008122498,0.0010941597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005491321,0.00057237933,0.001225617,0.00299785,0.0007642174,0.0035965284,0.0008846675,0.0016668324,0.009590995],"category_scores_gemma":[0.028954696,0.00038491466,0.0016300319,0.0049769655,0.001638722,0.004241807,0.003838317,0.0018249804,0.0014207932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013943597,0.00042430492,0.7804033,0.0010719247,0.0013479259,0.0010991986,0.001001038,0.08207276,0.0010229509,0.04584502,0.023140287,0.061177034],"study_design_scores_gemma":[0.0010054691,0.00083767285,0.7754634,0.00038167837,0.0012531573,0.0010792471,0.0015225905,0.08858267,0.0026007511,0.060591422,0.066422544,0.0002592773],"about_ca_topic_score_codex":0.011603797,"about_ca_topic_score_gemma":0.007727742,"teacher_disagreement_score":0.011603797,"about_ca_system_score_codex":0.0012029209,"about_ca_system_score_gemma":0.0010648698,"threshold_uncertainty_score":0.03208506},"labels":[],"label_agreement":null},{"id":"W4292367025","doi":"10.1001/jamahealthforum.2022.2685","title":"Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021","year":2022,"lang":"en","type":"article","venue":"JAMA Health Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Arnold Ventures; Swiss Cancer Research Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Kaiser Permanente; National Science Foundation","keywords":"Marketing authorization; Medicine; Authorization; European union; Agency (philosophy); Value (mathematics); Cohort; Drug; Family medicine; Business; Pharmacology; Internal medicine; Bioinformatics","score_opus":0.05984786430854934,"score_gpt":0.3167756284411808,"score_spread":0.25692776413263146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292367025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775229,0.0039476943,0.00030629864,0.0014090396,0.00005206091,0.00005013443,0.009540843,0.000024063183,0.0071469294],"genre_scores_gemma":[0.99331653,0.00068369944,0.00024445687,0.00035698447,0.000046885827,0.000024311223,0.0049503176,0.000006915145,0.00036995934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99437994,0.001865434,0.0007315121,0.0008115724,0.0016851844,0.0005263646],"domain_scores_gemma":[0.9619212,0.008134257,0.023871148,0.0010289436,0.0033126292,0.0017318765],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0062869163,0.00016600743,0.00039143104,0.0024173812,0.00031231108,0.0015956714,0.00042535792,0.00056233216,0.0021252453],"category_scores_gemma":[0.026787637,0.00012507223,0.00083798025,0.0033835664,0.00055155606,0.0011132832,0.00084267324,0.0008457634,0.0003244306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073476357,0.00007862696,0.9765633,0.000091578855,0.0002620946,0.00011660752,0.00012061175,0.00043522657,0.00012724375,0.00040721885,0.0031538124,0.017908921],"study_design_scores_gemma":[0.00004600255,0.00024319689,0.99202955,0.000090870664,0.0001246457,0.00064891664,0.00019885169,0.0006773448,0.00023588541,0.00014873545,0.005537271,0.000018763383],"about_ca_topic_score_codex":0.006899557,"about_ca_topic_score_gemma":0.008132933,"teacher_disagreement_score":0.9937131,"about_ca_system_score_codex":0.0014744736,"about_ca_system_score_gemma":0.0012585345,"threshold_uncertainty_score":0.033248782},"labels":[],"label_agreement":null},{"id":"W4292493763","doi":"10.1186/s40545-022-00442-y","title":"State capture through indemnification demands? Effects on equity in the global distribution of COVID-19 vaccines","year":2022,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Connaught Fund","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Equity (law); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Pandemic; Pharmacy; Business; Medicine; Virology; Computer science; Infectious disease (medical specialty); Political science; Family medicine; Outbreak; Internal medicine","score_opus":0.141513377471131,"score_gpt":0.4567318546955813,"score_spread":0.3152184772244503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292493763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70538956,0.015382295,0.0013558267,0.05622652,0.00034164725,0.00028010903,0.00058928976,0.000017026834,0.22041778],"genre_scores_gemma":[0.9927033,0.0036826176,0.00018392403,0.0018067523,0.000091038935,0.000105257306,0.000055130346,0.000007145206,0.0013649128],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9845185,0.009652689,0.00079372124,0.00079973135,0.002379351,0.001855933],"domain_scores_gemma":[0.88677025,0.09232409,0.013499377,0.0015629809,0.0044441144,0.0013992137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018884558,0.00024413294,0.00045957655,0.00342193,0.0023175043,0.0076600327,0.0009727682,0.0015405465,0.015283997],"category_scores_gemma":[0.07804898,0.0003145933,0.0009168704,0.006055418,0.0075146873,0.013985914,0.00640191,0.0019436724,0.0003909615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007768881,0.00041053133,0.1272821,0.011349253,0.00045748774,0.0015155874,0.385906,0.0008659609,0.00079522806,0.31867835,0.013829943,0.13813272],"study_design_scores_gemma":[0.00016995714,0.0004852857,0.28497657,0.01965509,0.00066344737,0.0005285107,0.55906653,0.0010166143,0.0012252996,0.049526,0.08259962,0.0000870804],"about_ca_topic_score_codex":0.0054842914,"about_ca_topic_score_gemma":0.0059217345,"teacher_disagreement_score":0.018884558,"about_ca_system_score_codex":0.0068423226,"about_ca_system_score_gemma":0.0077845682,"threshold_uncertainty_score":0.09987229},"labels":[],"label_agreement":null},{"id":"W4292507975","doi":"10.1016/j.healthpol.2022.08.006","title":"Reforms to the patented medicine prices review board and the introduction of new drugs in Canada: An observational study","year":2022,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Observational study; Drug approval; Drug prices; Food and drug administration; Alternative medicine; Family medicine; Drug; Environmental health; Pharmacology; Public economics; Internal medicine","score_opus":0.22429368624676035,"score_gpt":0.3960988533050458,"score_spread":0.17180516705828544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292507975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500444,0.0036377248,0.00020972065,0.02729602,0.00014438502,0.00022720282,0.011148328,0.00003456362,0.007257681],"genre_scores_gemma":[0.9869019,0.0017557831,0.0001960793,0.0032285512,0.00011469055,0.00006622832,0.003438073,0.000019752533,0.0042790226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9861879,0.001580263,0.00090798375,0.0009545082,0.004474908,0.0058944398],"domain_scores_gemma":[0.9080819,0.01499683,0.03436952,0.0020646234,0.020415606,0.02007147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005326644,0.0004951917,0.0011392973,0.0025426596,0.00651543,0.006543061,0.0037697612,0.006069019,0.0062954924],"category_scores_gemma":[0.043209124,0.0011015057,0.0014947413,0.009041257,0.003498779,0.0023115033,0.0024108605,0.009297991,0.0005103248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083948736,0.0013090123,0.96047413,0.00018286904,0.00041137217,0.00018791309,0.0039030183,0.001292928,0.00015546202,0.0044880603,0.017524399,0.009231323],"study_design_scores_gemma":[0.00011146557,0.00010176212,0.9867011,0.00013436815,0.00015295809,0.00004619822,0.00352105,0.00093088043,0.00011115687,0.0003099566,0.0078085363,0.000070522656],"about_ca_topic_score_codex":0.99701536,"about_ca_topic_score_gemma":0.9977951,"teacher_disagreement_score":0.15957731,"about_ca_system_score_codex":0.15957731,"about_ca_system_score_gemma":0.25712115,"threshold_uncertainty_score":0.9747712},"labels":[],"label_agreement":null},{"id":"W4292940661","doi":"10.1016/j.ijpharm.2022.122119","title":"Dosage unit uniformity and dissolution testing of extended-release pharmaceutical products marketed in the U.S.","year":2022,"lang":"en","type":"article","venue":"International Journal of Pharmaceutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Oak Ridge Institute for Science and Education; U.S. Food and Drug Administration; U.S. Department of Energy","keywords":"Innovator; Dosage form; Dissolution testing; Immediate release; Dissolution; Bioequivalence; Product (mathematics); Pharmaceutical manufacturing; Unit (ring theory); Six Sigma; Medical prescription; Generic drug; Business; Drug; Mathematics; Toxicology; Operations management; Pharmacology; Chemistry; Medicine; Marketing; Engineering; Bioavailability","score_opus":0.10813284835462067,"score_gpt":0.3489740002751549,"score_spread":0.24084115192053424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292940661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436826,0.00031887702,0.0015469309,0.000027911514,0.0000060650013,0.00016679487,0.0010485721,0.000025773441,0.002490886],"genre_scores_gemma":[0.99293447,0.0002097292,0.004012491,0.00003700278,0.0000101184,0.000056559504,0.0021058633,0.00001139762,0.000622394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970028,0.00077614107,0.0003208184,0.00040972763,0.001385747,0.00010489261],"domain_scores_gemma":[0.99379224,0.0016882216,0.0018801225,0.00044880883,0.0020181737,0.00017253721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025503216,0.00042959038,0.0002811004,0.0021009804,0.00048051632,0.00066968414,0.0003260268,0.00030636866,0.0012801229],"category_scores_gemma":[0.0063465396,0.00022404436,0.00046068188,0.002497836,0.0005592976,0.00048481554,0.00044979947,0.000299451,0.0004814186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031589982,0.0011219018,0.83329475,0.00029658515,0.0002763186,0.00072707346,0.0020966423,0.00241783,0.068238065,0.0007603115,0.0011966479,0.08641504],"study_design_scores_gemma":[0.000056648685,0.004843391,0.94073004,0.00003726658,0.00012087691,0.00088192674,0.0005423301,0.0030730087,0.04620111,0.00010673252,0.0033600146,0.00004661998],"about_ca_topic_score_codex":0.0058605024,"about_ca_topic_score_gemma":0.0049120975,"teacher_disagreement_score":0.0058605024,"about_ca_system_score_codex":0.0007945127,"about_ca_system_score_gemma":0.00047010733,"threshold_uncertainty_score":0.013487518},"labels":[],"label_agreement":null},{"id":"W4293382228","doi":"10.1016/j.kint.2022.07.029","title":"Barriers to accessing essential medicines for kidney disease in low- and lower middle–income countries|","year":2022,"lang":"en","type":"article","venue":"Kidney International","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; University of British Columbia","funders":"","keywords":"Essential medicines; Medicine; Context (archaeology); Public health; Population; Developing country; Health care; Environmental health; Family medicine; Business; Economic growth; Nursing","score_opus":0.02513666136522155,"score_gpt":0.2971133236447651,"score_spread":0.2719766622795436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293382228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63804466,0.027120475,0.00058103784,0.26741543,0.0018211532,0.00039627004,0.0035698863,0.00011902815,0.060932014],"genre_scores_gemma":[0.9537556,0.010429646,0.0007128724,0.031003458,0.0003980112,0.00016380935,0.0009826669,0.000031978536,0.0025218942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970483,0.00089226593,0.00030920518,0.00013043257,0.00044845926,0.0011713603],"domain_scores_gemma":[0.9920934,0.0021356002,0.0014264474,0.00014424742,0.0008896413,0.0033107465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036058226,0.00021610926,0.0005611609,0.00073539827,0.0027308734,0.003379738,0.000915049,0.0013650664,0.01547239],"category_scores_gemma":[0.010980576,0.00025671575,0.00073775573,0.001430472,0.0015076934,0.0028377506,0.00466747,0.002477412,0.0010160398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032102596,0.0006232469,0.53114045,0.0057615964,0.00023171463,0.0032260993,0.05779807,0.00016550772,0.0006568514,0.010437246,0.21309362,0.1765446],"study_design_scores_gemma":[0.00014885762,0.00044298885,0.56469667,0.010443717,0.00022388625,0.0032180042,0.15769829,0.00047358923,0.0003369702,0.0042037745,0.25792927,0.00018400422],"about_ca_topic_score_codex":0.057380766,"about_ca_topic_score_gemma":0.05055262,"teacher_disagreement_score":0.057380766,"about_ca_system_score_codex":0.0020332981,"about_ca_system_score_gemma":0.012264098,"threshold_uncertainty_score":0.11409354},"labels":[],"label_agreement":null},{"id":"W4293826008","doi":"10.1111/1756-2171.12422","title":"Does consumer demand pull scientifically novel drug innovation?","year":2022,"lang":"en","type":"article","venue":"The RAND Journal of Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Novelty; Consumer demand; On demand; Economics; Drug; Industrial organization; Microeconomics; Computer science; Commerce; Pharmacology; Medicine; Psychology","score_opus":0.05755306486378076,"score_gpt":0.266729548639784,"score_spread":0.20917648377600323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293826008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95925593,0.0019883795,0.004928365,0.010142747,0.0001354797,0.000095110656,0.0027764346,0.000075114694,0.020602426],"genre_scores_gemma":[0.99712366,0.00024600278,0.00021366731,0.0007502685,0.00014195882,0.000017482771,0.00048485328,0.00001764678,0.0010044711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683565,0.0010914378,0.00021710848,0.0006979281,0.00079809985,0.00035979474],"domain_scores_gemma":[0.9094333,0.060337644,0.020759827,0.003913102,0.0037060098,0.0018501311],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00612699,0.00030530934,0.000926579,0.0012957249,0.00050703523,0.0029965448,0.00075879804,0.0019522216,0.019379228],"category_scores_gemma":[0.041992757,0.0003499977,0.00087400706,0.001686269,0.0015457835,0.0024127248,0.0012041413,0.0018547958,0.0016795963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022926815,0.00061482855,0.9083026,0.00042841036,0.0009302444,0.0005051542,0.00094136107,0.0052287243,0.0025018908,0.027379632,0.007710008,0.043164458],"study_design_scores_gemma":[0.00023786796,0.00051904825,0.9189434,0.00016451823,0.00039138363,0.0004868948,0.0028202448,0.016097354,0.0019919954,0.04522942,0.012971931,0.00014592198],"about_ca_topic_score_codex":0.003185612,"about_ca_topic_score_gemma":0.0024124505,"teacher_disagreement_score":0.993873,"about_ca_system_score_codex":0.0012664963,"about_ca_system_score_gemma":0.00045762598,"threshold_uncertainty_score":0.064830005},"labels":[],"label_agreement":null},{"id":"W4294114282","doi":"","title":"Industrial manufacture of pharmaceutical tablets: 1° part: origins to 1945.","year":2016,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Society for the History of Medicine","funders":"","keywords":"Business; Process engineering; Manufacturing engineering; Engineering","score_opus":0.06806925802266213,"score_gpt":0.28445571005485976,"score_spread":0.21638645203219764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294114282","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07045877,0.22938177,0.011653662,0.011819498,0.0029750066,0.00027345313,0.003860007,0.0002656406,0.6693122],"genre_scores_gemma":[0.5957727,0.10802012,0.010788716,0.0026664946,0.0022829499,0.00018875973,0.0016323437,0.00016320952,0.27848482],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988681,0.00020771769,0.00012139718,0.00031420568,0.00032437942,0.0001641763],"domain_scores_gemma":[0.9980192,0.00087296544,0.00034351478,0.00025208676,0.0004455662,0.000066731016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010290267,0.000876958,0.00029023582,0.004368357,0.0016574954,0.0030991223,0.0006537648,0.0017750063,0.02173262],"category_scores_gemma":[0.0035991457,0.00051624817,0.00078993937,0.0032136694,0.003782427,0.0024696775,0.001871294,0.0014937132,0.0035585468],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003484846,0.00012121139,0.0043273345,0.0015301302,0.000056919747,0.00069254154,0.0033934135,0.0014430942,0.0016953262,0.70338154,0.03288321,0.25012678],"study_design_scores_gemma":[0.000020652567,0.00012649276,0.013860058,0.0008434419,0.00002402787,0.0004584256,0.0003069291,0.00032972932,0.003242428,0.028065909,0.95268655,0.00003527842],"about_ca_topic_score_codex":0.019241767,"about_ca_topic_score_gemma":0.012545428,"teacher_disagreement_score":0.02173262,"about_ca_system_score_codex":0.008202603,"about_ca_system_score_gemma":0.0024148524,"threshold_uncertainty_score":0.072702885},"labels":[],"label_agreement":null},{"id":"W4295242180","doi":"10.1016/j.ijindorg.2022.102878","title":"Collusion in the US generic drug industry","year":2022,"lang":"en","type":"article","venue":"International Journal of Industrial Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Center for Interuniversity Research and Analysis on Organizations; Queen's University","funders":"","keywords":"Collusion; Damages; Medicaid; Drug prices; Biosimilar; Control (management); Business; Economics; Competition (biology); Industrial organization; Public economics; Medicine; Health care; Law; Political science; Economic growth","score_opus":0.06563573854717865,"score_gpt":0.2768993012980632,"score_spread":0.2112635627508846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295242180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.947501,0.005907091,0.0042995233,0.018717766,0.00010018737,0.00008082984,0.0003518117,0.000048854905,0.022992987],"genre_scores_gemma":[0.9981352,0.0005270447,0.000096298245,0.00027721954,0.00006230611,0.000006430621,0.000031855616,0.0000022131246,0.00086138054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967024,0.0013692591,0.00018721595,0.00036002256,0.00044848112,0.00093253615],"domain_scores_gemma":[0.9589761,0.027643884,0.008770349,0.0010912382,0.0013493705,0.0021690463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005947795,0.00035410858,0.0011065144,0.0018573216,0.0018448111,0.004697081,0.00065356825,0.0035859665,0.0096069025],"category_scores_gemma":[0.024937272,0.0003861959,0.00069653656,0.0018886601,0.0031469932,0.0038536058,0.0040868856,0.0022528481,0.0006458117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031043242,0.000711901,0.3830274,0.0006589467,0.0006824623,0.0076679764,0.011183621,0.061722945,0.0021931096,0.37633708,0.040692512,0.11201769],"study_design_scores_gemma":[0.0009803168,0.0007467016,0.22107999,0.0005251122,0.00041617354,0.0015688965,0.02660397,0.12527694,0.0013379505,0.5970114,0.024140045,0.00031248416],"about_ca_topic_score_codex":0.011246475,"about_ca_topic_score_gemma":0.010091072,"teacher_disagreement_score":0.011246475,"about_ca_system_score_codex":0.0028482745,"about_ca_system_score_gemma":0.0015315447,"threshold_uncertainty_score":0.032138288},"labels":[],"label_agreement":null},{"id":"W4296654187","doi":"10.23880/pdraj-16000105","title":"Generic Drugs: The Landscape is Evolving So are the Mentalities?","year":2018,"lang":"en","type":"article","venue":"Pharmaceutical Drug Regulatory Affairs Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Geography","score_opus":0.05306494190187391,"score_gpt":0.2984594521955941,"score_spread":0.2453945102937202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296654187","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006251324,0.027508618,0.0014948903,0.9488918,0.0015315708,0.0000088023535,0.0003313137,0.000037713067,0.013943933],"genre_scores_gemma":[0.298408,0.11821787,0.004491034,0.5491522,0.020930937,0.00006248744,0.0005967852,0.0001910958,0.007949605],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926939,0.0030613837,0.00036746432,0.00093987695,0.001611769,0.0013255684],"domain_scores_gemma":[0.97252357,0.009577737,0.003150782,0.0012478381,0.006238596,0.0072615375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01761428,0.00057819753,0.0010619127,0.0020270902,0.0027350865,0.016920744,0.0025265529,0.011814729,0.019075835],"category_scores_gemma":[0.027986854,0.00051294145,0.0010058959,0.0029300817,0.010907913,0.020283189,0.003547464,0.014199853,0.0030991605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005541512,0.00029237077,0.018833242,0.0010991445,0.00025424152,0.00049833505,0.0017857063,0.0017436203,0.001251423,0.41653287,0.32917598,0.22797891],"study_design_scores_gemma":[0.00011486924,0.00024700272,0.025490532,0.0022154765,0.00010653131,0.0009166515,0.006356045,0.0015577272,0.0004233651,0.3981932,0.564079,0.0002994768],"about_ca_topic_score_codex":0.012386165,"about_ca_topic_score_gemma":0.019573981,"teacher_disagreement_score":0.019075835,"about_ca_system_score_codex":0.007920125,"about_ca_system_score_gemma":0.010386535,"threshold_uncertainty_score":0.09315431},"labels":[],"label_agreement":null},{"id":"W4297903762","doi":"","title":"Les dessous d’une vente en ligne de médicaments enfin encadrée","year":2014,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.03127907694969249,"score_gpt":0.26669068541863733,"score_spread":0.23541160846894485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297903762","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62595594,0.023964444,0.024461554,0.041334376,0.0064722053,0.0002891568,0.0038854566,0.0015416541,0.27209517],"genre_scores_gemma":[0.694506,0.0073051103,0.01123286,0.006218345,0.0021106915,0.00011173626,0.0012250354,0.000403576,0.27688658],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986957,0.00029811557,0.00006799193,0.00019515764,0.0005657018,0.00017735953],"domain_scores_gemma":[0.9938176,0.003018643,0.0008729199,0.00040456536,0.0010650799,0.0008212039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001381414,0.00037994105,0.000329266,0.00074440555,0.0014417088,0.0030873504,0.0004029563,0.0024821078,0.038415555],"category_scores_gemma":[0.008619524,0.00022681704,0.0008333657,0.0005517256,0.00088783755,0.0014647794,0.0007931674,0.0028823512,0.006059351],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005971199,0.0012212755,0.048145466,0.0017702626,0.0004975743,0.028203089,0.015398166,0.0020062064,0.12759714,0.106567375,0.090743266,0.5718791],"study_design_scores_gemma":[0.00011249266,0.0012305662,0.06463905,0.00069555436,0.00017463778,0.0095854,0.0035078707,0.0008956919,0.040193334,0.012343385,0.8665001,0.00012192031],"about_ca_topic_score_codex":0.0056868508,"about_ca_topic_score_gemma":0.0075953165,"teacher_disagreement_score":0.038415555,"about_ca_system_score_codex":0.0012741842,"about_ca_system_score_gemma":0.0013296702,"threshold_uncertainty_score":0.1285128},"labels":[],"label_agreement":null},{"id":"W4298088755","doi":"10.1001/jamanetworkopen.2022.31475","title":"Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products","year":2022,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Leukemia and Lymphoma Society; Arnold Ventures; Commonwealth Fund; Robert Wood Johnson Foundation","keywords":"Abiraterone; Medicare Part D; Actuarial science; Medicine; Computer science; Business; Pharmacology; Internal medicine; Prescription drug; Prostate cancer; Cancer; Medical prescription","score_opus":0.1913653680839787,"score_gpt":0.35833672226122176,"score_spread":0.16697135417724307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298088755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994474,0.00056729675,0.00033464318,0.00010913287,0.000007718804,0.00003264617,0.0038143368,0.000010384588,0.0006497932],"genre_scores_gemma":[0.99595886,0.00015154481,0.00023099847,0.000047523707,0.000018329221,0.000025698997,0.003314851,0.0000043021737,0.0002480479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99300635,0.004653971,0.0005192877,0.0006162039,0.00092788273,0.00027628234],"domain_scores_gemma":[0.9599044,0.022577789,0.013192656,0.001515329,0.0019676213,0.0008421751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007457272,0.00047274987,0.0005312139,0.0019899758,0.0002669692,0.0010303432,0.0008674998,0.0008011314,0.0023776058],"category_scores_gemma":[0.0297671,0.00041144196,0.0017570658,0.0024505884,0.0003430414,0.0009667852,0.0007636201,0.0009653327,0.00042575714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009181522,0.00021441912,0.9950405,0.000035436915,0.0006801809,0.000023531566,0.000036803398,0.00094622537,0.000041506475,0.00008055316,0.00017560062,0.0018071121],"study_design_scores_gemma":[0.000086177904,0.00084582187,0.9934837,0.000018100549,0.0003932743,0.0001593928,0.00010729566,0.0042753424,0.00014645883,0.000058283364,0.00041325568,0.0000129272585],"about_ca_topic_score_codex":0.011762607,"about_ca_topic_score_gemma":0.0077236304,"teacher_disagreement_score":0.011762607,"about_ca_system_score_codex":0.001175266,"about_ca_system_score_gemma":0.0008558456,"threshold_uncertainty_score":0.039438307},"labels":[],"label_agreement":null},{"id":"W4298147309","doi":"10.1200/jco.2022.40.28_suppl.013","title":"Medicare coverage and cost-sharing for abiraterone following generic entry.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Conquer Cancer Foundation","keywords":"Medicine; Beneficiary; Formulary; Medicare Part D; Cost sharing; Prescription drug; Market share; Generic drug; Product (mathematics); Competition (biology); Medical prescription; Marketing; Business; Family medicine; Drug; Finance; Pharmacology; Mathematics","score_opus":0.2614241358421591,"score_gpt":0.450878591896307,"score_spread":0.1894544560541479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95491433,0.0013851464,0.0004899856,0.00084317866,0.00002801187,0.00015489737,0.034884263,0.000039170725,0.0072610783],"genre_scores_gemma":[0.98831034,0.00017940003,0.00028445676,0.00016662973,0.00003110885,0.000067001805,0.010319654,0.000006691627,0.0006346904],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.997872,0.0005492018,0.00021004774,0.0002589885,0.00064668595,0.0004631043],"domain_scores_gemma":[0.99112564,0.0017922018,0.0055781524,0.00030738776,0.00057770417,0.00061884115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021548297,0.00028241237,0.000299427,0.0016498192,0.00037547262,0.00093746773,0.0005571417,0.0006104963,0.0055055707],"category_scores_gemma":[0.01194107,0.00019903923,0.0014141222,0.0027313135,0.0003081817,0.0008312247,0.0008854531,0.00082029315,0.00038748002],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074907514,0.000116867726,0.98050433,0.000095906944,0.0002874536,0.0001870926,0.000107086154,0.0024274597,0.00012384242,0.00096690643,0.0043847873,0.0100491755],"study_design_scores_gemma":[0.000057591515,0.00013862496,0.99118257,0.00005495415,0.00013137796,0.0003870202,0.00011767731,0.0039996644,0.00010668503,0.00038608478,0.0034252799,0.000012486102],"about_ca_topic_score_codex":0.035576,"about_ca_topic_score_gemma":0.030191721,"teacher_disagreement_score":0.035576,"about_ca_system_score_codex":0.0033262921,"about_ca_system_score_gemma":0.001678694,"threshold_uncertainty_score":0.07073784},"labels":[],"label_agreement":null},{"id":"W4299985524","doi":"","title":"Un partenariat émergent avec les patients permet de transformer un nouveau système relationnel dans le système de santé","year":2014,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"General partnership; Healthcare system; Computer science; Health care; Knowledge management; Process management; Business; Political science","score_opus":0.018095537401854933,"score_gpt":0.22644043438479772,"score_spread":0.20834489698294278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299985524","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21923245,0.0033891958,0.5071988,0.15532716,0.002838176,0.0009448472,0.0016815795,0.0016568209,0.107730865],"genre_scores_gemma":[0.897776,0.0013265503,0.05733419,0.0038494465,0.0014992012,0.00033835627,0.0004258185,0.0001937837,0.03725673],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9927897,0.0037323458,0.00040333482,0.0011901738,0.0011693441,0.00071517384],"domain_scores_gemma":[0.97820055,0.012617892,0.0023209383,0.0020752975,0.0025722436,0.0022131724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00821113,0.00068373786,0.001092306,0.0012330484,0.0028451642,0.006935028,0.0012741721,0.0034843464,0.036713548],"category_scores_gemma":[0.03608633,0.00047346667,0.0012883628,0.0011266012,0.0029622472,0.007930817,0.003489491,0.005636414,0.0034883837],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007494807,0.0005088445,0.047603957,0.0004878638,0.00026251675,0.00428526,0.006323921,0.01701904,0.004156416,0.7169244,0.03319566,0.16848263],"study_design_scores_gemma":[0.00031067943,0.00070396264,0.015970774,0.00047188945,0.0002589576,0.0050513283,0.0051327324,0.08486523,0.0033822574,0.7599391,0.12378027,0.00013275695],"about_ca_topic_score_codex":0.005607547,"about_ca_topic_score_gemma":0.0038011107,"teacher_disagreement_score":0.036713548,"about_ca_system_score_codex":0.0047683925,"about_ca_system_score_gemma":0.0065261093,"threshold_uncertainty_score":0.12281901},"labels":[],"label_agreement":null},{"id":"W4300556305","doi":"","title":"Disease Management Partnerships: Creating Health Solutions. Proceedings from a special symposium of the 4th annual Canadian Therapeutics Congress, May 27, 2007, Halifax, Nova Scotia, Canada.","year":2008,"lang":"en","type":"other","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nova scotia; Viewpoints; Medicine; Government (linguistics); Disease; Gerontology; Family medicine; Geography; Pathology; Archaeology","score_opus":0.07511817081654039,"score_gpt":0.24957106893856876,"score_spread":0.17445289812202835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300556305","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013695532,0.3796798,0.0018629024,0.35203183,0.009953861,0.00014185005,0.0022964024,0.00024199007,0.25242186],"genre_scores_gemma":[0.044064432,0.40093848,0.004960838,0.027544156,0.0037535664,0.0001976678,0.0029581722,0.00013985929,0.51544285],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999,0.00023215683,0.00004530343,0.000049209437,0.00045016062,0.00022321768],"domain_scores_gemma":[0.9958662,0.00087738904,0.00024933185,0.00009409132,0.0013881127,0.0015249287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002449663,0.000604897,0.00037363422,0.001601629,0.0029677022,0.00504405,0.0010219831,0.0024197395,0.056935545],"category_scores_gemma":[0.0045579523,0.00046382556,0.00025022562,0.0033189573,0.0018467832,0.0026161752,0.002336016,0.001900029,0.005440996],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010553103,0.000007188942,0.00012304909,0.00018426777,0.0000027428468,0.000036187266,0.00018150856,0.000059376573,0.00003694688,0.0050752545,0.9421842,0.05209866],"study_design_scores_gemma":[0.000015208849,0.0000056426875,0.00113347,0.00042389554,0.0000052121864,0.00006879755,0.00060082594,0.00006198843,0.00004544687,0.003103816,0.99452823,0.0000073028064],"about_ca_topic_score_codex":0.4580065,"about_ca_topic_score_gemma":0.7725405,"teacher_disagreement_score":0.4580065,"about_ca_system_score_codex":0.016156124,"about_ca_system_score_gemma":0.040394466,"threshold_uncertainty_score":0.9106812},"labels":[],"label_agreement":null},{"id":"W4301228716","doi":"","title":"Pharmaceuticals Ampoules, Industrial Pharmaceutical Production","year":2018,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Society for the History of Medicine","funders":"","keywords":"Ampoule; Production (economics); Business; Process engineering; Waste management; Engineering; Chemistry; Organic chemistry; Economics","score_opus":0.09219639712258808,"score_gpt":0.302752053586162,"score_spread":0.21055565646357388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301228716","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032960102,0.33119112,0.03489624,0.07453689,0.009576404,0.00021410384,0.0094311815,0.00089720974,0.5062967],"genre_scores_gemma":[0.50855696,0.11837598,0.016141957,0.0045761853,0.007831741,0.00025676898,0.0032585934,0.00020359363,0.34079823],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978661,0.00047575383,0.0001389414,0.00045959782,0.0009076981,0.00015185442],"domain_scores_gemma":[0.99692756,0.0013463887,0.0007640191,0.00026240826,0.00048074083,0.00021888992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010617499,0.00087782624,0.0006740264,0.002810153,0.0009644593,0.0050163516,0.0008636601,0.004735223,0.08596104],"category_scores_gemma":[0.005472201,0.00033326034,0.0005667212,0.0036726433,0.0020486505,0.005158923,0.0011505581,0.0020652115,0.017520675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005559813,0.00019032121,0.0019592168,0.002718218,0.000046928573,0.00047321708,0.00013454811,0.0069883177,0.0032056915,0.6660102,0.11162964,0.20608778],"study_design_scores_gemma":[0.000088983295,0.0002622075,0.005311468,0.0005498824,0.000045273584,0.0009455982,0.00026422713,0.0042926962,0.005062591,0.3052467,0.6778713,0.000059094535],"about_ca_topic_score_codex":0.0034417834,"about_ca_topic_score_gemma":0.0020377832,"teacher_disagreement_score":0.08596104,"about_ca_system_score_codex":0.0035834662,"about_ca_system_score_gemma":0.001792556,"threshold_uncertainty_score":0.28756833},"labels":[],"label_agreement":null},{"id":"W4302345706","doi":"","title":"Editorial: Guidelines for choosing drugs in chronic heart failure ||FREE PAPER||","year":2005,"lang":"en","type":"editorial","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Heart failure; Medicine; Intensive care medicine; Internal medicine","score_opus":0.2743391260302212,"score_gpt":0.5508293905336885,"score_spread":0.2764902645034673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302345706","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017999746,0.0027983848,0.00012816407,0.034173515,0.9620364,0.000021038617,0.000059943337,0.00004930235,0.0007153304],"genre_scores_gemma":[0.00025740496,0.002535101,0.00015643997,0.026215762,0.9674484,0.000031948755,0.00003695099,0.000046843055,0.003271127],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9886331,0.0028335263,0.002428215,0.00097498717,0.0044778185,0.0006523273],"domain_scores_gemma":[0.9330676,0.030301137,0.00441061,0.0018675815,0.024388751,0.005964221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014471194,0.005919652,0.0067204325,0.007154001,0.004350219,0.010080422,0.0065179314,0.028153077,0.01697988],"category_scores_gemma":[0.06799437,0.001765651,0.0046712197,0.003746965,0.0041243033,0.006903662,0.0018086996,0.03179298,0.018789485],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002027764,0.000013149475,0.000018827457,0.00011852035,0.000014123009,0.000048341033,0.0000053317244,0.000014972912,0.000008884102,0.0001314438,0.9972234,0.0023827958],"study_design_scores_gemma":[0.00019279716,0.000047429225,0.00047910181,0.0012020384,0.00012464267,0.00036174833,0.000060497325,0.00032608066,0.00010406967,0.0017145257,0.9953477,0.000039394716],"about_ca_topic_score_codex":0.002907491,"about_ca_topic_score_gemma":0.0059923977,"teacher_disagreement_score":0.028153077,"about_ca_system_score_codex":0.0042370115,"about_ca_system_score_gemma":0.004366062,"threshold_uncertainty_score":0.07653189},"labels":[],"label_agreement":null},{"id":"W4306317550","doi":"","title":"Research Ethics and Commercial Drug Development: When Integrity Threatens Profitability","year":2016,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Profitability index; Business; Drug development; Drug; Engineering ethics; Pharmacology; Medicine; Engineering; Finance","score_opus":0.7272862728730055,"score_gpt":0.6255946185515461,"score_spread":0.10169165432145943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306317550","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046906374,0.007505717,0.022108203,0.8055652,0.0018990478,0.00014653,0.000021319225,0.00006963909,0.11577802],"genre_scores_gemma":[0.8640051,0.0032399413,0.008187463,0.11162748,0.0024390493,0.0001973642,0.0000134809,0.00008951952,0.010200564],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8403612,0.114366665,0.004804329,0.0049886373,0.022779683,0.012699424],"domain_scores_gemma":[0.8094907,0.14121217,0.014487196,0.008242253,0.01343458,0.01313309],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.09709713,0.0005723065,0.0011068023,0.0019973363,0.019494642,0.0257517,0.0022676953,0.02809338,0.002852796],"category_scores_gemma":[0.13440374,0.0007329646,0.0010177095,0.0016873193,0.06856934,0.022708468,0.015089399,0.02901255,0.0008476683],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008354756,0.00008471188,0.0027484251,0.00020349695,0.0000306656,0.0067186765,0.05019686,0.00030128556,0.00072704913,0.9031218,0.019411864,0.016371654],"study_design_scores_gemma":[0.00007623677,0.00022919798,0.0014309706,0.0013855686,0.000038211467,0.012524285,0.06612211,0.001066648,0.0016025545,0.5953668,0.31996948,0.00018800203],"about_ca_topic_score_codex":0.002950515,"about_ca_topic_score_gemma":0.0036856756,"teacher_disagreement_score":0.9719066,"about_ca_system_score_codex":0.008740227,"about_ca_system_score_gemma":0.019509353,"threshold_uncertainty_score":0.51350486},"labels":[],"label_agreement":null},{"id":"W4306710478","doi":"10.5281/zenodo.7217469","title":"Towards a national PID strategy for Canada - Vers une stratégie nationale sur les PID pour le Canada","year":2022,"lang":"fr","type":"report","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PID controller; Humanities; Political science; Art; Engineering; Control engineering","score_opus":0.14737988622984852,"score_gpt":0.27991805761930993,"score_spread":0.13253817138946142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306710478","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02056609,0.021513205,0.027824318,0.6561786,0.0058792876,0.00121627,0.0042463066,0.0015036787,0.26107237],"genre_scores_gemma":[0.30276933,0.022666479,0.13727634,0.16917804,0.00076492986,0.0013577824,0.0058441423,0.0006017296,0.35954112],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9711831,0.0042543844,0.0009445594,0.0019197129,0.01273873,0.008959414],"domain_scores_gemma":[0.95159125,0.0022184325,0.00082427246,0.0008087093,0.027233826,0.01732345],"candidate_categories":["scholarly_communication","open_science"],"consensus_categories":[],"category_scores_codex":[0.029415708,0.001025782,0.0008318325,0.0049884194,0.020940099,0.022362415,0.0049933637,0.0072366917,0.013313874],"category_scores_gemma":[0.026358431,0.0008766547,0.0013579846,0.0053913267,0.007000781,0.009891803,0.011999213,0.008178931,0.0021858457],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009578013,0.00014018157,0.006135256,0.00074115745,0.00005541003,0.00046737885,0.008399832,0.0017352549,0.00079874194,0.3807901,0.49969035,0.10095056],"study_design_scores_gemma":[0.000019583738,0.000033211516,0.00356141,0.0006346759,0.000028373393,0.000083630744,0.008356697,0.0006956738,0.00033901315,0.012879956,0.97329754,0.000070338436],"about_ca_topic_score_codex":0.97787243,"about_ca_topic_score_gemma":0.9814388,"teacher_disagreement_score":0.9950066,"about_ca_system_score_codex":0.21252064,"about_ca_system_score_gemma":0.7222376,"threshold_uncertainty_score":0.9133644},"labels":[],"label_agreement":null},{"id":"W4307134787","doi":"10.1186/s40545-022-00464-6","title":"Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017–2020","year":2022,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Call for bids; Pharmacy; Business; Medicine; Medical emergency; Pharmacology; Computer science; Family medicine; Marketing; Procurement","score_opus":0.09498626884349634,"score_gpt":0.38939722757637607,"score_spread":0.2944109587328797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307134787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637627,0.0017507563,0.0031725827,0.0014801852,0.000097549506,0.00021746455,0.005761506,0.00006751672,0.02368977],"genre_scores_gemma":[0.99257445,0.00030738473,0.00085339556,0.00014387925,0.00005085737,0.000051384577,0.0024389212,0.000010562769,0.003569165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99257326,0.0017048003,0.00038726398,0.0007803351,0.002796364,0.0017579882],"domain_scores_gemma":[0.98365504,0.007467532,0.0044331257,0.0004750336,0.0012094231,0.0027597744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075209136,0.00022725583,0.00033326162,0.0012593685,0.0006655336,0.0020409322,0.00093388,0.0009010784,0.005640528],"category_scores_gemma":[0.01488496,0.0003838505,0.00065594225,0.0011654012,0.0008260175,0.0008960126,0.0016743602,0.0013093968,0.00061130413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008961304,0.0015868817,0.5549813,0.0013051734,0.00044676763,0.0029635292,0.0033605597,0.0612715,0.0059038354,0.083289884,0.07762132,0.19830805],"study_design_scores_gemma":[0.00073952985,0.0019606315,0.8274602,0.00026392247,0.00016358121,0.0013204458,0.0042589367,0.028890952,0.0029909003,0.008498075,0.12330513,0.00014761962],"about_ca_topic_score_codex":0.024762282,"about_ca_topic_score_gemma":0.021965092,"teacher_disagreement_score":0.024762282,"about_ca_system_score_codex":0.0063324915,"about_ca_system_score_gemma":0.0049159327,"threshold_uncertainty_score":0.049236298},"labels":[],"label_agreement":null},{"id":"W4307741138","doi":"10.22541/au.166723062.20984842/v1","title":"Is Thailand's hepatitis C treatment program at risk from its plans to join an Asia-Pacific trade pact?","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Intellectual property; Business; International trade; Trade agreement; General partnership; Market share; International economics; Economics; Political science; Finance; Law; Free trade","score_opus":0.09986663059078404,"score_gpt":0.3180389169392703,"score_spread":0.21817228634848623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307741138","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6358199,0.0056684455,0.0024655396,0.19364564,0.0008162446,0.0003431388,0.002455951,0.000091858645,0.15869328],"genre_scores_gemma":[0.98105407,0.003726437,0.001261419,0.008463701,0.00016736102,0.00008527674,0.0005893187,0.00002422251,0.0046282504],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928893,0.0038153094,0.00017573341,0.00025786465,0.0017733084,0.0010884623],"domain_scores_gemma":[0.9827183,0.0044866656,0.0052508414,0.00042064194,0.004106827,0.0030167296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050867535,0.00028268283,0.0003141021,0.0005211853,0.002047903,0.0058818185,0.0007816193,0.0015010643,0.009107201],"category_scores_gemma":[0.018252969,0.0002296917,0.00050949777,0.0023265402,0.0015385828,0.0042849067,0.0015020873,0.002761646,0.00078426115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019017672,0.0010136162,0.53720474,0.0019193571,0.0007981774,0.005512219,0.01085345,0.012300637,0.0021140329,0.05291398,0.08228564,0.2911824],"study_design_scores_gemma":[0.0002560579,0.0030727005,0.5123877,0.003205443,0.00063511427,0.006213635,0.13651077,0.013475257,0.0041417815,0.031206949,0.2885141,0.0003804785],"about_ca_topic_score_codex":0.03642501,"about_ca_topic_score_gemma":0.050888907,"teacher_disagreement_score":0.03642501,"about_ca_system_score_codex":0.0046869647,"about_ca_system_score_gemma":0.01393254,"threshold_uncertainty_score":0.07242596},"labels":[],"label_agreement":null},{"id":"W4308797786","doi":"10.1136/bmjgh-2022-010057","title":"A global social contract to ensure access to essential medicines and health technologies","year":2022,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"Center for Substance Abuse Prevention; UCB; United States Pharmacopeia; Unitaid; Leslie Dan Faculty of Pharmacy, University of Toronto; Gilead Sciences; University of Toronto; World Health Organization","keywords":"Social contract; Business; Global health; Public health; Public relations; Public administration; Medicine; Political science; Nursing; Politics; Law","score_opus":0.10424392277804646,"score_gpt":0.4529918066405506,"score_spread":0.34874788386250416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308797786","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051500697,0.0027576534,0.08954318,0.34990555,0.0015114814,0.00024140185,0.00026370547,0.000117520845,0.50415885],"genre_scores_gemma":[0.9118294,0.0021752473,0.022840887,0.028459353,0.0010308448,0.00032930344,0.0001586314,0.000081826,0.033094425],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98981524,0.0053470205,0.00041914862,0.0008244546,0.0022091004,0.0013850816],"domain_scores_gemma":[0.98948306,0.0047849044,0.0014608228,0.0012978102,0.0013607006,0.0016125498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017137695,0.0005006877,0.0005226997,0.0011869458,0.0038045126,0.00731976,0.00088731863,0.008628962,0.009124064],"category_scores_gemma":[0.020135354,0.00032424938,0.0008366605,0.00095241086,0.016243251,0.011458211,0.009589545,0.006383184,0.0007513074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000045333923,0.000009097396,0.00015279806,0.000007886992,0.0000026216196,0.000019743604,0.00022296597,0.00028578413,0.0000367887,0.99540895,0.0019404644,0.0019082889],"study_design_scores_gemma":[0.000025602407,0.000027159022,0.00044607895,0.00007613523,0.0000052337077,0.000058302187,0.00034605103,0.0011478083,0.00010459183,0.94286174,0.054884255,0.000016955935],"about_ca_topic_score_codex":0.004100239,"about_ca_topic_score_gemma":0.0035217265,"teacher_disagreement_score":0.017137695,"about_ca_system_score_codex":0.005881298,"about_ca_system_score_gemma":0.01248208,"threshold_uncertainty_score":0.09063387},"labels":[],"label_agreement":null},{"id":"W4308949677","doi":"10.1016/j.jval.2022.11.003","title":"Modeling Tiered Pricing Frameworks: A Simulation Approach","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Centre for Advancing Health Outcomes; University of British Columbia; St. Paul's Hospital; University of Toronto","funders":"Institute of Population and Public Health; Canadian Institutes of Health Research","keywords":"Computer science","score_opus":0.1747292760358831,"score_gpt":0.3388581767082557,"score_spread":0.1641289006723726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308949677","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17898715,0.00087977,0.78317773,0.0030082725,0.00018796396,0.00018619465,0.0010457565,0.00056487764,0.031962268],"genre_scores_gemma":[0.9284353,0.00048436396,0.06389884,0.00022964158,0.000075787146,0.00018808067,0.00033093704,0.00010795394,0.0062490124],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985355,0.0008618719,0.000055371907,0.00015043365,0.00016574234,0.00023116315],"domain_scores_gemma":[0.9913236,0.0069508366,0.00046456038,0.00034125624,0.0005346557,0.00038513646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030942028,0.0007617108,0.0015433369,0.0011818481,0.0008995445,0.0034778574,0.002781999,0.003553868,0.008809327],"category_scores_gemma":[0.012390709,0.0009453565,0.0014981213,0.0017969743,0.0013329764,0.0034869171,0.0015895942,0.0025206916,0.00056417036],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022581122,0.000042154108,0.00043965384,0.000010755682,0.000022882974,0.000025379,0.00003073121,0.9436894,0.000054640608,0.05403019,0.00035220876,0.0012794388],"study_design_scores_gemma":[0.000009919064,0.0000051475827,0.00003869574,0.0000026389548,0.0000046549435,0.0000038694684,0.000009834518,0.98491293,0.000014852058,0.014813442,0.00018029471,0.0000037243096],"about_ca_topic_score_codex":0.03156377,"about_ca_topic_score_gemma":0.021122988,"teacher_disagreement_score":0.03156377,"about_ca_system_score_codex":0.0027075754,"about_ca_system_score_gemma":0.0030213818,"threshold_uncertainty_score":0.062760055},"labels":[],"label_agreement":null},{"id":"W4309048291","doi":"10.9778/cmajo.20220063","title":"Time to potential for listing of new drugs on public and private formularies in Canada: a cross-sectional study","year":2022,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; York University","funders":"","keywords":"Formulary; Notice; Agency (philosophy); Listing (finance); Medicine; Marketing; Business; Public relations; Family medicine; Political science; Finance; Law","score_opus":0.09382472957189025,"score_gpt":0.32130927710620466,"score_spread":0.2274845475343144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309048291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800685,0.001261513,0.0001226045,0.0009269309,0.000025865415,0.000118432086,0.013612924,0.000019998282,0.0038433103],"genre_scores_gemma":[0.99521303,0.0005906324,0.00015019113,0.00027244797,0.0000108442155,0.000040441362,0.0029798455,0.00000906483,0.00073359476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973133,0.0001874644,0.0003021838,0.0004309114,0.000989726,0.0007763036],"domain_scores_gemma":[0.9895572,0.0011740347,0.0043220697,0.00031539152,0.0028491088,0.0017821508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017488635,0.000299047,0.00042846752,0.002098686,0.0023064876,0.002061927,0.0021746806,0.0009900762,0.005765386],"category_scores_gemma":[0.008102643,0.00060738175,0.0012436054,0.005903282,0.001004581,0.0012139509,0.0011960821,0.0017628403,0.00036625873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067305555,0.000032020525,0.9972754,0.00004845133,0.000052271254,0.00003351309,0.0004387507,0.000046302386,0.000027074117,0.00006784682,0.00079651026,0.0011143992],"study_design_scores_gemma":[0.0000044370713,0.000031021944,0.99772125,0.0000503874,0.00002838273,0.000042481057,0.0012675193,0.00013501199,0.00002474578,0.000013594812,0.0006692671,0.000011850552],"about_ca_topic_score_codex":0.98038155,"about_ca_topic_score_gemma":0.9795154,"teacher_disagreement_score":0.027714014,"about_ca_system_score_codex":0.027714014,"about_ca_system_score_gemma":0.030146284,"threshold_uncertainty_score":0.2010802},"labels":[],"label_agreement":null},{"id":"W4309361791","doi":"10.1503/cmaj.220324-f","title":"Sécurité d’approvisionnement pharmaceutique au Canada","year":2022,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University of Alberta; Mount Sinai Hospital","funders":"","keywords":"Population; Political science; Humanities; Medicine; Art; Environmental health","score_opus":0.020493225284868775,"score_gpt":0.2529000913621309,"score_spread":0.2324068660772621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309361791","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08262891,0.048725102,0.005815582,0.5350208,0.0043630945,0.00046166667,0.017457282,0.0006601189,0.30486736],"genre_scores_gemma":[0.6909214,0.037742484,0.007947061,0.042122785,0.002113676,0.00020715613,0.0071028164,0.00022367774,0.21161895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888311,0.0010416696,0.00033192456,0.00057496625,0.006716497,0.0025039369],"domain_scores_gemma":[0.9600979,0.003692706,0.0023813203,0.00078555354,0.022211403,0.010831188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005252153,0.0003558762,0.0005522644,0.0024652798,0.0030126884,0.004456534,0.001398667,0.002149163,0.018235859],"category_scores_gemma":[0.022368226,0.0004460406,0.00067025726,0.0033955101,0.0018164088,0.0012624243,0.0016080475,0.004237092,0.00132141],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004340741,0.0002084809,0.077616364,0.0007969832,0.00020829846,0.00052063074,0.0014795195,0.0026974818,0.0013080095,0.13517813,0.50904375,0.27050826],"study_design_scores_gemma":[0.00012748179,0.0001750354,0.24306366,0.00095726765,0.00006508116,0.00023263023,0.0006307344,0.0034600047,0.00088910747,0.004096208,0.7462191,0.00008362749],"about_ca_topic_score_codex":0.9883879,"about_ca_topic_score_gemma":0.9881342,"teacher_disagreement_score":0.877755,"about_ca_system_score_codex":0.122245006,"about_ca_system_score_gemma":0.34108463,"threshold_uncertainty_score":0.8869538},"labels":[],"label_agreement":null},{"id":"W4310688617","doi":"10.12927/hcpol.2022.26973","title":"Patent “Evergreening” of Medicine–Device Combination Products: A Global Perspective","year":2022,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Bruyère; University of Calgary","funders":"","keywords":"Perspective (graphical); Business; Intellectual property; Computer science; Political science; Artificial intelligence; Law","score_opus":0.1749606082079628,"score_gpt":0.3748205591258012,"score_spread":0.1998599509178384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310688617","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34294578,0.2560986,0.01596418,0.22735424,0.00088662055,0.00008642622,0.0013177325,0.000074519194,0.15527198],"genre_scores_gemma":[0.9261544,0.06321044,0.002225396,0.0058176625,0.0010324909,0.000016717717,0.00023690266,0.000021209575,0.0012847629],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963652,0.001443175,0.00018539678,0.00044346554,0.0010732476,0.00048942445],"domain_scores_gemma":[0.97051316,0.017713943,0.0056442544,0.0011476708,0.0037398986,0.0012410327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010585161,0.0005116423,0.00055028766,0.0052626445,0.00083358935,0.0062740427,0.0006082315,0.0018809036,0.00492858],"category_scores_gemma":[0.016575797,0.00014011757,0.00063455227,0.006491593,0.0046921195,0.0072771558,0.0021326686,0.0019528498,0.00021745278],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032882683,0.00023631423,0.10307353,0.0019103318,0.00028622354,0.0008477358,0.0029692925,0.006548989,0.002579953,0.39080155,0.017324956,0.47309232],"study_design_scores_gemma":[0.00006722031,0.0008900019,0.3247316,0.0054469155,0.00053615426,0.0027494223,0.011017889,0.008589575,0.0041443733,0.33364367,0.30805576,0.00012745132],"about_ca_topic_score_codex":0.003520145,"about_ca_topic_score_gemma":0.0037234223,"teacher_disagreement_score":0.010585161,"about_ca_system_score_codex":0.00294376,"about_ca_system_score_gemma":0.0039514136,"threshold_uncertainty_score":0.055980325},"labels":[],"label_agreement":null},{"id":"W4311150483","doi":"10.51731/cjht.2022.512","title":"Canadian Trends in Estimated Pharmaceutical Drug Purchases and Projections: 2023","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Audit; Annual growth %; Specialty; Private sector; Agricultural economics; Medicine; Accounting; Economics; Economic growth; Family medicine","score_opus":0.11798662010314265,"score_gpt":0.34642342254702213,"score_spread":0.22843680244387948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311150483","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15106949,0.011165548,0.007887132,0.013464755,0.0007693799,0.0002176488,0.7164236,0.001696969,0.09730553],"genre_scores_gemma":[0.57324594,0.015863761,0.014956451,0.0020221993,0.0002059278,0.00016758825,0.36449188,0.00036422815,0.028682051],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9979704,0.00006500255,0.00008583372,0.00015899606,0.0013889994,0.0003308928],"domain_scores_gemma":[0.9928705,0.00012486443,0.0002270112,0.00009432555,0.0064082583,0.00027506577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015347938,0.0011810518,0.0004446672,0.0043428787,0.0015607978,0.003365787,0.0014632829,0.0006578022,0.008842438],"category_scores_gemma":[0.004558437,0.00046268073,0.0018040977,0.009285925,0.00039634632,0.0012534496,0.00091617275,0.0015019759,0.0022943146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004982144,0.00015809025,0.2844387,0.0011887543,0.0008445865,0.00046624863,0.0007890331,0.042681787,0.00084499986,0.016204001,0.5177363,0.13414928],"study_design_scores_gemma":[0.00007926588,0.00008676819,0.53305954,0.0006101299,0.00028531352,0.00035878835,0.001435842,0.050858356,0.0018994643,0.0020555968,0.40899435,0.00027658374],"about_ca_topic_score_codex":0.99570763,"about_ca_topic_score_gemma":0.9931004,"teacher_disagreement_score":0.9450708,"about_ca_system_score_codex":0.054929193,"about_ca_system_score_gemma":0.067955896,"threshold_uncertainty_score":0.3985411},"labels":[],"label_agreement":null},{"id":"W4312203309","doi":"10.1177/17411343221146094","title":"Abbreviated new drug submission approval process: An overview","year":2022,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Innovator; Generic drug; Brand names; Product (mathematics); Drug; Business; Medical prescription; Prescription drug; Pharmacology; Marketing; Medicine; Mathematics; Finance; Pharmacokinetics","score_opus":0.17414686862717058,"score_gpt":0.34405085586261713,"score_spread":0.16990398723544656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312203309","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059932694,0.17151815,0.2377299,0.06094881,0.011380008,0.0159563,0.015704615,0.011803491,0.46896544],"genre_scores_gemma":[0.08677093,0.24424472,0.30623272,0.054932017,0.01819601,0.018186728,0.020365374,0.004386913,0.2466846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.92530024,0.025037367,0.012434755,0.0042235367,0.030042354,0.0029617678],"domain_scores_gemma":[0.8818678,0.033791374,0.017205458,0.012367003,0.050276894,0.004491404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.065683834,0.0016192896,0.0015111285,0.0069805174,0.0023714462,0.012240243,0.0042217355,0.005917929,0.035685357],"category_scores_gemma":[0.08363484,0.0017768593,0.0023932843,0.010137037,0.0028184084,0.009674771,0.004185536,0.0051404354,0.053927273],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032830558,0.00026014922,0.002069923,0.0038578298,0.00006924192,0.0004047697,0.00026921617,0.0022379209,0.0013874618,0.10105898,0.38713056,0.50092554],"study_design_scores_gemma":[0.000041817504,0.00018576847,0.0037709104,0.0007102362,0.000030191311,0.00072110095,0.000059185277,0.00096360256,0.0006029723,0.0065969056,0.98625076,0.00006655527],"about_ca_topic_score_codex":0.010341125,"about_ca_topic_score_gemma":0.009229113,"teacher_disagreement_score":0.065683834,"about_ca_system_score_codex":0.009646417,"about_ca_system_score_gemma":0.030069336,"threshold_uncertainty_score":0.3473735},"labels":[],"label_agreement":null},{"id":"W4312325246","doi":"10.56530/spectroscopy.mf9790d5","title":"Quo Vadis Analytical Procedure Development and Validation?","year":2022,"lang":"en","type":"article","venue":"Spectroscopy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Status quo; Pharmacopoeia; Computer science; Political science; Medicine; Law; Alternative medicine","score_opus":0.045783568263870485,"score_gpt":0.29474839649282036,"score_spread":0.24896482822894989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312325246","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024045112,0.015128537,0.0769906,0.78342885,0.027648516,0.00043656718,0.00041285428,0.0013514023,0.09219829],"genre_scores_gemma":[0.07509997,0.016559718,0.14914644,0.6506071,0.023296919,0.0013471078,0.0006677207,0.0018915478,0.08138347],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.734189,0.09996566,0.019204982,0.026491465,0.11147612,0.0086728195],"domain_scores_gemma":[0.61515933,0.15214077,0.025784476,0.055049043,0.14400911,0.007857378],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2497627,0.0012628988,0.0022794963,0.0036978319,0.006750755,0.026978604,0.006897087,0.024091672,0.012449003],"category_scores_gemma":[0.30859816,0.0020923195,0.0024706258,0.0030255343,0.03853369,0.025959449,0.009542614,0.02599297,0.015263702],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018430599,0.00027150143,0.0022771594,0.0017520133,0.00015898353,0.00029378597,0.0038523145,0.0004715408,0.0044416348,0.519861,0.26843384,0.19800197],"study_design_scores_gemma":[0.00007427749,0.0001303255,0.0015199782,0.0016515146,0.0000936388,0.00023706652,0.0013483332,0.00097361335,0.0037520789,0.173684,0.8163835,0.0001517382],"about_ca_topic_score_codex":0.019310249,"about_ca_topic_score_gemma":0.017659537,"teacher_disagreement_score":0.2497627,"about_ca_system_score_codex":0.013762266,"about_ca_system_score_gemma":0.06504964,"threshold_uncertainty_score":0.92517614},"labels":[],"label_agreement":null},{"id":"W4312491467","doi":"10.52937/hira.22.2.2.e8","title":"A Review of Foreign Pharmaceutical Pricing Structure: Focusing on a Drug Price Formula Based on Ex-factory Prices","year":2022,"lang":"en","type":"review","venue":"Health Insurance Review & Assessment Service Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Factory (object-oriented programming); Drug prices; Business; Economics; Computer science; Monetary economics","score_opus":0.36709803707687516,"score_gpt":0.5246153618002687,"score_spread":0.15751732472339353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312491467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011534778,0.99297005,0.00093865796,0.0017145261,0.000668133,0.000019217023,0.00011050031,0.000015939162,0.0024095916],"genre_scores_gemma":[0.0104135,0.9860395,0.0014356484,0.0009951221,0.0005280043,0.000025658475,0.00015752176,0.000016693406,0.00038837883],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99556434,0.0013934984,0.0009883193,0.00045462558,0.00147154,0.00012772097],"domain_scores_gemma":[0.983286,0.008478366,0.0023505331,0.0004339354,0.005196554,0.00025452834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007125483,0.0006604374,0.0014267226,0.009784703,0.0003262799,0.0022826532,0.001250637,0.001019392,0.0021523037],"category_scores_gemma":[0.02047006,0.00051045784,0.0013725732,0.014294814,0.000873185,0.0035137266,0.0006263088,0.0016486478,0.00070827757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013533868,0.00007326704,0.002405173,0.04582008,0.00035677772,0.00022537273,0.0002647562,0.0009444653,0.00051647803,0.014155797,0.040836208,0.8942663],"study_design_scores_gemma":[0.000053576645,0.00028601923,0.020571696,0.057122216,0.001110798,0.0015124257,0.00048190297,0.0012140936,0.0012692881,0.003183687,0.9130748,0.000119574],"about_ca_topic_score_codex":0.010033775,"about_ca_topic_score_gemma":0.0077059437,"teacher_disagreement_score":0.010033775,"about_ca_system_score_codex":0.0027658553,"about_ca_system_score_gemma":0.007074767,"threshold_uncertainty_score":0.037683606},"labels":[],"label_agreement":null},{"id":"W4312694691","doi":"10.30699/mmlj17.5.2.38","title":"Advanced therapeutic medicinal products (ATMPs) in Ischemic Stroke; novel therapeutic modalities from financial perspective","year":2022,"lang":"en","type":"article","venue":"Modern Medical Laboratory Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Therapeutic modalities; Modalities; Perspective (graphical); Ischemic stroke; Medicine; Stroke (engine); Treatment modality; Therapeutic effect; Business; Cardiology; Internal medicine; Computer science; Ischemia; Engineering; Artificial intelligence","score_opus":0.03666390862104501,"score_gpt":0.27802823023353423,"score_spread":0.24136432161248922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312694691","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015381427,0.8291768,0.007941265,0.07855576,0.0019064251,0.000045156976,0.0004984211,0.000036854435,0.06645796],"genre_scores_gemma":[0.28294057,0.6780279,0.006626938,0.009764108,0.01354259,0.000084386425,0.00020920947,0.00001470441,0.008789596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995801,0.00016129517,0.000040641295,0.000047102483,0.00012570931,0.000045227265],"domain_scores_gemma":[0.9985067,0.00076002337,0.00037433874,0.000035216126,0.00021607289,0.000107609245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011750417,0.00047060812,0.00058881636,0.0014361939,0.00028177284,0.0018657687,0.00036162403,0.0016184334,0.006402811],"category_scores_gemma":[0.001975225,0.00012267962,0.00046970107,0.0010043039,0.0012053945,0.0021038433,0.00056180905,0.0023444523,0.00048652408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087416684,0.0003951675,0.0016825785,0.0032980316,0.00019132814,0.0008449348,0.00008134687,0.0031782656,0.0030281444,0.3827396,0.03001608,0.5736704],"study_design_scores_gemma":[0.0005348536,0.001745241,0.011832351,0.005715441,0.000565748,0.004112242,0.00039402352,0.009366983,0.003727309,0.44830093,0.5135942,0.000110736546],"about_ca_topic_score_codex":0.00072217645,"about_ca_topic_score_gemma":0.0011412514,"teacher_disagreement_score":0.006402811,"about_ca_system_score_codex":0.0012106167,"about_ca_system_score_gemma":0.0013831345,"threshold_uncertainty_score":0.021419585},"labels":[],"label_agreement":null},{"id":"W4313246318","doi":"10.30968/rbfhss.2022.134.0897","title":"Pharmaceutical Pricing and Reimbursement Policies: lessons learnt and perspectives for Brazil","year":2022,"lang":"en","type":"article","venue":"Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Benchmarking; Sustainability; Business; Pharmaceutical policy; Pharmacy; Health policy; Health care; Public economics; Marketing; Economics; Medicine; Economic growth; Nursing","score_opus":0.06186880260856023,"score_gpt":0.3327012919209148,"score_spread":0.2708324893123546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313246318","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020697247,0.15523991,0.004152778,0.77183396,0.0029065132,0.00004914831,0.0002489287,0.000070347414,0.044801123],"genre_scores_gemma":[0.57356745,0.30852035,0.014703,0.0841633,0.004144749,0.00013894189,0.00028743726,0.00015577473,0.0143190045],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935696,0.003113523,0.0004508287,0.0003771398,0.0014452139,0.0010436364],"domain_scores_gemma":[0.98631185,0.008182802,0.001316701,0.00038681657,0.0024536704,0.0013480362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012411915,0.00061583717,0.0008364434,0.0024682095,0.002493118,0.009035172,0.0017013459,0.005326402,0.003632459],"category_scores_gemma":[0.021240473,0.00043963522,0.0011903209,0.004168633,0.004646296,0.0072733504,0.0033305064,0.0058383113,0.00040079118],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059777987,0.00016625042,0.0052380636,0.002904835,0.000062342064,0.0025498283,0.020456625,0.002382287,0.0011058281,0.7426775,0.067314215,0.1550823],"study_design_scores_gemma":[0.000025996149,0.000076703414,0.0082762,0.0060580266,0.00004956706,0.0014206945,0.0198948,0.0019267051,0.00046881533,0.12387108,0.83781874,0.0001126963],"about_ca_topic_score_codex":0.07167421,"about_ca_topic_score_gemma":0.078839734,"teacher_disagreement_score":0.07167421,"about_ca_system_score_codex":0.01657393,"about_ca_system_score_gemma":0.030217826,"threshold_uncertainty_score":0.14251405},"labels":[],"label_agreement":null},{"id":"W4313464329","doi":"10.22270/ijdra.v10i2.514","title":"A Comparison of the Drug Approval Process in the United States and Canada","year":2022,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug approval; Approved drug; Food and drug administration; Population; Clinical trial; Drug; Business; Family medicine; Pharmacology; Environmental health","score_opus":0.02606590921075354,"score_gpt":0.28600587898892915,"score_spread":0.25993996977817563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313464329","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19558671,0.32122198,0.0021790084,0.047690663,0.002012839,0.0015453163,0.02746015,0.0003054024,0.40199795],"genre_scores_gemma":[0.8350562,0.12774244,0.0035295044,0.010005246,0.00035581703,0.00048399006,0.008328283,0.00021542613,0.014283122],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9624396,0.005022245,0.0041889097,0.0016624372,0.02281153,0.0038753387],"domain_scores_gemma":[0.85545814,0.031131186,0.014980967,0.0014989427,0.08895834,0.007972444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013243526,0.00032766862,0.0009621741,0.012468386,0.003644847,0.0090492545,0.0013823102,0.0009899056,0.009298049],"category_scores_gemma":[0.07807315,0.0003763375,0.0018285408,0.027551549,0.0023069046,0.0023589996,0.0017999876,0.0016158004,0.0007099349],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044915467,0.0004514102,0.20988825,0.034001343,0.0021693185,0.0021718605,0.018168502,0.002232568,0.0015404703,0.083320916,0.182014,0.45954973],"study_design_scores_gemma":[0.00052815827,0.00036805045,0.5582224,0.019189585,0.0016908223,0.0012239937,0.020850424,0.00094174646,0.0010219378,0.0026139624,0.39299247,0.00035649395],"about_ca_topic_score_codex":0.95655775,"about_ca_topic_score_gemma":0.9722926,"teacher_disagreement_score":0.084635094,"about_ca_system_score_codex":0.084635094,"about_ca_system_score_gemma":0.18699302,"threshold_uncertainty_score":0.61407346},"labels":[],"label_agreement":null},{"id":"W4313885874","doi":"10.4212/cjhp.3422","title":"Correction apportée à l’article « Pénuries de médicaments au Canada au cours des 24 derniers mois : la situation ne fait que qu’empirer »","year":2023,"lang":"fr","type":"erratum","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gynecology; Humanities; Philosophy; Political science; Medicine","score_opus":0.03698480578361835,"score_gpt":0.27588317375853,"score_spread":0.23889836797491165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313885874","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023648402,0.0015626526,0.00029237522,0.14972559,0.8383189,0.000043523767,0.0013722358,0.00041599266,0.00803216],"genre_scores_gemma":[0.018608946,0.009416951,0.002662329,0.21095943,0.34380886,0.00028230273,0.0024406873,0.001006721,0.41081375],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940409,0.00051244255,0.0008358374,0.00055046886,0.0033155633,0.0007446381],"domain_scores_gemma":[0.9748576,0.005824405,0.0011371871,0.0009406933,0.016169833,0.0010702922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002991007,0.0018313942,0.0016738758,0.0030242847,0.0049054916,0.004995295,0.0029427845,0.009612098,0.042439934],"category_scores_gemma":[0.04590605,0.0009430297,0.0016531126,0.0030396972,0.0031349014,0.0018229202,0.0017722313,0.011881118,0.025062574],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009239687,0.0000027489898,0.00004356097,0.000032968237,0.000002728601,0.00009002847,0.000015756497,0.000019106299,0.000010844413,0.00043207713,0.9976847,0.0016562443],"study_design_scores_gemma":[0.000015682941,0.0000066536963,0.00062288233,0.00015471334,0.000009103454,0.00017389546,0.00006730726,0.00013121263,0.00010391044,0.000406228,0.9982875,0.000020930807],"about_ca_topic_score_codex":0.27806753,"about_ca_topic_score_gemma":0.22128192,"teacher_disagreement_score":0.7219325,"about_ca_system_score_codex":0.011974642,"about_ca_system_score_gemma":0.01602714,"threshold_uncertainty_score":0.552898},"labels":[],"label_agreement":null},{"id":"W4316661889","doi":"10.30953/bhty.v6.264","title":"Three Reasons Why Blockchain Adoption in Healthcare is a Success in Africa and LATAM","year":2023,"lang":"en","type":"article","venue":"Blockchain in Healthcare Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Blockchain; Session (web analytics); Business; Developing country; Health care; Healthcare system; Economics; Economic growth; Computer science; Computer security; Advertising","score_opus":0.08549450850414887,"score_gpt":0.3140297600175179,"score_spread":0.22853525151336906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316661889","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2988062,0.012709821,0.0053693117,0.5324267,0.0016038388,0.00016622545,0.00028791907,0.000068321,0.14856157],"genre_scores_gemma":[0.9610438,0.006977756,0.0011724981,0.014528503,0.0004268285,0.00010468615,0.0000941056,0.000052287425,0.015599495],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99574834,0.001401762,0.00014455782,0.00017156126,0.0006474722,0.001886304],"domain_scores_gemma":[0.98606306,0.00894368,0.0014523705,0.0002692027,0.0016426366,0.0016289935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070156245,0.00036354,0.00028626667,0.0012855742,0.004562108,0.008949015,0.00059875095,0.0037175296,0.010595498],"category_scores_gemma":[0.015216504,0.00024247964,0.00051094027,0.0019082295,0.003700104,0.006595024,0.0037133235,0.004822416,0.0008036171],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070466485,0.00028838307,0.046939414,0.0012520108,0.00009761746,0.0074049174,0.036327507,0.0011978428,0.003755089,0.65323746,0.09334787,0.15544717],"study_design_scores_gemma":[0.00017776179,0.0003407273,0.06076923,0.004238827,0.00013750064,0.0032585035,0.1408241,0.0038208829,0.006355973,0.18350758,0.5962799,0.0002889401],"about_ca_topic_score_codex":0.0052482756,"about_ca_topic_score_gemma":0.01050332,"teacher_disagreement_score":0.010595498,"about_ca_system_score_codex":0.0041990923,"about_ca_system_score_gemma":0.0067459894,"threshold_uncertainty_score":0.03710264},"labels":[],"label_agreement":null},{"id":"W4316814831","doi":"10.54194/hkbh7107","title":"Canada falls behind in new drug submissions compared with the United States and Europe","year":2023,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ceiling (cloud); Government (linguistics); Political science; Public administration; Economic history; History; Engineering","score_opus":0.07689724101818252,"score_gpt":0.31065178410661276,"score_spread":0.23375454308843024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316814831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.474924,0.018905355,0.0010566736,0.3217769,0.0021520348,0.00015674962,0.018521758,0.00019657359,0.16230994],"genre_scores_gemma":[0.95435566,0.0068027107,0.0004338275,0.018480474,0.00036511756,0.000021799513,0.0029092932,0.00009783206,0.016533395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.988242,0.0010376422,0.0005393991,0.00093330245,0.005572826,0.0036748901],"domain_scores_gemma":[0.96274465,0.004043216,0.005231596,0.00058356917,0.01668323,0.010713747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004925335,0.00023805663,0.0007300492,0.003358388,0.0052555,0.0075440346,0.0011059075,0.0017337217,0.008792622],"category_scores_gemma":[0.026283232,0.00031893802,0.0009481112,0.008159579,0.0014814679,0.002003829,0.0021275298,0.0027150395,0.00081422465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014492237,0.00018768242,0.6180245,0.0003242023,0.00048479927,0.00069032283,0.0024949985,0.0014478394,0.000541255,0.0233186,0.25975284,0.09128362],"study_design_scores_gemma":[0.00015188039,0.00008815424,0.84691054,0.00041729567,0.00022052653,0.00029147285,0.009394311,0.0018267874,0.0007807556,0.0018019222,0.13797253,0.00014392589],"about_ca_topic_score_codex":0.9898974,"about_ca_topic_score_gemma":0.99584144,"teacher_disagreement_score":0.05971995,"about_ca_system_score_codex":0.05971995,"about_ca_system_score_gemma":0.12793173,"threshold_uncertainty_score":0.4333006},"labels":[],"label_agreement":null},{"id":"W4317207459","doi":"10.1136/bmjgh-2022-010615","title":"Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator","year":2023,"lang":"en","type":"review","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Göteborgs Universitet; Binghamton University; University of Oxford; Bowling Green State University","keywords":"Business; Intellectual property; Transparency (behavior); Essential medicines; Preparedness; Health care; Economic growth; Economics; Political science; Law","score_opus":0.5196650525038878,"score_gpt":0.5622340756270625,"score_spread":0.042569023123174676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317207459","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014629891,0.006090572,0.052761693,0.38447914,0.0036870427,0.00027798777,0.00016066818,0.00030778896,0.5376053],"genre_scores_gemma":[0.74598163,0.004931053,0.03681905,0.11680316,0.0030617546,0.00056834443,0.00031279537,0.0003560681,0.09116607],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9828404,0.00718944,0.0008854834,0.0016983601,0.0045535243,0.0028326835],"domain_scores_gemma":[0.9867535,0.0065597435,0.0011677953,0.0018685802,0.0017532539,0.0018970288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029296977,0.00065881136,0.0006111559,0.0010413547,0.0056729387,0.015234822,0.002292074,0.013466204,0.021516768],"category_scores_gemma":[0.025909275,0.0004951266,0.0013142413,0.0006682854,0.016403286,0.02044354,0.018105693,0.0111481445,0.0025512096],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032838176,0.000034120778,0.0004546488,0.000113659706,0.000013028073,0.00016077301,0.0020462081,0.0005165857,0.00049716537,0.9605564,0.013205501,0.022369118],"study_design_scores_gemma":[0.00003065029,0.00010958008,0.00097102206,0.0006761888,0.000028506587,0.00026728027,0.0024055329,0.0011906491,0.0010930303,0.5443706,0.4487936,0.00006333601],"about_ca_topic_score_codex":0.0038023188,"about_ca_topic_score_gemma":0.0029670591,"teacher_disagreement_score":0.029296977,"about_ca_system_score_codex":0.004774495,"about_ca_system_score_gemma":0.016009634,"threshold_uncertainty_score":0.15493912},"labels":[],"label_agreement":null},{"id":"W4317209651","doi":"10.1007/s40258-022-00787-0","title":"The Impact of Suboxone’s Market Exclusivity on Cost of Opioid Use Disorder Treatment","year":2023,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Work & Health; Humber River Regional Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"Health Canada","keywords":"Buprenorphine; (+)-Naloxone; Medicine; Methadone; Opioid use disorder; Formulary; Public health; Listing (finance); Opioid; Emergency medicine; Anesthesia; Business; Family medicine; Finance; Internal medicine; Nursing","score_opus":0.14296312611907702,"score_gpt":0.40779766061785044,"score_spread":0.2648345344987734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317209651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920853,0.0010117819,0.0002968164,0.0010957922,0.000024115116,0.0000382438,0.0034247113,0.0000092032915,0.0020140128],"genre_scores_gemma":[0.9983047,0.00020242918,0.000117885174,0.00007888207,0.000012772887,0.000016140191,0.0007815829,0.000004967086,0.00048070555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964818,0.0014154589,0.00022284662,0.00037162518,0.00085483864,0.0006534341],"domain_scores_gemma":[0.97519356,0.0101465685,0.010445848,0.0007497328,0.0021425118,0.0013217458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026539566,0.00026020256,0.00036342477,0.00090692344,0.0003692598,0.0017457894,0.0011240729,0.0006358784,0.0037426015],"category_scores_gemma":[0.026152913,0.00023828645,0.0012364986,0.0016681881,0.0005381769,0.00089200644,0.0008653549,0.0014741676,0.00018699282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001926288,0.0003188721,0.97767454,0.000077225646,0.00082663435,0.00013208041,0.00014599515,0.0042775655,0.00016396808,0.0009309885,0.0010300996,0.012495825],"study_design_scores_gemma":[0.000028807515,0.0002364232,0.9944155,0.00002742234,0.00021515516,0.00007033931,0.00016199987,0.0038636993,0.00016692247,0.00016797418,0.0006344414,0.000011257466],"about_ca_topic_score_codex":0.2950157,"about_ca_topic_score_gemma":0.25610852,"teacher_disagreement_score":0.2950157,"about_ca_system_score_codex":0.010402536,"about_ca_system_score_gemma":0.0045505743,"threshold_uncertainty_score":0.586597},"labels":[],"label_agreement":null},{"id":"W4317757184","doi":"10.12927/hcpap.2023.27000","title":"Expensive Drugs for Rare Diseases in Canada: What Value and At What Cost?","year":2023,"lang":"en","type":"review","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ministry of Health; Canadian Centre for Applied Research in Cancer Control; Provincial Health Services Authority; Centre for Advancing Health Outcomes; Fraser Health; University of British Columbia","funders":"","keywords":"Value (mathematics); Medicine; Statistics; Mathematics","score_opus":0.17968401712704157,"score_gpt":0.369998009857088,"score_spread":0.1903139927300464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317757184","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014490777,0.9865215,0.00009115941,0.011479821,0.00027547588,0.000009598296,0.00012498157,0.0000027877309,0.001349787],"genre_scores_gemma":[0.0036926449,0.993573,0.00024411966,0.0018970184,0.000237024,0.000012287726,0.000056563607,0.0000027985839,0.00028449498],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943849,0.0015873561,0.00052590255,0.0002854558,0.0027760945,0.00044023182],"domain_scores_gemma":[0.9665531,0.020339083,0.003123401,0.0003025516,0.008512458,0.0011693485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008852194,0.00092609186,0.0033461128,0.0067396224,0.0014579528,0.005807615,0.001888573,0.003253354,0.0064081824],"category_scores_gemma":[0.041945834,0.00057042553,0.0017606039,0.0129991835,0.003413499,0.003114348,0.0011400344,0.0042079063,0.0005212131],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023814123,0.000052144384,0.0022562956,0.079199485,0.0010400758,0.00018931489,0.00034458478,0.0014390395,0.00013806144,0.058844987,0.11788228,0.73837554],"study_design_scores_gemma":[0.00019788576,0.00006745449,0.012976237,0.23354186,0.0027603484,0.0006317572,0.0010193011,0.0011840558,0.0002561063,0.030635085,0.716576,0.0001539247],"about_ca_topic_score_codex":0.76909727,"about_ca_topic_score_gemma":0.8433377,"teacher_disagreement_score":0.94887817,"about_ca_system_score_codex":0.051121816,"about_ca_system_score_gemma":0.12789313,"threshold_uncertainty_score":0.4645251},"labels":[],"label_agreement":null},{"id":"W4317757296","doi":"10.12927/hcpap.2023.26996","title":"Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?","year":2023,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University; University of British Columbia","funders":"","keywords":"Notice; Cancer drugs; Orphan drug; Medicine; Incentive; Cancer; Drug prices; Drug; Business; Pharmacology; Public economics; Bioinformatics; Internal medicine; Political science; Law; Economics","score_opus":0.11183386456248043,"score_gpt":0.32111253317854244,"score_spread":0.209278668616062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317757296","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005148058,0.0007864369,0.000051278064,0.99416995,0.00088692195,0.000004758939,0.000039294362,0.0000059625436,0.0035406994],"genre_scores_gemma":[0.008446539,0.0010920902,0.00017701658,0.9778136,0.0058467034,0.000021880895,0.000023563683,0.000015851865,0.0065627103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99464464,0.0018405514,0.0004457923,0.00065775635,0.0015534423,0.0008577909],"domain_scores_gemma":[0.9770701,0.016235784,0.0012383112,0.00059462094,0.0025286567,0.0023325023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008330376,0.0004565894,0.0014101618,0.0008420652,0.0044260053,0.0074661467,0.0016354284,0.057116438,0.011772816],"category_scores_gemma":[0.04570905,0.00057101436,0.001277714,0.0014087323,0.0071893996,0.00920408,0.002118622,0.028225465,0.0056245257],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079647514,0.000049586593,0.0025625252,0.000053637013,0.000018128692,0.0009355782,0.00032975659,0.00008669302,0.00016663587,0.03698287,0.93691057,0.021824434],"study_design_scores_gemma":[0.00024034575,0.00009514261,0.004735316,0.00047511503,0.00003951131,0.0013470929,0.0015029542,0.0011679099,0.00024784557,0.09708423,0.89293545,0.00012911818],"about_ca_topic_score_codex":0.030360524,"about_ca_topic_score_gemma":0.047043417,"teacher_disagreement_score":0.057116438,"about_ca_system_score_codex":0.008102095,"about_ca_system_score_gemma":0.011094173,"threshold_uncertainty_score":0.060367584},"labels":[],"label_agreement":null},{"id":"W4317801938","doi":"10.12927/hcpap.2023.26994","title":"Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?","year":2023,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Reimbursement; Context (archaeology); Business; Ethical issues; Political science; Engineering ethics; Law; Engineering; Health care","score_opus":0.13700332465864373,"score_gpt":0.3796049516641499,"score_spread":0.2426016270055062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317801938","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058786786,0.000645332,0.00010398774,0.9929454,0.00072411116,0.000010025244,0.000043573596,0.0000080086165,0.0049316436],"genre_scores_gemma":[0.01476684,0.0011612676,0.0005893789,0.9735512,0.00229816,0.000021067694,0.000031334777,0.00002135239,0.007559313],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877461,0.0018858898,0.00080207887,0.0010047699,0.004930624,0.0036305205],"domain_scores_gemma":[0.9568512,0.021232925,0.0018409176,0.0010349342,0.01219075,0.0068492973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014695236,0.00050168997,0.0010191095,0.0011363426,0.015924554,0.010357868,0.0041422173,0.04933495,0.008743206],"category_scores_gemma":[0.05486376,0.000683362,0.0014370189,0.0017518781,0.013503885,0.005971696,0.0031705194,0.039408464,0.0020265316],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003510647,0.000031125306,0.0036016614,0.0000954697,0.00002560535,0.001926722,0.0019197185,0.00030810825,0.00029403146,0.056943502,0.91500455,0.019814495],"study_design_scores_gemma":[0.00008634456,0.000031157913,0.0044960515,0.00045945263,0.000050953837,0.0011506911,0.0038617817,0.0015217883,0.00039734523,0.04233944,0.94539934,0.00020555969],"about_ca_topic_score_codex":0.8804176,"about_ca_topic_score_gemma":0.9368653,"teacher_disagreement_score":0.9373799,"about_ca_system_score_codex":0.0626201,"about_ca_system_score_gemma":0.17227925,"threshold_uncertainty_score":0.45434278},"labels":[],"label_agreement":null},{"id":"W4317936571","doi":"10.1016/j.jval.2023.01.008","title":"Generic Price Regulation and Drug Expenditures: Evidence From Canada","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Nottingham Ningbo China","keywords":"Copayment; Per capita; Incentive; Public economics; Government (linguistics); Prescription drug; Medical prescription; Cost sharing; Price elasticity of demand; Economics; Business; Health care; Health insurance; Economic growth; Microeconomics; Environmental health","score_opus":0.1379334060196279,"score_gpt":0.31495871854030644,"score_spread":0.17702531252067855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317936571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86171484,0.04261272,0.00043571007,0.02050114,0.0001349593,0.00011644296,0.031434238,0.000036177255,0.043013666],"genre_scores_gemma":[0.9718327,0.01617003,0.00026373597,0.0014903627,0.00008241294,0.000017871964,0.0063535706,0.000016656422,0.0037727328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727374,0.0003201701,0.00015451378,0.0002285945,0.0013611505,0.000661857],"domain_scores_gemma":[0.96973586,0.008681664,0.009138914,0.0007404737,0.009477164,0.002226006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00196076,0.00033256496,0.0007757457,0.0026836365,0.0018418755,0.0028493921,0.0012160612,0.0011541157,0.005782206],"category_scores_gemma":[0.017382002,0.0003960174,0.0010459671,0.0113435285,0.0019639165,0.00063824694,0.0008340195,0.001602674,0.00023069758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016872026,0.00024971802,0.92459863,0.00088156294,0.0009313344,0.0003340897,0.0008266257,0.002335691,0.00019763573,0.008075578,0.02497603,0.034905914],"study_design_scores_gemma":[0.00023167793,0.000073958305,0.9821348,0.00030888783,0.00067487196,0.000078033634,0.0008921989,0.000750416,0.00020583528,0.00068024796,0.013925567,0.000043549757],"about_ca_topic_score_codex":0.9955308,"about_ca_topic_score_gemma":0.9968509,"teacher_disagreement_score":0.041759185,"about_ca_system_score_codex":0.041759185,"about_ca_system_score_gemma":0.059560556,"threshold_uncertainty_score":0.3029855},"labels":[],"label_agreement":null},{"id":"W4318263088","doi":"10.1071/ah22280","title":"Potential therapeutic value of new drugs approved in Australia: a retrospective cohort study","year":2023,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Medicine; Food and drug administration; Pharmacology; Family medicine","score_opus":0.15016167952997864,"score_gpt":0.4036443178556346,"score_spread":0.253482638325656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318263088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502075,0.0012849608,0.00017059807,0.00015405272,0.000010029637,0.00008612162,0.001439217,0.000005807942,0.001828327],"genre_scores_gemma":[0.9979208,0.00061675924,0.00014120243,0.00011886084,0.000014135637,0.00006817543,0.00067201635,0.000005217766,0.00044282692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974195,0.00047264545,0.0005292091,0.00051881414,0.00079052016,0.00026922565],"domain_scores_gemma":[0.9896511,0.0011601222,0.0070252363,0.00045858155,0.0010442644,0.0006607108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002319581,0.00022147362,0.0008024556,0.0018080049,0.00062276865,0.001073267,0.00054535095,0.00048565574,0.0026155505],"category_scores_gemma":[0.0085282,0.00046622014,0.0010844433,0.0029697022,0.00044108092,0.0012442494,0.0010653589,0.0010360063,0.00052269595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014548138,0.00003865958,0.99667263,0.000105101564,0.00013840316,0.00015668484,0.00023399467,0.000049587266,0.00012167068,0.000077361015,0.00031801852,0.0019424711],"study_design_scores_gemma":[0.000011958997,0.00012872582,0.9974957,0.000043962547,0.000110362045,0.0006678847,0.00027490853,0.00019126917,0.000048532613,0.00004306473,0.0009738024,0.0000098525725],"about_ca_topic_score_codex":0.015323482,"about_ca_topic_score_gemma":0.012684617,"teacher_disagreement_score":0.015323482,"about_ca_system_score_codex":0.0013085883,"about_ca_system_score_gemma":0.0011546764,"threshold_uncertainty_score":0.030468583},"labels":[],"label_agreement":null},{"id":"W4318392168","doi":"10.1136/bmjopen-2022-068233","title":"Effects of the July 2018 worldwide valsartan recall and shortage on global trends in antihypertensive medication use: a time-series analysis in 83 countries","year":2023,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"National Heart, Lung, and Blood Institute","keywords":"Valsartan; Medicine; Economic shortage; Developing country; Angiotensin Receptor Blockers; Internal medicine; Economic growth; Blood pressure; Renin–angiotensin system; Economics","score_opus":0.07420581863229862,"score_gpt":0.36336065262001416,"score_spread":0.2891548339877155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318392168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965664,0.0003999734,0.00030688645,0.00012781138,0.000015201841,0.000009131406,0.0021070063,0.0000116444135,0.00045583333],"genre_scores_gemma":[0.99600214,0.00020366997,0.00016580074,0.0000381041,0.000017874896,0.000012389978,0.003421004,0.0000046202517,0.00013430923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877673,0.0004840394,0.00015737554,0.0002052619,0.0001933684,0.00018323648],"domain_scores_gemma":[0.9963643,0.0009136039,0.0020399378,0.00023885422,0.00026837768,0.00017485884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024774217,0.00037215522,0.00047243477,0.00078740704,0.00015494498,0.00083281717,0.0002899985,0.0003649754,0.0010220659],"category_scores_gemma":[0.004107147,0.00018569505,0.001411906,0.0017413957,0.00029192647,0.00051439466,0.0008778224,0.00062324724,0.00022839865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018794068,0.000033858578,0.9925849,0.000028670062,0.0003133344,0.00018622735,0.00010324319,0.0019762618,0.00008767511,0.000060823564,0.00052813446,0.003908926],"study_design_scores_gemma":[0.000008462417,0.00011884261,0.9944391,0.000027217526,0.0000962581,0.0001639454,0.00037264175,0.003862798,0.00012845724,0.00003197181,0.0007420749,0.000008299911],"about_ca_topic_score_codex":0.013720276,"about_ca_topic_score_gemma":0.007521034,"teacher_disagreement_score":0.013720276,"about_ca_system_score_codex":0.00042220994,"about_ca_system_score_gemma":0.00041701295,"threshold_uncertainty_score":0.027280807},"labels":[],"label_agreement":null},{"id":"W4318481751","doi":"10.2139/ssrn.4300678","title":"Valuing Pharmaceutical Drug Innovations","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.05936415886304829,"score_gpt":0.32074639959600765,"score_spread":0.26138224073295935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318481751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5236956,0.01607771,0.03716886,0.032867447,0.0007665178,0.00023050667,0.0007979621,0.00017309687,0.3882223],"genre_scores_gemma":[0.986312,0.002136237,0.0017159785,0.00040462177,0.00026483348,0.000020734478,0.00008864848,0.00001150281,0.009045581],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99761593,0.0009328912,0.000111117304,0.0002963326,0.00072757824,0.00031620762],"domain_scores_gemma":[0.9912389,0.005170245,0.0012507121,0.00048304393,0.00091957423,0.00093755557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004201687,0.0006254045,0.0008485257,0.0023453268,0.00062331674,0.007950648,0.00056001375,0.004412337,0.00976783],"category_scores_gemma":[0.019825844,0.00021600831,0.0005161178,0.0016722543,0.0018936557,0.0072590588,0.0016167292,0.002221957,0.00061767764],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042917972,0.00033675137,0.012536532,0.0003268211,0.0001669331,0.00041180666,0.0003239552,0.022435281,0.0029244397,0.8131126,0.0063699135,0.14062577],"study_design_scores_gemma":[0.000048265632,0.00046103974,0.008612864,0.00026789127,0.00010072622,0.00018372328,0.0008707477,0.03108729,0.0017163734,0.9288278,0.027772116,0.000051191517],"about_ca_topic_score_codex":0.0006749147,"about_ca_topic_score_gemma":0.00090070534,"teacher_disagreement_score":0.00976783,"about_ca_system_score_codex":0.0041423473,"about_ca_system_score_gemma":0.0018682993,"threshold_uncertainty_score":0.032676637},"labels":[],"label_agreement":null},{"id":"W4318482378","doi":"10.1007/s40278-023-32266-x","title":"Health Canada removes seven unauthorised health products from sale","year":2023,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Environmental health; Medicine","score_opus":0.0803977831446766,"score_gpt":0.3074767637964718,"score_spread":0.22707898065179521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318482378","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06999523,0.0061315843,0.0031027843,0.06455277,0.009863337,0.0012967677,0.0199716,0.0043117325,0.8207742],"genre_scores_gemma":[0.065785676,0.0010645669,0.0012588339,0.015252054,0.00043146117,0.00005214453,0.0032059925,0.0003568943,0.9125924],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99604225,0.0001607462,0.00009981921,0.00015224532,0.0028028984,0.0007420265],"domain_scores_gemma":[0.9945338,0.000995146,0.00021748147,0.00039454186,0.0026165438,0.0012425157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016533155,0.00066457584,0.00059964845,0.0018951658,0.0041373046,0.0036977509,0.0014535383,0.0046448056,0.07327364],"category_scores_gemma":[0.008168367,0.00073648954,0.0011015838,0.0012580461,0.0013379501,0.00052824774,0.0009754555,0.00491244,0.017908528],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032891036,0.00019972112,0.0054452857,0.00014985922,0.000046306868,0.000489922,0.00020802778,0.00022857952,0.002230507,0.0077816043,0.91437274,0.06851861],"study_design_scores_gemma":[0.00008922998,0.00009928195,0.031665053,0.00007750897,0.000044221946,0.00017768989,0.00023066184,0.00033729392,0.0022744988,0.0007568872,0.96420294,0.00004472906],"about_ca_topic_score_codex":0.8489106,"about_ca_topic_score_gemma":0.8968105,"teacher_disagreement_score":0.9862287,"about_ca_system_score_codex":0.013771266,"about_ca_system_score_gemma":0.049311005,"threshold_uncertainty_score":0.3039583},"labels":[],"label_agreement":null},{"id":"W4318586248","doi":"10.1186/s40545-022-00497-x","title":"Bridging the gap? Local production of medicines on the national essential medicine lists of Kenya, Tanzania and Uganda","year":2023,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"","keywords":"Tanzania; Essential medicines; Pharmacy; Business; Population; Medicine; Health care; Environmental health; Socioeconomics; Economic growth; Family medicine; Economics","score_opus":0.1414093113311773,"score_gpt":0.4141109217024941,"score_spread":0.2727016103713168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318586248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041253,0.0023087754,0.00036792562,0.0013602432,0.000018815877,0.000080300626,0.00115828,0.000010666076,0.004282445],"genre_scores_gemma":[0.997159,0.00071463373,0.0007074962,0.00030325394,0.000010440945,0.000086449785,0.0005404271,0.000009754973,0.00046862848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996709,0.0015584594,0.00041005595,0.0003496562,0.00040387193,0.0005690393],"domain_scores_gemma":[0.98949134,0.0031570636,0.0052199317,0.0005862952,0.0008711763,0.0006740826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041427403,0.00015626641,0.00031238285,0.0019995444,0.0009910667,0.0011860399,0.00075789215,0.00033304535,0.0066375216],"category_scores_gemma":[0.012522234,0.0003083619,0.00022060068,0.0038258624,0.0009851345,0.0018245529,0.0024243388,0.0004485704,0.0004663097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036773877,0.000083389816,0.9103512,0.0013337263,0.000065657856,0.0012791269,0.024653405,0.00016542329,0.0009019432,0.0023876962,0.004024506,0.054386083],"study_design_scores_gemma":[0.000022549599,0.0001337652,0.94115955,0.0011387545,0.000057444744,0.0012245807,0.038921196,0.0002974582,0.0004155894,0.00047240034,0.01613218,0.000024521984],"about_ca_topic_score_codex":0.014767684,"about_ca_topic_score_gemma":0.020369995,"teacher_disagreement_score":0.014767684,"about_ca_system_score_codex":0.0011905977,"about_ca_system_score_gemma":0.0015711093,"threshold_uncertainty_score":0.029363453},"labels":[],"label_agreement":null},{"id":"W4319304079","doi":"10.1021/cen-10105-buscon12","title":"Seqens opens a new research center","year":2023,"lang":"en","type":"article","venue":"C&EN Global Enterprise","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Center (category theory); Research center; Quarter (Canadian coin); Business; Technology transfer; Coronavirus disease 2019 (COVID-19); Chemistry; Political science; Medicine","score_opus":0.181746638650275,"score_gpt":0.40693887645403737,"score_spread":0.22519223780376238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319304079","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015017706,0.0072927405,0.009357869,0.12735206,0.016180394,0.00056575437,0.008426023,0.004063824,0.8117436],"genre_scores_gemma":[0.041445,0.0027303584,0.007009453,0.018530421,0.0031320734,0.00039049922,0.008064596,0.0005155772,0.918182],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994799,0.0008743612,0.00020676914,0.000955353,0.0022253087,0.0009391233],"domain_scores_gemma":[0.98461837,0.0020057794,0.00061367825,0.0014722857,0.0030471943,0.008242704],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005847546,0.0007203274,0.00066414627,0.0018375751,0.0032192543,0.005650762,0.00202931,0.0046005473,0.3093788],"category_scores_gemma":[0.006870588,0.00070323487,0.0009178914,0.0015080458,0.0012065144,0.004124885,0.004085896,0.0038286024,0.073735125],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035754175,0.00023563248,0.0015874491,0.0000963022,0.00001592926,0.00044170642,0.00007436961,0.00019819984,0.0008358339,0.05898354,0.88377786,0.053395625],"study_design_scores_gemma":[0.000071976174,0.00007609474,0.0010460638,0.00002993271,0.0000034049444,0.00011570917,0.00006212976,0.00015727637,0.00021438969,0.0020731194,0.9961343,0.000015681157],"about_ca_topic_score_codex":0.009165738,"about_ca_topic_score_gemma":0.016567994,"teacher_disagreement_score":0.3093788,"about_ca_system_score_codex":0.0050063115,"about_ca_system_score_gemma":0.02063239,"threshold_uncertainty_score":0.98508734},"labels":[],"label_agreement":null},{"id":"W4319655654","doi":"10.1371/journal.pone.0281076","title":"Identifying drugs with the greatest increases and decreases in spending per beneficiary using Medicare Part D: A cross-sectional study","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System","funders":"","keywords":"Cross-sectional study; Beneficiary; Medicine; Medicare Part D; Environmental health; Demography; Pharmacology; Business; Medical prescription; Finance; Prescription drug","score_opus":0.21101877892498927,"score_gpt":0.32973123845466196,"score_spread":0.11871245952967269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319655654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922883,0.0009698912,0.0002900954,0.00015940245,0.000018081424,0.00007376141,0.005374787,0.000008760817,0.0008168982],"genre_scores_gemma":[0.99362856,0.00052682025,0.0005127764,0.00028224432,0.000036650024,0.0001555384,0.0045827525,0.00000773394,0.00026698844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981184,0.00056447514,0.00034522364,0.00047425102,0.00031762177,0.0001801645],"domain_scores_gemma":[0.9923307,0.0015192317,0.004359017,0.00042497684,0.0008234362,0.0005425883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028658912,0.00031239772,0.00048156985,0.0019778053,0.0005985364,0.0009788903,0.0006347353,0.00082881964,0.0024886737],"category_scores_gemma":[0.007314225,0.00056158873,0.0011581723,0.0027319565,0.0003464542,0.0011374532,0.0009328363,0.0010649884,0.0007026755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045449586,0.000043943077,0.99904615,0.000022369459,0.00014935597,0.0000112681155,0.000036906087,0.000017596141,0.000028101504,0.000014243757,0.0001958587,0.00038866492],"study_design_scores_gemma":[0.000007563161,0.000091076705,0.9991381,0.00002319792,0.00009154014,0.00009594898,0.00012590684,0.0001196318,0.000027953998,0.000011215396,0.00026386438,0.0000040264144],"about_ca_topic_score_codex":0.007924374,"about_ca_topic_score_gemma":0.009075423,"teacher_disagreement_score":0.007924374,"about_ca_system_score_codex":0.00053760427,"about_ca_system_score_gemma":0.00059541076,"threshold_uncertainty_score":0.015756488},"labels":[],"label_agreement":null},{"id":"W4319741390","doi":"10.21203/rs.3.rs-2205634/v1","title":"Compliance of Public Health Facilities with Essential Medicines and Health Supplies Redistribution Guidelines in Mbale District, Eastern Uganda: A mixed-methods study","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Erasmus+; Trent University; Nottingham Trent University","keywords":"Redistribution (election); Compliance (psychology); Business; Public health; Environmental health; Medicine; Nursing; Political science; Psychology","score_opus":0.4832757902443569,"score_gpt":0.5372476069966008,"score_spread":0.053971816752243884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319741390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996482,0.00004301036,0.000036655383,0.000024712319,0.0000021595279,0.000036520767,0.00008759666,9.186899e-7,0.00012028332],"genre_scores_gemma":[0.99946076,0.000038412145,0.00011856058,0.000041224328,0.0000023365644,0.000116990384,0.00007030876,0.0000013550028,0.0001500431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.987973,0.007720264,0.0010391234,0.00085216836,0.0006576336,0.0017577508],"domain_scores_gemma":[0.9797086,0.010613723,0.006243039,0.0010137178,0.0013725009,0.0010483853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006098874,0.00063479156,0.0009982208,0.0017126364,0.0019005673,0.002196331,0.0017846548,0.0021721087,0.0025374696],"category_scores_gemma":[0.026106643,0.0016769727,0.00112209,0.0024214988,0.0019422818,0.0023809988,0.0023750134,0.0017649058,0.00043494822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011154383,0.0031852033,0.9707197,0.00023454445,0.00041817987,0.0002831899,0.01864464,0.00018507426,0.00022677198,0.0001673013,0.00029180787,0.004528095],"study_design_scores_gemma":[0.00012191284,0.0028841842,0.9571679,0.0001766606,0.00025609005,0.00019405573,0.037702367,0.00075015234,0.00018315288,0.00012873283,0.0003825149,0.000052378335],"about_ca_topic_score_codex":0.0288413,"about_ca_topic_score_gemma":0.031262223,"teacher_disagreement_score":0.0288413,"about_ca_system_score_codex":0.0022337204,"about_ca_system_score_gemma":0.0022381255,"threshold_uncertainty_score":0.05734682},"labels":[],"label_agreement":null},{"id":"W4320015086","doi":"10.2139/ssrn.4322653","title":"‘A Most Equitable Drug’: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Toronto","funders":"","keywords":"Pandemic; Convalescent plasma; Drug; Drug development; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; 2019-20 coronavirus outbreak; Virology; Intensive care medicine; Pharmacology; Infectious disease (medical specialty); Disease; Internal medicine","score_opus":0.4085873330674294,"score_gpt":0.3713114373033053,"score_spread":0.0372758957641241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320015086","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019720034,0.02613796,0.008557476,0.94704485,0.00648631,0.00008070137,0.00017579057,0.00007668553,0.009468289],"genre_scores_gemma":[0.21665585,0.047929462,0.0489942,0.6477086,0.032060105,0.00037155714,0.00028952525,0.00022119709,0.005769465],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9680396,0.026059499,0.0013799245,0.0013256342,0.0023802824,0.00081507413],"domain_scores_gemma":[0.9218271,0.052356556,0.0065027704,0.004852945,0.009467564,0.0049929894],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.06939225,0.0010824843,0.0025580928,0.002037243,0.001713443,0.0111777615,0.0026374564,0.014479371,0.01412942],"category_scores_gemma":[0.1327091,0.00069726584,0.0010538392,0.0017302567,0.014338222,0.024862431,0.004813242,0.012625568,0.0021453868],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014383617,0.0004137337,0.0020324464,0.0026519706,0.0006999337,0.00025236487,0.00053925626,0.0028593303,0.00088790164,0.5528859,0.21152133,0.22381759],"study_design_scores_gemma":[0.0008997467,0.0007791815,0.0019662173,0.0025202492,0.0002823987,0.0001461869,0.00084213854,0.0022373435,0.0008743028,0.79215,0.19716887,0.0001333878],"about_ca_topic_score_codex":0.0033914074,"about_ca_topic_score_gemma":0.004838232,"teacher_disagreement_score":0.93060774,"about_ca_system_score_codex":0.006009717,"about_ca_system_score_gemma":0.013454668,"threshold_uncertainty_score":0.36698568},"labels":[],"label_agreement":null},{"id":"W4320489785","doi":"10.1186/s12913-023-09095-2","title":"Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries","year":2023,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"London School of Economics and Political Science; Novartis","keywords":"Medicine; Reimbursement; Orphan drug; Authorization; Marketing authorization; Clinical trial; Food and drug administration; Drug approval; Family medicine; Medical emergency; Drug; Pharmacology; Internal medicine; Health care","score_opus":0.3014443096088063,"score_gpt":0.46646999681391416,"score_spread":0.16502568720510785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320489785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75949067,0.20713785,0.004097267,0.0044918084,0.00025920972,0.0007640809,0.008884842,0.000084259606,0.014790012],"genre_scores_gemma":[0.9655914,0.02828924,0.0022570146,0.0011880061,0.000053744065,0.00020502949,0.0021483474,0.000037153048,0.00023003857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.94932663,0.027805233,0.009072127,0.0055348272,0.0066455505,0.001615552],"domain_scores_gemma":[0.68086046,0.20260783,0.09376561,0.0076787975,0.011531012,0.0035563707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04091795,0.0004702951,0.0011625722,0.0049904482,0.0006076933,0.0034896482,0.0012784512,0.0012311126,0.005560543],"category_scores_gemma":[0.1590536,0.00072632864,0.0038147424,0.007718041,0.0018884472,0.0024627775,0.002461324,0.0013287454,0.0004927412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007126209,0.00029494416,0.76190025,0.014901221,0.008057952,0.0002703794,0.0019253124,0.0031260268,0.00016246352,0.00237864,0.0043658665,0.19549063],"study_design_scores_gemma":[0.0019017315,0.0023831355,0.9255811,0.026374774,0.013815548,0.00093232136,0.0032101423,0.0022279639,0.0009928088,0.0016022709,0.020846238,0.00013191867],"about_ca_topic_score_codex":0.022881817,"about_ca_topic_score_gemma":0.018195573,"teacher_disagreement_score":0.04091795,"about_ca_system_score_codex":0.0038600105,"about_ca_system_score_gemma":0.005933532,"threshold_uncertainty_score":0.2163974},"labels":[],"label_agreement":null},{"id":"W4321366269","doi":"10.1111/caje.12647","title":"Pharmaceutical regulation under market integration through parallel trade","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Economics/Revue canadienne d économique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Reimbursement; Business; Limit (mathematics); Authorization; International economics; International trade; Economics; Economic growth; Computer science","score_opus":0.30446322202520276,"score_gpt":0.2592729801322343,"score_spread":0.04519024189296844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321366269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6758252,0.0016489247,0.03298754,0.0072323335,0.00016938889,0.0002266594,0.00027221505,0.00019988012,0.2814378],"genre_scores_gemma":[0.9946726,0.00022500315,0.0009753505,0.00080676645,0.00009854551,0.000039511753,0.000029901788,0.000009951805,0.0031423145],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99466336,0.0016210355,0.0002899427,0.0011911702,0.00090512395,0.0013294619],"domain_scores_gemma":[0.9842694,0.006001027,0.0066882353,0.0013481358,0.0010140089,0.0006792251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048955255,0.0004938278,0.0013113037,0.00093487266,0.0018777784,0.0075048856,0.0009816249,0.003956093,0.017406784],"category_scores_gemma":[0.012697075,0.00059524307,0.002244765,0.0010097764,0.007344815,0.0057465294,0.005212962,0.004223193,0.00084858795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004781551,0.0006151161,0.017078856,0.00023993629,0.00029402992,0.001283652,0.00077492127,0.05219059,0.0042302064,0.89951414,0.0026620005,0.020638471],"study_design_scores_gemma":[0.0008103627,0.0007916129,0.03507362,0.00032008128,0.00046448823,0.00063860795,0.001399405,0.05944208,0.0041594803,0.87267196,0.024065996,0.00016240202],"about_ca_topic_score_codex":0.006408152,"about_ca_topic_score_gemma":0.0028009976,"teacher_disagreement_score":0.017406784,"about_ca_system_score_codex":0.0041698464,"about_ca_system_score_gemma":0.0029041986,"threshold_uncertainty_score":0.058231533},"labels":[],"label_agreement":null},{"id":"W4322579181","doi":"10.1016/b978-0-12-821047-5.00016-6","title":"Overview of Drug Development","year":2023,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Drug; Drug development; Medicine; Pharmacology","score_opus":0.11950277853261856,"score_gpt":0.29495843378124637,"score_spread":0.1754556552486278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322579181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041077466,0.5074527,0.0044243676,0.011905866,0.004256729,0.00015689558,0.000966301,0.00043475378,0.46999145],"genre_scores_gemma":[0.003753881,0.44117656,0.0044743144,0.0069929934,0.0027446111,0.00012715156,0.0007995169,0.0000879188,0.5398431],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996182,0.00006076262,0.000018810337,0.000055051158,0.00020075479,0.000046399473],"domain_scores_gemma":[0.9997844,0.00006612355,0.000020085052,0.000019234685,0.00006570835,0.00004447916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006175652,0.0012009684,0.0007996141,0.003345027,0.00049582863,0.002683418,0.000755447,0.0017308696,0.0794852],"category_scores_gemma":[0.0007308111,0.00046982148,0.0004712321,0.0031012283,0.000523347,0.002047401,0.0012801217,0.0020370628,0.04672933],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002692426,0.000057735528,0.00007508655,0.00088145,0.000009094207,0.00005960962,0.000027187183,0.0003002142,0.0006059285,0.025119781,0.40854234,0.56429464],"study_design_scores_gemma":[0.0000031481998,0.000013924091,0.00011446836,0.00015675888,0.0000024348687,0.00006706946,0.0000054187667,0.000044676148,0.000057097317,0.002822782,0.99671006,0.000002060175],"about_ca_topic_score_codex":0.0029744613,"about_ca_topic_score_gemma":0.008352057,"teacher_disagreement_score":0.0794852,"about_ca_system_score_codex":0.0017952261,"about_ca_system_score_gemma":0.0026487594,"threshold_uncertainty_score":0.2659045},"labels":[],"label_agreement":null},{"id":"W4322705791","doi":"10.2139/ssrn.4368340","title":"Strategic Tier Design in Health Insurance: The Case of Medicare Part D","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Formulary; Cost sharing; Actuarial science; Business; Tier 2 network; Medicare Part D; Population; Medicine; Operations management; Finance; Economics; Environmental health; Family medicine; Prescription drug; Engineering; Medical prescription; Nursing","score_opus":0.09244601672265143,"score_gpt":0.3205471601852412,"score_spread":0.22810114346258978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322705791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6563995,0.0015531698,0.08525458,0.023430312,0.00025830776,0.00055600813,0.0007691653,0.0002640765,0.23151492],"genre_scores_gemma":[0.98849165,0.00014810145,0.003690804,0.00051414233,0.000043110915,0.000034042318,0.000025471827,0.000013310838,0.007039419],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9933937,0.002670074,0.00014951578,0.00053266954,0.0005228003,0.0027311288],"domain_scores_gemma":[0.9932903,0.0033575792,0.00057862094,0.00065798487,0.0005188533,0.0015966106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071865,0.00048120803,0.0014584915,0.0010022279,0.003665627,0.008932499,0.0017708906,0.007851973,0.016679814],"category_scores_gemma":[0.011439259,0.00078858563,0.0018127726,0.0012932633,0.0046162917,0.004421981,0.003491143,0.00339839,0.0008393195],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040273144,0.00025445462,0.009568234,0.00008443521,0.00009453987,0.00093917525,0.00065559807,0.037981104,0.0012755315,0.9301296,0.0073218835,0.011292739],"study_design_scores_gemma":[0.0004951529,0.00025294322,0.008498235,0.000069062786,0.0001208348,0.0004540735,0.0026662769,0.11886925,0.0006190911,0.8565824,0.011237072,0.00013571884],"about_ca_topic_score_codex":0.05066559,"about_ca_topic_score_gemma":0.068940826,"teacher_disagreement_score":0.05066559,"about_ca_system_score_codex":0.009326303,"about_ca_system_score_gemma":0.0070595024,"threshold_uncertainty_score":0.10074139},"labels":[],"label_agreement":null},{"id":"W4323066860","doi":"10.1136/bmj.p524","title":"Canada’s promise to reform drug prices left in doubt as regulator is hit by wave of resignations","year":2023,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regulator; Drug; Drug prices; Computer science; Medicine; Political science; Business; Data science; Law and economics; Economics; Public economics; Pharmacology; Chemistry","score_opus":0.05341636750969777,"score_gpt":0.2984884466091468,"score_spread":0.24507207909944903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323066860","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015907969,0.0015739753,0.00054344453,0.9611597,0.007932479,0.000037138645,0.0005407754,0.0002128358,0.026408803],"genre_scores_gemma":[0.052312147,0.0015181439,0.0024471534,0.8653471,0.004861444,0.000046856985,0.00044520033,0.0002114141,0.07281065],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9660819,0.0034458796,0.0007213182,0.0013750354,0.020546561,0.007829398],"domain_scores_gemma":[0.92902684,0.0113716815,0.002460026,0.0019980005,0.02632863,0.028814852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01725495,0.000782841,0.0013349869,0.0023869162,0.008027547,0.016742537,0.0031161325,0.04686537,0.025253912],"category_scores_gemma":[0.08122177,0.00075787556,0.0028234571,0.0024375997,0.0080931485,0.0050834245,0.0033980992,0.025555925,0.005559895],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011811086,0.000046111898,0.0011598053,0.000086007916,0.00007072072,0.00018063509,0.00019550916,0.0004897572,0.00031124035,0.047661733,0.940143,0.0095374165],"study_design_scores_gemma":[0.0002150015,0.00007656529,0.0054938123,0.00020969319,0.000065754735,0.00010113319,0.00031900805,0.0009735465,0.0003765081,0.019042647,0.9729838,0.0001425157],"about_ca_topic_score_codex":0.8725051,"about_ca_topic_score_gemma":0.9076825,"teacher_disagreement_score":0.9365696,"about_ca_system_score_codex":0.06343042,"about_ca_system_score_gemma":0.30297378,"threshold_uncertainty_score":0.46022207},"labels":[],"label_agreement":null},{"id":"W4323321720","doi":"10.1377/hlthaff.2022.00873","title":"Patent Challenges And Litigation On Inhalers For Asthma And COPD","year":2023,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Generic drug; Certification; Formulary; Paragraph; Brand names; Medicine; Food and drug administration; Business; Competition (biology); Tying; Asthma; Marketing; Drug; Pharmacology; Law","score_opus":0.2140562939056647,"score_gpt":0.3259402132449904,"score_spread":0.1118839193393257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323321720","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25672525,0.052871127,0.0063599213,0.35209453,0.0016974214,0.00023760373,0.0013651026,0.00016366912,0.3284854],"genre_scores_gemma":[0.9072309,0.012162693,0.0012837986,0.052819822,0.0032509067,0.00012119405,0.00046229095,0.00002788516,0.02264048],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.977796,0.0058649546,0.0015400467,0.0018785472,0.009329086,0.0035913961],"domain_scores_gemma":[0.90144247,0.07508152,0.014829949,0.001911778,0.0042541344,0.0024801865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019339424,0.00032017616,0.0005608281,0.002961488,0.006016203,0.0072167777,0.0013451165,0.01536177,0.0062487694],"category_scores_gemma":[0.07191598,0.00051571894,0.0013540146,0.0026064436,0.0051516476,0.0057991245,0.0033099472,0.008433249,0.0012766479],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002110395,0.00015992996,0.023741087,0.00022434721,0.000057154357,0.0032676826,0.002264398,0.0021619927,0.0010276141,0.79904276,0.106329516,0.061512545],"study_design_scores_gemma":[0.0003278009,0.00091955124,0.1386831,0.002012282,0.00023244854,0.004835472,0.0041630026,0.008779254,0.003987555,0.23129493,0.6043981,0.00036662802],"about_ca_topic_score_codex":0.013857411,"about_ca_topic_score_gemma":0.00957146,"teacher_disagreement_score":0.019339424,"about_ca_system_score_codex":0.008220549,"about_ca_system_score_gemma":0.008569752,"threshold_uncertainty_score":0.102277875},"labels":[],"label_agreement":null},{"id":"W4323566916","doi":"10.3389/fpubh.2023.1103555","title":"Characteristics, risk management and GMP standards of pharmaceutical companies in China","year":2023,"lang":"en","type":"article","venue":"Frontiers in Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Business; Good manufacturing practice; Quality (philosophy); China; Production (economics); Product (mathematics); Risk analysis (engineering); Industrial organization; Marketing; Accounting; Finance; Economics","score_opus":0.062028872479209275,"score_gpt":0.32777889908420454,"score_spread":0.26575002660499525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323566916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99935776,0.000067453424,0.000043815446,0.00011443745,9.294263e-7,0.00000458611,0.000055540466,0.0000014147023,0.00035404428],"genre_scores_gemma":[0.99961746,0.000049329294,0.000031665066,0.000013350135,0.0000024398553,0.0000026961186,0.000083743835,5.379345e-7,0.00019888049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990901,0.00015391668,0.00013260567,0.00013455331,0.00027931377,0.00020966292],"domain_scores_gemma":[0.99300134,0.0010707943,0.0040614214,0.00022294444,0.0006082921,0.0010351341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015893369,0.00015320364,0.00022864528,0.0017164815,0.00064317783,0.0008946054,0.00030924685,0.00037037302,0.0011063763],"category_scores_gemma":[0.0030345703,0.00017987992,0.0003951348,0.0020536976,0.0006232371,0.0004928574,0.00060650444,0.00040702758,0.00012549704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002898209,0.00003898412,0.9960406,0.000007276197,0.000024698487,0.00013788368,0.00043375482,0.0005367445,0.00013212944,0.00024797604,0.00011249134,0.0022585667],"study_design_scores_gemma":[0.000003601863,0.000033292465,0.99803287,0.00000466081,0.000006200369,0.00004672192,0.00039462134,0.0011211252,0.000057147146,0.00011249792,0.00018110788,0.000006158827],"about_ca_topic_score_codex":0.042103928,"about_ca_topic_score_gemma":0.033146158,"teacher_disagreement_score":0.042103928,"about_ca_system_score_codex":0.0017834405,"about_ca_system_score_gemma":0.0021560316,"threshold_uncertainty_score":0.083717704},"labels":[],"label_agreement":null},{"id":"W4323657124","doi":"10.12927/hcpol.2023.27038","title":"Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?","year":2023,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University; Mount Sinai Hospital","funders":"","keywords":"Multinational corporation; Business; Legislation; Competition (biology); Pharmaceutical industry; Government (linguistics); Finance; Marketing; Industrial organization; Commerce; Biotechnology; Law","score_opus":0.4702360390005788,"score_gpt":0.47700875196003295,"score_spread":0.006772712959454141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323657124","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034020506,0.036908235,0.0029044668,0.83706796,0.001382073,0.00007103804,0.0006683294,0.00010313465,0.08687414],"genre_scores_gemma":[0.7072654,0.032198004,0.0047335587,0.20203844,0.0015528824,0.00005638277,0.0004945578,0.000091816546,0.05156894],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98787564,0.0013717974,0.0003299236,0.00055679394,0.0055565983,0.0043092803],"domain_scores_gemma":[0.9745866,0.007206698,0.0051192846,0.0006336522,0.0070971004,0.005356748],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007978248,0.00052860484,0.0010030766,0.0020825565,0.009929272,0.014630998,0.0013964324,0.0065447814,0.009585249],"category_scores_gemma":[0.032079853,0.00037506854,0.0008412837,0.005479423,0.006165672,0.0074585783,0.0031312914,0.007851334,0.0009363962],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021434271,0.00009550884,0.016820848,0.00031381618,0.00012671498,0.00036864966,0.0019369468,0.0011952237,0.00040411053,0.7751572,0.124029666,0.07933692],"study_design_scores_gemma":[0.00016548685,0.00014039919,0.038690098,0.0012294656,0.00015779033,0.00022967492,0.007640182,0.0026541986,0.0012196902,0.14908367,0.7985834,0.00020593836],"about_ca_topic_score_codex":0.8974136,"about_ca_topic_score_gemma":0.9296449,"teacher_disagreement_score":0.99202174,"about_ca_system_score_codex":0.06348801,"about_ca_system_score_gemma":0.101517275,"threshold_uncertainty_score":0.4606399},"labels":[],"label_agreement":null},{"id":"W4323657395","doi":"10.12927/hcpol.2023.27037","title":"Commentary: Reconsidering Pharmaceutical Research and Development Investments","year":2023,"lang":"en","type":"letter","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Carleton University","funders":"","keywords":"Investment (military); Narrative; Pharmaceutical industry; Economics; Narrative review; Accounting; Public economics; Political science; Business; Psychology; Law; Medicine; Philosophy; Politics","score_opus":0.561412250067235,"score_gpt":0.4614487213034497,"score_spread":0.09996352876378534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323657395","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001236876,0.00083335646,0.000027883414,0.9910404,0.0061641396,0.000004298675,0.00003235159,0.000010530152,0.001763347],"genre_scores_gemma":[0.0012311919,0.00023286861,0.000055579807,0.99142236,0.0044759857,0.000009429226,0.000008149435,0.000011585632,0.0025528313],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97601306,0.0048409402,0.0015886817,0.0025603601,0.01100049,0.003996441],"domain_scores_gemma":[0.9411431,0.035835072,0.0018142656,0.0011358599,0.013932689,0.006138957],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01643159,0.0011889373,0.00202558,0.0017164154,0.015958365,0.010230257,0.008687739,0.1370637,0.007553687],"category_scores_gemma":[0.070204675,0.0014390086,0.0023992257,0.002606556,0.016541598,0.00865413,0.004060506,0.08421734,0.005079374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025126265,0.000007747664,0.00011961639,0.000051009414,0.000008208645,0.00027536904,0.000494707,0.000048475627,0.00007622796,0.00894603,0.9871748,0.0027727308],"study_design_scores_gemma":[0.000061207895,0.000021113947,0.000643978,0.00039161812,0.000024507654,0.00026916122,0.0010428913,0.00022835204,0.00015323581,0.010822559,0.98626375,0.00007775343],"about_ca_topic_score_codex":0.41251627,"about_ca_topic_score_gemma":0.46657854,"teacher_disagreement_score":0.98356843,"about_ca_system_score_codex":0.047433455,"about_ca_system_score_gemma":0.0892805,"threshold_uncertainty_score":0.8202303},"labels":[],"label_agreement":null},{"id":"W4324020367","doi":"10.1007/s10729-022-09627-y","title":"Predicting drug shortages using pharmacy data and machine learning","year":2023,"lang":"en","type":"article","venue":"Health Care Management Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Economic shortage; Pharmacy; Health informatics; Medicine; Drug; Business; Public health; Family medicine; Pharmacology; Nursing","score_opus":0.1761174851863908,"score_gpt":0.3976542399635269,"score_spread":0.22153675477713608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324020367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98085886,0.00038058579,0.008772444,0.0010700413,0.000028759026,0.000133907,0.0054730345,0.00024246151,0.003039922],"genre_scores_gemma":[0.9910238,0.00018870678,0.0038879726,0.000078067394,0.000026474529,0.000024541392,0.0041999193,0.000006650103,0.00056392263],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9993562,0.00015562252,0.000050079023,0.00009086398,0.0001598737,0.0001873487],"domain_scores_gemma":[0.99484175,0.0026995288,0.0009190848,0.00021277151,0.00091846363,0.00040830183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017536886,0.00068195414,0.00054572354,0.0033435267,0.00055347505,0.0009942544,0.0007191377,0.0008067994,0.0019178113],"category_scores_gemma":[0.008775649,0.0004101553,0.0005507053,0.003103138,0.00035674594,0.0008964797,0.0006267826,0.00078095216,0.00040786696],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029876642,0.0005089639,0.35827854,0.000083667706,0.00010635051,0.00026859876,0.00006453893,0.60166323,0.0003383179,0.0013697551,0.003859438,0.033159774],"study_design_scores_gemma":[0.000035938596,0.00007786917,0.075840004,0.000020025249,0.00001534041,0.000031243173,0.00010466905,0.9207339,0.0003128577,0.0016038009,0.0012056477,0.000018705236],"about_ca_topic_score_codex":0.41902772,"about_ca_topic_score_gemma":0.3530214,"teacher_disagreement_score":0.41902772,"about_ca_system_score_codex":0.0047570644,"about_ca_system_score_gemma":0.0049944846,"threshold_uncertainty_score":0.8331774},"labels":[],"label_agreement":null},{"id":"W4327861569","doi":"10.46542/pe.2023.231.165179","title":"Towards a national pharmaceutical strategy in Lebanon: Ensuring access to quality and safe medications for all","year":2023,"lang":"en","type":"article","venue":"Pharmacy Education","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Business; Quality (philosophy); Accountability; Situation analysis; Pharmaceutical policy; Strategic planning; Population; Situational ethics; Pharmaceutical industry; Health care; Public relations; Health policy; Marketing; Medicine; Economic growth; Political science; Environmental health; Economics","score_opus":0.4150611379884795,"score_gpt":0.5223179111113145,"score_spread":0.10725677312283505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327861569","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2690691,0.041116115,0.017337084,0.43316725,0.0014657287,0.0009320991,0.0010620824,0.00021517403,0.23563536],"genre_scores_gemma":[0.8596951,0.020234387,0.04491907,0.03502249,0.00048340156,0.0005134474,0.0009799413,0.000030437888,0.03812163],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9972812,0.0012058881,0.00016924471,0.00015309977,0.0004830759,0.0007074435],"domain_scores_gemma":[0.997566,0.00048836303,0.0005015108,0.00005739595,0.00067805295,0.00070872245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006158027,0.0005018698,0.00024807584,0.0010729516,0.0025865692,0.0070878565,0.00071022316,0.002590235,0.0054936525],"category_scores_gemma":[0.0027501269,0.00016772645,0.00032881115,0.0009219408,0.0014578472,0.0026748257,0.0038414726,0.0017269546,0.00067515176],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034535938,0.0007941073,0.034326676,0.0028150433,0.000107479034,0.0032832003,0.0060291803,0.00591086,0.007776232,0.60009897,0.07371993,0.26479298],"study_design_scores_gemma":[0.0001547908,0.0006606609,0.044598475,0.0035080481,0.000077940815,0.0012241569,0.024048682,0.0061767558,0.0054866173,0.08708732,0.8268433,0.00013323533],"about_ca_topic_score_codex":0.014186763,"about_ca_topic_score_gemma":0.013193656,"teacher_disagreement_score":0.014186763,"about_ca_system_score_codex":0.012666614,"about_ca_system_score_gemma":0.05881363,"threshold_uncertainty_score":0.09190315},"labels":[],"label_agreement":null},{"id":"W4328055071","doi":"10.1136/bmjebm-2022-112005","title":"US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics","year":2023,"lang":"en","type":"article","venue":"BMJ evidence-based medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Food and drug administration; Drug; Pharmacology; Patient safety; Health care","score_opus":0.18732288818352935,"score_gpt":0.37053351688652847,"score_spread":0.18321062870299912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328055071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.808353,0.13352297,0.011651366,0.014230839,0.0013369883,0.0013768857,0.0072363988,0.00019097897,0.022100562],"genre_scores_gemma":[0.9894985,0.0043990896,0.0022211531,0.0011555176,0.0005033646,0.0003144631,0.0012719934,0.000038407157,0.00059755536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.7277871,0.15911782,0.049391866,0.015271131,0.045849785,0.0025823114],"domain_scores_gemma":[0.14906706,0.44996038,0.34250492,0.012685331,0.042975925,0.002806307],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.16083992,0.0005123436,0.0014244438,0.008500561,0.0011838276,0.0022530626,0.0021145782,0.002139912,0.003284586],"category_scores_gemma":[0.5066848,0.0006997475,0.0022337937,0.006557297,0.0014369383,0.003440688,0.0032359632,0.002504866,0.0005648838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001335207,0.000087038454,0.9702059,0.0017840927,0.0013716036,0.00023230916,0.0014694205,0.00028846838,0.00012600471,0.00041751296,0.004629537,0.018052865],"study_design_scores_gemma":[0.00027563068,0.00046696397,0.975966,0.0032260055,0.0014489513,0.002077961,0.0016571912,0.0021462487,0.0007380313,0.0010987839,0.010766064,0.00013214843],"about_ca_topic_score_codex":0.004240031,"about_ca_topic_score_gemma":0.0031772433,"teacher_disagreement_score":0.8391601,"about_ca_system_score_codex":0.0024928,"about_ca_system_score_gemma":0.0028413935,"threshold_uncertainty_score":0.85061294},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4361017494","doi":"10.1371/journal.pone.0281665","title":"Health professionals’ perceptions on local production and bioequivalence study of generic medicines: A cross-sectional survey of physicians and pharmacy professionals in Addis Ababa, Ethiopia","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Addis Ababa University","keywords":"Cross-sectional study; Medicine; Pharmacy; Family medicine; Descriptive statistics; Logistic regression; Public health; Multinomial logistic regression; Environmental health; Nursing","score_opus":0.2699100975351207,"score_gpt":0.4109659955495149,"score_spread":0.14105589801439422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361017494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996866,0.000045922003,0.000010412144,0.00005896249,0.0000015571835,0.000008123685,0.000015000909,2.622565e-7,0.00017330634],"genre_scores_gemma":[0.99959797,0.000119038916,0.00004284706,0.00007673235,0.000003398371,0.000010062043,0.000017422233,2.1675145e-7,0.0001322504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991954,0.00029028158,0.00008979718,0.000072288785,0.00017065961,0.00018154377],"domain_scores_gemma":[0.99713814,0.00094399246,0.00088251464,0.000053562988,0.00032313308,0.00065880304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018515298,0.00022840647,0.00025796608,0.00076154893,0.0008248676,0.0008331842,0.00026404898,0.0004935596,0.002343973],"category_scores_gemma":[0.0033073446,0.00034668465,0.00021775818,0.00066421495,0.0005447439,0.00043696977,0.00058000133,0.0004295339,0.0002577576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009068426,0.00051669887,0.97808766,0.00010729923,0.000026089532,0.00047723876,0.015733013,0.00004215786,0.0011430488,0.000036951886,0.00016850252,0.0035705916],"study_design_scores_gemma":[0.00001568857,0.0006434268,0.9499068,0.000076875986,0.000020320069,0.00046113454,0.047899105,0.0001515655,0.00018825146,0.000019714616,0.0006072128,0.000010040455],"about_ca_topic_score_codex":0.0075450237,"about_ca_topic_score_gemma":0.00957104,"teacher_disagreement_score":0.0075450237,"about_ca_system_score_codex":0.0006428769,"about_ca_system_score_gemma":0.00096056063,"threshold_uncertainty_score":0.015002191},"labels":[],"label_agreement":null},{"id":"W4362576010","doi":"10.1016/s1470-2045(23)00072-4","title":"Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Western University; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Tanzania; Medicine; Essential medicines; Referral; Health care; Family medicine; Public health; Environmental health; Socioeconomics; Economic growth; Nursing","score_opus":0.2611706477913128,"score_gpt":0.49857130540933786,"score_spread":0.23740065761802503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362576010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515957,0.0025414757,0.0008067916,0.00024775832,0.000015693686,0.00007366713,0.00091109617,0.000004472009,0.00023949707],"genre_scores_gemma":[0.99768627,0.000819571,0.0008145886,0.000074375006,0.000014116257,0.00011410842,0.00034019112,0.00000531648,0.00013158057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98297775,0.013938662,0.0005481103,0.0005621233,0.00036434745,0.0016089651],"domain_scores_gemma":[0.95778733,0.03524672,0.0045324806,0.0011089582,0.000710922,0.00061367045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013668009,0.0010754429,0.0017817037,0.0018751052,0.00085084746,0.0016519255,0.0017371617,0.001388196,0.0036727986],"category_scores_gemma":[0.030390752,0.00095109874,0.0041393605,0.003852978,0.0010733006,0.0022004563,0.0020346437,0.0017185427,0.00020463584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006331779,0.001721696,0.9333126,0.002601799,0.022546554,0.0009645644,0.0039004888,0.0047970354,0.00038385764,0.0024657596,0.0011693913,0.0198045],"study_design_scores_gemma":[0.0009982531,0.0036775097,0.9413909,0.0012665936,0.016063452,0.00071923767,0.016954903,0.014679969,0.0007937468,0.0013339543,0.0019731268,0.00014828668],"about_ca_topic_score_codex":0.08134358,"about_ca_topic_score_gemma":0.057052705,"teacher_disagreement_score":0.08134358,"about_ca_system_score_codex":0.0023220044,"about_ca_system_score_gemma":0.0019405022,"threshold_uncertainty_score":0.16174024},"labels":[],"label_agreement":null},{"id":"W4364378002","doi":"10.51731/cjht.2023.616","title":"Belimumab (Benlysta)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Belimumab; Reimbursement; Vial; Lupus nephritis; Medicine; Family medicine; Drug; Pharmacology; Internal medicine; Political science; Chemistry; Immunology","score_opus":0.11443310875397324,"score_gpt":0.3097521052128289,"score_spread":0.1953189964588557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364378002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016900536,0.7512031,0.0074828076,0.040937096,0.0023777229,0.00019267693,0.0055627185,0.00059221266,0.17475103],"genre_scores_gemma":[0.3665159,0.42985085,0.012155452,0.021549206,0.0021142778,0.00032147532,0.006913515,0.00011090624,0.1604684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999554,0.00015088363,0.000027690825,0.000053974258,0.00015694894,0.000056561406],"domain_scores_gemma":[0.99951005,0.0001638281,0.00011753743,0.000016556956,0.00011437404,0.00007772218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087623345,0.00025623915,0.00032901907,0.0006748674,0.0002657226,0.00080133183,0.00032846397,0.0005977081,0.0256242],"category_scores_gemma":[0.0014017192,0.000077850615,0.00041506963,0.00053586584,0.00032648433,0.0005408123,0.00047715197,0.0009676191,0.005371442],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009295413,0.00008376374,0.0012089871,0.0024077748,0.00014176368,0.00018245571,0.000033118762,0.00056942017,0.0020787653,0.013839187,0.15438347,0.82414174],"study_design_scores_gemma":[0.00037156395,0.0005454011,0.0062273014,0.0018501012,0.0001432411,0.0012541312,0.00004976361,0.0006722362,0.0029147456,0.0043538525,0.9815916,0.000026110833],"about_ca_topic_score_codex":0.009164447,"about_ca_topic_score_gemma":0.024591088,"teacher_disagreement_score":0.0256242,"about_ca_system_score_codex":0.0015554752,"about_ca_system_score_gemma":0.0015519328,"threshold_uncertainty_score":0.08572143},"labels":[],"label_agreement":null},{"id":"W4365799752","doi":"10.1093/jlb/lsad008","title":"Lessons from Canada’s notice of compliance with conditions policy for the life-cycle regulation of drugs","year":2023,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University","funders":"Health Canada; Simon Fraser University; Genome British Columbia; Public Health Agency; Public Health Agency of Canada; Genome Canada","keywords":"Notice; Compliance (psychology); Medicine; Business; Political science; Psychology; Law; Social psychology","score_opus":0.08908924928794298,"score_gpt":0.32358909040785355,"score_spread":0.23449984111991057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365799752","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058281608,0.004790824,0.004089989,0.8726309,0.0009978643,0.00023582162,0.0020801153,0.00013307184,0.05675987],"genre_scores_gemma":[0.6929121,0.003442628,0.009608128,0.28000122,0.0009926064,0.00017959747,0.000894077,0.000101970414,0.011867629],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.93020964,0.014710847,0.0026042743,0.003967077,0.034842014,0.013666233],"domain_scores_gemma":[0.78555727,0.10082085,0.011670665,0.006868935,0.077707835,0.017374339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.059305854,0.00053268985,0.0010199861,0.0024331743,0.008489525,0.015291758,0.003365309,0.009208252,0.0039174985],"category_scores_gemma":[0.15484622,0.0005596672,0.0015680715,0.0041527934,0.009483375,0.0050752815,0.002739231,0.013089387,0.00028450735],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00042332188,0.00027490067,0.06418732,0.00037682784,0.00018865243,0.0008249734,0.0060895025,0.011007656,0.0007395035,0.5286796,0.3271159,0.060091794],"study_design_scores_gemma":[0.00058168406,0.0004561293,0.18607812,0.0021337888,0.00037021318,0.00038929438,0.0086856475,0.016867377,0.0018546052,0.12515002,0.65677524,0.0006578098],"about_ca_topic_score_codex":0.9830562,"about_ca_topic_score_gemma":0.9786371,"teacher_disagreement_score":0.82185686,"about_ca_system_score_codex":0.17814316,"about_ca_system_score_gemma":0.39953652,"threshold_uncertainty_score":0.9532374},"labels":[],"label_agreement":null},{"id":"W4366003793","doi":"10.54194/ubaw5789","title":"Economic cost of cardiomyopathy in Canada 2018 to 2021: opportunity for cost avoidance through pharmaceutical innovation.","year":2023,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Cardiomyopathy; Productivity; Economic cost; Indirect costs; Business; Pharmaceutical industry; Medicine; Economics; Economic growth; Pharmacology; Heart failure; Accounting; Cardiology; Microeconomics","score_opus":0.1912754188480488,"score_gpt":0.39449892813338494,"score_spread":0.20322350928533614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366003793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6290546,0.030998817,0.0029504737,0.14037506,0.001257502,0.00056610804,0.15419723,0.0001641144,0.040436067],"genre_scores_gemma":[0.9585895,0.009366476,0.0013219988,0.0030103535,0.00028226333,0.000111480214,0.022075541,0.000019604433,0.0052227406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998381,0.00016717309,0.000070546834,0.000057340607,0.0006458125,0.00067812175],"domain_scores_gemma":[0.9931219,0.0006889372,0.0008993442,0.000077182,0.0038391731,0.0013735129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016215313,0.00039375178,0.00047685346,0.0016786923,0.0012399636,0.002305418,0.0008810112,0.00074766093,0.0028333755],"category_scores_gemma":[0.012535532,0.00023817808,0.0011498667,0.0032051697,0.00043013043,0.0009321345,0.001270032,0.0022892482,0.00016803443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064135826,0.00020473839,0.7521555,0.0008083348,0.00089976017,0.00037634856,0.00053479045,0.015267766,0.00019515192,0.019638004,0.14301787,0.06626041],"study_design_scores_gemma":[0.0001873687,0.00012866638,0.8926114,0.0011020874,0.0007247544,0.00023810299,0.0017967079,0.02000827,0.00037401172,0.0027441906,0.07999231,0.00009222307],"about_ca_topic_score_codex":0.991856,"about_ca_topic_score_gemma":0.9939547,"teacher_disagreement_score":0.072459444,"about_ca_system_score_codex":0.072459444,"about_ca_system_score_gemma":0.1260507,"threshold_uncertainty_score":0.5257325},"labels":[],"label_agreement":null},{"id":"W4366241520","doi":"10.1001/jama.2023.4034","title":"Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare","year":2023,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Medicare Part D; Medical prescription; Prescription drug; Medicare Advantage; Food and drug administration; Drug; Drug prices; Pharmacology; Public economics; Health care","score_opus":0.05251317172981099,"score_gpt":0.29046966829078247,"score_spread":0.23795649656097148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366241520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98903567,0.0020592099,0.00016916651,0.0010645917,0.00002020163,0.000029350536,0.002157017,0.00001668803,0.0054481914],"genre_scores_gemma":[0.9986815,0.00027116542,0.00015546154,0.0001273647,0.000020295265,0.000004513994,0.0006159293,0.0000011076163,0.00012272256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746084,0.0009346562,0.00024585467,0.00014062694,0.0009578165,0.00026013755],"domain_scores_gemma":[0.98789084,0.0023666848,0.0071916888,0.0002786855,0.0010729594,0.0011991186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002281012,0.00012966595,0.00020128263,0.0014828192,0.00030016014,0.0010445287,0.00018903306,0.00028261897,0.0014883264],"category_scores_gemma":[0.012341993,0.00007820456,0.0005076973,0.0013805407,0.0003494319,0.00046522034,0.0006784083,0.0004192007,0.00013534658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042363346,0.000072417206,0.9770756,0.00007835037,0.00022024992,0.000044750414,0.00009796506,0.00026383603,0.0002708769,0.00019792617,0.001097737,0.02015658],"study_design_scores_gemma":[0.000013538769,0.00015531642,0.9976246,0.00004035698,0.00007786493,0.000114646304,0.00008344913,0.00029564244,0.00021905798,0.00003855123,0.0013309361,0.0000060139723],"about_ca_topic_score_codex":0.013008626,"about_ca_topic_score_gemma":0.029007725,"teacher_disagreement_score":0.013008626,"about_ca_system_score_codex":0.0015364474,"about_ca_system_score_gemma":0.0010072192,"threshold_uncertainty_score":0.025865793},"labels":[],"label_agreement":null},{"id":"W4366449959","doi":"10.54194/iyua1228","title":"New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage.","year":2023,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer drugs; Business; Actuarial science; Public economics; Public health insurance; Health insurance; Economics; Economic growth; Medicine; Pharmacology; Health care; Drug","score_opus":0.06901277142227487,"score_gpt":0.33992617383932594,"score_spread":0.2709134024170511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366449959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6335902,0.06488167,0.0035116184,0.06593298,0.0010518787,0.0010049902,0.16667032,0.0001945919,0.063161686],"genre_scores_gemma":[0.9522421,0.012913053,0.0016695823,0.0024463667,0.00015503667,0.00013293038,0.020183504,0.000034222532,0.010223199],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9975407,0.0003367046,0.000075948104,0.00012770861,0.00084484543,0.0010739462],"domain_scores_gemma":[0.9968099,0.00071470795,0.0003572311,0.000051063187,0.001370028,0.000697181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001799155,0.0009052382,0.001264381,0.0019254531,0.0018974565,0.0035738035,0.001358918,0.0016461704,0.0039654346],"category_scores_gemma":[0.007951253,0.00060053234,0.0024705739,0.0059383158,0.0007400841,0.0010625245,0.0011443032,0.0029607618,0.00023757298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005568609,0.0010349759,0.21742792,0.0028242567,0.0063250163,0.0017597785,0.00085607934,0.26071662,0.0011517467,0.10395717,0.31862497,0.07975286],"study_design_scores_gemma":[0.0018501596,0.0007982063,0.46792576,0.00196935,0.007349428,0.00074560184,0.004718987,0.28907177,0.0018413381,0.017721102,0.20539075,0.0006176313],"about_ca_topic_score_codex":0.9938692,"about_ca_topic_score_gemma":0.9952754,"teacher_disagreement_score":0.13258731,"about_ca_system_score_codex":0.13258731,"about_ca_system_score_gemma":0.099628486,"threshold_uncertainty_score":0.9619928},"labels":[],"label_agreement":null},{"id":"W4366815796","doi":"10.1093/ajhp/zxad086","title":"National trends in prescription drug expenditures and projections for 2023","year":2023,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Prescription drug; Medical prescription; Medicine; Business; Drug; Biosimilar; Pharmacy; Environmental health; Family medicine; Pharmacology","score_opus":0.10673272107599613,"score_gpt":0.38887506839737795,"score_spread":0.2821423473213818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366815796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75661045,0.0058148,0.008633328,0.006283237,0.00030386107,0.000079544814,0.18511063,0.0008539348,0.036310203],"genre_scores_gemma":[0.9045707,0.0032210697,0.0054849125,0.0008506114,0.00010661302,0.00010779446,0.08245604,0.000055703735,0.003146616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999488,0.00008181048,0.000060771225,0.00007849058,0.00019658112,0.0000943149],"domain_scores_gemma":[0.99832505,0.00015116506,0.00055076374,0.000053011834,0.0007891546,0.00013080226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087786885,0.00052770745,0.00021404463,0.0018117927,0.00026337992,0.0011573667,0.00037692397,0.00051718496,0.0026541208],"category_scores_gemma":[0.0025604274,0.00017319038,0.0011720815,0.003623553,0.00016419297,0.0010410065,0.0005358216,0.0008559717,0.001065498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006924838,0.0002263032,0.7989867,0.0006509404,0.0006523001,0.00042117108,0.00027620862,0.058152165,0.0012380936,0.010371612,0.060265396,0.06806665],"study_design_scores_gemma":[0.000046899993,0.00023187297,0.826984,0.00037413088,0.00023724878,0.000987142,0.00093744136,0.07303489,0.0020564871,0.0037978382,0.091222234,0.00008983367],"about_ca_topic_score_codex":0.06714189,"about_ca_topic_score_gemma":0.051481422,"teacher_disagreement_score":0.06714189,"about_ca_system_score_codex":0.0027446968,"about_ca_system_score_gemma":0.0017676288,"threshold_uncertainty_score":0.13350219},"labels":[],"label_agreement":null},{"id":"W4367017517","doi":"10.1021/cen-09930-buscon10","title":"Canadian chemistry CROs to merge","year":2021,"lang":"en","type":"article","venue":"C&EN Global Enterprise","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Merge (version control); Management; Engineering; Library science; Chemistry; Business; Political science; Computer science; Economics; Information retrieval","score_opus":0.01829397506086774,"score_gpt":0.2677132402367854,"score_spread":0.24941926517591764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367017517","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008064003,0.0022381388,0.0007384563,0.04505459,0.010054649,0.00017522652,0.0020925472,0.0006871194,0.93815285],"genre_scores_gemma":[0.0053294864,0.002173998,0.0008975036,0.0157518,0.00074365403,0.000040506082,0.001492034,0.0003185953,0.97325236],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99344444,0.00019224525,0.00013041726,0.0005456201,0.004319016,0.0013682988],"domain_scores_gemma":[0.98960567,0.00020314334,0.00013871152,0.0004751413,0.005951735,0.0036256616],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020843183,0.0011789633,0.0006729599,0.003550405,0.011917475,0.012031835,0.002148292,0.006630523,0.5396531],"category_scores_gemma":[0.007175401,0.0008950121,0.0011970954,0.0034315828,0.001599267,0.003882086,0.0043542464,0.005878142,0.22930144],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012274581,0.000015177943,0.00012779921,0.000037674334,0.000003295408,0.000054817036,0.000036953825,0.000021338843,0.00012616848,0.014977172,0.9670115,0.017575646],"study_design_scores_gemma":[0.0000033176836,0.0000025385361,0.0001317787,0.000009299581,0.0000011055976,0.000018859879,0.00005293532,0.0000094410925,0.000034592264,0.00035510398,0.9993781,0.000002997143],"about_ca_topic_score_codex":0.6432673,"about_ca_topic_score_gemma":0.8282719,"teacher_disagreement_score":0.5396531,"about_ca_system_score_codex":0.029670786,"about_ca_system_score_gemma":0.09074717,"threshold_uncertainty_score":0.7176672},"labels":[],"label_agreement":null},{"id":"W4367181317","doi":"10.1007/s10961-023-10007-z","title":"Role of global public sector research in discovering new drugs and vaccines","year":2023,"lang":"en","type":"article","venue":"The Journal of Technology Transfer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Context (archaeology); Monetization; Product (mathematics); Biosimilar; Business; Medicine; Public relations; Political science; Law; Economics; Geography","score_opus":0.0910314511083042,"score_gpt":0.3314782690551307,"score_spread":0.24044681794682654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367181317","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17379943,0.13792188,0.019858079,0.17581986,0.0036745418,0.00046612934,0.008418557,0.0008517776,0.47918966],"genre_scores_gemma":[0.8875162,0.06753202,0.013097469,0.015484844,0.0030050562,0.0002095323,0.0026314962,0.0003672831,0.010156071],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9692723,0.014740349,0.0013088887,0.0031892136,0.0080041755,0.0034850463],"domain_scores_gemma":[0.84225297,0.07610901,0.02641348,0.020700103,0.023401435,0.0111230295],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.053906817,0.0010242058,0.0011579742,0.017857911,0.0023455815,0.021648424,0.0013410521,0.0023056506,0.013908768],"category_scores_gemma":[0.06430467,0.00048827747,0.0012639343,0.0285674,0.008330786,0.013368024,0.008125496,0.0039901515,0.002114699],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005727062,0.00032819307,0.15203613,0.004081645,0.00058665837,0.0011140971,0.0047397716,0.0028490166,0.0015041408,0.34628344,0.04389771,0.4420065],"study_design_scores_gemma":[0.00016380892,0.0004438623,0.13837174,0.0067303516,0.000798884,0.0022559813,0.011225354,0.003692218,0.0041796216,0.12279443,0.7091281,0.0002156672],"about_ca_topic_score_codex":0.0045222025,"about_ca_topic_score_gemma":0.003679587,"teacher_disagreement_score":0.9460932,"about_ca_system_score_codex":0.007633099,"about_ca_system_score_gemma":0.016401194,"threshold_uncertainty_score":0.2850899},"labels":[],"label_agreement":null},{"id":"W4375948981","doi":"10.54194/llaj7141","title":"Evaluation of the PMPRB regulatory performance on price review for new patented drugs in Canada, 2008-2021","year":2023,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Medicine","score_opus":0.14617859514532203,"score_gpt":0.3523666923102085,"score_spread":0.20618809716488648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375948981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7173205,0.012893863,0.0015351033,0.07304768,0.0008934006,0.0016925695,0.020762982,0.0006409038,0.17121297],"genre_scores_gemma":[0.97615594,0.0016341633,0.0011186597,0.006355678,0.00023592362,0.00013924512,0.0026463626,0.000048946575,0.011665131],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9606215,0.007403035,0.0012015121,0.0014509576,0.023964148,0.0053589502],"domain_scores_gemma":[0.8841718,0.035712074,0.009225972,0.001580757,0.060714893,0.008594574],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03670494,0.00060038327,0.0009256892,0.0024568897,0.0028146182,0.006299739,0.0023418798,0.0031536256,0.0027699235],"category_scores_gemma":[0.11319356,0.000681715,0.0011920445,0.0031561237,0.0022334345,0.0013889478,0.0012238433,0.00257821,0.00032836944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035928313,0.0027268208,0.2771931,0.004808872,0.0035225097,0.00080742163,0.0025703586,0.08494189,0.0075931596,0.054484144,0.2819855,0.24343795],"study_design_scores_gemma":[0.003762108,0.004322236,0.86249036,0.00057912996,0.0019424527,0.0001407514,0.0014252637,0.024461973,0.0043989853,0.0013103174,0.09492285,0.00024353665],"about_ca_topic_score_codex":0.9791692,"about_ca_topic_score_gemma":0.98249453,"teacher_disagreement_score":0.96329504,"about_ca_system_score_codex":0.13146043,"about_ca_system_score_gemma":0.23694065,"threshold_uncertainty_score":0.95381665},"labels":[],"label_agreement":null},{"id":"W4376113782","doi":"10.1177/00222429231177627","title":"Scientific Evidence Production and Specialty Drug Diffusion","year":2023,"lang":"en","type":"article","venue":"Journal of Marketing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tech University; McGill University","funders":"","keywords":"Specialty; Scientific evidence; Incentive; Novelty; Production (economics); Medical prescription; Business; Medicine; Marketing; Psychology; Family medicine; Pharmacology; Economics; Social psychology","score_opus":0.08508632673609888,"score_gpt":0.30096317634000214,"score_spread":0.21587684960390324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376113782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4594522,0.030922562,0.3074128,0.04866088,0.00071153534,0.003222452,0.0015161936,0.000561271,0.1475401],"genre_scores_gemma":[0.97310627,0.0028219211,0.019865809,0.00087206415,0.0002821143,0.00028588608,0.00017612391,0.000039084654,0.002550827],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9187939,0.049403526,0.006479736,0.0075191525,0.013682613,0.0041210223],"domain_scores_gemma":[0.26274812,0.6362646,0.06045206,0.01969866,0.0167702,0.004066363],"candidate_categories":["metaresearch","bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.109252855,0.0013118915,0.0023100742,0.011367993,0.0023257877,0.013951067,0.0025529878,0.0050439443,0.010253537],"category_scores_gemma":[0.37725386,0.0011312999,0.0030128632,0.007119605,0.010840623,0.015841858,0.0078986855,0.005672272,0.0010124886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011426833,0.0005873395,0.16703308,0.0027886825,0.0017775086,0.001517999,0.0042574597,0.02944459,0.0019326811,0.5969724,0.0034624422,0.18908307],"study_design_scores_gemma":[0.0007080344,0.0011865795,0.09878683,0.002117557,0.0012387014,0.001115314,0.0024874762,0.0445477,0.0040585194,0.816288,0.02712341,0.00034190016],"about_ca_topic_score_codex":0.0032661436,"about_ca_topic_score_gemma":0.0017921225,"teacher_disagreement_score":0.988632,"about_ca_system_score_codex":0.0078035034,"about_ca_system_score_gemma":0.0077494476,"threshold_uncertainty_score":0.5777912},"labels":[],"label_agreement":null},{"id":"W4376871824","doi":"10.1002/jia2.26097","title":"Antibodies for HIV prevention: the path forward","year":2023,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"World Health Organization","keywords":"Medicine; Commercialization; Licensure; Developing country; Human immunodeficiency virus (HIV); Public relations; Marketing; Economic growth; Business; Political science; Immunology; Economics","score_opus":0.070296958503392,"score_gpt":0.32802633374838935,"score_spread":0.25772937524499734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376871824","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000797234,0.45693097,0.00328905,0.50808966,0.012047918,0.000051159914,0.0002073732,0.00026147164,0.018325148],"genre_scores_gemma":[0.020955252,0.71541846,0.009651201,0.21354817,0.021332206,0.00011098087,0.00033232447,0.00014020053,0.018511247],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959074,0.0014290788,0.00017086233,0.00037892448,0.0013996615,0.0007140622],"domain_scores_gemma":[0.98823315,0.0058312695,0.00066954194,0.00036455656,0.0022311755,0.0026704054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013299225,0.0012826353,0.001369977,0.0014299232,0.0015583461,0.0064055473,0.0021083953,0.01219086,0.039549265],"category_scores_gemma":[0.012366919,0.0005024117,0.0010178878,0.0011558618,0.0046356088,0.014198418,0.004344357,0.01856615,0.011919688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027319256,0.00023037572,0.00049980695,0.0019279318,0.000053622403,0.00028251027,0.00026139928,0.00034410853,0.0010913524,0.13909602,0.39235765,0.46358204],"study_design_scores_gemma":[0.000057098947,0.00021577625,0.00031881634,0.0020534303,0.000027209473,0.00031718175,0.0002746469,0.00021825294,0.00029922157,0.051010046,0.9451846,0.000023598193],"about_ca_topic_score_codex":0.002393748,"about_ca_topic_score_gemma":0.0038312313,"teacher_disagreement_score":0.039549265,"about_ca_system_score_codex":0.003935843,"about_ca_system_score_gemma":0.0075982395,"threshold_uncertainty_score":0.13230544},"labels":[],"label_agreement":null},{"id":"W4378877688","doi":"10.1211/pj.2023.1.187380","title":"United States, Japan and Australia added to UK fast-track medicines approvals list","year":2023,"lang":"en","type":"article","venue":"Pharmaceutical journal/˜The œpharmaceutical journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Track (disk drive); Fast track; Business; Medicine; Engineering; Surgery; Mechanical engineering","score_opus":0.15077431501147326,"score_gpt":0.3890188955159428,"score_spread":0.23824458050446956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378877688","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035311854,0.01108724,0.0013506906,0.155087,0.09432878,0.00017972234,0.011499186,0.001238257,0.721698],"genre_scores_gemma":[0.010595545,0.0038508622,0.001706783,0.047569487,0.007177996,0.000114929215,0.0047321063,0.00023869141,0.9240137],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734735,0.00025319794,0.00023368104,0.00019064907,0.0015455504,0.00042953392],"domain_scores_gemma":[0.99310815,0.00050982623,0.00032041167,0.0002974967,0.004482613,0.0012815575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012465727,0.00069572526,0.00070572866,0.001994145,0.0022807764,0.004514541,0.0004635767,0.0037846859,0.19567077],"category_scores_gemma":[0.0061837877,0.0005867033,0.00095346046,0.0018529103,0.0005592422,0.002331515,0.0017828802,0.005171419,0.11543605],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002845418,0.0000064844417,0.00016782261,0.000038042002,0.0000037286445,0.00004994836,0.000017017428,0.000014813803,0.00008389078,0.0025285806,0.9817935,0.015267634],"study_design_scores_gemma":[0.000008562692,0.000010174075,0.000876874,0.000023213963,0.0000045666734,0.00004747767,0.000018901457,0.000013951342,0.00004302865,0.00017065307,0.998777,0.000005553908],"about_ca_topic_score_codex":0.031155625,"about_ca_topic_score_gemma":0.062219083,"teacher_disagreement_score":0.19567077,"about_ca_system_score_codex":0.002329883,"about_ca_system_score_gemma":0.007206703,"threshold_uncertainty_score":0.65458393},"labels":[],"label_agreement":null},{"id":"W4378953889","doi":"10.1161/atvbaha.123.319633","title":"Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies","year":2023,"lang":"en","type":"letter","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Grossman; Transparency (behavior); Library science; Medicine; Management; Political science; Law; Computer science","score_opus":0.33023247671162037,"score_gpt":0.34352235789877433,"score_spread":0.013289881187153962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378953889","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002838691,0.0005868202,0.00015166157,0.992652,0.0028940318,0.0000061873284,0.000019739573,0.00000835093,0.0033974114],"genre_scores_gemma":[0.00983159,0.0005823799,0.00033687195,0.97027236,0.011564033,0.000036893536,0.000014144173,0.000017273258,0.0073445207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9756688,0.009500935,0.0020977182,0.0018640959,0.0069949753,0.0038735277],"domain_scores_gemma":[0.8523947,0.12294171,0.0058715832,0.0025434785,0.007822602,0.00842586],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.029463334,0.0007038755,0.0017522575,0.00090501306,0.008848849,0.016303672,0.003467115,0.16691226,0.010055909],"category_scores_gemma":[0.15138987,0.0009926372,0.0014188179,0.0011798762,0.010001675,0.012651577,0.0053519835,0.0866319,0.004379142],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011136705,0.000057438156,0.0007245646,0.00006954353,0.000031839136,0.0014212474,0.0005800606,0.00017976311,0.00021025217,0.076502636,0.9073736,0.012737618],"study_design_scores_gemma":[0.0003757814,0.00006713018,0.0018389792,0.0005546673,0.00006265568,0.0012450836,0.0016805994,0.0024141192,0.0006540214,0.19528314,0.7956565,0.00016732307],"about_ca_topic_score_codex":0.010621644,"about_ca_topic_score_gemma":0.021816786,"teacher_disagreement_score":0.83308774,"about_ca_system_score_codex":0.009452107,"about_ca_system_score_gemma":0.020437095,"threshold_uncertainty_score":0.15581888},"labels":[],"label_agreement":null},{"id":"W4379209049","doi":"10.1007/s10620-023-07958-6","title":"Major Shifts in Acid Suppression Drug Utilization After the 2019 Ranitidine Recalls in Canada and United States","year":2023,"lang":"en","type":"article","venue":"Digestive Diseases and Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo; Women's College Hospital; University of Toronto","funders":"Agency for Healthcare Research and Quality; U.S. Department of Veterans Affairs","keywords":"Ranitidine; Economic shortage; Purchasing; Medicine; Business; Internal medicine; Marketing","score_opus":0.04252442719544593,"score_gpt":0.27674267282974574,"score_spread":0.23421824563429983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379209049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483412,0.0041820724,0.00017000426,0.021224074,0.00024793975,0.000038712205,0.019473452,0.000045996436,0.0062765856],"genre_scores_gemma":[0.98600763,0.0018760959,0.0001305839,0.0020601442,0.00009413997,0.000011493384,0.0063501894,0.000015631165,0.00345404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866426,0.00005614106,0.00009137465,0.00014451593,0.0004072803,0.0006363287],"domain_scores_gemma":[0.9952572,0.0003239579,0.0009996523,0.00008313138,0.0024236029,0.0009123472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010168741,0.00020439774,0.00052079937,0.0011677481,0.0014416366,0.0026457466,0.0011490269,0.0014191375,0.0034895441],"category_scores_gemma":[0.0047798497,0.00031230153,0.0009652366,0.0029718347,0.00068829476,0.0008527584,0.0011070215,0.002485053,0.00034381522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011088769,0.00019299054,0.93525064,0.00020648546,0.0003156874,0.00041767833,0.0021187477,0.0016783044,0.00061240094,0.0028315121,0.027111102,0.0281557],"study_design_scores_gemma":[0.000007873431,0.000022437256,0.9898896,0.00007658455,0.000030238676,0.000046431258,0.0022758287,0.000585135,0.00016432434,0.000076566,0.0068031834,0.000021672524],"about_ca_topic_score_codex":0.9916121,"about_ca_topic_score_gemma":0.9929883,"teacher_disagreement_score":0.032410827,"about_ca_system_score_codex":0.032410827,"about_ca_system_score_gemma":0.0487431,"threshold_uncertainty_score":0.23515815},"labels":[],"label_agreement":null},{"id":"W4379780978","doi":"10.2139/ssrn.4458169","title":"Legislating Bureaucratic Autonomy as a Potential Blame Avoidance Strategy in Westminster Polities: A Comparative Study of the Adoption of Oncology Drugs into the Provincial Formularies of Alberta and Ontario","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Blame; Formulary; Bureaucracy; Autonomy; Public administration; Political science; Pharmacology; Medicine; Law; Psychiatry","score_opus":0.03028208467888856,"score_gpt":0.29312128129419246,"score_spread":0.2628391966153039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379780978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646387,0.0002894055,0.0001975781,0.0038693533,0.0000151528775,0.00005234305,0.00003636245,0.000005122724,0.030896038],"genre_scores_gemma":[0.99600655,0.00012086956,0.00007251928,0.00046511967,0.0000049971727,0.0000067936467,0.000013015166,0.0000030783135,0.003307218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99125224,0.0015615381,0.00012308668,0.00036425493,0.0019788952,0.004719931],"domain_scores_gemma":[0.9877874,0.004388581,0.00280065,0.00043672463,0.0023383854,0.002248307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051361816,0.00014739143,0.00032302632,0.00085099984,0.0096175065,0.0058915457,0.0015513233,0.0022645064,0.0032792091],"category_scores_gemma":[0.015148411,0.0003618221,0.00038005604,0.0019960685,0.010827546,0.0014117373,0.0027332727,0.0029622626,0.00015362639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012862142,0.0008009007,0.4364244,0.00023462913,0.00027722662,0.001357853,0.27018166,0.0037352568,0.0032656793,0.20569372,0.010487217,0.06625521],"study_design_scores_gemma":[0.00018690836,0.00029994524,0.7266524,0.00017205674,0.00016486301,0.0001021298,0.21023184,0.0020464312,0.0009974884,0.00593681,0.053122193,0.00008700721],"about_ca_topic_score_codex":0.9828841,"about_ca_topic_score_gemma":0.9945134,"teacher_disagreement_score":0.8838226,"about_ca_system_score_codex":0.11617739,"about_ca_system_score_gemma":0.13830589,"threshold_uncertainty_score":0.8429299},"labels":[],"label_agreement":null},{"id":"W4380047185","doi":"10.36646/mjlr.56.2.inequitable","title":"Inequitable by Design: The Patent Culture, Law, and Politics Behind COVID-19 Vaccine Global Access","year":2023,"lang":"en","type":"article","venue":"University of Michigan Journal of Law Reform","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia; Yale University; GAVI Alliance","keywords":"Intellectual property; Equity (law); Scholarship; Context (archaeology); Politics; Global health; Health equity; Health care; Economics; Political science; Economic growth; Development economics; Law","score_opus":0.11493325089429801,"score_gpt":0.29714423648135635,"score_spread":0.18221098558705834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380047185","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31820768,0.009606007,0.015875649,0.2532324,0.0004898793,0.00006771013,0.00008106872,0.000055585188,0.40238395],"genre_scores_gemma":[0.9852483,0.0014356701,0.0007811188,0.007916952,0.00019521889,0.000020273194,0.000009182204,0.00002613951,0.0043671387],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9922587,0.0032670018,0.00020356677,0.0009775148,0.0019468775,0.0013463396],"domain_scores_gemma":[0.9858782,0.010156897,0.001346384,0.00094928633,0.0009668883,0.00070233055],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.011036967,0.00022966474,0.00030027234,0.0013191359,0.006954605,0.011521349,0.00068276835,0.0040280507,0.0041931327],"category_scores_gemma":[0.019682743,0.00028814565,0.00031213395,0.001287948,0.036720607,0.009674382,0.005363362,0.006969525,0.00032770832],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011670455,0.00002062414,0.001889126,0.000017853727,0.0000037490101,0.00007046882,0.0077044154,0.0001752709,0.00016225035,0.97638696,0.0019830524,0.011574596],"study_design_scores_gemma":[0.000024301375,0.000073566756,0.0073130135,0.0003165149,0.000019231507,0.00021448989,0.012884873,0.0013345615,0.0010227482,0.8580788,0.118675515,0.000042485586],"about_ca_topic_score_codex":0.007830257,"about_ca_topic_score_gemma":0.0072828177,"teacher_disagreement_score":0.9930454,"about_ca_system_score_codex":0.008497946,"about_ca_system_score_gemma":0.0056069912,"threshold_uncertainty_score":0.06165713},"labels":[],"label_agreement":null},{"id":"W4380149549","doi":"10.1016/j.jval.2023.03.1267","title":"HPR120 The Pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A Comparative Study Using Donabedian's Structure-Process-Outcome Framework","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Procurement; Pooling; Purchasing; Business; Process (computing); Outcome (game theory); Purchasing power; Process management; Economics; Marketing; Computer science; Microeconomics","score_opus":0.18835347595039248,"score_gpt":0.4017387286497625,"score_spread":0.21338525269937003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380149549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58561057,0.012298175,0.021106716,0.005826794,0.00015830553,0.000480965,0.002694777,0.00019759641,0.37162608],"genre_scores_gemma":[0.98431385,0.00196139,0.0037130043,0.00022908993,0.000023281998,0.000045543573,0.00037866065,0.000028860524,0.0093063675],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99567944,0.0011438627,0.00011684157,0.00027381952,0.0017797524,0.0010064197],"domain_scores_gemma":[0.99492043,0.0018672687,0.0003850825,0.0003643052,0.0020110335,0.00045184736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004844642,0.000471923,0.00082063285,0.00284646,0.0019509651,0.0051351683,0.0017912315,0.00079174916,0.0069945124],"category_scores_gemma":[0.00863607,0.0002796377,0.001187871,0.0071599237,0.0023961482,0.002186167,0.0012049077,0.0010241942,0.0003178192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037343783,0.00019579986,0.033505004,0.00037428926,0.00022080267,0.0002695097,0.0009934538,0.040970545,0.0004670146,0.8355746,0.009623983,0.0774314],"study_design_scores_gemma":[0.00031952388,0.0006526074,0.37089133,0.0005297991,0.001169204,0.00047485402,0.011306099,0.24483702,0.0013640048,0.25982967,0.10802305,0.00060289016],"about_ca_topic_score_codex":0.889362,"about_ca_topic_score_gemma":0.88489443,"teacher_disagreement_score":0.11063802,"about_ca_system_score_codex":0.043538503,"about_ca_system_score_gemma":0.044459008,"threshold_uncertainty_score":0.31589544},"labels":[],"label_agreement":null},{"id":"W4380149737","doi":"10.1016/j.jval.2023.03.951","title":"EPH69 Economic Impact of Clozapine Treatment Persistence: A Canadian Perspective","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Douglas Mental Health University Institute","funders":"","keywords":"Clozapine; Persistence (discontinuity); Schizophrenia (object-oriented programming); Perspective (graphical); Psychiatry; Medicine; Psychology; Computer science; Engineering; Artificial intelligence","score_opus":0.18758604027506046,"score_gpt":0.3728724681580302,"score_spread":0.18528642788296976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380149737","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12152706,0.066278026,0.001829893,0.48864397,0.00087850983,0.00007187252,0.011073429,0.000050483013,0.3096466],"genre_scores_gemma":[0.9067747,0.056888428,0.0011810029,0.012128709,0.0012976527,0.000027898208,0.0018869133,0.000051624982,0.019763093],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9971529,0.00034776842,0.000093191775,0.00014683147,0.0011757563,0.0010835666],"domain_scores_gemma":[0.99000096,0.0019819266,0.0010460396,0.00017640863,0.0051979073,0.0015967048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021768203,0.0005421338,0.0009299283,0.0037722352,0.0027524503,0.007217161,0.0013848856,0.0026657928,0.009799596],"category_scores_gemma":[0.012812333,0.00029672787,0.0013628899,0.0062908707,0.002728673,0.0016963045,0.0013993031,0.0045376867,0.00031090353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009250296,0.00023271471,0.04338448,0.0006846836,0.0006089388,0.0014030272,0.0010790555,0.018561436,0.00084364635,0.7584676,0.088511705,0.08529764],"study_design_scores_gemma":[0.00046026305,0.00025290085,0.28483963,0.0036449374,0.001406049,0.0009880401,0.007247518,0.026404407,0.0008972423,0.22951014,0.4437457,0.0006031424],"about_ca_topic_score_codex":0.9888924,"about_ca_topic_score_gemma":0.9842992,"teacher_disagreement_score":0.08609396,"about_ca_system_score_codex":0.08609396,"about_ca_system_score_gemma":0.114949964,"threshold_uncertainty_score":0.62465835},"labels":[],"label_agreement":null},{"id":"W4380319178","doi":"10.1211/pj.2023.1.174004","title":"World-renowned transparency expert appointed to lead pharmacy journal","year":2023,"lang":"en","type":"article","venue":"Pharmaceutical journal/˜The œpharmaceutical journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Transparency (behavior); Lead (geology); Business; Accounting; Medicine; Family medicine; Political science; Law; Biology","score_opus":0.19157781068085414,"score_gpt":0.39733003742291373,"score_spread":0.2057522267420596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380319178","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019142957,0.021062095,0.0021790983,0.49705887,0.43934798,0.00010719148,0.0004988427,0.00038770644,0.03744392],"genre_scores_gemma":[0.03842293,0.03150617,0.0051180883,0.16568598,0.26789153,0.00015504204,0.00072604814,0.0005419289,0.4899522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99132955,0.000947787,0.00079317886,0.0008928868,0.0047882,0.0012482787],"domain_scores_gemma":[0.91941327,0.0067791655,0.0060749855,0.0018021769,0.036256347,0.029674158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007680859,0.0007508379,0.0009991989,0.0032527295,0.0033272728,0.009322005,0.0008598792,0.0055805948,0.028216762],"category_scores_gemma":[0.036543686,0.0005758206,0.0008030771,0.0020649433,0.0018943802,0.00448579,0.002000876,0.0076077664,0.015279017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047528054,0.000015352409,0.00050245324,0.000100238,0.00001393774,0.00041136675,0.00006436411,0.000043923243,0.0003039129,0.0018204578,0.9731501,0.02352638],"study_design_scores_gemma":[0.000035920228,0.00004032508,0.002174647,0.0002456065,0.000024124902,0.0012434073,0.0002975659,0.00019781748,0.00044867652,0.0015744116,0.9936792,0.000038341535],"about_ca_topic_score_codex":0.0032850886,"about_ca_topic_score_gemma":0.007950632,"teacher_disagreement_score":0.028216762,"about_ca_system_score_codex":0.0031236054,"about_ca_system_score_gemma":0.016508648,"threshold_uncertainty_score":0.094394445},"labels":[],"label_agreement":null},{"id":"W4380761282","doi":"10.2139/ssrn.4472407","title":"Linking Medication Errors to Supply Chain Disruptions: Evidence from Heparin Shortages Caused by Hurricane Maria","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Economic shortage; Heparin; Supply chain; Business; Medicine; Actuarial science; Medical emergency; Internal medicine; Marketing","score_opus":0.044692274174022745,"score_gpt":0.3121411252201872,"score_spread":0.26744885104616445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380761282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941654,0.00064919004,0.00014038802,0.0018695851,0.000024742316,0.000020174359,0.0012905969,0.000005162619,0.0018346976],"genre_scores_gemma":[0.99698836,0.00089495454,0.00014289643,0.0003915584,0.00007135285,0.00001508282,0.00105606,0.000003996008,0.0004358313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787045,0.00087412074,0.00027946357,0.00019525504,0.00045844502,0.00032223843],"domain_scores_gemma":[0.92737514,0.024505498,0.039047632,0.0020001894,0.005058112,0.0020134964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029213114,0.00023915726,0.00021267614,0.0021699734,0.0005619386,0.0009642054,0.00066506787,0.0011781259,0.0035455683],"category_scores_gemma":[0.028859586,0.00032624102,0.0005087143,0.0036095628,0.00057617034,0.00076893053,0.0013961066,0.0014297147,0.0006803507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028890226,0.00018833899,0.990838,0.000092312206,0.0002095778,0.00024647833,0.00048995053,0.00034832035,0.00005792528,0.00011860314,0.0020018613,0.005119633],"study_design_scores_gemma":[0.000028372426,0.00019173694,0.9944765,0.00011915974,0.0001133679,0.0001488676,0.0025923606,0.0007881095,0.00008690404,0.00015014439,0.0012922678,0.000012096879],"about_ca_topic_score_codex":0.04619204,"about_ca_topic_score_gemma":0.043546498,"teacher_disagreement_score":0.04619204,"about_ca_system_score_codex":0.0008927372,"about_ca_system_score_gemma":0.001376237,"threshold_uncertainty_score":0.09184635},"labels":[],"label_agreement":null},{"id":"W4380794665","doi":"10.1161/circ.146.suppl_1.11314","title":"Abstract 11314: Essential and Evidence-Based Cardiovascular Disease Medicine Availability in Low-Cost Generic Drug Plans","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Formulary; Guideline; Canadian Cardiovascular Society; Pharmacy; Disease; Angina; Intensive care medicine; Family medicine; Internal medicine; Myocardial infarction","score_opus":0.07950785660559355,"score_gpt":0.2762262089856539,"score_spread":0.19671835238006036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380794665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.869745,0.009973957,0.003544953,0.0030030373,0.00005702213,0.00071111316,0.09723839,0.000115547315,0.015610964],"genre_scores_gemma":[0.9794509,0.001498761,0.0029863412,0.00039489142,0.000082107435,0.00025476565,0.014968326,0.000010946896,0.0003529826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98914796,0.0032261326,0.002453644,0.0008985527,0.0039023033,0.00037139285],"domain_scores_gemma":[0.9359721,0.029592372,0.028456386,0.001274533,0.003582656,0.0011219443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008839869,0.00033080872,0.0004889309,0.004960701,0.00033249555,0.0014945839,0.00089124136,0.0005991069,0.006694021],"category_scores_gemma":[0.039652865,0.00028134522,0.0013291282,0.008547938,0.00050484744,0.0016802889,0.0015131126,0.0007280629,0.00065836916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026046936,0.00009078186,0.96858805,0.0011411873,0.0004441428,0.00007027922,0.00015465448,0.00086525705,0.00010160942,0.00051696604,0.0042386097,0.023528114],"study_design_scores_gemma":[0.000045063247,0.0001324955,0.99193406,0.000505763,0.00023853581,0.0002088008,0.00014874837,0.0020743746,0.000154634,0.00032625065,0.004221218,0.000010064554],"about_ca_topic_score_codex":0.016254548,"about_ca_topic_score_gemma":0.011053614,"teacher_disagreement_score":0.016254548,"about_ca_system_score_codex":0.0017606323,"about_ca_system_score_gemma":0.0018533054,"threshold_uncertainty_score":0.046750307},"labels":[],"label_agreement":null},{"id":"W4380854239","doi":"10.1371/journal.pone.0286802","title":"New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Food and drug administration; Medicine; Agency (philosophy); Interquartile range; Environmental health; Family medicine; Surgery","score_opus":0.09656901190583728,"score_gpt":0.27768889680693015,"score_spread":0.18111988490109288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380854239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855576,0.0019248473,0.00029882955,0.00044438467,0.000043994543,0.00012769894,0.0086711105,0.000016248467,0.0029153884],"genre_scores_gemma":[0.9944711,0.00070357363,0.00025024684,0.00019642622,0.000023024473,0.0000717361,0.0038425522,0.000013072141,0.00042829235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9853425,0.002098291,0.0020348665,0.0021239202,0.006498065,0.0019022146],"domain_scores_gemma":[0.93623346,0.011069384,0.032050107,0.0017070966,0.014758221,0.004181729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008471298,0.00038518754,0.0006993855,0.0047462964,0.0018215933,0.0025693215,0.0015821394,0.001008908,0.0030649155],"category_scores_gemma":[0.025068894,0.0006772572,0.0015951396,0.0108975675,0.001393842,0.0015419546,0.0019177994,0.0018935511,0.00027947195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009181702,0.000030192487,0.99822074,0.000038541282,0.00019758173,0.000031546453,0.00019249463,0.00006756991,0.000016710854,0.00004527111,0.00038731575,0.0006802178],"study_design_scores_gemma":[0.000006570537,0.000051961,0.9978241,0.000044461256,0.00006344345,0.000083613595,0.0008775698,0.00023660772,0.000031852458,0.000013548323,0.0007513765,0.00001495538],"about_ca_topic_score_codex":0.75717974,"about_ca_topic_score_gemma":0.6979912,"teacher_disagreement_score":0.9870524,"about_ca_system_score_codex":0.012947648,"about_ca_system_score_gemma":0.01376314,"threshold_uncertainty_score":0.48850054},"labels":[],"label_agreement":null},{"id":"W4382048761","doi":"10.21203/rs.3.rs-3000650/v1","title":"Strengthening Access to Cancer Medicines for Children in East Africa: Policy Options to Enhance Medicine Procurement, Forecasting, and Regulations","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Procurement; Access to medicines; Business; Economic growth; Economics; Developing country; Marketing","score_opus":0.3873772056037338,"score_gpt":0.5009164817878442,"score_spread":0.11353927618411042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382048761","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.106569864,0.13230292,0.013618729,0.6831782,0.0017544511,0.00059248705,0.0014494935,0.00015757882,0.060376275],"genre_scores_gemma":[0.80592227,0.13532096,0.028093081,0.019221658,0.0015564488,0.0005505535,0.00036781075,0.000030405596,0.008936745],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99608105,0.0027802675,0.000151901,0.00012297447,0.00026322616,0.0006006311],"domain_scores_gemma":[0.982213,0.012849018,0.0025980321,0.00027015584,0.0010571855,0.0010124755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010266858,0.00042584035,0.00036674793,0.001380738,0.000829601,0.0048185503,0.00086458767,0.0023526899,0.0067557544],"category_scores_gemma":[0.015883425,0.0003205152,0.00043560375,0.0019678485,0.0013952139,0.004224962,0.0024538473,0.0023314452,0.0003128448],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039335235,0.00043706523,0.025727395,0.008919609,0.00018922471,0.0015320516,0.0032244276,0.03534026,0.0016990107,0.53742933,0.09929603,0.28581232],"study_design_scores_gemma":[0.00036733615,0.0008351726,0.07287042,0.026145851,0.0003531448,0.00091013376,0.023190955,0.037294958,0.0067219203,0.18027715,0.6507546,0.00027837916],"about_ca_topic_score_codex":0.015949443,"about_ca_topic_score_gemma":0.015278508,"teacher_disagreement_score":0.015949443,"about_ca_system_score_codex":0.006685241,"about_ca_system_score_gemma":0.011895552,"threshold_uncertainty_score":0.05429697},"labels":[],"label_agreement":null},{"id":"W4383620169","doi":"10.29259/jep.v21i1.20779","title":"Concentration and Competition in the Pharmaceutical Sector in an Era of Challenges","year":2023,"lang":"en","type":"article","venue":"Jurnal Ekonomi Pembangunan","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Al-Azhar University","keywords":"Competition (biology); Market share; Market concentration; Oligopoly; Pharmaceutical industry; Quarter (Canadian coin); Business; Index (typography); Herfindahl index; Industrial organization; Competitor analysis; Economics; Market structure; Marketing; Market economy","score_opus":0.12280218860041645,"score_gpt":0.33154994657540104,"score_spread":0.2087477579749846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383620169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9049969,0.0046943827,0.0055058333,0.013836873,0.00007188552,0.000054799813,0.0002124396,0.00002385917,0.07060306],"genre_scores_gemma":[0.9971836,0.0006893919,0.00030742373,0.0003129775,0.000046236353,0.000008980797,0.00002793422,0.0000024643389,0.0014208731],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980835,0.0006386304,0.000067454384,0.00024001252,0.0005218266,0.00044859832],"domain_scores_gemma":[0.9970898,0.0012028286,0.0010200562,0.00006545512,0.0003010097,0.00032094494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014331451,0.00016131367,0.00034307278,0.0015119489,0.001165782,0.003410908,0.0003153864,0.001199377,0.0026736301],"category_scores_gemma":[0.0034276585,0.00015402184,0.00032285915,0.0018283771,0.0021698962,0.0028452938,0.0014279344,0.00073913403,0.0002767855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055,0.0005450057,0.29223058,0.0004156962,0.00018510652,0.0043057497,0.005908116,0.030752404,0.003870202,0.5525499,0.014365523,0.094321825],"study_design_scores_gemma":[0.00011098827,0.00081412715,0.5224294,0.000507005,0.00013565707,0.0019154984,0.029564116,0.08888174,0.00386599,0.25013384,0.10140892,0.00023270787],"about_ca_topic_score_codex":0.008059544,"about_ca_topic_score_gemma":0.0065003387,"teacher_disagreement_score":0.008059544,"about_ca_system_score_codex":0.0043393527,"about_ca_system_score_gemma":0.0020073098,"threshold_uncertainty_score":0.031484365},"labels":[],"label_agreement":null},{"id":"W4384469248","doi":"10.54097/hbem.v15i.9223","title":"Assessing the Financial Stability &amp; Investment Potential of Pfizer Inc.","year":2023,"lang":"en","type":"article","venue":"Highlights in Business Economics and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Restructuring; Competitor analysis; Business; Capitalization; Accounting; Market capitalization; Finance; Stock market; Marketing","score_opus":0.07114409728497086,"score_gpt":0.28418836389609525,"score_spread":0.2130442666111244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7834679,0.017190589,0.005558276,0.028371474,0.00024197447,0.00016422932,0.0041636336,0.00009176996,0.16075008],"genre_scores_gemma":[0.99301094,0.0016814849,0.0009765966,0.00025992712,0.00012524397,0.000017569251,0.0008420724,0.0000062302515,0.003080004],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814165,0.0004031201,0.000098838864,0.00014765057,0.0009277533,0.00028100534],"domain_scores_gemma":[0.99006325,0.0035590064,0.0027024492,0.00019897375,0.0024545637,0.0010217613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044273543,0.0004085265,0.00021260216,0.0025357045,0.00060261315,0.0036222448,0.00029661783,0.00091448956,0.0034016892],"category_scores_gemma":[0.0144261,0.00013202423,0.00027750502,0.0017027371,0.0005642099,0.0026919781,0.0007632774,0.000914479,0.00083172595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014660273,0.00022491415,0.5731946,0.00035809798,0.00030142826,0.0015775738,0.000574066,0.026633795,0.001904881,0.090827145,0.04644996,0.2564876],"study_design_scores_gemma":[0.00013006944,0.0017679036,0.745016,0.00061028084,0.00032088283,0.0018252002,0.0026001043,0.09192385,0.006016616,0.04314102,0.10645866,0.00018948867],"about_ca_topic_score_codex":0.005727147,"about_ca_topic_score_gemma":0.0053350944,"teacher_disagreement_score":0.005727147,"about_ca_system_score_codex":0.0029286626,"about_ca_system_score_gemma":0.0019060432,"threshold_uncertainty_score":0.023414373},"labels":[],"label_agreement":null},{"id":"W4384655740","doi":"10.1136/bmjgh-2022-011535","title":"Improving access to medicines and beyond: the national volume-based procurement policy in China","year":2023,"lang":"en","type":"review","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"National Natural Science Foundation of China","keywords":"China; Procurement; Business; Health policy; Public administration; Public health; Medicine; Political science; Nursing; Marketing","score_opus":0.1955670357689519,"score_gpt":0.4918127980902169,"score_spread":0.296245762321265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384655740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0123700155,0.96921116,0.0011814114,0.0095655965,0.00025742946,0.00007289794,0.00010954063,0.000015002939,0.007216911],"genre_scores_gemma":[0.16965434,0.82567114,0.0014860937,0.0017021112,0.00030111166,0.00009383322,0.00010176344,0.0000067939573,0.0009828475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988883,0.0005385222,0.00009534466,0.000066593806,0.0002549675,0.00015630135],"domain_scores_gemma":[0.9991749,0.0004044694,0.00020087484,0.000028746057,0.00013788084,0.000053107586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037230863,0.00045077232,0.0008174096,0.0015593605,0.00034084113,0.001372959,0.00079016073,0.00089242595,0.0021280411],"category_scores_gemma":[0.0030074867,0.000194693,0.0007896643,0.0029750483,0.0011730911,0.0016355367,0.0010236625,0.00077407464,0.000098662276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031137478,0.00011457199,0.0053676385,0.035797227,0.0005860625,0.00030907308,0.00047565027,0.013393386,0.0009776995,0.16536276,0.014788067,0.76251644],"study_design_scores_gemma":[0.0008470653,0.001249347,0.100388356,0.06066073,0.0017788776,0.001188587,0.0010973873,0.015761342,0.0029166276,0.0767617,0.7371124,0.00023761463],"about_ca_topic_score_codex":0.030586066,"about_ca_topic_score_gemma":0.02807389,"teacher_disagreement_score":0.030586066,"about_ca_system_score_codex":0.005039015,"about_ca_system_score_gemma":0.015893469,"threshold_uncertainty_score":0.06081605},"labels":[],"label_agreement":null},{"id":"W4385330768","doi":"10.1001/jama.2023.13872","title":"Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists","year":2023,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Arnold Ventures; West Virginia University; National Heart, Lung, and Blood Institute; Gilead Sciences","keywords":"Medicine; Food and drug administration; Drug approval; Pharmacology; Drug","score_opus":0.07064725726388224,"score_gpt":0.2768829414632664,"score_spread":0.20623568419938418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385330768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41008803,0.35050768,0.004703655,0.009676033,0.0006616449,0.0011194776,0.09932661,0.00024110565,0.12367586],"genre_scores_gemma":[0.9093052,0.05715601,0.0024462505,0.002940864,0.0008029297,0.000815474,0.022026202,0.000049152557,0.0044578477],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.97419816,0.0050616213,0.005825029,0.002907866,0.011011362,0.0009960504],"domain_scores_gemma":[0.80158025,0.07931612,0.10762272,0.0022489629,0.008239847,0.0009920751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013989071,0.0004047523,0.00059955585,0.006861253,0.0006726505,0.0022684247,0.0009647433,0.0011890392,0.013550736],"category_scores_gemma":[0.077414066,0.00026052553,0.0023666315,0.010507274,0.00095042743,0.0030939556,0.0013416818,0.0013467696,0.0010242396],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030049293,0.0002262278,0.5002552,0.030529153,0.0028097627,0.0021683483,0.0013565399,0.001767973,0.001620805,0.01589889,0.051010054,0.38935205],"study_design_scores_gemma":[0.00048766405,0.0012232807,0.7178624,0.018943118,0.003988613,0.007120891,0.001430119,0.0009799894,0.002812267,0.0037707342,0.24123752,0.00014327189],"about_ca_topic_score_codex":0.003861452,"about_ca_topic_score_gemma":0.004356047,"teacher_disagreement_score":0.013989071,"about_ca_system_score_codex":0.0016644069,"about_ca_system_score_gemma":0.0033748269,"threshold_uncertainty_score":0.07398218},"labels":[],"label_agreement":null},{"id":"W4385600166","doi":"10.59962/9780774829212","title":"When Good Drugs Go Bad","year":2015,"lang":"en","type":"book","venue":"University of British Columbia Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.0369789116063117,"score_gpt":0.20661030923766546,"score_spread":0.16963139763135376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385600166","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022912384,0.1025838,0.00057524676,0.22284347,0.013493031,0.0000526307,0.00044882417,0.00021235432,0.65749943],"genre_scores_gemma":[0.048355624,0.09580698,0.0008297519,0.2223272,0.0065469304,0.00007138754,0.0004565486,0.00026374465,0.62534195],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798137,0.0003223603,0.00006948386,0.0001899899,0.00084152684,0.0005952524],"domain_scores_gemma":[0.9988054,0.00027355168,0.00009199889,0.00010241209,0.0003945142,0.00033210646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010737272,0.00069747586,0.0007932981,0.0017932799,0.0072040423,0.011391818,0.00077711313,0.0051689595,0.04556576],"category_scores_gemma":[0.0050900923,0.00048972847,0.00044086235,0.0016102092,0.009185076,0.009243688,0.0036063024,0.009216543,0.018912492],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047452188,0.00004760457,0.00087610626,0.00023320639,0.0000149796715,0.00030807737,0.0024998372,0.000049482325,0.00021038725,0.15523617,0.74220467,0.09827206],"study_design_scores_gemma":[0.000006736053,0.00001171239,0.0005556916,0.00029765238,0.000005591536,0.00020529369,0.0011128368,0.000015564876,0.000059363632,0.019117724,0.97860193,0.000009977302],"about_ca_topic_score_codex":0.055452168,"about_ca_topic_score_gemma":0.111665726,"teacher_disagreement_score":0.055452168,"about_ca_system_score_codex":0.008311532,"about_ca_system_score_gemma":0.01060297,"threshold_uncertainty_score":0.15243262},"labels":[],"label_agreement":null},{"id":"W4385712134","doi":"10.2139/ssrn.4524999","title":"Revisiting Canada’s Access to Medicines Regime in Response to COVID-19: A Review of the Legislation and its Underlying Objectives","year":2023,"lang":"en","type":"review","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Political science; Business; Medicine; Law and economics; Virology; Law; Economics; Outbreak; Infectious disease (medical specialty)","score_opus":0.17228192262712638,"score_gpt":0.4173108091332957,"score_spread":0.24502888650616933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385712134","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011882114,0.9368398,0.0002894188,0.03872142,0.0017634629,0.00016840888,0.0019030313,0.000042538828,0.019083686],"genre_scores_gemma":[0.021026695,0.9264775,0.0019853336,0.042034324,0.0012508279,0.0001378103,0.0009816376,0.000039517072,0.0060663815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99171036,0.00084651035,0.00063824106,0.0004160392,0.0051328177,0.0012560079],"domain_scores_gemma":[0.98007935,0.0052559213,0.0018860747,0.00034625272,0.010796537,0.0016358645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012412428,0.00079762476,0.0021368454,0.006227634,0.001978853,0.005726686,0.0031988306,0.0043142536,0.00534606],"category_scores_gemma":[0.024747767,0.00062354724,0.0014907137,0.009026765,0.0029538178,0.0017219171,0.001549607,0.0056633553,0.00065545546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023724139,0.00016642456,0.0022855734,0.03099693,0.00052594364,0.00027591517,0.00052338257,0.0018130993,0.0009344404,0.08527986,0.29862744,0.57833374],"study_design_scores_gemma":[0.00006716706,0.000055478205,0.007893955,0.020399807,0.00026589644,0.0000815099,0.00012940605,0.00017985176,0.00037825436,0.0020403143,0.96844906,0.000059276306],"about_ca_topic_score_codex":0.9050211,"about_ca_topic_score_gemma":0.9516244,"teacher_disagreement_score":0.09497893,"about_ca_system_score_codex":0.072863385,"about_ca_system_score_gemma":0.30102023,"threshold_uncertainty_score":0.52866334},"labels":[],"label_agreement":null},{"id":"W4385799063","doi":"10.1177/27551938231195434","title":"Canada and the pharmaceutical industry in the time of COVID-19","year":2023,"lang":"en","type":"article","venue":"International Journal of Social Determinants of Health and Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Government (linguistics); Intellectual property; Coronavirus disease 2019 (COVID-19); Waiver; Business; Pandemic; Pharmaceutical industry; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Economic growth; International trade; Political science; Medicine; Economics; Virology; Law","score_opus":0.09653762858303372,"score_gpt":0.42031398331893055,"score_spread":0.32377635473589683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385799063","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024334919,0.017781252,0.0006216902,0.82705694,0.0031531174,0.000051600302,0.0006893478,0.00003265816,0.1262784],"genre_scores_gemma":[0.6435945,0.024115752,0.0014309416,0.23106796,0.0020819732,0.000044887987,0.00043542273,0.00007259496,0.09715606],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9898372,0.001024411,0.0002019932,0.00069379597,0.0040250146,0.004217521],"domain_scores_gemma":[0.9850445,0.0030160656,0.00092029426,0.00024353077,0.004909809,0.005865852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005082368,0.0003710551,0.0006167952,0.002015187,0.014285626,0.013980648,0.0009268178,0.009221282,0.010821572],"category_scores_gemma":[0.016745064,0.0005704497,0.00051359116,0.0036544828,0.011532274,0.0035265791,0.00294329,0.011017898,0.0005838719],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003637519,0.00006659229,0.015520043,0.0002143102,0.00008105808,0.0011970215,0.004454563,0.00092812435,0.00040149913,0.69157666,0.24776863,0.037427694],"study_design_scores_gemma":[0.00009134711,0.000048289567,0.021904781,0.00047971017,0.000046002224,0.00019298481,0.006575434,0.00054481573,0.0003211174,0.024108138,0.94555867,0.00012875597],"about_ca_topic_score_codex":0.98180294,"about_ca_topic_score_gemma":0.98652005,"teacher_disagreement_score":0.8086274,"about_ca_system_score_codex":0.19137257,"about_ca_system_score_gemma":0.2365045,"threshold_uncertainty_score":0.9378932},"labels":[],"label_agreement":null},{"id":"W4385811185","doi":"10.1021/cen-10126-buscon3","title":"Sygnature acquires NuChem","year":2023,"lang":"en","type":"article","venue":"C&EN Global Enterprise","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Management; Marketing; Economics","score_opus":0.030960350725625047,"score_gpt":0.2937015129826314,"score_spread":0.2627411622570064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385811185","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004503908,0.0019105506,0.00068749615,0.018015185,0.002060335,0.00018156652,0.004156747,0.0020443772,0.9664396],"genre_scores_gemma":[0.018744057,0.0012193521,0.0004677728,0.0045078574,0.0005225855,0.00004647837,0.0034162176,0.0002726576,0.970803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989172,0.00005815739,0.000031899363,0.00016894362,0.000632766,0.00019095972],"domain_scores_gemma":[0.99712604,0.00018314311,0.00016232622,0.00021570787,0.0009995732,0.0013131902],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008902755,0.0005719616,0.0005345973,0.0013566589,0.0022079959,0.0036652703,0.0006514678,0.0020176722,0.4440821],"category_scores_gemma":[0.0037595977,0.00030970626,0.00033475918,0.0008936734,0.00063283043,0.0016604846,0.0012422416,0.0016117946,0.20679308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006943032,0.000039878734,0.0008762247,0.000054541877,0.0000034700035,0.00029845256,0.000042279262,0.000039781,0.00060138025,0.007385705,0.94971913,0.040869825],"study_design_scores_gemma":[0.00001884776,0.000030888797,0.0012160103,0.00003503462,0.0000027822673,0.0002479289,0.000041171967,0.000118167,0.00033285446,0.00045961278,0.997489,0.000007764158],"about_ca_topic_score_codex":0.039767582,"about_ca_topic_score_gemma":0.085416816,"teacher_disagreement_score":0.4440821,"about_ca_system_score_codex":0.004448215,"about_ca_system_score_gemma":0.010906648,"threshold_uncertainty_score":0.7929494},"labels":[],"label_agreement":null},{"id":"W4386014965","doi":"10.5267/j.ijdns.2023.7.016","title":"Balancing quality, cost, and uncertainty in pharmaceutical supply chain: A robust possibilistic flexible programming approach","year":2023,"lang":"en","type":"article","venue":"International Journal of Data and Network Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Supply chain; Robustness (evolution); Computer science; Risk analysis (engineering); Quality (philosophy); Compromise; Operations research; Supply chain management; Key (lock); Supply chain risk management; Management science; Service management; Engineering; Business","score_opus":0.20755897052586952,"score_gpt":0.40705098369067055,"score_spread":0.19949201316480103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386014965","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025487076,0.00067465246,0.9662841,0.00085961184,0.000033906297,0.000118743,0.00012496534,0.00008028887,0.006336655],"genre_scores_gemma":[0.87230605,0.0010193004,0.12276675,0.00016947207,0.00006566043,0.0004385115,0.00014400612,0.00004941466,0.0030409135],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975036,0.0014368152,0.00007702119,0.00027409993,0.00045517177,0.00025329026],"domain_scores_gemma":[0.99562657,0.0033886875,0.0004228473,0.00009547345,0.00033924088,0.00012717507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00456526,0.0017184396,0.0014837628,0.0019057029,0.0010043541,0.0034807238,0.0022450832,0.0028252043,0.0024382458],"category_scores_gemma":[0.0076639517,0.0013063474,0.0019407183,0.0021229489,0.0016481087,0.002521604,0.002382704,0.0023273872,0.00017182187],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015631917,0.000014248124,0.00015432033,0.000034435525,0.000025351626,0.000056754223,0.000020363806,0.98867655,0.000110551555,0.0087014185,0.000099778095,0.0020907158],"study_design_scores_gemma":[0.000004460945,0.00001153639,0.00004761115,0.000008922515,0.000009481922,0.000009487575,0.000013083518,0.9917076,0.000057882753,0.007984766,0.00013950562,0.00000561496],"about_ca_topic_score_codex":0.012559258,"about_ca_topic_score_gemma":0.007049465,"teacher_disagreement_score":0.012559258,"about_ca_system_score_codex":0.0030602596,"about_ca_system_score_gemma":0.0033859292,"threshold_uncertainty_score":0.02497232},"labels":[],"label_agreement":null},{"id":"W4386020454","doi":"10.11575/sppp.v15i1.74116","title":"Innovation in the United States Health-Care System’s Organization and Delivery","year":2022,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Health care delivery; Business; Delivery system; Health care; Medicine; Economic growth; Economics","score_opus":0.2832983419416387,"score_gpt":0.4974444714562654,"score_spread":0.2141461295146267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386020454","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022541454,0.018548388,0.009175195,0.7001139,0.010863484,0.00020258153,0.0004508908,0.00047512737,0.23762898],"genre_scores_gemma":[0.56590354,0.029726747,0.040600613,0.24880306,0.009325732,0.00069520273,0.00092575094,0.00018389523,0.10383541],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99018914,0.0029152592,0.0006103598,0.0011049486,0.003373903,0.0018063266],"domain_scores_gemma":[0.9879583,0.0030976664,0.0008211707,0.0010804456,0.0034432535,0.0035991748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011942944,0.00035158303,0.00030684716,0.0012018541,0.0033940035,0.0074854107,0.00087654573,0.005616805,0.009780449],"category_scores_gemma":[0.014393574,0.0002640112,0.00089451426,0.0015700706,0.0041909353,0.004388843,0.004630731,0.005540721,0.0012035335],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004122674,0.00019607387,0.0055239317,0.00012443036,0.00004060109,0.00012362521,0.0013805291,0.0010440656,0.00031161643,0.5638485,0.23755863,0.18980682],"study_design_scores_gemma":[0.00008811932,0.00027940268,0.009032756,0.000788261,0.00003268918,0.00012087474,0.0009892029,0.0012240466,0.00022887629,0.06310087,0.9240343,0.00008057048],"about_ca_topic_score_codex":0.057991233,"about_ca_topic_score_gemma":0.049279284,"teacher_disagreement_score":0.057991233,"about_ca_system_score_codex":0.015643708,"about_ca_system_score_gemma":0.04845184,"threshold_uncertainty_score":0.11530739},"labels":[],"label_agreement":null},{"id":"W4386158489","doi":"10.1016/j.healthpol.2023.104901","title":"Therapeutic value of new medicines not submitted to Health Canada 2014-2021: Cross-sectional study","year":2023,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Medicine; Alternative medicine; Food and drug administration; Value (mathematics); Family medicine; Environmental health","score_opus":0.1520727065641252,"score_gpt":0.43020886283504717,"score_spread":0.278136156270922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386158489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679312,0.0029846905,0.00020323068,0.0018559992,0.00007693687,0.000070257694,0.02299734,0.000025446669,0.0038548282],"genre_scores_gemma":[0.9866269,0.0008798305,0.00008991583,0.0004577788,0.000096663054,0.000037244332,0.009015992,0.0000113616525,0.0027843327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994557,0.0011464201,0.00063288066,0.0008709,0.0014231289,0.0013697562],"domain_scores_gemma":[0.9549397,0.011321667,0.022965074,0.001227782,0.004145298,0.0054004746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038675866,0.00039072323,0.00089418265,0.0030655118,0.0009808891,0.0028528625,0.0017636325,0.002712287,0.0062380894],"category_scores_gemma":[0.023592351,0.0006601445,0.0021484739,0.0055445377,0.0009989333,0.0015410555,0.0012804235,0.0036428184,0.0007958429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007446742,0.0003555925,0.99408156,0.000035633744,0.00056743587,0.00005151288,0.000076696015,0.00047195182,0.000045032943,0.00025065028,0.0017392042,0.0015801932],"study_design_scores_gemma":[0.00003409214,0.00021582989,0.9966127,0.000025232748,0.0003171892,0.00008409945,0.00023706582,0.0008942421,0.00008631455,0.0001010035,0.0013693097,0.000022927705],"about_ca_topic_score_codex":0.49059528,"about_ca_topic_score_gemma":0.39061505,"teacher_disagreement_score":0.99159473,"about_ca_system_score_codex":0.008405256,"about_ca_system_score_gemma":0.007433666,"threshold_uncertainty_score":0.9754794},"labels":[],"label_agreement":null},{"id":"W4386444416","doi":"10.1136/bmj-2023-076783","title":"Essential medicines lists are for high income countries too","year":2023,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Business; Traditional medicine; Medicine","score_opus":0.037359651623008465,"score_gpt":0.3385627885716187,"score_spread":0.30120313694861023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386444416","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017246528,0.003709453,0.000116605566,0.03827712,0.95410806,0.000047042733,0.00016910184,0.000087353685,0.0034679847],"genre_scores_gemma":[0.00028760126,0.005374736,0.0002503226,0.035954632,0.93732786,0.000091932605,0.00012210004,0.00009837003,0.020492457],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9814995,0.0034922056,0.002066698,0.001156437,0.010936508,0.00084863993],"domain_scores_gemma":[0.91673964,0.041993435,0.0059996666,0.002463496,0.025311545,0.007492199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019436698,0.0075283633,0.008829639,0.00975932,0.0046008728,0.019188588,0.0051506558,0.029796347,0.059524596],"category_scores_gemma":[0.09128663,0.0028387792,0.0054334947,0.0060590613,0.004182252,0.008825004,0.0026882386,0.03501294,0.040074617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025565014,0.00001162174,0.000009109611,0.00023541522,0.000020640093,0.000026353351,0.000005891656,0.000012090381,0.000017297443,0.00027435875,0.9965648,0.002796733],"study_design_scores_gemma":[0.00026389348,0.00003480779,0.00022924138,0.0009540536,0.00011914479,0.000054190536,0.00004156902,0.00014510246,0.00004957598,0.0018543751,0.99622536,0.00002873959],"about_ca_topic_score_codex":0.0061369836,"about_ca_topic_score_gemma":0.018716525,"teacher_disagreement_score":0.059524596,"about_ca_system_score_codex":0.0065315748,"about_ca_system_score_gemma":0.008999078,"threshold_uncertainty_score":0.19912958},"labels":[],"label_agreement":null},{"id":"W4386459882","doi":"10.1503/cmaj.230339-f","title":"Le Canada manque-t-il le bateau? Un inventaire des médicaments approuvés à l’international entre 2016 et 2020 qui n’ont pas été soumis à Santé Canada","year":2023,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BP (Canada); University of Toronto","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.016681296520231374,"score_gpt":0.2409230604027202,"score_spread":0.22424176388248884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386459882","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012280119,0.12408287,0.0039316737,0.7212783,0.008514403,0.00013440456,0.008234902,0.00022633006,0.12131702],"genre_scores_gemma":[0.40902525,0.24139467,0.015949825,0.16205595,0.0085213985,0.00027722638,0.005848275,0.0004568224,0.15647066],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99443203,0.00078204094,0.00016877342,0.00042044357,0.0033135356,0.00088311365],"domain_scores_gemma":[0.9840538,0.0028643932,0.0011914597,0.000388353,0.008192138,0.0033098725],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054436005,0.00045064258,0.0008626575,0.00222637,0.0031635873,0.009062691,0.0013032772,0.0030611865,0.02485597],"category_scores_gemma":[0.020345768,0.00033338205,0.0006902809,0.004752901,0.0034952909,0.0035672144,0.0012499266,0.005252318,0.0028884066],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006068147,0.0000811824,0.019263772,0.0011603595,0.00020979819,0.00020600812,0.00079469127,0.0007848282,0.00059551507,0.1881726,0.5700153,0.21810912],"study_design_scores_gemma":[0.00011016214,0.00011123674,0.016248902,0.0023064401,0.0001647532,0.00023304451,0.0009724042,0.001099592,0.00068897,0.011737692,0.9662298,0.00009699974],"about_ca_topic_score_codex":0.8735391,"about_ca_topic_score_gemma":0.90698075,"teacher_disagreement_score":0.9945564,"about_ca_system_score_codex":0.048142713,"about_ca_system_score_gemma":0.13912866,"threshold_uncertainty_score":0.34930152},"labels":[],"label_agreement":null},{"id":"W4386802621","doi":"10.1080/17441692.2023.2256822","title":"Can we move beyond vaccine apartheid? Examining the determinants of the COVID-19 vaccine gap","year":2023,"lang":"en","type":"article","venue":"Global Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Waiver; Global health; Health equity; Intellectual property; Political science; Right to health; Treaty; Public health; Economic growth; Social determinants of health; International Health Regulations; Pandemic; Business; Development economics; Coronavirus disease 2019 (COVID-19); Economics; Health care; Medicine; Infectious disease (medical specialty); Law","score_opus":0.17815326601026643,"score_gpt":0.36392277040081156,"score_spread":0.18576950439054513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386802621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5514061,0.011451688,0.002846622,0.37195745,0.00046701584,0.00007212749,0.0005698253,0.000034190718,0.061194997],"genre_scores_gemma":[0.99054855,0.0016438364,0.00036812937,0.0059408536,0.000115616036,0.0000410353,0.000074803174,0.00002387654,0.001243322],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9949431,0.0017878392,0.00012579272,0.0004206047,0.0007242061,0.0019984131],"domain_scores_gemma":[0.98249626,0.008958116,0.004147106,0.0005159757,0.0012933753,0.0025891853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005793887,0.00031667502,0.0006387672,0.0012836196,0.0026298424,0.0054887384,0.0012792563,0.0017534666,0.01224485],"category_scores_gemma":[0.026001917,0.00020608776,0.00057816063,0.0020736952,0.00463118,0.014821362,0.0072043287,0.005789074,0.00063379767],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003046234,0.0005754225,0.27485758,0.0007582658,0.00015871848,0.0009337789,0.037173927,0.0017879312,0.00068422256,0.53375584,0.030885197,0.11812458],"study_design_scores_gemma":[0.000051429583,0.00043200902,0.3165041,0.0025141025,0.00020519733,0.00046006156,0.1505867,0.00465943,0.0012402238,0.3368306,0.18640707,0.00010910863],"about_ca_topic_score_codex":0.014740769,"about_ca_topic_score_gemma":0.01362329,"teacher_disagreement_score":0.014740769,"about_ca_system_score_codex":0.003631786,"about_ca_system_score_gemma":0.010005948,"threshold_uncertainty_score":0.040963113},"labels":[],"label_agreement":null},{"id":"W4386810205","doi":"10.1007/s40278-023-46020-2","title":"Unauthorised health products seized in Canada pose health risks","year":2023,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Health risk; Environmental health; Business; Risk analysis (engineering); Medicine","score_opus":0.17403334397051054,"score_gpt":0.35339055990986845,"score_spread":0.1793572159393579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386810205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5217062,0.01415272,0.0017096878,0.2011154,0.0015957524,0.00016954796,0.015911713,0.00022869784,0.24341033],"genre_scores_gemma":[0.92131084,0.0047277054,0.0003368332,0.0050605303,0.00023346857,0.000009652744,0.0009439662,0.000031387954,0.06734558],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974246,0.00019804321,0.000058515674,0.00009957108,0.0015085686,0.00071082305],"domain_scores_gemma":[0.9927527,0.0014274131,0.0015918607,0.00017016199,0.0025446196,0.0015132624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014433084,0.00022923663,0.00020741939,0.0014811271,0.0021220066,0.0057954886,0.00055446033,0.002488024,0.011412092],"category_scores_gemma":[0.00824455,0.00027986415,0.00043898885,0.0020086935,0.0014363773,0.0009623913,0.00063131173,0.0033842304,0.00061170367],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013407455,0.0003908324,0.2580938,0.00048811603,0.0002660849,0.0017369426,0.0019673428,0.009828577,0.002147105,0.15442756,0.4728958,0.09641715],"study_design_scores_gemma":[0.00022428394,0.00024586395,0.48081356,0.0004868074,0.00028087813,0.00056976924,0.0084943,0.013631895,0.0038828964,0.018359795,0.47278365,0.00022631492],"about_ca_topic_score_codex":0.98341805,"about_ca_topic_score_gemma":0.9881847,"teacher_disagreement_score":0.052127518,"about_ca_system_score_codex":0.052127518,"about_ca_system_score_gemma":0.060925268,"threshold_uncertainty_score":0.3782134},"labels":[],"label_agreement":null},{"id":"W4386915635","doi":"10.2139/ssrn.4565049","title":"Repositioning Generic Drugs: Empirical Findings and Policy Implications","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Business","score_opus":0.05022915073974444,"score_gpt":0.32727096795832034,"score_spread":0.2770418172185759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386915635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82760894,0.04570756,0.0019634378,0.045017086,0.0006658746,0.00015777403,0.0028612365,0.000120509074,0.07589749],"genre_scores_gemma":[0.983102,0.010317469,0.00031089244,0.0014372376,0.00048421498,0.000012700698,0.00042583537,0.000011498136,0.0038981023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636453,0.0012406076,0.00037077724,0.00053023477,0.0007756893,0.0007181195],"domain_scores_gemma":[0.90630054,0.05901974,0.025109759,0.0027898997,0.0037309777,0.0030491224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005428712,0.00054992846,0.0013260142,0.0026483373,0.0007322413,0.006306067,0.0013593297,0.0033431342,0.020019433],"category_scores_gemma":[0.03301782,0.00032047878,0.0012891901,0.0038057233,0.0034053205,0.004008947,0.0011647602,0.0034849523,0.0010134976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005953313,0.0042752316,0.529707,0.0022236158,0.001371462,0.002786043,0.001502236,0.018149298,0.0030291688,0.13382874,0.02748134,0.26969254],"study_design_scores_gemma":[0.0012678467,0.0027083147,0.80078024,0.0016629412,0.0025230837,0.0018751833,0.009595936,0.020706516,0.005778076,0.0866709,0.06622435,0.00020651],"about_ca_topic_score_codex":0.022518435,"about_ca_topic_score_gemma":0.02824915,"teacher_disagreement_score":0.022518435,"about_ca_system_score_codex":0.0044360682,"about_ca_system_score_gemma":0.0041058874,"threshold_uncertainty_score":0.06697172},"labels":[],"label_agreement":null},{"id":"W4386997187","doi":"10.22270/ijdra.v11i3.613","title":"Similarities and differences in filing for Drug Master File in US, Canada and Europe","year":2023,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Sleep Medicine Foundation","keywords":"Discretion; Confidentiality; Business; Database; Computer science; Law; Computer security; Political science","score_opus":0.037005608732142564,"score_gpt":0.24562269380943796,"score_spread":0.2086170850772954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386997187","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20886211,0.015292943,0.005633248,0.02558064,0.0020724903,0.0014207884,0.043512445,0.0014419483,0.69618344],"genre_scores_gemma":[0.75931215,0.01527273,0.00963596,0.008831093,0.00028843427,0.00056367606,0.036803953,0.0016697482,0.16762216],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97575015,0.0012960025,0.0016394097,0.0015050627,0.013545106,0.0062643075],"domain_scores_gemma":[0.93074733,0.006815872,0.0031265821,0.0021474436,0.050959025,0.00620375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009760354,0.00044985264,0.0008973309,0.015628397,0.00639365,0.010542373,0.0030148216,0.0012365445,0.023221571],"category_scores_gemma":[0.059387185,0.0005578841,0.0011091491,0.019683009,0.0022359479,0.0023785715,0.0023436218,0.002511774,0.0035049936],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088721514,0.00027384277,0.12188656,0.0009990755,0.00024182737,0.0011302595,0.01149159,0.0026267115,0.0015903955,0.26268244,0.3689482,0.22724192],"study_design_scores_gemma":[0.00006791773,0.00008022141,0.5169398,0.0011785517,0.00007574818,0.0004409023,0.011284559,0.0008513147,0.0010785679,0.0025120382,0.46529016,0.0002002763],"about_ca_topic_score_codex":0.9689812,"about_ca_topic_score_gemma":0.970901,"teacher_disagreement_score":0.06776715,"about_ca_system_score_codex":0.06776715,"about_ca_system_score_gemma":0.10955436,"threshold_uncertainty_score":0.49168742},"labels":[],"label_agreement":null},{"id":"W4387122640","doi":"10.18357/anthropologica65120232605","title":"In Shortage: Understanding Global Antibiotic Supply Chains Through Pharmaceutical Trade Fairs","year":2023,"lang":"en","type":"article","venue":"Anthropologica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; University of Toronto","funders":"Norges Forskningsråd; Universitetet i Oslo","keywords":"Supply chain; Business; Economic shortage; Government (linguistics); China; Pharmaceutical industry; Industrial organization; Marketing; Medicine; Political science; Law","score_opus":0.2098393832347273,"score_gpt":0.3869765093128333,"score_spread":0.17713712607810597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387122640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73720443,0.003618323,0.026730599,0.034627218,0.0001749766,0.00014927625,0.00049740175,0.000072141236,0.1969257],"genre_scores_gemma":[0.9931378,0.0014969311,0.002080362,0.0004900231,0.000040552677,0.000026672464,0.00007324739,0.000012657009,0.0026416485],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99936515,0.00030698115,0.000019471001,0.00008124648,0.00006400987,0.00016326926],"domain_scores_gemma":[0.9960452,0.002032174,0.0011099817,0.00028029425,0.00024840797,0.00028391814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027388781,0.00031905025,0.00024881156,0.003502814,0.0028411408,0.00585148,0.00063505897,0.0014750247,0.011277255],"category_scores_gemma":[0.0066451123,0.00021836424,0.00032047115,0.0038681359,0.008039262,0.01803639,0.0044667767,0.0014743683,0.000277391],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007035482,0.00010482776,0.059153467,0.00019330194,0.000022126853,0.00096010056,0.048036512,0.004654134,0.00028932202,0.8350478,0.0038460998,0.04762198],"study_design_scores_gemma":[0.000023472685,0.0000886866,0.040060546,0.00059065135,0.000025935899,0.00025011634,0.10064658,0.007639068,0.00036698903,0.7617942,0.08847705,0.00003673975],"about_ca_topic_score_codex":0.010635984,"about_ca_topic_score_gemma":0.009883784,"teacher_disagreement_score":0.011277255,"about_ca_system_score_codex":0.004072,"about_ca_system_score_gemma":0.0020879393,"threshold_uncertainty_score":0.037726164},"labels":[],"label_agreement":null},{"id":"W4387259703","doi":"10.32983/2222-4459-2023-8-23-29","title":"The USA in the Global Pharmaceutical Market: The Current State and Development Prospects","year":2023,"lang":"en","type":"article","venue":"Business Inform","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Kementerian Pendidikan Nasional","keywords":"Pharmaceutical industry; Business; Pharmaceutical manufacturing; China; Capitalization; International trade; Political science; Biotechnology; Medicine; Law","score_opus":0.0943428840544055,"score_gpt":0.33530939012227207,"score_spread":0.24096650606786657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387259703","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0145021705,0.7072813,0.002196551,0.13481414,0.0047479086,0.000037448888,0.0004986673,0.00017014626,0.1357517],"genre_scores_gemma":[0.1617487,0.7862135,0.0053063435,0.023130896,0.004098501,0.000051704963,0.0005606618,0.000053833148,0.018835846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99910897,0.00021011627,0.00005780446,0.000110445704,0.00031164035,0.00020103848],"domain_scores_gemma":[0.9971103,0.0009358179,0.0004314285,0.00007077774,0.0007478476,0.0007037234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002452279,0.000392293,0.00042265854,0.0021447977,0.0011309104,0.0077017453,0.00065390806,0.0028114629,0.016688842],"category_scores_gemma":[0.0022499645,0.00015512503,0.0005337201,0.003555932,0.0017739927,0.009166027,0.0019168613,0.0023112283,0.0026664394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013070769,0.00018964174,0.0049911155,0.0017788464,0.000023650988,0.0004387135,0.00050376233,0.0003669779,0.0010789218,0.19509391,0.09385488,0.7015489],"study_design_scores_gemma":[0.000014104257,0.00029361405,0.007950342,0.0019799368,0.00003479344,0.0009539879,0.0020932783,0.00066771184,0.00060487457,0.021222427,0.96414363,0.000041192096],"about_ca_topic_score_codex":0.0021722028,"about_ca_topic_score_gemma":0.0028333338,"teacher_disagreement_score":0.016688842,"about_ca_system_score_codex":0.002252503,"about_ca_system_score_gemma":0.00523033,"threshold_uncertainty_score":0.055829763},"labels":[],"label_agreement":null},{"id":"W4387300633","doi":"10.4212/cjhp.3400","title":"Development of a Provincial Hospital Drug Formulary from 12 Former Regional Health Authority Formularies: Methods of Alignment","year":2023,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Saskatchewan Health; Saskatchewan Health Authority","funders":"","keywords":"Formulary; Drug; Medicine; Business; Family medicine; Pharmacology","score_opus":0.08855982958662595,"score_gpt":0.3439521878237842,"score_spread":0.2553923582371582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387300633","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7506433,0.00021012995,0.14050579,0.0022927714,0.00010534726,0.0073204404,0.0045301085,0.0014415126,0.09295064],"genre_scores_gemma":[0.6742646,0.00012225058,0.3063867,0.00019893554,0.000015899148,0.0008826949,0.005133532,0.00032049467,0.012674871],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993622,0.002243063,0.00043857293,0.00075103965,0.002209089,0.000736212],"domain_scores_gemma":[0.9878051,0.001695992,0.0011614133,0.001383021,0.007154138,0.0008002888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063698813,0.0004560811,0.0004964349,0.0026889353,0.0019832142,0.0031250876,0.0012554952,0.0006067806,0.008728993],"category_scores_gemma":[0.021170953,0.0006405242,0.000512389,0.0059446944,0.0005730931,0.0014848405,0.003004,0.001123214,0.0013596857],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011549942,0.0017766809,0.14658797,0.00053402316,0.00012680491,0.00056547107,0.0069894483,0.029605059,0.021582916,0.029885866,0.013557334,0.74763346],"study_design_scores_gemma":[0.001321925,0.005854109,0.42472678,0.0005147166,0.00045875733,0.0005693,0.02381605,0.21969153,0.07610019,0.01221379,0.23445341,0.00027943455],"about_ca_topic_score_codex":0.17246549,"about_ca_topic_score_gemma":0.19459853,"teacher_disagreement_score":0.98792297,"about_ca_system_score_codex":0.012077026,"about_ca_system_score_gemma":0.044664532,"threshold_uncertainty_score":0.34292328},"labels":[],"label_agreement":null},{"id":"W4387489899","doi":"10.61093/hem.2023.3-05","title":"A global analysis of trade policies in antimicrobial medicines","year":2023,"lang":"en","type":"article","venue":"Health Economics and Management Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Protectionism; International trade; Tariff; Revenue; China; Business; Commercial policy; International economics; Trade barrier; Access to medicines; Economics; Developing country; Economic growth; Political science; Finance","score_opus":0.08565237065164412,"score_gpt":0.36695176725364137,"score_spread":0.28129939660199726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387489899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86381716,0.009680226,0.0043998947,0.0041226503,0.000063870204,0.000036539393,0.002457233,0.000039173876,0.11538334],"genre_scores_gemma":[0.99074346,0.004301002,0.00073648297,0.00029204998,0.000024173276,0.000013102197,0.000522225,0.000017795468,0.0033497734],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99959487,0.0001283281,0.000017161956,0.0000623786,0.00007949287,0.0001178362],"domain_scores_gemma":[0.99917054,0.00028631993,0.00033665204,0.000046325385,0.00010349962,0.000056684996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006663812,0.00025306587,0.00023970287,0.0020631892,0.0003267811,0.0019552994,0.00014085959,0.00048509636,0.0046128877],"category_scores_gemma":[0.0011723611,0.00014107156,0.0007886153,0.0050691166,0.0005919774,0.0016395827,0.0007907969,0.00059786707,0.00019899766],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061181013,0.00018229001,0.31598994,0.000883142,0.00087983144,0.0018393309,0.0016646696,0.11919752,0.004345481,0.40956828,0.008854132,0.1359836],"study_design_scores_gemma":[0.00004213638,0.00041847906,0.74414915,0.00068544835,0.00055938103,0.001046825,0.007240468,0.038935553,0.002787645,0.079720736,0.124318466,0.000095754855],"about_ca_topic_score_codex":0.007177745,"about_ca_topic_score_gemma":0.007303718,"teacher_disagreement_score":0.007177745,"about_ca_system_score_codex":0.0019692136,"about_ca_system_score_gemma":0.0007735169,"threshold_uncertainty_score":0.0154316425},"labels":[],"label_agreement":null},{"id":"W4387603337","doi":"10.3389/fphar.2023.1153680","title":"Reimbursement decision-making system in Poland systematically compared to other countries","year":2023,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Agency (philosophy); Business; Specialty; Product (mathematics); Developed country; Grey literature; MEDLINE; Medicine; Actuarial science; Accounting; Health care; Family medicine; Economic growth; Environmental health; Political science; Economics","score_opus":0.08999092595789074,"score_gpt":0.384195768818402,"score_spread":0.2942048428605113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387603337","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95385575,0.029811477,0.0025175365,0.0022158537,0.00010888294,0.00042042433,0.0029795896,0.000021619548,0.00806881],"genre_scores_gemma":[0.99064857,0.005740001,0.0016355375,0.00032815858,0.000022093962,0.00018239657,0.0012234432,0.000010057647,0.00020969825],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9816682,0.008067968,0.004920181,0.0015566231,0.0024037063,0.0013834408],"domain_scores_gemma":[0.9814076,0.0071117366,0.008787712,0.00044480074,0.0016655572,0.0005826323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013203412,0.00034234027,0.0012999108,0.009581085,0.0006190835,0.0040673744,0.0005417466,0.00070042873,0.0017219229],"category_scores_gemma":[0.033291508,0.0004461867,0.0015684441,0.011611364,0.0010705079,0.0018668087,0.0025033026,0.0005605702,0.00014929859],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001892994,0.0002975314,0.8208329,0.011020686,0.003968338,0.0012706512,0.0055783447,0.0036459754,0.0004891654,0.011975346,0.003753018,0.13527504],"study_design_scores_gemma":[0.00046217386,0.0004972309,0.9419778,0.0082424255,0.0028203435,0.0017617879,0.010126181,0.00255637,0.00091366627,0.003801829,0.026722647,0.00011748685],"about_ca_topic_score_codex":0.007878772,"about_ca_topic_score_gemma":0.005553674,"teacher_disagreement_score":0.013203412,"about_ca_system_score_codex":0.0047738673,"about_ca_system_score_gemma":0.007369065,"threshold_uncertainty_score":0.06982714},"labels":[],"label_agreement":null},{"id":"W4387709855","doi":"10.1161/circoutcomes.123.010329","title":"Complex Picture of Prescription Drug Discount Programs and Out-of-Pocket Costs in Cardiovascular Disease","year":2023,"lang":"en","type":"letter","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Work & Health; Western University","funders":"","keywords":"Drug; Disease; Medical prescription; Prescription drug; Medicine; Intensive care medicine; Risk analysis (engineering); Business; Pharmacology; Internal medicine","score_opus":0.1554042076780597,"score_gpt":0.3223366822801893,"score_spread":0.1669324746021296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387709855","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004378306,0.0010864976,0.00024628156,0.990337,0.0010643541,0.000006167038,0.00027526912,0.0000068849286,0.0025993227],"genre_scores_gemma":[0.13435219,0.0027251288,0.0009536339,0.83072764,0.024748515,0.00004632646,0.0002142606,0.000046567202,0.0061857533],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9958197,0.002210868,0.00033764046,0.00042549445,0.0007687113,0.00043762106],"domain_scores_gemma":[0.9424055,0.048755016,0.0021846658,0.0010023633,0.002615674,0.0030367402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012629033,0.00034102803,0.0012500737,0.0010556737,0.0022916682,0.006760716,0.0016958403,0.026809884,0.008163411],"category_scores_gemma":[0.060977902,0.00074213854,0.0010161544,0.0014452464,0.0035890124,0.00840571,0.001968522,0.025198774,0.0013711936],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009081043,0.00028365932,0.02765265,0.0001861752,0.00028598367,0.0026867266,0.0015972655,0.0021543538,0.0005167828,0.13664638,0.77608943,0.050992496],"study_design_scores_gemma":[0.000788865,0.00021748354,0.07149287,0.0009223805,0.00030370688,0.0019945062,0.0062462385,0.016955696,0.00050438417,0.5678421,0.33231756,0.0004142084],"about_ca_topic_score_codex":0.038541466,"about_ca_topic_score_gemma":0.079715684,"teacher_disagreement_score":0.038541466,"about_ca_system_score_codex":0.0069115907,"about_ca_system_score_gemma":0.005609975,"threshold_uncertainty_score":0.07663429},"labels":[],"label_agreement":null},{"id":"W4388140755","doi":"10.53738/revmed.2023.19.848.2031","title":"Sommes-nous prêts à trouver le médicament qui guérit ?","year":2023,"lang":"fr","type":"editorial","venue":"Revue Médicale Suisse","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Gériatrie de Montréal","funders":"","keywords":"Physics","score_opus":0.04046216915727042,"score_gpt":0.28321336022061216,"score_spread":0.24275119106334175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388140755","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038061014,0.029429303,0.000089590525,0.23738033,0.7312244,0.000007379084,0.00004633631,0.000027877628,0.0017567158],"genre_scores_gemma":[0.000931794,0.011126104,0.00013210054,0.08336483,0.89456636,0.000020314246,0.000016350281,0.000034588465,0.009807602],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9898963,0.0031157108,0.00123866,0.0011961141,0.003873215,0.0006798787],"domain_scores_gemma":[0.9562138,0.028590504,0.0028131027,0.0010255075,0.008679919,0.0026771077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013591365,0.0030437922,0.004327769,0.0032891487,0.0034519027,0.010546821,0.00314869,0.040006887,0.016222639],"category_scores_gemma":[0.08039548,0.0011836624,0.0032260288,0.0018711328,0.0048072427,0.00767598,0.0016716415,0.03350559,0.008182614],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032225595,0.000010564708,0.00002493999,0.000248573,0.000033182183,0.00008419407,0.000027323178,0.000023158382,0.000026595995,0.0020774736,0.9924784,0.0049332753],"study_design_scores_gemma":[0.00007140253,0.00001981442,0.00020648834,0.00068894494,0.000055675104,0.00019655772,0.00006750598,0.000107333144,0.000053738713,0.003383019,0.99512166,0.000027830662],"about_ca_topic_score_codex":0.008219289,"about_ca_topic_score_gemma":0.016509872,"teacher_disagreement_score":0.040006887,"about_ca_system_score_codex":0.0063020736,"about_ca_system_score_gemma":0.0063749566,"threshold_uncertainty_score":0.07187885},"labels":[],"label_agreement":null},{"id":"W4388204217","doi":"10.1200/op.2023.19.11_suppl.149","title":"Who goes first? Patterns of cancer drug approvals across four major regulatory authorities: EMA, FDA, Health Canada, and PMDA.","year":2023,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"National Institutes of Health","keywords":"Medicine; Drug approval; Marketing authorization; Authorization; Drug; Regulatory agency; Cancer drugs; Regulatory science; Orphan drug; Pharmacology; Agency (philosophy); Food and drug administration; Public administration; Political science; Bioinformatics","score_opus":0.07314741834660451,"score_gpt":0.37649837883215,"score_spread":0.30335096048554544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388204217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723833,0.005482246,0.00071209256,0.0029014528,0.000040437197,0.0001631871,0.009292954,0.00006166383,0.00896259],"genre_scores_gemma":[0.9953564,0.00085646834,0.0005273585,0.00043556752,0.000026423055,0.000046832385,0.0018320886,0.000021634216,0.0008972022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99218893,0.001166434,0.0009559246,0.0018265275,0.002240801,0.0016214253],"domain_scores_gemma":[0.9506847,0.009321945,0.029478345,0.0013389335,0.00648156,0.0026944887],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051229005,0.0002087101,0.00043269873,0.0057773096,0.0010585402,0.001728379,0.0011821414,0.0009266139,0.0033589434],"category_scores_gemma":[0.017500414,0.00037809953,0.0008218407,0.007927311,0.001001304,0.0011382878,0.0013513177,0.0012843309,0.00056917337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016427394,0.000030024632,0.98633444,0.000071103925,0.00008286826,0.000113919305,0.00049923745,0.000093130075,0.00023586355,0.00041388083,0.0024728312,0.009488371],"study_design_scores_gemma":[0.000011814798,0.00003515829,0.99325883,0.000076501536,0.00004588751,0.0003077839,0.0012638438,0.00047672665,0.00028429978,0.00008604902,0.004137455,0.000015761143],"about_ca_topic_score_codex":0.2301987,"about_ca_topic_score_gemma":0.29661256,"teacher_disagreement_score":0.9948771,"about_ca_system_score_codex":0.005307078,"about_ca_system_score_gemma":0.0071552717,"threshold_uncertainty_score":0.45771754},"labels":[],"label_agreement":null},{"id":"W4388364365","doi":"10.1093/oso/9780195300956.003.0009","title":"Pricing Pharmaceuticals in a World Environment","year":2006,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Drug prices; Medical prescription; Pharmaceutical industry; Business; Political science; Public administration; Economics; Public economics; Medicine","score_opus":0.08465381535890906,"score_gpt":0.2776025955278644,"score_spread":0.19294878016895536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388364365","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037633732,0.008907957,0.0063609225,0.06493354,0.002358966,0.00007266071,0.0006640634,0.000102218255,0.8789659],"genre_scores_gemma":[0.8348845,0.011929625,0.008371379,0.032473788,0.0021736547,0.00009213018,0.00054071954,0.000113189526,0.10942104],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938705,0.0018441735,0.00020011395,0.00045075177,0.003003439,0.00063097867],"domain_scores_gemma":[0.99700767,0.0007483421,0.0004730574,0.00038257273,0.0011045696,0.00028380842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033766816,0.00026459104,0.00029133173,0.0014261852,0.0017695053,0.010963708,0.00046801142,0.002253296,0.012286353],"category_scores_gemma":[0.0055053094,0.00012355941,0.0003997777,0.002487651,0.0030026538,0.0038509674,0.0024190396,0.0024813807,0.0015841337],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004181566,0.000064125015,0.003934547,0.000086652406,0.000027572856,0.0002383929,0.0005130212,0.00088323094,0.0006799927,0.8953643,0.044401713,0.053764656],"study_design_scores_gemma":[0.00002135441,0.00014180764,0.008420648,0.00028065598,0.000029927276,0.0002792964,0.0016397904,0.0010836889,0.00089830265,0.12756085,0.85959864,0.000045105568],"about_ca_topic_score_codex":0.0078042983,"about_ca_topic_score_gemma":0.01070814,"teacher_disagreement_score":0.012286353,"about_ca_system_score_codex":0.0036036596,"about_ca_system_score_gemma":0.0049761957,"threshold_uncertainty_score":0.041101992},"labels":[],"label_agreement":null},{"id":"W4388573101","doi":"10.7189/jogh.13.04137","title":"The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian’s structure-process-outcome framework","year":2023,"lang":"en","type":"article","venue":"Journal of Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"University of Toronto; National Natural Science Foundation of China","keywords":"Outcome (game theory); Procurement; Process (computing); Business; Process management; Medicine; Computer science; Economics; Marketing","score_opus":0.10447860885336144,"score_gpt":0.42757986079761007,"score_spread":0.32310125194424866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388573101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95595986,0.01632236,0.0020012127,0.0008799401,0.000081807804,0.0009873817,0.0011797578,0.000014013081,0.022573616],"genre_scores_gemma":[0.9942807,0.0021789286,0.001710189,0.00022216489,0.000019000005,0.0003297845,0.00043781693,0.0000059962154,0.00081547716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9870411,0.0048942612,0.0006881164,0.001019844,0.0045003765,0.0018561663],"domain_scores_gemma":[0.9786466,0.009776021,0.0040192953,0.0009616192,0.005524514,0.0010719537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013013299,0.0008397451,0.0013390004,0.0054135094,0.0026735144,0.0025654559,0.0018150383,0.00097560696,0.0042896047],"category_scores_gemma":[0.027825432,0.00034917,0.0018620844,0.012422563,0.0032267724,0.0026261378,0.0024481171,0.0009888263,0.00013861987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004704432,0.0021378365,0.58414006,0.010968586,0.0037200216,0.0014763556,0.030028515,0.011760782,0.00084673305,0.14937383,0.007839703,0.19300309],"study_design_scores_gemma":[0.0004504154,0.002840503,0.91271925,0.0020606364,0.0037449484,0.00037631267,0.03272672,0.014709503,0.00075986335,0.0079005975,0.021301702,0.0004096699],"about_ca_topic_score_codex":0.82773,"about_ca_topic_score_gemma":0.78936595,"teacher_disagreement_score":0.9210073,"about_ca_system_score_codex":0.07899271,"about_ca_system_score_gemma":0.053374436,"threshold_uncertainty_score":0.5731349},"labels":[],"label_agreement":null},{"id":"W4388595568","doi":"10.1093/eurheartj/ehad655.2879","title":"Sex differences in incidence of self-reported adverse drug reactions after percutaneous coronary intervention","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina","funders":"","keywords":"Medicine; Percutaneous coronary intervention; Incidence (geometry); Conventional PCI; Odds ratio; Internal medicine; Acute coronary syndrome; Medical record; Cohort; Logistic regression; Pediatrics; Myocardial infarction","score_opus":0.0773156912344031,"score_gpt":0.30421478546780123,"score_spread":0.22689909423339813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388595568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980405,0.00050618657,0.000059253074,0.000026121763,0.000007650208,0.0000074378104,0.00065852824,0.0000044051017,0.0006899086],"genre_scores_gemma":[0.99937963,0.00008723271,0.000032323725,0.000011317516,0.000008804924,0.0000050201825,0.00033067624,0.0000012340641,0.00014368148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990226,0.00025938533,0.00016238731,0.00021289218,0.00023211734,0.00011054891],"domain_scores_gemma":[0.99502134,0.0010820456,0.002912935,0.0002802359,0.00035936345,0.00034396228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010271736,0.00014273122,0.00026491817,0.000722353,0.0001589272,0.0005084748,0.0002048457,0.00028921932,0.0027009773],"category_scores_gemma":[0.0035108295,0.00013791029,0.00047616966,0.0006326203,0.00014068307,0.00022892778,0.000245578,0.00029040856,0.00026643113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010888733,0.000015440768,0.9987835,0.000007671076,0.000042859254,0.000034679564,0.00002390993,0.000008371879,0.000052120995,0.000005405528,0.000041123734,0.000876082],"study_design_scores_gemma":[0.0000036696285,0.00006108161,0.99963284,0.0000035271562,0.000010936717,0.00014020602,0.00003053928,0.000037771693,0.0000266087,0.0000050233944,0.000046383517,0.0000014532311],"about_ca_topic_score_codex":0.0013472378,"about_ca_topic_score_gemma":0.0010732587,"teacher_disagreement_score":0.0027009773,"about_ca_system_score_codex":0.00012930467,"about_ca_system_score_gemma":0.00013419756,"threshold_uncertainty_score":0.0090357065},"labels":[],"label_agreement":null},{"id":"W4388682094","doi":"10.1177/10245294231210975","title":"Sick with “shareholder value”: US pharma’s financialized business model during the pandemic","year":2023,"lang":"en","type":"article","venue":"Competition & Change","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute for New Economic Thinking; Canadian Institute for Advanced Research","keywords":"Shareholder value; Shareholder; Business; Context (archaeology); Remuneration; Leverage (statistics); Argument (complex analysis); Economics; Finance; Corporate governance","score_opus":0.17579415078561544,"score_gpt":0.29735847495960993,"score_spread":0.12156432417399449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388682094","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24443689,0.0019298865,0.013857567,0.20735742,0.00048728744,0.00008616051,0.00012251135,0.00008703535,0.5316353],"genre_scores_gemma":[0.98271483,0.0003839639,0.00088779343,0.0089958785,0.00019894383,0.000031269214,0.000016484759,0.000019099909,0.0067517515],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99788433,0.00096997624,0.00003413209,0.00021808602,0.000325648,0.0005678008],"domain_scores_gemma":[0.9981912,0.00062075123,0.00026255826,0.00018750544,0.00020169724,0.0005363252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027081526,0.00028342148,0.00021243557,0.00082289043,0.0053259064,0.009738969,0.00073500065,0.0055131577,0.0053323265],"category_scores_gemma":[0.005084203,0.00019971389,0.0004457605,0.000574215,0.013051386,0.0075504347,0.004120523,0.005720485,0.00042116642],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030109444,0.000033387223,0.0011764454,0.0000052783357,0.000003083433,0.00021228434,0.002257178,0.0004056016,0.00019958348,0.98690444,0.00500515,0.0037675034],"study_design_scores_gemma":[0.00008210279,0.00011722564,0.005042909,0.00018432512,0.000015900012,0.00043792353,0.009797322,0.009201516,0.00056530035,0.86238194,0.11210118,0.00007238749],"about_ca_topic_score_codex":0.010607057,"about_ca_topic_score_gemma":0.00991719,"teacher_disagreement_score":0.010607057,"about_ca_system_score_codex":0.006066049,"about_ca_system_score_gemma":0.0036552434,"threshold_uncertainty_score":0.044012487},"labels":[],"label_agreement":null},{"id":"W4388723593","doi":"10.5731/pdajpst.2023.012850","title":"Worldwide Regulatory Reliance: Launching a Pilot on a Chemistry, Manufacturing, and Control Post Approval Change for a Vaccine","year":2023,"lang":"en","type":"article","venue":"PDA Journal of Pharmaceutical Science and Technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Timeline; Marketing authorization; Business; Authorization; Process (computing); Control (management); Process management; Medicine; Risk analysis (engineering); Computer science; Computer security","score_opus":0.06622890492828186,"score_gpt":0.31985040457497715,"score_spread":0.2536214996466953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388723593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7566957,0.0010507591,0.056270625,0.058663886,0.0024619948,0.019481514,0.0010936648,0.0035693147,0.10071259],"genre_scores_gemma":[0.8920368,0.0007937756,0.06333787,0.01564838,0.00040414702,0.0058252146,0.0013480062,0.00059240166,0.020013327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9734257,0.013611953,0.00090504775,0.0015656656,0.005739723,0.0047519174],"domain_scores_gemma":[0.94530314,0.018378144,0.0024653564,0.007036361,0.01667894,0.010137903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05427793,0.000937015,0.00043854967,0.0009909888,0.005732127,0.005867594,0.0024784212,0.0044071395,0.008666411],"category_scores_gemma":[0.057064813,0.0008155035,0.0012159756,0.00092489965,0.0039050388,0.0072355755,0.008069488,0.009313106,0.0032734585],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028074477,0.025941305,0.05768355,0.0021180653,0.00024245499,0.010183764,0.061899006,0.005956946,0.03483857,0.030756688,0.1461443,0.6214279],"study_design_scores_gemma":[0.0031318995,0.07817653,0.10631563,0.001376696,0.00031005996,0.0061831707,0.099069,0.010695891,0.03838105,0.020977518,0.6345676,0.00081493834],"about_ca_topic_score_codex":0.009201098,"about_ca_topic_score_gemma":0.015602517,"teacher_disagreement_score":0.05427793,"about_ca_system_score_codex":0.0046571917,"about_ca_system_score_gemma":0.019430224,"threshold_uncertainty_score":0.28705257},"labels":[],"label_agreement":null},{"id":"W4388729178","doi":"10.1371/journal.pmed.1004309","title":"Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019","year":2023,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Heart, Lung, and Blood Institute; West Virginia University; Arnold Ventures; Commonwealth Fund","keywords":"Medicine; Food and drug administration; Approved drug; Pharmacology; Business; Drug","score_opus":0.16312666031079368,"score_gpt":0.30623227175366174,"score_spread":0.14310561144286807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388729178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520927,0.0015317171,0.00018910908,0.00022791512,0.000019798823,0.00010624419,0.04432667,0.000015295713,0.0014907109],"genre_scores_gemma":[0.9629558,0.0008111571,0.00034327037,0.00025416756,0.000038260536,0.00023876193,0.03455093,0.00001651979,0.0007913208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99544346,0.00070364965,0.0011705292,0.0010368761,0.0009857558,0.00065976783],"domain_scores_gemma":[0.9730252,0.0043546776,0.017565846,0.0013835285,0.0024929983,0.0011776349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044872724,0.00033159903,0.00080209656,0.0035451117,0.0008551189,0.0017920663,0.001130878,0.0010962251,0.0035234655],"category_scores_gemma":[0.0144721195,0.00061873224,0.001515771,0.00721226,0.00041798246,0.0019242301,0.0013240662,0.0019312386,0.0011287142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005087448,0.00011021639,0.9963074,0.0000856242,0.00017569463,0.000059164508,0.00012598996,0.000083138184,0.000049944578,0.000057575562,0.0011821965,0.0012543313],"study_design_scores_gemma":[0.000039103794,0.00013511955,0.99732095,0.0000671703,0.00013071569,0.00019719475,0.00031240057,0.00032380104,0.000056400826,0.000025152425,0.0013783452,0.0000136062035],"about_ca_topic_score_codex":0.032078233,"about_ca_topic_score_gemma":0.032017127,"teacher_disagreement_score":0.032078233,"about_ca_system_score_codex":0.0016650852,"about_ca_system_score_gemma":0.001829091,"threshold_uncertainty_score":0.06378305},"labels":[],"label_agreement":null},{"id":"W4388835034","doi":"10.1001/jamainternmed.2023.6256","title":"Therapeutic Benefit From New Drugs From Pharmaceutical Companies","year":2023,"lang":"en","type":"letter","venue":"JAMA Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York University","funders":"","keywords":"Medicine; Otorhinolaryngology; Family medicine; Neurology; Psychiatry","score_opus":0.10819153057653096,"score_gpt":0.3272168631452734,"score_spread":0.2190253325687424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388835034","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001794051,0.0034347044,0.0003970934,0.7003911,0.011187382,0.000066876724,0.00035689716,0.00023433204,0.28213748],"genre_scores_gemma":[0.031450827,0.0035343624,0.00072168437,0.72774684,0.039831355,0.00015015932,0.0002348924,0.000115837436,0.19621406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717146,0.0005072241,0.00023142115,0.00026543927,0.0014244022,0.0004000134],"domain_scores_gemma":[0.9906906,0.0059277657,0.0004362681,0.00055414747,0.0011993449,0.0011919634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025352621,0.00048743805,0.0006538483,0.0008863309,0.0031009805,0.0041662063,0.0007483267,0.030982971,0.074671745],"category_scores_gemma":[0.029957537,0.0004132852,0.00096542604,0.001008027,0.0017797507,0.0034815676,0.001583351,0.012856544,0.039608452],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035908244,0.00004164897,0.00046026683,0.000049640694,0.000007335331,0.0007277862,0.000030061492,0.00006465149,0.0001027382,0.009266483,0.9737446,0.015468842],"study_design_scores_gemma":[0.00010238808,0.000050195787,0.0016824431,0.0002307331,0.000010981248,0.0013516633,0.000052451447,0.00039439107,0.00017432154,0.0099636605,0.9859676,0.00001920248],"about_ca_topic_score_codex":0.004152336,"about_ca_topic_score_gemma":0.009088726,"teacher_disagreement_score":0.074671745,"about_ca_system_score_codex":0.0035443387,"about_ca_system_score_gemma":0.005794,"threshold_uncertainty_score":0.24980187},"labels":[],"label_agreement":null},{"id":"W4388917607","doi":"10.5334/aogh.4151","title":"Improving Middle-Income Countries Access to Vaccines. A Blueprint to Overcome Current Challenges","year":2023,"lang":"en","type":"article","venue":"Annals of Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universitat Autònoma de Barcelona; University of Toronto; University of Washington; Florida International University","keywords":"Blueprint; Government (linguistics); Incentive; Business; Population; Economic growth; Public relations; Political science; Economics; Medicine; Environmental health; Engineering","score_opus":0.24258314271861117,"score_gpt":0.4428879483532788,"score_spread":0.20030480563466765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388917607","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03286576,0.01282888,0.08529291,0.7375271,0.0040376238,0.0008169478,0.00078545057,0.0014557767,0.124389604],"genre_scores_gemma":[0.44503373,0.017880967,0.31352457,0.16419916,0.001619059,0.0026108194,0.0018257265,0.0005611376,0.05274488],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9870151,0.0070549375,0.0004506964,0.0009564246,0.001657614,0.0028652449],"domain_scores_gemma":[0.9911102,0.0024806561,0.0008572048,0.0009881131,0.0015620069,0.0030017989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019793909,0.0025133563,0.0008119066,0.002738528,0.0053862785,0.013535524,0.003351755,0.012493027,0.012878937],"category_scores_gemma":[0.012976737,0.0007882426,0.0016851898,0.002154531,0.0070538963,0.016753757,0.018960489,0.010239474,0.0038364686],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017171394,0.000673207,0.0071433797,0.0025507368,0.00017030748,0.0011297468,0.021253653,0.0056561404,0.0051990063,0.42320043,0.20729208,0.32555962],"study_design_scores_gemma":[0.00008621959,0.0004426134,0.0037589574,0.0022990487,0.00006129156,0.00043076504,0.026919661,0.0020207688,0.0022521818,0.23070705,0.7309244,0.00009698681],"about_ca_topic_score_codex":0.0039314837,"about_ca_topic_score_gemma":0.0038574536,"teacher_disagreement_score":0.019793909,"about_ca_system_score_codex":0.0059011444,"about_ca_system_score_gemma":0.023399957,"threshold_uncertainty_score":0.10468149},"labels":[],"label_agreement":null},{"id":"W4389000566","doi":"10.1007/s40278-023-49354-x","title":"Sabril (vigabatrin) 500mg tablets containing trace amounts of tiapride released on Canadian market","year":2023,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Vigabatrin; Tiapride; TRACE (psycholinguistics); Chemistry; Pharmacology; Chromatography; Medicine; Psychiatry; Epilepsy; Anticonvulsant; Philosophy","score_opus":0.058716800843080334,"score_gpt":0.2784391706306147,"score_spread":0.21972236978753434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389000566","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58360153,0.02492655,0.006427393,0.022869837,0.0014642036,0.0009943659,0.026285307,0.0010569008,0.33237392],"genre_scores_gemma":[0.9136665,0.0048373877,0.0031301803,0.0015338572,0.00019588186,0.000058849742,0.0036519845,0.000045400117,0.07288004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994729,0.000055811193,0.00001772282,0.000046953475,0.00030897165,0.00009765713],"domain_scores_gemma":[0.9994252,0.00009344949,0.00006767144,0.000017636996,0.00028246926,0.00011366844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005090194,0.00018566071,0.00017877517,0.00068597327,0.000980302,0.00083866605,0.0004169392,0.00041769267,0.01232177],"category_scores_gemma":[0.0020073252,0.000091214104,0.00023919308,0.0006665403,0.00031416828,0.0002059049,0.00015182456,0.0008108156,0.00089840236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006214775,0.0007485376,0.040839136,0.0010256296,0.00017483214,0.0011272446,0.00072917173,0.0023249907,0.036533095,0.026231382,0.2295175,0.6545336],"study_design_scores_gemma":[0.00074292265,0.001515487,0.27969792,0.0004355352,0.00026558727,0.0012545197,0.00089787523,0.0065607415,0.019246249,0.0018937634,0.68736744,0.00012193657],"about_ca_topic_score_codex":0.82939965,"about_ca_topic_score_gemma":0.870165,"teacher_disagreement_score":0.17060035,"about_ca_system_score_codex":0.010282011,"about_ca_system_score_gemma":0.010980675,"threshold_uncertainty_score":0.34321004},"labels":[],"label_agreement":null},{"id":"W4389222395","doi":"10.1182/blood-2023-179050","title":"The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chimeric antigen receptor; Multiple myeloma; Health care; Expanded access; Family medicine; Internal medicine; Cancer; Immunotherapy; Economic growth","score_opus":0.035043998705333854,"score_gpt":0.3037439020210804,"score_spread":0.26869990331574656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98226917,0.003345307,0.00030836524,0.0039250855,0.000039699557,0.00018426996,0.0047096917,0.000011487825,0.0052070566],"genre_scores_gemma":[0.9946439,0.0007078379,0.0002917644,0.0020811837,0.00006133295,0.00026351176,0.0012836875,0.000008085266,0.0006586057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99640226,0.002119237,0.00039976565,0.00031900316,0.00040627483,0.00035350423],"domain_scores_gemma":[0.99358517,0.0019443111,0.003297572,0.00025002795,0.0002748771,0.0006479445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004388289,0.00024631832,0.00031731089,0.00068249344,0.0005690742,0.000965899,0.00057949265,0.00070075924,0.004159547],"category_scores_gemma":[0.00795395,0.00021214047,0.00073612086,0.0023105424,0.00046265914,0.0011910088,0.0012750912,0.0010483305,0.00052834314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009939246,0.00022300602,0.9832599,0.0003798934,0.00036893788,0.0001273677,0.0009699226,0.0000819319,0.00012727361,0.00035097575,0.00320915,0.009907665],"study_design_scores_gemma":[0.00048077814,0.0008966772,0.9829238,0.00054428534,0.00057274237,0.00055646815,0.0030576398,0.0003557058,0.00025682463,0.00040698214,0.009925434,0.000022597349],"about_ca_topic_score_codex":0.006534546,"about_ca_topic_score_gemma":0.010865531,"teacher_disagreement_score":0.006534546,"about_ca_system_score_codex":0.00079993915,"about_ca_system_score_gemma":0.001332626,"threshold_uncertainty_score":0.023207784},"labels":[],"label_agreement":null},{"id":"W4389279230","doi":"10.33140/tapi.06.01.14","title":"The Successful Launch and Diffusion of New Therapies","year":2023,"lang":"en","type":"article","venue":"Toxicology and Applied Pharmacology Insights","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Promotion (chess); Risk analysis (engineering); Pharmaceutical industry; Business; Value (mathematics); Field (mathematics); Marketing; Management science; Process management; Computer science; Engineering; Biotechnology","score_opus":0.04498046211781146,"score_gpt":0.2958214113893288,"score_spread":0.25084094927151734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389279230","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034379113,0.5024752,0.17357245,0.054912236,0.0024215188,0.0016256053,0.001637507,0.00037908144,0.22859728],"genre_scores_gemma":[0.3031679,0.56588113,0.10312067,0.00433875,0.0021451686,0.0009262534,0.000819667,0.00013877043,0.019461764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98805815,0.004274882,0.0011581241,0.0008746798,0.0049981936,0.0006359037],"domain_scores_gemma":[0.9750362,0.01806314,0.0030530188,0.00057712285,0.002730759,0.0005397712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01259916,0.0008455817,0.001429062,0.002593588,0.00071377185,0.007453031,0.0009931291,0.0027569483,0.006254902],"category_scores_gemma":[0.026113871,0.0005904599,0.0012775778,0.0021452745,0.0019675172,0.006269935,0.0024680486,0.0032824636,0.0022042308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016734653,0.00020719002,0.005254859,0.008084544,0.00033546146,0.0005318977,0.0005861329,0.011973033,0.0027063023,0.45493862,0.017576987,0.49763757],"study_design_scores_gemma":[0.00011000711,0.0008613001,0.011651717,0.011516482,0.0004941751,0.0010578084,0.0013450315,0.017460484,0.007771038,0.38292348,0.56453514,0.0002733035],"about_ca_topic_score_codex":0.0022935441,"about_ca_topic_score_gemma":0.0019334164,"teacher_disagreement_score":0.01259916,"about_ca_system_score_codex":0.0036940146,"about_ca_system_score_gemma":0.0065263812,"threshold_uncertainty_score":0.066631496},"labels":[],"label_agreement":null},{"id":"W4389568577","doi":"10.59890/ijaeam.v1i4.913","title":"International Trade in Pharmaceutical Products","year":2023,"lang":"en","type":"article","venue":"International Journal of Applied Economics Accounting and Management (IJAEAM)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Business; Intellectual property; Context (archaeology); Supply chain; Pharmaceutical industry; Globalization; Equity (law); Public economics; Industrial organization; International trade; Economics; Marketing; Biotechnology; Political science","score_opus":0.04632787595956736,"score_gpt":0.29711067106174577,"score_spread":0.2507827951021784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389568577","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003471909,0.025398161,0.0028600178,0.005815563,0.003299342,0.00010279365,0.0011482021,0.00024129561,0.9576628],"genre_scores_gemma":[0.13319494,0.07063895,0.008057935,0.008219388,0.0040547727,0.00034848976,0.0042555863,0.0004604371,0.77076954],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99464226,0.00079124706,0.00037898362,0.00079508976,0.0028074319,0.00058508164],"domain_scores_gemma":[0.99648017,0.00080671976,0.0006652554,0.0008309137,0.0008455713,0.00037147914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026537522,0.00085574447,0.000599353,0.0037862165,0.0022269886,0.012483713,0.0009213335,0.0028929312,0.09830019],"category_scores_gemma":[0.007748154,0.00033238967,0.0008728905,0.0067103757,0.0023122698,0.0053569456,0.0040032067,0.00345594,0.029580845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008088682,0.000056675657,0.0016921242,0.0006882294,0.000043608463,0.0004217008,0.0007720874,0.00031662703,0.0013798538,0.5863507,0.14357555,0.26462203],"study_design_scores_gemma":[0.000002783442,0.000026957949,0.0010335594,0.0002887314,0.00000652419,0.0003331068,0.00013091446,0.00006398377,0.00029988604,0.011552544,0.986254,0.0000070849205],"about_ca_topic_score_codex":0.0018197533,"about_ca_topic_score_gemma":0.0013551436,"teacher_disagreement_score":0.09830019,"about_ca_system_score_codex":0.0030648396,"about_ca_system_score_gemma":0.003933395,"threshold_uncertainty_score":0.32884687},"labels":[],"label_agreement":null},{"id":"W4389783746","doi":"10.19181/population.2023.26.4.15","title":"Economic affordability of medicines and its impact on households in Russia","year":2023,"lang":"en","type":"article","venue":"POPULATION","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Poverty; Population; Business; Consumption (sociology); Payment; Government (linguistics); Quarter (Canadian coin); Receipt; Health care; Economic growth; Economics; Environmental health; Medicine; Finance; Geography","score_opus":0.07679951011362599,"score_gpt":0.3512057057307321,"score_spread":0.2744061956171061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389783746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953526,0.0008063904,0.000118574615,0.000413321,0.000009131432,0.0000054275274,0.00035640248,0.0000031659483,0.0029349532],"genre_scores_gemma":[0.9992493,0.0003937018,0.000024830802,0.000013951978,0.000004502386,0.0000024922747,0.000094310446,7.049643e-7,0.00021621378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995578,0.00016818214,0.000025350451,0.000035952413,0.00006718602,0.00014548456],"domain_scores_gemma":[0.9994814,0.000090414505,0.00027274372,0.000018193747,0.000041787018,0.00009550049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002833288,0.00012559928,0.00023152874,0.0005422173,0.00040084982,0.00072205847,0.00022985293,0.00020142952,0.0022081735],"category_scores_gemma":[0.0010337131,0.0000983328,0.00044898532,0.00084122876,0.00032402133,0.00045324967,0.0010386197,0.00034461624,0.00014059644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012963924,0.00011842688,0.9789708,0.0000648063,0.00015416212,0.0005478223,0.0011327217,0.0012470856,0.00021683649,0.0035565575,0.0007469549,0.013114163],"study_design_scores_gemma":[0.0000037484467,0.00005667172,0.9939144,0.0000304193,0.00003784429,0.00020412047,0.0019444905,0.0012608436,0.000079271835,0.000648571,0.0018130525,0.0000065898744],"about_ca_topic_score_codex":0.023081994,"about_ca_topic_score_gemma":0.01397263,"teacher_disagreement_score":0.023081994,"about_ca_system_score_codex":0.00132238,"about_ca_system_score_gemma":0.00051218004,"threshold_uncertainty_score":0.04589528},"labels":[],"label_agreement":null},{"id":"W4390047045","doi":"10.1371/journal.pone.0293497","title":"Early observations of Tier-3 drug shortages on purchasing trends across Canada: A cross-sectional analysis of 3 case-example drugs","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Purchasing; Economic shortage; Medicine; Business; Tier 1 network; Environmental health; Demography; Computer science; Marketing","score_opus":0.22252209926742111,"score_gpt":0.32329267258706695,"score_spread":0.10077057331964584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390047045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99751246,0.00014809195,0.00013281069,0.00011893248,0.0000035409796,0.000040338207,0.0015548324,0.000005600317,0.0004833714],"genre_scores_gemma":[0.99810094,0.00014130551,0.0002405245,0.00007390734,0.000003355681,0.0000259874,0.0011401457,0.0000036715883,0.00027026137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809915,0.00024157025,0.00013124467,0.00029403035,0.00061312754,0.00062096695],"domain_scores_gemma":[0.99384284,0.00061213225,0.0024610418,0.0003292032,0.0017334585,0.0010212923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018145078,0.00035932448,0.00038349244,0.0014038634,0.0016387796,0.0010357453,0.001093955,0.0005169464,0.0014547374],"category_scores_gemma":[0.00467937,0.00042527443,0.000832058,0.0036720294,0.00095485314,0.00042034814,0.0011426269,0.0010035469,0.00015369013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039043,0.000025325233,0.99801886,0.000010088179,0.000031083116,0.00008651574,0.0004739908,0.00006732176,0.00007539348,0.00003317593,0.00024898327,0.000890224],"study_design_scores_gemma":[0.0000021229516,0.000023379243,0.9984316,0.000010661173,0.000011858165,0.00008046052,0.00081030553,0.00027049534,0.000039805516,0.00000982262,0.00030378203,0.0000057129514],"about_ca_topic_score_codex":0.9507263,"about_ca_topic_score_gemma":0.9600656,"teacher_disagreement_score":0.04927373,"about_ca_system_score_codex":0.014378112,"about_ca_system_score_gemma":0.017754426,"threshold_uncertainty_score":0.104321},"labels":[],"label_agreement":null},{"id":"W4390054136","doi":"10.57220/jatpb.v2i3.171","title":"Les métiers de l’industrie pharmaceutique et chaines de valeurs - Communication Introductive","year":2023,"lang":"fr","type":"article","venue":"Journal Africain de Technologie Pharmaceutique et Biopharmacie (JATPB)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.17023462981949525,"score_gpt":0.4080190340451326,"score_spread":0.23778440422563737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390054136","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018836668,0.08136971,0.046045627,0.04801225,0.015849294,0.00032775497,0.00166402,0.0009231974,0.7869715],"genre_scores_gemma":[0.15324482,0.0693576,0.046739794,0.0074671344,0.008736386,0.00037974943,0.001798501,0.000639075,0.71163696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99532336,0.001102833,0.00025236813,0.0006272879,0.002317934,0.00037623371],"domain_scores_gemma":[0.99397343,0.0022370638,0.0007517462,0.00044988754,0.0022046908,0.00038323604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003362986,0.0009982574,0.00044589821,0.0030859108,0.002433949,0.011127038,0.0010147924,0.0023393144,0.073834345],"category_scores_gemma":[0.007537065,0.00064127275,0.0006846674,0.0051499936,0.002212508,0.005897067,0.0021011753,0.0027673696,0.02291986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018048607,0.00012911261,0.0050806873,0.0009813376,0.00004159577,0.00047652135,0.004092648,0.0013880021,0.0024346597,0.25290155,0.25737286,0.47492042],"study_design_scores_gemma":[0.000006720185,0.000056010005,0.0029221014,0.00040100477,0.0000072789376,0.00032219393,0.0011705394,0.0004380822,0.00063185865,0.012819285,0.9812035,0.000021438103],"about_ca_topic_score_codex":0.012187804,"about_ca_topic_score_gemma":0.009463495,"teacher_disagreement_score":0.073834345,"about_ca_system_score_codex":0.0048874784,"about_ca_system_score_gemma":0.0050534056,"threshold_uncertainty_score":0.24700052},"labels":[],"label_agreement":null},{"id":"W4390104714","doi":"10.1007/s40258-023-00860-2","title":"An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone","year":2023,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Reimbursement; Negotiation; Payment; Reward system; Pharmaceutical industry; Business; Work (physics); Marketing; Health economics; Health care; Economics; Finance; Medicine; Pharmacology; Economic growth","score_opus":0.2573959301387196,"score_gpt":0.4467395295543763,"score_spread":0.1893435994156567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390104714","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08732396,0.0010593298,0.3033757,0.100142285,0.008125375,0.0013206872,0.0011887109,0.012590571,0.48487338],"genre_scores_gemma":[0.75138336,0.00034768134,0.072535045,0.014280813,0.0019392091,0.0007710838,0.00045129796,0.00079610717,0.15749526],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9873611,0.005226978,0.0005752098,0.0010355935,0.0038061945,0.0019950212],"domain_scores_gemma":[0.9383833,0.020708416,0.0036479624,0.010265013,0.010331014,0.016664255],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021227049,0.0005620798,0.00088481756,0.0016861277,0.002528658,0.0058273724,0.00284233,0.004538977,0.05287412],"category_scores_gemma":[0.08321644,0.0005816325,0.0007313476,0.0007997654,0.0023035388,0.007979105,0.010130063,0.0050393543,0.016263546],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013550939,0.0014687312,0.0076283733,0.00027536467,0.000087468536,0.00030726945,0.00081581634,0.0048830365,0.0027224731,0.30082428,0.27824122,0.40139085],"study_design_scores_gemma":[0.0017739511,0.0019391517,0.018235039,0.00055823656,0.00022295416,0.00063001283,0.0007646648,0.05880828,0.005434016,0.42071846,0.49037364,0.0005416339],"about_ca_topic_score_codex":0.0017748415,"about_ca_topic_score_gemma":0.0031204356,"teacher_disagreement_score":0.97877294,"about_ca_system_score_codex":0.0021204443,"about_ca_system_score_gemma":0.0077975253,"threshold_uncertainty_score":0.17688155},"labels":[],"label_agreement":null},{"id":"W4390399552","doi":"10.1016/j.ijcard.2023.131498","title":"Budget impact analysis of empagliflozin in the treatment of heart failure with reduced ejection fraction (BIAEMHeart)","year":2023,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Empagliflozin; Ejection fraction; Heart failure; Cardiology; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.0469847117435571,"score_gpt":0.3486967612350542,"score_spread":0.3017120494914971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390399552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86496055,0.01875908,0.024920126,0.017428225,0.0007323535,0.0018883294,0.01953846,0.00032636104,0.05144651],"genre_scores_gemma":[0.9878028,0.0017098661,0.0027349184,0.00070274156,0.00009486948,0.00032999276,0.0023011353,0.000027960314,0.0042957035],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99619174,0.0025183547,0.00013051057,0.00017118648,0.00031078915,0.0006774277],"domain_scores_gemma":[0.9933609,0.0048937164,0.00063816697,0.00016477921,0.00046381477,0.00047863252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066920933,0.0008167245,0.00205994,0.0012476969,0.00029674766,0.0019229401,0.00084972684,0.0011814378,0.008523303],"category_scores_gemma":[0.019592484,0.000682795,0.0023083747,0.0014704207,0.0004196033,0.0012166701,0.0014091684,0.0023470705,0.00029921814],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020253986,0.0016999014,0.02983358,0.0018593387,0.0042758286,0.00068526546,0.00014353372,0.8098273,0.0009483824,0.042969145,0.01878534,0.06871833],"study_design_scores_gemma":[0.012346575,0.0063091232,0.06944606,0.0012684055,0.00970532,0.0003951141,0.0007041595,0.85092115,0.0014297025,0.024667965,0.02262256,0.0001837907],"about_ca_topic_score_codex":0.04586086,"about_ca_topic_score_gemma":0.029706739,"teacher_disagreement_score":0.04586086,"about_ca_system_score_codex":0.0047744904,"about_ca_system_score_gemma":0.0066913776,"threshold_uncertainty_score":0.091187835},"labels":[],"label_agreement":null},{"id":"W4390572338","doi":"10.22270/ijdra.v11i4.631","title":"A Review on Approval and Registration Process of Medical Devices in Canada and India","year":2023,"lang":"en","type":"review","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada; Canadian Institutes of Health Research","funders":"","keywords":"Business; Health technology; Population; Medicine; Health care; Order (exchange); Marketing; Medical emergency; Finance; Environmental health; Economic growth","score_opus":0.05931262392609347,"score_gpt":0.34678687639898353,"score_spread":0.28747425247289005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390572338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026089328,0.99349904,0.00009242288,0.0008632157,0.00022935434,0.000035812343,0.00012356677,0.0000075890134,0.0048880954],"genre_scores_gemma":[0.0032214848,0.99488646,0.00022150582,0.00050616823,0.00008741809,0.000021242595,0.00008863727,0.0000036361034,0.0009634114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965485,0.00055449764,0.0005808545,0.00023581606,0.0018433165,0.00023720997],"domain_scores_gemma":[0.9871563,0.0069551617,0.0015236062,0.00020859267,0.0038153508,0.00034100516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004258789,0.0007323198,0.0014048797,0.0077402024,0.0012787532,0.0029788977,0.0016472184,0.0017530125,0.0077755013],"category_scores_gemma":[0.011677173,0.0004907982,0.00139316,0.010756113,0.0015176025,0.0015121166,0.0007790152,0.0017286309,0.0010752185],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013796422,0.00008878193,0.00081686385,0.083206564,0.0001788909,0.000442178,0.00035998147,0.00054680585,0.00046476503,0.01716252,0.07921793,0.8173768],"study_design_scores_gemma":[0.00003135358,0.000082909224,0.004816094,0.029594848,0.000299058,0.00074012415,0.00016771683,0.00010664381,0.00042563165,0.0006685136,0.9630251,0.00004201547],"about_ca_topic_score_codex":0.13160436,"about_ca_topic_score_gemma":0.1884207,"teacher_disagreement_score":0.9885019,"about_ca_system_score_codex":0.011498108,"about_ca_system_score_gemma":0.03397614,"threshold_uncertainty_score":0.26167673},"labels":[],"label_agreement":null},{"id":"W4390589706","doi":"10.5206/uwomj.v91i1.15684","title":"Primer on the Economics of Antimicrobial Resistance","year":2024,"lang":"en","type":"article","venue":"University of Western Ontario Medical Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Antibiotic resistance; Antimicrobial; Antibiotics; Incentive; Resistance (ecology); Drug resistance; Biotechnology; Biology; Intensive care medicine; Medicine; Microbiology; Economics; Ecology; Market economy","score_opus":0.03831665147591422,"score_gpt":0.23049730581301903,"score_spread":0.1921806543371048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390589706","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018114551,0.22409944,0.009547741,0.5729561,0.009975995,0.000045777197,0.00035659055,0.00004627296,0.18116061],"genre_scores_gemma":[0.09992852,0.507308,0.008345978,0.21018288,0.039277844,0.0001943147,0.00028586364,0.00016139672,0.13431522],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991103,0.0003281769,0.00003953055,0.0000846481,0.00034280258,0.00009460304],"domain_scores_gemma":[0.9942238,0.004343228,0.00019472673,0.00020286221,0.0008180659,0.0002174114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002317393,0.00055827794,0.0005792958,0.0017052151,0.001197213,0.0040268647,0.0009126659,0.00514949,0.015251915],"category_scores_gemma":[0.005771706,0.00036644927,0.00072851504,0.0020741127,0.004802345,0.006685532,0.0014746302,0.009264871,0.0027044408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013813558,0.000044055796,0.0002259434,0.00013018493,0.000008295509,0.000086947846,0.00015931859,0.0012103674,0.00013375268,0.82135355,0.14649653,0.030137213],"study_design_scores_gemma":[0.0000069394655,0.000019270285,0.0004451514,0.00091401616,0.0000034885309,0.0001338146,0.00014354815,0.0005193568,0.00009267758,0.37797657,0.61973023,0.000014909367],"about_ca_topic_score_codex":0.005955804,"about_ca_topic_score_gemma":0.004239767,"teacher_disagreement_score":0.015251915,"about_ca_system_score_codex":0.00486918,"about_ca_system_score_gemma":0.0030011155,"threshold_uncertainty_score":0.05102271},"labels":[],"label_agreement":null},{"id":"W4390690958","doi":"10.1136/bmj.q61","title":"US states want to buy cheap drugs from Canada—and the FDA says yes after three year delay","year":2024,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Internet privacy; Medicine; Law; Advertising; Psychology; Political science; Computer science","score_opus":0.015749725202793937,"score_gpt":0.2616464993760273,"score_spread":0.24589677417323336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390690958","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030998282,0.005944594,0.00006437932,0.09264675,0.8988825,0.00003596388,0.00023724712,0.00006376887,0.0020938246],"genre_scores_gemma":[0.0006032574,0.006964603,0.00014792908,0.09350505,0.88334024,0.00006773901,0.00013203846,0.00006585117,0.015173197],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9872273,0.0019054798,0.0012526491,0.0008686679,0.007913023,0.0008328276],"domain_scores_gemma":[0.9498737,0.023111729,0.0025380896,0.0011469721,0.017697813,0.0056317816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01449039,0.0054295356,0.0063441405,0.00688693,0.0054854853,0.013888788,0.005402261,0.041881006,0.022627862],"category_scores_gemma":[0.072654404,0.0022231583,0.0055397544,0.0044325297,0.0037458583,0.0060392814,0.0017592416,0.042506896,0.013515463],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036804842,0.000009818523,0.00001622408,0.00015059779,0.000030441859,0.000030457919,0.0000055209816,0.000013546189,0.000013417476,0.00020845378,0.9980714,0.0014134266],"study_design_scores_gemma":[0.0004556494,0.00006286585,0.00073034276,0.0015104448,0.00033856696,0.00009307022,0.00009185556,0.0002915497,0.000111866335,0.0028370433,0.9934145,0.00006225124],"about_ca_topic_score_codex":0.03952175,"about_ca_topic_score_gemma":0.090300396,"teacher_disagreement_score":0.96047825,"about_ca_system_score_codex":0.010673557,"about_ca_system_score_gemma":0.018036643,"threshold_uncertainty_score":0.07858342},"labels":[],"label_agreement":null},{"id":"W4390706712","doi":"10.1136/bmj.p2983","title":"US states want to buy cheap drugs from Canada—and the FDA says yes after three year delay","year":2024,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sign (mathematics); Business; Advertising; Drug approval; Control (management); Drug; Political science; Law; Medicine; Economics; Pharmacology; Management","score_opus":0.022759852932865986,"score_gpt":0.25905948532396683,"score_spread":0.23629963239110086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390706712","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022021658,0.0036436005,0.00017709906,0.92004067,0.00919615,0.000022204398,0.0015638041,0.0000827328,0.063071504],"genre_scores_gemma":[0.04307165,0.0074024214,0.0008498163,0.7273279,0.004749619,0.000036932823,0.0016470389,0.00011195318,0.21480273],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973717,0.000189758,0.00007321273,0.00012919828,0.0016291443,0.00060702],"domain_scores_gemma":[0.99266726,0.0012380278,0.00027933915,0.0001469761,0.0038209532,0.0018474694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016678841,0.00046921708,0.00038402274,0.00076556293,0.0052490174,0.0059762355,0.0006505654,0.009465926,0.03496798],"category_scores_gemma":[0.011670581,0.00032156866,0.0008861278,0.0010245929,0.0016734607,0.0022243022,0.0010095249,0.008080859,0.006192963],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027982469,0.000010744432,0.0009080334,0.000017113643,0.000011188553,0.00003940467,0.000026185888,0.000029259196,0.00008041044,0.0056946753,0.98793334,0.0052217892],"study_design_scores_gemma":[0.000041432755,0.000018948447,0.005488011,0.0001224498,0.000035354846,0.000063475134,0.0003450978,0.00018470194,0.00027608417,0.0024786405,0.99090016,0.000045689398],"about_ca_topic_score_codex":0.7864936,"about_ca_topic_score_gemma":0.8407894,"teacher_disagreement_score":0.2135064,"about_ca_system_score_codex":0.0155445235,"about_ca_system_score_gemma":0.038350187,"threshold_uncertainty_score":0.42952752},"labels":[],"label_agreement":null},{"id":"W4390718475","doi":"10.1136/bmj.q6","title":"“Safer supply” alternatives to toxic unregulated drug markets","year":2024,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Medical Research Council","keywords":"SAFER; Drug; Risk analysis (engineering); Computer science; Business; Pharmacology; Medicine; Data science; Computer security","score_opus":0.03137083908377133,"score_gpt":0.32380174966286995,"score_spread":0.29243091057909865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390718475","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043959124,0.008854753,0.00019409794,0.076500915,0.9123359,0.000024789155,0.00010388383,0.00007076929,0.0018710105],"genre_scores_gemma":[0.0006560185,0.008104707,0.00020298544,0.043877423,0.9417537,0.000028470255,0.00003407625,0.000036617592,0.0053059594],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98603463,0.004377388,0.0017770868,0.0007539075,0.006456626,0.00060044037],"domain_scores_gemma":[0.94007134,0.04072316,0.003092157,0.0012592968,0.011864103,0.002989991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01844021,0.0037899287,0.0048269653,0.004263513,0.002422644,0.0110967215,0.0054537347,0.027811503,0.027648728],"category_scores_gemma":[0.07147279,0.0015953484,0.004198761,0.0025589082,0.0044784304,0.010252448,0.0021010772,0.038423948,0.009013496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055373574,0.000023806206,0.00001579767,0.00074538385,0.00006606714,0.00006666371,0.000010536713,0.000057254696,0.00003203383,0.002020865,0.9919065,0.0049996004],"study_design_scores_gemma":[0.00048387502,0.00006565833,0.00031433426,0.0011896861,0.0002142345,0.00011750865,0.00006977506,0.00047495362,0.00014678079,0.013546361,0.9833286,0.000048128648],"about_ca_topic_score_codex":0.002494209,"about_ca_topic_score_gemma":0.007336486,"teacher_disagreement_score":0.027811503,"about_ca_system_score_codex":0.0047620693,"about_ca_system_score_gemma":0.0062031853,"threshold_uncertainty_score":0.09752226},"labels":[],"label_agreement":null},{"id":"W4391174480","doi":"10.1001/jama.2023.27966","title":"FDA Approves First State Program to Import Rx Drugs From Canada","year":2024,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; State (computer science); Family medicine; Pharmacology","score_opus":0.026196290745270495,"score_gpt":0.2634359670214808,"score_spread":0.23723967627621032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391174480","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063820477,0.002061349,0.00152545,0.050434545,0.0027272275,0.00091677083,0.0095385285,0.0021483293,0.9242658],"genre_scores_gemma":[0.030409943,0.0018584986,0.0018944837,0.030558312,0.0006526725,0.00013910666,0.0034197285,0.00035522366,0.9307119],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99765176,0.00009272841,0.000056634304,0.00018314131,0.0015470473,0.0004687934],"domain_scores_gemma":[0.99190664,0.00076574576,0.0001920482,0.00032361608,0.0053227074,0.0014893126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013218517,0.0004542895,0.00039834937,0.0014899515,0.0042592394,0.0027198843,0.0010038806,0.0038692513,0.18941905],"category_scores_gemma":[0.005966513,0.00046338674,0.0007610259,0.0011881596,0.001091004,0.00093752716,0.0006690708,0.0028846324,0.03775528],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006994641,0.00007459103,0.001826606,0.000060226197,0.000009002885,0.00012523185,0.000041331597,0.00006507516,0.0004379011,0.0041194735,0.96581215,0.027358435],"study_design_scores_gemma":[0.00006583675,0.000034360044,0.0036064489,0.000062971165,0.000007975685,0.00009990093,0.000056504294,0.00012785044,0.00032799985,0.00022019043,0.99537575,0.000014184093],"about_ca_topic_score_codex":0.7399485,"about_ca_topic_score_gemma":0.8506471,"teacher_disagreement_score":0.2600515,"about_ca_system_score_codex":0.012324927,"about_ca_system_score_gemma":0.0634358,"threshold_uncertainty_score":0.63366985},"labels":[],"label_agreement":null},{"id":"W4391331128","doi":"10.61096/ijamscr.v11.iss4.2023.405-412","title":"Planning and execution of dossier compilation of countries Germany, Canada and Australia","year":2023,"lang":"en","type":"article","venue":"International Journal of Allied Medical Sciences and Clinical Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Library science; Computer science","score_opus":0.4447478001565659,"score_gpt":0.5472880720657594,"score_spread":0.10254027190919346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391331128","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06980894,0.0030229383,0.19656861,0.011250965,0.0032444124,0.049252316,0.029205553,0.011814126,0.62583214],"genre_scores_gemma":[0.2056344,0.0030480456,0.38251084,0.0034324424,0.0005967923,0.01275521,0.025521606,0.0029320833,0.36356857],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98895276,0.0024199379,0.0010908186,0.0012574621,0.004764595,0.0015143317],"domain_scores_gemma":[0.9499155,0.007313479,0.0035318132,0.0046542482,0.03113475,0.0034502125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021542238,0.0006992409,0.00061994116,0.01016261,0.0043017934,0.005223859,0.0013886205,0.0013156289,0.047614645],"category_scores_gemma":[0.035400834,0.0010192256,0.00089948677,0.004406313,0.0011877521,0.0025775773,0.002233307,0.0022812723,0.019456351],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056790275,0.00050353474,0.009996827,0.0011515,0.00006727095,0.0018523735,0.0066230358,0.00911692,0.0136745805,0.06769846,0.43772623,0.45102128],"study_design_scores_gemma":[0.00009098118,0.00022105065,0.02178531,0.000628172,0.000045200053,0.00040343884,0.0031911125,0.0033217387,0.009866143,0.0041662706,0.95609355,0.00018699237],"about_ca_topic_score_codex":0.12808819,"about_ca_topic_score_gemma":0.09135487,"teacher_disagreement_score":0.8719118,"about_ca_system_score_codex":0.010588303,"about_ca_system_score_gemma":0.04476712,"threshold_uncertainty_score":0.25468522},"labels":[],"label_agreement":null},{"id":"W4391339917","doi":"10.1200/jco.23.02259","title":"Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies","year":2024,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ottawa Hospital; University of Toronto; University of Calgary; University of Ottawa","funders":"","keywords":"Medicine; Clinical endpoint; Expanded access; Drug; Progression-free survival; Oncology; End point; Surrogate endpoint; Intensive care medicine; Medical physics; Internal medicine; Overall survival; Clinical trial; Pharmacology","score_opus":0.2902808959613531,"score_gpt":0.4476403663145367,"score_spread":0.1573594703531836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391339917","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075271743,0.00047325567,0.00035750322,0.9830582,0.007087782,0.00003117757,0.00017715593,0.000033198765,0.008029098],"genre_scores_gemma":[0.00890581,0.00036369485,0.0008901348,0.956946,0.021113325,0.0000906235,0.00009621857,0.000035430814,0.011558629],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9873077,0.0053637787,0.0015939003,0.000879304,0.0033446322,0.001510772],"domain_scores_gemma":[0.9454197,0.036817197,0.0032620768,0.0014975053,0.0069977306,0.006005786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016953016,0.00087130844,0.0021195516,0.0011698825,0.0035105823,0.0073621618,0.0017323797,0.07242013,0.006444896],"category_scores_gemma":[0.07991238,0.00091219257,0.0015660445,0.0011136412,0.00401088,0.004555266,0.0029273161,0.0484671,0.0072446233],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016388913,0.00006233374,0.0019238858,0.000050398885,0.000021636057,0.0007607112,0.000113724556,0.00015068786,0.0002376502,0.01517691,0.96768963,0.013648509],"study_design_scores_gemma":[0.0006651594,0.00027445963,0.0059271604,0.0006506122,0.00007466882,0.0015181116,0.00045956852,0.0034294762,0.00073104474,0.07243648,0.9136471,0.00018603838],"about_ca_topic_score_codex":0.010498355,"about_ca_topic_score_gemma":0.025575984,"teacher_disagreement_score":0.07242013,"about_ca_system_score_codex":0.0061988267,"about_ca_system_score_gemma":0.013298224,"threshold_uncertainty_score":0.08965725},"labels":[],"label_agreement":null},{"id":"W4391391486","doi":"10.1177/17151635241228274","title":"Navigating rare disease medications: A pharmacist’s primer","year":2024,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Pharmacist; Primer (cosmetics); Disease; Family medicine; Pharmacy; Internal medicine; Chemistry","score_opus":0.06664439356504911,"score_gpt":0.3193632350511423,"score_spread":0.25271884148609314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391391486","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001289285,0.014280715,0.0003511724,0.98162997,0.001294312,0.000006125627,0.000029542536,0.000008312179,0.002270973],"genre_scores_gemma":[0.026663123,0.09169193,0.0025424885,0.85229456,0.02283927,0.000047729158,0.000078340076,0.000042280084,0.0038002557],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98936975,0.0036256965,0.0006664638,0.00089772197,0.0039217984,0.0015184946],"domain_scores_gemma":[0.9523464,0.02747263,0.0015573476,0.0005995519,0.011716086,0.0063080527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0147721395,0.000683334,0.0013999388,0.0028812236,0.007102415,0.011900407,0.0036142422,0.023382295,0.009011916],"category_scores_gemma":[0.046959825,0.0005308613,0.0009549719,0.0035454605,0.012691517,0.015776237,0.0047730994,0.027024094,0.001224484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035771427,0.00006721646,0.001128442,0.0006715566,0.000037954964,0.00066550425,0.0018621015,0.0005947296,0.000091052956,0.15230656,0.78024995,0.062289067],"study_design_scores_gemma":[0.00003641043,0.000028539247,0.0011417158,0.0026158695,0.000021994463,0.0006601253,0.0018352255,0.0005948609,0.000055968543,0.06212413,0.93083245,0.00005269077],"about_ca_topic_score_codex":0.39466575,"about_ca_topic_score_gemma":0.5163485,"teacher_disagreement_score":0.39466575,"about_ca_system_score_codex":0.035095546,"about_ca_system_score_gemma":0.10291533,"threshold_uncertainty_score":0.7847371},"labels":[],"label_agreement":null},{"id":"W4391925966","doi":"10.1186/s12962-024-00521-8","title":"Out-of-pocket pharmaceutical expenditure and its determinants among Iranian households with elderly members: a double-hurdle model","year":2024,"lang":"en","type":"article","venue":"Cost Effectiveness and Resource Allocation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina","funders":"Iran University of Medical Sciences","keywords":"Socioeconomic status; Medicine; Residence; Household income; Environmental health; Population; Socioeconomics; Demographic economics; Economics; Geography","score_opus":0.07406317561500915,"score_gpt":0.3215947664437094,"score_spread":0.24753159082870024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391925966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973653,0.0016936613,0.016731014,0.0032471565,0.00016406114,0.00023631903,0.0013849771,0.00008501588,0.0028047538],"genre_scores_gemma":[0.98987985,0.0008188063,0.0023902217,0.0002012088,0.0001153945,0.00014567241,0.00094170525,0.000018752335,0.0054883733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972856,0.0011346226,0.00011152356,0.0005458035,0.00019730646,0.00072514557],"domain_scores_gemma":[0.99355936,0.0035619054,0.0014111233,0.0002892422,0.00061261246,0.00056580664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040703407,0.0015752314,0.001991789,0.0017587602,0.00085477834,0.0023471687,0.0024209276,0.0017666295,0.007865387],"category_scores_gemma":[0.0068923268,0.0010418553,0.0045767156,0.0010221257,0.00088928355,0.0012180296,0.0022120115,0.0023221767,0.001058684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011145794,0.0010068724,0.8941003,0.00029397046,0.002452663,0.002490294,0.0008722093,0.061471164,0.00036841366,0.011757691,0.0071613197,0.01691059],"study_design_scores_gemma":[0.00033794128,0.0009788224,0.25202242,0.00033492103,0.0016605697,0.0013665148,0.0028103099,0.7234913,0.00031566713,0.01147603,0.005080047,0.00012543153],"about_ca_topic_score_codex":0.031552583,"about_ca_topic_score_gemma":0.016098998,"teacher_disagreement_score":0.031552583,"about_ca_system_score_codex":0.0012513376,"about_ca_system_score_gemma":0.0021835535,"threshold_uncertainty_score":0.06273788},"labels":[],"label_agreement":null},{"id":"W4391943901","doi":"10.1186/s12992-024-01019-x","title":"Pull me – push you? The disparate financing mechanisms of drug research in global health","year":2024,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Incentive; Economics; Health services research; Public economics; Business; Poverty; Pharmaceutical industry; Health care; Medicine; Economic growth; Market economy; Pharmacology","score_opus":0.14091040608390143,"score_gpt":0.4275877422889962,"score_spread":0.2866773362050948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391943901","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09180337,0.06558386,0.07226077,0.58776444,0.0017630273,0.00026323134,0.0009720589,0.00024002738,0.17934918],"genre_scores_gemma":[0.9415727,0.0245487,0.00817894,0.016795732,0.0021855806,0.00023899529,0.00013591228,0.00008711395,0.0062562986],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98680604,0.0090013975,0.00038794897,0.0006962956,0.0018573647,0.0012509718],"domain_scores_gemma":[0.96349096,0.026279705,0.004489408,0.0019714825,0.0018949275,0.0018735012],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02275785,0.0005304519,0.0008824911,0.003280988,0.0011299433,0.008944161,0.001238916,0.0043768017,0.010299241],"category_scores_gemma":[0.051232647,0.00050399115,0.00082366425,0.0029604197,0.010991249,0.010937565,0.004561482,0.0034825306,0.00083334104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007446473,0.000023240755,0.0029898994,0.00022324566,0.000057403493,0.000042914828,0.000213823,0.0021254572,0.000083696694,0.96387434,0.0059993514,0.024292365],"study_design_scores_gemma":[0.00009406021,0.00007613721,0.0061382893,0.0011596596,0.00009080532,0.00013806482,0.0006552581,0.0031590755,0.00034131634,0.9370059,0.051089566,0.000051867813],"about_ca_topic_score_codex":0.0028594788,"about_ca_topic_score_gemma":0.001785915,"teacher_disagreement_score":0.9772422,"about_ca_system_score_codex":0.0064857,"about_ca_system_score_gemma":0.005288335,"threshold_uncertainty_score":0.12035644},"labels":[],"label_agreement":null},{"id":"W4392012970","doi":"10.46747/cfp.700285","title":"How to navigate drug shortages with patients in primary care","year":2024,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"South Health Campus; Alberta Health Services","funders":"","keywords":"Economic shortage; Primary care; Drug; Primary (astronomy); Medicine; Business; Intensive care medicine; Pharmacology; Family medicine; Philosophy; Government (linguistics)","score_opus":0.019744556382947236,"score_gpt":0.22161957527016152,"score_spread":0.2018750188872143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392012970","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002544213,0.005602698,0.0016422493,0.9748174,0.0024912755,0.000074518204,0.00008816403,0.00012506926,0.0126144895],"genre_scores_gemma":[0.1644332,0.039927494,0.034744766,0.7227714,0.01934944,0.0007697016,0.00040145862,0.0004727547,0.017129676],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9726585,0.013103031,0.0009680679,0.0013474784,0.00721075,0.00471221],"domain_scores_gemma":[0.8964409,0.025855636,0.0045936476,0.002018513,0.013606939,0.05748443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02572785,0.00094019424,0.0016512688,0.0033518313,0.021650637,0.01911155,0.0042971573,0.015783131,0.02986539],"category_scores_gemma":[0.110474244,0.0013951893,0.0015947949,0.0030575464,0.0099380845,0.023217794,0.020949068,0.023968257,0.008931402],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004179033,0.00033395443,0.006058687,0.00073477224,0.00010783044,0.00079944206,0.008242801,0.00059129135,0.0001165397,0.012326656,0.83955467,0.13109152],"study_design_scores_gemma":[0.00026630537,0.00044025618,0.011197481,0.008333706,0.00016950403,0.0011830687,0.061504804,0.0013479113,0.00025254532,0.1363271,0.77867645,0.00030096582],"about_ca_topic_score_codex":0.12672564,"about_ca_topic_score_gemma":0.27458608,"teacher_disagreement_score":0.12672564,"about_ca_system_score_codex":0.018777695,"about_ca_system_score_gemma":0.10581367,"threshold_uncertainty_score":0.251976},"labels":[],"label_agreement":null},{"id":"W4392140350","doi":"","title":"Prescription and Non-Prescription Drug Classification Systems Across Countries: Lessons Learned for Thailand","year":2020,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Prescription drug; Medicine; Pharmacology","score_opus":0.499759900350272,"score_gpt":0.5469659205551132,"score_spread":0.04720602020484116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392140350","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3231345,0.22541703,0.022945568,0.37375107,0.0035166151,0.0006367825,0.0053320043,0.0002497391,0.045016687],"genre_scores_gemma":[0.8107181,0.14186071,0.02736142,0.0116746565,0.001147378,0.00035457814,0.0033136464,0.00018483002,0.003384723],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9885916,0.005725232,0.0017581471,0.0008706606,0.0022126806,0.00084163406],"domain_scores_gemma":[0.9188728,0.04110815,0.008872,0.0027660506,0.023368733,0.005012235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029053016,0.00048431143,0.000775033,0.004417462,0.0015679724,0.0076909834,0.0017356316,0.0011197046,0.0035739886],"category_scores_gemma":[0.05169367,0.00041624997,0.0010272303,0.014414187,0.0023070725,0.00947391,0.0031054546,0.0042447923,0.0003390751],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031259662,0.00022495528,0.18088356,0.0039659585,0.00025624927,0.0017033138,0.023086691,0.0034127345,0.00028121853,0.036595065,0.028591942,0.7206858],"study_design_scores_gemma":[0.00014608886,0.0007854061,0.38793224,0.04223357,0.00057015347,0.0031627682,0.13910039,0.017212585,0.0016943323,0.055405304,0.35125357,0.00050369016],"about_ca_topic_score_codex":0.14837182,"about_ca_topic_score_gemma":0.13634817,"teacher_disagreement_score":0.14837182,"about_ca_system_score_codex":0.008866032,"about_ca_system_score_gemma":0.028971272,"threshold_uncertainty_score":0.2950164},"labels":[],"label_agreement":null},{"id":"W4392580932","doi":"10.1007/s43441-024-00624-7","title":"Industry Perceptions and Experiences with the Access Consortium New Active Substance Work-Sharing Initiative (NASWSI): Survey Results and Recommendations","year":2024,"lang":"en","type":"article","venue":"Therapeutic Innovation & Regulatory Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Innovative Medicines Canada","funders":"Association of the British Pharmaceutical Industry; State Key Laboratory of Synthetical Automation for Process Industries; Innovative Medicines Canada","keywords":"Harmonization; Business; Market access; Work (physics); Transparency (behavior); Flexibility (engineering); Pharmacy; Public relations; Marketing; Medicine; Political science; Family medicine; Management; Engineering","score_opus":0.1849746633734487,"score_gpt":0.3627485352672676,"score_spread":0.17777387189381888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392580932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98840904,0.00023533672,0.00019941859,0.0048352773,0.000015619002,0.00005033213,0.00014578983,0.0000055034616,0.0061035617],"genre_scores_gemma":[0.99718446,0.00061801635,0.00028776933,0.0008327676,0.000015211096,0.000057854882,0.00009760298,0.0000043531004,0.0009019202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99079895,0.0054405034,0.00050053035,0.00026889864,0.0012344733,0.0017565595],"domain_scores_gemma":[0.97076786,0.014327868,0.006801804,0.0005305362,0.0037269357,0.0038449625],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01341564,0.000184814,0.00032449525,0.0009419655,0.0021309108,0.0034378492,0.0006170904,0.0008856871,0.0034826463],"category_scores_gemma":[0.024673048,0.00026544306,0.00041137665,0.0013557095,0.0013990259,0.0031988886,0.0028311093,0.0016349939,0.00038178582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012976998,0.0006172076,0.6590714,0.0004295189,0.000046594207,0.0007888039,0.2809521,0.00023372934,0.0006398183,0.0019804342,0.005650244,0.049460422],"study_design_scores_gemma":[0.000009995857,0.00023277721,0.25035498,0.00031209452,0.000017466316,0.00026708355,0.7361665,0.0002780773,0.00022809338,0.00043205373,0.011657828,0.00004308496],"about_ca_topic_score_codex":0.014736505,"about_ca_topic_score_gemma":0.012630127,"teacher_disagreement_score":0.98658437,"about_ca_system_score_codex":0.0018337204,"about_ca_system_score_gemma":0.0033901234,"threshold_uncertainty_score":0.070949495},"labels":[],"label_agreement":null},{"id":"W4392598004","doi":"10.18192/aporia.v16i1.7104","title":"Plaidoyer pour une « anti-préparation » consciente à la maternité","year":2024,"lang":"fr","type":"article","venue":"Aporia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Philosophy","score_opus":0.05900861195264472,"score_gpt":0.31842066510261413,"score_spread":0.2594120531499694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392598004","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07640732,0.01658835,0.033600286,0.43491742,0.0040937145,0.00014174794,0.00007704459,0.00024237575,0.43393174],"genre_scores_gemma":[0.8046441,0.006988915,0.009983333,0.04760982,0.0014580206,0.000165802,0.000037778813,0.0001486964,0.12896354],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99285275,0.0043265084,0.00016956305,0.00078420114,0.0011066854,0.0007602942],"domain_scores_gemma":[0.9924275,0.0035570455,0.0012159862,0.00072946405,0.001023597,0.0010464434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069002593,0.0004819581,0.00042434788,0.00069512747,0.0068085957,0.0057634288,0.0012405792,0.004431608,0.010010508],"category_scores_gemma":[0.012108329,0.00040119543,0.0004390937,0.0004278724,0.021008493,0.004223077,0.005025032,0.0077085188,0.0020931999],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007633393,0.000054902357,0.0028760307,0.00031340844,0.000028960052,0.0010084419,0.11300123,0.00013215459,0.002445021,0.8137742,0.025527949,0.040761333],"study_design_scores_gemma":[0.000019249686,0.0001075431,0.0035810675,0.0006668584,0.00002260527,0.0011571808,0.042341176,0.00024322594,0.0008041765,0.096356325,0.85464674,0.000053889755],"about_ca_topic_score_codex":0.007090011,"about_ca_topic_score_gemma":0.011298195,"teacher_disagreement_score":0.010010508,"about_ca_system_score_codex":0.0034847008,"about_ca_system_score_gemma":0.007285156,"threshold_uncertainty_score":0.036492527},"labels":[],"label_agreement":null},{"id":"W4392739550","doi":"10.1007/s40273-024-01369-9","title":"Reply to Comment on “A Framework for Fair Pricing of Medicines”","year":2024,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Business; Actuarial science; Economics; Medicine; Nursing","score_opus":0.08685281343077769,"score_gpt":0.36353599715388063,"score_spread":0.27668318372310297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392739550","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032263112,0.00042696824,0.00016129794,0.9860606,0.009095509,0.00002512856,0.0001572737,0.0000274535,0.003723096],"genre_scores_gemma":[0.0010863229,0.00008410098,0.000094607516,0.9895968,0.004667312,0.00003999941,0.000018524412,0.00001555215,0.0043967287],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9809833,0.004163516,0.0022562998,0.0023833744,0.005619088,0.004594398],"domain_scores_gemma":[0.96705306,0.021365533,0.0018665906,0.0008585514,0.005471979,0.00338421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018659646,0.0016160666,0.003396803,0.0016418885,0.010392585,0.012338442,0.007011427,0.2072659,0.012204648],"category_scores_gemma":[0.071641065,0.002421379,0.0038723052,0.0020956963,0.00797105,0.0077862814,0.0051283226,0.09884879,0.008457123],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080731064,0.000023856252,0.00029664268,0.000049445727,0.00003078617,0.0004419883,0.00026387093,0.00009346133,0.00010465075,0.009603019,0.98729634,0.001715234],"study_design_scores_gemma":[0.00031848118,0.0000696318,0.002760186,0.0006790611,0.00014027135,0.00039851738,0.0011313498,0.0010120779,0.00043102825,0.03459818,0.9581985,0.00026281725],"about_ca_topic_score_codex":0.05512546,"about_ca_topic_score_gemma":0.08288415,"teacher_disagreement_score":0.2072659,"about_ca_system_score_codex":0.015032438,"about_ca_system_score_gemma":0.020509342,"threshold_uncertainty_score":0.109609246},"labels":[],"label_agreement":null},{"id":"W4392763898","doi":"10.54194/ryjn9568","title":"Patented Medicines Expenditure in Canada 1990–2022 8TH Edition","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Attribution; Access to medicines; Operations research; Computer science; Library science; Medicine; Engineering; Psychology; Nursing; Public health; Social psychology","score_opus":0.05509737628602205,"score_gpt":0.31531164264622763,"score_spread":0.26021426636020556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392763898","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014961,0.022299612,0.0005561752,0.01857916,0.0047494643,0.00017515154,0.76673067,0.0010110873,0.17093757],"genre_scores_gemma":[0.16430207,0.040615067,0.00240522,0.005663369,0.0015849061,0.0002825589,0.35374403,0.00047648864,0.43092617],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9974468,0.000033256034,0.00008355815,0.00011619082,0.0018704407,0.00044967036],"domain_scores_gemma":[0.9934726,0.00020941765,0.0003929934,0.00009663443,0.0052387575,0.00058959523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077505014,0.0009335774,0.0006768997,0.006792743,0.0016395171,0.004389635,0.0016074368,0.0012743918,0.026310204],"category_scores_gemma":[0.0045031826,0.0004768655,0.00107157,0.014948665,0.0006624701,0.0011076101,0.0008780236,0.0015805328,0.005457473],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000690541,0.00001551102,0.0036735106,0.00041248935,0.00003585665,0.000059707163,0.0000984662,0.0006805027,0.00013026388,0.0055353134,0.9616517,0.027637755],"study_design_scores_gemma":[0.00005584401,0.000019701469,0.10098111,0.0005646073,0.00006276035,0.00012977264,0.00024847686,0.0010321405,0.00039646856,0.000776635,0.89568037,0.00005221916],"about_ca_topic_score_codex":0.99440444,"about_ca_topic_score_gemma":0.9929692,"teacher_disagreement_score":0.9248152,"about_ca_system_score_codex":0.07518479,"about_ca_system_score_gemma":0.12364653,"threshold_uncertainty_score":0.54550636},"labels":[],"label_agreement":null},{"id":"W4392778751","doi":"10.1017/jme.2024.20","title":"Aducanumab, Accelerated Approvals &amp; the Agency: Why the FDA Needs Structural Reform","year":2023,"lang":"en","type":"article","venue":"The Journal of Law Medicine & Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Agency (philosophy); Food and drug administration; Hard core; Drug approval; Public administration; Political science; Business; Drug; Medicine; Pharmacology; Sociology; Risk analysis (engineering)","score_opus":0.3608648809949944,"score_gpt":0.4087868544371139,"score_spread":0.04792197344211946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392778751","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013026281,0.0031370546,0.0026148355,0.9569385,0.00046560037,0.000032668788,0.000037262274,0.000027789303,0.023720004],"genre_scores_gemma":[0.59292984,0.0047112755,0.0057092374,0.38108262,0.0028798706,0.0001817028,0.000046488178,0.00007842557,0.012380513],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9823778,0.009107851,0.0006098372,0.0015383144,0.003517035,0.0028492154],"domain_scores_gemma":[0.95120627,0.035399158,0.0033498728,0.002179941,0.005174312,0.0026905024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026375249,0.00028629752,0.0005958825,0.0010691824,0.0069881137,0.012509087,0.0013909454,0.020250704,0.0065702195],"category_scores_gemma":[0.055167675,0.00046441532,0.00088151207,0.0011753729,0.01981364,0.014789763,0.0039455025,0.019599281,0.0011539728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005090941,0.000047193018,0.00092154887,0.00006739078,0.000009205988,0.00019144369,0.00090029615,0.00033848517,0.00038211804,0.93990153,0.045771252,0.011418555],"study_design_scores_gemma":[0.00028373234,0.00014087517,0.0034318704,0.00050423364,0.000039958428,0.00039414695,0.0023620687,0.0018164983,0.0012760697,0.61886007,0.3708088,0.00008155874],"about_ca_topic_score_codex":0.01628739,"about_ca_topic_score_gemma":0.012722091,"teacher_disagreement_score":0.026375249,"about_ca_system_score_codex":0.012768368,"about_ca_system_score_gemma":0.019154597,"threshold_uncertainty_score":0.13948733},"labels":[],"label_agreement":null},{"id":"W4392824428","doi":"10.2196/54250","title":"Development of a Consolidated Health Facility Masterlist Using Data From Polio Electronic Surveillance in the World Health Organization African Region","year":2024,"lang":"en","type":"article","venue":"JMIR Public Health and Surveillance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"World Health Organization","keywords":"Preprint; Poliomyelitis; Public health surveillance; Environmental health; Public health; Medicine; Virology; Computer science; World Wide Web","score_opus":0.17143091647165362,"score_gpt":0.35544023634374566,"score_spread":0.18400931987209204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392824428","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24695711,0.0016653446,0.1908363,0.004156318,0.0010685277,0.03871403,0.45671308,0.00942902,0.050460335],"genre_scores_gemma":[0.16718662,0.0013451733,0.4331012,0.00056653714,0.00020375624,0.016175892,0.37436658,0.00061279413,0.006441475],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9861,0.0035660057,0.004035838,0.0014929704,0.004213185,0.00059197936],"domain_scores_gemma":[0.9324025,0.0079888515,0.011821602,0.007573895,0.038324513,0.001888602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03291631,0.0009915276,0.0011910502,0.017787928,0.0011869306,0.0039111343,0.0025562237,0.00060351833,0.0068701934],"category_scores_gemma":[0.042105034,0.00093676546,0.0014767599,0.015796648,0.000396571,0.004883417,0.003216209,0.0013940884,0.0033339476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004094842,0.0006279647,0.4391794,0.0021255566,0.0005144554,0.00022092185,0.0030559744,0.0059587588,0.0024319512,0.0029022812,0.08709055,0.45548266],"study_design_scores_gemma":[0.00022195019,0.00091576466,0.7406972,0.0030094841,0.00044224167,0.0003054943,0.0059678815,0.018284919,0.008126537,0.0017048375,0.22009088,0.00023275406],"about_ca_topic_score_codex":0.032196205,"about_ca_topic_score_gemma":0.03039804,"teacher_disagreement_score":0.03291631,"about_ca_system_score_codex":0.0026213836,"about_ca_system_score_gemma":0.009571692,"threshold_uncertainty_score":0.17408013},"labels":[],"label_agreement":null},{"id":"W4392850706","doi":"10.38124/ijisrt/ijisrt24mar495","title":"Review on “Regulatory Approval Process of INDA, NDA and Anda in India and Foreign Countries (Us, Europe, China, Australia, Canada)”","year":2024,"lang":"en","type":"article","venue":"International Journal of Innovative Science and Research Technology (IJISRT)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"China; Business; International trade; Political science; Law","score_opus":0.06179209962641355,"score_gpt":0.3987023435406956,"score_spread":0.33691024391428204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392850706","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005477568,0.7645005,0.0018298207,0.058561046,0.05193705,0.0004204353,0.002344689,0.00029133566,0.11956739],"genre_scores_gemma":[0.009993299,0.7710744,0.0027278336,0.096488655,0.024308065,0.00049895205,0.0031695564,0.0001989688,0.091540225],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960821,0.00082265056,0.00055156957,0.00033417382,0.0019192907,0.00029021784],"domain_scores_gemma":[0.99027365,0.0035133045,0.0008347934,0.00022233733,0.004884322,0.00027152608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035220392,0.0007747443,0.0013292409,0.0033578756,0.0009520557,0.002617157,0.0025040002,0.003518642,0.0338219],"category_scores_gemma":[0.011342722,0.00041243486,0.0018490244,0.0035067596,0.0011685186,0.0022365288,0.00094020675,0.0031481108,0.01898585],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022214621,0.000012047016,0.0000437902,0.0029763014,0.000022938615,0.00008038389,0.00003347175,0.00006523806,0.00015300105,0.006095261,0.92915505,0.061340306],"study_design_scores_gemma":[0.000009577495,0.000012917385,0.00035988158,0.0019223077,0.000024217721,0.00014037042,0.000013525019,0.000013465135,0.000087525565,0.00051916705,0.99688894,0.0000080847585],"about_ca_topic_score_codex":0.009253204,"about_ca_topic_score_gemma":0.014257554,"teacher_disagreement_score":0.9907468,"about_ca_system_score_codex":0.0033550316,"about_ca_system_score_gemma":0.009508675,"threshold_uncertainty_score":0.11314559},"labels":[],"label_agreement":null},{"id":"W4392969076","doi":"","title":"Rational Drug Use Evaluation Based on World Health Organization Core Drug Use Indicators in Ethiopia: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Core (optical fiber); Medicine; Pharmacology; Computer science","score_opus":0.5424333075270054,"score_gpt":0.5827205667513982,"score_spread":0.0402872592243928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392969076","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035881181,0.9941432,0.00020916069,0.00026760277,0.0000747336,0.0008460287,0.00056686037,0.00000924899,0.00029507693],"genre_scores_gemma":[0.043557305,0.952936,0.0015404618,0.0003157416,0.000056565805,0.001134631,0.00037767025,0.000005351333,0.00007621225],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9864547,0.0041245203,0.005815513,0.000635163,0.00265065,0.00031930418],"domain_scores_gemma":[0.958491,0.029275034,0.007451284,0.00042792107,0.003920366,0.00043428462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016354827,0.0015336783,0.008761289,0.018421572,0.0007462174,0.0029639602,0.0017641346,0.0012407446,0.0020015475],"category_scores_gemma":[0.042076245,0.0009519455,0.007912264,0.015174468,0.00081992,0.0027741864,0.0015737864,0.0010065377,0.00012378796],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031690055,0.000036695026,0.002709661,0.9360848,0.010324341,0.00010913878,0.0002847657,0.00017340224,0.00011459133,0.00024075941,0.00073468726,0.048870314],"study_design_scores_gemma":[0.00036183343,0.00041720195,0.010424744,0.89690334,0.07920892,0.0003792734,0.0008134605,0.00027577498,0.0003358747,0.00030454816,0.010506861,0.00006808446],"about_ca_topic_score_codex":0.009975071,"about_ca_topic_score_gemma":0.028079998,"teacher_disagreement_score":0.018421572,"about_ca_system_score_codex":0.0060090297,"about_ca_system_score_gemma":0.018598592,"threshold_uncertainty_score":0.08649361},"labels":[],"label_agreement":null},{"id":"W4393192621","doi":"10.1186/s12910-024-01038-8","title":"Understanding drug exceptional access programs (DEAPs) in Canada, and their associated social and political issues","year":2024,"lang":"en","type":"letter","venue":"BMC Medical Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Simon Fraser University; Cegep Edouard Montpetit; Université de Montréal","funders":"","keywords":"Philosophy of medicine; Politics; Raising (metalworking); Context (archaeology); Political science; Political philosophy; Sociology; Public relations; Engineering ethics; Medicine; Law; Alternative medicine","score_opus":0.37904468244966255,"score_gpt":0.38707258716987186,"score_spread":0.008027904720209311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393192621","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035711918,0.0045637055,0.00022420348,0.9757229,0.0013114742,0.00001516615,0.00017521888,0.00001628722,0.014399874],"genre_scores_gemma":[0.071262754,0.004001296,0.0006555194,0.90891606,0.0024046316,0.000032659274,0.00009172457,0.000037488564,0.012597885],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9847398,0.0019340015,0.0006106628,0.0011188948,0.0057775965,0.0058190385],"domain_scores_gemma":[0.94963056,0.025720757,0.0023836952,0.0005341004,0.013074222,0.008656742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0110621555,0.0004195853,0.00085017557,0.0013823372,0.019738993,0.009909855,0.00360461,0.032438308,0.0047214045],"category_scores_gemma":[0.03829376,0.0005520075,0.0010371691,0.0021037743,0.015325642,0.0037024105,0.003867761,0.024748588,0.00044021607],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000053226737,0.00003078524,0.0039968626,0.00024817867,0.00003184946,0.0017835493,0.0057819905,0.00053197634,0.0003294449,0.21466441,0.750543,0.022004684],"study_design_scores_gemma":[0.00008526596,0.000026062347,0.014897823,0.0008978751,0.00007242255,0.0005802621,0.0063241404,0.0015227462,0.00036768822,0.05082125,0.92417747,0.00022697552],"about_ca_topic_score_codex":0.98366725,"about_ca_topic_score_gemma":0.99131995,"teacher_disagreement_score":0.8305629,"about_ca_system_score_codex":0.1694371,"about_ca_system_score_gemma":0.3105273,"threshold_uncertainty_score":0.9633352},"labels":[],"label_agreement":null},{"id":"W4393227939","doi":"10.1186/s12961-024-01131-9","title":"Choosing and accessing COVID-19 treatment options: a qualitative study with patients, caregivers, and health care providers in Lebanon","year":2024,"lang":"en","type":"article","venue":"Health Research Policy and Systems","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Saskatchewan","funders":"","keywords":"Thematic analysis; Pandemic; Qualitative research; Medicine; Health care; Pharmacy; Health administration; Health services research; Public health; Public relations; Nursing; Family medicine; Coronavirus disease 2019 (COVID-19); Economic growth; Political science; Disease; Sociology; Infectious disease (medical specialty)","score_opus":0.5203466824144755,"score_gpt":0.5666672211335124,"score_spread":0.04632053871903696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393227939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98705417,0.001866433,0.0012328501,0.005462432,0.0001554079,0.00030569354,0.00016433331,0.000014146791,0.0037444432],"genre_scores_gemma":[0.9919546,0.0016878742,0.00086016103,0.0026444094,0.00004435398,0.0004630398,0.00007187959,0.000022989681,0.002250662],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9912425,0.006429275,0.00022034625,0.0003695675,0.00033113177,0.0014071295],"domain_scores_gemma":[0.98400015,0.011230486,0.00093660917,0.00021619517,0.0011725023,0.0024440219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011777205,0.00079592864,0.0012295481,0.0012719854,0.014616658,0.0037585744,0.0018134622,0.0020925386,0.0049104565],"category_scores_gemma":[0.015269788,0.0007998812,0.00049217086,0.0014930342,0.0085400455,0.004472115,0.0054747267,0.004235053,0.00042074983],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024543362,0.000048727983,0.0016975903,0.00014731652,0.0000029391636,0.0007611726,0.99439234,0.000018779576,0.00018978913,0.00040906484,0.00052727823,0.0017804019],"study_design_scores_gemma":[0.0000022119145,0.000023868843,0.00035113082,0.000106703454,0.0000014223687,0.000079365025,0.9969465,0.000022092849,0.000037789825,0.00006906772,0.0023555863,0.000004251964],"about_ca_topic_score_codex":0.015205427,"about_ca_topic_score_gemma":0.028957447,"teacher_disagreement_score":0.015205427,"about_ca_system_score_codex":0.0066985087,"about_ca_system_score_gemma":0.0083446,"threshold_uncertainty_score":0.06228459},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"qualitative","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"qualitative","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4393243232","doi":"","title":"Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study","year":2021,"lang":"en","type":"review","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Business; Finance; Economics; Microeconomics","score_opus":0.3983765309248992,"score_gpt":0.5533024237406292,"score_spread":0.15492589281573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393243232","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010400444,0.9754013,0.0013038407,0.006854968,0.00031127728,0.0026939125,0.00086319214,0.000017285325,0.0021538767],"genre_scores_gemma":[0.16818412,0.8124775,0.008354598,0.0058599575,0.00019024668,0.0039659226,0.0005812024,0.000016293494,0.00037007718],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9076349,0.059051603,0.017223857,0.0021359262,0.012011829,0.0019417823],"domain_scores_gemma":[0.6379609,0.31219083,0.025758581,0.004586896,0.018409682,0.0010931025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.080557816,0.001130774,0.0045950916,0.016370453,0.0015876914,0.004988403,0.0024034053,0.003919443,0.0027480323],"category_scores_gemma":[0.23572262,0.00094442465,0.0050359583,0.028909022,0.001969971,0.006507811,0.0021688752,0.001958395,0.00025073095],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006743637,0.00014488622,0.01009696,0.83522433,0.008871659,0.0019270118,0.0043568355,0.0008967171,0.00033447763,0.010628243,0.010969993,0.11587461],"study_design_scores_gemma":[0.00028174306,0.00024907643,0.0056621917,0.91638774,0.018344628,0.000973684,0.006354618,0.00078139355,0.00026227176,0.0024899035,0.048121445,0.00009118648],"about_ca_topic_score_codex":0.036549415,"about_ca_topic_score_gemma":0.13218269,"teacher_disagreement_score":0.080557816,"about_ca_system_score_codex":0.018445453,"about_ca_system_score_gemma":0.0383024,"threshold_uncertainty_score":0.42603552},"labels":[],"label_agreement":null},{"id":"W4393246464","doi":"10.1097/01.cot.0001011416.51657.a8","title":"New Emphasis on Strategies to Increase Diversity in Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Oncology Times","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Emphasis (telecommunications); Diversity (politics); Psychology; Political science; Computer science; Telecommunications; Law","score_opus":0.2980308675641286,"score_gpt":0.46849855631652465,"score_spread":0.17046768875239604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393246464","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008105646,0.022286018,0.04849283,0.8707269,0.01659969,0.0008436158,0.00015415781,0.00065306184,0.03943308],"genre_scores_gemma":[0.027642027,0.017746352,0.070669435,0.81478155,0.039228193,0.004455092,0.00033371898,0.00075252296,0.024391044],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.62474495,0.25744405,0.017160466,0.026438683,0.06541883,0.008792977],"domain_scores_gemma":[0.3706766,0.44889882,0.022199363,0.053137198,0.05046539,0.0546226],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.42763683,0.002900859,0.0035635927,0.0064611416,0.0073042368,0.032769363,0.010424839,0.032752227,0.03770974],"category_scores_gemma":[0.4338926,0.0024693732,0.003774255,0.006290895,0.03393485,0.050103955,0.034189653,0.048405647,0.011821974],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031839727,0.0003463647,0.0012973438,0.0020289796,0.00032317237,0.00017413785,0.0030179769,0.0008987727,0.000582152,0.3299938,0.45218638,0.2088325],"study_design_scores_gemma":[0.00080342026,0.00035897203,0.0011676147,0.0025069213,0.000101286125,0.00027705473,0.0007053918,0.0007311961,0.00028865348,0.1859705,0.8069762,0.00011285412],"about_ca_topic_score_codex":0.002828909,"about_ca_topic_score_gemma":0.0049805134,"teacher_disagreement_score":0.57236314,"about_ca_system_score_codex":0.014511052,"about_ca_system_score_gemma":0.050795782,"threshold_uncertainty_score":0.7058257},"labels":[],"label_agreement":null},{"id":"W4393436566","doi":"10.1177/27551938241242602","title":"Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia?","year":2024,"lang":"en","type":"article","venue":"International Journal of Social Determinants of Health and Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"La Trobe University","keywords":"Graduation (instrument); TRIPS architecture; Intellectual property; Medicine; Developing country; Accession; Economic growth; Environmental health; Business; International trade; Political science; Economics; Law; Engineering","score_opus":0.07557188960058904,"score_gpt":0.4129608070347674,"score_spread":0.33738891743417837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393436566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96929795,0.0008824837,0.00019526797,0.015437129,0.000048217393,0.000049564846,0.0008691095,0.000004518045,0.013215876],"genre_scores_gemma":[0.9978574,0.00038339684,0.00004374199,0.000588438,0.000027552336,0.0000138423775,0.00016610594,0.0000012433429,0.0009181521],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987954,0.00039786147,0.00002750249,0.000101804406,0.00010372246,0.0005737106],"domain_scores_gemma":[0.99687034,0.0012516099,0.0009939382,0.000037055157,0.00020373848,0.0006433666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00228274,0.0002465171,0.000459763,0.00048499327,0.0008796578,0.003635914,0.0006215886,0.0019984304,0.006465695],"category_scores_gemma":[0.0052474793,0.0002094517,0.0005346205,0.00061559945,0.0015004377,0.0024735394,0.0015927205,0.0021775612,0.00033500855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011505104,0.0009781801,0.83352613,0.0004181353,0.0004048067,0.005026877,0.0017217126,0.04000176,0.0016214334,0.06803828,0.012860401,0.034251764],"study_design_scores_gemma":[0.00016738639,0.0009468896,0.92301077,0.00032833224,0.00018471773,0.00032535862,0.010554984,0.037393376,0.0009582898,0.016860176,0.009188087,0.00008173421],"about_ca_topic_score_codex":0.072154075,"about_ca_topic_score_gemma":0.055434328,"teacher_disagreement_score":0.072154075,"about_ca_system_score_codex":0.006328355,"about_ca_system_score_gemma":0.0029168495,"threshold_uncertainty_score":0.1434682},"labels":[],"label_agreement":null},{"id":"W4393995435","doi":"10.1001/jamanetworkopen.2024.4246","title":"Drug Shortages Prior to and During the COVID-19 Pandemic","year":2024,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Health Canada; Centers for Disease Control and Prevention; Agency for Healthcare Research and Quality; National Institutes of Health; Pfizer; Soochow University; Bristol-Myers Squibb; U.S. Department of Veterans Affairs","keywords":"Supply chain; Pandemic; Medicine; Economic shortage; Pharmacy; Drug; Business; Influenza pandemic; Odds; Logistic regression; Coronavirus disease 2019 (COVID-19); Environmental health; Family medicine; Marketing; Pharmacology; Disease","score_opus":0.08931792177657857,"score_gpt":0.34445319094747623,"score_spread":0.2551352691708977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393995435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943329,0.00062529725,0.00023764203,0.00043777938,0.0000158136,0.000032288368,0.0033915055,0.000007926305,0.0009188356],"genre_scores_gemma":[0.9971002,0.00035957785,0.00015870373,0.00015186294,0.000036254736,0.000037798607,0.0019364917,0.0000032438418,0.00021588521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975858,0.00072942785,0.00046818968,0.0004688286,0.00039799383,0.00034977475],"domain_scores_gemma":[0.9824179,0.002253621,0.013387288,0.00044335163,0.00071411266,0.0007836107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026702476,0.0001630046,0.00029160292,0.0009769337,0.0004006672,0.00072747027,0.000356299,0.0004584783,0.002496406],"category_scores_gemma":[0.010380964,0.00024370711,0.00047141002,0.0017843344,0.00033285454,0.0010546106,0.001100179,0.0006996508,0.00025093235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007315403,0.000021724934,0.99794716,0.000026695787,0.000026061693,0.00004118962,0.000089544665,0.00007314475,0.000042886546,0.00002631145,0.0002021817,0.0014298933],"study_design_scores_gemma":[0.000004065329,0.00008219433,0.99874336,0.000045722263,0.000012199283,0.000119596385,0.00031637182,0.0002048098,0.000047538506,0.000031865296,0.00038821658,0.0000040360933],"about_ca_topic_score_codex":0.012376229,"about_ca_topic_score_gemma":0.010639448,"teacher_disagreement_score":0.012376229,"about_ca_system_score_codex":0.00072709704,"about_ca_system_score_gemma":0.0011627848,"threshold_uncertainty_score":0.024608374},"labels":[],"label_agreement":null},{"id":"W4394013687","doi":"10.1016/j.clcc.2024.04.001","title":"Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission","year":2024,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Chugai Pharmaceutical; Ministry of Health, Labour and Welfare","keywords":"Reliability (semiconductor); Medicine","score_opus":0.2529162556889884,"score_gpt":0.44079737142532893,"score_spread":0.18788111573634053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394013687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4726134,0.014540948,0.3180202,0.04333064,0.008238467,0.003731238,0.04957014,0.0029030852,0.087051876],"genre_scores_gemma":[0.95774907,0.0008753344,0.024519464,0.0022372056,0.0011708924,0.00085134857,0.009510178,0.0003878602,0.0026987535],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.61896276,0.24787429,0.0586936,0.024042884,0.04534422,0.00508225],"domain_scores_gemma":[0.08888049,0.66231734,0.08660473,0.106988154,0.05303798,0.002171233],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.26085135,0.0009725699,0.002172241,0.009407793,0.0017557725,0.012272293,0.0049486267,0.0043413923,0.006997308],"category_scores_gemma":[0.80527806,0.0012264906,0.0023655512,0.011357307,0.005463465,0.0066836197,0.0041849,0.0056106052,0.0035087313],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030669544,0.0005488467,0.66707,0.0025005222,0.0028118042,0.0017117889,0.0030183536,0.032168195,0.0009828603,0.067047246,0.07013915,0.14893426],"study_design_scores_gemma":[0.0010685985,0.0012135999,0.44557187,0.004783142,0.0020599978,0.003560528,0.0030145675,0.1927639,0.014943979,0.14565161,0.18485844,0.00050978694],"about_ca_topic_score_codex":0.0051204194,"about_ca_topic_score_gemma":0.0027464111,"teacher_disagreement_score":0.26085135,"about_ca_system_score_codex":0.0029980738,"about_ca_system_score_gemma":0.004706619,"threshold_uncertainty_score":0.9115019},"labels":[],"label_agreement":null},{"id":"W4394063741","doi":"10.1016/j.healthpol.2024.105064","title":"The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis","year":2024,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of British Columbia; University of Toronto; Providence Health Care","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Product (mathematics); Reference price; Access to medicines; Economics; Drug prices; Business; Agricultural economics; Public economics; International economics; Developing country; Economic growth","score_opus":0.11381578181981207,"score_gpt":0.4023067996559829,"score_spread":0.28849101783617087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394063741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80212224,0.009643281,0.0030653619,0.036407135,0.00025939307,0.00077046134,0.021020843,0.00016109785,0.12655023],"genre_scores_gemma":[0.9876835,0.0027513246,0.0012371872,0.0023291307,0.00004364457,0.00008978733,0.0020856778,0.000019501234,0.003760215],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98835087,0.0017585874,0.00028409623,0.0005950737,0.0039818706,0.0050295107],"domain_scores_gemma":[0.9820499,0.0051289005,0.0018868827,0.00026680878,0.0088626975,0.0018047962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005595173,0.00056378765,0.00060548214,0.0026550714,0.0035617608,0.005581394,0.0019133267,0.0019776726,0.0042452603],"category_scores_gemma":[0.02104373,0.00044703326,0.0017514611,0.005291015,0.0016014101,0.0015367416,0.0012281933,0.0024357673,0.00019839048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0026011162,0.0009925552,0.418581,0.002451976,0.001807537,0.0022021534,0.0019319807,0.21162389,0.0034105114,0.16613197,0.09256198,0.09570329],"study_design_scores_gemma":[0.00072268146,0.0010214293,0.727159,0.0010030014,0.0021883904,0.00041193643,0.009364978,0.1255971,0.0044808146,0.011417951,0.11609015,0.0005425896],"about_ca_topic_score_codex":0.99282503,"about_ca_topic_score_gemma":0.9875802,"teacher_disagreement_score":0.7944037,"about_ca_system_score_codex":0.2055963,"about_ca_system_score_gemma":0.17571254,"threshold_uncertainty_score":0.9213957},"labels":[],"label_agreement":null},{"id":"W4394074624","doi":"10.6084/m9.figshare.14282639","title":"Access to medication in universal health systems – perspectives and challenges","year":2021,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Healthcare system; Computer science; Medicine; Health care; Political science","score_opus":0.24263575858736344,"score_gpt":0.3623568729058299,"score_spread":0.11972111431846647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394074624","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44405633,0.049623657,0.006154328,0.14269389,0.00043153748,0.00060857175,0.18529207,0.00011473344,0.17102492],"genre_scores_gemma":[0.9567309,0.010943806,0.004269608,0.003571421,0.00009842768,0.00050430663,0.021275677,0.00003221269,0.0025736177],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9932689,0.0037817692,0.00046456285,0.0004169405,0.0012846763,0.00078314735],"domain_scores_gemma":[0.98227215,0.01073603,0.0016057094,0.0010394285,0.0036398594,0.0007068124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006493051,0.000171252,0.000495136,0.003535421,0.0012673392,0.00362666,0.00069811323,0.00051532587,0.0077780485],"category_scores_gemma":[0.024534669,0.00017244424,0.00037385122,0.009137679,0.0015210327,0.0032577994,0.0031154645,0.0012071312,0.00024646727],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021674563,0.00014335195,0.14776,0.0092054345,0.0004354754,0.00070853496,0.0646424,0.004668061,0.00030650306,0.47728363,0.13851723,0.1561127],"study_design_scores_gemma":[0.00006661667,0.00006722764,0.18686967,0.011385727,0.00015341565,0.00026243983,0.08767205,0.00249235,0.00031328807,0.05677106,0.6538729,0.0000732687],"about_ca_topic_score_codex":0.33088592,"about_ca_topic_score_gemma":0.3290529,"teacher_disagreement_score":0.33088592,"about_ca_system_score_codex":0.014456124,"about_ca_system_score_gemma":0.012047615,"threshold_uncertainty_score":0.6579199},"labels":[],"label_agreement":null},{"id":"W4394078214","doi":"10.6084/m9.figshare.5976178","title":"Additional file 3: of Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Business; Cohort; Marketing; Medicine; Political science; Internal medicine","score_opus":0.22865380175844738,"score_gpt":0.3596082705807672,"score_spread":0.13095446882231984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394078214","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017995002,0.000023798513,0.000012225286,0.000040501134,0.000005389732,0.000009179985,0.9994423,0.00001525195,0.00027134456],"genre_scores_gemma":[0.0053609796,0.00016992266,0.00025151818,0.000103266866,0.0000176427,0.0002138454,0.9899402,0.000051401366,0.003891194],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991091,0.000062433974,0.00012496545,0.00016860984,0.0002828767,0.00025201117],"domain_scores_gemma":[0.99189186,0.0020881873,0.0008949555,0.00056656345,0.0039625205,0.0005958511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000990239,0.0009870718,0.0012832303,0.0042081964,0.001520549,0.002072763,0.002113486,0.00089070265,0.24114104],"category_scores_gemma":[0.013143759,0.00062121014,0.001415874,0.011124184,0.00040982777,0.0010500321,0.0013925366,0.001522244,0.024342868],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007949714,0.000021776024,0.00782436,0.00060874206,0.00007117194,0.000021403996,0.00004723495,0.00031595628,0.0000146579,0.00046588958,0.9885894,0.001939949],"study_design_scores_gemma":[0.0014860245,0.000055710952,0.21676303,0.0029992636,0.00040296753,0.00014462152,0.0009748365,0.0014668577,0.00032610176,0.0019529753,0.7733006,0.0001269273],"about_ca_topic_score_codex":0.90091383,"about_ca_topic_score_gemma":0.9292998,"teacher_disagreement_score":0.9905667,"about_ca_system_score_codex":0.009433304,"about_ca_system_score_gemma":0.020598592,"threshold_uncertainty_score":0.80669713},"labels":[],"label_agreement":null},{"id":"W4394134852","doi":"10.6084/m9.figshare.16836902","title":"Comparison of the registration process of the medicines control authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: benchmarking best practices","year":2021,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Benchmarking; Control (management); Process (computing); Business; Best practice; Operations management; Political science; Management; Marketing; Computer science; Engineering; Law; Economics","score_opus":0.16097664669030567,"score_gpt":0.3714897834477506,"score_spread":0.2105131367574449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394134852","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15178406,0.003316505,0.0022243294,0.0030039777,0.000098998855,0.0013052156,0.8096444,0.00030003255,0.02832253],"genre_scores_gemma":[0.30264395,0.002439816,0.0069747115,0.000608378,0.00004595482,0.0022652224,0.675064,0.0001344857,0.009823471],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910648,0.0032059015,0.0016132003,0.00084765843,0.0024261954,0.0008421972],"domain_scores_gemma":[0.9623824,0.008828301,0.008869543,0.0028102433,0.015719753,0.001389797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008140691,0.00038023526,0.00043445342,0.005585389,0.0008287916,0.0019422706,0.0009695154,0.0004389945,0.0065345797],"category_scores_gemma":[0.049665283,0.0003003336,0.0005670984,0.012814812,0.0003440449,0.0010072625,0.0014329616,0.0006964685,0.0015281069],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008080346,0.00020573768,0.4187749,0.0062889215,0.0006999215,0.00029902102,0.0028797146,0.0059068864,0.0008206231,0.015868405,0.46688527,0.08056255],"study_design_scores_gemma":[0.00018721166,0.00006001766,0.7116578,0.0012447026,0.00013697037,0.0001300019,0.001642933,0.0031738733,0.0007850921,0.0007060774,0.28020263,0.000072710296],"about_ca_topic_score_codex":0.5963083,"about_ca_topic_score_gemma":0.61227393,"teacher_disagreement_score":0.4036917,"about_ca_system_score_codex":0.008696479,"about_ca_system_score_gemma":0.016743753,"threshold_uncertainty_score":0.81213826},"labels":[],"label_agreement":null},{"id":"W4394294089","doi":"10.6084/m9.figshare.5976139","title":"Additional file 1: of Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Cohort; Business; Medicine; Political science; Internal medicine","score_opus":0.22976055365128062,"score_gpt":0.3583567912286175,"score_spread":0.1285962375773369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394294089","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019993384,0.000027370921,0.00001306817,0.000040400824,0.000005497994,0.0000101152345,0.99942684,0.000014428552,0.00026233756],"genre_scores_gemma":[0.0054981904,0.00020494052,0.00026730835,0.0001018735,0.000019106994,0.00024036621,0.989883,0.00004890648,0.0037364487],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990988,0.000064315675,0.00012375567,0.00017420649,0.00028919114,0.0002497605],"domain_scores_gemma":[0.9916727,0.0020793346,0.00095597,0.0005705416,0.004073567,0.00064781366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010047978,0.0009860257,0.0012702849,0.004420579,0.0015819382,0.0020117976,0.0021617028,0.00089174253,0.22182404],"category_scores_gemma":[0.013332642,0.0006461137,0.0012598466,0.012021258,0.0004211196,0.0010360369,0.0013878735,0.0015179362,0.024263168],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007485448,0.000022573018,0.0075905975,0.000601093,0.00006357526,0.000019308869,0.000047031586,0.00030151027,0.000013592327,0.00044720952,0.9887589,0.0020597351],"study_design_scores_gemma":[0.001356124,0.000059685248,0.22294791,0.0030811387,0.000379816,0.00014876887,0.00096368266,0.0014499754,0.0003116776,0.0018417123,0.7673334,0.00012614645],"about_ca_topic_score_codex":0.90109044,"about_ca_topic_score_gemma":0.93058485,"teacher_disagreement_score":0.22182404,"about_ca_system_score_codex":0.010087577,"about_ca_system_score_gemma":0.02231307,"threshold_uncertainty_score":0.7420753},"labels":[],"label_agreement":null},{"id":"W4394294954","doi":"10.6084/m9.figshare.5976196","title":"Additional file 4: of Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Business; Cohort; Marketing; Medicine; Political science; Internal medicine","score_opus":0.22707546494107814,"score_gpt":0.35919722462146814,"score_spread":0.13212175968039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394294954","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018870947,0.000025691214,0.000012733451,0.000043791344,0.000006001826,0.00000925001,0.9994197,0.000015633357,0.0002784855],"genre_scores_gemma":[0.0054401075,0.00017854877,0.00025018872,0.00010278688,0.000018766374,0.00021010939,0.9896852,0.000049750677,0.0040645245],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99909544,0.00006503165,0.00012360308,0.00016585237,0.00028553195,0.00026463356],"domain_scores_gemma":[0.9919127,0.0019602792,0.0009190649,0.0005652424,0.004018677,0.0006238883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009934087,0.0010001408,0.0012597169,0.004331,0.0015104875,0.0020447546,0.0021824278,0.0009076915,0.2331825],"category_scores_gemma":[0.012953993,0.00062756235,0.0014342375,0.011350745,0.0004017866,0.0010366816,0.0013823938,0.001512198,0.023960317],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008040292,0.000022004508,0.008078033,0.0005888849,0.00007204666,0.000020519654,0.000044035824,0.00032488425,0.00001439432,0.00044780227,0.9883469,0.0019601746],"study_design_scores_gemma":[0.0014228841,0.000055584238,0.22405069,0.0028689492,0.00040332944,0.0001337166,0.00093442266,0.0014323128,0.00033054894,0.0018078567,0.7664331,0.00012664839],"about_ca_topic_score_codex":0.9049353,"about_ca_topic_score_gemma":0.9311187,"teacher_disagreement_score":0.2331825,"about_ca_system_score_codex":0.009781382,"about_ca_system_score_gemma":0.021255841,"threshold_uncertainty_score":0.78007317},"labels":[],"label_agreement":null},{"id":"W4394513493","doi":"10.6084/m9.figshare.5976160","title":"Additional file 2: of Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Cohort; Business; Medicine; Political science; Internal medicine","score_opus":0.2240532599363119,"score_gpt":0.35846030474405927,"score_spread":0.13440704480774737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394513493","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018860905,0.000024275168,0.000012680431,0.00004181979,0.0000054092948,0.000009663816,0.9994367,0.000014447517,0.00026642004],"genre_scores_gemma":[0.0052589164,0.00016838661,0.00025248475,0.00010026365,0.0000177912,0.00021994073,0.99020934,0.000047427093,0.003725444],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9991002,0.00006273698,0.00012238463,0.00017126535,0.00028875942,0.0002546981],"domain_scores_gemma":[0.9918069,0.0020274413,0.00093056046,0.00056834816,0.004029792,0.00063683785],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009977368,0.0009846048,0.001266632,0.0043632044,0.001548077,0.0020611247,0.0021447376,0.00090229616,0.2265801],"category_scores_gemma":[0.012848026,0.00063787634,0.001347595,0.011536472,0.00041148037,0.0010145047,0.001387333,0.0015115385,0.023882024],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075167816,0.000022285478,0.007712674,0.0005874497,0.00006656464,0.000020866899,0.00004624829,0.00031178366,0.000013917556,0.00046257512,0.98873365,0.0019468047],"study_design_scores_gemma":[0.0013895353,0.000055569482,0.2152661,0.0028300867,0.00037764767,0.00014089582,0.00093288365,0.0014387383,0.0003066384,0.0018624081,0.7752772,0.0001223208],"about_ca_topic_score_codex":0.9016503,"about_ca_topic_score_gemma":0.92984253,"teacher_disagreement_score":0.9990023,"about_ca_system_score_codex":0.0095862495,"about_ca_system_score_gemma":0.021480687,"threshold_uncertainty_score":0.75798595},"labels":[],"label_agreement":null},{"id":"W4394726519","doi":"10.54194/qqvc3893","title":"Waiting for new medicines in Canada, Europe, and the United States","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Institute for Health Information","funders":"","keywords":"Political science; Business","score_opus":0.08095497517038194,"score_gpt":0.3309384742608487,"score_spread":0.24998349909046677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394726519","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28527594,0.07787341,0.001036845,0.3217466,0.00532891,0.00016273848,0.06932747,0.0004142312,0.23883386],"genre_scores_gemma":[0.8500013,0.028713875,0.0015313983,0.037743457,0.0013532031,0.00006756982,0.02565373,0.0002499374,0.054685555],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.993338,0.00020346505,0.00026364002,0.0003436482,0.002842837,0.0030085074],"domain_scores_gemma":[0.9835058,0.0012414353,0.002115045,0.00016966426,0.006363363,0.00660467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025674088,0.00032912006,0.00094562356,0.0030802477,0.0056273798,0.009465398,0.0017107056,0.0024056092,0.010633036],"category_scores_gemma":[0.008818187,0.00036043092,0.0011627687,0.008530273,0.0019887818,0.0027716495,0.0019494216,0.0045707305,0.0005341099],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005588471,0.00020669005,0.094437286,0.000530643,0.00036266653,0.0005286153,0.002030145,0.002731463,0.00037814028,0.118236154,0.7049345,0.07506489],"study_design_scores_gemma":[0.00024710785,0.00012909988,0.3946367,0.0018581245,0.00042174515,0.0003450371,0.0097953025,0.003647682,0.00086827885,0.012803983,0.57491386,0.00033312378],"about_ca_topic_score_codex":0.9940619,"about_ca_topic_score_gemma":0.9967673,"teacher_disagreement_score":0.9048557,"about_ca_system_score_codex":0.09514424,"about_ca_system_score_gemma":0.20061421,"threshold_uncertainty_score":0.690323},"labels":[],"label_agreement":null},{"id":"W4394743629","doi":"10.2139/ssrn.4789836","title":"Examining the Zero-Markup Drug Policy in China: A Structural Approach","year":2024,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bank of Canada; Government of Canada","funders":"","keywords":"Markup language; China; Drug; Zero (linguistics); Zero tolerance; Business; Political science; Computer science; Pharmacology; Medicine; XML; Linguistics; World Wide Web; Philosophy; Law","score_opus":0.028550087602585445,"score_gpt":0.2716049803296615,"score_spread":0.24305489272707606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394743629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761031,0.00058437017,0.0102592455,0.0038146004,0.000047437083,0.00013313223,0.0009063751,0.000080501806,0.008071129],"genre_scores_gemma":[0.9960711,0.00026040414,0.00076117745,0.00008886528,0.00003572308,0.000040010236,0.00021326536,0.00000993092,0.0025195377],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9983929,0.00045251963,0.00007661691,0.0002633557,0.0002053445,0.00060923956],"domain_scores_gemma":[0.9931873,0.0037469,0.0016092808,0.00025735528,0.0006958142,0.000503316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025366116,0.00067193713,0.0022973192,0.0025287431,0.0012839265,0.0026232942,0.0021030207,0.0020916844,0.009698212],"category_scores_gemma":[0.007088071,0.00076161063,0.0017408346,0.0024136833,0.0014389922,0.0022033574,0.0020706237,0.0018449121,0.0003353631],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005377705,0.0008558429,0.16515705,0.00044642432,0.00092180975,0.0016864949,0.00077055907,0.4440256,0.0023964348,0.35308766,0.0049696523,0.025144672],"study_design_scores_gemma":[0.00025021163,0.00054723735,0.07005785,0.000062167775,0.0006369684,0.000071146795,0.0010408958,0.87407154,0.0016127762,0.048547126,0.0030024552,0.00009955531],"about_ca_topic_score_codex":0.13105431,"about_ca_topic_score_gemma":0.09334613,"teacher_disagreement_score":0.13105431,"about_ca_system_score_codex":0.0061418163,"about_ca_system_score_gemma":0.01164121,"threshold_uncertainty_score":0.26058298},"labels":[],"label_agreement":null},{"id":"W4394931179","doi":"10.3389/fphar.2024.1376009","title":"Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia’s perspective","year":2024,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Janssen Pharmaceuticals","keywords":"Bioequivalence; Biosimilar; Medicine; Orphan drug; Risk analysis (engineering); Generic drug; Drug; Pharmacology; Intensive care medicine; Bioavailability; Bioinformatics","score_opus":0.04399446159296608,"score_gpt":0.3600853454760251,"score_spread":0.31609088388305906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394931179","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018131176,0.91625834,0.00087403075,0.052929994,0.0009585747,0.000057301677,0.00052998745,0.000021814676,0.010238746],"genre_scores_gemma":[0.10848949,0.8776977,0.0015183566,0.009938567,0.0010446097,0.00003040943,0.00029140885,0.000018038207,0.0009714888],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968995,0.0008248287,0.0006075748,0.0002397971,0.0011903109,0.0002379489],"domain_scores_gemma":[0.986886,0.0051240143,0.0024519071,0.00018986619,0.004781867,0.0005664645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074148704,0.0005577865,0.000635746,0.0042580147,0.0007328567,0.003424549,0.0006487259,0.0014081581,0.004092584],"category_scores_gemma":[0.012204211,0.00025482,0.0006333668,0.0047438014,0.0016592148,0.0031034108,0.0014524721,0.001695436,0.0004031682],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003740637,0.00007723511,0.023541426,0.018385855,0.00033038185,0.0015479873,0.0039276425,0.0008595826,0.00097535364,0.031216623,0.03901107,0.87975276],"study_design_scores_gemma":[0.000052471416,0.0003327142,0.059249308,0.027599372,0.00053136074,0.0063328054,0.011157627,0.0009220968,0.00091609795,0.005954552,0.8868172,0.00013437794],"about_ca_topic_score_codex":0.014637222,"about_ca_topic_score_gemma":0.01551127,"teacher_disagreement_score":0.014637222,"about_ca_system_score_codex":0.0059978934,"about_ca_system_score_gemma":0.009459272,"threshold_uncertainty_score":0.043518007},"labels":[],"label_agreement":null},{"id":"W4394999067","doi":"10.1136/bmj.q887","title":"When will Canada have national pharmacare?","year":2024,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia Hospital","funders":"","keywords":"Data science; Computer science; World Wide Web; Political science","score_opus":0.04842766164545893,"score_gpt":0.32485254233805333,"score_spread":0.2764248806925944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394999067","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003950532,0.009283788,0.000069208545,0.15626821,0.8303032,0.000045641435,0.0004340787,0.00006572285,0.0034906575],"genre_scores_gemma":[0.0013571306,0.016510688,0.00034140275,0.20186788,0.7469799,0.00010298818,0.00030955544,0.00012406988,0.03240647],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9867225,0.001423565,0.0012189641,0.00074185844,0.00849992,0.0013930803],"domain_scores_gemma":[0.944825,0.013627241,0.0020455576,0.0012024381,0.029134318,0.009165564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016895046,0.0037270696,0.005983636,0.005635839,0.009535888,0.015099155,0.006025612,0.039692607,0.0203586],"category_scores_gemma":[0.067353755,0.001855747,0.0040028687,0.005566915,0.0057927063,0.0067972806,0.0019728248,0.041745067,0.008665091],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018298026,0.0000053301605,0.000014619852,0.0001404741,0.000017592727,0.000018188712,0.0000072688313,0.000014027978,0.0000066398784,0.00024518708,0.99818194,0.0013304458],"study_design_scores_gemma":[0.00014114773,0.000017472046,0.0005178384,0.0009475998,0.00017433077,0.000042748856,0.0001326709,0.00013721784,0.00004578037,0.0016197172,0.99617565,0.00004776061],"about_ca_topic_score_codex":0.44494477,"about_ca_topic_score_gemma":0.69565815,"teacher_disagreement_score":0.9679975,"about_ca_system_score_codex":0.032002524,"about_ca_system_score_gemma":0.09240551,"threshold_uncertainty_score":0.88470984},"labels":[],"label_agreement":null},{"id":"W4395004529","doi":"10.1136/bmjgh-2024-015122","title":"Quality and safety for substances of human origins: scientific evidence and the new EU regulations","year":2024,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Quality (philosophy); Scientific evidence; Human health; Public health; Business; Environmental health; Political science; Risk analysis (engineering); Engineering ethics; Medicine; Engineering; Nursing; Epistemology; Philosophy","score_opus":0.24835577733704775,"score_gpt":0.4884743484454923,"score_spread":0.24011857110844456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395004529","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018462656,0.62880987,0.004086319,0.3175134,0.004441376,0.000066746994,0.0007551714,0.000022190523,0.025842283],"genre_scores_gemma":[0.455555,0.4022173,0.0057879984,0.118100844,0.015135667,0.00015967488,0.00085455616,0.000054750537,0.0021342717],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.93125117,0.042560786,0.0067849075,0.00493293,0.012781558,0.0016886522],"domain_scores_gemma":[0.4419686,0.48445344,0.036593664,0.015970536,0.018862195,0.002151451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0971561,0.0007198461,0.0025896663,0.0047198744,0.00091583363,0.00680839,0.0029565503,0.01070921,0.010920653],"category_scores_gemma":[0.20003057,0.00043793392,0.0033480409,0.0052850605,0.012342144,0.009543926,0.003917809,0.0080395695,0.0009422586],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035769318,0.0006877537,0.03613503,0.029147783,0.004690777,0.0006910268,0.0014549121,0.004652749,0.00060332875,0.5692367,0.04590313,0.3032199],"study_design_scores_gemma":[0.0010592286,0.0012124374,0.06949637,0.08810575,0.004682963,0.0005754355,0.0030151529,0.0026632408,0.0017229071,0.57666236,0.25053146,0.00027273895],"about_ca_topic_score_codex":0.0050740275,"about_ca_topic_score_gemma":0.0031393378,"teacher_disagreement_score":0.0971561,"about_ca_system_score_codex":0.0040399344,"about_ca_system_score_gemma":0.006381511,"threshold_uncertainty_score":0.5138167},"labels":[],"label_agreement":null},{"id":"W4395064528","doi":"10.1093/ajhp/zxae105","title":"National trends in prescription drug expenditures and projections for 2024","year":2024,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medical prescription; Prescription drug; Drug; Business; Medicine; Pharmacology","score_opus":0.08118293247098035,"score_gpt":0.38488180118219284,"score_spread":0.3036988687112125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395064528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7724893,0.0052505094,0.0076796403,0.0058694,0.00029603104,0.00007835234,0.16788156,0.00086323684,0.039591987],"genre_scores_gemma":[0.8888595,0.0033200914,0.0063552517,0.00076396414,0.00012498541,0.00012896273,0.09577539,0.000060363134,0.0046115066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994603,0.00009242366,0.00005971299,0.00007426407,0.00021630048,0.00009711815],"domain_scores_gemma":[0.99829954,0.00015032367,0.0005490804,0.0000505304,0.0008301349,0.000120386314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008711212,0.0005621733,0.00020719782,0.0021949385,0.00025415543,0.001186028,0.00040797293,0.000509508,0.0032582362],"category_scores_gemma":[0.0028325876,0.00019504825,0.0010679816,0.0034514517,0.00016760144,0.0011167742,0.0005553237,0.0007494357,0.0011549944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006760283,0.00021789891,0.78732175,0.000697248,0.00065739534,0.00039356246,0.0002533227,0.060560253,0.0011336323,0.010458894,0.06348173,0.07414826],"study_design_scores_gemma":[0.000050997376,0.00027279273,0.8002483,0.00037908574,0.00027310094,0.0009042934,0.00096620136,0.06710685,0.0021891396,0.0035828177,0.12393169,0.000094667375],"about_ca_topic_score_codex":0.06055159,"about_ca_topic_score_gemma":0.04356063,"teacher_disagreement_score":0.06055159,"about_ca_system_score_codex":0.0027450232,"about_ca_system_score_gemma":0.0017956952,"threshold_uncertainty_score":0.12039828},"labels":[],"label_agreement":null},{"id":"W4395097595","doi":"10.2139/ssrn.4756803","title":"Implementation of Pharmaceutical Alternatives to a Toxic Drug Supply in British Columbia: A Mixed Methods Study","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Centre for Disease Control; Providence Health Care; Simon Fraser University; University of Victoria","funders":"","keywords":"Drug; Business; Pharmaceutical sciences; Medicine; Pharmacology","score_opus":0.04697056385672035,"score_gpt":0.41170571349269874,"score_spread":0.3647351496359784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395097595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813133,0.00032425427,0.00011637839,0.00019742595,0.000006231184,0.00022385291,0.00030644285,0.0000029672638,0.0006910916],"genre_scores_gemma":[0.9959519,0.00047433565,0.0004912219,0.00033655198,0.000007642298,0.00032726457,0.0003915963,0.000006071487,0.0020134854],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.98902786,0.0052081207,0.0008312399,0.00087132386,0.0015409159,0.002520466],"domain_scores_gemma":[0.9708992,0.013738547,0.0063509373,0.0013886925,0.004666041,0.00295658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005918709,0.0006856916,0.0014564208,0.0017624946,0.0033636172,0.003304834,0.003214059,0.0026377297,0.003622902],"category_scores_gemma":[0.026850326,0.0011998169,0.0010065588,0.003956593,0.0018236171,0.0010821007,0.0025876432,0.003056824,0.00032447357],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007363047,0.007880096,0.9124451,0.0010794775,0.0020081343,0.0009948146,0.0139881605,0.0049794577,0.0007347643,0.0020809507,0.0032852122,0.04316069],"study_design_scores_gemma":[0.0008391589,0.0026596661,0.9469737,0.0006908785,0.001387333,0.00015324469,0.034535397,0.008676242,0.00053493114,0.00055966125,0.0028190918,0.0001707883],"about_ca_topic_score_codex":0.97509956,"about_ca_topic_score_gemma":0.9834306,"teacher_disagreement_score":0.047364976,"about_ca_system_score_codex":0.047364976,"about_ca_system_score_gemma":0.056678683,"threshold_uncertainty_score":0.34365857},"labels":[],"label_agreement":null},{"id":"W4396529856","doi":"10.1211/pj.2024.1.310914","title":"Medicines shortages affect almost a quarter of patients, patient group report shows","year":2024,"lang":"en","type":"article","venue":"Pharmaceutical journal/˜The œpharmaceutical journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Affect (linguistics); Quarter (Canadian coin); Group (periodic table); Medicine; Psychology; Geography; Chemistry; Communication; Archaeology","score_opus":0.05550231240624844,"score_gpt":0.3435196739663424,"score_spread":0.288017361560094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396529856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5701306,0.01831271,0.00072066335,0.23072466,0.0037656776,0.00014359716,0.017147323,0.00046444888,0.15859035],"genre_scores_gemma":[0.7757537,0.021426419,0.0006926115,0.13329592,0.0029367164,0.00012215856,0.0066213226,0.0000763318,0.05907477],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9993761,0.00006430255,0.000049908478,0.000059628357,0.00028120828,0.00016895047],"domain_scores_gemma":[0.99800617,0.00023405136,0.0007186294,0.00005359065,0.00047252988,0.00051508815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045422517,0.00017835444,0.00019915635,0.000555548,0.0011486334,0.0010253257,0.00021648852,0.0009497545,0.021203212],"category_scores_gemma":[0.0022469566,0.00017610859,0.0003423876,0.0011061719,0.00028226164,0.0011793369,0.0007762342,0.0012896236,0.0042712875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014810717,0.00020133182,0.30467802,0.00043430954,0.00009031292,0.00073919806,0.0019662098,0.0000718494,0.001758272,0.001243377,0.5265516,0.16211738],"study_design_scores_gemma":[0.00003893007,0.00020746842,0.7204965,0.00036766112,0.000049692513,0.0019810325,0.0071629323,0.000114375485,0.00064024056,0.0004449986,0.2684559,0.000040328167],"about_ca_topic_score_codex":0.025604837,"about_ca_topic_score_gemma":0.04150387,"teacher_disagreement_score":0.025604837,"about_ca_system_score_codex":0.00058112876,"about_ca_system_score_gemma":0.0012628211,"threshold_uncertainty_score":0.07093185},"labels":[],"label_agreement":null},{"id":"W4396691844","doi":"10.1002/puh2.172","title":"A new era for African health systems: Market shaping and the African Continental Free Trade Area (AfCFTA)","year":2024,"lang":"en","type":"article","venue":"Public Health Challenges","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"School of Oriental and African Studies, University of London","keywords":"Free trade; International trade; Business; Geography","score_opus":0.21764034752515427,"score_gpt":0.32911683666548014,"score_spread":0.11147648914032587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396691844","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0849357,0.04702654,0.008143367,0.6477005,0.0026016848,0.000118190284,0.00013006474,0.00009191966,0.20925207],"genre_scores_gemma":[0.8956638,0.025890121,0.006489419,0.0447479,0.0020567805,0.00009103489,0.000048721053,0.000072143965,0.024940118],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99703586,0.001542439,0.0000670816,0.00016783351,0.00028653198,0.00090028247],"domain_scores_gemma":[0.99729025,0.0012970807,0.0004505858,0.00011782099,0.00023112052,0.00061314035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055070906,0.0004992932,0.00027939255,0.0012591238,0.008289356,0.011582155,0.00078836764,0.0047681346,0.013814255],"category_scores_gemma":[0.004168647,0.00024876057,0.00044835577,0.0017112927,0.014316654,0.014189525,0.0074570323,0.0039667175,0.0006808765],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000384764,0.00003944372,0.0016780985,0.00029047648,0.0000100650805,0.00083537085,0.024790946,0.0002614644,0.0006799284,0.88360757,0.030028198,0.057740062],"study_design_scores_gemma":[0.00001743619,0.00009742253,0.0037473561,0.0009480381,0.000009545392,0.00060634466,0.050165474,0.0005642555,0.00045841155,0.23770843,0.70563745,0.000039799597],"about_ca_topic_score_codex":0.0051394305,"about_ca_topic_score_gemma":0.006455674,"teacher_disagreement_score":0.013814255,"about_ca_system_score_codex":0.0077732992,"about_ca_system_score_gemma":0.0107414685,"threshold_uncertainty_score":0.056399465},"labels":[],"label_agreement":null},{"id":"W4396771372","doi":"10.1002/puh2.185","title":"COVAX and COVID‐19 Vaccine Inequity: A case study of G‐20 and African Union","year":2024,"lang":"en","type":"article","venue":"Public Health Challenges","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta; Centre for Global Health Research","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Virology; Political science; Medicine; Infectious disease (medical specialty); Internal medicine; Outbreak","score_opus":0.3107931576374252,"score_gpt":0.39251075421302517,"score_spread":0.08171759657559996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396771372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942899,0.0005231946,0.00014430232,0.001534721,0.000008483771,0.00004467818,0.000048754475,0.0000022820916,0.0034037067],"genre_scores_gemma":[0.99789894,0.00068305887,0.00021656729,0.0003864809,0.000012895598,0.000048325644,0.000028254226,0.000004389728,0.0007210825],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9966888,0.0017527104,0.00008341777,0.00013709137,0.00022930253,0.0011087025],"domain_scores_gemma":[0.99670875,0.0015447545,0.0006939926,0.00010219517,0.00021251375,0.0007377104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002786976,0.00049756054,0.00060590566,0.002204278,0.009050995,0.0019824961,0.0012305927,0.0024181816,0.0039089],"category_scores_gemma":[0.0055502383,0.0003516385,0.00056761183,0.0033025353,0.002901182,0.0024889281,0.0046661324,0.0018815259,0.0002071834],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030975122,0.002137147,0.40259916,0.00058892113,0.000083593244,0.0557719,0.46630335,0.00068833475,0.0005977123,0.029563062,0.0067971754,0.034559846],"study_design_scores_gemma":[0.000034145825,0.00036143977,0.0867485,0.00060944154,0.000054903743,0.011946372,0.881306,0.0016510049,0.00027365718,0.003053992,0.013917029,0.00004353682],"about_ca_topic_score_codex":0.06842796,"about_ca_topic_score_gemma":0.0779197,"teacher_disagreement_score":0.06842796,"about_ca_system_score_codex":0.003820696,"about_ca_system_score_gemma":0.0035765383,"threshold_uncertainty_score":0.13605928},"labels":[],"label_agreement":null},{"id":"W4396904214","doi":"10.3389/fmed.2024.1379966","title":"Exploring regulatory flexibility to create novel incentives to optimize drug discovery","year":2024,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Western University","funders":"Genome British Columbia; Genome Canada","keywords":"Incentive; Flexibility (engineering); Business; Drug development; Set (abstract data type); Drug discovery; Drug; Face (sociological concept); Industrial organization; Public relations; Public economics; Knowledge management; Political science; Economics; Pharmacology; Medicine; Computer science; Market economy; Management","score_opus":0.14934270902731375,"score_gpt":0.31616412274447814,"score_spread":0.16682141371716439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396904214","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.055769116,0.07283676,0.46190223,0.107283935,0.0033001702,0.0006326557,0.0005294954,0.0006696377,0.29707602],"genre_scores_gemma":[0.8567037,0.032272123,0.081242055,0.013264912,0.0017541213,0.00076773466,0.00020877173,0.00016133169,0.0136252595],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99004185,0.0056027663,0.000395675,0.001030411,0.0019173515,0.0010118803],"domain_scores_gemma":[0.96744597,0.024759103,0.0029777454,0.0018623355,0.0021180764,0.00083668303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019823752,0.000612761,0.0008401941,0.0013222578,0.0012203081,0.0058676773,0.0020892324,0.0046209437,0.0099138105],"category_scores_gemma":[0.03430522,0.00051477505,0.0011161047,0.001071073,0.004954625,0.007203173,0.0033280174,0.0050361017,0.0009215947],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030213203,0.000048241673,0.0004856054,0.0003219483,0.00003383728,0.00006134952,0.00011392769,0.0078611,0.0007253054,0.962375,0.0035487134,0.024394674],"study_design_scores_gemma":[0.000081263875,0.00011110336,0.0009856975,0.0009797473,0.000049308306,0.00010584161,0.00023448913,0.013797439,0.0013088635,0.8773391,0.10494869,0.000058435464],"about_ca_topic_score_codex":0.0010663931,"about_ca_topic_score_gemma":0.0014935062,"teacher_disagreement_score":0.019823752,"about_ca_system_score_codex":0.0033176753,"about_ca_system_score_gemma":0.0071842144,"threshold_uncertainty_score":0.104839265},"labels":[],"label_agreement":null},{"id":"W4399024288","doi":"10.1093/oso/9780197512883.002.0005","title":"Preface","year":2021,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.10397851534805674,"score_gpt":0.27247607361984594,"score_spread":0.1684975582717892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399024288","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005687232,0.002787318,0.0015019606,0.008822623,0.0307081,0.00024454668,0.009934858,0.0011047131,0.9443271],"genre_scores_gemma":[0.0019522911,0.0013537526,0.0005563639,0.002622299,0.003783056,0.00009455453,0.006242891,0.00051781995,0.9828771],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993913,0.000062876636,0.00003775202,0.00009924918,0.00034049217,0.00006828332],"domain_scores_gemma":[0.99786747,0.00034580549,0.0000799201,0.0002829123,0.0011255825,0.00029826717],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067301927,0.00085961254,0.000681553,0.002030673,0.0021688608,0.0044771046,0.0012621814,0.0014606321,0.7381533],"category_scores_gemma":[0.0050136135,0.00035096935,0.00064551755,0.0021338908,0.0006198032,0.0034199448,0.00220361,0.0023475774,0.5833066],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018634672,0.000014621068,0.000045306722,0.00008280075,0.0000011524855,0.000035358516,0.00003296389,0.00002889188,0.00008493164,0.0031103494,0.97255003,0.023994925],"study_design_scores_gemma":[0.000002500404,0.0000051837596,0.00014467156,0.00005416179,5.887914e-7,0.00003529804,0.000035678575,0.000013063252,0.000040138537,0.0008567944,0.9988097,0.0000021794874],"about_ca_topic_score_codex":0.0033785275,"about_ca_topic_score_gemma":0.0043663727,"teacher_disagreement_score":0.26184672,"about_ca_system_score_codex":0.0015567287,"about_ca_system_score_gemma":0.0018998863,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4399051980","doi":"10.1503/cmaj.231485","title":"The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; Ontario Drug Policy Research Network; University of Calgary; University of British Columbia; Providence Health Care","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Retrospective cohort study; Cohort; Medicine; Business; Emergency medicine; Family medicine; Internal medicine","score_opus":0.026588856464486228,"score_gpt":0.2784963872388695,"score_spread":0.25190753077438327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399051980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98701155,0.00094438967,0.0003045978,0.00018021285,0.000016691498,0.00009121784,0.010285131,0.000013420722,0.0011528552],"genre_scores_gemma":[0.9933803,0.00058458175,0.00027604026,0.0001287926,0.00001408883,0.000060778562,0.0050550634,0.0000132495015,0.00048709434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708015,0.0001885867,0.0002511516,0.0007417146,0.0010565602,0.00068187254],"domain_scores_gemma":[0.9907809,0.00084854005,0.0045157564,0.00077629514,0.0021276432,0.000950886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002536806,0.000589261,0.000734604,0.0019044997,0.0017978187,0.0016768826,0.001912359,0.00081772276,0.0023235185],"category_scores_gemma":[0.0073262556,0.00066187535,0.0015415216,0.005449466,0.0010393794,0.0007935895,0.0012004937,0.0015130083,0.00032847808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016925554,0.000017352902,0.99810237,0.000026283664,0.00015740584,0.00004199545,0.0001414021,0.00009341333,0.000053178377,0.000081027894,0.00041598163,0.0007005309],"study_design_scores_gemma":[0.000022030055,0.000060802748,0.997451,0.000039575632,0.00018233444,0.000100904675,0.00040224975,0.00054290646,0.000085942505,0.00003640965,0.0010525445,0.000023310175],"about_ca_topic_score_codex":0.8763541,"about_ca_topic_score_gemma":0.87153,"teacher_disagreement_score":0.988643,"about_ca_system_score_codex":0.011357023,"about_ca_system_score_gemma":0.017030137,"threshold_uncertainty_score":0.24874812},"labels":[],"label_agreement":null},{"id":"W4399130092","doi":"10.31579/2578-8949/155","title":"The Role and Impact of Generics in Pharmaceutical Markets","year":2024,"lang":"en","type":"article","venue":"Dermatology and Dermatitis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Business; Economics","score_opus":0.0237849108650893,"score_gpt":0.3010564534153847,"score_spread":0.27727154255029535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399130092","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11178259,0.05332052,0.012773146,0.08885261,0.0013171956,0.00019305017,0.00076249026,0.0002901887,0.7307081],"genre_scores_gemma":[0.9383748,0.021895831,0.0035288087,0.011983186,0.0020536438,0.00007875154,0.00022711104,0.0001390833,0.0217188],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912815,0.0032617801,0.0002988433,0.001096248,0.0029314295,0.0011301151],"domain_scores_gemma":[0.98317516,0.00779506,0.0030513918,0.0016641343,0.0023166745,0.0019975933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01046998,0.00048116676,0.00055327226,0.0026658587,0.0033715742,0.016986782,0.0011653778,0.0037195254,0.024921926],"category_scores_gemma":[0.024420816,0.0004779873,0.00085954415,0.0023625114,0.011207574,0.016323658,0.005707923,0.004060658,0.0027974278],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013193753,0.000074707685,0.0054572495,0.00032251922,0.000022328568,0.00035206904,0.0013813137,0.00071585784,0.0007385781,0.91231906,0.011133367,0.06735098],"study_design_scores_gemma":[0.00008411085,0.00038456623,0.026728135,0.0015897244,0.00010338848,0.0010120537,0.004788888,0.0021939,0.0020717867,0.35452974,0.60637295,0.00014071242],"about_ca_topic_score_codex":0.004058021,"about_ca_topic_score_gemma":0.002537629,"teacher_disagreement_score":0.024921926,"about_ca_system_score_codex":0.007404745,"about_ca_system_score_gemma":0.0055003567,"threshold_uncertainty_score":0.083372116},"labels":[],"label_agreement":null},{"id":"W4399287699","doi":"10.7202/1105315ar","title":"L’IMPACT DU PARTAGE DES COÛTSSUR LA CONSOMMATIONDE MÉDICAMENTS","year":2000,"lang":"fr","type":"article","venue":"Assurances :","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Political science","score_opus":0.042976560350666194,"score_gpt":0.3052173484943256,"score_spread":0.26224078814365936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399287699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44315347,0.1409288,0.024374375,0.06324042,0.0035126228,0.00042269158,0.0011577934,0.00017162581,0.3230382],"genre_scores_gemma":[0.89955235,0.052924428,0.00739519,0.0077498783,0.000619044,0.0002722629,0.00026253352,0.000089768735,0.031134514],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9890905,0.0060148556,0.00040372225,0.0007262165,0.0029497878,0.0008149127],"domain_scores_gemma":[0.97004235,0.0214237,0.0036558576,0.0014942209,0.0023737676,0.0010100506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071351845,0.000514973,0.0006514529,0.0007127584,0.0010140496,0.0049043326,0.0010068134,0.0021968787,0.017701376],"category_scores_gemma":[0.025884343,0.0003353354,0.0014744013,0.0008469212,0.0029414557,0.0029302558,0.0024414363,0.00284278,0.0011401768],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023286554,0.0006787423,0.023264464,0.005779167,0.0011884278,0.00092290074,0.007507922,0.003848597,0.011365771,0.14864369,0.015941102,0.7785306],"study_design_scores_gemma":[0.00038255122,0.0057627494,0.13069169,0.010222075,0.0019425516,0.0024622714,0.008980314,0.0026170607,0.0172556,0.06145092,0.7580156,0.00021667246],"about_ca_topic_score_codex":0.008481938,"about_ca_topic_score_gemma":0.010839774,"teacher_disagreement_score":0.017701376,"about_ca_system_score_codex":0.0034828102,"about_ca_system_score_gemma":0.0062409425,"threshold_uncertainty_score":0.059217036},"labels":[],"label_agreement":null},{"id":"W4399615943","doi":"10.1016/j.phacli.2024.04.193","title":"Émergence de pharmacies de spécialités en Amérique du Nord : état des lieux, opportunités et enjeux","year":2024,"lang":"fr","type":"article","venue":"Le Pharmacien Clinicien","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science","score_opus":0.2783287277807524,"score_gpt":0.43998976770509557,"score_spread":0.16166103992434316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399615943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6403809,0.24567716,0.0025793076,0.056091487,0.0016419148,0.00029539663,0.0068243733,0.00011184139,0.04639755],"genre_scores_gemma":[0.8143266,0.15872869,0.0052969833,0.01151018,0.0005637348,0.00019841827,0.0024962972,0.00004681745,0.006832253],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768484,0.00067625765,0.00025795694,0.00033490243,0.00074118056,0.00030479868],"domain_scores_gemma":[0.97996634,0.007235626,0.0057073873,0.0004302658,0.0049578487,0.0017024663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004415579,0.00020965848,0.00043638743,0.0017622781,0.0008629527,0.0019851243,0.0005517351,0.00081427745,0.005621484],"category_scores_gemma":[0.012074443,0.00024608427,0.0006124262,0.0049235267,0.0010035603,0.0021451388,0.00089426205,0.0017670754,0.00039768175],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000692763,0.00024294521,0.49114895,0.012330906,0.0006237508,0.0013304317,0.015217234,0.0003028012,0.0016391844,0.011245534,0.03667746,0.42854807],"study_design_scores_gemma":[0.00011962388,0.00040082302,0.7198963,0.0133097805,0.0006837138,0.0023529094,0.026243009,0.00048468306,0.0008704076,0.0021125213,0.23343731,0.00008885191],"about_ca_topic_score_codex":0.12486171,"about_ca_topic_score_gemma":0.18628713,"teacher_disagreement_score":0.12486171,"about_ca_system_score_codex":0.0041973004,"about_ca_system_score_gemma":0.015676042,"threshold_uncertainty_score":0.24826986},"labels":[],"label_agreement":null},{"id":"W4399700239","doi":"10.1016/j.jval.2024.03.575","title":"EE276 Understanding Trends in Launch Prices across Canada, EU4, UK and the US for High-Revenue Drugs","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Revenue; Business; Economics; Finance","score_opus":0.1167373823229765,"score_gpt":0.33843671197016073,"score_spread":0.22169932964718425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399700239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8433053,0.0055797677,0.0015417866,0.013707592,0.00012109835,0.000048218364,0.06913982,0.00009278286,0.06646359],"genre_scores_gemma":[0.9612834,0.002700567,0.00091709447,0.0008042783,0.00007176125,0.00001537767,0.017951747,0.000050582206,0.016205134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99955934,0.000033238233,0.000021263382,0.000048674592,0.00017165954,0.00016581581],"domain_scores_gemma":[0.9974044,0.0005629482,0.0005158685,0.000056350113,0.0011841729,0.00027623225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061598537,0.00012654466,0.0001639239,0.0016996654,0.00035749646,0.0026278694,0.0003126641,0.00041447967,0.0092347795],"category_scores_gemma":[0.0039899847,0.0001292943,0.0004176186,0.0034305705,0.00016993769,0.0011017319,0.00040476865,0.00070372794,0.0012192555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005559216,0.00016146673,0.8198195,0.00022007986,0.00030263147,0.00019155876,0.0005399225,0.00498984,0.0009450116,0.015025767,0.054936264,0.10231193],"study_design_scores_gemma":[0.000011549622,0.000038588096,0.9514439,0.00009042232,0.000052921187,0.000040181985,0.0009794941,0.004392872,0.00058052386,0.0012070047,0.04114506,0.000017465905],"about_ca_topic_score_codex":0.66664475,"about_ca_topic_score_gemma":0.73162353,"teacher_disagreement_score":0.33335525,"about_ca_system_score_codex":0.005067446,"about_ca_system_score_gemma":0.0059904805,"threshold_uncertainty_score":0.6706369},"labels":[],"label_agreement":null},{"id":"W4399701066","doi":"10.1016/j.jval.2024.03.052","title":"P26 Analyzing Drug Shortages and Pricing: Lessons from Canada","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Economic shortage; Drug pricing; Business; Drug; Actuarial science; Medicine; Pharmacology","score_opus":0.09840679164151186,"score_gpt":0.32820577453091004,"score_spread":0.22979898288939818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399701066","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24925268,0.02890105,0.012114093,0.41625902,0.0011612815,0.00026300573,0.01961316,0.00033598003,0.2720998],"genre_scores_gemma":[0.92370576,0.012455626,0.003948931,0.0119588785,0.00078845385,0.000052996467,0.0029391465,0.00015146435,0.04399885],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9984616,0.00024939465,0.00005046535,0.0001298951,0.0004982395,0.0006103662],"domain_scores_gemma":[0.9847015,0.007360331,0.0006810385,0.0003400633,0.0056696194,0.0012474488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002691969,0.00043506204,0.0009203873,0.0020306122,0.0031180454,0.0052320966,0.0014356027,0.0021302223,0.015170337],"category_scores_gemma":[0.022402538,0.0002781402,0.0009194898,0.006001709,0.0026836197,0.0021449265,0.001231905,0.0034718502,0.00045702935],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002864738,0.00026724586,0.09982918,0.00046893363,0.00028520037,0.0005857476,0.0015198106,0.055028852,0.00019005174,0.38448432,0.34222007,0.11483409],"study_design_scores_gemma":[0.00028521635,0.0001439668,0.18056527,0.0012634805,0.0003916903,0.00019111356,0.012304534,0.11587682,0.00069997535,0.41238415,0.2756806,0.0002131483],"about_ca_topic_score_codex":0.99334127,"about_ca_topic_score_gemma":0.9926473,"teacher_disagreement_score":0.062306736,"about_ca_system_score_codex":0.062306736,"about_ca_system_score_gemma":0.11861838,"threshold_uncertainty_score":0.4520691},"labels":[],"label_agreement":null},{"id":"W4399707392","doi":"10.1016/j.jval.2024.03.1416","title":"HTA65 How Does Conditional Regulatory Approval Affect the Reimbursement of Drugs in Canada?","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Affect (linguistics); Business; Actuarial science; Medicine; Public economics; Economics; Political science; Psychology; Law; Health care","score_opus":0.05515011141921904,"score_gpt":0.284748897095249,"score_spread":0.22959878567602993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399707392","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45176217,0.011460153,0.002449811,0.31827796,0.0012944571,0.00032126266,0.014045702,0.0002779479,0.20011055],"genre_scores_gemma":[0.96478283,0.001600931,0.000516341,0.013600013,0.00035450846,0.000030810024,0.0010176311,0.00004642093,0.01805048],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9880215,0.0012953836,0.00034197082,0.0006931606,0.004549343,0.0050986656],"domain_scores_gemma":[0.9495657,0.0143487295,0.0048199557,0.0008749923,0.023371276,0.007019341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077476436,0.00030192267,0.0008015449,0.0018727409,0.0034976585,0.007713933,0.0019427781,0.004986574,0.010300232],"category_scores_gemma":[0.050770566,0.00046977313,0.00142733,0.002334704,0.0024588162,0.0014263387,0.001096071,0.005244712,0.00048663726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016448048,0.0003856573,0.33623695,0.00049114664,0.0010935331,0.0009199002,0.0015226573,0.0196789,0.0015108276,0.30240372,0.26597852,0.0681333],"study_design_scores_gemma":[0.0006890844,0.0003138788,0.70356363,0.00066632737,0.001183319,0.0002721871,0.002335199,0.028577479,0.0026957605,0.03110703,0.22819288,0.00040323788],"about_ca_topic_score_codex":0.9924448,"about_ca_topic_score_gemma":0.99326754,"teacher_disagreement_score":0.8852942,"about_ca_system_score_codex":0.11470583,"about_ca_system_score_gemma":0.19632259,"threshold_uncertainty_score":0.832253},"labels":[],"label_agreement":null},{"id":"W4399814181","doi":"10.1007/s40278-024-60672-3","title":"Temporary importation of US-authorised carbamazepine in Canada","year":2024,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Carbamazepine; Business; Neuroscience; Biology; Epilepsy","score_opus":0.04380543677391887,"score_gpt":0.27350236457286003,"score_spread":0.22969692779894116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399814181","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574759,0.0015368207,0.00017213554,0.012789849,0.00022340307,0.000048270875,0.0065338463,0.000079067,0.021140812],"genre_scores_gemma":[0.98170817,0.0008659219,0.00010736272,0.0011157736,0.000057541925,0.000005979121,0.0014110531,0.00002493611,0.014703175],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998973,0.00003181826,0.00004797441,0.000084187115,0.00038866,0.0004743211],"domain_scores_gemma":[0.9954045,0.0004583508,0.0008396806,0.00011791692,0.0021531275,0.0010265087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075675984,0.00015955156,0.00032379222,0.0010679201,0.0021023413,0.00297948,0.00069323176,0.0010758056,0.006532045],"category_scores_gemma":[0.004321232,0.00024208576,0.0005643081,0.001876815,0.0011720022,0.00052283646,0.00079594145,0.0018556038,0.00028063875],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004206339,0.0003828332,0.764029,0.00055977463,0.00031264804,0.0051322514,0.004211097,0.0045237094,0.0078534335,0.02481887,0.10486325,0.079106905],"study_design_scores_gemma":[0.00008444922,0.00011624144,0.94157296,0.000106524996,0.00010557411,0.0003751554,0.004650099,0.0023597758,0.0019621064,0.00037195737,0.048244093,0.00005104651],"about_ca_topic_score_codex":0.9908257,"about_ca_topic_score_gemma":0.993909,"teacher_disagreement_score":0.064484715,"about_ca_system_score_codex":0.064484715,"about_ca_system_score_gemma":0.07523357,"threshold_uncertainty_score":0.46787155},"labels":[],"label_agreement":null},{"id":"W4399920437","doi":"10.9734/bpi/prrat/v3/807","title":"Generic Drugs: The Evolving Landscape and the Mentalities","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Geography; Environmental ethics; Philosophy","score_opus":0.045822250736645545,"score_gpt":0.24446887345810717,"score_spread":0.1986466227214616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399920437","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01779913,0.054929208,0.0035106011,0.8362512,0.0019955798,0.00002697268,0.00020243424,0.000086749606,0.0851981],"genre_scores_gemma":[0.4362502,0.115995646,0.004588185,0.4086021,0.013467214,0.00009322018,0.00025048165,0.00025167025,0.02050123],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9935715,0.0026263022,0.00021931977,0.0007572802,0.002131525,0.00069410726],"domain_scores_gemma":[0.9918115,0.003597734,0.0010280345,0.0004559033,0.001003027,0.0021037704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008806808,0.00058173423,0.00070709194,0.002224026,0.00481096,0.01616764,0.0012971782,0.009382763,0.011499187],"category_scores_gemma":[0.011952485,0.00054806715,0.0005991979,0.002070134,0.020603763,0.023853052,0.008548933,0.0169925,0.00233184],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017258966,0.00018746477,0.0068140053,0.0005274585,0.00007888306,0.0012850331,0.016347274,0.00043170017,0.0009859466,0.64802915,0.16444643,0.16069406],"study_design_scores_gemma":[0.000041883275,0.00019195146,0.0059142527,0.001352473,0.000028276416,0.003379237,0.016206924,0.0006643133,0.00021665823,0.28111774,0.6907388,0.00014756613],"about_ca_topic_score_codex":0.005579311,"about_ca_topic_score_gemma":0.004847546,"teacher_disagreement_score":0.01616764,"about_ca_system_score_codex":0.0088440655,"about_ca_system_score_gemma":0.0047703455,"threshold_uncertainty_score":0.06416845},"labels":[],"label_agreement":null},{"id":"W4400142158","doi":"10.1016/j.drugpo.2024.104500","title":"Structuring adaptations: Resilience, restrictive deterrence, and the Cunningham precursor control papers","year":2024,"lang":"en","type":"article","venue":"International Journal of Drug Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of the Fraser Valley; Simon Fraser University","funders":"Social Sciences and Humanities Research Council of Canada","keywords":"Structuring; Scholarship; Deterrence theory; Resilience (materials science); Control (management); Psychological resilience; Work (physics); Psychological intervention; Deterrence (psychology); Sociology; Law and economics; Public relations; Business; Political science; Psychology; Social psychology; Economics; Law; Engineering; Management","score_opus":0.01986170707947487,"score_gpt":0.2962057741875001,"score_spread":0.2763440671080252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400142158","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18169945,0.018138088,0.2092792,0.107167095,0.0023570117,0.00085338124,0.00048199718,0.00038726165,0.4796365],"genre_scores_gemma":[0.9680586,0.002279971,0.014494188,0.004905673,0.000435116,0.00038249095,0.00006863096,0.00004384948,0.0093315225],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933867,0.0028060172,0.00039711574,0.0011981118,0.0015218189,0.00069032126],"domain_scores_gemma":[0.9843156,0.008192161,0.002291256,0.003082981,0.0012245921,0.0008934333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009040237,0.0006110648,0.0005241268,0.00199461,0.002910462,0.003913736,0.0018132784,0.0021557997,0.0073303143],"category_scores_gemma":[0.033403095,0.00027624692,0.0006906896,0.0015596278,0.018285187,0.006437736,0.0056128115,0.0035471353,0.0002199018],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022333159,0.000023996248,0.0010407042,0.00006246476,0.000013703967,0.00007425504,0.0014406794,0.00051904295,0.000070755115,0.9794286,0.0018792036,0.015424229],"study_design_scores_gemma":[0.00006056299,0.00013262835,0.0053477655,0.00042531185,0.0000552188,0.00017569061,0.0025966256,0.0023928846,0.00067563384,0.88226116,0.105825044,0.000051443574],"about_ca_topic_score_codex":0.005461701,"about_ca_topic_score_gemma":0.0040351734,"teacher_disagreement_score":0.009040237,"about_ca_system_score_codex":0.004322073,"about_ca_system_score_gemma":0.0042610685,"threshold_uncertainty_score":0.0478099},"labels":[],"label_agreement":null},{"id":"W4400264482","doi":"10.1186/s41256-024-00365-y","title":"Strengthening access to cancer medicines for children in East Africa: policy options to enhance medicine procurement, forecasting, and regulations","year":2024,"lang":"en","type":"article","venue":"Global Health Research and Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"Procurement; Harmonization; Essential medicines; Medicine; Business; Health care; Public health; Economic growth; Environmental health; Marketing; Nursing; Economics","score_opus":0.3348119429142283,"score_gpt":0.5405538434238999,"score_spread":0.20574190050967162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400264482","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03054137,0.1103047,0.01605892,0.80138016,0.00149244,0.00047809276,0.0007754944,0.00013479336,0.038834035],"genre_scores_gemma":[0.6045029,0.268359,0.051413767,0.060041137,0.0031532524,0.0011097856,0.0005304819,0.00005671006,0.010832988],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9931379,0.004871966,0.00034864954,0.00021781176,0.00049144594,0.00093223853],"domain_scores_gemma":[0.972409,0.021088349,0.0032565435,0.00036593288,0.0016995224,0.0011806787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01934769,0.00065616553,0.00061655504,0.0019837637,0.001432478,0.008090607,0.0012513364,0.0037789193,0.0065280916],"category_scores_gemma":[0.030337924,0.00047319755,0.00072708004,0.0024846522,0.002250777,0.008690183,0.003775598,0.0037715791,0.0004591855],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002493041,0.00020018703,0.00834464,0.005917907,0.00012963165,0.001012465,0.0026136343,0.032616,0.00096429617,0.6987092,0.06844996,0.18079282],"study_design_scores_gemma":[0.00024446085,0.000510178,0.017294977,0.020624196,0.00031259775,0.0006845712,0.014025642,0.028768213,0.003550447,0.2671017,0.64660156,0.0002814911],"about_ca_topic_score_codex":0.020553531,"about_ca_topic_score_gemma":0.02336471,"teacher_disagreement_score":0.020553531,"about_ca_system_score_codex":0.011147797,"about_ca_system_score_gemma":0.020177238,"threshold_uncertainty_score":0.102321565},"labels":[],"label_agreement":null},{"id":"W4400453556","doi":"10.1136/bmjebm-2024-sdc.111","title":"112 Dual use of prescription insurance: drivers and challenges","year":2024,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dual (grammatical number); Medical prescription; Business; Actuarial science; Computer science; Internet privacy; Medicine; Pharmacology","score_opus":0.17338242162222942,"score_gpt":0.28193197541469667,"score_spread":0.10854955379246725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400453556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688001,0.00083830534,0.00034832206,0.017355302,0.00010090386,0.0001117734,0.0006539817,0.000015746717,0.011775479],"genre_scores_gemma":[0.99674654,0.0006628257,0.00035286084,0.00078478566,0.000036192832,0.00006649318,0.0002460317,0.0000061799824,0.0010979786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965635,0.0009081651,0.00024531488,0.00023216798,0.0007221449,0.0013287384],"domain_scores_gemma":[0.9905351,0.0034165327,0.002267494,0.00019936173,0.0012770928,0.002304461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041893697,0.00023167406,0.00036489326,0.0012355067,0.002708749,0.004427062,0.0012821521,0.0010313508,0.008212598],"category_scores_gemma":[0.0148473475,0.00044025487,0.00057580415,0.0016747621,0.0011999307,0.00340444,0.004273346,0.0017277984,0.00062644336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044471635,0.00025504213,0.8696735,0.00043155643,0.000044229953,0.0011858917,0.07655505,0.00013746752,0.00021703765,0.0046651787,0.008818183,0.037972372],"study_design_scores_gemma":[0.000008402758,0.00011242691,0.35581568,0.0008693534,0.000024888195,0.0011340869,0.6126296,0.0010233663,0.00018806216,0.0032643627,0.02487237,0.000057432233],"about_ca_topic_score_codex":0.04157414,"about_ca_topic_score_gemma":0.054273088,"teacher_disagreement_score":0.04157414,"about_ca_system_score_codex":0.003785157,"about_ca_system_score_gemma":0.010731254,"threshold_uncertainty_score":0.08266431},"labels":[],"label_agreement":null},{"id":"W4400482662","doi":"10.55016/ojs/cpai.v3i2.71473","title":"International Day of Action (IDoA) Against Contract Cheating 2020—Update from the chair of the IDoA planning committee","year":2020,"lang":"en","type":"article","venue":"Canadian Perspectives on Academic Integrity","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Humber Polytechnic","funders":"","keywords":"Action (physics); Cheating; Business; Psychology; Social psychology","score_opus":0.0925396043227488,"score_gpt":0.31554512319227357,"score_spread":0.22300551886952477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400482662","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041785776,0.07703009,0.0076127676,0.5295397,0.082019396,0.002591909,0.007876464,0.0015170219,0.287634],"genre_scores_gemma":[0.059045255,0.06690995,0.03246095,0.43276742,0.019526184,0.0047610337,0.011485416,0.0016699592,0.37137392],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9705513,0.0033332994,0.0022936452,0.00094117405,0.016863808,0.0060168398],"domain_scores_gemma":[0.949116,0.0072646183,0.0033611283,0.001270894,0.0212985,0.017688867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.043459356,0.0015619976,0.0013927566,0.0033322733,0.0064439797,0.01768669,0.005958165,0.022682764,0.017282471],"category_scores_gemma":[0.046756245,0.0015655854,0.0023688856,0.0032193551,0.0045789103,0.0070727267,0.0090829255,0.023334315,0.009129376],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028817472,0.00008797105,0.00047559102,0.00042986768,0.000009512488,0.000099802695,0.00026781022,0.00021805712,0.0001770244,0.014509862,0.962166,0.021529686],"study_design_scores_gemma":[0.000010286455,0.000014844143,0.0011598907,0.0006007393,0.0000058410856,0.000045017914,0.0002627133,0.00006397964,0.0001287873,0.00089793507,0.9967804,0.000029482559],"about_ca_topic_score_codex":0.18691237,"about_ca_topic_score_gemma":0.18587984,"teacher_disagreement_score":0.18691237,"about_ca_system_score_codex":0.020577544,"about_ca_system_score_gemma":0.16117679,"threshold_uncertainty_score":0.3716488},"labels":[],"label_agreement":null},{"id":"W4400560618","doi":"10.34172/ijhpm.2024.8471","title":"Profits First, Health Second: The Pharmaceutical Industry and the Global South Comment on \"More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap\"","year":2024,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Pharmaceutical industry; Pandemic; Revenue; Equity (law); Global health; Negotiation; Coronavirus disease 2019 (COVID-19); Business; Economic growth; Health care; Economics; Medicine; Political science; Infectious disease (medical specialty); Finance; Law; Pharmacology","score_opus":0.1220237708135889,"score_gpt":0.43751940417401086,"score_spread":0.31549563336042197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400560618","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022081708,0.0015804642,0.00004543375,0.9898768,0.005567865,0.0000040925174,0.00006495751,0.000015820046,0.0026237476],"genre_scores_gemma":[0.0030714949,0.00086416403,0.000058402264,0.9849583,0.0057060863,0.00001587377,0.000020582187,0.000021953589,0.005283101],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961247,0.0010154943,0.00022870465,0.0007056945,0.0012957675,0.00062960724],"domain_scores_gemma":[0.9822366,0.013047344,0.0009037622,0.00047551538,0.001874027,0.0014627445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061238953,0.0012568029,0.0013202205,0.0009159986,0.007286546,0.008660996,0.0032958086,0.06438324,0.013080902],"category_scores_gemma":[0.024327574,0.0008935883,0.0015203622,0.0014881961,0.010035139,0.010012034,0.0036502834,0.057662666,0.0055341567],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019291201,0.000007765585,0.00013180403,0.000040108695,0.0000041014036,0.0001061089,0.00023083977,0.00003554003,0.0000684822,0.013232311,0.9847606,0.0013631041],"study_design_scores_gemma":[0.000066336885,0.00003880494,0.0017190916,0.0005443099,0.000022872371,0.00020381839,0.0015856895,0.00020267963,0.0003065138,0.019863207,0.9753386,0.00010806416],"about_ca_topic_score_codex":0.038163505,"about_ca_topic_score_gemma":0.049647976,"teacher_disagreement_score":0.06438324,"about_ca_system_score_codex":0.0070789484,"about_ca_system_score_gemma":0.011058797,"threshold_uncertainty_score":0.07588273},"labels":[],"label_agreement":null},{"id":"W4400575844","doi":"10.1016/j.drugalcdep.2023.109995","title":"ACCESS TO NO-COST PHARMACEUTICAL ALTERNATIVES TO ILLICIT DRUGS DURING INTERSECTING COVID-19 AND OVERDOSE HEALTH EMERGENCIES IN BRITISH COLUMBIA, CANADA: A QUALITATIVE STUDY","year":2024,"lang":"en","type":"article","venue":"Drug and Alcohol Dependence","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"British Columbia Centre on Substance Use; University of British Columbia","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Illicit drug; Medicine; Drug overdose; Medical emergency; Poison control; Virology; Drug; Pharmacology; Infectious disease (medical specialty)","score_opus":0.10169088519342474,"score_gpt":0.4116953125910158,"score_spread":0.3100044273975911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400575844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903217,0.000345672,0.00014401949,0.0034312736,0.00002260779,0.00012146754,0.00027088565,0.0000035974788,0.005338783],"genre_scores_gemma":[0.9952407,0.0006232777,0.00021221756,0.0011706551,0.000006417521,0.00008362896,0.00009159259,0.000009755809,0.0025617506],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9957236,0.001474496,0.00018936099,0.00025853713,0.00056746975,0.0017864677],"domain_scores_gemma":[0.98188895,0.007468128,0.0021428093,0.00030346928,0.003724955,0.004471637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042334064,0.00023698049,0.00062502077,0.0014830705,0.019377258,0.006101994,0.0024043084,0.002468037,0.0052498467],"category_scores_gemma":[0.014867734,0.00075532176,0.00038814216,0.0032662507,0.007716368,0.0023787413,0.004503591,0.0041538347,0.0002187556],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011897669,0.00016925743,0.044607498,0.00016646546,0.000016788974,0.0007989374,0.94297653,0.00012247698,0.00043651336,0.0025802858,0.00220086,0.0058053136],"study_design_scores_gemma":[0.0000037403374,0.000017304996,0.015048075,0.00012863691,0.0000054121188,0.000043401895,0.9810122,0.0000796752,0.000050029797,0.0000859088,0.0035096984,0.00001588388],"about_ca_topic_score_codex":0.9785533,"about_ca_topic_score_gemma":0.99021685,"teacher_disagreement_score":0.09495058,"about_ca_system_score_codex":0.09495058,"about_ca_system_score_gemma":0.12709542,"threshold_uncertainty_score":0.6889179},"labels":[],"label_agreement":null},{"id":"W4400607151","doi":"10.51731/cjht.2024.929","title":"Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ulcerative colitis; Medicine; Drug; Disease; Immune system; Crohn's disease; Pharmacotherapy; Immunology; Internal medicine; Pharmacology","score_opus":0.05527035259973597,"score_gpt":0.2868505913691179,"score_spread":0.2315802387693819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400607151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589251,0.0012745953,0.00018664333,0.00094942405,0.000014255103,0.000027187476,0.03469179,0.000023080664,0.0039078738],"genre_scores_gemma":[0.9767155,0.0010816178,0.00023194564,0.00012870431,0.000023326096,0.000027206288,0.020779127,0.0000069794532,0.0010056664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990761,0.00010239756,0.000093908755,0.00011525929,0.00027680057,0.0003355931],"domain_scores_gemma":[0.9959001,0.00056349166,0.0022111097,0.0000846789,0.0007620876,0.00047862588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050739106,0.0001701965,0.00031789255,0.0019168768,0.00037785183,0.001057369,0.0004893396,0.00027124406,0.0024500974],"category_scores_gemma":[0.0047040214,0.00019299591,0.0006794578,0.0049475916,0.00022673294,0.00045953342,0.00041357544,0.0009478845,0.00019098553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011194388,0.000036277444,0.99146444,0.00004865916,0.00012530366,0.000059528116,0.000090833106,0.0011127437,0.000054793818,0.0004932206,0.0024131604,0.003989062],"study_design_scores_gemma":[0.00000871609,0.000025646466,0.9953601,0.000030730684,0.000046609774,0.00011664402,0.00025869109,0.0014176731,0.00004664548,0.000057146663,0.0026256335,0.000005823658],"about_ca_topic_score_codex":0.7334144,"about_ca_topic_score_gemma":0.80262446,"teacher_disagreement_score":0.2665856,"about_ca_system_score_codex":0.008933158,"about_ca_system_score_gemma":0.006395471,"threshold_uncertainty_score":0.5363111},"labels":[],"label_agreement":null},{"id":"W4400761056","doi":"10.3390/jcm13144160","title":"The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Reimbursement; Medicine; Psychological intervention; Health care; Payment; Telemedicine; Public relations; Business; Nursing; Economic growth; Finance","score_opus":0.4487408114422912,"score_gpt":0.5329116212130095,"score_spread":0.08417080977071828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400761056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000090022426,0.99830294,0.000092593415,0.0009669895,0.00009134873,0.000002371293,0.00000672953,0.000002054678,0.00044487987],"genre_scores_gemma":[0.0012475236,0.99807525,0.0001422923,0.00026703376,0.00016565032,0.000005294247,0.000008257899,8.9245304e-7,0.0000877776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988813,0.00039077055,0.00017880749,0.000110416426,0.00034961148,0.000089057365],"domain_scores_gemma":[0.9955178,0.0035744375,0.000370636,0.000056230223,0.0003921856,0.000088729306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023925186,0.0006491594,0.0019718073,0.0022665123,0.000344322,0.0020436116,0.0007482846,0.0019893916,0.0042213565],"category_scores_gemma":[0.0067519196,0.00034680942,0.0013136,0.0020169597,0.00074686017,0.002015913,0.00087516377,0.0025297033,0.0006499512],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008512631,0.0000517638,0.00028584604,0.046012793,0.0004030452,0.00016005526,0.000094773,0.00089741475,0.00032474447,0.019307347,0.017597847,0.91477937],"study_design_scores_gemma":[0.00009358966,0.00018694732,0.0023955961,0.06867803,0.0010523311,0.0014741685,0.000335547,0.000714037,0.00035154898,0.02182933,0.9028397,0.000049104045],"about_ca_topic_score_codex":0.0022897338,"about_ca_topic_score_gemma":0.0042734747,"teacher_disagreement_score":0.0042213565,"about_ca_system_score_codex":0.0010588741,"about_ca_system_score_gemma":0.004028093,"threshold_uncertainty_score":0.01412183},"labels":[],"label_agreement":null},{"id":"W4400777797","doi":"10.31579/2690-8808/195","title":"Innovation and Marketing in the Pharmaceutical Industry","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Case Reports and Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Business; Pharmaceutical industry; Marketing; Industrial organization; Biotechnology","score_opus":0.3565552915519358,"score_gpt":0.49582272537934163,"score_spread":0.1392674338274058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400777797","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004082642,0.21733506,0.011705915,0.24467461,0.008815971,0.00019344117,0.0000685988,0.00015602796,0.5129677],"genre_scores_gemma":[0.3250015,0.28927058,0.016421359,0.15065065,0.044352755,0.0005509715,0.000118870725,0.00018843476,0.17344485],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9885182,0.0047720666,0.00034840775,0.0011640565,0.0041290373,0.0010682492],"domain_scores_gemma":[0.9897254,0.0061534545,0.0010491749,0.0004420944,0.0010187181,0.0016112152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009325634,0.0009941946,0.0009867653,0.0026765843,0.0051095802,0.015284943,0.0012674262,0.014139519,0.018337525],"category_scores_gemma":[0.0106235575,0.0003816381,0.00052259257,0.0037604033,0.033965025,0.016877947,0.007006038,0.010385976,0.0040079495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019109864,0.00004770289,0.00025407318,0.0002663657,0.0000066985467,0.0001279887,0.0013984011,0.00014040583,0.000096904085,0.9239823,0.031378727,0.04228136],"study_design_scores_gemma":[0.000023694805,0.00007856215,0.0006583225,0.0014252233,0.000008828368,0.00028981926,0.001049931,0.00026369348,0.00015487924,0.4497336,0.5462844,0.000029110219],"about_ca_topic_score_codex":0.0024719422,"about_ca_topic_score_gemma":0.002950166,"teacher_disagreement_score":0.018337525,"about_ca_system_score_codex":0.011310149,"about_ca_system_score_gemma":0.011085393,"threshold_uncertainty_score":0.08206123},"labels":[],"label_agreement":null},{"id":"W4400850656","doi":"10.1057/s41599-024-03452-0","title":"Novel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic investment ecosystem","year":2024,"lang":"en","type":"article","venue":"Humanities and Social Sciences Communications","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Finance; Demise; Bankruptcy; Financial services","score_opus":0.24234068727900754,"score_gpt":0.3431836947426274,"score_spread":0.10084300746361985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400850656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8880012,0.003639566,0.015780868,0.039847236,0.00020598655,0.00017139404,0.005231345,0.00021944013,0.04690298],"genre_scores_gemma":[0.9941017,0.0006810577,0.0019387626,0.00054607476,0.00013544997,0.000027919976,0.0009364971,0.000021365035,0.001611142],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9981358,0.00052579725,0.00018572768,0.00019376341,0.0006282289,0.00033061262],"domain_scores_gemma":[0.9672764,0.01402634,0.011799366,0.00085605215,0.004677235,0.0013645588],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0045434474,0.0004285821,0.00043702268,0.0054681282,0.0007753031,0.0050883894,0.00068988366,0.0014332469,0.0051300963],"category_scores_gemma":[0.02646681,0.00018638262,0.00050420733,0.0037147333,0.0012107596,0.0032794182,0.0016229098,0.00211666,0.0007768876],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047597638,0.0006126895,0.70811474,0.0006237976,0.00031661717,0.0044037118,0.0035113238,0.0200965,0.002705163,0.10501806,0.043145817,0.11097552],"study_design_scores_gemma":[0.000051334617,0.00037038536,0.6570259,0.0010544824,0.00020400979,0.0017556774,0.016709676,0.11805001,0.003009489,0.13811155,0.06338798,0.00026952304],"about_ca_topic_score_codex":0.010344757,"about_ca_topic_score_gemma":0.0075202016,"teacher_disagreement_score":0.9992247,"about_ca_system_score_codex":0.002521405,"about_ca_system_score_gemma":0.0021589953,"threshold_uncertainty_score":0.02402836},"labels":[],"label_agreement":null},{"id":"W4400882126","doi":"10.54194/gvuq2702","title":"Effects of the COVID-19 pandemic on the number and characteristics of public drug program beneficiaries in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Public health; Virology; Medicine; Political science; Geography; Nursing; Outbreak; Infectious disease (medical specialty)","score_opus":0.0803262306349016,"score_gpt":0.3250904177784581,"score_spread":0.2447641871435565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400882126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7223943,0.008706335,0.00030719014,0.094808124,0.00053811434,0.00029249457,0.14561188,0.0000869011,0.027254643],"genre_scores_gemma":[0.96536005,0.004378696,0.0002175611,0.0035668842,0.00015730185,0.00006618308,0.0175618,0.000019513853,0.0086719645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998171,0.00012976505,0.00009522986,0.0001148308,0.00065501075,0.000834203],"domain_scores_gemma":[0.99139965,0.00042861165,0.0015817676,0.00011111218,0.0029489766,0.003529894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009625522,0.00029701373,0.00057783036,0.0013319053,0.0022890118,0.002161964,0.0015074292,0.0011997547,0.0063854856],"category_scores_gemma":[0.0051183673,0.00037689396,0.0010050706,0.0032488483,0.0008662839,0.00078261987,0.0017376364,0.0020690854,0.00040901577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004802108,0.00017255782,0.8664292,0.00021618945,0.00030152273,0.00029684068,0.00083387736,0.0022376024,0.00019139996,0.0036863748,0.115104444,0.010049766],"study_design_scores_gemma":[0.00008436412,0.000029337116,0.9885089,0.00011288467,0.000056672183,0.0000358751,0.0012403306,0.0010767797,0.00006247499,0.00021263414,0.008546438,0.000033319768],"about_ca_topic_score_codex":0.9982705,"about_ca_topic_score_gemma":0.9989003,"teacher_disagreement_score":0.071689256,"about_ca_system_score_codex":0.071689256,"about_ca_system_score_gemma":0.09105883,"threshold_uncertainty_score":0.5201444},"labels":[],"label_agreement":null},{"id":"W4400885269","doi":"10.4324/9781003449331","title":"Economics of the Pharmaceutical and Medical Device Industry","year":2024,"lang":"en","type":"book","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"George Brown College","funders":"","keywords":"Pharmaceutical industry; Economics; Neoclassical economics; Medicine; Pharmacology","score_opus":0.08600410024668714,"score_gpt":0.3204982374258354,"score_spread":0.23449413717914824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400885269","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037905432,0.073812515,0.009243218,0.022387195,0.0013493564,0.00007982729,0.0004120315,0.00008758705,0.88883764],"genre_scores_gemma":[0.17189188,0.15563251,0.0072163506,0.008852347,0.0036561391,0.00022227764,0.00055662094,0.00012990007,0.651842],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895966,0.00021573738,0.000024275918,0.000077015735,0.00062834343,0.00009498263],"domain_scores_gemma":[0.9992743,0.0004246913,0.000071656745,0.000048430982,0.00013045178,0.000050409843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062545727,0.0005499408,0.0003717159,0.0014324131,0.0009581987,0.004246417,0.0004568153,0.0021454655,0.020387163],"category_scores_gemma":[0.0018346241,0.00044674551,0.0004744421,0.0013287865,0.0022190306,0.0033829377,0.0012470809,0.0018413749,0.0042079543],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015923475,0.000029111234,0.0003037232,0.00013701462,0.000010503377,0.00009489232,0.00007055364,0.0023277032,0.00019519072,0.8880556,0.07598863,0.032771237],"study_design_scores_gemma":[0.00000836151,0.0000372371,0.0015728652,0.00052849087,0.000009554919,0.00037027535,0.00016948988,0.0023779925,0.000218489,0.27047354,0.7242115,0.00002217872],"about_ca_topic_score_codex":0.0030670073,"about_ca_topic_score_gemma":0.0026329998,"teacher_disagreement_score":0.020387163,"about_ca_system_score_codex":0.0034070832,"about_ca_system_score_gemma":0.0025254113,"threshold_uncertainty_score":0.0682019},"labels":[],"label_agreement":null},{"id":"W4401022200","doi":"10.1001/jama.2024.13386","title":"FDA Greenlights Second Alzheimer Drug, Donanemab","year":2024,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Art history; Humanities; Art; Philosophy","score_opus":0.056795041827866495,"score_gpt":0.2863818921707187,"score_spread":0.2295868503428522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401022200","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03509795,0.22249255,0.004130606,0.15810704,0.024538377,0.0006310299,0.009002931,0.0025050181,0.54349446],"genre_scores_gemma":[0.18974,0.11922117,0.006681129,0.06386565,0.008202911,0.00061734056,0.008952146,0.00035635656,0.6023632],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994597,0.00011099171,0.000024581705,0.000084430394,0.00023687466,0.00008347022],"domain_scores_gemma":[0.99937016,0.000112310336,0.00006806037,0.000031902935,0.00021032298,0.00020731869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078069884,0.0004894578,0.00062266865,0.00060056755,0.0006891983,0.0013826493,0.00049502513,0.0016471761,0.036430106],"category_scores_gemma":[0.0013870721,0.00014849345,0.0005579383,0.00039890214,0.00036946844,0.00077893323,0.00045648534,0.0023480018,0.012208023],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015906444,0.0002073883,0.0008691993,0.00032229457,0.000055346572,0.00038581045,0.000029927392,0.00008855455,0.0029857575,0.0030647945,0.70642,0.2839803],"study_design_scores_gemma":[0.0015944991,0.0005853275,0.0022741794,0.00026153345,0.0000760616,0.0013093202,0.000033276832,0.000258688,0.0020747783,0.0014596588,0.99005425,0.00001838333],"about_ca_topic_score_codex":0.0013636604,"about_ca_topic_score_gemma":0.005410884,"teacher_disagreement_score":0.036430106,"about_ca_system_score_codex":0.0009693626,"about_ca_system_score_gemma":0.0017307246,"threshold_uncertainty_score":0.121870816},"labels":[],"label_agreement":null},{"id":"W4401177491","doi":"10.1257/pol.20220505","title":"Competitive Bidding in Drug Procurement: Evidence from China","year":2024,"lang":"en","type":"article","venue":"American Economic Journal Economic Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Bidding; China; Procurement; Business; Drug; Industrial organization; Public economics; Economics; Marketing; Pharmacology; Medicine; Political science","score_opus":0.03789529403700796,"score_gpt":0.3186712153463611,"score_spread":0.28077592130935314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401177491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97916806,0.0021365436,0.0009238295,0.0019331998,0.00002513318,0.00007467026,0.00045695843,0.000028356395,0.015253345],"genre_scores_gemma":[0.997566,0.0006093777,0.00016082762,0.00035071847,0.00001704295,0.000012657432,0.00024154416,0.0000033048184,0.0010384955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714357,0.0011263385,0.000118348784,0.0002215929,0.0005751765,0.00081486016],"domain_scores_gemma":[0.98864156,0.004189494,0.0037701903,0.0006755465,0.0019105239,0.00081260427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004187106,0.00034934282,0.0008114494,0.00096763065,0.0011592811,0.0016412251,0.0010855927,0.0008680046,0.0059142695],"category_scores_gemma":[0.009675565,0.0003270008,0.00088082487,0.002222729,0.0014559113,0.0009329515,0.001055097,0.0010575701,0.00041279692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030041633,0.0025627543,0.7601408,0.00090438814,0.0013467789,0.0021542863,0.0020518934,0.044532616,0.001881559,0.06881571,0.015397713,0.097207434],"study_design_scores_gemma":[0.002332957,0.0016817702,0.87666845,0.00017618186,0.00090780953,0.00035889997,0.0028745409,0.06996428,0.0031074083,0.018697148,0.023062542,0.00016798539],"about_ca_topic_score_codex":0.18811634,"about_ca_topic_score_gemma":0.16416104,"teacher_disagreement_score":0.18811634,"about_ca_system_score_codex":0.005739888,"about_ca_system_score_gemma":0.005473224,"threshold_uncertainty_score":0.37404275},"labels":[],"label_agreement":null},{"id":"W4401210807","doi":"10.1371/journal.pone.0308118","title":"Canadian status of “not acceptable” drugs as evaluated by Prescrire: A cohort study","year":2024,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"Health Canada","keywords":"Medicine; Interquartile range; Drug; Family medicine; Alternative medicine; Pharmacology; Internal medicine; Pathology","score_opus":0.088827961021543,"score_gpt":0.29628785591597306,"score_spread":0.20745989489443006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401210807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401456,0.00040678127,0.000039513074,0.00015243259,0.000009936518,0.000068555826,0.0029457517,0.000004782352,0.0023577039],"genre_scores_gemma":[0.9971539,0.0003842876,0.00007402017,0.000091769456,0.000011654644,0.000027569013,0.0016209724,0.000006738234,0.0006291516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978719,0.00014335435,0.0001087309,0.00034927984,0.0010711038,0.00045566694],"domain_scores_gemma":[0.9948639,0.0003555999,0.0018876721,0.0002669283,0.0016867992,0.00093906984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00133575,0.00037685086,0.00058277114,0.002191616,0.002178954,0.001828592,0.001028471,0.00071746856,0.0041692327],"category_scores_gemma":[0.004085025,0.00042686902,0.0009599897,0.004926104,0.00092924375,0.00084394566,0.0009373686,0.0012263563,0.0006397576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014475435,0.000053459546,0.9967578,0.000030997217,0.000048550155,0.000103909355,0.0005923025,0.000018003502,0.00007939473,0.000053551394,0.0006767201,0.001440599],"study_design_scores_gemma":[0.000010891095,0.00007770339,0.99770015,0.00001966402,0.000031267096,0.00015415426,0.0010208343,0.000081469196,0.000027298705,0.000016139835,0.0008462631,0.000014188337],"about_ca_topic_score_codex":0.82732254,"about_ca_topic_score_gemma":0.82777834,"teacher_disagreement_score":0.9925123,"about_ca_system_score_codex":0.007487714,"about_ca_system_score_gemma":0.009873425,"threshold_uncertainty_score":0.34738874},"labels":[],"label_agreement":null},{"id":"W4401220050","doi":"10.51731/cjht.2024.945","title":"Drug Shortages: A Scoring System to Evaluate and Prioritize the Clinical Importance of Drugs in Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Health care; Economic shortage; Psychological intervention; Population; Risk analysis (engineering); Intensive care medicine; Actuarial science; Business; Adverse effect; Environmental health; Nursing; Pharmacology","score_opus":0.0839966089288163,"score_gpt":0.3449682227445677,"score_spread":0.2609716138157514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401220050","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8502775,0.0031181045,0.03829687,0.0045892736,0.00023525298,0.0068805506,0.025803756,0.0013119993,0.06948672],"genre_scores_gemma":[0.8762977,0.0012425805,0.112299025,0.00031065964,0.000036405774,0.0009565934,0.0044726115,0.00004681835,0.004337485],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956215,0.0008008756,0.0006682746,0.00019721089,0.0022742788,0.00043775223],"domain_scores_gemma":[0.9856337,0.0024671054,0.001602149,0.00019125981,0.009012646,0.0010931022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048384317,0.00064399117,0.0005393187,0.007837676,0.0016444636,0.0019900827,0.0012887795,0.0004328396,0.0037386564],"category_scores_gemma":[0.01818698,0.00024785666,0.0008038545,0.0068081543,0.0006440268,0.0007472688,0.0015726074,0.00053672894,0.0004675671],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007859484,0.00033762303,0.64543325,0.0010106319,0.00024399739,0.00034632356,0.001624425,0.0056479215,0.001715759,0.0023775995,0.030221194,0.31025535],"study_design_scores_gemma":[0.00026224248,0.0007213776,0.89688474,0.0006282248,0.00033433348,0.00049598666,0.0046396144,0.055223074,0.0041111745,0.0020705645,0.034408852,0.00021973473],"about_ca_topic_score_codex":0.7838282,"about_ca_topic_score_gemma":0.86750156,"teacher_disagreement_score":0.2161718,"about_ca_system_score_codex":0.01991043,"about_ca_system_score_gemma":0.039929967,"threshold_uncertainty_score":0.43488973},"labels":[],"label_agreement":null},{"id":"W4401515421","doi":"10.1177/08404704241271237","title":"Do high drug prices fund pharmaceutical innovation?","year":2024,"lang":"en","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Institute for New Economic Thinking; Canadian Institute for Advanced Research","keywords":"Business; Stock (firearms); Dividend; Shareholder; Corporation; Cash; Monetary economics; Finance; Drug prices; Economics; Corporate governance","score_opus":0.10299272116347642,"score_gpt":0.36692248912746706,"score_spread":0.26392976796399065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401515421","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14540817,0.03545227,0.0039668465,0.41819972,0.001853956,0.00012106005,0.0019521137,0.0001671408,0.39287868],"genre_scores_gemma":[0.961317,0.007989941,0.00035534566,0.014384145,0.0019039811,0.00002241869,0.0001930697,0.0000232241,0.0138108665],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99811816,0.00028719587,0.000058055033,0.00019949465,0.00076589506,0.0005711495],"domain_scores_gemma":[0.9829594,0.0057312977,0.0061434894,0.00058109226,0.0024874203,0.0020972206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024642716,0.0002088116,0.00051141996,0.0018252999,0.0012710122,0.006589154,0.00073029066,0.0028951245,0.01877177],"category_scores_gemma":[0.032667536,0.00025045263,0.0003157471,0.0018291544,0.004338792,0.0042995494,0.0012274665,0.0018169674,0.0017572683],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045698896,0.00023109058,0.17007759,0.00031592452,0.00023047827,0.00044381263,0.001093187,0.00091772445,0.00040846883,0.5718738,0.10558279,0.14836814],"study_design_scores_gemma":[0.00041008033,0.00020051519,0.34527656,0.0005951815,0.00027701352,0.00072142144,0.002845668,0.0024304835,0.0011309477,0.30321753,0.342796,0.0000985918],"about_ca_topic_score_codex":0.08511054,"about_ca_topic_score_gemma":0.06260201,"teacher_disagreement_score":0.08511054,"about_ca_system_score_codex":0.0076341215,"about_ca_system_score_gemma":0.0091103045,"threshold_uncertainty_score":0.16923028},"labels":[],"label_agreement":null},{"id":"W4401600345","doi":"10.1016/j.atherosclerosis.2024.118210","title":"Validation of site-less strategies and long-distance drone-based delivery and collection system to promote access to innovative treatments for patients with rare or severe dyslipidemias","year":2024,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Innovaderm (Canada); Université du Québec à Chicoutimi","funders":"","keywords":"Drone; Delivery system; Computer science; Medicine; Operations management; Engineering; Biomedical engineering; Biology","score_opus":0.0673597188745463,"score_gpt":0.2918716164650965,"score_spread":0.22451189759055024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401600345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90335286,0.00052008854,0.057820193,0.005848123,0.0005169694,0.004666596,0.0025619683,0.0006892288,0.024023928],"genre_scores_gemma":[0.96502745,0.0001486752,0.029100712,0.0008460189,0.000058245703,0.0012376569,0.0006725267,0.000036240952,0.0028725523],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98423105,0.011493811,0.00060446316,0.0014059035,0.0015364615,0.00072836527],"domain_scores_gemma":[0.9575149,0.025240872,0.0038098346,0.0042368798,0.0070083276,0.0021892234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020805782,0.0005631544,0.0005672297,0.0007513092,0.00077938614,0.0027032478,0.001952481,0.0017947331,0.01122681],"category_scores_gemma":[0.04869244,0.00030948076,0.00086332316,0.0006270389,0.0008125284,0.0027575542,0.0015867981,0.0012387678,0.0019838098],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015893707,0.03822425,0.3252228,0.0018780924,0.001176956,0.00037646716,0.002435135,0.07429793,0.013957763,0.038853202,0.022838488,0.46484527],"study_design_scores_gemma":[0.00838334,0.0409673,0.4054954,0.0011424338,0.0018038198,0.0003504329,0.007969163,0.42908868,0.027380481,0.023501316,0.05339851,0.00051913195],"about_ca_topic_score_codex":0.012351377,"about_ca_topic_score_gemma":0.008211014,"teacher_disagreement_score":0.020805782,"about_ca_system_score_codex":0.0033240612,"about_ca_system_score_gemma":0.010412052,"threshold_uncertainty_score":0.1100328},"labels":[],"label_agreement":null},{"id":"W4401667000","doi":"10.31579/2693-4779/204","title":"Phase IV Drug Development:Post-Marketing Studies","year":2024,"lang":"en","type":"article","venue":"Clinical Research and Clinical Trials","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Drug development; Drug; Business; Marketing; Pharmacology; Medicine","score_opus":0.8494036240734456,"score_gpt":0.6818881618903232,"score_spread":0.1675154621831224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401667000","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56324446,0.041528065,0.034616906,0.011599646,0.0040986044,0.047428936,0.018201426,0.0011221179,0.27815983],"genre_scores_gemma":[0.9115853,0.009199798,0.014780824,0.0077605867,0.0018689046,0.015355986,0.00512816,0.00032196703,0.033998556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9706626,0.017060434,0.002658109,0.002080523,0.0064267837,0.0011115525],"domain_scores_gemma":[0.9078801,0.03713481,0.020051189,0.010519797,0.02096914,0.00344502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031701054,0.0006226194,0.0007972684,0.0010181027,0.0014568571,0.0033826018,0.00094142545,0.0013505259,0.023090791],"category_scores_gemma":[0.08034176,0.00041658484,0.0011324815,0.0015562358,0.0011050696,0.00229735,0.0016430888,0.002369458,0.005373988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033077862,0.007869732,0.09153384,0.0066244537,0.0011525196,0.00067928695,0.004702632,0.0006842958,0.005044805,0.011661725,0.054826345,0.78214246],"study_design_scores_gemma":[0.0038639244,0.08980755,0.18377158,0.00450821,0.0016906084,0.0018164275,0.003963471,0.0013623115,0.022775121,0.008954751,0.67728037,0.0002057289],"about_ca_topic_score_codex":0.0006967527,"about_ca_topic_score_gemma":0.0009484979,"teacher_disagreement_score":0.031701054,"about_ca_system_score_codex":0.0015655957,"about_ca_system_score_gemma":0.0032990118,"threshold_uncertainty_score":0.1676532},"labels":[],"label_agreement":null},{"id":"W4401705679","doi":"10.2139/ssrn.4894485","title":"When Haste Makes Waste: Fair And Equitable Treatment Violations in Canada's Feed-in Tariff Program Implementation and Lessons for Vietnam","year":2024,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tariff; Business; Natural resource economics; Waste management; Economic growth; Economics; International trade; Engineering","score_opus":0.037571521202226274,"score_gpt":0.3213171437703761,"score_spread":0.28374562256814984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401705679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47181758,0.0021636717,0.0023051163,0.44803447,0.0006323212,0.00022179126,0.0005687784,0.00006969507,0.07418665],"genre_scores_gemma":[0.96854454,0.0006032011,0.0009882186,0.016069416,0.000060458817,0.000053546537,0.000095243784,0.00005066388,0.013534677],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9764715,0.0055759274,0.00056819647,0.0009223068,0.0046756444,0.011786409],"domain_scores_gemma":[0.9702086,0.008863655,0.0022612354,0.0008845402,0.00911646,0.008665432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018419428,0.0002710887,0.0007045758,0.0010405316,0.018975286,0.016543748,0.0037465256,0.0068727355,0.0076838075],"category_scores_gemma":[0.039198354,0.0006114746,0.0006830739,0.0026061349,0.008871024,0.0051088,0.0044583557,0.011979365,0.0002099111],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006797279,0.0010566321,0.12974785,0.0003603979,0.0003132625,0.0016985608,0.061066046,0.01024248,0.00076652184,0.48468462,0.15514672,0.15423724],"study_design_scores_gemma":[0.0003737448,0.0004108193,0.23272814,0.0017978861,0.00040210682,0.00044989891,0.41472238,0.011953193,0.0025680335,0.12659192,0.20745957,0.00054228096],"about_ca_topic_score_codex":0.984464,"about_ca_topic_score_gemma":0.9929733,"teacher_disagreement_score":0.14468896,"about_ca_system_score_codex":0.14468896,"about_ca_system_score_gemma":0.36086655,"threshold_uncertainty_score":0.99203956},"labels":[],"label_agreement":null},{"id":"W4401707212","doi":"10.34172/ijhpm.8578","title":"Political Prioritization of Access to Medicines and Right to Health: Need for an Effective Global Health Governance Through Global Health Diplomacy Comment on \"More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap\"","year":2024,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; University of Toronto","funders":"","keywords":"Global health; Diplomacy; Essential medicines; Business; Corporate governance; Equity (law); Global governance; Intellectual property; Right to health; Politics; Health policy; Public relations; Economic growth; Political science; Health care; Economics; Law; Finance","score_opus":0.09869667137899918,"score_gpt":0.49157980994348005,"score_spread":0.39288313856448087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401707212","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016461078,0.0014415066,0.00014105669,0.9936655,0.0030550256,0.0000027426165,0.00001672037,0.0000037579118,0.0015090056],"genre_scores_gemma":[0.013716689,0.0019605274,0.00028575017,0.96841484,0.01246986,0.000021734655,0.000015008134,0.000025765583,0.0030898228],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9837427,0.007445761,0.00080449885,0.0019721673,0.003811422,0.0022234628],"domain_scores_gemma":[0.909684,0.076236516,0.0035726102,0.0008452422,0.0071101086,0.0025514334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018984497,0.00071584585,0.0015252199,0.0009773416,0.006195259,0.010706069,0.0039758654,0.048542704,0.0067415214],"category_scores_gemma":[0.053114895,0.00057126995,0.0015560596,0.001481527,0.018400215,0.012062919,0.004562149,0.045578685,0.001620036],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031008763,0.000012545197,0.00014270126,0.00021509062,0.000015862654,0.0003111584,0.0023658671,0.00023408039,0.00014860237,0.20133425,0.7901409,0.005047924],"study_design_scores_gemma":[0.0000649841,0.000032055752,0.00073537865,0.0011755397,0.000027861333,0.00020884027,0.0028264106,0.0005871365,0.00028975695,0.14569974,0.84823835,0.000113909024],"about_ca_topic_score_codex":0.02457831,"about_ca_topic_score_gemma":0.02810311,"teacher_disagreement_score":0.048542704,"about_ca_system_score_codex":0.013410522,"about_ca_system_score_gemma":0.01958541,"threshold_uncertainty_score":0.100400805},"labels":[],"label_agreement":null},{"id":"W4401809601","doi":"10.55016/ojs/sppp.v16i1.75913","title":"Canadian Competitiveness in the Health Life Sciences","year":2023,"lang":"en","type":"article","venue":"The School of Public Policy Publications","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regional science; Political science; Geography","score_opus":0.183320896328144,"score_gpt":0.3692191266091547,"score_spread":0.18589823028101068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401809601","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048224304,0.03133285,0.001960637,0.26630542,0.0012642135,0.000110549576,0.005391431,0.0001881247,0.64522254],"genre_scores_gemma":[0.8342927,0.042199295,0.0040837494,0.017732881,0.0005485371,0.00008242245,0.0035537563,0.00015669967,0.097349994],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900171,0.0007212156,0.00017408942,0.0005221542,0.005587174,0.0029782862],"domain_scores_gemma":[0.9888545,0.0010105675,0.00038146987,0.0002517006,0.0063290778,0.0031726086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047354363,0.00052494876,0.0005800323,0.004160546,0.009141095,0.011587576,0.0011417798,0.0015100704,0.014091212],"category_scores_gemma":[0.010491378,0.0002924814,0.00052662916,0.009567317,0.0032019778,0.0020787092,0.0027882778,0.0020980712,0.0007410365],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008408018,0.000026508804,0.013614079,0.000401935,0.00006359768,0.00020595198,0.0024365433,0.001288091,0.00029529099,0.62061334,0.27279103,0.08817958],"study_design_scores_gemma":[0.000019400466,0.000028069826,0.03560772,0.00046752224,0.000043678032,0.00010351084,0.004633461,0.00087207067,0.00030039105,0.019965487,0.93788105,0.00007763821],"about_ca_topic_score_codex":0.9901333,"about_ca_topic_score_gemma":0.99024934,"teacher_disagreement_score":0.17849818,"about_ca_system_score_codex":0.17849818,"about_ca_system_score_gemma":0.33962932,"threshold_uncertainty_score":0.95282567},"labels":[],"label_agreement":null},{"id":"W4401947764","doi":"10.1101/2024.08.26.24312600","title":"An evaluation of the adequacy of Indian national and state Essential Medicines Lists (EMLs) for palliative care medical needs - a comparative analysis","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Palliative care; Medicine; State (computer science); Traditional medicine; Family medicine; Business; Nursing; Computer science","score_opus":0.1354627508960776,"score_gpt":0.41681064245982663,"score_spread":0.28134789156374906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401947764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97096527,0.011206718,0.0009624342,0.0013270318,0.000051800853,0.0010295466,0.0023163685,0.00002677899,0.012113972],"genre_scores_gemma":[0.9927112,0.0037111337,0.0019603702,0.0002255504,0.0000197058,0.00048212754,0.0006161458,0.000012087757,0.0002616603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9642633,0.018034322,0.0075554806,0.0010457335,0.008093512,0.0010075031],"domain_scores_gemma":[0.81882167,0.115716286,0.02979809,0.0032286372,0.03082227,0.0016130656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04691875,0.00024831246,0.0008181889,0.017394139,0.0016358987,0.0037030408,0.0014577613,0.00044932548,0.0030094031],"category_scores_gemma":[0.12533005,0.00040998874,0.0015041162,0.018577227,0.0022855035,0.0052024806,0.004444692,0.00087207207,0.00021163076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016917959,0.0003464657,0.4299938,0.041944303,0.0017639403,0.0008737757,0.30118904,0.00038790962,0.0012118483,0.006220859,0.002985521,0.21139078],"study_design_scores_gemma":[0.00009974308,0.0012689682,0.49162817,0.01126274,0.0017651977,0.0008955194,0.4706639,0.00071499444,0.001051824,0.00085255905,0.019633066,0.00016334862],"about_ca_topic_score_codex":0.012552064,"about_ca_topic_score_gemma":0.022124374,"teacher_disagreement_score":0.04691875,"about_ca_system_score_codex":0.009402422,"about_ca_system_score_gemma":0.008779913,"threshold_uncertainty_score":0.248133},"labels":[],"label_agreement":null},{"id":"W4401982116","doi":"10.54194/kjry1417","title":"Benefit of expedited regulatory approval for oncology drugs eliminated by slow reimbursement reviews and price negotiations","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Reimbursement; Negotiation; Drug approval; Business; Pharmacology; Medicine; Political science; Law; Drug","score_opus":0.07052812717698538,"score_gpt":0.36358557158349397,"score_spread":0.2930574444065086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401982116","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23256631,0.013629792,0.027311666,0.4466764,0.00827815,0.004450847,0.002892996,0.003478281,0.26071566],"genre_scores_gemma":[0.7536776,0.0027509914,0.02611245,0.17260015,0.008668436,0.001400087,0.0014736059,0.0004490538,0.03286763],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.90358955,0.033987097,0.0073124813,0.0049897376,0.03966889,0.010452263],"domain_scores_gemma":[0.53206694,0.31091785,0.058146015,0.021746708,0.05467488,0.02244763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10424138,0.0012652128,0.0026038068,0.0067650303,0.0033726448,0.014349029,0.0033175712,0.016125146,0.018983994],"category_scores_gemma":[0.2631447,0.0015623634,0.005548336,0.0035367263,0.002999605,0.006277093,0.0056114015,0.012668487,0.0035401932],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009291271,0.0029938428,0.057973504,0.0022520537,0.002428505,0.0038040213,0.0008951241,0.02052629,0.010885725,0.124087006,0.36669588,0.3981668],"study_design_scores_gemma":[0.0150263505,0.008708772,0.3466157,0.0016633439,0.0040071337,0.004538785,0.0013767189,0.026672019,0.012807185,0.046341494,0.53110033,0.0011421571],"about_ca_topic_score_codex":0.008026298,"about_ca_topic_score_gemma":0.013125477,"teacher_disagreement_score":0.9919737,"about_ca_system_score_codex":0.009529837,"about_ca_system_score_gemma":0.04472832,"threshold_uncertainty_score":0.55128765},"labels":[],"label_agreement":null},{"id":"W4402002883","doi":"10.14740/jem997","title":"Trends in Teprotumumab Insurance Authorization and Socioeconomic Determinants of Teprotumumab Access","year":2024,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Socioeconomic status; Authorization; Environmental health; Computer security; Population","score_opus":0.053306856012336985,"score_gpt":0.3432354785950316,"score_spread":0.28992862258269464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402002883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998825,0.00008514412,0.000026811444,0.00008659455,0.000002221739,0.000004674783,0.0006057419,0.0000012298696,0.00036254368],"genre_scores_gemma":[0.9995492,0.000050398954,0.000024316738,0.000015793488,0.0000038216085,0.000004998655,0.000299872,8.03262e-7,0.00005078925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993525,0.000106728236,0.00009862365,0.000106865526,0.00014886785,0.00018633164],"domain_scores_gemma":[0.9956455,0.00062333676,0.0025462075,0.00010051543,0.00042234352,0.0006621093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007341855,0.00009222393,0.0001548698,0.0009930307,0.0004050831,0.0006650482,0.00030818966,0.00025510637,0.002448052],"category_scores_gemma":[0.003396372,0.00011148266,0.00031731272,0.0015028107,0.00023528474,0.0004716255,0.0005715406,0.00051134074,0.00020456483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001988458,0.000009433386,0.99948835,0.0000022474612,0.00000501567,0.000024582294,0.000035101195,0.000009151447,0.000027289796,0.0000120762825,0.000048242244,0.00031849602],"study_design_scores_gemma":[0.0000014619401,0.00002900595,0.9992717,0.000004443653,0.0000035469166,0.00011255209,0.00031420228,0.00010794607,0.00002680346,0.0000070822102,0.00011975326,0.0000015545938],"about_ca_topic_score_codex":0.016189203,"about_ca_topic_score_gemma":0.018043866,"teacher_disagreement_score":0.016189203,"about_ca_system_score_codex":0.0006746469,"about_ca_system_score_gemma":0.0007695323,"threshold_uncertainty_score":0.032189965},"labels":[],"label_agreement":null},{"id":"W4402079230","doi":"10.1101/2024.08.28.24312695","title":"Trends of use of drugs with suggested shortages and their alternatives across 52 real world data sources and 18 countries in Europe and North America","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Economic shortage; Real world data; Real world evidence; Development economics; Geography; Business; Natural resource economics; Economics; Data science; Computer science; Medicine","score_opus":0.11314689983133565,"score_gpt":0.32855807219478633,"score_spread":0.2154111723634507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402079230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638803,0.0019470423,0.0004812346,0.00018970379,0.00001084633,0.000049277995,0.032671098,0.000022399377,0.00074816454],"genre_scores_gemma":[0.9807647,0.0007440795,0.00091142434,0.000107423635,0.000015515996,0.00008436515,0.017258724,0.000009185071,0.00010452547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928019,0.0020271956,0.0024015678,0.0014327498,0.0009472906,0.00038925753],"domain_scores_gemma":[0.9679289,0.0068019796,0.020516144,0.0014274438,0.0026672294,0.00065826677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004581119,0.00025888562,0.00057762524,0.005315696,0.00026380815,0.0014911175,0.0006614251,0.0004848447,0.0009140535],"category_scores_gemma":[0.011780951,0.0003264669,0.00083807204,0.011282583,0.00037666192,0.0015053593,0.0013925828,0.0004731953,0.0001675019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000595016,0.000010302356,0.99759126,0.00013666971,0.00017954978,0.000024590849,0.00011712165,0.000099744546,0.00007362562,0.000034786208,0.00030143926,0.0013714752],"study_design_scores_gemma":[0.00000825854,0.0000322342,0.9977024,0.000109566856,0.00008009717,0.00017775859,0.00050744263,0.00032023867,0.00013381323,0.000023723373,0.00089521345,0.000009173132],"about_ca_topic_score_codex":0.014943317,"about_ca_topic_score_gemma":0.017401384,"teacher_disagreement_score":0.014943317,"about_ca_system_score_codex":0.000860448,"about_ca_system_score_gemma":0.00084490725,"threshold_uncertainty_score":0.029712617},"labels":[],"label_agreement":null},{"id":"W4402151108","doi":"10.53879/id.61.07.p0005","title":"GLAD TIDINGS FOR INDIAN PHARMACEUTICAL INDUSTRY","year":2024,"lang":"en","type":"article","venue":"INDIAN DRUGS","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Clinical trial; Government (linguistics); Waiver; Medicine; Procurement; European union; Approved drug; Business; Political science; Pharmacology; Drug; Law; International trade","score_opus":0.0641451679386877,"score_gpt":0.33054280192797586,"score_spread":0.2663976339892882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402151108","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003085308,0.014924663,0.00064940884,0.72402704,0.14305685,0.0000741488,0.00047361568,0.0011038097,0.11538184],"genre_scores_gemma":[0.005868815,0.012885589,0.0018735281,0.5748468,0.04915237,0.000117249256,0.000423634,0.0005489386,0.35428315],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937629,0.0008721188,0.00030454353,0.000545132,0.0032875275,0.0012277776],"domain_scores_gemma":[0.98638564,0.001951873,0.00068699376,0.0012960939,0.004948148,0.0047312737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057893954,0.0014688903,0.0012325945,0.002074006,0.0058834055,0.023655478,0.0024170014,0.019387243,0.15858003],"category_scores_gemma":[0.019967737,0.00071617606,0.0020647577,0.002455427,0.0040113926,0.011292162,0.00582706,0.026646942,0.14596209],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001400384,0.000021060861,0.00002709147,0.00004320234,0.0000023560463,0.00007264601,0.000031232626,0.00001746165,0.00006530691,0.009920977,0.98141897,0.008365582],"study_design_scores_gemma":[0.000006794058,0.000010095015,0.00007415267,0.000067549685,0.0000024586275,0.00007540766,0.00007486258,0.000019718895,0.00004310763,0.0037117621,0.99590355,0.000010429749],"about_ca_topic_score_codex":0.0080872895,"about_ca_topic_score_gemma":0.011837726,"teacher_disagreement_score":0.15858003,"about_ca_system_score_codex":0.0053436058,"about_ca_system_score_gemma":0.014588177,"threshold_uncertainty_score":0.53050303},"labels":[],"label_agreement":null},{"id":"W4402240112","doi":"10.12927/hcpol.2024.27334","title":"Federal Funding for Expensive Drugs for Rare Diseases: How Do We Pick and Choose?","year":2024,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; York University","funders":"","keywords":"Business","score_opus":0.1032238011079362,"score_gpt":0.3693521126074052,"score_spread":0.266128311499469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402240112","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016882564,0.033045962,0.0036987825,0.9543978,0.0018448008,0.00005033002,0.00018310972,0.000023077797,0.0050679385],"genre_scores_gemma":[0.23472151,0.10974511,0.028267415,0.6095171,0.012884612,0.0005690251,0.0005193647,0.00025127872,0.0035246275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.87437457,0.08321645,0.010150711,0.003927483,0.022600297,0.0057304823],"domain_scores_gemma":[0.6525389,0.28049168,0.017648406,0.005507816,0.03175618,0.012057098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.15839146,0.0009634207,0.0040548444,0.0074059335,0.0063249553,0.023397718,0.003789603,0.015821004,0.006421342],"category_scores_gemma":[0.36568654,0.0011545665,0.002179803,0.006453588,0.019574957,0.03411831,0.007107757,0.022214783,0.0021689907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037442608,0.00020896511,0.0126217725,0.004039562,0.0007995042,0.00037657758,0.0034153308,0.0025448399,0.00019983803,0.3385936,0.27730423,0.35952127],"study_design_scores_gemma":[0.00034061226,0.00013519908,0.0053751664,0.027965147,0.00041572144,0.000367127,0.006409025,0.0014624196,0.00037742595,0.6915127,0.2653055,0.0003339344],"about_ca_topic_score_codex":0.0324756,"about_ca_topic_score_gemma":0.04043255,"teacher_disagreement_score":0.15839146,"about_ca_system_score_codex":0.017237218,"about_ca_system_score_gemma":0.048432473,"threshold_uncertainty_score":0.8376641},"labels":[],"label_agreement":null},{"id":"W4402297416","doi":"10.55016/ojs/jah.v2023y2023.77200","title":"Responding to Unexpected Urine Drug Test Results: A Phenomenological Approach","year":2023,"lang":"en","type":"article","venue":"Journal of Applied Hermeneutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Test (biology); Urine; Drug; Psychology; Medicine; Internal medicine; Psychiatry; Geology","score_opus":0.06779407493633377,"score_gpt":0.28959157288263754,"score_spread":0.22179749794630377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402297416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58308864,0.01197559,0.13016364,0.125263,0.0016112361,0.0015898874,0.00038995486,0.00020225193,0.14571579],"genre_scores_gemma":[0.97735137,0.0030291541,0.010049483,0.00519948,0.00014545766,0.00036456168,0.00006586289,0.000060427774,0.0037342722],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.982225,0.014762564,0.00040787732,0.0007038481,0.0010248487,0.0008758875],"domain_scores_gemma":[0.9842902,0.012213794,0.0009035002,0.0006433667,0.00093025505,0.0010189511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017270021,0.0009063623,0.00072448567,0.0033560744,0.012289795,0.011913848,0.002852476,0.0048424858,0.0023842868],"category_scores_gemma":[0.019886507,0.00071500445,0.0008709042,0.0024140303,0.05530785,0.019570028,0.012521067,0.0067923027,0.00041181533],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001841459,0.000036983154,0.0008528385,0.00012779128,0.00000637024,0.00077724183,0.93142676,0.00019145235,0.000240413,0.062878735,0.0012689764,0.0021741898],"study_design_scores_gemma":[0.000011223548,0.000032177064,0.00047679222,0.00028863904,0.0000068507093,0.001049579,0.92535067,0.00054538436,0.00013812188,0.04130773,0.030751633,0.000041219235],"about_ca_topic_score_codex":0.0051805438,"about_ca_topic_score_gemma":0.0040985,"teacher_disagreement_score":0.017270021,"about_ca_system_score_codex":0.007937292,"about_ca_system_score_gemma":0.0053856657,"threshold_uncertainty_score":0.09133363},"labels":[],"label_agreement":null},{"id":"W4402394418","doi":"10.1108/jfc-05-2024-0150","title":"Valeant pharmaceuticals fraud","year":2024,"lang":"en","type":"article","venue":"Journal of Financial Crime","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Business; Criminology; Law and economics; Economics; Psychology","score_opus":0.08431013818497925,"score_gpt":0.3395549638580178,"score_spread":0.2552448256730386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402394418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82931817,0.00781973,0.0033006952,0.01709799,0.0003646611,0.00040969907,0.0029553387,0.00020944052,0.13852423],"genre_scores_gemma":[0.9793697,0.0016158342,0.002023126,0.0016676859,0.00015652907,0.000058759786,0.00072591426,0.000012865241,0.014369609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99285674,0.0017731555,0.00055372785,0.00080084166,0.0034401426,0.00057536626],"domain_scores_gemma":[0.9660514,0.011208999,0.01482197,0.0022109747,0.0044452953,0.0012613647],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004534136,0.00021228839,0.00019484416,0.0046912334,0.0014281431,0.0043262015,0.00068371184,0.0007694191,0.005219304],"category_scores_gemma":[0.024763383,0.00016609626,0.00019480217,0.0029068126,0.0012948933,0.0016954367,0.0016585735,0.0010478202,0.00076538237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037798815,0.0002732827,0.5607823,0.00058746693,0.00007812295,0.0027903826,0.0036449477,0.000933374,0.0015698747,0.0728785,0.047079988,0.3090038],"study_design_scores_gemma":[0.00004000877,0.0004266304,0.6159544,0.0014219494,0.00007755606,0.007296037,0.005362899,0.005313556,0.0060762977,0.011240605,0.3467116,0.00007848337],"about_ca_topic_score_codex":0.005731833,"about_ca_topic_score_gemma":0.0033233643,"teacher_disagreement_score":0.99923056,"about_ca_system_score_codex":0.003237777,"about_ca_system_score_gemma":0.0026456108,"threshold_uncertainty_score":0.023979127},"labels":[],"label_agreement":null},{"id":"W4402413658","doi":"10.51731/cjht.2024.970","title":"Drug Shortages and Patient Harms","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Economic shortage; Medicine; Intensive care medicine; Business; Pharmacology; Government (linguistics)","score_opus":0.05190415301851258,"score_gpt":0.2854990001977715,"score_spread":0.23359484717925894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402413658","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010288111,0.7977298,0.00058949325,0.17881787,0.0016483511,0.00027612713,0.0007263615,0.000015662663,0.00990827],"genre_scores_gemma":[0.15960756,0.7703784,0.0019178757,0.062083907,0.0039733923,0.00050743076,0.00039281647,0.000017837192,0.0011208082],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.943178,0.03061196,0.01394471,0.0013223805,0.009850471,0.0010924586],"domain_scores_gemma":[0.6615032,0.25563675,0.056390207,0.0038629868,0.020019084,0.0025877105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.045627184,0.0005111273,0.0027320513,0.0077189463,0.0016819407,0.006102535,0.0015879725,0.0055330154,0.007498477],"category_scores_gemma":[0.23907058,0.00078478595,0.0028980165,0.009141712,0.0048249476,0.01208809,0.0037005558,0.0044865184,0.0006386139],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007392805,0.00037581104,0.064969994,0.28114754,0.0031492827,0.0012775363,0.008390854,0.0005813098,0.00010473504,0.021958502,0.061692387,0.5556128],"study_design_scores_gemma":[0.00037554908,0.00077740836,0.056823615,0.6736215,0.003858051,0.0046377415,0.022543702,0.0004197021,0.00043379984,0.038874604,0.19741498,0.00021938689],"about_ca_topic_score_codex":0.006457849,"about_ca_topic_score_gemma":0.0059442297,"teacher_disagreement_score":0.99354213,"about_ca_system_score_codex":0.0061722435,"about_ca_system_score_gemma":0.012639788,"threshold_uncertainty_score":0.24130255},"labels":[],"label_agreement":null},{"id":"W4402602162","doi":"10.1007/s10018-024-00411-6","title":"Bioprospecting, drug choices and conservation of biological diversity under free trade","year":2024,"lang":"en","type":"article","venue":"Environmental Economics and Policy Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; MacEwan University","funders":"","keywords":"Bioprospecting; Diversity (politics); Social policy; Economics; Biology; Ecology; Political science; Market economy","score_opus":0.08351119623504226,"score_gpt":0.28663156292944125,"score_spread":0.20312036669439898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402602162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.816876,0.0135737285,0.028399765,0.029445872,0.00014192623,0.00013012759,0.0006523459,0.00006069302,0.11071966],"genre_scores_gemma":[0.9939322,0.0011439368,0.0009503215,0.0010814624,0.00008917003,0.00001676515,0.000035968285,0.000003559923,0.0027465285],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9978872,0.0011348232,0.00007658555,0.00022224999,0.00035195972,0.0003270978],"domain_scores_gemma":[0.98501706,0.009946872,0.002662262,0.0009929787,0.00058631133,0.00079455646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005856001,0.00028144126,0.00063255365,0.0012389225,0.0011378021,0.0042621465,0.0006590494,0.0039639813,0.005997663],"category_scores_gemma":[0.012992822,0.00020337131,0.0007059934,0.0010128437,0.005437302,0.0047060265,0.001536817,0.0013998416,0.0001779203],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018782066,0.00067090685,0.027996276,0.00051231286,0.00040241692,0.0005803851,0.0005109269,0.04784527,0.004907736,0.8156703,0.003652794,0.09537237],"study_design_scores_gemma":[0.00012601452,0.00042479803,0.016247107,0.00013574252,0.00007338784,0.00019528887,0.00037598857,0.0143946195,0.0012044584,0.9588538,0.007930428,0.000038428705],"about_ca_topic_score_codex":0.0055865175,"about_ca_topic_score_gemma":0.007234774,"teacher_disagreement_score":0.005997663,"about_ca_system_score_codex":0.0035124014,"about_ca_system_score_gemma":0.002457501,"threshold_uncertainty_score":0.030969918},"labels":[],"label_agreement":null},{"id":"W4402657255","doi":"10.1515/9782760650541-010","title":"Chapitre 9 Stayin’ Alive. L’importation de médicaments destinés au marché canadien comme stratégie de diminution des coûts aux États-Unis ?","year":2024,"lang":"fr","type":"book-chapter","venue":"Les Presses de l'Université de Montréal eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.06120549390267122,"score_gpt":0.24737485392561856,"score_spread":0.18616936002294734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402657255","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003915555,0.11424259,0.0024536403,0.17713584,0.010696292,0.00011314059,0.0005526567,0.00006203466,0.69082826],"genre_scores_gemma":[0.066233546,0.103982165,0.0034920059,0.040036324,0.0066503854,0.00013800914,0.0006236303,0.00014356428,0.7787003],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99941957,0.00013793723,0.00001951467,0.00008905209,0.0001937839,0.00014013347],"domain_scores_gemma":[0.99933237,0.00027378293,0.00006537937,0.00002487079,0.00017390159,0.00012957428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007539813,0.00050993776,0.0003859372,0.0008376114,0.0026578836,0.004492364,0.0007622732,0.0029525822,0.032260265],"category_scores_gemma":[0.0012941307,0.00024517212,0.00049244653,0.0015712132,0.0025619795,0.003257177,0.0012950882,0.0045406856,0.0048578163],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003372234,0.00007010351,0.0005619709,0.0005592394,0.0000115276725,0.00041997936,0.002676928,0.0005158834,0.0005332394,0.47756648,0.47209448,0.04495644],"study_design_scores_gemma":[0.000003325275,0.000013541198,0.0008325371,0.00045405503,0.0000033045114,0.000086846136,0.001327442,0.00006646695,0.000091994734,0.021046538,0.9760661,0.0000078870535],"about_ca_topic_score_codex":0.053750135,"about_ca_topic_score_gemma":0.09713643,"teacher_disagreement_score":0.94624984,"about_ca_system_score_codex":0.007453909,"about_ca_system_score_gemma":0.008634911,"threshold_uncertainty_score":0.10792136},"labels":[],"label_agreement":null},{"id":"W4402740932","doi":"10.62848/bjpain.v2i2.7711","title":"Estimation of Annual Need, Production and Per Capita Consumptions of Oral Morphine in Bangladesh","year":2022,"lang":"en","type":"article","venue":"Bangladesh Journal of Pain.","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Per capita; Estimation; Morphine; Production (economics); Agricultural economics; Economics; Econometrics; Medicine; Anesthesia; Environmental health; Macroeconomics","score_opus":0.037667646529220465,"score_gpt":0.2737302867947965,"score_spread":0.23606264026557602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402740932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865969,0.00016681202,0.00016112546,0.00014643105,0.0000021888163,0.000024974635,0.011270426,0.000005617972,0.0016254529],"genre_scores_gemma":[0.9948197,0.0003050195,0.00019378107,0.000012257692,0.0000027126744,0.000028937151,0.003829156,0.0000019732472,0.00080638885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977905,0.00004776039,0.00004862098,0.000039149963,0.000045135475,0.00004027113],"domain_scores_gemma":[0.99915004,0.00018185678,0.00039049826,0.00003702927,0.00013931654,0.00010113691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027125803,0.00017574926,0.0001354221,0.0010181962,0.00017623155,0.00047623183,0.0002778452,0.00021808501,0.0041228444],"category_scores_gemma":[0.0014070215,0.00018442214,0.00027659294,0.0018668808,0.00015845556,0.00037449328,0.00036862234,0.00022012331,0.00064193556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053652686,0.00002156432,0.9946919,0.00004815449,0.000030619016,0.00013721889,0.00025617902,0.0007067928,0.00018973969,0.00015585222,0.00046437292,0.0032439935],"study_design_scores_gemma":[0.0000034652414,0.00005167128,0.9947201,0.00001800955,0.00001400969,0.00019517225,0.0017710221,0.0015549422,0.00010387588,0.00008646464,0.0014721217,0.000009183819],"about_ca_topic_score_codex":0.053802982,"about_ca_topic_score_gemma":0.039683294,"teacher_disagreement_score":0.053802982,"about_ca_system_score_codex":0.0012067747,"about_ca_system_score_gemma":0.00040180996,"threshold_uncertainty_score":0.10697961},"labels":[],"label_agreement":null},{"id":"W4402850765","doi":"10.7324/japs.2024.204337","title":"A deep dive into the development of complex generics: A comprehensive review","year":2024,"lang":"en","type":"review","venue":"Journal of Applied Pharmaceutical Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Development (topology); Computer science; Artificial intelligence; History; Mathematics","score_opus":0.26800963047942034,"score_gpt":0.43417693833985627,"score_spread":0.16616730786043593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402850765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001617132,0.99811697,0.00010944535,0.00052749895,0.00011906347,0.000008556838,0.000023285666,0.000004497498,0.0009290071],"genre_scores_gemma":[0.0007951181,0.99830854,0.00018957484,0.00038141216,0.00010299165,0.0000068795825,0.000030247942,0.0000018101956,0.000183365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923134,0.00015447376,0.00016617957,0.00012605196,0.00026161998,0.000060372797],"domain_scores_gemma":[0.99793696,0.0012687094,0.00033667262,0.000043262142,0.00032068256,0.000093731745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016355594,0.00063379435,0.0012353867,0.0033146003,0.00038069207,0.0019757845,0.00080726354,0.0013404143,0.0047425022],"category_scores_gemma":[0.0029557014,0.00033520214,0.0012942798,0.0032724072,0.00068180106,0.0025312414,0.00088560954,0.0017082342,0.0009395629],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081811224,0.00007161738,0.00037521104,0.06850444,0.00014161147,0.00025582558,0.00022418232,0.00033490674,0.00090952223,0.009102663,0.025663098,0.89433515],"study_design_scores_gemma":[0.000016651284,0.00013897027,0.0011385123,0.020130603,0.00024331707,0.001019286,0.00013023836,0.0000982773,0.00024939663,0.0015586911,0.9752535,0.000022549153],"about_ca_topic_score_codex":0.0015635197,"about_ca_topic_score_gemma":0.0024388453,"teacher_disagreement_score":0.0047425022,"about_ca_system_score_codex":0.00093322404,"about_ca_system_score_gemma":0.003469975,"threshold_uncertainty_score":0.015865266},"labels":[],"label_agreement":null},{"id":"W4402854708","doi":"10.2471/blt.24.292359","title":"WHO Model list of essential medicines: visions for the future","year":2024,"lang":"en","type":"article","venue":"Bulletin of the World Health Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"World Health Organization","keywords":"Vision; Medicine; Data science; Computer science; Sociology","score_opus":0.024842999854390504,"score_gpt":0.3049278993978199,"score_spread":0.2800848995434294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402854708","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017833546,0.02270188,0.04953698,0.78287476,0.010339875,0.00039177082,0.005072815,0.0010978016,0.1262007],"genre_scores_gemma":[0.098327555,0.056759,0.47856948,0.2689127,0.010300369,0.0026554451,0.015151525,0.00096809893,0.06835578],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9716703,0.012338171,0.002486331,0.0011369865,0.010655723,0.0017123867],"domain_scores_gemma":[0.9494918,0.014241323,0.003848525,0.0031402297,0.025742989,0.0035351415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.039291527,0.002237806,0.0015844654,0.0076008425,0.0032879594,0.01529208,0.005665117,0.012287017,0.00881115],"category_scores_gemma":[0.05117715,0.0012487473,0.002360926,0.0068455082,0.0048873606,0.019858167,0.004942819,0.014479342,0.00573667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007863623,0.00008808,0.00078606285,0.0008913194,0.000045736764,0.00010989901,0.00035687492,0.0031289465,0.0001794087,0.4821009,0.45709234,0.05514185],"study_design_scores_gemma":[0.00004591033,0.000074352145,0.0007271451,0.0018623774,0.00006040107,0.00010259764,0.0004102769,0.0029420634,0.00029945548,0.16775101,0.8256133,0.00011100815],"about_ca_topic_score_codex":0.035432335,"about_ca_topic_score_gemma":0.0383543,"teacher_disagreement_score":0.039291527,"about_ca_system_score_codex":0.017806932,"about_ca_system_score_gemma":0.07179958,"threshold_uncertainty_score":0.20779598},"labels":[],"label_agreement":null},{"id":"W4402931038","doi":"10.58502/dtt.23.0033","title":"Organoid Global Regulatory Policy: A Cross-Sectional Study","year":2024,"lang":"en","type":"article","venue":"Drug Targets and Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Science and ICT, South Korea; National Research Foundation of Korea; Ministry of Education; National Research Foundation","keywords":"Organoid; Cross-sectional study; Environmental health; Medicine; Psychology; Neuroscience; Pathology","score_opus":0.043906901384400246,"score_gpt":0.32589823303287774,"score_spread":0.2819913316484775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402931038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91337323,0.051716536,0.0024320928,0.0042764395,0.00014122658,0.0007979953,0.014734488,0.000036038185,0.0124920225],"genre_scores_gemma":[0.9712058,0.016392095,0.0015397166,0.0034399785,0.00009719199,0.0008601127,0.0052215857,0.000054187705,0.0011894461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98771983,0.0051779645,0.0025332484,0.0016624646,0.0019837366,0.0009225861],"domain_scores_gemma":[0.94690055,0.02443563,0.019732747,0.0017156234,0.0060577583,0.0011576533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0147809,0.00030882203,0.00078103144,0.00794148,0.00094526366,0.0025097942,0.0005984765,0.0011618137,0.007128951],"category_scores_gemma":[0.025245925,0.0006195502,0.00094211946,0.011542617,0.0012737869,0.0034794905,0.0017404808,0.0011056114,0.0011866513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045819164,0.00027504453,0.92542446,0.0077641974,0.0005566968,0.0009451825,0.006399879,0.00021805549,0.00036923116,0.0054480066,0.008249488,0.043891698],"study_design_scores_gemma":[0.00004745242,0.0005498048,0.8673704,0.010193317,0.0010182795,0.0040195035,0.034897815,0.00048918335,0.00076408876,0.0018050871,0.07872937,0.00011560972],"about_ca_topic_score_codex":0.0038363847,"about_ca_topic_score_gemma":0.0033056303,"teacher_disagreement_score":0.0147809,"about_ca_system_score_codex":0.0021586388,"about_ca_system_score_gemma":0.00318278,"threshold_uncertainty_score":0.07816976},"labels":[],"label_agreement":null},{"id":"W4403087705","doi":"10.1016/s0140-6736(24)01549-6","title":"WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines","year":2024,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Management science; Business; Economics","score_opus":0.10596408588449997,"score_gpt":0.3644612869135918,"score_spread":0.25849720102909185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403087705","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016057127,0.96987903,0.00088160037,0.021719087,0.00026291478,0.000014452026,0.0001440135,0.0000052347914,0.005487959],"genre_scores_gemma":[0.03467056,0.9587308,0.0012602354,0.0038998132,0.00039255506,0.00003011591,0.000095179596,0.000012472352,0.00090825214],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995544,0.0029893315,0.00019747028,0.00017528249,0.00081061193,0.00028336802],"domain_scores_gemma":[0.98614395,0.01105756,0.0012206351,0.00015577748,0.0011939779,0.00022808599],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011888062,0.00057374925,0.001385771,0.002065127,0.0003927347,0.002884594,0.0014886601,0.0018195048,0.005726472],"category_scores_gemma":[0.01756317,0.0003427725,0.0007200488,0.0062442916,0.0016158473,0.0043611852,0.0010721377,0.0033311904,0.0008135131],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005349004,0.000061069164,0.0016501086,0.015891926,0.0006522044,0.00013632268,0.0013191694,0.0032353946,0.0003263254,0.21633357,0.033713873,0.7261452],"study_design_scores_gemma":[0.00021987785,0.000162663,0.009763979,0.037335753,0.0009683349,0.00037483757,0.002913021,0.0018868663,0.000619264,0.13401464,0.8116365,0.00010433172],"about_ca_topic_score_codex":0.018128222,"about_ca_topic_score_gemma":0.03675509,"teacher_disagreement_score":0.9881119,"about_ca_system_score_codex":0.006885528,"about_ca_system_score_gemma":0.0078111463,"threshold_uncertainty_score":0.0628708},"labels":[],"label_agreement":null},{"id":"W4403238055","doi":"10.3389/jpps.2024.13694","title":"Expanding the eligibility criteria for drugs in Canada’s time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines","year":2024,"lang":"en","type":"editorial","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.12993870346823802,"score_gpt":0.48394426767465515,"score_spread":0.35400556420641716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403238055","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042915974,0.019972015,0.04933311,0.5154379,0.0103103295,0.010509121,0.021173073,0.003108433,0.32724],"genre_scores_gemma":[0.2946974,0.016411573,0.17772233,0.32639763,0.0041399794,0.004381926,0.018477183,0.0012271935,0.15654472],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95269305,0.0077331094,0.004154136,0.0027040192,0.0256133,0.007102352],"domain_scores_gemma":[0.8435655,0.029426763,0.008325735,0.0053678993,0.08576196,0.027552139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.050992925,0.0009876391,0.0013872649,0.005057668,0.0072670355,0.013198554,0.0045008874,0.006450953,0.018404955],"category_scores_gemma":[0.075538926,0.0011059853,0.003181307,0.004646067,0.0037864917,0.004037,0.004746972,0.009296827,0.0041134832],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000732742,0.00033988833,0.015715217,0.001416358,0.00017649402,0.0009649061,0.0014429613,0.002334526,0.0028624306,0.08316671,0.6395197,0.25132817],"study_design_scores_gemma":[0.00032282164,0.00025602052,0.031667396,0.0013725653,0.000120051736,0.0004301798,0.0005108461,0.0023559323,0.0013931214,0.009223778,0.9520926,0.00025472874],"about_ca_topic_score_codex":0.7993779,"about_ca_topic_score_gemma":0.8595264,"teacher_disagreement_score":0.94066876,"about_ca_system_score_codex":0.059331235,"about_ca_system_score_gemma":0.31426874,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4403315467","doi":"10.1038/s43856-024-00594-9","title":"Antimicrobial drug pricing","year":2024,"lang":"en","type":"article","venue":"Communications Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Pfizer","keywords":"Antimicrobial drug; Antimicrobial; Drug pricing; Drug; Medicine; Business; Pharmacology; Microbiology; Biology","score_opus":0.11445133773982903,"score_gpt":0.34767839557450547,"score_spread":0.23322705783467645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403315467","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016317226,0.030765144,0.04717655,0.038733438,0.00527216,0.0005145489,0.005023333,0.0010166954,0.855181],"genre_scores_gemma":[0.6034296,0.041071992,0.02664042,0.015620153,0.008063236,0.0006262978,0.007219117,0.0005390011,0.29679024],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.994624,0.0010393839,0.00024271767,0.00044253943,0.0032768603,0.00037445643],"domain_scores_gemma":[0.99213576,0.0024442335,0.00047804153,0.0009595227,0.0029755596,0.001006881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003146452,0.0005554307,0.0006756851,0.0021409853,0.0008865952,0.0045342734,0.0015777008,0.0032606127,0.049244855],"category_scores_gemma":[0.022616623,0.00029511465,0.0011388963,0.002279362,0.0010299177,0.0023950941,0.0012270954,0.003046214,0.01027024],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003441249,0.00019706768,0.002313733,0.0003452455,0.000095662705,0.00023649611,0.00005821019,0.0060633137,0.0012570639,0.42607525,0.15180203,0.41121182],"study_design_scores_gemma":[0.00015204676,0.00043065986,0.0056995223,0.0005499547,0.0000792896,0.001218669,0.000077908764,0.010618702,0.0017570234,0.124181844,0.8551678,0.00006668396],"about_ca_topic_score_codex":0.0034584042,"about_ca_topic_score_gemma":0.0017344482,"teacher_disagreement_score":0.049244855,"about_ca_system_score_codex":0.0029009902,"about_ca_system_score_gemma":0.0036144261,"threshold_uncertainty_score":0.16474044},"labels":[],"label_agreement":null},{"id":"W4403333758","doi":"10.1001/jamahealthforum.2024.3391","title":"Competition in International Generic Drug Markets","year":2024,"lang":"en","type":"article","venue":"JAMA Health Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of Canada; Women's College Hospital; Public Health Ontario; University of Toronto","funders":"","keywords":"Competition (biology); Drug; Business; International market; Generic drug; Industrial organization; Drug prices; International trade; International economics; Public economics; Economics; Pharmacology; Medicine; Biology","score_opus":0.04426216404522113,"score_gpt":0.3156063757311991,"score_spread":0.27134421168597794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403333758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98598725,0.00076898566,0.00019328711,0.0007423152,0.000014606469,0.000015742728,0.0007760205,0.0000050653225,0.011496754],"genre_scores_gemma":[0.99833184,0.0001703184,0.000037234127,0.00015559857,0.000021105185,0.000007228325,0.00062880904,0.0000017692888,0.00064605515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989661,0.0002648015,0.00006417553,0.0001517702,0.00021431991,0.0003387599],"domain_scores_gemma":[0.9945439,0.0011698466,0.0027992493,0.00014232221,0.000391861,0.0009528013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016335183,0.00013846636,0.00036447903,0.0012473833,0.00043684358,0.001931382,0.00028756028,0.00078198774,0.0071553523],"category_scores_gemma":[0.0060740295,0.00015389368,0.00042238587,0.002107646,0.0005697314,0.0011144207,0.00086082314,0.0009035832,0.0005679151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022392883,0.00036275174,0.98176736,0.00003499644,0.00009232811,0.00017502008,0.00039564728,0.00097601424,0.00026827314,0.0065369024,0.0026185627,0.006548233],"study_design_scores_gemma":[0.000029042742,0.0001821911,0.9941333,0.000025558857,0.000034569788,0.00022858857,0.0006815188,0.00092361437,0.00011641196,0.0010415748,0.0025907482,0.000012883915],"about_ca_topic_score_codex":0.008035077,"about_ca_topic_score_gemma":0.00721015,"teacher_disagreement_score":0.008035077,"about_ca_system_score_codex":0.001005891,"about_ca_system_score_gemma":0.00065878406,"threshold_uncertainty_score":0.023937047},"labels":[],"label_agreement":null},{"id":"W4403503072","doi":"10.1002/pds.70035","title":"Keep Your Guard Up: The Potential Impact of Drug Shortages on Pharmacoepidemiological Studies","year":2024,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Pharmacoepidemiology; Drug; Economic shortage; Guard (computer science); Pharmacology; Medical prescription","score_opus":0.13480210616756663,"score_gpt":0.42431282890752264,"score_spread":0.28951072273995604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403503072","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008143917,0.19723406,0.0061582653,0.72328204,0.04900112,0.0003921656,0.0073422515,0.00026519224,0.008180951],"genre_scores_gemma":[0.11466264,0.1269021,0.017324148,0.6331897,0.09755301,0.0011219021,0.0028885875,0.0007403682,0.005617418],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.85756576,0.097512715,0.018017542,0.0071843467,0.018051354,0.0016683068],"domain_scores_gemma":[0.29360816,0.5626412,0.045129646,0.02681514,0.06031147,0.011494438],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.17697002,0.0009476434,0.0033614086,0.005024636,0.0027638923,0.010326423,0.0042542354,0.0107250335,0.026613617],"category_scores_gemma":[0.56172484,0.00078700343,0.0028178066,0.0064665275,0.004543111,0.016337799,0.006917278,0.009398572,0.007842881],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019675524,0.00021627075,0.04280341,0.019571224,0.0033920896,0.0012819882,0.002832686,0.0004371961,0.00029188438,0.013300387,0.64324164,0.2706637],"study_design_scores_gemma":[0.00078998454,0.0010009677,0.030722897,0.056659,0.0031666837,0.0034471,0.0047853244,0.0021914046,0.0010911959,0.0716679,0.82409054,0.0003870199],"about_ca_topic_score_codex":0.0039641224,"about_ca_topic_score_gemma":0.005956767,"teacher_disagreement_score":0.82303,"about_ca_system_score_codex":0.0025468268,"about_ca_system_score_gemma":0.00878874,"threshold_uncertainty_score":0.9359181},"labels":[],"label_agreement":null},{"id":"W4403536808","doi":"10.1177/20499361241281136","title":"Prescribing equity: physicians as advocates for access to essential medicines. A call to action from medical graduates","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Infectious Disease","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"McGill University","keywords":"Call to action; Equity (law); Action (physics); Access to medicines; Business; Family medicine; Medicine; Medical education; Public relations; Nursing; Political science; Marketing; Law","score_opus":0.07538764527644878,"score_gpt":0.40894845515167544,"score_spread":0.3335608098752266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403536808","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006611032,0.0010765686,0.000064945125,0.9963407,0.0008082012,0.000001965468,0.000004772907,0.0000025538272,0.0010390966],"genre_scores_gemma":[0.070530176,0.0051823617,0.00070813374,0.9076319,0.0116015375,0.000036649748,0.000014237611,0.000016528287,0.004278426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888038,0.0052247434,0.00032711637,0.0008004754,0.0021876332,0.0026562803],"domain_scores_gemma":[0.8920959,0.06539582,0.005037208,0.0019392766,0.00578314,0.029748665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.033156946,0.00051645096,0.0012271672,0.0011616129,0.008087175,0.01436758,0.002031048,0.052708164,0.014482889],"category_scores_gemma":[0.061363526,0.0006927906,0.0009814552,0.0007851851,0.027536042,0.019642878,0.011518053,0.04225518,0.0013598987],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020399556,0.00023307491,0.004893674,0.00033114653,0.000051131596,0.0009731035,0.010123772,0.00032312667,0.0005568418,0.22606765,0.6894527,0.06678986],"study_design_scores_gemma":[0.00041391043,0.00018699297,0.00947924,0.002787471,0.000069191294,0.00061797316,0.022467284,0.00093871553,0.00041129373,0.38779202,0.5746756,0.00016018764],"about_ca_topic_score_codex":0.01164713,"about_ca_topic_score_gemma":0.0237128,"teacher_disagreement_score":0.052708164,"about_ca_system_score_codex":0.007192269,"about_ca_system_score_gemma":0.03333131,"threshold_uncertainty_score":0.17535281},"labels":[],"label_agreement":null},{"id":"W4403652681","doi":"10.1017/cts.2024.635","title":"93 Investigating the minimal requirements for startup procurement by healthcare institutions in Ontario, Canada – CORRIGENDUM","year":2024,"lang":"en","type":"erratum","venue":"Journal of Clinical and Translational Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Procurement; Business; Health care; Engineering management; Operations management; Engineering; Economic growth; Marketing; Economics","score_opus":0.35582486771904426,"score_gpt":0.4187223117681354,"score_spread":0.06289744404909114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403652681","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58993375,0.0022732043,0.0030867967,0.027851727,0.00047411633,0.00092923705,0.10571805,0.00033109717,0.269402],"genre_scores_gemma":[0.8948304,0.00090506783,0.0032664018,0.0021969555,0.000080856895,0.00024467695,0.021506552,0.000108422944,0.07686066],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918671,0.00057144556,0.0005951139,0.00040439234,0.004351487,0.0022104504],"domain_scores_gemma":[0.96225166,0.0070737503,0.002163224,0.00087460433,0.024256261,0.0033805661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045480626,0.00021623354,0.0004794732,0.0019132156,0.0035123946,0.004635976,0.0015748672,0.0009923257,0.027854197],"category_scores_gemma":[0.027877955,0.0005289493,0.0006626801,0.0035908425,0.00081890175,0.0008866223,0.0011633392,0.0010529045,0.00203728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088376604,0.0001785443,0.48932248,0.001316589,0.00015975464,0.0014312301,0.005498932,0.0089656515,0.0015941032,0.033358023,0.39816988,0.059121024],"study_design_scores_gemma":[0.000056666624,0.00006417122,0.91013175,0.00023171333,0.00006929108,0.000101171594,0.0090686735,0.0027553572,0.00063880364,0.0008371553,0.07597409,0.00007110902],"about_ca_topic_score_codex":0.9949025,"about_ca_topic_score_gemma":0.99705803,"teacher_disagreement_score":0.88945377,"about_ca_system_score_codex":0.11054622,"about_ca_system_score_gemma":0.124248005,"threshold_uncertainty_score":0.8020727},"labels":[],"label_agreement":null},{"id":"W4403835855","doi":"10.54194/pggo7479","title":"State importation programs are unrealistic: diverting prescription drugs to American consumers would rapidly deplete the Canadian drug supply","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Innovative Medicines Canada; U.S. Department of Health and Human Services","keywords":"Business; Prescription drug; Medical prescription; Drug; State (computer science); Pharmacology; Medicine; Computer science","score_opus":0.05622939593768062,"score_gpt":0.32703699240706535,"score_spread":0.27080759646938474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403835855","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17228311,0.0041724034,0.004297069,0.4758818,0.0011399593,0.0001906528,0.005476931,0.00032157186,0.33623642],"genre_scores_gemma":[0.93129015,0.0034437266,0.0018017535,0.030460246,0.00055966544,0.000042749693,0.0008732738,0.000041348725,0.0314872],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99659735,0.0005478828,0.00009645727,0.0002380161,0.0017120581,0.0008081553],"domain_scores_gemma":[0.98736495,0.004685049,0.0012949413,0.00032297932,0.0051727677,0.0011592485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002804377,0.00037952635,0.00045979608,0.0007016985,0.002995586,0.005586743,0.00078728807,0.003786461,0.01191226],"category_scores_gemma":[0.020783236,0.00031323338,0.0007897986,0.0010889433,0.0027376956,0.0020388695,0.0010582332,0.0047190813,0.00047739266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077219936,0.00024918758,0.031040732,0.0004923158,0.00034152478,0.00035275394,0.0005624882,0.02427589,0.0024719783,0.47638506,0.4105663,0.052489568],"study_design_scores_gemma":[0.00089797075,0.0005359255,0.21363668,0.0009657434,0.0016868357,0.00045525545,0.0046850718,0.0832284,0.0072595757,0.24279322,0.44319636,0.00065896177],"about_ca_topic_score_codex":0.8757133,"about_ca_topic_score_gemma":0.8882515,"teacher_disagreement_score":0.9621849,"about_ca_system_score_codex":0.037815075,"about_ca_system_score_gemma":0.06943666,"threshold_uncertainty_score":0.27436888},"labels":[],"label_agreement":null},{"id":"W4403835971","doi":"10.54194/kjid4264","title":"Les programmes d’importation des États-Unis sont irréalistes : détourner les médicaments d’ordonnance vers les consommateurs américains épuiserait rapidement l’approvisionnement en médicaments au Canada","year":2024,"lang":"fr","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Institute for Health Information","funders":"","keywords":"Humanities; Political science; Forestry; Art; Geography","score_opus":0.07533527885452804,"score_gpt":0.3474552270517634,"score_spread":0.2721199481972354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403835971","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47758567,0.005535469,0.00759531,0.08171949,0.00041697707,0.00048054062,0.0012371358,0.00027928717,0.42515007],"genre_scores_gemma":[0.84957236,0.002340639,0.0039321207,0.008181663,0.00015085496,0.00013222068,0.00043761893,0.000055120156,0.13519736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952502,0.00062892446,0.000112540765,0.00023710754,0.0015853904,0.0021856925],"domain_scores_gemma":[0.98834795,0.003699612,0.0015865559,0.0004424441,0.002945171,0.002978258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003165758,0.00030783817,0.00035578848,0.0010881573,0.0039320122,0.005059931,0.00089788163,0.0022813038,0.019957377],"category_scores_gemma":[0.01116282,0.000390602,0.0006453601,0.0017064615,0.0020358649,0.0017727662,0.00216912,0.0033839713,0.0008018559],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010969671,0.0011296693,0.13563773,0.0010237582,0.00028096503,0.0014726964,0.014694121,0.011544392,0.010847862,0.35270938,0.09726048,0.37230203],"study_design_scores_gemma":[0.0003588645,0.0004572331,0.40941834,0.0011636482,0.00024127579,0.0003422983,0.0129599795,0.0068227765,0.0060844645,0.018154657,0.54382956,0.0001668582],"about_ca_topic_score_codex":0.8574029,"about_ca_topic_score_gemma":0.9194102,"teacher_disagreement_score":0.96588266,"about_ca_system_score_codex":0.034117356,"about_ca_system_score_gemma":0.07276038,"threshold_uncertainty_score":0.2868737},"labels":[],"label_agreement":null},{"id":"W4403940449","doi":"10.1001/jama.2024.17688","title":"Differences in Drug Shortages in the US and Canada","year":2024,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Agency for Healthcare Research and Quality","keywords":"Medicine; Economic shortage; Pandemic; Drug; Coronavirus disease 2019 (COVID-19); Public health; Environmental health; Pharmacology; Nursing; Disease; Internal medicine","score_opus":0.03758942869400588,"score_gpt":0.2566276584935385,"score_spread":0.21903822979953264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403940449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.964357,0.0023690483,0.00020547904,0.0019247803,0.00003982246,0.00008756677,0.023512088,0.000024727602,0.0074795187],"genre_scores_gemma":[0.99124396,0.0012857427,0.0001758588,0.00047671696,0.000013593197,0.00003585842,0.005714118,0.000010036549,0.001044097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836594,0.000105409825,0.00013651534,0.00022487751,0.0005988593,0.00056838884],"domain_scores_gemma":[0.9936958,0.00040517055,0.0021334551,0.00012161041,0.0024475374,0.0011963764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011097547,0.00023622657,0.00034589908,0.0026565115,0.0015984396,0.0010759763,0.00086340297,0.00032815602,0.002863758],"category_scores_gemma":[0.005090522,0.0002601594,0.0005437381,0.0069388584,0.0005640177,0.00053835183,0.0013131484,0.0006960021,0.0001872901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089750414,0.000021882666,0.9885408,0.000092407,0.00008397608,0.000086934015,0.0010284997,0.00011824243,0.00010701963,0.0002066303,0.003414569,0.006209222],"study_design_scores_gemma":[0.000004413577,0.000012146606,0.9963833,0.000070425616,0.000017284185,0.000048257403,0.0014447436,0.00012815281,0.000045480734,0.000025068843,0.0018100169,0.000010624205],"about_ca_topic_score_codex":0.9881942,"about_ca_topic_score_gemma":0.99122006,"teacher_disagreement_score":0.01718555,"about_ca_system_score_codex":0.01718555,"about_ca_system_score_gemma":0.02824284,"threshold_uncertainty_score":0.12469053},"labels":[],"label_agreement":null},{"id":"W4403976976","doi":"10.1371/journal.pone.0313298","title":"Impact of supply chain disruptions and drug shortages on drug utilization: A scoping review protocol","year":2024,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; St. Francis Xavier University; University of Toronto","funders":"","keywords":"Drug; Economic shortage; Protocol (science); Medicine; Pharmacology; Risk analysis (engineering); Intensive care medicine; Business; Alternative medicine; Pathology","score_opus":0.2755033707614196,"score_gpt":0.43813831595506075,"score_spread":0.16263494519364113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403976976","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005050887,0.003026429,0.0020791825,0.0007031302,0.0002200805,0.9885225,0.0035414158,0.000055703687,0.0013464959],"genre_scores_gemma":[0.0007204238,0.0044723856,0.0074276174,0.00034396793,0.00004977731,0.9854735,0.00094049453,0.000009213209,0.00056265533],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9572889,0.0145453075,0.018246783,0.0030282675,0.0051946226,0.0016960938],"domain_scores_gemma":[0.93737894,0.02029055,0.011242851,0.004699384,0.02358047,0.0028078433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10595201,0.004092119,0.009714649,0.024410196,0.004588555,0.008911637,0.0064269914,0.009271166,0.047147855],"category_scores_gemma":[0.0823507,0.003947459,0.0120177185,0.016071793,0.004410193,0.008836076,0.0085906545,0.0044673113,0.0124337515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025234364,0.00044865688,0.0018497896,0.8469485,0.0011043577,0.0013904278,0.004812824,0.0014165561,0.002151006,0.010270951,0.032627992,0.09445563],"study_design_scores_gemma":[0.0037541538,0.0012749062,0.007074552,0.72407126,0.004243499,0.0009885564,0.0044534914,0.0008566208,0.0018617989,0.0073275613,0.24375612,0.00033754035],"about_ca_topic_score_codex":0.005007832,"about_ca_topic_score_gemma":0.009746582,"teacher_disagreement_score":0.10595201,"about_ca_system_score_codex":0.016339524,"about_ca_system_score_gemma":0.10491521,"threshold_uncertainty_score":0.56033444},"labels":[],"label_agreement":null},{"id":"W4404329146","doi":"10.1111/caje.12744","title":"The design of external reference pricing schemes and the choice of reference countries and pricing rules","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Economics/Revue canadienne d économique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Reference price; Economics; Computer science; Econometrics; Business; Microeconomics","score_opus":0.22697849723629257,"score_gpt":0.2409314679348503,"score_spread":0.01395297069855772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404329146","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33220348,0.0012903552,0.6035729,0.0027469934,0.00018133597,0.000644427,0.0001885576,0.00028957048,0.05888238],"genre_scores_gemma":[0.9480994,0.00030087342,0.04880497,0.0001371328,0.000049924973,0.00017830785,0.00006749446,0.000052184037,0.0023096215],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9840681,0.0116374735,0.00068200094,0.0013665864,0.0014246941,0.0008210892],"domain_scores_gemma":[0.9508855,0.030560022,0.007467949,0.004876539,0.0045196847,0.0016904176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025861686,0.00069994957,0.0016171318,0.0017547531,0.0011373503,0.007149044,0.002385291,0.0027003363,0.0058096554],"category_scores_gemma":[0.06303862,0.00077538664,0.00084338896,0.0020603128,0.0037266677,0.0076060137,0.0033266542,0.002577543,0.0006587565],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046402312,0.0001780803,0.0035497027,0.00012704646,0.000084275845,0.00015856534,0.0002721516,0.12102453,0.0010506674,0.8370188,0.0013439188,0.034728248],"study_design_scores_gemma":[0.00037700703,0.0003911779,0.0017304557,0.00017996166,0.000094981384,0.00014345467,0.00032624937,0.31950217,0.002832215,0.66686237,0.007451919,0.00010801525],"about_ca_topic_score_codex":0.0010451389,"about_ca_topic_score_gemma":0.0006402102,"teacher_disagreement_score":0.025861686,"about_ca_system_score_codex":0.001991718,"about_ca_system_score_gemma":0.001917699,"threshold_uncertainty_score":0.13677126},"labels":[],"label_agreement":null},{"id":"W4404538988","doi":"10.1016/j.jcjd.2024.09.074","title":"Health-care Practitioners’ Intersectional Biases Towards T2D and Indigenous Populations","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"","keywords":"Medicine; Indigenous; Ecology","score_opus":0.08332580543600103,"score_gpt":0.31111351683627786,"score_spread":0.22778771140027682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738342,0.0014424413,0.00023128281,0.013459188,0.00007514198,0.00002029951,0.00011832264,0.0000021136261,0.010816922],"genre_scores_gemma":[0.9976629,0.00041574414,0.0001147322,0.0014190219,0.00006678409,0.000011712049,0.000026152527,0.0000032317457,0.0002795595],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.98130345,0.011466297,0.0011939846,0.0013248984,0.0029084375,0.0018028673],"domain_scores_gemma":[0.9229434,0.04341225,0.017005635,0.0034628464,0.007934067,0.0052417084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019169556,0.00013841027,0.00037125306,0.002240025,0.0038728882,0.0035759995,0.0011886186,0.0015892053,0.0048640184],"category_scores_gemma":[0.11557501,0.00042342415,0.00036458744,0.003215775,0.003799742,0.0029201922,0.0047319136,0.0021901024,0.00026146887],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000248424,0.00013894717,0.86591715,0.00013471564,0.00017585402,0.00023135864,0.11055482,0.00010161551,0.00016891342,0.0045138034,0.0016469816,0.016167426],"study_design_scores_gemma":[0.0000358809,0.00008191958,0.8365283,0.0005449316,0.00016208929,0.00046648158,0.15200454,0.00037546302,0.00017343748,0.0041011525,0.005485107,0.000040694504],"about_ca_topic_score_codex":0.13287412,"about_ca_topic_score_gemma":0.13395992,"teacher_disagreement_score":0.86712587,"about_ca_system_score_codex":0.0026036433,"about_ca_system_score_gemma":0.0046195923,"threshold_uncertainty_score":0.26420146},"labels":[],"label_agreement":null},{"id":"W4404734405","doi":"10.1016/j.ejor.2024.11.031","title":"Optimal co-development contracts for companion diagnostics","year":2024,"lang":"en","type":"article","venue":"European Journal of Operational Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Computer science; Business; Process management; Operations research; Mathematics","score_opus":0.2772292910362888,"score_gpt":0.4276035565451992,"score_spread":0.15037426550891042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404734405","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31683156,0.0024455853,0.5369355,0.008925128,0.00035960393,0.0023371102,0.0016670788,0.00047148071,0.13002703],"genre_scores_gemma":[0.88745826,0.00082648394,0.08668702,0.00044214493,0.00009036517,0.00094712037,0.0004481904,0.000085599924,0.023014814],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99448365,0.0029090825,0.0002478816,0.00071225397,0.00061035855,0.0010367697],"domain_scores_gemma":[0.97639966,0.015937964,0.0022460143,0.0012711457,0.001235536,0.0029096662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008426617,0.0011305263,0.0017643303,0.0011498082,0.0015039551,0.0032358356,0.0018554033,0.0044616903,0.01869933],"category_scores_gemma":[0.03228684,0.0013717068,0.00090503594,0.0010708302,0.0018806037,0.0045688367,0.0025036216,0.0038419052,0.0016103918],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010905996,0.0008917775,0.0050272783,0.00051702076,0.00010303884,0.0006529198,0.00052407745,0.3724494,0.0023030574,0.5326254,0.016818523,0.06699703],"study_design_scores_gemma":[0.0005201167,0.0005571631,0.0028281736,0.00026129463,0.00006532675,0.00040501938,0.00064748124,0.53169674,0.0016630328,0.4367022,0.024569472,0.000083865045],"about_ca_topic_score_codex":0.003417198,"about_ca_topic_score_gemma":0.0036228676,"teacher_disagreement_score":0.01869933,"about_ca_system_score_codex":0.004199896,"about_ca_system_score_gemma":0.0076808445,"threshold_uncertainty_score":0.06255543},"labels":[],"label_agreement":null},{"id":"W4404850065","doi":"10.18553/jmcp.2024.30.12.1349","title":"Fear of missing out: Drug availability in the United States vs Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Managed Care & Specialty Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Agency for Healthcare Research and Quality","keywords":"Drug; MEDLINE; Medicine; Environmental health; Pharmacology; Political science; Law","score_opus":0.04763722699797736,"score_gpt":0.3059557295201401,"score_spread":0.25831850252216276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404850065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9524614,0.002867227,0.00036219906,0.00938798,0.0000535237,0.000105184416,0.009089728,0.00001543233,0.025657209],"genre_scores_gemma":[0.996567,0.0007542854,0.00012861798,0.0008035121,0.000018504737,0.00001621168,0.0012350217,0.000004867973,0.00047194524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679595,0.00042723108,0.0002516916,0.00032135315,0.0014527566,0.0007509832],"domain_scores_gemma":[0.9760779,0.0044514597,0.0109803565,0.00039359272,0.004489266,0.0036073592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002892989,0.000122048725,0.00035925081,0.0020524852,0.0018339361,0.0018840636,0.0010069688,0.0005473671,0.004168261],"category_scores_gemma":[0.0153683135,0.00016903415,0.00058571826,0.0065228916,0.001520893,0.0010523023,0.0014307227,0.0016636844,0.00013418552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083008264,0.000026441365,0.9908524,0.000045451907,0.00006917718,0.00008938552,0.0007018603,0.00017556801,0.000018549012,0.0007202731,0.0029769868,0.004241039],"study_design_scores_gemma":[0.00000914858,0.000026282118,0.99157625,0.00019815234,0.00006559307,0.0001464162,0.0036123497,0.00068507413,0.000056164314,0.00027314582,0.0033307734,0.000020762593],"about_ca_topic_score_codex":0.94577956,"about_ca_topic_score_gemma":0.9584642,"teacher_disagreement_score":0.054220438,"about_ca_system_score_codex":0.017005408,"about_ca_system_score_gemma":0.023429248,"threshold_uncertainty_score":0.12338346},"labels":[],"label_agreement":null},{"id":"W4404863334","doi":"10.1017/s0266462324004768","title":"The intersection of prescription drugs and medical devices: the evaluation and funding challenges of two categories of emerging health technologies","year":2024,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Public Health Ontario; University of Toronto","funders":"","keywords":"Medical prescription; Health technology; Intersection (aeronautics); Emerging technologies; Business; Medicine; Political science; Pharmacology; Health care; Computer science; Engineering; Transport engineering","score_opus":0.07380527049704576,"score_gpt":0.4383761041072198,"score_spread":0.364570833610174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404863334","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030304316,0.27442205,0.060711227,0.52141875,0.0018406813,0.0005269558,0.001359175,0.0000819449,0.10933491],"genre_scores_gemma":[0.74372953,0.12842347,0.074321374,0.04334988,0.004395572,0.0017606559,0.0006289246,0.000121988414,0.0032686433],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.81322753,0.11532982,0.016387666,0.008178569,0.041877653,0.004998661],"domain_scores_gemma":[0.5869193,0.3455164,0.021761913,0.008807492,0.033351097,0.003643757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10504124,0.00080008665,0.0034222812,0.01946885,0.00396821,0.029659063,0.0032466208,0.009772246,0.003797189],"category_scores_gemma":[0.21678177,0.0010556601,0.0021401534,0.020802649,0.023509836,0.034885824,0.009884455,0.010667119,0.00039594134],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057461843,0.000057535373,0.0048622694,0.0018040838,0.00010022832,0.00008395933,0.0011660034,0.0013531733,0.0000654219,0.860255,0.006814586,0.12338031],"study_design_scores_gemma":[0.00010814869,0.0001575114,0.013491547,0.016216883,0.00023678887,0.0004015499,0.0069151064,0.005714642,0.0005168566,0.7897334,0.16634741,0.00016022271],"about_ca_topic_score_codex":0.020514002,"about_ca_topic_score_gemma":0.020711174,"teacher_disagreement_score":0.10504124,"about_ca_system_score_codex":0.02752011,"about_ca_system_score_gemma":0.038927875,"threshold_uncertainty_score":0.5555178},"labels":[],"label_agreement":null},{"id":"W4404947648","doi":"10.1377/hlthaff.2023.01244","title":"US Trends In Anticancer Medicine Pricing And The Impact Of Competition, 2014–20","year":2024,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biosimilar; Competition (biology); Drug prices; Inflation (cosmology); Medicine; Business; Public economics; Economics","score_opus":0.047256224064171945,"score_gpt":0.3620782030402909,"score_spread":0.31482197897611897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404947648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9451767,0.0035456158,0.0013832151,0.0030076734,0.000064540814,0.000024480722,0.035665702,0.000100220976,0.0110317655],"genre_scores_gemma":[0.9733203,0.0009431066,0.00055058603,0.00035700726,0.00010277407,0.000020018379,0.022788843,0.000023042374,0.0018943045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911195,0.0001988292,0.0001245596,0.00014334345,0.000264749,0.00015646462],"domain_scores_gemma":[0.9940578,0.0013252319,0.0031497062,0.0001487201,0.0010703905,0.00024809252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013672431,0.00017186545,0.00025037362,0.001847026,0.0001956081,0.001607896,0.00034997388,0.0005359345,0.002279903],"category_scores_gemma":[0.008521699,0.00017010079,0.00070902315,0.003850627,0.00029109878,0.0011461906,0.00062656845,0.00095037627,0.00033810077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008494472,0.00019919508,0.93917936,0.00013348236,0.0003290316,0.00016003363,0.00018304671,0.008831514,0.0005681547,0.006892791,0.016626073,0.026047759],"study_design_scores_gemma":[0.000025535253,0.00014747409,0.97400564,0.00004360436,0.00007127274,0.00023507302,0.00022378881,0.008359866,0.0005020669,0.00073840667,0.0156213315,0.000026043981],"about_ca_topic_score_codex":0.052632246,"about_ca_topic_score_gemma":0.03465008,"teacher_disagreement_score":0.052632246,"about_ca_system_score_codex":0.0027451355,"about_ca_system_score_gemma":0.0008803764,"threshold_uncertainty_score":0.10465175},"labels":[],"label_agreement":null},{"id":"W4404971548","doi":"10.1080/20523211.2024.2430441","title":"A pharmaceutical policy accident: collision of shareholder capitalism and Chinese state capitalism driving the shortage of an essential antibiotic","year":2024,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Piperacillin/tazobactam; Economic shortage; Business; Capitalism; State (computer science); Piperacillin; Medicine; Computer science; Political science; Law; Government (linguistics); Politics","score_opus":0.04635057395091741,"score_gpt":0.3942808531185116,"score_spread":0.34793027916759417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404971548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.948032,0.0005500737,0.0024608409,0.025726886,0.000110711284,0.00006331547,0.0001387966,0.000037211383,0.022880048],"genre_scores_gemma":[0.9969303,0.000300476,0.0003508953,0.00073773746,0.000023526956,0.0000126630175,0.00003461132,0.000003877214,0.0016058808],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990621,0.00020159945,0.000048703114,0.00014116682,0.0002425241,0.0003039275],"domain_scores_gemma":[0.99735177,0.0009143266,0.0008066488,0.00019817761,0.00040229506,0.00032672845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023659077,0.00026217982,0.0001882781,0.0012383107,0.0048189736,0.0037093456,0.0006315371,0.0011788533,0.004872751],"category_scores_gemma":[0.0030336527,0.0002538936,0.00038371462,0.0017381939,0.00516705,0.00257966,0.002592578,0.001567017,0.00021582551],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041872627,0.00023118229,0.42680708,0.0006224009,0.00015347858,0.013194518,0.12838493,0.0064570233,0.0073876,0.3234924,0.018646622,0.07420393],"study_design_scores_gemma":[0.000044847784,0.0002968222,0.56754863,0.0007482701,0.00025780886,0.0014616275,0.17793106,0.023383543,0.009247775,0.08876414,0.13005798,0.00025757367],"about_ca_topic_score_codex":0.08012773,"about_ca_topic_score_gemma":0.055325367,"teacher_disagreement_score":0.08012773,"about_ca_system_score_codex":0.012233499,"about_ca_system_score_gemma":0.011176266,"threshold_uncertainty_score":0.15932262},"labels":[],"label_agreement":null},{"id":"W4405034894","doi":"10.1016/j.pharma.2024.12.001","title":"Drug shortages in Canada, 2019–2023: A descriptive study","year":2024,"lang":"en","type":"article","venue":"Annales Pharmaceutiques Françaises","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Drug; Descriptive research; Business; Medicine; Pharmacology; Sociology; Social science","score_opus":0.07047308805051646,"score_gpt":0.3192722898304774,"score_spread":0.24879920177996095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91227084,0.0030654701,0.00015515478,0.003458083,0.000055114506,0.00017605048,0.0747483,0.0000390567,0.0060318345],"genre_scores_gemma":[0.97158056,0.0021287235,0.00015358515,0.0009499834,0.000046364305,0.00009232979,0.02123411,0.000013129012,0.0038013018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998461,0.000046799058,0.000116868236,0.000108137,0.00047737383,0.00078974094],"domain_scores_gemma":[0.99369806,0.00040131205,0.0020821404,0.000077696015,0.0020855756,0.0016552772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074037194,0.0003536843,0.0005400584,0.003428001,0.0022985525,0.0022436203,0.0014854388,0.0011226733,0.004597072],"category_scores_gemma":[0.0032523458,0.000419872,0.0011556734,0.011083345,0.00081851875,0.001061935,0.0014776307,0.0021416713,0.00048736934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024548842,0.00023630194,0.9730118,0.00027892206,0.00016214779,0.00023951782,0.0011326879,0.0006867973,0.0000953295,0.0008055814,0.016424483,0.0066810274],"study_design_scores_gemma":[0.000019075444,0.00004507725,0.98665327,0.00014799034,0.000048899357,0.00012180449,0.003987144,0.000784897,0.00006947131,0.00007194543,0.00802164,0.000028742033],"about_ca_topic_score_codex":0.9951357,"about_ca_topic_score_gemma":0.99658406,"teacher_disagreement_score":0.041608803,"about_ca_system_score_codex":0.041608803,"about_ca_system_score_gemma":0.075045474,"threshold_uncertainty_score":0.30189443},"labels":[],"label_agreement":null},{"id":"W4405397181","doi":"10.1177/00469580241307446","title":"Competition Among Pharmacies as a Determinant of Drug Expenditures","year":2024,"lang":"en","type":"article","venue":"INQUIRY The Journal of Health Care Organization Provision and Financing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Southeast University","keywords":"Pharmacy; Competition (biology); Drug prices; Drug; Market share; Business; Medicine; Public economics; Marketing; Economics; Pharmacology; Family medicine","score_opus":0.032050853813311644,"score_gpt":0.31792147072619686,"score_spread":0.28587061691288523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405397181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574846,0.0003907799,0.00037285988,0.00042219769,0.0000069436874,0.000014079357,0.0015202562,0.000008365875,0.0015161528],"genre_scores_gemma":[0.998803,0.00006984068,0.00008229306,0.00003139122,0.00001069023,0.0000040490645,0.0007505076,0.0000014779645,0.00024666465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984232,0.0003671438,0.00012161072,0.00032751425,0.00028892368,0.00047163357],"domain_scores_gemma":[0.9929274,0.002497015,0.0028765283,0.00028167176,0.00050080684,0.0009165856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010537942,0.00025062938,0.00053768134,0.0015378337,0.0005322532,0.0010922935,0.00048072872,0.00053953496,0.003758787],"category_scores_gemma":[0.00593965,0.0002223114,0.0010002138,0.0025753581,0.00044923133,0.0007464884,0.0009055458,0.0007435335,0.00023950524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000682061,0.0000468321,0.9943693,0.000016157845,0.00010104964,0.00013501936,0.000043646654,0.0017730369,0.00011870039,0.00053648354,0.00042124197,0.002370285],"study_design_scores_gemma":[0.000010877687,0.000051312556,0.9918167,0.000010317839,0.00004989602,0.00009477807,0.0001623104,0.006548915,0.00007894897,0.00022771361,0.0009387572,0.00000936439],"about_ca_topic_score_codex":0.08838421,"about_ca_topic_score_gemma":0.07962052,"teacher_disagreement_score":0.08838421,"about_ca_system_score_codex":0.0023020217,"about_ca_system_score_gemma":0.0022302044,"threshold_uncertainty_score":0.17573953},"labels":[],"label_agreement":null},{"id":"W4405483415","doi":"10.12927/hcq.2024.27492","title":"The Siren Call for Business Model Innovation in Healthcare","year":2024,"lang":"en","type":"article","venue":"Healthcare Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Siren (mythology); Health care; Business; Business model; Best practice; Health administration; Marketing; Management; Operations management; Public relations; Engineering; Political science; Economics; History","score_opus":0.09833059128394396,"score_gpt":0.35286216298461065,"score_spread":0.2545315717006667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405483415","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002338232,0.02383446,0.005370072,0.90059847,0.003937538,0.000012352589,0.00004310425,0.00005979361,0.06380595],"genre_scores_gemma":[0.49586606,0.0842741,0.017392179,0.32295147,0.015837763,0.0001491323,0.00013888998,0.0002828137,0.06310758],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9901294,0.00467071,0.00019549593,0.00051318604,0.0034888813,0.0010023428],"domain_scores_gemma":[0.98129636,0.011517757,0.0006051737,0.0015600417,0.002849312,0.0021714494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015200444,0.00045657545,0.0005664668,0.0011938688,0.0040894425,0.011905128,0.0012424315,0.0077235275,0.008309222],"category_scores_gemma":[0.028244592,0.00028120173,0.0006355073,0.0012757708,0.024647327,0.011733775,0.0042963964,0.0109130535,0.0014021624],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012173583,0.000010891203,0.00012311027,0.00007366036,0.000005100132,0.000037127422,0.00049687404,0.00032645126,0.00004444202,0.9177163,0.06610506,0.015048893],"study_design_scores_gemma":[0.00001445936,0.000017117107,0.00025648484,0.00047607935,0.0000054556535,0.0000825006,0.0010337128,0.0008983695,0.000105248415,0.42790815,0.5691834,0.000018995343],"about_ca_topic_score_codex":0.04981285,"about_ca_topic_score_gemma":0.048720963,"teacher_disagreement_score":0.04981285,"about_ca_system_score_codex":0.018958427,"about_ca_system_score_gemma":0.030853774,"threshold_uncertainty_score":0.13755363},"labels":[],"label_agreement":null},{"id":"W4405494467","doi":"10.1016/j.amjms.2024.12.009","title":"Medical care and prescription medication affordability by age group in the US, 2019 to 2023","year":2024,"lang":"en","type":"letter","venue":"The American Journal of the Medical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Key Research and Development Program of China","keywords":"Medicine; Medical prescription; Family medicine; Gerontology; Pharmacology","score_opus":0.03870002137705613,"score_gpt":0.31212884796082435,"score_spread":0.2734288265837682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405494467","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27453908,0.0072318,0.00027182765,0.5784511,0.0107870735,0.00013659765,0.07673924,0.00012874856,0.051714476],"genre_scores_gemma":[0.52689886,0.004650311,0.00037466353,0.39471707,0.009202349,0.0002432798,0.013698746,0.000052170664,0.05016251],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99900633,0.00013279638,0.00012152866,0.00007774949,0.00028499152,0.00037664254],"domain_scores_gemma":[0.99562114,0.0011988386,0.00095991953,0.00007951579,0.0010884603,0.0010520652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001229711,0.00019226747,0.00038347178,0.0007832182,0.0014002343,0.0015830721,0.00077034533,0.0051569683,0.00523947],"category_scores_gemma":[0.00888377,0.00028873744,0.0008492594,0.0019078735,0.00038977756,0.0008936057,0.0010135126,0.0032894711,0.0013811963],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082082336,0.00023045359,0.2589782,0.00016109672,0.00012370659,0.0008287931,0.00060862704,0.00050910626,0.0002803482,0.0027867926,0.7155391,0.01913299],"study_design_scores_gemma":[0.0003417676,0.00016919432,0.75469273,0.00062595314,0.00026600418,0.00047166037,0.003252389,0.0023922825,0.00068484305,0.002500016,0.23449543,0.000107806976],"about_ca_topic_score_codex":0.42477897,"about_ca_topic_score_gemma":0.6396774,"teacher_disagreement_score":0.42477897,"about_ca_system_score_codex":0.0040401244,"about_ca_system_score_gemma":0.0069994824,"threshold_uncertainty_score":0.84461296},"labels":[],"label_agreement":null},{"id":"W4405573853","doi":"10.51731/cjht.2024.1049","title":"Canadian Trends in Estimated Drug Purchases and Projections: 2024 and 2025","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Audit; Business; Biosimilar; Specialty; Agricultural economics; Medicine; Accounting; Economics; Family medicine","score_opus":0.08836610602824099,"score_gpt":0.3365487014798369,"score_spread":0.2481825954515959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405573853","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1256454,0.033012148,0.005905103,0.042538594,0.0013302095,0.00022552215,0.7146901,0.0016018703,0.075050995],"genre_scores_gemma":[0.60959816,0.036992323,0.014598318,0.006674362,0.00047866313,0.0002031916,0.31335568,0.0003990096,0.017700264],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9977169,0.000120463585,0.00015433542,0.0001822502,0.0013466332,0.00047944277],"domain_scores_gemma":[0.99012065,0.0002494495,0.00052659446,0.00012856981,0.008371013,0.0006038167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020395527,0.0010437733,0.00054565066,0.0045705982,0.0016079113,0.0033515256,0.001623746,0.0007460294,0.008368392],"category_scores_gemma":[0.0071430192,0.0004749018,0.0020340667,0.009872744,0.00059846195,0.0016714352,0.0011180077,0.0019570924,0.0018248004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041659366,0.00009213853,0.32116663,0.0023220335,0.0009832662,0.00041716162,0.0010796436,0.014138483,0.0004859647,0.014939221,0.5362511,0.10770779],"study_design_scores_gemma":[0.00007399586,0.000068453,0.6431056,0.0015328353,0.0004245472,0.00035630004,0.0022890498,0.019985937,0.0009889656,0.002256303,0.32861948,0.00029853656],"about_ca_topic_score_codex":0.995195,"about_ca_topic_score_gemma":0.9942788,"teacher_disagreement_score":0.057471815,"about_ca_system_score_codex":0.057471815,"about_ca_system_score_gemma":0.084583655,"threshold_uncertainty_score":0.41698915},"labels":[],"label_agreement":null},{"id":"W4405748357","doi":"10.1016/j.jval.2024.10.472","title":"EE188 Cost-Effectiveness of Rivaroxaban and Acetylsalicylic Acid Combination Therapy in Stable Cardiovascular Disease: A Global Perspective","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Rivaroxaban; Perspective (graphical); Medicine; Disease; Intensive care medicine; Internal medicine; Computer science; Artificial intelligence","score_opus":0.10481337094114629,"score_gpt":0.351128353095938,"score_spread":0.2463149821547917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748357","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12752818,0.55055493,0.0067997416,0.2172383,0.0020233914,0.000069112095,0.0042844554,0.000064513806,0.09143739],"genre_scores_gemma":[0.8561707,0.1253386,0.0020726006,0.008192829,0.004553211,0.00004949991,0.00096011965,0.000036043562,0.002626426],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972915,0.0018798593,0.0001194066,0.00011893653,0.00036908596,0.00022114757],"domain_scores_gemma":[0.99416095,0.0038379102,0.00096556376,0.00011188229,0.00059040147,0.0003332555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003976411,0.00050441164,0.00089473836,0.0015792247,0.00017112747,0.0029186597,0.00044946859,0.0018531582,0.0048398394],"category_scores_gemma":[0.010699046,0.00020225147,0.0015945481,0.0018959806,0.0009325783,0.0015872779,0.0007868295,0.0021573305,0.00032623045],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008461972,0.0006765549,0.046788216,0.005490681,0.007176704,0.00094475807,0.0002762887,0.06561974,0.0017022643,0.15153489,0.046232127,0.66509587],"study_design_scores_gemma":[0.0030786335,0.0064969556,0.2994204,0.019687034,0.014655655,0.005171582,0.0028414894,0.048684787,0.0027834466,0.23226093,0.36458603,0.00033311604],"about_ca_topic_score_codex":0.0043427157,"about_ca_topic_score_gemma":0.0047935564,"teacher_disagreement_score":0.0048398394,"about_ca_system_score_codex":0.002372007,"about_ca_system_score_gemma":0.001925794,"threshold_uncertainty_score":0.021029472},"labels":[],"label_agreement":null},{"id":"W4405748418","doi":"10.1016/j.jval.2024.10.812","title":"EE532 Budget Impact Analyses of Hemoglobin a1C and Lipid Panel Point-of-Care Testing With Afinion™ 2 in Italy and Canada","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbott (Canada); EVERSANA (Canada)","funders":"","keywords":"Point of care; Hemoglobin; Point-of-care testing; Point (geometry); Medicine; Internal medicine; Mathematics; Nursing; Immunology","score_opus":0.13227492991107148,"score_gpt":0.3457175300520665,"score_spread":0.21344260014099503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8581134,0.004524635,0.0009860084,0.01189865,0.00012192282,0.00041198215,0.086622044,0.00011538788,0.03720582],"genre_scores_gemma":[0.9592622,0.0015437091,0.0007990462,0.0008986099,0.000061025476,0.0001368315,0.024293793,0.000044926957,0.012959891],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99588853,0.0008816584,0.00014000706,0.00021018033,0.0010094016,0.0018703357],"domain_scores_gemma":[0.99097973,0.002676653,0.0012877338,0.00028023781,0.0032207821,0.0015548188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033297166,0.00048010843,0.00073639833,0.0017501401,0.0006528784,0.001870782,0.0012423038,0.0008136189,0.003904484],"category_scores_gemma":[0.015985519,0.00047597228,0.0014688581,0.004249275,0.00056696055,0.0005345698,0.0010509898,0.0014324943,0.00024238024],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00762819,0.0007912671,0.69700646,0.00059765467,0.0029701537,0.0006302536,0.00040309117,0.12123623,0.0005306508,0.017069079,0.10572482,0.045412146],"study_design_scores_gemma":[0.00079890835,0.00029254486,0.9471891,0.00018104806,0.0011737001,0.000107807995,0.0009049986,0.022839682,0.00054917537,0.0008901449,0.024985392,0.00008740188],"about_ca_topic_score_codex":0.98969203,"about_ca_topic_score_gemma":0.9889404,"teacher_disagreement_score":0.06467801,"about_ca_system_score_codex":0.06467801,"about_ca_system_score_gemma":0.063635394,"threshold_uncertainty_score":0.46927404},"labels":[],"label_agreement":null},{"id":"W4405751655","doi":"10.1016/j.jval.2024.10.1963","title":"HTA138 NICE vs SMC: Reimbursement Differences for Non-Oncology Orphan Drugs","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Nice; Reimbursement; Orphan drug; Medicine; Internal medicine; Family medicine; Oncology; Bioinformatics; Economics; Biology; Computer science; Economic growth; Health care","score_opus":0.13097741370356253,"score_gpt":0.3695815115593293,"score_spread":0.23860409785576675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405751655","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21844846,0.03857298,0.013476208,0.25338182,0.012532293,0.0011380813,0.07506851,0.0012716337,0.38611],"genre_scores_gemma":[0.9197771,0.0020803597,0.0051171137,0.03669349,0.005284132,0.0003608453,0.009982951,0.00042252318,0.020281397],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9716495,0.014180401,0.0016601699,0.0014781257,0.0085964445,0.0024353352],"domain_scores_gemma":[0.904995,0.07520543,0.006724203,0.002659607,0.0067836144,0.0036321501],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01600878,0.0003829612,0.0017676668,0.0021031438,0.00058229367,0.005206028,0.0016234677,0.006215184,0.04676281],"category_scores_gemma":[0.1417005,0.0005119138,0.003472751,0.0025835533,0.0013781992,0.0028033587,0.001833038,0.0052729137,0.0037420557],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017742196,0.00035139592,0.0245619,0.0014297343,0.0022981362,0.0002949218,0.0003610161,0.0066411668,0.0005648581,0.14077199,0.67632496,0.12865768],"study_design_scores_gemma":[0.021486906,0.005413584,0.2578481,0.004693642,0.007532931,0.0020453597,0.0018948967,0.047620784,0.0029351,0.14368407,0.5041324,0.000712255],"about_ca_topic_score_codex":0.019166224,"about_ca_topic_score_gemma":0.024789115,"teacher_disagreement_score":0.9839912,"about_ca_system_score_codex":0.0059131705,"about_ca_system_score_gemma":0.0056962003,"threshold_uncertainty_score":0.15643716},"labels":[],"label_agreement":null},{"id":"W4405751835","doi":"10.1016/j.jval.2024.10.1000","title":"EE720 Cost-Effectiveness of Faricimab in Canada for the Treatment of Patients With Macular Edema Secondary to Retinal Vein Occlusion","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Roche (Canada)","funders":"","keywords":"Macular edema; Medicine; Retinal Vein; Ophthalmology; Occlusion; Central retinal vein occlusion; Retinal; Edema; Surgery","score_opus":0.05709161194486376,"score_gpt":0.30844445534623777,"score_spread":0.251352843401374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405751835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772938,0.011963915,0.00011001239,0.0030144346,0.00010215971,0.00016774007,0.0017702283,0.000015717234,0.005562006],"genre_scores_gemma":[0.99583024,0.0021783798,0.00015797539,0.0003499146,0.000036219062,0.000018545661,0.00058595976,0.00000280307,0.00083993963],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994137,0.0001596003,0.000041023042,0.00004547277,0.00015158934,0.00018873553],"domain_scores_gemma":[0.99889874,0.00022233126,0.0002141359,0.00001560802,0.00023046193,0.0004187237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000622442,0.00033246892,0.00077020033,0.00041781415,0.00048191677,0.00094560784,0.00055771525,0.00071211375,0.0023403172],"category_scores_gemma":[0.0029670831,0.00019076896,0.0011886638,0.00091362465,0.00042138764,0.00032708375,0.00031405417,0.001246407,0.000093485054],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3758514,0.005490118,0.21303122,0.0028600572,0.0057761217,0.0018579677,0.00045114395,0.03325843,0.0047294004,0.005055352,0.022531493,0.32910722],"study_design_scores_gemma":[0.049034186,0.017016742,0.8707916,0.0010631446,0.008331106,0.0009861578,0.0011381055,0.035250816,0.0012773836,0.000962735,0.0139483595,0.00019964899],"about_ca_topic_score_codex":0.8972064,"about_ca_topic_score_gemma":0.9298366,"teacher_disagreement_score":0.102793574,"about_ca_system_score_codex":0.028264256,"about_ca_system_score_gemma":0.023235312,"threshold_uncertainty_score":0.20679784},"labels":[],"label_agreement":null},{"id":"W4405814046","doi":"10.1136/bmjopen-2024-087190","title":"Systematic review of the impact of the National Medication Price Negotiated Policy on the accessibility of drugs in China, 2016–2024","year":2024,"lang":"en","type":"review","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; China; Systematic review; Data extraction; Negotiation; Quality (philosophy); Government (linguistics); Drug prices; Scale (ratio); MEDLINE; Family medicine; Environmental health; Public economics; Political science; Geography","score_opus":0.19814285347898564,"score_gpt":0.49554012272792175,"score_spread":0.2973972692489361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405814046","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046593533,0.9912072,0.00028128974,0.0006430054,0.00021511893,0.0012323359,0.0011565194,0.000015993333,0.0005892668],"genre_scores_gemma":[0.06944765,0.92357457,0.0014632655,0.0011721785,0.0001663885,0.0029714028,0.0009524167,0.0000111016525,0.0002410284],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9761939,0.008546318,0.008964188,0.0013515502,0.00428881,0.00065513083],"domain_scores_gemma":[0.9637676,0.021475574,0.0090588275,0.0007744709,0.004507001,0.00041650597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019383432,0.0017369268,0.009507022,0.011301035,0.000990087,0.0031673214,0.0021149968,0.0023460614,0.0036347501],"category_scores_gemma":[0.068639636,0.0011401958,0.010321346,0.012224577,0.0012415024,0.0030448127,0.0019463885,0.001449571,0.00020204812],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026846683,0.000018493567,0.0014465784,0.96599054,0.0123963365,0.0001175373,0.0002821744,0.00012900136,0.000108117405,0.00026383673,0.0009923639,0.017986678],"study_design_scores_gemma":[0.00061062136,0.0003711696,0.010339383,0.8499209,0.12458788,0.0002715967,0.00056712556,0.00019795467,0.0003157661,0.0003964411,0.012359495,0.00006163647],"about_ca_topic_score_codex":0.017699635,"about_ca_topic_score_gemma":0.04179384,"teacher_disagreement_score":0.019383432,"about_ca_system_score_codex":0.008615153,"about_ca_system_score_gemma":0.033648446,"threshold_uncertainty_score":0.10251063},"labels":[],"label_agreement":null},{"id":"W4405883997","doi":"10.1007/s11245-024-10147-3","title":"There’s a Pill for That: Bad Pharmaceutical Scaffolding and Psychiatrization","year":2024,"lang":"en","type":"article","venue":"Topoi","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pill; Traditional medicine; Business; Medicine; Pharmacology","score_opus":0.09126687245089607,"score_gpt":0.3329104018149814,"score_spread":0.2416435293640853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405883997","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03158602,0.005553193,0.0026546381,0.90980226,0.0019038379,0.00003167595,0.00030326127,0.00011911795,0.048045997],"genre_scores_gemma":[0.81927454,0.0034873032,0.0015302842,0.1637631,0.0032385953,0.000055082954,0.00011724087,0.000118886055,0.008414962],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9945127,0.0023431315,0.00021444258,0.0004335403,0.0009904363,0.0015058107],"domain_scores_gemma":[0.96525925,0.011748709,0.004889512,0.0026100501,0.0039063348,0.011586225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070572766,0.0003105501,0.00068278523,0.0014607204,0.004182802,0.008471507,0.00087893556,0.0053395876,0.02702494],"category_scores_gemma":[0.03214804,0.00031635998,0.00056076125,0.0013618221,0.016450105,0.0071871635,0.0042316015,0.009406358,0.002412905],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006850187,0.0004211573,0.035112295,0.00031205124,0.00024228176,0.0003723416,0.0031622576,0.0008814603,0.00044413094,0.6270372,0.235508,0.09582189],"study_design_scores_gemma":[0.0004195713,0.00025327495,0.043800414,0.0012777327,0.00016970452,0.0005692139,0.009440216,0.001511206,0.0007381442,0.7380778,0.20356953,0.0001732237],"about_ca_topic_score_codex":0.023676716,"about_ca_topic_score_gemma":0.028244188,"teacher_disagreement_score":0.02702494,"about_ca_system_score_codex":0.0051990934,"about_ca_system_score_gemma":0.010753687,"threshold_uncertainty_score":0.09040749},"labels":[],"label_agreement":null},{"id":"W4406147092","doi":"10.1017/s0266462324001399","title":"OD01 Delays In Funded Access To Medicines: A Global Perspective","year":2024,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Access to medicines; Medicine; Family medicine; Business; Political science; Computer science; Nursing; Public health","score_opus":0.06452434491338832,"score_gpt":0.47013865551383216,"score_spread":0.40561431060044384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406147092","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07042668,0.3804732,0.002393146,0.45282033,0.004325104,0.00018857607,0.012588229,0.00014397598,0.07664081],"genre_scores_gemma":[0.58972025,0.32532915,0.0038854312,0.06553087,0.0033843727,0.00034233183,0.0049946,0.00018483272,0.0066280942],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98469514,0.006603273,0.0024075543,0.0011192849,0.0029829582,0.0021917636],"domain_scores_gemma":[0.8844338,0.07451664,0.021697402,0.001779134,0.012459199,0.0051137763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020566748,0.00039507187,0.0007487215,0.003533399,0.0010075882,0.006319971,0.0015165905,0.0030014552,0.018085448],"category_scores_gemma":[0.077600025,0.00045774662,0.0013002254,0.0075094863,0.0022089446,0.008940489,0.005492472,0.0043379064,0.0011907484],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010923008,0.00022480241,0.07836707,0.06543891,0.0009124712,0.002503564,0.016893288,0.003686601,0.0006836088,0.102879785,0.23186979,0.49544773],"study_design_scores_gemma":[0.00012847633,0.00045676835,0.06830232,0.050698552,0.00054257177,0.0023233274,0.019514468,0.00052184035,0.0007600365,0.016356826,0.84026074,0.00013401688],"about_ca_topic_score_codex":0.023663353,"about_ca_topic_score_gemma":0.014925679,"teacher_disagreement_score":0.023663353,"about_ca_system_score_codex":0.008736126,"about_ca_system_score_gemma":0.01685384,"threshold_uncertainty_score":0.10876864},"labels":[],"label_agreement":null},{"id":"W4406147582","doi":"10.1017/s0266462324001053","title":"OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example","year":2024,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Operations research; Management science; Econometrics; Medicine; Mathematics; Engineering","score_opus":0.1044055751217923,"score_gpt":0.4564719522510591,"score_spread":0.3520663771292668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406147582","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1065109,0.0011130107,0.841254,0.0026736585,0.00017159105,0.00059747347,0.0020671054,0.0011668042,0.044445485],"genre_scores_gemma":[0.6739739,0.001158708,0.3146887,0.00045400418,0.00008731339,0.00052182155,0.0008631094,0.000307981,0.007944442],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99766785,0.001327321,0.00008826084,0.00015859022,0.00046541632,0.00029253922],"domain_scores_gemma":[0.9809787,0.0150151355,0.0009211069,0.0006346416,0.002288598,0.00016185266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006711704,0.0013323392,0.0012147409,0.0019672792,0.00080496445,0.002648024,0.0018385429,0.0015228079,0.0071536927],"category_scores_gemma":[0.027917733,0.0008237541,0.0017497095,0.0020946993,0.000746286,0.0014600139,0.0014999543,0.0018198825,0.00055432506],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028152483,0.000038790782,0.0023293954,0.00008522752,0.00004089714,0.00009101558,0.00004498994,0.96752363,0.00015897956,0.016328642,0.0009865073,0.012343638],"study_design_scores_gemma":[0.000017189543,0.000014906855,0.00039812282,0.000032116313,0.000021768796,0.000018844123,0.000025128908,0.99286556,0.0001222478,0.004988429,0.0014854639,0.00001011957],"about_ca_topic_score_codex":0.34563494,"about_ca_topic_score_gemma":0.20278066,"teacher_disagreement_score":0.34563494,"about_ca_system_score_codex":0.0067283376,"about_ca_system_score_gemma":0.0145181315,"threshold_uncertainty_score":0.6872462},"labels":[],"label_agreement":null},{"id":"W4406218141","doi":"10.1002/alz.091118","title":"Potential Eligibility for Disease Modifying Therapies Among Individuals Referred to A Tertiary Care Memory Clinic in Calgary, Alberta, Canada: Implications for AD Biomarker Testing","year":2024,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary","funders":"","keywords":"Tertiary care; Biomarker; Gerontology; Disease; Medicine; Memory clinic; Family medicine; Psychiatry; Internal medicine; Cognitive impairment; Biology","score_opus":0.10142102305452218,"score_gpt":0.3454987637283511,"score_spread":0.24407774067382892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406218141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923724,0.0010150307,0.00015000386,0.0014396382,0.000020231219,0.000102475846,0.0023988467,0.000011835185,0.0024895389],"genre_scores_gemma":[0.9977519,0.0002612421,0.00025044347,0.0006198015,0.000015849417,0.000033775803,0.00071764574,0.000003163427,0.00034626716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99585766,0.0007852884,0.00036466733,0.0005909981,0.0011557213,0.0012456876],"domain_scores_gemma":[0.99071956,0.0015329211,0.0033170513,0.00029941823,0.002413029,0.0017179392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027869972,0.00033093078,0.0005007455,0.0014002322,0.0028221672,0.0016464447,0.0025078321,0.00067104434,0.0021847195],"category_scores_gemma":[0.008362443,0.00028432,0.0005111266,0.004441623,0.0010583467,0.00043449877,0.0010571254,0.0008452249,0.00016111047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009609716,0.000030160898,0.995977,0.000026200021,0.000024987552,0.00011305221,0.00024216862,0.00004668432,0.000054915217,0.000047993562,0.0007810045,0.0025597701],"study_design_scores_gemma":[0.000020900863,0.000044204528,0.9976459,0.00005234351,0.000039664574,0.000105868974,0.001364688,0.00033072243,0.00004234708,0.00003765027,0.0003078817,0.0000078475405],"about_ca_topic_score_codex":0.9614519,"about_ca_topic_score_gemma":0.97710836,"teacher_disagreement_score":0.038548112,"about_ca_system_score_codex":0.016489452,"about_ca_system_score_gemma":0.022611395,"threshold_uncertainty_score":0.11963993},"labels":[],"label_agreement":null},{"id":"W4406274851","doi":"10.1007/s40273-024-01465-w","title":"Projections of Public Spending on Pharmaceuticals: A Review of Methods","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Institut National d'assurance Maladie-Invalidité; Uppsala Universitet; Universidad Carlos III de Madrid","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Public finance; Business; Medicine; Public economics; Economics; Nursing","score_opus":0.4462416303200376,"score_gpt":0.5513911100974495,"score_spread":0.10514947977741185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406274851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015782348,0.96175414,0.023409273,0.0021686673,0.00033696793,0.00039197985,0.005339194,0.00022572237,0.004795921],"genre_scores_gemma":[0.010517811,0.9681764,0.01834861,0.00023853082,0.00019361115,0.00049112,0.0017415767,0.000050892373,0.00024134322],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907206,0.0045166034,0.0017858624,0.00092130364,0.0019133441,0.00014218617],"domain_scores_gemma":[0.948466,0.044480663,0.0023366495,0.0011248223,0.0034184046,0.00017343633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015305025,0.003443251,0.0035949878,0.016668634,0.00043918472,0.0041501005,0.0033291834,0.0012159616,0.007131652],"category_scores_gemma":[0.048819803,0.0013425517,0.005483738,0.026606578,0.00097408553,0.0044046626,0.0017942146,0.0016585443,0.0017410269],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016581951,0.00005773367,0.0030284354,0.094709836,0.0015677063,0.00012699259,0.00022772932,0.009746084,0.00008420539,0.008228413,0.011802236,0.8702549],"study_design_scores_gemma":[0.00018281903,0.0003020655,0.021582417,0.39918664,0.008566403,0.0015430198,0.0013491941,0.019127235,0.0015391927,0.04619248,0.49995995,0.00046853203],"about_ca_topic_score_codex":0.008458091,"about_ca_topic_score_gemma":0.0061700265,"teacher_disagreement_score":0.016668634,"about_ca_system_score_codex":0.0033622237,"about_ca_system_score_gemma":0.0068843057,"threshold_uncertainty_score":0.08094168},"labels":[],"label_agreement":null},{"id":"W4406412918","doi":"10.1016/s1541-9800(06)70999-1","title":"10.1016/s1541-9800(06)70999-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pill; Type 2 diabetes; Medicine; Pharmacology; Intensive care medicine; Diabetes mellitus; Endocrinology","score_opus":0.02599463254762982,"score_gpt":0.211687255459111,"score_spread":0.18569262291148117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406412918","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044190252,0.0004244336,0.00069481024,0.00048710886,0.00028565785,0.00009297021,0.0011336724,0.0009483015,0.9954911],"genre_scores_gemma":[0.0006509703,0.00018458297,0.00034951148,0.0002208836,0.00005496356,0.000047862726,0.0004713271,0.00015137577,0.99786866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935025,0.00005479842,0.000053788663,0.00022665838,0.0001806799,0.00013367592],"domain_scores_gemma":[0.9980844,0.0005496661,0.00014251034,0.000263784,0.00036793025,0.000591714],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010354557,0.0023252082,0.0016332896,0.0024506513,0.001851335,0.003812713,0.002676657,0.0056302305,0.98927116],"category_scores_gemma":[0.0020062192,0.00091569184,0.0011656248,0.0026180095,0.0015580173,0.0054080156,0.0028497784,0.0026231892,0.99249387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027413375,0.00018926064,0.00086397835,0.00049090147,0.00002698043,0.00018250276,0.00007987331,0.0004329144,0.0015047084,0.0063107642,0.37430733,0.61533666],"study_design_scores_gemma":[0.00004707375,0.00008375876,0.0007341118,0.00029003026,0.000011824924,0.00023054439,0.00009271054,0.00026843732,0.00035401704,0.0007669427,0.99709904,0.00002147561],"about_ca_topic_score_codex":0.0036842455,"about_ca_topic_score_gemma":0.00299036,"teacher_disagreement_score":0.010728836,"about_ca_system_score_codex":0.0011374132,"about_ca_system_score_gemma":0.0012463613,"threshold_uncertainty_score":0.015303314},"labels":[],"label_agreement":null},{"id":"W4406424652","doi":"10.1016/s0029-7437(07)70719-x","title":"10.1016/s0029-7437(07)70719-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Vital signs; Antibiotics; Business; Environmental science; Economics; Medicine; Anesthesia; Microbiology; Biology","score_opus":0.028707871958831753,"score_gpt":0.220413195142507,"score_spread":0.19170532318367525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406424652","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044862315,0.00054049527,0.0009186229,0.0005319028,0.00031087414,0.00009442911,0.0012744751,0.00096114166,0.99491936],"genre_scores_gemma":[0.00079332484,0.00023411108,0.00041744288,0.00019271893,0.000065387976,0.000056958317,0.00056118437,0.00018211023,0.99749666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937016,0.000059206304,0.00005224146,0.00020871092,0.00017194619,0.00013770317],"domain_scores_gemma":[0.9980703,0.0005788364,0.00017294317,0.00026248966,0.00031080437,0.0006046871],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011129227,0.0026462085,0.001893068,0.0030547322,0.0018301882,0.004631307,0.0033703553,0.00604433,0.9882406],"category_scores_gemma":[0.0019647353,0.0010983015,0.0012830959,0.0035701492,0.002348443,0.0058544655,0.0027924494,0.0031057072,0.99218917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025326564,0.00022116877,0.0009710636,0.0006203497,0.000039352013,0.00020168042,0.00010201481,0.00058266154,0.0017166834,0.0097212875,0.39182585,0.59374464],"study_design_scores_gemma":[0.000047002202,0.00007391425,0.00077729084,0.0003204946,0.000013488978,0.00023009039,0.00011336679,0.00034870443,0.00039694496,0.001076682,0.9965791,0.000022977252],"about_ca_topic_score_codex":0.004981544,"about_ca_topic_score_gemma":0.003304088,"teacher_disagreement_score":0.0117594,"about_ca_system_score_codex":0.0013722426,"about_ca_system_score_gemma":0.001599497,"threshold_uncertainty_score":0.016773283},"labels":[],"label_agreement":null},{"id":"W4406430700","doi":"10.1016/s0029-7437(05)71082-x","title":"10.1016/s0029-7437(05)71082-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.028634951249743162,"score_gpt":0.22028570712836135,"score_spread":0.19165075587861818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406430700","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045430486,0.00054229517,0.0009543221,0.00056787947,0.000321793,0.000095795396,0.001237192,0.0009896134,0.9948369],"genre_scores_gemma":[0.00078510493,0.00021976342,0.00041210788,0.00019043495,0.00006433462,0.0000552535,0.00052615587,0.00017534004,0.9975715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935323,0.00006238126,0.00005475282,0.00021693669,0.00017324078,0.000139435],"domain_scores_gemma":[0.99795675,0.0006240281,0.00017888051,0.0002830966,0.0003410361,0.0006161607],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011416255,0.0025750839,0.0019262094,0.0030147932,0.0018495067,0.0045758775,0.0033481761,0.006343341,0.98812544],"category_scores_gemma":[0.0020990316,0.0010812691,0.0013155612,0.0034403526,0.0022415249,0.005891904,0.002702866,0.003141175,0.99210125],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002631351,0.00021538093,0.00097276043,0.0006310344,0.000039295443,0.00020322326,0.00010689273,0.0005552843,0.0017229578,0.01017113,0.38097957,0.6041393],"study_design_scores_gemma":[0.00004578981,0.000076060634,0.00076606206,0.0003090481,0.000013491162,0.00022407586,0.0001077504,0.00033431302,0.00036962682,0.001082474,0.9966492,0.00002210514],"about_ca_topic_score_codex":0.0048375637,"about_ca_topic_score_gemma":0.0031382646,"teacher_disagreement_score":0.011874557,"about_ca_system_score_codex":0.0013486153,"about_ca_system_score_gemma":0.0016051823,"threshold_uncertainty_score":0.016937554},"labels":[],"label_agreement":null},{"id":"W4406441492","doi":"10.1016/s0029-7437(07)70349-x","title":"10.1016/s0029-7437(07)70349-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drugs of abuse; Psychology; Internet privacy; Business; Psychiatry; Computer science; Drug","score_opus":0.02859036513994322,"score_gpt":0.22036912489471336,"score_spread":0.19177875975477013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406441492","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004601961,0.0005189634,0.0009113505,0.0005300928,0.00031115688,0.00009864098,0.0012792042,0.0009821127,0.99490815],"genre_scores_gemma":[0.00077459693,0.00022433444,0.00042044863,0.00019629617,0.00006367961,0.000059391085,0.00054839585,0.00018666602,0.9975262],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936324,0.00005931791,0.00005266735,0.00021423465,0.00017162421,0.00013891186],"domain_scores_gemma":[0.998028,0.0005903382,0.00017553993,0.00026856852,0.00031577697,0.0006217896],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011402159,0.0027351882,0.001963864,0.0031081853,0.0019179691,0.0046864534,0.0034635698,0.0062471055,0.9887621],"category_scores_gemma":[0.0020009018,0.001142265,0.0013259692,0.003624741,0.0024178997,0.0060038203,0.0029261613,0.0031609237,0.99252933],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026047317,0.00022830785,0.0009774842,0.00062198826,0.0000397914,0.00020828782,0.00010512652,0.000589593,0.0017228093,0.009636764,0.39591414,0.5896952],"study_design_scores_gemma":[0.000048816706,0.000077554694,0.0007940456,0.0003313694,0.000013607903,0.00023205434,0.000117960764,0.00035298825,0.0003953692,0.0010613195,0.9965508,0.000024043613],"about_ca_topic_score_codex":0.005031557,"about_ca_topic_score_gemma":0.0033557825,"teacher_disagreement_score":0.011237919,"about_ca_system_score_codex":0.0013985856,"about_ca_system_score_gemma":0.0016318581,"threshold_uncertainty_score":0.016029537},"labels":[],"label_agreement":null},{"id":"W4406456288","doi":"10.1016/s0029-7437(05)70293-7","title":"10.1016/s0029-7437(05)70293-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Internet privacy; Medicine; Computer science; Pharmacology","score_opus":0.028228682005537003,"score_gpt":0.22016898416012312,"score_spread":0.19194030215458613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406456288","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000422811,0.00057490304,0.0008032841,0.0004770013,0.00032797706,0.00009741257,0.0010876126,0.00091856817,0.9952904],"genre_scores_gemma":[0.00073256,0.0002446819,0.0003679709,0.00020663434,0.00006926666,0.000058945625,0.0005068274,0.00018458466,0.9976285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920267,0.00007176506,0.0000658319,0.00028202578,0.00019704127,0.00018071628],"domain_scores_gemma":[0.9974069,0.0008222389,0.00019621354,0.00033520735,0.0004658318,0.00077356055],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013202941,0.0031084483,0.0024574015,0.0034359659,0.0023742127,0.0051265154,0.003923813,0.0071988944,0.989717],"category_scores_gemma":[0.002260372,0.0012807462,0.0016979866,0.0038509103,0.0027666497,0.0067532524,0.0033943793,0.0035204648,0.9936539],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003355086,0.000245758,0.0009832159,0.00074285606,0.00004841483,0.00023011105,0.00011925282,0.0006296909,0.0019205443,0.009296574,0.37821078,0.6072373],"study_design_scores_gemma":[0.000058350026,0.00011048755,0.00080516544,0.00043374463,0.000016992035,0.00026255072,0.00012715899,0.00036958206,0.000395218,0.0010560027,0.99633646,0.000028266484],"about_ca_topic_score_codex":0.0049306364,"about_ca_topic_score_gemma":0.0032033692,"teacher_disagreement_score":0.010282993,"about_ca_system_score_codex":0.0015533306,"about_ca_system_score_gemma":0.0017551567,"threshold_uncertainty_score":0.014667332},"labels":[],"label_agreement":null},{"id":"W4406457157","doi":"10.1016/s1544-8800(08)70406-8","title":"10.1016/s1544-8800(08)70406-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Medicine","score_opus":0.025871300324584498,"score_gpt":0.2114233789467951,"score_spread":0.18555207862221063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406457157","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042286515,0.00043622823,0.0006870082,0.00050890585,0.00027773954,0.000097461074,0.0012495121,0.001072822,0.99524754],"genre_scores_gemma":[0.0006564017,0.00018417495,0.00032222908,0.00021488659,0.000058888923,0.00004839855,0.00045754944,0.00016365228,0.99789387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939513,0.000049225473,0.000050492545,0.000213077,0.000166594,0.00012553931],"domain_scores_gemma":[0.9979488,0.00057724986,0.00016494081,0.00028607104,0.00039849212,0.0006243955],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010408236,0.0024456042,0.0017191538,0.0026097577,0.0017895254,0.004010571,0.002789791,0.005783215,0.99001116],"category_scores_gemma":[0.0019543467,0.0009583599,0.0012160479,0.0028368267,0.0016925305,0.0054457122,0.0029937709,0.00270356,0.99322695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029685482,0.00019235034,0.00083935854,0.000485329,0.00003129677,0.00018513383,0.00007592698,0.00046738307,0.0015766622,0.0059185284,0.399426,0.5905052],"study_design_scores_gemma":[0.00005719586,0.00008577595,0.00078809675,0.0002870737,0.000014152378,0.000230981,0.000096014955,0.0002834563,0.00038524342,0.00075115426,0.9969982,0.000022635373],"about_ca_topic_score_codex":0.0041104974,"about_ca_topic_score_gemma":0.0029518188,"teacher_disagreement_score":0.009988844,"about_ca_system_score_codex":0.0012052406,"about_ca_system_score_gemma":0.0012053256,"threshold_uncertainty_score":0.014247894},"labels":[],"label_agreement":null},{"id":"W4406478161","doi":"10.1016/s0029-7437(08)70385-9","title":"10.1016/s0029-7437(08)70385-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.02776337876948659,"score_gpt":0.21923287689649548,"score_spread":0.1914694981270089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406478161","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046200692,0.00054041645,0.000780128,0.00050430634,0.00032297237,0.00010783074,0.001172827,0.0009829892,0.99512637],"genre_scores_gemma":[0.000733939,0.00024302716,0.00039720608,0.0002261953,0.00006752367,0.000067914654,0.00051627366,0.00019581919,0.997552],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99922585,0.000066900764,0.00006451185,0.00028357937,0.00018663898,0.00017249238],"domain_scores_gemma":[0.9976126,0.0007515483,0.00018611121,0.00030966947,0.00040877887,0.0007313819],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013520038,0.0032211184,0.0024474058,0.0032862348,0.0023246736,0.005121241,0.0038553088,0.007168236,0.9900484],"category_scores_gemma":[0.0021876842,0.0013527296,0.0016620781,0.0038239022,0.0028797267,0.0068935347,0.003462451,0.0036243843,0.9938054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035551426,0.0002685344,0.0010792336,0.0007707376,0.000049376784,0.00024909058,0.00012586734,0.0006717142,0.0019172227,0.008788503,0.3940665,0.59165764],"study_design_scores_gemma":[0.00006598111,0.00011525608,0.00086528994,0.00047100912,0.000017832026,0.00028059297,0.00014829931,0.00038406515,0.0003784728,0.0010119642,0.99623114,0.000029989826],"about_ca_topic_score_codex":0.0052973856,"about_ca_topic_score_gemma":0.0034237304,"teacher_disagreement_score":0.0099515915,"about_ca_system_score_codex":0.0015841253,"about_ca_system_score_gemma":0.0017151788,"threshold_uncertainty_score":0.014194667},"labels":[],"label_agreement":null},{"id":"W4406486819","doi":"10.1016/s0029-7437(07)70150-7","title":"10.1016/s0029-7437(07)70150-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Drug; Pharmacology; Medicine","score_opus":0.029123797176607,"score_gpt":0.22112468531389062,"score_spread":0.1920008881372836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406486819","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004216584,0.00049604196,0.0008176385,0.00046608745,0.00030411783,0.00009165429,0.0011483681,0.0009519638,0.99530244],"genre_scores_gemma":[0.00072270614,0.00021326542,0.00035201115,0.00019228725,0.00006331715,0.000054175543,0.0005177462,0.00018844906,0.9976961],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992889,0.00006267336,0.000055760807,0.00024646195,0.00018647764,0.00015970597],"domain_scores_gemma":[0.99774384,0.00068994303,0.0001798861,0.00029006173,0.00040577337,0.00069050345],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011908613,0.0028853486,0.0021919298,0.0031762195,0.0021271745,0.00492793,0.0035289293,0.006389359,0.9894422],"category_scores_gemma":[0.0020629212,0.0012026494,0.0015036258,0.0036712843,0.0025101092,0.0059982087,0.0032079665,0.003239013,0.9934946],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000292673,0.00022364121,0.00094492,0.00062851666,0.000042925658,0.00020312946,0.00010344103,0.0006159581,0.0018597884,0.00868123,0.3964544,0.5899494],"study_design_scores_gemma":[0.000052773852,0.0000943063,0.0007557938,0.00036648582,0.000015111342,0.00023146783,0.00011731919,0.00037005177,0.00039975732,0.0009868343,0.9965844,0.000025586174],"about_ca_topic_score_codex":0.0048758667,"about_ca_topic_score_gemma":0.0032809179,"teacher_disagreement_score":0.010557771,"about_ca_system_score_codex":0.0014614175,"about_ca_system_score_gemma":0.0017035219,"threshold_uncertainty_score":0.015059292},"labels":[],"label_agreement":null},{"id":"W4406519309","doi":"10.1016/s0029-7437(08)70399-9","title":"10.1016/s0029-7437(08)70399-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Distribution (mathematics); Vital signs; Medicine; Pharmacology; Anesthesia; Mathematics","score_opus":0.027765111778826547,"score_gpt":0.21923854629980688,"score_spread":0.19147343452098034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406519309","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043885762,0.00051679567,0.0007991727,0.00051348424,0.00032450247,0.00010124624,0.0012185962,0.00096859434,0.99511886],"genre_scores_gemma":[0.0007403194,0.00022929847,0.00039645116,0.00020992165,0.000067831585,0.00006183539,0.00053952023,0.00019460643,0.99756026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99930954,0.000060997718,0.00005937675,0.00024311568,0.00017694416,0.00015015337],"domain_scores_gemma":[0.997799,0.0006763699,0.00018072265,0.00029543877,0.00038780304,0.00066078873],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012460117,0.0028608374,0.0022055337,0.003147984,0.0020462556,0.0050156284,0.0035596443,0.0065424503,0.9895335],"category_scores_gemma":[0.0020959338,0.0012158336,0.0015102532,0.0036539913,0.0026042056,0.0062105907,0.003152756,0.0034210063,0.9934023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030288773,0.0002482068,0.0009827917,0.0006669784,0.00004548152,0.00022554261,0.00010764269,0.0006049122,0.0018497023,0.008602268,0.39741033,0.5889532],"study_design_scores_gemma":[0.00005763954,0.00009588892,0.00082212436,0.0004038368,0.000015813157,0.00025701348,0.00012778514,0.00035924892,0.00037617434,0.0010083133,0.99644935,0.000026739053],"about_ca_topic_score_codex":0.0047855144,"about_ca_topic_score_gemma":0.0030423934,"teacher_disagreement_score":0.010466516,"about_ca_system_score_codex":0.0014459353,"about_ca_system_score_gemma":0.0016296392,"threshold_uncertainty_score":0.014929235},"labels":[],"label_agreement":null},{"id":"W4406521958","doi":"10.1016/s0029-7437(07)70666-3","title":"10.1016/s0029-7437(07)70666-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Traditional medicine","score_opus":0.028705292440169877,"score_gpt":0.220386226494674,"score_spread":0.19168093405450412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406521958","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041177563,0.0005198513,0.00086206914,0.000490756,0.00032804738,0.0000981045,0.0012667595,0.00094524364,0.99507755],"genre_scores_gemma":[0.0007444533,0.0002341691,0.0003866448,0.00019153561,0.00006762127,0.00005666217,0.00054438575,0.00018665566,0.9975878],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993155,0.000060644496,0.00005576261,0.00024049701,0.00018609106,0.00014149083],"domain_scores_gemma":[0.997818,0.0006694016,0.00017543673,0.00029161078,0.00041166012,0.0006339163],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011699587,0.0026976254,0.0020490803,0.0030965349,0.0018903491,0.0051672827,0.003340458,0.006044247,0.9890777],"category_scores_gemma":[0.0020354989,0.0011457435,0.0014265894,0.0038117392,0.0024213584,0.0058838376,0.0029653695,0.0033346638,0.99332654],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002659768,0.00022250254,0.0009426833,0.0006216194,0.00004398902,0.00019692357,0.00009640173,0.00062155246,0.001818858,0.008496243,0.39700338,0.5896699],"study_design_scores_gemma":[0.000050621682,0.00008333482,0.0007403073,0.00035964424,0.000015129433,0.00022582909,0.000108020526,0.00036230477,0.00038803738,0.0009423861,0.99669904,0.000025289355],"about_ca_topic_score_codex":0.004716193,"about_ca_topic_score_gemma":0.0030793124,"teacher_disagreement_score":0.010922313,"about_ca_system_score_codex":0.001406063,"about_ca_system_score_gemma":0.001629339,"threshold_uncertainty_score":0.015579283},"labels":[],"label_agreement":null},{"id":"W4406544985","doi":"10.1016/s1544-8800(11)70366-9","title":"10.1016/s1544-8800(11)70366-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Rivaroxaban; Medicine; Stroke (engine); Cardiology; Internal medicine; Atrial fibrillation; Warfarin; Engineering","score_opus":0.025935663386603074,"score_gpt":0.21137618844623124,"score_spread":0.18544052505962816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406544985","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038547453,0.0004910034,0.00073441805,0.00049542525,0.0002821744,0.00009577274,0.001369913,0.0010925742,0.99505323],"genre_scores_gemma":[0.0006688055,0.00022905825,0.00035914814,0.00022618074,0.000066354856,0.000054175907,0.00049762306,0.00017581592,0.9977228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993383,0.00005183855,0.000058458332,0.0002302039,0.00018860417,0.00013253697],"domain_scores_gemma":[0.9978861,0.0006307747,0.00018203702,0.0003052963,0.00036889315,0.00062685943],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011041389,0.002616689,0.0018546353,0.0028592737,0.0018323708,0.00426226,0.002932207,0.0061585493,0.9899198],"category_scores_gemma":[0.0020573176,0.0010615668,0.0012862625,0.0030287518,0.0017731147,0.005938963,0.0033031804,0.002979746,0.99306846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028300725,0.00019129096,0.0007756077,0.0005382773,0.000032676468,0.00018753202,0.00007397627,0.00052216253,0.0015962546,0.0062442035,0.39891756,0.59063745],"study_design_scores_gemma":[0.00005831344,0.000084586936,0.00076957484,0.00032301413,0.000014135316,0.00023670202,0.00009065209,0.00029280386,0.0003963854,0.0008549425,0.99685377,0.000025111387],"about_ca_topic_score_codex":0.004000335,"about_ca_topic_score_gemma":0.0029429456,"teacher_disagreement_score":0.010080218,"about_ca_system_score_codex":0.0012540484,"about_ca_system_score_gemma":0.0012080042,"threshold_uncertainty_score":0.01437813},"labels":[],"label_agreement":null},{"id":"W4406547413","doi":"10.1016/s1541-9800(05)70502-0","title":"10.1016/s1541-9800(05)70502-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Purchasing; Business; Economics; Marketing","score_opus":0.026391010340227453,"score_gpt":0.21255329252011973,"score_spread":0.18616228217989228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406547413","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041575273,0.00039354118,0.0007796137,0.00048069833,0.00026105522,0.00009191251,0.001041317,0.0009917368,0.9955445],"genre_scores_gemma":[0.00064999965,0.0001741971,0.0003516503,0.00021227189,0.000055419547,0.000045131503,0.00042636678,0.00015890531,0.997926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940753,0.000051547722,0.00005009717,0.0002038126,0.00016883724,0.00011829147],"domain_scores_gemma":[0.99794656,0.0005836047,0.00015675722,0.00029580836,0.00039708836,0.0006201371],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010233953,0.0021839496,0.0015333745,0.002537167,0.0016784046,0.0038331791,0.002635088,0.0056503974,0.98899823],"category_scores_gemma":[0.0020005477,0.0008782855,0.0011558969,0.0027142768,0.0014587833,0.005330271,0.0027333705,0.002513819,0.992299],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025213612,0.00019034176,0.00080853864,0.00045449866,0.000028204253,0.0001746083,0.000075289136,0.00043731558,0.0015139967,0.0065910122,0.37474748,0.61472654],"study_design_scores_gemma":[0.00004581306,0.00007574418,0.00072921737,0.00025904813,0.0000123019,0.00021244683,0.00008394918,0.00026419346,0.00035425316,0.00076395564,0.9971781,0.000021045076],"about_ca_topic_score_codex":0.003972479,"about_ca_topic_score_gemma":0.0029229468,"teacher_disagreement_score":0.011001766,"about_ca_system_score_codex":0.0011508929,"about_ca_system_score_gemma":0.0011966109,"threshold_uncertainty_score":0.01569271},"labels":[],"label_agreement":null},{"id":"W4406550215","doi":"10.1016/s1541-9800(05)70294-5","title":"10.1016/s1541-9800(05)70294-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Valdecoxib; Medicine; Chemistry","score_opus":0.02619341044334982,"score_gpt":0.21251417814070803,"score_spread":0.1863207676973582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406550215","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045867357,0.0004723911,0.0007817732,0.00052716257,0.00030325755,0.00009769757,0.0012030939,0.0010617762,0.9950942],"genre_scores_gemma":[0.0007060531,0.00019412879,0.00035599276,0.000236922,0.00006137175,0.000047885696,0.00048068713,0.0001673177,0.99774975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99934393,0.000055014643,0.000055684162,0.00022976215,0.0001798956,0.00013577199],"domain_scores_gemma":[0.997771,0.0006442197,0.00017661227,0.00030748162,0.00043970425,0.00066092395],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010689166,0.0024027398,0.0017265668,0.0026112923,0.0018536998,0.004091999,0.0028547852,0.005965266,0.98938316],"category_scores_gemma":[0.002051015,0.0009417591,0.0012497219,0.0028976996,0.0016093212,0.005653155,0.0029745447,0.0027479501,0.99285674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002881814,0.00020118813,0.0008661159,0.0004939389,0.000032152024,0.00018853035,0.00008100813,0.00047012794,0.0016158716,0.006191667,0.36892325,0.620648],"study_design_scores_gemma":[0.000054197717,0.00009067031,0.00079585717,0.00030445034,0.000014867448,0.00022821268,0.000093156064,0.00030018826,0.000411036,0.0008379778,0.996845,0.000024413152],"about_ca_topic_score_codex":0.0037368133,"about_ca_topic_score_gemma":0.0028573314,"teacher_disagreement_score":0.010616839,"about_ca_system_score_codex":0.0011955997,"about_ca_system_score_gemma":0.0012666458,"threshold_uncertainty_score":0.015143633},"labels":[],"label_agreement":null},{"id":"W4406550742","doi":"10.1016/s1541-9800(10)70047-8","title":"10.1016/s1541-9800(10)70047-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Internet privacy; Drug; Advertising; Web site; Computer security; The Internet; Medicine; World Wide Web; Pharmacology; Computer science","score_opus":0.027240964507213774,"score_gpt":0.21232299963668608,"score_spread":0.1850820351294723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406550742","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004529667,0.00049330166,0.00071819825,0.00044903252,0.00030446844,0.00009847863,0.0011769198,0.00096207194,0.99534446],"genre_scores_gemma":[0.00068030605,0.00022177548,0.00037605557,0.0002365392,0.000068583366,0.000057896646,0.0004890719,0.00016810838,0.9977016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993175,0.00005280677,0.00005681701,0.00024889485,0.00018284365,0.00014110762],"domain_scores_gemma":[0.9980129,0.0005824383,0.00015521618,0.00026974367,0.00035167873,0.0006279245],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010564392,0.002725724,0.0018219295,0.0026600992,0.0019272603,0.003813282,0.0030057945,0.006211851,0.98983115],"category_scores_gemma":[0.0018594081,0.0010306573,0.0013203318,0.002791804,0.0016926192,0.00581402,0.003137944,0.0028087185,0.99311936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032435128,0.00021344937,0.00085854874,0.00058331975,0.000031368905,0.000212855,0.0000808311,0.0004897759,0.0016912383,0.0056993817,0.3662623,0.6235527],"study_design_scores_gemma":[0.000064333435,0.00010704802,0.00084237783,0.00035756952,0.000015260126,0.00029148773,0.000099651916,0.0003036102,0.00042435332,0.0008591237,0.99660873,0.000026482701],"about_ca_topic_score_codex":0.0033896482,"about_ca_topic_score_gemma":0.0028694745,"teacher_disagreement_score":0.01016885,"about_ca_system_score_codex":0.0011914411,"about_ca_system_score_gemma":0.001158809,"threshold_uncertainty_score":0.0145046115},"labels":[],"label_agreement":null},{"id":"W4406551952","doi":"10.1016/s1544-8800(12)70391-3","title":"10.1016/s1544-8800(12)70391-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.027931763668062326,"score_gpt":0.20970490931573402,"score_spread":0.1817731456476717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406551952","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003980562,0.00046478072,0.0007888405,0.00047295008,0.00028236886,0.000093823386,0.0013084719,0.0010803432,0.99511033],"genre_scores_gemma":[0.0006560241,0.00021277186,0.00035202978,0.00020987385,0.00006509636,0.000049089675,0.00047271137,0.00016874632,0.9978136],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993875,0.000047016223,0.00005166264,0.00021553297,0.00017729292,0.00012099785],"domain_scores_gemma":[0.9980227,0.00058443565,0.00016722435,0.00028113934,0.00035977617,0.00058477075],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010155753,0.0024706316,0.0018144231,0.0027140805,0.0017906015,0.004152385,0.0028300823,0.0056646895,0.9893667],"category_scores_gemma":[0.0019109235,0.0009792816,0.0012325898,0.0029363686,0.0016713073,0.0057580923,0.0030444928,0.0027906585,0.9927026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027244916,0.00019099568,0.0007552317,0.00050669827,0.000031539526,0.00018254678,0.00007043493,0.0005255891,0.0015871174,0.006282438,0.38456503,0.60502994],"study_design_scores_gemma":[0.00005389998,0.00008572366,0.0007268709,0.0002987693,0.000013892612,0.00023022943,0.00008600404,0.00030187334,0.0004022365,0.0008151848,0.9969607,0.00002459364],"about_ca_topic_score_codex":0.0037455058,"about_ca_topic_score_gemma":0.0029112024,"teacher_disagreement_score":0.01063329,"about_ca_system_score_codex":0.0012427191,"about_ca_system_score_gemma":0.0011773215,"threshold_uncertainty_score":0.015167117},"labels":[],"label_agreement":null},{"id":"W4406552316","doi":"10.1016/s1553-3212(08)70162-6","title":"10.1016/s1553-3212(08)70162-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug pricing; Drug; Business; Medicine; Actuarial science; Psychiatry","score_opus":0.025938670110545424,"score_gpt":0.21121112305851594,"score_spread":0.1852724529479705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406552316","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037266084,0.00040926173,0.0006830438,0.00052468665,0.00024689914,0.00009482414,0.001268894,0.0010528417,0.99534684],"genre_scores_gemma":[0.00064698275,0.00018069237,0.00031770862,0.0002537162,0.00005280489,0.000054891014,0.0004894735,0.00016922997,0.9978345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935645,0.000054572727,0.000058469817,0.000231636,0.00017090506,0.00012785253],"domain_scores_gemma":[0.99790525,0.0006006785,0.00018350624,0.00030502334,0.00037662158,0.0006289043],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001190905,0.0025034857,0.001857684,0.0027356618,0.0019626596,0.0047157523,0.0030617001,0.0068184696,0.99052143],"category_scores_gemma":[0.0021664773,0.0010691783,0.0012848593,0.0029302505,0.0018979704,0.0064380136,0.0033045437,0.0028904346,0.99433964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027667763,0.00020290894,0.0009006692,0.0005122556,0.00003194671,0.00019279859,0.000086105305,0.0005135881,0.0013662865,0.0070608263,0.4413728,0.54748315],"study_design_scores_gemma":[0.000055141827,0.00007870805,0.0006928912,0.0003221065,0.000013222496,0.00022142447,0.000104588136,0.00027946426,0.00030879842,0.00093653676,0.9969626,0.000024479612],"about_ca_topic_score_codex":0.004520689,"about_ca_topic_score_gemma":0.0033969642,"teacher_disagreement_score":0.009478569,"about_ca_system_score_codex":0.0014364682,"about_ca_system_score_gemma":0.0014277045,"threshold_uncertainty_score":0.013519943},"labels":[],"label_agreement":null},{"id":"W4406552542","doi":"10.1016/s1558-0164(07)70380-2","title":"10.1016/s1558-0164(07)70380-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; User fee; Internet privacy; Pharmacology; Law; Political science; Computer science","score_opus":0.026647612257589846,"score_gpt":0.21276397070661227,"score_spread":0.1861163584490224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406552542","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031641408,0.00033835767,0.0006544276,0.00050223817,0.00025076215,0.000077079065,0.0010640493,0.00090383907,0.9958929],"genre_scores_gemma":[0.0005520114,0.00014819672,0.00026432303,0.00019791294,0.000053768843,0.0000364166,0.00040757115,0.00014070822,0.99819916],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940515,0.000051784402,0.00004753105,0.0002067013,0.00017265847,0.000116161646],"domain_scores_gemma":[0.9981554,0.00047685442,0.00014915252,0.0002551753,0.00038509312,0.0005784423],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009855406,0.002137606,0.0015224686,0.0026318468,0.0017939908,0.0044160965,0.0025533645,0.005497118,0.98982644],"category_scores_gemma":[0.0019360128,0.0009029537,0.0011079926,0.002801509,0.0016212071,0.005362586,0.0028504436,0.002504509,0.9931164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022262431,0.00016955644,0.00076348445,0.00039033685,0.000026643687,0.00016601851,0.00007082354,0.00042972487,0.0012901095,0.006989553,0.4487284,0.5407528],"study_design_scores_gemma":[0.00003968663,0.000056090656,0.0005480266,0.00022341972,0.000010087228,0.00017172827,0.00007533577,0.00021963878,0.0002653648,0.0007989523,0.9975745,0.000017298382],"about_ca_topic_score_codex":0.0040911147,"about_ca_topic_score_gemma":0.0033070557,"teacher_disagreement_score":0.010173559,"about_ca_system_score_codex":0.0012836037,"about_ca_system_score_gemma":0.0013438066,"threshold_uncertainty_score":0.014511287},"labels":[],"label_agreement":null},{"id":"W4406553560","doi":"10.1016/s1558-0164(09)70352-9","title":"10.1016/s1558-0164(09)70352-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Darbepoetin alfa; Medicine; Internal medicine; Cardiology; Kidney disease","score_opus":0.026148924671377267,"score_gpt":0.21188890949036543,"score_spread":0.18573998481898815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406553560","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035779772,0.00038410537,0.0006653286,0.00051686534,0.00026620034,0.0000790188,0.0011140095,0.00093508983,0.9956815],"genre_scores_gemma":[0.0006507566,0.00017334346,0.00029305863,0.00022639835,0.000062308914,0.000041472573,0.0004610099,0.0001523599,0.99793917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993505,0.000055002733,0.00005655442,0.00023239932,0.00017640565,0.00012908858],"domain_scores_gemma":[0.99797314,0.00054850965,0.00017189146,0.0002951422,0.00039019718,0.00062106684],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010812125,0.002306289,0.0016522707,0.0026840742,0.0018717786,0.004510377,0.0026951612,0.0059156492,0.99008465],"category_scores_gemma":[0.0020391112,0.0009879256,0.0011963825,0.00280296,0.0017919828,0.0058545545,0.0030295958,0.0026617593,0.9932011],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000262554,0.00018812744,0.0008390839,0.00045091892,0.00003123923,0.00018938202,0.00007895219,0.0004847003,0.0014190478,0.007294837,0.43334356,0.55541766],"study_design_scores_gemma":[0.00004868757,0.00007019032,0.00065986265,0.00027472546,0.000012334223,0.0002123179,0.00008695744,0.00025243883,0.00029608744,0.00091061555,0.99715483,0.000020883028],"about_ca_topic_score_codex":0.0040174304,"about_ca_topic_score_gemma":0.0030760788,"teacher_disagreement_score":0.009915352,"about_ca_system_score_codex":0.0012567054,"about_ca_system_score_gemma":0.0013162236,"threshold_uncertainty_score":0.01414299},"labels":[],"label_agreement":null},{"id":"W4406554175","doi":"10.1016/s1558-0164(11)70462-x","title":"10.1016/s1558-0164(11)70462-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Toll; Medicine; Economic shortage; Drug; Intensive care medicine; Death toll; Medical emergency; Pharmacology; Environmental health; Immunology","score_opus":0.02578226111751708,"score_gpt":0.21112772458101117,"score_spread":0.1853454634634941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406554175","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031693207,0.0004047626,0.00073787547,0.0005141174,0.000263598,0.00007341903,0.0011138044,0.00091974303,0.9956558],"genre_scores_gemma":[0.00060056837,0.0001789202,0.00029278494,0.00018433218,0.00005887695,0.000037940295,0.00041284668,0.00014485863,0.9980888],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99938655,0.000052730196,0.00005328322,0.00020713851,0.00018323403,0.00011708661],"domain_scores_gemma":[0.99810994,0.0005157286,0.00018151126,0.00028077647,0.00031708457,0.000594849],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010331465,0.0022349502,0.0014832407,0.0026912636,0.0017059555,0.004338868,0.0026417873,0.0056722234,0.98914576],"category_scores_gemma":[0.0020015265,0.0009409192,0.0010954802,0.002830296,0.0016297386,0.005832737,0.0030279588,0.0024763434,0.9921206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022629878,0.00016858816,0.0007626288,0.0004452084,0.00002733695,0.00017110394,0.00007478635,0.00046407754,0.0013132702,0.008075614,0.41986874,0.5684024],"study_design_scores_gemma":[0.000038033668,0.00005568898,0.00058293744,0.00022959057,0.000010294894,0.00018157503,0.00007245197,0.00022015024,0.00029815742,0.0009623849,0.9973309,0.000017911021],"about_ca_topic_score_codex":0.0036355252,"about_ca_topic_score_gemma":0.002895229,"teacher_disagreement_score":0.010854244,"about_ca_system_score_codex":0.0012102742,"about_ca_system_score_gemma":0.0012209865,"threshold_uncertainty_score":0.015482187},"labels":[],"label_agreement":null},{"id":"W4406576689","doi":"10.1016/s1553-3212(05)71129-8","title":"10.1016/s1553-3212(05)71129-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Business; Risk analysis (engineering); Medical emergency","score_opus":0.026922904835989067,"score_gpt":0.21353737456050176,"score_spread":0.18661446972451268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406576689","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003646645,0.00039705433,0.0006329188,0.0004774741,0.00025331072,0.000092143695,0.0011065536,0.001016443,0.99565953],"genre_scores_gemma":[0.0005947242,0.0001743617,0.0002714891,0.00023833578,0.00005228811,0.00005069948,0.00042874733,0.00015175556,0.99803764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992756,0.000062128725,0.00006360625,0.00026157792,0.000186523,0.00015053006],"domain_scores_gemma":[0.9976827,0.0006683935,0.00017864114,0.00033251167,0.0004279646,0.00070979603],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012025051,0.002660361,0.0020319112,0.0029401751,0.002221972,0.004743941,0.0031760142,0.007011311,0.9907901],"category_scores_gemma":[0.0022563708,0.0011059316,0.0013695778,0.0031306571,0.0019589001,0.0065152915,0.0035262122,0.002972844,0.9942753],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029493202,0.0002079933,0.0008950038,0.00053742493,0.000033293927,0.00019478296,0.00009523333,0.00052448036,0.0013861303,0.0069284677,0.4471777,0.54172456],"study_design_scores_gemma":[0.000055166453,0.00008415594,0.0007069371,0.0003363231,0.000014442078,0.00021768604,0.00010630742,0.000280542,0.0003094143,0.000877219,0.9969874,0.000024542684],"about_ca_topic_score_codex":0.004696065,"about_ca_topic_score_gemma":0.0036905922,"teacher_disagreement_score":0.009209871,"about_ca_system_score_codex":0.0014533057,"about_ca_system_score_gemma":0.0015049207,"threshold_uncertainty_score":0.013136685},"labels":[],"label_agreement":null},{"id":"W4406577037","doi":"10.1016/s1544-8800(11)70320-7","title":"10.1016/s1544-8800(11)70320-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cloud computing; Computer science","score_opus":0.025632120920001538,"score_gpt":0.21127035574530703,"score_spread":0.1856382348253055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577037","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039634507,0.00046766872,0.0007432626,0.00047233023,0.00025964703,0.000092166396,0.001227083,0.0010453911,0.9952962],"genre_scores_gemma":[0.0006476684,0.0002034144,0.0003414574,0.00021846293,0.00005986906,0.000050604685,0.00045266768,0.00016183419,0.99786407],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936,0.000051994455,0.00005478641,0.00021768508,0.00018342481,0.00013207977],"domain_scores_gemma":[0.9979735,0.00060944783,0.00017682744,0.00027558554,0.0003525149,0.0006121195],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010515292,0.0025286507,0.0017865202,0.0028252471,0.0018042756,0.0039363382,0.0028715653,0.005990239,0.9893171],"category_scores_gemma":[0.001996059,0.0009960348,0.0012095453,0.0028925515,0.0016723562,0.0057215,0.0031295177,0.0027480295,0.9926132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027444176,0.00018947183,0.0007731789,0.0005003274,0.000030866602,0.0001856679,0.00006987171,0.00051163626,0.0015467951,0.006191292,0.38453975,0.6051867],"study_design_scores_gemma":[0.000056473877,0.0000890054,0.00077987777,0.00032207518,0.000014013916,0.00023569458,0.00009002624,0.00030420008,0.00040502456,0.0008520412,0.9968267,0.000024716754],"about_ca_topic_score_codex":0.0039409664,"about_ca_topic_score_gemma":0.0031731306,"teacher_disagreement_score":0.010682881,"about_ca_system_score_codex":0.0012790315,"about_ca_system_score_gemma":0.0012155587,"threshold_uncertainty_score":0.015237808},"labels":[],"label_agreement":null},{"id":"W4406577073","doi":"10.1016/s1544-8800(12)70062-3","title":"10.1016/s1544-8800(12)70062-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"TOPS; Medicine; Internal medicine; Cardiology; Mathematics; Geometry","score_opus":0.027668782084862974,"score_gpt":0.20923693613771624,"score_spread":0.18156815405285326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577073","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004268954,0.0004479578,0.0007739519,0.00042313398,0.00026941265,0.00010060142,0.0011838234,0.0010345767,0.9953395],"genre_scores_gemma":[0.0006378535,0.00019449322,0.00035660117,0.00020336795,0.000060279468,0.000051715575,0.000437004,0.00015893175,0.9978998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993414,0.000050503506,0.000053955882,0.00024078669,0.0001780236,0.00013526798],"domain_scores_gemma":[0.9980919,0.0005545887,0.0001487697,0.0002647159,0.00034388958,0.0005961975],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010395581,0.0026663672,0.0019008078,0.0028205425,0.0020128454,0.003943097,0.0030251758,0.0060642436,0.989921],"category_scores_gemma":[0.0018751792,0.0010316805,0.0013312617,0.0029187307,0.0017915546,0.0058031594,0.0032111227,0.0028256264,0.9931619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033229118,0.00021350023,0.00084782345,0.0005724197,0.00003452475,0.00021705449,0.00008422258,0.0005222405,0.0017483501,0.0063777887,0.36893442,0.6201154],"study_design_scores_gemma":[0.000061685474,0.00010176918,0.0007614666,0.0003213689,0.000015199985,0.00027066877,0.00009944337,0.00030444533,0.00040975845,0.00080765865,0.99682105,0.000025519961],"about_ca_topic_score_codex":0.0037860835,"about_ca_topic_score_gemma":0.0031182412,"teacher_disagreement_score":0.010079026,"about_ca_system_score_codex":0.0012473596,"about_ca_system_score_gemma":0.0011500804,"threshold_uncertainty_score":0.014376402},"labels":[],"label_agreement":null},{"id":"W4406577317","doi":"10.1016/s1544-8800(10)70057-9","title":"10.1016/s1544-8800(10)70057-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cardiology; Psychiatry","score_opus":0.027131316626220314,"score_gpt":0.21248002331367394,"score_spread":0.18534870668745362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577317","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043939415,0.0005017964,0.0007155746,0.00045136793,0.0002936869,0.00009835479,0.001142348,0.0009821915,0.9953753],"genre_scores_gemma":[0.0006647563,0.00022492201,0.00036786418,0.0002319401,0.00006671438,0.000055888875,0.00046283138,0.00016026892,0.9977648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993051,0.0000528181,0.000059073922,0.00025297285,0.00018521272,0.00014473352],"domain_scores_gemma":[0.99797314,0.0005937728,0.00015832635,0.0002800919,0.00035330132,0.0006413263],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010635701,0.0027500705,0.0018538842,0.0027416863,0.0019758833,0.003885401,0.0030749224,0.0063763373,0.9899492],"category_scores_gemma":[0.0019271565,0.001046153,0.0013294447,0.0028153718,0.0017963432,0.0059074135,0.0031764188,0.0028663396,0.9930823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033085918,0.00021673899,0.00084567734,0.00057635544,0.000033138003,0.00021367964,0.00008156345,0.0005097862,0.001645122,0.0058316994,0.37024498,0.6194704],"study_design_scores_gemma":[0.0000661128,0.00010317622,0.0008213152,0.00035423393,0.000015952008,0.00028837338,0.000101932565,0.00030628964,0.00041542918,0.0008640471,0.9966366,0.000026464813],"about_ca_topic_score_codex":0.0038324997,"about_ca_topic_score_gemma":0.003111205,"teacher_disagreement_score":0.010050774,"about_ca_system_score_codex":0.0012559084,"about_ca_system_score_gemma":0.0011910219,"threshold_uncertainty_score":0.014336109},"labels":[],"label_agreement":null},{"id":"W4406577396","doi":"10.1016/s1544-8800(10)70220-7","title":"10.1016/s1544-8800(10)70220-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Advertising; Marketing","score_opus":0.02722052396972117,"score_gpt":0.2122894372475023,"score_spread":0.18506891327778113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577396","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003926415,0.00046122068,0.00064940215,0.00042527608,0.0002652459,0.00008916746,0.00113126,0.0009852333,0.9956006],"genre_scores_gemma":[0.0006479133,0.00020872138,0.00032188807,0.00020880857,0.00006307407,0.00004938136,0.00045226485,0.00016375918,0.9978841],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932575,0.000054237335,0.000055770415,0.00023949289,0.00018609456,0.00013865452],"domain_scores_gemma":[0.9978357,0.0006566173,0.0001705464,0.00028970357,0.00038682515,0.00066060387],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010370659,0.0026139314,0.0018340024,0.0028155006,0.0018794896,0.0038895851,0.0030149065,0.0059567415,0.9898358],"category_scores_gemma":[0.0019481425,0.0009792644,0.0012599071,0.002907321,0.0016790952,0.005584039,0.0032505146,0.0027190142,0.9930687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000304256,0.00019658,0.00078181224,0.00054033374,0.000030731084,0.00019013291,0.00007536353,0.00051102595,0.0015947737,0.005698608,0.3843042,0.60577226],"study_design_scores_gemma":[0.00006051502,0.000097620796,0.0007843618,0.00032060992,0.000014284534,0.0002467552,0.000093440474,0.00030090523,0.00040287923,0.0007972628,0.9968568,0.000024642937],"about_ca_topic_score_codex":0.0038255865,"about_ca_topic_score_gemma":0.0030240503,"teacher_disagreement_score":0.010164201,"about_ca_system_score_codex":0.0012535003,"about_ca_system_score_gemma":0.0011925583,"threshold_uncertainty_score":0.014497995},"labels":[],"label_agreement":null},{"id":"W4406578574","doi":"10.1016/s1541-9800(11)70561-0","title":"10.1016/s1541-9800(11)70561-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Drug; Business; Medicine; Pharmacology","score_opus":0.025921668061136226,"score_gpt":0.21129178116410732,"score_spread":0.1853701131029711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578574","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036309534,0.0003947905,0.0007670608,0.00043569945,0.00025468133,0.00008650507,0.0010557376,0.00095036137,0.9956921],"genre_scores_gemma":[0.00060075783,0.00019593182,0.00036109966,0.00020522515,0.00005711073,0.0000472974,0.00043111932,0.00016135382,0.9979401],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993925,0.000048450114,0.00005101165,0.00020576762,0.00018418505,0.00011808883],"domain_scores_gemma":[0.9980507,0.00055963063,0.0001583826,0.00028604295,0.0003453342,0.0005998574],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010103908,0.0022949718,0.0015738768,0.0026751629,0.0016350228,0.0038932299,0.0026855385,0.005581553,0.9890281],"category_scores_gemma":[0.001964437,0.0009196772,0.0011938262,0.0027476626,0.001462938,0.005526696,0.002983833,0.002578394,0.99220604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022513651,0.00018371915,0.00075370196,0.0004668515,0.000027911172,0.00017038724,0.00006831045,0.000476275,0.0014841788,0.0063573234,0.37346074,0.6163255],"study_design_scores_gemma":[0.00004232975,0.0000724698,0.0006861329,0.00028063063,0.000011752048,0.0002151573,0.000078333054,0.00026062282,0.00035966805,0.00078658503,0.99718434,0.000021888272],"about_ca_topic_score_codex":0.00370083,"about_ca_topic_score_gemma":0.0028459786,"teacher_disagreement_score":0.010971904,"about_ca_system_score_codex":0.0011708691,"about_ca_system_score_gemma":0.0011645074,"threshold_uncertainty_score":0.015650034},"labels":[],"label_agreement":null},{"id":"W4406578755","doi":"10.1016/s1544-8800(05)70501-7","title":"10.1016/s1544-8800(05)70501-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Restructuring; Drug; Business; Medicine; Pharmacology; Finance","score_opus":0.02627010568766792,"score_gpt":0.2124217790510539,"score_spread":0.18615167336338598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578755","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042450032,0.0004848122,0.0007470547,0.0005253087,0.0002880474,0.000088929715,0.0012026804,0.0010819045,0.9951568],"genre_scores_gemma":[0.00066244527,0.00019013543,0.0003096497,0.00021312322,0.000058714897,0.000042730662,0.00044939326,0.00015636295,0.99791735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99938583,0.00005094092,0.00005257204,0.00020963259,0.0001731982,0.00012780301],"domain_scores_gemma":[0.9978593,0.00061770075,0.00017801524,0.0002960732,0.00042132006,0.00062748016],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010199293,0.0023186412,0.0017053037,0.0026180034,0.0018175287,0.0041215895,0.0027248543,0.005868759,0.98901176],"category_scores_gemma":[0.0020111948,0.00092072494,0.0011710676,0.0028157695,0.0015824686,0.0054298164,0.0028998966,0.002632678,0.99258465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026324546,0.0001816216,0.0007835013,0.00045556884,0.000029627656,0.00017171237,0.00007226145,0.0004567979,0.0015149676,0.006102499,0.38508764,0.6048806],"study_design_scores_gemma":[0.000050923692,0.000083231265,0.00076217565,0.00028196225,0.000014020907,0.00021981765,0.0000901999,0.00029621023,0.00040583263,0.00082314847,0.9969502,0.000022319251],"about_ca_topic_score_codex":0.003954866,"about_ca_topic_score_gemma":0.0029573839,"teacher_disagreement_score":0.0109882355,"about_ca_system_score_codex":0.001226823,"about_ca_system_score_gemma":0.0012643303,"threshold_uncertainty_score":0.01567328},"labels":[],"label_agreement":null},{"id":"W4406578958","doi":"10.1016/s1544-8800(06)70590-5","title":"10.1016/s1544-8800(06)70590-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Business; Internal medicine","score_opus":0.026186897944017806,"score_gpt":0.21198253377700163,"score_spread":0.18579563583298384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578958","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044316653,0.00046217936,0.00077971315,0.00051382603,0.00027473844,0.00009818127,0.0012279899,0.0010967425,0.99510336],"genre_scores_gemma":[0.000680697,0.00018559957,0.00034350043,0.00021960076,0.000057568108,0.000045939247,0.0004471958,0.0001624487,0.9978575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993656,0.00005379657,0.000053905347,0.00021886827,0.00017560214,0.00013229607],"domain_scores_gemma":[0.99787617,0.000606839,0.00017138994,0.00029540382,0.00040961435,0.0006406044],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010584545,0.0023561832,0.0017036096,0.0026300724,0.0017876576,0.00395263,0.0027284357,0.005597556,0.98956656],"category_scores_gemma":[0.0020056628,0.00091475964,0.0011965506,0.0028098112,0.0016195918,0.005421937,0.0029114322,0.0026431684,0.99295336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000268611,0.00018693194,0.0008108909,0.00045333838,0.000030878924,0.0001758265,0.00007273817,0.00047160327,0.001503452,0.005866039,0.3803576,0.60980207],"study_design_scores_gemma":[0.000052234227,0.00008432464,0.0007677015,0.00029144832,0.000013883881,0.00022199049,0.00008980833,0.00029636623,0.000394238,0.00076648744,0.99699867,0.000022920445],"about_ca_topic_score_codex":0.0039919615,"about_ca_topic_score_gemma":0.003156409,"teacher_disagreement_score":0.010433435,"about_ca_system_score_codex":0.0012304485,"about_ca_system_score_gemma":0.0012110925,"threshold_uncertainty_score":0.0148819685},"labels":[],"label_agreement":null},{"id":"W4406579626","doi":"10.1016/s1541-9800(07)70169-2","title":"10.1016/s1541-9800(07)70169-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Spiral (railway); Computer science; Risk analysis (engineering); Medicine; Engineering; Mechanical engineering","score_opus":0.02666217223257894,"score_gpt":0.2128706147667031,"score_spread":0.18620844253412416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579626","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043618883,0.00041984167,0.00070226216,0.00048169206,0.0002895658,0.00009679307,0.0011471454,0.00095467217,0.99547184],"genre_scores_gemma":[0.0006607006,0.00019342283,0.000366879,0.0002468905,0.00006212941,0.000051200215,0.0004821161,0.00016503014,0.99777156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993387,0.0000534265,0.000053467476,0.0002389416,0.00017953286,0.00013593919],"domain_scores_gemma":[0.9980124,0.0005658569,0.00014740748,0.00026251623,0.00039152018,0.00062025076],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010455841,0.0025581245,0.0017065526,0.0025788355,0.0019802114,0.00408344,0.0028105755,0.00579503,0.98977834],"category_scores_gemma":[0.0018974725,0.0010052267,0.0012848935,0.0027790293,0.0017006868,0.0058561983,0.0030628664,0.0027989433,0.99291366],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029797974,0.00020874866,0.0009395769,0.0005277364,0.000031738888,0.0002099839,0.00008687996,0.00047712802,0.001669846,0.006358172,0.393203,0.59598917],"study_design_scores_gemma":[0.000054433884,0.000088706656,0.00074340636,0.00030284614,0.000013717638,0.0002559418,0.0001011576,0.00027778774,0.00037802104,0.0007717769,0.9969879,0.00002435147],"about_ca_topic_score_codex":0.0038761862,"about_ca_topic_score_gemma":0.0031797108,"teacher_disagreement_score":0.01022166,"about_ca_system_score_codex":0.0012248883,"about_ca_system_score_gemma":0.0012889225,"threshold_uncertainty_score":0.014579952},"labels":[],"label_agreement":null},{"id":"W4406579791","doi":"10.1016/s1541-9800(07)70660-9","title":"10.1016/s1541-9800(07)70660-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Class (philosophy); Drug; Drug class; Over-the-counter; Computer science; Artificial intelligence; Medicine; Pharmacology; Medical prescription","score_opus":0.026666071456422687,"score_gpt":0.21279161187513104,"score_spread":0.18612554041870835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579791","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004475834,0.00046702576,0.0007167176,0.0005452222,0.000296517,0.000095953525,0.0012395474,0.0010163337,0.9951751],"genre_scores_gemma":[0.00066937844,0.00020620489,0.00034848403,0.00025545288,0.00006306143,0.00004973596,0.00049424486,0.00016471474,0.9977488],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993667,0.000051863266,0.00005465219,0.00022300551,0.00017411319,0.0001296644],"domain_scores_gemma":[0.9979527,0.0005911266,0.00016432442,0.0002735322,0.00039635116,0.0006219527],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010508787,0.002418676,0.0016920957,0.002541684,0.0017711334,0.0040591178,0.0026694022,0.0058046835,0.98948205],"category_scores_gemma":[0.0019569555,0.0009597318,0.0012001324,0.0028396284,0.0016503715,0.005614784,0.0029215906,0.002843587,0.99285454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002649804,0.00019690374,0.0008599308,0.00048770735,0.000030436397,0.00018841944,0.00007801495,0.00045245598,0.0015713703,0.005900669,0.39431864,0.5956505],"study_design_scores_gemma":[0.000054024033,0.0000839198,0.0008080785,0.00031215366,0.0000144577525,0.0002410492,0.00009903164,0.0002867585,0.00039456284,0.0008146847,0.9968671,0.000024153256],"about_ca_topic_score_codex":0.0037313993,"about_ca_topic_score_gemma":0.0029279317,"teacher_disagreement_score":0.010517955,"about_ca_system_score_codex":0.0011735327,"about_ca_system_score_gemma":0.0012588383,"threshold_uncertainty_score":0.015002489},"labels":[],"label_agreement":null},{"id":"W4406579854","doi":"10.1016/s1541-9800(05)70839-5","title":"10.1016/s1541-9800(05)70839-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medical prescription; Prescription drug; Medicine; Family medicine; Internet privacy; Business; Pharmacology; Computer science","score_opus":0.026363787988863224,"score_gpt":0.21255457446099763,"score_spread":0.1861907864721344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579854","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048108122,0.0004976951,0.0007892075,0.00054198055,0.00031300908,0.00009836464,0.0012096232,0.0010553232,0.9950138],"genre_scores_gemma":[0.00074040215,0.0002052366,0.00037020992,0.0002497211,0.00006479506,0.000049902752,0.00049716234,0.0001684475,0.99765414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99934655,0.000054007745,0.000056575558,0.00022939012,0.00017724915,0.00013615382],"domain_scores_gemma":[0.99785703,0.0006198792,0.00017389593,0.00029572035,0.00042272249,0.00063063245],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010619386,0.0023891234,0.0017256784,0.002594195,0.0018533284,0.0040314402,0.0028534161,0.005933119,0.98904675],"category_scores_gemma":[0.0019944962,0.00092527294,0.0012382428,0.0028375739,0.0015898879,0.005706562,0.0029281098,0.0027923908,0.9926824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029482992,0.00020750682,0.0008896838,0.0005116274,0.000032847005,0.00019922687,0.00008215241,0.00046475802,0.0016789327,0.0063375006,0.36403447,0.6252665],"study_design_scores_gemma":[0.000054113832,0.00009234088,0.00081178686,0.00032034138,0.000014940772,0.00024688616,0.00009636599,0.00029680468,0.00041867545,0.00086512265,0.9967583,0.000024265242],"about_ca_topic_score_codex":0.00359952,"about_ca_topic_score_gemma":0.0027802095,"teacher_disagreement_score":0.010953248,"about_ca_system_score_codex":0.0011734583,"about_ca_system_score_gemma":0.0012382234,"threshold_uncertainty_score":0.01562345},"labels":[],"label_agreement":null},{"id":"W4406580593","doi":"10.1016/s1541-9800(06)71251-0","title":"10.1016/s1541-9800(06)71251-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacology","score_opus":0.026268584284418826,"score_gpt":0.2119329118657042,"score_spread":0.18566432758128537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406580593","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040672376,0.00037340145,0.00076603517,0.0004691393,0.00025569025,0.00009430021,0.0010710697,0.0010096024,0.99555403],"genre_scores_gemma":[0.0006252634,0.00016449216,0.00036391168,0.00021066675,0.000052839147,0.000045649296,0.0004425438,0.00015730479,0.9979373],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999373,0.000056529378,0.00005338993,0.00021074603,0.00018204055,0.00012436445],"domain_scores_gemma":[0.99795663,0.000575721,0.00015172458,0.00029993776,0.00039249417,0.00062357116],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010441203,0.002160146,0.001506054,0.002472322,0.0016646453,0.0038587474,0.0026294882,0.0055359676,0.9895494],"category_scores_gemma":[0.0020209576,0.0008705018,0.0011872657,0.002594221,0.0014391456,0.0052189026,0.002780075,0.002500488,0.99237907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002378036,0.00018360272,0.0007814163,0.00043857488,0.00002711557,0.00016665914,0.00007120874,0.00042501322,0.0014113868,0.0062598945,0.37010232,0.6198949],"study_design_scores_gemma":[0.000044672648,0.000074836156,0.00071194756,0.00025878756,0.000011786114,0.00021083369,0.00008061109,0.00024742738,0.00034783696,0.00073623116,0.99725384,0.000021208267],"about_ca_topic_score_codex":0.0037980205,"about_ca_topic_score_gemma":0.00295246,"teacher_disagreement_score":0.010450602,"about_ca_system_score_codex":0.0011324519,"about_ca_system_score_gemma":0.0011943175,"threshold_uncertainty_score":0.014906406},"labels":[],"label_agreement":null},{"id":"W4406653031","doi":"10.1016/b978-0-7020-7005-1.00056-3","title":"10.1016/b978-0-7020-7005-1.00056-3","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmaceutics; Medicine; Pharmacology","score_opus":0.0326948860166008,"score_gpt":0.20874598089232527,"score_spread":0.17605109487572446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406653031","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019177387,0.00049645395,0.0016680531,0.00042093176,0.0001664442,0.00005680113,0.0011914878,0.0013932036,0.9944148],"genre_scores_gemma":[0.00062579085,0.0002809452,0.0005398115,0.00013120717,0.000040774907,0.000040232626,0.0006019751,0.00030108728,0.9974381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99944395,0.000037911967,0.00003703105,0.00019899679,0.0001891115,0.00009297113],"domain_scores_gemma":[0.9979208,0.000708766,0.00016908714,0.0003495727,0.00036037125,0.0004915039],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010922805,0.0021437195,0.0016043237,0.0020674074,0.0011563005,0.0047299624,0.0028247612,0.0045359936,0.9809472],"category_scores_gemma":[0.0022161945,0.000899752,0.00088884734,0.002289821,0.0011386111,0.0051169177,0.0030969337,0.0023731873,0.9909944],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011922721,0.00012245217,0.00035409033,0.00035515902,0.000015594513,0.00008915989,0.000060998766,0.00043721235,0.0016048251,0.007140451,0.3556721,0.6340287],"study_design_scores_gemma":[0.000019094361,0.000037795737,0.00046290047,0.00024082688,0.000008242874,0.0001636824,0.000057078352,0.00019158397,0.00031894215,0.0016604889,0.9968257,0.000013781514],"about_ca_topic_score_codex":0.0032459511,"about_ca_topic_score_gemma":0.0027160922,"teacher_disagreement_score":0.019052804,"about_ca_system_score_codex":0.001093105,"about_ca_system_score_gemma":0.0009222337,"threshold_uncertainty_score":0.0271765},"labels":[],"label_agreement":null},{"id":"W4406660250","doi":"10.1525/gp.2025.127997","title":"The Inequitable Access to Vaccines and Medicines in Africa: A Critical Review of the African Pharmaceutical Technology Foundation (APTF)","year":2025,"lang":"en","type":"review","venue":"Global Perspectives","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Foundation (evidence); Access to medicines; Medicine; Political science; Engineering ethics; Engineering; Law; Intellectual property","score_opus":0.12031864409570749,"score_gpt":0.42761216014910686,"score_spread":0.3072935160533994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406660250","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049801285,0.99746084,0.000026509519,0.0019967763,0.00014437207,0.0000019574436,0.0000060108177,6.035882e-7,0.00031318812],"genre_scores_gemma":[0.0014195013,0.99752706,0.000067808825,0.00071108295,0.00018154978,0.0000053549675,0.0000062029085,8.0434944e-7,0.00008058489],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791795,0.00095630734,0.00027634104,0.00015747102,0.0005476804,0.00014418774],"domain_scores_gemma":[0.9879897,0.009867852,0.0007572892,0.000105356055,0.0011066811,0.00017307918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064276396,0.0007772993,0.0014874862,0.0042506615,0.0006281024,0.0022778441,0.00074154825,0.0023077398,0.002369262],"category_scores_gemma":[0.0141910855,0.0004674218,0.00071023975,0.0053549516,0.0015754912,0.0030596675,0.0010669312,0.0031376905,0.00039583133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096301716,0.000066546454,0.00038902494,0.08512353,0.00035191592,0.00022278188,0.0005862799,0.0007407666,0.000350447,0.07931789,0.084648855,0.7481057],"study_design_scores_gemma":[0.000023784918,0.00010255579,0.0016710873,0.09560851,0.00035390182,0.0004190823,0.00055757817,0.00018003478,0.00023228703,0.011579481,0.88924015,0.000031534517],"about_ca_topic_score_codex":0.006557797,"about_ca_topic_score_gemma":0.012201826,"teacher_disagreement_score":0.006557797,"about_ca_system_score_codex":0.0031675387,"about_ca_system_score_gemma":0.009999182,"threshold_uncertainty_score":0.033993065},"labels":[],"label_agreement":null},{"id":"W4406731639","doi":"10.1101/2025.01.21.25320791","title":"Modelling the impact of changes to prescription medicine cost-sharing schemes among middle aged and older adults","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medical prescription; Gerontology; Medicine; Nursing","score_opus":0.1245899008535493,"score_gpt":0.3228488154196551,"score_spread":0.19825891456610578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406731639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623053,0.0008553888,0.009013944,0.0027207467,0.00015291572,0.00044107588,0.011616785,0.0001203718,0.012773432],"genre_scores_gemma":[0.98995143,0.00026647185,0.0032839677,0.0002767447,0.000024647097,0.00027898623,0.0020573589,0.000021967877,0.0038383938],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99837106,0.000822878,0.000097659125,0.00023792456,0.00011920752,0.00035115148],"domain_scores_gemma":[0.9954627,0.0030075177,0.00054469233,0.00018723952,0.00040799676,0.0003898408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002867618,0.0007628422,0.0008499706,0.0009027403,0.0003232195,0.001913835,0.001861862,0.002145695,0.010248617],"category_scores_gemma":[0.012440499,0.0006229645,0.0025771519,0.0012820855,0.0005601149,0.0016418463,0.0015704025,0.0017975483,0.0006488192],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070564914,0.00034864905,0.043251738,0.0003151765,0.00037913374,0.00021416521,0.00024587297,0.93721014,0.0003183672,0.0068592634,0.002073426,0.008078422],"study_design_scores_gemma":[0.0005502754,0.0007766072,0.040839728,0.0002565765,0.0004025079,0.000097285396,0.0008273092,0.9384809,0.00032454793,0.008805594,0.008545771,0.00009289971],"about_ca_topic_score_codex":0.114743434,"about_ca_topic_score_gemma":0.0677905,"teacher_disagreement_score":0.114743434,"about_ca_system_score_codex":0.0051239184,"about_ca_system_score_gemma":0.0033347523,"threshold_uncertainty_score":0.22815114},"labels":[],"label_agreement":null},{"id":"W4406774139","doi":"10.1007/978-981-99-4566-5_4","title":"Application of Technology in Sub-Saharan Africa: The Rwandan Healthcare System Experience","year":2024,"lang":"en","type":"book-chapter","venue":"Translational systems sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Collège Boréal","funders":"","keywords":"Healthcare system; Health care; Geography; Computer science; Economic growth; Economics","score_opus":0.08452655635681565,"score_gpt":0.2960653719225102,"score_spread":0.21153881556569454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406774139","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81889844,0.043774266,0.0004351231,0.04035176,0.0004333596,0.00011637381,0.00029275968,0.000021967322,0.09567598],"genre_scores_gemma":[0.9335002,0.04739905,0.0007163118,0.0025979865,0.00013292913,0.00008319381,0.000080940146,0.000025592904,0.015463885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989458,0.00052492926,0.00004152122,0.00002690159,0.0000739948,0.00038692862],"domain_scores_gemma":[0.9989267,0.00055602315,0.00019536592,0.000026182459,0.00006697859,0.00022874946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019758493,0.00025022324,0.00019741849,0.00048026314,0.0014746673,0.0026916577,0.00040977134,0.00066587905,0.0037996576],"category_scores_gemma":[0.00264027,0.00019602185,0.00014564118,0.0016589984,0.0013075287,0.0018363729,0.0024284613,0.0011001319,0.00045102913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046782033,0.00059383194,0.07752214,0.0020644814,0.00009171553,0.016561046,0.2976172,0.0013956416,0.0050900183,0.117697656,0.04968219,0.43121624],"study_design_scores_gemma":[0.0000791112,0.00054220634,0.16897018,0.0024718384,0.00008572138,0.006699776,0.21388145,0.00043724137,0.0014847624,0.005519987,0.5997676,0.00006006158],"about_ca_topic_score_codex":0.013538128,"about_ca_topic_score_gemma":0.035958298,"teacher_disagreement_score":0.013538128,"about_ca_system_score_codex":0.0029161104,"about_ca_system_score_gemma":0.0060134777,"threshold_uncertainty_score":0.02691865},"labels":[],"label_agreement":null},{"id":"W4406811012","doi":"","title":"Methods for the comparative evaluation of pharmaceuticals","year":2005,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.797716233771923,"score_gpt":0.710190704503193,"score_spread":0.08752552926873003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406811012","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063869944,0.055726957,0.7673383,0.004900227,0.0037918526,0.04788433,0.02110808,0.0013715811,0.09149179],"genre_scores_gemma":[0.045010466,0.014049135,0.8146498,0.0012510656,0.0009738311,0.11147097,0.0069735055,0.00037637365,0.0052447696],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.58963555,0.31189176,0.039925676,0.014207908,0.042656526,0.0016826468],"domain_scores_gemma":[0.49311918,0.38591897,0.028882913,0.05518955,0.035660047,0.0012294451],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.22756661,0.0030929528,0.00562833,0.032281294,0.0021549903,0.009212551,0.0051481295,0.0034764775,0.047452644],"category_scores_gemma":[0.4072839,0.000996639,0.008139274,0.031245295,0.0049681417,0.009025784,0.008558071,0.0037013977,0.0055006514],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021316686,0.00036619962,0.0044903397,0.052942447,0.005705329,0.0002577492,0.0036185458,0.0037346394,0.0008253294,0.2978921,0.026059879,0.60197574],"study_design_scores_gemma":[0.0014869957,0.0016295554,0.015054436,0.031727992,0.005895617,0.00055440766,0.0038572934,0.008110217,0.0028162717,0.3597403,0.568665,0.0004619033],"about_ca_topic_score_codex":0.002447969,"about_ca_topic_score_gemma":0.0021739192,"teacher_disagreement_score":0.7724334,"about_ca_system_score_codex":0.0067475205,"about_ca_system_score_gemma":0.017432738,"threshold_uncertainty_score":0.9525479},"labels":[],"label_agreement":null},{"id":"W4406829526","doi":"10.1186/s12872-024-04411-y","title":"Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes","year":2025,"lang":"en","type":"article","venue":"BMC Cardiovascular Disorders","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Disease; Angiology; Heart disease; Essential medicines; Mortality rate; Intensive care medicine; Environmental health; Emergency medicine; Internal medicine; Public health; Pathology","score_opus":0.012704913442558106,"score_gpt":0.2463618022628229,"score_spread":0.23365688882026478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406829526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99517006,0.00097858,0.00018166052,0.00048591054,0.000013252516,0.000007045698,0.002242882,0.000010944191,0.0009096858],"genre_scores_gemma":[0.99836546,0.00016124842,0.00006692698,0.000036837213,0.000013225427,0.000004558888,0.0011930313,0.0000024306348,0.00015627003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986524,0.0005009652,0.00016032338,0.0002690802,0.00016024253,0.00025700752],"domain_scores_gemma":[0.98340976,0.0035711287,0.011054621,0.00051747146,0.00068711775,0.00076001027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023690194,0.00015698954,0.0002730898,0.001544227,0.00019014627,0.0011517237,0.00038407475,0.0005350648,0.0030412034],"category_scores_gemma":[0.00939338,0.00018840165,0.0007268965,0.0035129504,0.00041730763,0.00084190926,0.0009423546,0.0007400658,0.00032734266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000781404,0.000019003808,0.9974573,0.000015799955,0.00010584462,0.00003338394,0.00009236722,0.00021417608,0.000030443593,0.00006334361,0.00023982009,0.0016503505],"study_design_scores_gemma":[0.0000025036754,0.000028664881,0.9992461,0.000010973057,0.000019576462,0.000043816108,0.00016990094,0.00025671138,0.000014600878,0.000035310564,0.00016904953,0.000002813275],"about_ca_topic_score_codex":0.012475169,"about_ca_topic_score_gemma":0.0072642663,"teacher_disagreement_score":0.012475169,"about_ca_system_score_codex":0.0005101237,"about_ca_system_score_gemma":0.00036736848,"threshold_uncertainty_score":0.024805069},"labels":[],"label_agreement":null},{"id":"W4406843692","doi":"10.1016/j.ekir.2024.11.1225","title":"WCN25-19 THE IMPACT OF PUBLIC-PRIVATE PARTNERSHIP (PPP) IN NEPHROLOGY OF LOW-INCOME COUNTRIES (LIC), CASE OF RWANDA","year":2025,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Inland Hospital","funders":"","keywords":"Medicine; General partnership; Public–private partnership; Nephrology; Internal medicine; Family medicine; Economic growth; Finance; Economics","score_opus":0.042343939961860866,"score_gpt":0.3448422649274905,"score_spread":0.3024983249656296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406843692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4709679,0.0057242513,0.0017150462,0.11392006,0.0006327853,0.00017367188,0.00045242216,0.00003493606,0.40637892],"genre_scores_gemma":[0.977842,0.0012466823,0.0003264559,0.0024324628,0.00008276247,0.000041117022,0.000050398434,0.000009044225,0.017969053],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99742293,0.000855551,0.000045548426,0.000095685304,0.00020693625,0.0013734766],"domain_scores_gemma":[0.9984585,0.00045112782,0.00026280998,0.00007239899,0.00023422511,0.0005209308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021935846,0.00017422193,0.00018854794,0.0005927921,0.0025039895,0.0043091276,0.00034795777,0.0016447994,0.00975196],"category_scores_gemma":[0.004450701,0.00012524815,0.00027519828,0.0007242993,0.0018919674,0.0015014819,0.0025727027,0.0018671846,0.000462664],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023513129,0.00019218019,0.05539035,0.00035703366,0.000062434505,0.017589351,0.006391489,0.0015506587,0.0011090781,0.7968456,0.061017774,0.05925897],"study_design_scores_gemma":[0.00015797801,0.00043357554,0.18972757,0.0020809085,0.00015088821,0.010199063,0.03537725,0.003458002,0.0013599368,0.0810968,0.67585284,0.000105226005],"about_ca_topic_score_codex":0.035156928,"about_ca_topic_score_gemma":0.03747858,"teacher_disagreement_score":0.035156928,"about_ca_system_score_codex":0.00470368,"about_ca_system_score_gemma":0.0075581423,"threshold_uncertainty_score":0.069904625},"labels":[],"label_agreement":null},{"id":"W4406955750","doi":"10.1093/ofid/ofae631.153","title":"501. Impact of Implementation of World Health Organization (WHO) National Action Plans (NAP) on Antibiotic Rates: A Time Series Analysis of 38 Countries","year":2025,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Nap; Action (physics); Series (stratigraphy); Gerontology","score_opus":0.030685544137812968,"score_gpt":0.3797908788430524,"score_spread":0.3491053347052394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406955750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625456,0.00021280642,0.00028104812,0.000103272294,0.000013470331,0.000025724705,0.0025989988,0.000013739535,0.00049648597],"genre_scores_gemma":[0.9969392,0.000077137745,0.00021581125,0.000023848168,0.000008007197,0.000029097146,0.0025126322,0.0000054592724,0.00018885481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974126,0.0011181483,0.00025398794,0.0005431905,0.00029717037,0.00037493804],"domain_scores_gemma":[0.9928316,0.0024778969,0.00302078,0.0005605484,0.00066374,0.00044547333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043683304,0.0003943419,0.0004307833,0.0010356461,0.00028699933,0.0010420202,0.00052684627,0.00050976593,0.002201842],"category_scores_gemma":[0.008729691,0.00034875635,0.0017247391,0.0019132784,0.0003823885,0.00075642706,0.0009903215,0.0010737998,0.0005030742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014928487,0.00007330508,0.99495935,0.00002572789,0.00035935204,0.000107125554,0.00014281274,0.0013575274,0.00007859494,0.00007110123,0.00048598048,0.0021898437],"study_design_scores_gemma":[0.000014594594,0.00024922471,0.99292105,0.000020756102,0.000094117204,0.00008992811,0.00044265474,0.0053763352,0.000108498,0.000042186097,0.0006289575,0.00001159327],"about_ca_topic_score_codex":0.028095705,"about_ca_topic_score_gemma":0.011065933,"teacher_disagreement_score":0.028095705,"about_ca_system_score_codex":0.0006198003,"about_ca_system_score_gemma":0.0006524415,"threshold_uncertainty_score":0.055864334},"labels":[],"label_agreement":null},{"id":"W4407022977","doi":"10.1080/19460171.2025.2457529","title":"A critique of the moral economy of pharmaceutical development","year":2025,"lang":"en","type":"article","venue":"Critical Policy Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Moral economy; Economics; Economic system; Neoclassical economics; Political science; Positive economics; Sociology; Law; Politics","score_opus":0.1546600620893087,"score_gpt":0.42580587153243804,"score_spread":0.2711458094431294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407022977","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005638603,0.013668044,0.04827488,0.6758386,0.0016961735,0.00010518987,0.00012941376,0.000069627116,0.2545795],"genre_scores_gemma":[0.7116901,0.011661573,0.025698861,0.19407998,0.010477949,0.001040438,0.000074913885,0.00023344209,0.045042798],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.96455187,0.023342976,0.0009465178,0.0027548075,0.006911113,0.0014927384],"domain_scores_gemma":[0.9159979,0.070386514,0.0035824976,0.0042381473,0.004500277,0.0012947425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.041853912,0.0007838793,0.0013031325,0.002069356,0.0053846925,0.011569851,0.0033982995,0.014673951,0.0071547055],"category_scores_gemma":[0.056172777,0.0006957047,0.0016112815,0.0015563826,0.08345113,0.012116915,0.005683721,0.018236337,0.0012739204],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000037725033,0.0000025823454,0.00001925312,0.00001907409,0.0000019221739,0.0000064633086,0.0001484773,0.000097258795,0.000006093249,0.9967878,0.0021617631,0.0007456145],"study_design_scores_gemma":[0.000018491575,0.0000075319454,0.00005942561,0.00009678236,0.0000025458567,0.000017624303,0.00012380233,0.00031693702,0.00004108346,0.96632695,0.03298145,0.00000740653],"about_ca_topic_score_codex":0.004140174,"about_ca_topic_score_gemma":0.0023201683,"teacher_disagreement_score":0.041853912,"about_ca_system_score_codex":0.012153592,"about_ca_system_score_gemma":0.012079478,"threshold_uncertainty_score":0.22134733},"labels":[],"label_agreement":null},{"id":"W4407039729","doi":"10.1177/02698811241301219","title":"Challenges for switching central nervous system and psychiatric medication products: A review of the literature","year":2025,"lang":"en","type":"review","venue":"Journal of Psychopharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Addiction and Mental Health; McGill University; Lakehead University; Royal Ottawa Mental Health Centre; Adler; University of Ottawa; BC Mental Health & Substance Use Services; START Clinic; University of Toronto; NOSM University; University of British Columbia","funders":"Otsuka Pharmaceutical Development and Commercialization; Otsuka Pharmaceutical","keywords":"Central nervous system; Psychiatry; Medicine; Neuroscience; Psychology","score_opus":0.06234756944655868,"score_gpt":0.3709337971838254,"score_spread":0.30858622773726674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407039729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009869962,0.99942636,0.000035261502,0.00021682578,0.000035729765,0.0000047300377,0.00001320444,0.0000012189054,0.00016799236],"genre_scores_gemma":[0.0012569479,0.998428,0.00008885893,0.00012654092,0.00004722698,0.000006651549,0.000013462409,5.840719e-7,0.000031747055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800617,0.00052725425,0.00057465304,0.0002058248,0.0006101651,0.00007598079],"domain_scores_gemma":[0.98691005,0.010439663,0.0016463477,0.00009683825,0.0007866137,0.00012049693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037011995,0.00082584756,0.0024523875,0.005715248,0.00039012343,0.0018682015,0.0012890336,0.001917488,0.0036306544],"category_scores_gemma":[0.013311563,0.0005324721,0.002303059,0.0070205224,0.00063935353,0.0019017815,0.00072841445,0.0011726583,0.00037922055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013045763,0.0000661544,0.0008434312,0.34550023,0.0013334538,0.00024368221,0.00018556644,0.00056891015,0.00019510022,0.003481547,0.012782625,0.6346688],"study_design_scores_gemma":[0.000109894194,0.00028519012,0.009695739,0.5553734,0.009253573,0.0031645785,0.00074998743,0.0005819643,0.00037030692,0.0051371763,0.41517922,0.00009903507],"about_ca_topic_score_codex":0.004951922,"about_ca_topic_score_gemma":0.0077858428,"teacher_disagreement_score":0.005715248,"about_ca_system_score_codex":0.0019610631,"about_ca_system_score_gemma":0.005871072,"threshold_uncertainty_score":0.019574046},"labels":[],"label_agreement":null},{"id":"W4407052318","doi":"10.1186/s12992-024-01092-2","title":"States, global power and access to medicines: a comparative case study of China, India and the United States, 2000–2019","year":2025,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"Norwegian Institute of Public Health; Norges Forskningsråd","keywords":"Social policy; China; Health services research; Public health; Power (physics); Political science; Quality of Life Research; Economic growth; Health policy; Development economics; Socioeconomics; Medicine; Environmental health; Economics; Law; Nursing","score_opus":0.0695027404215106,"score_gpt":0.40318520942417524,"score_spread":0.33368246900266463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407052318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280167,0.00021449727,0.000082460356,0.00064365595,0.000008028882,0.000022357737,0.00022684138,0.0000018931934,0.0059986557],"genre_scores_gemma":[0.99827516,0.0003241618,0.00010095935,0.00013221778,0.0000047406115,0.000026689286,0.00018389965,0.0000025919346,0.00094951136],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99865687,0.0006076139,0.000046752517,0.00006453792,0.00015978375,0.00046444839],"domain_scores_gemma":[0.9973387,0.0014635307,0.000464252,0.00011765996,0.0003199275,0.00029582673],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0020053918,0.00026257083,0.00028391936,0.0029880677,0.003308972,0.002272655,0.00086886145,0.0009909194,0.0036729488],"category_scores_gemma":[0.0044200965,0.0002154088,0.00044053464,0.0068395073,0.0030699363,0.002598648,0.0031248084,0.0013136456,0.00014895064],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048772965,0.0006748573,0.5747335,0.00030081012,0.00017762053,0.018418951,0.31943896,0.0030328608,0.00047136785,0.042580314,0.008722449,0.030960524],"study_design_scores_gemma":[0.000036156936,0.0002095414,0.285694,0.00026338006,0.000071035516,0.0014310776,0.6871054,0.0023938091,0.0004188756,0.0018317435,0.020490836,0.000054149463],"about_ca_topic_score_codex":0.20690432,"about_ca_topic_score_gemma":0.2511283,"teacher_disagreement_score":0.99669105,"about_ca_system_score_codex":0.008848852,"about_ca_system_score_gemma":0.003918937,"threshold_uncertainty_score":0.41140002},"labels":[],"label_agreement":null},{"id":"W4407153016","doi":"10.1080/14479338.2024.2446894","title":"Rethinking medical innovation: organizing R&amp;D, responding to crisis, delivering health services","year":2025,"lang":"en","type":"article","venue":"Innovation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Business; Health services; Knowledge management; Medicine; Environmental health; Computer science","score_opus":0.08358214901746831,"score_gpt":0.35736626304380625,"score_spread":0.27378411402633795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407153016","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001794126,0.052623544,0.005663384,0.85163957,0.078611515,0.000044901317,0.0000607319,0.00011007366,0.009452149],"genre_scores_gemma":[0.13204594,0.18491587,0.02039802,0.21848911,0.42206144,0.00015863833,0.00012448103,0.00037794298,0.021428501],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9835988,0.008345942,0.0011417024,0.0014215988,0.0040391264,0.001452777],"domain_scores_gemma":[0.94355714,0.04060261,0.0044118734,0.0012957111,0.0054757413,0.0046569263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023797419,0.0008260022,0.0011611698,0.0030739796,0.0037684054,0.022841403,0.0026950852,0.013977434,0.004867064],"category_scores_gemma":[0.055532493,0.00059131114,0.001083643,0.0024772272,0.009046535,0.018713439,0.004509542,0.011720307,0.0015345899],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011511596,0.00005640938,0.001205486,0.0013831276,0.00009308657,0.0003605397,0.0024594753,0.001600766,0.0006498388,0.28585762,0.58460134,0.12161717],"study_design_scores_gemma":[0.000034294775,0.000052180556,0.0010932132,0.0008982469,0.000036678608,0.00015916544,0.0020075003,0.001158694,0.0003360121,0.17913713,0.8150182,0.00006873502],"about_ca_topic_score_codex":0.0028538757,"about_ca_topic_score_gemma":0.006000768,"teacher_disagreement_score":0.023797419,"about_ca_system_score_codex":0.0075570554,"about_ca_system_score_gemma":0.015610288,"threshold_uncertainty_score":0.12585431},"labels":[],"label_agreement":null},{"id":"W4407302242","doi":"10.1016/j.pmedr.2025.103004","title":"Sociodemographic variation in experiences with medication shortages among US adults","year":2025,"lang":"en","type":"article","venue":"Preventive Medicine Reports","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; New York University","keywords":"Medicine; Ethnic group; Medical prescription; Educational attainment; Marital status; Cross-sectional study; Demography; Anxiety; Household income; Socioeconomic status; Environmental health; Psychiatry; Population; Geography; Nursing","score_opus":0.01767686836340181,"score_gpt":0.28409588356086996,"score_spread":0.26641901519746813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407302242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804085,0.00023863859,0.00008868727,0.00019682737,0.000007181994,0.000018196917,0.0006888858,0.000002967872,0.00071773934],"genre_scores_gemma":[0.99930465,0.000110515386,0.00007607688,0.000059504237,0.0000068848317,0.000011801006,0.00036658393,8.195671e-7,0.0000631199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992167,0.0002803361,0.00015136648,0.000103722086,0.00014973973,0.000098102966],"domain_scores_gemma":[0.99714166,0.00054437685,0.0016531515,0.00010812395,0.0002412934,0.00031144646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010629826,0.0001132523,0.00018447737,0.000682286,0.0003086472,0.00040042266,0.00023953084,0.00030692705,0.0016004073],"category_scores_gemma":[0.0048504067,0.0001631094,0.00032198432,0.00078075205,0.000285356,0.00046955672,0.00069548195,0.00036003065,0.00012453979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016628397,0.00002138807,0.99804187,0.000015701167,0.000042300628,0.000029315073,0.00040058864,0.000028823753,0.000058449677,0.00002404489,0.00013825575,0.0011825094],"study_design_scores_gemma":[9.94143e-7,0.000019634075,0.9988092,0.000013479614,0.000005272756,0.000064770495,0.0008418307,0.000049197504,0.000012643437,0.000010961828,0.00016998289,0.0000019768158],"about_ca_topic_score_codex":0.011431992,"about_ca_topic_score_gemma":0.016024537,"teacher_disagreement_score":0.011431992,"about_ca_system_score_codex":0.00028156818,"about_ca_system_score_gemma":0.00039840466,"threshold_uncertainty_score":0.022730887},"labels":[],"label_agreement":null},{"id":"W4407394598","doi":"10.1371/journal.pmed.1004540","title":"Predicting patent challenges for small-molecule drugs: A cross-sectional study","year":2025,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"Canada Research Chairs; Arnold Ventures; Commonwealth Fund","keywords":"Scrutiny; Incentive; Business; Prescription drug; Competitor analysis; Biopharmaceutical; Competition (biology); Marketing; Medicine; Medical prescription; Public economics; Actuarial science; Economics; Pharmacology","score_opus":0.22884645656263,"score_gpt":0.3485031722485653,"score_spread":0.1196567156859353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407394598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977397,0.00026119853,0.00033400633,0.00012352367,0.000012545183,0.00004846122,0.0010442095,0.0000046388195,0.00043176624],"genre_scores_gemma":[0.9979527,0.00020812132,0.0003579442,0.000129368,0.00001967324,0.00005099561,0.001123934,0.0000029574219,0.0001543638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974273,0.0009940962,0.0003273842,0.0005399735,0.00046621353,0.0002450143],"domain_scores_gemma":[0.98490566,0.0061649797,0.005672268,0.0010016646,0.0012149231,0.0010403956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006402195,0.00032284376,0.0004831962,0.0010880184,0.0005601368,0.0011683094,0.00074520934,0.0009656344,0.002611223],"category_scores_gemma":[0.013142528,0.0005698978,0.0011416347,0.001496788,0.00039022553,0.0013365995,0.0008415759,0.0017586547,0.0005860905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056932873,0.00015105814,0.9988298,0.000010139664,0.00007823113,0.000018273164,0.000051270603,0.00006779877,0.00001927862,0.000023558972,0.00015011277,0.00054353144],"study_design_scores_gemma":[0.0000292144,0.0005280815,0.9959651,0.000029903718,0.00015062735,0.00018841101,0.0003862114,0.0020638022,0.00006087939,0.00008030953,0.0005059794,0.000011481818],"about_ca_topic_score_codex":0.0054523638,"about_ca_topic_score_gemma":0.0043442477,"teacher_disagreement_score":0.006402195,"about_ca_system_score_codex":0.00052430644,"about_ca_system_score_gemma":0.0008278681,"threshold_uncertainty_score":0.03385842},"labels":[],"label_agreement":null},{"id":"W4407406073","doi":"10.1080/23995270.2025.2466383","title":"Letter in reply: orphan drugs approved in Canada: availability and additional therapeutic value","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Wilfrid Laurier University; Arthur B. McDonald-Canadian Astroparticle Physics Research Institute; Fraser Institute","funders":"","keywords":"Orphan drug; Value (mathematics); Medicine; Mathematics; Biology; Bioinformatics; Statistics","score_opus":0.013255557436094852,"score_gpt":0.22773559034760632,"score_spread":0.21448003291151146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407406073","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015348996,0.0006350816,0.000040027728,0.9847541,0.013463662,0.000007877215,0.00015387661,0.00002120129,0.0007706575],"genre_scores_gemma":[0.0017872414,0.00064329524,0.00011902183,0.98213124,0.012020722,0.000013807716,0.000044518918,0.00002251348,0.0032177237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970914,0.00045612888,0.00037688043,0.00046257192,0.0010948763,0.0005181361],"domain_scores_gemma":[0.9817887,0.006691954,0.00085744134,0.00029983564,0.008070994,0.0022910852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030298952,0.00070126995,0.0018609707,0.0010822625,0.0041457987,0.0037536426,0.0025011862,0.037411585,0.010603219],"category_scores_gemma":[0.033556476,0.0007143799,0.0011543141,0.0013312047,0.0029465186,0.0029522227,0.001172584,0.03390074,0.005600885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002116117,0.000004073101,0.0001953144,0.000020113332,0.000006141126,0.00014284697,0.000028679404,0.000013719698,0.00003213761,0.0004100346,0.99786633,0.0012594442],"study_design_scores_gemma":[0.00009065657,0.00002936588,0.0018069173,0.00030397717,0.000047916154,0.0013280615,0.00049554976,0.00027827633,0.00030062173,0.0031707531,0.992015,0.0001329051],"about_ca_topic_score_codex":0.13436335,"about_ca_topic_score_gemma":0.15876701,"teacher_disagreement_score":0.86563665,"about_ca_system_score_codex":0.011203443,"about_ca_system_score_gemma":0.01941563,"threshold_uncertainty_score":0.26716256},"labels":[],"label_agreement":null},{"id":"W4407406145","doi":"10.1164/rccm.202406-1267rl","title":"Association between Industry Payments and Prescription of Inhaled Medications","year":2025,"lang":"en","type":"letter","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"U.S. Department of Veterans Affairs","keywords":"Medicine; Medical prescription; Payment; Association (psychology); Intensive care medicine; Environmental health; Pharmacology; Finance; Business","score_opus":0.04825964764613834,"score_gpt":0.33299041891708964,"score_spread":0.2847307712709513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407406145","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.413742,0.0040103253,0.00046144915,0.53667367,0.003002276,0.000050810748,0.0050166734,0.00005495618,0.036987826],"genre_scores_gemma":[0.90528595,0.0015378861,0.00031891686,0.071957774,0.007947321,0.000039398576,0.0011521224,0.00001873626,0.011741895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735105,0.0012070633,0.00031341778,0.0002000719,0.0005436983,0.0003847608],"domain_scores_gemma":[0.9262477,0.050799448,0.0114327725,0.0017321893,0.0057072784,0.004080621],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038664476,0.00009088591,0.00036718432,0.0012113998,0.0008874024,0.0015265536,0.0005208282,0.0071419845,0.007711737],"category_scores_gemma":[0.04014394,0.0002652981,0.000600056,0.001826109,0.00052492245,0.0005620884,0.0006075181,0.0050741457,0.0012012772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017117996,0.00030747257,0.9004771,0.000055084958,0.00018980973,0.0016381249,0.00016633677,0.00044978096,0.00024912594,0.0020350537,0.08176706,0.0109532345],"study_design_scores_gemma":[0.0002911596,0.00023275292,0.96615446,0.000112251815,0.00020946916,0.0012987556,0.00064443494,0.004922744,0.0002687519,0.0029320808,0.022886205,0.000046945894],"about_ca_topic_score_codex":0.020965194,"about_ca_topic_score_gemma":0.047226354,"teacher_disagreement_score":0.99613357,"about_ca_system_score_codex":0.0014143437,"about_ca_system_score_gemma":0.0018657473,"threshold_uncertainty_score":0.041686296},"labels":[],"label_agreement":null},{"id":"W4407694825","doi":"10.1136/bmjgh-2024-017788","title":"Public patient forwarding to private pharmacies: an analysis of data linking patients, facilities and pharmacies in the state of Odisha, India","year":2025,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"Tata Trusts; Bill and Melinda Gates Foundation","keywords":"Pharmacy; Private sector; Business; Medicine; Family medicine; Public health; Hospital pharmacy; Finance; Environmental health; Economic growth; Nursing; Economics","score_opus":0.16418873677861898,"score_gpt":0.41380805231089623,"score_spread":0.24961931553227726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407694825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720675,0.00004065639,0.00008703424,0.00004903863,0.0000016634434,0.000023715702,0.002341738,0.0000064304504,0.00024296831],"genre_scores_gemma":[0.99767894,0.00004991908,0.00018282326,0.000032541815,0.0000027658273,0.000035751615,0.0019331961,0.0000032251655,0.00008092226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978544,0.00065642863,0.0002844984,0.0003226259,0.00040547037,0.00047647156],"domain_scores_gemma":[0.99049485,0.0033388191,0.003976949,0.00078870106,0.00083892286,0.00056171726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012612927,0.00030391943,0.0004680545,0.0024931119,0.00088674104,0.0012232221,0.0011900925,0.0005959438,0.001487914],"category_scores_gemma":[0.0055789673,0.0005071875,0.00091636606,0.0071812766,0.000994854,0.00050904026,0.0019233613,0.00081964384,0.00034220374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019974615,0.000027134325,0.99836534,0.000024048739,0.00003796996,0.00007297532,0.00055304874,0.00009397037,0.00003979472,0.000020608128,0.00013129033,0.0006138473],"study_design_scores_gemma":[0.0000026375137,0.0000239982,0.9979048,0.000009490607,0.000021738437,0.00012308065,0.001460395,0.00026063356,0.000031244177,0.0000089502055,0.00014739623,0.000005676291],"about_ca_topic_score_codex":0.1396209,"about_ca_topic_score_gemma":0.12616663,"teacher_disagreement_score":0.1396209,"about_ca_system_score_codex":0.0016221907,"about_ca_system_score_gemma":0.0024184324,"threshold_uncertainty_score":0.27761644},"labels":[],"label_agreement":null},{"id":"W4407710006","doi":"10.1080/23995270.2025.2466380","title":"Orphan drugs approved in Canada: availability and additional therapeutic value","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Orphan drug; Value (mathematics); Medicine; Business; Pharmacology; Mathematics; Statistics; Biology; Bioinformatics","score_opus":0.01286622521603255,"score_gpt":0.2277308317862886,"score_spread":0.21486460657025605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407710006","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032709553,0.018577548,0.00052445696,0.94513124,0.011116354,0.000015836866,0.0035347615,0.000023779168,0.017805066],"genre_scores_gemma":[0.21928917,0.06892092,0.0026438928,0.63224775,0.060041785,0.000041954452,0.0027650911,0.00015367054,0.013895845],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9756291,0.0028548173,0.0019027143,0.0014240855,0.016000196,0.0021890847],"domain_scores_gemma":[0.85207003,0.06655039,0.01168034,0.0025148687,0.062137596,0.0050467923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010691125,0.00045772435,0.0011936101,0.0041594347,0.003802922,0.008049319,0.0026408841,0.005930594,0.008810005],"category_scores_gemma":[0.10180257,0.00044088817,0.0009906966,0.0073058964,0.005434608,0.0038176551,0.0017503677,0.009934861,0.0009761848],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014278984,0.000014053137,0.0099628065,0.0003755602,0.00011372414,0.00043587852,0.0004075474,0.00033886966,0.000067875226,0.02786437,0.9232686,0.037007976],"study_design_scores_gemma":[0.000103040526,0.000033301672,0.02844431,0.0028010856,0.00026310762,0.0010888341,0.0017339116,0.0023252838,0.00044598637,0.028768841,0.933755,0.00023740545],"about_ca_topic_score_codex":0.88906664,"about_ca_topic_score_gemma":0.9242728,"teacher_disagreement_score":0.11093336,"about_ca_system_score_codex":0.05125535,"about_ca_system_score_gemma":0.09325688,"threshold_uncertainty_score":0.3718853},"labels":[],"label_agreement":null},{"id":"W4407729573","doi":"10.1111/1758-5899.13485","title":"Protecting Access to Medicines After Cambodia Graduates From Least Developed Country Status: A Policy Analysis","year":2025,"lang":"en","type":"article","venue":"Global Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"University of Melbourne","keywords":"Graduation (instrument); Developing country; Business; Economic growth; Data collection; Public relations; Medical education; Political science; Medicine; Economics; Sociology; Engineering","score_opus":0.04403181996748217,"score_gpt":0.353463855924092,"score_spread":0.30943203595660984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407729573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9286903,0.0018230228,0.00092338736,0.022018777,0.00004930308,0.0007039693,0.00092380925,0.000009463825,0.044858],"genre_scores_gemma":[0.99346316,0.0011588635,0.00044707392,0.0011967246,0.000028784756,0.0002980376,0.000137837,0.0000024975652,0.003267053],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966564,0.0010958833,0.00009552463,0.00015361939,0.0002099692,0.0017886017],"domain_scores_gemma":[0.9884192,0.008279084,0.0011571405,0.00019583933,0.0006816268,0.001267049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005913084,0.0002032333,0.0003337942,0.0019290652,0.0035126565,0.0052909744,0.0010090758,0.0023318822,0.012280405],"category_scores_gemma":[0.008766102,0.00031829407,0.0005235486,0.0023743664,0.0025383122,0.0027841588,0.0029971716,0.0023301844,0.00026434293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013113641,0.0023380748,0.28981927,0.0033847338,0.00036763473,0.006437222,0.04217745,0.019804286,0.0047180005,0.5144266,0.016633654,0.0985817],"study_design_scores_gemma":[0.000328319,0.0018736066,0.5732868,0.0040090657,0.00038117424,0.00057421054,0.24816465,0.014735638,0.003800376,0.038721506,0.11394469,0.00017988286],"about_ca_topic_score_codex":0.06597791,"about_ca_topic_score_gemma":0.05561111,"teacher_disagreement_score":0.06597791,"about_ca_system_score_codex":0.027726956,"about_ca_system_score_gemma":0.019963237,"threshold_uncertainty_score":0.20117408},"labels":[],"label_agreement":null},{"id":"W4407875256","doi":"10.1080/20523211.2025.2465801","title":"Monitoring the impact of regulatory measures on medicine pricing in Thailand: an observation over a 16-year span","year":2025,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Systems Research Institute","keywords":"Span (engineering); Pharmacy; Medicine; Computer science; Family medicine; Engineering","score_opus":0.17182518522057164,"score_gpt":0.44777266721469966,"score_spread":0.275947481994128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407875256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759763,0.00032788666,0.00015305782,0.00017081609,0.00000500506,0.00002335497,0.0006448594,0.000006216412,0.0010711077],"genre_scores_gemma":[0.99821115,0.00063180504,0.00027722583,0.000047195157,0.000011038008,0.000026119353,0.0004195039,0.0000034199566,0.0003725221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987558,0.0003578749,0.00024081962,0.0001306998,0.0003891379,0.00012567984],"domain_scores_gemma":[0.9869767,0.0024695105,0.007775475,0.00037800198,0.0017587302,0.0006416027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018158952,0.0001694148,0.00021581932,0.0012208056,0.0006430157,0.0011515125,0.00047480446,0.00042531514,0.00079734134],"category_scores_gemma":[0.00831806,0.00020347779,0.00033729943,0.0031663147,0.0006790102,0.0010392779,0.0009521859,0.000865981,0.00020397917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013545562,0.00017391387,0.9593343,0.00031035568,0.00007979156,0.0013099975,0.0073808865,0.0006660197,0.0010135607,0.00029434814,0.0008489197,0.02845242],"study_design_scores_gemma":[0.0000031343736,0.00017577365,0.9887959,0.00005103036,0.000019291514,0.00062223757,0.0070130257,0.00048464697,0.0005188304,0.000059495535,0.0022365642,0.000020078049],"about_ca_topic_score_codex":0.020658087,"about_ca_topic_score_gemma":0.018307785,"teacher_disagreement_score":0.020658087,"about_ca_system_score_codex":0.0016188186,"about_ca_system_score_gemma":0.0019762856,"threshold_uncertainty_score":0.041075647},"labels":[],"label_agreement":null},{"id":"W4408045715","doi":"10.1016/b978-0-443-23848-2.00001-2","title":"The modern-day drug discovery","year":2025,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.029514141111000442,"score_gpt":0.25209926167335367,"score_spread":0.22258512056235322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408045715","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011549037,0.22483465,0.012006665,0.05494437,0.0067813275,0.000041753727,0.0002636135,0.0002269651,0.69974583],"genre_scores_gemma":[0.041261613,0.23108506,0.010371692,0.024242742,0.011590471,0.000106433436,0.00030581336,0.00022435597,0.6808117],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990306,0.0002698087,0.00003184013,0.00013064752,0.00047483726,0.00006228914],"domain_scores_gemma":[0.99899334,0.0005773472,0.000057789723,0.00013608208,0.00012440843,0.00011101474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018415563,0.0008042867,0.0007946914,0.0014212312,0.0007094932,0.004560807,0.0007657668,0.0031851744,0.037824843],"category_scores_gemma":[0.0025452103,0.00044765775,0.0003803393,0.0015608959,0.004561149,0.0061854934,0.0021869212,0.005092908,0.0122273695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024612209,0.000057321617,0.000080882004,0.00027706963,0.000012837425,0.000041548497,0.00007498676,0.00071254716,0.00038444204,0.6119297,0.1976099,0.18879414],"study_design_scores_gemma":[0.0000068700324,0.000018797133,0.00016796193,0.00023436273,0.0000027680594,0.00007097557,0.00003532542,0.00052524084,0.0001182337,0.24730505,0.75150627,0.000008248404],"about_ca_topic_score_codex":0.0014445976,"about_ca_topic_score_gemma":0.002541314,"teacher_disagreement_score":0.037824843,"about_ca_system_score_codex":0.0036734408,"about_ca_system_score_gemma":0.0024756147,"threshold_uncertainty_score":0.12653667},"labels":[],"label_agreement":null},{"id":"W4408070139","doi":"10.1111/1468-0009.70001","title":"The Political Economy of the World Health Organization Model Lists of Essential Medicines","year":2025,"lang":"en","type":"article","venue":"Milbank Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Politics; Population health; Health policy; Business; Political science; Economic growth; Health care; Economics","score_opus":0.019511533130018296,"score_gpt":0.2904597148692898,"score_spread":0.2709481817392715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408070139","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00900501,0.012114984,0.0067457925,0.8157741,0.0014867615,0.00010594034,0.00019189081,0.000038745213,0.1545368],"genre_scores_gemma":[0.68596154,0.016848443,0.01726167,0.25520426,0.003868522,0.0006703613,0.00036817713,0.00019461177,0.019622372],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9109223,0.057068482,0.0037973067,0.003900834,0.019211028,0.005099969],"domain_scores_gemma":[0.86823565,0.10264872,0.009282749,0.003266442,0.0135983415,0.0029680515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08193505,0.0006232526,0.0005838973,0.0039860355,0.008392754,0.020528588,0.0025207647,0.012408297,0.0054306947],"category_scores_gemma":[0.10770817,0.0008417568,0.00068730797,0.004239608,0.02661551,0.019124784,0.006642041,0.016979706,0.0009243948],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001757533,0.00002426689,0.00039511567,0.00016723185,0.0000074704553,0.00012201908,0.004710787,0.00037971674,0.00010361157,0.95198745,0.028234435,0.013850363],"study_design_scores_gemma":[0.000044108194,0.000051226212,0.0019230039,0.0021852942,0.000019768911,0.00014591655,0.010581961,0.0010759406,0.00043802086,0.44841728,0.5350032,0.000114260096],"about_ca_topic_score_codex":0.019398766,"about_ca_topic_score_gemma":0.014562112,"teacher_disagreement_score":0.08193505,"about_ca_system_score_codex":0.03190666,"about_ca_system_score_gemma":0.0332451,"threshold_uncertainty_score":0.43331915},"labels":[],"label_agreement":null},{"id":"W4408323895","doi":"10.1371/journal.pone.0319674","title":"Comparison of generic drug prices in Korea and eight high-income countries across four therapeutic classes","year":2025,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Health and Welfare","keywords":"Purchasing power parity; Index (typography); Currency; Price index; Drug prices; Purchasing power; Drug; Generic drug; Economics; Medicine; Pharmacology; Exchange rate; Public economics; Monetary economics; Macroeconomics","score_opus":0.10472904124764496,"score_gpt":0.32065322119760464,"score_spread":0.2159241799499597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408323895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946301,0.00031134,0.00019214605,0.000064136606,0.000009184232,0.000018686973,0.002718699,0.0000065461522,0.002049085],"genre_scores_gemma":[0.99657696,0.00016232875,0.00029934206,0.000023632405,0.000005363947,0.00001333284,0.002740023,0.0000028266932,0.00017620689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99960023,0.00006210661,0.000086377666,0.00006636304,0.0001101444,0.000074870935],"domain_scores_gemma":[0.9986519,0.00012510666,0.00080539973,0.000031264226,0.00027082916,0.00011554199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052469864,0.00029743763,0.00018292162,0.0022744213,0.00015803578,0.000719582,0.0002321023,0.00017977395,0.0010251324],"category_scores_gemma":[0.0014487946,0.00010784821,0.0005437492,0.0032150187,0.00019135521,0.0006415607,0.0004585777,0.00025506623,0.00012526152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003045495,0.00005491421,0.9855005,0.00011844243,0.00023614313,0.0003503373,0.000089295536,0.0010048596,0.00057188753,0.00041649013,0.0008865546,0.010466044],"study_design_scores_gemma":[0.000023012004,0.00009054224,0.99494535,0.000023758112,0.00009532481,0.000333321,0.0003988069,0.001722312,0.00044713414,0.000070418406,0.0018372964,0.000012688599],"about_ca_topic_score_codex":0.00887112,"about_ca_topic_score_gemma":0.009085433,"teacher_disagreement_score":0.00887112,"about_ca_system_score_codex":0.0010584086,"about_ca_system_score_gemma":0.0004967994,"threshold_uncertainty_score":0.017638922},"labels":[],"label_agreement":null},{"id":"W4408331463","doi":"10.2139/ssrn.5173506","title":"From Patents To Regulatory Exclusivities In Drug Development: A Comparative Transaction Cost Analysis","year":2025,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto","funders":"","keywords":"Transaction cost; Drug development; Business; Drug; Pharmacology; Medicine; Finance","score_opus":0.03822719959103591,"score_gpt":0.29305337889533845,"score_spread":0.2548261793043025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408331463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6716255,0.031064108,0.092265144,0.013179597,0.00037952897,0.00041439992,0.0014703842,0.00024257699,0.18935873],"genre_scores_gemma":[0.98096955,0.004342818,0.0028414824,0.00038059748,0.00019952927,0.00006209914,0.00016765665,0.000060578765,0.010975754],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9969177,0.0015937088,0.00014449643,0.0002769498,0.00058994675,0.00047715465],"domain_scores_gemma":[0.9113324,0.07915177,0.0036972421,0.001826026,0.0029831224,0.0010094309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005584984,0.0007754748,0.0018734069,0.0041263523,0.0010405454,0.0062547154,0.0021378999,0.003132006,0.034691643],"category_scores_gemma":[0.03923111,0.00095897535,0.002118396,0.0040421337,0.0035875568,0.012905607,0.0018918964,0.0042482344,0.00091122434],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010051988,0.00038460223,0.0066787302,0.0008272657,0.000296981,0.00062511786,0.00054109975,0.115769014,0.0007613175,0.8171076,0.006974921,0.04902818],"study_design_scores_gemma":[0.00032194008,0.0006674336,0.018962014,0.00049639674,0.0011250882,0.0007047319,0.0022270714,0.23490714,0.001328988,0.72740746,0.011677759,0.00017400703],"about_ca_topic_score_codex":0.008590284,"about_ca_topic_score_gemma":0.006720248,"teacher_disagreement_score":0.034691643,"about_ca_system_score_codex":0.004836816,"about_ca_system_score_gemma":0.0027854843,"threshold_uncertainty_score":0.11605507},"labels":[],"label_agreement":null},{"id":"W4408415758","doi":"10.1007/978-3-031-75570-5_11","title":"Legalization as an Alternative to Drug Prohibition","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tech University","funders":"","keywords":"Legalization; Drug; Business; Law and economics; Political science; Internet privacy; Law; Computer security; Medicine; Pharmacology; Computer science; Economics","score_opus":0.058841173331446374,"score_gpt":0.30395242437583975,"score_spread":0.24511125104439338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408415758","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055197133,0.005725036,0.005275755,0.02125142,0.00064078445,0.000044260658,0.0000881396,0.00007871376,0.9613763],"genre_scores_gemma":[0.44315898,0.0056177764,0.0064792493,0.028891519,0.002953819,0.00022487441,0.00013983037,0.00016197126,0.512372],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939091,0.0019094483,0.00019167892,0.0008509254,0.002054326,0.0010844396],"domain_scores_gemma":[0.9951544,0.002978345,0.00046324206,0.0006607394,0.00054424355,0.00019903985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033285744,0.000520269,0.0007219627,0.0018712183,0.002177362,0.006722906,0.0021087143,0.011585901,0.01975232],"category_scores_gemma":[0.008955767,0.0004706023,0.0009975429,0.00154319,0.009456323,0.0054884134,0.0033066547,0.008069553,0.002679827],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001055859,0.00002566201,0.00006382211,0.000019459594,0.0000036912206,0.000040046332,0.00008313271,0.00018443074,0.00009809916,0.98141575,0.009589107,0.008466336],"study_design_scores_gemma":[0.000044483637,0.00006394815,0.0008310387,0.00022322641,0.000022404154,0.00023602572,0.0001429421,0.0013713919,0.0008380876,0.61744463,0.37874955,0.00003219719],"about_ca_topic_score_codex":0.010168612,"about_ca_topic_score_gemma":0.013142925,"teacher_disagreement_score":0.01975232,"about_ca_system_score_codex":0.004727705,"about_ca_system_score_gemma":0.006127853,"threshold_uncertainty_score":0.06607813},"labels":[],"label_agreement":null},{"id":"W4408415837","doi":"10.1007/978-3-031-75570-5_6","title":"International Drug Law","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tech University","funders":"","keywords":"Drug; Law; Political science; Medicine; Pharmacology","score_opus":0.053721091987186956,"score_gpt":0.2766218533856966,"score_spread":0.22290076139850967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408415837","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017543345,0.00554825,0.00039685145,0.0048269536,0.0007459207,0.000033364886,0.00021037503,0.000062015635,0.9880008],"genre_scores_gemma":[0.005707865,0.0029112622,0.00034961323,0.0077028265,0.0007078592,0.00007864389,0.00015425416,0.00005572742,0.98233193],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985526,0.00022610542,0.00005209275,0.0002936936,0.0006704664,0.00020501317],"domain_scores_gemma":[0.9992643,0.00025358325,0.000050796858,0.00015034172,0.00020488439,0.00007608484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013918192,0.00102684,0.00079219934,0.0027338346,0.002861715,0.0073223556,0.0011363443,0.008148025,0.09857282],"category_scores_gemma":[0.0033759482,0.0005686783,0.000508095,0.0017339818,0.002714669,0.0032560923,0.002000402,0.006312241,0.04338869],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010150709,0.000029830497,0.00006442631,0.00006324748,0.000003942674,0.000036111604,0.000091579,0.00010067783,0.00013299794,0.44110537,0.51980835,0.038553286],"study_design_scores_gemma":[0.0000047726176,0.0000067620012,0.0001447819,0.0001134326,0.0000026788277,0.000035834117,0.000022482618,0.000089337576,0.00008406363,0.02860175,0.97088957,0.0000045607435],"about_ca_topic_score_codex":0.0145753985,"about_ca_topic_score_gemma":0.03127351,"teacher_disagreement_score":0.09857282,"about_ca_system_score_codex":0.0052621798,"about_ca_system_score_gemma":0.0049256557,"threshold_uncertainty_score":0.32975894},"labels":[],"label_agreement":null},{"id":"W4408729540","doi":"10.1093/oxfordhb/9780197766859.013.0029","title":"Pharmacare and Access to Medicines","year":2025,"lang":"en","type":"book-chapter","venue":"Oxford University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Carleton University","funders":"","keywords":"Traditional medicine; Business; Medicine","score_opus":0.079158638753823,"score_gpt":0.27754526452566664,"score_spread":0.19838662577184363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408729540","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046951533,0.03386522,0.00028455147,0.029325638,0.00019288267,0.000007597909,0.00029367203,0.000030499323,0.9313048],"genre_scores_gemma":[0.42897958,0.082135454,0.0008910699,0.013388487,0.00084158365,0.000024017667,0.0006749661,0.000038370392,0.47302648],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993393,0.00007802681,0.000010443406,0.00005095968,0.00031047387,0.00021081771],"domain_scores_gemma":[0.99941933,0.00022391275,0.000056123423,0.000032257136,0.00015329316,0.00011505197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003280434,0.0001765442,0.00020374026,0.001029011,0.001468642,0.004051056,0.00049858674,0.0015496329,0.041184],"category_scores_gemma":[0.0012635563,0.00013550256,0.00018791403,0.0022102261,0.0030334438,0.001750861,0.0014701841,0.001370792,0.0016494769],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009713084,0.000017313645,0.0011181078,0.00010034891,0.0000061981823,0.000083346626,0.0005839726,0.0003934229,0.000055906192,0.827228,0.10907385,0.061329793],"study_design_scores_gemma":[0.00000668236,0.000007328534,0.00655575,0.00038138957,0.000005763511,0.00011140805,0.0006209873,0.0002698543,0.00006696144,0.06090514,0.9310588,0.0000099600775],"about_ca_topic_score_codex":0.47472224,"about_ca_topic_score_gemma":0.56780285,"teacher_disagreement_score":0.47472224,"about_ca_system_score_codex":0.014181716,"about_ca_system_score_gemma":0.01417601,"threshold_uncertainty_score":0.9439181},"labels":[],"label_agreement":null},{"id":"W4408735635","doi":"10.63485/y5pjr-xme81","title":"Bioline budget in jeopardy","year":2008,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Double jeopardy; Business; Political science; Law","score_opus":0.10441882242277167,"score_gpt":0.308214273088274,"score_spread":0.2037954506655023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408735635","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025464187,0.012800007,0.000369479,0.69270885,0.016980123,0.00004017771,0.0031180785,0.00044865804,0.27098817],"genre_scores_gemma":[0.04711626,0.008473878,0.00074764265,0.14637052,0.005925728,0.0000738368,0.0022387565,0.0005898872,0.7884634],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771357,0.00027628758,0.00009027112,0.0002624987,0.0011648828,0.0004924776],"domain_scores_gemma":[0.9940333,0.001091549,0.00032315095,0.00049763435,0.0020946064,0.0019598515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028048719,0.00061367685,0.0006438607,0.00094917545,0.0041267993,0.007392296,0.0009425931,0.005649417,0.09265085],"category_scores_gemma":[0.018018672,0.00045093952,0.0003926387,0.00180822,0.0012813348,0.0027608054,0.0017403607,0.0064491294,0.020164896],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018357081,0.0000015298069,0.000098165976,0.000017005219,0.0000027153496,0.000027708244,0.000039764862,0.000022532013,0.000024797935,0.013105359,0.9831187,0.0035233584],"study_design_scores_gemma":[0.000007180948,0.0000036951558,0.00058479246,0.000036665206,0.000002665575,0.000014573164,0.00007424326,0.000035542424,0.000033164368,0.0010290752,0.9981725,0.000005870009],"about_ca_topic_score_codex":0.31881186,"about_ca_topic_score_gemma":0.5424097,"teacher_disagreement_score":0.31881186,"about_ca_system_score_codex":0.02225225,"about_ca_system_score_gemma":0.019988077,"threshold_uncertainty_score":0.6339123},"labels":[],"label_agreement":null},{"id":"W4409003440","doi":"10.53469/jssh.2025.7(03).08","title":"Regulatory in the Pharmaceutical Industry","year":2025,"lang":"en","type":"article","venue":"Journal of Social Science and Humanities","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Pharmaceutical industry; Medicine; Pharmacology","score_opus":0.1147506876549185,"score_gpt":0.3505887686937873,"score_spread":0.2358380810388688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409003440","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018335773,0.053228606,0.008894133,0.28908053,0.01886449,0.00020281154,0.00024096412,0.00053283916,0.62712204],"genre_scores_gemma":[0.09281451,0.07415586,0.012230175,0.411469,0.028795678,0.00046513602,0.0005246369,0.000623175,0.37892178],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9623879,0.011394101,0.0019806107,0.005683755,0.015117775,0.0034358709],"domain_scores_gemma":[0.9697197,0.011258726,0.0031610918,0.0033010263,0.008650433,0.0039089634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020408593,0.0011572576,0.0010687185,0.002396626,0.006588561,0.025737904,0.0021972833,0.018873377,0.045629177],"category_scores_gemma":[0.039756194,0.0006533979,0.000843411,0.0033683057,0.023864528,0.01659072,0.009054549,0.019092942,0.027261617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022305781,0.000053313495,0.00040116863,0.00037648084,0.000012348982,0.00022117967,0.0014024914,0.0001282471,0.000444094,0.60554016,0.31564063,0.07575759],"study_design_scores_gemma":[0.00000438694,0.000017363891,0.0001516676,0.00047044843,0.0000038475655,0.00013264775,0.00026322252,0.00003576207,0.00012948936,0.02520631,0.97357357,0.000011249226],"about_ca_topic_score_codex":0.00487298,"about_ca_topic_score_gemma":0.0032387022,"teacher_disagreement_score":0.045629177,"about_ca_system_score_codex":0.009820559,"about_ca_system_score_gemma":0.022318147,"threshold_uncertainty_score":0.15264481},"labels":[],"label_agreement":null},{"id":"W4409004611","doi":"10.1001/jama.2025.4583","title":"Trade Tariffs on Canadian Pharmaceuticals—Implications for US Drug Supply and Costs","year":2025,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Food and drug administration; Drug; Drug administration; International trade; Environmental health; Pharmacology; Business","score_opus":0.05027744393695012,"score_gpt":0.3193100062258937,"score_spread":0.2690325622889436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409004611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85942316,0.009421639,0.0015517584,0.010789289,0.00014580054,0.00016096148,0.05882819,0.000102559636,0.059576668],"genre_scores_gemma":[0.97690237,0.0032995662,0.00058324734,0.0005427454,0.00006650836,0.000029117817,0.009991242,0.000023653572,0.008561432],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750155,0.0001749658,0.00013265404,0.0001851431,0.0013091448,0.0006965053],"domain_scores_gemma":[0.9917219,0.0021077865,0.0025038333,0.00023882369,0.0026538332,0.00077370834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016719676,0.00042208497,0.0006153373,0.00529046,0.0024675333,0.0035459558,0.0009703374,0.0007317788,0.006922911],"category_scores_gemma":[0.012127383,0.00038205707,0.0010097456,0.01013321,0.0008454714,0.0008799302,0.00082393945,0.0012035335,0.00035475023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031871066,0.000110445755,0.8943251,0.00022100414,0.000444846,0.0004229053,0.0008293012,0.013997402,0.00027967343,0.032944396,0.025462179,0.030644055],"study_design_scores_gemma":[0.000039783583,0.000032766242,0.9604579,0.0001705316,0.00024311784,0.00017767587,0.0018518022,0.008992042,0.00041488966,0.0030087328,0.024555562,0.00005525985],"about_ca_topic_score_codex":0.9879111,"about_ca_topic_score_gemma":0.9907375,"teacher_disagreement_score":0.04840408,"about_ca_system_score_codex":0.04840408,"about_ca_system_score_gemma":0.033721726,"threshold_uncertainty_score":0.35119784},"labels":[],"label_agreement":null},{"id":"W4409027491","doi":"10.1093/jphsr/rmaf003","title":"Trust, transparency, and accountability in health and pharmaceutical systems","year":2024,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Transparency (behavior); Accountability; Law","score_opus":0.21673898432230537,"score_gpt":0.49982114948346024,"score_spread":0.28308216516115486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409027491","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12126197,0.01875248,0.081456736,0.35802108,0.0016883197,0.00024419703,0.00035632035,0.00016832497,0.41805053],"genre_scores_gemma":[0.9895377,0.0019755787,0.0024882748,0.002507341,0.00033870482,0.00004847594,0.000028420023,0.000018334724,0.0030572142],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.95410484,0.032276623,0.0018972883,0.0018805721,0.006224906,0.0036158462],"domain_scores_gemma":[0.90496916,0.0670951,0.011195687,0.008172526,0.0054255542,0.0031419897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030367143,0.00030306587,0.00058746315,0.002257844,0.0062143565,0.017595313,0.0012271584,0.0048972215,0.005282599],"category_scores_gemma":[0.051344674,0.0004850157,0.00053587835,0.0025502185,0.045053232,0.013614105,0.009069237,0.005528431,0.00038049291],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011586509,0.000009154021,0.00063023245,0.00006909459,0.000009804361,0.000057378802,0.0053698905,0.0005129606,0.000059636866,0.9869069,0.001993342,0.0043699723],"study_design_scores_gemma":[0.000013433076,0.000028423885,0.0013466503,0.00046778363,0.000011878945,0.00007777868,0.0039431863,0.0011849918,0.00020063222,0.94870627,0.043986928,0.000031958258],"about_ca_topic_score_codex":0.0067087202,"about_ca_topic_score_gemma":0.0029071688,"teacher_disagreement_score":0.030367143,"about_ca_system_score_codex":0.01240683,"about_ca_system_score_gemma":0.011533889,"threshold_uncertainty_score":0.16059875},"labels":[],"label_agreement":null},{"id":"W4409111735","doi":"10.1093/eurheartj/ehaf134","title":"Critical medications in cardiology: strategic policy of the European Medicines Agency","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Institutes of Health; Deutsche Forschungsgemeinschaft; European Commission","keywords":"Medicine; Agency (philosophy); Cardiology; Internal medicine","score_opus":0.11174514372226377,"score_gpt":0.3648778749610622,"score_spread":0.2531327312387984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409111735","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029329523,0.040656388,0.0025589839,0.8320782,0.011024006,0.00027323773,0.0007308362,0.00016355154,0.109581806],"genre_scores_gemma":[0.070657045,0.028392168,0.0130826095,0.794433,0.011251,0.0005555863,0.0006693787,0.0001514061,0.08080777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9818158,0.0049546612,0.0017864766,0.0020923088,0.0060262433,0.0033244325],"domain_scores_gemma":[0.9778972,0.007844027,0.0023709838,0.0009708131,0.0054003987,0.0055164867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026776241,0.0015517776,0.0014289492,0.0018483382,0.004240258,0.019505806,0.0040351865,0.07383196,0.010753692],"category_scores_gemma":[0.035221126,0.0011051876,0.0023693407,0.0022847534,0.003751926,0.01389389,0.0077603124,0.018865736,0.0041638925],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024188304,0.0003041819,0.0014308193,0.0007412707,0.00006670943,0.0010147959,0.00060183584,0.0010194213,0.0011974593,0.4350837,0.46882945,0.08946844],"study_design_scores_gemma":[0.00008097644,0.000083528896,0.0012230378,0.0014832222,0.000025904366,0.00024540327,0.00020209128,0.0005752396,0.00039792008,0.020287437,0.9753318,0.00006347282],"about_ca_topic_score_codex":0.013041532,"about_ca_topic_score_gemma":0.0092442995,"teacher_disagreement_score":0.07383196,"about_ca_system_score_codex":0.013042728,"about_ca_system_score_gemma":0.05977937,"threshold_uncertainty_score":0.141608},"labels":[],"label_agreement":null},{"id":"W4409323342","doi":"10.1016/j.jhealeco.2025.102996","title":"Procurement institutions and essential drug supply in low and middle-income countries","year":2025,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Procurement; Low and middle income countries; Business; Developing country; Economics; Economic growth; Marketing","score_opus":0.04875792013136287,"score_gpt":0.32286762259252866,"score_spread":0.2741097024611658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409323342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938036,0.0022202823,0.0010985164,0.00062600913,0.000015964877,0.000027131957,0.002149428,0.00001394387,0.004468364],"genre_scores_gemma":[0.99772877,0.0007059497,0.00023629943,0.000063005216,0.00001679789,0.0000132620935,0.0007829245,0.0000050755543,0.0004480623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987148,0.00040979253,0.00014744568,0.00013621862,0.00018022335,0.00041156044],"domain_scores_gemma":[0.9853904,0.0040365467,0.008619278,0.00027039155,0.00074325176,0.000940122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001627088,0.0002473444,0.0004566231,0.0014117735,0.00048725551,0.0017118134,0.00038365423,0.00035547063,0.0063527822],"category_scores_gemma":[0.007710846,0.00036088543,0.0005829292,0.0042125126,0.0008138058,0.001812325,0.0019765727,0.0008020106,0.00041986056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012926999,0.00006323453,0.9807567,0.00017293272,0.00014376796,0.00029095486,0.0004957876,0.0043475362,0.00012897544,0.0022054072,0.001203525,0.010061885],"study_design_scores_gemma":[0.00003008648,0.00013839542,0.98724896,0.0001706392,0.00009640499,0.00021242631,0.003108613,0.0025187882,0.00034960374,0.0018699463,0.00423491,0.00002127581],"about_ca_topic_score_codex":0.016146297,"about_ca_topic_score_gemma":0.014369053,"teacher_disagreement_score":0.016146297,"about_ca_system_score_codex":0.0014336734,"about_ca_system_score_gemma":0.001264071,"threshold_uncertainty_score":0.03210461},"labels":[],"label_agreement":null},{"id":"W4409665036","doi":"10.1093/ajhp/zxaf092","title":"National trends in prescription drug expenditures and projections for 2025","year":2025,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Disclaimer; Medical prescription; Prescription drug; Biosimilar; Drug; Medicine; Legislation; Business; Family medicine; Pharmacology; Political science; Law","score_opus":0.07321165051098799,"score_gpt":0.3892106735295695,"score_spread":0.3159990230185815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409665036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.776643,0.0074004806,0.009337757,0.0058395304,0.00033183847,0.000082035775,0.15738063,0.000861463,0.04212326],"genre_scores_gemma":[0.91487384,0.0030294387,0.005760049,0.0006102809,0.00009576142,0.000087218716,0.0721951,0.000037054026,0.003311226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944013,0.00009213877,0.00006895856,0.00008248955,0.00021851019,0.00009767349],"domain_scores_gemma":[0.9985038,0.00014503003,0.0005048739,0.00004262594,0.0006917854,0.00011178232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009662957,0.0004937022,0.00018939299,0.0022173612,0.00023802258,0.0011671269,0.00038813788,0.00047023303,0.00294536],"category_scores_gemma":[0.0028972572,0.00017042986,0.0010243903,0.0029888975,0.00015831193,0.0011682676,0.0005328529,0.00067409314,0.00087747036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005763342,0.0001897077,0.7746145,0.00085443194,0.00070405414,0.00038511422,0.0002837429,0.0654144,0.0009771528,0.012387761,0.059754442,0.0838583],"study_design_scores_gemma":[0.00004051559,0.0002635539,0.8144084,0.0004385916,0.0002816876,0.00081256847,0.0009564112,0.06988847,0.001786963,0.0030883197,0.10795024,0.000084279716],"about_ca_topic_score_codex":0.05935783,"about_ca_topic_score_gemma":0.045982677,"teacher_disagreement_score":0.05935783,"about_ca_system_score_codex":0.0028943606,"about_ca_system_score_gemma":0.0015449838,"threshold_uncertainty_score":0.11802465},"labels":[],"label_agreement":null},{"id":"W4409920326","doi":"10.1007/978-3-031-76774-6_7","title":"World Health Organization (WHO)","year":2025,"lang":"en","type":"book-chapter","venue":"AAPS advances in the pharmaceutical sciences series","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Business","score_opus":0.07528081969239535,"score_gpt":0.35499471303970803,"score_spread":0.27971389334731267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409920326","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015439475,0.14558831,0.004533009,0.028963875,0.02419772,0.00057509873,0.18545875,0.0022537531,0.6068855],"genre_scores_gemma":[0.015594604,0.15873241,0.011702497,0.014693781,0.0037105822,0.0014617132,0.11272163,0.0010164494,0.68036634],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994271,0.00008740764,0.0000454231,0.00007619563,0.00027359457,0.00009037564],"domain_scores_gemma":[0.9992582,0.00014071653,0.00013415591,0.000045708544,0.00031495735,0.000106232896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094391237,0.0021503586,0.0011474442,0.0019512372,0.00034370442,0.0018438472,0.0011747344,0.0016625578,0.059563454],"category_scores_gemma":[0.002027892,0.00032848935,0.0005980993,0.00502694,0.00044942021,0.0013207474,0.0008672011,0.0025217095,0.05178326],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002402104,0.000015831518,0.00023885178,0.000417131,0.000009238732,0.000018159511,0.000019978055,0.0001183176,0.00005912464,0.0025618325,0.9232424,0.0732751],"study_design_scores_gemma":[0.000015821803,0.000013408339,0.0018580101,0.0006737136,0.000012436299,0.0000572001,0.000039952596,0.000080905666,0.00007890573,0.0008852112,0.99627846,0.0000061214564],"about_ca_topic_score_codex":0.029130481,"about_ca_topic_score_gemma":0.020940043,"teacher_disagreement_score":0.059563454,"about_ca_system_score_codex":0.0010306102,"about_ca_system_score_gemma":0.0047268257,"threshold_uncertainty_score":0.19925964},"labels":[],"label_agreement":null},{"id":"W4409963014","doi":"10.1257/aer.20220276","title":"Does Entry Remedy Collusion? Evidence from the Generic Prescription Drug Cartel","year":2025,"lang":"en","type":"article","venue":"American Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Cartel; Collusion; Medical prescription; Drug; Business; Pharmacology; Medicine; Industrial organization","score_opus":0.04669584478231093,"score_gpt":0.3102293564347684,"score_spread":0.2635335116524575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409963014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8520863,0.011230533,0.0046833153,0.020585453,0.00022090664,0.00016100124,0.00088204874,0.00012384297,0.110026546],"genre_scores_gemma":[0.9924964,0.0021242038,0.00034707194,0.0015284199,0.00013838548,0.000014128853,0.00018388148,0.000012516062,0.0031549302],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99778605,0.001070541,0.00012741396,0.00023053365,0.00035018916,0.00043534182],"domain_scores_gemma":[0.950976,0.028095117,0.014587116,0.002547963,0.0021349434,0.0016588658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005559154,0.00033186912,0.0008412653,0.0009198845,0.001294347,0.0031738065,0.0010618666,0.0028038146,0.024135852],"category_scores_gemma":[0.028193347,0.00033644997,0.0008126744,0.00092897366,0.0023843981,0.0027605824,0.0025365744,0.0016925402,0.0023361302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008048944,0.0023076255,0.31452212,0.0027806,0.0013523416,0.005982688,0.005753317,0.022752956,0.004098767,0.32637456,0.080937654,0.22508852],"study_design_scores_gemma":[0.0058469507,0.0047611026,0.3833362,0.0020908634,0.002577097,0.002516964,0.016403982,0.06498251,0.0065941,0.36227444,0.1482013,0.00041448098],"about_ca_topic_score_codex":0.007361096,"about_ca_topic_score_gemma":0.006605276,"teacher_disagreement_score":0.024135852,"about_ca_system_score_codex":0.0012309825,"about_ca_system_score_gemma":0.0013768033,"threshold_uncertainty_score":0.08074248},"labels":[],"label_agreement":null},{"id":"W4409974707","doi":"10.2196/preprints.76730","title":"Medico-economic Evaluation of a Telehealth Platform for Elective Outpatient Surgeries: A Randomized Controlled Trial (Preprint)","year":2025,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Preprint; Randomized controlled trial; Telehealth; Medicine; Telemedicine; Effi; Physical therapy; Computer science; Surgery; World Wide Web; Health care; Economics; Database; Economic growth","score_opus":0.10149156870091623,"score_gpt":0.3680540091472616,"score_spread":0.26656244044634536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409974707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88309157,0.018308064,0.0025623988,0.0043010334,0.0055587227,0.074771196,0.00466654,0.00030923524,0.006431192],"genre_scores_gemma":[0.89886785,0.0052589863,0.0052026934,0.0027345556,0.002142739,0.0800037,0.0017133919,0.000031919288,0.004044112],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99542147,0.0030169762,0.0004703093,0.00042719077,0.00030569657,0.00035845026],"domain_scores_gemma":[0.99534506,0.0020887374,0.0013339919,0.0002490709,0.00037167486,0.00061150687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051935967,0.0018277724,0.003485605,0.0007861392,0.00074823474,0.0020354146,0.0011102521,0.0037482632,0.018052327],"category_scores_gemma":[0.011040315,0.00086429814,0.0054292884,0.0007550944,0.0013666969,0.0017270509,0.00084218517,0.002724791,0.0010652533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9836376,0.004422396,0.00036937481,0.0023792873,0.0021483265,0.00002133616,0.000024421379,0.00019190794,0.00021659936,0.00016532427,0.00080692343,0.005616513],"study_design_scores_gemma":[0.9761796,0.02074035,0.00068836403,0.00022178142,0.0012013661,0.0000067050278,0.000015328595,0.00031157766,0.000119379736,0.00012078003,0.00038300318,0.0000117852],"about_ca_topic_score_codex":0.0022697882,"about_ca_topic_score_gemma":0.0027357491,"teacher_disagreement_score":0.018052327,"about_ca_system_score_codex":0.0021618116,"about_ca_system_score_gemma":0.0031021114,"threshold_uncertainty_score":0.06039107},"labels":[],"label_agreement":null},{"id":"W4410006109","doi":"10.53555/sfs.v10i3.3564","title":"Next-Generation Medicines for Neurological and Neurodegenerative Disorders: From Discovery to Commercialization","year":2023,"lang":"en","type":"article","venue":"Journal of Survey in Fisheries Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Commercialization; Drug discovery; Neuroscience; Medicine; Business; Psychology; Bioinformatics; Biology; Marketing","score_opus":0.4626763968984163,"score_gpt":0.3418901994057735,"score_spread":0.1207861974926428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410006109","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005078246,0.42953575,0.02473922,0.2242874,0.037920013,0.00014626408,0.00052904076,0.00037239798,0.27739167],"genre_scores_gemma":[0.05734812,0.54206634,0.016658295,0.03787776,0.034257714,0.00022648991,0.00044061037,0.00027787435,0.31084684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989786,0.00020721415,0.00005244348,0.00008852366,0.0005972439,0.00007606476],"domain_scores_gemma":[0.99768424,0.0016661123,0.00017077585,0.000068911424,0.00025744343,0.0001524284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015220259,0.0005703649,0.00070443214,0.0010572689,0.00051833584,0.0050538974,0.00070736255,0.001942892,0.01413593],"category_scores_gemma":[0.004867888,0.00034028853,0.0007140199,0.0012910087,0.001583523,0.0062434063,0.0011836912,0.0040154676,0.00369435],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050316554,0.000058654816,0.0003272386,0.0008594523,0.00003257582,0.00010725316,0.00019741384,0.0025582665,0.0003905471,0.3071933,0.53747755,0.15074745],"study_design_scores_gemma":[0.000012337153,0.000054859745,0.00043330988,0.0007835292,0.000008874058,0.00014818094,0.0001207736,0.0011909803,0.00015839594,0.090946674,0.9061249,0.000017256294],"about_ca_topic_score_codex":0.0009814154,"about_ca_topic_score_gemma":0.0013499722,"teacher_disagreement_score":0.01413593,"about_ca_system_score_codex":0.0025913736,"about_ca_system_score_gemma":0.0028503109,"threshold_uncertainty_score":0.04728937},"labels":[],"label_agreement":null},{"id":"W4410208254","doi":"10.22214/ijraset.2025.70266","title":"A Review: Regulatory Affairs in Pharmaceutical Industry","year":2025,"lang":"en","type":"article","venue":"International Journal for Research in Applied Science and Engineering Technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regulatory affairs; Business; Pharmaceutical industry; Pharmacology; Political science; Medicine; Public administration","score_opus":0.11577416562913742,"score_gpt":0.43786508556008047,"score_spread":0.3220909199309431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410208254","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003751487,0.99677026,0.000035905698,0.0014057778,0.0008130863,0.000003745458,0.000010428358,0.000002382193,0.0009208854],"genre_scores_gemma":[0.0004583684,0.99662197,0.000055287408,0.0014299336,0.0010999588,0.000005778176,0.00001789368,0.0000011672296,0.00030960783],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800533,0.0005353593,0.00037775852,0.0002558887,0.0006951459,0.00013055316],"domain_scores_gemma":[0.9898364,0.0073437155,0.0012670157,0.00014596304,0.0011070056,0.00029982426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020228848,0.0012217474,0.0019340097,0.005278524,0.0007890276,0.004545514,0.0014065693,0.0048225876,0.0084638],"category_scores_gemma":[0.009390971,0.0004904741,0.0012563266,0.009098346,0.0018429188,0.005017316,0.0013807998,0.0036965425,0.0026979605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112555,0.00009490273,0.0005069424,0.08138273,0.00025464033,0.00037186535,0.0002706547,0.00046754212,0.00030617922,0.020220362,0.3060678,0.5899439],"study_design_scores_gemma":[0.000019981997,0.000058582504,0.0013758214,0.041660152,0.0001374285,0.00069490966,0.00014502421,0.000057965743,0.00007043839,0.0029057502,0.95285344,0.00002049006],"about_ca_topic_score_codex":0.0034817331,"about_ca_topic_score_gemma":0.005611795,"teacher_disagreement_score":0.0084638,"about_ca_system_score_codex":0.0031759616,"about_ca_system_score_gemma":0.0071910815,"threshold_uncertainty_score":0.028314233},"labels":[],"label_agreement":null},{"id":"W4410345262","doi":"10.1080/14636778.2025.2500756","title":"Capitalizing a cure: how finance controls the price and value of medicines","year":2025,"lang":"en","type":"article","venue":"New Genetics and Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Value (mathematics); Economics; Finance; Financial economics; Business; Mathematics; Statistics","score_opus":0.02679235073809223,"score_gpt":0.269839559880074,"score_spread":0.2430472091419818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410345262","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06693888,0.028772445,0.14146958,0.18194608,0.0031998095,0.00020915143,0.0017796073,0.0010866659,0.5745978],"genre_scores_gemma":[0.91035146,0.009839331,0.009070306,0.009526734,0.0017744481,0.000119410906,0.00017311054,0.00034154503,0.058803655],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9964765,0.0017297677,0.00008444178,0.00047937626,0.00066642516,0.0005635557],"domain_scores_gemma":[0.9815019,0.0137106655,0.0021421772,0.0008982897,0.00095759926,0.0007893868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051008416,0.0009453223,0.0010855569,0.0013181135,0.0013508108,0.011626104,0.0014493108,0.0061535053,0.023376776],"category_scores_gemma":[0.03386455,0.0007917416,0.000976919,0.0014821367,0.0061140796,0.011570446,0.0024176822,0.0048348536,0.0028319615],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001249365,0.000065805594,0.0017176995,0.00010263216,0.00009761331,0.00012027122,0.00024845573,0.012374225,0.00047120338,0.9247584,0.027832344,0.03208652],"study_design_scores_gemma":[0.0000553365,0.00006503131,0.0013604239,0.000107205204,0.00006170325,0.0000987613,0.00017976898,0.011707757,0.0005568407,0.93198204,0.0537518,0.0000734134],"about_ca_topic_score_codex":0.0088462345,"about_ca_topic_score_gemma":0.0049139108,"teacher_disagreement_score":0.023376776,"about_ca_system_score_codex":0.0057374723,"about_ca_system_score_gemma":0.004002494,"threshold_uncertainty_score":0.07820308},"labels":[],"label_agreement":null},{"id":"W4410490267","doi":"10.1073/pnas.2424665122","title":"Framework to identify innovative sources of value creation from platform technologies","year":2025,"lang":"en","type":"review","venue":"Proceedings of the National Academy of Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bridgepoint Active Healthcare","funders":"Pfizer","keywords":"Valuation (finance); Value capture; Portfolio; Competitive advantage; Knowledge management; Transformative learning; Emerging technologies; Process management; Business value; Computer science; Business; Risk analysis (engineering); Data science; Value creation; Marketing; Economics","score_opus":0.17395507902883053,"score_gpt":0.42278791214257494,"score_spread":0.2488328331137444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410490267","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008532444,0.33927375,0.5006405,0.015046424,0.00049825147,0.007383612,0.00467717,0.00045941278,0.12348846],"genre_scores_gemma":[0.15764396,0.21090057,0.6074664,0.0024983967,0.00026412675,0.011432973,0.0032995006,0.00007406021,0.0064200005],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935714,0.0033256738,0.0006273015,0.00046072138,0.0017844492,0.00023049947],"domain_scores_gemma":[0.9921023,0.0055549466,0.0007958444,0.00030282562,0.0011281573,0.00011590013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014138821,0.003477168,0.0022245308,0.02586053,0.0009996974,0.005872522,0.0028908565,0.0023762735,0.006022323],"category_scores_gemma":[0.014793933,0.0007612986,0.0032414368,0.015127289,0.0026196078,0.006149666,0.0036850243,0.002617101,0.001101321],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029577932,0.000071228635,0.0011518972,0.014223449,0.00048113364,0.00015962865,0.0005530449,0.008593312,0.0003005517,0.79482365,0.006453251,0.17315915],"study_design_scores_gemma":[0.00011920339,0.000163127,0.004253511,0.034107972,0.0014118097,0.0007330418,0.0015810063,0.020529242,0.0009318958,0.68687785,0.2491655,0.00012590483],"about_ca_topic_score_codex":0.006630087,"about_ca_topic_score_gemma":0.008675514,"teacher_disagreement_score":0.02586053,"about_ca_system_score_codex":0.008135379,"about_ca_system_score_gemma":0.012942718,"threshold_uncertainty_score":0.07477409},"labels":[],"label_agreement":null},{"id":"W4410741822","doi":"10.1080/14787210.2025.2511958","title":"Surge of branded generics and antimicrobial resistance: analyzing the antibiotic market dynamics in Pakistan through the WHO essential medicines and AWaRe lens","year":2025,"lang":"en","type":"article","venue":"Expert Review of Anti-infective Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Antibiotic resistance; Antibiotics; Antimicrobial; Resistance (ecology); Business; Traditional medicine; Medicine; Microbiology; Biology; Ecology","score_opus":0.022668821646140185,"score_gpt":0.3385934287291436,"score_spread":0.3159246070830034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410741822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6276259,0.29980898,0.0017349668,0.025965711,0.00042034878,0.00024915303,0.020946229,0.00006315495,0.023185639],"genre_scores_gemma":[0.8719226,0.120877855,0.0012313405,0.002061991,0.00032498367,0.000060589446,0.0025967374,0.000012015758,0.0009118522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989116,0.00022316791,0.00020818903,0.00017031057,0.0003412643,0.00014546944],"domain_scores_gemma":[0.99514884,0.0011529569,0.002532512,0.0000765104,0.00091216137,0.00017701386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013712354,0.00022917324,0.00034655016,0.0027278778,0.00024052727,0.0011639927,0.0003601812,0.00052654784,0.004168742],"category_scores_gemma":[0.004855279,0.0001599313,0.00044912827,0.0034435291,0.00035056105,0.0012482265,0.00051399105,0.0005448319,0.0003234624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033481925,0.00010480632,0.6490542,0.010555835,0.0003613776,0.0015262725,0.0026702608,0.0005011521,0.000558336,0.002806154,0.024864506,0.30666226],"study_design_scores_gemma":[0.00002782812,0.00019091208,0.92141217,0.0071816295,0.00044997237,0.0027628709,0.0070119165,0.0008918201,0.0005397094,0.00093001383,0.058539014,0.0000621949],"about_ca_topic_score_codex":0.02714619,"about_ca_topic_score_gemma":0.0352741,"teacher_disagreement_score":0.02714619,"about_ca_system_score_codex":0.0009834948,"about_ca_system_score_gemma":0.0036019664,"threshold_uncertainty_score":0.053976357},"labels":[],"label_agreement":null},{"id":"W4410771339","doi":"10.1371/journal.pone.0304930","title":"Key stakeholders’ views on the causes of medicine stock-outs in Mauritania: A qualitative study","year":2025,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Commission","keywords":"Procurement; Business; Essential medicines; Purchasing; Qualitative research; Pharmacy; Sustainability; Corporate governance; Accountability; Thematic analysis; Focus group; Health care; Marketing; Public relations; Medicine; Nursing; Finance; Economic growth; Economics","score_opus":0.49511013128402875,"score_gpt":0.384788650125002,"score_spread":0.11032148115902674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410771339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940252,0.0006183008,0.00056050206,0.0018666057,0.000024245137,0.000091368,0.00006584519,0.0000062238996,0.0027416507],"genre_scores_gemma":[0.9978085,0.0005344223,0.0002425966,0.00037584026,0.000006785827,0.000104315026,0.000023692432,0.0000052035834,0.00089864346],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99621814,0.0023893414,0.00014062972,0.00017577392,0.00026961628,0.00080658303],"domain_scores_gemma":[0.9945957,0.0037753272,0.00049208774,0.000105297666,0.00043950792,0.00059214944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005714194,0.0005191111,0.0006252185,0.0013965865,0.008104421,0.0026659032,0.0013301559,0.0014796717,0.0029995395],"category_scores_gemma":[0.007051742,0.00053448114,0.00040756224,0.0018624256,0.0058260052,0.0027503266,0.0037403672,0.0017830771,0.00021076665],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015855103,0.000015898255,0.0039024963,0.00012087058,0.0000037792688,0.0009696866,0.99170715,0.000028130804,0.00070610415,0.0006987902,0.00012341473,0.0017078003],"study_design_scores_gemma":[9.88497e-7,0.000016032249,0.0020342201,0.00009893223,0.000002739976,0.00010420238,0.9956489,0.000041320614,0.00011159673,0.00007445438,0.0018611663,0.000005336792],"about_ca_topic_score_codex":0.03706113,"about_ca_topic_score_gemma":0.03944585,"teacher_disagreement_score":0.03706113,"about_ca_system_score_codex":0.008161581,"about_ca_system_score_gemma":0.004348165,"threshold_uncertainty_score":0.07369083},"labels":[],"label_agreement":null},{"id":"W4410785113","doi":"10.1093/9780199289011.003.0077","title":"Other Data Exclusivity Periods for Pharmaceuticals","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.4203723916308167,"score_gpt":0.3738697711365231,"score_spread":0.0465026204942936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785113","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016830282,0.019669151,0.021660428,0.008414018,0.00096784317,0.00038935328,0.0031248247,0.0005084824,0.9284356],"genre_scores_gemma":[0.39522976,0.021297451,0.04518336,0.013408457,0.0032793425,0.0019340817,0.0074600587,0.0007175404,0.51149],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99400383,0.0013339216,0.00047884276,0.00074111164,0.0028398486,0.0006025212],"domain_scores_gemma":[0.9857706,0.0069566616,0.0013888848,0.002544579,0.0027644834,0.0005747456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062012505,0.0005484983,0.0005907715,0.0027007395,0.0022338394,0.006920456,0.0017041254,0.003268274,0.039674576],"category_scores_gemma":[0.020613126,0.00062528765,0.0016051907,0.0029002426,0.0018675171,0.0073061762,0.0021642025,0.0051317075,0.008861738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016825866,0.000120972305,0.0009999779,0.00033252113,0.000024135372,0.00018275734,0.00063012517,0.0017225759,0.0012554011,0.84089684,0.068492875,0.085173465],"study_design_scores_gemma":[0.00004519714,0.00012635383,0.003498625,0.000599027,0.000027356413,0.00038768834,0.0001903368,0.0013639566,0.0021352093,0.06886039,0.9227009,0.00006495057],"about_ca_topic_score_codex":0.005202836,"about_ca_topic_score_gemma":0.0037426923,"teacher_disagreement_score":0.039674576,"about_ca_system_score_codex":0.0057392186,"about_ca_system_score_gemma":0.0037361726,"threshold_uncertainty_score":0.1327247},"labels":[],"label_agreement":null},{"id":"W4410785146","doi":"10.1093/9780199289011.003.0067","title":"The Pharmaceutical Regulatory Approval Process","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Process (computing); Business; Computer science","score_opus":0.11884694240391803,"score_gpt":0.2976088339147337,"score_spread":0.17876189151081567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785146","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085864257,0.015144295,0.012438697,0.013727037,0.0020623412,0.00028859146,0.00025646764,0.0002281266,0.95499593],"genre_scores_gemma":[0.034745175,0.024558265,0.01311301,0.017039169,0.0027615991,0.00047498944,0.0006033521,0.00039182053,0.9063126],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98924387,0.0024184661,0.00053821574,0.0013617682,0.0058731497,0.0005645845],"domain_scores_gemma":[0.99301696,0.0033027295,0.00026420312,0.0007480049,0.0024811137,0.00018706756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072322506,0.00080548937,0.0005866102,0.0020136042,0.002743392,0.010343605,0.001679048,0.006073715,0.046498876],"category_scores_gemma":[0.012559324,0.0007679368,0.0006965157,0.002107995,0.005079095,0.0075333705,0.0027490114,0.0076628756,0.032988444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007276938,0.000023105471,0.00004849153,0.00011868359,0.0000025168144,0.00008662044,0.0004218151,0.00029222082,0.00019418432,0.8233567,0.11651121,0.05893729],"study_design_scores_gemma":[0.000002793747,0.000007619939,0.00006489053,0.00021634118,0.0000012375111,0.00006860954,0.000049266077,0.00008709794,0.00013537923,0.027897896,0.9714608,0.000008096165],"about_ca_topic_score_codex":0.0050971285,"about_ca_topic_score_gemma":0.0034296238,"teacher_disagreement_score":0.046498876,"about_ca_system_score_codex":0.0062909396,"about_ca_system_score_gemma":0.009655664,"threshold_uncertainty_score":0.15555418},"labels":[],"label_agreement":null},{"id":"W4410785208","doi":"10.1093/9780199289011.003.0010","title":"Drafting Pharmaceutical Patents","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.20637588000820187,"score_gpt":0.2992198143972779,"score_spread":0.09284393438907604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785208","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007101397,0.012168591,0.052554253,0.009917261,0.0016277558,0.0006478138,0.0006077446,0.00065291644,0.9147222],"genre_scores_gemma":[0.13738182,0.028487649,0.10800044,0.006473436,0.0014096899,0.00041178102,0.0019829816,0.0005936295,0.71525854],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933831,0.0011883191,0.00051914505,0.00066885474,0.003715234,0.0005253602],"domain_scores_gemma":[0.99190664,0.0026609488,0.00040048923,0.0017227104,0.0030424977,0.0002667022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007561258,0.0006484604,0.0005002622,0.0033385963,0.003286411,0.0075845243,0.0018179303,0.0029973127,0.03069387],"category_scores_gemma":[0.015007966,0.000571857,0.00074830424,0.0029646491,0.004402967,0.004845203,0.0024368868,0.0034881833,0.01000515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008579683,0.000022217318,0.00019984797,0.0001572495,0.000004360454,0.00012473803,0.0012762818,0.00078772905,0.00056970166,0.81257206,0.0546404,0.12963688],"study_design_scores_gemma":[0.0000039937086,0.000020456537,0.00022134479,0.00027199974,0.0000050509866,0.0001348159,0.00020444824,0.00046201627,0.0012319927,0.035585538,0.96184266,0.000015680398],"about_ca_topic_score_codex":0.019024251,"about_ca_topic_score_gemma":0.017229473,"teacher_disagreement_score":0.03069387,"about_ca_system_score_codex":0.008510997,"about_ca_system_score_gemma":0.014809988,"threshold_uncertainty_score":0.10268116},"labels":[],"label_agreement":null},{"id":"W4410785284","doi":"10.1093/9780199289011.003.0078","title":"Certified (Listed) Patents and Approval of Generic Drugs","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Certification; Business; Accounting; Law; Political science","score_opus":0.17339035689725518,"score_gpt":0.24916240777988546,"score_spread":0.07577205088263028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785284","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019624103,0.004895779,0.0024905128,0.0031174861,0.0005866069,0.000058505455,0.00017097368,0.00008308849,0.9866346],"genre_scores_gemma":[0.08917363,0.010332057,0.0035975773,0.00527647,0.0010676591,0.00009603471,0.00047952877,0.000071453156,0.8899057],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983553,0.00031179635,0.0000664902,0.00022212046,0.00090768083,0.00013653994],"domain_scores_gemma":[0.9987105,0.00053372374,0.00010958022,0.00013899665,0.0004422455,0.00006489342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011969694,0.00023172794,0.00019777118,0.0010093845,0.00096027326,0.0027609093,0.0006619993,0.0016604585,0.037890844],"category_scores_gemma":[0.0028078798,0.0002504321,0.0003090267,0.000900511,0.0016605456,0.0020729613,0.00077470415,0.001686469,0.007147068],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009738626,0.000027016986,0.000116444615,0.00012996978,0.0000018345376,0.000102404345,0.00024095118,0.00027919508,0.00023739821,0.82346076,0.11501248,0.06038183],"study_design_scores_gemma":[0.000007607447,0.000016329715,0.00047845507,0.00018814334,0.0000027796184,0.00011697537,0.000049964303,0.00025586272,0.00033233082,0.029019957,0.9695234,0.000008253098],"about_ca_topic_score_codex":0.0070923413,"about_ca_topic_score_gemma":0.010238764,"teacher_disagreement_score":0.037890844,"about_ca_system_score_codex":0.0030080471,"about_ca_system_score_gemma":0.004362026,"threshold_uncertainty_score":0.1267575},"labels":[],"label_agreement":null},{"id":"W4411002193","doi":"10.1093/ajhp/zxaf147","title":"Recent and anticipated novel drug approvals (2Q 2025 through 1Q 2026)","year":2025,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Pipeline (software); Drug; Medicine; Food and drug administration; Quarter (Canadian coin); Drug approval; Family medicine; Medical emergency; Pharmacology; Engineering","score_opus":0.09972721393004036,"score_gpt":0.37745700625177975,"score_spread":0.2777297923217394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411002193","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21465267,0.054924298,0.018657796,0.0949926,0.017200463,0.0019036062,0.09450117,0.0024656765,0.5007017],"genre_scores_gemma":[0.7701677,0.021552399,0.010903811,0.033351533,0.008582521,0.00067922304,0.038526107,0.00027810468,0.1159586],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969332,0.0003974982,0.00021502562,0.00021991518,0.0017764188,0.0004578452],"domain_scores_gemma":[0.99105865,0.0022437528,0.0025252018,0.00023258767,0.0028406272,0.0010991228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053960127,0.00039229376,0.00025417845,0.0022823536,0.0006693055,0.002620414,0.0004460638,0.0022958238,0.027568635],"category_scores_gemma":[0.01218117,0.00021063366,0.0014688057,0.0013013057,0.00046042062,0.0014325734,0.0010893631,0.0017600064,0.00542321],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016364881,0.00050303293,0.03737475,0.0019538177,0.0002157816,0.0018051844,0.0001820298,0.0067689866,0.0051022386,0.049171656,0.64353293,0.2517531],"study_design_scores_gemma":[0.00021282148,0.00086424977,0.13096534,0.00045080436,0.00008758223,0.0014430102,0.00017515685,0.002501083,0.0026917616,0.006319728,0.8542019,0.000086636355],"about_ca_topic_score_codex":0.00677643,"about_ca_topic_score_gemma":0.008427828,"teacher_disagreement_score":0.027568635,"about_ca_system_score_codex":0.002820831,"about_ca_system_score_gemma":0.004196804,"threshold_uncertainty_score":0.09222627},"labels":[],"label_agreement":null},{"id":"W4411094243","doi":"10.1038/s41571-025-01031-z","title":"Surrogate end points in oncology: aligning drug development incentives and patient needs","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Surrogate endpoint; Drug development; Incentive; Oncology; Drug; Internal medicine; Intensive care medicine; Medical physics; Pharmacology","score_opus":0.1841165872883653,"score_gpt":0.47868406450756495,"score_spread":0.2945674772191996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411094243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002153312,0.9924124,0.0007425367,0.005667,0.00024139856,0.000012674921,0.00004145884,0.0000072721423,0.00065993855],"genre_scores_gemma":[0.009531013,0.9846746,0.0015055278,0.0030497245,0.00080500095,0.000064027,0.00006744097,0.0000078816365,0.00029494756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99216545,0.005839729,0.00042233084,0.00032151333,0.0010304304,0.00022048957],"domain_scores_gemma":[0.96576446,0.03013213,0.0022460937,0.0002799015,0.0011933396,0.0003840118],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01586563,0.00086216326,0.0035566755,0.0018027759,0.00025020703,0.0026821308,0.0016443626,0.0031165401,0.005179324],"category_scores_gemma":[0.032729138,0.00042166913,0.0014547796,0.0024624013,0.0013137751,0.0030378397,0.0018559166,0.0045925574,0.0007094533],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047787136,0.00010843792,0.0008885275,0.02406039,0.0008916684,0.000083050225,0.000046274206,0.0035157364,0.0001275219,0.046109017,0.026096422,0.8975951],"study_design_scores_gemma":[0.0011255494,0.00066511804,0.0076625943,0.11754265,0.002358696,0.0009940406,0.00026496613,0.0050659166,0.00045415264,0.17042321,0.6932693,0.00017375925],"about_ca_topic_score_codex":0.0019376812,"about_ca_topic_score_gemma":0.004809495,"teacher_disagreement_score":0.9841344,"about_ca_system_score_codex":0.002739614,"about_ca_system_score_gemma":0.005216326,"threshold_uncertainty_score":0.08390647},"labels":[],"label_agreement":null},{"id":"W4411170659","doi":"10.17161/gjcpp.v9i2.20712","title":"Access to Indigenous and allopathic medicines: A systematic review of barriers and facilitators","year":2018,"lang":"en","type":"review","venue":"Global Journal of Community Psychology Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Indigenous; Traditional medicine; Medicine; Biology; Ecology","score_opus":0.15300739185184553,"score_gpt":0.4731624022940539,"score_spread":0.32015501044220834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411170659","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003245531,0.9947345,0.00017527363,0.0006129672,0.00007967062,0.0003714012,0.0002896655,0.000006076541,0.0004849832],"genre_scores_gemma":[0.032153703,0.96493596,0.0009609374,0.00059291953,0.000053715266,0.000944071,0.00021280549,0.0000058577034,0.00014015452],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98202467,0.007343757,0.005877995,0.00094850425,0.0032575496,0.00054748956],"domain_scores_gemma":[0.9088105,0.07377568,0.010981143,0.00073803077,0.004832634,0.00086208456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021111619,0.0011830876,0.0069972253,0.010892183,0.0012286864,0.0030976492,0.002071761,0.0018584287,0.00449819],"category_scores_gemma":[0.0791504,0.0011485191,0.0067218845,0.0111388285,0.0015191959,0.0039107664,0.0024497805,0.0015436404,0.00022441168],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012871716,0.000027941835,0.0013779335,0.953523,0.0039515262,0.000090619644,0.0015876557,0.000054894917,0.00008056444,0.00033398412,0.00077452464,0.03806872],"study_design_scores_gemma":[0.00010137485,0.00014619796,0.004965703,0.9589599,0.020421833,0.0002287142,0.0021606504,0.00004710521,0.00009947715,0.00024247234,0.012600096,0.000026412847],"about_ca_topic_score_codex":0.012442081,"about_ca_topic_score_gemma":0.040248007,"teacher_disagreement_score":0.021111619,"about_ca_system_score_codex":0.004833913,"about_ca_system_score_gemma":0.02644416,"threshold_uncertainty_score":0.11165029},"labels":[],"label_agreement":null},{"id":"W4411254450","doi":"10.1101/2025.06.11.25329435","title":"Social and private value created through commercialization of Gilead Sciences’ innovative medicines for Hepatitis C and HIV: a cross-sectional analysis","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"Bentley University","keywords":"Commercialization; Cross-sectional study; Value (mathematics); Human immunodeficiency virus (HIV); Medicine; Political science; Psychology; Sociology; Virology; Computer science","score_opus":0.1420615727454391,"score_gpt":0.40017154643666814,"score_spread":0.258109973691229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411254450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953537,0.000449639,0.00025871236,0.00020431899,0.000014606497,0.00007519315,0.002362352,0.0000035258033,0.001277977],"genre_scores_gemma":[0.9968978,0.0001774752,0.00020395988,0.00010805495,0.000039582665,0.00011928037,0.0017558673,0.000003371432,0.00069460005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542195,0.002123043,0.00046020633,0.00060982356,0.00095293974,0.00043200114],"domain_scores_gemma":[0.96742815,0.012643416,0.014635908,0.0010652074,0.0027193218,0.0015080138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006147885,0.00033154213,0.00036158296,0.0027211145,0.0005559217,0.0014786687,0.0007588146,0.00093876926,0.0063452083],"category_scores_gemma":[0.014149693,0.00030426035,0.0018272218,0.0021665196,0.00065178017,0.0014021598,0.001271783,0.0013437778,0.0007703629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017161568,0.00023025987,0.9961934,0.00003465104,0.00049216405,0.000028459219,0.0001915598,0.000132122,0.00003462303,0.0001805563,0.00043126263,0.0018792108],"study_design_scores_gemma":[0.000014554778,0.00025592506,0.99780256,0.00003547041,0.00015996926,0.00006984715,0.00053008756,0.00047625168,0.00005439027,0.00008976372,0.0005019022,0.00000919774],"about_ca_topic_score_codex":0.005354962,"about_ca_topic_score_gemma":0.004497776,"teacher_disagreement_score":0.0063452083,"about_ca_system_score_codex":0.0011208438,"about_ca_system_score_gemma":0.0007845141,"threshold_uncertainty_score":0.03251356},"labels":[],"label_agreement":null},{"id":"W4411460274","doi":"10.35629/4494-100227652769","title":"Pharmaceutical regulatory agencies and organization around the world scope and challenges in drug development","year":2025,"lang":"en","type":"article","venue":"International Journal of Pharmaceutical Research and Applications","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Transparency (behavior); Harmonization; Scope (computer science); Agency (philosophy); Drug development; Regulatory science; Globalization; Public relations; Medicine; Political science; Pharmacology; Drug","score_opus":0.23045994455796437,"score_gpt":0.4367126384633554,"score_spread":0.20625269390539103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411460274","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044983245,0.052277863,0.020032255,0.25973165,0.0019081881,0.00037559224,0.00039667115,0.0001689527,0.62012553],"genre_scores_gemma":[0.807417,0.049590956,0.016864832,0.06811078,0.0032591121,0.00062626466,0.0003752644,0.00019395744,0.05356187],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9668803,0.014681672,0.0018162394,0.0034650976,0.009723443,0.003433245],"domain_scores_gemma":[0.9503095,0.023068625,0.010121888,0.0030002731,0.009104514,0.0043952693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028489599,0.00041477373,0.00044075015,0.0033384822,0.0034492395,0.017821208,0.0012059611,0.0063305744,0.00867994],"category_scores_gemma":[0.033549834,0.0004531004,0.000616876,0.0060164738,0.008069087,0.006357263,0.00442834,0.0051545226,0.0014347995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044283035,0.00008289603,0.00612915,0.00019497734,0.000051421765,0.00016220708,0.0016659818,0.001291259,0.00030996036,0.88203686,0.028580174,0.07945083],"study_design_scores_gemma":[0.000032253505,0.00014744728,0.014751515,0.00098344,0.00003722786,0.0004042295,0.0049320785,0.0010530234,0.0004023908,0.15849754,0.81867456,0.0000843329],"about_ca_topic_score_codex":0.0052096075,"about_ca_topic_score_gemma":0.0039713886,"teacher_disagreement_score":0.028489599,"about_ca_system_score_codex":0.008277926,"about_ca_system_score_gemma":0.021469954,"threshold_uncertainty_score":0.15066922},"labels":[],"label_agreement":null},{"id":"W4411660605","doi":"10.51847/g68bgxyh0y","title":"10.51847/g68BGxyH0y","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Rivaroxaban; Drug; Medicine; Pharmacology; Internal medicine","score_opus":0.029545278218479097,"score_gpt":0.22240923156837925,"score_spread":0.19286395334990014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411660605","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014054856,0.0006599508,0.0007056477,0.0025664736,0.0007616879,0.00010639887,0.0028202308,0.0011531215,0.9898211],"genre_scores_gemma":[0.0032011045,0.00027061207,0.00032963758,0.0007253103,0.00017347455,0.000044095937,0.0009718686,0.00026037815,0.9940236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996873,0.00003721023,0.000018641478,0.00008597499,0.00010249675,0.00006846058],"domain_scores_gemma":[0.9992593,0.00014567711,0.00006745475,0.00010078698,0.00014312893,0.0002836446],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005960469,0.0015121901,0.0009306835,0.0017053743,0.0007324981,0.0020632038,0.0008966262,0.0034743026,0.97220075],"category_scores_gemma":[0.0010439691,0.00036703347,0.0005344791,0.0012076033,0.0008767408,0.0013538548,0.0021943634,0.0013075791,0.97514844],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002869592,0.00017564699,0.0011456311,0.00022508377,0.000015869693,0.00031586082,0.00004712346,0.0002185808,0.0013729059,0.0043906183,0.46847048,0.5233353],"study_design_scores_gemma":[0.00008611856,0.000056277437,0.001545477,0.00014980462,0.000005963043,0.00023435005,0.000041421023,0.00016041263,0.00027129732,0.0015221575,0.9959157,0.000010916457],"about_ca_topic_score_codex":0.0026215084,"about_ca_topic_score_gemma":0.002035093,"teacher_disagreement_score":0.027799249,"about_ca_system_score_codex":0.00085846084,"about_ca_system_score_gemma":0.00070452347,"threshold_uncertainty_score":0.03965217},"labels":[],"label_agreement":null},{"id":"W4411730067","doi":"10.25040/ntsh2025.01.22","title":"DIRECTIONS FOR IMPROVING PATIENTS’ ACCESS TO TREATMENT IN UKRAINE: CHALLENGES AND NEW OPPORTUNITIES FOR PHARMACEUTICAL PROVISION IN WARTIME","year":2025,"lang":"en","type":"article","venue":"Proceedings of the Shevchenko Scientific Society Medical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Business; Process management; Medicine; Engineering management; Engineering","score_opus":0.26532890988373137,"score_gpt":0.37884841326584384,"score_spread":0.11351950338211247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411730067","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030216064,0.06714209,0.0020062865,0.88813514,0.0011876554,0.000038511313,0.00039260826,0.000054025484,0.010827591],"genre_scores_gemma":[0.7970134,0.11794889,0.0070303916,0.06606786,0.0035488205,0.00019487804,0.0006388044,0.000050298837,0.0075066625],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622846,0.0019867017,0.00019606359,0.00018112661,0.00047389665,0.0009338064],"domain_scores_gemma":[0.9937459,0.0019541401,0.00082489336,0.00011599996,0.00068273325,0.0026763706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051028025,0.00028261708,0.00067731715,0.0010060943,0.0021928968,0.0072801188,0.0011199659,0.0041834475,0.007476627],"category_scores_gemma":[0.0070008584,0.00022744465,0.00062455895,0.0010679979,0.001996423,0.004441442,0.0056206975,0.0047195875,0.00056516443],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059441465,0.00073003746,0.03643021,0.0038646355,0.00028114562,0.0022474024,0.008120797,0.004653332,0.0012350869,0.45776892,0.16664256,0.31743142],"study_design_scores_gemma":[0.00022135765,0.0008061527,0.10017695,0.010337163,0.00019667644,0.0017243365,0.03955171,0.009074227,0.0010421025,0.22573341,0.61091316,0.00022269694],"about_ca_topic_score_codex":0.016793786,"about_ca_topic_score_gemma":0.016093064,"teacher_disagreement_score":0.016793786,"about_ca_system_score_codex":0.007781059,"about_ca_system_score_gemma":0.032915823,"threshold_uncertainty_score":0.05645579},"labels":[],"label_agreement":null},{"id":"W4411873872","doi":"10.2196/65978","title":"Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study","year":2025,"lang":"en","type":"article","venue":"JMIRx Med","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Timeline; Activity-based costing; Investment (military); Clinical trial; Business; Pharmaceutical industry; Payback period; Process (computing); Operations management; Finance; Risk analysis (engineering); Actuarial science; Operations research; Computer science; Medicine; Marketing; Economics; Engineering; Pharmacology; Production (economics); Geography","score_opus":0.10734961138691243,"score_gpt":0.419332029649971,"score_spread":0.3119824182630586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411873872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9308316,0.0072303633,0.037265074,0.00085232244,0.000056134202,0.013050293,0.0028121802,0.000041669115,0.007860338],"genre_scores_gemma":[0.9500166,0.00352344,0.034719218,0.00036483342,0.000047534515,0.0096390145,0.00084965525,0.000015340047,0.00082423585],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.94526356,0.043515097,0.0036621392,0.0018979523,0.004476309,0.0011850263],"domain_scores_gemma":[0.78046614,0.18555984,0.01891116,0.0030138236,0.010955638,0.0010933887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06651299,0.0013905314,0.0010723185,0.0046310257,0.00091177324,0.0037552745,0.0016560655,0.0014294235,0.0044806846],"category_scores_gemma":[0.07423905,0.0009620718,0.0046146247,0.003359558,0.00079482695,0.002465336,0.0021533207,0.0010015478,0.0002983237],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018754542,0.01222077,0.3816026,0.042511825,0.016349277,0.0049208906,0.0144067565,0.09071377,0.005197608,0.019370614,0.0036103623,0.3903411],"study_design_scores_gemma":[0.0050895563,0.06330709,0.38493103,0.018970424,0.026441446,0.004028212,0.052381624,0.36068013,0.023777248,0.023436232,0.0353431,0.0016139483],"about_ca_topic_score_codex":0.0055822195,"about_ca_topic_score_gemma":0.0063304426,"teacher_disagreement_score":0.06651299,"about_ca_system_score_codex":0.008133637,"about_ca_system_score_gemma":0.007847115,"threshold_uncertainty_score":0.35175848},"labels":[],"label_agreement":null},{"id":"W4411924841","doi":"10.1002/pds.70178","title":"Impact of Supply Chain Disruptions and Drug Shortages on Drug Utilization: A Scoping Review","year":2025,"lang":"en","type":"review","venue":"Pharmacoepidemiology and Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; St. Francis Xavier University; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Grey literature; Medicine; Observational study; Economic shortage; Drug; Medical prescription; Population; MEDLINE; Environmental health; Pharmacology; Pathology","score_opus":0.15614154994512472,"score_gpt":0.4606250153813216,"score_spread":0.30448346543619687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411924841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010727952,0.9967235,0.00017543341,0.0007725662,0.00021996014,0.000125933,0.00017438704,0.0000051084007,0.0007303517],"genre_scores_gemma":[0.0059612403,0.99302965,0.00027030948,0.00028966225,0.00013828366,0.00014074144,0.00010167414,0.0000024070248,0.00006601919],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99103993,0.003058142,0.003122272,0.0006375101,0.0017565461,0.00038565224],"domain_scores_gemma":[0.91279364,0.069136076,0.010030712,0.0007410106,0.0067747906,0.0005237247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013411203,0.0013727609,0.0032397874,0.016888902,0.0012463346,0.0049189636,0.0015612965,0.0029490874,0.0041279537],"category_scores_gemma":[0.0672801,0.001318541,0.005139599,0.01908081,0.0012072835,0.004279328,0.0022275862,0.001828688,0.00052016857],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014397842,0.00007741755,0.004947527,0.74685067,0.0035675077,0.00032917853,0.0010770494,0.00070305023,0.00015442005,0.0021501153,0.007608255,0.23239085],"study_design_scores_gemma":[0.000027747506,0.0001256181,0.00837331,0.9286283,0.008400845,0.0005775496,0.0013240883,0.00026507262,0.00018261453,0.0010077952,0.051039968,0.0000470133],"about_ca_topic_score_codex":0.01708957,"about_ca_topic_score_gemma":0.026432311,"teacher_disagreement_score":0.01708957,"about_ca_system_score_codex":0.0058810296,"about_ca_system_score_gemma":0.020309467,"threshold_uncertainty_score":0.07092607},"labels":[],"label_agreement":null},{"id":"W4412136694","doi":"10.17480/psk.2025.69.3.233","title":"Comparison of the Collection Status of Unused Medicines Domestically and Internationally and Derivation of Policy Implications","year":2025,"lang":"en","type":"article","venue":"Yakhak Hoeji","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.05404561871012296,"score_gpt":0.3692358187901013,"score_spread":0.31519020007997833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412136694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354952,0.002285221,0.0020474708,0.0037842505,0.00004291263,0.000100566314,0.002253195,0.00002121173,0.053970013],"genre_scores_gemma":[0.9955519,0.00082056015,0.0004800216,0.00013718057,0.000009693549,0.000022562628,0.00048403774,0.0000068883965,0.0024872052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782145,0.0008758702,0.00019530355,0.0002377972,0.000394882,0.0004746947],"domain_scores_gemma":[0.9926156,0.002214215,0.0026268014,0.00033927115,0.001884599,0.0003195456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024849218,0.00015590533,0.00024945693,0.0021349215,0.0004968951,0.0021058354,0.00048692303,0.00035687146,0.0049738707],"category_scores_gemma":[0.008298063,0.00013985914,0.00059487554,0.0037972217,0.00062546413,0.0019723733,0.0009730295,0.00058774464,0.0002897111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006439431,0.0002994365,0.8135716,0.0005630991,0.00031455347,0.0008825842,0.0018423389,0.00744712,0.0017997891,0.07292293,0.00328264,0.096429996],"study_design_scores_gemma":[0.000020723064,0.00017401486,0.9544373,0.00034864762,0.0001514212,0.00030688554,0.010029892,0.006682002,0.0023008035,0.006033229,0.019472063,0.000043018415],"about_ca_topic_score_codex":0.030780094,"about_ca_topic_score_gemma":0.03239411,"teacher_disagreement_score":0.030780094,"about_ca_system_score_codex":0.00386986,"about_ca_system_score_gemma":0.0032131881,"threshold_uncertainty_score":0.06120187},"labels":[],"label_agreement":null},{"id":"W4412264885","doi":"","title":"Ethicists’ commentary on appropriate use of pharmaceuticals","year":2022,"lang":"en","type":"article","venue":"Research at the University of Copenhagen (University of Copenhagen)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Computer science","score_opus":0.23526841565592915,"score_gpt":0.3347452267743214,"score_spread":0.09947681111839224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412264885","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020776081,0.0017759686,0.00008106359,0.98162305,0.014142718,0.0000062788968,0.000032846616,0.0000056031313,0.0021247303],"genre_scores_gemma":[0.0049169343,0.0004899622,0.00011009814,0.9755282,0.017292546,0.00002382963,0.000009957285,0.000016444319,0.0016120708],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.90659624,0.0387759,0.011294026,0.011183432,0.020484207,0.011666153],"domain_scores_gemma":[0.75698596,0.19639212,0.009655095,0.0057969973,0.02049709,0.010672688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06053112,0.0013040408,0.0036507535,0.0025646312,0.009656685,0.01389719,0.008224872,0.16611226,0.007080165],"category_scores_gemma":[0.19719394,0.002395248,0.0038954867,0.0029890637,0.025765516,0.01044141,0.008481958,0.14655069,0.0028773916],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011035788,0.000032668955,0.00021570644,0.00024027171,0.00008514965,0.0005011027,0.0016246175,0.00014201498,0.00013451517,0.061198015,0.93152416,0.004191458],"study_design_scores_gemma":[0.00028737506,0.00004396763,0.0013930779,0.0017380209,0.0001511352,0.00031146055,0.0015000856,0.0002328242,0.00041245273,0.053436458,0.9403255,0.00016765429],"about_ca_topic_score_codex":0.03105048,"about_ca_topic_score_gemma":0.033775233,"teacher_disagreement_score":0.16611226,"about_ca_system_score_codex":0.017471135,"about_ca_system_score_gemma":0.030911371,"threshold_uncertainty_score":0.32012302},"labels":[],"label_agreement":null},{"id":"W4412442816","doi":"10.1016/j.jval.2025.04.398","title":"EE106 Pressures Behind the Rising Costs in Canadian Private Drug Plans: 2018-2023","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Government of Canada","funders":"","keywords":"Business; Drug; Natural resource economics; Economics; Pharmacology; Medicine","score_opus":0.06595050093101903,"score_gpt":0.3183061291014316,"score_spread":0.25235562817041257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412442816","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13768193,0.013651448,0.0012819555,0.48638877,0.0038751964,0.00020381306,0.060152594,0.00034717083,0.29641712],"genre_scores_gemma":[0.74885625,0.011476548,0.0021426796,0.04730289,0.0023025325,0.00011996338,0.0143566495,0.00025805604,0.17318448],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9921996,0.00018872356,0.000106911786,0.00017282512,0.0048848246,0.002447081],"domain_scores_gemma":[0.9869135,0.0008563207,0.0007299204,0.00015183244,0.008642295,0.0027061831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030126772,0.00045691268,0.00045883132,0.0023641945,0.004210551,0.008957554,0.0010380464,0.0041909013,0.017791444],"category_scores_gemma":[0.016539846,0.00045256558,0.0012037543,0.0035840655,0.0013064047,0.0013996916,0.0016019813,0.00450874,0.0015658304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042781033,0.000077879144,0.03194987,0.0003305087,0.000118331314,0.00033030682,0.0009062814,0.0030143694,0.00077429146,0.123087324,0.7885807,0.050402276],"study_design_scores_gemma":[0.00007095968,0.00003446028,0.17171758,0.00035924144,0.00005980273,0.00010539086,0.0017032825,0.0023476689,0.00065169134,0.005928163,0.8169234,0.00009837373],"about_ca_topic_score_codex":0.9897119,"about_ca_topic_score_gemma":0.99316895,"teacher_disagreement_score":0.13702759,"about_ca_system_score_codex":0.13702759,"about_ca_system_score_gemma":0.18775328,"threshold_uncertainty_score":0.9942094},"labels":[],"label_agreement":null},{"id":"W4412443590","doi":"10.1016/j.jval.2025.04.877","title":"HPR153 The Reimbursement Status of Ustekinumab Across HTAs: A Global Perspective","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Ustekinumab; Reimbursement; Perspective (graphical); Medicine; Data science; Computer science; Internal medicine; Economics; Economic growth; Artificial intelligence; Disease","score_opus":0.10754833739723527,"score_gpt":0.40213819708472887,"score_spread":0.2945898596874936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412443590","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060690954,0.08558437,0.0018201543,0.72274953,0.002967063,0.000029662875,0.0028355473,0.00005727181,0.12326545],"genre_scores_gemma":[0.7750268,0.07795154,0.0025257743,0.11208555,0.016526693,0.00006279626,0.0015164918,0.000114507115,0.014189873],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9974927,0.0009661406,0.00015015993,0.00024848848,0.00059396256,0.0005485649],"domain_scores_gemma":[0.99134177,0.0037984233,0.0018289589,0.00022076628,0.001592019,0.0012181895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050373776,0.00029217094,0.0006073699,0.0016413962,0.0005492716,0.0066868654,0.00062590477,0.0057587856,0.007879945],"category_scores_gemma":[0.011671902,0.0002580182,0.0009693612,0.0027881612,0.0018777873,0.003071641,0.001581829,0.004962523,0.00073197787],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091738673,0.00020516294,0.022812376,0.0011234998,0.00035259174,0.001137829,0.00082933897,0.0044083176,0.0024222345,0.509371,0.18378693,0.27263328],"study_design_scores_gemma":[0.0002580773,0.0007079622,0.15661323,0.0059140353,0.0005783704,0.0023274743,0.0025250597,0.004937626,0.0020313847,0.12821493,0.69568574,0.00020614566],"about_ca_topic_score_codex":0.012880337,"about_ca_topic_score_gemma":0.010719147,"teacher_disagreement_score":0.012880337,"about_ca_system_score_codex":0.0039461716,"about_ca_system_score_gemma":0.004913538,"threshold_uncertainty_score":0.028631628},"labels":[],"label_agreement":null},{"id":"W4412752731","doi":"10.31579/2835-7957/036","title":"The Determinants of Study Productivity in Ethical Drug Discovery","year":2023,"lang":"en","type":"article","venue":"Clinical Reviews and Case Reports","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Calgary","keywords":"Drug discovery; Productivity; Drug; Business; Medicine; Pharmacology; Economics; Biology; Bioinformatics; Economic growth","score_opus":0.2354669300811779,"score_gpt":0.4596220946425224,"score_spread":0.22415516456134452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412752731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95868546,0.0026595339,0.0052137333,0.0136452755,0.00011708914,0.00023636263,0.00094076723,0.00006225584,0.018439433],"genre_scores_gemma":[0.99823666,0.00033279404,0.00046740222,0.00021324304,0.00008232353,0.00004983332,0.00013175138,0.000009214071,0.0004766741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.943267,0.031188233,0.0047358456,0.0024678134,0.01171376,0.0066273697],"domain_scores_gemma":[0.42775682,0.38116,0.11597253,0.02250633,0.018592725,0.03401158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04603989,0.00029853167,0.0004772664,0.007407595,0.002744462,0.005559426,0.0017250198,0.0010642989,0.0058504627],"category_scores_gemma":[0.25514892,0.0004257545,0.00078773504,0.0066820243,0.006591071,0.0032243042,0.0056812908,0.0021250541,0.00093420385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014803637,0.00012941365,0.97579396,0.00005303594,0.000101657104,0.00019938928,0.0023691931,0.0004896131,0.00012272624,0.0032342293,0.0016875246,0.015671244],"study_design_scores_gemma":[0.000035598,0.0001750458,0.98386973,0.00010553074,0.000030401752,0.00032879642,0.0054665026,0.0013096054,0.00020626262,0.0047151777,0.003734125,0.000023242574],"about_ca_topic_score_codex":0.008434816,"about_ca_topic_score_gemma":0.0070772194,"teacher_disagreement_score":0.04603989,"about_ca_system_score_codex":0.004662836,"about_ca_system_score_gemma":0.00593349,"threshold_uncertainty_score":0.24348515},"labels":[],"label_agreement":null},{"id":"W4412840461","doi":"10.1186/s12913-025-13211-9","title":"Decolonizing global health: Africa’s pursuit of pharmaceutical sovereignty","year":2025,"lang":"en","type":"review","venue":"BMC Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Medicine; Health informatics; Nursing research; Public health; Health administration; Sovereignty; Healthcare policy; Health policy; International health; Nursing; Political science; Law; Politics","score_opus":0.3543299700210595,"score_gpt":0.5415522939152496,"score_spread":0.18722232389419013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412840461","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025579445,0.6968066,0.0039666994,0.21339269,0.0014153012,0.00023533462,0.00036629077,0.00003666775,0.058200985],"genre_scores_gemma":[0.48204646,0.48147467,0.0054539884,0.02687589,0.0008894391,0.0003950739,0.00017379597,0.000029815303,0.0026609732],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98041403,0.013174222,0.0015244444,0.00095366867,0.0027744372,0.001159191],"domain_scores_gemma":[0.92178273,0.068270005,0.00569099,0.0014130636,0.0021836422,0.00065965374],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.025690095,0.0005154415,0.0008927691,0.0051320363,0.003401597,0.012014751,0.0011643143,0.003807443,0.005252669],"category_scores_gemma":[0.045161124,0.00037649108,0.0007533212,0.009444316,0.015601953,0.017845085,0.0067436383,0.0049335426,0.00043936208],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012823236,0.000038203656,0.0024521598,0.066868916,0.00020769285,0.001417434,0.10548163,0.0006033656,0.0009239724,0.50191915,0.03123213,0.2887271],"study_design_scores_gemma":[0.00005878019,0.00016221189,0.0055680554,0.15489425,0.00028662934,0.0010543589,0.10844638,0.00029415137,0.0008633,0.10520436,0.6231074,0.000060161557],"about_ca_topic_score_codex":0.005109922,"about_ca_topic_score_gemma":0.006846578,"teacher_disagreement_score":0.9965984,"about_ca_system_score_codex":0.009851233,"about_ca_system_score_gemma":0.025927378,"threshold_uncertainty_score":0.13586384},"labels":[],"label_agreement":null},{"id":"W4412910932","doi":"10.3389/fpubh.2025.1588227","title":"Lessons learned from redesigning public health medicines supply chain model in Uttar Pradesh, India","year":2025,"lang":"en","type":"review","venue":"Frontiers in Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health","funders":"University of Manitoba; Bill and Melinda Gates Foundation","keywords":"Procurement; Business; Essential medicines; Supply chain; Vendor; Health facility; Operations management; Call for bids; Public health; Medicine; Marketing; Environmental health; Engineering","score_opus":0.3267707216040615,"score_gpt":0.40658743431958383,"score_spread":0.07981671271552232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412910932","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5648316,0.0066015255,0.10735639,0.1990006,0.0017316643,0.0021507803,0.0007113849,0.0018209864,0.11579502],"genre_scores_gemma":[0.85961527,0.005744899,0.11547348,0.0071105435,0.00021167159,0.00024609378,0.00045319076,0.00017509193,0.010969713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99272513,0.0037111363,0.0004764348,0.0005717427,0.0014110858,0.0011044455],"domain_scores_gemma":[0.98800045,0.004066395,0.0009049845,0.0015818591,0.003696589,0.0017496563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00873589,0.0006687075,0.00028503354,0.0014274353,0.0032741914,0.009323992,0.0025295804,0.0020147841,0.002463982],"category_scores_gemma":[0.011170013,0.000505261,0.0007276252,0.0020868666,0.0033371812,0.007880256,0.0042011747,0.004186444,0.0007812097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033154088,0.0014248054,0.048982184,0.004041292,0.00017109922,0.008237299,0.09130078,0.047766805,0.012191349,0.18960595,0.050032787,0.54591405],"study_design_scores_gemma":[0.00016819914,0.0018840565,0.035464596,0.0031820012,0.00031285203,0.0037231531,0.14210558,0.043348793,0.013380742,0.076783486,0.67918056,0.0004660246],"about_ca_topic_score_codex":0.03783964,"about_ca_topic_score_gemma":0.042202003,"teacher_disagreement_score":0.03783964,"about_ca_system_score_codex":0.011416148,"about_ca_system_score_gemma":0.0273703,"threshold_uncertainty_score":0.08283037},"labels":[],"label_agreement":null},{"id":"W4413092746","doi":"10.2139/ssrn.5354318","title":"Lagged-Price Reimbursement Contracts: The Impact of Medicare Part B on Pharmaceutical Price Growth","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Reimbursement; Economics; Business; Monetary economics; Actuarial science; Health care; Economic growth","score_opus":0.042356727904565065,"score_gpt":0.3385289669320769,"score_spread":0.29617223902751183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413092746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9328643,0.007824871,0.0031081522,0.033846095,0.0008223799,0.00004408127,0.007592747,0.00026466424,0.013632664],"genre_scores_gemma":[0.9920385,0.0011195493,0.00016095862,0.0006989956,0.0002394261,0.000007437988,0.0011006377,0.000029284409,0.004605163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978719,0.00071615883,0.00011243644,0.00029071572,0.00026123787,0.00074763264],"domain_scores_gemma":[0.9666826,0.02311954,0.005336074,0.0006756584,0.0013625375,0.002823479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054717027,0.00057331956,0.0012265531,0.00086039753,0.00077525503,0.0055189673,0.0014996978,0.005163901,0.019406797],"category_scores_gemma":[0.03176352,0.0005232403,0.0012313554,0.0016480082,0.0013220356,0.0031366243,0.0015792338,0.005049303,0.0013821832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015214707,0.0034708553,0.47543222,0.0010207443,0.0011668402,0.0036666638,0.0009025128,0.18187322,0.0043583647,0.13880254,0.07674252,0.09734882],"study_design_scores_gemma":[0.0015186986,0.0024856445,0.48422077,0.00032909957,0.0015736072,0.00067253545,0.002755392,0.3737865,0.004863023,0.10777488,0.019724332,0.00029546837],"about_ca_topic_score_codex":0.04207859,"about_ca_topic_score_gemma":0.030949712,"teacher_disagreement_score":0.04207859,"about_ca_system_score_codex":0.0029462553,"about_ca_system_score_gemma":0.0047292127,"threshold_uncertainty_score":0.08366734},"labels":[],"label_agreement":null},{"id":"W4413228424","doi":"10.22541/au.175489038.81543204/v1","title":"Maximizing Medicine Access through Trade Credit Optimization in Subsidized Fixed-Price Markets","year":2025,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Subsidy; Business; Economics; Monetary economics; Market economy","score_opus":0.13751882401341683,"score_gpt":0.35093172933214944,"score_spread":0.2134129053187326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413228424","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30672097,0.001052692,0.6667279,0.0018526257,0.00013216767,0.0004501859,0.000554875,0.00026578744,0.022242831],"genre_scores_gemma":[0.9814488,0.00028479085,0.015026328,0.00006764505,0.000027819406,0.00008664823,0.00006265536,0.000022623684,0.0029726888],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983646,0.00082858576,0.000063072126,0.0003194812,0.00014232745,0.0002818492],"domain_scores_gemma":[0.9947561,0.0032769113,0.000995969,0.00023154235,0.00035121507,0.0003882489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038327037,0.0009999493,0.0015254202,0.0006862764,0.00066071283,0.0034896655,0.0011836214,0.0020430204,0.00777324],"category_scores_gemma":[0.01150251,0.0006957869,0.0010672549,0.0006699769,0.0025057218,0.0036121977,0.0018391109,0.002160732,0.0003233135],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032909465,0.0001480145,0.0016856226,0.00013064439,0.000052482475,0.0002666297,0.0001006166,0.8698911,0.00089740107,0.11522145,0.0010556206,0.010221351],"study_design_scores_gemma":[0.000107070584,0.00010088939,0.00055278133,0.0000379089,0.000033306398,0.00003644255,0.000078978796,0.89763373,0.00040461056,0.09984346,0.0011477487,0.000023108341],"about_ca_topic_score_codex":0.0061263307,"about_ca_topic_score_gemma":0.0033834407,"teacher_disagreement_score":0.00777324,"about_ca_system_score_codex":0.0028311696,"about_ca_system_score_gemma":0.0024252753,"threshold_uncertainty_score":0.026004136},"labels":[],"label_agreement":null},{"id":"W4413418246","doi":"10.1001/jamahealthforum.2025.2631","title":"Estimating Costs of Market Exclusivity Extensions For 4 Top-Selling Prescription Drugs in the US","year":2025,"lang":"en","type":"article","venue":"JAMA Health Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicare Part D; Competition (biology); Prescription drug; Generic drug; Biosimilar; Market share; Managed care; Business; Drug prices; Actuarial science; Medical prescription; Orphan drug; Marketing; Health care; Medicine; Economics; Public economics; Drug; Pharmacology","score_opus":0.046400109252674154,"score_gpt":0.3416201360266369,"score_spread":0.29522002677396275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413418246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104637,0.0005528558,0.0005650902,0.00016604451,0.000005846255,0.000038737486,0.0069766757,0.00001420554,0.00063429493],"genre_scores_gemma":[0.9919477,0.00038791713,0.0006868914,0.00005439266,0.000013708398,0.000057330293,0.006628295,0.000004688495,0.00021915686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990138,0.00032192442,0.0001774854,0.00022400895,0.00013847672,0.00012427234],"domain_scores_gemma":[0.99340135,0.0020775076,0.003635544,0.00023918362,0.00037200336,0.0002744318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017057696,0.00048944337,0.00031514443,0.0019620387,0.00019668591,0.00072441867,0.0004964205,0.00044512528,0.0017370915],"category_scores_gemma":[0.008754694,0.0003652481,0.0015475751,0.0021150077,0.00029077454,0.000785276,0.0008838582,0.00065051636,0.00016768488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035798489,0.00006890432,0.9850306,0.00004392349,0.0003511415,0.000043220993,0.000021435506,0.009469825,0.000054566994,0.00032514977,0.000505115,0.0037279818],"study_design_scores_gemma":[0.00008364019,0.00046810746,0.9502113,0.00010391198,0.00050220505,0.00033836922,0.00019858833,0.04502799,0.00033720274,0.0007584299,0.0019428546,0.000027336002],"about_ca_topic_score_codex":0.029844286,"about_ca_topic_score_gemma":0.024524085,"teacher_disagreement_score":0.029844286,"about_ca_system_score_codex":0.0020905402,"about_ca_system_score_gemma":0.0013188915,"threshold_uncertainty_score":0.059341133},"labels":[],"label_agreement":null},{"id":"W4413524744","doi":"10.64628/aam.pdkrm3vgr","title":"With a pharmacare bill on the horizon, Big Pharma’s attack on single-payer drug coverage for Canadians needs a fact check","year":2023,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Business; Drug; Advertising; Marketing; Internet privacy; Public relations; Computer science; Medicine; Political science; Pharmacology","score_opus":0.1597124393687321,"score_gpt":0.3040678482647292,"score_spread":0.1443554088959971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413524744","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013467082,0.0018455076,0.0004174775,0.9509311,0.016601896,0.000027556,0.0018585698,0.00014879367,0.026822355],"genre_scores_gemma":[0.029487649,0.00333094,0.002347058,0.8821431,0.016143966,0.000045213506,0.002192588,0.00022308632,0.0640865],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98773116,0.0007846499,0.00031533686,0.00053150736,0.008362311,0.0022751093],"domain_scores_gemma":[0.95199525,0.01119763,0.0019729664,0.0012721539,0.017973697,0.01558834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009064301,0.0009928457,0.0015085032,0.0022059965,0.008402705,0.011393757,0.0021825107,0.021331886,0.04671179],"category_scores_gemma":[0.053863496,0.0006496456,0.002655828,0.0025755982,0.004234866,0.0065488103,0.002028721,0.023749748,0.0069562877],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000512459,0.000022122103,0.00065291714,0.000026513051,0.00002066121,0.00004732204,0.000034528726,0.000089282265,0.00008953089,0.012314939,0.9808303,0.005820603],"study_design_scores_gemma":[0.00012063454,0.00006188717,0.006952514,0.00027761812,0.00005904403,0.000098297576,0.0004655136,0.0006943058,0.0001982154,0.009294194,0.9816589,0.00011881639],"about_ca_topic_score_codex":0.82164663,"about_ca_topic_score_gemma":0.8792903,"teacher_disagreement_score":0.17835337,"about_ca_system_score_codex":0.031417947,"about_ca_system_score_gemma":0.08931177,"threshold_uncertainty_score":0.35880744},"labels":[],"label_agreement":null},{"id":"W4413553793","doi":"10.64628/aam.5u6t5dmv6","title":"How coronavirus is contributing to drug shortages in Canada","year":2020,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Economic shortage; Coronavirus; Pandemic; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Drug; Business; Virology; Medicine; Pharmacology; Outbreak; Infectious disease (medical specialty); Government (linguistics)","score_opus":0.11115672424989165,"score_gpt":0.29711354379569005,"score_spread":0.1859568195457984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413553793","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66012865,0.014576988,0.0007607099,0.26527262,0.00058377243,0.000094933486,0.009537228,0.00006840907,0.048976794],"genre_scores_gemma":[0.98222727,0.004934725,0.00018311276,0.0037465869,0.00021669843,0.000009466686,0.0008811229,0.000019409472,0.007781572],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974751,0.00022213763,0.000076229146,0.0001112978,0.0005843245,0.001530939],"domain_scores_gemma":[0.98944783,0.0014827362,0.0015819886,0.000118216005,0.004089381,0.0032799176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017080577,0.00017013193,0.00044871768,0.0017104603,0.0029664342,0.004101672,0.00090143346,0.0015145923,0.008068973],"category_scores_gemma":[0.010474734,0.00028812478,0.00065470254,0.0038493047,0.0013826216,0.00093835685,0.0011537024,0.0021051622,0.00020006229],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056866196,0.00027356975,0.61250025,0.00065875973,0.0004903689,0.0011341638,0.0030202544,0.019359501,0.00056755746,0.112159364,0.19766317,0.0516044],"study_design_scores_gemma":[0.00014851642,0.000102224934,0.79427236,0.0006699752,0.00034780533,0.0003364952,0.015644403,0.020211915,0.00060357404,0.020774513,0.14672351,0.0001647705],"about_ca_topic_score_codex":0.9957419,"about_ca_topic_score_gemma":0.9966428,"teacher_disagreement_score":0.09744646,"about_ca_system_score_codex":0.09744646,"about_ca_system_score_gemma":0.15567726,"threshold_uncertainty_score":0.70702684},"labels":[],"label_agreement":null},{"id":"W4413604366","doi":"10.64628/aam.aekeksfp3","title":"High drug prices in Canada are just one side of a bad equation","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University of British Columbia","funders":"","keywords":"Drug; Drug prices; Economics; Econometrics; Medicine; Monetary economics; Pharmacology","score_opus":0.16855811577615437,"score_gpt":0.2889533723425736,"score_spread":0.12039525656641925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413604366","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23701167,0.020270245,0.0061480296,0.5898384,0.0024052209,0.00011966463,0.015971538,0.00037248578,0.12786278],"genre_scores_gemma":[0.9408061,0.0072214627,0.0013910531,0.016505241,0.00082007627,0.000014072005,0.0016874615,0.00009017303,0.031464443],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829644,0.00015185689,0.00008437275,0.00023419021,0.0006146991,0.00061844],"domain_scores_gemma":[0.9949502,0.0010511897,0.0010169721,0.00020062119,0.0018992738,0.0008817665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014969761,0.00043048838,0.0010747827,0.0013952465,0.0024378237,0.0049428004,0.0009025748,0.0028211733,0.013754463],"category_scores_gemma":[0.01027059,0.00037147006,0.000560038,0.002841253,0.0025716238,0.0028088482,0.0011030608,0.0050637154,0.00064819225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041431971,0.00014868658,0.18871303,0.00039331068,0.00043490704,0.00081534183,0.00080894784,0.010577669,0.00065624935,0.38180962,0.34379393,0.07143395],"study_design_scores_gemma":[0.00037156855,0.00009964797,0.32458556,0.000515561,0.00084074255,0.00063465245,0.0038778565,0.03589209,0.0020659624,0.4195367,0.2112472,0.0003324372],"about_ca_topic_score_codex":0.97593915,"about_ca_topic_score_gemma":0.9762332,"teacher_disagreement_score":0.031813446,"about_ca_system_score_codex":0.031813446,"about_ca_system_score_gemma":0.049562924,"threshold_uncertainty_score":0.23082376},"labels":[],"label_agreement":null},{"id":"W4413610783","doi":"10.64628/aam.r77cf6mka","title":"NAFTA negotiations may threaten pharmacare","year":2018,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Negotiation; International trade; Political science; Business; Law and economics; Economics; Law","score_opus":0.1456492107694341,"score_gpt":0.34386428390033874,"score_spread":0.19821507313090464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413610783","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0389042,0.008429976,0.002836426,0.597096,0.0040684226,0.00008961856,0.0011971971,0.0003018965,0.34707624],"genre_scores_gemma":[0.63759315,0.003708334,0.0019358617,0.22173166,0.0060490547,0.0002136365,0.0005974323,0.00019843216,0.12797244],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9847195,0.003995146,0.0006557753,0.0013651156,0.0050798934,0.0041846256],"domain_scores_gemma":[0.9761277,0.014598418,0.002889291,0.0015481771,0.0031531786,0.0016831617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015556226,0.0007010083,0.0009773532,0.0020485627,0.0062070102,0.017499847,0.0016645361,0.0390395,0.036499836],"category_scores_gemma":[0.06387597,0.0008396084,0.0020239237,0.00221162,0.0031489865,0.009071996,0.004617725,0.012974098,0.004720096],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000658687,0.00020351821,0.006130309,0.00012927107,0.00016835702,0.0008194826,0.00077846233,0.0016073851,0.0006284636,0.76734614,0.1929782,0.028551634],"study_design_scores_gemma":[0.00029365538,0.00014932883,0.009116091,0.00035532983,0.00014962006,0.0004606203,0.0011469278,0.0027690073,0.0008956978,0.28290534,0.7016412,0.00011729564],"about_ca_topic_score_codex":0.025560455,"about_ca_topic_score_gemma":0.031283192,"teacher_disagreement_score":0.97443956,"about_ca_system_score_codex":0.011947885,"about_ca_system_score_gemma":0.013229412,"threshold_uncertainty_score":0.12210411},"labels":[],"label_agreement":null},{"id":"W4413632792","doi":"10.64628/aam.hajum63tw","title":"How the pharmaceutical industry uses disinformation to undermine drug price reform","year":2023,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Disinformation; Pharmaceutical industry; Drug; Business; Law and economics; Economics; Political science; Pharmacology; Medicine; Law; Social media","score_opus":0.1344081908847762,"score_gpt":0.3305701986658463,"score_spread":0.1961620077810701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413632792","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054998383,0.0066495836,0.011788776,0.72131217,0.0015146885,0.000091179514,0.00017607001,0.0002105924,0.2032585],"genre_scores_gemma":[0.88274527,0.0022924994,0.0027396027,0.096977495,0.0017260112,0.000055478034,0.000039724513,0.00009838496,0.013325521],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97623694,0.013223846,0.0005804069,0.001463995,0.0054781353,0.0030166616],"domain_scores_gemma":[0.90199125,0.07486838,0.006683949,0.004643066,0.0086208,0.0031925964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031479813,0.00042565083,0.00071232684,0.0025325397,0.00294165,0.01568393,0.0017329536,0.01644775,0.010794039],"category_scores_gemma":[0.11207444,0.00052843103,0.0008545161,0.0016243838,0.011068835,0.011387501,0.004759243,0.011133289,0.0016240282],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003304836,0.00022229482,0.0040963767,0.000179232,0.00012828485,0.0002560709,0.0016523015,0.0024217004,0.0006568588,0.90231544,0.050576545,0.03716436],"study_design_scores_gemma":[0.00036224513,0.0002666658,0.0053398665,0.0004718063,0.00020118858,0.00022906356,0.001872413,0.0071139266,0.0034180244,0.7595701,0.22101703,0.0001376372],"about_ca_topic_score_codex":0.009671865,"about_ca_topic_score_gemma":0.0076649575,"teacher_disagreement_score":0.031479813,"about_ca_system_score_codex":0.00891933,"about_ca_system_score_gemma":0.013280285,"threshold_uncertainty_score":0.16648316},"labels":[],"label_agreement":null},{"id":"W4413654452","doi":"10.64628/aam.frre7j36d","title":"How Big Pharma deceives you about drug safety","year":2018,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Drug; Business; Pharmacology; Medicine","score_opus":0.07817871533396767,"score_gpt":0.2955563714328716,"score_spread":0.21737765609890394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413654452","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026530646,0.008837982,0.008984033,0.8468421,0.0030513916,0.000032592914,0.00091680704,0.00015493229,0.10464942],"genre_scores_gemma":[0.75402135,0.00754387,0.0028441746,0.18221998,0.0072197854,0.000043156,0.00036420257,0.00027959474,0.04546388],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9874894,0.0063236593,0.0006143491,0.0011135396,0.0032131837,0.0012458183],"domain_scores_gemma":[0.8794969,0.08378075,0.013651277,0.0077343984,0.010137548,0.005199161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014943787,0.0004741559,0.0009715363,0.0020311368,0.0022795754,0.009907156,0.000723978,0.009593993,0.029019326],"category_scores_gemma":[0.14119402,0.00040593368,0.0006846475,0.0015991392,0.0064458456,0.01177616,0.0022559466,0.010589771,0.0046200133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007017852,0.00018865449,0.027736973,0.00036001304,0.00055047154,0.0006755458,0.0018327443,0.0022906703,0.0006269844,0.4952133,0.35981968,0.11000326],"study_design_scores_gemma":[0.00009222455,0.0001039799,0.011109271,0.0005773481,0.00019108223,0.00072749524,0.0017943627,0.0036035134,0.0012913552,0.8188469,0.16155492,0.00010766965],"about_ca_topic_score_codex":0.005588022,"about_ca_topic_score_gemma":0.0039320216,"teacher_disagreement_score":0.029019326,"about_ca_system_score_codex":0.0037148604,"about_ca_system_score_gemma":0.0034815925,"threshold_uncertainty_score":0.09707934},"labels":[],"label_agreement":null},{"id":"W4413723315","doi":"10.1080/19397038.2025.2547595","title":"Enhancing sustainability of medical devices procurement in Low- and Middle-Income Countries","year":2025,"lang":"en","type":"article","venue":"International Journal of Sustainable Engineering","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Sustainability; Low and middle income countries; Procurement; Business; Middle income; Low income; Natural resource economics; Developing country; Economic growth; Economics; Socioeconomics; Marketing; Demographic economics","score_opus":0.011374227882080068,"score_gpt":0.2766659095221207,"score_spread":0.26529168164004063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413723315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69952786,0.012566506,0.05058666,0.029697321,0.00020553598,0.0011118266,0.0007053222,0.00022530653,0.20537362],"genre_scores_gemma":[0.98402023,0.0030875239,0.010994783,0.00050494884,0.000018757171,0.00014693911,0.000111167705,0.000013055325,0.0011026821],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9895125,0.0071459473,0.0004701241,0.00028477752,0.0010181037,0.001568586],"domain_scores_gemma":[0.9876787,0.006096627,0.0025047758,0.00056515855,0.0023487336,0.0008059759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013132484,0.0005854439,0.00041093962,0.0039095166,0.0024337962,0.008713745,0.0008749345,0.0013505786,0.0034200652],"category_scores_gemma":[0.015490676,0.0003458823,0.0007153214,0.004060182,0.003235488,0.0034899437,0.007216891,0.0009445142,0.0003482596],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029248555,0.0006294174,0.23624226,0.00757449,0.00049662875,0.0038023146,0.01661105,0.045725614,0.0060442314,0.26777506,0.009220528,0.40558589],"study_design_scores_gemma":[0.00010919463,0.0016601873,0.27806228,0.01422921,0.0004332196,0.0018118795,0.13846761,0.020731464,0.01632608,0.21727532,0.31055486,0.0003386599],"about_ca_topic_score_codex":0.004366601,"about_ca_topic_score_gemma":0.0055988245,"teacher_disagreement_score":0.013132484,"about_ca_system_score_codex":0.006980676,"about_ca_system_score_gemma":0.016968224,"threshold_uncertainty_score":0.06945205},"labels":[],"label_agreement":null},{"id":"W4413817962","doi":"10.1093/ajhp/zxaf237","title":"Recent and anticipated novel drug approvals (3Q 2025 through 2Q 2026)","year":2025,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Medicine; Drug; Pipeline (software); Food and drug administration; Drug approval; Quarter (Canadian coin); Approved drug; Family medicine; Medical emergency; Pharmacology","score_opus":0.0997740453492516,"score_gpt":0.37765968062551564,"score_spread":0.27788563527626403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413817962","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22127824,0.047526244,0.021867784,0.08861231,0.016621597,0.002336515,0.098622605,0.0028339145,0.5003009],"genre_scores_gemma":[0.7768233,0.018552616,0.013123144,0.038513552,0.008374762,0.0008769529,0.040780757,0.0003461429,0.10260875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99646425,0.00046204476,0.0002629227,0.00023133158,0.0020074327,0.0005721107],"domain_scores_gemma":[0.9885107,0.002923495,0.0033401437,0.00033446334,0.0035289212,0.0013622276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00602184,0.00041509708,0.0002912845,0.002415311,0.00076514494,0.002824409,0.00049906224,0.0025704855,0.026595762],"category_scores_gemma":[0.013932331,0.00022975235,0.0018557751,0.0014565006,0.0005379015,0.001379153,0.0011929969,0.002039473,0.005431063],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019921013,0.0005310935,0.048043273,0.0018746551,0.0002799232,0.0020915326,0.00020111434,0.007780819,0.0050923578,0.04830083,0.6554639,0.22834845],"study_design_scores_gemma":[0.00026628698,0.00093765155,0.15406795,0.0004622337,0.00012207561,0.0017748834,0.00019010065,0.0028149004,0.003208839,0.0075972127,0.8284475,0.00011033388],"about_ca_topic_score_codex":0.009204446,"about_ca_topic_score_gemma":0.011149522,"teacher_disagreement_score":0.026595762,"about_ca_system_score_codex":0.0030495783,"about_ca_system_score_gemma":0.0054720556,"threshold_uncertainty_score":0.088971734},"labels":[],"label_agreement":null},{"id":"W4413989514","doi":"10.4103/equest.equest_16_23","title":"The generic dilemma","year":2023,"lang":"en","type":"article","venue":"EyeQuest","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dilemma; Computer science; Epistemology; Philosophy","score_opus":0.10457971171092077,"score_gpt":0.29915470496726093,"score_spread":0.19457499325634015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413989514","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023074888,0.012952002,0.0033330733,0.71192557,0.012070239,0.000052459258,0.00035481344,0.00016786529,0.2568366],"genre_scores_gemma":[0.08443369,0.014157924,0.0037387616,0.75067943,0.022392541,0.00013261964,0.0004271757,0.0004436924,0.123594165],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933296,0.0019585788,0.00031489163,0.0013814713,0.0021969848,0.00081858214],"domain_scores_gemma":[0.991285,0.003179039,0.0005483949,0.0012829946,0.0017334087,0.0019710774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008598064,0.00083108735,0.0008106059,0.001423172,0.004782098,0.01192162,0.0023847134,0.01400075,0.07780829],"category_scores_gemma":[0.028894434,0.00039038647,0.0007694102,0.001310235,0.016243275,0.017015113,0.006740863,0.017588405,0.023004554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054548073,0.00003619988,0.0004593393,0.00012546241,0.000012174988,0.00057244365,0.00089614064,0.000070064554,0.000107790234,0.52099806,0.42945462,0.047213163],"study_design_scores_gemma":[0.000016038251,0.00001987157,0.00015731381,0.00031423286,0.00000510185,0.0010032334,0.0006875678,0.000068571855,0.000049836734,0.08791431,0.9097527,0.00001120802],"about_ca_topic_score_codex":0.0032518653,"about_ca_topic_score_gemma":0.0031773536,"teacher_disagreement_score":0.07780829,"about_ca_system_score_codex":0.005591616,"about_ca_system_score_gemma":0.006800781,"threshold_uncertainty_score":0.26029468},"labels":[],"label_agreement":null},{"id":"W4414030360","doi":"10.20944/preprints202506.2476.v2","title":"Reforming Drug Pricing: Institutional Lessons from Most Favored Nation (MFN) and Value‐Based Care (VBC) Across Three Health Systems","year":2025,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Value (mathematics); Drug; Drug pricing; Health care; Business; Economics; Economic growth; Medicine; Pharmacology; Actuarial science; Statistics; Mathematics","score_opus":0.24988319166014705,"score_gpt":0.4013813811024603,"score_spread":0.15149818944231325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414030360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5484698,0.0052460325,0.10578435,0.08738763,0.00042680718,0.0007033405,0.00026552897,0.0001369707,0.25157952],"genre_scores_gemma":[0.9864334,0.00064384344,0.010624739,0.0013938287,0.000032365664,0.000077786906,0.000029668641,0.000019038574,0.0007452513],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97647506,0.015716895,0.00063987053,0.0014362363,0.0033764162,0.0023555295],"domain_scores_gemma":[0.9841399,0.008510882,0.0017880587,0.0018498247,0.0021248693,0.0015864287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024065241,0.00040059103,0.00073890435,0.001631789,0.0034111883,0.013901392,0.0020372209,0.0022935814,0.0025786096],"category_scores_gemma":[0.0289115,0.00032358762,0.0008896891,0.0022420604,0.02247087,0.0096793445,0.0081544705,0.0035417292,0.00016097318],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014472529,0.00013963484,0.010176231,0.0002809407,0.00011919216,0.00015112445,0.0053741317,0.009821934,0.00040014886,0.9084759,0.0028333757,0.062082782],"study_design_scores_gemma":[0.00017847636,0.0006286558,0.018583242,0.00092413987,0.00018806671,0.00016381816,0.018369107,0.024272809,0.0013496929,0.8900086,0.045204666,0.0001287652],"about_ca_topic_score_codex":0.028247606,"about_ca_topic_score_gemma":0.03142486,"teacher_disagreement_score":0.028247606,"about_ca_system_score_codex":0.02202003,"about_ca_system_score_gemma":0.023205727,"threshold_uncertainty_score":0.15976721},"labels":[],"label_agreement":null},{"id":"W4414085393","doi":"10.1111/dewb.70004","title":"Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches","year":2025,"lang":"en","type":"article","venue":"Developing World Bioethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Stem Cell Network; Government of Canada","keywords":"Intellectual property; Reimbursement; Market access; Transformative learning; Access to medicines; Expanded access","score_opus":0.4161552245505158,"score_gpt":0.4065649724819838,"score_spread":0.00959025206853198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414085393","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016650796,0.014051146,0.20973375,0.25075164,0.0015748584,0.00077011,0.00012859868,0.00016285785,0.50617623],"genre_scores_gemma":[0.7980141,0.016046705,0.11596397,0.028993407,0.0012230136,0.0018953898,0.00011975599,0.0001499526,0.037593715],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98740005,0.0065095783,0.00038732422,0.0009043607,0.0033007378,0.0014979534],"domain_scores_gemma":[0.99304247,0.0039554643,0.00058840413,0.0005681896,0.00074971706,0.0010958645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011506288,0.001876984,0.0008710258,0.0045907465,0.004049731,0.017353436,0.0019876475,0.013218629,0.010850091],"category_scores_gemma":[0.013454179,0.0010573807,0.0013042955,0.00189844,0.028017985,0.018458879,0.018014358,0.009627717,0.0014465903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009834406,0.000028327859,0.00007390952,0.00005450957,0.000005520129,0.000050674655,0.00044917187,0.00039341644,0.000073092,0.99195087,0.0011836496,0.0057270043],"study_design_scores_gemma":[0.00004746416,0.00006699229,0.00021965025,0.00035317036,0.000014715494,0.00016707162,0.0020980202,0.0017484144,0.00031765664,0.93602943,0.05890371,0.000033796434],"about_ca_topic_score_codex":0.002933763,"about_ca_topic_score_gemma":0.0036069055,"teacher_disagreement_score":0.017353436,"about_ca_system_score_codex":0.010057685,"about_ca_system_score_gemma":0.020647328,"threshold_uncertainty_score":0.07297397},"labels":[],"label_agreement":null},{"id":"W4414300864","doi":"10.12927/hcpol.2025.27665","title":"Access, Value, and Reform: An Analysis of Canada’s Pharmaceutical Policy Framework","year":2025,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Arthritis Patient Alliance","funders":"","keywords":"Legitimacy; Argument (complex analysis); Intellectual property; Pharmaceutical industry; Pharmaceutical policy; Focus (optics)","score_opus":0.07612181545382497,"score_gpt":0.4148379755231695,"score_spread":0.3387161600693445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414300864","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11068152,0.00991985,0.009749642,0.14768293,0.0002618764,0.00041882432,0.0020508424,0.000117403324,0.71911716],"genre_scores_gemma":[0.971982,0.0024304274,0.0025090137,0.005322142,0.00019049383,0.00013350724,0.00019534015,0.000035535224,0.017201519],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.988356,0.0020895086,0.0001661642,0.0005203967,0.0034941798,0.0053737825],"domain_scores_gemma":[0.9922315,0.0032387478,0.00040916467,0.0003516595,0.002138591,0.0016304172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049129785,0.0004959634,0.0011725359,0.0037981777,0.010127825,0.016036015,0.0024859277,0.0059655374,0.009652067],"category_scores_gemma":[0.013003197,0.0004989797,0.0013678494,0.005946893,0.011805019,0.0037338093,0.00418394,0.0052978927,0.0002832456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001044705,0.000017376626,0.00055862847,0.000019994915,0.0000127281255,0.00005505731,0.00025337888,0.0024573198,0.00003545159,0.9916596,0.003209199,0.0017107716],"study_design_scores_gemma":[0.0001374546,0.00007725063,0.011785109,0.0004007204,0.00017341308,0.00010481258,0.0030256489,0.021295723,0.00030012228,0.8360645,0.12650186,0.0001333504],"about_ca_topic_score_codex":0.937241,"about_ca_topic_score_gemma":0.93660957,"teacher_disagreement_score":0.19612163,"about_ca_system_score_codex":0.19612163,"about_ca_system_score_gemma":0.16222192,"threshold_uncertainty_score":0.93238497},"labels":[],"label_agreement":null},{"id":"W4414316021","doi":"10.20944/preprints202506.2476.v3","title":"Balancing Innovation, Access, and Equity in Drug Pricing: Comparative Institutional Lessons for Advancing Universal Health Coverage","year":2025,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Equity (law); Incentive; Reimbursement; Health care; Prescription drug; Universal design; Drug prices; Drug pricing","score_opus":0.37451414521758114,"score_gpt":0.47499740253716755,"score_spread":0.1004832573195864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414316021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42588052,0.014652885,0.08400812,0.07138586,0.00039644176,0.000743301,0.000297797,0.0001502701,0.40248477],"genre_scores_gemma":[0.99114203,0.0014164656,0.0058948128,0.00077437056,0.00004808506,0.00010053588,0.000024173802,0.000014505407,0.0005849533],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97731507,0.015391974,0.0007000322,0.0008658328,0.0029267233,0.0028003773],"domain_scores_gemma":[0.96555793,0.025011456,0.0027334625,0.0024223302,0.0026819068,0.0015928809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0319122,0.00042703468,0.00079282385,0.0036114547,0.0026421805,0.012445996,0.0019018151,0.0021805689,0.006468584],"category_scores_gemma":[0.0487384,0.00028386197,0.0010077371,0.0030677903,0.020973492,0.0130330585,0.009527478,0.002530843,0.0002281229],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019774641,0.0001702075,0.0091985455,0.00046700213,0.00009173936,0.00013063985,0.0037897297,0.0066318037,0.0004194864,0.90790683,0.0011701711,0.06982597],"study_design_scores_gemma":[0.00021654114,0.0006016621,0.0288583,0.0020076206,0.0003608563,0.00015776043,0.019118512,0.010124694,0.0024124782,0.90057474,0.035462562,0.000104284925],"about_ca_topic_score_codex":0.009160135,"about_ca_topic_score_gemma":0.010258487,"teacher_disagreement_score":0.0319122,"about_ca_system_score_codex":0.01763653,"about_ca_system_score_gemma":0.022777244,"threshold_uncertainty_score":0.16876984},"labels":[],"label_agreement":null},{"id":"W4414372245","doi":"10.52609/jmlph.v5i4.225","title":"Pharmaceutical Access and the Human Right to Science","year":2025,"lang":"en","type":"article","venue":"The Journal of Medicine Law & Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Human rights; Right to health; Access to medicines; Right to development; Foundation (evidence); Sociology of scientific knowledge","score_opus":0.16149570208009176,"score_gpt":0.4463558219406761,"score_spread":0.28486011986058435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414372245","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020264369,0.015555582,0.014584026,0.23331927,0.00064064754,0.000059886435,0.0002708056,0.000051719802,0.7152536],"genre_scores_gemma":[0.88766974,0.010925976,0.0070080627,0.046018098,0.0021968703,0.00021727975,0.00016441978,0.000055807104,0.0457437],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98685116,0.006634414,0.0005762718,0.0017343757,0.0029036228,0.0013000513],"domain_scores_gemma":[0.98079145,0.013215698,0.0016392387,0.0019873793,0.0015120454,0.00085423235],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.010902801,0.00033208402,0.0007138151,0.0013670094,0.0044866125,0.010240093,0.0011273726,0.012006395,0.015398894],"category_scores_gemma":[0.018127386,0.00032586674,0.00068405236,0.0014453627,0.031128708,0.0076310867,0.0065920046,0.007744463,0.0020773702],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006937062,0.000007571855,0.00011596776,0.00001808103,0.0000036893334,0.000042601292,0.00021689055,0.00009093408,0.0000488185,0.9957124,0.0018351391,0.001900912],"study_design_scores_gemma":[0.00001632084,0.00001725652,0.0003096837,0.00012466792,0.0000059743093,0.00009415349,0.00020554384,0.00021118592,0.00010178332,0.9453229,0.053579256,0.000011403545],"about_ca_topic_score_codex":0.004234072,"about_ca_topic_score_gemma":0.002780318,"teacher_disagreement_score":0.9955134,"about_ca_system_score_codex":0.004256296,"about_ca_system_score_gemma":0.0063769775,"threshold_uncertainty_score":0.057660222},"labels":[],"label_agreement":null},{"id":"W4414417581","doi":"10.1016/s2468-2667(25)00194-x","title":"Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Efficacy and Mechanism Evaluation Programme; Health Canada; Sanofi Genzyme; Horizon 2020 Framework Programme; Innovative Medicines Initiative; Teva Pharmaceutical Industries; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Gilead Sciences; European Federation of Pharmaceutical Industries and Associations; European Commission; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Economic shortage; Cohort study; Cohort; MEDLINE; Cross-sectional study; Health services research","score_opus":0.15431116463588618,"score_gpt":0.328001423853658,"score_spread":0.17369025921777181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414417581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924786,0.0002538659,0.000117256226,0.00006872311,0.00000939566,0.00004828114,0.0066320105,0.0000059924873,0.0003859308],"genre_scores_gemma":[0.9897356,0.00031928095,0.00033047705,0.00014514563,0.000015741807,0.00014496496,0.008959697,0.000011718807,0.00033738598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812764,0.00051218324,0.00024492762,0.00062027853,0.00023975594,0.00025528506],"domain_scores_gemma":[0.9959044,0.0004965392,0.002108698,0.00048131438,0.0005106976,0.00049832027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023752812,0.00045921182,0.000495637,0.0019165102,0.000601299,0.0012026683,0.0010321612,0.00071674277,0.0018985077],"category_scores_gemma":[0.0043146326,0.00055542437,0.0012549118,0.0028814946,0.00038541033,0.0013284234,0.0019886256,0.0007865757,0.00041247616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016925625,0.000046229918,0.9979619,0.00002726699,0.00021557228,0.00006654671,0.00022605098,0.0000507188,0.000084619365,0.00001704131,0.00043246723,0.0007024508],"study_design_scores_gemma":[0.000017365388,0.00006537082,0.99856913,0.00002597436,0.0000645045,0.00017189604,0.00040312624,0.00019068849,0.00002888211,0.000010878067,0.00044302503,0.000009062653],"about_ca_topic_score_codex":0.04684933,"about_ca_topic_score_gemma":0.050733343,"teacher_disagreement_score":0.04684933,"about_ca_system_score_codex":0.0011637992,"about_ca_system_score_gemma":0.00075811206,"threshold_uncertainty_score":0.0931533},"labels":[],"label_agreement":null},{"id":"W4414783537","doi":"10.1136/bmj.r2086","title":"No supply, no survival: why patients must be involved in global trade decisions","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada","funders":"","keywords":"Global health; MEDLINE; Globalization; Trade barrier","score_opus":0.08241594915191612,"score_gpt":0.3325882499405844,"score_spread":0.25017230078866826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414783537","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0116411345,0.003143565,0.0011388664,0.96678233,0.0012457889,0.000007601712,0.000042542248,0.000013318716,0.0159848],"genre_scores_gemma":[0.5924579,0.0051253983,0.0013937047,0.39113718,0.0056215413,0.00003282254,0.00005823749,0.000098892,0.004074313],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98873353,0.0074122977,0.0004381141,0.00053647795,0.0012689808,0.0016106769],"domain_scores_gemma":[0.94039065,0.040431514,0.0041137664,0.0016128541,0.0039645513,0.009486735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017179439,0.0003097346,0.0005770524,0.0005580412,0.0032422876,0.00924643,0.0009378917,0.013424346,0.014022892],"category_scores_gemma":[0.070895314,0.00041598777,0.0006612984,0.00082671916,0.018549468,0.011405891,0.003800401,0.01920738,0.0017278023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054994854,0.00027367024,0.03294421,0.00042558418,0.0003600547,0.0023383861,0.011765432,0.001672108,0.00047923127,0.45245373,0.37249312,0.12424456],"study_design_scores_gemma":[0.00013174402,0.000073743504,0.0051879226,0.00083989894,0.00006895237,0.0009070827,0.01370634,0.00076895347,0.00015059808,0.8626886,0.11539526,0.0000809544],"about_ca_topic_score_codex":0.0041020717,"about_ca_topic_score_gemma":0.0058506844,"teacher_disagreement_score":0.017179439,"about_ca_system_score_codex":0.0033084028,"about_ca_system_score_gemma":0.0064501218,"threshold_uncertainty_score":0.090854645},"labels":[],"label_agreement":null},{"id":"W4414810172","doi":"10.1177/17151635251365666","title":"Empowering pharmacists in Canada’s drug shortage response","year":2025,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Southlake Regional Health Center; University of Toronto","funders":"","keywords":"Economic shortage; Drug; MEDLINE; Pharmacy; Action (physics)","score_opus":0.03707103138297102,"score_gpt":0.28469199977417464,"score_spread":0.24762096839120362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414810172","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023335256,0.0010516674,0.00026605462,0.9490109,0.0012603136,0.00009236294,0.00013496447,0.00004502458,0.024803488],"genre_scores_gemma":[0.4744752,0.0017708713,0.0011183599,0.49402887,0.0017146983,0.00010263983,0.0001260248,0.000057091882,0.026606325],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.977445,0.004078982,0.00044749703,0.0007446216,0.004469198,0.01281482],"domain_scores_gemma":[0.9158077,0.011122097,0.0029951227,0.0005866067,0.013156238,0.056332234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015962731,0.00045016213,0.0005741272,0.0017780766,0.017779658,0.010925532,0.0029189915,0.018828677,0.014625782],"category_scores_gemma":[0.041869108,0.0007819873,0.000792921,0.0016920456,0.0058142594,0.003202389,0.009054995,0.017034926,0.00086023693],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030242422,0.0006237738,0.028334122,0.00044908866,0.0001228874,0.0020749553,0.011556657,0.0027919447,0.0011526557,0.06545527,0.81910807,0.06802813],"study_design_scores_gemma":[0.00042601686,0.000214736,0.057796434,0.00073111965,0.000082648396,0.0003070668,0.0255743,0.0030639197,0.00053706457,0.018122828,0.8928962,0.00024774842],"about_ca_topic_score_codex":0.9287439,"about_ca_topic_score_gemma":0.9745076,"teacher_disagreement_score":0.9060883,"about_ca_system_score_codex":0.09391169,"about_ca_system_score_gemma":0.42239425,"threshold_uncertainty_score":0.6813802},"labels":[],"label_agreement":null},{"id":"W4414870087","doi":"10.1377/hlthaff.2024.01476","title":"Impact Of Risk Evaluation And Mitigation Strategies On Generic Approvals Of US Pharmaceutical Products","year":2025,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Orphan drug; Drug approval; Risk assessment; Generic drug; Drug; MEDLINE","score_opus":0.08643639301125396,"score_gpt":0.39813488528357427,"score_spread":0.3116984922723203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414870087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9201475,0.006355708,0.013205854,0.010683484,0.00014797108,0.0008636478,0.0017708163,0.00033030318,0.046494737],"genre_scores_gemma":[0.9953251,0.00059719436,0.0022295401,0.00043273714,0.00006598167,0.00007414297,0.00025878093,0.000009323584,0.0010070666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9821702,0.01023112,0.0011579784,0.0012999695,0.002935818,0.0022049763],"domain_scores_gemma":[0.76023287,0.16631302,0.0612076,0.0038474104,0.005311371,0.003087646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028804163,0.0006045797,0.0006105903,0.0020067873,0.00058971305,0.0029348638,0.00068360235,0.0014465242,0.0055948626],"category_scores_gemma":[0.11058873,0.00040332234,0.0012771569,0.0011993684,0.0010565519,0.002512588,0.0015445999,0.002872969,0.00033691074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033644722,0.0020071538,0.51278406,0.0007606205,0.0010319087,0.0008240387,0.00035693386,0.14134915,0.0030269956,0.06481025,0.009567052,0.26011732],"study_design_scores_gemma":[0.001015384,0.0072009787,0.6894976,0.00063639873,0.0013183885,0.0007828129,0.0019045146,0.2143736,0.010913399,0.04499329,0.027078422,0.0002852265],"about_ca_topic_score_codex":0.008174136,"about_ca_topic_score_gemma":0.005911024,"teacher_disagreement_score":0.028804163,"about_ca_system_score_codex":0.004525129,"about_ca_system_score_gemma":0.007015203,"threshold_uncertainty_score":0.15233284},"labels":[],"label_agreement":null},{"id":"W4415240387","doi":"10.12927/hcpap.2025.27699","title":"Of Big and Small Swings: Toward a Hybrid View of Healthcare Systems Governance","year":2025,"lang":"en","type":"article","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decentralization; Corporate governance; Politics; Healthcare system; Multi-level governance; Health care","score_opus":0.10186257084592829,"score_gpt":0.31345880171901924,"score_spread":0.21159623087309096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415240387","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015622568,0.009443046,0.10257118,0.77461565,0.0021462634,0.0000589465,0.000087070766,0.00009863335,0.095356606],"genre_scores_gemma":[0.85950977,0.0049273395,0.024759078,0.09362007,0.0047635036,0.00023241909,0.00007152389,0.00012969274,0.011986603],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98894054,0.0075545684,0.00023547966,0.0010414929,0.001373273,0.0008546531],"domain_scores_gemma":[0.9896137,0.006582482,0.00066033815,0.0010385477,0.00092611095,0.0011788899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01343197,0.00048395447,0.000752854,0.0019037522,0.0038557334,0.015807148,0.0024532718,0.008076874,0.002837543],"category_scores_gemma":[0.010347052,0.00040882768,0.0008904825,0.0017266694,0.040773984,0.018595329,0.0060307635,0.009278278,0.00042946363],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007949479,0.0000029893197,0.00013742827,0.000014603103,0.0000059142544,0.000020481702,0.0015681627,0.00030072939,0.000030717427,0.99237883,0.003756711,0.0017754773],"study_design_scores_gemma":[0.000010120107,0.000006920136,0.00023498302,0.000065519256,0.0000052629857,0.000022960981,0.0014751051,0.0012240497,0.000027684875,0.96564597,0.03127281,0.000008667528],"about_ca_topic_score_codex":0.005969271,"about_ca_topic_score_gemma":0.008494448,"teacher_disagreement_score":0.015807148,"about_ca_system_score_codex":0.007578467,"about_ca_system_score_gemma":0.0055643446,"threshold_uncertainty_score":0.07103586},"labels":[],"label_agreement":null},{"id":"W4415262181","doi":"10.1161/hyp.82.suppl_1.th144","title":"Abstract TH144: Single-Pill vs Multi-Pill Antihypertensive Therapy: A Systematic Review of Adherence and Outcomes","year":2025,"lang":"en","type":"article","venue":"Hypertension","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blood pressure; Pill; Randomized controlled trial; Antihypertensive drug; Medication adherence; Clinical trial; Meta-analysis","score_opus":0.11327410363315352,"score_gpt":0.3026027819117154,"score_spread":0.1893286782785619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415262181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002642321,0.9927543,0.00030243336,0.0005311205,0.00021799607,0.0015681996,0.0015981996,0.000024448336,0.00036100182],"genre_scores_gemma":[0.07141543,0.9159959,0.0025230478,0.001660733,0.00025522313,0.006289249,0.0013492022,0.000029698378,0.00048153967],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97676384,0.009294966,0.008547141,0.0013691549,0.0034800489,0.0005449086],"domain_scores_gemma":[0.95048845,0.033373162,0.011111438,0.00073685846,0.0036816758,0.00060835044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017558744,0.001838842,0.017310588,0.011377757,0.0009551102,0.0035518592,0.0022051055,0.0025378824,0.007893336],"category_scores_gemma":[0.06024569,0.0012245359,0.014093113,0.0127680795,0.0011911046,0.003576375,0.002347862,0.0015915259,0.00036047367],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030147508,0.00000928536,0.00067159854,0.97573066,0.015563798,0.00003910502,0.00008696636,0.000049532755,0.00006525492,0.00010671083,0.0006621477,0.0067135207],"study_design_scores_gemma":[0.0009844508,0.00029369202,0.005802444,0.817593,0.16808529,0.00016295323,0.00022520123,0.00014448151,0.00015928791,0.00033750772,0.006168908,0.000042807944],"about_ca_topic_score_codex":0.009424156,"about_ca_topic_score_gemma":0.022451432,"teacher_disagreement_score":0.017558744,"about_ca_system_score_codex":0.0059936703,"about_ca_system_score_gemma":0.013736473,"threshold_uncertainty_score":0.09286058},"labels":[],"label_agreement":null},{"id":"W4415341523","doi":"10.51594/imsrj.v5i8.2073","title":"Pharmaceutical market analytics for therapeutic equity: Data-Driven models for expanding access to essential medicines","year":2025,"lang":"","type":"article","venue":"International Medical Science Research Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"","keywords":"Analytics; Transparency (behavior); Essential medicines; Predictive analytics; Equity (law); Big data; Corporate governance; Pharmaceutical industry; Personalized medicine","score_opus":0.509892727248921,"score_gpt":0.6056956383928648,"score_spread":0.09580291114394379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415341523","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07189121,0.0029618668,0.8417843,0.031624105,0.0005329563,0.0003758473,0.002011128,0.0004962098,0.048322406],"genre_scores_gemma":[0.90580213,0.002287828,0.076346226,0.0015082634,0.00043451178,0.0003924925,0.0007518402,0.00013457313,0.012342095],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99693954,0.0017106291,0.00011144297,0.00045455465,0.00045433515,0.00032946802],"domain_scores_gemma":[0.9802537,0.015721148,0.001453909,0.0006374192,0.0013300163,0.0006037833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076812226,0.0010410973,0.0010725718,0.0016819502,0.00089842203,0.0054094056,0.0020984625,0.002968885,0.008589358],"category_scores_gemma":[0.027895743,0.00066891685,0.0015334389,0.0016327004,0.0024078968,0.0056036506,0.0031971615,0.0041332184,0.0006937707],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009593873,0.00013359643,0.004708669,0.000113299786,0.00006354724,0.00016013344,0.0003295123,0.46857494,0.00020674898,0.5007785,0.0043647727,0.020470357],"study_design_scores_gemma":[0.000013970555,0.000024559762,0.00036225774,0.00004429189,0.000015406587,0.00003107758,0.000076384495,0.80280703,0.000060993243,0.19353275,0.003016177,0.000015010475],"about_ca_topic_score_codex":0.012806491,"about_ca_topic_score_gemma":0.0097127175,"teacher_disagreement_score":0.012806491,"about_ca_system_score_codex":0.0044708075,"about_ca_system_score_gemma":0.0038843772,"threshold_uncertainty_score":0.04062265},"labels":[],"label_agreement":null},{"id":"W4415364752","doi":"10.3389/jpps.2025.14721","title":"A survey of regulatory recommendations for waivers of in vivo bioequivalence studies of generic products for certain dosage forms by participating regulators and organisations of the International Pharmaceutical Regulators Programme. Part 2","year":2025,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"World Health Organization","keywords":"Bioequivalence; Dosage form; Biopharmaceutics; Pharmaceutical industry; Pharmaceutical technology; Biopharmaceutics Classification System","score_opus":0.3901406023800169,"score_gpt":0.46923390284230093,"score_spread":0.07909330046228402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415364752","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007284414,0.93305004,0.004612228,0.018260052,0.0010546341,0.0012344369,0.0058559407,0.00019285841,0.028455444],"genre_scores_gemma":[0.03786087,0.9216212,0.013392293,0.0135090025,0.0004857618,0.0016158108,0.006173976,0.00012380365,0.005217314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97792816,0.006895869,0.0061415015,0.0011813812,0.007241863,0.0006113344],"domain_scores_gemma":[0.91335034,0.052304894,0.016086772,0.0018465152,0.015513898,0.00089755794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.042802773,0.00072898075,0.0016642262,0.008598914,0.0006482018,0.0020589826,0.0021532204,0.0035357284,0.005089044],"category_scores_gemma":[0.057778385,0.00080441125,0.0018097148,0.011831805,0.00081773766,0.0022176185,0.0011228737,0.0030630496,0.0019596384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029273314,0.0001877656,0.0028807507,0.048551977,0.0002627759,0.0002626589,0.00068939634,0.00084492227,0.0032197207,0.0116758505,0.11006457,0.82106686],"study_design_scores_gemma":[0.00008717126,0.0002692472,0.015674666,0.037174616,0.0004991033,0.00066560274,0.0004331226,0.00027374082,0.001991654,0.0015196379,0.94133353,0.00007797991],"about_ca_topic_score_codex":0.006034686,"about_ca_topic_score_gemma":0.0068425136,"teacher_disagreement_score":0.042802773,"about_ca_system_score_codex":0.003055589,"about_ca_system_score_gemma":0.012310435,"threshold_uncertainty_score":0.22636539},"labels":[],"label_agreement":null},{"id":"W4416118304","doi":"10.1136/bmj-2023-074982","title":"Pharmaceutical governance system for costly drugs through human rights due diligence","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Due diligence; Human rights; Corporate governance; Access to medicines; Drug industry; Pharmaceutical industry","score_opus":0.07714213236827773,"score_gpt":0.37202548228979476,"score_spread":0.29488334992151705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416118304","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002592684,0.0018297966,0.011637979,0.8728224,0.007068522,0.0001737202,0.00013198995,0.00018729648,0.10355556],"genre_scores_gemma":[0.24497722,0.002250586,0.014822464,0.57439697,0.021523323,0.00088736095,0.00020977568,0.0003288168,0.14060345],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.94693744,0.022899717,0.002498544,0.004666644,0.015704222,0.0072934087],"domain_scores_gemma":[0.92270476,0.035413414,0.007543985,0.010724629,0.014794485,0.00881872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.053159002,0.00062095764,0.0008902908,0.0015219796,0.0046701934,0.015730191,0.0021707325,0.02451426,0.013476654],"category_scores_gemma":[0.13829611,0.000675489,0.0013149831,0.001056713,0.0139919715,0.009678339,0.0068653966,0.02033857,0.004024987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028264389,0.000047625457,0.00049117854,0.000050960247,0.000034625435,0.00006597187,0.00037947085,0.0004114708,0.00019252146,0.78143424,0.20079334,0.016070405],"study_design_scores_gemma":[0.00014740939,0.00007595768,0.0015564123,0.00024830608,0.000034383724,0.00012564982,0.00020819709,0.0017952676,0.0005992071,0.52716815,0.46795437,0.000086725384],"about_ca_topic_score_codex":0.007653225,"about_ca_topic_score_gemma":0.006178948,"teacher_disagreement_score":0.053159002,"about_ca_system_score_codex":0.008478975,"about_ca_system_score_gemma":0.029210057,"threshold_uncertainty_score":0.28113502},"labels":[],"label_agreement":null},{"id":"W4416118360","doi":"10.1136/bmj-2025-084839","title":"Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Engineering Link (Canada)","funders":"Helse- og Omsorgsdepartementet","keywords":"Equity (law); Reimbursement; Procurement; Collective action; Drug pricing; Cost sharing; Action (physics); Drug industry","score_opus":0.12570153501976172,"score_gpt":0.41489632833850487,"score_spread":0.28919479331874315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416118360","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04701019,0.008155259,0.08118596,0.66264063,0.007845818,0.00022433307,0.0004270347,0.0004560492,0.19205473],"genre_scores_gemma":[0.80020225,0.003461761,0.03957332,0.12564334,0.0060411696,0.00018640011,0.00021156271,0.00020451832,0.024475794],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98928213,0.006475053,0.000354623,0.0006352452,0.0020940034,0.0011589098],"domain_scores_gemma":[0.97648245,0.0164027,0.0014264714,0.002051336,0.0022431584,0.0013940101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019665448,0.00071448064,0.0008910971,0.0010251827,0.0009615912,0.0075598205,0.0012763464,0.0043462203,0.0135912495],"category_scores_gemma":[0.039785367,0.00036370897,0.0018411347,0.0012470958,0.0025304842,0.004288497,0.00462639,0.00562936,0.0009896848],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097354624,0.0007120178,0.008036764,0.00034116398,0.0011169121,0.000113575385,0.0005397184,0.018773403,0.00075922674,0.51131165,0.1708405,0.2864816],"study_design_scores_gemma":[0.0006120818,0.0003453867,0.0123789,0.000582612,0.0009799512,0.00016223427,0.0013148404,0.0463132,0.0020448817,0.7722796,0.16279942,0.00018685502],"about_ca_topic_score_codex":0.0046529365,"about_ca_topic_score_gemma":0.010090063,"teacher_disagreement_score":0.019665448,"about_ca_system_score_codex":0.0042578364,"about_ca_system_score_gemma":0.0046762377,"threshold_uncertainty_score":0.10400206},"labels":[],"label_agreement":null},{"id":"W4416121160","doi":"10.1208/s12248-025-01159-x","title":"Regulatory Divergence in Narrow Therapeutic Index Drugs: A Comparative Review of the US, EU, Japan, Canada, and South Korea","year":2025,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Science and ICT, South Korea; Ministry of Food and Drug Safety; Chung-Ang University","keywords":"Harmonization; Regulatory science; Interchangeability; Bioequivalence; European union; Guideline; Index (typography); Divergence (linguistics)","score_opus":0.04029268370459185,"score_gpt":0.27603438765258287,"score_spread":0.23574170394799102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416121160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015175458,0.9966899,0.00011319173,0.00045173528,0.00005452359,0.000049628812,0.00033263664,0.0000036573738,0.0007870356],"genre_scores_gemma":[0.017515274,0.9804119,0.0005250111,0.0009889444,0.000032952998,0.000068884336,0.00034329688,0.000006553776,0.00010715145],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921176,0.001765714,0.002952928,0.00067754055,0.0021957152,0.00029058708],"domain_scores_gemma":[0.9722082,0.014655914,0.0060523055,0.00040553583,0.006180647,0.0004973479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011020086,0.00062610285,0.0032542697,0.016581401,0.000803565,0.0029259473,0.0014371305,0.0011579843,0.002507305],"category_scores_gemma":[0.024026332,0.0004584892,0.004009381,0.02549899,0.0013461725,0.002027754,0.0015277236,0.0010822522,0.00016564109],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005432956,0.000052003175,0.0035942383,0.64220387,0.004173298,0.0002886525,0.0012395263,0.00034929282,0.0007965494,0.0031056025,0.0057058493,0.33794773],"study_design_scores_gemma":[0.00019503797,0.0005837364,0.04397352,0.62795067,0.041021608,0.0014166578,0.0029863045,0.0002244992,0.0009917057,0.0012660917,0.27925736,0.00013283803],"about_ca_topic_score_codex":0.044404183,"about_ca_topic_score_gemma":0.1035834,"teacher_disagreement_score":0.9555958,"about_ca_system_score_codex":0.0062384354,"about_ca_system_score_gemma":0.030955326,"threshold_uncertainty_score":0.08829141},"labels":[],"label_agreement":null},{"id":"W4416291706","doi":"10.1136/bmj-2025-086516","title":"Policies to promote affordability and access across the life cycle of costly new drugs","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Engineering Link (Canada)","funders":"Helse- og Omsorgsdepartementet","keywords":"Equity (law); Health insurance; Access to medicines; MEDLINE; Health policy","score_opus":0.06965475877918414,"score_gpt":0.3892486314678055,"score_spread":0.3195938726886213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416291706","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022256603,0.00192957,0.00247179,0.9793482,0.0032005634,0.000028555065,0.0002022683,0.000054854037,0.010538606],"genre_scores_gemma":[0.12893723,0.0042082905,0.009362254,0.83701277,0.010922336,0.00015937469,0.00025722862,0.00011754365,0.009022946],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9880212,0.005060404,0.0006737441,0.00069961464,0.0030217688,0.0025233524],"domain_scores_gemma":[0.915941,0.052091107,0.009025398,0.0038059794,0.010307736,0.008828743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024133021,0.00070265774,0.0006716771,0.0016851706,0.0014481104,0.009839055,0.0016307211,0.02211755,0.0114971325],"category_scores_gemma":[0.1484718,0.00059399876,0.0016186992,0.0016326109,0.0054210424,0.012402607,0.005614488,0.015606295,0.0016312987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023023541,0.00036875627,0.0048554316,0.000465771,0.0001925989,0.00012320817,0.00057808723,0.0053016604,0.000605961,0.48290086,0.45573276,0.048644625],"study_design_scores_gemma":[0.0005043188,0.00016548288,0.009932876,0.0011950792,0.00014130684,0.00018612859,0.00094790244,0.0051928386,0.0013040353,0.42403305,0.5562572,0.00013973795],"about_ca_topic_score_codex":0.02416317,"about_ca_topic_score_gemma":0.021868367,"teacher_disagreement_score":0.02416317,"about_ca_system_score_codex":0.008836477,"about_ca_system_score_gemma":0.029794017,"threshold_uncertainty_score":0.12762916},"labels":[],"label_agreement":null},{"id":"W4416432011","doi":"10.2139/ssrn.5748329","title":"Pharmaceutical Governance System for Costly Drugs Through Human Rights Due Diligence","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Due diligence; Human rights; Corporate governance; Legislation; Pharmaceutical industry","score_opus":0.04790202717491207,"score_gpt":0.3326700863694269,"score_spread":0.28476805919451487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416432011","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18492204,0.0031721669,0.24347235,0.1058831,0.0014148585,0.0008728319,0.0006655326,0.0005592102,0.45903784],"genre_scores_gemma":[0.964067,0.0003394933,0.006507653,0.002554831,0.0007713719,0.00015502972,0.000049160513,0.000035672074,0.02551977],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9868652,0.0060375407,0.0005273331,0.0020180861,0.0023569933,0.0021948987],"domain_scores_gemma":[0.97687596,0.010601723,0.004218385,0.0036432652,0.0026651316,0.001995549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014357644,0.00047037358,0.00093978806,0.0012243493,0.0016033723,0.0074533657,0.0012736359,0.005913465,0.014937232],"category_scores_gemma":[0.037087828,0.00039480985,0.00078004925,0.0007835919,0.004196519,0.004790368,0.0033244607,0.004197603,0.0012460954],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053591673,0.0000639399,0.0012387316,0.000048418122,0.000040444127,0.00013292051,0.00013526232,0.0034097005,0.0004312179,0.9721531,0.008228404,0.014064338],"study_design_scores_gemma":[0.0001556273,0.00008273355,0.0021065152,0.000077448254,0.000036559133,0.000116924086,0.00009551059,0.015755003,0.000542943,0.96098465,0.020014951,0.00003109828],"about_ca_topic_score_codex":0.0023016867,"about_ca_topic_score_gemma":0.002127111,"teacher_disagreement_score":0.014937232,"about_ca_system_score_codex":0.0037751927,"about_ca_system_score_gemma":0.005701751,"threshold_uncertainty_score":0.07593137},"labels":[],"label_agreement":null},{"id":"W4416564553","doi":"10.1136/bmjgh-2025-018960","title":"The association between drug shortages and prices across 74 countries: uncovering global access inequities","year":2025,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Economic shortage; Per capita; Global health; Association (psychology); Health policy; Inequality; Global South","score_opus":0.050820532014487795,"score_gpt":0.4272680012587912,"score_spread":0.37644746924430345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416564553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627006,0.0012048493,0.0002035758,0.00015490982,0.0000045435313,0.000012414153,0.0013063315,0.000003841803,0.0008395064],"genre_scores_gemma":[0.9987465,0.00042810568,0.00017695784,0.00003193016,0.000010331199,0.000014420257,0.0005508439,0.0000025462248,0.00003830534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998497,0.0005493477,0.00031389072,0.00025006488,0.00022879023,0.00016090895],"domain_scores_gemma":[0.98907006,0.0038460558,0.005799072,0.00039204632,0.00057095545,0.00032183688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026251888,0.00020006095,0.0004282113,0.003982849,0.00025345973,0.0007449524,0.00037450917,0.0002777369,0.0022605094],"category_scores_gemma":[0.009142775,0.00020947245,0.00061820855,0.0070881983,0.00050450396,0.0011486138,0.0013874308,0.00033037626,0.00016001321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028015189,0.00001335501,0.9961628,0.00009604518,0.00009533274,0.000054353834,0.00024084994,0.00008273795,0.000034473404,0.00007803274,0.00013438099,0.0029796346],"study_design_scores_gemma":[0.000002907434,0.000039215156,0.9977442,0.00007496605,0.000051617644,0.0001323836,0.0010247435,0.00033589106,0.000032765485,0.00012569774,0.00043091422,0.0000046025216],"about_ca_topic_score_codex":0.0050092856,"about_ca_topic_score_gemma":0.0051049404,"teacher_disagreement_score":0.0050092856,"about_ca_system_score_codex":0.00033880206,"about_ca_system_score_gemma":0.0004465503,"threshold_uncertainty_score":0.0138834715},"labels":[],"label_agreement":null},{"id":"W4416716456","doi":"10.1001/jamahealthforum.2025.4078","title":"Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages","year":2025,"lang":"en","type":"article","venue":"JAMA Health Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Health Canada; Agency for Healthcare Research and Quality; National Institutes of Health; U.S. Department of Veterans Affairs; Arnold Ventures; University of Southern California; Soochow University","keywords":"Drug; Economic shortage; Angiotensin Receptor Blockers; Health care; Beta blocker; Cohort; Drug approval","score_opus":0.03200195601084249,"score_gpt":0.30027097698535626,"score_spread":0.26826902097451377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416716456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97112614,0.0006341898,0.00046964412,0.00082935585,0.00004495975,0.00004946214,0.025023745,0.000026826063,0.0017958166],"genre_scores_gemma":[0.98134667,0.00027378454,0.00028943399,0.00029865894,0.00006970092,0.00008677018,0.01624308,0.000008330386,0.0013835628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810696,0.00043529246,0.00030902264,0.00040241028,0.0004149348,0.00033144405],"domain_scores_gemma":[0.9920474,0.0010211149,0.005437536,0.0004543197,0.00061785144,0.00042188432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022495545,0.0003145519,0.00034423568,0.001158851,0.00049307925,0.00095801795,0.0007455713,0.00065026194,0.003966772],"category_scores_gemma":[0.010576585,0.0002664875,0.0012269099,0.0018513456,0.00029795078,0.0007855342,0.0010727895,0.0012218108,0.000576161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107541135,0.0000566293,0.9959039,0.000023686976,0.00016781347,0.000031215684,0.00007085727,0.00020703749,0.000023072473,0.00007039409,0.0012162887,0.0021215463],"study_design_scores_gemma":[0.00001609444,0.000070483504,0.9973687,0.000055000655,0.00010937759,0.00010228331,0.0001479121,0.00090748887,0.00006883585,0.00009997283,0.001046712,0.000007142266],"about_ca_topic_score_codex":0.049277913,"about_ca_topic_score_gemma":0.041182034,"teacher_disagreement_score":0.049277913,"about_ca_system_score_codex":0.0009388649,"about_ca_system_score_gemma":0.00095858675,"threshold_uncertainty_score":0.09798217},"labels":[],"label_agreement":null},{"id":"W4416784074","doi":"10.1017/s026646232510322x","title":"A method to identify prescription drug targets for health technology reassessment","year":2025,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CARE Canada; University of British Columbia; University of Alberta; University of Calgary","funders":"Health Canada","keywords":"Medical prescription; Specialty; Health technology; Perspective (graphical); Prescription drug; Drug; Focus (optics)","score_opus":0.04389190415973355,"score_gpt":0.48394699974316047,"score_spread":0.4400550955834269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416784074","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027540551,0.0010382967,0.94451725,0.0011012452,0.00027832316,0.004605979,0.010199735,0.0034429685,0.007275625],"genre_scores_gemma":[0.1227789,0.00025243018,0.86473686,0.00029943284,0.00008891429,0.0048118625,0.0046125446,0.00017322274,0.0022457922],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9889264,0.0051921243,0.0014988846,0.0017749249,0.0023308487,0.00027680318],"domain_scores_gemma":[0.93875957,0.042534087,0.005986578,0.0050789113,0.007166765,0.00047413784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01681189,0.0015388569,0.0013018114,0.009056633,0.0007593152,0.003107064,0.0015665718,0.001501624,0.011025986],"category_scores_gemma":[0.09680943,0.0006282913,0.0028182718,0.006201086,0.0007069066,0.001481264,0.0021196788,0.0014881146,0.002374277],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016968729,0.0005925001,0.08918633,0.0031350176,0.0017660653,0.00062959467,0.0016595222,0.022174003,0.006587791,0.03355137,0.029318606,0.80970234],"study_design_scores_gemma":[0.0017358069,0.0014511491,0.075961135,0.0013811821,0.0019204016,0.001666605,0.002083964,0.66000503,0.01480275,0.110848695,0.12764345,0.0004997942],"about_ca_topic_score_codex":0.0051491335,"about_ca_topic_score_gemma":0.0054264083,"teacher_disagreement_score":0.01681189,"about_ca_system_score_codex":0.0010775339,"about_ca_system_score_gemma":0.00441508,"threshold_uncertainty_score":0.08891082},"labels":[],"label_agreement":null},{"id":"W4417300028","doi":"10.1002/hec.70073","title":"Physician Agency and the Zero‐Markup Drug Policy in China: Evidence From a Structural Model","year":2025,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bank of Canada","funders":"National Natural Science Foundation of China","keywords":"Agency (philosophy); Government (linguistics); Profit margin; Medical prescription; Margin (machine learning); Drug; Prescription drug; Profit (economics); Public policy","score_opus":0.052911106474017984,"score_gpt":0.33294176342045273,"score_spread":0.28003065694643475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417300028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937744,0.000422141,0.0019888235,0.0010628065,0.00001466586,0.00003405956,0.00032666928,0.000038462116,0.0023379768],"genre_scores_gemma":[0.9986614,0.00025460203,0.00021111759,0.000042536503,0.0000156667,0.000007847516,0.0001507883,0.0000033786687,0.00065266964],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985306,0.0004747608,0.00008057632,0.00023166301,0.00017663787,0.0005057023],"domain_scores_gemma":[0.9912077,0.0042008692,0.0030378539,0.00038152243,0.0005373836,0.00063467294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026200064,0.00059459865,0.0013399611,0.0016154237,0.001032112,0.001984146,0.0012548974,0.0010115616,0.0047082985],"category_scores_gemma":[0.005403342,0.00043519083,0.001369401,0.0018673411,0.0016542271,0.0013884136,0.0013368726,0.0010942823,0.0003125875],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013564859,0.0010761749,0.58832556,0.0003272136,0.0009549141,0.001700678,0.0011067921,0.29297408,0.0017803909,0.07808241,0.0042518955,0.028063478],"study_design_scores_gemma":[0.00056734675,0.0005641882,0.2534379,0.000047533224,0.00057925325,0.00011653101,0.00072513905,0.7203533,0.0008980638,0.019386996,0.0032284928,0.00009522674],"about_ca_topic_score_codex":0.16413948,"about_ca_topic_score_gemma":0.09763176,"teacher_disagreement_score":0.16413948,"about_ca_system_score_codex":0.0062156343,"about_ca_system_score_gemma":0.004759632,"threshold_uncertainty_score":0.32636815},"labels":[],"label_agreement":null},{"id":"W4417474620","doi":"10.63209/2025.1611","title":"Le médicament est une technologie de plus en plus coûteuse : sommes-nous prêts à la financer et l’encadrer adéquatement?","year":2025,"lang":"","type":"article","venue":"Pharmactuel","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Government (linguistics); Context (archaeology); China; Investment (military)","score_opus":0.044820504759147006,"score_gpt":0.3444996867297355,"score_spread":0.2996791819705885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417474620","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033796525,0.028821602,0.0010980258,0.9551282,0.002964755,0.0000052249793,0.00005894213,0.00002579538,0.008517881],"genre_scores_gemma":[0.4058053,0.14137653,0.00964111,0.35049412,0.046062984,0.000081649785,0.00031616064,0.00025838387,0.045963846],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98907626,0.005242459,0.0007218573,0.0009210323,0.0028555538,0.0011828758],"domain_scores_gemma":[0.94439685,0.02586591,0.007737559,0.003011765,0.012519417,0.0064684297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0168823,0.00056559284,0.0012012508,0.0015710802,0.0021659774,0.0152074965,0.0013376437,0.011619285,0.015828542],"category_scores_gemma":[0.06818688,0.00038390647,0.0007269907,0.0020108742,0.011305405,0.023927717,0.0029169938,0.012110348,0.0033790008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000642182,0.0005314306,0.006535892,0.0010624711,0.00021246746,0.0005015987,0.0014760463,0.00087404903,0.0011469043,0.51776344,0.24642286,0.2228307],"study_design_scores_gemma":[0.0001677149,0.00022018708,0.0048619043,0.0025834509,0.000093212446,0.0007586051,0.0028789858,0.0009298352,0.00058854185,0.29251888,0.6942868,0.00011183201],"about_ca_topic_score_codex":0.014542191,"about_ca_topic_score_gemma":0.0141042415,"teacher_disagreement_score":0.0168823,"about_ca_system_score_codex":0.0069572004,"about_ca_system_score_gemma":0.018188188,"threshold_uncertainty_score":0.08928323},"labels":[],"label_agreement":null},{"id":"W45620804","doi":"10.1533/9781908818089.17","title":"Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy * *This chapter is based upon material in: M. Sawicka and R.A. Bouchard, ‘Empirical Analysis of Canadian Drug Approval Data 2001–2008: Are Canadian Pharmaceutical Players “Doing More With Less?”’ McGill Journal of Law &amp; Health 3: 87–151 (2009); R.A. Bouchard, J. Sawani, C. McLelland, M. Sawicka, and R. Hawkins, ‘The Pas de Deux of Pharmaceutical Regulation and Innovation: Who’s Leading Whom?’ Berkeley Technology Law Journal 24(3): 1461–522 (2009); R.A. Bouchard, R.W. Hawkins, R. Clark, R. Hagtvedt, and J. Sawani, ‘Empirical Analysis of Drug Approval-Patenting Linkage for High Value Pharmaceuticals,’ Northwestern Journal of Technology &amp; Intellectual Property 8(2): 1–86 (2010).","year":2012,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Linkage (software); Record linkage; Public health; Drug; Political science; Public economics; Medicine; Economics; Pharmacology; Environmental health; Chemistry; Population","score_opus":0.15380247312126555,"score_gpt":0.33563357590399856,"score_spread":0.181831102782733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W45620804","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009289014,0.50148606,0.0028693976,0.098404095,0.0049834843,0.00004764539,0.0020187858,0.00011263846,0.38914892],"genre_scores_gemma":[0.02833048,0.5508377,0.004808764,0.046550088,0.021739068,0.00021429232,0.0024962053,0.00012286108,0.3449005],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99946886,0.00012716255,0.000020168065,0.0001157539,0.00020281025,0.00006531495],"domain_scores_gemma":[0.99888736,0.0007476462,0.000059542155,0.000029932427,0.00018253048,0.0000929564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000678776,0.00091600115,0.0006303083,0.0022056755,0.0020976018,0.004242391,0.0010015115,0.0035953873,0.05395174],"category_scores_gemma":[0.0013812858,0.0004012224,0.0002815454,0.0070835277,0.002931708,0.0040256507,0.0011397847,0.004038383,0.012688052],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012895196,0.000043601638,0.00021582884,0.00069971837,0.000004570818,0.000057999976,0.00038379888,0.00037562146,0.00006605266,0.32226807,0.5837923,0.09207946],"study_design_scores_gemma":[0.0000030420465,0.000009732729,0.00073209225,0.0010005092,0.0000026714818,0.00007814366,0.00017834798,0.00013982788,0.000039381182,0.05760418,0.9402027,0.000009370744],"about_ca_topic_score_codex":0.02565957,"about_ca_topic_score_gemma":0.029769683,"teacher_disagreement_score":0.99598795,"about_ca_system_score_codex":0.0040120305,"about_ca_system_score_gemma":0.004523617,"threshold_uncertainty_score":0.18048656},"labels":[],"label_agreement":null},{"id":"W48989372","doi":"10.1007/bf03256677","title":"Drug Approval Times and User Fees","year":2008,"lang":"en","type":"article","venue":"Pharmaceutical Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Government (linguistics); Business; Agency (philosophy); Approved drug; Drug; Payment; User fee; Finance; Drug approval; Resource (disambiguation); Orphan drug; Public economics; Medicine; Pharmacology; Economics","score_opus":0.10931244738849398,"score_gpt":0.3302034876115756,"score_spread":0.2208910402230816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W48989372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6781485,0.021852056,0.02177855,0.022189032,0.0006435857,0.00012163106,0.0076078856,0.00071647676,0.24694236],"genre_scores_gemma":[0.9751414,0.0015023096,0.0006193426,0.0004138546,0.00030046346,0.000018383691,0.0006914424,0.00008734085,0.021225473],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9956949,0.0015373757,0.00041737646,0.00034957688,0.0010364478,0.00096432393],"domain_scores_gemma":[0.88327456,0.08329359,0.01800349,0.003635758,0.0068129324,0.0049795946],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038475792,0.00048282466,0.0009231283,0.0031950835,0.0010048121,0.0060810745,0.00080000353,0.0029821512,0.038272947],"category_scores_gemma":[0.08799577,0.00059802434,0.0012037262,0.0033922829,0.0011552101,0.005577478,0.001001388,0.0040883725,0.0031436516],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060344273,0.00073930726,0.18754798,0.0007243319,0.00064847746,0.0019825744,0.0014342996,0.04054593,0.0022046007,0.51452893,0.053499743,0.19010939],"study_design_scores_gemma":[0.00066756207,0.0010836041,0.33639854,0.0005071425,0.0012662136,0.010871291,0.002501895,0.11054965,0.004361244,0.424262,0.10714834,0.00038256796],"about_ca_topic_score_codex":0.005491485,"about_ca_topic_score_gemma":0.0049993163,"teacher_disagreement_score":0.9961524,"about_ca_system_score_codex":0.0028675867,"about_ca_system_score_gemma":0.0014791947,"threshold_uncertainty_score":0.12803578},"labels":[],"label_agreement":null},{"id":"W51974226","doi":"10.25071/1929-8404.34702","title":"Trade Agreements and Pharmaceutical Patent Protection: Implications for the Governance over Pharmaceutical Products in Canada","year":2012,"lang":"en","type":"article","venue":"Healthy Dialogue","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Business; Intellectual property; Pharmaceutical industry; Government (linguistics); Revenue; Corporate governance; Legislation; International trade; Profit (economics); Commerce; Industrial organization; Economics; Finance; Law; Biotechnology","score_opus":0.21825874156395117,"score_gpt":0.3369003616118901,"score_spread":0.1186416200479389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W51974226","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17337042,0.014501661,0.005122268,0.3062712,0.0002849096,0.00024398028,0.001599768,0.00009363929,0.49851218],"genre_scores_gemma":[0.9715758,0.0042503932,0.0010854453,0.007848399,0.000111090616,0.000031975855,0.00014504099,0.000015735275,0.014936158],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98996174,0.0012247293,0.00028366188,0.00061705423,0.0032015392,0.0047112433],"domain_scores_gemma":[0.9825571,0.007324794,0.0025044915,0.00053963566,0.004516933,0.0025570346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004686916,0.0002864204,0.00057509384,0.0020682022,0.009635317,0.012398331,0.0013600211,0.004328708,0.0091018975],"category_scores_gemma":[0.022674473,0.00039181573,0.00074972893,0.0051013087,0.010174512,0.0037533734,0.0028416151,0.0045143785,0.00019204686],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035440273,0.000022446296,0.0070749163,0.000071188064,0.000023707358,0.00022554434,0.001340492,0.002727657,0.00012246167,0.96694726,0.011954263,0.009454467],"study_design_scores_gemma":[0.0002459,0.000068996356,0.07610983,0.0007976139,0.000162402,0.00016265588,0.009552053,0.013662685,0.00079128414,0.5962677,0.30192602,0.00025277035],"about_ca_topic_score_codex":0.9895272,"about_ca_topic_score_gemma":0.988356,"teacher_disagreement_score":0.16923596,"about_ca_system_score_codex":0.16923596,"about_ca_system_score_gemma":0.20994163,"threshold_uncertainty_score":0.9635685},"labels":[],"label_agreement":null},{"id":"W53958636","doi":"","title":"Generic drug pricing in Canada: components of the value-chain","year":2010,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Business; Production (economics); Quality (philosophy); Set (abstract data type); Value (mathematics); Pharmacy; Predictability; Generic drug; Industrial organization; Actuarial science; Economics; Microeconomics; Computer science","score_opus":0.07276100822290306,"score_gpt":0.306301668767136,"score_spread":0.23354066054423295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W53958636","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16997804,0.011635789,0.04998175,0.046201367,0.00031703638,0.0006289851,0.003390117,0.00031666624,0.71755034],"genre_scores_gemma":[0.9439008,0.005290548,0.012807377,0.0009278499,0.0001301371,0.00004546324,0.00061005953,0.000044432454,0.036243297],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99558026,0.00036351607,0.0001062386,0.00028242837,0.002537382,0.0011300971],"domain_scores_gemma":[0.9969465,0.0005771597,0.00031307503,0.00018814305,0.001502806,0.00047237854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012662563,0.00051942765,0.00050885446,0.0025436068,0.0043267705,0.009039954,0.0014170099,0.0020480743,0.009875658],"category_scores_gemma":[0.008002441,0.0005656001,0.00082013017,0.006338894,0.0040178024,0.0036932917,0.0019103495,0.0019905448,0.0006163298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005258543,0.00004202796,0.01111964,0.00010480845,0.00003169274,0.000277739,0.00038686857,0.010111522,0.0004188889,0.9106856,0.013667422,0.05310129],"study_design_scores_gemma":[0.000076104654,0.00006298722,0.07059333,0.00036491232,0.00016504155,0.0003833361,0.0015552335,0.05998504,0.0011611012,0.69741195,0.1680495,0.00019135808],"about_ca_topic_score_codex":0.9603217,"about_ca_topic_score_gemma":0.945501,"teacher_disagreement_score":0.09493337,"about_ca_system_score_codex":0.09493337,"about_ca_system_score_gemma":0.076399334,"threshold_uncertainty_score":0.68879306},"labels":[],"label_agreement":null},{"id":"W603589202","doi":"10.5040/9798400658679","title":"Government Relations in the Health Care Industry","year":2003,"lang":"en","type":"book","venue":"Praeger eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Health care; Business; Political science; Public relations; Public administration; Law; Philosophy; Linguistics","score_opus":0.06575916763636572,"score_gpt":0.29240046226551675,"score_spread":0.22664129462915103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W603589202","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013467082,0.051823292,0.0013691053,0.10699559,0.0017430632,0.000027180251,0.000052368418,0.000094296345,0.8365484],"genre_scores_gemma":[0.120959245,0.05380494,0.0021304253,0.03851492,0.002668304,0.00008838606,0.00010525817,0.000115689276,0.7816129],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988373,0.00038476096,0.000021141319,0.00006290018,0.00047905013,0.00021482266],"domain_scores_gemma":[0.9991492,0.00043969683,0.00006491178,0.000040829003,0.00021125414,0.000094014365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007813199,0.00025533364,0.0001635121,0.0009170487,0.0040942384,0.0071852277,0.0004571026,0.0024700828,0.00840044],"category_scores_gemma":[0.0021891543,0.00021902629,0.00023413,0.0024464047,0.00581389,0.003762467,0.0011878653,0.003317147,0.0018887285],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000025580357,0.000006258542,0.00006823409,0.000024550525,0.00000116888,0.00002252408,0.0014015483,0.0001660159,0.00002276415,0.69648486,0.28635287,0.015446661],"study_design_scores_gemma":[0.0000023727014,0.0000024017347,0.00026008155,0.00010607279,0.0000011667584,0.000018331377,0.0008206647,0.000104750055,0.000024586165,0.055963967,0.94269276,0.0000028591676],"about_ca_topic_score_codex":0.15315886,"about_ca_topic_score_gemma":0.20662874,"teacher_disagreement_score":0.15315886,"about_ca_system_score_codex":0.018433068,"about_ca_system_score_gemma":0.018723069,"threshold_uncertainty_score":0.30453473},"labels":[],"label_agreement":null},{"id":"W617391686","doi":"","title":"PATENT EXPIRATION AND COMPETITION: A DYNAMIC LIMIT PRICE MODEL","year":2014,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Limit price; Economics; Monopoly; Microeconomics; Expiration date; Price elasticity of demand; Competition (biology); Limit (mathematics); Price discrimination; Product (mathematics); Industrial organization; Price level; Monetary economics","score_opus":0.1283713316083809,"score_gpt":0.3382978775211224,"score_spread":0.20992654591274149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W617391686","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19576474,0.0041799075,0.55973643,0.018263599,0.00045053198,0.00031520156,0.0019368689,0.00046267515,0.21889001],"genre_scores_gemma":[0.9097331,0.0017810424,0.020955993,0.000988472,0.0002660416,0.00036471864,0.00035077627,0.00009732117,0.06546249],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99874085,0.00041149932,0.0000484809,0.00025456765,0.00022221621,0.00032245647],"domain_scores_gemma":[0.9967462,0.0018078722,0.00045006862,0.00018175608,0.0003122792,0.00050176086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025913455,0.0011408612,0.002789621,0.001604122,0.0013090832,0.0054300716,0.0051357117,0.007888674,0.019245114],"category_scores_gemma":[0.007581882,0.0012478057,0.0020583214,0.0015383756,0.003436895,0.0059359153,0.002851029,0.003773866,0.002439538],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107436535,0.0002079336,0.00079001865,0.00010924493,0.00005629908,0.00071472506,0.00019501145,0.28067932,0.0012571383,0.70745784,0.003496753,0.0049281707],"study_design_scores_gemma":[0.00013512858,0.00006854111,0.00028176658,0.00003209634,0.00003701072,0.0001872403,0.000068009016,0.7555979,0.000118364616,0.24022308,0.0031953608,0.00005543793],"about_ca_topic_score_codex":0.008907674,"about_ca_topic_score_gemma":0.005184258,"teacher_disagreement_score":0.019245114,"about_ca_system_score_codex":0.0032262942,"about_ca_system_score_gemma":0.0026984827,"threshold_uncertainty_score":0.06438136},"labels":[],"label_agreement":null},{"id":"W62752865","doi":"","title":"Pulse : Drug price index sees first increase in 5 years","year":2000,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Index (typography); Price index; Medicine; Population; Mandate; Consumer price index (South Africa); Agricultural economics; Business; Economics; Monetary economics; Environmental health; Econometrics; Law","score_opus":0.011922423602531165,"score_gpt":0.2281588042150788,"score_spread":0.21623638061254763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W62752865","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014734594,0.017076673,0.0025813298,0.016429752,0.010119466,0.00047859218,0.56966454,0.0054701194,0.36344495],"genre_scores_gemma":[0.1778452,0.028118098,0.007359705,0.017188223,0.007964841,0.0007272197,0.50855154,0.0015838973,0.2506614],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99796885,0.000110449044,0.00020121069,0.00023774707,0.0013231337,0.0001585685],"domain_scores_gemma":[0.99549156,0.00033937252,0.00084073335,0.00017875303,0.0026724923,0.00047702994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008162389,0.001146911,0.0006662408,0.004195565,0.0004946921,0.0031533765,0.0008510188,0.0011874025,0.057430666],"category_scores_gemma":[0.006533177,0.00026156162,0.0007336386,0.0077649434,0.00037082328,0.0026669353,0.00090702233,0.0024904746,0.0495582],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023327538,0.000046769073,0.012351436,0.0004377264,0.000046908528,0.00007845092,0.00003392452,0.00012405266,0.0002425118,0.002274175,0.9056848,0.07844595],"study_design_scores_gemma":[0.000082837265,0.00013619875,0.0730699,0.00023865221,0.000037788257,0.00052990194,0.00008553513,0.0004096015,0.00053737423,0.0010288742,0.92379946,0.000043869266],"about_ca_topic_score_codex":0.014084728,"about_ca_topic_score_gemma":0.012863825,"teacher_disagreement_score":0.98591524,"about_ca_system_score_codex":0.0017007419,"about_ca_system_score_gemma":0.0015695079,"threshold_uncertainty_score":0.19212472},"labels":[],"label_agreement":null},{"id":"W64546397","doi":"10.1007/978-94-007-6205-3_9","title":"Beyond Benefit Sharing: Steps Towards Realizing the Human Right to Health","year":2013,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Right to health; Computer science; Business; Internet privacy; Political science; Human rights; Law","score_opus":0.11236233673714394,"score_gpt":0.31545841366198446,"score_spread":0.20309607692484052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W64546397","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028498555,0.025132239,0.061154462,0.39507523,0.0033691032,0.00008833016,0.00015795541,0.00014941118,0.5120234],"genre_scores_gemma":[0.47270986,0.050132435,0.05824567,0.15631668,0.012093594,0.00045974873,0.00030504432,0.00048478632,0.24925224],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9931263,0.0037345926,0.00015656748,0.0005088252,0.001708003,0.0007657239],"domain_scores_gemma":[0.9926428,0.0050456775,0.00022399689,0.00080540084,0.00068124017,0.00060082553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011304573,0.0008849786,0.0010945508,0.0008409923,0.00234697,0.011103751,0.0019209041,0.011454626,0.01738363],"category_scores_gemma":[0.015153484,0.000401424,0.00070046243,0.0012391802,0.017972494,0.016225105,0.005107353,0.013553687,0.0031255586],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006588793,0.000015394196,0.000029493487,0.000032973294,0.0000048894276,0.000012768787,0.0001646096,0.00022525723,0.000036250705,0.97243506,0.016916,0.010120724],"study_design_scores_gemma":[0.000003868063,0.00000379552,0.000039410126,0.00007969117,0.0000020225482,0.0000149509815,0.00007959767,0.0001892,0.00004633862,0.9389943,0.06054227,0.0000044188523],"about_ca_topic_score_codex":0.004624746,"about_ca_topic_score_gemma":0.004859365,"teacher_disagreement_score":0.01738363,"about_ca_system_score_codex":0.004759801,"about_ca_system_score_gemma":0.012783548,"threshold_uncertainty_score":0.05978501},"labels":[],"label_agreement":null},{"id":"W6885838126","doi":"10.1371/journal.pone.0238618.s002","title":"Total pharmacies in British Columbia by regional Health Authority, 2018.","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regional hospital; Public health; Pharmacy; MEDLINE","score_opus":0.15783933262593325,"score_gpt":0.30685439525341834,"score_spread":0.1490150626274851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6885838126","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07227245,0.012377791,0.00045785683,0.015841674,0.0008041886,0.00014486325,0.7420608,0.0006452686,0.15539515],"genre_scores_gemma":[0.3216296,0.013368363,0.0012582748,0.0039118794,0.00025219744,0.00021541554,0.17628428,0.0002459391,0.48283392],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9989145,0.000067246714,0.00007276695,0.00013906031,0.0004685951,0.00033784937],"domain_scores_gemma":[0.9976351,0.0002507619,0.0002113472,0.00005387136,0.0014328815,0.00041602747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038331226,0.00039697214,0.00033385502,0.0020122307,0.0013199201,0.002259183,0.00097460265,0.00065708294,0.029987283],"category_scores_gemma":[0.0037158576,0.00037105472,0.00036885944,0.006595153,0.00035781236,0.0007787306,0.00061820383,0.0014246521,0.005074591],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018431437,0.00003263015,0.019783827,0.0003561201,0.00004336637,0.00012943534,0.00012324253,0.0010777093,0.0000926099,0.0033792178,0.94441986,0.030377647],"study_design_scores_gemma":[0.000105185354,0.000031508636,0.3554066,0.00045429694,0.00007006548,0.00018187023,0.0015484584,0.001791934,0.00029656093,0.0010186498,0.63905454,0.000040292012],"about_ca_topic_score_codex":0.97162646,"about_ca_topic_score_gemma":0.98926485,"teacher_disagreement_score":0.029987283,"about_ca_system_score_codex":0.023228668,"about_ca_system_score_gemma":0.028492523,"threshold_uncertainty_score":0.16853654},"labels":[],"label_agreement":null},{"id":"W6886001749","doi":"10.14288/1.0048260","title":"Toward a national pharmaceuticals strategy : a summary of the 2006 health policy conference of the UBC Centre for Health Services and Policy Research","year":2014,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Pharmaceutical policy; Health policy; Health care; Activity-based costing; Medical prescription; Health economics; Healthcare policy; Health services","score_opus":0.10230072085461027,"score_gpt":0.32295164033279244,"score_spread":0.22065091947818216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6886001749","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013679594,0.07082241,0.0015352633,0.8568939,0.02072859,0.00075356575,0.003454476,0.000119877666,0.044323917],"genre_scores_gemma":[0.025900912,0.14285508,0.020346241,0.60720766,0.017153341,0.0028572702,0.0068193492,0.00036534446,0.1764948],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98063123,0.0036752226,0.0012632862,0.0011537012,0.009258309,0.004018185],"domain_scores_gemma":[0.98160744,0.0038163743,0.0011440718,0.00038078325,0.008023684,0.0050276387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03846805,0.0020209672,0.0013931334,0.004386743,0.004858897,0.021508979,0.0037260214,0.026874095,0.015004625],"category_scores_gemma":[0.03018706,0.0010512673,0.0015475898,0.006760725,0.002319142,0.007927832,0.005730369,0.019596808,0.004638397],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059069665,0.0001617519,0.0005339144,0.0012551586,0.00002597233,0.00016430131,0.0003428892,0.000713757,0.00034557426,0.051645845,0.9149859,0.029765842],"study_design_scores_gemma":[0.000026799742,0.000027553193,0.0018981674,0.0013821202,0.000016299911,0.000036883222,0.0003712216,0.00016305923,0.00025001925,0.0047819945,0.9910041,0.000041828458],"about_ca_topic_score_codex":0.06505181,"about_ca_topic_score_gemma":0.08130364,"teacher_disagreement_score":0.9615607,"about_ca_system_score_codex":0.038439285,"about_ca_system_score_gemma":0.110084675,"threshold_uncertainty_score":0.27889788},"labels":[],"label_agreement":null},{"id":"W6887928990","doi":"10.17632/msfp8h2nb8.1","title":"Data File 1.15 with descriptives","year":2024,"lang":"en","type":"dataset","venue":"Data Archiving and Networked Services (DANS)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Data collection; Multinational corporation; Investment (military); Pharmaceutical industry","score_opus":0.08292197931516887,"score_gpt":0.2867628703411219,"score_spread":0.20384089102595304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6887928990","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000118070515,0.000009300898,0.00005780048,0.00004355401,0.0000094983625,0.000037037633,0.9990878,0.000040936324,0.00059606804],"genre_scores_gemma":[0.00091751403,0.000050403272,0.00048455968,0.00010598043,0.0000126246705,0.000814354,0.99525815,0.00006590423,0.0022905641],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831784,0.0002988686,0.000356234,0.00041194374,0.0003386273,0.0002766163],"domain_scores_gemma":[0.992007,0.0027969114,0.0009153239,0.0009373909,0.0028554515,0.00048797912],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022189748,0.001078603,0.0009764931,0.0039936835,0.0009844932,0.0021883098,0.0018368092,0.0013642535,0.29445773],"category_scores_gemma":[0.01515895,0.0008081806,0.0005940815,0.008529434,0.00039198817,0.0014051795,0.001378318,0.0017109523,0.12638724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004705692,0.000038794515,0.0016459344,0.00035472002,0.000010245308,0.000017225604,0.00004077108,0.0001832933,0.000033949407,0.00070190243,0.99500644,0.001919708],"study_design_scores_gemma":[0.0003377197,0.000034172754,0.012039116,0.0006147082,0.000025378811,0.000048446684,0.0004532976,0.0003025029,0.00019887154,0.0021356496,0.9837715,0.000038721657],"about_ca_topic_score_codex":0.030201336,"about_ca_topic_score_gemma":0.03475955,"teacher_disagreement_score":0.70554227,"about_ca_system_score_codex":0.0019501054,"about_ca_system_score_gemma":0.0036607038,"threshold_uncertainty_score":0.98505926},"labels":[],"label_agreement":null},{"id":"W6888493640","doi":"10.20381/ruor-28250","title":"Neglecting the Essentials: Addressing Barriers to Accessing Off-Patent Essential Medicines for Neglected Diseases in Canada","year":2022,"lang":"en","type":"article","venue":"uO Research (University of Ottawa)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Essential medicines; Access to medicines; Context (archaeology); Essential drugs; Developing country; Government (linguistics); Health care; Malaria; Global health","score_opus":0.15089084588209475,"score_gpt":0.3357436257738092,"score_spread":0.18485277989171442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6888493640","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1716444,0.018534185,0.0024648868,0.7091929,0.00207943,0.000835174,0.0009789203,0.0002360583,0.094034076],"genre_scores_gemma":[0.6856911,0.02753132,0.0089153955,0.25061998,0.00041314002,0.00032307164,0.000734044,0.00023965548,0.025532309],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882758,0.0016520201,0.00046903398,0.0008844119,0.0038814426,0.004837278],"domain_scores_gemma":[0.93524426,0.008993687,0.0026336862,0.0006816789,0.01450633,0.03794024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009577742,0.00052654935,0.0008734862,0.0018890504,0.034723625,0.014304231,0.005064314,0.005144663,0.012429561],"category_scores_gemma":[0.031807054,0.0007929089,0.0009148629,0.0036660347,0.008981676,0.007177195,0.010826458,0.011511882,0.00096172077],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004066636,0.0009148029,0.10051099,0.0029584083,0.000244566,0.007542964,0.115145594,0.0008986945,0.0025047679,0.061644193,0.4048751,0.3023533],"study_design_scores_gemma":[0.00031903305,0.00040742598,0.10069958,0.0055553718,0.00028921192,0.002571501,0.24211869,0.002425043,0.0011282316,0.017687447,0.62602514,0.0007733932],"about_ca_topic_score_codex":0.9924678,"about_ca_topic_score_gemma":0.99662894,"teacher_disagreement_score":0.14025815,"about_ca_system_score_codex":0.14025815,"about_ca_system_score_gemma":0.5798985,"threshold_uncertainty_score":0.9971787},"labels":[],"label_agreement":null},{"id":"W6892867441","doi":"10.5281/zenodo.12808805","title":"Conscience May 2024 Policy Brief - European Parliament Proposes Reforms to Legislation Around Pharmaceutical Data Exclusivity","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Parliament; Legislation; Economic shortage; Pharmaceutical industry; European commission; Legislature; European union","score_opus":0.15732390372923538,"score_gpt":0.34985003780658586,"score_spread":0.19252613407735047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6892867441","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004474188,0.008577637,0.0028635405,0.612719,0.04230739,0.00072587724,0.0030497406,0.000490126,0.3247926],"genre_scores_gemma":[0.027974727,0.00245298,0.0023904017,0.511971,0.0077771754,0.00067392964,0.0009844147,0.00025335082,0.44552207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98672336,0.002461788,0.0009182272,0.0015314999,0.0056292615,0.0027358928],"domain_scores_gemma":[0.9841919,0.007771988,0.0011651397,0.0009501525,0.004155472,0.0017652529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01568851,0.0010814953,0.0010908741,0.001546929,0.0057122842,0.014795601,0.0027002671,0.049199667,0.03651239],"category_scores_gemma":[0.052526485,0.0010636734,0.0018460591,0.0015922391,0.0026055225,0.0078003,0.003144535,0.021053584,0.018535975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012492538,0.00013031765,0.0005816381,0.00022893328,0.000019396684,0.0006235004,0.00035277006,0.00037166802,0.00077301246,0.16473697,0.81828845,0.013768418],"study_design_scores_gemma":[0.00004405075,0.00003879924,0.0011573784,0.0002098916,0.000010675991,0.00008797619,0.00013987542,0.0001358674,0.00032128743,0.008607422,0.98920536,0.000041360585],"about_ca_topic_score_codex":0.024697969,"about_ca_topic_score_gemma":0.031015905,"teacher_disagreement_score":0.049199667,"about_ca_system_score_codex":0.008172126,"about_ca_system_score_gemma":0.015159155,"threshold_uncertainty_score":0.12214619},"labels":[],"label_agreement":null},{"id":"W6902442863","doi":"10.6084/m9.figshare.7305146.v1","title":"Additional file 1: of Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare","year":2018,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Politics; Medical prescription; Prescription drug; Government (linguistics); Access to medicines; Drug industry; Drug","score_opus":0.06281212473487068,"score_gpt":0.2760136842271803,"score_spread":0.21320155949230962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902442863","genre_codex":"dataset","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017706143,0.00010159195,0.00004536896,0.0005420997,0.00002426962,0.00009366268,0.99432325,0.000045439498,0.004647197],"genre_scores_gemma":[0.028726544,0.002700483,0.0027946278,0.0020259256,0.00029658986,0.0015793203,0.9105687,0.00031834125,0.05098951],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988172,0.00010123183,0.00013853426,0.000106518375,0.0006015864,0.00023505186],"domain_scores_gemma":[0.97360444,0.0108438805,0.0017256264,0.00047908723,0.012493596,0.0008533587],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012919041,0.0006347997,0.00084693247,0.0055972827,0.0015470955,0.0020173362,0.0015097448,0.0008400869,0.6338522],"category_scores_gemma":[0.022843003,0.00045993304,0.0009113155,0.016296567,0.00036826756,0.0016059215,0.0007914437,0.0011964508,0.03320142],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031382013,0.000015793763,0.0012220413,0.0011776917,0.0000125096685,0.000018049277,0.000038925584,0.0002515828,0.000008626639,0.00091118336,0.98993486,0.006377422],"study_design_scores_gemma":[0.0010177225,0.000052261395,0.08819475,0.005820189,0.00015277264,0.00014727913,0.000819143,0.0018652743,0.00019508264,0.004048057,0.8975785,0.00010905181],"about_ca_topic_score_codex":0.9131076,"about_ca_topic_score_gemma":0.9412354,"teacher_disagreement_score":0.6338522,"about_ca_system_score_codex":0.016725205,"about_ca_system_score_gemma":0.031234413,"threshold_uncertainty_score":0.52226543},"labels":[],"label_agreement":null},{"id":"W6904840632","doi":"10.1371/journal.pone.0318509.s003","title":"Proportion of generic drugs by quarter (%).","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Drug industry; Payment; Procurement","score_opus":0.05071055892004477,"score_gpt":0.2780006825665216,"score_spread":0.22729012364647683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6904840632","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019455458,0.00023577108,0.00045911525,0.0004631179,0.00036625806,0.00011274992,0.98420876,0.00062290597,0.01158584],"genre_scores_gemma":[0.048968725,0.0011893001,0.0036425432,0.0015785326,0.0004572735,0.00077281415,0.8682519,0.0011451009,0.07399383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987702,0.00012582532,0.00015890587,0.00021279616,0.00049166055,0.00024061186],"domain_scores_gemma":[0.99480814,0.001658018,0.0007344441,0.00030100852,0.0022659847,0.00023241043],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00097410835,0.0009386279,0.0007227682,0.0039373087,0.00031689036,0.0013702634,0.0014402213,0.000479699,0.3370928],"category_scores_gemma":[0.011644463,0.0004121159,0.0012807059,0.00532221,0.0002093822,0.0014215304,0.0008851261,0.0016075202,0.09262193],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012340047,0.000031625797,0.0038684974,0.00084368006,0.00004405362,0.000019309284,0.000023187942,0.00030812464,0.00013147666,0.0014446197,0.97887987,0.014282115],"study_design_scores_gemma":[0.00043608385,0.0001171717,0.11886903,0.0010794842,0.00013149466,0.00031802565,0.0006899161,0.001733398,0.0020317135,0.0024006146,0.87212086,0.00007220357],"about_ca_topic_score_codex":0.03957145,"about_ca_topic_score_gemma":0.026915483,"teacher_disagreement_score":0.3370928,"about_ca_system_score_codex":0.0014821768,"about_ca_system_score_gemma":0.0011507794,"threshold_uncertainty_score":0.9455567},"labels":[],"label_agreement":null},{"id":"W6911824122","doi":"10.5281/zenodo.12808014","title":"Conscience June 2024 Policy Brief - FTC Challenges Improper Patent Listings","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Commission; Enforcement; Food and drug administration; Pharmaceutical industry; Government (linguistics); Administration (probate law); Drug industry; Statement (logic)","score_opus":0.15457951881237803,"score_gpt":0.288046317309842,"score_spread":0.13346679849746396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911824122","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016818438,0.002384852,0.0007219054,0.84644634,0.013304111,0.00015657762,0.0005703739,0.00021960169,0.13451439],"genre_scores_gemma":[0.02461614,0.0014811645,0.0010565345,0.7649907,0.00825481,0.0003211768,0.00025890788,0.00014865397,0.19887188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9852481,0.0030400534,0.00081497733,0.0015846196,0.006477517,0.002834739],"domain_scores_gemma":[0.96681523,0.019910073,0.0015766688,0.0013862961,0.008077022,0.0022347209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01621843,0.0013669488,0.001033527,0.0020938483,0.010992468,0.019561088,0.0036144212,0.07901777,0.031829268],"category_scores_gemma":[0.08023306,0.00097640057,0.0016075806,0.0019343726,0.004712007,0.009378682,0.003172636,0.029407898,0.014188884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026409649,0.00006408252,0.00026292005,0.000048109512,0.0000057074526,0.0003831269,0.00018460561,0.0002435484,0.00022016703,0.067968845,0.9250053,0.0055871657],"study_design_scores_gemma":[0.000039934595,0.00003342329,0.0006166677,0.00022526809,0.000009055303,0.0001173714,0.0003667949,0.00035081283,0.0002664454,0.015202973,0.982714,0.00005713933],"about_ca_topic_score_codex":0.06445876,"about_ca_topic_score_gemma":0.05894372,"teacher_disagreement_score":0.07901777,"about_ca_system_score_codex":0.015486735,"about_ca_system_score_gemma":0.029147148,"threshold_uncertainty_score":0.12816715},"labels":[],"label_agreement":null},{"id":"W6911910953","doi":"10.5281/zenodo.12808015","title":"Conscience June 2024 Policy Brief - FTC Challenges Improper Patent Listings","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Commission; Enforcement; Food and drug administration; Pharmaceutical industry; Government (linguistics); Administration (probate law); Drug industry; Statement (logic)","score_opus":0.15457951881237803,"score_gpt":0.288046317309842,"score_spread":0.13346679849746396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911910953","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016818438,0.002384852,0.0007219054,0.84644634,0.013304111,0.00015657762,0.0005703739,0.00021960169,0.13451439],"genre_scores_gemma":[0.02461614,0.0014811645,0.0010565345,0.7649907,0.00825481,0.0003211768,0.00025890788,0.00014865397,0.19887188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9852481,0.0030400534,0.00081497733,0.0015846196,0.006477517,0.002834739],"domain_scores_gemma":[0.96681523,0.019910073,0.0015766688,0.0013862961,0.008077022,0.0022347209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01621843,0.0013669488,0.001033527,0.0020938483,0.010992468,0.019561088,0.0036144212,0.07901777,0.031829268],"category_scores_gemma":[0.08023306,0.00097640057,0.0016075806,0.0019343726,0.004712007,0.009378682,0.003172636,0.029407898,0.014188884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026409649,0.00006408252,0.00026292005,0.000048109512,0.0000057074526,0.0003831269,0.00018460561,0.0002435484,0.00022016703,0.067968845,0.9250053,0.0055871657],"study_design_scores_gemma":[0.000039934595,0.00003342329,0.0006166677,0.00022526809,0.000009055303,0.0001173714,0.0003667949,0.00035081283,0.0002664454,0.015202973,0.982714,0.00005713933],"about_ca_topic_score_codex":0.06445876,"about_ca_topic_score_gemma":0.05894372,"teacher_disagreement_score":0.07901777,"about_ca_system_score_codex":0.015486735,"about_ca_system_score_gemma":0.029147148,"threshold_uncertainty_score":0.12816715},"labels":[],"label_agreement":null},{"id":"W6911923086","doi":"10.5281/zenodo.14373074","title":"Conscience Issue Tracker - December 2024","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Conscience; Intellectual property; Diversity (politics); Property (philosophy); Ethical issues","score_opus":0.07832215433419211,"score_gpt":0.2921950974026684,"score_spread":0.21387294306847632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911923086","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00084668904,0.0006508161,0.0014108402,0.037418928,0.07565701,0.0010663219,0.004422029,0.004049074,0.8744783],"genre_scores_gemma":[0.0018996203,0.00014937232,0.0003611153,0.016061306,0.0053558922,0.00028398592,0.0013315898,0.0009288046,0.9736284],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98930126,0.0005832525,0.00038344663,0.00055683334,0.0073813326,0.0017939316],"domain_scores_gemma":[0.9761469,0.004348798,0.0010130428,0.0018850375,0.0134025635,0.0032036286],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0069719884,0.0013136775,0.0016789514,0.002821652,0.006343007,0.013421403,0.0029766285,0.019562162,0.40215933],"category_scores_gemma":[0.03449388,0.0012835127,0.0014429868,0.0017876296,0.001315471,0.004188544,0.0037971043,0.0130731845,0.39390922],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001420475,0.00001962122,0.000043294516,0.000015402753,0.0000010200379,0.000021745323,0.000008513366,0.0000093122035,0.00004648408,0.0007650526,0.99533683,0.0037184788],"study_design_scores_gemma":[0.000039168284,0.000021223048,0.00053506787,0.000057396624,0.0000026066618,0.00002165076,0.00003275374,0.00008041211,0.0001276823,0.00078415126,0.99827814,0.000019752815],"about_ca_topic_score_codex":0.02187268,"about_ca_topic_score_gemma":0.050283328,"teacher_disagreement_score":0.40215933,"about_ca_system_score_codex":0.003908956,"about_ca_system_score_gemma":0.009682486,"threshold_uncertainty_score":0.85274714},"labels":[],"label_agreement":null},{"id":"W6920139598","doi":"10.60692/0n3wp-c2q08","title":"A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators Programme","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Innovator; Product (mathematics); Comparator; Bioequivalence; Selection (genetic algorithm); Interchangeability","score_opus":0.12779784346627945,"score_gpt":0.29902041718757816,"score_spread":0.1712225737212987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920139598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73003525,0.03536724,0.04343265,0.064231254,0.0012586099,0.010879992,0.008530337,0.001086162,0.10517858],"genre_scores_gemma":[0.9078512,0.018455049,0.037716884,0.017409842,0.0003978478,0.0054057655,0.005205664,0.00037286693,0.00718495],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.8447683,0.07810024,0.023837617,0.0054979553,0.042452257,0.0053436966],"domain_scores_gemma":[0.6877645,0.14127845,0.061368857,0.010496676,0.091045424,0.008046092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.16372773,0.0005481612,0.000943173,0.007350421,0.0024585472,0.0060270424,0.0021018493,0.0034449855,0.0039960416],"category_scores_gemma":[0.19095841,0.0008113691,0.0013832195,0.008894727,0.0023169783,0.0043798825,0.0041893697,0.0035793092,0.0014772183],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011040327,0.0010305066,0.31648338,0.007949824,0.00041597013,0.0009185141,0.066113494,0.0011607243,0.011291863,0.01679171,0.08349641,0.49324366],"study_design_scores_gemma":[0.00013902619,0.0014383572,0.32572964,0.009579433,0.00021402058,0.0018028005,0.061975647,0.0021348863,0.0043107425,0.002641141,0.5896635,0.00037084788],"about_ca_topic_score_codex":0.003852222,"about_ca_topic_score_gemma":0.002074315,"teacher_disagreement_score":0.16372773,"about_ca_system_score_codex":0.003812639,"about_ca_system_score_gemma":0.011324858,"threshold_uncertainty_score":0.8658854},"labels":[],"label_agreement":null},{"id":"W6920327271","doi":"10.60692/0zr1n-0ew62","title":"A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators Programme","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Innovator; Product (mathematics); Comparator; Bioequivalence; Selection (genetic algorithm); Interchangeability","score_opus":0.12779784346627945,"score_gpt":0.29902041718757816,"score_spread":0.1712225737212987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920327271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73003525,0.03536724,0.04343265,0.064231254,0.0012586099,0.010879992,0.008530337,0.001086162,0.10517858],"genre_scores_gemma":[0.9078512,0.018455049,0.037716884,0.017409842,0.0003978478,0.0054057655,0.005205664,0.00037286693,0.00718495],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.8447683,0.07810024,0.023837617,0.0054979553,0.042452257,0.0053436966],"domain_scores_gemma":[0.6877645,0.14127845,0.061368857,0.010496676,0.091045424,0.008046092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.16372773,0.0005481612,0.000943173,0.007350421,0.0024585472,0.0060270424,0.0021018493,0.0034449855,0.0039960416],"category_scores_gemma":[0.19095841,0.0008113691,0.0013832195,0.008894727,0.0023169783,0.0043798825,0.0041893697,0.0035793092,0.0014772183],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011040327,0.0010305066,0.31648338,0.007949824,0.00041597013,0.0009185141,0.066113494,0.0011607243,0.011291863,0.01679171,0.08349641,0.49324366],"study_design_scores_gemma":[0.00013902619,0.0014383572,0.32572964,0.009579433,0.00021402058,0.0018028005,0.061975647,0.0021348863,0.0043107425,0.002641141,0.5896635,0.00037084788],"about_ca_topic_score_codex":0.003852222,"about_ca_topic_score_gemma":0.002074315,"teacher_disagreement_score":0.16372773,"about_ca_system_score_codex":0.003812639,"about_ca_system_score_gemma":0.011324858,"threshold_uncertainty_score":0.8658854},"labels":[],"label_agreement":null},{"id":"W6920726385","doi":"10.6084/m9.figshare.13520769","title":"Additional file 2 of Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Repurposing; Cohort study; Cohort; Research design; Drug repositioning","score_opus":0.10711145725889681,"score_gpt":0.29908811177450473,"score_spread":0.19197665451560791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920726385","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002850385,0.000013716363,0.00007237249,0.00015903015,0.000018458017,0.000093582225,0.9955994,0.00006805168,0.0036903739],"genre_scores_gemma":[0.010962238,0.00018717331,0.0011041536,0.00087962195,0.00017500063,0.0019393327,0.947543,0.00032022694,0.0368893],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983437,0.00024680106,0.00039801295,0.00026849163,0.00052707107,0.0002158951],"domain_scores_gemma":[0.96078193,0.021774149,0.0062309057,0.0021800753,0.008016215,0.0010166782],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017630114,0.0006669155,0.00092886126,0.0032651997,0.00096856675,0.0013347643,0.0016231849,0.001190041,0.84130824],"category_scores_gemma":[0.036376245,0.00060837273,0.0007390418,0.007621549,0.00024237446,0.0026081868,0.0012011119,0.0010515227,0.16353187],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013928475,0.000047918966,0.0023902943,0.00051687553,0.0000146461325,0.000031726497,0.00003074322,0.00012497435,0.000022072121,0.00068663864,0.992661,0.0033338498],"study_design_scores_gemma":[0.0043302597,0.00029330957,0.08561913,0.0028682929,0.00012597762,0.00042526776,0.0006640862,0.0012292165,0.00046205323,0.005972927,0.89790016,0.000109392706],"about_ca_topic_score_codex":0.025743637,"about_ca_topic_score_gemma":0.028466156,"teacher_disagreement_score":0.84130824,"about_ca_system_score_codex":0.0017015922,"about_ca_system_score_gemma":0.0026287632,"threshold_uncertainty_score":0.22635448},"labels":[],"label_agreement":null},{"id":"W6923187526","doi":"10.1371/journal.pgph.0003173.s002","title":"Disclosure Package from Global Affairs Canada.","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product (mathematics); Underpinning; Good manufacturing practice; Technology transfer; Control (management); Global health; Biopharmaceutical; Incentive","score_opus":0.05622127931285924,"score_gpt":0.26242137251785114,"score_spread":0.20620009320499189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6923187526","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007292653,0.005379528,0.0007494941,0.14452589,0.03997129,0.0010263841,0.054162495,0.00062845077,0.75282717],"genre_scores_gemma":[0.012556131,0.003895536,0.0014210703,0.039139014,0.0037873606,0.00089309155,0.0154039115,0.00033299052,0.92257094],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962463,0.00041018584,0.00019788886,0.00044234825,0.0019841036,0.0007191266],"domain_scores_gemma":[0.9885117,0.0018847703,0.0005108378,0.00073432724,0.0065726973,0.0017856384],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030854254,0.00068350433,0.0008118938,0.0014331739,0.0026576915,0.004486376,0.002345019,0.0042831637,0.55731755],"category_scores_gemma":[0.016772904,0.00055031123,0.00050069584,0.0024615629,0.0008024112,0.0018764186,0.002014972,0.0043387017,0.15399955],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000128188885,0.0000045256493,0.000071323004,0.00007638207,0.0000012355447,0.000030659612,0.000030346984,0.000009787577,0.000016348285,0.0025219312,0.9877679,0.009456705],"study_design_scores_gemma":[0.000009441412,0.0000037959203,0.00031788234,0.00014475657,0.000001503576,0.00004641357,0.000077704455,0.000030699535,0.000019623956,0.0004603773,0.99888295,0.0000047403373],"about_ca_topic_score_codex":0.10967378,"about_ca_topic_score_gemma":0.15766655,"teacher_disagreement_score":0.8903262,"about_ca_system_score_codex":0.0061905165,"about_ca_system_score_gemma":0.027753118,"threshold_uncertainty_score":0.6314328},"labels":[],"label_agreement":null},{"id":"W6928842172","doi":"10.3897/jhr.61.13466.figures12-17","title":"Figures 12-17 from: Zhang YM, Gates MW, Shorthouse JD (2017) Revision of Canadian Eurytomidae (Hymenoptera, Chalcidoidea) associated with galls induced by cynipid wasps of the genus Diplolepis Geoffroy (Hymenoptera, Cynipidae) and description of a new species. Journal of Hymenoptera Research 61: 1-29. https://doi.org/10.3897/jhr.61.13466","year":2018,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nucleofection; Gestational period; TSG101; Dysgeusia; Liquation; Hyporeflexia; Fusible alloy; Triacetin; Diafiltration","score_opus":0.1097413014785781,"score_gpt":0.2647673897106358,"score_spread":0.1550260882320577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6928842172","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013401003,0.0017613203,0.0021898234,0.0011119748,0.004945236,0.00032078274,0.15725307,0.0017591942,0.8293185],"genre_scores_gemma":[0.016614426,0.0031233924,0.006884848,0.00033021468,0.00080239645,0.00024143566,0.16583084,0.0020944679,0.804078],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999526,0.00002220083,0.000018920506,0.000063400505,0.00029749091,0.00007189626],"domain_scores_gemma":[0.9990777,0.00008114684,0.00005479549,0.00007973899,0.000603552,0.00010308191],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026098618,0.0012062686,0.000584551,0.0033344754,0.0014458266,0.0018074774,0.001210954,0.0007005939,0.6851755],"category_scores_gemma":[0.0022805932,0.00035334562,0.0007936395,0.00488164,0.0007846782,0.0016082888,0.0009076949,0.001423879,0.36016163],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003358757,0.000009978367,0.00032554328,0.0001944082,0.0000044598064,0.00007172745,0.00008342428,0.00014787413,0.00018607242,0.0016217626,0.974323,0.022998108],"study_design_scores_gemma":[0.0000047895437,0.0000034467762,0.001603244,0.00006977053,0.0000027245815,0.00005666768,0.000052298994,0.00004703555,0.000085624175,0.00031854404,0.99775237,0.000003477555],"about_ca_topic_score_codex":0.13330662,"about_ca_topic_score_gemma":0.21997362,"teacher_disagreement_score":0.8666934,"about_ca_system_score_codex":0.0028879272,"about_ca_system_score_gemma":0.0028737835,"threshold_uncertainty_score":0.44905895},"labels":[],"label_agreement":null},{"id":"W6930118434","doi":"10.5281/zenodo.12738404","title":"Fostering Second Language Acquisition of Canadian Primary School Children: A Critical Evaluation of Vygotsky's Learning Theory in the French Immersion Programme","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Learning theory; Curriculum; Second language; Language acquisition; Second-language acquisition; Activity theory; Social learning theory; Perspective (graphical); Comprehension approach","score_opus":0.07939214198086982,"score_gpt":0.29950015817948505,"score_spread":0.22010801619861525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930118434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9557624,0.003500682,0.0007360354,0.0028271899,0.000106917854,0.00047291577,0.00009028743,0.000024072342,0.03647955],"genre_scores_gemma":[0.9918532,0.00245654,0.001015979,0.00027311136,0.000024330546,0.00015457762,0.000048577098,0.000010921016,0.004162785],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99471706,0.0021037622,0.00014708338,0.0004560874,0.0012771705,0.0012988192],"domain_scores_gemma":[0.99264705,0.0036817312,0.00036410973,0.00018539761,0.0024921023,0.0006296024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0098067,0.00095065485,0.00090874813,0.0035644493,0.014581906,0.004597858,0.0018828516,0.001481788,0.0017408526],"category_scores_gemma":[0.012233176,0.00043335152,0.0006147106,0.003609201,0.011090663,0.001633428,0.0042505004,0.0022625495,0.0001247416],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000196295,0.00032578065,0.009188837,0.0006107682,0.000020164465,0.0016235055,0.92643136,0.00016115035,0.0017238357,0.016194904,0.0018761322,0.041647285],"study_design_scores_gemma":[0.000048314916,0.00065833883,0.073681496,0.00087020395,0.00013313853,0.00045325136,0.8459607,0.00032468777,0.0029982224,0.002098457,0.07266909,0.00010410663],"about_ca_topic_score_codex":0.8187374,"about_ca_topic_score_gemma":0.8725166,"teacher_disagreement_score":0.18126261,"about_ca_system_score_codex":0.067517176,"about_ca_system_score_gemma":0.05687855,"threshold_uncertainty_score":0.4898737},"labels":[],"label_agreement":null},{"id":"W6939251345","doi":"10.6084/m9.figshare.15982357.v1","title":"Additional file 1 of Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process","year":2021,"lang":"en","type":"article","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Process (computing); Negotiation; Property (philosophy); Public access","score_opus":0.17733928516874625,"score_gpt":0.34571894096086764,"score_spread":0.16837965579212139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939251345","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032681882,0.0000051099987,0.000060297352,0.00015122423,0.000007303307,0.000074048636,0.99672806,0.00004563022,0.002601519],"genre_scores_gemma":[0.01743913,0.00010806009,0.0017577303,0.00041228125,0.000060526792,0.0028716947,0.9500416,0.00024581898,0.027063163],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988186,0.00020125796,0.00017640661,0.00016369867,0.00039310733,0.00024677182],"domain_scores_gemma":[0.9621581,0.024903508,0.0030294156,0.0012797277,0.0075975163,0.0010317251],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018004418,0.0005125341,0.0005574974,0.0027949866,0.0013463591,0.001873184,0.0012822498,0.0010017849,0.80485],"category_scores_gemma":[0.03864451,0.00036062492,0.00047534067,0.006323739,0.00030746622,0.0020653177,0.0010753784,0.0010379446,0.117770314],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008217003,0.00006438543,0.0029344852,0.000561148,0.000008643042,0.000023363511,0.00016136374,0.00020486173,0.000023865932,0.0010620311,0.9906317,0.004242066],"study_design_scores_gemma":[0.0016613168,0.00014739057,0.07656419,0.0024660865,0.00006277489,0.00014848751,0.004530605,0.0013002577,0.000554187,0.0064218156,0.9060403,0.000102497375],"about_ca_topic_score_codex":0.10572259,"about_ca_topic_score_gemma":0.12670231,"teacher_disagreement_score":0.8942774,"about_ca_system_score_codex":0.0029173791,"about_ca_system_score_gemma":0.0055997143,"threshold_uncertainty_score":0.27835774},"labels":[],"label_agreement":null},{"id":"W6939270230","doi":"10.60692/7cydj-hev51","title":"The availability of essential medicines for cardiovascular diseases at healthcare facilities in low- and middle-income countries: The case of Bangladesh","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Poisson regression; Health care; Public health; Disease; Quality (philosophy); Essential medicines; Thiazide","score_opus":0.043504558252278794,"score_gpt":0.23853931963378847,"score_spread":0.19503476138150966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939270230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427575,0.0008722045,0.00011321938,0.0014135481,0.000008169235,0.00003279048,0.0008495823,0.0000022400257,0.0024325813],"genre_scores_gemma":[0.9986778,0.0007374912,0.00008512085,0.00008894484,0.0000049097457,0.000011967085,0.00019021952,0.0000017358973,0.00020181577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988651,0.00031103648,0.0001469277,0.0001890593,0.00014848026,0.0003393827],"domain_scores_gemma":[0.99757606,0.00045581517,0.0011093741,0.0001415493,0.0003590309,0.00035819437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008636576,0.00041522,0.00042907614,0.0014210086,0.0011419664,0.0013242888,0.0007515763,0.0006769868,0.0038743787],"category_scores_gemma":[0.0034638876,0.0004458869,0.0006423756,0.0033779973,0.0009234107,0.0012142834,0.0016135835,0.0009136208,0.00031878392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052672738,0.000032682176,0.9883245,0.0001251817,0.00007109922,0.0027713855,0.0030571024,0.00007947258,0.00019976014,0.0005164214,0.0005571312,0.0042125513],"study_design_scores_gemma":[0.000011587967,0.000066098226,0.9705875,0.00024268744,0.000085179774,0.0028614271,0.023020275,0.0004967964,0.00009727696,0.00030881728,0.0021808506,0.000041480536],"about_ca_topic_score_codex":0.1969468,"about_ca_topic_score_gemma":0.17912649,"teacher_disagreement_score":0.1969468,"about_ca_system_score_codex":0.002731354,"about_ca_system_score_gemma":0.0018444861,"threshold_uncertainty_score":0.3916009},"labels":[],"label_agreement":null},{"id":"W6939811928","doi":"10.6084/m9.figshare.15982357","title":"Additional file 1 of Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Process (computing); Negotiation; Property (philosophy); Public access","score_opus":0.1685218022715173,"score_gpt":0.3158965118918517,"score_spread":0.1473747096203344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939811928","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025324902,0.0000054968177,0.000064256186,0.00014382228,0.000007743982,0.000056252426,0.99670225,0.000055006698,0.0027118672],"genre_scores_gemma":[0.016774204,0.00011861811,0.0019272045,0.00041519577,0.000060502964,0.0022145917,0.95204514,0.00036968727,0.02607486],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9989496,0.00019088834,0.0001469756,0.00015684895,0.00033118806,0.00022462111],"domain_scores_gemma":[0.9603888,0.028312707,0.0025200318,0.0013601723,0.006473085,0.0009452923],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017211557,0.00050303485,0.00055996707,0.0028803058,0.0011433308,0.0019038509,0.0012329632,0.0009557724,0.8462069],"category_scores_gemma":[0.037706133,0.0003728431,0.00052132166,0.0070416625,0.00031763382,0.0023104313,0.0010464321,0.0010315734,0.14977926],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063982625,0.000042658332,0.0020365813,0.00047726842,0.00000797464,0.000017445445,0.00010207607,0.00021208705,0.000016703681,0.0010524995,0.9925402,0.0034306645],"study_design_scores_gemma":[0.0014740289,0.000113305316,0.05549464,0.0021601694,0.000056588375,0.00013104395,0.0029221645,0.0012955049,0.0004147466,0.0073103523,0.92853767,0.00008990411],"about_ca_topic_score_codex":0.08167479,"about_ca_topic_score_gemma":0.09461325,"teacher_disagreement_score":0.9183252,"about_ca_system_score_codex":0.0026056923,"about_ca_system_score_gemma":0.0047274535,"threshold_uncertainty_score":0.21936709},"labels":[],"label_agreement":null},{"id":"W6958049139","doi":"10.6084/m9.figshare.13520769.v1","title":"Additional file 2 of Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Repurposing; Cohort study; Cohort; Research design; Drug repositioning","score_opus":0.10711145725889681,"score_gpt":0.29908811177450473,"score_spread":0.19197665451560791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958049139","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002850385,0.000013716363,0.00007237249,0.00015903015,0.000018458017,0.000093582225,0.9955994,0.00006805168,0.0036903739],"genre_scores_gemma":[0.010962238,0.00018717331,0.0011041536,0.00087962195,0.00017500063,0.0019393327,0.947543,0.00032022694,0.0368893],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9983437,0.00024680106,0.00039801295,0.00026849163,0.00052707107,0.0002158951],"domain_scores_gemma":[0.96078193,0.021774149,0.0062309057,0.0021800753,0.008016215,0.0010166782],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017630114,0.0006669155,0.00092886126,0.0032651997,0.00096856675,0.0013347643,0.0016231849,0.001190041,0.84130824],"category_scores_gemma":[0.036376245,0.00060837273,0.0007390418,0.007621549,0.00024237446,0.0026081868,0.0012011119,0.0010515227,0.16353187],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013928475,0.000047918966,0.0023902943,0.00051687553,0.0000146461325,0.000031726497,0.00003074322,0.00012497435,0.000022072121,0.00068663864,0.992661,0.0033338498],"study_design_scores_gemma":[0.0043302597,0.00029330957,0.08561913,0.0028682929,0.00012597762,0.00042526776,0.0006640862,0.0012292165,0.00046205323,0.005972927,0.89790016,0.000109392706],"about_ca_topic_score_codex":0.025743637,"about_ca_topic_score_gemma":0.028466156,"teacher_disagreement_score":0.84130824,"about_ca_system_score_codex":0.0017015922,"about_ca_system_score_gemma":0.0026287632,"threshold_uncertainty_score":0.22635448},"labels":[],"label_agreement":null},{"id":"W6958214953","doi":"10.6084/m9.figshare.19382403","title":"Additional file 1 of Trends in Canadian prescription drug purchasing: 2001–2020","year":2022,"lang":"en","type":"article","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Queen Elizabeth II Health Sciences Centre; Université Laval; University of British Columbia; University of Toronto; Institute for Clinical Evaluative Sciences; University of Calgary","funders":"","keywords":"Medical prescription; Prescription drug; Drug; MEDLINE","score_opus":0.07907137573426799,"score_gpt":0.2933697309112414,"score_spread":0.21429835517697343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958214953","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000110366214,0.0000144863425,0.000018004268,0.00007949372,0.0000094502875,0.00002193171,0.99798054,0.000031122738,0.0017346764],"genre_scores_gemma":[0.0051696696,0.00018940168,0.0005339687,0.00026798376,0.000045449553,0.00026406217,0.9772241,0.00008338034,0.016221888],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986505,0.00006828576,0.00014603195,0.00015893517,0.00067116285,0.0003050169],"domain_scores_gemma":[0.9867756,0.0018767694,0.0009560485,0.00034214513,0.009401982,0.0006474879],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009696504,0.000758802,0.00078367174,0.004945634,0.0015669424,0.0016035524,0.0015543604,0.00070888194,0.5562245],"category_scores_gemma":[0.012786581,0.0004493266,0.000753444,0.014275049,0.00023607277,0.0010774811,0.00089083216,0.0009488672,0.062742166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025766825,0.000013842126,0.001591758,0.00028723964,0.000009268346,0.000012029343,0.000021818421,0.00013226016,0.000008539907,0.00038697617,0.9944212,0.003089225],"study_design_scores_gemma":[0.00058895815,0.00005111034,0.11096297,0.0012257448,0.00007423472,0.00008536041,0.00052116485,0.0014017588,0.00025983414,0.0012467804,0.8834985,0.00008362002],"about_ca_topic_score_codex":0.923871,"about_ca_topic_score_gemma":0.94279754,"teacher_disagreement_score":0.5562245,"about_ca_system_score_codex":0.01202265,"about_ca_system_score_gemma":0.024632992,"threshold_uncertainty_score":0.63299185},"labels":[],"label_agreement":null},{"id":"W6958653981","doi":"10.6084/m9.figshare.19382403.v1","title":"Additional file 1 of Trends in Canadian prescription drug purchasing: 2001–2020","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Queen Elizabeth II Health Sciences Centre; Université Laval; University of British Columbia; University of Toronto; Institute for Clinical Evaluative Sciences; University of Calgary","funders":"","keywords":"Medical prescription; Prescription drug; Drug; MEDLINE","score_opus":0.07381285126224263,"score_gpt":0.25989332782598645,"score_spread":0.18608047656374382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958653981","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009299165,0.000014101809,0.000017619463,0.00007371597,0.00000941023,0.000020109224,0.997891,0.000034000845,0.001847073],"genre_scores_gemma":[0.004876005,0.0001938457,0.0005467688,0.0002570633,0.000044758155,0.00024716774,0.9767676,0.000099775316,0.01696703],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9987656,0.00006302644,0.00013018011,0.0001500204,0.0006039668,0.00028724023],"domain_scores_gemma":[0.98753613,0.001872433,0.0008541999,0.00033912543,0.008779605,0.00061850867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093815936,0.0007527858,0.0007757876,0.004934296,0.0015039194,0.0016510175,0.0015100446,0.000694277,0.6070194],"category_scores_gemma":[0.012355426,0.00045241372,0.00075363426,0.014401375,0.00024175801,0.0011477694,0.00088947336,0.0009261496,0.07476981],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023826187,0.000011977098,0.0012150556,0.00026411758,0.000008272695,0.00001069513,0.000018729928,0.00012411214,0.0000073243937,0.00037674623,0.99495703,0.0029821333],"study_design_scores_gemma":[0.0005666954,0.00004461709,0.08826785,0.0011598812,0.000065163425,0.00008131635,0.00044439116,0.0012725528,0.00022672175,0.001342116,0.9064509,0.000077637385],"about_ca_topic_score_codex":0.9109711,"about_ca_topic_score_gemma":0.93210876,"teacher_disagreement_score":0.6070194,"about_ca_system_score_codex":0.011264725,"about_ca_system_score_gemma":0.02222922,"threshold_uncertainty_score":0.56053907},"labels":[],"label_agreement":null},{"id":"W6966599021","doi":"10.48448/7m2p-c507","title":"Economic analysis of the sustainability ofnational pharmacare in Canada","year":2022,"lang":"en","type":"other","venue":"Underline Science Inc.","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic analysis; Sustainability; Government (linguistics); Production (economics)","score_opus":0.027269151129613155,"score_gpt":0.29310477551452846,"score_spread":0.2658356243849153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6966599021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8023714,0.005150134,0.0015503066,0.045104932,0.00017762838,0.00022226258,0.013040986,0.00010433245,0.13227803],"genre_scores_gemma":[0.9842907,0.0015772111,0.0003076068,0.0005100978,0.00003379674,0.000013979006,0.001048482,0.000016976963,0.012201111],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981748,0.00015382364,0.000048418133,0.0000988117,0.00045771795,0.0010663825],"domain_scores_gemma":[0.99700683,0.00044329095,0.00035593653,0.00007010377,0.0013022635,0.000821567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009258237,0.00026773108,0.00045740115,0.001350547,0.0031533602,0.0048535718,0.001098166,0.001153765,0.006902537],"category_scores_gemma":[0.0061491416,0.00030053096,0.00074483803,0.0031948495,0.001186228,0.0008864947,0.0013960846,0.0017265743,0.00018829426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007735101,0.0003527283,0.2324171,0.00044412233,0.0006312164,0.0013432844,0.0010536127,0.159819,0.00086641667,0.45198363,0.09111313,0.059202325],"study_design_scores_gemma":[0.00030188676,0.00024314766,0.5145844,0.00054306403,0.0007211892,0.00032316722,0.011449329,0.24451631,0.0016919137,0.067214325,0.15814795,0.00026334572],"about_ca_topic_score_codex":0.99541557,"about_ca_topic_score_gemma":0.996748,"teacher_disagreement_score":0.86431766,"about_ca_system_score_codex":0.13568233,"about_ca_system_score_gemma":0.13082102,"threshold_uncertainty_score":0.9844488},"labels":[],"label_agreement":null},{"id":"W6968165057","doi":"10.5281/zenodo.12808804","title":"Conscience May 2024 Policy Brief - European Parliament Proposes Reforms to Legislation Around Pharmaceutical Data Exclusivity","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Parliament; Legislation; Economic shortage; Pharmaceutical industry; European commission; Legislature; European union","score_opus":0.15732390372923538,"score_gpt":0.34985003780658586,"score_spread":0.19252613407735047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968165057","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004474188,0.008577637,0.0028635405,0.612719,0.04230739,0.00072587724,0.0030497406,0.000490126,0.3247926],"genre_scores_gemma":[0.027974727,0.00245298,0.0023904017,0.511971,0.0077771754,0.00067392964,0.0009844147,0.00025335082,0.44552207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98672336,0.002461788,0.0009182272,0.0015314999,0.0056292615,0.0027358928],"domain_scores_gemma":[0.9841919,0.007771988,0.0011651397,0.0009501525,0.004155472,0.0017652529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01568851,0.0010814953,0.0010908741,0.001546929,0.0057122842,0.014795601,0.0027002671,0.049199667,0.03651239],"category_scores_gemma":[0.052526485,0.0010636734,0.0018460591,0.0015922391,0.0026055225,0.0078003,0.003144535,0.021053584,0.018535975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012492538,0.00013031765,0.0005816381,0.00022893328,0.000019396684,0.0006235004,0.00035277006,0.00037166802,0.00077301246,0.16473697,0.81828845,0.013768418],"study_design_scores_gemma":[0.00004405075,0.00003879924,0.0011573784,0.0002098916,0.000010675991,0.00008797619,0.00013987542,0.0001358674,0.00032128743,0.008607422,0.98920536,0.000041360585],"about_ca_topic_score_codex":0.024697969,"about_ca_topic_score_gemma":0.031015905,"teacher_disagreement_score":0.049199667,"about_ca_system_score_codex":0.008172126,"about_ca_system_score_gemma":0.015159155,"threshold_uncertainty_score":0.12214619},"labels":[],"label_agreement":null},{"id":"W6968605403","doi":"10.5281/zenodo.14373075","title":"Conscience Issue Tracker - December 2024","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Conscience; Intellectual property; Diversity (politics); Property (philosophy); Ethical issues","score_opus":0.07832215433419211,"score_gpt":0.2921950974026684,"score_spread":0.21387294306847632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968605403","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00084668904,0.0006508161,0.0014108402,0.037418928,0.07565701,0.0010663219,0.004422029,0.004049074,0.8744783],"genre_scores_gemma":[0.0018996203,0.00014937232,0.0003611153,0.016061306,0.0053558922,0.00028398592,0.0013315898,0.0009288046,0.9736284],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98930126,0.0005832525,0.00038344663,0.00055683334,0.0073813326,0.0017939316],"domain_scores_gemma":[0.9761469,0.004348798,0.0010130428,0.0018850375,0.0134025635,0.0032036286],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0069719884,0.0013136775,0.0016789514,0.002821652,0.006343007,0.013421403,0.0029766285,0.019562162,0.40215933],"category_scores_gemma":[0.03449388,0.0012835127,0.0014429868,0.0017876296,0.001315471,0.004188544,0.0037971043,0.0130731845,0.39390922],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001420475,0.00001962122,0.000043294516,0.000015402753,0.0000010200379,0.000021745323,0.000008513366,0.0000093122035,0.00004648408,0.0007650526,0.99533683,0.0037184788],"study_design_scores_gemma":[0.000039168284,0.000021223048,0.00053506787,0.000057396624,0.0000026066618,0.00002165076,0.00003275374,0.00008041211,0.0001276823,0.00078415126,0.99827814,0.000019752815],"about_ca_topic_score_codex":0.02187268,"about_ca_topic_score_gemma":0.050283328,"teacher_disagreement_score":0.40215933,"about_ca_system_score_codex":0.003908956,"about_ca_system_score_gemma":0.009682486,"threshold_uncertainty_score":0.85274714},"labels":[],"label_agreement":null},{"id":"W6979717166","doi":"","title":"Access to Medicines and Pharmaceutical Policy in New Zealand: Comparing the issues with United Kingdom, Australia and Canada","year":2012,"lang":"en","type":"dissertation","venue":"ResearchSpace (University of Auckland)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Legislation; Public policy; Access to medicines; MEDLINE","score_opus":0.16589470376204832,"score_gpt":0.3852437831592027,"score_spread":0.2193490793971544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6979717166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9267416,0.008347131,0.00013603743,0.020108448,0.00006476982,0.00006532172,0.00212843,0.0000075997527,0.04240076],"genre_scores_gemma":[0.98917204,0.0040238975,0.00013883162,0.0005613679,0.000032060216,0.000016489845,0.0003562367,0.000007136049,0.0056920275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978352,0.00022688009,0.00015441865,0.00013838183,0.0008736732,0.0007713775],"domain_scores_gemma":[0.9939458,0.0013111982,0.0018711742,0.00012145761,0.0013603147,0.0013900752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013893486,0.00021870241,0.00065956055,0.0017798871,0.0017052703,0.004773874,0.0007507732,0.0011426411,0.005940179],"category_scores_gemma":[0.010735922,0.00030094126,0.000999059,0.006590568,0.0020766815,0.0024703976,0.0022272014,0.0020706179,0.00018566161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021458636,0.0006101985,0.7735648,0.0010464333,0.0009841921,0.003429868,0.023829281,0.0053963084,0.0013843436,0.07640972,0.023377823,0.08782116],"study_design_scores_gemma":[0.00005540513,0.00008701459,0.97211796,0.00015304238,0.00014122609,0.00013288239,0.010585753,0.0008618262,0.00017433608,0.0017882616,0.013856397,0.000045877612],"about_ca_topic_score_codex":0.97641695,"about_ca_topic_score_gemma":0.98318106,"teacher_disagreement_score":0.03539352,"about_ca_system_score_codex":0.03539352,"about_ca_system_score_gemma":0.0207144,"threshold_uncertainty_score":0.25679916},"labels":[],"label_agreement":null},{"id":"W6980405817","doi":"","title":"Canadaâs Patented Medicines (Notice of Compliance) Regulations: Removing Inefficiencies to Encourage Generic Competition","year":2011,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Monopoly; Incentive; Competition (biology); Key (lock); Competition law; Action (physics); Property (philosophy)","score_opus":0.02593581445305174,"score_gpt":0.19429556188577377,"score_spread":0.16835974743272203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6980405817","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024006058,0.0064069377,0.0054330193,0.13762647,0.0010533232,0.0007168922,0.0027541067,0.0005667607,0.8214364],"genre_scores_gemma":[0.4161014,0.009516565,0.030421859,0.06979453,0.00071435864,0.00039154117,0.001953246,0.00025269817,0.4708538],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9869915,0.0007314272,0.00028804928,0.00050779147,0.009303064,0.002178137],"domain_scores_gemma":[0.9884688,0.0025583713,0.0008286997,0.0005879379,0.0062471326,0.001309037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006024558,0.0003441932,0.00032795084,0.0025803065,0.0067302086,0.0068549,0.0015257573,0.0050390894,0.012943067],"category_scores_gemma":[0.020321641,0.0004175991,0.00066068163,0.0033166646,0.0045815473,0.0018570555,0.0013785575,0.0036490401,0.0018950205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009013998,0.00010345329,0.005367936,0.0002918613,0.000026202728,0.00032255982,0.0022045632,0.0009110947,0.0018758501,0.41147926,0.48870867,0.08861846],"study_design_scores_gemma":[0.00010359845,0.00005664159,0.023677276,0.0002823496,0.000077965575,0.00015770746,0.00068756595,0.00095177547,0.0024365452,0.012453471,0.95902884,0.00008624737],"about_ca_topic_score_codex":0.93048024,"about_ca_topic_score_gemma":0.9619626,"teacher_disagreement_score":0.06951976,"about_ca_system_score_codex":0.05270638,"about_ca_system_score_gemma":0.22923937,"threshold_uncertainty_score":0.38241333},"labels":[],"label_agreement":null},{"id":"W6986330833","doi":"","title":"Pattern Development Secures Power Purchase Agreement For 147 MW Wind Project In Quebec | Press Releases News | Print Financial &amp;amp; Investing Articles","year":2015,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Power (physics); Investment (military); Framework agreement; Wind power; Agreement","score_opus":0.15204177243044553,"score_gpt":0.322231385339997,"score_spread":0.17018961290955148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6986330833","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00902533,0.00046833622,0.0014422924,0.0073801824,0.0007300182,0.0004940959,0.019756712,0.0015709463,0.95913213],"genre_scores_gemma":[0.011004608,0.000115328665,0.00041520718,0.0005538073,0.000059843365,0.000050688628,0.0026426932,0.00019204285,0.9849658],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862707,0.000050085935,0.000019643136,0.000082789076,0.00088893564,0.00033147322],"domain_scores_gemma":[0.9969919,0.00019287581,0.00007901224,0.00019402555,0.0020814284,0.00046069443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012775852,0.0004257285,0.0003783296,0.0012500951,0.0033246516,0.0041278517,0.000950054,0.0024379522,0.325043],"category_scores_gemma":[0.003600028,0.0005278584,0.0004988886,0.0010655838,0.0006273118,0.00080916425,0.0006178171,0.00164637,0.064592436],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007894115,0.000056046778,0.001859744,0.000044095872,0.0000067575443,0.00010550807,0.00006335851,0.00039644522,0.0004964174,0.004788644,0.96907425,0.023029828],"study_design_scores_gemma":[0.00004578943,0.00003660413,0.013442595,0.000038606584,0.0000051241523,0.000022975304,0.00014014893,0.0007614139,0.00052950147,0.00047063406,0.9844869,0.000019689694],"about_ca_topic_score_codex":0.89861715,"about_ca_topic_score_gemma":0.9535387,"teacher_disagreement_score":0.325043,"about_ca_system_score_codex":0.017008048,"about_ca_system_score_gemma":0.03342186,"threshold_uncertainty_score":0.96274424},"labels":[],"label_agreement":null},{"id":"W6986792601","doi":"","title":"Regulating Prescription Drug Costs","year":2020,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Legislation; Prescription drug; Drug prices; Drug; Government (linguistics); Pharmaceutical industry; Pharmacy; Negotiation","score_opus":0.04680653514389867,"score_gpt":0.2647484021467481,"score_spread":0.21794186700284945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6986792601","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007306037,0.013067964,0.018360456,0.112801366,0.00856015,0.0011684855,0.0021408356,0.0010945743,0.83550006],"genre_scores_gemma":[0.31975326,0.02232255,0.035547044,0.33964694,0.022025747,0.0038230484,0.0040807365,0.0012548864,0.25154585],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9651765,0.0060532806,0.0023728576,0.003497795,0.02015594,0.0027435373],"domain_scores_gemma":[0.94114023,0.023262737,0.005363672,0.0060702683,0.02043831,0.0037246977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015088287,0.0010506696,0.0008857846,0.0039362577,0.002856151,0.00972757,0.0031734263,0.007971092,0.033329573],"category_scores_gemma":[0.08541978,0.0008997027,0.0015982045,0.002301128,0.0030449196,0.004313969,0.0044974727,0.008851131,0.011798846],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007142266,0.0002086481,0.0055195163,0.00050666375,0.00009688788,0.0001301353,0.0006486749,0.0012056156,0.0015243907,0.2889786,0.53142166,0.16968776],"study_design_scores_gemma":[0.0000493269,0.00007643128,0.005410966,0.00065984944,0.000036072775,0.000119395416,0.00013482966,0.00064414984,0.00074044074,0.015983196,0.9760853,0.000059972783],"about_ca_topic_score_codex":0.017127153,"about_ca_topic_score_gemma":0.011017613,"teacher_disagreement_score":0.033329573,"about_ca_system_score_codex":0.007900064,"about_ca_system_score_gemma":0.01914777,"threshold_uncertainty_score":0.111498535},"labels":[],"label_agreement":null},{"id":"W6988033236","doi":"","title":"What happens to drug use and expenditure when cost sharing is completely removed? Evidence from a Canadian provincial public drug plan","year":2020,"lang":"en","type":"article","venue":"UTS ePRESS (University of Technology Sydney)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cost sharing; Medical prescription; Prescription drug; Drug; Public health; Public expenditure; Interrupted time series","score_opus":0.11421004361224801,"score_gpt":0.24098269376778977,"score_spread":0.12677265015554176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6988033236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9244835,0.004641093,0.00018610148,0.03827164,0.0001496463,0.00014495724,0.008553144,0.000020283194,0.023549652],"genre_scores_gemma":[0.9921394,0.0010585199,0.00010507499,0.0021362188,0.000043973458,0.000028030992,0.001424768,0.0000069374096,0.003057119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9899989,0.0017352937,0.0004006395,0.0005575936,0.0025255792,0.0047819503],"domain_scores_gemma":[0.96622676,0.011154287,0.008325581,0.0015622783,0.0073015545,0.005429461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005154195,0.0002950626,0.0011180014,0.001458191,0.0033028931,0.0037608945,0.0031536152,0.0023601241,0.006651206],"category_scores_gemma":[0.036966126,0.00060969935,0.0017836161,0.005756043,0.0026049602,0.0015147936,0.0020233276,0.003970891,0.00036785213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021291217,0.00069230393,0.92029536,0.0004958358,0.00095172646,0.00050216634,0.0051192376,0.0030280005,0.0002041579,0.012984259,0.025322316,0.028275587],"study_design_scores_gemma":[0.00027862127,0.000113485316,0.98023236,0.00020810416,0.00050200976,0.000051448613,0.0063138525,0.0011736432,0.00012349969,0.0011935985,0.009751311,0.000058024907],"about_ca_topic_score_codex":0.99569535,"about_ca_topic_score_gemma":0.9970861,"teacher_disagreement_score":0.07022398,"about_ca_system_score_codex":0.07022398,"about_ca_system_score_gemma":0.115287915,"threshold_uncertainty_score":0.509513},"labels":[],"label_agreement":null},{"id":"W6990104931","doi":"","title":"Cost-Control Mechanisms in Canadian Private Drug Plans","year":2013,"lang":"en","type":"article","venue":"PubMed Central","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Prescription drug; Medical prescription; Private sector; MEDLINE","score_opus":0.03216132063005531,"score_gpt":0.22208007700175467,"score_spread":0.18991875637169936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6990104931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9142887,0.008393684,0.0014194087,0.012442669,0.00006344753,0.00035153038,0.0069108764,0.000095492775,0.056034293],"genre_scores_gemma":[0.9925867,0.0017471688,0.0006514543,0.00039137073,0.000024368353,0.000030457624,0.0010457974,0.0000070334627,0.0035157339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946631,0.00035868975,0.00015933703,0.00033185765,0.0024506582,0.0020362935],"domain_scores_gemma":[0.99202853,0.0014167128,0.0024885968,0.00034803236,0.002313994,0.0014041791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020161835,0.0002844976,0.00040091824,0.0029748064,0.0026163617,0.003797281,0.0012740496,0.0008171884,0.0038249341],"category_scores_gemma":[0.011393799,0.00039097678,0.00064598134,0.0044469205,0.0013860626,0.00095227157,0.0011099735,0.0009439555,0.00010713236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059828645,0.0005092023,0.5558414,0.0005645269,0.00053656864,0.00082414615,0.003914832,0.023331791,0.0013079542,0.18981633,0.053026397,0.16972858],"study_design_scores_gemma":[0.00027182605,0.00015495406,0.8791083,0.00045602355,0.0003132414,0.00031851287,0.0035370667,0.01983106,0.00086544873,0.009778145,0.08521267,0.00015282736],"about_ca_topic_score_codex":0.982781,"about_ca_topic_score_gemma":0.9827444,"teacher_disagreement_score":0.09342249,"about_ca_system_score_codex":0.09342249,"about_ca_system_score_gemma":0.063376874,"threshold_uncertainty_score":0.67783076},"labels":[],"label_agreement":null},{"id":"W6990586902","doi":"","title":"Drug importation programs","year":2019,"lang":"en","type":"article","venue":"State Elections Enforcement Commission (State of Connecticut)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Agency (philosophy); State (computer science); Work (physics); Federal law; Public health; Prescription drug","score_opus":0.028965842298806894,"score_gpt":0.27425889389174574,"score_spread":0.24529305159293885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6990586902","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036777048,0.003353339,0.004463618,0.006535979,0.001788989,0.00189542,0.113234036,0.008197519,0.85685337],"genre_scores_gemma":[0.015623355,0.0066076373,0.0109102,0.014035779,0.0008781251,0.0019235372,0.103883445,0.0024054078,0.84373254],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779403,0.00022498629,0.00020357594,0.00027517596,0.001186612,0.00031565176],"domain_scores_gemma":[0.99207497,0.0016151441,0.0009154027,0.00074059464,0.0036282446,0.0010256269],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019848864,0.0010576335,0.0005560847,0.0044034123,0.0021294248,0.002473742,0.0018155487,0.0020617426,0.55097425],"category_scores_gemma":[0.008044584,0.0007097837,0.000753853,0.0039134165,0.00039986326,0.0038465231,0.0030667663,0.002052789,0.3264535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006799342,0.00017921961,0.00092388806,0.00041218093,0.0000054976977,0.00007169075,0.00007281152,0.000048266676,0.00046909368,0.002269024,0.8768587,0.11862151],"study_design_scores_gemma":[0.000018120147,0.000035747602,0.001169376,0.000112699294,0.0000036075637,0.000063545165,0.00003556703,0.000031445168,0.00029399522,0.00027698456,0.9979504,0.000008479962],"about_ca_topic_score_codex":0.008800829,"about_ca_topic_score_gemma":0.013726876,"teacher_disagreement_score":0.55097425,"about_ca_system_score_codex":0.001746738,"about_ca_system_score_gemma":0.0054773027,"threshold_uncertainty_score":0.64048076},"labels":[],"label_agreement":null},{"id":"W6995590984","doi":"","title":"Pharmacy Choice - Pharmaceutical News - Enanta Pharmaceuticals Posts 3rd Quarter Financial Results [Manufacturing Close - Up]","year":2014,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmacy; Community pharmacy; Pharmaceutical industry; Financial Audit","score_opus":0.07110142399607393,"score_gpt":0.34022185369366537,"score_spread":0.2691204296975914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995590984","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017313191,0.0019020824,0.00036276132,0.010719921,0.0025449363,0.00013170583,0.042306025,0.00095457997,0.9393467],"genre_scores_gemma":[0.005578966,0.0007574621,0.00020876408,0.0014938118,0.00084960385,0.00006053317,0.0071816156,0.00032020887,0.983549],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986399,0.00010062226,0.000050841714,0.0001428691,0.00079722475,0.00026851133],"domain_scores_gemma":[0.995615,0.00075915176,0.00037898758,0.0003188879,0.0016790254,0.0012488707],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014347682,0.000749879,0.00076184655,0.002855654,0.0021755032,0.00825211,0.0012004817,0.0045345407,0.4714632],"category_scores_gemma":[0.00831806,0.0005476476,0.00070371595,0.0034625663,0.0005645754,0.0023815609,0.0014040546,0.0034982786,0.21574457],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005327313,0.000056385277,0.000323513,0.00004538607,0.0000046127775,0.000021027767,0.000008109329,0.000075514465,0.000045654266,0.0034034832,0.98380184,0.012161103],"study_design_scores_gemma":[0.000059454316,0.000049596038,0.008635255,0.00013466335,0.000009312227,0.000034437027,0.000057305926,0.00044505007,0.00043581918,0.002959983,0.987152,0.000027096961],"about_ca_topic_score_codex":0.031882897,"about_ca_topic_score_gemma":0.08092291,"teacher_disagreement_score":0.4714632,"about_ca_system_score_codex":0.004295721,"about_ca_system_score_gemma":0.0059760343,"threshold_uncertainty_score":0.7538936},"labels":[],"label_agreement":null},{"id":"W6998544407","doi":"","title":"An Analysis of Trends of Generic Drugs and Biologic Prices in the U.S.","year":2023,"lang":"en","type":"article","venue":"Chapman University Digital Commons (Chapman University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Generic drug; Medicaid; Drug prices; Quarter (Canadian coin); Prescription drug; Medical prescription; Health care; Competition (biology)","score_opus":0.05731280158880058,"score_gpt":0.23954448636631454,"score_spread":0.18223168477751395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6998544407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95187104,0.0008508175,0.00042266274,0.0006939916,0.000040346706,0.00003492912,0.04258368,0.00006473255,0.0034378285],"genre_scores_gemma":[0.9520895,0.00066835375,0.0011747795,0.0003070127,0.000051219806,0.00006599346,0.044635512,0.000027072248,0.000980657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990989,0.0001371937,0.00014286637,0.00018648327,0.00032862255,0.00010589462],"domain_scores_gemma":[0.9949279,0.000880046,0.0021298921,0.00015386363,0.0016687084,0.00023953542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010951108,0.00026095734,0.00023029144,0.0025805605,0.00024833568,0.00088642084,0.00038423,0.00038812324,0.002001721],"category_scores_gemma":[0.004569932,0.00018367282,0.00055915426,0.0069421222,0.00017502916,0.0006965303,0.00041836174,0.0006288739,0.00065411377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000143076,0.000078264035,0.9814153,0.000072087765,0.00012345903,0.000072930416,0.00014471462,0.0006811991,0.00014336214,0.00026201786,0.006833039,0.010030516],"study_design_scores_gemma":[0.000007942627,0.00006467729,0.9925442,0.00003537061,0.00003693698,0.00009806718,0.00030924627,0.0021055213,0.00015616174,0.000058624133,0.0045732195,0.000010100214],"about_ca_topic_score_codex":0.06429912,"about_ca_topic_score_gemma":0.04962615,"teacher_disagreement_score":0.06429912,"about_ca_system_score_codex":0.0011605048,"about_ca_system_score_gemma":0.0013547473,"threshold_uncertainty_score":0.1278497},"labels":[],"label_agreement":null},{"id":"W6998936394","doi":"","title":"$1.43 Billion in Sales Expected for Olin Co. (NYSE:OLN) This Quarter","year":2021,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Payment; Economic forecasting","score_opus":0.08764716818813396,"score_gpt":0.3213196038342383,"score_spread":0.23367243564610435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6998936394","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024279978,0.00130528,0.000484112,0.004751332,0.0020467858,0.000100109406,0.031829532,0.0013904369,0.9556645],"genre_scores_gemma":[0.0028533933,0.0006516354,0.00015107886,0.0006237527,0.0002150565,0.000040874682,0.008817346,0.00019364196,0.9864531],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997757,0.000017080702,0.00000920236,0.0000341338,0.000116306495,0.000047585876],"domain_scores_gemma":[0.9996551,0.000028278291,0.00002461314,0.00001924328,0.00013739975,0.00013529975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003121179,0.00087698264,0.0003224187,0.0010886042,0.0008311206,0.0024298711,0.0003740505,0.0014364526,0.44919437],"category_scores_gemma":[0.0012367694,0.00025319232,0.00035545658,0.0008324844,0.00033010708,0.001148546,0.0012355602,0.0014204694,0.39327908],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003962674,0.00002451603,0.00021539374,0.000039160892,0.0000015953334,0.000013260479,0.0000045485276,0.000072150695,0.00014429635,0.0012552519,0.9826636,0.015526501],"study_design_scores_gemma":[0.000030917992,0.000029281167,0.0028604944,0.000081980135,0.0000023622044,0.000031905733,0.00003443886,0.00029984687,0.00024282037,0.0006901853,0.99568945,0.000006390818],"about_ca_topic_score_codex":0.023399243,"about_ca_topic_score_gemma":0.034998357,"teacher_disagreement_score":0.44919437,"about_ca_system_score_codex":0.0014978511,"about_ca_system_score_gemma":0.0019650017,"threshold_uncertainty_score":0.7856574},"labels":[],"label_agreement":null},{"id":"W7000498065","doi":"","title":"Financieringssystemen van ziekenhuisgeneesmiddelen : een beschrijvende studie van een aantal Europese landen en Canada","year":2004,"lang":"nl","type":"article","venue":"KCE repository (Belgian Health Care Knowledge Centre)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Work (physics); Action (physics); Higher education; Government (linguistics)","score_opus":0.0195610633908832,"score_gpt":0.2641517286258521,"score_spread":0.24459066523496892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000498065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91610795,0.028208986,0.0010737918,0.008845035,0.0001152329,0.00020881668,0.0072347485,0.000028348615,0.038177002],"genre_scores_gemma":[0.966604,0.012625118,0.0012219448,0.00043430043,0.000024827516,0.0000968754,0.002605497,0.000029469042,0.016358005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951049,0.00055471103,0.00024931808,0.0003693689,0.0025111563,0.0012105078],"domain_scores_gemma":[0.99510926,0.0013364305,0.0010145447,0.00023389759,0.0013719226,0.00093393674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003479315,0.0003328993,0.0009766081,0.0022370024,0.0031518347,0.008519939,0.0018320576,0.0011103954,0.008632377],"category_scores_gemma":[0.012627361,0.0005964476,0.00055913266,0.0062213484,0.0021642353,0.002479718,0.002790445,0.0016464627,0.00040263895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009826543,0.0009118104,0.6243032,0.0012624826,0.0012608335,0.0014062858,0.028686335,0.0070362287,0.00057942665,0.08381011,0.03669851,0.21306208],"study_design_scores_gemma":[0.00018111076,0.0002087449,0.7523193,0.0026170653,0.0010725798,0.0006358699,0.037583124,0.0033617117,0.0009883188,0.012627941,0.18822698,0.00017727728],"about_ca_topic_score_codex":0.97926396,"about_ca_topic_score_gemma":0.98716694,"teacher_disagreement_score":0.049678292,"about_ca_system_score_codex":0.049678292,"about_ca_system_score_gemma":0.07582994,"threshold_uncertainty_score":0.36044294},"labels":[],"label_agreement":null},{"id":"W7000827123","doi":"","title":"Glossary of landscape terminology = A tájmeghatározások szószedete (részlet)","year":2010,"lang":"hu","type":"article","venue":"Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Québec Science (Canada)","funders":"","keywords":"Glossary; Terminology; Subject (documents); Medical terminology","score_opus":0.032958275106286,"score_gpt":0.2568176636346533,"score_spread":0.2238593885283673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000827123","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017512752,0.023408864,0.024102602,0.0046266615,0.0069372924,0.00047313454,0.24157141,0.004605574,0.6925233],"genre_scores_gemma":[0.04299779,0.051523842,0.047309473,0.006555666,0.004390967,0.0019167959,0.38579616,0.016819436,0.4426899],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994429,0.000147784,0.000119848395,0.00009652138,0.00014457552,0.000048441558],"domain_scores_gemma":[0.99892694,0.0003563866,0.00010716102,0.00015782099,0.00038768369,0.00006394021],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053121796,0.0014771332,0.001235845,0.0048170188,0.0012508985,0.005634282,0.0014383224,0.0012666392,0.3696673],"category_scores_gemma":[0.0032124952,0.0005097985,0.00072382385,0.009948242,0.0006940802,0.0060710846,0.0024923661,0.0018879457,0.27541587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053589785,0.000019376568,0.00015822699,0.0013850313,0.000010768385,0.0001128691,0.0002904046,0.0001896798,0.0004106744,0.0293945,0.9119305,0.056044433],"study_design_scores_gemma":[0.0000050609474,0.000003260462,0.00020750864,0.0002397822,0.0000042663773,0.00008123606,0.0000787511,0.00004951022,0.000052525127,0.0024354754,0.99683374,0.000008858647],"about_ca_topic_score_codex":0.0055095926,"about_ca_topic_score_gemma":0.00522427,"teacher_disagreement_score":0.3696673,"about_ca_system_score_codex":0.0012062426,"about_ca_system_score_gemma":0.0010045421,"threshold_uncertainty_score":0.8990931},"labels":[],"label_agreement":null},{"id":"W7001760524","doi":"","title":"Le marché pharmaceutique canadien, cas des antiasthmatiques","year":2005,"lang":"fr","type":"other","venue":"OpenGrey (Institut de l'Information Scientifique et Technique)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Line (geometry); Identification (biology)","score_opus":0.04510073411197137,"score_gpt":0.30839487814859584,"score_spread":0.2632941440366245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7001760524","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023936857,0.5671443,0.0016810083,0.22586551,0.0075355526,0.000048646474,0.0018168971,0.00013810015,0.17183316],"genre_scores_gemma":[0.40196478,0.39169398,0.0033452478,0.012035252,0.01729027,0.000096127,0.0015120297,0.00013321027,0.17192903],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986099,0.00033641935,0.000088683606,0.00013439018,0.0006710525,0.00015948548],"domain_scores_gemma":[0.99787176,0.0008561821,0.0004974183,0.000117470176,0.00035584468,0.00030134319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012636133,0.00041088986,0.0004418746,0.0016509442,0.0008008101,0.003723157,0.0005925272,0.0017936861,0.02008576],"category_scores_gemma":[0.008647815,0.00018953894,0.00035232608,0.0026416716,0.0012029433,0.0014659447,0.0007165679,0.0027870568,0.0027987317],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008263456,0.00017270085,0.009292993,0.001693712,0.00014156562,0.0044650137,0.0008561715,0.00090476393,0.0011630534,0.15056947,0.3364156,0.49349874],"study_design_scores_gemma":[0.00007994086,0.000073959374,0.015321094,0.0005634214,0.00005023396,0.005976547,0.00036587083,0.00047055603,0.00037240164,0.017823838,0.95888263,0.000019422334],"about_ca_topic_score_codex":0.03775359,"about_ca_topic_score_gemma":0.04446655,"teacher_disagreement_score":0.9622464,"about_ca_system_score_codex":0.0042397045,"about_ca_system_score_gemma":0.004104238,"threshold_uncertainty_score":0.07506764},"labels":[],"label_agreement":null},{"id":"W7001773500","doi":"","title":"L’antiextractivisme comme engagement transnational ancré en ville : parcours de vie et d’engagement de personnes migrantes","year":2023,"lang":"fr","type":"dissertation","venue":"EspaceINRS Institutional Digital Repository (Institut National de la Recherche Scientifique)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Politics; Identity (music); Ethnic group; Face (sociological concept)","score_opus":0.19920147407238492,"score_gpt":0.37586445733250157,"score_spread":0.17666298326011665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7001773500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7234599,0.0035756386,0.0068239947,0.023327831,0.00027125084,0.000060793038,0.00013518689,0.000037656002,0.24230771],"genre_scores_gemma":[0.9852519,0.000801459,0.000513706,0.00084693416,0.000025242161,0.000041973708,0.000028235094,0.000017315624,0.012473149],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9975637,0.0015050431,0.000053002535,0.00022862654,0.00023156562,0.0004180757],"domain_scores_gemma":[0.9983646,0.00066772103,0.00029708148,0.00014913683,0.00021646864,0.00030492345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021471484,0.00034265456,0.00025825793,0.0007921231,0.008396755,0.0073370873,0.0010260419,0.0018535163,0.008655046],"category_scores_gemma":[0.0025725143,0.00019138769,0.0002904531,0.0010345194,0.01943852,0.0061389417,0.007338115,0.0026096932,0.000713827],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018937095,0.000015299674,0.00498142,0.000068328416,0.0000064950223,0.00029178144,0.9286438,0.000042127,0.00034339423,0.058483176,0.001032571,0.0060726297],"study_design_scores_gemma":[0.0000045651404,0.000028751823,0.009506049,0.00020027006,0.000008598353,0.00028829704,0.88487405,0.00008660268,0.00018837978,0.0071666418,0.097627744,0.00001990054],"about_ca_topic_score_codex":0.058322698,"about_ca_topic_score_gemma":0.077650726,"teacher_disagreement_score":0.058322698,"about_ca_system_score_codex":0.0040098475,"about_ca_system_score_gemma":0.0033259303,"threshold_uncertainty_score":0.11596644},"labels":[],"label_agreement":null},{"id":"W7001874183","doi":"","title":"Les Aspects financiers de la formation et du perfectionnement des maîtres au Québec : rapport préliminaire /","year":2015,"lang":"fr","type":"other","venue":"Bibliothèque et Archives nationales du Québec (Québec government)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Perspective (graphical); Class (philosophy); Government (linguistics)","score_opus":0.02916627549098894,"score_gpt":0.2553178151566228,"score_spread":0.22615153966563384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7001874183","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57787573,0.07064368,0.007966649,0.03511627,0.00043239276,0.00016295075,0.009943279,0.00012864872,0.29773042],"genre_scores_gemma":[0.89534086,0.018290538,0.0032887806,0.0006274037,0.00014312744,0.00003373106,0.001439535,0.000031559528,0.08080449],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99918896,0.00013007356,0.0000363311,0.00009878756,0.000336696,0.00020909499],"domain_scores_gemma":[0.99740535,0.0004657014,0.00043286255,0.00010396863,0.0014042621,0.00018783532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012177699,0.0004752668,0.0003409313,0.0029319003,0.0027685515,0.004893705,0.0007706001,0.0007596644,0.014766194],"category_scores_gemma":[0.004415753,0.00023999557,0.0004701851,0.005045804,0.0012354779,0.0017687734,0.0005764227,0.0010481427,0.00045097864],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046727245,0.00019491598,0.26194033,0.0013442958,0.00049127295,0.0018351335,0.010348081,0.018846132,0.0023348096,0.39384502,0.07640704,0.23194574],"study_design_scores_gemma":[0.00005713142,0.00007131178,0.73254603,0.0012891676,0.00024153585,0.00041700475,0.008101355,0.013474085,0.0020341328,0.023682626,0.2179321,0.00015352441],"about_ca_topic_score_codex":0.9871694,"about_ca_topic_score_gemma":0.99073595,"teacher_disagreement_score":0.04557242,"about_ca_system_score_codex":0.04557242,"about_ca_system_score_gemma":0.029533138,"threshold_uncertainty_score":0.33065253},"labels":[],"label_agreement":null},{"id":"W7002144078","doi":"","title":"Mitattavasti, tavoitteellisesti ja toteutettavuus huomioiden : vanhuspalvelusuunnitelmien toimenpiteet tarkastelussa","year":2022,"lang":"fi","type":"dissertation","venue":"Jyväskylä University Digital Archive (University of Jyväskylä)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Set (abstract data type); Quarter (Canadian coin); Order (exchange)","score_opus":0.022988034281606666,"score_gpt":0.21205952639748826,"score_spread":0.1890714921158816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002144078","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15697934,0.01624103,0.008983582,0.018267408,0.0041862507,0.0003478181,0.003798023,0.00087486673,0.7903217],"genre_scores_gemma":[0.24222285,0.008118444,0.010126593,0.003069008,0.00049008784,0.00018494038,0.0023945584,0.0006187503,0.7327748],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9990503,0.00013486411,0.000051743213,0.00023117097,0.00033423817,0.00019772178],"domain_scores_gemma":[0.99923027,0.0001520262,0.00008591586,0.000062711886,0.00029555455,0.00017353032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001045125,0.00049208524,0.00041814847,0.00084719836,0.0032919482,0.0050818617,0.0006226345,0.0012482967,0.063917674],"category_scores_gemma":[0.0013474437,0.00034189018,0.0005054583,0.0010098043,0.001245689,0.0024404132,0.0036107292,0.0024522312,0.014376131],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001035097,0.0007037773,0.03040782,0.0029673597,0.00013138207,0.0030003886,0.032527372,0.000626961,0.07308357,0.10276021,0.1710866,0.58166945],"study_design_scores_gemma":[0.000007721467,0.000073746705,0.008751656,0.00022197611,0.000024849633,0.00027182174,0.0041089384,0.000081680075,0.0053605535,0.0018954086,0.97917545,0.000026111276],"about_ca_topic_score_codex":0.015964717,"about_ca_topic_score_gemma":0.040173184,"teacher_disagreement_score":0.063917674,"about_ca_system_score_codex":0.0024683387,"about_ca_system_score_gemma":0.004597668,"threshold_uncertainty_score":0.21382588},"labels":[],"label_agreement":null},{"id":"W7002173420","doi":"","title":"The Minnesota Daily, December 1, 2008","year":2008,"lang":"en","type":"other","venue":"University of Minnesota Digital Conservancy (University of Minnesota)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Microform; Postal service; Quarter (Canadian coin)","score_opus":0.030013827553690847,"score_gpt":0.20100284433330529,"score_spread":0.17098901677961445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002173420","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012640592,0.007864859,0.0003440691,0.008772411,0.005917036,0.00006670459,0.012760016,0.00087295397,0.9621379],"genre_scores_gemma":[0.0012084563,0.0016240805,0.000101636964,0.00046832146,0.00023236705,0.000011779624,0.0018818995,0.00009464332,0.99437684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969184,0.000022715994,0.000013901458,0.000049259386,0.00018737106,0.00003491169],"domain_scores_gemma":[0.99930334,0.000037537753,0.000038165774,0.00006331563,0.0003826481,0.00017505013],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037914593,0.0005805649,0.000306091,0.00096241065,0.0012177796,0.004194728,0.00047617647,0.00083299173,0.36402395],"category_scores_gemma":[0.0016800305,0.00027778003,0.0001680402,0.0012641684,0.0002551139,0.0015553196,0.0009404728,0.001143309,0.29680866],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007258583,0.000005029024,0.00009341611,0.000017115592,5.1248077e-7,0.000008914052,0.000013054974,0.000010154007,0.000032679465,0.00059578783,0.9856242,0.013591983],"study_design_scores_gemma":[9.958496e-7,0.000002023424,0.0007034427,0.00002750024,4.3791886e-7,0.000007239094,0.000019755216,0.000009641825,0.000019631489,0.000068409434,0.99913955,0.0000013575185],"about_ca_topic_score_codex":0.022487016,"about_ca_topic_score_gemma":0.11742943,"teacher_disagreement_score":0.36402395,"about_ca_system_score_codex":0.0018560013,"about_ca_system_score_gemma":0.0023156782,"threshold_uncertainty_score":0.90714264},"labels":[],"label_agreement":null},{"id":"W7002227520","doi":"","title":"Monilajisen empatian ilmaisuja alakoulussa","year":2024,"lang":"fi","type":"other","venue":"Lauda (University of Lapland)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Life style; Civil servants; Quarter (Canadian coin)","score_opus":0.034725154147827154,"score_gpt":0.23499068947438337,"score_spread":0.20026553532655622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002227520","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2884422,0.0050887093,0.007350997,0.009539388,0.003040976,0.0002666031,0.0020445215,0.0010267273,0.6831999],"genre_scores_gemma":[0.29927707,0.002059485,0.006578829,0.0016088869,0.00025801247,0.00012732908,0.001473823,0.00036560482,0.68825096],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.99901605,0.000099879486,0.00004614134,0.00017776599,0.00035705237,0.00030322353],"domain_scores_gemma":[0.99867505,0.00012774026,0.00015174449,0.00012102061,0.0005600138,0.00036431686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009904461,0.00057720754,0.00045444912,0.0009234762,0.0036657788,0.0045943195,0.0007869506,0.0009908302,0.08078283],"category_scores_gemma":[0.001230418,0.0004658272,0.0006194191,0.0008211006,0.0012800625,0.0015781395,0.003935138,0.0019643763,0.02017884],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019041896,0.0009631088,0.10905,0.0018344626,0.00020545427,0.0029887678,0.03291818,0.0008066514,0.11888007,0.043543167,0.15112822,0.5357777],"study_design_scores_gemma":[0.000015770062,0.00027373646,0.051052757,0.00020749161,0.00005093056,0.00060224003,0.01249671,0.00016034856,0.011772658,0.0015713157,0.9217464,0.000049645725],"about_ca_topic_score_codex":0.01710801,"about_ca_topic_score_gemma":0.07510151,"teacher_disagreement_score":0.08078283,"about_ca_system_score_codex":0.00250956,"about_ca_system_score_gemma":0.003955571,"threshold_uncertainty_score":0.2702455},"labels":[],"label_agreement":null},{"id":"W7002252651","doi":"","title":"$183.30 Million in Sales Expected for Ameresco, Inc. (AMRC) This Quarter","year":2017,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Payment; Revenue; Work (physics)","score_opus":0.07510458233060528,"score_gpt":0.311888415331472,"score_spread":0.2367838330008667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002252651","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019629765,0.0015793002,0.0005229799,0.0037004666,0.0015604289,0.000101997764,0.033895317,0.0017636775,0.9549129],"genre_scores_gemma":[0.004094296,0.0011336795,0.00018711519,0.00072322326,0.0003782077,0.000042599528,0.014828748,0.000348949,0.9782632],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995254,0.000026756374,0.000016388085,0.00006010816,0.00029681457,0.00007441972],"domain_scores_gemma":[0.9992737,0.000065338565,0.000053835352,0.000046221165,0.00031191035,0.00024899436],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005128263,0.0007168432,0.00031887752,0.0018981788,0.0007017212,0.0028802499,0.00064097974,0.0011307002,0.42835906],"category_scores_gemma":[0.0023829048,0.00023294722,0.0004349664,0.0014183896,0.00041183163,0.0012576645,0.0011087782,0.001572886,0.3524121],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031226373,0.000023724957,0.0002334156,0.0000422016,0.0000018720409,0.000010899298,0.0000056269228,0.00006964473,0.00009069994,0.0013924623,0.98203593,0.016062291],"study_design_scores_gemma":[0.000024216288,0.000023522321,0.002403295,0.000093490016,0.000002503691,0.000031427036,0.00003407864,0.00019631485,0.00021873329,0.00073584483,0.99623126,0.000005270343],"about_ca_topic_score_codex":0.020540375,"about_ca_topic_score_gemma":0.03155107,"teacher_disagreement_score":0.42835906,"about_ca_system_score_codex":0.0020828478,"about_ca_system_score_gemma":0.00312682,"threshold_uncertainty_score":0.8153764},"labels":[],"label_agreement":null},{"id":"W7002630461","doi":"","title":"Neki aspekti demografske prošlosti župe Nova Gradiška prema matičnoj knjizi krštenih župe Nova Gradiška 1878.-1890. = Some aspects of the demographic past of the parish of Nova Gradiška = according to the parish registers of baptisms from 1878-1890","year":2017,"lang":"sh","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nova (rocket); Nova scotia; Metis","score_opus":0.07524214947052232,"score_gpt":0.28349770185384304,"score_spread":0.20825555238332072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002630461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68332237,0.0066120685,0.00047068298,0.0042754775,0.00027621567,0.000054311382,0.043369126,0.000047426285,0.2615723],"genre_scores_gemma":[0.9505255,0.0027351552,0.0003545721,0.00019493993,0.000060833267,0.000038773884,0.010038667,0.000025572579,0.0360259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999689,0.000059090642,0.00002289167,0.00004386317,0.000061872735,0.00012331917],"domain_scores_gemma":[0.9995964,0.00008221043,0.0001521231,0.00002748431,0.00008227576,0.000059526832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028074018,0.0001957678,0.00015587635,0.0017090832,0.0011887385,0.0017274168,0.0002682945,0.00025046864,0.018065233],"category_scores_gemma":[0.0012859427,0.00012149809,0.00013127128,0.003968159,0.0006488087,0.0008553764,0.0013063225,0.0004162498,0.0015283863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041798214,0.000085614614,0.63019156,0.0012456765,0.000120791585,0.0014168927,0.032038607,0.0009331037,0.0009217971,0.13927728,0.0905084,0.102842264],"study_design_scores_gemma":[0.000012652406,0.000026026793,0.72859734,0.00029952417,0.000022787453,0.0003602433,0.018320968,0.00007983841,0.00036324534,0.0032250807,0.24867395,0.000018376533],"about_ca_topic_score_codex":0.115453586,"about_ca_topic_score_gemma":0.2166918,"teacher_disagreement_score":0.115453586,"about_ca_system_score_codex":0.0018145345,"about_ca_system_score_gemma":0.0020953405,"threshold_uncertainty_score":0.22956318},"labels":[],"label_agreement":null},{"id":"W7014270823","doi":"","title":"Pharmaceutical Exhaustion","year":2019,"lang":"en","type":"article","venue":"Scholarly Commons (University of the Pacific)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Statute; Drug prices; Pharmaceutical industry; Position (finance); Order (exchange); Patent law; Patent infringement","score_opus":0.05096727005572499,"score_gpt":0.23701106875059164,"score_spread":0.18604379869486665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7014270823","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006949433,0.02246387,0.003508506,0.050494637,0.011448171,0.00036565991,0.0016263328,0.00059598853,0.90254736],"genre_scores_gemma":[0.085070424,0.019600295,0.002577157,0.19030394,0.0060288063,0.0007236101,0.0033998622,0.00059116766,0.69170463],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99240017,0.0012032784,0.0006030515,0.0014125396,0.002929158,0.001451741],"domain_scores_gemma":[0.99579996,0.0013023292,0.00031004206,0.0006567313,0.0014057172,0.00052517094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006802565,0.0011461814,0.00094257103,0.0026022445,0.0058272895,0.0117536085,0.0024861312,0.010306145,0.10107524],"category_scores_gemma":[0.01447218,0.00068934646,0.0018469054,0.001997474,0.0033623914,0.0055976566,0.009241855,0.011849139,0.034809444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023217514,0.00013163438,0.0013718932,0.00067120435,0.000044840705,0.0012275929,0.0010036172,0.0002569463,0.0006219726,0.41478884,0.43860415,0.14104511],"study_design_scores_gemma":[0.000022667613,0.000044791956,0.00041851253,0.00020554841,0.000013032791,0.0002516324,0.000106789965,0.0000531872,0.00034830687,0.0077939364,0.99072886,0.000012774316],"about_ca_topic_score_codex":0.0061332854,"about_ca_topic_score_gemma":0.0064148414,"teacher_disagreement_score":0.10107524,"about_ca_system_score_codex":0.006557841,"about_ca_system_score_gemma":0.010140515,"threshold_uncertainty_score":0.33813035},"labels":[],"label_agreement":null},{"id":"W7017607181","doi":"","title":"Breaking the Vial: Leveraging North American Regulatory Models and Market Practices to Reform Insulin Pricing in the United States","year":2025,"lang":"en","type":"article","venue":"Digital USD (University of San Diego)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Expediting; Restructuring; Enforcement; Legislature; Government (linguistics); Limiting; Constraint (computer-aided design); Evasion (ethics); Vetting","score_opus":0.04583983515196348,"score_gpt":0.25258009365123973,"score_spread":0.20674025849927624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7017607181","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16117978,0.008789911,0.03652814,0.46080583,0.002040538,0.00027079182,0.00041628405,0.0005381678,0.32943055],"genre_scores_gemma":[0.86168975,0.007014057,0.026283558,0.07670293,0.00077556836,0.0001791133,0.0002587566,0.0001467221,0.026949594],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9946085,0.0024924218,0.00019122858,0.00049011206,0.0014966016,0.00072118756],"domain_scores_gemma":[0.9913606,0.004191088,0.0009171554,0.0008046927,0.0018882016,0.00083822163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014613444,0.00022954174,0.00025976432,0.0009929007,0.0031374565,0.008702128,0.0013089554,0.003997623,0.005260573],"category_scores_gemma":[0.022468036,0.00037021947,0.0007693685,0.0012459423,0.003996258,0.0045126965,0.0031949636,0.0064562946,0.0005364351],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018491386,0.0005440747,0.011200479,0.00014270093,0.000057892204,0.00031130784,0.002463948,0.013688194,0.00091239315,0.7259206,0.103147395,0.14142613],"study_design_scores_gemma":[0.00038004367,0.0003960427,0.02866289,0.0010806032,0.00019170159,0.00015435094,0.00454467,0.035078272,0.0019062805,0.32498753,0.60238695,0.00023074544],"about_ca_topic_score_codex":0.08649572,"about_ca_topic_score_gemma":0.12408501,"teacher_disagreement_score":0.08649572,"about_ca_system_score_codex":0.009122826,"about_ca_system_score_gemma":0.02516077,"threshold_uncertainty_score":0.17198455},"labels":[],"label_agreement":null},{"id":"W7019278859","doi":"","title":"Forward Pharma Reports Fourth Quarter and Year End 2016 Financial and Operational Results","year":2017,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Financial Audit; Work (physics); Revenue; Payment","score_opus":0.039128289001113654,"score_gpt":0.28421300199751903,"score_spread":0.24508471299640538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7019278859","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002566147,0.0017594502,0.0013227363,0.0074519026,0.0040395805,0.00038415173,0.21107006,0.002531328,0.7688746],"genre_scores_gemma":[0.00631448,0.001248206,0.0006503554,0.0006049888,0.0008380355,0.00014643146,0.070156075,0.000924821,0.9191166],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954081,0.00026129017,0.00021423769,0.00035729803,0.0032056544,0.0005534378],"domain_scores_gemma":[0.9908813,0.0008833295,0.000736825,0.0008451278,0.0052478155,0.0014055157],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003762233,0.001473966,0.0010640372,0.005560723,0.0012206929,0.008165558,0.001285456,0.0020793115,0.3832476],"category_scores_gemma":[0.013451636,0.000607556,0.000895189,0.004537706,0.000887662,0.003393086,0.0017215261,0.0025910323,0.39819407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012142737,0.00006374239,0.0004419724,0.00007634963,0.000006863817,0.000017054177,0.000009773144,0.00021119685,0.00008716151,0.0032801577,0.9789008,0.01678356],"study_design_scores_gemma":[0.00011977707,0.00006370479,0.005386495,0.00017359486,0.000012334554,0.0000342358,0.00004688015,0.00077709043,0.0011775536,0.0048446865,0.9873345,0.000029259007],"about_ca_topic_score_codex":0.022159034,"about_ca_topic_score_gemma":0.022022694,"teacher_disagreement_score":0.3832476,"about_ca_system_score_codex":0.005398583,"about_ca_system_score_gemma":0.009742891,"threshold_uncertainty_score":0.8797224},"labels":[],"label_agreement":null},{"id":"W7023538373","doi":"","title":"Pharmacy Choice - Pharmaceutical News - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2014","year":2014,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmacy; Fiscal year; Community pharmacy; Revenue","score_opus":0.08429951513084548,"score_gpt":0.3551227256445844,"score_spread":0.2708232105137389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7023538373","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036526516,0.001743782,0.00062511495,0.020674828,0.0038479303,0.00031458845,0.11453124,0.0013428477,0.85326695],"genre_scores_gemma":[0.008928442,0.0007083564,0.00034993488,0.0018498504,0.001014629,0.00010855995,0.019140273,0.00037308878,0.96752685],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741745,0.00018288956,0.00007977405,0.00019123282,0.0017310609,0.0003974979],"domain_scores_gemma":[0.9934297,0.0012515717,0.0005523046,0.00042268314,0.0026463564,0.001697311],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028386253,0.00081157236,0.0009161993,0.003312092,0.0020396516,0.008912323,0.0013413344,0.0039179935,0.3477885],"category_scores_gemma":[0.01333714,0.0005065642,0.00060273486,0.0032152035,0.0006997885,0.0021956812,0.0018016599,0.0037765095,0.16914137],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019369536,0.000094745104,0.0005202046,0.00005110798,0.000008291457,0.000024323183,0.000010946581,0.000111693465,0.00005662125,0.0035470678,0.9857103,0.009670994],"study_design_scores_gemma":[0.00014911922,0.00006884167,0.00853023,0.00010566726,0.0000125522765,0.000028760438,0.00008058399,0.0008022253,0.0007481257,0.0029031201,0.9865415,0.000029254976],"about_ca_topic_score_codex":0.034617748,"about_ca_topic_score_gemma":0.059162498,"teacher_disagreement_score":0.3477885,"about_ca_system_score_codex":0.005644616,"about_ca_system_score_gemma":0.008758013,"threshold_uncertainty_score":0.93030053},"labels":[],"label_agreement":null},{"id":"W7037115462","doi":"","title":"Concerning Expanding the Canadian Prescription Drug Importation Program to Include Prescription Drug Suppliers from Nations Other Than Canada upon the Enactment of Legislation by the United States Congress Authorizing Such Practice.","year":2021,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Medical prescription; Prescription drug; Drug; Drug industry","score_opus":0.03282459435015501,"score_gpt":0.28928899233461713,"score_spread":0.25646439798446213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7037115462","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016446443,0.0033117943,0.0027468714,0.3148559,0.0033780057,0.0013545109,0.005000536,0.0011866739,0.65171915],"genre_scores_gemma":[0.054592386,0.0025097472,0.005479053,0.5958931,0.0009912568,0.00052914745,0.0013030347,0.00019289779,0.3385094],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9828668,0.0010982738,0.0005085406,0.001097877,0.009529636,0.004898899],"domain_scores_gemma":[0.9790446,0.005902606,0.0005373312,0.0010920609,0.010931957,0.0024913808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010263369,0.0012124932,0.00078453997,0.0022177917,0.021384269,0.007554098,0.004232962,0.034582123,0.020052293],"category_scores_gemma":[0.023621934,0.0012813336,0.0020600597,0.0030501932,0.0045756255,0.0030284626,0.0031419995,0.012132027,0.0057162344],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055667882,0.00012846586,0.0028814916,0.00009030138,0.000025751504,0.0006597571,0.0012434032,0.00047522696,0.001099935,0.05865906,0.9199396,0.014741486],"study_design_scores_gemma":[0.00013872165,0.00006397529,0.017161349,0.00033850738,0.00010350944,0.00027085884,0.0017881263,0.00083431357,0.0014657301,0.0059026494,0.97170097,0.00023123792],"about_ca_topic_score_codex":0.9647067,"about_ca_topic_score_gemma":0.9875338,"teacher_disagreement_score":0.039980687,"about_ca_system_score_codex":0.039980687,"about_ca_system_score_gemma":0.19994767,"threshold_uncertainty_score":0.29008156},"labels":[],"label_agreement":null},{"id":"W7042713180","doi":"","title":"Preliminary discussion of Canadian drug purchasing programs","year":2003,"lang":"en","type":"book","venue":"State Library's electronic repository (State Library of Massachusetts)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Purchasing; Government (linguistics); Drug industry; Drug Company","score_opus":0.016581637183766887,"score_gpt":0.21422839305242344,"score_spread":0.19764675586865654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7042713180","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010519861,0.0026255583,0.0005846697,0.065349676,0.00067355874,0.00021900683,0.002249995,0.00006892618,0.91770875],"genre_scores_gemma":[0.16786267,0.0035862708,0.0015139476,0.03579116,0.0004830093,0.00024626922,0.0010564649,0.000070628674,0.7893896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956559,0.00033716246,0.000076287746,0.00023315371,0.0017378484,0.001959555],"domain_scores_gemma":[0.9961511,0.0009837617,0.000071861476,0.00010913774,0.0022425787,0.0004415663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020079194,0.00066070305,0.00048527724,0.002952908,0.015371338,0.0075092907,0.0018876061,0.0043389304,0.054097604],"category_scores_gemma":[0.0087016225,0.00042753402,0.001071811,0.0054968237,0.0018396692,0.0021084554,0.0010758609,0.003642607,0.0019637537],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005226959,0.000080061785,0.0019464702,0.00012125374,0.000009507513,0.0001629629,0.0014445846,0.0006403306,0.00014146733,0.46285996,0.499737,0.03280414],"study_design_scores_gemma":[0.000034424524,0.000032260297,0.012387524,0.00010874559,0.000035423982,0.00005262075,0.0024100726,0.00051685586,0.00039476817,0.011158458,0.972828,0.000040813407],"about_ca_topic_score_codex":0.9867596,"about_ca_topic_score_gemma":0.99418926,"teacher_disagreement_score":0.09238058,"about_ca_system_score_codex":0.09238058,"about_ca_system_score_gemma":0.096744284,"threshold_uncertainty_score":0.67027116},"labels":[],"label_agreement":null},{"id":"W7042902537","doi":"","title":"Research Output of the Canadian Pharmaceutical Industry: Where Has All the R&amp;D Gone?","year":2006,"lang":"en","type":"article","venue":"PubMed Central","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mandate; Accountability; Productivity; Pharmaceutical industry; Data collection; Relation (database)","score_opus":0.22960896577037648,"score_gpt":0.33509372884882765,"score_spread":0.10548476307845117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7042902537","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016389027,0.09686909,0.0015826361,0.7717109,0.0025630076,0.000068128305,0.009032173,0.0003077114,0.10147747],"genre_scores_gemma":[0.6004428,0.24729964,0.008466857,0.0665574,0.0044292053,0.00014183644,0.010142245,0.00049016526,0.062029857],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9835497,0.002072563,0.0007185622,0.0007963861,0.010292722,0.0025699679],"domain_scores_gemma":[0.93361884,0.007989643,0.004253831,0.0013102553,0.045142464,0.007685035],"candidate_categories":["metaresearch","bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.015398142,0.0008644011,0.0011994336,0.008715874,0.0054145623,0.01650586,0.0028313394,0.002467802,0.0139214415],"category_scores_gemma":[0.06304406,0.00035715633,0.0008991718,0.02318898,0.0044942712,0.007224486,0.0018819019,0.0026908887,0.002751369],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040250362,0.00007422399,0.03628522,0.005553843,0.00023704406,0.00043543312,0.0021748021,0.0010229581,0.0007581049,0.078388624,0.4335012,0.44116613],"study_design_scores_gemma":[0.00007249031,0.00009827591,0.19496578,0.004445148,0.00034756976,0.00020128362,0.005486348,0.001387467,0.0018689918,0.017126352,0.7737483,0.00025201496],"about_ca_topic_score_codex":0.95536596,"about_ca_topic_score_gemma":0.95675075,"teacher_disagreement_score":0.99128413,"about_ca_system_score_codex":0.10592472,"about_ca_system_score_gemma":0.20138232,"threshold_uncertainty_score":0.7685412},"labels":[],"label_agreement":null},{"id":"W7070996707","doi":"","title":"THE ROLE OF COMMUNITY RADIO IN POLITICAL PARTICIPATION IN THAILAND A CASE STUDY:THE 3 SOUTHERN BORDER PROVINCES OF THAILAND(YALA- PATTANI- NARATHIWAT)","year":2025,"lang":"en","type":"other","venue":"Andalas University eThesis (Andalas University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Constitution; Community radio; Legislation; State (computer science); Government (linguistics); Politics; Subject (documents); Control (management)","score_opus":0.029102923079181168,"score_gpt":0.26799353621721644,"score_spread":0.23889061313803528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7070996707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715557,0.00048337356,0.0002187708,0.0018752189,0.000022392729,0.00008156956,0.000037700644,0.0000050975577,0.025720255],"genre_scores_gemma":[0.99665666,0.00040680938,0.00014048046,0.00016107378,0.000009360136,0.00003267005,0.000017892326,0.000004568318,0.0025704254],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99586016,0.0024162568,0.000063242056,0.00013661469,0.00024164171,0.0012821181],"domain_scores_gemma":[0.9944792,0.002763224,0.00058515783,0.00009989189,0.0003692459,0.0017032101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025119663,0.00045176625,0.0002763823,0.0016154265,0.020540753,0.0068942336,0.0015421074,0.002454062,0.005723383],"category_scores_gemma":[0.0030177587,0.00037712706,0.00032142247,0.0031090172,0.009925704,0.002834773,0.0054712174,0.0027049694,0.0002948199],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009450226,0.00027173353,0.03388186,0.00025368406,0.000014614164,0.022805367,0.9190748,0.00036992674,0.00047087698,0.011750088,0.0019383959,0.009074121],"study_design_scores_gemma":[0.0000044379117,0.000025081916,0.004930139,0.000065707885,0.0000036648737,0.00074966333,0.98763674,0.00013742555,0.0000614625,0.00021295487,0.006165478,0.00000729846],"about_ca_topic_score_codex":0.14949125,"about_ca_topic_score_gemma":0.27961028,"teacher_disagreement_score":0.14949125,"about_ca_system_score_codex":0.009403186,"about_ca_system_score_gemma":0.0105479555,"threshold_uncertainty_score":0.29724222},"labels":[],"label_agreement":null},{"id":"W7072191129","doi":"","title":"United Therapeutics Corporation Reports 2017 Fourth Quarter And Annual Financial Results","year":2018,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Corporation; Quarter (Canadian coin); Annual report; Financial Audit","score_opus":0.06956009106558061,"score_gpt":0.289212810338711,"score_spread":0.21965271927313038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7072191129","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007182764,0.0015212126,0.0005743458,0.009108142,0.0049046283,0.00016687435,0.015825488,0.0011421271,0.96603894],"genre_scores_gemma":[0.0019438416,0.0008721785,0.00023700572,0.0008094182,0.00077485625,0.000064720145,0.0043884674,0.0003052844,0.9906042],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967025,0.00020598315,0.00014493002,0.0002651713,0.0021802713,0.0005011046],"domain_scores_gemma":[0.9933943,0.00072810875,0.00039471986,0.0007455513,0.0033385486,0.0013987302],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024245486,0.0013182071,0.0009931428,0.004966525,0.0016937371,0.009662237,0.0012911778,0.003834133,0.5651748],"category_scores_gemma":[0.010784435,0.0006018494,0.0010148315,0.0032466345,0.00125583,0.0029198993,0.002185544,0.004028887,0.5431628],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003680547,0.0000716549,0.00016093686,0.000037132504,0.0000044578537,0.00001927997,0.0000060471243,0.000064062006,0.000055348646,0.0042207823,0.97567743,0.019645996],"study_design_scores_gemma":[0.00003814106,0.000022074226,0.0009459722,0.00009831527,0.000006157628,0.000021586045,0.00002153148,0.0002289542,0.0003428593,0.0027412046,0.99552405,0.000009275157],"about_ca_topic_score_codex":0.011096339,"about_ca_topic_score_gemma":0.015513128,"teacher_disagreement_score":0.5651748,"about_ca_system_score_codex":0.004997194,"about_ca_system_score_gemma":0.009264725,"threshold_uncertainty_score":0.6202253},"labels":[],"label_agreement":null},{"id":"W7094423423","doi":"","title":"Rebuttal: Are drugs too expensive in Canada?","year":2006,"lang":"en","type":"article","venue":"PubMed Central","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"","score_opus":0.027320650565238868,"score_gpt":0.20900810707096062,"score_spread":0.18168745650572177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094423423","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01060753,0.01885209,0.00021034441,0.91073114,0.008933889,0.000043243403,0.003830072,0.00009315782,0.04669856],"genre_scores_gemma":[0.3083886,0.023012351,0.0012149197,0.5638085,0.014884563,0.000078255696,0.00224642,0.00031212284,0.086054325],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9857991,0.0010158977,0.0008016759,0.00096070545,0.008667295,0.002755359],"domain_scores_gemma":[0.90338564,0.02121159,0.0055717784,0.0015711621,0.0534177,0.014842114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008025452,0.00068501884,0.0012671389,0.0038378248,0.0065573687,0.013629597,0.004103238,0.015018945,0.02814565],"category_scores_gemma":[0.07224433,0.00048432758,0.0011007923,0.0056622727,0.0054084463,0.004405491,0.0016552481,0.011410436,0.0018916379],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026091907,0.00003426978,0.007061857,0.00033813823,0.00009202215,0.00043824027,0.00041499294,0.00031829768,0.00014785449,0.045465637,0.9168439,0.028583903],"study_design_scores_gemma":[0.00027822846,0.00008542105,0.030015273,0.0016394368,0.00046505668,0.00044454762,0.0028772545,0.0013408617,0.00067360554,0.022679899,0.9392582,0.00024231557],"about_ca_topic_score_codex":0.9646157,"about_ca_topic_score_gemma":0.96755457,"teacher_disagreement_score":0.07710068,"about_ca_system_score_codex":0.07710068,"about_ca_system_score_gemma":0.22417714,"threshold_uncertainty_score":0.55940723},"labels":[],"label_agreement":null},{"id":"W7095689335","doi":"","title":"Based Pricing, and Drug R&amp;amp;D: A Critique of the National Forum on Health’s Recommendations for","year":2016,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical policy; Drug pricing; Pharmaceutical industry; Drug industry; Health policy","score_opus":0.14177728946198262,"score_gpt":0.3759072137089961,"score_spread":0.23412992424701348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095689335","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012517978,0.013694312,0.0042812056,0.91467154,0.0024480876,0.00012142448,0.0007691797,0.00007928922,0.06268331],"genre_scores_gemma":[0.13264172,0.017616984,0.019303147,0.773898,0.0046836184,0.0005216259,0.0004403578,0.00021345235,0.05068108],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.8787068,0.02349238,0.0034036278,0.0067542167,0.0802514,0.0073915105],"domain_scores_gemma":[0.87289697,0.06837526,0.0044106366,0.0047828336,0.045821495,0.003712784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05685242,0.0013082013,0.001639828,0.0052500633,0.008236175,0.014578412,0.0071948403,0.019760722,0.007408472],"category_scores_gemma":[0.15102659,0.0011554846,0.002250077,0.006053211,0.02523575,0.0071868813,0.0037612035,0.02340442,0.0010839357],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003535285,0.000027686649,0.00067060767,0.00021836112,0.00003287529,0.00003728589,0.00070694304,0.0006042544,0.00004375368,0.7411517,0.24301182,0.013459428],"study_design_scores_gemma":[0.00017245515,0.000045276334,0.0046619168,0.0012686177,0.00007814281,0.000058750895,0.0007609906,0.0021471812,0.00032313826,0.14556529,0.84475297,0.00016532234],"about_ca_topic_score_codex":0.9409773,"about_ca_topic_score_gemma":0.9301564,"teacher_disagreement_score":0.9409773,"about_ca_system_score_codex":0.13415141,"about_ca_system_score_gemma":0.26460642,"threshold_uncertainty_score":0.97334117},"labels":[],"label_agreement":null},{"id":"W7095857588","doi":"","title":"Stand-specific litter moisture content calibrations for the Canadian Fine Fuel Moisture Code","year":2016,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Litter; Water content; Moisture; Hydrology (agriculture); Growing season; Summer season","score_opus":0.13995058770106816,"score_gpt":0.27580489241558204,"score_spread":0.13585430471451387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095857588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8405954,0.002297914,0.054815866,0.00035948865,0.000089043344,0.00037280403,0.08340216,0.0022594065,0.015807787],"genre_scores_gemma":[0.950725,0.0003354453,0.016782612,0.00006889553,0.000008582087,0.000109674525,0.029653795,0.00023868443,0.0020773425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915504,0.00012672706,0.000028392174,0.00024178407,0.00031887414,0.00012919153],"domain_scores_gemma":[0.9963516,0.00074772973,0.00043594275,0.00046835578,0.001805439,0.00019095269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027825031,0.00062277546,0.0004259642,0.0018174086,0.0008383073,0.0009232136,0.0021784338,0.0004918257,0.0027177641],"category_scores_gemma":[0.0095000295,0.0004231306,0.00092908135,0.0030248337,0.00034296748,0.00054995966,0.00061255373,0.0007088026,0.0007666058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002836776,0.00008954537,0.6713257,0.00024178924,0.00055609987,0.0001101824,0.000312341,0.22486205,0.0019560328,0.0041501173,0.02413757,0.07197495],"study_design_scores_gemma":[0.000025497351,0.000023930279,0.77735364,0.00007614229,0.00005383677,0.00006236711,0.0001806746,0.20992425,0.0011636602,0.0012223278,0.009850286,0.000063363026],"about_ca_topic_score_codex":0.9425161,"about_ca_topic_score_gemma":0.96268934,"teacher_disagreement_score":0.05748391,"about_ca_system_score_codex":0.012672172,"about_ca_system_score_gemma":0.006245771,"threshold_uncertainty_score":0.11564481},"labels":[],"label_agreement":null},{"id":"W7095922627","doi":"","title":"All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association. CMAJ Commentary © 2009 Canadian Medical Association or its licensors Online-1","year":2015,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Health care; Action (physics); Prescription drug; Modalities; Public health; Quality (philosophy); Health policy","score_opus":0.06897379749991155,"score_gpt":0.3233310078082529,"score_spread":0.25435721030834135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095922627","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019206388,0.008787474,0.00015008067,0.40060657,0.50919807,0.0000867137,0.0007025434,0.00015313535,0.08012339],"genre_scores_gemma":[0.008071915,0.012643397,0.00033875776,0.2634923,0.5462052,0.00011003887,0.00050593336,0.00020611542,0.16842629],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99652207,0.00041871713,0.00022092869,0.00041954737,0.0019220418,0.00049658923],"domain_scores_gemma":[0.9815216,0.0056592626,0.0006711478,0.00056700694,0.009723204,0.0018577086],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030186037,0.0009709505,0.0015915086,0.0015720318,0.0054442766,0.004164816,0.0026329209,0.017977031,0.15736122],"category_scores_gemma":[0.03562971,0.00066618976,0.0012126843,0.0017292078,0.0022456592,0.001702493,0.0010160092,0.014164566,0.07220228],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009201465,0.000002996695,0.000017134265,0.000043725136,0.000002656216,0.000024504783,0.000007729797,0.000006163948,0.000011514849,0.00034735346,0.99788874,0.0016383486],"study_design_scores_gemma":[0.00001686517,0.0000048130773,0.00017682227,0.000253293,0.0000074814343,0.000046881352,0.00003877889,0.000032009357,0.000029653489,0.00042039788,0.99896324,0.000009711018],"about_ca_topic_score_codex":0.061255395,"about_ca_topic_score_gemma":0.09690673,"teacher_disagreement_score":0.8426388,"about_ca_system_score_codex":0.007299553,"about_ca_system_score_gemma":0.010766433,"threshold_uncertainty_score":0.5264257},"labels":[],"label_agreement":null},{"id":"W7096147182","doi":"","title":"Editorials Shortages of medicines: a complex global challenge","year":2011,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Listing (finance); Medical prescription; Pharmacy; Developed country","score_opus":0.22820267274929762,"score_gpt":0.3320988859884149,"score_spread":0.1038962132391173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7096147182","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009055542,0.003529778,0.00007954208,0.058696646,0.9344575,0.000017051407,0.000111221176,0.00006146623,0.0029563291],"genre_scores_gemma":[0.0007999805,0.002277837,0.000059466933,0.016666356,0.97495234,0.000012473805,0.000031937143,0.000023514143,0.0051760655],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955114,0.00068988523,0.0005937508,0.0005330768,0.0023469075,0.0003250568],"domain_scores_gemma":[0.96252805,0.019775685,0.002469382,0.00108778,0.010822926,0.0033162304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050200378,0.0030788966,0.002246342,0.003289027,0.0026632787,0.0065195337,0.0029356133,0.013028447,0.02317774],"category_scores_gemma":[0.031040018,0.00091058644,0.0019331016,0.0016741474,0.0022816567,0.004305551,0.001020324,0.011864536,0.014375362],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021044558,0.000013363804,0.000052220268,0.00016320242,0.000009006591,0.000109666355,0.000011161831,0.000025667792,0.000027191454,0.00025345528,0.99583817,0.0034759173],"study_design_scores_gemma":[0.000049498158,0.000037361708,0.0005556207,0.00057906914,0.000027313565,0.00033516093,0.00006584129,0.00017340221,0.00010852164,0.0014656179,0.9965823,0.000020265416],"about_ca_topic_score_codex":0.0014181979,"about_ca_topic_score_gemma":0.0025466005,"teacher_disagreement_score":0.02317774,"about_ca_system_score_codex":0.0026003628,"about_ca_system_score_gemma":0.0023757818,"threshold_uncertainty_score":0.0775373},"labels":[],"label_agreement":null},{"id":"W7096393613","doi":"","title":"Chapter 7. Follow-Up of Drugs After Market Entry","year":2015,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Confusion; Order (exchange); European union; Point (geometry); Relevant market; Pace; European market; Recall","score_opus":0.056829135645747764,"score_gpt":0.26390494302479994,"score_spread":0.20707580737905218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7096393613","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07068969,0.08990612,0.030002322,0.09150244,0.006657829,0.0013741578,0.0112024825,0.00054892944,0.698116],"genre_scores_gemma":[0.4464274,0.05891241,0.015249681,0.016288687,0.0048294757,0.0012412881,0.007367787,0.0002981021,0.44938505],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99710244,0.00072747114,0.00019999324,0.00033007195,0.0011732294,0.0004667131],"domain_scores_gemma":[0.9929844,0.003109451,0.0013943827,0.000704042,0.0014169571,0.00039076808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003788798,0.00030753983,0.00040220426,0.0015721238,0.0013030662,0.0031015186,0.0015244698,0.0028398132,0.045869634],"category_scores_gemma":[0.018169649,0.00026156963,0.001226941,0.0017731924,0.0007639134,0.00299035,0.0013293624,0.00309475,0.006512733],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049217424,0.00054107764,0.020986646,0.0010897615,0.000086768145,0.001078378,0.0021313757,0.002545164,0.00083986606,0.28902432,0.19700444,0.4841799],"study_design_scores_gemma":[0.00006912846,0.00046763246,0.05820074,0.0029848719,0.00011526724,0.0008973894,0.0017762532,0.0025423581,0.0030416641,0.09299574,0.8367993,0.00010970258],"about_ca_topic_score_codex":0.012947708,"about_ca_topic_score_gemma":0.012145087,"teacher_disagreement_score":0.045869634,"about_ca_system_score_codex":0.0026323048,"about_ca_system_score_gemma":0.0032072787,"threshold_uncertainty_score":0.15344918},"labels":[],"label_agreement":null},{"id":"W7096731832","doi":"","title":"1 Prescription Drug Importation, Investment and Employment in Michigan","year":2004,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Authorization; Investment (military); Drug prices; Profit (economics); Developed country; Legislation","score_opus":0.04145971896364928,"score_gpt":0.2684537624425883,"score_spread":0.226994043478939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7096731832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53389466,0.0057760812,0.0003008361,0.09532571,0.00023815737,0.00008597483,0.0047107763,0.00004879828,0.35961902],"genre_scores_gemma":[0.8164539,0.0069583827,0.00036845947,0.006582456,0.00045689862,0.00015957316,0.0015242567,0.000017427472,0.1674787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970466,0.00005790709,0.00000913373,0.000025617253,0.00008255175,0.00011999222],"domain_scores_gemma":[0.9990637,0.0003072104,0.00017148543,0.000014869535,0.00009292051,0.0003498119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003189289,0.00012983853,0.00011427092,0.0007206234,0.0032279845,0.0019586708,0.0004665909,0.0012529,0.019990345],"category_scores_gemma":[0.0012636972,0.0001455551,0.00014739564,0.0014230208,0.00050349586,0.0010002633,0.0011091268,0.0013214609,0.0008817679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018892578,0.0006746521,0.4444413,0.00012253954,0.00006134142,0.0028674875,0.0027587023,0.0012324785,0.0005576868,0.17538671,0.3068705,0.064837694],"study_design_scores_gemma":[0.00004405319,0.00017496057,0.60973644,0.00024244026,0.00003941727,0.00075960025,0.0055565326,0.004077243,0.0006672948,0.01928783,0.35936078,0.000053452855],"about_ca_topic_score_codex":0.102117196,"about_ca_topic_score_gemma":0.317885,"teacher_disagreement_score":0.102117196,"about_ca_system_score_codex":0.0043884576,"about_ca_system_score_gemma":0.0029745984,"threshold_uncertainty_score":0.2030456},"labels":[],"label_agreement":null},{"id":"W7096934275","doi":"","title":"Pharmaceuticals:Therapeutic Interchange and Pricing Policies","year":2003,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public policy; Government (linguistics); Policy analysis; Control (management); Negotiation","score_opus":0.14755683101077438,"score_gpt":0.3356307257229736,"score_spread":0.1880738947121992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7096934275","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056586615,0.00990923,0.008297487,0.05612544,0.002080423,0.00013356612,0.008239584,0.0010074641,0.9085482],"genre_scores_gemma":[0.22853853,0.020131182,0.019110307,0.03013305,0.007623218,0.00049562997,0.006829024,0.00081410614,0.686325],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958864,0.0010364086,0.00026399948,0.00035863376,0.0020171101,0.0004373708],"domain_scores_gemma":[0.9949517,0.0018293879,0.00067648507,0.0007946047,0.0011566139,0.0005910917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002967203,0.0007365998,0.00062006264,0.0024846557,0.0015268669,0.008037908,0.0010278049,0.007906053,0.089417785],"category_scores_gemma":[0.016450258,0.00050829066,0.000875004,0.0048492257,0.0017425315,0.0045257867,0.0013751857,0.0042190603,0.03383391],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022754543,0.0001273491,0.0009988686,0.0001672479,0.000025981635,0.00010004731,0.00010110334,0.0010681978,0.0005840446,0.42797017,0.4698381,0.09879132],"study_design_scores_gemma":[0.00008798196,0.00007200643,0.0029108324,0.00016084244,0.000050563605,0.00045639853,0.00007529172,0.001505637,0.00089137786,0.081275575,0.91247517,0.00003835405],"about_ca_topic_score_codex":0.010111465,"about_ca_topic_score_gemma":0.009023596,"teacher_disagreement_score":0.089417785,"about_ca_system_score_codex":0.005270373,"about_ca_system_score_gemma":0.0062864786,"threshold_uncertainty_score":0.2991323},"labels":[],"label_agreement":null},{"id":"W7100260058","doi":"","title":"The structural dynamics of the pharmaceutical industry.” The Industrial Geographer 1(2","year":2004,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prima facie; Monopoly; Pharmaceutical industry; Profitability index; Marginal cost; Drug prices; Production (economics); Function (biology)","score_opus":0.07547870745844683,"score_gpt":0.30357298793757814,"score_spread":0.22809428047913133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7100260058","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021891067,0.023169033,0.038308255,0.16220598,0.0007632762,0.00009374416,0.0011793014,0.0001595591,0.75222975],"genre_scores_gemma":[0.75582206,0.025850799,0.018605297,0.008768955,0.001056847,0.00015159496,0.0006357703,0.00007766407,0.189031],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99947184,0.00015718064,0.000009422029,0.000084383675,0.00016473976,0.00011238423],"domain_scores_gemma":[0.99944395,0.00014974095,0.00010345175,0.00006939006,0.00014070456,0.00009273098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006496766,0.00036391863,0.00018134771,0.0013000526,0.0021472445,0.003632651,0.00061202823,0.0019176697,0.015575142],"category_scores_gemma":[0.0018449298,0.00028804128,0.00040822892,0.0017453175,0.007615078,0.0037294608,0.0017310616,0.0017814009,0.0014946702],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003923295,0.0000037542386,0.000636872,0.000016751666,0.0000033871918,0.000026743337,0.00030818683,0.0010624524,0.000040334897,0.969081,0.021475745,0.007340961],"study_design_scores_gemma":[0.0000072435905,0.00001050893,0.003363118,0.000079683414,0.000006382779,0.00006164678,0.00058392005,0.0034153478,0.000094731855,0.5863134,0.40605325,0.000010744803],"about_ca_topic_score_codex":0.10596764,"about_ca_topic_score_gemma":0.105698794,"teacher_disagreement_score":0.10596764,"about_ca_system_score_codex":0.009632742,"about_ca_system_score_gemma":0.0062763286,"threshold_uncertainty_score":0.2107017},"labels":[],"label_agreement":null},{"id":"W7100451192","doi":"","title":"that full credit, including © notice, is given to the source. Poor Quality Drugs and Global Trade: A Pilot Study","year":2014,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Subject (documents); Quality (philosophy); Developing country; Cover (algebra); Data collection; Developed country","score_opus":0.14914574327520916,"score_gpt":0.3432836778518924,"score_spread":0.19413793457668324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7100451192","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025991295,0.00060798146,0.0015721427,0.020446299,0.0065111695,0.00040240405,0.1694501,0.0038731273,0.79453766],"genre_scores_gemma":[0.010183896,0.0015379336,0.00092004315,0.0008907865,0.00077475654,0.00025926382,0.06490237,0.0022401323,0.918291],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985568,0.00014971494,0.000099989826,0.00016042979,0.0008345397,0.00019852023],"domain_scores_gemma":[0.9815492,0.003507108,0.0010629703,0.0032551375,0.008042889,0.0025827175],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021136336,0.0007138175,0.0009403456,0.0046470966,0.0016061647,0.0060466505,0.0014589494,0.0020952397,0.90835524],"category_scores_gemma":[0.020068552,0.00047270776,0.00076588505,0.008546152,0.0005837009,0.004564664,0.0037025746,0.0018456735,0.79342455],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032309243,0.000025379051,0.00048985786,0.000056963247,0.0000018616904,0.000019895886,0.000043165044,0.000025363952,0.00007462256,0.0013330654,0.98030055,0.017596992],"study_design_scores_gemma":[0.00004008611,0.000023603736,0.0037369728,0.00013387931,0.0000034624854,0.00005816375,0.00027660868,0.00019635491,0.0002485636,0.0011061225,0.9941584,0.0000177821],"about_ca_topic_score_codex":0.012521026,"about_ca_topic_score_gemma":0.012321643,"teacher_disagreement_score":0.091644764,"about_ca_system_score_codex":0.002091347,"about_ca_system_score_gemma":0.0042590355,"threshold_uncertainty_score":0.13072008},"labels":[],"label_agreement":null},{"id":"W7103226220","doi":"","title":"Product Listing Agreements (PLAs): A New Tool for Reaching Quebec's Pharmaceutical Policy Objectives?","year":2013,"lang":"en","type":"article","venue":"PubMed Central","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Listing (finance); Product (mathematics); Confidentiality; Biopharmaceutical; Control (management); Pharmaceutical industry; Set (abstract data type)","score_opus":0.06969561617402108,"score_gpt":0.2964608127857783,"score_spread":0.2267651966117572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7103226220","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020316191,0.016507404,0.060300462,0.37021178,0.0018852775,0.00068927475,0.007711972,0.002410302,0.5199673],"genre_scores_gemma":[0.6142639,0.01323813,0.120491624,0.050331898,0.0013968465,0.00067421386,0.0030265097,0.00034723533,0.19622964],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945517,0.0019016354,0.00024895451,0.00043917174,0.0021349844,0.0007235106],"domain_scores_gemma":[0.9805638,0.009281488,0.0016622758,0.0014570177,0.005710088,0.0013252363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009772818,0.00046586298,0.000542889,0.003985549,0.0040168082,0.009578882,0.0020410353,0.004886317,0.02476398],"category_scores_gemma":[0.035108563,0.00043317227,0.00049903436,0.005248231,0.003164494,0.0059817303,0.0015687975,0.002845789,0.0015613999],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007488822,0.000044498625,0.0038169287,0.00033278848,0.000025160554,0.00022325545,0.0007584885,0.004115213,0.00027986127,0.5986119,0.2541761,0.13754079],"study_design_scores_gemma":[0.00013851692,0.00005156921,0.008770772,0.00077023014,0.000055597713,0.00014225158,0.0008064932,0.011777577,0.00055975263,0.05932753,0.91743165,0.00016805474],"about_ca_topic_score_codex":0.9243655,"about_ca_topic_score_gemma":0.93595487,"teacher_disagreement_score":0.95286816,"about_ca_system_score_codex":0.04713181,"about_ca_system_score_gemma":0.08224666,"threshold_uncertainty_score":0.3419668},"labels":[],"label_agreement":null},{"id":"W7110897213","doi":"10.5281/zenodo.17860521","title":"Conscience December 2025 Policy Brief - GENEROUS Model Impacts on Prescription Drug Prices for Medicaid","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicaid; Prescription drug; Medical prescription; Drug prices; Medicare Part D; Government (linguistics)","score_opus":0.07184608447955902,"score_gpt":0.3091163548979934,"score_spread":0.23727027041843435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7110897213","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006978944,0.0046568546,0.0017430182,0.40131697,0.016900392,0.0006366116,0.008065928,0.0008924669,0.55880886],"genre_scores_gemma":[0.06588855,0.0047362,0.0031490603,0.42591867,0.006274629,0.0011620978,0.0035292564,0.00034272438,0.48899892],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99328595,0.0015386094,0.00022239349,0.00035025197,0.0033796846,0.0012231526],"domain_scores_gemma":[0.99221075,0.003409308,0.00044023222,0.00032175655,0.002283862,0.0013340445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007607662,0.0008373066,0.00059636374,0.0013475368,0.0044255154,0.008794064,0.0021506525,0.015444718,0.053335533],"category_scores_gemma":[0.024636978,0.000742923,0.0013835634,0.0012333216,0.0011295951,0.004065648,0.0027595784,0.010080327,0.013033421],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011317351,0.00014565887,0.00037922824,0.000076268596,0.00000910577,0.00017135659,0.00008121126,0.0006170461,0.000338128,0.0433216,0.9440946,0.010652484],"study_design_scores_gemma":[0.00012482543,0.00011767826,0.0028447576,0.00019129559,0.000016699769,0.00007235076,0.000262241,0.0008239637,0.00047364607,0.008461893,0.9865479,0.00006273923],"about_ca_topic_score_codex":0.06682041,"about_ca_topic_score_gemma":0.08210561,"teacher_disagreement_score":0.06682041,"about_ca_system_score_codex":0.010477448,"about_ca_system_score_gemma":0.019626256,"threshold_uncertainty_score":0.17842513},"labels":[],"label_agreement":null},{"id":"W7110939033","doi":"10.5281/zenodo.17860520","title":"Conscience December 2025 Policy Brief - GENEROUS Model Impacts on Prescription Drug Prices for Medicaid","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicaid; Prescription drug; Medical prescription; Drug prices; Medicare Part D; Government (linguistics)","score_opus":0.07184608447955902,"score_gpt":0.3091163548979934,"score_spread":0.23727027041843435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7110939033","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006978944,0.0046568546,0.0017430182,0.40131697,0.016900392,0.0006366116,0.008065928,0.0008924669,0.55880886],"genre_scores_gemma":[0.06588855,0.0047362,0.0031490603,0.42591867,0.006274629,0.0011620978,0.0035292564,0.00034272438,0.48899892],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99328595,0.0015386094,0.00022239349,0.00035025197,0.0033796846,0.0012231526],"domain_scores_gemma":[0.99221075,0.003409308,0.00044023222,0.00032175655,0.002283862,0.0013340445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007607662,0.0008373066,0.00059636374,0.0013475368,0.0044255154,0.008794064,0.0021506525,0.015444718,0.053335533],"category_scores_gemma":[0.024636978,0.000742923,0.0013835634,0.0012333216,0.0011295951,0.004065648,0.0027595784,0.010080327,0.013033421],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011317351,0.00014565887,0.00037922824,0.000076268596,0.00000910577,0.00017135659,0.00008121126,0.0006170461,0.000338128,0.0433216,0.9440946,0.010652484],"study_design_scores_gemma":[0.00012482543,0.00011767826,0.0028447576,0.00019129559,0.000016699769,0.00007235076,0.000262241,0.0008239637,0.00047364607,0.008461893,0.9865479,0.00006273923],"about_ca_topic_score_codex":0.06682041,"about_ca_topic_score_gemma":0.08210561,"teacher_disagreement_score":0.06682041,"about_ca_system_score_codex":0.010477448,"about_ca_system_score_gemma":0.019626256,"threshold_uncertainty_score":0.17842513},"labels":[],"label_agreement":null},{"id":"W7112968676","doi":"","title":"The Supply and Demand of Ozempic in America: An Economic Analysis","year":2025,"lang":"","type":"article","venue":"Hollins Digital Commons (Hollins University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Supply and demand; Market rate; Demand management; Market demand schedule; Negotiation; Pace; Price mechanism; Government (linguistics); Economic shortage; Demand shock","score_opus":0.023722796400801657,"score_gpt":0.24570150802754773,"score_spread":0.22197871162674607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112968676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93137276,0.003838466,0.0015932493,0.024140297,0.000096297044,0.000051446907,0.006119606,0.000033739347,0.032754283],"genre_scores_gemma":[0.98598886,0.003628966,0.0006435241,0.0010769353,0.00016444863,0.000043041226,0.0021466028,0.000022528784,0.0062850844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99952245,0.00015104402,0.000017948018,0.00008592082,0.000113968454,0.00010867315],"domain_scores_gemma":[0.99755645,0.0015085385,0.0004653078,0.000040940642,0.00024971212,0.00017896877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080613245,0.00012624216,0.00033065453,0.001078695,0.00080574956,0.0025778152,0.0004840481,0.0009924789,0.00629082],"category_scores_gemma":[0.002758139,0.00037194227,0.0004959459,0.0022476611,0.0006127277,0.0013048042,0.0007808941,0.0020644984,0.0005498593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001349448,0.0018802756,0.5997613,0.000536074,0.0004929323,0.0023704486,0.003995751,0.04465185,0.002216342,0.18107735,0.10319355,0.058474693],"study_design_scores_gemma":[0.00028879108,0.00046899478,0.6621887,0.00036965768,0.0002895837,0.00075951975,0.016465656,0.16631806,0.000999392,0.041405447,0.11018552,0.00026071767],"about_ca_topic_score_codex":0.082516894,"about_ca_topic_score_gemma":0.060326323,"teacher_disagreement_score":0.082516894,"about_ca_system_score_codex":0.004686713,"about_ca_system_score_gemma":0.0018414679,"threshold_uncertainty_score":0.16407323},"labels":[],"label_agreement":null},{"id":"W7113389128","doi":"","title":"The Problem With Consumer Affordability of Prescription Medications in the United States","year":2025,"lang":"","type":"article","venue":"ScholarWorks (Walden University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prescription drug; Medical prescription; Sample (material); Test (biology); Categorical variable; Perception; Perspective (graphical); Politics; Independence (probability theory)","score_opus":0.02377217500834838,"score_gpt":0.24721514213832327,"score_spread":0.22344296712997488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7113389128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83531815,0.010115324,0.002373677,0.088063,0.0002286159,0.000045055578,0.00038223137,0.000022935104,0.06345098],"genre_scores_gemma":[0.9934301,0.0015705285,0.0005587524,0.0035835344,0.00007906759,0.00001848969,0.000056557197,0.0000046306563,0.000698275],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940679,0.003004766,0.0003549227,0.0002620029,0.002050121,0.0002603356],"domain_scores_gemma":[0.97665554,0.016341338,0.00393515,0.00065654604,0.0017031572,0.0007082895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009042436,0.000086655855,0.000277299,0.0008558709,0.0016206554,0.0023537658,0.00037073315,0.0012450786,0.0040670037],"category_scores_gemma":[0.01952173,0.00021011697,0.00037020814,0.0010967312,0.0015145001,0.0020999918,0.0013028168,0.0015536508,0.00013538387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054128043,0.00049708213,0.6031971,0.00039093706,0.00019605333,0.0008796924,0.020553688,0.0009367161,0.0008337303,0.08855759,0.025142606,0.25827348],"study_design_scores_gemma":[0.00007713983,0.00037206121,0.837005,0.001275086,0.00017511519,0.0013514224,0.030607719,0.004545728,0.0008588259,0.038469154,0.08514398,0.0001188041],"about_ca_topic_score_codex":0.030010724,"about_ca_topic_score_gemma":0.054176137,"teacher_disagreement_score":0.030010724,"about_ca_system_score_codex":0.0021782077,"about_ca_system_score_gemma":0.0016659596,"threshold_uncertainty_score":0.059672117},"labels":[],"label_agreement":null},{"id":"W7117187611","doi":"","title":"Consequences of Canada&amp;rsquo;s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access","year":2025,"lang":"en","type":"article","venue":"Dove Medical Press (Taylor and Francis Group)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Government (linguistics); Negotiation; Alliance; Medical prescription; Legislation; Agency (philosophy); Pharmaceutical industry","score_opus":0.08296075741659138,"score_gpt":0.34195497486780824,"score_spread":0.25899421745121687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117187611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.717339,0.010455102,0.00087867863,0.104224205,0.0008002543,0.00062801864,0.034501694,0.00013025923,0.13104291],"genre_scores_gemma":[0.9669317,0.0029972089,0.0013791493,0.012578002,0.000293483,0.00016987891,0.0065279054,0.000041432697,0.009081243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9335778,0.008716311,0.0054315142,0.0021411509,0.042495485,0.0076376814],"domain_scores_gemma":[0.8056895,0.056666292,0.06089007,0.0037396923,0.057704948,0.015309476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017763741,0.0002886736,0.00040274468,0.0030599588,0.0034425096,0.0048215347,0.0016310255,0.0020232294,0.005632655],"category_scores_gemma":[0.11331563,0.0005700627,0.0010406055,0.0065142973,0.0014410533,0.0011747937,0.0018750312,0.0028061233,0.0004265072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011344543,0.00025923067,0.7656155,0.0005092229,0.00031074148,0.0007599344,0.0020341042,0.0021816385,0.00031878226,0.010408765,0.13512324,0.081344426],"study_design_scores_gemma":[0.000099551864,0.000109089284,0.9214941,0.00046548355,0.00010342944,0.00042488668,0.002824865,0.001758433,0.00043565856,0.00059727754,0.0715855,0.00010164419],"about_ca_topic_score_codex":0.8998361,"about_ca_topic_score_gemma":0.9332152,"teacher_disagreement_score":0.9460857,"about_ca_system_score_codex":0.053914282,"about_ca_system_score_gemma":0.08010846,"threshold_uncertainty_score":0.3911773},"labels":[],"label_agreement":null},{"id":"W7118160689","doi":"10.65393/qcpr1945","title":"PATENT LINKAGE: NEXUS BETWEEN INNOVATION, ACCESS, AND REGULATORY AUTHORITY","year":2025,"lang":"","type":"article","venue":"Indian Journal of Legal Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Discretion; Patent infringement; Linkage (software); Incentive; Generic drug; Biosimilar; Premise; Pharmaceutical industry","score_opus":0.12608247779494702,"score_gpt":0.3632457093283946,"score_spread":0.2371632315334476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7118160689","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32721037,0.0073440187,0.12248424,0.035640046,0.0001595729,0.0001988003,0.00019501633,0.00014436475,0.50662357],"genre_scores_gemma":[0.9936707,0.00065484946,0.0022835673,0.00038107415,0.00008328829,0.000041102034,0.000012060801,0.00000615187,0.00286724],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9897188,0.003881007,0.0004928548,0.0014767853,0.0028098496,0.0016206573],"domain_scores_gemma":[0.9735478,0.018741434,0.00417279,0.0012275832,0.0014578217,0.0008525664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009789944,0.00019767351,0.00057915004,0.003547225,0.0028056484,0.010411644,0.001272261,0.0038929416,0.009844198],"category_scores_gemma":[0.02559362,0.0003366948,0.0007949493,0.0025437847,0.015454111,0.0153768165,0.0063607134,0.0035568194,0.0005064288],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014947538,0.00001527853,0.00087059685,0.000026973985,0.0000055060023,0.000068648005,0.00040315924,0.00074768777,0.00013292303,0.992515,0.00014942614,0.0050498247],"study_design_scores_gemma":[0.000035145946,0.00009425262,0.004111218,0.00013654478,0.00003927063,0.00020514775,0.0012084693,0.0029450194,0.00061404443,0.97357,0.017009156,0.000031655327],"about_ca_topic_score_codex":0.0029089774,"about_ca_topic_score_gemma":0.0015781305,"teacher_disagreement_score":0.010411644,"about_ca_system_score_codex":0.0055938596,"about_ca_system_score_gemma":0.008282459,"threshold_uncertainty_score":0.0517748},"labels":[],"label_agreement":null},{"id":"W7123667155","doi":"10.18609/cgti.2020.195","title":"Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies","year":2020,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Health care; Health economics; Strategic planning; Primary care; Pricing strategies","score_opus":0.06493991700503458,"score_gpt":0.24846393984950116,"score_spread":0.18352402284446656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7123667155","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018855577,0.0372516,0.08698724,0.48713613,0.016023137,0.005778347,0.021990031,0.003910735,0.32206717],"genre_scores_gemma":[0.21552975,0.08264236,0.35400218,0.07302919,0.012562764,0.008096915,0.06986084,0.0025113549,0.18176462],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882018,0.004351987,0.00083986076,0.0005533313,0.0033109433,0.002742129],"domain_scores_gemma":[0.95643246,0.00905177,0.0024769125,0.0016798232,0.014374602,0.015984472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02772689,0.0013257804,0.001073316,0.0044617625,0.0016147223,0.013191365,0.003773425,0.0072318497,0.09865851],"category_scores_gemma":[0.04011118,0.00083618355,0.0018739491,0.003687371,0.0014535168,0.008318437,0.004998249,0.0061477483,0.019142257],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000513986,0.00066395523,0.004061103,0.0012659058,0.00007351602,0.00041780193,0.00032152614,0.00502561,0.0009807884,0.14369746,0.49591017,0.3470681],"study_design_scores_gemma":[0.00023281708,0.0006199226,0.011080416,0.0018482037,0.00006747836,0.00027588272,0.0007540059,0.0070551173,0.0010993375,0.053439476,0.92342013,0.00010707518],"about_ca_topic_score_codex":0.024493037,"about_ca_topic_score_gemma":0.021688726,"teacher_disagreement_score":0.09865851,"about_ca_system_score_codex":0.009716135,"about_ca_system_score_gemma":0.07742901,"threshold_uncertainty_score":0.33004558},"labels":[],"label_agreement":null},{"id":"W7125587383","doi":"10.1109/iciip68302.2025.11346187","title":"Predicting Drug Shortages for Healthcare Supply Chain Optimization Using Machine Learning","year":2025,"lang":"","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Supply chain; Economic shortage; Discontinuation; Reimbursement; Random forest; Health care; Predictive analytics; Support vector machine","score_opus":0.05552146520820622,"score_gpt":0.3229401431799093,"score_spread":0.2674186779717031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7125587383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5030984,0.0014933809,0.48144114,0.0037434155,0.00013071299,0.00031721132,0.0015695113,0.0014818836,0.006724365],"genre_scores_gemma":[0.96924645,0.00026010434,0.028135294,0.000107218984,0.00003869422,0.0000612796,0.0006458651,0.000017150474,0.0014879403],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996686,0.00011488985,0.000022847169,0.00005503819,0.000065713844,0.00007289936],"domain_scores_gemma":[0.9986343,0.0008565251,0.00017411224,0.00003484477,0.00021954566,0.00008067111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011179683,0.00058808445,0.00068807177,0.001116588,0.0005163348,0.00096786296,0.0005593592,0.0006565724,0.0020390237],"category_scores_gemma":[0.0033211617,0.00038705487,0.00046791663,0.0010262253,0.00026519035,0.00069329183,0.0005295204,0.0007404104,0.00022911973],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038029822,0.000060415976,0.007985914,0.00003145329,0.000029522113,0.000032112363,0.000014670459,0.9700815,0.00015478411,0.0007158312,0.0008684378,0.019987386],"study_design_scores_gemma":[0.0000024502078,0.000009524,0.0004936604,0.0000031333914,0.00000299931,0.0000021370806,0.000008917454,0.9987406,0.00005198126,0.000583317,0.00009931016,0.0000020022057],"about_ca_topic_score_codex":0.1250611,"about_ca_topic_score_gemma":0.095688336,"teacher_disagreement_score":0.1250611,"about_ca_system_score_codex":0.002388527,"about_ca_system_score_gemma":0.0038988336,"threshold_uncertainty_score":0.24866635},"labels":[],"label_agreement":null},{"id":"W7127003672","doi":"","title":"The determinants of pricing in pharmaceuticals: are U.S. prices really higher than those of Canada?","year":2007,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nationality; Quality (philosophy); Product (mathematics); Power (physics); Market power; Phenomenon","score_opus":0.07821765299775091,"score_gpt":0.330124632635825,"score_spread":0.25190697963807407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7127003672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97509325,0.004097091,0.00036171515,0.005409827,0.000050206985,0.000017955472,0.0026212807,0.000022456095,0.012326362],"genre_scores_gemma":[0.9976446,0.0008868026,0.00009652898,0.0001728338,0.000017536633,0.00000207944,0.0008155643,0.00000494862,0.0003591881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989312,0.000115616414,0.00006514615,0.00012504823,0.0004444631,0.00031859273],"domain_scores_gemma":[0.9913155,0.0018817664,0.003951409,0.00022326365,0.0016123984,0.0010157257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095095334,0.00015425919,0.00041328734,0.0015729578,0.0012039572,0.0022479454,0.00042464226,0.000632286,0.0022818237],"category_scores_gemma":[0.0091099255,0.00016377986,0.00048762027,0.00517638,0.0009676085,0.0009786764,0.0006055226,0.0011179274,0.0002467567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009020501,0.00004667691,0.975668,0.000044527864,0.00014851031,0.00018578312,0.000501529,0.0014075768,0.00019446894,0.003071128,0.0036464701,0.014995207],"study_design_scores_gemma":[0.000007600164,0.000022095825,0.9946201,0.000023984972,0.00004676236,0.00006443287,0.00061752147,0.0009952248,0.00020662454,0.00046693673,0.00291187,0.000016826296],"about_ca_topic_score_codex":0.8342582,"about_ca_topic_score_gemma":0.8481196,"teacher_disagreement_score":0.1657418,"about_ca_system_score_codex":0.0062028766,"about_ca_system_score_gemma":0.0064237975,"threshold_uncertainty_score":0.3334357},"labels":[],"label_agreement":null},{"id":"W7132882939","doi":"","title":"Are brand-name and generic warfarin interchangeable?: a pharmacological and behavioural investigation","year":2003,"lang":"","type":"dissertation","venue":"TSpace","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bibliographical Society of Canada","funders":"Canadian Institutes of Health Research","keywords":"Warfarin; Anticoagulant; Clinical trial; Significant difference; Major bleeding","score_opus":0.1835528815152761,"score_gpt":0.3598957590367011,"score_spread":0.17634287752142502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132882939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957783,0.00051488087,0.00008280538,0.001408328,0.0000149688485,0.000052334086,0.00007627566,0.000001768431,0.0020703073],"genre_scores_gemma":[0.99772257,0.00041306354,0.00013695924,0.0010400354,0.00003035389,0.000037508336,0.000053267202,0.0000012534773,0.0005650353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980375,0.00089861744,0.0001335519,0.00022280026,0.00053039595,0.00017712842],"domain_scores_gemma":[0.9905454,0.0049333777,0.003000536,0.00021795413,0.00041064044,0.00089203584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003331895,0.00016757587,0.0005010508,0.0006220811,0.00073966314,0.0013765227,0.00040308113,0.0014650159,0.003983978],"category_scores_gemma":[0.013511591,0.00036542292,0.00041733906,0.0005496274,0.001294323,0.0017168884,0.00037473845,0.0013671233,0.00036765754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003204013,0.008107595,0.92033815,0.00039305497,0.00057091593,0.00028336133,0.01644663,0.00017104959,0.00095492916,0.0012011732,0.0011306163,0.047198616],"study_design_scores_gemma":[0.00043356116,0.0046846825,0.9778922,0.00008622561,0.00017225587,0.0004560656,0.011982441,0.0010483294,0.00014736103,0.001305547,0.0017453755,0.00004595385],"about_ca_topic_score_codex":0.004330725,"about_ca_topic_score_gemma":0.0059563825,"teacher_disagreement_score":0.004330725,"about_ca_system_score_codex":0.0006717985,"about_ca_system_score_gemma":0.00055196916,"threshold_uncertainty_score":0.01762098},"labels":[],"label_agreement":null},{"id":"W7132927048","doi":"","title":"From inventors to predators: Have brand firms crossed the line by marketing authorized generics","year":2007,"lang":"","type":"dissertation","venue":"TSpace","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Heritage; Library and Archives Canada","funders":"University of Toronto","keywords":"Incentive; Innovator; Intersection (aeronautics); Product (mathematics); Product line; Brand names; Generic drug","score_opus":0.060187578765359,"score_gpt":0.37574419182412033,"score_spread":0.3155566130587613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132927048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.497799,0.01170491,0.014219775,0.15447028,0.0007234789,0.0002402177,0.00046419722,0.00011670066,0.32026142],"genre_scores_gemma":[0.9653985,0.0040979353,0.00070480304,0.014214539,0.00039779526,0.000054316348,0.00005427554,0.000019847384,0.015058026],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99555653,0.0018662473,0.00016119456,0.00090912345,0.0007093859,0.00079757115],"domain_scores_gemma":[0.95590144,0.030989854,0.008432493,0.0016043003,0.0014913924,0.0015804904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009080385,0.00034662418,0.000833174,0.001424456,0.004595233,0.013528502,0.0011616223,0.008988593,0.0205103],"category_scores_gemma":[0.03482575,0.0005793538,0.0006783185,0.0014250184,0.013083887,0.021483127,0.004294353,0.0053130467,0.001351962],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048018523,0.00021227822,0.026069876,0.00036867236,0.00010218816,0.0010805193,0.011390297,0.0008944802,0.0007510121,0.8677405,0.033152238,0.05775774],"study_design_scores_gemma":[0.00038025007,0.000494319,0.023380408,0.00086694246,0.00022202838,0.0011149152,0.024638232,0.0036754347,0.0024276872,0.81400526,0.1285853,0.00020920469],"about_ca_topic_score_codex":0.006188026,"about_ca_topic_score_gemma":0.004565464,"teacher_disagreement_score":0.0205103,"about_ca_system_score_codex":0.0039499593,"about_ca_system_score_gemma":0.0024163462,"threshold_uncertainty_score":0.06861377},"labels":[],"label_agreement":null},{"id":"W7162564964","doi":"10.1071/hp070408","title":"'Linkage' pharmaceutical evergreening in Canada and Australia","year":2007,"lang":"en","type":"article","venue":"Australia and New Zealand Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Monopoly; Competitor analysis; Pharmaceutical industry; Product (mathematics); Intellectual property; Quality (philosophy); Patent infringement; Drug prices; Generic drug; Monopolistic competition","score_opus":0.17966585111918265,"score_gpt":0.40400948994738667,"score_spread":0.22434363882820402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7162564964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80761343,0.005152481,0.00051120284,0.08224607,0.00033555584,0.00021263171,0.002053168,0.00010734397,0.10176805],"genre_scores_gemma":[0.95924014,0.0015180398,0.0004562973,0.008070765,0.000076403216,0.00003690452,0.00053207396,0.000019391184,0.030049996],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944194,0.0005006115,0.00017658882,0.00028414518,0.0019108932,0.0027082376],"domain_scores_gemma":[0.9834991,0.0018988405,0.0016984046,0.00029977248,0.006074091,0.0065298486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033678066,0.00020475841,0.00066655525,0.0024698055,0.006375391,0.00713954,0.0013316383,0.002871078,0.006366764],"category_scores_gemma":[0.013808358,0.00037327645,0.0006144248,0.0054315627,0.0019284437,0.0022842512,0.0038174177,0.002929044,0.00023628467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013325852,0.00077688915,0.37248212,0.00083725824,0.00041034483,0.004557906,0.02443089,0.009019656,0.0027180824,0.259743,0.13422827,0.189463],"study_design_scores_gemma":[0.00009399357,0.00015186795,0.8364326,0.0002447823,0.00011309722,0.00024088367,0.014340944,0.0031960984,0.0005201847,0.0072342195,0.13733183,0.000099481906],"about_ca_topic_score_codex":0.982284,"about_ca_topic_score_gemma":0.99102545,"teacher_disagreement_score":0.0879443,"about_ca_system_score_codex":0.0879443,"about_ca_system_score_gemma":0.15467721,"threshold_uncertainty_score":0.6380836},"labels":[],"label_agreement":null},{"id":"W73329298","doi":"10.1007/978-0-387-44961-6_15","title":"The Application of PK/PD Modeling and Simulations During Lead Optimization","year":2007,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pharmaceutical industry; Drug development; Lead (geology); Food and drug administration; Business; Risk analysis (engineering); Operations research; Engineering; Medicine; Drug; Pharmacology","score_opus":0.09603546112784378,"score_gpt":0.29652023711340475,"score_spread":0.20048477598556097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W73329298","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007375435,0.0009224764,0.9731399,0.0005999979,0.00016505727,0.00007943792,0.00021385678,0.0013070472,0.016196752],"genre_scores_gemma":[0.33630466,0.0024657736,0.64349055,0.00047554853,0.0003200281,0.0005251853,0.00041166402,0.0011230708,0.014883525],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.999126,0.00046504475,0.000045684632,0.000090536865,0.00022734783,0.000045246874],"domain_scores_gemma":[0.9944707,0.0046056574,0.00020788587,0.0003192184,0.00032234093,0.00007417087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020957412,0.0010666888,0.0014333957,0.0004666067,0.00065005093,0.0018965652,0.0012892633,0.0015954063,0.006583678],"category_scores_gemma":[0.008634466,0.0009914525,0.0009721747,0.00070530176,0.0006644685,0.0018367935,0.00089698244,0.0021655147,0.001433079],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005399511,0.000043083688,0.00028503928,0.00008349841,0.00004046956,0.000055515993,0.000048639948,0.93277234,0.00069986307,0.02674677,0.0023252263,0.03684549],"study_design_scores_gemma":[0.000007765193,0.000008911604,0.000036550544,0.000011042503,0.000006359896,0.00001560787,0.0000048587685,0.98404825,0.0006590225,0.013180607,0.0020149113,0.0000060593675],"about_ca_topic_score_codex":0.00907878,"about_ca_topic_score_gemma":0.004986356,"teacher_disagreement_score":0.00907878,"about_ca_system_score_codex":0.0010151129,"about_ca_system_score_gemma":0.0016143911,"threshold_uncertainty_score":0.022024632},"labels":[],"label_agreement":null},{"id":"W75642366","doi":"10.1007/978-90-481-9051-5_16","title":"Medical Market Failures and Their Remedy","year":2010,"lang":"en","type":"book-chapter","venue":"Boston studies in the philosophy of science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Market failure; Intellectual property; Medical research; Stimulus (psychology); Business; Government (linguistics); Public economics; Government regulation; Law and economics; Public relations; Political science; Economics; Medicine; Law; Psychology; Microeconomics; Pathology; Psychotherapist","score_opus":0.1378611544377615,"score_gpt":0.330159618704188,"score_spread":0.19229846426642647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W75642366","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03154868,0.042708408,0.01809837,0.50933164,0.0038734602,0.00006568173,0.00015642143,0.00022531043,0.39399192],"genre_scores_gemma":[0.8935083,0.011610536,0.0032919832,0.028555896,0.008001199,0.00008840279,0.000059652535,0.00010352883,0.054780617],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9969168,0.0012427603,0.00011792938,0.00036185744,0.00078461814,0.00057618634],"domain_scores_gemma":[0.98829776,0.006398238,0.0018233134,0.0016672593,0.00091987074,0.00089355814],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.007670163,0.00038133914,0.0008018681,0.0013427743,0.0018989542,0.0037985442,0.0011396192,0.00868466,0.013228597],"category_scores_gemma":[0.036618043,0.00034457765,0.000445885,0.00096860464,0.014476363,0.0063861473,0.0030787606,0.011896365,0.0011713749],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020120848,0.000022439366,0.0001642884,0.000017650911,0.000005969658,0.00006997562,0.00021246697,0.00033450843,0.000040835497,0.9750993,0.014622695,0.009389733],"study_design_scores_gemma":[0.000049285703,0.00001677775,0.00044296874,0.00005912345,0.00000369394,0.00007715829,0.0001498511,0.0007337328,0.000053356456,0.9570682,0.04133808,0.000007796019],"about_ca_topic_score_codex":0.0017008617,"about_ca_topic_score_gemma":0.0014066409,"teacher_disagreement_score":0.99810106,"about_ca_system_score_codex":0.0021654952,"about_ca_system_score_gemma":0.0028122573,"threshold_uncertainty_score":0.044254065},"labels":[],"label_agreement":null},{"id":"W848354343","doi":"","title":"America's New War on Drugs: Should the United States Legalize Prescription Drug Reimportation;Note","year":2005,"lang":"en","type":"article","venue":"Journal of legislation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Drug; Political science; Law; Law and economics; Medicine; Economics; Pharmacology","score_opus":0.06479299018952714,"score_gpt":0.314348602120677,"score_spread":0.24955561193114986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W848354343","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014515494,0.013437689,0.00037337022,0.8552622,0.017623013,0.00014645609,0.0003780282,0.00014845547,0.11117927],"genre_scores_gemma":[0.0082701,0.0040418995,0.00065285404,0.9207787,0.007265184,0.00017342785,0.00008131354,0.000044454653,0.058692075],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960848,0.00072989246,0.00028143017,0.00075757346,0.00124118,0.0009051278],"domain_scores_gemma":[0.9939627,0.0034628196,0.00031948314,0.00025779754,0.0012151143,0.0007821462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004489806,0.0012302146,0.0008334936,0.0008781248,0.010515587,0.008684529,0.0027488964,0.058779046,0.01143349],"category_scores_gemma":[0.010096914,0.0010480019,0.0012210388,0.0007976997,0.005024393,0.008305804,0.002534735,0.029749095,0.0059437337],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025415438,0.00006498099,0.0005257518,0.00004921262,0.000008022814,0.00037549925,0.0003634315,0.00005297482,0.00019142445,0.036830753,0.95522714,0.0062853172],"study_design_scores_gemma":[0.00004566655,0.00004446746,0.0015760658,0.0002938401,0.000015981774,0.0001945108,0.000836849,0.00020628542,0.00026130592,0.011177664,0.9852874,0.000059912254],"about_ca_topic_score_codex":0.08395353,"about_ca_topic_score_gemma":0.14969245,"teacher_disagreement_score":0.08395353,"about_ca_system_score_codex":0.006215387,"about_ca_system_score_gemma":0.019710863,"threshold_uncertainty_score":0.16692972},"labels":[],"label_agreement":null},{"id":"W866392653","doi":"10.1503/cmaj.150395","title":"Generic drugs in Canada: an examination of tiered pricing","year":2015,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Reimbursement; Drug pricing; Scheme (mathematics); Computer science; Operations research; Medicine; Business; Actuarial science; Political science; Law; Engineering; Mathematics; Health care","score_opus":0.04195725427389521,"score_gpt":0.2453930281293674,"score_spread":0.20343577385547218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W866392653","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2905547,0.07205616,0.004907274,0.15372586,0.00071328785,0.0005245067,0.0057107913,0.00016550785,0.47164187],"genre_scores_gemma":[0.94913983,0.025870223,0.002703079,0.011037805,0.0002593172,0.000032493648,0.00071913534,0.000054428612,0.010183661],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.98882174,0.0007123193,0.0002522926,0.0005507903,0.0074005835,0.0022624026],"domain_scores_gemma":[0.9846993,0.0022415475,0.0015518789,0.00042823583,0.0086054485,0.0024736961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032073369,0.00033169988,0.0004977261,0.0047834595,0.005418215,0.0088332705,0.0022075924,0.0020216492,0.0054219295],"category_scores_gemma":[0.012685693,0.00045168723,0.0009378971,0.013087644,0.00460108,0.0025394824,0.0018014987,0.0029501813,0.00020724544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023588986,0.00021309147,0.10430424,0.0005097165,0.00013660816,0.0007168986,0.0029634929,0.006651442,0.0005557146,0.6593327,0.079487436,0.1448928],"study_design_scores_gemma":[0.00014041315,0.000190857,0.54109484,0.0016713616,0.0002849587,0.0006739658,0.008250226,0.01999706,0.0007155415,0.069257654,0.35738593,0.00033714122],"about_ca_topic_score_codex":0.992358,"about_ca_topic_score_gemma":0.9947153,"teacher_disagreement_score":0.16491872,"about_ca_system_score_codex":0.16491872,"about_ca_system_score_gemma":0.15149306,"threshold_uncertainty_score":0.9685759},"labels":[],"label_agreement":null},{"id":"W86747047","doi":"","title":"Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Agency (philosophy); Food and drug administration; Kingdom; Family medicine; Environmental health","score_opus":0.16624883208139715,"score_gpt":0.2785195936212857,"score_spread":0.11227076153988855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W86747047","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026177255,0.020185146,0.010682546,0.063718416,0.006687255,0.006918316,0.013178578,0.0024818117,0.84997076],"genre_scores_gemma":[0.17983517,0.0133060645,0.024866011,0.030619979,0.0015153225,0.0053176954,0.011458289,0.00052145805,0.73256],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.97468424,0.00722716,0.0011606268,0.0011211523,0.01284121,0.0029656528],"domain_scores_gemma":[0.8957894,0.018379087,0.007814807,0.0065342,0.044572275,0.026910314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018494792,0.00059726904,0.0006423952,0.0030317036,0.0037324599,0.0038801134,0.0015487757,0.0013996944,0.09981823],"category_scores_gemma":[0.04274262,0.00064619316,0.00078526547,0.0019860088,0.0016738839,0.00094787136,0.0031176065,0.001522797,0.030150954],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039201064,0.00014984809,0.011357984,0.0008911767,0.00007420614,0.0005217428,0.0010518639,0.0003295144,0.002685831,0.0079107145,0.5920119,0.3826231],"study_design_scores_gemma":[0.00004745423,0.00010898283,0.031047987,0.00033044335,0.000026682033,0.0003524806,0.0004110328,0.00021161677,0.0004090471,0.00025980157,0.96677107,0.00002334584],"about_ca_topic_score_codex":0.38652727,"about_ca_topic_score_gemma":0.42628944,"teacher_disagreement_score":0.98364884,"about_ca_system_score_codex":0.016351184,"about_ca_system_score_gemma":0.13717107,"threshold_uncertainty_score":0.76855487},"labels":[],"label_agreement":null},{"id":"W883499483","doi":"10.1007/s00228-015-1889-9","title":"Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons","year":2015,"lang":"en","type":"article","venue":"European Journal of Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Interchangeability; Bioequivalence; Equivalence (formal languages); Point estimation; Sample size determination; Statistics; Econometrics; Medicine; Statistical power; Sample (material); Mathematics; Computer science; Pharmacology; Pharmacokinetics; Chromatography","score_opus":0.3642071753732102,"score_gpt":0.45116830184339196,"score_spread":0.08696112647018178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W883499483","genre_codex":"methods","genre_gemma":"methods","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38718122,0.0552167,0.49058574,0.020027637,0.006066637,0.0034232528,0.005406668,0.0019115717,0.030180601],"genre_scores_gemma":[0.96372175,0.0011225203,0.029147843,0.0023033456,0.0007740918,0.0008748714,0.0006226217,0.0006427994,0.0007901766],"study_design_codex":"meta_analysis","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.17124152,0.74471295,0.033191532,0.028587202,0.019113855,0.0031529788],"domain_scores_gemma":[0.017347671,0.95466316,0.0068443697,0.018207278,0.0022990466,0.00063848856],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.64814395,0.0042431867,0.009241016,0.005318687,0.0017700224,0.008541383,0.0058062663,0.009663542,0.008064821],"category_scores_gemma":[0.8754998,0.00308825,0.024891343,0.0061945133,0.0127560105,0.013155356,0.0069840783,0.011878576,0.0011308936],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09385554,0.0008767459,0.2893965,0.0105786165,0.3009597,0.0038196757,0.008426584,0.038641993,0.007113628,0.048614297,0.009204852,0.18851177],"study_design_scores_gemma":[0.026276806,0.017788526,0.32211468,0.0049279165,0.1952576,0.00646267,0.0017220075,0.1575673,0.021513311,0.2163975,0.028540783,0.0014309094],"about_ca_topic_score_codex":0.0013769508,"about_ca_topic_score_gemma":0.00081694475,"teacher_disagreement_score":0.35185605,"about_ca_system_score_codex":0.0016344811,"about_ca_system_score_gemma":0.001966492,"threshold_uncertainty_score":0.4339012},"labels":[],"label_agreement":null},{"id":"W911318732","doi":"10.1177/009885880803400404","title":"Right Idea, Wrong Result—Canada's Access to Medicines Regime","year":2008,"lang":"en","type":"article","venue":"American Journal of Law & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; CITES; Developing country; Population; Essential medicines; Developed country; Health care; Environmental health; Economic growth; Economics","score_opus":0.06179088103315592,"score_gpt":0.321001022982301,"score_spread":0.25921014194914505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W911318732","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03094664,0.006633861,0.0011215596,0.37881464,0.0029462269,0.0001688295,0.0019271348,0.000120187644,0.577321],"genre_scores_gemma":[0.4144395,0.00580455,0.0024689178,0.274229,0.0011700608,0.00012182156,0.0008106533,0.00014329617,0.3008122],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917672,0.0005002764,0.00019028339,0.00057369826,0.004783694,0.0021848194],"domain_scores_gemma":[0.9897794,0.0016355275,0.00027318104,0.00040027229,0.004869133,0.0030425857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032071918,0.000286401,0.00047735422,0.0011888219,0.013906216,0.00925393,0.0016115322,0.00729382,0.022826524],"category_scores_gemma":[0.016455173,0.00031021246,0.00066439476,0.0016306884,0.004916234,0.0024077971,0.0023459229,0.008085431,0.0011377778],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013154205,0.000107120846,0.014170878,0.00012544745,0.000066317574,0.000985043,0.0019630077,0.00060516736,0.0005229186,0.48526758,0.4267458,0.0693092],"study_design_scores_gemma":[0.000113016526,0.000046630168,0.01988538,0.0002956342,0.000054618446,0.00037414493,0.001067399,0.00095980073,0.00032242297,0.025340196,0.95142883,0.000111969035],"about_ca_topic_score_codex":0.9777321,"about_ca_topic_score_gemma":0.98909724,"teacher_disagreement_score":0.9312592,"about_ca_system_score_codex":0.068740785,"about_ca_system_score_gemma":0.15263371,"threshold_uncertainty_score":0.49875164},"labels":[],"label_agreement":null},{"id":"W935276731","doi":"10.1080/12507970.2004.11516814","title":"Réapprovisionnement des unités de soins : Portrait de six hôpitaux québécois et français","year":2004,"lang":"fr","type":"article","venue":"Logistique & Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"HEC Montréal","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.06065155444455676,"score_gpt":0.30938147143113737,"score_spread":0.2487299169865806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W935276731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613125,0.002542278,0.001566146,0.006566064,0.000049930855,0.00012503105,0.0006961695,0.000031990443,0.027110012],"genre_scores_gemma":[0.9777616,0.0010538852,0.0010008886,0.00032655513,0.000014430401,0.000035009954,0.00019656091,0.000009409179,0.019601777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985677,0.0003298252,0.000044405242,0.000113256596,0.00028768496,0.0006571171],"domain_scores_gemma":[0.9959973,0.0005639364,0.00062066,0.0001151485,0.001242656,0.0014603327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011759346,0.00022317962,0.00021251722,0.0011273522,0.0031869716,0.0024802457,0.00094709866,0.0008572245,0.0074464097],"category_scores_gemma":[0.00323264,0.00018997246,0.00031230273,0.002010082,0.0015350766,0.0006991629,0.001026838,0.00083967077,0.00045418146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007038407,0.0003868727,0.61617404,0.00039115126,0.00017455671,0.0027004823,0.05654408,0.010683712,0.0041855434,0.033722267,0.021211524,0.25312194],"study_design_scores_gemma":[0.000035762147,0.00023585829,0.8693947,0.00017386042,0.000056046636,0.00051843916,0.041369952,0.003326346,0.00071189966,0.0012501164,0.08286118,0.00006580709],"about_ca_topic_score_codex":0.8839547,"about_ca_topic_score_gemma":0.9458397,"teacher_disagreement_score":0.116045296,"about_ca_system_score_codex":0.029240962,"about_ca_system_score_gemma":0.021615116,"threshold_uncertainty_score":0.23345739},"labels":[],"label_agreement":null},{"id":"W935542713","doi":"","title":"Confusion and Contradiction: Untangling Drug Importation and Counterfeit Drugs","year":2005,"lang":"en","type":"article","venue":"California Western international law journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Counterfeit; Confusion; Contradiction; Drug; Counterfeit Drugs; Business; Pharmacology; Medicine; Law; Psychology; Political science; Philosophy; Epistemology; Psychoanalysis","score_opus":0.020017478445066964,"score_gpt":0.26013142341088263,"score_spread":0.24011394496581567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W935542713","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051755764,0.062058646,0.011069332,0.62496483,0.0039537936,0.00008921804,0.00011052981,0.00008913189,0.24590872],"genre_scores_gemma":[0.86727446,0.017528228,0.0030164467,0.10120669,0.0034290964,0.00014469019,0.00009027717,0.00011642471,0.0071937083],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97767055,0.015614305,0.00052705384,0.0014718095,0.0028526587,0.0018636776],"domain_scores_gemma":[0.9519043,0.038205832,0.00349575,0.0016520441,0.0027980858,0.0019440374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01841035,0.000946414,0.0011205102,0.00607612,0.020342737,0.018505823,0.0027886848,0.011798068,0.00601626],"category_scores_gemma":[0.033040192,0.00080568314,0.00082029466,0.004176574,0.11478052,0.047517,0.017435981,0.02151978,0.0009995645],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004538531,0.00003676168,0.001580706,0.00023111865,0.000012483258,0.0014025952,0.18211071,0.00007385481,0.000084289604,0.7805514,0.021547591,0.012323149],"study_design_scores_gemma":[0.000036042737,0.000033999644,0.0012969848,0.0010254072,0.000019896679,0.001880479,0.15610325,0.00047265837,0.00021854929,0.61704016,0.22182277,0.00004982101],"about_ca_topic_score_codex":0.008009091,"about_ca_topic_score_gemma":0.00894551,"teacher_disagreement_score":0.020342737,"about_ca_system_score_codex":0.015778746,"about_ca_system_score_gemma":0.009716636,"threshold_uncertainty_score":0.11448336},"labels":[],"label_agreement":null},{"id":"W93927275","doi":"10.1017/s0012217300003978","title":"Accès aux médicaments : quelle responsabilité pour les compagnies pharmaceutiques?","year":2004,"lang":"fr","type":"article","venue":"Dialogue","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Political science; Philosophy; Humanities","score_opus":0.11500926255038771,"score_gpt":0.34708948757365726,"score_spread":0.23208022502326955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W93927275","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08429154,0.01947817,0.047778264,0.48804176,0.0009484943,0.00016093254,0.00014645894,0.0000811333,0.3590733],"genre_scores_gemma":[0.9258663,0.008610066,0.0053857323,0.021274643,0.0010182856,0.00014216658,0.00002996734,0.00002549699,0.037647277],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9893734,0.0061745755,0.0002739733,0.0006622353,0.0022664673,0.0012493241],"domain_scores_gemma":[0.9807711,0.011032037,0.0024349075,0.00087186,0.0024031273,0.002486894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008882795,0.0005630192,0.00063061895,0.0018151298,0.003879524,0.0104239145,0.0009975102,0.006873839,0.016910775],"category_scores_gemma":[0.019171054,0.00035524316,0.0006123842,0.0012403782,0.017100139,0.006228112,0.0042539225,0.0048278887,0.0011995073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004610933,0.000079610225,0.002177297,0.000135779,0.00001874795,0.000109917455,0.0018179455,0.0008753214,0.00026654708,0.9727428,0.003389038,0.018340882],"study_design_scores_gemma":[0.00004607691,0.00018202094,0.0077360454,0.0007764253,0.000038332444,0.00035282853,0.004815834,0.0011970245,0.00052531005,0.8318473,0.15243214,0.00005055368],"about_ca_topic_score_codex":0.006787193,"about_ca_topic_score_gemma":0.004736369,"teacher_disagreement_score":0.016910775,"about_ca_system_score_codex":0.007077079,"about_ca_system_score_gemma":0.0111463005,"threshold_uncertainty_score":0.05657214},"labels":[],"label_agreement":null},{"id":"W94138530","doi":"10.1177/070674371205700405","title":"A Population-Based Study of the Use of Selective Serotonin Reuptake Inhibitors before and after Introduction of Generic Equivalents","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Psychiatry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Manitoba Health; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Paroxetine; Sertraline; Escitalopram; Citalopram; Medical prescription; Fluoxetine; Fluvoxamine; Venlafaxine; Medicine; Population; Pharmacoepidemiology; Psychiatry; Reuptake inhibitor; Antidepressant; Pharmacology; Serotonin; Internal medicine; Environmental health","score_opus":0.04942814246395809,"score_gpt":0.260365855879023,"score_spread":0.2109377134150649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W94138530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990671,0.00010455912,0.000035406603,0.000054272863,0.000007629516,0.000018097071,0.00048293525,0.0000019861902,0.00022806667],"genre_scores_gemma":[0.9987112,0.00008294684,0.00008274079,0.00008808056,0.000013421315,0.000024465458,0.0006161409,0.0000017423644,0.00037918004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917173,0.00025316834,0.00005667258,0.00016930958,0.00017986013,0.00016928134],"domain_scores_gemma":[0.99825686,0.00019849106,0.00064517173,0.0001379461,0.00040070724,0.00036078837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010799284,0.00033541233,0.00034198,0.00087775005,0.00070808415,0.0008207588,0.00054243335,0.0010042198,0.0012489811],"category_scores_gemma":[0.003029976,0.0005196178,0.0006667131,0.001685497,0.00042246984,0.00066983193,0.00048832543,0.0013524275,0.00044731627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010760076,0.00012547118,0.99878794,0.000006060759,0.000061269435,0.000039428505,0.00023319137,0.000014793277,0.00010164503,0.000007483746,0.000073945164,0.00044112795],"study_design_scores_gemma":[0.000008006133,0.00010904805,0.9994978,0.0000020953892,0.000013263883,0.000030008297,0.00020861319,0.000038384456,0.0000102194535,0.000003464773,0.0000766919,0.0000024458388],"about_ca_topic_score_codex":0.13713166,"about_ca_topic_score_gemma":0.1369702,"teacher_disagreement_score":0.8628683,"about_ca_system_score_codex":0.0017138436,"about_ca_system_score_gemma":0.0017600927,"threshold_uncertainty_score":0.27266693},"labels":[],"label_agreement":null},{"id":"W9436761","doi":"10.3833/pdr.v2011i9.1531","title":"Sanofi’s Aventis Pharma Subsidiary to Acquire Nutraceuticals Business of India’s Universal Medicare","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Nutraceutical; Portfolio; Quarter (Canadian coin); Marketing; Finance; Medicine","score_opus":0.1334269315679914,"score_gpt":0.33087790487588586,"score_spread":0.19745097330789446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W9436761","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012024104,0.20302983,0.0022400983,0.23306346,0.006268869,0.00044856136,0.0054817214,0.00042577175,0.5370175],"genre_scores_gemma":[0.17004439,0.19209348,0.0039648297,0.053962052,0.004721317,0.0003533787,0.005461279,0.00011376823,0.56928545],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988564,0.00017804753,0.00006208833,0.00010295996,0.00061699434,0.0001834527],"domain_scores_gemma":[0.99521035,0.0012932054,0.00049467105,0.00016125734,0.0022375418,0.00060291006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020471758,0.00030825136,0.00032458652,0.0012352708,0.00041791634,0.0019741312,0.00038022656,0.0016170248,0.031409185],"category_scores_gemma":[0.004791903,0.00016193152,0.00043497264,0.0011560941,0.0003454881,0.00078286155,0.00033757964,0.0015731067,0.008136394],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022596713,0.00007135675,0.0016516902,0.00069890794,0.000056023946,0.00015208205,0.000039867886,0.00026179996,0.000729394,0.057114597,0.82426333,0.11473499],"study_design_scores_gemma":[0.00009742545,0.00010131369,0.005466511,0.00030901658,0.000035811165,0.00017100558,0.00003946508,0.00018321742,0.0004735681,0.0013988276,0.9917133,0.000010477409],"about_ca_topic_score_codex":0.011245494,"about_ca_topic_score_gemma":0.013880792,"teacher_disagreement_score":0.031409185,"about_ca_system_score_codex":0.0025627082,"about_ca_system_score_gemma":0.01029806,"threshold_uncertainty_score":0.10507417},"labels":[],"label_agreement":null}]}